,Person,Condition,Drug,Observation,Measurement,Procedure,Device,Visit,Negation,Qualifier,Temporal,Value,Multiplier,Reference_point,Mood,Post-eligibility,Pregnancy_considerations,Informed_consent
0,"['Metformin);|Women', 'screening.|Male', 'a:||Aged', 'patients:||Age', 'Women|Aged', 'Ulcerative', 'DOAC).||F.', 'Ib:||Male', 'ED)|Adult', 'Man|women', 'Code|Pregnant', 'Prisoners', 'area|Under', 'process|Male', 'months.|Adults', 'guidelines)|Age', 'requires', 'females', 'Screening.|Men', 'must:||Be', 'accrete', 'placement).**True', 'Baseline|Not', 'Mid-life', 'Mexican consulate', 'Young patients', 'year|Age', 'Pregnancy|Women', 'Part', 'Young', 'temporarily', 'Form||', 'adolescent girls', 'surgery|Age', 'urethral)|Male', 'patients;|Male', 'vesicles', 'childbearing age', 'minors', 'Teenage', 'gemcitabine)|Age', 'pregnant', 'cooperative', 'years|Individuals', 'care|Age', 'males', 'persistent', 'umbilicus|Age', 'parturients', 'risk uncontrollable', 'Man', 'birth)||Age', 'Prisoner', 'Excess', 'surgery;|Women', 'Adults', 'suggest', 'frequent', 'child', 'Weight', 'metastasis;|Age', 'female|Adults', 'Adult', 'Young adult', 'old|Male', 'preoperatively||Female', 'supine', 'form;|Female', 'n=420', '28/02/2023||', 'Individual', 'Female|Age', 'Preschool', 'form.|Age', 'F', 'histology;|Age', 'infants', 'pregnancy|patients', '1.|Life expectancy', 'C', 'UNL)/dL', 'years.|Male', 'ovary', 'signed;|Male', 'Paediatric', 'General', 'Subscale', 'Criteria：||Age', 'geographically stable', 'Outpatient', 'outpatients', 'years|male', 'well;|Male', 'male,|age', 'BMD|Age', '≥10)|Participants', 'measles', 'patient.|Age', 'maintained', 'metabolic', 'years.|History', 'Excluded', 'requirement', 'invasive', '||Male', 'adult', 'pregnant|Not', 'RDEB|Age', 'analysis.|Aged', 'MIS-C', 'neonates', '2).|Male', 'amenorrhea|Women', 'Youth age', 'part in another research study', 'year.|Age', 'Child', 'Adolescent', 'Female;|Age', 'ia:||Men', 'diabetic.||Aged', 'collection:||Male', 'iteria||Children', 'ICF).|age', 'Cases:||Male', 'lethargy', 'women|age', 'disease|Age', '≥30)|Pregnant', '●', 'COVID-19;|Age', 'Male|Age', 'institution|Women', 'patients|aged', 'surgery.|Patients', 'Healthy|Male|Age', 'ages', 'criteria13.|Male', 'rationale', 'age.|Individuals', 'naïve', 'OR|Age', 'hypertension)|Women', 'sexual relationships', 'ultrasound).||13.Female', '|Women', 'Angeles grade', 'years.|Pregnant', '1.Adult', 'University.||women', 'articipants', 'age).|Female', 'comprehension);|Age', 'volunteers:||Age', 'placenta', 'YA', '10', 'any other', 'consent|Adults', 'signature.|Age', 'age|Stage', '21|Male', 'collection)||Patients', 'enrollment:||Male', 'Randomization||Significant', 'Singapore', 'Veterans', 'Fairly', 'first degree', 'cytology;|Age', 'age>/=', 'old,|Primiparous', 'signed||', 'year', 'Term', 'patients.|Age', 'incident|Intubated', 'female.|Age', 'treatment.|Women', 'Males|Age', 'childbearing||', 'pregnancy|Malaysian', '≤1', 'sex;|Age', 'The', 'hyperlipidaemia|Sportsmen', 'cardiotoxicity):||Male', 'days|Patient', 'malformation|Combined', 'One', 'Controls)||Age', '5.0|Eastern', 'RI)|Age', 'Part A', 'prisoner', 'randomization|Female', 'form.|Male', 'volunteers.|Age', 'months|Mild', 'diagnosis|Age', 'Voluntary', 'rowers', 'inclusive)|Male', 'range|Women', 'children|Children', 'weeks|Women', 'adolescent', 'initiated.|Men', 'WCBP', 'torsion|Women', 'polyps', 'old.|Gestational', 'samples collected', '1;|Female', 'body weight', '1999;|Men', 'A', 'participants:||Between', 'injection|Men', 'fatigue.||Female', 'procedure.|Female', 'a:||Male', 'Subject:||Males', 'AE', '≥1500/µL|Platelets', 'Resident', 'carers', '1.Patients', 'PASI', 'practice|Reiki', 'both sexes', 'INR)>1.7', 'elderly', 'Accident', 'weeks|Currently', '13', 'volunteers.|Aged', 'not', 'Not', 'ALL)||Adult', 'women|Older', 'Assuit', 'Franciscan', 'implantation|Age', 'female|Age', 'American|Be', 'under-', '≥2|No', 'laboratories.|Patients', 'axilla.|Age', 'ataract', 'years|Only', 'FiO2', 'adenocarcinoma|Age', 'diseases.|Refused', 'Inmate of correctional', 'mmunicating,||Over', 'setting|Aged', 'or;|Age', 'Babies', 'Major', 'Form.|Male', 'activity|Women', 'Institutionalized', 'Radiologically', 'Facility', 'Ages', 'However', 'hildren', 'Criteria:||Age', 'mastectomy|Age', 'ABNT', 'teria:||Mothers', 'participants:||Adult', 'Group A', 'entry.||Women', '≥450ms', 'Aged', 'unit|Male', 'Criteria||Age', 'ranges', 'malignancies;|2.Male', 'Minors', 'events.|Patients', 'children', 'appointment', 'genders', 'FCBP', 'y||Do', 'household', 'ADULT', 'a:||Age', 'histopathology;|Age', 'Additionally', 'pericardial', 'Pregnant,|under', '2016:||For', 'ICF).|Female', 'Axilla can accept sentinel lymph node biopsy', 'below:||Leukocytes', 'ED|Age', 'part in another research', 'MRI|Female', 'Population:||Adults', 'criteria);|Age', 'chemotherapy.|Age', 'man', 'VEM|Age', '≥4.|History', 'weeks.|Female', 'active', 'period|Age', 'GBM).|Age', 'Women|Age', 'trial.||Male', 'Woman', 'first MDD episode', 'cancer;|both sexes', 'enrollment;|Males', 'CRITERIA||Children', 'true', 'IV|LVEF', 'Rubella', 'except', 'athletes.|Age', 'prophylactic use of', 'inpatient', 'therapy;|age', 'I|Need', 'patients|Male', 'pediatric', 'People', 'procedure.|Male', 'life.|Age', '/L', 'birth)|Age', 'adults|female', 'preferred', 'prolonged', 'years|Female', 'Younger', 'male', '01.11.2022||', 'etc.|Age', 'histology.|Age', 'dentures', '≥24|Current', 'form|Age', 'mpox|Age', 'woman', 'Caucasian', 'patients|Age', 'atient', 'TBI', 'latex', '||Men', 'procedures.|Age', 'neurolens', 'however', 'ICSI.|Age', 'years', 'Wegener', 'Willis.|Age', 'outpatient)|Age', 'splenectomy)|Age', '≥65years', 'activities.|Male', 'Workers', 'months|Adults', 'Women;|Age', 'imprisoned', 'age.|Children', 'ia:||Age', 'age|Freely', 'age|≤', 'pathology|Age', 'Neonates', 'old|Patients', 'babies', 'written;|Female sex;|Age', 'alanine aminotransferase>5', 'result', 'complications|Women', 'Females|Age', 'weeks;|Women', 'LTX|Age', 'parents|child', 'procedures|Age', '1/10', '20', 'smokers', 'over|Weigh', 'meeting inclusion', 'condoms', 'radiography.|Age', 'rubella', 'New', 'subjects|Age', 'First degree family member', 'incarcerated', 'Born', 'excluded.||Ages', 'Participants:||Adult', 'being', 'Mutiple', 'Campylobacter', 'Male', 'members', 'BMI>25|Age', 'Smokers', 'Bilateral', 'disease.|Male', 'Systemically', 'age|male', 'Newborn', 'parental', 'Smoker', 'years.|Age', 'volunteers:||male', 'C|Female', 'which', 'stents', '.|Patients', 'yet', 'Parkinsonian', 'Female|Ages', 'preschool', 'practitioner', 'PD', 'IIIB', 'pustules', 'women', 'Members', 'Criteria||adults', 'genres.|Age', 'sUA', 'participants', 'biopsy.|Age', 'varicella', 'robands):||Adults', 'chemotherapy|Age', 'symptoms.|Participants', 'II.|Age', 'peri-operative', '50', 'females|Adult', 'previously|Women', 'polyhydramnios', 'ccRCC|Age', 'Respiratory', 'male|be', '1.|Female', 'Women', 'Female', 'parent', '||Female', 'female', 'Years', 'participants:||Ages', 'Excluding', 'FOCBP', 'Both', 'Infants', 'h|Age', 'site|Women', 'above|Age', 'old|Women', 'consent|Ages', 'TMS|Pregnant', 'consent.|Age', 'prisoners', 'III.|Age', '55years', 'English|Age', 'women.|Age', 'EV', 'atients):||women', 'Students', 'they||are', 'meglitinides', 'regular user', 'Males', 'Confirmation', 'Participants', 'Chinese', 'angiomas).|Male', 'persons', 'volunteer', 'infant', 'cancer;|Women', 'months|Patients', 'patients;|Patients', 'smoker', 'use.|Male', 'unit,|female', 'participants.|Female', 'IC1]:||Able', 'BTKi|Male', 'impaired', 'weeks;|women', 'Diplegic children', 'Gender', 'TT', 'PTSD).|Female', 'treatment.|Life expectancy', 'years;|Diagnosis', 'weeks|Female', 'procedures|Women', 'Junior', 'w/o', 'both genders', 'WOCBP', 'allowed;|Life expectancy', '≥III;|Obstructive', 'Volunteers', 'baseline|ES', 'rare', 'volunteer:||Age', 'Functioning', 'Being', 'abuse|Immunocompromised', 'Infant', '≥140', '|Hospitalized', 'smoker|Alcohol abuse|Currently', 'You', 'criteria:||Children', 'a:||Stage', 'Youth-Caregiver', 'Pediatric', 'slightly', 'months|Children', 'problems|Aged', 'II:||Women', 'adults', 'Children', 'Patients:||Age', 'Leukocytes', 'overbathing', 'subjects||Age', 'pregnancy;|Those', 'described', 'criteria:||Male', 'physician', 'Youth residing', 'Age≥18', 'NMOSD', 'mandatory.|Participants', 'Mothers', 'men', 'women:||Aged', 'males|Age', 'Arm', 'products|Female', 'signs', 'months|Age', 'volunteers|Age', 'parent||', 'RFA).|Age', 'criteria|Age', 'Ver', 'ranged', 'visibly clotted|Specimens', 'Extremely low', '1、Patients', 'If', 'PA|Age', 'males.|Pregnant', 'cryoglobulinemia|Age', 'wards|No', 'old', 'Pre-', '1.Age', 'Both sexes', 'hepatocellular', 'hours|Pacemaker', 'aged', 'criteria||Age', 'youth', 'points)|Age', 'ale', '≥18', 'outpatients|Age', 'teenagers', 'analysis|Male', 'Westergren', 'rare patients', 'EGA||Age', 'resident', '2.|Pregnancy', 'Participants:||FVC', 'SLE)|Female', 'regular strenuous exercise', 'opposition|Acquired', 'Emergency', 'Subjects:||Male', 'Meglitinides', 'years|Histologically', 'Criteria:||Male', 'treatment|Measurable', 'Outside', 'negative.|Male', 'negative.|Patients', 'MCC||Age', 'Outpatients', 'subjects;|Age', 'recipient', 'years.|Both', '18', 'passes', 'are:||Male', 'Un', 'mPAP', 'Age', 'iteria:||Male', 'Men', 'child age', 'high', 'atients', 'first response', 'Did', 'Nurse', 'Is', 'sex|age', 'Black|Male', 'women;|Age', 'part in other research', 'amplification;|Histologically', 'aging', 'age', '2|Aged', 'Household members', 'prophylactic', 'Dementia||Men', 'rare solid tumor|Age', 'weeks|Nulliparous', 'status;|Women', 'toxic', 'they:||are', 'pain|Aged', 'Female|Caucasian|Age', 'Measles', 'NA', 'under age', 'age|Both', 'girls', 'WOMEN', '5/10', 'Finally', 'inclusive.|Not', 'malalignment', 'lesions|Age', 'flaps|Multifocality', '1996)|age', 'University', 'Females', 'Patient]||Adult']","['breast cancer staging', 'chronic disease|growth failure', 'tumor', 'traumatic epilepsy', 'basal cell carcinomas of the skin.|Any clinically significant abnormalities', 'poor oral hygiene', 'primary cancer treatment', 'ligamentous injuries|previous meniscectomy', 'primary COVID-19 vaccination', 'latent tuberculosis', 'nasopharyngeal malignancies', 'xerophthalmia', 'chickenpox vaccines', 'SESSAD', 'intestinal transit function', 'aesthetically unacceptable upper eyelid position', 'hemodynamic instability', 'OX-40 agonists.|Receive research treatment', 'age|Normal skin sensation', 'rectal prolapse', 'thymoma', 'chemotherapy-induced thrombocytopenia', 'corneal disorders', 'skin biopsy|Diagnosis', 'reactive arthritis', 'aortic stenosis|Indication', 'maternal leukocytosis', 'adenomatous colonic polyps', 'rectal bleeding', 'Generalized Anxiety Disorder Scale-7', 'worse on the Retina Society Terminology Committee Classification', 'extra hepatic spread;|Previous', 'MDS)/acute myelocytic cell', 'renal comorbidities', 'mmHg|pregnancy|clinical heart failure', 'findings', 'arterial hypervascularity', 'breast feeding|Body mass less', 'serious medical disorders', 'singleton', 'ischeamic heart disease', 'AOM', 'cord compression.|Participants', 'breast carcinoma in situ', 'severe scalp discomfort', 'normal tension', 'gastric bypass', 'anatomical abnormalities', 'psychological deficit', 'natural health products', '≥40%.|Patients', 'interlobar fissure', 'disease-modifying treatment', 'postinfectious cough;|Wind-cold', ""morton's neuroma|over 18 years"", 'delayed allergic reaction', 'SMM', 'neonate.||D.', 'poor health of the child after birth', 'bipolar I disorder', 'non-cervical origin|Dizziness', 'inflammation)|Celiac disease', 'chronic obstructive pulmonary disease);|Patients', 'Common Terminology Criteria', 'illegal recreational drug', ""Steven's"", 'Dry Eye symptoms', 'arrhythmias|Mechanical complications', 'extracoronary arterial', 'sudden', 'transient ischemic attack|QT interval', 'non-sterilised', 'immunosuppressive disorder', 'bronchiolitis||', 'inflammatory myopathies', 'attenuate immune response', 'foster care.|Does', 'sequential complex wound care procedures', 'judged by the investigators', 'migraine headaches', 'donate sperm from', 'skin-related condition', 'Chronic Kidney Disease Epidemiology Partnership (', 'CAR T cell', 'rhonchi).|Clinician consideration', 'Primigravida', 'related to HIV', 'month|diabetic foot ulcers', 'squamous carcinoma、adenocarcinoma、adenosquamous carcinoma', 'etc.).|Autoimmune disease', ""Huntington's disease.|Patient"", 'good compliance.||', 'AV block.|Known', 'human beings', 'acute cauda equina syndrome|Inability to complete', 'third degree atrioventricular block;|severe', 'dietary supplements|Treated', 'Inflammatory bowel disease|Signed', 'weight loss diet', 'angioedema episodes', 'lumbar disc herniation|Plan', 'IV|Obesity', 'UAC', 'multiple sclerosis|EDSS', 'traumatic injury;|Any', 'PNES|Inability', 'legs consistent', 'needle sickness', 'arterial hypertension', 'transtibial amputations|Ankle', 'inflammatory lung', 'residual stenosis', ""Wegener's syndrome"", 'intervertebral disc height', 'heart rate<50', 'health problems', 'cases of COVID-19', 'disc herniation', 'pulp necrosis.|Absence', 'knee-related', 'liposuction', 'colitis);|Participants with diseases', 'anterior coronary artery bypass grafting', 'visceral failure', 'Lactation', 'ocular imaging,|Refractive error', 'major diseases', 'non conformity of the range of motion of', 'CA125', 'hemoptysis symptoms', 'residential', 'inflammatory condition', 'other diseases associated', 'cerebral palsy', 'drug-induced parkinsonism', 'central herniation of', 'wound infection', 'hair thinning', 'diopters.|Corneal thinnest pachymetry', 'failure of the circulatory', 'sequential complex wound care', 'familial adenomatous', 'carcinomatous meningitis|Diagnosis', 'periods of hypoxic ischemia', 'urinary system disease.||', 'target lesion', 'medical problem', 'hemopoietic factor', 'pathological hypermobility', 'B-cell lymphoma', 'ESNEFT', 'psychotropic substances;|KPS', 'acute local sepsis|Patients', 'localized MSK', 'gingival cancer', 'clinical gastrointestinal bleeding', 'traditional Chinese medicine', 'Local recurrence', 'small bowel', 'affect pain', 'malignant glioma', 'psychological factors', 'chronic tendency', 'claudication', 'cerebral vasculitis', 'lymphedema', 'metastasis;|Malignant tumors', ""Huntington's chorea"", 'right heart strain where', '.|ACL injury', 'duration of illness', 'venous thrombotic', 'sedentary behavior)|Depressive symptoms', 'extranodal tumor mass', 'exudative eczema', 'sutures', 'disease|pregnancy|skin infection', 'peripheral arterial embolism', 'months)|Cardiorespiratory pathology incompatible', 'met|Leptomeningeal metastases|Rapid disease progression', 'Episodic migraines', 'signs of the patients', 'gluten intolerance', 'modified T-cell', 'atrial septostomy', 'left atrial appendage occlusion', 'anterior uveitis', 'physical disorders', 'hypofibrinogenemia', 'local curable cancers.|Uncontrolled', 'Colles fractures', 'hospitalization.|Eligible', 'mother|MS relapse', 'inclusive;|Type 2 diabetes mellitus', 'myocardial infarction|ELIGIBILITY CRITERIA', 'former drug og alcohol', 'radioactive isotopes', 'shingles virus', 'Protein S Deficiency', 'febrile seizure', 'glucose', 'primary hypothyroidism', 'peri-implantitis', 'Diabetic mellitus', 'non-controlled', 'lack of coagulation factor', 'encephalopathies', 'drug abuse;|Systemic diseases judged by researchers', 'chronic obstructive pulmonary disease.|Temperature', 'cryptogenic organizing pneumonia', 'surgical indication)|Placental abnormalities (previa', '+6 dioptre|astigmatism', 'tenderness', 'stenosis of', 'Alcoholism', 'T4 disease', 'spinal cord compression', 'rescue pain', 'premalignant skin lesion', 'agitation', 'superficial EAC', 'Eaton-Lambert myasthenic syndrome|Has hypersensitivity', 'lateral ankle sprain copers', 'chronic venous insufficiency', 'month.|Serious infectious diseases', 'Minnesota', 'hypersensitivity);|Neurological patients', 'VHB', 'acute illness|The', 'olfactory disturbances', 'active', 'neurovascular complications', 'multiple Endocrine Neoplasia Type 2 (MEN 2', 'metastatic LN', 'ASCVD|diabetes mellitus', 'walking', 'manic-depressive psychosis);|Acute coronary syndrome', 'temp-catheter', 'hemodynamic compromise,|Symptomatic severe', 'sodium hypochlorite solution', 'urinary sample collection|Other concerns', 'plasmapheresis', 'multiparous', 'mixed type', 'jugular ingurgitation', 'diaphragm;|Atrial fibrillation', 'sleep disorders', 'varices|Pregnancy|Severe comorbidities', 'screening Infection', 'ascites fluid', 'acute illness occurring', 'eosinophilic duodenitis|Known', 'colorectum', 'Acute Promyelocytic Leukemia.|Subjects', 'tight valvular lesions),|known obstructive sleep apnea', 'ptosis|Significant facial', 'disease:||Renal cell carcinoma', 'hemodialysis|Bilateral renal cell', 'IOLs', ""Burkitt's lymphoma"", 'Presence', 'congenital cardiopathy.|Neonates', 'multiple chemical sensitivities', 'malignant pathologies', 'abdominal drain', 'congenital developmental anomalies', 'primary immunodeficiency', 'gynaecological cancer', 'on.|Hepatic encephalopathy', 'prostatic hyperplasia', 'Secondary myopia', 'Pulmonary infiltration≥', 'complex class', 'chronic hepatitis B infection|Absence', 'institutional pneumonia', 'acute suicidal thoughts', 'osteoarthrosis', 'multiple sclerosis|relapse', 'impaired immune system', 'end stage disease', 'anxiety disorders).|Psychotic disorder', 'month,|The type', 'common immunodeficiency', 'COVID MDT', 'metastasis', 'HBsAg reactive', 'sick sinus syndrome', 'maxillary sinus lift;|general health problems', 'deterioration of', 'inter-2 risk', 'immunosuppressive agent.|Hypersensitivity to the active ingredient or any of the excipients', 'Prolonged Exposure', 'Congenital diseases', 'heart diseases|Malignant disease', 'antileukemic therapy.|Breast feeding.|Impairment', 'circumferential defect', 'al)|Intracranial tumor', 'spine surgery)|Expected', 'visible lesions', 'endometrioid ovarian', 'Renal dysfunction', 'nonlactating', 'Pulmonary failure', 'Polycystic kidney disease', 'angina|Major surgical procedure', 'nephrolithiasis', 'continuously.|Maternal hypersensitivity', 'multiple risk factors', 'neuropsychological dysfunction', 'replacements.|Symptomatic disc herniation', 'suicidal attempt).||11', 'immunomodulatory effects', 'essential thrombocytosis', 'comorbid condition impacting', 'liver invasion);|life expectancy', 'vesicoureteral reflux', 'fallopian-tube cancer|Has', 'malignant syndrome|History', 'apheresis', 'sleep disorder - particularly', 'inferior limb length', 'drug-induced immune thrombocytopenia', 'centration', 'Redwing', 'diseases of the parathyroids', 'genital target lesion', 'Hemodynamic instability', 'SPC', 'mild COVID-19', 'Absolute iron deficiency', 'cured.||Localized prostate cancer', 'cervical DDD', 'Turner syndrome', 'Acute Illness|Life expectancy', 'structural integrity;|The', 'limits exercise capacity', 'POLs', 'infections.|Body mass index', 'cicatricial pemphigoid', 'reproductive system infection', 'iTTP.|Participant', 'cancer related', 'ulcerative colitis.|Diseases', 'dental abnormalities', 'dysfunction;|Acute attack', 'local skin basal cell carcinoma', 'or|Hypocalcaemia', 'severe osteoporosis', 'health literacy', 'intraepithelial neoplasia', 'performed.|New York Heart Association (NYHA) class', 'myalgia', 'physically active.|High', 'preclude', 'co-morbidity', 'urolithiasis|diabetes|thrombophlebitis', 'education condition', 'acute Hypoxemic Respiratory Failure', 'Myocardial zymogram', 'bacterial infections', 'pack of cigarettes', 'compromised airway|uncontrolled seizures', 'overt injury', 'inotropes', 'criteria required:||The cancer specialist considers', 'blindness', 'venous catheterization', 'pituitary adenoma', 'viral vasculopathy', 'SLC7A7', 'gastric satiety', 'extensive dental damage', 'reversible condition', 'injection', 'therapy|Colorectal cancer', '.|Metastatic lesion', 'biological problems', 'deep rest', 'as:||hepatic transaminases', 'Guillain-Barre Syndrome.|Subjects receive', 'pathology', 'Substance Abuse', 'neurologic symptoms suggestive', 'fibrolamellar carcinoma', 'paternal allele', 'rare disorders', 'impaired sensation', 'neurocutaneous disorders', 'hyperactive/impulsive', 'judged by the investigator to be unsuitable for clinical trials', 'attention-deficit/hyperactivity', 'loose stools', 'infectious diseases|Claustrophobia|Physical disability|Any mental disorders', 'chlorazol black preparation', 'obstructive coronary artery disease', 'further detail.|Anemia', 'transfusion history.||', 'deep-brain stimulation (DBS)', 'old||individuals residing', 'teeth that', 'humanized antibodies,', 'cervical intraepithelial neoplasia', 'Varicocele', 'myxofibrosarcoma', 'irritated bladder', 'Helicobacter pylori infection', '3C', 'pyloric stenosis', 'progressive severe pathology of poor prognosis', 'non-ischemic cardiomyopathy', 'non-tuberculosis', 'imaging pneumonia', 'type 1 diabetes mellitus', 'renal impairment|Urine protein', 'thoracic outlet syndrome|patient', 'significant observation', 'iron-deficiency anaemia)|insomnia|obstructive sleep apnea|night', 'hepatitis C|Uncontrolled pleural effusion', 'growth factor therapies|Abuse of drugs and/or alcohol|Participation in another biomedical study', 'fungal infection of the treatment areas', 'carotid artery disease revascularization', 'sites of disease', 'PTH', 'extensive-stage small cell lung cancer', 'pneumonitis.|Chronic Obstructive Pulmonary Disease (COPD)', 'medical condition;|Patients', 'etc.)|Allergy', 'neurological disease.|Positional club foot.|Those', 'bleeding problems', 'concomitant pathologies', 'vital prognosis', 'international prognostic scoring', 'non-squamous cell carcinoma', 'deep vein', 'primary psychiatric diagnosis', 'permanent neurologic deficit', 'poultry)|Active joint infection', 'NA', 'spastic CP', 'valgus', 'dermatitis|Participation', 'Remission', 'sleep apnoea|hyperthyroidism', 'multi-infarct', 'dysphonia', 'orofacial pain', 'painful chronic pancreatitis', 'preterm birth', 'Kellgren', 'loss of viable myocardium', 'Hyperthyreosis', 'regional neuraxial (intrathecal', 'ago)|Perioperative iatrogenic adverse events', 'neurological lesions', 'lower extremity edema;|pregnancy', 'non-ERT treatments', ""Gilbert's syndrome|LDL"", 'Nile virus', 'chemotherapy-induced', 'IFNα preparations', 'celiac sprue', 'metabolic bone disease', 'treated in situ grade 1', 'Cervical cancer', 'impaired digestive tract integrity', 'respiratory tract infection.|Body mass index', 'anxiety controlled', 'postoperative BCDVA', 'brain contusion', 'generalized seizure disorder', 'unresectable cholangiocarcinoma', 'pulmonary RRP', 'reproductive active', 'thromboembolic event:||cerebral vascular accident/stroke', 'chronic liver damage|previous', 'Chronic Fatigue Syndrome (M79 .7', 'RDS', 'Liver insufficiency', 'ovarian stimulation.|During', 'basic diseases', 'functional scoliosis', 'corneal haze', 'CBCT', 'Cirrhosis', 'recurrent autonomic dysreflexia', 'neck structures', 'Hypoacusis', 'Marfan Syndrome', 'Infected', 'T2 airway', 'labor|Known maternal intestinal stenosis', 'amyotrophic lateral', 'bevacizumab)|No assessable archival tumor tissue', 'ocular condition|Cataract', 'language impairment;|Peripheral vascular disease;|Severe cardiovascular disease', 'renal stones', 'benign', 'discharge),|suicidal tendency', 'lung neuroendocrine carcinoma', 'Schizoaffective disorder', 'immunodeficient condition', 'K. pneumonia', 'Restrictive lung disease', '|Systemic diseases', 'conditions||Evidence of disease', 'progressive brain metastases.|Major surgical procedure', 'legal blindness', 'Injectable disease', 'vertebral joint pathology', 'policies', 'surgically with curative', 'focal disease', 'esophageal bleeding', 'Global developmental delay/concern', 'CCA', 'Specimens', 'dependence DSMIV', 'criteria of MCI', 'Index (GI)', 'stroke attack', 'hepatic enzyme elevation', 'immune-deficiency', 'Traditional contraindications', 'seaweed', 'aortic valve area', 'vascular endothelial growth factor receptor (VEGFR) directed therapies', 'Type I diabetes mellitus', 'acute bacterial conjunctivitis', 'adequate therapy|Known CAD', 'suicidal ideation|Non-English speakers', 'pain -||', 'growth patterns', 'hypertensive encephalopathy', 'Poor exercise', 'cervical disc disease', 'UC).|Participants', 'impaired renal function;|Patients', 'vitamin B12', 'tumour for injection is located adjacent to the jugular vein).|Are', 'HBsAg positive', 'Infectious Diseases Society', 'acute dyspnea', 'donation|Infectious disease testing|MCW BMT', 'bilateral movement', 'age|Histologic', 'super-eruption|Self-reported', 'uncontrolled intercurrent illness', 'sarcoidosis syndrome', 'lumbosacral radiculopathy', 'locations', 'transfusion', 'inoperable surgically resectable', 'mixed ampullary', 'metastatic disease.|Vulvar cancer', 'Stargardt disease', 'etc.)|Not', 'external drainage|Psychiatric illness/social', 'malignant lesions', 'colorectal cancer|Understands verbal', 'alcohol screen', 'venous access.|Second malignancies', 'Secondary FS;|Primary', 'chronic bronchitis;|Patients', 'clinical pain', 'infiltration into', 'head and neck chemotherapy', 'attempt', 'malignant solid tumor', 'lower gastrointestinal bleeding', 'connective disease', 'extensive adhesions', 'cervical spine fracture', 'biliary tract carcinoma', 'asymptomatic ischemia', 'Localized tumors', 'impaired elimination|Known kidney', 'diabetes mellitus|Absence', 'jugular tympanum', 'sickle cell trait', 'cetuximab.|Gastrointestinal disorders', 'crohn disease', 'gastrointestinal stromal tumor;|Tumor tissues', 'human serum albumin', 'ductal carcinoma in situ', 'non-recovered fractures', 'aortic aneurysm).|Cirrhosis of the liver', 'pregnancy.|-', 'chest wounds|Volunteers', 'Internal Medicine residency', 'interpersonal issues', 'good health means', 'external hemorrhoids', 'psychiatric risk factors', 'Hirschsprung disease', 'cardiomyopathy state(s', 'endurance', 'epidermal growth factor receptor (EGFR)', 'poor oral hygiene|Plaque score', 'HSD', 'nodules|Patients', 'medial joint space', 'acute renal failure|Autoimmune diseases', 'deep breath', 'clinical condition', 'functional asplenia.|Thrombocytopenia', 'autoimmune disease.|Greater', 'good function.||Other protocol', 'FMC', 'systemic antimicrobial', 'anti-cancer therapy', 'decreased RV function', 'inducing', 'vitamin D deficiency', 'glucose-galactose malabsorption|Those', 'urine protein&lt;(++', 'disease/condition', 'third month||', 'type 1 ROP', 'clinical stage T3a', 'light sensitivity condition;|Loss of', 'non-pancreatic', 'stop smoking medications', 'hyper-autofluorescence', 'renal biopsy;|Had', 'vital signs values', 'cutaneous squamous cell carcinoma', 'extra renal replacement therapy', 'inadequate visualization of the liver', 'vaginal ring', 'historic hypocalcemia', 'preoperatory eye', 'meningococcal disease', 'pulmonary hypersensitivity pneumonitis', 'seizure disorders.|Mania.|Primary', 'Joint United States/European Union Initiative', 'linguistic deficits', 'sexually mature', 'hearing impairment', 'investigator.|Active malignancy', 'severe cardiological pathologies', 'marrow function', 'diabetic retinopathy.|Recurrent', 'depressive mood disorder', 'lymphocytic leukemia.|Other cancers', 'Right ventricular cardiomyopathy', 'physical impairment', 'Kawasaki disease', 'pulmonary artery embolism', 'anaplastic astrocytoma', 'Chronic Illness.|Spine', 'rare genetic disease', 'atrial fibrillation|Patients', 'water|Chronic diseases', 'colorectal cancer|Receiving oncology services', 'nicotine patches', 'medial rectus muscle(s', 'compartment syndrome', 'Spinal cord metastasis', ""Dupuytren's contracture"", 'Left atrial appendage', 'mood dysregulation disorder', 'cognitive impairment.|Previous', 'rise', 'level', 'in situ cervical carcinoma|Patient', 'severe hypertension', 'bone metastasis located', 'neurocognitive disorder|Age', 'neurological findings', 'oppositional defiant disorder', 'major sensory impairment', 'pure adenocarcinoma', 'close friends|Adults', 'HT', 'neck mobility)|Nasal infection', 'morbid obesity', 'bilateral cataracts.|Bilateral retinal vein', 'Colon carcinoma', 'inability to read English', 'calculi', 'septal deviation', 'medical contraindication', 'arrest', 'non-pharmacological treatment', 'inflammatory bowel disease/syndrome', 'brain perfusion problems', 'GTV', 'Yukon Chrome PC', 'haemorrhagic diseases', 'therapy.||Measurable lesions', 'LV thrombus', 'prostate neuroendocrine carcinoma', 'antecedent condition', 'chronic hepatitis B virus', 'right heart catheterisation).|Randomized no earlier', 'cigarettes', 'primary biliary', 'bipolar affective', 'heart kidney)|Contraindication to renal biopsy|Refusing biopsy|Kidney transplant', 'Intolerant', 'coronary syndrome', ""cutaneous Kaposi's"", 'blood vessels', 'chronic medical problems', 'rheumatic diseases);|Known hypersensitivity', 'histiocytic', 'conditions.|Concurrent', 'MDRD);|Negative pregnancy test', 'substance abuse disorder', 'non-proliferative diabetic retinopathy', 'periodontal disease', 'mucosal lesions', 'bulky lymph nodes', 'bleeding constitution', 'Lactating|Blind|Deaf|Abnormal ECG', 'additional risk factors', 'weight- loss treatment', 'genetic disorder', 'hypoperfusion signs,||Fluid overload', 'type', 'erythromycin]);|Significant traumatic injury', 'congenital lumbar', 'nicotine habits', 'left heart valve disease', 'severity of depression|TRD', 'Quick Dementia Rating System', 'autoimmune nature', 'PDL-1-negative', 'attack', 'gastroesophageal reflux disease', 'naming disorder', 'diseases related', 'required|Serious neurological diseases', 'chronic glucocorticoid use)|Severe pre-existing neuropathy|TKA for', 'aortic sclerosis', 'nonopioid pain medications', 'obstructive pulmonary', 'wheeze', 'impaired quality', 'Internal prolapse', 'co-morbidities', 'embolism', 'pathological information.|(6)candidates', 'acute cerebrovascular condition', 'pulmonary function|Willingness', 'immune deficiency|History of', 'nasal abnormality', 'organic mental dysfunction|Participate', 'DKA)|Uncontrolled hypertension', 'azoospermia', 'liver disease.||Prior', 'Secondary membranous nephropathy', 'chronic defecatory motility disorders|Current', 'abuse of alcohol', 'acute intermittent porphyria', 'liver pathology', 'head and neck malignancies', ""Peyronie's disease"", 'intravascular coagulation', 'intestinal parasitosis', 'CYP3A inducer', 'cranio-cerebral trauma|Acute ear canal', 'giant', 'recurrence of marrow disease', 'Intubated', 'types of interventions', 'acute necrotic collection', 'randomization|Psychosis', 'medullary thyroid cancer', 'consumption of any drug metabolizing enzyme', 'venous embolism', 'medial LAD lesion', 'seizure(s)|Able to give informed consent|Patient receives EEG', 'permitted.||Positive serologic', 'speaking', 'overbite|Bruxism', 'parent(s)/legal representative(s', 'organic psychosis', 'light source', 'Intern nurses', 'hepatic steatosis', '-sensitive enteropathy', 'suicidal risk|PTSD', 'Uncorrectable coagulopathy', 'study variables', 'recreational drugs', 'prolapse', 'breast abscess', 'mental disorders.|The', 'fibrous histiocytoma', 'Major depressive disorder', 'periventricular leukmalacia', 'limit sleep positions', 'chronic diseases;|The', 'psychotic spectrum disorders', 'Guillain-Barré syndrome.||Individuals', 'substance abuse.|HIV-infection', 'neuroleukemia', 'examination|Subject', 'secondary school', 'Contra-indications', 'mitral valve repair (MVR)', 'hyper tension.|People', 'Target Disease', 'Akili EndeavorRxTM', 'acute major vascular compromise', 'adjuvant whole breast external beam radiotherapy', 'autoimmune disease|Diagnosis', 'conduction abnormality', 'SCC).|Skin disease', 'objective)|Co-infection', ""partner's vasectomy"", 'hypocomplementaemia', 'speaking|Those', 'in-situ carcinoma', 'Pelvic injury', 'cirrhosis|Active central nervous system lymphoma|Patients', 'parenthood', 'color vision impairment', 'watery stools', 'metastatic repetitions', 'symptomatic condition', 'palliative surgery.|Preoperative American Society of Anaesthesiologists (ASA) score', 'skin herpes lesion', 'brain metastatic lesions', 'pain disturbances', 'another malignancy tumor', 'orotracheal', 'system;|Suffering from autoimmune', 'medications).|Uncontrolled hypertension', 'major depression.||Inclusion Criteria', 'intracranial target lesion', 'Compliant', 'poor compensation', 'hepatitis B virus', 'age.|Eastern', 'ocular malignancy.|Subjects', 'available medical records|For', 'GI perforation', 'hypoplastic head|Patients', 'behavioral impairment', 'pulmonary arterial embolism', 'shock', 'autoimmune disease|Other', 'conduction disturbances', 'physiological facial skin', 'platinum-containing regimens', 'Type 1 Diabetes Mellitus|The', 'hypertensive encephalopathy.||Patients', 'myelodysplastic syndrome|For', 'functional class', 'local thrombolysis', 'intentional dietary restrictions', 'physically active', 'dosing interruptions', 'Convergence Insufficiency', 'indolent lymphoma', 'behavioral disorders', 'diseased skin', 'pulmonary hypertension|End-stage renal disease|Cardiac transplantation|Impairment', 'epilepsy-like', 'secondary dysmenorrhea', 'Schistosomiasis infection', 'regular menstrual', 'occupational condition', 'common carotid', 'CPS', 'Cognitive impairments sufficient', 'swelling', 'HIV testing positive.|Is', 'instable angina', 'haemolytic response', 'rare disease-associated', 'ocular involvement', 'aortic coarctation', 'narcotic analgesic', 'Cervical Pathology (ASCCP)', 'medical conditions Failure', 'cerebrovascular incidents', 'previous injury', 'Stevens Johnson syndrome', 'diseases of the cardiovascular', 'spinal cord damage)|Have', 'neurofibromatosis type 1 (NF-1', 'NS', 'Breast cancer', 'complement deficiencies', 'vitamin E supplements|Consume', 'dermal lesions', 'meningeal involvement|Treatment', 'epithelial defect', 'Traumatic Brain Injury (TBI)', 'national health authorities', 'valvular stenosis', 'Pregnancy.|Mentally disabled', 'pedal for anterior tibial', 'etc.);|uncontrolled hypertension', 'cataract.|Corneal opacities', 'ovarian stimulation.|Allergy', 'anti angina drugs', 'lost to follow-up)', 'malignant biliary', 'resected lesions', 'mycobacteria', 'hemorrhage;|Ischemic cerebrovascular', 'chronic low back pain', 'Type 2 diabetes,|Age', 'protozoal infection', 'inhalational injury', 'congenital heart defect', 'actively seeking', 'colon surgery', 'chronic diseases|Patients', 'prolonged reversible ischemic neurological deficit', 'online QCA', 'genetic condition', 'Good general health', 'joint fracture', 'postnatal oxygen saturation', 'chronic corneal epitheliopathy', 'antibody||Exclusion Criteria', 'Human immunodeficiency virus (HIV) antibody test', 'embryonal tumor', 'foreign objects in both wrists.|Participants must agree to adhere to the lifestyle considerations.||Healthy Controls', 'HIE', 'knee extension', 'cardiac shunts', 'non-Type 1 diabetes|Unable to use a', 'allowed.||Postmenopausal', 'muscle strain injury', 'amnestic presentation', 'abdominal malignancy', 'isolated febrile', 'measurable lesion', 'inflammatory bowel disease)|Aged', 'organic heart diseases', 'psychotic symptoms|acute', 'Respiratory disease', 'neurocognitive disorder', 'cervical carcinoma', 'middle cerebral artery (MCA)|Occlusion (regardless of location', 'knee arthralgia', 'knee pathology|Balance', 'acute pulpitis', 'hearing loss', 'hemangioblastoma', 'Attention-deficit hyperactivity disorders (', 'incidental fall|Patients', 'neural pain', 'VHL syndrome', 'skin diseases', 'autoimmune hepatic disorders', 'follows:||For', 'pleural effusion drainage', 'hip protheses prohibit accurate MR', 'chronic diseases;|Sexual behavior', 'Major congenital malformations', 'Vulnerable', 'fixed anatomical', 'immunologic test;|11', 'orthopedic injuries', 'amount of alcohol', 'nail beds', 'adrenal dysfunction', 'not resolved', 'Normal cardiac function', 'urethral cancer', 'relinquish caring responsibilities', 'idiopathic interstitial pneumonias', 'eyelid valgus', 'skin abnormalities', 'angiosarcoma', 'diabetic neuropathic pain', 'live involvement', 'human epidermal growth factor receptor 2 (HER2) mutations', 'Medullary Thyroid Carcinoma (', 'morbid obesity)|High', 'congenital abnormalities of the GI track, the cardiovascular system', 'ankylosing spondylitis diagnosis||', 'cancer risk physicians', 'SSS', 'HLA allele', 'tumour tissue', 'dynamic image criteria', 'rheumatoid pregnant diabetes', 'carpel tunnel syndrome.|Severe COVID-19', 'intracranial hemorrhage', 'hepatoma', 'vaginal dryness', 'clinical manifestations later', 'dystrophic scarring', 'brain function disorders', 'reconstructed||High-risk features', 'exon 19 del', 'traditional Chinese medicine labels', 'mitochondrial function', 'balance disorder', 'hormonal sensitive cancers|Assumption of hormones', 'septal defect', 'heart rate monitoring', 'bipolar affective disorder|major depressive disorder', 'concomitant condition', 'immunosuppressive states', 'hypertrophy', 'local IRB', 'chronic hepatic disease', 'T2-T4aN0M0 (CT/MR', 'placental abnormalities', 'chronic hepatitis D virus (HDV) infection', 'of:||Food allergies;|Presence', 'Obstructive sleep apnea syndrome', 'repeatedly', 'heart conditions', 'rhonchi', 'SDH', 'bone metastasis', 'Neck deformity', 'injectable tumor(s)', 'peptic ulcer disease', 'impaired epithelial barrier', 'toxic optic neuropathy', 'arterial thrombus', 'atypical parkinsonism', 'SDs', 'defiant disorder', 'period;|Prolonged QT syndrome', 'Urinary Tract Infections', 'Memory Disorder Clinic', 'balance problems', 'Brain metastasis', 'acute ischaemia', 'bone fracture', 'oral lesions', 'injectable hormones);|A vaginal ring', 'hepatic encephalopathy.|Oesophageal variceal bleeding', 'speak Catalan', 'complex RD', 'acute gastrointestinal illness', 'Gynecological infections', 'portal fistula', 'skin wound', 'acute neurological deterioration.||C.', 'co-', 'chronic Pain|Psychiatric pathology', 'normal coagulation test', 'vital signs', 'cerebral vascular accident (CVA)', 'Heart Association heart failure', 'Renal Impairment:||obstructive urinary tract diseases', 'complex congenital heart diseases', 'thoracoabdominal', 'cardiovascular diseases', 'risk of suicide', 'symptoms of infection', 'conjunctival pathology', 'chronic obstructive pulmonary disease).|Uncontrolled epilepsy', 'JIA', 'type 2 diabetes.|Subjects', 'thyroid function', 'ankle conditions', 'clear renal cell carcinoma', 'hypoglycemic event', 'MS exacerbation', 'optimal dosage.||', 'arrythymia', 'homeless', 'severe depression', 'monomorphic VT', 'fludarabine + cyclophosphamide', 'major cardiovascular diseases', 'idiopathic small fiber neuropathy', 'inguinal hernias|Surgeries', 'clinical laboratory parameters', 'rheumatologic conditions', 'good condition', 'palliative care.|Neurodegenerative', 'impaired renal function:||dehydration', '-pharyngeal swab', 'radiological pneumonia', 'C|Patients deemed unsuitable for enrolment by the investigator', 'local moderate amount of radiation therapy', 'Ulcerative Colitis;|Ability', 'chronic periodontitis;|Refusal', 'by||Mild dementia', 'cerebral embolism', 'infection related', 'renal stent', 'renal damage factors', 'DLBCL leg type', 'Measurable disease', 'acute ischemic stroke；|Time intervals', 'epileptic seizures,|lower extremity contractures,|botulinum toxin', 'vastus lateralis', 'Cypass', 'facial injuries', 'renal disease.|Considering', 'chronic medical condition/s', 'HCC|Occlusion', 'peroneal nerve lesions|Cognitive', 'asthma exacerbation event', 'occlusal carious lesions', 'acute urinary tract infection', 'deep occlusal decay', 'oligometastatic prostate cancer', 'Anovulatory cycles Pcos||', 'those therapeutically induced', 'systemic abnormalities', 'vasomotor instability', 'eligible.|Participants unable to undergo contrast', 'intracranial stenosis', 'physical condition', 'drugs abuse', 'nasal diseases', 'functional impact;|Known contraindication', 'detectable HIV RNA', 'localized non-melanoma skin cancer', 'unexcised tumors', 'recombinant human', 'cardiac atrial', 'introducing', 'venipuncture.|Acute illness', 'etc.);||Cardiac function', 'arteriovenous thrombosis', 'acute advanced diseases', 'of:||Gastroesophageal Reflux Disease', 'non-valvular atrial fibrillation|Scheduled minor bleeding risk procedure(s', 'Bowel', 'abnormalities on', 'lymphoproliferative disease', 'ISSNHL', 'non-aneurysmal causes', 'pregnancy check', 'inducer effects', 'seizure disorder;|diabetes', 'Health Questionnaire (PHQ-9)', 'congenital malformations', 'solid organ transplant;|Use', 'Spina Bifida', 'caregiver|No known allergy', 'known infection', 'mucous membranes', 'fructose intolerance', 'basal cell skin carcinoma', 'renal cell carcinoma', 'including:||malabsorption', 'CIC rearrangement', 'Lumbar medial branch block', 'schizoaffective disorders', ""Chron's disease"", 'tumor manifestations outside', 'Neuroendocrine tumors', 'orthopedic conditions', 'Unable to tolerate to fiber especially vegetables|Type 1 diabetes', 'various pathologies', 'hepatic impairments', 'extra-pulmonary TB infection', 'ophthalmic disease', 'high risk NHL', 'intestinal resection', 'AIDS-defining disease', 'pelvic floor prolapse', 'PTSD;', 'impact glycemic control', 'lung Inflammation', 'cardiac valvular disease', 'Primary liver cancer', 'T2-T3N2aM0', 'bronchus intermedius', 'Mitral Stenosis|Cancer', 'communication barrier|Having problems', 'bleeding time', 'multiple pregnancy', 'shock waves', 'dialytic support|Hepatic dysfunction', 'hypothyroidism||', 'coagulation indicators', 'AMS', 'malignancy.|Participant', 'neurological disorders beyond TBI|Having', 'RF', 'control|Not', 'colorectal cancer|Chemotherapy required|Measurable scannographic', 'combined diseases', 'hyperviscosity', 'thrombophlebitis', 'HIV infection.|Patients', 'pathological fracture', 'cardiovascular disease.|Uncontrolled', 'comatose', 'bronchial obstruction', 'midbrain', 'PARP inhibitors', 'Intent)|Any of the Suicidal Behavior', 'Acute renal failure', 'hematologic diseases', 'refractory disease|For', 'idiosyncratic reaction', 'Rett syndrome', 'long QTc syndrome', 'malignant disease|Enrolled', 'respiratory disease exacerbations', 'retinal vascular disease than DR|Refractive errors', 'oropharyngeal dysphagia', 'lumbar muscle', 'Complement deficiency', 'impaired motor function', 'primary nasopharynx', 'PIH macules', 'more)|From', 'locomotor system,|Neurological pathologies', 'painful spinal metastases', 'Plus lesions', 'unhealthy alcohol', 'death certificate', 'oral squamous cell carcinoma', 'Medical Conditions:||Participant', 'vascular occlusive diseases', 'lower extremity fracture', 'cauda equina syndrome', 'cohort 3|Have', 'malignant tumor pathology', 'RSS', 'cardiac diseases', 'mental health diagnosis', 'localized swelling', 'substance abuse)|If the risk of suicide', '4|Oligodendroglioma', 'paediatric renal tumour|A', 'speech impairment', 'present malignancies', 'critical issues', 'Leptomeningeal carcinosis', 'RMLO', 'restenotic target lesion', 'endocrine issues', 'hypertrichosis', 'non-compliant', 'breathing difficulties', 'hepatitis B (HBV) surface antigen (HBsAg)', 'rheumatoid arthritis|Active cardiovascular disease like congestive heart failure', 'H2RA', 'transitional facility', 'cerebral artery blood supply', 'pylori infection', 'myeloid sarcoma', 'meditation', 'gastrointestinal tract lesions).|Refuse', 'Chronic Diseases', 'acute inflammation|Lacking of', 'condyloma', 'thyroid-related disorders', 'distal clavicle resection|Patients with', 'solid foods', 'liver Qi stagnation', 'nCOV-19', 'abdominal malignancies', 'asthma exacerbations', 'skin involvement', 'lactose', 'diseases.|Unconscious', 'Chronic heart failure', 'chronic skin diseases', 'removal;|Colon resection', 'refractive stability', 'Carotid atherosclerotic stenosis', 'septal defect repair', 'poor coronary revascularization|Advanced', 'cognitive condition', 'bone disorders', 'refractory to', 'severity', 'potential damage', 'normal sensation', 'hepatitis C virus infection (HCV)', 'direct involvement', 'maternal uniparental disomy', ""primary Sjogren's syndrome"", 'MAOI', 'above|Ability to read', 'attention-deficit hyperactivity', 'traumatic brain damage', 'metastatic incurable malignancy', 'to:||Acute coronary syndrome', 'clinically stable', 'upper gastrointestinal surgery.|Patients allergic', 'abstain from sex', 'head circumference', 'cirrhosis|Moderate liver disease', 'referring pulmonologist|Not', 'conditions of the arms', 'individual safety', 'disease|Eastern', 'benign congenital hyperbilirubinemia', 'hepatitis B {known HBV surface antigen (HBsAg)', 'third degree atrioventricular block.|Severe', 'pleural fluid cytology', 'ascariasis|COPD', 'maxillary sinus atrophy', 'diffuse type gastric carcinoma.|Any', 'primary sleep disorder', 'recovered from the', 'included).||C. HLA-matched', 'reduced kidney function', 'fracture dislocation', 'home|Cognitive impairment', 'Echocardiography.|Active infection', 'cough bleeding', 'aneurismal disease', 'DEXA', 'renal affection.|Patients', 'electrolyte replacement', 'evolution|Refractory pain', 'non-infectious', 'allogenic bone marrow transplantation', 'somatic symptom', 'glucagonoma', 'malignant hyperthermia', 'HCV', 'arthropathy', 'permanent eyeliner', 'depression - substance', 'hepatitis|Hepatitis C virus', 'motor limitations|Mental impairment leading', 'thyroid disease|Kidney disease', 'hepatitis C;|Patients', 'Immunocompromised', 'renal abnormalities', 'congenital eye', 'hepatitis B virus (HBV) infection', 'vagus nerve|Severe pain', 'anastomosis)||Concomitant pancreatitis', 'above myocardial ischemia', 'gastrointestinal tract lesions).|Patients', 'tumor surgical resection', 'constant', 'CIS or|Ta/T1', 'clotting factors', 'polyneuropathy|Intolerance', 'Pericarditis', 'bleeding disorder;|Participation', 'prostate cancer.|Diagnosed', 'arrhythmia|Unstable angina pectoris', 'permanently sterilized', 'transient ischemic attach', 'severe exacerbation', 'chronic medical condition', 'nasal antihistamines', 'definition Active disease', 'hypercalcemia|Neurodevelopmental disabilities of the LAR/Parent/Guardian/Caregiver', 'brow lift', 'oncological pathology', 'Eczema', 'head and neck squamous cell carcinoma (HNSCC)', 'reverse)|osteoarthritis', 'Multiple surgeries', 'cosmetic products', 'self-harm behaviors|Cognitive impairment', 'metabolic endocrine disorders', 'craniospinal XRT', 'annuloplasty rings', 'biodegradable facial tissue augmentation therapy', 'kidney injury;|Patients', 'esophageal cancer;|The', 'depressive syndrome', 'month.||Lymphoplasmacytic Lymphoma', 'non-small cell lung cancer.||Phase II', 'liver lesions;|Patients', 'neuropsychiatric diagnosis', 'stimulants|Active infection', 'maintenance', 'fecal incontinence', 'Acute Lymphoblastic Leukemia', 'ELIGIBILITY', 'phospholipid syndrome', 'CKD stage 5', 'hematopoietic system', 'complete data|patients', 'tobacco use disorder only', 'chlamydia', 'exposed bone', 'familial history of', 'epilepsy|Vulnerable populations', ""Alzheimer's disease.|Patients"", 'gender；|Esophageal cancer', 'curative intent', 'spinal deformity', 'density', 'viruses|Active bacterial', 'disorder of blood cells', 'cannabis|Children', 'intracardiac thrombi', 'destructive osteitis', 'psychiatric illness,|Volunteer', 'divercation of recti', 'complaint of neck', 'phantom limb pain', 'active pneumonia', 'pre-randomization screening labs drawn and study protocol', 'before||', 'refractory/relapsed', 'irregularity', 'transverse neck lines', 'pT1)||', 'paroxysmal nocturnal hemoglobinuria', 'been stable', 'corneal thinning', 'trait anxiety', 'Target lesion', ""Gilbert's syndrome"", 'limb|Malignant diseases', 'dry eye disease', 'acute COVID-19 infection;|COVID-19 pneumonia', 'language', 'SBP', 'Pure tone', ""Waldenstrom's macroglobulinemia"", 'thrombotic disease', 'coeliac disease', 'mixed hepatocellular carcinoma', 'conjunctival', 'HER2-targeted monoclonal antibodies', 'common variable', ""fibrosis|Wilson's disease|Hepatocellular carcinoma|Known"", 'potential cystic', 'pulmonary disorder|Any autoimmune', 'antiviral treatment;|Renal dysfunction', 'well.|Pre-treatment score', 'sexual activity', 'primary lung diseases', 'neural disorders', 'significant alcohol', 'rescue breathing', 'guidelines|Lack of', 'focal neurological deficit', 'intractable radiculopathy', 'renal transplant', 'postmenopausal', 'epileptic', 'severe conditions', 'signs of symptoms', 'third degree heart block', 'breast cancer cells', 'hematopoietic bone marrow volume', 'unresectable squamous cell carcinoma', 'acute lung disorders', 'acute promyelocytic leukemia.|Radiologically-detected', 'AOSD.|Active disease', 'HBV(Hepatitis B Virus', 'diagnosis|Uncontrolled hypertension', 'hypopharyngeal carcinomas', 'rhenium-186', 'acute changes', 'ERCP pancreatitis', 'delirium tremens.|Physical', 'anatomical landmarks).|LAS copers', 'metabolic bone disease|Metabolic', 'third trimester', 'third molars).|Good oral hygiene|protrusion cases', 'cT1a mass', 'isolated extramedullary', 'autoimmune-associated', 'Perinnial allergic rhinitis', 'eye|Uncontrolled glaucoma', 'episodic migraine.|The', 'Hepatic', 'intrapartum hypoxia', 'rhabdomyolysis||Concurrent ocular', 'life expectancy|Pulmonary embolism', 'scorable facial', 'alcohol behavior', 'B-cell lymphoma|high-grade', 'weeks|Pregnancy', 'systemic pathologies', 'Cheng', 'comorbid disease (infection', 'ischemic diseases', 'electrocardiographic abnormalities', 'RET fusion', 'congestive heart failure', 'above||', 'haematopoietic disorder', 'skin irritations', 'non-isolated tricuspid valve surgery', 'Histoplasma capsulatum', 'increased albuminuria', 'agranulocytosis', 'rheumatic conditions', 'thromboembolic concerns', 'cardiovascular diseases.|Prior allogenic', 'sulphonyl urea', 'consent|Post-stroke', 'fatal disease', 'value|HIV infection', 'eye conditions', 'CMV viremia', 'pathological lesion', 'Temporomandibular Disorder', 'chronic diseases;|Contraindications', 'oesophageal carcinoma', 'age)|Thrombocytopenia', 'severe psychological problems', 'intestinal biopsies', 'Black', 'squamous cell carcinoma of the skin', 'abuse.|Pregnant', 'coronary interventions', 'Lunit Inc.', 'submucosal fibroids', 'congenital deficiency', '/eczema', 'chronic autoimmune condition', 'hyperglycemic-hyperosmolar state||ii', 'ocular pathology', 'vestibular diseases', 'age;|Screens', 'lupus|Vasculitis', 'restrictive bariatric surger', 'surgical margin status', 'renal dysfunctions', 'developmental conditions', 'Aneurysm', 'poor-risk', 'health care', 'subglottic stenosis', 'systolic dysfunction', 'spondylarthritis;|scoliosis', 'dermatological manifestations', 'superficial non-invasive bladder tumors', 'contemplation', 'contagious skin diseases', 'hemodialysis|Women', 'non-invasive basal', 'haematological disorder', 'hyperpolarized xenon-129 MRI.||', 'autism', 'etc.).|Cognitive impairment', 'cerebrospinal fluid culture', 'aspiration pneumonia', 'cornea lesions', 'uncontrolled autoimmune phenomenon', 'mild cognitive impairment|females', 'paranoid personality disorder', 'joint disorder', 'TEEs', 'metabolic encephalopathies', 'poor general condition Coagulation dysfunction', 'meningitis', 'bleeding disorders', 'dexmedetomedine.|Neuraxial anesthesia.|Cardiovascular disease', 'sitting time)|Body mass index [BMI]', 'ovarian cystectomy', 'third molars)|Normal salivary flow||', 'coronary atherosclerotic heart disease|The', 'vascular hemophilia', 'bipolar related disorders', 'pain sensitivity', 'macular degeneration.||', 'RP Disease', 'Overweight', 'hopeless teeth|Patients on analgesic', 'hepatitis B virus surface antigen (HBsAg)', 'maternal mirror syndrome', 'Year|Transfer', 'heart burn', 'Basedow disease', 'ischemic cerebral vascular accident', 'hemorhagic hemiplegia||Brunnstrom upper extremity motor stage', 'lack of', 'Skin reaction', 'non-melanoma basal cell carcinoma', 'tracheal intubation.||', 'infection with', 'Squamous Cell', 'visible lesion', 'atrial shunt', 'clinical reference assessments', 'Ocular criteria:||Co', 'infections common terminology criteria', 'HBsAg(+', 'acute GVHD', 'isolated metastasis', 'glucose-6-phosphate dehydrogenase deficiency', 'HTN)|ELE', 'central vein', 'arrhythmias.|Primary cardiomyopathies|Significant pulmonary disease', 'C|Vital signs may', 'neurological pathologies', 'BAI).|report', 'uterine anomalies', 'TIA|Untreated thrombosis', 'major thoracic deformities', 'T2D||Renal impairment', 'fibrosis', 'fluorescence in situ hybridization (FISH) testing', 'superficial mucosal cancers', 'keloidal tendency', 'Renal insufficiency|Clinical diagnosis', 'lower limb stenosis', 'nosebleed', 'abdominal wall configuration', 'calculated by the Cockcroft-Gault equation.||-||', 'circulatory disease', 'cognitively capable', 'sleep apnea symptoms', 'Nonalcoholic steatohepatitis', 'acute diarrhea', 'generalized anxiety disorder|Current', 'maternal cardiorespiratory arrest', 'subacromial', 'diabetic neuropathy,|Active otitis', 'wheat', 'postpartum nursing', 'liver metastases)|Total bilirubin', 'consciously have long COVID-19 symptoms', 'baldness', 'lateral internal sphincterotomy', 'multiple injuries).|Multiply', 'coagulation abnormalities', 'biochemical recurrence following American Urological Association', 'Province)|Chronic stroke', '70%|Measurable disease', 'ICD-9 172.x', 'endodontic failure', 'dementia|Traumatic Brain Injury', 'infiltration of lymphocytes', 'otitis media,|the ability', 'nonischemic heart disease', 'residual thrombocytopenia', 'reproductive capacity', 'severe diabetes', ""Willebrand's disease"", 'systemic illness;|Novice', 'traumatic brain', 'atherosclerotic heart', 'LTBI', 'congenital metabolic disease', 'psychotropic substance abuse', 'inadequate response', 'extra hepatic portal vein obstruction', 'significant hypersensitivity', 'celiac disease|patient', 'chronic pancreatitis|Symptomatic gallbladder', 'focal neurological deficits', 'treatments', 'CSF', ""type 2)|Bachelor's degree or higher level"", 'gingival trauma', 'gastric ulcer disease', 'head trauma with loss of consciousness', 'characteristic radiographic abnormalities', 'organ involvement', 'acute coronary syndrome|Decompensated', 'NYHA classification);|uncontrolled hypertension', 'lateral sclerosis', 'Covid symptoms', 'chest infection', 'metastasis;|Inability to swallow', 'infection|Server liver', 'immune compromised', 'systemic amyloidosis', 'risk of involvement on', 'aspergillus disease', 'S6 segmentectomies', 'chronic hepatitis B (HBV)', 'SEP', 'congenital malformations|Antibiotic treatment', 'traumatic brain injury;|Comorbidities', 'treated carcinoma', ""Behcet's disease"", 'functional asplenia.|Active duty', 'cardiac insufficiency class', 'adequate bone marrow', 'good medical health', 'hepatitis B virus [HBV] surface antigen positive', 'infective treatment;|Allergic constitution', 'Rheumatoid arthritis', 'lung infection', 'optic disc', 'metastatic brain lesions', 'recurrence of prostate cancer', 'distal internal carotid artery beyond the bulb', 'HNSCC', 'psoriasis.|History of disease stimulated', 'Habitrol', 'restrictive lung disease|Exercise', 'of the disorder', 'vegetables', 'associated toxicity leading', 'inactive toxoplasmosis', 'prothesis', 'blindness|Patients', 'Healthy adult', 'patellofemoral pain', 'TPPV', 'correct', 'anaplastic oligodendroglioma', 'chronic kidney disease (CKD,', 'Atrial flutter treated', 'end-stage Acquired immunodeficiency syndrome', 'cured.|Skin cancer', 'chronic limb pain', 'major event', 'generalized pain', 'pulmonary atresia', 'access|Able to read', 'prolonged QT-interval.|Current treatment includes', 'metabolic syndrome).||Gastro', 'Adverse Events V5.0', 'feasibility study|RCTs randomising animals', 'black female|Not', 'renal functions', 'distant metastasis;|Active autoimmune diseases', 'tympanic', 'intracranial hypertension symptoms', 'pelvic fractures', 'initiative|Suicidal ideation', 'study|Self-report', 'buccal cancer', 'stroke onset|Arm impairment', 'involvement of the pericardium.|Age', 'Africa', 'liver diseases.|Body mass index', 'refractory to standard treatment', 'vascular tortuosity', 'weight-loss drugs', 'juvenile rheumatoid arthritis', 'congenital dental defect', 'affective disorder', 'colonic adenocarcinoma', 'avoidance of musical performance situations|Reporting psychological distress', 'renal transplantation|Both', 'swollen joint (', 'sarcomatoid bladder cancer|Distant metastatic carcinoma', 'myeloma', 'alterations conferring', 'subarachnoid', 'prevent polyps', 'dose|Functional NET', 'human immunodeficiency virus (HIV)', 'chronic intestinal disease', 'alternative condition', 'serious diseases；|Infection', 'idiopathic juvenile osteoporosis', 'digital pressures', 'buttock', 'anaplastic lymphoma kinase (ALK) fusion', 'chronic pain syndrome', 'heart block', 'sarcoma', 'bilateral musculoskeletal pain', 'hepatitis B virus(HBV)', 'enrollment;|Active infections', 'hemodynamically stable', 'lentigo maligna', 'infection;|Active hepatitis B', 'natural food colourings', 'trifascicular block', 'acute respiratory tract infections||', 'mild blepharitis', 'tuberculosis;|Pneumonitis', 'upper gastrointestinal hemorrhage', 'nodal stage', 'heart beat', 'solitary lesion', 'immune deficiency|History of cancer', 'Cisgender', 'have:||A stable', 'Acute Coronary Syndrome (ACS)', 'breast cancer.||', 'vasovagal collapse', 'metastatic adenocarcinoma', 'neuroglycopenic symptoms', 'root coverage procedures', 'colorectal tumors;|Preoperative imaging reveals', 'bags.|One-sided', 'local regulations.|Female', 'major root', 'sleepiness', 'thoracic surgery.|Patients', '2021|Other malignancy', 'benign or resectable', 'bladder storage symptoms', 'inspection indicators', 'memory complaints|demanding clinical consultation', 'heart implants|require a hearing aid to hear properly|claustrophobia|metal fragments', 'mental disability', 'prostatic involvement', 'surgical events', 'folate metabolism disorder|Caregiver', 'rumination', 'breastfeeding.|3', 'anticoagulation therapy|Pregnant', 'auto-immune disease', 'Postoperative neuropathy', 'posttraumatic', 'brain metastasis|Patients', 'autonomic dysfunction', 'abnormal skin sensation', 'indication;|Clinical signs of neuropathy', 'refractory AML', 'cerebral hemorrhage', 'primary diseases.|Allergic to the ingredients', 'acute depression', 'primary stability', 'ophthalmic symptoms', 'effective cough', 'intracranial hypertension', 'herpes simplex', 'eye tumors', 'malformations', 'bowel', 'bidirectional shunts.|Patients', 'Infection|pregnancy|allergy', 'amoeba', 's/p', 'calm', 'extensive bowel resection', 'renal tumour|Urothelial cancer|End', 'communication problem|Having', 'neurological disorders|Implanted', 'Coagulation/bleeding disorder', 'short QT syndrome', 'non-encephalitis disorders', 'germander', 'derivatives.|Only applicable', 'genetic therapy;|7.The proiferation', 'molluscum).|Had', 'traumatic brain injury/head injury', 'dyspnea after direct chest trauma', 'genetic disease', 'NSTEMI).||Cardiogenic Shock', 'Vasovagal Syncope', 'allowed.|Neuromuscular disorder', 'December 31', 'Normal hearing thresholds', 'unexplained symptom|Previous illness', 'revascularisation of', 'good compliance;|Healthy', 'primary burn', 'injury|Training', 'extra-articular manifestations', 'parasites', 'primary valve disease', 'vestibular schwannoma', 'criteria of CSVD', 'resulted', 'seborrheic blepharitis)|Have eyelid abnormalities', 'middle cerebral arteries', 'resected skin cancers', 'cosmetic', 'anal fissure symptoms', 'mmHg),|Not being obese', 'lumbar spine surgery|Progressive', 'RTX.|Active cutaneous disease', 'Complete left bundle branch block', 'cognitive frailty', 'clinically serious', 'structural brain lesion', 'vaccine injury', 'natural health', 'peripheral neuropathy|liver disease', 'signing', 'Suicidal Behavior', 'residence making', 'suicidal tendencies;|Pregnant', 'Disseminated Intravascular Coagulation', 'non-loop diuretic aside from aldosterone antagonists', 'patients|bruxism', 'sensorineural hearing loss', 'mitral stenosis;|14.9', 'deep vein stenosis|A', 'intestinal polyps|Known', 'colon by', 'intrahepatic recurrence', 'liver diseases|patient refusal|substance', 'hydrodissection cervical', 'Trans', 'secondary cause of hypertension|Anatomy', 'infection|Normal bone marrow', 'biliary disorder', 'cardiac surgeries.||Refusal of parents.|Ischemia', 'low back pain.|Having reached', 'anti- arrhythmia', 'cancer|Diagnosis', 'hematological malignancy', 'keratinocyte carcinoma', 'thyroid disorders', 'non-culprit coronary artery lesion', 'diabetes|Diagnosed insomnia', 'brain tumor multidisciplinary committee', 'suprachoroidal hemorrhage', 'recovered.||', 'placenta previa|Clinical diagnosis', 'cardiac abnormalities', 'pulp stones.|Root dilacerations', 'Anxiety Disorders', 'mRECIST standard;|Liver function', 'autoimmune thyroid', 'Nulliparous PCOS', 'CKMB', 'acute liver failure.|Participants', 'torsional ventricular tachycardia', 'AND|who required ionotropic support', 'venous thrombosis', 'enhancement lesions', 'hyperactive coagulation states', 'cardiac pathology', 'gestational hypertension', 'anti-tumor therapy', 'hepato-cellular carcinoma', 'third gender', 'midfoot', 'Reversible causes', 'acute myocarditis/pericarditis', 'brain stimulators', 'Type 2 diabetes mellitus|Obesity', 'maternal concerns', 'Novel Coronavirus Pneumonia', 'cranial epidural disease', 'rheumatism immune system disease', 'ACTH-dependent', 'disease|Symptomatic', 'sudden hypotension', 'autoimmune diseases;|Lactating', 'smokers|Alcohol abuse', 'computer|Can read', 'concomitant eye disease', 'autoimmune-associated uveitis', 'head or neck', 'ischemia of the lower extremity', 'non-mRNA COVID-19 vaccine', 'valvular vegetations', 'criteria of the eleventh edition of the International Classification of Diseases of the World Health Organization', 'anticoagulation||xii', 'transient detectable viremia', 'uncontrolled illness', 'brachytherapies', 'pre-/perimenopausal', 'attention disorder', 'RV strain', 'carcinoma in situ of the cervix.|Prior endocrine therapy', 'breastfeeding|Very dry', 'oligometastatic bone disease', 'coagulopathic disorder', ""doctor's advice of any other medical"", 'undifferentiated carcinoma', 'liver disease||C', 'physical signs of disease', ""Takayasu's arteritis"", 'generalized malignancy', 'asthmatic disease', 'co-occurring KIT', 'cortico-nuclear', 'metabolic', 'pose a risk from heating', 'obstructive sleep apnea syndrome', 'ISS', 'Type 2 diabetes mellitus', 'hip replacement', 'physiological condition', 'cardiac rhythm disorders', 'haemochromatosis', 'parasitic', 'antibody.||Female', 'UTIs|Severe skeletal malformations', 'progressive disease.|Prior palliative radiotherapy', 'delirium', 'congenital immunodeficiency conditions', 'Local anesthesia.|Patients', 'horizontal head rotation', 'controlled infection', 'cephalic.|Chronic kidney disease', 'middle cerebral artery M1', 'atopic dermatitis', 'reflex motor signs deficits|previous', 'states', 'prolonged QTcF interval', 'metformin.|Diabetic patients.|Cancer', 'neurological deficits trauma|pregnancy', 'food sensitivities', 'suffers from diseases of the blood', 'chronic hepatic failure', 'mentally healthy', 'neurodevelopmental difficulties', 'magnesium', 'structural pathology', 'STK11|Men', 'paracentesis|hepatic encephalopathy', 'carbohydrate absorption', 'carcinoma in situ cervices uteri', 'excessive thrombus', 'micro-calcifications;|The', 'renal disease|pregnancy|lack of', 'extensive-stage SCLC|to', 'aspergillosis|COPD', 'liver viral disease', 'axillary temperatures<37.3°C/99.1°', 'mild pain', 'Humoral/B-', 'pain relief', 'congenital eye diseases|errors of refraction|lens opacities|low-quality OCT', 'DVT)|Pulmonary', 'confirmed auto-immune type 1 diabetes;|absence', 'uterine cancer||a', 'criteria of activity', 'febrile diseases', 'intense cold', 'cervical stenosis', 'acute bleeding|Patients', 'Health Fairs', 'liver disease,|history', 'diastolic', 'stereognosis', 'diabetes mellitus|Unable to', 'acute condition', 'genetic problem', 'neck disease', 'Anorexia', 'last|Inability to swallow a tablet', 'year.||Pericarditis', 'liquid stools/d).|Self-reported', 'medulloepithelioma', 'pulmonary disease', 'interstitial lung disease|Diseases', 'Primary brain tumor', 'tumor pathological examination', 'dry syndrome', 'obstructive airway disease', 'recovery plasma', 'thyroid papillary carcinoma', 'Risk factors', 'medial deltoid', 'Liver Dysfunction', 'previous neuropathy', 'gastrointestinal inflammation /ulcer', 'anaphylactic reactions', 'calcaneal fracture|Open reduction Lisfranc/metatarsal', 'arrhythmias;|noncardiac factors', 'hockey', 'SMARCB1-deficient renal medullary carcinoma', 'reduced ejection fraction', 'major cognitive impairment.|BMI', 'premenopausal', 'infected bronchiectasis', 'non-communicating hydrocephalus', 'back pathology', 'bariatric surgery|Emergence', 'postoperative ventral hernias', 'chronic obstructive pulmonary disease', 'hepatitis C. Screening for chronic conditions', 'Serious basic diseases Intolerable surgery', 'type 9 (PCSK9) inhibitor', 'cholecystitis', 'Cerebrovascular disorders', 'brain diseases', 'impact on the', 'middle cerebral artery', 'substance use disorder of', 'women|Critically ill', 'hepatitis C;|Positive', 'seizures|Pregnant', 'hemorrhagic ulcer', 'required;|150 mmHg', 'S3-guidelines', 'Comorbidities', 'progressive NET|Prior treatment', 'thoracic aortic aneurysms', 'systemic complications', 'intracranial mass', 'females.|smokers.|systemic disease', 'associated hypertriglyceridemia', 'early cord', 'erythrodermic psoriasis', 'dysnatraemia', 'organic gastrointestinal disorder', 'active cancer', 'malignant', 'days)|Good general health|Able', 'DRFs|Multiple trauma', 'idiopathic scoliosis.|They', 'rare histologic HCC', 'constant diplopia|Documented evidence', 'Kartagener syndrome', 'spinal surgery|Having', 'impending herniation', 'capacity', 'somatic diseases', 'serous retinopathy', 'significant smoking', 'choroiditis', 'plot ROI', 'type 2 diabetes mellitus|No DR', 'Professional athletic Smoking', 'aversion', 'difficulty breathing.|Risk factors', 'disseminated intravascular coagulation;|Active hemorrhage;|Uncontrollable infection', 'sleep disorder', 'Secondary Caregiver):||Has', 'disease recurrence', 'valgus/varus deformities', 'pain group:||recent injury', 'glioblastoma|Genetic disorders', 'CKD)|Malignancy|Chronic infection', 'attention deficit', 'TORCHES infection', 'indicates', 'Siewert', 'pathological causes|deep', 'multi-parametric magnetic resonance imaging|Gleason score≤', 'metabolic diseases', 'progressive lesions', 'skin ulcers', 'active angina', 'self-harm|Symptoms', 'breast cancer;|A', 'axis activity', 'gynecological diseases', 'poor peripheral circulation', 'SPECT', 'poor drug control', 'non-conservative', 'language interpreter required', 'pulmonary metastases', 'Clinically stable', 'dysfunction of the liver', 'situations judged by the investigator', 'amenorrhea.|Chronic inflammatory condition', 'old;|Acute ischemic stroke', 'disease;|Antitumor', 'neurotypical development|between', 'caries;|Children', 'Hemodynamically instability', 'hypocalcemia', 'myocardial disease', 'Questionnaire)|Serious cognitive impairment', 'cardiovascular disease,|5d', 'Spanish|ability', 'hepatitis B immunoglobulin', 'hodgkin lymphoma', 'normal|Allergy', 'chronic hepatitis treated', 'dyspigmentation', 'upper airway tumors', 'criteria for', 'neurological symptoms attributable', 'nested', 'emales', 'heart block|Off-pump CABG', 'peripheral neuropathy', 'chronic physical disease', 'hypogammaglobulinemia', 'ill', 'terminal illness|Patients', 'thrombotic target lesion', 'wrist extension', 'type II Mobitz', 'Glucotrol', 'moderate renal impairment', 'soft tissue involvement', 'ocular media', 'alcohol use disorder.|Lifetime diagnosis', 'co-twin', 'chronic kidney disorders', 'myelodysplastic syndromes (MDS)', 'Renal Cell carcinoma', 'Physical conditions', 'lichenoid contact reaction', 'hepatitis C', 'AIDS])|Active infection', 'significant abnormality', 'virus hepatitis', 'neurological disease|Rheumatological disease|Malignant disease|Previous spinal surgery', 'cyclosporine eye-drops 6weeks', 'unable to tolerate venipuncture', 'Myocardial Infractus', 'native superficial femoral', 'cortico-visual', 'common cold medicine', 'Hispanic|Diagnosis', 'venous disease', 'pre-diabetes', 'FEV1 ≤ 50%;|dyspnea', 'humanized antibodies', 'dermabrasion', 'medial temporal lobe atrophy scale', 'ideation', 'upper limb impairment', 'liver cirrhosis|White blood cells', 'regular health insurance||', 'diabetes mellitus.|Emergency conditions', 'program.|Ability', ""Wegener's Granulomatosis"", 'acute pathologies', 'cancers)|Lack of consent', 'systemic anticancer treatment', 'colorectal cancer screening', 'clotting disorders|Uncontrolled hypertension', 'silicone|Terminal medical condition', 'familial amaurosis', 'background', 'Acute Cystitis', 'renal parenchymal', 'teria', 'traumatic family events', 'lightheadedness', 'unknown HIV status|Bacterial STI', 'postoperative complications', 'ITP', 'in situ carcinomas', 'Bipolar Affective disorder', 'non-melanoma skin carcinoma', 'acute haemorrage', 'hepatocellular cancer||5-patients', 'ischemia-driven', 'gastric/intestinal motility', 'extramedullary leukemia', 'communication problems', 'Persistent hypertension', 'myelopathy', 'periprosthetic fracture', 'adenopathy|Tumor stage T1', 'tuberculosis', 'premature ovarian failure', 'neurological impairment', 'inconvenient to take care of themselves', 'good communication', 'malignancy outside head and neck region', 'tuberculosis infection;|11)Patients', 'common variable immunodeficiency', 'interstitial lung', 'organ transplantation;|Poor diabetes control', 'endometriosis|Polycystic ovaries syndrome', 'endotracheal suctioning', 'hepatitis B virus infection', 'intubated', 'physical XM tests', 'fetal abnormalities|Inability to communicate', 'cerebritis', 'positivity by FISH', ""College London's Queen's Square"", 'Respiratory', 'non-dominant', 'bedside nurses', 'serosal effusion', 'penile-vaginal penetration.|Please note', 'abnormality|Fetal congenital infection', 'renal impairment function qualifications', 'water stop""', 'disc disease', 'above|Normally resides', 'root fracture', 'CHARGE syndrome.||', 'cultures developed', 'allergy;|Psychiatric comorbidities', 'inflammatory spondyloarthropathy', 'hepatitis C|Known clinically significant', 'nephritis', 'SUD)|Diagnosis', 'illnesses;|Diabetes mellitus', 'isolated cancers', 'comorbid diseases', 'end-stage renal disease|operated patients', 'hyperglycemic hyperosmolality', 'acute myocardial infarction', 'gastrointestinal tract', 'vitamin deficiency', 'cognitive difficulties', 'upper urinary tract urothelial cancer', 'd-TGA post', 'thromboembolic disorders', 'congenital coagulation disorders', 'limitations', 'end stage hepatic', 'aortic insufficiency', 'glabellar wrinkles', 'impairment|Preterm', 'nutritional risk', 'alopecia', 'reversible causes', 'cervicovaginal specimens', 'NIPPV', 'POEMS syndrome.|Symptomatic', 'period;|Human immunodeficiency virus', 'isolation|Ophthalmologic impairment of prematurity', 'squamous epithelial cell skin cancer', 'musculoskeletal pathologies contraindicated', ""or|Ménière's disease"", 'spinal cord compression|Uncontrolled', 'alcohol dependence;|Female', 'underlying disease', 'hyperpurine', 'lost response', 'renal functions.|Eastern', 'acting appetite suppressants', 'spinal manual', 'Wilms tumor', 'enteritis', 'adequate standard treatment', 'months;|chronic heart failure', 'replacement therapy|Stable diabetes mellitus', 'etc.);||Male', 'carcinoma in situ of the cervix);|history', 'additional neurologic condition', 'diabetes - HbA1c', 'gastrointestinal bleeding.|Abnormal clotting function', 'menstrual period|Desires', 'previous burns', 'extensive alopecia', 'stimulating factor therapy', 'correlative research.|REGISTRATION', 'limit static', 'Adjuvant cohort', 'spinal ankylosis', 'hepatic disorder', 'schizophrenia', 'acute interstitial pneumonia|Any condition', 'impaired organ perfusion', 'sudden death.||4', 'ischemic events', 'days);|brain metastases', 'spastic', 'herpes zoster infection', 'suboptimal SVS quantification', 'AST', 'compressive radiculopathy', 'Multiple pregnancies', 'evidence consistent with active', 'drug therapy.|A high', 'metabolic disease|Clotting', 'MDE', 'central events', 'pre-treatment', 'newborn|Weight', 'synbiotics supplement', 'congestive heart failure,|unstable angina', 'fistula.|Elective procedures.|Pregnancy', 'Lapp lactase deficienct', 'T2 Flair', 'hypertrophic heart disease', 'tumor flare', 'Reverse Total Shoulder Arthroplasty', 'medical illness.|Active infection', 'respiratory condition', 'good health absent', 'cervical cancer in situ', 'participants|Body mass index', 'investigating centres|Need', 'extensive facial', 'clinically controlled', 'tumor mutational burden', 'middle ear inflammation', 'senile dementia', 'Fibromyalgia', 'inflammatory arthritis of spine|Severe bone conditions', 'localized gingival/mucosal', 'adverse reaction assessments', 'researchers', 'compulsory detained', 'free of', 'tumour sample', 'exposure keratitis', 'ipsilateral axillary nodes', 'thin skin', 'Lewy body disease', 'inflammatory bowel disease.|Patients', 'Complex Super Flavonoids Super Antioxidants Quercetin Supplement Essential-C', 'simple bone metastasis', 'clinical osteoporosis', 'allergic', 'Cauda Equina', 'cardiac shunt', 'narrow spinal canal|Hemostasis abnormalities', 'neurological disorders capable', 'continuous positive', 'criteria|Clinical Dementia', 'contraindicates contact lens', 'thoracic RT', 'renal involvement|thrombophilia|BMI', 'Visit 2)|Unable', 'peripheral nerve injury', 'neurodegeneration', 'limbs.|oliguria', 'significant alcohol abuse', 'tuberculosis (TB positive);|Subjects', 'mellitus type', 'judicial order.|Is under the age of legal consent', 'post-eruption destroyed|The', 'transient ischemic attack|Uncontrolled hypertension', 'stimulant ADHD medications', 'criteria international classification', '17p deletion', 'severe pulmonary diseases', 'chemotherapy;|Mental illness', 'lactating;|Psychiatric disorder', 'prolonged signs', 'radiotherapy.|Autoimmune diseases', 'mechanical hemodynamic support|Need', 'conditions related to glycemic disorders)|hypertension', 'difficulty collecting normal', 'systemic infection', 'judged by clinicians to be clinically significant;|Subject', 'renal damage', 'psychological disorders.|Fibromyalgia', 'end-stage renal diseases', 'extensive left atrial ablation', 'hemorrhagic disease', 'Healthy Controls:||Healthy', 'immunodeficiency syndrome.|Known asplenia', 'vaginal sponges', 'rhythm disturbances', 'pre-melanoma skin lesions', 'LGD', 'child- bearing potential', 'drug-eluting balloon', 'myeloid malignancies', 'ipsilateral cervical rotation', 'in situ bladder cancer.|History', 'gastrointestinal malignancy|Locally', 'diabetes|Fetal chromosomal/structural', 'intraocular lymphoma', 'Healthy volunteers:||use', 'Primary tumor', 'atrophy', 'Chickenpox', 'degenerative central nervous system (CNS) disorder', 'plaque psoriasis lesion', 'functional abnormalities', 'autoimmune', 'Oklahoma', 'reversible factors;|Left atrial appendage depth', 'pathogenic BRCA', 'ankle fractures', 'traumatic pancreatitis.|Primary pancreatic tumors', 'coagulation factors', 'face lift', 'needles|Active skin', 'Gastrointestinal dysfunction', 'immunocompromised state', '1;|Hepatocellular carcinoma', 'latent tuberculosis;|Hepatitis', 'upper gastrointestinal surgery.|Diabetes type', 'dystrophies)Any proliferative diabetic retinopathy', 'completed curative treatment', 'gastric variceal bleeding', 'central serous', 'upper extremity occlusive peripheral vascular', 'platelet transfusion', 'colonic eosinophilia.|Patients', 'Parkinson Disease', 'unrealistic expectations.|Severe bruxism', 'DSM-5);|Insomnia symptoms', 'Multi-limb trauma', ""idiopathic Bell's palsy"", 'myocarditis', 'mCSPC', 'pupillary reflex present', 'deep injection of', 'childbearing potential.|Age', 'spinal cord hemorrhage', 'as:||Unstable angina', 'postoperative inflammation', 'cystic echinococcosis', 'diseases|Peripheral lung cancer involves', 'angiography.|Ability to swallow oral tablets', 'normal organ', 'rare disease', 'vision changes', 'infliximab', '1;|Colorectal cancer', 'irregular astigmatism', 'kyphosis', 'weight-loss', 'carcinomatous meningitis.|Prior treatment', 'visible corneal scar', 'craniofacial syndrome', 'abdominal hernia|Diabetes|Severe Hypertension', 'Virologic failure', 'febrile neutropenia prophylaxis', 'vasculitis', 'acoustic stimulation', 'uncontrollable seizures', 'chronic dialysis.|Bleeding disorders', 'alcohol breath test;|Subjects', 'cesarean section|Single birth|giving birth', 'therapy.|Human immunodeficiency virus', 'radioembolization', 'Renal disease', 'congestive heart failure|Unstable angina', 'hypertension|Plastic surgery involvement', ""Behçet's Disease"", 'HF', 'transient stroke', 'active obstructive', 'arthrofibrosis', 'kidney disease', 'neurological problems|newborn-mother pairs', 'stress', 'traumatic brain injury|History', 'obstructive atherosclerosis', 'non-TNFi biologic disease', 'acne', 'involvement of the brainstem', 'sexually active)|mental status alteration', 'Black African', 'Infection', 'Access', 'cerebrovascular disease|Adult', 'child.|Active carious lesion.|Labial', 'drug-induced pneumonitis', 'skeletal dysplasias', 'BFRT', 'Open wounds', 'Unilateral acute stroke', 'colonic dysplasia', 'FSHD1', 'age|Participants', 'tumour lesions', 'acute ischemic stroke|Imaging examination', 'partial denture', 'visual impairment', 'solid tumor disease', 'reactive airway disease', 'neuroblastoma', 'B12', 'grunting).||Exclusion', 'cheloids;|Allergy to device components;|Immune system', 'steroid myopathy', 'loco regional interstitial pneumonia', 'Follicular non Hodgkin lymphoma', 'not.|Blood clotting disorders', 'common femoral artery surgery', 'Multiple gestation', 'clear suicide plan', 'collected analgesic-free.|Subject', 'adenomas|Type 1 diabetes', 'anticoagulants|active intravascular coagulation', 'lenses|Diagnosis', 'Type 2 Diabetes Mellitus;|Self-managing', 'Heart Rate (HR)', 'ECG abnormality', 'bleeding risk factor', 'congenital abnormality', 'cardiogenic shock', 'diarrhoea', 'panhypogammaglobulinemia', 'nonhematologic toxicity', 'basal septal hypertrophy', 'hospital cardiac arrest', 'kidney impairment', 'folate', 'cardiac dysfunction', 'dermatomyosclerosis inflammation', 'judged by the investigators to be ineligible for this study for', 'ocular pathologies', '0.00D', 'brain lesion', 'solid organ transplant|Medical', 'functional cardiac imaging scan', 'clinical necessity', 'vulnerable', 'hematopoietic growth factor treatment', 'malignant lymphomas', 'tumor diseases.|Diseases', 'uni-', 'national Track', 'solid organ transplantation|Use of any investigational agent', 'extensive early ischemic change (', 'cerebrovascular lesion', 'serious disease', 'dialysis', 'benign premature ventricular', '50 kilometers', 'recurring fistulas', 'delayed hypersensitivity reactions', 'hepatitis B infection', 'multicentric breast cancer lesions', 'Assiut university heart hospital', 'primary care clinic', 'coronary thrombosis', 'exception of alopecia', 'structural abnormalities', 'Neurologic condition', 'Language troubles|Disability', 'gastrointestinal fistulae', 'septic', 'SITA Faster).|Glaucoma definition', 'axial arthritis', 'coke', 'diabetic retinopathy', 'hemodiafiltration|No', 'Diverticulitis', 'psychotic state when', 'restrictive lung disease', 'desaturation', 'androgen-secreting tumors', 'brain', 'symptoms', 'localized Gleason 6 prostate cancer', 'communication barriers', 'removed)|Mental health disorders', 'generalized osteoarthritis', 'neurotoxicity', 'substance use|HIV', 'for:||Osteoarthritis', '6-MWT', 'Other', 'Familial Cancer Syndrome', 'equilateral axillary lymphadenectomy|anesthesia preoperative status', 'Ischemic stroke', 'root resorption', 'completed pulmonary', 'Significant', 'living donor|Not', 'nevus lipomatosis', 'NTM', 'heterosexually active', 'chronic metabolic diseases', 'progressive neurodegenerative', 'solid-pseudopapillary tumor;|Known', 'diabetic polyneuropathy', 'bleeding of the internal', 'glomerular diseases', 'respiratory disorders|major', 'Cardiac dysfunction', 'MoCA', 'immunosuppressives', 'functional asplenia', 'skin allergies|pregnancy', 'rapid test)|clinical condition', 'hepatitis C infection', 'heart failure;|normal', 'chronic tactile deficits', 'urosepsis', 'ICP-248 tablets', 'interpreter available||', 'vertical root fracture', 'Asthma exacerbation', 'biliary salt diarrhoea)|Previous colorectal surgery', 'impaired muscles', 'OAB dry', 'Helicobacter Pylori', 'additional injuries', 'atrial tachyarrhythmia', 'TKI-intolerant', 'nicotinic habits', 'neurogenic bladder dysfunction', 'communication difficulties|No', 'breast cancer|Synchronous', 'clinical bleeding symptoms', 'right coronary artery lesion.|Excessive overlap', 'bleeding disorder)|Life expectancy', 'acute exacerbation of COPD.||', 'mitro-aortic surgery', 'urethral prosthesis.|Bladder neck', 'aortic aneurysm;|Uncontrolled ventricular tachycardia', 'space syndrome', 'schizophrenia-spectrum disorders|Can read', 'Asymptomatic', 'Complex regional pain', 'C01)|Cognitive impairments', 'mental health issues', 'Liver cirrhosis', 'traffic injuries|coagulation disorders', 'prostatic adenocarcinoma|cardiac', 'impact on balance and gait;|Mini Mental State (MMSE)', 'Metastatic prostate cancer', ""Parkinson's disease);|Pregnancy"", 'limb loss', 'expert liver pathologists|fluency', 'evolocumab);|Pregnancy', 'involvement of the', 'Injury severity score(ISS', 'antigen-4', ""Huntington's disease|Current"", 'normal physical examination results', 'sexs;|Progressive disease', 'slides', 'need emergency', 'apical periodontitis', 'corneal dystrophy', 'Type 1', 'respiratory illness', 'vision issues', 'medically compromised', 'esophageal manometric findings', 'renal insufficiency|Left main coronary artery stenosis', 'CNS infections', 'lactation|Lack of informed', 'preterm birth|In', 'progressive musculoskeletal disorders', 'contrast|Renal dysfunction', 'Corneal injuries', 'organ failure;|The', 'neurodevelopmental condition', 'preserved liver function', 'hemodynamic stability', 'COVID-19 infection:||dyspnea', 'P. falciparum', 'compression fracture', 'treated in situ cervical carcinoma', 'Accountability', 'dysfunction that could affect study drug', 'recurrent depressive disorder', 'IRP|responsive to cold', 'Gastrointestinal disorders', 'toxic manifestations', 'shoulder migration percentage', 'lung cancer,|Scheduled', 'COMT', 'benign prostatic hyperplasia', 'parasitic ocular', 'tuberculosis (TB XE', 'neuropsychiatric conditions', 'acutely suicidal', 'neovascular glaucoma', 'medical conditions', 'gastroduodenal ulcer', 'chromosome 15q11-q13', 'cervical radiculopathy', 'complex sleep apnea).|Previous', 'liver disease|Smoke', 'Smoldering MM|Suffering from', 'herpes zoster', 'behavioral', 'osteomyelitis|diabetic peripheral neuropathy|homozygous familial', 'cardio-metabolic disease', 'renal/liver failure', 'tried antidepressants off-label', 'lower limb peripheral', 'herpes simplex infection', 'upper limbs;|painful syndrome', 'Atypical anorexia nervosa', 'hepatitis C virus (HCV) infection', 'movement;|Internal pathologies', 'Displaying acute respiratory', 'schizophreniform disorder', 'HER2 overexpression', 'drainage procedures|Uncontrolled', 'passive smoking,||pregnancy', 'reduced speech recognition', 'SMI', 'score of:||14', 'Douro e', 'lactating|Tobacco', 'CMC-1 OA', 'psychiatric diseases', 'chronic inflammatory disease', 'cyst fenestration', 'hepatitis C virus infection', 'electroencephalographic anomalies', 'death|Pregnant', 'spine fractures', 'skin infections of the investigational', 'adrenal nodules', 'communication disorders.|In', 'hemolysis-related test', 'HIV infection|Tuberculosis', 'pleural effusions', 'psychotic features', 'non-CTD.|Patient', 'immune deficiency disease.|Immediate family member', 'severe reflux esophagitis', 'acute coronary syndrome', 'painful bruise', 'intracranial aneurysm', 'bowel dysfunction', 'postmenopause', 'gastrointestinal motility disorder', 'percutaneous transhepatic biliary drainage|Patients', 'non-obstructive coronary artery disease', 'other respiratory disease', 'non-pulmonary sepsis', 'maternal myasthenia', 'cognitive problems|Malignancy', 'auditory disabilities', 'liver metastases', 'malabsorptive conditions', 'tumour process.||Patients', 'vision difficulties', 'major medical illnesses', 'autoimmune disease.|History', 'swallowing dysfunction', 'glomerulonephritis', 'juvenile myelomonocytic leukemia.||2', 'memory impairment (AAMI)', 'orthodontic bands.|Presence', 'generalized developmental disorder', 'intestinal cramping', 'anatomic asplenia', 'noncavitated', 'Tachypnea', 'hemianopsia', 'arterial thrombotic events', 'chronic diseases|Alcohol', 'bacterial vaginosis/candidiasis', 'tumor bleeding', 'consent.|Thoracic surgical', 'autoimmune related', 'liver metastases should', 'AVDs', 'esophageal adenocarcinoma;|clinical', 'death before protocol completion', 'Hepatitis viruses', 'QT prolongation syndrome', 'reasons|uncompensated cardiac-', 'uterus removal).|For', 'geographical factors', 'bone marrow failure syndrome', 'distorted nasal anatomy', 'FEP', 'mild scoliosis', 'vegans).|Pregnant', 'ulcers', 'gastroschisis', 'hemorrhagic stroke.|Patients', 'hepatobiliary involvement of malignancy', 'allergic bronchopulmonary aspergillosis cystic fibrosis', 'striving', 'partum', 'gonorrhea', 'isopropyl alcohol', 'psychotherapy;|Allergy', 'post-concussional symptoms', 'anticoagulation|Substance abuse', 'car damage|Teen', 'mental illness j) In', 'hematencephalon', 'multiple myeloma.||- Stroke', 'iron overload conditions', 'primary immunodeficiency diseases', 'PAC', 'shoulder stiffness', 'inflammatory gingival enlargement', 'Rheumatoid arthritis|Long-term', 'exon 7 + confirmed point mutation of the SMN1', 'tumor biopsy|Pregnancy', 'nonalcoholic steatohepatitis', 'systemic pathology', 'brain bleeds', 'brain.|Uncontrolled infection', 'proliferative disease', 'ischemic stroke.|Patient', 'joint involvement', 'traumatic malocclusion|Pregnant', 'femur fractures', 'mucinous adenocarcinoma', 'Acute heart surgery|Adult', 'synchronous metastases', 'gastric outlet', 'post-treatment brain MRI', 'viral infections).|AIDS', 'couples', 'non idiopathic.|An', 'type 2 diabetes|Treatment with', 'completed Phase 1 of the', 'adenosquamous carcinoma', 'evacuation disorder', 'foot Chronic Kidney disease', 'simple luer', 'vascular anomaly', 'wheal reaction', 'Adenocarcinoma of the prostate', 'high-risk upper tract urothelial carcinoma', 'Mucinous adenocarcinomas', 'TFL', 'organicity', 'extradural hemorrhage', 'chronic kidney failure', 'intrastromal corneal ring segments', 'organ failure|Previous renal transplantation', 'nasal cannula', 'PCR)|Hepatitis B virus', 'PRN', 'metachronous tumors|Communication disability', 'Seguí', 'C infections', 'Sclerodermia', 'Android app-compatible smartphone', 'pulmonary organ', 'target acupoints|With histories', 'unforeseen clinical need', 'implanted brain stimulator)|conditions', 'neck radiation,|Cervical spine', 'haemolytic anaemia', 'acute sentinel event', 'TNBC breast cancer', 'solid tumors.|Subjects should', 'etc.);|2', 'measles mumps rubella', 'MCI consistent', 'comorbid health condition', '/cerebrovascular disease', 'weight changes', 'bilateral hand pain', 'infected wound', 'pharmacologic', 'isthmic spondylolisthesis|not able to understand written information and communicate', 'extensive armpit', 'familial long QT syndrome.|Symptomatic atrial', 'ans|Patients', 'abnormal heart rhythm', 'inflammatory bowel', 'penile anomalies', 'Unresectable cholangiocarcinoma', 'amyloidosis|Known hiatal hernia|Known gallbladder and choledochal stone', 'progressive glomerulonephritis', 'Raynaud disease', 'menarche.|Acute illness', 'isolated congenital cardiac anomaly', 'left ventricular failure arrhythmia', 'complete obstruction', 'tubal infertility', 'ELIGIBILITY CRITERIA', 'AF episodes', 'autoimmune disorders.|Child', 'scar|Standard logarithmic visual acuity charts measure the BCVA', 'facial lymph nodes biopsy', 'in situ cervical carcinoma', 'chronic bipolar disorder', 'recurrence of endometrioma|recurrent endometrioma', 'subdural abscess', 'congenital heart disease.|Patients', 'gliomas).|Astrocytoma', 'cardiovascular comorbidity', 'Psychiatric illness', 'Mild renal impairment', 'Transfusion-dependent', 'congenital/organic cognitive condition', 'persistence ventricular tachycardia', 'ileal conduit.|The American Society of Anesthesiologists Physical Status classification system', 'CD20-targeted drugs', 'sound primary canines', 'neck surgery|have coagulation disorders|on anticoagulants|are pregnant|allergic to bupivacaine|anyone', 'acute myelogenous leukemia', 'etc.)|Advanced cardiomyopathies', 'behavior', 'oral burning pain', 'extra-coronary', '1 year|Documented poor compliance', 'good general health.|Agreement', 'neurological problems|orthopedic', 'gland(s)||', 'known diagnosis', 'AIDS-defining illness', 'impaired mental status', 'unable to swallow oral medication', 'electricity,|Not', 'chromophobic cell carcinoma', 'organomegaly', 'adults||', 'Psoriasis flare', 'osteitis pubis', 'death|Uncontrolled intercurrent illness', 'Idiopathic PAH', 'Willebrand disease', 'diarrhea', 'hypothyroidism stabilized', 'clinically probable', 'inferior vena cava.|Uncontrolled hypertension', 'transient ischemic attack.|Chronic treatment', 'pleural fluid indicates ""', 'cardiac arrhythmias.|Uncontrolled hypertension', 'vascular parkinsonism', 'penicillin|Acute illness', 'thrombin time>21s', 'chronic HF', 'medical complications', 'declaration of informed consent;|elementary school certificate', 'human immunodeficiency virus (HIV) seropositive status', 'affect outcome measures', 'procedures.|Pregnant', 'active tuberculosis', 'primary neurodevelopmental condition', 'Medically compromised patients|Pregnant', 'Unable to undergo', 'vaginal infection', ""read CT's"", 'Clinical bleeding', 'coronary artery bypass grafting', 'intracranial oligometastases', 'urothelial carcinoma', 'lymphangitic spread', 'valvular heart disease|Patients', 'reactogenicity to vaccines', 'storage disorder', 'anomalies|Placenta previa', 'spine;|Kinesiologic impairments', 'food', 'Syndrome|Porphyria|Epilepsy|Myasthenia', 'tolerance diaries', 'primary tumors', 'peritoneal membrane cancer', 'foot fractures of', 'implantation;|Target lesion', 'spinal infection', 'normal organ function', 'Cardiogenic shock', 'HBV DNA', 'external skin lesion', 'chronic immune system', 'poor tolerance', 'type 2 diabetes≥', 'Ewing sarcoma', 'FOS', 'endoscope', 'cystic fibrosis)|Such', 'future pregnancies', 'idiopathic angioedema', 'macrobiopsy', 'Microscopic colitis', 'C hepatitis', 'adoptive immunotherapy', 'psychiatric diagnoses.|Patients', 'antiepileptic drugs|chronic alcohol', 'mildly reduced ejection fraction', 'agents.|Active infection', 'adjuvant chemotherapy', 'Adjustment of antihypertensive medication', 'temporomandibular joint pain', 'contraindicated for MDCT', 'lateral semicircular canal (', 'psychosocial support', 'black stool', 'functional disability', 'exitus', 'bone loss beyond initial', 'leukemia.|Clinical concerns', 'corneal endothelial dystrophy', ""Gilbert's Disease"", 'teeth with periodontal', 'recovered.|Presence', 'malignant space', '|Common', 'hypoxic-ischemic phenomena', 'allowed)|Secondary osteoarthrosis', 'lung disease||Patient', 'psychiatric distress', 'kidney malformation', 'system|Bilateral tubal occlusion vasectomized partner', 'major mood disorder', 'HCV)|Hepatitis B virus', 'intolerance', 'digestive insufficiencies', 'carious lesions reaching', 'progressive MS', 'chronic pulmonary disease|patients', 'traumatic amnesia', 'maternal tachycardia', 'hypovolemia).|positive culture', 'coma', 'age|Smoke', 'disease states', 'degenerative valvular heart disease', 'chronic haemolytic anemia', 'respiratory pathology', 'lung ADC', 'DQT.|Chronic pain', 'GCV', 'T2D remission', 'enterocolitis', 'non-orthopedic specialties.|Primary', 'Alcohol abuse', 'esophageal esophageal', 'attention deficit disorder', 'major delayed toxicity', 'influenza', 'cerebellar diseases', 'months|Detectable human immunodeficiency virus (HIV)', 'stroke；|Sleep disorders', 'syncope', 'nutritional supplement', 'resistant', 'hemodynamic alterations', 'benign gynecologists', 'TIGIT', 'congenital lung abnormality', 'brain malformations', 'neurological problems', 'prosthodontic technical complications', 'ankylosing spondylitis|Current infection', 'infection of', 'digestive disorders', 'mixed hearing loss', 'craniofacial abnormalities', 'fluorescence in situ hybridization (FISH) methodology', 'sperm donation', 'renal cell cancer', 'allergia', 'neovascularization', 'middle cerebral', 'MRSA infection', 'respiratory dysfunction', 'urinary tract diseases|endocrine', 'sapheno-femoral junction (SFJ) incompetence', 'Pulmonary edema', 'developed disease', 'vascular disease', 'obstructive cardiomyopathy', 'lower extremity joint disease', 'lactase preparations', 'isolated Gilbert syndrome', 'psychiatric risk', 'brain trauma', 'hyper-acute stroke', 'Localized non-CNS radiotherapy', 'confirm ovarian', 'residual microscopic disease', 'give written informed consent', 'Gastrointestinal (GI) disorders', 'cross-sectional', 'target cancer', 'active pulmonary diseases', 'regular aerobic', 'behavioural stress symptoms', 'multiple lesions', 'cured.|Noninvasive cervical cancer', 'cold sensation', 'pre-menopausal', 'pharmacological study|If', 'candidate to receive', 'lung metastases amenable', 'irregular cornea.||Biomicroscope findings', 'major surgical', 'gastrointestinal (GI) issue of the upper GI tract', 'candidemia', 'Familial Adenomatous Polyposis', 'complex regional pain syndrome', 'cocoa', 'Chronic obstructive pulmonary disease)||', 'urine', 'cystitis', 'chorioangioma', 'major events/changes', 'Polycystic ovarian', 'cataplexy', 'anemia', 'haemorrhage', 'ductal adenocarcinoma;|treated', 'thrombotic lesion e', 'non-combusted', 'intrinsic liver disease', 'Superficial diabetic ulcer', 'digestive tract bleeding', 'immunodeficiency virus', 'CKD)|Congestive heart failure (CHF)', 'organic gastrointestinal disease', 'language impairments', 'checklist)|understanding of verbal', 'behavioral concerns|Uncontrolled seizure disorder|Pregnant', 'solid organ transplantation.|Patients', 'AD criteria', 'evolutive neuro', 's-creatinine', 'psychiatric problem', 'anticancer therapy.|Ongoing', 'retraction', 'spinal cord abnormalities', ""Multicentric Castleman's"", 'substance of abuse', 'chest trauma', 'photosensitive epilepsy', 'lymphoblastic leukaemia', 'Knee pain', 'hepatitis B virus (HBV) DNA levels', 'disorders of metabolism', '/ M0|Tumor resectable', 'fibrolamellar hepatocellular carcinoma', 'deep ulcer', 'epidermal growth factor receptor (EGFR) sensitizing mutations', 'chemiluminescent microparticle immunoassay', 'intramuscular bleeding', 'human immunodeficiency virus (HIV) antibody positive;|Abnormal chest X-ray', 'pre-pregnancy normal weight', 'orthodontic treatment|Failure', 'equinovarus', 'congenital immunodeficiency disorders', 'non surgical initial periodontal treatment', 'liver cirrhosis:||ALB<35', 'residual alopecia effects', 'hepatitis C virus [HCV] ribonucleic acid', 'multiple endocrine', 'bullous disease', 'assistance)|Able to communicate', 'nasal sinus packing', 'FoundationOne CDx Cancer Genome', 'inflammatory disorder', 'hereditary collagen', 'poor quality video', 'simple cervical tumor rupture', 'GH receptors.||Applicable', 'degenerative neurologic disease', 'osseous instabilities', 'anal surgery).|Physical disability', 'neuropsychiatric disorder', 'systemic manifestations', 'nonalcoholic fatty liver', 'Acute viral hepatitis', 'osteosynthesis', 'acrophobia', 'fulvestrant', 'Follicular Lymphoma', 'weakness', 'terminal ill', 'parasitic infections', 'non-invasive/in situ cancer).|Pregnancy', 'gastrointestinal malabsorption syndromes', 'relapsing remitting MS', 'cell disease', 'moisture', 'wind', 'tumorous lesions', 'localized squamous skin carcinomas', 'lithiasis', 'myeloblastic leukemia', 'area|Availability', 'immune dysfunction syndrome', 'condom with spermicide', 'journal decides to send', 'cardiovascular collapse', 'upper limb', 'cardiac repolarization', 'comorbidity stable', 'downs syndrome', 'clinical intervention.|Myocardial infarction', 'HIV-AIDS infection.|Patients', 'cardiac amyloidosis', 'wrist injury', 'chronic lung diseases', 'hypobetalipoproteinemia|any disease', 'Major Depression.|uninterruptable central nervous system medication', 'changes in performance status', 'non-febrile convulsions', 'myocardial infection', 'hematopoietic functions', 'serious headache', 'gastrointestinal-related abdominal surgery', 'posterior circulation stroke', 'inflammatory disease);|Terminal illness', 'intrahepatic cholangiocarcinoma', 'treatment.|uncontrolled hypertension', 'analysis process', 'acute kidney failure', 'tapered off', 'Plasma Cell Leukemia', 'treatment complications', 'Neurotrophic Keratopathy', 'severe esophagitis', 'acute anemia', 'Arteriovenous thrombosis', 'large cell carcinomas', 'dementia|Inability', 'cognitively impaired individuals', ""Parkinson's diagnosis"", 'increased intracranial', 'non-left main bifurcation lesion', 'cough reflex);|Endotracheal suctioning', 'claustrophobia|Participation', 'women;|Chronic cardiac insufficiency', 'medical treatment||', 'middle cerebral artery (', 'non-stroke etiology', 'substantial weight change', 'major neurological deﬁcits', 'SMARCA4-deficient tumors)|Patients', 'nasal inhalers', 'fungal infection;|Bleeding disorder;|Amputations', 'lower limb', 'Early stage', 'Unemancipated minors', 'pectus arcuatum', 'disease develops more', 'cerebral metastasis|Diabetes mellitus', 'human immunodeficiency (', 'Transient Ischemic', 'arrhythmic events', 'JAKi', 'psychotic disorders|History of', 'primary obsessive compulsive disorder', 'criterion', 'vision loss)|able', 'nonsquamous non-small cell lung cancer', 'valvular heart disease', 'infection indicators', 'radiographic bone loss', 'neurological, orthopedic', 'salivary gland carcinoma', 'fistulas', 'Sleep disturbances which result', 'polymerase chain reaction test', 'autoimmune disease.||Note', 'glucose-galactose malabsorption|History', ""bruton's tyrosine kinase (BTK) inhibitor treatments|History"", 'ductal carcinoma in situ of the breast)', 'chest wall deformity', 'individual basis.|Active malignancy', 'IRC', 'Yorkshire', 'ischemic heart disease|patients', 'restrictive pulmonary diseases', 'isolated from the same', 'baseline.||Major depression', 'warts', 'Idiopathic PD|Diagnosis', 'restrictive pericarditis', 'clear-cell subtype|Previous', 'leg type|Intravascular large B cell lymphoma|EBV+ DLBCL', 'Singapore||', 'acute complications', 'malignant tumors|Diagnosis', 'anal fissures', 'function indicators', 'Stable disease', 'dependence,|Medical diseases|Psychiatric comorbidities,|Pregnancy', 'excellent prognosis', 'contralateral neck', 'mental system diseases', 'alleles', 'pulp exposure', 'familial haploidentical donor|Written', 'distant metastatic disease;|Patients', 'spinal disorders', 'Professional soccer', 'basal cell carcinoma).||Asthma', 'age.|Is healthy', 'RA|Fibromyalgia', 'autoimmune disease|obese', 'tuberculosis infections', 'transitional cell carcinoma', 'cord compression.|Concurrent', 'electrocardiographic', 'chemotherapy|Pregnancy|Cognitive impairment', 'end-stage organ failures', 'months|Absence', 'bilineal acute leukemia', 'T stage', 'lesion|Post-void residual', 'between lesion', 'communication problems|Systolic blood pressure', 'Chronic ulcers', 'lymphoid malignancy', 'dendritic cells', 'cardiorespiratory dysfunction', 'infection.|Previous residence', 'cognitive disability', 'macrocephaly', 'growth factor support therapy', 'mild abnormalities', 'DME threatening the center', 'inflammatory bowel disease', 'motion sickness Habitual', 'vascular impairment', 'Antisocial Personality Disorder', 'thoughts of being better off dead', 'deep vein thrombosis|Untreated lymphedema|Untreated', 'humoral dysfunction', 'urgency-frequency', 'maculopathy', 'extensive cerebrovascular', 'endocrine disorder causes', 'radical therapy.|At least 1', 'CNS involvement|Patients', 'cranial nerve function deficits', 'April 2021|patients', 'acute infections|Renal failure', 'generalized RNFL thinning', 'adenopathy', 'non-invasive lesion', 'tea)|Agrees', 'spinal cord injury)|Patients', '24-hour', 'confirm menopause', 'bronchial hemorrhage', 'head and neck cancer (HNC)', 'Community-dwelling|BMI>30', 'von willebrand diseases', 'depression|Substance', 'cariously exposed immature', 'sports performance', 'invasive breast cancer', 'researchers made', 'Harmonisation', 'human immunodeficiency virus (', 'cardiovascular disability', 'spread', 'Hoehn', 'hypokalemia', 'ovarian clear cell', 'anorectal obstruction', 'paraffin-', 'craniofacial injury', 'right to left', 'malignant lymphoma', 'heat attack', 'bipolar disorders.|Presence', 'residual carcinoma', 'term', 'major injuries', 'psychotic features)|Intelligence quotient<70', 'cervical trauma', 'scalp disorders', 'convalescent plasma', 'hazardous use', 'symptomatic', 'drug-induced QTcF prolongation', 'distant metastatic disease||High', 'climbing', 'C;|History of', 'microscopy colitis', 'non-polyposis syndrome', 'Acute diarrhea', 'COVID 19 vaccinations||Donor Exclusion Criteria||ABO', 'venous malformation', 'gastrointestinal (digestive) disorders', 'lack of justification', 'testicular tumor', 'acid reflux', 'tumour malignancy.|Have evaluable', 'myeloproliferative disorders', 'idiopathic peritonitis', 'H influenzae', 'pulmonary vein ablation', 'value|Stable CF disease', 'gastrointestinal anomalies', 'leukemic organ involvement', 'spinal cord|Metastasis', 'liver enzyme level (ALT and/or AST', 'GYN cancer', 'T2-4N0-2 breast cancer', 'other pulmonary disorders', 'both ovaries intact', 'congenital laxity', 'rotator cuff tear group', 'human immune defect virus (HIV)', 'chronic granulomatous diseases', 'idiopathic pulmonary fibrosis).||Respiratory infection', 'therapy|Known hypersensitivity', 'skin allergy', 'upper limb deformity', 'pericardial infiltration', 'ischemia occurred', 'substance intoxication', 'CAG', 'left leg', 'acquired factors', 'Personnel', 'inability to swallow formula products', 'fear levels', 'vitreoretinal surgery|laser', 'non-H. Pylori gastritis', 'suture lift', 'major thromboembolic event', 'local regulations.|Previous', ""Parkinson's disease;|Participate"", 'Chronic Kidney Disease-Epidemiology', 'Tecfidera', 'Major Depressive Disorder||', 'non-LBBB', 'kidney stones|Hip', 'intracranial internal carotid', 'headache', 'disease-free survival', 'vestibular- symptoms', 'support noncompliance', 'Vulvodynia', 'nivolumab;|Active infection', 'caries;|Presence of', 'non-invasive ventilation', ""static Physician's"", 'Unhealthy', 'common femoral endarterectomy', 'Jaundice', 'Lisfranc injury', 'radical gastrectomy.||', ""Paget's Disease"", 'fusion proteins|Known hypersensitivity', 'diabetic ketoacidosis)||', 'schwannoma', 'laryngeal surgery|Initiation', 'mentally handicapped.|Contraindication', 'epileptic attack', 'chorioamnionitis', 'old|Outdoor ambulant||', 'ID', 'psychiatric disorders|written', 'posterior pharyngeal', 'mechanical cause for CS', 'dietary', 'localized prostate cancer,|Continuing post-operative', 'lobular inflammation', 'premenstrual syndrome', 'recreational drugs|Regularly', 'fants', 'malignant hyperthermia|History of', 'intolerable', 'cardiopathy', 'mediastinal emphysema', 'child-bearing plan', 'thenar muscle', 'staged of peripheral vascular disease|Hypersensitivity|Patients', 'media opacities', 'HRP', 'memory loss|Interest', 'Sequelae', 'crying', 'Adverse Events', 'pyoderma', 'substance abuse/dependence', 'ankle instability|Ankle', 'vocal response', 'periodic', 'Multi vascular lesions', 'Multiple Sclerosis)|Neurotypical', '# CTCAE', 'VSD)|Stroke', 'affect sensitivity', 'left colon', 'squamous cancer|Distant metastasis', 'Eaton-Lambert disorders||Patients', 'obstructive sleep apnea hypopnea syndrome', 'adnexal pathology|Systemic diseases', 'AstraZeneca staff', 'hepatitis A virus', 'Lugano lymphoma response evaluation criteria', 'chlamydia infection', 'inflammatory response syndrome', 'organs function', 'solid tumor', 'synchronous', 'poor hygiene', 'vasopressor dependence', 'progressive brain metastases', 'aggressiveness', 'Sarcoidosis syndrome', 'fever', 'chronic pain.|Localized infection', 'comfrey', 'oxidative stress', 'orthopedic', 'Infection||', 'transilluminable iris', 'traumatic head injury', 'aortic valve insufficiency', 'debilitating disease', 'uterine fibroid', 'persistent erythema', 'paracetamol.|Fecal incontinence', 'mmHg|Active malignancy', 'hemorrhagic metastases', 'radiographic measurable lesion', 'alchoholic disorders', 'sessions', 'pain catastrophizing', 'cardiac arrhythmic syncope', 'chronic tuberculosis infection', 'celiac disease)|known renal', 'basidiomycetes contents', 'limiting symptoms', 'diseases.||Active IgG4-RD', 'Obesity Hypoventilation Syndrome', 'non-ambulatory', 'irinotecan gastrointestinal', 'acute GI illness', 'brain metastasis enlargement', 'environmental factors', 'cystoid macular edema', 'therapy;|Acute complications', 'Flurazepam', 'Multicentric Castleman', ""'s main tissues"", 'stage 0.1,2', 'peptic ulcer digestive', 'IOCBP', 'IHCA', 'associated pneumonia', 'Ectopic pheochromocytoma', 'incontinence', 'virus', 'Sick sinus syndrome', 'radiosensitive histologies', 'scan|Subject', 'native kidney disease', 'brain metastases|ECOG PS score', 'performing an MRI', 'surgically treatable tricuspid regurgitation (TR)', 'upper gastrointestinal ulcer/bleeding', 'good quality image', 'DS', 'mixed dentition', 'settings|Active seizure disorder', 'disposition field', 'meaning minimal', 'dementia|For', 'dementia;|be minimally capable of imagining motor', 'restrict participation in high-intensity exercise|Arthroplasty', 'solid malignancy', 'extensive bleeding', 'acute pathology', 'cancer premenopausal', 'anatomical sterility', 'binocularity', 'ocular comorbidities', 'fruits', 'structural cardiac disorders', 'active peptic ulcers', 'serious skeletal malformations', 'lumbar disc levels.|Actively', 'surgically sterilized.|7', 'menstrual discomfort', 'exclusionary.|Active malignancy', 'chest radiation', 'polyarteritis nodosa', 'recorded hypertension', 'cranial disease status', 'Pennsylvania Health System', 'infectious diseases.|women', 'acute oral', 'hepatitis C virus (HCV) antibody', 'miscarriages.|Male factor infertility', 'unilateral THAs', 'colic resection', 'SARS', 'unreliability', 'hyperprolactinemia', 'ribociclib + fulvestrant', 'hernia', 'Group:||Active suicidal ideation', 'clinical manifestations of RD', 'common carotid artery center|Implantation', 'Major Depressive Episode', 'MPN symptoms', 'Hepatitis B infection', 'chromosomal disorders', 'benign etiology', 'acute exacerbation of hepatitis', 'pelvic disorder', 'acute pulmonary oedema', 'amputations', 'recurrent sinusitis', 'condition of irritated', 'Residual ductal carcinoma in situ', 'ischemic disease', 'condomless sex criteria', 'baseline;|Pregnant', 'progressive addition lenses', 'local recurrence after surgery', 'refractory to BCG', 'mixed adenosquamous carcinoma', 'facial skin damage', 'field experience|Participants labeled', 'Dementia', 'filariasis', 'pathognomonic signs', 'hip fractures', 'orthopedic impairments', 'hepatic function', 'Renal failure', 'Interstitial lung Disease', 'distant metastatic', 'rheumatoid arthritis flare-up', 'atrial appendage thrombus', 'craniocerebral trauma', 'rarely eats sweet snacks', 'large bowel obstruction.|Judgment', 'inclusive||', 'liver disease|Cystic fibrosis|HIV', 'nephrectomy;|presence', ""late-stage Alzheimer's dementia"", 'psychiatric condition|Major surgery', 'hepatitis C.|Participants currently participating in a clinical trial.|Participants', 'Sleep Quality Index', 'Diabetes', 'CNS complications', 'non-MR', 'esophageal varices.|A current', 'tamponade', 'dietary interventions', 'type II diabetes', 'disease progression', 'Psychiatric diseases', '.|Active infection', 'motor neuritis', 'localized non-melanoma', 'anticoagulated states', 'ligament injury', 'cerebellar deficits|Ability to ambulate', 'therapy|Requires', 'bilateral tubal ligation', 'immunotherapy', ""Crohn's Disease"", 'malignant tumors|Drug', 'diploma degree||', 'stroke events', 'primary physician preference', 'skin scraping stains', 'intestinal stenosis', 'severe arrhythmias', 'adjustment of medication requiring', 'familial hypercholesterolemia|PCSK9 inhibitors', 'pancreatic disease|Systemic glucocorticoid treatment', 'CYP2A6 inhibitors /inducers', 'kidney failure|Cancer', 'cardiac hypertrophy', 'parasitic infestation)|Hepatocellular carcinoma||Infiltrative disorders', 'disease severe', 'smooth muscle Sarcoma);|No', 'narcolepsy', 'total bilirubin>3 ×', 'ventricular rhythm', 'urinary catheter', 'primary teeth', 'human epidermal growth factor receptor', 'injectable hormones', 'demonstrates deficits', 'vascular abnormalities', 'PBMT', 'C|other disease related to fatty liver', 'managed malignancy', 'singleton pregnancies', 'muscular pain', 'meningococcal meningitis', 'Infectious Disease HIV infection', 'type 1 diabetes|Currently', 'bladder disorders|Able', 'localized squamous cell carcinoma of the', 'skin conditions|Skin allergies', 'L210W', 'active lesions', 'pituitary disorders', 'discoid lupus', 'pelvic organ cancer', 'endocarditis', 'colon-related diseases', 'reduced renal function.|Patients', 'neurologically stable', 'posterior tibial', 'laryngeal pulmonary', 'thromboembolic effect', 'incisal margin', 'vestibular', 'HFpEF', 'muscle enzymes', 'herpetic infection|Autoimmune disorders|corneal thickness', 'SPID Cystic Fibrosis|patient', 'safeguarding issues', 'non typical neurodevelopment', 'mucosal', 'suicidal ideation.|Healthy', 'secondary reactions to cancer', 'multiple foot', 'LNs', 'Drug response', 'vascular thrombosis', 'arterial system', 'atypical chest pain', 'hematologic disease', 'spastic disease).|With severe heart', 'Liver Cirrhosis', 'flexor carpi radialis rupture|Previous', 'diffuse erythema', 'persistent seizures', 'vagus nerve stimulation', 'active malignancies', 'cardiorespiratory diseases|orthopedic', 'CFTR RD', 'BD', 'Priority', 'APN', 'Intellectually disabled|Autism Spectrum Disorder|Psychotic disorder', 'measurements|Active malignancy', 'pancreatic transection margin|Patients', 'Multiples', 'fetal toxicities', 'eosinophilic granulomatosis polyangiitis', 'circumferential bone defect', 'etc.;|Pregnancy', 'Chronic digestive system', 'non-cardiac surgery.|The', 'difficulty breathing.|Score', 'solid tumour', 'hyperthyroidism', 'refractory nausea', 'PDD', 'Intractable HF', 'changes in biomarkers', 'seizure|Botulinum toxin injection', 'UWS', 'drug misuse', 'concurrents medical condition', 'serologic testing', 'abnormalities of the ear', 'tumour bone disease', 'colonic neoplasia', 'completed)|Hematogenous BJI', 'physical abnormality', 'histiocytosis', 'lack of ability in oral intake', 'CPAM', 'idiopathic scoliosis', 'autoimmune diseases;|Known', 'Target occlusion', 'idiopathic interstitial pneumonia', 'metastases measurable', 'disease by standard positron emission tomography', 'depression and/or anxiety|Can', 'chronic focal pain', 'pneumoconiosis', 'spatial perception', 'therapy|Pregnant', 'dermographism', 'adrenal tumor', 'symptomatic infection', ""calculation of the recruited cohort's mean body mass index"", 'squamous cells', 'heart failure|other severe diseases', 'test||', 'vitreomacular traction', 'COPD(chronic obstructive pulmonary disease', 'lung failure', 'METS|Pregnant', 'marginal zone lymphoma (MZL)', 'caries lesions|never', 'persistent atrial', 'valvular heart disease.|History', ""Parkinson's Disease"", 'intracardiac thrombus', 'minimal consumption', 'Hepatic Impairment', 'candidate for surgical management|Patient', 'progressive neurodegenerative disease|Patients', 'Power Doppler positivity', 'Complex root canal', 'poor skin condition', 'clinical hemorrhage', 'oliguria', 'muscle toxicity', 'inducible urticaria', 'months;|Fertile', 'HIV infections|Participants', 'acute MI', 'glaucoma eye surgery', 'candida infection', 'dietary supplement.|Females', 'Ⅳ level;|Liver', 'respiratory instability', '|localization', 'herpetic diseases', 'Acute Ischemic Stroke 2018|Patients', 'inhalant allergy', 'abnormal bowel movements predominantly diarrhoea', 'neurologic status', 'maxillary sinus disease', 'hypothyroid patients', 'tender joint count', 'showed', 'liver metastases|Renal function', 'infectious complications', 'vagus nerve stimulators', 'corneal distortion', 'anergy', 'interstitial lung disease|Other', 'corticosteroid therapy.|Active malignancy', 'throat symptoms', 'judged by the doctor that they do not need', 'chronic urticaria', 'Hip fracture', 'diabetes', 'spinal cord stimulators);|Demand', 'multiple endocrine neoplasia syndrome type 2 (', 'adverse event.||', 'abnormal glucose homeostasis', 'benign paroxysmal positional vertigo', 'viral keratitis', 'poor drug control;|Participate', 'impaired decision-making capacity (IDMC)', 'intercurrent diseases', 'ocular infection', 'index ACS', 'gait disturbance', 'pregnant women.||', 'obstructive cardiomyopathy.|Chronic anemia', 'fibrous endarteritis', 'refusal|Cancer', 'covid-19', 'seizures|history of seizures', 'feeling hypoglycemia', 'corneal epithelial lesions', 'systemic diseases,|malignancy,|immunodeficiency,|infectious', 'risk-benefit', 'fibrovascular proliferation', 'diseases;|Participants', 'progressions', 'angioneurotic oedema', 'gaze palsy', 'diabetes;|14.7', 'digital device||', 'organ diseases', 'karyotype anomaly', 'intercurrent medical issue', 'neuropathic damage', 'hospitalizations', 'other illness that would', 'alpha-1-antitrypsin', 'systemic immune suppression', 'sleep disturbances', 'disseminated intravascular coagulation;|participation', 'chronic renal disease', 'inoperable bladder cancer|patient', 'systemic diseases.|Participated', 'Neisseria gonorrhea', 'solid malignancies', 'kidney disease|Polycystic ovary syndrome', 'lower extremity fractures', 'congenital immune deficiency', 'spastic cerebral palsy', 'orthopedic condition', 'OSA treatments|Resting', 'dysphagia', 'hyperthyroid diseases', 'criteria described', 'weight loss program', 'ME/CFS', 'depression/', 'non-cancer', 'minimum disease', 'immunodeficiency.|Participant', 'investigator;|Pregnant', 'PARP-inhibitors', '15);|Chronic kidney disease', 'regions.|Patients', 'muscle groups)|Screen failure', 'psychosocial condition', 'bilateral proximal muscle weakness', 'breast cancer|Confirmed diagnosis', 'periodontal disease.|Patients', 'liver transaminases', 'myoma|irregular menstrual cycle|past', 'Toxicities', 'target depression', 'carpal tunnel syndrome', 'wall motion abnormalities', 'T1|Regular smoking', 'main portal vein|Pregnant', 'Prostate adenocarcinoma', 'symptoms related', 'AIDS);|Allergic reactions', 'chronic pancreatitis', 'unilateral vestibular hypofunction', 'early signs of psychosis', 'non-psychotic symptoms|Score≥40', 'intestinal infection|Children', 'traumatic injury.|Current', 'carcinoma in situ of the cervix;|Severe', 'reducing PSA', 'unilateral breast cancer', 'autoimmune sclerosing cholangitis', 'cardiac malformation', 'nervosa', 'membranous', 'central serous retinopathy', 'prolonged QT interval syndrome', 'hypertensive encephalopathy|Significant', 'respiratory deficit', 'cessation of breast feeding', 'squamous cell carcinoma of the skin|Patients', 'neurological illness|Healthy', 'chest wall ± supraclavicular region', 'singleton pregnancy|Pregnant', 'abstain from regular consumption of probiotic supplements', 'tanning beds', 'Alzheimer', 'cachexia', 'T2 hyperintense lesion', 'associated comorbidities', 'isolated extramedullary leukemia.|Patients', 'Hidradenitis Suppurativa||', 'persistent infection', 'gastrointestinal ulcer', 'genetic diseases,|cystic fibrosis,|chronic pulmonary diseases,|gastrointestinal', 'plasmacytoma', 'abnormality consistent', 'hyperosmolar coma', 'tumors deemed', 'neuroendocrine carcinoma', 'Chlamydia trachomatis', 'illness|Aged', 'home care|Age', 'hereditary indirect hyperbilirubinemia', 'intraabdominal abscess', 'teeth with', 'procedures|Neurologically stable', 'corneal pathology', 'arteriovenous thromboembolism events', 'cerebrovascular accident.|Interventions', 'hepatic failure|Individuals', 'therapy.|Connective tissue diseases', 'hypotension', 'lack of effectiveness of', 'frozen sperm', 'gastrointestinal disorder', 'lack of compliance with clinic visits', 'cultural communities', 'cardiac chest', 'reduce cancer risk', 'Short term', 'etc.)|major psychiatric illness', 'external biliary shunt', 'parent(s)/legal representative(s) able to understand the language used in the investigation centre', 'herbal preparations', 'mitral valve repair', 'mean air conduction threshold', 'women|Acute illness', 'steatosis;|Surgery', 'compensation claim', 'autoimmune disease|No', 'Hypoglycemia', 'stable angina', 'skin care', 'gastroparesis|history of eating', 'ischemic strokes', 'kinase inhibitors', 'judged by the investigator', 'pneumonia；|Arteriovenous thrombosis', 'degenerative disease|Adolescents', 'drunk alcohol', 'bipolar depression', 'stroke.|Sufficient sensorimotor', 'months|Inability', 'FA', 'chronic renal disease;|Drug addiction', 'cutaneous basal cell carcinoma.|Failure', 'Right-handed', 'resected prostate cancer', 'Von Willebrand disease|Adult|Followed-up', 'acute heart failure|Patients', 'mediastinal uterus', 'Stable euthyroid status', 'metabolic dysfunction.||Additional Key Exclusion Criterion', 'bleeding.|Malabsorption syndrome', 'lower limb problems', 'local infection thrombus', 'abnormal bladder function', 'recurrence in ≤12 months of', 'atrioventricular block', 'chronic disorders', 'dysregulated breathing', 'acute episodes of asthma', ""chronic Crohn's disease"", 'diabetes retinopathy', 'heart disease|Inclusion', 'lower extremity fragility fracture|an', 'Bisphosphonates', 'isocenters.|Measurable disease', 'difficile infection diagnosis|antimicrobial treatment', 'right-handed', 'alternative cancer', 'neurologically asymptomatic', 'cultures', 'total cystectomy', 'antimetabolites', 'M2 segment', 'criteria of the International Classification of Diseases 11th Edition (ICD-11) diagnostic criteria for MDD;|15≤', 'Takotsubo syndrome', 'gastric adenocarcinoma', 'biological cancer', 'paroxysmal atrial', 'naso-sinus', 'artificial menopause', 'acute upper airway upper infection', 'disease of the central nervous system|patient', 'post-cardiac injury syndromes', 'breast lumpectomy.||', 'left ventricular thrombus', 'QRS evolutions', 'isolated common iliac artery stenosis', 'pleural effusion.|Uncontrolled hypertension', 'deleterious effects', 'Autoimmune hypothyroidism', 'localized treatment', 'digestive system diseases', 'semi-professional athletes|Body Mass Index', 'metastatic brain', 'hemodynamic compromise|parents', 'Patellar tendinopathy', 'pulmonary rehabilitation', 'lines of treatment', 'congenital uterine anomaly', 'treatment failure', 'left atrial appendage electrical isolation', 'laparoscopic cholecystectomy|Patients', 'babies', 'pulmonary involvement', 'Sensory disorder', 'eosinophilic asthma', 'inguinal hernias', 'corneal melting', 'keloid scar formation', 'body|Valvular disease', 'corticosteroid spray', 'pre-eclampsia', 'vasectomized partner.||For', 'length difference', 'HR-MDS', 'intracranial mass|Prohibitive lumbar spinal disease|Enrollment', 'breast cancer|Prior breast augmentation or reduction|Participation', 'non-COVID-19 related', 'coagulative disorders|Renal impairment|Sickle cell disease|Thrombotic diseases|Comorbidities', 'orthopnea', 'internal mammary', 'HTLV', 'permissible for disease control', 'Anorexia Nervosa|Body', 'hypoesthesia', 'arteriovenous thrombotic events', 'antitumor activity', 'ipsilateral breast cancer.|Oncoplastic', 'restarted FVIII prophylaxis', 'serious psychiatric disorders', 'SMZL', 'acquired immunodeficiency', 'macular', 'multiple events', 'Chronic Peptic Disorders', 'permanent discontinuation', 'traction', 'neurological disorder|Patient', 'procedure.|Recurrent bladder cancer.|History', 'PFTs', 'diabetes type 1', 'breast feeding;|not', 'kidney diseases', 'breast-feeding.|Women of', 'neurodegenerative pathology', 'ago|Patients', 'Symptomatic', 'ecchymoses', 'B-cell lymphomas', 'exception of anxiety', 'metastases', 'irreversible pulpits', 'head trauma.|Current', 'acute trauma', 'produce autonomic neuropathy', 'intercurrent acute illness', 'autoimmune paracancer syndrome', 'abdominal malformation', 'bleeding events|Abdominal fistula', 'neurodegenerative disease.|Allogeneic stem cell transplant', 'mood disturbance', 'cerebral vascular event.|Pregnancy', 'myxedema)|symptomatic peripheral', 'solid organ malignancy|Available results', 'cardiac causes', 'obsessive compulsive disorder', 'esophageal cancer;|A', 'type-1', 'acute attacks', 'VVS', 'signs of', 'salivary gland pathologies', 'immune diseases', 'psychical diseases', 'pose an unacceptable risk', 'melanoma in situ', 'constituting', 'irritable bowel disease', 'hepatitis B|Participants', 'squamous carcinoma', 'brain death', 'muscle mass', 'microscopic perineural invasion', 'Prostatic carcinoma,', 'severe respiratory conditions', 'transient cerebral ischemic seizures', 'acceptable||', 'impaired glucose tolerance.|No evidence', 'Human immunodeficiency viruses', 'ethnicity||Social network', 'Parkinsons disease|Stable', 'inflammatory disorders).||2.Vascular syndrome', 'mixed phenotype acute leukemia', 'GSW', 'Type 2 DM|Patients', 'criteria of the oncological departments', 'papillary muscle rupture', 'pathogenic variants', 'LDi>1cm', 'completing the protocol', 'cholesteatoma', 'disorder of metabolism', 'right first dorsal interosseous (FDI)', 'severe COPD', 'systemic anticancer', 'BCOR rearrangement', 'tension-type headache', 'age|Arrhythmia', 'detectable HBsAg', 'electrolyte abnormality).|Pregnancy|Use', 'femoral intertrochanteric fracture', 'Acute Respiratory Distress Syndrome (', 'double-barrier method of birth control', 'local anesthetics|Puncture site infection|Lack of signing of informed consent|Age', 'surgery;|Active infections', 'aortic pathology', 'traumatic brain injuries', 'situ).||Meningeal metastasis', 'chronic alcoholism', 'adrenal', 'reversibility', 'adjunct fenestrated cuff', 'Kaposi sarcoma', 'pulmonary vascular diseases', 'comorbid conditions', 'aortic aneurysm', 'T4|Stage N1|Stage', 'right pulmonary artery', 'hypoglycemia episodes', 'primary care providers', 'defibrillator implants.|alternative neurological disorders', 'thyroid diseases', 'human immunodeficiency virus (HIV) test', 'amblyopia', 'postoperative perineural local anesthetic infusion', 'intracranial neoplasms', 'skin BCC', 'colloids|Severe heart diseases', 'eosinophilic bowel disease', 'sacroiliitis on MRI', 'Cardiac failure', 'uterine cancer', 'poor general health', 'progressive motor deficit)|history of spine surgery|obvious', 'anterior cruciate ligament (ACL)', 'exclusion factor', 'fungemia', 'hemorrhage)|postoperative complications', '-risk disease', 'smoking|Subjects', 'mitral regurgitation)|permanent', 'lactating.|Allergic to fenofibrate', 'swimming', 'acute fracture', 'gr|Vaginal delivery|Breastfeeding already started|Absence', 'non-injectable recreational drugs.|Consenting', 'Barrow', 'extra-pulmonary reasons', 'cervical cap).||', 'enclosed environment', 'macular lesions', 'third relapse', 'dysphagia|Degenerative neurological condition|Severe visual impairment|Severe', 'impaired glucose tolerance)|In good general health', 'inflammatory process|Previous neck', 'ADHD', 'solid organ transplantation|History', 'thalassemia major', 'cerebrospinal fluid examination;|The', 'unresectable surgical contraindications', 'multiple polyps', 'breastfeeding|Planning to give birth', 'bronchial hyperreactivity', 'renal diseases', 'corneal hypoesthesia', 'abnormal immune function', 'cars made', 'febrile illness', 'truncus arteriosus', 'available electronic health records', 'refractory ascites', 'Ulcerative', 'pre-stroke functional disability', 'free of disease', 'Nancy University Hospital.|Patients', 'cardiac abnormalities|Major surgery', 'instable neuropsychological', 'malignant tumor|HIV', 'convulsive syndrome', 'unknown.|Willingness', 'symptomatic angina pectoris', 'colonoscopy;|Metastatic lesions', 'respiratory issues', 'congenital infection', 'consent|Presence', ""Parkinson's syndrome.|Cognitive impairment"", 'lack of normalization', 'acinar cell carcinoma of the pancreas', ""Burkitt's lymphoma.|History"", 'neurologic condition', 'mitochondrial encephalomyopathy', 'preoperative stroke', 'gastric ulcer bleeding', 'using NSAIDs,|Pregnancy', 'secondary NS', 'H.pylori infection', 'inflammatory bowel disease|Arrythmias', 'acute suicidal ideation||Healthy Controls||Inclusion Criteria:||Written informed consent|Adults', 'Primary Language', 'hyperthyroidism|Myxedema coma|Subclavian', 'intracranial pathology;|Documented pulmonary hypertension;|Uncontrolled', 'maxillary deficiency', 'lichen simplex chronicus', 'Rotational trauma', 'post-injury', 'elastosis', 'CIK cells', 'feeling coerced', 'antibiotics|Human immunodeficiency virus', 'length of hospital stay', 'can', 'alcohol dependence', 'inherently abnormal', 'endotracheal intubation||', 'urinary', 'old.|Ability to read', 'autoimmune-related', 'carotid atherosclerosis', 'baseline pain', 'adenosquamous -carcinoma of the cervix', 'Crohns disease', 'cognitive dysfunction|Diseases', 'bone tumors', 'Early Treatment Diabetic Retinopathy Study (', 'natural sugar substitutes.|Children', 'chronic Hepatitis B surface antigen', 'cerebrovascular disease|Using CPAP', 'Holter monitoring|Atrial', 'Obstructive sleep apnoea', 'co-stimulation signal;|8、Serum', 'hypothyroidism stable', 'cancer;|Cardiac arrhythmias', 'cyanotic heart disease', 'asthma symptoms', 'secondary depressive disorders', 'tubular sclerosis', 'solid, peripheral lung lesion', 'symptom of EGIDs', 'hyperglycaemia', 'spouse', 'anxiolitic type', 'prolonged bradycardia', 'Medullary Thyroid Carcinoma', 'therapy.|Abnormality', 'lumbar spinal', 'radiographic sacroiliitis', 'Unstable angina pectoris', 'uterine cancer|Severe infection', 'etc.)|Presence of', 'non-fatal bleeding events', 'central obesity', 'renal insufficiency;|Autoimmune disorders', 'Somatization', 'alveolar inflammation;|Had', 'neuromediated', 'sinus tracts|thick', 'ICD', 'autoimmunity', 'renal issues', 'immune response', 'type of cancer', 'myeloproliferative disorder', 'cutaneous ageing', 'Lymph nodes', 'Cowden syndome', 'solid organ transplantation.|History of other malignancy', 'custodial child', 'diagnosis);|Diagnosis', 'pneumonia took', 'spinal cord stimulation', 'good health', 'medial femoral cortex', 'complain of neck pain|Decrease range', 'ipsilateral nodes', 'cardio-cerebral disease', 'Chronic Kidney disease', 'colorectal adenocarcinoma', 'pregnancy.1|Cases of', 'extensive small bowel resection', 'hypercoagulability', 'Advil', 'lamina dura', 'exertional SOB protocol', 'Anterior left block', 'bleeding tendency|Drug abusers', 'myofascial pain', 'major psychiatric condition', 'renal dysfunction;|Have hypertension', 'hepatitis C infection|Any', 'good aerobic', 'Arthus', 'genetic conditions', 'Prolonged QT interval', 'non-small cell lung cancer|Patient', 'hepato-renal echo', 'intestinal occlusions', 'basal factor level', 'medullary hematopoiesis function', 'tracheal intubations outside', 'organic gastrointestinal', 'medial mastoid muscle', 'substance-induced psychosis', 'SJS', 'ethnically Japanese).|Healthy', 'OAR', 'hemolytic anemia).|Anemia', 'r', 'teeth in the maxillary', 'peripartum cardiomyopathy', 'Child-Bearing Potential', 'drug abuse disorder|New probiotics', 'malignant hematologic', 'Renal tumors', 'autoimmune disorders.|The', 'macular dystrophies', 'retinal vein occlusion|Active intestinal disease', 'primary outcome includes', 'skin fragility', 'neurological disorders|Surrent chronic pain', 'allergic reaction', 'chronic hypotony', 'duration of', 'narcotic painkillers', 'emotional condition', 'BJI', 'severity of depression', 'impaired decision making', 'hormonal contraceptives|premenopausal', 'uncontrolled infection', 'corneal epithelial disease', 'traumatic brain injury|Any vestibular disorder', 'post exertional malaise', 'serologic evidence', 'iridotomy', 'disseminated intravascular coagulation.|Patient', 'physically unable to communicate|Currently joining other', 'bone edema', 'NSAIDs Pregnancy', 'MN', 'consent.|Epitentorial glioblastoma', 'syphilis screen', 'immune system disorder', 'acquired melanosis', 'NAVA', 'complex congenital heart disease', 'setting', 'death|Pregnancy', 'large B cell lymphoma', ""traumas|positive Adam's"", 'concussions', 'urothelium cancer', 'not eligible.||ii', 'traumatic cerebral hemorrhage', 'recreational use of soft drugs', 'Neuromuscular Muscle Disease', 'Systemically healthy', 'allergic reaction.|those', 'epileptic seizure', 'tumor tissue block made', 'Criteria for control subjects:||Men', 'coronary', 'chronic obstructive pulmonary disease.|Uncontrolled', 'cardiogenic pulmonary oedema|Patients', 'amblyopia|3-12 years', 'chronic pulmonary conditions|Concomitant', 'look back', 'vitritis', 'intercurrent illness(es', 'constitutional symptoms', 'Sinonasal', 'CTCAE grade', 'serous', 'portal hypertensive gastropathy|pregnancy', 'skin lesions', 'change of disease-modifying treatment', 'criteria required:||o The cancer specialist considers', 'Muscle diseases', '|concussion', 'pregnancy|No allergy history|Signed informed consent||', 'subdural hematoma', 'cognitive function', 'therapeutic apparatus', 'arteriopathy', 'acute rhinitis', 'HFrEF', 'metabolic liver disease', 'Los Angeles classification', 'vital signs abnormalities', 'loco-regional metastasis', 'infertile', 'platelet transfusion failure', 'depression scale', 'cirrhosis.|Participants', 'lymphoma cell proportion', '≤12|Acute ischemic stroke', 'household', 'deep necklace lines', 'Sunburn', 'Patents', 'diseases of the biliary tract', 'flexor tendons of the wrist', 'intra medullary hemolysis', 'SVD', 'Premenopausal Breast Cancer', 'heart failure|After', 'Coeliac Disease (CD)', 'lose weight', 'Corona Virus Disease 2019(COVID-19', 'sensory disorders', 'Colorectal cancer', 'breast-feeding.|Mental disorders', 'bilateral involvement', 'familial risk', 'genetic syndrome', 'osteoarthritic changes', 'ASPECTS', 'terminal HF', 'CT brain', 'probiotics;|gastrointestinal disorders', 'cyclic vomiting syndrome', 'shoulder myopathy', 'local anesthetics.|Coagulation disorder|Infection', 'resting ECG', 'CNS', 'cardiac PET', 'IHQ', 'vegan|metabolic diseases', 'hemorrhagic stroke|Participants', 'persistent vessel', 'inadequate bone marrow', 'contact lens best corrected distance vision', 'anterior permanent tooth', 'nocturnal symptomatic', 'perinatal hypoxia', 'SLE manifestations', 'hepatitis C virus|Pregnancy', 'reflux esophagitis', 'autoimmune diseases;|Carriage of', 'Intracranial measurable lesions', 'chiropractic care', 'systemic antitumor therapies', 'regular alcohol consumption', 'horizontal defect', 'arteriovenous malformations', 'HER2 exon 19', 'stressful conditions', 'hypertension', 'Padang', 'pulmonary fibrosis.|Pregnant', 'born preterm', 'diffuse pain', 'superficial thrombophlebitis', 'coagulopathy)|Renal failure', 'positive disease', 'swelling of the vestibule.|Normal gingival', 'practice providers (APP)', 'chronic digestive tract', 'triathlon', 'cognitive impairment||MCI:||Cognitive changes', 'acquired immune deficiency syndrome', 'ventricular rate>150 bpm', 'lower extremity injuries', 'acute dystonia', 'photographs', 'care|Surgical tube', 'respiratory tract', 'alcohol dehydrogenase inhibitors (ADHs)', 'manic episodes', 'criteria||Back pain', 'photopsia', 'mitochondrial disease', 'nasal pathologies', 'liver disease|secondary causes', 'removable orthodontic appliance', 'eclampsia', 'hepatic insufficiency resulting', 'calf muscle hypertrophy', 'extrapulmonary).|Skin diseases', '1.Inclusion criteria', 'thyroid cancer treatment', 'persistence of symptoms.||', 'Postgraduate', 'health risk', 'syndrome', 'UVB', 'exon 20 insertion mutation', 'surgically sterilized.|Patient', 'stiffness|Thoracic outlet syndrome', 'uncontrolled diseases', 'ectopic', 'secondary progression', 'severe illness', 'Poor vital sign stability', 'endocarditis prophylaxis', 'Locations', 'non-transient haematological abnormalities;|Renal dysfunction', 'chordoma', 'drugs|Previous neurologic', 'Multiparous', 'hypothalamic injury', 'recurrence in the last 5 years', 'Massachusetts|Household income', 'hyperaldosteronism', 'PTU', 'remote consent||', 'coagulation factor deficiency|Known coagulopathy', 'respiratory tract Infection', 'ITP)|Diagnosis', 'cardiovascular risk factor', 'supraventricular arrhythmia', 'chest retraction', 'malignancy Hypocalcemia', 'HGSOC', 'CSID', 'genetic mutation linked', 'bilateral LHBT injury', 'bricker bladder', 'unidimensional tumor', 'infected with HIV', 'immunodeficiency conditions', 'non-invasive respiratory support', 'endodontic etiology', 'schizophreniform psychosis', 'random prostate biopsy', 'CNS Sarcoma.|Patients', 'rectal', 'T2 sequences', 'closed head trauma|Evidence', 'clinical presentation developed.|Neurodegenerative disorder', 'premature coronary heart disease||', 'respiratory physician', 'hypercapnia', 'PCNSL', 'Interrupted Attempt', 'Gastric cancer', 'acute arrest', 'menstrual cycles', 'sclap syndrome', 'pituitary obesity', 'uterine cervical carcinoma in situ', 'media opacity', 'herbal medicine', 'OAB', 'localized disease', 'fucose metabolism);|Tn polyagglutination', 'Bronchiolectasis', 'TD)/extrapyramidal symptoms', 'Radial artery malformation', 'gesture', 'intraocular condition', 'abdominal cramps pain ends after periods', 'retinal damage', 'unstable cardiovascular disease.|BMI', 'nursing', 'systemic complication', 'hypovitaminosis D', 'restenotic/occluded', 'inflammatory carcinoma', 'systemic autoimmune diseases.|Significant', 'hepatitis C;|Evidence', 'Neuroendocrine carcinoma', 'C-Virus', 'life-threatening organ dysfunction present.|Acceptable vascular access for CKRT', 'diabetic ketoacidosis event', 'controlling bladder function', 'DVCAD', 'focal neurologic findings', 'uncontrollable clinical problem', 'psychologic problems', 'perfusive heart failure', 'insomnia disorder', 'endoscopy|Inability', 'nerve stimulators', 'tongue base', 'unsterilized', 'associated α-thalassemia;|Active bacterial', 'gastroparesis|History of scleroderma|Hospitalized', 'cesarean|Pregnancy', 'early postpartum period|Premenopausal', 'malignant disorder', 'bone infections', 'GVH disease', 'malignant liver tumors', 'alpha-1-antitrypsin deficiency|Known sensitivity to medications', 'Motor Neuron Diseases', 'optic neuropathy progression', 'heart attack', 'thrombopenia', 'systemic blood diseases', 'Cerebral Palsy|Age', 'syringomyelia', 'Novolog', 'Consistent', 'menstrual periods', 'renal impairment group.|Glomerular filtration rate', 'glucocorticoid therapy.|Use of', 'vaping devices', 'conditions on the study measurement tools)|21 years old', 'correlative studies.|Candidates', 'superficial vein thrombosis [SVT]', 'phlegm dampness constitution', 'national healthcare coverage', 'extrapulmonary organ dysfunction', 'non-syndromic retinitis pigmentosa', 'electrical injury', 'coagulation disorder.|Is', 'Valgus deformity|Body MAss Index (BMI)', 'concomitant diseases', 'Transfusion dependence', 'coronary bypass surgery|Tall', 'artery cannulation', 'prostatic hypertrophy|Patients', 'COVID-19 diagnosis code', 'carnitine translocase deficiency', 'gall bladder stones', 'teaching', 'peritoneal dialysis|Diagnosis', 'chronic anemia', 'pituitary gland prolactinoma', 'spontaneous menstrual bleed', 'DVT)/pulmonary embolism', 'contrast hypersensitivity', 'chancroid', 'respiratory episode', 'Wolff-Parkinson-White syndrome', 'major psychosis', 'malabsorptive disorders|Decompensated', 'somatic disease', 'APL', 'infections diseases', 'withdrawn from that study).|Inability to provide informed consent', 'chronic neuropathic pain', 'Long QT Syndrome).|Venous access', 'maternal morbid obesity', 'asymptomatic hepatitis B virus (HBV) carriers', 'intravenous bubble study', 'drink alcohol', ""Wilson's"", 'adjuvants', 'Hepatitis B Virus', 'Ocular factor', 'disc areas respectively', 'complex coronary lesions', 'parasitic infections of the gastrointestinal tract;|psychiatric diseases;|chronic inflammatory diseases of the gastrointestinal tract', 'ocular comorbidity', 'suicidal/homicidal', 'acute comorbidities', 'isolated lesions', 'intracranial infections', 'CYP3A4 substrates|Nursing mothers|Pregnancy', 'myocardial infarction;|Hypotension;|Internal malignancy', 'HIV infection|Received', 'stoma', 'multiple tumors', 'stopped nursing', 'primary tumor', 'Malignant head/neck', 'type 1 diabetes mellitus|Patients', 'internal root resorption', 'paresis', 'priority', 'bone metastases AP', 'hyperlipidemia/dyslipidemia', 'joint dislocation', 'remission|Cognitive impairment', 'alcohol-drug dependence|Patients', 'autoinmunological disorder', 'hemophilia B', 'HER2-expressing (immunohistochemistry [IHC]', 'dementia)|Lack', 'narcotic pain', 'renal disease|Hypertensive', 'valval varicosities', 'meaningfully engage', 'Spinal cord metastases', 'chronic hepatitis B infection', 'Gastrointestinal ulcer', 'significant diseases', 'additional malignancy', 'progressive neurologic disorders.|History', 'multifocal disease', 'colon cancer diagnosis|Stage', 'needles', 'IPAA|Bad functional outcome||', 'hypertensive disease', 'Psychiatric Disorder', 'chronic kidney disease (CKD)', 'cruciferous vegetables', 'breastfeeding.|Any condition', 'Psychosis', 'CCNE1 amplified tumors', 'ketones', 'Claustrophobia;Metal implants;chronic kidney disease≥stage', 'severe hepatic impairment', 'papillary muscle abnormalities;|age', 'TEN', 'ischemia).||', 'foveal ischemia', 'carcinoma in situ of the breast', 'ovarian endometriomas', 'tuberculosis (TB)', 'pulmonary artery thrombosis', ""worker's compensation claims relating"", 'Iron overload disorders', 'progressive supranuclear palsy', 'comorbid personality', 'malignant hyperthermia,|morbid obesity|Alcohol', '|• respondents', 'calculated in minus cylinder', 'posterior communicating', 'deep femoral artery', 'type 1 diabetes|Hypothyroidism', 'surgical illness', 'congestive heart failure.|Uncontrolled angina', 'haematological malignancy', 'Disability', 'events of pneumonitis', 'falls', 'kidney cancer', 'multiple accidental trauma', 'lobar degeneration', 'lactation', 'trichotillomania', 'Virginia', 'recurring pain|Injuries', 'inflammatory disease etc)||', 'chronic complications', 'structural congenital heart defect', 'lumbar spine surgery|Currently under care', 'Petersen 2004', 'non-proliferative retinopathy', ""Reiter's syndrome"", 'sleep profiles', 'serious lung disease', 'asthma episode', 'ischemic cerebrovascular disease.|Take ticagelor', 'C-section', 'coronary disease events', 'pulmonary TB disease', 'local anesthesia||', 'intent|Substance dependence disorder', 'psychiatric impairments', 'd)Hepatic focal lesions', 'fasciitis', 'migraine aura', 'cerebral vascular events', 'lymphoproliferative diseases', 'recovered from any toxicity of prior therapy', 'tracheal dysplasia', 'ileocolon bladder replacement surgery', 'weeks|Diagnosis', 'systemic scleroderma.|Blood diseases', 'malignant disease|rheumatoid arthritis', 'DSM-5 disorder', 'potent inducer', 'acute swallowing disorders', 'Encephalopathy grade', 'squamous-cell carcinoma', 'living independently|Dementia', 'uncontrolled disease', 'intra-uterine abnormality', 'non-treated', 'NSGCT', 'radiologic evidence', 'nervous disorders', 'atherosclerotic diseases', 'pose addiitonal risk', 'neurological impairment/disorder', 'optimal heart failure', 'human T-cell lymphoma virus (HTLV)-I/II', 'pseudarthrosis', 'IRF4 rearrangement Please note', 'special type diabetes', 'Allergies', 'risdiplam', 'brain metastases|Any', 'months|Symptomatic heart failure', 'Acid Reflux Disease', 'stage IIIC disease', 'participate||', 'above.|Able to communicate effectively.|Did', 'congestive heart failure.|Use', 'conjunctival eye involvement', 'aortic regurgitation bundle width/left', 'placenta', 'hepatitis C|Systemic infection', 'Nephrotic Syndrome', 'persistent hypotension', 'posttraumatic stress disorder', 'solid and/or cystic abnormalities', 'nodules', 'liver cirrhosis.|Patients', 'generalized retinal nerve fiber layer (RNFL) thinning', 'spinal cord injuries.|Patients', 'haematological abnormalities', 'acute physical illnesses|If', 'caries activity', 'psychiatric diseases.||', 'metabolic factors', 'Instrumental activities of daily living (IADL)', 'mucus|Active urinary', 'Serious basic diseases', 'hyperphosphatemia', 'inflammation', 'immune-', 'woody edema', 'localized lesions', 'pregnancy diabetes', 'oropharynx cancer', 'mainstream', 'atrial tachycardia ablation', 'Cholangiocarcinoma', 'processes', 'nutritional ketosis', 'QT-syndrome.||-', 'complete spinal ankylosis', 'claudication symptoms', 'cognitive disorders', 'Dysgnosia Neurogenic bladder', 'urinary diseases', '20/100', ""Petersen's criteria"", 'Secondary cause', 'Gastrointestinal bleeding', 'left ventricular dysfunction', 'bariatric surgery|current', 'severe thrombocytopenic purpura', 'quantify numbness', 'high-risk prostate cancer', 'hypersensitivities', 'primary T1 bladder cancer|Diagnosis', 'relationships in group settings|In', 'Familial Hypercholesterolemia|BMI', 'systemic health conditions', 'low microsatellite instability', 'hemorrhage', 'plain yogurt', 'hypoxia', 'ophthalmological conditions', 'renal anomaly', 'local sepsis', 'active cancer diagnosis', 'cured carcinoma', 'unilateral internal carotid artery (ICA)', 'various reasons', 'target ulcer|Leg ischaemia', 'luetic arteritis', 'throat swelling', 'hepatic synthetic impairment', 'meningioma', 'swallowing disorders', 'approval of diabetes', 'involvement of family continues', 'myasthenia gravis;|Preoperative delirium', 'renal artery occlusion', 'recurrence after surgical resection', 'IMV', 'acceptable physical condition', 'spleen deficiency syndrome.||', 'chronic total occlusion', 'Clinical dementia rating CDR=0', 'antidiabetic drugs.|Ability', 'non-suicidal self-injury behavior.|No virtual', 'asthma controller medications', 'partial colon resection', 'psychiatric diseases|Clinical', 'inactive autoimmune disease', 'Heart disease', 'preeclampsia', 'sensation', 'cutaneous adverse reactions', 'NED)|Xerostomia', 'sinus augmentation', 'extensive interstitial', 'Arrhythmia', 'thoracic cancers', 'malignant bowel obstruction', 'nonconvulsive SE', 'Child-bearing Potential', 'disease process', 'analysable tissue.||If archival tissue', 'chronic obstructive pulmonary disease|Technical', 'canal treated teeth', 'adhesions', 'episodes of facial paralysis', 'neurological disease,|Lack of', 'lesions|Addictions|Mental diseases', 'shoulder arthroplasty', 'NSCLC', 'pituitary diseases', 'hematologic malignancy|Diagnosis', 'chronic painful', 'adverse reactions)|Previously endovascular repair of the aorta|Only thoracic aorta|No informed', 'peritoneal dialysis.|Interstitial lung disease', 'primary malignancy.|Participants', 'pain palliation', 'signs of hypoperfusion', 'Pericardial disease', 'adenocarcinoma of the gastroesophageal junction', 'CR relapse', 'cholecystitis||Concomitant liver', 'Paget', 'urinary symptoms', 'neurologic symptoms', 'disorders related to immune suppression', 'mild cognitive', 'autoimmune esophageal disease', 'tumor crossing', 'vomiting|Gastrointestinal disorder', 'renal impairment|History of seizures', 'corneal conditions', 'prostate cancer', 'Hypertensive deep perforator arteriolopathy', 'exertional chest pressure/pain', 'acute coronary symptoms', 'cortical screws', 'human immunodeficiency virus (HIV) infection|Patients', 'M45', 'unexplained fever', 'glucose-galactose malabsorption.|Those', 'Myomas|adenomyosis|endometriosis', 'glenoid fracture', 'symmetrical positions', 'Oral tetracyclines', 'narcotic medication|Meet criteria', 'benign breast tumor', 'liver disease|Jaundice', 'stenosis', 'living beyond initial cancer treatment', 'chronic atrial arrhythmia', 'sarcoidosis.|Age', 'invasive lesions', 'memory impairment', 'large vascular disease', 'kidney functions', 'sleep-related breathing', 'investigator;|Intractable nausea', 'obstructive pulmonary disease|Patients', 'hot', 'cerebral shunts', 'determines', 'endometrioid endometrial cancer', 'renal function)|Life expectancy', 'human immunodeficiency virus (HIV) - protease inhibitors', 'VDS Mobile;|Prefers', 'systemic treatment|Small bowel obstruction|REGISTRATION', 'contrast media', 'infectious joint disease', 'damage', 'myelofibrosis', 'congenital QT syndrome|Resting', 'comorbid major neuropsychiatric', 'Nursing', 'arteriosclerotic peripheral blood', 'muscle spasm', 'multiple cardiovascular events', 'none of the exclusion criteria', 'acute attack', 'month|Objective pathological performance', 'Wilson disease', 'suctioning only|streaks', 'retinal surgery|Previous', 'poor oral hygiene.|Patients', 'Osteopenia/Osteoporosis', 'lack of support', 'corneal ulceration', 'contraindications|Inability', 'portosystemic shunt', 'hepatosplenomegaly', 'plausible cause of symptoms', 'Evolut™ PRO+', 'thinning', 'significant illness', 'progressive rheumatism', 'ACL injury', 'bDMARDs', 'consent|Infant', 'Cr≤1.5×ULN|Negative urine', 'estrogen-receptor positive', 'airway disease', 'components thereof', 'debilitating arthritis', 'gastrointestinal (GI) obstruction', 'drastic lifestyle', 'serious head injury', 'chemical burns', 'renal-mass patients:||Men', 'cochlear anomaly', 'arrhythmogenic heart disease', 'myelodysplasia related dysplasia', 'diabetic ketoacidosis.|Surgical admission', 'unpleasant sensation', 'myocardial markers', 'post-COVID condition', 'communication problems||Those', 'fetal heart disease', 'polypoidal choroidal vasculopathy', 'normal.||Exclusion', 'comorbid mental illness', 'unilateral TKAs', 'immunodeficiency disorder', 'acute promyelocytic leukemia.|Isolated', 'renal exeresis', 'lung cryobiopsy', 'patients|patients/crarers', 'hypothalamus-pituitary disease.|administration', 'Drug abuse', 'women|Chronic illness', 'gingivitis|xerostomia', 'throat pain', 'diabetes|male', 'risk factors related', 'Lymphoepithelial carcinoma Salivary duct carcinoma Adenocarcinoma', 'Inadequate vein access', 'anatomically intact', 'significant interaction potential', 'gastrointestinal (GI) function', 'non-invasive respiratory support|Parent(s)/guardian(s', 'enrollment.|Hepatic encephalopathy', 'circulatory arrest|Preoperative', 'pathological hypo', 'metabolic equivalents|Myocardial infarction', 'hiatus hernia', 'Kalafat E', 'brain parenchymal', 'substance misuse', 'extracorporeal circulation', 'and/or critical COVID', 'performance;|Ventilator dependence', 'semi-permanent', 'negative.||', 'skin phototype', 'retinal surgery.|Is', 'incapacitating psycho-affective disturbance', 'coronary heart', 'PSH', 'oncological comorbidities', 'others)|Chronic condition', 'Poor quality imaging', 'mild intermittent', 'impairment of the heart', 'non infectious', 'CSU inadequately controlled', 'HIV antibody test.|Presence', 'mild eczema', 'acute myocardial injury', ""neuropathy|Chronic kidney disease|Raynaud's phenomenon|Peripheral vascular disease"", 'Shoulder joint fear test', 'brain radiation', 'medullary plasia', 'neurosarcoidosis', 'feeling pain.||', 'carcinoma in situ /', 'Medical issues', 'chronic wound', 'ventricular rhythm disorders', 'shoulder infection', 'upper respiratory-tract infection', 'customized exoskeletal orthosis', 'Hypersensitivity disease', 'sleep apnea syndrome', 'professional competition', 'congenital lactase deficiency', '≤3.5mm.|Target lesion', 'systolic pressure≥160 mmHg', 'PAH', 'nucleic acid test', 'ASAS criteria||', 'arterial thromboembolic events', 'interventional study|Diagnosis', 'carotid artery disease', 'traumatism', 'years;|documented cerebrovascular accident', 'conjunctiva congestion', 'renal impairment', 'esophageal varices.|Patients', 'tumor burden', 'normal lateral', 'glomerulonephritis.||•', 'desquamating rash', 'urine pregnancy', 'bulbocavernous reflex', 'permitted.||Does not', ""Down's disease"", 'febrile neutropenia', 'limb ataxia', 'Gastrointestinal bleeding Anesthetic drugs', 'between -5.00D to +5.00D|Cylinder ≤ 3.00D|Normal K values', 'Costello syndrome', 'condoms.|Able to swallow 2 empty capsules size', 'end-stage renal disease', 'hypertensive encephalopathy.|Toxicity', 'partial cystectomy.|Prior malignancy', 'good compliance||', 'competitive sport.|Good health', 'Marfan syndromes', 'ring', 'liver invasion);|Cardiac function', 'growth factors', 'in situ cancers.|Participant', 'sensations of incomplete bowel evacuation', 'intra-articular injection', 'local recurrence', 'pathological changes', 'distal arterial occlusion', 'Malignant cancer diagnosis|Traumatic', 'monkeypox infection', ""anticonvulsive medication.|In the investigator's judgment"", 'superficial esophageal', 'adenomyosis', 'chronic stable hepatitis', 'mental disorder;|It', 'BW|CNS lymphoma', 'sclerosis', 'angina pectoris # myocardial infarction', 'Infectious diarrhea', 'auto-immune disorders', 'drugs;|pregnancy;|acute local', 'cerebral stroke', 'GHD', 'birth|congenital malformation|consanguinity', 'acute polyradiculitis', 'other disease', 'etc.)|Excessive alcohol', 'multiple-organ transplants', 'Los Coihues clinic', 'medical trauma', 'oral cavity|Autoimmune diseases', 'Multiple pregnancy.|Gestational', 'thoracic spine', 'CNS leukemia.|Uncontrolled infection', 'astigmatism', 'liver metastasis;|Kidney function', 'alcohol use', 'urogenital abnormality', 'HER2 overexpression by', 'APML', 'unexplainable sudden death', 'cardiac arrhythmias|Uncontrolled', 'paramedics', 'Narcolepsy', 'biochemical recurrence of prostate cancer', 'emergence', 'neutropenic fever', 'Vertical sleeve gastrectomy||iii', 'myocardial infarction related', 'anaphylactic shock)|Pregnancy', 'epithelial ovarian cancer|Documented platinum resistant', 'right ventricular enlargement', 'colorectal metastasis', 'inflammatory rheumatic conditions etc.)|Pregnancy|Malignancy|severe cognitive function disorder', 'heavy drinking', 'squamous non-small cell lung cancer', 'intracranial tumor', 'antimycotic', 'abdominal infections', 'vasovagal syncope;|Baseline systolic blood pressure', 'H. pylori eradication therapy.|Voluntary Hp eradication', 'Serious cardiac illness', 'regular menstrual periods', 'brain parenchymal metastases', 'nervous system diseases', 'Hodgkin lymphoma', 'CIN]/cervical carcinoma', 'shoulder anterior dislocation', 'criteria of the International Society of Ultrasound', 'anterior chest wall surgery', 'air oxygen saturation', 'healing disorder', 'T-scores', 'months|Cardiovascular disease|Comorbidities making', 'tortuous lesions', 'degenerative neurological disease', 'active bowel disease', 'impairs motor', 'loco-regional anesthesia', 'ICF)|Autoimmune disease', 'cytokine defects', 'psychiatric disorder|Self-reported', 'non-metastatic diseases', 'pancreatic cystic', 'nutricosmetic supplement', 'manifestations', 'Gynecologic Cancer InterGroup (GCIC) criteria', 'cardiovascular problems', 'amenorrhoea|Cephalic presentation', 'breast cancer|had completed breast cancer surgery plus chemotherapy|were able', 'oral intake,|On pain medications', 'AIDS-defining opportunistic infections', 'Hepatitis)|Renal insufficiency', 'Multidisciplinary ALS clinic|Currently', 'lactation.|Thyroid dysfunction.|Peripheral neuropathy', 'motor complications|DBS', 'indexes', 'spinal cord stimulator', 'although unplanned pregnancy', 'dermatological disease', 'intractable benign paroxysmal positional vertigo', 'Experience tinnitus', 'immune mediated disease', 'Spinal metastasis', 'regional recurrence', 'muscle dystrophy', 'magnitude.|Good candidate', 'competitors of renal tubular excretion', 'idiopathic clubfoot', 'neurological signs', 'ventricular rhythm disorders||For', 'Vestibular hypofunction', 'clinical examination||', 'syphilis infections', 'rotator cuff', 'HSV', 'months||Acute pain', 'urinary tract infection', 'Polyneuropathy', 'glenoid deficiency.|Patients', 'systemic targeted therapy', 'anginal symptoms.|Unable', 'congenital immunodeficiency diseases;|Active autoimmune disease', 'STEMI type myocardial infarction', 'chemotherapy sensitive', 'primary liver tumor(s)|Serum', 'HbSD', 'Myofascial Temporomandibular Disorder', 'hypotensive response', 'satisfactory response', 'inflammatory disorder|Paraneoplastic syndrome of', 'middle cerebral artery occlusion', 'brain scan results;|Refuse', 'cardiorespiratory disease', 'target intracranial lesion', 'RECIST 1.1)|Able and', 'idiopathic RLS', 'mediastinal B Cell lymphoma', 'aneurysmal disease', 'available muscle anabolic/catabolic agents', 'Criteria for', 'proctosigmoiditis', 'dentin hypersensitivity', 'Skin conditions', 'radiotherapy complications', 'myeloproliferative neoplasms', 'sepsis|Contraindications', 'Lower Urinary Tract Symptoms|married', 'breath fresheners', 'infection resolution', 'inflammatory joint diseases', 'Unable', 'coagulation defects', 'HAE', 'organic cause of pain)|Healthy control', 'nodules on', 'severe disability', 'cm)|Pregnant', 'Unstable metabolic condition', 'family history;|Needle fainter;|Those', 'proceeding', 'Vitamin D deficiency', 'paraffin-embedded', 'criteria for hypertension', 'surgically cured|Severe', 'complete bilateral cleft', 'mRNA coronavirus disease', 'Urinary Tract Infection (UTI)', 'intramuscular injections.|Contact', 'Eating Disorder Scale', 'bone disease.|Peri-prosthetic femur', 'NRU', 'CTCAE version 5 grade < and equal to1 prior to enrollment', 'autoimmune disease|Unstable cardiovascular disease|Glucose lowering medications', 'Sjögren syndrome)|intraoperative complications', 'fetal abnormality', 'associated symptoms', 'results.|Active infection', 'inter-1 risk CMML', 'congenital adrenal hyperplasia', 'motor disabilities||', 'discharged from the', '-risk myeloma', 'signs of aggressiveness and hostility', 'ophthalmologic diseases', 'chronic cerebral hypoperfusion', 'systemic disorder|Osteoporosis', 'disease quality of life index', 'hose', 'COPD,|Physician decision', 'hip pathology', 'conservative therapy', 'criteria of the American College of Rheumatology||had', 'hospitalization|Congenital heart disease', 'drugs|Known sensitivity', 'ipsilateral iliac lesions', 'autoimmune disease.|Untreated', 'swelling);|Bacterial infection', 'Transthoracic Echocardiography).|Aortic pathology', 'salivary duct carcinoma', 'malignant neoplasms.|Decompensation', 'bleed)|D-dimer of', 'syrinx', 'brain diseases.|Arrhythmia', 'epithelial skin carcinoma).|For', 'ml|lower urinary tract anomaly|urinary tract', 'chronic health', 'malignant ascites', 'pelvic mass', 'Parkinson disease.|Patients', 'HER2 positive breast cancer', 'trauma High intraoptic pressure Pulmonary Hypertension', 'hemorrhagic transformation|Subjects', 'physically capable', 'cerebral infarction disease.|Patients', 'esophageal cancer;|Radical resection of tumor', 'signs of progression', 'hemodialysis.|Hepatic insufficiency classified', 'growth factor support', 'major physical impairment', 'congenital heart diseases', 'retinal function', 'acute coronary syndrome|Treatment', 'implantable neurostimulation systems', 'P. vivax malaria', 'H02', 'psychotic disorder.|Diagnosis', 'previous myocarditis', 'lateral forearm radiographs;|Complete clinical', 'treatment.|Laboratory evidence', 'Adverse effects', 'IC|Reflex syncope', 'acute urethritis', 'HIV-negative||EXCLUSION', 'obstructive lung disease', 'active bacterial', 'ischemic rest pain', 'Initial atrial fibrillation', 'Acute Lymphocytic Leukemia', 'cardiac failure|<18', 'NP swab', 'affect', 'feature', 'hypoadrenalism', 'systemic malignancies', 'adhesive capsulitis', 'other eye diseases', 'age|Female', 'tumor stage', 'Singleton pregnancies|Previous cesarean deliveries|Gestational age (', 'cerebrovascular diseases;|12)The', 'preterm premature', 'complicated allergy', 'Scleroderma', 'good oral hygiene|18', 'recurrence-free time', 'tumour progression', 'mantle cell lymphoma', 'digital examination|COVID-19', 'epilepsy);|Mental disorders', 'multi-ligament pathology|Follow-up surgical procedures', 'membrane,|Primiparous', 'infectious diseases;|Those', 'traction bronchiectasis', 'cerebrovascular disorders;|a', 'ingredients;|Active infection', 'CT imaging|Patient', 'biopsy pathology', 'C.|Positive test result for HIV', 'Mood', 'terminal chronic disease', 'convulsions', 'poor quality of the images', 'fetal malformations', 'schizophrenia).|severe obesity', 'medication conditions', 'curatorship|Patient deaf', 'adenovirus', 'stage head', 'candidate for RTS segmentectomy', 'parasitic disease', 'syndromic conditions', 'their disorder', 'local skin', 'gastrointestinal illness', 'mechanistic confounders', 'hydration in neck', 'pectus excavatum', 'pregnancy failure', 'autoimmune rheumatic disease;|Patients', 'Pregnancy|Surgeries', 'galactosaemia', 'hypoxic seizures', 'amenorrhea', 'physician|Diabetes Mellitus', 'post-partum', 'treatment;|Current active hepatitis;|HIV antibody', 'epicranial venous accesses|upper respiratory tract infections|refusal of informed consent', 'Postoperative pathology', 'vascular complications', 'Significant mobility', 'neuromuscular disorders', 'Multiple Sclerosis', 'Impaired height', '●Visual defect', 'instability', ""secondary Sjogren's"", 'acute COVID-19 syndrome diagnosis', 'impact the quality', 'worse cognitive impairment', 'B)|Hemophilia severity', 'CNS lymphoma', 'Akkanat SBF Nursing', 'uncontrolled asthma|Asthma', 'multi-gene', 'punctal stenosis||', 'primary caregiver|With end-stage renal disease', 'BLB-201', 'posterior reversible encephalopathy syndrome', 'deep brain stimulation.|Use of ambroxol in', 'shoulder surgery|Presence', 'nasal flapping)|(5', 'multiple solid tumors', 'inducer', 'cervical spine pathology', 'target vessel thrombectomy).|Any', 'perennial nasal', 'malignant tumors;|Pregnant', 'clarify the etiology', 'San Francisco) classification', 'thyroid disorder', 'increased risk for breast cancer|Age', 'daily smoking', 'non-injury', 'liver cancer|Scheduled', 'lysis', 'Pulmonary tuberculosis', 'type 2 diabetes||Diabetes-related', 'tonic parasthesia', 'non-TED', 'recurrent pericarditis', 'pathogenic mutations', 'dependence that', 'clusion', 'not tolerate', 'baby intubated', 'left main stenosis', 'left sided', 'vascular occlusions', 'uncontrollable pleural effusion', 'aortic regurgitation valvular disease', 'anterior teeth', 'neurological disorder(s).|Active autoimmune disease', 'recurrence of the primary tumor', 'anserine bursitis|pain', 'malignancy in head and neck region|No', 'Mitral stenosis', 'significant disease', 'non-cardiac disease', 'nodes consistent', 'intermediate-2 risk PMF', 'hypothalamic obesity', 'infectious liver disease', 'others.|Enrollment', 'abdominal segment', 'CIS', 'disorder|unable to read', 'facility', 'aneurysm', 'RUBBERDAM', 'swabbing', 'etc.;|At present', '61)|≥1 measurable lesion', 'intestinal perforation', 'untreated obstructive sleep apnea', 'distant lymph node', 'autoimmune disorders);|Active autoimmune disorders', 'muscle stimulation', 'cognitive impairments', 'impaired renal', 'HBV)|Active autoimmune disease', 'mediastinal lymphoma', 'irritable bowel syndrome|Current', 'benign pathology', 'granulocyte colony', 'risk thereof|Splenomegaly', 'enemas', '|General pathology', 'erythema', 'drug abuse test', 'older|Confirmed COVID-19', 'delayed response evaluation', 'autoimmune diseases;|Known severe', '6MP', 'severity levels', 'pseudomembranous colitis', 'inflammatory bowel disease|Patients', 'tendency', 'Gynecologic Mesonephric', 'invasive breast malignancy', 'diabetes diagnosis|Blood disorder', 'hypoxic brain', 'rarely', 'Serological activity', 'restrictive eating disorder', 'transient ischaemic attack', 'lung diseases', 'ulcer diseases', 'chronic hypokalaemia', 'gastrointestinal disease|Abdominal surgery', 'ocular disease', 'thought', 'instable ischemic', 'Severe pathology', 'bulky calcified aortic valve leaflets', 'Primary Arthrosis', 'gradient lens', 'drug-induced hepatitis', 'liver dominant disease', 'nonischemic cardiomyopathy', 'disease of the digestive tract', 'Pediatrics', 'craniofacial syndromes', 'acute hypoxemic respiratory failure|Routine assessments', 'Respiratory system disorders', 'retinal disease', 'bone marrow failure disorders', 'current cancer diagnosis', 'significant hemorrhage', 'kidney +', 'idiopathic dilated cardiomyopathy', 'human T-lymphotropic virus (HTLV)', 'post-stroke', 'incompatible with safe use of a', 'clinical symptoms consistent', 'risk of bleeding', 'Major Depressive Disorder', 'smoking|Presence', 'progressive loss', 'medical risk', 'vitiligo localized', 'type of ophthalmic neuropathy;|Severe', 'respiratory muscles', 'colitis).|Systemic disease', 'non diabetic', 'metastatic disease', 'acute psychotic symptoms', 'motility', 'Systemic disease', 'sensory block', 'drawal of', 'motor deficit', 'concomitant liver diseases.|ALT/AST', 'dyskinesia;|age', 'light chain increase', 'intractable pain', 'spinal fractures', 'pneumococcal disease|Allergy', 'diurnal preference type', 'postoperative pathological', 'controller treatments', 'CCS', 'Uncontrolled epilepsy', 'radiation;|previous neck', 'anxiety disorder|Having any', 'Guillain-Barré syndrome.|Known', 'Pain Syndrome', 'complete wound', 'Central serous retinopathy (CSR)', 'ischemic heart disease|Acute exacerbation', 'Thoracic Oncology Staging Manual|Histological', 'Sinus arrhythmia', 'erythromyelemia', 'unrevascularized left main disease', 'poor risk cytogenetics', 'preferred).||', 'malignant tumors|10.Other conditions', 'cardinal signs', 'type 2 diabetes|Currently pregnant||AND||2', 'secondary diabetes', 'hyperparathyroidism', 'dialysis.|History of malignancy', 'major organ systems', 'Coronary artery disease', 'darigabat.||Healthy', 'gastrointestinal obstruction', 'ADT', 'chronic digestive pathology', 'chemotherapy.|Anti-cancer agents', 'esophageal lesion', '3|Anaplastic Oligodendroglioma', 'historic', 'leukemia', 'allergic reaction.||Inability', 'large vessel occlusion', 'craniospinal disorders', 'PEIT', 'substance addiction|Antisocial personality disorder|Inability to participate in group sessions|Current', 'acute lung disease', 'Seizure activity', 'carcinosis', 'NRAS mutations', 'allergic syndrome', 'Somatic - No', 'cardiac heart failure', 'to：||HIV infected (', 'recurrence developed', 'obstructive kidney disease', 'difficulties', 'atrial fibrillation.|Non-English-speaking', 'dry eye symptoms (Dryness,', 'Ingram Cancer Center', 'Common symptoms', 'varices', 'dietary habits', 'systemic lupus', 'acute therapy.||', 'proportion', 'malignant tumour', 'to receive', 'CD123-positive', 'alcohol addiction', 'orthostatic hypotension.|Positive hepatitis panel', 'local wound complications', 'heart attack);|currently', 'newborns need', 'pleural infection.|Known sensitivity', 'chronic kidney disease.|Evidence', 'age|Presentation', 'soles', 'extra matches', 'aplastic anemia', 'cirrhosis-related', 'Japanese encephalitis vaccination', 'intact cognition', 'itch', 'tactile sensitivity first', 'concomitant cancer', 'infection;|Mental disorders', 'Nasal bone deformity', 'haematological disorders', 'liver lesion', 'pathological Q waves', 'atrial tachycardia', 'MYC', 'risk factor for hypoglycemia).|No', ""HLRCC)|Reed's"", 'presbyopia', 'esophageal echocardiography|Pregnancy.|Disorganized arrhythmias', 'immune disorders', 'delayed allergic reactions', 'postural orthostatic tachycardia syndrome', 'uncontrollable diseases', 'pertussis', 'CADASIL', 'use disorder', 'SC injections.|Uncontrolled hypertension', 'therapy.|Symptomatic spinal cord compression.|Evidence', 'arterial revascularization', 'liver cancer/metastasis', 'tuberculosis ( TB )', 'carcinoma in situ of the uterine cervix', 'difficulty understanding the subject', 'second malignancies', 'lower extremity ulcers', 'primary symptoms', 'mental disorders.|Disturbance', 'oligometastatic disease', 'fundus varices', 'chronic pancreatitis||Note', 'pneumonitis.|Active autoimmune diseases', 'Clinical symptoms consistent', 'Autoimmune disorders', 'mutant', 'specialized home', 'serious complications', 'spinal fracture', 'angular gyrus', 'non-periodontitis', 'medical events', 'psychiatric disorders.|Anyone', 'in situ carcinoma', 'hereditary angioedema', 'fatal bleeding episode', 'acute exacerbation', 'low back pain', 'complete esophageal obstruction', 'duodenal atreaia', 'intravenous immune globulin', 'hematopoietic system diseases', 'living communities', 'extensive gastrointestinal resection', 'cigar smoking', 'pain of the knee|History of thrombosis', 'alcohol abuse.|Active pregnancy', 'breakthrough pain', 'Inflammatory arthritis||D. Peripheral vascular disease||E.', 'disclose PHI||', 'unresolved psychiatric illness', 'anterior prolapse', 'upper GI', 'major dietary changes', 'tests|normal menstrual cycles', 'complete left bundle branch block', 'essential thrombocythemia', 'chronic renal dysfunction', 'delirium|Contraindication', 'subepithelial scarring', 'ground glass opacities', 'cannulation site', 'muscle aches', 'esophageal adenocarcinoma pathology', 'follows:||Pulmonary embolism', 'toxicities', 'lymph nodes of the breast', 'progressive jaundice', 'PET', 'osteoarthritis matched', 'squamous cell Ca of adnexa', 'cognitive dysfunction;|Serious complications', 'disorder|Participation', 'extramedullary infiltration', 'MRD positive disease', 'adrenal metastatic carcinoma', 'hormonal functions', 'Adequately treated', 'in critical condition', 'weeks)|Neck pain', 'vertigo disorder', ""malignant hyperthermia|Raynaud's disease"", 'cancer|Structural abnormalities', 'school graduate,|Can read', 'biliary salt', 'cardial insufficency|Long term oxgenation therapy|immobility|BMI', 'chemotherapy.|Hormone receptor status', 'consciousness disorders', 'incurable malignancies', 'vitamin B12 supplements', 'to:||Nationality|Mental health status|Substance', 'serious diseases', 'pelvic inflammatory diseases', 'chronic systemic infections', 'abnormal physical', 'pituitary inflammation', 'SaO2', 'cautery', 'orthostatic syncope', 'type 2 diabetes|Own a smart phone/tablet|HgbA1c drawn', 'endometriosis,|Able to read', 'peripheral pulmonary lesions', 'chronic hepatitis of any etiology', 'non-palpable breast cancer', 'trachomatis', 'solid tumors].|Expected survival', 'organ bleeding', 'dry eye symptoms', 'CTA', 'DKD', 'Wiskott Aldrich syndrome', 'erythrocyte syndrome', 'pain|Uncontrolled pleural effusion', 'poor arrhythmia control', 'superficial cervical plexus block', 'Poor acoustic window', 'intraarticular fractures', 'severity of fibrosis', 'Chronic Pain Anxiety Depression', 'neurological diagnoses|Not being able to participate in a neuropsychological examination', 'intraabdominal bowel calcification', 'schizoid personality disorder', 'neurologic disease(59', 'thoracic malformation', 'substance dependence|Hospitalization', 'requirements|Contra-indications', 'pulmonary bulla', 'ASD|want', 'hepatitis B virus(HBV) DNA in', 'hypertension.|Inability to swallow oral medications.||Darolutamide', 'Non obstructive CAD', 'chronic infectious diseases.|Evidence', 'neuroinflammatory disease', 'incest', 'ESCC|For cholangiocarcinoma', 'Medically free', 'normal monthly menstruation', 'concomitant disease', 'infectious pathology', 'drug-induced liver disease', 'abortion', 'psychological fragility', 'bleeding control|Those', 'reflex syncope|had', 'critical cardiac disease', 'vaginal delivery)||', 'platelet inhibitory properties', 'cyanotic cardiac disease', 'end of chemoradiotherapy treatment', 'gastric varices|Significant motility disorder', 'mania', 'painful states', 'SUI', 'helminthic infection', 'non-melanoma', 'hemorrhagic shock', 'Fibroscan>9,5 KPa;|NAFLD fibrosis', 'dyshemoglobinemia', 'ophthalmologic inflammatory disease', 'right bundle branch', 'spine deformities|patient', 'possible interaction', 'difficulties|extensive concentration', 'preoperative pain', 'blood relatives', 'end-stage renal disease|Planned kidney transplantation||The expanded standard donors (ECD)', 'hysterectomy|Those', 'ocular symptoms', 'diabetes mellitus|chronic', 'pulmonary hypertension|Major surgery', 'pulmonary hypertension.|Participation', 'irreversible vision loss', 'undergoing cancer treatment)||If', 'claustrophobic anxiety', 'participation|Chronic liver disease|NYHA class', 'pancreatic adenocarcinoma', 'abnormal pain', 'general bone disease', 'HDRS', 'lipid abnormalities', 'internal carotid', 'head and neck malignancy', 'anosmia.|Major depression', 'TMJ disorder', 'severe drug allergy', 'dermatological disorders', 'Diabetic complications', 'abnormality', 'cancer related surgeries', 'autoimmune antibody', 'gastrointestinal conditions', 'SIS ≤4|Not understanding the Italian language|Patients', 'cardiac surgeon)|Eligible', 'COVID infection', 'vaginal infections;|Intaken antibiotics', 'SDC', 'chronic pulmonary hypertension', 'chronic immunological pathology', 'chronic pancreatitis.|participants', 'Kwashiorkor', 'co morbidities', 'penile-vaginal intercourse', 'tumor response', 'diabetes medicines', 'Ascites|Hyponatremia', 'autoimmune diseases;|6', 'mental illness|Females', 'primary colonic lesion', 'visible', 'Chronic hypertension', 'good', 'immunologic disease', 'progressive infection', 'Age<18 y.o.;|The Transcatheter Heart Valve (THV)', 'characteristics', 'pulmonary embolism|renal failure', 'cardiac arrhythmias|Cerebral vascular accident/stroke', 'interstitial lung disease', 'metal', 'splenic embolization|prior decompensation events|inability to fit into MRI', 'respiratory disease', 'palliative care.|Survival prognosis', 'acute ischemic stroke:|Lack of follow-up CT', 'functional etiology', 'SFTPC', 'superficial bladder tumor', 'critical illness', 'versus host disease', 'patients||Hemodynamically stable', 'muscle damage', 'arteriovenous thrombosis events', 'Esophageal squamous cell carcinoma', 'recurrence of leukemia', 'Infectious diseases,|Patients', 'Intracranial neoplasm', 'sepsis)|Chronic kidney disease', 'clinical data|Severe complications', 'unstable renal function', 'MTC', 'dressing)||France', 'lymphoma mass', 'myopic macular lesion', 'consistent neurologic', 'respiratory diseases.|Abnormal', 'benign inflammatory stenosis.|Concomitant bowel abscess', 'transanal total mesorectal excision', 'consumption of more', 'nonspecific neck pain', 'obesity', 'analysis|Cerebral bleeding', 'infections causing bacteremia', 'Type 2 diabetes recorded', 'adulthood|Allergic rhinitis', 'epithelial tear', 'menstrual cups', 'Newborns', 'haemostasis disorder', 'local complications', 'acute limb edema', 'squamous cell carcinoma|Patient enrolled in another clinical trial testing', 'months.|Radicular pain', 'acute coronary event', 'thromboembolic complications', 'cardio-embolic etiology', 'close margins', 'coagulation defects|Patients', 'hepatic medical condition', 'more|Current coffee drinkers', 'SSA', 'tans', 'Mechanical pain', 'Poor image quality', 'supine rest.|Renal impairment', 'liver disease.|Participants', 'structural lesion', 'AOHP contact lenses.|Habitual', 'adenocarcinoma', 'non-alcoholic fatty liver', 'lymphoblastic lymphoma', 'Healthcareworkers', 'multiple endocrine neoplasia syndrome type 2.|Have', 'Severe Intellectual disability', 'congenital scoliosis', 'neurologic events', 'Latent Autoimmune Diabetes', 'skull fractures', 'barriers', 'rapid sequence', 'acute coronary heart disease|Previous', 'hepatorenal disease', 'ocular tumors)|reduced transparency', 'bleaching', 'valvular heart disease;|Serious', 'clinical monitoring', 'DQB1 alleles', 'secondary atrial fibrillation', 'nationality', 'PDL-2', 'clothing', 'ankle joint injury', 'external genitalia', 'coronary arteries atherosclerosis', 'physical lmitations', 'Invasive Mycosis', 'lesions thought', ""Huntington's disease.|16"", 'above cardiac failure', 'Drusen', 'non-investigational anti-neoplastic agents', 'depression|Prior brain surgery', 'scoliosis developed', 'congenital myasthenic syndromes', 'N3 disease irrespective of', 'CD22 +', 'alcohol use disorder', 'renal transplantation||', 'physical examination|Participants', 'organic mental disorders', 'NAFLD', 'observable response', 'Anaemia', 'psychotic disorders/schizophrenia', 'communicable disease agents', 'wi-fi', 'inflammatory brain', 'chronic musculoskeletal conditions', 'hemorrhagic transformation', 'deep NMB', 'sepsis|Grade 2 /grade', 'myopathy|Hypothyroidism|If', 'IBS', 'primary disease medicine related', 'old)|Complaint of vagina laxity|Willingness', 'pre-menopausal status', 'Dysautonomia', 'diameter stenosis', 'DCIS', 'squamous cell cancer of the', 'Ponesimod', 'chronic bronchitis', 'sensory deficit', 'cold agglutinin syndrome', 'CAP', 'weight loss device', 'surgically sterile||', 'acute severe infection', 'weight monitoring', 'Cardiopulmonary insufficiency', 'acute febrile infection', 'pathology that involves', 'days|Leukopenia', 'colonic resection', 'difficulty in swallowing capsules.|Any condition', 'delayed hypersensitivity reaction', 'diastasis recti.|Surgery', 'Asymptomatic brain metastases', 'Singleton pregnancy|Pregnancy week', 'colonic transposition', 'painful stimulus', 'cerebrovascular events);|Any', 'primary care encounter', 'electrical devices|Subjects', 'good health status||', 'clinical hepatic decompensation', 'POMC', 'platelet aggregation.|Participant', 'maternal cardiac arrhythmia', 'Screening.|Seizure disorder', 'Lack of sensation', 'incidental adrenal mass|classic', 'monthly monitoring of ALT', 'type 2 diabete mellitus', 'psychiatric', 'tumor bone metastasis', 'lack of internet access', 'treatment.|Participant', 'stable antiseizure', 'degenerative changes', 'Prior infections|Retinal Disease', 'radical skin basal cell', 'developed tumors', 'pill esophagitis', 'autoimmune thyroid disorder', 'therapy|Partial response', 'congenital immunodeficiency diseases', 'juvenile arthritis);|restricted mobility', 'Upper extremity paresis', 'progressive dysfunction', 'Relapsed lymphoma', 'valvular disease,|anemia', 'cerebral vasculitis/', 'glaucoma.|Persistent toxicities', 'epilepsy drugs', 'etc.)|Current substance', 'Hemodynamically stable', 'breast-feeding|Any condition', 'chronic liver disease|allergy to montelukast|female', 'cauda equina syndrome|Coagulopathy|Allergic', 'ingredient present', 'etc.;|Newborns', 'hemodialysis|Atrial tachycardia', 'MIH', 'alopecia universalis.|Alopecia', ""worker's compensation"", 'similar conditions per investigator judgement', 'intracranial metastases', 'early-stage ALS', 'HIV infection|Poorly controlled', 'muscle relaxation', 'cardiovascular pulmonary', 'TIA||', 'cerebral diseases||', 'unconsciousness', 'neuromuscular disease', 'clinically inadvisable', 'paralytic intestinal obstruction|patients', 'eating disorders)|gastrointestinal disorders/disease', 'medication|Active tuberculosis', 'liver-related complications', 'radiculopathy', 'solid organ dysfunction|Patients', 'type 1 diabetic', 'phrenic nerve dysfunction', 'precludes', 'hemorrhagic', 'non-cardiac operations', 'Multiple sclerosis', 'profound neutropenia', 'signs of cutaneous dryness', 'endometrial carcinoma breast carcinoma', 'peritoneal carcinomatosis', 'severe autoimmune disease', 'catheter infection', 'chemotherapy|Known bleeding diathesis', 'asthma-related medications', 'left bundle branch block.|Patients', 'Traumatic Brain injury;|admission', 'malfunctioning|Acute infections', 'AOC', 'major adverse cardiac event', 'PTT', 'communication disorder', 'anarthria', 'Unresponsive Wakefulness Syndrome', 'hepatitis C;|History', 'transfusion-dependent', 'arteriovenous thromboembolic', 'post-HCT therapy', 'Acute illness', 'myopia', 'restrictive cardiomyopathy|Has active myocarditis', 'squamous cell skin cancer', 'myeloid tumor', 'bipolar disorder', 'antibody-mediated diseases', 'degenerative bone', 'hip joint disease', 'primary Amyloid Light chain (AL)', 'Secondary hypertriglyceridemias', 'grossly visible', 'oncologic disorders', 'Infertility', 'bronchial', 'applications', 'inclusion document.|Suspected', 'inappropriate response', 'coagulopathies', '15)|Acute exacerbation', '.|Acute infection', 'NMIBC', 'Ulcertive colitis', 'localized cutaneous fungal infections', 'uncorrectable INR>1.5', 'stimulant use disorder', 'primary immunodeficiency|Other malignancies', 'ENKTL', 'media', 'apparent dry eye', 'rectal fibrosis', 'pancreatic insulinoma', 'hallux valgus', 'FNA', 'maternal intrapartum temperature', 'hypochlorhydria.|Prior varices', 'increased pain', 'preterm', 'SKYTROFA', 'postoperative cognitive impairment', 'resected early', 'non-reticulated', 'liver metastasis.|Participants', 'gonorrhea],|Urinary tract infection|Osteomyelitis|Brucellosis|Toxoplasmosis,|Tuberculosis|Leptospirosis|Lyme disease|Mononucleosis|Hepatitis|Parasitic infections', 'Pregnancy Criticall illness', 'invalidates mismatch', 'pMN', 'insomnia;|excessive alcohol', 'Unstable/', 'chemotherapy|Tumor', 'ECG)).|Those', 'impact on balance', 'alpha-interferon', 'Gastrointestinal diseases', 'Prion disease', 'unresectable cancer', 'organic brain disorders', 'exertional angina', 'Criteria for exclusion of volunteers from the study:||psychiatric illness', 'essential tremor', 'therapy|Active seizure disorder', 'oral ulceration', 'indications|Type 1 Diabetes', 'allogeneic bone marrow transplant', 'restless leg syndrome', 'olanzapine;|Know arrhythmia', 'hemorrhagic event', 'sensitive mutation', 'brain injury|Presence', 'Coronary heart disease', 'mean systolic gradient across PV', 'corticoid', ""Meniere's disease"", 'upper genital infections|Patient under legal', 'hepatopathy', 'parafunctional habits.|Acute', 'chromosomal aberration,|premature', 'perimenopausal', 'unstable ischemic heart disease', 'pregnancy test;|Allergy', 'week|willingness', 'digestive system conditions', 'congestive heart failure;|Clinically significant', 'heart failure decompensation', 'prolonged loss', 'lithotripsy||', 'end-stage', 'platelet disorders', 'congenital immunodeficiencies|Patients', 'Pedal ulcer', 'seizures disorder', 'eye-sight', 'months|Hemodynamically stable', 'C', 'brain metastases;|Receiving', 'talar component change', 'scoring', 'cerebral vascular event|Active cardiac conditions|Valvular heart diseases|Hypotension', 'cardiovascular disease|neurologic conditions|disease affecting metabolism', 'exacerbation', 'Centre Hospitalier', 'JMML)||JMML', 'normal renal', 'months|Frequency', 'systemic neurological disease', 'somatic BRCA1', 'cycles).||Confirmation from the Centre des Thérapies Experimentales', 'MRI contraindications', 'continuous abuse', 'site;|Psychoaffective disorder', 'depression in remission', 'non-systemic therapy', 'lymphoma polyps', 'least 1 lesion', 'non-cardiac admittable diagnosis|HEART score', 'metabolic disturbances', 'unlimited;|Hepatic encephalopathy', 'non-serious', ""Parkinson's disease|Diagnosis"", 'Adverse Events Version 5.0 [CTCAE', 'carcinoma|gastric cancer', 'communication problems|Persons', 'squamous cell carcinomas of the skin', 'ketone supplement', 'Burkitt lymphoma', 'polytrauma.|Acute cerebrovascular accident.|Infection-inflammatory disease of CNS', 'somatic conditions', 'maternal pathologies', 'unresectable local advanced', 'palpable tumor', 'primary tumor locations', 'rupture', 'Alexandria Main University Hospital.||', 'm2,|unstable thyroid dysfunction', 'renal artery stenosis', 'thus', 'weeks.|Normal fundus', 'inadequate language proficiency not allowing', 'imaging|Active malignancy', 'bacteriuria threshold', 'extensive stage disease', 'Multiple Endocrine Neoplasia syndrome type 2 (MEN 2', 'intraoperative bleeding', 'vestibular symptoms', 'diabetes|Inability', 'terminates spontaneously', 'Interstitial cystitis', 'diphtheria', 'unresectable solid cancer', 'NET', 'Aortic pathologies', 'functional pain disorder', 'Maternal drug abuse|Infant', 'paranasal sinuses', 'unusual reactions', 'penile curvature||', 'anuria', 'tumour', 'involvement of the splenic hilar', 'subclinical insomnia symptoms', 'psychiatric diseases|covid-19 positivity', 'distress syndrome', 'former users', 'Surrey', 'criteria for IVF', 'personality disorders;|musculoskeletal diseases', 'pharyngitis responds', 'Diagnostic modalities', 'hypersplenism', 'acuity', 'colonoscopy:||Colorectal cancer', 'tissue infection', 'infections Organ/System', 'gastric varices|Coagulopathy', 'tumor disease', 'early lung cancer', 'gastrointestinal malignancy|Patients', 'acute episodes of illness', 'normal course of conception', 'hematopoietic system|Active cancers|Acute', 'ischemic-hypoxic encephalopathy', 'kidney stone glomerulonephritis', 'malignant disease', 'Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]', 'peptic esophagitis', 'respiratory sequelae', 'eighteen.|Submucosal', 'aortic lesion', 'gastrointestinal anatomy', 'coagulation markers', 'screening|Symptomatic disease', 'pathological types', 'carcinomas in situ', 'intracardiac shunt', 'CT + contrast', 'esophageal motility disorder', 'unilateral partner violence', 'gastric outlet dysfunction', 'congenital uterine abnormalities', 'scabies', 'RBC', 'liver transplant', 'cellulitis', 'non-COVID-19 inactivated vaccine', 'heart disease.|Morbid obesity', 'interstitial lung disease.|Patients', 'CRRT', 'cognitive competence,|Additional eye problems', 'hemiplegia|heart failure', 'refractory disease.|Phase', 'heart failure|Unstable angina', 'abstain from donating sperm', 'cerebrovascular accidents', 'thromboembolic events', 'oral malignancy', 'echocardiography|Subject', 'ADHD condition', 'or|>1 focal lesion', 'Pfizer COVID-19 vaccines', 'oral manifestations', 'surgical shunt', 'compromised circulation', 'Nephew handheld device illuminates', 'COPD|Chronic hypoxia', 'Simple Calculated Osteoporosis Risk Estimation', 't', 'uncertain interaction', 'debilitating lung disease', 'pain-free', 'acute respiratory', 'extensive ureterolysis|Blood loss', 'viral rhinitis', 'Normal Hepatic Function Only:||Healthy', 'peripheral T cell lymphoma', 'eye abnormalities', 'malaria species', 'cannula site infection', 'symptom', 'CH14', 'gastrointestinal reactions', 'bilateral lung disease', 'users||diagnosis', 'hilar cholangiocarcinoma', 'functional deficits', 'disease deemed not', 'neuropsychiatric disorders', 'amyloidosis', 'Metastatic breast cancer', 'thyroiditis', 'poor physical condition', 'fecal impaction|Suspicion', 'breast feeding|myocardial infarction', 'pain.|Extensive osteosynthesis', 'pellucid marginal degeneration', 'non-cardiac cause|Participation', 'hypoglycemic symptoms', 'intervention|Functional impairment', 'bleeding body constitution', 'underlying illness', 'colorectal sessile polyps', 'scalp oncologic defect|Complete', 'surgical weight loss procedures|medical conditions', 'exudative neovascular', 'complex regional pain syndrome type I', 'anti-angina medication.|PRE-REGISTRATION', 'histological type differentiation', 'visually induced', 'idiopathic sudden death', 'Consumption of water', 'intramuscular injection|myocardial infarction', 'PPP', 'deep vein thrombosis (', 'chronic pain disorder', 'Hypertrophic obstructive cardiomyopathy', 'non-melanoma carcinoma', 'Primary refractory MM', ""Alzheimer's dementia"", 'study:||Type 1 diabetes mellitus', 'Characteristic imaging manifestations of COVID-19 pneumonia', 'general hypersensitivity', 'leptomeningeal leukemia', 'portal vein tumor thrombus', 'skin reactions', 'granulocyte stimulating factor):||1', 'cancer disease|Serious disease', 'anomalies', 'noted subsequent progression', ""Parkinson's disease|Autoimmune disease"", 'leptomeningeal related tumors', 'nerves', 'neurologic diseases.|Participants', 'bronchitis', 'CRC;|Recist1.1-defined disease', 'Type 2 diabetes||If', 'e.g.renal impairment', 'neither cancer renders', 'acute myocardial infarction||Participants', 'TRASTUZUMAB AND PERTUZUMAB', 'cancer outside', 'craniocerebral injury', 'symptomatic COVID-19', 'malignant freckle moles', 'NE||', 'Cr≤1×ULN', 'femoropopliteal arteries|Significant stenoses', 'leukostasis', 'Type I diabetes', 'betel quid', 'type of cataract', 'cancer|clinical tumor classification', 'Significant pain', 'perforated wounds', 'uncontrollable infections', 'criteria|Myocardial infarction', 'germ cell tumors', 'Mixed urothelial', 'esophageal atresia', 'viral pneumonia', 'AIDS)||Allergies', 'hypertension.|Other diseases', 'psychiatric illness|Self-report', 'HZ', 'family member.|In stable condition.|Clear consciousness', 'differentiated thyroid cancer', 'tactile fever', 'peripheral neuropathy.|Female', 'those allergic', 'granulomatous vasculitis', 'Mental disorders', 'psychiatric disorder.|Failure', 'co-morbid', 'uterine anomalies|Maternal-fetal Rh alloimmunization', 'histological type', 'exfoliative skin conditions', 'light fat tongue', 'non-curative', 'criteria of the American Diabetes Association (plasma glucose', 'radiological stability', 'diabetic dry mouth|Usage', 'Coagulation disorder|Active infection', 'malignancy', 'HER2-positive', 'benign strictures', 'solid-tumor malignancy', 'hypercoagulable condition|Baseline study visit', 'milk proteins|chronic diseases,|carious lesions', 'pus on probing|bone loss ≤ 2 mm', 'creates', 'oral hygiene routine,|antibiotic treatment', 'NSTEMI', 'Wegener granulomatosis', 'EIS', 'secondary hypothyroidism', 'AML relapse', 'neuropathic muscular', 'Aβ deposits', 'hyper laxity', 'lateral +/-', 'postacne scars', 'mental illness', 'dysuria', 'mixed meal', 'Diagnostic Standards for Hepatitis B issued', 'disturbances of color vision.|History of arterial', 'right medial deltoid', 'organic brain diseases', 'hypersensitivity', 'amnestic', 'reading difficulties', 'Inflammatory Bowel Disease', '-MOP', 'umbilical cord mesenchymal stem cell-derived extracellular vesicles.|The patient fully understands the purpose', 'Diastema', 'Medical complications', 'female.|Oral squamous cell carcinoma', 'acute thrombosis|Presence', 'skin anytime', 'acne vulgaris', 'cognitive delay', 'autonomic neuropathy', 'spinal cord stimulators', 'adequate ulnar collateral flow', 'autoimmune condition', 'etc;|Pregnancy', 'modified duties', 'orthostatic tachycardia', 'QT interval corrected', 'stable angina attack', 'local anesthesic', 'prolonged loss of', 'substance abuse', 'none|ELIGIBILITY CRITERIA', 'end-stage phase of HCM', 'cardiovascular disease).||', 'rinsing', 'diagnosis code', 'extensive burn', 'tumor involvement', 'hypotension;|Uncontrolled autonomic', 'Pelvic floor muscle tenderness', 'corrective insoles', 'HIV positive).||I.', 'local anesthesia|Pregnancy', 'Ascites', 'preterm rupture', 'major heart', 'limit digital media use m', 'laptop computer', 'autoimmune thyroid diseases', 'Chronic Myeloid Leukemia', 'fathers', 'solid component', 'autoimmune liver diseases', 'PASC', 'chiropractic care.|Voluntary', ""Alzheimer's disease.|Not"", 'hepatitis *', 'left atrial appendage tissue', 'hyperhidrosis', 'relapsing BPPV', 'miscarriage syndrome', 'inadequate bowel cleanliness', 'perception of sensation', 'Syndromic diagnosis', 'met:||Residual invasive disease should', 'myasthenia gravis', 'canal sized #60', 'high-risk cardiac diseases', 'runny nose', 'feeding disorder', 'IMPs', 'drug abuse;|In the judgment of the researcher', 'neural invasion', 'peritoneal carcinosis', 'brain changes|Diagnosis', 'infective diseases', 'cardiac comorbidity', 'COVID-19 infection|According', 'positive human immunodeficiency virus (HIV)', 'congenital neurological defect', 'acute allergy', ""Hashimoto's disease"", 'intra-spinal disease', 'septicemia', 'TNEP', 'preventive dental health treatment.|Availability', 'Contraindications', 'ocular disease|Double', 'adrenal hematoma', 'psychiatric neurological disorders', 'dihydropyrimidine dehydrogenase (DPD) activity', 'urothelial cancer', 'episodic migraine', 'active cancer therapy', 'fear of water', 'dysthyroidism', 'macular degeneration|presence', 'pain-relief', 'diagnosis', 'chronic painful condition.|do', 'muscle pain', 'metastatic cancer', 'symphysis pubic joint', 'brain metastases|Use', 'Membership', 'adequate for tumor classification', 'treated carcinoma in situ', 'CNS disorder', 'symptoms of disease', 'cognitive conditions', 'paraesthesia', 'kidney transplant rejection', 'resting periods;|Able', 'AUD', 'infected diseases', 'reproductive plans||', 'diagnosis;|Obesity', 'cardiac arrhythmia Failure', 'Coronary Syndrome', 'organic problems', 'mental disorders|Medications', 'systemic organic diseases', 'hip surgeries', 'idiopathic LBP|report pain', 'myoneural disorders|Congestive heart failure', 'drug-induced liver injury;|Evidence of', 'Acute asthmatic attack', 'Interferons', 'protective measures', 'normalized ration', 'clinics|GERD', 'consolidation', 'Vitamin B12 deficiency', 'SOC', 'ICA', 'end-stage renal failure', 'present):||- Measurable', 'bleeding diathesis', 'renal tumor enucleation', 'Severe heart disease', 'Chronic viral illness', 'Classical Hodgkin Lymphoma', 'postoperative pain', 'chimeric cell therapy', 'unstable medical illness', 'Likewise', 'radically resected carcinoma', 'organic brain dysfunction', 'contraception', 'rare diseases studied', 'generalized periodontitis', 'prostatic intraepithelial neoplasia', 'sinus dysfunction', 'heart murmur', 'Cough', 'teeth in each jaw quadrant,|plaque index', 'COVID-19 pneumonia', 'non-invasive carcinoma of the', 'borderline resectable', 'malignant diseases', 'process.|Able to bring', 'lactation;|Allergic constitution', 'compromised immune system|patients', 'engage', 'heart failure|Myocardial infarction', 'additional disease', 'insurance.|Parent(s)/legal representative(s', 'valve disease', 'fertilized eggs', 'fungal nasal sinusitis', 'cervical spine injury', 'disseminated disease', 'lenalidomide refractory', 'progressive disease course|Pregnancy', 'esophageal erosion.|serious illness', ""erb's palsy/brachial plexus"", 'annular disruption', 'liver cancer - primary', 'persistent depressive disorder', 'functional iron deficiency||Hemoglobin', 'benign lesions', 'ocular motility', 'transfusion dependent', 'congenital brain hypoplasia', 'injury', 'cardiorenal', 'bulbar conjunctival congestion', 'ALA', 'intellectual disability.|Be', 'Resected specimens', 'primary peritoneal cancer', 'treatment:||Absolute neutrophil count (', 'malignant solid tumors', 'pharyngeal swabs', 'abuse;|Pregnant', 'chlamydia trachomatis', 'pseudogout arthritis', 'myocardial related symptoms', 'primary psychotic disorder', 'macular changes|Concomitant ocular disease|Not', 'ulcer lesions', 'HIV)14', 'spinal orthosis', 'binocular visual difference', 'cytomegalovirus', 'various indication', 'non-squamous carcinoma', 'recreational IV drug use', 'Positivity', 'cognitive behavior', 'SLNB', 'atypical ductal hyperplasia', 'tinnitus before working', 'controls);|Mental illness', 'musculoskeletal disturbances', 'Treated periodontitis', 'non-cardiac limitations', 'renal replacement therapy|Untreated', 'non-small cell lung cancer', 'nonischemic cardiomyopathy.|Known', 'APA', 'solid-organ transplantation.|Hypersensitivity', 'maligned disease', 'underlying conditions', 'mixed cholangiocarcinoma', 'corticosteroid inhalers', 'colorectal cancer.|Metastatic colorectal cancer', 'aortic stenosis|Recurrent syncope|Active', 'PCED', 'bleeding from the', 'drug-related pneumonitis', 'radiographic pathological condition', 'treatment|Unable', 'peritoneal dialysis||All Cohorts:||Participants', 'sleep effects', 'hypertrophic scars', 'HAP', 'hypersensitivity reaction', 'wrongdoing', 'contralateral microfocus score', 'anesthesia|Inability', 'normal BP', 'postural hypotension', 'complex polypectomies', 'bronchial wall thickening', 'medical risk factors', 'congenital uterine malformations', 'December 31, 2015', 'contraindicate contact', 'CNS lesions', 'mild alcohol use disorder)|Prior', 'Nivolumab.|Patients', 'anatomical asplenia', 'vocal cord dysfunction', 'uterine pathology', ""Waldenström's macroglobulinemia"", 'familial hyperchylomicronemia', 'knee osteoarthritis|Scheduled', 'ventricular tachyarrhythmias', 'fungal infection|Presence of any', 'Adverse effects of', 'suicidal', 'similar problems', 'Health Fairs services', 'poor compliance;||20', 'cosmetic facial procedures', 'sperm from the day', 'Amnestic MCI', 'MERS', 'immune disease', 'acute asthma symptoms', 'acute respiratory tract infection', 'Moderna COVID-19 vaccines', 'malabsorption syndromes|Known', 'COVID-19-associated', 'malignancy bronchoscopy', 'cardiovascular involvement', 'cerebellar disorders', 'persistent autoimmune diseases', 'identifying', 'depression consistent', 'Cerebral Palsy|GMFCS level', 'confirmed.|glioma', 'Bone marrow suppression', 'nerve root compression', 'pervasive developmental disorders', 'severe illnesses', 'major mental disorder', 'Stevens Johnsons syndrome', 'periodontal suprabony', 'serotonin syndrome', 'abdominal cancer', 'digestive system disease', 'Marlborough', 'retinal bleeding)|Tumors', 'lesions measurable', 'limb paralysis', 'in situ bladder cancer', 'atrophic', 'Rheumatologic disease', 'suicidal attempts.||Other protocol defined exclusion criteria could apply', 'motor disorder', 'haematological cancers.|Being Native Egyptian', 'Android mobile device (smartphone)', 'teeth in contact', 'permanent residence', 'axillae', 'valvular heart disease)|For', 'critically ill', 'Inadequate bone stock', 'endocrine system disorders', 'peptic ulcers', 'tumor immunotherapy', 'Cardiovascular disorders', 'aortic arch atheroma', 'heterozygous familial', 'etc.)||Ongoing bleeding', 'Culture', 'neurological system', 'Healthy men|BMI', 'sized pleural effusion', 'isolated TBL', 'HER2-negative', 'rotator cuff rupture', 'anatomical risk factors', 'disease significantly', 'necrotic lesions', 'surgery.|histomolecular pathology', 'gastrinoma', 'tuberous sclerosis', 'Pulmonary edema|Intracranial hemorrhage', 'condition.|Patients', 'uncontrolled epilepsy', 'chronic insomnia disorder', 'coronary vessels', 'congenital pupil defects', 'liver steatosis', 'extensive areas', 'Parkinson\'s Disease"" (ABC-PD', 'adrenal pheochromocytoma', 'AD:||IGA score', 'iced', 'allele mismatches', 'cardiovascular disease;|Oncological disorders;|Neurological symptoms of disorders;|Osteoarthritis;|Spondylolisthesis', 'drugs;|Chronic diseases', 'arterial hypertension.|Hypocalcemia', 'hemophilia B;|Had', 'cervical intraepithelial', 'vasculitis disease', 'vertebral fractures|Pancreatitis', 'neuronal stimulator', 'complex chronic conditions|Child', 'prolonged QT|Active seizures', 'acute toxicity admitted to emergency units of', 'Wilsons disease', 'gallbladder carcinoma', 'sperm-producing', 'pressure sores', 'endometrial sarcoma', 'Sleep apnea symptoms', 'localized basal cell', 'difficulty cooperating', 'second malignancy', 'glass opacities', 'bone marrow transplant.|Malignancy', 'PPA', 'emotional instability', 'perceptual disorders', 'Substance Use Disorder', 'renal function', 'implanted needles', 'illness.|Active infection', 'lower urinary tract surgery|Inability', 'bladder cancer|Do', 'chronic leukemia', 'thyroidal condition', 'months)|Acute pulmonary embolism', 'release|Returning', 'paroxysmal nonepileptic events', 'sunburn', 'pressure pain', 'ALS|Frontotemporal Dementia', 'NIV', 'meibomian gland', 'borderline-resectable', 'malignant tumors;|Implantation of functional electronic', 'HIV) infection', 'cervical spine disorder.||Peripheral', 'giant cell tumor', 'congenital immunodeficiency disease', 'emesis', 'non-CNSL', 'impaired aerobic', 'COPD)/emphysema', 'eye defects', 'heart defect', 'disease COPD|Male', 'hepatocellular carcinoma', 'polyp retrieval failure', 'confirm depression', 'lumbar', 'itrathecal anathesia', 'Unconscious', 'pulmonary complications', 'primary lesion', 'dialysis|Critically ill', 'encephalomyelitis', 'superior mesenteric artery|Known delayed gastric emptying|Known', 'complex lymphatic anomalies', 'oral sex.||', 'HER2 expression', 'dyslipidemia', 'destruction', 'skin type', 'intraoperative signs', 'dysrhythmia', 'mold infection', 'psychotic disorders|Self-reporting type', 'spinal cord injury|Previous', 'hepato-biliary', 'donate sperm；|The', 'physical conditions', 'Diabetic patients|Symptomatic coronary artery disease', 'cerebropathy', 'growth restriction', 'related conditions', 'similar patients)|Positive crossmatch', 'aortic stenosis)|Pulmonary hypertension||iii', 'etc.|Ocular abnormalities', 'malabsorption)|haematological disorders', 'mildly reduced left ventricular ejection fraction', 'hemiplegic CP', 'including||Hepatitis C virus (HCV)', 'cardiac ischaemia', 'poor candidate', 'isolated', 'under investigation', 'baseline.|Positive response', 'abrasions', 'therapies.|Taking other medications', 'confirmed malignancy', 'Cardio-specific', 'Intracranial hemorrhage', 'MDS on marrow examination', 'aspergilloma', 'intracranial jugular veins', 'post COVID-19 condition', 'mental health providers', 'skin infection|terminal illness', 'skin defects covering', 'end stage chronic disease . Furthermore', 'Diagnosed dementia', 'B personality disorders', 'Criterion A.|Able', 'chronic liver diseases|Recent', 'bronchial carcinoma.|Intolerant', 'gastroesophageal reflux cough', 'PTFE', 'chronic wounds', 'human immunodeficiency virus (HIV) infection.||8', 'invasive infection', 'heart failure therapies', 'thoracic lymph nodes', 'unstable condition', 'gastrointestinal malignancies', 'etc.)|Glomelular Filtration Rate (GFR)', 'substance abuse|Major', 'disease free', 'autoimmune complications||Active disease', 'other condition', 'mutant NSCLC', 'Iron metabolism disorders', 'type II diabetes mellitus', 'dementia|Positive Confusion', 'physical activity intervention', 'squamous cell skin', 'hives|Active inflammation', 'rectal adenocarcinoma;|Pathological differentiation', 'cardiopatie congenite e tumori maligni', 'acute wounds', 'meibomian gland dysfunction', '|Active tuberculosis', 'Arrhythmias', 'central serous chorioretinopathy', 'cardiac ascites', 'spastic hemiplegic CP.|Their chronological age ranged', 'multiple myeloma);|Coagulopathy', 'personality disorder;|depression', 'involvement of the main portal vein.|Hepatic vein invasion', 'right ventricular dysfunction', 'drug interaction', 'toxic psychosis', 'MEK', 'Conscious level.|Uncooperative patients|Those', 'schistocytes', 'screening|Uncontrolled diabetes mellitus', 'collecting duct carcinoma', 'extremely obese', 'sperm donor|BMI', 'esophageal diseases', 'contraindicating surgical resection', 'talking', 'upper gastrointestinal bleeding', '/capsular damage /weakness', 'nail biting', 'severe head trauma', 'foot ulcer', 'cerebrovascular ischemia/hemorrhage', 'possible malignancy', 'OADs', 'functional reversibility|Chronic respiratory failure', 'systemic illness|Known dementia', 'etc.)|Current use of', 'estimation', 'cancer),|neurological conditions', 'neglectful of their skin care.|Those', 'deep submucosal', 'vascular diseases', 'involvement in health-related litigation', 'actinic keratoses', 'impaired liver functions', 'chronic ailment', 'criteria of the 1990 ACR', 'respiratory infection', 'spinal canal stenosis,|The', 'GBM', 'antidepressants|Diagnosis', 'renal insufficiency;|had physical disability', 'vascular events', 'pain condition', 'bacterial pharyngitis', 'another risk factor', 'phsycological disease|Register', 'NK)||Clinical findings', 'incapacitating delusional ideation.|Patients', 'GI infection', 'non-castrate', 'substance abuse.|Major infection', 'CHF exacerbation', 'bipolar I', 'Myofascial Pain Syndrome (MPS)', 'neurological and orthopedic', 'heart disease including:||angina pectoris', 'gastrointestinal resection', 'cerebrospinal fluid (CSF) cytology', 'Type 2 Diabetes;|Glycated', 'Allergic disorders', 'infectious diarrhea', 'lateral neck', 'cognitive disorders incompatible', 'cardiac arrest', 'limiting physical disabilities - to the extent that they', 'ground-glass opacity', 'stable medical disorders', 'foot', 'Symptoms relapsed', 'EPI made', 'tract discontinuity|Sepsis', 'dermatological disorder', 'chronic medical conditions', 'acute myocarditis', 'lumbar discopathy', 'Android operating', 'Normal', 'pulmonary|hypertension', 'Type 2 diabetes|Part B', 'excessive tortuousity', 'tuberculosis|Immunodeficiency', 'G2 neuropathy).|Male', 'reflex abnormalities', 'localized injection site reaction', 'interstitial lung disease|Hepatitis', 'subjects):||- obesity', 'mild autoimmune skin disorders', 'skin sensitivity', 'tumour from the block', 'terminal renal failure.|Participation', 'malignant carcinoma', 'purpose,|Hemodynamically stable', ""asperger's syndrome"", 'psychiatric disorders|Inflammatory', 'RLS', 'aphasia|Normal functional neuroimaging', 'spleen', 'thyroid disease|Head', 'Postpartum Depression Predictors Inventory (PDPI)', 'chronic stable glaucoma', 'intracranial pressure probe', 'sight impairment', 'capillary hemangiomatosis', 'severe neurologic lesions', 'Pregnancy Allergy', 'appropriately certified).||', 'hip joint diseases', 'lower limb reaching performance', 'intraarticular pathologic conditions', 'hypercoagulability syndrome).|Participants experiencing', 'chronic heart', 'major depressive episode|Active substance use disorder|Participation', 'EBUS procedure|pregnancy', 'maternal death', 'ventricular septal defect', 'Eaton-Lambert syndrome', 'xerosis||', 'substance overuse', 'suppurative thrombophlebitis', 'cardiac pacemaker)|Tissue', 'corneal transplant.|Receiving', 'chest tightness', 'intracranial lesions', 'epigastric pain', 'biological response', 'alcohol abuse|Evidence', 'artifact)|Previous coronary artery bypass graft', 'intestinal ischemia', 'intolerance of the drugs used in the study.|Combined', 'persistent risk factor', 'before inclusion failure', 'family hereditary disease', 'prominent splenomegaly', 'intracranial abnormality', 'generalized polyarthritis', 'tachycardia-induced', 'pathological mobility', 'cognitive disabilities,|Patients', 'generalized lymphedema.|Pregnant', 'Benign Biliary Strictures (BBS)', 'another disease', 'primary neuromuscular disease', 'PDAC|No', 'major functional disability', '2017.|3', 'esophageal strictures', 'indicators:||Acute hypotension', 'tumor emergencies', 'impairment of lung function', 'systemic allergic reaction', 'lobar pulmonary artery', 'sadomasochism', 'genetic predisposition', 'Eating disorder diagnosis|Pregnancy', 'MMUT type methylmalonic acidemia', 'heart valve disease', 'mitral surgery|Patients', 'benign conditions', 'Remestemcel-L).|Participants', 'rhythm abnormalities', 'respiratory impairment', 'nuclear sclerosis', 'diagnostic code', 'systemic inflammation', 'poor drug compliance', 'hemodynamic changes', 'healed carcinoma in situ cervicis uteri', 'ASO', 'Infectious diseases', 'positive screen', 'spinal instability', 'neoplasms,|tendency', 'edentuolous site', 'difficulty swallowing', 'loading', 'positive symptoms', 'vaping daily', 'cardio/cerebral', 'congestive heart failure|Uncontrollable hypertension', 'PKU', 'difficulty focusing', 'consensus criteria', 'excessive alcohol', 'Esophageal stenosis', 'thrombotic events', 'eligible.|Hepatocellular carcinoma', 'infection of the index', 'major branches (LAD,', 'non-investigational intervention', 'recurrence risk', 'joint replacement)|Decompensated heart failure|Heart failure', 'esophageal stenosis', 'retinopathy', 'parathyroid carcinoma', 'manage plaque psoriasis of the scalp', 'idiopathic pneumonitis', 'neuroarthropathy', 'dental pain', 'Mutant', 'pancytopenia', 'alcohol abuse.|Other diseases', 'bleeding prone disease', 'portal hypertensive', 'fasting hypoglycemia|Pregnancy', 'non-melanoma skin cancer);|Patients', 'good general condition', '|Acute infections', 'bronchoalveolar lavage fluid', 'HBV', 'MELD score>35;|Other circumstances in', 'skin draping', 'needle mesotherapy', 'history|Those', 'congenital urinary abnormality', 'auditory brainstem response', 'HIV1/2 antibody', 'dextrocardia', 'solid tumor malignancy', 'deep venous thrombus', 'subcutaneous tumors', 'polyneuropathy', '2021)||Astrocytoma', 'prehospital cardiac arrest', 'third degree block', 'motor dysfunction', 'testicular disease|Fertility problems', 'hookwire', 'non-melanoma skin cancer in situ cervical cancer', 'ICR', 'facial nerve palsy', 'progestogen- containing', 'age|Signed parental', ""dadih's vla"", 'academic procrastination', 'drug reaction', 'fetal', 'alcohol consumption', 'cardiovascular disease|No', 'clinical AIDS|Screening transabdominal', 'physical activities', 'identifiable risk factors', 'verbal communication abilities.|The child', 'Hyperplasia', 'microcephaly', 'oral hygiene appointments', 'retinal disease;|have', 'brainstem', 'tachycardic', 'weight loss regimen', 'balance disorder|Primary sensory impairment', 'refuses to answer', 'noncompliant', 'anti-anxiety medication', 'kinase domain', 'epithelial bladder tumors', 'normal hepatic function', 'disorder|Pregnancy', 'etc.|immunodeficiency disease', 'neuromuscular diseases', 'psychiatric illness|Inability', 'subretinal fluid seen on', 'fetal tachycardia', 'cervical lesions', 'liver transplantation;|active', 'thromboembolic event', 'monoclonal antibodies directed', 'PSC)|Primary biliary cirrhosis', 'adjustment disorders', 'lower extremities|Acute injury of the musculoskeletal structures of', 'clinician', 'adenocarcinoma in situ of cervix', 'hypoglossal nerve stimulator', 'challenges related', 'Healthy lowlanders', 'neonatal co-morbidities', 'cancer-associated myositis', 'metabolic syndrome|Chronic elevation', 'allergic diseases', 'acute pulmonary conditions', 'asymptomatic reservoir', 'peripheral nerve blocks', 'BLV', 'Unwilling', 'multiple system atrophy', 'Physically active', 'Acute Promyelocytic Leukaemia', 'neurocognitive deficit', 'signet-ring cell carcinoma', 'individual eGFR', 'symptom of fever', 'IIID heart failure', 'psychological medical condition', 'facial nerve palsy|Infection', 'chemoradiotherapy；|Unable to tolerate chemotherapy；|There are at least one', 'dystonia;|Normal brain MRI;|The', 'renal tubular acidosis', 'immunologic disorders', 'associated stroke', 'diabetic mellitus', 'kidney function', 'delayed muscle pain', 'non-suicidal self-harm)|Recent', 'Bankart lesion', 'suppress ovulation', 'acute infectious illness', 'cerebral pathology', 'cardiac damage', 'CAD', 'traumatic brain injury|Pregnant', 'Hepatitis C virus (HCV) antibody (+)', 'arterial line', 'healing', 'bleeding.|Hemolytic disorder', 'spray-on', 'GLP-1-analoga|Emergency surgery|Chronic', 'thrombocytopenia', 'artery.|Cardiogenic shock', 'metastases of prostate cancer', 'Fever', 'mouse chimeric antibody', 'muscle injury', 'drug-drug', 'delivering', 'urinary disease|Previous surgery', 'respiratory viral infection', 'neurological evolution.|Neurological diseases', 'NSTEMI event', 'drug absorption', 'resected basal', 'concurrens serious', 'sight-threatening', 'neurological illnesses', 'disabling pathologies', 'neuromyelitis optica spectrum disease', 'ischemic heart', 'acquired pneumonia', 'drug treatment,|Endometriotic lesion', 'nerves|Inability to tolerate', 'himself', 'autoimmune skin disorders', 'prolonged QT interval corrected', 'female.|Age', 'symptoms observed.||(2', 'liver disorders', 'structural cardiac anomalies', 'insufficiency||cardiovascular dysfunction', 'uncontrolled seizures', 'depression.|Suffers', 'abnormalities', 'distal radius fractures', 'HEPA', 'chronic skin disease', 'staging', 'mildly obese', 'prostate cancer|Scheduled', 'early dementia', 'partial remission', 'eruption', 'scan|Allergy', 'screener', 'HER2 receptor taking', 'autoimmune rheumatic diseases', 'non-insulin-dependent', 'age|Major amputations', 'histologic confirmation.|Inability', 'Acute myocarditis', 'hereditary problems', 'radiation retinopathy', 'knee osteoarthritis', 'serious mental illness', 'automatically discharges', 'TZD', 'head injury resulting', 'transit metastasis', 'carcinoma|receive first cycle of chemotherapy|receive cisplatin-based chemotherapy|able to read', 'HIV-positive testing', 'concomitant illnesses', 'infectious pulmonary', 'terminal illness.|Participants', 'malignant tumor.||No', 'CF liver disease|chronic kidney', 'immunodeficiency.||Primary immune deficiencies.|Human immunodeficiency virus (HIV) infection', 'etc.)|child impairments', 'pancreatic ductal epithelium', 'cerebrovascular diseases,|Hematologic disorders|Liver', 'NSCLC|Measurable disease', 'Glenohumeral joint instability', 'bleeding symptoms|CT', 'RV) dysfunction', 'significant donor', 'acute cortical fracture', 'achalasia', 'procedure)|untreated arrhythmias', 'physical condition|In', 'hydrops fetalis', 'right colon cancer', 'chronic supplemental oxygen|Respiratory rate', 'clinical factor', 'therapeutic response', 'psychiatric diagnosis', 'pathogen|HIV', 'Alzheimer type', 'acute infection', 'gluteal folds', 'dyspnea', 'Lung Disease', 'end-exhale', 'intracranial radiation', 'menstrual cycles).|Subject', 'colon polyps', 'FS-1502.|Active infection', 'physiological abnormalities', 'significant bowel resection', 'non-cigarette nicotine containing products', 'HBcAb positive', ""Charcot's disease"", 'viral myocarditis', 'Inflammatory Bowell Disease.|Bilateral hip prosthesis', 'pembrolizumab.|Patients', 'sensitization', 'old.|Mandibular total edentulism.|Presence of sufficient', 'National AIDS', 'treatment|Active ocular infection', 'impairs speech comprehension e', 'infection|Severe heart failure', 'mild TBI', ""Graves'orbitopathy"", 'congenital malformation', 'liver disease kidney failure', 'Gastric stump cancer', 'covid', 'disease making', 'PHQ-9),|psychotic disorder', 'SpO2<90', 'HCV virus', 'malignancy.|Active infection', 'major depressive episode', 'heart failure|Anemia|Hemoglobinopathy|Sepsis', 'ferromagnetic', 'keratitis).||Criteria:||-', 'N20 cortical response', 'primary FS', 'shoulder pathologies', 'phacoemulsification cataract extraction', 'draining fistula', 'transfusion support', 'H. pylori eradication treatment', 'polytoxicomania', 'human immunodeficiency virus (HIV) test)||A subject', 'admitted alcohol abuse', 'communication barriers|Patients', 'systemic exposure', 'structural heart disease', 'psychiatric reasons', 'known cancer predisposition syndrome', 'A2B530', 'AIDS defining events', 'recurrent events', 'narrowing of the colon|Previous', 'Unable to tolerate', 'bone cancer', 'antithrombotic', 'neoantigen identified', 'irregularities|amblyopia|anisometropia|coexisting ocular', 'target individual', 'contraindicating canakinumab', 'sleep quality', 'interstitial lung disease).||', 'Interstitial Lung Disease', 'multimorbidity', 'respiratory insufficiency', 'FOLFOXIRI', 'upper respiratory tract infection|Emergency surgeries', 'phenylephrine.|Hypernatremia', 'hypoalbuminaemia', 'exercises|Exercising regularly', 'primary breast cancer', 'actionable genomic alteration', 'phonophobia', 'participation|Alcohol abuse', 'Hyper Mobility', 'substance dependence', ""Marfan's"", 'Underweight', 'females|Absence of', 'vascular hypertension', 'v5.0', 'neuropathic pain|patient enrolled', 'juvenile arthritis', 'neurological disorders;|Failure', 'respiratory comorbidity', 'carious lesion', 'hypotension (BP', 'chronic inflammatory disorders', 'breastfeeding.|Metallic implants', 'serous adenocarcinoma histologic epithelial cell type', 'chronic diseases of the cardiovascular', 'metabolic mineral storage disorders', 'superficial skin surfaces', 'polymyalgia rheumatica', 'arrhythmias;|Cardiomyopathy', 'symptoms indicating', 'medication|known allergies', 'OBI', 'Pain controlled', 'Fabry disease', 'tubal ligation|Abstinence', 'concomitant disease.||7', 'lobular carcinoma', 'old|Ability', 'solid organ transplant.|Participant', 'advance tumors', 'right ventricular cardiomyopathy', 'contradicted to MRI or TMS', 'hypertension.|Patients', 'Gestational Diabetes', 'Allergic diseases', 'MDD', 'acute hemorrhage', 'musculoskeletal cancer', 'MRSE', 'PAF', 'Anemia', 'spinal anesthesia||', 'ileus', 'contra-indicating', 'upper respiratory tract infections', 'arterial blood', 'cytomegalovirus colitis', 'psychiatric condition', 'rheology', 'Peripheral T-cell lymphoma', 'Lymphocytic Leukemia', 'acromioclavicular joint disease', 'serious health problems', 'kabuki syndrome', 'old|Bucco-palatal bone width', 'OVID-19 infections', 'right upper quadrant pain', 'basal cell skin', 'arrhythmia', 'specimens for sequencing', 'inclusive.|Healthy', 'non-invasive monitoring', 'vitreous degeneration', 'adverse hypersensitivity', 'photoaggravated pathologies', 'Native German speaker', 'ventricular ectopic beats', 'tumor type', 'rescue medicine.||', 'spine infection', 'bpm|Tachycardia', 'infection.|Presence of another malignancies.|Granulocyte count', 'human immunodeficiency virus positivity', 'World Health Organization (WHO)', 'cTTE', 'NSAI', 'colorectal disease|Digestive resection', 'hypothyroidism', 'contrast allergies', 'muscle imbalance', 'associated dysfunction', 'bladder alteration', 'GERD related symptoms', 'AIDS).||7', 'iodine|Chronic kidney disease', 'bariatric surgery|bleeding disorders', 'obstetric cholestasis', 'immunocompromise', 'spinal cord', 'measurable disease', 'Toxic Epidermal Necrolysis', 'gall bladder cancers', 'PsA|Patients', 'laparoscopy|Chronic respiratory failure', 'intake|Family income', 'Acute Respiratory Syndrome Coronavirus', 'progressive cancer', 'Active bleeding', 'acquired immunodeficiency syndrome', 'chemotherapy|PROSTATE CANCER', 'Identify', 'substance abuse.|Pregnancy', 'parkinsonism', 'pre-liver failure:||Extreme weakness', 'chronic kidney failure|pregnant/breastfeeding|medication', 'inotropic support', 'idiopathic RBD', 'infection|systemic manifestations of infection', 'resected tumor', 'judged by the investigator with clinical significance', 'referral', 'lesion', 'COVID-19 infection|Current', 'Liver tumors', 'non-intact', 'Hypocalcaemia', 'Acute health', 'habits', 'non-cardiac surgery', 'treated therapeutically', 'teeth extracted', 'giant intracranial', 'recovered from all AEs', 'neurotmesis', 'NSCLC|Start of chemotherapy', 'pain on clinical examination', 'other exacerbation', 'ISS:||•', 'spinal dysraphism', 'oral comprehension disorder', 'acute spinal pain|Acute arthritis', 'health problem', 'pituitary problems/surgery', 'sepsis shock', 'gastric sleeve)|Pregnancy|Bowel motility disorders|Minimally invasive pancreatoduodenectomy', 'multi-focal contact lenses.|Current', 'third degree heart block)|Any factors', 'drug abusers', 'pulmonary embolism|Type 1 diabetes', 'reversible pulpitis', 'cervical disc', 'head trauma (loss of', 'advanced cancer', 'Peritoneal metastatic carcinoma', 'nephrotic-range proteinuria', 'PsO)/psoriatic arthritis', 'sensitive substrates', 'Relapsed AML', 'Mentally compromised', 'percutaneous coronary intervention|Heart rhythm abnormalities|Congestive heart failure', 'sickle cell disease|Pregnancy', 'endothelial decompensation', 'optic nerve diseases', 'traditional Chinese medicine therapy', 'breast cancer.|If', 'motor neurone disease', 'thyroid disease', 'Guillain-Barré syndrome.|Behavioral', 'large liver tumors', 'chronic diarrhoea', 'degenerative ocular', 'familial adenomatous polyposis syndrome', 'T1b renal cell carcinoma', 'cerebral infarction.|Pregnant', 'perforation', ""Turner's syndrome"", 'right eye', 'primary renal glucosuria|Liver disease', 'latest infection', 'solid tumors.|Male', 'surgery|Otorrhea', 'natalizumab||NOTE', 'chronic nephritis.||Cardiovascular', 'Pathological fractures', 'skin pathology', 'trumatic mandibular fractures', 'proteinuria level', 'menstrual disorders', 'transitional epithelial carcinoma', 'solid tumor.|Physical state score', 'obstructive sleep apnea Hypotension (SBP <', 'competition participation.||Chronic ankle instability', 'pancreatic neuroendocrine tumor|Suspicion', 'spondylodiscitis', 'intra cranial metastasis', 'osteoporosis)|Peripheral neuropathy', 'unresolved issues', 'thymomegaly', 'GI issues', 'dysphagia)|cervical myelopathy|neoplastic lesions|vertebral artery insufficiency|upper cervical ligamentous instability,|spondylolisthesis|hypermobile cervical spine|cervical fracture inflammatory|cardiac', 'manic episodes|Severe psychological impairment|Previous use', 'yoga', 'bipolar mood disorder', 'alopecia areata', 'inflammatory disorders', 'acute cerebrovascular accident', 'gaming addiction|Lack of', 'causative disorder', 'implant procedure|Pericardial disease', 'lung disease', 'non-healed wounds', 'colo-colic anastomosis|No', 'servings of caffeinated', 'radiographic bone loss)|Dental implant mobility', 'synovial sarcoma', 'NSAD', 'dermatomyositis', 'confirmed|Active malignancy - Cancer', 'third of the crown missing|Children', 'acute coronary syndrome.||', 'liver impairment)|Cancer', 'specifically dermatomyositis', 'systemic autoimmune disease', 'curable skin cancer', 'acute bacterial', 'chronic dialysis|Hemodynamic monitoring', 'cardioplegic', 'hepatitis B virus vaccine', 'functional asplenia.|Autoimmune disease/autoinflammatory condition.|Any medical', 'COPD patients:||COPD', 'immunodeficiency syndrome', 'kidney disease);|Patients', 'Neck cancer treated', 'Male factor', 'POP', 'dyspepsia', 'HFrEF|Patient', 'Systemic autoimmune diseases', 'squamous differentiation', 'conditions precluded study inclusion', 'gastric motility issues', 'immunotherapy etc.)|Concomitant disease', 'criteria for psychosis', 'mechanical complication', 'from osteomyelitis', 'volume defects', 'shoulder pain', 'bone stock', 'hoarseness', 'tumors', ""Good's syndrome"", 'genetic problems', 'thoracic devices', 'biochemical recurrence of prostate-specific antigen', 'epatic failure', 'GC', 'brain stem', 'barrier', 'axonal injury', 'impairment of immunological function', 'herpetic infection', ""PFO's"", 'proliferative diabetic retinopathy', 'tumor progression', 'teratogenic effects * Therefore', 'allergic asthma allergic', 'NEU', 'H. pylori-eradication therapy', 'infection;|Unstable cardiac disease', 'allergy reaction', 'congestive heart failure rated', 'CAR T-cell', ""Dunnigan's"", 'placed other instruments', 'tRNA', 'Primary chronic insomnia|Comorbid chronic', 'genital itching', 'bulk CNS disease', 'unstable illness', 'secondary hyperparathyroidism', 'respiratory problems', 'stenosis in intracranial', 'skin discoloration', 'CNS disease|Participants', 'secondary antiphospholipid syndrome .|Patients', 'Monocular disease', 'nutritional status;|Neoplasm;|Contraindication', 'NCD', 'representatives', 'AIDS-associated', 'human immunodeficiency virus (HIV) antibody', 'months|Infants', 'mixed density', ""Parkinson's disease|have"", 'behavioral tasks|Absolute contraindication', 'mCRC', 'degenerative diseases', 'Irritable Bowel Syndrome (IBS)', 'complete psychometric questionnaires', 'implantable progesterone-based', '36.|High risk pregnancy', 'tonometry', 'sick cell disease', 'SUSVIMO', 'skin disorders', 'congestive heart failure.|History', 'tumor involves left language function area', 'patellar instability|Any contraindication', 'rheumatoid arthritis (', 'age||', 'skin lesion', 'colorectal cancer|Previous bowel resection', 'immunodeficiency diseases;||Pregnant', 'hepatomegaly', '25|Risser sing did', 'upper limb surgeries', 'surgical wounds', 'impaired end organ perfusion', 'unwillingness', 'psychological disturbance', 'gross hematuria', 'bilateral vestibular hypofunction', 'cutaneous stoma;|Food allergies;|Recent', 'inflammatory optic neuropathy', 'scale|Inability', 'curative intent|Plan', 'arterial thrombotic diseases', 'radioactive conditions', 'type psoriasis', 'judged by the investigator to be inappropriate for this study', 'solid organ transplantation;|Received', 'respiratory infection.||Consent', 'stork', 'cancer|Prior bladder cancer', 'pulmonary infection', 'visit.|Asthma stability', 'PSIS', 'extra-renal autoimmune disease', 'cerebral ischemic attack', 'consent collected from subject able to understand information given', 'Scoliosis', 'urgency incontinence', 'end-diastolic LV wall thickness', 'criteria of cold', 'conservatorship,|Mentally impaired', 'pack-years|signature', 'refractory /', 'Cushing syndrome', 'good health|Between the', 'PSI|Patients', 'anatomic pathology', 'intrahepatic cholestasis', 'MIMEDX', 'nephrotic rickets', 'MLO', 'ductal carcinoma in situ treated', 'urinary tract', 'Blood disorders', 'renal failure|Metabolic disorders', 'neck burns', 'co-infections', 'old|Septic shock', 'joint infiltration', 'paralytic ileus', 'arterial thrombosis', 'central neck', 'primary biliary sclerosis', 'EF', 'retina detachment', 'sepsis', 'NAFLD|Hepatitis B-C', 'required|Simultaneous bone augmentation', 'interpret', 'primary osteoarthritis', 'aperture', 'moles.|Pregnant', 'QT extension syndrome', 'acute pain|Contraindications', 'residual lesions', 'chronic diarrhoeal disorders', 'organ functions', 'orthopedic issues', 'violent behavior', 'thromboembolic disorder.|Personal', 'gastrointestinal disease.||', 'criteria of', 'plus disease', 'intracranial hemorrhage);|Subjects', 'renal disease|Neurological diseases', 'physical activity habits', 'adrenal insufficiency|Use of', 'HMDs', 'features', 'extremity lymphedema', 'Stevens-Johnson syndrome|active blepharitis', 'hepatitis C.|Patients', 'coagulation defects.|Acquired Immune Deficiency Syndrome (', 'linguistic impairments|Inability to participate', 'disease recurrence on aromatase inhibitor treatment', 'Screening.|Renal dysfunction', 'Malignant mesothelioma', 'inflammation (edema', 'leptomeningeal disease.|Active tuberculosis.|Significant', 'extrapulmonary tuberculosis', 'Irritable Bowel Syndrome-diarrhea type', 'respiratory disease|Significant renal disease|Significant liver', 'mild COVID-19 symptoms', 'uterine agenesis.|Body mass index (BMI)', 'smell,|No communication', 'squamous-cell skin cancer', 'small-cell carcinoma', 'disorder|Body mass index', 'M. tuberculosis', 'intracardiac thrombosis', 'spastic hemiplegic CP', 'myeloid malignancy', 'OXT', 'acute provoked', 'hematologic', 'specialization', 'uterine fibroids|American society of anesthesiologists', 'stricture', 'introducer sheath', 'viral hepatitis B', 'multiple sclerosis||', 'somatic symptom disorder', 'nose bleeds', 'acute coronary syndrome|Patient', 'lupus erythematosus', 'common cancer types', 'scars', 's/p thyroidectomy', 'congestive heart failure;|Acute', 'Primary cardiomyopathy', 'organic diseases', 'hepatitis B virus surface antigen', 'Mitutoyo Corp', 'deliberate self-harm', 'teeth in', 'Mexican', 'anchoring area diameter range 7~25 mm', 'above hypertension', 'chills', 'kinds of', 'traumatic causes', 'differentiation type', 'archival tumor', 'thrombotic disorder', 'Painful comorbidities.|Unemployed women.|Pregnant', 'digital rectal examination', 'motion sensitivity', 'squamous', 'fetal anomalies', 'spleen abscess', 'pathological diseases', 'alcohol breath tests', 'ambulatory units', 'colon cancer|Patient', 'Swallowing pills', 'Bursitis', 'instability|Pleural infection', 'Early Learning', 'judged by the investigator.|Any previous', 'knee braces', 'protected health', 'ventricular septal defects|ventricular assist', 'lifestyle modification', 'hepatitis B virus carriers', 'uterine cavity.||', 'hypercoagulability diseases', 'dynamic left ventricular outflow tract obstruction', 'nervosa|Owns', ""gastrointestinal disease(Crohn's disease"", 'clinical stage T1', 'ulcerative disease', 'fermented foods', 'serious conditions', 'coagulopathy', 'thrombotic events occurred', 'neuro-cognitive', 'AVNRT', 'renal impairment||A marked prolongation', 'localized pain', 'colitis', 'loose consistency stools', 'adverse outcome', 'shoulder joint).|Diagnosis of autoimmune disorder.|Initiation', 'AFO', 'nerve atrophy', 'occupational risk', 'tumor related pain', 'allergic bronchopulmonary aspergillosis', 'deep nerve block', 'judged as unable to fully comply with study therapy', 'Cognitive impairments', 'oral disorder', 'gastrointestinal insufficiency', 'fainting|Head trauma|Presence of', 'myocardial ischemia;||Severe cardiopulmonary', 'Angiographically compromised SB', 'reactive hyperemia index', 'painful area', 'chronic ITP', 'heart failure', 'obvious causes', 'low back pain)|Unresponsiveness', 'prolonged general anesthesia', 'medication;|Symptomatic brain metastases', 'hyperadrenergic state', 'pain sensation', 'symptoms controlled', 'acute cholecystitis beyond', 'granulomatous disease', 'consumption coagulopathy|subarachnoid hemorrhage', 'ocular hypertension', 'childbearing potential', 'decompressive craniectomy', 'clinical consideration', 'fetal anomalies|Contraindication', 'menopause', 'organ dysfunction', 'mitral annulus calcification', 'impairment|Myasthenia gravis', 'skin|Carcinoma in situ of the cervix', 'malignant pleural', 'Knee OA symptoms', 'sexes,|respectablee pancreaticoduodenal tumors', 'malignant neoplastic disease', 'hypertensive encephalopathy.|Symptomatic congestive heart failure', 'plasma', 'acute systemic disease', 'Thyroid dysfunction', 'cervical instability', 'Mental retardation', 'cardio-cerebrovascular disease;|Subjects', 'cerebral aneurysms||', 'Acute Coronary Syndrome', 'orthodontic bands.|Tumor(s', 'corneal disease.|Know human immunodeficiency virus', 'primary CAD', 'GI disease', 'psychological condition', 'hemorrhagic diseases;|Pulmonary hypertension', 'organ transplantation;|Concomitant diseases', 'pericardial constriction.|Invasive mechanical ventilation', 'atrial arrhythmia', 'hyperglycemic-hyperosmolar state', 'clinical laboratory profiles', 'asthma treatmen', 'antiepileptic drugs)||ix', 'excessive scarring', 'illicit drug abuse', 'syndrome.|Active ocular conditions', 'weight loss treatment', 'brain related injury', 'knee osteoarthritis.|Giving', 'multiple substance dependence', 'functional impairment', 'cachexia performance', 'anesthesia|Lack of response', 'chest recession', 'Fit', 'recreational cannabis', 'ophthalmic diseases', 'Clinical Dementia', 'radical melanoma', 'rejection.|Patients', 'solid component suspicious', 'gastric varices', 'chronic oxygen', 'mitochondrial disorders', 'CCW0T4', 'high-risk proliferative', 'liver disorders|Autoimmune disorders|Sickle cell disease|Placenta Previa|Abruptio Placentae|Eclampsia', 'breast-feeding|patients', 'wash', 'persistent toxicities', 'neurosensory disorder', 'solid tumour malignancy', 'abstain from tobacco', 'disease.|Progression of disease', 'Von Willebrand disease', 'balance deficits', 'brain-death', 'modified Hoehn', 'esophageal symptoms', 'finger loss', 'cardiorespiratory diseases', 'chronic pulmonary condition', 'Refusal', 'arterial thromboembolic event', 'active viral', 'child-bearing age|Pregnant', 'HIV 2', 'aortic stenosis|Severe concentric', 'impaired renal function', 'poor quality', 'little assistance;|Ability to understand and sign informed consent.||', 'messenger ribonucleic acid', 'non-melanoma skin cancer;|Patients', 'demonstrated disease', 'liver transaminase', 'peripheral vasculopathy', 'mental alteration', 'major residual complications', 'ILD/pneumonia', 'seizures.|Depression', 'neoplastic', 'myelodysplastic syndrome', 'OI', 'etc.)|chronic renal disease|peripheral', 'Neisseria gonorrhoeae', 'trauma-related', 'Mitral Regurgitation', 'functional ADAMTS13', 'F32', 'adaptations', 'Chronic Pancreatitis', 'substance abuse.|The', 'cervical disc herniation', 'infiltration;||Prior therapy wash-out - At least 2 weeks', 'septal', 'core antibody);|Positive', 'chronic neurological disease', 'neck stiff ness', 'imaging modalities', 'and|Unable to use the hearing aids', 'organ damage|unable', 'curative-intent', 'aortic wall', 'indicative of psychosis', 'HPV-induced etiology of the lesion(s', 'adjuvant platinum-based', 'ostomy', 'hypercoagulability disorder', 'summarized', 'sickle cell', 'pulmonary artery invasion|History of', 'Other factors', 'OUH', 'BCSC', 'apnea-hypopnea', 'right to', 'Virginia Commonwealth', 'addictive behavior', 'glioma', 'chromosome 21', 'liver functions', 'rotator cuff surgery', 'core biopsies', 'various causes', 'Adequately treated carcinoma in situ', 'Sleep Condition Indicator', 'solid meal', 'protein S deficiency', 'autoimmune disease;|Those', 'temporomandibular joint disorder|participants', 'milk protein allergy', 'chest water;|Atrial fibrillation', 'high-risk arrhythmias', 'AstraZeneca COVID-19 vaccine', 'local practice).||Clinically significant', 'hyperkeratotic lesions', 'exposed tendons', 'nasopharyngeal nonkeratologic carcinoma', 'PULMONARY TB disease', 'diabetic coma', 'chronic leukaemia', 'Arthrogryposis', 'malformations).|Cerebral amyloid angiopathy', 'glucose homeostasis', 'arrhythmic disturbances', 'deep intratumoral injection procedures', 'abdominal wall', 'psychiatric disorder.|Psychotic disorder', 'poor risk categories', 'heart murmur test', 'early menopause', 'cerebral anoxo-ischemia', 'situational prophylaxis', 'targeting', 'Type 1 DM', 'ankle injury', 'Vulnerable persons', 'immune thrombocytopenic purpura', 'hepatitis C or', 'Neurological conditions', 'physical scars', 'coagulation dysfunction', 'neuropsychiatric symptoms', 'neurological symptoms suggestive of', 'cough treatments', 'face-lift', 'Human immunodeficiency virus (HIV) infection', 'cyanotic cardiac malformations', 'steal syndrome', 'breast-feeding women|Subject', 'thyroid dysfunction,|history of', 'chronic hepatitis C', 'acute pulmonary edema', 'parttime staff||EXCLUSION', 'RHNe:|Ankle fractures', 'psychiatric abnormalities', 'nonsmoking', 'semi-quantitative assessment of the degree of aortic regurgitation', 'brachial nerve', 'systemic problems', 'cerebrovascular disease|Hachinski Ischemic Score', 'Hemophilia', 'pulmonary emphysema', 'limit evaluations||Exclusion Criteria', 'vulvovaginal symptoms', 'hyperandrogenism', 'eneral study]||Chronic pain', 'spinal cord surgery)|Onset', 'head injury', 'mild balance impairment', 'nerve block', 'electrocautery skin incision||', 'Univentricular heart', 'ventricular dysrhythmias', 'hepatitis B core antibody', 'atrial myxoma', 'scleral buckle surgery|cases', 'Alcohol Dependence', 'acceptable forms of birth control', 'Pacemaker|Arrythmia|Uncontrolled hypothyroidism', 'adrenal insufficiency.|Patient', 'suicidal ideation.|Liver function enzymes', ""Gilbert's disease|Patient"", 'vulvovaginal inflammation', 'neonatal death', 'hypercalcemia', 'chronic disorder', 'glucose-galactose malabsorption.|A', 'ETV6', '½ pack/day x', 'exceptions', 'major cardiovascular problems', 'lower leg anterolateral chronic', 'radiation cystitis', 'strain injuries', 'chronic pain condition', 'genital tract', 'HELLP syndrome', 'local neoplasia', 'Rheumatoid arthritis disease', 'lesion.|Vertebral deformity', 'Goldmann applanation tonometer', 'GVHD', 'diseases;|Chronic renal failure', 'morphological abnormalities', 'antibacterial mouthwash', 'mucosal melanoma', 'primary disability types', 'frozen semen', 'disease-modifying drugs', 'SpO2<92%.|Known human immunodeficiency virus (HIV)', 'Angelman Syndrome', 'Chronic Kidney Disease Epidemiology Collaboration', 'child-bearing potential.|Biologic therapy', 'neuroendocrine tumors', 'implanted devices.|Need', 'generalized periodic discharges', 'bleeding|Pregnant', 'degenerative disc disease renders procedures more technically difficult.|Coagulopathy.|Patient refusal', 'instability,|Pregnant athletes', 'Injury Severity Score>15', 'anticoagulants|Bladder obstruction', 'Congenital foot deformities Cognitive impairments', 'incidental findings', 'macular edema;|Perioperative complications;|Congenital', 'II disorder', 'cerebral oedema', 'Complex arrhythmia', 'MNV)|Early AMD|Healthy', 'major psychiatric illness', 'vital signs.|The', 'life-threatening reactions', 'knee deformity', 'abortifacient effects', '-related', 'pre-invasive cervical cancer).||4', 'breastfeeding|previous', 'pericarditis typical chest pain', 'affect immune function', 'epigastric burning', 'intrahepatic cholangiocarcinoma;|Tumor', 'gender-', 'gastrointestinal (GI)', 'malignant tumours', 'heart transplantation|End-stage kidney disease', 'cerebral artery aneurysm clips', 'İntracrabial pathology', 'adverse event', 'Citizen', 'competitive outcomes', 'breast cancer.|Unstable angina', 'former cigarette smokers', 'IDS', 'urinary reproductive system', 'swollen joint observed', 'sleep apnea', 'premalignant lesions', 'NSCLC - adenocarcinoma', 'severe disease|serious mental illness', 'effectively applicable', 'femoral nail', 'additional risk factor', 'Long QT Syndrome).|Require', 'pain medication|Spinal inflammation', 'entirely vegetarian', 'criteria of the Rode Kruis Vlaanderen', 'immunological disorders', 'Health Promotion Agency (NAHPA)', 'non-portuguese speaker', 'digestive tract fistula;|Unhealed wound ulcers', 'hypercardia tachycardia', 'physically able', 'leukemic PTCL', 'fencing', 'lower extremity amputation|Significant cognitive impairment', 'psychoses', 'COVID-19 disease', 'retinal anatomical abnormality', 'onset in the last', 'fish.|Diagnosis of diseases about collagen metabolism', 'confusion', 'Osteoporosis', 'Russell-Silver Syndrome', 'Suicidal Thoughts', 'Renal function:|6.3.1', 'not tolerate standard treatment.||Phase', 'cognitive limitation).|Participation', 'palmar hyperhydrosis.|Patients', 'diabetes-associated disease', 'chronic illness|plasma total cholesterol', 'needle fainting|Those', 'Sepsis', 'stage breast cancer', 'Haemato-oncology disorder', 'worsen', 'heart disease', 'breast cancer chemotherapy', 'renal impairment|Any contraindication', 'Intensive care nurses', 'sclerosis|Stroke|Serious psychiatric condition', 'kidney dysfunction.|Allergies to milk', 'pregnancy related complications', 'cognitive deficit', 'eosinophilic bronchitis', 'computer);|lives', 'teeth have', 'source|Pulmonary hypertension', 'renal failure).|Contraindication', 'gallbladder disease', 'systemic anticancer treatment|Contraindication of anaesthesiology character|Contraindication to MRI|Participation', 'solid non-infiltrative disease', 'Coronary Artery Disease (CAD)', 'inner elbow', 'vagus nerve stimulator', 'Chediak-Higashi syndrome', 'autoimmune disease.|Patients', 'MUD', 'cervicogenic dizziness', 'vascular related diseases', 'normal)|V Rarely burns', 'Atrial fibrillation', 'cerevascular malformation', 'diabetes type 2', 'chronic rhinosinusitis', 'eosinophilic esophagitis|Hiatal hernia', 'respiratory physiotherapy', 'left main', 'arrythmia|allergy', 'coronavirus infection', 'clotting factor abnormality', 'bisoprolol dose|Uncontrolled diabetes mellitus', 'GERD)|Smokers|Pregnancy', 'MELD-Na', 'major organ injury', 'hyperosmotic hyperglycaemic non-ketotic', 'immunosuppressive medications|Toxicity related', 'Infectious Diseases Sequential Scale', 'materials|Ability', 'muscle injuries', 'type 2 MI', 'chronic intestinal diseases', 'Parkinson', 'local cities', 'inclination', 'pruriginous lesions', 'chronic analgesic', 'Glaucoma', 'Type 1 diabetes', 'primary sensitivities', 'depressive disorder)|other than MCI', 'liver congestion lesions', 'progressive multifocal leukoencephalopathy).|Patients', 'relapsing after standard therapy', 'TIA).|Symptomatic carotid', 'progressive neurological deficit', 'monomorphic VT morphologies', 'cognizance;|body mass index', 'hydroxychloroquine.|Collect', 'supraventricular arrhythmias', 'cancer thrombus', 'candida cultures', 'Pregnancy,|Lack of health', 'C6 of the CEAP classification(1', 'congenital long QTcF syndrome', 'incompatible with electroporation', 'normal sterile', 'melena', 'acute aortic', 'Previopus endoscopic', 'visual hallucinations', 'hepatitis B virus (HBV) DNA test|Negative hepatitis C virus (HCV) antibody test', 'ionisation radiation', 'soft tissue injuries of the affected finger or adjacent fingers', 'intoxication.|Respiratory impairment', 'colon adenocarcinoma', 'retinoid', 'pre-implantation', 'polycystic ovary syndrome', 'spina bifida', 'juvenile DM', 'nutritional fragility', 'read', 'learning disabilities).|Inability', 'neurological disease Seizures', 'vision impairments', 'ILD)/pneumonitis', 'smoking of any substance', 'carcinoma in situ of the oral cavity', 'fertile', 'RVO', 'ANCA-associated vasculitis', 'Exclusion criteria||Neurological injury', 'pulmonary thromboendarterectomy', 'spontaneous bleeding abnormality', 'pain|Uncontrolled', 'tuberculosis infection.|Patients', 'dizziness|Implanted', 'Clostridium difficile', 'etc.|Pregnant', 'old,|Acute pancreatitis', 'pose a risk to the subject safety', 'status).||Women', 'exists.||For', 'neurological diseases|previous hysterectomy', 'cognitively disabled people|mechanical ventilation', 'musculoskeletal diseases', 'platelet disorder', 'chronic disease|pregnancy|general contraindications', 'exposed to any immune checkpoint inhibitor;|Participated in another study;|Immunodeficiency;|Received allograft；|Unmanageable hypertension', 'M. tb infection', 'singleton pregnancy.|Second trimester.|No contraindications', 'immune deficiency/immunosuppression;|Diagnosed', 'lymphatic/vascular invasion', 'non-cardiac cause', 'wean off pain medications', 'Type I', 'thrombotic episodes', 'Heparin Induced Thrombocytopenia type 2 (', 'left ventricular outflow tract.|Stroke', 'bleeding diseases', 'multiple factors', 'impaired balance', 'signs of bruxism', 'bone health', 'sexual dysfunction', 'detectable HIV viral load', 'metastases outside liver', 'unstable cardiac condition', 'giardiasis', 'physically unable to give their written consent', 'MIGS', 'chloramphenicol', 'MRI.||Endocrine disorders', 'skin manifestations', 'diabetic tractional retinal detachement threatening', 'pain - located', 'hepatitis B.', 'unstable angina|Retinitis', 'chronic lateral epicondylitis', 'scleroderma', 'multi-organ failure|No', 'Aphonia', 'ocular surgery.|Systemic diseases', 'Screening.|Any malignancy', 'Parkinson disease', 'open-heart surgery', 'mental retardation', 'pulmonary lymphangitis', 'removable orthodontic braces/bands', 'valvular pulmonary stenosis', 'days;|Optimal corrected vision loss', 'external webcam.||- Exclusion Criteria', 'restricted mouth openings', 'cutaneous adnexal melanoma', 'stroke|Patients', 'Primary adrenal insufficiency (', 'corneal oedema', ""Hodgkin's lymphoma"", 'years|Clinically stable', 'disease progression by observation', 'acute heart failure', 'freckles -like moles', 'good-quality retinal', 'bicipital tendinitis', 'Genitourinary system disorder', 'subjective cognitive impairment', 'thyroid eye disease', 'pectus carinatum', 'cancers|Prior cancer', 'edentulous maxillary', 'renal diseases;|uncontrolled diabetes', 'heart failure.|Is', 'bigeminy', 'SARS-CoV-2.|Participant', 'uncontrolled immune-related endocrinopathies.|Abnormal pulmonary function', 'bundle-branch', 'Hypertensive disorders', 'potentially fatal cancer', 'pulmonary embolism.|History of aneurysms', 'intracranial metastases;|Known', 'acute suicidal ideation.|Patient', 'chronic renal failure', 'language problem', 'Tenderness', 'basocellular carcinoma;|Current', 'chronic dialysis|Acute urinary obstruction', 'exhaustion', 'capillary leakage syndrome', 'acute T-lymphoblastic leukemia', 'supraspinatus tendinopathies', 'Male clients', 'sustained hypertension', 'primary OAG', 'absorbable threads', 'concha bullosa', 'chest drain', 'changes in chest imaging', 'acquired dyschromatopsia', 'non-degradable internal fixation system', 'N3 neck disease', 'CTA|Pulmonary hypertension', 'familial history consistent with pHLH', 'structural lung disease', 'TXA', 'symptomatic pericarditis', 'sadness', 'unstable mental disorders', 'Bipolar Disorder (BPD)', 'scleral buckle', 'neurological pathology|Clinical depressive syndrome|High', 'intracranial subarachnoid', 'PARP', 'digoxin', 'hereditary bleeding tendency', 'liver decompensation', 'hepatitis C (HBC)', 'mixed carcinoma', 'acute cause of pain', 'trauma exposure', 'syndromic myopia', 'deep fungal infection', 'resectable lesion', 'muscular dystrophy', 'non-study ETT|Declined', 'developmental malformations', 'drug side effects', 'gluten-free', 'epidural metastasis', 'hereditary macular disease', 'infected', 'variceal hemorrhage', 'binge drinking', 'bleeding diathesis|pregnant', 'brain malformations;|neonatal', 'vocal cord paralysis', 'carotid stenosis|Permanent residence', 'mitral valve insufficiency', 'pathological origin|Sudden cardiac arrest|Documented', 'intraventricular hemorrhage', 'middle chest', 'Paramedic', 'relevant diseases', 'allergic skin diseases', 'discretion', 'rheumatic heart disease', 'LV systolic dysfunction', 'abuse disorder', 'non-small cell lung cancer|Patients', 'gestational diabetes mellitus', 'hemorrhagic esophageal varices', 'pulmonary condition', 'extra-pulmonary neuroendocrine carcinoma', 'transient abnormal myelopoiesis', 'acute impairment of functional status', 'mixed genotype', 'organ abnormalities', 'intense respiratory muscle work', 'B-cell', 'caffeine dependence', 'paroxysmal supraventricular tachycardia', 'problems|endocrine diseases', 'congestive heart failure|Decompensated', 'BC', 'lack of toe proprioception assed', 'HIV 1/2 antibodies', 'muscle relaxation exercise', 'ischemic EKG', 'erosive esophagitis', 'inferior', 'non classical variety.|Patients', 'companion', 'chronic)|1', 'fungal infection|Positive serum test', 'retinal artery occlusion', 'neurosensory retinal detachment', 'Contact dermatitis', 'GI abnormalities', 'Pancreatic pathology', 'mix-infection|Healthy individuals', 'antiepileptic drug withdrawal', 'rectal swab collected', 'vein|Acute pancreatitis', 'lack the', 'Health personnel employed', 'acute symptoms', 'adequate renal function', 'CTCAE v5.0', 'lack of smartphone|homelessness', 'technical aids', 'intractable bronchial asthma', 'psychotic disorder;|At', 'Major gastrointestinal problems', 'ABPI', 'Unifocal disease', 'renal mass|Caucasian', 'cerebrovascular disease)|Head', 'mild cognitive impairment (MCI)', 'systemic involvement', 'swallowing difficulties', 'anxiety treatment.|Severity of symptoms', 'build', 'abnormal findings', 'renal cancer|Unstable angina pectoris', 'passive ER-ROM', 'Noyes', 'Depressive disorders', 'inguinal hernia', 'thymoma-associated', 'viral vascular diseases', 'asymptomatic prostatic cancer', 'systemic effects', 'singleton living fetus.|Previous', 'subjects:|Presence', 'topical treatments.|Eczema Area Severity Index (EASI', 'controlled Carcinoma in situ of the cervix', 'splenomegaly|Massive nodes', 'eosinophilic granulomatosis', 'narcotic consumption Inability to provide', 'trabeculotomy', 'painful diabetic neuropathy', 'Grant', 'right ventricle', 'ulcer wounds', 'self-prone', 'AV block type II', 'thromboembolic event.|Patients', 'systolic BP', 'T-cell large', 'diseases of the gastrointestinal tract', 'abstain from taking', 'hyperplenism', 'Hereditary BC genes', 'morbidly obese', 'old|Alcohol Use Disorde', 'pose risk', 'ischemia.||Ischemic symptoms', 'liver disease cerebrovascular accident', 'substance use disorder.|Pregnancy', 'acute limb ischemia', 'cerebrovascular diseases', 'functional foods', 'signs of cancer', 'C virus', ""Child's"", 'lesions outside', 'Corneal scars|Patients', 'Lymphoma', 'acute facial palsy', 'extensive adhesion', 'demyelination.|Uncontrolled hypertension', 'Sleep disorder', 'osteopath', 'type 2', 'bipolarity', 'cancer;|atrial fibrillation', 'evaluable disease', 'Germ Cell Tumor', 'Acute complications||', 'QTc syndrome', 'biochemical menopause', 'arterial ulcer', 'atrial fibrillation)|Renal', 'hepatitis B core antibody [HBcAb]', 'CT plain', 'hyponatremia', 'Leukemia', 'mobile LV thrombus', 'mild hepatic impairment', 'ankylosing spondylitis', 'adenomyoma', 'multivessel coronary artery disease (CAD)', '|brain tumor', 'lower extremity tibia', 'cholangitis)||vi', 'primary ITP', 'arteriovenous malformation', 'skin breakdown', 'meningeal involvement', 'contraindicating', 'PML);|Malignancies', 'effusion', 'hip fracture', 'proliferative retinopathy', 'months|Anemia', 'chronic disease.|Diagnosed', 'Hepatitis B virus carriers', 'gastric ulceration', 'zone).|Previous corneal cross-linking', 'heart rate (HR)', 'diabetes|Mental instability', 'cervical fracture', 'optic nerves', 'Right upper quadrant mass/pain/tenderness', 'extrahepatic distant', 'uterine cancer||Symptomatic', 'imaging|Patients', 'parafuctional habits', 'Major organ functions', 'variceal bleeding).|Participants', 'corneal opacities', 'type 3A', 'suicidal attempt', 'pulmonary heart disease', 'acute pancreatitis', 'infectious keratitis', 'duodenal-pancreatectomy surgical', 'stereotactic brain radiotherapy<1', 'deep breathing techniques', 'uveitis.|Are', 'urinary infection', 'arrhythmias|Significant cognitive impairment', 'ALL', 'neutropenic sepsis', 'reversible ischemia severity', 'sigmoidal resection|Portal hypertension', 'bone problems', 'Structural scoliosis|Patients', 'residual depressive symptoms', 'liver cirrhosis.|Symptomatic brain metastases', 'human immunodeficiency virus [HIV]', 'inflammatory disease|Study', 'Glioblastoma', 'replacement|Percutaneous transluminal coronary angioplasty', ""Crohn's disease.||The"", 'head and neck cancer', 'co-morbidities;|Recent', 'HBsAg).|Participant seropositive', 'unstable physical health', 'nasopharynx carcinoma', 'tetanus', 'palpable abnormalities', 'structural abnormality', 'HER2 amplified', 'parkinsonism-syndrome|Participants', 'cardiac insufficiency', 'malignant process', 'poor glycemic control||Patients', 'chronic immune', 'Lactating', 'RTH', 'Shoulder girdle', 'pancreatic insufficiency', 'Zimmer Biomet components implanted in accordance with product labeling||', 'heart rhythm', 'generalized developmental', 'flash pulmonary edema', 'hepatitis B vaccination', 'arterial hypertension||', 'adverse reaction.|Subject', 'chronic hepatitis B (HBV) infection', 'toxoplasmosis', 'SNHL', 'Anatomical risk factor', 'ureteral stone|Urinary diversion|Active infection|Untreated cancer', 'analgesic', 'autoimmune disease;|Severe infection', 'trehalose dihydrate', 'acute stage)||-', 'alcohol', 'actively suicidal|the presence', 'infection symptoms', 'amelogenesis imperfecta', 'tumor growth rate', 'strain lesion type', 'cerebrovascular disease.|Participants', 'autism spectrum', 'Acute pulmonary embolus', 'hemoptysis', 'uncontrollable neurological', 'colorectal cancer risk', 'episodes|Typical clinical manifestations', 'mydriatic eye', 'chronic underlying disease', 'extracranial lesions', 'rare actionable genomic alterations', 'failure|Renal failure', 'NOS|DLBCL associated', 'amnesia|Concussive symptoms', 'post-menopausal', 'is measurable disease', 'T3N1M0', 'delayed gastric emptying syndromes', 'uncontrolled angina', 'fistula', 'myocardial ischemia', 'infections|Known allergy', 'definitive dental care', 'hypercellular myxoid liposarcoma', 'siblings', 'defibrillator.|Ongoing infection', 'Cognitive Impairment (MCI)', 'replicating', 'chemotherapy|Eastern', 'intestinal dysfunction', 'progressive central nervous system (CNS)', 'right-handed;|diagnosis', 'lateral collateral ligament|A', 'apnea|Need', 'H3K27M midline', 'CRC', 'ia||Sex', 'cystic periventricular leukomalacia', 'Ovulatory dysfunction', 'persistent AKI', 'duodenal-jejunal bypass sleeve', 'primary stenosis', 'PAD', 'UPS', 'hepatic flexure)|Surgical resection', 'brain metastases/CNS', 'hepatitis B core Ab [HBcAb]', 'chronic respiratory insufficiency', 'drug-related', 'duodenal polyps', 'language communication', 'prolonged PQ', 'solitary thyroid nodule', 'SBRT lesions|Patients', 'psychotic disorder.|Current', 'distant metastasis.|Participants', 'back pain|Patient', 'pervasive developmental', 'visual impairments', 'gt;2L', 'anorectal disease', 'systemic anticancer drugs', 'positive.|18', 'HIV]/acquired immunodeficiency syndrome', 'HLA - A0201', 'tegaderm', 'respiratory disorders', 'Lumbar instability', 'although', 'primary immune deficiency.|10', 'ventricular tachy-arrhythmia', 'external beam radiotherapy', 'Infectious disease', 'complex cardic anomalies', 'impairment of mobility', 'GREM1', 'cumulative seizure', 'insertion.|Medical disorders', 'homolateral cardiothoracic surgery.|Allergy', 'EDS)|Participation', 'obstruction', 'malignancy|Urogynecologic disorders|Females', 'amnesia', 'involvement of the first branch of portal vein', 'cholangiocarcinoma recurrence', 'urine protein immunoelectrophoresis', 'sesbania agati', 'pain disorder', 'papillary disease', 'localized PC', 'metal allergy', 'solid organ transplant|Active therapy', 'etc.);|Pregnant', 'clinical indication lesions', 'sickle cell anemia', 'gastroenterological interventionalists', 'tuberculosis test', 'Systemic lupus erythematosus', 'cerebral vasculitis.|Evidence', 'refuses participation', 'shoulder dislocation', 'hyperthyroidism|Pregnancy|Failure', 'dysmenorrhea', 'competes', 'type 2 diabetes', 'included)||Definition of refractory:||No response', 'demonstrated disease progression', 'restenotic lesion.|Target lesion', 'Common exclusion criteria|Left-handedness', 'virus-associated', 'place to stay', 'nasal septum deviation', 'ility', 'end-stage organ', 'prolonged period', 'eligible|Gastrointestinal pathology', 'manic episode|Is currently imprisoned', 'respiratory', 'neurological causes', 'acute inflammatory process', 'lumbar epidural lipomatosis', 'consent|Regular menstrual cycle', 'cranial anatomical alterations', 'dry AMD', 'oncogenic PIK3CA', 'choanal polyps', 'Singaporean citizen', 'silicosis', 'auditory', 'months;|Diabetic ketosis', 'acute plaque', 'malignant tumours|Patients', 'malignant tumor|Any', 'self report)|right', 'Adverse pregnancy reaction', 'facing', 'folic acid', 'Black/African', 'PROM', 'irregular heartbeats', 'mild traumatic brain injury/concussion', 'congenital hepatic fibrosis', 'disagree with the research requirements', 'reversible adverse events', 'dermatological disorders-psoriasis', 'intermittent hemoptysis', 'cervical cancer in situ treated', 'invasive bladder cancer', 'substance abuse condition', 'depressive symptoms', 'mild Covid-19 (WHO criteria)/Confirmed diagnosis', 'musculoskeletal injury/operation', 'facets of attrition', 'atherosclerotic', 'facial palsy', 'congenital anomaly', 'cerebral parenchymal', 'germline ATM', 'hemorrhagic tendency', 'bone fracture.|Renal failure', 'PT010', 'pigmentary disorders', 'intentional communication behaviors', 'severe obesity', 'study outcome', 'malignant tumors.|Life expectancy', 'regional block', 'portal hypertension;|Peptic ulcer', 'Us', 'metastatic prostate cancer.||3', 'carcinoma in situ of any type', 'chronic intractable obsessive-compulsive disorder', 'Loose stools', 'respectively).|300 cancer', 'sinus lift', 'oral supplemental probiotics', 'hypertrophic scar', 'lateral growth tumors', 'available liver enzymes results', 'localized prostate cancer treated', 'family income', 'umbilical cord blood', 'chronic diarrhea', 'amoebic dysentery', 'Qp', 'chronic HBV infection', 'comfort care measures only.|Refractory shock', 'CRPC', 'Diabetes mellitus type', 'signs of gastritis', 'cervical spinal stenosis', 'comorbidity risk(s)', 'communication disorders', 'newly HIV', 'keratitis', 'Medium brown', 'sleep|any allergies', 'nr-axSpA', 'genetic neurologic disorder', 'course of disease', 'acral melanoma', 'acute abnormalities', 'intravenous thrombolysis||', 'calcific tendonitis', 'congenital condition - inability to stop taking anticoagulants', 'swallowing difficulties.|Age', 'primary myelofibrosis', 'inhibitor|Previous histologic', 'demyelinating syndrome', 'CAA', 'Limb Ischaemia', 'poor oral hygiene|radiation therapy of head and neck cancer|intraoral soft', 'activity;|Pregnant', 'plain radiography findings', 'hepatitis B.|Co-infection', 'situations that the investigator believes', 'repetitive seizures', 'acute cerebral infarction', 'intestinal metaplasia', 'disease.|Participant', 'e.g.suicidal ideation', 'visual field.|Refractive disorders', 'surgical procedure|Hypercapnia', 'oral hygiene', 'rubeosis iridis', 'digestive tract diseases', 'Acute coronary event', 'malabsorption disease', 'intracerebral haemorrhage,|chronic', 'sequelae of PDR', 'superficial skin infection', 'spinal cord compression|History', 'autoimmune hepatitis', 'PPI dependent', 'early discharge by violating treatment', 'ophtalmological involvement', 'patellofemoral dysplasia', 'mass', 'measurements|Aortic ectasia', 'VEGFR', 'drug induced', 'Medically stable', 'local activity', 'licensed vaccines', 'procedures.|Skin lesion', 'colorectal cancer|Patients', 'cerebral arteries', 'frozen', 'neurologic dysfunction', 'oral mucositis', 'replicating HBV', 'Prevention.|For', 'lack of infarction', 'hepatitis E.|Hospital admission', 'incurable disease arising', 'retentive teeth', 'CML', 'adequate pharmacological treatment|Continuous NSAID use|Preferably otherwise medication-free', 'MDS', 'ambulatory peritoneal', 'prostate cancer|Strong', 'heart disease||', '≥8 days|Have', '3)Angina pectoris', 'Neurological pathologies', 'present ulcer', 'myocardial infarction|Insufficient mental', 'colonic mucosal', 'orthopedic injury', 'historical home BP assessments', 'etiological disorders', 'strawberries', 'abuse of illicit drugs', 'retinoschisis', 'myeloid growth factor support', 'transperitoneal partial', 'condition.|Recent surgeries.|Pregnancy.|Back pain', 'cardiovascular diseases|Evidence', 'deviates notably', 'pulmonary hypertension)|Cardiac disease', 'cranial trauma', 'Farsi', 'consent|Clinically stable', 'isolated gestational diabetes', 'progressive hearing loss of the contralateral', 'regions Ocular symptoms', 'progressive pathology Renal', 'old:|B-ultrasound', 'contagion from COVID-19|For', 'renal artery aneurysm', 'sweeteners', 'thrombotic microangiopathy', 'host response|Inability', 'feeling of tiredness', 'impairment in mental status', 'traumatic injuries', 'liver metastases ≤5', 'ventricular failure', 'restless leg syndrome)|progressive', 'male breast cancer', 'fundus lesions', 'left atrial spontaneous echo contrast', 'toxicity', 'systemic infection|Patients', 'diabetic ketosis', 'pulmonary embolus', 'behavioral disorder', 'Glioblastoma outside', 'recurrence', 'distal biliary stricture|Need', 'neurologic disease|other severe', 'progressive supranuclear gaze palsy', 'good general health||Key', 'rare embryonal tumors', 'know human immunodeficiency virus (HIV)', 'renal pelvis', 'consumption.|Patients', 'Granulomatous lung disease', 'large prospective cohort study', 'age|Diabetes', 'showed abnormal', 'cardiovascular disease', 'tuberculosis|Clinically severe', 'neurologic pathologies', 'bleeding', 'judged unsuitable to participate in the study by the Investigator', 'arteries overlap', 'eosinophilic gastroenteritis', 'high disease', 'intranodular lesion', 'cervical lymphadenopathy', 'cerebral ischemia/hemorrhage', 'Personalized Cancer Therapy', 'tumor-related diseases', 'chest surgical wounds', 'salivary gland', 'sporadic', 'IMDC symptoms', 'chronic lesions', 'chronic HBV carriers', 'Disc lesion', 'congenital syndromes of the craniofacial area.|Anterior', 'arteriovenous fistula', 'stressors', 'Pregnants', 'Acquisition', 'good organ function.|Male', 'left appendage closure device|Presence', 'hypertension|Celiac disease', 'chronic renal failure.|Patients', 'cerebrovascular accidents|Recent cardiac', 'parents);|Able to read', 'acute pulmonary embolism', 'uncontrolled angina pectoris', 'systemic anticancer agent', 'functional speech', 'eliminated gravity', 'breast carcinoma', 'anoperineal dressings', 'peripheral vascular disease.|The participant', 'epidemic defects', 'paraplegia bone metastasis', 'Colorectal Carcinoma', 'empyema', 'skin changes).|Prior treatment', 'bladder dysfunction.|Children', 'judged by the treating physician', 'Knee Osteoarthritis', 'acute conditions', 'electrolyte abnormalities', 'osseointegrated', 'lower back pain', 'cardiac event.|any', 'allowed.|Uncontrolled hypercalcemia', 'anatomical anomaly', 'mellitus|Scleroderma|Memory impairment', 'myometrial invasion.||', 'extensive chronic', 'BT', 'intact pulmonary function', 'exon 14 skipping', 'potential malignancy', 'impaired glucose', 'unacceptable adverse events', 'extracranial metastases', 'autoimmune encephalitis', 'cerebrospinal meningitis', 'chronic HCV disease', 'muscle degenerative disorders|Drug', 'cancer in', 'suicidal behaviors', 'monogenic cause of', 'PHPT', 'Pyloric obstruction', 'productive cough', 'community-acquired pneumonia', 'aortic insufficiency|Dissection aneurysm', 'hypertension;||Arrhythmia', 'cardio-circulatory function', 'blood cancer', 'main tremor symptoms', 'chemoradiation', 'subcutaneous tophi', 'endobronchial disease', 'nodal disease', 'appendages', 'abnormalities.|Concomitant disease', 'Acute Lung Disease|Chronic lung disease|Developmental Delay', 'traumatic origin|Ocular infection', 'acute diarrhea)|chronic gastrointestinal disease', 'native Italian speakers;|ability', 'primary BC', 'NSCLC|Tumor tissue EGFR', 'extra whole', 'non-proliferative diabetic retinopathy (', 'negative tumors', 'medical devices.|Pregnancy', 'non-Steroidal anti-inflammatory drugs (NSAIDs) amiodarone', 'DAPT contraindications', 'polyclonal antibody.|Allergy', 'intestinal disorder', 'cholangiocellular carcinoma', '3|Glioblastoma', 'retinal angiomatous proliferation', 'etc.).|Male', 'infection|Human immunodeficiency virus', 'ocular surgery.||', 'gastrointestinal functions,|Smoking,|Dieting,|Pregnancy', 'Coeliac Disease.|Lactose intolerant', 'non-epileptic events', 'localized squamous', 'hemostasis disorders|Renal function', 'interaction', 'Smoking|Systemic disease|Pregnancy', 'old|Refractory cardiogenic shock', 'urachus', 'injuries|acute illnesses|chronic disease|musculoskeletal limitations|during convalescence', 'pathological symptoms/', 'degenerative myopia', 'Thyroid problems', 'subthreshold symptoms', 'AND|Peripheral tumor', 'heart rhythm disorder', 'manic episode|acutely', 'Third Hospital.|Male', 'hemostatic disorder', 'surgically sterilised', 'core', 'SPID', 'lower limb mononeuropathy', 'lung cancer', 'ONJ', 'ATG', ""Parkinson's disease)||Contra-indications"", 'histologic transformation', 'N2c disease', 'extension|Active infections', 'tentorial SDH|Hypersensitivity', 'Ascites drainage frequency', 'third-space fluid', 'cardiometabolic-disorder', 'infection of the wound', 'chronic neurological', 'G93.3', 'cardiac rhythm abnormality', 'psychiatric disposition', 'epidermal growth factor receptor', 'DH', 'allowed.|Pleural fluid', 'type 1 diabetes:||use of aldosterone', 'compartment syndrome).|Participants', 'intolerances', 'intracranial hemorrhage;|Left ventricular thrombosis', 'unacceptable toxicity', 'CAR T', 'pulmonary arteries', 'peripheral neuropathy,|chronic pain', 'incontinence surgery|simultaneous', 'acute myelocytic leukemia(AML', 'non-acceptable', 'fibrinogen abnormalities & deficiency', 'metabolic disorders),||For', 'rheumatoid disease', 'preserved ejection fraction picture', '45|Skin type', 'primary solid (irrespective of the status of the primary tumor)|Patients', 'cataract', 'type 9 (PCSK9)', 'MAC', 'radically resected carcinoma in situ', 'pleural ascites changes', 'acute obstruction', 'bone marrow depressants', 'being|Inability', 'vulvar lubricants', 'substance use', 'obsessive-compulsive disorder|Uncontrolled', 'WOMAC pain', 'endobronchial transbronchial', 'visible rash', 'cervical screen', 'complicated pneumonia', 'dead virus', 'anterior communicating aneurysm||', 'amniotic products', 'immune checkpoint-inhibitor therapy', 'adverse reaction', 'Skin rash area', 'PACS', 'structural lung', 'myelodysplastic syndromes', 'treatment|Chronic HCV infection', 'cardiovascular disease|Pregnancy', 'major psychiatric disorders', 'upper extremity trauma', 'Urolithiasis', 'fungal viruses', 'diabetic nephropathy|Active cancer', 'decreased hepatic function', 'necessity of parental', 'pathology|Neurological pathology|Orthopedic pathology', 'corneal virus infection', 'atherosclerotic plaque risk factor', 'brain metastases.|Patients', 'organ transplantation;|Poorly controlled', 'Chronic adrenal failure', 'extrahepatic cancers', 'respiratory diseases;|Any', 'multi-vessel percutaneous coronary intervention (PCI)', 'medical comorbidities', 'Thrombotic thrombocytopenic purpura|High clinical', 'chronic GI disease', 'cancer of the gastrointestinal tract|Have', 'schistosomiasis', 'steroid-induced', 'osteochondrosis', 'childhood asthma', 'liverchirosis', 'symptoms;|Human immunodeficiency virus', 'decreased behavioral', 'situ;|Pregnant', 'psychologically', 'SC', 'unresectable NSCLC', 'colonic', 'Radiation-related', 'restrictive lung diseases.|All', 'addictive substance', 'Tourette', 'microscopic colitis;|Serious', 'remained stable', 'lymph node lesions', 'acute disseminated encephalomyelitis', 'gastroesophageal disease', 'HERCEPTIN', 'genetic features', 'bleeding:||A. Myocardial infarction', 'myocardial ischemia|Sign', 'thyroid disease|Patients', 'inflammatory rheumatism', 'congestive heart disease', 'abnormal MRI', 'COVID -19 infection|Hemoglobin', 'sleep-related', 'dialysis status|Persistent pruritus', 'discharged from the ED|Significant', 'field coverage', 'clear bleeding tendency', 'monomers|Pregnancy|Chronic disease', 'edema', 'colonic resections', 'L861Q', 'Hence', 'neuropathy', 'alpha blockers.|Large prostate volume relative to pelvic arch width that can hinder proper placement of applicator insertion', 'HIV-1 infected', 'Hematologic malignancy', 'large atrial septal defect', 'cardiac dysfunctions', 'external radiation therapy|Known hypersensitivity', 'Lyrica', 'orthostasis', 'closest relative.||', 'incurable HNC', 'congenital QT prolongation', 'uterine fibroid not responding to medical treatment', 'Kitgum', 'aside from malignancy exception', 'GI illness', 'bipolar', 'clinical significance need treatment', 'acute chest pain', 'complex arterial anatomy', 'viral hepatitis|Pregnancy', 'rooms', 'normal intracranial pressure hydrocephalus', 'viral hepatitis', 'gastroschisis repair)|Foreseen surgical duration', 'intracerebral hemorrhage.|Stroke', 'lowest injury-related', 'subhyaloid hemorrhage.||', 'complex congenital heart disease.|Pulmonary hemorrhage.|Cardiopulmonary arrest', 'kidney disease.|women', 'major comorbidities', 'fresh frozen plasma', 'extragastric measurable lesions', 'Asplenia.|Severe', 'non-allergic drug reaction', 'solid of any size', 'end their life', 'acute medical conditions', 'gingivitis/periodontitis', 'registration|Brain metastases', 'increased bleeding', 'Madison', 'renal denervation.|Presence of', 'Porto Alegre', 'instruments', 'cognitive impairment', 'alcohol abuse|Regular consumption of', 'laboratory findings', 'radiological findings', 'junction adenocarcinoma', 'other cancer', 'Clinical insomnia', 'total lactase deficiency', 'lower limb trauma', 'histopathologic features of', 'non-user', 'limb ischaemia', 'urinary stress incontinence', 'INRC criteria.|Organ functions', 'oral mucosal lesions', 'intrauterine pathology', 'interstitial pneumonia.||Patients', 'respectively|able to walk', 'active hepatitis', 'Diabetes Mellitus Type 2.|Ability', 'neurological disorders|Have eccentric fixation', 'digital services', 'medical history|renal failure', 'distal biliary stent dysfunction', 'patella fracture|A', 'months.|Nasopharyngeal carcinoma', 'half siblings', 'major cardiac abnormalities', 'genders|Blunt head trauma', 'rheumatoid arthritis,|Those', 'conditions are unsuitable for participation in this study by the investigator', 'mechanical heart', 'pelvic floor muscle', 'cauda equine syndrome', 'co-infection', 'Hepatitis C virus infection', 'indicating parkinsonism', 'Chronic total occlusion', 'facet joint pain|patients', 'hyperthermic convulsions', 'etc.).||Cardiac function', 'rods', 'asthenospermia', 'associated with', 'treatment.|Ventricular arrhythmia', 'SAP', 'unlimited;|primary hepatocellular carcinoma proved', 'Student', 'coagulation diaorders', 'native aortic valve disease', 'hemophiliacs', 'musculo-skeletal', 'neurological disorders', 'addiction||', 'intercurrent conditions', 'malignant hematologic diseases', 'neurofibromatosis type 1', 'erosive OLP', 'neurological disorder|Uncontrolled endocrinology disease', 'Ulcerative disease', 'abundant gingivorrhagia', 'skin folds', 'CFTR', 'pelvic pain', 'GuillainBarre syndrome', 'Low back pain', 'hepatitis B infection.||Positive serological tests', 'morbidity', 'clinical disorder', 'download', 'cytokine deficiency', 'oral allergy', 'alcohol withdrawal syndrome|opiate', 'normal brain', 'removable', 'fluid imbalance', 'mitral valve stenosis', 'external rotation', 'active coronary heart disease', 'lower urinary tract symptoms||', 'prostate cancer treatment', 'mitochondrial myopathy', 'bladder', 'NRAS mutations.|NSCLC', 'immune system disease', 'liver metastasis.|Renal function', 'postrenal obstructive nephropathy|History', 'eggs', 'ODD', 'DM', 'FECD', 'Restenotic lesions', 'tuberculosis infection;|A', 'chronic active diseases', 'Papillary Renal Carcinoma', 'tracheal stenosis', 'years.|Nasopharyngeal carcinoma', 'mydriasis', 'genetic disorders', 'carbon monoxide level', '≤5 X ULN', 'tacrolimus /mycophenolate', 'breast cancer|Pathological', ""Addison's disease"", 'Generally healthy', 'post menopausal', 'type 2 diabetes|Limited', 'problems subscale|endorse suicidality', 'intolerance|Renal dysfunction', 'chronic cardiopulmonary insufficiency in', 'decompensated HF', 'digestive tract tumors.|Participants', 'intracranial arterial thrombus', 'colorectal cancers', 'poor urinary control', 'vascular claudication', 'translocations;|Concomitant diseases', 'Second malignancy', 'non-invasive diagnosis', 'spontaneous menopause', 'therapeutic anticancer vaccines.||', 'horseshoe varus', 'atrial diameter≥', 'acute episode', 'umbilical cord mesenchymal stem cell-derived exosomes', 'allergic hypersensitivity', 'Duchenne muscular dystrophy', 'torso', 'immunosuppressive disease', 'cystic fluid', 'structured suicidal ideation', 'metallic fragments', 'Light chain multiple myeloma', 'genital infections', 'brain metastases;|uncontrolled pleural effusion', 'CNS disease symptoms', 'good general health', ""abnormal Allen's test higher target than 65 mmHg"", 'non-childbearing potential - should', 'Medically healthy', 'spastic diplegic cerebral palsy', 'bone marrow invasion', 'eye disease', 'primary dystonia', 'recorded', 'type of dementia', 'biliary tract', 'Magnesium Chloride Hexahydrate', 'Native language', 'Child Bearing Potential', 'V600E', 'lack of sufficient motor skills', 'allergic asthma', 'CSS', 'enlargement of', 'arthrogryposis', 'prolonged bleeding', 'seizure free', 'Strictures', 'endoscopic mucosal resection', 'acute alcohol-associated hepatitis', 'type of limitations', 'radiologic evidence.|CT', 'colon cancer|Prior anterior resection of the rectum|Medical', 'akathisia', 'Acute exacerbation of COPD', 'acute respiratory virus infection.|Patients deemed unsuitable for stem cell therapy', 'Conditions', 'primary malignant tumor', 'Inflammatory Bowel Disorder', 'major schizophrenia', 'Metastases', 'completed cancer treatment', 'abdominal sepsis', 'acid COVID-19 vaccines', 'rotator cuff related', 'oncological diseases', 'neuropathic chronic pain', 'nasal congestion', 'cardiopulmonary issues', 'hypertonic hyperglycemia', 'prolonged analgesic', 'available surgical specimens', 'Chronic hepatitis B virus', 'pulmonary disease|daily opioid pain', 'micoalbuminuria', 'ovarian suppression', 'carcinoma in situ after radical resection', 'sudden death', 'motor impairment', 'high-risk disease', 'concussion', 'peripheral arterial thrombosis', 'hepatic neoplasms', ""criteria of the site's screening consent"", 'NAFLD associated', 'homeless shelter', 'deafness', 'cardiovascular health', 'urinary stones', 'non-infectious diseases', 'pleural effusion|cardiovascular insufficiency', 'bilateral disease', 'coronary heart disease', 'ischemic rest', 'anterior segment infection', 'subcutaneous retaining structure', 'GBM specimens', 'normal)|Abnormal renal function', 'diffuse MSK', 'cranial deformities', 'chronic fatigue syndrome', 'Krabbe disease', 'mixed non-small cell', 'responses from text earlier', 'high cholesterol levels', 'extensive abdominal', 'depression|referral for heart transplantation', 'resting sinus rhythm heart rate', 'heart disease).or', 'soft tissue infection overlying', 'recurrent seizures', 'atrioventricular node disease.|Absence', 'positivie reaction', 'airflow obstruction', 'replication-deficient adenoviral vaccines', 'immunosuppressive conditions', 'mixed warm', 'etc;|Patients', 'distant', 'preoperative sensory neural hearing loss', 'breast cancer.|patients', 'OLE', 'mental diseases.|Infections', 'spinal cord injury|Pregnancy|Untreated Urinary Tract Infection', 'TB infection', 'spastic diplegia', 'HIV infection|Pregnant', 'withdrawal from the study', 'cancer patient|able to start a', 'breath', '|Eclamptic', 'parkinson', 'cerebral bleeding|Claustrophobia|In operated apparatus', 'hepatitis B carriers', 'aortic heart disease', 'natural cycle', 'caries rate', 'etc.;|Patients', 'SAPHO syndrome', 'leukocyte adhesion defects', 'local anaesthetic', 'hepatic failure', 'atherosclerotic risk factors', '0.|No neurological disease', 'chronic conjunctival diseases', 'Schizophrenia Spectrum', 'Pleural effusion', 'ocular findings', 'psychiatric disease', 'pineal region tumors', 'deep dermal scarring', 'homeopathic preparations', 'chest pain condition', 'trauma.|No', 'papillary muscle rupture);|Need', 'skating', 'glenohumeral arthritis|Acromioclavicular arthritis', 'DRESS syndrome', 'patellar knee pain', 'pneumonia;|Active tuberculosis infection', 'poor glycemic control', 'M1a', 'dihydropyrimidine dehydrogenase (DPD)', 'accidental injury', 'acute ischaemic stroke', 'neurologic deficit', 'gastric diseases', 'problems of the heart', 'malignant cancer', 'women|Persons', 'stoke', 'Marfan syndrome.|Pathologic myopia', 'malignant tumor;|Presence', 'nausea', 'knee pain program', 'impending fracture', 'impaired state', 'partum depression', 'pathological type', 'abstain from any sexual activity that could result in pregnancy', 'dry eye', 'valvular pathology;|Chronic alcoholism', 'gynecologic malignancy recurrence.||', 'relapse treatment', 'hypophysitis', 'glaucoma', 'Pulmonary Fibrosis', 'multifocal contact lens', 'pose a risk to study personnel', 'tumor stage T1c', 'abdominal wound', 'treatment|Acute infection', 'NOS)|Follicular lymphoma', 'trying to become pregnant.||Any medication', 'knee pain', 'infections of abnormal frequency', 'therapeutic toxicity', 'lack of expected doubling', 'Healthy', 'branch', 'brief psychotic disorder', 'neuroleptic malignant syndrome.|Current', 'Vaginal Adventitia', 'cauda equina', 'chronic cardiac arrhythmia', 'aviremia', 'network.|In', 'food disorder', 'multiple metastases', 'corneal scars', 'congenital intrauterine infection', 'neurologic causes', 'thyroid cancer', 'consent|Lower urinary tract symptoms|Planned', 'Primigravid', 'collegial validation', ""Schlemm's canal"", 'asthma', 'acute watery diarrhea', 'months|PROSTATE CANCER', 'evaluable tumor lesion', 'penetrating', 'progressive metastatic', 'lesions.|Culprit vessels', 'variceal bleeding|Known', 'Couples', 'obstructed defecation', 'RPOC', 'chronic health evaluation', 'cerebral disease', 'esophageal motility', 'postoperative residual stone fragments', 'extraperitoneal metastases', 'VUS', 'erectile dysfunction.||', 'Right-handed|diagnosis', 'functional failure', 'disorder of vigilance compromising', 'uncorrectable coagulopathy.|Patients', 'similar local applicable', 'comfortable learning', 'colonic polyps', 'adverse reactions', 'type 2 diabetes.|New presentation', 'chronic HCV infection', 'extensive loss', 'cytogenetic abnormality indicative of myelodysplasia', 'clinical manifestations of any clinically significant', 'impaired enteral absorption of medication|History', 'knee varus', 'liver disease)|Thromboangiitis', 'native vessels.|Patient', 'pulmonary hemorrhage', 'child-bearing', 'schizotypal personality', 'intra-cardiac mass', 'presentation anomalies', 'judged by the Investigator to be incompatible with participation in the study', 'renal dysplasia', 'unstable endocrine disease', 'DNM2 mutations', 'moderate dementia', 'Deep brain stimulation', 'significant HF', 'bone marrow', 'uncomfortable symptoms', 'cervical in situ cancer', 'pregnancy on', 'neurological compromise', 'intolerance to the', 'Hyperferritinemia', 'limit visual potential', 'active pulmonary infection', 'corneal ophthalmopathy;|Peripheral neuropathy', 'spouses', 'intestinal obstruction;|Pregnant', 'Obese', 'psychological issues', 'squamous cell cutaneous carcinoma', 'kPa;|Abnormal laboratory inspection indicators', 'Local pathology', 'Burket', 'physical impairment related', 'tumor tissue (IHC)', 'vaginal deliveries', '2|benign obese', 'keratoconus)|corneal epithelial defect', 'Pregnancy|Allergy', 'CAPS manifestations', '50', 'tuberculosis 7', 'apical abscess', 'anatomy', 'clinical response', 'Congestive Heart Failure (CHF)', 'criteria for initial resuscitation with admission to', 'hip girdle pain', 'Patent foot main', 'pituitary dysfunction', 'ischemic aetiology', 'depression)|Agree', 'third degree atrioventricular block', 'Ex-heavy smokers', 'bleeding disorders.|Cholelithiasis', 'restrictive bariatric', 'pancreatic ductal adenocarcinoma', 'COVID exposure', 'end-organ disease)|Anticoagulation use|Bleeding dyscrasia|Use of', 'sugar', 'metabolic disease|Allergies', 'lymphoproliferative disorders', 'transient ischemic attack.|Age 21', 'coagulation disorder|Left bundle branch', 'chronic pain state.||(2', 'reasons|Women', 'bile reflux gastritis', 'physician assistants', 'colonic obstruction', 'intention', 'lower extremity surgery|Pregnancy|Severe hypermobility syndromes|Severe', 'etc.|Is comfortable', 'right-sided temporary mechanical support', 'Yang', 'ANCA vasculitis', 'deemed suitable', 'lateral epicondyle', 'OC', 'except hypothyroidism', 'Fibrosure', 'cognitive disability;|reports', 'age;|Alopecia areata', 'simple hernia', 'pleural effusion.|Pleural', 'test.(20)|History of pain around', 'early-stage', 'significant CAD', 'Putonghua|Able to read traditional', 'Conjunctival', 'coronary artery disease (CAD)', 'prolonged episodes of pain', 'behaviour;|Signature', 'renal failure', 'intestinal strictures|Chronic', 'neuromyotonia', 'vertigo', 'hMPV infection', 'M1 disease.|Bowel obstruction determinated', 'concomitant pathology', 'hepatitis C (HCV) infection', 'spinal anatomical factors', 'calculation formula);Acute coronary syndrome', 'renal insufficiency|cardiac insufficiency', 'brain metastasis treatment', 'digestive tract', 'iron deficiency anemia', 'cerebral feeding artery', 'infection|Diagnosis', 'haematological pathology', 'suicidal thoughts', 'HIV positive);|Active infection', 'mucosal areas', 'benign prostate enlargement', 'lotions|Fragile skin vulnerable', 'Screening.|Febrile illness', 'other infection', 'left atrial appendage anchor', 'as:||1', 'progressive diseases', 'non-emergency abdominal surgery', 'CPC', 'missing', 'abstain from taking these to the end of the Treatment Phase', 'conditions effecting ADL task performance|Language barriers|Known substance abuse', 'nasal polyps', 'permanent harm', 'major depressive disorder)|an', 'suicidal ideation.|Clinically significant', 'dacomitinb', 'opportunistic infection', 'hypothyroidism|Any disorder', 'Endometriosis', 'cutaneous leishmaniasis', 'target lesion length', 'IRB.|The', 'carcinoma in situ of breast', 'vestibular system', 'cutaneous warts presented', 'Goodpasture syndrome', 'chronic pulmonary', 'non-cardiac', 'primary psychotic disorder|History', 'alcohol drinking|male', 'ILD/ pneumonia', 'interprofessional care.|At', 'colitis-associated', 'right heart catheterization', 'cardiac thrombus', 'hypoglycemia coma', 'adequate dexterity', 'signal transduction inhibitors', 'ventricular wall', ""Schlemm's"", 'condition|Fibromyalgia', 'Human epidermal growth factor receptor 2', 'CNS hemorrhage', 'acute rehab|Diagnosis', 'exercise training|unstable angina', 'acute onset focal symptoms matching', 'Malignant Mesothelioma', 'chronic productive cough', 'AV block e', 'Renal Impairment', 'cerebral apoplexy', 'Type 1 diabetes|Type 2', 'bleeding.|Significant neuropathy', 'embolic events', 'infectious disease|Has autoimmune diseases', 'Medical claims', 'malignant nerve sheath tumor', 'adrenal insufficiency|Significant', 'significant physical abnormalities', 'behavior disorders', 'anaphylactoid reaction', 'current illness with', 'venous bleeding', 'Matutes immunophenotype score', 'servings', 'autism spectrum disorder', 'low back', 'undetermined etiology', 'refusal|Contraindication', 'malignant tumor;|(c', 'pheochromocytoma;|Pregnant', 'Pulmonary arterial hypertension', 'residual limb', 'Pregnancy|Pelvic organ prolapse', 'Singleton pregnancy', 'intracerebral haemorrhage', 'pus', 'PPL', 'neurological diseases', 'Motor Neuron Disease (not ALS)|able to lie in MRI scanner', 'carotid sinus', 'PDAC tumor', 'NP-C.|NP-C', 'spondylosis', 'esophageal reflux disease', 'alveolar soft', 'residual adverse effects', 'liver disease|Previous gastric bypass', 'skeletal condition', 'acute decompensation of HF', 'orthopedic implants.|Areas', 'paraffin', 'SCS', 'myeloma defining', 'DiGeorge syndrome', 'mycobacterial infection', 'liver metastases).|Aspartate aminotransferase', 'contracting HIV', 'drug eluting stent||', 'follicular lymphoma Inclusion', 'Exclusions', 'proteinuria resolves', 'substrates of CYP2C8', 'vulvar pain', 'chronic kidney disease.|Prior diagnosis', 'chronic perforation', 'coagulation functions', 'immunochromatographic assay.|No symptoms', 'PET imaging||Pregnancy', 'inclusive|Regular menstrual', 'resectable', ""Alzheimer's Disease"", 'Puerperant', 'months|pregnancy', 'anaplastic lymphoma kinase (ALK) translocations|NSCLC cohorts', 'aortic valve disease|ability', 'adrenal mass', 'hirsuitism', 'progressive organ dysfunction', 'psychosis|Neck pain associated', 'liver diseases', 'musculoskeletal disorder', 'sudden cardiac death', 'SPMS);|absence of cortisone therapy', 'inflammatory bowel disease||Regarding', 'Movement Disorder', 'systemic corticoid', 'CNS lymphoma involvement', 'AIDS/HIV', 'degenerative disc disease', 'PASS);|Italian native', 'systemic infections', 'mitrofanoff', 'non-COPD respiratory', 'seminal vesicle invasion', 'castration-sensitive prostate adenocarcinoma', ""worker's compensation claim"", 'abstain from marijuana/cannabis', 'shoulder fracture', 'etc.)|Uterine bleeding', 'poor short', 'neurotoxic chemotherapy|Known polyneuropathy', 'trochleoplasty|Significant osteoarthritis', 'motility disorder', 'unstable angina;|New', '1)inhalation injury', 'Cardiovascular Diseases', 'poor general condition||Severe', 'intrauterine death', 'tumors|Melanoma', 'distant lymph node metastases', 'NCI', 'dysesthesia', 'malignant thymoma', 'mTBI', 'metabolic condition', 'AML', 'soft tissue injury', 'breast-feeding.|Uncontrolled intercurrent illness', 'aortic valve regurgitation.|Concomitant', 'Thrombocytopenia', 'drug administration.|', 'tetraplegia', 'curative measures', 'cognitive level', 'liver metastases.|Aspartate aminotransferase', 'systemic periodontal basic treatment', 'clinically significant episode', 'tracheostomy tube', 'epithelial cell skin cancer', 'physically inactive', 'infratentorial bleeding volume', 'bleeding-prone', 'Autism Spectrum Disorder -', 'corneal scar)|The', 'type 1A', '|Clinical indication', 'black feces', 'prolonged comprised immunity', 'cranio-cerebral trauma', 'environmental - bronchospastic allergies', 'free fasciocutaneous flap', 'Chronic HD', 'constipation', 'sexually transmitted infection', 'painful physical condition', 'cardio pulmonary disorders', 'chronic disorders|Mobile device', 'genetic skin cancer', 'periodontitis)|Mucosal diseases', 'lung tumor', 'gender|Systemic sclerosis', 'cervical insufficiency', 'drug-related pulmonary toxicity.|Patients', 'congenital diaphragmatic hernia', 'lower limb pathology', 'informal', 'tablet|Frontotemporal Dementia', 'Surgically sterilised', 'Eosinophilic gastroenteritis', 'Failure', 'therapeutic interventions', 'etc.).|Failure', 'deficit|severe', 'HCC-cholangiocarcinoma', 'psychiatrically stable', 'cancer of', 'FIGO', 'cardiovascular pathology', 'colonic diseases', 'gastroesophageal reflux', 'diminished ovarian reserve|Clinical diagnosis', 'old|Receiving', 'early-stage prostate cancer', 'verbalized sensitivity', 'disseminated malignancy', 'incident AF', 'chronic heart disease', 'paravalvular', 'squamous NSCLC', 'human epidermal growth factor receptor 2 (HER2) status', 'Major depression', 'Pregnacy|Metastatic', 'non-viral-HCC', 'cognitive illness', 'left cheek', 'suppositories', 'ICH', 'thin white', 'Thyroid disturbance', 'febrile illness|Hemoptysis|Uncontrolled', 'palms', 'hereditary non-polyposis', 'pathology of keratinizing squamous cells', 'nocturnal enuresis', 'recreational drug', 'Parkinson s disease', 'C-urea breath test', 'peer:||old burns injury', 'PYP', 'vertebroplasty', 'left atrial volume index', 'CT scan', 'pain scales', 'organic lesions', 'anal fissure', 'interstitial nephritis', 'anaphylactic reaction', 'Pathological diagnosis', 'impaired daytime functioning', 'refractory candida vaginitis', 'active UC', 'heavy machinery', 'cerebrospinal stimulators', 'neuropathic corneal pain', 'mycosis', 'paraplegia', 'large vessels', 'corneal injury', 'muscle relaxant', 'EEN', 'anterior myocardial infarction):||Chest pain', 'breast surgery|Diagnosis', 'cerebral artery', 'hypothermia', 'REM sleep behavior disorder|Insomnia disorder', 'panretinal photocoagulation', 'primary cardiac lymphoma', 'ES-SCLC', 'TGM1-deficient ARCI|Clinical diagnosis', 'birth asphyxia', 'Sjogren syndrome', 'renal disease|discharge from hospital', 'cancer|Planning', 'hemisphere season', 'acute liver injury.|Patients', 'fibrinolysis', 'foot ulceration.|Severe', 'diastolic hypertension|Neurodegenerative disorders', 'structural brain abnormalities', 'PIVC', 'idiopathic pancreatitis', 'nerve infiltration', 'tumors.|Chronic respiratory pathologies', 'etc.)|Congestive heart failure (CHF)', 'Visual field defects', 'manage breakthrough pain', 'unstable angina.|Major surgical procedure', 'limits life expectancy', 'hepatitis B DNA(-', 'rapid disease progression', 'neoplastic cells', 'COPD', 'non-cardiac elective surgery', 'lack of social support', 'resting conditions', 'discomfort', 'organic GI abnormalities', 'secondary scoliosis', 'neurological involvement', 'stroke|Rectal prolapse', 'myeloproliferative Neoplasms', 'Chicago', 'human immunodeficiency virus.|Drug', 'idiopathic membranous nephropathy', 'nerve damage', 'pregnancy)|Somatic illness', 'pathological conditions', 'spinal lesion', 'program requirements;|All', 'communication barriers|Students', 'primary colon cancer', 'neoplasia|Chronic pancreatitis|Acute pancreatitis', 'induces liver metabolism of drugs', 'nurse', 'retinal changes', 'Neoadjuvant', 'G-CSF', 'medication overuse headaches.|Changes', 'other pathology', 'resolved', 'hematoma', 'recurrent diarrhea', 'ADHD medication', 'nocturnal myoclonus|Center', 'recurring bronchitis', 'cardiac event', 'back pain', 'ROM', 'renal injuries).|COVID-19 persistence', 'gout|Active gallstone disease', 'coronary artery ectasia', 'deep vertical periodontal lesions', 'uterine carcinomas||', 'respiratory effort|Documented', 'still under intensive cancer treatment', 'screening|Women', 'Adult diabetic', 'physical activity contraindications', 'Normal coagulation function', 'cytolytic T lymphocyte-associated antigen-4', 'atherosclerotic CVD', 'ESCC', 'SFU', 'criteria on lymphoscintigraphy', 'Ruptured membranes', 'brain disorders', 'nephrotic range proteinuria', 'myopia defocus glasses', 'biological cancer therapy', 'ER+/HER2- BC', 'Tumor Necrosis Factor', 'T. trichiura', 'Irregular menstrual cycle', 'Gastrointestinal (GI) tract illness', 'thrombocytopenia.|Documented bacteremia', 'teeth', 'High risk pregnancy', 'Invasive Bladder Cancer', 'otitis external|Tumors', 'preoperative neck pain score', 'hemodynamic compromise', 'contraindicate DBS', 'drainage of', 'optic disc damage', 'staphylococcal blepharitis', ""Cobb's"", 'Arthritis', 'histopathology;|Esophageal squamous cell carcinoma', 'allergic response', 'lactation|Cigarette smoking', 'psilocybin', 'rotator cuff disease', 'psychological conditions', 'IgE-mediated reaction', 'leptomeningeal disease|Patients', 'Deep vein thrombosis', 'furcation involvement of Class III|Patients', 'disease of the vestibular organ|Previous arthroplasty', 'phobia', 'radiologic studies', 'restrict Lumoral use|Pregnancy', 'humeral head fracture', 'pulmonary fibrosis', 'thrombocytopenia|Known reaction', 'brain abscesses', 'chronic granulocyte growth factor support;|Hemoglobin', 'r healthy', 'bronchospasm', 'echocardiography;|Abnormal coagulation function', 'SVD including:|Cardioembolic source|Carotid', 'cirrhosis.|Patients', 'various factors', 'End stage renal disease', 'clinical cancer-free state', 'of||proliferative diabetic', 'history.|Pheochromocytoma', 'radio basilic', 'clinical manifestations of Yin deficiency', 'Cesarean delivery.|Multi gravida', 'hemoglobinopathy,|Pregnancy,|Morbid obesity', 'iritis', 'isolated commissural prolapse', 'venous insufficiency', 'burning', 'breast cancer', 'renal artery contains renal artery stenosis', 'psychotic', 'octoxinol-9', 'metabolic abnormalities.|Results', 'Chronic Kidney Disease-Epidemiology Collaboration', 'screening|Acute renal failure', 'screening;|Upper gastrointestinal bleeding occurred', 'N. meningitides|Household', 'oral/injectable contraceptives', 'participants.|Able to voluntarily provide', 'Perforation', 'interruption', 'Comorbid diagnosis', 'conjunctival scarring', 'cardiomyopathy|Uncontrolled hypertension', 'liver failure - AST', 'habitual diet)|Regular tobacco', 'Hepatic cirrhosis', 'dysphagia|Patient', 'untreatable hearing loss', 'glucose intolerance', 'depression disorder', 'inflammatory disease|General medical conditions', 'renal graft', 'riteria:||Age', 'multidisciplinary ALS clinic|Currently', 'kidney disease|Metformin', 'moderately reduced', 'focal pain', 'FFPE tumor block', 'Restless Legs Syndrome', 'type immunodeficiency virus', 'general pathology', 'infected individual', 'hepatic carcinoma', 'judged at high', 'malabsorption syndrome', 'primary tumor.|Lateral neck cysts', 'debilitating pulmonary disease', 'psychotic disorders', 'externalizing problems', 'contraindicating intramuscular', 'corynebacteria diphtheria', 'macular traction syndrome', 'malignant arrhythmia;|ECOG (Eastern Cooperative Oncology Group', 'doctors', 'Tuberous Sclerosis', 'infiltrative type', 'appears relapse', 'gastroesophageal reflux|laryngeal', 'flow', 'excluded.|Lymphoma', 'atelectasis', 'full menstrual cycle', 'pedaling rate;|cardiovascular diseases', 'unable swallow whole tablets', 'breastfeeding|Substance abuse', 'PARP inhibitor', 'panic attack', 'intrahepatic strictures', 'face pathology', 'COVID-induced', 'fungal infection(s)|Abnormal ECG|Has', 'cancerous', 'primary cancer', 'myocardial viability', 'Chronic coronary syndrome', 'non-chemotherapy-induced thrombocytopenic bleeding', 'hyperglycemic events', 'acute illness.and pregnancy', 'products labeled', 'upper gastrointestinal surgery|Patients', 'neurologic disorder.|Has', 'deep diabetic ulcer', 'localized headache', 'months|Significant', 'acute UGIB presenting', 'infectious gastroenteritis', 'spinal disease', 'proximal femur fracture', 'multiple dental implants', 'extensive external beam radiation therapy', 'nicotine gum', 'pelvic endometriosis).||', 'auditory canal stenosis', 'pregnancy|cystitis', 'mental disease', 'rapid atrial fibrillation', 'feasibility', 'communicating the Dutch language.|Written informed consent', 'posttreatment hypersensitivity reactions', 'immunocompromised diseases', 'non-pregnant', 'oral liver cancer targeting drugs', 'Malignant processes', 'Retinitis Pigmentosa', 'distant metastases|Synchronous', 'involvement in other research', 'Diabetic gastroparesis', 'completely resectable RCC', 'Insomnia Disorder.|Veterans', 'palpable adenopathy', 'analytically validated', 'Autoimmune toxicities', 'generalized disease', 'autoimmune diseases;|Known human immunodeficiency virus (HIV)', 'pregnancy urine tests', 'systemic hypotension', 'dysfunction of heart', 'pancreatitis.|Unable to swallow', 'intratumoral necrosis', 'Photodermatitis', 'bowel resection;|Gastro-intestinal ulcers', 'primary BC diagnosis', 'teratogenic toxicities', 'included);|Health status', 'Acute injury', 'lungs', 'autoimmune (', 'prostate carcinoma;|Successfully completed', 'Chronic viral hepatitis', 'antiparasitic', 'autoimmune-mediated', 'metabolic interventions', 'transferring', 'sinusitis', 'cutaneous Kaposi', 'Evans syndrome', 'Eaton-Lambert disorders.|Patients', 'crescentic collection of', 'chronical medical condition|Women', 'communication over videoconference', 'nervous system disease', 'stomach disease', 'judged by the investigator to have no clinical significance are also', 'psychological diseases Sensitive', 'carotid artery', 'Pennsylvania Hospital||', 'Increased intracranial pressure', 'Celiac Disease', 'latent TB infection', 'linguistic level', 'permitted.|Anti-cancer agents', 'criteria of the American Diabetes Association;|BMI', 'neckline taken.|Subject psychologically able to understand the study related', 'colchicine|Stroke', 'objective eye', 'A dementia', 'reproductive system', 'EMR', 'kidney dysfunction', 'syndromic obesity', 'Stable psoriasis', 'Acute coronary syndromes', 'multi-gated', 'chronic thromboembolic pulmonary', 'drug allergy', 'increased nuchal translucency', 'tumor tissue sample', 'semi-permanent dermal fillers', 'peptic ulcer disease|NSAID', 'communication trainings', 'mercury', 'physically independent.||Stage', 'myocardial infarction etc|Uncontrolled', 'inability to swallow', 'migraine||', 'multicentricity;|Pregnant', 'regular alcohol', 'severe pulmonary insufficiency', ""Gilbert's disease.|Patients"", 'intracranial diseases;|Coronary heart disease', 'heart disease.|Pregnant', 'childbearing', 'fungal nail infection', 'malignancy does', 'malignant tumor', 'inflammatory skin conditions', 'allergy history.|Subjects', 'monogenic diabetes|Participants', 'homozygosity', 'rare diseases', 'reduced level', 'rheumatoid factor', 'spermicide||NOTE:||Use of', 'localized cancer', 'pain on percussion test.||Radiographic criteria:||No sign of radiolucency', 'FI', 'vitreous hemorrhage', 'large T-cell lymphoma', 'full mouth bleeding score', 'viewing', 'Noonan syndrome', 'acute hypoxemic respiratory failure', 'pancreatic disease)||Concerns', 'HIV-2 type patients;|Other severe', 'schedule||', 'severe physical illness', 'Perthes disease', 'solid organ', 'neonatal retinopathy', 'lymphocytic leukemia(CLL)', 'chronic joint pain.|Lack', 'primary outcome of the study|Outborn', 'Hepatitis B virus surface antigen (HBsAg)', 'PCR positive skin', 'periprosthetic fractures;|old fracture', 'cutaneous fistula', 'parasitic infection.|Atopic dermatitis', 'Lapp lactose deficiency', 'renal disorders.|Patient', 'myeloma protein', 'vision problem', 'IUGR', 'patients|Pregnant', 'mixed SCLC histopathological', 'genetic sequencing', 'contraindicated drug', 'muscle conditions', 'non-melanoma skin cancer', '/or carcinoma in situ after radical resection', 'urinary tract infection irrespective of the presence', 'progressive aphasia', 'myasthenic patients|Allergy', 'Adult epileptic', 'adrenocortical dysfunction', 'interstitial pneumonitis', 'recommendations;|Inability', 'ulcerative proctitis', 'lower limb hemiparesis', 'sleep-disordered breathing', 'type 2 diabetes of the Ministry of Health', 'restless legs syndrome RLS', 'mental disorders;|A', 'paracentesis|Uncontrolled symptoms', 'Posterior Reversible Encephalopathy Syndrome', 'joint condition', 'painful chronic wounds', 'autism spectrum disorder|Those', 'leukemic cells', 'digestive issue', 'antipyretic', 'impact on prognosis', 'carcinoid syndrome', 'medical histories', 'hepatocholangiocarcinoma', 'NMO', 'preventive effects', 'bariatric surgery|active GLP-1 receptor agonist treated diabetes', 'dormant dermatologic disease', 'inflexible spinal deformities', 'gastric protectors', 'chemotherapy;|Patients allergic', 'IBD)|Colorectal Cancer', 'respiratory distress', 'liver transplantation.|Symptomatic pleural effusion', 'mental inabilities', 'exon 20 insertion mutation is allowed).|Must', 'urinary incontinence', 'systemic disease|Patient', 'indicates iron deficiency', 'ligament ruptures', 'skin cancer|Known proliferative retinopathy', 'congenital hemophilia', 'behavioral problems|several mental', 'functioning biliary stent.|Persons', 'orthopedic disorder', 'pancreatic diseases', 'primary spinal cord', 'customary lifestyle', 'heart failure;|There', '||Male', 'sudden cardiac', 'cerebral hemorrhage)|Severe', 'blood diseases', 'syndromic disorder|Abnormal neurological examination Invasive', 'communication barriers.||', 'behavioral disorders incompatible', 'obstruction|Uncorrectable coagulopathy|Any diminutive', 'primary caregiver.|Diagnosis', 'sneezing', 'permitted|Severe hepatic disease', 'HPRC)|Birt-Hogg-Dubé Syndrome', 'full rotator cuff tears', 'Poor sleep quantity', 'decreased renal function', 'age|Single chronic SCI', 'contraindicating regular contact lens', 'seizure', 'corrected QT (QTC)', 'invasive ovarian', 'TGW', 'sign of diabetic retinopathy', 'squatting', 'hepatitis B disease', 'endodontic treatment.|Healthy patients.||', 'swelling.|Negative response', 'generalized dermatologic disease', 'end-stage DKD', 'partial bone healing', 'macular oedema', '||Minor', 'endocrine neoplasia syndrome type 2 (', 'osteolytic + osteoblastic', 'dystonic reaction', 'chronic HIV-1 infection.|Evidence', 'poor cognitive state', 'distal symmetrical polyneuropathy', 'right ventricular', 'renal functions|Clearance', 'cardiac disease|neuromuscular', 'angina', 'neoplastic pathologie', 'Distant metastasis', 'bacillus tuberculosis', 'syphilis infection', 'score symptoms', 'post-transplant', 'implant mobility', 'T4 tumors', 'systolic pressure', 'transient ischemic attack [TIA', 'CPS ≥1', 'degree of fibrosis', 'ACS)|Splenic sequestration|Dactylitis|Requires', 'aneamia', 'dosing frequency', 'abnormal mental status', 'dyspeptic symptoms', 'emotional conditions controindicating participation to the study', 'disorder|International normalized ratio', 'endometrial cancer.|At least one measurable lesion', 'pathologies', 'judged by the researcher to be unsuitable for participation|Unwilling to participate in the trial', 'bilirubin ≤1.5×ULN', 'Screener)|Current psychosis', 'ocular ischemic syndrome', 'cardio-vascular condition', 'transient ischemic neurologic', 'communication impairments limiting communication', 'eye of the subject', ""Crohn's disease"", 'Early GC', 'Acute Rhinitis Symptoms', 'thrombocytopenia syndrome', 'hyperthyroidism|Enrolment', 'periodontal', 'solid organ transplantation.|Any other disease', 'Professional football', 'primary unilateral TKA.|The', 'unreliability||Local exclusion criteria:||Any', 'medical problems threatening', 'dental category.|Involved teeth', 'inflammation of the lungs', 'accompany multiple factors', 'drug abuse;|Other factors', 'pulmonary vein isolation', 'blood coagulopathy', 'degenerative pathology', 'keratopathy|Active infection', 'auditory neuropathy.|Additional health factors', 'acquired dental anomalies', 'pregnancy plans|Comorbidities', 'Sonographers', 'for:||Cardiometabolic risk factors', 'vascular disorders', 'other diseases', 'MPAL', 'capsular bag', 'ventriculo-atrial shunt', 'underlying cancer disease', 'consumption of alcohol', 'normal cardiac conduction', 'black pepper|Women', 'germline defect', 'plasma cell leukemia', 'fracture reductions', 'lupus related flare', 'asking', 'farm', 'CT chest', 'anxiety', 'considered stable', 'extra-CNS', 'criteria of the Inflammatory Bowel Group of the Gastroenterology Branch of the Chinese Medical Association', 'Healthy Subjects:||Evidence', 'Tumor disease', 'Malignant neoplastic diseases', 'IHC 2+', 'local amyloid deposition', 'pedagogy', 'venous leg ulcer', 'systemic therapy.|May', 'consciousness,|Active alcohol', 'infrarenal AAA /aorto-iliac AAA', '4|Anaplastic Astrocytoma', 'endobronchial disease|Tumor', 'WPH', 'myocardial infarction.|Active progressive infection', 'humoral immunodeficiency', 'tricuspid valve regurgitation', 'heart failure.|An ECG', 'intestinal organic diseases', 'Amyotrophic Lateral Sclerosis (ALS)', 'refractory to standard therapeutic options', 'opacity', 'aHUS', 'urinary retention', 'Chronic ankle instability', 'non-intracranial evaluable lesion', 'not polyps', 'months;|End stage renal failure;|Participation', 'stable remission', 'thyroid operation|pregnancy', 'bursal', 'tremor', 'surgical decortication', 'coagulation dysfunction|Those', 'nickel', 'non-detectable viral charge', 'autoimmune disorder;|With', 'screening.|Uncontrolled hypertension', 'abnormal renal function', 'coronavirus disease', 'myeloproliferative disease', 'GI preparations', 'ear.|Diagnosis', 'gastrointestinal absorption', 'psychiatric illness/social', '||I-1', 'intra articular pathology', 'dysplasia of the', 'intracranial infection', 'Mental illness', 'macular fovea', 'tumor DNA damage repair dysfunction', 'digital fundus photography camera', 'nasolacrimal duct obstruction NLDO', 'disease|cognitive impairment', 'anterior cerebral', 'cm.|Gastrointestinal diseases', 'adverse drug reactions|Severe allergic reaction', 'liver disease;|chronic kidney disease', '15N tracers.|Treatment for patella tendinopathy', 'courses', 'COPD|Rectal prolapse', 'spinal cord embolism syndrome', 'Hepatitis B', 'upper back', 'skin changes', 'ischaemic cerebrovascular disease', 'anchylosing spondylitis', 'perinatal COVID-19', 'skin damage', 'Chronic Pelvic Pain', 'prurigo', 'Seizures', 'DSM-5 anxiety disorder', 'SFA', 'it.|Previous surgeries', 'prostatic adenocarcinoma', 'neuroleptic treatment', 'neurologic conditions', 'motor problems', 'AIDS related complex (ARC)', 'periocular rosacea', 'Childhood glaucoma', 'lower respiratory illness', ""Parkinson's disease|Color blindness"", 'Candida spp.', 'curatorship,|Pregnant', 'allergic conditions', 'distal popliteal', 'symmetrical pitting', 'available values', 'medication|Other malignancy', 'partial response', 'hepatic glycogen accumulation', 'motor function', 'arrhythmia occurred', 'atherosclerotic origin|Cerebrovascular disease', '6 months).|Chronic diseases', 'Male participants|Healthy', 'peripheral VA', 'sleep behavior problem', 'functional diseases', 'ICF);|male', 'heart condition|Diabetes', 'complications；|5.Pregnancy', 'liver disease:.|Acute cholecystitis', 'deep venous thrombosis', 'molar pregnancies', 'cerebral', 'moderate depressive episodes', 'IgE-mediated', 'refusal.|Local infection', 'heart dysfunction', 'alcohol-containing beverages', 'ASMs', 'hepatic functions|Able', 'poor response', 'Pulmonary Embolism', 'dissociative identity disorder', 'mitral valve repair;|Patients operated', 'airway anatomical disorder|Patients', 'relaxed', 'orthostatic hypotension|Patients', 'positions', 'ambulatory', 'spine orthopedic surgery||', 'Trandolapril', 'stressful life events', 'immunosuppressive diseases', 'Angina', 'months|Cardiovascular disease', 'sensation of', 'replication-deficient adenoviral vectors', 'febrile seizures', 'superficial bladder cancers', 'FT3', 'Primary Liver Cancer', 'cause tissue damage from twisting', 'acute infections.|Known', 'liver failure.|Acute', 'papilloma', 'papillary cancer', 'lymphatic feature', 'neurological defects', 'cardiac conduction abnormalities', 'liver metastases present|Serum', 'Metastatic lung cancer', 'clinically;|MDD', 'constrictive pericarditis;|Dialysis', 'hypointense', 'acute aortic dissection', 'Lymphedema', 'scalp trauma', 'lateral patellar dislocation', 'major sensory', 'bone cysts|Complete', 'major cardiovascular disease', 'Human immunodeficiency virus (HIV)', 'needle phobia|Have immunosuppression', 'Sarcoidosis', 'tumor histopathology should', 'allogeneic HCT', 'systemic disease', 'hepatitis B virus surface antigens', 'renal hypertension', 'recurrence post resection', 'France:||Vulnerable populations', 'type II', 'pacemaker)；|Pulmonary interstitial lesions；|End-stage', 'primary aldosteronism', 'pulmonary right-', 'amount of keratinized tissue.|Attachment', 'borderline personality disorder', 'Hg|Congestive heart failure', 'serious disorders', 'lack of competency', 'acute liver failure|Severe', 'serious head trauma', 'retinopathy of prematurity', 'Glucose-6-phosphate dehydrogenase', 'Transient ischemic attack', 'persistent arrhythmias', 'Postmenopause;|Vegetarian diet;|Pregnancy', 'non-active', 'pleural adhesion', 'allergic rhinitis', 'pure squamous cell carcinoma', 'bleeding;|Pulmonary tuberculosis', 'liver brightness', 'hypertension|Positive insulinoma', 'chronic stable heart', 'Eating Disorder Examination Questionnaire 6.0 total', ""Quincke's"", 'paroxysmal tachyarrhythmia', 'Deep Vein Thrombosis', 'LFTs', 'demyelinating diseases', 'Familiarity', 'allowed.|Symptomatic VT', 'galactosemia disease', 'knee OA pain', 'symptoms consistent', 'pancreatic', 'criteria of the World Health Organization,|Hemoglobin A1c (HbA1c)', 'NRAS mutations.|Thyroid carcinoma', 'hereditary fructose intolerance', 'self-control', 'Interstitial Cystitis', 'stable mood disorders', 'convincing allergic reaction', 'cervical spondylosis', 'RP', 'subdeltoid subacromial bursitis|Pain intensity', 'structured physical activity', 'abnormal urinary constituents', 'anatomic abnormality of the kidney|Fecal incontinence', 'congenital deformity', 'insufficiency', 'intestinal polyps|Any', 'ambulant', 'Vaginal swab', 'T2-T8|Male', 'high myopia', 'early-stage BC', 'implanted ferromagnetic', 'PAS', 'active myocarditis', 'formula|Hepatic disease', 'calculated with GDS)|Excessive', 'acute prostatitis', 'severe bronchitis', 'clotting factor V Leiden disease', 'self criticism', 'digestion', 'heart problems|any condition', 'fetal status', 'sequential bilateral cochlear implant', 'Type 1 ROP', 'tiny tissue biopsies', 'gastrointestinal tumor', 'cerebral regions', 'lactation|Uncontrolled hypertension', 'asymptomatic left', 'blood sickness', 'germinal-center', 'USN', 'metabolic bone disease|use', 'thrombosis events', 'spinal cord disorders', 'emergency presentation', 'entorhinal cortex', 'OH', 'chronic schistosomiasis', 'clinical manifestations of ASD in addition to DSM-V Criteria|Assessment', ""gray's disease"", 'lupus headache', 'chronic stomach', 'Metatarsal', 'capecitabine)|possess', 'bleeding diatheses', 'anamnesis', 'bleeding constitution;|major', 'Mixed tumors', 'Magnesium', 'RET', 'Herpes Zoster', 'Escalation back-fill', 'hepatitis B core antibody (HBcAb)', 'Musculoskeletal disorders', 'cirrhosis', 'pronounced impairment of their visual', 'target ulcer|Target ulcers', 'biopsy|Adequate bone marrow', 'clinical apathy', 'adult siblings', 'abstain from strenuous physical activities', 'porphyria', 'sickle cell crisis', 'treated dyslipidaemia', 'venous disease|Muscle disorders', 'Trauma-induced', 'acute cerebrovascular disease', 'CNS oedema', 'speak, read', 'viable bowel loops', 'target lesion.|Previous treatment', 'menstrual', 'renal impairment.|Patients', 'chronic widespread pain', 'active seizures', 'Legs Syndrome', 'early onset sepsis', 'allergy', 'marginal ulceration', 'LCC', 'illness(es', 'vocal tics', 'applied', 'skin type I-IV|Has', 'pain responsible', 'psychiatric diagnosis|Reading', 'anorectal malformation', 'HIV2', 'RR diastolic', 'criteria of the Diagnostic and Statistical Manual of Mental Disorder', 'judged by the investigators as unsuitable', 'allergic symptoms', 'rheumatic diseases', 'orthopedic disorders', 'multicystic dysplasia', 'primary tumor diameter', 'keratokonus', 'herpes zoster chicken', 'Obstructive Sleep Apnea Syndrome', 'back', 'pyelonephritis', 'hilar adenopathy', 'lower extremity trauma', 'ETV', 'heart problems', 'PTSD|Able', 'diastolic dysfunction', 'retinal diseases', 'peritonitis', 'inherently reduced mobility', 'neurodevelopmental', 'vitamin K deficiency', 'splenectomy', 'lower extremity orthopedic surgery', 'medications|Refractory hypertension', 'interfering changes', 'drugs|premorbid dementia', 'hepatitis C (', 'depressive disorder', 'consumption of', 'all|Hemorrhoidal disease', 'chest wall deformities', 'psychosis;|Malignant tumors', 'balance impairment', 'cell death', 'peripheral neuropathies', 'leptomeningeal carcinomatosis|Female', 'disease consistent', 'MMRp', 'solid organ transplantation|Pregnant', 'spinal cord compression meningitis', 'genetic SVD)||', 'neurology', 'HIV positivity', 'atrial septum', 'flow-limiting', 'ical cancer', 'neuritis optica', 'giant papillary conjunctivitis.|Patients', 'hypertensive encephalopathy|Severe', 'prothrombotic', 'surgical diseases', 'hematological cancer', 'cancer treatments).|Chemotherapy treatment', 'machinery', 'liver impairment', 'solid tumor cancer', 'HER2 genomic tumor', 'ovarian pathology', 'modified Bleeding', 'liver toxicity', 'hip conditions', 'DRM', 'kidney disorder', 'intestinal diversions', 'escalation;|Ischemic cardiomyopathy', 'collagenosis', 'squamous cell Ca of the surface', 'chronic illness,||Having', 'Tobacco Use Disorder', 'material|Mental retardation', 'liver failure', 'indeterminate colitis', 'acute medical crisis', 'fibrillation|Chronic kidney disease (CKD)', 'mild asthma', 'congestive heart failure|Myocardial infarction', 'liver transient eleastography', 'Morbid', 'uretroprostatic disorder|Subjet anxious', 'heart disease;|patients admitted to our polyclinic with the diagnosis', 'tumor shape', 'infection herpes simplex', 'conditions of immunosuppression', 'isolated extrasystoles|Women', 'disenrollment', 'mucinous carcinoma', 'chronic illness', 'food intolerances', 'ear|Recent head', 'resulting in events defined', 'celiac disease)|Imaging findings', 'Uncontrollable pleural effusion', 'intestinal bleeding', 'chronic digestive disease', 'Those athletes', 'Cushing Syndrome', 'diastolic dysfunction#', 'acute (emergency) surgery;|Patients not capable of cycling on a cycle ergometer;|Patients', 'deep brain stimulation intervention', 'hypertrophic scarring', 'Severe Depressive', 'liver function.|Cardiac function', 'umbilical hernia', 'painful conditions', 'proctitis', 'chest diseases', 'fibrous dysplasia', 'BPH', 'psychotic disorder)|Conditions', 'PSA progression', 'chronic diseases', 'hemorrhoidal disease|failure', 'exophytic mass.||≥ 18', 'treatment type', 'abdominal pain.|Allergic reaction', 'HR+ disease', 'immunosuppressive intolerance', 'percutaneous coronary intervention.|Uncontrolled hypertension', 'peak exercise|(For', 'transfusion of whole blood', 'Rheumatoid Arthritis)|Reduced mental capacity', 'socio-economic limitations', 'retinitis pigmentosa', 'vaping complications', 'emergency intracranial hematoma', 'neoplasia', 'ischemic cerebral infarction', 'neoadjuvant chemotherapy.|Tumors', 'NSAIDs + steroids).|Immune system', 'idiopathic sensorineural hearing loss||', 'relevant pathology', 'lichen planus pilaris|Presence of pruritus of the scalp', 'weight loss effort', 'intranodal lesions', 'neurodevelopmental delay', 'Ovarian cancer', 'maternal disease', 'phase|Cephalic vertex', 'pulmonary hypertension', 'microfracture', 'modified T cells', 'rivastigmine|Cognitive disorder', 'Autism Spectrum Disorder', 'familial Colorectal Cancer type X;|Positive Fecal Immunochemical Test;|Use anti-platelet agents', 'vocal cord disorder', 'SPF', 'chronic obstructive pulmonary disease exacerbation', 'eye infection', 'Singleton pregnancy|Age', 'mixed urinary incontinence.|Understand Spanish to be able to self-complete the questionnaires', 'PGT', 'either:||Elevation', 'antithrombin deficiency).|Intracranial hemorrhage', 'pN1c melanoma', 'thrombus', 'painful diabetic sensorimotor polyneuropathy', 'CSPC', 'urinary tract infection.|Pregnant', 'high-grade serous', 'abrasion|Pregnancy', 'temporomandibular joint dysfunction', 'deemed resectable', 'Kütahya||Newborns', 'childhood febrile seizures', 'candidate TB vaccine|Within', 'autoimmune disease|Positive human immunodeficiency virus', 'neurological comorbidities;|Absence of postural deformities', 'Testing for HIV', 'pain pump', 'congenital long QT syndrome.|History of clinically significant', 'item', 'post-vaccination', 'mean diastolic blood pressure', 'PGDM1400LS', 'various immunosuppressive', 'neurological disability,|The child', 'level I', 'Inability to undertake exercise', 'deep brain', 'chromosomal anomalies', 'multiple endocrine neoplasia syndrome type 2', 'irreversible pulpitis.|Normal periapical condition', 'photosensitive skin', 'toxic neuropathy', 'thoracic kyphosis', 'old;|Diagnosis', 'weight loss programme', 'Schizophrenia|Psychotic', 'donate sperm', 'oedema', 'extranodal lesions', 'extra-maxillary/zygomatic', 'non-vegetarian', 'SB', 'decreased response', 'acute STEMI', 'herpes', 'etc.)|Acute angle closure', 'NP swab taken', 'airway malformations', 'chronic musculoskeletal pain', 'iodine', 'ischemia tendency', 'congenital ADAMTS13 deficiency', 'genetic liver disease', 'provoked vestibulodynia', 'University.|Distant metastasis', 'colorectal cancer syndromes', 'haemodynamic instability', 'pituitary dysfunction);|Steroids', 'lymphatic anomaly', 'refractory autoimmune', 'Fabry', 'neonatal withdrawal syndrome', 'Acute Respiratory Syndrome', 'cardiac structural alterations', 'coronary embolism', 'C|HIV', 'drug induced parkinsonism', 'Eleveld', 'pulmonary fibrosis|Uncontrollable pleural effusion', 'nares swab collected', 'prolonged erection', 'fainting', 'Burkitt lymphoma.|Patient', 'radio-frequency ablation', 'cronic sickness', 'traumatic occlusion', 'male', 'macular degeneration);|Patients', 'blood dyscrasia', 'external-beam radiation therapy', 'HFpEF definition', 'neuroimaging abnormality', 'solid organ transplantation|Active', 'chronic thrombotic pulmonary disease.|SBP≥180mmHg', 'polyuria', 'QT corrected using', 'disease|Asymptomatic prostate cancer', 'sociological condition', 'radioactive pneumonia', 'pinguecula', 'impaired glucose tolerance (IGT)', 'stroke,|Cauda equina', 'general anxiety disorder', 'left main stem (LMS) disease.|Patients', 'cardiometabolic diseases', 'facia', 'Multimorbidity', 'digital communication', 'infectious', 'HIV+', 'Multiple tumors', 'end-tidal carbon dioxide (CO2)', 'third-year LSMU students;|18', 'acute AMI', 'tracheoesophageal fistula', 'cerebral commotion', 'calculated from the', 'biliary tract diversion|Suspected', 'coronary artery bypass graft', 'neurological disorders|Organic diseases of the small', 'local AL', 'blood picture', 'non-aplastic anemia', 'unable to swallow tablets', 'risk)|deep venous thrombosis', 'wrist synovitis', 'palpable spleen', ""Alzheimer's disease"", 'coagulopathy disorders', 'biliary obstruction', 'dyspnea symptoms', 'residual effects', 'hepatitis B virus core antibody (HBcAb)', 'pneumonitis.|Active infection', 'ovarian borderline tumour', 'renal replacement therapy|ongoing treatment', 'mitral valve surgery', 'odontogenic abscess', 'adjustment', 'peritoneal dialysis.|Patients', 'gallbladder stone disease', 'dementia|Diagnosis', 'disease affecting immune system function', 'renal cancer lung metastasis|Unstable angina', 'central involvement', 'Streptococcal protein', 'Chronic diseases', 'internal eye', 'traditional Chinese medicinal products', 'organic heart disease', 'insignificant sinus bradycardia', 'disease by CT', 'hernia.||Positive Psychiatric Disorders Screening Questions:||Positive screen for depression', 'cutaneous DLBCL||Prior therapy', 'hypertensive encephalopathy.||20', 'bladder tumour found', 'abnormalities of the pupil', 'secondary infertility', 'Adverse (CTCAE)', 'regular menstrual cycles', 'abdominal wall hernia|Refusal', 'predominantly adenocarcinoma', 'Section 6.5.2', 'diffuse glomerulonephritis', 'laryngeal nerve paralysis|Non-native Italian speakers', 'acute hypersensitivity reactions', 'variceal bleeding events', 'progressive kidney disease', 'adverse health conditions', 'marks', 'renal function||', 'retaliatory response', 'atopic keratoconjunctivitis', 'atherosclerotic vascular disease', 'major comorbidity', 'brain parenchymal metastasis', 'severe allergy;|Known hypersensitivity', 'progressive aggravation;|Treatment-naive', 'SAM', 'disorders - insomnia', 'HIV +', 'migraine headaches.||-', 'human immunodeficiency virus (HIV) antibody|History', 'breast-feeding|Life expectancy', 'respiratory tract infections', 'progestogenic', 'pulmonary hypertension.|Hyperthyroidism|Pheochromocytoma|Hypoglycemia', 'autoimmune thyroiditis', 'MEN2)|acute pulmonary exacerbation', 'non-fasting glucose', 'physiological hypofunction', 'nasal septal perforation', 'feeling in the wound care', 'cerebrovascular disease.|A family history', 'squamous cell carcinomas', 'autoimmune diseases;|Regular', 'benign nature', 'pancreatic islet cells', 'neurological pathology|Having limiting', 'bundle branch block (BBB', 'impairment of renal function|Urinary tract infection', 'Intact', 'osteoarthritis of', 'progressive bone metastasis', 'audio- recorded a clinic visit', 'antigens', 'fibrostenotic stricturing', 'female;|Centrally obese', 'upper extremity', 'heart valve(s', 'ACURATE neo™', 'local ovarian surgery', 'non-atherothrombotic etiology', 'cerebrovascular hemorrhagic disease', 'additional anxiety problems', 'Chronic Kidney Disease Epidemiology Collaboration formulae', 'solid tumor||Combination arms key inclusion criteria||Males', 'local health', 'demyelinating disease', 'Sixty PCOS', 'Liver Diseases (AASLD) criteria', 'prognosis|Preterm prelabor', 'fundoplication', 'Chronic illness', 'cardiac disease.|Patients', 'increased sensitivity to the effects', 'rheumatological conditions', 'contra-indications', 'dentoalveolar maxillary protrusion', 'variants of CNS function disorder', 'abnormalities of the anterior segment', 'genetic muscle diseases', 'allo-transplantation.|Erythropoietin', 'arteritis', 'chronic phase', 'higher)|Acute nasal trauma', 'deep breathing', 'atherosclerotic cardiovascular disease', 'myocardial infarction;|the', 'COVID-19 acute', 'systolic', 'treated malignancies', 'language levels', 'persistent night pain', 'resident', 'signs of Covid-19', 'arterial distal', 'days|Excessive exercise', 'lack of cognitive function', 'intrabony defects', 'acute coronary syndrome|Acute respiratory failure', 'extremity injuries', 'lack of testing supplies', 'intestinal ulcers', 'kg|Chronic viral infection', 'distant metastases.|The', 'managed carcinoma', 'recreational drugs.|Known', 'mental dysfunction', 'acute pancreatitis|Any biliary stricture etiology', 'villous atrophy', 'chronic coronary syndromes|Signed', 'TB meningitis', 'frostbite burns', 'optic atrophy', 'abdominal drain insertion', 'ganglioneuroblastoma', '22.20mmol)|Uncontrolled hypertension', 'thyroid nodule', 'inclusion|Total', 'exacerbation of', 'superficial punctate keratitis', 'impairment|chronic pain syndromes', 'painful symptoms', 'normal|Malignant neoplasm', 'musculoskeletal pathologies', 'primary immunodeficiency|Any condition', 'use.|unstable cardiac condition', 'TOS', 'biochemical recurrence', 'Disease-free survival', 'hepatitis B vaccine.|1st', 'reduced ejection fractions', 'Secondary causes', '18+|Ability to read', 'ear canal stenosis', 'months|Restriction of neck movements', 'function', 'Bankart injury', 'arrhythmia|Myocardial infarction', 'toxidromic symptoms.|Acute intoxication', 'primary sclerosing cholangitis (PSC):', 'speech', 'respiratory failure', 'refuses neoadjuvant chemotherapy', 'influenza virus infection', 'progressive disease,|VAS≤2/10,|FIRST', 'avascular necrosis|Gastrointestinal reflux disease', 'tuberculosis (TB).|Patients', 'malignant hypertension', 'procedures|Acute kidney injury', 'infectious illnesses', 'CVA sequelae', 'chronic hepatitis B virus (HBV) infection', 'unresectable malignancy', 'only|Symptomatic pulmonary hypertension', 'UK brain bank', 'Sleep Disorder Group', 'vascular malformations', 'infantile Krabbe disease', 'poor prognosis', 'severe internal diseases', 'Amenorrhea after cancer treatment', 'nutritional solutions', 'women|Physically', 'developmental delays|Patients', 'hydronephrosis', 'ancillary effects', 'thin greasy moss', 'bleeding conditions', 'herniation disoriented patients|patients', 'cranial nerves', 'vitreoretinal surgery,|Coexisting cataract', 'Tuberculous arthritis', 'responding radiologic response', 'impaired consciousness', 'education- matched', 'congenital heart defects', 'fractures of the upper', 'microsatellite instability-high', 'ultrasound)||', 'breast-feeding.|Concurrent malignancy', 'curable non-melanogenic skin cancer', 'learning disorders', 'pericarditis', 'human granulocyte colony-stimulating factor', 'granulomatous lung diseases', 'infection of the genital tract||', 'PPU', 'Hypotension', 'mechanism disorder', 'third trimester bleeding Placenta', 'plastic left heart) Condition', 'Genitourinary Syndrome', 'congestive heart failure|Active', 'tumour necrosis factor', 'disorders,|Uncontrolled hypertension', '≥5/µL', 'slow reaction', 'persistent cough', 'comorbid like Cardiovascular', 'stroke|significant', 'bronchial tree', 'diabetes mellitus|Immune diseases|Patients', 'recession type-1/2 recession', 'pulmonary fibrosis.|History', 'intestine tract problems', 'venous thrombotic event associated', 'liver cirrhosis.|The', 'unresectable solid tumor|Prior standard therapy', 'orthopaedic injuries', 'peptic ulcer diseases', 'fissure', 'hemorrhagic stroke|Presence', 'understanding of Norwegian', 'surgical indication', 'delayed loss of consciousness', 'Gilbert-.Meulengracht syndrome', 'respiratory failure Hypertension', 'acute hepatitis infection|History of chemotherapy', 'intrauterine retention|Trophoblastic retention', 'sight problems', 'seborrhoea', 'asthma|Poorly controlled asthma', 'vitamin B12 deficiency', 'developmental defects', 'colonoscopy|Adequate bowel', 'solid organ transplant.||Patients', 'communication of informed consent', 'HBeAb positivity', 'acute ischemia', 'PD dementia', 'lower extremity unilateral DVT', 'chilliness', 'duodenal ulcers', 'cerebral hemispheric lesion|Patient informed', 'septic shock', 'Intentional ketogenic', 'anxiety-related disorder', 'gingiva infection', 'Septic shock', 'consonant clusters', 'Acquired immunodeficiency syndrome', 'POBA', 'intraarticular hip pathology.|Hip pain', 'disease|cognitive dysfunction', 'keratinized gingiva recession of the gingiva non smokers free', 'drug pump', 'pregnancy test|Unwilling', 'pathological condition', 'abscesses', 'drug-induced pneumonia', 'criteria of the American College of Rheumatology 2016', 'diabetic keratopathy', 'Intracavitary fluid', 'central pathology panel', 'face recognition difficulties', 'muscle', 'circulatory problems', 'motor fluctuations', 'home||', 'diabetic foot ulcer', 'Athletes', 'atrophic rhinitis', 'ocular infection|Evidence', 'osteomyelitis;|diabetic peripheral neuropathy;|homozygous familial hypercholesterolemia;|absolute contraindication', 'neurological disease|Weight change', 'herpetic keratitis', 'chronic dialysis.|Acute pulmonary embolism|Transfusion', 'traumatic stress disorder|Terminal', 'unconscious', 'epileptic encephalopathy', 'Sex Hormones', 'disability to read', 'neck tumors', 'belongs', 'higher|High grade disease', 'glucose metabolism abnormalities', 'severe depressive disorder', 'cardiac decompensation', 'onset of seizures', 'Arrhythmia|Cognitive change', 'special condition', 'liver transaminase.|Any disease', 'epilepsy;|diagnosis', 'obvious diseases', 'Epidermolysis Bullosa', 'mechanical pneumonia', 'amyotrophic lateral sclerosis)|Medical', 'thyroid', 'foot pathology', 'assessment team member.|Clinical', 'Guillain-Barré', 'ISNCSCI', 'available on iOS14 and higher and Android 8.0 and higher', 'hemochromatosis;|glucose-6-phosphate deshydrogenase deficiency', 'Large core infarction', 'Pulmonary vascular disease', 'comfortable with communication', 'short life expectancy', 'DSA)|Total ischemia time', 'spinal abnormalities', 'Type 1 diabetic|subject under chemotherapy', 'difficulty walking ¼ mile', 'localized AL amyloidosis', 'inflammatory bowel disease (IBD)', 'leisure', 'treatment||Tumor related symptoms', 'immunodeficiency disease', 'atrophy involves', 'unstable conditions', '30Ncm.||Exclusion', 'birth defect', 'speech problems', 'adenocarcinoma of the cervix', 'urinary tract loss', 'immunosuppression|Prior immunotherapy|Recent vaccination', 'cross-sectional imaging:||o Tumor', 'systemic embolism', 'CD137', 'human immunodeficiency viruses (HIV) infection', 'fiberoptic intubations', 'chronic pain', 'cryoglobulinemia', 'cranberries', 'streptococcal disease', 'inflammatory muscular disease', 'sensory', 'mandibular ridge', 'Cardiac activity', 'severe mental disorders', 'sitting systolic', 'history|Medically', 'pain relief medications|Patients', 'buprenorphine|Active withdrawal', 'gastrointestinal condition', 'pathological staging', 'thrombosis disease', 'kidney function|Sign the informed consent form for this clinical study||', 'non-irradiated evaluable lesions;|Subjects', 'acute ischemic syndromes resulting', 'congenital immune-deficient disease.|Has', 'manic episode', 'from neck pain', 'dipstick', 'Stroke', 'cardiovascular/cerebrovascular disease', 'chest wall diseases', 'brain injury', 'infection|Pregnancy', 'infectious hepatitis', 'NAFLD/NASH', 'nasotracheal intubation.||', 'ischemia of the lower limbs|Patient already', 'skin basal', 'hamartoma', 'DLI.|HLA loss', 'good general health.|Maxillary anterior tooth', 'valvular defect.|Patient', 'NCSE', 'elective breast cancer', 'Unsufficient organ function;|Have', ""Bell's palsy"", 'eligible.|Symptomatic central nervous system metastases', 'pulp bleeding', 'ocular dryness', 'Normal healthy', 'hypertension.|Hepatic', 'predisposing risk factors', 'condition.|Emergency condition', 'difficulty comprehending', 'follicular phase', 'unresectable assessed by', 'heparin induced', 'understanding instructions|Significant communication deficits', 'dietary allergies', 'hormonal disease', 'anatomically distinct toxicities', 'liver kidney microsome antibody', 'immunosuppressive disorders', 'severe attentional deficit', 'Acute synovitis/arthritis', 'rheumatic valvular heart disease', 'Amenorrhea after cancer', 'acid|Tested', 'vasculitis)|Congenital immune deficiency', 'cancer', 'urinary frequency/urgency', 'previous eye surgery', 'pathological diagnosis', 'Postpartum', 'judged by the Investigator;|Participants', 'difficulty swallowing;|Patients', 'cardiovascular etiology|Ventricular arrhythmia', 'cervical injury', 'life support', 'vaping', 'abstain from heterosexual activity', 'perianal disease', 'Cyclothymia', 'etc.).|Potential for pregnancy', 'leptomeningeal hemosiderosis', 'hepatocellular carcinoma.|Known intolerance', 'Congenital Anomalies of the Kidneys and Urinary Tracts (CAKUT)', 'psychomotor diseases', 'weight loss|Participants', 'MWFCC', 'hypothermia:||Risk of encephalopathy', 'bile reflux', 'PH-LHD', 'cuts', 'congenital long QT syndrome|Myocardial infarct', 'Leptomeningeal disease|Uncontrolled', 'criteria:||Hunt-Hess grade', 'Ocular lesions', 'seasonal allergic rhinitis', 'Aspergillus infections', 'post-acute sequelae', 'Eosinophilic Esophagitis', 'Chronic neck pain/injury', 'hypercortisolism', 'glucocorticoid eye', 'rales', 'eye|Ocular Surface Disease Index (', '1st', 'ECOHIS duplication', 'breast tumors', 'acute cardiac inflammation;|Allergic', 'Seborrheic', 'upper tract urothelial cancer', 'allogeneic bone marrow', 'urethra', 'clinical stage of T1c to T4', 'underlying', 'vestibular disease', 'primary SCC of the oropharynx', 'dysmetria', 'participation||Contra-indications', 'psychoactive substances)|Mental disorder', 'contra-indication', 'CNS related disorders', 'emergency conditions', 'sleep hypoxemia', 'progressive pulmonary fibrosis', 'associated edema', 'sepsis;|14', 'wildtype|Anaplastic lymphoma kinase (ALK)', '5(minor tissue loss', 'thyrotoxicosis', 'Bronchogenic carcinoma', 'visiting LUMC', 'solid organ malignancy', 'Interstitial pneumonia', 'HGBCL', 'cT4b(non-curatively-resectable', 'adrenal crisis', 'positive||', 'intra ocular inflammation', 'unclear local recurrence', 'psychiatric symptomsEvidence', 'cecum', 'galactose intolerance', 'benign prostate hypertrophy', 'fallopian tube cancer|Patients', 'neuromyelitis optica', 'Females.|Children', 'cerebral complications', 'PrCa', 'Female', 'injuries|Pathologic fracture', 'hepatitis B virus surface antigen positive', 'Regular cheese', 'Incontinence-Associated Dermatitis', 'major cognitive impairment', 'biopsied lesion', 'overhangs', 'Malaysian', 'impaired responsiveness', 'third degree AV block', 'arrythmias', 'neuropathic etiology', 'peritoneal signs', 'regional wall motion abnormality', 'craniofacial malformation syndrome', 'breast feeding.|Current therapy', 'drug-induced psoriasis', 'Otherwise', 'septic shock;|Body mass index', 'musculoskeletal conditions', 'France', 'Serious mental disorder', 'probiotics|Clinically', '1- Lupus nephritis', 'regular cold sores', 'drug use', 'mechanical neck pain', 'research|Minors|Persons unable to express', 'paroxysmal AF should', 'familial cancer burden', 'non-smoker;|primary', 'avascular necrosis', 'shoulder girdle', 'humanised antibodies', 'syndromic etiology', 'blood glucose-lowering drugs|Blood pressure', 'asthma exacerbation', 'adenocarcinoma of the stomach', 'problems of neurogenic origin|Any condition', 'wrist osteoarthritis', 'criteria of anthropometric data||Man', 'Presymptomatic Infection', 'eyelid abnormality', 'Neurosurgery', 'gluten', 'Infectious changes', 'Acute lymphoblastic leukemia', 'valvular heart disease|Myocardial infarction', 'radiation colitis', 'active disease process', 'third stage||', 'coronary arterial', 'athletes', 'other socket', 'alcohol dependency', 'bladder-neck obstruction', 'sacral spinal stenosis', 'substance abuse,||Consumption of', 'impairment', 'persistent AF', 'main organ functions', 'pituitaries', 'Henry Ford Orthopedic', 'Permanent atrial fibrillation|Pregnancy', 's macroglobulinemia', 'poor diabetic control', 'active infection', 'painful Morton s neuroma', 'personal health', 'plates', 'any disease', 'psychological comorbidities', 'investigator.|measurable disease', 'organic disease', 'internal trichiasis', 'lower extremity bypass', 'Temporomandibular Joint Syndrome', 'dilations of the renal pelvis', 'palpitations', 'antithrombosis', 'unsure of pregnancy', 'feeding', 'neuro-developmental conditions', 'therapeutic paracentesis', 'cytogenetic abnormality regardless of', 'amines', 'bleeding.|General disorders', 'solid tumours with', 'Alzheimer disease', 'impact the absorption of oral drugs', 'macular pathology', 'communication barrier', 'Secondary insomnia', 'monoclonal antibody.|Burkitt lymphoma', 'intercurrent disease', 'scarification', 'JAK2 V617F', 'breast feeding|Non-cardiac co-morbid conditions', 'convex probe', 'biochemical function', 'read Urdu Language||', 'Metabolic Syndrome', 'unrinary system', 'normal renal function', 'gastroesophageal reflux barrier', 'coronavirus', 'mentally handicapped', 'ovarian cyst', 'Cushing disease', 'risk of suicide;|(K', 'asymptomatic type', 'surgery|Systemic condition', 'poor nutritional status', 'percutaneous ablations', 'psychiatric conditions|Patients', 'breast feeding||For', 'bleeding;|History of digestive tract perforation', 'co-stimulation signal;|8.Serum creatinine', 'asthma-COPD overlap', 'hereditary hemorrhagic physique', 'potential effects on immune function', 'acute suicidal tendencies|Having gynecological diseases', 'residual neurologic symptoms', 'alcohol-containing', 'difficile infection', 'meningiomas', 'main organs function well', 'typhoid', 'complex pulmonary resections', 'liver disease|History', 'Fractures', 'hump)|proven endocrine hypertension', 'indemnities for clinical trial higher or equal to 4500 Euros,|Under legal', 'recurrence.|Patients', 'intensifying tactile', 'corneal scarring', 'drainage procedures', 'depressive symptomatology', 'bronchoscopies', 'autoimmune disease|Patients', 'Tlaquepaque', 'vascular beds', 'ovarian failure', 'acute critical illness', 'C1 inhibitor deficiency', 'GvHD', 'language comprehension', 'acute pneumonia', 'thyroid problems', 'language barrier.|Other conditions', 'hypoxic encephalopathy', 'diagnosticated cancer', 'esophagogastric fundic varices', 'cardiovascular symptoms', 'uncorrectable coagulation disorders', 'processed|Secondary cancer', 'infections contra-indicated', 'NCI-CTCAE version', 'Pulmonary systolic pressure', 'infection|Drug abuse', 'clinical stages', 'signet-ring cell carcinoma of the prostate', 'haemorrhage|Severe infection', 'botulism', 'acute life-threatening bacterial', 'abnormal bleeding', 'familial hypercholesterolemia', 'inflammatory exacerbation', 'signaling', 'Acute ischemic stroke', 'liver damage', 'evaluable lesion;|The main organs function', 'congenital deafness', 'months.|Heel pain', 'r breast implant subjects:||Age', 'intracerebral hypertension', 'substance addiction', 'coherent speech observed.|Available written Informed Consent', 'neonatality', 'Important comorbidities', 'TNM', 'refractory', 'mixed apneas', 'sequence', 'neurological disease|Currently', 'corn starch', 'etc.)|language barrier', 'migration of stones', 'Diabetes of', 'ischemic', 'degenerative liver', 'Creutzfeldt-Jakob disease', 'bacterial urethritis', 'congenital of acquired|Chronic anal fissure|Active rectal inflammation', 'pulmonary hypertrension', 'metastatic prostate cancer disease', 'cRORA)|Exudative AMD', 'paraseptal emphysema distribution', 'support|respiratory failure', 'subgingival biofilm', 'arrival to', 'autoimmune connective tissues', 'mellitus', 'congenital neutropenia disorders', 'miastenic syndromes', 'senile groin eczema', 'colon rupture|a', 'risk factors', 'haemostatic', 'acute major depression', 'pathosis.|Presence of root calcification', 'neuralgia.|Recent infections', 'musculoskeletal pain -', 'sterilization confirmed.|For childbearing', 'neuronal disorder', 'intersectional stigma', 'multicenter|Signature', 'disease|poor oral hygiene|ıncomplete orthodontic treatment|being a smoker|working', 'EBV infection', 'Valvular heart disease', 'bone ankylosis', 'thrombotic disorders', 'involvement of the skin', 'comorbid illicit substance use disorders', 'adjustment in the type', 'exposed to avalglucosidase alfa', 'surgery;|Active infection', 'treatment;|50 UC', 'volume lesion', 'fungal infections', 'lower incisors', 'middle ear disease', 'fibroid', 'patulous eustachian tube dysfunction', 'bilateral tinnitus', 'required.|Uncontrolled hypertension', 'renal function.|Willingness', '3rd degree burns', 'tissue ischemia', 'fetal membranes', 'nasopharyngeal non-keratinizing carcinoma', 'Vision problems.|Medically instable patients.|Balance disorders.|Other musculoskeletal condition of shoulders', 'months;|Hepatocellular carcinoma', 'atopic syndrome', 'intracranial bleeding / hemorrhage', 'gynaecological symptoms', 'infarction lesion', 'Android phone||', 'Corneal astigmatism', 'drinking', 'aortic aneurysm|Uncontrolled asthma|Arterial desaturation', 'target aneurysm', 'renal impairment|Pulmonary disease', 'resections', 'distant metastasis|metastatic RCC|Eastern Cooperative Oncology Group', 'intraprocedural stent thrombosis', 'peripheral neuritis', 'hypertensive crisis;|In the period of decompensation', 'mental disorders;|Planned pregnancy', 'Renal Impairment.(Creatinine Clearence', 'status', 'Community-dwelling', 'Epidermoid', 'implant cochléaire', 'personality-related disorders', 'substance abuse|Infection', 'urinary urgency incontinence', 'predicted|Clinically stable', 'herbal preparations/medications', 'PTSD diagnosis|Speaks', 'bone pathologies', 'orthostatic hypotension (reduction', 'contraindicated to peripheral nerve blocks|Patients', 'menorrhagia', 'appendix cancer', 'coronary artery disease', 'skin type I', 'type I diabetes', 'Harlequin syndrome', 'coaching', 'aortic injury', 'drug components|The', 'adverse response', 'alcoholic drinks', 'associated conditions', 'grey-zone lymphoma', 'cerebral aneurysms', 'arrhythmia events', 'cyanosis', 'CCCA))|Refusal', 'MMA', 'treatment.|Recurrent', 'drug-related pulmonary', 'abnormal values', 'cardiac vascular disease', 'retinal problems', 'nasopharyngeal carcinoma', 'macular edema', 'supportive housing', 'suicidal plans;|Are', 'Hodgkin', 'thrombocytopenia|Diamond-Blackfan', 'percutaneous transluminal coronary', 'age|Symptomatic coronary artery disease (CAD)', 'herpetic infections', 'parasitic colitis', 'hepatitis C:', 'trans-nasosphenoidal surgery', 'alcohol-containing food', 'chronic ulcers', 'factor XII', 'nonsegmental vitiligo', 'clinical symptoms consistency', 'non-MRI', 'non-hormonal contraception', 'mitochondrial trifunctional protein [MTP] deficiency syndrome', 'prostatic hypertrophy', 'cerebral damage', 'disease|Residents', 'neovascular macular degeneration', 'calculated by the Fridericia', 'FXM(+)|Active infection|Hematologic malignancy', 'detectable sections.|Blood', 'recurrent injury', 'Nulliparous', 'periodontal disease detectible', 'type 1 DM infection bariatric surgery', 'asymptomatic CNS metastases', 'hemolytic anemia.|HIV-positive', 'discharge under hospice|listed', 'malignant tumors;|The', 'hypotensive episodes', 'biochemical examination:||TBIL<1.5×ULN；|ALT', 'bronchospastic disease', 'muscle weakness)|body mass index', 'receptor occupancy', 'better|Human immunodeficiency virus', 'metabolic dysfunction)|or', 'PICCLINE-type peripheral venous', 'nodal recurrence Note', 'associated congenital malformation', 'solid mass in CT', 'carbohydrate metabolism', 'neighboring municipalities', 'Skin disease', 'namely diabetes mellitus', 'lymphoma|PAP associated', 'major illness', 'Japanese', 'chronic acid', 'cardiovascular complication', 'several symptoms', 'cardiovascular clinical symptoms', 'non-resectable metastases', 'early stage disease', 'medically unstable|contraindications', 'immunosuppressants|Neutropenia', 'parenteral antibacterial', 'middle-income neighbourhoods', 'pose', 'upper-limb neurodynamic', ""Wilson's Disease"", 'venous thrombotic events', 'head or neck radiotherapy', ""Cushing's disease"", 'Guillain-Barré syndrome|Current', 'Simplified Oral Hygiene Index', 'end of Consolidation', 'cerebral diseases', 'bothersome pain', 'parasitic lung disease', 'immunosuppressive medications|Patients', 'PRWHE', 'chronic glomerulonephritis', 'varicella zoster virus', 'Ventricular tachycardia', 'organic GI', 'COPD),|Postpartum', 'obstructive hydrocephalus', 'E', 'Impairment', 'limb fractures.|Patients', 'cerebrovascular abnormalities', ""Movement's impairments"", 'completed curative antiviral', 'errors of metabolism.|Known', 'ILD|Autoimmune ILD|Nonspecific interstitial pneumonia|Occupational lung disease|Combined pulmonary fibrosis', 'topical preparations', 'injury|Concomitant injuries', 'criteria for MCI', 'surgically sterilized', 'Heparin-induced thrombocytopenia', 'CYP3A4 sensitive substrates', 'extrahepatic cholangiocarcinoma', 'Good disease control', 'muscle loss', 'superficial vein thrombosis', 'fundus pathological change', 'SCID);|Possibility', 'severe mental illness', 'implantable|Intrauterine device', 'care||', 'Multi-Visceral transplant', 'glucose-galactose malabsorption.|Receipt', 'RCA', 'seizure disorder', 'condition of', 'neurologic sequelae', 'CBCT|Primary failure', 'necrosis', 'Francilien', 'disease features', 'radiologic recurrence', 'chronic medical illness', 'Growth factor', 'chronic pain treatment', 'obstetric indication', 'difficulty initiating sleep', 'end organ', 'retinal prosthesis', 'light brown""', 'psychotic spectrum disorder', 'pre-cancerous lesions', 'genital tract hemorrhages);|Enrollment', 'PAH contraindications', 'hypertension||Relative', 'cerebral aneurysm)|Severe hypertension', 'classic Hodgkin', 'subretinal drusenoid deposits|Intermediate AMD', 'rare cancer', 'B-cell repopulation', 'Covid in its acute phase', 'major mobility disorder', 'terminal malignancy', ""Gilbert's disease).|ALT"", 'judged stable', 'hemoglobinosis', 'archival tissue should', 'affect drug absorption', 'disease progression after response', 'lower extremity arterial bypass.|Ongoing', 'aneurysmatic', 'cardiovascular disease|peripheral neuropathy', 'fractures|Arteriovenous thrombotic events', 'hypomania', 'mixed handedness|Use of', 'toxic nephropathy', 'non-pharmacological', 'psychiatric conditions deemed', 'T3 disease', 'neurologic signs', 'herniated disk', 'disabling anxiety', 'therapeutic effects', 'adequate organ function', 'CF pulmonary therapy', 'clinical laboratory findings', ""Parkinson's disease|≥ 18 years"", 'sinoatrial block', 'bradyarrhythmias|Hypertrophic cardiomyopathy|Significant', '|metastatic renal cell carcinoma', 'cord compression', 'clinical seizures', 'Severe urinary tract', 'gastrointestinal complications', 'appendiceal', 'good general body', 'pylorus-preserving', 'Spouses', 'concomitant disorders', 'soft tissue disease', 'sick sinus node syndrome', 'hypopharynx|Ability', 'bleeding event', 'psychosis;|Asplenia', 'inflammatory bowel disorders', 'pus on aspiration', 'DVT/PE', 'thyroid abnormalities', 'excessive erythema', ""Paget's disease"", 'communication problems participated', 'informal caregiver|Subject', 'biochemically confirmed).||', 'malignant obstructive mass', 'middle ear infection', 'neurodegenerative disorders', 'acute toxicities', 'multiple allergic manifestations', 'aneurysm)|Oncological diseases', 'chest drainage|lack', 'digital ischemia', 'homicidal risk|Vaccination', '/exclusion', 'cardiac syncope', 'exon19 deletion', 'Inflammatory diseases', 'pneumococcal pneumonia', 'traumatic wound', 'single||', 'obstructive diseases', 'e those', 'metastatic renal cell carcinoma', ""Reynaud's syndrome"", 'Cerebral palsy', 'moribund', 'impaired cognition', 'malignant tumors|Patients', 'Calgary depression Scale', 'chronic pulmonary disease', 'distant metastasis;|Life expectancy', 'AV node', 'retinal or fundus', 'metastatic brain lesion', 'hematuria|subcutaneous bleeding', 'distal common bile duct tumor lesions', 'congenital cataracts', 'etc.)|Uncontrolled hypertension', 'vulvar tumor', 'Lambert-Eaton-Syndrome', 'meningeal tumors', 'breast-feeding|Patients', 'rheumatic heart disease;|Mechanic tricuspid valve patients;|Patients', 'severe malnutrition', 'shoulder circumference', 'genetic forms', ""St John's"", 'bone marrow transplantation||Neoplastic', 'Being', 'Initiation', 'allogenic organ transplantation.||Active', 'index diabetic foot ulcers', 'inflammatory arthritis condition|Collagen', 'vaccumextraction)|labour induction|pregnancy-related disorders|perineal tear', 'inflammatory joint disease', 'MoCA)|Excessive alcohol use', 'gastrointestinal pathology', 'affect psoriasis', 'basal skin cancer', 'peripheral circulation', 'HIV positive', 'Academicians', 'frequent bleeding', 'functional compromise', 'SAHA', 'CT|Lesions outside of the designated lung areas', 'conditions.|Pregnant', 'duodenal cancer', 'solid tumor|Be on', 'definitive surgery|Anemia', 'incisional margin positive;|The', 'benign thyroid nodule', 'Prostate Cancer', 'alcoholic fatty liver', 'MCI-AD', 'intestine segment resection', 'peripatellar pain', 'liver metastasis.||Kidney function', 'clinically detectable', 'nociceptive scrotal', ""Alzheimer's"", 'thyroid disease|No', 'renal chemistry', 'HIV)-infection', 'type of cancer the participant', 'disc prolapse', 'Metastasis', 'progressive neurological pathology', 'lung neuroendocrine tumors', 'intracranial expansive process', 'tumour/nodal volume', 'coronary disease', 'treatment stable', 'active scleroderma', 'mandibular cystic defect.|Cystic', 'renal', 'trauma related disorders', 'Tumour', 'right hand;|Detectable stimulation-evoked', 'renal function|Adequate liver function|Adequate', 'Under court', 'urinary incontinence||Continuous urine leakage|Active depression|Comorbid illnesses', 'acute stroke', 'corneal burns', 'actively interacting', 'cardiovascular disorder', 'exertional compartment syndrome (CECS)', 'toxicity intolerance', 'cerebral metastases;|Refusal', 'prostate adenocarcinoma', 'intratracheal lesions', 'acute HF decompensation.|Optimal drug treatment', 'amyotrophic lateral sclerosis spinal', 'materially affects gait', 'mental diseases', 'as:||Pathological dry eye', 'incisional hernia repair', 'scalp pruritus', 'skin wounds', 'mixed invasive Candida', 'joint infection', 'Hepatitis B core antibody (HBcAb)', 'CLL', 'Infections controlled', 'early-stage NSCLC', 'alcohol consumption (mL) x alcohol content (%) x 0.8||Subjects', 'volume overload', 'non-melanoma skin cancer.|Major trauma', 'maternal cardiac disease', 'polyangiitis', 'radiculopathy|low back pain', 'neurological deficits', 'diagnosed COVID-19', 'bariatric surgery|Chronic neutropenia', 'antiplatelet therapy.|Not meet inclusion criteria', 'urinary tract bleeding', 'regular contact', 'other causes', 'Hospitalized', 'functions of main organs', 'biliary tract disease', 'hypoglycemia unawareness', 'cytotoxic T lymphocyte associated protein (CTLA-4) inhibitors.||History of another primary malignancy', 'atrophic skin', 'retinal conditions', 'Suicidal Ideation-Past', 'heart failure;|Thromboembolic events', 'narrow intrerdental site ≤2', 'bruxism habits', 'intrathoracic', 'Chronic Obstructive Pulmonary Disease (COPD)', 'hypothalamic-pituitary diseases', 'site;|Candidemia', 'chair pick-up test', 'diabetes mellites', 'human immunodeficiency virus (HIV) disease', 'SERD therapy.|Radiotherapy', 'chronic Hepatitis C', 'obstructive pulmonary disease', 'Inflammatory arthropathy', 'idiopathic hypersomnia|non', 'globin aplastic anemia', 'genital mycotic', 'hypovolemia', 'peptic ulcer', 'inflammatory lesions', 'PCD', 'consistent pain', 'chronic viral infections', 'normal serum creatinine|Adequate pulmonary function', 'Brest', 'valve disease|need', 'Colpo', 'serious arthritis', 'musculoskeletal system disease', 'bone metastasis.|Current pregnancy.|Formal', 'Cervical radiculopathy|Cervical kyphosis', 'blood malignancy', 'severe heart', ""parkinson's disease"", 'weeks;|Anemia', 'rectal cancer disease.|The lower margin of the tumor', 'investigator|Systemic active infection', 'radiographically detectable', 'substance use disorders.|Past month', 'Primary brain', 'Disorder', 'voice disorder', 'treatment|Allergy', 'acute infections', 'subdeltoid arthrosis', 'comorbidities.|Participant', 'cervical cancer in situ after', 'pulpitis', 'MMRV', 'trying to conceive.|High alcohol consumption', 'systemic diseases;|Those', 'age.|hospital admissions', 'periodontal diseases', 'anus', 'impaired safety of swallow', 'SaO2>95%)|Anemia', 'chest', 'legal involvement', 'chronic stable', 'Radiation Proctitis', 'Multiple Atrophy System (MSA)', 'cerebral infarction occurred', 'drug-induced myopathy', 'clinical stage T1-T2', 'symptoms of', 'MGUS', 'hereditary coagulation disorder', 'clinical depression', 'Thrombocythemias', 'genital fistula', 'difficulty breathing', 'hematopoiesis', 'Neutropenia', 'impact on quality of sleep studies', 'cerebral vascular disease.|Patients', 'sleep-disrupting', 'chronic stable angina', 'psychiatric illness|Not', 'urethrocele', 'in-situ malignancy', 'hyposplenia', 'refractory gout', 'hepatic fibrosis', 'bleeding tendency', 'white coat', 'etc;|Severe infection', 'Dermatological disorder', 'LDH', 'abnormalities.|Myocardial infarction', 'benign neoplasm', 'interstitial pneumonia/interstitial lung disease', 'COVID-19|not being', 'spinal anesthesia.|Metastatic bladder cancer', 'distinct', 'ligamentous involvement', 'primary cancers', 'Wisconsin metropolitan area|Healthy', 'haemorrhagic)|Upper limb weakness', 'Treponema', 'breast cancer|Locally advanced', 'physical fitness', 'subacute bacterial endocarditis', 'chest radiography;|Enlarged liver', 'aortic stenosis|Uncontrolled arrhythmia', 'Coronavirus Disease', 'acquired tuberculosis infection', 'signs of dry eye', 'gastrointestinal function.|Hypersensitivity to the active substance', 'choroidal neovascular (CNV) lesions', 'retinal disorder||Treatment', 'breastfeeding|End stage renal disease', 'Immunodeficiencies linked', 'autoimmune disease|Active infection', 'optic neuritis', 'medullary thyroid cancer.|History', 'lens', 'thoughts of suicide', 'asCOVID-19', 'myopic related fundus', 'mellitus|Cardiovascular disease', 'good oral hygiene.|Systemic healthy', 'exertion.|Pregnant', 'acute diverticulitis|toxic megacolon', 'obtained.|The', 'biliary duct disease', 'treatment|Glaucoma', 'post-chemotherapy', 'PPPD', 'duration)||Unipolar depression', 'mild aortic stenosis', 'Siewert type I', 'neurodevelopmental deficits', 'eye diseases', 'Chronic kidney disease (CKD)', 'inadequately controlled heart disease', 'concurrent diseases', 'macular disease)|OCT scan', 'degenerative neurological disorders;|Participants', 'aggressive behavior', 'reduced HVA', 'intolerance|Allergy', 'atherosclerotic disease|Absence', 'Arrest', 'skin grafting.||', 'benign bilharzial cystitis', 'ventricular dilatation', 'psychotic affective disorder', 'first', 'SMARCA4-mutations', 'porcine products|Anaphylaxis', 'disease；||Tumor related', 'inhibiters', 'SCCAI>10', 'venous serum bicarbonate', 'significant reaction', 'disease of the gastrointestinal tract', 'abnormal scarring', ""Wilson's disease"", 'chronic diseases.|Pregnancy', 'ovarian cancer|Histologies', 'cooperated', 'growth hormone', 'seriously endangers', 'vertex', 'early disease', 'intraocular pathology', 'hypermagnesemia', 'anaphylaxis', 'neuroma', 'mitral valve repair/replacement (MVR)', 'rectal prolapse|Pelvic pain', 'tricuspid regurgitation', 'circulatory disorders', 'tendon-related diseases', 'ganglionic neuroma/paraganglioma', 'traumatic brain injury;|History', 'homicidal', 'juvenile myelomonocytic leukemia', 'pregnancy|No native Dutch speaker', 'end of infusion therapy', 'Mixed adenocarcinoma', 'neglect', 'ulcerative colitis', 'acute neurological deficits', 'oral cavity cancer', 'imaging T stage are noted', 'hyperbilirubinemia', 'substance use disorder.|Veterans', 'immune-mediated thrombocytopenia', 'main renal arteries', 'congenital lung disease', 'Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI', 'limit alcohol consumption to no', 'epileptic seizures.|The', 'hemodynamic conditions', 'cholangiocarcinoma', 'extremity claudication', 'functional program.||', 'B- ALL', 'thoracic pathologies', 'primary malignancy', 'chemotherapy;|Patients', 'increased cough', 'short contact dithranol', 'pulmonary exacerbation', 'malignant tumors;|Fully', 'dietary program);|Physical changes', 'ticagrelor)|Active malignancy', 'atrial ﬁbrillation', 'Chronic skin problems.|Seizure', 'cerebrovascular diseases|clinical depression', 'Alveolar Echinococcosis', 'gastrointestinal bleeding judged', 'telemonitoring|cognitive impairment', 'cardiac illness', 'osteogenesis imperfecta', 'M2', 'corticobasal syndrome', 'ichthyosis', 'chemical abuse', 'present hypothyroidism', 'anaesthesia', 'disease findings', 'keratinized tissue.|Intact socket wall before the extraction', 'rectal stenosis', ""atherosclerosis|Raynaud's phenomenon|Coagulopathy"", 'native coronary arteries', 'vasospastic process', 'ROHHADNET)|Weight loss', 'involvement of the sphincters)|Patients', 'hepatitis C;|The', '||Deafs', 'behavior disorder', 'horizontal skin bands', 'dehydroacetic acid', 'hepatitis C;|Use of', 'squamous cell carcinoma|primary lesions', 'Lynch syndrome-related cancers', 'spontaneously menopausal', 'ultrafiltration failure', 'hepatitis B associated nephritis', 'brain edema', 'bupivacaine|pregnant', 'terminal oncological disease', 'breast feeding.|Craniocerebral injury', 'clonidine may enter the study', 'lateral epicondylitis', 'obsolete pulmonary tuberculosis', 'cure', 'mAb.|Progressive disease', 'degenerative joint disease', 'Cooperative Oncology Group (', 'randomization|Positive COVID-19 infection', 'endocrinopathies stably', 'Systemic pain', 'chronic medical condition||', 'Started', 'spondylolisthesis|Spinal infection', 'impact on health outcomes|Dementia - Mini Mental State Exam score', 'AMD|Diabetic retinopathy', 'moderate hepatic impairment', 'TELA', 'method of contraception|Healthy', 'ACC', 'small bowel obstruction', 'skin ulcers|Patients', 'adequate immune response', 'forms', 'SSc', 'C:||Males', 'inhalation', 'air leaks', 'resistant depressive symptoms', 'heart rhythm disorder;|Pulmonary pathology', 'cleft palate.|Clinical diagnosis', 'PMR relapse', 'abnormalities making insertion of the Focal One® catheter difficult.|Anatomical abnormality of the rectum', 'brain trauma.|Exposure', 'mechanical defect.|Diastolic dysfunction', 'end-organ failure', 'CNS shunt', 'cardiac disease:||Myocardial infarction', 'intracranial aneurysm)|Serious abnormalities in ECG', 'progressive symptoms', 'Pregestational diabetes mellitus', 'calculated by the CKD-EPI', 'adrenal androgen-secreting tumors', 'carcinoma in situ of cervix', 'Ⅲ atrioventricular block', 'other adenovirus vector', 'brain neoplasms', 'up-front docetaxel', 'bleeding disorders.|Participates', 'lamina dura|Absence', 'syndromic obesity|For', 'cyclosporine).|Present alcohol', 'begun', 'cerebellar abnormalities', 'large edema', 'UC starting ozanimod therapy', 'passive joint limitation', 'obese', 'neurodegenerative disease', ""Crohn's colitis"", 'structural brain injury', 'colonic inflammation|Have', 'liver cirrhosis;|Renal failure', 'autoimmune diseases|Malignancy|Chronic HBV infection', 'mitral regurgitation|Heart failure', 'CNS disease;|2.Patients', 'immunization failure', 'criteria of the international ""Global Initiative for Asthma""', 'eye surgery|medication', 'slight edema', ""Gilbert's Syndrome"", 'chromophobe RCC', 'Suprasacral SCI', 'laboratory abnormalities', 'intracranial atherosclerotic stenosis', 'facial jowls', 'disorders|Neurological disorders', 'concussive events of', 'extracorporeal life support|Renal impairment', 'disorder;|Active gastrointestinal graft', 'cryo myectomy', 'and|Patients', 'recreational drug/alcohol use that', 'bacterial vaginosis', 'int-2 risk', 'common iliac artery stenosis', 'gastrointestinal tumors', 'hemorrhage.|Creatinine clearance (Cr)', 'sensitivity to the components of the inhalers', 'endurance athletes', 'organic nerve damage', 'weeks|Inability', 'corneal diseases|Patient', 'seasonality', 'PTC', 'Knee osteoarthritis', 'Acute Stroke', 'respiratory tract diseases', 'physical deficits', 'kidney function disease', 'Gastric adenocarcinoma', 'active)||Active inflammatory bowel disease', 'parasitic fungal', 'GEJ', 'TBIL≥2×ULN;|History', 'inflammatory cell infiltration', 'cardiovascular|musculoskeletal disease', 'hepatitis C virus (HCV)', 'renal dysfunction|Pregnancy', 'skin bottlecer', 'ventricular outflow tract', 'females)|In', 'behavior|Laboratory abnormalities', 'hypoaldosteronism', 'Atrial Fibrillation', 'excessive intraocular bleeding', '-||Associated pathologies', 'hysteroscopic tubal occlusion procedure', 'thirds of the roots should', 'mucopexy', '-malleolar fractures', 'SRE', 'Male breast cancer', 'T staging', 'Transverse', 'steatosis||-||', 'criteria:||Symptomatic adenopathy|Organ function impairment', 'airway sensitivities', 'familial adenomatous polyposis', 'lack of any needed', 'abnormal physical examination', 'spleen deficiency', 'versus intrinsic liver', 'duplicate reponses|Bariatric surgery ype (', 'chromophobe renal cell carcinoma', 'pain perception|Hemorrhagic conditions|Septic conditions', 'corneal stroma', 'cervical disc disorders|Tumor|Fibromyalgia|Mental', 'drug absorption, distribution, metabolism, excretion', 'metabolic pathology', 'Type 1 Diabetes Mellitus', 'PYH', 'product.|Cardiological pathologies', 'affect appetite', 'interstitial lung diseases', 'impairment of level of consciousness', 'diabetes.|Impaired immune system', 'Childhood stroke', 'foreign bodies.|Implantable neurostimulation systems|Cochlear', 'pneumoniae sensitive', 'end stage liver disease|Chronic kidney disease', 'interventricular septal defect', 'pathologies,|Vestibular system disorders', 'macular retinal', 'dentition exclusions', 'Autoimmune mediated hypothyroidism treated', 'solid cancer', 'Mexico', 'convulsive disorder.|Significant', 'contraceptive method', 'fallopian tube cancer', 'mineral metabolism', 'fixed residence', 'gum bleeding', 'metal traces|Known allergic reaction', 'acute pain site of chest', 'CTCAE GI', 'nerve growth factor (NGF) antagonists.|Subject uses', 'renal transplant|Use', 'renal dialysis;|Acute', 'axillary nodes', 'health risk behaviour', 'child bearing potential - post-menopausal', ""disease Alzheimer's"", 'infraspinatus', 'acute mesenteric ischemia', 'aneurysm related', 'cerebrovascular episodes)|Alcohol', 'joint pain', 'mycotic aorto-iliac aneurysm', 'Liver lesions', 'acute MS relapse', 'CNS damage', 'third party assistance', 'Intramural Hematoma', ""Gilbert's disease|Individuals"", 'acids supplements|Current', 'anxiolytic', 'liver malignancy', 'autoimmune disorders', 'impaired mental', 'neuromuscular injury', 'revascularization|Cardiogenic shock', 'autoimmune comorbidities', 'Disability:||Health issues', 'neurologic issue', 'normal tympanic', 'leishmaniasis', 'symptoms thereof', 'pleural empyema', 'PTSD', 'pregnancy|acute infections', 'chronic congestive heart failure', 'POCUS', 'cutaneous lupus', 'etc.|Pruritus', 'Colorectal Cancer', 'colonic transit study.|Inability', 'meningeal disease', 'burned', 'sensitive to the ingredients contained in the products|The test patient consents to the restorative treatment', 'hemorrhagic disorders', 'thromboembolic disorders|Cerebrovascular accident', 'higher bladder permeability', 'distant metastasis', 'localized prostate', 'removal).|Uncorrectable bleeding', 'left main disease|Unability', 'pregnancy outcome', 'conditions affecting the determination of test', 'drug absorption disorders；|Other conditions deemed inappropriate for inclusion by the investigator。', 'lasting effects', 'r the FDGs:||>18 years', 'Primary substance', 'plantar fasciitis', 'respiratory acidosis', 'tumor excision', 'cystic mass', 'contact lens', 'simple extramedullary recurrence;|Pregnant', 'resting oxygen saturation', 'refractory shock', 'SGK', 'trying to become pregnant', 'years|Elective bicaval', 'extra-regional', 'discharged between', 'United States', 'mentally disabled', ""Demirjian's classification"", 'LVEF<30%|Active peptic ulcers', 'hepatitis15 infections', 'Neurological injury.|Active infection', 'adequate organ function:||ANC', 'PSC', 'drug abuse,|Pregnancy', 'local health authority', '-||', 'cerebrovascular accident', 'unexplained sudden death', 'paraolfactory cortex', 'breathing disorder', 'HIV positive;|10', 'Siewert I- III', 'deep vein embolism', 'old|Tachypnea', 'drug-induced pancreatitis|Pseudocyst compressed gastrointestinal', 'self-declaration', 'signs of illness', 'Skin sensitivity', 'uterine malformations', 'neurologic problem', 'comorbid illness', 'cerebral circulation).|Uncontrollable hypertension', 'Smart Discharges', 'coronary IVL', 'fever.|Chronic diseases', 'chronic cholecystitis', 'CMS studies||Exclusion', 'alchohol dependence', 'atrial fibrillation ablation', 'severe plaque psoriasis', 'systemic pneumonia', 'Indications', 'lymphatic component|Clinical diagnosis', 'Exon19 deletion', 'extreme', 'cardiac-related cause|Alcohol', 'kidney injury dialysis procedures', 'SMA syndrome', 'prolonged marrow aplasia.||Donor', 'systemic therapy.|Measurable target tumor lesions', 'multi trauma', 'axial eye', 'anterior dislocation', 'papillary thyroid carcinoma', 'CNS gliomas', 'withdrawn from that study)|Inability to provide informed consent', 'acute lung diseases', 'horizontal axis', 'psychological problems related', 'hypoglycemia', 'skin infection', 'feeling clogged', 'Fridericia', 'enteral feedings', 'bladder function|Acceptance', 'limb disorders', 'biliary tract obstruction', 'carcinoma in situ of the cervix;|6', 'asymptomatic intracranial metastasis', 'recruitment.|Spontaneously breathing', 'vasculopathy', 'dizziness|Patients', 'third degree atrioventricular heart block', 'pleomorphic lobular carcinoma', 'structural brain', 'preoperative cardiogenic shock', 'cardiomyopathies];|Diabetes', 'trying to get pregnant|Participated', 'SNRI', 'pericardial constriction|RHC contraindicated', 'arterial hypertension|Have', 'Stable Disease', 'allergic purpura', 'signs of stroke', 'neurological symptoms', 'pleural', 'hyperglycemic crisis', 'substance use disorder', 'PVC', 'Treponema pallidum infection', 'testicle', 'teratogenic effects', 'acute stroke;|③', 'radicular symptoms', 'obstructive left main', 'Coagulopathies', 'non-healing wound/ulcer/bone', 'available archival tumor', 'Cardiovascular instability', 'liver abnormalities', 'medical history||', 'mild renal impairment', 'renal tumor', 'older|Self-reporting subjective cognitive complaints', 'residual cancer', 'spherical power targeted', 'mAb.||For', 'upper respiratory tract infection', 'cardiac pacemaker', 'thrombotic events)|Unable', 'mixed cholangiosarcinoma', 'myocardial infarction occurred', 'reduced EF', 'Lumosity', 'COD', 'neuropathy.|Previous Fracture/ trauma', 'gastric cancer|Gastric cancer', 'routes', 'mRCC', 'intoxication', 'premature ovarian insufficiency', 'malignant disease.|Impaired mental', 'Impaired liver function', 'erythropoietin dependence', 'persistent regurgitation', 'pregnancy|Currently seeing', 'Active smoker', 'complete clinical response', 'hospitalized covid-19', 'impaired cardiac function', 'early rectal cancer', 'CSF circulation', 'occupational reason', 'SIMU', 'Renal insufficiency', 'main duct involvement', 'Developmental delay', 'lung dysfunction', 'resting heart rate>100 bpm', 'express', 'comorbidities|Smokers|Previous failures', 'associated syndrome', 'circulatory collapse', 'impact onto daily activities', 'tuberculosis dispensary', 'pre-)eclampsia', 'spinal cord injury', 'pathological myopia', 'bacterial origin|presence', 'inflammatory-demyelinating diseases of the central nervous', 'β-thalassemia', 'alteration of consciousness/mental state', 'interstitial anticancer therapy', 'hepatitis BsAg', 'Healthy participants|Body mass index', 'neurological illness', 'mental impairments', 'mosaicism', 'autoimmune pancreatitis', 'cerebrovascular accident.|Patients', 'Rectal cancer|Adenoma', 'HER2-low breast cancer', 'Kearns-Sayre syndrome', 'prostate resection', 'granulocyte macrophage', 'substance abstinent', 'multiple-gated', 'transient ischemic attack/strokes', 'digestive tract obstruction', 'blood dyscrasias|Septic', 'HIV-1 infection.|3', 'alzheimer', 'other malignancies', 'valgus of lower limb axis', 'affect spirometry', 'degenerative corneal', 'autoimmune diseases;|extruded', 'residence', 'DXA', 'peptic ulcers;|subjects who test', 'study.|Regular alcohol consumption', 'BKV', 'personality disorder|Already', 'treatment.|Generalized impairment', 'provocation pain tests', 'associated', 'relapsing multiple sclerosis', 'surgically evaluated', 'mechanical spine', 'Withdrawal symptoms', 'knee surgery|known allergies', 'acute respiratory infection', 'judged by the investigator to be unsuitable for continuing the research;|The subject does not adhere to the protocol', 'HIV-associated malignancy', 'complicated cataract|corneal opacities', 'upper lateral incisor', 'primary hematologic disorder|Petechiae', 'visible papillary disease', 'herpetic keratitis).|Have', 'ventilation;|Acute stroke', 'vulvovaginal infection', 'upper urinary tract obstruction', 'absolute neutrophil', 'trasverse colon cancer.|Surgical', 'pre-MDS', 'major bowel resection', 'irregular cycle||Medication:||Current', 'AERD', 'pulmonary ventilation disorder', 'acute safety concerns', 'intracerebral haemorrhage admitted', 'chronic obstructive pulmonary disease)|A', 'childhood leukoplectic disease', 'hydrogen breath', 'fracture did', 'Intra-abdominal disease', 'co-twin subsequently', 'progressive marrow failure', 'alcohol use|No', 'curable non-melanoma skin cancer', 'regulatory authorities', 'non-acetylsalicylic acid antiplatelets', 'female;|Advanced inoperable colorectal cancer', 'Waldenström Macroglobulinemia[WM', 'decompensates', 'clinicopathologic diagnosis', 'postoperative ventral hernias median', 'infection of any kind', 'included)|suspicion', 'non-responders', 'pneumonias', 'serum sickness', 'dermal fillers injection', 'disease||Castration-sensitive status', 'pathologic myopia', 'DP', 'meningiomas located', 'sinus tract.|Presence', 'bone marrow involvement;2', 'arterial revascularization|Stroke|TIA|Peripheral arterial disease', 'carotid artery stenosis', 'Cerebral hernia', 'NSCLC disease', 'solid organs|History of diabetes mellitus', 'abdominal diastasis', 'Arkansas', 'right-handed adult', 'solid organ transplantation.|Previously', 'hepatitis B (HBV) surface antigen', 'upper abdominal surgery', 'fracture|mental illness|immune disease', 'tracheobronchial foreign bodies', 'family problems', 'mild cognitive impairment', 'rifaximin|gastrointestinal bleeding', 'chronic alcohol abuse', 'hematologic malignancy)|Chronic inflammatory digestive', 'lack of accurate procedural', 'concussive symptoms', 'bone loss', 'renal cancer', 'histological remission', 'Leukopenia', 'coronary insufficiency', 'non-insulin diabetes medications', 'severe diseases', 'moderate covid-19', 'behavior modification program', 'problematic behavioural issues', 'chronic gastrointestinal conditions associated', 'deep', 'neuroendocrine tumor syndrome', 'stabilized conditions', 'psychotic disorder NOS|Current', 'local skin infection', 'neurodegenerative conditions', 'hospitalization.|Inability', 'shoulder problems', 'levels.||In', 'heart', 'pathological jaundice', 'ataxia telangiectasia', 'Diabetes Mellitus', 'primary solid malignancy', 'mouse', 'metabolic lesion', 'KA|Neurological dysfunction compromising', 'retinal morphology', 'digestive disease', 'lymphomas', 'recurrence of radiofrequency ablation|Left ventricular ejection fraction', 'psychiatric disorders|Vulnerable', 'resulting obstruction', 'severe vestibular disorder', 'radially.|Negative response', 'acute SARS CoV-2', 'lung conditions', 'survival', 'lactose intolerant', 'substance-use disorders', 'language barrier', 'cellular immunodeficiencies', 'impaired absorption of oral medication', 'family requires', 'Hemorrhoidal disease', 'percutaneous left atrial appendage occlusion', 'inadequate bowel preparation quality', 'post-event', 'hypoxic respiratory failure', 'non-RCC malignancy', 'nonalcoholic fatty liver disease', 'alcohol misuse', 'venous thromboembolism', 'study:||Subjective Cognitive Degeneration', 'MTB complex', 'anxiety disorder', 'lower extremity fractures|high intracranial pressure|pressure ulcers', 'CNS trauma', 'T3 tumors', 'VWM disease', 'peripheral polyneuropathy', 'basal cell carcinoma|Porphyria|Pregnancy', 'economic condition', 'colorectal cancer liver metastasis|CTs', 'Asthma', 'disorders|inability to answer perioperative questionnaires', 'penile-vaginal penetration.||A', 'verbal abuse', 'rapid breathing', 'cyclothymic disorder', 'dependent', 'chronic migraine', 'AV-block)|Serious', 'clinical jaundice', 'alcohol)|liver cirrhosis', 'trustees voluntarily signed informed consent forms', 'Hepatitis C virus', 'facial nerve palsy|Medical condition', 'pneumonia.|Acute respiratory failure', 'HER2 ++', 'irritable bowel syndrome symptoms', 'scoliosis', 'orthostatic hypotension|Abnormal blood pressure fall', 'Impaired cognition', 'alcohol septal ablation', 'IIIc', 'HIV|History of organ', 'orthodontically banded', 'obstructive lesions', 'breast-feeding', 'addictive disorder', 'absorption|Inflammatory bowel disease|Diseases', 'cancer|Patients', 'Systemic Disease', 'ocular trauma|Relevant', 'autoimmune liver disease.|History', 'loss of response', 'glottic', 'myocardial infarction|Acute coronary syndromes|Stable', 'etc.;|Those', 'heart block|Congestive heart failure', 'diabetic renal disease', 'antacid', 'Neuromuscular disease', 'acute systemic infection', 'panic disorder', 'T2D||Diabetes-related', 'Lewy Bodies [', 'hydroelectrolytic disorders', 'infections|Patients', 'coagulation disturbance', 'diagnostic of AF', 'tinea infections', 'pelvic floor disorder', 'unstable diabetes', 'bismuth complexes', 'tertiary', 'familial affiliation', 'intraventricular hemorrhage||For', 'focus of infection', 'NS lesions', 'high renal chemistry', 'cardiac arrythmias', 'PsA', 'Shwachman syndrome', 'intestinal injury|Poor compliance', 'sick leave|Pregnancy|Acute physical', 'keratinizing squamous cell carcinoma', 'temporomandibular disorder', 'difficile diarrhea', 'non-VTE', 'ampulla of Vater (AoV) carcinoma|Participants', 'visible retinal pathology', 'adenoid cystic carcinoma', 'IHC 2+ plus', 'visual disturbances', 'December 2024 and||', 'gastrointestinal (GI) disease', 'signs of disease activity suggested', 'PENG block', 'cardiac risk', 'transdermal patch', 'ischemic stroke', 'NPPC', 'close friend', 'Tumor Necrosis Factor inhibitor', 'open wounds', 'PTSD symptoms', 'junction disorders myasthenia gravis', 'Follicular lymphoma', 'conscious level|Patients', 'acute malnutrition', 'spinal', 'esophageal lesions', 'injury.|Neuromuscular disease', 'pancreatic ductal', 'organic Gastrointestinal (GI) disease', 'alopecia totalis', 'renal cyst', 'Peripheral arterial disease', 'completed.|Uncontrolled intercurrent illness', 'give rise to cognitive sequelae|People', 'third-space effusion', 'resting respiratory failure', 'gastrointestinal absorption of drugs', 'chronic obstructive pulmonary disease;|Patients', 'chronic injury', 'exhaustion disorder', 'chronic infection', 'vagina', 'polycystic ovarian morphology', 'Indoor oxygen saturation', '½ of the dorsal annulus', 'BCVA', 'seborrheic dermatitis', 'pigmentary glaucoma', 'ales', 'results|Glaucoma', 'valvular heart disease|Morbid obesity|Intubation difficulty|Drug', 'substance abuse|No claustrophobia|Mesial temporal sclerosis', 'poor perfusion', 'coexistence', 'fetal complications', 'drug abuse|Allergy', 'Myelodysplastic syndrome (MDS)', 'Diabetes mellitus type 1|Treatment', 'HBV)|Hepatitis C virus', 'signs of severe', 'ulcer bleeding);|21)Patients', 'hemorrhagic infarctions', 'neonatal alloimmune thrombocytopenia|Balloon not able', 'superficial temporal', 'cavity structures', 'overlap syndrome', 'malformative pathology', 'skin cancers;|Metastatic SCC', 'uterine adhesions', 'pregnancy|No functional impairments', 'endocrinologic diseases', 'pregnancy.|Maternal HIV', 'obstructive sleep apnea', 'black African', 'iPTH', 'biologic Disease-Modifying', 'neurostimulators|Pregnant|Inability to read', 'pathologic root resorption.||', 'organic handicap', 'conditions that could', 'hemiparesis', 'Pregnancy', 'Injuries', 'non-cardiac condition', 'primary pulmonary hypertension', 'bowel|Complete main portal vein', 'PF', 'renal function||Key', 'diabetes foot', 'administration;|Active autoimmune diseases', 'spinal pathology', 'pulmonary embolism symptoms', 'coronary arterial disease', 'temporal pain', 'residential house', ""consciousness|Dementia|Amnesic disorders|Neoplastic diseases of the central nervous system|Demyelinating diseases|Parkinson's Disease|Muscular"", 'urine loss', 'ventilators', 'écrit', 'unhelpful speech language thoughts', 'obesity hypoventilation syndrome', 'childhood;|Patients', 'Unstable medical illness', 'dermatitis|Has been bathed', 'endocarditis.|Current DSM-5', 'co-morbid condition', 'myelopathy|communication problems|pregnancy', 'epithelial ovarian cancer.||Note', ""Gilbert's disease|Uncontrolled congestive heart failure|Active infection"", 'pregnancy,|Not allergic', 'acute coronary syndromes', 'SMaRRT-HD', 'pulmonary conditions.|Presence', 'congenital fetal malformations', ""individual's"", ""Parkinson's disease.|History"", 'latent infections', 'HIV infected', 'hemorrhagic disease|Administration', 'PANC', 'pre-/peri-menopausal', 'suicidal behavior|Requires inpatient treatment', 'extensive changes', 'antifungals|Active primary immunodeficiency', 'HER2+ breast cancer.|Concomitant', 'criteria of the Japan Thyroid Association.|TSI', 'prescribed|Chronic obstructive pulmonary', 'affirmative response', 'diabetic neuropathy', 'ataxia-telangiectasia', 'ureteral false passage', 'Muscular Dystrophy', 'chronic hydrocephalus', 'primary thought', 'heart failure).|Hyperthyroidism.|Uncontrolled hypothyroidism', 'CP', 'issues of claustrophobia', 'inflammatory diseases', 'metastatic infection', 'chondromalacia', 'HIV-infection', ""Wegener's granuloma"", 'non-emergent', 'solid organ transplant.||NOTE', 'coronary stenosis', 'lymphogranuloma venereum', 'neurologic function.|Subjects', 'neurological dysfunction', 'secondary malignancy', 'clinical thrombophilic conditions;|twin', 'acute illness -', 'unrestorable tooth', 'mouth wash', 'previous neoplasms', 'prolonged exposure', 'findings|Abnormal fundus examination|Ocular disease', 'PAC obstruction', 'Myocardial infarction occurred', 'Prescence', 'Melanoma', 'emotional tension', 'coordinating site', 'mmHg|Drub abuse', 'rheumatoid purpura', 'pain syndromes|use', 'Earlier corneal', 'unstable angina', 'bladder insufficiency', 'malignancy)|Serious mental illness', ""Alzheimer's disease.|Mini-Mental State Exam (MMSE)"", 'naïve', 'IDH wildtype', 'pulmonary hyperinflation|Collateral ventilation positive|FEV1 post lysis', 'sputum sample', 'pill', 'cardiac rhythm loss', 'cm)|Duodenal stenosis|Post- surgical altered anatomy|Benign disease', 'chronic neurological condition', 'participant:||• Child in care', 'lymphocyte-clearing chemotherapy', 'like anaemia', 'upper limb disability', 'hyper parathyroidism', 'traumatic brain injury|A', 'Gastroparesis', 'allergic reaction,|Having', 'health disparity', 'hyperemia', 'bilateral neck adenopathy', 'impaired cognitive functions', 'disorder,|substance abuse disorder,|autistic spectrum', 'Pneumocystis pneumonia', 'diabetes type 2|History', 'irradiated lesions', 'chronic arthritis/osteoarthritis', 'acute urinary retention', 'respiratory diseases)|Symptomatic peripheral neuropathy', 'chronic hypoxemic respiratory failure', 'microangiopathy', '# level.||', 'photosensitivity|hypertrophic scars', 'hernial cure', 'allergic disposition', 'coarse patchy infiltration', 'If BP', 'aortic valve disease', 'breast-feeding.|Brain', 'nerve injury', 'shoulder joint bursitis', 'refractory AML:||A', 'post-traumatic knee arthritis', 'flexible cholangiopancreatoscope', 'trauma vertebral fracture', 'cardiac arrhythmias', 'polyps', 'cola', 'hyperlipidemia', 'recurring pain', 'precursor neoplasms:||2nd', 'Corona virus', 'acute infection diseases|Endometriosis', ""Parkinson's syndrome"", 'Prostate cancer', 'cough adequacy', 'RSV infection', 'NSCLC cancer', 'obsessive-compulsive disorder', 'physical impairments', 'upper gastrointestinal surgery', 'shoulder abduction', 'serious anatomical damage', 'esophageal squamous cell', 'not', 'digital communication devices', 'or|Myocardial infarction', 'pituitary adenomas', 'endometriosis cyst', 'antibiotic prophylaxis.|Hepatitis', 'of cancer', 'months|Mini-mental state examination≥25|Biceps ≤2', 'APRI', 'Acute Myeloid Leukemia', 'hepatitis C.|Major surgery', 'insomnia', 'visuospatial memory)|Cognitive impairment', 'Wegener granuloma', 'drug for COVID-19 prevention', ""Gilbert's Disease)|AST(SGOT)/ALT(SGPT"", 'myocardial compromise', 'muscular dystrophy|Patients', 'multi-focus soft lens', 'metabolic functions', 'chronic hepatitis of', 'unexplained serum AST/ALT', 'ever worn', 'fertility', 'malignant mesothelioma', 'Ankylosing Spondilitis etc.)||Systemic diseases', 'bowel movement', 'glomerulonephritis|Primary electrolyte imbalance disorders', 'mobile cancerous lesion', 'physically active people who exercise vigorously', 'infectious bone defects', 'end-dose', 'carotid arterial stenosis', 'individual seizures', 'alcohol use disorders', 'minimal bleeding', 'child-earing', 'cognitive disability|Patients', 'degenerative lumbar spine disease', 'failure of', 'exclusions', 'medical reasons', 'transient ischemic neurological attack (TIA)', 'second stroke', 'impaired adults.|Uncontrolled', 'esophagitis', 'detectable hepatitis B virus', 'structural anatomy', 'exclusion.|Electrocardiographic abnormalities', 'ventricular hemorrhage', 'chronic opioid abuse', 'extensive psoriasis', 'joints disease activity score', 'Hemoglobin A1C)|current', 'cranial nerve involvement', 'encephalitis', 'standard chemotherapy;|No remission', 'cardiometabolic risk', 'reproductive potential.||', 'acute suicidality|Current alcohol', 'AD||National Institute on Aging', 'venous insufficiency C4', 'mental health disorder.|Access', 'thrombosis', 'sensitive)|II always burns easily', 'skin atrophy', 'mental illness.|Asplenia', 'abdomen', 'impaired cardiac', 'hyperpigmentation', 'hemorrhagic diathesis', 'cancer.|Hypocorticism', 'tiredness.|Muscle', 'standard deviations', 'submucosal myoma', 'diabetes mellitus|Pregnancy', 'radioactive 125I seed', 'study disease', 'Acute Pancreatitis', 'resolved infection', 'Bacillus Tuberculosis', 'poor renal function', 'continuously lived', 'poor vascular puncture conditions', 'retinal degeneration', 'dementia', 'compromised health', 'autonomic symptoms', 'seizures', 'hepatitis C virus.|Suffering', 'disorders|Intrauterine polyps|Thrombophlebitis', 'impact of opioids', 'positive XM', 'hypoxemia', 'acute promyelocytic leukemia', 'tendinitis', 'Screening.|Participant', 'cardiac conditions', 'Adverse Events version 5.0 grading', 'guttate', 'surgery|Women', 'inflammatory stiffness', 'circumstances unsuitable', 'radical nephrectomy|standard flank incision', 'cognitively impaired adults,|has', 'hypersensitivity|Active abdominal wounds', 'chest tube drainage', 'type May choose', 'early enteral nutrition||Patients', 'sun exposure', 'PRES)).|Those', 'lower limb disabilities|Breastfeeding', 'normal defecation characteristic', 'hydroxypropylmethylcellulose', 'breast cancer in situ', 'ureteral catheterisation [IV]', 'Erasme University hospital', 'progressive neurological dysfunction', 'hemianesthesia', 'CIFFTA', 'type 2 diabetes mellitus|Contraindications', 'rectal cancer', 'local disease', 'HPAH', 'non-smokers;|For dental implant groups', 'respiratory rate', 'acute exacerbation of respiratory disease', 'difficile related diarrhea', 'special communication needs.|Subjects', 'metabolic syndromes', 'intolerance of the ingredients', 'HFOV', 'reversible toxicity', 'associated abnormalities', 'bleeding on probing', 'organ transplantation);|The', 'FACS', 'breast feeding||Exclusion Criteria For Control Subjects:||Active bacterial', 'hypersensitivity reactions', 'systemic hypersensitivity reaction', 'right heart failure;|Left ventricular ejection fraction', 'PD', 'target organ damage;|A', 'etc.)|Serious medical illness', 'acute cardiovascular event', 'degenerative arthritis', 'cough severity', '1)complex fistula', 'cytomegalovirus infection|History of', 'genital skin breaks', 'acid reflux disease', 'hear disease', 'CNS instrumentation', 'lumbar spinal stenosis', 'intestinal type gastric carcinoma', 'major mental illness', 'HIV.|Active bacterial infection', 'Neuromyelitis optica', 'generalized epilepsy', ""Alzheimer's disease;|MMSE score"", 'pleural disease', 'target vessel tortuosity', 'active bleeding', 'traumatic stress disorder', 'OR|Lactate dehydrogenase (LDH)', 'epithelial damage', 'soft meningeal disease', 'renal disease.|Sensitized', 'intracranial segment', 'local anesthetics|Local infection', 'ventricle heart disease', 'anyone positive', 'ventricular fibrillation', 'EAC', 'intracranial hemorrhagic', 'insuline-dependent', 'conductance catheterization|Pregnancy', 'natural menopause', 'Cognitive Scale', 'vision abnormalities', 'aural habilitation', 'corticosteroid infiltration', 'screening|Stroke', 'disorders|Current gastrointestinal condition', 'digital workflow', 'arterial hypotension.|Hypersensitivity', 'Left main stenting', 'bacterial dysentery', 'pregnancy diagnosis', 'mixed types', 'hepatocellular carcinoma|Barcelona Clinic Liver Cancer', 'PTEN loss', 'Parkland Diabetes', 'heart valve function defect', 'fetal deformities.||', 'somatic of social disease/problem', 'manifest psychosis', 'gastrointestinal surgery|Underlying severe', 'alienia', 'functional limitations|Body mass index (BMI)', 'pancreatic duct adenocarcinoma', 'pneumonia', 'inflammatory and immune system disorders,|Type I', 'left ventricle damage', 'intraocular hemorrhage', 'Infectious colitis', 'midline hernia', 'living independently.|Unstable illness', 'ESRD', 'non-renal conditions', 'joint pain)|No weigh loss', 'muscle pains', 'cirrhosis|Fibroscan', 'irregular menstrual cycle', 'non-valvular atrial fibrillation', 'acute decompensation of cirrhosis', 'frontotemporal dementia', 'motor skills', 'B-cell Lymphoma', 'arrival to the hospital', 'Smoking', 'Target vessel diameter', 'HIV/AIDS', 'implantable left ventricular assist devices;|use', 'coagulation factor deficiency', 'CD4^+ T lymphocyte', 'gastrointestinal disease', 'abstinence;|Co-morbidity', 'immunoglobulin M', 'bovine-derived products;|Patients', 'fluorescence in situ hybridization [', '5）high risk factors', 'body pain', 'operable diseases', 'Intracranial bleeding', 'lacerations', 'Lapp lactase deficiency', 'primary cancer arising', 'alertness', 'ductal carcinoma in situ of the breast post radical', 'radio frequency', 'Substantial co-morbidity', 'recurrence or disease', 'extensive stage', 'primary neoplasms', '|Hepatitis B virus infection', 'cerebral palsy.|Diseases', 'third party personnel', 'Diagnostic criteria', 'surrounding TMJ|Dislocation', 'inner forearm the beginning of the product application phase;|Willing', 'MDT', 'somatic mutations', 'human T-cell leukemia', 'polycystic kidney disease', 'altered renal function', 'gastric ulcer', 'Acute musculoskeletal symptoms', 'renal dysfunction||', 'radiculalgia', 'ischaemic attack', 'mitral valve', 'stroke|Peripheral arterial disease', 'brief Mental State Examination Scale', 'herein described', 'gastrointestinal bleeding', 'cardio-cerebrovascular diseases', 'sleep aids', 'anti diabetic drugs', 'containing unstained', 'brain stem lesions', 'renal disease|Alcohol', 'hepatitis B/C|Known', 'clinical abnormal symptoms/signs|There', 'hormone deficiency', 'hypercapnic exacerbations', '-reading.|Cares', 'response', 'invasion', 'hepatitis C virus (HCV) antibody positive', 'lotions', 'SIHD', 'lack of efficacy.|Participant', 'type two diabetes.|BMI', 'tractional diabetic retinopathy', 'Tumor tissue should', 'surgery|Intrinsic lung disease', 'parenchymal brain metastasis', '54 Gy', 'leukapheresis', 'SFR', 'diabetes drug', 'conditions', 'polycystic ovarian syndrome', 'congenital anomaly of the spine', 'Palmaris Longus PL', 'bowel perforation|Diagnosis', 'gastric surgery|Coagulation', 'hepatopulmonary shunt', 'right volar forearm', 'lumbar disc herniation', 'breast cancer treatment|Non ductal', 'tortuosity of the Brachiocephalic trunk', 'blood involvement', 'upper extremity|Peritoneal dialysis|Catheter', 'significant disorders', ""Wright's classification"", 'bronchial asthma|History', 'hemorrhoidal disease', 'poor healing wound', 'mitral stenosis.|Hypertrophic obstructive', 'cardiac condition', 'alcohol abuse|Is using', 'malignant conditions', 'hepatitis B virus [HBV]', 'thyroid neoplasms', 'aerobic', 'conditions like neurological conditions|Any infection|Tumor|Spinal Surgery|Cognitive Impairments|Refusal to sign consent|patients taking', 'paraneoplastic syndrome', 'thoracic surgery;|Pregnant', 'fertile partners should', 'Wide carious lesion', 'Obstetric Pathology of the FPG', 'visceral spread', 'major physical injury', 'structural deformities', 'female|regular smokers|disturbed glucose', 'good general health.||Adequate oral hygiene,|Patients', 'vitamin B12 deficiency anemia', 'vaginal discharge', 'cervical pain', 'porphyria Allergy', 'HR+', 'ophthalmologic disorder', 'heart failure|A', 'respiratory muscle', 'intestinal tract', 'Spectrum Disorder', 'coronary/peripheral artery bypass graft', 'cardiogenic shock|Severe', 'CYP1A1-inhibitors', 'Pediatric Bronchial Asthma', 'type of diabetes', 'ipsilateral adrenal metastasis', 'radiotherapy|Active infectious disease|Active bleeding|Severe renal insufficiency', 'conditin', 'radiological pathology', 'cystic neoplasm', 'ischaemic stroke', 'food allergy(ies);|Vegetarians;|Restrained eaters', 'chronic systemic diseases', 'third-degree', 'genital warts', 'age)|Body mass index', 'rheumatoid', 'neurological pathology', 'systemic disease,|pregnancy', 'multiple sclerosis|Having', 'Prepare', 'rheumatoid arthritis||Exclusion related to Tuberculosis (TB):||Active TB', 'health coverage', 'secondary cardiac insufficiency', 'Unilateral disease', 'acute intracerebral hemorrhage', 'non-epithelial tumors', 'Spinal cord', 'cardiac events|Patients', 'isotretinoin', 'vaginosis', 'positivity on immunoassay', 'Epidermal growth factor receptor', 'urticaria factitia', 'clinical indicators', 'fatty liver|anorexia', 'chronic active hepatitis', 'Cystic Ovary sundrome||', 'thoracic nodal disease', 'ceerebal spinal fluid (CSF)', 'aortic position|Congenital heart disease', 'non-childbearing potential|Female', 'hepatocerebral dystrophy', 'hyperglobulinemia)|pregnancy', 'immunoreumatologic disease', 'socio-economic status', 'adrenal disease', 'continuously normal', 'pancreatic cystic tumor;|The', 'liver kidney cardiac', 'iron overload', 'targeting IL-17', 'refuses', 'traumatic and pressure wounds', 'lower-limb orthopedic', 'thrombosed internal', 'rheumatoid polyarthritis', 'deficits', 'glomerular crescent', 'unhealed wounds', 'neurocognitive impairment', 'retinal vasculitis', 'self-isolate', 'stricturing', 'immunocompromised|Vaginal infection', 'iron stores', 'antiphospholipid syndrome', 'acute events', 'degenerative conditions', 'primary APS', 'fruit allergy', 'familiar Alzheimer disease.|Alcohol', 'inadequate bowel preparation', 'occupational responsibilities', 'steatosis-inducing drugs', 'degenerative neurological', 'Generalized Anxiety Disorder', 'bowel congestion', 'circulatory diseases', 'neurology OPD', 'Leishmania infections.|Evidence', 'acute lesion', 'cmH2O)(27)||', 'difficulty maintaining sleep', 'meeting', 'nail', 'difficulty understanding visual analog scale (VAS)', 'active diseases', 'pulmonary inflammation', 'selected healthy', 'autoimmune enteropathy', 'Diagnosing fibromyalgia', 'severe mental comorbidity', 'L858R', 'GPC3+', 'chemotherapy|Chronic renal insufficiency|Abdominal ascites|Infection', 'cardiac implantable electronic device', 'psychiatric disorders', 'contra-indication.|Patient', 'language barriers.|Patients', 'Unilateral pain', 'immune reaction', 'breast-feeding.|Has', 'hospice care.|Active cancer', 'FrieslandCampina R&D.', 'stage kidney disease', 'BBSA', 'hepatitis B core antibody positive', 'chronic diarrhea.|Active peptic ulcer.|Major', 'central apnea', 'language barriers', 'non-psychotic MDD', 'congestive heart', 'TMD).|Dental', 'samples|Tumor tissue block', 'skin carcinomas', 'lymphoma.|Multicentric carcinoma', 'personality disorder|Borderline personality disorder|Antisocial personality disorder.|History', 'ERT||', 'chronic symptoms', 'forehead', 'back ache', 'occupational therapies', 'chronic active Hepatitis B', 'hematochezia;||', 'gastrointestinal stromal tumor;|Toxicity', 'epilepsy|Kidney failure', '≥18||Diagnosis', 'excessive alcohol intake', 'CF|Diagnosis', 'needle biopsies', ""Cushing's syndrome"", 'high grade glioma', 'deep water.|Chronic pain', 'occupational conditions', 'calcification', 'HIV)|Cholestatic disease|Alcohol', 'FND', 'colorectal cancer team', ""Paget's disease|Breast deformities"", 'retinal detachment|History', 'disease|Cervical carcinoma', 'obliterative bronchiolitis', 'ARSACS', 'hepatocellular injury', 'musculoarticular pathology', 'acute proximal humerus', 'androgens', 'brain metastasis', 'ballooning degeneration', 'arterial inflow', 'chickenpox', 'organic pathology', 'clinics|Asthma', 'HbSβ0 thalassemia', 'impaired fasting glucose.||Females', 'solid neoplasm', 'portacaval shunting', 'Nuclear factor KappaB Ligand', 'radiofrequency destruction', 'hematologic dyscrasia', 'viral hepatitis infection', 'side;|Ability', 'eligbility', 'arthroclisis', 'bleeding tendency(hemophilia)|Receiving', 'visit|Symptomatic hypotension', 'standard postnatal', 'angioedema.|Idiopathic urticaria', 'lymphatic stasis', 'signs of cord compression', 'body.|High myopia', 'heart failure|Individuals', 'fibrotic conditions', 'unstable cardiac disease', 'contra-indicate', 'symptoms of psychosis', 'corneal infection', 'A|Chronic renal failure', 'visceral metastases', 'lyme disease', 'signs of GI bleeding', 'Alzheimer s disease', 'progressive MS;|Previous treatment', 'primary kidney', 'adenoid cystadenocarcinoma', 'elevation', 'auditory and visual', 'in-situ cancers', 'classical Hodgkin lymphoma', 'bleeding diathesis.|Uncontrolled haemorrhage', 'endothelial dysfunction', 'clinical stage', 'rheumatoid arthritis|Avascular necrosis', 'psoriasis.||', 'Gestation|Institutionalization', 'adenocarcinoma|clinical stage T4', 'anesthetic survival', 'tardive dyskinesia.|Known', 'severe basic diseases', 'hepatitis E vaccine', 'urinary system surgery', 'rheumatologic disorder', ""Crohn's disease.|Diagnosis"", 'diabetic macular edema', 'liver injury', 'ependymoblastoma', 'osteopetrosis', 'vitamin C', 'pain score', 'valvular heart disease.||', 'psychosis symptoms', 'ALL)/lymphoma|Myelodysplasia', 'myoma', 'severity|Intellectual disability', 'recreational soccer', 'histologic malignancies', 'antiviral', 'WIFI', 'arthropathies', 'skin reactions|History', 'exertional dyspnea', 'optic neuropathy', 'separation anxiety disorder', 'intratemporal complications.|Patients', 'Digestive Disease', ""Gilbert's syndrome|serum"", 'in situ cancers', 'polycythemia', 'assessments||', 'old||Diagnosis', 'vaginal-ring', 'nerve conduction impairment', 'right cheek', 'chronic illness that limits their participation in physical activities|Participants', 'involvement in prescribed therapy', 'pulmonary lymphangitis.|Known', 'rheumatic immune system disease', 'recurrence of malignancy', 'cavum', 'malignant solid', 'PARQ', 'Atrial fibrillation ablation', 'retinal breaks (MRBs)', 'main organs|7', 'acutely psychotic.|Provider', 'binge eating,|Psychiatric disorders', 'breast feeding|Unable', 'internal disease', 'vascular injury', 'Squint', 'eGFR determinations', 'delayed cord clamping.||No time', 'hemiplegia', 'cT4b disease', 'renal function.||', '/carcinoma', 'HBV infection status', 'syndesmotic injury', 'clinical manifestations', 'severe dry eye', 'homozygous factor II', 'hepatic deficiency', 'joint', '28).|Metastatic disease', 'HIV-1 infection', 'TAS2R38 gene)|Overall healthy', 'abnormal coagulation function', ""Celiac's disease|Hypothyroidism|Unstable"", 'GCase activity', 'NCGS symptoms', 'rotator cuff tears (mRCT', 'met:||Measurable disease', 'dietary fiber', 'genetic defects', 'large intraventricular hematoma;|(4', 'problem affecting the vision', 'pregnancy.|Renal impairment', 'actively employed', 'nasal pharyngeal', 'early-stage mycosis fungoides', 'solid malignant tumors', 'malignancy).|HIV infection.|Pregnancy.|Are', 'substance use disorder.|May have', 'attributes', 'acquired immune deficiency syndrome-defining opportunistic infection', 'pregnancy|Gestation', 'breast cancer (MBC', 'revision spine surgery|Liver disease', 'trigeminal neuralgia', 'infection of the knee joint', 'metabolites', 'primary malignancies', 'anaphylactic shock', 'screening||Significant Pulmonary Hypertension', 'obstructive pneumonia', 'distant organ metastasis;|Incomplete', 'immunocompromised|Diagnosed with cancer', 'facial disfigurement', 'bronchitis|Allergy', 'cardiac rhythm regulators', 'cardiovascular event|Poorly', 'labs:||Abnormal liver function', 'Hospitalization)|Symptoms', 'ectoparasitosis', 'analgesics.|Pregnancy', 'average pain', 'ASCVD', 'recovered from all adverse events', 'Involvement in another concurrent', 'in-situ cancer', 'solid organ transplantation;|Uncontrollable', 'functional activity', 'acupuncture needles.|Pregnancy', 'superficial bladder cancer cancer', 'Syndromic', 'extra hilar lymph nodes', 'biochemical hyperandrogenism', 'poor cooperation.||Inclusion criteria', 'rish of infection', 'thrombotic diseases', 'child-bearing FFCD', 'risk proliferative diabetic retinopathy.|DME', 'fiducial markers', 'paraplegic patients', 'program;|Diagnosis', 'Systemic infection', 'NTRK3', 'esophageal dysmotility', 'periodontal surgery|Unstable endodontic conditions', 'cystic disease|prenatal', '90%|Concomitant pathology', 'menstrual cycle', 'surgery|Previous swallowing', ""Gilbert's syndrome).|Alanine"", 'skin of the neck.|History of', 'hypothyroidism.|Those', 'cervix|Superficial bladder', 'higly effective contraception', 'involuntary behavior', 'oral Valganciclovir.|Absence', 'gastroesophageal reflux|Severe', 'head & neck cancer specialist', 'impaired comprehension', 'GEJC', 'Duodenal Ulcer', 'cervical drainage', 'CNS metastases', 'abnormal curvature', 'rhinopharyngitis gangosa', 'breast.|Macroscopic intravascular invasion into', 'solid organ transplantation|Patients', 'RASopathy', 'chemotherapies.|Treatment', 'population:||Lung cancer', 'CVS', 'cetera', 'Psoriatic Arthritis', 'therapy;|ECOG score', 'epidemic typhus', 'chronic impairment', 'home ventilator|Immediate tracheal', 'surgical pathology', 'etc)|Medical contraindications', 'Myasthenia gravis', 'correction|Renal disease', 'fungal sinusitis|cystic fibrosis', 'intestinal anomalies', 'unresectable tumors', 'investigator.|Active infection', 'neurological disability', 'unhealthy', 'valvular disease', 'vaccinations', 'pelvic exenteration', 'xerosis', 'cancer in situ currently', 'PED', 'national mental health', 'large vessel occlusion stroke', 'vascular lesions', 'immunodeficiency', 'clinical findings', 'IDU).|Clotting disorder', 'voiding dysfunction', 'proxy.|Known allergy', 'retinal thickness', 'ALK+ systemic anaplastic large T-cell lymphoma', 'weight loss surgery', 'neurologic toxicity', 'vein steal syndrome', 'breast-feeding patients', 'mitral valve disease', '1||organ function：||Kidney function', 'illegal substance abuse', 'toxic megacolon', 'Cohort||Consecutive adult', 'systemic cancer therapy', 'chronic bladder pain', 'asymptomatic BMS', 'drug-induced interstitial lung disease', 'recreational drug use|Known allergie', 'renal dialysis', 'Diabetes Self-Management Education', 'Macular Degeneration', 'basal cell skin cancer', 'Deep Brain Stimulation - DBS);|Subject', 'neurological diseases;|survivors', 'pT1 breast cancer', 'core antibodies', 'chronic hemiparesis', 'Transition', 'endocrine neoplasia syndrome type 2', 'hemodynamic instability|history of', 'recovered from radiotherapy toxicities', 'ultrafiltration failure|Mental retardation', 'scleroderma.|Silicone', 'Evaluable lesions', 'health foods', 'liver cirrhosis', 'rhinitis', 'Myocardial infarction', 'therapy|Age', 'non-Hodgkin lymphoma', 'pathological dry eye', 'fibromialgia síndrome', 'disease.|Localized prostate cancer', 'atopic keratoconjunctivitis).||(if', '≥18|World Health Organisation', 'CNS leukemia involvement', 'speech disorder.|Self-reports', 'amyotrophic Lateral Sclerosis)||Schizophrenia', 'obstructive spirometry|History', 'bilateral tooth loss', 'systemic diseases', 'flamenco dance.|To', 'hypospadias||', 'pulmonary arterial events', 'kidney cancer related to urinary collection system', 'vascular variation', 'autoimmune disease.|Clinically', 'burr holes', 'breast feeding|Patients', 'gastrointestinal tract surgery;|History', 'calcified lesions', 'large tumors - tumors', 'poor diabetes', 'non-melanoma skin cancer.|Patients', 'liver disease.||', 'chemical peel', 'acute intraluminal thrombus', 'conversion', 'exacerbation of congestive heart failure', 'combined immunodeficiency disease', 'rejection Sema-RTx', 'bladder neck contracture', 'sexual abuse', ""face's"", 'cardiopulmonary dysfunction', 'ulcer disease', 'history|Psychiatric comorbidity|Chronic diseases', 'osteomalacia;|Osteoporosis', 'gastrointestinal inflammation', 'mEMA', 'temporomandibular joint', 'allergy|Heart disease', 'complex nature', 'status|Active Congestive Heart Failure', 'hospitalization|diagnosis', 'inflammatory bowel diseases (CD', 'gastrointestinal disorders/diseases', 'arrhythmia|Presence', 'eyebrow ptosis', 'HER2-low metastatic breast cancer', 'knee arthritis', 'series', 'liver disease.|Are', 'stool disorders', 'concomitant illness', 'somatoform disorder.|Pregnancy', 'Human Immunodeficiency Virus [HIV', 'serum hepatitis', 'PTSD Checklist', 'limb amputations', 'chronic bronchial inflammation', 'ethnicity adjustment', 'asthma exacerbation treated', 'legs into leg trays', 'leptomeningeal disease|Uncontrolled', 'abuse', 'left atrial volume', 'traumatic brain injury', 'Liver malignant tumors', 'disorder psychopatology', 'INCLUSION CRITERIA FOR AERD', 'months;|Cardiovascular disease', 'healed wounds', 'episodic headache', 'deficits.||Healthy', 'chronic obstructive pulmonary diseases', 'facial clefts', 'females)|Psychiatric illness', 'GI conditions', 'accreta', 'Myofascial pain syndrome', 'Major bleeding', 'liver disease|No', 'oral hygiene.|Patients', 'suicidal tendency', 'Dysphagia', 'UE support', 'including:||Complete remission', 'B-NHL', 'atresia', 'Pancreatitis', 'cardiopulmonary disorders', 'psychosomatic diseases', 'malignant tumors;|Liver/lung metastasis;|No pathology', 'brushing', 'Regular menstrual cycles', 'contracting TB', 'genital tract bleeding', 'lymphatic system diseases', 'pathological findings;|Bone metastasis', 'Cataracts', 'judged by the doctors', 'extramedullary disease', 'breast malignancy', 'Preimplantation', 'NOS sarcoma', 'baseline.|Participant', 'masticatory muscles', 'reason|Cognitive impairment', 'COVID-19 risk', 'autologous liver', 'AD involvement', 'abdominal skin', 'histologically distinct', 'diffuse carcinoma in situ', 'non-allergic drug reactions.|Relevant diseases', 'drug|Sensitivity', 'kidney toxicity', 'clinical liver failure', 'tumor site', 'TMD', 'severe health problem', 'breast-feeding.|Participants', 'fulfilled:||Spinal cord compression', 'HIV)|Patient', 'teeth Visually intact occlusal surfaces', 'risk of coronary heart disease||', 'drug abuse', 'VT)|Ventricular fibrillation', 'diverticular stricture', 'reading', 'metastases;|Impossibility', 'major liver disease', 'therapy|Received Botox', 'blood coagulation', 'thyroid surgery;|The', 'early malignancy', 'anti-diabetic', 'Exclusion Criteria：||Wtih', 'D|Esophageal strictures', 'left ventricle', 'hyperuricemia', 'illness.|Pre-existent', 'retrosternal pain', 'clinicopathologic data|patients', 'tumor locations', 'labor|Pregnant', 'musculoskeletal condition', 'toxin shock', 'language barrier limiting', 'skin type VI', 'pre-eclampsia|Blood pressure', 'synthetic 2D image', 'autoimmune hemolytic anemia', 'long QT Syndrome', 'pre-cancerous skin lesions', 'impaired coagulation', 'physically active enough', '|Trauma', 'fibrolamellar cell carcinoma', 'tuberculosis infection', 'respiratory support', 'bleeding;|Habitual constipation', 'surgical drainage', 'coincidental stroke', 'Chondrosarcoma', 'prosthetic factors', 'thought disorder', 'neurodermatitis -', 'cardiovascular function', 'cardiac valve disease', 'hypotrichosis', 'sensitive mutations', 'major chronic diseases', 'deep brain stimulation)|Conductive hearing loss', 'BRCA1/2m cancer', 'IHC1+', 'disease|Neurological disease', 'chronic neurological disorders', 'progressive mCRPC (progression', 'malignant tumors|Will receive antitumor drugs|Could', 'opioid use disorder', 'hypoglycaemic events', 'predominantly classic', 'head and neck', 'alcohol acute intoxication', 'rheumatic heart disease;|Patients', 'primary diseases of the testes', 'poor condition', 'episodic prophylaxis', 'metabolic abnormalities', 'liver failure.|Congenital heart defects.|Malignant neoplasm', 'vitiligo.|For', 'colorectal cancer surgery', 'renal dysfunction', 'canal stenosis', 'STEMI myocardial infarction|Sepsis', 'non-CNS disease completed', 'pyruvate carboxylase deficiency', 'skeletal disease', 'hormonal deficiencies.|Known chromosomal aneuploidy', 'infectious endocarditis', 'BKV)-DNAemia', 'injection site reactions', 'prednisolone|Acute bacterial infection', 'Pulmonary hypertension', 'deep dry', 'CT changes', 'pneumonia complications', 'concomitant liver diseases.|ALT', 'ESRF', 'MSH2', 'PCR.|Positive hepatitis C antibody', 'Low back pain.|Any traumatic', 'dys-gammaglobulinemia', 'adverse event leading', 'radical resectable carcinoma', 'blepharochalasis', 'varus', 'nasal cavity diseases (rhinitis', 'chronic conditions', 'drug-drug interactions)|Gastrointestinal pathology', 'peripheral neuropathy.|Patient', 'purulent meningitis', 'HIOC', 'finger smoothing', 'identifiable causes""|The', 'progressive neurological disorders', 'Regional Pain Syndrome', 'comorbidity of syndromes', 'open fracture', 'investigation.|Patients enrolled', 'mental conditions', 'hypopituitarism', 'cognitive disorder', 'conditions of the shoulder resulting', 'maxillofacial trauma', 'in situ cervival', 'disease assessment|Active infection', 'renal calculi', 'pancreatic malignancies|Allergy', 'SPMS', 'cholestasis', 'risk factor(s', 'breast feeding|Background therapy of any oral AADs', 'months;|General Physical Condition (ECOG)', 'Hemiparesis', 'bowel diseases', 'draining', 'acute/chronic', 'bifascicular', 'heart block|Interrupted', 'atrial thrombus', 'unable to undergo', 'spinal cord trauma)|Lead toxicity', 'PLWD', 'extensive colonic resection', 'eye surgeries', 'ambulation', 'severe anaphylactic diseases', 'physical rehabilitation.||', 'non-epithelial cancers', 'Familial Cancer Syndrome.|Prior receipt', 'cardiac arrhythmias.|Stroke', '/L', 'H. pylori', 'cardiomyopathy)|Pulmonary comorbidity', 'life limiting illness', 'polyradiculoneuritis', 'NSCLC resectable', 'fits', 'Medication Patches', 'complete bowel obstruction', 'Chronic HF', 'patients|Age', 'carotid atheromasia', 'HER3 targeted', 'cardiovascular disease|A', 'in situ uterine cervical carcinoma', 'valgus deformity', 'dialysis dependence', 'local infection', 'cranial deformation|Patients', 'bullous skin disease', 'leptomeningeal spread', 'Pure pleural lesions.|Clinical instability', 'exhibiting fever', 'type 2 diabetes mellitus', 'severe preeclampsia', 'clinical workflow.|Diagnostic radiologists', 'disruption', 'lower limb arthroplasties', 'nervous system tumor', 'muscle disorders', 'toenail onychomycosis', 'radical basal cell carcinoma', 'Aortic Stenosis', 'Hepatitis C.|Uncontrolled diabetes mellitus', '4|Active liver disease', 'Interventions', 'abnormal wave band is found in electrocardiogram;|Indoor baseline blood oxygen saturation>92%;|Total bilirubin', 'Covid-19 disease|Postmenopausal', 'shampoos', 'autoimmune disease|Positive test', 'adequate hepatic function', 'concomitant infection', 'Atherosclerotic Cardiovascular Disease', 'contrast allergy', 'diabetic diseases.|Uncontrolled hypertension', 'severe rhythm disturbances|cancer', 'Cardiac disease', 'chronic obstructive lung disease', 'FOLFIRI', 'Impaired renal function', 'widespread bridging fibrosis', 'intracerebroventricular cerliponase alfa.|Ocular surgery', 'problem drinking', 'colorectal cancer', 'major cardiac condition', 'ductal carcinoma in situ of the breast', 'psychotropic disease', 'hepatic impairment.|Hypermagnesemia', 'antiglaucoma drugs)|any', 'manic episodes.|Veterans', 'Diabetes Mellitus|Hereditary glucose-galactose malabsorption', 'draining sinus tract', 'generalized hypermobility', ""n'ayant reçu"", 'recurrence|acute bacterial sinusitis', 'tumor mutations', 'restorations', ""Crohn's Disease.|Patients"", 'bone disease', 'Traumatic spinal', 'Prisma Health Maternal-Fetal', 'LIN', 'Criteria:||Clinically healthy', 'adequate organ functions', 'genotype mutations', 'upper extremity rehabilitation', 'systemic hemorrhage', 'atrial fibrillations', 'lens opacity affect the observation of the fundus', 'persistence of prostate cancer', 'pulmonary aspergillosis', 'basilar artery', 'HTA', 'endocrinological disorder', 'pressure ulcer', 'aphasia', 'criteria of the European Society of Cardiology (ESC)', 'persistent epithelial defect', 'systemic inflammatory diseases', 'cancer in situ', 'type of presentation', 'genetic metabolic diseases', 'myeloproliferative neoplasm', 'cardiovascular conditions', 'inadequate cough', 'depressed skull fracture', 'Deep Throat Saliva (DTS)', 'hemorrhagic predisposition', 'Refractory lymphoma', 'compensatory collateral branches of the portal', 'Premenopause;|Diagnose', 'uterine abnormalities', 'idiopathic pneumonitis.|Evidence', 'thymic carcinoma', 'passive cervical motion', 'disseminated herpes zoster', 'viral hepatitis type B (HBV)', 'atherosclerosis', 'shock wave lithotripsy (SWL)', 'functional method', 'Adult obese', 'esophageal disease', 'acute disease exacerbation', ""Hodgkin's disease"", 'meningeal involvement.|Patients', 'hematopoietic growth factors', 'squamous cell carcinoma of the oropharynx|Patients to be treated', 'local active ulcer lesions', 'impaired renal function).|Mental disorder', 'serious personality disorder', 'Major depressive disorder;|Fractures;|Traumatic Brain', 'diabetic complications', 'neuropathic pain|No sedatives', 'somatic cloning abnormalities', 'loss of appetite', 'pulmonary artery systolic blood pressure', 'respiratory malformation|Acute respiratory infection', 'Gilbert syndrome', 'airway responsiveness', 'tuberculous cystitis|History', 'non-atherothrombotic mechanism', 'acute respiratory failure', 'pregnancy|Malignancy', 'difficulty initiating', 'hay', 'type 1 diabetes|treatment with artificial pancreas device|absence', 'normal PSA levels|Participants', 'chronic pulmonary disease|Patients', 'good renal', 'solid benign', 'bifascicular block', 'infection of the affected burn', 'prion diseases', 'salivary gland cancers', 'distant metastases|In', 'age|Pregnant', 'pulseless electric activity', 'systemic factors', 'diabetes complications', 'Lymphocytic Lymphoma', 'hepatitis infection', 'Hepatitis C.|A positive', 'Symptoms', 'metabolic syndrome', ""Werlhof's disease"", 'cervical spine', 'tuberculous lesions', 'heavily weighted', 'serious illnesses', 'juvenile idiopathic arthritis', 'hypotonia', 'score)>60.||', 'Regulatory Disorder', 'trial.|Concurrent medical condition', 'erythema multiforme', 'ileostomies|Inflammatory bowel disease|Colonic optimization', 'bleeding risks:|3.1', 'malignant disease.|Uncontrolled', 'CTCL', 'recurrence after', 'rescue laxatives', 'collapse', 'hypogonadism', 'LVAD),|Pregnant', 'surgery.|Prior glaucoma surgery.|Pseudoexfoliation', 'lactation.|Potentially unreliable', 'suboptimal difference', 'internal conditions', 'Gilbert heald diseases', 'treatment)|ALK rearrangements', 'known hypertension', 'managing hepatitis', 'G3 NET).|Uncontrolled blood pressure', 'investigator.|Active bleeding disorder', 'GERD', 'psychotic disorder', 'mitral isthmus', 'gastroenteritis that', 'early stage brest cancer|Breast ptosis', 'paracentesis', 'light chain type', 'dosing cycles', 'cardiac infarction', 'breast cancer|using AI', 'percutaneous transluminal coronary intervention', 'chronic toxicities', 'hepatitis C virus|Previous treatment', 'IgE-mediated reactions', 'France Intergroupe Syndrome', 'cryo', 'nonmelanoma skin cancers', 'Rheumatoid', 'risedronate', 'progressive neuromuscular disorder', 'months|Self', 'human immunodeficiency virus [HIV] infection', 'developmental disorders;|Presence', 'active virus infections;|History of', 'compressive neuropathy', 'platelet dysfunction', 'with spermicide', 'radiographic disease', 'immunological disease', 'complex of instrumental', 'active autoimmune disorders', 'psychosocial criteria', 'lower limb amputation|Intra-articular steroid', 'secondary peripheral neuropathy', 'Sleep Disorders-the', 'unresectable factors', 'cardiac stenting', 'squamous cell in situ skin carcinomas|Treated', 'acute thyroid storm', 'non-reactive HIV-1 antibody', 'abnormal metabolism', 'dermatofibrosarcoma protuberans', 'respiratory tract infection', 'vertebrates', '6.Gastrointestinal Bleeding', 'Canadian Diabetes', 'seasonal affective disorder', 'schizotypal personality disorder', 'CNS infection', 'Stable coagulation', 'stress incontinence', 'myeloproliferative neoplasia|Presence', 'Health Questionnaire-9 items (PHQ-9)', 'diseases of the skin', 'renal dysfunction.|Ongoing', 'personality disorder', 'diastolic ≥100 mmHg', 'cutaneous horns', 'ischemic ECG changes', 'mm|No periodontal disease history|Non-smokers|Fluent in English||', 'pemphigus', 'retropulsion', 'local health authority.||Unable', 'consumption of grapefruit', 'corneal opacity', 'intestinal cancer;|Patients', 'anterior segment abnormalities|Presence of ocular', 'mental deficiency', 'carcinoma in situ of the breast.|Severe', 'pathological abnormality', 'Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation', 'calculated risk for breast cancer', 'sinus rhythm|autonomic', 'Gaucher disease', 'lymph nodes enlargement', 'HBV-DNA<2000 IU/ml', 'dilated bowel loops', 'Gr-etiology', 'nerve lesions', 'parafunctional habits', 'arterio', 'teeth size', 'criteria:||No disorder', 'cutaneous infection', 'Nodal spread', 'dysfunction', 'diseases,|inflammatory bowel', 'organ disease', 'sensitivities', 'Hepatitis B virus(HBV) infection', 'deep dyspareunia', 'impression', 'chronic diseases|Signs', 'infectious complication', 'TIA', 'coagulation disorders|Patient', 'irritability', 'Hg|Current', 'implant surgery.|Active infection', 'diastolic dysfunction)|Hepatic dysfunction', 'Diabetes Mellitus (DM)', 'non-sterilized', 'visuospatial memory)||', 'ECG', 'rheumatoid diagnosis', 'wrinkles', 'Liver functions tests', 'PAH classified', 'non-syndromic CLP.||', 'infarction|local infection', 'acute mental illnesses.||They abuse', 'exotic citrus fruits', 'chronic hypothyroidism', 'radiation-induced pulmonary fibrosis', 'fibroScan', 'primary brain tumor', 'infusion reaction', 'sensory defects', 'pressure ulcers', 'eosinophilic oesophagitis', 'hemodynamics', 'Myocardial Infarction', 'give free', ""primary Sjögren's syndrome"", 'atrial/ventricular', 'gastrointestinal diseases.|With', 'android mobile', 'as:|Clinical lacunar stroke syndrome', 'B cell lymphoma', 'dependence|Current depressive episode', 'clearly diagnosed;|Acute infection', 'HIV)-1', 'severe arthritis', 'cardiac disease.|Morbidly obese', 'GI dysfunction', 'CHB patients.||', 'renal condition', 'limb threatening', 'chronic renal insufficiency', 'MVD', 'dependent persons.|Inability', 'Orthopaedic', 'ECV|Chronic pain', 'altruistic kidney donor', 'diseases.|Cataracts', 'non research related', 'coagulation defects|Chronic obstructive pulmonary disease exacerbation', 'Memorial Herman Hospital-Texas Medical', 'diplegia', 'Confirmed T2DM diagnosis', 'cerebral brain perfusion', 'neonatal pneumonia', 'vape', 'pericardial friction rubs', 'ocular toxicity', 'osteoarthritis of the knee', 'genitourinary tuberculosis', 'pneumocystis pneumonia', 'required|Clinically stable', 'in situ cancer', 'MPNs', 'Carcinoid syndrome):||30', 'renal function.|Patients', 'ambulation|Medical contraindication', 'Gilbert', 'breast-feeding|Any', 'Xiaoyan lidan tablets', 'homeotherapy', 'legs', 'carcinoma', 'bacterial skin infections', 'Heart Failure|A left ventricular ejection fraction', ""Crohn's disease|Recent"", 'heart stent', 'etc.;|Previous', 'CTCAE adverse events', 'haemato-oncological malignancy|Adults', 'epidural block', 'upper respiratory tract', 'Coronavirus disease', 'Impella CP', 'end-stage kidney disease', 'Coma', 'know autonomic', 'TIMI blood flow', 'heart rate', 'solid organ metastases (liver, lung', 'mass lesion', 'satisfy cravings l', 'questionnaire|Regular menstrual cycles', 'angioid streaks', 'ear pathology', 'chronic illness.|History', 'coronary artery stenosis', 'consent|Definition', 'gluconeogenesis', 'managerial conditions.|Patients', 'acute rheumatic fever', 'non-hyperaemic tests.|Functional limitation', 'non ST segment', 'uveitis|Monocular', 'Gestational DM.|Visual', 'concussion symptoms', 'coronary lesion', 'moyamoya disease', 'recurrent disease should', 'Retinitis', 'diabetes distress', 'Infections', 'amniocentesis', 'anal fistula', 'mixed-meal tolerance test (MMTT) conducted at least 21 days from diagnosis', 'alternative syndrome', 'visceral disorder', 'femoral hernia', 'laparotomic fibroid resection', 'enteropathies.|Whose parents', 'Acute penetrating, puncture', 'liver metastasis exists', 'neuritic symptomatlogy y referred.|Rigid claw', 'chronic infections of the CNS', 'vital signs|Clinically significant', 'temporomandibular joint disorders.|Patients', 'cardiac metastases', 'enzyme inducer', 'abnormal voice', 'Vascular disease', 'internistic diseases', 'surgical revascularization|Left main', 'systolic 90mmHg|Haemothorax', ""Infectious Diseases Drassanes Vall d'Hebron"", 'moderate alcohol', 'transplantation|active cancer|liver disease', 'sickle cell trait.|Participant', 'chronic pruritus', 'renal disease)|Recent', 'NCI CTCAE grade', 'skin condition', 'acquired immunodeficiency syndrome.||Patients', 'benign ovarian masses', 'diagnostic radiology', 'transient venous thrombosis risk', 'umbilical cord tissue|Willing', 'Allergic reaction', 'odynophagia', 'cytokines;|Previous', 'candidate to surgical treatment', 'IHC', 'ileal involvement', 'pancreatic mucinous', 'ischemic ulcer', 'risky pregnancy', 'pain from', 'classroom level factors', 'VDTS induced Tension neck syndrome', 'consumption of citrus fruits', 'reproductive ability must be', 'muscle weakness', 'communication problem,|Not', 'ECGs', 'surgery.|Dysautonomia', 'psoriasis patches', 'skin discolouration', 'neurovascular event', 'septic shock:||•', 'BDTX-189', 'intestinal absorption', 'renal functions.|Myelodysplastic syndromes (MDS)', 'institutionalization', 'meaures', 'chromosomal nondisjunction', 'daytime frequency', 'MTB', 'upper airway pathology', 'diabetes type-II', 's MR compatibility', 'DS8201a', 'language barrier|uncompleted questionnaire', 'remain overnight', 'non-smokers', 'lung nodule', 'psychosis develops', 'serous ovarian carcinoma', 'bone marrow tumor', 'delusional disorders', 'spinal instrumentation', 'acanthopanax senticosus', 'spastic diplegic cerebral', ""rehabilitation training|Participant's parents"", 'lower limb amputations', 'glaucoma family', 'Sponsor)|Muscle weakness', 'high disease activity', 'complete left bundle branch block|Hypertension', 'AIDS-related illness', 'refractive astigmatism', 'esophageal obstruction', 'Polymorphous adenocarcinoma', 'liver metastases|Total bilirubin', 'favorable', 'extensive skin diseases', 'psychotic disorders,|Untreated', 'bimaxillary protrusion', 'skin quality', 'facial pain', 'national health care system (AME are not allowed).||', 'PD|Diagnosis', 'soaps', 'traumatic brain injury|Metal implantations', 'treated carcinoma in situ of the cervix', 'pulmonary vascular', 'major hemorrhage', 'Obstetrics）stage|Physical condition', 'viral infections', 'phlebitis', 'entrapment neuropathy', 'submucosal invasion', 'therapy|Active bleeding needing blood transfusions', 'neuropathies', 'retinal detachment||', 'good physical health', 'hepatitis B virus(HBV) infection', 'muscle ache', 'dietary supplement', 'surgically altered anatomy', 'spastic type cerebral', 'sperm from testes biopsy', 'hypertrophy cardiomyopathy', 'vertebral artery disease', 'intense physical effort.||physical exertion.||Subjects not taking', 'eye injury', 'persistence fatigue assessed via FACIT', 'immunosuppressive condition', 'inflammatory diseases of the nervous system', 'primary teeth|Children', 'serious infection.|Intercurrent illness', 'neurologic disease|A', 'gastrointestinal ulcers', 'echocardiographic', 'chronic monocytic', 'radiculopathies', 'head and/or neck chemoradiation therapy|Existing indwelling neurostimulation device', 'acute noncomplicated dermatitis superficial corticosteroid therapy', 'clear disease', 'disease stabilization', 'positive breast cancer', 'neoplastic wound', 'Cardiovascular instability Visual', 'LMS', 'chronic pain derived', 'upper arm', 'neurosis', 'difficulty swallowing whole capsules,||Additional', 'GPC3 positivity by IHC', 'Binocular vision dysfunction', 'localised squamous cell carcinoma of the skin', 'lumbar puncture|Secondary causes', 'hemolytic anemia', 'Parasomnia', 'leg pain', 'blind|housebound', 'Inflammatory pseudotumor', 'bariatric surgery;|not', 'local anorectal problems', 'alcoholic hepatitis', 'systemic diseases.||Patients', 'human serum albumin (HSA)', 'hemolysis|Unstable angina', 'passage disorder', 'Clubs', 'fetal distress', 'mixed well-differentiated/dedifferentiated', 'margins positive', 'severe bone injury', 'giant liver cysts', 'acute psychosis', 'consent||CONTROLS||Uneventful pregnancy', 'resistance', 'neurocognitive function', 'food protein induced enterocolitis', 'cataracts;|Refractive errors', 'common terminology criteria', 'upper extremity sensation', 'AECI', 'noncalcified solid pulmonary nodules visible', 'hip', 'pharmacologically treated', 'hemorrhagic stroke', 'critical conduit(s', 'bronchial artery penetration', 'proper organic function', 'functional disorders', 'renal transplantation|Tubulointerstitial diseases', 'partial obstruction', 'stomach pain', 'cerebellum disease', 'comorbid medical illness', 'impact metabolism', 'carious lesions;|No lesions', 'recurrent infection', 'Type 2 diabetics', 'high performance liquid chromatography', 'non-small cell lung cancer.||For cohort A', 'decrease', 'kefir', 'PTNS', 'URR', 'brief psychotic disorder.|History', 'menstrual bleeding episodes', 'age|Good surgical candidate', ""Quinquaud's decalcifying folliculitis"", 'Schools', 'hepatosenomegaly', 'non-epileptic', 'tablet touch screen', 'renal carcinoma', 'Oral pathology', 'lunar facies', 'labral tear', 'bladder cancer cancer', 'dehydrate deposition disease', 'GLP-1 RA.|Any condition', 'bi-fascicular block', 'HCC', 'invasive cancer', 'centimeters tall|Be residing', 'intestinal disorders', 'macromolecular protein preparations', 'Cancer metastases', 'made.|In stable', 'congestion', 'endoscopic remission', 'former smoker|airway infection', 'facial trauma', 'left main coronary artery', 'congenital hypertrophic pyloric stenosis', 'nocturnal dyspnea', 'juvenile-onset SSc|Having', 'pulmonary insufficiency', 'pulmonary nodules', 'musculoskeletal impairment', 'Acquired ImmunoDeficiency Syndrome', 'refractory to FVIII', 'sulfonylureas', 'soiling', 'levels of anxiety', 'secondary immunodeficiency', 'pregnancy-induced', 'lumbar disc hernia', 'Healthy resident', 'Myeloid Leukemia', 'neurological sequelae', 'drug-derived);|7', 'predominance of SUI', 'reduced occupational employability medical', 'Otological infection|Tympanic', 'congenital QT', 'oral ulcers', 'common iliac artery dissection tumor diameter', 'CNS involvement.|Stroke', 'Cohort Orthopedic Controls||1', 'respiratory pathologies', 'anaplastic thyroid', 'primary immune disorders', 'heart rate|phosphodiesterase type 5', 'liver function test', 'sports)|Pregnancy', 'primary dry eye', 'neurological, developmental', 'better|Participant', 'primary headache', 'antibiotics|Iron overload condition', 'discitis', 'ACS', 'Soft tissue infection', 'cognitive deficits', 'hepatic dysfunction', 'mandibular setback', 'Xerostomia.|Patients smoking', 'ovarian diseases', 'lumbar spine tuberculosis', 'urinary system abnormalities', 'consent|RV dysfunction', 'secondary immune deficiencies', 'COVID-19.|Mental illness.|Receipt of plasma', 'multiple endocrine neoplasia syndrome type 2|Have serum aspartate aminotransferase', 'heart disease|use', 'comorbid psychiatric illness', 'recovered from all treatment-related', 'urinary tract calculi', 'solid phase immunoassay).|RECIPIENT', 'NSAIDs|kidney dysfunction', 'sexually transmitted diseases', 'mandibular first', 'primary canines', 'native aortic stenosis', 'obstructive sleep apnea|Patients', 'criteria of the German ""S3 guideline non-restorative', 'genders|Presence', 'peripheral nerve disease', 'antagonists|Autosomal dominant polycystic kidney disease', 'lung mass', 'cystic carcinoma', 'Infectious Disease Committee', 'non-resolving', 'suicidal behavior', 'Rash', 'metabolic disease', 'internal bleeding', 'chocolate', 'Kidney Diseases', 'decerebrate posture', 'painful procedures', 'acute leukemia', 'periapical disease', 'IPAH', 'systolic heart failure', 'multiple organ failure', 'type-2 diabetes', 'Minimal bleeding', 'Global Pharmacovigilance', 'fixed neurologic deficits', 'stomach stagnation syndrome;|Signed', 'psychomotor delay', 'HIV-negative||Health Professional', 'urgency frequency', 'primary AL amyloidosis.|Major surgery', 'months;|The main organs function well', 'FSCP).|Patients', 'palliative intent|Patients', 'pelvic tenderness', 'drug abuse.|Pregnant', 'anti-infection treatment', 'Moyamoya disease', 'calcified shadow lesions', 'chronic plaque psoriasis', 'secondary immune disorders', 'JMT103', 'not allow', 'end organ damage', 'fallopian tube damage', 'mild alcohol', 'UINTED KINGDOM', 'urine pregnancy testing', 'recurrence on or after their most recent therapy.||6', 'peripheral artery disease (PAD)', 'choroidal melanoma', 'acute illness.|Metabolically unstable', 'myometrial vascularity)||', 'addictive', 'Arteriovenous thrombosis events', 'steatohepatitis', 'celiac disease', 'miscarriage', 'hereditary thrombophilia', 'eligible.||Active infection', 'deformities', 'Native', 'conditions|Active infection', 'event|Chronic renal failure', 'obstructive jaundice', 'stabilization', 'TUD', 'Mediolateral', 'ACLR', 'Infertile', 'current illness', 'heterozygous mutation', 'membranes thus', 'needed)|Cognitive impairment', 'autoimmune skin condition', 'Multiple Sclerosis Spectrum', 'nasal septal defect', 'alar ligaments|vertebra', 'functional changes', 'S deficiency', 'cetuximab|Known bleeding disorders', 'dextromanuality;|Chronic disorder', 'bone impairments', 'vision disorder', 'liver parenchymal biopsies', 'matching variables', 'countries', 'coronary bypass', 'although the production of TIL', 'therapy;|Hepatic dysfunction', 'Univasc', 'thyroid supplement', 'management|Malignant cancer', 'biallelic mutations', 'nuclear bone scan', 'artificial tears|non-compliance to the study protocol', 'World Health Organization', 'California', 'leptomeingeal leukemia', 'bone metabolism regulation drugs', 'true:||is', 'nodules.|Known allergy to', 'accessible tumor', 'ischemic heart disease', 'solid tumor malignancies', 'individual item', 'multiple lumbar punctures', 'anterior open bite', 'acute gout flare', 'hereditary colon cancer', 'extrapulmonary TB infection', 'amphetamines', 'infection of the hip', 'PCR|Human Immunodeficiency Virus', 'reduced RV function', 'idiopathic osteoarthrosis', 'relatives', 'Neurological disease|Psychiatric disease|Obesity', 'organ transplantation;|Other malignancies', 'cytomegalovirus infection', 'Inflammatory bowel disease', 'tree nuts', 'C.|Prior allergic reaction', 'TEE', 'neurological disorder|Electroconvulsive therapy (ECT)', 'Weight loss', 'Sanjad-Sakati syndrome', 'infantile', 'Urothelial Carcinoma', 'contraindication', 'anti-coagulation regimen therapy', 'histiocytic neoplasms', 'walk back to the chair', 'intractable hypertension.|Suffering', 'cardiological symptoms', 'unstable;|Have severe', 'renal biopsy|Recipients', 'intracranial toxicity', 'old|Evidence', 'systemic cancer', 'degenerative disease', 'secondary membranous nephropathy', 'refractory symptoms', 'left main bronchi', 'Multiple Myeloma', ""Hirschsprung's disease"", 'papillary thyroid cancer|Patients', 'age.|Other pathologies', 'Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)|Hypersensitivity to semaglutide', 'learning', 'colonic tumor', 'Epithelial ovarian', 'peripheral vascular disease)|4.Serious', 'hepatitis panel', 'bladder onabotulinumtoxinA', 'cosmetic filling agent allergy', 'gastrointestinal haemorrhage', 'effect vision', 'Ex-smokers', 'majority', 'extensive colitis', 'complicated hemophagocytic syndrome.|Allergic', 'CSAMI', 'stenotic lesions', 'higher peripheral neuropathy', 'chronic bacterial infection', 'bariatric surgery|previous', 'high-risk factor', 'limb', 'thoracic outlet syndrome', 'healthcare role', 'rheumatoid disorders', 'common cold', 'CD123 targeting therapies', 'rash', 'lifestyle of the volunteer.||5', 'arterial aneurysm', 'carcinomas', ""St John's wort"", 'abnormal laboratory tests', 'whiplash injury', 'popliteal artery lesions', 'arthroscopically', 'respiratory arrest,|Coagulopathy', 'Immunodeficiency:||Congenital immunodeficiency', 'underlying comorbidities', 'QTc>430ms', 'thymic epithelial tumor', 'rheumatologic diseases', 'chronic apical periodontitis', 'flat oral mucosal lesions', 'head injuries', 'cor pulmonale', 'ms;|Complete left bundle branch block', 'Irritable Bowel Syndrome', 'Heparin.|Non-cardiac co-morbid conditions', 'diabetes type', 'acute sport', 'fear', 'flares', 'Cerebral stroke', 'laryngeal tumor', 'IHC3+', 'cutaneous melanoma', 'Ductal Carcinoma In Situ (', 'neurologic disease.|The dose', 'Shoulder, neck', 'St Paul', 'CDI', 'Insomnia symptoms', 'inflammatory cytokine syndrome', 'disease-free state', 'cold autoimmune hemolytic anemia', 'intervention||Non-cardiac comorbidity', 'speculum', 'neurologist.|Speech disorder', 'promotional reasons', 'nerve stimulator|dental', 'COVID-related', 'severe visual impairment', 'bacteraemia', 'cerebrovascular stroke', 'regional infections', 'patellar dislocation', 'generalized anxiety disorder|no', 'haplotype-matched', 'psychiatric conditions', 'taste disturbances', 'major depression', 'N1 disease', 'material dependence', 'hyperactivity', 'psychologic problem', 'diseases;|Respiratory tract infection', 'congestive cardiac failure', 'HER2-low tumor expression', 'labyrinthitis', 'rapidly disease', 'local tumors', 'adhesive disease', 'hypothyroidism -||Exclusion Criteria', 'unstable arrhythmias', 'autoimmune immune hemolytic anemia;|Human immunodeficiency virus (HIV) infection', 'eating disorders', 'chronic renal failure.|Substance', 'pre-treatment imaging', 'congenital anomalies', 'chronic lichen simplex', 'cancer-directed', 'footnote 3].|Known diagnosis', 'benign angiopathy', 'poor bowel', 'Ta', 'gastro-oesophageal reflux', 'outcome assessments|lack of access', 'dyspnea).||', 'BRAF', 'assessment|Vulnerable populations', 'PE', 'cardiac rehab', 'common diets)|Pregnancy', 'treatment.|All lesions', 'CSEU La Salle|not', 'inattention symptoms', 'pancreas infection', 'BPPV of', 'systematic disease', 'keratoconus stages', 'hypodense', 'ecchymosis', 'reason|Ventricular dysfunction', 'eosinophilic gastrointestinal diseases', 'paroxysmal cold hemoglobinuria', 'chronic gastrointestinal disorder', 'mechanically ventilated.||', 'Depression', 'Herbal preparations/medications', 'extensive ankylosis', 'blood cultures', 'coffee', 'extra-hepatic diseases', 'extramedullary lesions', 'in-situ', 'airway inhalation', 'Time from injury', 'cancer-related treatment', 'bladder catheter|Previous prostatic surgery', 'small tumors', 'psychiatric illnesses', 'solid tumors|Treatment', 'tight stenosis', 'cardiac disease|Pregnancy', 'gastric reflux', 'Ice pick', 'Orthopedic', 'splenic sequestration', 'suffered respiratory diseases', 'Legius syndrome.||Applicable', 'evaluates dry pruritus', 'nonmelanoma skin cancer', 'Study Eye', 'judged by the investigator to be unsuitable for participation in this trial', 'secondary cause of hypertension', 'primary sclerosing cholangitis', 'Early Head Start', 'Screening|Diabetes mellitus', ""M. Crohn's"", 'histopathological features', 'lumbar compression pain', 'thyroid disease).||The medical disease', 'LV diastolic dysfunction', 'ventricular paced rhythm', 'materials.|Females', 'progressive neurological symptoms', 'Angina pectoris', 'Squamous cell carcinoma', 'rheumatoid arthritis).|The', 'neoplasm|Shoulder surgery|Cervical', 'cryptogenic perianal fistulas|Patients', 'LGL', ""Fridericia's"", 'intracranial hemorrhagic diseases', 'dyspeptic symptoms should', 'gastrointestinal bleeding|Participation', 'drug-induced myositis', 'low-grade dysplasia (LGD)', 'mechanical low back pain.|Males', 'mental confusion', 'vital sign abnormality', 'hematuria', 'WON', 'gastrointestinal motility|Patients', 'bacterial infections;|Unstable cardiovascular', 'cardio-pulmonary', 'hernia repair|Patients', 'progressive neurological deficit,|The', 'epilepsy;|pregnant', ""Cushing's Syndrome"", 'etc.|Depression', 'infection|Allergy', 'vascular pathology', 'diagnosed cancer', 'Marfan syndrome', 'pancreatic surgeries', 'endocrine disease|Drink heavily', 'Congenital bone marrow failure', 'Lumbar Discopathy', 'HREC', 'MI', 'human coronavirus infection', 'suffer', 'prostatitis', 'coagulative disease', 'follicular lymphoma|Patients', 'BRCA test|Has documented', 'ocular inflammation', 'muscle hypertrophy|Taking Narcotics', '|Previous left atrium', 'venous thromboembolic events', 'diabetes|terminal illness|myocardial infarction', 'psychotropic drug abuse', 'functional pathology', 'acceptable surrogate', 'POEMS syndrome', 'simplex of eye', 'ICD-9-CM', 'cardiovascular disease.|Active HBV(hepatitis', 'GIB)).|Presence', 'perineural invasion|Patients', 'DNase).|Uncorrectable bleeding diathesis', 'functions of the main organs', 'burning sensation', 'carotid', 'structural brain disease', 'liver functions|patients', ""Crohn's disease.|Patients"", 'breast cancer|Women', 'hyper-sensitivity', 'ingredients|Pregnancy|Irregular menstrual bleeding', 'another type of', 'document stable', 'renal disease|Allergy', 'brain metastases', 'exposed to passive smoke', 'fracture|Poly-trauma', 'pervasive developmental disorders across developmental', 'BRIP1', 'mucositis', 'external).|Molars', 'Bulky Disease', 'cystic components', 'neutropenia', 'large moles', 'allergy.|Pregnant', 'Sinus bradycardia', 'dietary condition', 'End-stage stage renal disease', 'types of infections', 'physical activity', 'excessive hairiness, edema', 'premalignant lesions|Previous malignancy', 'pain syndromes', 'macroglobulinemia', 'bronchial artery embolization|Uncorrectable', 'necrotizing enterocolitis', 'hypereosinophilic syndrome', 'placental abruption|Clinical diagnosis', 'lupus', 'third-line therapy|Last follow-up', 'close', 'head and neck radiotherapy', 'lack of standard treatment', 'Health care workers', 'blind', 'albuminuria 2+ and above', 'Terminal ill', 'hearing deficit', 'spinal tumor', 'Serious illness', 'acute perinatal event', 'malignant hyperthermia).|Severe obstructive pulmonary', 'NASH', 'worse heart disease', 'malignancy|pregnancy|acute infection|Lack of ability to sign informed consent forms on their own', 'cancer treatment.||Major surgical procedure', 'rheumatic diseases.|Degenerative neurological disease.|Major', 'old|Vietnamese', 'characterized depressive episode', 'endometrioma', 'inflammatory bowel disease (IBD) treatment', 'uncontrollable hypertension', 'haemoglobin electrophoresis', 'HIV VL suppressed', 'infection|Uncontrolled pleural effusion', 'Exclusion Criteria||Medical conditions', 'involvement', 'Females|Able to read Urdu Language|Pregnant', 'Adverse Events CTCAE', 'classical follicular lymphoma', 'fungal infection of the treatment', 'treatment.|Active infection', 'voice disorders', 'preauricular lymphadenopathy', 'hypoplastic left heart syndrome', 'acute imflammation.|Other myopia control interventions', 'Open', 'hypothyroid', 'serological immunity', 'cutaneous stoma|Current', 'atherosclerotic cerebrovascular', 'Inability to take', 'congenital bone disorders', 'valve lesions', 'bipolar II|Clinical indications', 'psychosis NOS', 'malignant disease|Bone', 'maxilla & mandible||', 'primary glomerulonephritis', 'pneumococcal infectious diseases', 'psychotic disorder|Intellectual disability|Severe', 'favorable benefit', 'depth1 down', 'months|Hypersensitivity', 'Hepatitis C virus (HCV)', 'episodes', 'bone fractures', 'conduction defects', 'illness;|Predisposition', 'China Liver Cancer Staging', 'CYP3A4-inductors', 'bladder sarcoma', 'open lesion', 'responsible for pain', 'consent|Pancreatic cancer diagnosed||', 'blistered', 'Contraindication', 'CFRD|Screening', 'diabetic cardiomyopathy', '50 kg.|Healthy', 'peripapillary diffuse chorioretinal', 'type C', 'diabetic ketoacidosis', 'medical comorbidity', 'severe abdominal pain', 'serious pathology', 'permissible Renal function||Either:||Serum', 'hypertension;|Alanine aminotransferase', 'cognitive impairment|psychiatric instability', 'brain injury|Psychiatric instability', 'inflammatory myopathy', 'hypoacusis', 'pT1-2N1', 'falls|Clinically stable', 'Hidalgo', 'potential confounding|PROSTATE CANCER', 'primary immunodeficiency;|For Hepatitis B (HBV)', ""Parkinson's disease disease"", 'reversible cause', 'reduced mental capacity|Patients', 'left atrial appendage', 'IA', 'HLA typing);|Vaginal', 'carcinoma in situ of the prostate', 'normal uterus', 'Rotavirus', 'BK virus', 'substance misuse disorder|live', 'non-prescribed', 'esophagus varices', 'regions', 'class|Valvular heart disease', 'ataxia', 'CETD', 'alcohol breathalyzer', 'multiple rib fracture', 'biliary tract cancer', 'CAD);|Pulmonary hypertension', 'enclosed infection', 'severe valvulopathies', 'heart disease|Presence', 'disease.|Patients', 'gastrointestinal perforation', 'knee trauma', 'TPR', 'mental abnormalities', 'T2DM||', 'type 2 diabetes.||The study eye', 'arterial disease', 'altered mental', 'infected ear', 'penile fracture', 'chronic comorbidities.|People', 'vegetation', 'old(male', 'Quantiferon result|Quantiferon positive', 'radiotherapy;|Previous', 'developmental anomalies', 'CNS status', 'is required.|Pregnancy', 'excluded|Cardiac paraganglioma', 'reactive eluate', 'physical retardation', ""Crohn's"", 'lensometry', 'renal replacement therapy.|Anyone', 'neurodevelopmental disease)|Patient bearing', 'human immunodeficiency virus (HIV) infection;|A', 'HSC', 'parasympathetic antagonists|Kidney disease', 'reversible cause;|Diminished functional', ""Marfan's syndrome.|Metabolic disorders.|Previous knee surgeries.|Cartilage"", 'ULN|allergic', 'main pancreatic', ""Wegener's granulomatous disease"", 'BCC', 'DPB1', 'SBP)>180 mmHg', 'Relative contraindications', 'hypertensive disorders', 'non-mass enhancement', 'diabetes-related', 'fibrillar amyloid', 'axicabtagene ciloleucel|Uncontrolled', 'intracerebral hemorrhage', 'anorectal bleeding', 'benign esophageal stricture', 'thrombocytopenic purpura', 'children injury', 'retinal imaging', 'systemic exposure.||Male', 'menstrual bleeding', 'mental diseases.|Allergic reaction', 'endocrine dysfunction', 'bone lesions', 'common comorbid diagnoses', 'anterior cruciate ligament tears', 'multiple glioma metastases', 'chronic gastrointestinal diseases', 'colorectal disease', 'drug instructions', 'drug-induced liver injury.|Diagnosis of', 'infective processes|Have cancer', 'intubation;|Chronic pneumonia', 'penile cancer', 'blood stasis', 'fetal abnormalities', ""acute Crohn's disease"", 'chronic pelvic pain', 'medication abuse', 'Inability to read', 'allowed|Total serum bilirubin', 'psychiatric pathology.|Rheumatic pathology', 'as:||Potassium', 'Guillain-Barre syndrome', 'ECMO OR|Septic shock OR|Multiple organ failure|Prior therapy with plasma from a recovered COVID-19 patient', 'EIT', 'localized cancers', 'scrotal pain', 'cancers|Medical conditions', 'oocyte donation|Undergoing preimplantation', 'infected patients', 'dependence;|Lack of', 'spinal nerve compromise).|Patients', 's-TDAPT', 'unable to tolerate toxicity', 'treatment modalities', 'tumour tissue sample (', 'secondary obesity', 'urogenital bleeding', 'critical condition', 'lentigo malign', 'electrolyte imbalance', 'biliary disorders', 'criteria.|Liver tumors', 'breast infection', 'lymphocytic enteritis', 'upper extremity sequelae', 'vital signs measurements', 'unable to consent.)|Potential interference from another study (', 'evaluable lesions', 'bilirubin obstruction', 'triplets', 'tumor thrombus', 'C),|endocrine diseases', 'acute onset neurological deficit attributable', 'haematological malignancies', 'atypical mycobacterioses', 'solid organ transplantation.|Idiopathic pulmonary fibrosis', 'Liver Diseases', 'CNS tumor.|Morbidly obese', 'nasopharyngeal swab', 'hypothyroid obesity', 'communication problem,|The child', 'living independently|Able', 'old;|able to read', 'high-density mapping catheter', 'lactobacillus tablets', 'breast disease|Diabetic patients,|medication', 'ductal carcinoma in situ of the breast;|having', 'tumor size', 'radiation therapy.|unstable angina', 'Model For End-Stage Liver Disease (MELD)', 'chronic neuropathic pain.||3', 'episodic migraines', 'communication aids', 'squamous cell carcinoma of aerodigestive', 'Malignant Tumors Expressing Fibroblast-activated', ""primary Sjogren's syndrome|Evidence"", 'neurotoxic effects', 'trying to get pregnant', 'cutaneous lesions.|Children', 'renal function||Renal impairment', 'Eye diseases', 'ASAS axial spondyloarthritis classification', 'abdominal obesity', 'another cancer', 'carcinomatous meningitis', 'solid organ transplantation.|History', 'acute liver failure:||Chronic liver disease', 'participation.||EXCLUSION', 'dementia)|Physical impairment', 'child bearing', 'anterior circulation', 'mental diseases|Autoimmune-illness', 'abnormal ECG', 'phacoemulsification cataract surgery', 'ocular surgical', 'lung nodules', 'cPTSD', 'hepatitis C|Pregnant', 'teeth in each quadrant', 'pulmonary comorbidities|Mental illnesses', 'limit absorption of oral medication;|Vaccination', 'convulsion', 'precancerous lesion', 'involvement of the aortic arch', 'neuropathic diseases', 'conditions judged by the researcher', 'cerebrovascular diseases|Implantation', 'heavy drinker', 'end-organ failure conditions', 'solution', 'rheumatoid arthritis);|other neurological diseases', 'terminal illness.|9', 'recreational smoking', 'urinary tract infection|solitary kidney|Concomitant pathology', 'necrotic lung disease', 'MCI-LB', 'smartphone|Speaks', 'ADULT', 'compensatory cirrhosis', 'hopping', 'intractable hypertension', 'Unmarried', 'contradicting', 'multistick', 'Malignant tumors', 'neurological -or rheumatic disease', 'concomitant injuries', 'Carcinoma', 'allowed.|Uncontrolled intercurrent illness', 'Renal Impairment||Body mass index', 'communication regarding safety procedures', 'carcinoma in situ of the cervix', 'MCL)|Follicular lymphoma', 'infectious disease;|Patients', 'pulmonary arterial', 'neonatal disease', 'dumping syndrome', 'CCF', 'esophageal dilatation', 'Congestive heart failure||17', 'co-incident spinal tumor', 'intact', 'nasal wash', 'acute symptomatology', 'lung disease.|Measurable', 'acute anterior circulation ischemic stroke', 'focal onset epilepsy', 'need treatment', 'chronic medications|did not', 'known allergy', 'heart pump', 'brain-only', 'painful diabetic wounds', 'study medications.|Septicemia', 'metabolic diseases;|Had hypersensitivity', 'acute displaced', 'Cohort II)|Confirmed ADHD diagnosis', 'Child:||not', 'characteristic clinical features', 'consciousness disturbance', 'congenital heart disease|To', 'neurosensory deficiency', 'parent(s)/legal guardian(s) must be capable of understanding', 'disease|Neuropsychiatric disease', 'Hepatic diseases', 'genetic diseases', 'lymphocyte counts', 'chromosomal structures', 'impaired intestinal function', 'neurologic disorder;|6.patients', 'radioactive tracer', 'intestinal cavity perforation', 'medication|Hepatic tumor burden', 'drug-dependent', 'straight leg raise', 'Android operating system', 'portal cavernomatosis', 'liver cyst', 'neurolens', 'piercings', 'MUITYH associated polyposis', 'chronic stable angina|Forced', 'refractory Hypertension', 'severe infections', 'NOS-induced', 'invasive diseases', 'HPV-related', 'schizophrenia spectrum disorders', 'sufficient interaction', 'chronic viral infection', 'light chain multiple myeloma', 'chemotherapies', 'chronic diseases|Vegetarians', 'breast cancer|No breast MRI', 'conceiving', 'pneumopathy', 'substantial weight loss', 'clinical providers', 'Lesion', 'Anorexia Nervosa', 'Union', 'pulmonary disorders;|Toxic reactions', 'Alcoholism guidelines', 'myocardial infarction|QT-related', 'pulmonary infarction', 'trial.||Active infection', 'Schizophrenia', 'cooperation.|Participant', 'right-handed participants|normal', 'Chronic neurologic conditions', 'tuberculosis;|Active infection', 'tumor invasion', 'Spinal Cord Injury', 'elective surgeries', 'incompatible', 'mantle cell NHL', 'complex neurobiological', 'spinal muscular atrophy|Pregnancy', 'systemic symptoms', 'Subarachnoid hemorrhage', 'hypertension,|Epilepsy', 'mild dermatophytosis', 'prostate cancer|Patients', 'imperfecta', 'HER2-positive breast cancer by histopathology', 'ulcerative disease|Treatment', 'type 2|gastrointestinal diseases', 'tumor lesions', 'chronic respiratory failure|had respiratory distress syndrome', 'gastric outlet obstruction.|Abdominal fistula', 'decreased appetite', 'basis.||Diabetes mellitus (DM)', 'dietary changes', 'caries lesions', 'concurrent disease', 'occupational reasons', ""Crohn's disease)|malignant"", 'solid organ transplantation.||5', 'deep brain stimulator)|Is', 'chronic physical illness', 'parturiente', 'weaves', 'Prader Willi syndrome', 'bleeding OR|an inhibitor test BU', 'intracranial pathology;|Co-morbid disease', 'Chronic renal', 'OFF-medication.||Exclusion', 'IIIC disease', 'stenotic lesion', 'Hepatitis C infection', 'disease of the central nervous system|Other conditions', 'related genes', 'peripheral artery stenosis', 'mainly', 'gastrointestinal surgery|The', 'aortic valve stenosis|pregnant', 'parathyroid', 'residual malignant tumors', 'prosthetic joint', 'retinal tear', 'months;|Untreated Zn deficiency', 'nare obstructed', 'type II DM', 'recurrent cholangitis', 'respiratory decompensation', 'transverse colon', 'enlarged submandibular salivary', 'penile intraepithelial neoplasia.|9', 'premalignant skin lesions', 'natal vaginal', 'general anesthesia.||Patients', 'psychotic episode', 'pancreatic neuroendocrine tumors', 'those conditions', 'HLA-G tumor expression', 'Cardiovascular disease', 'specialized care', 'atopic dermatitis exacerbations', 'bleeding|Patients', 'nonaffective psychotic disorders', 'endoscopic features', 'subtype', 'behavioral health', 'Ipsilateral common femoral artery occlusion', 'G-6-PD deficiency', 'hepatitis C. Note', 'treatments;|Soild malignant tumor', '- Human immunodeficiency', 'pacemaker indication', 'breast-feeding patients|Non MR', 'DME', 'transient ischemic attack|Corrected QT interval', 'acute renal failure', 'oxygen', 'intubated COPD', 'acute myocardial', 'delayed endolymphatic', 'years.|Asplenia', 'respiratory hazards', 'chemotherapy|Usage', 'genotype);|Symptomatic', 'sound maxillary premolars', 'neurological system diseases', 'cognitive impairment.||Exclusion Criteria', 'multi-focal disease', 'complete tumor resection', 'Decreased BCVA', 'in situ cervical', 'Neurological disorder', 'joint pain reflected', 'normal karyotype', 'attention deficit hyperactivity disorder', 'etc.)|Known allergy', 'HIV)-1 infection', 'Xuezhikang', 'malignant colorectal tumor;|Multiple', 'acute depressive episode|bipolar disorder', 'spinal stenosis', 'aortic valve stenosis', 'watery diarrhea', 'painful joint', 'mixed neuroendocrine', 'bladder sensation', 'uncorrectable vision loss', 'TB)|Significant trauma', '2˚of eversion', 'not regularly monitored', 'Eastern Oncology Consortium Physical State Score', 'cutaneous scrotal lesion,|fever', 'abstain from recreational cannabis', 'spinal injury', ""Parkinson's Disease Dementia"", 'muscle.|Gunshot wounds', 'HPV-related head', 'anchoring zone diameter 4.5~9', 'MEN2|Suicidal ideation', 'major depressive disorders', 'cardiac failure);|General contraindications', 'skin contact|having cold urticaria', 'secondary headaches', 'motor', 'inflammatory bowel disease.|Screening', 'perianal fistulae', 'inflammatory bowel syndrome', 'cardiac ischemia', 'minutes)|active cancer', 'Hypertensive', 'teeth replaced', 'hBET|Cognitive problems', 'immunocompromised', 'neural retina', 'clinical events', 'riteria:||On', 'breast-feeding.|Anyone', 'distal branches', 'native language interpreter', 'Healthy condition', 'Professional basketball players', 'stimulating factor support)|Platelet count', 'idiopathic club', 'ferromagnetic implants', 'separation difficulties', 'liver cirrhosis|Positive test', 'solid tumors only', ""Still's disease"", 'type 1 diabetes:||14 - 80 years', 'parafunctional habits.|Inadequate inter-arch', 'non-cardiac comorbidities|Treatment', 'neuromuscular pathologies', 'acute hypercapnic respiratory failure', 'chronic periodontitis', 'macromastia', 'end-stage renal disease (ESRD)', 'hypertension;|Absence', 'chest pain', 'crystalline pathology', 'HIV infection.||A positive test', 'horse-shoe shaped', 'mediolateral compartment|Knee OA', 'neuroleptic medications|Diagnosis', '6):||Diagnosed', 'tinea capitis', 'abdominal pain', 'Dialysis-dependent|Medically', 'acute hepatitis', 'respiratory muscle strength', 'Covid-19 infection', 'acute febrile processes', 'Corona Virus Disease', 'transverse myelitis', 'distress', 'criteria|WithoutoOvarian pathology', 'atherosclerotic artery disease', 'histories', 'singleton pregnancies|at term', 'ischaemic changes', 'ventilation support', 'interval', 'vitrectomy|glaucoma', 'punctal occlusion', 'months.|Pain rating', 'inflammatory breast', 'postinfectious', 'neurodermatitis', 'HIVAb', 'exon 20', '25post COVID-19', 'chronic gastritis', 'CE+CABG', 'related pathology', 'third degree atrioventricular', 'local therapies.|At least one measurable lesion', 'non-HMA therapy', 'Ⅳ congestive heart failure', 'gastrointestinal tract tumors', 'acute lymphoblastic', 'lacrimal passage obstruction', 'pathology of the central nervous system.|Subjects', 'Interstitial lung disease', 'decreased exercise tolerance', 'cerebral arteriovenous malformation;|Be', 'associated cardiac pathologies', 'vital signs||stable', 'brittle', 'preserved ejection fraction.||clinical diagnosis', 'hair', 'tumor-infiltrating lymphocytes', 'skin|Squamous cell carcinoma', 'intestinal malabsorption', 'osteolytic lesions', 'gynecologic malignancy', 'deep venous thromboembolism', 'months)|Acute diverticulitis', 'necessity', 'Target lesions amenable', 'AICD', 'Hepatitis C', 'TSK', 'apical lesion', 'homicidality', 'left bundle branch', 'primary hypercholesterolemia', 'toxin conjugates', 'genetic abnormalities', 'hearing disorder', 'therapeutic antibodies', 'alteration in mental status', 'major depressive disorder)|18', 'chronic constipation.|History', 'type of pathology', 'neuropathic symptoms', 'poor ovarian', 'administration|Measurable disease', 'local squamous cell carcinoma', 'comorbidities', 'systemic alteration', 'febrile episode', 'tuberculosis of the bladder', 'irregular cornea;|Known pregnancy', 'primary lymphoma', 'HCV infected', 'parasomnia', 'solid organ transplantation|Any other disease', 'swallowing pills', 'right-dominant', 'Gilbert-Meulengracht syndrome);(3', ""Fredericia's QT correction formula"", ""Fridericia's [QTcF]"", 'positive functional compensation', 'health related quality of life|Pregnancy', 'major cognitive disorder', 'sclerosis|Between', 'nulliparous', 'external beam radiation therapy', 'digestive diseases', 'Lewy Bodies', 'aspiration difficulties', 'cardiovascular disability status', 'type Ⅱ diabetes mellitus', 'heart disease|Peripheral arterial disease', 'thyroid dysfunctions|Having', 'CLTI', 'chronic angioedema', 'adenocarcinoma of the colon', 'day.|Active smokers', 'interstitial thermal therapy (LITT)', 'folliculitis', 'pulmonary dysfunction', 'symptoms.|PILL-5 questionnaire', 'rotator cuff tears', 'neurological illness.|Renal', 'mentally handicapped|Participants', 'dentophobia', 'home oxygen', 'cerebrospinal fluid involvement', 'Pneumocystis jirovecii pneumonia', 'drugs.|Presence', 'PAH|PAH associated', 'learning disabilities', 'keloid formation', 'swelling of the mouth', 'unstable angina pectoris', 'leiomyosarcoma', 'orthodontic', 'basketball', 'fatigue syndrome', 'Hepatitis', 'high dependency device', 'PCOS', '-gestational diabetes', 'mild cognitive impairment.|Older', 'death', 'visual symptoms', 'duplex kidney', 'tracheal intubation;|Those', 'calculated by the Schwartz formula|Conjugated', 'lupus crises', 'hypertrophic obstructive cardiomyopathy', 'pneumonia.|Serious infection', ""inflammatory bowel diseases(Crohn's disease"", 'erythropoietin dependency', 'maternal intrapartum fever', 'femoral artery disease', 'brainstem metastases', 'malignant tumor;|Previous surgical operations', 'atherosclerotic disease', 'etc.);|Active autoimmune diseases', 'hemodynamic instability|Uncorrectable coagulopathy|Severe pulmonary hypertension|Acute coronary syndrome|Intermediate-high-risk', 'socially impossible', 'vegan diet|Intolerant', 'contraindicated|Mechanical complications', 'acute arterial thrombosis', 'disease.||Fully treated carcinoma in situ', 'breast cancer;|Concomitant diseases', 'pulmonary fibrosis|Severe renal disease', 'kidney function impairment', 'histological diagnosis', 'ocular allergies', 'steatosis', 'transfusion therapy|Abnormal TCD', 'cerebrovascular damage', 'Anterior circulation stroke', 'including:||Poor blood pressure control', 'Acute promyelocytic leukemia', 'good-quality', 'infection of the target knee', 'visual impairment|Known pregnancy|Implanted', 'posterior circulation ischemic stroke symptoms', 'primary lung adenocarcinoma', 'thrombolytic therapy.|Prophylactic use', 'ulcerations|acute febrile processes|diagnosis', 'lack of effective treatment;|Measurable lesions', 'prior immune checkpoint inhibitors', 'fetal comfort reasons', 'unmanaged bipolar disorder', 'complex medical conditions(e.g', 'oligomenorrhea', 'membranes.|History of', 'mechanical mitral valve prosthesis', 'PMBCL', 'diagnostic criteria', 'directive to withhold life-sustaining treatment|Morbid state', 'antiarrhythmic medication.)|Active infection', 'maternal HIV infection', 'pulmonary thromboembolism', 'cerebrovascular disease||', 'severe autoimmune diseases', 'cardiac disorder', 'lymph node involvement', 'restrictive cardiomyopathy|Congenital heart disease', 'spinal dysraphism,|urinary', 'dilation|Presence of disorders', 'arthrocentesis', 'geographic conditions', 'liver mass', 'intra-uterine devices', 'autoimmune disease)|Diagnosis', 'alcoholic heart disease', 'hereditary disorders', 'aorta dissection', 'consent|Cardiopulmonary healthy||', 'cholestatic', 'hypodiploidy', 'type 2 diabetic', 'major depressive disorder|History', 'swab', 'platinum complexes', 'invasive malignancies', 'modified', 'Rhegmatogenous Retinal Detachment (', 'transient ischemic attack|history', 'retina dystrophy', 'uncontrolled hypertension', 'active:||Autoimmune disease', 'end of life care', 'peritoneal dialysis;|Patients', 'nostril skin', 'traumatic CSF leakage.|(2', 'secondary diabetes mellitus', 'supplemental oxygen|renal disease', 'columnar metaplasia', 'doubtful', 'hip osteoarthritis', 'extra-CNS disease', 'left homelessness', 'consent.|Currently use diapers', 'antiherpetic activity', 'optic disc drusen', 'diarrhea related diseases', 'gastrointestinal symptoms', 'scleral fixated lens||', 'drug-induced hepatotoxicity', 'another injury', 'primary causes', 'adenocarcinoma of the', 'centrifugation ring', 'distant extensive metastasis', 'polyp', 'guidelines.|Participant', 'fear of needles', 'valvular heart disease.|PRE-REGISTRATION', 'premenstrual symptoms', 'chronic entrapment syndromes', 'microscopic colitis)|Chronic kidney', 'inheritable CNS spinal malformations|Previous pregnancy', 'surgically sterile', 'PET)|Patient exposed to analgesic', 'sinus bradycardia', 'Recalcitrant chronic functional constipation', 'criteria of the definition of sarcopenia', 'DEX', 'balance impairments', 'canal inflammation', 'neurological conditions|visual', 'Deep vein thrombosis (DVT', 'cardiovascular risk factors', 'antibodies to', 'severe stenosis', 'other comorbidities', 'instance cancers', 'Hypertension', 'hemodialysis;|Other diseases', 'diaphragmatic function', 'large cell carcinoma', 'neither cone beam nor conventional CT|Patients', 'solid organ transplant|Any potential', 'fibrolamellar HCC', 'severe pneumonia', 'late infantile Krabbe disease', 'gastrointestinal bleeding.|Myocardial infarction', 'pathogenic variants of CYP4V2', 'safety risk（In healthy', 'active endocarditis', 'HPV', 'gastrointestinal inflammatory conditions', 'hemorrhagic/thrombolytic stroke', 'blood disease', 'end-stage cancer', 'alcohol].|Inability', 'Guillain Barre syndrome', 'adverse habits', 'Multiple lesions', 'moderately impaired', '20lbs', 'membranes', 'breastfeeding.||Contraindications', 'impaired decision-making capabilities', 'criteria not', 'intestinal carriage|Terminal disease', 'identifiable cause of fibrosis|The', 'multigated acquisition', 'oesophageal varices', 'coagulation status|Willingness', 'extranodal mass', 'head and neck tumors', 'CT;|hemiplegia symptoms', 'chronic liver diseases', 'follicular', 'acute endocarditis', 'primary health care', 'smaller caseloads', 'squamous metaplasia', 'complete remission', 'noise trauma', 'eruptive breakdown.|Restorable teeth|Permanent molars', 'asthmatic bronchitis', 'cardiac rehabilitation', 'infections;|poor blood glucose', 'situ|Concomitant diseases', 'immune Thrombocytopenia', 'head/brain', 'address pressure injury', 'EKG:||ST segment elevations|T-wave inversions vii', 'progressive sclerosis', 'clonic activity', 'intestinal functions', 'signs consistent with acute ischemic stroke,|Patients', 'surgeons;|Not lung adenocarcinoma', 'mobile device|medical condition', 'complicated appendicitis', 'PGA', 'Cytomegalovirus', 'Hereditary problems', 'chronic pain syndromes', 'restless legs syndrome.|Exposure', 'dental devices|Unable', 'chronic respiratory diseases', 'traumatic bleeding', 'matched', 'traumatic zonulolysis', 'treatment|Peripheral neuropathy', 'hallucinations|Motion sickness', 'cervicitis', 'vasoconstrictive side', 'large pericardial effusion', 'significant infection', 'hepatitis B:||Aged', 'hypertension|Preoperative renal failure', 'keratinized gingiva crestally', 'Hereditary Hemorrhagic Telangiectasia', 'CADASIL||Focal lesions', 'discharged from hospital', 'diabetic ketoacidosis (DKA)', 'removable orthodontic devices.|Patients', 'tachyarrhythmias', 'iatrogenic conditions', 'National Health System', 'fainting blood', 'irregular menstrual cycles.|History', 'carcinoma in situ', 'gastric motility', 'venipuncture', 'cardiorespiratory arrest', 'liver abnormalities|Other', 'Autoimmune lymphoproliferative syndrome', 'oral analgesic', 'GWI symptoms', 'surgical portosystemic shunt', 'allergic dermatitis', 'left ventricular impairment', 'mastectomy.|Diagnosis of breast cancer', 'severe comorbidities', 'Eaton-Lambert', 'bifurcation', 'frozen plasma', 'criteria of tinea versicolor', 'cataracts', 'irrespective of resolution.|Serious infections', 'conduction block', 'developmental delays', 'gastrointestinal motility|Heart disease', 'active eye diseases', 'pathological diagnosis;|According to the relevant standards', 'bilateral ovaries', 'early relapse', 'support of the pelvic floor', 'spherical soft contact lenses', 'heartburn', 'perception', 'impairment in cognition', 'serious condition', 'study)|Pregnancy', 'chronic functional Diarrhea', 'gastrointestinal obstructions', 'brexucabtagene autoleucel', 'tibia', 'cognitive complaints|all', 'rhTNK-tPA', 'chronic health problem', 'acute illness,|Cancer|HIV|Systemic inflammatory disease', 'short bowel syndrome.|History of', 'liver inflammation', 'Mild discomfort', 'Dementia||Unstable medical conditions', 'lack of effective treatment.||', 'deeper gingival recession', 'NMD', 'cauda equina compression', 'Normotensive', 'pathological UIP type/possible', 'neuroendocrine differentiation', 'arrythmia', 'severe COVID-19', 'fractures|hematoma', 'inmates', 'chest surgery.|Known hypersensitivity', 'years|Esophageal pathology', 'inflammatory diseases;|Secondary myopia', 'Cognitively-Unimpaired', 'valve disorder;|Urgent hospitalisation', 'changes in corneal epithelium', 'disorder|Active cancer', 'gastrointestinal (GI) abnormalities', 'ocular allergy|Inability', 'pills|Allergy', 'sinus tachycardia', 'FSHD', 'pharmacy records', 'traumatic injury.|Use of any P-gp inducer', 'acute CV19 infection', 'cardiac rhythm', 'therapeutic', 'diabetes mellitus', 'healthy dental implants', 'clearance', 'viral hepatitis C', 'MEPA||', 'rheumatoid arthritis)|For', 'Acute infectious rhinitis/rhinosinusitis', 'Aspergillosis', 'RV infection', 'knee OA', 'lentigo maligna (', 'pseudoexfoliative glaucoma', 'Psoriasis Area', 'CML)||1', 'local residence;||', 'rheumatological disease', 'lymphopenia', 'taxanes', 'dialysis center', 'hematological cancers', 'cystic', 'progressive relaxation', 'gastroduodenal obstruction/bleeding', 'immunodeficient disease', 'auditory problems', 'duodenal ulceration', 'not.|Active tuberculosis', 'Nivolumab.|Evidence', 'chronic tuberculosis infections', 'vascular causes', 'hepatic dysfunction.|Pregnancy', 'spinal anesthesia|Disease', 'liver function|adequate renal', 'cardiac disorders', 'Systematically healthy', 'acute diseases.|Pediatric', 'lenalidomide treatment|Uncontrolled hypertension', 'cholangitis', 'neuropsychological condition', 'chemotherapy),Including', 'chronic asthma', 'behavioral conditions', 'degenerative condition', 'mastitis', 'pain scores|does', 'anti- obesity medications', 'chemotherapy;|B-cell', 'Alcohol dependence', 'transfusion dependence', 'food.|Participation', 'chronic traumatic encephalopathy', 'IgE-dependent', 'S768I.|Intracranial disease', ""British Columbia's public physician information.||iv"", 'Insomnia', 'CVRx', 'primary obesity', 'Neurofibromatosis', 'Type II', 'abnormal functions', 'lying down', 'vaginal rings', 'substance abuse treatment', 'etc.|Cardiovascular diseases', 'chronic disease', 'mental disorder', 'rheumatoid arthritis;Fracture', 'arthritis manifestations', 'Nrf2', 'Open scalp wound', 'BK viremia|Known hypersensitivity', 'disease complications', 'radiology.|Osteoarthritis', 'shoulder joint', 'HIV positive.|Highly allergic', 'pathology affecting voice', 'non removable removable', 'Secondary cancer', 'vision', 'diathermia', 'major affective disorder', 'secondary dysmenorrhea.|Females', 'peptic ulcer disease;|Major', 'H. pylori infection|Active smoking|Ongoing', 'consumption of food', 'cytology different', 'adverse events.|History', 'Chronic Cough (UCC)', 'Uterine Pathology', 'poor general health.|patients', 'bladder pain', 'hypothermic circulatory arrest|Left', 'complaint of', 'judged by the investigator as clinically significant', 'intracranial injury', 'abdominal abscesses', 'progressive deepening', 'acute ischemic stroke.||', 'abnormal physical findings', 'autoimmune rheumatic disease.||Note', 'leveled congestive heart failure', 'applicable the neck', 'etc.)|Pupil abnormality', 'Continuous Glucose Monitoring (CGM)', 'infiltrative cardiomyopathy', 'cognitive disorders.||', 'VISTA-targeted therapy.|Prior history of', 'thyroid organ pathologies', 'intestinal lesions', 'hours|Non-first AMI.|Pregnancy', 'hepatic impairment group.||Key', 'mmHg|diastolic BP', 'conservative treatment|3', 'mechanical circulatory support', 'HGBL', 'liver metastases);|Any antitumor treatment', 'matériel métallique susceptible de concentrer les impulsions de radio fréquence', 'Skin infections', 'extracranial embryonal tumors', 'flatulence', 'cancer treatment', 'paralytic disease|Patient', 'cervical dysplasia', 'diabetic gastrointestinal lesions', 'respiratory system disorder', 'unilateral involvement only', 'smart-phone|can', 'Autoimmune liver disease', 'osteoporotic fracture', 'Siewert type', 'arterial hypotension', 'complaints of regurgitation', 'arterial plaque', 'barrier|Fitting', 'lower respiratory infection', 'recurring infection(s', 'probiotic absorption', 'covid syndrome', 'cutaneous xerosis', 'esophageal perforation', 'metabolic diseases.|Revision surgery', 'papillary renal cell carcinoma', 'XIAP', 'acute cholecystitis treated', 'optic nerve disorders', '2）Unstable angina', 'rectal STI', 'mixed tumors', 'COPD pulmonary hypertension', 'GIT', 'freckle', 'institutional commitment', 'hypertensive gastropathy;|Upper gastro-intestinal bleeding', 'cyst wall', 'render the block technically difficult', 'Misight', 'Internal Medicine', 'AIDS-defining conditions', 'diabetic diarrhea.|Diagnosis', 'Diabetic kidney disease;|Small vessels', 'egg protein', 'febrile|Body temperature', 'valve stenosis', 'scarring alopecia', 'modalities', 'bone fracture sustained', 'hepatic encephalopathy;|Diagnosis of', 'acute COPD exacerbation', 'Psoriasis static clinician overall assessment PGA', 'recreational drugs of abuse', 'Medical condition', 'fossa mass', 'Lung diseases', 'perineal symptoms make', 'Posterior circulation', 'Criteria', 'muscle tension', 'deficiency diseases', 'intracranial arteriovenous malformation;|Intracranial artery stenosis', 'Degenerative changes', 'drugs.|chronic pain', 'intervene', 'aCML', 'intracranial space-occupying lesions', 'etc.).|Uncontrolled hypertension', 'thyroid enlargement', 'diabetic ketoacidosis.|Medical records', 'type of meditation', 'HTLV2', 'Rejection', 'parafunctional habit.|having infection', 'prescreened', 'benign prostatic obstruction;|Patients', 'rotator cuff injury', 'communication barrier (visual', 'between oct 1st 2021', 'inclusion.|Dates', 'injectables', 'Gaillard', 'pulp necrosis.|Radiographic evidence of incomplete root development', 'acute cerebrovascular', 'risk of its development', 'suicidal tendencies', 'mucopurulent cervicitis', 'predisposition syndrome', 'fetal macrosomia', 'liver metastases.||International normalized ratio (INR)', 'malignant illness', 'Gout', 'recurrence of the', 'early stage skin cancers', 'uterine tumors', 'psychological disorders|Use of drugs affect central nervous system|Substance abuse|Chronic pain|Pregnancy|Seizure disorders|Cardiovascular', 'QT interval prolongation', 'cardio-thoracic disorders', 'cancer meningitis', 'reproductive age should', 'ECHO).|Ventricular arrhythmias', 'atrial septal repair', 'pressure)|lung disease', 'radiographic findings consistent', 'pelvic ring fractures', 'BV', 'Local anesthetic allergy', 'joint purulent infection', 'diabetes beyond drug control', 'self-harm behaviors', 'Basal cell carcinoma', 'CNS diseases', 'concomitant diseases；|Allergic', 'breathing problems', 'clinically serious diseases', 'ischemic brain lesion', 'disease', 'ocular disease|VA', 'surgically resectable', 'surgery)|Behavioural disorder', 'Stable', 'French.|Patients', 'those with claudication', 'intubation technically', 'judged by the investigators to be unsuitable for the trial.|Pregnant', 'Medical instability', 'acquired hemolytic anemia.|For the', 'left anterior hemiblock', 'gastrointestinal disorders', 'heart transplantation||', 'conjunctival goblet cells', 'nodal arrhythmias', 'bleeding events', 'viral disease', 'tuberculosis.|Bacteria', 'calculated using height', 'Mason', 'Type B atrophic gastritis', 'ipsilateral breast cancer', 'mentally ill', 'allergic constitution', 'gallstone disease', 'heart rate (', 'sequelae', 'respiratory infections', 'non-primary', 'significant pain', 'tachycardia/bradycardia', 'loco-regional therapy', 'drug susceptible pulmonary TB', 'infectious diseases.|Systemic', 'CRT-D', 'Sequent please', 'Pregnant', 'Lower extremity peripheral artery disease', 'scalp discomfort', 'caffeine-containing food (coffee, green tea', 'lymphoma infiltration', 'Achilles tendinopathy', 'cardiac function', 'good recall availability||', 'type 2 diabetes|Using glucose-lowering medication', 'Pathological', 'atrial fibrillation||Performance status evalutated', 'unstable candidate', 'death ideation""', 'Nonchildbearing potential', 'Adenocarcinoma', 'spinal compression', 'challenges', 'contact lens intolerance', 'compressive symptoms', 'daytime impairment', 'hepatitis B DNA (PCR) testing', 'pelvic inflammatory disease (PID)', 'subsequent remission', 'extremities', 'sickle cell ulcer', 'autoimmune disease|Active', 'diabetes/hypertension', 'cardiac cerebrovascular', 'malignant pheochromocytoma', 'FM', 'impact the absorption of study treatment', 'sweating', 'Sitagliptin treatmet', 'Arthus reaction', 'Adverse events', 'intense stressful events/life changes', 'cardiopulmonary arrest', 'Ischemic heart diseases', 'communication issues', 'poor wound', 'metastases.|Active gastrointestinal diseases', 'Anxiety', 'chronic hepatitis B|Treatment', 'singular epileptic seizure', 'Liver disease', 'exception of', 'ischemic stroke.|ADAMTS 13<10%,', 'vertebro basilar insufficiency', 'heart diseases', 'arterial hypertension|No hypertension', 'primary membranous nephropathy|UPCR', 'Respiratory failure', 'head and neck squamous cell', 'diabetic neuropathy.|History of', 'lack of contraception', 'lactose intolerance', 'their plasma donations', 'primary headaches', 'disease|Reduced mobility', 'auditory neuropathy.|Deafness', 'drug contraindicated', 'kidney diseases.|Use', 'clinical multidisciplinary team (MDT);|The ECOG PS', 'libido', 'DDLPS tumors', 'navigational bronchoscopy', 'superficial bladder tumors', 'acute neurological disorder', 'physical activity|Alcohol', 'hives', 'neurological disorders neurological disorders', 'M3.|Presence of', 'neurologically normal', 'transient ischaemic attack (TIA)', 'sweating disorders', 'Serous effusion', 'Uncontrolled hypertension', 'chronic gastrointestinal', 'colon polyp', 'excessive drinking', 'cardiac athletes.|Haematological disease', 'lipid storage diseases', 'brain metastases;|Any condition', 'thyroid condition.|Usage', 'Congenital Heart Disease (ACHD) surgery|Endocarditis|Reoperation', 'squamous intraepithelial neoplasia', 'radiographically measurable lesion', 'positive airway pressure', 'HIT-2', 'gout', 'pathological indicates', 'cancer specialist considers', 'systolic EF&lt;40%|Kidney failure', 'autoimmune known disease for', 'xiii', 'sweated extremities', 'nasal crust', 'Acute pancreatitis', 'rheumatic mitral valvular heart disease', 'Active infection around', 'GI tolerance', 'ICD shock', '|Pregnant', 'atypical anorexia nervosa', 'CIU refractory to H1 antihistamines', 'major roles', 'pigmentation disorders', 'hepatitis B virus DNA level', 'asthma;|Aortic aneurysm', 'chemotherapy beforehand;|Mental illness', 'drinks alcohol', 'hepatic transaminase levels', 'variceal bleeding prophylaxis', 'chronic opioids', 'zaleplon', 'Traumatic brain injury', 'LM', 'lumbar degenerative diseases|patient', 'found thymoma', 'withhold facial cosmetic treatments', 'minutes).|Traumatic brain injury', 'hepatitis B (HepBsAg+)', 'severe hearing problems', 'CNS-3 involvement', 'renal impairment||Glomerular filtration rate should', 'perioperative care', 'glucose-galactose malabsorption', 'immune disorder', 'withdrawal syndrome|renal failure', 'complete bowel obstruction|Immunotherapy', 'confluent staining', 'combined diseases of the cardiovascular', 'laparoscopy|Peritoneal metastasis', 'gastric spasticity', 'primary pulmonary disease', 'varus talipes', 'antithrombin deficiency', 'histological features', 'pubic symphysis diastasis', 'Type 1 diabetes|age', 'valvular abnormalities', 'canal configuration', 'acupuncture syncope', 'obstructive epicardial coronary artery disease', 'porphyria.|Uncontrolled concurrent illness', 'renal failure.|Addison', 'Down Syndrome', 'cystectomy', 'Tokyo guidelines|symptom onset||', 'failure,|Obesity,|Uncompensated diabetes,|Autoimmune disease', 'tinnitus', 'Tricuspid Stenosis', 'inflammatory conditions|Lactase deficiency', 'colorectal cancer|Colorectal cancer', '1.Failure of', 'target DFU', 'metastatic breast cancer', 'epithelial ovarian cancer', 'including||DLBCL', 'pulmonary lymphangitic carcinomatosis|Significant', 'orautoimmune disease history|Meningeal metastasis', 'nasal tract malformations', 'endobronchial ultrasound', 'neurologic diseases', 'chronic pain.|Contraindication', 'medically significant', 'areata alopecia', 'sinonasal malignancy', 'Intercurrent illness', 'infection.|Presence', 'transient ischemic attack (TIA):', 'adjustable rings', 'surgery).||', 'basal-cell carcinoma', 'progressive familial intrahepatic cholestasis', 'unacceptable bleeding risk', 'consent.|Medical disorders', 'no measurable lesion', 'intestine disease', 'heart failure exacerbation', 'hormonal pathology - primary', 'uterine submucosal myomas', 'treatment|Ongoing fever', 'interstitial lung disease;|Current', 'Multiple Chronic Conditions', 'papilloma skin lesion', 'abnormal ECGs', 'neoplastic diseases', ""psychiatric disorders||Parkinson's"", 'primary osteochondrosis', 'digital maturity', 'syndrome|Symptomatic peripheral neuropathy|Systemic', 'current COVID-19 disease', 'cognitive impairment|Informed', 'sitting diastolic BP', 'medication impairing immune response', 'respiratory distress syndrome', 'NCI CTCAE', 'mild depressive symptoms', 'need root canal treatment', 'pulmonary disease|Bleeding disorder', 'condition', 'permanent deformity', 'clinical signs', 'systolic BP measurements', 'disabled', 'gingivitis', 'rotational ankle fractures', 'drug food allergy', 'Streptococcus infection', 'immunotherapy induced', 'musculoskeletal disease|no removable', 'OSCC', 'open wound', 'Arthritis|Fibromyalgia', 'granulocyte macrophage-colony', 'dialyzed', 'non-investigational', 'hypothyroidism)|An inability to provide informed consent|Use of', 'alcohol disorder', 'kidney function|Difficulty', 'structural heart disease.|Family history', 'AXIN1/2', 'Akershus University Hospital', 'unmanageable urinary incontinence.|Participants', 'cardiopathic asthma', 'organ impairment', ""judged by the investigator to potentially interfere with the subject's compliance"", 'third trimester|Menstrual-like', 'continuous treatment.||Contraindication', 'special populations', 'eating disorder', 'serous ovarian cancer', ""Huntington's disease"", '50 kilogram', 'dental disease', 'levonogestrel|Thromboembolic disease|Experiencing bleeding', 'portal vein thrombosis', 'thereof.|Sleep apnea', 'contra-indication).||Heterozygous Familial Hypercholesterolemia', 'Covid-19 virus', 'NMO spectrum disorder', 'substance-induced', 'MoyaMoya disease', 'alternative laryngeal pathology', 'vegetarian', 'Primary Obesity Surgery Endoscopic (', 'complaint of anxiety', 'HIV)/acquired immune deficiency syndrome', 'apical periodontitis|Healthy', 'intracranial glioblastoma multiforme', 'Lower limb injury', 'overall findings', 'Signs', 'polycystic liver disease|Active bleeding', 'ARDS', 'contraceptive measures', 'cognitive alterations', 'type 2)|Uncontrolled thyroid', 'prolonged QT syndrome.|Uncontrolled', 'ligamentous damage', 'COVID symptoms', 'motor neuron disease', 'severe trauma', 'equivalent|refusal', 'weeks;|Hepatic encephalopathy', 'proprietary Chinese medicine.|18-70 years old', 'Relapsing Remitting MS', 'alcohol use disorder|Women', 'periodontal disease|dental cracks', 'benign polyps', 'CNS malignancy.)|Have', 'conditions;|poor oral hygiene', 'pons', 'stimulating factor [GCSF', 'pulmonary hypertension|Patients', 'severe arrhythmia', 'situ|Patients', 'pulmonary function|Men', 'hepatitis C antibody(-', 'semi-permanent prosthesis', 'Cystic Echinococcosis', 'developmentally delayed', 'multiple trauma', 'stent.|Target lesion', 'familial', 'consent.|Mentally stable', 'endocrine disease', 'seizures responding to dexamethasone/analgesic/antiepileptic agents', 'congenital abnormalities|Ability of the participant', 'intracranial hemorrhage).|Prior', 'intraepithelial cervical', 'SARS-CoV-2|<18', 'brain condition', 'tubal ectopic pregnancy visible', 'compulsive disorders', '||Lack of', 'ocular disease|Has read', 'mental health treatment', 'thromboembolism', 'megacolon', 'T1', 'criteria of the European Society of Cardiology guidelines|Consent of the patient (or legal representative) to participate in the study||', 'Suicidal Ideation', 'Chronic renal failure', 'H. pylori infection', 'colon conditions', 'respiratory difficulty', 'hypercholestrolmia etc;|Abnormality', 'otitis', 'AIDS|Rheumatoid arthritis', 'medical disorder', 'mRESIST', 'urinary bladder', 'treated|Other neoplasia', 'lung lesions', 'genetic abnormalities - APL', 'blance disorders', 'major depression disorder', 'Myalgic Encephalitis/Fibromyalgia/Chronic Fatigue Syndrome', 'Bleeding diathesis|Patient', 'local origin|cardiovascular disorders', 'Müllerian agenesis', 'acute pancreatitis.|Patients', 'developmental medical conditions.|Teeth', 'sexually explicit videos', 'primary peritoneal carcinoma|Inoperable', 'COVID infections', 'rapid weight loss', 'Visual impairment', 'epithelial carcinoma', 'nearby regions', 'situ)；|Active hepatitis', 'caries risk assessment', 'colonic necrosis', 'anti-tumor', 'subject|males', 'spinal cords', 'face wounds', 'eosinophilic', 'convulsive conditions', 'screening.|Brain metastasis', 'senile pruritus', ""crohn's"", 'cardiac events', 'subtotal gastrectomy|Esophageal varices', 'autoimmune diseases;|Patients', 'foreign objects in the eyes', 'hemoglobin electrophoresis', 'Retinal vein occlusion', 'urticaria eczema', 'major depressive disorder.|Pain', 'Patients:||- Died', 'pain normal', 'PSVT', 'immunosuppressant', 'III)|Congestive heart failure', 'solitary plasmacytoma', 'inflammatory AAA|Prior surgical repair of an AAA|Renal dialysis', 'local anesthetics|Failure', ""Little's disease"", 'schizophrenia-spectrum disorder', 'atopic eczema', 'submucous cleft palate|Neuromuscular disorders.|Patients', 'orthostatic hypotension;|Any photosensitive disease', 'metastatic diseases', 'Anaplastic lymphoma kinase) fusion', 'informant', 'UGI neoplastic lesions', 'diagnostic block', 'months.|Active liver disease', 'complicated pregnancies', 'hilar', 'accessible teeth', 'obstructive pulmonary disease|Kidney failure', 'HDSS', ""Crohn's disease.|Active"", 'psychiatric diagnosis,|not', 'orthostatic hypotension', 'belfantii', 'organ damage|Failed medical abortion', 'viral response', 'febrile illness|Patients', 'CNS disease;|Participants', 'unexplained serum AST', 'hypertrophic rhinitis', 'lack cognition', 'major head trauma|Life expectancy', 'inflammatory oral mucosal diseases', 'organic mental disorder', 'renal panels', 'RCD', 'parenchymatectomy', 'criteria:|Fever|Splenomegaly|Cytopenia', 'index ACS event', 'chronic renal', 'acute otitis media', 'secondary parkinsonism', 'type I diabetes mellitus', 'malignant tumor.|Not suitable', 'choroidal rupture', 'tumor-related fever', 'Cyanotic congenital cardiac lesions', 'lower limb injury', 'psychotic co-morbidities', 'age)|diagnosis of Hypertension', 'chronic diseases|cardiovascular diseases', 'functional defects', 'end stage renal impairment', 'deep vein thrombus', 'endoscopically resected', 'compensatory behavior', 'spinal surgery.|Inability', 'aspermia', 'Hepatic segment）||', 'diverticular disease|Uncontrolled', 'cutaneous sarcoidosis', 'non-infectious pathology', 'lifestyle considerations', 'chromosomal abnormalities', 'nonoxynol-9 lubricant', 'black plaque', 'infection|Pregnant', 'asplenia.|Short Bowel Syndrome', 'SCLC stage', 'Thresholds', 'coagulation diseases', 'ILD/pneumonitis', 'idiopathic scoliosis||', 'neovascularization|Congenital eye abnormality|Uncontrolled glaucoma|Pseudoexfoliation syndrome|Amblyopia|Uveitis|AMD', 'non-tuberculous mycobacterial infection', 'Hepatocellular carcinoma|Patients', 'pheochromocytoma', 'cosmetic weight loss', 'to:||Fatigue|Alopecia|Skin disorders|Stable neuropathy|Endocrinopathies', 'neurocognitive disorder.|Signs', 'Diabetic', 'dry eye syndrome medications', 'congestive heart failure|Recurrent', 'lymphoma manifestation', 'preparations', 'retinal oxygen saturation', 'dermatosclerosis', 'Acute Coronary Syndrome-STEMI', 'other malignancy', 'Liver Diseases criteria', 'old|Diabetes mellitus|Diabetic autonomic', '5q-SMA established', 'serious depressive condition', 'solid renal mass ≤3cm', 'Cardiogenic Shock', 'neurologic event resulting', 'Carotid Stenosis', 'Health Center', 'enrollment|Sensitivity', 'imatinib.|Unavailable CPSS', 'mild respiratory failure', 'neuro', 'acute insult', 'carcinoma.|Measurable disease', 'surgical complications', 'tongue cancer', 'humeral/ulnar', 'Coronary Artery Disease', 'antibiotics.|Malabsorption syndrome', '2|Metastatic disease', 'cerebral ischemic', 'Antacid', 'hepatitis C virus [HCV] RNA', 'rhinorrhea', 'non-ATTR amyloidosis|Advanced', 'breast-feeding||a', 'impact participation|Diagnosis', 'inadequate sinus bradycardia', 'asymptomatic', 'psychiatric disorders|if the', 'Resident', 'end of PCI procedure', 'hypoplasia', 'QTcF interval', 'intensive care|anorexia nervosa|developmental', 'randomization;|Deep vein thrombosis', 'anticancer agents', 'valvular atrial', 'ACR)|Healthy', 'simultaneous kidney pancreas', 'Gilbert s Syndrome', 'ectopic kidney.|preoperative imaging inadequate', 'left heart disease', 'chronic opioid analgesic use.|Any contraindication', 'thyroid issues', 'language disorders', 'organs', 'good function', 'radiological disease', 'gastrointestinal (GI) disease that could affect the absorption, distribution, metabolism', 'scalp tenderness', 'drainage fluid', 'hematopoietic stimulating factors', 'complaint from pain', 'substance use disorder|Taking any physician-directed', 'vertical split type pincer', 'normal coagulation', 'ipsilateral ischemic', 'endocrine-induced', 'pulmonary tuberculosis', 'enrolled.|Bilateral hydronephrosis', 'tumors|Osteoporosis|History of trauma|Metabolic disorders|Rheumatoid', 'genitourinary cancer', 'chronic myelomonocytic leukemia', 'hips|Current osteomyelitis', 'surgical site infection SSI', 'involvement of the knee', 'cardiopulmonary insufficiency', 'solid organ transplant.|Received chemotherapy', 'and||Diagnosis', 'romantic relationship|Having', 'somatic illness', 'renal cell carinoma', 'deep carious', 'T1 bladder cancer', 'familial polyposis syndrome', 'early prostate cancer', 'Merkel cell carcinoma', 'Kawasaki', 'cancer treated', 'hepatitis Note', 'fetal morphological abnormality|Emergency context', 'mycophenolic acids', 'criteria for exclusion of parents from the study are:||Caring for other dependent people (elderly,', '4,200 feet', 'children', 'HER2 gene copy number', 'Restasis', 'acute impairment', 'congenital enzymopathy.|Systemic connective tissue diseases', 'morphologic remission', 'thrombosis incident|Traumatic nerve injury', 'NSCLC.||Psychological condition', 'organ impairment|Case', 'esophageal cancer||', ""Richter's transformation"", 'epidermal growth factor receptor (EGFR) mutation', 'liver dysfunction', ""Richter's Transformation/transformed"", 'leukopheresis', 'cognitive deterioration', 'equivalent|Renal function', 'substance use disorders', 'non-antipsychotic medications', 'anatomic anomaly', 'therapy|Lack of proficiency', 'paediatric Cystic Fibrosis Centers Competences (CRCM)|did not participate', 'homicidal ideation', 'Lambert-Eaton syndrome', 'prosthetic mitral valve', 'left atrial ablation', 'IL-2|Bowel ischemia/perforation', 'contractures', 'vitreous hemorrhage)|Uncontrolled hypertension', ""doctor's"", 'aprepitant', 'postural instability', 'past abuse', 'necrosis,|Cancerous wound', 'GIT manifestations', 'impossible to perform', 'cerebrovascular diseases:||Myocardial infarction', 'HER2-targeted therapy.||-≥', 'aortic calcification', 'carcinoma Mucoepidermoid carcinoma', 'non-small cell lung cancer.||Eastern', 'systematic antitumor therapy', 'esophageal motility disorders', 'recovered from prior toxicities', 'lymphoma refer', 'substitute decision makers', 'posterior transverse deficiency', 'infection.|Elevated troponin I.', 'non-GCB DLBCL', 'Cardiac', 'nighttime menstrual', 'malignant cells', 'wound', 'Comorbid condition', 'neurogenic bladder collapse', 'head and neck soft tissue defect', 'knee joint stiffness', 'NJ', 'cardiac coherence', 'bronchoalveolar lavage fluid cytology', 'infections|Chronic inflammatory diseases', 'immune system diseases', 'transvaginal ultrasound.||', 'fracture,|Personal disorders', 'ulceration disease', 'cHL', 'oral hygiene|Alcoholism', 'urinary tract abnormalities|Current UTI|Using Phexxi', 'mixed myelodysplastic/myeloproliferative syndrome', 'cerebrovascular systems deemed unsuitable for inclusion by the investigator', 'HFR', 'prolonged sitting', 'congenital hyperinsulinemia.|Current use', 'bone mass', 'autoinflammatory disorders', 'motion artifacts|Images', 'CHARGE syndrome', 'carnitine palmitoyltransferase', 'congenital diseases', 'prostate carcinoma in situ', 'direct interaction', 'gastrointestinal issues', 'flaccidity', 'psychoanalysis', 'malignant tumors;|Cohort extension of', 'non-malignant', 'Zantac', 'anginal symptoms', 'actionable aberrations', 'psychiatric interview;|At least moderate', 'endocrinopathies', 'progressive liver fibrosis', 'oral cancer', 'calculated by the Cockcroft', 'type of TKI', 'Learning disability', 'T2)', 'riteria', 'Cardiac symptoms stable', 'thoracic aortic diameters', 'malignant features', 'splanchnic thrombosis', 'dermatologic diseases', 'immunodeficiency|Food allergies', 'mechanical hemolytic anemia', 'Asthma-', 'early gastric cancer', 'UTI', 'acute kidney injury.|Patients', 'serious eye infection', 'rebound nasal congestion', 'keratopathy', 'leakage|pregnancy', 'postpartum hemorrhage', 'neck carcinoma', 'indicting questionable disease', 'bleeding abnormality', 'local regulations.||', 'Cognitive impairment|Allergy', 'gastric esophageal', 'thromboembolic pulmonary hypertension', 'motor neuron disease|One or more', 'cognitive-behavioral alterations', 'several comorbidities', 'T-wave morphology', 'hematoma block', 'prolonged sitting.||', 'genital hemorrhage', 'metastatic biopsy|Measurable disease', 'organic brain damage', 'common bile duct carcinoma', 'progressive cerebellar', 'relapsing forms', ""Reinke's edema|cyst of the vocal fold|nodule of the vocal fold|polyp of the vocal fold||Exclusion criteria:||previous laryngeal"", 'spinal block', 'anti dsDNA (', 'hypertrophic cardiomyopathy', 'macrolides', 'Tumor lesions', 'care', 'mitral valve regurgitation', 'arterial embolism', 'penile cancer surgery', 'scale|Abnormal sensation', 'ocular disorders', 'swallowing disorder|Subject', 'third degree atrioventricular block;|New', 'health conditions', 'mitotic figure', 'hepatic diseases', 'pain on percussion denoting apical periodontitis.|Periapical radiolucency', 'acute COVID-19 symptoms', 'untreatable high blood pressure)|Ascites', 'hyperopia', 'breastfeeding|Inability', 'PHPT and DM', 'nodes', 'impaired gastrointestinal absorption', 'renal insufficiency', 'marrow infiltration disorder', 'pectus excavatum;|Opioid', 'Abnormality', 'local cervix in situ', 'or|nonproliferative diabetic retinopathy', 'major complications', 'urethral stenosis', 'Other pathology interacting', 'MRCP', 'upper part', 'hypertensive, DM', 'abnormal coagulation profile', 'immune function disorders', 'visible liver lesion', 'diagnostic criteria questionnaire)||', 'e', 'infectious illness', 'screening.|galactose intolerance', 'post-infection', 'pulmonary failure', 'microscopic dermatopathology', '+1.50D & +1.75D||Be willing', 'radiation exposure', 'Malignancies', 'trauma|Whiplash|Degenerative changes|Signs', 'clear corneas', 'heavy alcohol', 'expertise', 'indigestion', 'drug-induced QTc prolongation', 'hypertrophic cardiomyopathy|Uncontrolled atrial', 'chronic kidney disease|Patients', 'ophthalmological disorder', 'those', 'etc.).|Current smokers', 'cystic fibrosis.|Known', 'RX', 'trial.|Extra-cranial radiotherapy', ""Tourette's Disorder"", 'refractive surgical procedure)||Have', 'lineage', 'fresh intestinal anastomoses', 'CNS chloromatous disease', 'COPD|Diagnosis', 'liver disorder', 'CNS leukemia', 'child visible', 'developmental disorders', 'haemorrhagic complications', 'bone marrow failure', 's/p Coronary artery bypass graft surgery', 'surgical problems||Babies', 'hemostasis', 'cerebral spinal fluid pleocytosis', 'axial spondyloarthritis', 'cardiac malformations', 'tissue|Active endocarditis', 'responsive disease', 'Diabetic Retinopathy developed', 'functional cardiac disease.||', 'Mycobacterium tuberculosis infection.|Major', 'cerebral vascular accident', 'renal comorbidities|Pulmonary hypertension|CF-related', 'proprietary Chinese medicines', 'Healthy volunteers:||Healthy', 'hematological disease', 'medical claim', 'black skin pigmentation', 'malignancy|Active Hepatitis', 'blood stasis constitution', 'Primary insertional Achilles tendinopathy|Platelet Rich Plasma (PRP)', 'congenital bronchopulmonary dysplasia (BPD)', 'primary SCC', 'major organ dysfunction', 'primary kidney disease', 'Neisseria', 'gastric tract problems', 'etc.|Has>5 cm lesions', 'elastic tissue disease,|history', 'hepatitis delta virus (HDV) coinfection', 'etc.)|Cardiac abnormalities', 'HIV1/2', 'multiple malignancies', 'ascites', 'daily symptoms', 'esophageal reflux', 'neuropsychiatric diseases', 'elbow joint pain', 'r UT', 'blood disorder', 'Brain lesions', 'appendicitis', ""Crohn's disease|Patients"", 'Covid-19 symptoms', 'augmented virtual reality application', 'crack', 'psychosis).|The', 'abnormal coagulation function;|(3', 'proof of malignancy', 'lack of control of their aggressiveness.|Positive impulsivity', 'male breast', 'recreational use', 'proprietary Chinese medicine', 'pressure injury', 'renal anemia', 'confirm disease', 'reticular changes', 'predialytic chronic kidney disease', 'functional bowel disorder.|HV', 'neurological manifestations', 'light chemical peels', 'malignant colorectal disease', 'musculoskeletal problems', 'hepatitis B virus DNA', 'liver transplantation.|Systemic failure', 'disease-modifying agents', 'renal failure|Refusing the procedure|patients', 'INR resulted', 'obstructive physiology', 'portal hypertensive gastropathy|Pregnancy', 'cognitive dysfunction', 'brain disease', 'acute inflammation', 'antisocial personality disorder', 'skin eczema', 'and/or arm pain', 'endometrial carcinoma.|Known', 'secondary hypogonadism', 'rectal swab', 'Pulmonary', 'precordial pain', 'cold sores', 'milk products|Taking lipid-lowering medications', 'Sjrögens', 'acute intestinal disease', 'type 1 diabetes|Diabetes duration', 'Visual', 'dysgeusia', 'mandibular alveolus', 'parasomnias', 'HCV ribonucleic', 'metal fragments', 'carrying bags', 'intracranial vasculopathy', 'acute asthma exacerbation', 'assessable lesions', 'total lesion', 'light white', 'previous CA', 'skin autoimmune disorder', 'diabetic ketoacidosis.|Have', 'CTCAE grade 1', 'refractory CLL', 'swelling may pose a risk to critical anatomical structures|Participants', 'intravesical dosing', 'normal transaminases values', 'skin basal cell', 'rhythm disorders', 'mitral valve prolapse', 'used||Pulmonary hypertension', 'Relapse', 'functional sign of dyspnea experienced', 'Inflammatory bowel disease (IBD)', 'hypotension)|Acute kidney injury', 'signs of cirrhosis', 'hepatic impairment;|Presence', 'hemangiomas', 'right branches', 'clinical manifestations of', 'sigmoid-colon cancer', 'sleep apnea-hypopnea syndrome', 'hypogonadism.|Participant', 'excluded.)||Pregnant', 'peripheral nerves', 'lumbar echography||', 'moxibustion smoke', 'cerebero-vascular disease', 'congenital megacolon', 'mild background diabetic retinopathy', 'depth of infiltration', 'esophageal resection', 'scleroderma.|Substantial overlap', 'brain tumors.|A current', 'inferior turbinate hypertrophy', 'type 1 diabetes', 'electro-shock', 'cerebrospinal fluid);|White blood cell count', 'criteria)|Maternal cardiac disease', 'basis|Symptomatic brain metastases', 'hypoglycemic episodes', 'pancreatic cancer', 'chronic long-standing corticosteroid', 'impaired cognitive dysfunction', 'local dermatological problems', 'expenditure', 'H. Pylori associated gastritis', 'MPN)|Report', 'etc.);|Food allergies', 'gastrointestinal (appendectomy', 'months;|Positive response', 'Study', 'allergic diseases|A', 'abstain from dry eye/MGD medications', 'non-proliferative', 'abstain from use of these medications', 'malignant tumors;|Patient', 'mixed urinary incontinence symptoms', 'uterine fibroids|Azospermia', 'peripheral neuropathy exists', 'hemostatic defect', 'autologous HSCT', 'patient.|Hypertensive disorder', 'lupus nephritis', 'back injury', 'neurological abnormalities', 'homozygous sickle cell anemia', 'autopsy', 'Congenital Neutropenia', 'exposure|Congenital heart disease', 'systemic rash', 'DR', 'hypercapnic ARF', 'injection|Contraindication', 'Orthodontic', 'RAS', 'Uterine diseases', 'associated pathology', 'alcoholism', 'Left common carotid artery', 'subcortical gray', 'extracerebral bleeding', 'age|Screens', 'epigastric soreness', 'systemic inflammation interaction', 'glaucoma,|Dense cataracts|Dense vitreus opacities|Autoimmune retinopathy-like clinical picture|Any degree', 'Multidisciplinary Spine Conference review|Maximum', 'neoplasm|Instrumental deliveries', 'complex congenital malformations;|congenital pulmonary disease;|severe sepsis', 'PC20', 'physical damage.|Doctor disapproval.|Be', 'corneal disorder', 'vitamin preparations', 'pregnancy plan', 'PRp', 'knee injury', 'bipolar disease', 'reason;|Cachexia state;|Known', 'mental disorders/', 'disc sequestration|Previously treated', 'non-healing wound', 'Neurological chronic disorders|Spinal disraphism|Spinal rheumotological disorders', 'end-stage renal disease|Unavailability', 'encephalopathy', 'Therapeutic response', 'mammary carcinoma', 'clinical Ph.D./M.D||', ""non-Parkinson's disease-suspected"", 'light brown', 'Myelodysplastic Syndrome', 'GeneXpert', 'somatic chronic condition', 'pulmonary disease|Previous treatment', 'responsible physician considers', 'acute rehabilitation', 'Clinical Dementia Rating [CDR] score', 'endobronchial biopsies', 'stress urinary incontinence', 'neuroaxial anesthesia.||Exclusion', 'radical cystectomy', 'rosacea', 'disc herniation causing S1', 'saliva', 'neurological disease.|Have', 'digital equipment', 'end of chemotherapy', 'influenza infection', 'congenital defects', 'substance abuse judged by the investigator', 'diseases of the central nervous system', 'inflammatory disease|Congenital', 'IgA nephropathy', 'malignancy active', 'aniridia', 'maternal chronic diseases', 'trauma||', 'primary substance use disorder', 'post- menopausal', 'ischemic symptoms', 'Muscle skeletal injury', 'breast-feeding|VA-ECMO application for causes', 'cycles', 'sporting events', 'malignant liver lesions', 'lower respiratory tract', 'metabolic dysfunction|ALT', 'trans', 'Chronic renal insufficiency', 'complete loss', 'errors of', 'contraceptive sponges', 'liver diseases;||C', 'Multiple intestinal carcinomatosis|Previous', 'days|Medical condition', 'Hypersensitivity', 'type 1 diabetes diagnosis|Ability and willingness to undergo non-invasive arterial stiffness', 'oligometastatic brain disease', 'unhealed wound', 'primary membranous nephropathy', 'cerebral herniation syndrome', 'organ damage', 'Breastfeeding|Cognitive impairment', 'end organ hypoperfusion', 'gastroesophageal reflux disease.||', 'RAT', 'between luxation', 'herpetic keratitis).|Have fluctuations', 'Carcinomatous meningitis', 'delayed hypersensitivity', 'failure', 'nephrotic syndromes', 'medical center', 'non-resectable', 'trial.||Person with infection', 'bladder carcinoma', 'therapeutic abdominal paracentesis', 'LRI', 'months|Local inflammation', 'CMV', 'participation|alcohol abuse', 'cutaneous-mucosal disease', 'PMSS scale.||Exclusion', 'ocular conditions', 'major hallucinations', 'noncardiovascular disease', 'listeriosis', 'allergic reaction|Patient', 'third spacing fluid;|Concomitant diseases', 'gastrointestinal stricture|Patients', 'degenerative joint disease.|Patients', 'geographic atrophy', 'HIV infection);|Patients', 'liver malignant lesion', 'neurological disease|Acute disease', 'history.|Lactic acidosis', 'local allergic necrotic reaction', 'viral skin infection', 'kidney stones', 'Cervical carcinoma in situ', 'loss of sensation', 'blepharitis', 'holistic consideration', 'GRIN-related disorder', 'antibodies targeting', 'acute sepsis', 'novel coronavirus', 'other malignancies|Active HIV infection', 'valvulopathy', 'diverticulitis;|Liver fibrosis;|Abdominal aortic aneurysm;|acute phlebitis;|Severe', 'required.||Myelodysplastic syndrome', 'procedures.|Adverse events', 'psychotic illnesses', 'HPV|Previous cancer', 'metabolic disorders|Children', 'external postural support', 'years|Kidney Disease Improving Global Outcomes', 'stimulating factor', 'impact absorption, distribution, metabolism', 'predisposition', 'PD.|A diagnosis', 'skin cancer', 'Mycobacterial species', 'alcohol withdrawal;|Presence', 'agent|Active infection', 'scoliotic curve', 'mitral valvulopathy', 'cardiopulmonary disease|Renal dysfunction', 'moderate brown', 'normal tracing', 'lactate dehydrogenase (LDH)', 'drug', 'Cerebral hernia.||Treatment', 'skin epidermoid cancer', 'pulmonary embolism', 'cholelithiasis', 'isolated mandible fractures', 'severe alcohol withdrawal|Unable', 'posterior uveitis', 'function|Unable to take part', 'compromised facial', 'jejunal CD only|Severe complex', 'aztreonam', 'tumor DNA', 'Severe calcified lesion', 'GI obstruction', 'stool', 'lift off test', 'brain scarring|Healthy', 'blood pressure', 'decoction', 'electrolyte disturbances', 'causalgia', 'Achilles tendonitis', 'aeroallergen', 'longest cross sectional diameter', 'focus groups||Adults||Hispanic', 'end-diastolic wall thickness', 'genital disorders', 'AIDS|Patients', 'cutaneous enterostomy|Pregnancy', 'erythematosus systemic lupus', 'generalized anxiety', 'intervention.|Active infection', 'heart allograft,|written informed consent obtained', 'brain injuries', 'grandparents', 'stable|Unilateral internal carotid artery', 'finger abduction in left', 'SARS-CoV-2.||Children', 'pulpal necrosis', 'standard deviations SDs', 'idiopathic thrombocytopenic purpura.|7', 'sebaceous epithelioma', 'bilateral damage.|Active suicidal', 'toxic effects', 'lack of response', 'anosmia', 'hepatitis B (HBsAg)', 'CTCAE 5.0)|The need', 'Pediatric cancer', 'cerebral hernia', 'Systemic disorder', 'neurological health', 'atrial dilatation', 'spasticity', 'prosthetic joint infection', 'severity (CMS ≤', 'kidney transplantation;|Previous allergy', 'month).|No infectious fever', 'nasopharyngeal carcinomas', 'lung involvement|Other types', 'preoperative astigmatism', 'sputum', 'chronic dyspepsia', 'colon present', 'pathology of etiology', 'superficial skin cancers', 'indicators', 'T3 colonic adenocarcinoma', 'metavir F3 fibrosis', 'McCune Albright syndrome', 'ballooning).|Presence', 'neurological symptoms return', ""Buerger's disease"", 'multifocal BC', 'gastrointestinal abnormalities', 'NASCET', 'kidney function injury', '||Inclusion', 'femoral neck fracture', 'etc.);|surgical interventions', 'components;|Uncontrollable systemic diseases', 'hematologic function', 'organ transplantation;|Imaging', 'tibia|Intramedullary nail', 'HCV disease', 'IMB', 'α-thalassemia', 'native duodenal', 'in situ cervical cancer.|Note', 'left internal thoracic artery', 'pathology;|Delivery', 'tympanic membrane', 'Unable to stop anticoagulation therapy', 'ethnic minority', 'Necrosis', 'leukemia reaction', 'paroxysmal/persistent', 'contraindicates surgical treatment', 'tuberculosis pneumonia', 'gestational trophoblastic', 'graft rejection', 'alcohol drinking', 'intolerant', 'macroscopic lesions', 'symptomatic hypogonadism', 'adenosquamous cell carcinoma', 'disc herniation in lumbar', 'HER2+', 'cough of unknown cause', 'endocrinal disease', 'skin basal cell carcinoma', 'sclerosis.|Inflammatory bowel disease', 'cognitive disorders players', 'Darier disease', 'refractory chronic otitis media', 'non-nitrosourea-containing cytotoxic chemotherapy regimen', 'carotid stenosis).|No usable home blood pressure cuff available|Diagnosis of hypertension', 'AMI', 'technical performance', 'classification code', 'kidney disease|Chronic obstructive pulmonary disease|Thyroid dysfunction', 'cryolipolysis', 'lung fibrosis', 'complete root development.|Presence', 'dermatological condition', 'membrane defect', 'lower limb impairments', 'millisievert', 'neurologic disease.|Participant', 'circadian rhythm', 'Fracture', 'Adolescence', 'space occupying lesion', 'strongly', 'active ulcer', 'macular scarring', 'active neuropathy', 'visually estimated stenosis', 'plaque', 'Superficial vein thrombosis', 'Atypical parkinsonism includes', 'proceed.||Acute Myeloid Leukemia', 'medical advice', 'kidney function.|Voluntary participation in research.||', 'resection', 'tympanometry', 'complex retinal detachment', 'IV|On stable doses of background PAH therapy', 'CKD|Absence', 'autonomic dysfunction|Current', 'superficial bladder cancer.|Prostate cancer', 'non-emergency surgery', 'liver malignant tumor', 'isolated motor delay', 'mild cognitive impairment of a dysexecutive', 'human epidermal growth factor receptor 2 therapy/targeted therapy', 'abnormal retinal', 'diabetes mellitus;|Patients', 'scalp reduction', 'rabies', 'MORES', 'gastrointestinal dysfunction', 'femoral vein stenosis', 'respiratory system disease', 'biochemical hyper androgenesim.|Polycystic ovaries.||', 'breastfeeding.|Chronic pain', 'duodenal', 'Deep Brain Stimulation (DBS)', 'clotting factor inhibitors', 'parasitic pathogenic enteric infection', 'cord rupture', 'parathyroid gland', 'coli colitis', 'toxic epidermal necrolysis', 'omega-3', 'Pancreatic tumors', 'increased activity of the hypothalamic-pituitary- adrenal axis', 'vergence', 'epithelial neoplasia', 'immune deficiency disorders', 'joint dislocations', 'chronic kidney disease', 'retinal vein occlusion', 'gynecologic infection', 'myasthenia gravis|Not', 'complete injuries', 'sAML', 'drug hypersensitivity reaction.|25', 'Brugada syndrome', 'coronary artery bypass', 'medication usage|Sexually active', 'active ulcer lesion', ""Parkinson's disease"", 'event;|Acute pathology', 'cancer treatment;|The', 'congenital cardiac anomaly diagnosed||Exclusion Criteria common to the 2 groups (Cases and', 'hearing impairments', 'loss of the entire', 'formula-fed|Having', 'score of cornea', 'histology|Received cancer care', '-situ carcinoma', 'valvular heart', 'medullary carcinoma', 'quadriceps disorders', 'orthodontic treatment;|Craniofacial anomaly', 'head-brain trauma', ""Addison's"", 'successive therapeutic lines', 'isolated proteinuria', 'non-invasive carcinoma', 'day|no pregnancy', 'Type 2 Diabetes', 'line', 'myositis)|Coronary artery disease', 'psychotic disorder|Have', 'radiologic signs of', 'neurodegenerative disorders;|disorders', 'X-linked hypophosphatemia', 'gastric ulcers', 'ovarian tumors', 'vaginal bleeding', 'clinical manifestations of COVID-19', 'neonatal alloimmune thrombocytopenia', ""Alzheimer's disease|Patients"", 'cardiovascular disorders.|Presence', 'end-stage diabetic kidney disease', 'HIV-2 infection', 'valvular condition', 'Metastatic colorectal cancer', 'copper-metabolism', 'pain problem', 'atherosclerotic coronary artery disease (CAD)', 'distal common bile duct.|Patients', 'disease-free', 'ocular discomfort', 'anemia Impairment', 'Neisseria meningitidis', 'alcohol withdrawal', 'upper extremities', 'suicidal risk', 'infiltration of the phrenic nerve', 'stroke symptoms', 'Acute renal', 'spermatic cord block', 'anxiety disorders', 'trying to conceive|Involved in another clinical study', 'colon cancer|Completed surgical resection', 'age|Ability', 'cough disorder', 'food anaphylaxis', 'permanent atrial fibrillation', 'epidermal growth factor receptor (EGFR) activating mutation positive', 'solid organ transplant|Provider concern', 'folate deficiency', 'clotting disorders', 'aplastic', 'non-orthopaedic trauma.|Other condition', 'OSD symptoms', 'motor seizures', 'osteoarticular comorbidities', 'lymphoproliferative disorder', 'age.|Pregnant women.|People', 'transient ischemic attack|Any cardiac', 'GH', 'nasolabial folds', 'appendicular skeletal', 'NHL', 'cervical lesion', 'nasal disease', 'bowel habits', 'chronic TB infection', 'Type II diabetes', 'isolated limb', 'retinal pathology', 'are:||Inclusion criteria:||Permanent', 'kidney transplantation|Having', 'residual symptoms', 'synovial hyperplasia', ""Johnson's syndrome"", 'solid tumor(s)', 'severe dermatosis', 'Pathologies', 'optic nerve damage', 'Child', 'severe allergic', 'parent(s)/legal representative(s) able to comply with the protocol', 'LGS', 'covert', 'HIV||Pregnant', 'shingles', ""Bruton's tyrosine"", 'mixed hepatocellular/cholangiocarcinoma', 'non-surgical sterilization', 'blended', 'parenteral hydration', 'drug-related pulmonary toxicity;|Hepatitis B patients', 'rotator cuff arthropathy|pacemaker|infectious process', 'radial forearm free flap', 'Churg-Strauss', 'muffled hearing', 'cancer)|myocardial infarction', 'Systemic diseases', 'autoimmune conditions', 'Job syndrome', 'cardiac pathologies', 'Congenital deformity of spine', 'Mild Cognitive Impairment', 'ocular disorders|Interstitial pneumonitis', 'aortic insufficiency|Known amyloid heart disease|Group', 'risk of failure', 'bladder fibrosis)|Poor performance status', 'potential activity against TPE', 'localized basal', 'stage of', 'B-cell lymphomas||diffuse', 'breast feeding.|In', 'ventral hernias', 'rearrangements of MYC', 'females|heavy smokers', ""Frey's"", 'urolithiasis', 'brain trauma dementia', 'Ascites controlled', 'pancreatic neuroendocrine tumor', 'needle aspiration', 'hepatic disease', 'digestive tract ulcers;|The researchers', 'lupus);|recent symptoms of illness', 'acute otitis', 'visceral crisis', 'pulmonary embolism,|Intracranial hemorrhage', 'criteria of the American Joint Committee on Cancer (AJCC)', 'fatty liver disease', 'situations', 'Neuropsychological alteration', 'Adverse Events [CTCAE]', 'venous ulcers', 'diabetic ketoacidosis-hyperosmolar state', 'ASCT', 'major depression/bipolar', 'non-muscle', 'confirmed disease', 'acute pericoronitis.|Usage', 'EMSculpt', 'suicidal/homicidal ideation', 'controllable arrhythmia', 'falciparum parasitemia', 'interstitial disease', 'medical disorders', 'severe reactions', 'right hand(s', 'neurological diseases|Presence of', 'chronic gastrointestinal disorders', 'pulmonary congestion', 'associated adenomyosis', 'immunosuppression.|Evidence of', 'microangiopathic hemolytic anemia', 'neuroendocrine prostate cancer (NEPC)', 'ERCP', 'hepatitis B virus(HBV', 'acute heart failure|', 'Positive Airway Pressure', 'histopathologically.|Any bleeding disorder', 'HER2-negative BC', 'mucogingival defects', 'ventricular arrhythmias', 'situs', 'PTEN mutations', 'psychiatric disorder', 'months;|diabetic foot ulcers', 'root canal treatment||', 'follicular lymphoma 3B (FL-3B)', 'arterial ischemic stroke', 'collateral ligament integrity|Rheumatoid Arthritis (', 'hemochromatosis|Risk', 'tarsal abnormalities', 'hepatitis B cirrhosis', 'anatomy)|Symptomatic duodenal stenosis', 'pulmonary parenchymal disease', 'Secondary orthopedic', 'stiffness', 'DA', 'amyl nitrite', 'Malignant solid tumors', 'major depressive episodes', 'visual', 'Suicidal behavior', 'Chronic wound', 'potentially hepatotoxic substances;||E', 'Roanoke', 'inner ear function AND|Behavioral open-set word recognition', 'renal denervation|Systolic heart failure', 'Health Group', 'associated telomeropathies', 'squamous cell carcinoma of', 'setting:||Has', 'toxin-induced', 'solid tumors - colorectal', 'anterior choroidal', 'basal cell cancers', 'checkpoint inhibitors', 'Melanesia', 'bladder tumors', 'cavitated lesions', 'hypoventilation', 'pregnancy|Participation', 'bone metastases', 'Acute ischemic stroke|Acute intracerebral', 'normal vision', 'nodular pinguecula', 'thrombotic tendency', 'arterial cannulation', 'painful disorders', 'gestational diabetes|Patients', 'Cre8™', 'Diagnosis', 'bone marrow volume).||3', 'anti- tuberculosis', 'intramucosal carcinoma', 'idiopathic intestinal pseudo-obstruction', 'therapy;|Psychiatric disorders', 'ureteral mucosal laceration', 'bulimia', 'HIV-positive', 'sports activities', 'varicose vein pathology', 'arrhythmias', 'physical diseases', 'motor impairments', 'peritoneal dialysis', 'sinus rhythm', 'chronic GvHD', 'etc.)||Healthy', 'poor mental status', 'reasonable', 'solid organ transplantation', 'distal intracranial carotid artery', 'Aimovig', 'allowed.|Participant', 'past complications', 'urticaria|Active skin conditions', 'anatomically narrow', 'OCD', 'glucose metabolism', 'required|PROSTATE CANCER', 'breathing', 'procerus muscle', 'sickness|Epileptic insults', 'primary event', 'nervous system disorders', 'Impaired glucose tolerance', 'graphesthesia', 'excluding:||Malignant tumors', 'retinal drusen', 'similar build', 'drug-induced', 'health-related', 'Target Lesion', 'past eye diseases', 'sinus tracts', 'common cold virus', 'successfully osseointegrated', 'non-cardiac disease;|Pregnancy;|Type 1 diabetes', 'bulky cervical adenopathy', 'uterine cervical cancer', 'copper-banded', 'degenerative lumbar disease|age', 'blood disorders', 'very deep carious', 'clinical features', 'plateletopenia', 'sebaceous adenoma', 'inadequate organ function', 'mental health', 'facial skin diseases', 'Atrioventricular conduction disorder|Having Bradycardia', 'criteria below.||- Lymphoma', 'hemorrhagic diseases', 'Impaired mental status', 'psychoactive substance abuse', 'neurotic excoriations', 'persistence of symptoms', 'human T-lymphotropic virus (HTLV) infections', 'small bowel proximal', 'hematologic malignancy', 'fluid overload', 'acute coronary syndrome;|preoperative', 'neutral effects', 'aortic tortuosity|Subject', 'paraaotic nodes', 'produce allergic', 'consisting of neck', 'malaise', 'morphologic relapsed', 'chronic coexisting illness', 'Renal Tubular Acidosis', 'atypical lobular hyperplasia', 'neck cancer', 'assessment approaches', 'antimicrobial therapy|Known allergies', ""extensive Crohn's disease"", 'abnormal bleeding episodes', 'age|Intermittent claudication', 'alcohol breath test', 'dementia|Cognitive impairment', 'translocated RCC', 'vulvar-vaginal cancer', '≥40ppb||Poor disease', 'females.|Postpartum', 'gait pathology', 'non-cancer indication', 'esami del sangue', 'excludes skin', 'puncture-aspiration|Cuff pathology', 'alcohol abuse.|Is', 'acute diabetic complications', 'axillary temperature', 'liver stiffness', 'end-of-life care', 'vascular obstruction', 'homozygous deletion of survival', 'language difficulties|Known pregnancy|Unable', 'gestational diabetes', 'facial nerve paralysis', 'potassium excretion disorder', 'Internal Medicine residency trainees', 'teeth present', 'granulomatosis', 'health insurance.||Cisgender', 'urinary system', 'sexually transmitted', 'Critically ill', 'clinical significance', 'localized skin infections', 'hypernatremia|Persistent diarrhea|Acidosis', 'sexually transmitted disease', 'heart disease.|Have', 'cephalohematoma', 'primary ciliary dyskinesia|dependence', 'leptomeningeal carcinomatosis', 'chronic regional pain', 'myositis', 'serious injury', 'code|Opportunistic infections', 'unresectable tumor causes', 'otomycosis', 'vision deficit', 'contraindicating physical exercise|Diagnosis', 'poor left ventricular function', 'retinitis', 'breastfeeding;|Active tobacco', 'Starfruit', 'constitution', 'future weight loss procedures', 'coaches', 'weight loss supplements', 'residency', 'lattice degeneration', 'premalignant disease', 'early breast cancer;|Indication', 'Acute febrile infection', 'disease outside', 'Traumatic Brain Injury.|Previous targeted synthetic', 'permanent blindness', 'HIV:||HIV infection', 'Chronic Obstructive Pulmonary Disease|FEV1', 'conditions.|Active epilepsy', 'prolonged QT interval time', 'major organ toxicity', 'Hay fever', 'autoimmune pathology', 'a:||Ischemic stroke', 'CNS metastasis', 'various', 'nasopharyngeal cancer', 'urinary tract infections', 'hemolymphatic system', 'Isolated tumor cells', 'Toxoplasma gondii', 'thyroid condition', 'microcrystalline cellulose', 'lung damage', 'hyperammonemia', 'liver abscesses', 'pneumococcus|Additional condition', 'WCT', 'CpG 1018', 'lactation|Major family changes', 'bone marrow insufficiency', 'fatty hepatic disease', 'limb.|Significant renal', 'congenital immune-deficient', 'located.|Subjects can hold still', 'CNS relapse', 'simple urinary tract infection', 'FFPE', 'heart valve replacement', 'pregnant；|endometriosis', 'brain arteriovenous malformation', 'spondyloarthritis', 'renal allotransplantation', 'CNS disease；|2、Patients', 'dermatitis', 'factors', '- encephalopathy', 'cases of novel', 'retinal detachment', 'bruxism', 'bipolar episodes', 'bioprosthetic', 'Right ventricular infarction', 'Cohort A:||iii', 'HF)|Myocardial infarction', 'antifungal', 'continued activity of pericarditis', 'ocular herpes zoster', 'cocoa intolerance', 'HAE type', 'no diameter criteria)|Pseudoaneurysms', 'CML blast crisis', 'autistic disorder', 'abnormal coagulation', 'enlargement of the left atrium', 'third-line', 'cocaine use disorder', 'target aneurysms', 'neurological condition', 'acute disease', 'Solid Tumors (RECIST)', 'associated Telomere Disorders|Nijmegen Breakage Syndrome|ERCC6L2|Patients', 'systemic absorption', 'skeletal malignancies', 'glycemia-related', 'simmondsia chinensis', 'neurofeedback', 'CEBPA|Acute prolymphocytic leukemia', 'intestinal paralysis', 'Surgically', 'image', 'Atherosclerotic cardiovascular disease', 'benign tumor excision', 'recovered from all radiation-related', 'Hepatic steatosis', 'donor|Previous solid organ transplant|Multi-organ transplantation|Previous treatment', 'upper quadrant pain', 'otitis media', 'Hemodynamic compromise', 'drug addicts|pregnancy', 'pituitaritis', 'major medical condition', 'cM0;|non-radiologic', 'developmental disorders-motor skills', 'defecation irregularity', 'disease)|Meniscal rupture.|Condylar', 'cough symptoms', 'Senseye DT:||Vision impairment', 'insomnia)|sleep disorders', 'stimulating factors', 'eye tumours|In', 'symptoms from', 'T2DM', 'ECP', 'digestive condition', 'exclusion|Cannot read', 'spastic disorder', 'muscular disease', 'Collodion)|Clinical condition', 'synthesis dysfunction', 'hypo-/hyperparathyroidism', 'suffered fractures', 'concerns', 'cervical radiculopathies', 'hammer toes', 'dysfunctional voiding', 'autosomal dominant hypocalcemia', 'degenerated surgical bioprosthetic aortic valves', 'recurrent episodes', 'eyebrow lift', 'radical radiotherapy|Gleason score', 'end-organ damage', 'signs of inflammation', 'craniotomy', 'cause of death', 'Surgically sterile', 'old|Pleural infection', 'resting chest pain', 'progressive sclerosing cholangitis', 'Anxiety Disorders inpatient unit', 'sepsis|Local anatomical distortion', 'Oncolytic virus', 'stressor', 'inflammatory cardiomyopathy', 'Severe dyskinesia', 'sensorineural deafness', 'cancer diagnosis,|no communication problems', 'AIDS', 'contraceptive pills', 'respiratory arrest', 'unstabilized coronary artery disease', 'radiotherapy|Previous malignancies', 'inflammatory arthritis', 'Nausea', 'Meningomyelocele', 'vagus nerve stimulation devices', 'Neurological disease|Psychiatric disease|Benzodiazepines', 'bladder cancer', 'solid organ transplant.|RECIPIENT', 'REZUM', 'mild sleep apnea', 'neurological conditions', 'Excess alcohol', 'tuberculosis infection|Participants co-infected', 'Mellitus', 'feeling sad', 'arteriovenous prosthesis', 'progressive disease.|The', 'comorbid mental health disorder|No', 'spinal bleeding', 'former smokers', 'uterine agenesis', 'non-compliance', 'assessments.|Temporary resident', 'insufficient pain', 'corrected gestational age)|Maternal', 'gluten sensitivity', 'recurrence of tumor', 'Coronary Heart Disease', 'increased postcapillary pressure', 'syphilis;|Renal failure', 'gastrointestinal tract disease', 'diabetes mellitus (DM)', 'abnormalities of vision', 'autoimmune disorder', 'medullary thyroid cancer;|Known thyroid cancer', 'Acute Coronary Syndrome|Physical barriers', 'British Columbia where SmartMom', 'hepatitis infection.|Female', 'actively smoking', 'patella.|Pain', 'management|Patients', 'motor disorders', 'functional disorder.|Drug abuse', 'ARRPAC', 'alcohol urine', 'weight loss medications|Currently', 'iridocyclitis', 'VTE', 'pancreatic abscess', 'heamturia', 'conduct disorder', 'complexes', 'CBD', 'co-existent second malignancy', 'solid organ transplant.|History of', 'NMN', 'family factors', 'massive rotator cuff tear||', 'severe dry eye/ocular surface disease', 'controlled seizures', 'type II papillary renal cell carcinoma', 'functional deficit', 'from hypertension', 'gastrointestinal surgery|Have type I diabetes|Thyroid disorder', 'gunshot wounds', 'breast cancer|Primary malignancies', 'distant metastasis|Severe liver', 'skin carcinoma', 'included.|Unilateral radiculopathy pain', 'sebaceous adenocarcinoma', 'blood system diseases', 'Medical disorder', 'HER2-directed therapy', 'Polycystic Ovarian Morphology', 'Acute myelogenous leukemia', 'tumor infiltrating', 'Diabetes Mellitus.|Use of', 'ballooning', 'carcinoma.|Primary immune deficiency.|Presence', 'bone metastasis AKP', 'RET oncogenic driver alterations', 'dysphasia', 'alcohol use)|Patients', 'vaginal infections', 'infection of the brain', 'digital CBT', 'hepatitis A', 'systemic immune system diseases', 'hepatic decompensation', 'related disorder', 'neuropathy;|acute cardiovascular events', 'contraindications', 'mild anemia', 'methemoglobinemia', 'EVAR', 'reconstructed|Duplicated collecting system', 'obstructive hypertrophic cardiomyopathy', 'Lagevrio', 'blueberries', 'assessment confirms', 'gastrointestinal stenosis|Implanted', 'autoimmune disease', 'UPMC', 'rapid clinical', 'substantive liver disease', 'adjuvant chemoradiation', 'non-invasive', 'post menopause', 'retinopathy.|Unable to receive acupuncture treatment continuously', 'resistant prostate cancer', 'skin care professional', 'HD', 'Von Willebrand Disease', 'adenocarcinoma of the pancreas', 'bipolar affective disorder', 'TBC', 'ECG abnormalities', 'breast-feeding.|Patients', 'Lung Cancer', 'memory disorder', 'facet arthropathy', 'Breakage Syndrome', 'severe hearing loss', 'intravenous busulfan with documentation', 'non-glioma', 'endovascular adequate occlusion', 'anormal corneal topography', 'adenosquamous', 'incompatibility', 'Type 2 Diabetes Mellitus', 'lymphoid acute leukemia', 'psychotic symptoms;|Subjects', 'psychiatric disease|To', 'medical processes', 'poor general condition', 'cognitive symptoms', 'Glucose-6-Phosphate Dehydrogenase (G6PD)', 'pulmo-/cardiovascular disease', 'suicidal ideation;|The child', 'basic liver diseases', 'febrile of uncertain origin or meningoencephalitis', 'macrovascular tumor', 'arterial thrombolysis', 'spinal cord involvement', 'head trauma,|persistent disorder of consciousness (DOC)', 'heel.|Pain', 'Potentially vulnerable', 'Hepatic impairment', 'chronic seizures', 'Malignant Hematology ward', 'Rubella virus', 'multidisciplinary metabolic rehabilitation', 'cutaneous viral', 'solid tumors).|Have adequate organ function.|Fresh', 'months;|Stable disease', 'hepatitis D virus', 'etc.);|Congestive heart failure', 'diagnosis|Chronic kidney disease', 'renal injury', 'digitalis', 'vascular white matter lesion', 'diaphragmatic hernia|Patient', 'Type 2 diabetes|A1c', 'excludes twins', 'intestinal tumors', 'autonomic involvement|Other types', 'peripheral waves', 'local hyperthermia).|Acute pain', 'therapy.|Symptomatic Multiple Myeloma', 'post-SCI/D', 'auditory condition', 'fungal infection', 'chronic back pain', 'learning impairment', 'BCG', 'criteria for diagnosis', 'thyroid-related diseases', 'inflammatory skin disease', 'sustained cure', 'bone disorder', 'alcohol abuse.|Chronic nausea', 'acute liver injury', 'thalassemia', 'tumor of the index', 'bleeding risk', 'Inflammatory Bowel', 'chest wall injury', 'Retinopathy', 'idiopathic pneumonia', 'other tumors', 'AADC deficiency', 'intracranial infectious diseases', 'Mycotic', 'Gallstone disease', 'neuropathic joints|6', 'gastritis|Pregnancy', 'dental fluorosis', 'bruises', 'ZMC fractures', 'old|normal eyesight', 'active infection of HIV', 'transient ischemic attack|History', 'maternal abnormalities', 'good health conditions', 'somatic condition', 'drug-related pneumonia', 'transplantation|Pregnant', 'large leiomyomas', 'melanoma lesion', 'teeth|crowding,|systemic diseases', 'nonmelanoma skin', 'anaphylactic', 'communication problem', 'salicylism', 'Type I hyperlipoproteinemia', 'early-stage cervical', 'spirits/hard liquor', 'sepsis)|Anemia|Renal dysfunction', 'acute tubular necrosis', 'chew gummies nutritional supplement', 'nuclear', 'barring stable thrombosis', 'cardiac valve surgery;|Previous cardiac surgery', 'neurogenic bladder', 'infectious colitis', 'brain by imaging', 'acute rejection', 'tattoos', 'metabolic disease.|Consume', 'primary brain tumors', 'cardiac arrhythmia', 'third space effusion', 'upper gastrointestinal anatomy', 'liver resections', 'mental illness resulting', 'neurological disease;|15', 'extra-esophageal symptoms', 'congenital hypothyroidism', 'renal vascular disease', 'main renal vein invasion', 'Dominant Arteriopathy', 'meningeal metastases', 'specifically:||Hemorrhagic disorder', 'vaginalis', 'Subretinal drusenoid deposits|Intermediate AMD', 'peritoneal effusion|Leukemic phase', 'orthodontic treatment.|Craniofacial abnormalities', 'gastrointestinal abnormality', 'autoimmune diseases.|A', 'squamous cell carcinomas of the skin|History of', 'radicular pain.|Systemic diseases', '-risk', 'females|History of hypersensitivity', 'core biopsy|be', 'lacticacidosis', 'pancreatic injury', 'dental malformation', 'subaortic obstruction|Mitral regurgitation', 'consensus between PI(surgeon', 'fixation', 'MF', 'reduced', 'America', 'Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI', 'neurological pathologies|decompensated methabolic', 'neuropathy.|Rheumatoid arthritis.|Myopathy.|Cognitive impairment', 'chronic inflammatory', 'study|Diagnosis', 'hematopoietic abnormality', 'complication', 'HLA', 'refractory lymphoma', 'Healthy obese', 'electrophysiologic disease', 'Barthel Index.|Cognitive impairment', 'unilateral sensorineural hearing loss', 'vestibular disorder', 'lower limb surgery', 'major depression of sufficient', 'major neurological disorders', 'mental health disorders', 'Blood tumor', 'fruit drinks', 'corrected QT (QTc)', 'craniofacial malformation', 'vomiting', 'overt disease', 'cancer (CA)', 'fracture fixation', 'irregular shaped node', 'gastrointestinal perforation.|Cognitively', 'double vision', 'brain oligometastases||', 'disproportional bone growth.|unhealed skin lesions', 'skin|Asymptomatic prostate cancer', 'renal pelvis status', 'steroids|Chronic kidney disease', 'persistent ovarian clear cell carcinoma', 'Celiac disease diagnosis)|Diverticulitis', 'lymphocytic lymphoma', 'liver function', 'archival primary', 'activated T cells', 'cavotricuspid isthmus dependent', 'iron allergy', 'lung', 'contraindicated|Failure', 'non-sustained', 'cosmetic problems.|Clinical thyrotoxicosis', 'Acute cystitis|Bladder cancer|Chronic prostatitis|Bladder stone|Stress incontinence', 'antifungal treatment.|Known', 'AV-block', 'resected cutaneous basal cell', 'compromised immune system;|Patients', 'urethral injuries', 'pathological processes', 'nephropathies', 'myelodysplastic subtype anemia', 'isolated laminotomy', '*6/*6', 'cerebellar disease', 'Relapsing remitting', 'NAC', 'hematemesis', 'obstructive sleep apnoea', 'microvasculature', 'hypertensive emergency', 'C1 Inhibitor deficiency|Patient over 18 years old||', 'upper extremity problem of', 'ectasia', 'traditional supplement)|Participants contraindicated', 'signs of macula', 'anterior segment pathology', 'home', 'traumatic nerve injury', 'CNS lymphoma.|Patient', 'adverse risk factors', 'Scoring', 'renal function，Blood', 'stent thrombosis', 'FBT', 'SBP)≥150mmHg and<180mmHg', 'mL]/ minute [min]/1.73 meter square [m2', 'hematopoietic diseases', 'crescent', 'diabetes mellitus type 2', 'Healthy eye', 'Chronic refractory pain', 'Neuromuscular Diseases', 'active.|Pregnant', 'protective treatment.|Uncorrectable coagulation dysfunction', 'skin conditions', 'carotid disease', 'randomization.|Active hemorrhage', 'atrioventricular junction disorder', 'transferase disorders', 'provided)|major cognitive deficit impacting the ability to read', ""Parkinson 's disease"", 'speech disorders', 'ARNI', 'localized prostate cancer', 'malignant tumor diseases', 'persistent jaundice', 'contra indicates dental treatment.|Use', 'Attention Deficit Hyperactivity Disorder', 'pregnancy tests', 'pnemonia', 'degenerative rotator cuff tear', 'hot bath', 'cancer therapy-induced', 'adults|Overlap syndrome', 'Posterior staphyloma', 'ethic authorities', 'hepatobiliary tubular cell carcinoma', 'naltrexone;||Pregnant', 'mild dyspnea', 'difficulty breathing.||', 'diabetes mellitus|renal failure', 'sarcomatoid hepatocellular carcinoma', 'reporting bruxism', 'erectile dysfunction', 'Armour Thyroid', 'Poor organ function|The lesion', 'gastrointestinal ulcer(s)', 'transient ischemic', 'recreational drugs|Medical treatment', 'dry corneal conjunctivitis', 'painful arc test result', 'PCC', ""Huntington's"", 'CMMRD disposition', 'injectable lesions', 'mutations', 'microphthalmia', 'Uncontrolled hypercalcemia', 'oesophagus', 'hysterosalpingography', 'morphological remission', 'Primary tumor locations', 'bipolar coagulation', 'external root resorption|pain on percussion', 'breast-feeding.|Clinically', 'scoliotic attitude', 'hepatic insufficiency', 'diabetes Mellitus', 'cannabis dependence', 'chronic systolic heart failure', 'CNS disorders', 'SARS-CoV-2;|Negative qRT-PCR nucleic acid test', 'angioneurotic edema;|respiratory failure', 'urgency urinary incontinence', 'disorders', 'adenocarcinoma of the prostate|Undergoing radical prostatectomy', 'thromboembolic disease', 'associated cause of hereditary', 'congenital anomalies|Need of', 'trying to conceive', 'screening.|Renal dysfunction', 'augmented bladder', '||Over', 'leptomeningeal metastases', 'lung malignancy', 'invasive infections', 'bacterial endocarditis.|Evidence', 'judged by the investigator.|Current smokers', 'Cooperative children.|Healthy', 'October 1st', 'CTP', 'inclusive|Meet the', 'a:||Successful', 'Extrahepatic tumor burden', 'feeling of weakness', 'idiosyncratic', 'fainting of needles', 'drug allergies', 'medial compartment of the knee', 'between diagnosis', 'preterm delivery', 'ADRD', 'flashlight', 'hip dislocation', 'types of tumors', 'acute local infection|Missing the adjacent second molar', 'HBVDNA', 'descending colon', 'acute pain', 'alcohol liver disease', 'pre-coma', 'UIP type', 'disease activity', 'poor surgical candidate', 'invasive disease', 'infections- malaria', 'reconstruction|Diagnosis', 'criteria consistent', 'neurotrophic keratitis', 'COVID- 19 infection', 'tricuspid valve dysfunction', 'urinary problems', 'Target lesions', 'plan', 'cardiopulmonary failure', 'spermia', 'atrial', 'respiratory support.||', 'woman.|Chronic kidney disease', 'breastfeeding|Food allergies', 'narcotic analgesics.|Alcohol', 'Health Group:||Neurological diseases', 'signs of cardiac', 'Intensive care survivors|Surviving COVID-19', 'impairment;|Head trauma', 'non-epileptic seizures', 'metastases to the axillary lymph nodes', 'hypertension|Fracture', 'pilocarpine iontophoresis', 'tendinopathy', 'distant metastases N0M0.|MRI visible tumor', 'plasma cell dyscrasia', 'HBV carriers', 'disability', 'inducible ischemia', 'laundry detergents', 'surgical operations|Surgeries', 'bowel ischemia', 'bulimia nervosa', 'superficial bladder neoplasms', 'Colitis Organisation', 'cancer diagnosis', 'intestinal necrosis', 'acutely ill', 'membranes;|Serious complication;|Be absent', 'PC', 'hypertension.|Suffering from coagulation disorders', 'non-squamous NSCLC', 'muscular dystrophy;|Any condition', 'hypomanic episode', ""child's assent given before"", 'acute myeloblastic leukemia', 'interstitial pneumonia/lung disease', 'heart arrhythmia', 'Primary osteoarthritis', 'solid tumors.|Subject', 'Class IC|Reflex syncope', 'genetic pathology', 'acute blood loss', 'other main organs', 'assess speech perception', 'developmentally disabled', 'male-LUTS', 'maladaptive behavior', 'GPs', 'ovarian cone resection', 'old|Registered', 'severe mental disorder', 'portable technologies', 'Rectal adenocarcinoma', 'criteria|Bladder disorders supposedly', 'retinal laser photocoagulation', 'acquired angioedema', 'Skin pathology', 'chronic hepatitis B）.|Age', 'immunodeficiency syndromes', 'kidney after liver transplant', 'HBeAg', 'Haemophilus influenzae infections', '|Intellectual Deficiency', 'bleeding disorders.|Patients', 'Expanded Disability Status Scale', 'Organizational Credits Type a and b', 'sync', 'pathology of the maxillofacial region (benign', 'Viremia', 'basal-cell carcinoma of the skin', 'risk', 'Reactive Airway Disease', 'vasculitis infectious diseases', 'active COVID-19 infection', 'Unspecified intestinal', 'deep/medium-deep chemical peels', 'face mask materials|Active inflammation', 'ovarian cancer|Capable of understanding written', 'multiple stones', 'hyper-thyroidism', 'suicidal ideation', ""Graves' disease"", 'completed.|Active Malignancy', 'Vestibular Schwannoma', '||Bipolar', 'gynecological malignancy', 'Inflammatory Bowel Disease Unclassified', 'Local conditions contraindicating CIRT', 'breast-feeding|More than 5 days of tuberculosis treatment', 'chronic pain|Uncooperative patients|Neurological deficit', 'kidney injury', 'autoimmune diseases|Diagnosis', 'chronic illness|runny nose', ""feeling of instability'"", 'electrical devices|Seizure disorders', 'motion impairment', 'years|Tracheal tube diameter of 5.0 mm', 'oncoplastic', 'internal', 'P03', 'liver function impairment', 'chronic cancer-related', 'significant disorder', 'nursing woman.|Participation', 'isolated MYC', 'spinal cord pathologies', 'Cohort 1(Aortic stenosis):||Male', 'moles', 'cancer-related', 'third and/or fourth dose considered as booster', 'limb pain', 'other reasons|Chromosome karyotype analysis', 'Iatrogenic Esophageal Perforation', 'tissue expander', 'diseases of the cardiovascular system', 'bleeding gastric ulcer', 'structural heart disease|Possible', 'Histoplasma', 'Involvement of axilla', 'clinical leads).||', 'interpret pain', 'vessel tortuosity', 'HIV disclosure', 'communication disorders|Patients with alcohol', 'MRD positivity', 'deep tendon reflexes', 'priapism', 'reproductive age|Seeking conception|Diagnosis of a septate', 'Limb fractures', 'Placenta previa', 'lumbar spine surgery', 'systemic immune activation drugs', 'extremity problems', 'Pulmonary Hypertension', 'Wifi', 'clinical symptoms', 'traumatic head injuries', 'nerve damage.|Anyone', 'Thought', 'American Pathologists (CAP)', 'neurological disorders|Neuroleptic treatment', 'positive);|Active infections', 'thrombotic thrombocytopenic purpura', 'hypercoagulable conditions', 'acetabular fracture', 'urinary tract infection.|Severe immune deficiency', 'bilateral pleural effusion', 'controlled eye inflammation', 'maxillary incisors', 'cerebral ischemia)|Patients', 'intracranial atherosclerosis', 'euthymic', 'h).|Weight Stable', 'extraintestinal muscle strength', 'asphyxia', 'Injury', 'criteria of the international classification of ICSD-3|Restless legs syndrome', 'thrombolytic therapy;|Thrombolytic therapy', 'intestinal wall', 'systemic sclerosis', 'skeletal deformities', 'B|be immunosuppressed (', 'cryo-lipolysis', 'intermediate risk disease', 'mental instability', 'restrictive lung disease)|Clinically unstable', 'drinking alcohol', 'older|Symptomatic angina', 'neurodegenerative diseases', 'ventricular arrhythmia', 'non accessible lesions', 'sleep difﬁculties', 'cancerous meningitis.|Pleural effusion', 'symptoms stabilize', 'distress syndrome ECMO VA', 'diagnostic criteria referring to the 2022', 'abscess', 'learning challenges.|unable', 'acute psychiatric disorder', 'fetal harm', 'native coronary artery', 'cardiac surgery.|Contraindication', 'drug use|Students', 'posterior wall isolation)|Left ventricular ejection fraction', 'alpha-1 antitrypsin deficiency', 'Combined Immunodeficiency', 'manageable hypothyroidism', 'congenital epilepsies.|Presence of any', 'Archival', 'sedentary lifestyle', 'acute illnesses.|Normal', 'Individual intolerance', 'caring', 'neoplasms', 'allergic disease|Diagnosis', 'coal tar', 'compliant', 'days|Monitoring', 'consent;||Therapeutic response rating', 'MMSE', 'radiological documentation|Glioblastoma', ""Hodgkin's"", 'primary LSG||', 'leg length discrepancy', 'laboratory abnormality', 'corneal scar', 'contralateral diaphragmatic paralysis', 'hay fever', 'leukemic infiltration', 'primary hyperaldosteronism', 'spinal cord lesions;|Unclear', 'poly-axial correction', 'Niemman pick', 'residual alopecia', 'remain stable disease', 'multifocal soft contact lenses', 'events judged by the Investigator', 'AGHD', 'inflammatory disease||For', 'hepatic insufficiency.|Non-proficiency', 'vasovagal nature', 'schistocytes|Severe hypertension', 'genetic factors', 'neurological functioning|Any health', 'acute ischemic cerebral infarction', 'Sternal anomalies', 'dependency', 'cutaneous disorders', 'atherosclerotic heart disease', 'non-reproductive age', 'HBeAg seroconversion', 'criteria|Neoplastic disease', 'cornea', 'retinal break', 'symptoms of rhinitis triggered', 'thoracic perfusion', 'readily accessible', 'complete occlusion', 'consciousness disorder', 'endometrial serous carcinoma', 'incompetence', 'HIV detectable viral load', 'degenerative disorders|youth', 'inflammatory diseases of the face', 'punctal cautery.|Ocular injury', 'acute myocardial ischemia', 'coronary revascularisation', 'hepatopulmonary syndrome|Retransplantation', 'as:||Hematological functions', 'clinically significant.|Uncontrolled hypertension', 'mixed bilateral hearing loss|wearing a hearing aid', 'Beverage Addiction alcohol', 'G12V', 'laboratory abnormality including:||Absolute WBC count', 'auditory impairment|Cognitive impairment', 'Septic Shock.||In', 'high-density lipoprotein', 'Active infection', 'chest wound', 'chest drainage', 'Liver stiffness measurement (LSM)', 'discoid resection,|Patient', 'risk disease', 'extrahepatic oligometastasis', 'good oral health', 'ligamentous injury', 'clotting', 'metastases treated', 'breast ductal carcinoma in situ', 'recessive inheritance patterns', 'epithelioid sarcoma', 'liver involvement', 'vascular impairment of', 'COPD)|Pregnancy.|Contraindications', 'non-digital AWV', '-glycemia', 'traditional medicines', 'psychological instability', 'home|Executive deficits', 'bisexual|Be HIV', 'neurological deficit', 'chronic heart failure', 'periodontal health', 'oesophageal cancer', 'bilateral neck irradiation|written', 'Occluder dislocation', 'Carcinoma in situ of the cervix', 'TMDM myalgia', 'pelvic kidney', 'pleomorphic rhabdomyosarcoma', 'mental disorders', 'glaucoma|Central retinal artery occlusion', 'overactive bladder alone|Previous', 'geographic tongue', 'combined injuries', 'Android mobile device', 'Visual impairment||-', 'thromboangiitis obliterans', 'absolute contraindications', 'Physically disabled|Smoke', 'Child Welfare Services in the state', 'acute thrombosis', 'heat sensitivity disorders.|Presence of fever', 'psychiatric diseases|Pregnancy', 'Cataract', 'post traumatic arthritis', ""Parkinson's Disease.|The"", 'bone pain', 'cognitively impaired', 'medical issues', 'non-autoimmune condition', 'skeletally mature adolescents', 'squamous epithelial carcinomas', 'investigator|Serious adverse reaction', 'primary brain or base of skull tumour', 'fragility fractures', 'enteropathies.|Selective IgA deficiency', 'HBsAg positivity', 'IHC 1+', 'diabetic nephropathy', 'terminal disease||Swallowing issues||Self-reported', 'extracorporeal membrane oxygenation', 'pustular psoriasis', 'diseases of the heart', 'tobacco chewing', 'NTRK inhibitor treatment;|At least one measurable lesion', 'adequate treatment|ANC', 'consumption of almonds', 'uncorrectable bleeding diathesis.|Patients', 'fact of pregnancy', 'lower extremity contractures', 'liver iron overload', 'ealthy', 'violence', 'transient brain dysfunction', 'vaginal cancer', 'Covid -19||', 'hypovolemia|Orthostatic hypotension|Hyponatremia', 'thrombotic event', 'obstructive coronary artery', 'ischemic colitis', 'alveolar lamina', 'brain natriuretic peptide', 'ulcerative colitis;|Polyposis', 'CNS tumor', 'foot ulcers', 'breast cancer|Patients', 'albinism', 'extrahepatic obstruction', 'primary cause of muscle weakness', 'calculated using', 'residual hypothyroidism', 'subtance abuse|Any disease state', 'abnormalities of laboratory tests', 'local anesthesia.||', 'Bipolar disorders', 'Progressive disease', 'ROP', 'hypertrophic cardiomyopathy1', 'milk protein may cause allergic reactions', 'tic disorder', 'aortic stenosis|use of', 'Chronic digestive disease', 'guilt cognition factor', 'IRA', 'Preterm', 'containing red', ""Fredericia's formula"", 'chronic hepatitis C infection', 'acquired hypothalamic obesity', 'childrearing potential', 'hematochezia', 'signs', 'pregnancy|Inflammatory bowel disease|Alcohol', 'classification)|Significant renal disease', 'anxiety symptoms', 'asymptomatic brain metastasis lasts', 'CF', 'hyper-hydration', 'nodal lesions', 'Postoperative distal metastasis', 'vertebral bone metastasis', 'edentulous', 'Hallucinations Questionnaire', 'Chronic pruritus', 'medial wound', 'old|Complaint of flank pain|Pain score', 'neurological disorders like dementia', 'pace-makers', 'natural course);|Women with', 'questionnaires', 'acquired brain injury||Diagnosis', 'static forehead rhytides (score', 'prolonged gastrointestinal', 'severe mental disease', 'non permeable', 'exon 19 deletion', 'passive smoking', 'spondylolisthesis', 'cardiac surgery;|Recent stroke', 'surgical site infection', 'psychological abnormalities', 'anticancer', 'selected household', 'surgical contraindications', 'lung malformations', 'prolonged QTc', 'cytogenetic', 'gastroesophageal combination adenocarcinoma', 'etc.|unstable angina pectoris', 'abuse;|Mental disorders;|Failure', 'Stevens-Johnson syndrome', 'Temporomandibular joint disorders', 'assistant', 'unknown HIV status', ""Kikuchi's disease"", 'endocrinopathy', 'IOTA benign endometrioma|bilateral', 'coagulation disorders.|Mental', 'wear.|Corneal radius', 'psychic functions', 'acquired brain injury', 'Patients:||-', 'lung infections', 'disease of the liver.|Clinically', 'intracranial tension', 'hepato-renal syndrome.|Disease', 'skin cancer).||', 'Mild Cognitive Impairment""', 'hypertensives;|Cancer or its', 'cervical pathologies', 'DCIS)/lobular carcinoma', 'dialysis treatment|Claustrophobia|Known pregnancy', 'refractory heart failure', 'cardio-metabolic abnormalities', 'multi-drug resistant HIV infection', 'oesophageal atresia', 'mitral insufficiency', 'HBsAg carriers', 'similar condition', ""Reiter's arthritis"", 'accessory pathway|Signs', 'BS1', 'major trauma', 'medically stable', 'psychotic disorder|Autism', 'chronic hemolysis', 'Rheumatoid Arthritis', 'early psychosis', 'colonoscopy)||', 'secondary disease state', 'blood system disease', 'HDV', 'lactating', 'staged cT1-4aNxM0', 'neurotrauma', 'normal cognition||', 'uncorrectable hypokalemia', 'episodic', 'Severe Illness', 'power field(HP', 'chronic physical condition', 'pneumococcal disease', 'meningeal metastasis.|Expected lifetime', 'urinary tract obstruction', 'hobbies', 'impaired sensation.|During pregnancy', 'esophageal small cell carcinoma', 'gall bladder cancer)|HER2', 'concomitant medical conditions', 'aortic cross-clamp', 'Substance Involvement Screening Test nicotine dependence score).|Be', 'transfusion-dependent).||Has', 'abnormal renal function;|Include', 'Human Immunodeficiency Virus (', 'Inability to receive', ""cozen's test"", 'Calcemia', 'bleeding symptoms', 'QT prolongation', 'and>470', 'vasculitis .|Diagnosed hepatocellular carcinoma', 'antidiabetic agents.|Patients', 'injection pain', 'exception made', 'visual field loss', 'microscopic colitis', 'chronic dermatological condition', 'congestive heart failure (CHF)', 'Undergo general anaesthsia', 'spine instability', 'age|pregnancy|typical nodules', 'self-harm', 'glycemia', 'metastasis Cancer excepted', 'therapeutic products', 'horizontal laryngectomy', 'hyperosmolar hyperglycemic state.|2', 'kidney failure', 'surgery.|Active urinary tract infection', 'inflammations', 'emotional disorders', 'trigeminal autonomic cephalgia', 'NOS', 'ventricular arrhythmia|Chronic oxygen', ""Burkitt's"", 'systemic disorders', 'NSAI treatment||', 'pain syndrome', 'Antigenemia', 'autoimmune diseases|Antibiotic premedication requirement|History', 'UNTREATED gastrointestinal disorders', 'keratinized gingiva|Intact buccal bone wall|Adequate plaque control (FMPS ≤ 25%)|Adequate bone quantity allowing', 'viral DNA+', 'peripheral neuropathies|Unable', 'punctual occlusion', 'comorbid disease|Not', 'Eldakhla General hospital', 'germline disorder', '≥72 h.||', 'blackouts|Relevant', 'hepatic cystic echinococcosis', 'infectious serum markers of HIV', 'clinical atherosclerotic disease', 'cognitive impairments;|Presence', 'non-smoking', 'administration.|Medical condition', 'heavy thrombus burden', 'Acquired Immune Deficiency Syndrome (', 'allergic reactions', 'keratinized tissue at', 'bone marrow suppression', 'place a peripheral venous access', 'prophylaxis', 'extracranial lesion', 'chronic kidney', 'ascites drainage', 'stage', 'Essential Hypertension', 'sarcomatoid HCC', 'acute kidney injury|pregnancy|Allergic', 'adverse drug reaction|age', 'nociceptive chronic pain', 'Respiratory Syndrome', 'Restricted', 'predominantly horizontal', 'sensitive EGFR alteration', 'Urine loss', 'spastic CP hemiplegia', 'musculoskeletal injuries|Any surgery', 'Astroblastoma/NM-1', 'chronic renal diseases', 'thus might', 'or|inflammatory bowel disease', 'clinical contact', 'liver conditions unsuitable', 'mental health problems', 'adjuvant ET.|Diagnosis', ""Grave's disease"", 'Thrombopenia', 'aortic regurgitation neck width', 'intracranial bleeding of', 'pharmacological conditions', 'childhood febrile', 'self-injurious behavior|Have', 'macular disease', 'hence influence deviations from standard acute care', 'present.|For AML', 'macroscopic residual disease', 'progression.||Invasive malignant disease', 'adjuvant chemotherapy).|Adequate organ', 'heart failure.|The', 'sensitive skin', 'malignant tumor;|Previous', 'intestinal barrier function', 'urinary tract infection,|The child', 'moving of residence', 'Acute ailments', 'strongly recommended.|Patients', 'Housekeeping', 'external root resorption', 'acute symptomatic pulmonary embolus|Abdominal aortic aneurysm', 'substance use disorder.|Substantial cognitive impairment.|A diagnosis', 'aortic/mitral stenosis', 'pancreatic neuroendocrine carcinoma', 'adequate glucose control.|Hypothyroidism provided', 'angioedema of the larynx', 'Venous insufficiency', 'human immunodeficiency virus (HIV) infection', '3 cancer', 'Dermatological reaction', 'disability|Sustained organ damage', 'Cerebral infarction', 'NRx Pharma', 'traumatic cataract', 'neurodegenerative movement disorders', 'type 1 NSTEMI', 'maculopathy|Active COVID-19 infection', 'drug toxicity', 'weight loss', 'Type 1 diabetes mellitus', 'refuses NGS;|Emergency surgery;|Patients', 'hepatitis B core antibody [HBc Ab', 'vertebral block', 'guardian|Not recorded', 'compulsive alcohol abuse', 'mental disorders.|The investigator', 'SLT', 'sensory impairments', 'diabetes|diabetic macular edema', 'primary sclerosing cholangitis (PSC)', 'alpha hydroxy acids', 'attributable to CLL)|Aspartate aminotransferase', 'cardiac disease', 'psychiatric illness,|No physical', 'suicidal attempts||Other protocol defined exclusion criteria could apply', 'excessive leg pain', 'Nasopharyngeal carcinoma', 'autologous oocytes;|using the Oura Ring smart device', 'arterial wounds', 'hamstring injury', 'cytokine release syndrome (CRS)', 'cardiac symptoms', 'further growth', 'AE', 'vaginal swab', 'ureteral calculi', 'abnormal breath sounds', 'latent infection', 'intranasal/inhaled steroids', 'cervical cancer|Unable', 'B-cell malignancy', 'respiratory insufficiency,|sleep', 'T1 lesions', 'collections,|participant', 'local inflammation', 'general disease', 'vitamin B12 deficiency.|Sign the informed', 'enrolled)|Symptomatic congestive heart failure', 'native Mandarin Chinese speakers||', 'Lung injury', 'dysrhythmias', 'vascular disease|Pregnancy', 'transgender men|Platelet count', 'other immune function disorders', 'simplification', 'renal function impairment', 'Macular Pathology', 'dementia.|The', 'retinal hole', 'cerebrovascular conditions', 'paresthesia', 'CAR', 'classical Hodgkin', 'gender;|Differentiated thyroid carcinoma (DTC)', 'vasculitic disease', 'weight stable', 'sialadenitis', 'febrile convulsions', 'adrenal cortex suppression', 'chemotherapy);|Clinical recurrence', 'uterine tear', 'retinal vascular alterations', 'infection;|uncontrolled diabetes', 'leptomeningeal metastasis', 'Polytrauma', 'glucose-galactose', 'Myeloid Neoplasms', 'lack of availability. GDMT', 'myocardial infarction.|Left', 'ischemia', 'cystic cavity', 'abstain from', 'coagulation factor', 'ocular lesions', 'restrictive anorexia nervosa', 'rotational flap.||For', 'hepatitis', 'discretion.|Pregnant', 'lupus discord', 'obstructive sleep', 'lactic acidosis', 'sildenafil).||Cardiac comorbidity', 'pre-dementia', 'smokers.|Patients', 'neurological disease', 'irregular thrombus', 'monkeypox', 'NCV', 'cognitive impairment -', 'irregular breathing', 'mentally handicapped person)|Poor general condition', 'full haplotype match', 'cardiac ventricular lymphoma involvement|Requirement', 'weight loss medication', 'B virus', 'herniated', 'hallucinations', 'kidney disease|Severe hypertension', 'glandular lobe', 'Micro', 'attributed', 'NSCLC.|Is', '64Cu-DOTATATE', 'hepatic impairment|Diagnosed', 'CLN2 disease', 'Bradbury-Eggleston syndrome', 'early malignancies', 'Tokyo', 'functional assessments|Acute infections', 'squamous-cell', 'morphological brain MRI', 'ms|Complete left bundle branch block', 'adoption of child away from', 'Includes', 'bone lesion', 'high-grade', 'nasal polyp', 'lung disease.|The', 'low-grade GI bacterial infection', 'malignant disease(s', 'acute lymphoblastic leukemia', 'abstain from alcohol', 'nucleic acid detection', 'abilities', 'cirrhosis|Annual risk of HCC', 'collection|Anemia', 'MRI|Drug use', 'dry cough', 'breast cancer resistance protein (BCRP)', 'breast cancer recurrence', 'soft bandage contact lens).|No', 'Visit 2.|Renal dysfunction', 'influenza virus', 'IBS symptoms', 'emotional liability|French speaking|Availability', 'hypercoagulable states', 'old|Ability to read', 'variable immunodeficiency', 'neurologic deficits|revision surgery|neuropathies', 'metastatic disease presented', 'chronic kidney disease;|Risks', 'Mental Health Disorder.|No', 'deep facial sagging', 'CF exacerbation', 'pregnancy.|Participants', 'brucea javanica oil injection/capsule', 'alveolar soft-part sarcoma', 'glaucoma drainage', 'Prilosec', 'onset of symptoms', 'drug-related pulmonary toxicity.||Significant', 'autistic spectrum disorder', 'retinal vein', 'sensory neuropathy', 'MRI contraindication.|Pregnancy', 'late preterm', 'asthma severity', 'Primary MN', 'autoimmune hemolytic', 'consumption of poppy seed-containing products', 'clinically active infection', 'previous neck RT', 'cohorts C4', 'cancer|Pregnancy', 'ACL insufficiency', 'communication disorders|Severe pregnancy complications', 'percutaneous coronary intervention|The reference diameter of the target vessel', 'developmental delays||', 'controlled hypertension', 'mixed cryoglobulinemia', 'hepatitis B', 'alcohol intake|Patients', 'rheumatoid arthritis.|Subject', 'malnutrition', 'neurodegenerative manifestations', 'instability|Presence', ""Pathria's"", 'tumor cavitation', 'septic shock|Stroke', 'intolerance to eye drops used for pupillary dilation', 'HFNEF', 'active collagenosis', 'bowel involvement', 'weeks,|Acute cerebrovascular accident,|Transfusion reaction,|Severe', 'chronic stroke', 'pain distribution', 'mitral valve heart disease', 'fallopian tube', 'syncopal episodes resulting', 'Haemodynamic instability', 'alcohol abuse/dependence', ""hypertension|Bell's palsy"", 'refrain', 'major disease', 'colon', 'reduced corneal', 'clinical practice|Other malignancy', 'cardiac arrest.||', 'non child bearing potential', 'Type 2 diabetes', 'systemic disorder', 'malignant arrythmia', 'melancholy features', 'inadequate quality', 'Lymphoproliferative disorders non immune-mediated|Lymphoproliferative disorders', 'gold fiducial markers', 'squamous cell skin carcinoma', 'injury)|Open reduction', 'Wrinkle Severity Scale', 'radio-iodine ablation', 'Ca', 'congenital illness', 'poor tolerability', 'associated myofascial pain', 'cognitive deficiency', 'diabetes mellitus|Patients', 'leptomeningeal disease', 'coronavirus infections', 'permanent visual', 'right-to-left shunt', 'demonstrable liver metastases', 'genotype', 'lower respiratory tract infection', 'chemotherapeutics', 'duodenal ulcer', 'pneumonia|Signs', 'restless leg disorder', 'chest syndrome', 'regular aerobic exercise', 'hyperosmolarity', 'lack of efficacy) trial', 'conditions that interfere with the proper conduction of the trial|Dementia', 'old|Primary DDH||', 'CRLF2 F232C', 'traumatic metal implants', 'liver resection', 'acute care', 'PET examinations|ongoing pregnancy', 'infection of the lower', 'vitiligo', 'dental loss', 'babesiosis', 'severe autonomic dysreflexia', 'foot injuries', 'stroke', 'bariatric surgery|Volunteers', 'team-patient alliance.|Life expectancy', 'glucocorticoid', 'Lymphangitic carcinomatosis', 'Bachelor', 'tumor markers', 'sevelamer carbonate', 'hemoglobinopathy', 'non-healing ischemic ulcer', 'lower extremity surgeries', 'spinal cord diffuse midline', 'postoperative infections', 'brain injury itself', 'comorbidities:||(1', 'unilateral ischemic', 'middle finger', 'opinions', 'febrile 72 hours prior to or', 'convulsive disorders', 'bladder dysfunction', 'co-existent/', 'dyslexia', 'lack of appetite', 'late miscarriage', 'communication problem|Having another neurological condition', 'kidney inflammation surgery', 'Ischemic Stroke', ""Gilbert's disease.|The"", 'amyotrophic lateral sclerosis', 'sugar-free', 'Systemic antitumor therapy', 'herpes eye infection', 'abstain from smoking', 'Acute Leukemias', 'Human Immunodeficiency virus (HIV) infection', 'liver disease.|Schizophrenia', 'infiltration', 'unmanageable toxicity', 'carotid auscultation', 'medical condition', 'Sensation', 'Airway Center', 'autoimmune diseases);|Daily smoking', 'wound healing', 'congenital cardiopulmonary deformity|The patient', 'Spinal cord injury', 'heart condition', 'detective HBV-DNA', 'irregular breathing|It is necessary to inhale', 'acute rhinosinusitis', 'injury;|Pregnant', 'epidural hemorrhage', 'older|Type 1 diabetes', 'other carcinomas', 'mental change|Patients', 'HR+ breast cancer', 'refractory to medical treatment', 'hysterectomy', 'transient disorders', 'Primipara|cesarean', 'Type 2', 'Malignancies|Cervical Radiculopathy', 'pulmonary tuberculosis infection', '4):||Considered stable', 'knee OA|pain', 'good general', 'Renal Impairment||Hemoglobin', 'dementia disorder', 'progressive neurological disorder', 'Normal Hepatic Function', 'Hypertensive Stage 2', 'lateral radiographsof', 'upper extremity fractures', 'HLA-matched donor', 'need drainage', 'rhabdomyolysis', 'super-refractory status', 'hunter syndrome', 'acute exacerbations', 'bleeding disorder', 'auditory impairment||', 'psychotic disorder;|High suicidal risk', 'physical activity|Taking', 'chronic headache/migraine|The', 'adrenal insufficiency', 'ORIF', 'alcohol abuse|language', 'chronic renal dialysis.||18', 'human immunodeficiency virus - HIV', 'hyperesthesia', 'local laboratory.|Measurable disease', 'increased risk', 'equivocal lesions', 'WHF', 'Mood Disorder Questionnaire', 'somatic disorders', 'FH-deficient renal cell carcinoma', 'breathing disorders', 'serious malnutritions', 'neurodevelopmental delay|type', 'high dependency device:||Lower', 'superficial lymph nodes', 'life-threatening illness', 'oral health', 'adverse effects', 'proprioceptive deficits', 'traumatic stress symptoms', 'associated co-morbidities|Those', 'pleurodesis', 'systemic combinational therapy', 'rare solid tumors', 'Lupus', 'Nondisabled Participants:||Health issues', 'uncorrectable hearing', 'congenital immunodeficiencies', 'giant cell', 'liver failure|Beck Depression Inventory Chinese version 2.0 score', 'Ulcerative colitis', '45,X karyotype', 'immobilization', 'liver dysfuction (', 'unavailable', 'donate bone marrow', 'inflammatory response', 'leukocytosis)|Confirmed COVID-19 infection', 'mood', 'retinal image taking.|Distressed', 'primary cardiovascular diseases', 'digital ECG', 'laryngeal edema', 'left ventricular failure', 'nonproliferative retinopathy severe', 'pacemaker implantations', 'lymphocytic leukemia', 'reversible ischemia', 'personality disorder)|history of', 'Bleeding diatheses|Uncontrolled', 'CL regularly', 'months|Pregnancy', 'old|Health workers', 'retinal holes.|Any', 'evolution.|Internal rotation ROM limited.|Positive provocation pain tests.||', 'Healthy Population:||Under', 'become', 'Bronchiolitis', 'gastric surgery|Heart diseases', 'bone metastases alone.|Progress', 'reaction', 'alcohol abuse', 'chronic minor', 'difficulty concentrating', 'complaint', 'colonoscopy.|Active colitis', 'about to undergo', 'macroscopic disease', 'facial restorations.|Tooth', 'bariatric procedures.||Presence', 'milli-international units per milliliter (mIU/mL).|Patients', 'CMML', 'druggable molecular drivers', 'Clinical Dementia Rating', 'generalized osteoporosis', 'irregular severe', 'Respiratory Infection (URI)', 'protrusions', 'depression|Inability', 'cryptorchidism', 'acute/decompensated', 'abdominal effusions|An', 'Acute Exacerbation|be', 'malignant thyroid disease', 'hematological malignancies', 'bronchopulmonary dysplasia', 'sexually abstinent.||ii', 'palpable tumors', 'maintaining sleep', 'respiratory disorders,|pathological conditions', 'lower limb function|Osteonecrosis', 'acute severe', 'Extreme mobility issues', 'conjunctival flap', 'heart disorders', 'adequate medication|Angina pectoris', 'recreational activities', 'sensitive urine pregnancy test', 'G6PD-deficient', 'cutaneous hypersensitivity', 'UHDRS', 'Menopause', 'furuncle', 'think you might', 'endocrinal', 'tuberculosis.|Active bleeding', 'alloHCT from', 'Relationship Quality Scale', 'inflammatory;|infectious', 'alcohol dependence disorder', 'health', 'sections of', 'semantic variant', 'total circulatory arrest (TCA)', 'hepatic impairment||Hepatic Impaired', 'dihydropyrimidine dehydrogenase (DPD) deficiency', 'cord prolapse', 'inflammatory bowel diseases', 'non-dialysis', 'distant metastasis;|Those', 'fenamates', 'age|Willing', 'guardian', 'stroke /embolic events still', 'completed breast cancer therapy', 'anesthetic risk', 'ancillary procedures.|Female', 'tumor pathological condition', 'ventricular shunt', 'hypermetric saccades)|Palsy', 'bipolar disorder;|Diagnosis', 'recovered from the toxicity', 'signs of loss', 'chronic medical disease', 'needing bowel resection', 'impaired communication', 'HIV', 'clinical gross dermatology', 'brain MRI.|Participants', 'intraventricular conduction delay', 'numbness', 'alcohol and/or', 'turns', 'abstain from sexual', 'blind-loop', 'corneal surgery|Capacity', 'non-live', 'jaw disease', 'Extracorporeal Membrane Oxygenation', 'Isocitrate dehydrogenase', 'musculoskeletal disorder prohibits', 'Pain', 'post-vagotomy||xiv', 'Prolific Academic platform||', 'hematologic malignancies', 'comorbid illnesses', 'kidney disease.|Patient', 'Screening.|Anemia', 'GLP-1 RA', 'GI condition', 'photodamage of', 'heart condition.||Applicable', '¹⁴C-urea breath test', 'obstructive pulmonary diseases', 'reflex changes', 'crohns disease', 'fibrosarcoma', 'Deformations', 'cognitive measure of attention', 'natural teeth', 'infection....', 'Diabetes of the Young (MODY)', 'acute injury', 'vaginal douching', 'FLT3 mutations|Uncontrolled bacterial', 'Wounds', 'inclusive.|Negative', 'antepartum hemorrhage', 'generalized joint diseases', 'Syndrome', 'singleton birth,|no pre-existing', 'cyst', 'physical comorbidities', 'acute radicular LBP', 'thrombus burden lesions', 'substance abuse disorders', 'pain treatments', 'familial lipomatosis', 'Cervical spondylotic radiculopathy.|Cervical kyphosis', 'progressive neurological disease', 'bleeding diatheses.|Active infection', 'in situ squamous cell carcinoma', 'ocular inflammatory diseases', 'deep pits', 'although short-acting sedatives', 'inhibits ovulation', 'M. Djamil', 'M1 prostate cancer', 'migraine attacks|Willingness', 'sexual orientations', 'steroid inhalers OK', 'documenting systolic dysfunction', 'Ruminative Response Scale (RRS) score', 'others:||malignant disease', 'and||Lack of proficiency in English', 'liver insufficiency', 'lower extremities', 'any eye diseases', 'non-orthopedic', 'bilateral sensorineural hearing loss', 'DES implantation.|Known', 'donate blood', 'spondylitis', 'pMMR)/Microsatellite Stable (MSS) subtype', 'unresectable.|Measurable disease', 'meningitis symptoms', 'abnormal cardiovascular system', 'methionyl-transfer RNA', 'attempted suicide', 'faint', '||healthy', 'hereditary hepatic diseases', 'neurosurgery societies', 'dexterity issues.|Unable', 'substance use would also interfere with the effects of the intervention.|history of', 'Neoplasia', 'severe immune system-related diseases', 'hepatic laboratory abnormalities', 'thyroid Hyperfunction', 'biochemical indicators', 'autosomal-dominant hypocalcemia', 'Suicidal ideation', 'core drilling', 'good dental state', 'muscular diseases', 'thoracic deformities', 'idiopathic bradycardia', 'urea cycle enzyme defect', 'non-ischemic dilated cardiomyopathy', 'cardiac tamponade', 'ipsilateral stenoses', 'propofol.||No known allergy', 'mustache;|Pregnancy', 'Moderna', 'anticipates', 'systemic antibacterial', 'Former smokers', 'Toulouse', 'sick-leave', 'thrombosis/embolism', 'hepatic functions', 'W2', 'Comorbid illnesses', 'saxenda).|Anemia', 'fruit powder', 'autoimmune disease.|Other immunocompromising condition', 'reduced EF.|Has', 'malignant central nervous system diseases', 'in-situ bladder cancer', 'syndrome|Congenital pneumonia', 'nasopharyngeal cancers', 'Amyloidosis', 'psychological disorders.||', 'conscious level.|Pregnancy', 'progressive lymphadenopathy|Progressive lymphocytosis', 'genitourinary diseases', 'substantial disrepair', 'metastases to liver;|Serum total bilirubin (TBIL)', 'CKD-EPI formula.|Serum', 'atrial septal defect', 'sleep phase syndrome', 'emphysema', 'human papilloma virus', 'hepatic tumors', '10 sec.|Glaucoma', 'good general health|Selected teeth should', 'Singleton pregnancies.||Cephalic presentation', 'nicotine abuse', 'ankle fracture|Ankle injury', 'somatic symptoms', 'end-stage renal disease)|Attended a', 'rheumatic/autoimmune diseases', 'Nondiabetic', 'normal activities', 'Bells palsy', 'abstain from postoperative smoking|If a subject does not receive', 'end stage kidney disease|Moribund', 'thoracic kyphotic deformity', 'lymphoma)|irritable bowel', 'opacities', 'pulmonary disease;|Major surgery', 'infectious pneumonia', 'persistent diarrhea', 'G2', 'substantive medication|Alcohol', 'vital sign abnormalities', 'Waldenström Macroglobulinemia', 'Gait', 'depression symptoms', 'postcentral gyri', 'glucocorticoid dosage', 'juvenile idiopathic scoliosis', 'physically unable to yoga', 'chronic psychiatric disorder', 'archival tissue', 'aspiration', 'Obsessive Compulsive Disorder', 'plaque psoriasis', 'undesirable reactions', 'important disease', 'CNS pathology', 'tinnitus|Objective tinnitus|Known', 'mild head injury', 'childhood asthma/', 'etc.;|Asplenia', 'nephropathy,|Elevated serum creatinine level', 'previous malignancy', 'diabetic neuropathy).||4', 'malabsorption', 'Chronic headaches', 'vasovagal-related', 'mucosal head', 'endotracheal intubation|Age', 'Although USPSTF', 'T1 carcinomas', 'muscular involvement', 'solid organ transplantation|Female participants', 'drug dependency', 'calcitonin.|Patients', 'recurrence-free survival', 'electric scooter', 'chronic cough|Use of the following', 'mass lesions', 'mentally sub-normal', 'pleural effusion', 'SAMU', 'lateral patellofemoral instability|TT-TG', 'antifungal azoles', 'Contaminated cell cultures', 'comprehension disorders', 'severe dysplasia', 'abstain from intensive muscular effort,|Inability', 'non-atrophic gastritis', 'malignant tumors|before', 'horseradish', 'involuntary weight loss', 'ventilatory support', 'abdominal abscess', 'antiandrogens', 'E-Stimulation', 'autoimmune vasculitis', 'cerebrovascular dysfunction', 'intractable', 'menopause|Inability', 'dermoid cyst', 'countable motor seizures', 'drainage procedures.|Known', 'collagen diseases', 'GI disorders', 'mild COVID-19 disease', 'reproductively capable', 'Inflammation', 'skin tone', 'endometrioid', 'Coronavirus', 'Primary hypothyroidism', 'Southern Sweden', 'focal neurological signs.|Presence', 'eye protrusion', 'herpetic keratitis|Human Leukocyte Antigen (HLA) typed allograft|Pregnancy', 'uncorrectable abnormal coagulation', 'excessive facial asymmetry', 'CNS involvement', 'atypical femoral fractures (', 'introduction.|Anatomic abnormality', 'expert radiologist).||', 'deemed unsuitable for inclusion', 'judged by the investigator to be unsuitable for participation in this study', 'Unfavorable candidacy', 'brachial plexus injury', 'alternative communication (AAC)', 'GLP-1RA', 'alcoholic cirrhosis', 'pre-gestational diabetes|Sickle cell disease|Major fetal', 'hypoxic ischemic encephalopathy', 'agenesis', 'record', 'traumatic pathology', 'normal renal function||Individually matched', 'suicidal ideation/behavior', 'choroidal neovascularization', 'ocular abnormalities', 'primary tumor recurrence', 'autoimmune disease|Complication of pulmonary fibrosis', 'hematochromatosis', 'myocardial enzymes', 'non-COPD', 'primary renal disease.|Evidence', 'actively being', 'months|Excessive alcohol consumption', 'increased intraocular pressure', 'HIV antibody', 'gross cognitive impairment', 'diabetes.|Pregnant', 'hypernatremia', 'skin cancers', 'Ankylosing Spondylitis (AS can', 'superficial bladder carcinoma', 'PTPN2 deletion described', 'refusal|Allergy', 'peripheral olfactory tract involvement', 'translations', 'viruses', 'preclude bone marrow', 'Credentialed clinicians', 'geographical condition', 'hyalinosis', 'Uncontrolled anxiety', 'hours|Shock', 'lymphoma|follicular lymphoma', 'gonorrhoea', 'QRS complex tachycardia', 'interstitial cystitis|Bladder Pain', 'abortions', 'CPUP Sweden', 'psychiatric complications', 'drug-induced fibrosis', 'serviceable vision', 'meningeal metastasis.|Gastrointestinal dysfunction', 'Anaplastic Lymphoma Kinase status.|Adequate pulmonary function||', 'carotid stenosis', 'rigidity', 'acute myeloid leukemia|Participant', 'neuropathic pain medication.|Pregnancy', 'organ support', 'COH', 'systemic reaction', 'ileal conduits', 'Ineligible renal artery anatomy', 'end-stage renal disease|Standard peritoneal balance test shows', 'ischemic attack', 'cardiac pacemaker;|14.3', 'Skin co-morbidity', 'spastic diplegic CP', 'Morrisania', 'cutaneous DLBCL leg', 'Womens', 'blackberries', 'colony stimulating factor', 'varicose ulcer', 'chemotherapy)|Normal karyotype', 'Hyperthyroidism', 'chronic obstructive pulmonary disease|Left heart failure', 'STEC', 'facial nerve', 'bone metabolism alterations', 'singleton pregnancy', 'neurological tests;|neurological', 'intact ovaries', 'neurotransidal);||Featured pulmonary fibrosis', 'esophageal variceal bleeding', 'etoposide|Complete Response', 'cancer immunotherapy', 'motivation.|having bruxism', 'self-harming', 'nonmalignant chronic musculoskeletal pain', 'singleton fetus', 'INSP', 'hyponatraemia', 'inflammatory disease', 'permitted.||Female', 'focal liver lesions||', 'calculated from 3 ECGs', 'comorbid rheumatic disease', 'mixed etiology', 'congenital defect syndrome', 'painful swallowing', 'mentally handicapped.|Patients', 'vasomotor symptoms', 'urine chemistries', 'psychological pathology|Do', 'features|Type 1 diabetes', 'brain metastases|Additional malignancy', '50 mmHg', 'Preterm birth|Diagnosis', 'peptic ulcer bleeding', 'additional risk factor for coronary artery disease|Presence of microvascular disease', 'transrectal', 'inconvenient conditions', 'soft tissue sarcoma of the trunk or extremities', 'Mindful Courage effectively|BMI', 'renal insufficiencies', 'defecations', 'procedures|MDS', 'main organs', ""Felty's syndrome"", 'Chronic Illness Therapy (FACIT) Cough item', 'SAD', 'OR|Refractory disease', 'HADS', 'Recovery Center', 'light sensitivity', 'unstable coronary disease', 'systematic diseases|Disorders compromise wound healing|Bisphosphonate medications|Patients', 'Siewert type II', 'RNA sequencing', 'similar syndrome', 'periodic breathing', 'Angioimmunoblastic T-cell lymphoma', 'Nasal Polyps', 'respiratory failure|Pregnant woman|Patients', 'lower urinary tract symptoms:||Inclusion', 'old|Pregnant', 'urea cycle', 'HGG', 'heart failure|Rheumatoid arthritis', 'posterior mandible', 'Central America', 'Acute myeloid leukemia', 'Porphyria', 'primary care parents', ""Netherton's syndrome"", 'hemorrhages', '≤8', 'pituitary insufficiency', 'sensory disability', 'nanocarrier eluting stent', 'infection.|Evidence', 'left colon resection surgery', 'perineal tear', 'prothrombin complex concentrate', 'HIV seropositive status', 'CD20+', 'complete intestinal obstruction', 'vegetarian.|Those', 'carcinoma in situ cervices', 'venous thrombosis.||Plans', 'herniated disc', 'non-responsive', 'chronic sinusitis', 'PTSD;|Low score', 'dynamic forehead rhytides', 'Haematoma', 'bacterial infection', 'skin test', 'systemic immunosuppressants', 'herpes zoster meningitis', 'healthy controls):||-', 'binocular vision abnormalities', 'traumatic brain injury|Pregnant|Current smoker', 'type 1 neurofibromatosis', 'terminal cancer', 'psychiatric problems', 'drinking episode', 'congenital deformity of the spine', 'alterations in pain sensation', 'IV;|Refractory hypertension', 'non-restorable teeth', 'macroscopic residual lesions', 'bladder neck', 'congenital QT syndrome', 'exacerbations', 'untreatable claustrophobia|Implanted', 'menstrual cramps', 'individual', 'optimally debulked(a residual tumor', 'PLHIV', '- thyroid cancer', 'obtained||The', 'protein macromolecules', 'Systemic Lupus Erythematosus', 'myocardial revascularization', 'mental health symptoms.||', 'chronic liver disease||3-patients', 'bladder epithelial tumor', 'Neuropathy', 'Medical conditions||Only', 'Parents', 'obstructed nasal', 'Parkinson disease)|Dementia', 'ipsilateral occlusions', 'Ductal carcinoma in situ of breast);|The', 'functions of heart', 'secondary suicide attempt', 'lower extremity sequelae', 'pelvis|PROSTATE CANCER', 'insensitivity', 'spinal deformity|BMI', 'liver damage drugs', 'type of intervention', 'hemodynamic failure', 'organic brain stem injury', 'acute papillary muscle', 'modified T cell therapy.|Active', 'psychomotor retardation', 'h|Chronic pancreatitis', 'situations|Pregnant', 'CYP4A6', 'striae atrophicae', 'disorders|Willingness', 'Pahang.|Age between 20 - 65 years', 'bone diseases', 'chronic condition making', '1- Contraindications', 'myopathy', 'complaint of neck pain', 'unstabe angina', 'Diabetes type', 'Hepatopulmonary syndrome', 'non-diabetic renal diseases', 'Diabetic Nephropathy', 'severely overweight', 'substance induced', 'distant organ metastases', 'coagulation profiles', 'criteria for alopecia areata', 'sickle cell disease', 'EB-101 treatment;|The', 'cutaneous warts', 'renal disease', 'BT shunt', 'chronic migraines', 'hypocortisolism', 'cerebral 18F-FDOPA PET examination', 'HBV DNA detectable', 'drug pneumonia', 'breathing difficulty', 'F50.0 Anorexia nervosa', 'hyperlaxity', 'idiopathic pulmonary fibrosis.|Respiratory infection', 'major bleeding event', 'agents.|Other malignancy', 'ADNM-20', 'hypo', 'standardize mechanism', 'hypertriglyceridemia', 'cardiac arhythmia', 'INSTI', 'QTcF', 'acute Wilson disease', 'distant metastases|Adequate contraception', 'heart arrythmia', 'fibrosis;|Interstitial lung diseases', 'medical disease', 'depression|Allergic constitution', 'aneurysms', 'metastatic biliary tract cancer', 'renal disease|The', 'metabolic diseases.|Athletes', 'immunomodulatory dugs;|persons', 'inadequate muscle mass', 'TAVI', 'hemodynamic unstable arrhythmia', 'renal disease;|Known titanium', 'noninfectious pneumonitis', 'erosive reflux disease', 'practice walking|Skin lesions', 'delusional disorder).|Self-reported', 'absorption of the study', 'deep chemical peeling', 'cancer risk syndromes.||Inclusion', 'foot pain', 'growth hormones', 'T2b tumor', 'nonresectable', 'syphilis', 'excessive risk', 'unable to tolerate', 'gross psychosis', 'immune deficiency syndrome', 'major gastrointestinal surgery', 'medical diseases', 'nodal marginal zone lymphoma', 'irreducible arrhythmia', 'adverse drug reaction', 'fluorescence in situ hybridization (FISH)', 'unresectable hepatocellular carcinoma||', 'spine fracture|Current condition', 'atypical endometrial cells', 'immunodeficiency.||7', 'OMNI', 'arteriosclerosis', 'valgus.|Alterations of the cognitive state', 'drugs);|Active hepatitis', 'acute respiratory distress syndrome', 'abnormal topography', 'mimic|Cerebral embolism', 'chronic cough|joint', 'facial tissue augmentation therapy', 'metastases|epidermal growth factor receptor (', 'sarcopenic obesity', 'type glioma', 'episcleritis', 'grade glioma', 'study.|Intentional naps', 'Monoclonal gammopathy', 'screening.||-', 'digital video oculography', 'archival tissue from biopsy', 'curators|Psychological disorder', 'non-urgent care visit', 'drugs.|Patients Unable', 'obstructive sleep apnea syndrome|""Class', 'eria:||Male', 'lupus nephritis)|Primary', 'patients|chronic skin diseases', 'another HP form', 'cerebrovascular accident)|prolonged compromised immunity', 'UBM', 'Heart failure', 'esophageal squamous cell carcinoma', 'bacteriuria', 'ocular surgery|refusal', 'disseminated intravascular coagulation)|Thrombocytopenic purpura|Patients', 'Plain', 'hypodense ischaemic changes', 'solid organ transplantation.||Patient', 'generalized gingivitis', 'Cancer', 'multi-canal).|Patients', 'to.||Additional exclusions', 'varicose vein', 'Human T-cell Leukemia Virus (HTLV)', 'ischaemic heart disease', 'corneal ulcers', 'necessitates', 'period.|Pregnancy', 'inflammatory bowel disease-unclassified', 'cervical disorders', 'risk|Body mass index<30|No risk', 'myocardial injury', 'obsessive compulsive', 'recruitment)|On', '34)|Unilateral lesion', 'spinal muscular', 'LPL).|Relapsed disease', 'underlying disease status', 'immunologic abnormalities', 'GI motility', 'HFNO|Sleep apnea syndrome', 'normal transaminases', 'macular degeneration|Glaucoma|Patients', 'knee OA|Candidate', 'cerebrovascular accident|Contra-indications', 'tendon injury', 'Multiple System Atrophy', 'renal disease)|Disease', 'intravenous-inhalation anesthesia', 'radiologic finding', 'Serious diseases', 'adverse factors', 'MRI)|Weight loss', 'non-alcoholic fatty liver disease', 'carcinomatous meningitis.|Prior malignancy', 'cross-addiction', 'primary breast tumor', 'hepatitis/aspartate aminotransferase', 'gastrointestinal signs', 'stable condition', 'additional neurologic disease', 'vasculitis;|Systemic lupus', 'colorectal cancer pathologically||patients', 'megaloblastic anemia', 'QTc<450ms', 'major conditions', 'traditional remedies', 'urinary frequency', 'inflammatory autoimmune disease', 'PENTOCLO', 'iris', 'non-hematopoietic organ system', 'HIV-1', 'POEM', 'cardiac pacemaker)|pregnancy|incarceration|chronic opioid/tramadol', 'medical history.|Peripheral blood white', 'malignant bone marrow infiltration', 'e.g.||infectious disease', 'cerebrovascular accident|noncompliance', 'actionable BRAF', 'Pulmonary disorders.|Metabolic disorders', 'inattentive type', 'solid organ transplant|Patients', 'cognitive disorders|Contraindication', 'TIPS', 'vitiligo||', 'Exclusion criteria', 'Metastasic cancer', 'arthralgia', 'COVID', 'old|Chronic Tinnitus', 'secretory otitis media', 'diabetic hypertonic coma', 'AIDS-defining condition', 'candidiasis', 'HIV|Participant', 'fracture neck', 'heart disease;|Serious comorbidities', 'urinary tract,|The child', 'parenchymal lesions', 'good general health.|Not', 'parotitis', 'intraocular media opacity', 'primary peritoneal cancer;|After surgery', 'apnea-hypopnea index (AHI)', 'orthopaedic disease', 'repair|Poly-trauma status', 'eosinophilic oesophagitis|Uncontrolled', 'left heart failure', 'give consent)|Lack', 'developmental coordination disorders', 'render nasal', 'pharyngitis', 'refractory MM', 'brain tumors', 'neurological degenerative disease', 'cerebrovascular disease.|Uncontrolled diabetes', 'cardiac disease|Positive test for HIV', 'neuromyelitis optic;|Clinical evidence', 'psychiatric disease|No vision', 'leukoaraiosis', 'irreversible pulpitis', 'Lyme disease', ""Cushing's"", 'reduction,|good general health', 'oral pharyngeal', 'Healthy volunteers||Individual', 'vena cava);|Cirrhosis', 'allergic rhinitis|Nasal', 'breast feeding.|Known hypersensitivity', 'bladder disorder', 'left flank areas', 'antiparkinsonian therapy|Able', 'new visual field defect', 'Poitiers', 'HMGCR', 'chronic heart failure;|Platelet count', 'causative factors', 'Dermatomyositis', 'local health authority.|The use', 'septal aneurysm', 'zonular dialysis', 'impaired mobility', 'mature first', 'acute T lymphoblastic', 'breast cancer that:||is advanced', 'TLS+ sarcomas', 'chronic gastrointestinal disorders;|Previous', 'BMS', 'left ventricular hypertrophy', 'salivary glands diseases', 'ulcerative keratitis', 'lack of effective treatment', 'underlying oxygen dependent', 'circulatory shock', 'acute medical conditions|Informed', 'right ventricular myocardial infarction', 'malignant hepatic tumor', 'urticaria', 'Dialysis', 'lactation|Current infection', 'malignant neoplasm', 'months|Current urinary tract infection|Recent', 'obstructive left colonic cancer', 'resting left bundle branch block', 'Back Surgery Syndrome', 'left ventricular systolic dysfunction', 'older|Diagnosis', 'autoimmune disease|active', 'limb pathologies', 'Diabetics', 'non-response', 'facial fractures', 'recurrence BPPV', 'back;|Metastatic lesions', 'Incapability', 'atopic asthma', 'A)|Concomitant injuries', 'diabetes mellitus|Diabetes duration', 'chest compressions', 'intracranial hematoma', 'risk drinking||', 'basal-cell', 'chronic SCI', 'partial dihydropyrimidine dehydrogenase deficiency', 'neuromedical comorbidities', 'Hemorrhagic Stroke', 'GI disorder', 'immunosuppressant diseases|Periodontal maintenance', 'radical nephroureterectomy.|Patients', 'bone defect', 'cycles|cognitive status', 'arthritis', 'Digestive system disorder', 'gastrointestinal bleeding.|Patient', 'plexus nerve block', 'Chester', 'arrhythmia|Psychiatric', 'unresectable metastases of the primary colorectal cancer', 'gynecologic cancer', 'carotid bruits', 'mechanized pneumonia', 'thrombocytopenia syndrome||-', 'infection|Sexually transmitted diseases', 'gastric bleeding', 'premature ventricular contractions (PVCs)', 'solid organ transplant|Prior hematopoietic cell', 'gingival swelling', 'haemodynamic compromise', 'AAT', 'AV block', 'gait disorder|Patients', 'turning', 'CeD', 'primary ovarian cancer', 'lymphomatous lesion', 'main renal vessel', 'metabolic disturbance', 'transient ischemic attack.|A', 'hypoglycaemia', 'liver metastases.|Bilirubin', 'rheumatism', 'age.|Either gender|Patients', 'addiction|psychiatric issues', 'mm.||Exclusion criteria:||known allergy', 'human immunodeficiency virus (HIV) positivity', 'distant disease', 'colonic mucosal disease|On', 'aPTT', 'local inflammation|Cyst|Mucosal disease', 'first recurrence', 'intestinal obstruction;|5', 'squamous cell carcinoma in situ of the skin', 'gross residual disease', 'cough', 'floor physical therapy', 'cosmesis.|T1-T2 N0 lesions', 'ligament injury etc.|Non-ambulatory', 'exudative lymphocytic pleural effusion', 'metastatic breast cancer;|Measurable disease', 'removable partial prosthesis', 'chronic hepatitis B', 'stroke|Need', 'cm.||Prior checkpoint inhibitor therapy', 'cognitive impairment|Neurological disorders', 'suicidality', '≤200 mmHg', 'radicular back pain', 'high-grade dysplasia', 'sensitivity', 'antiviral therapy;|Uncontrolled hypertension', 'non-removable objects', 'textured expander', 'rheumatoid nodules', '.|acute illness', 'neurodevelopmental disorder', 'lower risk disease', 'infection;|chronic diseases', 'foreign bodies', 'spinal cord compression.|History', 'Exclusion Criteria', '1.Prevalence', ""Crohn's dsease"", 'variceal bleeding', 'contraindicated.|Measurable disease.||Inclusion Criteria', 'germline disorders', 'rhabdomyosarcoma', 'Stable condition', 'SDRs', 'organic cause', 'communication barrier;|Severe liver dysfunction', 'Epilepsy|Inability', 'Disease', 'chronic cystitis', 'non-heterosexual', 'chronic Obstructive Lung Disease', 'progressive|Acute coronary syndrome', 'extrahepatic metastasis;|Malignant abdominal', 'clinically recognized hernia', 'oligospermia', 'chest tube)|bloody dressings', 'history|Psychotically seizures', 'RIS', 'pulmonary edema', 'specific personality disorder', 'unstable conditions judged by the investigator.|The', 'persistent reactions', 'muscle-tendon injuries', 'recurrence of malignant tumor;|Patients', 'cardiac color ultrasound', 'hypo-/hyperthyroidism', 'BTC|A World Health Organisation', 'paradoxical bronchospasm', 'acute kidney disease', 'fetal distress|Clinical diagnosis', 'palpable distant radial', 'neurosyphilis', 'index stroke', 'etc.;|Hepatitis B virus surface antigen (HBsAg)', 'nutritional conditions', 'decreased gastrointestinal motility', 'cytopenia', 'ST elevation,|cardiogenic shock', 'post COVID-19', 'infectious cutaneous disorders', 'baseline|Psoriasis Area', 'uncontrollable diabetes mellitus|Patients', 'obstructive lymphocele.|Malnutrition.|Urosepsis', 'congenital heart', 'chronic cough', 'selective deficiency of IgA', 'vascular invasion', 'hypovolemia|Patients', 'severe immune deficiency', 'high grade dysplasia', 'rare hereditary disorders of', 'secondary AML', 'progressive neurologic dysfunction', 'moderate exacerbations', 'hereditary bleeding disorders', 'perimeningeal metastases', 'breastfeeding|mental retardation', 'olfactory dysfunction', 'chronic pelvic', 'pulmonary fibrosis.|Leptomeningeal disease', 'pronounced effects', 'CHF', 'interstitial lung disease.|Participants', 'arteriovenous bridging therapy', 'blood tumors', 'SMA', 'subscapularis tendinopathy', 'external iliac', 'urinary calculi', 'immunostimulant therapy|Known', 'cardiotoxicity', 'trouble urinating', 'in-situ disease', 'etc.)|bleeding disorder', 'active proctitis', 'Cambodian', 'active infections', 'lymphoma|Follicular lymphoma', 'noninvasive bladder cancer', 'vascular involvement', 'autoimmune disease.|Major surgical procedure', 'weight loss drugs', 'omphalocele', 'Spontaneous amenorrhea', 'adenocarcinoma of the rectum', 'metastases.|Active autoimmune disease', 'HIV-status', 'atrial fibrillation|Albumin', 'deaf', 'renal arterial vessel', 'prolonged baseline QTc interval', 'Secondary parkinsonism', 'sedation assessment|Abuse', 'occlusion', 'progressive cardiovascular pathologies', 'hereditary deficiency', 'Chronic skin conditions', 'systemic hypertension', 'cardiac problems', 'antiparasitic use', 'Learning Disorder', 'intravenous (IV) contrast', 'acute facial injuries', 'malignant tumor|Unable', 'pronounced hepatotoxic effects', 'Salmonella colitis', 'culture-proven', 'frequency', 'uncontrolled seizure', 'avoiding insomnia', 'infectious diseases|Participants', 'central venous thrombosis', 'exon 21', 'incisional hernias', 'medication.|Hepatic insufficiency resulting', 'ligamentous laxity', 'condition|Past adverse reaction', 'allergic conjunctivitis', 'spinal cord metastasis', 'criteria below:||Fever|Splenomegaly|Cytopenias', 'lactation.|Chronic bowel disease', 'intracranial lesion', 'transient ischemic attack', 'acute coronary disease', 'Tolerability', 'Russia', 'Philadelphia chromosome (Ph chromosome', 'gastrointestinal diseases.|Participants', 'command of the Dutch language|Signed', 'PCL', 'persistent abnormal', 'permanently infertile', 'herpetic blepharitis', 'clinical infection', 'parent(s)/legal guardian(s) if the patient is minor according to local regulation)', 'urinary tract infection|Pure', 'formula intolerance', 'progressive disease', 'muscle tightness', 'alcoholic liver', 'malabsorption issues', 'old|Clinical symptoms', 'hepatocellular carcinoma.||Patients', 'chronic pain medications', 'autologous BCMA CAR-T', 'congenital heart defect|Extracorporeal membrane oxygenation (ECMO', 'neovascular retinopathy', 'bariatric) surgery', 'severe streptococcal disease', 'graft|Acute liver failure|Living donor liver transplantation|Controlled donor asystolia|Treatment', 'angioneurotic edema', 'II).||Mature', 'passive dorsiflexion', 'monoclonal gammopathy', 'residents|Critically ill', 'spine fracture', 'skin problems', 'eating behavior', 'secondary glioblastoma', 'type 1', 'involvement of the trapezius', 'non-malignant organ diseases', 'dysautonomia', 'deep burns|Volunteering', 'abstain from sexual activity', 'UK brain bank criteria', 'kind|Mental impairment leading', 'lactation;|Coagulopathy', 'Stickler Syndrome', 'non-targetable lesions', 'Gallstones', 'focal shock', 'HIV-1 infection|If', 'good quality retinal', 'acute myocardial infarction.|Patients', 'behavioral reaction', 'disc hemorrhage', 'subacute bowel obstruction', 'immunologic etiology', 'ischemic heart diseases', 'Systemic sclerosis', 'infraorbital hollows', 'Psychiatric disorders', 'localized SCLC', 'brain herniation', 'lactation;|Allergy', 'Utah', 'histoplasmosis.|Pregnant', ""Tourette's Syndrome"", 'tumor hemorrhage', 'anticholinergic properties', 'aortic valvular disease', 'acute respiratory tract infections', 'physically capable of pregnancy', 'xerostomia', 'progressive pulmonary autoimmune', 'Aphasia|Pregnancy', 'anterior chamber;|Corrected visual acuity', 'diabetic foot', 'asthma inhalers', 'subretinal hemorrhage', 'right carotid artery', 'polymer particles', 'malignancy.|Patients', 'herpetic eye disease', 'neoplastic disease', 'Class 1 Black', 'chronic neck', 'complex medical conditions', 'endocrinologist|Cardiovascular diseases', 'functional hand|In overall good health', 'nocturnal hypoglycemia', 'osteomalacia', 'functional NET', 'carious lesions', 'pyloric obstruction', 'Syphilis', 'dermatopolymyositis', 'progressive neurological deficits', 'nondiabetic', 'chronic physical diseases', 'Chronic Obstructive Lung Disease', 'spine issues', 'severe hemorrhage', 'early-stage breast cancer treated', 'skin pigmentation', 'synthetic opiates', 'cerebrovascular events', 'leprosy', 'β+', 'OS', 'atrial fibrillation', 'thrombophilia', 'inflammatory rheumatic disease|Patients', 'hemorrhagic stroke|partecipants', 'pregnancy', 'congenital coagulation abnormalities', 'tachypnea', 'functional limiting arthritis|Orthopedic condition', 'cerebral contusion', 'radiological fractures', 'heart transplant;|Known allergies', 'thrombotic thrombocytopenia', 'chronic illnesses', 'infectious process', 'kidney-liver transplantation', 'unidentified', 'pacemakers.|Atrial fibrillation', 'uremic encephalopathy', 'pretreatment disease', 'years;|renal decompensation requires', 'multiple endocrine neoplasia Type 1.|Use', 'address cancer inequalities.||Paired clinicians||Clinicians', 'major hepatic dysfunction', 'vital sign measurements', 'fetal developmental anomaly', 'acute interstitial nephritis', 'idiopathic orthostatic', 'caustic gout', 'chest X-ray', 'pelvic nerve damage', 'solid organ transplant.|Use', 'Immature', 'lateral decubitus|For healthy', 'underlying etiology', 'rashes', 'idiopathic abdominal pain', 'acute infections of the genitourinary system', 'cervical carcinoma in situ', 'bilateral tubal occlusion Hysterectomy', 'pancreatic cystic tumor', 'gastroesophageal varices', 'COVID-19|Acute common cold|Influenza|Fever', 'isolated nucleoside reverse transcriptase inhibitor mutations', 'liver systems', 'Visual Behavior', 'abdominal effusion', 'structural brain lesions', 'present;|Severe infection', 'Liver function abnormalities||Transaminases', 'Oglethorpe', 'thyroiditis controlled', 'cT1a stage)|Regional lymphadenopathy', 'acute cholecystitis.|Refusal', 'MRI)|stroke', 'non-tumor vaccines', 'laboratory testing.||Male', 'discontinuity', 'hypersensitivity allergic', 'perineum', 'Mental disorder', 'HCV infections', 'chronic bacterial', 'substance-related disorders', 'PLMS', 'arteritis of the', 'clipping;|poor general condition', 'Reverse Total Shoulder Arthroplasty|Concomitant tendon transfer|Planned', 'intestinal surgery)|Subjects', 'Irritable bowel syndrome', 'hospital|Hemodynamic instability', 'Metabolic syndrome', 'old;||Mitral valve insufficiency', 'rest pain', 'associated anomalies', 'CABG+valve', 'CNS metastatic disease', 'signs of psychosis', 'non-hematopoietic malignancy', 'meconium aspiration syndrome', 'urinary bleeding', 'congenital nephropathy', 'STOP-bang', 'polycythemia/hypovolemia', 'eradication history||', 'orbital injury/fracture).|Rash', 'interstitial cystitis', 'keratinized gingiva', 'evaluable lesion', 'clear progression', 'TIA)|Pulmonary', 'weight loss diet.|Participate', 'recovering', 'uncommon tumors.|Pancreatic metastasis', 'anterior segment', 'gastric emptying', 'enzyme linked immunosorbent assay (ELISA', 'childhood asthma).|Is mentally or legally incapacitated', 'antitumor therapy;|Known', 'malignant disease；|Life', 'pancreatic adenocarcinoma|Part', 'PPV-MF', 'anterior placental localization abdominal wall of', 'degenerative arthrosis', 'Clinical expertise', 'risk-enhancing factors.|If', 'obstructive coronary artery disease||coronary angiography', 'residual lesion', ""Gilbert's disease;|Alanine"", 'induction remission', 'pack-years', 'transplant', 'keratoconjunctivitis sicca', 'average', 'acute mental disorders', 'emotional problems', 'impairment of body', 'remaining colon', 'preserved reproductive potential|Participants', 'mild periodontitis', 'prolonged smoking', 'pseudomeningitis', 'OR|transformation', 'Endocrine system disorder', 'abdominal pleural effusion', 'major cognitive impairmentInability to speak and read', 'acute brain infarction', 'radiation pneumonia', 'expert', 'contraindicate contact lens', 'hospitalisation', 'baseline condition', 'hypoglycemic seizure', 'normal hepatic function:||Healthy', 'parathyroid hormone', 'deficiency disorders', 'disorders|Mental retardation|Substance abuse', 'total sensory altering disorders', 'difference', 'group:||Diabetes mellitus', 'meniscus injury', 'exception of fatty liver', 'stuffy nose', 'nutritional deficiencies- B12', 'exit criteria.||Exclusion Criteria - Adults:||Unable', 'dystrophy|Myasthenia gravis|Periodic', 'vaginal prolapse', 'congestive heart failure,|The', 'agoraphobia', 'maternal haemorrhage/trauma', 'squamous epithelial cell skin cancer).|Patients', 'factors,|neurological illness', 'acute mental health difficulties|sexual assault', 'raspberries', 'monotherapy cycles', 'posttraumatic symptoms', 'CAR T cell infusion only', 'Aortic Ulcers', 'trial;|Poor health condition', 'non-biological', '6.|Treatment of lesions', 'PMS', 'tumor-related', 'submucosal)|Cancer', 'psychological disorders.||Known sensitivity', 'BMI', 'metabolic disorders.||Participants', 'Type 1 diabetes;|The', 'Traditional Medicare', 'withdrawal', 'localized squamous cell carcinoma of the skin', 'disease|Orthopedic injuries', 'cardiomyopathy', 'manic or depressive', 'pathologic jaundice', 'Nice|social security affiliate|systemically healthy|healthy', 'CAKUT', 'thyroid preparations', 'not tolerate standard agents', 'prolonged QT-interval syndrome', 'lipid metabolism disorders', 'Chronic Coronary Syndrome', 'asthenia', 'hydrosalpinx', 'active disease', 'ethylenediaminetetraacetic acid clearance', 'HBV infection', 'Hashimoto syndrome', 'chronic pain syndromes|Chronic opioid', 'multiple fractures', 'retina', 'primary carcinoma', 'blindness).|Musculoskeletal disorders', 'arthritis diseases', 'primary lung disease', 'orthopaedic', 'allergic constitution;|Study', 'stroke;|history of congestive heart failure;|preoperative NT-proBNP', 'refuses blood', 'significantly impaired cognition.|Children', 'lower incisors|Patients', 'prior in situ cancer treated', 'supraventricular tachycardia', 'osteogenesis', 'risk of disease', 'KIT exon 9 mutation', 'ischemic changes', 'Urinary Tract Infection', 'intravesical BCG', 'P.E. £', 'etc.;|Active infections', 'chronic hypertension', 'chronic renal failure;|Dysuria', 'syndrome;|Huge', '-menopausal', 'less pain', 'subcutaneous emphysema;|Hemodynamic instability', 'vestibulodynia', 'non-candidate', 'cardiovascular incident', 'anal pain', '1st degree', 'non-reducible joint limitations', 'accident stroke', 'episodes of urinary incontinence', 'judged inappropriate by the trial host', 'renal impact|Major medical', 'emotional disorder', ""parkinson's"", 'significant stenosis', 'mild obstructive sleep apnea', 'anaphylaxis|Pregnant', 'Mood Disorder Questionnaire (MDQ)', 'attrition', 'chronic nausea', 'early postural instability', 'acute effects', 'cardiofaciocutaneous syndrome', 'iver cirrhosis', 'orogastric tube|Apgar', 'HBVc+', 'HIV antibody positive', 'polycythemia vera', 'paraganglioma', 'requires', 'compromised response', 'keratoacanthoma', 'infiltrative diseases', 'Hp infection', 'drug dependence', 'thoracic injury', 'contraceptive skin patch', 'screening|Previous cornea', 'radial extracorporeal shock', 'renal-artery', 'condomless vaginal', 'disease condition', 'orthodontic treatment;|Children', 'spinal lesions', 'renal vein', 'active;|Active infection', 'immune system pathologies', 'medical abnormalities', 'acute mycardial infarction (AMI)', 'difficulty understanding the patient)|Patient', 'stable;|Active tuberculosis', 'autoimmune diseases', 'Obstructive sleep apnea', 'C.|HIV-infected', 'days).|One cycle', 'mastectomy|Unilateral lymphedema|Arm circumference', 'abnormal physical or', 'rheumatologic disease', 'dermatological diseases', 'chronic inflammation', 'UCSF', 'uncontrollable', 'hepatic encephalopathy', 'pancreatic pathology', 'neck stiffness|Headache', 'abdominal prostate', 'food allergy', 'epilepsy|Epileptogenic medications|Chronic', 'Psychotic', 'Kaposi', 'infection.|Uncontrolled hypertension', 'Candida albicans', 'non-ischemic cardiomyopathy|Major surgery', 't(15;17)(q22;q12);PML-RARA).|Diagnosed', 'harm to others', 'liver metastases|Negative pregnancy test||', 'mass excision biopsies', 'thyroid replacement', 'corona virus disease', 'neuro-degenerative diseases', 'cancer urinary bladder', 'skin redundancy', 'HbA1c>7.5|Neuromuscular pathology', 'functions', 'movement disorders', 'SAH', 'renal denervation procedure', 'ovarian cystoadenofibroma', 'defects', 'local basal cell', 'lichen simplex chronicus of vitiligo', 'abnormal result of physical examination', 'upper gastrointestinal', 'stromal loss', 'multiple endocrine neoplasia', 'isolated skin', 'Soft tissue damage', 'peritoneal metastasis', 'neurologic level', 'intracardiac mass', 'monogenic genetic diseases', 'tumor tissue', 'febrile seizure;|Known', 'heart rate disorder', 'chorioretinal atrophy', 'human immunodeficiency virus', 'involvement of sigmoid colon', 'transverse maxillary deficiency', 'wheelchair', 'SINEMA).||And', 'underlying lymphoma', 'dome-type morcellation||', 'multiple allergies', 'serous cavity effusion', 'schizophrenic spectrum disorder', 'neonatal risk conditions', 'child-fathering potential', 'monoclonal proteinosis', 'propulsive', 'active malignancy', 'pulmonary hypertension;|Cerebrovascular accident occurred', 'lytic lesions', 'HER2 protein', 'lateral neck dissection', 'irrigant', 'claustrophobia', 'feeling trauma-related guilt', 'Astra Zeneca', 'respiratory disease|Dysrhythmic heart disease|Beta', 'cyanotic', 'serious eye disease', 'left bundle branch block', 'hyperkalaemia', 'established COVID-19 disease', 'host-versus-graft (HVG)', 'persistent atrial fibrillation', 'relapse', 'Screening.|Adequate liver function', 'malignant arrhythmias', 'females),cardiac arrhythmia', 'Acute infection', 'Herpes simplex virus', 'Hepatitis carrier', 'noise', 'resolution', 'polyarticular rheumatic disease', 'Malignant neoplastic wound', 'cerebrovascular event.|PD peritonitis', 'left atrial enlargement', ""closest relative's informed consent"", 'breast-feeding women|Subject treated', 'flexibility', 'discrete pulmonary nodules', 'healthy volunteers|Adults', 'bone deformity|Previous infection', 'musculoskeletal symptoms', 'organic brain disorder', 'generalized convulsive seizures', 'galactosemia|Probiotic allergies', 'conditions|Active suicidal ideation', 'myeloid leukemia', 'worse performance status', 'intercurrent disease|Hematuria', 'TAVI complication', 'acute respiratory syndrome corona virus 2', 'irinotecan allergic reactions', 'PLB1004', 'growth factors.|Females', 'chemical gastritis', 'treatment', 'inflammation states', 'erythropoiesis', 'LANPC', 'otitis externa', 'depression', 'GI bleeding', 'tetracyclines).|Uncontrolled hypertension', 'acute kidney injury ""AKI"" risk', 'tuberculosis (TB', 'large bowel diverticulitis', 'indemnities for clinical trial higher or equal to 4500 Euros.||After', 'prenatal infection', ""Wegener's granulomatosis"", 'passive smoker||', 'multifocal esophageal cancer', 'complex congenital heart disease|A fetus', 'nasal obstruction', 'inguinal hernia|Patients', 'prognosis|Psychiatric disorders', 'nerve excision', 'acute pulmonary insufficiency', 'observable motor seizure', 'Cerebrospinal fluid pressure', 'HCVAb positive', 'cognitive dysfunction|progressive', 'Chronic Kidney Disease', 'coccydynia', 'poor ovarian responder', 'neurologic / seizure', 'primary bone tumors', 'mental condition', 'Psoriasis', 'BK viremia', 'bleeding from the genital tract', 'unit of alcohol', ""intestinal Behçet's disease"", 'secondary conditions', 'detectable autoantibodies', 'extensive coagulation necrosis', 'expected recurrence', 'vasovagal reactions', 'TKI', 'levels of motion sickness', 'Clinical Modification [ICD-9-CM', 'congenital cardiac', 'In bladder cancer', 'conjunctivitis', 'children|First dental', 'fibromuscular dysplasia', 'numeric pain', 'nitroimidazoles', 'white kidney beans.|Subjects BMI', 'endodontic treatment|No pain', 'primary biliary cirrhosis', 'asymptomatic Hepatitis C virus', 'hepatic impairment', 'congestive failure', 'traffic.|Criteria', 'Hungarian', 'small molecule', 'lichenifications', 'Symptomatic lesions', 'systemic treatment.|Participant', 'mixed cholangiocellular carcinoma|Massive tumor progression', 'progressive physical illness', 'cholangiography', 'dementia|Language barrier', 'epilepsy|Contraindications', 'HBV after infection', 'non-smoker', 'alcohol abuse|Participation', 'disability application process.|Natural therapies', 'transient ischaemic attack [TIA', 'esophageal neoplastic', 'basal cell skin lesion', 'retinal degenerative', 'hemorrhagic gastric ulcer', 'localized prostate cancer.|Urine bacterial culture', 'HIV.||In Botswana', 'upper GI bleeding', 'neuropsychiatric disorders,|gastrointestinal tract eosinophilic disorders,|use', 'months.|Prior cystectomy', 'prolonged QTcF', 'HER2-negative status', 'habitually worn', 'fetus', '|Irregular menstruation,|Not', 'self-injurious behavior.|Epilepsy', 'large blood vessels', 'intraventricular obstructive gradient', 'Guillain-Barre syndrome (', 'skin type I-', 'inflammatory breast cancer.|Patients', 'visible abdominal distention', 'abnormal bleeding|Predictable risk of difficult intubation|Body mass index', 'therapies)|Contra-indications', 'prostatitis|Macroscopic hematuria', 'mental impairment', 'peripheral neurotoxicity', 'tuberculous', 'metastatic prostate cancer||', 'Resistant', 'HER2-mutated', 'classic', 'non-cancerous pain', 'Intractable nausea', 'impairment of the immune system', 'Small bowel obstruction', 'occupational lung diseases', 'bleeding incidents', 'ovarian masses||-||', 'investigator.|Contraindications', 'clinical abnormalities', 'substance misuse/abuse', 'consistent facial skin status', 'immunologic deficiency', 'adrenalitis', 'sarcomas', 'end-stage cirrhosis', 'HLA-DRB1*09:01', 'e-reader', 'chronic coronary artery disease.||-||', 'non-intracranial surgery', 'M.O.F syndrome', 'Chronic Hepatitis B', 'involvement in developing', 'keratoconus（Corneal stromal thinning', 'gastroesophageal cancer', 'musculoskeletal injuries', 'alive virus vaccination', 'inflammatory myositis', 'MM', 'swept-source OCT biometry available', 'Primary refractory', 'metal shavings', 'dyspareunia', 'Epistaxis)|Post cardiac arrest', 'Inadequate distal runoff', 'ampullary adenocarcinoma', 'HER2-targeted therapy', 'sporadic cold sores', 'Dysfunction (MGD)', 'traumas', 'end-stage hepatic', 'WHZ', 'tricuspid valve', 'breast cancer.|Patients', 'inflammatory causes', 'reappearance of blasts', 'poor expectoration', 'Guillain-Barre', 'diverticula', 'mostly horizontal', 'renal/urologic disease', 'gait', 'uremia diabetes', 'AV-node disturbing medicament', 'acute drug injury', 'servical disc pathologies', 'COM701', 'Bone pain', 'breast-feeding.|Females', 'metastatic lesions.|Active autoimmune', 'Urinary tract', 'poor placental perfusion', 'nail gels', 'structural lesions', 'another malignancy', 'hepatitis B/C.|Acute', 'renal failure|Neurologic', 'dense breasts', 'paranoid disorders', 'events', 'surgery;|Presence', 'tertiary hyperparathyroidism', 'space-occupying diseases', 'vision impairment', 'OASIS', 'a:||Healthy', 'eye;|active eye infection', 'adenocarcinoma of the breast|Performance status', 'antisynthetase', 'unclassified colitis', 'orthostatic blood pressure', 'disease activity (DAS28>3.2)', 'management.|Active lung disease', 'unstable hypertension', 'vascular risk factor (hypertension', 'painful wound care procedure', 'either:||Men', 'intramuscular injections;|Gastrointestinal insufficiency', 'disease process|Imaging', 'left main visual stenosis', 'severe pulmonary disease', 'chronic cardiac insufficiency', 'glucose monitoring sensor wear', 'brain orientation therapy', 'Diabetic insipidus', 'chemo-', 'polytrauma', 'PCP', 'thyroid carcinoma', 'psychiatric disorders,|use', 'trichiasis', 'age;|Localized prostate cancer', 'liver-related laboratory test results', 'cholangitis)|Chronic liver infection', 'testing', 'young healthy', 'fetal congenital malformations', 'non-HIV-associated', 'impact drug absorption or metabolism', 'vaping|Clinically stable', 'Delaware', 'atopic disease', 'asymptomatic small', 'Human immunodeficiency virus (HIV) antibody', 'fibrotic interstitial lung disease', 'regional lymphadenopathy', 'national health insurance||', 'Impairments', 'gall bladder', 'insulin autoimmune hypoglycemia', 'damp-heat syndrome', 'erythropoietic', 'ischemic heart disease;|New', 'major medical problems', 'cerebellar oculomotor abnormalities', 'acute appendicitis', 'peritoneal transport function', 'Indication', 'Emergency medicine', 'autoimmune hypothyroidism', 'disease recurrence;|other communication problems', 'rotator cuff tear|History of cervicobrachial', 'bronchial asthma', 'drinking episodes', 'measurements instruments', 'macular atrophy', 'Acute kidney injury', 'asthma.||', 'chondral lesion', 'hypercapnic acidosis', 'Hepatic insufficiency', 'physical disability', 'renal replacement therapy.|Inability to undertake', 'diseases of heart', 'retinal hemorrhage|Current active liver disease', 'gastrointestinal diseases|Surgical events', 'disability|Contra-indication', 'infectious processes', 'cerebrovascular event|Known liver cirrhosis|Known cancer', 'bacteriemia', 'cardiopulmonary function', 'excessive volitional stool', 'focus of treatment', 'traumatic hand', 'glucocorticoid-induced myopathy', 'rickets', 'death syndrome', 'commercially available coronary stents', 'adequate follow', 'Peripheral vascular disease.||Obesity', 'endocrinologic bone disorders|Osteomalacia|Distant foci of infections', 'physical performance|Cognitive impairment', 'coagulation factor deficiency|Coagulation Disorders', 'status.||Drug treatment:||Antihypertensive drugs', '≥II)|Cerebral amyloid angiopathy', 'severe psychosis', 'anaplastic lymphoma kinase (ALK)', 'neurologic affection', 'bronchial asthma|Diabetic', 'spherical design|Habitual soft contact lenses', 'thyroid carcinoma|among European centers', 'normal menstrual history|Had', 'language competency', 'pancreatitis|Symptomatic cholelithiasis|Hepatic insufficiency', 'deep vein thrombosis', 'complete heart block', 'pulmonary disease|Psychosomatic disorders', 'HFNI', 'carcinoma in situ of the breast/cervix', 'hidradenitis', 'interstitial fibrosis', 'ureteropelvic junction obstruction', 'carcinoma in situ of the uterine', 'elimination', 'urosepsis|Cirrhosis', 'T2', 'drug.|Hypersensitivity reaction', 'anticancer treatments；|Subjects signed informed consent；||', 'local retinal detachment', 'acute myocardial infarction.|Current hospitalization', 'renders', 'chronic lung disease of prematurity', 'SFN', 'chronic pathology', 'congestive heart failure|Unstable angina pectoris|Unstable', 'distal biliary obstruction', 'unilateral cleft|infants', 'clinically uncontrollable hypertension', 'carcinoma thrombus', 'epithelial ovarian carcinosarcoma', 'treated carcinoma in situ of the cervix.||Have', 'acute psychotic mental health state', 'clinical guidelines.||', 'post-cancer', 'endolymphatic hydrops)|Lesion', 'immunomodulation', 'primary neurological disorders', 'infection,|Acute pancreatitis', 'secretion;|Gastric bypass', 'impairment of liver', 'images.||Autistic Spectrum Disorder', 'blood thinning treatment|Unstable', 'OR|Spanish speaking||', 'anesthesia', 'High quality genomic DNA', ""participate.||Alzheimer's disease"", 'histopathologic evidence.|Patients feasible', 'hip prosthesis dislocation Cognitive dysfunction', 'revascularization surgery.|Trophic ulcers of the lower extremities.|Critical and urgent', 'Sponsor)|Ambulatory', 'uterine sarcomas', 'type of COVID-19', 'chronic radiation enteritis', 'hepatic insufficiency/disease|Pregnancy', 'Angelman syndrome', 'medulloblastoma', 'atrial fibrillation|Cardio myopathy', 'implants|Claustrophobia|Not willing', 'Type II diabetes mellitus', 'spondylotic myelopathy', 'immunodeficiency disease||19', 'intertriginous areas', 'somatic pathology', 'non-directed', 'vegetarians', 'canal permanent tooth', 'diaphragmatic pacer', 'dysfunctions|pregnancy', 'BEST1-associated VMD', 'cardiac angina', 'acute medical problems', 'massive myocardial infarction', 'glaucomatous changes', 'portal lymph nodes', 'gait abnormalities', 'part.||Reasons', 'diseases.|Non-revascularizable surgical', 'pulmonary vein obstruction', 'neck cancer surgery', 'clinical cervicitis', 'upper abdomen', 'splenic abnormalities', 'associated enteropathy', 'consumption of caffeine-', 'cranial nerve block', 'avulsion fracture', 'nL', 'pelvic diseases', 'multi-organ transplant', 'reduced immune', '5q-autosomal', 'tortuosity of intracranial artery', 'non', 'lupus hepatitis', 'chronic kidney diseases|rheumatoid arthritis', ""Malgaigne's notches)|Posterior"", 'Burned', 'fluorescence in situ hybridization [FISH]', 'bleeding difficulties', 'intensive housing services', 'diathesis', 'unmanageable hypertension', 'endobronchial disease.|The lesion', 'hyperthermia', 'infectious disease|probands psychiatric diagnoses|patients', 'dysarthria', 'cognitive impairment|Alcohol consumption', 'heart surgery|Oncological diseases', 'Allergic constitution', 'drug-induced lung disease', 'PID', 'Cardiovascular diseases', 'relapsed ovarian cancer', 'bowel cancer', 'thrombolysis', 'prolonged duration', 'renal pelvis carcinoma', 'spine metastases', 'acute pancreatitis,|An', 'older|Decisional competency to provide consent and cognitive ability to participate fully in study procedures|Body size', 'mentally capable', 'anal intraepithelial neoplasia.|An', 'proprietary Chinese medicine for cancer control', 'adequate barrier contraception', 'uncorrectable visual', 'mixed incontinence', 'RD', 'drug induced liver injury|Prior liver transplantation', 'ischemic bowel disease', 'nonaffective psychosis', 'altered mentation', 'tumor vaccines', 'normal coagulation function', 'hardware issues', 'alcohol abuses', 'cerebral neoplasm', 'fissures.|Fissures', 'sinus-tracts', 'atherosclerotic lesion', 'atrial flutter', 'complexity', 'systemic disease|Neck', 'adenocarcinoma of the gastroesophageal junction;|(2', 'EGFR sensitive mutation', 'cardiogenic shock|Subjects', 'glaucoma).|Systemic disease', 'reflux disease', 'criteria:||Definitive NASH', 'splenic enlargement', 'skin dermabrasion', 'gastrointestinal system', 'left coronary artery dominance', 'breastfeeding|Coagulopathy', 'non-contact sport', 'Pterygium', 'ischemic macular disease', 'Mild hepatic impairment', 'myocardial infarction|vesical stones|active Urinary Tract Infection|patient', 'arrhythmia;|(4', 'diseases（malignancy', 'risk karyotype', 'thromboembolic disorders|History', 'cocaine addiction', 'sleep disorders|Pregnancy', 'vaginitis', 'cerebral edema', 'incentive program', 'upper limb abilities', 'psychotic disorder.|Use', 'attention', 'Hyperphosphatemia', 'co-diagnosis', 'macular degeneration', 'venous sinus', 'depression|Suicidality|Bipolar disease', 'Bleeding', 'tachycardia', 'renal system|Antibiotic use', 'Dysarthria', 'acute alcohol toxicity', 'liver metastases||estimated glomerular filtration rate (eGFR):', 'Emphysema diseases', 'LFS 5|Fitzpatrick skin', 'irrespective of p16 status', ""Huntington's disease.|Patients"", 'encephalopathy grade', 'colorectal cancer surgery.|Body mass index', 'Cryptococcosis', 'hormonal imbalance', 'active proliferative retinopathy', 'major injury', 'biliary drainage', 'malocclusion;|ANB Angle', 'stroke ischemic', 'disease of the heart', 'affect osteogenesis', 'isolated wound', 'thyroid disorders,|Adults', 'Arthralgia', 'Egyptian syndrome', 'mmHg);|Inability to swallow', 'gestation diabetes', 'ETI', 'ischemic core volume<50ml', 'resectable disease', 'impaired fasting glucose (IFG:', 'septal hypertrophy', 'turbid', 'congenital deafness).||', 'cuff tear arthropathy (CTA)', 'type 2 diabetes|Concurrent treatment', 'abruption', 'implant type', 'moderate Covid-19', 'COPD condition', 'comfortable CL wear', 'acute systemic infections', 'noticeable||', 'Renal Disease', 'Hepatic encephalopathy', 'annuloplasty;|Patients', 'swelling of the skin surrounding the wound created', 'chronic tear cystitis', 'non-MRI-safe cardiac pacemaker', 'previous diseases', ""St John's Wort"", 'cause|HIV-infection', 'radiotherapy;|Pyloric obstruction', 'cerebrovascular disease.|Child', 'acid folic deficiency', 'parathyroid disease', 'Chronic bronchitis', 'hepatitis B core Ab positivity', 'MCI', 'hepatitis C virus [HCV] antibody positive', 'Atherosclerotic Cardiovascular Disease (ASCVD)', 'cardiovascular event', 'HRCT||', 'postpartum angiopathy', 'debilitating injury', 'MS', 'tumor necrosis factor inhibitors', 'lactation period|Participation', 'Sotos syndrome', 'chromatosis', 'tumor biopsy', 'hypoalbuminemia', 'Diagnostic Arm):||Acute injury', 'liver conditions', 'systemic syndrome', 'symptoms of angina pectoris', 'smokers.|Pregnant', 'Chronic stroke', 'Cancer Survivor Inclusion Criteria:||Adult daughter of the identified cancer survivor', 'cardiac arrhythmia.|Psychiatric', 'immunity', 'severe coronary heart', 'permanently sterile', 'electric devices', 'atopic dermatitis active', 'developmental', 'breast-feeding|Fever', 'old|are judged healthy', 'acute climate changes||', 'acute epididymitis', 'intracranial hemorrhage|Previously randomised', 'sleep efficiency', 'infection of HIV', 'pulmonary exacerbations', 'colon carcinoma', 'wall extension', 'seizure disorders', 'female<470 ms', 'non-intentional weight loss', 'instability|Cervical spondylosis', 'deep brain stimulators.|Joint replacement', 'disease.|Localized', 'burns', 'anorgasmia', 'allergy)|Chronic Kidney Disease', 'chronic somatic diseases|Type', 'hepatitis C.', 'Chronic allergic rhinitis||Allergic', 'communication problems.||', 'BCC)|Inflammatory bowel disease|Mammography', 'physical disease', 'intraductal papillary mucinous neoplasms', 'depression|Language', 'urinary obstruction', 'Physiotherapy', 'bronchial hyperresponsiveness.|Patients', 'hepatocellular carcinoma|hepatitis B', 'heterozygous deletion', '4L nasal cannula', 'HER2-targeted therapy.-', 'maternity', 'helminthic infections', 'congenital anomalies affecting', 'glycogen storage disease', 'self-injury', 'cervical epithelial cancer', 'infection|Concurrent involvement', 'NM-101', 'retinal hemorrhage|uncontrolled hypertension', 'chronic intractable', 'Kidney disease', 'intolerance Exclusion', 'breast cancer|Adult', 'intravascular lithotripsy', 'solid tumor.|HIV infection', 'versus host reaction', 'T1c tumor', 'unstable diseases', 'irregular corneal astigmatism', 'pulmonary disorder', 'skin rash', 'ureteral perforation', 'alcohol abuse|Psychiatric disorders', 'uterine cervix;|Decompensated heart failure', 'arthritic conditions', 'socket-related', 'RVFAC', 'Porocarcinoma', 'nonsense', 'unsuitable medical histories', 'right atrium', 'metabolic etiology;|Time', 'hepatorenal syndrome', 'Myocardial obstruction', '7）renal failure', 'joint diseases', 'atraumatic C2-', 'malignant neoplasms;|Presence', 'adult seizure', 'Unilateral hydronephrosis', 'benzapril', 'helminths infections', 'coagulation disorder|Hypertensive crisis', 'Once disease', 'heart disease；|3、Pregnant', 'Acute Ischemic Stroke"";|confirmed', 'diagnostic pathology', 'Autism Spectrum Disorder|Enrolled', 'bleeding episodes', 'intercurrent illness;|Major surgical procedure', 'severe joint disease', 'psychiatric conditions;|Neurodegenerative neurological diseases', 'cutaneous pathology', 'tongue Italian|Semiresidential rehabilitation program||', 'Distant metastatic disease', 'RCVS', 'judged unsuitable to participate in the study by the Investigator.|Patients', 'hyperosmolar nonketotic diabetic coma', 'genomic risk', 'interventions', 'foot pressure sores', 'primary heart', 'muscle diseases', 'Socorro County|does', 'heparin-induced thrombocytopenia contraindicating', 'acute brain infarct', 'heart disease|Ability', 'bone metastasis.|Receive Nasogastric tube', 'paranasal sinusitis', 'brachial plexus', 'viremia', 'immunizations', 'SSD', 'pulmonary regurgitation', 'transient loss of consciousness', 'plasma cell disorder', 'heart-kidney transplantation|Recipients', 'caries free', 'TEAVIGO', 'severe medical illness', 'carcinoma of the breast', 'interact', 'plegia', 'RWP', 'Autistic Spectrum Disorder', 'valvular heart diseases', 'serious infections', 'post occluder implantation;|20', 'arthrosis', 'dietitian-prescribed', 'consent|Pregnancy|Cancer|Deemed unsuitable by study physician', 'attention deficit hyperactivity', 'extrarenal pathology', 'programme||', 'soft tissue sarcoma|Candidate', 'mycotic', 'CTLA4 inhibitor.|Previous chemotherapy', 'hernia repairs', 'hormonal factors', 'PML).|Concomitant diseases', 'acute neonatal hyperammonaemia', 'immunodeficiency;||Tumor-related', 'peroneal vessels', 'bladder malignancy|surgically altered detrusor', 'album bone marrow', 'muscle atrophy', 'blood loss', 'psychiatric disorders|Acute', 'clinical disorders', 'normal pressure hydrocephalus', 'hypertensive patient', 'represent G3 disease', 'minimally classic', 'cancerous pathology.||', 'residual cognitive', 'human immunodeficiency virus;|The', 'cutaneous lesions', 'cardio-cerebrovascular accident', 'human immunodeficiency virus infection', 'diabetes;|Contraindications', 'type 2 diabetes mellitus|Patients', 'score of', 'efficiency', 'level|Polytraumatic injuries', 'GAD', 'uncertain pathology', 'tortuosity', 'RDEB', 'hereditary CRC', 'judged by the investigator to potentially affect the results of the study', 'testing criteria||', 'chest deformities|Patient', 'living fetus,|Not', 'lymphoma lesion', 'involvement of the first branch of portal vein.|hepatic vein invasion', 'breast cancer|premenopausal', 'extrapulmonary infection', 'epileptic disease', 'required|Periodontal disease', 'auditory impairment', 'Chronic Obstructive Pulmonary Disease', 'unknow pregnancy status', 'micro-focused ultrasound', 'T stage|N2 adenopathy', 'anatomical abnormality', 'urethra cancer', 'NSCLC diagnosis|Prescribed', 'DIC).|Hematologic disease', 'hypnotherapeutic sound-files|The', 'hematological diseases', 'asthmatic', 'lifestyle factor', 'distant metastasis.|Prior chemotherapy', 'third-degree relatives', 'cognitive issues', 'neck|previous stroke', 'tuberkulosis', 'local anaesthetics|Renal', 'arrhythmia)|Cheynes-Stokes', 'PCI.|Acute Coronary Syndrome', 'systemic diseases.|Received', 'gait impairment', 'UC', 'recurrent immune diseases', 'chronic tranquilizer', 'mandibular condylar fracture', 'serious physical illnesses|Substance abuse', 'upper gastrointestinal ulceration', 'rehabilitation program;||For stroke', 'cuff tear arthropathy', 'systematic diseases', 'foot ulcers.|Patients', 'coma|Age', 'breastfeeding|Alcoholism', 'systemic allergic disease', 'tinea', 'mmHg)|Renal impairment', 'clinical conditions', 'axonotmesis', 'mechanical complications', 'Pregnancy Cognitive dysfunction Dementia', 'hypertonia', 'immunotherapy.|Measurable lesion', 'LV dysfunction', 'coloboma', 'substance abuse syndrome', 'resected basal cell carcinoma', 'Mental diseases', 'antecedent MDS', 'venous thromboembolism prophylaxis', 'renal dysfunction;|HIV', 'head trauma', 'interest;|Allergies', 'schizoaffective syndrome', 'cardiac failure', 'tumors around', 'nonmelanomatous skin cancer', 'neurologic disease', 'pulmonary edema|Uncontrolled', 'tolerance', 'non-DM cause', 'systemic illnesses', 'pre-diabetic', 'dementia|non-English speaking|nursing home residents|hospice enrollees', 'macular changes|Severe', 'hours.|Diagnosis', 'endometrial dysplasia/carcinoma', 'type I diabetic', 'co-dominant', 'English|At risk of gonorrhoea infection', 'adrenal hyperfunction', 'functional seizures', 'healthy', 'systemic allergy', 'ocular condition', 'is/+GI symptoms Inclusion criteria||i', 'Renal Disease formula);|Suspected', 'peripheral muscle weakness', 'breast-feeding|Congestive heart failure|Chronic obstructive pulmonary disease|Chronic renal failure|Those', 'FUS', 'Nasal swab', 'Puerto Montt', 'myotonic dystrophy', 'Lewy body dementia', 'solid-organ transplant', 'bariatric weight loss surgery/procedures', 'chronic osteomyelitis', 'screening|Pancreatic cancer', 'blood clotting disorders', 'sinus arrhythmia', 'diplopia', 'malignant neoplastic', 'supra-', 'inflammatory states', 'cMET exon 14 skipping', 'chronic renal disease.|Mosaicism', 'Relapsing-Remitting Multiple Sclerosis', 'weight loss herbal', 'liver metastases;|Coagulation Function', 'physical activity patterns', 'online questionnaires', 'oesophageal dysmotility', 'age.|Uncontrolled seizure disorder.|Diffusion', 'cerebral circulation', 'esophageal', 'PEX', 'acutely psychotic', 'anaesthesia-involvement)|Procedures', ""Ebstein's anomaly"", 'Major Depressive Disorder.|have', 'colonic mucosal dysplasia', 'hemophilia|bilateral involvement of the knee', 'gastric perforation', 'heart defects', 'Clinical infection', 'pulmonary vein', 'congenital immunodeficiency', 'signs of encephalopathy found', 'Acute pelvic pain', 'SCCHN', 'radiological abnormalities', 'psilocybin).|Allergy', 'major renal dysfunction', 'maxillary incisors|Patients', 'CFTR modulator use', 'gastrointestinal (GI) condition', 'local treatment;|No indication', 'ground-glass opacification', 'Bambini con diagnosi clinica', 'connective tissue disorder', 'recanalized embolus.|Presence of any of the following unequivocal cardiac sources of embolism', 'anaphylaxis reaction', 'head and neck radiotherapy|Patient', 'abdominal fistula', 'multiple sclerosis|Must', ""Parkinson's disease.||"", 'auditory neuropathy', 'AA', 'systemic disease|Heavy smokers', 'ventricular systolic dysfunction', 'pregnancy|Blind', 'solid foods||', 'brain metastases:|Brain metastases', 'stable points', 'RV dilatation', 'SCC', 'prolonged standing', 'myocarditis|Conditions', 'renal dysmetabolism,|hypothyroidism', 'traumatic patellar subluxation', 'compartment syndrome||Examples of included', 'progressive disorders', 'PET brain scans.|Adequate', 'vascular disease|pregnancy|secondary hypertension|atrial fibrillation', 'localized, dermatomal herpes', 'slope', 'therapeutic hypothermia', 'brain injuries|Alcohol', 'benign prostate disease', 'silica', 'nicotine dependence', 'sensory deficits', 'musculoskeletal injury', 'Endometrial Cancer', 'leptomeningeal metastases.|Myeloma', 'gastroesophageal junction adenocarcinoma', 'diffuse peritoneal disease', 'nodular liver', 'Adverse Drug Reaction||History of', 'symptomatic diseases', 'systemic mast cell disease', 'intracranial', 'kidney failure|Pregnancy', 'inadequate linguistic abilities', 'nonalcoholic steatohepatitis||The', 'CT image', 'structural cardiac', 'exogenous melatonin.|Phase delay syndrome', 'venous sinus thrombosis', 'type 2 DM', 'lactation.|Febrile illness', 'chronic gastrointestinal illness', 'concomitant autoimmune diseases', 'screening;|Malignant disease', 'birth defects', 'local unfavorable intermediate', 'trauma', 'incidental pulmonary nodule (IPN) on', 'unexplained death', 'Bordeaux', 'neutrocyte', 'myocarditis.|Troponin T (TnT)', 'pseudohypoparathyroidism', 'microvascular dysfunction', 'hepatis B virus', 'prior treatment]|Patients', 'liquid stools', 'malignant cancers', 'oncologic disease|no bone fractures', 'bladder outlet obstruction', 'cardiovascular insufficiency', 'HAV', 'diseases of blood', 'eCRF', 'articipants', 'Paralytic hip DX', 'gestation|Willingness to', 'infertility', 'pulmonary hypertension|Age', 'dizziness|ineligibility to MRI scanning', 'achlorhydria', 'HIV disease', 'nerve stimulator', 'complications', 'hypersensitivity.|Participant', 'laparoscopic exploration', 'additional maliganancy', 'judged by the investigator to be unsuitable to participate in this study', 'hypercoagulable state', 'vertigo|Myelopathy', 'psychological disease', 'pancreatitis', 'steno-obstructive lesion', 'Acute cholecystitis', 'delta wave', 'hypertensive crisis', 'autoimmune-associated hypothyroidism', 'Attention-deficit hyperactivity', 'skin disease around PICC', 'abdominal free air', 'cervical spondylolisthesis', 'uncontrolled autoimmune disorder.|Pregnancy', 'cerebral oxygen saturation', 'immunodeficiency disorders', 'maintenance antimicrobial', 'non-small-cell lung cancer', 'Community health workers working', 'recurrence free', 'Heart Failure', 'local anesthetics.|Localized infection', 'affect GH', 'cyclic peritoneal', 'hereditary hemochromatosis', 'sequela', 'unmanaged major psychiatric disorder||', 'activities;|Healthy', 'hepatic resection', 'GTPS', 'liquid malignancies', 'localized skin conditions', 'JNT-517', 'dengue', 'Partial Response', 'illicit drugs;|Brain pathology', 'GI infections', 'orthodontic treatment|Aggressive', 'cognitive behavioral', 'irreversible neuropathy should', 'asymptomatic brain metastasis', 'adverse events related', 'hour;|Suffering', 'myasthenic syndrome', 'degeneration of a surgical bioprosthetic valve', 'Ischaemic heart disease', 'non-small cell lung', 'Radio- opaque renal stone', 'menopausal symptoms', 'Power Doppler negative', 'Autoimmune Hemolytic Anemia', 'cerebral vascular malformations', 'CIS)|History', 'psychiatric disorders.|Persons', 'inflammatory rheumatism||For A1-2', 'primary liver cancer', 'swallowing capsules', 'isolated extra', 'development.|Suspicion of malignancy', 'cervical spine.|Signs of', 'Ménières disease', 'trauma-focused', 'thrombosis tendency', 'early gastric cancer.|Subjects', 'drug-related pulmonary toxicity', 'RV implantable cardiac device', 'hyperlordosis', 'hearing', 'clinical laboratory abnormality', 'hypertensive brain disease', 'hyposmia', 'glucose-insulin', 'physical disability.|Resorption', 'impact the absorption of study intervention.||Note', 'prostate carcinoma', 'right heart catheterization mean pulmonary arterial pressure', 'VDS Mobile|Prefers', 'ocular trauma', 'pacemaker/impantable', 'MK-8591A-017', 'treatment;|Arteriovenous thrombosis events', 'confirmatory serum pregnancy test', 'Functional Diarrhea', 'major neurological disorder', 'obliterating arterial disease', 'breast cancer carcinoma', 'Alcohol Use Disorder', 'type A', 'radio-immunoconjugates', 'pose a risk to the participant', 'absorption disorders', 'T2-4 any N', 'circulation', 'useless tissue available|Information consent', 'venous thromboembolic disease', 'RECIST v1.1', 'Sarcoma', 'Bipolar disorder', 'root pain', 'pleural infection', 'Chronic Kidney Disease Epidemiology Collaboration creatinine-', 'collagen disorders', 'primary liver disease', 'Diabetes Care', 'urological diseases', 'progressive neurologic conditions', 'upper limb pathology', ""Schmorl's nodes"", 'nutritional disorders', 'congenial', 'seizure.||Frequent headaches', 'liver malignant lesions', 'clinical complications', 'triggers.|Serious cardiovascular disease', 'a disorder', 'chronic cardiopulmonary disease', 'cardiogenic shock|Moribund', 'should avoid pregnancy for seven months after the date of their last treatment with', 'injections|Stable hypothyroidism', 'acute infarcts lesion', 'Mental Retardation', 'criteria apply:||Has biallelic CLN2', 'involvement of the pulp', 'changes in lifestyle', 'disease.|Pregnant', 'neither eye', 'medication PRN', 'pre-stroke', 'increased intracranial pressure|pregnant', 'breast feeding|Medication', 'infectious disease', 'substance use screen', 'Depo Provera', 'leukemic CNS involvement', 'irregularities', 'extracapsular extension', 'Chronic liver failure:||The', 'hepatic', 'Cardiac insufficiency', 'acute severe colitis (ASC)', 'endocrine tumors', 'neurological complication', 'lymphoplasmacytic lymphoma', 'invasive breast carcinoma', 'cognitively well preserved', 'infection comorbidities', 'dietary modification', 'adherence problem', 'female.||Reproductive characteristics||For', 'cholecystectomy,|presence of', 'filler injection', 'h', 'Uncontrollable arrhythmia', 'speech barrier', 'hematological disorders', 'events of alopecia', 'alcohol use|Multiple pregnancies', 'spontaneous activity absent', 'abnormal conduction system.;\\|Active infection', 'breastfeeding|Recent injuries|Known sensibility', 'underlying diseases', 'biliary disease', 'ventilation disorders', 'headaches|The', 'seasonal allergies', 'instrumental activity', '-situ disease', 'drug dependence;|Mental disorders', 'pose a hazard to tissue handling.|Undergoing fertility', 'chronic systemic illness', 'congestive heart failure|Transmural myocardial infarction', 'period.|Active hepatitis', 'Human immunodeficiency virus', 'middle school staff', 'psychiatric disorders|Chronic diseases', 'mandibular posterior teeth|Overall', 'Acute Variceal Bleed|Child', 'multiple tophi', 'leiomyoma', 'upper GI surgery.|Ascites.|Inability to tolerate', 'nasal spray', 'female;|Age', 'behavioral factors', 'retinal vein occlusion;|Evidence', 'primary malignancies developed', 'acute ischemic stroke|Unable', 'riboflavin notably):||pregnancy', 'infection of the skin', 'clinical emergency', 'corneal dystrophy|Uncontrolled', 'impaired power', 'functional dependence', 'functional verbal communication', 'essential hypertension', 'congenital musculoskeletal deformities', 'loss', 'cardiovascular complications', 'cardiac conduction', 'calculated by the central laboratory.|Any other laboratory', 'hemopoiesis', 'ocular herpetic infection', 'heavily calcified', 'hypertensive heart disease', 'non-fluent speakers of the English language||TT Genotype', 'acute inflammatory processes.|Implantation of', 'OA symptoms', 'secondary arthritis', 'N02', 'head and neck radiation', 'refractory ALL', 'membranous glomerulonephritis', 'Unability to undergone', 'non-pathogenic Fabry', 'acute suicidal risk', 'normal);|Structural heart disease', 'non-invasive basal cell skin cancers', 'neonatal encephaolopathy', 'colorectal', 'large carious lesions', 'cardiac surgery|contraindication', 'hepatitis B (HBV)', 'left ventricular hypertrophy.|Known', 'health issues', 'fetal chromosomal', 'Tumors', 'nonchildbearing potential', 'liver tumors', 'skin crepiness', 'delirium|Hypotension', 'omental cake', 'healthy patient', 'olfactory problems', 'Progressive Aphasia', 'non-insulin dependent', 'neoplastic disease.|Active mycobacteria', 'immunosuppressive drugs.|Pregnancy status.|Incapacity', 'complex arrhythmias', 'rectal polyps', 'contrast reaction', 'anterior permanent', 'Screening.|Orthostatic hypotension', 'carbon monoxide (CO)', 'idiopathic constipation', 'cardiogenic shock|Life expentency', 'samples', 'acute confusional state.|Renal function impairment', 'ductal carcinoma in situ of the breast after radical', 'maxillary sinus augmentation)|Partial', 'molecular profiling', 'limb ischemia|amputation', 'tumour cells.||Patients', 'metastatic breast cancer;|Progression', 'recruitment|Able to read', 'intestinal failure', 'Hunner lesions', 'inflammatory rheumatic diseases', 'cognitive problems', 'S. pneumoniae.|Coagulation', 'significant abnormal', 'bradyarrhythmia', 'drainage', 'spondyloarthropathy', 'bulky disease', 'inclusive|Healthy', 'non alcoholic fatty liver disease', 'new brain metastasis', 'procedures|stage 2 hypertension', 'clearance;|Difficulty swallowing', 'renal function.|Left ventricular ejection fraction', 'headset Cognitive impairment causing inability to consent Unable to walk', 'HIV antibody.|The', 'TMAs', 'Chronic pain', 'functional limitations', 'level|Regular menstrual cycle', 'laboratory liver profile', 'Severity rated', 'skin comorbidities', 'heart valves', 'preserved ejection fraction', 'esophageal varices.||', 'toxic reaction CTCAE', 'corneal lesion', 'Chronic thromboembolic pulmonary embolism', 'eschar', 'caffeine sensitivity', 'dizziness', 'ischemic optic neuropathy.|no', 'cerebral infarction', 'pain below the buttock|Must', 'nonalcoholic hepatic steatosis', 'Black British', 'local treatment.||Symptomatic', 'physiological dyspnea.||Exclusion', 'PTCL', 'generalized urticaria', 'low back pain|Hip injury', 'dependence on', 'enhancer sequence', 'subtypes:||Follicular lymphoma', 'miscarriage,|Having speech disorder', 'schizophrenia spectrum disorder', 'cutaneous SCC', 'esophageal stricture', 'colorectal cancer|Persons', 'respiratory tract (inhalation)', 'deep systemic tumor tissue', 'reproductive potential.||Agrees', 'life-limiting', 'akinetic', 'acute mitral cord', 'local esophageal inflammation', 'feathers', 'singleton pregnancy.|The CDH', 'CRC)|previous colonic resection|Returning', 'clinical laboratory abnormalities', 'weeks|Nasal swab positivity', 'self-catheterisation', 'Acute pulmonary edema', 'localized tumors', 'viral infection', 'absorb oral medications.|Clinically', 'chronic steroids|A physical', 'coronary revascularization);|4', 'infection|Myocardial infarction', 'irreversible damage', 'couple - both partners', 'carcinosarcoma', 'bipolar mood', 'evaluation|Post-hysterectomy', 'non-white race', 'vigilance disturbances', 'haematological disease', 'malignant tumors:||Malignant tumors', 'respiratory diseases;|Abnormal liver', 'paranasal sinus', 'mixed histology', 'Active hemorrhage', 'multiple myeloma', 'Hepatitis B core antibody positive', 'distant metastasis;|Patients', 'posterior segment inflammation', 'palliative causes', 'neurological pathologies).|Non-Italian education', 'B-cell lymphoma[PMBCL', 'inflammatory eye disease', 'alcohol detection', 'virologic failure', 'anterior cruciate ligament rupture.|Subjects', 'self-tanners', 'IIH', 'active malignancy.|Patient', 'left shoulder pain', 'mineral deposition (', 'diazepam', 'esophageal varicose veins', 'skin disease', 'Former', 'secondary diseases', 'conduction disorder', 'with:||mastitis|granulomatous mastitis|breast fillers', 'cardio', 'autonomic involvement', 'endometriosis lesions', 'Psoriasis area', 'permitted|For NSCLC', 'GADA', 'aplastic bone marrow', 'kidney disease.|Neurodevelopmental disorders', 'Dyslipidemia', 'chronic hemolytic anemia', 'CNS tumors', 'permanent teeth', 'Hypofibrinogenemia', 'Pagets disease', 'hepatic vein', 'T-cell therapy', 'recurrent infections', 'relapsed leukemia', 'chronic pain|Allergy', 'PCR', 'ketoacidosis', 'Psychotic disorder', 'interstitial lung disease.|The', ""Crohn's disease|A"", 'preoperative)|End-stage renal disease', 'deep brain stimulation', 'calculated by Cockcroft and Gault equation)', 'nodal metastasis', 'ankle fracture', 'brain infarction', 'gastrointestinal stromal tumor', 'gastrointestinal ulcerative disease|Patients', 'neurosurgery', 'refractory cardiac arrest', 'spinal mobility,|Participants', 'pathological colonic adenocarcinoma|Clinical TNM classification', 'eligible;|Uncontrolled heart disease', 'primary discharge diagnosis', 'symptom exacerbation', '≤110', 'Claustrophobia', 'HBsAg loss', 'squamous cell carcinoma of the skin).||a', 'allergic conjunctivitis/rhinitis', 'progressive multifocal leukoencephalopathy|History of', 'further investigation', 'normothermia', 'non-plaque psoriasis', 'stroke type', 'disease like asthma', 'wall hernia|diaphragmatic hernia|coagulation', 'papilledema', 'cervical disc compression', 'bronchopleural fistula|hemodynamic instability', 'screen depressive symptoms', 'breastfeeding;|Hyperglycemia', 'fortified yogurt', 'radiologic progression', 'corona virus disease-2019 (COVID-19)', 'deep venous thromboembolism threatening', 'accumulation diseases', 'hypertensive encephalopathy;|Subjects', 'liver biopsy.||Abnormal liver function', 'fulminant colitis', 'cure;|Measurable lesions', 'dragon fruit', 'diabetic hyperosmolar non-ketotic coma;|Hyperglycemia', 'dieting program|As', 'inadequate response/non-response', 'pleocytosis', 'varus deformities', 'IDH1+ AML', ""Barrett's"", 'compromising heart failure', 'fibrosing', 'Men||self-identify', 'deep caries', 'croscarmellose', 'procedures.|Significant risk factors', 'LAA stroke', 'catalase deficiency', 'Clinically meaningful deterioration', 'S4+', 'malnutrition.|Nutritional risk index', 'crystal-induced arthritides', 'bone marrow biopsies', 'C.|Acute infectious diseases', 'posttraumatic facial scar||', 'serious hypertension', 'endocrine diseases', 'sufficiently physically active', 'lateral ankle pain', 'non-cardiac causes.|Systolic blood pressure', 'Chronic Pain', 'anatomically not resectable', 'squamous cell carcinoma of the skin in situ)；|Any one of HBV surface antigen', 'poor imaging quality', 'communicative disorders', 'familial cancer syndromes', 'lifetime bipolar disorder', 'coagulopathy type', 'intestinal obstruction;|Patients', 'pericardial effusion', 'palpable mass', 'acute thoracic aortic dissections|Age', 'ulcerative diseases', 'infiltrative (granulomatous)', 'bursitis', 'darkest black""', 'IV);|uncontrolled hypertension', 'swallowing disorder', 'Exclusion criteria|Patient', 'optimal dosage', 'deviated septum', 'osteoarthritis', 'mentally impaired', 'type 2)|Immunocompromised state', 'available pathology records', 'pleural metastasis', 'acute COPD exacerbation||COPD', 'clinicians', 'non-malignant cause', 'allogenic bone marrow transplant', 'pain killers', 'Myelogenous Leukemia', 'pulmonary encephalopathy', 'hearing problem', 'pain on most days', 'intact maxillary first premolars', 'communicational,|Mental disability', 'prolonged QT syndrome;|Patients', 'lobar degeneration dementia', 'recovery from toxicity', 'Mild cognitive impairment', 'classical disease|English speaking', 'surgical bleeding', 'intercurrent illness', 'Refractory Chronic Cough (RCC)', 'vascular dementia', 'iron deficiency', 'behavioral issues', 'typing of', 'implantation failure', 'brain tissue compression;|the subject', 'Chronic inflammatory diseases', 'coagulopathy.|Patients', 'Cognitive impairment|Anamnesis', 'cardiopulmonary', 'mesenteric vein tumor thrombus', 'chronic dialysis therapy|New', 'definitely recommended standard treatment regimen', 'lactate dehydrogenase', 'multi-function spectacles', 'leukocyte dysfunction', 'infiltration of organs;|Those', 'liquid burns', 'nonvalvular atrial fibrillation', 'excimer Laser.|Desire', 'facial rejuvenation', 'neuralgia', 'angina|Unstable angina', 'functional loss', 'acute event', 'either:||1', 'ventricular arrhythmia|Cardiac conduction abnormalities', 'hepatitis C virus ribonucleic acid', 'Cerebral-placental index', 'deep vein thrombosis (DVT)', 'mandibular excess', 'antiseptic use', 'Hereditary', 'problems,|normal vision', 'hypogonadism.|genetic disorders/polymorphisms', 'nasal spray inhalation', 'intermediate-1 risk PMF', 'complex chronic condition', 'Nonmelanoma skin cancer', 'irritable bowel', 'conservative treatment||', 'systemic therapy;|Human immunodeficiency virus (HIV)', 'overseeing activities related to product.|Have participated in any clinical study involving the test sites', 'IRM', 'smoke', 'mitral valve surgery||', 'GUILLAIN-BARRE syndrome', 'primary teeth.|Uncooperative child', 'NSCLC，whose disease', 'American Joint Committee on Cancer', 'prognostic factor', 'tractional detachments', 'FISH', 'adverse risk factors;|Relapse', 'lamellar ichthyosis|Two target areas', 'solid tumor|All other toxicity parameters', 'crackles', 'SARS-CoV-2 infection', '1 hypertension', 'cutaneous head & neck angiosarcoma', 'blood draws.|Presence', 'endocardial catheterization', 'unstable disease', 'Painful Arc', 'Invasive carcinoma', 'cerebellar deficits|any other', 'gastrointestinal (GI) bleeding', 'intestinal disease', 'HER2 status', 'L871Q mutation', 'anatomical locations', 'pelvic infection', 'uterine anomaly', 'psychotic features,|meets diagnostic criteria', 'heart failure|Angina|Arrhythmias|Cardiomyopathy|Valvular heart', 'indicator lesion', 'urinary system diseases', 'arthroplasty', 'cancer types', 'Intestinal malabsorption', 'neurologic deficits', 'brain tumor imaging', 'smoking|hypertension|coronary disease|diabetes|hyperlipidemia|kidney damage|cerebrovascular', 'Spinal Injury Association (AISA)', 'basal cell skin cancer|Patient', 'included)|Asymptomatic status|Normal', 'criteria from the study:||Cognitive', 'neurotoxic chemotherapy|Cognitive difficulties', 'gastrointestinal disorders|Medications', 'alcohol-related', 'solid tumors);|Responsible', 'Chronic myelomonocytic leukemia', 'vascular compression', 'Bronchiectasis', 'refuses to', 'PIK3CA', 'Intolerance', 'kidney disease (CKD)', 'IPF', ""Alzheimer's dementia.|The"", 'ovarian endometrioma', 'venous outflow obstruction', 'visceral bleeding', 'immune dysregulatory diseases', 'deformity.|Leg pain', 'heart aneurysm', 'image loss', 'third of the territory of the middle cerebral artery', 'vessel).||Active hemoptysis', 'inflammatory skin conditions|Active cold sores', 'acute thrombus', 'transient adverse effects', 'several distinct cutaneous sites', 'consent.|Sensory loss', 'Asperger syndrome', 'medical comorbidity|Poorly controlled diabetes|Pregnancy', 'fear of cancer recurrence', 'vertebral column pathology', 'glucose-galactose malabsorption);|>1 episode', 'tomography|functional evidence', ""child's assent"", 'Tumor type', 'pus on aspiration|At least', 'subchondral insufficiency fractures', 'malignant tumor;|Clinical symptoms', 'gastrointestinal bleeding|Other conditions', 'completely resolved', 'prerenal azotemia', 'normal glucose tolerance', 'respiratory insufficiency|Psychiatric disorders|Pregnancy', 'localised skin cancer', 'skin treatments', 'Linch syndrome', 'inferior gluteal folds.||', 'splenectomy|End stage renal disease', 'contraindications deformity of the ear', 'immunostimulant', 'craniectomy', 'persistent alveolitis', 'Carious teeth', 'systemic treatment.|Known HIV', 'pulmonary disease|Uncontrolled diabetes', 'Orthostatic hypotension', 'osteonecrosis', 'distant organ', 'Neonates', 'TTS', 'macadamia', 'glucose-galactose malabsorption.|10', 'severe depressive symptoms', 'persistent cancer pain', 'Buerger disease', 'metabolic illness', 'presence', 'before COVID-19 infection', 'dyslipidaemia', 'gluten free', 'PCR+ swab', 'autoimmune disease;|Human immunodeficiency virus (HIV) infection', 'Lung cancer', 'lymphoma-Hemophagocytic Lymphohistiocytosis.|EBV-DNA', 'major small bowel surgery);|Woman', 'painful joints', 'for:||Malignancy', 'idiopathic thrombocytopenic purpura', 'residual defects', 'impact on safety', 'assessable lesion', 'symptoms health questionnaire', 'allergic reaction;|Blood transfusions', 'serious ulcer', 'chemotherapy;|Human immunodeficiency virus', 'chronic hepatitis', 'multiple pregnancies', 'r Nondisabled', 'Peptic Ulcer', 'non-CNS lesions', 'skin biopsies', 'hemochromatosis', 'drug sensitivity', 'Substance abuse', 'rheumatic disease', 'hypertension|Heart failure.|Musculoskeletal pathology', 'COVID-19 PCR test', 'running experience|Injury free', 'Stuffy', 'developmental delay,|The child', 'metastatic site', 'sensitivity to vestibular palpation', 'Shift', 'acute care areas', 'VSD', 'MSA-P', 'thyroid nodules', 'diabetes;|Abnormal coagulation function', 'progression.||Measurable disease', 'Functional physical limitations', 'cardiopulmonary disease', 'functional disorder', 'serious alcohol', 'vital prognosis;|Diagnosis', 'day)|Concomitant disease', 'malignant tumor|Clinically significant', 'Type 1 Diabetes', 'Glaucoma patients.|Media opacity', 'GIST', 'product.|Heterozygous Familial Hypercholesterolemia', 'influenced pain threshold', 'acute coronary syndrome;|Patients', 'Clinical picture', 'indications', 'hypersensitivity pneumonitis', 'Bleeding disorders', 'acne scars', 'upper tract disease', 'neural foraminal stenosis', 'progressive liver fibrosis;|7', 'lifestyle of the patient)|Male', 'prasugrel|presence', 'autoimmune skin conditions', 'immunodeficient condition resulting from disease', 'neuroleptic medication|History', 'alpha-1 adrenergic antagonist|Severe', 'mixed SCLC NSCLC', 'periampullary carcinoma', 'physically demanding', 'contributing aetiologies', 'neuropsychologist).||', 'bladder augmentation', 'human epidermal growth factor receptor 2-negative', 'hemorrhagic tendency.|Serious infection', 'Inflammatory', 'anorexia nervosa', 'somatic disorder', 'osteonecrosis|Cerebrovascular', 'pulmonary hypertension|Over', 'genital infection', 'fetal congenital malformation,|Not', 'Poor oral hygiene', 'Medically compromised', 'metastatic lesion', 'convulsive seizures', '↓ skin', 'leg ulcer', 'male infertility factor', 'GM-CSF autoantibody test', 'stomach diseases', 'Myeloid leukemia', 'clinical bleeding.|Neonatal encephalopathy', 'cerebrospinal fluid malignancy.|Checkpoint inhibitor drugs', 'Fecal incontinency', 'support|Able to communicate with Cantonese', 'incisional glaucoma surgery', 'Pathological fracture', 'QTc', 'weeks,|Psychiatric comorbidities', 'hepatitis B virus (HBV) deoxyribonucleic acid', 'Helicobacter pylori eradication', 'droplet precautions|Order for bedrest', 'breast-feeding.|Any Psychological, familial', 'symptomatic manifestations', 'cerebral circulation disorder', 'hemodynamic disorders', 'fructan intolerance', 'renal disease|Immunosuppression|Inflammatory bowel', 'increased bleeding tendency', 'total mastectomies', 'CI612', 'F32.0', 'women|End stage renal disease', 'diabetes|Risk factors', 'leukemia - Disease', 'distant metastases', 'primary psychotic', 'root canal retreatment', 'STEMI', 'genital itching.||', 'gynecologic abnormalities', 'metabolic problem', 'anterior uveitis.|Ocular trauma resulting', 'lactation|terminal malignant disease', 'renal failrue', 'oocytes', 'questionnaire', 'neurologic disorder', 'verapamil|Known hypersensitivity', 'sunflower', 'tumor|neurological disease', 'immunodeficiency infection', 'diabetes type I', 'contraindicates', 'non-AD diseases;|Not', 'pulmonary tuberculosis;|Diagnosis', 'mixed occlusion.|Integrity of the buccal surfaces of the reference teeth', 'Allergic', 'Surgical Complication', 'type of osteomyelitis', 'PKCS', 'primary ADHD', 'chemical cystitis', ""anesthesia.|Patient's consent"", 'non melanoma skin cancer', 'hepatitis C and', 'CSVD', 'transaxillary thyroidectomy;|Benign lesions', 'iteria:||Male', 'lower extremity CRPS Type 1 (also called RSD-Reflex Sympathetic Dystrophy', 'QTcF)<470 msec', 'marathon', 'CLL);|Presence of', 'chewing', 'metatarsalgia', 'lacuna stroke|Need', 'refractive error', 'carious teeth', 'traumatic spinal cord injury', 'psychotic disorder|Alcohol', 'Hirschprung disease', 'carcinoma in situ of the cervix,|Has no more', 'distant metastasis;|Subjects', 'cancer of the gastrointestinal tract', 'cold testing|the periodontal stage of the tooth should be I', 'idiopathic disease', 'HER2 positive disease', 'significant bleeding', 'non-leukemic oncologic', 'health products', 'coronary sinus', 'study;|Ocular infection', 'sensory motor dysfunction', 'intestinal stoma', 'impaired platelet function.• Increased risk of perforation', 'ankylosing', 'cutaneous basal cell carcinoma', 'perineural invasion', 'Urological Diseases', 'paroxysmal cold', 'multiple sclerosis);|Pregnancy', 'cardiac surgical', 'neonatal infection', 'heart insufficiency', 'dislocation', 'allowed;|Cerebrovascular events', 'obstetric complications', 'diverticular stenosis', 'musculoskeletal disorders like OA', 'breast diseases', 'mesothelioma', 'depressive episode', 'retinal detachment surgery', 'limb weakness', 'communication barriers lack of informed consent', 'nalmefene|acute psychiatric comorbidity', 'hepatitis C infection.||Gastrointestinal abnormalities', 'issues', 'acute event associated', 'hemorrhagic symptoms', 'peripheral vascular disease', 'oncologic disease', 'cancer in remission', 'malignant infiltration', 'endocrine system disease', 'inflammatory bowel.|Previous', 'pulmonary lesions', 'cross-provincial', 'Left atrial diameter (', 'detection of raise', 'partial thromboplastin', 'MEN2', 'IRCCS Policlinico San Donato;|Signed', 'poliomyelitis', 'QT syndrome', 'pseudotuberculosis', 'hepatotoxicity', 'postpartum', 'chronic parasitic infections', 'death occurred', 'primitive immature', 'unstable angina pectoris.|Patients', 'colorectal cancer;|Patients', 'cervical spinal canal stenosis', 'CRC.||Preference', 'hours.|Anoxic brain injury', 'procedure|Pregnant women|Terminally ill', 'LVO', 'cerebrospinal fluid samples', 'involuntary weight', 'Alzheimer Disease', 'bleeding NCI', 'hepatic capsule invasion', 'Cognitive disorders', 'metabolic ketoacidosis', 'schizophrenic disorder', 'type of carcinoma', 'embolic disease', 'gastrointestinal cancer diagnosis||', 'Unstable angina', 'valgus)|Systemic auto-immune rheumatic disease|Arthroscopy', 'including:||use of any drugs known to induce', 'total gross resection', 'neurological disorders rheumatologic diseases', 'eligible.|Active infection', 'illness', 'TIA.|ECG-diagnosed', 'autonomic neuropathy);|treatment', 'suicidal ideations', 'regional nodal involvement (cN+) may be included irrespective of clinical T stage', 'pathological changes.|Cognitive impairment', 'lock', 'CHD', 'death date', 'vertical gaze paralysis', 'chronic health condition|English', 'tracheostomy', 'HIV)|Hepatitis B virus', 'Endophthalmitis', 'wrist fractures', 'biologics.||Hematological malignancy', 'photosensitization-related', 'Type 1 Diabetes Mellitus||', 'illness|Chronic lung disease', 'screening|Type 1 diabetes mellitus', 'diagnosis);|Arteriovenous thrombosis events', 'tinnitus maskers', 'deep femoral artery (DFA)', 'acute mixed phenotypic leukemia', 'encephalopathy|Respiratory failure', 'clinically normal', 'chronic lichenia simple', 'metabolic health', 'Adult morbidly obese', 'premorbid disability condition', 'stimulating factor treatment', 'primary outcome', 'pediatric cancer', 'axSpA', 'functional constipation', 'active autoimmune diseases', 'constrictive pericarditis', 'Inflammatory bowel diseases', 'age|Post-menopausal', 'anticancer immune', 'elbow Humerus', 'hypovolemia.|Sepsis-induced', 'associated cervicobrachialgia', 'renal impairment.|Patient', 'musculoskeletal issues', 'convulsions|The', 'pulmonary disease-', 'obstructive pulmonary diseases|Hepatic cardiac', 'Vascular dementia', 'extensive extrapulmonary metastasis', 'clinical verifications', 'migraine-associated disorders)|Participation', 'PTEN', 'age),|prisoners', 'non-DN', 'lichen planus', 'Polysubstance abuse', 'immune complexes', 'time.|Active infection', 'Chronic Kidney Disease Epidemiology Collaboration formula)|White blood cell count', 'brain tumor', 'multicentric disease', 'brain damage', 'lollipop swab collected', 'sucrose', 'primary ciliary dyskinesia', 'liver stiffness measurements', 'Peutz-Jeghers syndrome', 'code||', 'days);|Infection', 'SCLC', 'risk factor||', 'breast ductal carcinoma', 'precancerous lesions', 'gluten-free bread', 'urologic malignancy', 'prolonged QTc syndrome', 'hypercapnic respiratory failure', 'alcohol abuse|History of psychosis', 'anticancer therapies', 'T2D)|History', 'surgical indication.|Altered pain perception', 'CNS-3 leukemic involvement', 'vision 20/100', 'cell mass', 'hydroelectric shock wave lithotripsy', 'extraarticular physeal fractures', 'baseline;|COVID-19 infection', 'ype 1 Diabetic', '1.Patients', 'intolerant neoplasms', 'interstitial lung disease(ILD', ""Hashimoto's"", 'papillary thyroid', 'auditory impairments.|Diabetic', 'lumbar instability', 'seriously ill', 'patellofemoral arthrosis', 'liver abscess', 'skin system', 'renal vasculitis', 'CKD-EPI Creatinine', 'caries', ""Parkinson's dementia"", 'tumors/infections', 'former smoker', 'heart failure||(a', 'fetal growth restriction|Clinical diagnosis', 'failure to respond to fucose', 'alcohol intoxication', 'signs of infection', 'undetermined colitis|Rheumatic diseases', 'bleeding|Hemodialysis', 'sperm DNA fragmentation', 'cardiac conduction disease', 'Chronic lymphoblastic leukemia', 'acute myeloblastic leukemia.|Patient', 'refractory angina pectoris', 'schizophrenia|clinical stability', 'oropharyngeal carcinoma', ""Fridericia's Formula"", 'image morphological', 'papules', ""Alzheimer's disease|able"", 'non-cancer pain', 'good condition.|Prior intolerance', 'external perforation', ""Humphrey's perimetry"", 'skin tumors', 'chronic renal disease.|Noonan-related disorders', 'hepatic sinusoidal obstruction', 'mild obstructive lung disease', 'metabolic diseases.|History', 'retardation', 'Complex study|Unlikely', 'heart disease;|3.Pregnant', 'Chronic ischemic stroke', 'risk cytogenetics', 'neurological Wilson|Uncontrolled portal hypertension', 'complicating condition', 'acute myeloid leukemia', 'kidney disease|Reported abnormal', 'Unable to undergo sample collection|Pregnancy', 'HCV)|Infection', 'cardiac sarcoidosis', 'target vessels', 'major bleeding', 'types of cancer', 'epilepsia', 'RA typical erosions.||3', 'soft tissue pathology', 'resistant HTN', 'plant sterols', 'solid organ transplant.|Those who are currently pregnant', 'T2-4|Patients', 'AIDS)-related illness', 'post injury', 'left atrial catheter ablation', 'haemorrhagic', 'non-ST-segment elevation myocardial infarction', 'HBeAg negative', 'genitourinary abnormalities', 'meaning', 'superficial digital flexor tendon injuries', 'NVAF', 'impaired synthetic liver', 'migraine', 'intraductal carcinoma', 'OLP', 'aortic dissection).|Rhythm disorders', 'neonatal problems', 'FH-RCC', 'mild intercurrent illness', 'osteomyelitis', 'medical illness', 'viral loads', 'malnutrition|Pregnant', 'obstetric surgery|Allergies', 'localized prostate carcinoma', 'eye dryness', 'extranodal lymphoma', 'PROS-2).||', 'tablet computer', 'impaired hepatic function', 'non-study ETT', 'HbSOArab)|Age', 'disorders|cardiovascular disease', 'adenocarcinoma of', 'language disorder', 'TBI', 'lower limb surgeries', 'concomitant disease states', 'extremity dysfunction', 'African', 'Contraindicated', 'ventricular septal rupture);|Any', 'inner ear function.||Children', 'brain surgery|Current abuse', 'obstructive sleep apnea|Written', 'periodontal diseases.|Systemic diseases', 'neoplasm', 'ADHD||', 'chest wall + supraclavicular', 'major depressive illness', 'Robson scoring', 'recurrent disease', 'bone oligometastases', 'Human Epidermal growth factor Receptor 2 (HER2)', 'mental illness.|Positive analysis', 'periodontal disease|Teeth', 'inhaled hormones);|Suffering from mental illness;|The patient has', 'Nephrotic syndrome', 'accountability', 'bedsores', 'been amenorrhoeic', 'in situ', 'CRPS', 'root disorders', 'venous sinus stenosis', 'HRT', 'dihydropyrimidine dehydrogenase deficiency', 'CRC)|Colorectal Cancer', 'PDGFR', 'cerebrovascular event', 'conjunctival symptoms', 'solid organ transplantation;|Intestinal obstruction', 'renal agenesis', 'suspicious embolism', 'xerostomia;|Systemic inflammatory diseases', 'mean pulmonary vascular resistance', 'confirmed COVID-19 infection', 'motor vehicle accident', 'non-surgical root', 'excessive alcohol consumption', 'congenital disease-causing disorders', 'disaccharides', 'lymphoma|Human immunodeficiency virus infection', ""Quincke's edema"", 'pharmacotherapeutic histories', 'kidney disease|Coronary artery disease', 'tumor tissue also possible).|Patient has given', 'intrahepatic tumor burden', 'diabetic foot wounds', 'inheritable CNS spinal malformations', 'consent|Anuria', 'standard deviations below the mean on the famous faces test', 'Peripheral Nerve Stimulation', 'pre-radiation ultrasound', 'histologically-', 'primary tumour', 'cancers', 'high microsatellite instability', 'HIV seropositivity||Administration', 'walks', 'nonmodifiable bleeding', 'national guidelines.|For', 'active smoking', 'fatal hemorrhage', 'corticosteroids|Symptomatic', 'BCs', 'tumor perforation', 'tracheoesophageal fistulas|Evidence', 'HCV infection', 'Norplant', 'judged by the principal investigators', 'neurocognitive disorders', 'chronic infectious diseases', 'light therapy|Female', 'bladder tuberculosis', 'renal mass core biopsy', 'growth factor', 'middle ear occlusion', 'comorbid psychiatric conditions', 'Allergic bronchopulmonary aspergillosis', 'membranous nephropathy', 'analphabetic', 'months;|Pregnancy', 'MCI)|Subjective cognitive complaints|Evidence', 'glomerulosclerosis', 'sunglasses', 'severe diaper dermatitis', 'chronic hepatitis need', 'molar teeth', 'vesicle cyst', 'Transgender Females|HIV', 'illiteracy|inability', 'gastrointestinal surgery;|patients', 'basal cell carcinomas', 'alcohol/substance abuse disorder).|Is', 'functional dyspepsia', 'appendiceal cancer', 'rapid maxillary expansion|Presence', 'essential fatty acids', 'tuberculosis|Serious infection', 'ametropia', 'risk prostate cancer', 'familial combined hyperlipidemia', 'oxalate nephropathy', 'major neurologic deficits', 'cystic neoplasms', 'impairment of cognitive', 'castration resistant prostate cancer', 'atheroma', 'gastrointestinal chronic conditions associated', 'close contact', 'indication;|Clinical manifestations', 'major depressive disorder', 'treatment-free interval', 'left-sided', 'abstain from participating in another interventional clinical study', 'muscle disease', 'injectable melanoma lesion', 'distal embolization).|Presence', 'SLL', 'Fanconi anemia', 'hepatitis C ribonucleic acid', 'hyperinsulinemia', 'cancer thrombosis', 'large vessel stroke', 'suicidal tendency.|Usage', 'host factor', 'isoflavones.|Blood pressure', 'pulmonary vascular resistance', 'umbilical cord', 'spleen-kidney yang deficiency', 'Long QT Syndrome', 'below:||Degenerative anterolisthesis|Pars defect', 'unexplained alarm features', 'lesions', 'cardiopulmonary diseases', 'left main stem coronary stenosis|Asymptomatic severe', 'head pain', 'bodily problems', 'resolved disease', 'genital tract malignancy|Prior', 'unstable coronary artery disease', 'breast cancer|Non pregnant', 'malaria.||Exclusion criteria||Circulatory failure', 'radiation hepatitis', 'gastrointestinal malformations', 'malignant disease.|Pregnancy', 'urinary tract infections.|Pregnant', 'infiltrative disease', 'persistence of lung parenchymal abnormalities', 'intraarticular injection into the glenohumeral joint within', 'NRS)|Subject', 'physical dysfunction', 'radiological progression', 'acute care hospital', 'alpha-1-antitrypsin disease).||2', 'vascular injuries', 'small lesions', 'hepatitis C virus (', 'executive functions', 'assessment|Pregnant', 'Fetal chromosomal', 'neurologic illness', 'increased intracranial pressure/hypertensive hydrocephalus', 'mixed urinary incontinence', 'consent.|Pregnant', '40 lupus', 'zonular weakness', 'virus infection', 'CTCAE v4.03', 'Cardiovascular disorder', 'CMHC providers are:||Employed', 'statins|Sensory impairments', 'Ankylosing Spondylitis', 'solid organ transplant.||Current', 'organic sleep disorder', 'Thyroid disorder.|Current', 'tumor lysis syndrome', 'canal-treated', 'hours|Adult', 'localized skin cancer', 'general conditions', 'myelohypoproliferative diseases', 'lorazepam', 'intense pulsed light [IPL]', 'serious medical condition', 'BK nephropathy', 'age|Understanding', 'breast-fed more', 'IVUS', 'HCQ', 'attendings', 'local guidelines|Conditions', 'above.|No vision', 'TDP-43 Encephalopathy', 'delayed toxicity|Patients', 'Cervical pain', 'bone marrow nucleated cells', 'distal renal artery', 'relapsed lymphoma', 'rare brain tumor.|Signed', 'EGFR', 'non-negotiable canals|Teeth', 'unsuitable candidate', 'clinical symptoms only', 'immunological functional defects', 'LAM avulsion', 'major malformation|Neuromuscular condition', 'visual disturbance|Congenital conditions of the cervical spine|It is of primary concern', 'posterior pelvic pain provocation test (P4)', 'back trouble', '≥1 Abluminus NP', '2:||Viral failure', 'acute cardiovascular events', 'rectal cancer|Completed surgical resection', 'pure alcohol', 'breast cancer;|At least one', 'sleep problems', 'sinus node dysfunction', 'metastasis tissue', 'CSF||', 'inflammatory skin diseases', 'mechanical damage', 'disease-modifying drugs (Diaserein', 'Streptococcus pneumoniae infection', 'venous thromboembolic disease|Transfusion', 'medical conditions stable', 'immune related neuropathy', 'neuropathic character', 'hormonal hypersecreting adrenal mass,|symptoms', 'acute constipation', 'deltoid ligament injury confirm', 'SCA type STEMI', '6th-8th graders|identified', 'pregnant', 'inflammatory condition|Current treatment', 'acquired immune function defects', 'height|Poor oral hygiene', 'psoriasis lesions', 'SBP>140/90 mmHg', 'CIRT|Nodal involvement', 'rabies victim', 'PSA', 'disease of the spine', 'reproductive tract', 'organ system dysfunction', 'nervous system disorder', 'Dizziness', 'refractory glaucoma', 'discharged from hospital before 10', 'groups||Neurobehavioral disorder', 'diverticulitis', '②be cancer', 'malignant pleural effusion', 'NCCN risk group criteria', 'AIDS-HIV', 'respiratory virus', 'mental illness|Clinically', 'cervical spine issues|Chronic vertigo|Vestibular problems', 'Cardiac).|Fetal malformation', 'benign musculoskeletal origin.||Tension myositis syndrome', 'CMV infection', 'Long QT Syndrome.|Positive serology test', 'uterine carcinoma', 'aphthous ulcers', 'respirators after arterial thrombectomy||', 'hepatitis C;|Human immunodeficiency virus (HIV)', 'non-restorable', 'sleep-associated symptoms', 'hypoxemic ARF', 'surrounding organs;|No abdominal seeding', 'angina pectoris', 'oral candidiasis', 'hyper/hypothyroidism', 'under eye', 'pulp sensibility', 'squamous cell carcinoma lesions', 'stayed', 'kidney problems', 'coagulation times', 'domestic', 'pulmonary fibrosis|Any condition', 'day).|Systemic disease', 'impact growth', 'extrahepatic distant metastases', 'pre-excitation syndrome', 'arteriovenous (AV) fistula', 'acute glucocorticoid', 'septum deviation', 'S6 segmentectomies|S4', 'Down syndrome etc.)|Presence', 'judged to be postmenopausal', 'more|type 2 diabetic', 'asymptomatic gallstones', 'cerebellar tonsillar hernia|Severe atlantoaxial dislocation|Osteochondroplastica|Rheumatoid arthritis|Down syndrome|Refurbished', 'acute respiratory syndrome', 'delirious', 'reporting anxiety symptoms', 'histopathological type', '~minimal neuropathy', 'nephron loss calculated on the average of the two previous years', 'Sensation of incomplete evacuation', 'cardiac arrythmia', 'Neurosurgery FPG;|Be', 'auscultatory abnormality', 'hire', 'subjective reasons', 'end-stage organ failure', 'organs;|Active severe infection', 'identifiable pathology', 'comprehensible reasons', 'respiratory system', 'intestinal adhesions', 'chronic insomnia|Insomnia Severity Index (ISI)', 'daytime sleepiness', 'naked eye', 'valvular heart disease)|BMI', 'disorder|Having', 'failure of BTK inhibitor therapy.|3)', 'above depressive symptoms', 'diet|Able to take pictures', 'temperature', 'cardiogenic shock.|Previous coronary artery bypass graft surgery', 'elsewhere)||', 'Painful', 'Periodontal disease', 'abdominal infection', 'shunt|Brain tumors', 'PCM-detected', 'subgingival', 'malignant pericardial effusion', 'etc.;|Metallic implants', 'AF-related catheter ablation', 'gastritis', 'limb ischemia', 'ectopic varices', 'toxic response', 'AIDS-related illnesses', 'structural anatomic defects', 'are:||Inclusion Criteria:||Presence', 'liver disease;|Uncontrolled', 'lubricants.||Baseline symptoms score', 'cider vinegar', 'infantile FSHD|Pregnancy', 'incompatible with', 'decubitus position|Extreme heart rates', 'intestinal ulcerative disease', 'Renal artery stenosis', 'arousal difficulties', 'anaplastic lymphoma kinase (ALK) translocation', 'chronic nasal obstruction', 'CTS', 'kidney transplants.||', 'bicortical fracture', 'autoimmune neuromuscular disease', 'Iron deficiency anaemia', 'disability|previous', 'Down syndrome', 'caries risk', 'primary liver Cancer of the', 'fundus surgery;|Those with eye diseases', 'Hematological disease', 'brain health risk factors', 'menstrual pain', 'crescentic glomerulonephritis', 'massive pleural', 'disease of the aorta', 'Homologous Recombination Proficiency (', 'Class V glomerulonephritis', 'uncontrollable mental illness', 'distant metastases ruled', 'under court', 'pulp involvement', 'inadequate liver function', 'pulmonary infiltrates', 'impossible to apply therapy', 'extra precautionary measure', 'prior bladder instillation', 'end stage renal disease', 'comorbid somatic illness', 'tried', 'old;|Mitral valve insufficiency', 'left ventricular function', 'Thyroid cancer', ""clinician's judgement|patient"", 'vitreomacular adhesion', 'active COVID-19', 'hepatic metastasis', 'extensive-stage SCLC', 'polio', 'hirsutism', 'ollege graduates', ""complicated meckel's diverticulum||"", 'distal femur fracture around', 'Premature group:||-', 'serious disorder', 'adenocarcinoma of prostate.|Prostate cancer', 'spinal injuries|severe', 'thrombotic tendencies', 'buccal bone wall loss', 'spontaneous subarachnoid haemorrhage', 'chemotherapy,|Peripheral artery disease', 'cardiac repolarization abnormality', 'insertable', 'fails', 'individuals|Not', 'human immunity Epidemic defect virus', 'local infections around', 'marginal explainable', 'CADASIL - Cerebral Autosomal', 'skin care products', 'intermittent claudication', 'bladder pain syndrome', 'Type 2 diabetic', 'canal infection', 'joint.|Inadequately controlled pain', 'essential thrombocytopenia;|local skin ulceration', 'carriers', 'uterine factor infertility', 'chronic liver diseases;|Patients', 'decompensation Hepatic', 'pathological origin|Sudden cardiac arrest|Unprovoked', 'blood thinning', 'fungal conjunctivitis', 'etc.|Systemic abnormalities', 'tape', 'lymphatic component||Unaffected', 'Peripheral neuropathy', 'Atrial fibrillation|Active pacing', 'hepatitis B vaccine.|Maternal use of', 'gastric cancer', 'focal lesions', 'right sided', 'squamous cell', 'hair loss', 'poor bone density).|The', 'traditional Chinese', 'meningeal enhancement', 'artificial nutrition|advanced dementia|admission', 'morphological changes', 'HBsAg+', 'lung metastases', 'wall thrombosis', 'urgency', 'Brain metastases', 'lymphatic disease.|Lymphatic anomalies', 'visible on CT planning|Medically inoperable disease', 'LSD', 'bleeding C', 'Bilateral disease', 'females).|Participant', 'lung injury', 'esophagogastric junction;|ECOG PS', 'breastfeeding;|Cognitive', 'asymptomatic|Thoracic disease', 'aortic disease', 'SCAD', 'non-interventional study', 'liver disease.|Systolic BP', 'MEPL', 'thoracic aorta.||Patients', 'insufficiency|Thoracic outlet syndrome|Cervical spine', 'abdominal nature', 'products containing dihydroepiandrostenedione', 'thalamic glioma', 'non-infected diabetic foot ulcer', 'self-diagnosis', 'photosensitivity', 'Insomnia Disorder', 'serious injury occurred', 'malignant mass', 'arteriovenous sheath', 'exaggerated fears', 'chest wall bone disease', 'GA', 'disorder,|Metabolic alcaloosis', 'metastatic disease||2a', 'preserved reproductive potential', 'COVID-19 infection', 'Hungary);|Diagnosis', 'hepatic disorders', 'periventricular leukomalacia', 'pregnancy|refusal', 'intraoperative complications', 'psychiatric problems.||', 'PBH', 'Autoimmune hepatitis', 'Rigshospitalet', 'renal functional compensation', 'year|Diagnosis', 'aorta aneurysm', 'a:||Patients', '/epileptic', 'lumbar spinal disease', 'trans-gastric views.|Life expectancy', 'deprived', 'excessive bleeding', '1|Hepatocellular carcinoma', 'metastatic ovarian', 'hyperglycemia', 'Michigan campus', 'pathology of the central nervous system (CNS)', 'systemic therapies|Patients', 'UA', 'immunological disorder', 'drug-induced deafness.|Basic information is incomplete', 'End-stage renal disease|Oliguric', 'kidney surgery;|People', 'ring X mosaicism', 'symptoms attributable', 'purpura nephritis', 'intraperitoneal', 'HMB', 'vital functions', 'POTS', 'severe dementia', 'dizziness|Intestinal obstruction|Patients', 'biopsies', 'breast cancer surgical resection', 'COVID)-19 vaccines', 'solid cancers', 'Cognitive disturbance|Psychotic symptoms', 'CT|Under', 'CEUS', 'transfusion dependence|Patients', 'schizotypal disorder', 'perforation;|Arteriovenous thrombosis', 'chemotherapy|GYNECOLOGIC CANCER', 'intracranial arterial stenosis', 'nonpain indication', 'perforated ulcer', 'drug absorption and metabolism', 'congenital agammaglobulinemia', 'associated adverse events', 'hormonal disturbances Pregnant', 'pipe).|Systemic conditions', 'device||Double-barrier method', 'Facial pain', 'auditory disorders contraindicating', 'left bundle block', 'unusual neurocognitive disorders', 'intraocular inflammation', 'dependence on alcohol', 'acute organ damage beyond cardiomyopathy', 'maternal trauma', 'tumor necrosis factor inhibitor', 'old|Female', 'responded', 'arrythmia|Unstable', 'filled teeth', 'impaired glucose tolerance', 'myocardial zymogram CK', 'colorectal cancer (HNPCC)', 'Type 1 diabetes.|Recent', 'peritoneal effusion', 'reproductive age|vaginal birth||', 'cardiovascular condition', 'urinary retention.||Subjects', 'AIHA', 'distant localizations', 'Subacute Stroke', 'bladder removal', 'fibrillation', 'intra-cardiac shunt', 'psychosomatic disorder|Tumor.|Infection', 'serious psychological disorders', 'inflammatory related illness', 'CPR', 'chronic bladder inflammation', 'age;|Montreal Cognitive Assessment (MoCA)', 'angiographic complication', 'lactation.|22', 'criteria of KDIGO', 'hip disease', 'basal cell carcinoma', 'mentioned', 'periodic alcohol', 'significant breathing', 'vaginal douche products', 'pulmonary stenosis', 'Malabsorptive conditions', 'tonic-clonic seizure', 'Model for End-Stage Liver Disease (MELD)', 'primary melanoma', 'dry eye syndrome', 'palliative care', 'idiopathic pulmonary', 'Ventricular arrhythmia', 'cardiac problem', ""child's"", 'immunity related disorder', 'bladder permeability.|Patients', 'schizophrenia|Contraindication for vaginal delivery|A', 'extra-pulmonary', 'renal disease.|Patients', 'kidney deficiency', 'progressive muscle relaxation', 'other)|Spondylolysis', 'exclusion criteria around', 'extrahepatic disease；|No complications', 'neurological disorders|assumption', 'chronic leukemic lymphoma', 'acne|Patient', 'extramedullary myeloma', ""Parkinson's medications"", 'partial obstructions of', 'visual deficit', 'age|Physically healthy', 'liver malignant tumors', 'ASAT', 'Uncomplicated', 'vascular aneurysms', 'hemorrhagic tendency|The', 'mixed tumor', 'breast tissue expander', 'central vision', 'involvement of the trunk', 'FFA', 'chronic tonsillitis', 'unresectable melanoma', 'spinal cord injury);|Patients', 'sensitivity to methylphenidate', 'kidney diseases|Bilateral lymphedema|Skin diseases|Cellulitis', 'psychiatric disorders||', 'ascites infection', 'them|Positive 24h pH-metry', 'chest drains|Presence', 'Carcinoma in situ of the breast', 'lung condition', 'successful,|Health follow-ups', 'Acute periapical abscess', 'normal chromosomal microarray (CMA)', 'subarachnoid hemorrhage;|A history', 'T2DM||Type 1 Diabetes Mellitus', 'psychosocial distress.||Complete', 'sign of infection', 'Morbid obesity', 'heparin-induced', 'progressive multifocal leukoencephalopathy.|Patient', 'meditation|Turns', 'passive knee extension degree', 'AND|Spinal pain score', 'developmental deformity.|Good oral', 'active cancer treatment', 'community violence|report', 'cold antibody AIHA', 'severe dry eye disease', 'recovered from any effects', 'arrival', 'occluded contact.||', 'primary lung cancers', 'pulmonary pathology', 'hemiablation', 'atrial appendage thrombosis', 'acromegaly', 'carpel tunnel syndrome', 'Bronchial Asthma', 'metastatic prostate cancer', 'cognitive functions', 'hepatitis B virus [HBV] DNA', 'Pneumocystis jirovecii', 'aggravation', 'episodic hangover', 'renal impaired patients||Patients', 'congenital syndrome', 'intrahepatic tumor lesions', 'teeth|Sever', 'concurrent illness', 'facial deformity', 'Criteria||Evidence of hepatitis B', 'allowed.|Prophylactic', 'positioned.|Abnormal pain behavior', 'bacteremia', 'paroxysmal atrial fibrillation/flutter', 'hypoproteinemia', 'signs of pulpal infection', 'constant dominant strabismus', 'enema', 'pathological remission', 'Acute decompensation', 'coronavirus pneumonia', 'donor type', 'sinus cancer|Pregnancy', 'renal artery', 'abstain from illicit drugs', 'pilonidal sinus', 'fatigue.|endocrine autoimmune disease', 'endometrial cancer|Meeting physical activity', 'coagulopathy|Severe renal disease', 'squamous cell skin carcinoma.|Currently pregnant', 'ectodermal dysplasia', 'childhood trauma', 'visit|Substance', 'type 1 diabetes;|severe diabetes-related', 'examination.|Biliary obstruction', 'correlative research||', 'psychiatric disorders.|HIV infection', 'thoracic neoplasms', 'aortic aneurysms', 'chronic knee pain', 'permanent dermal fillers', 'diabetic peripheral', 'genicular nerve block', 'neonatal stroke', 'localized skin cancers', 'pain', 'cardiovascular disorders.|Diabetic ketoacidosis', 'proteinuria', 'progressive dyspnea', 'hepatitis C.|History of', 'type 1 diabetes.|Unable to communicate', 'unintentional weight loss', 'sodium overload justifying the prescription of loop diuretics', 'myocardial infarction', 'extrahepatic disorders', 'allergic reactions.|Patients', 'non-communicable diseases', 'recurrence through', 'spinal cord trauma', 'HIV-infected', 'biliary tract tumors|Patients', 'illness|Active infection', 'DM-BTPS', 'immunoadsorption', 'Diabetes mellitus', 'immunodeficiency;|Severe infections', 'localized squamous cell cancer of the skin', 'isokinetic muscular assessments|Cognitive', 'refractory cachexia;|Bleeding', 'adverse events', 'laboratory values', 'deficiency', 'etc.|Peripheral neuropathy', 'bacterial fluorescence imaging', 'leukaemia', 'Developmental', 'carbohydrate-restricted diet', 'affect bladder function', 'irritable bowel syndrome', 'extra abdominal injuries', 'cuboid bone', 'SARS-CoV-2;|The', 'coagulation disorders', 'culprit lesion', 'self harm behaviours', 'localized infection', 'CBT', 'acute liver failure.|Allergic', 'dependence', 'peripheral nerve stimulation', 'chronic cholestatic disease', 'acute severe asthma', 'elevations', 'chronic health problems', 'testicular cancer', 'traumatic lesion', 'SPECT scan', 'Unilateral transtibial (', 'anterior circulation infarction', 'non-cardiac procedures', 'facet disease', 'malignant tumour.|Patients', 'respiratory cessation', 'Acute mental health crisis', 'participants.|Chronic kidney disease', 'light for myopia control', 'papillary carcinoma', 'EGFR-sensitive mutation', 'progressive metastatic castration-resistant prostate cancer', 'PET centre', 'neurological disorder', 'personality disorders|Patients', 'albuminuria', 'right vastus lateralis muscle', 'rotator cuff tendons', 'mainly liver cirrhosis', 'microcytic', 'mutant glioma', 'other respiratory diseases', 'esophageal surgery.|Esophageal stricture', 'judgement)|Attention-deficit hyperactivity disorder', 'structural damage', 'electrolyte EudraCT#', 'brain organic disorder', 'malnutrition status', 'surgically unresectable', 'excessive drinking.|Known allergy', 'hemorrhagic tendency(bleeding>30ml', 'chronic atherosclerotic obliteration', 'psychiatric disorder(s)', 'neurological disorders|Knee trauma', 'chronic pulmonary heart disease', 'allotransplantation', 'child-bearing potential', 'genital adverse effects', 'adverse drug reactions', 'autoimmune disease|with', 'revision ACLR', 'mood disorders', '}', 'Jacob-Creutzfeld Disease', 'phenylketonuria disease', 'posterior hemiblock', 'neuroendocrine tumor', 'STI', 'DNA', 'IgE-mediated event', 'hemodialysis|Active infectious diseases', 'leaks', 'liver enzyme inducer', 'bone marrow involvement', 'prognosis', 'prolonged resuscitation', 'polymyalgia rheumatic', 'peritoneal lesion', 'superficial bladder cancer', 'respiratory diseases.||', 'T1c', 'Class 4 heart disease', 'Peripheral nerve', 'swallowing tablets', 'common femoral veins', 'small bowel resection|A', 'immune dysfunction', 'participate|Withdrawal of informed consent', 'endoscopic obesity', 'brain metastatic lesion', 'disease|Concomitant disease', 'dermatitis herpetiformis', 'intracranial occlusion', 'sinus heart rate', 'Chronic disease', 'laceration wounds', 'extranodal lesion', 'surgery;|Connective tissue disorders', 'COPD patients|COPD', 'lack of autonomy', 'residual macroscopic disease', 'urinary system tumors', 'clinical manifestations of eczema', 'late pregnancy', 'cerebrovascular structures|Scheduled postoperative inpatient overnight', 'peripheral nerve pathology', 'alcoholic drinks daily|Tobacco', 'inguinal herniation', 'malaria', 'Generalized Anxiety Disorder questionnaire', 'uveitis', 'other eye disease', 'pulmonary valve implantation', 'risk factors for PPD', 'CLL)|Small lymphocytic lymphoma', 'chronic pancreatitis.|Any impairment', 'focal refractory epilepsy', 'etc.)|Mental disorders', 'central neurological impairment', 'participant)|Personality Disorder', 'thyroid goiter)||Both', 'mixed nodules', 'bipolar type I disorder', 'lymphoma cells', 'herpetic stromal', 'Iron sucrose|Pregnant', 'anaplastic lymphoma', 'osteoarthritis of the', 'upfront cystectomy', 'limit clinical visualization', 'evaluable tumor sample', 'non melanoma', 'calories', 'ultrafiltration', 'hiatal hernia', 'clinical sense', 'facial involvement|Subject', 'nervous system disease|ASA IV|emergency surgery|patients', 'neurologically unstable', 'psychiatric observation.|Chronic alcohol abuse', 'peritoneal dialysis.|Traumatic injury', 'injectable tumors', 'Pittsburgh Sleep Quality Index)|Education level', 'Chronic liver failure', 'organ enlargement', 'interstitial changes', 'Aarhus University Hospital', 'non -febrile', 'artery disease', 'anaphylaxis.|Severe asthma', 'non-V600E', 'exon 20 insertion', 'premature ovarian', 'APTT', 'alcohol breath', 'sagittal split', 'urological disease', 'brachial plexopathy', 'monogenetic', 'cabin|Patient allergic', 'Human Immunodeficiency Virus', 'optic disc excavation', 'blood donations', 'Complain of', 'antibodies', 'mental health conditions', 'orthodontic treatment.|Systemic disease', 'total colectomy;|Other autoimmune diseases', 'secondary immune deficiency', 'AV block f', 'leucopenia', 'motor vehicle', 'pregnant|Speaks', 'heart rate.|Be able', 'ocular malignancy', 'immunodeficiency state', 'urinary retention|Concomitant intravesical botulinum injections|Concomitant prolapse surgery|Known', 'subcutis', '≥9.0%;|Active bacterial', 'adverse skin condition', 'middle ear balance', 'chronic alcohol', 'memory disorder|the carious lesion', 'intravenous iron', 'burning mouth syndrome', 'infectious condition', 'Chronic Lymphocytic Leukemia', 'sodium stearyl fumarate', 'FVC', 'rotator cuff tear|History of', 'brain abnormality', 'solid malignant neoplasms', 'clinical symptoms of', 'Medical instability limiting', 'hemolytic', 'PCR)|For infections', 'nondoubly-irradiated', 'hepatitis B polymerase chain reaction (PCR) evaluation before', 'Menopausal', 'limiting', 'local regulations.|In', 'hypervolemia|kidney failure|pregnancy', 'liberty|Pregnant', 'duct carcinoma in situ', 'mandibular incisors', 'Pulmonary embolism', 'tumor shrinkage', 'sexuality', 'Systemic contraindications', 'facial volume defects', 'nerve injuries', 'T2 hyperintense lesions', 'swallowing therapy|between', 'bowel like IBD', 'gastric tumor', 'metastatic lesion accessible', 'nail changes', 'ventricular hypertrophy', 'stage|Histological evidence', 'chest adhesions', 'intervention;|Vascular embolism', 'dependent persons|Emergency procedure', 'depolarization', 'abstain from heterosexual intercourse', 'significant condition', 'cardiac surgeries.|Intra-cranial surgery.|Chronic pain', 'congenital nystagmus', 'asymptomatic brain metastases', 'hepatic metastases', 'compromised peripheral circulation', 'compromised immune status.|Children', 'related diseases', 'chronic gastrointestinal conditions', 'GI tract disorders', 'exposure|Known bleeding disorder', 'clinically localized', 'pre-injury walking', 'intravascular thrombus aspiration', 'delayed type hypersensitivity', 'TED', 'point tenderness', 'pseudoexfoliation syndrome', 'intracavitary', 'myocardial damage', 'housing instability', 'major mutational driver genes', 'mixed subtype', 'mild stenosis', 'Memory Impairment Screen', 'non-atherosclerotic renal artery stenosis;|Pregnancy', 'inflammatory condition;|Live', 'therapy.||Chronic Lymphocytic', 'serologic findings suggestive of', 'recurrence of OC', 'Myocardial Injury', 'rheumatic disorders', 'Mild periodontitis', 'hepatitis B reference', 'pancreatic cancer patients.||', 'points;|Blood pressure', 'immune-mediated disease', 'respiratory motion', 'bleeding disorder|Organic GI diseases', 'traumatic event', 'primary induction failure', 'hyperosmolar states', 'FT4', 'etc.)|Major illness', 'measure-confirmed', 'ischemic heart disease|Patients', 'hypoxic ischemic lesions', 'down syndrome', 'extra peritoneal biopsy', 'malignant meningiomas|Patients', 'end-stage liver disease', 'non-melanocytic skin cancer', 'internal diseases', 'heparin-induced thrombocytopenia', 'acromegaly;|diabetic ketoacidosis', 'cervical medial branche block', 'pancreatic duct stenosis', 'allergy symptoms', 'treatment|Parkinson disease', 'initiating Ofatumumab', 'disseminated intravascular coagulation', 'Little', 'non-correctable causes', 'progressive central nervous system (CNS) metastases', 'corneal abnormalities|Participants', 'hip prosthesis', 'functional impairment.|Medically non-adherent', 'complex care).||', 'brain metastases treated', 'etc.);|interval between', 'mental symptoms', 'COVID-19 have entered', 'hepatitis B virus (HBV)', 'RP||', 'BCC)/squamous cell carcinoma', 'Initiating', 'tubal ligation', 'complete stiffness', 'common carotid artery|Absence', 'Swedish.||No in situ magnetic device', 'positive air pressure', 'rheumatic autoimmune diseases.|Female', 'partial rotator cuff tear', '6.Active infection', 'surgical menopause', 'medullary hypoplasia', 'mental incompetence', 'malignant tumors', 'coeliac disease|Presence', 'longest diameter', 'vital signs results.||Additional Key Inclusion Criteria', 'pathological records confirm+B72ed', 'maxillae', 'neurological co-morbidities', 'vigorous physically activities', 'gynecological tumors', 'risk|Active infection', 'anatomic abnormalities', 'fluorescence in situ hybridization +', 'haemodynamically stable', 'acute reversible angiopathy', 'primary lung cancer', 'recurrence of disease', 'DKA', 'pathology of the facet joints of the involved', 'idiopathic anaphylaxis', 'small meningioma', 'neurological disorders|Difficulty complying', 'Herpes Simplex infection', 'hepatic cirrhosis', 'lues.|Concomitant diseases', 'non-melanoma skin cancer);||B', 'HAE attacks|Participation', 'visceral metastasis;|8', 'progressive growth', 'cardiovascular instability.|aggressive', 'chronic care', 'restenotic chronic total occlusion', 'prophylactic antibiotics);|Active autoimmune diseases', 'collateral circulation', 'OSAS', 'mental illness;|Autoimmune disease', 'old;|Diagnosis of IBD', 'Epilepsy', 'right heart Doppler ultrasound', 'detect infection', 'valvular disease|Clinically significant', 'human Papilloma Virus', 'dosing gap.|Participant', 'Hepatitis B virus infection', 'FAPI', 'exceptions:||--Autoimmune hypothyroidism', 'TB', 'frequent exacerbations', 'FPMs', 'Those', 'acute myeloid Leukemia', 'fructooligosaccharides', 'WPAFB)|Able', 'severe hepatic', 'non-hydantoin', 'PSMA positive', 'etiology|Autoimmune hepatitis', 'NIMV', 'absent|Appropriate HR response', 'echinococcosis', 'Poseidon criteria', 'rare systemic diseases', 'primary plasma cell', 'primary rectal tumor', 'abnormalities of medical', 'modifying the pain threshold', 'Sierra Nevada Healthcare System', 'breath carbon monoxide reading', 'autoimmune diseases.|Received', 'distant metastases|Contraindication', 'anatomical landmarks.|Localized infection', 'severe pulmonary hypertension', 'extensive family', 'autoimmune disorders).||Serology screen', 'digital photographs', 'herpes simplex virus infection', 'diagnosed pathology', 'spinal deformity;|At rest', 'cutaneous basal', 'liver cirrhosi;|Endoscopy shows', 'asthma controller medication', 'hip dysplasia', 'esophageal adenocarcinoma', 'months;|Biochemical recurrence', 'Esophageal Carcinoma', 'gestational', 'radical operation', 'congenital abnormality in metabolism', 'target lesions', 'chronic sleep disorders', 'comorbidity', 'COVID-19', 'retinopathy|diabetic maculopathy', 'SNB', 'congenital long QT syndrome', 'coexistent migraine', 'traditional cryo|Pregnant', 'contrast sensitivity', 'bilateral total mastectomy|If', 'sudden unexplained', 'involvement of the furcation|a minimum', 'assessing suitability', 'musculoskeletal disease', 'advanced periodontitis', 'tachyarrhythmia', 'age|Children', 'prolonged bleeding||**Please note this protocol', 'miles from cardiac rehab center', 'substantial potential', 'lower GI complaints||', 'clear margins', 'amplification|Measurable disease', 'major cognitive problems', 'St Eloi vascular medicine team and vascular radiologist performing the endovascular treatment)|Age', 'long QT syndrome', 'procedures.||Renal cell carcinoma', 'non-melanoma skin carcinomas', 'gastrointestinal disease|Secondary AL amyloidosis', 'self-injurious ideation', 'eczema', 'atypical Parkinsonism', 'extraction socket', 'disorders|Spondylolisthesis|Inflammatory neck pain|History', 'chondral pathology', '1|Diabetes mellitus', 'postoperative platinum therapy', 'traumatic dental injury', 'immune checkpoint inhibitors', 'thyroid gland dysfunction', 'good quality', 'acute course treatment', 'tumor resection|Ability', 'ATIII deficiency', 'monocarbon metabolism', 'attention-deficit disorder', 'important organs', 'neurosensory impairment', 'prechiasmatic field', 'not the first-born child', 'orthopedic disability', 'CTCAE grade ≤1', 'myocardial ischemia|Detection', 'tumor extension into the stomach', 'gingko biloba', 'gastrointestinal bleed 2', 'Marburg virus disease', 'Clinical insomnia symptoms', 'concomitant skin', '≤200 mg.||', 'borderline symptoms', 'T1DM', 'psychology', 'breast lesions.||', 'oligo-progression', 'chills|congestion', 'congestive heart failure.||Patients', 'spinal cord compression.|Participants', 'pericardial disease', 'invasive carcinoma', 'source|Chronic obstructive pulmonary disorder', 'carcinoma in situ of uterine cervix', 'self-awareness', 'lower extremity injury', 'intestinal tuberculosis', 'Amyotrophic lateral sclerosis', 'Ductal carcinoma in situ', 'unresectable HCC,|(b', 'bleeding diathesis,|Presence', 'human immunodeficiency virus (HIV) antibody positive', 'place of residence', 'Critical illness', 'concentration disorders', 'roxithromycin)).|Contra-indication', 'vaccine reactions', 'acute renal insufficiency', 'disease|Relevant weight loss drugs', 'extra-uterine disease', 'megacolon|Persisting maternal tachycardia', 'restrictive diseases', 'systemic condition', 'auto-immune cytopenia', 'athletic types', 'physically present||', 'localized breast cancer', 'degenerative lesions', 'left main coronary', 'structural cardiomyopathy', 'NF1 syndrome', 'projection', 'intracranial vascular malformation', 'amyloidosis|Myelomatosis|Monoclonal gammopathy', 'Bipolar Disorder', 'hypertension|Type 1 diabetes', 'complete portal vein thrombosis of the portal vein', 'DLBCL', 'milk)||Inclusion Criteria:||Males', ""Colon-Rectal Cancer Duke's class"", 'Liver Disease', 'menstrual cramps|Consumption', 'consciousness;|Spinal cord electrical stimulator', 'PI.|Pregnancy', 'neurologic injuries|Pathological fracture', 'feeling of pressure', 'Osteoarthritis', 'epidural disease', 'leptomeningeal metastases|Diverticulitis', 'dietary concerns', 'chronic renal failure|Evidence', 'msec', 'SE', 'therapy||Melanoma:||BRAF V600E', 'examination|Suspicious lesions', 'behavioral health services', 'Chronic Atrophic Gastritis', 'nasal cavity abnormalities', 'respiratory illnesses', 'Nonpregnant', 'T2 lesions', 'Sjogrens Syndrome', 'normal pressure', 'neurodevelopmental disorder.||OR||3', 'females|Healthy', 'non-English speakers', 'T wave abnormalities', 'Obesity-related||-', 'apnea', 'control;|Active infection;|Known allergy', 'asked', 'severe injury', 'idiopathic intracranial hypertension', 'erosive gastritis', 'hepatic impairment||Hepatocellular carcinoma.|Acute', 'Bronchospasm', 'pulmonary embolism.|Patients', 'surgery|Pregnancy', 'autoimmune hypothyroidism.|Skin diseases', 'worse congestive heart failure', 'immunodeficiencies', 'febrile childhood', 'cerebrovascular clinical symptoms', 'age|Postoperative surgical patients|Signed', 'mitral stenosis;|Electrocardiogram QTc', ""Parkinson's disease dementia"", 'intercurrent infection', 'base', 'Bruton disease', 'solution.|Subject', 'liver function damage', 'FSGS', '≤6/10|Vaginal bleeding', 'COVID-19 infections', 'severe lupus pneumonia', 'hemoglobinuria', 'hemispheric stroke', 'Rheumatoid Arthritis.|Patients', 'bone marrow functions', 'functional extranodal involvement', 'diagnosis|Active autoimmune disease', 'major morbidities compromising', 'auto-immune', 'cardiogenic pulmonary edema', 'weight-loss therapy', 'major internal', 'impaired cognition|Children', 'epilepsy', 'sacroiliac arthritis', 'corneal degeneration', 'First Episode Psychosis', 'etc.;|Suffering', 'DU', 'C.|Autoimmune diseases', 'lupus)|Chronic systemic pain', 'angle glaucoma', 'acute lithiasic cholecystitis', 'symptoms of COVID-19', 'chronic kidney disease.|Unstable cardiac', 'chronic renal insufficiency (', 'malignant tumors;|Exclude', 'deterioration', 'coagulation function', 'non-culprit lesion', 'progressive multifocal leuko-encephalopathy', 'acute asthma exacerbation.|The', 'neurological disorder(s)', 'cT3N0)|Candidates', 'consent|Age', 'Subacromial', 'hypothalamus|Hemochromatosis', 'mental condition rendering', 'disc height', 'right ventricular pacing', 'mixed cell carcinoma', 'traumatic origin||', 'nonischemic', 'liver invasion', 'channelopathies', 'acute pericarditis', 'inclusive|Asymptomatic Carotid Artery Disease (diameter stenosis', 'Acute coronary syndrome', 'fatty acids', 'insoles', 'endocrine disorders|Physical handicaps', 'Inflammatory bowel diseases.|Use', 'abnormalities|Physical findings', 'malignant neoplasms', 'Uni-', 'ARF', 'pathological symptoms', 'HCV.|Participant', 'risk reduction', 'PFO', 'Diabetes Mellitus type', 'OSA', 'chronic active infection', 'sinus infection|Refusal', 'STDs pathogen infection', 'antihypertensive drugs.|Systemic diseases judged by investigators', 'concomitant diseases|Enrolment', 'significant trauma', 'endocrine distrubances(DM', ""Bruton's tyrosine kinase inhibitor ("", 'grade 3/4 pneumonia', 'abnormal orgasm', 'HTN controlled', 'internal pathologies', 'myeloma defining events (MDE', 'medical conditions|Unable', 'extremities.|musculoskeletal pain', 'benign disease', 'classification|5 Infection', 'retinoblastoma.|Allografted patient.|Patient', 'hematogenic infectious diseases', 'extensive meningeal metastases', 'drug-refractory epilepsy', 'benign neoplasms', 'acute coronary syndrome.|History of diagnosis', 'psychiatric pathologies', 'gynecologic malignant disease', 'Epithelioid sarcoma', 'physical disabilities', 'tumoral évaluable', 'sleep-related car accident', 'mediastinal mass syndrome|Admission', 'cardiac pacemakers|Patients', 'upgrade', 'acute medical condition', 'esophageal achalasia', 'Alberta area||Patient', 'gastrointestinal hemorrhage', 'weeks|Acute LVT', 'bladder retention', 'spinal radiculopathy', 'unacceptable risk', 'arterial stenosis', 'MSM', 'bleeding diathesis,|Difficult intubation expected,|Obese,|Emergency', 'local hypersensitive necrosis reaction', 'Skin Cancer Exclusion', 'cardiorespiratory injury', 'distant metastases.|Experience', 'human immunodeficiency HIV infection', 'organic heart disease|With basic disease', 'pension application|Simultaneous participation in other clinical/interventional trials', 'delay', 'signs of pulpal infection|No signs of pulpitis', 'embolism|Evidence', 'febrile infections', 'HEV', 'abstain from drinking', 'non-MRI compatible', 'hematologic disorders', 'cardiac disease.|Liver', 'pleural effusion.|Patients', 'better|No', 'symptoms cause', 'noninfectious illness', 'congenital ptosis', 'endometrial carcinoma', 'cognitive impairment|Inability', 'cardiac dysfunction;|Allergic', 'T-LBL', 'autoimmune hepatitis/enteritis', 'cerebral occupying lesion;|fusiform aneurysm', 'inflammatory illnesses', 'XY genotype', 'placenta accreta', ""Paget's"", 'retinal vascular lesions', 'molecularly consistent', 'low back pain|having', 'hepatitis C virus antibody', 'permit compliance', 'C infection', 'venous thromboembolism|fibrinolytic condition', 'sacroiliitis', 'chronic pulmonary aspergillus disease', 'HER2 gene amplification', 'MANDIBULAR', 'non-steroidal anti-inflammatory drugs (NSAIDs)', 'nose', 'AMD', 'Organic gastrointestinal diseases', 'malnutrition;|pregnancy;|inability', 'AHI', 'chronic debilitating conditions', 'narcotic use', 'new onset hypertension in pregnancy after', 'autoimmune disease|Psychiatric', 'recall period|Anemia', 'reproductive stage', 'inflammatory bowel diseases|Patients', 'radiation', 'anemic conditions', 'FIGO IB3', 'chronic skin condition', 'HTT', 'undetectable|c', 'populations', 'Uncontrollable diabetes', 'sacrospinal ligament fixation', 'Hepatocellular Carcinoma', 'pulmonary hypertension)|Metastatic malignancy', 'chronic disorders of the rectum', ""Raynaud's syndrome"", 'soft tissue lesions', 'skull base fracture', 'complex regional pain', 'main renal artery diameter', 'plus spermicide', 'multiple injuries', 'solid tumors', 'related scarring', 'pregnancy|Airway Mallampati grade II, III and IV|Allergy', 'cranial disease', 'chronic obstructive lung disease|patients', 'naturally postmenopausal', 'extrahepatic metastasis', 'vocal cord', 'effects', 'inflammatory process', 'psychiatric illness.|Patient', 'lower back &', 'organic heart', 'adverse reactions associated', 'hours|Presence', 'Adverse Events (CTCAE)', '0.80|lower limb stenosis', 'alcohol abuse disorder', 'immunodeficient state', 'unilateral hearing loss', 'type 2 diabetes|Current', 'food allergies', 'secondary orifices should', 'impairment of gastrointestinal (GI) function', 'CTCAE', 'acromioclavicular arthrosis', 'chronic infectious diseases.||For', 'Acute Myocardial Infarction', 'grade of alopecia', 'lower spinal malformations', 'sudden hearing loss', 'complex injuries||', 'brain lesions', 'Initial', 'acute infection.|Participants', 'meningeal contrast enhancement', 'intestinal fistula', 'UV', 'Exceptions', 'uremia', 'DNA positive', 'explanation', 'type I papillary renal cell carcinoma', 'breast ductal carcinoma in situ after radical surgery', 'acute infection|Any disorder', 'hopeless tooth,|Healthy periodontal condition,|Presence', 'restrictive cardiomyopathy', 'hypertension)|bleeding disorders', 'complex rehabilitation', 'generalized systemic disease', 'dental problems', 'supra-ventricular arrhythmia.|Left', 'supplemental NAM', 'contralateral breast cancer', 'superficial femoral', 'women;|Pathological fractures', 'chronic chest infection.|Severe obesity', 'acute nerve lesion)|denied', 'history|Psychiatric comorbidity|Chronic disease', 'pregnancy complications', 'intracavitary lesion', 'disc prolapse|dysfunction', 'lung abscess', ""Sjogren's disease"", 'malignancy Addiction', 'distant metastatic lesion', 'life-threatening disease', 'viii', 'benign vascular disease', 'complex partial seizures', 'urolithiasis|thrombophlebitis', 'circumferential difference', 'lung abnormalities', 'arteriovenous thrombolysis', 'brain MRI.|Known', 'third molars.||', 'chronic infections', 'ischemic types', ""Sjögren's syndrome"", 'metastatic malignancy', 'hypertension.|Acute coronary syndrome', 'Medically compromised patients.||Patient', 'Infectious Disease (ID)', 'tumor disease|Acute infection', 'UK', 'hyperlipidemia,|Known hyperthyroid disease|Endocrine disorders', 'non lactation', 'jaundice', 'painful site (surgery may cause', 'index ischemic stroke', 'HIV diagnosis', 'acute cervicitis', 'lower limb ischemia criteria', 'Immunity disorder', 'allogenic organ transplant|Active', 'nursing involvement', 'involuntary', 'slimming', 'procaine.|Contraindications', 'epilepsy.||Exclusion Criteria', 'German', 'lifestyle habits', '3)|Current malignancy', 'Respiratory disorder', 'hospitalized|Patients', 'rheumatism/organs', 'malabsorption syndromes', 'drug addiction', 'acute symptoms|Agrees to cognitive examinations', 'liver disease', 'hepatitis E virus', 'genetic testing)|SGOT', 'systemic comorbidities', 'hepatitis b virus', 'suspectable autoimmune disease', ""Marfan's syndrome"", 'blood coagulation disorder', 'acute type A aortic dissection combined with severe', 'medical problems', 'matching between healthy volunteers', 'immature', 'malignant obstructive', 'session)|Back pain', 'Intestinal Tract diseases', 'medical condition.|Patients', 'Sjögren syndrome', 'enzyme-linked', 'spine|peripheral nerve injury', 'HER2 positive', 'psychotic symptoms', 'general syndrome', 'Cystic fibrosis', 'Thessaloniki', 'endoscopic manifestations', 'left bundle branch block.||Must', 'stress urinary incontinence symptoms', 'old|Cancer', 'Yang-deficiency type', 'psychiatric pathology', 'vasovagal syncope', 'immunologic test;|For females', 'mixed.|Difficulty urinating|Hematuria|Pregnancy|Patients', 'disease history;|Axillary temperature', 'clotting disorder', 'carcinoma in situ of bladder', 'deep carious lesion', 'main organ', 'document lymphoma', 'MRD+ disease', 'keratoconus', 'minimal oral lesions.|T1', 'Systemic Lupus Erythematosus International Collaborating Clinic (SLICC)', 'exudative AMD', 'aphakia', 'MAFLD', 'respiratory pathology|Use', 'human Immunodeficiency virus (HIV)', 'General Internal Medicine|CareSource', 'altered pain', 'centrilobular nodules.||Progressive ILD', 'tumor metastasis', 'extra-pulmonary TB', 'lapp lactase deficiency', 'breath alcohol', 'metastatic tissue', 'BCMA-directed', 'acute lymphoblastic leukemia|enrollment', 'respiratory depression', 'cardio-vascular', 'corneal epithelial defect', 'chronic platelet disorders', 'life threatening illness', 'tumour (FFPE) tissue block', 'curable malignancies', 'type 2)||At least one additional risk factor for heart failure:||Coronary artery disease', 'long QT syndrome.|A pre-existing', 'impaired lung function.|Active', 'upper tract urothelial carcinoma', 'Chronic Obstructive Pulmonary', 'previews scars|infections|anemia', 'implant removal)||Age', 'active ulcers', 'multiple bullae|Severe hypertension', 'weight bearing system|Cognitive deficits', 'manifestations of', 'middle ear surgery', 'MRKH syndrome', 'depressive', 'acute suicidal tendencies|No', 'puncture drainage', 'TTT', 'treatment.|Active hepatitis B or', 'Insomnia disorder', 'recurrence of ischemic stroke', 'dysplasia', 'abnormal liver', 'metabolic dysfunction.|Participation', 'acute renal', 'Brachial plexus', 'lower respiratory symptoms', 'health care medicines', 'serious head injury.|Subject', 'acute coronary', 'distraction free', 'IgE mediated reactions', 'reduction of', 'kidney disease|pregnancy|nursing|pacemakers|metallic cardiac valves|magnetic', 'Distal Ureteric Calculi', 'floor of mouth', 'autoimmune rheumatic', 'variceal bleeding;|regular', 'glenohumeral joint arthritis', 'non-radicular', 'solid tumor；|Adequate bone marrow reserve', 'functional limitation', 'systemic conditions', 'autoimmune gastritis', 'Familial Pancreatic Cancer (FPC).||Exclusion Criteria', 'Pulmonary NTM', 'chronic antithrombotic treatment|Atrial fibrillation', 'overactive bladder', 'MyDay', 'ICF)|Pregnant', 'drugs;|Plan', 'non-opposition', 'AF', 'alcohol overuse', 'treatment data;|Patients', 'target VEGF', 'been menopausal', 'acute pulmonary exacerbation|Pregnant', 'Syphilitic serum positive should', 'large enough', 'CL', 'or|osteopenia', 'Confirmed CF diagnosis', 'spinal cord dysplasia', 'solitary rectal ulcer syndrome', 'benign tumors', 'Unilateral radicular pain', 'neoplasia|pregnant', 'F;|Healthy', 'deemed refractory to EITHER', 'mastoidectomy', 'papillary thyroid cancer|patients', 'bite.|Poor oral hygiene', 'adverse effect', 'cognitive impairments/psychiatric', 'refractory disease', 'systemic illness', 'congenital hearing loss', 'FH', 'parafunctional habits|Patients', 'impact immune function', 'degenerative kidney', 'pregnancy|Consumed decongestions', 'squamous call carcinoma', 'refusal', 'abdominal aortic aneurysm', 'borderline personality disorder)|Have', 'EC', 'endocrine disorder', 'venous thrombus', 'myocardial infarction|Autoimmune diseases|Neurodegenerative', 'fully resectable', 'UCLA', 'cardiovascular', 'neuroendocrine cancer', 'Talcahuano cities|Demonstrable ability', 'kidney function.|Diabetes mellitus type I.|Diabetes type II', 'light therapy|Active infection', 'fungal infection;|Upper GI bleeding', 'endometriosis', 'myocardial infarction.|Unstable angina', 'medical team considers', 'solid tumor|Phase 1 only', 'uropathies', 'bundle branch block', 'tumor not', 'cardiac findings', 'months|Trophic ulcers', 'pulmonary eosinophilic syndromes', 'months|Regular alcohol', 'analyses.|Age|Participant', 'venous thromboembolism;|Myocardial infarction', 'basal', 'Osteomyelitis', 'OLE Period:||-', 'schizoaffective disorder', 'communication barrier and|Do not volunteer', 'bleeding tendency.|Revision', 'photophobia', 'ablation|Acute infection', 'chronic obstructive pulmonary disease;|any', 'ulna fracture', 'craniotomies', 'cerebral spinal fluid [CSF]', 'esophageal cancer;|patients', 'trophic disorders', '≥8;|thyroid dysfunction', 'end-stage heart failure', 'syncope.|Had', 'older|Measurable disease', 'complaint of supra-esophageal symptoms', 'sedentary balance', 'mild to moderate|Healthy sense of smell', 'caries-free', 'congenital long QT syndrome.|QT interval corrected', 'duplication of GSV', 'Premature', 'pulmonary embolism;|Other severe', 'aneurysm|Thoracoabdominal aortic aneurysm Elective', 'ischemia demonstrated', 'complete bundle branch block', 'cerebral edema lesions', 'pelvic floor', 'PCR positive', 'fetal demise', 'Autoimmune Encephalitis', 'underlying condition', 'unpredictable motor fluctuations', 'type of bottlecer', 'end-stage diseases|Patients', 'neurologic disorder|Contraindications', 'secondary hyperaldosteronism|Those', 'LCX', 'optic nerve pathologies', 'NRAS', 'RAF', 'non irradiated lesions', 'manifest neurologic progression', 'heart failure)|The', 'RAD51C', 'inflammatory bowel disease|To', 'IPSS INT-2', 'LNG', 'diagnostic criteria referencing biopsy', 'local pathology', 'cryo-sauna,|recreational', 'alcohol consumption|Alcohol', 'end-stage liver failure', 'related disorders', 'cranial tumor', 'chronic diseases|Participants', 'tumor lesion', 'complaint has been', 'cognitive impairment|neurological', 'ABALONE', 'Neck Cancer', 'prolonged PT', 'pressure lesions', 'rheumatological diseases', 'area|Concomitant auto-immune disease', 'hyperemesis', 'active muscle disease', 'defecation disorders', 'comorbid conditions like (obesity', 'OTOF mutations', 'Residents', 'respiratory sinus arrhythmia|History', 'gastric junction adenocarcinoma', 'hypertensive glomerulopathy', 'wall motion abnormality', 'distant radial artery', 'osteoporosis', 'onset angina', 'acute medical illness', 'wheezing', 'inflammatory disease),|patients', 'substance', 'a:||Prostate cancer', 'patchy chorioretinal atrophy', 'liver transplant|Patients', 'PCR.|Participant', 'Unable to read', 'chest disease', 'therapy||Vaccination', 'associated DM', 'eligibility.||Exclusion', 'chest wall', 'taxane doublet', 'nerve root', 'invading lungs syndrome', 'inadequate tumor coverage', 'Synthetic liver failure', 'non-CNS tumors', 'LA-CAB', 'MFCL', 'Meet cancer', 'hepatocarcinoma', 'cerebral ischemic seizure', 'circadian dysfunction', 'recurrence of preeclampsia.|Aspirin', 'criteria:||Inflammatory breast cancer', 'motility disorders', 'rhinitis medicamentosa|Documented', 'Crohn disease|Portal hypertension|Severe hepatic', 'upper gastrointestinal perforation', 'pancolonic virtual chromoendoscopy|Colon mucosa visibility', 'co-morbid conditions', 'neurological damage', 'nose).|Skin phototype', 'neurological syndromes', 'lumbar puncture:|Haemostasis disorder', 'cardiac pacemakers|Pregnancy', 'non-pharmacologic intervention', 'clear-cell subtype', 'nephritic syndrome', 'adenoiditis', 'abdominal skin condition', 'in situ prostate cancer', 'genetic FTD', 'ocular diseases', 'hepatic impairment|Renal impairment', 'ACDF', 'acute liver failure', 'withmediastinal lymphadenopathy', 'radiation enteritis', 'PTSD||Non-PTSD', 'fainting spells', 'fungal infection.|Active HIV', 'infections.|Human immunodeficiency virus (HIV) infected', 'blood glucose monitoring', 'congenital VWD', 'colorectal cancer screening||', 'Primary lesions', 'limit spine motion', 'natural rubber latex', 'cognitive dysfunction.|Join other similar clinical researchers', 'diarrheal illness', 'chronic pain syndrome|pain', 'RT treatment|Metastatic disease', 'traumatic brain injury|Patients with comorbidities', 'type mCRC', 'buccal wall).|The', 'zygomaticomaxillary complex (ZMC)', 'Covid- 19 infection', 'type II diabetes|Scheduled surgery', 'poor behavior', 'lung transplantation|Active cancer treatment', 'disease|Active malignancy', 'randomized bleeding', 'skin allergies', 'Waldenström macroglobulinemia', 'myometrial pathology|having', 'venous wounds', 'scalp psoriasis', 'atrial fibrillation|good acoustic apical window|left', 'pain onset||2', 'heightened anxiety', 'good home care||', 'PONV', 'etc;||Normal organ function', 'periocular infection', 'perianal pain', 'Morton s neuroma', 'vitamin E', 'systemic vasculitis', 'left bundle branch block|Musculoskeletal diseases', 'Schizoaffective disorders', 'PPD', 'non-colorectal gastrointestinal cancer', 'First ischemic stroke', 'spermicide||', 'primary dentition).|Healthy', 'medicine injuries', 'painful condition', 'cytologically positive', 'COVID 19;|Elevated', 'possible pregnancy', 'to hypogonadism', 'heart transplantation|Cardiac tumors|Pericardial disease||Metabolic Syndrome||Following', 'early atrophy', 'altered cognitive status', 'pituitary dysfunction)|9', 'psychiatric co-morbidity', 'right heart failure.|History', 'procedure;|Intracranial tumors', 'nonactive hay', 'comorbid disease', 'financial incentives', 'selected DMTs', 'lipid disorder', 'severity of depression.|Failure', 'metastatic lesion|On combined ADT', 'chronic obstructive pulmonary disease)|Rheumatoid arthritis of the lower extremities|Severe', 'terminal illness', 'significant pathologies', 'greasy moss', 'BAFF inhibitors', 'double malignancy', 'cancer therapy', 'prolonged QtC interval|Concomitant', 'isolated rotational ankle', 'end of induction', ""special conditions seriously endanger the patient's health"", 'DVA', 'weight loss aids', 'renal MRI|High', 'C;|alcoholism', 'metabolic neuropathies', 'caffeinated beverages', 'OPC', 'cardio-vascular disease', 'choroideremia', 'carpus', 'lymphoid neoplasms', 'borderline ovarian tumors (BOT)', 'motor disability', 'intellectually disabled', 'behavioural dysregulation', 'Gilbert disease', 'conventional synthetic disease-modifying antirheumatic drugs', 'early response', 'condomless', 'HER2+ disease', 'mixed dyslipidemia|Part', 'common complication', 'or|Radiographic findings', 'neurological disorder;|Diagnosis', 'accessible lesions', 'Iatrogenic obesity', 'adrenal diseases|History of', 'old;|Relapsing disease', 'transient cerebral ischemic attack))|Patients', 'acute upper respiratory tract infection', 'regurgitation of the mitral', 'urinary retention related', 'biliary salt diarrhea', 'esophageal squamous carcinoma', 'cough frequency', 'sinopulmonary disease', 'musculoskeletal pain', 'Gallbladder carcinoma', 'subretinal fluid', 'conditions associated', 'disease relapse', 'pituitary function.||Patients', 'chronic obstructive pulmonary disease|Combined', 'front teeth of the upper and lower jaw,|Written declaration of informed', 'resection of the stomach', 'pulmonary embolism|Psychological', 'horizontal.||', 'topical ophthalmic preparations', 'cerebral small vessel disease', 'early lens', 'EGFR-sensitive mutations', 'acute bleeding tendency', 'interstitial lung disease.|NI-9', 'criteria related to the study procedure', 'autoimmune thyroid disease', 'implant', 'gout flare', 'IIA', 'swallowing', 'use)|Planned', 'variant', 'distant metastatic lesions', 'drug treatment,|A head injury', 'stable COPD', 'cardiopulmonary conditions.|Individuals', 'retinal thickening', 'HTN', 'multiple organ dysfunction', 'demonstrates', 'inflammatory conditions|Concurrent congestive heart failure', 'serologic status', 'arterial vascular disease', 'painful diabetes neuropathy', 'autoimmune polyendocrine syndrome type 1', 'type 1 myocardial infarction', 'nonketotic coma', 'probiotic', 'developmental abnormality', 'auditory problem', 'equivalent)|Ocular pathology', 'psychologically compromised', 'chest discomfort', 'Pregnant|Incarcerated|Age', 'Hepatitis B virus', 'neurological deficit,|Exercise', 'clinical findings AND|Nerve abnormalities', 'Ambulatory', 'trauma.|Cervical myelopathy.|Inflammatory arthritis', 'risk factors resulting in TB exposure', 'lactation;|Mental retardation', 'amino acid(s', 'progressive multifocal leukoencephalopathy (PML)', 'hemophilia|pregnancy|cancer|burns', 'acute HF', 'RVAD', 'interferons', 'arterial obstructive disease', 'Macular edema', 'chemotherapy|Allergy', 'osteopo- rosis', 'hepatoblastoma', 'cancerous pathology', 'fallopian tube cancer/primary', ""Down's syndrome/Trisomy"", 'renal systems', 'progressive state', 'microscopic margins', 'hyperglycemic hyperosmolar syndrome', 'carcinomatous meningitis.|Subjects', 'facial palsy|Localized oral lesion', 'Other injuries', 'IBD|Active Hepatitis B', 'secondary osteoporosis', 'acute myocardial infarction|Non-sinus rhythm', 'Viral hepatitis', 'inferior gluteal folds', 'syndromic clubfoot', 'nonpainful disorders', 'allergies', 'bladder stones', 'clitorodynia', 'indemnities', 'hyperplasia', 'rectovaginal fistula', 'renal artery diseases', 'HCV ribonucleic acid', 'UCDCCC', 'limb fracture', 'ductal adenocarcinoma', 'bilateral breast cancer', 'intracranial bleed', 'move away', '90|Mild renal impairment', 'rectal cancer.|Pregnancy|Hypercoagulability disorders', 'retention urinary tract', 'TCM syndrome differentiation', 'persistent asthma', 'failure;|other malignancies', 'immunoglobulin preparations', 'ethics committee', 'upper premolars', 'language communication difficulties', 'syphilis antibody', 'recurrence for', 'illness|0-2', 'diseases', 'chemotherapeutic drugs', 'positive tumors', 'judged by the study doctor to have clinical significance;|Chest x-ray', 'progressive proptosis', 'restenotic', 'non-inclusion criteria||•', 'artery occlusion', 'facial cellulitis|Allergy', 'chronic hypoxic conditions', 'local treating physician', 'enrollment|Arrhythmia', 'bone sarcomas', 'learning disability', 'migraine headache', 'HER2-expressing', 'gastrointestinal diseases', 'heart valve', 'vitreous macular traction', 'non-epileptic psychogenic seizure', 'acute reinfection', 'renal disorder', 'breast cancer screening', 'healthy tissues', 'AS -||Exclusion Criteria', 'parasitic infection|Infection', 'total mesolectal resection', 'targeting insomnia', 'ultrasonic lipolysis', 'old|Abscence', 'radioactive iodine', 'rejection of surgery)|Karnofsky Index', 'dehisced wound', 'vertebro-basilary artery insufficiency.|Patient', 'Movement disorder', 'follicular lymphoma)|HIV-seropositive|Age', 'malformation', 'noncompliance', 'HER2+ status|Patient', 'TRUS', 'Tumour spread', 'abnormal clinical chemistry', 'sleep terrors', 'macrolides|No hepatic failure', 'pose a safety concern.|History of stroke', 'mental health symptoms', 'invalid contact information.|3', 'throat diseases', 'partial familial lipodystrophy', 'impaired lung', 'criteria from the International Myeloma Working Group)|Presence of CRAB criteria', 'myeloid neoplasm', 'idiosyncratic reactions', 'mellitus|cold sensitivity', 'risk factor for bleeding ex', 'uterine bleeding urinary tract infection', 'basal cell cancer', 'Obesity', 'epileptic seizures', 'Avoiding Pregnancy', 'Panic disorder', 'open response', 'Unilateral breathing impairment', 'potential manifestations', 'benign hepatobiliary diseases', 'present.|A main complaint', 'clinical manifestations of any physical', 'non traumatic bleeding', 'penetrating head injury', 'tients:||diagnosis', 'severe obstruction', 'psychosis', 'judged by investigators.|World Health Organization (WHO) performance status', 'Pervasive Developmental Disorder', 'thyroid dysfunction', 'language barrier|Patient', 'consent;|inability to read', ""Kaposi's sarcoma"", 'situ|Superficial bladder cancer', 'radiation induced', 'deep cavity||-', 'proximal stenosis', 'promyelocytic', 'diabetes HbA1c', 'HM61713', 'anomalies.|Fetal macrosomia', 'Mixed endometrioid patient', 'co-administered vaccines', 'common biliary track', 'diabetes ketoacidosis', 'ptosis;|Congenital cataract', 'acute heart disease', 'affective episode', 'Malignancy', 'lymph node metastasis', 'primary Sjogren syndrome).||Fibrosing', 'small bowel disease', 'Major hematologic', 'deformity', 'emergent care', 'diarrhea symptoms', 'atypical symptoms', 'mild disease severity', 'chest wall radiotherapy', 'Vaginal inflammation', 'Wegener syndrome', 'chronic essential hypertension', 'HLH syndrome', 'hysteria|ocular surgery|amblyopia|anisometropia|strabismus|systemic disease', 'retinal vascular pathologies', 'Shock', 'associated diseases', 'respiratory insufficiency disease', 'irregular beat', 'vocal fold pathology', 'infection|prescence', 'Heparin Induced Thrombocytopenia', 'sympathetic dysfunction', 'teeth should', 'mothers;||The fact', 'chronic wasting diseases', 'leptomeningeal involvement', 'urine dipstick', 'VUMC', 'adjuvant radiation', 'uncorrectable coagulopathy', 'similar GI conditions', 'mobile technologies', 'intraretinal fluid', 'tuberculosis Still', 'occlusive diseases', 'multi-organ dysfunction', 'esophageal pathologies', 'Heart Disease', '1-', 'CNS metastases.||14', 'network of the ISMAR registry', 'again', 'blood glucose', 'IgG4-RD', 'lipodystrophy', 'open cavities', 'valvular disease|infectious pathologies|autoimmune diseases|haematological diseases|serious kidney', 'preoperative antitumor', ""Hb Bart's edema"", 'anterior basement membrane dystrophy', 'criteria:||Medical conditions', 'B-CLL/SLL', 'urinary schistosomiasis|Bladder', 'myelomonocytic leukemia', 'hypertensive encephalopathy|Patients', 'disc displacement', 'Gestational diabetes mellitus', 'upper airway cough syndrome', 'carnitine metabolism', 'liver elasticity tests', 'tobacco containing', 'Deep orbits', 'living kidney', 'T2 N1 M0( AJCC 8th', 'Structural Racism', 'neurological disease|Upper limb', 'condomless anal sex (CAS)', 'rheumatoid arthritis.|Patients', 'alimentary tract hemorrhage', 'cancer treatment contraindicates this protocol', 'change in sensation', 'mild liver disease', 'malignant tumors;|Have', 'Normal voice on days of participation', 'hypotony', 'ischemic cardiopathology', 'acute morbidity', 'Hepatitis C infections.|Evidence', 'cystic leukomalacia', 'old|Anatomically feasible', 'adequate surgical tumor tissue', 'Ex-moderate level smokers', 'Wolff-Parkinson- White syndrome', 'black tea', '17b-estradiol', 'isometric exercise', 'primary immunodeficiency.|Active infection', 'medical abnormality', 'lymph nodes', 'surgery|Potentially resectable', 'weakened immune system', 'dentinal exposure', 'HIV infection|Active tuberculosis', 'intracranial surgery|A', 'HIV-2', 'physically violent behaviors.|Initiation', 'horseshoe kidney', 'heart failure|Other medical condition', 'tumor immune mechanism', 'CYP2D4', 'persistent rhinitis', 'extensive prosthetic rehabilitation|Teeth', 'psychiatric|Cancer', 'B-type natriuretic', 'hypertensive encephalopathy|those', 'haematuria', 'Otherwise healthy', 'muscle of the lower extremity', 'acute provoked seizure', 'monodose Dry Powder Inhaler (DPI) device.|Able to perform acceptable pulmonary function testing', 'none||Family Members||Inclusion Criteria:||aged', 'lack of access', 'HCV.|Known HIV infection', 'implanted electrical', 'kidney infections', 'HER2-targeted therapy.|For', 'inflammatory bowel disease|Habitual constipation', 'deemed stable', 'hyperglycemic symptoms', 'PJP', 'malignant tumors.|Received', '≥50%)|Borderline bilateral PA stenosis', 'HIV care scheduled', 'satisfaction', 'autoimmune disorder.||', 'abnormal muscle tension', 'terminal disease', 'non-IBC breast cancer', 'involvement of lymph nodes;|Prior therapy', 'tumoral diseases|Inguinal', 'sterilization', 'intermediate features', 'basal cell cancer of the skin', 'Nonchildbearing Potential (', 'psychotropic substance', 'Brain HQ', 'Philipps Dreamstation', 'Systemic condition', 'hepatitis B virus (HBV) surface antigen positive', 'Acute Respiratory Syndrome-Corona virus disease(SARS-COV)19 vaccines', 'Autoimmune disease', ""Parkinson's Dementia"", 'antihistamines', 'intestine necrosis', 'disorder|Renal dysfunction', 'GI cancer', 'epidural)|Intracranial arterial stenosis', 'drowsy', 'intracranial pressure|Critically ill', 'intermittent causes', 'portal vein hypertension', 'expanded disability status scale', 'head trauma resulting in loss of consciousness', 'severe coagulation disorders', 'Diabetes mellitus|Change', 'electrolyte imbalances', 'degenerative', 'condoms', 'clouding', 'large molecule protein products', 'non-life-threatening', 'myocarditis;|Medical conditions', 'acute reversible cause', 'arterial pathology', 'painful', '|Genital tract infection', 'procedures.||Failed to respond', 'malignancy|varices bleeding', 'functional abilities', 'malignant hypertension attack', 'irreversible surgical infertility', 'non-adenoviral vectored', 'linguistic incapability', 'surgical condition', 'chronic medical diseases.||', 'psychotic depression', 'phenothiazines', 'diclophenac', 'alcohol consumption|no', 'Serious infection', '⑦ Abnormal', 'Acute exacerbation', 'azathioprine,|Who did not', 'elective heart surgery', 'BEP.|Pregnant', 'behavioral problems', 'acute cholecystitis', 'interleukin-2 preparations', 'metastatic cancer.||Severe', 'Eisenmenger syndrome', 'Severity (CGIS)', 'abnormal heart function', 'Systemic Lupus Erythematodes', 'common iliac artery (CIA)', 'obsessive disorder', 'hypertention;|Receiving immunosuppressive therapy;|Emergency surgery', 'Sickle Cell disease', 'condition incompatible with driving simulator', 'infection|pregnancy|allergy', 'facial lift', 'Pregnancy women|HIV', 'Gastric ulcer', 'immunocompromising conditions', 'speaking|Cognitive impairment', 'possible effects checkpoint inhibitor therapy', '||Cardiogenic shock', 'LCPD', 'co-morbid ocular', 'psychological problems', 'ago)||Stable disease', 'idiopathic cough', 'acute exacerbation of COPD', 'subarachnoid hemorrhage', 'Chronic hepatitis B virus carriers', 'Screening.|Female', 'acute infectious disease', 'examination;|Nonlocal recurrence', 'medication.|Acute coronary syndrome', 'normal CA 125 blood level', 'non-infectious pneumonia', 'Versus Host Disease', 'tumor necrosis factor', 'major physical disease', 'manic depressive illness', 'frontal alopecia', 'Mild severity disorder', 'electromagnetic system', 'hypothyroidism|Suffering', 'alteration', 'Android OS', 'arrhythmias - valve disease', 'human T-cell lymphotropic virus (HTLV-1)', 'vaginal health', 'HGD', 'including-0.50', 'visit;|Current infection', 'unforeseen public health', 'LPM', 'acute GvHD.|Suitable haploidentical donor.|Performance', 'persistent pain resulted', 'COVID-19 symptoms', 'Chest pain', 'ventricular tachyarrhythmia', 'cognitive comorbidity', 'Chronic Coronary syndrome', 'athletes -', 'oncological disease', 'HCV;|Symptomatic', 'chronic heart failure|chronic kidney disease', 'psychiatric interview.|Current', 'anti-cancer treatment', 'pulmonary surgery;|Solitary lesions', 'hepatitis B (seropositive for', 'cerebrovascular disease;|pregnancy', 'bladder-', 'vertical skeletal dysplasia', 'human epidermal growth factor receptor 2 (HER2).|Unresectable locally advanced', 'Psychical disorder', 'neuropsychiatric', 'histopathologically /cytologically', 'valve replacements', 'derived preparations', 'acute intoxication', 'vascular condition', 'foreign objects in both wrists.|Agree to adhere to the lifestyle considerations.||EXCLUSION CRITERIA:||Participants', 'spinal malformation', '≧', 'screening|Pregnant', 'Human Papilloma Virus', 'kidney transplant|The treatment medication', 'mast cell stabilizers', 'distant metastasis|Patients', 'type of psychotherapy', 'renal impairement|Patients', 'pulmonary diseases', 'digital rectal', 'active periodontal disease', 'endocrine system diseases', 'cutaneous inflammatory', 'fistulous tract', 'AIH)|Primary sclerosing cholangitis', 'digits', 'Cardiac arrhythmias', 'breast cancer|Stable phase', 'physical findings', 'liver dry', 'catatonic symptoms', 'endocrine disorders', 'mental illness,|Not', 'anaemia', 'focal aware', 'Uterine Septum', 'renal functional abnormality.||History', 'non-relapsing', 'Neurological disorders', 'gastrointestinal motility', 'prohibitive calcification', 'cessation', 'ischemia related to AF|An investigational drug used', 'cases on:||Age', 'HIV);|HBV DNA', 'consensual kink activities', 'musculoskeletal chronic pain', 'good overall health', 'axillary levels', 'atherosclerotic lesions', 'esophagogastric disease', 'Autism', 'chronic joint diseases', 'relapsing-remitting MS', 'mental disorders;|Any condition', 'gastrointestinal event', 'affect aerobic', 'storage diseases', 'anticoagulants;|Chronic bleeding diathesis;|Active', 'nasal symptoms', 'symptomatic HF', 'increased lesion', 'urethral stricture', 'fibrolamellar cell carcinoma;|Extrahepatic', 'substance abuse;|Active psychiatric', 'regular smoking', 'fetal anomaly', 'lymphoma therapy.|Patient', 'pigmented lesions', 'abnormal impedance', 'stydy protocol|Contraindications', 'VHL disease', 'NIHSS>17', 'adverse events|Extraintestinal manifestations', 'pain medication|Spinal inflammation,|Spinal tumor|Covid|Pregnancy', 'multiple endocrine neoplasia syndrome type 2|Have been', 'mild pulpitis', 'emotional-behavioral disturbance', 'hepatitis C active infection', 'alpha-1-antitrypsin deficiency);|Drugs', 'familial hypercoagulability', 'diseases|Fresh cycle', 'RBANS', 'tuberculosis (BCG)', 'macromolecular protein', 'superficial venous thrombosis', 'needle rollers', 'promyelocytic leukemia', 'negligible', 'Rheumatic arthritis', 'age|Having', 'Pathological changes', 'local mental health legislation/regulations.|Subjects', 'vitreous haze', 'toutic', 'Type 1 diabetes mellitus;|Retinopathy', 'gastrointestinal organic diseases', 'intestinal occlusion', 'Chronic Kidney Disease (CKD)', 'eyes', 'acute anterior cruciate ligament (ACL) rupture', 'bronchial brush specimen', 'large bowel .|Cholangiocarcinoma', 'days;|Hyperkalemia', 'hearing problems', 'idiopathic HPT.|Diagnosis of HPT', 'central pathology', 'monogenic cSVD', 'unprovoked stroke', 'month.|Anemia', 'unmodified', 'coronary angiogenesis', 'polymorphic ventricular tachycardia', 'NF2 defects', 'height-adjustable', 'spinal muscular atrophy linked', 'malignant tumors;12', 'COVID19 Pneumonia Acute respiratory failure', 'parasitic infection', 'anaesthetic room', 'anaplastic lymphoma kinase (ALK) mutation-positive', 'calculated by Cockcroft and Gault equation|Patient is able', 'HLA-E agents', 'CNS3 disease', 'diseases.|Allergy', 'esophageal cancer', 'eria:||heart failure', 'rectocele', 'peptic injury', 'diabetes type 2|Patients', ""Gaucher's disease"", 'renal rickets.|Those', 'metabolic acidosis', 'special communication needs.|Pregnancy', '|Elective noncardiac', 'acute ischemic', 'apical', 'hepaititis B', 'SARS CoV-2', 'intra-spinal canal mass', 'compensatory heart failure', 'Progressive pulmonary fibrosis', 'RCC', 'cirrhosis|Anticoagulant', 'left bundle-branch', 'addiction', 'unstable radial head', 'non-diabetic reasons', 'terminal condition', 'inflammatory conditions', 'HIV-1 positive', 'gastrointestinal pathologies', 'autoimmune disease.|Ascertained hypersensitivity', 'etc.)|Demonstrating sensory limitations', 'Wolff Parkinson White', 'absorption of medications.|Other situations that the investigator determines', 'color sensitivity', 'hemophobia', 'intact membranes|Viable', 'left atrial diameter', 'clinical history.||', 'adrenocortical carcinoma', 'Simple urinary tract infection', 'vertebral bodies;|Axial neck pain', 'bronchiolitis', 'severe autonomic dysreflexia|Metal implants', 'quadriplegic CP', 'serological sequelae', 'adrenal gland function|Refusal', 'schwannomas', 'hyperhomocysteinemia', 'alopecia.|Spinal cord compression', 'Complications', 'breast feeding|Refusal', 'Left heart diseases', 'neurodegenerative disorder', 'demonstration of a QTc interval', 'kidney insufficiency.|Patients', 'TTP|Medical contraindication', 'limitation of care', 'urologic anomalies', 'cardiovascular disorders', 'Docusign|Currently employed', 'preclude response', 'controlled hypophysitis', 'systemic treatment.|Uncontrolled hypertension', 'squamous cell carcinoma;|He', 'dyschromia', 'colon cancer', 'acquired condition', 'ocular manifestations.|Rash', 'absorption):||depot injection', 'kidney insufficiency;|(2', 'birthing centre planned', 'hypotensive episode', 'prostate cancer;||>2-month', 'metabolic abnormality', 'gastric outlet obstruction', 'thyroid dysfunction)||Patients', 'diabetic glomerulopathy', 'rhinitis symptoms', 'malignant blood disease', 'oral lesion', 'chronic atrophic gastritis', 'condomless anal', 'Esophageal varices', 'central nerve system', 'disease of', 'arthrocentesis of the index joint', 'root fracture.|Lack', 'scarring', 'Displaying symptoms', ""Peyronie's Disease"", 'HLA B*58:01', 'AJCC).|Initial diagnosis', 'sores', 'for:||Cervical carcinoma', 'ortic stenosis', 'oocyte retrieval', 'refractory solid tumor', 'Primary health Centres:||located', 'breastfeeding;|4.Active infection', 'hepatitis C virus', 'left to right shunt|Prior', 'cirrhosis;||Chronic liver disease', 'Hepatitis C virus (HCV) antibody', 'developmental dysplasia', 'pulp necrosis', 'diffuse herpes', 'arrhythmic heart condition', '/new malignant lesions', 'transient cerebral ischemia', 'chronic left heart failure', 'Kostmann syndrome', 'pathological involvement', 'intense pain', 'infectious diagnosis|Admission', 'nuclear expression', 'age.|Cognitive impairment', 'cardiac conduction defects', 'stable diseases', 'histopathology incloud squamous cell carcinoma', 'Autoimmune diseases', 'gynecologic organs', 'residual COVID-19', 'primary gonarthrosis', 'pleural fluid collection', 'radiation phobia', 'CCD', 'cardiac involvement', 'injection;|Clinical symptoms', 'systemically healthy', 'marginal zone lymphoma', 'needle core biopsy', 'Mycobacteria tuberculosis', 'adjustments', 'lichen erosive', 'hemianopia', 'cervical trauma pathology|ACDF', 'chronic dialysis,|Acute pulmonary embolism,|Transfusion', 'myocardial infarction event', 'infection of the uterus', 'gastrointestinal disorders.|Patients', 'arteriovenous thrombotic event', 'urinary incontinence surgery||', 'Heart rhythm modifying disease', 'preterm neonates:||Neonate', 'clinical ischemia', 'inflammatory arthropathy', 'antiphospholipid syndrome|Active bleeding|Cardiogenic shock', 'sleep restriction|shift workers', 'CNS disease', 'heavy smoking', 'mobility issues', 'posterior instability', 'difficulty seeing', 'heart conduction', 'sperm from the date of administration of the first investigational drug', 'alcoholics|AIDS', 'bradycardia', 'speaker|Baseline pain rating', 'migraine status', 'ovarian cyst excision', 'fulminant disease', 'primary malignancy;|mental disorder', 'capitis', 'inflammatory bowel disease.|Currently', 'sion Criteria:||Grandmother|Self', 'supplemental oxygen', 'Acute wound', 'asymptomatic viral hepatitis', 'cirrhosis of the liver', 'Other diseases', 'neurological function', ""Gilbert 's syndrome"", 'castration-resistant prostate cancer.|PRE-REGISTRATION', 'SpA features', 'locoregional disease', 'nickel|Participant', 'concomitant conditions|Patients', 'sensorineural hearing deficits', 'regional wall motion', 'menstrual period|Patients', 'corrective osteotomies', 'nocturnal desaturations', 'PrCa diagnosis|PrCa', 'persistent pain', 'give birth', 'lymphoblastic leukemia', 'sprain', 'drug abuse|Chronic diseases', 'primary amyloid light chain (AL)', 'pelvic conditions', 'local skin conditions', 'surgically-corrected disease', 'HIV;|Pregnant', 'cardiac anginal chest pain', 'macrovascular disease', 'MDM2/MDM4', 'autoimmune disease.||Have', 'territorial stroke', 'engaged in deliberate self-injury', 'anal stenosis', 'Type 1 diabetes|Hemoglobin', 'angioedema', 'Multiple Organ Failure Syndrome', 'cystic changes', 'intentional aerobic', 'substance substance-related disorders', 'metabolic dysfunction', 'uterine diseases;|Patients', 'immunotherpy', 'bladder cancer|Patients', 'Tuberculosis', 'generalised auto-immune arthritic disease|BMI>35|insulin dependent', 'wrist problems', 'translocations causing disease', 'acquired immune deficiency', 'mood disorder', ""Parkinson's specialist"", 'itching', 'metabolic disease|Medications', 'excluded|RECTAL CANCER', ""Raynaud's disease"", 'incorporating', 'congenital long QT syndrome（Male≥', 'arterial occlusive disease', 'neuropsychiatric pathology', 'Complement-mediated', 'Relapsing Nephrotic Syndrome', 'restless leg syndrome)|Serious', 'good oral hygiene', 'capsules', 'residual disease', 'Neuropathic pain', 'poor sleep quality', 'lower back', 'castration resistant prostate cancer|Potential participant', 'localized low-risk prostate cancer', 'clinical diagnosis,|2', 'non-infectious pneumonitis', 'Keratoconus', 'AIDS-defining opportunistic infection', 'reporting signs', 'acquired diseases', 'abdominal surgery;|(2', 'population|Pregnant', 'Thrombosis', 'genetic', 'cirrhosis.|Impaired renal function', 'HIV infection', 'sexual orientation of the patient ensures compliance', 'mental health difficulties', 'DRB1 allele match', 'auto-immune disorder', 'circadian rhythms', 'graft failure', 'being', 'peritoneal cancer', 'unfavorable effects', 'autoimmune hemocytopenia', 'histrionic personality', 'acute psychiatric illness', 'carcinosarcoma|Unable and/or', 'myocardial Infarction', 'seizure|Liver failure|Dyslipidemia|Congenital coagulopathies', 'feeling dizzy/lightheaded|Not currently', 'non-dilated LV chamber', 'deep venous ulcer', 'white coat hypertension', 'women|Peripheral neuropathy', 'Uveitis', 'surgical revascularization,|Unfavourable anatomy', 'Chronic kidney disease', 'visceral malignancy', 'CXCL9 levels', 'solid tumours', 'respiratory failure.|Denying', 'communication difficulties', 'nociplastic type||', 'women;|Mental disorders', 'endotracheal intubation|Persons', 'T2-weighted imaging quality', 'antitumor traditional', 'painful cranial neuropathy', 'treated', 'fallopian tube cancer.|Platinum resistant', 'contact allergens', 'acute porphyria', 'hippocampus', 'squamous intraepithelial lesions', 'malignant hyperthermia;|inclusion', 'Extramedullary leukemia', 'reduced joint function', 'metastatic lesions', 'share', 'Nasopharyngeal carcinoma liver metastases', 'gastrointestinal infection', 'intending', 'primary bladder cancer', 'heart allograft|written informed consent obtained', 'spinal cord metastases', 'multifocal atrophy', 'scleritis', 'benign prostatic', 'androgenetic alopecia', 'mild seborrheic dermatitis', 'periapical bone destruction', 'color defect', 'adenocarcinoma of the lung', 'congenital number anomaly.|Patients', 'local clinical practice||', ""Pick's disease"", 'chronic gastrointestinal diseases|Inability to chew', 'acute diseases', 'painful pathology', 'decreased mouth', '65|unable to read/', 'renal metastasis.|Participants', 'mimicking disease', 'diameter|quantifiable bleeding', 'modification of diabetes treatment', 'upper extremity injury', 'MTrPs have', 'angiitis', 'moderate asthma', 'extensive periodontal therapy', 'Distant', 'urinary ostomy', 'standard drinks of', 'trastuzumab induced', 'Lesions', 'metabolic disorders', 'tolerability', 'upper respiratory tract obstruction;|Obvious bullae', 'non-melanoma skin', 'protrusion', 'active pulmonary', 'intracranial hematomas', 'Aerobic vaginitis|Clinically manifest', 'upper left', 'injuries', 'nclusion Criteria:||Diagnosed dementia', 'chondrodysplasia', 'elbow dislocation|Cancer|Rheumatoid arthritis|Severe', 'kidney failure|Acute coronary syndrome', 'epcoritamab.|Active CNS lymphoma|Neuropathy', 'Dominant polycystic kidney disease', 'Marginal Zone Lymphoma (MZL)', 'extensive radical oncologic maxillectomy', 'root-form dental', 'esophageal reflux Myasthenia gravis Coagulation disorders', 'chronic condition', 'neurologic disability', 'absorbtion', 'COPD)|Chronic kidney disease (CKD)', 'hepatitis 10', 'medical history|Gastrointestinal disease', 'Temporomandibular Disorders', 'coagulation dysfunction.|The toxicity of', 'patient.|Psychiatric disease', 'CTCAE toxicity grade', 'distal ulna fracture AO 2U3A1.1)|Pregnancy|Vulnerable people|Distal ulna fracture', 'prostate cancer|Contraindication', 'Moderate renal impairment', 'haemoglobinopathy', 'Diabetes|Cardiovascular disease', 'verruca', 'guardians', 'open abdominal wounds', 'recurrence occurs 6 months after', 'HCM', 'Generalized Anxiety Disorder Scale', 'criteria of the American Academy of Neurology||', 'hyperselectivity;|Current cancer', 'MR', 'functional vision', 'Taiwanese.|Those', 'pneumonectomy|Corrected QT interval', 'autonomic dysreflexia', 'neuroborreliosis', 'genetic syndromes', 'prebiotic supplement', 'neurocognitive testing|a', 'mobilized peripheral blood stem cells', 'SS', 'lower limb function.||Patient', 'major hepatic', 'good kidney function', 'Preeclampsia', 'chronic constipation', 'abrasion', 'calceneal fracture Infection', 'criteria of the Department', 'horizontal', 'immunomodulating drugs|Estimated glomerular filtration rate (eGFR)', 'judged unlikely to interfere with study conduct', 'impaired gastrointestinal function|The', 'non-cardiac syncope', 'nocturia|Botox', 'weight loss therapy', 'aphasia;|Brain disease', 'popliteal arteries', 'bilateral sinonasal polyps', 'vascular malformation', 'ventriculoatrial shunt', 'AV) block', 'liver function tests', 'Schizophrenia spectrum', 'breast-feeding.||Participants', 'evaluating micronecrosis status|gross tumor necrosis', 'secondary involvement', 'calcified target lesion', 'coronary pneumonia plasma', 'seizures;|Significant eye diseases', 'Sleep Disordered Breathing', 'ENPP1 Deficiency', 'intrabody ferromagnetic', 'endophthalmitis', 'immunosuppression', 'acute sickness', 'hip injury', 'glucose-6-phosphate dehydrogenase', 'soft tissue sarcoma', 'women;|Patients', 'alcohol withdrawal seizure', 'thrombotic microangiopathies', 'sleep disorders|No', 'thoracic esophageal', 'mild allergic rhinitis', 'hepatitis B virus (HBV) DNA', 'disease conditions', 'head trauma.|Neoplasia.|Prior neurodegenerative disease.|Prior diagnosis', 'clinical observation', 'local anesthetics.|Local infection', 'pulmonary arterial hypertension', 'spinal cord injuries', 'refractory hypertension', 'CNS parenchymal', 'cotrimoxazole:||allergy,|advanced liver', 'intestinal infection', 'cancer stage', 'antiphospholipid antibody syndrome', 'tumor bleeding occurred', 'specific syndrome', 'dystonia', 'urination|Those', 'Healthy menopausal', 'Mesonephric-like cancer', 'peritoneal metastases', 'these diseases', 'not dementia', 'imaging|Peripheral arterial disease', 'therapeutic colonoscopy.|Polyposis syndromes', 'neurological, visual', 'cold', 'metabolic encephalopathy', 'fungal disease', 'RV dysfunction', 'Pregnant|End-stage kidney', 'esophageal temperature', 'intractable expectoration', 'chronic respiratory disease', 'non-FDA-approved IBD therapy||Cohort', 'Psychotic Disorder Studies', 'complex anal fistula', 'unmanaged hepatitis infection)|be', 'metastatic disease|Adequate bone marrow function|Adequate', 'tumor necrosis', 'polyposis|Comorbid diseases', 'regulatory agency', 'diabetes)|Uncontrolled pain', 'incessant pericarditis', 'breast-feeding;|Current', 'chronic gastroenterological disorders', 'cardio-circulatory assistance', 'medication changes', 'infrapopliteal', 'ALT abnormalities', 'femur', 'deep femoral arteries', 'concomitant conditions', 'acute cardiac ischemia', 'respiratory symptoms', 'Distant metastatic', 'acute ischaemic event', 'regurgitation', 'hypokalaemia', 'perianal hematoma)|Anal stenosis', 'effusion|Significant neurologic disease', 'behavioral symptoms', 'familial hyperchylomicronemia||ii', 'systemic illness;|Novice football', 'intra-articular', 'acute ischemic stroke symptom.||Time', 'organ failure', 'infection|Symptomatic congestive heart failure|Unstable angina pectoris|Cardiac', 'radical cystectomy|Variant histologies', 'Heart color Doppler ultrasound', 'high bleeding risk', 'pancreatic carcinoma', 'asymptomatic sustained ventricular', 'Generalized Anxiety', 'endured other diseases', 'placenta previa', 'cerebral aneurysm', 'cognitive impairment|Patients', 'Criteria RBD patients:||•', 'both)|Hepatitis C infection', 'from eye dryness', 'ability to read', 'unclassifiable with features', 'renal dysfunction;|Hypertension', 'mellitus|Diabetic Macular edema', 'paralysis', 'changes', 'non-lymphatic tumors', 'esophageal ulcer', 'growth hormone deficiency', 'Nanaimo', 'major gastrointestinal tract surgery', 'discharged from the hospitals', 'sarcopenia Be able', 'actively enrolled', 'hepatorenal syndrome)|Acute infection|Pregnancy', 'etc.).||ASD siblings', 'pancreatic metastases', 'GEBT);|TCM Syndrome differentiation', 'ampullary abdomen', 'rheumatoid arthritis)|Contraindication to MRI|Pregnancy', 'expansive injury', 'severity disorder', 'metropolitan', 'questionnaires.|Inflammatory bowel disease|Lactose intolerance', 'canal stenosis|osteophytes', 'deep attenuation', 'facial acne vulgaris', 'neuroendocrine carcinomas', 'strongly discourage', 'function.|Inability', 'therapy.|Progressive disease', 'cytogenetic abnormality', 'Enterocolitis Syndrome', '- Premenopausal', 'mitral stenosis', 'galactosemia', 'biphasic Doppler arterial waveforms', 'Kimura disease', 'acute liver failure.|The', 'Convergence insufficiency symptom Survey', 'gluteal area', 'Endometrial', 'early manifest', 'haemorrhagic stroke.||K.', 'IMN.||', 'etc.)|25 0H vit', 'parathyrometaplasia', 'systemic inflammatory disorders', 'lower extremity rehabilitation', 'Hepatitis B virus (HBV)', 'bleeding;|In diabetes', 'physically unhealthy', 'nocturnal respiratory support', 'course of COVID-19', 'lateral border of the', 'cerative colitis:||Signed informed', 'prolonged QT syndrome', 'FD19;|Patients', 'language impairment', 'aortic stenosis', 'brain cancer', 'eosinophilic esogaphitis.|Inflammatory bowel disease.|Mastocytosis.|Immunocompromised', 'shoulder complex', 'biopsy.|Active autoimmune diseases', 'nonprogressive disease', 'asthma|Chronic obstructive pulmonary disease|Restrictive lung diseases|Sick sinus syndrome|Sinus bradycardia|Hypertension|Chronic hypotension|Ischemic heart disease|Coagulopathies|Hepatic insufficiency|Renal insufficiency|Diabetes', 'anterior cerebral artery (', 'paravertebral block', ""Gilbert's"", 'cerebrovascular', 'FS-LASIK', 'uveitis|Presence of baseline hypoalbuminemia|Fever', 'astrocytoma', 'auscultation type sphygmomanometer|Those', 'prescription eyeglasses', 'viewed heterosexual pornography', 'gastrointestinal (GI) bleeding ≤3 months|Severe (', 'RV dysfunction|Significant abnormalities', 'chronic hip pain', 'anterior chamber inflammation grade', 'preterm labor', 'carcinoma uterine cervix in situ', 'tablets', 'primary immunodeficiency virus infection', 'migraine diagnosis.||', 'elbow pain', 'solid tumor carrying HRR', 'excipients;|Pregnancy', 'radical cervical carcinoma in situ', 'Intracranial arterial stenosis', 'Hepatocellular carcinoma', 'criteria of active MM', 'pelvic effusion', 'psychosurgery.|Borderline personality disorder,|Schizotypal', 'bone tumor', 'phobia symptoms', 'primary lesions', 'Participation MUSCLE', 'normal size', 'chronic kidney disease)|History of', 'genitourinary prolapse beyond the introitus', 'gastrointestinal bleeding;|severe end-stage diseases', 'third degree heart block|High risk', 'Normal renal function', 'clonic spasm', 'Siblings', 'colitis ulcerosa|Active cancer', 'CTNNB1 mutation', 'Glaucoma patients:||Age', 'ventricular arrhythmias|Contraindication', 'types of pain', 'recurrence of metastasis', 'meetings', 'anti-coagulation treatment', 'acute thrombophlebitis', 'overweight', 'pressure', 'non-healed dental', 'skin disorder', 'mental disorders.|Persons', 'CRITERIA:||1', 'Risk Pregnancy', 'Demonstrated indicators', 'sarcoidosis', 'optic nerve head', 'ventricular septal defect;|Cardiogenic shock', 'pelvis|Neurogenic bladder', 'stated).||NOTE', 'systemic cartilage disorders', 'Renal tumor', 'recurrence.|For AML', 'Unresectable locally advanced', 'acute COVID-19', 'VF damage', 'blood sugar', 'painful arc test', 'caregivers).|significant cognitive impairment', 'severe hearing deficits', 'bleeding lesion', 'Medicine Voice', 'bloody diarrhea', 'therapy.|Systemic conditions', 'T2 lesion', 'chronic uveitis', 'left ventricular hypertrophy cardiomyopathy', 'PROMIS depression', 'thyroid surgery;|clinical conditions', 'eczematous dermatitis', 'Acute Respiratory Syndrome-Coronavirus 2', 'severe COVID-19 infection', 'renal dysfunction.|The', 'severity insomnia', 'isolated sick sinus syndrome.|Pregnant', 'other disorder', 'breast feeding|(7', 'Nantes', 'sensitizing epidermal growth factor receptor (EGFR)', 'judged by the investigator to be highly', 'keloids', 'acute eye conjunctivitis', 'decreased systolic function', 'resting hypotension (BP', 'practice true abstinence', 'pathological criteria', 'mini-stroke', 'acute choelcystitis', 'H.pylori eradication', 'metallic particles', 'N- acetylglucosamine-6-sulfatase GNS', 'sperm/fertilization', 'higher|Near native dutch speaker||', 'recreational drugs.|Treatment', 'core Ab positive', 'functional neurological deficit|Subject', 'human immunodeficiency virus (HIV) antibody results|Evidence', 'CWI', 'therapy|HIV-infection', 'Bacillus Tuberculosis.|Hypersensitivity', 'right heart failure', 'distant corrected visual', 'manual maneuvers', 'chronic HBV', 'Perinatally infected', 'oropharyngeal cancer', 'cardiac clinical symptoms', 'G719X', 'primary knee arthritis', 'classical chondrosarcoma', 'neoproliferative disease', 'ocular organic lesions', 'tumour production', 'PROP', 'functions in activities of daily living', 'severe respiratory failure', 'ambulatory-aided', 'old.|Acute COVID-19', 'disturbed consciousness', 'oropharyngeal swab', 'potentially resectable', 'respiratory diseases', 'gastric emptying abnormality', 'former severe SUD', 'GPDs)|status epilepticus resolved', 'chronic NSNP.|Office', 'etc.)|Pregnant', 'RT', 'male vasectomy', 'cerebral vascular disease', 'systemic malignancy', 'exposed to radiation', 'person|Ability', 'varus deformity', 'autism spectrum disorder;|4', 'chronic diseases-related', 'certain eye diseases', 'solid tumor.||Phase', 'physically disabled).|Patients', 'metastases of', 'HIV infection.|Receive', 'AVNRT||', 'non-reader', 'pulmonary tuberculosis.|Viral', 'venous cord', 'supraventricular rhythm (visible P-waves', 'aortic regurgitation', 'severe infection', 'osteopenia', 'ovarian cancer|Subjects', 'unusual site thrombosis', 'kidney failure|Troublesome side effects', 'thrombolytic therapies.|Subject', 'HR+ MBC', 'biliary abnormalities', 'fetus|Maternal hypersensitivity', 'cognitive complain', 'acute liver failure syndrome', 'wounds', 'squamous skin cancer', 'chemotherapy.|Terminal cancer', 'corneal ectasia', 'Cholangitis', 'bleeding episode', 'calculated by Cockcroft and Gault equation).|Baseline left ventricular ejection fraction', 'confirms', 'wash cloth', 'non-melanoma skin cancer|Carcinoma in situ of breast', 'interstitial pulmonary disease', 'MEOPA|Nasal breathing disorders', 'Psychotic Disorders', 'anorexia', 'deep venous embolism', 'fluorescence in situ hybridization', 'Trauma', 'glucose control);|Mental retardation', 'insufficiency fracture', 'gynecological cancer', '|For Normal', '≥1 of', 'chronic pyelonephritis', 'B cell disorders', 'amelogenesis', 'Paraffin', 'distant metastasis|Lesions', 'acute infectious diseases', 'cardiac T2*', 'communicative impairment', 'cervical cancer|Participants', 'behavioural impairments|Communication disorders', 'Vegetarian', 'A3 segment of the anterior cerebral artery (ACA)|Occlusion of the P2 or P3 branch of the posterior cerebral artery', ""Parkinson's disease|Other"", 'cirrhosis|Congestive heart failure', 'Measureable disease', 'osteogenesis insufficiency', 'duct carcinoma', 'gliosarcoma', 'severe neuropathy', 'non-cardiac disease|Currently', 'non-melanoma skin carcinoma|Social', 'colorectal resection', 'pharmacy coverage', 'Chronic obstructive pulmonary Disease (COPD)', 'T-cell-negative severe', 'risk of rupture', ') infection', 'enterocolitis|Pneumothorax|Skull fracture|Major congenital anomalies|Suspected', 'liver disease,|malignant tumor', 'acute cholangitis', 'LVDD', 'serological panel.|Active HIV', 'carcinoma in situ of the cervix.|Psychiatric illness', 'urinary tract infection|multiple ureteric stones,|presence', 'breast feeding;|Malignant tumors', 'nonchild-bearing potential', 'testing abnormality', 'acute brain injury', 'pancreatobiliary disease', 'chronic inflammation|HHV8+ DLBCL', 'Coagulopathy', 'botox', 'malignant small bowel obstruction.|Cardiac abnormalities', 'enrolment.|High myopia', 'SCLC mixed', 'disease states:||Dumping syndrome', 'short gut syndrome', 'Patellofemoral dislocation', 'intracranial tumor history|Death', 'systemic medical condition', 'pulmonary embolism；|Patients', 'ocular health', 'special precautions).|Seizure disorder', 'psoriatic lesions', 'heart disease|Cardiac disorders', 'neuro-', 'clinical manifestations of skin', 'type 2 diabetes mellitus;|2', 'chronic forms', 'network services', 'chronic high-dose', 'non-peritoneal metastasis|PRE', 'ulcerative colitis;|an', 'PD).|Hospitalized', 'Spinal Injury Association (ASIA) Impairment Scale', 'acute diseases.|Volunteers', 'acute brain disease', 'mCRPC', 'orthodontic appliances|Treatment plan', 'mandibular arch', 'product|Inability', 'primary surgical procedure', 'end organ function|Histologic documentation', 'therapy;|sleep apnea syndrome', 'sporting life', 'non-specialized school|If', 'deposition disease', 'unstable cardiovascular disease', 'tumor mass', 'hepatic function|FEV1', 'cardio-thoracic surgery', 'Solitary renal', 'bleeding disorder|platelet counts', 'type 2 diabetes||Ability', 'cardiac disease|Patients', 'ABO', 'gastrointestinal obstruction;|Patients', 'head laceration', 'major cancer', 'personality disorders', 'human immunodeficiency virus (HIV) infection|Is', 'vascular deficit', 'months.|3≤OABSS≤11.|No abnormality', 'herpes virus', 'Reversible Encephalopathy Syndrome', 'sleep disturbance|Is', 'brain tumor|Patients', 'Psoriatic ARthritis', 'leptomeningeal metastasis;|Active', 'Rectal prolapse', 'consumption', 'minimal change nephropathy', 'Stable Ischemic Heart Disease', 'kidney disease|have', 'coagulation disorders).|Bacterial', 'breast cancer resistance protein (BCRP) inhibitors|statins|warfarin', 'actively', 'resection cavities', 'systemic arterial hypertension', 'consent|not regularly physically active', 'LBSL', 'congenital myopathies', 'hereditary nephropathy', 'drug-associated thrombocytopenia', 'pervasive developmental disorder|Acute suicide risk|Documented', 'Head', 'injectable contraceptives.|Nervous', 'nutritional metabolism disorder|Those', 'vulvar intraepithelial neoplasia', 'equally effective hormones', 'obsessive-compulsive', 'perineal pain', 'T4N0-1M0', 'intracranial haemorrhage', 'regular menstrual cycle', 'type 2 diabetic|diagnosed', 'gynecologic oncologists', 'psychiatric disorders;|Dementia', 'cerebral small vessel diseases', 'multi-organ transplantation.|Poor compliance.|Unable', 'endotracheal intubations', 'structural anomaly', 'metabolic system', 'alternative diagnosis', 'reproductive capability will need', 'traumatic brain injury|unable', 'nodularity', 'poor ovarian response', 'General contraindications', 'Cerebral Palsy', 'Atlantia', 'mycotic infections', 'General Criteria||Skin conditions', 'severe mental illness)|Plans', 'completion.|Pregnant', 'spontaneous coronary dissection', 'cannabinoids.|Non-correctable vision', 'impact on fatigue.|Diagnosis', 'serious psychologic disease', 'peripheral neuropathy|Hepatic', 'chronic obstructive pulmonary', 'comorbid condition', 'Black American', 'avian', 'impulse control disorder', 'relief abnormalities', 'liver kidney', 'germline DNA', 'myocardial ischemia|systolic BP', 'TMZ', 'chronic total occlusion (CTO)', 'Eating Disorders adult', 'Pelvic malignancy', 'intrahepatic', 'period;|Abnormal liver function', 'malignancy;|Pregnancy', 'NTRK', 'hip flexion limitation', 'lactating|Neuropsychiatric disorders', 'regular behavioral', 'gluten enteropathy', 'fetal malformation|Fetal', 'diabetic neuropathy)|BMI', 'care.|Measurable disease', 'contraindicated the use of argatroban', 'facial', 'antibodies targeting PD-1', 'chronic heavy smokers', 'disease.|Suspicious microcalcifications', 'acute cardiac condition', 'bone marrow involvement;4', 'lymphoma', 'genetic lesion', 'skin defects', 'TrPs||Inclusion', 'insomnia symptoms', 'professional knowledge judged to have', 'IMP', 'auxiliary nurses', 'viremic hepatitis', 'ankle instability', 'good cognitive status', 'motor symptoms', 'HLA-G-positive', 'ischaemia', 'major episode', 'structural bone abnormalities', 'HAMD<17', 'thoracic ultrasound)||', 'primary myelofibrosis (', 'cGVHD).|Patients', 'hemoglobin', 'mucosal lymphoma', 'HbSB0 thal', 'congenital QT prolongation.|Systolic blood pressure', 'maxillary sinusitis', 'criteria below:||Blood routine examination criteria shall meet:||(No blood transfusion', 'gout attack', 'serious heart', 'chemotherapy.|Hepatic', 'memory loss|Not interested', 'NHP', 'pathology threatening', ""Parkinson's Disease Cognitive Rating Scale"", 'lymphoepithelioma-like', 'serious physical disease', 'structural extracardiac anomalies', 'pleural effusion|Patient', 'liver metastases;|Coagulation function', 'muscle function', 'systemic autoimmune diseases', 'structural brain abnormality', 'acute abdomen', 'Major complication', 'PK)/pharmacodynamics interaction', 'active hemorrhage', 'home bilevel', 'Metastatic disease|Pancreatic tumor', 'endorectal probe', 'IV).|Existence', 'metabolic diseases)|Other severe diseases', 'Squamous cell', 'health-care', 'hyperimmunized', 'articular destruction', 'mechanical obstruction', 'chronic eczema', 'eye disorders', 'candida endocarditis', 'lower extremity bone fracture', 'autonomic dysregulation', 'dependence on spectacles for near work', 'physical support', 'Spreading Depolarizations II (SDII)', 'PN', 'MRI.|Previous malignancies', 'traditional Chinese medicine and/or its analogue', 'common carotid artery', 'retinal reattachment surgery', 'mucinous adenocarcinoma.|dMMR', 'squamous cell skin cancers', 'thoracic kyphosis>70°', 'major organs.||', 'pancreatic cancer;|conversion therapy', 'complex communication needs|Control of eye motility', 'non-cardiorespiratory symptoms', 'mental disability|Able', 'osteoporotic vertebral', 'ambient air.|(2', 'EKG abnormality', 'retinal vessels', 'prostate cancer|In', 'endometrioid carcinoma', 'self-identifying', 'cognitive remediation', 'vascular immunoblastic T-cell lymphoma', 'screening.|Pregnancy.|Cardiovascular disease', 'Cystic Fibrosis', 'acute infections.|Smokers.|Pregnancy', 'high-quality', 'septum syndrome', 'altered mental status', 'lactant', 'brain injury|Minimal time', 'brushing habits|Fixed orthodontic treatment|Active', 'nasal bleeding', 'Hepatopathy', 'psychological disorders', 'left bronchial segments B2', 'impaired thyroid', 'non-culprit-lesion stenosis', 'SPA', 'transition', 'infarction|percutaneous coronary revascularization', 'pain|Refusal', 'pelvic segment disease of the ureter', 'hepatic abnormalities', 'non-melanoma skin cancers', 'toxic shock', 'lower extremity pain', 'signs of epidermal loss', 'hereditary CAA', 'serious illness', 'reason|Neurological disorders', 'respiratory diseases);|Diseases', 'special health care', 'multiple endocrine neoplasia type', 'eye trauma', 'Inability to withdraw', 'infected with COVID-19', 'right atrial disease', 'tumor.|Pregnant patients.|Any condition', 'placental anomalies', 'monoculture', 'pulp inflammation', 'Ileus', 'malignant bladder', 'cT2c-T3a', 'hemolytic-uremic syndrome.|Active HIV', 'amytrophic lateral sclerosis', 'renal disfunction，ie', 'portal hypertension', 'infective endocarditis', 'glomerular disease', 'non-musculoskeletal', 'Criteria HIV+', 'ischemic chest pain', 'breastfeeding|Cerebral diseases', 'urine drug abuse', 'unstable housing', 'EMTs', 'myocardial ischemia)||', 'betel quid chewer', 'Los Angeles', 'coagulation abnormality|Major surgery', 'months|Expression', 'EB virus', 'teeth in the oral cavity.||', 'clusion Criteria:||Healthy adult', 'hot flashes', 'familial variant|FIRST-DEGREE RELATIVES', 'or|Occlusive lesions', 'major contraindications', 'nodal involvement', 'axillary staging', 'proteasome inhibitors', 'diabetes mellitus)|investigator discretion for safety reasons', 'joint disease', 'rare mutations', 'benign prostate tumor/hypertrophy', 'Cognitive Impairment', 'deep vein thrombosis of the lower extremities', 'PERJETA SPCs.|Known hypersensitivity', 'fibromyalgia', 'Healthy Controls:||Those', 'granulocyte-colony stimulating factor', 'Uncontrolled Diabetes.|Coagulation', 'multiple pregnancy|comorbidity', 'congenital ichthyoses', 'number of tumors', 'cardiovascular effects', 'striae', 'psychological debility', 'pancreatic head malignancy', 'OCV||', 'hypoglycemic coma', 'empyema|Acute inflammations', 'lung pathologies', 'living conditions', 'rectum;|Physical condition', 'APS', 'Laron syndrome', 'precapillary PH', 'climbing stairs', 'acute physiology', 'knee OA|On orthopaedic waiting', 'opioid abuse', 'brain structures', 'caries dentium', 'congenital heart disease', 'end stage lung', 'partial brain radiation', 'cancer navigation', 'lumbar pathology', 'GI function', 'Healthy rabbits|Rabbits', 'resected basal cell', 'paraneoplastic syndrome.|Current', 'Austria', 'sleep-related breath disorder|History', 'stage liver disease', 'oral tongue', 'Huntington disease', 'orthodontic treatments,|Presence', 'primary central nervous system lymphoma', 'inflammatory disease|vision impairments|orthopaedic problems', 'general hemorrhagic diseases', 'antihypertensive drug.|Hypertension', 'implanted|Symptomatic heart failure', 'dissociative disorder', 'difficulty in voiding', 'adjustment disorder', 'progressive pulmonary fibrosis|For', 'non-stable', 'metastatic melanoma.|In', 'congenital bleeding disorder|History', 'feeling faint', 'B-cell lymphoma(PMBCL', 'skin cancer resection', 'thrombus;|Uncontrolled heart failure', 'human immunodeficiency virus(HIV', 'clinical comorbidity', 'deep inspiratory breath-hold', 'musculoskeletal pain disorders||', 'autoimmune diseases.|Known', 'digestive stoma', 'thrombotic microangiopathy||Diagnosis of end-stage kidney disease (ESKD)', 'autoimmune mechanism', 'respiratory syncytial virus', 'symptom-free interval.|Functional disability', 'thrombopoietic factors', 'compliance issues', 'type 2 Diabetes Mellitus', 'cerebral trauma', 'left main lesion', 'available.|Encephalitis', 'Gestational diabetes', 'disorder of coagulation', 'radiographic findings', 'simple dyslipidemia', 'risk factor', 'drainage of the effusion', 'Mild bilateral disease', 'stability', 'flutter;|A chemical cardioversion procedure', 'normal menstrual cycle.|Spending', 'Music performance anxiety', 'factor|Cardiovascular disease', 'bone healing', 'intestinal obstruction', 'joint|medically stable', 'surgically resected', 'cardiovascular disease.|Chronic hepatitis B', 'levels of parental rejection', 'co-morbid disease', 'lumbar injection|Stage', 'ex14m-wildtype', 'iptacopan', 'sedative use disorder', 'respiratory insufficiency|Pregnancy|Neoplasm', 'CentriMag™', 'stage I tumors', 'fumarate hydratase deficiency renal cell carcinoma', 'mitral valve surgery coronary artery bypass graft surgery', 'macular hole', 'brain dysfunction', 'balance disorders', 'Peripheral vascular disease', 'SCLC)', 'chromosomal disease|Patients', 'large adenoma', 'malignant neoplasia', 'television', 'Bulimia Nervosa', 'physical problems|Females', 'impaired renal function,|The', 'periodontitis', 'residual tumor', 'epididymitis', 'cardiac surgery,|Hemodynamic', 'knee infection', 'severe disease', 'neonatal sepsis', 'dehydration|The child takes analgesics', 'pain severity', '1|Able to swallow capsules||For Phase', 'epidural hematoma', 'folic acid deficiency', 'myasthenia', 'diabetes;|uncontrolled hypertension', 'surgical approaches', 'end-organ T2DM', 'contra-indicated', 'skin-related complications', 'Ischemic heart disease', 'Platelet dysfunction syndromes', 'atypical anorexia', 'CVD', 'organ perforation', 'cyst drainage', 'blood pressure disorders', 'fever.|Clinically stable', 'ophthalmological diseases', 'uterine fibroids', 'large scars', 'pneumocystis jirovecii', 'Hepatobiliary Oncology', 'Metabolic liver disease e.g Gauchier', 'alone.|Able to swallow liquids', 'Bleeding complications', 'hematology abnormalities', 'AKI', 'Presbyopia', 'chronic diarrhea|Diagnosis', 'focal lesion', 'infection;|Human immunodeficiency virus', 'spontaneous stools', 'therapy.|Prior invasive malignancy', 'thoracic trauma', 'local health authority.|Medical conditions', 'acute gastrointestinal disease', 'transfusion therapy|Known', 'abdominal metastasis', 'complex dysrhythmias', 'T', 'this.|Excessive weight loss', 'lack standard', 'Mixed Gas CCR', 'heart failure|Left ventricular dysfunction', 'pharmacotherapies', 'lymphatic system disease', 'medication interactions|Hemochromatosis', 'chronic health condition', 'transplant recurrence of FSGS.|Ability', 'neurological disorder|written informed consent Right Hemisphere Damage', 'pose a health risk', 'prior hemorrhage', 'Criteria for selection of', 'hypergammaglobulinemia', 'Exon 19 deletion mutations', 'CAR-T cells', 'marrow aplasia', 'spinal pathologies', 'HFpEF||', 'nephrectomy.|Patients', 'episodes of disease', 'Right-heart acoustic contrast', 'leg ischemia', 'spinal anomalies.|Intracranial', 'perinatal disease', 'singleton pregnancy|Being', 'progressive multifocal lenses', 'non-disclosure', 'factor deficiency', 'pain management.|Received', 'Contra-indication', 'glucose tolerance|use of tobacco|participation', 'homozygous factor V mutation|Presence', 'age|Speaks', 'neurodegenerative disease|Medication', 'childhood atopic dermatitis', 'PH', 'lack of bleeding upon', 'narcotic addiction', 'nasal infection', 'femoral', 'ENKTCL', 'pseudocholinesterase deficiency', 'CAP.||', 'upper central incisor', 'NOS|HHV8+DLBCL', 'suitable conditions for telehealth appointments', 'major congenital anomaly', 'month||', 'pneumonectomy);|Nutritional deficiency', 'refractory multiple myeloma', 'chronic respiratory failure', 'patients;|Septic shock', 'minimal activity', 'hospitalization;|Active infections', 'inhalation injury', 'cHP', 'active cancers', 'bleeding volume', 'consent|Active autoimmune disease', 'general condition', 'severe angina', 'epithelial ovarian', 'cardiac dysrhythmia', 'CVA', 'mitral valve replacement (MVR)', 'vaccine allergic reaction', 'vision loss', 'mild- moderate-severe', 'cerebellar metastasis,|the condition', 'ambulatory assistive devices', 'ductal breast carcinoma in situ', 'epistaxis', 'Recurrence', 'hypomagnesemia', 'valve failure', 'total deafness', 'head injury,|metal implant', 'duodenal gastro', 'musculoskeletal comorbidities', 'major traumas', 'primary peritoneal carcinoma', 'non-metastatic breast cancer|Self- reported', 'evolutive allergic', 'medical history:||Liver cirrhosis', 'organic disorders', 'cervical surgery|Cervical spine tumor.|Rheumatoid arthritis', 'brain aneurysm', 'concomitant skin conditions', 'kidney insufficiency', 'ALK+', 'malignant brain tumor', 'inadequate distal outflow.|Significant inflow disease.|Acute', 'metabolic diseases|infectious diseases|epilepsy', 'circulatory', 'seizure.|Cryptogenic', 'type 2 narcolepsy', 'syndrome|Neurological diseases|Mental illnesses|Myopathic diseases|Bilateral upper extremity', 'being HIV', 'bradycardia|severe obstructive lung', 'acute hepatitis B', 'seeing', 'exertional hypoxemia', 'END', 'adjuvant ET', 'HYQVIA', ""above||Exclusion criteria:||Can't read"", 'date|Leukopenia', 'acute glomerulopathy', 'good patellofemoral mobility', 'procedures|Body mass index', 'cognitive diseases', 'mental health clinicians', 'Periodontal disease|Systemic diseases', 'lower priority', 'primary disease', 'musculoskeletal involvement', 'peripheral nerve injuries;|Pain', 'gastrointestinal disease/abnormalities', 'acute episodes', 'chronic intestinal pseudo-obstruction', 'back|Current osteomyelitis', 'congestive heart failure)|Previous treatment', 'urinary diversion|Existing catheter related', 'conditions that confer medical complexity', 'dependence on drugs', 'clinical indication deemed', 'urogenital symptoms,|not', 'movement disorder', 'non-ulcer functional dyspepsia', 'defocus spectacles', 'cognitive domains', 'therapeutic limitation', 'consistent DH response', 'vertebral stenosis', 'brain injury|Established invasive', 'mental disabilities', 'nonmeasurable disease', 'cerebral infarction;|(3', 'menstrual cycle irregularities', 'hepato-renal contrast', 'septate', 'orthopedic disease', 'irreversible neurologic disease', 'Cohort 2:||Evidence', 'simple painkillers)|Have', 'chronic lung disease', 'diseases of acromegaly-induced', 'metastatic tumor biopsy', 'hazardous.|Psychiatric illness', 'residence location', 'cooperate.|Current alcohol', 'liver adverse events', 'post-menopausal status', 'strongly recommended', 'pregnancy loss', 'marrow failure', 'physiological sleep problems', 'acromioclavicular joint osteoarthritis', 'biochemical hypothyroidism', 'fungal infections|Poor', 'non-valvular', 'popliteal artery', 'judged by researcher;|Patients need', 'chronic dermatological', 'Mental Retardation,|GMFCS level', 'pleomorphic adenoma', 'florid autoimmune diseases', 'variceal bleeding|HIV', 'measurable diseases', 'brain MRI lesion', 'inflammatory bowel disease patients.||', 'acute ischemic stroke|Stroke', 'cerebrovascular disease', ""Bietti's"", 'ophthalmologic disease of prematurity', 'infectious conjunctivitis', 'sinoatrial blockade', 'Skin diseases', 'valvular aortic stenosis', 'small bowel resection)|Pregnant', 'splenomegaly', 'Santiago Chile', 'clarity', 'generalized seizure', 'soma height loss', 'transcriptomic profile', 'neurologic, GI', 'from other diseases', 'botanical preparations', 'hepatobiliary', 'probe', 'polymyositis', 'digestive system', 'spinal malformation Fetus', 'intracranial artery stenosis', 'demonstration of a QTcF interval', 'drug use disorder', 'indicated|Sarcoma', 'polygraphically recorded', 'colonic occlusion', 'renal impairment|Patients', 'Transient Ischemic stroke', 'non-metastatic disease', 'metabolic rehabilitation||', 'lactating|Active skin cancer', 'alcohol consumption habits/risky', 'axial spondyloarthropathy', 'incidental', 'chronic rhinitis', 'STOP-BANG', 'primary vulvar squamous cell carcinoma', 'local allergic necrosis reaction', 'sleep apnea.|Pulmonary embolism', 'copper', 'renal conditions', 'oncological diseases|COPD', 'pLVAD device.|Left ventricle rupture.|Cardiac tamponade.|Subject', 'CNS vasculitis', 'infantile cerebral palsy', 'Psychiatric', 'PET from', 'alveolar bone).|Five', 'glaucoma-associated', 'reflux symptoms', 'cardiac', 'retinal specialists', 'capivasertib', 'chronic lumbopelvic pain', 'treated,|Not Severe asthmatic', 'tACS', 'cerebral aneurysm clips', 'problems', 'behavioral disorders.|Treatment', 'Asian', 'organ transplantation.|Widespread metastases', 'criteria:||recent myocardial infarction|recent', 'severe clinical illness', 'iagnosis', 'mmHg)|Ventilation dysfunction', 'metastatic disease.|ER', 'disease-free interval', '(obstructive', 'breathing frequence', 'localized and not', 'aneurysmal subarachnoid hemorrhage', 'thermal allodynia', 'drivers.|Ability', 'glioblastoma', 'squamous cell carcinoma.|Clinical symptoms of COVID-19', 'psychotic symptoms.|no', 'malignant tumors.|3', 'mild psoriasis', 'supraspinatus', 'multiple thrombosis', 'prostate cancer|Neoplasia', 'nasal', 'ketogenic', 'legs syndrome', 'recurrence occurred', 'renal insufficiency|Severe sensitivity', 'Parkinsonism', 'Chronic liver disease', 'clinical hyperthyroidism', 'upper limb surgery', 'Nicoderm', 'local skin infection|Hypersensitivity', 'non-cirrhotic portal hypertension', 'bladder neck collapse fibrosis', 'admitted to stroke intensive care unit (ICU)', 'type-2 DM', 'perianal abscess', 'COPD exacerbation', 'cessation counselor', 'visual defects', 'continuous atrial fibrillation', 'medication known', 'not.||', 'short bowel', 'coma scale.|Facial', 'auto-immune hemolysis', 'ANKRD26|germline mutations', 'thyroid gland', 'coagulation', 'allergic disease', 'Mild Cognitive Impairment (MCI)', 'cogntive impairement', 'neurological disease)|use of psychoactive substances|decreased level of cognitive functioning|people', 'low disease activity', 'hypertensive encephalopathy|Significant vascular disease', 'years|Ambulatory impairments', 'retinal migraine', 'apheresis staff.||Negative', 'lower extremity disability', 'hepatic tumors|OR', 'adrenal diseases', 'abnormal anemia', 'weeks)|Persistent heart rate (HR)', '/pain', 'acute illness', 'chest pain syndrome', 'RA', 'kidney disease;|Hypersensitivity', 'oncolytic virus', 'Unresectable locally advanced/metastatic', 'generalized dysmotility', 'keratinized tissue at the site selected', 'VOC)|Acute chest syndrome', 'end stage emphysema', 'valvular heart disease|Prosthetic cardiac valves', 'pSS', 'stable lesions', 'detectable viral infection', 'combined immunodeficiency', 'vivo.|Skin lesions', 'Low Back Pain', 'disease of the uterus|Malignancy', 'bronchial insufficiency', 'comorbid disorder', 'criteria', 'involves', 'hepatitis D virus|Patients', 'shoulder trauma', 'visceral myopathies', 'non-obese', 'Thrombolysis|atrial fibrillation|contra indications', 'REM', 'progressive pathologies|Impossible', 'HM', 'tumour slides', 'nasopharyngeal malignancy', 'alcoholic steatohepatitis', 'Pervasive Developmental', 'MPM', 'hypersensibility', 'orthosis', 'child being sick', 'risk surgical candidates', 'disease|Skin diseases', 'large B-cell lymphoma', 'Diabetes Mellitus).|Coronary artery disorders .|Neurological disorders.|Recent musculoskeletal injuries.|Renal disorders.|Hepatic disorders.|Skin hypersensitive.|Smokers', 'fungus', 'retinal vascular', 'Adverse Events)|Patients', 'SNHL|inability to read', 'muscle activity', 'Disease progression', 'COVID-19 human immunoglobulin', 'severe depressive', 'HR+/HER2- breast cancer', 'chorioretinal dystrophies', 'paraproctitis', 'rejection of anti-depressant medication and|no', 'infectious state', 'Kidney Disease Improving Global Outcomes', 'monocytosis', 'motion sickness', 'neuropsychiatric disease', 'superior mesenteric vein', 'localized sarcopenia', 'palliative care.|Neurodegenerative disorder.|Comprehension aphasia.|Dementia', 'fatty liver', 'gait speed<1m/s and/or', 'menstrual period', 'syndrome;|Systemic lupus erythematosus;|Pathologies', 'breast cancer liver metastases', 'LVSD', 'stress cardiomyopathy', 'comfort care', 'unresectable solid tumor', 'antithrombotic therapy;|Significant anemia', 'motor neuropathy', 'oxygen-dependent', 'cheese', 'verebral palsy', 'orthostatic hypotension (decrease in systolic blood pressure', 'malignancy.|Serious infections', 'modifying renal', 'pregnancy-related', 'judgement|Borderline personality disorder', 'Endometrial cancer', 'acute respiratory illness', 'rejuvenation', 'hereditary liver disease', 'chronic substance abuse', 'asthma condition', 'site eczema', 'painful disease', 'autoimmune liver disease', 'gallstones', 'brushing habits|No', 'orthopaedic disability', 'bronchial thermal ablation', 'chronic obstructive disease|History of', 'complete response', 'glioblastoma multiforme', 'neurological deficiency', 'electrolyte disorders', 'good patellofemoral mobility|Ability', 'Pneumonia', 'non-vital permanent immature', 'neurofibromatosis', 'fungal pneumonia', 'brain|Active infection', 'spinal diseases', 'mass occupying lesion', 'drug-resistant epilepsy', 'carcinosarcomas', 'fetal bradycardia', 'asymmetrical disease', 'intracranial atheroma)|Acute', 'addictive drugs|Pregnant', 'Hyper-IgG4 syndrome', 'C-Section', 'potentially impacting', 'mucosal involvement', 'transient wall motion abnormality', 'alcohol use.|Participants', 'congenital QT extension syndrome', 'sickle cell anaemia', 'Spastic diplegic/ hemiplegic CP', 'criteria:||Diabetes mellitus type', 'Central adiposity', 'FCR', 'gastrointestinal malabsorption', 'Celiac disease|Immune suppression|intestinal obstruction|Oropharyngeal dysphagia', 'Type 2 DM', 'normal hepatic function||Certified', 'cuff', 'primary rectal cancer', 'maxillary retrognathism', 'thyroid hormone T3', 'surgically inoperable T4b tumours', 'psychological symptoms', 'diabetes.|Treatment', 'electrolyte disorders|Coronary artery disease|Cardiac arrhythmia', 'PTSD||', 'breast cancer records', 'sinus', 'treatment responder', 'NSCLC/', 'breast feeding|Mental health status|Daily total sugar intake||Inclusion Criteria:||Malaysian', 'pregnancy|Allergy', 'arterial insufficiency', 'etc.)|Pregnancy', 'oocyte||', 'normal cognition', 'paroxysmal atrial fibrillation', 'poly-articular', 'major debilitating inter-current illness that', 'pituitritis', 'gastrointestinal disorders;|Taking vasoactive medications', 'nodal recurrence', 'Response', 'diseases like osteoporosis', 'Romanian', 'not match carpal tunnel syndrome', 'pregelatinized starch', 'urogenital problem', 'chest pain recurs', 'teeth from', 'breast development|gastroesophageal reflux', 'Hyperglycemia', 'motor weakness', 'liver lesions', 'oligosecretory myeloma', 'subsequently became diabetic', 'hyperalgesia', 'coma score', 'implantation;|Malignant neoplasms', 'accessible archival tumor tissue', 'protease inhibitor', 'atraumatic lateral epicondylitis symptoms|Symptoms', 'intestinal inflammatory disease', 'traumatic brain injury,|Major neurological problems,|Current substance use disorder', 'polyarteritis', 'tear)|No tolerance', 'transurethral prostate surgery.|Patients', 'biochemical pregnancy losses', 'congenital disease', 'main symptoms', 'learning disability must:||Be', 'menopausal', 'vascular disorder', 'urologic', 'radiographically measurable', 'inversion trauma', 'affected)|Arterial blood circulation', 'T1b tumor', 'cervical spine defects', 'impaired fasting glucose', '2002≥3', 'caries penetrating entire', 'marcular pathology', 'cystoscopy impossible', 'activity level)||uncontrolled hypertension', 'critical disease', 'Coagulation disorders', 'congenital heart disease|Monochorionic twins|Suspected', 'restenosis', 'revascularisation', 'collagenous sprue', 'dental caries', 'chronic abdominal pain', 'auditory canal (IAC)', 'light alerts', 'cerebrospinal fluid', 'upper respiratory infection', 'medical condition|Any disorder', 'geographical factor', 'hyperosmolar hyperglycemic state', 'infection||', 'Williams Syndrome', 'valve replacement|Permanent', 'consent|Contraindications', 'band aids', 'serious disease.|Unstable cardiovascular function', 'thyroid function disorders', 'pregnancy,|Presence', 'fumarates', 'preserved reproductive function', 'HIV|Inability', 'eosinophilic gastritis', 'RET targeted therapy', 'Diabetes mellitus Atrial fibrillation Coronary disease', 'language problems', 'high cholesterol', 'clear virus', 'proliferative diabetic retinopathy (PDR)', 'drug overuse', 'pathological lesions', 'local stenosis', 'using PD-1', 'thermal burn injuries', 'neurological level', 'opioids,|Not being', 'superficial bladder', 'adverse drug reactions to more than one class', 'from cardiac arrest', 'Disease related inclusion criteria:||1', 'SLC', 'abnormal uterine bleeding', 'musculoskeletal disorders', 'canalicular obstruction', 'excessive smoking', 'type 2 diabetes defines', 'histologies', 'visceral abscesses', 'stress disorder', 'duodenal adenocarcinoma', 'hyperkalemia', 'adenocarcinoma of the prostate|Undergone orchiectomy', 'early satiety', 'disclosure', 'judged by the investigator to affect the present', 'recurrent type', 'CAPS feature', 'Malignant tumours,|Patients', 'pulmonary disorders|Minors', 'endocrinologic disorders', 'Type 1 diabetes|Type 2 diabetes||', 'dMMR)/ microsatellite instability', 'cerebral vascular malformation', 'systemic scleroderma', 'mechanical allodynia', 'lentigo maligna melanoma', 'ventriculoperitoneal shunt', 'DIC', 'cognitive barriers', 'high bleeding tendency lesions', 'psychiatry', 'Mycoplasma hominis', 'psychiatric care|Persons admitted', 'mental pathology', 'Unresectable', 'in-situ cervix cancer);|Known', 'iv)|patients', 'services from the physician manned', 'local contraception;||', 'metabolic diseases|Known malignancy', 'impaired lung function', 'leiomyomia subclassification', 'cervical cancertment', 'back-up', 'endometrial polyp', 'affect sensation', 'Liver diseases', 'Maculopathy', 'vocal cord palsy', 'non remission', 'meningeal metastasis', 'another condition', 'superficial cancer', 'life-threatening', 'DMDD', 'fibromas', 'causing issues', 'nasal intermittent', 'peritoneal dialysis;|arrhythmia', 'facial functional impairment covering', 'non-melanoma skin cell cancers', 'chronic autoimmune hepatic disorders', 'shoulder diseases|Rheumatic diseases|Diabetes|Psychiatric diseases|Vascular diseases|Cancer|Infectious diseases|Skin', 'claustrophobic', 'urinary malformation', 'Oocytes', 'congenital abnormalities', 'Acute trauma', 'autoinflammatory disease', 'psychosocial diseases', 'Hepatic excretion dysfunction', 'nocturnal symptoms', 'failure to respond to FVIII', 'vessel carcinoma', 'angina symptoms', 'GIT anomalies', 'inner ear disease', 'specialist considers', 'refractory angina', 'intraabdominal injuries', 'ventricular flutter', 'involves regular blood tests', ""Hashimoto's thyroiditis"", 'pulmonary veno-occlusive disease', 'disorder of the reproductive system|Male', 'liver enzyme', 'nervous system damage', ""child's illness"", 'MELD', 'pupillary defect', 'acute illness.||Personal', 'sports training.||The procedure', 'acute respiratory infections.|Presence', 'corticosteroids;|Subjects', 'clinical stage I', 'active cardiac arrhythmias', 'blood transfusion', 'rest).|Diastolic blood pressure', 'ADHD symptoms', 'surgeries', 'fracture;|Asthmatic bronchitis', 'adrenal gland disorders', 'malignant disease.|Patients', 'Hyperglycaemia', 'conditions related to impaired peripheral circulation|Suffering', 'any eye condition', 'radicular pain', 'fluorosis', 'chronic urinary conditions', 'head and neck squamous cell carcinoma', 'sensitivity deemed', 'neck stenosis', 'prenatal infections', ""Huntington's Disease diagnosis.|Pre-existing"", 'intercurrent illnesses', 'suicidal attempts|Severe', 'Recurrent breast cancer', 'aortic insufficiency III', 'homeostasis', 'X-link', 'immune deficiency', 'primary staging', 'recovery earlier', 'recurrence of platinum sensitive', 'Diabetic Macular Edema', 'adenocarcinoma of the prostate', 'skin ulcer', 'Autism Spectrum Disorder.|Males', 'judged to require', 'child-bearing||', 'intrauterine trophoblastic retention', 'clinically manifest Acquired Immune Deficiency Syndrome (', 'ER+ breast cancer', 'urogenital infection', 'Health workers', 'early stage', 'Colon cancer', 'renal disease,|Frequent headaches', 'isolated febrile seizure', 'organ injury', 'contraceptive measures;|Able to communicate well', 'spinal cord disease', 'SLE', 'hepatitis C infection|Recipients', 'volume deficit', 'CNS comorbidity', 'viral encephalitis', 'inhaled preparations', 'deep brain stimulators', 'skin hypopigmentation', 'ischaemic rest pain', 'major depressive', 'noninfectious pneumonia', 'proteinuria 2+', 'renal hypoplasia', 'pulmonary function', 'fatty liver diseases', 'LBP', 'immunotherapy-related myocarditis', 'breastfeeding;|4、Active infection', 'pulmonary hypertension|Active', 'Schizotypal Personality Disorder', 'non-CNS disease', 'mental disorders;|Hypersensitivity constitution', 'necessary tests.|7', 'anterior segment dysgenesis', 'side effects', 'Collin syndrome', 'HF related', 'extensive bilateral', 'CLBP', 'vulvovaginal pain', 'aortic dissection', 'pleomorphic sarcoma', 'cardiac monitoring', 'third party)|emergency', 'HIV-related thrombocytopenia.|Pregnancy', 'hypertensive encephalopathy.|with', 'chronic SpO2<90', 'traditional herbal medicine for antitumor purposes', 'mild alcohol use disorder', 'tumour flare', 'Chromosomal abnormalities', 'small cell carcinoma', 'fractures', 'gastroparesis', 'fluid malignant cells', 'hyper-', 'hard stools', 'sarcomatoid features', 'distant lymph node disease;|Patients', 'recreational inhalants', 'liver disorders|Autoimmune disease|Sickle cell', 'anal dilatations|OR', 'dermatitis lesions', 'lichen sclerosus', 'cardiac arrhythmic', 'etc.)|significant', 'inclusive.|Availability', 'TT3', 'skin biopsies|Use', 'placenta abruption', 'non-vital tooth', 'hospitalization|Cardiomyopathy', 'Voluntary', 'breast cancer;|Patients', 'tobacco', '16））Any disorder', 'tumor pain', 'venous reflux', 'inability to swallow acalabrutinib', 'transplantation|Type 1 diabetes|Rejection episodes of the kidney graft', 'neurological disease,|previous bariatric surgery,|weight loss', 'chronic condition susceptible', 'Meeting', 'cross-sectional imaging (CT or MRI', 'developmental disorder', 'pelvic prolapse', 'neurodegenerative disease|Systemic', 'Retinal Detachment', 'kg)|Medical condition', 'spasticity picture', 'SARS-CoV-2', 'spondylolysis', '≥ 9.0%)|renal impairment', 'lymphoma leukemia', 'nasal trauma', 'fasting hyperglycemia', 'finger extension', 'papillary thyroid cancer', 'hereditary spherocytosis', 'MPO)|Active', 'Adverse Events (CTCAE) version', 'brain infection', 'Poor quality of', 'ovarian cancers', 'severe personality disorders', 'progressive cognitive decline', 'Widely bridging fibrosis', 'autoimmune disorders.||', 'intense orofacial', 'mixed urinary incontinence|prolapse', 'psychotic disorder NOS', 'base of tongue', 'common carotid artery stenosis', 'major congenital malformations', 'laboratory test abnormalities', ""Gilbert's disease"", 'anatomical urinary tract abnormalities', 'Child:||Chronic conditions', 'Wound', 'alteration of skin surface providing contraindication for', 'everolimus-eluting stent', 'primary immune deficiency', 'spontaneous circulation', 'intestinal motility disorder;|Alcohol', 'multiple capsules', 'chronic neuropsychological disorders', 'opportunistic infections', 'vitals|Infection', 'traumatic corneal ectasia', 'nicotine use', 'mild depression', 'painful joint.|Participants', 'profound bradycardia', 'alpha-1-antitrypsin deficiency|History', 'coronary angiography.||For', 'bowel disease', 'adequate response', 'high-risk', 'tardive dyskinesia', 'vertebral anomalies|intra-aortic balloon pump', 'resected basal cell carcinoma|Severe', 'solid or', 'pneumonitis.|Active autoimmune disease', 'oppositional behavior', 'basal ganglion disease', 'anticoagulant factor', 'deep fascia;|ECOG Physical status score', 'infectious diseases', 'heart function', 'myeloproliferative neoplasia', 'Epithelioid hemangioendothelioma', 'signs of bacterial conjunctivitis', 'randomization;|Fibromuscular dysplasia', 'pregnancy|Bipolar disorders', 'hypertension;|Mental disorder;|Drug', 'substances|Heart failure', 'medication;|no cognitive impairment', 'brief psychosis', 'Adults|Chronic pain patients|Dutch speaking', 'adult mental health outpatient', 'Insomnia Severity Index score', 'primary effusion DLBCL', 'Black/African American', 'not controlled', 'imaging|Concomitant cholecystitis', 'headache||', 'memory loss', 'antigen,|Positive', 'neurological injury', 'dental abscess', 'osteosarcoma', 'human papilloma virus infection;|Immune function defect', 'chronic atrial fibrillation', 'contraindicate', 'impaired skin', 'extra nodal lesions', 'generalized cervical', 'corneal ulcer', 'Benign pancreatic disorders', 'Diabetes|Placenta accreta spectrum|Hypertensive disorders', 'interstitial lung disease.|≥', 'Medicine Clinic', 'gastrointestinal (GI) perforation', 'reproductive potential', 'diaphragmatic hernia)|Nasal bleeding', 'variceal bleed', 'cold urticaria', 'TMJ', 'CSEU La Salle|ability to perform all the clinical tests', 'difficulty communicating', 'Systemically free', 'clear tendency', 'Sickle cell anemia', 'glenohumeral arthritis', 'hopeless teeth extraction', 'Functional HPT|Transient', 'difficulty achieving', 'non-malignant organ', 'Lateral Epicondylitis,|Pain localized', 'unresectable solid tumors', 'contemporaneously with the dermal injury', 'exfoliative dermatitis', 'thrombosis of the lower venous system', 'locoregional recurrence', 'between 01/03/2020', 'night|Chronic nasal obstruction', 'Salivary gland disease', 'obstructive Eustachian tube dysfunction', 'systemic anticancer therapy', 'radiofrequency lesion', 'community-dwelling', 'skin-sensitivity', 'virus replication', 'another COVID-19 vaccine.|Persons', 'acute pulmonary embolism|Acute', 'dangerous arrythmia', 'inner forearm),|hyperhidrosis', 'actively under custody of law enforcement', 'GOSE', 'syphilis.|Participants reports', 'urethral conditions', ""Crohn's disease.|fistulizing"", 'herniation', 'upper limb,|Traumatic', 'uterine myomas', 'Consensus Criteria', 'congestive heart failure|Those', 'serious illness resulting', 'impact on', 'multiple sclerosis', 'physical illness', 'carotid stenosis)|Coagulopathy', 'inadequate perfusion', 'chronic dermatitis', 'national policies', 'extranodal tissues', 'abnormal thyroid function.|Evidence of', 'narcotic substance', 'conventional therapeutic interventions', 'renal calcium', 'musculoskeletal deficiency', 'Bipolar', 'drain|Active auto-immune disease', 'nocturia', 'pneumonitis', 'verbal communication problems', 'trauma|Irregular cornea', 'personal risk factors', 'peripheral vascular', 'abnormality altering the anatomy of the nose', 'node dysfunction', 'multiple anastomoses', 'peripheral artery disease', 'signs of disease', 'CC', 'urinary outflow', 'HR˗ MBC', 'contraindicate regular contact lens wear', 'granulocyte-colony-stimulating factor [', 'hepatologic diseases', 'chronic liver failure', 'reactivity|Recent eye surgeries', 'hepatorenal syndromes', 'progressive neurological disease|Claustrophobia|Brain injury', 'familial genetic disease', 'disease ≥5 years', 'meningeal dissemination|Individual', 'nursing.|Acute infection', 'motor evoked potential', 'uveal melanoma Exclusion', 'Gastroparesis 9', 'Guillain Barré Syndrome', 'metastatic prostate cancer.|Breast cancer', 'thyroid abnormality', 'metastatic setting.|Measurable', 'neurodevelopmental disorders', 'weight loss medications', 'incisors', 'delusions', 'Cerebrovascular disease', 'oxygen therapy)|Solid cancer', 'hemolytic disorders', 'pancreatic lesions', 'colitis|Cystic fibrosis|<10', 'subcutaneous', 'chronic hemoglobinopathy', 'hand ischemia', 'RV failure', 'neuroretinal disease.|Patients', 'ductal carcinoma', 'acute major illness', 'aortic stenosis;|Acute endocarditis', 'neuropathic pain', 'liver cirrhosis Child Pugh C|Radiation rectitis|Neurological disease', 'virginal', 'CBA', 'painful intercourse', 'keratinized mucosa', 'care|acute suicidality|excessive physical aggression', 'randomization;|Valvular heart disease', 'pneumococcal vaccination|having been', 'deep vein thrombosis/pulmonary embolism', 'causes', 'local prostate cancer', 'tumor pathology', 'chronic inflammatory diseases of the gastrointestinal tract', 'adenoviral COVID-19 vaccines', 'traumatic brain injury.|Participants', 'non-metastatic', 'lactational amenorrhoea method (LAM)', 'hypertensive encephalopathy；|Pregnant', 'circulatory system', 'chronic fatigue|Patient', 'liver infiltration', 'palpable splenomegaly', 'traumatic function deficits', 'COVID-19 admitted', 'Definitive indication', 'Parkinsonism Diabetic', ""Parkinson's"", 'renal disease)|drug assumption', 'cutaneous SCCs', 'neurologic compromise.|Reported', 'allergic anaphylactic reactions', 'forced admissions', 'renal disease syndrome', 'episodes of bowel incontinence', 'Obsessive-compulsive', 'affective disorders', 'unstable heart disease', 'splenic damage', 'vertebral osteoarthritis', 'menstrual pain|Self-reported', 'neurological, cancers', 'singleton viable pregnancy', 'coronary arteries', 'tumor sample.|For', 'IN', 'SCI', 'refractory relapse', 'gastrointestinal bleeding.|Patients', 'anti-cancer', 'bypass', 'soft tissue sarcoma of following subtype', 'PCR COVID-19 infection', 'human immunodeficiency virus.|Presence', 'cancer therapeutics', 'cyanotic congenital heart disease', 'associated sinus tract', 'lower limb fractures', 'skin disturbances', 'distant metastatic disease', 'spontaneous pain', 'reduced mobility', 'periorbital congestion or edema', 'active cancer disease|Conditions', 'IVF', 'lower symptoms', 'type 1 diabetes|Before', 'psychosocial problems|Dysphasia', 'generalized erythrodermic psoriasis.|Psoriatic arthritis', 'renal sympathetic denervation', 'obstructive pulmonary disease;|History', 'diagnostic nerve block', 'associated sinus', 'surgically infertile', 'non-cancer pain condition', 'end stage renal', 'juvenile rheumatoid arthritis (JRA)', 'normal renal function||Age-matched', 'wall /pedicle', 'gait deficit', 'disabilities', 'physiotherapy', 'paraffin block', 'spinal cord compression.|Participant', 'anxiety depression', 'carcinoma in situ of the bladder', 'nuclear factor-κB ligand (RANKL) antibody', 'HGSNAT', 'French;|Total blindness', 'cardiac structural', 'spinal metastases', 'contrast enhancement', 'generalized anxiety disorder', 'organ transplantation|Terminal illness', 'extrahepatic metastases', 'mineral supplement', 'hallucinogens', 'Cortica', 'type 2 diabetes of the Ministry of Health.|Pregnancy', 'joint diseases|Ongoing treatment', 'papillary thyroid carcinoma;|Existed meningeal metastasis', 'device|Unstable cardiac disease', 'psychiatric disorders|Mental', 'feet', 'gastrointestinal function', 'disease factors', 'implanted defibrillator|Claustrophobia', 'communication impairment', 'standard of care in cath lab)|Asthma', 'Asymptomatic right bundle branch block', 'dairy products', 'HER2-positive status', 'invasive cancers', 'acute ethanol', 'sensory impairment making', 'in situ breast cancer', 'from smoking', 'significant comorbidities', 'Guillain-Barré syndrome', 'isolated extramedullary relapse;|Patients', 'atypical extrinsic staining', 'drug-free', 'diabetes risk status.||Pregnancy', 'rectal adenocarcinoma', 'ovarian function', 'asymptomatic laboratory abnormalities', 'choledocholithiasis', 'bronchial thermoplasty', 'chronic arterial disease', 'screening.|Substance abuse', 'acute gastritis', 'staining', 'Diabetic Retinopathy', 'acute respiratory disease', 'drug resistant', 'optic nerve disease', 'idiopathic thrombocytopenia', 'visible textural lesions', 'bleeding tendency;|are', 'insulinoma', 'cognitively normal', 'prolonged travel', 'AKP', 'non cirrhotic portal hypertension', 'gastrointestinal fistula', 'stuffy', 'IRLS score', 'heterosexual activity', 'polycystic ovarian', 'cardiac rhythm control.|Montreal Cognitive Assessment', 'reproductive age；|Appropriate biochemical indicators', 'intolerability', 'retinal', 'indication', 'malignant biliary obstruction', 'pulmonary function impairment', 'healing disorders', 'working', 'GI symptoms', 'colorectal carcinoma', 'functional states;|B-ultrasound', 'clinical states', 'bilateral internal iliac', 'Medtronic', 'needles|Pregnancy', 'idiopathic generalized anhidrosis', 'fracture', 'poor oral', 'enroll:||Type I diabetes', 'etc.)|Continued pain', 'type of lymphoma', 'alcoholic liver disease', 'renal stenosis', 'free vertical resection margins', 'resected squamous cell carcinoma', 'local skin malignancy', 'acceptable representatives', 'abnormal heart rhythms', 'surgery|Anaemia', 'hemodynamic unstability|Redo coronary artery bypass surgery|Intraoperative complication', 'drug hypersensitivity', 'maternal immune-mediated disorders', 'folic acid related drugs', 'infections', 'subarachnoid haemorrhage', 'anxiety symptoms||Exclusion', 'months;||The main organs', 'national health', 'drug-induced liver', 'chronic active Hepatitis C', 'refuses the', 'impaired consciousness|Protected persons', 'CNV lesions', 'leak|Biliary stricture length', 'non-surgically treated hydrosalpinx', 'CNS)|Pregnant', '≥35|Neurocognitive impairment', ""unanesthetized Schirmer's Test"", 'transient ischemic attacks', 'palpable penile plaque|Penile curvature', 'end stage treatment|People', 'rectal gonorrhea', 'Wilson disease)||v', 'pancreatic cancer treated', 'history);|any renal impairment', 'paediatric malignancy', 'liver cancer', 'post-cricoid', 'chemical menopause', 'substance abuse|Ongoing', 'vision problems', 'pathological findings', 'human albumin);|Uncontrolled systemic fungal', 'visceral herpes zoster', 'removable orthodontic', 'acceptable disease-free', 'and|Mental disorders', 'spinal scoliosis', 'intracranial bleeding', 'gynecological malignancies', 'comorbid disorders', 'frontotemporal lobar disease', 'fibrosis;|Chronic HBV infected', 'HIV).|Active infection', 'bleeding coagulopathies', 'extramedullary relapse', 'extensive bilateral brainstem infarction on CT', 'B-cell tumor', 'skin laxity', 'comorbid health conditions', 'cashew', 'Housing', 'HLA typing);|Normal suprapubic', 'carcinoma in situ of the', 'primary AL amyloidosis', 'granulocytic sarcoma', 'apical reaction', 'Congestive heart failure', 'unrepaired abdominal injury', 'dispatch', 'surgery|Dizziness', 'Main organs', 'tensor threads', 'autoimmune diseases|COPD', 'chronic stable angina)|>18', 'liver metastasis', 'Paroxysmal supraventricular', 'foreign body sensation', 'autoimmune hemolytic anemia).|Bone marrow disorder', 'restrictive pulmonary disease', 'calculated from the highest value.||On a standard of care combination PAH therapy', 'asplenia', 'isolated mitral valve repair', 'radical local treatment.||According to the evaluation standard of curative effect', 'hypobetalipoproteinemia', 'diabetic', 'BICR', 'upper limb injury', 'IgE) tests', 'abnormal lens findings', 'pathological fractures', 'PANSS', 'organic brain disease', 'Tension neck syndrome', 'between the lesion', 'Assiut University hospital', 'probenecid', 'Obstructive Sleep', 'Undiagnosed children|Inadequate', 'surgical infection', 'multiple liver tumors', 'malignant tumors;|Patients', 'T-cell lymphoma', 'deploy ETUDES interventions', 'myocardialinfarction', 'criteria of depression', ""Parkinson's drugs"", 'disorder', 'gastric bleeding.|irritable bowel syndrome', 'resistant hypertension', 'autoimmune mediated', 'events not', 'discharged from the hospital', 'liver metastases)|alanine aminotransferase', 'chronic pain disease', 'contraindicate exercise', 'localized carcinoma of the skin', 'acute ischemic stroke', 'PSAD values||', 'ulcer', 'painful physical restrictive condition', 'ILD|Rheumatic autoimmune disease', 'peripheral arterial lesions', 'focal epilepsy', 'breast ductal carcinoma in situ treated surgically with curative', 'tumor|Hepatic insufficiency', 'difficulty collecting venous blood', 'functional', 'Fluorosis', 'primary hypogonadism', 'difficult|refusal', 'kg|Hypocalcaemia|Contraindications', 'gastroenteritis', 'malformation|Premature', 'CPAP therapy;|Patient', 'anomaly.|Ectopic pregnancies', 'impact on skin reactions', 'zygapophyseal joint osteoarthritis|Failure', 'hemorrhoidopexy', 'fluent', 'retinal vein occlusion)|Any condition', 'anaesthesia-involvement', 'SWI', 'higher||', 'serious abnormalities', 'mixed IBS', 'regularly|Febrile illness', 'septic arthritis', 'cerebral blood vessels', ""atypical Parkinson's syndrome"", 'skin infections', ""bone's tumors"", 'fetal anomalies)|Opioid tolerance', 'feeling of discomfort', 'urinary tract infection;|oliguria', 'K.', 'calcified lesion', 'works', 'Diarrhea', 'chronic GI conditions', 'another medical condition', 'breastfeeding|inability', 'wheelchair.|New Permobil chairs', 'external resorption', 'pancreatic cancer||Exclusion Criteria', 'Severe infection', ""Armstrong's criteria|related"", 'unstable cardiac arrhythmias', 'epithelial ovarian cancer.|Not amenable', 'portal vein tumor', 'antiphospholipid antibodies', 'inflow tract', 'traumatic pupils|Those', 'pathologic mobility', ""Down's syndrome"", 'non-Parkinson-related', 'ethnically Japanese', 'aortic regurgitation fraction', 'tissue block', 'distal metastases', 'middle cerebral artery feeding', 'breast cancer related lymphedema||', 'interstitial pneumonia', 'Primary tumors', 'Cutaneous Sarcoidosis Activity', 'pure red', 'localized basal cell carcinoma', 'decompensation;|Systemic diseases', 'anorectal symptoms', 'contraindicated', 'diabetic peripheral neuropathy', 'psychotic disorder;|Use', 'older,|Schizophrenia', 'RBCs', 'transient ischemia', 'non-HCC', 'infiltrative lesion', 'baseline mobility', 'bipolar disorders', 'in situ cervical cancer', 'need', 'dementia.|Prior cardiac', 'inflammatory bowl disease.|Patients', 'luminal metastases', 'infectious states', 'PTB', 'Allergy', 'Spondyloarthritis', 'eosinophilic esophagitis', 'multiple endocrine neoplasia type 2', 'cohorts', 'etc.)|Persons not', 'thromboembolic episodes.|History', 'lung function impairment', 'Neuromotor diseases', 'enteropathies', 'transient ischemic attack (TIA)', 'ID（iron depletion）|Clinical diagnosis', 'postoperative recurrence', 'refractory gross hematuria', 'cerebellar stroke', 'glucose-galactose malabsorption.|Patients', 'sports like tennis', 'relationship difficulties', 'pericarditis|Acute pulmonary embolus', 'cognitive impairment/dementia', 'ligament injuries', 'brain tumours', 'dysthymia', 'anabolic steroids.|Excessive', 'pancreatoblastoma', 'corporeal diseases', 'circulatory disorder', 'unstable medical condition', 'Scale|women', 'T4)|Distant metastases', 'stroke|Symptomatic HF', 'nuclear medicine radiologist|Palliative radiation doses', 'serous cavity drainage', 'anticoagulants||Adequate biliary drainage', 'multi-organ failure', 'Ulcerative Colitis', 'disease|Sites', 'organic disorder', 'psychological diseases', 'tumor recurrence', 'undertake aerobic', 'MSA', 'HSV-1 infection', 'cardiac dysrhythmias', 'auditory impairment,|Current', 'unable to swallow', 'solid organ transplantation.|Patient', ""Gilbert's Syndrome)|AST(SGOT)/ALT(SGPT"", 'posterior teeth', 'fascicular block', 'severe pulmonary fibrosis', 'age:||Amenorrheic', 'sebaceous neoplasm', 'amendable to surgical resection', 'PTE', 'rapid rise', 'peripheral venous cannula placed', 'tumor-related pain', 'type of ophthalmic neuropathy;|Other', 'swelling episodes', 'ER pathology', 'intracranial haemorrhage.|Pregnancy', 'benign hematologic', 'High grade Carcinosarcoma Squamous cell carcinoma Carcinoma ex', 'Kidney dysfunction', 'hyper-IgE syndromes', 'OSCI', 'neurological brain disease', 'chronic ankle instability', 'bleeding tendency disorders', '-age 40', 'organic causes', 'brain metastases.||Patients', 'lung disease||Exclusion', 'distant metastasis;|Tumors', 'aneurysm;|intracaverous internal carotid artery aneurysm;||Exclusion criteria', 'Bleeding symptoms', 'neurological disorders;|history', 'Hyperosmolar hyperglycemic syndrome (HHS)', 'interocular difference', 'lumen stenosis', 'communication', 'tendon injuries', 'subsequently recorded', 'TIM study||Exclusion Criteria', 'biopsy|HBsAg', 'anatomical deformity', 'Passive ROM', 'elimination disorders', 'completely relieved', 'autoimmune thyroid disorders', 'attributable to disease', 'motor skills disorders', 'rheumatoid arthritis', 'general contraindications', 'maxillary edentulous', 'heart failure|Severe ventricular rhythm disorders|Severe functional limitation', 'CPT', 'consume pain medication', 'chronic home NIV||', 'hereditary polyposis', 'high-risk criteria', 'criteria of the Consensus Opinion', 'post-arrest encephalopathy', 'passive dorsi-flexion of the ankle.|Able to walk', 'tumor tissue block', 'prescribed pain', 'corneal edema', 'habitual non-adherence', 'examples', 'idiopathic pulmonary fibrosis', 'pigmentary OAG.|Patients', 'T2a tumor', 'retinal vascular disease', 'Isometric muscle contraction', 'systemic autoimmune', 'schizophrenia spectrum', 'abnormal uterine bleeding||', 'normotensive pheochromocytoma/paraganglioma', 'immune deficiency disease', 'caregiver|Admission', 'cardiac issues', 'old|Diagnosis', 'gluten-free diet', 'Asian ancestry|Do', 'mobility', 'drug abuse|Clinically significant', 'valve diseases', 'brain aneurysm clips', 'heterogeneous hepatic echotexture', 'chemotherapy|RECTAL CANCER', 'digestive ulcer', 'organic pathologies', 'pregnancy;|age<18', 'blood DNA', 'ankylosis', 'Secondary AIHA', 'normal anatomy', 'uterus', 'valve damage', 'carotid artery dissection', 'nocturnal pain', 'UTIs', 'renal tumors;||Adequate hematopoiesis', 'immune deficiency diseases', 'lack of cooperation', 'M1 disease', 'tempomandibular problems', 'self-harming behaviors', 'local symptoms of myeloma', 'power -0.75 D', 'gestational diabetes mellitus|Possible ethanol', 'deep tumor tissue', 'oral diseases', 'language difficulties', 'CTCAE peripheral neuropathy;|The', 'benign gastric lesions', 'prolonged QT interval', 'homelessness', 'back-transfer', 'impairs visual field testing.|Inability to perform', 'joint||H. Bilateral medial unicompartmental knee', 'PET Center safety screening checklist', 'autoimmune disease.|Prior treatment', 'urinary system bleeding occurred', 'commit suicide', 'clinical disease progression', 'T215Y', 'protease inhibitors', 'pulmonary inflammation|Combined', 'high fever', 'epithelial basement', 'drug-induced liver injury', 'chronic pulmonary disorders', 'synergistic T-cell receptor', 'coagulation disorder', 'allergic dyspnea', 'chronic liver', 'external spermicide', 'end the surgery|Preoperative adjuvant therapy was given', 'IHC(3+', 'main duct papillary mucinous neoplasms', 'mental health condition', 'ligament deficiency|present', 'incompetent cervix', 'early learning', 'Uterine pathologies|Endometrial bacterial', 'endocrinopathies:||Cushing syndrome', 'liver carcinoma', 'functional damage', 'gastrointestinal diseases.|Weight loss', 'knee injury|hypertension|thrombophlebitis|inflammation|myositis', 'ankle sprain', 'ROS1', 'CNS symptoms should', 'conversion disorder', 'upper limb function', 'endotracheal tube', 'myocardial dysfunction', 'Guillain-Barré Syndrome', 'organ transplantation.||J.', 'distant metastases seen on', 'life-limiting anomaly|Allergy', 'unilateral ischemia', 'gastric varices.||Significant cardiovascular disease', 'clinical periodontal loss', 'risk factor(s)', 'refractory myeloma', 'SARS)-coronavirus 2', 'Permanent atrial fibrillation', 'COPD|Unstabile angina', 'Minimal changes', 'lens opacity', 'muscle invasion', 'discharged home', 'inflammatory processes', 'non-psychotic major depressive disorder.||', 'Richmond Agitation-Sedation Scale', 'secondary cancer', 'glycolic acids', 'skin with lesions', 'Prader Willi Syndrome', 'cyclosporine)|Pregnant woman|People under', 'Liver Diseases (AASLD)', 'Unstable COPD', 'drug-induced QTc', 'perianal diseases', 'pitaya', 'prediabetic state', 'since initial injury', 'disease|Diagnosed with ABC/MBC', 'ganglioma', 'simple excision', 'brain abscess', 'primary prostate cancer', 'stroke.|Montreal cognitive assessment (MoCA)', 'temporomandibular joint disorders', 'Mixed tumor', 'hypoperfusion', 'chronic thromboembolism)|Fibrinolytic disorders', 'pleural mesothelioma', 'signs of dementia', 'stage cT4a', 'mental health disorder', 'etc.;|Severe infection', ""Gilbert's disease|PT"", 'loss of sense', 'PROSTATE CANCER', 'Hypovolemic shock.|Severe organic heart disease', 'bronchiectasis', 'B12 vitamin deficiency', 'somatic condition(as controlled', 'Shoulder pain', 'Anatomy', 'chronic pain disorders', 'immunosuppressive drugs.|Treatment', 'clinical varieties', 'past HBV infection', 'anaplastic thyroid cancer|Unresectable anaplastic thyroid', 'Severe deficit', 'medicine|chronic diseases', 'Multicentric Castleman Disease.|Current active liver disease', 'congenital glaucoma', 'neoplasic pathology', 'maternal anemia', 'preservative allergy|No', 'cornea disease', 'Leukocyte count≥3.0×10', 'procedural revascularisation', 'structural changes', 'Hep C infection', 'impaired intestinal circulation', 'dietary supplementation', 'SSR', '/pulmonary disease', 'digital subtraction (DS)', 'ileal resection', 'ventricle hemorrhage', 'related eye care products', 'narcissistic personality disorder', 'metastatic biliary tract carcinoma', 'colorectal cancer;|Malignant tumors', 'Premenopausal', 'Benign uterine lesions', 'surgery.|Patients', 'chronic headache conditions', 'pulmonary abnormalities', 'liver disease.)|Seropositive', 'target disease', 'reviewed by the investigator.||', 'HIV testing', 'distal trachea-oesophageal fistula', 'chronic chest diseases', 'gastrointestinal bleeding tendencies', 'clinical disease', 'malignant arrhythmia', 'ischemic event', 'adverse events of the protocol', 'urothelial cell NMIBC', 'alpha-lipoic acid', 'intestinal obstruction;|Tumor', 'illness|Severe motor impairment', 'Tumor', 'EBUS-TBNA|Visible', 'breast cancer cells.||', 'cerebral vasoconstriction syndrome', 'malignancies|Severe renal impairment', 'local site', 'localised prostate cancer', 'absorb oral medication.||Additional inclusion criteria', 'excessive hair', 'intracranial arteriovenous malformations', 'bone metabolism', 'heart rhythm disturbances', 'April', 'Complicated diseases', 'traditional Chinese medicine treatment', 'type of catheterization', 'aorto-iliac', 'chronic anxiety', 'azanaway', 'endometrial polyps', 'RESTORED', 'changes in dietary', 'sets of blood cultures', 'MRI|Accepted to receive general anaesthesia||', 'fundus diseases', 'developmental disorders|Disease', 'Acute stroke', 'feels better)||', 'normal sinus rhythm|Procedures:|CABG|CABG +', 'judged by the researcher to be unsuitable for this clinical trial', 'crisis', 'risk carcinoma', 'progressive multifocal leukoencephalopathy', 'progressive local', 'secondary vestibular diagnoses', 'cold extremities', 'sports injury', 'infarction', 'serous cavity effusion drainage', 'radiation pneumonitis', 'Chronic neck pain', 'expect', 'WBH', 'Adrenal insufficiency', 'HPV18 infection', 'breast cancer||', 'surgical sterility', 'native Italian speaker.|Refusal', 'Deep occlusion', 'sensory neuropathy symptoms', 'unresolved inflammation', 'keratoconjunctivitis sicca.|Have', 'breast cancers|Women', 'non-menopausal', 'neoplasms).|Surgical interventions', 'transmittable disease', 'progressive bone deterioration.|Patients bone stock', 'periodontal condition', 'reproductive ability', 'hereditary immunodeficiency', 'medication|Known intolerance', 'craniospinal RT', 'chronic disease||Population 3:||-', 'poor vision', 'inflammatory symptoms', 'peritoneal carcinoma', 'pneumonia.|Active infection', 'infection complications', 'colorectal cancer surgery|Diabetes', 'Pregnancy,|An', 'fetal heart tracing', 'compensated|Acute heart failure', 'immunodeficiency condition', 'multifocal contact lenses|Known', 'restrictive respiratory dysfunction', 'developmental disability', 'Calculus pancreatitis|gall bladder', 'BP', 'nodular oral involvement', 'diseases;|Hepatitis B virus', 'hematological events/diseases', 'liver transplantation||', 'Resection', 'local pathological defects', 'hepatic pathology', 'severe diarrhea', 'drug eluting', 'cerebral ischemia', 'available hepatic imaging results', 'ovarian suppression agents', 'drug-induction therapy', 'urine leakage episode', 'axillary metastasis', 'FPIES).|Diagnosis', 'localized infections', 'non-psychotic|Hamilton Rating Depression Rating Scale', 'criteria ≤7 years before screening', 'soft tissue infection', 'ECG abnormality should perform', 'small lymphocytic lymphoma', 'endometrial cancer', 'cervical cancer', 'chronic home oxygen therapy', 'LVEF<50%).|Patients', 'under investigation for HIV-associated', 'organ transplantation.|21', 'invasive malignancy', 'renal disorders', 'posterior cruciate ligament (PCL)', 'tubal occlusion', 'liver tumor', 'donating plasma', 'complaints', 'psychiatric disorders|On home', 'GH receptors', 'screening|Serious illness', 'etc.).|Guillain-Barre syndrome', '-inflammatory rheumatic disease', 'digestive dysfunction', 'chemoradiation;|No', ""Dercum's disease"", 'Diabetic Kidney Disease', 'autoimmune thrombocytopenia.|Salivary gland disorder', 'criteria.|Hematopoietic growth factors', 'vestibular impairment', 'verbal learning', 'basal cell', 'trying to become', 'gastrointestinal diseases|On coagulant therapy', 'old|Unilateral eye', '1st-trimester', 'rapid eye movement', 'absorption;|diagnosis', 'AIDS);|Active tuberculosis', 'reason|Allergy', 'etc.|acute myocardial infarct', 'cutaneous primary site of squamous cell carcinoma of the head and neck|Has known', 'uncontrollable pleural', 'psychological disorder', 'major oral hard', 'skin GVHD', 'PMID', 'inflammatory diseases;|Refusal', 'T-cell', 'sarcomatoid carcinoma', 'dosing', 'SS genotype', 'corrected QT interval', 'local MM', 'passive external rotation<30˚', 'loco-regional lesions', 'p53 abnormalities', 'airway obstruction', 'pack', 'UC|Evidence', 'psoriasis', 'cerebral edema|Presence', 'organ rejection30,31', 'good health meaning', 'congenital nonbacterial', 'SARS-CoV-2|Allergy', 'Cystic', 'screening.|Active hepatitis B', 'CRSV', 'atherosclerosis;|Hypersensitivity', 'lymphadenopathy', 'months stable', 'binocular vision dysfunction', 'renal diseases;|(b', 'locoregional therapies', 'ocular lesion', 'non-COVID-19 bacterial', 'autism spectrum disorder|Major mood', 'alpha-1-antitrypsin deficiency.|history', 'stable angina pectoris', 'antecedent schizophrenia', 'systemic autoimmune disease|Ongoing', 'uterine rupture', 'solid organ transplantation.||14', 'unequivocal evidence of disease', 'Cardiac Arrest', 'hemolysis', 'solitary kidney', 'light perception', 'breast cancer;|Prior treatment', 'leukocyte', 'CNS malignancies', 'inflammatory rheumatic disease', 'extensive uterine fibroids', 'lower-limb endovascular', 'iron intolerance', 'rotator cuff tear', 'N2 disease', 'al;|Known HIV', 'psychiatric symptoms', 'Obsessive Compulsive', 'hospitalization|Active infection', 'pregnancy|No smoking', 'psychiatry disease', 'lithotripsy', 'peripheral nerve block', 'future', 'old|BMI', 'Pulp exposure', 'etc.).|Rheumatic diseases', 'ASD', 'schizoaffective illness', 'major depressive episode|Patients', 'LBCL', 'functional gastrointestinal diseases', 'vascular diameter', 'decompensation of', 'nitinol', 'fetal alcohol syndrome', 'renal impairment|Anomalies', 'zinc', 'ductal in-situ breast cancer', 'Celiac disease', 'medullary thyroid carcinoma', 'endocrinological disorders', 'anterior tongue', 'autonomic thyroid adenomas', 'archival', 'acute inflammatory infiltrate', 'primary Sjögren syndrome', 'fetal movement|HIV Positive', 'duskiness', 'hypertension.|Inability to administer Darolutamide', 'corneal diseases', ""cutaneous Kaposi's sarcoma"", 'Postmenopausal', 'head lesion', 'perfusion lesion', 'hPAP', 'gynecological disease', 'Neurodevelopmental disorder', 'memory problems', 'age|Previous breast surgery', 'years|Diabetes Mellitus type', 'severe renal insufficiency', 'obstructive endometrial polyps,|Irritable bowel syndrome|Major abdominal', 'nephropathy', 'thiopental', 'radical resection carcinoma in situ)', 'cavernomas', 'stable disease', 'COVID vaccine|missing Hepatitis', 'irritable bowel syndrome/disease', 'left pulmonary artery', 'vertical phoria', 'systemic disease capable', 'refusal;|Patient', 'CRT', 'largest intracranial lesion', 'distal flexion posture', 'cough medicines', 'aid|In general', 'Metabolic dysfunction', 'spontaneous menstrual cycle', 'HBeAg status', 'bisphosphonates.|Vertebral fracture', 'Alcoholic Steatohepatitis', 'periodontal health status', 'esophageal variceal disease', 'hip pain', 'spinal disease|Coagulopathies|Pregnancy|VAS pain level', 'respiratory conditions', 'IHC2+', 'intend to receive', 'Children', 'isolated functional', 'Respiratory diseases', 'asymptomatic atrial fibrillation', 'acute dental symptom', 'allergic shock', 'hospitalized', 'weight-bearing', 'compliance problems', 'pigmentation disorder', 'Hodgkin disease', 'failure to respond', 'abscesses|Prosthetic joint infections', 'tumor diameter', 'implantable defibrillators', 'local anesthetic|Hypothyroidism', 'neuromuscular disorder', 'of:||Celiac disease', 'nasal absorption specimens per protocol', 'sclerodermia', 'retinal reattachment', 'stool softeners', 'increased intracranial pressure', 'inclusive).|In good general health', 'Multiple Endocrine Neoplasia Type 2 (MEN 2', 'detectable', 'tobacco use|Established', 'nervous system', 'colonic plastic surgery', 'stroke)|Previous malignancy', '/reaction', 'bronchial asthma;|Patients', 'middle cerebral artery [', 'antitumor', 'medullary thyroid carcinoma.|Presence of', 'inv(16)/t(16', 'carnitine deficiency', 'substance use disorder|cognitive disability|language barrier', 'left main PCI|Patients', 'renal cell', 'tumor;|Serious cardiac insufficiency', 'gastrointestinal tract condition', 'community dwelling', 'perception problems|Receiving', 'transient).|Diseases of the digestive system', 'Polycystic ovaries', 'SC injections|Uncontrolled hypertension', 'allergy;|Presence of an organic GI disease', 'alcohol-containing product', 'purpura', 'lactation;|Electrocardiographic findings', 'classification);|Vaginal dysbiosis', 'Agile Onboarding process', 'screening:||Post-menopausal', 'pneumonia|Empyema', 'pancreatic disease', 'intact bladder', 'lung collapse', 'consistent histologic', 'e.g.hepatic impairment', 'FIB-4>2.67', 'Human epidermal growth factor receptor 2 (HER2)', 'gastrointestinal surgery|Patients', 'Clinical T-stage', 'vaginal condition', 'therapy|Gastric cancer', 'hyperkyphosis', 'sexual intercourses', 'glaucoma tube shunts', 'variceal bleeding|Uncontrolled hepatitis B infection', 'neurologic disease)|Pregnancy', 'topical lesions', 'primary dysmenorrhea', '|Atraumatic (pain) complaints', 'CYP3A4-inducing', 'toxic injury', 'granulomas', 'cancer|Participates', 'autonomic abnormalities', 'infection.|Subjects', 'peripheral arterial disease', 'post-residency clinical experience within their field of practice;|Have', 'COVID pneumonia', 'herpes zoster keratitis', 'HCW', 'aortic cross-clamping', 'acidosis', 'cerebrovascular diseases;|(2', 'conduction abnormalities', 'consent|Allergy', 'acute respiratory distress', 'third-stage COPD', 'stage diseases', 'autonomic neuropathy|Known diabetes', 'traumatic cardiopulmonary resuscitation', 'drug abuse|Uncontrolled severe hypertension', 'carcinomatous meningitis.|New recurrence of osteosarcoma metastasis', 'cerebrovascular disorders', 'HPV-associated', 'oral polio', 'psychiatric illness', 'primary tumor not', 'neurologic disease|patient', 'contracture', 'ischaemic colitis', 'not attended the intervention', 'discharged home safely', 'renal Impairment subjects||30', 'face masks', 'Gilbert-Meulengracht syndrome', 'residual breast tumors', 'neck pain', 'human immunodeficiency', 'chronic liver disease', 'cardiovascular comorbidities', 'Craniofacial abnormalities', 'ankle pain', 'TUDCA', 'students|university staff', 'pathways.|Active autoimmune disease', 'diabetic gastroparesis', 'weight gain', 'primary solid tumor', 'asymptomatic heart failure', 'bleeding complications', 'ILD', 'AV fistula', 'exploitations', 'MTAP protein', 'hepatitis virus infection', 'sleep disruptions)|alcohol', 'autism recorded', 'MRI|Structural brain lesion', 'ventricular tachycardia', 'immune thrombocytopenia', 'bradycardia.|Acute exacerbation', 'MI|Acute heart failure', 'Smokers;|Uncontrolled diabetics', '||Allergy', 'child', 'history).|Congenital malformation of the lower limb.|Anomalies', 'MRI)).|Individuals', 'chronic bowel disorders', 'HER2-neg breast adenocarcinoma', 'sexual behavior', 'OCL', 'osteoporosis),|psychiatric disorders,|cancer', 'adrenal insufficiency|Clinically significant', 'memory loss)||PCP Inclusion', 'Biopsies', 'neurological,', 'De Quervain tenosynovitis', 'restrictive cardiomyopathy|Congenital heart disease|Pulmonary hypertension|Surgical procedures involving', 'smoking', 'segmentectomies', 'chronic pelvic pain|History', 'endometrial cancer clearly', 'intervention|spontaneous sinus', 'medical center COVID-19-specific', 'acute febrile illness', 'lactase deficiency', 'decompensated disease', 'right bundle branch block', 'Neurological disease.|Patients', 'Posttraumatic Stress Disorder', 'Churg-Strauss syndrome', 'hypocalcemic seizure', 'NSCLC stage', 'judged by the principal investigator or sub-investigator to be inappropriate for this study.||At', 'inclusion;||For HFpEF', 'identities', 'hemolytic conditions', 'pitting edema', ""LUTS|Stable Parkinson's medication"", 'organ transplants;|Toxicity associated', 'breastfeeding|Study physician discretion', 'Thrombosis Center', 'dry mouth syndrome', 'serious infection', 'infectious disease;|malignancy', 'sufficient)|No nephropathy', 'liver', 'Local skin infection', 'mixed small cell component', 'OPD', 'Type 2 Diabetes||-', 'basically normal coagulation', 'developmental delay', 'synovium necrosis', 'dietary restrictions', 'myasthenia gravis|Those', 'contraceptive hormones', 'mental deficits', 'clinical keratoconus', 'cystic fibrosis', 'traditional medicine', 'sucurase-isomaltase deficiency', ""Sjogren's syndrome"", 'mental health concerns', 'thyroid related diseases', 'diabetes symptoms', 'Acute infection|Unstable vital', 'pleural fluid', 'drop arm test', 'thyroid pathology', 'leucoderma', 'good general physical health.||Exclusion', 'migraines', 'complete disease', 'dysfunction of the skin', 'end-stage renal', 'heart disease.|Women', 'preexisting disorders', 'Comorbidity', 'Acute intestinal obstruction', 'locoregional nasopharyngeal carcinoma', 'capture.||Healthy', 'Acute Ischemic Stroke', 'Acute urinary', 'SRS', 'Chronic hepatitis B', ""angel's"", 'dairy allergy', 'lumbar spine', 'chronic gastrointestinal disease', 'non static', 'lytic bone', 'hepatitis delta virus', 'cutaneous signs', 'ETANTR', 'deep vein thrombosis|Upper', 'disabling disease', 'recovered from any surgical effects.|Participant', 't-cardiac surgery', 'disseminated lupus erythematosus.|Diagnosis', 'ovarian cancer', 'intact membranes', 'autoimmune diseases|No', 'malignant melanoma', 'lymphoma.|Multiple Myeloma', 'metastatic melanoma', 'Lugano lymphoma', 'defect', 'primary biliary cholangitis', 'preoperative)|Metastatic disease', 'septum', 'armpit', 'hemiplegic CP|Non-ambulant', 'hypotermic circulation arrest', 'primary dysplasia', 'unresectable lesions', 'arthritis|enthesitis-related', 'metastatic tumors', 'chronic schizophrenia', 'cardiorespiratory pathologies', 'hemophagocytic lymphohistiocytosis', 'circulatory arrest', 'melanoma', 'kidney disease|Abnormal liver function', 'third interstitial fluid', 'serostatus unknown.|Passes Test of Understanding (', 'trichomoniasis', 'genital herpes', 'common iliac veins', 'physically too ill', 'breast feeding|unable', 'intestinal anastomosis', 'recreational user', 'Mullerian agenesis', 'in situ cervical cancers', 'acute musculoskeletal injury', 'extra-pulmonary disease', 'pharmacodynamic indicators', 'hypnotic BZDR', 'vigorous physical activities', 'deep brain stimulator', 'pituitary insufficiency disease.|Concurrent', 'renal osteodystrophy', 'year;|Allergy', 'comorbid substance misuse', 'Fontan surgery|Abernethy', 'polydipsia', 'cannabis|Unwilling', 'sick', 'cough variant asthma', 'fallopian tube-', 'anatomical uterine disorders', 'brain atrophy', 'diabetics', 'transfusion of red blood cells', 'tumor cervical pain.|Pregnant', 'Lungwena Health Centre catchment', 'myocardial amyloidosis', 'neurogenic orthostatic hypotension', 'anticancer therapy|Diagnosis', 'COVID vaccines', 'neurotoxicity occurred', 'flare', 'tumor-directed therapy.|The', 'worry', 'thoracentesis', 'tendonitis', 'intervention;|Known intolerance', 'radical hysterectomy', 'Pontoise', 'organic brain syndrome', 'chemotherapy.|Squamous cell carcinoma', 'pulmonary', 'reliant|assistive walking device reliant', 'imaginable pain', 'Neurocognitive Disorder', 'age;|Willing', 'coagulation function|Intracranial', 'clinical signs of||Hypertension', 'fruit acids', 'pulmonary interstitial disease', 'impaired natural ventilation', 'congenital syphilis', 'nursing|Substance abuse', 'Type 2 diabetes|HbA1c', 'traumatic or disease-related', 'CKD|Concurrent systemic infection', 'progressive multiple sclerosis', 'atrophic gastritis', 'gravidarum.|Molar pregnancy', 'mild dementia', 'burn injuries', 'Clinically healthy', 'miscarriages||Antiphospholipid syndrome', 'postpartum bleeding', 'AV block|Sick sinus syndrome', 'feeling dizzy', 'to organ donation|In', 'remission', 'tumor resection', 'coronary atherosclerosis', 'normalized', 'hypertensive encephalopathy.|Persisting toxicity related', 'rare reaction', 'mutations.|Colorectal carcinoma', 'digital media', 'malignant transformation.||', 'kongenital ptosis', 'CMV DNAemia', 'peripheral fluid overload', 'male factor infertility', 'treponema', 'memory loss complaints||', 'Relapsing Remitting [', 'invasive breast cancer.|Anatomic', 'primary immunodeficiency|Uncontrolled', 'local UVA', 'CT', 'concomitant haematological diseases', 'venous thromboembolic event', 'diffuse intravascular coagulation', 'self-questionnaires', 'vertebral deformity)|Allergy', 'lactation.|Hypokalemia', 'auriculoventricular conduction disorders', 'squamous cell carcinoma', 'basal cell carcinoma of the skin', 'renal transplant,|The', 'code', 'general medical conditions', 'relapsing MS', 'breastfeeding;|Serious diseases', 'hepatic SOS', 'chronic epithelial disease', 'psychological illness', 'cancerous meningitis', 'cutaneous toxicity.|Prior exposure', 'thymoma metastasis；||No', 'as||Hemochromatosis|Alpha-1 Antitrypsin deficiency|Autoimmune hepatitis', 'chronic inflammatory diseases', 'syncopal episodes', 'major organ failure', 'acute COVID', 'disc herniation|Those', 'Tested swab', 'Spinal Injury Association Impairment Scale', 'ovary|Ability', 'Chiari malformation', 'multiple locations', 'rare histologies', 'hepatitis D virus (HDV)', 'pregnancies', 'screening|Significant medical condition', 'adverse systemic', 'prolonged QTc interval', 'human immunodeficiency virus (HIV) virus infection', 'skin adhesive allergy', 'serous tumors', 'hemodynamic evidence', 'dihydropyridine sensitivity', 'post-vaccination reaction', 'pulmonary dysfunction.|Current', 'lack of Norwegian skills', 'phenylketonuria', 'HGB', 'COVID 19', 'teria:||community-dwelling dialysis', 'generalized tics', 'familial long QT syndrome', 'band ligation', 'Chronic obstructive pulmonary disease', 'drug use|Prior BCG vaccination|Other vaccination', 'end-organ function', 'traumatic scoliosis', 'clinical lung injury', 'esophageal fistula', 'pelvic inflammation', 'random follow-up|Persons', 'cytotoxic T-lymphocyte-associated protein', 'meningeal metastases|Pleural effusion', 'Crohn´s disease', 'forced vital capacity (FVC)', 'hysteromyoma', 'nasopharynx', 'resection.|Patient eligible', 'menstrual cramp pain', 'peripheral vascular diseases', 'myelodysplasia', 'lack of diagnosis', 'bronchiolitis-interstitial lung disease|Desquamative', 'cardiovascular events', 'UTIs)|Intraoperative bladder', 'hyperthyroidism;|Significant abnormal', 'chronic disease|Not', 'impairment of renal function', 'Mammaprint', 'Comorbidity bearing', 'congential opitc abnormal', 'asthmatic syndrome', 'brain injury|Illiteracy|Status of hypertonus', 'vascular diseases arrhythmia', 'cardio-cerebrovascular diseases||Note', 'deep brain stimulation);|diagnosis', 'large stroke', 'metabolic disorder', 'Hypothyroidism', 'ultrasound remission', 'hematologic tumors', 'transplanted|ABO-incompatible', 'absolute T-lymphocyte', 'hospitalisation for angina', 'Gout||vi', 'liver failure|positive anamnesis', 'heparin|Previous left heart ablation procedure', 'asepsis', 'renally impaired', 'liposarcoma', 'T2 mapping imaging sequences', 'HIV infection.|Abuse', 'indicates endometriosis lesions', 'transvaginal rectopexy', 'radical surgical resection.|Aged', 'dilated cardiomyopathy', 'Breast cancer patients|Therapy', 'Type 1 Diabetic patients):||No exclusion criteria||Inclusion', 'thrombocytopenia.|Clinically significant', 'Healthy gestational term', 'rapid disease response', 'Cell cultures', 'positive diagnosis', 'Proliferative diabetic retinopathy', 'mental health literacy', 'thyroid eye disease||', 'lymphocyte', 'UNMC pathology review', 'lower limb edema', 'condition;|Diabetes', 'esophageal cancer;|Pre-treatment', 'rare', 'massive internal', 'delayed-type hypersensitivity reactions', 'intra-cranial progression', 'resected carcinoma', 'psychiatric illnesses|pregnancy', 'behavioral health-related', 'cutaneous psoriasis', 'superficial non-invasive bladder tumor', 'major aortic & other', 'visible skin disease', 'water;|Pulmonary edema', 'months|Colon-rectal cancer', 'second opinions', 'UTP', ""Institute's"", 'intestinal function', 'lung tuberculosis', 'gastrointestinal malignancy', 'pervasive developmental disorder', 'recovered from any toxic effects', 'chronic pain|Presence', 'Intracerebral hemorrhage', 'solid tumors|Evidence', 'glomerulitis', 'language difficulty', 'systemic lupus erythematosus', 'psychiatric comorbidity', 'inflammatory breast cancer', 'tunnel syndrome', 'vital sign', 'lost to follow-up for the same period', 'digital otoscope', 'ria:||Healthy', 'meningococcal infection', 'acutely infected', 'liver damage symptoms', 'month.|Patients', 'reduced LVEF', 'newborns', 'infarction|neurological impairments', 'Infection|Pregnancy|allergy', 'acute optic neuritis', 'atorvastatin.|Active peptic ulcer disease', 'bladder mass', 'CT)|Normal serum levels of sodium', 'Resides', 'oedematous malnutrition', 'cerebro-vascular accident', 'non-healing active wound', 'to:||Peptic ulcer disease', 'spontaneous labor', 'digital', 'MDRO infection', 'alcoholics', 'mental health care', 'above foot ulcer', 'nonionic contrast media', 'primary heart disease', 'Septic Shock', 'cryostimulation', 'significant head injury', 'ductal carcinoma in situ is allowed.||Consolidating thoracic radiotherapy', '≥6 months|A', 'Dumping', 'atients', 'Epidermolysis', 'prostate cancer.|Patients treated', 'ISOLATED', 'IHD', 'acute periapical infection', 'uncontrolled infection||B.', 'third grade atrio-ventricular block', 'genetic obesity', 'perioral dermatitis', 'ascites encephalopathy', 'judged by the researchers', 'periapical pathology', 'acupuncture', 'mitral regurgitation', 'facial wounds', 'prolonged sitting||', 'seizure description', 'non-compensated hypertension', 'Abbott', 'partial thickness loss of dermis', 'abnormalities of glucose metabolism', 'temporomandibular disc displacement', 'uncontrollable disease', 'INS', 'atrial fibrillation|NT Pro', 'several limit function|Patients', 'chronic neck pain', 'liver fibrosis', 'month)|without swallowing disorders', 'Guillain Barré syndrome', 'bleeding diathesis|Participants', 'daltonism', 'Myelodysplastic syndromes (MDS)', 'ocular rupture', 'impaired decision-making', 'Cerebral Palsy,|located', 'aetiologies', 'ocular disorder', 'irreversible disease', 'bronchiolitis obliterans', 'Human immunodeficiency virus(HIV', 'cholelithiasis||', 'visceral disease', 'esophageal varices', 'pericarditis.|Positive pregnancy', 'reactions', 'solid tumor diseases', 'pathological hypo-', 'pleural drainage', 'colon remaining', 'neurologic disorders', 'compression', 'Young', 'leukopenia', 'relapsed disease', 'right-handed.|We', 'acute anaphylaxis', 'carcinoma|Lack of tumor', 'Mild fibrosis', 'congenital cataract', 'Hashimoto thyroiditis', 'hemophilia', 'cerebral tumors', 'cardio-cerebrovascular disease', 'HER2+ breast cancer', 'main artery', 'ventricle dysfunction', 'antidiabetic drugs.|Treatment', 'calcific stenosis', 'and|Difficulties', 'contact dermatitis', 'virologic response', 'Thalassemic', 'Type 2 Diabetes made', 'rectal sensory dysfunction', 'Bacterial infection', 'CGM', 'lung cancer|Patients', 'non-hematological', 'years|Diabetes', 'Staying of the baby in the Neonatal Intensive Care Unit|34', 'non alcoholic fatty liver', 'vigilance disorders', 'synovitis', 'acute kidney injury', 'exercise-induced', 'rheumatological pathology|Psychiatric pathologies', 'natural dentition', 'Deep Brain Stimulation', 'non-measurable', 'visit.|Able', 'preoperative)|Sepsis', 'abnormal symptoms', 'Multi-ligament knee', 'Bronchial asthma', 'Primary symptomatic', 'coronary vasomotor abnormalities', 'brain metastases;|Previous treatment', 'acute symptomatic seizures', 'motivational deficit', 'patient|Local infection', 'Asking', 'motor system', 'focal neurologic deficits', 'relapsing-remitting', 'autoimmune disease|diabetes', 'follicular lymphoma', 'osteoporotic vertebral fracture', 'refractory pain|Patients', 'non-Malay', 'healed carcinoma', 'Gilbert Syndrome', 'familial disorders', 'digestive segment', 'cancer disease', 'functional gastrointestinal disorders', 'cerebral artery aneurysm clips|The', 'adenocarcinoma of the breast', 'care.|Patients', 'G6PD deficiency', 'sinus extract', 'intracerebral lesions', 'marathon runners', 'precipitated', 'diffuse glioma', 'perfusion', 'stiffness & tenderness', 'stage of infarction', 'lymphoma Hodgkin lymphoma', 'cirrhosis;|Patients', 'heart rhythm) pathologies', 'disabling general disease', 'insomnia|Diagnosis', 'poorly controlled', 'sciatica', 'metoclopramide|Pheochromocytoma', 'temporomandibular joint disc displacement', 'renal function.|Prior anti-cancer therapy', 'locoregional anesthesia||', 'occipital nerve block', 'C reactive protein', 'thoracic radiation', 'preparation', 'liver metastases|good renal function', 'multimorbidity inclusion criteria', 'chronic subdural hematoma', 'associated disorders', 'reversible obstructive syndrome', 'criteria for anxiety', 'definitive pathological diagnosis', 'localized gangrene', 'trans dermal patch', 'underlying decay', 'Moribund', 'e-cigarette use|Prior experience', 'HLH', 'peptic ulcer disease|Ability', 'kidney transplant|Patients', 'suicide ideation score', 'Asymptomatic metastatic lesions', 'supraventricular premature beats,|diagnosis of', 'vision disturbances|Hematuria', 'Nonunion', 'Glomerular hematuria', 'organic pneumonia', 'intracranial metastasis', 'EPO', 'good general health).|Only', 'Emphysema', 'SNHL).|Patient', 'Android 10+', 'lower urinary tract symptoms', 'least stable', 'secondary causes', 'pulmonary rales', 'psychiatric comorbidities', 'total serum bilirubin≥85umol/L；|Coagulation', 'intact brain metastasis', 'sleep disturbance', 'chronic pancreatitis|Presence', 'bacterial prostatitis', 'medication|pregnancy', 'Mitral valve severe stenosis', 'ICD)|Secondary', 'chronic lymphocytic leukemia', 'fibromyalgia;|Serious psychiatric disorders', 'traumatic brain injury,|18 years', 'isolated lesion', 'bullous pemphigoid', 'agueusia', 'inclusion;|Acute heart failure', 'inflammatory diseases of the central nervous system', 'Unilateral rotator cuff tendinopathy', 'knee joint pain', 'urinary tract stricture', 'solid organ transplantation.|Pregnancy, lactation', 'coronary artery disease - Uncontrolled hypertension', 'major seizure disorder', 'pernicious anemia', 'ILD)/pneumonia', 'diverticular disease', 'more)|Arrhythmia', 'corneal disease', 'relationships in group settings|Not in a relationship with a', 'health service managers', 'sepsis|Open pressure ulcers', 'progressive multifocal leukoencephalopathy|Active hepatitis B infection', 'good-quality photographic imaging||nAMD subject||The', 'solid organ transplant', 'MX-0 after TURB||Controls', 'digestive tract disease', 'myomectomy|Allergy', 'chronic headache', 'socio-economic background', 'mixed histologies)|Preoperative FIGO stage', 'diabetes disease|no', 'disease evidence', 'persistent disease', 'Signature', 'joint effusion', 'Crohn disease', 'pathological indications', 'nephrotic syndrome', 'Fertile', 'alpha-1 antitrypsin', 'returning', 'HLA matched', 'radioopaque renal stones', 'acne lesions', 'respiratory tract symptoms', 'anomaly', 'developmental disorder.|Is', 'solid tumor:||Head', 'Users', 'lower limb amputees', 'cardiovascular disease|Uncontrolled hypertension', 'impaired hypoglycemia awareness', 'morphological disease', 'cervical', 'macroscopic hematuria', 'multiple extranodal disease', 'spectral-domain optical coherence tomography', 'bpm],|110', 'tuberculosis (TB,', 'involvement of adjacent structures(T4b', 'choose to receive', 'General Internal Medicine', 'Neurological disease', 'T2bN0M0', 'therapy)|autoimmune diseases', 'Parkinsons disease', 'lordosis', 'airway hyperresponsiveness', 'arteriopathy);|primary orthopedic conditions', 'primary care clinics.||Exclusion', 'wall gaps', 'paranoid、antisocial Personality Disorder', 'type I', 'inductive effects', 'heart function disorders', 'venous sinus stenting|Visual loss', 'access to Emergency Department', 'randomization;|Heart failure', 'schizoaffective psychosis|Stable on medication', 'non-penetrating', 'resting symptoms', 'doubts', 'chronic pulmonary diseases', 'diabetes;|Abnormal liver function', 'hepato-renal', 'Obstructive Sleep Apnea', 'HDF', 'cognitive deficits|no', 'disease-related', 'ischemic lesion', 'responses from', 'degenerative aetiologies', 'intracranial tumors', 'skin squamous cell carcinoma', 'malignancies', 'kidney failure|ALT', 'haemoptysis', 'cancer diagnosis|On hospice', 'habitually consumes', 'health care products', 'impaired heart function', 'Acute myocardial infarction', 'keloid scarring', 'heel-prick screening', 'lipstick', 'congenital joint disorders|Other inflammatory arthritis', 'polyethylene bearing', 'predominantly cystic nodules.|Pressure', 'Chronic medical disorders', 'COVID-induced cognitive impairments|memantine use', 'neurologic', 'macular inflammation', 'DVT', 'glioblastoma treatment-related', '24-hour urine collection', 'peptic ulcer disease.|Patients', 'HPV status', 'Lisfranc injuries', 'patients|Pregnant patients|Clinically suspected', 'primary T1 bladder cancer', 'unexplained syncope|Recent', 'joint surgery.|Acute pain', 'traumatic injury', 'Candida vulvovaginitis', 'lack of metabolism', 'infection', 'eosinophilia', 'gastroenteric tumors', 'Spontaneously breathing', 'reactive depression', 'pulmonary thrombotic embolism*.||Prior to the initial futility assessment', 'feeling of inability to tolerate', 'large molecule monoclonal antibody drugs', 'tumor-associated', 'answer questions', 'spinal traumata', 'brain metastasis resection', 'remain stable', 'cavitated lesion', 'ovarian', 'autoimmune neuropathies', 'muscle strengthening', 'hypopharyngeal cancer', ""reasons;|Gorlin's syndrome"", 'combining inhibit ovulation', 'clastic anger.||Non-objection of the', 'CST≥300', 'therapeutic hormones', 'diabetes mellitus type', 'joint inflammation', 'lymphovascular infiltration', 'early-stage malignancies', 'acute coronary syndrome|High-sensitivity', 'uncontrollable heart disease', 'atherosclerotic peripheral artery disease', 'hereditary diseases', 'scheme|Pregnant', 'treatment).|HIV infection', 'squamous cell skin carcinomas.|Non-invasive', 'healthy|Experienced menopausal', 'Hypoxemia', 'redundant', 'type of WHO II or III,', 'solid organ transplantation;|Patient', 'pancreaticoduodenal cancers', 'restless legs syndrome', 'nodal lesion', 'short bowel syndrome', 'facial anomaly', 'partial tear', 'moving', 'setting.|Other solid tumor', 'epidermal growth factor for wound healing', 'mucosal malignant melanoma', 'intramural fibroid that distorts the', 'ALS', 'fatty liver disease.|Patients', 'haemophilia', 'radiotherapy|Hematological disorders', 'treated off-protocol', 'health condition', 'foot infection', 'popliteal artery lesion', 'Vitiligo', 'colorectal surgery;|Tumor', ""Morton's neuroma"", 'guttate psoriasis', 'historic dysmenorrhea', 'unconjugated hyperbilirubinemia', 'immunodeficiency diseases', 'pulmonary nodule', 'deepest lesion', 'premature ovarian failure|Clinical diagnosis', 'TNBC', 'therapeutic protein preparations', 'premenstrual dysphoric disorder', 'English|Diabetes|Ongoing cancer', 'dialysis modalities', 'ulcerative colitis;|Women', 'psychological distress', 'preoperative clinical evaluation;|The', 'months)|History of', 'Infective endocarditis', 'polyhydramnios.|Maternal Diabetes', 'narcissistic personality disorder|Individuals', 'pupils', 'exertional malaise', 'heart associated conditions|changing physical activities', 'non MRI-compatible metallic implants', 'child bearing potential', 'SP).|Intact rotator cuff', 'motor deficits', 'aspergillosis', 'upper limbs.|Metabolic diseases', 'antiphospholipid syndrome-related', 'controls)||Exclusion Criteria', 'platelet refractoriness', 'fixation indicated||', 'native aorta', 'low back pain symptoms', 'unstabilized organ damage', 'noninfectious', 'tumor tissue sections', 'MCD', 'Cognitive impairment', 'intestinal P-glycoprotein', 'good health|consent', 'conditional incentives', 'cerebrovascular ischemia', 'bariatric surgery|Uncontrolled hypertension', 'course of COVID-19:||Oxygen saturation', 'neurological symptoms should', 'maternal obesity', 'Atrial fibrillation|Left ventricular thrombus|severe', 'diverticulosis', 'health supplement', 'TMS;|Suicidal thoughts', 'cKIT mutation|Normal karyotype', 'psychosis risk syndrome', 'cooperate|Orthopedic impairment', 'myocardial infarction events', 'extrapyramidal disorders', 'multidisciplinary consultation)|Hepatocellular carcinoma', 'acute polyneuropathy', 'claustrophobia)|Chronic renal disease', 'HCT', 'autoimmune hyperthyroid disease', 'entry)|Hepatocellular carcinoma', 'heart by contiguity and primary effusion lymphoma', 'Necessity', 'HER2', 'cerebrovascular disease|Taking LDL cholesterol', 'acute decompensation', 'cerebral edema|Rapid neurological improvement', 'Normal GH secretion', 'HIV-positivity', 'digoxin toxicity|Undergoing surgery', 'elective off-pump cardiopulmonary bypass surgery||', 'tuberculosis should', 'falls|Severely impaired cognition', 'acute coronary syndrome|acute', 'bowel obstruction', 'IgM)|Congenital uterine abnormalities', 'criteria are cancer survivors', 'complicated diverticulosis', 'perinatal asphyxia', 'SIS', 'primary diseases', 'uninterrupted', 'acute ischemic stroke:|Age', 'O(6)-methylguanine-DNA methyltransferase', 'pulmonary obstructive chronic disease', 'tuberculosis.|History of trauma.|Subject', 'random;|Immune deficiency', 'sequential chemoradiation', 'pituitary dysfunction)|Presence', 'other depressive disorders', 'former', 'kidney-diseases', 'colorectal cancer treatment', 'transient ischemic attacks.|Uncontrolled kidney disease', 'skin depigmentation', 'acute attack of gout', 'protection statement', 'dyspnoea', 'nail lichen', 'short bowel syndrome.|Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.|Major cardiovascular diseases', 'hepatitis C virus [HCV]', 'diabetes mellitus-related illness', 'AD involvement|Worst pruritus numerical', 'idiopathic forms', 'corticosteroids|Recognized immunodeficiency diseases', 'developmental decline', 'abstain from non-prescription', 'organic brain diseases.|Pregnant', 'completed SOC', 'cerebellar subtype', 'reversible encephalopathy syndrome', 'recovered from the effects', 'therapy|Measurable disease', 'delusional disorder', 'weeks|Treatment', 'radioactive exposure', 'stroke|Liver disease', 'ductal carcinoma in situ of breast', 'Lynch syndrome', 'local meningeal metastases', 'SMILE', 'malignant tumor（In healthy', 'hypercholesterolemia', 'hypoparathyroidism', 'human immunodeficiency virus (HIV) antibody test', 'syndesmotic injury|Previous ankle injury.|Multiple trauma of the lower extremities.|Rheumatoid arthritis', 'outpatient exacerbation', 'neurologic deficit|The', 'MoCA])|Possible peripheral neuropathy', 'antitumor therapy.|Allergy', 'CSCR', 'sclerosing cholangitis', 'hemorrhagic constitution', 'primary gonarthrosis|Grade', 'uncontrollable epilepsy', 'obesity-related comorbidities', 'liver metastases from']","['additional ophthalmic surgical intervention', 'microbiota restoration therapies', 'similar compounds', 'agonists|progesterone', 'bisphosphonate', 'investigational drug component', 'Ozanimod', 'Motrin', 'SUVO', 'oral antihypertensive drugs', 'AD', 'chocolate', 'alike', 'component of Linovera®', 'Bleomycin etc.);|Drugs influencing tubulin', 'semiquantitative results', 'IPAH', 'anti-integrin', 'Android phone', 'over-the-counter topical creams used for the treatment', 'entecavir', 'Phenytoin', 'immune stimulating medications', 'device components', 'hydroxyzine', 'monoamineoxidase inhibitors', 'anti-THSD7A', 'hyperglycemic drugs', 'margins', 'anti-infection treatment', 'atogepant', 'prothrombotic medical products', 'serotonin', 'anti-retroviral drug', 'periocular corticosteroids', 'Systemic corticosteroids', 'Tolvaptan', 'clomifene', 'phenytoin sodium', 'Cayenne hospital', 'accidents', 'dynamic contrast-enhanced', 'anti-depression treatments', 'NCCN', 'antibiotic eye', 'intravitreal)', 'nasogastric tube inserted', 'immunosuppressive medication).|Subject', 'amifampridine', 'VEGF-receptor signaling', 'immune-modulatory therapy', 'tumors', 'oral opioids', 'Cannabidiol', 'Lumefantrine|Receipt', 'Heparin', 'biologic immunomodulatory agents', 'saline', 'increta', 'nateglinide', '≤470 milliseconds', 'trastuzumab deruxtecan', 'MTD', 'aortic stenosis|Patients', 'tisirolimus', 'monomorphic', 'Atkins diet', 'speak Tamil', 'Infertile', 'anti-hypertensive drugs', 'adenosine diphosphate', 'imiquimod', 'KM602', 'Magrolimab', 'transdermal contraceptives', 'Steroid', 'sulfa-drugs', 'anti-PD-1/anti-PD-L1 antibodies|RE', 'antihypertensive drug therapy||', 'Burnaby', 'betablockers', 'S768I', 'oral sodium valproate.|Completed', 'polyoxyethylene', 'BTKi', 'neuroendocrine differentiation|Prior immune therapy', 'IBM', 'tyrosine kinase inhibitor', 'days|Prescription drugs', 'drugs that are', 'adult', 'antiulcer medications', 'anti-inflammatory drugs.|Examples', 'AMICS', 'histidine', 'L occlusions', 'glucocorticoids β Receptor blockers', 'Miglustat', 'anabolic steroid supplements', 'visit|Biologics', 'Immunosuppressive drugs', 'ponatinib', 'contrast media.|Patients', 'age||', 'opioid overdose', 'Breztri', 'herbal drugs', 'component of the study.|Patients', 'plural', 'restart medication', 'Prokera', 'disorder;|Patients', 'interferon inducers', 'episodes [MELAS]', 'glucocorticoid containing medication', 'CTX', 'Apatinib mesylate', 'amphetamines', 'restricted medications', 'anti-CD19', 'ICS use', 'recombinant tissue plasminogen activator', 'Vaccinium species', 'secretions', 'medication controlled hypertension', 'ultrasound contrast agent', 'marrow-suppressive therapy', 'non-steroidal anti inflammatory drugs (NSAIDs)', 'aCGH', 'anti-CD38 monoclonal antibody', 'nucleic acid amplification (NAAT)', 'tixagevimab', 'AE related to lenalidomide', 'endorses', 'algorithms|Significant', 'leflunomide', 'CRRT machine', 'heavy menstruation', 'preventive vaccines', 'component of Cadonilimab.|Preoperative pathology', 'contrast media|Suspected aortic dissection|Parenchymal organ surgery', 'hormonal drug therapy', 'products containing nicotine', 'TFGB3', 'milk together with positive specific IgE against', 'eye||Ocular Health:||Ocular drug toxicity', 'fluoroquinolone', 'psychopharmacological agents', 'cladribine tablets', 'components of the study irrigation system.|Patients', 'antifungals', 'argatroban', '3rd trimester', 'anti-PCSK9', 'contraceptive anti-coagulants', 'hydrochlorothiazide', 'erytromycin', 'component of the study intervention(s);|Receipt of medications', 'N06AA', 'clinicians', 'mobility.|Patients', 'vitamin D-containing dietary supplements', 'tacrolimus containing medications', 'cetuximab alone', 'ripretinib treatment||', 'Nivolumab', 'antihypertensive agents|No coronary atherosclerosis', 'antidiabetic', 'anti-CD70', 'anti-alopecia', 'Amyvid®).|Participation', 'arthroscopic partial', 'inhaled corticosteroid (ICS)', 'aromatase inhibitor', 'procedural medications', 'iodinated contrast agent-enhanced', 'Treponema pallidum antibody', 'PH medications', 'component of the drug', 'quinine sulfate', 'DTG', 'medications for Type 2 diabetes|Self-reported', 'oral steroid therapy', 'angiotensin receptor neprilysin inhibitor (ARNI)', 'systematic systemic treatment', 'antidiarrheal medications', 'fluconazole', 'CTD', 'coumadin', 'immunoglobulin treatment', 'Myorisan', 'adequate organ function||', 'dofetilide', 'Monopril', 'VF', 'acute use', 'traditional Chinese medicine', 'low flow', 'anti-CD20 antibodies and BTK inhibitors', 'ivosidenib', 'anti-inhibitor coagulant concentrates', 'enfortumab vedotin', 'oral anti-DM only|Patients', 'H2 blocker', 'IMDH inhibitors', 'chronic systemic immunosuppressive therapies.|Patients', 'P2Y12 inhibitors therapy', 'anticalcium drugs', 'tranquillizers', 'sodium channel blocking anti-seizure medications|Additional exclusion criteria apply', 'savolitinib', 'manage distress', 'vitamin K antagonist', 'combined liver', 'component of the formulation||History', 'clinics', 'Anthracycline', 'peptide 1 agonist', 'vaccine-induced', 'molecular confirmation', 'mood stabilizers', 'long-acting cabotegravir', 'Creatinine', 'frenulum', 'contrast agents', 'immune related neurologic disease', 'anaesthetics', 'Hypoglycemic drugs', 'Diuretics', 'Cannabis', 'VKA', 'felbamate', 'total lymphatic irradiation', 'opioid|Baseline', 'SIRPα antibody', 'alclometasone dipropionate 0.05%)|No', 'anti-PD-1 monoclonal antibody', 'epilepsy|Receiving drugs', 'components used in the program.|Pregnancy', 'norepinephrine', 'droxidopa', 'experimental medications', 'propofol.||7', 'FISH', 'contrast agent side effects', 'antifungal agents', 'dipeptidyl peptidase-4 inhibitors', 'opioid pain', 'drugs used in the study', 'Prader-Willi syndrome', 'platelet-rich plasma', 'systemic steroid hormone', 'basal-bolus insulin', 'ciprofloxacin', 'durvalumab', 'olsalazine', 'strong CYP3A4 inhibitor', 'Anti-resorptive bone therapies', 'analysis;|Able', 'medium', 'microbiota', 'GLP1 receptor agonist.|Previous', 'low potency topical steroids', 'somatropin', 'iodinated contrast media.|Segmentectomy', 'Reside', 'famciclovir', 'esketamine', 'gamma globulin', 'myeloblasts', 'domvanalimab', 'pars planar', 'GnRH analog', 'local guidelines not feasible', 'vaccine-related component', 'pioglitazone|Good general health|BMI', 'therapeutic mouthwash', 'tDCS', 'systemic immunosuppressive medications', 'law|Patients', 'amphetamine-dextroamphetamine)|Self-reported', 'hypoglycemic regimen', 'pain medication regimen', 'herbal supplements', 'psychoactive medications', 'Selective Serotonin Reuptake Inhibitor (SSRI) medication', 'ALTO-100', 'cylinder', 'laxative', 'years|Medical', 'antipsychotic drugs', 'monoamine oxidase inhibitors;|Use', 'enrollment|Weigh', 'Meibomian gland', 'cyclooxygenase', 'minocycline', 'antiepileptic drugs).||Psychiatric', 'antiarrhythmic drug', 'prednisone', 'ambavirumab', 'anti-HER2 targeted drugs', 'local governmental recommendations', 'specifically', 'components of black seed', 'anti-CMV medications', 'anti-cholinergic', 'immune modulatory agents', 'merestinib', 'Intravenous immunoglobulin', 'mammogram', 'povidone-iodine', 'non-steroid anti-inflammatory drug', 'atilizumab', 'toothpastes containing alcohol-based compounds', 'fast ventricular rate atrial fibrillation', 'KIT', 'FP);||Adequate organ', 'atomoxetine', 'ethics', 'dentin;|Children', 'components of the investigational products', 'furmonertinib', 'tobacco regularly (', 'Sotalol', 'pure alpha blockers', 'Micronase', 'BRAF', 'oxycodone', 'Zika natural', 'colorectum', 'hospital admission', '≤2 mg total daily of', 'dynamic full-field optical coherence tomography observation', 'antimuscarinic drugs', 'recombinant protein containing', 'recalcitrant warts', 'anti-coagulants|Inability', 'intermediate acting', 'beta-3 agonist', 'type local anesthetics', 'component of the drugs recommended for use in this protocol', 'type)', 'physiological glucocorticoids', 'weeks;|Patients', 'contraceptive measures voluntarily', 'ICT-devices', 'triamcinolone', 'hypoglycemic tablets', 'anti_platelet medications', 'iron infusions|Hemoglobin', 'antihypertensive medications', 'Refralon®', 'Departments', 'sulfinpyrazone', 'g/24 hours', 'drugs targeting another kind of stimulation', 'define', 'Rybelsus', 'sertraline', 'antipsychotic agents', 'non-midline|Isolated ostomy site takedown', 'anticholinergic', 'AVNRT', 'Gadolinium contrast agent.|Before', 'STIs', 'weight', 'ateplase', 'subunit vaccines', 'punch', 'cholinesterase inhibitor', 'Benzoic Acid', 'hair growth treatment', 'PI3K inhibitors', 'GBC', 'anti platelet therapy', 'vasoactive drugs,|-pneumothorax,|-death', 'investigational drug therapy for MM', 'drug treatment.|Having significant', 'neurotoxin', 'strong CYP3A4 inducers.|Previous treatment', 'congenital malformations|Case scenarios', 'nicotine', 'recombinant erythropoietin', 'medium full rotator cuff tear|Unilateral rotator cuff injury|Voluntarily accept randomized controlled', 'gonadotropin-releasing', 'paracetamol/ibuprofen', 'anti-tumor biological therapy', 'Global Initiative for Obstructive Lung Diseases', 'Endostar', 'intravenous (IV) anti-infective agents', 'reboxetine', 'primidone', 'medications known', 'withn', 'phosphodiesterase type 5 inhibitors;|use', 'nonsteroidal antiinflammatory drug (NSAIDs)', 'monoclonal antibody therapies|Pregnant', 'AEDs', 'sensor placement', 'pomalidomide', 'soluble IL-2 receptor', 'medical grade adhesives', 'inhaled beta 2-agonists alone', 'conventional endoscopic ultrasonography:||Poor physical condition', 'anti-EGFR antibody', 'opioid-use', 'other supplements', 'SUD', 'allergies.||No antibiotics', 'Treatments', 'granulocytes', 'components of the local anesthetics', 'local destructive therapies', 'anti-integrin antibodies', 'inhaled antibiotic', 'Immunoglobulins', 'fatigue', 'famitinib', 'Antithrombin', 'posaconazole', 'aspirin.|Stroke', 'Potassium Chloride, Calcium Chloride Dihydrate', 'systemic immunoglobulins', 'hours,|Patients', 'MDMA', 'Transfusion (red blood cell', 'lenalidomide', 'etomidate', 'xanthine-rich food', 'anti-inflammatory medications|Pregnancy', 'monoamine oxidase', 'nicotine user', 'ocular topical medication', 'consent||', 'mRECIST', 'Azacitidine', 'IV medication', 'norepinephrin', 'vaping products', 'ravulizumab', 'Korea', 'strong CYP3A4 inhibitors.|Participants', 'golimumab', 'antiplatelet agglutination drugs', 'opioids agonists', 'anti-hypertension medications.||', 'immunosuppressive drugs treatment', 'ACEi', 'antiparkinson agents', 'live attenuated intranasal influenza vaccines', 'HVPG', 'metformin', 'topical hormone replacement therapy (HRT)', 'mitotan', 'immunosuppressive dose', 'escitalopram', 'lidocaine.|Patients', 'MAS', 'mepivacaine', 'salt-modifying drugs', 'Bulle at', 'decongestant', 'candy', 'lipopolysaccharidosis', 'CABP', 'microphone', 'compounds of similar chemical or biologic composition to monoclonal antibodies', 'injection', 'analgesics', 'Pakistan', 'eplerenone', 'topical ophthalmic corticosteroid therapy', 'ranibizumab', 'treatment arm)||', 'anti-fibrotic treatment', 'fluoropyrimidine chemotherapy', 'Diabetes medication', 'crizotinib', 'QS-21', 'residual', 'COX-2', 'Regional citrate anticoagulation', 'local', 'Rifaximin', 'Amateur', 'plant drugs', 'CNS2 status', 'PHQ-9', 'antineoplastic drugs', 'enzalutamide', 'bisphosphonates', 'growth', 'medications:|Tricyclic antidepressants', 'systemic supraphysiologic glucocorticoids', 'used medications', 'antihypertensive medication|Alcohol intake', 'capecitabine', 'CYP2C8 inducer', 'anti-TNF agents', 'AXL inhibitors', 'strong p-glycoprotein', 'medications classified', 'envafolimab', 'Preparatory Acts', 'permanent products', 'drug-related pneumonitis.||Female', 'letermovir', 'histamine H2 blockers', 'herbal', 'octreotide', 'cabazitaxel', 'electrolytes|Patients', 'anti-VEGF therapy', 'ergotamine', 'cyclooxygenase-2 [COX 2] inhibitors', 'give oral informed consent', 'oocytes', 'component of the durvalumab formulation', 'colorectal neuroendocrine carcinomas||', 'antiepileptic drug', 'BID', 'oral corticosteroid (CS)', 'sunflower', 'CTs', 'anti-HER2 treatment', 'SLUMS', 'iodinated contrast agents', 'dopamine agonists||Any of the following:||Pregnant women|Nursing women|Men', 'immunomodulating agent', 'components of the drugs used in the study;|Presence of immunodeficiency', 'third DBPCFC study visit|Patient', 'ganglioside drugs', 'artificial suntan', 'nicotinamide', 'frontline', 'NHB', 'pyridoxine', 'cytarabine', 'Open', 'necrotic tissue', 'local center.|RECIPIENT', 'antirotinib hydrochloride', 'tobacco products', 'secondary MH', 'ZYTIGA', 'mineralocorticoid receptor antagonist', 'Denosumab', 'great vessel', 'oral drugs', 'analgesic medication use before surgery', 'PTH', 'immunohistochemistry', 'MRPA', 'narcotic drug usage|Restrictive', 'glycated hemoglobin (HbA1c)', 'apantamide', 'oral analgesics abuse', 'drugs PO', 'over-the-counter preparations', 'Barbiturates (BAR)', 'anti-PD-1 ligand-2', 'dopaminergic medication', 'azole', 'medium upper', 'sivelestat', 'Antiepileptics', 'Fridericia-corrected QT interval', 'vaginal contraceptives', 'NA', 'anti-tumor bioactive traditional', 'parenteral nutrition).|Active injection drug use', 'urinary catheters', 'direct thrombin', 'zinlirvimab', 'cyclobenzaprine', 'hydroxycitric acid', 'Doxorubicin', 'prohibited medication', 'anti coagulant therapy', 'supportive growth factor', 'adaptations', 'health products', 'irrespective of cause', 'factor XIII in plasma', 'Carboxyhemoglobin', 'COVID-19 inactivated vaccine', 'metastasized', 'regional disease).|Amenable', 'epcoritamab', 'Kellgren', 'immunosuppressive drugs)|Uncontrolled', 'herbal therapies/traditional', 'Acarbose', 'vaccination receipt', 'various growth factors', 'anticonvulsant medications|Chronic organ disorders', 'shoulders', 'give oral consent|Patient', 'leukotriene antagonists', 'methotrexate', 'IL-11', 'somatostatin', 'Medicine', 'anti-fungal antibiotics', 'medicinal cannabis', 'dexmedetomidine', 'CYP3A4)', 'lidocaine', 'anti epileptic drugs', 'cytotoxic drugs', 'antiallergic drugs', 'silicone used', 'RDS', 'visit|Stable medication/psychotherapy regimens', 'nicotine replacement', 'anti-TB therapy', 'inhaled antibiotics', 'ocular', 'nonpharmacological treatments', 'adequate treatment', 'full siblings|Parent/guardian', 'anti-angiogenesis agents', 'anxiety perfectionist', 'anti-vascular targeted drugs);|HBsAg', 'yohimbe', 'breastfeeding|Body mass index (BMI)', 'immune suppressive agents', 'mood stabilizer drugs', 'benzamide', 'thiamazole', 'Rutin', 'MEN2', 'postpartum', 'tipranavir', 'diabetes|SGLT-2 Inhibitor', 'psychiatric drugs', 'chicken proteins', 'topical retinoid', 'bismuth-containing drugs', 'Breas', 'tazarotene', 'study|Patients', 'pregabalin medications', 'angiotensin II receptor blockers', 'MRD® assay', 'ALK inhibitors', 'nAMD', 'necrotic pulps|Non-restorable', 'BP medications', 'antiarrhythmic agents', 'Live vaccine', 'hypoglycemic agents', 'aromatase-inhibitor.|No adjuvant', 'exemestane)||', 'component;；|Immunosuppressive drugs', 'Commugny', 'checkpoint inhibitor', 'anti-diabetic drugs', 'Supportive Periodontal Treatment||', 'nutraceuticals', 'OR:|Option', 'perphenazine', 'cell growth factor supportive treatment', 'strong CYP3A4', 'BCC', 'uterotonics', 'non-steroidal anti-inflammatory medications', 'London', 'edaravone', 'strong CYP3A4 inhibitors', 'prescription therapies', 'sodium deoxycholate', 'coumarin anticoagulant', 'albumin allergy|Patients', 'drugs known to significantly induce', 'oral steroid inhalation', 'premedication for hypersensitivity reactions', 'vitamin B12', 'immunosuppressant drugs', 'antiplatelet therapy drugs', 'eye steroidal drugs', 'orthodontics', 'national guideline-advocated COPD therapy).||Exclusion', 'motion)||', 'MPAs', 'UDS', 'systemic anti-cancer therapy', 'denosumab', 'drug-coated balloon angioplasty', 'alternative supplements', 'Steroids', 'medications which could induce torsades de pointes', 'medications use', 'each drug required', 'bakuchiol', 'LB|Patients on', 'JIS', 'oral antidiabetic drugs', 'bee products', 'drugs acting on insulin sensitivity', 'drug treatment', 'anticonvulsant drugs|Children', 'self)"")|Anti-depressant', 'PDE-5 inhibitors', 'tetracycline-class', 'allowed.|Coumadin', 'CD137 agonists', 'B agonists', 'collaborating||', 'anti-Smith antibodies.||6', 'fluorouracilines', 'knee corticosteroid', 'cisgender', 'study drugs Beta-lactams', 'asprin', 'components of the study interventions', 'conventional catheter', 'implanted neuromodulation devices.|Amputation of the lower limb.|Age', 'N06AX', 'gallstone complications', 'chronic corticosteroid treatment|Participants', 'Synthroid', 'viscosupplementation', 'regional lymph nodes', 'non-steroidal anti-inflammatory', 'drugs that inhibit platelet aggregation', 'azactidine', 'volume>70mL', 'ERT', 'Psychosomatics', 'anticholinergic bronchodilator', 'anti-platelet agents', 'doravirine/islatravir', 'anti-inflammatory medication', 'Cox-Maze IV', 'components of the formulation(s) used.|Patient', 'cholesterol drugs', 'human serum albumin', 'oral corticosteroid[s', 'Dolutegravir', 'multivitamins', 'JAK fusion', 'Miravalle', 'antiparkinsonian drugs', 'onasemnogene abeparvovec', 'systemic antibotics', 'their inducers', 'nonsteroidal anti-inflammatory drug (NSAID)', 'oral 5-phosphodiesterase inhibitor', 'Immunoglobulin-M', 'anti-tuberculosis treatment', 'medications listed in Appendix I', 'values', 'anti-coagulant therapy', 'TURBT', 'isoflavone-derived supplements', 'anti-hypertensive monotherapy', 'adalimumab', 'anti PD1/PD-L1 inhibitors|No', 'human', 'recombinant human thrombopoietin', 'Lung', 'medium chain triglyceride-containing', 'abortifacient effects', 'non-steroidal immunosuppressants', 'polytetrafluoroethylene', 'Lugano', 'pharmaceutical agents', 'H2 receptor blockers', 'methylphenidate products.|Subject', 'blood', 'anti-cancer therapy', '5 minutes', 'grains', 'meningococcal vaccine', 'methimazole', 'hereditary', ""Entecavir's salt-free"", 'drug trials', 'LH-RH analogue', 'lactose excipients', 'leuk-lifting drugs', 'strabismus repair', 'histology)||METex14 mutation|Epidermal Growth Factor Receptor (EGFR)', 'oral steroid use|Current', 'iron -deficiency|Other medical condition', 'immunosuppressive therapy|Hiv-ag /AB test result', 'long-acting anticholinergic drug', 'immune globulin', 'macromolecular drug', 'first drug', 'regular drug treatments', 'technetium', 'sedative use', 'short-acting β2-agonists', 'thymidine phosphorylase (', 'Casirivimab', 'assent|Parent', 'direct oral anticoagulant', 'nostriptyline', 'nasal itching', 'allergy|Lidocaine', 'rasburicase [Elitek', 'old|Newly', 'inhaled corticosteroids +', 'guideline', 'membranes|Regular uterine contractions', 'medications known to have', 'anti-programmed cell death protein 1 (PD-1)', 'loop diuretic therapy', 'asthma)|Participants', 'gastric acid inhibitors', '-0.203×', 'abdominal migraine', 'medication that', 'GnRH agents', ""study drug's"", 'trifluridine/tipiracil', 'Metoprolol', 'caffeine-containing drinks', 'months;|Patients', 'ocular decongestants', '≥1 noninsulin antidiabetic drugs', 'propofol', 'local guidelines.||Severe active comorbidities', 'study medications', 'component of the investigational medicinal product', 'CNS1', 'anti-PD-1 monoclonal Ab or their excipients.||29', 'AqueousJoint.|If', 'cracks', 'opioids', 'dystocia', 'BCAA', 'medication related to obesity', 'cyclic tetrapeptide', 'CAH', 'drug-coated balloon', 'mucoid', 'solution', 'bile acid', 'Atezolizumab', 'worsen', 'multi)kinase inhibitors', 'immunosuppressive therapy;|an', 'selenium', 'systemic opiates', 'agents used in the study|Participants', 'musculoskeletal disease:||① Atopic dermatitis', 'GLP-1 analogues', 'POD1', 'telbivudine', 'acid supplements', 'Vancomycin', 'Childhood', 'CYP3A-Inhibitors', 'synthetic cage insertion', 'gemcitabine-based', 'single agent', 'Omalizumab', 'IL-13 inhibitors', 'multiple drugs', 'titanium metals', 'CYP3A4', 'local contraindication', 'donated components', 'over-the-counter medications)|Receives primary care', 'bile acid deficiency', 'Sulfonamide', 'LVEF', 'CE', 'cigarettes', 'corticosteroids', 'Utidelone', 'culprit', 'anti-infective', 'investigational drug therapy', 'nasal tube feeding|Patients', 'pentoxifylline', 'topical lidocaine', 'dreadlocks', 'Interleukin-2)', 'low-dose heparin', 'meningococcal infections.||', 'NVAF', 'components in the formulation|Willingness and ability to initiate intermittent catheterization post-treatment', 'migraine', 'conventional antibiotics', 'blood vessels', 'drugs used for routine sedation', 'good oral hygiene|Patients', 'antiseptic solution', 'sodium hydroxide', 'left ventricular assist device', 'local anesthetic', 'hemorrhoids', 'antibiotic therapy', 'Roaccutan', 'AZI', 'lapatinib', 'lebrikizumab', 'everolimus', 'similar drugs in clinical trials.|Received', 'peramivir', 'tagraxofusp-erzs.||Primary', 'tramadol', 'finerenone.|Contraceptive use', 'topiramate', 'systemic immunosuppressant medication', 'peanut', 'insulin prescription', 'physiotherapist||', 'immunosuppressive medications.||16', 'CYP 2C8 inhibitors', 'screening', 'macicentan', 'African', 'OSFED', 'ocular drying', 'type', 'thrombolytic drugs', 'neoplasm', 'checkpoint inhibitor therapy', 'beta-hydroxyl acids', 'polyester', 'melena', 'Durvalumab', 'histopathologically', 'chicken', 'Technetium-99m-tilmanocept', 'oral hormonal contraceptives plus', 'drugs used in the study|participation in other clinical trials', 'anti-hypertensive medications', 'peroral anticoagulation', 'gadolinated contrast', 'beta blocker therapy|Resting SBP', 'peptide receptor radionuclide', 'iron-containing supplements', 'prescription hypnotics', 'antispasmodic agents', 'retinoid', 'steroids|Systemic corticosteroids', 'HRT', 'sensitive CYP3A substrates', 'permanent drug discontinuation', 'BAL0891', 'anti-rejection medications', 'CDC X-match)|Contraindicating', 'components of study', 'PWI', 'CYP3A inducer', 'angiotensin converting enzyme 2 (ACE-2)', 'intranasal', 'antihyperglycemic medication', 'Opioids', 'hydrocortisone treatment', 'troleandomycin', 'poly-N-[Tris(hydroxymethyl)methyl] acrylamide', 'serotonin modulators', 'anti-epileptic', 'anti-cholinergic medication', 'IPL', 'GHB', 'anxiety medication', ""St. Joseph's Hospital under Dr. Silverman"", 'strong inhibitors of CYP2C8|Females', 'email|Provide', '3rd degree heart blocks', 'lobcavir', 'direct extraction', 'intranasal steroids', 'inhaled cannabis', 'tissue', 'walks', 'NOAC', 'recreational drugs', 'ziprasidone', 'medication(s)|Having', 'cough unresponsive to treatment for underlying conditions', 'local anesthetic allergy|Coagulative disorder|Corticosteroid', 'topical prescription treatment', 'asthma medications', 'honokiol', 'Pgp', 'anlotinib hydrochloride', 'rilpivirine', 'strong CYP3A4 inducers', 'lorundrostat', 'breast|Patients', 'cognitive stimulants', 'MEDI5752', 'stains', 'growth factor', 'lonapegsomatropin', 'prescription osteoporosis medication', 'CI632', 'anti-diabetic medication).|Disorders of coagulation', 'antiarrhythmic medications', 'combustible tobacco products', 'aggression', 'lactic acid bacteria', '3CL protease inhibitors', 'loop', 'antibacterial drugs', 'topical BPO', 'FOLFIRINOX', 'immunosuppressive medications.|Patients', 'DC', 'Belgium', 'anti-TNF therapy', 'Oral fluorouracil', 'porcine-derived', 'fSWT', 'Inhaled steroids', 'android phone', 'hydrocodone', 'Congenital Heart', 'sodium-dependent glucose', 'lovastatin', 'non-steroidal anti-inflammatory drugs)|Signs', 'regular antibiotic use', 'steroid implants', 'prescription medications/products', 'dermatologist;|Ustekinumab', 'variants', 'steroids.|Eyelids', 'adoptive immune cell therapy', 'ticagrelor', 'paroxetine', 'chloramphenicol', 'mild oral dysplasia||', 'orotracheal', 'fludarabine', 'intravesicular anesthetic', 'progesterone', 'angiotensin-converting enzyme (ACE)', 'VATS', 'trial.|Concomitant medications', 'components in the cocktail', 'CYP3A) inhibitor', 'Prasugrel', 'entecarvir', 'pain assessed in proximity of the wound', 'dehydroepiandrosterone', 'calcitonin', 'anti-hemorrhoidal treatment', 'intravitreal steroid injections|Concurrent participation in another clinical trial|Females', 'doxepine', 'official institution', 'qualitative platelet defect', 'renin receptors blockers', 'supplements derived', 'medications known to act as substrates', 'oral anti-infective therapy', 'bedaquiline', 'bile acid binders;|Lactose intolerance;|Participation in another study', 'anti-PD-1 antibody', 'lurasidone', 'germline tissue', 'therapy.|Relevant medications', 'Basal-bolus', 'TNF', 'antioxidant supplements', 'SGT-2 inhibitor', 'Nellis AFB', 'Decadron', 'PCS', 'SoC', 'study visit|Infection', 'anti-tumor drug treatment', 'pembrolizumab', 'Nonsteroidal anti-inflammatory drugs', 'Orlistat', 'sauna', 'remains stable', 'amiloride', 'patellofemoral arthroplasty|Patients', 'potassium iodide treatment', 'old|Willingness', 'CPS', 'oral', 'smartphone components enabled', 'aerobic exercise', 'antileukotriene', 'SENC', 'drug-related rash', 'Vaseline', 'Povidone K', 'monoclonal antibody therapy|Palliative radiation', 'Gestation', 'dopaminergic medications', 'admission|Insulin therapy', 'sulfonamide derivatives', 'enzyme-inducing antiepileptic drugs', 'oxandrolone', 'flecainide', 'immunoglobulin', 'GLP1 agonist', 'corticosteroid treatment', 'methoxyflurane', 'age|Physician', 'TDF', 'homocysteine cycle', 'any drug', 'PTSD|History', 'Restasis®', 'anti-platelet medication|Impossibility', 'CRP', 'monotherapy TKI', 'examination indicators', ""St. John's wort"", 'anti-inflammatory intervention', 'Perjeta', 'setrusumab', 'drug allergy|Patients', 'osteoporosis agents', 'NPRS|mouth', 'monoclonal antibodies in history;|a positive test', 'anti-TNF antibodies', 'components of LB101|Participants', ""St. Joseph's Health Care standard MRI screening questionnaire"", 'HBVsAg+', 'dopamine receptor blocker', 'topical anesthetics', 'Neurologic disorders|patients', 'anti-estrogens', 'Plasma-Lyte®', 'immunosuppressive treatments;|patients', 'dupilumab', 'anabolic medications', 'anticoagulation therapy|Receiving pharmaceutical treatment', 'TXA', 'contraceptives excepted', 'antispastic agents', 'antibiotic receipt', 'Factor Xa inhibitors', 'over', 'mycophenolate mofetil + hydroxychloroquine +', 'inhaled bronchodilators', 'components of the formula;|Diagnosis', 'Short Form-36', 'Leukotriene receptor antagonists', 'Chronic Liver Failure.|Suspicion', 'SGLT2 inhibitors|Pregnancy', 'components of the monoclonal antibody', 'monoclonal antibodies|Known', 'UAS7', 'digoxin', 'acute drug', 'psychoactive drugs', 'immune modulating', 'TD2', 'parenteral corticosteroid use', 'immunoglobulin replacement therapy', 'Xenical', 'feverish', 'Special', 'low-renin', 'Docetaxel', 'Sodium-glucose Cotransporter-2', 'CYP 2C8 inducers', 'IL-12', 'MRG003', 'IMDC', 'Depo leuprolide', 'β-lactam drugs', 'ethanolamine drugs.|People', 'components of study intervention', 'muscular dystrophy', 'inhaled corticosteroid (ICS) medication', 'local/grille photocoagulation', 'medications used in this study', 'tiragolumab', 'cyclophosphamide treatment', 'mechanical ventilation|Patients', 'remimazolam', 'SNRIs', 'conventional cytogenetics', 'immunosuppressors', 'component of', 'phentermine', 'Norepinephrine', 'ventricles', 'obeticholic acid', 'oral steroid', 'conventional polyethylene', 'camptothecin', 'SCA type STEMI', 'next organ', 'haloperidol', 'COVID- 19 vaccine', 'ventilation', 'logistics', 'psychoactive agents', 'mifepristone', 'study medication restrictions', 'trifluridine', 'Basiliximab', 'dulaglutide', 'porcine pancreatic enzyme products', 'electronic devices', 'antiplatelet therapy.|History', 'emicizumab irrespective', 'combination oral contraceptives', 'imaging agents', 'tumour tissue', 'JS015', 'prolonged antibiotic therapy', 'Anti-TNF', 'immune-suppressive medication|Uncontrolled intercurrent illness|Active auto-immune disease', 'enzyme-inducing anti-epileptic medications', 'BMT', 'Axi-cel;|non-CR', 'immune checkpoint inhibitor targeting CTLA-4', 'Primidone', 'Internet|32nd gestational week', 'paracetamol', 'BTK inhibitor', 'HPV vaccine', 'Gadolinium', 'anti-LAG-3 agent', 'barbiturates', 'manifest refractive sphere', 'appropriate antibiotics', 'stiripentol', 'pemphigoid', 'Bupropion', 'retinoic acids', 'similar medication', 'anti-syphilis treatment', 'licensed vaccine', 'Dupilumab', 'assistant educator', 'bilateral salpingo-oophorectomy', 'alpha-2 agonists', 'antibiotic therapies', 'High Grade Non-Muscle', 'alpha-glucosidase inhibitors', 'CAPOX', 'rivaroxaban.|Active peptic ulcer disease', 'MSA|Patients', 'thymoquinone', 'antihypertensive drug', 'steatogenic medication', '1st-generation anti-androgen', 'anti-VEGF IVT injection', 'armodafinil', 'various vaccines', 'anti-coagulation', 'antibody therapies', 'SA1', 'reason,|chronic decompensated diseases', 'immune-suppressive doses', 'macrolide', 'variants underlying', 'cannabidiol narcotics', 'therapies', 'tucatinib', 'levetiracetam', 'medication and/or dental material', 'classic angiographic', 'growth hormone boosters', 'drug-', 'hormone receptor', 'refractive state.||', 'cisplatin', 'murine', 'postoperative medications', 'Hydrargyrum', 'inhaled)', '3rd metatarsophalangeal joint', 'anti-estrogenic hormonal therapy.|Diagnosis', 'platelets Drugs', 'CHVs', 'drugs affecting reproductive', 'drug-active', 'macrolide antibiotics', 'component of ENV-101', 'immunosuppressive drugs;|Use of', 'anamnesi', 'thyroid medication should', 'dopaminergic drugs', 'orthodontic', 'antibiotics/anti-virals', 'serious medical condition;|Think', 'analgesic drugs before surgery', 'proton-pump inhibitors', 'AVB mechanism', 'CYP3A inducers/inhibitors', 'loop diuretic', 'counts', 'Serplulimab', 'duplex kidney', 'gilteritinib', 'anti-inflammatory effect', 'macrogolglycerol hydroxystearate', 'JIA', 'molecular assessed stage IIA', 'Darolutamide', 'dihydropyridine calcium channel blockers', 'IO', 'component of the experimental vaccine', 'prescription medications', 'compounds of similar chemical or biologic composition to peposertib', 'intravenous steroid therapy;|Chronic treatment', 'corticosteroids|Patients', 'those medications used in the treatment', 'whole', 'mellitus(DM', 'Octreotide infusion', 'imaging contrast', 'PLT', 'NOACs', 'small intestine', 'pirenzepine', 'Taxane chemotherapy', 'betamethasone', 'QOL', 'hospitalized|one', 'phosphodiesterase inhibitors', 'parenteral corticosteroids', 'PDE inhibitors', ""St. John's Wort"", 'AIDS).|Pregnant', 'Transfusion', 'plavix', 'fentanyl patch', 'antihistamine medications', 'leukocytosis', 'pus aspirate', 'soft tissue sarcomas', 'anti-hbs', 'additional ICS treatment', 'proteins MLH1', 'thyroid medication).|Unable', 'P2Y12 inhibitors', 'headache medications', 'IVIG', 'sindilizumab', 'anti-inflammatory medications.|Patients presented', 'Ocular Herpes', 'Covid-19', 'aspart', 'oral steroids.|Severe obstructive sleep apnea.|Recent', 'Reslizumab', 'components of the SHAPE medical system', 'multivisceral resection.)|patients', 'hypertensive drugs counts', 'old|Youth', 'mexidol', 'dyes', 'and|Creatinine', 'ICM-203', 'vaccine containing', 'supplements', 'cytotoxic chemotherapy|Willing', 'erythropoietin stimulating agent', 'Natalizumab', 'drugs abuse', 'Regional Department', 'fexofenadine HCL', 'months|Bilateral cleft', 'Tramadol', 'HFNC', 'impetigo', 'recombinant human', 'immune serum globulin infusions.|Known substance', 'local anesthetic|contraindications', 'foveal CST', 'PCNL', 'discontinue antibiotics', 'special', 'cellular products', 'MM|Absolute neutrophil count (', 'symptomatic medication', 'cobicistat-containing products', 'futibatinib or its excipients', 'biphasic dyskinesia', 'modified', 'monoclonal antibody treatments', 'international guidelines', 'outside', '-Zo)|Anti-MDA5', 'anticonvulsant therapy', 'bile acid sequestrants', 'tocilizumab', 'beta-lactam antibiotics', 'cortical depth adjustment', 'PET avid', 'direct medical intervention', 'contrast agents;|Severe renal', 'psychomimetic drugs', 'immunomodulatory medications', 'components of the investigational product.|Clinical suspicion', 'bulletin', 'antitumor drugs', 'immunosuppressive agents|baseline blood', 'breastfeeding;|Chronic', 'Sorafenib', 'paclitaxel-containing', 'selective slowing', 'Sodium Chloride for Injection USP', 'moderate inhibitors', 'diazoxide', 'Cardiogenic shock|Patients', 'DMARD', 'anti-inflammatory', 'nirmatrelvir', 'intravenous antimicrobials', 'compounds of similar chemical or biologic composition.|The', 'Temozolomide', 'CYP3A4 inhibitor', 'polyp', 'blood thinning', 'Swedish|On sedatives', 'Immunoglobulin-G', 'tyrosine kinase inhibitor (TKI) therapy', 'methylxanthine-containing drinks', 'studied drug', 'GCA', 'non-nucleoside reverse transcriptase inhibitors', 'glucagon-like', 'influenza-like illness', 'thrombophilia|Platelet counts', 'anti-inflammatory medications.|Contraindications to the use of', 'satisfy one', 'platelet rich plasma', 'visit|Systemic steroids', 'methylprednisolone', 'analgesic', 'traditional Chinese', 'alcohol', 'oral glucose-lowering', 'guidewire', 'laxative effect', 'direct oral anticoagulants', 'MUC', 'H2-blockers', 'anti-inflammatory medications', 'parenteral anticoagulants', 'intramuscular administration', 'anti-TNFα', 'combined liver-kidney', 'magrolimab', 'curcumin products', 'atypical antidepressants', 'Ascending aorta;Left ventricle assistance device', 'potent CYP3A4 inhibitor', 'immune-mediated conditions', 'intravenous contrast', 'anti-osteoporotic drugs;||• medical conditions', 'diets', 'quinolones', 'not||', 'excisional]', 'tenofovir', 'blood thinning products', 'MAO', 'etc.)|Diabetes', 'pembrolizumab + chemotherapy', 'PARP inhibitors', 'membranes', 'Edaravone', 'calcium channel blockers including:||Diagnosis of', 'drugs altering blood pressure', 'strong analgesic drugs|Patients', 'topical medication', 'Amiloride hydrochloride', 'nirmatrelvir/ritonavir', 'tobacco users.|Subjects', 'antiarrhythmics', 'prescription drug', 'CRC', 'sIL-2 receptor', 'mobile-phone', 'antioxidant drug', 'sedative-hypnotic drugs;|history', 'induction', 'PAD', 'salivary gland stimulants', 'moxifloxacin', 'alclometasone dipropionate', 'intraoperative complications', 'afatinib', 'Chlorthalidone', 'Glucosamine', 'drug-related', 'anti-cholinergics', 'report||', 'Rivaroxaban', 'Teriflunomide', 'anti-TB treatment.|Medical', 'JAK inhibitor', 'conventional imaging (CI)', 'concurrently medications', 'urinary infection.||Drugs:||Antimuscarinics', 'proteins of human origin', 'insulin', 'CME', 'COHb', 'Fontan-palliation|Pulmonary hypertension', 'obesity drugs', 'youth sport organization', 'S SARS-CoV-2', 'age|Inadequate', 'Ethics', 'nutraceutical product', 'medications containing enzymes.|Individuals states they regularly consume probiotic supplements', 'topical scalp treatments', 'cardio toxic agents', 'consume ONS', 'Amantadine', 'SCA3', 'GPIHBP1', 'components of the radiopharmaceutical', 'class III anti arhythmic drugs', 'drug abuser', 'components of the topical medical device.|Participation', 'hormone', 'neuraminidase-expressing bacteria.|Use of any prescription medication', 'CYP3A)', 'hydroxy acid', 'antipyretic drugs', 'ANY', 'hydroxytryptamine-3 receptor antagonists', 'xanthine-containing beverages', 'diagnostic sodium fluorescein used in the study;|Self-reports', 'long-acting anti-', 'adjuvant drugs', 'Fitbit DMD', 'liver drug enzyme inhibitors chlorpromazine', 'hepatotoxic drugs', 'medication containing probiotics', 'its components', '3rd degree heart block|Liver impairment', 'opioid medication e', 'Lewis', 'orthotics', 'proteins', 'anti-platelet drug', 'vigabatrin', 'part', 'antiprotozoal agents', 'anatomic', 'rinses', 'tizanidine', 'mycophenolic acid', 'anthracycline-containing sessions', 'nasal septum deviation', 'ULN;|Urine protein concentration', 'substances,|the use of any medication', 'rifampin/rifabutin', 'lactose', 'Clonidine', 'fusion proteins', 'NG', 'urine drug screening', 'rescue drug containing', 'Pennsylvania Hospital', 'detoxification', 'initiate CBT', 'intravenous immunoglobulin', 'darbepoetin alpha', 'L Note', 'inhaled glucocorticoid treatment', 'PleurX', 'Covid-19 after positive PCR', 'Risperidone', 'drugs known to prolong QT/QTc', 'migraine medication', 'antithrombotic drugs', 'caffeine intake survey', 'cytochrome P450 3A4', 'topical retinoids', 'medication for depression', 'anti-citrullinated protein', 'folic acid', 'systemic corticosteroid therapy', 'hydroquinidine', 'Inducing substrates', 'dobutamine', 'drugs used in the study.|A disease or the use of drugs', 'AIHA', 'PDE3 inhibitors', 'Catron', 'NPRS', 'mineral salts', 'combination Paracetamol/Ibuprofen|patients', 'over-the-counter drugs', 'agents.|Concomitant medications', 'agents used in study|Patients', 'months)|Entecavir', 'barbiturates medications', 'immune checkpoint inhibitor', 'anti-VEGF', 'anti-tumor therapies', 'TNF-α inhibitors', 'ventricle；|Used immunosuppressants', 'prebiotic', 'Glulisine', 'glaucoma medications', 'naratinib', 'Mulhouse', 'eyeball', 'gentamicin', 'erythropoietin', 'injectable hyaluronic acid', 'procedure execution.|Moderate gastro-esophageal reflux disease', 'Acid Citrate-Dextrose (ACD)', 'regional', 'chloroquine', 'mobile phone', 'systemic anti-infective therapy|Previous major surgery', 'SGLT2- inhibitors', 'organ transplant.|Is', 'Immunocompromised', 'hepatitis C;|Patients', 'local anaesthetics.|Infection', 'knee OA', 'viscous lidocaine', 'clenching||-', 'antidiarrheal agents', 'regional block', 'pemetrexed', 'oral lichen planus', 'transfusion allowed)||ANC', 'non-steroidal antiinflammatory drugs', 'COVID-19 monoclonal antibody', 'Bamlanivimab', 'polypropylene', 'ambrisentan', 'anti-inflammatory drugs|taking', 'diaminopyridine', 'prescription', ""vegans|Don't own"", 'monoclonal antibody treatment', 'crescentic body', 'cobicistatdanoprevir', 'cane', 'either||1', 'ramucirumab', 'β-adrenoceptor antagonist therapy', 'bromocriptine', 'postoperative ventilation|Refusal', 'adenosine', 'cosmetic products', 'Bosentan', 'study vaccine components', 'psychotropic drug', 'days;|De', 'pinnaverium', 'sibutramine', 'equivalent)|Alpha-1 antitrypsin deficiency', 'give full agreement', 'immunoglobulin therapy', 'contrast media.|Pregnant', 'other immune-modifying drugs', 'PaO2<6.0 kPa|6-minute walk', 'syncope|Patients', 'GH509', 'component of the atezolizumab', 'chemotherapy agents', 'Cefoxitin', 'fast acting insulin aspart', 'full DSM-5 diagnostic criteria', 'Gem', 'illiterate', 'oral diuretics', 'zoledronic acid', 'toxin induced', 'anti-angiogenic-directed treatment', 'cobimetinib', 'select hospitals', 'antifungal drugs', 'anabolic steroid', 'stanozolol', 'drugs that inhibit platelet function', 'acamprosate', 'strains', 'anti-psychotics', 'anti-inflammatory agents', 'systemic anti-infective therapy', 'recombinant proteins', 'SGLT2 inhibitor family', 'oral hygiene', 'lobes', '5-year follow-up||Exclusion Criteria', 'opiates', 'methylenedioxymethamphetamine [MDMA', 'complains of pruritus', 'chimeric antigen receptor therapy', '5-FU|Uncontrolled intercurrent illness', 'iodinated contrast agent carried out before surgery;|Signed informed consent', 'IFNα for antecedent PV', 'anti-endomysial antibodies', 'biologic therapies', 'nasogastric tube placement', 'licensed vaccines', 'vasoactive support.|Aortic arch', 'target stone', 'macitentan', 'Thyroid disease.|Drugs causing chronic diarrhea', 'oral anti-coagulant therapy', 'adjuvanted COVID-19 vaccine', 'MAP', 'oral mucositis', 'haploidentical donors', 'allogeneic tissue/solid organ transplant.|Patients', 'combination antiretroviral therapy', 'divine', 'ocular anti-VEGF therapy', 'PD medications', 'transfusions', 'CYP3A strong', 'medications that may influence cognitive performance', 'taxane-based', 'lithium);|Patients', 'multiline salvage chemotherapy', 'hydroxamic acid', 'Atypical antipsychotics', 'Misoprostol', 'teripartide', 'immune-suppressive therapies.||Group', 'oral beta', 'dopamine drugs|Patients', 'inhaled steroids|Daily steroids', 'emapalumab', 'oral nonsteroidal anti-inflammatory drugs (NSAIDs)', 'SGLT2 inhibitor|Elevated plasma NT-proBNP', 'neck surgery.|Semi-permanent', 'CNS stimulants', 'lixisenatide', 'Relenza®', 'acetazolamide', 'another COVID-19 vaccine', 'compounds of similar chemical or biologic composition to TAS-102.|Current therapy with other investigational agents', 'medications know', 'study products', 'histotype)', 'concomitant medications that could impact the effects', 'instrumental examinations', 'Guidelines', 'nitrosoureas', 'CNLC IIb-IIIb', 'antiretroviral', 'anti-RANKL therapy|Systemic corticosteroids', 'specific medications', 'cardiac beta-blockers', 'sunscreens', 'non-steroidal anti-inflammatory analgesics', 'anti-cytokine therapies', 'copper supplements', 'immune-related severe', 'passive antibody therapy specific to COVID-19', 'anti-NKG2A', 'Memantine', 'liver medicine|Subjects', 'Anlotinib', 'drugs used in this study;|Unsuccessful', 'medication change', 'oral testosterone', 'Latex', 'anti-tumor necrosis', 'compounds of similar chemical or biologic composition to resiquimod', 'Minidril®', 'systemic steroid stimulants', 'lopinavir', 'Flumadine', 'DFU', 'Medications', 'intravenous cyclophosphamide', 'ASA use', 'anti-fibrosis||', 'hypomethylating agents', 'ionogram', 'visualized', 'Rho(D', 'potassium chloride', 'life|Hospitalized', 'antipsychotic drug', 'hallucinogenic drug', 'platelet medications', 'residual immune-related AEs', 'viloxazine', 'surgery|Patients', 'injection site', 'anticonvulsants', 'chlorohexidine', 'potassium supplements', 'anti-small plate(3 days', 'amivantamab', 'oral hygiene measures outside', 'BCC.|Chemotherapy', 'ketamine', 'window periods.|Receipt', 'neoadjuvant', 'drugs used specifically to induce weight', 'DPP-4 inhibitor', 'multi-organ transplants|Transplanted kidney disease', 'vaccines', 'extraction', 'antidiabetic medication', 'contraceptive injection', 'NSAIDs', 'cholinesterase inhibitors', 'ICH)|Had', 'strong hemodynamic support', 'failure,|renal failure|hormone replacement therapy|use', 'CBT', 'comfort measures', 'nicotine users', 'fluvastatin', 'medication readjustment', 'drugs used in the study;|Anxiety', 'electroencephalogram', 'oral supplements', 'Holter', 'gliomas', 'intravenous (IV) antibiotics', 'Mycophenolic acid', 'component of the IMP', 'hormonal receptor positive breast cancer|Plan', 'hygiene-dietary measures|High-resolution manometry (HRM)', 'antiplatelet,', 'anti-TNF alpha', 'trigone', 'herbal products', 'eHF', 'anti-hyperglycaemia agents', 'chatbot|Smartphone', 'heparin analogs', 'dissociative disorders|Present or antecedent', 'adequate PTA treatment.|Subjects held in custody', 'infraclavicular', 'MIPSS70-plus', 'trastuzumab', 'glutamine', 'HDT', 'liver disease；|Patients', 'UDCA', 'component of the study drug.||Concomitant treatment', 'Glycopeptide', 'components of BCD-217', 'metal implants;|Patients', 'K', 'Pradaxa®', 'SMN2', 'COC', 'vometinib', 'bociotinib', 'monoclonal gammaglobulin Dz', 'pioglitazone', 'Texas', 'taxane-platinum', 'nitric oxide donors', 'sitting', 'dose reduction', 'components of the drug|epilepsy|severe renal impairment', 'caffeine-containing beverages.|Using', 'thrombocyte', 'Cardiology', 'oral corticosteroid therapy', 'ileum', 'PDE5 inhibitor', 'nivolumab', 'confirmed)||OR||2b', 'cytosine', 'age|Clinical', 'moderate CYP3A4 inhibitors', 'ALD', 'anti-angina', 'stat', 'artificial UV', 'semi-elective noncardiac surgery', 'PD-1 inhibitor', 'opioid containing agents', 'Cytochrome P-450', 'hemodynamic assist device', 'selective serotonin reuptake inhibitors', 'components of the investigational drug or its analogues|2', 'dysplastic', 'anti-4-1BB targeting drugs', 'components of the anesthetic solution', 'phosphodiesterase inhibitor', 'age|Migraine', 'hydrogenated castor', 'thiazide diuretics', 'breastfeeding.|Drug-drug interaction', 'panic attacks', 'ACEi)/angiotensin receptor blockers (ARB', 'histamine-2-receptor antagonist|Dual antiplatelet therapy|Combined antiplatelet', 'Australian study only||Non-English-speaking', 'AIDS drugs', 'PAH therapeutics', 'accompanied', 'eculizumab', 'Dexmedetomidine|Nitrous oxide', 'psychological drug intake|Pre-', 'glatiramer acetate', 'autoimmune disorder;|bisphosphonate therapy', 'Bulkamid®', 'components of the study vaccines', 'Paxlovid', 'oral polio vaccine', 'women;|terminal', 'anti-CTLA-4', 'systemic anticoagulation', 'study medication.|Enrolment', 'compounds of similar chemical or biologic composition to imatinib', 'hypomanic symptoms|Has attempted suicide', ""oral anti-Parkinson's disease medications"", 'California State University San Marcs|between', 'immune therapy related adverse event', 'topical bland moisturizers/emollients', 'APC', 'anti-histamine', 'Polyethylene', 'citrate', 'HGL', 'lacidophilin', 'oral Factor Xa inhibitors', 'erythropoietic drugs', 'oral medications', 'similar medications', 'loco-regional therapy', 'inducers-barbiturates', 'naltrexone-bupropion', 'AZA', 'Inhaled Corticosteroids', 'experimental drug treatment', 'wheat', 'grapefruit products', 'corticosteroid', 'prescriptions', 'Sodium Borate Decahydrate', 'N', 'pursue bariatric surgery', 'INH', 'valaciclovir', 'antianxiety agents', 'CYP 3A4 potent inhibitor', 'canagliflozin', 'lymphatics', 'third-generation EGFR-TKI.|Previously', 'esophagogastroduodenoscopy', 'invasive medical device', 'intravenous contrast agents', 'Mesothelin-CAR', 'aromatase anti-estrogen', 'ALK TKI', 'closed reduction', 'necrotic pulp.|Patients', 'monoclonal antibodies;||Active', 'contraceptives', 'first-', 'shell fish|Auto immune disease', 'oral sildenafil', 'owns', 'morphine milligram equivalents', 'compounds of similar chemical or biologic composition to decitabine or filgrastim.|Participants', 'prescription drugs.|Is', 'addictive agent', 'AID pump', 'topical antifungals', 'LTBI', 'beta-HCG serum', 'normal;|Oral anticoagulants', 'MLL rearrangements', 'Infliximab', 'contrast agent|eGFR<45 mL/min/1.73m2', 'pyrotinib', 'anti-platelet', 'not)|Patients', 'alkaloid', 'large intestine', 'exenatide', 'antiparasitics', 'anti-retroviral therapy (ART)', 'rapid', 'clonidine', 'Axi-Cel', 'contraindicated medications', 'Cequa®', 'immunomodulators', 'combination oral contraceptive', 'investigational product excipients', 'Fibroscan', 'treatments', 'BCD', 'Immunoglobulin-D', 'autoantibodies).||Anti-synthetase autoantibody', 'component of the bevacizumab', 'CSF', 'antibody treatment', 'diuretic medications', 'Azvudine', 'cannabis derived products|Cochlear implant', 'contrast agents.|Doubts', 'endoscopists', 'angiotensin II receptor blockers (ARBs)', 'antibiotic', '1cm2', 'preoperative troponin/hypersensitive', 'NAC);|≥', 'anti-anxiolytics', 'satisfy the investigator of fitness', 'Palivizumab', 'SAVR', 'cisapride', 'immune checkpoints', 'intravenous access.||', 'migraine onset age should', 'immune-related toxicity', 'oral levothyroxine', 'hMPV', 'fine lines', 'steroid-based medications|(5', 'or|Creatine kinase', 'component of the IP formulation.|Chronic use', 'soluble guanylyl cyclase', 'imidazole antifungals', 'goserelin', 'sodium hyaluronate', 'medication for asthma/seasonal', 'short-acting steroidogenesis inhibitors', 'antibodies', 'topical glucocorticoids;|Uncontrolled heart diseases', 'anti-tuberculosis prophylaxis', 'compounds of similar chemical or biologic composition to ADI-PEG 20', 'COX-2 inhibitors', 'mineralocorticoid antagonist', 'acromegalia', 'IL-34-blocking', 'Inoculate', 'mercurial antiseptic', 'intravitreal', 'esomeprazole', 'sapropterin', 'strong inhibitor', 'Rennes', 'anti-SARS-CoV-2', 'ATI', 'monoclonal immunoglobulins', 'parenteral antibiotics', 'LA agents', 'chlorhexidine containing mouthwashes', 'direct factor Xa inhibitor betrixaban', 'intravenous iron', 'chemotherapeutic anti-plaque', 'carbapenem', 'monoclonal antibodies to the interleukin 6 / interleukin', 'sodium stearyl fumarate', 'isoflavone supplements', 'Oseltamivir', 'leuprolide depot', 'experimental monoclonal antibodies', 'equivalent|Steroids', 'age|ASA', 'azithromycin', 'chronic opioids', 'CTCAE 5.0.||Adequate organ function', 'non-steroidal anti-inflammatory drugs (NSAIDs,', 'Pirkanmaa', 'mannitol', 'entecavir suppression|Prior treatment for', 'anti-HBV treatment', 'PDE6B', 'triamterene', 'perforin', 'cytotoxic chemotherapy.|Patients', 'nitrosourea', 'antidepressant', 'nonsteroidal anti-inflammatory drugs (NSAIDs)', 'dopamine-reducing agent', 'ocular assessments', 'Intrauterine', 'hydroquinone applied', 'verbal', 'Sandostatin®', 'cardiogenic', 'components of the device.|Participants', 'sintilimab', 'prescription oral', 'colestipol', 'agents', 'antiarrhythmic drug prescription', 'anti-resorptive', 'Adalimumab', 'sodium valproate', 'angiotensin-converting enzyme inhibitors', 'stents', 'CYP3A4/5 inducers', 'iodinated contrast agent||', 'phosphodiesterase-5 inhibitors', 'Galantamine', 'tranquilizers', 'NT2', 'tepotinib', 'ropivacaine', 'immunoglobulin M (', 'prophylactic antibiotic treatment', 'microcrystalline', 'immunosuppressive therapy.|Pregnant', '5-MeO-DMT.|Has', 'diathermy', 'Padua', 'strabismus', 'agents used in study||Patients', 'Tourette', 'Lobeglitazone', 'topical steroid application', 'anti-angiogenic agents', 'antidiabetic drug', 'indwelling tube', 'SAMA', 'anti-tumor radiotherapy', 'indwelling', 'topical treatment', 'anti-CD19 targeted therapy', 'biotherapy', 'insulin sensitizing medications', 'anti-mesothelin CAR-T cell', 'neo)adjuvant chemotherapy', 'bathroom', 'anti-CLL-1 monoclonal antibody', 'Xen Gel Stent', 'valganciclovir', 'anesthetic drug', 'nivolumab-relatimab', 'congenital long QT syndrome.|Patients', 'anti-COVID-19', 'OACs', 'CFTR modulator', 'meglitinides', 'exfoliants', 'food products', 'ECMO', 'regorafenib', 'topical anti-glaucoma medication', 'butylphthalide', 'immune-mediated disease', 'Cyclophosphamide', 'irinotecan', 'amoxicillin', 'short-acting beta-adrenergic', 'vessels', 'anti-ENA assessment', 'methylene diphosphonate bone scan', 'HCMS', 'equivalent||', 'direct', 'inattention', 'liver drug enzyme inducers barbiturates', 'tocilizumab||Absolute neutrophil count (ANC)', 'fluorescein injection', 'component of the SC0245 tablets', 'compounds of similar chemical or biologic composition to ATI-2231 or other agents used in the study.|History of acute', 'immunomodulators|Transplantation|Cancer|Autoimmunity|RZV after COVID-19 vaccination|COVID-19 PCR+ before COVID-19 vaccination|Other types of COVID-19 vaccines', 'Entresto', 'antibody targeting T cell co-regulatory', 'L-[ring-13C6]-phenylalanine', 'oral prednisolone steaglate', 'Sodium hydroxide', 'anticoagulation drugs', 'potassium supplementation', 'anti-B-cell maturation antigen (BCMA) targeted CAR T-cell therapy', 'non-steroidal medications', 'beta blockers', 'mirabegron', 'progression', 'oral typhoid vaccine', 'MRO', 'antibacterial agents', 'paclitaxel polymeric micelles', 'N5-N7', 'insulin pump therapy', 'vegetarian', 'TPO receptor agonists', 'GSK3511294 (', 'monoamine oxidase inhibitor', 'drugs that could cause hepatic steatosis', 'enzyme-inducing properties', 'ARDS', 'contraceptive measures', 'Wageningen', 'treatments antihypertensives', 'ventricular assist devices.|ESRD', 'absorption inhibitors', 'surveys|live', 'Immunomodulators', 'antiandrogen', 'strongly inhibit CYP3A4', 'long-acting rilpivirine', 'thermogenics', 'percutaneous', 'psychoactive substances)||CONTROL', 'MDM2 inhibitors', 'DKA', 'drugs of similar chemical classes|Participant', 'peanut oral immunotherapy', 'St. Olavs hospital', 'anti-lymphoma therapy', 'angiotensin-receptor blockers (ARB)', 'fish products', 'live born', 'GBS', 'axitinib', 'MRA|Understands oral', 'immune systems.|Is', 'drug containing berberine', 'alpha-blockers', 'controller medications', 'left ventricular (LV) hypertrophy', 'sulphonylureas', 'solubilize carfilzomib', '0.742 [female]', 'angiotensin II receptor antagonists|Diabetes mellitus|Patients', 'Semaglutide', 'rabeprazole', 'contrast medium|Subjects', 'Avelumab', 'supplements containing', 'GnRH agonist suppression.|Embryo Transfers', 'knee injection', 'romisvir', 'Mutaflor®', 'anticoagulation/antiplatelet medication|History', 'CYP2C19 inducers', 'study-related activities', 'Ehlers Danhlos', 'conventional treatment;|two or more recurrences;|persistent extramedullary leukemia;|For', 'radionuclide', 'strong inducers of CYP3A enzymes', 'Emergency Medicine', 'basal-bolus', 'nivolumab monotherapy', 'Symlin', 'renal insufficiencyor', 'fluphenazine', 'non-steroidal medication|Any contraindication', 'injectable paclitaxel', '5-alpha-reductase inhibitors', 'VPA', 'drug-eluting stents', 'xylocaine adrenaline - Subjects', 'Chloroquine', 'depot injection', 'HAMD-17 scale', 'glucocorticoid containing medications', 'medications required for', 'adrenergic agonists', 'Dalpiciclib /Pyrotinib', 'Amikacin/', 'emergency', 'curative systemic', 'alpha-2 agonist', 'local antibiotics|Current', 'systemic regimen', 'immunosuppressive therapies|use of mouthwash containing', 'study drug treatment', 'other drugs', 'monoamine oxidase inhibitors', 'orthokeratology lenses', 'anti-ulcer drugs', 'Novosyn®', 'anti-platelet medication', 'drugs used in this institute', 'inflammatory diseases;|(3', 'contrast agents used in the study.|Female', 'nifedipine', 'MMI', '5-alfa-reductase inhibitors', 'anti-histaminic agents;|Contraindication', 'Leflunomide', 'SBPs', 'Eliquis', 'Cobicistat', 'anti-PD', 'ACE-I', 'eggs', 'biosimilar agent', 'CYP3A4 inducers', 'anti-tumor', 'anti-tumor therapy', 'venetoclax', 'lamotrigine', 'drug where CNS toxicity', 'rosuvastatin', 'over 100 bpm', 'strong inducers of CYP', 'contrast injection|Normal CSF composition|High CSF opening pressure', 'anti-psychotics)|if', 'iron storage disorders|Recent treatment', 'natural medications', 'cobicistat prescription', 'sodium oxybate', 'contraceptive measures consistent', 'buprenorphine dose', 'contrast product', 'amlodipine', 'fondaparinux', 'contrast medium allergy', 'Aumolertinib [formerly Almonertinib])||For', 'Mipomersen', 'non-physiological arrhythmia judged by the investigator', 'fingolimod', 'COVID-19', 'nafcillin', 'immunosuppressant', 'iloperidone', 'Twins', 'RZV', 'component of the study drug；|Participated', 'drug-drug interaction medication', 'lebrikizumab may', 'Phenothiazine antipsychotics', '3rd lumbar vertebral body)|Informed consent for study participation||', 'conventional treatment', 'TERC', 'Definity ®.|Cardiac disease', 'CTCAE v5.0|An', 'medications known to alter metabolism or digestion', 'atropine', 'systemic steroid therapy', 'histidine hydrochloride', 'begins', 'topical acne drug', 'muscle relaxers', 'supplemental corticosteroids', 'medications|Chronic steroid use|Contra-indications', 'type II skull base', 'Etesevimab', 'Calcium channel blockers', 'YMSM', 'oral morphine equivalent|History', 'ocular drug release device implantation', 'opioid analgesic therapy', 'lymphoid tissue tumors', 'topical ophthalmic solution', 'topical therapies', 'Prescription medication', 'immune checkpoint inhibitors', 'Trabectedin', 'metabolic', 'anti-COVID-19 drugs', 'topical cream;|Known', 'autism|mental', 'inflammatory disorders|Patients', 'several drugs', 'rituximab:||Within one year of screening|At', 'noradrenaline reuptake inhibitor', 'conventional breast MRI', 'febrile', 'inhaled steroidal drugs', 'herbal agents', 'CTCAE grade ≤1', 'IMMUNOCOMPROMISED', 'systemic immunosuppressive', 'components of RO7515629', 'Xray', 'aminopenicillins', 'change medication', 'topical iodine', 'sulfamethoxazole', 'magnesium sulfate', 'V600E', 'recombinant FVIII for', 'pharmacological agents', 'curcumin', 'lipid', 'hip|Participant', 'aspirin|Pregnant', 'immunosuppressive agents.||(4', 'reason|Meets criteria', 'Glucose-Lowering Medications', 'immune-related', 'vortioxetine', 'INR monitoring', 'L-Dopa', 'beta-alanine', 'diethylenetriamine pentaacetate', 'Metoclopramide', 'nail products', 'damage|Patients', 'urine drug screening test.|Woman', 'pain relief', 'target lesion.||Adequate organ functions', 'immunoenhancers', 'situ；|Patients', 'intolerance medications', 'inducers of CYP3A4', 'anti-CD38 therapy', 'OAG', 'omeprazole', 'MRD', 'indwelling catheter', 'nasal congestion', 'abusive drugs', 'carbamazepin', 'low-dose warfarin', 'Vitamins', 'anti-coronavirus treatment', 'Amyvid®', 'potassium channel blockers', 'medications in order', 'T3', 'CYP3A', 'drug reactions', 'nematavir/ritonavir', 'pheniramine', 'III antiarrhythmic drugs|History of reflex syncope', 'stereotactic radiosurgery', 'monoclonal antibodies related compounds', 'similar drugs for antitumor therapy;|Received', 'contrast materials', 'adjunctive bupropion', 'therapy', 'gepants', 'medium probability', 'monoclonal antibody;|Patients', 'Thymoglobulin', 'SE', 'security.|Antiplatelet agents', 'cessation medication', 'non-steroidal anti-inflammatory drug (NSAID)', 'creatine', 'Cytochrome P450 (CYP) 2C8 inhibitors', 'nodular', 'anti-angiogenic therapy', 'neurotoxic', 'intervention|Moderate', 'PSV', 'SSI', 'anti-sensitivity toothpaste.|Participant', 'tetriodothyronine', 'somatic drugs', 'Caribbean', 'systemic immunosuppressive agents', 'cumulative dose', '1N hydrochloric acid', 'contraceptive sponge', 'drug dependence|Treatment', 'chlorpromazine', 'Polysorbate-80-containing infusions.|Medical', 'canakinumab', 'anti-tumor vaccine treatment', 'antimuscarinic medication', 'PAV+', 'indocyanine green|Patients', 'components of the implants|Patient with physical or', 'Guide', 'Everyone', 'misoprostol', 'study vaccine dose.|Immunosuppressive therapy', 'analgesics；|Patients', 'Instagram', 'depressants', 'detrermines', 'anticancer agents', 'VAD', 'NSAID drugs', 'rasagiline', 'musculoskeletal injuries;||Athletes', 'aortoiliac disease).||HV', 'lersivirine', 'Festival', 'oophorectomy', 'antihypertensive', 'Balaguer', 'anti-PD-1/anti-PDL-', 'medications that would increase the risk of', 'hypnotic drugs', 'Budd-Chiari syndrome', 'organs', 'hematopoietic stimulating factors', 'Juvenile Idiopathic Arthritis (', 'pancreatic insulin', 'component of the drugs', 'cyclodextrins', 'phone', 'RVEF', 'FSGS', 'juvenile MLD', 'non-nucleoside reverse transcriptase inhibitor', 'arthroscopic', 'angiotensin converting enzyme inhibitors', 'factor Xa inhibitor', 'Mood stabilizers', 'axial', 'out)|Intrauterine fibroids', 'fusidic acid', 'paints', 'herbal product', 'immunosuppresive medications', 'topical retinoid use', 'drink rich', 'immunostimulants', 'atorvastatin', 'Spiral', 'aminotransferase(ALT', 'Diaphragm', 'sodium-glucose cotransporter 2 [SGLT2] inhibitor', 'prochlorperazine', 'thyroid medications', 'supportive care', 'components of study therapy|Systemic amyloid light-chain amyloidosis', 'strabismus (exotropia or', 'Dengue', 'lenatinib', 'children', 'vitamin K antagonists', 'inhaled SANO', 'upper.|Good oral', 'levofloxacin', 'physiotherapy regimen', 'deterioration', 'prescription drugs;|The', 'vegan diets', 'Calcineurin inhibitor', 'injectable antibiotic therapy', 'HIV protease inhibitors', 'hormone anti-tumor treatment', 'mucosal malignancy|Scheduled to undergo treatment for their malignancy', '5.|children', 'GLP1-RAs', 'Lactose', 'profile|High-grade trochlear dysplasia', 'Azacytidine', 'vaccine candidate', 'consume caffeine', 'hormonal moisturizers', 'lines of', 'live attenuated vaccines', 'corticosteroid injection(s', 'endocardial myocardial biopsy', 'Furmonertinib', 'anti-arthritic', 'component of the study vaccines', 'alternative drug', 'pembrolizumab formulation|Known allergy', 'efalizumab', 'non-steroidal drugs', 'fatty acids', 'drugs under any of the following conditions:||a) Change in dry eye medication', 'oral anti-diabetic drugs', 'monoclonal antibody;|Prisoners', 'Moderna COVID-19 vaccine', 'antipsychotic drugs|American Society of Anesthesiology (ASA) status', 'Lamotrigine', 'iodinated contrast|Patients', 'labeled syndromic', 'factor IX inhibitor', 'antimuscarinic agents', 'MAD', 'medications used.|Chronic kidney disease', 'Martinsville', 'ociperlimab', 'compounds with', 'anti sectertory drugs', 'antithrombotic medication to cancer patients||', 'sodium valproate.|Any other contraindication/s to sodium valproate', 'components of GDC-6036 or', 'doxorubicin', 'OTC medication', 'ocular media', 'cannabis-use', 'targeting agents', 'possible curative treatment', 'contrast media|The', 'drugs used in this study', 'compounds of similar chemical or biologic composition to etoposide', 'drugs that inhibit gastric acid secretion', 'intravenous (IV) diuretic', 'Twitter', 'trazodone', 'gadolinium', 'over-the-counter (OTC)', 'normal;|Troponin', 'bosutinib', 'crystalline', 'SBIRT', 'K-max', 'missed', 'NJ', 'Transfusions', 'Gillet test||', 'immune system diseases', 'hypercalciuria;|drugs', 'medications used to treat AUD', 'Couples', 'molecular pathology.|No', 'neuroprotective drugs', 'renin inhibitor', 'inotropic drugs', 'VF)|Electrical storm', 'contraceptive jelly', 'anticholinesterase inhibitors', 'immunosuppressant use', 'contrast agent|patient', 'component of the product', 'Mycophenolate Mofetil', 'danazole', 'dermabrasion', 'saliva substitute treatment', 'antibiotics;|Patients', 'synbiotics', 'tocainide', 'hypolipidemic drugs', 'sulfa', 'surfactant', 'Radiesse®', 'short-acting antipsychotic drugs', 'ampreloxetine', 'combined ACEI', 'psychiatric medication', 'systemic steroid treatment', 'immune treatment', 'Glargine', 'anti-ALK inhibitors', 'low-molecular-weight heparin', 'surgery.|Participant', 'sodium bicarbonate', 'full left angle', 'HAE attacks', 'angiotensin II receptor blocker (ARB', 'thiazide-type diuretics|Prescribed', 'medications that prolong the QTc interval', 'orthognathic', 'nutritional supplements', 'occurs', 'immediate post-operative MRI', 'CFC', 'CFTR modulators', 'non steroidal anti-inflammatory drugs', 'UTI', 'sildenafil-based drugs', 'mTOR inhibitor', 'fluoroquinolones', 'tuberculosis', 'Baricitinib', 'non-steroidal anti-inflammatory drugs (NSAIDs)', 'surgeons', 'treatment medication', 'beta-blockers);|3.patients', 'Vitamin K', 'ocular surface', 'intravenous vasodilators', 'warfarin;|Participated', 'offspring', 'gaze', '50', 'live virus', 'non-anti TNF biologics', 'monoclonal antibody products', 'influenza vaccination', 'topical ophthalmic medication', 'proton-pump inhibitors|Insufficient knowledge of the Dutch language|Pregnancy', 'fibrin', 'influenza remedies', 'thrombolytic', 'penicillin', 'clascoterone', 'inhaled corticosteroid therapy', 'macrolides', 'tobacco substances', 'mTOR) inhibitors', 'CYP P450 2C8 inducers', 'anti CD20 therapies', 'component of the study', 'medications by mouth including laryngectomy', 'AHT medications', 'Flupenthixol decanoate', 'document||', 'systemic therapy.|A', 'Empagliflozin', 'antidepressants drugs', '3rd degree heart block|QTc', 'Ofatumumab', 'beta-agonist', 'Long Acting Muscarinic Antagonist', 'bevacizumab', 'ICG', 'anti-anxiety', 'furosemide', 'low molecular dextran', 'Gaviscon', 'contraceptive precautions', 'soft-tissue lesion biopsy', 'atrium', 'PVB', 'injectable medications', 'drugs of abuse', 'DHEAS', 'imaging', 'components of BCD-100.|A history of', 'DBP≥120mmHg', 'influenza ≤120 days before study intervention', 'Citric acid', 'anti-Leishmania therapy', 'vitamin K antagonists;||CTCAE', 'anti-allergy', 'GnRH antagonist', 'food supplements', 'lactovegetarian', 'milk', 'anti-blastic agents', 'immunosuppressive drug treatment', 'Oxervate', 'conventional imagine', 'corrective glasses', 'orthodontic treatments', 'imipramine', 'alpha-blocker medication', 'Use antispasmodics', 'drugs acting on immunophilins', 'Rimantadine', 'oral immunosuppressants', 'peptide-1 analogues|Lithium|Diphenhydramine|dopamine', 'IL-2 related toxicities', 'Serotonin', 'Flourish', 'germline ANKRD26', 'hormones', 'alcohol.|Consumes excessive amounts', 'topical corticosteroid treatment', 'drug abuse;|The researcher believes', 'topical anesthetic cream', 'sternocleidomastoid', 'immunosuppressant orally', 'antidepressant treatments', 'squaric acid dibutyl ester [SADBE', 'abused drug', 'component in its formulation', 'took medications', 'selective inhibitor of nuclear', 'flow cytometry analysis', 'neratinib', 'long-acting beta agonist', 'agents used in the study|Individuals', 'entrectinib', 'phencyclidine', 'oral)', 'recombinant)', 'Ticlid', 'lineage', 'immunosuppressive drugs', 'ofatumumab', 'cyclosporine.||Oral corticosteroids', 'Hormonal contraceptive', 'PEG tube', 'ICS)', 'immune suppression therapy ≤4', 'ICS administration', 'anti-RANKL', 'human immunoglobulin', 'MDE', 'IM drug', 'risk|Immunoglobulin G', 'protein supplements', 'oral stimulants', 'thalamus', 'psychotherapeutic drugs', 'emicizumab', '|Anastomosis preformed', 'canine to 1st molar area', 'Tofacitinib', 'topical steroidal medications', 'steroidal', 'antidiarrheal medication', 'non-live vaccines', 'Tixagevimab', 'smartphone', 'strong CYP3A4 inhibitor -azole antifungals', 'CBP', 'LR769', 'anti-MM', 'contains small amounts', 'GSK3511294', '2L', 'deucravacitinib', 'non-steroidal anti-inflammatory drugs|Serum potassium', 'F31)|moderate', 'Thioridazine', 'low vitamin D levels', 'anaphylactoid reaction', 'gentamycin', 'aspergillus', 'UK', 'assessments offered', 'anti-obesity', 'MSI', 'components of the test', 'Curettage', 'anti-MET/EGFR', 'agents targeting', 'direct thrombin inhibitor', 'antimigraine medications', 'erythromycin', 'German', 'ICS', 'Leeloo®', 'medication on prescription for peripheral neuropathy', 'human origin;|Patients', 'DFMO', 'fuglitagliptin', 'rapamycin', 'Levonorgestrel Intrauterine system', 'anger', 'remifentanil', 'live virus vaccine', 'local anesthetics', 'glucocorticosteroids', 'more energy', 'systemic glucocorticoid treatment', 'apatinib', 'Reiter', 'PCP)/ketamine drug abuse', 'calcineuPririn inhibitors', 'pimavanserin', 'oligo', 'components of QLF32101；|Have uncontrollable', 'study drugs Medication', 'antihypertensive drugs.|Myocardial infarction', 'anti-fungal therapy', 'statin', 'intranasal sprays', 'inhaled corticosteroid therapy;|Patients complying', 'antiarrhythmic drugs', 'age;|participants', 'OAC', 'anti-treponema pallidum', 'COX)-2 inhibitors', 'Restylane® Lyft Lidocaine', 'EHPAD', 'antiviral drugs', 'milk products', 'dalfampridine', 'Sogroya', 'tremelimumab', 'GPX4', 'Vitamin K deficiency', 'immunoglobulin M [', 'any GLP receptor agonists', 'prostaglandins', 'Goserelin', 'SBRT', 'donor;|Patients', 'N1C', 'unlicensed vaccine', 'contraceptive methods', 'metal fragments', 'anti toxoplasma therapy', 'psychoactive medication use|Healthy', 'urethral diverticulum', 'English|an', 'anti-inflammatories', 'varicella vaccine', 'caffeine', 'supplements containing L-arginine', 'CYP2C9', 'single-agent pembroilizumab', 'progestin sensitive neoplasia.|History', 'knee|Ipsilateral femoral', 'nonoperative therapies', 'rifamycins', 'immunosuppressive agents||NOTE', 'exudate', 'intravenous ICG', 'CKD)-EPI', 'CNV', 'commercial dental products', 'diuretics beta-blockers', 'ID:||- Iron deficiency', 'anti-neoplastic therapies', 'investigational agents related', 'Firefighters', 'Irinotecan', 'systemic corticosteroid use', 'health supplements', 'topical treatments', 'diphenhydramine', 'piperaquine', 'AR inhibitors', 'Avastin', 'anti-cancer activity', 'nephrotic', 'toriplimab', 'mTBI', 'KMT2A', 'Mandarin||', 'dopamine agonists;|being able to walk independently', 'antioestrogens', 'inguine-scrotal hernia|Imprisoned hernia|Use of Gonadotrophins|Use of anabolic steroids', 'conventional pacemaker', 'acitretin', 'human gamma globulin', 'abutments', 'aspirin acceptable).||Healthy volunteers||Inclusion Criteria:||1', 'nasal high-flow oxygen therapy', 'migraine attacks', 'Venous-capillary', 'dopamine-blocking agents', 'sprains', 'fine lines/wrinkles', 'lidocaine patch', 'components of the NUC-3373 drug product formulation (super refined polysorbate', 'local anesthetic solutions', 'infliximab', 'anti-platelet therapy', 'tyrosine kinase inhibitors', 'grapefruit/grapefruit juice', 'consumer products', 'Gefitinib', 'tezepelumab', 'gliptin', 'Spanish- speaking|ACE score', 'anti-nausea medication', 'angiotensin converting enzyme inhibitors.|Chronic diarrhea', 'non-anti-TNF biologic', 'TAVR', 'anti-VEGF injection', '|Alkaline phosphatase (ALP)', 'cirrhotic', 'ibuprofen containing agents', 'any vaccine', 'letrozole', 'compounds of similar chemical or biologic composition to GEN-1', 'trial medication', 'systemic steroids therapy', 'punctum plug', '3rd year)||', 'donated', 'blisters', 'alpha blocking drugs', 'central analgesics', 'Midline Glioma', 'blocks', 'norfloxacin', 'IV TXA.|Prior', 'tattoo', 'acids', 'remazolam', 'acne', 'non-Clozapine antipsychotic', 'intraprostatic implant', 'brimonidine', 'anti-inflammatory medications.|Subject', 'NASIDs', 'bevacizumab combination', 'drug-induced pneumonitis', 'nonsteroidal anti-inflammatory drug use|oral bisphosphonate', 'stabilized', 'midodrine', 'systemic condition).|INR', 'medicinal product study', 'antithrombotic medications', 'anti-CD38 antibody drug|Uncontrollable', 'tobacco|Active malignancy', 'anticancer medication', 'PBMC', 'hygiene', 'pazopanib', 'components of the mRNA', 'inhaled corticosteroid hormones', 'Cymbalta', 'potassium-sparing diuretics', 'phenprocoumon', 'over-the-counter (OTC) products', 'topical application', 'higher|Patients', 'local guidance.|Any vaccination', 'mucosal protective drugs', 'Accutane', 'Cl', 'ULT', 'heterologous vaccination', 'YOUTH||Youth', 'vitamin preparations', 'platelet-lifting drugs', 'simple analgesics', 'fluoride gel being used in this stufy|Patients', 'Ustekinumab', 'B drugs', 'Spine Center|Scheduled', 'drugs related to the oral lesions', 'Regiocit®', 'compounds of similar chemical or biologic com-position', 'calcineurin inhibitors', 'trademark', 'medications used to treat Attention Deficit Disorder', 'etc.);etc.||4', 'AAA617', 'ex20ins inhibitors', 'imipramine types', 'Glucocerebrosidase', 'citicoline', 'compounds of similar chemical or biologic composition to study agents', 'oral corticosteroid use', 'components thereof|If HCV Ab positive', 'rosacea', 'PAR', 'systemic antibiotic therapy', 'SC NTZ', 'vasoactive medication', 'antipsychotic medication|No', 'methylxanthine drinks or foods', 'TAF', 'matched sibling donor (MSD)', 'anti-infective drugs', 'eGFR<45', 'equivalent;|Steroids', 'local anesthetic administration|systematic use of analgesic agents preoperatively|chronic pain syndromes preoperatively|neurological', 'theophylline', 'liver volume|Antibiotic', 'oral lenvatinib', 'endometriosis', 'contraceptive options described', 'cycles', 'intense pulsed light treatment', 'IGSC', 'nephrotoxic agents', 'materials used', 'components of the drug formulation.|Subjects', 'monoclonal antibody products;|Pregnancy', 'antidepressant medications', 'cramps', 'systemic anti-tumor therapy', 'lifelong anticoagulation', 'GLP-1 receptor agonist', 'recombinant vaccine', 'nicotine-containing', 'angiotensin-converting enzyme (ACE) inhibitors', 'components of investigational drugs|Screening test AST', 'Oral Antidiabetic|No sensory loss', 'ACE Inhibitors', 'xanthine', 'LQTS', 'apalutamide', 'anticoagulant drugs|Corticosteroids', 'moderate CYP3A4 inducers', 'contraception.|Aged', 'drugs containing atazanavir', 'drugs prescribed in a chronic schedule OR|Complez Chronic Condition||', 'medication regimen', 'SGLT2 inhibitor.|Hepatic hydrothorax|Hepatic encephalopathy', 'Exclusionary medications', 'pleomorphic', 'heat', 'antitubulins', 'VS-6766', 'H2 receptor antagonist', 'anti-rejection drugs', 'systemic corticosteroid medication', 'carob leaf', 'iron chelation regimen', 'opioid injection', 'antisecretory drugs', 'serum alpha-fetoprotein', 'abuse drugs', 'oral antidiabetics', 'vitamin', 'smartphone number', 'nicotine consumed', 'over 2 days prior|If', 'Treponema pallidum', 'prilocaine-type local anaesthetics', 'TEAE', 'cyclopyrrolone', 'immune prophylaxis', 'neuroendocrine', 'seconds).|No medication', 'drugs altering bone metabolism', 'ocular anti-VEGF medication', ""St. John's Wort / CYP2C9"", 'strong CYP inhibitors', 'medical-grade adhesives', 'IL-1 inhibitors', 'milk products|Soy allergy|Pea allergy|Participating in a structured', 'neurovascular', 'nurse', 'severe liver', 'components of the investigational product;|16)Subjects', 'ointments', 'sedative drugs|Patients', 'anti-treponemia pallidum antibody', 'oral steroids', 'G-CSF', 'immunosuppressives', 'localized anti-neoplastic therapy', 'adjunctive therapies', 'medications:||Anti-diabetic medications', 'TMS.|Primary', 'ADHD medication', 'Berlin definition', 'delivery room surfactant', 'oral hypoglycemic agents', 'intranasal medication', 'drugs used in the study protocol|History of premature birth|Diagnosed metabolic syndrome|Known hepatic insufficiency', 'Colestipol', 'polymyxin', 'prolonged corticosteroid therapy.|Patients', 'actionable molecular alterations', 'NRAS', 'PWS', 'androgen receptor inhibitors', 'antispasmodic drugs', 'TEAEs', 'non-cirrhotic portal', 'RAD51C', 'aminoglycosides', 'anti-herpes medication', 'Polman', 'ICV', 'topical anti-cellulite treatments|Pregnant', 'TNF) inhibitor', 'components of the drugs of the investigational procedure|Patient under guardianship', 'PACs', 'liver disease|All medications', 'contrast material|Malignancy|Pregnancy|Uncontrollable medical', 'iron -deficiency', 'antiplatelet drug intake.|Cutaneous infection', 'radioactive agent', 'medication regimen.|Not fluent', 'similar anti-coagulants', 'Ritalin', 'astemizole', '5hT2A medications', 'immune-weakening medications:||i', 'drug components of this protocol', 'topical anaesthesia', 'taxane regimen', 'Collins', 'sulfa containing drugs|Inability', 'monoclonal antibody therapy', 'live attenuated', 'cilgavimab', 'anti-androgen drugs', 'topical anti-muscarinic|Significant central corneal scarring', 'antinausea agents', 'Ketamine', 'adefovir dipivoxil tablets', 'drug', 'abatacept', 'DLB', 'methylprogesterone', 'Choline', 'cisplatin-base chemotherapy (BEP)', 'Residents', 'mental drug abuse', 'anti-cancer therapy.|Pregnant', 'injectable anti-diabetic medications', 'long-acting injectable regimens', 'hematocrit', 'sulfites', 'topical ocular steroids treatments', 'systemic immunosuppressive medication', 'hormonal', 'stimulant laxatives,|major abdominal surgery,|inflammatory bowel disease,|infectious diarrhoea,|allergic diseases a|psychiatric disorders', 'substance', 'combination insulin products', 'citalopram', 'anesthetic analgesia|Psychological disorders|Coagulopathies|Infection', 'gabapentinoids', 'dissociative anesthetics', 'prohibited medications', 'Type 1', 'quinidine', 'pennyroyal', 'defines', 'compound analgesics', 'SUs', 'antiplatelet agents', 'medication infusion device.|Because TMS does not penetrate deeply into the head', 'stool', 'immunosuppressive agents.|Primary central nervous system (CNS) disease', 'quinolone derivates', 'dextromethorphan', 'strong inhibitor of cytochrome P450 3A4', 'pork foods', 'UUI', 'HBV vaccine', 'psilocybin', 'active drug therapy', 'anti-HBs', 'NSAIDS', 'exploratory drug', 'immune compounds.|Patients', 'corticosteroid inhalation', 'biologic therapies;|Previous organ transplant;|Administration', 'iodinated contrast', 'albumin (ALB', 'N03', 'meloxicam', 'components', 'MMF', 'any blood products', 'Implanon®', 'components of the study drugs', 'tranexamic', 'Dalteparin', 'mental illness;|The researcher believes', 'clarithromycin', 'components of the formulation', 'medications for these conditions', 'antibody-containing combination regimen', 'compounds of similar chemical or biologic composition to ZEN003694', 'vonoprazan', 'sodium nitroprusside', 'completed', 'LTRA', 'contrast medium|Pregnant', 'immune related', 'Neomycin', 'capmatinib', 'albumin paclitaxel', 'prescription medication|Pain', 'Indocyanine Green', 'hormonal drugs', 'Ipilimumab', 'anti-dopaminergic medications', 'immunosuppressive', 'dialysis.|Patients', 'adequate serology', 'bismuth agents', 'disease related', 'compounds of similar chemical or biologic composition to ADI-PEG', 'inhaled corticosteroids', 'setting.|Note', 'injectable corticosteroids', 'prolonged antibiotic-therapy', 'interleukins', 'Clozapine before initial lab work obtained Non-Clozapine treatment', 'over-the-counter supplements', 'local label|Treatment', 'organ transplants', 'Global Impressions Scale', 'HIV.|Any medications', 'ecstasy', 'age.|Baseline ECG', 'CYP2C8', 'cobalt chromium', 'low molecular weight heparin', 'Cockroft-Gault', 'dacarbazine', 'sodium glucose cotransporter', 'polyethylene', 'CCR5 antagonist', 'Sinemet', 'incretin analogues', '[', 'albumin preparations', 'HDAC inhibitors;|Known allergy', 'taxane', 'postmenopause', 'systemic hormonal therapy', 'Mirabegron', 'contrast medium|Patient under legal', 'PARP inhibitor', 'anti-myeloma treatments', 'opioid analgesic', 'drug metabolizing enzymes', 'gemfibrozil', 'CYP2C8 inhibitor', 'hospice', 'Underaged', 'cytotoxic chemotherapy drugs', 'Assent', 'LMW heparin', 'amitriptyline', 'neuroactive prescription medications', 'suppository', 'components of peritoneal dialysis fluid|Complicated', 'basal-bolus insulin therapy', 'anticoagulant therapies', 'diabetes;|Patients', 'furquintinib', 'local Ethics', 'pursue IUT', 'Global Initiative', 'including:|Metformin', 'certolizumab', 'long-acting dihydropyridine calcium channel blockers', 'months|Significant', 'opioids.|Proton pump inhibitors', 'discipline', 'methylated drugs progress', 'drugs of similar chemical class.|Concurrent treatment', 'sodium phenylbutyrate', 'drugs involved', 'AHOD1331', 'AMI', 'canine', 'NTRK2', 'beta', 'NPDR', 'HBs Ag', 'anthracycline-containing polychemotherapy regimens', 'inhaled steroids.||High dose', 'nicotine gum', 'mebeverine', 'antidepressant therapy', 'African Americans||Inclusion criteria', 'ocular antimicrobial solutions', 'CYP3A4 potent inducer', 'vaccine administration.|5', 'over-the-counter products', 'oral warfarin', 'Evaluation', 'pantoprazole', 'ozanimod', 'mechanical ventilator support after surgery', 'Flourish HEC Vaginal Care', 'drugs (anticoagulation therapy', 'Zavicefta', 'dynamic', 'terminal ileum', 'immediate life-saving', 'thiopurines', 'anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery', 'nicotine inhalers', 'vinca alkaloid', 'skin medication', 'PCO2 in arterial blood', 'influenza-related respiratory symptoms', 'components of investigational drug;|Indications', 'toremifene', 'lovenox', 'constraints', 'human-derived protein', 'supportive periodontal', 'topical steroid injections', 'cevostamab', 'AXL', 'acetylsalicylic acid', 'tislelizumab', 'lithium', 'drug targeting T-cell', 'components of BCD-100 or', 'scalp reduction', 'major abdominal', 'antiepileptic drugs', 'atezolizumab', 'Local Anaesthetic medications|Abnormal', 'docetaxel).|Distant metastases', 'rTMS', 'hairs', 'implanted medication', 'implant', 'Chlorambucil', 'narcotics', 'BMD treatment', 'variant', 'glitazones', 'benzoic acid', 'Ceftriaxone', 'hormonal contraceptive', 'MAO inhibitors', 'TTE', 'protease inhibitors boosted', 'nephrectomy', 'amantadine', 'IL-36R) inhibitors', 'multivalent influenza vaccines', 'permanent material', 'vasoactive medications', 'topical lubricants', 'ticagelor', 'articular reconstruction', 'systemic beta agonist).||', 'wine', 'bile acid diarrhea|Compromised immune system', 'strong inhibitors of P-gP', 'Meperidine', 'puncture tissue', 'ROBERT', 'antipsychotic medications', 'related medications', '≥6.206', 'concomitant medications', 'anti-PD1', 'thymidine', 'epinephrine', 'immune hemolysis', 'nerve tissue', 'intravenous administration of diuretics|Any injection fraction', 'agents used in the study.|In the opinion of the treating Investigator', 'RAD52', 'alpha blockers', 'opiates used for a reason', 'iodine containing', 'steroids-', 'Ontario', 'narcotic analgesics', 'atropine sulfate', 'soluble guanylate cyclase stimulators', 'antimicrobial agents', 'neurological disease;|history', 'sodium nitrite', 'antibody targeting the T-cell co-stimulation', 'PhQ9', 'evolocumab', 'Otoneurologist', 'OCTA images||', 'FI', 'anti-donor HLA antibody', 'CDSS', 'drug ingredients', 'ensifentrine', 'CBTi|Self-reported', 'SSRIs', 'long-acting beta-adrenergic', 'systemic anti-neoplastic', 'oxaliplatin-containing', 'mTOR inhibitors', 'drug related toxicity', 'anti-tumor activity', 'antiplatelet anti-coagulant', 'mepolizumab', 'potent systemic inhibitor', 'Soluble CEA', 'anti-coagulant medication', 'oral anti-androgen', 'anti-histamines', 'HS', 'nimotuzumab', 'MRF', 'mycophenolate mofetil', 'Ethosuximide', 'Endoscopist', 'immunoglobulin preparations', 'polyisoprene only', 'syphilis antibody', 'IUGR', 'atezolizumab-bevacizumab', 'Sleep Number® bed.|Subjects', 'selective beta-blocker', 'Corticosteroids', 'cerebellum', 'anwser', 'voids', 'Neisseria meningitidis', 'chemotherapeutic drugs', 'NRIs', 'ICIs', 'TDT', 'potassium-competitive acid blocker', 'cabotegravir', 'medication known to substantially affect sleep', 'fructan', 'semaglutide', 'BYON4228', 'anti-CD20 monoclonal antibody.||Subjects with transformed FL', 'someone', 'anti-depressive medication', '|Systemic steroid therapy', 'amikacin', 'migraine headache', 'Ensifentrine', 'non-steroidal anti-inflammatories).|Chronic use', 'neurological problem|Any contraindication', 'suppressant medication', 'zanubrutinib', 'component of the study regimen', 'Classic AFE', 'antipyretic', 'opioid drugs', 'fracture)|Systemic illness|Subacromial', 'egg', 'CNS)-active medications', 'remains blinded to', 'compounds of similar chemical or biological composition to calcipotriene', 'PSP', 'non-vaccine', 'corticosteroid medication', 'nicotine addiction),|Regular treatment', 'Famitinib', 'Patients:||Female||Ultrasonographic', 'immunosuppressive drug', 'regional lymph node', 'cutaneous lichen planus lesions', 'radioactive iodine', 'misunderstanding of instructions|severe cardiac', 'age;|Pseudophakic', 'immunotherapeutic agents', 'angiotensin converting enzyme (ACE) inhibitors', 'TKA', 'seafood', 'valproate).|Pregnant', 'microscopy', 'months.||Patients', 'antispasmodic', 'conventional silicone', 'Thymoglobulin®', 'disinfectant', 'Oral hydrocortisone', 'Cytokines', 'spermicide.||• Sexual abstinence;||Effective from the first administration of entrectinib', 'NAGLU', 'glyburide', 'orlistat', 'haemorrhoids', 'MET', 'immunomodulating drugs', 'compounds of similar chemical or biologic composition to ACTOplus Met', 'L-histidine', 'muscle relaxants', 'acid sequestrants', 'anti-OX40 antibody', 'systemic steroid', 'psychedelics', 'local guidelines', 'calcium channel blocker medication use|Monovision', 'allowed.|Routine blood tests', 'malaria drug trial', 'Firefly', 'proton pump inhibitor - PPIs', 'physiological corticosteroid replacement therapy', 'GMC', 'immediate local treatment.|Previously treated', 'components of the study medications', 'anti-rejection medication', 'CDK2/4/6 inhibitor', 'physiologic corticosteroid replacement therapy', 'procedure|carotid stenting', 'assessment', 'biologic DMARDs', 'edoxaban', 'nucleic acid amplification test', 'medications influencing cognitive functions', 'anti-IgE (', 'Topical ophthalmic antibiotics', 'scopolamine', 'Accutane®', 'contrast material).|Have', 'Molecular', 'bisphosphonate drugs', 'ICDs', 'doxorubicin≥360', 'carnitine', 'manage insomnia', 'ET', 'TCS', 'neuroimaging.|Time', 'immunosuppressive doses', 'Neoplasm', 'stimulant', 'immunotherapy agents', 'MR|MRI unsafe implants', 'psychotropic medication', 'ophthalmic antibiotics', '5 - aminosalicylic acid', 'topical dermatologic', 'low molecular weight', 'Anti-VEGF injection.|Tractional macular', 'operationalized', 'cephalosporins', 'osteofascial compartment syndrome;|Structural bone', 'LA) enlargement', 'study drug.|Is', 'inactive vaccines', 'magnesium stearate', 'IIa', 'southern hemisphere season', 'OR|primary mediastinal', 'vitrectomy', 'centers.|Inadequate', 'Total Insulin', 'hyperforin', 'Danacol', '3rd degree', 'anastrozole', 'HDAC inhibitors', 'propofol pharmacodynamics', 'component of MRG002', 'drugs that could influence sleep patterns', 'chemotherapy regimen', 'NSAID', 'ASCT', 'fallopian tubes', 'epirubicin', 'olanzapine', 'PDS', 'steroidal/non-steroidal anti-inflammatory', 'high potency', 'special diets', 'nonsystemic steroids', 'antiplatelet agents.|Able to communicate adequately', 'Sodium-dependent glucose', 'iodine contrast agents', 'human regular', 'drugs used in this program', 'ultrasound contrast medium', 'Electrodesiccation', 'ileocolic', 'Itilima', 'chemical drugs', 'immunosuppressive medication', 'sodium-glucose-cotrasporter2-inhibitor', 'abductor pollicis brevis (APB)', 'UC3', 'intravenous steroids', 'Costa Rica', 'emergency cesarean', 'hyaluronic acid implants', 'duration|Insulin pump', 'anti-allergic medication', 'ranitidin', 'old,|pregnancy', 'low-dose', 'steroid drugs', 'aminolevulenic acid', 'anti-platelet aggregation agents', 'TNF-α inhibitors.|Women of childbearing potential', 'SGLT2 inhibitors|Severe hepatic impairment', 'nicotine-free', 'COVID vaccine', 'sunitinib malate', 'receptor blockers', 'Lidocaine Hydrochloride Injection', 'prescription drugs', 'MCA', 'monoamine oxidase inhibitors (MAOIs)', 'L1 inhibitors', 'Paracetamol', 'hybrid closed loop system;|Currently', 'chemo', 'nicotine substitutes|Active', 'enoxaparin', 'FBM', 'luekotriene receptor antagonist', 'mexiletine', 'anti-depressant', 'epinephrin', 'active substance', 'CAR-T therapy', 'DQB1', 'components of the investigational product', 'Anti-PD-1 antibody', 'poly-L-lactic acid', 'pelvis', 'subunit recombinant vaccine', 'Oral steroids', '≤5 oral antidepressant treatments', 'neostigmine', 'percentage', 'ciclosporin', 'Seventy', 'cytoreductive agents', 'toxin-induced', 'herbal remedies', 'anticonvulsant', 'checkpoint inhibitors', 'Kazakhstan', 'influenza', 'ledocaine', 'adaptive components of ADEPT', 'combined oral', 'parenteral antibiotic therapy', 'folic acid drugs', 'departments', 'medications used in the study.|psychiatric disorder.|ASA', 'interventional drug clinical trials', 'valacyclovir', 'electrodesiccation', 'fosphenytoin for', 'CDK2 inhibitor', 'newer generation DES', 'direct oral anti-coagulants', 'STEPCARE neuroprognostication substudy', 'dopamine nitrate', 'Sotalol|4', 'KRAS G12D inhibitor', 'creatinine', 'Lymphoid Tissue tumors', 'venous access', 'Dexcom G6', 'anticholinergic correctors|Pregnant', 'Luteolin', 'local anesthesia', 'Definity ®', 'immunosuppressive-dose', 'rectum', 'Leukemic phase', 'strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9', 'psychostimulants', 'HIV-2', 'triglyceride', 'systemic glucocorticoids', 'ICS/LABA', 'norepinephrine reuptake inhibitors', 'conventional otoscope', 'combination regimen', 'smart phone', 'conventional CT|Admitted', 'TNFα', 'Patellofemoral', 'component of the tested product', 'fast acting insulin analogues', 'nerve blockers', 'anti-resorptives', 'parenteral nutrition,|Metabolic disorders', 'mineralocorticoid antagonist therapy', 'metabiotics', 'H2 blockers.|Prokinetic agents.|Medications', 'administration|Pregnant', '5 millimeters', 'subluxation', 'mofetilmycophenolate (MMF).Steroid resistance', 'nickel', 'systemic steroid medication', 'nasal swabs collected', 'vaccine products', 'Maxilene', 'abiraterone acetate', 'DMT', 'hormonal drugs|In', 'conventional medical treatments', 'Cladribine', 'monoclonal antibody/components of the study intervention', 'urine', 'nitrates', 'erythromycingemfibrozilsimepreviramiodarone', 'Decitabine|positive for HIV', 'benzimidazole compounds', 'immunosuppressants.|Patients with', 'drugs used in this study.||3', 'conventional chemotherapeutics', 'anti-IgA.|Failed', 'nystagmus', 'oral contraceptive pill', 'daratumumab', 'Quinolone', 'nitrate containing medications.|Beta blockers', 'haemorrhage', 'components of Nutridrink Compact Protein', 'caffeine-containing substances.||Loss', 'study-related procedures/medications.|Previously enrolled', 'ribavirin', 'methylsulfonylmethane (MSM)', 'direct acting oral anticoagulants).|Chronic hypertension', 'TNF inhibitors', 'C7 by indirect immunofluorescence (IIF)', 'dopamine receptor blockers', 'anti-seizure', 'Deep Venous Stenting.||', 'beta2-adrenergic agonists', 'calcineurin inhibitor', 'actigraph', 'SFA', 'Remifentanil', 'nicotine replacement therapy|2', 'antihistamines', 'cytostatic|Active cancer|Liver', 'gemtuzumab ozogamicin', 'exam gloves', 'Regafenib', 'atypical antipsychotics', 'punctum plugs', 'systemic antibiotic therapy.||Active', 'prasugrel', 'Influenza vaccinations', 'EPO)/interleukin-11', 'triptans', 'long-acting injectable antipsychotic', 'vitamin supplements', 'contraceptive diaphragm', 'phytosterols', 'Gynecology', 'influence serum lipids', 'anisometropic', 'Topical Janus kinase', 'anti-HER2 therapy', 'hormonal contraceptives', 'contraindicated drugs related to this trail|Patients who take', 'long-acting antipsychotics', 'aspirin-containing products', 'CYP2C9 substrates', 'dabigatran', 'Cisplatin-containing', 'solid organ transplantation;|Patients', 'allogeneic tissue/solid organ transplant|Prior malignancy', 'low-grade glioma', 'Local readings', 'Grapefruit', 'ASMs', 'HDAC inhibitor', 'intravenous corticosteroids', 'bariatric surgery)|Congestive heart failure', 'single drug expansion stage', 'Avelle™ NPWT|Subject', 'growth hormone.|Smoking|Known rheumatoid disease', 'orthostatic hypotension|Patients', 'phenothiazines', 'anti-osteoporosis therapy', 'anti-HER2 therapy|Documented', 'PBM', 'vincristine', 'Chlorothiazide', 'contrast-enhanced MRI', 'Lisinopril', 'osteosynthesis', 'mRNA drugs.|Have', 'nonspecific alternative therapy', 'steroidal drugs', 'Xarelto®', 'IFN-γ inhibitors', 'immune-related adverse event(s)', 'medications the Principal Investigator (PI) believes may interfere with healing of the target DFU|Subject who', 'ANY anticoagulants', 'institution', 'dysplastic syndromes', 'transmucosal (TM)', 'systemic corticosteroid 10 days before injection', 'raltegravir', 'anti-retroviral drugs', 'arirprazole', 'anti-tumour necrosis factor [TNF] agents', 'noradrenaline', 'agonists', 'drugs simultaneously', 'enrollment;|Therapeutic antibiotics', 'prolonged corticosteroid therapy', 'anti-cancer regimen', 'intravenous anti-infective', 'Ropivacaine', 'nasal sprays', 'contraceptive patch', 'contrast material|Uncorrectable coagulopathy', 'immune suppressant', 'local steroid', 'predefined medications', 'systemic therapies', 'Oral fluorouracil drugs', 'week|Antihypertensive medication', 'corticosteroid injection', 'foretinib', 'long-acting biological therapies', 'periocular corticosteroid', 'antineoplastic agents', 'anti-tumour necrosis factor', 'diabetic agents', 'local anesthetic drugs', 'systemic antibiotics', 'biological agents', 'hyaluronic acid|Hematologic', 'non-cardiological serious surgical intervention', 'amide anesthetics', 'full sibling', 'stimulants', 'anxiolytics', 'monoclonal antibody monotherapy', 'various', 'dentin', 'systemic immunomodulating therapies', 'PDE-5-inhibitors|Clinically', 'others beta-lactams|Patients', 'orthodontic retainer.||Participant', 'are:||systemic contraceptives', 'prescription pain medications', 'xanthine-containing products', 'topic', 'carvedilol', 'ticlopidine', 'meninges', 'Anyone', 'immunosuppressive drugs|previous', 'components of the TXA formula', 'microcrystalline cellulose', 'eyelid', 'Class III anti-arrhythmic drugs', 'cRP', 'drug-drug interactions', 'anticholinergic medications', 'basata', 'Lansky Play-Performance Scale', 'writes', 'inulin', 'local administration', 'anabolics', 'clindamycin', 'tricuspid valve|Patients', 'fludrocortisone', 'polylactic acid', 'topic steroids', 'local anesthetic allergy|Patients', 'ayahuasca', 'fluoropyrimidine', 'anti-relapse therapy', 'ophthalmic steroids', 'calcinrurin inhibitors', 'CPK', 'cumulative number', 'Folic acid', 'Accompanied', 'EHS', 'prescription medicines', 'domperidone', 'probiotics', 'tyrosine receptor inhibitor', 'lithium disilicate', 'intraarticular steroids', 'pancreatic', 'TU2218', 'compounds of similar chemical or biologic composition to tomivosertib', 'intravenous alimentation', 'tissue engineered', 'Delegates', 'Ramucirumab', 'Paris', 'Atenolol', 'HA.|To treat', 'VTAMA', 'medications (NSAIDs', 'booster agents', 'contrast agent', 'landline', 'immune-oncology agent', 'erlotinib', 'adenosine pathway', 'anti-inflammatory drugs', 'pro-/prebiotics', 'cumulative total', 'ICD-10]', 'MCS device', 'anti-cancer treatment', 'compounds of similar biological composition to HSV-1', 'monoamine oxidase inhibitors [MAOIs]', 'immunoglobulin A', 'blepharospasm', 'serotype', 'opioid medications', 'angiotensin receptor blockers (', 'lesbian', 'pyrrootinib', 'neuropsychiatric', 'arcuate', 'fast acting insulin', 'amide-type local', 'anti-hypertensive medication', 'investigational ER-directed therapy', 'opiate', 'IV).|If analgesics', 'antidepressant medication', 'midline shift.|Known arterial condition', 'components of the masticatory system', 'topical prescription ophthalmic drops', 'obstetrics', 'vitals signs', 'acenocoumarol', 'higher potency', 'ATD', 'components of tea tree', 'flavonoids supplements', 'type of psychotherapy', 'anti-tumor necrosis factor (', 'antirheumatic drug-inadequate responder', 'mesothelin-directed antibodies', 'DS252A', 'medication abuse|Pregnant', 'local anesthetic|Pregnant', 'Zmachine', 'Pramlintide', 'Diabeloop', 'Territories', 'onasemnogene abeparvovec|Clinically significant abnormalities in laboratory test', 'chronic medications', 'Factor IIa inhibitors', 'bictegravir', 'antipruritic drugs', 'components of the topical medical device|Participation in another clinical trial', 'applied steroids', 'good oral hygiene|Medically', 'monoclonal antibodies;|Patients', 'D0', 'sympathicomimetic medication', 'suxamethonium', 'immunoglobulin isotype', 'Celebrex', 'pioglitazone hydrochloride', 'systemic immunomodulate treatment', 'povidone', 'murine protein-containing products', 'dominant strabismus', 'selective beta blockers', 'anti-fungal', 'anamnesis', 'components of the treatment.|Clinically significant', 'environmental toxins', 'antiepileptic drug use intracranial metal', 'antibody drug-conjugate', 'local anesthetic used|morbid obesity', 'regional disease|Unable to undergo MRI', 'topical glaucoma medications', 'Magnesium', 'TKi', 'endometriosis purpose;|Gastrointestinal', 'Archamps', 'immunosuppressive drugs|Signs', 'tobacco-', 'Gd-DTPA', 'acezotocin', 'anti-viral medication', 'Mellaril', 'Monoamine oxidase inhibitors [MAOIs]', 'S-MRI', 'confirmatory antibody-pattern', 'crisaborole', 'alpha-adrenergic antagonists|patients', 'dihydroxyacetone', 'peptide 1 (GLP-1) receptor agonists', 'Cannabinoids', 'months|Congestive heart failure|Serum', 'acting beta2 agonist (LABA)', 'anticoagulation', 'low-grade psoriasis', 'component of the investigational drug;|Pregnancy', 'hands', 'immune tolerance induction (ITI) therapy|have a known', 'secukinumab', 'direct injection', 'T2 mapping non-contrast sequences', 'vedolizumab', 'inhaled insulin', 'hazelnut', 'steroidal anti inflammatory drugs', 'Telithromycin', 'Hopkins', 'endocrine abnormalities|Patients', 'CYP17 enzyme inhibitors', 'ACE inhibitor', 'medication use', 'tofacitinib', 'Berger', 'alpha-linolenic acid-containing substances', 'men|Negative 4th generation', 'Exenatide', 'Epidermal growth factor receptor (EGFR)', 'High Tibial Osteotomy', 'IUD contraception.|Patients', 'arbidol and', 'anti-glaucoma medications', 'pembrolizumab excipient', 'Seekonk', 'BCaTa-T4', 'anabolic steroids', 'BCL-2 inhibitor', 'full-dose', 'aspirin containing', 'screening|BCVA', 'varenicline', 'surgery|Target MAP', 'PD-1 antibody therapy', 'radioimmunoconjugate', 'gemfibrozil)|High-dose niacin', 'Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitor', 'injectable contraceptives', 'auriculotherapy', 'proton pump', 'simvastatin', 'stereotactic radiotherapy', 'Yakult.|Abnormal liver', 'cyclin-dependent', 'cyclophosphamide', 'drugs structurally similar to fenofibrate', 'steroids & benzodiazapines', 'frontal cortex|Subacute stroke|Age', 'Statin', 'eyes', 'combined angiotensin-converting enzyme inhibitor', 'medications inducing constipation.|Pregnancy', 'Rituximab', 'Glycerin', 'anti-depressants', 'antiplatelet therapy|thrombophilia|contraindication to endovascular revascularization', 'bisulphite containing drugs', 'DC-CIK', 'carbetocin', 'Heplisav', 'neck irradiation', 'local requirements)|Age', 'angiotensin receptor blockers (ARB)', 'exon 14 jump mutation', ""catecholamine-releasing paragangliomas|Parkinson's Disease|Epilepsy|Pregnancy"", 'adequate organs', 'Eltrombopag', 'monoclonal antibody drugs', 'vitamin K deficiency', 'SGLT2 inhibitor family drugs', 'anti-sperm antibody (+)', 'Mitomycin C', 'milk proteins|Currently prescribed', 'components of study drug', 'immunosuppressive agent', 'digestive ostomy.|Decompensated', 'carb', 'b-DMARD', 'Symmetrel®', 'Sarnat scoring system', 'hypertension medication', 'non-steroidal anti-inflammatory therapy', 'Raltegravir', 'conventional anticoagulation treatment', 'hair growth', 'oral iron chelation', 'pain medication', 'traditional Chinese medicines', 'vasopressor', 'Reamberin', 'involves mutilating surgery', 'low-level laser therapy', 'rivaroxaban', 'IST agents', 'SBE', 'anti-AAV9 neutralizing antibody', 'intraocular', 'kidney malfunction', 'oral paracetamol', 'anticoagulation medication', 'components of the product', 'Spironolactone', 'medium or greater depth chemical peel', 'darbepoetin', 'anti-DKK1', 'vitamin-mineral supplements', 'components of the drug', 'etoposide therapy|Subjects', 'Thyroid disorder|Liver disease|Kidney', 'Gynecologist', 'amide type local', 'spironolactone', 'midazolam', 'oral hygiene measures', 'anti-depressant treatment', '/chlamydia', 'stenting', 'Tucatinib', 'genetically-modified T- cells', 'long-acting beta', 'Midline', 'refractive surgery|Ocular', 'chemotherapy.|Testosterone', 'contraindicated combination drug', 'local anesthetics|Those with', 'neuromuscular disorder.|Patients', 'mesalamine', 'vomiting)|Chronic', 'intranasal influenza vaccine', 'GLP1-', '6-mercaptopurine', 'gynecology', 'CAG', 'mitomycin', 'SPRMs', 'anti-epileptic treatment(s', 'milvexian', 'hypomethylaing agents', 'IVT injection', 'hypokalemic drugs', 'defactinib', 'etiology', 'single agent anti-platelet therapy', 'trastuzumab plus', 'ocular anti-VEGF product', 'ipilimumab + nivolumab', 'gastric pancreatic', 'placebo', 'signe', 'Methamphetamine', 'Hematology', 'sitagliptin', 'anti-T cell immunoreceptor', 'immunosuppressant medications', 'TCR', 'medication used', 'dihydroergotamine', 'Dynamic hip screw).||', 'Intranasal', 'amide local anesthetics|History of epilepsy', 'component of rhBNP;|Participated', 'antihyperglycemic agents', 'intravenous general', 'inhaled glucocorticoids|A brief course of corticosteroids', 'hysterosalpingogram', 'immune response.|Any surgical procedure', 'efavirenz', 'anti-obesity medications', 'antihypertensive drugs to control blood pressure', 'Antidepressant Treatment', 'topical carbonic anhydrase inhibitors', 'Regorafinib', 'sodium cromoglycate/nedocromil', 'left ventricular assist devices', 'bolus insulin', 'multivitamin supplements', 'iodine contrast', 'etc.);|Immunosuppressive drugs', 'Aspart', 'medications used in this study.|Pregnancy', 'amide-type anesthesia', 'older|Baseline estimated daily total', 'cannabinoid products', 'enteral', 'caplacizumab', 'oral drug absorption', 'Leucovorin', 'components of the tested device', 'SASP', 'regional anaesthesia', 'drug dependence.|Participants', 'prokinetic agents).|HV', 'drugs required in the test;|Patients', 'Benadryl).|Caffeine', 'classes online', 'DMS 5|Never', 'medications that affect(s)', 'semi-quantitative test', 'benralizumab', 'immune-mediated diseases', 'FOLFOX', 'dissecting', 'components of injection', 'surgery', 'Oral Steroids', 'food supplements containing NAD+ precursors', 'feminine hygiene', 'component of the Trivalent', 'growth factor support|Absolute neutrophil count (ANC)', 'MR).|Patients', 'N+patients', 'tricyclic antidepressant', 'basal-', 'equivalent)|Local steroid', 'preservative-free', 'loratadine', 'immunosuppressive therapy;|pregnancy;|breastfeeding;|allergy', 'RP2', 'taxane doublet.||Neoadjuvant chemotherapy', 'anti-cholinergic agents', 'components of the formulation used', 'otalgia', 'CFRD', 'hetrombopag', 'oral antibiotics|No', 'procedures)|Oral antibiotic', 'polyurethane', 'cephalosporins AND|The', 'migraine after', 'PHGG', 'Internet access', 'age|Indication for surgical extraction', 'pertuzumab', 'anti-epileptics', 'balsalazide', 'inhaled anticholinergics', 'conventional implant maintenance protocol;||(iii', 'Polymyxin', 'Thiazolidinedione', 'LMD', 'PLA2R auto-antibody', 'piroxicam', 'non-prescription drugs', 'gastroprotective medication', 'Psychotherapy', 'orthokeratology', 'disallowed medications', 'analog', 'BCG', 'adjustments', 'anti-diarrheal drugs', 'hormone anti-tumor therapy', 'medication use that contraindicates', 'rifabutin', 'Fridericia formula', 'NDRIs', 'sotorasib', 'bosentan', 'topical or', 'avatrombopag', 'testosterone', 'taurine', 'Systemic Therapies', 'medications introduced', 'intraocular tumors', 'arotinib', 'intramuscular steroid', 'upadacitinib', 'antiplatelet aggregation therapy', 'anlotinib', 'microglia activation metrics', 'deficient mismatch repair (dMMR)', 'Amnesteem', 'local anesthetic allergy,|Coagulation disorder,|Morbid obesity', 'allogeneic', 'excluded.|Pregnant', 'nicotine consumption', 'vasodilators', 'CYP2C9 inducers', 'CYP3) inhibitors', 'atropine drugs', 'investigational drug under investigation', 'medications known to be associated', 'sessions', 'subcutaneous immunoglobulin', 'malignancies;|Patients judged by the investigator', 'soluble guanylate cyclase (sGC)', 'psychotherapy', 'Detemir', 'monoclonal antibody therapies', 'all||', 'drug-related toxicity.|Known', 'Polysorbate', 'blood products', 'monoclonal', 'anti-fatigue agents', 'psychiatric medications', 'radiation|alcoholics', 'Sodium hyaluronate', 'Curcumin', 'opioid analgesic medicine', 'including||immunosuppression', 'soft tissue lesion', 'steroids used solely', 'non-steroidal anti-inflammatory drugs.|Pre-', 'give birth', 'iodine', 'inconclusive molecular diagnosis', 'live viral non-replicating vaccines', 'Ventricular Assist', 'cefoxitin', 'anticholinergic drugs', 'Fc fusion proteins', 'metyrapone', 'gastric balloon', 'higher)|Children', 'ADHD medications', 'haemophiliacs', 'medications used in this study.|Neuro-muscular', 'Lunelle', '5-minute Apgar score', 'give blood', 'oxaliplatin', 'antitussive medication', 'tamoxifen alone', 'drink rich in xanthine', 'etravirine', 'MZL', 'investigational agents', 'interferon', 'lidocaine hydrochloride|Free from musculoskeletal injury', 'physiologic glucocorticoids', 'erythropoietin-stimulating drugs|Infections', 'Italy||', 'CCR5 + by IHC', 'medications contraindicated', 'propranolol', 'ARIs', 'elotuzumab', 'FLT3 ITD', 'immune suppressive medicine', 'defactinib|Defactinib', 'cytokine release syndrome (CRS) event|Symptomatic', 'oral iron', 'anti-wrinkle products', 'blood derived medications', 'local anaesthetic agents', 'compounds of similar chemical or biologic composition to magrolimab', 'medications used in this protocol', 'geriatrics', 'GU', 'immune-related disorders', 'contraceptive barriers', 'edoxaban otamixaban', 'interventional devices;|Severe cardiac', 'distal MCA segments', 'β-blockers.|Patients', 'resident anaesthetist', 'ANC counts', 'panitumumab', 'mineralocorticoid receptor antagonists', 'type of gastrocsoleus lengthening', 'dasatinib', 'inhibitors of complement factors', 'intravenous antibiotics', 'oseltamivir', 'opioid treatment', 'memantine', 'stable medication regimen', 'immune response modulators', 'progestin receptor (PR)', 'old|Patients', 'tingling', 'non-steroidal anti-inflammatory agents', 'alternative medication', 'protonic pump inhibitors', 'local anaesthetics|use of medications', 'live vaccine immunisations', 'dilthiazem', 'considered.|SRNS', 'immunosuppressive regimen)|Participant', 'radioisotope tracers', 'anti-cancer traditional', 'CYP P450 3A4', 'thrombopoietin', 'PSAs', '3rd party biopotential electrode.|Having', 'systemic antibiotic', 'human immunoglobulin preparations', 'refractive state.|Pregnant', 'bolus', 'sprays', 'EZH2 inhibitors', 'cytotoxic drug treatment', 'symbiotic supplements', 'asthma,|Took medications', 'anti-tumor drugs', 'dalteparin', 'component of the therapy', 'components of the vaccine', 'porcine-derived medical products;|Those', 'medications used to perform endovascular intervention', 'traditional Chinese medicinal products', 'imatinib', 'exercise tests|Psychiatric disorders|Recent trauma', 'proton pomp inhibitors', 'angiotensin receptor blocker (ARB)', 'silicone adhesive', 'intracerebral hemorrhage|Modified rankin score (', 'eluxadoline', 'arginine', 'nonspecific S-T', 'Oncology (ASTRO', 'NTXMCO-004', 'MIBC', 'stereotactic Body Radiotherapy (SBRT', 'tested drug component;|inflammatory breast cancer', 'antacids', 'light', 'metronidazole', 'neprilysin inhibitor', 'beta-blocker drugs', 'thermopulsation', 'cross midline', 'lung', 'intrauterine contraceptive', 'ABZ', 'anti-anginal', 'intravenous amino-bisphosphonates.|Active infection', 'saxagliptin', 'induction agents', 'Rehabilitation department', 'Systemic antibiotic', 'antihypertensive drugs', 'Monoamine oxidase (MAO) inhibitors', 'milvexian-the end of', 'SAM', 'immune-modulating therapies', 'conventional treatments - both maximally tolerated doses of anti- arrhythmic drugs', 'contraceptive measures described', 'monoclonal antibodies;|Allergy', 'their medications', 'anti-tumor treatment', 'TPO-R agonists', 'Tricyclic antidepressants', 'required|Prior organ allograft', 'greater;|Previously enrolled in this study;|Unable to understand', 'decisions', 'regional sporting', 'anti-CD47 monoclonal antibody fusion protein.|Subjects', 'contraceptive measures to avoid pregnancy', 'AIDS).|Patients disagreeing', 'combined modality chemotherapy/radiation', 'NAC', 'agent targeting vascular endothelial growth factor (VEGF)', 'anogenital', 'nizatidine', 'Paclitaxel', 'IV antibiotics', 'cisatracurium', 'migraine|Participant', 'hypertensive emergency', 'ARB drugs', 'urinary catheter', 'electrophysiological examination|Recurrent episodes of disease', 'vinblastine', 'vitiligo only', 'transfuse blood', 'antagonists', 'deuremidvir hydrobromide tablets', 'platelet transfusions|Solid organ transplant', 'mouth rinses.|Participants', 'tivozanib', 'radiographics', 'strong cytochrome p-450', 'FBT', 'component of the study vaccine', 'Clozapine', 'ionic', 'topical corticosteroids', 'Macrolide', 'PDE5 inhibitors', 'non-study vaccine', 'drug used in this trial', 'anticholinergic treatment', 'PIRADS', 'PTA<40%;|No', 'long-acting ART', 'anti-citrullinated protein antibodies', 'antithrombotic agents', 'anti-viral treatment', 'phosphodiesterase type 5 (PDE5) inhibitors', 'Ambrisentan', 'small', 'tetrandrine tables', 'components of the drug.|Systolic blood pressure', 'topical products', 'None ability', 'anti-microtubules.|Patients', 'iron chelation', 'Fontan-type palliation||Who', 'timolol', 'GLP-1 receptor agonists', 'dexamethasone implant', 'pathogenic', 'medicine', 'component in its formulation;|Hypersensitivity', 'high-concentration', 'components of the', 'barium enema', 'mesoridazine', 'immune checkpoint therapy', 'fish proteins', 'nivolumab/sindilizumab/tirelizumab', 'medication altering GI motility;|Pregnant', 'implantable)|intrauterine device', 'Systemic antibiotics', 'monacolin', 'bloody stool', 'materials used to ""vape"".|Any', 'components of treprolizumab', 'platelet count|Provide informed consent||', 'guardians', 'jawline', 'anti-tumor effects', 'investigational drug/devices', 'doravirine:||Delstrigo®', 'immune-related alopecia', 'pharyngeal', 'Tripterygium', 'podophylotoxin', 'components of the test product;|Disturbed absorption', 'iOB-discordant MZ', 'Systemic corticosteroid therapy', 'salt', 'give informed consent|Pregnancy', 'disease modifying drugs', 'tricyclic anti-depressants', 'carvedilol therapy', 'Metolazone', 'Sumatriptan', 'drug components', 'oral anticoagulation', 'anti-hormonal agents', 'anti-depressant medication', 'ursodeoxycholic acid', 'aminoglycoside antibiotics', 'antiproliferative agents', 'Contraceptive implants', 'prescription dry eye therapy', 'components of the formulation.|The', 'ER targeting agents', 'Low Molecular weight Heparin', 'drug-elimination', '≥20 Gy', 'interference drug', 'diuretics', 'platelet inhibitors', 'oral glucocorticoids', 'ACL', 'drugs used in this study;||(2', 'Synagis®', 'gemcitabine hydrochloride', 'penpulimab', 'micro-discectomy', 'protein drugs', 'immunological agents', 'screening.||Key', 'incentive spirometry|Patients', 'medicine specialist', 'IVT-AFL treatment', 'soft tissue sarcoma', 'CYP 3A4', 'women;|Patients', 'Panadol', 'MINOCA', 'anti-aging therapies', 'etoposide', 'scans', 'components of the study', 'Nimatevir/ritonavir', 'Fludrocortisone', 'coryza', 'monoclonal antibody products.|Pregnancy', 'local-regional therapies', 'drugs altering cardiovascular', 'non-steroidal anti-inflammatory drug (', 'pMMR', 'local therapies||', 'anti-convulsant therapy', 'psychoactive medication|Regular use', 'darunavir', 'sticks', 'SGLT2 inhibitor', 'strong inducers of cytochrome P450 1A2 (CYP1A2)', 'platelet', 'chemical agents', 'days|Excessive caffeine', 'ibuprofen', 'abuser', 'baseline', 'salicylic acid', 'adolescents', 'skin adhesives', 'guanethidine', 'topical immunosuppressive agents', 'steroid replacement', 'TNFα inhibitor', 'antihypertensive medication', 'over-the-counter (OTC) product', 'aciclovir', 'Global Impressions', 'diuretic agents', 'vital signs;|Using sertraline', 'Indapamide', 'taxane regimen.||Key', 'intravaginal', 'albiglutide', 'mitoxantrone', 'low-dose vaginal estrogen', 'anti-Complement', 'components of the study vaccine', 'bevacizumab combination therapy', 'SC immunoglobulin', 'hyperaldosterone', 'leukemic', 'component of test drug', 'administrate milrinone', 'sodium channel blocker (SCB)', 'systemic anti-cancer therapy (SACT)', 'reads', 'group)|Singleton birth|Gestational', 'products containing beans', '3rd (2) line team', 'Latuda', 'kinidine', 'sidabamine', 'diltiazem', 'enrollment.||Narcotic analgesics', 'dimethylacetamide', 'vasodilatory substance', 'mycophenolate sodium', 'opioid substitution therapy', 'riluzole', 'component of test drug;|Patients', 'carrilizumab', 'mirtazapine', 'streptomycin', 'radioactive iodine contrast agents', 'Cerebrolysin', 'day)|Tobacco use', 'Ivirtinib maleate', 'samarium', 'esmolol', 'tobacco products|Vapers', 'exercise', 'immunosuppressants', 'III antiarrhythmic drugs', 'linavir', 'T-DM1.||Patients', 'anti-angiogenic mab drugs', 'prescription pain', 'strong CYP3A4 inducer', 'pelvis restraints', '3rd generation EGFR TKI|No clinical benefit', 'gadolinium contrast', 'caffeine use disorders', 'botanical', 'Lupus Nephritis.|Patients', 'Cabazitaxel', 'coconut', 'H2 antagonists', 'antipsychotics.||Patients', 'age.|Concomitant medications', 'neuroendocrine features.|Prior therapy', 'histamine containing gamma globulin preparations', 'INOCA|Patients', 'hormonal replacement therapy.||', 'cantharidin', 'redifferentiation agents', 'oral hygiene incompatible', 'JAK inhibitors', 'normal hepatic', 'any additional asthma controller medications', 'prokinetic medications', 'immune suppressants', 'LEPR', 'over-the-counter medications.|Use of', 'platelet transfusions', 'lidocaine containing topical compounds', 'components of the study drug/comparator', 'operation', 'corticotropins', 'specialized drugs', 'component of the interventions', 'anti-4-1BB targeting', 'phosphodiesterase type 5 inhibitors', 'thiazide diuretic', 'topical amitriptyline', 'investigational medications', 'drug involved', 'sleep medication', 'total', 'rapid acting human', 'sodium-glucose co-transporter', 'local antiallergic drug treatment', 'dextrometropine', 'Oxytocin', 'hospitalizations', 'grapefruit juice', 'anti-cancer agents', 'BTC', 'clopidogrel;|Previous kidney', 'QuiremSpheres®', 'pharmaceutical compounds', '≤5 elimination', 'acetylcholine/adenosine/nitroglycerine', ""drug delivery pumps.|Subject's"", 'low molecular heparins', 'early', 'Dapagliflozin', 'antipsychotic medication', 'compounds of similar chemical or biologic composition to Sipuleucel-T', 'systemic analgesics', 'contrast media|Ongoing sepsis', 'anti-tumor effect', 'MIE', 'drugs containing the same', 'local anesthetic product|History of wound healing disorders', 'CPI', 'bacitracin', 'systemic antibiotics therapy', 'MDI', 'anti-sclerostin antibody', 'tremelimumab combination', 'NGS testing||', 'age|esophageal', 'systemic medication', 'therapeutic anticoagulants drugs', 'arrived', 'natural products', 'long-acting fillers', 'Hb≥9.5', 'drugs targeting EGFR.|Treatment', 'ADHD.|Are studying', 'psychoactive substances', 'biguanide drugs', 'stimulant drugs', 'PARP-inhibitors', 'Cephalosporin', 'HPV vaccine|Resides', 'sympathomimetics', 'Lorcaserin', 'potassium citrate supplements should discontinue', 'antibody treatments for cancer', 'immunobiological drugs', 'VAR', 'trametinib', 'heparins', 'Medications used to treat neuropathic pain', 'contrast', 'thyroid', 'Chemotherapy', 'interventional radiology', 'live attenuated chicken pox', 'Rapamycin', 'xanthine-rich beverages or foods', 'CRi', 'antiplatelet agent', 'components used in the formulation of the interventions', 'albumin', 'alternative medicine products', 'Anti-resorptive bone agents', 'skyline', 'beclomethasone dipropionate', 'urine drug abuse tests', 'additional readings', 'medications used in the study|Epidural or peridural', 'combative', 'marmalade containing', 'toxins', 'Vitamin K antagonists', 'topical medicines', 'topical nonsteroidal anti-inflammatory drugs [NSAIDs]', 'L-arginine)|Any', '5-HT4 agonists', 'medications;|Insulin-dependent', 'full combined pharmacogenomic profile', 'MPH', 'thermogenic supplements', 'insulin||iv', 'abnormal hematology', 'cerebellar gait', 'antibody-drug', 'compounds of similar chemical or biologic composition', 'neuroleptics', 'lichenoid drug reactions.|Patients', 'carboplatin', 'itacitinib', 'abnormal platelet aggregation', 'Zostavax', 'chronic steroid', 'InterVapor®', 'illicit drugs', 'CD137', 'Postmenopause', 'drugs acting on human uric acid', 'anti-¬CTLA-4', 'ethylhexylglycerin', 'darolutamide', 'beta receptor blockers|Repeated measurement', 'Canada', 'warfarin', 'anti-depressives', 'ketolide', 'oral retinoids', 'titanium cage implant', 'transportation', 'Sculptra', 'potent CYP3A4/5 inducers', 'first cousins', 'local anti-tumor therapy', '-Tyr', 'Dynamic hip screw fixation', 'depot naltrexone', 'IL-1 inhibitor', 'cisplatin o', 'ONS', 'Captisol®', 'ixekizumab', 'peptide-1', 'headphones', 'drug related', 'prevention drugs', 'pregabalin', 'adequate organ', 'Grapefruit juice', 'hydralazine', 'disease.|Systemic steroid therapy', 'immune deficiencies', 'daily medication', 'abuse|Positive for', 'myocardial infarction|Nabilone', 'topical drug products', 'monoclonal antibody component.|Female subjects', 'levamisole', 'Wolff-Parkinson-White', 'prescription drug substance use disorder', 'Disorders|Hemophilia', 'cardiotoxic agents', 'topical ophthalmic medications|Eyelids', 'bullet fragments', 'herbal preparations', 'IR assessments', 'immune modulating agent', 'RO7247669', 'component of the Event', 'delayed gastric emptying', 'eutidrone injection', 'component of the dengue vaccine', 'antibody drug conjugate', 'SQIG', '3rd MTPJ', 'platelet-rich blood', 'kinase inhibitors', 'analgesic medications', 'cardonirimab', 'Sleep Number', 'taurolidine', 'anti-CTLA-4 therapeutic antibody', 'interleukin-2', 'medications prior', 'myocardial infarction|Participant', 'PEG', 'Mediterranean', 'L-dopa-based drug intake parameters', 'oral methotrexate', 'phentermine-topiramate [Qsymia', 'psychoactive stimulants', 'components of the liquid mixed meal', 'homeopathic', 'anti-CD20 monoclonal', 'RP3', 'concomitant medication', 'compounds of similar chemical or biologic composition to any agents used in the study.|History of', 'lepirudin', 'cortisol drugs', 'sindillizumab', 'Mitoxantrone', 'amplification', 'Lovavulo®', 'chronic steroids', 'full-dose oral', 'anti-oxidants;|Regular use of', 'anti-HB viral therapy；|10 IU/ml≤HBsAg≤3000 IU/ml.||', 'SABR', 'antiparkinsonian medications', 'nusinersen', 'hyperbaric oxygen therapy|Cognitive decline', 'dosing:||• Hemoglobin (Hb', 'antidepressant treatment', 'regional anesthesia||', 'polyalkylimide', '+1,-90', 'Osseointegration', 'rheumatic valvular heart disease', 'PUVA', 'compounds of similar chemical or biologic composition to 177Lu-LNC1004', 'alirocumab', 'monoamine oxidase inhibitors activity', 'PCV13 vaccination', 'contraindicates grapefruit juice consumption|allergic', 'hormone herapy;|Prior treatment', 'cladribine', 'local anesthetic medications', 'G719X', 'anthracycline-containing drugs', 'Bisphosphonates', 'nirmatrelvir-ritonavir||', 'oral opioid', 'GPA', 'over-the-counter drug', 'corticosteroid hydrochloride', 'thyroid-replacement hormones', 'cytokine', 'dronedarone', 'M01', 'methylxanthine-containing', 'Mandarin', 'discharge|normal liver', 'rifampicin', 'Iodine', 'antiemetic in combination', 'Xenical]', 'Bebtelovimab', 'Regional', 'drugs that target immune regulatory points', 'vaping', 'narcotic receptor agonists|Taking Monoclonal', 'allopregnanolone', 'branaplam', 'Amoxicillin', 'strong CYP3A4 enzyme', 'Low molecular weight heparin', 'Gynecology criteria', 'human serum albumin;|Hemorrhagic', 'prednisone-equivalent).|Caregivers withdraw', 'basilar migraine', 'residents', 'ketamine Specific', 'study drug components.|Substance abuse', 'augmentation agent', 'parabens', 'Tanshinone IIA', 'Azvudine tablets', 'non-steroidal anti-inflammatory drug', 'methotrexate corticosteroids', 'antihistamine-containing cold remedies', 'realized', 'pradaxa', 'anti-IL5/5R therapy', 'divalproex sodium', 'SGLT2 inhibitors.||Note', 'anti-CD137 antibody', 'Tislelizumab', 'myocardial infarction;|Patients', 'interventional measures', 'sequelae.|Patients', 'mins', 'complicates', 'atazanavir', 'strong inducers of CYP enzymes', 'day', 'omega-3 supplements', 'anesthetic', 'anti-coagulants|Mullerian', 'non-combined chemotherapy', 'clinically;|23', 'Methotrexate', 'wounds', 'fibrates', 'VDS services', 'IEI||', 'Platelet', 'buprenorphine', 'contraceptive methods|Men', 'empirical antibiotics', 'hyaluronic acid injection', 'Clavulanic Acid', 'Neutrophil', 'neuraxial', 'PFTs', 'oral anticoagulation use', 'Enzalutamide', 'anti-asthmatic effects', 'compounds of similar chemical or biologic composition to the treatment', 'CYP2C9 inhibitors', 'ACEI/ARB', 'traumatic origin', 'SGLT-2 inhibitors', 'immunoglobulin products', 'GEP NET', 'herbal remedies|Known', 'VIN', 'medication related side effects', 'local anesthetic bupivacaine', 'component of V116', 'immune system', 'topical antibiotics', 'type 1 diabetes|4', 'genitourinary', 'ultrasonic gastroscopy', 'Lazertinib', 'GLP-1 receptor', 'Gastroenterology', 'analgesics regularly', 'autumn', 'gastric tube', 'secukinumab treatment', 'immune modulators', 'prescription anticoagulation', 'investigational devices', 'ITD', 'adenosine triphosphate', 'anti-parkinsonian medications', 'medicinal products', 'anti-tumor Chinese', 'venlafaxine', 'Inhaled Corticosteroid', 'live attenuated viral vaccine', 'regional anesthesia', 'diabetes medication', '5-MTHF', 'beta-blockers.|Medications', 'immunosuppressive therapy.|Moderate', 'local hormonal products', 'ruxolitinib', 'psychoactive drug', 'peginterferon', 'chemotherapy', 'over-the counter medications', 'medication for obesity', 'Impella®', 'drug use', 'trial-related assessments', 'examine', 'local recurrences', 'drugs chemically related to the investigational product', 'nasal decongestants', 'sequential', 'Rifampin', 'orthodontic appliances', 'contraceptive', 'MPN', 'nonstudy muscle biopsies', 'aromatase inhibitor therapy', 'anti-PTH agents', 'LH-RH analogue.|Metastases', 'TAMs', 'local therapies', 'Traditional drugs', 'PolyCarbonate', 'thereof', 'steatogenic medications', 'vaginal medication', 'hormonal therapies', 'sodium-taurocholate cotransporting', 'dipyridamole', 'IL-6 inhibitor', 'anti-coagulating therapies', 'investigational vaccines', 'contrast medium', 'Express', 'Inhibitors', 'anti-tumor system', 'LNP-containing vaccine', 'antagonist', 'hygiene products', 'endothelin receptor antagonists', 'Penicillin', 'Ticagrelor', 'local steroid injections', 'furosemide equivalents', 'full recovery', 'olive leaves/olive oil|Use', 'anti-cancer chemotherapy', 'Brigatinib', 'components of pembrolizumab', 'Dengzhanxixin Injection，edaravone', 'Sodium-glucose', 'pyrazinamide', 'psychoactive medication|Prior brain injury|Metal in body|History', 'DPP4 drugs', 'vEEG', 'Centers', 'components of NasaClip or', 'antidiabetic medications', 'thyroid drugs', 'agonist', 'Oral Medicine', 'antiplatelet therapy|thrombophilia|active cancer|active autoimmune disease|liver disease', 'cobicistat', 'sugemalimab', 'microscopic blood', 'antihypertensive drugs remained unchanged', 'endostatin', 'investigational vaccine', 'enasidenib', 'histamine H2 receptor antagonists', 'guidelines recommended HF drugs', 'amines', 'fluoxetine', 'ocular medication', 'SOD1', 'conventional immunosuppression|History of splenectomy', 'anti-PD-1(anti', 'diclofenac sodium', 'anxiolytic medication', 'direct acting antiviral', 'neuromodulator medication', 'Cyclosporine', 'sirolimus', 'mescaline', 'non-steroidal anti-inflammatory drugs (NSAIDs once daily or more', 'third-generation EGFR', 'TS:||•', 'materials used.|Participants', 'immunosuppressive medications.|History of collagen disorders', 'Juvenile open', 'medication on', 'morphine', 'blood components', 'local topics', 'stereotactic', 'anti-hypertensive drugs;|Evidence', 'natural remedies', 'Retinoic Acid', 'postovulation methods', 'CBC', 'passive anti-amyloid immunotherapy', 'PPSV23', 'teriparatide', 'GFR)(SRFipsilateral', 'asenapine', 'fine', 'hyperglycemic hyperosmolar state', 'Sotrovimab', 'teropavimab', 'gallstone', 'intrauterine contraceptive devises', 'diagnostic agents', 'nine major vaginal pathogens circulating', 'PDE4 inhibitors', 'analgesic used', 'TBSA', 'Class IA antiarrhythmic medications', 'rivastigmine', 'terfenadine', 'anti-HB viral therapy;|10 IU/ml≤HBsAg≤3000 IU/ml.||', 'flucytosine', 'diuretic|Beta-blockers|Glucocorticoids|Anti-epileptic medications', 'contraceptive use', 'antibody-based anti-SARS-CoV-2 prophylaxis', 'component of the APX-115 formulation.|History of acute kidney injury', 'organ', 'cimetidine', 'maprotiline', 'topical glucocorticoid therapy', 'TMZ', 'conventional DMARDs', 'vascular access', 'tricyclic', 'food supplements containing MSM', 'drugs or foods', 'buspirone', 'immediate local therapy', 'lenalidomide-based', 'acarbose', 'thymosin', 'vasopressin', 'harnesses', '5-HT3 antagonists', 'Benzodiazepine', 'local anesthetic agnets|Previous lumbar spine surgery', 'study drug', 'traditional', 'polyisoprene', 'immune-checkpoint inhibition.|Adequate haematological function:|Adequate renal function:|Adequate liver', 'nimodipine', 'Lenfacitinib', 'nine', 'Alpha blockers', 'components in the eye drops.|Diode laser treatment', 'Caffeine bolus', 'anthropometrics', 'reside', 'nicotine-containing products', 'oral antibiotic', 'months|Neck pain averaged', 'anti-DS-DNA antibodies', 'rescue medication', 'inhaled budesonide', 'spine', 'IMP', 'experimental immunoglobulins', 'drugs containing malate', 'stent material', 'Beta-blockers', 'oral antibiotic intake', 'immunosuppressive therapies', 'role', 'sole substance abuse', 'Ljungman', 'compounds of similar chemical composition to the study drugs.|Pregnancy', 'anticancer drug', 'aspirin', 'siltuximab', 'prostaglandin synthase inhibitor', 'otilonium bromide', 'phosphodiesterase (PDE) inhibitors', 'exosuit', 'live vaccine', 'delavirdine', 'systemic diseases|who', 'dopamine agonists', 'warfar', 'anyone', 'immunosuppressive therapy.|Subjects', 'Eurocrine® database', 'oral pain medications', 'spouse', 'mefloquine', 'allowed.||Patients', 'AI', 'lecithin', 'dialysis||End-Stage Renal Disease (ESRD)', 'grapefruit', 'drugs used in the study.|Infection', 'heparin', 'CYP3A4 inducers/inhibitors', 'strong inhibitor of CYP3A', 'intraprostatic calcifications', 'adjuvant', 'study medicine', 'non-steroidal anti-inflammatory drugs (', 'soft tissue healing', 'interventional studies.|Agrees', 'live-attenuated vaccine', 'anti-CD20 antibody', 'columnar-lined esophagus||', 'components of the IMP', 'Rivastigmine tartrate', 'Fontan', 'contraceptive rings', 'oral agents', 'benzodiazepine', 'immune response', 'nurse anesthetists', 'At rest', 'anti-hypertensive', 'sedative hypnotics', 'pharmacologic agents', 'components of the influenza vaccine.|History', 'motility drugs', 'intravenous steroid', 'oxcarbazepine', 'NOSES', 'Trastuzumab', 'pain subsiding medication', 'hours|FDC', 'tyrosine kinase inhibitors,', 'characterized', 'anti-glutamic acid decarboxylase', 'antidiabetic Drugs', 'liraglutide', 'Lorlatinib', 'TTTS', 'medications used.|Chronic opioid users.|Patients', 'Paclitaxel etc.);|Topoisomerase inhibitors', 'body', 'Posaconazole', 'contrast agents.||Receive live', 'mineral substitution', 'PDGFRβ-fusion', 'somatostatin analog', 'elbow area', 'SCI67', 'Sulfasalazine', 'immune modulatory therapy for autoimmune', 'serotonin norepinephrine reuptake inhibitors', 'interpret material|Outside', 'steroid-', 'sedative medication', 'nonprescription drugs', 'hypopneas', 'OUD', 'drugs targeting V-set', 'IV anti-infectives', 'evaluate', 'radioparticle implantation', 'drug components of this', 'Proton-pump', 'prophylactic antibiotics', 'regional nodal metastasis', 'components used in the AFM28 drug product preparation', 'Investigational medication', 'enoxacin', 'hemorrhagic cystitis|Recipients', 'therapeutic drugs', 'brigatinib', 'fatty acid', 'CYP3A and/or P-gp', 'drugs targeting the same target|Subjects', 'hypotensive drugs', 'blood product', 'psychic', 'nicotine patches;|In the last', 'Gemcitabine', 'injection containing rapid-acting insulin', 'gastric acid suppressing medication|Chronic use', 'heparin compounds', 'lines of vision loss', 'bile acid malabsorption (BAM)', 'influence BMD', 'LA', 'contrast agent;|Renal impairment', 'strong inhibitors of CYP3A4 are', 'agent', 'aerobics', 'medications that alters the', 'anesthetic drugs', 'fibrogenic agents', 'components of the study drug', 'Colesevelam', 'fluoresceine dye', 'non-steroidal anti-inflammatory drug chronically', 'HDAC inhibitor-like activity', 'inhaled corticosteroid', 'orthokeratology lens|With anisometropia', 'sodium citrate dihydrate', 'vaccine-related components.|Prior episode of CDI', 'approved COVID-19 vaccines', 'medications that could interact with vitamin D status|Individuals regularly taking daily Vitamin D supplementation', 'radioactive drug trials', 'fish oil supplements', 'G-CSF analogs|Corticotherapy||Exclusion', 'HBV vaccines', 'folinic acid', 'contraceptive implant', 'non-steroidal anti-inflammatories', 'guide', 'Vyvanse', 'alpha hydroxy acids', 'PFP', 'component of the test device|2', 'L-citrulline.|Participants', 'esophageal varices||', 'BTK inhibitor therapy for MCL', 'anti-anginal agents', 'Lysine', 'research||', 'premedication', 'anti-CD20', 'excisional biopsy', 'levobupivacaine', 'Alcon', 'naloxone', 'nanoalbumin-bound', 'Osimertinib', 'specific drugs', 'Mirapex®', 'toothpaste', 'bypass agents', 'Section', 'Tyrosine Kinase Inhibitor (TKI).|5', 'PD medication', 'IFX was judged by medical history|The disease', 'azathioprine', 'preoperative anti-tumor treatment|Pregnant', 'cryobiopsy||', 'cereal', '3rd metatarsal head (MTH)', 'L', 'phentermine-topiramate (Qsymia)', 'anomalous hemoglobins.|Patients', 'antihypertensive medication|Fasting glucose', 'years|Diabetes mellitus||', 'CTCAE grade', 'salicylate', 'fluoropyrimidine-based chemotherapy', 'Merkel', 'PFT', 'monoamine oxidase (MAO) inhibitor therapy', 'TQB3909', 'migraine drugs', 'angiotensin-converting-enzyme inhibitor', 'systemic anti-infective agents', 'imipenem', 'study drug sintilimab', 'anti-IL-17 antibody', 'anti-retroviral therapy', 'BRACE', 'dipeptidyl peptidase IV inhibitors', 'GLP-1) analogs', 'POAF', 'comparable molecular method', 'vitamin K', 'antidepressants tricyclics', 'bilvalirudin', 'gliadin', 'regimen', 'raw', 'bendamustine', 'iodine-containing drugs', 'parenteral administration', 'clopidogrel', 'organ transplantation|A', 'component of iodinated contrast', 'angiogenic drugs', 'III antiarrhythmic agents', 'asimadoline', 'VEGFR inhibitors', 'oral corticosteroid', 'anti-tumor indications', 'anti-CD20.|ECOG≤2.|Adequate hematologic', 'NMS', 'thrombolytic agent', 'Lenvatinib', 'xanthine diet', 'mycophenolate', 'bilateral', 'antibiotic drugs', 'MAT', 'Realgar-Indigo naturalis', 'i.e.g', 'strong P450 CYP3A inhibitor', 'CXR', 'walk', 'excipients of', 'immunosuppressive medications|Patients', 'increased N-terminal prohormone B-natureitic peptide (BNP)', 'adjuvant components', ""device's components"", 'herbal medication', 'adrenaline', 'anti-PD-1 immunotherapy combined chemotherapy', 'Remdesivir', 'PKMYT1 inhibitor', 'intense pulsed light (IPL)', 'VF assessment', 'alkylating agents', 'lincomycin', 'steroid medication', 'Paramedics', 'months:|systemic antibiotics', 'topical preparations', 'over-the-counter weight loss', 'systemic chemotherapy', 'SSNRIs', 'galantamine', 'over-the-counter NSAID use on', 'open.|Operation transfers', 'alone', 'curatively|Systemic steroid therapy', 'anakinra', 'platelet-elevating drugs', 'thioridazine', 'over-the-counters', 'allogeneic transplant|CML blast crisis|Active', 'inducers - barbiturates', 'vesicant medications', 'months||Baseline', 'inhalers', 'Cocaine (COC)', 'Neisseria meningitidis vaccination', 'C1-INH products', 'immunosuppressive agents).||', 'anti-depressents', ""Drugs|Drugs Used in Parkinson's Treatment|Drugs Used in the Treatment"", 'anticancer drugs', 'iodinated contrast agent;|End-stage renal disease', 'immunosuppressive/immunomodulating drugs', 'monoclonal antibodies.|A', 'defecate', 'swelling||Patients on medications', 'histamine-2 blockers', 'lactic acid', 'St. Joseph Urgent Care Centre', 'Growth factor', 'tablet', 'immunosuppressive drug therapy', 'potassium competitive acid blocker', 'celecoxib', 'anti thymocyte globulin', 'Inhibitors - SSRI', 'histologically', 'booster', 'analgesic medication', 'hydroxychloroquine', 'quinidine).|Concomitant medications', 'aumolertinib', 'Vegan', 'Neonatal Intensiv Care Unit/Pediatric Intensiv Care Unit (NICU/PICU', 'relocate', 'midline incision.||Anticipated incision length', 'complement inhibitor', 'MET amplification', 'hemorrhagic shock|Patients', 'anti-PD(L)1 therapy', 'solids', 'molecular-targeted therapy agents', 'hormonal agents', 'anti platelet aggregation drugs;|Chronic cardiovascular', 'Oral combination products', 'immunomodulating drug', 'monitoring modality', 'Propranolol', 'Sohag Faculty of', 'cannabis-based products use', 'concomitant beta-blockers', 'DPP IV inhibitors', 'neutrophil', 'hepatotoxic medications', 'solutions', 'SLC7A11', 'type of emergency laparotomy', 'bedside', 'PNH', 'retinopathy.|diabetes|hypertension|or', 'inhaled influenza vaccine', 'epilepsy medications', 'topical decongestants', 'wooziness alone', 'intravitreal injection', 'ustekinumab', 'PT>14s', 'anti-CD20 therapies:||Receipt of a live', 'PMS2', 'Gynecologists', 'cholinergic drugs', 'live components', 'CTAP', 'penciclovir', 'component of the cell therapy', 'adenine', 'OTT', '5-Fu drugs', 'ranitidine', 'Indwelling catheters', 'adrenergic stimulators', 'dexlansoprazole', 'HIV-1 protease inhibitors', 'tryptophan', 'conventional dose', 'Bisphosphonates may continue.|Eastern Cooperative Oncology Group (ECOG) performance status', 'Juvéderm® Voluma XC', 'anteroposterior)/CT', 'DOACs', 'ivermectin', 'agents used in the adjuvant standard-of-care regimen', 'varicella', 'ascorbic', 'segmental', 'FEV1≥1.2L', 'non-invasive respiratory support', 'CVD', 'noradrenaline dopamine', 'Dabigatran', 'gemcitabine', 'Marfans', 'aura', 'palbociclib', 'investigational drugs', 'drugs used (nivolumab and ipilimumab', 'RRT', 'pericardium', 'topical steroid', 'mealtime insulin', 'immunosuppressant medication', 'requirements.||-', 'brexpiprazole', 'avelumab', 'immune checkpoint inhibitor therapy', 'herbal medicine', 'beans', 'chemotherapeutics', 'anti-fungal)|evidence', 'rehabilitation regimen', 'including:||VS-6766', 'azacytidine', 'systemic corticosteroid therapy;|Pregnant or', 'Ureteral calculus', 'ketone', 'immune-mediated', 'quinine', 'iT2D-discordant MZ', 'electron microscopy', 'Clomiphene', 'pontine', 'angiotensin receptor blocker|Evidence of subclinical heart failure', 'serotonergic drugs', 'multivitamins containing', 'coumarin agents', 'tricycle antidepressants', 'anti-inflammatory*', 'component of the HeartWatch|Dextrocardia', 'anti-VEGF injections', 'thyroxine replacement', 'vitiligo', 'similar drug', 'drugs used in the treatment of cancer', 'Lurasidone', 'fractures;|23', 'vaccination.|Previous influenza vaccination', 'pituitrin', 'PDT', 'MCL', 'Methimazole', 'eliminate', 'glucocorticoid', 'epileptic seizures,|severe language impairment,|other neurological', 'ER)+/progesterone receptor', 'anti-tumor necrosis factor', 'immunosuppressive treatment.|Anti-phospholipid syndrome.|Fibromyalgia (fibromyalgia will', 'enzyme inducing anti-epileptic medications', 'over-the-counter solutions', 'components of the investigational drug product.|Previous treatment', 'anti-retrovirals', 'MIPSS7021', 'mineral supplements', 'nonspecific chronic', 'NSAID medications', 'components of GVX-002', 'systemic drug', 'OTC drug', 'recombinant human blood product', 'intraoperative administration', 'tamoxifen', 'opioid allergy.|abnormal', 'remdesivir', 'anti-epileptic therapy', 'oral cannabinoids', 'Trieste', 'nucleic acid amplification (NAA) test', 'psychoactive drug regimen', 'DPP4 inhibitors', 'postural', 'immune deficiency|Chronic fungal', 'critical COVID-19', 'drugs Known allergy to the studied medications', 'TAS-102', 'strong CYP3A4 p-glycoprotein enzyme inducers', 'MTrPs', 'direct oral anticoagulant)|Known', 'letaxaban', 'PEB', 'tamponades', 'oral ketoconazole', 'deoxycholic acid', 'thyroxine', 'anti-coagulant treatment', 'chemotherapeutic agents', 'iodine-', 'live-attenuated', 'molecular assays', 'systemic prednisolone', 'anticoagulants|Patients', 'immune system effector proteins', 'anti-CTLA4', 'valproic acid', 'restrict medications', 'clotting inhibitor', 'hysterectomy', 'anti-SARS', 'buprenorphine|Requiring immediate', 'off steroids', 'soft tissue imaging disease progression', 'radio-', 'therapeutic anti coagulation', 'SERDs', 'L-dopa', 'tacrolimus plus', 'LPD', 'applied drugs', 'over-reader|Forced expiratory volume', 'ethylene vinylacetate', 'recombinant thrombopoietin', 'age|Participant', 'cytotoxic chemotherapy', 'mechanical ventilator', 'intralesional corticosteroids', 'amino transferase (ALT)', 'cholestyramine', 'lazertinib', 'Marfan syndrome.|Strabismus', 'dinoprostone', 'transferase', 'strong CYP1A2 inhibitors', 'antipsychotics', 'pharmacologic anxiolytics', 'kidney related growth retardation', 'cumulative tobacco', 'factor VIII inhibitor bypass activity (FEIBA)', 'antipsychotic drug treatment', 'Lanreotide', 'Seasonal influenza vaccines', 'aminoquinolines', 'biologic drug', 'radiographically', 'inflammatory rosacea', 'contraceptive methods.|Metastatic malignant tumors', 'male|Children', 'Selective serotonin reuptake inhibitors', 'anti-obesity medication|No', 'medical grade', 'injectable cyclophosphamide', 'CNI', 'midline catheter', 'antiarrhythmic drug (AAD)', 'reserpine', 'immune globulins', 'drugs of similar chemical classes', 'low-carb', 'steroids', 'homicidal behaviors', 'amiodarone hydrochloride', 'local treatment|Previously treated', 'compounds chemically', 'dopamine', 'combination chemotherapy', 'immune effector cell-associated neurotoxicity syndrome (ICANS)', 'allergies.|Adolescents', 'lactose monohydrate', 'previous anti-tumor treatment', 'lines of TKI therapy', 'Pseudoexfoliation', 'topical steroids', 'antithrombotics', 'seminal vesicles', 'oral naltrexone', 'heterologous vaccine', 'systemic anti-tumor drugs', 'Substages', 'LVAD implant', 'oxiracetam', 'anti-serotoninergic 5HT3', 'sunless tanners', 'RUNX1', 'prebiotics', 'study ingredients|Individuals', 'hypertension medications', 'diltazem', 'mood', 'inclusive)；|Patients', 'Taiwan.|Individuals', 'Live vaccines have been vaccinated', 'glaucoma medication', 'albendazole', 'hormonal systemic therapy', 'Cordarone®', 'Vardiman', 'anti-anxiety medicine', 'Propofol', 'detemir', 'apixaban', 'low molecular weight heparin)|High dose antiplatelet therapy', 'interventional radiologist', 'nonsteroidal anti-inflammatory drugs', 'sedative drugs', 'contrast media 2- Raised', 'systemic anti-VEGF', 'IST', 'tics', 'Ⅳ', 'Normal liver', 'Pentacam', '3rd degree atrioventricular (AV) block.|Bradycardia', 'inducers CYP3A4', 'Seville oranges', 'Clopidogrel', 'avoid drug interactions.|Known pregnancy', 'histopathology;|Disease', 'Toujeo', 'mitomycin C)|Received wide field radiotherapy', 'anti-cancer medication', 'topical corticosteroid', 'anti-obesity drugs|Recent HbA1c', 'Technician', 'childbirth', 'systemic drugs', 'examinations', 'Pembrolizumab', 'abnormalities.||4', 'medication|Insulin user', 'menin inhibitor treatment.||Subjects', 'pelvic', 'fine reticulin', 'PPIs', 'component of the ophthalmic formulation', 'refractive surgery)|Pseudo-pterygium', 'high||', 'antihistamine', 'SF-12', 'UAMS', 'TPO agonist', 'anticoagulant drugs', 'Monoamine oxidase inhibitors', 'anti-HBV drugs', 'tissue expander-', 'toothpastes', 'Cisplatin/Carboplatin', 'chest', 'component of the medicinal product formulations', 'liver disease|Absolute neutrophil count (ANC)', 'medication overuse', 'sodium-glucose cotransporter', 'veins assessed', 'compounds of similar chemical or biologic composition to Piperacillin', 'mRNA vaccines', 'sensitive CYP3A4 substrates', 'operate machines', 'recombinant antibody-related fusion', 'Lispro', 'systemic corticosteroid agent', 'systemic steroid hormones', 'L-dopa|calcitonine|ocreotide|Interferon alfa|sucralsulfate|botulinum toxin injections', 'LVAD', 'Metronidazol', 'allogeneic tissue/organ transplantation', 'mineralocorticoid antagonists', 'lagophthalmos', 'Lutetium', 'lover', 'platelet aggregation inhibitors', 'Mitomycin', 'Remission-1', 'PET)-avid', 'contrast agent allergy', 'ACA', 'ICS with LABA in combination before Screening.||A', 'eltrombopag', 'intravenous anti-infective therapy', 'milk-containing food product', 'anti-tumor vaccine', 'immunomodulating medications', 'later.|Had', 'acetaminophen', 'drug metabolizing', 'decongestants', 'high-dose', 'component of the IMP formulation', 'medications.|Active suicidal ideation.|Risk', 'head-', 'pseudoephedrine', 'blackcurrants', 'vitamin D supplements', 'Crizotinib', 'dornase alfa', 'iron supplementation', 'nicotine containing products', 'faecal calprotectin', 'non-)investigational products', 'Zanamivir', 'study drug||', 'steroid|Taken steroid', 'medium-to-high dose ICS combined', 'contrast dye|non-willingness', 'radiological criteria.|Full-field visual evoked potential', 'lactate', 'immune-associated supplements', 'strong CYP3A inducers', 'anticholinergic agents', 'xanthine oxidase inhibitors', 'proteasome inhibitor', 'risdiplam', 'Tolvaptan sodium phosphate', 'antinuclear antibody (ANA) screen', 'antimalarials', 'traditional herbal treatments', 'teriparatides', 'Carboplatin', 'interferon beta', 'secretagogues', 'anticoagulant', 'ifosfamide administration', 'Metropolitan', 'placenta', 'bovine-derived', 'immunoglobulins', 'COX-inhibitors.|Known malignancy.|Pregnancy', 'Sodium Hyaluronate', 'CM-101 antibody', 'rescue medications', 'Prosigna', 'nasal', 'anti-PD-1 antibody treatment', 'US', '5 minutes after stopping exercise.||', 'thienopyridine pretreatment', 'injection drug', 'dietary supplements', 'de-novo biopsy', 'Poziotinib', 'Phenobarbital', 'Nicoderm', 'blotches', 'supplements|PPI therapy|Known', 'esomeprazole magnesium enteric-coated tablets', 'investigational medication', 'basal insulin', 'over-the-counter medications', 'M3 marrow', 'GLP-1 RA', 'hormonal medication', 'cetuximab', 'agent targeting', 'some drugs', 'authorizations', 'fish oil|Vegetarian|Tobacco smoker|Current', 'Primipar', 'medication known', 'dostarlimab', 'leukotriene modifiers', 'migraine variant', 'anti-arrhythmic therapy|Evidence', 'lumefantrine', 'anti-CD137', 'naltrexone', 'cytostatic drugs', 'compounds of similar chemical or biologic composition to leuprolide depot', 'systemic anti-infective treatment', 'Hypnotics', 'Zilretta)', 'non-insulin', 'quetiapine', 'Ranolazine', 'antiplatelet therapy;|thrombophilia;|active cancer;|active autoimmune disease;|liver disease', 'dimethyldioxyamphetamine', 'RA', 'PPI', 'growth hormone', 'Cabozantinib', 'pediatrics', 'cancer)|connective tissue disease|neurologic disease', 'inhalable steroids', 'human serum albumin);|Patients', 'Prohibited drugs', 'regional nodal RT|No', 'peptide receptor radionuclide therapy', 'anti CD20', 'component of the Investigational Medicinal Product (IMP)', 'Labetalol', 'medication used in the procedure', 'components of the SHAPE test', 'non-stimulants', 'entetrazumab', 'T1D', 'polyene paclitaxel', 'live-virus vaccine', 'anti-coagulant', 'potent CYP 2C8 inhibitors', 'CrCl', 'pyrrolidine', 'tamsulosin hydrochloride', 'contraceptive measures outlined', 'medium-to-high dose ICS.|Subjects', 'intravenous [IV]', 'TIPS implantation', 'low oocyte quality.|Cases', 'maximal pain', 'heart stents', 'anti-platelet drugs|Rescue PCI', 'components of the test dressings|>72 hours', 'RIPC', 'beta -blockers);|Patients', 'narcotic drugs', 'vorinostat', 'hyperosmolar state', 'immediate intervention.|Has', 'hydrochloride salt', 'clofazimine', 'oral prednisolone', 'nicotine patches (Aim 2)|Considered by the investigator', 'topical calcineurin inhibitors', 'nicotine containing product', 'COVID-19 human immunoglobulin', 'medications/supplements/therapies', 'tricyclic antidepressants', 'prone position|Refusal', 'FOG', 'prescriptive medication', 'Argatra®', 'sotalol', 'liver metastases)||Adequate renal function:||creatinine', 'oral corticosteroids', 'prediabetes', 'pelvis|Self-reported', 'Allergology', 'medications exempted', 'dynamic hip screw', 'obinutuzumab', 'parenteral depot corticosteroids', 'myopia control treatment', 'Opiates', 'prescription medicine', 'voriconazole', 'fatty liver', 'cetylpyridinium chloride', 'globe', 'FLT3', 'lenvatinib', 'LVSD', 'anti-osteoporosis medications', 'tenofovir alafenamide', 'anti-inflammatory medication|No weight loss', 'betrixaban', 'nilutamide', 'over-the-counter cold sore', 'immunosuppressive agents.|Participants', 'topical skin treatments', 'severity|Moderate', 'versa', 'Müllerian agenesis).||Exclusion Criteria||Patients are', 'conventional angiography|Undergoing thrombolysis with catheter directed lytics|Clinically sober', 'Alcaine', 'fibromyalgia|Infectious', 'phosphatidic acid', 'Liraglutide', 'retinoic acid', 'Th2 cytokine inhibitors', 'rheumatoid arthritis4', 'human antihuman antibody response', 'components of the investigational', 'daclizumab', 'inhaled tobacco products', 'topical steroids|pregnant', 'Apalutamide treatment||', 'C);|Previous liver', 'gallstones', 'phenothiazine', 'investigational treatment for antecedent myeloid neoplasm', 'CMBs', 'biologic drugs targeting the immune system', 'MPA', 'Gadobutrol', 'Labcorp', 'acromegaly|Active drug', 'ACL reconstruction', 'Bevacizumab combination therapy', 'nitrosourea-containing chemotherapy regimen', 'INR', 'component of the vaccine formulation used', 'OSE-279', 'Intravenous immune globulin', 'carboxylic acid', 'anti-tumor traditional', 'insulin lispro injection)||', 'caffeine-containing food', 'determines', 'Seldane', ""St. John's Wart"", 'cabozantinib', 'contrast media', 'opioid', 'chlorhexidine', 'pathologic', 'power exchange', 'Topiramate', 'U.S. Centers', 'anti PD-1', 'QRS', 'Antibiotic', 'anti-CD20 therapy', 'corticosteroid treatment|Active malignancy', 'components of this medication.|Patients', 'allogeneic HSCT|Patients', 'baloxavir marboxil', 'sulphonamide', 'SSc', 'caffeine-containing foods', 'nucleic acid', 'oriental herbs.|Binge drinking', 'medication malignancy Acute', 'Seromycin', 'disease-relieving drugs', 'anti-hepatitis B agents', 'leukotriene antagonist', 'component of the atezolizumab formulation.||Active', 'examination', 'Tamfu', 'components thereof', 'Corticosteroid physiologic replacement therapy', 'hematopoietic stimulating factor drugs', 'full thickness loss of dermis', 'JAK-inhibitors', 'prednisone equivalent.||Conditions', 'Zestril', 'methamphetamine', '1|Preserved', 'Immunosuppressive', 'medications', 'Inhaled medication(s', 'etc.)|Had oral', 'receive another COVID-19 vaccine', 'iodinated contrast agents|Colorectal neoplasia', 'hybrid closed-loop system.|Current use', 'readings', 'anti-tumor treatments', 'severe drugs', 'SCA1', 'hyaluronic acid', 'sodas', 'antiandrogens', 'St. Jude investigator-initiated study', 'oral anti-diabetic drugs||Adult', 'H2 receptor inhibitor', 'interest|Allergic reaction|wish', 'older|anti-HD-positive', 'components used in the study', 'hyroxycholorquine', 'dantrolene sodium', 'deformations', 'H2 blocker.|Excessive use', 'strong inducers of CYP3A4', 'chronic anti-coagulation treatment', 'antiprotozoals', 'single drug', 'first generation', 'diabetic medications', 'endometrioid', 'medicinal cannabinoid products', 'anti-cancer drugs', '5-fluorouracil', 'IL-17 receptor|Participants treated', 'local anaesthesia', 'tobacco containing products', 'antiepileptics', 'monoclonal antibodies for RA', 'time.|Chemotherapy', 'nuclear medicine gastric emptying study||', 'anticoagulation therapies', 'rhPro-UK', 'anti-sensitivity ingredients', 'hair growth products', 'drugs that could decrease the seizure threshold|Amantadine sensitivity|Cardiopathy', 'anti-epileptic drugs', 'Dehydroacetic Acid', 'semi-permanent', 'injection therapies', 'carbimazole', 'reslizumab', 'PI3Kα inhibitor treatment', 'anti-retroviral', 'GLP-1) receptor agonists', 'prostaglandin', 'GSM', 'anti-psychotic medications|Cognitive impairment limiting', 'cobalt chrome', 'Prednisone', 'magnesium levels', 'adhesives|Chronic pain', 'immunosuppressive drugs.|Receipt', 'medications for sleeping problem|Use of benzodiazepine|Patient with kidney', 'immunosuppressants for', 'components of the study treatments|Any condition, which in the opinion of the investigator', 'drugs abuse.|Prior stroke.|Prior myocardial infarction', 'HIV antibody', 'diabetes|Alcohol-', 'thin', 'component of the formulation.|History of anaphylactic shock.|Presence of', 'transferrin saturation', 'prophylactic antibiotic therapy', 'oesophageal', 'Hismanal', 'ganciclovir', 'H2 receptor antagonists', 'anticholinergic agents|Spravato', 'anti-TNF-a therapy', 'vegan', 'berberine', 'anti-anxiety drugs', 'AGO Guidelines', 'nucleic acid test', 'compounds of similar chemical or biologic composition to any of the study drugs', 'Android phones.||', 'systemic corticosteroid therapy;|pregnant', 'quinolone type drug use', 'prokinetics', 'Sodium calcobutrol', 'antihemostatic medication', 'xanthine derivatives|Severe iron deficiency', 'DTP-containing', 'Centre for International Health', 'immunosuppressive medications|Prisoners', 'BTK inhibitors', 'anti-tumor antibody', 'opioid drugs used in the anesthetic protocol.|Drug', 'Cholestyramine', 'commercial assays', 'IVUS assessment', 'Fluzone®', 'drugs used in the study|Renal insufficiency|Liver failure-Neurological abnormalities', 'SPS before randomization', 'aristolochic acid', 'Dr. Cipto Mangunkusumo', 'thalami', 'OTC analgesic medication', 'Pabolizumab', 'methacholine', 'Hydralazine', 'milk/lactose', 'ECG patch', 'athletics', 'growth factors', 'investigators.|Stable medication regimen', 'the products', 'Factor D', 'arginine hydrochloride', 'receive prednisone', 'hard drugs', 'Global Initiative for Asthma', 'component of the test device|Medical', 'oral glucose', 'uricosuric agents', 'albumin macroaggregate', 'oral contraceptive pills', 'neuropsychiatric symptoms.|Exclusion criteria', 'colorectal cancer|Adequate haematological function', 'inhaled glucocorticoids', 'live viral vaccine', 'fish food', 'Ghanim', 'Interferon', 'Fontan circulation', 'left atrium', 'systemic glucocorticoid', 'mesotherapy products', 'Plavix', 'Glucocorticoid', 'MMR', 'cheekbones', 'high grade NHL', 'Ruxolitinib', 'Regional nodal metastases', 'beta-blockers|Metallic implants', 'dostarlimab components', 'ammonium acryloyldimethyltaurate/vp copolymer', 'Phencyclidine', 'long-acting beta-2-agonists', 'monoclonal antibodies.|Known', 'alpha adrenergic blocking agents', 'sedative', 'ethacrynic acid', 'immunosuppressive or', 'prone', 'contraceptive method', 'Imaging', 'allergy|Concomitant medication', 'monoamine oxidase (MAO) inhibitors', 'mRNA influenza vaccine', 'melatonin', 'topical JAK inhibitors', 'contraceptive pill', 'chemotherapy.|Patients', 'vitamins A', 'grapefruit containing', 'IL-2', '3rd generation EGFR', 'physiotherapist', 'tangerine', 'anti-CD70 directed therapy', 'R1', 'oesophageal catheter', 'Citrulline', 'organ function||Key', 'paclitaxel', 'abietron acetate', 'local glucocorticoids', 'anti-oxidant vitamin supplement', 'calcium channel blockers', 'contraceptive tablets', 'study drug dose until seven days after study drug administration', 'immune drugs', 'immune-related diseases', 'systemic medication for immune system)|Subjects', 'anti-vascular targeting', 'antiarrhythmic agents|Subjects', 'parenteral nutrition', 'cytogenetics', 'isoniazid', 'Erythropoietin', 'dimethyl sulfoxide', 'seasonal influenza vaccine', 'adjuvant pembrolizumab', 'strong CYP3A inhibitor', 'immune-related AEs', 'antihypertensive agents', 'intestine', 'Afebrile', 'glucocorticoids', 'opioid analgesia', 'tetraiodothyronine', 'antiplatelet therapy', 'VWD', 'platelet dysfunction;|Allergic', 'drug eluting stent (DES)', 'immediate treatment', 'topical anesthesia', 'contrast dye', 'trismus', 'alginates', 'Teriparatide', 'study antibiotics', 'oral antipsychotic medication', 'near Tallahassee', 'ocrelizumab', 'valbenazine', 'procainamide', 'regular medications', 'components of the therapeutic approach', 'components of BCD-178', 'intravenous (IV)', 'oral drug', 'α2-adrenergic agonists', 'multiple medications', 'lunch', 'gabapentin-pregabalin', 'anti-CD19 antibody products', 'proton pump inhibitor', 'give GP contact details.|Participating', 'local rashes', 'Ectoin®', 'systemic immunosuppressants', 'topical ocular medication|Patients', 'regular', 'CRITERIA:||age', 'anthracyclines|left', 'topical JAK inhibitors|Current', 'antiplatelet therapy.|Provision of informed', 'chemotherapy sensitive', 'painkillers', 'syn-', 'Prostate', 'chlorambucil', 'subseptate', 'anti-EGFR agents', 'antiplatelet treatment', 'component of the rituximab', 'inhaled products', 'nonsteroidal anti-inflammatory', 'immediate hospitalization|Bad', 'dextran', 'amphilimus', 'prescription drugs||If supplements', ""St. Joseph's Hospital"", 'PD-1 inhibitor therapy', 'medication for osteoporosis', 'controlled substances', 'anti-seizure medications', 'PRRT', 'conventional imaging', 'zimberelimab', 'oral hygiene products', 'vitamin products', 'opioid addiction', 'polyamide', 'sulfonylurea', 'feet||', 'anti-hypertensive medicines', 'intraarticular corticosteroids', 'CTCAE ≤1', 'iron treatment', 'Beliumumab', 'resveratrol supplements', 'anti-EGFR', 'drug oral lichenoid lesions', 'corticosteroid use', 'pitavastatin', 'beta receptors', 'OAT3 substrates', 'meat', 'oral 5ASA', 'Adolescents', 'drug cocktail medications', 'inhaled corticosteroid plus', 'folate supplements', 'LBP', 'electronic implant', 'nicotine-containing liquid for electronic cigarettes.|Current', 'renin', 'postbiotics', 'trigeminy', 'oral sulphonylurea', 'fish oil', 'sulfa drugs', 'Snellen equivalents', 'thin veins', 'anti-tau drugs trials', 'glycerol', 'antithrombotic medication', 'components of the study treatment formulations.|Rare hereditary problems of', 'mood altering', 'Atkins]', 'hours|Glycoprotein IIb-IIIa inhibitors', 'Clozaril', 'Nicotine gum', 'titanium dioxide', 'topical scalp over-the-counter (OTC)', 'Fridericia', 'beta-blocker|Prior', 'Canagliflozin', 'neurotrophic tyrosine receptor kinase (NTRK)', 'linagliptin', 'vaccinate live', 'stabilizers', 'desktop computer', 'DPP-4 inhibitors', 'connective tissue diseases;|Those', 'agents used in this study.|Active central nervous system/brain metastases', 'relapse.|Patients', 'bismuth', 'drugs that could affect cognitive function', 'anti-TB treatment', 'antithyroid drugs', 'preservative', 'systemic agents', 'prebiotic supplements', 'anti-cytotoxic T-lymphocyte', 'leuprolide', 'Thiazolidinediones', 'Alpelisib', 'Relenza', 'conventional laparoscopy', 'intrauterine contraceptives', 'glofitamab', 'corrective lenses', 'component of the test treatment;|Known contrast agent', 'MTX', 'QTcF', 'cycloplegia drugs', 'NGS', 'medications listed in Appendix 1', 'anti-diarrhea treatment', 'growth factor support', 'components of similar chemical or biologic composition to either cemiplimab', 'systemic medications', 'nonselective beta-blockers', 'caffeine effects', 'anti-cancer therapy|Known severe', 'study period|youth', 'musculoskeletal limitations)|Practicing yoga', 'NTRK3 alterations', 'training', 'TAVI', 'physiologic steroid replacement', 'biologic treatment', '5-alpha reductase', 'zoster vaccine', 'OTC analgesics', 'medication used radio frequency precautions previous', 'low intensity therapy', 'anti-angiogenic drugs', 'systemic anti-cancer', 'levomethadyl acetate', 'biologic medications', 'nonpregnant', 'xanthine-containing', 'tobacco', 'anti-platelet therapy.|Known intolerance', 'similar cosmetics', 'HRT regimen', 'SHP2 inhibitors', 'CYP3A inducers', 'non-steroid anti-inflammatory drugs', 'immunosuppressive medicine', 'silicon dioxide', 'Pertuzumab', 'wall segments', 'migraine days', 'Leronlimab', 'medication.|Children', 'inhaled steroid therapy', 'Phentermine', 'typical neuroleptics', 'study materials', 'routine drugs', 'Ultra', 'oral anti-coagulants', 'component of the Holter monitor|Known allergy', 'cyclosporine nefazodone', 'strongly inhibit CYP3A4/CYP3A5', 'menin inhibitors', 'non-ARB/ACEI', 'IL-12 either alone', 'volatile anaesthetics', 'TTH', 'NSAIs', 'CGM derived glucose', 'injectable contraceptive', 'esmolol hydrochloride', 'roxatidine', 'irrespective of', 'anti-hyperglycemic drugs', 'eliminate severe', 'NCT01506141', 'prednisolone', 'WP3', 'neuroactive drugs', 'anthracyclines', 'NCT04329104', 'express', 'ampreloxetine hydrochloride', 'suntan', 'components of the vaping liquid.|Eye trauma', 'opioid medication', 'Inhaled corticosteroids', 'belimumab', 'anti-drug antibody', 'TNF) inhibitors', 'systemic anti-infective therapy occurs', 'monolavir capsules', 'DMPA', 'anti-phospholipid antibody syndrome', 'penicillin antibiotics', 'oral isotretinoin', 'azacitidine', 'DPP4 inhibitors|4', 'proteins of murine origin', 'β-thalassemia', 'systemic anti-inflammatory drugs', 'oral contraceptive', 'nicotine use', 'Baloxavir Marboxil', 'monoclonal antibody|Known central nervous system metastases', 'SARS-CoV-2||', 'anthracycline drugs reach threshold', 'components of the fNIRS device', 'hormonal prescription oral contraceptives', 'nilotinib', 'necrotic material', 'NS:||•', 'vaccination', 'diphenoxylate', 'Probiotics', 'avanafil', 'valerian', 'CYP1A2', 'megestrol acetate', 'nitrous oxide sedation', 'full Extension', 'neuromuscular blocking agent||', 'antiepileptic medication', 'systemic anti-inflammatory agents', 'sulphonamides', 'load medications', 'component in its formulations', 'anti-PVRIG', 'soluble receptors', 'IVH', 'Belantamab', 'amphetamine', 'emigrate', 'catechins', 'Amifostine;|Chronic alcoholism;|Known hypersensitivity', 'porcine-derived materials', 'litigation regarding', 'antihypertensive drugs;|Patients', 'potassium supplements||Other protocol defined', 'anti-VEGFR small molecule tyrosine kinase inhibitors', 'micro-needling', 'exercise|functional limitation', 'deoxyribonucleic acid', 'immune tolerance induction', 'immunomodulating medicines', 'everolimus-eluting stents', 'oxytocin', 'Bempedoic Acid', 'nivolumab plus', 'calcium channel blockers including:||significant', 'sucralfate', 'plasma derived', 'anti-PD-(L)1 monoclonal Ab', 'medication prescribed', 'FFP', 'Captopril', 'selective inhibitor of the DLL3 pathway.|Participant', 'immune suppression|Desire to have', 'BWR', 'iron-deficiency anemia||', 'topical diltiazem', 'growth hormone;|Sexual precocity;|Abnormal liver', 'monofocal hydrophobic acrylic intraocular lens||', 'Islanders', 'beta subunit', 'Ascertained previous surgical extraction/s of third', 'inactive components', 'Hydrochlorothiazide', 'Novocaine', 'beta-blockers treatment.|Morbid obesity (', 'nurse-anaesthetist', 'study drugs', 'anti-emesis drugs', 'm+', 'Kuantan', 'Levodopa||', 'local therapy.|Existing neurocognitive', 'oral decongestants', 'chemotherapy drugs', 'Nivolumab/Etigilimab combination therapy.|Known', 'Amifostine', 'ABL1 amplification', 'immunotherapeutics', 'anticonvulsant medication', 'components of the radiolabeled pharmaceutical', 'liver ultrasonography).||', 'BRAF inhibitors', 'TIPS', 'anti-GD2 monoclonal antibody therapy', 'anti-hepatitis B virus;|Glomerular Filtration Rate (GFR)', 'ocular diseases;|Bilateral moderate', 'breastfeeding.|Active drug', 'periocular steroid treatment', 'lispro', 'granulocyte colony', 'sarcomatoid', 'strontium', 'oral prednisone', 'diabetes medications', 'chloride', 'intraoperative drugs', 'neuromodulation', 'Amsacrine', 'GLP-1)', 'Ludeal®', 'immunosuppressive medications', 'TPO-RA', 'SMF', 'tafasitamab', 'Fio2', 'Anti-retroviral agents', 'low molecular weight heparins', 'ketoconazole', 'fish oil capsules', 'analgesic drugs', 'bioprosthesis;|Possible', 'live vaccination', 'albumin transfusions', 'inhaled drugs', 'nivolumab after', 'anti-BCMA', 'medications that', 'drugs of similar chemical classes|Pregnant', 'immune-suppressive', 'Pediatrics', 'loop diuretic dose', 'azelaic acid', 'drugs used in this study.|Subjects', 'spermicidal agent', 'materials contained', 'oncogenic driver alteration', 'mianserin', 'DFCI for necessary data collection.|Ability to understand', 'antibiotic treatment', 'antiplatelet', 'modafinil', 'SGLT2 inhibitor.|Pregnancy', 'prevents access', 'components of the study treatment', 'low grade intermediate-risk', 'esophageal stricture|Patients', 'psychotropic agents', 'alectinib', 'non-steroidal anti inflammatory drugs', 'non-steroidal anti-inflammatory medications|inability', 'Antibiotics medication', 'amylin mimetics', 'parenteral iron products|Non-iron deficiency anemia', 'heterozygous', 'computer', 'immediate local treatment', 'medications used in the postoperative course.|Either eye does not', 'other medication', 'core antibody alone', 'anti-lipid', 'monoclonal antibody|WOCBP', 'Obstetrics', 'degludec', 'Amisulpride active ingredient', 'GU pelvic', 'Glaucoma,|Diabetes', 'BMS', 'allowed.|Proton pump inhibitors', 'lactation,|Taking medication', 'polycaprolactone', 'stimulant medication', 'Gabapentin', 'beta-oxidation', 'verapamil', 'addictive substances', 'over-the-counter (OTC) medications', 'isosorbide dinitrate', 'over-the-', 'Runyankole', 'obinatuzumab', 'A2 Biotherapeutics', 'local anaesthetics|infection', 'Dialysis', 'anti-HLA antibody status', 'thalidomide', 'systemic corticosteroid treatment', 'tetracyclines', 'drug abuse;|Surgical intervention on heart', 'adequate answering of the questionnaires)|No previous', 'agents used', 'liver drug metabolizing enzyme drugs', 'Alemtuzumab', 'spontan vaginal delivery', 'COVID-19 vaccines', 'sunitinib', 'migraine headache.|Episodic migraine', 'desipramine', 'g•kg-1•min-1；|At rest', 'coumandin', 'Covid-19 Vaccine Center set up', 'CCS', 'GLP-1', 'pegvaliase', 'meningococcal vaccination', 'component of the investigational', 'Salmonella', 'oxygen|Chronic infective disease', 'phospholipid', 'anti-LAG3', 'medications that could interfere with orthodontic tooth movement.|History of trauma', 'adebrelimab', 'Imatinib', 'combination analgesics', 'Gentamycin', 'steroids bursts', 'anti-angiogenic therapies', 'supplements containing hyaluronic acid', 'cyclosporine', 'conventional brackets|3.The treatment', 'Apalutamide', 'beta-blockers|Participants', 'senna', 'ADT', 'national', 'compounds of chemical or biologic composition similar', 'inhaled medication', 'anti-tumor necrosis factor-α [TNF-α] agents', 'mini AVR', 'antiplatelets', 'fiber supplements', 'related compounds', 'component of ST-01|Any contraindication', 'PV', 'anti-PDL1 immunotherapy|Prior chemotherapy', 'injectable corticosteroid', 'HFO devices', 'chromium', 'Cytochrome P450', 'absorb oral antibiotics', 'CHV supervisors', 'kava', 'anti-tumor indication', 'long-acting muscarinic antagonists', 'medical-grade', 'passiflora', 'modification for use', 'Relmacabtagene Autoleucel Injection', 'bismuth complexes', 'Cisplatin', 'iodine agents', 'ferritin', '7.Moderate', 'hormonal implant||', 'vitamins known', 'lytics.|Iodine', 'nitroimidazole', 'Lithium', 'nalidixic acid', 'dexamethasone equivalents', 'smartphone running', 'immune globulin product', 'Selective Serotonin Reuptake Inhibitors', 'study drug components.|Pregnancy', 'immune system disorders', 'antibiotic protocol', 'menstruation', 'anti-HCV therapy', 'tissue damage', 'glycerin', 'contraceptive method.|Drug abuse', 'PMS2).||', 'anti-cancer', 'Sohag hospitals.||', 'penitentiary institution', 'long-acting nitrates', 'Herbal drug', 'angiotensin receptor blocker)|blood pressures', 'read|Parents', 'nefazodone', 'anti-PD-1', 'endocrine', 'SLIT', 'TCAs', 'corticosteroid nasal spray', 'spinal', 'Lublin', 'adrenal corticosteroid therapy', 'Orlistat/Xenical', 'hormonal patch', 'DIBH', 'bisphosphonates injection', 'pneumonia vaccine', 'IVF', 'drugs of similar chemical classes.|History', 'QTcB', 'lavender|Patients', 'caffeine-containing', 'cisplatin based|GYNECOLOGIC CANCER', 'Antihypertensive drugs', 'beta-blockers|Patients', 'drugs involved;|Pregnancy', 'Omega-3 supplements', 'sigmoid', 'oral anticoagulation therapy', 'physiotherapy', 'injectable|intrauterine device', 'narcotic', 'strong cyp3a inducers', 'intranasal influenza vaccines', 'I', 'Testosterone', 'KRT', 'acne medications', 'compounds of similar chemical or biologic composition to chemotherapeutic agents', 'methacholine challenge', 'titanium', 'Transportation', 'chronic)|Previous abdominal', 'components of the study drug.|Committed', 'anti-thyroid drugs', 'paritaprevir', 'hormonal agent', 'mineralocorticoids', 'HSCT', 'MRI- incompatible devices', 'dairy products', 'TKI inhibitor-related', 'GnRH agonist', 'components of the soap used for bathing', 'acid treatments', 'IUD', 'anti-tumor therapy;|Pregnant', 'reason;|Common Terminology Criteria', 'SA2', 'l-asparaginase.|On lomitapide', 'EDSS', 'components of the vaccine products', 'Tizio', 'FGR', 'low C4 complement', 'Ofatumumab.|Ofatumumab', 'ophthalmologic corticosteroids', 'donate', 'study vaccine', 'agents used in study.|Uncontrolled intercurrent illness', 'dalteaparin', 'PD-1 inhibitors', 'local corticosteroid injections', 'local anesthetics|allergy', 'growth factors support', 'anticoagulant drug medication', 'EOT', 'guidelines', 'ENaC inhibitors', 'anti-vascular endothelial growth factor inhibitor', 'intravenous immune globulin', 'Sodium Chlorite', 'cidofovir', 'drug-related inflammatory lung disease.|Active', 'III anti-arrhythmic drugs)|Second', 'satralizumab', 'non-steroidal antiinflammatory', 'give informed consent||Exclusion', 'drug-related grade', 'TICS', 'topical glucocorticoids', 'fish oil/krill', 'live attenuated virus', 'restoration', 'over-the-counter medication', 'antifibrinolytics', 'malaria vaccine', 'perfloxacin', 'disease|Participants', 'antispasmodics', 'mineral', 'cyanoacrylate', 'OHT', 'immediate antibiotics', 'Sunitinib', 'balance problems|Chronic ankle injuries||', 'cotinine', 'enzymes', 'belantamab mafodotin', 'moisturizers', 'PET', 'IVT', 'inhaled oxygen', 'nasal vaccine', 'components of the product||* Note', 'tacrolimus', 'narcotic sedatives', 'n-3 fatty acids', 'National Audit', 'local anesthetic-only', 'BHA', 'contraceptive diaphragms', 'antihypertensive treatment)|High levels of LDL-cholesterol', 'IIb', 'kanamycin', 'flow anesthesia application', 'cobalt', 'reduction', 'compounds of similar biological', 'local medication', 'setting.|Patients', 'carnitine products', 'anticoagulation medications', 'methionine-containing medicines', 'antiangiogenic drugs', 'anti-CMV trial', 'compounds of similar chemical or biologic composition to (investigational new drug [IND] agent[s]', 'salazosulfapyridine', 'neoantigen synthetic long peptide vaccine.|2', 'sleep supplements', 'artificial tanners', 'porcine-', 'prolgolimab', 'prevent IV contrast allergic reaction', 'hydroquinone on the target area', 'vitamin B12 supplements', 'direct acting antiviral therapy', 'anti-PD-1- ligand-1', 'Chronic medications', 'video', 'anti-SARS-CoV-2 drugs', 'malaria drug', 'medications used', 'Duncan', 'medications/products', 'methylenedioxymethamphetamine', 'Davis', 'cannabis', 'pain.|Positive ICVM findings|If', 'symbiotics', 'anti-arrhythmic', 'normal gastroscope|Endoscopic dilation', 'conventional', 'oral antidiabetic medicine (OAM)', 'derivatives', 'aromatase inhibitors', 'oral busulfan', 'neomercazole', 'anti-metabolite', 'dysrhythmia|Diabetes', 'Mitoxantron', 'intravenous (IV) contrast', 'strong CYP2C8 inhibitor', 'immunosuppressive therapy|Active', 'eye|IVT drug delivery to any eye', 'hormone therapy)|Regular tobacco', 'depot or vaginal ring', 'ACI', 'immunosuppressive drugs.|Has', 'Prednisolone', 'cardiotoxic agents should', 'restricted medication', 'cosmetics', 'Anti-psychotics', 'egg protein|Seasonal', 'systemic anti-cancer therapies', 'vaginismus', 'GLP-1 agonist', 'bullet', 'combination ART regimen', 'parenteral anti-infective treatment', 'filgrastim', 'anti-human immunodeficiency virus', 'dopamine agonist', 'noninjection', 'cashew', 'phenylcyclohexidine', 'resected', 'doxepin', 'strong CYP3A4/5 inhibitor', 'tamsulosin', 'Sinovac®', 'beta-blockers', 'Bacillus tuberculosis).|Has', 'noninvasive ventilator support while', 'acetylcholinesterase inhibitors', 'suprachoroidal steroids', 'fish', 'Tricyclics', 'medication that reduce', 'Austin', 'norephinephrine', 'Nickel', 'W1D1', 'medications known to be CYP2D6 substrates|Current use of medications/dietary supplements/alternative therapies', 'drugs that could', 'immune-related pancytopenia', 'DMD', 'vecuronium', 'topical analgesics.||Use', 'Tetracycline', 'confirmed COVID-19', 'Caffeine Consumption Questionnaire.|Consumption of', 'TERT', 'heparin-induced thrombocytopenia.||Table 1', 'medication for acute', 'immunsuppressive medication', 'platelet concentrate', 'nicotine patch', 'Etoposide', 'non-steroidal anti-inflammatory drugs (NSAIDS)', 'interferon alpha before index date.|Patients with pregnancy', 'any medications', 'component of IVIEW', 'probenecid', 'raloxifene hydrochloride', 'immune activation profile', 'Ophthalmology', 'malignant tumors;|Patients', 'CYP4503A inhibitor', 'strong inhibitor of BCRP', 'Oral Anticoagulants', 'onartuzumab', 'NCS', 'medication|Participants', 'beclomethasone', 'diabetogenic medication', 'Previct Drugs', 'bupivacaine allergy|Fetal distress', 'fish oils|able to swallow softgel', 'anti-VEGF agent', 'DHEA', 'investigational agent', 'characteristics', 'Glucophage', 'long-acting injectable hormonal contraceptive', 'non variceal hematemesis||2', 'anti-cancer therapies', 'soft tissue fillers', 'Losartan', 'daridorexant', 'proteins of porcine origin.|Other exclusion criteria', 'anti-acids', 'prostaglandin analogues', 'OGIB', 'inducers of CYP2B6', 'potent inhibitors', 'anti-psoriatic', 'Boric Acid', 'pimozide', 'days|Pregnant', 'Salmonella Conjugate Vaccine', 'Psychiatric Diseases|Drugs', 'Chinese drugs', 'supplements containing folate', 'trial drugs', 'FESS', 'compounds of similar chemical or biologic composition to study agent(s)|Research participant', 'low-carbohydrate', 'ototoxic drugs', 'histologic', ""St. John's"", 'amiodarone', 'fluids', 'MTC', 'anticoagulant medications', 'Lacosamide', 'parenteral methotrexate (MTX) therapy', 'oxidaze)-B inhibitors', 'Toripalimab', 'oral anticoagulants', 'omalizumab', 'caffein', 'pain medications', 'hyaluronic acid infiltration', 'metal implant', 'pharmacologic contraceptives', 'fluvoxamine', 'infections|Pregnancy|Lactation|Hb', 'allogeneic HSCT', 'decitabine', 'desvenlafaxine', 'Tamiflu®', 'Mg', 'Triamterene', 'anti-inflammatory/immune', 'psychoactive medication', 'immune therapy', 'medications for treatment of asthma', 'psychological disease.|Relative', 'PT009', 'Rapido', 'IANB', 'MCV', 'esophagus', 'drug abusers|Judgment', 'oral thiazolidinediones', 'cotrimoxazole', 'vemurafenib', 'components for', 'compounds of similar chemical or biologic composition to tegavivint', 'live virus vaccines', 'systemic anti-HER2 therapy', 'late onset SLE', 'H1 antihistamine', 'Dr. Dhall on the basis', 'rashes', 'study medication', 'Herbal medicine', 'antirheumatics', 'urinary sodium analysis', 'fentanyl', 'anti-cancer agent', 'peptide-1 receptor antagonist', 'anti-hypertensives', 'treponema pallidum antibody', 'vaccine products.||***This', 'Medication', 'remains blinded to what', 'antioxidant', 'Cephalosporins', 'components of the study intervention.|The participant', 'anti-NSCLC indications', 'evolution', 'T2 (Annex 2)|Stage Nx', 'liothyronine', 'prescription stimulants', 'vitamin D analogues', 'anticonvulsant treatment', 'antibody drugs', 'local corticosteroids', 'fMRI', 'area', 'H2 blockers', 'telemedicine', 'compounds of similar biologic composition.|Patients', 'brain|Antipsychotic medication', 'intraluminal antacids', 'Hyaluronic Acid', 'acetylcholine HCL', 'bronchodilators', '20', 'guanine', 'peptide-1 receptor agonists', 'modified live virus vaccine', 'NAFLD', 'component of any study drug', 'prophylactic antibiotic', 'pain related', 'amino acid supplements', 'morphine milligram', 'immunosuppressive medications|Severe bowel', 'streptogramin antibiotics|Patients', 'panoramic', 'ampicillin', 'immediate local', 'treatment;|Systemic steroid therapy', 'leukotriene receptor antagonist', 'sedating medications', 'Osteoporosis-medications', 'vehicle', 'systemic anti-cancer chemotherapy', 'regional anesthesia technique', 'prokinetic drugs', 'biologic materials', 'western medicines', 'Sodium Chloride', 'withhold anticoagulation', 'drugs of similar chemical classes.|Participants', 'treatment||16', 'none ablative procedures', 'IMIDs', 'anti-HBV therapy', 'immediate treatment.|Poor', 'antiarrhythmic medication', 'component of the study regimen.|Current treatment', 'prescriptions medications', 'Ringer Lactate', 'MSA', 'immune deficiency|Symptomatic heart', 'ethionamide', 'dengue vaccine', 'Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST)', 'eyelids', 'levonorgestrel', 'inhaled steroids', 'transplant', 'antiplatelet medication', 'alemtuzumab', 'screening|Patients', 'gonadotropins', 'substrates of cytochrome CYP2C8', 'local approved anti-SARS-CoV-2 drugs', 'study drug components', 'recombinant hirudin', 'CYP3A4) inhibitors', 'conventional chemotherapy', 'gabapentin', 'bolus tube', 'EAC', 'varicocelectomy)||', 'hospitalisation', 'ingenol mebutate', 'short acting beta2 agonist', 'conventional techniques', 'national guidelines', 'grapefruit ingredients;|The', 'drugs known to be moderate', 'SMS', 'chili peppers', 'agalsidase beta', 'Vagal nerve', 'Artificial Tears', 'old.|supine', 'murine products', 'cholecystectomy|Prisoner|GB cancer|Advanced cirrhosis|Untreated coagulopathy|No indication', 'tyrosine kinase inhibitors;|The number of primordial cells', 'TNF antagonists of other biological', 'Systemic steroid', 'component of the study products(YY001', 'pethidine', 'citric acid monohydrate', 'gastroscopy', 'daytime anxiolytics', 'study vaccine components|Previous smallpox', 'Thiazide diuretics', 'prokinetic', 'anti-TNF-α agents', 'oral fluorouracils', 'beta-blocker', 'component blood', 'Aspirin', 'anticoagulation drugs.|Asthmatic', 'trial-related procedures', 'head||Active', 'confine surgery', 'anti-fibrinolytic medications|Participants', 'anti-viral therapy', '≤26.|mRS ≤1', 'medication for hypertension', 'MCA lesions', 'several agents', 'Digoxin', 'elbow region.|Steroid injections', 'potassium containing salt substitute', 'regrowth', 'MIH', 'grapefruit hybrids', 'Morphine', 'polyethylene glycol', 'optimal medication', 'anti-B cell biologics', 'gastric acid', 'BCL-2', 'strong P-glycoprotein', 'Zollinger-Ellison syndrome', 'anthracycline', 'ICS/LABA regimen', 'vitamins', 'expanders', 'Jaktinib', 'sodium chloride', 'nelfinavir', 'immune-modulating', 'leucine', 'anti-Interferon gamma antibodies', 'beta lactams', 'histamine', 'local anesthetics Inability', 'after ASCT', 'tubulysin', 'biologic agent', 'component of the formulation|Medication side effects', 'component of the imaging agent', 'immunosuppressant therapies', 'sedative-hypnotic drugs', 'drugs for urinary incontinence', 'vedolizumab|Ustekinumab', 'platelet aggregation inhibitor', 'medications that would influence exercise performance', 'medications to control weight', 'incidental medication', 'RSPO2/3', 'anabolic agents', 'local anaesthetics|bleeding disorders|morbid obesity', 'camrelizumab', 'drugs known to prolong QT interval', 'live vaccine therapy', 'antiplatelet therapy|contraindication', 'anatomical sites;|Major surgical treatment', 'oral anti-infective agents', 'cytotoxic chemotherapy regimen', 'UTIs', 'PET)-avid metastasis', '92228', 'dimethyl fumarate', 'nonsteroidal anti-inflammatory drugs)|Has any condition', 'Period.|6MWD', 'regimens', 'Lincomycin', 'nasal steroids', 'hybrid 18F-NaF PET-CT imaging', 'clozapine', 'Venetoclax', 'anti-CTLA-4 antibody', 'statin drugs', 'vaccine-related', 'Methylprednisolone', 'milliseconds.|LVEF', 'anti-epileptic drugs.||Additional specific inclusion criteria', 'components of MDK-703', 'above|Full-time', 'sedatives', 'pomegranate', 'anti-tumor necrosis factor agents', '1).|Classical orthostatic hypotension', 'protease inhibitors', 'GLP-1 agonists', 'Glogau,|presenting glabellar static wrinkles', 'agents used in this study.|Subjects', 'Relatlimab', 'Antiplatelet', 'immunosuppressive agents', 'antidepressants', 'anti-infective therapy', 'periodontal probing depth', 'house', 'oral hygiene maneuvers', 'conivaptan', 'monoclonal antibody-based therapies', 'direct thrombin Inhibitors', 'interventional cardiologist', 'depot of such treatment', 'mesenteric artery', 'Spirometry', 'fibrinoid necrosis,|', 'vaccine therapies', 'cephalosporin', 'vitamins/dietary supplements', 'fumarate', 'medications used in the study|Women', 'Statins', 'replacements', 'Entecavir', 'carisoprodol', 'rapid acting analog', 'mOCS/ maintenance oral corticosteroid dose', 'orbital radiotherapy|Euthyroid state||', 'RTX', 'SRT', 'bypass surgery|whose CCTA evaluation', 'PICCline placement', 'N-BPs|Estimated glomerular filtration rate (eGFR)', 'transfer', 'polatuzumab', 'drug used', 'systemic corticosteroids', 'drug Remaxol®', 'inhibitor', 'glucagon-like peptide', 'strong inducers of Cytochrome P450 3A4', 'intravenous contrast agent', 'additional medications', 'arteritis;|Patients', 'topical corticosteroid injections', 'systemic anti-infection therapy', 'human growth hormone', 'thrombolytics', 'Arginine', 'user', 'lymphoma);|Bone marrow function', 'Chapelle', 'aphthous herpetiform ulceration', 'radioactive agents', 'components of the injectable solution', 'components of the study intervention', 'antihypertensives', 'Antibiotics', 'antianginal medication', 'drugs targeting other T-cell co-stimulatory receptors', 'natalizumab', 'IV diuretics', 'topical ocular corticosteroids', 'FLT3 inhibitor', 'soft tissue grafting', 'anti-Xa inhibitors', 'local anesthetic drug|Can pass', 'dawnone', 'Guideline', 'beta-interferons', 'systemic immune suppressive therapy.|Initiation', 'youth teams', 'β-blockers', 'molecular swabs', 'prediabetic state', 'local Ethics Committee requirements.||', 'antidepressant medication|History', 'anticalcineurins', 'rheumatoid', 'histamine-receptor antagonists', 'antibody drug conjugate (ADC)', 'coronavirus vaccine', 'therapeutic agents', 'nickel-titanium', 'L-Citrulline Malate', 'Atlanta classification (Banks et al', 'bivalirudin', 'goggles)||', 'components the filgrastim formulations evaluated', 'molnupiravir', 'risperidone', 'topical ophthalmic prescription', 'supine', 'antirheumatic drugs', 'fluoropyrimidine containing chemotherapy', 'herbs', 'anesthetics', 'trophic', 'Goserelin combination therapy', 'medications that reduce GI motility', 'ITB', 'antioxidant vitamins', 'herbal medications', 'scoring', 'Polyvinyl Alcohol (', 'thyroid replacement', 'hypoglycemic treatment', 'Methamphetamines', 'infliximab anti-TNF therapy', 'progestin', 'pramlintide', 'experimental drugs', 'investigational products', 'anti-arrhythmic therapy', 'hydrocortisone', 'hole laparoscopic', 'cleft palate repair', 'Ibuprofen', 'aspirin-containing product', 'anti-resorptive medications impacting the bone', 'plasma exchange', 'completed steroid tapers', 'COVID-19 vaccine', 'nucleic acid/antigen test negative.||', 'famotidine', 'serotonin metabolism CYP 450 inhibitors', 'xarelto', 'osimertinib', 'rituximab', 'fusion', 'pain modifying medications', 'oral hypoglycemic agent(s)|Lifetime use of serotonergic psychedelic drugs', 'wheelchair', 'clot', 'paclitaxel drug therapy', 'drugs prescribed for indications', 'components of study drug|Cannot properly administer study drug|Clinically significant', 'Neo-T', 'caspofungin', 'adenovirus vaccine', 'viral vector vaccines', 'asthmatics', 'oral anti-androgens.|Patients', 'Myleran®', 'conventional allogeneic', 'AOMs', 'Class III antiarrhythmic agents', 'recombinant antibody-related fusion proteins)||History of', 'methyltestosterone', 'TNG462 or its', 'Opiates (OPI)', 'HIV infections;|Patients', 'Nioxin', 'faricimab', 'zonisamide', 'Anti-Xa-inhibitors', 'iodinated contrast media|any of the following', 'anthracycline drugs', 'Sabin', 'anti-AAV9 antibody titers', 'study|Blood donation', 'compounds of similar chemical or biologic composition to durvalumab', 'pyridostigmine', 'TME therapies', 'Bisoprolol', 'Prevacid', 'neurological diseases|Prior use of medications', 'LLT', 'intravenous antibiotic', 'plastics', 'compounds of similar chemical or biologic composition|Planned additional surgery to the surgical breast', 'adequate contraceptives', 'drugs known to be higher metabolized by this enzyme', 'medication known to cause itching.|Psoralen', 'Metamucil', 'related coumarins.|At screening', 'drugs used in the study|Previous thoracic surgical procedures', 'LBBB', 'metal components', 'drugs targeting the HGF', 'antiplatelet medications', 'saquinavir', 'esophagogastric junction adenocarcinoma.|Mismatch repair deficient (dMMR) adenocarcinoma', 'defaecation||', 'steroid containing inhalers', 'Global Impressions-Severity', 'anti-AML treatment', 'nicotine-containing substances', 'agitation|Hemodynamic instability|Uncorrected', 'oxaliplatin-containing therapy', 'Lupron', 'immunosuppressive drugs.|Pregnant', 'Creatine Phosphokinase', 'hypoglycemic drugs', 'antihypertensive treatment)|Basic ICT knowledge', 'treatment', 'Bohannon', 'nivolumab for', 'IV contrast', 'BET inhibitors', 'cannabis products', 'radiolabeled substance', 'systemic anti-tumor treatment', 'related hypnotics', 'immune-suppressive disease', 'CBD related products', 'sigmoidoscopy', 'BCNU', 'F4)|Fibroscan', 'component of the chemotherapy regimen', 'Endocrinology', 'anti TNF|Vegans (vegetarians may', 'DS252', 'factor concentrate', 'RBC', 'mitomycin C', 'OTC drugs', 'St. Louis encephalitis', 'XCCM view', 'immune suppressive medication', 'CRRT', 'non-steroidal anti-infilamatory drugs', 'protein supplements used in sports', 'injectable contraceptive medroxyprogesterone', 'specialists judged', 'venous blood', 'CTPA', 'direct acting antiviral drug', 'component of ibuprofen', 'cerebrovascular accidents', 'Antihypertensives', 'ultrasound contrast', 'relevant.||Patients', 'lenalidomide-refractory', 'drugs of the same class|If capable of reproduction', 'components of metabolic syndrome', 'WBH', 'MIH;|Children', 'insulin lispro', 'months|Vertigo', 'gelatin', 'pacemakers', 'immunosuppressive therapies).|3', 'dipyramidole', 'beta human chorionic gonadotropin (β-HCG) pregnancy test', 'mitochondrial antibody', 'analgetics', 'pharmacotherapeutic agents', 'influenza vaccines', 'prophylactic medication', 'TKI', 'anti-coagulation therapy', 'component of Camrelizumab', 'components used', 'Oral contraceptives', 'Insulet', 'adhesives', 'IVT anti-VEGF treatments', 'defective', 'oral hypoglycemics', 'provocation', 'anti-cyclic citrullinated peptide', 'esotropia', 'interventional drug', 'Lactobacillus', 'propoxyphene', 'homeopathic remedies', 'opioid pain medications', 'Sintilimab', 'component of the ATRIGEL Delivery System.|Concurrent', 'biologic agents', 'sulfasalazine', 'intravenous drugs', 'anti-TB prophylaxis', 'local anesthetics|Patients', 'Nalbuphine', 'tumor vaccine', 'topical cosmetic products', 'ipilimumab', 'vagal', 'factor Xa inhibitors', 'codeine', 'neuroendocrine tumor|Having ADKP', 'topical haemorrhoid medications', 'IDD|has', 'glulisine', 'nonstatin drugs', 'Fosinopril', 'parenteral administration of Gd-based contrast agents|Evidence', 'quinine sulfate|Inability to swallow pills', 'human proteins', 'oral bisphosphonates', 'Ferumoxytol', 'strong CYP3A4 inhibitors.|On strong', 'prescription medicinal products', 'Third Edition', 'rheumatoid arthritis|Receive', 'Bictegravir', 'albumin-bound', 'Tacrolimus', 'articaine', 'sampling|Stable medication', 'human albumin', 'glecaprevir', 'android', 'long-acting analog', 'murine proteins', 'third vaccination', 'murine monoclonal', 'anti-inflammatory (', 'agent targeting another stimulatory', 'weeks|Oral antibiotics', 'age|Driver', 'drugs related to the aforementioned diseases,|Pregnancy,|Patients', 'oral hypoglycaemic', 'grades', 'smart phones', 'pramipexole', 'abnormal pattern||', 'CISC', 'anti-hypertensive eye drops', 'Ionogram', 'drugs used in the procedure', 'Palynziq®', 'dressing components', 'potent CYP3A4 inhibitors', 'cycloserine', 'hyoscine', 'cerebellar disease|Known', 'mRNA vaccine', 'averaged', 'microarray', 'lamivudine', 'Synchronous', 'sildenafil', 'antiplatelet drugs|Is', 'immune-suppressive therapy', 'sarcomas', 'persantin', 'ICS/LABA/LAMA', 'antiretroviral drugs', 'curators', 'Molars', 'anticoagulation medications|rheumatoid', 'taxane chemotherapy', 'nitrous oxide', 'under medications', 'organ-confined prostate cancer', 'pexidartinib', 'drugs known', 'Teprotumumab', 'CYP3A4/2C8 strong inducer', 'Thyrotropin', 'histological type', 'medicines', 'drug components;|Patients', 'LB', 'IL-6 inhibitors', 'FVIII', 'empagliflozin', 'duloxetine', 'PMF', 'acid suppressor', 'prilocaine', 'non-steroidal anti-inflammatory agent', 'contrast media;|Patients', 'drugs chemically related to belantamab mafodotin', 'pediatrician', 'unmarketed drugs', 'negative mammography', 'Lefort [osteotomy', 'immunosuppressive condition.|Resides', 'midline shift', 'pentamidine', 'study agents', 'Fludarabine', 'ICS with LABA in combination for asthma', 'sepiapterin', 'indium', 'anti-PD-1/L1', 'Moexipril', 'statins', 'immune therapy therapy', 'strong CYP3A-Inhibtors', 'baseline.|Baseline PN-related', 'component of cisplatin', 'over-the-counter', 'anti-retroviral agent', 'psychotropic medications', 'gait', 'months.|Engaged', 'mmHg|Stroke', 'contraceptive medications', 'albumin-bound type', 'tetracyclic antidepressants', 'behavior;|Active substance', 'old|Hospitalized', 'anti-TB drugs regimen', 'penicillin group antibiotics', 'ticlodipine', 'ICS +LABA + LAMA', 'nucleic acid testing', 'Cilgavimab', 'probiotics supplements', 'component of the products', 'Tazobactam', 'Perindopril', 'cone-beam computer tomography (CBCT) imaging', 'soft drugs', 'antidepressant drugs', 'Amphetamines', 'nutritional therapy|Anti-TNF', 'hematopoietic growth', 'anti-EGFR monoclonal antibody', 'pancreatic lipase inhibitors', 'anti-COVID-19 indication', 'metoprolol', 'ICI in combination with', 'oral antibiotics', '5-FluoroUracil (FU)', 'anti-coagulants|Recent', 'Etoposide etc.).|Contraindications', 'corticosteroid therapies', 'filgotinib', 'mixed insulin', 'MRIs', 'passed,|20-30 minutes', 'beta-adrenergic antagonists', 'eribaxaban', 'nonsteroidal agents', 'smallpox vaccine', 'artificial tears', 'anti-glaucoma drugs', 'compounds of similar chemical or biologic composition to tigilanol tiglate', 'ventricular-assist device patients|Hospice patients|Patients', 'anti-dopaminergic antipsychotic drugs', 'Adequate organ', 'gymnastics', 'topical use', 'Creatinine Phosphokinase', 'dimethyl', 'oral care products', 'immunoglobulin ≤6 months before receipt of any study vaccine', 'HBV anti-viral prophylaxis.|2', 'adjunctive debulking', 'testing', 'doxorubicine', 'YAG', 'IV opioids', 'fexofenadine', 'targeting drugs', 'Antidepressant Treatment Response Questionnaire (ATRQ)', 'immunosuppressive drugs.|Any', 'antihistaminic medication', 'muscarine-receptorantibodies', 'oral hypoglycemic agent', 'statin medications', 'hyaluronic acid)|Participates', 'medications that could not interfere with the central nervous system|Children', 'Niuhuang', 'telithromycin', 'tenofovir prodrugs', 'cyp)3a inhibitors', 'Fluphenazine decanoate', 'P2Y12', 'dimethyl sulfoxide (DMSO', 'boceprevir', 'psoriasis|Active PsA', 'short-acting beta-agonist', 'SLP', 'sodium iodide', '3rd degree atrioventricular', 'hormonal contraceptives|medication', 'systemic drug products', 'PICCline', 'study drug absorption', 'ketobemidone', 'proprietary drugs', 'Prophylactic medication', 'low SpO2', 'Children', 'NCRT', 'non-steroidal anti-inflammatory drug.|Use', 'studied drugs', 'amnesia alone', 'anthracquinone', 'expression', 'recombinant human erythropoietin', 'monoclonal antibody.|Significant', 'paclitaxel liposome', 'thiazolidinedione', 'intense pulsed light therapy (IPL)', 'over-the-counter drug abuse', 'Azathioprine', 'intraocular corticosteroids', 'glucagon-like peptide-1', 'status,|pregnancy,|on', 'CVS', 'hormone receptor agonists,|current', 'dihydropyridine', 'digestive medication', 'HAC', 'Lenvatinib combination therapy', 'Explicit', 'mRNA) vaccines', 'traffic accidents', 'Garmin', 'psychoactive substances;|Pregnant', 'anti-diarrheal agents', 'materials', 'rocuronium', 'grapefruit fruit', 'hybrid lenses', 'cytosine arabinoside', 'Senza System', 'vasovagal syncope||', 'immunosuppressive effects.|Hematologic abnormalities.|Renal impairment.|Hepatic impairment.|Increased LDH', 'Miglitol', 'asthma medication', 'Class III antiarrhythmic medications', 'Neurontin', 'azole Antifungal drugs', 'vaccine components', 'Emergency', 'strong inhibitors', 'PRRMs', 'excipient', 'melatonin|Antipsychotic medications|Opioid medications', 'lurbinectedin', 'mild crowding', 'hypoglycemic therapies', 'sensitive CYP1A2 substrates', 'Ehlers Danlos syndrome', 'cicadae', 'HBsAb after vaccination', 'components of the study product.|Subjects', 'Mepolizumab', 'vardenafil', 'systemic retinoids', 'interventional agent', 'SOC', 'Migraine', 'vaccinations', 'drugs that impair bone quality|Diagnosis', 'Laval', 'substance dependence|Patients', 'systemic corticosteroid immunosuppressive dose', 'treatment-related', 'PARPi drugs；|Symptomatic brain', 'COVID-19|adults', 'drugs used in the study protocol|Patients', 'cardiovascular medications', 'components in the Nicotinamide Riboside (Niagen®', 'surrounding area', 'RECIST1.1)||Sufficient organ', 'musculoskeletal injuries;|Athletes', 'vaccine', 'study vaccines', 'ARB', 'immunosuppressive steroids', 'combination products', 'sodium voltage-gated channel alpha) 9A', 'teriflunomide', 'Keratinized tissue', 'ABR', 'aids', 'conventional myeloablative conditioning regimen', 'Proton pump inhibitors', 'etc|Pregnant', 'T2', 'Angiotensin II Receptor Blockers', 'echinocandin', 'component of RC28-E', 'vincristine).|CYP3A4 Inhibitors', 'CDK4/6 inhibitor combined', 'hormonal treatments', 'biologic', 'craniofacial growth', 'live attenuated vaccination', 'weekly methotrexate', 'nucleic acid testing [NAT]', 'urine drug screen);|Primary diagnosis', 'Ethylhexylglycerin', 'phenytoin', 'cisplatin/carboplatin', 'Pemetrexed', 'bile acid metabolism', 'compounds of similar chemical or biologic composition to triapine', 'caffeine-rich', 'depot corticosteroid', 'compounds that are chemically', 'ARNi', 'flutamide', 'baclofen', 'Vitamin K antagonist', '5-year', 'acid inhibitor', 'median', 'regional anesthesia|Plan', 'vinorelbine', 'Youth', 'Cremophor® EL', 'rheumatoid arthritis,|Malignant tumor involving the craniocervical region,|Heart conditions', 'toothbrush', 'nicotine-containing product', 'anti-hyperglycemic medications', 'angiotensin-converting enzyme inhibitor', 's-albumin', 'desktop computers', 'European', 'combination systemic therapy', 'GAIL', 'anti-inflammatory properties', 'occasions', 'zotarolimus', 'potassium binder agent', 'bupropion', 'glucosamine', 'gefitinib', 'short acting muscarinic antagonist', 'systemic corticosteroid', 'etc;|22', 'ASA', 'sleeping aids', 'procedural', 'Lidocaine', 'Apatinib', 'sufentanil allergy|Renal', 'ILD', 'more)|platelet antiaggregants', 'bupivacaine', 'potent inhibitor', 'beta-lactamines', 'Tyrosine kinase inhibitor', 'phosphodiesterase type 5 inhibitor', 'frontal', 'doctor', 'component of neuroendocrine histology', 'vancomycin', 'fluocinolone acetonide implant', 'non-small cell lung cancer', 'intravenous amino-bisphosphonates.|Patients', 'components of niraparib', 'cytokines', 'clofibrate', 'mycophenolate-based', 'anti-HER2 ADCs for', 'anti-epidermal growth factor receptor treatment', 'oral beta-blocker', 'Android compatible smartphone', 'lorcaserin', 'LMWH', 'serotonin reuptake inhibitors);|Use of phosphodiesterase inhibitors', 'brackets', 'iFR', 'Episodic migraine', 'peritoneum', 'monoclonal antibodies', '[18]F-', 'Coumadin', 'Lidocaine HCL', 'intrerdental site ≥2mm.|Compliant', 'diclofenac', 'immunosuppressive agents;|Diagnosis', 'antiemetic medication', 'photosensitizing medication', 'Metformin', 'discoloration', 'vestibular migraine', 'lansoprazole', 'QBX', 'Adderall', 'live vaccines', 'radionuclide scan', 'topical agents', 'anti-social personality disorder', 'Adynovate', 'abuse', 'embolic materials', 'Decitabine alone', 'Atlanta classification', 'anti-biotics', 'ATN1', 'non-tobacco products', 'KRAS inhibitor treatment', 'combination medication', 'anti-inotropic effects.|Patients', 'catheter', 'MSH1', 'tralokinumab', 'thrombopoietin receptor agonist (romiplostim', 'TKIs', 'dysarthria', 'component of the RO7247669', 'melanoma|Patients', 'formalin tissue sample|Eastern Cooperative Oncology Group (ECOG) performance status', 'hemodynamically moderate', 'chin area', 'live attenuated vaccine', 'non-steroidal anti-inflammatory drugs', 'liver', 'Topical steroids', 'anti-itch products', 'methylamphetamine', 'recombinant Herpes Zoster', 'acyclovir', 'RANKL inhibitors', 'anti-arrhythmics|Chronic malabsorption syndromes|Cholestasis|Acute illnesses', 'treatment regimen', 'major tissue', 'ADC drugs', 'phones', 'mesothelin', 'sodium-glucose linked transporter-2 inhibitor (SGLT-2i)', 'biopsy collected', 'anti-diabetics', 'unapproved drug', 'drugs targeting the immune system', 'catecholamine', 'procaine amine', 'local anesthesia|Patients', 'anti-B-cell therapies', 'toxin exposure;|Coronary event', 'anti-CD20 monoclonal antibody.|Follicular lymphoma', 'tyrosine kinase (JAK) inhibitor', 'components of the investigational drug', 'live-saving treatment', 'anti inflammatory)', 'Alpha-glucosidase inhibitors', 'vitamin K dependent', 'drugs Known allergy to the', 'pimecrolimus', 'mass pump inhibitors', 'piperacillin-tazobactam', 'migraines', 'intravenous lines', 'Carbamazepine', 'intravenous glucocorticoids', 'alfentanil;|Panendoscopy', 'low-molecular heparin', 'antibody-based drugs.|Existence of any concurrent', 'polymethyl methacrylate', 'IASP', 'drug abuse', 'nucleic acid amplification techniques (NAAT)', 'rifampin', 'parenteral glucocorticoids', 'inhaled nitrous oxide/oxygen.|Progressive', 'anti-VEGF responsiveness|Subject', 'Screening.|Moderate', 'migraine related headache', 'SRS', 'purine', 'beta carotene', 'anti-diabetic', 'interacting medications', 'normal dihydroepiandrostenedione sulfate', 'High Blood pressure (JNC)', 'drugs used in the postoperative period.|Patients', 'cemiplimab', 'anti-Her-2 medication', 'antidiabetic drugs/regimens', 'play', 'SGLT2 inhibitors', 'verrucous', 'narcotic medication', 'local anesthesia|Subsequent visit', 'paraphenylenediamine', 'LA anteroposterior diameter of more than 55 mm|Patients', 'satisfy', 'terzepatide', 'azole antifungals', 'experimental drug', 'drug-coated balloon catheter (DCB)', 'prophylactic migraine treatment', '3rd molars', 'nonsteroidal anti-inflammatory medications', 'Insulin', 'low-potency topical corticosteroids)|Subject', 'levothyroxine', 'CDK4/6 inhibitors', 'bupropion/naltrexone', 'angiotensin converting enzyme inhibitor (ACEI)', 'Nebivolol', 'Aminosalicylates', 'injectable steroids', 'EEG', 'physiologic corticosteroid replacement', 'vaccine ingredients', 'similar drugs', 'depigmentation treatments', 'monoclonal antibody', 'Influenza', 'remains', 'stent', 'anti-VEGF monoclonal antibody', 'compounds of similar chemical or biologic composition to oxaliplatin.|Any other medical', 'thiacycline', 'ULN|existing', 'opioid use disorder', 'online live-chat application', 'turmeric-containing supplements', 'angiotensin converting enzyme(ACE) inhibitors', 'positive drug screening results', 'gone', 'BTK inhibitors treatment', 'Jantoven', 'online delivery', 'TNF blockers', 'bivalirudin treatment.||Positive PF4-immunoassay', 'bends', 'over-the-counter sleep medication', 'PPA', 'PTH analog', 'amphotericin', 'combined', 'components of jelly', 'nicotine replacement products', 'painkillers daily', 'carbamazepine', 'meropenem', 'any medication', 'GLP-1 analogs', 'sunburn', 'iodinated contrast material', 'Baseline', 'illegal drugs', 'premix insulin', 'acting steroids', 'mL∙kg-1∙min-1', 'ACR', 'neck|Physician evaluator classifying', 'oral multivitamins', 'inhalation steroids', 'Nusinersen', 'meibomian gland', 'basal insulin regimen', 'transgender', 'ocular steroids', 'budesonide', 'PTH-like drugs', 'PBC', 'complement inhibitors', 'growth factor therapy', 'antimicrobial medication', 'antibiotic use', 'antibody-drug conjugates', 'multivitamin', 'age|Patients', 'regional lymph nodes,|3', 'ocular corticosteroids', 'adequate anti-depressant trials|Participants', 'anti-PD-1/anti-PD-L1 antibodies||ELIGIBILITY CRITERIA', 'rural secondary school', 'sensitive CYP', 'local heat', 'nucleic acid screening', 'oral tyrosine kinase inhibitors', 'tamoxifen Infertility treatment', 'uterine', 'mainly antiarrhythmic drugs', 'mTOR-inhibitors', 'device|patients', 'polystyrene sulfate', 'fermented milk', 'Sitagliptin', 'compounds of similar chemical or biologic composition to study agent.|Active diarrhea.|Clinically significant', 'fruit acids', 'ADKP', 'perivisceral AAA repair.|Participants', 'MOUD', 'triacetin', 'docusate', 'components of the drugs', 'UFH', 'SGLT2) inhibitors', 'aripiprazole', 'angiotensin converting enzyme inhibitor', 'butyrophenone', 'fractionated', 'COVID-19 mRNA vaccine', 'beta2-agonists', 'boosters', 'anti-angiogenic targeted', 'anemia.|BMI', 'BRCA1/2', 'chronic systemic steroids', 'Sodium-glucose co-transporter-2', 'baricitinib', 'TNF inhibitor', 'LT4', 'combined treatment', 'compounds of similar chemical or biologic composition to pembrolizumab', 'regional policy makers', 'components of the tested', 'nivolumab after nivolumab plus', 'triton-X-100).|Any contraindication', 'medication as treatment for depression', 'anti-TNF biologics', 'growth restriction', 'spermicides', 'nefazadone', 'Coroflex®', 'nucleoside analogues.|The researchers', 'antidepressant regime', 'allograft', 'dapagliflozin', 'strong blinks', 'mercaptopurine', 'ifosfamide', 'antiseptics', 'Smartphone', 'immunosuppressive drugs|Morbus Wilson|AIDS', 'local anesthetics|Bleeding disorders', 'loop diuretics', 'opioid analgesics', 'ICI', 'carboplatin-containing regimen', 'Anticoagulants', 'donate blood products', 'oral cortisone pills', 'drugs used in the study.|Patients', 'anticoagulants).|Participant', 'temozolomide', 'biopsy43', 'monoclonal protein', 'nortriptyline', 'FSRS', 'propofol anesthesia||', 'anti-lipidemic drugs', 'components of the IdegLira', 'component of the atezolizumab formulation|Known allergy', 'trial-related intervention', 'midline fetal presentation', 'chin', 'antibiotics', 'HAS', 'nonsteroidal anti-inflammatory agents', 'dB|Patients', 'fundoscopy', 'antimuscarinics', 'nitroglycerin', 'aromatase inhibitorI', 'anti-receptor activator of', 'coils|Stents', 'surgical', 'topical medications|History of', 'dual anti-platelet therapy', 'medication pumps', 'cibenzoline', 'sedative-hypnotics', 'Raloxifene', 'mycophenolate mofetil|Patients', 'study.|Immunosuppressive medication', 'local steroid injection', 'cytotoxic agents', 'CDK4/6 inhibitor', 'compounds of similar chemical or biologic composition to atezolizumab', 'silicone', 'anti-tachycardia pacing', 'noradrenaline reuptake inhibitors', 'systemic corticosteroid drugs', 'TGN', 'contrast allergy', 'telephone', 'pelvic surgery|Intrauterine', 'topical antimicrobial/anti-inflammatory therapy', 'zanamivir', 'Covid-19 vaccines', 'abiraterone', 'mitotane', 'regional nodal', 'dadih sauce until delivery.|Abortus', 'oral medication', 'PaO2<6.0 kPa|6-minute walking', 'Claravis', 'nephrotoxic drugs', 'antibody-based therapy to first TG6050 administration', 'membranes|any', 'Methadone', 'quit|Own a', 'long-acting', 'nicotine products', 'compounds of similar chemical or biologic composition to the agents used in study|Patients', 'SGLT2 -inhibitors', 'antiallergy drugs', 'Halifax', 'Microsoft Teams', 'Orlistate', 'ocular medications', 'amikacin.|ECG', 'ICUs', 'minimum cumulative dose', 'brolucizumab', 'immunoglobulin G [IgG]', 'Upadacitinib', 'K domains', 'Carvedilol', 'time.|Regular urinary incontinence|Feeding', 'anti-GERD therapy', 'potent CYP1A2', 'salt-restricted', '5-alpha-reductase inhibitor drugs', 'polysaccharide', 'ventricular assist device', 'disease modifying agents', 'ganglioside-monosialic acid', 'drugs', 'methylergonovine administration|Hypersensitivity to methylergonovine', 'halofantrine', 'sacituzumab', 'ITIM domains', 'antidiabetic agent', 'extensive residual', 'immunosuppressive therapies|A', 'retinoids', 'Japan', 'dolutegravir-based', 'drugs that cause immunosuppression.|Non-English speakers', 'mg/8h', 'Granulocyte growth factors', 'dolutegravir-based ART', 'atropine drops|Undergoing another myopia control treatments', 'augmentation medication treatments', 'L-lactide', 'anti-PD-(L)1', 'immune-modifying drugs', 'anticoagulants', 'Warfarin', 'intravenous [IV] antibiotics', 'cumulative', 'hysteroscopy)|Abnormal parental karyotype|Instable or exacerbation of auto-immune diseases', 'eGFRC≤30', 'CI622', 'IV|Blemish-prone', 'Bevacizumab', 'topiramate.|Diuretics', 'medication affecting sleep', 'oriental medicines', 'psychiatric medications stable', 'telaprevir', 'CSII', 'neuropsychiatric diseases;|Deaf', 'inotropic agents', 'disopyramide', 'third-generation EGFR-TKIs', 'full access', 'myorelaxant drugs', 'influenza vaccine', 'Murcia.|Dancers', 'cannabinoids', 'GnRH-analogues', 'topical ocular drops|Bilateral eye', 'vincamine', 'rare', 'radiographic contrast agents', 'medications that cause', 'bexarotene', 'type of psychological management', 'cessation medications', 'desumumab', 'long-acting anti-coagulants', 'liquidation mimics pseudocyst|Pseudocyst formation', 'basal insulin}', 'anti-epileptic medications', 'great vessels', 'oral antidiabetic agents', 'smartphones', 'component of the MDI.|Any clinically relevant', 'Ovarian irradiation', '-1.|Absolute neutrophil counts', 'age|Pregnant', 'potassium sparing diuretics)|Anti-coagulant medication', 'xenogeneic proteins', 'IgE.|Urine M-protein', 'rifapentine', 'short-term oral cortisol', 'dehydration drugs', 'glycopyrrolate', 'niacin', 'Android smartphone', 'national guard', 'Check-in of Period', 'obtained.||Patients', 'cytokine antagonists|Regular', 'any antibody treatment', 'supplements containing vitamins', 'antibiotic administration', 'protein targeting Vascular Endothelial Cell Growth Factor (VEGF)', 'sympathomimetic drug', 'anticholinergics', 'antiemetic', 'oral anti-infectives', 'tenecteplase', 'topical administration', 'iodinated contrast agent', 'mothers|patients', 'BTK inhibitor therapy', 'Franklin', 'spherical', 'give full informed consent|Females of reproductive potential', 'components of the assigned study', 'PCT', 'staples|metallic fragments', 'ascorbic acid', 'B7', 'nonsteroidal anti-inflammatory drugs (NSAIDS)', 'Calcineurin inhibitors', 'direct oral anticoagulants|Persons', 'study-related procedure', 'alcoholics', 'Pepcid', 'prescription oral anti-inflammatory/immune', 'Cytochrome P450 3A4', 'IVb, resectable', 'tetracycline', 'topical)', 'hypnotics', 'MLH1', 'doravirine', 'anesthetic sedation', 'migraine prophylaxis|Started', 'P2Y12 inhibitor', 'pharmacist', 'RIF', 'EGFR inhibitors', 'NSCLC.||Prior MET inhibitor therapy', 'photo', 'live outside of the country', 'hormonal contraception|Metformin treatment|pregnant', 'thiazolidinediones', 'psychotropic drugs', 'DOAC', '3rd degree atrioventricular (AV) block', 'platelet antiaggregants', 'intranasal corticosteroid||', 'malignancies;|Patients', 'ethanolamine API', 'Ehlers-Danlos Syndrome', 'elastane', 'regimens containing', 'glucagon', 'Rheumatoid', 'L.1121-8', 'minimum depth of 2mm|Defective previous', 'Gemtuzumab', 'serotonin syndrome|No prolongation', 'hydroquinone', 'germline', '3rd east of HCPA;|Received the following chemotherapy', 'ICS alone', 'chronic corticosteroid therapy|There', 'Opioid', 'Jak inhibitors', 'anteroposterior', 'abacavir', 'resveratrol', 'diplopia', 'neomycin', 'permanent medication', 'setting.|ECOG', 'tyrosine kinase inhibitors (TKI)', 'central stimulants', 'potent CYP3A4/5 inhibitors', 'formoterol fumarate', 'Bacillus tuberculosis).||Diagnostic assessments:||Participants', 'TAF1', 'progesterone alone', 'etc;|Liver', 'flow cytometry', 'Fidaxomicin', 'erythropoietin stimulating agents', 'Herceptin', 'drives', 'intervention),|No congenital', 'therapy|Biologics', 'alpha-blocking medication.|Prior pelvic radiotherapy,|History', 'components of the studied therapeutic formulation', 'the vaccine(s) used in the study', 'IV).|Pregnant females|Teeth', 'prophylactic anticoagulation', 'medications associated', 'oral contraceptives', 'over-the-counter androgenic hormone or androgen precursor', 'adhesive products contained', 'HBV', 'KRASG12C inhibitor + EGFR inhibitor combo|Patients', 'similar products', 'TAPSE', 'compounds of similar chemical or biologic composition to study agent|Known bleeding disorders', 'esophageal', 'propafenone', 'xevinapant', 'sorafenib', 'SU', 'Sierra', 'anti-tumor necrosis factor [TNF] agents', 'Lidocaine Hydrochloride|Cardiovascular disease - complete heart block', 'drugs of the drugs containing the same class', 'antidiabetic drugs', 'technology', 'lids', 'contrast;|More', 'bile', 'nicotine/tobacco products', 'penicillin|Oral contraceptive', 'Mallya', 'hormonal contraceptives.||Specific', 'oral calcineurin inhibitors', 'amide-type local anesthetic', 'systemic beta blockers', 'aminosalicylic acid', 'foscarnet', 'iodinated contrast media|Contraindications', 'H2-receptor antagonists', 'Risdiplam', 'Systemic drugs', 'illegal drug/substance abuse', 'lactulose (prebiotics)', 'conventional analgesia', 'decide ahead', 'CGM', 'Lomitapide', 'aminoglutethimide', 'anti-diabetes medications', 'benzodiazepines', 'International Council for', 'GEP NET|Concurrent anti-cancer treatment', 'steroid', 'internalizing', 'compounds related to darolutamide', 'coumarin-derived vitamin K antagonist anticoagulants', 'nasal steroid', 'TURP', 'IVT of', 'TL', 'treatment modality', 'biologics', 'systemic steroids', 'finasteride', 'Plasma Glucose (FPG)', 'anti-anxiety medication', 'medication pump', 'components of the Velocity Implant or Delivery System|Written informed consent', 'long-acting growth factor', 'anti-coagulants', 'b', 'lysergic acid diethylamide', 'dopamine antagonists', 'chondroitin sulfate', 'medications containing', 'noninsulin glucose-lowering medications', 'antibody-depletion therapy', 'Anyone meeting New York Heart Association criteria for Class', 'represents', 'L-carnitine', 'dipeptidyl peptidase-IV inhibitor [DPP-4I]', 'topical and inhaled agents', 'Delstrigo®', 'vildagliptin', 'NNRTI', 'ECG', 'BIC', 'drug substance', 'testosterone-blocking treatment', 'linaclotide', 'potassium competitive acid blockers', 'nodular liver', 'manipulation', 'closed-globe trauma|RRD', 'topical ophthalmic agents;|contact', 'investigative medication', 'anti-cancer small molecule', 'prescription medication', 'demethylated drugs', 'indinavir', 'prescription drug abuse', ""St. John's Rehab"", 'duodenal switch', 'anti-lymphoma', 'monoclonal antibody.|Major surgical procedure', 'components contained', 'PI3K', 'oral contraceptive steroids', 'ALK inhibitor therapy', 'CYP3A4 potent inhibitor', 'docetaxel', 'Nitrosourea', 'RAAS inhibitors', 'immunosuppressive therapy|Non-healing wound', 'components of the intervention drug', 'raloxifene', 'mediastinal lymphadenopathy)||', 'hypericum perforatum', 'lies', 'similar products/formulations|The', 'PSRT', 'azacitdine', 'Narcotic Analgesic Effects|Anesthetic Drugs|Neuromuscular Blocking Drugs - Patients', '3rd molars).|No', 'seizures.|Patients', 'systemic fibrinolytic therapy', 'CYP3A inhibitor', 'TAK-755', 'bloating', 'myeloproliferative', 'constitutional platelet dysfunction', 'preventative medication dosing', 'ACE inhibitors', 'oral medication.|Patients', 'daily analgesics', 'anti-phlogistic agents', 'joints.|Investigational drug', 'compounds of similar chemical or biologic composition to S-1.|Concomitant medications', 'HAV', 'topical medications/treatments', 'MEK inhibitors', 'parenteral anti-infective', 'articipants', 'Naltrexone', 'HLH', 'antivirals', 'poly-ADP ribose polymerase (PARP)', 'drug-drug', 'molecular markers', 'neurotrophic tyrosine receptor kinase inhibitor', 'CYP3A4 inhibitors', 'harp', 'topical contraceptives', 'esophageal stents', 'drug absorption', 'illicit drug', 'drugs under investigation.||', 'monomorphic VT below detection rate of ICD', 'contraindicate surgery.|Participant', 'consume food products', 'craniofacial district', 'mipomersen', 'components of this test drug', 'LZD', 'antibody', 'Bumetanide', 'direct oral anticoagulant therapies', 'anti-coagulant.|Patient', 'St. John´s Wort', 'materials in the sessions', 'stone kidney', 'antiplatelet drugs', 'anti-spasmodic', 'anti-CD20 monoclonal antibody', 'Screening.|Depot antipsychotic use', 'hormonal contraceptive implant', 'urinary diversion', 'Early Learning)|Child', 'beta3 adrenergic', 'antibody-drug conjugate', 'SynergEyes', 'enzyme inducers antiepileptic drugs', 'antirejection medications', 'immunosuppressive agents|Patients', 'atypical antipsychotic medications', 'Wellbutrin', 'medium-acting corticosteroids', 'T1bN0M0', 'AKs)', 'anti-PD-1/', 'antiplatelet aggregation drugs', 'last menstruation', '3rd degree heart block', 'Factor IX inhibitor', 'dexamethasone', 'investigational drug treatment', 'contrast material|Patients undergoing', 'methylphenidate', 'veltuzumab', 'FIX agents', 'contraceptive requirements|Body mass index', 'aminoglycoside antibiotics|previous treatment', 'angiotensin receptor blockers', 'VC005', 'Trazodone', 'Riluzole', 'food used in the trial', 'anticoagulant / antiplatelet agents|patients', 'clexane etc.)|Patients', 'pandemic influenza vaccines', 'corticoids', 'mango', 'immunosuppressive medication.|Patients', 'medication', 'TCI', 'nafinavir', 'IUDs', 'Selective serotonin-norepinephrine reuptake Inhibitors', 'injection drugs', 'Clinics', 'anticoagulant agent', 'spontaneous mobility|Previous surgical procedures', 'Iscador® P', 'diabetologist', 'blood-derived products', 'varespladib', 'group.||Key', 'psychotropics', 'component of the study medication', 'LAMA', 'drugs e.g renal', 'antiretroviral therapy|Effective contraception', 'sprain,|on medication', 'inhaled tobacco)|Illicit drug use', 'DRB1', 'immune-checkpoint inhibitor', 'Metvix', 'opioids/pain', 'dolutegravir', 'peripheral musculoskeletal disorders|New consultation', 'AHAs', 'allergy shots', 'antiplatelet therapy;|Known allergy', 'topical phosphodiesterase inhibitors', 'H2 blockers.|Currently', 'anti-arrhythmics', 'glabellar lines', 'auxiliary materials.|Donate blood', 'Cirrhotic', 'long-acting basal', 'months||is', 'intranasal decongestant', 'odynophagia', 'drug-related pulmonary toxicity', 'fluoride', 'cleft', 'vaginal medications', 'routine care.|Wards', 'loco-regional block', 'phenobarbital', 'ranolazine', 'rifaximin', ""Tenofovir's salt-free"", 'lenalidomide should', 'peptide-1 receptor agonist therapy', 'HCL System', 'missense', 'nirmatrelvir.||Diagnostic Assessments:||Known', 'Plasmalyte', 'peptide', 'Covid-19 vaccine', 'NMPA', 'drugs used in this protocol', 'iron supplements', 'Levothyroxine', 'Total', 'beta blocker', 'hormonal contraceptives should', 'RNA', 'strong painkillers', 'beta-carotene', 'those supplements', 'related drugs', 'alefacept', 'sevoflurane', 'Zuclopenthixol decanoate', 'done', 'amphetamine medication', 'olive oil', 'makes the', 'Rickham catheter', 'antioxidants', 'colchicine', 'kidney related', 'device materials;|Previous pericardiotomy', 'protease inhibitors indinavir', 'supraclavicular', 'antihypertensive drug treatment.||Exclusion criteria:||Under treatment', 'tetracaine', 'intravitreal implants', 'mesalazine', 'small molecules', 'SER', 'non-steroidal anti-inflammatory drugs [NSAIDs]', 'medicinal substances', 'penicillins', 'months|Best-corrected visual acuity', 'Gadolinium contrast', 'talc', 'component of the study drug.|Have', 'immunosuppressant medication.|Participant', 'anticardiolipin anti-bodies', 'Receives successful', 'oral NSAIDs', 'immunomodulatory drugs', 'Prilocaine', 'anti-arrhythmic medications', '≤45%.|Brain Natriuretic Peptide (BNP)', 'chronically drug abuse|Smokers', 'cimetidine D', 'oral antibiotic medication', 'anti-inflammatory treatments', 'topical medications', 'pravastatin', 'polatuzumab vedotin', 'local anesthetic drug', 'Xiidra', 'osilodrostat', 'therapeutics delivered', 'itraconazole', 'components of', 'myocardial segments', 'LN', 'Surgery', 'immunosuppressive biologic', 'strong inducers', 'clofarabine', 'erythrocyte', '3rd generation TKI', 'cumulative inadequate', 'vasoactive drugs', 'direct oral', 'C1D1', 'isopter III4e', 'prescription systemic NSAIDs.|Known', 'miconazole', 'pathogens', 'lipoproteins', 'online', 'MMAE', 'levoketoconazole', 'emergency room visit', 'anti-CD19 therapy', 'components of the drug|Liver disease', 'vaporized', 'angiotensin II receptor blocker (ARB)', 'echocardiographic', 'Hormonal contraceptives', 'THC', 'influenza vaccine)|Previous vaccination severe', 'Ocrelizumab', '3rd', 'Baclofen-amitriptyline-ketamine', 'Enoxaparin', 'Buprenorphine/opioids', 'meta-iodobenzylguanidine-accumulating focus (foci)', 'ischaemic heart', 'CYP3A4 substrates', 'chronic medication', 'HIV-2 antibody', 'Optidril®', 'Norepinephrine Reuptake Inhibitors', 'sphincterotomy|Percutaneous liver biopsy|Biopsy', 'trial-related intervention.|High', 'anticoagulation medicine', 'pia maters', 'topical anesthetic', 'local anaesthesia|Treatment technologies', 'anesthesia;|Pregnant', 'androgen receptor', 'tirofiban', 'ophthalmology', 'anticoagulant medication', 'valproate', 'intravenous thrombolytics treatment', 'GACs', 'local measurement', 'sodium hyaluronate;||Have', 'dapsone', 'health institution', 'baseline.|Anti-tumor necrosis factor', 'Vitiligo', 'gestational diabetes)|having', 'immunomodulatory agents', 'injectable drugs', 'LR769 -', 'growth hormone|Use', 'anticoagulant regimen', 'loser photocoagulation', 'cytostatics', 'peripheral venous catheter', 'drug medication', 'onset of rescue intraarterial', 'component of the formulations', 'related products', 'analgesic drug', 'SCN', 'Diplomatic Post Office', 'kinesio tape', 'topical prescription retinoids', 'irradiation', 'abetalipoproteinemia|on medication related', 'immunosuppressive effects', 'trial products', 'methotrexate.||-', 'strong CYP3A inhibitors', 'fish allergy', 'anti-CD4', 'genes', 'anti-EGFR therapy Note', 'phosphodiesterase type 5 (PDE5)', 'any antipsychotics', 'selective serotonin reuptake inhibitor', 'GLP-1 RAs', 'AIG||', 'PCSK9 Inhibitor', 'intranasal corticosteroids', '5-α-reductase inhibitors', 'donepezil', 'anticoagulants;|bone metabolism disorders;|infections', 'connective tissue diseases.|Those', 'methadone', 'contraceptive ring', 'cavotricuspid isthmus-dependent', 'MCD', 'midline', 'thalassemia|Solid organ', 'naloxone hydrochloride', 'capsaicin', 'CYP)2C8 inhibitor', 'sedatives|Upper extremity venous', 'Sandostatin® LAR', 'NGS testing', 'Third Affiliated Hospital', 'platelet aggregation', 'CYP3A inducers|Refusal', 'High grade B-cell lymphoma (HGBL)', 'tirzepatide', 'conventional cups', 'high drug', 'imdevimab', 'investigational product', 'antiallergics', 'pretreatment drugs', 'Octreotide', 'proton pump inhibitors', 'oral contraceptives [OCPs]', 'beta-blocker medical therapy', 'syndromic', 'consensus', 'drugs administrated', 'CYP3A inhibitors', 'local steroids', 'components of CM310 injection', 'STUPP regimen', 'mumps vaccine', 'formalin-fixed', 'metformin≥', 'meibomian', 'Cleft', 'adhesives used in medical dressings', 'vaccination;|Impaired immune function', 'molecular profiling', 'cholesterol sulfate complex', '5-FU', 'felodipine', 'amoxicillin-a.', 'IIIa NSCLC|Candidate', 'anti-parasitic drugs', 'HILT', 'anti-viral prophylaxis', 'tranquilizing', 'similar drug treatment', 'sleep agents', 'drinks containing caffeine', 'antibiotic allergies', 'anti-cancer indications', 'Grade', 'contains molecular alterations', 'synthetic', 'TCHP', 'immune suppressive treatment', 'nevirapine', 'Lansky', 'islet autoantibody', 'kidney', 'contrast performed', 'v1.1.||Exclusion Criteria：||Participate', '1A2-inducing', 'glucocorticoid drugs', 'pembrolizumab combination', 'components of CM326 injection', 'systemic antibiotic treatment', 'antimalarial', 'sensitive substrates', 'suitable veins', 'Traditional Chinese Medicine', 'investigational drug', 'components comprised in preparations.|Diabetics|Chronic kidney disease', 'component of the study drug', 'local regulations||', 'components of behavioral activation', 'supplements|creatinine', 'anti-KIR3DL3 monoclonal antibodies (mAb).|Any systemic anti-cancer therapy', 'investigative drug', 'danazol', 'mRNA', 'prescription treatment||', 'monoclonal antibody;|Evidence', 'PCSK9 inhibitors', 'Taxane', 'hematopoietic', 'components of the study treatment|Known', 'anticoagulants incompatible', 'intravenous iron product', 'FLT3 mutation/duplication', 'ritonavir', 'low-molecular-weight', 'antidepressants of the triptyline', 'anti-HER3 antibody', 'nonsteroidal anti-inflammatory drug', 'SMILE', 'HIV monoclonal antibody (product', 'drugs containing steroids', 'dihydroepiandrostenedione sulfate', 'portal vein thrombosis|Hepatocellular carcinoma', 'selected drugs', 'remibrutinib', 'exemestane', 'liver enzyme inducers', 'antipsychotic', 'FibroScan', 'prescription blood thinners', 'nerve bundles|Patients', 'anti-DS-DNA antibody score', 'retained products of conception in diagnostic hysteroscopy.|Medical need', 'kidney disease|Conception', 'DFCI for necessary data collection.|May not be able to comply with the safety monitoring requirements of the study', 'excipients', 'Tamoxifen', 'direct thrombin inhibitors', 'herbal medicines', 'varices|Planned liver biopsy', 'intravitreal anti-VEGF injections', 'midline abdominal incision', 'transmucosal fentanyl', 'repaglinide', 'grapefruit-containing', 'Oxaliplatin', 'or;|triglyceride']","['foreign bodies', 'Cohort Expansion Phase):', 'joint surgery|Ankylosing', 'EXCEPTION', 'CTP', 'situations in which the investigator judged that the patient was not', 'expected survival', 'affect interpretation of the results of the study', 'unable to communicate', 'enrolled in treatment programs|Hemoglobin', 'children)|Inability to lie still', 'chocolate', 'yoga', 'radiographic evidence suggesting', 'cognitive impairment.|Be enrolled in 01M0254', 'partners are', 'participated in mindfulness based projects for more', 'meet the inclusion criteria.||Teacher Inclusion', 'sleep medication(s)', 'participated in a research protocol', 'predicted life expectancy', 'commit the time requested', 'remain located in the Pittsburgh area', 'participated in other clinical studies', 'eggs', 'loss of balance', 'render the subject s participation unsafe', 'plan', 'commit to performing the required study tasks|Can speak/understand English||', 'sedentary individual', 'close to the tumor site', 'enrolled in the pilot', 'entry into study.|Abnormality', 'participated in another clinical trial within 30 days or within', 'render them unlikely to follow the protocol', 'situations that would limit compliance with study requirements.|4', 'Misunderstanding of the French language;|Participation in another interventional trial of category', 'unable to consent', 'breastfeeding.|Any other reason', 'Signed Informed Consent obtained from patient/parent/legal guardian/independent witness', 'unable to communicate in Dutch', 'psychotic|at risk', 'cigarette consumption', 'lactation|Active', 'sudden death.||6', '1|Life expectancy', 'insufficient Chinese ability;|Subjects', 'willing to participate in the study', 'unable to return', 'problem in reading and understanding the semi-structured socio-demographic', 'not.|Subject reports', 'signed an informed consent||', 'surgery|Life expectancy', 'constraints|Life expectancy', 'risk of pulmonary aspiration:||GERD|Pregnancy||Anticipated airway difficulties:||Mallampati', 'participated in any clinical trials or research', 'prevention scheme', '3+.|Predicted survival', 'unable to receive standard therapy', 'willing and able to comply with the study protocol', 'participated in another clinical trial protocol', 'progression of the illness leading the consulting physician to offer treatment', 'render the patient unable to understand his/her participation in the study', 'difficulty staying asleep ""Moderate', 'Signed informed consent;|MFS diagnosis', 'unable to maintain contact with the healthcare professional.|Use', 'sudden', 'Loss of sensation', 'genetic sequencing to characterize', 'risk of CD', 'situations related', 'limit life expectancy', 'prevention of cardiovascular disease|Use', 'situations that would interfere with patient safety', 'changes', 'pace- makers', 'sleep disorders|Pregnancy|Deviation', 'breast feeding|Psychological', 'the activity of CYP3A in the liver', 'sleep disturbances', 'suicidal ideation', 'meeting the inclusion criteria', 'speak French|Chronic', 'Professionals||Participant', 'life expectancy beyond the initial 3 months post-treatment', 'incarceration', 'progression of disease following treatment', 'Dialysis dependent', 'available at https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx', 'HV', 'vegetarian diet', 'Insufficient Danish', 'cease smoking', 'physical assault', 'willing to participate|Patients', 'enrollment|Fluent English speaker', 'genetic aberration identified either', 'sleep disorders.|Children', 'unable to read', 'enrolled in other clinical studies', 'Sprututbytesprogrammet in Uppsala defined', 'render a subject inappropriate for study participation', 'prevention of SCD|Persistent right', 'involuntary detention', 'lacks the ability to comprehend', 'Unable to acquire ECG', 'prevention of contrast media allergy', 'entry into this study|COVID-19', 'cooperate with the baseline', 'adjusted', 'obtaining', 'dialysis|Life expectancy', 'difficulty in expressing herself', 'admission', ""enrolled in another clinical investigation in which the intervention might compromise the safety of the subject's participation in this"", 'grafting', 'participated in a similar intervention program', 'close sinus lifting||', 'entry into this study:||The subjects agree', 'enrolled into another clinical study continuously', 'difficulty in ventilation', 'close to Ho Chi Minh city', 'living in the community|Able', 'suggesting', 'expected to receive', 'partners plan', 'Cockcroft-Gault formula)|Serum aspartate aminotransferase', 'unique exclusion criteria', 'unable to follow the research procedure;|2.Patients', 'unable to use crotches', 'Unable to complete cognitive function evaluation', 'cognitive function|Substance abuse', 'ulcerative', 'progression cannot', 'remain in the Little Rock area', 'MTX.|part of a', 'living with HIV:', 'violent behavior', 'situations that would limit compliance with study requirements|Autoimmune', 'enrolled on this protocol', 'insufficient clinical', 'unable to ambulate', 'living in postcodes', 'Insufficient clinical information', 'anemia.|Fecal incontinence|Patient', 'excess blood loss', 'any other psychological problems', 'living situation', 'situations that would limit compliance with study requirements.|Evidence', 'fetal growth restriction', 'life threatening', 'expected life of', 'Cockcroft-Gault formula)|ECOG score', 'rates in spouses', 'Unable to give informed consent', 'unable to safely', 'visit plan', 'suicidal behaviour', 'colorectal cancer|Agree to provide tumor/normal tissue', 'meet all inclusion criteria|Another child from the household', 'render the patient inappropriate', 'risk for TB.|Any major surgery', 'expected survival time≥', 'situations that would limit compliance with study requirements.|Gross tumor invasion of the stomach', 'native Chinese speaker', 'volume of disease to allow implantation of the microdevice|Patient', 'Signed informed consent obtained before any study-related activities', 'prevention of endometriosis recurrence|Medical conditions', 'difficulty accessing veins', 'physical activity recommendations of', 'unfavorable risk', 'unable to understand the informed consent process', 'Living in a nursing home|Presence', 'Established', 'radiographic signs', 'inpatient services', 'prevention of thrombosis', 'intent', 'unable to communicate verbally', 'employee', 'Unable to consent for research', 'render the participant unable to meet the requirements of the protocol', 'Healthy', 'postoperative intensive care', 'life threatening condition', 'lactation,|fixed', 'sponge', 'limit compliance', 'change in level of care', 'Children admitted', 'maintenance dialysis||Providers', 'USN:||- clinical diagnosis', 'prevention interventional research study|Upper arm circumference', 'myometrial invasion', 'sleep medication|unable to attend laboratory visits', 'risk of airway obstruction|No high', 'unable to undergo contact x-ray', 'remain in the central Arkansas area', 'ECMO.|Patient affiliated to the Social', 'Etcetera', 'noncompliance to medical regimens', 'risk of vitamin C deficiency', 'etc.).|Not', 'unable to follow', 'participated in other interventional clinical trials', 'upgrade', 'patient refusal;||known', 'participation in rehabilitation|A neurologic disorder', 'method of birth control', 'pediatricians', 'Cohort 2', 'situations that limit participation compliance with study procedures', 'accepted into the UHS COVID follow-up', 'situations related to COVID-19 pandemic', 'Unable to suck on a swab.|Previous participation', 'lesion(s', 'iRECIST|Life expectancy', 'nursing|Unwilling', 'Signed informed consent form before', 'life-saving intervention', 'Refuse to participate in the study|Myocardial injury', 'method of contraception', 'unable to use smartwatch', 'old|Cooperative', 'processing speed', 'screening.|life expectancy', 'conceive children', 'soy', 'unable to verbalize symptoms of', 'prevention of', 'needling', 'risk of diabetes', 'occlusion locations', 'progressed on', 'unable to interrupt', 'radiographic evidence consistent with cirrhosis of the liver.|Adequate renal function', 'labor', 'speak English|Current psychosis', 'adjuvant therapy.|The first lymph node dissection', 'Cockcroft-Gault', 'limit compliance with study requirements||PRE-REGISTRATION', 'insufficient patient compliance to participate in this clinical study', 'expected to', 'PD', 'entry into this study|Known', 'willing to allow the child to participate', 'signed the informed consent on', 'remain on the birth control until', 'sleep schedule until the end of the study|Willingness', 'possible myocarditis/pericarditis', 'Living in out-of-home care|15 years', 'cleaning).|10', 'difficulty in urination', 'meet the appropriate criteria for DCD donation', 'close to Porte de la Chapelle', 'offspring', 'participated in a study of an investigational agent', 'Life-threatening disease|Conditions', 'render the patient at high', 'covered', 'unable to swallow', 'breast feeding|History of', 'genetic risk (common', 'weeks|Previously completed', 'support|Congenital anomalies|Uncontrolled hemodynamics|Severe airflow', 'willing to take nutritional supplements', 'unable to take miglustat', 'sleep aids|Diagnosed sleep disorder|History', 'changes in weight and lung function', 'hormonally active', 'change in thickness of liquid', 'managed in the judgment of the investigator', 'dialysis fistula', 'dyspnea on exertion;|Any condition', 'physiologically capable of becoming pregnant|Blood pH<7.32|>1 episode', 'difficulty with visits|Bariatric surgery', 'tobacco use', 'initiation', 'participated in other clinical trials within 30 days of the screening date|Other cases where the investigator judges that participation in the clinical trial is inappropriate due to ethical reasons', 'noncompliance with medication.||Unwillingness or inability to follow the procedures outlined', 'diet', 'acupoints are unaffected.|All patients enrolled on the study will have their informed consent.||', 'Patient-led', 'remain in Wenzhou', 'signed informed consent||- Patient benefiting from French social insurance system||', 'unable to continue treatment', 'contraceptive precautions', 'cohort entry date|3', 'situations that would limit compliance with study requirements.|The', 'unable to give informed consent|Any other condition', 'S. aureus', 'violence', 'detoxicating from substances|the inability to comprehend the intervention', 'situations that are', 'sleep disorder|PSQI score', 'age|Using', 'method of avoiding pregnancy', 'unable to express', 'soy food products|Use of', 'enrolled in other courses on scientific writing 12 months prior', 'remain on the', 'Cockcroft-Gault formula;|Subjects', 'enrolled a sufficient number', 'MW|having', 'priapism|Pregnant', 'volume difference', 'situations in this study', 'situations that limit compliance with research requirements.|Pregnant', 'close relative', 'Signed Informed Consent obtained before', 'radiation exposure', 'premature contact', 'meet all inclusion criteria', 'physical activity', 'expected risk of progression to ESKD', 'Changes in medication use for the management of VWM disease symptoms', 'risk of', 'disorders of consciusness', 'breastfeeding.|Any other condition that', 'meet the inclusion criteria|Other patients', 'signs', 'expected life', 'artificial tears.|Significant eye lid droop blocking the pupil.|Persistent blurry vision', 'anticipated', 'precludes', 'unable to oral', 'PD|Current alcohol', 'Unable to read English', 'Unwillingness to stop digital media', 'Signing of a specific informed consent for participation to the study|Female sex||Population', 'feeding', 'screening|Able to understand the nature of the study', 'unable to conduct the follow up visits per protocol', 'soy protein', 'any other condition that may increase the risk associated with study participation', 'participated in other interventional clinical studies', 'admitted in the included unit', 'participated in other diabetes education research projects will be', 'limit compliance with study requirements|Pregnant', 'Signed Informed Consent Form (ICF)', 'situations that would limit compliance with study requirements|Unwilling', 'method of contraception|Persistent leucopenia', 'unable to understand relevant medical information', 'Unable to have', 'Family history', 'unable to undergo anthropometric assessment;|Body mass index', 'Head', 'affiliation to a social security scheme|Patients under guardianship', 'injections into', 'speak Hebrew', 'speak English Pessary practitioners|Lacking', 'risk of bleeding;|Chronic renal failure', 'link to dry eye', 'sexual partner', 'living in the Greater Victoria area', 'stopped smoking', 'Risk Level', 'partners of child-bearing potential', 'wash out period', 'nasopharyngeal swabs', 'sexual abstinence.|Other acceptable', 'inadequate biventricular pacing', 'researchers', 'ICU admitted', 'unable to undergo surgery', 'risk of bleeding|Anatomopathological sampling not feasible|Patient', 'monotherapy', 'consistent with PNH', 'expert adult', 'Cockcroft-Gault|The effects of the study therapy', 'errors in data collection', 'Signed informed consent|Adequate renal', 'Breast feeding', 'CTR', 'stimulants|unstable diabetes|bupropion', 'Refusing to participate in the study|Having significant vision', 'pregnancy|Life expectancy', 'change in bowel habit', 'expected to recur', 'older|Patients', 'situations that would limit compliance with study requirements.|Participants', 'genetic variant', 'Enrolled in another interventional clinical research trial in the previous', 'score for cornea', 'unable to consent to surgery', 'paraffin', 'asthma.|Past', 'cooperate fully with the Investigator|Have', 'risk of fractures', 'diseases:|Irritable Bowel Syndrome', 'close relatives of the study site personnel', 'contradiction to tRNS', 'volume ≥70ml', 'Medical', '1.|Expected survival', 'metabolic syndrome|concurrent participation in another research study', 'willing to follow and able to complete', 'lactating', 'psychiatric illness,|Presence of', 'Sexual activity can', 'remain in follow-up', 'surgery;|Without systematic metastasis', 'genetic evidence', 'prosthesis in maxillary arch.|Patients', 'requires', 'dyspnea on exertion|Stable clinical condition', 'preexisting', 'HBV.|Clinical evidence', 'situations that would limit compliance with study requirements|Prior external beam radiation therapy', 'Signed the informed consent', 'risk for suicide', 'hence cannot', 'involuntarily incarcerated.|Participants', 'participated in the other', 'minimal risk', 'breast cancer|Patient treated', 'problems in cooperation', 'in smoking pattern', 'unable to complete study questionnaires', 'Living in areas', 'close consent', 'family-social', 'difficulty in digestive tract absorption or disorder.|Female', 'unable to receive', 'violent', 'situations that other investigators consider unsuitable for enrollment', 'IMP', 'Successful', 'unable to complete follow', 'risk of falling|bone metastasis', 'Cooperation difficulties', 'sleep related disorders', 'life event', 'Volunteers|BMI', 'difficulty to stay fasting', 'sexual', 'Signed informed consent', 'bruising', 'remain at the study center', 'Limited mobility', 'aortic arch', '1.|Life expectancy', 'situations of ""non-re-admission"" decisions in intensive care', 'unable to swallow medication', 'volume of', 'sleep quality etc.;|PSQI score', 'agitated', 'participated in other interventional drug', 'participation in another interventional', 'Risk of Malnutrition', 'outpatients', 'Psychiatric Care|Protected', 'life-threatening condition', 'insufficient medical records', 'Non English Speaking', 'changes in position', 'sleep disorders|Enrolled', 'RECIST', 'risk of inducing torsades de pointes', 'included.|Agreed to participate in the study', 'excess blasts-2 (', 'valid certification of catastrophic illness', 'review.|Life expectancy', 'disorder|Current DSM-5 substance', 'bound.|Residence in skilled nursing', 'unable to complete', 'procedures|Patients capable of understanding the investigational nature', 'constipation', 'Unable to consent|Pregnant', 'Cockcroft-Gault equation|Alanine aminotransferase (ALT)', 'preeclampsia|Pregnant', 'submucosal', 'situations that would limit compliance with study requirements.|Pregnant', 'currently residing', 'difficulty in complying with the requirements of the study', 'life situations', 'constitutes an exclusion', 'sleep disorders||', 'Informed consent|Established diagnosis', 'Parents not fluent', 'expected survival duration', 'Failure', 'family medicine|had', 'situations that would limit compliance with study requirements.|REGISTRATION', 'sexual assault', ""at investigator's discretion"", 'stainless steel', 'Signed informed consent|Patient', 'participated in other skills training programs|are not interested', 'nicotine product use', 'refuse to accept standard treatment', 'sexual dysfunction||', 'Expected survival', 'nonsurgical', 'risk of cerebral herniation', 'incapable of completing', 'render the subject ineligible for HSCT', 'progressed after', 'genetic cause for obesity', 'progression to AML', 'participated in other clinical research trials within 3 months before randomization|Participant', 'situations that would limit compliance with study requirements.|Plans to father a child while enrolled in this study', 'difficulty in standing', 'stress disorder|taking opiates|pregnant', 'situations that would compromise patient safety', 'situations that would limit compliance with study requirements||Any organ transplant', 'rapport diet', 'breastfeeding,|Known', 'patient related outcome', 'risk for severe hemorrhage.|Has', 'Unable to wear', 'expected need', 'first degree', 'sleep maintenance', 'contrasts|Incompatible implants', 'years.|Histopathology', 'university hospital', 'network through mobile phone;|Sufficient reading', 'insufficient comprehension of the Dutch language', 'unable to give', 'progressing', 'literate', 'situations that would limit compliance with study requirements||Active', 'unable to use', 'unable to follow protocol requirements|Patients', 'signed the informed consent form.||', 'childbearing plan', 'MRI.|Tumor in non eloquent brain region', 'recently admitted', 'ive.google.com/drive/folders/1eqhYGcjNDNnk_cKTgiKQyX3ntdD3xLnY?usp=sharing', 'expected survival period', 'maintenance hemodialysis', 'minimize risk of bias in study findings', 'clinical involvement;||', 'Signed informed consent before any study', 'lack of time', 'unable to use highly effective methods', 'partners of', 'volume that', 'breastfeeding.|Any other condition', 'enrolled voluntarily', 'Signed informed consent;|Men', 'conduction system;|Patients', 'cooperate swallow therapy||', 'dexamethasone|Any other condition that', 'sufficient understanding of the study', 'living environment', 'setting', 'willing to follow study procedures||', 'play.|Sampling of convenience', 'remain in Central Kentucky', 'genetic risk of prostate cancer', 'limit survival', 'maintaining follow-up;|Epilepsy/seizure', 'incapable of giving informed consent', 'bias interpretation of the trial results', 'Soy allergy|Amputation|Significantly', 'Unable to complete', 'BCG.|Life expectancy', 'breast MRI', 'enrolled in other interventional clinical trials', 'Signed informed consent obtained', 'signed consent||Exclusion', 'Predicted survival', 'attenuation of the', 'risk of pulmonary embolism', 'genetic risk score||', 'insufficient ability to understand written and spoken Dutch', 'breast treated', 'close attention', 'cooperate to observe adverse reactions', 'Cohort A or B', 'Difficulty in understanding the Portuguese language to answer the questionnaires;|self-report', 'situations that would limit the safety of a biopsy', 'drug exposure.||Patients', 'volume of diffusion restriction visually assessed', 'sexual intercourse;||• Female', ""child's parent"", 'possible risk to the fetus', 'mucoid', 'progressed on treatment', 'infertile', 'involuntarily incarcerated|Subjects', 'nurse', 'nursing.|Substance abuse.|Psychiatric problems', 'participated in any regular', 'progression of disease on', 'managed by the functional method', 'render the administration of the investigational product hazardous', 'Signed informed consent|Type 1', 'Unmarried', 'progression of clinical symptoms despite', 'Unable to take oral medications.|Clinically active', 'difficulty of follow-up observation', 'breast feeding.|Decision of', 'resolved', 'unable for FMT', 'egg donation', 'expected difficult', 'interpersonal stress', 'lose weight', 'Cockcroft-Gault|The effects of ATI-2231on the developing human fetus', 'bacteria susceptible to', 'cigarettes', 'enrolled in', 'unable to complete the survey.|Child is a ward of the state', 'Residing', 'Missing', 'risk of aspiration|obese', 'plant sterols', 'render a subject unsuitable for inclusion|Unwillingness to', 'genetic mutation', 'working in cancer-related positions', 'meeting the inclusion criteria|any reason', 'risk of seizures', 'Insufficient understanding of the study', 'written general informed consent|patients', 'difficulty in voiding', 'remain in the same program', 'Cockcroft-Gault glomerular filtration', 'life habits', 'Unable to communicate', 'risk of future CVD', 'meeting the inclusion criteria|Not wanting', 'volume paracentesis|Central venous catheter', 'unable to lie flat', 'entry into this protocol', 'risk of gastric cancer', 'sexual maturity', 'difficulty in swallowing drugs', 'Parents unable to find out', 'Unable to obtain', 'situations that would limit compliance with study requirements|Pregnancy|Known', 'unable to get MRI', 'Cohort E', 'Cockcroft-Gault formula.|For', 'phototherapy', 'participated in another trial', 'life-limiting illnesses', 'radiographic evidence consistent with cirrhosis of the liver|Adequate renal function', 'pancreatitis|Known', 'physicians', 'render them unable to comply with study procedures', 'managed medically|Life expectancy', 'physiologically capable of becoming pregnant.|Female', 'incapable to follow the trial', 'shortness of breath', 'Signed informed consent|Patients', 'unable to take effective contraceptive measures;|Patients', 'unable to follow protocol requirements', 'Unable to read', 'enrolled in another therapeutic clinical trial', 'method of', 'changes in respiration.|obese subjects', 'bilirubin', 'change in glucose control medications', 'difficulty with blood sampling through venipuncture.||Individuals', 'r mutation carriers:||Pathogenic Parkin', 'involuntarily committed', 'Unable to understand spoken', 'wheelchair/bed bound|< 6 month life expectancy', 'family (first-degree relative', 'lesion;|Expected survival', 'phobia', 'radiographic evidence', 'Unable to give informed consent.|Unable to use', 'Expected survival period', 'enrollment.|Expected survival', 'PNH', 'Refused to participate', 'incarcerated', 'close family||Inclusion criteria', 'parents from the district', 'LHRH agonists', 'Smokers', 'Unable to independently kneel', 'minimal risk of recurrence', 'expected to respond to treatment', 'Unable to provide informed consent', 'render them unsuitable for inclusion', 'change in antitussive therapy', 'partners of childbearing potential', 'speaking', 'volume challenges', 'refuse to participate in the study|Parents of individuals', 'Signed informed', 'unable to avoid', 'situations that would limit compliance with study requirement', 'Signed informed consent|At least 19 years of age|≥60 days prior to study enrollment', 'Expected survival time', 'willing to consent to be training', 'Unable to reliably complete follow', 'completion.|History', 'participated in another clinical trial', 'signed an informed consent form', 'situations that would limit compliance with study requirements.||Urinary tract infections', 'chemotherapy|Ability to understand and the willingness to sign a written informed consent document|Self-identification', 'melanoma)|life expectancy', 'loss of consciousness', 'comorbidity.|Able to communicate coherently', 'difficulty to apply exercise program', 'render the patient ineligible.|Availability of', 'Signed Informed Consent Form (', 'sleep period', 'PSC)|History', 'sedation', 'remain in the study area', 'Unable to sign', 'life expectancy', 'subordination|Subject understanding', 'difficulty understanding', 'violent behavior|a potential discharge location anticipated', 'predicted closure length', 'recruitment residing', 'breast cancer|Previous vacuum-assisted biopsy', 'NIV|Inability to give informed consent', 'apheresis product available', 'life threatening impairment of the cardiovascular', 'cortico-basal syndrome', 'stroke|>1 week and < 8 weeks post stroke|New', 'Children:||enrolled', 'move', 'birth plan', 'seen in ultrasound examination', 'radiotherapy;|Expected survival', 'render the patient unable to comply', 'nursing', 'Refusing to participate in the study', 'Psychiatric co-morbidities', 'apheresis product', 'participated in an interventional study', 'difficulty with sub-cutaneous injection(ex', 'Eligibility', 'speak French|Parents of', 'participated in an investigational study', 'unable to complete the study', 'participated in other research programs', 'technical difficulties', 'incompatible with life|Receiving palliative care|Patients', 'close contact', 'willing to take effective contraceptive measures', 'person with dementia', 'low survival rate', 'diuretics|Prior', 'remain in the off position', 'rare EGFR mutations', 'render the subject unsuitable for study participation', 'sleep habit changes', 'unable to lie still', 'willing to enroll|Possess', 'Unable to provide informed consent in English', 'manipulating the device|Persons deprived of their liberty by administrative', 'hospitalized in cancer', 'diabetes|Contraindication to surgery|Contraindication to MRI|Contraindication to PET scan|Contraindication', 'hydroxychloroquine|Life expectancy', 'silver|Presence', 'nasopharyngeal surgery|Severe facial trauma', 'difficulty biting|Subjects', '""stable"" diabetes mellitus', 'unable to cooperate to answer the questionnaires|unable to view the videos', 'perioperative risk', 'meet the', 'Clear preoperative consciousness', 'hospitals|Able to read', 'choking', 'expected risk of', 'risk of bladder', 'psychiatric condition).||Staff', 'lung activity', 'women|Life expectancy', 'participated in another clinical trial in the last 2 months', 'meeting the', 'alterations in electroencephalogram', 'Unable to understand the surveys', 'signed and informed consent|For', 'remain in the clinic', 'Pupils', 'nodal basin ultrasound surveillance', 'living at home', 'LVA burden', 'inadequate understanding of Danish or English language.|Any other condition', 'Unable to understand or communicate in English|Serious mental health problem|Unable to give informed consent', 'difficulty with communicating in Japanese)|Confirmed diagnosis of', 'risk of recurrence.|Breast cancer', 'refuse to participate/to give consent|presence', 'unable to answer questions correctly|Critically', 'unable to have', 'risk of recurrence', 'progression associated', 'Vulnerable populations also may include members', 'quit smoking', 'risk of progression', 'consistent with HCC', 'Unable to complete the initial assessment', 'genetic research', 'MitraClip|Current', 'unable to comply with trial obligations', 'life-threatening conditions', 'sleep duration', 'incapable of performing mobility', 'participation into a clinical study', 'situations that would limit compliance with study requirements|Pregnant', 'sexual relationships in', 'dietetic plan', 'chemotherapy|Life expectancy', 'Phobias like', 'sexual abuse|Child', 'unable to make consent,|unable to communicate', 'sleep latency', 'sAML', 'render the subject unsuitable for the study', 'cooperate with nurses', 'senile cataract|patients scheduled', 'Unable to understand', 'risk of ovarian reserve alteration', 'Photosensitive epilepsy|Uncorrected visual deficiency|Any significative impairment', 'admitted to the neonatal unit after 24 hours|Mothers who do not', 'sleep apnea|Presence', 'unable to provide informed consent', 'changes in HF therapy dosage', 'expected lifetime', 'Signed informed consent||Subjects', 'Laboratory evidence', 'living with HIV', 'emergency situations|Whose parents or caregivers', 'Cockcroft-Gault equation', 'Signed informed consent;|Males', 'signing the informed', 'Refuse to complete study requirements', 'expected remaining treatment duration', 'life-threatening illness', 'unable to oral take', 'entry into this study', 'changes in bowel habits', 'insufficient anti-conception', 'change the medical regimen', 'donate.|Life expectancy', 'close proximity to the upper airway and', 'recently initiated)', 'unable to attend', 'exposures', 'radiation therapy;|The targeted wound', 'signed the informed consent after receiving information about the purpose', 'render the patient ineligible', 'immobilization', 'stress symptoms||', 'contraception.|Life expectancy', 'chemical peel', 'unable to lie down', 'Able to swallow a Tylenol sized', 'conversion', 'Illiteracy|Refusal to take part', 'insufficient Dutch language proficiency|Mental retardation', 'dyspnea at rest', 'Living in', 'risk of deteriorating renal function:||Hypertension', 'blurred', 'prevention of sudden cardiac death', 'life expectancies', 'participated in other interventional clinical trials within', 'unable to participate', ""family medicine||Children's medical records"", 'RAD51D', 'eligibility', 'nicotine use|History', 'suicidal risk', 'progressed on standard therapies', 'unable to swallow the capsules', 'flaring', 'stainless steel.||Stage 2||Inclusion', 'Chlamydia', 'inadequate English-language speaking skills', 'condomless sex', 'participated in the focus groups discussions', 'Able to communicate,|Who agrees to participate', 'incapable of understanding', 'lifespan', 'falls', 'enrolled in other clinical studies;|Mixed lung cancer', 'willing to follow', 'unable to cooperate with treatment', 'expecting survival time', 'unable to complete follow-up tests.|No', 'limited|Estimated survival time≥', 'Cohort 1', 'lab values|Severe asthma', 'smoking', 'changes in hormonal birth control|night shift', 'limit compliance with study requirements', 'embolization', 'unable to give consent', 'willing to continue this supplement', 'meet the exclusion criteria', 'unable to swallow oral medication', 'incapable of radical local treatment', 'breastfeeding', 'irreversible pulpitis||', 'HCC)|History', 'old|Diagnosis of HCC', 'family members', 'Rehabilition in Enschede', 'difficulty swallowing|To have', 'unable to follow protocol requirements to complete the study;|Subjects', 'genetic testing.|Separate written informed consent', 'living with HIV/AIDS|Patients', 'entry into this study.||Participant', 'expected in RDEB patients', 'scheduled', 'Signed informed consent form||Characteristics', 'parents infected', 'psychiatric provider able', 'ICU stay|Informed consent|Presence', 'alcohol excess', 'unable to consent|English', 'participated in other clinical trials', 'changes in type of glucose lowering therapy', 'risk of anaphylaxis', 'cohort B)||*e.g', 'difficulty in venous blood collection', 'radiographic evidence of', 'Life expectancy', 'Central small recurrences deemed', 'stone burden', 'unable to observe home isolation|the presence', 'Patients', 'breastfeeding;|Insufficient fluency', 'soy products', 'birth weight', 'Estimated life expectancy', 'living in a care facility;|(H', 'entry into the treatment', 'Breastfeeding', 'FBSS', 'sexual relationships', 'possible interference with the impedance signals|A', 'remain alert', 'close family history', 'enrolled in intervention', 'unable to understand the purpose', 'Spanish speaking', 'absent', 'immunotherapy with checkpoint', 'any other', 'situations that', 'willing to sign an informed consent', 'SCNSL.|Patients', ""life expectancy from the clinician's point of view|health problem limiting ability"", 'recently admitted to hospital', '2|Life expectancy', 'risk of suicide', 'premature birth;|An enrolled patient living in the same', 'abstinent', 'Parents not', 'Refused to participate in the study', 'render the participant', 'notching', 'Dental students', 'compliance', 'Cohort Study).|ART restart', 'available in our unit like cardiac', 'risk of suicide assessed using the Columbia Suicide Severity Rating Scale', 'ubjects MUST:||Be able', 'situations that would limit compliance with the study requirements.|Patients', 'allowing', 'unable to collaborate', 'Informed Consent Form;|A diagnosis', 'childbirth plan', 'single-', 'patent foramen', 'managed in outpatient', 'unable to wear', 'psychiatric disorders|Patients', 'test.|Life expectancy', 'close of the deceased|Persons', 'injections into the joint', 'speak English', 'Refered to a participating clinic regarding surgery', 'participated in clinical trials of other drugs', 'INTENTION to quit;||C', 'Breast Feeding|Poor baseline health conditoin|Disability to complete lung function test|Receiving pirfenidone', 'expected to limit survival', 'Pregnancy.|Life expectancy', 'sufficient Dutch', 'hardaliye regularly', 'care for condition', 'willing to follow and able to complete all study', 'handle a computer with internet connection||', 'progressed through', 'unable to take', 'irinotecan can cause', 'Unable to understand the information', 'cognitive impairment|Capable of providing', 'participated in a facial clinical test', 'expected hospitalization', 'unable to reliably', 'sexual minority', 'genetic susceptibility', '1.Plan to leave Nanjing', '/ smoking', 'snuffing', 'nodal sites of involvement|Risk of local compressive symptoms|Splenomegaly', 'identify', 'unable to follow protocol requirements|Any condition', 'female-', 'walking difficulties', 'partners of childbearing age', 'admitted in Besançon University Hospital|exigible for', 'Cognitive level', 'breastfeeding|Active symptomatic', 'Cohort 1 and 2:||1', 'participated in the study NCT04081337.||', 'breast cancer;|Bilateral breast cancer', 'Caring', 'age|Patients', 'risk of recurrence per investigator judgement)', 'invade adjacent organs', 'breastfeeding;|Expected survival', 'entry into the study.|Patient', 'ability;|Life expectancy', 'solely', 'risk of autoimmune disease|Major surgery', 'family-based intervention', 'Unable to comprehend consent /or withdrawal', 'unable to feel vibrations from the device on their wrist', 'impairs walking', 'close (', 'Unable to cooperate with inspection', 'Unable to be reached', 'intervention|Life expectancy', 'Diagnosis', 'situations that would limit compliance with study requirements|Any other illness or condition', 'sexual activities', 'remain on this background therapy', 'breast surgery||', 'willingness to comply with all study procedures', 'intolerance|life expectancy', 'Nicotine dependent individuals', 'close relatives', 'risk for developing perinatal depression', 'situations in', 'LHRH analogs)', 'antihyperglycemic medication|Cohorts A0', 'unable to travel', 'lose weight or follow', 'vaccination|Current', 'meet all inclusion criteria||Inclusion', 'iTTP event', 'Unable to understand the Dutch language|Pregnancy', 'treatment initiation', 'genetic syndromes (Down Syndrome', 'changes in work environment', 'estimated life expectancy', 'life expectation', 'metabolic activity', '""runner\'s high', 'equipment.|Typically smoking', 'parents refuse to participate in the study', 'remain in the area', 'postmenopausal state', 'situations that would limit compliance with study', 'situations that would limit compliance with study requirements', 'family members||', 'unable to undergo', 'involuntarily incarcerated', 'life span', 'enrolled in another clinical trial', 'ambulation', 'child psychiatry', 'living child', 'breast cancer|Previous chemotherapy', 'noncompliance with', 'preceding enrolment|written informed consent||', 'genetic syndromes associated', 'Unable to use the mobile phone application', 'cysts', 'unable to provide consent', 'endovascular AVF creation', 'family history|History', 'radiographic evidence of OA', 'family of investigator site personnel', 'unable to understand the protocol|Patient under curatorship or guardianship', 'participated in a knee OA exercise program', 'comply scheduled follow-up|Comprehension disability', 'render the participant ineligible for the study', 'partners of child bearing potential', 'B;|Expected survival', 'Students enrolled', 'remain in a sitting position', 'risk of harm', 'sleep walking', 'entry into the amniotic sac this pregnancy|contraindications', 'unable to communicate in English', 'breastfeeding.|Refusal to sign the informed consent form', 'abstinence', 'consent', 'situations that would limit compliance with study requirements|Prior radiation to the left chest wall|Patients', 'cooperate about the', 'Nursing', 'Living in the United States|Adults', 'participate|Life expectancy', 'Cockcroft-Gault formula', 'available curative therapy', 'stainless steel nickel', 'consistent with PAR-Q+.|Having', 'managed by watchful waiting', 'University of Cincinnati Hospital', 'smokers', 'estimated survival', 'render them ineligible', 'change of endocrine therapy', 'willing to accept', 'pT', 'render the subject unable to meet the requirements of the protocol', 'breast cancer|have completed', 'dysplasia;|Difficulty in reaching the designated position of the balloon used for ischemic post-conditioning;|Stenting', 'insufficient compliance', 'Insufficient amount', 'managed for CKD/ESKD invited to participate|Ability', 'volume surgical', 'Breast-Feeding', 'quiet', 'risk of recurrence.)|Participant', 'pace-maker', 'cooperate with treatment;|Judgment by the investigator', 'risk of fracture', 'cooperate with blood sampling', 'expected ICU stay', 'genetic evidences', 'breast cancer;|History', 'unable to take oral medication', 'progression on gemtuzumab', 'Undergoing', 'participated in prior', 'parent', 'height;|absence', 'progressed on androgen receptor therapy', 'difficulty with communication in English without', 'remain off', 'situations that would limit compliance with protocol requirements.|New York Heart Association (NYHA) class', 'unable to communicate with the treating team', 'acceptable.|Any other condition', 'risk of developing pressure ulcers', 'predicted survival', 'cigarette smoking habit||', 'regulatory', 'met:||Written informed consent obtained before', 'speak English||', 'breast cancer.|Receipt of live', 'willing to sign the informed consent form', 'enrolled in another investigational device', 'screening;|History', 'unable to intervene', 'auditory', 'sexual activity to decrease the risk for inclusion of a woman', 'warfarin|Known', 'Inadequate hematological', 'Speak English', 'sleep disorder,|The', 'changes in balance and mobility', 'Illiterate', 'render the participant unable to provide informed consent|Subjects with visual impairment', 'signing the informed consent form approved', 'eating', 'Signed Informed Consent Form(s)|Age', 'suicidal;|Currently engaging', 'any other condition', 'requiring', 'situations that would limit compliance with study requirements.|Patients', 'M1c);|Fertile', 'difficulty in agreeing', 'bisexual', 'TSH level', 'Sorafenib.|Expected survival', 'applied in', 'childbearing age|Life expectancy', 'close proximity', 'person with life-threatening illness', 'render the individual unable to independently provide consent', 'Unable to comply', 'participated in other drug', 'psychiatric disorders|History', 'regurgitation.|Evidence', 'unhealthy diet', 'incapable of following postoperative care instructions', 'incapable to provide informed consents', 'remain in the hospital', 'psychiatric inpatient', 'unable to provide their own consent', 'Unable to follow-up', 'enrolled in another organized weight loss', 'signed the informed consent to participate in the study||', 'wellbeing', 'partners plan to become pregnant', 'participated in clinical trial of another drug', 'unable to communicate in French', 'unable to swallow the study agent', 'radiographic interpretation', 'participated in another brain stimulation experiment the same day', 'enrolled in MMT/Atlantis|Capable', 'participated in another clinical study', 'Unable to understand Danish', 'living in nursing homes', 'render the subject unable to comply', 'illiterate', 'unable to answer the questionnaires', 'render the participant ineligible for the study.|Immediate family member', 'Cohort 2:||Age', 'living with dementia', 'laser resurfacing)', 'willing to follow up.|Medically stable', 'Cockcroft-Gault formula).|Positive test', 'entry into the study.|The subject on', 'enrolled into', 'life-threatening', 'leftover tissue available from the surgical resection of their tumor available to request', 'risk of recurrence）', 'Unable to give consent Unable to answer the questionnaire', 'risk of becoming pregnant', 'unable to do the long TUG', 'progressed from a', 'risk for neurological abnormlaities', 'expected survival time', 'remain in a relaxed reclined position', 'render the participant unable to comply', 'incapable of conception', 'histological evidence', 'excepting', 'Cockcroft-Gault formula||For', 'willing and capable of participating', 'artificial insemination', 'Signed informed consent form and assent form', 'signed informed consent', 'difficulty in complying with the study protocol|Participation', 'Unable to understand study information.|Unable to provide', 'risk of bone fracture|platelets', 'nDNA', 'hemochromatosis|History', 'unable to take effective contraceptive measures;|11', 'Signed informed consent;|Body weight', 'risk of pregnancy', 'situations that would limit compliance with study requirements.|History', 'unable to give informed consent|Medical diagnosis', 'Signed IRB approved written informed consent/', 'old;|Expected survival', 'sexual activity', 'unable to swallow pills', 'able to read', 'unable to travel to the clinic.|Subjects', 'situations in which corticosteroid use', 'situations that would limit compliance with study requirements.|Have', 'unable to undergo serial gynaecological follow-up', 'unable to understand what participation to the study entails', 'entry into', 'Unable to walk|Children', 'unable to engage in the informed consent process', 'speak and read Dutch', 'unable to adequately', 'unable to undergo surgery|Unwilling to accept medical treatment', 'pericardial cavity', 'participated other clinical trials', 'limit compliance with study', 'it|Episodes of', 'objectives.|Life expectancy', 'participated in another clinical trial of', 'risk of HIV exposure', 'close to blood vessels', 'unable to continue', 'willing to maintain TLC', 'render a patient unsuitable for inclusion.||ALT', 'render the patient unable to safely cooperate with the study tests', 'unable to speak English', 'body mass index', 'artificial valve|life expectancy', 'anticipated subscapularis tenotomy', 'chemotherapy|Evidence of pregnancy', 'pregnancy.|No', 'participated in more', 'complying with research procedures', 'unable to provide', 'Refusing to follow the study|Have', 'willing to sign informed consent.|Patients', 'risk of death', 'RT-PCR test', '≤2|Life expectancy', 'telemetric data.||Exclusion', 'difficulty in cooperating.|Subjects', 'volume for standard-sized', 'agrees to phone', 'known', 'admitted for care to the Adult Inpatient Unit at', 'co-enrollment|Likely', 'unable to fill', 'Signed Informed Consent Form|Male', 'close relatives signed informed consent', 'enrolled a sufficient number of each group representation', 'risk of harming self or others', 'unable to swallow oral medications.|Subject', 'probable', 'undetermined significance|Patient willing to consent for the study', 'Cohort C||Aged', 'cigarette smokers', 'ritten informed consent', 'unable to undergo MRI investigations', 'risk of future cognitive decline', 'Baseline.|Lack of willingness to abstain from the consumption', 'method of birth control the treatment period', 'lose sufficient body weight after participation in a structured lifestyle modification programme', 'Unable to participate in self-management programmes', 'risk of volume overload', 'participation in any strict weight loss control program', 'enrolled in other clinical trial', 'recently started,|Patients', 'participated in other clinical trials in the past', 'breast operation', 'expected to stay in the hospital', 'risk of pulmonary', 'resident|Able to read', 'Unable to communicate their medication use', 'living with depression', 'risk of psychosis includes', 'sleep in the house', 'cooperate with treatment', 'bronchoscopy|Life expectancy', 'life-sustaining equipment', 'participated in other investigational clinical trials', 'unable to travel to the NIH.|Have', 'any other condition that', 'willing to participate', 'progression of disease', 'tanning', 'preparation', 'managed for CLD/cirrhosis', 'situations that would limit compliance with study requirements.||Assessed', 'participated in another interventional clinical trial within', 'Signed study Informed Consent Form|Karnofsky Performance Status (KPS)', 'ejaculation disorders;|suffer from mental disorders', 'psychiatric disorder|History', 'life-expectancy', 'speak English|have', 'Gault equation|Absolute neutrophil count', 'sleep related impairment', 'Nursing student', 'fertility plan', 'Radiographic evidence', 'difficulty in venous blood collection.|Vigorous exercise should', 'meet the inclusion criteria', 'life expectancy assessment', 'constitute a health risk', 'month);|Keep your diet', 'change in behavior proposed', 'sleep disorders|Sleep only', 'parturient', 'undergoing', 'signed the informed consent', 'progression to severe', 'sleep disturbance', 'risk for pregnancy', 'family history;|Patients', 'unable to receive oxaliplatin', 'progressed on immune checkpoint inhibitor therapy', 'difficulty breathing|Chest pain|Hospitalization', 'willing and capable of providing informed consent|Patients', 'sex with men|Has access', 'tobacco', 'volume in the first second (FEV1) / Forced', 'Signed informed consent;|Age', '1p19q codeleted', 'unable to take effective contraceptive measures;|10', 'unable to take effective contraceptive', 'risk of stroke', 'pedunculated Subserosal', 'change in dietary supplementation', 'risk of local infection', 'unable to tolerate', 'willing to assent', 'expected exposure', 'written informed consent in accordance with ICH/EU', 'Latex|Participation in another investigation', 'sexual activity per week', 'participated in other clinical trials within 30 days', 'unable to consent for themselves', 'risk of coagulation dysfunction', 'Insufficient handling of the language', 'children||', 'Fulfilled', 'baby,|Speaks', 'brief ""virtual"" interactions with the study coordinator quarterly', 'breast cancer.||-', 'participated in other virtual reality studies regarding', 'refuse to local treatment;|More than 2 weeks from', 'unable to consent|Individuals', 'family interventions', 'physiologically capable of||becoming pregnant', 'limit compliance with study requirements.|Patients', 'close biological relatives', 'Unable to consent|Unwilling', 'epilepsy|Claustrophobia', 'EGFR overexpression', 'authorised indication. The treatment decision', 'breast feeding|Current excessive alcohol use|Suicidal', 'expected to continue', 'Working', 'Living in long-term care facilities', 'insufficient tissue surrounding the knee.|Severe damage', 'willing to consent to the child participating', 'IDU', 'physiologically capable of becoming pregnant', 'unable to fill a self-administered questionnaire|Patients', 'ISS:||Age:||- Male', 'plexus irradiated', 'difficulty in swallowing', 'volume to perform both', 'Cohort TBI', 'Intends to receive', 'situations that would interfere with compliance with study requirements', 'allogeneic', 'sleep quality||', 'malignancy;|Life expectancy', 'hearing', 'sufficient clinical data.||', 'Cohort 3.||', 'difficulty planning', 'Neurological disease|Active cancer|Life expectancy', 'insufficient language proficiency', 'incapable to communicate their perspective, context', 'render a diagnosis', 'situations that would limit compliance with study requirements|Prior', 'difficulty with', 'progression on appropriate', 'unable to undergo MRI of the spine', 'treatment plan', 'Cockcroft-Gault formula||Left', 'unable to undergo MRI (', 'cTTP', 'Cockcroft-Gault Formula)|Total', 'limited.|Estimated survival', 'restrictive diet/restricting', 'Written informed consent|Chronic', 'refuse to participate', 'unable to take effective contraceptive measures', 'incapable to consent themselves.|All male', 'Signed informed consent to participate in the study;|In', 'render the patient inappropriate for', 'infections|Further exclusion criteria apply', 'commit to complete', 'close supervision)|Able', 'expected survival time>6', 'participates', 'Cohort 3:||ALK+ NSCLC|2 samples', 'Able to read', 'situations that would limit compliance with study requirements.|All English- speaking', 'inpatient', 'cigarette every day', 'close physical contact.|Athletes.|Subjects with', 'situations that would limit compliance with study requirement.|History of another', 'patients；|Expected survival', 'family history clinic', 'Insufficient bone marrow reserve', 'tattoos', 'Cockcroft-Gault estimation|Concurrent participation', 'an arm or leg fracture', 'ICU-level', 'ceiling of care', 'multitargeted VEGFR TKI therapy', 'refuse to participation in the study', 'expected to resolve', 'possible risk for adverse events', 'BCL6||Histologic transformation', 'progression of', 'Signed the informed consent form (ICF)', 'willing and capable of understanding the purpose', 'EFGR sensitive gene mutation', 'cessation of menstrual activity', 'risk of autoimmune disease', 'native English speaker', 'unreliability', 'Cohort A - MAC', 'expected life span', 'range of motion', 'protective supervision', 'suggested by sudden death', 'sputum purulence', 'centers|English-speaking', 'entry into a body cavity', 'sleep problems||', 'admitted to the neonatal unit after delivery', 'consistent with angina', 'unable to swallow tablets', 'remain in Puebla, México', 'signed a free and informed consent form|Patient affiliated', 'unable to swallow niraparib capsules/tablets.|Documented', 'family support|Coronary artery disease', 'difficulty following directions', 'permitted.|Life expectancy', 'risky|Life expectancy', 'wife can recognize', 'Unable to give informed consent|Histological high-risk features', 'undetected', 'expected to become pregnant', 'risk of considerable harm from standard treatment', 'situations that would limit compliance with study requirements;|Significant', 'situations that would limit compliance with study requirements|Receipt', 'motor threshold|Children', 'midodrine.|Unable to administer an oral medication', 'parental', 'noncompliant with the protocol', 'close relatives.||', 'unable to lie on the scanner', 'unable to communicate;|unable to participate in intervention', '0~1.|Life expectancy', 'uterine cavity', 'postgraduate student', 'entry into this study.|Known', 'smoke research', 'LHRH analogs', 'unable to swallow entrectinib intact', 'admitted to icu and received', 'risk of bleeding', 'incapable of providing consent to participate in the research study will also', 'emptying|Urgency', 'participated in other clinical trials within', 'volume expansion', 'unable to understand and communicate', 'immobility', 'participated in upper extremity weight', 'difficulty in venous blood taking', 'needle entry sites', 'situations that would limit compliance with study requirements.|Any', 'volume drawn', 'willing to install the WHOOP Mobile Application software|Full-time US', 'insufficient quantity', 'cancer)|Chronic smoking', 'enrolled in hospice', 'risk of surgical complications|Access', 'unable to take oral medications;|Invasive respiratory support', 'cigarette smoking', 'inflammation)|Patients unable to', 'Life-threatening', 'render the participant unsuitable for psilocybin', 'unable to take oral drugs|patients', 'signed an informed consent||Exclusion', 'affiliation coverage', 'difficulty in follow-up', 'clear suicidal plans', 'living farther than 30 mills', 'risk of end-organ damage', 'enrolled in another investigational study', 'risk of fracture;|Anemia', 'perfusion MRI.|All exclusion criteria', 'inadequate English language skills', 'living with RRMS', 'move from the study area', 'subcutaneous', 'reproductive sexual activity', 'neonatal intensive care unit', 'entry into this', 'need a combination', 'family member', 'sleep health dimensions', 'Cohort 4.|Chemotherapy', 'Signed informed consent form;|Male', 'problems of cooperation', 'meet the inclusion criteria described', 'pacing leads', 'Cohort I', 'Unable to receive', 'breastfeeding|vegetarian', 'unable to continue the research', 'suspicious', 'immunotherapy induced', 'sexual partners', 'render the subject medically unstable', 'family members able to understand the study protocol', 'indeterminate', 'changes in working environment', 'Cohort A3', 'failed', 'Scoring', 'Refuse to participate|Lack of health insurance (French social security)|Under', 'bowel urgency|Have demonstrated', 'sexual activity has been', 'Willing to take', 'Cockcroft-Gault formula.|REGISTRATION', 'address in a state', 'family medicine physicians', 'sleep apnea|Life expectancy', 'psychiatric disorders|Unable to read', 'managed in other centers|Patients', 'necessary anaesthesia|Varus/valgus malalignment', 'Genetic Syndromes', 'swing', '0~2.|Life expectancy', 'change in therapy', 'intracranial compliance', 'difficulty in breathing', 'cooperate with non-drinkers', 'Unable to lie supine', 'recently recovered', 'expected to cause death', 'hypertension;|Serous cavity effusion beyond clinical control', 'managed in the', 'family history', 'refuse to draw blood', 'Cockcroft-Gault formula|For', 'incapable of pregnancy', 'limit active therapies|Protected person', 'family plan', 'Parents unable to answer the questionnaire', 'render the subject unable to perform appropriate post-operative', 'access another psychological intervention', 'risk calculator assessment A', 'enrolled in another clinical study', 'willing to follow the requirements of the study protocol', 'entry into this study.|Any condition', 'changes in serum biomarkers', 'insufficient bowel preparation', 'difficulty in walking', 'cSAH', 'willing and able to sign an informed consent', 'genetic syndromes', 'risk of hypokalemia', 'limit compliance with study requirements|Autoimmune disease', 'progression to ESRD|Does', 'close to the tendon injury.|Combined flexor', 'dyspnea in pregnancy||Cardiac', 'difficulty understanding the study', 'endocrine', 'potential fertility', 'disease.|Life expectancy', 'Pregnancy|Dementia|Physique making ultrasound', 'special diet', 'changes in medication).|Naïve', 'idiosyncrasies', 'enrolled into the study.||Inclusion Criteria For Control', 'Unable to provide', 'unable to read text', 'Never', 'Caton-Deschamps ratio', 'risk of reflux aspiration', 'expected life expectancy', 'remain in the study', 'physiologically capable', 'premature ventricular contractions', 'Life-limiting illness', 'Cockcroft-Gault method', 'incapable of following postoperative care', 'never smoked', 'unable to sign informed consent', 'unable to cooperate to complete the eye assessment|Ophthalmic diseases', 'met;|Written informed consent;||', 'participated in other anti-tumor drug-related clinical trial in the 4 weeks before', 'life-limiting', 'willing to sign a release of medical records to the research team|Male', 'unwilling', 'signed the informed']","['hours|lack of availability of either SFO', 'biopsy|Eastern Cooperative Oncology Group (ECOG) performance status', 'Athletes|QTc interval', 'satisfactory:||o Corrected mean QT interval', 'Diastolic', 'Unsatisfactory blood pressure control', 'peripheral arterial', 'aerobic physical activity per week)|existing', 'alcohol + stimulants)|min', 'KPWA', 'hepatitis B surface antigen (HBSAG)', 'Visual Analog Scale (VAS)', 'CABG + AVR||', 'ROS1.||Basic normal function', 'ventricular rate', 'plasma/serum glucose', 'urine drug test', 'type-2 diabetes', 'Potassium', 'old;|ECOG performance status score', 'WHO criteria.|Age', 'survival time', 'leukocyte count', '1;|Predicted survival', 'psoralen', 'Diagnostic Statistical Manual (DSM)', 'pregnancy test result||', 'L Dex > 10 units.|Willingness', 'HAT', 'Bone Marrow Function Defined as:||Peripheral absolute neutrophil count (', 'PAP test', 'NT-ProBNP', 'both genders|Aging', 'Beck Depression Index (BDI-II', 'RECIST version 1.1.|Eastern Cooperative Oncology Group (ECOG) performance status', 'peripheral arterial ischemia|Cold', 'palliative care|Ability', 'CKiD', 'calculated by Cockcroft Gault equation;|Alpha-fetoprotein', 'sufficient organ function：', 'mean pulse rate', 'international normalised ratio (INR)', 'severity score average', 'Modified Ashworth scale', 'night', 'PHQ-9 indicating depression caseness|consent', 'Neurological Classification', 'Novel Coronavirus antigen|Novel', 'nodes|Detectable preoperative plasma ctHPVDNA', 'peripheral blood eosinophil count', 'numerical rating scale', 'PCR', 'months|VAS pain score', 'Cooperative Oncology Group (ECOG)', 'Alanine transaminases', 'Academic Year 2018-19|Children', 'neoantigen prediction|Patients', '-cholesterol', 'Mass General Brigham|any', 'peg-filgrastim', 'T-ALL/LBL.|CD7', 'v1.1.|ECOG PS', '1|Life expectancy', 'Avelle™ NPWT System', 'anti-HCV Ab positive', 'hepatitis C virus (HCV).||Unable to', 'TcpO2', 'New York Heart Association|Cerebrovascular accident', 'rapid urease test', 'New York Heart Association Classification', 'impairs function', 'left ventricular ejection fraction≤30%;|Patients', 'Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.|Eastern Cooperative Oncology Group performance status', 'acid test', 'CAR T-cell', 'New-onset diarrhea', 'ACLR', 'average air-bone-gaps', 'human immunodeficiency virus|Active hepatitis', 'Urine human chorionic gonadotropin (HCG)', 'urine protein/creatinine', '≤110', 'pathology|Severe speech impairment', 'screening.||Blood ALT', 'Depression Inventory score', 'ECOG (Eastern Cooperative Oncology Group) scale|American Society of Anesthesiology (ASA) score', 'Common Terminology Criteria', 'moderate amount', 'sudden', 'hypertension)|Oxygen saturation', 'Barts Health NHS Trust', 'biological', 'Delays between cycles', 'residual changes', 'bone marrow function||Haemoglobin', 'New York College of Cardiology Cardiac Function', 'IDS-SR16', 'ambulatory blood pressure monitoring', 'modified GELF criteria:||Symptomatic adenopathy|Organ function impairment', 'European Cooperative Oncology Group (ECOG) performance status', 'human immunodeficiency virus antibody (HIV)', 'national standards).||Age:||- Male', 'BMI SDS', 'human immunodeficiency virus (HIV) antibody', 'estimated lymph node metastasis', 'GLIM criteria', 'American Indian/Alaska Native', 'PCO2', 'hepatitis B virus (HBV) surface antigen (HBsAg)', 'bone marrow function disorder', 'antinuclear antibodies', 'CAR T cell', 'serum progesterone', 'Kura Oncology||For AML', 'beta Human Chorionic Gonadotropin (hCG) pregnancy test', 'numeric rating scale', 'NCI-CTCAE version 5.0 [Appendix 3].|Unresolved grade', 'detectable RNA', 'CDK', 'alert||', 'trochanteric fracture', 'language function test', 'PRC test', 'absolute WBC count', 'CD4+ T cell', 'calculated using CKD EPI SCr', 'Screening.|Body Mass Index (BMI)', 'progesterone receptors', 'ALAT', 'Gleason score', 'supine blood pressure (BP)', 'kg.|Body mass index', 'American Society of Anesthesiologists physical condition', 'ECOG Performance Scale.|Patients', 'HDL cholesterol level', 'panel reactive antibodies (PRA)', 'oxygen saturation', 'NCI CTCAE version 5.0.|Active autoimmune disease', 'PASI score', 'Cooperative Oncology Group Scale', 'visit)|Left ventricular ejection fraction', 'liver disease|Emergency surgery|Reintervention', 'Asia Impairment Score', 'plasma lactate levels', 'Bilateral breast cancer;|No pathological diagnosis;|Remote', 'inpatient length of stay', 'Alpha Gal Syndrome', 'child-pugh score', 'Active Monitoring Phase of the study).|PRE-REGISTRATION', 'Cockroft-Gault.|Capable of understanding', 'serum aldosterone levels', 'aspartate transaminase (AST)', 'enterectomy.|Active hepatitis B (HBsAg and/or HBcAb positive', 'serum bicarbonate level', 'single level', 'thoracic extension', 'ASTCT criteria', 'surgery;|Functional Mitral Regurgitation', 'Pfeiffer test classified', '90 minutes', 'placenta accreta spectrum (PAS) disorders', 'residual stenosis', 'American Association for the Study of Liver Disease (AASLD);|the diagnosis of', 'gestational diabetes|Pregnant', 'eye.|Uncontrolled intraocular pressure', 'creatinine (Scr)', 'partial gastrointestinal function', 'RECIST version 1.1', 'organ function|Hemoglobin', 'expected length', 'Response Evaluation in Solid Tumors (RECIST 1.1).||', 'creatinine estimated eGFR', 'blood counts', 'GINA levels', 'CKD-EPI creatinine clearance', 'HAS-BLED score≥', 'SARS-CoV-2 antigen', 'Forced Expiratory Volume 1/Forced Volume Capacity ratio', 'Rutherford-Becker classification category', 'drinks for', 'residual toxicities', 'Antibodies to donor red blood cell antigens', ""Morgan Stanley Children's Hospital"", 'BI-RADS 2 (Benign)', 'refractory;||Evidence of cell membrane GPRC5D expression', 'Food Protein-Induced', 'Total bilirubin (TBL)', 'foot clearance', 'Screening.|Body temperature', 'AZS:||sperm concentration', 'IPN program herein described||Part B of the study will seek', 'peripheral nerve function', ""Child's gestational age"", '5.Hemoglobin(Hb', 'modified RECIST for HCC', 'Time interval', 'LDL cholesterol', 'WSAS score', 'serum glutamic oxaloacetic transaminase', 'Modified Ashworth scale.(56)|Both', 'HBV DNA levels', 'CSAMI', 'CTD', 'San Giuseppe Hospital', 'International Classification of Headche Disorders', 'hepatitis C positivity in combination', 'hemoglobin A1c ≤10% as', 'Nijmegen score', 'NPC', 'EF', 'SPP', 'response evaluation criteria', 'estimated likelihood of recurrence', 'serum M-protein', 'international classification criteria.||Group', 'ICDAS score', 'Systolic blood pressure', 'modified RECIST 1.1. For the purposes of this study measurable disease', 'EHS classification', 'Including:||Unsatisfactory blood pressure control', 'trauma)|Pupil diameter', 'Absolute Neutrophil Count (ANC)', 'Ferriman-Gallwey scale', 'antibodies or fusion', 'diastolic BP>100', 'HAMD', 'hepatitis C virus ribonucleic acid', 'National Cancer Institute Common Toxicity Criteria', '10)Adequate blood pressure', 'Creatinine', 'liver biopsy', 'hepatitis C RNA', 'Forced Exhaled Volume)', 'International Classification of Diseases 10th Revision', 'Rheumatic', 'T4 disease|Presence of', 'blood test abnormalities', 'UPDRS', 'hemoglobin (HbA1c)', 'thin endometrium', 'thyroid disease)|Hemoglobin A1c', 'Total Bilirubin', 'smoke', 'glucose', 'screening.|Left ventricular ejection fraction', 'Pap smear', 'ULN)，Bilirubin', 'norepinephrine', '10-item Perceived Stress Scale', 'Inclusion Criteria:||aged', 'FISH', 'LAVI', 'Prader-Willi syndrome', 'American Society of anaesthesiologist ASA physical status', 'short PR interval', 'ECOG performance status score', 'SARS-CoV-2 infection', 'toxin test', 'Pain Numerical Rating Scale', 'prothrombin time', 'Estimated glomerular filtration rate', 'myeloblasts', 'mean QTc', 'PSA value', 'hepatitis B surface antigen (', 'hemoglobin level (HGB)', 'ASA class', 'serum albumin level', 'heart rate (QTcF)', 'HIV index;|Positive Hepatitis B surface antigen (HBsAg)', 'Corrected QT interval', 'CHF);|Left ventricular ejection fraction', 'cylinder', 'serum anti-ttg antibodies', 'Go test execution time', 'serum glutamate-pyruvate transaminase', 'Histoplasma antigen in the urine', 'Stage', 'Postmenstrual', 'RECIST v1.1|ECOG', 'Mayo Clinic Gonda', 'walking', 'Nasal abnormality history', 'hepatitis B virus surface antigen', 'LDL-C', 'pulmonary artery systolic pressure estimated', 'Nippy', 'sponge', ""National Institute on Aging-Alzheimer's Association (NIA-AA)"", 'extrahepatic metastasis;|ECOG score', 'Plasma NRG-1 level', 'Cesarean section', 'instability.|Baseline ECOG', 'ALT & ALT', 'Response Evaluation Criteria in Solid Tumors (RECIST v1.1)', 'Rhizarthrosis DELL', 'Modified Melasma Activity and Severity Index (mMASI) score||', 'average blood pressure', 'normal,|Respiratory rate', 'BRAF', 'obligatory documents.|To', 'IOLs', 'blood pressure MAY still', 'Positron Emission Tomography (PET)', 'BOTOX®', 'International Normalized Ratio (', 'period).|Age', 'Communication Complexity Scale|sufficient motor skills', 'overall (GI) symptom score', 'allowed.||Alanine transaminase (ALT) serum glutamic-pyruvic transaminase', 'compartment syndrome|Serious hepatic dysfunction', 'blood cultures', 'YMRS score', 'hemodialysis|Age', 'hepatitis B virus carriers', 'HURS Pneumology', 'respiratory rate ≥20 breaths per minute', 'smoking history', 'ankle instability|History', 'protein', 'Smoking history', 'male partner).||Exclusion Criteria', 'New York Heart Diseases (NYHA) heart function', 'partial prothrombin tests', 'treatments|Single level', 'repeat levels', 'nutrition program', 'NCI-CTCAE 5.0', 'weight related comorbidities', 'Short Bowel Syndrome).|Patients', 'ECOG-ACRIN PET/CT scanner approval.||For', 'transaminase (AST)', 'Glogau Skin', 'weight', 'glomerular filtration rate (eGFR) estimated', '|Platelet count', 'ultrasensitive TSH', 'Glomerular filtration rate (GFR)', 'G6PD activity', 'lost of >10% of their weight over a period of the last 6 months', 'rapid test for HIV', 'ACTH', 'best obstetrical estimates|', 'inter-2 risk', 'Barcelona', 'left ventricular diastolic dysfunction', 'DN4 score', 'Best corrected visual acuity (BCVA)', 'antibodies to hepatitis B core antigen [anti-HBc]', 'As:||Creatinine clearance', 'PSQI', 'urine pregnancy test before vaccination', 'enterally', 'Child-Turcotte-Pugh (CTP) class', 'morphologic systemic left', 'BARC', 'Microbiology and Immunology lab', 'estimated glomerular filtration', 'Glomerular Filtration Rate (eGFR)', 'Estimated survival', '2.|Life expectancy', 'NJ|Patients', 'hepatitis C virus antibody (HCVAb)', 'Ankylosing Spondylitis Disease Activity Index (BASDAI)', 'hepatitis C virus (HCV) antibodies', 'PCR test', 'Legg-Calvé-Perthes disease', 'prothrombin time (PT)', 'skilled nursing home', 'urine alcohol test', 'serum BNP', 'resting pulse', 'American Heart Association/American Cardiac College', 'greyish white', 'PHQ-9 score', 'ASA（American Society of Anesthesiologists)', 'Body mass index', 'partial thromboplastin time(aPTT', 'HBV-DNA copies', 'HIV test results|As applicable use', 'PEEP', 'commercial CAR T-cell infusion', 'Treatments', 'Inclusion Criteria||aged', 'plasma HIV-1 RNA', 'mean PAP', 'fasting', 'vitamin D levels', 'QRS complex', 'risk mitigation program', 'prostate specific antigen (PSA)', 'International Normalized Ratio (INR)', 'Involuntary Movement Scale', 'double-lung', 'thyroid peroxidase antibodies', 'TMB score', 'bone marrow involved)||Absolute', 'aqua', 'haemoglobin M disease', 'cytotoxic T lymphocyte-associated', 'giredestrant plus abemaciclib', 'BCL2/BCL6', 'AJCC cancer', 'UFC', ""Maudsley's Mill's and"", 'bone mineral density of the lumbar vertebra', 'mRECIST', 'total bilirubin ≤1.5×ULN', 'potassium levels', 'preclude', 'syphilis serology test result.|History of', 'residual bone crest||', 'plasma', 'hemoglobin A1c)||', 'Beck Depression Inventory-II (BDI)', 'liver / renal', 'energy', 'cholesterol', 'HVPG', 'ULN)|Absolute Neutrophil Count', 'urine cotinine test', '11)Poor overall condition', 'Hepatitis C antibody', 'New York Heart Association functional classification system|Uncontrolled hypertension.|Subject', 'MAS', 'National cancer institute-Common terminology criteria', 'caregiver|Patient demonstrates', 'forced expiratory volume in first second (FEV1) / predicted value', 'criteria below:||Multiple myeloma', 'total bilirubin≤1.5×normal upper limit (ULN)', '1|Adequate organ functions||', 'partial thromboplastin time (APTT)≤1.5 x ULN .|Left ventricular ejection fraction', 'cooperate|Chest drains|Pneumothorax', 'UCSF|ASA', 'Volunteers', 'CABP', 'HCV RNA.|Known hypersensitivity', 'drug initiation', 'BCL-6|Availability of archival', 'Stress-induced', 'remnant bowel', 'age|Informed', 'residual', 'thyroid papillary carcinoma;|Active autoimmune disease', 'mass index [BMI]', ""New York Heart Society's functional"", 'QTc', 'total serum bilirubin', 'hemoglobin A1c', 'prostate cancer.|Patient', 'PD1 antibody therapy', 'carcinoma BCLC D under best supportive', 'equivalent);|MMSE', 'PHQ-9', 'IQ', 'menstrual period (LMP)', 'hepatitis C virus infection (HCV antibody', 'American Thyroid Association (ATA)', 'modified T cells.|Previous anti-CD19/anti-CD3 therapy', 'HgbA1c', 'Institute Withdrawal Assessment', 'glomerular heart rate (eGFR) estimated by', 'III|MAS score', 'education-matched healthy', 'Free Androgen Index', 'Novo lesion', 'attention-deficit/hyperactivity', 'physical activity', 'Unmarried|Age', 'Cardiac Index', 'height', 'adolescent volunteers enrolled in', 'pain index', 'antiretroviral therapy.|Age', 'Covid|be', 'Investigator).|Swollen joint count', 'definition from American Cancer', 'serum trough level', 'National Institute for Health', 'Systemic exclusion', 'calculated by Fridericia formula', 'ASA House of', 'Manager Inclusion Criteria:|Employed', 'CRi.||ECOG performance status', 'pregnancy;|vaginism;|urinal infection;|oncological disorders;|epilepsy;|skin problems;|if they', 'systolic velocity', 'MRS Rankin', 'Penetration Aspiration Scale score', 'Bronchial provocation test', 'mean pain scale', 'calculated by CKD-EPI formula', 'SPO2', 'BID', 'HCV);|moderate', 'anti-HER2 treatment', 'Baseline||Exclusion Criteria', 'Doppler velocity index', 'outpatient surgical procedure', 'mRECIST v1.1|Child-Pugh score Class', 'prostate-specific antigen', 'liver failure.|History', 'cardiac function abnormalities', 'white blood cell count', 'serum pregnancy tests should', ""UK Working Party's Diagnostic Criteria"", 'score corrected for', 'ABV', 'HBV-DNA);|Patients', 'Level IV centers', 'hepatitis B surface antigen as the only evidence of prior exposure may participate in the study.|Note: Hepatitis C antibody-positive', 'HCV-RNA levels', 'inhibitors|Hematocrit', 'screening.|Angle-closure glaucoma', 'estimated Glomerular Filtration Rate (GFR)', 'HBV DNA test', 'Child-Pugh C classification', 'PTH', 'immunohistochemistry', 'glycated hemoglobin (HbA1c)', 'Cognitive dysfunction|Pathological fracture|Fracture', 'PCL-5', 'SUV)|Absolute neutrophil count (', 'ANPS', 'consent|ASA IV|Neurological disorders|Patient', 'applicable.|Karnofsky performance status', 'Collaborative Oncology Group Performance status', 'alanine transaminase (ALT;', 'A1C', 'months|Insomnia Severity Index Score', 'Residual sensory neuropathy', 'hepatitis B surface antigen [HbsAg]', 'Active Monitoring Phase of the study)||', 'ULN)|Total bilirubin', 'stage 3)||Being', 'partial thromboplastin time (aPTT) prolongation', 'Sweden', 'OI', 'Performance Score (KPS)', 'Mycoplasma genitalium', 'Sexual Gender Minority Community||Exclusion Criteria', 'creatine phosphokinase|Blood sugar', 'Child-Pugh A;|ECOG', 'Total Functional Capacity (TFC)', 'modified protocol employed', 'Bahir Dar', 'valgus', 'outpatient blood pressure medication prescription|Moderate', 'Physical Activity Readiness Questionnaire[29]', 'average QTcF', 'SHIM', 'glomerular filtration rate (eGFR)', 'Absolute neutrophil ANC', 'Sponsor.|Eastern Cooperative Oncology Group (ECOG) performance status (PS)', 'TLE', 'HIS', 'ankylosing', 'Serum creatinine (Cr) ≤1.5×ULN', 'Hamilton Depression Scale', 'increased levels of BNP', 'Vestibule depth', 'pain interference score', 'total score 10+|Bipolar disorder', 'TnI levels', 'partial thromboplastin time (APTT) should', 'TTP', 'undergoing UCBT;|ECOG score ≤2;|Voluntary participation in this clinical trial', 'Necker Enfants-Malades hospital', 'limb weakness', 'size of varices', 'Karnowsky performance status index', 'aspartate transaminase（AST）<2.5 ULN;|Serum', 'amyloid cardiomyopathy|Hemoglobin', 'gammaGT', 'with WHO grade IV', 'anti-hepatitis C virus (HCV)', 'HCV RNA).||14', 'underlying plasma cell proliferative disorder:||Hypercalcemia', 'ECOG scale|Participants', 'partial thromboplastin clotting time (aPTT):', 'full thickness', 'positivity rate', 'Multi Gated Acquisition) scan', 'protein S deficiency', 'Pittsburgh Sleep Quality Scale|A scale score', 'hemoglobin ≤9 g/dL|At least one of the following', 'Panel Reactive Antibody score', 'platelets count', 'creatinine clearance rate calculated', 'remission duration', 'days;|Total bilirubin', 'or|BMI', '||""Neuropathic Pain', 'isolated bilirubin', 'participate;|BMI', 'CBCT', 'greater.|ECOG performance status', 'baseline|Systolic blood pressure', 'antibodies/antibody-drug conjugates', 'speech intelligibility index', 'ASA classification', 'disorders.|Life expectancy', 'Maximum inspiratory pressure', 'systolic blood pressure reading', 'AFI', 'men)|Body mass index', 'hemolysis|Total bilirubin', 'hemoglobin A1c>8.0%);||12', 'a:||≥18', '200mcg|Mannitol DRR', 'postpartum', 'Coagulation INR', 'aspartate aminotransferase(AST', 'plasmatic albumin', 'liver function ALT', 'pharyngeal molecular swab', 'HER2 negative metastatic', 'Visual analog scale [VAS]', 'RECIST 1.1);|ECOG PS', 'eligible.|Major surgical procedure', 'prothrombin time (APTT)', 'SSS score', 'nAMD', 'Body Mass Index [BMI]', 'PT)/partial thromboplastin time (PTT)', 'alanine transferase (ALT)', 'antigen test', 'ferritin levels', 'mg/24 hour|Positive test', 'liver metastasis;||• Alkaline phosphatase (ALP)', 'student||', 'partial thromboplastin time (APTT) ≤1.5×ULN', 'Cobb angle', 'CK', 'modified MRC', 'Dehydrogenase B Deficiency', 'short stature homeobox', 'emergency preview', 'Human immunodeficiency virus (HIV) infection', 'IDH', 'Lung-specific intercurrent', 'NCI CTCAE v5.0', 'estimated eGFR', 'HH.||Household Level Exclusion Criteria||HH', 'ISUP', 'Back Pain Patients||Inclusion', 'faecalis bacteremia;|Urine culture', 'hepatitis C test', 'Transverse maxillary constriction|Patients', 'serum follicle stimulating hormone', 'Malnutrition corrected', 'hemoglobin (Hb)≤60g/L|History of', 'UDS', 'APGAR score', 'OIT exclusion', 'criteria required:||The cancer specialist considers* surgery', ""International Headache Society's International Classification of Headache Disorders"", 'carbon monoxide diffusion test (DLCO)', 'liver biopsy Heart disease', 'pulse oximetry', 'sweat chloride', 'salivary flow', 'screening||Hemoglobin', 'Aspartate aminotransferase (AST)/ (serum glutamic-oxaloacetic transaminase', 'DMFS', 'RECIST 1.1 standard', 'Response Evaluation Criteria in Solid Tumors.|Postmenopausal', 'extracorporeal circulatory', 'end organ function', 'hepatitis B core antibody', 'old;|ASA Grade', '18F-FES PET/CT', 'prescribed)||Systolic blood pressure', 'NIHSS', 'VAF', ""Laschman's drawer test"", 'alcohol screen', 'toxigenic CD strain.||', 'MAB', 'pro-BNP', 'ASA Physical Status Classification System', 'expected ICU length of stay', 'Creatinine|Total bilirubin', 'general clinical condition', 'LV EF', 'findings.||Adequate bone marrow reserve', 'VO2', 'South Africa|Good English proficiency', 'capillary glucose', 'fasting LDL-C≥ 4.9 mmol/L', 'screening.|Active hepatitis B or', 'Age18 years|Screen', 'mean aortic pressure', 'MPOX', 'Serum pregnancy tests', 'FPG', 'Cooperative Oncology Group Performance Status', 'detectable protein expression by IHC in', 'vital signs measurements', 'Serologic test positive(Hepatitis B', 'Forced expiratory volume in 1 s (FEV1)', 'left MCA', 'peripheral blood blasts', 'left ventricular diameter: male>60mm', 'Lymphocyte count', 'synthetic function', 'anticentromere antibodies', 'Liver function test results', 'T4', 'urinary M protein levels', 'macular photocoagulation)|Macular edema', 'Calculated creatinine CL>40', 'CGI-S', 'NYHA Grades', 'urine protein', 'Bone marrow biopsy', 'flexion ROM', 'Berlin Definition criteria|Onset of ARDS', 'serum', 'urine HCG test', 'EBV PCR test', 'HGBL-DH/TH)|High-grade', 'lateral surgical approaches', 'muscularis propria layer|Aged', 'Godin Leisure-Time Exercise Questionnaire Health Contribution', 'various basic functions', '559th MDG', 'fasting plasma', 'tumor size', 'AUDIT', 'serological test', 'largest diameter', 'thyroid function|Type 1', 'Amenorrhea', 'New York Heart Association (NYHA) Functional Classification Class IV', 'metastasis|Eastern Cooperative Oncology Group (ECOG) performance status', 'ECOG physical fitness status score', 'NCI-CTCAE v5.0', 'Inventory of Depressive Symptoms-Self-Rated', 'Bell Score', 'HBV DNA testing', 'lactates', 'number of parities', 'SOX/FOLFOX/CAPEOX', 'old|Patients with CD', 'Malnutrition', 'telemedicine consultations', 'blood bilirubin', 'RT2 buccal gingival recession', 'urgency|Body mass index', 'arms||BMI', 'cutaneous area', 'WHO classification', 'thymidine analog mutations', 'Arterial partial oxygen pressure', 'AIS', 'WHO criteria)|Normal', 'ASIA', 'Cumulated Ambulation Score', 'months|Body mass index', 'women|Body mass index', 'ECOG score', 'blood pressure deemed unsuitable', 'dual screen contraception', '5cm||', 'Stephens Elementary School', 'ID.||Comorbidity ASA class', 'PD Society Brain Bank diagnostic', 'maintenance HD', 'FSCP', 'level', 'Bachelors level', 'pulse oximetry.||For SCD', 'transfusion allowed)||Lymphocyte Count', 'PVR', 'count', 'estimated value', 'HCV RNA PCR obtained', 'transaminase (ALT)', 'body mass index BMI', 'ECG evidence', 'ASA-PS', 'T ≤ ULN', 'Ventricular Ejection Fraction (LVEF)', 'IGA', 'Short Physical Performance Battery', 'ICPI', 'Hepatic function|Total bilirubin', 'hepatitis B core antigen antibody test', '18F-fluorodeoxy glucose positron emission tomography', 'modified Mc Donald criteria|Stable', 'bone marrow hematopoietic function', 'Friend', 'ratio FEV1/CV', 'carboxyhemoglobin', 'EULAR/ACR classification criteria.|Renal biopsy showed lupus', 'GEP-NEN', 'C|Heart rate', 'Thai Binh province|Speaks', 'Ureteral', 'HCV RNA test', 'guardianship|parents non-native speaking', 'cystatin C', 'quantiferon gold test collected', 'newborn blood gas|Apgar score', 'RSI', 'CCLRU', 'Prothrombin Time(PT', 'platelet levels', 'Lawrence OA', 'participants|Age', 'forced expiratory volume (FEV1)', 'HER2 IHC score', 'influencing QTc', 'hepatitis B virus surface antigen(HBsAg', 'Hospital stay', 'LVEF', 'Gross Motor Classification (GMFCS) level', 'Arm T)|Absolute neutrophil count (ANC)', 'hepatitis B core antigen (anti-HBc', 'BMI ranged', 'ECOG score 0~2', 'corticosteroids', 'MUD', 'American Association for Cancer Research [AACR]', 'culprit', 'Alpha-glucosidase inhibitors.|Glycated hemoglobin', 'residual bone height|Sufficient bone width', 'macroalbuminuria', 'moderate physical activity', 'Schiff sensitivity score', 'Forced expiratory volume in 1 second / post-bronchodilator', 'mRS', 'MDG', 'Resting blood pressure', 'HBV-DNA copy number', 'serum glutamic pyruvic transaminase [SPGT', 'qualitative HIV DNA/RNA', 'bleeding disorder|Platelet count', 'UHR', 'left ventricular end diastolic volume (LVEDV) index', 'chronical pathological skin conditions', 'American Society of Anesthesiologists (ASA) Physical Status', 'HBV DNA.|ECOG physical fitness score', 'ALT (SGPT)<= 1.5 UNL|Sign a formal informed consent', 'Fridericia corrected QT interval', 'maternal age', 'ENT', 'rifampin.||Additional non-inclusion criteria', 'Two blood pressure measurements', 'home oxygen use|Recent exacerbation', 'smoking test', 'ALP', 'serum free light chains', 'forced expiratory volume in 1 second (FEV1)', 'radiographic alveolar bone loss', 'romantic partner||Inclusion Criteria', 'thyroid-stimulating hormone levels (TSH)', 'ECOG PS', 'African', 'Renal Association lower limit for ""mild"" kidney failure).|Willingness to sign a consent', 'serum human chorionic gonadotropin (hCG)', 'anti-HIV', 'triglyceride level', 'blood TSH', 'urine β-HCG results', 'AGO-score', 'RECIST version 1.1|Symptomatic brain metastases could receive prior treatment', 'Quick Dementia Rating System', 'serology for hepatitis C virus', 'prostate cancer|Metastatic castration resistant prostate', 'memory function', 'total bilirubin [TBL]', 'RANO-BM standard', 'Urine dipstick', 'alopecia)|Absolute neutrophil count', 'modified Bruce exercise tolerance test duration', 'serum test', 'Bilirubin ≤1.5X upper limit of normal (ULN)', 'hepatitis C virus antibodies', 'New York Society of Cardiac Function', 'Albumin≥', 'psoralen plus ultraviolet A radiation', 'buccal bone thickness ≤1mm assessed by CBCT.|Sufficient apical bone to place an', 'NCI Common Terminology Criteria', 'plasma Phe levels', 'stage III hypertension;|Hepatitis B', 'hepatitis B virus surface antigen [HBsAg]', 'International Classification of Diseases', 'GMFCS level', 'CRPS', 'fragment length analysis', 'MoCA test', 'American Society of Anesthesiologists class', 'estimated glomerular filtration rate assessed', 'systolic function', 'COVID-19 convalescence plasma treatment', 'bone metastasis);|Uncontrolled central nervous system metastases', ""National Institute of Aging-Alzheimer's Association (NIA-AA) (2011) criteria.|Mini-Mental State Examination (MMSE) score"", 'intracranial pressure', 'Vanderbilt University Medical Center', 'partial thromboplastin time（APTT）', 'GCS', 'Intense Pulse Light', 'medium-deep chemical peels', 'Best-corrected visual acuity', 'HIV test result;|Positive test', 'renal dysfunction.|NYHA class IV congestive heart failure', 'adjustment of', 'investigator.|New York Heart Association Class', 'speaking', 'BIA', 'criteria of Guidelines', 'systolic velocity ratio', 'IPL', 'serum folate', 'section', 'Rutherford classification|presence', 'HBV-DNA PCR', 'partial thromboplastin time (aPTT or PTT)', 'beastfeeding', 'American Society of Anesthesiologists physical status classification', 'test for hepatitis B active infection (HBsAg)', 'walks', 'systolic blood', 'titanium||CLINICAL EXCLUSION CRITERIA', 'definition', 'pregnancy test', 'Hemoglobin A1C', 'antibodies against checkpoint inhibitors.|Patients', 'esophageal intraepithelial eosinophil count', ""UK Brain Bank'"", 'HAS-BLED', 'HCV viral load', 'American Society of Clinical Oncology/College of American Pathologists 2018 criteria', 'Forced Expiratory Volume in the first second (FEV1)', 'British Columbia.|Children', 'ASA status', 'Response Evaluation Criteria in Solid Tumors (RECIST 1.1)', 'ASIA rating', 'older,|elective thoracic surgery,|under general anesthesia.||', 'prostate cancer:|Patients', 'partial thrombin time (APTT)', 'MCO', 'Cardiac Resynchronization Therapy (CRT)', 'TNM classification', 'Visual Acuity:||Best corrected distance visual acuity (BCDVA) score', 'OPD cohort|Hemoglobin', 'cardiac troponin values', 'lab)|Patients', 'estimated Glomerular Filtration Rate [eGFR]', 'significantly increased intracranial pressure', 'Diffusion- Weighted Imaging (DWI)', 'Child Pugh Class', 'absolute count', 'neurological index', 'Colorectal cancer;|Inflammatory bowel disease', 'Metastatic RCC Database Consortium', 'partial thromboplastin time ≤1.5× ULN', 'urine-hCG', 'Phagocyte deficiency.||Human immunodeficiency virus', 'Pulse rate', 'QuantiFERON-TB Gold test.|A positive COVID-19 test', 'progesterone', 'FFPE tumour material:||SLFN11-expression', 'subtypes:||human immunodeficiency virus', 'hepatitis B virus', 'Utilization', 'Tiko platform', 'estimated 10-year', 'Symptom Score', 'surgeon|ECOG score', 'anti EGFR monoclonal antibody treatment;Previous chemotherapy', 'serum creatinine|ECOG score', 'OSDI', 'amount', 'study.|Abnormal blood pressure', 'Cooperative Oncology Group (ECOG) performance status', 'transaminase', 'total bilirubin ≤3 × ULN||Serum', 'See', 'total bilirubin ≤3 × ULN.||Serum albumin', 'HER2 testing guidelines|Is hormone receptor', 'small (< 10mm', 'international panel criteria', 'increase exhaled carbon monoxide levels', '≥30', 'long axis', 'test for hepatitis B', 'functional class', 'platelet ratio index (APRI)', 'Serum Cr ≤1×ULN', 'skilled nursing facility|Current', 'bispecific antibodies', 'OHCA', 'placenta lies directly over the internal os for pregnancies', 'Coagulation function', 'attention deficit hyperactivity disorder', 'AOBP DBP', 'residual alopecia effects.||Active', 'drug-screen', 'glomerular filtration rate estimation.|Participants', 'CAR-T cell therapy;|Use', 'system|body mass index', 'systolic blood pressure [SBP]', 'numeric rating score', 'body mass', 'CPS', 'OR|Urine protein dipstick', 'urine protein excretion', 'generalized alveolar bone loss', 'sublingual temperature reference', 'oral', 'Arterial partial pressure of oxygen', 'lost blood', 'RECIST Version 1.1|ECOG performance status score', 'screening;|Functional General Assessment Table (GAF)', 'criteria of ESC', 'Gestation', 'estimated glomerular filtration rate', 'risk score', 'III-IV functional class', 'hepatitis C co-infection.|As', 'Gleason sum', 'immunoglobulin', 'CMV end organ disease', 'Aalborg University Hospital)|Treatment initiation', 'average worst pain', 'CRP', 'hours;|ICDSC score', 'American College of Cardiologists (ACC) guidelines', 'blood level', 'Smoking|Regular strength', 'Boston scientific Genus/Gevia|Unable to complete follow-up visits|DBS brain targets', 'natriuretic peptides.|Sedentary', 'IL-6 level', 'Basic pulmonary diseases', 'severe hearing loss);|Cognitive', 'modified New York criteria', 'IPSS scale', 'level of understanding sufficient', 'imaging collected', 'HIV-1 RNA level', 'hepatitis C found', 'total sampling amount', 'sensitising EGFR mutations', 'fatal hemorrhage;|Coagulation dysfunction', 'Fondazione Policlinico Universitario A. Gemelli of Rome', 'BGF', 'Pain Visual Analog Scale (VAS)', 'Visual analog scale-pain.|Acute COVID-19 patients', 'calculated Cockcroft-Gault creatinine clearance', 'obtained less', 'Largest diameter', 'Total Hip replacement made', 'HIV antibody test positive;|Hepatitis B (immunological test results', 'hemoglobin ≥9.0 g/dL;|Adequate liver function', 'New York Heart Association cardiac disease', 'EGFR', 'Fatigue causing disease', 'buccal alveolar bone loss', 'Zn plasma levels', 'Recipient Exclusion Criteria below', 'pro-biotics|Current substance use disorder', 'females.|History of hepatitis C antibody', 'gallstones|Body mass index', 'serum ferritin concentration', 'QuantiFERON® TB Gold test', 'Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).|Fully recovered from the acute toxic effects', 'partial thromboplastin clotting time (aPTT)', 'serum pregnancy', 'West Haven criteria)|Ammonia', 'Fondazione Policlinico Universitario A. Gemelli IRCCS,|written informed consent.||', '1236G', 'partial Mayo score', 'aeroallergen|Total serum IgE level', 'creatinine (Cr) ≤1.5×ULN', 'stool + occult blood test', 'serum creatinine (Cr)', 'BOP', 'etc.|Body mass index (BMI)', 'Minimal Consciousness State (MCS)', 'VDYNE SYSTEM', 'harm-benefit ratio', 'stroke|Creatinine clearance', 'investigator.|QTcF', 'hemoglobin (HbA1C)', 'Flow measure', 'weight loss|History of malignancy', 'routine blood', 'CRC patients.||', 'Lansky play', 'IIID', 'PVI|A left common ostium of the pulmonary veins', 'old;|ECOG PS', 'MoCA)|willing', 'Hb<100g/L', 'patients;|Hepatitis B core antibodies (HBCAB)', 'interval', 'Response Evaluation Criteria in Solid Tumours (RECIST version 1.1)|Participants', 'minimum alveolar concentration', 'American Society of Anesthesiologists status', 'Prostate-specific antigen (PSA)', 'American society of Anaesthesia', 'Southwest Oncology Group (SWOG) Specimen Tracking System||NOTE', 'RR-DLBCL;|Age>18', 'Standardized Mini Mental Test score', 'study|Estimated glomerular filtration rate', 'Symbol Digit Modalities', 'blood pressure (ELE)', 'calculated by Cockcroft-Gault formula);|Liver function:|Total bilirubin', 'metastasis;|Child-Pugh liver function', 'QTc levels', 'Gleason score=10', 'Response Evaluation Criteria in Solid Tumours (RECIST)', 'Urethral', 'MVA', 'modified RANO criteria||', 'aorta length', 'Response Evaluation Criteria In Solid Tumors (RECIST)', 'CFS score', 'status;|Left ventricular ejection fraction', 'PSA', 'T-cell/histiocyte', 'Global Impression score', 'blood platelets', 'Child-Pugh', 'physical examination|Normal ECG||Inclusion criteria', 'Journal of Cardiology', 'vital signs evaluation', 'New York Heart Association heart disease', 'PAR-Q)|BMI', 'Fondazione Policlinico Gemelli IRCCS Rome', 'serum bicarbonate', 'BMT', 'B-cell', 'International standardized ratio', 'THC.|Axillary temperature', 'cholesterol level', 'left ventricular ejection farction (LVEF)', 'HIV 1/2 antibodies', 'prothrombin international normalized ration', 'serum glutamic pyruvic transaminase [SGPT]', 'premorbid IQ', 'pregnant;|are', 'MMSE score', 'Minute Walk Test and MLHF Quality of Life Questionnaire', 'heart valve abnormalities', 'Hepatitis C', 'NYHA', 'Screening|Serum hepcidin', 'air.|ECOG performance status', 'International Consensus Classification', 'Exosuit Shift', 'waist', 'monoclonal antibodies (when possible)', 'serum vitamin B12', 'creatinine clearance rate', 'BRAF mutational status.|WHO performance status', 'and||', 'moderate stress', 'Pap test should', 'PR', 'intraocular pressure (IOP)', 'DSM Axis I disorders', 'malnutrition corrected', 'partial thrombin time (aPTT) values did', 'PROMIS', 'Modified CTSI Pancreatitis Severity Index', 'urine pregnancy test done', 'Neck Disability Index (IDC) questionnaire', 'alpha-glucosidase inhibitors', 'haematocrit', 'viral load.|Negative hepatitis B surface antigen (HBsAg) test', 'shorter|Absolute neutrophil count', 'Thoracic Oncology 2016.|WHO Performance Status', 'Bone Marrow Failure Syndromes', 'CTCAE v5.0', 'resting heart rate of', 'QuantiFERON', 'hemoglobin value', 'European Association for the Study of the Liver', 'test for Hepatitis B surface antigen', 'ClCr', 'local laboratory:||Absolute neutrophil count', 'SARS-CoV-2 antibody test', 'FEV1 value', 'bone metastasis', 'total body weight', 'month;|Known pregnancy', '1;|Life expectancy', 'ABPI', 'commercial release criteria', 'IL-6', 'volume-viscosity swallowing test', 'ABC)|T-cell', 'suicidal ideation/suicide', 'Pain onset', 'gamma glutamyl transferase[GGT]', 'MDS Clinical Diagnostic Criteria', 'ROME criteria', 'Haag-Streit Diagnostics', 'serum creatinine eGFR', 'Roux-en-Y gastric bypass', 'total bilirubin should', 'serum chemistry panel', 'bone blood supply limitations', 'monoclonal antibodies treatment', 'hospital stay', 'Ankle Disability Index-Sport survey score', 'allograft participants);|Positive COVID-test results', 'CAR T-cell therapy.|Isolated extramedullary leukemia.|Philadelphia-chromosome positive ALL', 'Hurley stage 2|BMI', 'platelets remaining', 'pyrexia', 'craniocaudal diameter', 'liver cirrhosis:||Chronic hepatitis B virus（HBV', 'stage IIa-IIIc', 'Cerebral Blood Flow (rCBF)', 'International Association', 'Reanimation AD||', 'United Kingdom Brain Bank criteria.|Ability to communicate well', 'clearance creatinine', 'Consecutive patients,|>18 years', 'hepatitis C (HCV RNA', 'Clonal cytogenetic abnormalities consistent', 'temperature', 'Exclusionary laboratory values', 'NRS)|age', 'SARS-CoV2 infection', 'vital signs', 'systolic BP', 'plasma HIV RNA', 'VEGF TKI treatment', 'SARS-CoV-', 'respiratory rate≥', 'counts', '0.9%]).|HIV-1 RNA', 'hepatitis B viral surface antigen at Screening.|Is currently participating in or has participated in a study with an investigational product', 'weeks.|Adequate blood count', 'Rankin scale', 'RECIST v1.1;|ECOG performance status', 'partial thromboplastin time', 'national research centre reports.|Their weight and height', 'thyroid function', 'rapid antigen test', 'OHI-S score', '||A. Neck breathers', ""UPMC St. Margaret's Hospital|unilateral"", 'manage self-care', 'Modified Ashworth Scale|Both genders', 'submaximal test (RER', '68Ga-NODGA-LM3 should', 'Korean Mini-Mental Status Exam', 'C virus', 'complicates test interpretation)|Nasopharyngeal mass', 'mean corrected QT interval', 'NCI CTCAE v.5.0', 'PLT', 'ROS1 rearrangements|Patients', 'Growth Standards median for their age', 'Total serum bilirubin', 'ECOG Score', 'Hb)||9.0', 'Glomerular filtration rate (GFR) estimated by', 'normal|Abnormal thyroid function', 'SCORE', 'transfusion allowed)||Lymphocyte count', 'Blood pressure', 'Child-Pugh Score.||Matched Healthy Participants:||Participant', 'local regulatory standards', 'Kellgren-Lawrence Grades', 'hepatitis B surface antigen (HbsAg)', 'overall survival', 'static Physician Global Assessment (sPGA)', 'hepatitis B core antibody [HBcAb]', 'APGAR', 'International Cancer Control (UICC)', 'Short Form score', 'months)|Hiatal hernia', 'blood glucose detection', 'glomerular filtration rate (GFR)', 'L|Platelet count', 'Systemic Blood Pressure (SBP)', 'cranial form|absence', 'American College of Rheumatology/European League', 'age||Preoperative GFR', 'albuminuria ≥2+ should', 'Outcomes Measurement Information System', 'New York Heart Association (NYHA) cardiac function', 'alanine transaminase (ALAT)', 'Crest® Cavity Protection', 'nephropathy;|Assess glomerular filtration rate ( eGFR )', 'International Physical Activity Questionnaire (IPAQ)', 'regular physical education courses.|The', 'RECIST v.1.1', 'DOAC]).||Amylase', 'Serum creatinine', 'CMV PCR) found', 'Rankin score', 'disease duration', 'Rehabilitation Care Service.|Patient abstinent from', 'angiographic diameter stenosis', 'HAMD-21', 'UK Parkinson Disease Society Brain Bank Clinical Diagnostic Criteria', 'Columbia Suicide Severity Rating Scale', 'disorders|less', 'ULN)|Hemoglobin', 'ASA type I', 'arterial blood pressure', 'uric acid', 'Good Clinical Practice', 'Platelet ≥50×10^9/L', 'bone marrow exposure', 'hepatitis B DNA test', 'Rutherford', 'Medium size', 'heart rate (HR)', 'shortening fraction', 'HFNC', 'semen parameters.||', 'RECIST v1.1 evaluation.|Life expectancy', 'NPC.|ECOG performance status', 'Viral hepatitis： Hepatitis B Virus (', 'HBV DNA every', 'old.|ECOG performance status', 'modified', 'ALL', 'gestational age estimated', 'grade', 'HCV antibody positive', 'angina|moderate o severe', 'Abbreviated Mental Test < 6)|Modified Ashworth score', 'aspartate transferase (AST)', 'elevated', 'Qigong', 'human immunodeficiency virus [HIV]', 'urine leakage amount', 'Hanifin & Rajka diagnostic criteria of atopic dermatitis', 'dose|Total bilirubin', 'TMD,|Age', 'Cardiac ejection fraction', 'North American Adult Reading Test', 'Hepatitis B antigen (', 'NIHSS-Item 6 score', 'outside Chittenden County)|Proficient in English||', 'Estimated Intelligence Quotient', 'ngml-1;|Systolic blood pressure', 'WHO Child Growth Standards', 'UC Berkeley expert', ""Bruton's tyrosine kinase (BTK)"", 'New York Heart', 'minimal PSMA expression', 'ALP 5.0 ULN', 'serum pregnancy test done', 'NIH Clinical Center||EXCLUSION CRITERIA:||An individual', 'serum HCG pregnancy test', ""Vanderbilt Children's Hospital"", 'Numeric Pain Rating Scale|18', 'CDAI score betwenn 220', 'Peripheral neuropathy', 'forced expiratory volume in 1s/forced vital capacity (FEV1/FVC)<70% predicted, FEV1<80 % predicted after bronchodilation corresponding to a Global initiative on Obstructive Lung Disease (GOLD)', 'antibodies (DSA)', 'anti-myeloma treatment', 'mean blood pressure', 'ANC', 'Amercian Society of Anesthesiologists classification', 'months.|Best Corrected Visual Acuity', 'nasal polyps|History', 'weeks|Total bilirubin', 'European Society of Cardiology (ESC)', 'Social Security.||Exclusion', 'alcohol', 'Tellegen Absorption Scale', 'arthroplasty|Body Mass Index', 'Intensive Care Unit admission', 'HSV-', 'flash glucose monitoring device.|Ability to comprehend', 'moderate physical activity level', 'shock;|Cardiac function', 'modified fibromyalgia', 'EULAR/ACR classification criteria.|Patients', 'Ovation Alto Endograft', 'Active Monitoring Phase of the study).||', 'peripheral arterial disease;|preoperative serum albumin', 'carotid arterial stenosis;|Asymptomatic', 'WSPH Group', 'Marginal Zone B-Cell Lymphoma', ""UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic"", '≥75 minutes/week', 'pulmonary capillary wedge pressure (PCWP)', 'Dexcom Clarity account', 'urine pregnancy test results', 'Partial Thromboplastin Time (aPTT):', 'SAF', 'HPV', 'PAD (ABI', 'urine collected', 'Eastern Cooperative Group (ECOG)', 'MAO', 'Off ventilatory', 'reduced calcium level', 'apical pulse rate', 'mini-mental test', 'organ function damage', 'prostate size', 'ECOG (Eastern Cooperative Oncology Group Performance Status Scale', 'Liver stiffness value', '≥0.450', 'Omega', 'maximum standardized uptake value (SUVmax', 'cord blood', 'FSH levels', 'response (BDR)', '.|Body mass index (BMI)', 'etc)|Adequate oral hygiene', 'CRC', 'GA', 'serum bilirubin', 'CAR T-cell infusion are detailed in the protocol', 'Absolute Lymphocyte Count', 'hearing-visual impairment|Ability to read', 'GG3', 'PAD', 'HBsAg', '13C/14C breath test', 'New York Heart Association functional classification III- IV).|Left ventricular ejection fraction', 'Serum immunoglobulin free light chain level', 'balloon)|Lesion length', 'HPV-HR e/o', '.Physical status ASA II.||', ""child's parent(s"", 'physical', 'thromboplastin time', 'prothrombin time>16s', 'partial thrombin time exceeding the upper limit of normal', 'NEUT', 'smokers', 'spinal pain score', 'modified version of the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ)', 'estimated survival', 'best-corrected visual acuity (BCVA)', 'NCI CTCAE version 4.03)', 'absolute neutrophils count', 'CMV DNA test', 'hyperglycemia', 'DOXYCYCLINE', 'thyroid diseases|hepatitis', 'Mobitz', 'oral EGFR-TKI therapy', 'EIP', 'estimated glomerular filtration rate (GFR)', 'National Health System', 'gamma-glutamyl transferase [GGT]', ""NCAEM's EM-SART"", 'Lacks adequate premorbid literacy', 'alcohol breathalyzer test|Current', 'assessments|Resting saturation', 'spiral CT，For general CT', 'CAR-T', 'BHD-BSS collected', 'HEART score', 'neurologic disease|Total sperm count', 'Asians])||(BMI cut-offs', 'HBcAb', 'OSDI score', 'RLS Severity Rating', 'criteria in SCAI definition|Subject has NSTEMI', 'gastro-intestinal endoscopy', 'normal sex hormone levels', 'absolute neutrophil count [ANC]', 'ACOG', 'assessments|Fasting Plasma Glucose (FPG)', 'SWSF rate', 'MRS should be right-handed', 'Vectris™ SureScan™ MRI 1x8 subcompact and', 'alanine transaminase (ALT)', 'hepatitis C viral load', 'ECoG score', 'planned.|Off-pump surgery', 'Serum Glutamate Oxalate Transaminase (SGOT', 'QT interval', 'FEV1', 'Post-Traumatic Stress Disorder Checklist', 'E. coli Nissle', 'blood pregnancy', 'Prostate Imaging-Reporting', 'alanine aminotransferase (ALT [SGPT', 'extension-flexion movement', 'part', 'ER expression', '/1.73m2);|Systolic blood pressure', 'criteria of sarcopenia.||', '6 months)|Between grade', 'CAR-T cell preparations', 'human immunodeficiency virus (HIV1)', 'HCV RNA.||Current', 'breath test for alcohol', 'MOCA score', 'Fetal Weight 3Kg - 4Kg|Gestational', 'subclinical levels', 'Imaging showed peritoneal', 'anti-Programmed cell death-ligand', 'ULN|Prothrombin', 'autologous SCT OR|Beyond 1st CR', 'GM-CSF', 'anti-HBc', 'HEADS-UP HIV disclosure intervention', 'thyroid function|History of abnormal adrenal function|History of pituitary disease|History', 'inclusive)|Body mass index', 'AIHA', 'serum transaminases', 'Black/African', 'CAR T cell infusion.||Meets criteria', 'serum amylase', 'Serum creatinine ≤1.5×ULN；||All', 'American Society of Anesthesiologists (ASA) physical status', 'inclusive.|Body mass index', 'adults"".|Habitual bedtime', 'liver enzymes activity', 'NPRS', 'serum glutamic-pyruvic transaminase [SGPT]', 'peanut SPT', 'NP', 'PCIA', 'antinuclear antibodies (ANA)', 'Systolic blood pressure [SBP]', 'months interval', 'New York College of Cardiology', 'suicidal thoughts.|Age', 'fasting HDL-C', 'TUNEL assay', 'ALN OATF', 'FMA', 'RECIST criteria', 'HER2 IHC 0 (ISH- or untested)|was', 'North Carolina', 'coagulation test', 'medication history||', 'international normalized ratio (INR):', 'KOH test', 'meeting Physical Activity', 'mentioned', 'HCV', 'ARV', 'test day|BMI', 'clearance', 'viral hepatitis C', 'performance', 'TSH level', 'screening.|CD4 T-cell count', '+ Ejection Fraction', 'skinfold thickness measurement', 'entry criteria)|Prothrombin time (PT)/ partial thromboplastin time (PTT)', 'glomerular filtration rate (EGFR)', 'reviewer.|ECOG score', 'Endogenous creatinine clearance rate', 'MEDOPP485_MIRADORCSP', 'SELENA-SLEDAI PGA', 'Weigh', 'stroke|age', 'hepatitis B surface antigen ( HBsAg )', 'CCC', 'modified natural cycles|Poor ovarian response', 'microbiota modulation activity', 'Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)', '1.Age', 'triple negative)|Radiology', 'GGO', 'serum estradiol', 'blood pressure|Body Mass Index', 'pulmonary artery systolic pressure (PASP)', 'caries index', 'female.|Over', 'MoCA score', 'Modification of ACE-ARB agents', 'Berlin criteria [14]', 'total bilirubin ≤3 times upper limit of normal', 'angle', 'SIRS criteria,||• SOFA', 'months;|Best corrected visual acuity', 'women.||Body mass index', 'CAIT score', 'gelatin.||Additional Exclusion Criteria for', 'actigraph measurement inaccuracies', 'Covid-19 test', 'Index', 'Part C:||Known hypersensitivity to', 'MRI)|Bodyweight', 'ASAT', 'complement', 'aortic arch replacement', 'erecta dislocation|Presence', 'FFA', 'DREAM Cohort.||', 'hysterectomy.|Life expectancy', 'serum IgA level', 'EKG', 'refuses emergency CABG surgery', 'illiterate', 'absolute FEV1 increase of', 'TBL.|Hemoglobin levels', 'international normalised ratio', 'glycated hemoglobin', 'systolic HTN', 'American College of Sports Medicine', 'MRA', 'IUP', 'GIT complaint.(control', 'PARP inhibitor maintenance|Women', 'intelligence quotient', 'Prothrombin', 'liver enzyme values', 'week||', 'hemoglobin ≥10,0 g/dL', 'hepatitis B surface antigen [HBsAg] test', 'SES-CD', 'fasting blood glucose [FBG]', 'older.|ECOG performance status', 'QIV', 'Child-Pugh grade', 'White european ethnicity;|Signed informed consent;||', 'CK-MB)|High risk CAD', 'serologically', 'liver function Total bilirubin', 'early stage thyroid carcinoma);|Severe comorbidities', 'SBP', 'consent|ASA physical status', 'HCL', 'arrival', 'apical bone height', 'SARS-CoV-2).|Participant', 'viral serology deemed', 'hypertension|Previous bariatric surgery|Chronic gastrointestinal disease', 'absolute eosinophil count', 'Transaminase (ALT)', 'urine HCG pregnancy test', 'Mass Index', 'Insomnia Severity Index', 'digestive enzymes', 'creatinine clearance [CrCl]', 'MAP', 'Piper Fatigue Scale|A score', 'Although MRI', 'Rouen University Hospital|Clinico-biological intolerance', 'diameter', 'BI-RADS', 'hepatitis B DNA titer', 'MD Anderson Cancer Center Institute', 'Child Health', 'National Soccer League', 'Arm T)|Platelets', 'generalized epilepsy|Patients', 'haptoglobin', 'EHR', 'depth of', 'HCV virus titer test value', 'Quigley Hein Plaque Index (TPI) score', 'GDS-15', 'volunteers;|Body mass', 'condition.|Body mass index', 'systemic infection|ASA score', 'Numeric Rating Scales', 'New York Heart Society Heart disease', 'Meet ASAS classification criteria', 'DSM-IV standards', 'Beck Depression Inventory II (BDI-II', 'urine laboratory test results', 'NYHA level', 'weight loss|Slight symptoms', 'years.|ECOG PS - 0/1-2.||', 'dysmorphophobia|BMI', 'cotinine test', 'screening);|Body Mass Index (BMI)', 'EIA', 'old;|ECOG score', 'hip|Body Mass Index', 'thyroid function|Concurrent', 'PHQ-9 9th item score', 'serum follicle stimulating hormone (FSH) levels', 'Body Mass Index ranged', 'body mass index', 'Weight', 'residual toxicity', 'Respiratory Rate:', 'NYHA class IV).|Active malignancy.|Pregnancy.|Hepatic Failure', 'INR (international normalized ratio', 'urine M-protein', 'MRI)||', 'Expansion Cohort9 Specific Inclusion', 'pain', 'proteinuria', 'comprehends Danish|A score', 'prothrombin time INR', 'hr)|Aged', 'Heart function', 'ejection fraction;|Storage diseases', 'hindsight', 'sm1', 'hepatitis B core antibody-positive', 'pregnancy rate', 'Child Class', 'serum glutamic-oxaloacetic transaminase [SGOT]', 'troponin levels', 'North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria ([D - N]/D x 100, where N', 'Total Cholesterol', 'vitamin B12 levels', 'CD4)+ T-cell count', 'LVA of', '10 evenings', 'Pain Catastrophizing Scale', 'Tropical Medicine Departments', 'MICR).|Patients', 'toxicity', 'salivary rate', 'Gold test', 'pulse rate measurement', 'antimicrobial before blood sample collection', '10 minutes', 'recurrence', 'Coperative Oncology Group Performance Status', 'Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) .||', 'NITROUS OXIDE', 'cm|Malignancies|Abnormal HR esophageal manometry|Esophageal', 'below:||• glomerular filtration rate (GFR)', 'weight loss|Gastrointestinal surgery', 'Bedside Schwartz eGFR', 'Minimal age', 'criteria below:||LAM First line', 'NSAIDs', 'HIV-1 RNA determinations', 'Serum calcium', 'Prostate Cancer Working Group', 'ALT levels', 'Gamma Glutamyl Transferase', 'Kellgren-Lawrence Staging', 'HER2 pathological test', 'serum pregnancy test', 'older|Self-identify', 'creatine kinase-MB [CK-MB]', 'New onset symptoms', 'Child-Pugh liver function rating', 'NP PCR test criteria.|Enroll', 'join the group voluntarily', 'lesion level', 'study|Body mass index', 'qualifying levels of tactile', 'Visual Analog Scale', 'female.||Disease', 'bleeding', 'CIRS-G ≥1 score', 'BNP:||NT Pro BNP', 'Drug Burden Index score', 'Ad26.COV2.S', 'VSV-G antibodies', 'alkaline phosphatase (ALP)', 'Serum pregnancy test', 'Phe concentration measurements', ""New Wilson's Disease Index Score"", 'Classification of', 'Syphilis antibody positive;|Active hepatitis B (HBsAg positive', 'Clearance Rate） ≧30 ml/min', 'National Institutes of Health|Known allergy to the Chinese medicines', 'Physical status American society Anesthesiologists ASA', 'GKS Prime Flex Mobile', 'osteogenesis imperfecta|Body Mass Index (BMI)', 'estimated glomerular filtration rate ((e)GFR)', 'CELF Preschool-2', 'albuminuria', 'Plasma IL-6', 'block|Heart rate', 'serum human chorionic gonadotropin [hCG] test', 'MoCa Score', 'North American Symptomatic Carotid Endarterectomy', 'Medina', 'EFW', 'MEC', 'sustained blood pressure', 'old|Symptomatic multi-level degenerative cervical spondylosis', 'kidney function abnormalities|non-sinus rhythm', 'BET inhibitors|History of inability to tolerate', 'early stage ""', 'alcohol level', 'national institute of health stroke score scale (NIHSS)', 'forced expiratory volume in one second (FEV1)', 'weight-related', 'preclude blood sampling|Fear', 'Stellate Ganglion Block Contraindications||-', 'NT proBNP', 'BV', 'hepatitis B virus surface antigen (HBsAg)', 'Regular exerciser|BMI', 'alcohol breath screen', 'total LDL', 'ALD', 'ILD clinic)||For healthy controls:||Age≥60', 'anti-HBc antibody', 'FISH +)', 'sharp', 'total stent length', 'pregnancy test result.||For', 'hours|Xanthines', 'National Heart Center Harapan Kita', 'allowed.||Absolute neutrophil count (ANC)', 'ACQ-5 score', 'partial cystectomy.|Patients', 'Aortic Landing Zone:||Outer curvature length', 'ASD)|A Full Scale IQ score', 'dementia;|Platelet count', 'Pulmonary function testing', 'BPP', 'rapid ventricular tachycardia', 'physical activity levels', 'Modified Ashworth scale|In', 'residual hearing', 'EU', 'Xiaoaiping tablet/injection', 'USLD', 'DNA', 'progesterone-receptor-positive/HER2', 'Waist circumference', 'protein C', 'monomicrobial E. faecalis', 'Nantes University Hospital', 'MDPH', 'bone marrow involvement', 'Phacoemulsification ± canalicular micro-invasive', 'human immunodeficiency virus antibodies', 'process:||To receive induction', 'considered);|ejection fraction', 'SUVmax', 'prognosis', 'Metabolic', 'Agile F (F4) score', 'serum hepatitis B surface antigen (HBsAg)', 'gestational age)|Birth weight', 'DRSS', 'years|Plasma HIV-1 RNA viral load', 'SARS-CoV- hospitalization', '≤1.5|Serum creatinine', 'AAIRS', 'Child-Pugh classification|congenital', 'reversibility test', 'Insomnia Severity Index (score of', 'pro-convulsant action', 'Bun', 'cardiac function', 'Minimal Consciousness State (eMCS)|Presence of muscle activity', 'Ambassador Program', 'inclusive)|Body Mass Index (BMI)', 'IBS-C', 'N', 'condition|Positive C-SSRS result|Vegan|Possibility', 'hepatitis B core antibody (HBc-Ab)', ""UNITED KINGDOM PARKINSON'S DISEASE SOCIETY BRAIN BANK (UKPDSBB) criteria||PD"", 'cognitively intact.||', 'TLE participants:||new', 'Ronald Reagan medical center', 'absolute insulin deficiency', 'Prostate Cancer Working Group (PCWG3)', 'right ventricle systolic pressure (RVSP)', 'therapies.|Eastern Cooperative Oncology Group (ECOG) performance status', 'CTCAE grade III-IV', 'antiviral mediations|Temperature', 'serum LDL', 'AN,|Body mass index', 'modified radical', 'Absolute Lymphocyte Count (ALC)', 'residual macroscopic disease', 'OCS DCD Heart CAP', 'residual biopsy', 'contraceptives', 'ICS score', 'NCI CTC v3.0', 'Alanine Transaminase (ALT) level', 'ASA Ⅰ~Ⅲ;|BMI', 'Fiebig stage', 'UK (United Kingdom', 'partial nephrectomy', 'glycosylated hemoglobin', 'national level', 'ICF).|Age', 'hepatitis B virus (HBV) test', 'assessment;|Bilirubin', 'casts', 'straight leg raise test', 'not;|Severe blood dyscrasia;|Blood clotting disorders', 'progesterone receptor-positive', 'hypertension;|Systolic blood pressure', 'performance score', 'prostate cancer;|The', 'NCI-CTC version', 'glucocorticoid therapy|Other diseases', 'recovery time', 'estimated number', 'residual lymph node involvement regardless', 'neutral Granulocyte absolute count', 'Fibroscan', 'partial thromboplastin time [aPTT]', 'urinary catheter|History', 'fasting glucose (plasma glucose', 'AFP', 'NATIONAL Cancer Institute Standard for General Terminology of Adverse Events (NCI-CTCAE 5.0', 'unites', 'education levels', 'SGOT', 'CSF', 'collecting center', 'ERS', 'failure rate', 'Rapid-onset obesity', 'white count', 'total prostate volume|PSA', 'FEV1%', 'muscle test values', 'G12R', 'viral load.|Ability', 'Body', 'RECIST v1.1.|Mesothelin should', 'ambulatory class', 'Serum total bilirubin', 'Neutrophil Count (', 'liver metastases.|Creatinine', 'thrombocytes', 'BDI score', '||age', 'serum PSA values', 'dialysis.|Platelet count', 'hepatitis B surface antigen', ""Morbus Hansen's"", 'SpO2', 'APTT', 'either:||Platelet count', 'Frankl Behaviour Rating Scale', 'Tricuspid regurgitation velocity (TRV)', 'saturation', 'ICP', 'resting average diastolic blood pressure', 'packed red blood cells', 'CPK retest', 'consent.|Body mass index', 'Long QT', 'v5.0 level', 'HBV titer', 'special needs|Aged', 'antibodies', 'sedentary', ""Behcet's disease"", 'old|Adequate blood tests', 'eGFR measure', 'ankle and HbA1c below 8||', 'hepatitis B e antibody (HBe-Ab)', 'history.|Body mass index', 'Short Portable Mental Status questionnaire', 'anti-hepatitis B surface [HBs]', 'Systolic Blood Pressure (SBP)', 'International Classification of Diseases 10th Revision [', 'HIV viral load', 'hemoglobin below lower limit of normal reference range', 'glycated haemoglobin (HbA1c)', 'TCPO2 30 mmHg', 'SpO2]', 'Classification Score', 'radiation.|ECOG performance status', 'GOLD criteria|Being', 'FVC', 'peripheral blood', 'partial-thickness burn injury', 'transaminase values', 'block|NYHA Class', 'AJCC', 'gingival index', 'vegetables', 'Cooperative Oncology Group Performance score', 'UOC', 'creatinine levels', 'EVA scale', 'CPT Class', 'Lawrence', 'syphilis serology test results', 'Morbid obesity(BMI', 'NCI-CTCAE v4.02', 'salivary function', 'urinary cultures|SHIM score', 'autoantibodies [GAD65', 'serum vitamin D level', 'Genetically proven', '≥18|ASPECTS', 'LDL', 'pregnancy test|A positive test for SARS-CoV2', 'T4 sec.', 'patients.|Body mass index', 'resting partial pressure of oxygen in standard ambient conditions of', 'serum sodium', 'Bpm)|Decreased level', 'ketamine.|Body circumference', 'estimated remaining', 'follow-up.|No', 'bone marrow function.|At least 1 measurable not', 'steroid refractory', 'CMV serological status||', 'hepatitis C antibody positive', 'PI)|Karnofsky Performance Status', 'ASSIST assessment)|experience of', 'criteria:||Creatine kinase (CK)', 'ejection fraction|echocardiographic acoustic window adequate', 'end-stage malignant disease)|Moribund', 'urine protein quantity', 'serum beta-human chorionic gonadotropin (ß-HCG) test', 'sufficient level of mental development', 'calculation|Total Bilirubin', 'between completion of local treatment', 'muscle region suitable for biopsy', 'West-Haven classification', 'Child - Pugh', 'human immunodeficiency virus (HIV)', 'English|Body Mass Index (weight/height ratio', 'leg length', 'antibodies in sera', '50 Gy EQD2', 'pulmonary miliary metastatic pattern', 'PFT protocol.|Patients', 'GGT', 'modified Rome IV criteria for functional constipation (FC):', 'radioisotope glomerular filtration rate (GFR)', 'RAI refractory thyroid cancer', 'forced expiratory volume (Pre-BD FEV₁', 'autoimmune antibodies', 'nodal stage', 'syphilis spirochete antibodies.|Abnormal blood calcium', 'estimated from the Dietary Screener Questionnaire (DSQ)', 'scleroderma.|Clinicians should consider', 'points,|Having given birth', 'platelet cell count', 'old.|ECOG PS score', 'serum calcium', 'transaminase levels', 'premorbid mRS', 'ICF);|KPS score', 'ECMO', 'pulmonary function testing|BMI', 'left ventricular longitudinal strain', 'Cre8™ EVO stent', 'hemoglobin ≤120', 'Al Raghy hospital', 'HBV surface antigen', 'allowed.||Platelet count', 'sleepiness', 'serum β-hCG', 'FT4', 'ESC', 'National Cancer Institute General Adverse Event Term 5.0 (NCI CTCAE V5.0)', 'cardiac index', 'ASA score ≥3)|Signed written', 'gestational age).|Rupture', 'direct', 'oxygen saturation of blood', 'serum creatinine (Scr)', 'compartment pressure measurements', 'Regional Maternity Hospital', 'failed', 'troponin investigation|Patient requires resuscitation|Patient requires cardiologist consultation', 'Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1|Eastern Cooperative Oncology Group performance status', 'test|Best corrected distance visual acuity', 'aspiring high level athlete', 'IHC score', 'hepatitis B surface antigen (HBsAg)', 'months|New York Heart Association (NYHA) Class', 'NYHA grade III and IV)', 'liver fibrosis;|No', 'Diagnosis(PGD', 'Cushing Syndrome).|History of depressive disorder', 'serum ALT', 'NCI-CTCAEv5.0 Grade', 'European Society of Cardiology', 'hepatitis B virus (HBV)', 'higher|AUDIT', 'months;|Physical condition score', 'DNA copy number', 'GI score', 'CD4+ T cell function', 'ADI', 'duration|SALT score', 'Alkaline phosphatase (ALP)', 'haemoglobin concentration', 'malignancies;|Advanced stage breast cancer', 'NCI CTCAE v', 'American Society of Anesthesiologists (ASA)', 'anemia);|Prothrombin time', 'North American Symptomatic', 'ARDS', 'longest diameter', 'smoking history;|mRS≤2', 'AST≦2.5ULN', 'LH', 'months.|Adequate organ function .|Females', 'detectable HIV-1 RNA', 'abscess clearance', 'rapid test|age', 'Creatinine Clearance', 'Liver function abnormalities', 'physician|age', 'muscle test score', 'condition|Left ventricular ejection fraction', 'Comfort B Scale', 'SSDI', 'apical to gingival margin),|Clinical attachment level', 'December 31', 'resting SBP', 'NSAIDs + opioid', 'International Myeloma Working Group (IMWG) consensus', 'ANC≥1.5×10^9/L', 'serum bilirubin level', 'LSAS score', 'UIHC Movement Disorders clinic|Owns', 'C-TEN', 'PR);||Major organ function', 'definition: immunohistochemical (IHC)', 'hepatitis C PCR positive', 'weight change +/-', 'DLBCL Failure', 'resulted', 'mild).|No structural abnormality', 'international Delphi consensus', 'mass index', 'old;|ECOG PS score', 'Mass General Brigham', 'transverse position|Transperineal ultrasound', 'BESS', 'ASCOCAP criteria', 'Modified Telephone Interview for', 'DWI image', 'Lower motor neuron disease', 'liver resection;|Liver function', 'T1', 'bone marrow plasma cells', 'Calculated Estimated Glomerular Filtration Rate (eGFR)', 'serum pregnancy test||Agreement', 'European NMSC-registry', 'Groningen Frailty Indicator', 'UVB protection sunscreen factor 50', 'anticoagulants|BMI', 'glutamic aminotransferase', 'PSA levels', 'PLWH|HIV-1 RNA', 'stroke)|Conditions', 'hepatitis B DNA', 'IM', 'days||Hyperandrogenism:||Clinically', 'calcification angle', 'NT-proBNP', 'cirrhosis.|Barcelona Clinic Liver Cancer (BCLC)', 'alanine aminotransferase(ALT) continues', 'ECOG Performance Status score', 'enrol', 'patients:||Age', 'ALT)(serum glutamate pyruvate transaminase [SGPT]', 'J. Severe', 'auto-inflammatory disease', 'GAD-7', 'suicidal thoughts.||Age', 'Oncology Group performance status', 'MGH-ATRQ|At Screening', '1|Adequate organ function|Able to swallow tablets|Able to understand and voluntarily sign', 'residual neurologic deficits', 'weeks||Karnofsky Performance Scale (KPS)', 'International Metastatic RCC Database Consortium (', 'operation;||Body mass index', 'SFTPB', 'nasal systematic screening,|MRSA', 'comorbidity index', 'serum total bilirubin level', 'AVR +', 'Glomerular Filtration Rate)', 'ECG finding|QTc interval', 'forced expiratory volume in the first second (FEV1)', 'intercycle variation', '/L;|white blood', 'serum aspartate transaminase (AST)', 'tip stiffness', 'PLT<100×10', 'International Working Group 2006 (', 'Node positive patients', '120 minutes', 'total bilirubin (TBL)', 'European Amputte Football Championschip|field player', 'months.|QTc', 'gestational', 'Mallampatti Grades', 'AF|left ventricular ejection fraction', 'Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)', ""modified GELF (Groupe d'Etude des Lymphomes Folliculaires)"", 'disease;|Positive urine HCG test results of', 'reading English|Can swallow', 'left ventricular filling pressures', 'ESI 3|Return visit', 'Platelet Rich Plasma) injection', '10m walk test|Lower extremity Fugl-Meyer', 'hepatitis C reference', 'creatine phosphokinase', 'serum glutamic-oxaloacetic transaminase)/ALT', 'Left ventricular ejection fraction', 'malignancy|MELD score', 'neutrophil count (', 'Anorectal malformation', 'UCLA Health', 'milk|Body Mass Index (BMI)', 'EF LV', 'Body Mass Index (BMI) ≧', 'Fridericia corrected QT Interval (QTcF)', 'diastolic pressure≥100 mmHg', 'range|Total Cholesterol', 'Gamma-GT', 'glomerular filtration rate (GFR) can also be used in place of creatinine', 'non-mRNA', 'severity item rating', 'CAR T-cell administration', 'international criteria', 'syphilis antibody positive.|The toxicities', 'Creatinine clearance rate (CrCl) calculated', 'used||INCLUSION CRITERIA FOR HEALTHY', 'histological grade', 'VAS score', 'alanine aminotransferase>2× ULN', '≤120', 'MSS', 'months)|Less', 'Fatigue Severity Scale', 'metabolic', 'SCARED Questionnaire|Can fluently read', 'Platelet below the lower limit of normal|existing severe organ injury|combined', 'node', 'transplantation|life expectancy', 'gamma knife coagulpathy sepsis', 'tumors|Eating disorders|History of', 'bone marrow aspirate', 'residual hemodynamically significant', 'following:|Glomerular filtration rate (GFR)', 'FEV1/FVC ratio', 'protocol|ECOG performance status', 'Criteria of NYHA', 'Creatine', 'serum creatinine values', 'eGFR', 'or;|Platelet count', 'mm)|Systolic pulmonary arterial pressure', 'bone marrow invasion', 'CD4+ count', 'Medication-induced psychosis', 'Ghent University Hospital who developed', 'Triglycerides', 'serology for Hepatitis B Surface Antigen', 'CSS', 'dorsal root ganglion (DRG) stimulation', 'transaminase AST', 'regimen|Expected survival', 'Platelet count', 'Leipzig score', 'lung function', 'urine drug screen', 'İntracranial mass surgery|Craniotomy|ASA', 'gestational test (serum) result', 'RECIST 1.1|Life expectancy', 'Systolic Blood Pressure', 'ALT / AST', 'months;|Increased intracranial pressure', 'self-rating scales|right-handedness|HIIT', 'IIEF score', 'stool production', 'Blood 2009 114', 'moderate## disease', 'fasting plasma triglycerides', 'and|Written informed parental consent', 'IHC.|Adequate organ function/reserve per local labs|Adequate liver function', 'disease severity|Unequivocal cortical sensory deficit', 'Minto model)||', 'Albumin (ALB)', 'Unregulated arterial blood pressure', 'Kaohsiung Municipal Ta-Tung Hospital.||', '8F-size', 'pain relief', 'Bone age not', 'sitting BPs', 'left breast cancer;|Planned whole-breast ± supraclavicular region', 'ACAM2000', 'successive RNA PCR', 'PULSE', 'USA)||', 'angle-recession glaucoma', 'leadership program', 'averaged BP', 'plasma alanine aminotransferase (ALT)', 'BSSO', 'hepatitis B surface antigen (HBsAg) carriers', 'serum glutamic-pyruvic transaminase', 'ER-positive', 'MRD', 'B-Hb', 'paediatric records;|age', 'diastolic', 'Public School in Asthma CHAMPS||', 'CTLA', 'residual neutropenia', 'NT-proBNP of', 'RECIST v1.1|Available archived tumor tissue sample (Part 1a)|Willingness to provide consent for biopsy sample', 'best corrected monocular distance visual acuity', 'Weight/size', 'instance of physical IPV', 'hepatitis C virus (HCV) ribonucleic acid', 'DLBCL', 'serum transaminase ≥2× upper limit of medical reference', 'Neutrophil count', 'Princess Maxima Center', 'Early CT Score', 'combine affordable housing assistance', 'RAEBt', 'Portsmouth Hospitals University NHS Trust||', 'Left-sided', 'Absolute neutrophil value', 'Male patients|American Society of Anesthesiologists physical status', 'RECIST V1.1.|Child-Pugh score', 'Karnofsky Performance Status (KPS)', 'sufficient amount', 'calculated', 'ALK', 'PADUA score', 'HAMD score', 'Bone marrow blasts', 'CKMB test values', 'hydroexfoliation cytopathology of the chest and abdomen', 'quantitative HCV RNA results', ""Amiens Picardie University Hospital (CHU Amiens Picardie)|Child's affirmative agreement"", 'GP1', 'CROSSOVER FROM ARM', 'MLA', 'rest', 'modified Oswestry', 'Serum creatinine (Cr)', 'hepatitis C virus [HCV] RNA', 'reduced ejection fraction', 'between the', 'fasting lipids', 'NYHA grade', 'American Gastroenterology Association (AGA)', 'technology use|The', 'Resident', 'Gynecological malignancy.|Low corporeal myoma', 'Serum creatinine ≤2X ULN', 'QTcF interval', 'RECIST 1.1;lymphomas', 'modified radical mastectomy', 'malaria test', 'radiation)|Body Mass Index (BMI)', 'Neutrophil Count (ANC)', 'FIT', 'takes', 'remains eligible.||Specific inclusion criteria for colorectal cancer:||10.1', 'weight distribution).|Is', 'NIHSS score', 'left ventricular ejection fraction)|no structural', 'left ventricular end diastolic pressure', ""New York Heart Association's Class III or IV functional capacity|Uncontrolled hypertension"", 'Penn IRB #', 'viral load', 'RECIST version 1.1 guidelines.|Disease progression', 'iron saturation', 'General Inclusion Criteria', 'C-reactive protein', 'inpatient stay', 'pain syndrome|Cervical foraminal stenosis|Cervical disc herniation|Herpes zoster||', 'HIV status', 'International Classification of Headache Disorders 3rd edition.|Occipital', 'American Society of Anesthesiologists grades', 'caries rate', 'etc.;|Patients', 'New York Heart Association NYHA scale);|If myocardial infarction occurs', 'mean systolic blood pressure', 'CD4+ T cell counts', 'crystal induced arthropathies', 'wheelchair bound).||Cancer Survivor', 'AOBP DBP of 85-110 mmHg|At Randomization: ABPM', 'Rutherford classification', 'HH.||Individual Level Inclusion', 'NeuroQoL Cognitive Function', 'eligible;|ECOG Performance Score', 'Peri-implantitis proven', 'metastases have', 'Child-Plugh score', ""CAR T-cell therapy|Transformation of CLL (Richter's transformation);|Prior"", 'HCV antibody-positive', 'WHO grade 3|Glioblastoma', ""Beck's Depression Index (BDI).|Participant has"", 'Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) target lesion', 'Blood pressure measurements', 'lower kidney function values', 'treatment;|INR > 1.5;|Platelets count', 'metabolic function', 'hepatitis B virus deoxyribonucleic acid positive', 'Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1)', 'creatinine clearance rate (CCR)', 'children', 'National Neurological Institute ""C. Mondino""', 'december 31st', 'RAI stage', 'ASA grade', 'Visual Analogue Score (VAS)', 'ARR', 'below:||absolute neutrophil count', 'indicates', 'enzyme level', 'International Myeloma Working', 'bursal side||', 'NCI CTCAE v5.0)≤', 'prostate biopsy', 'CKMB values', 'age|Infant', 'coagulation function', 'hepatitis B & C, HIV|Severe', 'angle kappa', 'dipstick results),|BMI', 'HCV antibody.|Positive HIV', 'syphilis antibody positive;|Any drug', 'PD|Disease duration', 'monoclonal antibodies)', 'ANC≥', 'instituting GH', 'hemoglobin A1c) HbA1c laboratory abnormality.||*The investigator should use his/her clinical judgment to decide which abnormalities', 'trans thoracic echo|Age', 'SCABP', 'CDAI score', 'liver invasion', 'serum progesterone level', 'systolic blood pressure<90mmHg', 'Italian Society of Endocrine Surgery', 'No||-', 'fetal heart rate abnormalities', 'pain treatment|American Society of Anesthesiologists physical status', 'Lung Cancer"" issued by the International Association for the Study', 'measurement of ≥30mmHg', 'Braden Scale.||', 'American Society of Anesthesiologists (ASA) Physical Status classification', 'postural instability', 'HCV Ribonucleic Acid', 'International Ankle Consortium guidelines.||Criteria for inclusion', 'ASPECTS score', 'Serum Glutamic-oxaloacetic Transaminase/Aspartate Aminotransferase (SGOT /AST', 'palliative care program', 'ALT double the upper limit of normal', 'transaminase (ALT) ≤3 x upper limit of normal (ULN)', 'Alanine transaminase (ALT)<1.5x ULN);|Adequate renal function', 'response evaluation criteria in solid (RECIST)', 'human immunodeficiency virus (HIV).|Participation in another clinical study', 'organ function:||Bone marrow', 'local regulations.|Patient', 'Partial thromboplastin time APTT', 'Y-chromosome mosaicism', 'ISI', 'pinhole', 'Head Start Educators:||Provision of signed', 'Partial Thromboplastin Time (PTT)', 'fingertip pulse oximeter saturation', 'kidney failure|Magnetic resonance', 'wound', 'viscosupplementation injection)|Body mass index', 'Urine protein', ""American Society of Anesthesiologists' physical status"", 'a:||Body mass index', 'PVI performed|Isolated valve replacement', 'platelet rich plasma (PRP) procedures', 'HER2 test', 'ADOS', 'transaminase levels.|known contraindications to', 'hepatitis C', 'pulmonary function test', 'Intelligence Quotient', 'Dyspnea', 'left-handed|severe', 'prophylactic anticoagulation)|Liver Function Test|Renal function', 'Modified Mini-Mental test.||', 'American Urological Association (AUA) diagnostic criteria', 'H63D compound heterozygous HFE-gene', 'CAR T-cell therapy per standard of care practices', 'bone mass', 'MDD treatment', 'urine retention', 'LIA', 'calculated by Cockcroft-Gault formula).|fertile', 'residual height', 'arm||BMI', 'Apgar score', 'Neutrophil count (', 'urine toxicology', 'ECG.|Sustained ventricular arrhythmia', 'Ph-Impedencemetry', 'growth factors|Platelet count', 'WHO Performance Status', 'CPB|Age', 'mean air conduction', 'fasting glucose', 'randomization||sUA level', 'fetal heart rate', 'alimentary obesity.|BMI', 'MMSE score≤ 17 points', 'ASA Class', 'weight managent supplements|Blood transfusion', 'serum protein immunoelectrophoresis', 'A1c', 'New York Cardiological Association', 'bpm).|Systolic blood pressure', 'CD137)|Body mass index', 'Spherical Equivalence Refraction', 'bone marrow', 'esophageal gastric junction adenocarcinoma', 'WHO criteria', 'NCT', 'CCS)|Coronary Arterial Bypass Grafting', 'Positive Score', 'FIB-4', 'level of the spinal', 'liver histology', 'ALT should be ≤5×ULN).6', 'combined HIV antigen/antibody test', 'CIA score', 'Hepatology', 'absolute neutrophil count', 'hepatitis C virus antibody', 'nonchildbearing potential|Body weight', 'gender.|Age', 'Barca', 'Ottawa Hospital Neurovascular Unit', 'months.|acceptable organ function', ""calculated by Cockcroft and Gault's equation|Willing"", 'quantitative detection', 'IgM HBcAb negative.|Female', '2.|Absolute neutrophil count (ANC)', '50', 'AHI', 'transitional phase', 'New York Presbyterian - Weill Cornell Medicine (NYP-WCM', 'viral PCR', 'oncologic procedures).|ECOG Performance Status', 'screening.|Body mass index', 'prostate-specific antigen(PSA', 'CD4+ T-cell', 'DEFENDER trial|Active endocarditis', 'left ventricle end-systolic volume', 'HTT', 'uptake', 'hemolytic PNH clone|Randomly receive ATG', 'Moffitt Cancer Center/|Adult', '1;|Expected survival', 'Visual Analog Scale|Does not live in Eastern Cape confirmed', 'bone marrow function.||', 'Blood Pressure (BP', 'RNA test(s', 'neutrophil granulocyte', 'CDC Category C event|Active', 'screening.|Body weight', 'SARS-CoV2 test', 'armpit body temperature (body temperature', 'Child Anxiety Related Disorders (SCARED)', 'basal serum follicle-stimulating hormone (FSH)', 'National Cancer Institute (NCI)', 'prostate cryoablation|Major neurological conditions', 'Sufficient organ function', 'New York Heart Association Functional Classification|Malabsorption syndrome', 'Recurrence after hematopoietic stem cell transplantation;|There', 'calculated glomerular filtration rate (GFR)', 'Article 1121-5 of the Public Health', 'AI|Estimated glomerular filtration rate (eGFR)', 'NIH scale|Normal', 'progesterone receptor [PR]', 'factors judged by the clinic team to be', 'German speaking||', 'International Society of Lymphology', 'CD20+ mature', 'hepatitis C.|Known history', 'packed red blood cell (', 'SARS-CoV-2 PCR test', 'neurosurgery|creatinine clearance', 'HBV-RNA copies', 'LHRH agonists/antagonists', 'maximum Gleason score', 'NRP);|Patients', 'platelet count<10', 'T)|Creatinine clearance', 'Trauma Care Continuum of the province', 'e', 'CTCAE', 'SHS', '1|Adequate organ function||', 'Insomnia Severity Index|>2.5 kg additional weight loss', 'weight reduction plan|Received pharmaceutical', 'Glycaemia', 'urine toxicity screening', 'American Thoracic Society (AGS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Association', 'sustained blood pressure (BP)', 'serum HBV-DNA', 'lactation|Glomerular filtration rate', 'class)|Systolic Blood Pressure', 'length of stay', 'helminth parasitic infections', 'Karnofsky score', 'prevalent end-stage renal disease', 'old|Former stage', 'cough score', '18F-FDOPA PET/CT', 'Pirads', 'Neutrophils (ANC)', 'cystatin C [CysC]', 'international standardized ratio', 'FMT administration|Toxic megacolon|Anaphylactic allergic reactions', 'Multisyllabic Lexical Neighborhood Test (MLNT)', 'resident of Colombia', 'liver metastases|Absolute neutrophil count (', 'Modified Hoehn', 'both', 'Hemoglobin A1c (HbA1c) measurements', 'prolonged QT/QTc', 'AST', 'radiation|Body Mass Index (BMI)', 'AIS score', 'drug abuse;|6', 'NRS score', 'androgen receptor-negative salivary gland carcinoma', '/mcL|Total Bilirubin', 'SMCQ', 'serum K', 'menstrual cycles.|Typically requires', 'm2|Hemoglobin A1c', 'plasma prothrombin activity', 'aspartate transaminase [AST]', 'LATITUDE™ Home-Monitoring-System', 'anti-hepatitis B core antigen (HBc)', 'old;|CD19+', 'ISS7 score', 'MBP', 'Pulse', 'serum pregnancy test.|6', 'Atlanta Classification of Acute Pancreatitis.||2.1 Abdominal pain indicative of pancreatitis', 'ATC', 'AMI presentation.|Patients', 'hepatitis C|History of malignancy', 'RECIST 1.1.|Patients', 'Flexor Carpi Radialis (FCR)', 'serum creatine', 'quantitative PCR', 'Mean arterial blood pressure', 'chest size', 'preculture.|Life expectancy', 'residual neurological deficit', 'spherical equivalent lens power', 'D3 levels', 'serum B-HCG pregnancy test', 'outside ipsilateral levels', 'NYHA class', 'average amount of', 'Alanine aminotransferase/aspartate aminotransferase', 'MGH research staff', 'German', 'HR-NMIBC', 'pulmonary arterial pressure', 'Modified Norwood-Hamilton Scale.|Subject', 'procedure duration', 'TFI', 'LOC', 'NOS)|T-cell/histiocyte', 'residual adverse effects', 'lost blood or donated', 'Modified Electric', 'Rustogi Modification of the Navy Plaque Index', 'pulse rate outside', 'nasal stimulation schirmer test', 'aorta diameter', 'total SOFA score', 'Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)', 'Na', 'neurologist|Disease duration', 'mellitus|Hemoglobin A1c (HbA1c)', 'diastolic ≥90 mmHg', 'HbA1c level', 'albumin infusion|Serum total bilirubin', 'New York Heart Association (NYHA) cardiac function grading standards', 'Ejection Fraction', 'PPG SNR', 'Ankle Disability Index score', 'urine Pregnancy test', 'SD Severity Score', 'Kaiser Permanente Northern California (KPNC)', 'hepatitis B virus DNA', 'pregnancy test occurs', 'periodontitis|cigarette smokers|non smokers||', 'International Classification of Headache Disorders (ICHD) -3 (', 'PTP', 'Serum M protein', 'months|Exclusive enteral nutrition', 'RECIST v1.1 are', 'below:||leukocytes', 'weighing', 'serum pregnancy testing', 'Saturation levels', 'RECIST v1.1|ECOG performance status', 'SBRT', 'Visual', 'prothrombin time（PT', 'Hepatic Bilirubin', 'maximum diameter', '8th', 'tumors harbor oncogenic drivers', 'TTF', 'ALT ≤5 × institutional ULN', 'partial thrombin time', 'maximum diameter ≤ 5cm|Or the number of tumors', 'period.|UAS7 score', 'thyroid surgery.|aged', 'ineffective.|Liver function test ALT, AST>2 times the upper limit of reference value', 'RNA quantitative positive should complete antiviral treatment', 'MCI)||Age', 'average)|Body mass index', 'calculated by Cockcroft-Gault Equation).||Adequate Coagulation function', 'RECIST version 1.1 .|Life expectancy', 'Total score 10+|Psychotic spectrum', 'per consensus guidelines|Provision of informed consent', 'y-glutamyl transferase', 'ranged between grades', 'COVID-19 Rapid Antigen Test (RAT) should be', 'Alanine aminotransferase (ALT) levels', 'flexion deformity', 'National Eye Institute (NEI) scale', 'Ventricular Ejection Fractions)≤ 50%.|History of ischemic stroke', 'serum HCG', 'General exclusion', 'RECIST standard v1.1', 'Bristol Stool Scale', 'Child Pugh B (score 7-9 points)|further inclusion criteria apply||Inclusion criteria applying only to participants with normal hepatic function:||Individually matched', 'serum creatinine', 'EDSS scale', 'left-sided.|The CDH', 'old|Eastern Cooperative Oncology Group (ECOG) Performance Status', 'American Society of Anesthesiology classification', 'platelet transfusion', 'New breast cancer progression', 'NCI', 'Albumin', 'aspartate aminotransferase AST', 'ginseng', 'blast count', 'BCR::ABL', 'SaO2 value', 'AML', 'progesterone receptor expression;|ECOG score', 'standardized uptake value', 'hepatitis B core(HBc)-total positive', 'stage unspecified OR|Two Urinary Albumin-to-Creatinine Ratio (ACR) test', 'ICDAS', 'criteria||BMI', 'nasal high-flow oxygen therapy', 'modified radical mastectomy.|Body mass index', 'SELENA-SLEDAI score', 'cm||Body Mass Index (BMI):', 'Same', 'stool frequency Score', 'antibodies (ACPA)', 'pain rating', 'modified Toronto Clinical Neuropathy Score', 'age|New York Heart Association (NYHA) functional', 'renal function.|Blood pressure', 'HBV-DNA>10,000 copy/mL;HCV-Ab', 'left ventricular ejection fraction(LVEF)<50%|Uncontrolled', 'pulmonary arterial wedge pressure (PAWP)', 'NCI-CTCAE version 5.0 [Appendix 3].|Known hypersensitivity', 'RPR', 'urine culture', 'Adolescents adopted', 'CSF cytology', 'Rome-IV criteria', 'NCI-CTC', 'Medication Overuse Headache', 'extracorporeal Membrane Oxygenation', 'International Union of Immunological Societies (IUIS) Committee.|Participant', '50kg(woman)|Body mass index (BMI)', 'Blood pressure [BP', 'Ccr', 'imprinting center defects)|Diagnosed', 'hepatitis B virus surface antigen and', 'Response Evaluation Criteria in Solid Tumors (RECIST) version', 'infarction;|Life expectancy', 'Hepatitis C antibody tests', 'anti-HCV Abs are detected.|Negative for Hepatitis B surface antigen.||For', 'SARS-CoV-2 pneumonia', 'special dietary', 'Left ventricular function', 'peripheral blood eosinophil cells', 'minutes.|Platelet count', 'RECIST v1.1 criteria.|Eastern', 'HBV viral load', 'Antibodies to HCV).|Participant', 'achalasia)|Age', 'respiratory rate ≤', 'inclusive|Weigh', 'INR/PT≤', 'NYHA Class', 'ULN)|Alanine aminotransferase (ALT)', 'local laboratory reference range', 'Body mass index>30', 'FIGO', 'RECIST v1.1|Eastern Cooperative Oncology Group (ECOG) performance status', 'n', 'diagnosis|ECOG PS', 'ULN)|Absolute neutrophil count (', 'New York Heart Association (NYHA) functional classification', 'Pathology suggested MVI', 'random plasma glucose (RPG)', 'Weight Control', 'AF', 'MGH Blood', 'bariatric surgical procedure||', 'blood activity', 'mmHg.|Diastolic BP', 'Neck circumference', 'Beck Depression Inventory', 'Aspartate aminotransferase', 'GMFCS', 'NYHA III_IV)|Cirrhosis Child B-C', 'Partial Mayo score', 'HCV titer detection value', 'Tegner activity level', 'gamma-hydroxybutyrate', 'Analgesic', 'ASA Status', 'CL', 'ingredients|Systolic blood pressure', 'anti-signal regulatory protein α (SIRPα) therapy.||Has', 'Transderm-Nitro', 'hospitalization|BP', 'MMG', 'inhibitor test', 'manual', 'Cl', 'HDRS-17 Item #3', 'ICH', 'Creatinine clearance rate CG', 'ARISCAT score', 'AOBP DBP of', 'bone quality|Treatment', 'American Association for the Study', 'Minnesota Research Authorization Retrieval Tool).|Patients', 'Efferon LPS NEO column', 'maximum mean Modified Gingival Index (MGI)', 'controller', 'international normalized ratio [INR]', 'Urine filtration', 'serum β-HCG pregnancy test', 'Besides', 'angiokeratoma|Estimated glomerular filtration rate (eGFR)', 'Heart Rate (HR)', 'Partial Thromboplastin Times', 'ECG abnormality', 'systolic LV function', 'German Association for Psychiatry', 'New York Heart Association Class IV', 'NOVO Hospital (Pontoise site)', 'EC', 'serum chemistry parameters:||An', 'CAR T cell infusion.||Use of', 'estimated length', 'inclusive.|Body weight', 'hepatitis B e antigen (HBeAg)', 'sound extracted upper', 'E. coli', 'inpatient claim', 'Mesothelin protein', 'urinary incontinence,|The child', 'corrected calcium', 'Numeric pain rating scale', 'CLs', 'Catholic University of Sacred Heart in Rome', 'antibodies to rAAV', 'serum Na', 'screening visit.||☞ BMI', 'TAF', 'metastases on PET imaging are', '68Ga-NODGA-LM3 PET/CT', 'Lewy Body Dementia', 'Gestational diabetes||Pregnancy', 'dialysis', 'Respiratory rate', 'total central corneal', 'Clinical Dementia Rating Scale', 'Moderate', 'RECIST 1.1', 'ethanol breath test', 'Go test', 'coronary calcium score', 'Total bilirubin (TB)', 'MD Anderson pathology', 'preserved EF|Patients', 'alternatively score 2+', 'Fibrosis', 'COVID-19 restrictions).||Inclusion', 'PACLITAXEL', 'transthyretin cardiac', 'hemoglobin (HbA1C) test', 'commercial assays|Exclusion Criteria', 'meeting Rome IV Criteria', 'basal', 'Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.|Estimated life expectancy', 'HDL-C', 'PAP (CPAP', 'cardiolipin-lecithin antigen', 'thrombophilia test', 'RT|Life expectancy', 'alcohol unit', 'body temperature', 'restenosis).||Ejection fraction', 'regular sporting activity', 'prolonged thromboplastin time', 'brachial index', 'HBcAb)|Positive total HBcAb test', 'musculoskeletal', 'Ottawa Hospital Stroke Prevention Clinic', 'neurotoxicity', 'Gorno-Tempini criteria)18', 'Criteria:||Age', 'NOVO Hospital - Pontoise site||Exclusion Criteria', 'treatment|extensive reading', 'Prothrombin time', 'HELLP', '50 years|IPSS', 'Cough Peak Flow (CPF) measurement', 'RECIST 1.1 criteria；Chemotherapy', 'foods|Systolic blood pressure (BP)', 'test result', 'Fudan University Shanghai Cancer Center', 'HBV-DNA detection', 'lost', 'Face Memory Test', 'DSM 5 criteria', 'stroke patients:||age', 'Endoscopy showed esophageal', 'capillary plasma glucose', 'AF)|Baseline AFEQT score', 'National Cancer Institute General Adverse Event Term 5.0 (NCI CTCAE V5.0) level 1 toxicity', 'III.|Body mass index', 'Cervical cancer|Pregnancy', 'nurse', 'PHQ-9M', 'Glascow Coma Score (GCS)', 'orthostatic test', 'creatinine clearance rate (CCr)', 'MoCA', 'AST(SGOT)/ALT(SGPT', ""National Health Commission of the People's Republic of China ("", 'white matter injury', 'RECIST v1.1 (Phase Ib Part', 'wide field', 'resolved', 'creatine kinase (CK) concentration', 'hemoglobin S/beta0 thalassemia', 'definition: 1)', 'sustained BP', 'Bone marrow function', 'alanine tracers', 'plasma viral load (HIV RNA', 'mm3||Hepatic function', 'spirometry with', 'age.|ECOG PS', 'left ventricular wall movement disorder;|Mitral/aortic disease', 'Diabetes Research Center in Providence', '18F-Florbetapir', 'for IgA ≥0.5 g/dL', 'RECIST 1.1.|Progressive disease', 'Prothrombin international normalized ratio', 'ROM', 'CDK4-related genes.|ECOG score', 'enrollment.|ECOG performance status', 'cirrhotic status', 'PACS-CFS', 'Henry Ford Health|Is', 'piflufolastat', 'Polymorphonuclear neutrophil count', '≤2.5×ULN;|Expected survival', 'mom)|Cardio-respiratory pathology', 'followed:||R-ISS stage', 'Capacity Classification of', 'creatinine clearances (CrCl)', 'International Normalized ratio (INR)', 'patient|Acute transmural myocardial infarction', 'HbsAG', 'Absolute neutrophil count (', 'bariatric surgery.|Being', 'participants)|Weight', 'dialysis|Comfort care only|Total bilirubin', 'move|Life expectancy', 'ICG dermal backflow|Age', 'WBC count', 'serum sex hormone levels', 'plasma concentrations', 'DLB', 'Child-Pugh|contraindication', 'mean score', 'Strong Memorial Hospital/SHARP healthcare', 'hematocrit', 'assessment tools|Uterine sound size', 'American Society of Anaesthesiologists classification ASA', 'eGFR reduction', 'Body mass index [BMI]', 'teeth', 'estimated Glomerular Filtration Rate (eGFR)', 'PPHN discovered', 'Hemoglobin ≥9.0 g/dL AST (GOT)', 'AVA', '3months|Systemic right ventricle ejection fraction≤40%, assessed on echocardiography||', 'VRE', 'HPV-DNA Expression.|HPV', 'Botulinum toxin', 'hemoglobin (HGB)', 'partial-thickness burn', 'partner||sexual abstinence||Effective methods:|progestogen-only oral hormonal contraception', 'Bilirubin-Total', 'stool', 'probing depth', 'quality index', 'Body Mass Index', 'formoterol fumarate studies', 'blood pressure', 'bilirubin', 'Höglinger criteria||', 'IV);|unstable ischemic heart disease;|inability', 'psilocybin', 'hemoglobin values', 'lipase', 'PROMIS-Anxiety short', 'RACE score ≥5 score', 'Visual Analog Scale||', 'anti-HBs', 'urinary test', 'thickness for archival storage;|6', 'T4 and', ""Metabolic Diseases||Thyroid disease|Addison's Disease|Cushing's Syndrome|Aldosteronism|Hypoaldosteronism|Pheochromocytoma|Disorders"", 'GMF level', 'medication OFF', 'women)|blood pressure', 'ESC Heart Failure', 'microalbuminuria', 'cirrhosis Child', 'hemoglobin (Hb', 'ALT level', 'GLEASON / ISUP', 'Accountability', 'Twins born', 'MGB', 'body temperature ≥37.5℃', 'DICOM', 'CD4+ cell count', 'Alanine aminotransferase', 'gestation', 'International Prostate Symptom Score (IPSS)', 'GDS-S', 'residual diameter stenosis', 'tranexamic', 'reduction rate ≤20%', 'months|Uncontrolled hypertension|Arrhythmia', 'New York Heart Association (NYHA);|Subjects with', 'calculated creatinine clearance', 'PPLs)|PPL size', 'fasting blood sugar', 'III|Body Mass Index (BMI)', 'antibodies or', 'IIEF-EF', 'Barcelona Clinic Liver Cancer(BCLC', 'linear LV mass', 'axial length', 'T4 levels should', 'kgs)|Any current problem which', 'Taiyuan|Primary school children', 'syphilis antibody positive', 'Cardiac function', 'American Society of Anesthesiologists (ASA) score', 'serum creatinine below', 'UPMC Home Health Care of Central PA|English', 'estimated Global Filtration Rate (eGFR)', 'serum FLC ratio', 'refuse it|Liver function', 'alanine aminotransferase [ALT]', 'partial thickness injury', 'polypnoea', 'DAS28 score', '1|Total bilirubin', 'bilirubin levels should', 'bone marrow)|Plasma cell leukemia|Previous chemotherapy', 'aminotransferase level (ALT)', 'hepatitis C virus (HCV) infection', 'serum HDL-C', 'PS score', 'total Mayo score', 'Homozygous hemoglobin SS (HbSS)', 'residual CNS symptoms/deficits', 'Blood count', 'amylase', 'cesarean|Prenatal hemoglobin level', 'slippery', 'primigravida)|Single pregnancy|Third trimester', 'Physical Activity Guidelines for American adults|research-grade accelerometer records sufficient aerobic physical activity', 'Karnofsky Performance Status Scale', 'partial pressure of', 'hepatitis C virus infection', 'beta-HCG', 'hemoglobin (HbA1c): Screening period', 'echocardiography|Life expectancy', 'UK PD Society Brain Bank criteria', 'Screening.||Eosinophil count', 'ECG findings', 'Serum albumin (ALB)', 'Spinosa Semen etc.;|Average', 'New York Heart Association (NYHA) grade≥2', 'hepatitis C (HCV antibody', 'Equinoxe Proximal Humerus Fracture', 'Cockroft-Gault', 'CDR memory score', 'methylhistamine values', 'HIV test', 'OCS', 'heart rate response', 'comorbidities|Mental retardation|Pregnancy|History', 'PPD', 'headset uncomfortable||Project 2:||- Cognitive impairment', 'Cor TRICUSPID ECM Valve|Left', 'Nancy University Hospital', 'postoperatively;|Ground glass-dominant lung nodules|Consolidation-to-tumor ratio (CTR)', 'National Eye Institute grading.|Patients', 'Response Assessment', 'NYHA classification Class', 'Partial Thromboplastin Time(APTT', 'ACPP-SCCM criteria', 'haemodialysis|creatin level', 'surgery|ASA physical status', 'UK Brain Bank Criteria|modified Hoehn', 'prostate cancer allowed.|Concomitant somatostatin analogs', 'HBV-DNA positive|Severe', 'Gleason', 'fasting insulin level', 'chemotherapy.|ECOG', 'impairment|mini mental test <24|deformity', 'CAR T cell infusion', 'gestational age ≥37 weeks|Birthweight', 'Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1', 'hepatitis C virus infection.|It', 'Tear Film Break Up Time less than 10 seconds|Ocular Surface Disease Index', 'Suicidal Ideation from Columbia Suicide Severity Rating Scale', 'Serum albumin', 'ILAE', 'Acid Reflux Severity Scale (ARSS)', 'urine flow rate (Qmax)<15 ml/s;||4', 'intimate partner', 'Native Dutch speaker', 'New York Heart Association (NYHA)', 'anogenital cancers|Willing', 'drug metabolism enzymes', 'urinary protein level', 'HER2+', 'eligible).|Left ventricular ejection fraction', 'CAR-T cell infusion', 'alpha-fetoprotein', 'Coagulation||International Normalized Ratio (INR)', 'TCP', 'Major Functional Disabilities-Neurological Function Score (MFD-NFS', 'peripheral blood HCV RNA', 'system;|Gleason Score', 'AMI', 'American Fertility Score (AFS)', 'RECIST v1.1|Can provide archived', 'NPDR', 'estimated glomerular filtration rate [eGFR]<45 mL/min', 'certificate;|Having', 'interval corrected', 'acquisition interval of the slices', 'International Cancer Control [UICC].|ECOG performance score', 'Tiko Platform', 'See section', 'Gangnam Severance', 'SARS-CoV-2 virus', 'fasting blood glucose (FBG)', 'Rutherford score', 'serum creatinine clearance', 'hepatorenal syndrome;|Alanine aminotransferase (ALT)', 'Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Eastern Cooperative Oncology Group performance status', 'Specifically: Blood pressure', 'hepatitis B virus deoxyribonucleic acid', 'Aspartate Aminotransferase (AST)', 'Nijmegen Questionnaire score NQ', 'Forced Expiratory Volume in 1 second (FEV1)', 'inclusive.|Body mass index (', 'ICG test before operation', 'corrected serum calcium', 'renal function Serum creatinine', 'hepatitis B virus DNA copy number', 'IKD', 'respiratory frequency', 'Serum levels of amylase', 'American Society of Clinical Oncology', 'Sexual Health Inventory', 'prostate MRI', 'Phosphatase', 'Aminotransferase (AST)', 'human immunodeficiency virus antibody (HIV-Ab', 'Histologically', 'American Society of Anesthesiologists (ASA) Physical Status Class', 'Come Scale (GCS)', 'elevated transaminases', 'estimated glomerular filtration rate [eGFR', 'FVIII activity', 'Fibrinogen', 'transferring', 'RECIST 1.1|Is', 'GSV reflux', 'BM', 'MORES', 'Visual Acuity:||Best-corrected distance visual acuity (BCDVA) score', 'total MGD score', 'COVID-19-mRNA vaccinations', 'radiographic bilateral grade', 'hepatitis C infection;|Pregnant', 'suicidal thoughts/tendency', 'urine toxicology screening|Previous treatment', 'implant', 'serum calcium levels', 'IIA', 'HBA1c', 'North Star Ambulatory Assessment', 'profound', 'Mega Green Tea Capsules Life Extension', 'plasma ALAT', 'iodine refractory', 'alkaline phosphatase levels', 'hepatitis B PCR', 'participant|life expectancy', 'positive pressure ventilation.||Exclusion Criteria', 'RECIST 1.1.|Eligible tumor tissues', 'HTN', 'glomerular filtration rate', 'EMR', 'ECG lead placement||', 'Blood Institute guidelines', 'partial dentation.||No mobile teeth', 'West Yorkshire ICB region.|A primary care practice', 'ER', 'Intox etc.)|Chronic kidney disease', 'hepatitis C virus (HCV)||', 'IOS', 'modified Mayo score', 'natural teeth.|Complete', 'ACR criteria', 'developmental quotient', 'serum anti-GM-CSF receptor antibody test', 'dual anti platelet therapy (', 'liver metastases|Hemoglobin ≥9.0 g/dL|Platelets', 'months;|ECOG score', 'viral RNA', 'New York Association', 'regular alcohol', 'indocyanine green test', 'Hemoglobin A1c', 'old.|Body mass index', 'National Cancer Institute [NCI] Common Terminology Criteria', 'IgA', 'Hypoxic-ischemic encephalopathy', 'pack years]).||Current alcohol', 'HO)|Age', 'viral hepatitis markers', 'RECIST 1.1.|Adequate organ', 'Block test score', 'dual users)|200', 'test for HIV', 'FIO2', 'anti-donor HLA antibody', 'Carnation Care Center', 'receptor tyrosine kinase', 'Moderate activity disease', 'Manual', 'seconds||Appropriate', 'hepatitis C viral infection', 'bone marrow cell morphology', 'months)|Body mass index (BMI)', 'RECIST V1.1 evaluation', 'ACQ', 'Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)|Eastern Cooperative Oncology Group (ECOG) performance status', 'American Society of Anesthesiology (ASA)-score ≤ 3', 'POLICY MAKERS', 'Hepatitis B virus surface antigen (HBsAg)', 'facial skin', 'MUGA', 'Thomsen', 'serum glutamic-oxaloacetic transaminase', 'neutrophil absolute count (ANC)', 'syphilis antibody', '18F-DOPA-PET', 'Oxygen saturation', 'CMU', 'circulatory blood', 'Article', 'urine protein +', 'FOCUS GROUPS WITH HEALTHCARE PROFESSIONALS|Unable', 'screening:||Alanine aminotransferase (ALT)', 'thyroid hormone supplementation', 'Parkinson plus syndromes', 'Bedridden', 'ACUVUE® OASYS MAX', 'ejection fraction||', 'nerve disorders|Epilepsy|A copper spiral', 'study.|Tumor size', 'https://members.childrensoncologygroup.org/prot/reference_materials.asp|Estimated glomerular filtration rate', 'hepatitis C antibody (HCV Ab)', 'Severity Scale', 'anti-HIV Ab)', ""United Kingdom Parkinson's criteria Brain Bank disease (Hughes et al"", 'thyroid function tests', 'anti-donor HLA antibodies', 'blood pressure|No abnormalities', 'positive pressure ventilation', 'anti-hepatitis C Ab', 'Hemoglobin (HB)', 'best radiological response', 'blood test', 'CDC criteria', 'ATEZOLIZUMAB', 'test', 'Child-Pugh grade C);|Patients', 'Pro S|Oncological condition|Positive HIV', 'Kosin University Gospel', 'video conferencing.||', 'either||FRI criteria|CDC criteria', 'hematology retest analyzed', 'posterior circulation', 'preoperative value|Methemoglobin', 'Mallampati score', '≤1.5×ULN|Creatinine clearance #50', 'Beck Depression score of >30*|History', 'skilled nursing', 'TLCO', 'RECIST v1.1 criteria.|Patients', 'respiratory function', 'hepatitis C antibody test result', 'CLIA', 'physical examination.|History of bleeding diathesis', 'Alanine Transaminase)', 'anti-hepatitis C virus (HCV) antibody (Ab)', 'GH', 'children enrolled', 'menstrual bleeding questionnaire proposed by', 'SPT to Dermatophagoides pteronyssinus', 'HCV genotype test)||Individuals', 'testing laboratory;|Bilirubin ≤1.5x ULN', 'polyp size', 'progesterone-containing', 'total bilirubin (TBIL)', 'Child', 'Concentration scale', 'diastolic pressure', 'venous hematocrit value', 'participation;|Body mass index', 'arterial embolus,|(2)being residents of Northern Norway,|(3)willing', 'weight-matched', 'physical activity|log', 'UACR', 'HCV antibody', 'National University Hospital of Iceland', 'hepatitis C virus infection;|Known', 'preformed antibodies', 'Sohag University Hospital', 'time interval', 'mini MoCA', 'residual thyroid', 'spherical equivalent', 'creatinine clearance rate (Ccr)', 'drugs.|Systolic blood pressure', 'absolute platelet count', 'GFR', 'hepatitis B core antibody (HbcAb)', 'HCV antibodies).||', 'Fondazione Policlinico Gemelli Hospital||', 'SPT', 'Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 disease.|Patients', 'International normalized ratio (INR)', 'AGGF1', 'visual impairing|neurological', 'UC Davis|ADHD', 'serum pregnancy test.|Male', 'WHO Group', 'medication inducing considerable surgical risk', 'trial.|Acute coronary syndromes', 'maximum serum creatinine', 'serum hepatitis B surface antigen', 'Mild Cognitive Impairment', 'pro-VEGF treatment', 'Creatinine clearance rate (Ccr)', 'excretion', 'Serum creatinine (CR)', 'Angle-closure', '635mg)|Baseline FEV1', 'laboratory test values', 'interferon|Alanine transaminase', 'surgery)|Best corrected distance visual acuity', 'ATS/ERS standards', 'average amount', 'either:||rHu EPO', 'age|Postoperative midline exploratory laparotomy', 'or;|high-density lipoprotein', 'Gross Motor Function Classification System', 'expansion|Absolute neutrophil count', 'cardiac MRI.||', 'hemoglobin A1c (HbA1c)', 'HCV virial load', 'PCR;|Oxygen saturation', 'Insomnia Severity Index (ISI) score', 'age;|CD20+', 'HBV DNA', 'Karnofsky score, KPS)', 'germline VHL alteration', 'monospecific DAT strongly positive', 'HCV RNA levels', 'alcohol urine test', 'National Institutes of Health Stroke Scale (NIHSS)', 'systolic pressure', 'GMFM level', 'New York Heart Association [NYHA] classification grade', 'plasma Cr', 'months|Hb level', 'age|INR', 'NIBUT', 'NYHA class IV heart', 'ASCT', 'estimated metastasis', 'speaking|American Society of Anesthesiologists (ASA)', 'weight-reduction medications', 'controlled arterial hypertension', 'anti hepatitis B virus treatment', 'mean pressure', 'COVID-19 viral antigen.|Chest', 'HIV viral load.||HIV', 'natural menses', 'enlarged QTc interval', 'orthostatic position);|Body mass index', 'transplantation;|Positive EBV serology', 'Risk Myelodysplastic syndrome', 'urine dipstick', 'Normalized Ratio (', 'subcutaneous injections.|Performance level', 'NAS', ""Kerr's criteria"", 'estimated glomerular filtration rate (eGFR)', 'New York Heart Association (NYHA) functional', 'New York Heart Association', 'patients|body mass index', 'TBUT test', 'American Society of Anesthesiologists) Class', 'platelet inhibitory effects', 'ERCP', 'periodontal', 'Pulse Rate (PR)', 'Princess Máxima Center', 'blood glucose', 'Hepatitis B test', 'dysgraphia', 'blood pressure medication', 'serology', 'COVID vaccine', 'one;|aged', 'SARS-CoV', 'detectable hepatitis B Deoxyribonucleic Acid (DNA)', 'alanine aminotransferase', 'rheumatology care from Duke Health', 'electrophysiology test', 'HIV-1 infection|Age', 'FLT3+', 'deeply settled brain tumours.||', 'visual', 'sufficient level', 'CAR-T therapy', 'White Blood Cells', 'age|Smoke', 'Screening.|Weight', 'Visual Analogue Scale (VAS)', 'Lubben', 'Rheumatology:||age', 'spontaneous INR', 'pulmonary artery pressure', 'medium-high risk MDS', 'o Exclusion criteria', 'pregnancy test (βHCG)', 'FTTIP condition|Agency leaders', 'normal blood pressure', 'anti- programmed death-ligand', 'poly-L-lactic acid', 'reduced ejection fraction|Cerebral ischaemic stroke', 'TSAT', 'Insomnia Severity Index (ISI);|ability to adhere to a diet', 'LV', 'Epworth sleepiness score', 'hepatitis B virus [HBV] surface antigen [HBsAg]', 'SIRP', 'coagulation profile', 'eligible|BMI', 'Aspartate transaminase (AST)', 'University students', 'PGI-S).||In', 'Total Score', 'bone metastases', 'hemoglobin ≤6.5%;|LDL-cholesterol', 'positive pressure support', 'urinary protein quantification', 'drinks containing xanthines', 'urine-HCG', 'insufficient renal function', 'logists:||age', 'procedures;|Age', 'prostate biopsy.|Subjects', 'months|Current BMI', 'Covid-19 PCR positive', 'creatinine', 'pro BNP is', 'FIbromyalgia Rapid Screening Tool', 'academic test', 'corrected corrected QT interval', 'section 9.13.||Disease', 'evaluation|Clinical Dementia Rating Global', 'ejection fraction.||Acute', 'general health support', 'New York Classification of Cardiac Function', 'self-report|Weight', 'fasting plasma insulin', 'arterial', 'HIV antibody test positive', 'ACR criteria)|50 years', 'drug abuse).|Creatinine', 'Emergency surgery;|Patients', 'test for pregnancy', 'Posttraumatics Stress Scale', 'Longest diameter of lymph nodes', 'eGFR).||Or:||Serum Creatinine', 'cardiac monitoring|Body weight', 'weight loss.||Pregnant', 'breathing', 'ASA physical condition', 'nasal swabs collected', 'R1 resection);|both sexes', 'CHUA', 'TTP (ADAMTS13 activity', ""Schirmer's test"", 'luteinizing hormone-releasing hormone (LHRH) analogs', 'months|Report HIV status', 'gynecological organ deposition|BMI', 'urine', 'estimated creatine clearance', 'total hepatitis B core antibody (HBcAb) test', '≤40|Hemoglobin', 'mediastinal large B cell lymphoma||AND||Chemotherapy', 'child between the', 'test for hepatitis B virus (HBV)', 'anti-hepatitis B core [HBc] antibody negative)', '90 diastolic|Carboxyhemoglobin levels', 'physical condition/renal function', 'left appendage AP', 'nadir oxygen saturation', 'RECIST v1.1;|Eastern Cooperative Oncology Group performance status', 'MRI-2)|Brain MRI', 'fasting blood glucose', 'American Society of Anesthesiologists (ASA) class', 'anti- Programmed cell death protein', 'RECIST 1.1 criteria', 'General Criteria||Provision', 'New York Heart Association (NYHA) classification', 'aminotransferase', 'age|Karnofsky Performance Scale (KPS)', 'BrainChild-04|Life expectancy', 'Olsen grade 2)|The decision to undergo ADL-PDT', 'NCI CTCAE v5.0).|Patients', 'gallium', 'bone marrow edema', 'screening|Hepatitis C virus', 'systolic pulmonary pressure', 'partial response', 'Thyroid-Stimulating Hormone (TSH)', 'motor function', 'Columbian Hospital', 'KAFO', 'arterial pH', 'IPS', 'alcohol breath test', 'HBSAg', '3.|Systemic arterial pO2', 'supine blood pressure', 'cells', 'Ankle Instability Tool (CAIT)||', 'serum beta-hCG', 'Syphilis test positive;|Serious heart disease', 'FDG', 'COVID-19 test', 'M3)|Patient', 'human immunodeficiency virus (HIV) antigen', 'axillary temperature', 'males.|For Growth Hormone (', 'HPV-screen-positive', 'MOCA', 'distilled spirits', 'Pain Medicine Center.|Current', 'Response Evaluation Criteria in Solid Tumors (RECIST)', 'Kg).|Intrauterine Growth Restriction (IUGR)', 'chromosomal breakage test', 'Child-Pugh C).|no informed consent signed', ""Bourgogne Franche-Comté'|Fluent"", 'preschool', 'diastolic blood pressure [DBP]', 'MRE|Orofacial CD', 'MDQ', 'randomization;|Life expectancy', 'SCFE', 'oestrogen receptor expression', 'education level.|Clinical Dementia', 'fasting albumin-corrected blood calcium level', 'age|Healthy|Body mass index', 'weeks|Wound Area', 'direct bilirubin fraction', 'MSI-H', 'Spanish|Body mass index', 'hepatitis B core antigen] antibody test', 'American Society of Anesthesiologists physical status', 'INR should', 'HTLV1 antibody positive) should', 'CD4+ T cell count', 'GPT', 'Estimated Glomerular Filtration Rate (eGFR)', 'Partial thromboplastin time (PTT):', 'mean age', '68Ga-FAPI-46', 'cardiac valve morphology', 'months;|Eastern Cooperative Oncology Group (ECOG)', 'precautions below differ', 'Blood Transfusions', 'OBS1', 'direct bilirubin', 'normalized CD4 count', 'serum immunoglobulin', '50+', 'M.D. Anderson radiology', 'RECIST v1.1 criteria;|Female', 'plt count', 'modified USPSTF criteria|Contraindication', 'special equipment', 'prothrombin activity', 'liver metastases);Cr', 'Human immunodeficiency virus (HIV)', 'international normalized ratio abnormality', 'venous thromboembolism|History', 'Heart Rate', 'Arbor stage', 'cumulative score', 'Tumour tissue collected after', 'minute Apgar Score', 'RECIST v1.1 definition.|Physical condition score', '2015)|Geriatric Depression Scale-Short Form (', ""Patrick's Faber test"", 'Beck Depression Inventory-II (BDIII) score', 'Palliative Performance Scale|Able to communicate in English', 'ESI', 'lesion size', 'Hg.|Anticipated stay', 'anti-Hepatitis C Virus antibodies', 'European Position Paper on Rhinosinusitis', 'indoor oxygen saturation ≥95%;|Cardiac function', 'Thyroid function', 'minimum sensitivity', 'parasitic infestation|Acute exacerbation of', 'hearing impairment|Inflammatory bowel disease', 'relapses;|Bone marrow relapsed', 'Fibrinogen ≥1.0 g/L', 'Anyone', '# reverse transcriptase polymerase chain reaction', 'CAP score', 'Beck Depression Inventory-II (BDI-II)', 'CNS metastases|History', '-Age group', 'Pain Patients||Inclusion', 'Glomerular filtration rate', 'serum immunoglobulin free light chain', '≥0.5', 'NE', 'Total bilirubin (TBIL)', 'reverse transcription polymerase chain reaction', 'Leukocytes', 'least)|Chronic respiratory failure', 'Screening:||Positive hepatitis B', 'homicide risk|Night shift', 'FFPE', 'ALL|Age', 'antigen test.|Presence', 'CPAP therapy.||', 'Hemoglobin', 'medium -weight lungs', 'modified W.A.R. score', 'hepatitis B core antibody (HBcAb;', 'HF between', 'ECOG status', 'blood urea', 'Screening.|In good general health', 'ATNLS Grade', 'transfusion)|Absolute neutrophil count (ANC)', 'NCI-CTCAE version 5.0', 'human immunodeficiency (', 'raw score ≥17|PAP intolerance', 'triglycerides', 'serologic test', 'Alanine aminotransferase (ALT)', 'minute walk test', 'General anesthesia', 'Anti-HIV2', 'Bristol Score', 'Fasting', 'New York Heart Society Class', 'Alcohol Use Disorders Identification Test (AUDIT', 'FDG-PET scan results', 'QRS duration', 'predictive value', 'Blood Count (', 'histopathology;|ECOG performance score', 'screening;|Positive HIV test', 'inclusive.|Body weight index', 'BORG scale.||', 'indocyanine green (ICG)', 'researchers;|Viral load', 'etc.)|BMI', 'bpm)|Severe pulmonary dysfunction', 'Beck', 'Hepatitis C virus RNA', 'creatinine level', 'Classification', 'cardiac echocardiography|Hepatitis', 'Absolute neutrophil count|1.5 x', 'metabolic diseases;|History', 'WHO group', 'acenocoumarol', 'Human Papilloma Virus', 'HER2-negative breast cancer', 'SARS-CoV-2;|Pregnancy', 'ECOG (Eastern Cooperative Oncology Group)≤2;|expected survival', 'initiating hemodialysis', 'Total calcium', 'eGFR MDRD-4', 'Diagnostic and Statistical Manual of Mental Disorders, 5th Edition', 'vital pulp|A restorable tooth', 'alanine aminotransferase(ALT', 'HIV antibodies', 'partial thromboplastin time (aPTT/PTT', 'classroom teacher|NEU Seydişehir', 'screening||Key', 'prothrombin concentration', 'old|Histopathologically', 'Beijing', 'PLASMIC score', 'ALT/AST≤ 3×ULN', 'ETDRS', 'FFR', 'HbA1C', 'Down Syndrome|Need of Dental', 'Hb)≥', 'IOP', 'Quantitative phase exclusion', 'Fasting blood glucose', 'anamnesis', 'urine biochemistry', 'serum creatinine level', 'American Society of Anesthesiologist physical status classification', 'combination|HbA1c', 'cessation', 'traumatic exposure', 'CD4 count', 'hepatitis B core antibody (HBcAb)', 'anti-hepatitis B core antibody positive (HBcAb+)', 'hemoglobin of 9-10 g/dL;|Medical', 'Hepatitis C infection.||Chronic', ""Schirmer's Test"", 'Numbered Pain Rating Scale', 'sperm motility', 'ISMI score', 'heparin|Resting blood pressure', 'glioblastoma|Eastern Oncology Group (ECOG) performance status', 'antidiabetic treatment|Age', 'quantitative total urine protein measurement', 'alfa reductase inhibitors', 'HCV viral load|Patients', 'lymphoma|Serum total bilirubin', 'special care nurseries).||', 'hepatitis B surface antigen-reactive', 'Millipede System.|Clinical symptoms', 'ACR/EULAR 2015 score ≥8|Able and', 'modified Boston neuroradiological criteria(Table 9)', 'departmental guidelines).|Any splenic biopsy|Hypervascular masses', 'RECIST version 1.1 criteria||', 'Serum M-protein level', 'EHRA', 'MMP', 'cross-match test', 'White Blood Count', 'blood count', 'kidney functional', 'hepatitis B surface antigen positive', 'fasting test', 'Modified Caregiver Strain Index.|Social disconnection', 'aerobic activity', 'DLMO', 'finger pulse oximetry corrected by oxygen supplementation', 'HbA1c', 'Karnofsky Performance Scores (KPS)', 'estimated blood', 'Cerebral Functional Monitoring (CFM)', 'Bilateral lesion|Development', 'cervical cytology', 'HBV-DNA titers', 'AIDS', 'NYHA heart function', 'SAGA BFR application', 'thyroid hormone', 'hepatitis C active infection', 'Boston Scientific EMBLEM', 'HIV-1 antibody', 'alkaline phosphatase (AP)', 'applied', 'Anti-CD20 monoclonal antibody', 'extend period beyond 8', 'ERT Treatment naïve', 'maximal transaortic velocity', 'Glycated hemoglobin (HbA1c)', 'SpO2 measurement', 'modified-Cutaneous Dermatomyositis Disease Area', 'Alanine AminoTransferase', 'pertinent medical criteria', 'WHO.|Age', 'mean grip strength', 'forced expiratory volume in 1 second (FEV1) to forced vital capacity ratio>0.70', 'PCWP', 'HBV surface antigen (HBsAg) result', 'Lansky play performance scale', 'outside pathology', 'hepatitis B virus DNA (HBV-DNA', 'vital signs findings', 'resting HR', 'hepatitis C antibody (HCVAb)', 'Alkaline phosphatase', 'screening||※ BMI', 'screening|BMI', 'PTT (aPTT)', 'peripheral granulocyte count', 'serum albumin', 'analgesic block.|Body mass', 'FAC', 'human immunodeficiency virus (', 'ischemic colitis.|History of', 'absolute neutrophilic granulocyte count', 'international normalized ratio in coagulation test', 'perceptual disturbances', 'Pulmonary Artery Pressure', 'by:||Left ventricular ejection fraction', 'thyroid replacement dose', 'serum β-hCG test', 'AP', 'ANC count', 'Diastolic Blood', 'Serum virology test', 'hepatitis C (', 'genitourinary small cell carcinoma', 'mRS score', 'anesthetics +', 'CBD', 'manifest refraction', 'traditional Chinese medicines', 'Urine protein <+', 'Lower extremity orthopedic surgery', 'GU symptoms/conditions', 'Sipuleucel-T treatment|Eastern Cooperative Oncology Group (ECOG) performance status', 'moderate', 'Bone Marrow Failure syndromes', 'serology for HIV', 'averaged QTcF values', 'international normalized ratio', 'probable', 'Clermont-Ferrand University Hospital', 'partial cystectomy|Previous total colectomy', 'Digital rectal exam', 'age|Aspartate aminotransferase', 'SARS CoV-2', 'HBV DNA+).|Active hepatitis C', 'ECOG Performance Score', 'RCC', 'Regional Perinatal Service Center|Able to communicate in English||', 'General Ability Index (GAI)', 'maximum diameter 2 cm)|RPOC', 'TFBUT', 'symptom severity scale', 'form|Bilateral hearing thresholds', 'old|American Society of Anesthesiologists score', 'American Society of Anaesthesiologists (ASA) physical status', 'PBC-specific antinuclear', 'screening|Negative hepatitis B surface antigen (HBsAg) test', 'NCI-CTCAE v.5.0', 'stated).|Left ventricular ejection fraction', 'serum total bilirubin (TBIL)', 'Performance status', 'Ejection fraction', 'copy number', 'EGD', 'serum κ/λ free light chain ratio.|ECOG score', 'hepatitis C antibodies', 'meeting physical activity guidelines|Individuals', 'cardiac surgery|intracranial', ""Mohs' surgery"", 'anticardiolipin', 'Male|Age', 'metabolic equivalents', 'intense pulse light procedure', 'Cooperative Oncology Group (ECOG) performance status score', 'prothrombin time (PT) ≤1.5×ULN.|SpO2', 'GVHD);|Neutropenia', 'CAG', 'San Michele Hospital IRCCS Istituto Auxologico Italiano in Milan||', 'hepatitis B surface antibody positive', 'required|ECOG Performance Status', 'modified Dandy criteria', 'Screening.|Stable body weight', 'Canadian Cardiovascular Society Angina Class', 'Hematology', 'Depression Scale score', 'UCP)|Manual Ability Classification System (MACS)', 'anti-T cell immunoreceptor', 'Neuropsychiatric Inventory domain score', 'Organ Function||A. Bone Marrow Function:||Peripheral absolute neutrophil count (', 'Vernier height gauge', 'partial pneumonectomy.|Pulmonary function test', 'Interval', 'expected intensive care stay', 'headache', 'N1', 'old|Normal Body Mass Index (BMI =', 'Comorbidity Index', 'Beck Depression Inventory|Willingness and willingness to participate in the research|Completed', '1.Voluntarily enrolled', '60%)|Absolute neutrophil count', 'International Classification of Headache Disorders', 'AAC', 'hepatitis B PCR positive', 'pulse rate', 'remimazolam infusion|History of hypersensitivity', 'hepatitis B virus surface antigen (HBV sAg', 'Base excess', 'Medication Exclusions:||Failure', 'mini-mental state examination score', 'solid tumors.|Dose Expansion Phase', 'CKD-EPI|UACR', 'modified United States Preventive Services Task Force and American College of Obstetrics', 'Rome IV criteria for IBS-C.', 'gender unlimited;|right hand;|Han', 'systolic anterior motion of the mitral valve leaflets', 'kg|Distal radius +/-', 'venipuncture.|Triglycerides', 'hepatitis B virus core antibody', 'ALT ≤3.0x', 'PPT', 'International classification of disease', 'as:||absolute neutrophil count (', 'SpO2 saturation monitoring||Receiving standard postoperative of care||•', 'resolve.||Systemic arterial thrombotic', 'mmHg|Diastolic Blood Pressure', 'Brush test (dynamic)', 'women|body mass index', 'calculated)|Body mass index (', 'partner.||In Aims', 'RSV MAT-039 studies', 'GABAbr-antibodies', 'urea nitrogen', 'anti- Programmed Death-ligand', 'by:|Creatinine clearance', 'moderate physical exercise', 'hemoglobin A1c (HbA1c) level', 'hepatitis C virus', 'oral iron|BMI', 'See Section 10.8.1', 'recovery program', 'overall disc herniation (extrusion or protrusion', 'IV)|Left ventricular ejection fraction', 'preeclampsia bulletin criteria.|Pregnant', '60%<FEV1', 'mean pulmonary artery pressure', 'IBS-M (', 'anti-hepatitis C virus [HCV] antibody [Ab]', 'give up HCT', 'Serum total bilirubin (TBil)', 'plasma sodium', 'Schiff sensitivity score criteria', 'LMD', 'anti-HCV antibody', 'hepatitis C infection NOTE', 'BSA', 'Physical Activity Readiness Questionnaire', 'UK dietary recommended values)|currently pregnant', 'WASO', ""Jack's test"", 'Singleton pregnancy|Age', 'antibodies to HRV-39|Current', 'RRP', 'adjustments', 'Spends', 'history|systolic blood pressure', 'Amblyopia', 'fever', 'estimated duration of surgery', 'QT interval corrected (Fridericia)', 'f-SRS|The', 'testosterone', 'human immunodeficiency virus (HIV) infections', 'Lund-Mackay score', 'HADS - Depression score', 'HIV-1 RNA', 'research,|Body mass index (', 'ULN.|Total bilirubin', 'body Mass Index (BMI)', 'plasma creatinine', 'monoclonal antibodies (mAbs)', 'RECIST v1.1.|For the phase Ia', 'estimated glomerular filtration rate (eGFR) ≧', 'CMV-DNA copies', 'technology literacy', 'compliance.|Creatinine clearance', 'diabetes duration', 'chronotype MSFSC', 'spirometry test', 'residual urine volume', 'Platelets count', 'supplemental oxygen', 'ASA score', 'serum glutamate pyruvate transaminase', 'hepatitis C virus infection.|Primary immunodeficiency disorder', 'HCG rate', 'ACUVUE® OASYS 1-Day.|Has refractive astigmatism', 'modified Rankin Scale', 'FMBS values', 'HPA axis', 'ASA physical status I- II|Age', 'Renji hospital|age', 'MADRS', 'staff)|Age between', 'Montreal Cognitive Assessment Scale', 'worst pain rating', 'hepatitis B surface antigen (HBsAg)|Hepatitis C', 'absolute leukocyte count', 'arterial pressure', 'esophago-gastro-duodenoscopy|Gastro', 'alveolar bone height', 'Nordic diet recommendation.||', 'European Society of Cardiology (ESC) recommendations', 'boys', '≥1.0 g of protein', 'treadmill contraindications)|Intact skin', 'gestational age||', 'planar mesh', 'end expiratory-pressure (PEEP) ≤8 cmH2O', 'CDAI', 'total bilirubin', 'neonatologist judges intensive care', 'mean bone audiometry', 'scan|Baseline QTc interval', 'HER2 negative|Bilateral breast cancer.|Stage IV breast cancer.|Benign', 'NYHA classification NYHA)', 'VL', 'RV size', 'serum AST', 'Skåne University Hospital||', 'tattoos', 'monoclonal antibodies within', 'systolic blood pressure measurements', 'pregnancy test|Clinical', 'platelet ≥80×10^9/L', 'HCV viral', 'itching', 'Residual salivary flow', 'August', 'Bone height', 'pregnancy test (serum)', 'modified radical mastectomy||', 'Von Frey test', 'hepatitis B surface antigen (HBsAgB)', 'SMMT score', 'ASA PS', 'Naloxegol plasma levels', 'ATS-ERS', 'telephone.||Exclusion criteria', 'neuroendocrine small cell components|Site(s', 'hepatitis C virus (HCV) antibody', 'prostate biopsy|Prostate', 'psychogeriatric inpatients', 'gold standard VO2 max', 'ROADMAB™ CDST', 'SARS', 'diastolic BP', 'anti-HIV antibody', 'LFT', 'COVID-19)""by Ministry of Health of the Russian Federation', 'old|Patients', 'MSA-P (', 'old|ECOG score', 'EGFR sensitive mutations', 'Hamilton score', 'patch|Age', 'old|Unresectable histologically', 'New York Heart Association Class', 'PCWG', 'Jean Mermoz Hospital||', 'CAR-T cell', 'Schirmer', 'Numerical Rating Scale', 'Intensive Care Unit', 'serum total bilirubin', 'pharyngeal molecular swab|Adult', 'hemoglobin A1C (HbA1c)', 'hepatitis B virus core antibody (HBcAb)', 'oral food challenge.|The', 'eligible.||Left ventricular ejection fraction', 'Lens Opacities Classification System (LOCS)', 'creatininemia', 'pembrolizumab + chemotherapy|Patient', 'NACC FTLD guidelines|Apathy', 'MSD DOR/ISL', 'NYHA cardiac function rating', 'neonatal antigen load', 'hepatitis C virus (HCV) (+)', 'mean arterial blood pressure', 'Intensive Care Unit (', 'haemoglobin A1c (HbA1c) level', 'Karnofsky scale)|Life expectancy', 'test result).|Requires treatment', 'Blood Count', 'haemoglobin', 'Shortening fraction', 'autonomously functioning thyroid nodules (', 'liver enzyme elevation', 'measurement of systolic blood pressure', 'MRA evidence of', 'VAS eye dryness severity score', 'ACS|Life expectancy', 'RECIST 1.1;|Life expectancy', 'hepatic function', 'mastectomy|ASA physical status', 'refusal.|body mass index', 'age;|ASA', 'false', 'RECIST v1.1:||in', '4)ECOG PS score', 'MIBC', 'Serum Bilirubin', 'systolic blood pressure<90 mmHg', 'Fasting glucose', 'prostate cancer histologically', 'liver metastasis;||• Serum albumin', 'ferritin values', 'calculated by Cockcroft-Gault formula);|For', 'alkaline phosphatase', 'international normalized ratio(INR)', '177Lu-DOTATATE', 'ND', 'mRankin score', 'iodine uptake', 'left ventricular ejection fraction ≥40%|Pulmonary function', 'hepatitis B surface antigen [HBsAg]-positive', 'expression;|ECOG score', 'VAS pain intensity questionnaire.|Be an appropriate candidate', 'Short Portable Mental Status Questionnaire', 'Child-pugh liver function score', 'liver function', 'imprinting center defects)|Angelman Syndrome', 'response assessment.|ECOG status', 'quit.|Negative urine toxicology', 'alanine transaminase (ALT) ≤3 times the ULN.|Patient has adequate bone marrow function', 'Pain Clinic physician', 'longer|Recent initiation', '100,000/µl)|hemoglobin', 'SNF', 'urine light-chain (M-protein', 'recovery', 'alanine aminotranferase (ALT)', 'left subclavian artery;|Heart transplant', 'Cockroft-Gault formula)|Life expectancy', 'perinatal hypoxic-ischemic encephalopathy', 'failure rate of', 'Fracture neck of femur', 'months|Average blood pressure', 'glomerular filtration rate ≤50 mL/min/1.73m2', 'NYHA functional class', 'old;|Eastern Cooperative Oncology Group (ECOG) performance status', 'DSM criteria|Autism/Schizophrenia|Clinically significant', 'BM biopsy;|Absolute neutrophil count (', 'GvHD post bone marrow transplant', 'HBV-DNA load', 'salivary flow.|Children enrolled for other studies', 'GvHD prophylaxis|Creatinine clearance', 'airline flight', 'NHS', 'NAC', 'bone metastasis);||Albumin', 'North Carolina Immunization Registry', 'smoking cessation', 'tunnel syndrome|weakness', 'Serum Creatinine', 'HB', 'Child-Pugh Classification', 'anti-HBc antibody result are', 'age|presenting VAS score', 'to||Clinical SLEDAI', 'hemoglobin [Hb]', 'RECIST version 1.1||Patients should', 'UK resident', 'serum total cholesterol', 'plasmocyte BCMA expression positive;|5.Echocardiography', 'PENE', 'ACR classification', 'L-Dopa concentrations', 'FBT', 'hemoglobin concentrations', 'New York Heart Association Classification (NYHA)', 'NYHA functional grade', 'Hematocrit below 10%', 'Absolute neutrophil count(ANC)≥1.5×109/L', 'meniscal root/radial repair', 'Head Start Educators:||Does', 'ALT ≤5 times ULN|9', 'a:||Patients Entering from the Parent Studies||1. Patients with', 'spatiotemporal asymmetry', 'hepatitis B surface antigen (HBsAg) reactive', ""Assiut University Children's Hospital"", 'PEC', 'Mycobacterium', 'age|Weigh', 'aspirin + P2Y12 inhibitor)|History of', 'DOAC])||Estimated glomerular filtration rate (eGFR):', 'bone age', 'included.|Best Corrected Visual Acuity (BCVA)', 'Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1 on first imaging', 'follows:||Hemoglobin', 'PELD score', 'pregnancy tests', 'between Screen #', 'platelet≥100×10', 'Absolute neutrophil count(ANC', 'Fasting blood sugar levels', 'New York Heart Association (NYHA) Functional', 'systolic', 'Respiratory Society (ERS) acceptability criteria.||', 'International Headache Society', 'cervico-facial malformation.|Control', 'eria:||Over', 'BMI>30', 'anti-Programmed cell Death 1 (PD1) / anti-Programmed cell Death Ligand', 'Arizona', 'forced expiratory volume in 1 s', 'peripheral blood stem cell', 'JAK2', 'arrhythmias.|Uncontrolled arterial hypertension', 'HIV antibody positive);|Active hepatitis B', 'thyroid/parathyroid dysfunction', 'QTc interval duration', 'Visual analog scale', 'MF59C.1', 'urologic procedures', 'serum ferritin', 'RECIST criteria|Reduction', 'Rankin Scale', 'serum glutamic pyruvic transaminase', 'alanine aminotransferase (ALAT)', 'NYHA Ⅱ level', 'criteria of ""disease stabilization""', 'following:||total bilirubin', 'Body Mass Index (BMI)<18.5 or', 'hypoproliferation；|Eastern Oncology Collaborative Group Physical Status Assessment', 'European Working Group On Sarcopenia-2 criteria (EWGSOP-2)', 'follows:||Hematological Neutrophils', 'CD4', 'G-CSF)', 'compartment syndrome|Fasciotomy', 'CRP level', 'months;||Major organ function', 'Blood creatinine', 'Geisinger Primary Care Physician assigned|Completes', 'hepatitis C virus (HCV) antibodies unless HCV Ribonucleic acid', 'white blood cell (WBC)', 'Enrolled in City of Hope (COH)', 'Mass Index (BMI', 'lymphoma population lacking antigen expression', 'Undergraduate', 'Grad', 'NYHA cardiac function class', 'liver function tests', 'wide spectrum antibiotics', 'hypospadias repair|Raised serum creatinine', 'Global CDR score', 'Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version 1.1);|Eastern Cooperative Oncology Group (ECOG) performance status', 'estimated Glomerular filtration rate (eGFR)', 'BOMC', 'hemoglobin ≥60 g/L', 'international standardized ratio of prothrombin time', 'lymphoma:||• Phase IIa', 'lift head from', 'Kellgren & Lawrence radiographic', 'impairing arterial pressure', 'Bone marrow primitive cells recovered', 'University Student Mental Health (ELSAM)', ""Schirmer's Test score"", 'CTP', 'creatinine ≤1.5x ULN', 'speech', 'Fondazione Policlinico Universitario ""A. Gemelli"" IRRCS||', 'Mass Index (BMI)', 'screening|Body Mass Index (BMI)', 'supine BP', '/Alanine aminotransferase (ALT):', 'MINOCA', 'ECOG performance status)|Subjects', 'synthetic-DMARDs.|For', 'white blood cell', 'months.||Appropriate organ function:||Creatinine', 'MSI-H subtype', 'depth of local effusion', 'International Association of Pancreatology/American Pancreatic Association', 'King Chulalongkorn Memorial Hospital|aged', 'HCV RNA test results', 'HBVDNA', 'HIV-1 RNA test', 'NCI CTCAE v5.0 Grade', 'transrectal ultrasound|Serum creatinine levels', 'platelet', '-and|body mass index', 'BIL', 'plasma total bilirubin', 'cardiac function level', 'adjusted QTc', 'CD4 counts', 'adolescents', 'urine M protein level', 'RECIST v1.1 definition;|Physical condition score', 'renal function test results', 'Wood units||Pulmonary function tests', 'anti-HIV antibodies', 'MoCa test', 'partial prothrombin time (PTT)', 'peripheral arterial vessel).|Chronic kidney disease', 'Gestational age', 'stem-cell transplant', 'attachment level', 'Forced Expiratory Volume in one second (FEV1)', 'Phe concentration', 'diabetes|BMI', 'Investigator,|Body Mass Index (BMI)', 'WHO lymphoma classification criteria', 'hepatitis C virus treatment', 'Up', 'systolic blood pressure>160 mmHg', 'American Society of Anesthesiologists (ASA) physical', 'screening|Absolute neutrophil count', 'weight change', 'randomization|ECOG Performance Score', 'Child-Pugh C.|History', 'RECIST 1.1 although measurable disease', 'Best Spectacle Corrected Visual Acuity (BSCVA)', 'perioperative care related to vascularized lymph node transfer|Concurrent', 'hepatitis B surface antibody (HBsAb)', 'Larimer County', 'testosterone level', 'SGLT2i|Systolic blood pressure (SBP)', 'RECIST v1.1|At least', 'NIH COVID 19 Treatment Guidelines', 'maximum diameter ≥10mm);|Serum cortisol', 'Hemoglobin level', 'TRRIP consensus criteria', 'hemoglobin should', 'Karnofsky index', 'bone marrow reserves|Life expectancy', 'urine durg screening;|Pregnant', 'testing for HIV', 'males.|For GH treatment', 'NIH PROMIS depression scale', 'liver injury|History of', 'rocuronium|Body mass index', 'Antibodies) treatment', 'GPs', 'Prothrombin time-international normalized ratio', 'absolute neutrophil count (', 'study|2 Revision rotator cuff repair|3 Patient consent', 'FLAIR', 'Mean pulmonary arterial pressure', 'Parenteral nutrition contributing', 'arent/Guardian', ""Flippin' Pain campaign"", 'one).|Previous arterial cannulation', 'HCVAb', 'HBeAg', 'duration remission', 'serum creatinine (SCR)', 'Health Coaching Mental Health Screening Questionnaire score', 'screening|Body mass index', '18F-FDG PET/CT examination', 'nclusion Criteria:||Left-sided Impella', 'Sex:', 'HIV 1/2 antibodies positive).||Active hepatitis C', 'bone fracture.|At', 'OFS', 'total lymphocyte count', 'therapeutic bronchoscopy)|body mass index', 'abdominal sepsis|Acute respiratory failure||', 'creatinine clearance rate (CrCl)', 'between MMSE score', 'serum pregnancy test (β-hCG', 'International Classification of ROP (ICROP) criteria', 'total', 'International normalized ratio', 'hepatitis;|Aortic arch dissection;|Major surgery', 'hospitalizations', 'Royal Marsden Hospital', 'BTC', 'CTCAE v5.0.|Unstable thrombotic events', 'HBV DNA titer in peripheral blood', 'HCV RNA.||Known human immunodeficiency virus (HIV)', 'simple tissue expander replacement', 'hepatitis B virus deoxyribonucleic acid [HBV-DNA]', 'Female|', 'serum alpha-fetoprotein (AFP)', 'urine pregnancy test (UPT)', 'signature|Age', 'NORA).||', 'thyroid papillary carcinoma;|Uncontrolled clinical cardiac symptoms', 'Karnofsky', ""Home Care Service's assistant's criteria"", 'VV ECMO', 'organs;|age', 'European Society of Cardiology 2020 guidelines|Practice', 'NBGFR', 'NCI-CTCAE version 5.0 [Appendix 3]', 'NCI CTCAE 4.03', 'STS score', 'AFP levels', 'gestational week', 'hepatitis C RNA levels', 'MSK', 'neutrophil count', 'Reverse Transcriptase polymerase chain reaction', 'syphilis spirochete antibody test results.|Patients', 'BCL2 translocation|Patients', 'pregnancy|Body Mass Index', 'COVID-19 PCR test should', 'cardiac ejection fraction', 'Forced Expiratory Volume (FEV)', 'expected score', 'prostate cancer in situ)', 'urine screens', 'ISNCSCI', 'HR +', 'partial thromboplastin time (APTT) ≤1.5ULN;|Pregnancy tests', 'blood fluidity', 'liver transaminases', 'alanine transaminase (ALT/SGPT', 'length', 'Total Body Surface Area (', 'albumin', 'leukemic involvement|total bilirubin level', 'American Society of Anaesthesiologists (ASA) status', 'alcohol test (breath', 'pulmonary imaging.|Any medical disease', 'ATM', 'thyroid-stimulating hormone (TSH ≤ 10', 'Axial Length', 'human gingival fibroblast|Healthy gingival tissue||', 'Blood glucose stable', 'GOS', 'hole population -||Exclusion Criteria', 'Platelet count≥', 'in remission', 'ITE', 'General Physician/Family Practitioner', 'bone marrow image indicates', 'modified medical research council', 'LDL cholesterol levels', 'sFLC level', 'self report):||Age', 'old|American Society of Anesthesiologists (ASA) physical status', 'HOMA-IR index', 'LSM', 'liver function tests||vii', 'HTLV-II|Active bacterial', 'Serum AST', 'left/right bundle branch block', '50|American Society of Anesthesiologists Physical Status', 'Karnofsky Performance Scale', 'Ib', 'Alzheimer', 'Rutherford category', 'serum ALT level ≤ULN', 'Korean', 'mass index(BMI)≤27.0kg/m2||', 'hemoglobin ≥9.0 g/dL', 'prostate cancer.|PRE-REGISTRATION', 'STOP-Bang score', 'GSI-T score', 'total bilirubin levels', 'weeks|American Society of Anesthesiologists physical status classification', 'AVB', 'CAR T cells', 'Organ involvement/compression', 'attenuation parameter', 'potassium', 'serum free light chain ratio', '# HEART failure', 'total cholesterol', 'study|Hemoglobin', 'CDR score', 'serum alkaline phosphatase level', 'serum tumor biomarkers', 'bariatric surgery|Patients', 'modified version of the Physical Activity', 'sentinel node negative|Ductal carcinoma in situ DCIS', '3×ULN);|Alanine transaminase (ALT)', 'SEHEPS questionnaire', 'Diagnostic radiologists', 'ECOG-PS score', 'Florence', 'points;|Left ventricular ejection fraction', 'New York Heart Association (NYHA) functional classification score', 'Gout Classification Criteria', 'Serum IgG4 levels', 'rapid ventricular response', 'New York College of Cardiology class', 'ATS/ERS', 'systolic blood pressure (BP)', 'NPI-ES', 'American Society of Clinical', 'cycles|ECOG PS', 'Criteria||Age', 'dual in situ hybridization [DISH])|Any', 'National Institutes of Health [NIH, 2020]', 'serum test.|Physician discretion', 'months|HbA1c levels', 'hepatitis C infection.||Hepatitis B infection', 'Lumbar spondylosis|Lumbar disc prolapse|Sacroiliac joint', 'weight records', 'urine protein<2 (+)', 'employed full-time', 'painful arc test', 'Response Evaluation Criteria in Solid Tumors (RECIST)|For treatment', 'UNL|Total bilirubin', 'intraocular pressure)|Patients', 'escalation stage', 'rapid plasma regain (RPR) test (+)', 'body temperature≥', 'MMSE', 'B6', 'pharyngeal pain.||', 'Hb', 'physical activity/exercise', 'gamma release test results', 'HCAb', 'autologous transduced T cells', 'international normalized ration [INR]', 'ECG changes', 'fasting blood work', 'amplification', 'HCV-RNA test indicates viral replication]', 'child between', 'Mayo Clinic Neurology Multiple Sclerosis Clinic.|Control', 'EGFR-TKI', 'cSCC', 'UHDRS score', 'Karnofsky performance score', 'Hemoglobin A1c (HbA1c)', 'Borg scales', 'ASPECT', 'residual alopecia', 'liver function related diseases', 'HASBLED score', 'SOC RT', 'adult T-cell', 'MGH', 'WHO', 'LIKD', 'Family Member||Participant', 'Performance Status', 'alcohol test', 'NIH', 'QuantiFERON®-tuberculosis Gold (QFT-G', 'proliferative LN Class', 'National Comprehensive Cancer Network(NCCN', 'inpatient rehabilitation|Knowledge of German to understand study material', 'lymphoma)|Total bilirubin', 'serum fasting glucose level', 'partial prothrombin time (PT)', 'urine dipstick value', 'pseudoexfoliation', 'ASL', 'CMV seropositive|Total serum bilirubin', 'spirit 40%);|History', 'FCXM', 'men),|Vitamin B12 levels', 'anti-HBc [antibody', 'Forced Expiratory Volume in 1 second (FEV1)60-80%.|Children', 'creatinine clearance', 'left ventricular thrombus', 'left ventricular ejection fracture (LVEF)', 'DSM-IV standard', 'nicotine products.|Positive screen', 'PSP-CBS', 'HBV DNA copy', 'DAT ≤1+', 'Montreal Cognitive Assessment', 'women|Systolic blood pressure', 'Matched Healthy', 'G12V', 'sporting', 'endogenous serum EPO', 'Risk Estimation', 're-)resection|Age', 'urethra', 'CDR scoring', '6 minutes', 'tuberculin skin test', 'changes|Body Mass Index (BMI):', 'Bristol Stool Scale (BSS)', 'thyroid function tests|Use', 'Creatinine level', 'San Raffaele', 'baseline Hamilton Depression Scale', 'orthopnea', 'Hospitalization', 'parenthood plan', 'Hunt-Hess grade I-', 'HTLV', '2016 WHO Classification', 'moderate facial skin condition', 'blood HCG test', 'best-corrected distance visual acuity (BCDVA)', 'Platelet', 'Platelet count<90 × 10^9/L', 'SMZL', '68Ga-PSMA SUVmax', 'positive|Active viral hepatitis|Females', 'Neutrophil', 'CEMO Villa Sur', 'UV overexposure', 'HCV RNA.|Known hypersensitivity reaction', 'short cervical length', 'Hanifin and Rajka criteria', 'months;|CHILD', 'Physical activity', 'National Institute on Aging', 'CHM', 'American Association of Anesthesiologists (ASA) physical condition', 'serum chemistry', 'topoisomerase', 'RECIST version 1.1 at least 1 cm with contrast enhanced', 'Myopia', 'diameter;|Left ventricular ejection fraction', 'hepatitis C virus RNA', 'instead|Total bilirubin', 'facial deformities|Height', 'estimated visual potential', 'Short Blessed Test', 'physiotherapists', 'National Stroke Institute for Neuropathic Speech Disorders and Association for Alzheimer Disease and Related Disorders)', 'ITD', 'Absolute neutrophil Count)/µl', 'Fasting plasma glucose', 'serum intact PTH concentration', 'systolic blood pressure [BP]', 'platelet counts', 'rheumatoid arthritis)|Coeliac disease|Score', 'Hemoglobin ≥9.0 g/dL', 'liver score', 'Glomerular Filtration Rate', 'gestational age.|BMI', 'thyroid-replacement hormone', 'MEK protein kinase inhibitors;|Prior radiation', 'spot urine sample', 'New York heart association [NYHA] class', 'New York Heart Association (NYHA) Classification', 'resting heart rate (HR)', 'ASCT refractory, including:||Disease progression', 'nano Litre)|Hemoglobin', 'navicular height', 'NYHA Class IV);|have mental disease', 'American Society of Anesthesiology (ASA)', 'blood platelet', 'apical lesion.||', 'dual-antiplatelet agents.|Active use of', 'Northeast Texas area', 'Beck Depression Inventory-2 (BDI-II) score', 'Hamilton depression rating scale', 'Neuroscience Institute medical', 'International Federation of Obstetrics', 'thyroid papillary cancer;|Allergy to', 'screening.|Positive pregnancy test', 'PASP', 'evaluated;|ECOG score', 'plasma CMV PCR post-enrollment', 'cryo time period', 'West Yorkshire QIP||', 'GSW', 'White blood cell', 'LV thrombus||Right Sided Impella||Inclusion', 'BCMA expression', 'Left ventricular end-diastolic diameter (LVEDD)', 'drug abuse.|Donation', 'CSF cytology|Karnofsky', 'Negative Syndrome Scale', 'left ventricular ejection fraction<50%;|Patients', 'care|body mass index', 'normal].|Body Mass Index (BMI)', 'HDL-cholesterol', 'serum potassium, calcium', 'serum phosphorus concentration', 'CAR-T therapy)|MONOCLONAL ANTIBODIES', 'US Virgin Islands', 'Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.|Women must', 'Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1||Females of child-bearing potential', 'old；|Hamilton Anxiety Rating Scale', 'ER/PR', 'adjuvant setting.|Eastern', 'natural teeth||', 'hemorrhagic origin);|Disease duration', 'EDSS score', 'Alanine aminotransferase (ALT) Aspartate aminotransferase(AST', 'urine test|not', 'size', 'UMilan', 'radioisotope GFR', 'impairment', 'serum t-PSA>10ng/ml', 'General Inclusion', 'walking speed', 'inpatient care', 'T-spot test', 'ABO', 'serum creatinine-based CKD-EPI formula12).|Oxygen saturation', 'Hgb', 'American Society of Anesthesiologists (ASA) physical class', '6)BCLC stage C', 'RECIST version 1.1;|Fertile', 'refractory neuroblastoma|Adequate organ function', 'Blood Institute Guidelines', 'BCMA-targeted therapy', 'limited.|ECOG performance status', 'numeric pain rating scale.|To', 'neutrophil absolute count', 'White Blood Count (WBC)', 'ejection fraction', 'PPD skin test', 'serum Na+ levels', 'CAR-T cell infusion therapeutic program', 'MCL|Platelet count', 'RECIST 1.1.|Documented HER2 exon 20 insertion mutation.|Eastern', 'screening.|ECOG performance status', 'South Korean COPD patients(Bronchodilator test results FEV1/FVC', 'Platelet count≥75×10', 'immunocompromised status', 'CTFG HMA 2020 (Appendix II', 'hepatitis C virus (HCV) antibodies (Abs).|Hemoglobin', 'Lawrence Level', 'urine protein volume ≥1.0 g', 'function:|Total bilirubin', 'psychiatric problems,|No', 'human immunodeficiency virus (HIV) test', 'minimal residual disease (MRD)', 'Marrow', 'QuantiFERON®-TB Gold (QFT-g) assay', 'pleural effusion|The serum pregnancy test', 'Manual Muscle Test-8', 'HCV serologies', 'prothrombin time (PT)>ULN+4 seconds', 'infertility clinic', 'pulmonary vein|preoperative ECOG physical state score', 'junction adenocarcinomas|Absolute neutrophil count', 'ECOG', 'Arabic speaking||', 'pathologies|Psychiatric pathologies|Cardiac arrhythmias|Chronic obstructive pulmonary disease|osteo-muscular', 'AP length maximum 10 mm).||', ""Bechterew's syndrome)|Rheumatological conditions"", 'sPAP', 'neuroleptic drugs|History', 'serum pregnancy test|Willing', 'Karolinska Exhaustion Disorder', 'perceived stress', 'inclusive|Body Mass Index (BMI):', 'V600E mutation|MMR proficient', ""modified Rotterdam's criteria||"", 'Myelodysplastic/myeloproliferative neoplasms (', 'Schirmer test', 'National Cancer Institute Common Terminology Criteria', 'HCV-RNA>1,000 copy', 'International Federation of Gynecology', 'hepatitis C virus antibody (HCV Ab)', 'UH CMC', 'limb length discrepancy compensation', 'Alberta Stroke Program Early CT Score', 'hepatitis C virus [HCV] antibody serology testing)', 'systolic blood pressure', 'NST).||', 'ILAE recommendations||', 'risk level', 'Child-pugh', 'Thyroid stimulating hormone (TSH)', 'prothrombin time versus control', 'procedures|Systolic blood pressure', 'basic knowledge & skills of computer', 'sufficient', 'RECIST v1.1 criteria|Hg', 'DDH', 'SCD', 'allograft function', '27+', 'Ankle Instability Instrument (CAIT)', 'RZL-012-SMFC-P2US-001', 'liver function test values', 'Assessment of SpondyloArthritis International Society (ASAS) classification criteria', 'creatinine clearance estimated by', 'SARS-COV-2 antibody', 'kidney function)：|Creatinine clearance', 'International Movement Disorders Society MDS', 'American Society of Anesthesiologists (ASA) classification', 'GEA eligible', 'BI', 'urine drug screen (UDS)', 'National Health Commission', 'Response Evaluation Criteria in Solid Tumors (RECIST) v1.1||', 'pregnancy test assessed', 'UK working party criteria', 'hepatic transaminases', 'Extended Disability Status Scale', 'Child-Pugh scale.|If', 'or|IV Phenobarbital.|Body mass index (BMI)', 'Glaskow coma scale', 'nasal septal deflections', 'T2D).|Body mass index', 'Absolute neutrophils', 'surgical intervention|iv', 'NIHSS1a score', 'Alanine transaminase(ALT', 'level|Age', 'Depression Scale', 'Karnofsky performance level', 'penetrating TBI|History of disabling neurological', 'fetal heart rate baseline', 'estimated glomerular filtration rate ˂', 'special dietary habits;||Lactating', 'Absolute neutrophil count', 'NCI-CTCAE version', 'Serum creatinine ≤1.5xULN', 'HBs antigen test', 'Karnofsky function status', 'tidal volume', 'Gallup Indian Medical Center', 'stopped', 'INR and/or aPTT', 'syphilis antigen', 'Childhood Autism Rating Scale', 'modified Rankin score', 'IMP', 'hepatitis C antibody);|alcohol abuse', 'uPCR', 'SAINT', 'AIS|Age', 'quantities', 'glycemia', 'ECOG performance score', 'Bone marrow sample', 'TNM', 'male|20', 'GDM)|Age', 'Fiebig stages', 'Marathon Rotterdam 2023|Tympanic temperature', 'hepatitis B virus antibody (HBcAb)', 'ventricular ejection fraction', '500/µL.|Platelet count', 'drug toxicology screen|Conditions', 'pregnancy test)|Lactating', 'HCV antibody test', 'breast feeding|BMI', '1.|Life expectancy', 'seniors', 'ECG results', 'Modified Ashworth Scale', 'mean supine HR', 'AHI)>30', 'hemoglobin', 'NOS', 'readings show', 'WONCBP||Body mass index (BMI)', 'creatinine GFR', 'Barcelona stage b', 'right ventricular mechanical circulatory support||', 'CNS radiation', 'ALB)<28', 'NOVO hospital - Pontoise', 'Baseline.|INR', 'bleeding index', 'Prothrombin rate', 'training load', 'screening lipids||Triglycerides', 'germinal center', 'stress test', 'QTc interval.|Prior', 'hemoglobin levels', 'serum anti-ttg concentrations', 'GBA', 'glomerular Filtration Rate [GFR]', 'Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.||Disease progression', '1.|Blood counts', 'medications.|Systolic BP', 'RECIST', 'both|being', 'following:||Total bilirubin', 'alcohol breathalyzer test', 'UNL|Systolic blood pressure', 'Mexican Social Security Department.|Adults', ""New York Heart Association's functional grading system"", 'tympanosclerosis of', 'low blood pressure', 'muscle function', 'peroxidase', 'urine drug screening test', 'IND', 'T)|Total bilirubin', 'splenomegaly|Hemoglobin', 'stage', 'AND|Peripheral blood eosinophil', 'HCV DNA', 'US)|category', 'VATS lobectomy||', 'left ventricular myocardial hypertrophy', 'modified Hachinski Ischaemia score', 'Visual Analogue Scale', 'moderate levels', 'PaCO2', 'CCr', 'spot urine protein/creatinine ratio', 'GM2 gangliosidosis', 'self-report|HIV-positive status', 'urine drug screen/alcohol breath test', 'Response Evaluation Criteria in Solid Tumors (RECIST) v1.1|Life expectancy', 'Treprostinil', 'Public Health Region', 'quantitative real time(qRT', 'donate sperm.||', 'HIV antibody test result', 'baseline QTc', 'Residence in foster care', 'PTPN11', 'Blood routine test', 'drinking', 'Barcelona Clinic Liver Cancer (BCLC)', 'VRC H1ssF_3928 mRNA-LNP', 'endogenous FIX activity levels', 'ECCO international guidelines', 'gestational age|Living', 'serum FSH values collected', 'Prolonged QT interval', 'Glomerular filtration rate (CCr)', 'documented.||Absolute neutrophil count (ANC)', 'MMM', 'Unresectable stage III or IV,', 'Incisional hernia', 'Triglyceride level.|BMI', 'estimated glomerular filtration rate [eGFR]', 'Serum Glutamic Pyruvic Transaminase(SGPT', 'anti-hepatitis C virus antibodies (HCVAb)', 'residual disease|Myelodysplastic syndrome', 'MSLN', 'Total bilirubin≤1.5 times the upper limit of normal', 'Progesterone Receptor (PR)- positive.|HER2/neu-negative.|Ki67≥30%.|Clinical', 'Serum potassium levels should', 'New York grading system', '10', 'biological therapy.||Hemoglobin', 'investigator;|Adequate hematological function', 'serum AST/ALT', 'ammonia level', 'expected length of hospital stay', 'GEA score', 'generalized', 'National Cancer Institute [NCI]-Common Terminology Criteria', 'West Yorkshire ICB', 'apprehension test;|traumatic anterior dislocation of the glenohumeral joint requiring', 'human immunodeficiency virus (HIV) infection', 'kidney function Creatinine≤', 'provocation.|Left ventricular ejection fraction', 'Modified Gingival Index (MGI).|Have a mean bleeding on probing score', 'mean aortic gradient', 'general medical condition', 'Lansky Play score', 'Neutrophil count≥', 'definition should', 'CDC recommendations|Evidence', 'postmenstrual age', 'LA classification', 'increased levels', 'weight loss', 'eosinophilic RCC', 'hepatitis B surface antigen test|ALT', 'renal disease;|Known malignancy;|Secondary constipation', 'MoCA total score', '||Neutrophil absolute count', 'prostate Multiparametric MRI', 'malunion 9.Leg length discrepancy BMI', 'corrected gestational age', 'serum biochemistry functions', 'plasma Hb1Ac≥', 'special health care', 'criteria.|ECOG performance status', 'WHO Classification', 'New York Heart Association [NYHA] Class', 'medication effect|Aspartate aminotransferase (AST)', 'urine drug abuse', 'STN', 'glycated haemoglobin [HbA1c]', 'Modified Rankin Score', 'regular exposure', 'total HBcAb test.|Negative hepatitis C virus (HCV) antibody test', 'HCV viral titer test value', 'peripheral blood cells', '1.Gynecologic oncology', 'child receive vaccine.|≥18', 'screening:||alanine aminotransferase (ALT)', 'FT surgical procedure', 'palatal tissue harvesting', 'angina)|Heart rhythms', 'autologous SCT', 'UK Brain Bank', 'HCV viral load|ELIGIBILITY CRITERIA', 'Neck lymph nodes exist', 'Viable', 'Basilar Artery Recording can be made', 'Alcohol Use Disorders Identification Test', 'Section', 'III', '1.||Adequate organ function', 'Cobb angle larger', 'HER2 amplification ratio', 'viral load test', 'United Kingdom Brain Bank criteria of bradykinesia', 'CrCl)|Total bilirubin', 'HBsAb test', 'General Activity scale (PEG)', 'WHO Lymphoma Classification', 'plasma EBV DNA', 'CAR', 'FISH)|Karnofsky PS scale', 'international normalized ratio (INR)', 'CTCAE grade', 'Bristol Stool Form Scale (BSFS)', 'serum pregnancy test before randomisation and should be repeated', 'local labs|Negative serum pregnancy test', 'weight stable', 'IgM)|b', 'mild: 0~24', 'BRACE', 'HBsAg test', 'Hepatitis B virus (HBV) viral load', 'Loading dose of antiplatelet agents', 'serum total bilirubin (STB)', 'gestation cervix length', 'transaminases', 'following:||Tumor size', 'peripheral arterial disease.||Pregnancy||ASA Class', 'milk-specific serum Immunoglobuline E', 'total Mayo Score (MMS)', 'obligatory', 'Lansky Level of Performance (LPS) score', 'normal||creatinine clearance', 'HPB', 'West Yorkshire QIP', 'IHC +++', '10|During remission', 'Performance Scale', 'Weschler Abbreviated Scale Intelligence', 'WIfI', 'aminotransferase (ALT)', 'Nancy University Hospital for ENT assessment', 'National University Hospital', 'AHS EHR|Acute Kidney Injury (', 'local laboratory reference ranges).||22', 'IGA score', 'gold fiducial marker implantation', 'Routine urine test result indicates', '2023|Age between', 'female|', 'interferon gamma release assay (IGRA)', 'Total bilirubin ≤1.5×ULN', 'hepatitis', 'FEV1/FVC', 'mean arterial pressure', 'Anti-Glomerular Basement Membrane Disease', 'ECOG Performance Status', 'Alanine Aminotransferase (ALAT)', 'Respiratory support of', 'below:||Leukocytes', 'dialysis|Acute heart failure|Acute coronary insufficiency|Vascular surgery', 'complicates test', 'NCI-CTCAE v5.0(the investigators', 'hematology', 'RIVM guidelines))|BMI', 'modified Bleeding Index19 score', 'Smoking includes', 'Anderson Silverman Score (ASS)', 'creatinine clearance>30', 'general physical condition', 'left ventricular ejection', 'Hemoglobin (Hb)', '> CTCAE 5.0', 'UK retirement', 'Responder Index', 'T1-T2N2bM0,', 'resting ECG', 'CD4+) count', 'residual bone width', 'CDC', 'evolution||• Exclusion criteria||Pacemakers|Coagulation disorders|Pregnancy|Active neoplastic', 'MMS test', 'inadequate level of hearing', 'DOI', 'neutrophilic granulocyte absolute count', 'TAK-771-3005.|If', 'Child-Pugh Class', 'DMF', 'Physical Activity Guidelines for American', 'screening|Hemoglobin concentration', 'hepatitis C virus ribonucleic acid (RNA)', 'HCV RNA copy number', 'MMs', 'ALT)(serum glutamic pyruvic transaminase [SGPT]', 'CD4+ T-cell count', 'conventional RT', 'Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT', 'ROS1 fusion-positive Non-Small Cell Lung Cancer', 'students|Not', 'musculoskeletal)|Calcium', 'creatinine [Cr]', 'American thoracic society dyspnea scale|Hepatic dysfunction', 'prostate gland/bed', 'serum blood pregnancy test', 'Modified Ashworth Score', 'criterion.|Bilirubin', 'serum protein electrophoresis', 'residual survival', 'liver-enzymes', 'histologically', 'Osteoarthritis Research Society International (OARSI) atlas|Had', 'ALT (GPT):', 'Hepatitis B (HBc)', 'numeric pain rating scale', 'European Hernia Society classification incisional hernias|Body mass index (BMI)', 'required|Absolute neutrophil count (', 'TYMP', 'Intensive Care Units||', 'serum triglyceride levels', 'Lansky Scale', 'kidney disease|BMI', 'hepatitis B seropositivity', 'diastolic pressure over 96mmHg.|19', 'partial thromboplastin time (PTT)/ activated PTT (aPTT)', 'urinary albumin/creatinine ratio', 'AST ≤5×ULN);|Alkaline phosphatase (AKP) ≤2.5×ULN|Creatinine clearance rate', 'RECIST criteria following the most recent line', 'pain rating score', 'residual volume', 'HistoSonics Edison System.|Subject', '59th Medical Support Group', 'meeting Inclusion criteria', 'serum transaminase elevations', 'CT ASPECTS', 'rapid HIV test', 'neutrophil', 'lesion length', 'diastolic blood pressure', 'PNH', 'CHB', 'estradiol levels consistent with menopause', 'bone marrow reserve', 'hepatitis B', 'eligibility criteria', 'hepatitis C virus(HCV', 'oxygen saturation index', 'PRO Symptom Survey', 'forced expiratory volume/forced vital capacity (FEV1/FVC)', 'Basic Cognitive Ability Test (BCAT)', 'Smokers', 'psoriasis treatments', 'Screening.|Inadequate renal function', 'screening.|Absolute lymphocyte count', 'estimated creatinine', 'adequate organ function', 'RECIST criteria 1.1', 'Unilateral plus axial involvement', 'suicidal ideation|a co-morbid serious health', 'cardiac frequency', 'alcohol expiratory test', 'Tartu University Hospital Sports Traumatology Centre', 'potential|Life expectancy', 'old.|Body Mass Index', 'estimated GFR', 'RECIST 1.1).|Evidence of RAS', 'foetal heart rate', 'gamma-glutamyl transferase (GGT)', 'PRO-SVD', 'serum vitamin B12 levels', 'American Association of the Study', 'gamma-aminobutyric acid', 'bone marrow function', 'Total lesion length', 'Impaired Participants:||-Clinical laboratory test results:||Platelet count', 'QT interval corrected using', 'Left-handed', 'General Activity (PEG) scale', 'Ca', 'normal sodium level', 'etc.)|Drug', 'life expectancy', 'hemoglobin below study requirements.|Renal function requirements', 'intensive care unit', 'transfusion support|Hemoglobin', 'Angelman Syndrome/Prader Willi Syndrome', 'AKI', 'decreased ejection fraction', 'HCV RNA test|History of pneumonia', 'HBV DNA level', 'estradiol levels', 'OAB', 'genotype', 'lower respiratory tract infection', 'urine hCG', 'gestational age|French-speaking', 'calculated score', 'Pugh score', 'hepatitis B virus surface antigen is', 'UNC IRB SOP', 'partial thromboplastin time (APTT) ≤1.5×ULN|International Normalized Ratio', 'folic acid supplementation.|History', 'WPI', 'WHO ICD-10 classification', 'months|Significant arterial circulatory disorder', 'modified Timed-up-an-Go test65', 'peripheral arterial injury|disease', ""National Institute on Aging-Alzheimer's Association workgroups on"", 'nasal trauma).|Frequent epistaxis', 'sterilized.|Body mass index (BMI)', 'Liver Function||Bilirubin', 'Black/African American;|English speaking', 'Rankine Scale', 'hepatitis C.|Known existence of Gilbert syndrome|Use of medicinal plants/dietary supplements', 'areas', 'TCH', 'CDR', 'liver function test(s', '3;|Ashworth score', '70|body mass index', 'stroke', 'approximated', 'criteria.||Total bilirubin', 'oral hygien.||', 'oral CAL', 'MCL', 'Body Mass Index (ΒΜΙ)', 'urine dipstick reading should', 'months;||Major organ functions', 'somatoform', 'serum creatinine unit', 'Cor TRICUSPID ECM Valve would', 'calculated estimated glomerular filtration rate [eGFR]', 'Left Assist Ventricular Device (LVAD)', 'short diameter', 'neurofilocytes', 'Prolonged QTc interval', 'Mayo global score', 'RECIST v1.1 criteria;|Patients', 'European Society of Human Reproduction', 'Body Surface Area (BSA) involvement', 'lesion Response Evaluation Criteria in Solid Tumors (RECIST)', 'DBS technology', 'Rome IV criteria for', 'AASLD', 'Visual-ICE ablation', 'FT4 levels', 'Blood Glucose', 'Cockroft-Gault formula).||', 'HCV RNA', 'hepatitis B surface Antigen carriers', 'modified Cornell medical index||', 'Karnofsky greater than or', 'New York Heart Association (NYHA) functional classification system', 'intraocular pressure;|Moderate', 'total hip.|Body mass index', 'RASS', 'American Society of Anesthesiologists (ASA) Classification', 'QuantiFERON TB', 'wide QRS', 'Haemoglobin', 'limit;|ECOG PS', 'teaching', 'human immunodeficiency virus|History', 'investigator.|Positive urine pregnancy test', 'chemotherapy.|Iron storage levels', 'IMR', 'urine albumin-to-creatinine ratio', 'national file of volunteers in biomedical research', 'alanine aminotransferase (ALT) level', 'Serum bilirubin', 'RECIST v1.1;|5. Eastern Cooperative Oncology Group (ECOG) Performance Status', 'CKD3', 'staphyloma||(Children Cohort)||Aged', 'numeric pain rating score', 'short-term antiplatelets', 'white', 'waist circumference', 'Thyroid Stimulating Hormone)|Vitamin B12 levels', 'Lymphocyte Count', 'prostate MRI contacting', 'AST)(serum glutamic-oxaloacetic transaminase', 'as:||systolic blood pressure', 'fasting glucose (IFG)', 'random blood sugar', 'Renal Function:||Creatinine clearance', 'National Capital Region|able to read', 'national/local regulations.||', 'urine protein quantification', 'local anesthetics|BMI', 'urine hCG test', 'quantitative pilocarpine iontophoresis', 'none)|competitive level', 'duration', 'urine pregnancy test upon admission', 'investigator.|Absolute neutrophil count', 'QRS interval', 'Hepatitis B core antibody (HBcAb)', 'color Doppler ultrasound.|Normal liver', 'CLL', 'Karnofsky 70%|Age < 16 years', 'fibrinogen', 'NIH CC', 'above|Unilateral trans-tibial amputees|Ambulate', 'Serum Cr≤1.5×ULN|Activated', 'Ag Rapid Test.|Positive blood alcohol test', 'NCI common terminology criteriafor adverse events (CTCAE) Version 5.0 (NCI CTCAE Version 5.0)', 'basic level of technological literacy', 'HCVRNA', 'ULN).|Bilirubin value', 'RECIST v1.1.|Adequate bone marrow function', 'bone marrow/stem cell', 'acid.|Hemoglobin level', 'Anti-HBV treatment', 'subsequent blood pressure readings', 'Google Play stores|Ability to lie supine', 'periodontal status', 'aspartate Aminotransferase(AST', 'Rutherford class', 'Barthel score', 'urine test', 'CNI', 'American Society', 'P.E.', 'glomerular filtration rate]', 'therapy|Blood pressure', 'Response Evaluation Criteria in Solid Tumors 1.1 criteria', 'hemorrhagic disease|Active Infective', 'factor V Leiden gene mutation', 'DREAM cohort.|Inclusion criterion', 'Alkaline phosphatase (AKP)', 'white spot lesion', 'American Society of anaesthesiologists physical status', 'polyp removal.|CT-verified stenosis', 'platelet level', 'PEFR', 'glutamate transaminase (ALT)', 'DLB):||Probable DLB', 'GRF', 'Residual endocrine', 'anti-PD-1/anti-PD-L1 treatment', 'PSMA PET/CT|Adequate', 'New York Heart Association|Myocardial infarction', 'light beige"" approximately 10 participants', 'Transaminases', 'screening|Allogeneic HSCT', 'Urinary protein', 'Gait function', 'estimated blood volume', 'Yahr Scale', 'cardiac ejection index', 'old.|Life Expectancy', 'TEN', 'Viral load', 'Beck Depression Inventory-II scale', 'Quantitative Sensory Testing (QST)', 'Hepatitis B Core Antibody (HBcAb)', 'arrival time into the initial ICU.|The treating physician anticipates', 'RAD51D', 'SARS-CoV-2 detection', 'MSI-H patients.|The', 'calculated by Cockcroft-Gault formula).|The', 'National Task Group-Early Detection Screen for Dementia (NTG-EDSD).|Disclosure', 'criteria of Hanifin and Rajka (1980).|AD lesions', 'STEP', 'Beighton hypermobility score', 'samples.|Age', 'thyroid replacement medication.|May', 'labile blood pressure', 'numeric rating scale.|Continue', 'anticoagulants|ECOG performance status', 'serum follicle-stimulating hormone (FSH) level', 'Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)', 'MGB hospital', 'ALT', 'glomerular filtration rate estimation.|Urinalysis', 'Family Practice - Emergency Medicine', 'examinations.|Alanine aminotransferase (ALT)', 'normalized ratio', 'SCORAD index', 'CD4 lymphocytes', 'likelihood of', 'ER in Al Hussein University Hospital.|Patients', 'Kellgren Lawrence grade', 'alkaline phosphatase [ALP]', 'hepatitis B core antibody positive (HBc stands', 'ULN)|Glomerular filtration rate (GFR)', 'Eastern Cooperative Oncology Group Performance Status', 'drinks per day', 'Intensive Care Unit|Known hypersensitivity', 'laboratory test findings', 'classification|Meets IPSS-R classification', 'kg|Haemoglobin level', 'Intensive Care Unit stay', 'GD1.|Determination of', 'human immunodeficiency virus antibody (HIVAb)', 'bone marrow reserve function', 'old|17-Hamilton Depression Rating Scale', 'Alkaline phosphatase (', 'cardiac intensive care unite', 'ND4 [G11778A]', 'Response Evaluation Criteria In Solid Tumors 1.1', 'Montgomery-Asberg Depression Rating Scale', 'salivary flow rate', 'T-cell count', 'rapid rate', 'confirmatory hepatitis C polymerase chain reaction test.|Recent exposure', 'serum calcitonin', 'SDMT', 'PBMCs', 'ACA', 'Response Evaluation Criteria in Solid Tumor (RECIST)', 'STOP-BANG', 'Kaufman Brief Intelligence Test (KBIT).|Must have', 'calculated by MDRD)', 'Severity Index Activity Score (m-CDASI-A', 'criteria above||Inclusion Criteria:', 'mean SBP', 'Risk Index', 'best corrected spectacle distance visual acuity', 'thyroid-stimulating hormone <LLN', 'Indeterminate', 'loading activities|Palpable pain', 'palpable size', 'Residual flow after LAAC', 'RCT', 'age|Willing', 'serum glutamate phenylacetate transaminase', 'bone height', 'Human immunodeficiency virus (HIV) infection (', 'Facial Wrinkle Scale', 'random time fasting blood glucose', 'hematocrit (Hct)', 'hours.|ECMO duration', 'LDH', 'level|Total bilirubin', 'SAE', 'milliseconds,|Known Left ventricular ejection fraction', 'spinal anesthesia|Morbid obesity (BMI', 'expected risks.||', 'screen ASQ Tool)|History of psychosis', 'HIV', 'hepatitis C virus RNA test', 'count (', 'acid-base balance disturbance|Mechanical ventilation', 'placenta', 'Creatinine Cystatin C-based Chronic Kidney Disease in Children', 'PET scanners|weight', 'New York Heart Association (NYHA) class', 'total homocysteine', 'Hb ≤120', 'quantitative hepatitis B virus (HBV) DNA', 'NCI CTCAE 4.03 level', 'urine protein (UPRO)', 'Dyspnea Severity Item', 'DEERS', 'stool pattern IBS', 'SARS-CoV-2);|Be able', 'MCS', 'Nasal stimulation schirmer test', 'individual patient|Normal CCT range', 'skilled nursing homes', 'resting periods;|Height', 'total serum bilirubin (TSB)', 'alpha-fetoprotein (AFP)', 'Pain', 'weight change|Positive tests', 'response(s', 'Psychosis Risk Syndromes (SIPS)', 'A1c value', 'Cr clearance', 'RECIST v1.1 criteria;|ECOG PS', 'wake time', '1|Human immunodeficiency virus', 'total bilirubin ≤3 times the upper limit of the normal reference range', 'American Society of Anaesthesiologists grade', 'anti hepatitis C antibody', 'sexes.|Age', 'HBV DNA viral load', 'Native Hawaiian/Pacific', 'residual interstitial lung abnormalities', '6;|Baseline ASPECTS', 'inferior alveolar', 'MDI +/-', 'soy protein/lecithin', 'urinary protein', 'Child Pugh score', 'blood pressure||Systolic blood pressure', 'MERS-CoV', 'left ventricular dysfunction', 'RECIST V1.1 criteria;|The', 'shortened QTcF', 'Logical Memory II subscale', 'RA', 'creatinine clearance (CCR)', 'plt', 'PPI', 'itching symptom|Patient', 'prostate biopsy:||Suspicious prostate nodules', 'Rome IV criteria)|rectal diameter', 'Total blood cell loss', 'including:||INR', 'months;|ECOG score≤2', 'FOBT/FIT', 'flavonoids Milk Thistle Other', 'DSM-IV.||', 'BIRADS', 'childhood autism rating scale', 'Barcelona-Clinic Liver Cancer [BCLC] staging classification', 'MSI status', 'CD4+', '6+ months of', 'urinary protein>3.5g/d', 'menstrual function', 'BDI-2', 'IL7R/JAK/STAT pathway activation', 'serology for Hepatitis C.|Received oral', 'Enalapril/Enalaprilat', 'carbon dioxide partial pressure', 'modified Rankin Score', 'CrCl', 'glomerular filtration rate (', 'plasma glucose', 'International Autoimmune Hepatitis Study Group', 'years.|Body mass index', 'old;|ASA Level', 'scale|Life expectancy', 'not);|Age', 'RECIST v1.1；|Pathologically', 'ELIGIBILITY CRITERIA (FOR STEP 2', 'pulmonary capillary hemangiomatosis|Persistent pulmonary hypertension', 'Prothrombin time PT', 'IABP', 'residual shunt', 'hepatitis B core antibody [HBcAb] test', 'Consideration should also be given to the intracranial location of the tumour and potential risk should swelling occur', 'Aspartate-amino-transferase (AST)', 'oocyte donation|Age', 'Hamilton Depression Rating Scale', 'protocol|Mean corrected QT interval corrected', ""volunteer's verbal report"", 'RECIST version 1.1|Have adequate organ function|Cardiac function test', 'Prostate-specific antigen', 'serum β-HCG', 'diastolic blood pressure>110mmHg|Target organ damage', 'bone marrow regeneration', 'creatine kinase', 'WHO medical eligibility criteria', '1.1|ECOG Performance Status', 'DSM', 'modified Schwartz formula', 'age|Positive skin-prick test', 'detectable HIV RNA levels', 'NSCLC', 'Altman Self-Rating Mania Scale', 'maximal aerobic', 'expectancy', 'months;|Adequate organ function', '1q21 amplification/t(4;14)/t(14;16)/t(14;20)/17p deletion/TP53 mutation', 'distraction test', 'Aspartate transaminases', 'Greece', 'T4 levels', 'menstrual period', 'average overall pain severity', 'IDH1/FLT3', 'Poverty Map of Families', 'FVIII inhibitory antibodies (', 'DSM-IV and NINCDS-ADRDA criteria.|3', 'depth', 'contraindicated;|Survival expectancy', 'cumulative total length', 'CAR T-cell therapy', 'medication .|Treatment', 'Atrophic', 'Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria', 'antibodies or fusion proteins.||Positive', 'myocardial scintigraphy.||Left Bundle Branch Block', 'Glucose Tolerance Test (OGTT)', 'modified Ferriman-Gallway score', 'echocardiogram|Adequate pulmonary function', 'platelet (PLT)', 'International Classification of Diseases-10.||', 'Lansky performance level', 'NCI-CTCAE v5.0 classification', 'Rapid urease test +ve||', 'asthma|Body mass index', 'glycosylated hemoglobin is', 'prostate cancer', 'SLICC', 'AMY', 'FSFI Scale', 'NIAAA Alcoholic Hepatitis Consortia', 'Cooperative Oncology Group (ECOG) physical status score', 'T size', 'See Appendix', 'life span', 'treated.|ECOG Performance Status', 'Amsler-Krumeich classification|Other ectasias', 'National Cholesterol Education Program', 'radiosensitizing platinum', 'RECIST v1.1)', 'Body Weight (kg) / {Height(m)}2||Patients', 'AOBP SBP', 'granulocyte colony- stimulating factor support|Lymphocyte count', 'center', 'stenosis', 'cardiac catheterization', 'estimated creatinine clearance', 'Yahr score', 'smoking|body mass index (BMI)', 'Inadequate MBC tissue', 'microsatellite stable MSS colorectal cancer by', 'baseline.|Red blood cell', 'paraffin specimens', 'INR', 'HOVON', 'ANC)≥', 'OS rate', 'antral follicle count', 'coli', 'MIC', 'Cooperative Oncology Group (', 'sodium', 'NASH CRN scoring scale', 'Loes score', 'VAS criterion', 'intracranial pressure)|thrombocytopenia', 'Screening.|Eastern Cooperative Oncology Group (ECOG) performance status', 'RECIST V1.1 evaluation criteria', 'limb length', 'progesterone receptor (PR)', 'stool test', 'QRS', 'rapid urine pregnancy test', 'provincial universal health insurance coverage', 'Nursing', 'serum specific IgE measurement|Age', 'North Zealand Hospital.||Exclusion criteria||Concomitant fracture of the ulna', 'NCI-CTCAE v5.0;|7', 'hepatitis B Surface antigen positive', 'Child C status|Diagnosed', 'ASA Physical Status', 'CDC lists asthma', 'Cavity Protection toothpaste.|Self-reported', 'inhalation', 'Acid Reflux', 'creatinine clearance CrCl', 'MRQ', 'Rutherford Becker Classification', 'angle-closure glaucoma', 'adrenal replacement dose', 'Estimated glomerular filtration rate (eGFR)', 'pleural effusion', 'SAMU', 'Prone spine surgery', 'average VAS score', 'WHO functional class', 'soy protein powder', 'OLP diagnosis.||', 'HER2-positive BC.|Multifocal cancer', 'aspartate aminotransferase /alanine aminotransferase', 'genders|American Society of Anesthesiologists (ASA) physical status', 'platelet values<150,000/ml', 'International Working Group on', 'fixation surgery.|Malignancy.|local infection|Psychological problem.|language', 'serum potassium concentration', 'prolactin levels', '18F-FAPI PET/CT scan', 'European Dermatology guidelines:||Recurrent', 'Serum ALT/AST', 'RNA test', 'BCS)||', 'risk of fracture', '|Age', 'pack year smoking history.|Subjects', 'White blood cell count', 'Body mass index (', 'Child-Pugh C cirrhosis', 'TC', 'radiation burden', 'diastolic blood pressure>90', 'platelet count (', '1;|Child-Pugh score', 'coma score', 'American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP', 'urine pregnancy test', 'coagulation parameter studies', 'Total platelet count', 'pyelectasis', 'Lost follow-up', 'volume', 'resting blood pressure', 'hepatitis C viruses', 'Maternal age', 'Radiology Department', 'ER-', 'ELISPOT response', 'HIV serology', 'Bone Broth Diet book', 'heart rate increase from', 'International Classification of Disease tenth', 'enrolled.|Body mass index', 'Surgical Follow-up', 'PSH', 'gamma glutamyl transferase [GGT]', 'glomerular filtration rate eGFR≦30', 'FISH +', 'fasting triglycerides', 'self-employed workers', 'heart rate limits', 'valve replacement|Permanent', 'HIV antibody', 'Illiterate', 'Lumbar Punctures for', 'transferrin saturation', 'A|ECOG performance status', 'tested HCG', 'serum TGs', 'HER2 negative);|Subtype of similarity network fusion-4', 'hemoglobin level', 'PMAs', 'Performance Status (KPS)', 'stool H pylori antigen.||', 'hepatitis C virus (HCV)', 'tests:||Systolic Blood Pressure', 'ABI', 'European country|Body Mass Index', 'education|Stable pharmacological treatment', 'Nested Sub-Study:||Eligible to receive', 'AMH :', 'salvage', 'serum pregnancy test should', 'present):||LVEF', 'best corrected visual acuity', 'grades of gliomas', 'oral cavity malignancy|Active oral cavity', 'Estimated birth weight', 'ALSFRSR score', 'plasma HIV ribonucleic acid', 'urine pregnancy', 'language function assessment', 'MRS', 'Resident of Chelsea', 'National Tuberculosis Control Programme guideline Thailand', 'lacking hip extension', 'National Cancer Institute (NCI) CTCAE version 5.0 Grade ≤1', 'chemotherapy.|Left ventricular ejection fraction', 'New Onset Diabetes', 'sensory blockade|Unexpected complications', 'Quigley-Hein Plaque Index.|Signed Informed Consent', 'white blood count', 'urine drug test;|Habitually consumed', 'NCI-CTC AE', 'Diastolic Blood Pressure (DBP)', 'Latin American Caucasian descent.|A female', 'thickness', 'Quantiferon TB-Gold test', 'Twamley', 'liver Function Test', '3.Hepatitis C virus (HCV) antibody positive', 'HCV RNA below the lower limit of quantification', 'TBL', 'serum free light chain (sFLC)', 'anticovid plasma use;|Vaccination', 'measurement', 'AGC', 'Glucocorticoid', 'AAA', 'National Institute of Child Health', 'FISH+.|Left ventricular ejection fraction', 'Myocardial enzymes', 'FEVAR', 'salivary secretion', 'kidney function test', ""Child's Class"", 'Hein', 'astigmatism', '10|Age', 'MDRD eGFR', 'HBV load', 'Active Monitoring Phase of the study)|REGISTRATION', 'intraepithelial papillary capillary loop', 'New York Heart Association classification', 'psychiatric hospital|active', 'FDG-PET/CT', 'function-altering mutations', 'PHQ-8 score', 'Shrapnel / Bullets', 'systolic blood pressure(SBP', 'SIB', 'Haag-Streit USA', 'purified protein derivative (PPD)', 'formula.|Absolute neutrophil count', 'serum glutatmic pyruvic transaminase', 'prothrombin', 'Lactation period', 'transrectal', 'and|Interest', 'moya-moya disease', 'Bone conduction thresholds', 'serum alanine aminotransferase (ALT)', 'US);|stage', 'sensitivity score', 'weigh', 'partial prothrombin time (APTT)', 'cervical cancer F IGO stage', 'DSM-V criteria', 'Cre8™/Cre8™ EVO', 'urine protein ≤1+', 'thallium stress test', 'total shoulder arthroplasty', 'kidney|Human immunodeficiency virus', 'GSCOMBO', 'residual bone height', 'thyroid function;|14', 'criteria to treat):||ANC', 'MELD', 'MAO inhibitors.|Medical instability', 'ANC level', 'variables:||Participants levels', 'months；|Body mass index', 'hepatitis C virus（HCV）', 'GFI score', 'Depression score', 'grade atrioventricular block', 'total bilirubin ≤3 × ULN||Alanine aminotransferase (ALT)', '68Ga-NY108 Positron Emission Tomography', 'QTc interval', 'ECOG physical state score.|Available initial', 'descending thoracic aortic aneurysm', 'modified Plaque Index (mPI)', 'National Institute of Neurological Disorders and Stroke Diagnostic Criteria', 'life size picture', 'blood transfusion', 'creatinine clearance levels', 'National Institute on Alcohol Abuse', 'Partial pressure of', 'average pure tone hearing threshold', 'plasma total cholesterol', 'O2) saturation', 'syphilis test positive;|Severe mental disorders', 'women|Body mass index (', 'surgeries', 'antibodies to syphilis', 'Multiuser Clinical Research Center', 'ADOS consists of', 'Modified Mallampati classification', 'by:||serum creatinine level', 'Lille University Hospital|Age>= 18 years|Patients having expressed their non opposition||', 'respiratory rate (RR)', 'UNTREATED', '≤8', 'HIV 1/2 antibodies)(HIV testing', 'Hepatitis B surface antigen (HBsAg) reactive', 'RECIST version 1.1.|Left ventricular ejection fraction', 'MRI incompatible criteria', 'short esophagus|Defective gastroesophageal reflux barrier', 'NEC', 'Estimated Glomerular Filtration Rate', 'MyChart)||', 'urine delta-9 tetrahydrocannabinol', 'UWSF rate', 'woman comprised', 'Regenerative Tissue Matrix', 'rocuronium|ASA', 'Kellgren & Lawrence||-', 'glomerular filtration rate estimation', 'Bilirubin value', 'ROS1-positive', 'MBCT', 'HCV antibody assay', 'Serum Glutamic Pyruvic Transaminase/Alanine Aminotransferease (SGPT /ALT', 'SC blood flow', 'quantification of HCV DNA', 'Diastolic blood pressure', 'Pancreatic Enzyme Replacement Therapy', 'estimated using', 'Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'Bucks', 'glomerular filtration rate ( eGFR≥60', 'Abbreviated Test Score of', 'human immunodeficiency virus (HIV) (+)', 'parasite count', 'Down Syndrome.|Under', 'individual', 'Permanent strabismus;|History', 'drinks/day', 'thinnest location|Corneal opacity', 'serum hepatitis B virus DNA polymerase chain reaction (PCR)', 'BPH||', 'serum follicle-stimulating hormone level', 'contraindicate bronchoscopy FEV1', 'early stage', 'combination blood pressure medications containing', 'pleural effusion.|Abnormal preoperative chest x-ray', 'CSMC Echocardiography', 'hepatitis B test', 'aspartate amino-transferase', 'absolute white blood cell count', 'GIR Score', 'Imaging Core Labs confirm suitability for treatment with the VDyne System.||', '||- Serum creatinine', 'points|Cardiac function', 'abdominal circumference', 'forced expiratory volume in 1 second [FEV1]', 'RECIST v1.1|Adequate organ function', 'DBP', 'Black / African', 'filtration rate (GFR)', 'PLT count', 'WHO criteria||', 'effective regurgitation orifice area', 'modified Rankin scale', 'SCABP;|SOFA score', 'lipase levels', 'Visual Analog Scale|Live in Eastern Cape', 'assess speech perception performance', 'CA153 carbohydrate antigen', 'HCV GT', 'pulmonary function', 'ENTRECTINIB', 'Adolescents', 'HCV RNA positive);|Active infections', 'Gestational Age', 'white blood cells', 'LBP', 'egg white', 'GABA/opioid medication', 'CD4+ cell counts', 'National Marrow Donor Program criteria', 'CD4 cell count', 'HER2 negative);|Subtype of similarity network fusion-3 (SNF-3)', 'Follicle Stimulating Hormone (FSH).|If Screening pregnancy testing', 'UMN BMT program standard processes', 'thrombus burden', 'PRRQS', 'platelets≥', 'partial thromboplastin time (APTT):', 'simplified Oral Hygiene Index', 'hypoglycemia', 'progesterone (PR)', 'tanning', 'Fridericia', 'Interdental CAL', 'CPK level', 'hepatitis B viral load', '-arterial extracorporeal', 'NCI CTCAE 5.0 grading criteria]', 'Eastern Cooperative Oncology Group (ECOG) performance status', 'Modified Barthel Index (MBI)', 'human immunodeficiency virus antibody (HIV Ab)', 'Amsler-Krumeich classification|Non-contact lens', 'ASCVD risk score', 'Getting', 'Google Chrome web', 'NYHA classification', 'HR', 'bleeding|glomerulus filter rate', 'IVIG treated', 'ASA classificaion', 'Ph chromosomal negative classic', 'trolley bags', 'age.|Serum glutamic-pyruvic transaminase', 'Serum AMH', 'Dyspnea grade', 'pregnancy urine test', 'glomerular filltration rate', 'Body weight', 'urine cotinine', 'Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST', 'M0 BCa', 'GEP', 'IAD)|Expected length of stay of seven', 'QTcF', 'MTX', 'Hanifin & Rajka atopic dermatitis', 'PLP patients:||age', 'Memory Complaint Scale', 'left ventricular ejection fraction Left ventricular ejection fraction(LVEF)<50%;|Acute bacterial', 'AVA index', 'Mayo Clinic Diagnostic Criteria', 'DAKO HercepTest™ score', 'Hepatitis B surface antigen [HBsAg] reactive)', 'hepatitis B core antibodies', 'ethinylestradiol +', 'serological pregnancy test', 'prothrombin time (PT) ≤1.5×ULN', 'older|Being capable of reading', 'molecular characterization', 'administration.|Karnofsky performance status', 'left ventricular ejection score (LVEF) ≥50%;|6.The', 'Karnofsky ≥60%', 'Assiut University Hospitals', 'GABA', 'Girohaler® inhaler', 'New York Heart Association [NYHA] classes', 'Screening|Estimated glomerular filtration rate', 'modified Kansas GWI', 'CAT score', 'PCL score', '68Ga-Dotatate PET', 'MSH6', 'Forced Expiratory volume/Forced vital capacity (FEV1/ FVC)', 'and,|Mini Mental Status Exam (MMSE) score', 'SOFAS score', 'Meeting', 'SARS-CoV-2', 'urea breath test', 'margins|ECOG performance status', 'HERCEPTIN SPCs.|Overexpression of HER2', 'prostate cancer.|Subjects', 'aspartate amino transferase (AST)', 'residual neurological symptoms resolved', 'Intensive Care Unit (ICU)', 'cut off score', 'household less', 'specific antibody test', 'Urea', 'fecal Hp antigen test', 'National Cheng Kung University Hospital', 'actionable EGFR mutations', 'detectable HCV RNA', 'American Thoracic Association/American Association of Thoracic Physicians exercise test guidelines)|Oral glucocorticoids|Receive long-term oxygen therapy', 'express', 'walk speed', 'AST/ALT', 'filtration rate', 'PIF', 'old|To', 'DBP≥90', 'Urine M-protein level', 'hypopnea])|Life expectancy', 'white cells', 'AIDS Healthcare Foundation Healthcare', 'normalized ratio (INR)', 'higher|Histologic Grade Group', 'total hepatitis B core antibody', 'bleeding.|ECOG performance status', 'standardized uptake value (SUV) max', 'physical status', 'hepatitis B|Active hepatitis C||Evidence of', 'serum pregnancy test.||', '1.|Adequate organ function', 'serum pregnancy test (β-HCG', 'Alkaline Phosphatase', 'MSA-C', 'Creatinine Clearance Rate (CCR)', 'gestational diabetes||Stable daily dose(s', 'ERAS guidelines;|age', 'PCD Insertion', 'IC-MPGN treatment', 'human immunodeficiency virus (HIV) antibody/antigen', 'months.||Protocol B:||Inclusion Criteria:||Males', 'thyroid carcinoma;|Active tuberculosis infection', 'Prostate Imaging Reporting & Data System (PIRADS)', 'Ultrasound Consensus Criteria', 'ICD-11,|Age', 'hepatitis B surface antigen [HBsAg]', 'heart function', 'aspartate aminotransferase AST≤2.5', 'DCI', 'platelet transfusion|Neutrophil count', 'left ventricular ejection fraction≤40%)', 'Diabetic|Body mass index', 'Agatston Score', 'MPAs - mycophenolate mofetil', 'ME/CFS CCC criteria', 'Insomnia Severity Index score', 'Black/African American', 'very hard stools', 'Alberta Health Services)|Presence', 'Columbia-Suicide Severity Rating Scale', 'plasma potassium', 'Response Assessment recommendations', 'partial pressure', 'PaO2/FiO2', 'Montreal classification|Active colitis', 'Forced Expiratory Volume in first second greater than 200 mililiters and 12%|Provided written informed consent for participation in this study||', 'blood creatinine', 'normal|Estimated glomerular filtration rate (eGFR)', 'Informed Consent||', 'absolute neutrophil', 'NHW|BMI', 'PCSL', 'pulmonary capillary wedge pressure', 'modified rule', 'metastases resection||R0', 'HIV-1', 'weighs', 'dopaminergic pharmacological control;|Absence', 'extension lag', 'ECOG physical status', 'American Diabetes Association recommendations)|Owns a cell phone capable', 'trial).|Body mass index', 'RECIST version 1.1 (only applicable for phase 1b dose-expansion', 'RANO-BM', 'neutrophile granulocyte count', 'anesthesia;|Total bilirubin', 'Gestational age (', 'Stress Scale', 'Pain Rating Scale', 'cervical disc herniation|History of', 'quantitative PCR test for HBV deoxyribonucleic acid', 'G8', 'choline PET/CT) should', 'TIPS', 'Prothrombin time PT≤1.5ULN|Normal thyroid function', 'HBs antigen +', 'Prothrombin time (PT)', 'Alanine Aminotransferase (ALT)', 'Beck Depression Inventory-II (BDI-II).|Significant', 'granulocyte colony', 'kidney transplantation)|both', 'characteristics;|Gross motor function classification scale', 'CEFTRIAXONE', 'Sars-CoV2', 'strontium', 'left ventricular systolic function', 'MVR + coronary artery bypass grafting', 'Geriatric Medicine outpatient clinic patient|On', 'drug abuse test', 'MUAC', 'type|Uncontrolled blood pressure', 'hepatitis B (HBV) surface antigen', 'Hb level', 'ankle brachial index (ABI)', 'CAL', 'Performance of', 'visits.||Exclusion Criteria - Children:||Formal', 'PSADT', 'Hepatitis C test', 'lactation.|Haemoglobin', 'hypoRT:||Residual', 'UK National Health Service staff member from the South-East', 'RVSP', 'modified Cornell Medical index.|Non- smokers.||', 'definition: standard immunohistochemistry', 'Minimental score', 'system;|Acute suicidal', 'CCCA', 'Gastroscopy', 'modified Functional Ambulatory Classification score', 'Guam', 'MSLN test', 'nocturia', 'Basal Cell Carcinoma', 'measurement of ADAMTS13 level', 'Bristol stool type 6-7).|Patients with neurogenic bowel dysfunction.|Participation in research', 'NCEP ATP', 'urine pregnancy tests', 'Singaporean Permanent Resident|Age', 'European Association of Neuro-Oncology-European Society', 'hemoglobin concentration', 'NM', 'residual corneal stromal thickness', 'old|ECOG Performance Status', 'SARS-CoV-2 test', 'New York Heart Association (NYHA) functional class', 'foot fracture|Lower extremity amputation related to HELEF||', 'vital sign|Females', 'Response Evaluation Criteria in Solid Tumors (RECIST v1.1).||9', 'testing laboratory.|ECOG performance status', 'overall survival rate', 'v1.1.|Adequate organ function', 'pro-thrombotic disorders', 'glycosylated haemoglobin', 'HBsAg serology test', 'Hep C Ab', 'II.|Age', 'pulmonary arterial systolic pressure (sPAP)', 'cover test', 'Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;||Criteria', 'human immunodeficiency viral infection (', 'New York Heart Association standard Class', 'National Health', 'Blood coagulation', 'alanine transaminase (ALT) levels', 'maximal orifice diameter of LAA is', 'American Society of Anaesthesiology', 'New York Heart Association (NYHA) rating', 'alanine transaminase (ALT)/ aspartate aminotransferase(AST', 'drug treatment.||Clinical stability Ability of', 'survival', 'BMS', 'left ventricular hypertrophy', 'NYHA grade Ⅲ or Ⅳ', 'INTERVIEWS WITH', 'Anti-COVID-19 vaccine||', 'NYHA GRADE III-IV', 'NOTCH signaling pathway.|In Cohort 1 only', 'Modified Ashworth Scale.|Participants', 'Hemoglobin (Hgb)', 'Moya-Moya disease', 'absolute', 'adult level', 'recumbent length', 'heart rate values', 'pacemakers.|Pregnancy.|Body mass Index (BMI)', 'oral Hydroxyurea', 'left ventricular systolic dysfunction', 'MMRP', 'subscore<5).|Age', 'anti-hepatitis C virus', 'HBV-DNA test', 'beta-2 glycoprotein [', 'RECIST v1.1.|have', 'CCS', 'GH treatment', 'IHC 1+/2+', 'bone sarcoma|At least one year', 'normal.|Left ventricular ejection fraction', 'National Cancer Institute- Common Toxicity Criteria', 'renal disease||Estimated GFR', 'dependent', 'NYHA classification);|8', 'screening.|Syphilitic antibody positive.|Trauma', 'blood pressure（SBP', 'RECIST v1.1 criteria', 'peripheral blood HCV RNA also', 'Thromboembolic event', 'ALC', 'treated;|ECOG systemic state', 'risk prostate cancer|Good compliance', 'UVFP', 'RECIST v1.1 criteria.|Detectable', 'indeterminate', 'Biological', 'fasting plasma glucose', 'female.|Aged', 'Arbutus berry sensibility.|Arbutus berry daily consumption', 'RANO-BM criteria', 'single score', 'DME|Best corrected Visual Acuity of 20/320', 'liver enzymes|Patients', 'ADT', 'hemoglobin A1c interpretation|hemoglobin A1c', 'albumin concentration', 'Ejection Fraction (EF)', 'total survival', 'baseline|Glucose levels', 'female.|Body Mass Index (BMI)', 'heart surgery', 'enrollment|Eastern Cooperative Oncology Group (ECOG) performance status', ""Chassaignac's tubercle"", 'Beck Depression Inventory-II (BDI-II', 'macular optical coherence tomography', 'endograft used|Successful EVAR', 'North Cumbria', 'human immunodeficiency virus (HIV) Ab', 'PALF-Study', 'WHO Group 5.|Historical', 'Atlanta classification of OP (2012)', 'TBUT', 'Main organ functions normal', 'Sarcopenia in Older People (EWSGOP-2) criteria', 'Big Brothers Big Sisters', 'European Medicines Agency blood volume limits', 'Alberta Stroke Program Early CT Score (ASPECTS)', 'New York Heart Association [NYHA]', 'AMI);|Prior surgical myocardial revascularization', 'hepatitis C antibody test', 'semen analysis', 'ASCO/CAP HR testing', 'forced expiratory volume during the first second (FEV1)', 'ferritin', 'anti-HBc immunoglobulin G (IgG)', 'absolute neutrophil count [CAN]', 'stool routine + occult blood', 'prostate cancer|ECOG performance score', 'turning', 'birth|Apgar score', 'residual cancer ruled', 'Cor TRICUSPID ECM Valve will be the physiological right-sided atrioventricular', 'Boston Bowel Preparation Score', 'NYHA function class', 'glomerular filtration rate [GFR]', 'serum status.|Smallpox vaccination', 'CD4 T-cell count', 'days)|Hemoglobin', 'serum levels of TMAO', 'Albert 2011 criteria', 'Estimated GFR', 'Mitomycin C|Age', 'eyelid retraction correction;|Poor thyroid function control', 'oral temperature', 'serum ferritin threshold', 'hydrogen breath test', 'Serum aspartate aminotransferase', 'serum triacylglycerol', 'urine capture', 'aPTT', 'serum chemistry values', 'Calculated creatinine clearance', 'anti-PD-1', 'Generalised Anxiety Disorder-7 questionnaire (GAD-7)|≤5 on the PhQ-9', 'Health Care Services Stockholm County)|Scored 19', 'RECIST 1.1 after first-line', 'vaccine-induced antibodies', 'aquatic exercise program.||', 'load blood glucose', 'average length of stay', '≥1.5×109//L Platelet count', 'PAP refusal.|BMI', 'anti-dsDNA serum antibody test|Diagnosis of LN', 'urine pregnancy test|In', 'best corrected distance visual acuity', 'QTc interval.||F. History', 'Historical genetic test results consistent with Fabry mutations', 'irradiated|ECOG performance status', 'alopecia)|ECOG', 'gestational age|24', 'inclusive|Body mass index', 'hemoglobin count', 'progesterone receptor expression', 'Early Head Start/Head', 'dextrose|Hemoglobin', 'palate.|Both sexes.|Age range', 'RK', 'expiratory pressure', 'National Institutes of Health in the post-COVID convalescence arm (', 'NY Heart Association grade', 'MYC', 'nasal congestion subscore', 'TCPO2 30 mmHg).|Ability to attend study visits|Ability', 'NICE', 'RECIST v1.1 assessment', 'Canadian Cardiovascular Society class IV angina symptoms|Left', 'hours|ASA Physical Status Class', 'aspartate aminotransferase>3 × ULN', 'BCVA', 'FISH HER2 negative);|at least one measurable or evaluable lesion', 'None', 'serum myocardial enzyme', 'HER2 tyrosine kinase inhibitor therapy', 'hepatitis B surface antigen and Hepatitis B virus deoxyribonucleic acid', 'HIV virus loading', 'hepatitis B virus (HBV) surface antigen (HBsAg) obtained', 'Severity Index score', 'feet', 'criteria below:||Hepatitis B virus (HBV):', 'PPP):||Inclusion:||Age', 'hepatitis B surface antigen [HBsAg] test)', 'bilirubin level', 'copper 64 DOTATATE scan', 'overall proportion', 'radiographic bilateral', 'visit.|Systolic blood pressure', '18F-FDG-PET scan', 'New York Heart Association [NYHA Grade', 'OSU-TBI-ID)|Significant', 'following:||Platelet counts', 'crown root fracture', 'Basics', 'Randomization|BMI', 'serum total testosterone', 'EDSS', 'hepatitis C virus (HCV)|Unwillingness', 'RNA dependent', 'Physical Activity Readiness Questionnaire (PARQ)', 'PCR test/antigen dectection', 'FGR', 'anti-Hepatitis C Abs', 'ovarian function', 'Part', 'screening.|Body Mass Index(BMI', 'serum human chorionic gonadotropin', 'ESRD).||Participants', '6 months.||', 'count (PLT)', 'platelets', 'Preoperatory corneal astigmatism', 'monoclonal antibody test IMMY® Clarus)', 'score', 'platelet count;|BP could', 'HCV-RNA', 'American Thoracic Society', 'female|ECOG performance status', 'kidney function abnormalities|Colorectal', 'AKP', 'ECOG Performance status', 'MGMT promotor status', 'Back in ACTion', 'physical score', 'subarachnoid hemorrhage;|bleeding', 'HD grades', '1.Resident population', 'Hanifin and Rajka (1980)', 'GMFC level', 'urine toxicology screen', 'adult head', 'renin activity', 'dual-energy X-ray', 'nuclear GFR', 'CXCL9', 'CNS specific treatment', 'age|ASA class', 'HCV RNA detectable', 'National Cancer Institute General Adverse Event Terminology 4.03 (', 'agents capable', 'Absolute lymphocyte count', 'INR）', 'working', 'Merck Sharp & Dohme (MSD)-sponsored clinical studies', 'bone remodeling', '2 levels between C2', 'Flexor Digitorum Superficialis FDS', 'study;|Body weight', 'direct bilirubin level', 'RECIST 1.1.|Patients harboring exon', 'prothrombin time>15s;|Diagnosed primary liver', 'prothrombin time prolongation', 'cardiac index<2.2 L/min/m2', 'Urine red blood cell counts≥', 'UNL|Creatinine', 'ULN;|Aspartate aminotransferase', 'old.|ECOG score', 'Odense University Hospital|Age', 'modified Asworth scale|Unable to maintain', 'SMA', 'min;|Absolute neutrophil count', 'hepatitis C disease', 'Serum alanine aminotransferase (ALT)', 'attention deficit hyperactive disorder', 'hemoglobin (HB)', 'Ag/Ab) combo', 'Dyspnea Index score', 'Suicide-Risk-Assessment-C-SSRS', 'ESS', 'left ventricle left', 'PANSS score', 'SaO2', 'anti- CTLA-4 antibody', 'planned.|Age', ""National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria|treatment naive for any acetylcholinesterase inhibitors"", 'SELENA-SLEDAI clinical symptoms', 'CTA', 'angle closure glaucoma', 'monoclonal antibodies/biologics', 'telephone Montreal Cognitive Assessment (MoCA)', 'INR can be safely reversed to≤1.7', 'UPMC Children', 'Creatine kinase (CK)', 'standard American College of Rheumatology (ACR) clinical', 'cardiothoracic surgeon).|Age', 'local labs|Adequate renal function', 'Numeric Pain Rating Scale.|History', '||Serum creatinine', 'needed;|Lung function capacity', 'Syphilis test', 'urinary sodium', 'nasal vasculature', 'program|GMFCS Levels', 'Predicted vital forced', 'inclusive;|BMI', 'residual stenosis of', 'Hematological||Absolute neutrophil count', 'CD4 T lymphocytes', 'COVID-19 less', 'Total bilirubin (serum)', '18|Life expectancy', 'Berlin Definition of ARDS|Under mechanical ventilation||', 'PLMS index', 'RECIST v1.1. Tissue samples', 'normal cholesterol', 'Blue Lake Biotechnology]).|Chronic rhinitis', 'PTA', 'QTc time', 'FISH detection found', 'NJ|Participants', 'hepatitis C infection|Concurrent', 'calf circumference', 'anti-hepatitis B core antibody HBc', 'lesion count', 'COVID-19 test result', 'Gram-negative etiology', 'QTcB interval', 'anti-human immunodeficiency virus', 'extension of', 'estimated glomerular filtration (eGFR)', 'male QTc', 'DLCO per alveolar volume (DLCO /VA', 'Prostate-Specific Membrane Antigen (PSMA)', 'Kellgren-Lawrence score', 'AMD);|Best corrected visual acuity (BCVA)', 'speech articulation|good potential', 'seminal plasmic elastase', 'GCS≤8|Dysphagia', 'respiratory rate 10', 'HCV viral load.|Patients', 'PET scanning.|Right-handed.|Fluent', 'IDD', 'stage D maturation stages .|Patients', 'urine albumin-creatinine ratio [ACR]', 'platelet count', 'serum pregnancy test results', 'Visual Analysis Scale', 'Augusta University Institutional Review Board [AU IRB]', 'left ventricular ejection [LVEF]', 'HIV antibody test', 'serum beta human chorionic gonadotropin', 'DMD', 'equivalent|FAAM score', 'leukocytes', 'tension headache', 'ASA)||', 'DSM-V', 'special units', 'bone metastases)|Creatinine Clearance', 'VEF', 'Hepatic||Total bilirubin', 'left ventricular ejection fraction<50%.|Patients', 'Child-Pugh classification', 'Modified Medical research council', 'PCR test result|Patients', 'Total score', 'New York Heart Association Classification Class', 'liver allograft', 'Diagnostic Exclusions:||Meeting lifetime DSM-5 criteria', 'residual signs', 'postoperative evaluation|Mechanical circulatory assistance', 'autoimmune antibody', 'RECIST v1.1|ECOG PS', 'Local Sponsorship|Location in Bavaria|Schools with', 'meeting inclusion criteria', 'anti-mullerian hormone(AMH', 'Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria|The main organs function', 'Hamilton Anxiety Rating Scale', 'Mass General Brigham system|patients', 'slice thickness', 'Glomerular Filtration Rate (GFR)', 'Objective Structured Clinical', 'EDE', 'New York Heart Association functional class', 'APRI', 'dual-light lens', 'GvHD)|Having', 'smoking.|Active H. Pylori infection|Weight', 'HIV antibody tests.|Patient is in the active stage of HBV', 'tempro-frontal region for', 'reasons', 'plasma alanine aminotransferase', 'Classification of Cancer', 'IMU.|Hemoglobin', 'T-cell lymphoma', 'Modified Rodnan Skin Score (mRSS)', 'González San Segundo', 'enrolled.)|Left ventricular ejection fraction(LVEF)≥40%|Absolute neutrophile counts≥1000/mm3|Thrombocyte≥30000/mm3|Total bilirubin(TBIL', 'Child B', 'resting ventricular rate', 'mean AVG', 'prostate cancer|Previous urinary tract infection', 'Neut', 'maximal posology tolerated by the patients stable', 'hours|Serum Cr', 'ASG + TBE Device', 'total parenteral nutrition', 'restoration.|Residual alveolar bone width', 'Total bilirubin', 'dyspnea grade', 'ALT (GPT)', 'BDAE', 'HRD', 'positive|Active hepatitis', 'scheme.|Age', 'serum Human Chorionic Gonadotropin (HCG)', 'medication on anti- rheumatic drugs', 'serum creatinine (Cr) ≤1.5×ULN', 'hepatitis B surface antigen positive [HBsAg] result)', 'serum free light chain (sFLC) ratio', '+ T cell therapy', 'GSRS', 'RECIST 1.1 standards;|ECOG PS score', '||AST', 'Alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN)', 'ventricular mass index', 'potassium level', 'International standardized ratio (INR)', 'as:||Absolute neutrophil count', 'Adult end', 'national health care system|major', 'Barthel Index score', 'weeks,|body mass index', 'platelet ≥100×10^9/L', 'isolated pancreatic exocrine insufficiency', 'anesthesia;|Surgery time', 'NASH CRN fibrosis staging', 'mean QTcF', 'modified Ashworth scale', 'hepatitis C (HCV)', 'Dow University Hospital Ojha Campus', 'lumbar levels', 'off-axis bleeding|Diagnosis', 'suitable body habitus', 'adult|requires laboratory test', 'PCA).|A proximal M2-MCA', 'OS', 'heart rate variability (HRV) test', 'oral cavity||', 'GD1 severity scoring system', 'Child Pugh', 'LV systolic function', 'pregnancy', 'venous plasma', 'Total Mayo Score', 'LV filling pressure', 'AML|Eastern Cooperative Oncology Group (ECOG) performance status', 'resident physicians', 'Standard Beverage Units (SBU)', 'mean VAS', 'plasma amylase', 'HD patients|Age', 'Body height', 'Mg', 'females|Platelet count', 'Prothrombin G20210A mutation', 'female;|ECOG performance status score', 'Adolescent Inpatient Program (', 'palliative care|Severe angina|Unstable arrhythmias|Severe infection|Heart failure', 'liver tumors|Prothrombin time', 'T-score', 'bruton tyrosine kinase inhibitor', 'organ function', 'epressed Adults)||Age', 'BRCA 1/2 mutations', 'PEDT', 'Serum creatinine clearance', 'YMRS', 'BMD', 'Serum bilirubin||1.5 x upper limit of normal (ULN)', 'tans', '4)|Body mass index', 'RECIST version 1.1;|Genetic test results', 'creatine kinase (CK)', 'Borg', '70|Adequate cardiac function', 'International Classification of Diseases Edition', 'ADL', 'anti-HCV Ab+', 'treponema pallidum antibody', 'prostate cancer|Person of', 'Medication', 'Married infertile', 'Concept Medical Inc.', 'international normalization ratio [INR]', 'AST/PLT', 'systolic blood pressure (oSBP)', 'New York Heart Association class', 'RANO criteria', 'HMA CTFG', 'MAR', 'criteria for 1.3 chronic migraine', 'therapy|Platelet count', 'Numeric Rating Scale', 'residual non-invasive disease', 'Mayo score', 'BAK', 'AAA maximal diameter ≥7cm.|Physical inability to exercise', 'old.||Control:||●Healthy', 'Child-Pugh C)|Clinically', 'serum follicle-stimulating hormone', 'hepatitis C virus (HCV) RNA', 'leukemia organ involvement|AST', 'mainly Classes Ia', 'level of care', 'RECIST V1.1 criteria', 'registration)|Absolute neutrophil count (', 'NAFLD', 'National Institute of Allergy', 'respiratory rate', 'stage IVa', 'Modified Mallampati', 'molecular classification', '690ADY monofocal IOLs', 'NHS specialist learning disability', 'Total bilirubin ≤1.5×ULN (upper limit of normal)', 'estimated blood loss', 'criteria:||• Mild', 'My Action Plan electronic letter', 'Vital signs', 'criteria aligns', 'UTUC of T2', 'BTC before surgery', 'WHO criteria.|Children', 'IBS', 'Kaiser Permanente Georgia', 'COVID-19 rapid test', 'metastasis exists', 'LOCS III).||', 'Cambodian School of Prosthetics', 'Normolipidemia Total cholesterol (plasma)', 'Absolute neutrophil', 'DCIS', 'female≥', 'surgical graft|Lesion location', 'Hunt Hess Grade', 'USPSTF', 'Response Evaluation Criteria in Solid Tumors [RECIST]', '12th grade education level', 'procedural revascularisation.|Current', 'Spherical equivalent', 'Hepatic fibrosis stage', 'Heart Association Class', 'criteria of SEPSIS-3 (2016,', 'cardiac valve repair.|Previous episode', 'Aarhus University Hospital in Denmark.||Inclusion criteria were:||Age', 'PMS score', 'Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST)', 'ALP)≤', 'hepatitis B surface antibody [HBsAg] test', 'longest axis', 'antibodies to HIV 1/2).|Participant seropositive', 'average', 'therapy;|Glomerular filtration rate', 'American Heart Association', 'serum creatinine elevation', 'total HBcAb test', ""Unified Huntington's Disease Rating Scale"", 'circumference', 'mmHg|Cardiac ejection fraction', '||Inclusion Criteria:||acute stroke', 'SNUH', 'ankle-brachial systolic index (ABSI)', 'Chronical pathological skin conditions', 'CMV-DNA', 'HIV antibody test positive.|Active infection', 'response evaluation criteria in solid tumors', 'Numerical Rating Scale|Cognitively able to participate as measured by the Short Portable Mental Health questionnaires', 'average score', 'Cooperative Oncology Group (ECOG) Performance status', 'glomerular filtration rate (eGFR) estimated by', 'estimated recurrence risk', 'BMIs', 'Child-Pugh C).|Thrombocytopenia', 'NHLBI criteria|Caregiver', 'percentile)||Biochemical signs', 'body weight loss', 'Investigator.|Spectral Domain Optical Coherence Tomography', 'DPT student', 'Allred score', 'RECIST 1.1|Receiving immune checkpoint inhibitor therapy', 'ECOG performance status', 'moderate hPAP lung disease severity requiring therapy in the opinion of the Clinical Site Investigator and/or', 'difference', 'syphilis test', 'D.|Best corrected visual acuity', 'Dry Eye Disease (DED)||Symptoms of', 'total corneal', 'Child-Pugh classification),|Unresolved biliary hypertension syndrome,|Acute thromboembolism of the pulmonary artery', 'aspartate transaminase', 'Decreased visual acuity attributable primarily to DME 3', 'average heart rate detected', 'angle grade', 'meniscectomy', 'IMC', 'ILLUMISITE', 'total serum bilirubin (TBIL)', 'ESRD', 'inclusive.|Diastolic blood pressure', 'RECIST v1.1.|ECOG PS score', 'partial oxygen pressure', 'WHO classification|Treatment', 'Physical Activity', 'antithrombin III level', 'hemoglobin (Hgb)', 'voiding residual', 'MIH', 'DIS cohort.||Exclusion', 'alpha-blocking medication.|Prior pelvic radiotherapy.|History', 'effect""|Age', 'bone marrow function:||absolute neutrophil count', 'Crea-Clearance', 'recovery room|ASA physical status', 'mmHg|heart rate', 'BBPS', 'Peritoneal Regression Grading Score (', 'stated).|Creatinine clearance', 'BMI', 'Hemoglobin A1c (HgbA1c)', 'Smoking', 'B|Life expectancy', 'Monoclonal antibodies and antibody-drug conjugates', 'EPSI', 'liver function abnormalities', 'platelet glycoprotein (GP)', 'EASI score', '1|Predicted survival', 'CF patients.|Normal kidney function estimated by', 'gestational period', 'anti-hepatitis', 'palpation|Oxford score', 'ALT should', 'Vital signs criteria', 'New York Health Association', 'lost weight', 'atrium size', 'alanine transaminase (ALT) ≤3 x upper limit of normal', 'detectable hepatitis C viral load', 'fibrinogen levels', 'PEM', 'PTT', 'MDT', 'CPT codes', 'GINA', 'HSS7 score', 'American Society of Anesthesiologists classification);|Age', 'Urine M-protein', 'Boston Bowel Preparation Scale', 'fasting plasma glucose (FPG)', 'DERS total score', 'HCV Ab', 'Berg Balance Scale.|Scoring', 'drug abuse screen', '##:', 'urine test for alcohol', 'European Society of Cardiology/European Respiratory Society (ESC/ESR', 'National Marrow Donor Program Guidelines', 'Serum potassium', 'international normalized', 'Hepatitis C infections.|History', 'antineutrophil cytoplasmic antibodies (ANCA);|Positive anti-HIV', 'addiction centre,|Patients', 'female;|ECOG score', 'EPR-3', 'spinal surgery||Specific pathology', 'bilirubin levels', 'Nantes University Hospital.||', 'response', ""National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, 1984)"", 'International Cancer Control', 'ULN|Karnofsky Performance score', 'color vision', 'total bilirubin>2 times the upper limit of normal value|Urinary', 'ranges.|Body mass index', 'Corrected Visual Acuity', 'modified Rankin scale score', 'estimated 2000', 'Ghent criteria', 'HDV).|Body mass index', 'INR ≤1.6', 'ECOG physical condition score', 'NYU Institutional Research Ethic Board', 'mmHg|diastolic blood pressure', 'NMIBC', 'andalanine aminotransferase', 'ASA status-I', 'RECIST V1.1 (', 'oncology surgeon.|Patient OMS', 'cystoscopic findings', 'RECIST v 1.1|Signed written', 'SRT', 'hyperthermia|Body mass index', 'Total hemoglobin', 'alanine transaminase', 'B12 vitamin supplements.|Involvement', 'AGO', 'Absolute Neutrophil Count', 'gold standard CMR)||<18', 'New York Heart Association [NYHA] grade', 'NYHA classes', 'PLHIV)|CD4 count', 'CIRS-G-Score', 'Tinnitus Functional Index.|Participant', 'ventricular response', 'leukemia|ECOG Performance Status', 'months|Current suicidal ideation', 'resting ankle-brachial index (ABI)', 'benzodiazepine addiction', 'LA volume', 'IBS-M', 'bone specimens.|No abnormalities', 'RECIST V1.1', 'fasting glucose level -', 'Platelet transfusion', 'American Society of Anesthesiologists (ASA) classes', 'pulmonary function test FEV1/FVC<70%, FEV1<80% predicted value).|Previous', 'Mayo Clinic Rochester|Scheduled', 'RECIST Version 1.1.||Eastern Cooperative Oncology Group (ECOG) performance status', 'HIV antibody positive', 'Interventional Radiology Department', 'General criteria', 'Arm T)|Aspartate aminotransferase', 'hepatitis C virus (HCV) antibody test result', 'permanently alters intestinal absorption', 'cleft palate', 'gamma gutamyl transferase', 'vitamin D level', 'CEAP', 'Glycosylated hemoglobin (HbA1c)', 'Response Criteria in Solid Tumors (RECIST)', 'mmHg|Heart rate', 'weight reduction', 'Neutrophil absolute value', 'anti-HIV antibody positive', 'modified ESD technique', 'RECIST v1.1 at', 'NYHA Class III heart failure', 'female|ECOG performance status score', 'ECOG Performance Status Scale', 'plasma amyloid-beta test', 'GAI', 'American Thoracic Society (ATS) criteria for acceptability and repeatability', 'spontaneous tidal volume', 'ventricular', 'triglyceride concentrations', 'botulinum toxin type B', 'absolute lymphocyte count', 'Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1).|The results of laboratory examination', 'American Society of Anaesthesiologists Physical Status', 'tyrosine kinase domain', 'RECIST criteria 1.1.|History', 'EULAR / ACE', 'CD4+ T lymphocyte count', 'screening.||Fellow Eye Inclusion Criteria:||Best Corrected Visual Acuity ETDRS letter score', 'RASS score', 'UMCG', 'University hospital center', 'Creatinine (Cr)', 'Hôpital Jean-Talon orthopedic outpatient', '18F-DCFPyL', 'vaginosis', 'random blood glucose', 'calculatedb creatinine clearance (GFR can also be used in place of', 'European Society of Cardiology guidelines||', 'International Normalised Ratio (INR)', 'antigen positive Covid', 'Underwent gastroscopy in hospitals mentioned', 'pain VAS score', 'Modified Ross Heart Failure Classification', 'endogenous creatinine clearance', '6th grade reading level', 'scoring', 'CDR functional domain', 'General', 'urine rheology', 'Bortezomib+Dexamethasone+Daratumumab', 'International Physical Activity Questionnaire (IPAQ)|Absence of any chronic condition', 'procedure|Body mass index', 'hepatitis C (RNA PCR-positive infection', 'glomerular filtration rate<25 mL/min/1.73 m2', 'ULN|Serum creatinine', 'MMSE test', 'hepatitis C-virus (HCV)|Participation in another study', 'AF|Age', 'ribociclib + AI', 'progesterone receptor [PgR]', 'GCS score', 'Cr)≤ 1.5× upper limit of normal (ULN)', 'DFU duration', 'IMP)|Previous adjustment', 'QRS interval|Liver function test', 'anti-Echinococcus antibodies (WHO-IWGE', 'survival rate', 'MEK protein kinase inhibitors;|Use', 'months,|Relapse refractory', 'urine drug screening；|Surgery', 'American Association of Anesthesiologists physical standards', 'TnT', 'human immunodeficiency virus', 'increased blood pressure', 'General disease;|Uncontrolled hypertension', 'Roma Ⅳ function constipation|Symptoms begin', 'Loeys-Dietz syndrome', 'Suicidal Ideation section of the C-SSRS', 'Kwai Chung Estate:||age', 'WaveTec ORA', 'serum hematological functions', 'ASC)||', 'Rome IV criteria', 'HPV-LR)||', 'Bodyweight', 'calculated eGFR', 'fluoridation program.|Adverse reaction', 'human immunodeficiency virus|Known', 'human immunodeficiency virus (HIV) infection.|Participation in', 'rare gynecological malignancies|written informed consent|patient', '|cranial tumors.|Meningitis.|sub-arachnoid', 'bone marrow plasma cell percentage', 'estimated gloverular filtration rate (eGFR)', 'cardiac glycosides', 'RECIST v1.1 and', 'DSM-IV-TR', 'meeting', 'Child-Pugh status', 'alanine transaminase [ALT]', 'National Kidney Foundation', 'AVMs', 'pneumococcal vaccine;|History bacterial pneumonia', '10 minutes||Exclusion', 'My Action Plan initiative focuses on|Has', 'old|World Health Organization (WHO) Performance Status', 'random glucose', 'rapid urine drug screen', 'pulse', 'males|Aged', '≥10s.|GMFCS levels', 'San Raffaele Hospital', 'hepatitis B core antibody positive', 'PRO', 'serum albumin≥3g/dl', 'National Comprehensive Cancer Network (NCCN)', 'NDI Questionnaire raw score', 'diagnosis|American Society of Anesthesiologists (ASA)', 'HCV antibody test result', 'peripheral blood HBV DNA titer', 'BBS', 'local age of majority).|Ability to understand and willingness to sign an IRB approved written informed consent document.||', 'Fingertip Pulse Oximeter', 'platelet function', 'physical examination.|Age', 'systolic arterial blood pressure', 'cardiac co-morbidity', 'New York Heart Association (NYHA) congestive heart failure', 'Prothrombin Time (PT)', 'minimum speed', 'Lung cancer-Asthma', 'Acid Reflux/GERD', 'anti-HBc+', 'cardiac power', 'Forsyth County||', 'alanine transaminase (ALT)/aspartate transaminase (AST)', 'Hepatitis C antibody positive|HIV antibody positive|Other diseases', 'Swallowing Screen', 'CD4-T cell count', 'ECOG score for performance status', 'bone scan;|≥', 'Mini Mental Test', 'reverse configuration)||', 'actigraph measurements', 'Mayo Score', 'fecal elastase', 'equal mean blood pressure', 'years|body mass index', 'RECIST version 1.1, there is', 'IHS', 'International Classification of Disease-10', 'Boston score of Bowel preparation≤ 6 points|Patients', 'modified Rome IV FC criteria', 'Emergency colonoscopies|Inflammatory bowel disease', 'Absolute neutrophil counts', 'uninsured||', 'forced termination of the study', '9|Absolute neutrophil count', 'mitomycin C', 'outpatient)|Mini-Mental State Examination (MMSE)', 'urinary cotinine test', 'PCa', 'noted', 'both.|ASA physical status', 'venous blood', 'women)|Type', 'NCI-CTCAE', 'Child care providers', 'serum human chorionic gonadotrophin', 'Pseudo-ventricular aneurysm|Concomitant diseases', 'partial thrombin time (APTT) ≤1.5×ULN;|Thyroid function', 'hemoglobin A1C [HbA1C]', 'MGH site)||Inclusion', 'dermatology', 'QTc Fridericia', 'Word Memory Test of symptom validity.|Current inclusion', 'bodyweight', 'Oswestry Disability Index (ODI)', 'semiquantitative score', 'months)|Body mass index', 'Geenius HIV-1/HIV-2', 'viral copy', '18F-Fluselenamyl', 'Direct bilirubin', 'HDV)|Persistent toxicities', 'urine human choriogonadotropin (hCG)', 'FiO2', 'hemoglobin A1c blood', 'sustaining breathing', 'singleton gestation', 'Reunion University Hospital', 'New York Heart Association (NYHA) work', 'homicide', 'OSDI questionnaire score', 'registration.|New York Heart Association', 'Kellgren-Lawrence femorotibial osteoarthritis|Isolated', 'medium-risk/high-risk kidney cancer', 'prostate', 'serum hCG Ectopic', 'CWP', 'Prostate cancer Working Group (', 'deficit|Recurrent CVA|Neurological condition', 'hepatitis C antibody (HCV Ab).|Patients', 'screening:||Systolic blood pressure', 'lymphocyte count', 'Pittsburgh Sleep Quality Inventory (PSQI', '/μL|Platelets', 'isotope clearance', 'haemoglobbin', 'Partial thrombin Time (aPTT)', 'ranges', 'serum levels', 'BP', 'hepatitis B surface antibody', 'drinks per week', 'American Society of Anesthesiologists (ASA) Physical Status Classification System', 'bariatric surgery.|Hepatitis', 'women|Blood pressure', 'ANC)||≥', 'training program', 'anti-PD-(L)1 agent-naïve', 'corrected QTc interval', ""child's vaccination"", 'average corrected QT interval', 'American Society of Anesthesiology (ASA) class', 'Beta-Human chorionic gonadotropin', 'thyroid-stimulating hormone', 'Bilirubin', 'New York Heart Association classes', 'HER2-negative status', 'Serum bilirubin≤', 'girdle trauma.|any specific pathology', 'HOMA-IR', 'Estimated Glomerular filtration rate (GFR)', 'Collaborative Oncology Group (ECOG) performance status', 'Forced Expiratory Volume in the first second)', 'weeks;|ECOG', 'glomerular filtration rate (eGFR):', 'moderate TBI|Current', 'eGFR formula).|Resting corrected QT interval', 'alpha fetoprotein', 'echocardiogram|Mass General Brigham PCP affiliation', 'moderate intensity aerobic', 'SDS', 'antioxidants.|Their blood pressure', 'prostate-specific antigen (PSA)', 'minimal support||', 'spirit', 'mild upper respiratory tract infection', 'Left ventricular ejection fraction(LVEF', ""child's visible"", 'vitamin C', 'pain score', 'motor impairments|History of', 'Screening.|Body weight', 'Dizziness Handicap Inventory (DHI)', 'blood coagulation function', 'creatine clearance', 'BOP),|mobility', 'above|Rectal bleeding|Inflammatory Bowel', 'Hepatic function', 'interval progression', 'Maximal dose of vasopressors', 'TBil≥85.5', 'bone mineral density', 'total lissamine green conjunctival', 'VAS (Visual Analogue Scale).|have sufficient cognitive ability to fill in the various questionnaires (Level B2 French),||', 'best-corrected E-ETDRS', 'Partial Mayo Score', 'ECOG scale).|Life expectancy', 'legs preoperatively|Body Mass Index (BMI)', 'rest|Systolic BP', 'serum hCG pregnancy test', 'Hamilton Depression rating scale', 'New York Heart Association class|Severe valvular heart disease', 'absolute neutrophil value', 'Bruton tyrosine kinase (BTK) inhibitor', 'BUN', 'systolic pulmonary artery pressure', 'Childhood Autism Rating Scale-Second Edition).|The', 'corrected QT interval', 'BCR-ABL/t(9;22', 'failure,|Left ventricular ejection fraction', 'anuria.|In addition', 'Pembrolizumab)|Physician clearance', 'ESSPRI', 'serum HCG examination', 'ASA physical status', 'Pulse oximetry', 'younger.|Karnofsky performance status', 'atrial volume index', 'Yahr staging', 'cleft palate (CP)', 'complete blood count', 'Uncertain diagnosis.|Age', 'Asian Sarcopenia Working Group (ASWG)41 and the WHO definition of obesity for the Asian population', 'blood urea nitrogen (BUN)', 'MGMT', 'digital HIV disclosure', 'muscle enzyme', 'mmHg.|Heart rate', 'hepatitis B surface antigen [HBsAg] reactive)', 'Bulimic Investigatory test', 'kidney function test results', 'serum potassium', 'American Society of Anesthesiology)', 'RECIST v1.1 progression).||', 'PSA before urinary retention', 'Forced expiratory volume in the first second/Vital capacity (FEV1/VC', 'transferrin saturation TSAT<20%', 'partial SCCAI score', 'less)|Body Mass Index', 'response evaluation Criteria in Solid Tumors (RECIST,', 'residual upper extremity hemiparesis.||Key', 'midline shift', 'late preterm period', 'Endogenous creatinine', 'GCSF support', 'last ejection fraction', 'HiDAC', 'EU driving license.|At least 21 years old|Active driving', 'WHZ', 'Renal Estimated GFR', 'antinuclear antibodies test', 'serum free light chain', 'estimated glomerular filtration rate (EGFR)', 'Silverman score', 'Alanine transaminase (ALT)', 'long QTc interval', 'inclusion|Trans meridian travel', 'Penn IRB # 825503', 'SII', 'thyromental length', 'study)|80% compliance', 'ULN|Absolute neutrophil count', 'insulin treatment', 'signature.|In possession', 'SJLIFE', 'measurement instructions|Indication for', 'Licensed Egyptian', 'American society of anesthesiology', 'old|BMI', 'physical function', 'between 08:00-20:00', 'partial thromboplastin time (PTT)', 'K219Q).|Plasma HIV-1 RNA', 'SARS-CoV-2 vaccination', 'progesterone receptor by immunohistochemistry (IHC)', 'International Classification of Diseases (ICD)', 'Scr', 'Hepatitis B surface antigen antibody', 'RECIST 1.1 criteria;||Good organ function:||neutrophil', 'measurement|Absolute neutrophil count (ANC)', 'eligible.|ECOG PS', 'Bordeaux University Hospital', 'Marrow Function Absolute neutrophil count (', 'fasting Triglyceride', 'weight management.|Be involved', 'ETH-155008.||Corticosteroids', 'ODI', 'overall DSM 5 criteria', 'AFE', 'MPL', 'serum follicle-stimulating hormone level (FSH) level', 'CIC', 'Diazepam', 'fracture|Fracture Related', 'home blood pressure monitoring', 'Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition', 'National Institute of Mental Health criteria', 'hemoglobin remains', 'HBV-DNA', 'Metavir Score', 'semen volume', 'QT interval corrected', 'overall severity score', 'cGFR', 'Blood test', 'serum follicle stimulating hormone (FSH', 'partial elbow extension', 'reference value limit;|Hepatitis C (HCV) antibody positive', 'antibodies to COVID-19', 'sociocultural level', 'esophageal pressure values', 'maximum weight', 'anti-PLA2R autoantibody test', 'gastrin levels', 'HIV RNA level', 'numeric pain rating scale||', '||Left inferior frontal gyrus lesion', 'Skåne University Hospital', 'Cooperative Oncology Group performance status score', 'urine toxicology screen.|Excessive alcohol intake', 'Probands', 'MAS/HLH)after CAR-T therapy', '959th MDG', 'FAMILY MEMBERS OF', 'Polman C', 'total bilirubin level', 'abnormal levels of estimated glomerular filtration rate (eGFR)', 'neutrophils', 'energy expenditure', 'CAR-T cell therapy', 'T MRI)|epilepsy/neurology', 'capillary blood', 'Inflammation status', 'CRT', 'urea', 'HCV-RNA level', 'phosphatase (ALP):', 'Human immunodeficiency virus (HIV) antibody', 'blood pressure elevation', 'HBeAg status', 'SPO2>91%', 'American College of Sports Medicine standards', 'HCV Ab and', 'Rutherford-Becker', 'Novel Coronavirus Pneumonia(Trial Version', 'total score', 'menstrual history', 'Trans thoracic echocardiography', 'HBV-DNA quantification', ""Frankel's scale"", 'oxyhaemoglobin saturation', 'menstrual cycle', 'AP length', 'HBV DNA|HBV DNA levels', 'prostate adenocarcinoma.|Men', 'prothrombin (PT)', 'contraindicating surgical treatment|physical examination', 'LILRB4', 'value|Prothrombin time International ratio (INR)', 'Children', 'QTc interval.|QTc interval', 'ECOG performance status scale.||patients', 'prostate-specific membrane antigen positron emission tomography', 'kidney function;|IGF levels', 'modified scale', 'surgery|ASA', 'tuberculin test', 'peripheral blood stem cells harvest', 'carcinoma|Total Bilirubin', 'PLT)≥', 'rheumatology care', 'FMA-UE score', 'factor IX', 'HER2 negative early', 'kidney disease|BNP', 'partial thickness burn', 'bone mineral density measurement', 'anti-HCV antibodies', 'urine protein>1+ receive 24-hour urine protein quantification', 'virus SARS-CoV-2', 'HIV-RNA', 'National Taiwan University Hospital.||Exclusion criteria： Our exclusion criteria', 'hepatitis B virus (HBV) DNA test', 'T-MoCA Short', 'WBC', 'resuscitation effort)|pH', 'absolute neutrophil count (ANC)', 'including:||Unsatisfactory blood pressure control', 'psychotic symptoms|Are', 'predicted|Adequate liver function', 'fatigue;|tear secretion test', 'Boston Scientific', 'plasma antibody therapy', 'GOLD', 'excludes autoimmune-mediated', 'Organ function level', 'points;|Life expectancy', 'HDL cholesterol levels).||', 'INR remaining', 'attempts', 'calculated by Cockcroft-Gault method', 'Montgomery-Åsberg Depression Rating Scale', 'Emergency', 'weeks;|ECOG PS score', 'progesterone receptor', 'New York Heart Association [NYHA] Functional Classiﬁcation', 'below.||Ages', 'female).|Left ventricular ejection fraction', 'human immunodeficiency virus test', 'Miglustat-naïve', 'Geriatric Depression Scale', 'criteria below:||AML (relapsed, de-novo', 'ICA', ""Child's class"", 'erythrocyte sedimentation rate (ESR)', 'KIT mutation|Disease recurrence', 'blood DNA methylation', 'Logical Memory IIa subtest', 'wall thickness', 'interferon gamma release test.|A white blood cell (', 'LHR', 'EPOR fusions', 'bone marrow function|Body', 'myasthenia gravis;|MGFA Class', 'gestational age', 'CAR T cell treatment', 'Alcohol Use Disorders Identification Test (AUDIT)', 'PSA level', 'PRO-C3', 'maximum variation', 'ECOG PS score', 'partial parenteral nutrition', 'vaccine', 'age|Calgary Syncope', ""facial Bell's palsy|Pregnancy|Diabetes|Epilepsy|Severe hypertension,|Renal"", 'extracorporeal blood', 'Cooperative Oncology Group performance status', 'Amputees (unless both groups have similar', 'blood pregnancy test', 'BIOLI-D delivery system.|Patients submitted', 'gamma-glutamyl transferase', 'T2', 'estimated left ventricle ejection fraction', 'partial thromboplastin time (PTT) test', 'pcASPECTS score', 'Numerical Pain Rating scale', 'peripheral arterial disease', 'n=180)||Age', 'Child-Pugh class', 'serum total bilirubin ≤1.5×ULN', 'urine protein creatinine ratio (UPCR)', 'NIDDM', 'Insomnia Severity Index (ISI)', '68Ga-PSMA-11 which', 'cesarean section Postmenstrual', 'Child-Pugh rating', 'RECIST v1.1.||Current cirrhotic status', 'TICS-M', 'wide field irradiation for<4 weeks', 'failure|Ischemic stroke|Respiratory insufficiency|Infection|Inflammatory diseases|Active cancer||Surgical Patents', 'of age|ECOG performance status', 'Mile Square Health Center|age', 'month).|absolute neutrophil count', 'intraocular pressure', 'spinal cord metastases|Active infections', 'Modified Ashworth Scale|able to follow verbal instructions|able to stand unassisted', 'GCSI score', 'anesthesia', 'Youth', 'Rutherford Category', 'MABC', 'Left Ventricular Ejection Fraction LVEF', 'Body mass index (BMI)', 'prothrombin time [PT]', 'ALT ≤3 x upper limit of normal (ULN)', 'sensitive pregnancy test', 'Sexually Transmitted Infection', 'bone marrow blasts', 'thorax configuration', 'Best Corrected Visual Acuity of 20/30', 'floxuridine (FUDR)', 'international standardized ratio (INR)', 'ASA', 'serum pregnancy test;|Concurrent participation in another interventional study；|With other diseases', 'respiratory exchange ratio', 'weight changes|History', 'Form||', 'ILD', 'sensitive)|III burns', 'ESR', 'AST ≤3x ULN*|EF >35%', 'MOUD).|Body mass index', 'HBV CAb', 'Heart rate', 'synthetic thyroid hormones', 'estimated', 'perennial night shift', 'serum TSH', 'Sars-CoV-2', 'stroke unit||', ""calibrated Oral Examiner's opinion"", 'NCI Common Toxicity Criteria', 'Viral Load +||C. Alcoholic steatohepatitis', 'ECpella', 'child', 'viral load undetectable||', 'iFR', 'serum PTH levels', 'CGI', 'PMS2 protein expression', ""Modified Ashworth's scale level"", 'plasma pregnancy test', 'Child Protection Services for the fourth', 'thyroid gland function', 'monoclonal antibodies', 'C-CAT score', 'serum Cr ≤ 1.5 × ULN', 'International Classification of Disease Clinical Modification', 'quantitative RT-PCR results of BCR mRNA::ABL1 available', 'smoking', 'functional status', 'platelet disorders|Thrombocytopenia', 'physical activity level consistent', 'drinks containing grapefruit', 'Serum', 'anti-hepatitis B surface antibody (HBs)', 'Yahr stage', 'National Comprehensive Cancer Network of the United States', 'IV|Active bleeding|Pregnancy|Life expectancy', 'acting beta2 agonist (SABA)', 'MoCA total', 'average HER2 copy number/cell', ""Bell's Palsy"", 'localized Gleason score', 'hip accelerometer daily.||', 'STTAC),|ulnar translocation,|Kienbӧck disease,|radial', 'HCV viral load.|Participants', 'AAV9 neutralizing antibody titer', 'blood cholesterol', 'glomerular filtration rate (eGFR according', 'Acne Severity Scale', 'ambulatory blood pressure', 'modified Ashworth scale.|Patients', 'blood HBV DNA should', 'European Working Group', 'hepatitis C Ribonucleic acid test', 'National DPP.||A. DPP Inclusion Criteria:||1) BMI', 'MRD negativity', 'liver', 'extranodal tumour mass', 'serum creatinine ≤1.5×ULN', 'General/Ocular Inclusion Criteria||1', 'Thyroid hormone replacement medication', 'human immunodeficiency virus antibody', 'disease|ECOG performance status', 'met:31||CD4+ T-cell count', 'pathology containing neuro-endocrine differentiation', 'monocyte clone size', 'Hepatitis B surface antigen (HBsAg)', 'ASA anesthesia', 'Axumin PET/CT scans', 'SAMHSA suicidality', 'American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guidelines', 'stroke test', 'head circumference larger than 60 centimeters', 'hepatitis C antibody', 'healthy boys', 'serum beta-human choriogonadotropin (β hCG', 'systolic blood pressure>150 mmHg', 'Nocturnal tube feeds|BMI', 'Rapid Maxillary Expander', 'population:||BMI', 'Platelets', 'quantitative HIV viral load', 'font size', 'thyroid function test', 'hepatitis C virus antibody [HCVAb]', 'normal range;|bilirubin', 'nerve root compression', 'BRCA', 'Youngstown State University|', 'birth weight', 'Caucasian.|Age', 'baseline|Diastolic blood pressure', 'serum alanine oxalacetic aminotransferase', 'GH stimulation test', 'Multidimensional Perfectionsm Scale', 'European Respiratory Society (ERS) Global Lung Function', 'state|Any significant condition', 'hair loss;|HIV antibody test results', 'peripheral neuropathy|Life expectancy', 'research.||Specific exclusion criteria', '1.2.|Platelet count', 'complicates test interpretation)|Cholesteatoma', 'Kellgren-Lawrence', 'age||Alanine aminotransferase (ALT)', '4|Body Mass Index (BMI)', 'test spermatic cord block', 'total hepatitis B core antibody (HBcAb)', 'Beck Depression Inventory at baseline|Long-life DSM-IV axis', 'Daytime hypercapnia', 'modified Bernoulli', 'blood coagulation', 'Body Mass Index (BMI < 40', 'LDL-C.||', 'detectable viral load', 'prandial blood sugar level', 'Barr virus', 'TSH', 'lactating.|Present gastrointestinal disease|Present Coronavirus disease (COVID-19) symptoms|Develop diseases', 'Blood Alcohol Concentration (BAC)', 'arterial (angina pectoris', 'mutes neurological objectivity;|impossibility of recruitment', 'serum tears', 'aortic arch atheroma', 'antibodies for', 'Total stent length', 'screening TSH', 'blood oxygen saturation', 'ribociclib + ET treatment', 'velocity', 'puzzles', 'HCV viral copy number', 'urine screening test', 'moderate-high', 'hepatitis C infection.|Participation in another clinical trial', 'reduced ejection fraction|be able to speak', 'HER2-negative', 'Systolic BP', 'Grades', 'American Society of Anaesthesiologists (ASA) Physical Status', 'supination', 'hepatitis B antigen [HBsAg]', 'HCV antibodies', 'cm|Lung shunt', 'predominantly acute SDH|Presence of brain contusion', 'albumin transfusion', 'Cumulative Illness Rating Scale', 'BI-RADS 1 (Negative)', 'left ventricular shortening fraction', 'oral steroids|Severe valvular heart disease', '1;|Survival time', 'VO2 peak', 'Body Surface Area (BSA)', 'EMN', 'Basal Cell Carcinoma）；|Informed consent', 'Adult Infusion Center', 'LNFS).|Age', 'serum troponin', 'GDS', 'EEG', 'B.E.', 'adolescent', 'lymphoma;|Age', 'abruption', 'EULAR criteria', 'Alanine aminotransferase(ALT)≤2.5×ULN', 'neuropsychiatric disorders|It', 'hours|ASA physical status classification', 'IHC1+', 'HCV serology test.|Esophageal Gastric Duodenoscopy', 'African American', 'gestational age,|where', 'ECGI system.||', 'kidney function abnormalities Colorectal cancer', 'orthodontic purpose.|Age', 'bone marrow cytogenetics', 'LV ejection fraction', 'Medicontur Medical Engineering', 'guardian.||Healthy volunteers Healthy subjects', 'Alanine transaminase', 'WOMAC pain score', 'Alkaline Phosphatase levels', 'drug Specific criteria', 'QT syndrome.|QTc', 'STOP-Bang', 'Beck Depression Scale', 'normal|Total bilirubin', 'ALTor AST', 'platelet concentration', 'VO2max', 'HPA', 'Body Mass Index (BMI)', 'CPD|Age', 'National Heart', 'renal function', 'B lymphocytes count', 'Tany N2-N3 premenopausal', 'international normalized ratio (INR)≥1.5)', 'UK universities', 'hepatitis C virus [HCV] antibody positive', 'urine HCG test results', 'Resident in Fu Jen Catholic University Hospital||', 'alanine aminotransferase (ALT)', 'corrected DLCO', 'American Society of Anesthesiology class', 'PR IHC showed', 'HCV antibodies);|Any', 'New York Heart Association (NYHA) cardiac disease', 'gastroenteral bleeding;|Known hypersensitivity', 'general quotient', 'ACR', 'Nice center university hospital|Secondary vertebral fracture', 'random plasma glucose', 'glycosylated MUC1 expression', 'identify', 'Local anesthetic allergy|Coagulopathy|American Society of Anesthesiology physical status', 'HBV surface antigen [HBsAg]', 'thyroid stimulating hormone (TSH)', 'emergency C-section', 'PBC', 'anti PD-1/PD-L1', 'American Cancer Society', 'Sars-COV-2 infection', 'rapid response.||', 'agents amount', 'lymphoma)|High grade B-cell lymphoma', 'serum creatinine levels', 'serum HBV DNA', 'drug screen', 'RECIST criteria v1.1|Eastern Cooperative Oncology Group(ECOG) performance status', 'Minimal - mild pleural fluid deemed unsuitable', 'following:||Systolic BP', 'bone marrow(≥5% blasts', 'ADT + Enzalutamide', 'Child-Pugh score', 'RR systolic', 'forced expiratory volume in the first second of expiration', 'stature', 'modified Boston', 'physical testing|Habitual protein consumption', '6-month', 'BM biopsy;|Platelet count', 'weight control', 'platelet count<100', 'Young Mania Rating Scale', 'Corneal thickness', 'Functional Classification Level:', 'Corrected serum calcium', 'Thyroid Stimulating Hormone (TSH)', 'Anesthesiology', 'signaling pathway of TGF|Has', 'FTCD', 'American Samoa).|Is currently participating in a COVID-19 vaccine', '9.||A pre-operative', 'pregnancy|ASA', 'ejection', 'aspartate aminotransferase [AST]', 'General App Study', 'monoclonal antibodies) ≤28 days', 'calculating creatinine clearance', 'Cooperative Oncology Group (ECOG) Performance Status', 'AUDADIS surveys.|Completion of written', 'human immunodeficiency virus antibody (', 'WHO)|Life expectancy', 'CD)4+ count', 'quantitative Hepatitis B Virus-DNA test', 'screening)|Platelet count', 'ECG QT interval corrected', 'antigen rapid test', 'hemi diaphragm', 'urinary drug screen', '65 years|body mass index', 'range|Platelet count', 'adrenal-cortical insufficiency', 'anti-Treponema pallidum specific', 'NASH Clinical Research Network (CRN) classification', 'endoscopic subscore', 'Modified List of Highly Effective Methods', 'FENa', 'hematocrit (HCT)', 'ECOG (Eastern Cooperative Oncology Group) performance status', 'Positive||Testosterone level', 'standardized uptake volume maximum (SUVmax', '≥0.6 BU/mL.|Treatment', ""Hanifin's criteria"", 'absolute granulocyte count', 'pregnancy test done', 'Islands Region.|CUD syndrome', 'intracerebral hemorrhage.||The exclusion criteria are:||pre-stroke', 'Hepatitis C virus antibody', 'ejection fraction.||Have', 'HBV surface antibody)).|Evidence', 'ADOS consists', 'Mayo Clinic facilities', 'Font-UP Grand Fontaine Laboratories', 'omega', 'modified Mayo Clinic Diagnostic Criteria', 'Insomnia Severity Index)|Fluent', 'hepatitis B virus surface antigen (', 'base deficit', 'average recorded blood pressure', 'test;|ECOG PS score', 'London Health Sciences Centre', 'short axis', 'Left Ventricular Ejection Fraction', 'ZI Mannheim|Age', 'RECIST V1.1.', 'prostate biopsy|Feasibility', 'facial IGA score', 'severity score', 'Nijmegen modification of the Bethesda assay', 'serum β-human chorionic gonadotropin (β-hCG', 'standardized Mini-mental Test (SMMT)', 'small hernia', '50 bpm', 'serum beta-human chorionic gonadotropin [β-hCG', 'emphysema*|Numeric Rating Scale', ""National Institute on Aging -Alzheimer's Association (NIA-AA)"", 'HIPPA Research Disclosure', 'prolonged QTc interval', 'LAZ', 'Modified Medical Research Council Dyspnea Scale', 'Transferase (AST)', 'total serum bilirubin>2 × upper limit of normal (ULN)', 'diastolic blood', 'raw score', 'hepatitis B surface antigen must', 'urinalysis|Abnormal arterial pressure', 'II).||Exclusion criteria were||diabetes mellitus|smoking|pregnancy;|diagnosis of anxiety disorders/psychiatric', 'albumin level', 'as:||Absolute neutrophil count (', 'NCI CTCAE 5.0', 'Visual Analogue Pain Score', 'Partial Thromboplastin Time (aPTT)', 'Newborn', 'adult CRCM', 'National Cancer Institute - Common Terminology Criteria', 'Ejection Fraction (HFNEF)', 'platelet count≥80×109/L', 'Belinostat/beleodaq', 'HAM-D', 'Android version 10', 'forced vital capacity (FVC)', 'CK levels', 'bispecific antibody', 'Prostate Cancer Working Group Criteria', 'Short Form|Functional Assessment', 'quantitative hepatitis C virus (HCV) RNA results', 'old.|Amputation', 'ULN|Alkaline phosphatase', 'mild physical activity', 'months;|Good organ function level', 'cleaners.|Age', 'Bismuth type', 'serum creatinine indexes', 'PROP super-tasters', 'constraints herein', 'Prisma Health Maternal-Fetal', 'hepatitis B virus (HBV)carriers with HBV DNA', 'cervical length', 'left ventricular ejection fraction', 'Energys|No', 'prediabetes(Hb A1C', 'Taipei City|Cognitive function', 'impaired function', 'American College of Rheumatologyhttps (ACR)', 'United Kingdom Brain Bank Criteria|Clear written informed consent from each participant in the trial.|Patients', 'protein kinase inhibitors', 'ACQ-6 score', 'HgA1c', 'Yahr stage I-III|Persistent subjective cognitive complaints', 'ISTH BAT', 'lesion|ECOG performance status', 'left/right', 'long bone fracture', 'kidney cancer.||Eastern', 'LMF', 'Response Evaluation Criteria in Solid Tumor', 'HCV viral load|Participants', 'mean supine diastolic BP', 'blood loss', 'anticoagulants', 'CD4+ T-cells', 'Creatinine clearance', 'cannabis.|Current smoking', 'Reappraisal subscale).||', 'best corrected', 'alveolar bone volume and height', 'blood glucose level', 'granulocyte-colony', 'pneumology', 'synovial', 'close corrected visual acuity', 'serum human chorionic gonadotropin (hCG) pregnancy test', 'Coagulation function International normalized ratio (INR)', 'atherosclerosis', 'heart rate abnormalities|Presence', 'Aspartate aminotransferase (AST)', 'IPSS-M', 'stage M1.|IPSS Score', 'modified Allred score).||Clinical Stages', 'Geriatric Depression Scale Short Form (GDS_SF).||5. Accept participation in the study', 'CIS (carcinoma', 'screening.|PANSS score', 'study.|Life expectancy', 'concentration', 'prostate cancer working group (', 'Neutrophils', 'average hernial gate width', 'Gross Motor Function Classification System (GMFCS) level', 'Gamma glutamyl transferase', 'Short', 'rapid test);|Body temperature', ""Cushing's syndrome)|Change"", 'estimated duration', '1；||Organ function：||Kidney function:||Serum', 'months.|ECOG Performance Status', 'creatinine clearance)|Participated', 'RECIST 1.1 criteria|NSCLC', 'Neuropsychological score', 'liver tests.|Presence', 'OIT allergen', 'quantitative immunoglobulin levels', 'partial thromboplastin time (aPTT)', 'weight reducing diet.|The', 'physical examination.|GMFCS level', 'a:||Phase', 'primary Gleason grade', 'Coma Scale', 'Article 9.||', 'Gleason Score', 'HIV)|Clinical signs', 'tumor.|Child Pugh Score', 'glycosylated hemoglobin (HbA1c)', 'modified Cockcroft-Gault equation', 'extend|Maximal interval period', 'multiplex PCR', 'hyperthermia.|Weigh', 'CD8+ T lymphocyte', 'Child-Pugh-Turcotte (CPT) classification system', 'oral temp', 'strength', 'expected length of stay in EICU', 'electronic blood pressure', 'illing', 'Platelet Ratio Index (APRI)', 'DDLPS', 'Arbor Classification Type of patient and clinical characteristics|Eastern Cooperative Oncology Group (ECOG) performance status', 'IIIv', 'ECG findings.|Blood lead level', 'Physical Activity Reading Questionnaire', 'DSM V criteria', 'UC', 'minimal size', 'serum creatine phosphokinase (CPK)', 'EULAR', 'HDRS-17 score', 'INR.|Albumin', 'Pediatric Medicine Unit II', 'urine albumin-creatinine ratio [UACR]', 'gamma-glutamyl transferase(GGT', 'Assessment System- ICDAS II)|Children whose caregivers have means of communication (mobile phones).|Completion of an informed consent to participate in the study.||', 'international normalized ratio (INR) ≤1.5xULN', 'extensive bone marrow involvement', 'Geriatric Medicine Clinic|on', 'Azema classification', 'Prothrombin time>1.5×ULN', 'inflammatory index', 'functional status score', 'Frankle behavior rating scale,|3', 'platelet thromboplastin time (aPTT)', 'duplex ultrasound||Baseline LDL-C level should', 'prothrombin time (', 'Child grade B', 'spherical', 'Male QTc', 'European Leukemia Net (ELN)', 'PCT', 'age|BMI', 'ULN);||Alanine aminotransferase (ALT)', '18F-FET', 'Severity Index', 'physical activity level', 'IIIA', 'Institute of Pathology', 'AMH', 'as:||creatinine clearance', 'residual upper extremity impairment|Brain lesions', 'MLH1', 'Alkaline phosphatase (AKP) ≤2.5×ULN', 'QuantiFERON Gold', 'Mallampati classification', 'atients', 'NR', 'Aspartate Aminotransferase (SGOT', 'far corrected visual acuity', 'leucocytes', 'Dependent gait|Aphasia|Any hearing', 'healthy', 'regular physical activity', 'population;5）Left ventricular ejection fraction（LVEF）is', 'females|White blood cell count', 'oral hygiene||', 'RANO criteria.|KPS ≥60.||Additional specific inclusion criteria', 'fasting morning blood sugars', 'CAGE', 'race|eGFR', 'Response Evaluation Criteria in Solid Tumor Version 1.1 (RECIST v1.1', 'New York Heart Association)', 'length limits.|De novo', 'Characterization of Healthy Research Volunteers for NIMH Intramural Studies .|Have their radial artery pulse checked', 'old|American Society of Anaesthesiologists (ASA) Physical Status', 'Neutrophil Count', 'test for hepatitis B surface antigen', 'supine HR', 'peripheral arterial disease.|Coagulopathy.|Uncontrolled', 'sperm count test', 'hepatitis B viral protein [HBcAg]', 'platelet count<100×109', 'blood PCR test', 'National Institutes of Health;|Duration', 'anti- Programmed death-ligand', 'lactation period', 'flow cytometry', 'Postural Orthostatic Tachycardia Syndrome).|Is', 'coagulopathy|Temperature', 'eligible.|Oxygen saturation', 'test:||systolic blood pressure', 'In the first 7 days of enrollment', 'VRE stool cultures', 'quantitative', 'Harvey-Bradshaw Index', 'functional status.||', 'serum potassium level', 'specialist Physicians', 'HBV', 'expected duration', 'TAPSE', 'anti-PD-(L)1 agent-naïve cholangiocarcinoma', 'bruising.|Hemoglobin level', 'Serum creatinine ≤1.5×ULN;|Urine protein', 'LVEF（left ventricular ejection fraction', 'Epworth Sleepiness Scale', 'ME/CFS Canadian Consensus Criteria (', 'foreseeable duration', 'Numeric pain rating scale||', 'OC-DC vaccines', 'lipase examination', 'consciousness||•', 'Zubrod performance status', 'female;|years≥', 'PSAD', 'Canadian Consensus Criteria|residence', 'renin mass', 'Blood Flow Restriction', ""CPR inside hospital's other departments.|Signs of sure"", 'calculation|Total bilirubin', 'resting corrected QT interval', 'SCCHN', '≤51.3', 'MSP', 'BP ≤150/90 mm Hg', 'total bilirubin (TBIL)≤1.5×upper limit of normal (UNL)', 'routine glucose values', 'stress echo', 'rejection|ASA', 'visit', 'MDRD formula).|Serum levels of magnesium', 'Left ventricle ejection fraction', 'anti HCV antibody', 'cervical disc levels', 'stage hepatitis B surface antigen negative', 'TURP', 'Cooperative Oncology Group', 'bilateral normal range', 'thyroid-stimulating hormones|On cancer', 'child length', 'urine analysis results', 'NYHA Grade', 'test;|Creatinine clearance', 'urine drug screen for amphetamines', 'RECIST v1.1 standard', 'International Classification of', 'typhoid vaccine.|Uncontrolled HIV infection', 'urine protein quantitative', 'forced vital capacity', 'SIRS', 'Blood Pressure monitoring (standard of care)||Exclusion:||Patients', 'serum total bilirubin (TB)', 'radiotherapy.|WHO PS', 'INR and aPTT: For patients', 'female participants|ALT', 'VLU', 'modified RECIST 1.1 criteria', 'alcohol breath test.|Received', 'meeting PPD criteria for TB exposure', 'BOTOX', 'Creatinine CL', 'BOR', 'ECG', 'Inconclusive Diagnosis', 'following:||Total Bilirubin', 'mean pulmonary arterial pressure', 'UNL|TSH', 'CTCAE v5.0 grade', 'vitiligo|Grade', 'HIV antigen/antibody', 'HBV-DNA test indicates virus replication|Patients', 'urinary ﬂow rate measurement (Qmax)', 'pounds|Hemoglobin', 'serum Ca', 'Child Pugh C).|Patients', 'anti-Hepatitis B Core (HBc)', 'urine screen', 'IBL', 'quantitative assessment indicates', 'mono-', '1.4)|Age', 'bone density|Acute orthopedic problems', 'VAS', 'Leukocyte count', 'Barts Bank partners||18', 'Urine Albumin Creatinine Ratio', 'longer|ECOG Performance Status', 'kidney function', 'T-Cell Lymphoma', 'Mallampati', 'Cooperative Oncology Group (ECOG) score', 'PSRT', 'Plt', 'Common Terminology Criteria (CTC)', 'MODERATELY CURVED ROOT CANALS||', 'HIV infection|Active hepatitis B', 'condition|Cancer|Heart failure|Ischemic stroke|Initiation', 'Hemoglobin (HGB)', 'definition: immunohistochemistry', 'fasting blood', 'responsible care giver', 'HAV', 'estimated glomerular filtration rate (eGFR) by', 'inclusive|Body mass', 'NYHA Classification', 'aspartate aminotransferase', 'archival specimen.|ECOG performance status', 'Moribund', 'Aspartate aminotransferase(AST', 'diastolic blood pressures', 'ICS use|Diagnosis of COPD', 'HLH', 'Lenalidomide should', 'modified UPDRS scale', 'preserved ejection fraction|Sinus rhythm|New York Heart Association (NYHA) Class', 'anti-HBc (+)', 'ABCD2 Score', 'higher|can read', 'CAR-T/HCT', 'serum antibodies', '||axSpA population:||Peripheral spondyloarthritis,|Unavailability of chest CT scan', 'ISUP Grade groups', 'SGPT', 'female|HIV negative|have', 'EPO', 'OA', 'viral serology', 'cytogenetics WHO (2016) revised classification of MDS as MDS', 'serum hCG', 'acute', 'UCLA Loneliness', 'UCLA Health DOM Primary', 'organ function;|Treatment related', 'years.|ECOG PS score', 'oral glucose tolerance test', 'hours;|extracorporeal circulatory assistance', 'NI):||NI-1', 'RECIST Version 1.1 (Annex 1)', 'bone marrow function:|Absolute neutrophil count', 'calculated free testosterone', 'staging', 'sweat test', 'mmHg)|Platelet count', 'diastolic LV', 'serum pregnancy tests', 'FSU sites||Inclusion Criteria:||healthy', 'end-stage kidney disease', 'dexamethasone', 'heart rate', 'creatinine ratio', 'body-mass index', 'Short Physical Performance Battery (SPPB)', 'PaO2', 'HELLP syndrome|Acquired color vision deficiency|Significant bleeding', 'collection|Body Mass Index', 'body weight', 'drinks day', 'Frankl Behavioral Rating Scale)|legal guardian consents', 'platelet glycoprotein autoantibodies positivity', 'international normalized ratio of', 'close friend/associate also enrolled/currently', 'progesterone-receptor expression', 'medication', 'WINGS-IP1 Smartphone Application V1.0 can be installed (required operating systems', '||②Alanine aminotransferase (ALT)', 'HCV RNA test results||Known positive test', 'immunoglobulin G reaches', 'early-stage (', 'transfusion allowed)||Absolute neutrophil count', 'MD', 'stage IIIB-IIIC', 'white cell count', 'Mayo Endoscopic Sub-Score (MESS)', 'drinks', 'estimated Glomerular Filtration Rate', 'cryoablation|ECOG performance status', 'serum aspartate aminotransferase', 'partial thromboplastin time (aPTT) ≤1.5×ULN|Serum creatinine (Cr) level', 'EGFR Exon 19 deletion.|NSCLC', 'General/Ocular Exclusion', 'BMI≤18.5)|Age', 'AST)(serum glutamic oxaloacetic transaminase', 'CECT|body mass index', 'LAMA', 'Numeric Pain Rating Scale.||', 'ARC clinic HNA', 'sensory exam findings', 'PAWP', 'acid exposure time (AET)', 'required.|Absolute count', 'and|Pregnancy', 'FNB', 'age|Eastern Cooperative Oncology Group (ECOG) performance status', 'Karnofsky performance status', 'breath test', 'protein-corrected calcium', 'varicocelectomy|ASA Status', 'vertical bone height', 'BRAF V600E/V600K', 'Manager Exclusion Criteria:|Read', 'MRI-2', 'Apnea Hypopnea Index', 'Individual Case Safety Report (ICSR)', 'Ion™ Endoluminal System (SSCB)', 'DLCO', 'protocol;|Negative blood pregnancy test', 'national language||', 'serum potassium correction|Severe acute', 'RHI', 'local echo graphic criteria', 'National Institute for - - Health and Care Excellence osteoarthritis', 'Users', 'hearing', 'Creatinine value', 'bone marrow function including:||Haemoglobin', 'IHC', 'German language.|Age', 'Mayo endoscopic score', 'unmethylated.||Personalized neoantigen DNA vaccine', 'peripheral arterial vasculopathy||Specific criteria', 'basic proficiency', 'Mass General Brigham questionnaire', 'United Kingdom Brain Bank criteria|Presenting', 'Prosigna score', 'Screening.|Alanine aminotransferase (ALT)', 'Screening.|Body mass index', 'study|Estimated glomerular filtration rate (eGFR)', '1.|Negative HIV test', 'hematocrit values|Pregnancy|Body weight', 'IPSS', 'antibodies to hepatitis B surface antigen [anti-HBs', 'modified version of the Physical Activity Readiness', 'test for hepatitis B-', 'valve area', 'aspartate transaminase (ASAT)', 'HistoSonics Edison System.||', 'metallic surgical arterial material', 'RECIST v1.1', 'ECG morphological abnormalities', 'weight reduction program.||', 'PHQ-9M item #9', 'Mayo Clinic Health System', 'CAR T cell therapy', 'mean BP', 'moderate level', 'Aspartate transaminase', 'serum pregnancy test.|Documented', 'RNA', 'wrist circumference', 'cardiac pathology|Psychiatric diseases|Asthmatic', 'HIV1', 'ECOG (Eastern Cooperative Oncology Group)', 'Response Evaluation Criteria in Solid Tumours (RECIST 1.1);|Disease progression occurs after', 'GM-CSF autoantibody test|PAP associated', 'screening.|FEV1/FVC', 'CA125 carbohydrate antigen', 'alefacept', 'Global Impression Scale Disease Severity CGI-S severity score', 'fasting blood glucose level', 'urine hCG pregnancy test', 'Sustained VT', 'disease-specific', 'HDF', 'Special Health Care', 'LDL-Cholesterol', 'HCV RNA viral load', 'hepatitis C (HCR-RNA', 'NYHA grade ≥2);|Uncontrolled', 'SER', '6-minute walk test', 'Rest Scale', 'urinary pregnancy test', 'hemoglobin (Hb)', 'New York Heart Association (NYHA) Class', 'simple laboratory abnormalities', 'Creatinine clearance rate (CRCL)', 'Section 6.5.2 Table', 'electrocardiogram).|Body weight', 'pregnancy test results', 'ALT/AST', 'UTUC', 'Recist version 1.1:|ECOGPS:0-2', 'old.|ECOG Performance Status', 'anisometropia', 'calculated visual acuity', 'investigator.|Human immunodeficiency virus', 'international normalization ratio', 'VAS scale|Age is', 'CD4+ T-cell counts', 'alkaline phosphatase (AP) ≤1 x ULN|Total bilirubin ≤1 x ULN|Troponin', 'troponin negative', 'Bath AS Disease Activity Index (BASDAI) score', 'Mullen Scales', 'MGH Cancer', '24-hour urinary copper excretion', 'MTX-HD', 'permit acquisition', 'Platelet ≥75 x', 'SB diameter ≥2.3 mm)|(3)', 'T score', 'estimated gestational age', 'CGI-S score', 'immune test results;|Acute', 'endogenous creatinine clearance rate', 'ALP)≤ 2.5×ULN||TSH', 'Modified Rankin Scale (mRS)', 'HDL cholesterol', 'alloHCT|Cardiac ejection fraction', 'outpatient treatment.|a severe', 'residual hearing thresholds', 'PRO questionnaires', 'EuroSCORE score', 'Lansky Play Score', 'packed red blood cell', 'occasional PVCs', 'FEV1/forced', 'Comorbidity Index (HCT-CI', 'growth rate', 'Endogenous creatinine clearance', 'requirement.|expected survival', 'eosinophil count', 'Hemoglobin ≥8.0g/ dL', 'DTR', 'mmHg|Diastolic blood pressure', 'partial thromboplastin time (APTT)', 'annual failure rate', 'Human immunodeficiency virus', 'household enrolled', 'calculated by CKD-EPI formula)||Note: For patients', 'CHILD-PUGH', 'arterial blood', 'Formalized ethical decision to withhold', 'Child - Pugh classification', 'included.|Body mass index', 'Armpit temperature', 'takes 30 minutes', 'international normalized ratio (INR) values', 'thin pulse', 'International standardized ratio INR', 'Aspartate transaminase(AST', 'triglyceride TG', 'partial thromboplastin time (APPT)', 'apical periodontitis.|18', 'modified Rankin', 'Nugent score', 'Human Leukocyte Antigen (HLA)', 'fundus photographs.|Normal optic disc.||', 'Partial Pressure of Oxygen in', 'human serum albumin (HSA)', 'control group):||normal EF LV', 'packed red blood cell transfusion', 'Prestroke modified rankin scale', 'maxillo-facial traumas|nasopharyngeal', 'Movements Disorder', 'study;|Blood count', 'performance status', 'inconclusive test', 'London Health Sciences Centre (', 'Age||Age', 'monoclonal B lymphocytes', 'Gross Motor Function Classification System (GMFCS).||', 'FIMAGE|Baseline MRI from', 'liver metastasis|Serum creatinine', 'hepatitis C (HCV) antibody', 'HER2 Exon20ins small molecule inhibitors', 'HER2-positive breast cancer', 'bone regeneration', 'common terminology criteria', 'irradiation', 'hepatitis B antigen', 'resting heart rate', 'urine analysis', 'genital temperature', 'kidney transplantation|Ongoing AKI', 'CGI Severity score|Patient', 'a1c hemoglobin', 'waist worn', 'plasma cells', 'hepatitis C (HCV RNA positive);|Patients', 'LV function remains preserved.|Signed', 'systolic PAP', 'hepatitis B (HBV)', 'excludes pre-cancerous', 'penetrates the CSF', 'residual hematopoietic cells;||Two', 'ECOG physical state score', 'serum free light chain (FLC) level', 'weight fluctuation', 'RECIST v1.1).|0', 'aspartate aminotransferase)/ALT', 'DSM IV criteria', 'Methodology||', 'URR', 'blood function', 'right ventricular mechanical circulatory support', 'drug test', 'Identify', 'HBV DNA copy number positive', 'NRS', 'glomerular filtration rate (eGFR<30 ml/min', 'prothrombin time (INR)', 'hepatitis C virus (HCV) carriers', 'Android OS ≥5.0', 'Definition: Stroke', 'Patients:||Age', 'serum ferritin level', 'CCS IV angina|STEMI', 'Stage IV)|American Society of Anesthesiologists ≥IV|Previous laparotomy|BMI', 'ASCO/CAP', 'alanine aminotransferase ALT (SGPT', 'respiratory event index (REI)', 'HER2', 'Pediatric Chest Diseases Unit of Hacettepe University Faculty of Medicine', 'Mothers', 'SARS-CoV-19', 'Incomplete questionnaire|Under', 'RECIST v1.1.|ECOG PS', 'split renal function', 'female|ECOG PS', 'urine drug screen for cannabinoids|taking any medication', 'Asan Medical Center', 'serum human chorionic gonadotropin test negative results', 'arthro Magnetic Resonance Imaging', 'CLcr', 'hepatitis B surface antibody (HBsAb) test', 'Grade', 'synthetic', 'hepatitis C viral infection.|Female', 'Physics lead', 'recurrence interval', 'Lansky', 'apnea index', 'RECIST version 1.1;|Postoperative pathological diagnosis', 'SIS', 'Specialist Rehabilitation Unit 1 of the ""E. Spalenza - Don Gnocchi ""of Rovato.|Overall score', 'cervical disc', 'anti-lentiviral antibody test', 'definition of obesity', 'carbohydrate-protein supplementation', 'GGT levels', 'birth length', 'HBV DNA titer', 'likelihood of reduced image quality', 'GOT', 'liver enzymes', 'multiple blood pressure', 'etc.).|XZB-0004', 'age.|Zubrod Performance Status', 'preserved ejection fraction', 'modified WHO criteria.|Patients', 'STEM CELL TRANSPLANTATION:||Autologous', 'TREATMENT ARM APPENDIX TO WHICH THEY ARE ENROLLED.||Core Inclusion', 'hepatitis B surface antigen and peripheral blood hepatitis B virus deoxyribonucleic acid', 'Visual Analog Scale Score', 'Left Ventricular Ejection Fraction (LVEF)', 'plasma viral load', 'hepatitis C virus [HCV]', 'liver function test', 'Individual values', 'anti-anxiety medication|Are lactating', 'SGRQ score', 'Prothrombin time/international normalized ratio', 'hepatitis B virus [HBV] deoxyribonucleic acid', 'BDI', 'ASCO-CAP HER', 'Arm circumference', 'New-onset', 'modified Schwartz formula)|Stroke', 'NIC-FTD', 'memory function score', 'RACHS', 'postural hypotension).|Heart rate', 'LV LV', 'Uric acid level', 'saliva secretion xerostomia', 'Hg|White blood cell count', 'Saint Louis University Mental Status (', 'hepatitis B surface', 'human immunodeficiency virus (HIV) antibody test', 'Gross Motor Classification Scale Levels', 'genotype test|Previously HCV', 'radioisotope glomerular filtration rate', 'local lab;|The Eastern Cooperative Oncology Group (ECOG) performance status', 'Total protein', 'ECOG PS ≤2||Underwent ASCT', 'serum triglycerides', 'International normalized ratio (INR)≤ 2×ULN;|8', 'old.|Mini-Mental State Examination score', 'Rome IV criteria for IBS-C', 'Lansky score']","['Heart Team consensus', 'vegan diet', 'first recurrence.|Tissue', 'open pancreaticoduodenectomy', 'stent placement', 'Centre IRCCS Policlinico San Donato;|Signed informed consent;||', 'standard treatment options|Patient recruited from the Region of Northern Jutland', 'liver cancer|Prior', 'toxin treatment', 'typical computerized tomography (CT) evidence of viral pneumonia.|All enrolled', 'inguinal hernia repair', 'control of symptoms', 'cessation therapies.|Expectant ladies', 'preoperative screening', 'screening):|White blood cells', 'verification', 'painful procedures', 'carbohydrate antigen)||Having', 'mRECIST v1.1', 'parenteral delivery', 'assessment procedures|Cortico-steroid', 'diagnostic puncture', 'Discharged on insulin therapy', 'major noncardiac surgery', 'urine drug test', 'assessment of coronary artery disease.||', 'steroids;|Progression', 'allogeneic tissue/solid organ transplant|Known severe', 'B vaccination', 'YAG laser', '™ MRI 2x8 leads', 'chest computed tomography', 'computed tomography scan|Participant', 'available therapy', 'imaging examination', 'haploidentical donor with', 'physical exam', 'fluorescent treponemal antibody (FTA)', '2-hour period what most people would', 'histopathological examination', 'rated', 'primary series of COVID-19 vaccine', 'radiotherapy-induced angiosarcoma', 'Adoptive Cell Therapy (ACT)', 'epithelial ablation.||', 'peritoneal equilibrium test', 'icodextrin dialysate|Participation', 'PAP test', 'total hip replacement surgery', 'complaint of bruxism|no psychological drug|no active', 'glycaemic emergency', 'general hair care products', 'computerized tomographic angiography', 'hip cannulated screws', 'laparoscopic gynecological', 'vascular access dysfunction', 'first COVID-19 vaccine', 'TAVI procedure', 'Global Impression', 'rarefaction|Necrotic pulp upon', 'emergency mass vaccination', 'complete sexual abstinence', 'CT scan|Pregnant', 'computerized tomography.|At least one', 'coagulation treatment', 'hormone regulating therapy', 'spherical grasping item of the Fugl-Meyer Upper Extremity Subscale to allow', 'nicotine replacement therapy', 'hormone replacement therapy|steroid therapy|antiretroviral therapy', 'co-existing', 'real-time quantitative polymerase chain reaction (QT-PCR) with', 'cell infusion.|Chemotherapy', 'hepatic encephalopathy|History', 'sentinel node biopsy (SNB)', 'pre-first treatment levels', 'PCR', 'laparoscopic surgery.|Suspicion', 'diet|Persons', 'gastric bypass', 'autologous CAR-T cell therapy.|Part 2 (dose expansion):||A. Histologically', 'drug treatment|American', 'brain stem', 'residual refractive error', 'lymph node have', 'barrier', 'suggested', 'standard therapies.||', 'special reprogramming circuit', 'radiofrequency ablation', 'whole blood', 'Montreal Cognitive Assessment test', 'blood hormone levels (FSH and estradiol in premenopausal range', 'augmented therapy', 'QT syndrome|Current treatment', 'imaging trolley restrictions', 'affect neuropsychological test performances', 'trastuzumab deruxtecan', 'arthroscopic knee surgery', 'periodontal plastic surgery', 'sinus surgery', 'coronary artery reconstruction;|14.4', 'emergency surgery.|Known', 'transient ischaemic attacks [TIA]', 'intraoperative dissection', 'B-mode US|CEUS', '12-lead electrocardiography', 'ulcerans', 'mediastinoscopy', 'concurrent therapy', 'transcatheter aortic valve replacement;|Concomitant', 'cranial electronic medical devices', 'extracorporeal membrane', 'intracorporal injections', 'single-level anterior cervical fusion', 'heart bypass surgery', 'study;|Participation', 'manual therapy', '™ Endoscopic Suturing', 'hookah', 'labral tears.|Surgical procedures', 'sudden', 'biological', 'visit.|Blood donation', 'further investigation', 'medical photography', 'metacarpal osteotomy', 'ultrasound guided procedures', 'control visits).||Non-inclusion criteria:||Volunteers', 'maintain antiviral treatment', 'carotid artery intervention', 'coronary bypass', 'medical examination book|For', 'structured psychotherapeutic interventions', 'adult', 'systemic therapy regimen', 'endobronchial polymer/', 'conventional imaging (CT/MRI', 'forgo surgery', 'heart intervention', 'EUS-guided biopsy samples', 'laser/surgical therapy of the scalp', '12-lead ECG monitor', 'percutaneous left ventricular assist devices)|Life expectancy', 'allogeneic hematopoietic stem cell transplantation;|Is pregnant', 'chemotherapy treatment', 'CAMH chart review', 'routine reduction', 'radiology residents', 'endoscopic mucosal resection (EMR)', 'non-myeloablative', 'herbal remedy', 'lateral epicondylitis|did', 'RBC transfusion', 'product|Whole blood donation', 'rhinoplasty surgery', 'World Health Organization', 'Locoregional treatment', 'test|Renal replacement therapy', 'optimal medical therapy;|<40 days from the index myocardial infarction', 'medication,|body mass index (BMI)', 'Hip arthroscopy', 'irreversible organ function damage', 'relugolix containing therapy', 'employment', 'home oxygen therapy).|Pregnancy', 'Vascular Surgery Unit,', 'radiographic assessment', 'hepatic arterial perfusion', 'slit lamp examination', 'months|Ipsilateral hip', 'HPV testing', 'CCC)|≥5 current medications', 'tendon rupture.|Symptoms of', 'fresh biopsy sample', 'chemo-radiation therapy|Unable to give consent|Pregnant', 'Animal organs', 'histone mutation', 'head MRI', 'colorectal surgery', 'clinical study treatments', 'digestive surgery', 'heart failure|Active', 'Start education staff', 'rescue PCI', 'oxygen therapy', 'spinal anesthesia', 'Antitumor therapy', 'potential QTc-prolonging medications should', 'eccentric fixation', 'MenB vaccine|Unable to give informed consent', 'urologic surgery', 'assessment|Good operative', 'surgical diagnosis', 'enterotomy', 'bilateral SEEG pairs', 'interventional pulmonology procedures with radial probe endobronchial ultrasound', 'gastroesophageal junction (GEJ)', 'program', 'endometrial biopsy', 'conventional restorative procedures.|Good oral hygiene', 'local treatment recommendations', 'tomography,|Acute myocardial infarction', 'infantile', 'otitis|Recent head injury,|psychiatric', 'ASD cut-offs|Capacity to follow the study procedures', 'therapeutic injunction', 'esophageal echocardiography (TEE)', 'systemic regimens', 'bilateral oophorectomy', 'intraperitoneal treatment', 'elective cardiac surgery', 'coronary artery stenosis of 30% - 90% in diameter', 'allogeneic HSC transplantation', 'immunochemotherapy', 'discontinuation of treatment', 'PD-1 immunotherapy', 'Core Biopsies sub-study', 'chemoimmunotherapy', 'cladribine tablets', 'Montreal Cognitive Assessment scale', 'peripheral arterial intervention', 'biochemical examination', 'control group:||Healthy control', 'HDAC inhibitors.|Active treatment', 'HER2 immunohistochemistry (IHC) test', 'emergency endotracheal intubation', 'maxillofacial surgery', 'hours|Multi organ transplant', '24-hour urine collection for determination of creatinine', 'renal artery bypass surgery', '120 days after the final dose of any study drug|If sexually active in a way that could lead to pregnancy', 'Triple vessel coronary artery disease (TVCAD)', 'CHG', 'Cryotherapy', 'thyroid replacement therapy', 'consistent from screening though the entire study duration.|Consistent use of', 'standard of care imaging done', 'complete interviews', 'topical hormone therapy', 'residential', 'morphologic evaluation', 'instrumental examination methods', 'congenital organ absence;|Patient', 'extensive Small Cell Lung Cancer', 'active treatment', 'femoral osteotomy', 'antidiabetic', 'Blood biochemical examination showed', 'HBOT', 'ENT surgery', 'systemic chemotherapy line.||A chemotherapy line', 'aggressive treatment', 'barrier birth control measures', 'Shiga Toxin-', 'mucousal resection', 'Treponema pallidum antibody', 'episodes of wheezing.||History', 'clinical study procedures|Vaccination', 'complex cryptoglandular transsphincteric anal fistula', 'fundus', 'low-FODMAP', 'local laboratory', 'national exercise guidelines', 'primary head and neck', 'intraoperative assessments', 'bariatric laparoscopic surgery', 'RF)|Stable RA therapy', 'rapeseed oil|History', 'tympanostomy tube)|Presence of TM perforation', 'LKB1 mutation status', 'dupilumab therapy', 'Signed Informed Consent|able to achieve', 'caretakers receives', 'SOC screening', 'exercise testing||', 'target coronary angiography agent', 'preceding biopsy|skin infection', 'B-cell lymphoma', 'videofluoroscopy', 'supine rest|Standard', 'inappropriate.|Penetrative vaginal sex', 'first vaccination', 'routine follow-up visit', 'robotic surgery', 'cumulative dose of more than 15 mg/kg;|Evidence of infection', 'CT coronary angiogram', 'target node', 'small intestine transplantation', 'bismuth subsalicylate', 'left unilateral mastectomy', 'fetal growth restriction (FGR)', 'focal neuroretinal rim thinning', 'ureteral stenting', 'staging surgery', 'small intestinal stoma;|Perforated', 'maintenance therapy,|Experiencing disability', 'bone marrow haematological function', 'clinical laboratory determinations.|Body mass index', 'nasopharyngeal wash|participation', 'small molecule targeted therapy', 'heart-related surgery', 'cycle', 'pancreaticoduodenectomy', 'OCT', 'whole blood transfusion', 'small-cell carcinomas', 'immunosuppressant 90days', 'vagal nerve stimulator', 'uspicion of', 'standard treatment regimens', 'cardiopulmonary resuscitation|Critically ill', 'a:||Previous treatment', 'exclusionary concomitant psychotropic', 'discontinuation of DOR/ISL.|Is a HTE participant', 'liver biopsy', 'chemoradiotherapy', 'radical surgeries', 'Renal stone', 'Mini International Neuropsychiatric Interview [M.I.N.I.]', 'atrial septostomy', 'major organ system function', 'cumulative exposure', 'implanted chemotherapy', 'radiological staging', 'microscopic examination', 'admitted for end of life care|Patients', 'HFNC oxygen therapy;|Obstruction of nasopharynx cavity;|Platelet<60 × 109/L；|Need tracheal intubation;|The', 'coronary artery disease|Be over 40 years', 'renal-replacement', 'medication treatment', 'MRI scans|undergoing', 'inactivated vaccines', 'pelvic adhesion', 'cervical rotation toward', 'thin endometrium', 'isolated surgical', 'chemotherapy infusions hospitalized', 'peripheral stem cells', 'IRM', 'CPB procedure', 'assessment of thyroid stimulating hormone levels', 'ledge formation', 'smoke', 'therapy escalated', 'Total Bilirubin', 'effective contraceptive measures', 'FISH', 'implanted graft', 'intestinal biopsy', 'wedge resections', 'lipid nanoparticles', 'joint injection|Diagnosed', 'imaging MRI', 'Assessment System', 'cycling exercise|Prescribed medication to control heart rate|Prescribed medication', 'SmartMom program', 'gastric emptying breath test [GEBT]', 'treatment-related toxicities', 'albuterol', '12-lead safety ECG', 'regular nasal', 'O2 saturation', 'study|Bariatric surgery', 'Suez Canal University Hospital', 'female))/(72 x creatinine', 'supportive care treatment', 'reliable visual field testing', 'confirmatory EGD testing', 'ablation therapy', 'Blood routine examination standards', 'spine revision surgery', 'radical chemoradiotherapy', 'occupational therapy sessions.||', 'corneal Surgery', 'neo]adjuvant therapy', 'organ transplant.|Major surgery', 'heart failure.|Participant', 'ablation/radiotherapy', 'leg)|Acute sunburn', 'fluid therapy', 'immunohistochemical detection', 'Polymerase chain reaction (PCR)', 'biliopancreatic diversion', 'simple tympanoplasty healed', 'Argon Laser Trabeculoplasty||iStent', 'permanent sterilization', 'active', 'lung tissue|History of', 'restoration.|mandibular prognathism', 'products；|Hospitalization', 'R0 resection', 'arthroplasty', 'inotropic support|not', 'vertebral bodies.||', 'blood clots', 'concomitant posterior repair', 'Demineralized water', 'cyst surgery', 'disease;|Secondary radiotherapy', 'major treatment', 'minimally invasive', 'walking', 'RHC', 'fragility hip fracture', 'percutaneous coronary', 'diagnostic liver biopsy obtained', 'immunosuppressive purposes', 'cryptococcal antigen in the CSF', 'Cesarean section', 'transfused blood', 'cognitive deficit|Neurological deficits', 'peribulbar treatment for DR', 'oncology care', 'Venous access already', 'surgical repair of the rotator cuff tear', 'placement of MCS', 'Maintenance Immunotherapy', 'apheresis donation', 'cumulative dose of', 'open care', 'PET scans tracer injections', 'requirements|insulin treatment', 'practice||', 'Pulmonary Rehabilitation', 'digital rectal examination', 'mental disability|Pregnancy', 'bronchoscopy including:||active acute lung infection', 'intermetatarsal treatment', 'completed definitive therapy', 'ventral mesh rectopexy|Total rectal', 'hospital admission', 'scheduled surgery', 'e-cigarettes)|Abuse', 'Intensive Care Unit stay).|History of any respiratory disorders', 'Micropulse laser|Trabeculectomy', 'Cardiovascular Magnetic Resonance examination', 'nutrition intervention of the Prehabilitation intervention bundle', 'consistent ART adherence.||(B', 'Gout treatment', 'TICS-M|Severe rheumatologic or orthopedic diseases', 'artery prosthetic', 'completed CT imaging', 'axillary sentinel nodal biopsy', 'periapical radiographs', 'partial resection of the intestine;|', 'environmental stimulation', 'computed tomography [CT] scan of the thorax', 'mental health institution by virtue of an order issued', 'lymph node assessment.)|Enrolled', 'enzyme inducing anti-epileptic drugs', 'blood system', 'blood cultures', 'congenital heart disease surgery', 'bypass;|complex cardiac surgery', 'recurrent laryngeal cancer', 'Magnetic Resonance Imaging (MRI)', 'lifestyle modification', 'intraepidermal puncture', 'sessions of the CST program,|Patients', 'invasive intervention', 'drug delivery device', 'Physical therapists', 'Total laryngectomy', 'craniectomy', 'epigenetic therapy', 'Edinburgh Postnatal Depression Scale (EPDS)', 'permanent study intervention discontinuation in study KGBI', 'bimaxillary osteotomy', 'fresh biopsy', 'Structured Interview', 'small-cell lung cancer', 'splenic sequestration', 'OSDI questionnaire', 'weight', 'neuropsychological testing indicates', 'COVID-19 treatment', 'intra articular joint injections of', 'institution of VA ECMO||Exclusion criteria||Patients staying', 'dorsal rhizotomy', 'regional prescribing information.|Participant', 'radiographic', 'primary total knee arthroplasty.|Patient is able to understand the study design', 'hormonal changes', 'inhalation general anesthesia', 'unilateral total knee replacement surgery|Patients hospitalized', 'thromboprophylaxis', 'complete incompetence in working with computers', 'B-ultrasound', 'bariatric evaluation|Eligible for endoscopic', 'coronary blood flow', 'exclusive radiotherapy', 'discontinue treatment', 'cognitive behavioral therapy', 'GDS)|at least one', 'soy', 'Chest CT angiography', 'test material', 'former treatment', 'TENS unit', 'single viral load measurement', 'cardiac surgeons', 'light path of the NIRS probe', 'PDx monotherapy', 'vascular function measurements', 'months.|Bariatric surgery', 'antithrombotic treatment', 'radiotherapy treated', 'World Health Organisation (WHO) performance status', 'venous procedure', 'bilateral ovary transvaginal ultrasonography', 'imaging reveals', 'labor', 'allogeneic organ transplant', 'World Health Organization (2016) guidelines', 'special nutrition program|Not using laxatives||', 'spinal anaesthesia', 'medication management', 'strenuous exercise ≥5 h/week|Blood', 'unilateral knee', 'apheresis', 'Carotid Endarterectomy', 'latex.|Radiographic', 'full-field ERG', 'Holter ECG monitoring', 'intra-articular steroid injection', 'local resection', 'Montreal Cognitive Assessment)|actively', 'completed initial treatment', 'Hormonal contraception', 'exocrine pancreatic insufficiency/malabsorption|Clinically instability', 'inclusive.|No', 'clinical suspicions combined', 'Treatments', 'follicle stimulating hormone (FSH)', 'gastrointestinal surgery', 'infertility treatment', 'adenocarcinoma;|Bone imaging', 'sitting blood pressure', 'study.|Pregnancy.|Antibiotic treatment.|Active', 'LGR5 expression', 'translating into', '12-lead', 'MRI|Regular use', 'GIST', 'complete dentition', 'stress fracture|Pregnant women|Non-English speakers|Medicare', 'ileostomy', 'ovum donation', 'smart cell phone', 'epidural labor', 'indications', 'constituents|Previous knee injection', 'XANTH', 'colonoscopy procedures', 'retroperitoneoscopic laparoscopic partial nephrectomy', 'Hematopoietic System||Anemia|Leukemia|Myeloproliferative diseases|History', 'B-cell lymphomas.||Disease', 'percutaneous coronary intervention|Type 2', 'cervical surgery', 'Bilateral Oophorectomy Post-menopausal', 'Mohs surgery', 'vertebral body metastasis', 'primary TKA|Patients', 'local tests', 'laminoforaminotomy', 'histological examination of the material obtained', 'clinical investigation plan-required follow-up visits', 'European guidelines)|Starting infliximab', 'ICD implantation|hypertrophic', 'Trauma Surgery', 'polysomnography', 'intraprocedural pacing maneuvers', 'Transcatheter Bicaval Valves System', 'completed antiviral treatment', 'CT-STAR.|Limited', 'occupational therapy|Current', 'invasive procedures', 'lumbar puncture|Lacks capacity|Hospitalized individuals', 'sleeve gastrectomy', 'clinical laboratory evaluations', 'transmetatarsal amputation', 'plasma', 'pelvic ultrasound|Desires IUD removal||', 'Optical Coherent Tomography (OCT) examinations', 'classes|spine surgery', 'palliative care|older', 'coronary artery bypass grafting.|Participation in other clinical trial in the 30 days before enrollment.|The existence', 'glaucoma treatment', 'tumor assessments', 're-irradiation', 'surgery.|Planned laryngoscopy', 'dental x-rays|Have', 'Physical restriction', 'kidney biopsy.|Kidney biopsy', 'regular anti-inflammatory', 'stay on them for the duration of the study.|Sebacia laser treatment', 'empirical antibiotic therapy', 'additional procedures', 'Baseline.|Transjugular intrahepatic portosystemic shunt', 'immunosuppressive dose', 'carotid artery stents', 'graft versus host disease', 'treatment protocol', 'elective surgery ranging', 'target focus radiotherapy', 'psychotherapeutic treatment', 'Kidney transplant', 'carotid', 'urine β-HCG pregnancy test', 'bedside tracheostomy', 'plasma therapy', 'study||Gastroscopy', 'injection', 'triple therapy', 'magnetic resonance imaging performance', 'salvage laryngeal resection', 'psychopharmacological intervention', 'friable granulation', 'National Health Survey', 'fluoropyrimidine chemotherapy', 'gastrointestinal risk assessment index|liver cirrhosis|known iron deficiency anemia|recent fibrinolytic therapy|active cancer|end-stage renal failure|life expectancy', 'psychosis section', 'Gastric tube', 'Cardiac echocardiography showed', 'ultraviolet B therapy', 'shoulder arthroscopy', 'Institutional Review Board (IRB)-approved informed consent', 'smell change', 'Mantle cell lymphoma (MCL)', 'placement|Previous surgery', 'Genomic testing', 'Small intestine', 'ventriculostomy', 'pure variant', 'chest HRCT scan', 'fecal occult blood test(FOBT', 'transurethral resection of bladder tumor.|.Written informed consent.||', 'etc.)|Abdominal surgery', 'PMA.|Previous history of polyabortion', 'Coronary Artery Bypass Grafts', 'coagulation tests', 'maintenance treatment', 'physical therapy sessions', 'major surgery', 'arthroscopic RM surgical procedure', 'SL|Positive cytology', 'whole-brain radiation', 'Flockhart Table TM', 'cosmetic surgery', 'Cervical Trauma', 'SD-OCT', 'implant drive prosthesis', 'brain cancer|Cerebrovascular accident', 'ovariectomy', 'robotic therapy', 'bilateral simultaneous TKA|Patients', 'hemiarthroplasty', 'Phototherapy', 'WSL', 'standard of care Axi-Cel will be enrolled in this study).|At least 1 measurable lesion', 'Linac MRI', 'Changed TNF', 'curative surgery||', 'Reisberg', 'cardiac ultrasound', 'gastric stump cancer|congenital acquired immune deficiency', 'surgical condition.|Patients', 'computed tomography angiography (CTA)', 'imaging techniques', 'diagnostic study||Decision tree classification', 'anterior compartment repair', 'adjuvant radiotherapy (ART)', 'Health', 'major pulmonary blood', 'pathological examination.|Patients', 'undergo surgery', 'GBS-related weakness', 'bacterial culture', 'herniorrhaphy', 'canine retraction into the extracted premolar||', 'radiology', 'additional surgery', 'full thickness supraspinatus', 'transthoracic echocardiogram studies', 'intravesical immunotherapy', 'SLUMS', 'optimal antihypertensive', 'Extracorporeal Membrane Oxygenation - ECMO', 'EUS', 'woman|Laparoscopic surgery|Surgery', 'maintenance therapy (PARP-inhibitors', 'gastrointestinal surgery (absorption of test product', 'synovial fluid sample', 'X-ray.|Subject', 'exertion|Stable treatment regimen X', 'brain radiotherapy before.|Patients', 'mediastinal radiotherapy', 'psychiatric)||Patient Specific', 'bladder cancer|Bilateral', 'Open', 'oral antiviral treatment', 'surgery of the liver', 'hepatic disfunction related to the', 'gastric banding', 'canine retraction into the extraction site', 'metabolic disease|History of', 'smartphone device', 'gastrostomy tube placement', 'Lumbar spine segments', 'Refusal', 'drugs|Major surgery', 'lung transplant|Left ventricle ejection fraction', 'atherectomy device', 'local treatments', 'living donor candidate per the standard living donor selection process', 'exercise|participants should know the greek language in order to understand the instructions', 'sternotomy', 'vaping)|Have donated blood recently', 'immunohistochemistry', 'bilodigestive shunt|for TARE -', 'optimal medical management;|No', 'laparoscopic examination', 'Structured Clinical Interview for DSM-IV;|the score of Hong Kong Montreal Cognitive Assessment', ""computerized tomographic images|Patients' parents' inclusion criteria"", 'nasopharyngeal swabs', 'messenger ribonucleic acid', 'compensated', 'rapid sequence induction', 'first-line standard treatment', 'CT scan slice', 'umbilical artery end diastolic flow.|Diabetes', 'treatment of', 'hematopoietic stem cells', 'immunotherapy agent', 'parenteral iron infusion', 'refractive error', 'hormonal profile', 'small amounts of', 'visited', 'adjuvant therapy have recovered.|5)', 'hair growth procedures', 'donated a unit of blood', 'allogeneic organ transplantation|Active', 'complex procedure', 'compression therapy', 'palliated', 'Continuous sedation', 'hypnotic therapy', 'anatomical resection of the lung (lobectomy', 'Trometamol', 'pelvic floor surgery', 'Receipt of transfusion of blood products', 'conceive before', 'line scoring', 'anti-infective therapy.|Patients', 'scientists', 'ECG leads.|Hemodynamic instability (SBP >220 or <80', 'cardioangioplasty', 'infertility surgery', 'Bicuspid aortic valve.|LV systolic dysfunction', 'soft tissue fixation of the shoulder', 'spinal anesthesia Morbid obesity(BMI>40', 'imaging balloons', 'coronary angioplasty', 'Electroconvulsive therapy', 'c-ros oncogene 1 (ROS1) fusions', 'medical attention;|size of head, neck', 'homologous PMA techniques|Age', 'IUD insertion', 'various organ', 'meniscus repair with', 'robotic procedure', 'mitral implantation', 'brain imaging after central nervous system', 'radical local treatment', 'gastric motility|Upper GI symptoms', 'ventilator assisted ventilation after endotracheal intubation;||(3', 'FFRCT', 'anticoagulant treatment', 'clinical laboratory test abnormalities', 'imaging modalities', 'standardized physical therapy', 'complete repair', 'allograft biopsy', 'invasive testing (amniocentesis', 'Professional hospital cleaners', 'nicotine addiction', 'actively participates', 'curative-intent', 'cholangioscopy', 'verbal communication disability (hearing and', 'tracheal intubation', 'mechanical ventilation||', 'TTP', 'said regimen', 'chemotherapy-induced', 'unequivocal cardiac sources of embolism', 'HER2 amplification', 'ASD closure device', 'childhood seizures.|History', 'for|Diagnostic colonoscopy', 'combined CABG', 'IOL Master biometry)|dioptric power of', 'T cell co-stimulation blockers', 'implant insertion', 'measures of lung function/inflammation', 'venous insufficiency.|Features of', 'gastric sleeve.||', 'years|Coronary artery bypass grafting', 'allergen desensitization therapy', 'MRI scanning:||The', 'various fusion partners', 'abdominal ultrasonography', 'mechanical ventilation|Hospitalization', 'enroll.|Pathological', 'parenteral chemotherapy', 'midazolam intervention', 'Intrathecal chemotherapy', 'ataxia', 'cytology.|Diagnosis', 'assisted reproductive technology (ART) treatment', 'activities of daily living', 'malabsorption syndrome|Prior treatment', 'abdominal computed tomography scan', 'transvaginal ultrasound findings', 'antifibrotic therapy', 'Polymerase Chain Reaction (PCR)', 'produce allergy', 'chemotherapy induction therapy', 'confirm hormone receptor status', 'abdominal imaging data.|Body mass index', 'adequate treatment', 'cosmetic therapy', 'screening procedures', 'plan"" categories', 'hand therapy', 'postoperative endocrine therapy', 'medical intervention', 'antibiotic therapy;|Clinically', 'fresh biopsy tumor tissue', 'lung perfusion', 'single antihypertensive medication;History', 'injection therapy', 'surgical procedures required', 'consistent exercise training)|Weight stable', '75-g oral glucose tolerance test', 'Hyalistil Bio PF treatment', 'regular oral montelukast', 'appendectomy', 'therapeutic antibody', 'corneal refractive laser surgery', 'fasting glycaemic target', 'non-hormonal moisturizers', 'sexual', 'PET/CT scanner qualification procedures', 'hormone replacement', 'open injury)|Intramedullary nail', 'treatment stimulation', 'MUGA scan assessed', 'hospitalization|Medically stable|Expected life expectancy', 'ventricular pacing percentage', 'situational prophylaxis', 'targeting', 'surgery;|palliative intent;|patients ineligible for', 'placement of a chest strap,|Person', 'chromosomal analysis', 'small molecule inhibitor.|History of', 'sedation medication||Exclusion', 'lenvatinib treatment', 'Emergency operation', 'T-DM1', 'transfemoral TAVI implantation scheduled', 'enzyme tests', 'antigen test', 'cardiological consultation', 'paraffin sections', 'prostetic heart valves', 'imaging diagnosis', 'study||Fecal Donor Inclusion Criteria:||A healthy donor', 'rapid influenza diagnostic test (RIDT)', 'baseline CT scan', 'urinalysis', 'Experimental Sessions', 'pyloroplasty', 'vertebral artery occlusion', 'single antihypertensive drugs', 'Stay Independent Brochure (', 'produce hepatic steatosis', 'RA treatment', 'radiation therapy-induced', 'clinical ASCVD', 'Autologous stem cell transplant', 'unilateral total knee arthroplasty||Exclusion Criteria||Patient refusal.|Major cardiopulmonary disorders|Uncontrolled', 'lymph node metastases|Availability', 'Twelve-lead electrocardiogram', 'Resonance Imaging (MRT) examination', 'standard first-line therapy', 'lipid-lowering medications required', 'gastric protection', 'lower blood glucose|Taking', 'hemorrhoidal bleed', 'systemetic therapy', 'WASID', 'stay locally', 'endoscopic biopsy|Cystic fibrosis|Hypothyroidism', 'lying around', 'emergency open-heart', 'Treponema pallidum antibody).|Creatine kinase (CK)', 'cardiopulmonary rehabilitation', 'liver transplantation', 'vision-impacting comorbidity', 'outpatient', 'sialolithiasis', 'Multiple Gated Acquisition Scan', 'CHD', 'PET scan', 'ophthalmologic exam', 'tracheostomy', 'cardiovascular procedure', 'blood thinners|Known hypersensitivity', 'primary knee arthroplasty', 'close relative).|Major surgery', 'pathology review', 'Clinical Coronary artery diseases|Heart failure', 'MRI scans.|Please', 'RTX induction', 'exercise testing', 'transfusion', 'iron therapy', 'vertebral column disorder|Chronic use', 'good organ function|Positive HER2 cell membrane', 'first-time caregiver', 'oral antidiabetic drugs', 'drug treatment', 'polymerase chain reaction (PCR) assay', 'emergency care admission', 'androgen deprivation therapy|Bilateral hip', 'intestinal repair', 'produce reliable', 'erythrocyte transfusions', 'rapid fluctuation of renal function', 'injection into the target knee joint of glucocorticoid', 'therapeutic education program', 'cisgender', 'AIH', 'therapy|Favorable for inclusion', 'tympanoplasty', 'venous access to allow collection of multiple blood samples.||Negative Covid PCR test upon', 'allogeneic stem cell transplantation.|Receiving any other investigational agents', 'acid suppressive therapy', 'TMJ steroid', 'systematic treatment', 'chemotherapy cycle', 'local regulatory requirements.||', 'open renal surgery', 'checkpoint therapy-related immune AEs', 'laparoscopic surgical procedures', 'oocyte picked', 'imaging studies|Prostate', 'externalized behavioral disorder(s):||running away', 'esophageal varices.||History', 'surgical sympathectomy', 'EIT', 'European guidelines (ESC)', 'magnetic resonance', 'early MMR vaccination', 'blood investigations', 'inguinal hernia treatment', 'vascular access catheter devices', 'ersons', 'regional lymph nodes', 'autologous hematopoietic stem cell transplantation (HSCT)', 'germline mutation in CDKN2A', 'GVHD', 't(4;14', 'fluoride therapy', 'ipsilateral lumpectomy', 'smokeless tobacco', 'bypass surgery', 'line of standard frontline therapy', 'Australia antigen)', 'EBUS', 'cardiovascular surgery', 'major surgery Surgical treatment;||Concomitant diseases', 'fibroscan measures', 'classical cesarean', 'lumbar catheter', 'total knee', 'NFS', 'isolated surgery', 'invasive examination', 'coronary artery bypass graft (CABG) surgery', 'agonist treatment', 'behavioral intervention', '2-hour plasma glucose', 'rare missense variant', 'left-sided breast cancer', 'separated', '6 months of Screening.|Any', 'antiretroviral therapy', 'small ASD)|Cardiac conduction defects - arrythmias', 'history|Diagnosis', 'exercise|smoking cigarettes', 'artificial tears.|Application', 'Incisional Hernia whit length', 'local MRI safety questionnaire', 'edentulous maxilla', 'AI therapy', 'keratoplasty', 'coronary angiography - this', 'wedge resection', 'gastric vessels)|Infiltrative tumors|Target vessel sizes', 'recent surgery', 'pelvic radiotherapy|TURP', 'percutaneous rhizotomy', 'baseline measurements||Exclusion', 'verbal pre-study drug screen', 'nasopharyngeal swab', 'polymerase chain reaction (PCR)', 'histopathologic', 'Institutional Review Board', 'blood', 'IUD)|Total hysterectomy', 'radiation oncology residents', 'neck|radiotherapy', 'anti-cancer therapy', 'rescue inhaler', 'MRI scan|Patients', 'abdominal CT scan of the liver', 'administered.|Major surgery', 'first-line therapy', 'WHOOP', 'World Health Organization) classification', 'vascular imaging', 'pacemaker implantation||Tilt test is recommended but not mandatory', 'serological test', 'facial lattice laser cosmetic;|(5', 'subscapularis repair', 'largest diameter', 'elective closed reduction of nasal bone fracture||', 'antipsychotic treatment', 'vaginal ring', 'anticancer therapies', 'Infertility surgery', 'stones', 'therapeutic procedure', 'psychotropic medications)|A', 'orthodontic treatment', 'standard therapy available||*', 'lung imaging shows', 'completed therapy', 'clear-headed', 'control pain', 'vital emergency room,|patient', 'posturography', 'protocol therapy', 'T-cell counts', 'glaucoma.|Previous treatment', 'Teens.|Serious medical condition.|Stage I', 'institutional level.||Major surgery', 'potential delivery of', 'bilateral ankle stabilization surgery.|Patients', 'Head Ratio - O/E', 'exercise testing per ATS', 'immunotherapy treatment', 'resection option', 'mechanical heart valve', 'radionuclide ventriculography', 'blood potassium', 'breast MRI', 'OR|Computed Tomography (CT) criterion', 'panic disorders.|Meets', 'complete cruciate ligament tear', 'conditioning', 'bile duct injury repair', 'home oxygen therapy', 'hysterectomized', 'allogeneic hematopoietic stem cell transplantation;|10', 'surgical sterilization', 'activities related to daily life', 'dental X-rays', 'coronary events|History of heart failure|Known diagnosis of', 'anterior circulation', 'optimal antihypertensive treatment', 'steroid therapy', 'vision problems|No uterine contraction', 'definitive fixation', 'pelvic radiation therapy|RECTAL CANCER', 'CT scan contrast premedication', 'intraprocedural Cone Beam CT', 'hepatic hilum', 'practice sexual abstinence', 'convulsion', 'refractive status.|Other reasons', 'GI bleed', 'genotyping', 'history)|Pacemaker|Congestive heart failure|Family history', 'blood testing/predictive', 'trastuzumab-emtansine', 'ulna|Surgical procedure done around', 'complete full course of FMT treatment;|the clinical', 'treatment||Body mass index', 'Structured Clinical Interview for DSM IV-TR', '0.75D|Corneal surgery', 'bone marrow hematopoietic function', 'orbital radiation therapy', 'urinalysis results', 'radio frequency ablation', 'supplementary oxygen', 'allogeneic organ', 'iodine DTC treated', 'spread glabellar lines', 'substantial support', 'ultrasonic circular cyclocoagulation [', 'allogeneic hematopoietic stem cell transplantation.|Participation in another clinical study', 'worsen', 'brain surgery|Ferromagnetic metal in head', 'graft-versus-host disease (GVHD)', 'radical treatment .|In', 'curative antiviral treatment', 'peripheral artery revascularization', '|Urine culture', '24-hour creatinine clearance', 'serologic test for HIV', 'CD20 expression', 'active extension', 'transdermal NTG patch', 'activities of daily living independently|They', 'clear-cell component', 'Polymerase Chain Reaction (PCR) in sputum', 'densitometric examination', 'medical attentions', 'annual contraceptive failure rate of', 'Radiofrequency Ablation', 'ablation surgical procedure', 'AV fistula creation', 'laboratory test investigation', 'applicable:||One chemotherapy', 'single operation have achieved', 'OIT treatment', 'Hauser Diary', 'Fugl-Meyer score', 'small incision lenticule extraction', 'anticancer treatment-related', 'birth control implant', 'mRNA therapy', 'pancreatic β-cell dysfunction', 'primary care', 'implant repair', 'cardiac procedure', 'Exercise Assessment', 'vaginal microecological improvement products', 'realistic expectations', 'CBCT imaging', 'antitumor treatment', 'therapy|Full passive ROMs', 'RE-entry program', 'covid process||Exclusion criteria:||Being a professional', 'psychotherapy treatment', 'target vessels', 'Gynecological laparotomy', 'surgery||', 'cigarettes', 'sitting position', 'pallidotomy', 'chimeric antigen receptor T cells (CAR)', 'transcatheter aortic valve replacement', 'chemotherapy for cancer', 'future dialysis access creation', 'luteinizing hormone releasing hormone (LH-RH', 'brain MRI screening.|Subjects', 'contraceptive gels', 'knee extension/flexion)', 'percutaneous coronary angiography', 'standard of care creatinine', 'dreadlocks', 'intensive care unit (ICU)', 'trauma-focused therapy', 'ovarian surgery', 'overlay restoration', 'FEV1 percent predicted', 'B-cell lymphoma.|Patient', 'lipid-regulation therapy', 'knee replacement|severe hip', '/sensitivities', 'positron emission tomography (PET)', ""pathological assessment.|Paget's disease of the nipple.|Synchronous"", 'time-dependent', 'intra articular injection', 'blood vessels', 'Developmental Assessment of Young Children', 'target the first year of exiting homelessness', 'emergency situation', 'left ventricular assist device', 'normothermic regional perfusion', 'Biochemical test', 'E. Coli infection', 'ECP treatment', 'antibiotic therapy', 'Chemotherapy-induced', 'first-line regimen containing immune checkpoint inhibitor therapy.|the best outcome', 'Extended-Release Narcotics', 'immunotherapy drugs', 'free gingival graft', 'phototherapy', 'gastric/bariatric', 'first dose of study treatment]).||Hemoglobin', 'Combination therapy', 'Orthopaedic surgeries', 'food dye', '1 full cycle', 'prosthetic restoration', 'internal carotid artery', 'open surgical repair', 'neoadjuvant therapy', 'Peritoneal Carcinomatosis Index (PCI)', 'rapid blood transfusion', 'vascular access method', 'thymic surgery', 'preoperative', 'intraocular bleed', 'vestibulectomy', 'insufficient', 'screening', 'adjuvant treatment standard', 'Magnetic Resonance Cholangiopancreatography [MRCP]', 'hydration', 'and-6.00D);|Best corrected vision', 'operation.|Pregnancy.|Radiation therapy', 'standard treatments', 'implant prosthetic part|Smokers|pregnancy', 'Cardiogenic shock|Current hospitalization', 'interventional study.|Involvement', 'Global Initiative for Chronic Obstructive Lung Disease (GOLD)', 'renal biopsy', 'Screening.|Positive PCR test for SARS-CoV-2', 'checkpoint inhibitor therapy', 'test procedure', 'chemotherapy plus', 'implant surgery', 'daily morphine milligram equivalents', 'surgical sterilization of the woman', 'alternative methods', 'dislocation.|Previous surgery', 'histopathologically', 'extracorporeal organ support||', 'allergen immunotherapy', 'pneumonectomy', 'recognized risk of gastrointestinal perforation', 'Percutaneous Coronary Intervention (PCI)', 'PET-MF', 'food frequency protocol', 'topical treatment/product', 'abdominal wound vac)|Patients', 'physician.|Colonic CT findings', 'oral rescue therapy', 'focused ultrasound', 'brain CT/MRI', 'internal fixation', 'prolotherapy', 'rotational atherectomy', 'Blood biochemistry', 'left heart valve surgery', 'Mini-Mental Status Examination', 'Quality Index (MQI)|No low MQI', 'diagnosis|Current', 'genitourinary surgery', 'CPAP therapy', 'antihypertensive therapy', 'interventional embolization of aneurysm', 'TPFLA surgery', 'Fresh biopsy pre-treatment', 'bone marrow function|Patients', 'brain imaging abnormalities|History of', 'Umbilical artery pulsatility index', 'examinations.||Angiographic', 'B-ultrasound examination', 'adrenocorticotropic hormone (ACTH) stimulation', 'elective surgical procedures', 'healthcareworkers', 'TNFi)-exposed for HS.|For biologic naïve', 'local treatment|Psychological, familial', 'Gorno-Tempini', 'bone surgery', 'chest CT examination', 'pelvic contrast-enhanced CT', 'standard practice involves medical team members asking', 'detoxication therapy', 'small percentage of NETs', 'complete medical record', 'health reasons.)|Be', 'physical contraception', 'combined procedure', 'conventional imaging. Initial treatment may include', 'clinical anterior instability', 'quality of the data.||-', 'local regulations.|Participants', 'syphilitic patients;|Uncontrolled blood pressure', 'local injection', 'hernia surgery', 'traditional diagnostic imaging (CT', 'stent implantation', 'oral antiviral agent', 'antipsychotics)|Current UTI', 'gels', 'screening:||Mean resting corrected QT interval', 'BIA', 'brachytherapy', 'IPL', 'ASCVD recommendation', 'EBUS-TBNA', 'intracranial bleeding,|Those', 'DBD organ donors|DCD organ donations outside of Cambridge University Hospital|DCD donors', 'optimal antihypertensive treatment.|Stroke', 'arterial catheterization:||Known', 'ICD-10).|Fulfilling spirometric diagnostic', 'adjuvant hormone therapy', 'Student Risk Screening Scale-Externalizing.|receiving the majority of services in general education settings|in 3rd, 4th, or 5th grade level.||', 'internal radiation therapy', 'test drugs', '≥30%|Cervical spine imaging', 'baseline.|Not', 'Xofluza™', 'cell transplantation', 'restrictions', 'recreational drugs', 'polymerase chain reaction only may participate in this study.|Stage IV NSCLC', 'Sipuleucel-T (Provenge®', 'local laboratory assessment:||In-situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17', 'cognitive behavioral therapy (CBT)', 'local irradiation', 'mechanical MCS device', '1.0D|Previous corneal surgery', 'cryoplasty', 'Computerized tomography (CT) scan', 'alternative medical cause', 'specifically infusion reaction', 'sarcomeric HCM adult', 'total abdominal hysterectomy', 'thyroid surgery/ablation)|TSH', 'pregnancy test', 'criteria:||Alanine aminotransferase (ALT)', 'thyroid lobectomy', 'regular imaging of the brain', 'fluoride prophylaxis', 'fibromiyalgia', 'lumbar puncture;|Central nervous system metastasis', 'vericiguat', 'osseous lesions|History of', 'bile duct cancer', 'T cell histiocyte rich large B cell lymphoma', 'T-cell surface inhibitory receptor', 'regular antenatal check-ups；Pregnant', 'Intra-operatively|Intra-operative', 'sequelae|Upper limb amputation', 'digital subtraction angiography examination', 'World Health Organization (WHO) criteria', 'ABI examination', 'biopsy.|Kidney biopsy', 'radiotherapy', 'visits|Adequate hematologic function', 'combined hormones', 'metabolic control', 'stereotactic radiation therapy', 'full treatment cycle;|Patients', 'stem cell transplantation|Patients', 'photodynamic therapy', 'full details of', 'lung CT', 'clinical laboratory exam', 'radiotherapy.|Steroid therapy', 'ribociclib + ET', 'IDH mutation are excluded|Patients', 'SGA:||•', 'endovascular therapies', 'electrolyte abnormalities|medication non-compliance|uncontrolled', 'angioplasty', 'radiologic assessment', 'baseline screening test', 'TICS-M1', 'allogeneic tissue/solid organ transplant|Pregnant', 'bone health', 'android phone', 'pelvic organ prolapse.|Vaginal', 'hormone replacement therapy', 'induction regimen', 'metastasis|Candidate', 'Modification of Diet in Renal Disease (MDRD) formula', 'behavioral therapy', 'lumbar disc', 'poor control of diabetes', 'limb leads', 'blood cell growth factor', 'endoscopic ultrasonography', 'psychometric tests;||20', 'laser hair removal treatments', 'percutaneous BP', 'abuse|emergency', 'cell therapy|Prior treatment', 'Preoperative arterial oxygen partial pressure', 'e-mail access', 'regular electronic', 'local radiology assessment', 'abdominopelvic CT', 'hernia operation', 'mechanical GI obstruction|Radiation', 'cardiovascular events.||Exclusion', 'complete endoscopic obstruction', 'birth control patch', 'unilateral electrode placement||', 'endoscopic techniques|Life expectancy', 'major scars|Unable', 'Athletic Sleep Screening Questionnaire""||', 'physical aggression', 'immunosuppression therapy', 'lateral deltoid region', 'endoscopy', 'radiopharmaceutical therapy', 'thermal laser', 'preoperative examination|Patients deemed by the clinical investigator because', 'excisional biopsy|previous axillary surgery|failure', 'surgically corrected', 'F-HIFU treatment', 'fetoscopic surgery', 'blood product transfusion', 'emergency neurosurgical intervention', 'DME', 'amount', 'systemic oncological treatment', 'oxygen', 'medium chain triglyceride', 'episodes of vaginal bleeding', 'informational meeting||', 'PRK surgery', 'segmentectomy', 'preoperative routine tests', 'revascularisation surgery', 'steroid pre-treatment', 'rhythm management system revision', 'open-heart surgery', 'esophageal gastric junction cancer;|Patients', 'liver transplant|Participation', 'intraocular inflammation;|Treatment', 'EVT', 'Pancreatic pseudocyst', 'IOS Device||', 'B-cell depleting therapies', 'small bowel resection', 'control of', 'chronic oral administration', 'interventional clinical trial.|Symptomatic CNS metastases', 'laser ablation', 'androgen deprivation therapy (ADT)', 'recto-vaginal', 'TMZ concurrent radiochemotherapy', 'blood sample', 'Chemotherapy、radiotherapy', 'open wound|İnflammatory', 'surgery relating to the musculoskeletal system.|disorder related', 'DXA scan', 'arterial puncture', 'graft intervention', 'bladder diverticulum', 'peritoneal dialysis fluid', 'therapy|Antibiotic therapy', 'ultrasound scan', 'hematopoietic stimulator treatment', 'leukemic organ involvement.||', '24-hour urine collection of protein', 'pharmacologic intervention', 'allogeneic stem cell transplantation.|Patients', 'Oophorectomy', 'graft-versus-host therapy.|Treatment', 'kidney impairment.||Additional inclusion criterion', 'reconstruction.|Operation transfers', 'anemia).||Infant inclusionary criteria:||infants', 'cervical vagotomy', 'weeks|Contraindication', 'autologous bone marrow transplantation', 'oral isolated mandibular fracture fixation', 'ocular surgery', 'ketogenic supplements|Currently', 'DOTATATE scan', 'regiment of diabetes', 'lenalidomide dose adjustment', 'optic nerve organs', 'surgery related', 'hypoglycemia treatment', 'MRI safety criteria.|Body Mass Index (BMI)', 'reliable VF tests', 'bilateral oophorectomy or|hysterectomy', 'urine microscopy', 'radiological progression', 'HBV vaccination', 'ensure vaccination', 'pathological intra-partum course (e.g.,', 'NS', 'normal periapical radiograph', 'refractive medium turbidity', 'FGG procedure', 'sized compression garment', 'liver failure;|Easy', 'musculoskeletal structures in', 'corticosteroid treatment', 'adrenal replacement therapy', 'MINI|suicide risk', 'revision of polypectomies)|Incomplete examination', 'consent|Active treatment', 'HCV treatment', 'small therapeutic window|The patient does not take any drug or product', 'first generation androgen receptor antagonists', 'gall stones.|History', 'cerebrospinal fluid cytology', 'congenital cardiac surgery', 'dental implant site', 'immuno-oncologic agents', 'standard adult', 'palliative intent', 'US territories', 'electrical medical device', 'aqua therapy', 'successful treatment of superficial bladder cancer', 'lateral localization', 'RNA vaccine', 'neurological disorders.|Pregnant', 'Italy', 'local health authority-approved testing methods', 'VIBe Scale)|Ongoing radiotherapy on the wound', 'palliative treatment.|Pregnant', 'smartphone capable of', 'psychosocial intervention targeting similar', 'light-chain amyloid deposition', 'chest CT|Duration of illness ranged', 'consolidation treatment', 'salvage radiation therapy', 'chest CT scan.|Patients', 'quality endoscopic', 'arthroscopic surgery', 'sport injury|participated', 'sacrocolpopexy|Desires surgical treatment', 'local radiotherapy', 'TB tests', 'spinal MRI|Life expectancy', 'systemic chemotherapy treatment', 'Criteria:||- European experts', 'PD-1 treatment progression', 'imaging collected', 'coronary artery disease||', 'reproducible reactions', 'IVUS', 'spherical refractive error', 'Treatment Expert', 'HCQ', 'vascular surgeons', 'skin prick tests', 'pharmacological visceral hyperalgesia.||Patients', 'intra-arterial thrombolytics', 'season', 'major abdominal surgery', 'open AAA repair with', 'prenatal ultrasound', 'EGFR', 'therapy|History of Human Immunodeficiency Virus (HIV)', 'oral nutritional supplement|Anyone', 'physiological substitutive doses', 'capnography', 'screening|Regular alcohol consumption', 'standard Cognitive-Behavioral Therapy', 'herniotomy', 'ARV therapies subsequently', 'palliative local treatment', 'allogenic stem-cell', 'AIDS).|Has', 'participation|Absolute neutrophil count (', 'modification of diet in renal disease (MDRD) equation', 'vascular access thrombosis', 'Tissue blocks', 'surgical sterilization procedure', 'pancreaticojejunal mucosa anastomosis', 'intracranial lesions|history of head trauma resulting', 'pathological reports', 'endoscopic assessment of the larynx', 'conventional oxygen therapy', 'chest scan', 'therapeutic intent', 'laid down', 'inpatient surgery', 'Bicuspid Aortic Valve not clearly', 'quit CC|Change', 'growth of the soft tissues).|Willing to follow all study procedures', 'Modification of Diet in Renal Disease (MDRD) formula or CKD-EPI', 'SD-OCT examinations', 'pelvic X-ray.||Control', 'medical situation', 'remote angiographic control', 'special dietary requirement', 'initiate medical therapy', 'common foods|require total parenteral nutrion|blood dyscrasia', '|(3', 'imlifidase|IVIg treatment', 'palliative treatment', 'thorax surgery', 'gastric fluid anti-parietal cell antibodies', 'locoregional treatment sites', 'imaging studies', 'allogeneic blood', 'medulla oblongata', 'chimeric antigen receptor T-cell (', 'blood cell transfusion', 'successive screening measures|Any clinically important abnormalities', 'emergency contraception', 'common aeroallergen|Methacholine', 'embryo-lethality', 'Prolonged QTc', 'clinical laboratory results', 'venetoclax treatment', 'minimum temporal resolution', 'Rascovsky criteria)17', 'betaine supplementation', 're-booked for provocation days', 'catheter angiography', 'prophylactic therapy', 'cecal intubation', 'gynecologic surgical procedure', 'chest CT scan.||NOTE', 'clinical laboratory requirements:||Creatinine clearance', 'FDG PET/CT', 'Endoscopic Ultrasound [EUS]', 'Leptomeningeal involvement;|CNS complications', 'bilobectomy', 'valve intervention', 'endoscopic residual tumor after a maximal TURBt', 'apneas/hypopneas', 'DBS surgery)|Surgery', 'Injections', 'duplex ultrasonography', 'steroid therapy|Is', 'distant flap reconstruction.|Inability', 'kidney biopsy results', 'lesion|In-stent restenosis|Side branch lesion|Chronic total', 'ventilation', 'materials|Nonsmoker|Caries free||', 'ultrasound testing', 'endocorporeal laser lithotripsy|using a reference laser (Holmium:', 'hemodynamic monitoring with the Starling monitor', 'pelvic organ prolapse|Indication', 'stent graft components', 'Global Deterioration Score', 'Echocardiogram', 'expected corrected', 'special education can', 'consultation dating', 'MRI', 'hair transplant', 'individuals|Regular cannabis', 'reported', 'PCR)/next-generation sequencing (NGS)', 'endoscopic mucosal resection|ERCP', 'opiates|Pregnancy|Emergency surgery', 'video-assisted thoracoscopic - (VATS)', 'region of the cornea|A sum corneal', 'risk|High surgical risk', 'chronic fatigue syndrome.|A complication', 'tibial nerve stimulation', 'temporal artery biopsy result|Concurrent', 'PET imaging|PSA', 'standard tapering of 1 mg/kg', 'transurethral prostate resection', 'definitive radiation therapy', 'urogynecological surgery', 'before surgery', 'pancolonic chromoendoscopy', 'progression (CT confirmed', 'sedative action', 'prepuce', 'DIY-AID system', 'PENTO', 'transcatheter arterial chemoembolization (TACE or TAE', 'B-cell', 'pelvic organ', 'Emergency Room [ER]', 'HPV vaccine', 'mechanically ventilated phase of ICU admission||', 'local investigator|For PRRT substudy', 'LF-MRI', 'itch.|Previous treatment', 'graft procedures|good general health|willing', 'Technical Experts only)|Does', 'surgery|Endoscopic resectable gastric cancer', 'aside', 'first dose of study treatment]).|Serum total bilirubin', 'total ovariectomy', 'palliation ≤7 days prior to starting study drug', 'supplemental oral calcium treatment', 'analgesic injection intervention', 'lower limb amputation', 'heart transplantation|Left ventricular ejection fraction', 'pelvic radiation|History', 'self-test themselves', 'periapical x-ray|No', 'chimeric antigen receptor T-Cell(CAR-T) immunotherapy', 'CT completed', 'local investigator', 'Admission', 'CT scan pretherapy', 'vascular perfusion of the target limb', 'oral cashew immunotherapy', 'lactation|acute coronary artery disease|use of hormonal contraception', 'vaginal contraceptive ring', 'neo)adjuvant therapy', 'allogeneic stem cell transplant.|RECIPIENT', 'injection sites|Any surgery scheduled', 'Postoperative surgical histology', 'Local replacement steroids', 'brain irradiation', '12-month', 'cardiac hospitalization', 'control pleural effusion', 'bone metastasis', 'Idiophatic Parkinson Disease||H&Y stage I', 'immunotherapy;|Weak treatment', 'palliative therapy|localized non-metastatic', 'open tibia', 'complete insertion of the electrode array.|Diagnosis', 'MRI|Patients', 'echocardiogram', 'bariatric bypass surgery', 'evaluation;|Abnormal', 'therapies', 'X-ray).|Patient', 'neuroimaging techniques', 'T-ALL', 'dental hygiene prophylaxis', 'B cell targeted therapy', 'MR angiography', 'facial laser therapy', 'R0 resection CANNOT', 'sexual therapy', 'LOAPT', 'inguinal hernia', 'liver biopsy histology', 'since surgical resection', 'Roux-en-Y gastric bypass', 'B-cell depletion therapy', 'holding', 'gastric surgery|Major systemic diseases|Pregnancy', 'hospital stay', 'iteria:||Maternal pre-pregnancy BMI', 'share CGM', 'voluntary blood donation', 'test reports', 'conditions resulting in immune compromise', 'sample of adolescents between', 'PET/CT scan', 'Holter monitor', 'RASopathy||', 'ICU', 'testing of FSH levels', 'ABC sinus augmentation', 'stent design.|Target lesion', 'home oxygen', 'B-cell lymphoma types', 'bilateral ovariectomy surgery.|Patients', 'remaining', 'neurological examination -||Exclusion Criteria', 'partial amputation', 're-treated', 'mitral valve surgery|Patients', 'tecar therapy', 'enterectomy', 'rectum;|Radical surgery', 'medical illness|Autism Spectrum Disorder|Comorbid alcohol', 'tracheosthomy', 'temperature', 'keloid formation', 'contrast imaging', 'SARS-CoV2 infection', 'Local therapy', 'vital signs', 'nasopharyngeal swab tests', 'VEGF TKI treatment', 'depression screening result', 'ultrasound examination', 'real-time cine imaging', 'cytological examination', 'electrolyte supplementation)|Clinically significant', 'cognitive function tests', 'treatment for', 'graft versus host disease.|The', 'IVUS examination suggests severe calcified lesions', 'ART restart criterion', 'first dose of study treatment]).||* Criterion', 'valvuloplasty', 'rapid antigen test', 'major head trauma|Intracranial lesion|Cardiovascular disorders', 'standard screening tool', 'conventional lifestyle intervention', 'adrenal replacement steroid doses', 'viral control', 'biological sex', 'begin treatment', 'planned surgery', 'low dose chemotherapy', 'primary treatment', 'assessment|Intracardiac lead', 'great saphenous vein', 'pegvaliase treatment', 'islet cell transplant', 'functional peritoneal dialysis catheter.|Patients', 'European League', 'primary reverse total shoulder arthroplasty', 'pre-hospital care from the emergency medical services 83 (', 'resolve GI symptoms', 'pathological biopsy', 'DNA testing.|Antiviral prophylaxis', 'criteria:||Absolute neutrophil count', 'kidney graft after renal transplantation', 'FMSE', 'T-cell costimulatory agents', 'laboratory examination', 'corrective therapy drugs', 'epidemiology collaboration', 'protocol treatment', 'Anticancer therapy', 'ASMs|Provision', 'robot-assisted radical', 'surgery.||Exclusion criteria||Other causes', 'February 2022||', 'MRI safety criteria.|Left handedness', 'small molecule targeted drugs', 'bronchoscopic procedure', 'finger prick blood', 'antitumour therapy', 'fear conditioning paradigm', 'bile duct drainage', 'chronic lung condition|Speaks', 'Alternative therapy', 'lateral radiographs|Femoral anteversion', 'inguinal hernia repair surgery', 'Global Assessment (sPGA)', 'standard therapies', 'clinical relevance|History of any of the following conditions:|Myocardial infarction', 'introduction of antidepressants', '75g anhydrous glucose dose', 'complete restaging TURBT to confirm absence', '≥6 months.|A mini mental state examination (MMSE)', 'hypodontia', 'postoperative imaging studies.|Willingness', 'interventional clinical study follow-up|Persons', 'progestins.|Abnormal transvaginal ultrasound', 'pint of blood', 'CT-contrast.|PCSK9-inhibitor treatment|Life expectancy', 'focal uterine lesion', 'cerebrovascular disease||', 'benralizumab treatment', 'subsequent standard treatment regimen.|Previous histopathologic', 'done structured physical activity programs', 'chest computed tomogram (CT)|History of', 'trauma-focused group', 'trauma of the cervical spine|Non-cooperative', 'power analysis', 'medical oncology residents', 'TOP-Mini', 'synthetic implantation', 'fractures;|Previous organ transplantation', 'Good Clinical Practice', 'general anesthetic||Exclusion Criteria:Caregivers (study participants', 'first trimetric', 'chronic anticoagulant therapy', 'done plastic surgery', 'neurotoxin treatment', 'HFNC', 'complete.|Blood biochemical indicators', 'outpatient care', 'salvage treatment', 'open cystectomy', 'Functional Ambulation Categories (FAC)', 'cesarean delivery|Signed', 'small-molecule targeted therapy<2 weeks', 'special', 'EMA', 'Systematic Coronary Risk Evaluation (SCORE2) algorithm', 'period.**||*Including vaccine', 'invasive ventilatory therapy', 'chest CT scan evaluation', 'primary knee arthroscopy', 'bispectral index monitoring;|ASA score', 'chest high resolution CT scan', 'MMD reduction', 'Plasma-Lyte® 148 are considered appropriate fluids|Blood glucose level', 'standard treatment plan', 'vaginal delivery', 'clear cell subtypes', 'adrenal replacement doses', 'full blood count', 'clinical imaging', 'allogeneic hematopoietic stem cell transplantation.|Existence', 'antihypertensive drugs;|Vaginal reconstruction', 'Revibe Connect', 'Sleeve gastrectomy', 'tumor surgical treatment', 'standard treatment after cataract surgery', 'oral contraception', 'Lumbar Disc Herniation surgery', 'topical eye medication', 'cutaneous GvHD|History', 'intravenous infusion', 'active chemotherapy', 'immunomodulatory medications', 'accepted method of birth control', 'meal size', 'open-label Phase', 'intraocular metal', 'tobacco cessation program', 'pelvic location', 'preoperative cone beam computed tomography', 'chest x-ray', 'Hormone-replacement therapy', 'diseases.|Alanine aminotransferase (ALT)', 'primary unilateral TKA|Patients', 'expert reports', 'immunohistochemistry test result', 'Histologic types of carcinoma', '1)The anesthesia', 'intranasal examination', 'heart transplantation physical therapy course in a Physical therapy', 'SF3B1 mutation', 'SNG', 'radiofrequency cautery', 'cladribine tablet initiation', 'intestinal resection', 'subsequent treatment cessation', 'systemic immunomodulatory therapy', 'orthopedic surgery', 'scalp procedures', 'biological therapy', 'shooting', 'control leukocytosis', 'complete MRI)||', 'GCA', 'frozen blastocyst transfer.|Maternal', 'magnetic resonance imaging (MRI)', 'cardiovascular disease.|May', 'PUVA therapy', 'weeks|Neonates', 'while others', 'allogenic stem-cell transplantation.|Major surgery ≤28 days prior', 'technical data sheet): Hypersensitivity', 'Nordic Nutrition Recommendations||', 'capecitabine.|Previous treatment regimens', 'adjuvant vaccines', 'value);|Normal physical examination', 'parasitological Giemsa-stained direct smears.|Acute lesions of', 'cytology', 'alcohol', 'unchanged antidiabetic therapy', 'U.S. Air Force School of Aerospace Medicine', 'Intensive Care Unit admission', 'vertebrobasilar insufficiency 3.Cervical spine', 'hemorrhage)|separation', 'recurrent advanced head', 'and|Luteinizing hormone', 'first cycle', 'cognitive behavior therapy', 'die||', 'anthracycline therapy', 'simple declaration', 'General Procedures', 'GAP', 'primary vaccination series', 'chemo-therapy', 'Composite International Diagnostic Interview|Willing and able to provide full informed consent|Responds', 'leukemic organ involvement.|Renal function', 'allogeneic tissue/solid organ transplant|A WOCBP', 'anemia treatments', 'laryngoscopy', 'focal cortical siderosis', 'vitamin B12 supplementation', 'R1 resections);|Patients', 'Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ)', 'electrocardiogram (ECG)', 'cysts', 'partial sternotomy|Surgery', 'dynamic ECG', 'transurethral angiography', 'myeloablative allogeneic HCT.|Overt stroke', 'Schwartz formula);|Without', 'impossible intubation criteria:||Mallampati', 'medical treatment every', 'Plasma AADC activity', 'colorectal procedure', 'surgical incision', '|glomerular filtration rate eGFR', 'mini-mental test', 'Asthma Control Questionnaire-7 (ACQ-7) Score', 'liver lesions|Planned simultaneous resection of', 'implant restoration', 'medical exam', 'etc|Patients', 'ICD therapy', 'sugar substitute products', 'plasma derivatives', 'ethics board', 'physical therapy/rehabilitation', 'simple suture procedures', 'multigated acquisition', 'interruptions', 'Caesarean mode of delivery can', 'IIA2-IVA stage', 'cell phone', 'Neoadjuvant therapy', 'health insurance|GERD', 'lesser tuberosity osteotomy', 'rapid kidney function', 'position change', 'delayed thromboprophylaxis', 'Harris Health Hospital ED', 'Amuru distric in Uganda|providers at HCIIIs', 'chronic systemic treatment', 'design simplification', 'military sexual trauma.|Between the', 'complete remission', 'local therapy should', 'induction', 'rTMS intervention;|2', 'cardiac rehabilitation', 'onset of central nervous system diseases', 'local puncture', 'bpm)|Previous LVAD implantation', 'Spontaneous Coronary Artery Dissection', 'report||', 'dialysis treatment', 'open-ended', 'prednisone|Indication', 'Ultrasound shoving steatosis', 'Intensive Care Unit (ICU) indication', 'Rescue Specialist Educational', 'a:||Patients', 'prostatic urethral length', 'erythropoietin|Major surgery', 'Cysts', 'AAA617 treatment', 'transthoracic echocardiogram studies not able', 'IL-15 agonists;|Participant', 'major surgical treatment', 'open gastrectomy', 'hepatoprotective therapy', 'partner vasectomy', 'cataract extraction', 'cytologic analysis', 'inflammation|Current treatment', 'sacral neuromodulation (SNM)', 'Pancreatoduodenectomy', 'Hysterectomy', 'visited their transplant specialist', 'hip flexion', '10 days|Participation in another trial aimed', 'open Ivor Lewis esophagectomy', 'neuroendocrine differentiation of', 'palliation of symptoms', 'pelvic radiation therapy', 'peritoneal dialysis.|History of', 'stent planned', 'sleep diary', 'copy of the Phe508del mutation.|Healthy volunteers', 'endoscopic palliation', 'palliative radiation therapy', 'plain x-ray', 'biopsies', 'practice guidelines.|Patients', 'duplex', 'heart valve surgery', 'clinical laboratory examination;|Uncompensated hemodynamical failure', 'complaint of memory loss|scoring', 'experimental typhoid vaccine', 'radiotherapy|Unable to undergo a', 'normal sex hormone levels', 'lateral scapular slide', 'transthoracic echocardiography|Written informed consent||', 'chemotherapy treatment ongoing|Patients', 'Spinal surgery', 'teratogenic study drug', 'keratotomy', 'bifurcation', 'brain magnetic resonance imaging', 'India', 'allogeneic stem cell transplant', 'deep sedation', 'psychiatric care||1-', 'tobacco user||', 'renal organ function laboratory values', 'brain stimulation', 'volume control', 'cognitive function.|Chemotherapy', 'axillary lymph node', 'R0.|Insufficient liver reserve function', 'nasal septum deviation', 'therapy;|Chemotherapy', 'radiology residents employed by', 'DMT intervention', 'vaginal speculum examination', 'AHOD1331 therapy', 'Botulinum toxin treatment', 'postoperative invasive', 'lipid-rich', 'cardiac resynchronisation', 'donated blood', 'supplemental oxygen||Women', 'psychological rehabilitation therapy', 'Magnetic resonance imaging', 'mainly intranasal steroid spray', 'IVF cycle', 'fear of cancer recurrence inventory (FCRI)|have a', 'corrected vision', 'Hospital', 'radiation therapy|Known severe', 'psychiatric outpatient', 'systemic application', 'target knee refractory', '75mg acetylsalicylic acid', 'Jugular access of the Steerable Catheter with', 'protocol requirements.||Solid tumors', 'standard ultrasound', 'neoadjuvant chemotherapy|Contraindications', 'febrile neutropenia|Persistent fever', 'admitted', 'Study A)|Taking', 'Transrectal prostate ultrasound', 'World Health Organization criteria);|Diagnosed with LANPC', 'rapid delivery,|Contraindication', 'urine dipstick.|Diagnosed medical condition', 'hormone replacement therapy (HRT)', 'chemoimmunotherapy regimens', 'Primary immunization', 'centrally read MRI', 'PleurX', 'biological drug therapy', 'penile biological vibration threshold test suggesting', 'Graft versus host disease', 'liver tests', 'Arterial oxygen saturation (', 'liquid nitrogen', 'rubber band ligation', 'cranial fractures|Pregnant', 'pelvic organs prolapse', 'venous access to allow collection of blood samples||', 'chest imaging (X ray', 'cardiopulmonary testing', 'dialysis)|Major surgery', 'vessel|Bifurcation', 'HIV treatment', 'infection|Osteoporosis|Osteomyelitis|Local burns|Recent failed intraosseous', 'surgical procedure takes', 'open heart surgery', 'pleural fluid cytology', 'trial|Previous treatment', 'complete urinalysis', 'contingency management', 'exercise therapy', 'TB treatment', 'TUNEL assay', 'prosthetic socket|Soc Socket made', 'tunnel surgery', 'declarations', 'intrathecal chemotherapy', 'intraocular metallic', 'aesthetic rhinoplasty', 'several caesarean sections', 'head or neck surgery', 'anti-tumor therapies', 'Dialysis treatment', 'standard testing||', 'Structured Clinical Interview for DSM-5, Research Version (SCID-5-RV)|Heavy alcohol consumption', 'DEXA', 'substitute decision maker is able to provide written informed consent to participate in the study||', 'minutes9', 'donation of blood', 'laser prostatectomy', 'induration', 'corneal spherical aberration', 'oral semaglutide', 'health care workers', 'transfemoral TAVI|Emergent TAVI|Noncardiovascular comorbidity reducing life expectancy', 'resumption of treatment', 'Musculoskeletal injury|Dietary supplements|Medication|Allergy', 'rheumatological diseases||Non-plaque psoriasis|Rheumatoid arthritis|Osteoarthritis|Gout|Reactive arthritis|Ankylosing spondylitis|Axial spondyloarthritis|Enteropathic arthritis|Plantar fasciitis|Systemic lupus erythematosus', 'brace treatment', 'regular marijuana user', 'retroviral therapy', 'enteral nutrition', 'standard of care therapy', 'Biochemical tests', 'sepsis|Coagulation function', 'have:||read the Informed Assent|been given', 'optimal medical therapy)||Evidence of following cardiovascular disease', 'knee OA', 'HBV reactivation every', 'screening;|Acute metabolic complications', 'Transcranial Magnetic stimulation (Transcranial Magnetic Stimulation (TMS)', 'palliative care', 'standard of care pregnancy test', 'bone marrow primordial cells', '12-lead ECG measurements', 'full study treatment period', 'temporal relationship of', 'willing', 'extracorporeal circulation|No coronary lesion|No peripheral arterial disease', 'trastuzumab treatment', 'emergent intervention', 'delayed treatment', 'non study fluid', 'CABG', 'tumor surgery', 'screening|Myocardial infarction', 'spine surgery|Acute', 'complete percutaneous revascularization;|ACS', 'technical reviews', 'online English proficiency test', 'facial surgery', 'procedures', 'prescription', 'surgical procedure.||', 'blackouts|Donation', 'copy of the IRB/IEC-approved', 'BTKi treatment', 'uncompensated organ failure', 'pathological test', 'ciliary body.|Prior eyelid', 'hormonal replacement therapy', 'Hormone replacement therapy', 'potentially curative therapy', 'β-carotene', 'steroid hormone', 'allogeneic hematopoietic cell transplantation', 'stay to undergo longitudinal microdialysis|Absolute neutrophil count (ANC)', 'Sitagliptin treatment', 'toric soft contact lenses', 'volumetric MRI', 'subtotal resection of their tumor and developed enlarging', 'standard treatment intolerant', 'lateral radiograph', 'bilateral adnexectomy', 'renal replacement therapy)|Body mass index', 'hyperprogression', 'cosmetic treatments', 'Migraine Screen Questionnaire||', 'rectal resection', 'Surgical Complication(s)|IOL', 'World Health Organization (WHO)|Deemed clinically appropriate', 'imaging quality.|Diagnosis', 'India.|Previous vaccination', 'nerve blocks|Excellent ultrasound', 'prophylactic antiviral treatment', 'chest pain)|Major cardiovascular event', 'liver function|Radiotherapy', 'ophthalmic imaging', 'Tezspire for the first time due to', 'antiviral medication', 'platelet infusion', 'denosumab).|Major surgery', 'Recruitment', 'Standard General Terminology', 'PET-CT|Medical comorbidities', 'consolidative local therapy', 'intense exercise', 'Routine', 'diagnostic robotic bronchoscopy', 'rehabilitative intervention', 'systematic chemotherapy', 'bone flap', 'abdominal surgery|Rectal', 'commitment therapy', 'hematopoietic system', 'prophylactic antibiotic coverage', 'ectropion', 'radiation-induced oophorectomy', 'small enough for the standard-of-care resection', 'SARS-CoV2) infection', 'technological equipment', 'Protected', 'ionized calcium', 'local anesthetics|Contraindication', 'EKG', 'customized exoskeletal orthosis|Unable', 'bladder onabotulinumtoxinA injection', 'Gem', 'adrenal insufficiency).|Have', 're-treatment', 'monitoring device inserted through the esophagus', 'diagnosis|White blood cell counts', 'venous cannulation', 'autologous stem-cell transplantation', 'intravesical BCG therapy|Systemic immunosuppressive therapy', 'ultraviolet B phototherapy', 'IDH1 mutation', 'salvage chemotherapy', 'health||', 'complete unilateral cleft lip(reach floor of the nose)||', 'treatment.|Previous treatment', 'hard liquor', 'gastric varices;|Need puncture', 'ocular injections', 'restorative treatment.|Children', 'pretreatment endoscopic biopsies.||Clinical', 'emicizumab therapy', 'IB biopsy-proven', 'nucleoside reverse transcriptase inhibitors therapy', 'treatment for neck pain', 'remain on protocol therapy', 'pelvic surgery|Postpartum', 'outpatient hysteroscopy', 'anatomical deformity,|recent', 'Small Lymphocytic Lymphoma (SLL)', 'manifest refraction spherical equivalent (MRSE)', 'elementary school classroom teacher', 'occupational therapy treatment', 'transfusion of blood products', 'axicabtagene', 'fundus imaging', 'oropharyngeal swabs|Diagnosis', 'C-SSRS', 'brain metastasis.|Prior therapy', 'endometrial thickness', 'medical therapy|known severe', 'specific treatment', 'transplantations', 'homeless|Significant', 'corticosteroid therapy should', 'lobectomy', 'REALM-SF|Moderate', 'CSF-1R', 'DVT intervention', 'diagnostic x-rays', 'awakening phase.||', 'POLE mutation analysis', 'reduction procedure', 'chronic dialysis', 'hepatectomy procedures', 'UCMC clinics', 'small screen recreation', 'in situ hybridization (ISH)', 'Medical Conditions||corrected', 'target therapy', 'asubareolar breast lymphoscintigraphy injection', 'control twin', 'prescription being', 'infezione', 'laryngeal mask anesthesia|American society of anesthesiologists', 'domized', 'language therapy program', 'Structured Clinical Interview for DSM-5 - Research Version [SCID-5-RV]', 'cesarean scar|cesarean', 'video games', 'full physical examination', 'symptomatology related to MMS|Chest CT (after maximum 48 hours', 'reclining', 'RICU', 'gastrointestinal surgery.|History of', 'physician|Palliative care', 'delusional disorder|Onset', 'cephalometric', 'regular RBC transfusion', 'intestinal cleansing', 'Autism Diagnostic Observation Schedule-2 (', 'oral antiretroviral therapy (ART)', 'allogeneic tissue/solid organ transplant.|Patients', 'smoking cessation pharmacotherapy', 'combination antiretroviral therapy', 'transfusions', 'topic treatment', 'DNA repair gene', 'medical conditions|no', 'insufficient image quality', 'adequate contraception', 'YLWH', 'clinical laboratory test results not mentioned', 'pause treatment', 'SABR safely|Negative pregnancy test', 'archival biopsy', 'TKI therapy', 'brain metastases.||Is', ""placement of the CSI pVAD device|Subject's vasculature"", 'left magnetic material', 'Heart Pacemakers / Wires', 'rescue chemotherapy', 'molar restorations|gastroesophageal disorders|severe internal dental darkening|presence', 'neurological surgery|Previous application of CIMT', 'haemodialysis', 'panretinal laser photocoagulation in the study eye', 'scheduled procedures', 'psychotherapy||', 'small cell component.|Patient', 'biologic therapy', 'rehydration', 'first MACE', 'arthrodesis', 'EHR', 'renal transplant', 'psychosocial treatment', 'stent-assisted', 'drug treatment of hypertriglyceridemia;|Hypertension', 'major cardiac surgery', 'rehabilitation treatment', 'pharmacological treatments', 'assistive technology', 'graft-versus host disease', 'cognitive dysfunction|Combination of other pain conditions', 'cardiopulmonary stress test|Impossibility of prescribing', 'surgical procedure', 'congenital deformity|parents reject to attend', 'afternoon working time||', 'treatment|Palliative radiotherapy', 'mechanical circulatory support', 'TTP|At', 'physician|ROM restriction', 'Major cardiac surgery', 'cotinine test', 'squamous cell carcinoma;|Have', 'radiopharmaceutical injection', 'uterine surgery', 'biological analysis', 'artemisinin therapy', 'Refractive Surgery', 'compulsory secondary education', 'chest HRCT fibrotic', 'cancer treatment', 'removed', 'preoperative echocardiogram', 'histological variant', 'ACR 2016 criteria|Between', '|Patients', 'transient ischaemic attack|Carotid artery stenosis', 'small-molecule tyrosine kinase inhibitors', 'stent|Percutaneous surgical stone', 'cryosurgery', 'arterial monitorization||', 'small molecule targeted therapy<2 weeks', 'CCTA', 'laser treatment|Contraindication to the fundus imaging systems used in the study', 'digital substraction angiography', 'pharmacological androgen deprivation therapy', 'operative fixation', 'throughout', 'systematic immunomodulatory drugs', 'plain balloon', 'Ataxia-Telangiectasia', 'psychotropic medication|Insufficient German language skills', 'stem cell', 'GBS vaccine', 'computed tomography/magnetic resonance imaging (CT/MRI)|Patients', 'HIV transmission', 'complete periodontal treatment', 'weeks,|Tolerant', 'endocrine therapy change', 'standard migraine therapy', 'biological therapies', 'interventions|stationary accommodation', 'calibrated', 'therapeutic doses of', 'DFU', 'tactile temperature', 'Thoraco-abdominal aortic aneurysm', 'hormone treatments', 'investigators|Off systemic therapy', 'histological confirmation', 'immunization program', 'adnexal Myoma FIGO staging', 'peripheral revascularization', 'artificial tear sodium hyaluronate treatment', 'therapeutic ultrasound', 'tubal ligation/salpingectomy', 'lumbar fusion for fracture', ""QT corrected for heart rate by Fridericia's formula [QTcF"", 'Temporary resident', 'bone marrow dysfunction|Patients', 'talus|External fixation', 'surgical procedure||', 'transilial bone biopsy incision', 'placement of vascular access devices', 'vaginal estrogen treatment|Use of vaginal estrogen', 'lumbar puncture', 'immunotherapy-induced toxicities', 'metastatectomy', 'Elective surgery|Index of', 'allogeneic cell', 'radiological-guided', 'interbody fusion group', 'joint subluxation/dislocation|Severe degenerative', 'atherosclerotic disease.||iv', 'CMR examination', 'electrical stimulation', 'transanal-NOSES||patients', 'hEDS', 'subsequent chemotherapy;|Abnormal', 'abuse,|hysterectomy', 'diagnostic MRI', 'application|Aerobic exercise', 'fractional curettage||', 'radiotherapy fraction.||Completion', 'tyrosine kinase inhibitor.|Patients', 'GNB', 'laparoscopic procedures including', 'electrocardiogram (ECG) examination', 'ultrasound|uncertain fetal head', 'predicted.||Standard of care (SOC) therapy', 'small administrative unit in Ethiopia)|Pregnant', 'radiography', 'contrast brain MRI', 'extraction', 'trial|Leptomeningeal disease|Uncontrolled pleural effusion', 'rapid EEG', 'screening|Newly', 'conventional therapy', 'Holter', 'health screen', 'vaginal tears', 'HPV vaccine communication', 'laparoscopic-assisted gastrectomy|American Society of Anesthesiologists(ASA', 'periodontal pocket|Students', 'consumer tests', 'specially designed myopia control', 'surgical procedures ≤28 days of beginning study drug', 'health care', 'Cervical foraminal stenosis|Cervical central stenosis|Cervical disc herniation|Cervical spondylolisthesis|Prominent arm pain', 'light therapy|Psychiatric disorders|Cognitive decline|Working', 'unsuccessful implantations,|patients with', 'endodontic treatment', 'complete neuropsychological measures', '3D ultrasound', 'magnetic resonance imaging (MRI) scan', 'chronic steroid therapy.|Myocardial infarction', 'intraoperative opioid administration|Planned maintenance anesthesia', 'baseline CT', 'interventional radiologic procedure||', 'World Health Organization (WHO) classification system for tumors of the hematopoietic', 'preoperative ventilation', 'major surgical intervention', 'either:||Conventional flow cytometry', 'bilateral knee OA', 'knee osteoarthritis|Concussion', 'standard treatment.|ECOG≤2.|Expected survival period', 'BCL-2 inhibitor|Anticancer therapy', 'Laser therapy|Epilepsy|Anticoagulant therapy|Pacemaker|hemorrhagic diathesis|Photosensitizing drugs|Known Photosensibility|Neck', 'pharmacologic doses', 'intrathecal therapy', 'justification for its avoidance', 'Cesarean delivery', 'tissue biopsy after completion of CD19 targeted therapy', 'dermatological treatment', 'experimental treatment', 'pituitary hormone deficiencies', 'sex-steroid intake)|Antral follicular count (AFC) in both ovaries', 'World Health Organization classification of myeloid neoplasms', 'Standard multivitamin', 'SMN2 splicing', 'prevention treatment', 'NCT02893787)|Discontinued chemotherapy', 'x-ray', 'therapy|Bilateral cochlear', 'clear surgery', 'coronary computed tomography angiography before', 'Bedside Schwartz [Schwartz and Work, 2009]', 'vesico-vaginal fistula', 'intrathecal anesthesia', 'cranial surgeries', 'call centers', 'lower extremity salvage surgery||', 'signet ring cell carcinoma', 'standard-of-care neuroimaging', 'elective oral', 'therapeutic oral', 'unclamped renal tumor enucleation', 'target SpO2', 'allogeneic organ transplantation', 're-transplant.|Patients', 'prior stem cell transplant|Participation in other studies', 'CT of the neck', 'blood donation', 'Youth Readiness Intervention (YRI)', 'Chimney Technique', 'T cell therapy)||Alanine', 'regular controls|Pregnant', 'target vessel contains visible thrombus.|Pregnant', 'Cardiology', 'spermicide.||Effective from the first administration of atezolizumab', 'weeks;|Surgical procedures', 'anorectal manometry', 'β human chorionic gonadotropin [β-hCG]).||When', 'open pancreatoduodenectomy|Provided', 'commercial tests', 'endometrioid endometrial adenocarcinoma.||• Note', 'intra-arterial thrombolysis.|Detection of', 'blood chemistry test', 'MRI/ PET scan procedure', 'Probing', 'endoscopic procedures', 'previous corneal surgery', 'implant treatment||', 'sharp', 'periodontal support', 'GnRH agonist therapy', 'occupational therapy', 'sedative therapy', 'assisted vaginal delivery', 'regular endoscopic surveillance|Gastric localization of', 'adrenocortical hormone therapy', 'revascularisation procedure', 'imaging evaluation|Patients', 'chemotherapy infusion', 'T-VEC', 'treatment-Part 2', 'common carotid artery diameter range', 'nocturnal saturation study|Sleep apnea-hypopnea syndrome', 'allogeneic tissue/solid organ transplant|Known active central nervous system (CNS) metastases', 'Assessment Method score', 'health education intervention should', 'heart failure)|planned surgery', 'barrier methods of contraception', 'exercise stress test', 'admitted to intensive care unit', 'diagnostic coronary angiography', 'requirements||Baseline Characteristics||Healthy', 'European Neuromuscular Centre (ENMC)', 'MRI examination;|4', 'AWV', 'ASMs;|Previous treatment', 'Paxlovid', 'PET centre physician.||Known', 'strength exercise', 'laparoscopic cholecystectomy', 'systemic anticoagulation', 'endoscopic examination', 'live-virus vaccination', 'CAR- T therapy', 'vaginal delivery whether maternal', 'Friedericia', 'ESD procedure', 're-symptomatic', 'ecological momentary assessment application||', 'NCT NCT04297683).||', ""Centre d'Evaluation"", 'gynecological surgery|general', 'clear hyperdense opacities', 'anticancer treatments', 'emergency situation|Person of legal age under legal protection', 'electrical tracing', 'standard chemotherapy regiments', 'Claudin 18.2 targeting agent.|Prior therapy', 'versus-host disease.||Is', 'open biopsy', 'Cranial CT confirmed', 'tissue dysoxia', 'previous exam', 'pathological tissues', 'adjuvant therapy', 'general anesthesia|Is', 'gastric potential of hydrogen (pH)', 'Mini-Cog', 'blood stem cell transplant|Stroke', 'inclusive.|Normal laboratory tests', 'intraocular lens implantation', 'mechanical ventilation.||', 'interventional research|Preparation', 'implant procedure', 'fraxel laser therapy', 'surgical myectomy', 'RP-EBUS', 'urodynamics studies|Presence of', 'IP|Major surgery', 'transient elastography method', 'ocular hypotensive medication', 'wheat', 'CT contrast media.|Participant', 'cycloplegic autorefraction', 'regular opioid', 'iliofemoral vein(s', 'left-ventricular assist device', 'dental implant restorations', 'arthroscopic surgery.||', 'small molecule clearance method', 'quadrantectomy', 'pathologic examination', 'dialysis session', 'abdominal visceral', 'MRI scans', 'combination immuno therapy', 'index', 'lymphoma therapy', 'esophagogastroduodenoscopy', 'autologous stem cell transplant|Patient', 'chemoradiation', 'invasive medical device', 'Lean normoglycemic individuals:|Lean', 'cesarean section|Spontaneous start', 'Complete blood count', 'T-SPOT.TB test', 'medical condition|Abnormal potassium dosage (below 3.1 mmol/L', 'open reduction internal', 'line of treatment', 'blood routine', 'partial resection', 'Ayurvedic', 'assisted reproduction', 'Structured Clinical Interview for DSM-5|Have current depressive symptoms', 'non-hormonal barrier contraceptive method', 'Quantiferon result.|Patients', 'unilateral oophorectomy', 'individual intervention', 'heart blood', 'IDU', 'Activities Specific Balance Confidence scores|Demonstrate', 'computed tomography scan', 'hospice care', 'Cystoscopies', 'restricted range of motion', 'endoscopic ultrasound', 'coronary CT angiography', 'adequately treated|Allergen immunotherapy', 'Charcot-Marie-Tooth disease|Major surgery', 'partial nephrectomy', 'smartphone|Can regularly wear', 'adrenal replacement steroid', 'cytoreductive therapy', 'surgical treatment;|Preoperative cranial MRI', 'limits activities of daily living|LBP should', 'radiographic documentation', 'curettage', 'cervical disc surgery', 'basilar artery occlusion', 'standard logarithmic visual acuity chart', 'placement of transducer arrays|Patients', 'subsequent assessment of local reactogenicity.||Note', 'Cohort Only||•', 'heart valve surgery|Being transfer to service', 'autologous hamstring', 'reflex syncope||', 'treatment of radiotherapy', 'glucose-lowering', 'Intensive care unit', 'temporally interrupted', 'allogeneic tissue/solid', 'sacral neuromodulation device', 'meniscal repair surgery', 'knee arthroplasty', 'PYLARIFY PET', 'HLA matching', 'peripheral interventional procedure', 'quality spirometry', 'physiological dose', 'viral therapy', 'urine drug screen||Positive alcohol test.||Any consumption of citrus fruits', 'urine sample', 'Fibroscan', 'hiatal hernia', 'T-LGLL', 'treatments', 'Italian Ministry of Health list)|pregnancy-related disorder|frailty defined', 'histologic verification', 'upfront surgery', 'motivational enhancement therapy', 'treatment|History of', 'intracerebral hemorrhage.|Time from', 'test panel', 'haemodialysis treatments', 'ACTs', 'intraoperative blood transfusion', 'company magnetic resonance package', 'therapeutic radiation', 'Suppressive therapy', 'back surgery', 'transrectal ultrasound imaging', 'inhaled glucocorticoid therapy', 'germline variant', 'S768I mutation', 'Joint Commission', 'ACL-surgery|No', 'psychotropic drugs|History of', 'episode|insufficient comprehension of the Dutch language|physical', 'KRASG12C mutation', 'living donor renal transplant', 'sonohysterography', 'dose.|Montreal Cognitive Assessment (MOCA)', 'partial discectomy', 'remote management', 'drugs.|Pathologically suggested', 'lung cancer', 'urine safety tests', 'ATG', 'primary tumor reduction', 'mechanical ventilation.|start', 'intracytoplasmic sperm injection', 'behavioral treatment', 'implant reconstruction', 'spirometry quality', 'axillary lymph node cytology', 'lung transplantation', 'nonstudy anticancer therapy', 'VR HMD device|Participants', 'robotic-assisted rectal', 'total colonoscopy|Having', 'coronary artery bypass)||For Telerehabilitation group:||Internet connexion (computer or', 'treatment|Chronic treatment', 'Simple -Y abnormality can', '12 (twelve)', 'mothers;||Vaginal delivery planning,|Be', 'postoperative radiotherapy of the breast', 'complete resection of', 'p16 immunohistochemistry', 'rescue', 'HAV IgM Ab)', 'bone anabolic therapies', 'cryoablation catheter occurs', 'anatomic shoulder arthroplasty', 'p16 expression', 'Flow cytometry', 'about', 'metallic implant', 'gastric antiacids', 'smartphone model', 're-transplant', 'bowel resection', 'secondary cause', 'preoperative therapy', 'root;|Aortic valve replacement associated', 'revascularization', 'fluorescent in situ hybridization (FISH)', 'verbal explanations', 'radical resection of', 'intravitreal', 'health care professionals)|comorbid acute', 'general anesthesia', 'cesarean delivery .|Primi', 'standard protocols|Orthopedic surgical intervention', 'clear etiology;|Previous', 'cardiothoracic surgery or,|adipositas or,|granulomatosis', 'SRFcontralateral from PVA', 'graft versus host disease.|Active autoimmune disease', 'disease|Total bilirubin', 'nitrate therapy', 'finger prick measurements|In the judgement of the treating clinician critical care area', 'percutaneous coronary intervention|Patients', 'preoperative co-morbidities.|Provision', 'psychological treatment for CUD', 'transcranial doppler ultrasound', 'AGIR', 'instrumental activities of daily living', 'IP components;|Eye surgery', 'stent for intracranial aneurysm', 'Plan', 'standard care', 'peripheral blood', 'Global Impression Severity', 'effective birth control method2', 'obesity treatment', 'donate sperm.|General good health', 'emergency intervention', 'corrected visual acuity', 'suppressant therapy', 'living donor|Meets institutional criteria', 'chest CT', 'SCS implant', 'chest surgery', 're-testing for pregnancy', 'RSV MAT vaccine', 'elective surgery', 'invasive testing', 'medical therapy', 'Emergency Medicine postgraduate residency', 'revision', 'vaginal mesh implantation|Abnormal result', 'AHT therapy', 'correct', 'RHC data||', 'dental therapy', 'lateral elbow', 'intrauterine hormone-releasing system', 'repeat resection', 'ocular assessments', 'orbital radiotherapy', 'rheumatological disease||', 'medical nutritional treatment', 'percutaneous valvular intervention', '3D CT', 'Unilateral spatial', '2022|Endoscopic procedure', 'neurosurgical intervention', 'etc.)|Radiation Therapy', 'Effective contraceptive', 'enteral tube feed as part of nutritional management', 'Complex constructed', 'routine physical examination', 'lumbar puncture site|Taking', 'antiviral therapy;|Active HBV', 'plain imaging', 'conventional surgery', 'allogenic organ transplant', 'UGIB onset', 'excision of pilonidal sinus.|Location of the orifices should', 'supplements|Participated', 'vaccine vaccination', 'less anatomic derangement', 'transplanted', 'nerve root infiltrations||', 'cystectomy', 'contralateral knee', 'Rivermead Post Concussion Symptoms Questionnaire (RPQ).||', 'surgical operation restrictions', 'standard first-line', 'item 1.a of the NIHSS).|Patients', 'T cell engaging', 'routine laboratory tests', 'living donor combined kidney', 'CABG surgery', 'dystonia surgery', 'Bacille Calmette Guerin -vaccination', 'donation of blood product', 'vertebral body.|Chest CT performed', 'dose of', 'QI|Major surgery', 'circulatory arrest|Surgery', 'autologous bone marrow transplantation.|Significant', 'immunosuppressive therapy.|Pregnant', 'therapy of ACE inhibitor', 'MTAP', 'major organ transplantation', 'antianaphylactic treatment', 'health examination', 'transfemoral TAVR', 'total thyroidectomy', 'broncho-alveolar', 'standard of care', 'first dose of NM1F):||Any therapy', 'restriction regimen', 'interventional procedure', 'implant placement.|Unable', 'hold breath', 'pelvic physical therapy', 'pembrolizumab treatment', 'fundus examination', 'unsuitable for MRI follow-ups', 'ophthalmic examination', 'TED', 'gastric band', 'target arterial stenosis||', 'topical treatment', 'ionotropic support', 'biotherapy', 'suppose', 'dynamic magnetic resonance imaging (MRI)', 'orotracheal intubation||', 'bureaucratic officials', 'percutaneous nephrostomy', 'Coronary CTA(Coronary computed tomography', 'CT examinations|There', 'PTC drug sensitivity', 'baby', 'PET)/computed tomography (CT)', 'pharyngeal surgery', 'rehabilitative treatment', 'Cognitive Processing Therapy', 'major onco-surgey||', 'venous return|Ventricular septal defect', 'genetic testing', 'restricted access', 'ECMO', 'supportive measures', 'CSI)/whole ventricular irradiation', 'Youth Participants||Motor condition', 'line of therapy treated', 'local radical therapy', 'RF ablation system', 'cardiac resynchronisation therapy', 'blood neutrophil count (', 'endoscopic ultrasound).|No evidence', 'spinal root compression|Whiplash injuries|Cervical spinal stenosis|Having', 'antiretroviral therapy (ART)', 'standard CNVAMC ophthalmological examination.|The subject', 'surgical resection of the stomach', 'transfusion are permitted', 'EIT examination', 'pelvic MRI contrast + contrast', 'escalation of medical therapy', 'CT-imaging', 'IA injection', 'days).|Systemic chemotherapy', 'Frozen sperm source|Presence', 'seafood|Regular consumption of', 'common femoral', 'total hip arthroplasty||', 'adrenocorticotropic hormone (ACTH)', 'hormone Intra Uterine Device', 'thoracic surgery', 'IVCM|Decreased corneal', 'potentially curative surgery', 'allogeneic tissue/solid organ transplant', 'knee joint replacement', 'preservative|Treatment', 'small pupil||zonular dehiscence|preexisting corneal', 'organ transplantation', 'physiological replacement doses of hormone therapy', 'functional genioplasty', 'Enzyme Replacement Therapy', 'ovulation|Blastocyst embryo', 'vaccination.*||Acceptable contraception', 'surgical equipment', 'PCI', 'mechanical - spermicide', 'small changes', 'malabsorption syndrome|Had surgery', 'sleep-aid', 'First Hospital;|Complete baseline clinical', 'propofol|Tracheostomy|Supra-glottic', 'cytological assessment evaluations', 'Regional Hospital||', 'Chromaffin tumours', 'progression', 'total knee arthroplasty|4-6 weeks', 'Gastric Surgery Outpatient Clinic of HC-UFG;|Patients', 'bladder invasive procedure', 'intra-articular disorder;|Magnetic resonance imaging (', 'Prelabour', 'hormone therapy', 'infection|Receipt of blood products', 'corticosteroid prophylaxis', 'Rehabilitation Care institution', 'e-mail', 'tubal ligation', 'Fibroscan scan with', 'Syme amputation', 'therapeutic intervention', 'stress diagnosis|Symptoms are', 'First time', 'rectal primary tumor bleeding', 'Upper endoscopy', 'clinical care.|DFU is', 'vegetarian', 'fundus photography', 'medication therapy management.|Non-English', 'pelvic radiotherapy|Radiotherapy', 'ocular refractive anatomy', 'intrauterine', 'progression on therapy', 'palliative care|End', 'thalamotomy', 'acne rosacea', 'chest X-ray|Rales', 'Alternative therapies', 'regular tobacco', 'standardized screening questionnaire', 'Cl creat&gt', '12-lead electrocardiogram (', 'longest diameter', 'immunotherapy response assessment', 'contraceptive measures', 'cardiac medications', 'surgical incision healed well', 'chronic conditions|Lives', 'Elective cardiac surgery||', 'Signed', 'D2 lymph node dissection', 'Spine Disease||', 'ventilation support|Implanted stimulator', 'trace elements', 'radiological findings', 'lung function tests', 'mucosal biopsy', 'Chest X-ray', 'Section 13.1.2 Contraception', 'screening contrast brain MRI may still', 'periodontal surgery', 'endocrine therapy', 'endotracheal intubation.|Contraindication to', 'larger procedure', 'coronary intervention.|3', 'vaginal delivery|Fetal demise', 'vestibular schwannoma|Indication', 'cervical radiofrequency', 'infection|Living donor kidney recipient|Acute', 'excisional biopsy specimens', 'EHR records|Stable methadone', 'physical examination abnormality', 'gastrostomy', 'pons', 'GBS', 'structured exercise', 'e CXR', 'allogeneic stem cell transplantation|History of known', 'FLA regimen', 'cranial computerized tomography (CT) scan.|High-velocity', 'resulted', 'magnetic resonance imaging (MRI) studies', 'implantation', 'vertical root fracture|Teeth', 'cm.|Concurrent radiotherapy', 'sulphonylureas', 'Global Impression of', 'CSII therapy', 'implantation of left ventricular assist device', 'complete MRI scan', 'endoscopic treatment', 'arrhythmias|standard treatment', 'collateral circulation', 'oral hygiene|completion of orthodontic treatment|non smoker|Not working', 'injury|Previous physical therapy treatments|Joint instability|Frequent migraines|Spasmodic torticollis|Inflammatory rheumatic diseases|Peripheral nerve entrapment|Severe psychiatric illness|Pregnancy|Other conditions', 'ESA treatment', 'small-molecule targeted drugs', 'heart dose estimated', 'dialysis|Metastasized malignancy|Left', 'effective contraceptive tool', 'hair loss;|Inability to tolerate', 'coherence tomography (OCT)', 'ipsilateral percutaneous nephrolithotomy', 'pretreatment imaging', 'surgery (resection', 'recto-vaginal fistula|Previous anorectal posterior compartment', 'endovascular treatment', 'interventional clinical study|Treatment with another investigational drug', 'frequency ultrasound', 'small bowel surgery|Patients', 'exposition', 'Plasma cell', 'mental health treatment', 'Contraception', 'radiopharmaceutical preparation', 'See Study device', 'renal denervation|Renal artery stent|Polycystic kidney disease', 'intra-aortic balloon pump (IABP) therapy', 'behavioural variant FTD', 'endometrial cancer|Indication', 'supportive medical treatment', 'study-related activities', 'Assessment System (ICDAS) score', 'adjuvant aromatase inhibitor therapy', 'SOC chemotherapy', 'radionuclide', 'etc.);|regular anterior corneal astigmatism', 'stent delivery', 'STI testing', 'cognitive activities', 'centralised analysis of RAS', 'therapy for JIA', 'secondary treatment', 'CaHA)', 'standardized Giemsa microscopy.|Weighs', 'first psychotic episode', 'voluntary cough assessment (', 'restrict regimens to those mentioned in section on ARVs Antiretroviral Therapy or|The participant is ARV experienced', 'recto-sigmoid junction|Histological diagnosis', 'additional chemotherapy', 'surgery plus', 'Endocrine therapy', 'GAD-7', 'cancer chemotherapy', 'local surgical therapy', 'CT imaging||', 'Infantile Cerebral Palsy', 'complete questionnaire(s', 'STN stimulation', 'primary surgery', 'coronary artery bypass graft + valve repair/replacement', 'glucocorticoid containing medications', 'coronary intervention', 'tobacco product|Prisoners|Cannot consent', 'testing session', 'III|Laparoscopic abdominal surgery', 'EUS|endoscopic ultrasound', 'educational program', 'vaginal health index', 'hard exudation', 'cardiovascular interventional procedure', 'complete esophageal reconstruction', 'emergency', 'endoscopic procedures related to gallbladder resection', 'laboratory panel', 'excipients;|Prior treatment', 'usual care checks/clinical', 'correction', 'physical therapy examination', 'Neck Surgery & Audiology', 'radiofrequency ablation.|Concomitant coagulopathic state', 'endodontic treatment|increased inclination of the maxillary incisors towards the labial|the subject had', 'coronary angiography results', 'coronary artery bypass grafting (CABG)', 'B-scan', 'intervention-induced toxicity', 'coronary artery disease|prescription', '7.Re-entry device reach', 'caries risk assessment', 'FLC assay', 'immediate', 'unplanned surgery', 'patellofemoral joint loading activities', 'minus cylinder convention', 'anti-tumor therapy', 'lung imaging changes', 'Conservative treatment', 'health facilities (Aim 2)||For Aim 2, activity 4, investigators will enroll approximately 804 randomly selected', 'Structured Interview for', 'optimal medical management.|Active coronary artery disease', 'Spanish-speaking|Own a', 'axillary lymph node dissection', 'World Health Organisation', 'video recorded', 'e.g.brain stem lesions', 'vertebral artery disease|End stage renal disease', 'vital organ failure', 'autologous HSC infusion.|Participant', 'pathological fractures;|Poor control of', 'computed tomography using contrast agents', 'vital blood vessels', 'local surgical investigator', 'stress ball', 'receive radiotherapy', 'syndrome|diagnosis', 'sphicterotomy', 'blood work', 'resected HR-cSCC', 'therapeutic anticoagulant therapy', 'graft augmented prolapse', 'TMJ surgery', 'preoperative MR', 'general admission floor', 'first-line platinum-containing standard regimens', 'World Health Organization recurrent grade 2, 3 OD (IDH mutated', 'stress reduction techniques', 'standard Flow AML MRD assay.|Age', 'Fine Needle Biopsy (', 'medication|Planned treatment', 'Complete oral tolerance', 'hematopoietic function', 'Virological examination results (', 'maintenance ECT', 'allogeneic hematopoietic stem cell transplantation.|The patient', 'gastrointestinal endoscopy', 'laboratory results:||Absolute neutrophil count', 'conventional treatment', 'patients||Population', 'tibiofemoral OA', 'standard regimen', 'CAD||Coronary angiogram', 'clear margins', 'systemic steroid therapy', 'head CT', 'target therapy before.|Pregnancy tests', 'dose reduction of palbociclib', 'cardiac sympathicectomy|Having', 'EUS-guided hepatico-gastrotomy|Patient', 'bone disorder;|patients', 'ulcer)|Lower extremity amputation', 'hydrogen peroxide', 'assisted reproductive technology|Abnormal uterine arteries Doppler', 'medical monitor consultation', 'CS.|Previous major uterine surgery', 'CT show', 'hypertonic saline', 'Metal parts in the body (piercings', 'foetal growth restriction', '-ET', 'Implantation', 'biological treatment', 'histologic examination', 'anterior knee pain', 'recommendation of MIE', 'hematopoietic stem cell transplant|Moderate thrombocytopenia', 'completed pelvic MRI before surgery from 2017 to 2022||', 'HSC transplantation', 'action barriers.||Control group||Inclusion Criteria:||Suffer from symptoms', 'signet ring cell', 'interventional clinical studies.||', 'nephroureterectomy', 'pelvic oncological resection', 'blood cell count>3.5×109/L', 'patient eye receives', 'allogeneic cell-', 'YAG laser capsulotomy', ""Paediatric Emergency Department of the Children's Hospital"", 'node', 'therapeutic purposes', 'primary treatment failure', 'RCD', 'facial procedures', 'Following surgery types:||Orthopedic|Thoracic|Abdominal/Pelvic||Other inclusion criteria:||Initiation', 'bone marrow aspirate', 'immunosupressive therapy', 'neural transplants', 'HPV vaccine initiation', 'complete evaluation by medical providers', 'PET-CT scan', 'disability|Misunderstanding of questions', 'lipid panel', 'intraspinal anesthesia', 'Clear cell RCC', 'standard regimen chemotherapy', 'microscopic colitis.|History of pancreatitis', 'surgically', 'general MRI exclusions', 'interventional clinical trial which does not involve administration of an IMP and', 'bone marrow invasion', 'first menstrual cycle|Low serum estradiol levels', 'Pathologic staged', 'emergency department access', 'coronary artery stenting', 'suppressive cART', 'tumour tissue sample (from archival tissue', 'clinical treatment', 'Model warning signs of PID', 'congenital anatomic anomalies of the IVC', 'full supportive care', 'combined sexually transmitted diseases', 'lipid', 'ovarian ablation', 'dental procedure', 'refractive media opacification', 'MIUC', 'cognitive impairment||', 'endoscopy spinal surgery', 'medial collateral ligament (MCL) insufficiency', '12-lead Electric Cardiogram', 'elective craniotomy', 'lung function', 'radiotherapy in head and neck region', 'endoscopic mucosal resection', 'HPV vaccine providers|no clinic', 'refractive procedures|Preoperative visual acuity', 'analysis of the tissue or increase the risk to subject.|Must', 'arterial access', 'heart transplantation', 'intraoperative CSF outflow from the ventricle noticed by the surgeon)|Adults over the age', 'local CLIA', 'procedural sedation', 'Gilbert syndrome),|alanine transaminase (ALT)', 'PET scan imaging', 'Knee surgery', 'repair of', 'surgery|Curative resection|Minimally invasive', 'look TURB', 'first dose of study treatment]).|Urinalysis', 'treatment for alcohol', 'HFO', 'Whipple procedure', 'pharmacological treatment', 'sFLC ratio', 'open abdominal', 'idiopathic scoliosis||', 'first premolars extractions||', 'routine clinical care', 'ETV6|germline mutations', 'tibial osteotomy', 'vagotomy', 'DARS2 mutation analysis.|Able to understand Dutch', 'catheter artery chemoembolization', 'CRRT treatment|Patients', 'liver biopsy sample', 'Inpatient treatment', 'transdermal hormone contraception', 'medical supervisor', 'oncology care|Sufficient clinical status', 'thoracic surgery|Mechanically Ventilated', 'gynaecological pelvic examination', 'confirmation', 'tunnel revision surgery|Associated surgery', 'psychological treatment', 'Montreal Cognitive Assessment (MoCA) score of < 20,|Severe visual impairment', 'anticoagulant treatment.|Involvement', 'complete pulpotomy|Diagnosis should be irreversible pulpitis.|The tooth is restorable and free from advanced periodontal disease|Soft tissues around', 'index PCI', 'protocol section', 'completed local therapy', 'pars plana vitrectomy', 'needle biopsy', 'immunotherapy directed', 'reconstructive flap surgery', 'duodenopancreatectomy', 'device treatment', 'concussion', 'CT perfusion', 'ROS-1 rearrangement', 'Oslo University hospital (OUH)', 'refractions', 'CLIA)-certified laboratory', 'CT scan pretherapy medication', 'chemo-immunotherapy', 'pelvic organ prolapse||Vaginal bulge symptoms', '12-lead ECG).||', 'therapy', 'adaptational strategies|Mental illness', 'Schoolchildren||', 'conditions;|single pregnancy;|fetal growth restriction (FGR)', 'peri-implant', 'investigator|Cholecystectomy', 'Weaning', 'complete block', 'intrathecal cytarabine', 'tissue blocks', 'pancreatic surgery|Patients', 'maximal CPET||Patients', 'immediate intervention', 'extra leak', 'Essure', 'drug therapy|History of', 'cardiopulmonary resuscitation|Patients', 'treatment catheters - patients', 'Hôpital Paris Saint-Joseph', 'first-line antiviral medication.|voluntarily sign the informed consent form.||', 'cerebrovascular intervention', 'Magnetic Resonance Imaging', 'nickel titanium).|Any contraindication', 'ranibizumab injection', 'cataract surgery.|Transparent', 'primary knee arthroplasty procedure|PHQ-ADS', 'total colectomy', 'radiation-induced', 'standardized', 'spirometry testing', 'experimental therapy Note: Off-label therapy', 'voluntary control', 'CNS lymphoma.|Participants', 'Chronic opioid use', 'optimal dose of', 'insufficient imaging quality of CT', 'physiotherapy||One-sided knee osteoarthritis', 'sleep on|Wear', 'Shingrix', 'bilateral orchiectomy;|Painful bone metastases', 'focal brain radiation', 'operation;|Receive antibiotic treatment', 'chronic fatigue syndrome', 'cumulative dose', 'transoral surgery', 'conventional cerebral angiography', 'clinical indications.|Current simvastatin use', 'hematopoietic stimulators', 'cancer screening', 'X-ACKT', 'mechanical prosthetic heart valve', 'AVR-RD-02', 'video-enabled computer', 'intestinal absorption of NP-101 enteric coated', 'IVF treatment', 'hypoplasia', 'genetic loci', 'chest computed tomography (CT) scan|Active tuberculosis|Significant cardiovascular disease', 'breast surgery', 'antiestrogen therapy', 'radiotherapy dose', 'carotid surgery', 'HCV therapy', 'oophorectomy', 'small cell NEC', 'antihypertensive', 'GBM diagnose', 'variable decelerations', 'insufficient respiratory drive|Prolonged (', 'medical attention|Current', 'injection site.|Donation of blood', 'computed tomography to confirm the diagnosis||', 'fronto-parietal dysfunction', 'graft maintenance', 'vaginal delivery,|Normal vaginal delivery,|Emergency caesarean section,|Preterm pre labour rupture', 'infarction|Peripheral arterial disease|Carotid artery disease|Unexplained shortness of breath|Congestive heart failure', 'baseline;|Macular laser treatment', 'left ventricular dilatation', 'dietary IBS treatment', 'ICHD', 'open operation for peripheral artery disease', 'DBS leads', 'pelvic .|Postoperative biochemical recurrence', 'hematopoietic stimulating factors', 'central pancreatectomy', 'unchanged AD routine', 'versus initial', 'm2).|Creatinine clearance rate (CRCL):', 'Permanent sterilization methods', 'mechanical ventilation,|Receiving', 'abdominopelvic CT scan|scheduled', 'laparoscopic colectomy procedure', 'cease', 'orthodontic reasons||', 'immunomodulatory action', 'intestinal obstruction);|Allergic to the test drug or its excipients;|Persons deemed unsuitable for inclusion by the researcher', 'peripheral endarterectomy', 'CD19', 'regular menstruation cycle', 'provocative tests', 'hydrocelectomy', 'local requirements.|The LAR/parent/guardian', 'percutaneous valve intervention', 'allogeneic/autologous hematopoietic stem cell transplantation', 'local practice.||', 'FTD medications', 'BRAFV600E', 'fundus visualization|uncontrolled glaucoma|papillary excavation', 'lipid lowering', 'hematopoietic stimulating factor treatment', 'CT-angiography of the aorta', 'hormonal replacement frozen embryo transfer', 'corticosteroids.|Major surgery', 'MRI scanning', 'bladder biopsy', 'Sports', 'Intrathecal Baclofen', 'women|Glomerular filtration rate (CKD-EPI eGFR', 'cardiac computed tomography angiography|For', 'pelvic resection', 'stereotactic body radiotherapy', 'patellar knee pain', 'good oral', 'peripheral blood apheresis', 'cesarean section', 'radiotherapy of the face and neck', 'supportive care', 'gastrointestinal tract|Drugs', 'simple concussion', 'Total Daily Dose', 'good oral hygiene|absence', 'completed prior therapy', 'Congenital adrenocorticosis', 'RTX treatment', 'tobacco use disorder|Is', 'Immunohistochemistry/Immunocytochemistry (IHC/ICC)', 'adrenocorticotropic hormones', 'Siewert', 'women|Persons', '12-lead ECG).|Inflammation', 'Reproductive Health Care (ASSIR; Atención a la Salut Sexual i Reproductiva', 'hormone treatment', 'prostate biopsy', 'cognitive rehabilitation treatment', 'deterioration', 'Antibiotic treatment', 'thyroid disease,|uncontrolled', 'conventional root canal treatment', 'video conference software', 'counting fingers', 'reimplantation following device failure', 'fine needle aspiration', 'Irregular cornea|Choroidal hemorrhage|Microftalmos', 'liver failure|Laboratory results', 'stay still.|Patients', 'requires laparotomy', 'Endothelial Growth Factor Receptor (VEGFR) targeted therapy', 'chest computed tomography (CT) scan.|Any other diseases', 'prevention of thrombosis', 'intent', 'Botox therapy', 'focal motor SE.|For SE', 'surgical sterilization of partner', 'sedative types', 'radiation pneumonitis|Prior radiotherapy', 'stent length', 'cardiovascular risk factors:||Cardiogenic chest pain occurs', 'adjustable gastric banding', 'conventional treatment initiated', 'major surgical operations', 'pancreatic hormone stimulant', 'CABG))|Elective cavoatrial cannulation', 'Suspicions', 'hepatic impairment|Patients', 'transanal pull through|Whose parents', 'endovascular interventional treatment', 'Therapy Related Criteria Guidelines', 'Special education classrooms', 'routine blood test', 'regional lymph node metastases|Presence', 'linezolid susceptibility.||', 'inguinal hernia||', 'personalized alignment surgical technique', 'ARF', 'anti-microbial treatment', 'chimeric antigen receptor T-cell immunotherapy therapy', 'bilateral mastectomy', 'Phenoxyethanol', 'factor IX inhibitor', 'transportation issues|Organ transplant patients|Patients', 'hormonal contraceptive pills', 'steroids|any form', 'lateral view', 'organ system', 'narcological dispensary;|Maternal', 'prenatal ultrasound screening|Delivery', 'endovascular mechanical thrombectomy', 'surgical sterilization.|Inability', 'reconstructive vaginal surgery', 'corrective mitral valve surgery', 'complete right bundle branch block', 'open head wounds|Ventricular shunts|Bleeding disorders|Known brain', 'corrective surgery', 'B-mode ultrasound', 'stiff knee gait', 'oral zinc treatment', 'myopia control intervention', 'medication|History', 'coeliac.|Previous', 'partial dentures.|Casts', 'blood stream infection', 'completed the Informed consent form and volunteering to participate in the study|Not having', 'Mistral Delivery System', 'computed tomography angiography', 'Diagnostic Subcommittee of China Association of Traditional Chinese Medicine', 'possible curative treatment', 'simple prostatectomy', '1:||Adequate Organ Function Laboratory Tests System', 'cardiac catheter ablation', 'EHR system.|No recorded', 'robotic-assisted laparoscopic radical prostatectomy', 'pharmaceutical treatment', 'wound', 'assessments|traumatic amputation', 'Systemic chemotherapy', 'days.||Bronchial thermoplasty procedure', 'knee osteoarthritis||', 'Davidson Trauma Scale)|is sub-optimally engaged in HIV care', 'first-generation antiandrogens', 'transcranial direct', 'tobacco cigarette smoking', 'Age≥18years|Optimal medical therapy', 'pathological histology', 'access to the femoral vein', 'Modification of Diet in Renal Disease (MDRD) Study equation', 'lateral flexion directions', 'Pittsburgh Sleep Quality Index (PSQI)', 'CT examination', 'asthma', 'radiographic dislocation', 'treatment episode|World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status', 'electrocardiography', 'Transfusions', 'radical surgical resection', 'emergency surgery', 'hormonal therapy', 'inhibitors- SSRI-antidepressant', 'hepatic function||Total bilirubin', 'joint prosthesis Insufficient cooperation', 'pulmonary angiography', 'Indwelling Foley catheter user', 'T-DM1.|Symptomatic central nervous system (CNS) metastases', 'modified electroconvulsive therapy', 'drug therapy targeting VEGF', 'emergency reperfusion therapy', 'revascularization procedure', 'fresh biopsy material', 'abdominal source|C. Difficile', 'field radiotherapy (', 'conical excision', 'genetic testing of tumor tissue', 'bone marrow transplant;|Patients', 'Isolated ipsilateral unifocal breast lesions;|Histologically', 'through therapy', 'intra-aortic balloon pump (IABP) support', 'experimentation', 'Note:||Local surgery', 'myopic refractive error', 'Revision)|Kidney transplant', 'rapid tumor reduction|Patients', 'sentinel', 'endocrinopathies', 'fetal heart rate', 'HEV', 'primary care provider|Access', 'elective procedures', 'colorectal cancer screening', 'proctoscopic examination', 'benzodiazepines|Current treatment', 'biopharmaceutical produced in Chinese hamster ovarian cells', 'Structured Clinical Interview for DSM Disorders (SCID))||Sel -reported drinking', 'PROs', 'vitrectomy surgery', 'PPHN', 'stay', 'MECT', 'pancreatic enzyme replacement|Criteria for', 'completed chemoprophylaxis', 'emergency coronary angiography or|Among the patients', 'emergency surgical', 'cessation of exogenous hormonal treatment', 'total knee prosthetic infection|Patients', 'non-inclusion criteria:||Unsuitable veins', 'percutaneous intervention|Stroke', 'complete PSSE training actions', 'subsequent biopsy conducted', 'bone marrow', 'PaO2)/oxygen inhalation concentration', 'haematopoietic colony', 'Mini International Neuropsychiatric Interview', 'IVIG transfusion', 'convulsions.||All enrolled', 'pretreatment', 'empiric antibiotic therapy', 'Enrolled', 'SD-OCT|Ability and willingness to comply with the treatment', 'neuromotor disorders.|Children', 'UTI', 'retinal imagingfor', 'wine).|Blood donation', 'change', 'diurnal variation', 'chemotherapy regimens', 'mechanical ventilation,|Not', 'thermal ablation', 'pathology allows urothelial carcinoma', 'Health volunteers||Known hepatitis B,', 'intratumoral hemorrhage|Subjects', 'CYC induction', 'Note:1', 'interstitial brachytherapy', 'intraoperative surgery', 'Hormonal Replacement Therapy', 'whole-brain radiotherapy', '2-stenting technique', 'drug therapy', 'imaging testing', 'Cervical foraminal stenosis|Cervical central stenosis|Cerivcal disc herniation|Cervical spondylolisthesis||', 'revision surgery|Patients', 'pharmacologic thromboprophylaxis', 'Extensive hepatectomy', 'optimal treatment', 'influenza vaccination', 'reduction of anterior shoulder dislocation', 'intra aortic balloon - pump', 'security system||For Control Group (', 'lumbar spinal stenosis|Age', 'first-onset dyspepsia', 'hormonal vaginal ring', 'radiation', 'fainted', 'bronchoscopic biopsy', 'shortness of breath|Oxygen saturation', 'coronary artery bypass graft ≤6 months|History of clinically significant', 'periodontal surgery/root', 'Model enrolled families', 'focus takes iodine', 'repolarization', 'heart rate correction', 'completed vaccine priming', 'esophageal radiotherapy', 'Coronary artery bypass graft (CABG)', 'regular exercise habit', 'chemotherapy|Solid organ transplantation|Two', 'bone marrow transplantation/HIV', 'chorionic villus', 'permanent sterilization (hysterectomy', 'small concentration changes may lead', 'robotic hysterectomy', 'Hospital Salvador', 'dynamic CT scan', 'initiation', 'Enterococci', 'T2*', 'sarcomeric genes identified);|Signed informed', 'Montreal Cognitive Assessment [MoCA]', 'SARS-CoV series|persons', 'ethnic minority group (self-identified', 'gastric cardia,|Biopsies', 'EGFR TKI therapy', 'regional sleep pathology center', 'implantation of a transcatheter heart valve of the SAPIEN family because', 'common bile duct stone', 'Egyptian', 'first therapy', 'RSV MAT-009', 'simple hernia', 'suppressant medical therapies', 'hard', 'open surgical repair per the protocol requirements|The', 'physical aggression towards self or others', 'arthroscopic RM surgery', 'imaging', 'histopathology.|Abdominal pelvic CT', 'rectal bleeding||', 'caesarean delivery under regional', 'blood system tumors', 'alcohol breath testing', 'target DFU is located)', 'gallbladder surgery', 'multi-attachment orthodontic treatment', 'molecular targeted therapy', 'germline predisposition', 'Trendelenburg position', 'bilateral orchiectomy', 'consistent with liver cirrhosis.|two', 'colposcopy', 'immunotherapy regimens', 'cholestyramine|Current use', 'immunosuppressive treatments', 'stent;|Previous coronary procedures', 'standard chemotherapy', 'Preoperative donor specific antibody', 'signed informed consent.||Exclusion', 'standard of care chemotherapy', 'general anesthesia.|Preexisitng rectal fistula.|No', 'epilepsy);|Antibiotic treatment', 'good insulin control', 'ultrasonography', 'Interventional Radiology criteria.|Patients', 'pneumococcal vaccination|Contraindication', 'vitamin D supplementation', 'colectomy', 'e', 'supportive therapy', 'contraceptive treatments', 'Structured Interview for DSM-5 (SCID-5).||', 'Clinical Study Experience:||-', 'whiplash', 'days;|Bilateral mastectomy', 'invasive dental surgery', 'standard AHT cardiovascular medication', 'Mini International Neuropsychiatric Interview Plus (MINI plus', 'standard of care CA', 'corticosteroid treatment therapy', 'Anti Retroviral Therapy', 'allogeneic Hematopoietic Stem Cell Transplant', 'Montreal Cognitive Assessment(MoCA)', 'adequate standard treatment', 'single viral load measurements', 'gastrointestinal emptying', 'lipid screening', 'graft-versus-host disease.|History of any of the following cardiovascular diseases', 'renal replacement therapy', 'MYBL alterations', 'repair of two different types of hernia they can', 'healthy|non-smoking|non-diabetic', 'total arthroplasty', 'surgical management|Preoperative prostate volume', 'intubation||', 'ventriculoperitoneal shunt placement', 'major categories of surgeries|American Society of Anesthesiologists (ASA)', 'treatment for infection', 'tubal ligation/occlusion', 'reaction.|Hospitalization', 'Quotient', 'transfers;|Weak control of the trunk;|Inability to stand', 'luteinizing hormone-releasing hormone [LHRH]', 'Clinical SLEDAI= 0|Criterion', 'gastrointestinal surgeons', 'complete questionnaires||', 'myelopathy|Positive vertebrobasilar artery test,|Pregnancy', 'triplicate12-lead ECG.|History of (non-infectious', 'assessment with ultrasound', 'T-SPOT test', 'conventional migraine prophylaxis.||', 'Abdominal Surgery', 'ileocolic resection', 'propofol|Emergency surgery', 'mucus after biopsy', 'TITANIA studies.|Capable of giving signed informed', 'months.|Major surgical procedure', 'standard of care x-ray.|Subject', 'ventilator therapy', 'safe anaesthesia', 'screening investigation the investigators consider', 'first dose of study treatment]).||', 'spirometry overread', 'DH relief', 'consolidation therapy', 'mild aortic valve stenosis.|Prior exposure', 'staged PCI after randomization|Any condition that', 'immuno-therapy', 'ICE.||Intra Procedural', 'eye.|Bilateral restricted fundal view', 'full participation in the study', 'knee MRI', 'hematologic transplantation', 'historical ECHO', 'blood sample collected', 'systemic treatment for cancer', 'hemostasis', 'NOL monitoring can', 'ventilatory support|Patients', 'reflex testing', 'labor induction', 'ureteroscopy', 'suppressive oral antiviral', 'chest x-ray|Clinically', 'trauma.|Metal implant devices', 'combined anterior-posterior surgery', 'lymphodepleting chemotherapy', 'two-hour plasma glucose', 'physiotherapy modalities', 'intralesional injection therapy', 'haematological neoplasia', 'PET/CT', 'smartphone', 'low dose anti-coagulant treatment should', 'emergency procedure||', 'supportive treatment', 'other surgery of the gastrointestinal tract', 'registry:||(1', 'effective sterilization operations', 'Prediabetes', 'facetectomy', 'Behavioral concerns', 'Departmental Program of Advanced Cellular Therapies', 'pleural biopsy', 'wash out period', 'serotherapy', 'stereotactic surgery', 'Trauma Related Guilt Inventor.|not', 'child;|Normal thyroid function', 'open reduction', 'chronic pancreatitis|Mechanical ventilation', 'barrier method', 'hyaluronate', 'RRD', 'vegan/vegetarian', 'alternative diagnosis)(Cabrera Martimbianco', 'small molecule agent', 'researchers', 'music therapy', 'PIRS surgery', 'complete decongestive therapy (CDT)', 'unusual preoccupation', 'maintenance immunosuppression after', 'refusal|Contraindication', 'endoscopic discectomy', 'single fraction radiation therapy', 'abdominal computed tomography(CECT', 'standardized osteotomy', 'dental prophylaxis', 'Roswell Park|Not under', 'bone marrow cytology', 'Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog', 'knee TKA||', 'radiation colitis|Bacterial', 'complete treatment', 'bowel resections', 'induction treatment.|Uncontrolled', 'angiography', 'subjective evaluation', 'Winblad consensus criteria|Presence', 'psychiatric hospitalization', 'remifentanil', 'cervical arthroplasty', 'major surgery planned', 'live virus vaccine', 'Electroconvulsive treatment', 'curative treatment options|No chemotherapy', 'brain stimulation treatment (', 'implantation of the Alcon SN60WF lens', 'arterial desaturation', 'donation of blood/plasma', 'procedural sedation.|Pregnancy', 'skin prick test||', 'systemic glucocorticoid treatment', 'dynamic Gait Index score', 'CELS resection', 'autologous CAR-T cell therapy.||Eastern', 'inactivated vaccine', 'coronary artery bypass graft surgery|Co-morbidity', 'medial sternotomy|Patient able', 'lineal blood relatives', 'SCS', 'palsy.|Current hospitalization', 'full thoracoscopy', 'oral glucose lowering therapy', 'allogeneic hematopoietic stem cell transplantation;|Inoculate live', 'Abatacept elimination half-life', 'MRI scan|Unable to receive', 'extrahepatic sites of disease (site of disease', 'transdermal hormone contraception|Placement of an', 'ideations', 'regional anesthesia.|Evidence', 'AF catheter ablation procedure', 'clinical trials', 'Fecal occult blood test', 'graft vs host disease|Radiotherapy treatment', 'perfusion MR studies', 'primary percutaneous coronary', 'hemolytic syndrome.|History of', 'colonoscopy', 'OAC', 'irreversible sterilization', 'antiviral drugs', 'Foley catheter insertion', 'HER2 gene amplification was found in primary', 'inguinal hernia cure|General anaesthesia proposed', 'functional neuroendocrine tumors', 'MINI', 'uterine curettage', 'further diagnostic procedures', 'cosmetic tests', 'vaccination series', 'transient increase in blood pressure', 'transurethral resection of bladder tumor', 'Coronary Artery Bypass Graft (CABG)', 'SBRT', 'safe access', 'menstruation|pelvic pain|vaginal discharge|sudden weight', 'postoperative imaging (CT/MRI).|The', 'toric intraocular lens', 'laparoscopic surgeries||', 'thoracic MRI planned', 'contraceptive methods', 'antigen expression', 'enteral catheter', 'other procedures', 'main organ', 'cardiac mitral', 'haploidentical donor sourced HSCT|Hematopoietic Cell Transplantation', 'pelvic organ prolapse', 'emergency use authorization', 'percutaneous implantable', 'produce visual field', 'hospitalization', 'YAG laser procedure.|Accept', 'Nocturnal desaturation', 'antiviral regimen', 'upper gastrectomy', 'functional ileus|Patients', 'better||', 'immunocompromised state', 'Hemodialysis', 'endotracheal intubation', 'earlier surgery', 'stopped menstruation', 'heart disease.|Having', 'spherical contact lenses', 'open of', 'sentinel node biopsy', 'X-ray examination', 'EUS-guided approach for any reason|Patients', 'intradermotherapy', 'PPCI', 'urography', ""clinical laboratory findings that the investigator believes may interfere with the results or increase the patient's risk of treatment complications"", 'DSA', 'light-altering devices', 'PCT session', 'cooperative.||', 'platelet transfusion', 'reduction procedures', 'adequate standard therapy', 'local therapy', 'verbal instruction.||Anatomy', 'topical treatments', 'autologous platelet cryopreservation', 'bone marrow transplantation;|drug abuse', 'age|Hospitalized', 'evaluation.|Matched for sex, age (± 10 years', 'lumbosacral spine surgery level from', 'index date|Participation', 'primary total conventional hip replacement', 'allogeneic stem cell transplantation.|Being able to understand and read', 'Fetal growth restriction', 'hospitalised', 'open oral food challenge', 'radiographic imaging showing', 'pelvic US||gBRCA1/2 testing results nor provided', 'insufficient radiological documentation|Patients', 'graft versus host disease medications', 'mechanical circulatory', 'MRI spine imaging', 'line of chemotherapy', 'excluded.|Surgical treatment', 'biventricular', 'psoriasis treatment', 'COVID Prevention Program.||Exclusion Criteria: 1)', 'first-line TKI', 'thoracic major operations', 'submitted', 'homolateral iliac inflow lesion', 'blood drawing procedures', 'prophylactic antibiotics|Subjects taking', 'laser trabeculoplasty', 'control associated symptoms', 'infection.|Major surgery', 'definitive surgery', 'absorption of oral agents|Patients', 'urine culture', 'stem cell transplantation', 'GIRD', 'treatment of the study', 'Thymoglobulin therapy', 'constipation', 'BP readings', 'general anesthesia.|Patient', 'DRE', 'donate sperm starting at screening', 'abdominal mesh|Planned vaginal mesh', 'gastroduodenal surgery|Open abdominal wounds', 'Study', 'pelvic radiation', 'session (solarium)', 'age|good general health|born', 'Institutional Review Board (IRB)', 're-resection', 'lateral knee radiographs.|Patients', 'optic nerve involvement;|Corneal ulcers', 'intracranial angiography (', 'DMEK corneal transplantation||', 'local standard-of-care investigations', 'periodontal attachment .|Patients', 'rectal surgery', 'thoracic surgery)|undrained', 'DBS stimulator)|History', 'local study appointments|Written', 'liver flow ablation', 'laparoscopic gynecological surgery.|Adults', 'HBV antiviral therapy', 'SAPB.|Defective coagulation.|Infection', 'CNS directed therapy', 'thyroidectomy for cancer surgery.||', 'autologous HSCT', 'percutaneous paravalvular leak closure', 'imaging findings', 'stress', 'day.|Surgical procedures', 'therapy introduced', 'immuno-oncology agent', 'rapid intravenous blood-pressure control', 'allogenic hematopoietic stem cell', 'dietary omega-3 fatty acid supplements', 'steroid hormone use.|Other', 'acquisition scan', 'coronary artery fractional blood flow', 'lymphoma symptom control', 'targeted therapy', '6|Arterial access', 'salicylates|Urinary obstruction|Porphyria|Glucose-6-phosphate dehydrogenase', 'MRI imaging', 'percutaneous revascularization;|CT imaging of the thorax', 'Health Screening Questions', 'repair with', 'local CNS therapy', 'oropharyngeal swabs', 'spine surgeries', 'Namsos', 'left bisegmentectomy', 'hormonal contraceptive;|IUD;|Prescription hormonal contraceptive', 'lateral wheightbearing radiography of the affected foot.||', 'extensive conization', 'chest X-ray).|Other conditions', 'verbal instructions|Access to the internet', 'bpm)|Cholecystectomy', 'lipid-lowering therapy.|Patients', 'cardiac intervention', 'walnut', 'Magnetic Resonance Imaging [MRI', 'finger pulse', 'Percutaneous coronary', 'Routinely sleeps', 'barrier method from initial drug administration until 90 days after the last dose of study drug.|Ability to understand', '25-hour urine collection for', 'confirm assay', 'routine dilated OCT scans.|Patients', 'IP plus', 'measurements.|Body mass index', 'pathology.||Completion of surgical resection of tumors', 'Immunotherapy', 'gold therapy', 'injection/Endoscopic mucosal resection', 'TACE', 'local laws.||Exclusion criteria.||Patients', 'chronically', 'routine therapy', 'alternative medications', 'graft versus host disease (GVHD', 'abdominal aortic artery lesion', 'months；|Major organ function', 'allohematopoietic stem cell transplantation;|Active central nervous system metastasis', 'bone marrow aspiration', 'small pupil/floppy', 'complete clinical', 'Oral contraception', 'resting electrocardiography (EKG)', 'clinical assessment', 'dehydration treatment', 'experimental intervention', 'pathological fractures.|Those deemed unsuitable to partake', 'platinum therapy', 'brain metastases|Participant', 'posttraumatic amnesia', 'entry', 'abdominal ultrasound results', 'radiation oncology note.|Access', 'ahead of end of this study(for garantee of enough', 'CNO tribal region', '≥1 month|Known', 'Cytofluorimetry analysis', 'wAIHA', 'hyperosmolar coma|Patients admitted', 'MRI contrast', 'systemic therapy|Expansion Cohort', 'systemic therapy directed', 'therapeutic procedures', 'signature|Patients', 'transfontanellar ultrasound scan', 'Mitomycin C|Renal transplantation', 'confirmatory laboratory findings', 'vertebroplasty', 'complete rupture', 'transcutaneous oxygen saturation', 'abdominal aortic aneurysm', 'cryotherapy', 'great difficulty for oral drugs', 'Teaching Hospital', 'Resuscitated', 'CT scan', 'placement of an', 'chemotherapy combination cycles', 'technetium scintigraphy', 'intravesical treatment', 'craniocerebral surgery', 'suppressive therapy', 'laboratory test results', 'dystrophies|Media opacification', 'risky labor,|Postpartum bleeding,|Epidural analgesia', 'endoscopic guided biopsies', 'radical cystectomy', 'local therapy like TEM.|Histologically verified dMMR', 'allogeneic hematopoietic stem cell transplantation|Those who', 'Asthma Control Test (ACT < 20', 'Percutaneous Coronary Intervention', 'total mastectomy', 'elective procedure', 'UCLA', 'autologous SCT||Note', 'brain imaging', 'AC', 'Regular exerciser - defined', 'EOE', 'analgesic treatment', 'contralateral knee surgery', 'major surgical treatment|Inability', 'radiotherapy-related toxicity have recovered to grade 1 or less', 'of COVID-19 vaccine', 'Wheelchair', 'standard drug therapy', 'electric shocks', 'flutter ablation', 'gastric acid suppressant therapy', 'sex-steroid', 'intraocular refractive interventions', 'chronic oral', 'PET imaging', 'conventional MRI', 'oral trauma', 'total gastrectomy)|nutrition Risk Screening', 'Maudsley-staging', 'dialysis', 'English|reporting', 'axial CT imaging', 'allogeneic stem cell transplantation|Known hypersensitivity', 'Epidiolex', 'irreversible sterilization surgery', 'morphology', 'imaging exam', 'Imaging Core Labs|Intolerance', 'glucocorticoid treatment', 'gastrointestinal bleeding;|Received', 'liver surgery||', 'intra-thoracic', 'pelvic ultrasound', 'general intensive care unit', 'placement of coronary artery stents', 'quadrangular resection of the posterior leaflet', 'intraocular surgery', 'Ethics Committee', 'transarterial chemoembolization (TACE)', 'allow', 'lose weight||', 'major intracranial artery (internal carotid artery [ICA]', 'osteoporotic vertebral fractures.||', 'standard premedication', 'Digital Subtraction Angiography', 'immunosuppression|Under treatment for', 'need oxygen saturation', 'prolapse repair utilizing', 'baseline biopsy', 'cumulative dose should', 'B-ultrasound show', 'reproductive organ', 'PIVC', 'COVID vaccination', 'lipid lowering medications', 'symptom control', 'Poor control of hypertension', 'biological sample collection', 'lead treatment related', 'pain control treatment', 'tubectomy', 'homeopathy', 'pelvic MRI scan', 'desaturation', 'physiologic testing', 'non-hormonal method', 'biological therapies Addiction', 'polymerase chain reaction (PCR) test', 'Mismatch Repair', 'viral hepatitis|Patients', 'safety|Serious psychological', 'standard regimens', 'induction therapy；|Patients', 'resected by surgery', 'hematopoietic stem cell mobilization', 'gastric stasis)|Known bile duct fistula', 'treat COVID-19', 'lumbar punctures', 'ultrasound treatment', 'endoscopic ablation therapy of the esophagus.|Older than 18 years', 'Re-do', 'clinical study procedures|Prospective', 'radiofrequency ablation therapy', 'between biopsy collection', 'caffeine consumption|Plasma donation', 'global aphasia', 'Doppler echocardiography', 'T cell', 'kidney transplant procedure', 'cardiopulmonary bypass', 'biopsy definition', 'Chest X-ray examination', 'coronary stent', 'meniscus tears', 'donation', 'infusion reactions', 'B-cell recovery|Active central nervous system (CNS) involvement', 'corrective magnesium supplementation', '12-lead electrocardiogram (ECG)', 'active panel', 'targeting therapy', 'T0 scan done', 'left anterior branch block', 'extensive head motion', 'localised radiotherapy related pneumonitis', 'treatment-resistant depression (TRD)', 'bilateral SMILE treatment', 'GT6', 'ROS', 'abdominopelvic imaging', 'admitted to IRCCS Sacro Cuore Don Calabria Hospital', 'psychological illness|Current treatment', 'resolved', 'IBSconstipation', 'heart-rate adjusted', 'pancreatectomy', 'vertical descending saccades|Diagnosis of', 'testing of tumor PD', 'common bile duct stones', 'autologous blood product', 'urosepsis', 'O2 therapy', 'total cells analyzed', 'ergonovine provocation test', 'slit-lamp examination', 'management', 'Glenohumeral arthritis', 'gastric sleeve', 'left atrium ablation', 'stress reduction', 'total knee arthroplasty (', 'focal therapy', 'lumbar surgery|Any previous', 'exam', 'unicompartmental knee arthroplasty.|≥18', 'local anesthesia impossible to administer.|Children that are not allergic', 'lumbar vertebrae', 'enrolment.|World Health Organization (WHO) performance status', 'coronary artery bypass surgery', 'confirmatory', 'Hepatitis B vaccination', 'Paraesophageal Hernia noted', 'tubal ligation procedures', 'Mini International Neuropsychiatric Interview for Children', 'Treponema pallidum (TP) antibody', 'immunodeficiency;|Ejection fraction', 'medical procedures of the high-grade VIN', 'esophagectomy', 'lactulose therapy', 'gastric banding).|History', 'cardiac CT', 'corneal refractive surgery)|Prior vitrectomy', 'neoadjuvant chemotherapy', 'myelosuppressive chemotherapy', 'combined thyroid treatment', 'chronic oral anticoagulant', 'allogeneic stem cell transplant|Prior solid organ transplant|Cancer therapy', 'corrective treatment', 'ablation treatment', 'intrapleural tPA', 'acute care panel', 'EHR review', 'Aortic infection|Mycotic Aneurysm|Aortic', 'standard COVID-19 screening', 'thrombolytic treatment', 'ESCC', 'pathological hip fractures', 'HER2-target treatment', 'cytoreductive radical prostatectomy', 'nicotine-', 'index;|pregnant', 'bilateral elective neck dissection', 'Cardiopulmonary diseases|Previous cardiothoracic', 'gastrectomy', 'vigorous exercise for more than 5 times per week|Alcohol', 'spray therapy', 'hepatic arterial embolization', 'drug', 'abatacept', 'bone marrow transplant', 'allogeneic stem cell transplant|Patients', 'stay admitted to the wards at least till the next day after surgery.|Participants have to be in the possession', 'Residents', 'administered|renal replacement therapy|known hypersensitivity', 'cholecystectomy|Recent hospitalization', 'shoulder surgery', 'sclerosing injection therapy', 'cerebral infarct|Pregnancy', 'chemotherapy treatment,|In', 'Immunohistochemistry (IHC)', 'abortion(s', 'local testing.|Patient', 'hypofractionated radiotherapy', 'quantitative analysis of CT measurement|No smoking>6', 'bicuspid aortic valve|Subjects', 'evaluating MRI', 'insertions', 'shortness of breath', 'TB examination', 'whole body vibration (WBV)', 'moment of inclusion', 'substance use,|pregnancy', 'Intent', 'craniospinal irradiation', 'prophylactic cranial irradiation', 'investigator|Recent colonoscopy', '120 mg of caffeine', 'SMA therapy', 'sexual hormone drug use', 'stool', 'medical condition|History', 'chest imaging suggests', 'local standard-of-care investigations|Increased risk of bleeding', 'VR therapy', 'local laboratory testing per American Society of Clinical Oncology', 'coherent speech', 'nerve root', 'complete tarsorrhaphy', 'adrenal replacement doses ≤10 mg daily prednisone equivalents', 'assisted reproductive technology (ART)', 'EBV polymerase chain reaction (PCR) test should', 'i.e.|Spherical refractive error', 'allogeneic hematopoietic stem cell transplantation;|People known to be allergic to the drugs used in this study;|People', 'Graft vs Host disease', 'standard score.|No contraindication to surgery', 'aortic repair', 'hepatic arterial infusion chemotherapy', 'verbal aggression includ- ing both arguments', 'carotid endarterectomies|Patients', 'vision tests', 'complete) brachytherapy', 'this treatment', 'Standard therapy failure', '% plasma cells', 'pace maker', 'cancer|Active microbial infections|Neuromuscular', 'first immature', 'MGB', 'hyaluronic injections', 'regular doses', 'live fetus,|Can', 'Bedside Schwartz Formula', 'foley catheter placement', 'C-SSRS Lifetime', 'thoracic surgery|parent', 'previous surgery of the intended study knee', 'buccal attachment loss', 'vital organ function', 'Palliative treatment||Medical', 'cystourethroscopy', 'exercise regimen', 'surgery,|endocarditis,|aortic root repair surgery|aortic dissection|heart beating surgery,|heart transplantation', 'neurological intensive care unit', 'oral steroids)|Acute myocardial infarction (AMI)', 'periodontal surgery Gingival thickness', 'lines chemotherapy', 'intensive induction by their treating physician', 'strenuous exercise ≥5 h/week', 'chronic lung disease|Restrictive lung disease', 'veterans', 'donated blood ≥200mL within', 'enteral nutrition support', 'CT scan;|muscular weakness', 'abdominal surgical history;|Gallbladder gangrene perforation;|Changes', 'paravertebral blocks', 'chest CT scan|History of', 'abdominal surgery', 'invasive procedure Procedures', 'mobility|chair-bound', 'radial keratotomy', 'pharmacological intervention', 'Massachusetts General Hospital State versus trait Assessability Face and Ecological validity Rule of 3Ps (MGH SAFER) criteria interview;|Had nonresponse', 'renal artery angiography;|Able to follow the study protocol', 'etc|Enrollment', 'baseline|Major surgery', 'beta human chorionic gonadotropin (β-hCG', 'clinical symptoms|at least 2', 'Ultrasound examination', 'completed', 'neuraxial anesthesia|History of', 'Willing', 'liver biopsy obtained', 'brain MRI', 'pharmacologic boosters cobicistat', 'systemic therapy', 'MpBC', 'biological drugs therapy', 'TAVR procedure', 'corticosteroid therapy', 'palliative care|Estimated survival', 'polymerase chain reaction (PCR) test results', 'clinical laboratory test', 'tocilizumab treatment', 'rapid molecular tests', 'CMC-1 OA', 'need intervention', 'heart transplantation|Patients', 'major abdominal surgery.||Exclusion criteria||Emergent surgery;|Abdominal vascular surgery', 'assessment of treatment response', 'biological immunotherapy', 'fistula repair', 'distal amputation', 'Rehabilitation Clinic', 'congenital cardiac abnormalities', 'SBU', 'rhythm strip', 'heart ultrasound', 'occupational therapists', 'organ transplants', 'renal transplant|Estimated glomerular filtration rate (eGFR)', 'laparoscopic abdominal surgery|American Society of anaesthesiologist class', 'atezolizumab treatment', 'six-item screener', 'fracture.|Major surgical procedure', 're-operated', 'bronchoscopic lung volume reduction||', 'period;|Blood donation', 'NASCET', 'gastric stimulation device surgically implanted', 'head and neck bone resection', 'knee X-ray examination', '¹³C-urea breath test', 'anticancer therapy|History of,', 'HIV test', 'test of illicit drugs', 'status||', 'intravenous therapy', 'complete assessment instruments|Chronic widespread', 'period.|Major surgery', 'lumbar puncture.||', 'orthodontic treatment.|Anti-inflammatory medication', 'acute treatment', 'fiberoptic laryngoscopy', 'Reactive"" test result of Hepatitis B & C, HIV', 'preoperative spirometry)||', 'left internal thoracic artery', 'slit lamp exam', 'cognitive', 'unique combination of', 'chemo-radiotherapy|Serious medical comorbidities', 'intravaginal DHEA', 'assessment.|Macroscopic intravascular invasion into the hepatic', 'tumor blocks', 'transient neuromuscular blockade|Bronchopleural fistula', 'life-sustaining therapies limitation decision was made|Patients hospitalized', 'upper digestive tract surgery|patients after trachea surgery|patients', 'invades', 'paramagnetic materials', 'adjunctive treatment', 'adeno-', 'HSCT)|Autologous stem cell transplant', 'smartphone usage||', 'hospice', 'open surgery.)||', 'surgery disseminated cancer disease', 'CD20|Prior treatment', 'distal landing zones', 'medical assessment', 'restricted patterns of', 'syncopal recurrences', 'laser surgery', 'World Health Organization (', 'stent are located', 'SmPC)|Fulfillment of the indication', 'home|Peritoneal dialysis time', 'Prediabetes Risk Test score', 'medical doctor|Medication', 'thoracoscopy', 'Inactivated viral vaccines', 'traffic citation|Vehicle', 'transfemoral TAVI', 'intramuscular injections', 'transsphenoidal surgery', 'emergency room|Post-traumatic chest pain', 'Single Fiber Electromyography', 'Teams', 'cancer therapy', 'regimens of chemotherapy', 'Endovascular treatment plan', 'brain computed tomography', 'ophthalmologic examination', 'World Health Organization (WHO) classification criteria for lymphohematopoietic neoplasms', 'surgery;|Previous', 'computer tomography', 'under chemotherapy', 'pre-operation plasma', 'orthodontic treatment|Optimum oral hygiene|Maximum', 'concurrent', 'cleft orthognathic surgery.||Exclusion', 'positron emission tomography/computed tomography (PET/CT', 'impulse control difficulties', 'organ transplant', 'bilateral hysterectomy', 'inguinal hernia repair is the main operation', 'antidepressant therapy', 'endovascular Abdominal Aortic Aneurysm Repair', 'surgical limb amputation', 'facial plastics procedure', '12-lead ECG.|History', 'Assessment Method score|Patients', 'transfusion ≤14 days of screening|aspartate aminotransferase', 'local therapy|First', 'IP on Day 1.|Lymphopenia', 'Digital rectal examination', 'external radiation therapy', 'screening|Oxygen desaturation', 'CT)or Magnetic Resonance Imaging (MRI) shows that the tumor', 'bronchoscopy', 'neurotoxic chemotherapy', 'enco/bini', 'Postoperative angiography', 'Plasma donation', 'hepatic veins', 'percutaneous contraceptive patches, IUD device', 'focal laser ablation', 'axis', 'intracoronary imaging', 'emergency dental treatment', 'metabolic panel', 'clear boundary on CT', 'ACL revision', 'concurrent resection of organs', 're-screening', 'bone biopsy staining', 'indication biopsy', 'thyroxine replacement are permitted||', 'herniectomy', 'stem cell transplant||Patients', 'local testing on', 'Wechsler Memory', 'dental trauma history', 'Histologically', 'supplemental food', 'blood cell (', 'daily treatment', 'imaging procedure', 'medical examination', 'complete survey', 'standard biologic therapy', 'ICU stay', 'extensive resection of', 'concomitant administration', 'Vertical Sleeve Gastrectomy', 'SUI|Gynecological surgeries', 'Diplegic Cerebral palsy|(GMFC', 'radiation 16 gray', 'sitting BP', 'vital signs examination', 'visits|World Health Organization (WHO)', 'implant', 'STS', 'vascular access catheter', 'IMP treatment', 'resuscitation maneuvers|Severe respiratory illness', 'skin laser surgery|Patient', 'physical exertion,|Any', 'permit access to wearable device', 'traumatic injury|Exclusion criteria', 'ICI) therapy', 'TTE', 'molecular profiling;|Written', 'behavioral strategies', 'Regular access', 'sample of the polyp', 'Ferrara', 'nephrectomy', 'preoperative ultrasound', 'several treatment sessions', 're-test', 'clinical laboratory tests)|BMI', 'smokeless tobacco.||Participants', 'checkpoint therapy-related immune mediated AEs', 'cesarean deliveries 6 months before the inclusion', 'treatment.|Antibiotic use', 'hormone therapy.|People', 'site(s)', 'chemistry panel', 'chronic systemic steroid therapy', 'variants|Concomitant treatment', 'emergency obstetrical care', 'Circular', 'IDA（iron depletion anemia）|In the second trimester of pregnancy', 'ER', 'coronary artery bypass', 'left pancreatectomy', 'ECHO).||Adequate organ', 'monitoring of water intake from food and liquids.||11', 'power seating', 'frontline therapy', 'digital palpation', 'palpation common extensor tendons', 'anticoagulant therapy.|Ascites', 'intra-aortic balloon pump/ ventricular assist device therapy', 'procedural intervention', 'vision rehabilitation', 'possible causes).|No have undergone', 'Transmural myocardial infarction', 'vaginal deliveries,|Presentation', 'immunosuppressive/immunomodulatory substances', 'laser therapy', 'hematopoietic stem cell transplantation|Active pulmonary tuberculosis', 'atrioventricular junction ablation', 'questionnaire.|Donation of blood in excess', 'intracerebral metallic foreign body', 'FDG-avid lesion', 'spermicidal', 'hematopoietic stimulating factors.):||Hemoglobin (HB)', 'neurologic examination', 'tobacco smoker|A contraindication', 'small cell lung cancer', 'interferons', 'conventional imaging techniques (CT', 'molecular testing (deletion of', 'treatment focal intramuscular injection', 'GI surgery', 'abdominal surgery.|Previous', 'transplanted graft', 'resuscitation from cardiac arrest|Significant neurological deficit', 'produce TE voice.||', 'antimicrobial agents', 'percutaneous needle tenotomy', 'haplo donor', 'Clinical Study Experience:||Is', 'therapeutic chest X-ray', 'clear cell renal cell', 'bladder fistulae|History', 'slides.||Patient characteristics||Eastern cooperative oncology group (ECOG) performance status', 'therapy for breast cancer.|Patients', 're-enter the group after chemotherapy', 'US.|Patients', 'periodontal therapy', 'urine routine examination', 'placement of ANNE One|Any condition (social or medical)', 'open wound over insertion site|Prior', 'drug intervention', 'internal radiotherapy', 'criteria:|Cardiac diseases.|Burn', 'medical disorders|Pregnant', 'anti-infective treatment', 'cashew nuts cashew', 'bone marrow involvement;3', 'field.|Local mismatch repair (MMR) immunohistochemistry (IHC) results available (both deficient mismatch repair (dMMR)', 'PET imaging radioligand', 'general anesthesia.|Operations', 'SMILE surgery', 'circulatory accidents', 'Technical Advisory Group', 'Hematological function#||-White blood cell count', 'SBT', 'bone marrow cell morphology', 'urethral catheterization', 'HCV tests', 'SPMSQ', 'palliative ostomy', 'rule', 'supramarginal resection', 'malignancy.|Undergoing procedures', 'QL1604 excipients|Radiotherapy', 'lymph node', 'MT).||', 'ABL1 fusion', 'intra-articular corticosteroid injection', 'histological examination|Patients', 'neurologic deficit))|Thymus gland problems', 'bone marrow suppressant', 'Consultant Dermatologist.|Patients', 'lead extraction', 'rescue therapy', 'pathological tissue types of non-small cell lung cancer', 'antidepressant regiment', 'ethics committee', 'therapeutic treatment', 'nutritional risk screening', 'routine blood tests', 'national asthma registry|Patients', 'Maswa', 'banding;|History', 'favorable intermediate risk', 'augmentation cystoplasty', 'lipid metabolism', 'viral testing', 'therapeutic anticoagulation therapy', 'resuscitation 10 minutes after birth', 'medical implant device', 'drugs|spinal anesthesia contraindicated|kidney failure|epilepsy', '12-point', 'pharmacologic treatments|Untreated periodontitis.|Poor oral hygiene', 'restrictions.|Radical radiotherapy', 'finger prick screening', 'thyroid disease)|Hormonal Replacement Therapy', 'CTI ablation', 'general anaesthesia|Patients', 'cryoablation.|Radiotherapy', 'lumbar puncture cytology', 'cardiogenic shock|Patients', 'injection treatment', 'alternative treatments', 'pretreatment endoscopic', 'volume [ABV] beer', 'oral glucocorticoid therapy', 'transient increase in stressful experiences|Use of', 'hours|Randomisation', 'intramuscular injection;|History', 'GEM program', 'characteristic signs', 'assessing viral burden', 'testing procedures', 'previous pneumonectomy', 'blood test', 'thyroid organ', 'pathological score', 'clear cell renal cell cancer (ccRCC)', 'test', 'regular physical activities', 'local treatment mainly', 'adjuvant radiotherapy', 'duty service members|>18 years old|Present to the emergency department', 'biopsy)|Active peptic ulcer', 'erythropoietin therapy', 'Ultraviolet light therapy', 'transarterial chemotherapy', 'microsurgical breast reconstruction', 'dendritic cell vaccine', 'SD-OCT|Total lesion size', 'dual antiplatelet therapy', 'mesenchymal stem cells isolated', 'Bilateral oophorectomy', 'radical concomitant radiochemotherapy', 'regular vinyasa', 'psychotherapeutic intervention', 'regional lymph node', 'skilled nursing', 'ICD code', 'breastfeeding', 'complete resection of limited colorectal metastases to liver', 'orthodontic treatment|Students', 'kidney after heart', 'study|Plasma donation', 'pharmacologic therapy', 'prevention', 'microscopy', 'technical logistical personnel', 'invasive coronary angiography', 'tests|Forgo donation of blood', 'combination hormones [containing estrogen', '™ catheters|Written informed consent||', 'blood oxygen', 'antiviral therapy', 'local-regional treatment', 'properly functional prosthetic', 'T cell infusion', 'address current', 'coronary artery reperfusion', 'revision knee arthroscopy', 'Conflict Tactics Scale', 'lung lesion(s)/nodule(s', 'cross section imaging by', 'blood pressure.||Exclusion criteria', 'thoracotomy', 'IDH1 mutation from testing of a primary', ')|Symptomatic knee osteoarthrosis', 'contraceptive injection Note', 'stem cell therapy', 'computerized tomography', 'criterion.|Serious medical comorbidities', 'Marijuana cigarettes.|Participation', 'cardiac MRI', 'dental treatment', 'hormone replacement therapy only', 'therapy exists', 'sorafenib treatment', 'nasopharyngeal swabs more difficult to perform', 'medical procedures', 'endoscopy-biopsy pathology', 'Sohag University Hospital', 'assessment', 'standardized psychometric tests', 'cranial CT', 'pretreatment CT', 'open', 'autologous transplantation waiting list', 'PrCa resulting', 'PN|Total estimated BSA treatment area', 'GBA1 pathogenic variant', 'standard unit', 'Regional recurrences', 'Churg-Strauss', 'surgical consultation', 'Hodapp Anderson Criteria||', 'small molecule investigational drugs', 'inotropic/adrenergic support', 'palliative surgery planned|Radiological signs suggesting metastases not accessible to surgical removal', 'small cell neuroendocrine carcinoma', 'hormone replacement therapy);|Those', 'coronary artery bypass grafting', 'Blood Biochemistry', 'herpetic neuralgia;|At Screening', 'ET', 'week|Current oral anti-diabetic', '6 months duration|Eaton', 'Electroconvulsive Therapy', 'autologous stem cell transplantation|Measurable MM disease', 'FRAIL questionnaire', 'immunosuppressive doses', 'Ethnic Health Research', 'pharmacist-related services', 'psychotropic medication', 'full mouth plaque score<30%|Previous non-surgical periodontal therapy', 'Nerve Stimulation (VNS)', 'Laparoscopic PPGL resection||', 'systematic psychotherapy', 'D-mannose supplements', 'latest international recommendations', 'EXCEPT', 'cardiac examination', 'e-diary', 'Histology', 'chondroplasty', 'Epilepsy surgery', 'Bariatric surgery', 'cause).|Corneal surgery', 'hypertensive patients|Those incapable of verbal communication', 'traumatic surgery', 'deep anesthesia', 'Bacillus Tuberculosis)|Major surgery', 'placental position|Scheduled', 'laboratory test values', 'gastric varices|patients', 'BORG scale.||Willing', 'know Turkish', 'hypertension|Major surgical treatment', 'visit.|Previous treatment', 'sequencing|Peripheral blood', 'general anaesthesia', 'vitrectomy', 'full table.|Therapy-related AML|Patients', 'peripheral vein puncture', 'First-time', 'abdominal chemotherapy', 'Rapid Estimate of Adult Literacy', 'intratumoral cavitation', 'palliative systemic therapy', 'tissue biopsy', 'Botulinum toxin injection treatment', 'allogeneic hematopoietic stem cell transplant', 'intraoperative conversion', 'R1 resection', 'Primary Care Provider (PCP) clearance', 'arthroscopic knee surgery)|BMI', 'caesarean delivery|Age', 'situations', 'congenital epiphora', 'inhaled treatment', 'chest auscultation|Clinically relevant', 'small-cell carcinoma component.|History', 'regular consumption', 'chemotherapy regimen', 'B-cell type', 'produce a sputum plug', 'face mask|Baseline blood glucose', 'exhausted', 'intensive therapy', 'psychosocial therapy', 'exclusive CIRT treatment', 'radical radiotherapy', 'small bowel resection)|History', 'bypass grafting', 'Histological examination|Withdrawal of ICF', 'endoscopic procedure', 'adjuvant chemotherapy', 'embryo transfers', 'diagnostic biopsy|Patients capable', 'primary procedure', 'PET-CT already', 'spine surgery', 'brain MRI Neurological tumoral, degenerative', 'oocyte donation', 'psychopharmacological treatment', 'medication.|Physical examination', 'oropharyngeal candidiasis', 'pharmacological medical treatment', 'hematopoietic stem cell HSCs transplant', 'Holter ECG', 'tonic-clonic seizures|A clinical indication', 'first surgery||', 'induction attempt', 'Maintenance therapy', 'ECT', 'Surgical Intermediate Care Unit (SIMU)|Informed consent obtained||', 'lumbar cytology', 'compounds|Siblings of the participants will not', 'lipodystrophy', 'blood glucose', 'talk', 'collagens);|Urine protein', 'refusing chemotherapy', 'thin rectovaginal septum', 'regular medical therapy', 'ventricular pacemaker implantation', 'bariatric surgery', 'serology', 'cardiac echocardiogram', 'nonselective β-blocker', 'hot ampullectomy', 'endovascular interventional therapy', 'intubation shortly after', '1 supervisor', 'Metastases Directed Therapy', 'central MRI reader.|Participants', 'RECIST1.1 criteria;|HRD gene mutation', 'bone marrow involvement||NOTE', 'genetic stem cell therapy.|Diagnosis of significant', 'left anterior', 'clear cell renal cell tumor', 'primary total knee', 'Open groin incision', 're-expressed MDRD equation', 'lacunar cerebral infarction', 'Simpson method）<35%；|24', 'triphasic CT angiography.|Execution of mechanical endovascular thrombectomy procedure', 'Cryoablation', 'insulin therapy', 'cutaneous vagus nerve stimulation', 'intraarticular knee injections', 'hasty', 'active antiresorptive treatment', 'CNS imaging (CT', 'visual', 'knee X-rays', 'SD-OCT)|Mean foveal thickness', 'Small cell lung cancer', 'instance medications', 'chest pain|Known allergy', 'monitoring of rejection after lung transplantation|The patient should undertake', 'hospital system', 'positron emission tomography-computed tomography [PET-CT]', 'defective color vision|History', 'sling placement|Known', 'birth control pills', 'baseline screening test for S. aureus nasal colonization,|Parent/adult', 'CSS therapy', 'puncture', 'lactose-free diet', 'herbal remedies', 'complete online questionnaires||', 'cochlear implants|Received TMS, tCS', 'hematopoietic stem cell transplantation|Adult patients', 'liver cirrhosis)|Drug dependance history|Untreated', 'systemic therapy|Major surgery', 'fibroid treatment', 'plasma cell leukemia', 'ECG extraction', 'chest surgeries', 'full mouth Plaque Index', 'CT chest', 'chemotherap|Planning CT starting', 'study|Compression therapy', 'anticancer treatment of', 'clinical laboratory tests suggestive', 'postoperative therapy', 'treatment non-responder||', 'between end of radiotherapy', 'refused treatment', 'intensive induction OR|For', '2015).|Mini-Mental State Examination score', 'UVB phototherapy', 'DEXA scan', 'completion of therapy', 'prognostic risk group', 'extensive abdominal spread|WHO/ECOG performance status', 'video technology', 'hormone-based treatment for breast or', 'platelet inhibition therapy', 'nephrotomy', 'venous access', 'allogeneic organ transplant.|Receipt of', 'local anesthesia', 'sperm donation', 'abdominal surgery;|body mass index (BMI)', 'completed endocrine induction therapy', 'allogeneic hematopoietic stem cell transplantation|Stem cell transplantation', 'bone graft', 'bilateral neck adenopathy.|Immunohistochemical staining', 'emergency visits', 'autologous hematopoietic stem cell transplant', 'valve surgery', 'complete SARS-CoV-2 vaccination.|Start vaccination', 'peritoneal dialysis', 'radiofrequency thermoablation', 'intracranial aneurysm clips', 'disease|Esophageal dilation', 'institutional program', 'smart phone', 'solid organ transplantation', 'screening contrast brain MRI', 'isolated blips', 'fondaparinux sodium', 'systemic therapy|history', 'automated', 'cesarean delivery|Gestational age', 'mechanical ventilation|procedures related', 'psychosocial consultation', 'placement of vascular access device', 'skeletal radiography', 'etc.)|Major surgery', 'Global Impression-Severity', 'foreshortening', 'histopathological types', 'safe placement', 'PET/CT imaging', 'Replacement therapy', 'gastric surgery', 'ICSI', 'bilateral iliac veins', 'endoscopic eradication therapy', 'trecheostomy done', 'typhoid vaccine', 'local ablative therapy', 'treatment of HS.|Total', 'bile duct narrowing', 'cosmetic procedures', 'planned surgical procedures', 'uterine sounding', 'reirradiation', 'extensive recuperation', 'CT guided bone biopsy', 'Macroscopic incomplete resection of the primary tumor', 'local guidelines.||Exclusion criteria||Prior', 'bilateral ovariectomy', 'computed tomography venography (CTV)', 'conventional CT', 'satisfaction', 'optimal treatment|Thoracic deformation (For example, pectus excavatum/carinatum', 'nitrates', 'signature|Good general health status|Planned ophthalmic/plastic surgery', 'cell transfusion', 'tips of the electrodes', 'Biopsy', 'complex surgery', 'stereotactic therapy', 'maintain peripheral arterial oxygen saturation', 'World Health Organization definition of osteoporosis', 'Interim Guidelines ""Prevention', 'diagnostic surgery', 'magnetic resonance imaging-diffusion', 'recession with recession', 'hormonal birth control products', 'transarterial embolization', 'cardiac interventional therapy', 'hormonal contraception', 'CT imaging', 'mental health', 'sterilization', 'safe surgery', 'intrauterine device', 'inhaled oxygen concentration', 'Evaluation to Sign Consent tool.|Is', 'single-blind food challenge tests', 'Positron Emission Tomography -Computerized Tomography scan', 'injection of hyaluronic acid', 'clear pathological diagnosis', 'biological investigational therapy', 'CT pulmonary angiogram', 'tumor resection of bladder', 'laboratory safety tests (serology', 'intravesical chemotherapy', 'antifungal therapy', 'local XRT.|Subjects must', 'cardiac surgery', 'antihistamines', 'MDI);|peripheral neurological lesion', 'access study assessments', 'chemotherapy;|Other researchers think it', 'neuroleptic treatment', 'optimal antihypertensive treatment.||iii', 'central laboratory test', 'chest radiograph', 'Natural Health Product]', 'forming procedure', 'HBV therapy', 'physical malfunction of the sensor sites which would', 'Incarcerated', 'volume sensitive HF phenotype', 'CT scan premedication', 'child enrolled', 'tissue biopsy after completion of clinical visit', 'interventional procedures', 'O.A', 'cardiac transplant', 'local treatment guidelines', 'intra-articular injections', 'upper abdominal surgery;|Patients', 'cervical arthrodesis', 'chest radiotherapy before|Bacteria', 'aortic', 'local laboratory determination', 'hormonal intrauterine device', ""BPH)|On urethral Foley's catheter"", 'allohematopoietic stem cell', 'Therapy Related Criteria', 'erythematotelangiectatic rosacea', 'microdiscectomy)|Having surgery', 'blood glucose control', 'multigated acquisition scan (MUGA)', 'Tours', 'birth date|Birth', 'abuse|Critical surgery procedure', 'walk full weight bearing', 'percutaneous thermoablation', 'hamstring', 'axillary temperature', 'Rituximab treatment', 'Inpatients', 'vascular access that could make unsafe PCI;|Patients', 'meniscal flap tear|Patients', 'quality of life', 'systemic antitumor therapy', 'transplantation|Laparoscopic surgery||', 'diagnostic CT [', 'surgical management', 'treated in situ carcinoma', 'clinical laboratory tests', 'laser ablative procedure', 'common femoral artery after a previous', 'EBUS-TBNA/EBUS-TBCB', 'imaging evidence);|Estimated', 'TFE3 rearrangement renal cell carcinoma', 'intravesical therapy', 'hormone therapy)|Significant', 'lumbar spine.|MRI results', 'regular menstruation', 'radiographic imaging consistent', 'serum β-chorionic gonadotropin test)', 'back surgery syndrome', 'liver transplant list|use of', 'ambulatory', 'radical pelvic surgery|History', 'curative salvage prostatectomy', 'FULFIL THE ELIGIBILITY CRITERIA OUTLINED BELOW', 'oriental therapy', 'disease);|Active fungal', 'chronic antibiotic therapy', 'radiculopathy|Vascular claudication|Anterior knee pain', 'intravenous iron therapy', 'hormonal therapy directed', 'S-ICD implantation', 'endovascular revascularization', 'left ventricular hypertrophy (', 'radiographic evidence|Infection', 'whole grains', 'Nicotine replacement therapy', 'hyperlipidemia|Be', 'lipid lowering-drugs', 'metabolic rehabilitation', 'lumbar neuroaxis', 'botulin toxin injection', 'surgical excision alone|Planned palliative', 'transcatheter arterial chemoembolization', 'retention of ovary function', 'biochemical profile', 'Rapid Antigen Test Device.|Participants who did not change their diet within three months before the screening day and are willing', 'insufficient comprehension of the Spanish language', 'chemotherapy regimen|Engage', 'erforming', 'psychotropic substances', 'Electrical impedance tomography monitoring', 'caesarean section scar dehiscence', 'Cannabaceae plant family (', 'CT scans/MRI obtained', 'autologous transplantNatural Killer Cell Malignancies', 'open fallopian tube', 'Intragastric balloon removed', 'caffeine daily consumption', 'products.|Participation', 'allogeneic cell therapies', 'total knee arthroplasty surgery', 'exon 14 mutations', 'CAG for', 'screening assessment', 'systemic therapies', 'General Surgery', 'definitive treatment', 'corticosteroid injection', 'intervention therapy', 'hepatitis|High blood pressure|Elevated transaminases', 'artificial tear substitutes', 'assistance', 'gastrointestinal surgery making oral drug administration impossible', 'standard MASD treatments|life expectancy', 'staging scans', 're-', 'Neutral Video Session', 'standard neuropsychological examination', 'allogeneic HCT', 'mucogingival surgery', 'cataract|Regular total corneal astigmatism', 'blood cell', 'primary intervention file between', 'liver volume', 'Terminal state', 'biological agents', 'regular annual mammography', 'orthodontic treatment,|inflammation', 'abnormalities|Mini-Mental Status Examination', 'blood cell transfusion|Dialysis', 'irrespective of valvular heart disease|Inability to provide informed consent|Participation in another clinical trial', 'pelvic lymphadenectomy', 'basilar invagination', 'splenic surgery|Prior radiation', 'standard methods|Primary', 'instilled radiolabeled sodium', 'needle phobia.|Participation', 'potential medications', 'facial treatment', 'imaging technology', 'cALD', 'ICU)|Pulmonary artery catheter', 'forbid transfusion', 'invasive cancer;|No surgical treatment', 'Definitive treatment', 'Plasma Cell Leukemia', 'computed tomography imaging of the abdomen', 'BRAFV600E mutation', '24-hour urine protein quantitative test', 'aspirin monotherapy', 'trained neurologists.||', 'MR imaging', 'sympathectomy', 'IUS Levonorgestrel Intra Uterine System (Mirena)', 'ABA therapy', 'histological analysis', '50 g spirits', 'radiotherapy of the head', 'eating disorder|Restricted', 'catheter change', 'intracoronary provocative test', 'heart valve replacement', 'active surveillance.|Inactive', 'Montreal Cognitive Assessment screening test score', 'primary therapy', 'blood donation from clinic admission', 'DIPG', 'histologic evaluation', 'hronic ETDD):||>3 months', 'curative intent therapy', 'UV therapy', 'anti -tuberculosis treatment', 'Periodontal treatment', 'pancreatic', 're-induction', 'implant placement', 'conventional anticoagulant therapy.|Severe bleeding tendency', 'completed this therapy', 'standard doses of salicylates', 'neural stimulation', 'hemo-', 'graft from a donor that', 'PEP-DC1 vaccines', 'left heart disease|Patients', '5)||Chronic treatment', 'Lymphodepleting chemotherapy', 'ultrasound imaging', 'secret||', 'testing begins|If', 'small enclosed spaces', 'Histological confirmation', 'seizure control', 'coronary artery bypass graft (CABG)', 'Biliopancreatic diversion||Clinical concern', 'peritoneal dialysis;|Blood', 'clinical tests', 'Health Maintenance', 'exercise ECG', 'ITB treatment', 'total hip replacement after', 'polymerase chain reaction test', 'imaging ASCVD', 'chest pain.|Previous CABG', 'smart technology', 'stent placed', 'Renal transplant', 'Surgically', 'endovascular therapy|A', 'unchanged antihypertensive drugs', 'radical mastectomy', 'cumulative smoking status', 'chest CT scan.||Note', 'major conjunctival surgery', 'biweekly therapy', 'tubal surgery', 'liraglutide).|Gastroparesis|Low carbohydrate diet', 'emergency surgeries|Surgeries', 'local laboratory testing.|Patients', 'blood cancers:||1', 'pneumococcal vaccine', 'rapid-', 'preoperative education of the patient during consultation.|Patients will be required to stop smoking', 'étranger métallique', 'psychotropic medication changes', 'refractive surgery.|Down syndrome', 'Visit 2 baseline||Exclusion Criteria', 'preoperative imaging', 'Pathological confirmation', 'lipid lowering therapy', 'standard induction chemotherapy regimen', 'gastrointestinal surgery 6) Suffer from mental illness', 'medical reasons.||Cohort', 'baseline||', 'radioactive iodine treatment', 'T-cell transfer therapy', 'percutaneous sacral fixation|Enrollment', '-reading.|Receiving care', 'donated whole blood', 'urine drug Screening', 'emergency surgeries', 'close monitoring', 'isolated CRLM', 'surgical intervention|Previous treatment|Cancer', 'fungal culture', 'spinal surgery,|major surgery', 'left ventricular enlargement', 'palliative first-line therapy', 'regular treatment', 'local laboratories', 'hours|Baseline platelet count', 'volume analysis for split renal function|Patient', 'local palliative radiation therapy', 'perfusion index values', 'cellular immunotherapy', '21)/RUNX1-RUNX1T1', 'COVID testing', 'rapid fatigue', 'FFR', 'small interfering RNA51)||', 'WhatsApp users|preclinical medical students', 'intra-knee', 'hammer toes', 'Fludeoxyglucose F-18 (FDG) avid', 'histology|International Federation of Gynaecology', 'inguinal hernia|Incarcerated inguinal hernia|Hernia', 'therapeutic endoscopy|Patients', 'optimal medical therapy', 'permits assessment of the skin fold condition(s', 'anamnesis', 'control biopsy', 'hospital documentation|Spinal imaging of the stimulator system||', 'abdominal surgery|Patients', 'corticosteroid intraarticular injection', 'peripheral oxygen saturation', 'TRS', 'confirm DIPG', 'gastrointestinal surgery|Active duodenal', 'cessation', 'electrocardiographic', 'implant loading protocols|Uncontrolled', 'Triglyceride TG≧500', 'clinical manifestation', 'clinical laboratory test value', 'Tumour removed', 'radiographic imaging.|Target stone', 'repetitive MRI body scan|Requires chemotherapy', 'nerve root decompression|Patients have', 'dental implants.|Having adequate bone quality', 'vascular surgery', 'without||a normal EKG', 'VHC', 'Emergency Reception Service (ERS)', 'immunotherapy (SCIT) Note', 'transplant donor', 'brain surgeries', 'pulmonary embolism|History of', 'blood transfusion|Life expectancy', 'transient elastography', 'outpatient therapy', 'craniotomy', 'Percutaneous coronary intervention', 'immuno-oncology therapy', 'allogeneic stem cell transplantation (HSCT)', 'refractive surgical procedures', 'pleuroscopy', 'Initiative.|Clinicians', 'anticoagulation', 'ileocolonic surgical resection', 'mineral panel', 'regular opiate', 'Intraoperative radiotherapy', 'blood count', 'Transfemoral unilateral amputation', 'caries treatment', 'screening echocardiogram', 'pregnancy testing', '1-4', 'oncologic surgery', 'puncture biopsy', 'Tumour biopsy', 'women;|Bilateral mastectomy', '24-hour urinary assessment', 'IGF-1 therapy', 'histopathology report||', 'vision design|Valid contact lens prescription', 'hepatic blood flow', 'myomectomy', 'Wechsler Memory Scale IV', 'headache,|Not', 'thyroid hormone', 'Immature roots viii', 'immunosuppressive intent', 'MRI examination - patients', 'corneal refractive', 'laparoscopic donor nephrectomy', 'pancreatic CT scan', 'physiological melanin hyperpigmentation', 'imaging physicians', 'intestinal stent implantation.|', 'psychotic|Unstable general medical condition|Current use of', 'medical treatment', 'Xioami smart band', 'comparative genomic hybridization', 'arthroscopic shoulder surgery|patients', 'osteotomy', 'first-line immunization', 'allogeneic stem cell transplantation', 'intervention procedures', 'CHUV', 'airway surgery', 'vaccination plan', 'laparoscopic liver surgery', 'step counting', 'fine needle biopsy', 'cesarean delivery,|In cesarean delivery', 'laser therapy.|Eyes', 'rapid plasma reagin', 'autologous stem cell infusion', 'stereotactic radiotherapy', 'RZV immunization regimen.|Pregnancy', 'cadaver donor transplant', 'pancreatic surgery', '24-hour', 'chest discomfort|Primary assignment', 'transrectal ultrasound', 'polymerase chain reaction (PCR) result before', 'emergency surgery；|No', 'infraorbital nerve distribution', 'focal ischemia of the brain', 'B-cell maturation antigen (BCMA)', '12-ECG showed', 'Effective medications', 'DIEP flap breast reconstruction.|Performance status', 'Induction therapy', 'factor:|Surgery', 'local radiation therapy', 'assessment sessions.||', 'GRIN', 'Participates', 'refractive outcomes', 'found.||General Inclusion Criteria:||Give written informed consent', 'ETV', 'prophylactic purposes', 'stabilized dose', 'retinopathy|Ambyopia|Extremely shallow anterior chamber|Severe chronic uveitis|Pregnancy', 'blood loss|Recurrent', 'bladder instillation therapy', 'Hydroxyurea|previous cytotoxic therapy', 'unfractionated heparin', 'splenectomy', 'expected cystectomy surgery', 'Nuss procedure', 'oral sex', 'hip surgery', 'NAST)|received sentinel lymph node biopsy (', 'complete retinal degeneration', 'UST dose', 'months.|No XANTH supplementation', 'upper airway surgery', 'shortness of breath on exertion', 'transplantation', 'bone marrow transplant.|Any', 'craniofacial trauma/surgical', 'hair growth', '""target lesion""', 'before.|History of organ transplant', 'blood biochemistry', 'manifest refraction', 'esophageal stent', 'apparent medical reason', 'VV-ECMO', 'extensive intra-abdominal surgery|To', 'positron emission tomography (PET) scan', 'artificial disc replacement)|History', 'ketamine therapy', 'vasopressor', 'Pemetrexed + Cisplatin Therapy.|Willing and able to comply with all aspects of the treatment protocol.|Provide written informed', 'confirmatory imaging', 'chronic opioid', 'cumulative doxorubicin', 'radioactive iodine contrast material', 'cervicogenic headache.|Stable', 'par)enteral antibiotic', 'small VSD', 'interventional research||For control', 'RBC transfusions|failed', 'Blood biochemical examination', 'positron emission tomography', 'bilateral ovariectomy In', 'Emergency Use Authorization vaccine', 'ends).|Physical examination', 'cesarean delivery|Receive spinal anesthesia', 'hospice care|inability to communicate', 'varenicline nasal spray', 'planned vaccination', 'cardiopulmonary exercise test', 'physiotherapy for neck pain', 'ablation procedure', 'papulopustular rosacea', 'RCC', 'extraocular surgery', 'old;|Bronchoscopy', 'erythrocyte sedimentation rate', 'radical operation for their primary tumor', 'liver transplantation;Known', 'Gastric band', 'cervicovaginal junction.|History of extensive abdominal surgery', 'leukemic organ involvement', 'digital subtraction angiography', 'fresh vaginal samples', 'stenting', 'TME therapies.||', 'standard dose vitamins.|Donation of plasma', 'old.|Good oral hygiene', 'complete oral examination', 'flexible ureteroscopy', 'female)|Uses recreational', 'modulating therapy', 'IC-MPGN', 'EGD', 'upper endoscopic ultrasound', 'surgical bilateral oophorectomy', 'bleeding.|Underwent colonoscopy', 'ileocaecal resection', 'metabolic equivalents', 'heart/lung', 'standard treatment regimen', 'Wechsler Intelligence scale)|acuity levels suggesting need', 'computed tomography scan premedication).||Active', 'Wechsler Memory Scale - Revised', 'monogamous relationship', 'endocrine disorder,|Any bariatric surgery', 'splenectomy||', 'chest radiotherapy', 'Medical trainee', 'EVAR', 'FISH testing', 'histology', 'planned arthroplasty', 'antimicrobial therapy', 'kidney transplant.|Planned surgery/procedures', 'placebo', 'bone scan.||', 'IVT injection', 'maintaining suction', 'US|Preoperative CT-Scan', 'standardized meal', 'inguinal hernia repair|Be', 'major surgical surgery', 'replacement therapy use', 'electrotherapy', 'cardiac surgery episode', 'breast surgeries', 'Mild Trauma Brain injury (TBI)', 'computed tomography imaging', 'seeking therapy', 'fecal calprotectin', 'intervention delivery in their clinical role|Begin employment', 'resective periodontal surgery', 'minor procedures', 'further treatment', 'thorasic surgery', 'complete elimination', 'extensive tattoos', 'implant target artery - assessed', 'knee replacement surgery of the target knee.|Subject requires', 'iliofemoral DVT||', 'endodontic therapy|Mandibular first molars', 'palliative radiation', 'biotargeted therapy', 'revision total', 'thermal pulsation', 'cognitive impairment);|Pregnant', 'stent thrombosis.||Written Informed Consent to participate in the study.|Antiplatelet Naïve on admission', 'first-line therapy.|imaging evaluation (CT or MRI', 'baseline pre-bronchodilator', 'radiologic imaging contrast', 'scoliosis)|A lifetime', 'cancer|Adjuvant chemotherapy', 'full active treatment', 'sample donation|Personal', 'diagnostic TURBt', 'Nasopharyngeal Swab (NPS)', 'colonectomy', 'antipsychotic therapy', 'radiofrequency.|Previous sternotomy operation', 'open thoracic surgery', 'complete endometrial ablation', 'intensive chemotherapy', 'maintenance therapy|Within 6 months of completion of initial treatment', 'significant surgery', 'venous access sufficient', 'embolization therapy', 'household food preparation|read/speak English', 'pharmacological treatment).|Proficient', 'umbilical hernia', 'autograft technique', '12-lead ECG)|History', '≥1 coronary', 'median sternotomy', 'special social situations', 'adenosquamous', 'SMILE procedure', 'allogeneic organ transplantation|Control', 'Global initiative for', 'surgery', 'transvaginal ultrasound', 'Airway management', 'biological anti-tumor therapy', 'lower cumulative dose of glucocorticoid', 'standard treatment options||• Phase IIb', 'ileocolonoscopy', 'ligament surgery', 'retinopathy|Amblyopia|Extremelly shallow anterior chamber|Severe chronic', 'sacral neuromodulation', '""', 'transfusion of whole blood', 'dual-therapy inhalers', 'oocyte retrieval', 'ureteral stones', 'screening blood sample', 'internal monitoring', 'Experimental', 'Previous surgery', 'bileaflet origin;|Patients operated', 'transfusion of platelets|Documented evidence', 'Transcranial Magnetic Stimulation Adult Safety Screen', 'professional exercise therapy', 'smart ring', 'tirbanibulin treatment', 'Yukon Choice Flex stent', 'study.|No treatment', 'simple confusional state assessment test', 'cerebral scan', 'symptomatology', 'thoracic surgery before|Patients', 'show', 'therapy with', 'therapy targeting CEACAM5.|Prior maytansinoid DM4 treatment', 'caustic ingestion', 'familial history', 'antihypertensive drugs|Voluntary participation', 'organs function', 'opioid maintenance treatment', 'treatment guidelines', 'CT enterography (CTE)', 'Unusable x-rays', 'steroid treatment', 'cooperative||', 'WUSM', 'Lumbar epidural lipomatosis', 'Psychotherapy', 'angioplasty ± stenting', 'donation of more than 400 mL', 'Digital mammography', 'cardiac transplant surgery', 'serious respiratory diseases', 'NSM procedure', 'VATS lung resection', 'graft source', 'lipid-lowering treatment', 'hospitalisations', 'prone predisposition', 'language intervention', 'intracranial electrodes', 'iliofemoral DVT|Prior venous stent', 'triplet chemotherapy', 'directional coronary atherectomy', 'gastric bypass/bariatric', 'HCV reactivation', 'Fridericia formula', 'spinal column', 'definitive local therapy', 'pre-transplant blood sample', 'TACE treatment', 'standard therapy exists', 'Elective PCI', 'assessment of medical history', '12-lead ECGs.|BMI', 'guardian.|Feel comfortable discussing', 'hematologic function.||Laboratory tests', 'animal protein (', 'cognitive function evaluation', 'small molecule anti-angiogenic TKI drugs', 'hormonal treatment', 'world', 'Testing for HIV', 'allogeneic', 'Ultrasonography', 'gestational age)|Multiple', 'SCLC.|Participants', 'protocol biopsy', 'open head injuries/lacerations|Those', 'calcification of the apical foramen', 'lower grades', 'competitive rower', 'vascular ultrasound', 'sessions', 'single-barrier method', 'lung lesion', 'psychotherapy', 'R0 resection effect);|Postoperative ctDNA-positive', 'Internet-connectable device', 'intravenous anesthesia', 'spirometry test', 'muscle biopsy', 'small molecule targeted drug therapy', 'smartphone|Willing', 'supplemental oxygen', 'refusal|Suboptimal echocardiography', 'multimodal rehabilitation program', 'transfusion|Creatine ≤1.7 x upper limit of normal (ULN)', 'anorectal surgery', 'criteria.||non-nodal lesion', 'complete remission.|Current treatment', 'instruments.|Protrusion of the 50A Imaging Balloon', 'anal surgery', 'slit-lamp', 'LVRS', 'long-stay unit|Non affiliation', 'X ULN)|Aspartate aminotransferase', 'donate sperm', 'ECHO', 'total wrist arthroplasty', 'oximeter|False nails', 'clinical laboratory assessments', 'treat CNS disease', 'cyclosporine therapy', 'IA injection of PRP in the target knee', 'kidney biopsy findings', 'maintenance chemotherapy', 'testing of proteinuria', 'complete blood cell count', 'local lymph node metastases', 'expression of', 'country guidelines', 'ocular vision', 'antiemetic therapy', 'lipid nanoparticle', 'gastric balloon', 'central lymph node', 'hysteroscopic)|Pelvic exam findings considered', 'videofluoroscopic swallow', 'sessions|Surgery', 'DBT', 'whole pelvis radiation therapy', 'TAVR abdominal CT||', 'substitute decision maker is able to provide informed consent|Patient', 'Individuals enrolled in other physical training programs', 'hospitalization|Current acute', 'Emergency surgery Cardiovascular', 'online survey panel called KnowledgePanel|able to complete survey', 'abdominal radiotherapy', 'Immunosuppressive therapy', 'optic nerve involvement', 'surgical bypass', 'RCTs', 'esophageal cryotherapy', 'mindfulness intervention', 'Ebola', 'chemotherapy|Histology consistent with adenocarcinoma', 'psychotropic treatment', 'ipsi-', 'left side', 'sedentary lifestyle Intrauterine growth restriction', 'clinical management', 'mRCC|Major surgical procedure', 'Study procedures', 'enteral medication|Patients', 'AVA indexed', 'Positron emission tomography (PET) SUV', 'discontinuation of prior therapies', 'propranolol', 'progression over', 'preventive treatment', 'fresh tumor biopsy collected on Day 1 of treatment', 'tertiary neonatal intensive care unit', 'cycloplegic refraction', 'X-Ray)||', 'women;|Oral iron therapy', 'tympanometry|Familial', 'oral iron', 'Cardiac Rehabilitation (NACR) outcome', 'polymerase chain reaction', 'surgical intervention.||Exclusion', 'canal treatment', 'radiographic contrast agents.|Bladder outflow obstruction', 'endoscopic ICG injection', 'PCI|PCI', 'DME treatment', 'Vertical sleeve gastrectomy iii', 'medical history|Uncontrolled', 'regional prescribing', 'Surgical Amputation|Patients', 'treatment-naive', 'professional desensitizing therapy', 'PICC', 'site procedures', 'β-HCG over expression', 'real-time polymerase chain reaction (PCR) measurement', 'empiric therapy', 'August', 'slit-lamp findings;|Abnormal fundus examination;|Ocular disease', 'apical with anterior', 'therapeutic mastectomy|Patients', 'pelvic effusion).|uncontrolled', 'Standard risk for Treatment Related', 'opioid therapy', 'intravascular imaging', 'Esophagogastroduodenoscopy', 'hip/knee replacement', 'penetrating keratoplasty', 'cervical biopsy', 'chest radiation', 'progressive- addition lenses', 'tumour biopsy', 'persistent airflow limitation', 'coronary artery bypass graft (CABG) surgery|Inability to clearly identify', 'types of surgery not involving the digestive', 'good oral hygiene', 'carcinoma|Prior chemotherapy regimen|Treatment', 'thoracic surgery|Patients', 'aspiration biopsy', 'Left anterior descending artery [LAD]', 'chemo treatment', 'Chest pain|ECG changes|Elevated', 'Orthopedic surgery', 'therapeutic dose', 'heart valve repair/replacement', 'gynecologic oncology', 'brain imaging examination', 'specialized environment|Contra indication', 'SARS', 'subjects;|The investigator believes', 'Multifocal IOLs|Combined surgery', 'Small cell component).|ECOG performance status', 'surgery intervention', 'MRI procedures', 'opioid treatment', 'patients|BMI<35||', 'frenuloplasty', 'Small Lymphocytic Leukemia', 'Video Session', 'Periodontal Disease||Exclusion||3 months patients should have', 'FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL', 'invasive cancer|neurological', 'peritoneal implantation metastasis', 'treatment of non-autoimmune', 'electric pulp testing', 'real-time', 'hernia', 'therapeutic endoscopic procedure(s', 'lipid-lowering', 'B-cell NHL expressing CD20 by immunohistochemistry (IHC)', 'genetic', 'receive treatment', 'pelvic organ surgery.|the use', 'coronary artery bypass graft', 'myopia control', 'pharmacotherapy', 'analgesia||', 'selected control persons', 'compansatory strategies.||', 'Surgical procedure', 'permanent treatment', 'gastrointestinal disease|Gastrectomy', 'doublet chemotherapy', 'pathological fractures|Patients', 'Hallym', 'cardiac transplantation', 'lamp', 'dialysis before surgery', 'scope||-', 'hepatobiliary surgery', 'placement of a tenaculum and/or uterine sound', 'produce a negative pregnancy test', 'valve repair/replacement', 'coronary artery anomaly', 'placebo fields', 'static fine lines trend', 'seizure|General surgery', 'lung metastasis', 'Bicuspid Aortic Valve by', 'partial gastrectomy', 'receveid', 'Oral Contraceptive pills|Patients', 'European Union (', 'DED', 'mitral valve surgery', 'universal', 'trial SCS period', 'voided', 'cholesterol drug treatment;|Elevated triglycerides', 'alternative medical cause)|Male', 'hospitalization||', 'Wechsler Intelligence Scale', 'fecal occult blood test', 'January 2020)|Chest radiographs from patients with', 'optical coherence tomography', 'open cholecystectomy', 'prosthetic revision surgery', 'disease|Assistive reproductive technology', 'antidepressants.|Short procedures', 'stent intervention;|Kidney size', 'hepatic function', 'vascular surgery)|45 years', 'prebiotics daily', 'bilateral tubal litigation', 'general surgery', 'hair color', 'open-chest surgery', 'hemorrhoidal prolapse', 'open incisions', 'adjuvant systemic treatment', 'e cigarettes', 'cholecystectomy.|Typical imaging', 'theCardiac Surgery Department of', 'focal laser', 'subpectoral reconstruction|Patients', 'chemo-radiation', 'participation.||Details', 'ANTICOAGULANT THERAPY', 'telemetry monitoring', 'corrective liver transplant', 'Lewy body dementia developed', 'diagnostic angiography', 'situ hybridization (FISH)', 'treated', 'venous blood collection;|history', 'standard therapy.|A histologically', 'Therapeutic Arm):||Participants', 'electroconvulsive therapy (ECT)', 'deterioration of clinical conditions', 'colonoscopy done', 'mature tooth.|control', 'professional medical attention', 'standard STUP treatment', 'abdominal aortic aneurysm contiguous', 'orthognathic surgery', 'spine tumours||', 'flags', 'transmural myocardial infarction', 'share', 'complete inhalation oxygen', 'traumatology clinic', 'PET procedures', 'chart review', 'PEP treatments', 'medical procedure', 'supplemental oxygen equipment', 'procedure(s', '12-lead ECG QTcB', 'paraesophageal hernia repair||', 'NSAIDs;|Positive diagnosis', 'mental health triggers', 'bilateral tubal ligation', 'recovery', 'immunotherapy', 'gastroesophageal junction', 'clear band', 'video recording|Affiliated', 'immunosuppressive therapy|Prior exposure', 'mitral valve repair (', 'sperm donation plan', 'interventional studies', 'radiation therapy.|Carriers of', 'emmetropia', 'graft', 'stent treatment', 'Impulse Control', 'standard treatment progress', 'anti-tumor treatment', 'proportion of days covered (PDC)', 'infusion', 'major organ transplant', 'coronal hippocampal scan:||Age-adjusted', 'surgical overflows', 'donated blood of', 'expected surgery', 'hemodiafiltration', 'Local testing', 'quantitative assessment of proteinuria', 'axillary lymph nodal dissection (ALND)', 'Revibe Technologies', 'double antiplatelet therapy', 'barrier laser', 'relevantly orally', 'intubation', 'small intestinal stricture', 'smoking cessation', 'autologous stem cell transplant;|Organs', 'lymphoma.||Normal Organ', 'glaucoma surgery', 'consisting of cetuximab in combination', 'hypertensive emergency', 'pain|Back surgery', 'thyroid ultrasound examination', 'subsequent curative surgery', 'chest HRCT fibrosis|The severity of ILD', 'central', 'disease|Hemoglobinopathy|Ehlers-Danlos', 'radiofrequency of the', 'early access program', 'diagnostic biopsy surgery', 'serological tests', 'complete information', 'hematological organ function laboratory values', 'quality of the data.|Current substance use disorder', 'antagonists', 'blood culture', 'test drug components', 'local control', 'vertebral levels', 'sensorized t-shirt', 'gastric cancer|Patient', 'tumor biopsy sample', 'Appendectomy', 'intracranial surgery', 'assessment|PD-related medication change', 'PET examination', 'percutaneous intervention', 'Thyroid Transcription Factor 1 (TTF-1)', 'allogenic organ transplantation.|Participants', 'graft biopsy', 'sensorimotor deficits incompatible with the cognitive training,|Former treated episode', 'venous blood collection', 'histological variants.|Patients', 'tracheal obstruction.|Reported', 'first treatment of HAIC', 'brain MRI checks', 'hippo therapy', 'COMP360 psilocybin therapy', 'intestinal ulcers;|Blood', 'local health', 'radiotherapy exists', 'Echocardiographic examination', 'coronary artery stenoses', 'bladder stone extraction', 'cervical biopsy pathology', 'internal carotid artery peak', 'temper tantrums', 'longer.|Major surgery', '1 x ULN||HIV RNA', 'smartphone||', 'Signatera testing', 'peanuts|Left-handedness|Current smoker', 'steroidal replacement therapy', 'ankle surgery', 'prophylactic mastectomy', 'pregnancy tests', 'gastric emptying breath test', 'visit|Body mass index', 'Surgical operation', '12-lead electrocardiogram', 'tumour on imaging', 'EGA', 'lenalidomide therapy', 'contraindication;|Electroconvulsive therapy', 'genetic analysis', 'Bladder control scale', 'Immunodefiecency|Hematological', 'complete quality of life questionnaires', 'personal care consumer products', 'mechanical spermicide', 'vaginal vault suspension', 'consent|Bilateral ureteroscopy', 'CT angiography.|Execution of', 'ASCT treatment', 'left ventricular dilation', 'curative surgery', 'cessation of exogenous', 'MR', 'Surgical System', 'dietary treatment', 'injection pain|Unable to communicate verbally|Pregnant', 'Covid-19 infection|Contraindication', 'restricted eating patterns', 'injections', 'PSMA-radiotherapeutics', 'physical exercise', 'general clinical examination', 'inotropic support|Participants', 'anticoagulation treatment', 'prophylactic use):||Blood routine examination', 'platinum chemotherapy', 'meniscal repair|simultaneous meniscectomy', 'abrasion', 'fresh', 'caloric restriction', 'primary entry tear', 'CERAB treatment', 'Rankin Scale', 'mutations', 'assessment procedures', 'rigid contact lenses', 'tonic pupils', 'barrier methods', 'axillary temperature ≥38ºC', 'pathology testing', 'radiotherapy after', 'unicompartmental knee', 'congenital penoscrotal web', 'cardiologic investigations|Negative pregnancy test', 'rhinoplasty', 'molar maturation', 'concomitant surgery', 'temozolomide treatment interruption', 'X-ray absorptiometry', 'lateral sprains', 'chest CT scan', 'abdominal surgical procedure', 'vasectomy', 'CT examination|Hepatic encephalopathy|Systemic infection', 'Auburn AL', 'systemic hormone therapy', 'major pelvic surgery,|inability to receive informed information,|inability to participate', 'liver function tests', 'small body size', 'CABG surgery||', 'surgical sterilisation', 'SCCHN.|For', 'Muscular strength', 'single-pool Kt/V', 'R1 resections);|Presence of minimal extra-regional disease', 'computed tomography', 'favorable versus moderate versus poor risk status.|Adequate hematologic', 'Liver biopsy demonstrating cirrhosis', 'stress steroid doses', 'mucosal endoscopic resection;|Patient', 'balance-', 'extensive dental therapy.|Participant', 'fundus exam', 'Blood coagulopathies|Infection', 'topical treatment of the target knee joint including', 'serial CT scans', 'salvage cardiac surgery', 'PET/CT scan|Individual the investigator otherwise considers ineligible for participating in the study [', '6 receptor.|Previous therapy', 'bariatric intervention', 'immunosuppression', 'adolescents of the selected classes of the participating schools', 'thin-section CT scans', 'general danger sign|Be', 'androgen deprivation therapy', 'chest tube placement', 'routine laboratory examination', 'hematologic transplant', 'autologous hematopoietic stem cell transplantation', 'function', 'local legislation', 'Neuroimaging', 'TCF3-HLF', 'fully healed ridge type 4|sufficient bony', 'adrenal cortical insufficiency.|Patients', 'T cell costimulation inhibitor', 'lymphocytic lymphoma.|For CLL', 'scans', 'potential VA testing if necessary).|Subjects must have', 'robotic-assisted laparoscopic surgery', 'clinical observation', 'Rinvoq treatment', 'coronary artery bypass graft surgery', 'GI surgeries', 'hospice ward', 'stent implantations', 'preterm delivery', 'total knee replacement surgery', 'functional assessments', 'individual safety of perioperative administration of NO||', 'Lorazepam', 'Codex test category C and D,|Barrier of the language,|Psychiatric disorder', 'Structured Clinical Interview for DSM-5 (SCID-5);|Diagnosis of treatment-resistant depression', 'behavioral variant', 'World Health', 'complete surgical treatment', 'hole inguinal hernia repair surgery', 'pelvic surgery;|Endometrial biopsy', 'fibrate therapy', 'radiographic studies', 'baseline', 'Tibiofemoral knee osteoarthrosis', 'adolescents', 'allogeneic transplant', 'uterine pathology|Hormonal therapy', 'fetal head deeply engaged in the pelvis defined', 'non-inclusion', 'paleo', 'supplementary screen contraceptive method', 'expression of CD70', 'pathological examination', 'radical gastrectomy', 'preventative treatment', 'rheumatological disease,|To', 'control brain metastases', 'reduced RF', 'tests', 'coronary revascularization procedure', 'complete nephroureterectomy', 'procedure', 'abrasive laser treatments', 'cytoreductive surgery (CRS)', 'ultrasound device', 'Standard therapy', 'DBS surgery', 'standard dose of multivitamins', 'World Health Organization (WHO) classification in 2016', 'inoculated', 'blood thinner)|Uncontrolled DM', 'digital exam', 'revision surgeries|Patients', 'incremental exercise test to volitional fatigue', 'local assay being used if the limit of detection', 'ipsilateral iliac artery treatment', 'adjuvant hormonal therapy', 'skin biopsy', 'bone marrow transplant||', 'remain off of antipsychotics', 'central review of', 'palliative surgery;|prior pelvic radiotherapy;|hyperthermic intraperitoneal', 'fetal death|Failed vaginal birth|Planned general anesthesia|gestational hypertension disease', 'cerebellar ataxia', 'Teeth Inclusion Criteria Minimum of 10 teeth One tooth from each sextant', 'FIGO（International Federation of Gynecology', 'Ataxia', 'medication|Being', 'reads', 'intraocular lens.|Patients', 'amphotericin)|Critical preoperative status', 'fecal occult blood test.|Clinically significant prolactin elevation', 'chest after cardiac surgery|Patient', 'vaginal sampling|Delivery', 'complete resection', 'CH Guy Thomas in Riom are included in the study:|Children', 'surgical revascularization', 'aesthetic treatments', 'GnRHa therapy', 'Autologous Stem Cell Transplant procedure|Pregnancy|Eye diseases', 'Rapid Diagnostic Test|Fever', 'complex PCI', 'liver transplant patients|HIV', 'general anaesthetic', 'standard treatment', 'language intervention program', 'D2 lymphadenectomy', 'Usual Health after', 'spiral CT', 'diabetes', 'presacral neurectomy|Concurrent surgical procedure', 'psilocybin treatment', 'optimal medical treatment);|Urine routine', 'B fibula facture', 'exercise', 'fine-needle aspiration.|Normal serum thyroid hormone levels||', 'OSNA|Molecular analysis', 'bile duct cancer)|ECOG Performance score', 'intra-articular', 'stable treatment', 'navigation bronchoscopy', 'hygiene measures regarding', 'urethroplasty', 'dynamic imaging', 'hepatic resections', 'irritation', 'arthroplasty surgery', 'MRI.|Active malignant disease', 'personal consultee|Presentation', 'permit ingestion', 'manipulative treatment', 'pelvic radiotherapy|History of', 'placenta previa', 'initiating therapy', ""vagal nerve stimulation);|Subject's parent/caregiver"", 'G-CSF|Able', 'years|Neurological examination', 'anal prolapse surgery', 'surgical cytoreduction', 'standard therapy regimen', 'interventional clinical trial|Patient', 'Tiantan Hospital Right-handed', 'neurological condition|History', 'blood sugar control', 'platelet transfusions', 'placement of implant', 'rapid diagnostic test', 'quality of the study', 'local institutional practice', 'rescue medicine', 'Simple Clinical Colitis Activity Index (SCCAI)', 'smallpox', 'operation', 'placement of graft', 'genital piercing(s)', 'month|antibiotic treatment', 'routine cardiac allograft vasculopathy (CAV)', 'tumor selected', 'anticancer therapy-induced', 'physical tests', 'adequate fluid therapy', 'foreign protein', 'X-ACKT.|Subject', 'penumococcal vaccination|willing', 'housing|Veterans', 'serological testing .|History', 'treatments treatment', 'hospital admission|Proficiency in', 'graft-versus-host disease|Known', 'graft from a donor <', 'Cognitive Behavioral Therapy', 'pretreatment endoscopic biopsies specimens', 'pelvic organ prolapse|Available', 'hospitalizations', 'lymph node progression', 'Inflammatory Bowell Disease|Bilateral hip prosthesis', 'calicheamicin-conjugated antibody', 'PECS blocks', 'World Health Organization.||', 'routine access to CSF', 'consolidation chemotherapy', 'ART initiation', 'Wechsler Abbreviated Scale of Intelligence (WASI-II)|Individuals', 'stent delivery and deployment judged by investigators', 'transscleral cycloablative procedures', 'immunomodulatory therapy', 'permitted.|Investigational therapy', 'ADT treatment', 'Xanthan gum', 'hematopoietic stem cell transplantation.||Previous treatment', 'inclusive)|In good general health', 'Pathological types', 'pause therapy', 'surgery of the cervical|spine|Diagnosed cases of Torticollis', 'fatal result||', 'Schnider model', 'home||', 'conventional imaging (CT and/or', 'extracorporeal volume shifts associated', 'extensive enterectomy', 'first facial trauma surgery', 'topical treatment regimen', 'apply hormones topically', 'regular antituberculosis therapy', 'medication treatment compliance', 'months|Radical radiotherapy', 'smartphone||Key', 'transesophageal echocardiography', 'pelvic surgery;|Infection', 'polymerase chain reaction (PCR) result', 'DICOM format', 'radical nephrectomy', 'Hispanic/Latino', 'systemic therapy|History of', 'salpingo-oophorectomy', 'alternative cause for malocclusion', 'consultation focusing', 'alternative therapy', 'urogenital infection,|Anorectal anatomy incompatible', 'conventional coagulation tests', '4)|Retinal laser', 'mechanical thrombectomy', 'coronary artery bypass grafting|Pregnancy', 'sport program', 'supplemental vitamins', 'local PI.||', 'chlorhexidine|Antibiotic prophylaxis', 'effective contraceptive', 'renal surgery', 'spontaneous coronary artery dissection', 'endovascular embolization procedure', 'GIFT device implementation able to complete timesheets||Diagnostic', 'regular vitamins', 'PET/MRI referral package', 'X-ray|Intake', 'brain tumor.|Scheduled for craniotomy', 'AIDS).|Any', 'Treatment Related', 'lipohypertrophy', 'molar extraction', 'occipital-cervical fusion.|Actively', 'surgical sterilization.||Subjects', 'methods of contraception', 'cortisol injection', 'Activities Specific Balance Confidence Scale', 'bone marrow implantation', 'cyclo-ergometer|Refusal of consent', 'interventional radiology', 'general anesthesia periods', 'renal fusion anomalies', 'behavioral variant frontotemporal dementia', 'tuberculosis.|Major surgical procedure', 'consultations', 'artificial hearts', 'previous therapy', 'SLL)||Prior Therapy Criteria', 'CRi', 'irreversible surgical sterilization by hysterectomy', 'histologic features of ALD.||', 'injection volume', 'vulvar/vaginal cancer|Undergoing', 'old,|Not knowing', 'physiotherapy treatment', 'lumbar spine surgery', 'inotropic therapy', 'expert radiologist).||For existing', 'local ED Services.||', 'bone stock remains', 'Botulinum Toxin', 'patient|Patients', 'video computer', 'regular diameter)||', 'Emergency procedures', 'converted procedures', 'medical records|Affirmative response', 'decompression surgery', 'World Health Organization [WHO]', 'changed psychological treatments', 'interim assessment', 'trauma-focused treatment', 'Individualized Education Program', 'coronary angiogram', 'diagnostic CT scan permits good visualization', 'sex', 'local label information|History', 'endoscopic ventriculostomy', 'LSM', 'Rush Emergency Department (ED)', 'intraarterial digital subtraction angiography of the ipsilateral leg|Patients', 'abdominal procedure', 'concerning structural abnormality seen on MRI;|Substance', 'large segmentation radiotherapy', 'heated intraperitoneal chemotherapy', 'glucocorticosteroid treatment', 'screening|Repeated measurement of systolic blood pressure', 'standard blood test|If the participant', 'percutaneous biopsy', 'repair of fracture', 'serologic test results', 'Imaging studies show', 'chronic steroid', 'Stent', 'medical treatments', 'COVID-19 plasma', 'thrombolytic therapy)|Prior CABG', 'ultraviolet phototherapy', 'Lung Transplantation;|re-transplantation', 'Stintilimab Injection formulation', 'hematopoietic stem cell transplantation', 'urine β-hCG)||iii', 'autologous stem cell transplantation', 'required|If sentinel node', 'hypo-/ hyperechoic areas', 'cesarean delivery', 'cardiovascular intervention', 'oncolytic virus|Prior treatment', 're-implantation of internal implant', 'corrective pelvic organs prolapse', 'arterial Yttrium therapy.|Is', 'chest pain|Echocardiogram already', 'transarterial chemoembolization (TACE) therapy', 'Recovery', 'revision arthroplasty|arthroplasty', 'regular exercise', 'legs.|Self-reported', 'transportation', 'AVB', 'stable therapy', 'General inclusion', 'attenuation parameter', 'IA thrombectomy)|Stable vital signs', 'revision surgery', 'vital signs).||Exclusion Criteria||Medical', 'venous blood flow', 'general surgery||', 'valvular repairing surgeries|Functional status', 'palliative care services|Those', 'hepatic arterioembolization', 'superficial femoral artery (SFA)', 'blood sugar control medications', 'pitted fruit', 'pacing indication g', 'ROS1 fusion', 'Univentricular physiology|Systolic blood pressure<90mmHg|Glomerular filtration', 'immunosuppressive therapy', 'antibiotics|Diabetes', 'activity assay', 'complete remission.||Biphenotypic/Undifferentiated/Prolymphocytic', 'rapid ventricular response', 'Roux-en-Y gastric bypass surgery', 'vaginal plastron', 'Marfan', 'implant surgery||', 'abdominal B-ultrasound', 'percutaneous carotid coronary dilatation', 'Antiviral therapy for HBV', 'intervention|Anticoagulant therapy', 'mitral valve repair', 'uterine subtotal/total excision', 'CD113;|Major surgery', 'psychiatric stabilization unit made', 'participants:||Former knee surgery', 'cellular therapy', 'BCT oncoplastic surgery', 'chest CT scan screening;|Neurological', 'caesarean section', 'pelvic external beam radiotherapy', 'cancer|Persons', 'LIFT', 'complex aortic surgery', 'lumbar MRI examination', 'sedentary lifestyle', 'cognitive assessments', 'delayed gastric emptying', 'MRE', 'General Health Questionnaire - see attached document)|Body mass index (BMI)', 'cerebral infarction).|Have', 'routine regimen', 'cellular treatment', 'resected tissue', 'interleukin-2', 'emergency CABG', 'longer permits therapy', 'coronary bypass surgery', 'brain imaging||', 'abdominal CT scan', 'criteria|Magnetic resonance imaging (', 'trial treatment', 'molar postextraction', 'HER2 test results', 'renal replacement therapy|Enrolled in another drug', 'implant site,|Periodontally', 'brain magnetic resonance imaging (MRI).|Participants', 'FA', 'donation of plasma', 'first physiological delivery;|no previous', 'ECG changes', 'menstruation cycle time periods', 'ezetimibe|Solid organ transplant', 'aneurysmal coil embolization', 'immunostimulatory agents', 'arthroscopic shoulder procedures.||', 'emergency craniotomy', 'restart ART', 'Renal artery stenosis|BMI>35 Kg/m^2|Patient', 'SABR', 'trial measures', 'T0-T4a', 'imaging progression', 'hepatic metastasectomy', 'and|Elective caesarean section', 'interventional test device', 'test.|Baseline fresh tumor biopsy', 'vascular access of the non-study extremity', 'TRT', '12-lead ECG.|Uncontrolled arterial hypertension', 'OCTA examination', 'T-CMMSE', 'primary radiation therapy', 'Marshall standard', 'verapamil hydrochloride);|Patients', 'salvage surgeries', 'multifocal soft contact lenses', 'radiotherapy treatment', 'medical attention', 'Regorafenib therapy', 'hospitalisation for COPD', 'sPGA evaluation', 'light chain ration', 'done surgeries', 'Focal Laser', 'hematopoietic stem cell transplantation.|No eligiblity', 'estrogen therapy', 'implant treatment', 'lung surgery', 'watching videos', 'GPA', 'pathological diagnosis', 'OTC emollients||', 'structured psychological intervention', 'affects elimination', '-permeable lenses', 'cytokine', 'treated for JIA', 'hypofractionated stereotactic radiotherapy', 'first dose of study treatment]).|Absolute neutrophil count (', 'localized insertion site', 'settings|Prior treatment', 'therapeutic purpose', 'computed tomography [CT]', 'radical radiotherapy (≥66Gy)', 'MAD|Current treatment', 'diagnose of advanced', 'cryoablation', 'OSA therapy', 'sustain market rent', 'sterilization surgery', 'secondary regular education|Intention to participate', 'refractive surgery-related', 'primary total knee arthroplasty|18', 'complete occlusion', 'Western nootropic', 'complete spinal', 'anticoagulation treatment regimen', 'balloon dilatoplasty', '120 days before initiation of study treatment', 'bone window', 'strabismus surgery', 'endoscopic retrograde cholangiopancreatography', 'treatment for cancer', 'localized treatment', 'complete intubation procedure|Intubation failed', 'coronary revascularisation', 'excision of', 'subsequent IUT', 'hip arthroscopy', 'orotracheal intubation', 'electrical monitoring', 'lumbosacral surgery', 'Montreal Cognitive Assessment', 'pulmonary rehabilitation', 'World Health Organization (WHO) Performance Status (PS)', 'standard pelvic imaging (MRI/CT).|High-tier intermediate risk', 'palliative intervention', 'cytokine therapy', 'thoracolumbar fusion', 'RAF fusion', 'PCI|Successful treatment', 'childhood vaccines', 'renal insufficiency|History of abdominal surgery', 'consider pacemakers', 'antibiotic eradication', 'invasive sampling procedures', 'preoperative corneal pachymetry minus calculated', 'annual ophthalmic exam', 'laparoscopic surgery', 'standard clinical practice;|ECOG Performance PS score', 'colonoscopy examination', 'intubation;|Cardiac implantable electronic', 'chest wound', 'lung resection', 'special investigation', 'axillary ultrasound', 'physical examination|periarticular bone pain on physical examination|absence', 'severity||', 'Emergency surgery', 'CNS treatment', 'older|Empirical therapy', 'gastric bypass surgery|Pregnant', 'laparoscopic hysterectomy.||', 'expected cardiac surgery', 'terminates treatment', 'acute low-velocity', 'Hospitalization', 'active WSL', 'central laboratory immunohistochemistry', 'hepatic impairment|Acute kidney injury', 'AV graft until the poststudy visit||', 'palpation of the patellar facets,|pain when stepping down', 'renal replacement', 'hospitalization plans', 'extensive radiotherapy', 'gastric bezoar, achalasia', 'therapeutic anticoagulation', 'mismatch repair (MMR)', 'electrical impedance tomography', 'Head computed tomography', 'innate', 'laboratory testing', 'core biopsy', 'fundus imaging systems used in the study:||hypersensitive to light|recently', 'endovascular revascularization|organ transplantation', 'prevent', 'robotic-assisted laparoscopy', 'kidney stone|Active malignant diseases|Known substance addiction|Pregnancy or breastfeeding|Participation in another study', 'Dual Anti Platelet Therapy', 'transurethral resection', 'local standards of care', 'CMR', 'egg donation plan', 'PFTs', 'surgical biopsy', 'old,|general anesthesia', 'induction chemotherapy', 'suprarenal/visceral segment', 'screening|Intensive AML therapy', 'antitumor herbal therapy', 'local anesthetics;||Communication barriers', 'canalicular surgery', 'pathology after radical resection', 'intensification', 'Polymerase Chain Reaction [PCR]', 'oral anticoagulant therapy', 'AAP.||', 'nasal intubation', 'cognitive impairment;|A', 'orthodontic treatment|Patients', 'lipid-lowering agent over', 'laser', 'endovascular procedures', 'pharmacological methods', 'chimeric antigen receptor (CAR) T-cell therapy.|Participants', 'computed tomography (CT) / magnetic resonance imaging (MRI)', 'epidural steroid', 'completed intervention', 'dipstick urinalysis', 'Coronary angiogram', 'Pathologic', 'renal replacement therapy.|Acute contrast-induced', 'World Health Organization (WHO) criteria|Ability and willingness of the legal guardian to comply with study protocol', 'females;|Major organ surgery', 'frontline treatment', 'blood screening', 'gastric tube', 'local regional treatment areas', 'Modification of diet', 'months).|An ECG', 'fluid accumulation', 'laparoscopy', 'intraoperative', 'lipid-lowering therapy', 'colorectal resection', 'General Surgery Department', 'anatomical irregularities', 'regional anesthesia', 'clinical laboratory test value|Allergic to a', 'Lumbar Listesis|Presence of', 'whole-body status', 'multifocal VIN grade', 'lipid-lowering drug', 'psychological intervention', 'allogeneic hematopoietic stem cell transplantation;(12', 'RBC]', 'keratorefractive surgery', 'parenteral nutrition could also be included in the group;Total bilirubin (TBIL)', 'preoperative chemotherapy', 'single-jaw surgery', 'chemotherapy', 'imaging status;|Asymptomatic', 'Therapeutic Arm):||Severe', 'extracorporeal membrane oxygenation', 'breast ultrasound', 'its original prescription', 'radiographic findings|Willingness', 'suppressive ART', 'triphasic computed tomography (CT)', 'audiology examination', 'flow oxygen therapy', 'suppress muscular contractility', 'vaccine.|Positive screening test results', 'transplantation|Transplant donor', 'sequential', 'homozygous deletion of exon 7 of the SMN1', 'baseline|Concomitant hydroxyurea (HU) therapy', 'PRP', 'violence', 'sequential therapy', 'amiodarone therapy', 'GI malignancy|Known GI functional', 'medication /treatment||/intervention', 'immunosuppressive drugs).||*Replacement therapy', 'ACLR surgery', 'breastfeeding|Workers', 'employ contraceptive measures', 'care visit|hospitalization', 'transarterial radioembolization', 'mechanical ventilatory support after surgery;|Current participation in another interventional study;|Previous participation', 'colostomy', 'implant placement|Teeth', 'ALECTINIB', 'transthoracic echocardiography should', 'HF therapy', 'local therapies', 'endoscopic partial laryngectomy', 'blood draws', 'small room for whole-body indirect calorimetry|Unwilling', 'focal blood supply arteries can', 'electrical cardioversion|Signed', 'intensive treatment', 'IUD)|vasectomy', 'ocular treatment', 'biochemical indexs', 'Management', 'primary unilateral first metatarsal bunionectomy surgery', 'hydrocephalus|Children', 'bulimia).|Baseline plasma fasting glucose', 'molecular procedures required', 'injection of DARATUMUMAB', 'clinical study experience||Participation', 'osteophyte formation', 'coronary arterial', 'rgan transplant', 'PCI/CABG', 'extensor mechanism', 'small cell lung cancer transformation', 'pathological tissue biopsy', 'cesarean surgery', 'numerical scale', 'first-line', 'World Health Organization (WHO) 2016:||Diffuse', 'General Inclusion', 'T-spot test', 'hematochezia', 'antigen COVID-19 test', 'Identification', 'mechanical ventilator support,|No', 'lung irradiation', 'abdominal massage application restrictions', 'SF-36 forms.||exclusion criteria||Being', 'histological', 'special education classroom', 'requirement of the ECOG physical fitness score', 'days|Major surgery', 'frozen lung biopsy', 'revascularization|Associated', 'Ribociclib treatment', 'anticancer therapy recovered to grade ≤1', 'first TACE therapy', 'isolated sharp waves', 'septorhinoplasty', 'amputation surgery', 'MRI brain', 'B-cell immunodeficiencies', 'stress cardiac magnetic resonance', 'Liver transplantation', 'ultrasound guided biopsy;||3', 'knee replacement|Orthopedic trauma', 'invasive medical procedure', 'glenohumeral translation', 'seen on ultrasound', '30 fractions', 'first-line chemotherapy', 'acute change', 'intestinal stenosis|History', 'upper gastric', 'screening)|Left', 'User', 'systemic immunosuppressant therapy|Class III/IV', 'drug treatment stabilized', 'Inadequate control of hypertension', 'episiotomy', 'experimental therapy', 'ligamentous injury.|Have nomeniscectomy', 'curative radiation therapy', 'radiograph of the knee', 'gastric CT', 'first ECG', 'major surgical resection', 'heart valve surgery|Being', 'ocular anesthesia', 'enoxaparin prophylaxis', 'Intensive Care (IC)', 'World Health Organization recurrent grade 1, 2, 3 glioma', 'antineoplastic treatment', 'Mini-International Neuropsychiatric Interview (MINI) version', 'completed antiviral therapy', 'pancreatic enzyme replacement therapy)|A participant', 'steroid therapy;|radiation', 'intensive care unit admission|Pregnancy', 'laparotomy', 'stratified', 'surgical procedures', 'amyloid PET scan', 'biochemical investigations', 'SSD control', 'gait rehabilitation', 'MEK1/2 mutation.|Major surgery', 'ipsilateral supraclavicular', 'ready', 'CBC', 'special dietary requirements', 'endocrinopathy', 'tobacco smoking', 'curative treatment', 'knee osteoarthritis|Having completed', 'Menstruation', 'arterial line placement', 'transradial amputation', 'polymerase chain reaction shows', 'control blood', 'pacemaker|Medical history of', 'therapy.|Radiation therapy', 'available standard therapy', 'complete revascularization', 'excimer laser', 'treatment of cancer', 'asphyxiation', 'facilities for blood', 'gynecological examination', 'Laparoscopic Upper Gastrointestinal', 'PRRT treatment', 'major operation', 'TBSA', 'bariatric surgery||', 'transcranial magnetic stimulation (TMS)', 'radiation therapy', '≥2 endoscopic subscore', 'ALV.|Contraindications mentioned', 'bowel surgery', 'chemotherapy.|Radiotherapy', 'Gemelli|Pregnant', 'pituitary MRI findings', 'fresh blood', 'sling', 'extracorporeal membrane oxygenation (ECMO)', 'bilateral neck', 'insufficient motivation', 'lacquer cracks', 'practice-pharmacists', 'laser treatment', 'surgery criteria|Brain MRI with', 'organ', 'major trauma', 'first surgery', 'ovarian stimulation', 'bone marrow radiotherapy', 'donation plan', 'homicidal risk.|Participants', 'Orthodontic indication', 'normal laryngoscopy', 'topical glucocorticoid therapy', 'target.|Autologous stem cell transplant', 'small to allow MBI assessment', 'dental council of', 'pelvic area|Pregnancy', 'drainage procedures', 'benzodiazepine detoxification.|Participation', 'hematology examination', 'focal segmental', 'complete imaging', 'vascular access', 'Baseline CCTA visit', 'treatment of the iliac artery lesion', 'partial hospitalization', 'cardiac revascularization', 'brain tumor.|PHQ-9 screening score', 'small-molecule inhibitors', 'emergency surgery;|Patients', 'pain management.||Matched Control Individuals', 'GvHD', 'mechanical block', 'abdominal aortic dissecting aneurysm', 'recurrent malaria.|Had autoimmune diseases', 'first dose of study', 'histological biopsy', 'standard assessments', 'complete absorption of swelling', 'bilateral ETSB procedure', 'Acellular Dermal Matrix', 'neoadjuvant treatment', 'periodontal situation', 'local treatment', 'clinical surgical procedure', 'including:||Physical examination', 'produce abnormal sunlight responses.|History', 'cumulative fluid balance', 'pathologic examination of the surgical specimen', 'lumbar region past 3 days', 'corneal refractive surgery', 'variceal bleeding.|Historical', 'echocardiography', 'bone marrow function，Conforming', 'limbal stem cell deficiency', 'talk therapy', 'gastric bleeding;|History', 'renal mass biopsy', 'consent|Institutionalized', 'Sahlgrenska University Hospital in Gothenburg,', 'nutritional therapy', 'lipid lowering drugs', 'surgically-assisted rapid palatal expansion (SARPE) surgery', 'local recurrent', 'violet light', 'examination;|Poor imaging quality of refractive interstitial opacity;|Macular edema', 'QT prolongation', 'whole brain MRI', 'assessment of baseline NIHSS score (dementia', 'enteral nutrition from N/', 'breast conservation therapy', 'assessment method', 'vaginal mesh', 'screening).|History of pulmonary hypertension.|Clinically apparent', 'IMP', 'cardiopulmonary resuscitation', 'herbal therapies', 'abutment', 'hematopoietic stem cell/bone marrow transplantation.|IgA deficiency', 'optimal stabilization regimen', 'autologous stem cell transplant|MDS associated', 'Hormone therapy', 'gastrointestinal symptomsandradiological imaging (', 'routine treatment', 'treatment injection sites|Marked facial dermatochalasis', 'Professional working', 'immunosuppressive therapies', 'integral treatment method', 'dual x-ray', 'standard of care targeted therapy', 'aesthetic surgery.|Be involved', 'vasopressors).|Expected amputation', 'discontinuation of statin|Pregnant', 'Hormone-sensitive', 'testing procedures.||For HC:||A', 'knee arthroscopy', 'complete screening', 'open surgical repair of', 'infection treatment', 'radiation treatment involved', 'managed', 'Emergency contraception', 'small-molecule target therapy', 'intestinal infusion', 'MRI scanner|Orthodontic braces', 'rehabilitation', 'EEG testing', 'Diagnostic procedures', 'standard phacoemulsification cataract', 'age|Clinically', 'Brain MRI', 'open pelvic surgery', '+12.|Anterior pelvic tilt', 'peripheral nerve blocks|Contraindication', 'limit;|Renal biopsy', 'standard dental implant (diameter >4mm)|Age', 'surgical liver resection', 'implantation surgery', 'control the CNS disease', 'anyone', 'biopsy', 'antineoplastic therapy', 'stent surgery', '2-hour plasma glucose level', 'spiral CT reports', 'lose body weight||', 'endoscopic biopsy', 'replacement therapy', 'fruit juices ingestion', 'local intervention (surgery', 'urological surgery', 'Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome,|all students of', 'T-DM1 treatment', 'chronic graft vs. host disease', 'adjuvant', 'video-regulation kit', 'Carcinoembryonic antigen (CEA)', 'dynamic therapy', 'ASA treatment', 'assessment center', 'special groups', 'intrauterine hormone release system', 'Diagnostic electrocardiographic picture', 'studies|Regular consumption of similar ingredients', 'cardiac risk assessment of the investigator', 'whole breast radiotherapy', 'focal treatment', 'self-rated symptom score', 'lumbar puncture：Cerebrospinal fluid composition analysis，Cerebrospinal fluid pressure measurement；Cerebrospinal', 'behavioral health treatment', 'hospitalization);|Pregnancy;|Previous intestinal surgery;|Concomitant intestinal infection', 'tumor ablation', 'sixty years', 'anaphylactoid life-threatening', 'trans vaginal ultrasonography', 'hypertensive retinopathy.||History', 'prophylaxis', 'IE.|Cardiac transplantation', 'confirmatory biopsy', 'treatment lines', 'ECG.|Normal ejection fraction', 'nerve block|Patients', 'intrahepatic bile duct cancer exists', 'Major surgical procedures', 'facial wrinkle augmentation surgery', '12-lead Electrocardiogram', 'dysplasia|generalized hypermobility|revision surgeries', 'contraindicating magnetic resonance imaging.|Pregnancy', 'Complex CHD', 'supervised maximal exercise test', 'regular prophylaxis', 'submucosal', 'patients|Liver transplant', 'surgical treatments', 'combination therapy', 'those involving IL-2', 'blood pressure;|A history', 'spinal surgery', 'intercostal nerve cryoablation', 'Clonal plasma cells', 'rehabilitation activities', 'month;|X-rays showed', 'FAK', 'Receving treatment', 'screening endoscopy', 'World Health Organization (WHO HAEM 5)(e.g', 'treated.|Major surgery', 'characterized', 'MTB suggests', 'disease|Previous vaccination', 'standard medical treatment', 'VVA', 'genetic testing obtained', 'blood oxygen saturation after exercise (below 94% or decrease of', 'rapid wash-out', 'laparoscopic radical prostatectomy + pelvic lymphadenectomy;|ECOG score', 'diagnostic imaging', 'analytic sample of clients', 'orthodontic procedures', 'Lipid lowering medication', 'next organ transplant', 'radiation therapy.|Uncontrolled', 'HPV test', 'Perioperative Goal Directed Therapy', 'inotropic/vasopressor drug support|contraindications', 'local anesthetics.|Revision Surgeries.|Refusal', 'intraoperative endoscopy', 'cardiopulmonary bypass pump', 'myocardial scintigraphy', 'SW|Previous surgeries', 'genetic testing before|Had', 'Income Cut-Off (LICOs)', 'steroid therapy.||Adequate organ', 'open-label placebo study', 'orthodontic treatment|periodontal surgery', 'medical history).|Haemoglobin levels', 'Atrioventricular nodal re-entrant tachycardia', 'photoprotection measures', 'preoperative multiparametric MRI', 'needing resection', 'special dental care unit of the CHU Estaing', 'alone.||Uncontrolled intercurrent illness', 'physiological blood loss', 'Weschler IQ test|Concern of emotion dysregulation', 'lens-corrected visual acuity', 'Aristotle', 'video telehealth equipment', 'prehospital emergency care||', 'diagnostic surgical procedures', 'Monosomy', 'flow cytometry evaluation of red blood cells', 'optical coherence tomography (OCT)', 'proportion of tumor in total liver volume was ≥70%;|Patients with', 'verbal confirmation', 'PEP-CTN', 'heavily treatment-experienced (HTE)', 'electrical impedance tomography monitoring|body mass index', 'Transcranial Magnetic Stimulation - TMS', 'thoracic epidural analgesia||', 'standard immunosuppressive therapies', 'supplemental observations', 'discal surgery', 'Prolonged Exposure Therapy', 'planned intervention', 'latex,|No scheduled', 'chest X-ray|Informed consent||', 'electrical cardioversion', 'luteinizing hormone releasing hormone [LHRH', 'arterial bypass grafts', 'Institutional Review Board (IRB).||', 'cerebral angiography', 'first episode', 'leading edge of prolapse', 'relapse);|Glomerular filtration rate qual', 'percutaneous coronary intervention (PCI)', 'radiotherapy lesions', 'epicardial coronary artery', 'SpaceOAR hydrogel', 'evacuation', 'hepatic dysfunction|Ejection fraction', 'electrocardiogram (ECGs)', 'B treatment', 'treatment strategy', 'brain stem|Clinical suspicion of', 'variable airflow limitation', 'dual injectable sustained-release cabotegravir-rilpivirine therapy', 'clinical examination', 'visit|Dialysis sufficiency', 'cardiac magnetic resonance imaging (CMR)', 'HRCT diagnosis UIP type/possible', 're-evaluation', 'local regulation||', 'immunosuppressive agents|History', 'ECT treatment', 'common carotid artery [CCA]', 'intraocular procedures', 'BJI', 'reflex cough stimulus)||Exclusion criteria:||unable to participate', 'pancreatic neuroendocrine tumors;||Baseline', 'homozygous) deletion', 'cardiopulmonary exercise testing', 'botox surgery', 'household distances|having medical', 'cosmetic surgery procedure', 'adrenal replacement doses ≤10 mg/day', 'CYP3A induction', 'RSV MAT-004', 'access', 'topical therapy', 'pelvic infection|History', 'special types', 'violent crime victimization', 'CT /MR/ EUS', 'treatment from mental health professionals', 'CNB', 'consisting', 'postoperative management', 'intestinal surgery', 'sentinel biopsy', 'bariatric device insertion', 'technical surgical complications', 'MVS)|Conventional cardiac surgery', 'loose anagen hair', 'oral chemotherapy', 'computed tomography (CT) prophylaxis).||5.5) The washout period of previous anticancer treatment', 'first AF ablation procedure|Written informed consent|Paroxysmal', 'Peritoneal Carcinomatosis Index [PCI]', 'radiation therapy|concurrent antibiotic treatment', 'abdominoplasty', 'pelvic organ prolapse|Pelvic organ prolapse-quantification', 'FVIII concentrates prophylaxis', 'open surgery|Completion surgery', 'bilateral selective neck dissection', 'localized radiotherapy', 'convalescent plasma therapy', 'MDD)|At baseline', 'pathological blocks', 'haematology', 'atrial septum occluder|Presence', 'brain metastasis;|Ventriculoperitoneal', 'upper endoscopy', 'older|(3', 'ocular surface staining', 'Baseline exam', 'eHNA intervention', 'excisional biopsy', 'DLBCL).||4)At least one measurable', 'home medications', 'diseases|Abdominal surgery', 'line of therapy', 'boundary value).|Proper bone marrow', 'coronary arterial bypass graft', 'follows:||HER2 expression', 'successful resection', 'Fibro Scan', 'variceal treatment', 'digital therapy', 'idiopathic nephrotic syndrome|Glomerular filtration rate (eGFR)', '0~1;|Surgical treatment of', 'surgical fixation', 'fusion mapping biopsy', 'therapeutic doses', 'Section', 'daily opioid', 'cerebellar region', 'coronary computed tomography', 'Transthoracic echocardiography', 'lumbar puncture procedures;|Presence', 'total laparoscopic hysterectomy Body mass index', 'HER2 insertion mutation', 'coronary', 'EBRT', 'urine testing', 'screening|Positive screen', 'mRNA vaccination', 'Lumbar foraminal stenosis|Lumbar central stenosis|Lumbar disc herniation|Lumbar spondylolisthesis||', 'thermoregulatory', 'Tertiary', 'ophthalmological examination', 'plasma cell dyscrasias', 'interventional treatment', 'sleep assessment questionnaire', 'mechanical ventilation).|Severe liver disease', 'emergency procedure|Patient', 'either:||One soft tissue lesion', 'PFT', 'fluid restrictions', 'progression|Major surgery', 'help', 'ectopic placed kidneys', 'band', 'optic nerve sheath fenestration', 'major non cardiac surgeries.||', 'induction of labor', 'pleural fluid examination', 'endoscopic retrograde cholangiopancreatography (ERCP', 'disease treatment', 'liver transplantation|contraindication', 'quality of the data', 'refuse surgical resection', 'World Health Organization growth (WHO)', 'anti-retroviral therapy', 'chest computed tomography (CT) scan.||E. Active autoimmune disease', 'surgery of the lumbar spine;|Patientes', 'cognitive function', 'IP on Day 1.|Moderate to severe', 'dedicated respiratory intensive care unit||', 'inotropes|Pregnant', 'gastric varicose veins', 'CT-scan', 'magnetic resonance imaging [MRI', 'regimen', 'fontan procedure', 'organ transplant recipient.||Concurrent disease', 'fracture|Open reduction tibial plateau', 'tear film break-up time lower than 7', 'hernias', 'neurological o other nontumor-related dysphagia|Patients total laryngectomized|Patients', 'diuretic therapy', 'Transfusion Dependent β-thalassemia', 'blood 25(OH)D concentration', 'target vessels/plaques', 'imaging liver biopsy', 'resected basal cell', 'egg donation', 'bariatric surgery procedures', 'bilateral', 'agents|Topical phosphodiesterase type 4', 'active therapy.|Participate in', 'spinal/general anaesthesia', 'Gestational diabetes|Clinical diagnosis', 'ICD placement', 'bone marrow reserves', 'CXR', 'digital examination', 'hematology', 'oral dose of', 'laparoscopic gallbladder removal', 'general anesthesia|Body weight', 'monoclonal antibodies.|Major surgery', 'anticoagulant medicines.|Patients', 'release surgery Tier 2|Spinal stenosis|History of', 'walk', 'chemical anticoagulation before', 'Residing', 'complete modules|Completed', 'monkeypox', 'normal operation', 'lung metastasis amenable for SBRT', 'acquisition of informed', 'electrical storm', 'IVF fresh embryo transplantation', 'Health Assessment Checklist', 'local investigator||', 'pulp involvement||Exclusion', 'fresh tissue biopsy', 'phosphodiesterase-5 inhibitors|Pregnancy', 'biological sample collection procedures', 'diagnostic biopsy', 'transcatheter mitral valve repair', 'endocrine treatment', 'exists concurrent Gilbert syndrome', 'surgically sterilized', 'systemic chemotherapy', 'hypertension)|Passive full knee extension', 'allogeneic stem cell infusion.|Cellular therapy', 'cystic duct', 'Mental Health Services Administration', 'regular surveillance', 'blood purification', 'RBC infusion', 'steroid hormone medications.|Medications', 'sclera', 'coloplasty', 'hereditary disease;|Normal cardiac function', 'Transcatheter Aortic Valve Implantation', 'walk continuously', 'gastric biopsy (histopathology)', 'smokeless tobacco.||Participants of reproductive potential', 'local guidelines)|Caffeine consumption', 'RCA', 'spiral CT scan diameter of the measurable lesion', 'lose', 'catheter insertion', 'nerve root decompression', 'extramedullary leukemic cell infiltration.|Meet', 'spine SRS/SBRT', 'subsequent therapy', 'imaging by', 'first-line SSA', 'interventional clinical study within', 'vital organ primary diseases', 'Technical Data Sheet.|Participation', 'infusion therapy', 'hematopoietic stimulating factor therapy', 'blood transfusions', 'periapical radiograph||', 'T-BIL', 'remain eligible', 'stress reduction protocol', 'horomonotherapy', 'tPA of EVT)|Patient', 'ECHO)|Baseline QTc interval', 'tenant implementation champion|Be', 'routine', 'histologically', 'multidimensional flow cytometry (MDF)', 'KOA', 'foot ulcer|Receiving oral antidiabetic', 'psychotropic medications dosage', 'Systematic treatment', 'conversion TKA|Patients', 'targeted treatment', 'special types of renal parenchymal damage', 'PCI)|acute coronary syndrome|heart failure|chronic obstructive pulmonary disease', 'NGS analysis', 'percutaneous treatment', 'oral immunotherapy', 'Arterial access', 'prescription records of', 'surgical adhesion of the pleura', 'ultrasound monitoring outside the study', 'vertebral artery dissection.|History of', 'studies', 'organ transplant candidate|Pulmonary', 'small-molecule kinase inhibitor has been accepted', 'ophthalmoscopy', 'assessment of the mechanism of syncope', 'prescription of analgesic regimen', 'urologic anomaly|Unplanned cystoscopy|Cancer surgery|Urogynecology', 'Montreal Cognitive Assessment (MoCA) score', 'neurological disease|No', 'clinical laboratory testing', 'clinical-pathological risk features', 'ICS)|Asthma', 'cerebral MRI', 'X-TOLE3', 'congenital cataract.||-', 'panel', 'programmable ventriculoperitoneal shunt', 'Doppler ultrasound evaluation', 'bilateral thigh', 'in-exsufflation device', 'FISH detection', 'loop electrosurgical excision procedure', 'Colposcopy', 'blood cell count', 'cardiovascular diseases||-', 'surgically removed；|Patients', 'cerebral artery [ACA]', 'equivocal imaging', 'congenital heart diseases.|Fetal hydrops.|Babies', 'biochemical blood analysis', 'Hypertensive disorder|Cerebrovascular disease|Mental disorder', 'Hospital Israelita Albert Einstein', 'stay in local area', 'Coronary anathomy', 'cervical fusion surgery|Co-morbidity', 'ERT treatment', 'leukemic organ involvement.||Renal function', 'strenuous physical exercise (body building', 'laboratory safety tests', 'intrahepatic cholangiocarcinoma|History', 'first COVID-19 prophylaxis dose', 'endothelial keratoplasty||', 'Expert Consensus', 'iTBS treatment', 'arterial Doppler ultrasound evaluating for biphasic dorsalis pedis', 'radiation after surgery', 'clinical laboratory findings', 'lipid-lowering drugs', 'ESA treatment - discontinuation', 'Treponema pallidum (TP) Ab;||6', 'cardiac surgery procedures', 'histopathologically;|Adjuvant chemotherapy regimens', 'analgo-sedation', 'oral danish||', 'biological agent therapy', 'good conservative treatment', 'gastrointestinal procedures', 'gynaecologic surgeries:|scheduled (elective) cesarean section|cesarean section', 'Fatty degeneration visible', 'life', 'lumbar isthmic spondylolisthesis', 'Radiation', 'licensed treatment', 'play therapy', 'lung consolidation', 'screening|Planned septal reduction treatment', 'chest computed tomography (CT) scan.|Any lung disease', 'choose craniotomy', 'session stimulation protocol|Fluent', 'abdominal (FAPD)', 'typic for IBD e.g.||Diarrhea', 'aiming', 'trophoblastic retention', 'bilateral knee TKA', 'small cell components', 'annexectomy', 'standard of care treatment', 'local regulations:||Provision of informed consent', 'XM) test', 'rectal', 'bone marrow function', 'surgical clips', 'palbociclib', 'optimal Endocrine therapy', 'small molecules.||', 'general anesthesia|American Society of Anesthesiologists Physical Status', 'tenodesis', 'RRT', 'steroid injection|Confirmation', 'hour', 'emergency sternotomy', 'auxiliary ventilation', 'hematopoietic stem cell', 'conventional urodynamics|Able to tolerate', 'intensive care unit', 'Lateral deviation of the mandible', 'local heart team', 'certolizumab pegol', 'computerized tomography (CT) colonography', 'mRECIST v1.1 required', 'OAB', 'severity x frequency', 'total knee replacement (EXKnee) Jorgensen', 'Ampullary lesions||Single ampullary lesion', 'distal bile duct carcinoma (DBC)', 'light therapy', 'cross sectional imaging', 'surgical treatment', 'karyotype.|Fetal echocardiogram', 'preoperative dialysis', 'genital organ surgery', 'multichannel radionuclide angiography (MUGA)', 'pharmacological therapy', 'quinine', 'standard of care treatment.|Patients', 'Radiofrequency lesioning into the index knee', 'small molecule anti-angiogenic', 'holter ECG evidence', 'liver resection', 'hepatic function:||total bilirubin', 'trainees protected time', 'receptor modulator therapy', 'eligible|Radiation therapy', 'areas', 'craniocerebral CT;|DCI was', 'dermatoscopy', 'ventral hernia repair', 'curative liver resection||', 'elective adenotonsillectomy surgery overnight', 'local anaesthetics of amide type', 'vitiligo', 'first trimester ultrasound', 'Metal', 'next- generation sequencing', 'metal parts around', 'local anaesthetics derived from para-aminobenzoic acid (PABA)', 'male sterilization', 'Initiation', 'implanted MRI', 'corrective cardiac surgery|Vitally stable||', 'prostatectomy', 'T-DM1;|Be able to understand and voluntarily sign the written Informed Consent Form (ICF).||', 'HRCT findings', 'old|Kidney transplant', 'quality of life and/or interfere with their ability to manage their heart failure care regimen', 'excision', 'diagnostic magnetic resonance imaging (MRI)', 'Screening.|Known immunocompromised status', 'liquid transplantation|Pregnant', 'temporal artery', ""congenital adrenal hyperplasia.|Thyroid diseases.|Cushing's syndrome.|Diabetes"", 'caffeine);|pregnant', 'local requirements.||Participant', 'pericardiectomy', 'enteral medication;|Inability to understand', 'vascular disease||', 'surgical flap;|Having', 'ultrasound-detected', 'bone marrow biopsy', 'ventricular puncture drainage', 'physical restrictions', 'gastroenterology departments of Amiens-Picardie University Hospital', 'clinical cut-off on', 'head CT with contrast', 'first lung transplantation|Patient', 'invasive treatment', 'Dutch speaker|Singleton pregnancy', 'European ancestry', 'insulin|peripheral edema|recent hospitalization|known allergy to any study drug|polyuria', 'injection of botulinum toxin', 'hernia repair', 'PAR-Q+)|Physical limitations', 'month.|Cardiac ultrasound LVEF≥50%', 'lung imaging', 'platelet donation', 'antigen test collected', 'living donor kidney transplantation.||', 'first orthodontic consultation', 'cognitive behavioural therapy', 'stone apparent', 'consultation', 'questionnaires||Additional inclusion criteria', 'hemorrhoidectomy', 'postural', 'coronary artery bypass graft|Indication', 'autologous HCT', 'laboratory tests', 'complex-PCI', 'oral anticoagulant treatment', 'bypass graft surgery', 'limb viability.|Contraindication', 'histologic margins', 'treatment targeting', 'medicinal product|2 weeks', 'CPT sessions', 'health facilities (Aim 2)||Investigators', 'local laboratory analysis;|Treated', 'Hormone anticonception drugs', 'chest X-ray/CT', 'lubal tigation', 'temporal artery biopsy before study enrollment|Chronic use of', 'TANITA', 'bilateral-oophorectomy', 'vaccine treatment', 'trapezoid excision-whole', 'ultrasound skin', 'PSMA PET imaging', 'microbial cell count.||', 'cytologic documentation of incurable', 'sentinel node status', 'capsular reconstruction', 'control associated', 'hysterectomy', 'validated immunohistochemistry (IHC)', 'bypass graft|acute coronary syndrome', 'Referral', 'kidney transplantation', 'intraoperative open-surgery', 'diagnostic purposes', 'Cardiac surgery', 'assessment of pulmonary artery systolic pressure||', 'points;|Cervical histological examination', 'Liver transplant', 'adrenal cortical hormone replacement', 'receives group treatment', 'old;|Chest CT showed pulmonary nodule', 'reduction mammoplasty operation||', 'Burlo Garofolo"" Emergency Department', 'fecal management system', 'gastrointestinal [GI] surgery', 'HIF-1', 'elective suptatentorial craniotomy', 'unilateral total knee arthroplayts (', 'indirect ophthalmoscopy', 'rule out CNS disease.|Prior chemotherapy/radiation', 'International Neuropsychiatric Interview for Schizophrenia', 'neoadjuvant radiation', 'pregnancy;|Term delivery (', 'Hôpital Sainte-Marie', 'cytotoxic chemotherapy', 'clinical laboratory', 'Montreal Cognitive Assessment (MoCA) scale.|The subject does not have', 'autologous HSC gene therapy', 'anticoagulation on emergency department assessment', 'palliative radiotherapy should', 'ORIF', 'botulinum toxin treatment', 'D-cycloserine', 'Congenital heart', 'verbal demonstration of understanding', 'corticosteroid).|Previous treatment', 'ventilatory control', 'nasal prongs', 'early treatment discontinuation', 'hormonal birth control', 'radiological treatment', 'hematopoietic function|8 Normal', 'Good understanding of the German language.|Understanding the procedures', 'standard dose of gadolinium-based MRI contrast agent', 'cytoreductive surgery', 'clinical intervention', 'bone marrow smears', 'major abdominal surgery|aged', 'coagulopathy|Platelet cell count', 'open knee surgery', 'restrict consumption of nuts', 'radiographically', 'salpingectomy', 'vasectomy procedure', 'vacuum pump therapy', 'CMR implantable devices', 'congenital malformations|the', 'colonoscopy unit', 'Aesthetic medical procedures', 'correctly corrected view', 'analysis||', 'lower limb|Revascularization procedure', 'urine test', 'partner;|Vasectomy', 'open repair', 'laser photocoagulation of the retina|previous severe eye injury|acute eye', 'Health Center.|Not illiterate', 'neuraxial anesthesia|Scheduled', 'oral surgical antibiotic prophylaxis', 'molecular assay', 'Hospitalized', 'starting radiotherapy', 'urine culture revealing', 'therapeutic radiopharmaceuticals|Contra-indications', 'subsolid target lesion', 'Coagulopathy.|Distant metastasis.|Body mass index', 'mesenteric artery revascularization|No available CT imaging', 'upper GI endoscopy|Symptoms of', 'combination chemotherapy', 'hematologic blood counts', 'anticoagulant therapy|Nasal deformity|Pregnancy', 'periapical radiograph', 'rehabilitative treatment of disorders of consciousness', 'autonomy', 'standard treatment regime', 'medical surgeries', 'transvaginal ultrasound examination', 'mini-mental status exam', 'otoscopy', 'oral absorption of', 'e-mail address', 'amputation', 'mild residual MR', 'candidates', 'fine needle aspiration biopsy', 'inotropes|Elimination of inclusion criteria|negative culture', 'partial mastectomy', 'immobilization', 'maintain dietary habits', 'chronical drug', 'bariatric surgery|Open to communication', 'quality of the data|Any contraindication to whole blood transfusion', 'single antiplatelet therapy', 'technical equipment', 'ACLR surgery|Participants willing', 'effective birth control method', 'cardiac procedures', 'full mouth plaque score < 20 %', 'PCD', 'exercise-induced asthma', 'bone marrow).||', 'Congenital Heart Surgery Mortality Category (STAT\\STS-EACTS', 'digestive system surgery', 'bone scan (ECT)', 'restorative therapy', 'pathogenic germline', '|Conservative treatment', 'cognitive treatment of insomnia|Capacity to understand the study', 'tail resection', 'study activities', 'sensorized chest band', 'STEP', 'partial resection of the colon', 'single surgery', 'exchange', 'urinalysis||Hepatic panel', 'numerical documentation of', 'criteria.||Effective contraception', 'morphological', 'restrictive diet', 'gastric resection/bypass', 'falls', 'treatment regimens', 'lateral nerve palsy|Severe emphysema|Cardiac conduction block|Local', 'radionuclide therapy', 'IHC assay', 'gynecologic surgery', 'adjuvant chemotherapy/immune therapy', 'histologic types', 'mL|Baseline biopsy', 'embolization', 'normalized ratio', 'Inpatient treatment of the baby in the surgical neonatal intensive care unit', 'brain magnetic resonance imaging (MRI)', 'clinical exam', 'clarity', 'first-line oxaliplatin-containing standard therapy', 'autologous transplant', 'type1 DM.|Arabic speaker.|Smart phone', 't-shirt', 'antibiotic therapy|Major surgery', 'psychotropic medication regime', 'lumbar spinal surgery', 'endovascular repair', 'discontinue', 'antihypertensive drug treatment', 'pneumococcal vaccination', 'sensitive assay', 'product.|Involvement', 'MS|Additional immunosuppression', 'Severity Index (EASI)', 'motile sperm. Similarly,', 'renal ultrasound', 'caesarean delivery)', 'first treatment modality', 'implant insertion procedure', 'physical examination|Current', 'rapid antigen test [RAT]).|Participants will be randomized no longer than 48 hours from the onset of the COVID-19 related symptom of the index patients.|Participants', 'nuclear magnetic resonance;|Pathological diagnosis', 'histopathology falls into one of the following', 'Skeletally immature', 'allogeneic tissue/organ transplantation', 'stem cell transplant', 'clinician specializing', 'frozen fresh plasma', 'T-cell count', 'other treatment', 'terminal treatment', 'pelvic node dissection', 'chemoembolization', 'osteoporosis|Ipsilateral total knee arthroplasty', 'IV|Myocardial infarction', 'DAPT', 'brain MRI allowing', 'prolonged knee flexion.||', 'neural modulation treatment', 'digital imaging', 'T-cell receptor', 'health', 'instrumental swallowing assessment', 'G12C.|Major surgery', 'graft-versus-host response', 'conventional treatment of HLH|Having not achieved', 'vitamin D supplements', 'paternal uniparental disomy', 'biochemical', 'cEEG', 'oral imaging examination', 'islet cell autoantibody', 'trabeculectomy', 'Mount Sinai West', 'Follicular Lymphoma[FL]', 'renewed endoscopy', 'polymerase chain reaction test result.|Known hypersensitivity', 'interventional clinical trial therapy', 'bilateral orchidectomy', 'Arthroscopy', 'total artificial heart (TAH)', 'recessive SMA', 'corticosteroids therapy', 'Medicine Session', 'Advance canaloplasty device', 'bilateral mastectomies', 'periodontal treatment|pregnancy|minors|antibiotic therapy', 'coagulopathy.|Bilateral knee pathology', 'rule out', 'hypospadias repair', 'tyrosine kinase inhibitor (TKI)', 'fetal intervention', 'secretagogues', 'claudication.|Major surgical operation', 'isolated myectomy', 'multifocal contact lenses', 'melatonin supplementation', 'fecal occult blood ++ and above at baseline', 'intestinal System surgery', 'Granulocyte-colony', 'adjuvant PARP inhibitor', 'special pregnancy care|It', 'autologous transplantation.|History of plasma cell leukemia', 'Global Assessment (PGA)', 'placenta', 'erythrocyte maturation agent luspatercept can', 'local anaesthetics', 'shrapnel', 'cytoreductive chemotherapy', 'Global Assessment (IGA,', 'neurological symptoms|Current active liver disease', 'ROX', 'standard temozolomide', 'fresh frozen tumor tissue', 'stress echocardiography', 'gynecology-oncology|Planned sling revision', 'monoclonal plasma cells', 'urine drug screen|Positive urine alcohol test|Positive severe', 'parathyroid intervention', 'systemic immunostimulant therapy', 'salvage total laryngectomy', 'substance abuse|Known increased', 'lifestyle intervention', 'hip replacement surgery|Patients', 'standard of care therapies', 'continuous treatment', 'menstruating', 'posterolateral thoracotomy', 'cell transplant', '≥2 directions', 'TS:||• Diagnosis', 'trastuzumab deruxtecan treatment', 'immuno-stimulatory agent', 'Palliative local treatment', 'procedures:|Blood test|Change of', '12-lead EKG', 'CSMC echocardiogram lab||', 'Auer rods noted', 'bypass graft', 'M3 marrow', 'dialysis vascular access procedures', 'SPVN06 treatment', 'behavioural therapy', 'mechanical forces;|chronic', 'previous surgery', 'etc.|3', 'intracranial CTA images.|Intracranial aneurysm', 'gastric/duodenal', 'Global Assessment scale', 'ejaculation', 'graft-versus-host disease;|Use', ""Wood's lamp fluorescence|No treatment for versicolor in"", 'Vascular amputation', 'rapid antigen testing (RAT)', 'lipid metabolism|Use', 'Underwent', 'stem cell boost', 'vascular examination', 'therapeutic intent.|Intent', 'implantation surgery||', 'atherectomy', 'security system|Effective contraception', 'hepatic encephalopathy|Patient', 'Structured Clinical Interview for DSM (SCID)', 'mesotherapy', 'SGL2-i),|myocardial infarction', 'major heart surgery', 'Typbar-TCV', 'lateral nerve targets', 'central laboratory', 'frequency of meditation', 'metabolic abnormalities:|Hypertensions', 'percutaneous intervention [', 'open midline incision|Presence of', 'DCE-MRI', 'CT assessment', 'preoperative HIT,|cardiac surgery', 'left ventricular dysfunction', 'HRCT chest suggestive of', 'alternative treatment', 'full biochemistry profile', 'penile genitourinary surgery|ASA', 'intra-vaginal gel moisturizers', 'Emergency Use Authorization (EUA)', 'epoetin alfa', 'liver biopsy consistent', 'upper GI surgery', 'steroid replacement therapy', 'communication problem|Application', 'dual antiplatelet therapy|Uncontrolled intercurrent illness', 'allogeneic blood stem cell transplantation|symptomatic CNS-involvement with MDS', 'chest computed tomography (CT) scan|History', 'anticoagulant agents|Patients', 'Structured Clinical Interview for DSM-5 (SCID)', 'insufficient organ function', 'contraindicate quality control', 'MR spectroscopy', 'chemo-radiation therapy', 'above refractive error', 'major pelvic surgery', 'various reasons', 'World Health Organization classification system.|Patients', 'Montreal Cognitive Assessment score', 'cleft palate repair surgeries||', 'eligible treatment episode', 'optimally', 'electrocardiograph', 'ocular inflammatory diseases', 'vigorous exercise conditioning defined', 'laparoscopic sleeve gastrectomy surgery|signed', 'Permanent sterilization includes hysterectomy', 'blood donated', 'isolated aortic valve surgery', 'oral surgical interventions|Patient is able to give inform consent||', 'standard medical care', 'chemotherapy treatment|Adequate serum levels', 'cervical lymph node dissection|Metastatic disease', 'exercise tests|Being on', 'treatment for amblyopia', 'chemoimmunotherapy induction', 'psychotropic mediation', 'ECG.|History of allergy to study drug', 'G719X mutation in exon 18', 'literature corrected', 'homicidal', 'lactation|Psychiatric illness|Multifocal hernia', 'stress testing', 'handbags', 'intra-articular infiltration', 'mental health examination', 'intracranial tumours.||Applicable to children', 'intra aortic balloon pump [IABP]', 'clinical laboratory test results', 'hair transplants', 'Pittsburgh PSQI sleep quality index (Buysse et', 'major organ transplant|History', 'Arabic language|patients', 'cryocompression therapy', 'invasive cardiac surgery', 'donate blood', 'preventative therapy', 'ocular laser surgery', 'cranial radiation', 'dialysis|concomitant therapy', 'Swiss vaccination', 'subtalar fusion', 'IABP', 'Rehabilitation.|Holding', 'pelvic inflammatory disease|uterine fibroids', 'radiofrequency', 'Biochemical tests should', 'rapid progression', 'postoperative radiotherapy', 'lung transplant', 'cervix;|Major surgery', 'special precautions', 'optimal treatment effect should be PR', 'anterior repair', 'assessment of function', 'endomyocardial biopsy', 'valve procedure', 'percutaneous endoscopic gastrostomy', 'dental anomalies||Generic inclusion criteria - all participants', 'RF treatment', 'antimicrobial therapy|History of (non-infectious', 'rapid antigen detection', 'transient elastography||Patients', 'routine laboratory test', 'exercise bike||', 'bisphosphonates therapy', 'prediabetes', 'irreversible surgical sterilisation', 'device therapy', 'Male sterilization', 'ACL revisions', 'assessing functional lung changes', 'vascularized polyp', 'shoulder arthroplasty', 'intravenous treatment', 'myopia control treatment', 'hematopoietic stem', 'NSCLC', 'CGM technology', 'tip torsion', 'CKD5', 'MR antagonists', 'Fitbit every day', 'Peripheral blood stem cells', 'menstrual period', 'lung resection|Left ventricular dysfunction', 'cumulative amount', 'glaucoma|Current treatment', 'verbal feedback.|Female|Over the age', 'therapeutic hydrodistension', 'PCI trials|A', 'local Investigator', 'positions|To show', 'stable.|Major surgery', 'visible porosities', 'local standard care', 'facial surgeries', 'herbal treatments', 'small molecule therapy|Received', 'vitreo-retinal surgery', 'cardiac CT angiography (CCTA)', 'stem cell transplants', 'SUBLOCADE', 'histological assessment', 'Surgery of the', 'DSA examination', 'evaluable lesion.||3', 'knee replacement', 'overnight hospital admission', 'ART therapy', 'palliative radiation treatment', 'RU<150ml', 'blood therapy', 'eligible.|Hormonal therapy', 'standard Crockcroft-Gault formula', 'quality stereoscopic fundus photography', 'thrombectomy', 'orotracheal entubation Age', 'copper IUDs', 'abdominal radiotherapy,|Surgical operations', 'surgical hardware', 'head CT scan', 'tobacco use|Habitual excessive alcohol use|Weight change', 'retest analyzed', 'computed tomography (CECT) examination', 'Distal penile hypospadias|Urethral', 'cervical rotation test', 'Mini mental test score', 'hemodialysis', 'equivalent|Major surgery', 'McDonald criteria|Expanded Disability Status Scale', 'RECIST v1.1)', 'acceptable contraception', 'vaginal sonography', 'non-visceral structure', 'orchiectomy', 'B-scan ultrasound', 'abdominal laparotomy', 'normal activities', 'vaginal orthosis', 'Montreal Cognitive Assessment|able to read', 'curative surgical resection', 'sitting systolic blood pressure', 'cosmetic treatment', 'complete response', 'vertebral column|History of', 'local excision biopsy.|Written informed consent provided.|Clinically suspected', 'systematic treatment regimens', 'intubation;|Hospitalizations for COPD', 'volume depletion', 'haemorrhoids.|Previous haemorrhoidectomy', 'pathogenic mutation(s', 'biological related parents||', 'ACL reconstruction', 'potential drug-drug interactions|Enrolled', 'treatment|pharmacological treatment', 'ventilation|Other treatment', 'computed tomography (CT) scanning should', 'secondary surgery', 'therapeutic oral or', 'continuing treatment', 'asthma therapy', 'regulate fluid volume', 'secondary procedure', 'analyzed biopsy.||Patients', 'sessions of intervention', 'Regular smoking|Dietary', 'bone marrow transplantation;|Active pulmonary tuberculosis infection', 'equivocal BCC lesion||', 'dental surgery', 'action', 'occlusion|Cardiac surgery', 'chemotherapy|History', 'vasectomy||', 'Computed Tomography', 'biological therapies|Addiction', 'refractive', 'clinical scenario', 'surgery.|Redo surgery', 'total amputation', 'Residual whole blood', 'dialysis|Type 1 diabetes', 'effective contraceptive method', 'Dallas area||', 'chlorhexidine', 'pathologic', 'regular electronic reporting|Inclusion', 'local anesthesia treatment', 'ICV ERT treatment', 'complaint of low back pain|Able to speak', 'birth control', 'pituitary function', 'ACIP recommendations', 'organic GI disease|Suspicion', 'remedial treatment after ASCT', 'cardiogenic shock|PCI', 'video recording||', 'multiplex real-time PCR TaqMan probe', 'practice in laparoscopy', 'program requirements||', 'consistent use of', 'simultaneous treatment', 'SLE treatment regimen', 'Computed Tomography [CT]', 'poor oral hygiene.|Patients', 'agent|Investigational agent|Surgical intervention|Radiation intervention', 'regimens of the concomitant medication', 'antigen test obtained from a sample collected from blood', 'distant metastasis;|received induction chemotherapy', 'head trauma resulting in loss of consciousness|Personal', 'Sternotomy wires stents', 'chronic fatigue', 'transcorneal electrical stimulation', 'Percutaneous transluminal coronary angioplasty (PTCA)', 'inhalation', 'transplantation treatment', 'subsequent confirmatory PSA value', 'therapy;|Major surgical treatment', 'circumcision).|Fetal opioid exposure.|Administration of sedating agents', 'small residual tumour mass', 'hypertension)|pregnancy', 'dose escalation stage', 'quality;|Target coronary vessels', 'standard neuropsychological evaluation|Brain injury', 'rehabilitative treatments', 'months|Experienced resolution', 'hospital stay|Analphabetism|Anacusis', 'EICU', 'gestations|fetal surgery', 'racerebral hemorrhage||Inclusion', 'reciprocal relationship', 'referral resulting', 'chloroquine treatment', 'examination', 'Primary immunization phase:||The', 'surgical sterilization of male partner', 'local guidelines|Active medical problem', 'endovenous intervention of truncal varicose veins', 'ventriculo-peritoneal shunt', 'gastric stapling', 'hematopoietic stimulating factor drugs', 'IVF-ET', 'assisted ventilation', 'abdominal CT', 'circumcision surgery', 'interventional radiology.||', 'hospital program', 'lymphoma symptom', 'brain CT', 'general anesthesia||', 'polymerase chain reaction (PCR) testing for HBV-DNA', 'mediastinal mass syndrome|No', 'Fragile X', 'Caribbean ancestry', 'World Global Gastroenterology Organization|IBS-SSS', 'whole brain radiotherapy', 'proximal gastrectomy', 'standard of care craniotomy', 'clinical laboratory determinations', 'Cheneau-Toulouse-Munster brace', 'transbronchial biopsy', 'praziquantel (PZQ)', 'anti-tumor treatments', 'heterokaryotypic monozygotic pair discordant', 'crizotinib monotherapy', 'chronic total occlusions PCI|Patients', 'Total mastectomy', 'Longstanding', 'pelvic organs', 'TC', 'surgical intervention/procedure', 'radical mastectomy;|Pathological examination', 'control asthma symptoms', 'oral lesions|Local irradiation therapy|Oral communication with sinus after the extraction', 'standardized test', 'first dose of drug.|unstable', 'curative-intent surgery', 'leads|Inpatient admission', 'bilateral pheochromocytoma|Patients suspected', 'CMML).|Prior treatment', 'T-DXd', 'clinical medical director', 'hemodialyzed', 'stent delivery devices', 'vision soft contact lens', 'psychiatric treatment', 'maintaining oxygen saturation', 'major head and neck', 'further detailed', 'CTS|Steroid injection for CTS|Physical treatment for CTS in', '2-hour OGTT glucose', 'PEP', 'testing tissue', 'bone augmentation', 'small amount', 'palliative intracranial radiation therapy', 'regular exercise program', 'Rupture', 'steroid prescription', 'emergency endoscopy|Deeply sedated & anesthetized', 'breastfeed', 'seminal fluid||Key Exclusion Criteria||Patients will', 'foreign hormone therapy', 'dental treatment experience|showed willingness to participate||', 'addiction treatment', 'liver resection surgery', 'chronic knee', 'chronic oxygen therapy', 'months；|regular menstruation', 'Metropolitan DC area||', 'Oura smartring', 'dialysis|Alanine aminotransferase', 'special types of diabetes', 'brain tumor|Referral routine MRI study.||', 'extracorporeal circulation', 'transcranial magnetic stimulation therapy', 'HCV infection;|chemotherapy', 'hand|Cervical Lateral flexion', 'pulmonary open surgery', 'LP implantation surgery||', 'gastroesophageal junction.|Synchronously', 'allogeneic transplant.|No bridging therapy', 'bone scan;|Prior treatment by', 'imaging suggests', 'vaccine therapy', 'cervical operation', 'test treatments', 'injection therapies', 'TLD treatment', 'meniscal knee injury', 'investigator.|Untreated narrow angle', 'Assisted Reproduction', 'duplex ultrasound velocity ratios', 'carotid stenosis||', 'full rehabilitation', 'CT Angiography (CTA)', 'B-cell lymphoma-2(BCL-2', 'periodontal surgery|Teeth', 'radical concurrent chemoradiotherapy', 'physical aggression toward', 'chest imaging examination showed', 'ophthalmic solutions', 'diagnostic imaging rotational', 'herbal supplement', 'focal youth', 'fine needle aspirate (FNA)', 'gastric volume', 'plain CT scan|dementia', 'endometriosis;|Laparoscopic surgery', 'translation support||', 'daily disposable', 'cytotoxicity assay', 'hospital stay of', 'regular hemodialysis', 'bilateral neck radiation', 'target eye selection criteria： Best corrected visual acuity', 'SCOFF screening questionnaires|Participation', 'brain radiation', 'Thai racial factor', 'endoscopy sedation', 'stool analysis', 'timely treatment', 'transferrin saturation', 'eating', 'chest CT|Patients', 'vertical descending supranuclear gaze', 'pre-procedure', 'HBV antiviral prophylaxis|Is', 'systemic glucocorticoid therapy', 'antiviral therapy|Pregnant', 'fumarates', 'fraxel laser treatment;|Subjects', 'antisense oligonucleotide', 'town professionals', 'Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV', 'Soliris|Concomitant', 'trauma-related distress', 'computed tomography (CT) scan', 'World Health Organization classification).3|No', 'index hospitalization', 'valve repair', 'general anesthesia.|Subject', 'quality CT', 'performed.|Preoperative endoscopic examination', 'AF ablation', 'standard chemotherapy regimen', 'coronary intervention procedure', 'treated for periodontitis', 'MRI.|Positive centralization', 'mandibular third molars.|Impaction classified', 'neurologic evaluation procedures', 'bone marrow infiltration', 'surgical repair of pectus excavatum.|Young', 'TN', 'Erythrocyte transfusion', 'Institutional Review Board/Independent', 'shortness of breath (dyspnea)', 'refractive error surgery', 'local prescribing information', 'standard of care neoadjuvant chemotherapy', 'treated by laparotomy', 'ustekinumab treatment', 'mechanical intestinal obstruction.|Nasogastric tube', 'practical clinical experience||Exclusion Criteria', 'initiation of therapy', 'debulking surgery', 'Mechanically ventilated', 'Transplantation', 'distal pancreatectomy', 'mm|Preoperative CT scan', 'isolated patients:||Patient', 'breatfeeding|positive breath test', 'cT3c-d', 'cardiac magnetic resonance', 'in situ hybridisation (ISH)', 'spinal epidural abscess', 'emergency surgery||', 'discontinuation from study', 'radioactive implants', 'cancer.gov).|Active acute graft versus host disease (GvHD)', 'distant organ sites|Having', 'coronary bypass treatment', 'Hybrid closed-loop', 'radiation for', 'oral contraceptives|Herbal therapy', 'blood draws|Acute', 'video calls', 'disclosure', 'months：During', 'first carpometacarpal osteoarthritis', 'risky pregnancy|No need', 'simple inhalation', 'fresh pathological tissues', 'partial colectomy', 'historically HER2 IHC 0 only|Was', 'tuberculosis.|History', 'clinical rotation||', 'malabsorption;|Past treatment', 'intra-articular injection', 'major organs', 'concomitant treatment', 'antiepileptic therapy', 'intensive care treatment|Active life-threatening diseases', 'structural imaging', 'ciliary body', 'Laser Trabeculoplasty (SLT)', 'latest laboratory', 'RHD)|unilateral stroke|first', 'oral contraceptive pills', 'Congenital Heart Surgery', 'liquid biopsy', 'digital intervention', 'mandatory biopsy', 'Technical Experts only)|Live', 'pain.|Potent opioid analgesics', 'Natural Skin tone/skin', 'medical therapy;|Esophageal varices', 'clinical chemistry', 'Diseased knee joint|Knee osteoarthritis|Any musculoskeletal problem', 'allogeneic stem cell', 'Samsung Medical', 'pelvic radiation.|Suspected', 'complete remission(CR', 'anamnesis|patient', 'immunomodulatory therapy|Prior allogeneic transplantation|HSCT graft DSA ≥3000 MFI|Current', 'MMR', 'Cohort', 'shock|Surgery', 'bone marrow blasts.|Pregnancy', 'salvage radiotherapy', 'Imaging subcohort', 'imaging tests', 'maintaining internet access', 'Anticoagulation', 'colonic surgery', 'emergency thrombectomy', 'bilateral axillary lymph node dissections|Already', 'applied procedure', 'brain stimulation techniques (Electroconvulsive Therapy - ECT', 'gastric surgery|Acute gastric', 'expression:||HER2 protein expression', 'longest nerve graft available', 'Acute Coronary Syndromes:|Haemodynamic instability|Cardiogenic shock|Recurrent/refractory', 'small intestinal resection', 'Medical Monitor review', 'neurointerventional treatment', 'contraceptive method', 'historical MRI.|No', 'Imaging', 'publicly supported medical assistance', 'gastric surgery;|gastroscopy', 'Classification of Airflow Limitation in COPD (GOLD) system', 'medical care|Patients', 'psychosocial intervention', 'Mini Internacional Neuropsychiatric Interview (MINI)|Score on the', 'tracheal intubation assisted ventilation', 'prosthetic', 'etc.;|Preoperative MRI shows only perforator infarction', 'Trauma induced', 'percutaneous tracheostomy procedure||', 'FDG-PET/CT', 'resection of the primary tumor (c)', 'cataract surgery', 'cutaneous graft-versus-host disease', 'small amounts from straining', 'tumour therapy', 'cutaneous surgical procedure', 'mechanically ventilated', 'cessation treatment', 'liver function reserves', 'leukemia treatment', 'electrocardiogram (ECG) abnormality that in the opinion of the investigator would preclude safe participation in the study.|Patients', 'brain radiation treatment volume should', 'regular medical checks', 'anticancer treatment', 'Musculoskeletal injury|Dietary supplements|Medication', 'Caesarean section', 'clinician|Prospective', 'Surgical sterilization', 'fluid bolus', 'gland hypertrophy|Complete clinical', 'restricted civil', 'assisted reproduction (WOCBP subjects', 'chronic fatigue syndrome.|Treatment', 'nerve block|No', 'Neurological Surgery', 'antihypertensive treatment|antihypertensive treatment stable', 'progression of treatment', 'visits|Adequate hepatic function', 'aortic root surgery', 'hysteroscopic surgery', 'extracorporeal membrane oxygenation treatment', 'assay', 'scabies treatment', 'radiotherapy;|Large panel NGS', 'subsequent surgical', 'T-DXd.|Any substance abuse', 'lymphomas.|Prior therapy', 'first-line platinum-based chemotherapy|Receipt of avelumab1LM', 'orthotopic heart transplantation', 'transplanted organs', 'adrenocortical hormone replacement', 'unique treatment options', 'placement of vascular access device.||14', 'neurosurgical interventions', 'curative anticoagulant therapy', 'position-emission tomography (PET) scan', 'assessment imaging of the tumor by CT', 'Biochemical examination', 'upper gastrointestinal endoscopy', 'lumbar steroid injection', 'otolaryngology', 'MCL.|At least one measurable lesion.|Subjects', 'parenteral nutrition', 'facial cosmetic treatments', 'blood transfusion', 'nasal surgery', 'hypoglycaemia|Patient', 'Cervical foraminal stenosis|Cervical central stenosis|Cervical disc herniation|Cervical spondylolisthesis||', 'routine endomyocardial biopsy', 'old)|Undergoing procedures below', 'balneotherapy program', 'Doppler echocardiography|Life expectancy', 'knowledge of reading', 'receptive oral sex', 'cognitive therapy', 'fecal occult blood', 'hormonal treatment|- Written', 'chest x-ray|History', 'liver surgery;|be', 'Lennox-Gastaut syndrome.|Seizures', 'stable treatment dose', 'antiplatelet therapy', 'surgeries', 'vascular pathology|extrapyramidal', 'buccal swab for HLA testing|Willing', 'reactivation of a latent infection', 'standard intraoperative', 'intratumoural treatment', 'years|Spirometry', 'etc.||Major organ function indicators', 'mutational hotspots)', 'lymph node biopsy', 'curative surgery/radiation', 'definitive local treatment', 'venous surgery', 'major surgical procedure', 'arthroscopic cuff repair surgery|American Society of Anaesthesiologists (ASA) Physical Status', 'oral resection/reconstructive surgery|Undergoing surgery', '5.Previous treatment', 'percutaneous transluminal angioplasty (PTA)', 'RBV', 'Lung cancer|CT scan available|Gross Tumor Volume available||', 'reconstruction', 'target blood pressure', 'thyroidectomy', 'bone marrow aspirates', 'physical examination.|In', 'unipolar ablation', 'flexion rotation test', 'bispectral index', 'Modification of Diet in Renal Disease (MDRD)', 'peripheral artery bypass graft|Cerebrovascular accident', 'regular medications', 'imaging procedures', 'hormone vaginal ring', 're-biopsy', 'major abdominal surgery||', 'gastric surgery|Known hypersensitivity to batroxobin', 'corneal implant', 'unauthorized medications', 'cytological documentation of', 'implant measures', 'ocular examination', 'hippotherapy', 'cephalometric digital radiograph', 'lateral skull|upper motor neuron facial palsy|segmental muscle', 'neuromodulation treatment||Exclusion criteria:||Contraindications', 'standardized gastric scintigraphy study|Resides in the Calgary', 'permission;|blood donation', 'blood thinner prescription', 'foam sclerotherapy', 'biochemical tests', 'oral prophylaxis', 'bile duct exploration', 'mid urethral sling operations', 'polymerase chain reaction testing', 'dissection', 'imaging scan', 'Malignant non-RCC', 'botulinum toxin injection', 'interventional ablation', 'RSV', 'Screening.|Failed', 'chronic medical', 'first-line endocrine therapy', 'primary vaccination', 'bladder augmentation surgery', 'thoracoscopic lobectomy|ASA', 'laparoscopic right', 'alternative experimental therapy', 'need anesthesia', 'allogeneic stem cell transplant|Systemic corticosteroid steroid therapy', 'appendicitis surgery', 'arthroscopic anterior', 'definitive therapy', 'known', 'endoscopic', 'bone fracture.|Patients', 'first-line standard therapy', 'cranial aneurysm).|Pregnancy|During the exclusion period', 'percutaneous procedures', 'standard-of-care medications', 'alterations', 'standard therapy', 'clinical stages T2-4a', 'interventional therapy', 'Treponema pallidum antibody Tp-Ab', 'cancer|Kidney dialysis patients|Patients', 'emergency caesarean', 'technology access', 'thyroid hormone replacement treatment', 'discontinuation of treatment with', 'hematopoietic stem cell transplant', 'conventional imaging', 'Indication Biopsy', 'National Immunization Day in', 'previous laboratory examination', 'stay pediatric services', 'molar in the row with no neighbour tooth', 'routine examination', 'alternative medical cause]', 'salvage therapy', 'vertebral artery [VA', 'Enchanced anterior-posterior diameter', 'percutaneous ethanol', 'cognitive decline,|relevant visuo-perceptive', 'Platelet transfusions', 'central coordination disorders', 'Epiphyseal region general trauma', 'standard insulin treatment', 'infection|Difficult sonoanatomical visualisation of the target area (SCTL, ITTC etc', 'thyroid ultrasound', 'thrombolytic therapy', 'trapeziectomy', 'menstrual cycle period', 'abdominal laparoscopic', 'allogeneic BMT|History of pre-existing', 'standard drink', 'diagnostic CT scan', 'cranial nerve III', 'Assuit University hospital', 'atrial fibrillation ablation', 'First trimester', 'walk independently,|He', 'biological effective dose calculations', 'ACS treatment|Current', 'temporal artery temperature reference.|English-or Spanish-speaking', 'orthodontic treatment.||', 'urine routine', 'large spectrum antibiotic', 'preoperative inotropes', 'surgical intervention', 'practice effective contraception', 'synovectomy', 'total pelvic', 'HPV screening', 'percutaneous coronary artery intervention', 'intraurethral suppositories|Prior pelvic surgery', 'hemorrhage)|significant refractive', 'pupillary dilatation to allow acquisition', 'PEF', 'chimeric antigen receptor (CAR) T-cell therapy', 'Transesophageal echocardiography', 'standard of care RT', 'polymerase chain reaction (PCR)|Anticancer therapies', 'cytotoxic therapy', 'Sperm normal morphology rate ≥4%;|No', '131I treatment', 'coronary artery bypass grafting|Patients', 'aortic dissection', 'placement', 'dialysis treatment|Renal replacement therapy', 'surgery of the bones of the lower limbs performed', 'risdiplam|Upright head control', 'conservative therapy', 'walk indoors', 'endourological ureteral manipulations', 'right ventricular mechanical circulatory', 'cardiac monitoring', 'anatomical regions', 'dysfunction History', 'biphenotypic acute leukemia- Disease status', 'Eyberg Child Behavior Inventory- ECBI', 'percutaneous coronary intervention', 'mental illness|participation', 'imaging of the colonic mucosa', 'COVID-19 vaccination', 'Mini International Neuropsychiatric Interview (MINI))|Presence of', 'living', 'Walkasins Haptic Module|Ability to complete the functional outcome measures', 'local regulations).||2 Chronic AD', 'bone fracture|Admission to trauma ICU', 'subcompensated hydrocephalus', 'endoscopic esophageal dilation', 'expression of the activation marker DR', 'mechanical ventilation/ECMO', 'metallic plates', 'small cell carcinoma', 'valve replacement surgery;|Dilated cardiomyopathy', 'societal guidelines||', 'EMA application', 'sarcomatoid features', 'active internet connection||', 'repetitive spinal flexion', 'subject.;Physical examination', 'intrapleural therapy', 'implant contraception', 'gastrointestinal endoscopy|ASA Physical Status', 'cardioversion', 'Systemic treatment', 'corrective lenses', 'tobacco users', 'traditional imaging procedures', 'blood tests', 'oral therapy', 'burn medications', 'periocular treatment', 'follicular lymphoma|grade', 'history|pelvic organ prolapse', 'clinical intervention trial|Mental incapacity', 'heart transplant', 'permanent', 'Standardisation Initiative (IDDSI) level', 'curative resection', 'Revision total knee', 'combination treatment', 'serology testing for anti-gluten protein antibodies|History of', 'TAVI', 'biologic treatment', 'activities', 'immunosuppressive therapy).|Very', 'aortic surgery', 'conventional flexible', 'isolated IFNγ/CXCL9', 'image inclusion criteria', 'tracheal tube capping', 'refuse treatment', 'procedural anticoagulation', 'definitive resection', 'ketogenic diet', 'cancer|Delayed gastric emptying', 'intermenstrual spotting Large Cesarean scar niche', 'preoperative evaluation', 'blood samples;|ECOG PS', 'simple appendectomy', 'S-ENG', 'maternal antibiotic treatment', 'secondary first carpometacarpal osteoarthritis', 'tobacco', 'tonsil adenoidectomy,|the operation time is 10~60 minutes,|sign informed consent.||', 'Special Education classes', 'cardiac pacemaker', 'ESWT', 'cirrhotic portal hypertension;|Ultrasound', 'constrictive physiology', 'computed tomography (CT) of the lungs', 'lymphodepletion.|Allogeneic stem cell transplant', 'registrational clinical trial.|Participants', 'bile duct invasions visible', 'months.|Clinical vaccination', 'aorta stent', 'vFFR computation', 'blood coagulation;|Immunosuppressive therapy', 'Radiation therapy', 'cytological documentation of adenocarcinoma of the colon', 'complete revascularisation', 'rabbit proteins|Previous treatment', 'Therapy||Prior therapy', 'biological selection.|If', 'fresh biopsy specimen', 'quit CC smoking|Reports', 'bone marrow transplant.|Non-leukocyte', 'study materials', 'Emergency EBUS cases|ASA score', 'immunotherapy.|Major surgery', 'coherence tomography angiography', 'Abdominal surgery', 'anticoagulation therapy|Cardiovascular condition Cardiac shock', 'program.|In therapy', 'surgery of the shoulder', 'dipstick testing', 'surgical ablation', 'subsequent assessment', 'radical surgery', 'ultrasound', 'breast reconstruction', 'Montreal Cognitive Assessment (MoCA).|Only applicable for those patients', 'exposure therapy', 'antimycotic treatment', 'total stone burden volume', 'Natural Head Position|unsuitable radiographs', 'PET/MRI scanner limit;|Known allergic reaction', 'functional disability||Exclusion criteria:||Participation', 'complete autologous HSCT', 'heart failure|Intracardiac clot', 'histological examination', 'chest CT scan reveals severe', 'molecular testing (deletion of maternal allele of', 'become|pregnant', 'endovascular thrombectomy', 'major surgeries', 'cancer|Has started', 'radiation of the scalp', 'endolaryngeal surgery|>18 years old|Volunteer to participate in the study||', '12-lead ECG;|Thyroid-stimulating hormone (TSH)', 'University Hospital (UH) standard bronchoscopy', 'preoperative examination', 'standard monitoring for cardiac surgery|Target', 'father|Hydrotherapy treatment takes', 'complete esophagogastric tumor resection.|Patient', 'liver CT', 'intussusception', 'cesarean delivery|Patients', 'chemotherapy-immunotherapy', 'allogeneic stem cells transplantation', 'radiographic examination', 'malignancy|Concurrent chemotherapy', 'chronic treatment', 'remain off for the duration of the study', 'rhythm control drugs', 'corneal abrasion', 'brain imaging indicating CP', 'nonamyloid control arm in aim 1).||Diagnosis of heart failure', 'RAS mutation status', 'complete cardiac MRI', 'consulting ophthalmology', 'clinical laboratory tests).|BMI', 'antibiotic prophylaxis', 'Medical conditions||Significant', 'Radiation Oncology Core (IROC) for', 'transhepatic artery chemoembolization (TACE)', 'focal radiation', 'allogeneic cell transplanters.|Have', 'β-thalassemia', 'serological testing', 'surgical sterilization (vasectomy', 'transoral resection', 'microbiopsy', 'standard physical therapy', 'bicuspid aortic valve|Non-calcified aortic stenosis||Identified risk of coronary occlusion', 'vascular resection', 'screening.|active orthodontic therapy|regular consumption of medications', 'months|Liver biopsy', 'emergency surgery|Life expectancy', 'whole-brain image', 'Nerve Stimulation', 'study treatment', 'rigid orthokeratology lenses', 'drugs|Concurrent', 'brachial plexus surgery before|patients', 'World Health Organization criteria', 'antimicrobial treatment', 'started', 'COVID-19 vaccines);|Pregnant', 'vaccination', 'isolated cleft', 'oral absorption of medications.|Patients', 'ESA treatment - non-response', 'postoperative corneal astigmatism ≤0.75D|mesopic pupil size', 'MV stenting', 'prevention risk management', 'remotely|Regular access', 'it.|Expectation of survival beyond 1 week', 'catheter ablation|Persistent atrial fibrillation', 'renal function tests', 'surgical resection of MBM', 'prone position ventilation', 'revascularization procedures', 'dietary restriction leading', 'H&E section', 'biopsy|Axial CT scan', 'sitting time|BMI', 'Step-Reduction Phase)|Regular tobacco', 'diffuse', 'Modified Electric therapy', 'tuberculosis.|History of meningococcal infection', 'food allergies|Advanced kidney disease', 'genetic conditions|no parental', 'DXA', 'hematopoietic transplantation', 'dose)；|Systemic treatment', 'hospital care', 'surgically treated', 'preoperative examinations', 'lipid-regulating therapy', 'B-cell targeted therapy', 'e-cigarette', 'acceptable birth control', 'thrombolytic anticoagulation therapy.|At screening', 'months|being', 'corneal transplantation', 'Student Risk Screening Scale-Externalizing', 'disorders|Pregnant', 'mutations leading', 'left ventricular hypertrophy related', 'atopy', 'histopathology|missing', 'skin disease|Elevated body', 'remain on the waiting list', 'anatomical deformation', 'allograft graft', 'percutaneous procedures for microdevice implantation', 'small to tap in which case the patient is eligible.|Patients must', 'palliative radiotherapy targeting bone metastases', 'rapid peritoneal solute transfer rate', 'Table 1|Clinical history', 'standard of care acute stroke', 'pathogenic mutations', 'allogeneic hematopoietic stem cell transplantation.|The treatment', 'anticancer treatment like chemotherapy', 'electrolyte supplementation', 'Bypass surgery|Contradiction for CCTA', 'main stem', 'viral reactivation should', 'special type diabetes|History of', 'clinical blood chemistry measurements', 'thoracic epidural analgesia', 'dental braces|Full Scale Intelligence Quotient', 'institutional setting', 'amblyopia);|Patients', 'complete periodontal diagnostic', 'validated assay', 'Covid FPG Vaccination', 'inpatient', 'variceal bleed', 'psychological therapy', 'local therapies;|Indication', 'open hemorrhoidectomy', 'lesional procedures', 'FFP', 'fresh mount microscopy||', 'suspicion thereof', 'escalations', 'small group discussions', 'study start|CT scan', 'major bowel resection', 'sole intrahepatic intraarterial chemotherapy', 'ultrasonic window', 'immunosuppressive therapy.|Receipt of', 'RT).|High-risk biochemical recurrence (BCR)', 'old.|Will', 'small cell carcinoma of the urinary system', 'CIS', 'localization|Patients', 'Electrocardiography', 'functional dental implant', 'B-cell depleting therapy', 'Pathogenic germline variant', 'endoscopic submucosal dissection', 'Cerebrovascular Division', 'consumption of any products included', 'autologous TCR-T cells', 'months,|Surgical operation', 'traditional therapy', 'criteria:||≥75 years', 'ACL surgeries', 'breast puncture biopsy', 'university', 'myocardial infarction|History of', 'Periodontal pocket depths(PD)', 'standard regiments', 'elective caesarean section.|Patients', '2);|Able to read', 'hormonal oral contraceptives', 'hematopoietic stem cell transplantation;|Hematologic malignancies did', 'nuclear magnetic resonance', 'permitted.||Autologous stem cell transplantation (SCT)', 'local regulatory requirements', 'Regular exercise', 'Controindications', 'systemic anticancer therapy', 'immunomodulatory treatment regimen.|No smoking', 'first-line drugs', 'conventional treatment only.|Age', 'live virus vaccination', 'esophageal achalasia||', 'Sahlgrenska University Hospital||', 'stent rescue', 'granulocyte colony', 'COVID', 'birth dose of OPV', 'CD|Stool culture', 'pancreatoduodenectomy', 'English|Owns a cell phone', 'graft-versus-host-disease (GVHD)', 'intracranial carotid artery', 'bariatric surgery|Myocardial infarction', 'Segmentectomy', 'Cooper Pediatric Gastroenterology practice in Camden', 'screening|Uncontrolled intercurrent', 'World Health Organization(WHO', 'total endometrial ablation', 'insufficient palatal donor sits', 'Cassini topography devices)||', 'Treatment Protocol', 'surgical treatment|range of motion impairment', 'Global Initiative for Asthma (GINA)', 'anticoagulation therapy', 'upper abdominal surgery', 'TPO-RA', 'Horne-Ostberg Morningness/Eveningness questionnaire', 'percutaneous endoscopic gastrostomy (PEG) tube may be eligible. For any such participant', 'Ruxolitinib:|History of hypersensitivity', 'back pain|indication', 'drug screening test', 'bedtime|Active smoking|Current drug', 'vertebrobasilar artery', 'bicuspid insufficient valves', 'fiberoptic intubation', 'molecular methods', 'intralesional platelet rich plasma treatment', 'flexible laryngoscopy', 'Pittsburgh Sleep Quality Scale', 'HF treatments', 'liver disease.||Patients', 'live vaccination', 'anticancer therapy', 'likely cause functional deficits', 'hematopoietic stimulating factor', 'vaginal examination', 'medial tibiofemoral OA', 'heart catheterization', 'percutaneous ethanol injection', 'violation of the calvarium', 'delayed implant', 'fecal occult blood 1+', 'injectable therapy', 'Gastroscopy', 'radiographically visible root canal', 'Rhythm Therapy - IPSRT', 'LNG implant', 'giredestrant + inavolisib arm)||Confirmation of biomarker', 'non-hormonal highly effective method of contraception', 'small cell types', 'Transcatheter mitral valve implantation', 'ART', 'treatment delivery', 'transfusion of blood', 'antiandrogen therapy', 'Mantle Cell Lymphoma (MCL)', 'antibiotic treatment', 'PSMA PET/CT', 'urine pregnancy tests', 'molar surgery|Physical status', 'PCA|previous treatment', 'breast reduction', 'attempted', 'NICU admission', 'lactation|Previous gastrectomy', 'screening;|Chest X-ray', 'IP on Day 1.|Total serum bilirubin', 'alectinib', '+6 Diopters|Cylindrical refractive error', 'corrective heart surgery', 'etc.);|Major surgery', 'eye surgery', 'zonular dialysis', 'tumor reduction surgery', 'anastomosis|Planned surgery', 'surgical repair', 'injection procedure', 'standard therapy options exist', 'functional assessment', 'revision total knee arthroplasty|Osteoarthritis', 'treated for latent TB.|Previous', 'GREM1 expression', 'insulin therapy schemes Later', 'DXA scans', 'survival', 'BMS', 'sites|Untreated', 'Alberta area||', 'subtotal resection', 'pulmonary surgery', 'left ventricular hypertrophy', 'Screening + ET', 'induction chemoimmunotherapy', 'graft surgery', 'joint fluid analysis', 'bifocal lenses', 'bullectomy', 'cell therapy', 'bone marrow (BM)', 'unresectable CLRM,|Had', 'exercise induced', 'Cesarean Delivery', 'pelvic MRI', 'low protein diet', 'hyperbaric oxygen therapy', 'optimal dose of levodopa', 'radical surgical treatment', 'Dialysis', 'preoperative transthoracic echocardiography|Condition', 'fluoroscopic', 'transdermal hormone contraception|Sexually active', 'intestinal Immunoglobulin E levels', 'Physical examination', 'peripheral venipuncture);|Those', 'cranial magnetic resonance imaging (MRI);|Hematological parameters', 'bile duct disease', 'ocular nerve injury;|Neurological disorders;|disc disease', 'surgery procedures', 'anorectal surgery;|suspicion of anamnestic', 'pelvic radiation|Patients', 'nocturnal breathing disorders|Patients', 'platelet transfusion therapy', 'polyurethane|Hospitalized', 'US examination of AS shows', 'supplemental oxygen therapy|A diagnosis of', 'analgesic therapy', 'biomedical therapy', 'ATP', 'plain CT KUB)||', 'esophagoscopy', 'prenatal ultrasound examination;|consent to the intervention in the form of', 'orthodontic treatment.|Good oral hygiene', 'placement of the implant', 'surgical treatment|Angiography revealed', 'neoadjuvant chemotherapy|Axillary lymph nodes involvement', 'transdermal estradiol|Current use', 'NRS=', 'Sponsor employee|Failure', 'video camera|Seen', 'first-line PD-1 inhibitors', 'DEXA examination', 'carcinomatous meningitis.|History', 'hospital admission)|Renal disease', 'pulmonary artery catheter', 'stimulators|Cardiac', 'MMR-varicella', 'treatment methods', 'extraction indication', 'arteriosus stenting', 'ABG', 'subglottic);|Patients', 'Assessment Incomplete', 'ROM restriction', 'laparoscopic resection', 'Taiwan label', 'continuous anticonvulsant treatment', 'robotic bronchoscopy', 'ADT', 'Wechsler Adult Intelligence Scale - Second Edition', 'GITQ collected', 'involves treatment', 'lipid-lowering medications|sleep apnea|fragmented sleep|have', 'treatment-related MDS', 'emergency procedures', 'endoscopic resection', 'CERAB procedure', 'line of standard chemotherapy regimens', 'Montreal Cognitive Assessment (MoCA)', 'bacteria', 'heart surgery', 'pancreaticoduodenectomy|Undergoing surgery', 'magnetic resonance imaging scan)|Able', 'Physiotherapists', 'ligamentoplasty', 're-amputation|Severe malabsorption disease', 'chest computed tomography (CT)', 'colorectal surgery|Hearing disorders|No', 'incomplete endoscopy', 'thoracic region', 'blood transfusion therapy', 'inhaled general anesthesia', 'definitive operation to remove the tumor(s) pending', 'quality of the data.||ESRD patients with the following etiologies||Autoimmune disease', 'thyroid hormones', 'World', 'Influenza vaccination should', 'allogeneic SCT', 'Sponsor approval.||Dose Expansion', 'radiological knee osteoarthritis||', 'pelvic health physiotherapy', 'sub)mucosal dissection|Distant metastasis', 'SD- OCT', 'orthodontic treatment.|Patients', 'sterilization procedures', 'standard therapy.||Other Inclusion Criteria:||1', 'later allograft nephrectomy', 'spirometry', 'estrogenic vaginal ring', '-EJ', 'transperitoneal radical nephrectomy', 'inclusion|Blood donation', 'quarantine period', 'CIBINQO', 'resurfacing laser', 'M1b', 'DBT exam', 'total pancreatectomy', 'enteral tube feeding', 'lumbar diseases|patient', 'enteral tube', 'complete colonoscopy', 'psychiatric hospital admission', 'neurological diseases|Surgery', 'M1|Mastectomy', 'interrupted', 'nerve impingement', 'magnetic-sensitive ink|Other', 'coronary artery', 'Physical Therapy II.||', 'systemic infection);|Patients', 'exercise alone', 'opioid use|Uncontrolled', 'nerve stimulation', 'radiological imaging suggestive', 'control of vasogenic edema', 'ablation', 'Computed Tomographic', 'Surgically treated trauma', 'autoimmunity tests (ANA', 'Dose Escalation Cohort Specific Inclusion Criteria:||Refractory to standard available', 'vacant', 'DWI', 'volume resuscitation).|Patients', 'bypass', 'reinforced', 'flow cytometry crossmatch', 'PROCEDURES||Significant coronary artery disease', 'blood consumption (ABC) score', 'open wounds', 'close ophthalmological monitoring.||H.', 'Polymerase chain reaction (PCR) test for HCV RNA', 'gene-corrected macrophages', 'conventional open-heart', 'spinal', 'corticosteroid nasal spray', 'biopsy procedures', 'proportion of blasts', 'maintenance stage cardiac rehabilitation', 'penile surgery', 'emergency room', 'X-rays series', 'special diet', 'radical treatment', 'IVF', 'HER3 expression', 'intensification therapy', 'infection|Immunosuppressant therapy|Coagulation disorder|Surgery', 'abdominopelvic imaging + technetium bone scan', 'fine-needle aspiration', 'clinical laboratory tests.|Individually matched', 'skin examination', 'study therapy', 'treatment related', 'brain imaging after CNS-directed therapy', 'vertebral fractures|other major lumbar spine structural abnormalities|comorbid health conditions', 'urine tests', 'archive biopsy', 'KMT2A-rearranged', 'laboratory tests.||', 'autologous PRP injection', 'aesthetic treatment', 'auxiliary examination', 'sigmoid', 'oral anticoagulation therapy', 'bile duct)', 'surgery of the gastrointestinal tract', 'FDG PET scan', 'dienogest treatment', 'physiotherapy', 'lumbar puncture:||Infection near the puncture site', 'vaccine label', 're-excision', 'booster vaccination', 'Assessment', 'IVF procedure|Electronic implants', 'General Practitioners', 'adjuvant treatment|patients', 'Local treatments', 'cumulative dose of doxorubicin', 'PSQ', 'Spine surgery|Spinal hernia|spondylolisthesis|Spinal infections|Severe spine deformities|Neural diseases|Upper', 'therapy-related MDS', 'major organ transplant|Active pneumonitis', 'Global Assessment (IGA)', 'PCR analysis', 'pelvic operation for non-obstetric cause', 'radical therapy (surgery', 'laparoscopic procedures', 'quality-of-life questionnaires', 'coordination', 'full vaccination regimen', 'orthodontic treatment|no', 'schuss view', 'done facial injections', 'mirror therapy', 'Antigen expression', 'treated for ALL or AML||Note', 'extensive washing after harvest will minimize systemic exposure', 'upper abdominal surgery|Pregnancy', 'arterial revascularization', 'digital evacuation', 'chemotherapy-induced hair loss', 'UC|Rectal topical therapy (enemas or suppositories', 'CNS -directed therapy', 'medical tests.|ASA type > II|Current pregnancy', 'autologous CAR-T cell therapy.||B. Histologically confirmed marginal zone', 'normal CT scan', 'pathological confirmation', 'intercostal retraction).||', 'arterial catheter', 'brief technology', 'endothelial disorders|Ocular surgery', 'chemotherapy-induced neuropathy', 'cognition', 'transjugular intrahepatic shunt (TIPSS)', 'oral surgery', 'EBER', 'plasma donation', 'major organ system.|Have', 'open liver resection.||', 'revision total knee arthroplasty', 'bile duct obstruction', 'bone marrow transplant.|History', 'thyroid surgery', 'RIS', 'endotracheal intubation;|Anesthesia risk classes', 'immunomodulatory drug (IMiD)', 'maternal cardiac findings', 'apnea|Current', 'SISH', 'colorectal ESD', 'obliterative procedure).|History', 'cardiac color ultrasound', 'vascular access necessary', 'cutaneous melanoma|Eligible for', 'month|primary hyperparathyroidism|revascularization', 'orthopedists', 'ART regimen', 'left minithoracotomy;|Patients', 'adjuvant immunotherapy', 'barrier contraception', 'elementary school', 'provocative concentration', 'AXIN1', 'propolis', 'blood thinners', 'SLR)|Posterolateral disc bulge', 'verify normal QTc', 'intravenous MRI contrast agent', 'complete left bundle branch block', 'menstruation every', 'standard treatment exists', 'vasodilation', 'subsequent ostomy', 'complete surveys', 'NRT', 'nerve block procedure', 'axillary node dissection|physical status', 'endoscopic management', 'colorectal metastases|Surgical resection by means of a bilobectomy', 'lower rhytidectomy', 'checkpoint pathways', 'etc|Before screening', 'PE)|PE', 'complete medical', 'bone marrow radiation.||A serum creatinine', 'IP on Day 1.|Neutropenia defined', 'preoperative treatment', 'Ocular surgery', 'local site investigator/radiology', 'months;|Physical examination', 'cell transfusions', 'functional tests', 'transcutaneous oximetry measurement (TCOM)', 'cardiac disease;|A', 'oral rinse material', 'Mitigation Strategy (REMS)', 'ataxia-telangiectasia', 'palpation', 'participate.|Stereotactic Radiosurgery (SRS)', 'medical intervention Disorder', 'allogeneic hematopoietic stem cell transplantation|Patients', 'hysteroscopy|Predict operation duration', 'abdominal region', 'assisted reproductive techniques,|electing cesarean section.||Exclusion criteria', 'Characterizing of Freezing', 'orthodontic treatment|No', 'thalamus|Previous treatment', 'synthetic marijuana', 'standard alternative treatment options', 'intracranial EEG', 'KBAS', 'visit)|Self-reported', 'first-year paramedic student,|not', 'localized treatment (surgery', 'assisted reproductive technology', 'assessment of pulmonary function', 'standard-of-care abdominal laparoscopic surgical procedure', 'dual therapy', 'TMB testing', 'oxygen therapy.||', 'medical management', 'lateral flow test', 'video', 'surgery.||Previous surgery', 'sedative/hypnotic drugs', 'transdermal):||II', 'nonspecific LBP', 'spectroscopy', 'classical mycological methods', 'Structured Clinical Interview for DSM-5 (SCID) criteria for schizophrenia', 'functional materials', 'disease.|Major surgical procedure', 'Oral Health Department', 'postoperative variation in performance', 'judicial order|History of', 'palliative purposes', 'chemo - port.|Patients', 'local testing', 'expected procedure', 'gastric acid secretion', 'CTA', 'examination.|Total WORC percentage score', 'Copper-64 DOTATATE scan', 'West Nile', 'operations', 'hip anatomy', 'transient ischemic attacks', 'treated by', 'Treatment', 'vertebral artery dissection|Signs', 'intracranial carotid artery;|Successful recanalization', 'cardiovascular surgeons', 'HCV)|Allogenic organ transplantation', 'pathologic etiology', 'facial active treatment', 'oncological treatment', 'graft disfunction 2 weeks prior', 'HPV vaccination', 'HIV vaccine trial', 'physiologic replacement dose', 'burn trauma', 'major organ surgery', 'Diyala Governorate', 'diagnostic testing', 'complete exercise trials|Use of investigational drugs', 'device treatments', 'target temperature', 'skin tests', 'Normalisation Ratio', '3-lead ECG Holter', 'transfusion therapy', 'arthritis|Wound', 'simple dental treatment', 'Thyroidectomy', 'allogeneic stem cells', 'maintenance prednisone therapy', 'tendon turnover|Former participation in a study', 'adenomatous polyp', 'hormone implant', 'B cell depletion agent', 'local label', 'IOL power', 'visceral organs', 'Maxillofacial Surgery', 'surgical operation', 'curative intention|preparatory CT visit', 'venous thrombosis;|(4', 'GRYR', 'gastrointestinal surgery/disease', 'clinical intervention;|Have', 'conventional radiation therapy', 'Structured Clinical Interview (SCID)|Daily smoker/nicotine', 'abortion', 'prespecified asthma action', 'radiotherapy;|Adequate organ function', 'hospitalized covid-19 patient.|full consciousness', 'marrow transplant', 'trifocal TFLIO130C IOL', 'regular proton pump inhibitor', 'inflammation|Ocular surgery', 'brain imaging evaluation', 'juridical order.||', '160mmHg|Renal biopsy', 'Duplex UltraSound', 'open vascular surgery', 'SUI', 'futibatinib:||Major surgery', 'Dietary treatment', 'stationary cycling', 'fetal membrane separation', 'resected', 'stable treatment regimen', 'neoadjuvant treatment|Patients', 'laboratory assessments', 'intensive care therapy', 'computerized tomography scan', 'stool examination', 'intratumoural injection', 'continuous oxygen therapy', 'conventional imaging (', 'render anesthesia', 'sports tape', 'vaccination scab', 'hospital', 'allogeneic hematopoietic stem', 'adult vaccination', 'imaging diagnosis;|The', 'Sleeve Gastrectomy', 'exercise treatment', 'carotid revascularization', 'neoadjuvant therapy|progression', 'cancer;|melanoma;|hepatocarcinoma;|gynecological cancer;|colorectal cancer;||lung cancer.||2', 'bariatric procedures', 'laboratory screening panels', 'perineal tear).|Failed conservative treatment', 'clinical laboratory determinations beyond', 'primary care consultation', 'imaging (CT', 'open abdominopelvic surgery', 'ureteral surgery|Pregnancy|Pediatric populations|Ischemic heart disease|Congestive cardiac failure|Complicated', 'scalp;|Scalp microinfusion', 'fluid restriction|Change', 'chest HRCT', 'PVTT typing', 'blood collection', 'radioactive particle implantation', 'coronary artery disease)|T2DM complications', 'Hidradenitis Suppurativa', 'interviews||', 'antihypertensive medications.||', 'intraocular surgeries', 'evolution of the response', 'primary antihypertensive therapy', 'stage surgery', 'synchronous biopsy', 'tissue obtained', 'venous thrombosis|heart failure|sepsis|cerebral edema|hypertensive encephalopathy|hypoglycemia|hepatic encephalopathy|fluid-electrolyte disturbances|acute-chronic renal failure', 'periodontal screening', 'psychotropic medication|Life expectancy', 'gastric bypass surgical intervention|Capable of', 'TRANSPLANTATION', 'gastric Potential of Hydrogen (pH)', 'Resting ECG', 'whole abdomen radiation therapy', 'x-ray therapy', 'stent thrombosis.|Planned', 'elective major surgery', 'clinical investigation plan', 'ethanol.|Blood ethanol concentration', ""Fridericia's formula|History"", 'Maintenance Immunotherapy (desensitization)', 'attributes of vestibular dysfunction', 'consensus panel criteria', 'decompression involving', 'ovarian ablation therapy', 'T cell infusion only', 'bilateral total knee', 'Multiple organ failure', 'tympanic membrane|Anatomy', 'AFib', 'anticoagulant drugs.|Children', 'postoperative cardiac surgery.||Exclusion', 'HIV transmission until', 'physical therapy', 'T-cell costimulatory', 'reactive HIV-1 antibody', 'NGS panel testing', 'chemotherapy drug', 'intervention', 'sperm concentration', 'Rapid Assessment of Physical Activity (RAPA) score', 'positive|Chemotherapy', 'autologous hematopoietic cell transplantation', 'left subclavian artery diameter', 'complete gastrointestinal obstruction.|Patients', 'barrier contraceptive measure', 'local institution;|Bone marrow involvement', 'European Association for the Study of the Liver (EASL) clinical diagnostic criteria', 'total parenteral nutrition', 'interpersonal relationship therapy', 'Computerized tomography (CT)', 'Stop menstruation', 'contraception|Subjects', 'allogenic hematopoietic stem cell transplantation', 'chronic BPA release', 'bicuspid aortic valve', 'transdermal hormone contraception.||In case', 'Infantile Spinal Muscular Atrophy type II|Accompanied', 'Thoracic Aortic Disease||', 'despite', 'clinical mammography', 'Android processor', 'slit lamp', 'initiation.|Patient', 'Coronary Artery Bypass Grafting', 'foreign hormone treatments Record of', 'Efferon CT device', 'implant site(s', 'allogenic stem-cell transplantation||Current use of', 'radiotherapy/chemotherapy', 'rectal cancer|Previous pelvic RT', 'oxygen therapy|heart failure', 'available treatment', 'gastric stimulator', 'alcohol pharmacotherapy', 'Major surgery includes', 'graft from a DCD', 'spinal fusion across', 'absorbable sites Hormone therapy', 'functional', 'optimal medical treatment', 'transcranial magnetic stimulation', 'first trimester ultrasound assessment of', 'venous angio-MRI', 'clotting tests', 'IFX use', 'completed FIT testing', 'variations', 'fibrosarcoma.|No treatment', 'Immunomodulatory therapies', 'resting echocardiogram|Recent (', 'major blood vessels', 'Mitral regurge replacement Surgery', 'Tumor biopsy', 'neurologist,|Expanded Disability Status Scale', 'intra cranial tension.|Space occupying', 'multi organ transplant recipients', 'botulinic toxin injection', 'histologic', 'physical examination', 'antiviral medications', 'FLC ratio', 'Assessment of Understanding (AoU)', 'MTC', 'oral treatment', 'small amount of suprachoroidal hemorrhage', 'anticoagulant/antiplatelet therapy', 'additional biopsy attempt', 'Bilateral knee surgeries', 'neurosurgical resection', 'sperm donation from initial drug administration until 90 days after the last dose of study drug.|Females of childbearing potential', 'dose-escalation stage', 'albumin|extracellular hyperhydration', 'invasive ventilatory support.|Participant', 'change of cochlear implant processor model', 'criteria|A sample', 'local radiation', 'metal implant', 'cardiac angioplasty', 'Rheumatology consultation', 'allogeneic HSCT', 'bilateral pulmonary artery bands)|Presence', 'intervention|Active illicit substance', 'regular Holter electrocardiography', 'scoliosis surgery', 'local WIC agency sites where either the telehealth solution', 'vertebral artery', 'lipid-reducing drugs', 'ocular metallic foreign body', 'liver function||Key', 'immunosuppressant medical treatment', 'objective exercise capacity', 'special treatment', 'whole Brain radiation therapy (WBRT)', 'vasectomized sole partner', 'SPO2<95%)|BMI>35 kg/m2|Refusal', 'Graft vs Host Disease', 'allohematopoietic stem cell transplantation);|Symptomatic brain', 'discharged after', 'local regulatory agencies', 'e.g arm in plaster', 'perfusion MRI', 'World Health Organization guidelines', 'smart-phone', 'clear-cut', 'organ function', 'index endoscopy', 'chest X-ray', 'passive flexion', 'qualitative β-hCG', 'YMRS', 'diagnostic procedures', 'cardiac bypass surgery', 'household distances', 'thoracic CT scan', 'dental treatments', 'MVPA every', 'treatment program trial version 10 guidelines"" issued', 'maintaining oral hygiene', 're-identification risk', 'identical HLA transplant', 'surgical valve replacement', 'small screen/video game recreation', 'urine drug screen|Positive urine alcohol test|Any', 'allogeneic hematopoietic stem cell transplantation.||HIV antibody positive', 'limited exercise', 'study|Central corneal thickness', 'diagnostic arthroscopy', 'androgen deprivation therapy (', 'bone augmentation of the sites to be treated;|poor oral hygiene;|smoking', 'walk unaided|Can read', 'kobnerization', 'Bloating', 'CT-perfusion', 'roux-en-y gastric bypass||', 'physical organ transplantation;|There', 'series of', 'bladder surgery', 'emergency surgery|Cardiac transplant', 'IVF||', 'intracranial dissection|Medical history', 'hepatic impairment|Major surgery', 'poor knee alignment|Patients', 'TMD-specific treatment', 'cesarean', 'PAR-Q|Participating in another research project', 'adjuvant treatment', 'bleaching', 'local principal investigator', 'lymph node surgery', 'transperineal ultrasound||', 'face-down position after vitrectomy combined with', 'first medico-psychological consultation', 'ultrasound insonification of the polygon circle', 'congenital hip deformities', 'lung implant/prosthesis', 'fMRI', 'Norwood palliation', 'toric IOL implantation', 'Emergency cesarean section', 'need', 'secondary medical care', 'oxygen saturation readings', 'breastfed', 'CNVAMC', 'CD|Complete blood count', 'resected specimen.|Age', 'peripheral blood cell apheresis', 'oral hormones plus', 'painful knee', 'tumor histopathology', 'dental extraction surgery', 'primary arthroplasty procedure', 'electrical stimula- tion', 'birth control pill', 'analgesia|immunosuppressive therapy', 'method of contraception', 'piloromyotomy', 'fecal occult blood 2+', 'capillary refill', 'radiotherapy-related toxicity', 'dose reduction of IVIG therapy', 'cranial metal implants', 'instrumental activities', 'LV dysfunction|Participation', 'still|Ferromagnetic metallic implants', 'triphasic CT scan of the liver', 'atypical anatomic structural variation', 'nerve conduction study', 'lumbar disc surgery', 'CPAP).|Normal head ultrasound', 'complementary treatment', 'pelvic organ prolapse|Post-menopausal', 'therapy targeting', 'intra-arch spaces for future prosthesis.||', 'bone scans', 'aneurysm|Significant pulmonary hypertension|Various', 'repairment surgery', 'treatment for augmentation and', 'ovarian lesions|Wtih pathological ovarian results|Willing', 'local hormone therapy', 'clinical SLT assessments', 'impairs cognition', 'trastuzumab treatment.|At least one', 'autologous PLT collection|Age', 'abdominal cramping', 'anticoagulant therapy', 'optimal medical management', 'chemo/radio/targeted therapy', 'TKI treatment', 'chimeric antigen receptor T-cell ratio below the lower test limit', 'mainly antrum', 'MRI safety criteria.|Pregnancy', '1% lidocaine', 'intercourse.|Participant', 'electromagnetic stimulation|Hair', 'bone marrow examination', 'partial meniscectomy', 'DCIS', 'chest X-ray examination', 'gastric emptying', 'completing therapy', 'inhaled therapy', 'e-cigarettes', 'follows:||Transmural myocardial infarction', 'active knee inflammation|non-adherence', 'therapeutic exercises||', 'study|History', 'orthoptic liver transplantation||G', 'chest radiography', 'peritoneal cytology|Reduction', 'CAP', 'PPV-MF', 'Pregnancy|Smoking|>5 kg', 'instrumental treatment', 'fracture procedures', 'intra-operatively|Patients', 'first booster dose.|Is eligible', 'TNK(Perfusion imaging completed', 'visitation restrictions', 'immunomodulatory treatment', 'facial rejuvenation treatment', 'lymph node tissue samples from subjects with hematologic tumor-related symptoms', 'teeth aesthetics.||Exclusion', 'e-cigs', 'transplant', 'biopsy-proven', 'criteria||pregnant', 'Emergency surgery.|Pregnancy.|Breastfeeding|Patients', 'Autologous transplant', 'ticagrelor treatment|patients', 'open surgical biopsy', 'vertigo attacks', 'Shoulder surgery', 'bilateral vasectomy', 'conventional chemotherapy', 'small cell neuroendocrine prostate cancer', 'extracorporeal membrane oxygenation device', 'cancer|A', 'testicular trauma2|History of surgery', 'urea nitrogen (BUN)', 'intracranial lesions|History of head trauma resulting', 'reactivation', 'statins.|Major surgical intervention', 'distal blood flow||', 'expert', 'whole brain radiation', 'piperidine derivatives.|3', 'cognitive impairment.|Patients', 'laparoscopic surgeries', 'liposomal doxorubicin;|ECoG PS score', 'hospitalisation', 'surgery of the gastrointestinal tract)', 'cranial epidural disease.||--Note', 'conventional techniques', 'co-medications', 'optimal therapy.|Prior bone marrow transplant', 'X medications).|Be a site member', 'rehabilitation program', 'blinatumomab therapy', 'biliopancreatic', 'cardiopulmonary bypass heart surgery', 'baseline ECG', 'perfusion scintigraphy', 'myelogram|Previous treatment', 'safety procedures', 'stent insertion', 'deep inspiration breath-hold technique', 'biopsy-', 'carotid artery|Angiography revealed', 'sole source', 'intra-articular injection therapy', 'Rybelsus therapy|Known', 'femoral artery access', 'locoregional therapy', 'imaging assessment', 'percutaneous interventional procedure', 'spiral CT scan', 'ALK fusion', 'gastroscopy', 'whole brain radiotherapy|Karnofsky performance status (KPS)', 'VAS,|extra-muscular disease activity', 'barrier contraceptive measures mentioned', 'hormone birth control patch', 'blood type incompatible transplantation', 'combined immunotherapy|Written informed consent||', 'mitral valve repair for flail', 'clinical laboratory test values', 'fundamentally complicate rehabilitation from the procedure', 'treatment intervention|Radiation therapy', 'treatment for ADHD', 'meniscectomy', 'audiological rehabilitation', 'transvaginal sonography,||', 'blood drawing', 'sCAP therapy', 'episodes of', 'endovascular procedure', 'confirmatory procedures', 'regrowth', 'X-ray', 'cholecystectomy', 'PTCA', 'translocations', 'bone marrow transplantation', 'enteral tube feeds.|Non-English-speaking', 'gastric acid', 'exclusive', 'CT scans', 'total knee arthroplasty', 'gastric bypass (bariatric) surgery', 'Surgical lumpectomy', 'implant-based restorations', 'teriparatide treatment', 'completed the first treatment', 'glycaemic control', 'maximal oxygen consumption', 'hepatic panel', 'oral surgical procedures', 'fluid resuscitation', 'bilateral orchiectomy should continue androgen deprivation therapy (ADT)', 'lung scan', '12-lead electrocardiogram (EKG)', 'hemi-arthroplasty', 'periodontal wound', 'intervention surgery', 'time to surgery', 'RD repair', 'surface treatment', 'oocyte donation cycles', 'repair of same||Participant', 'whole-body', 'immunosuppressant therapies', 'carotid endarterectomy', 'adenoidectomy', 'supine position after', 'lower extremity surgery', 'postoperative recovery', 'musculoskeletal surgery', 'Extrahepatic metastases;|Previous', 'adrenal surgery', 'Subcutaneous Biotherapy', 'quality checks', 'computed tomography (CT) per the RECIST v1.1.||Mesothelioma||Patients', 'hormonal implant', 'regional/epidural anesthesia', 'treatments for cancer', 'pre-vaccination', 'recovered after treatment', 'intraosseous access', 'Surgical liposuction', 'cytotoxic chemotherapy regimen', 'Strabismus Surgery||', 'caesarean delivery with spinal anesthesia|Native to their resident altitude', 'MDT', 'major organ system', 'cervical ripening', 'autologous IVF cycle', 'biliary surgery', 'unequivocal TNBC histology', 'donated 1 unit', 'SS-OCT', 'C-SSRS questions', 'Assisted Procreation (', 'radiographic imaging', 'transcatheter interventions', 'aortic regurgitation assessment', 'regimens', 'major surgical procedures (craniotomy', 'hip arthroplasty', 'heart MRI detection of', 'HCV).|Gastrointestinal surgery', 'receive', 'isolated procedure', 'intestinal pathogen', 'complaint of fever,|The child', 'radiological confirmation test', 'surgical specialist.|Cardiac function', 'diuretic treatment|Estrogen', 'surgery.|Be able', 'orbital irradiation', 'coronary artery bypass graft (CABG);|Previous incomplete percutaneous myocardial revascularization', 'baseline CT scans|known', 'peripheral artery revascularization|Uncontrolled', 'pathological optical coherence tomography angiography (OCTA))]||For female', 'ovarian torsion||', 'frozen section-based).|Pre-enrollment patients LPS', 'gastrostomy tube', 'surgical sterilization should take effective contraceptive measures', 'UDCA treatment', 'Perioral facial hair', 'bilateral cycloplegic autorefraction', 'color vision', 'Social Insertion Center', 'endoscopic intervention', 'regular electronic reporting|Pregnant', 'transdermal hormone contraception.|Placement of an', 'retroperitoneoscopic donor nephrectomy', 'Biochemistry laboratory', 'non-live vaccine', 'shoulder dystocia', 'standard World Health Organization criteria)|Anaemia (Hb<7g/dL),|Any', 'rapid antigen test on Day -1.|Is seropositive to N', 'standard treatment.|Possess venous access', 'operation time', 'gestational diabetes.|Participation', 'crystalline dystrophy (BCD)', 'mechanical ventilation;|Age', 'major surgical procedures', 'investigations', 'blastocyst biopsy for', 'random sample', 'pre-pectoral implant-based', 'IEC)/institutional review board (IRB)', 'polymerase chain reaction (PCR) HCV RNA', 'lipid metabolism - thyroid-', 'small molecule targeted agents', 'study;|Open head injury', 'Type of surgery', 'SWT', 'requirements|Experienced clinical benefit', 'SRT', 'student enrolled', 'immunochromatographic assay', 'consistent use of long sleeve shirts', 'intrathecal treatment drugs', 'lumbar disc herniation', 'bone flap reattached', 'PEA', 'bone marrow transplantation|History', 'Saint Quentin', 'transfer', 'femoroplasty', 'breastfeeding|Drug treatment', 'collected data||', 'evaluation', 'percutaneous kyphoplasty', 'blood component', 'DME|Major ocular surgery', 'Lumoral treatment', 'general anesthesia arterial catheterization', 'pain control', 'randomization|Coronary artery calcium (CAC) score', 'Inactivated influenza vaccine', 'completed PR', 'special design', 'small cell features.|Prior malignancy', 'molecular analysis', 'Fridericia method>470ms', 'endotracheal tube', 'chemical peels treatment', 'orthodontic treatment|Absence', 'skin laser surgery.|80 years', 'genetic testing||', 'small amount of', 'regional lymph node positive', 'rheumatologic diseases|Concomitant therapies', 'copy of the IRB/IEC-approved written', 'electroconvulsive therapy.|Suffering from', 'thoracic belt placement', 'user', 'Regional Hospital', 'rapid antigen assay for SARS-CoV-2', 'Prevention', 'aflibercept therapy', 'standard therapy;||Stage Ia: Subjects with', 'dialysis therapy', 'impairs cooperation', 'restricted', 'lung reduction surgery', 'hysterectomy|Elective surgery|Informed consent obtained|ASA', 'kidney transplantation|History of', 'allogeneic hematopoietic stem cell transplantation', 'congenital anomalies|Gastrointestinal anomalies|Suspected', 'tracheal intubation twice;|Patients with mental illness', 'pain)|Left-handedness|MRI-exclusion criteria', 'conduction', 'egular menstruation', 'primary role of', 'suspension', 'Mayo endoscopic subscore assigned', 'local legislation).|Able to provide', 'radical trachelectomy', 'safe surgical resection', 'placement of central venous access catheter', 'left ventricular hypertrophy|Active cardiac disease', 'celiac screening', 'institutions', 'm2||', 'ethanol', 'Richmond Agitation-Sedation Scale', 'locoregional anesthesia', 'renal puncture biopsy', 'Rheumatology', 'bile duct cancer||', 'chronic ambulatory dialysis', 'chronic disease,|Parents', 'stay still', 'simulation treatment', 'aortic stenosis|Unwillingness', 'β-blockers', 'Montreal Cognitive Assessment (MoCA) score ≤ 24', 'groin puncture', 'monoclonal Ab in combination', 'ICD))|eye implants|ear', 'conventional imaging tools', 'Invasive ventilation', 'allogeneic stem-cell transplantation.|Major surgery', 'cranial tumors;|Nuclear magnetic examination', 'cold therapy', 'previous surgery on the gastrointestinal tract', 'Ultrasound', 'Bupropion-naltrexone', 'simple excision', 'lymphocyte depletion regimens', 'blood flow', 'Coronary artery bypass grafting (CABG)', 'Allergan Aesthetics', 'walk overground', 'Imaging examination', 'things separately.||The first one', 'Continuous Glucose Monitoring Device', 'nicotine dependence)|Head injury', 'adequate birth control', 'therapy with androgen deprivation therapy', 'In vitro Maturation (IVM)', 'physiotherapeutic treatment', 'mechanical control', 'gynecological examination||', 'acute ward|Trainee arts therapists', 'sticking out the tongue', 'focal-to-bilateral', 'herbal medications', 'enzyme replacement therapy (ERT)', 'transfusion of any blood', 'cumulative dose of doxorubicin was', 'alternative therapies', 're-stenotic lesions', 'therapy program', 'procedures|Chronic AD present', 'dental work', 'bronchiectasis', 'spinal fracture.|Participants', 'Congenital glucose-galactose', 'beta International Classification of Headache Disorders),|to', 'exogenous hormone therapy', 'video calls||', 'venoarterial extracorporeal membrane oxygenation (VA-ECMO)||', 'outpatients', 'changing medications', 'PET/CT scan|Eligible for radical prostatectomy||', 'routine tests', 'CT pulmonary angiography', 'spinal fusion', 'alveolar ventilation', 'ethnicities', 'treatment toxicities resolved', 'ocular surgical intervention', 'qualifies', 'common extensor', 'clean intermittent self-catheterization|Current', 'autologous tissue', 'immunosuppressive medications.|History of', 'resistance to JAK inhibitors', 'damage;|Disabling', 'banding surgery', 'total cervicectomy', 'ureteroscopic lithotripsy surgery', 'e exposed', 'plasma exchange', 'COVID-19 vaccine', 'Magnetic Resonance', 'D-J ureteric stent placement', 'Cockroft-Gault formula', 'inoculation with a', 'surgical intervention of any kind for', 'lung transplantation|Patients', 'drug treatment related', 'Tubal ligation', 'address walking function|Botox injections', 'lines of therapy', 'biochemical analysis of blood', 'fusion', 'mechanical ventilation', 'androgen targeted therapy', 'pathological biopsy;|During the screening period', 'Cognitive Behavioral Treatment for distress (MBCT-D)', 'wheelchair', 'ICD interrogation', 'ACR 1990;|Active TAK', 'reproductive hormone therapy', 'stem cell infusion', 'epilepsy;|endocrine diseases;|cancer|receive anti-proinflammatory cytokines therapy', 'clinical examination of the patients', 'Electroconvulsive Therapy (', 'chronic oral anticoagulant|Comorbidities', 'computerized tomographic images.|Hospital staff', 'goserelin therapy', 'T. Cruzi|Rapid plasma regain (RPR) test positive|Participants', 'rupture', 'prior intervention that could impact the procedure', 'plasma concentration', 'Clinical Application of Aromatase Inhibitors for Premenopausal Female Breast Cancer Patients', 'smokeless tobacco use', 'trachelectomy', 'color Doppler ultrasonography;|Uncontrolled', 'glucocorticoid therapy', 'hormonal IUD', 'whole brain radiotherapy (WBRT)', 'lateral neck dissection', 'lymph node lesion', 'hip flexion contractures||', 'HCV|Positive test for alcohol', 'SBP.||malignancy.|Antibiotic therapy', 'urine dipstick testing', 'conventional radiotherapy', 'paraffin blocks', '3D electromagnetic navigation', 'COVID-19 bivalent vaccine', 'palliative stereotactic radiation', 'OCT examination', 'acute illness|Recent ultrasound contrast', 'lung CT results', 'therapeutic vaccination', 'stent insertion.|Patient', 'B cell repletion|Participant', 'common bile duct', 'document analysis of PSA levels recorded', 'B cell non-Hodgkin', 'arthroscopic classification|Patient', 'concussion resulting', 'orthodontic treatment.|Participants', 'patients.|Periodontal therapy', 'gastric reduction duodenal switch', 'cardiac implantable electronic device', 'quantitative coronary angiography', 'completed chemotherapy', 'pulse', 'renal transplantation', 'microfocused ultrasound device', 'incentive spirometry', 'target knee', 'rhythm management device', 'pathogenic mutation', 'Graft Versus Host Disease (aGVHD)', 'topography method)||', 'give proper treatment feedback', 'arthropathy,|high-velocity trauma,|fracture|low back pain', 'pulp tests)|No', 'thyroid surgery|patients', 'produce a reliable hearing test', 'radiologic investigations', 'tear film production', 'urethral', 'regional anesthesia techniques studied', 'bone augmentation procedures', 'endoscopic variceal ligation|Colonoscopy', 'Magnetic Resonance Angiography).|MRI performed', 'Anatomical Implant', 'treatment.|Concomitant treatment', 'electrocardiogram', 'local hospital guidelines', 'collateral vessels', 'PET /CT showed', 'Although procedures', 'surgery of the cervical spine|Corticosteroid injection', 'bifurcation lesion|Stable coronary artery disease', 'Ozanimod therapy', 'riteria:||•', 'implant birth control', 'neurological disease|Having', 'chest Computed Tomography (CT) scan|Participants', 'cortisol testing', 'Mechanical circulation', 'MRS)/magnetic resonance imaging', 'occurring', 'treatment', 'nephrotic syndrome|Prior treatment', 'implanted', 'professional dental cleanings', 'therapeutic clinical', 'total hysterectomy', 'surgical interventions', 'subsequent surgery', 'sigmoidoscopy', 'pleural thickening', 'metabolic diseases|Revision surgery', 'study|Participation', 'oncolytic virotherapy.|Radiotherapy', 'CMR imaging', 'nutrition therapy', 'Core needle biopsy', 'orthodontic appliance therapy', 'Cognitive Assessment (MoCA) score', 'pathological types', 'rate control medication|BiVP% + ventricular premature complex (VPC%)', 'pMMR/MSS', 'Therapeutic Radiology', 'RBC', 'manual treatment of the diaphragm', 'liver transplant', 'meniscus repair surgery', 'urinalysis tests', 'advance cardiac life', 'full thickness cuff', 'rapid immunosuppressive treatment', 'Ofatumumab initiation', 'TASC', 'legislation in Germany', 'etc.)|Use of', 'clinical role', 'PCa', 'plain CT scans', 'noted', 'PCR testing', 'Fibroscan cut-off of 12.5', 'emergency situations', 'blood pregnancy examination', 'immunosuppressant treatment', 'palliative drainage surgery', 'single dressing,|Wound', 'venous blood', 'occipital neuralgia', 'PDOX testing.|Patients', 'thoughts of self-harm', 'Radial Artery Access', 'autologous stem cell transplant', 'coronary artery intervention', 'regular dialysis', 'cerebrovascular accidents', 'assessment sessions', 'standard of care clinical considerations have', 'consultant cardiologist', 're-examination', 'X-ray contrast angiography', 'Target DFU', 'complex abdominal wall reconstruction|Class', 'induction therapy', 'sleep restriction therapy', 'endovascular intervention', 'primary immunodeficiency|Pregnant or lactating', 'radiation treatment', 'study||', 'endarterectomy', 'cigarillos', 'pelvic radiotherapy', 'regular pharmacological prophylaxis', 'intensive care', 'CR1 unable to tolerate', 'TIGIT inhibitor treatment', 'tobacco cigarettes', 'annual lipid check modifier', 't', 'Revision arthroplasty', 'msec.|ECG', 'anti-coagulation therapy', 'gastroenterostomy', 'congenital nonhemolytic hyperbilirubinemia', 'cumulative target radiation treatment volume exceeding 2 cubic centimeters.|Patients', 'major organ (heart disease', 'Diagnosing', 'beta human chorionic gonadotropin [β-HCG] test', 'stable.|Adequate organ system functions.|Patients should receive', 'sterilization procedure took', 'axillary node dissection|Completion of the treatments', 'enrollment;|Active gastric', 'stem cell apheresis', 'Expert Consensus Recommendations|Hypertrophic cardiomyopathy', 'ocular surface surgery', 'allogeneic hematopoietic stem cell', 'continental U.S.', 'household contact', 'analysis of the study', 'self-assessment', 'Practical Issues', 'small molecule', 'biological products', 'RP o', 'herbal therapy', 'PET scanning procedures under this protocol', 'lepra)|Current treatment', 'vascular access catheters', 'Occupational therapy', 'radiographic progression', 'pain therapy', 'joint surgery', 'aortic prosthetic valve|Contraindication', 'limit.|Immunosuppressive therapy', 'tumor vaccine', 'CT angiography', 'lactation.|Major surgery', 'met|Major surgery', 'Brugada', 'corneal transplant', 'compromised incisor aesthetics', 'Local surgery', 'hernia noted', 'standard therapy available', 'MRI monitoring|Patients', 'postoperative intubation/ventilation', 'special dietary requirements.|History', 'training program', 'Mobius stent', 'physiological doses', 'basilar artery [BA]', 'heart failure|Pregnant', 'TAK-788', 'voluntarily.|Take effective contraception', 'Section 5.4', 'acute pneumothorax', 'formulation.|Major surgery', 'ICI therapy', 'preoperative radiotherapy', 'acute surgery', 'ETHOS simulation imaging', 'European Association for the Study of the Liver guidelines of HCC management;|at least one measurable lesion', 'tinnitus therapy', 'chest CT-scan', 'substances:||COVID-19 vaccine', 'standard concurrent intensity-modulated chemoradiotherapy', 'radioactive therapy|Previous PSMA-targeted radioligand', 'large blood vessels', 'steroid injection', '24-hour urine collection for determination of creatinine clearance', 'total pelvic radiation therapy', 'Dasatinib|Having', 'genetic mutation', 'Transient Elastography', 'diphtheria toxoid', 'thoracic fusion', 'cosmetic procedure', 'child|Pathology', 'prophylactic antiviral therapy', 'future treatment', 'bilateral nerve sparing technique', 'Tremor', 'Ohio area||', 'hepatic dysfunction|History of drug', 'general anesthesia surgery', 'coronary arterial bypass graft surgery', 'Cytohistological confirmation', 'Resistant', 'anatomic variation resulted', 'shaving scalp hair', 'antiviral', 'antimetabolite therapy', 'Perfusion MR scans', 'treated for dysrhythmias', 'intracerebral hemorrhage:|Major surgery', 'partner;|Tubal ligation', 'vital signs|Unwilling', 'melenas|Oral iron', 'verbal learning', 'clinical laboratory determinations.|Body mass index (BMI)', 'oxygenation measures|Palliative care', 'lung cancer.|Documented', 'complete occlusive lesions;|The', 'donated blood components', 'accommodation', 'preoperative EKG', 'maintenance therapy', 'disease;|Positive blood', 'started treatment', 'non-repeating', 'systemic antiviral therapy', 'major oral hard', 'radiotherapy area', 'blood cell transfusions', 'hormonal NET-related', 'physicians', 'T-cell', 'median annual income', 'leukemic cells reappear in peripheral blood', 'treatment|destructive behavior reinforced', 'complete procedures required', 'Lansky Play scales', 're-exposure', 'steroid hormones', 'brain MRI should', 'disease;|Major surgery', 'conventional therapies for IBS;|Absence of red flags', 'MRI scan.|Biopsy', 'taxane chemotherapy', 'Tobacco use|Reports', 'assessment of estimated Glomerular Filtration Rate (eGFR)', 'living donor transplantation', 'ascites|Baseline oxygen saturation', 'discontinuation of the antiplatelet', 'acknowledge the strong advice to abstain from sexual intercourse with', 'complete blood count', 'Blood donation/loss', 'rehabilitation unit', 'oral nutritional supplements', 'psychotropic pharmacologic treatment', 'postoperative echocardiography', 'local clinical practice.||Age:||Male', 'systemic steroidal therapy', 'drug chemotherapy', 'breastfeeding;|Continuous hormonal therapy', 'prophylactic treatment', 'shortness of breath (SOB)', 'tobacco use||', 'SA3', 'chronic obstipation', 'magnetic resonance imaging.|Life expectancy', 'Mini-Mental State Examination', 'pelvic physiotherapy treatments', 'transparent dressing adhesives|Palliative care', 'terminal illness|Pregnancy|Participation', 'lost control', 'recreational purposes', 'axillary temperature≤37.0℃.||', 'functional recovery', 'carcinomatous meningitis.|Major surgery', 'regular psychological therapy', 'complete eradication therapy', 'esophageal catheter insertion', 'cetuximab targeted therapy', 'rehabilitative', 'vasopressor therapy', 'ANA', 'aorta surgery', 'gene mutation diabetes', 'closed pleural biopsy', 'radio-chemotherapy', 'intra-articular reasons', 'looks ahead', 'emergency coronary angiography', 'Twin gestation|Scheduled cesarean delivery', 'endovascular recanalization', 'Tumour sample', 'obliterative arteriopathy', 'laparoscopic sleeve gastrectomy', 'continuous wave Doppler;||', 'defects.|Current hospitalization', 'psychotropic medications', 'self-report|Parent experiencing', 'insulin treatment', 'tonsillectomy', 'dental fillings', 'femoral artery retrograde puncture', '5-year follow-up;|Patient', 'suitable stem cell donor identified', 'conization', 'copper intrauterine', 'antibiotic susceptibility test', 'treated for cancer', 'tracheotomy', 'endocrine therapy-based regimens.||Note', 'harmonized definition (IDF --------2009)|Availability to be followed in the follow-up', 'biochemistry', 'confusional syndrome|Participation', 'FSS', 'liver surgery volume (open', 'MCL|Renal function', 'zoster sine herpete', 'chest imaging did', 'elastic ultrasound-guided biopsy', 'plastic surgery', 'endoscopic variceal ligation', 'these):||Arterial blood', 'general anesthesia|Patients', 'HRCT scan', 'qualitative identification of barbiturates', 'chemotherapy|Diagnosis', 'nitinol', 'percutaneous endoscopic gastrostomy|Patients', 'Sepsis-3 definition', 'ophthalmological', '12 lead- electrocardiogram [ECG]', 'bilateral knee arthroplasty', 'chemo-radiotherapy resolved', 'ECG lead placement', 'disseminated herpes simplex', 'preclude surgery', 'intra articular injections);|Physiological doses', 'prosthetic surgery|Patients', 'probiotic treatment', 'non ICPI treated', 'intravesical installation therapy||', 'vascular delivery path including:||Abdominal aortic aneurysm 4.0 cm or greater', 'CIC', 'treatment for AML: For disease control', 'proximal femoral surgery', 'Mini-Mental State Exam', 'chronic blood transfusions', 'Transthoracic Echocardiography', 'QT interval corrected', 'ACDF surgery', 'head', 'D2 of menses.|On D2 scan', 'general anesthesia;|High risk of pulmonary hypertension', 'PCR for microsatellite stability (MSS)', 'irreversible organ damage related', 'vital signs|Having completed the first 24 hours of life', 'sedation', 'acquisition scan (MUGA)', 'periapical radiographs.|Periodontally compromised teeth.|Endodontic retreatment', 'implant placement|Not enough radius bone proximally for device implantation', 'enucleation', 'chemistry', 'active major organ system disease', 'WAIS4', '12-lead ECG results', 'hormone intervention', 'adjuvant whole pelvic radiation therapy', 'blood-borne infection', 'metabolic disorders,|fetal hydrops', 'chronic medical treatment.|Does', 'laboratory test results.|Understands the study procedures', 'practice birth control', 'face mask', 'perfusion MR imaging of their', 'resectable|Previous radiotherapy', 'radiation therapy.|Nonsmall cell lung cancer', 'ASCVD', 'tubal sterilization', 'complete exercise intervention;|Illiteracy (disability to read', 'OIT food', 'pancreatic head', 'GI function:||Uncomplicated', 'cochlear implant system,|Duration of cochlear', 'ophthalmic examination.|Patients', 'preoperative puncture biopsy', 'testing', 'Cognitive impairment|Contracture', 'aminoglycosides;|Patient', 'fractional laser resurfacing', 'elective repair', 'intra-arterial treatment', 'thyroid replacement hormone', 'WASID method);|Intracranial artery stenosis', 'BMT.||Plasma Cell Leukemia', 'fine needle aspirate', 'Transcatheter aortic valve implantation', 'lumbar decompression surgery', 'C.|Positive blood test for HIV', 'treatment for head and neck cancer', 'Health Organisation (WHO) performance status', 'hepatic elastography', 'conventional imaging with CT of the abdomen', 'Tabrecta® (Capmatinib)', 'MUGA scan', 'creatinine.|Oral therapy', 'kidney biopsy', 'age|Prisoners', 'aesthetic procedures', 'first trimester', 'menstrual history', 'standard methodology', 'Cardiac ultrasound examination showed', 'Functional Mobility Screen (FMS)', 'SLEDAI', 'lens availability).|Best Corrected Visual Acuity (BCVA)', 'bacterial blood culture', '≤8 g per day for', 'reorganisation of neural networks|Persons', 'bone resorption apparent', 'chest computed tomography (CT) scan', 'Cardiac Resynchronization Therapy', 'menstrual cycle', 'neck|Evaluation of CT amenable', 'hematopoietic stem cell transplantation|Participants', 'analytes', 'Frankel scale', 'hospitalized', 'penile-vaginal', 'Mechanical ventilation', 'RSV vaccine', 'neck surgery deliveries', 'biochemical assessments', 'control pleural', 'histologic evidence|Active UC defined', 'unequivocal progression after radiotherapy;|Histopathologically', 'median laparotomy seems possible', 'floor reeducation programs', 'periodontal surgery||', 'laser treatment.|Moderate to severe hypertension', 'dialysis regimen', 'vascular puncture', 'antibiotic therapy.|Participant', 'transthoracic echocardiogram', 'concurrent chemoradiotherapy', 'Ommaya capsule;|CT examination', 'stool softeners', 'coronary stent treatment', 'transfers', 'radical cystectomy|Agrees to participate in study procedures||', 'thyroid hormone replacement therapy', 'continuous ventricular pacing', 'pathological examination confirms', 'clear cell', 'etc.|Prenatal examination of the fetus with chromosomal abnormalities', 'local epidemiology', 'botulinum toxin type A medication', 'pathological sites', '18):||CHARACTERISTICS INTERMEDIATE RISK', 'small intestinal bacterial overgrowth (SIBO)', 'vulvar-vaginal examination', 'isolated aortic valve replacement', 'materials', 'onset of GBM', 'indexes examination', 'standard laboratory criteria.||Main', 'routinely timed anatomy ultrasound', 'hormonal treatments|Documentation of irreversible surgical sterilization by', 'emergency cardiac surgeries|Patients', 'verbal consent|Contraindications', 'resuscitation', 'urine examination', 'treatment|Diagnostic renal biopsy', 'orthodontic therapy||-', 'chronic therapy', 'replacement|open thoracic aortic and thoracoabdominal aortic surgery|atrial', 'donated plasma', 'Emergency', 'device|Impairment of GI function', 'protective measures', 'those enrolled', 'whole-body positron emission tomography', 'escalation of therapy', 'radiographic evidence|Magnetic Resonance Enterography (MRE)', 'consolidation', 'brain blood flow', 'quit smoking', 'SOC', 'primary PCI', 'adrenaline auto-injector', 'stay in shelter', 'prenatal clinic|Anticipate vaginal delivery initially', 'Radical resection', 'head trauma with unconsciousness', 'undertake MRI components of the study', 'versus graft direction', 'various hormonal contraception', 'LTWP', 'natural teeth.|Sufficient', 'pelvic irradiation', 'Clear Cell Renal Cell Carcinoma Metastatic', 'PET scans', 'open treatment', 'arterial dissection', 'replacement treatment Note: For other medical conditions', 'gastrointestinal endoscopy/colonoscopy', 'aortic coarctation.|Patient', 'primary radiotherapy', 'Open-Trial Selective Reminding Task', 'coronary computed tomography angiography', 'local laboratory method', 'Institutional Review Boards', 'sedative hypnotic use|Sleep disorder', 'contraception', 'revascularisation therapy', 'graded exercise test', 'only);|Total colectomy', 'local hospital medical records.|During the period from September 1, 2022 to December 31, 2023, participants who received', 'serological examination', 'immunohistochemical staining', 'vaccine', 'gynecological laparoscopy', 'complete TCD study', 'regular periods', 'PET-CT', 'anal sex', 'local site investigator', 'borderline resectable', 'steatorrhea).|Major surgery', 'RA|Patient', 'good organ function:||Hematology', 'kidney disease|Supplement use', 'blood pregnancy test', 'renal dialysis', 'cardiogenic shock|Patient', 'surgical resection of their tumour', 'anesthesiologic treatment', 'vaginal reconstructive surgery', 'viral suppressive therapy', 'swab SARS-CoV-2 RT-PCR test', 'ultrasound probe', 'least:||A chemotherapy regimen', 'orbital decompression', 'regular access', 'Hypertension|Diabetes|Smokers|Cardiovascular disease|Secondary hyperlipidemia|Renal insufficiency|Hyperthyroidism|In diet|Pregnant', 'coronary artery bypass)|live', 'hormonal treatments', 'twelve regular sessions', 'local knee inflammation', 'small molecule tyrosine kinase inhibitors.|Patients', 'self-reported visual exam', 'initiated||PSMA PET scan', 'probing', 'target CD4+ T cells', 'routine care samples', 'video capsule endoscopy', 'invasive procedure', 'pregnancies|vaginal birth after Cesarean|twin', 'anaesthetic procedure', 'Radiotherapy', 'classical complement activation', 'X-Ray', 'implants|tubal ligation clips|non-removable', 'TICS-M', 'nasal irrigation therapy', 'transcutaneous oxygen pressure (TcPO2)', 'prepuberal onset of hypertension', 'ethnic backgrounds||', 'allogeneic hematopoietic stem cell transplantation.||', 'brain imaging after central nervous system (CNS) directed therapy', 'biochemical analysis', 'Monitoring', 'tobacco use|SCCHN', 'IL-2 therapy', 'diabetes|coronary revascularization', 'anesthesia', 'first IMID', 'palliative radiotherapy', 'study|Presence', 'prosthetic knee replacement surgery', 'ileocolic intussusception', 'clinical laboratory values', 'hepatic arterial blood to the lung', 'DWI image ASPECTS score', '-Immunoglobulin G', 'interventional clinical study follow-up;|Receiving', 'conventional dental procedure|Sound', 'active therapy', 'FCI scanner couch||', 'disruption of the lung', 'dental procedures', 'Primary vaccination', 'quantitative assessment of the degree of aortic regurgitation', 'Pelvic Organ Prolapse Quantification', 'hormone therapies', 'breastfeed their infants||Sexually active', 'cholecystectomy operation,|No orientation', 'virological test', 'endovaginal ultrasound', 'conversion', 'histological evaluation', 'ESR', 'chest x-ray)CXR|CT scan', 'malignant tumors;|Pathological examination', 'Heart rate', 'sublobectomy', 'estimated', 'facial fine lines', 'emergency caesarean (red code', 'symptoms.|Renal function eGFR eGFRCysC', 'chest X-radiography', 'cariogenic diet', 'oral examination', 'early intervention', 'lung imaging showed', 'distal subtotal gastrectomy', 'axillary dissection would also be permitted', 'non-small cell lung cancer', 'APA', 'pancreatic resection', 'secondary vision impair Synechia', 'MRI contrast material', 'transurethral resection of the prostate', 'intravesical surgical manipulation||Intravesical therapy', 'syndesmophytes', 'axillary lymphadenectomy', 'assessments|Oral Glucose Tolerance test', 'reliable birth control method', 'COPD.|Combined surgery', 'invasive coronary angiogram', 'Literate', 'peritoneal dialysis treatment', 'LMWH', 'knee surgery', 'higher;|pregnant', 'biological DMARDs.|Patients', 'MRI scan', 'function tests', 'nutritional intervention study', 'statin therapy', 'multivalvular surgery', 'ECHO).||Pregnant', 'kidney|Estimated glomerular filtration rate (eGFR)', 'computed tomography CT imaging.||', 'bilateral BWR', 'endoscopy unit of Tropical Medicine', 'triazole prophylaxis', 'neuroimaging', 'eyelash abnormality||Study Procedures:||Known hypersensitivity', 'transthoracic echocardiography', 'EMDR', 'prostatitis.|Medical treatment (α blockers', 'FISH negative|Hematological', 'palliative therapy', 'bisphosphonate therapy', 'to:||combination oral contraceptives|implanted contraceptives|intrauterine devices||Effective methods', 'homes:||Specialized nursing homes', 'lifestyle-treated)|Dialysis|High risk immunological transplantation', 'conservative treatment', 'nrTMS rehabilitation', 'quantitative analysis', 'radiation therapy.||Failure', 'complete knee joint replacement', 'peritoneal dialysis|A', 'food.|Plasma donation', 'dynamic TcpO2 recording||', 'Dentistry Anesthesia', 'setting|Major surgery', 'AF catheter ablation', 'surgical resolution|Surgical procedures takes', 'catheter', 'invasive ventilation', 'hypersensitivity|Prior treatment', 'trastuzumab.||Patient', 'eyelid surgeries', 'surgical reconstruction', 'CW modality', 'mechanical ventilation.|shock.|other organ dysfunction', 'general anesthesia.|Cervical stenosis|Previous failure', 'coronary revascularization', 'effective sterilization', 'suicidal', 'laparoscopic biopsy', 'exogenous estrogen supplementation', 'cardiopulmonary bypass (CPB)', 'carotid stenting', 'MERS', 'testing.|Incessant VT', 'Salvage operation', 'CS.|Singleton pregnancy.|Patient', 'cardiac death|Cerebrovascular accident', 'treatment regimen', 'B-NHL', 'Cognitive Behavioral Therapy for Insomnia', 'major surgery leading', 'tissue acquisition to allow', 'Urogynecological surgery', 'control rings', 'RD', 'ET treatment', 'inadequate treatment', 'diagnostic purposes.|Child able to accept detailed', 'dorsum transcutaneousoxygen test (TcPO2)', 'bevacizumab therapy', 'prolonged ventilation', 'specialized treatment', 'loop electrosurgical excision procedure|Early miscarriages', 'physical exercise training;|Patients', 'myringotomy', 'regular sex', 'Pittsburgh Sleep Quality Index).||', 'chest computerized tomography (CT) evidence', 'medical therapy).|Mean resting correct QT interval', 'upfront resection', 'Preimplantation', 'local infection|Coagulation disorders|History of', 'emergency procedure', 'complete quality', 'cesarean delivery under spinal anaesthesia|who developed PDPH', 'Partial nephrectomy', 'radiochemotherapy OR|Recurrent', 'special types of diabetes|Suffering from', 'allogeneic organ transplantation.|Active', 'Vasectomy', 'standard of care (SOC)', 'heart-lung transplants|Life expectancy', 'chest XR or', 'exercise interventions', 'bone graft to stabilize', 'sterilization procedure', 'jejunoplasty', 'placement of', 'core infarct', 'Cognitive Behavioral Therapy (CBT)', 'baseline MRI associated', 'vaginal prolapse|Inflammatory Bowel Disease|Irritable Bowel Syndrome|Systemic disease', 'regular medication', 'Technical Experts||Provide clinical care', 'Expert Consensus Recommendations|AL amyloidosis', 'spinal cord stimulation|English', 'PML).||Serologic status', 'minimally invasive surgery', 'oral intubation', 'Variant', 'SRS', 'Daytime hypercapnia', 'stem cell transplantation.|Patients', 'blood coagulation', 'midurethral mesh sling', 'Doubly Labeled Water (DLW) assessment', 'preoperative CAT-Scan||', 'eradication treatment', 'fresh tumor biopsy', 'condition(s', 'vaginal delivery,|', 'toxin extrusion (MATE) substrates', 'lumbar spine', 'β-hCG', 'blood oxygen saturation||', 'TSH', 'meniscal tear', 'tumor immunotherapy', 'allowed|Previous chemotherapy/radiotherapy/targeted/immunotherapy therapy', 'MR Angiography', 'drugs|Vitamin D poisoning|Expected survival', 'antiretroviral treatment', 'blood oxygen saturation', 'Montreal Cognitive Assessment (MOCA)', 'local regulations', 'various basic functions||', 'spleen biopsy', 'bone marrow MRD', 'imminent', 'local operations', 'imaging (CT or MRI', 'acute cholecystectomy', 'transmural infarction', 'small intestine resection.||Anamnesis of', '||Diagnosis', 'neurological exam', 'biochemistry tests', 'capillary blood access', 'MRI safety', 'EMG', 'multi-organ', 'target lesions.||Eastern Cooperative Oncology Group (ECOG) performance status', 'local read', 'mechanical (spermicide in conjunction', 'restrictive eating', 'immunosuppressive/cytotoxic therapy', 'standardized treatment|Uncontrolled hypertension', 'substitute decision maker', 'myeloproliferative neoplasm.|Participant', 'aortic valve surgery', 'coronary vessels', 'postnatal chest CT-scan', 'hormone-replacement therapy', 'allogenic stem cell transplant', 'antihypertensive therapy|Heart Failure', 'Laparoscopic appendectomy', 'total intravenous anaesthesia (TIVA)', 'bone-implant osseointegration', 'automated perimetry', 'melanoma', 'response|Pulmonary fibrosis|Obstructive sleep apnea syndrome|Lung', 'great risk', 'vulnerability factors.|pregnant volunteers|volunteers', 'clinical ocular signs', 'high concentration', 'medical supervision', 'brain metastases.|Pregnant', 'stent', 'surgical orchidectomy', 'Global Assessment', 'genital herpes', 'surgical decompression|Surgical resection', 'examination.|Active ocular herpes zoster', 'liver biopsy.|Model', 'cytology;|Received', 'full eye examination', 'prevent virus activation', 'Infected surgery', 'slit-lamp examination results of the screening clinic', 'liver surgery.|nonoperative treatment', 'chemo/radiation treatment', 'brain condition|severe head trauma|epilepsy', 'Open Wound', 'chemo-radiotherapy', 'thoracoscopic lobectomy', 'cardiac consultation', 'bilateral peripheral venous access', 'rTMS application', 'Fine Needle Aspiration (FNA)', 'bile duct epithelial cell', 'perimetry', 'low FODMAP diet', 'Gated Cardiac Blood Pool Scan or echocardiogram.||k', 'target femoral artery dissection', 'corrective therapy', 'allogenic haemopoietic stem cell transplantation.|Patients should', 'filtering surgery', 'deep analysis', 'chronic otitis.|Surgery', 'standard anti-tuberculosis treatment', 'humans', 'health care professionals', '3-d score', 'Dental School of Medical Faculty Carl Gustav Carus', 'palliative.|Major surgery', 'medical treatment program', 'transfusion of red blood cells', 'Maxillofacial Surgery Department', 'degenerative problems|Those players', 'allogeneic hematopoietic stem cell transplantation;|Brain', 'autologous transplant.||Myeloproliferative Neoplasms/Myelofibrosis - with', 'foreseeable modification', 'PSMA PET', 'treatment;|Allergic to chemotherapy drugs;|Cancer free period', 'abdominal imaging', 'complete grip strength measurement', 'relugolix combination therapy', 'massive effusion.|Central lung squamous carcinoma', 'cognitive impairment.|Renal disease.||MR imaging findings', 'complete detection', 'Casts', 'bilateral IOL implantation', 'knee flexion', 'tumor biopsy', 'routine gynaecological examination||', '12-lead ECGs', 'lactation period|Mobile teeth', 'pathogenic mutation of BRCA1, BRCA2', 'rescue treatment', 'imaging examinations confirm', 'highflow oxygen', '24-hour dynamic electrocardiogram', 'clicking', 'fine needle aspiration/biopsy [FNA] cell blocks', 'TOVA', 'tricuspid repair', 'revision THA', 'PPI-treatment', 'finger flexion', 'computed tomography (CT)', 'complete recovery', 'otological surgery', 'visit.|Body mass index', 'employ adequate contraception', 'half-life', 'glaucoma|Cataract surgery', 'restricted pool', 'mastectomy', 'screening program', 'HCV eradication', 'lung/heart disease', 'percutaneous transluminal angioplasty', 'psychosocial treatments', 'first dose of study treatment]).|Aspartate aminotransferase (AST)', 'local ablation', 'Asthma Control Test|Have a', 'ferromagnetic metallic implants', 'World Health Organization|Recent', 'treatment of the disease', 'adjuvant chemotherapy/immunotherapy(/HER2)', 'allogenic hematopoietic stem cell transplant', 'vital organ transplantation', 'cervical dilatation', 'congenital syphilis', 'breast surgery||', 'tyrosine kinase therapy should be considered in this context.|Participants', 'fractures;|Open fractures;|Pathological fractures;|Malignancy;|Malnutrition;|Chronic diseases', 'tobacco cessation medications', 'pregnancy||', 'stature', 'cardiac imaging;|Left Ventricular Ejection Fraction', 'laboratory values:||Absolute neutrophil count', 'ectopy', 'extremity surgery before completion of follow-up.|Patients', 'walk unassisted', 'First time oocyte acceptors', 'percutaneous endoscopic gastrostomy|Healthy subjects:|Major surgery', 'HER2 expression', 'Core biopsy', 'revision of the Atlanta classification', 'ocular surgery procedures should', 'Rapid Test or PCR test', 'intra-peritoneal surgeries', 'clear cell renal cell carcinoma', 'tumor resection', 'CNS local therapy', 'weight control', 'neck surgery', '3）Myocardial infarction', 'non-oral contraceptive method', 'combined treatment', 'facial aesthetic surgery', 'inhalational lung injury||', 'adrenal replacement steroid dose', 'child care', 'metastasis-directed ablative therapy methods', 'canaloplasty surgery', 'radical resection', 'psychotropic drugs)|previous', 'extensive restoration', 'brain MRI scan;|The', 'brain surgery', 'clinical laboratory test are', 'maintaining', 'OnabotulinumtoxinA treatment', 'ocular surgeries', 'adjuvant endocrine therapy', 'local testing results.|Patient', 'GU toxicity|Patient', 'donated ingredients', 'transrectal ultrasonography', 'periodontal attachment loss.||Clinical Attachment Loss (CAL)', 'therapeutic dose range', 'Physical Therapy', 'kidney transplant', 'isolated', 'preoperative radiotherapy/chemotherapy', 'cataract surgeries', 'resuscitation decision', 'functional endoscopic sinus surgery', 'hypermobile septum', 'temporal lobes', 'CT', 'radiotherapy to head and neck', 'blood cell infusion', 'standard-of-care treatment', 'day surgery', 'Birth Control Implant', 'b) diaphragm', 'computer tomography (CT)', 'meniscus surgery', 'surgical patient|Patients', 'Pathology suggested satellite foci', 'skin prick test', 'confirmatory neuroimaging', 'evaluable disease.|Prior treatment for mCRPC with', 'CNO)|Be enrolled in High School|Live', 'NUDT', 'Aware Recovery Care', 'general medical conditions', 'intensive induction chemotherapy', 'pathological tissue', 'receives', 'small cell', 'blood chemistry', 'bone augmentation procedures|patients', 'carbohydrate counting', 'lumbar surgery', 'assessment of the vaccination', 'Radiology Imaging Network Cancer Center Group (', 'FSRS', 'clear', 'Bilateral treatment of the target lesions', 'chin', 'World Health Organization (WHO) 2016', 'open PPGL resection', 'Microsurgical technique', 'pre-procedure benzodiazepine', 'regular drug control', 'fundoscopy', 'sympathomimetic drug harmful', 'Remarks', 'TBI|traumatic brain injury|written informed consent||Schizophrenia:||Diagnosis of Schizophrenia|written informed consent||', 'prolapse surgery', 'practice of physical activity', 'coronary angiography images', 'clear contra-indication', 'older|Kidney transplantation', 'hysterotomy', 'laser-assisted in situ keratomileusis', 'Hôpital Marie-Lannelongue', 'Re-Entry program', 'intra-articular cortisone injection', 'chemo plus CPI', 'granulocyte infusion', 'inhalation of study medication', 'abstinence', 'survival data||', 'surgical', 'ablation of the cavotricuspid isthmus|Documentation of', 'antibody therapy', 'abdominal radiation', 'standard chemotherapy-induced', 'cognitive ability;|pregnant', 'postoperatively|Index procedures', 'digestive organ resection', 'open femoral', 'radiological investigation of chest', 'insufficient vaccination', 'star fruit', 'total body irradiation', 'combined organ resection', 'Section 5.1.8', 'recanalization of vascular access', 'Computerized Tomography scan of the chest, abdomen', 'open cardiac operation', 'Magnetic Resonance Imaging (MRI) of the chest or abdomen', 'invasive mechanical ventilation', 'limbal blood vessel ischemia', 'TACE)|Thermal ablation', 'consensus panel of the International Myeloma Workshop.|PART', 'adjuvant systemic therapy', 'hematopoietic cell transplantation', 'tibiofemoral knee OA', 'time of biopsy', 'adjuvant DD-AC/T', 'vertebral artery occlusions', 'life|RBC transfusion', 'Mini Mental Test score below 24|Posterior circulation stroke', 'verbal inquiry)|Chronic systemic pathologies', 'interventions', 'buprenorphine treatment program', 'cardiac angiography', 'CP|Knee flexion retraction assessed in supine position', 'DBS controller', 'cardiothoracic surgery', 'local treatment.|Major surgery', 'chest pain|ECG', 'preoperative physical examination', 'video record clinic visits', 'treated for Frey syndrome', 'first-time surgery||', 'cognitive testing', 'lipid-lowering agents', 'Health Assessment Form)', 'allogeneic stem cell transplantation.|Patient', 'pathological histological', '/emergency procedures', 'indexed aortic valve area', 'facelift)|Cosmetic surgery procedure', 'hysteroscopy', 'consistent access to Wi-Fi', 'pace-maker', 'lipid-lowering medications);|willing and able to be on GnRHagonist', 'gastric sleeve resection', 'blood pressure medications', 'clear histopathology', 'ward', 'frozen embryo transfer|Ongoing infection|Patients under guardianship', 'antibioprophylaxis', '24-hour urine collection).||Prothrombin time', 'superficial non-metastatic cancers', 'regular endometriosis', 'cardiomyopathy|symptomatic coronary artery', 'standard-of-care ICI|Ability', 'treatment-related edema', 'major organ function', 'lipid lowering supplements', 'home oxygen therapy|History of narcolepsy|Use of', 'therapeutic endoscopic procedures', 'hormone elution)|Bilateral tubal occlusion', 'eye surgery||', 'topography method)|Irregular cornea', 'Re-screening', 'local country', 'laser treatments', 'gentle probing.|Increased probing', 'orthopaedic surgery', 'hernia repairs', 'lactation;|Significant GI surgery', 'incision biopsy', 'vaginal sex', 'gastrointestinal resection', 'surgical cut-down|Pregnancy', 'TURP surgery', 'tension', 'organic nitrates', 'pharmacologic classes:||Competitive antagonists', 'unequivocal progression', 'blood loss', 'alternative dose-', 'ultrasound remission', 'gene therapy', 'Echocardiography', 'Triage', 'lower endoscopic diagnostic evaluation where the investigation', 'immunosuppressive therapy.||- Seropositive for HIV', 'ventilator-associated pneumonia', 'enteral medications', 'chemotherapy|Concomitant treatment', 'visit.|Total SARA score', 'Arch Aortic pathologies', 'suspend antiplatelet drugs', 'polyp resection', 'COVID-19 rapid tests', 'thoracic imaging', 'PAH Group', 'venous bypass graft lesions PCI|Patients', 'reliable internet connection', 'Speckle Control"" study', 'infarction|coronary artery bypass grafting surgery|heart valve surgery|percutaneous coronary intervention', 'atherosclerosis', 'oral provocation test (POC)', ';|Pregnant', 'image quality', 'Tartrazine aluminium lake', 'age>50yrs，≤85yrs；|Normal control', 'allogeneic Hematopoietic stem cell transplantation', 'mammography', 'HIFU treatment', 'hematopoietic growth factors', 'cesarean section surgery|Having', 'subsequent systemic therapy', 'scales', 'IVF attempts|Using', 'elective abdominal surgery', 'neurologists', 'Permobil power wheelchair', 'anticoagulation therapy|History of', 'volume reduction surgery', 'dietary intervention', 'know', 'septal reduction therapy - surgery', 'maintenance haemodialysis', 'polymerase chain reaction assay', 'endoscopies', 'refractive surgery history;|The refractive medium', 'coronary artery bypass surgery||', 'local standard of care', 'Palliative radiotherapy', 'Renal Replacement Therapy', 'placement of a', 'valvular surgery', 'Gastrostomy', 'parenteral treatment', 'undergo', 'dynamic arteriography', 'ultrasound guided injection', 'regular pharmacologic treatment', 'starting AI therapy', 'local laboratory (IHC 3+', 'complete coronary revascularization', 'coronary angiography', 'high concentration capsaicin concentration', 'exercise tolerance.|Being', 'Inactivated virus vaccines', 'exercise intervention', 'first-line platinum-based regimen chemotherapy', 'TBSA)|No active wound infection', 'victimization', 'screening).|Pulmonary function FEV1', 'great vessels', 'rectal PCR', 'constituent of the sarilumab product.|Patients', 'antiviral treatment', 'rheumatologist;|able to read', 'hip replacements.|Lives', 'prescription eye medications', 'anticoagulation/antiplatelet therapy', 'vascular anatomy', 'capillary blood sample obtained', 'palliative chemotherapy', 'Implanted', 'speech therapy', 'affirming mastectomy', 'antithrombotic therapy', 'Global deterioration Scale', 'antiretroviral therapy regimen|CD4', 'gradual progression', 'UC', 'histological types', 'Computed Tomography Angiography (CTA)- source', 'first-line treatment', 'single fraction', 'axillary lymph node biopsy should', 'database|Clinical', 'perfusion index measurement', 'Rhizotomy procedure canceled|For Healthy control', 'conceive', '|Indication to biopsy', 'head MRI)|DOC', 'reduced activation of the tibialis', 'festival medical staff', 'Acetazolamide therapy', 'metal materials;|Life expectancy', 'World Health Organization (WHO) classification', 'vaginal surgery', 'complete physical examination', 'reconstructive knee surgery|BMI', 'arthroscopic ambulatory', 'anticancer chemotherapy', 'jogging test', 'transitional cell', 'lymph node dissection', 'resected basal cell carcinoma', 'MSK Exercise Physiologist', 'covid vaccine', 'innoculations', 'donor screening', 'reverse shoulder arthroplasty', 'electrical stimulation-induced exercise', 'rapid-acting analog', 'head trauma', 'antiretrotroviral therapy (ART)', 'LRRK2 pathogenic variant.|The', 'filling the bladder', 'Heart transplantation|Subjects', 'intra-cardiac', 'intraspinal surgery', 'biological agent', 'surgical fixation|No', 'cardiology', 'vascular surgery of', 'percutaneous transthoracic needle biopsy', 'conventional surgical aortic valve replacement', 'mental health care', 'suprachoroidal', 'DRB1 loci', 'Elective surgery', 'vaginal methods', 'inhalation anesthesia', 'emergency termination of pregnancy', 'viral polymerase chain reaction (PCR) from the blood', 'medical', 'Revlimid REMS® program', 'standard therapies for neuropathic pain||', 'genotoxic chemotherapy', 'fecal microbiota transplantation', 'systemic treatment.|Prior', 'IHD', 'CECS', '1]:||Single oral temperature', '65|Elective surgery', 'biologics|Oral immunotherapy (', 'tigecycline treatment', 'computed tomography (CT)|The subjects', 'health prevention examination', 'local advanced', 'psychotropic drugs', 'stent surgery patients|Angioplasty', 'regimen.|Provision of evaluable tumor sample', 'allogeneic stem cell transplantation;|10', 'assisted self-monitoring', 'need occasional ventricular pacing', 'magnetic resonance angiography', '24-hour periods', 'systemic antiviral therapies', 'lines of chemotherapy', 'oral magnesium supplementation', 'definitive radiotherapy', 'bilateral salpingectomy', 'Teen', 'treatment|Inability to swallow oral medications', 'revision TKA', 'ACTH replacement therapy', 'laparoscopy|A', 'blasts|Therapy-related', 'physical therapy treatment', 'diagnostic-therapeutic PL.|Signed', 'Montreal Cognitive Assessment (MoCa)', 'PKU', 'prophylactic regimens', 'rapid-acting analogs', 'TB|Current treatment', 'fractional flow reserve', 'month|Surgical treatment', 'transfemoral delivery of the DurAVR™ THV|Anatomy', 'IL-6 inhibitory therapy', ""Tourette Syndrome|Huntington's"", 'exercise program', 'radical therapy', 'equivocal PSMA PET', 'quality/quantity control criteria', 'pathological records of', 'small intestine|Chemotherapy', 'spirits.|Positive smoke breathalyzer indicative of smoking', 'control solution', 'Ecological Momentary Assessment', 'emerging', 'bone marrow aspirate morphology', 'standard treatment available.|4', 'deemed ready', 'baseline organ function', 'residual radiographic', 'flow cytometry', 'electroconvulsive therapy', 'first-time offender', 'gastric neoplasm.|Neurological', 'laser therapy|Eyes', 'pathogenic variant', 'allogeneic tissue/solid organ', 'treated for diabetes for more than 3 months|Glycated', 'injection of SPVN06.|Subjects with', 'first oocyte pickup Understands german language to fill out questionnaire||', 'conbercept intravitreal', ""Maudsley's test"", 'Testing', 'immuno-suppressive drugs', 'standard conservative therapy', 'small intestine resection', 'organ tissue.|Slit lamp', 'expected duration of anesthesia', 'trauma activation', 'simulation imaging', 'Treatment Periods.|Receipt', 'pelvic surgery', 'resting state ECG QTc', '24-h', 'Active working workers', 'intracranial stent treatment', 'surgical treatment plan|Surgery', 'invasive breast cancers', 'urethral strictures', 'physiological doses of', 'dextrocardia', 'abdominal ultrasound', 'General Surgery clinic.|No verbal', 'undertake emergency operation', 'resection|Patient', 'established', 'Xe-MRI date.||', 'pelvic floor|forceps', 'exercise MRI', 'traumatic amputation', 'baseline angiography', 'histopathology', 'abdominal surgeries', 'Congenital Neutropenia Disorders|germline mutations', 'endometriosis procedures', 'PET scanning', 'Photorefractive keratectomy (PRK)', 'bile', 'spinal anesthesia|Contraindication', 'PET-CT images', 'delay treatment', 'mini-mental exam score', 'sleep,||', 'IVIG therapy', 'external radiotherapy', 'rehabilitation treatment site', 'fraction sizes', 'clinician referral', 'curative standard therapy exists.|Adequate organ', 'routine MRI', 'PGD', 'plastic surgery closure', 'RAI', 'muscular recovery', 'physiological glucocorticoid for adrenal', 'percutaneous coronary angioplasty', 'childhood immunization program', 'Screening', 'Insufficient control of the Dutch language to read', 'genital herpes episode|Pregnant', 'dentures|Extensive restorations', 'drugs historically associated', 'local law.||', 'coronary angiography|Pregnancy', 'OCTA', 'brain surgery|General Anesthesia', 'TIA])|current treatment', 'positron emission tomography / computed tomography', 'colonoscopy referral', 'adrenal hormone replacement therapy', 'systemic aminoglycoside antibiotic', 'CGM', 'dimensions sand', 'abnormal CT or EEG', 'steroid', 'physical activities', 'major surgical operation', 'treatment period|Available study', 'myopia).|History of vitrectomy', 'vascular reperfusion therapy', 'temozolomide regimen', 'manometry|Upper endoscopy', 'e.g.||brain MRI', 'C5 polymorphism rendering', 'instrumental delivery', 'major abdominal surgery|History of neurological and mental illness|Usage of', 'spherical equivalent refractive error of +0.50D', 'cathodic antigen (POC -CCA', 'manipulated graft', 'bariatric procedure', 'bone marrow progenitor cell transplantation', 'week|Gastroduodenoscopy', 'blast sample', 'chest imaging [X-ray', 'antimicrobial therapy;|Use', 'b', 'tumour types', 'natural sterilization', 'PAH specific', 'anterior perineal resection', 'live virus|Allergen hyposensitization therapy|Growth factors', 'RGP', 'ECG monitoring by implantable loop recorder (ILR)', 'brain radiotherapy', 'Bariatric surgery general anesthesia', 'first graders', 'standard protocol', 'bicuspid aortic valve|Severe aortic regurgitation|Severe mitral', 'tomography', 'computerized tomography [CT])|Postmenopausal female', 'M+', 'major disorders.|Used', 'user nurses', 'transpupillary thermotherapy', 'fetal surgery', 're-mineralizing agent', 'fluid infusion', 'consistent with supplement regimen', 'vertebral surgery', 'ocular accommodation', 'stomach resection', 'full trisomy 21', 'regular exercise programme', 'venous puncture', 'Egyptian Nursing', 'refractive surgery', 'photochemotherapy', 'gastric bypass surgery', 'antifungal treatment', 'echocardiogram (ECHO)', 'metabolic panel/basic', 'delayed CT scan.|Time', 'ECG', 'cecostomy', 'onset of symptoms;|A history', 'Emergency surgery|Patients', 'criteria:||Antibiotic treatment', 'surgical periodontal procedures.|Full mouth plaque', 'mechanical thrombectomy procedure.|Thrombus retrieved', 'intra-articular loose body.|Subject', 'pretreatment chemotherapy', 'nodular liver lesion', 'radiotherapy-related', 'patient):||Surgical procedure', 'breast imaging test', 'core biopsy.|Tumor lesion', 'staged PCI', 'quantitative polymerase chain reaction (qPCR) test', 'intracranial', 'local therapy (surgery', 'Major surgery', 'cardiac imaging', 'Bethesda assay', 'adjuvant therapy (allow', 'Chronic Care Model.|patients', 'adrenalectomy', 'months|Pathological esophageal acid exposure', 'stand', 'HP MRI can', 'immuno-suppressants', 'LHRHa', 'ocular Herpes simplex', 'lines of therapy for PTLD (', 'blood transfusion|Aortic dissection', 'local palliative RT', 'small cell lung cancer.|Willing and able to comply with scheduled visits', 'catheter ablation', 'perfusion', 'first-line anti-HER2 therapy', 'Haplo donor selection', 'collaborated', 'Intra-Uterine Device', 'digital weighing scale;|can', 'PET/CT scanner.|Participant', 'carotid dissection', 'bowel resection/reconstruction', 'general anesthesia risk', 'apply for compensation', 'trauma', 'surgery|Endotracheal intubation', 'treatment|Neurosurgery', 'organ surgery', 'botulinum toxin', 'liver imaging findings', 'occipital nerve block', 'unsuccessfully completed colonoscopy', 'pelvic radiotherapy|Currently', 'bloating', 'prenatal care', 'Gastric variceal bleed|Bleeding related to coagulopathy|Other causes of portal hypertensive', 'preparation', 'Screening procedures being', 'surgical therapy', 'receive surgery', 'active anticancer therapy', 'DJ stenting|Pregnancy|Ureteral Strictures|Complicated Surgery', 'ICI therapy should', 'stent implantation;|It', 'practice effective barrier contraception', 'vertebral end-plate sclerosis', 'Global Deterioration Scale', 'consent|Indication', 'PYX-106 treatment', 'emergency surgery|Patients', 'Tmax>6s', ""Health Commission of the People's Republic of China"", 'anti- retroviral therapy', 'first lymph node dissection', 'exercise.|Chronic fatigue syndrome', 'time-restricted eating', 'rapid plasma reagin (RPR)', 'antivirals', 'consent;|Elective operation of', 'dental implant surgery', 'e-cigarettes daily;|Having a', 'retropubic mid-urethral sling surgery', 'Hormonal therapy', 'chest computed tomography scan (CT-scan).|Moderate', 'Technical Advisory Group on', 'renal impairment||Renal', 'hepatectomy', '2ry causes', 'brain scan', 'surgical operations', 'esophageal stents', 'capsule|Diagnostic endoscopy', 'general anesthesia.|Patients treated', 'lines of therapy.||Adequate organ function', 'TERIA:||To', 'EPO', 'suitable treatment option.||', 'common femoral artery', 'transplanted organ', 'intravitreal injections', 'periodontal treatment', 'open surgery|Having another surgical procedure', 'CAMH chart review).|BMI', 'intraocular vision-affecting', 'Natural Head Position (', 'polymerase chain reaction (PCR) test results for:||Acute', 'decompression or discectomy revision surgery,|Are', 'abdominal aorta||', 'percutaneous nerve evaluation (PNE)', 'first permanent', 'oral glucose tolerance test', 'standard X-ray', 'encephalopathy|Patient', 'allogeneic HCT for', 'urinary diversion', 'medical rescue', 'total hip arthroplasty', 'standard peritoneal dialysis', 'inadequate contraception', 'psychotherapeutic o psychological support', 'linear leptomeningeal metastases', 'knee replacement surgery', 'oral hormone therapies', 'recognized', 'liver disease;|Drug addiction', 'Polymerase chain reaction (PCR) test|Plasma donation', 'follicular lymphoma|primary mediastinal', 'G3460A mutation', 'MF|Splenic irradiation', 'addiction|Conditions', 'weeks||', 'women|>9', 'physiotherapeutic intervention', 'imaging features', 'Treated', 'regular vitamin k', 'rectal mucosa.|Patient', 'facial nerve trauma|History of treatment', 'Palliative radiation', 'videoconference||', 'brain ablation/surgical procedure|Neurological injury', 'TIMI blood flow', 'heart rate', 'radiological examination', 'RRT),|Previous transjugular intra hepatic portosystemic shunt', 'Saint Quentin Hospital||', 'reinfusion', 'toxicity|Received treatment', 'cranio-spinal radiation', 'age|≥1 first-degree relative', 'blood thinners|Pregnant', 'donate blood safely|Allergies', 'stay in hospital', 'Supplemental Assay', 'standard-dose estradiol HRT', 'Cardiopulmonary Rehabilitation Unit for physiotherapy applications', 'total hip replacement', 'curative therapy', 'hepatic resection', 'hemostat behind symphysis||', 'Darolutamide monotherapy', 'thyroid carcinoma||', 'myopia treatment', 'laparoscopic hysterectomy', 'thickened CMT', 'Clinics', 'PET-CT contraindications', 'quantitative polymerase chain reaction [qPCR]', 'full COVID-19 vaccination', 'T1.|Previous radiation therapy', 'criteria:||Antiviral therapy for HBV', 'COVID-19 related hospitalization', 'wrinkles around', 'standard Godin Leisure-Time Exercise Questionnaire', 'mental illness;|Previous', 'medical emergency', 'graft-versus-host disease', 'central testing', 'total gastrectomy', 'RAP)|Suspected', 'antibacterial therapy', 'autologous stem cell transplantation.|5)', 'mechanical knee pain', 'effective treatment', 'computed tomography study', 'antitumor therapy', 'whole brain radiation therapy', 'parenteral fluid rehydration', 'biological equivalence test', 'screening tests', 'trial|Previous randomization', 'biopsy-proven MCD/MesGN/FSGS recurrence', 'CT scan premedication).|Receipt of live', '12-lead ECG', 'prolonged treatment', 'cardiovascular prophylaxis', 'extremity surgery', 'surgical excision', 'psychotherapeutic treatment completed', 'coronary artery bypass graft surgery|Sinus bradycardia', 'HER2 test report', 'standard MRI contraindications', 'adequate birth control measures', 'oral nutritional supplement', 'esophageal surgery', 'visible|Partial retained IUD', 'MR contrast material', 'MRI exam', 'lumpectomy', 'electrical tracing of the heartbeat', 'IV|Peripheral oxygen saturation', 'Confusion Assessment Method-ICU', 'chronic anticoagulation', '12-lead ECG.||', 'isolated surgical Cox-Maze IV', 'oral surgery wounds have', 'revision components', 'test article therapy', 'corneal surgery', 'hypotensive symptoms:||Baseline hypotension - resting supine', 'herbal weight loss', 'immunotherapy /or anti-vascular therapy', 'barrier contraceptive', 'blood cell transfusion therapy', 'paclitaxel chemotherapy', 'quantitative polymerase chain reaction (PCR)', 'verbal communication in Turkish,|IV treatment', 'Open angel glaucoma', 'analysis of natriuresis', 'erectogenic medications', 'primary arthroscopic repair|between', 'ocular trauma', 'open posterior', 'preoperative examinations show', 'Robotic Cardiac', 'lower gums', 'confirmatory serum pregnancy test', 'hematopoietic stem cell transplant.|Receipt of any investigational agent', 'antiretroviral therapy (HAART)', 'revision procedures|Individuals', 'peripheral artery disease|Individuals', 'polymerase chain reaction (PCR) test or antigen test', 'focal hypoechoic areas', 'PRP injection', 'needing laser lithotripsy', 'ICD interrogation.|>3 distinct clinical monomorphic VT morphologies', 'EMS', 'immunosuppressive therapy|eGFR', 'biologic immunomodulatory therapy', 'facial plastic surgery', 'agents|Biologic therapy', 'Physiotherapy treatment', 'medical treatment;|ASA status', 'pacemakers.|Hospitalized', 'tendon transfer', 'ECGs', 'experimental drug|Patient', 'emergency surgery|Neurosurgical', 'radio-immunoconjugates', 'upper GI endoscopy', 'Residual sizable fragments', 'unilateral total adrenalectomy', 'CT scan abnormality', 'days|Inotropic therapy', 'hospital|Pregnant', 'transfusion support', 'disease control', 'lateral periorbital site.|Infection', 'shoulder arthroscopy surgery.|American society of anesthesiologists classification', 'other surgery of the gastrointestinal (GI) tract that could interfere with the pharmacokinetics of the trial medication', 'open nephrectomy.|Physical status', 'contrast brain magnetic resonance imaging (MRI)', 'complete hysterectomy', 'screened;|Physical examination', 'TCF3-PBX1', 'wrist circumference', 'chest CT scan.|Resolution of SARS-CoV-2 infection', 'invasive ventilatory support', 'arterial thrombosis||', 'Edinburgh Postnatal Depression Scale', 'CIT', 'neurological examination', 'eHNA intervention /ARC intervention to patients who are living with and beyond cancer.||Team members||1. Clinicians', 'interventional study', 'Usual Health after SARS-CoV-2 infection', 'electrical stimulation area|Intrathecal baclofen (ITB) device|Pregnancy', 'done', 'contraindicate surgery', 'surgical resection', 'vulvectomy', 'endoscopic examination||', 'complete small', 'MACE appendicostomy', 'complete', 'alternative treatment modalities', 'little help', 'transarterial chemoembolization', 'gastric resection', 'frontline LOCK sleep huddles', 'HF-SRT)|A', 'small molecules', 'combination of Rekovelle', 'bilateral tubal ligation.|Acceptable methods of birth control', 'study|Major surgery', 'haemoptysis', 'HF Emergency Department', 'RATS', 'routine urine test', 'graft versus host disease (GVHD)', 'adequate prophylaxis', 'supplemental oxygen.|Administration of other NMDA-receptor antagonist treatment', 'total laparoscopic hysterectomy', 'cardiac ultrasonography', 'brain injury|Uncorrected vision', 'head computed tomography (CT)', 'chest computed tomography (CT) scan|Active tuberculosis (TB)', 'endoscopic ultrasonography of pancreas', 'kidney surgery', 'HSC infusion', 'effective antibiotic therapy', 'Blocked fallopian tubes', 'Doppler ultrasound assessment', 'standard glasses of alcoholic beverages per day|Smoking', 'mismatch repair protein (', 'left cardiac shunt', 'immuno-modulators', 'pancreatic surgery|No', 'age|Prior treatment', 'DVT', 'small intestinal bacterial overgrowth', 'standard of care regimens', '24-hour urine collection', 'implantable neuromodulation device', 'Arterial Blood (PaO2<60)', 'immunomodulatory drugs', 'early treatment', 'STEMI|Primary percutaneous coronary intervention|De-novo', 'harmonic endoscopic ultrasound imaging', 'HPV vaccination rates', 'stone', 'chimeric antigen receptor T-cell therapy', 'hematopoietic stem cell allograft.||NI-12', 'tendon repair', 'OTRs', 'condoms.|Previous surgery', 'thoracic radiotherapy', 'phacoemulsification extraction', 'AP X-ray', 'cervical epidural steroid injection', 'regulations.|Aged', 'early intervention center treating first episodes of psychosis|Professional involved', 'nerve blocks', 'function:|Pregnant', 'electrocardiographic examination', 'abdominal massage|Failure', 'Surgery', 'focal palliative radiotherapy', 'desensitization therapy', 'regular phlebotomies|Nut allergy|Pregnancy', 'Toronto Alexithymia Scale', 'pelvic pathology.|Recurrent implantation', 'hyperemesis gravidarum treatment', 'chemotherapy sensitive.||Large Cell', 'coronary stenting', '2D echocardiography', 'undertake lung biopsy', 'Dual energy x-ray absorptiometry', 'functional imaging', 'septal reduction therapy', 'dietary modification', 'Fitbit device||', 'rescue treatments', '12-lead ECG examinations', 'PET imaging|Complete destruction of the stimulation target region (M1 or', 'mechanical ventilator|Premature', 'poor control', 'optimal drug therapy after cardiac surgery', 'phone access', 'radical radiation therapy', 'open abdominal surgery', 'gynecological surgery', 'gastric erosion', 'complete PROs', 'hair health products', 'echocardiographic', 'immunomodulatory agent', 'first remission onward', 'concomitant procedures', 'bone marrow naive cells', 'bone scan', 'autologous', 'ICU monitoring and treatment', 'rehabilitated', 'topical immunosuppressive agents|Combination topical agents', 'blood biochemical examination', 'Assessment of Understanding (AoU): volunteer demonstrates understanding of this study', 'AK-105 treatment', 'blood pressure control', 'cystoscopy', 'hematopoietic stem cell transplantation.|Central nervous system leukemia', 'active intervention', 'flexible sigmoidoscopy', 'lymph node capsular invasion', 'visit|Trauma', 'standard of care post-operative', 'Hematological examination', 'mechanical termination of slow pathway conduction', 'fresh cycle embryo transfer', 'chronic medication', 'focal ablation', 'aspirin therapy', 'Genetic analysis', 'androgen-deprivation therapy|Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures', 'control', 'complete vaccine regimen', 'spinal anesthesia||', 'congenital hemoglobin disease', 'draw|Participant donated blood', 'radiographic International Caries Detection', 'feet)|Open calcaneal fractures', 'Fine Needle Aspirations (FNA)', 'Chimeric antigen receptor (CAR) T cell therapy', 'thrombolysis or thrombectomy', 'placement of vascular access', 'vital organs', 'mechanical contraception', 'open surgery.|Opposition of the patients and their representative to the study', 'French||Non-inclusion', 'total knee prosthesis', 'local laboratory).|Free thyroxine', 'color Doppler ultrasound', 'knowledgeable informant', 'previous treatment', 'supine position', 'Radical surgery', 'MRI examination', 'ICU|ICU stay', 'intra-articular knee pathology|Previous lower extremity surgery', 'venous cholangiography', 'herbal medicinal preparations', 'polymerase chain reaction (PCR) test positive', 'immunomodulatory agents', 'GWI', 'TCM treatment', 'adequate therapy', 'anticoagulant regimen', 'MRI contrast please contact', 'laboratory', 'surgical resection specimen', 'nasopharyngeal polymerase chain reaction test', 'gastrointestinal polypectomy', 'excisional surgical biopsy', 'bone biopsy', 'conventional CT scan', '24-hour urine collection for determination of creatinine CL', 'Cognitive Behavioral Therapy - CBT', 'static PET study.|The', 'enteral nutrition||Uncontrolled', 'dialysis modalities', 'Emergency Use Authorization', 'MMSE.(Mini Mental Status Examination).|Patients', 'extraction of premolars', 'bone regeneration', 'optimal resection', 'magnetic resonance imaging', 'ocular hypotensive', 'irradiation', 'gastric restrictions', 'percutaneous nephrostomy tube exchange', 'sport injury|their concentration', 'urine analysis', 'ELN', 'applicable puncture', 'World Health Organization (WHO)', 'HP MRI', 'health-related quality of life (HRQoL)', '|Prior therapy', 'coil embolization)|Plan', 'immunosuppressive therapy - with', 'treatment should', 'single-sided', 'viral replication', 'total joint arthroplasty', 'breast surgery given', 'stroke;|under treatment', 'first molecular remission', 'EKG.||History', 'localized radiotherapy for analgesic purposes', 'arrhythmia.|Major surgery', 'immunosuppressive treatment', 'replacement hormone therapy', 'coronary stent implantation', 'rate control', 'first dose of', 'months;|Surgical procedures', 'emergency treatment', 'criteria:||Absolute neutrophil count (', 'blood chemistry tests', 'end organ damage|Morbid', 'small-molecule inhibitor', 'product.|History of any one of the following cardiovascular conditions', 'renal replacement therapy|Liver failure', 'maxillary first premolar extraction', 'radical prostatectomy', 'polypectomy', 'CBIT', 'arthroscopy', 'esophageal varices|Patients', '24-hour urine collection.||Any', 'chest imaging', 'platelet aggregation', 'refuse surgery', 'small molecule therapy', 'inhalations', 'intraperitoneal therapy', 'general aneathesia||', 'apical bone.||', 'inotropic support', 'emetogenic chemotherapy', 'referral', 'exists', 'Eighty Cervical spondylosis', 'screening laboratory tests', 'pelvic examination', 'hypoglycemic treatment regimen', 'hospice care|Left-sided', 'tuberculosis|Receipt of', 'HCC', 'stem cell preparation', 'paget hast', 'study procedures', 'DMD mutations', 'rate control strategy', 'intolerance|Insufficient', 'coronary artery calcified lesion', 'samples', 'lactating|Abdominal surgery', 'reason||Additional Screening Procedures', 'HTRA1).|Beneficiary of a social security system|Having given their written consent||Non inclusion Criteria:||Contraindication', 'pathologic evaluation', 'local procedures', 'immature|Cannot puncture', 'tooth extraction', 'reoperation', 'surgical indication of radical', 'general health status', 'Peri-implant health', 'open surgery', 'global GFR x', 'insufflation).||', 'Congenital genital malformation', 'lives);|8.Resolution of all acute reversible toxic effects', 'pelvic veins', 'tobacco use|No', 'immunosuppressant therapy', 'Shoulder arthroplasty', 'carbapenem Serum concentration', 'open hepatectomy', 'clinical features NS', 'routine neuroradiological examination', 'Precision Oncology Decision Support (PODS) group', 'intramuscular injection', 'endourological stone surgery', 'small molecule medications', 'opioid therapy.|Stable vital signs', 'head circumference big enough for surgery.|Historical diagnosis', 'sequential implantation', 'physical findings recognized', 'mechanical testing', 'Mental Health Brain Health Imaging Centre Guideline.|clinically relevant abnormality observed', 'urethrectomy', 'Cozen tests', 'Head CT', 'radiologic imaging', 'test-Oxford grading|Tear secretion test', 'surgery;|Postoperative CAPRA-S score', 'DBS-STN', 'Child Assessment Service in Hong Kong', 'SIS', 'teeth erupted', 'ventricular rates', 'Alternative Fistula Risk Score', 'ELISA', 'biomicroscopy', 'refuse standard therapy', 'caffeine therapy', 'puncture of non-compression vessels', 'spinal stenosis.|History', 'completed treatment', 'EVUSHELD', 'subsequent MRI tumor', 'Traditional Chinese Medicine', 'JZP441 clinical study|Positive alcohol test', 'autologous stem cell transplant|Patients with Burkitt lymphoma', 'radiologic procedures done', 'cell proliferation', 'primary anesthesia care team', 'CBL', 'conventional physiotherapy', 'HLA-haploidentical NK-cell donor available||', 'local great vessels', 'allogeneic stem cell transplantation indications;|Age', 'duodenal biopsies', 'criteria.||White blood cells', 'effective sterilization operation', 'ID materials', 'designee|Pregnant', 'laser treatments|Dark brown', 'blood transfusion support', 'arthrocentesis||', 'standard treatment;|According to the RECIST 1.1 standard', 'patch tests', 'stress urinary incontinence||', 'neuropsychological intervention', 'plasma cell infiltration with fibrosis', 'bowel resection.|Diagnosis of fecal incontinence', 'Cambridge-Hopkins Screening questionnaire', 'myeloablative conditioning', 'trauma)|digital exam', 'blood-test of alcohol', 'neuraxial analgesia', 'adrenal replacement steroids', 'pain control etc.)|Patient already enrolled in another therapeutic trial involving', 'emergency room treatment', 'systemic treatment', 'patients|Heart transplant', 'rheumatologic disease||', 'biological therapy<3 weeks;|Herbal therapy', 'therapeutic regimen', 'glutamine Enzyme (ALT)', 'femoral artery puncture site', 'surgical technique', 'bedside testing to establish level of cognitive function', 'lead placement|Patient condition', 'finger-prick test', 'therapeutic education program|Patients', 'audiological profile impacting ability to participate', 'liver function tests/AST', 'exogenous hormones from', 'gastric scintigraphy [GES]', 'intra-articular steroid injections', 'adjuvant oxaliplatin-based chemotherapy', 'YAG posterior capsulotomy;|Intraocular', 'T cell therapy', 'herbal medicines', 'MCA stem [M1', 'baseline EKG readings)', 'extract bile', 'clinical intervention;|Grade', 'Radiology', 'Chest CT scan', 'pancreatic operations|Emergent operation|Conversion', 'Pregnancy|Conditions', 'subtotal gastrectomy', 'multiple surgeries', 'Cranial magnetic resonance imaging (MRI) plain scan']","['None', 'ventricular pseudoaneurysm', 'metal incompatible', 'IUS', 'WBCs', 'hormonal implants', 'cardiac resynchronization therapy device (CRTD)', 'inactivated', 'NTRK fusion', 'patch', 'device implantation', 'AD', 'implant device', 'intracranial space-occupying lesion', 'vascular access', 'urethral stricture', 'study medicine.|Peripheral neuropathy', 'prosthetic vascular bypass graft', 'restorations.|Defective restorations', 'intrauterine growth restriction', 'IUD', 'prosthetic devices', 'endovascular access', 'middle ear infection|parotid gland tumor|malignant', 'intrauterine device application', 'implanted metal device', 'active implants', 'inactive vitiligo', 'dental prostheses', 'central venous device', 'septal myectomy|Restrictive', 'sleep-inducers|Chronic heart failure', 'device impacting', 'metal worker', 'intracranial artery', 'hemorrhages after IVT injection', 'dialysis catheter', 'implantable pacemakers', 'subcutaneous implants', 'Poor venous access', 'allogeneic bone marrow transplantation|Administration of a live', 'artificial sources of ultraviolet radiation', 'mismatch-repair system', 'interval', 'nurse practitioners', 'implanted neural', 'intrauterine growth retardation', 'psychiatric disorder.|Coronary artery disease', 'condom plus spermicide', 'ILD', 'frozen shoulder', 'infusion pump etc.|Pregnant', 'central venous catheterization', 'superficial venous thrombosis', 'allogeneic bone marrow transplant', 'penile plication', 'absolute contraindication', 'laboratory confirmed', 'implantable contraception', 'implanted programmable device', 'implantable contraceptives', 'foreign objects in the eyes', 'pacemaker installation', 'implanted cardiac', 'implantable cardioverter-defibrillato', 'urethral catheter', 'fluid meconium-stained amniotic', 'implanted pacemaker', 'magnetic dental', 'emergency cardiac', 'aortic valve area indexed', 'pacemaker leads', 'inferior vena cava|Situs inversus|Patients', 'Depo shot', 'cardiogenic shock|Patients', 'alcohol abuser', 'implantable device', 'implantation plan', 'sleep-inducing drugs', 'allogeneic bone marrow transplantation.|Prior malignancy', 'incl', 'vascular stents', 'pain associated', 'Pulmonary vascular resistance [PVR]', 'hard lenses', 'implanted cochlear', 'cessation|Meets DSM-5 criteria', 'immunosuppressant', 'bypass surgery.|Able', 'immunocompromised state', 'metallic implants located', 'implanted electromedical device', 'potentially curative', 'inductive effect', 'intracardiac lines', 'ulcerative colitis；|Subjects', 'intracranial vertebral artery', 'prosthetic valve replacement', 'location services enabled', 'inferior vena cava tumor thrombus);|Contraindications', 'medical implants', 'irreversible toxicity', 'implantable cardioverter', 'vascular invasion', 'Bimaxillary protrusion', 'central venous catheter placement', 'histological confirmation', 'implanted pulse generator', 'LF-MRI', 'artificial', 'implanted electronic device|Receiving oral', 'Medtronic', 'walker', 'inferior venous tract|Enrolment', 'Uncooperative children.||Children', 'right ventricular volume overload', 'magnetic devices)|Claustrophobia.|Atrial', 'metal implantation', 'PLMD', 'Central Venous Catheter', 'Metal braces', 'metal prostheses', 'interleukin-2)', 'aortic valve area', 'complex vascular anatomy', 'central venous catheters.|Secondary bacterial', 'intrauterine contraceptive devices', 'implantable medical device', 'permanent implant', 'intrauterine hormone release system', 'prosthetic - mechanical', 'undetectable', 'implantable pacemaker', 'implantable methods|Intravaginal', 'unresectable', 'thyroid disease|Diagnosed', 'prosthetic materials', 'intracranial large vessel occlusion', 'implanted metal parts', 'CL prescription', 'immunotherapy-containing regimen', 'central venous occlusion', 'sudden cardiac', 'peripherally inserted central catheter (PICC)', 'implanted medical devices', 'intracranial metallic', 'peacemaker implantation', 'prosthetic valve.|A post-surgery', 'pacemaker implantation||Inclusion Criteria:||1', 'intrauterine hormone-releasing systems', 'central venous access catheter(s)', 'parkinsonian', 'chin implant', 'endovascular interventional therapy.|Known', 'Implantable cardioverter defibrillator implantation', 'wheelchair', 'potentially difficult airways', 'implantable cardioverter defibrillator', 'intracranial vascular malformation|Thrombolytic therapy', 'implanted electronic devices', 'device clinical trials', 'Intrauterine Device', 'central venous line', 'suprapubic catheter', 'magnetic pacemakers', 'aortic valve of', 'central acting medication', 'Sulfonamides', 'barrier method (spermicide', 'condom', 'prosthetic heart valve replacement;|21', 'allogeneic bone marrow transplantation);|Severe infection', 'prosthetic heart valves', 'sleep medication', 'EGD', 'larynx.|No systemic therapy', 'prosthetic heart valve|Occlusion of the', 'urethral plate', 'pacemaker implantation|Ability', 'cochlear implant', 'hormone receptor', 'injection site photograph', 'emergency setting', 'intracorporeal metal', 'implanted electronic system', 'assistive devices', 'M3814', 'low venous capital', 'BTC', 'PEF', 'intratumoral injection procedures', 'cardiac valve', 'subdermal implants', 'pacemaker implantation', 'hospital cardiac', 'aneurysm rupture', 'Aneurysm Clips', 'speak Catalan', 'unruptured intracranial aneurysm', 'defibrillator.|Metal implants', 'implanted metal|Known', 'study nurse', 'implanted devices.|Clinical team does not', 'intramuscular implant', 'potentially curative resection', 'intracardiac vegetations;|Acute myocardial infarction', 'intrahepatic bile duct stones', 'OTC', 'implantable venous port', 'cART regimen', 'intra uterine system', 'ACR criteria|Tibiofemoral knee osteoarthrosis', 'magnetic dental implants', 'NIV equipment', 'MR-incompatible implant', 'aneurysm clips', 'anatomical differences', 'premature ventricular beats', 'prosthetic heart valves;|Claustrophobia;|Pregnancy', 'NGOs', 'inferior frontal', 'prosthesis', 'shrapnel fragments', 'sleep disorder|Diagnosed', 'central venous access catheters', 'implantable cardioverter defibrillator(ICD', 'cerebral vascular accident (CVA)', 'fragile X)|Cerebral palsy|Acquired', 'barrier contraceptives', 'hot yoga', 'shrapnel', 'indwelling catheter', 'mechanical valve', 'reduced epicardial flow', 'femoral venous anatomy', 'device other than percutaneous transluminal coronary angioplasty (PTCA)', 'urethral', 'demand pacemaker', 'psychoactive substances', 'pregnancy plan', 'DVT interventional', 'femoral artery', 'subcutaneous implant', 'MPNs', 'central venous catheter-related', 'inferior vena cava filter', 'carotid artery bruit', 'allow confirmation', 'central catheter', 'metal clips', 'central venous jugular', 'endoscope', 'implanted', 'neural pacemaker', 'venipuncture materials', 'intracardial lines', 'vascular access device', 'fallopian tubes', 'left side breast cancer', 'included.|Healthy volunteers.|Patients', 'depression', 'implantable contraceptive devices', 'incompatible foreign material', 'implanted devices', 'venous angioscan', 'pacemaker placement', 'aortic valve replacement (AVR)', 'colorectal cancer|Able to understand', 'interventional antenatal clinics', 'cardiac pacemaker', 'chemotherapy pumps', 'Urethral stricture', 'intrauterine IUD', 'aortic valve area (AVA)', 'implanted electro-medical', 'potentially curative treatment', 'anticonvulsants);|high risk', 'implanted electrical device', 'implanted cranial', 'artificial limb', 'prosthetic antagonist', 'VF', 'Indwelling Foley catheter', 'dialysis', 'vascular diseases;|Cardiovascular', 'IC', 'NOS)|Primary mediastinal large B-cell lymphoma', 'Intra uterine system', 'LHSC', 'vasopressors|Not expected', 'saphenous vein', 'nicotine patch', 'pacemaker', 'foreign objects', 'implanted metal', 'metabolic bone', 'progesterone implants', 'implanted medical electronic devices；|high', 'aortic valve replacement', 'toric contact lens', 'implanted stimulator devices', 'intrauterine devices', 'Cerebral venous outflow disturbance', 'pacemakers', 'anticoagulants.|Vital prognosis', 'AIS', 'infusion equipment', 'mechanical heart valve', 'venous catheter', 'intracranial atherosclerotic occlusive disease', 'contraceptive method failure', 'mechanical cardiac support device', 'expected curative outcome', 'intracranial metal', 'implantable loop recorder;|Severe aortic valve stenosis', 'vascular clips', 'cochlear implants', 'intracardiac thrombus|Patients', 'pneumatization device', 'central vascular access device', 'implantable cardiac electronic device', 'barrier method of birth control', 'implanted cardioverter defibrillator', 'PCA', 'NIV', 'barrier method alone (diaphragm', 'forms of', 'caries in any primary tooth(controls).||', 'historically', 'artificial sunlight', 'iOS', 'implantable defibrillator', 'prosthetic heart', 'colorectal primary', 'vascular occlusive diseases|76', 'histologically confirmed', 'peacemaker', 'activated implants', 'implanted neurostimulators', 'Pacemaker', 'histological material', 'implanted contraceptive device + physical barrier', 'cochlear implantation', 'implanted CSF device', 'veno-venous ECMO', 'hyperosmolar state', 'screws', 'intratumoral injection', 'intracranial vascular malformation.|History of any intracranial hemorrhage', 'implanted electronic', 'inactive CNS metastasis', 'intra articular injection)|Systemic corticosteroids', 'Inc. study', 'remifolencil injection', 'reduced toxicity', 'contraindicated;|metal implants', 'implantable venous infusion port', 'irreversible surgical sterilisation by hysterectomy', 'hypo-/ hyperechoic areas.|18', 'antiviral therapy|Clinically significant', 'soft contact lenses', 'Central venous cannulation', 'delayed dental implant', 'central venous catheters|Patients', 'prosthetic device', 'condom plus diaphragm', 'Clinical EEG', 'central venous access', 'interventional clinical trials after', 'prediabetes', 'study;|Able', 'venous access', 'implantable cardiac device', 'supracondylar humeral fracture', 'PRP injection', 'eliquis', 'implanted brain stimulator', 'orthodontic devices', 'seven overlapping CPP', 'psychiatric care;|Systemic injections', 'intracranial hemorrhage|recent gastrointestinal bleeding', 'Implantable Cardioverter Defibrillator (ICD) shock|Patients', 'aortic valve repair/replacement (AVR)', 'degenerative muscular', 'aHUS', 'superior vena cava syndrome', 'spinal muscular', 'central venous pressure', 'irreversible toxicity not', 'metal grafts', 'allogeneic bone marrow transplantation;|Contraindications', 'metal in head', 'implanted Linx device', 'ACL degeneratio mucosa', 'heart pacemaker', 'venous device', 'mechanical tricuspid valve replacement|History', 'aortic valve repair (AVR)', 'immunosuppressant systemic therapy', 'metal implant', 'Micellar waters pH', 'allogeneic bone marrow transplantation;|14', 'artificial heart valve', 'disorder|Receive prenatal care', 'cytological confirmation', 'ARV regimen', 'iliac vessels', 'minimally invasive', 'medical prescription', 'spermicides', 'ventilation dysfunction;|Known', 'implanted metal device;|Inability', 'stroke;|concomitant medical', 'implantable pacemaker|Complete heart block', 'epidural electrodes|Other ferromagnetic metallic intracranial', 'interbody bone graft', 'intracardiac clot|Cardiovascular', 'left ventricular thrombus.|Previous aortic valve replacement', 'first primary breast cancer', 'implantable cardiac pacemakers', 'musculoskeletal systemic diseases', 'breast implant', 'Fragile skin', 'implanted contraceptives', 'intense activities', 'implanted electronic medical device', 'corneal contact lenses', 'ingredients|Metal implants', 'hormone receptor positive breast cancer', 'special biomarker', 'dialysis-depended renal failure|Class', 'implant site', 'mental illness;|10', 'prosthetic valve', 'inferior vena', 'left ventricular assist device', 'cardiac resynchronization therapy', 'barrier method plus', 'implanted metal device|At high', 'implantable hormone contraceptives', 'magnetic devices', 'metal parts', 'rare hereditary problems of', 'vascular endothelial growth factor (VEGF) inhibitors', 'intrauterine spirals).|For', 'left ventricular', 'aortic valve', 'metallic implant', 'cardiac stents', 'intrauterine system', 'fixation devices', 'mental illness.|Confused', 'IVB HPV-unrelated oropharyngeal', 'LTWP start date', 'toric contact lenses', 'artificial penis', 'goblet cells', 'vascular stent', 'degenerative tricuspid', 'cochlear implants);|impossibility', 'sunken eyes', 'barrier methods;|Total abstinence;|Sterilization', 'aortic valve stenosis|Already', 'avec statut', 'implantable electronic heart device', 'iliac artery resulting', 'body implants', 'artificial insemination|Naturally obtained', 'shunts', 'prophylactic regimen', 'intrauterine device', 'cardiac pacemakers', 'implantable electronic', 'artificial heart pacemaker', 'reproductive capacity treated or', 'Implanted devices', 'suture laceration', 'spinous balloons', 'method of birth control', 'condom in combination with contraceptive cream', 'intracardiac device', 'aortic valve intervention', 'PDFF', 'implanted electronic devices|patients', 'inferior vena cava', 'BCAAs', 'inferior vena cava thrombus', 'intracardiac clot', 'caries in any primary tooth(cases).|Medically free', 'ultrasound)|Cardiac resynchronization therapy device', 'aortic valve replacement/repair|Combined', 'artificial heart valves', 'ADC', 'AE interpretation', 'DSM-5', 'larger implants', 'allogeneic bone marrow', 'Occlusive cap (diaphragm', 'pace maker', 'forms of contraception', 'contraceptive diaphragm', 'implanted cardiac defibrillator)|Type', 'iliac artery target lesion.|Patient suffers', 'neurological diseases|People with vision', 'tricuspid valve repair', 'intrauterine growth', 'implanted cardiac assist device;|Acute', 'saphenous vein graft||', 'cardiac devices', 'inhalation', 'Notifiable infectious diseases', 'condoms', 'intrauterine hormone-releasing system', 'implanted electrical medical device', 'hypersensitivity|Severe cardiac', 'control systemic disease', 'left ventricular (LV)', 'contact lenses', 'central venous access device insertion', 'shrapnel inside body)|currently', 'seizures,|No migraine', 'inadequate venous', 'PDx monotherapy', 'iliac artery', 'histological proven', 'spectacle cylinder', 'cardiac resynchronization therapy device', 'corticoid application', 'mental implants', 'stent implantation', 'advisory contact persons', 'SCNSL actively', 'other implants', 'implanted stimulation neuromodulation system (sacral', 'investigational', 'epidural corticosteroids', 'South', 'inadequate anatomic visualization', 'stents', 'Osteoporosis-medications', 'dental implants', 'USAFSAM', 'histologically definitive', 'IPMNs', 'implanted pacemakers', 'implanted medical devices|Currently under treatment', 'epidural steroid injection (', 'penile implant', 'aortic valve replacement|Surgical approach through', 'potentially immunocompromised condition', 'metal shrapnel', 'epidural steroid injection', 'Cardiac pacemaker', 'implanted cardiac pacemaker', 'brain devices', 'intracranial vascular abnormalities.|Clinically significant', 'electrodes', 'neurological deficits|Psychiatric', 'linear', 'photosensitive seizures.|Pregnancy', 'intestinal microbiota', 'diaphragm', 'WFNS', 'Implantable Cardioverter Defibrillator', 'urethral sphincter', 'implanted vagus nerve stimulator', 'surgical implants', 'neurostimulators', 'AE associated', 'epidural steroid', 'OLT', 'Inclusion criteria:||Age', 'artificial implants', 'palbociclib', 'Implantable venous port', 'reduced ankle-brachial index', 'women|Cardiac pacemaker', 'intermediate risk prostate cancer', 'allogeneic bone marrow transplantation|Prisoners', 'pacemaker implantation -||Exclusion Criteria', 'congenital systemic-to-pulmonary shunts', 'implantable cardioverter-defibrillator', 'GGOs', 'intrauterine contraceptive', 'prosthetic heart valve', 'biopsy-proven', 'score>=15|Able', 'psychotropic substances', 'PTE', 'illegal substances', 'intermediate risk', 'bifocal lenses', 'contraceptive patch', 'treated|Metallic implants', 'addictive substances', 'maneuvers', 'digital devices', 'potentially alter absorption and/or excretion', 'sufficient venous access', 'immunotherapy-related toxicity occurred', 'pacemaker delivery system', 'endobronchial coils', 'condom with spermicide', 'pacemaker replacements', 'outpatient prescription', 'central venous access device', 'intracranial metal material', 'pacemaker wires,', 'MRI conditional implants', 'central venous catheter', 'Condom', 'cerebellar', 'prosthetic valve .|patients', 'intra uterine device', 'PCP', 'intrauterine pessars', 'metal implants', 'left ventricular outflow tract obstruction', 'urethral anatomic feature', 'implanted cranial neuromodulation device', 'central venous access devices', 'urethral discharge', 'innate musculoskeletal diseases', 'hormone receptor-positive', 'intracranial hypotension|Known thrombophilia', 'pacemaker implantation|Contraindications', 'incompatible metal implants', 'PVA', 'implanted hormonal contraceptives', 'implanted medication pump', 'increment in inotropic vasopressors', 'ACEi', 'implantable neurostimulation', 'orthodontic devices hiding FPMs', 'including||severe eczema|parental', 'etc).|Cardiac pacemaker', 'implantable cardioverter defibrillators', 'implanted cardiac devices)|Atrial fibrillation', 'interventional clinical trial.|Anticipated change', 'orthodontic appliances', 'binocular implantation of Asqelio', 'biopsy-', 'device implant', 'implanted medical devices|Medical condition', 'indwelling catheters', 'permanent catheter', 'implanted metallic', 'cardiac resynchronization therapy (CRT)', 'close contact', 'urinary catheter', 'direct', 'implanted defibrillator', 'arterial hypervascular focal lesion', 'NE metro area', 'scalp shrapnel', 'LAMS', 'condom with spermicide from screening', 'implanted cardioverter defibrillator (ICD)', 'allogeneic bone marrow transplantation', 'Frozen Shoulder', 'visible inflammatory skin disease', 'hair dyes', 'implantable venous access port', 'aortic valve stenosis||', 'implantable cardioverter defibrillator (ICD)', 'psychiatric illnesses|Those', 'low failure rate', 'coronary artery disease|Patients', 'e', 'implanted CSF access device', 'FMS', 'implantable intrauterine device', 'primary/1 booster', 'Union Internationale', 'prosthetic heart valves|With antiplatelet drugs|History', 'implanted electronic device|Patients', 'ileostomy losses', 'mechanical ventilation|People with Heart', 'implanted delivery pumps', 'permanent implants', 'permanent pacemaker', 'implantable electronic device', 'implanted metallic devices', 'inferior vena cava involvement', 'mechanical valve replacement intervention (surgical', 'aortic valve area<1cm2', 'artificial heart', 'bi-allelic SMN1 mutations', 'cardiac pacemaker / defibrillator', 'implantable contraceptive', 'longer|Implantable cardiac monitor', 'watchful waiting', 'vaping devices', 'plates', 'Metal implants', 'vegetarian', 'circular stapler for anastomosis', 'sunless tanner', 'artificial cardiac pacemaker', 'Permanent sterilisation methods', 'prosthetic valve implantation', 'implantable cardiac', 'implanted heart pacemaker', 'Cochlear sponsored investigation', 'infusion pumps', 'cataract formation', 'haemodynamic compromise', 'ileac valve', 'histopathologically proven', 'prescription', 'circular stapled esophagogastric anastomosis||', 'intracranial artery;|Intracranial tumor', 'cochlear-implant', 'youth', 'prosthetic material', 'neurovascular injury|Poly trauma', 'potentially curative therapy', 'psychiatric inpatient', 'contraceptive measures', 'Robert Wood Johnson University Hospital', 'condom plus diaphragm with spermicide', 'hormone receptor positive', 'Implanted electronic devices', 'permanent pacemakers', 'mitral valve replacement', 'implanted cardioverter-defibrillator', 'PEG tube', 'punctal plugs', 'services|resides', 'implanted cardiac device', 'implantable)', 'Cardiac Resynchronization Device (CRT)', 'Aortic valve replacement', 'consciousness|Cardiac pacemaker', 'neuropsychiatric', 'ART initiation.|Caregivers', 'coronary artery', 'implantable progesterone', 'cancer)|cardiac pacemaker', 'penile injection', 'helmet', 'heart valves', 'NCLM', 'biomedical devices', 'implanted cardioverter-defibrillator (ICD)', 'implanted cardiac devices', 'mechanical devices', 'verifiable contact', 'intracranial implant', 'saphenous vein graft', 'pacemaker should', 'cerebral vascular accident', 'implanted ventricular assist', 'central venous catheter inserted', 'immunotherapy for allergies', 'carotid artery', 'implanted electronic device', 'spectacle independence after surgery|IOL power', 'metallic implants', 'adhesive dressing', 'nitrate|Inability for', 'primarily interhemispheric', 'intrauterine contraceptive device', 'implanted intraocular lens', 'isolated unilateral DIACFs', 'handle electronic devices', 'implantable cardiac defibrillator', 'cardiac pacemaker implantation', 'gastrostomy tube', 'intrauterine device)|self', 'subclavian artery', 'PFO occluder', 'prosthetic aortic valve.|Echocardiographic evidence', 'intrauterine device))||', 'cessation devices', 'peripherally inserted central catheter', 'endovascular repair;|Endovascular repair', 'barrier method', 'healthy', 'magnetic implants', 'implanted medical device', 'prophylactic', 'Dementia||Men', 'psychiatric services', 'allogeneic bone marrow transplantation.|Patients', 'cardiac defibrillator', 'implanted electrodes', 'mechanical ventilator', 'implantable', 'pacemaker implantation|Planned ablation', 'croscarmellose sodium', 'ER', 'special dietary habits|adults', 'malar melasma', 'hemodialysis unit', 'cardiac resynchronization', 'contraception.||-', 'incompatible implants', 'ventral abdominal', 'metallic contraceptive device', 'aortic valve re-intervention', 'implanted electrical devices', 'Ultra high resolution CT of the temporal bone available||', 'worker', 'naltrexone)|Lifetime DSM-5', 'contraceptive pill', 'barrier method of contraception', 'implantable devices', 'implanted device', 'artificial joints', 'prosthetic heart valve|Bicuspid aortic valve|Known cardiomyopathy', 'ferromagnetic implants', 'contact lenses wearing|Diagnosis', 'cardiac resynchronization therapy device|Participants', 'clinical cardiac symptoms']","['None', 'pediatric cardiac ICU (PCICU)', 'pediatric LUM-201 GHD study', 'U.S.', 'management', 'measurement|Fetal heart rate abnormalities', 'Pediatric Anxiety Rating Scale', 'Well-differentiated', 'University Hospital inpatient psychiatric unit.|Decision', 'inpatient overnight stay.|The', 'obvious', 'University of Westminster;|A first generation student (FGS)', 'Confirmation', 'University of Virginia', 'University of Massachusetts', 'pediatric intensive care unit (PICU)', 'Pediatric Infectious Diseases Society/Infectious Diseases Society', 'in intensive care medicine', 'pediatric allergology unit', 'Pediatric intensive care unit', 'University Hospital ""Fondazione Policlinico Universitario Agostino Gemelli (FPG)', 'University of Extremadura.|Students', 'prescribe', 'pediatric physical therapy.|Children', 'neonatal intensive care unit', 'Hospital workers working', 'Absolute Contraindications||Perforated', 'consistently', 'outpatient department', 'University of Colorado', 'pediatric B cell', 'Permanent', 'University (OHSU)', 'inpatient', 'pediatric emergencies of', 'Neonatal period', 'outopatient', 'Emergency department access', 'Active', 'pediatric endocrinology||', 'University hospital', 'Neonatal Intensive Care Units (NICU)', 'pediatric cancer|Patient', 'pediatric neurologists', 'University of Ottawa,', 'UCLA renal transplant', 'Licensed', 'allogeneic bone marrow transplantation', 'study period.|Acute pancreatitis', 'admission', 'Adult IBD', 'Anticipated difficult', 'Pediatric Rehabilitation course for the first time in the Fall semester of the academic year', 'West China Hospital||', 'outpatient physical therapy', 'Admission Certificate of Qianfoshan Hospital', 'Wi-Fi network.||', 'indicated|Age', 'Adult intensive care nurses', 'out-hospital', ""Neonatal intensive care Unit Assiut University Children's Hospital"", 'Pediatric Acute Liver Failure', 'outpatient primary care visits', 'pediatric weight management', 'outpatient clinic', 'respiratory intensive care unit', 'signed||Mild Cognitive Impairment (MCI)', 'University Hospital', 'Adult', 'University Hospital Inselspital in Bern.|Patients', 'Riley Hospital for Children|Intact colonic motility', 'outpatient clinic surgery', 'pediatric intensive care unit', 'University of Copenhagen on the psychiatric clinical rotation||', 'inclusion|Acute traumatic burst fracture', 'University Hospital of Amiens||', 'Emergency Department', 'Ib', 'inpatient hospital care', 'pediatric neurology outpatients clinic', 'psychiatric inpatient', 'ambulatory care', 'study period.|Test', 'University of Cincinnati Hospital', 'pediatric intensive care', 'Outpatient', 'outpatient department||', 'moment of inclusion in retrospective cohort study|Patient', 'outpatients', 'outpatient clinics', 'neonatal intensive care', 'neonatal intensive care||', 'Rehabilitation', 'psychiatric diagnosis,|The', 'Emergency', 'Wake Forest Baptist Health', 'exception', 'pediatric surgical center.||', 'pediatric emergency room,|Age range', 'Pediatric Clinic/Day', 'outpatient care', 'completed weeks', 'Washington University School of', 'neonatal intensive care unit length of stay', 'screening).||', 'pediatric first aid for constipation (', 'scheduled', 'outpatient', 'amiodarone)|diabetes', 'outpatient clinic of Assiut university||', 'University Hospital emergency room', 'Pediatric Emergency Clinic', 'adult emergency department', 'pediatric primary care', 'outpatient HF clinic', 'University of Michigan|Must', 'University Medical Center', 'IC-8', 'ambulatory', 'Pediatric Emergency room', 'pediatric intensive care Assuit University cardiology Institute', 'University of Foggia', 'pediatric clinical rheumatology providers', 'Community Healthy Activities Model Program for Seniors (CHAMPS) Physical Activity Questionnaire for Older Adults|Cognitive impairment (', 'outpatient clinic of origin', 'University Hospitals', 'Unclear', 'Adolescents', 'Neonatal intensive care unit', 'University of Maryland Addiction Treatment Program', 'University of Kentucky', 'pediatric cardiac', 'ER', 'emergency department visit', 'standardized uptake value (SUV) mean', 'neonatal intensive', 'study institute', 'adult basic life', 'emergency department visits', 'Skåne University Hospital.||', 'Emergency Department nurses', 'pediatric oncology department of', 'University of Chicago Medical', 'ultrasound||', 'Gradual', 'Pediatric Hematology Service|4 weeks', 'ambulatory surgical', 'University of Wisconsin Hospital', 'pharmacorefractory', 'Ambulatory', 'Neonatal Intensive Care Unit', 'up into the throat).|The', 'interventional clinical research', 'pediatric rheumatologist).||', 'pediatric brain tumor|Patient', 'interventional clinical research treatment', 'investigator.|Life expectancy', 'outpatient clinic for surface ocular diseases.|patients']","['with the exception of those with an', 'iteria:||identify', 'do', 'compromises adherence to', 'Unavailability', 'intended', 'Do not', 'fertile people', 'Not including', 'Absence', 'NOT eligible', 'no smoking', 'With the exception of', 'patients|Not', 'no greater', 'with the exception of following malignancies after curative therapy:', 'no PR', 'women|Less than', 'extended', 'Not excluded', 'cannot understand', 'condition||HEALTHY', 'with the exception of any of the following:||Adequately treated', 'other oncological', 'failing to', 'angina;|Unstable', 'Denial of', 'no prior', 'can not quit', 'protections.|Tattoos', 'through', 'no change', 'with the exception of the following types', 'NOT received', 'fractures', 'allowed', 'Without', 'Except', 'not obtain', 'with the exception of appendectomy,', 'healing touch', 'does not apply', 'except', 'weeks.|Heamodynamically', 'no significant', 'not participating', 'cannot be', 'except alopecia);|Those', 'other', 'other day)', 'except the', 'successful', 'not not', 'No', 'with the exception of:||Intranasal', 'prohibited', 'Agree to', 'indolent', 'w/o', 'does not', 'excessively', 'Absence of', 'a:||Cohort 1', 'no age', 'previous', 'with the exception of the OBERON', 'cannot wear', 'with the exception for', 'does not go', 'predominant', 'excluded', 'no new', 'no exclusion', 'lack of', 'aucasian|Willing to', 'activities|Not', ""doesn't"", 'can use', 'lack of data regarding', 'provided free', 'with the exception of the cancer under investigation in this study and', 'without', 'no other', 'survival time<0.5', 'exceeding 210', 'from the current', 'other treatment.|Patients', 'not been', 'never', 'with the exception of thyroiditis.|Subjects affected by', 'with the exception of amniotic membrane transplantation. Patients', 'before', 'compromises the affected limb|A stable', 'failed', 'other equivalent', 'not receiving', 'measured from the', 'cooperation|Clinically significant', 'can not', 'history', 'from', 'Not to', 'no menses', 'not able', 'non-', 'Not pregnant|Not', ""not eligible.||*'consider"", 'compromises ability to', 'lack of treatment for a major psychiatric disorder', 'besides', 'months|Patients free', 'no sun', 'facility', 'Not received', 'Lack of', 'with the exception that', 'have the potential to affect bone', 'aside from the known', 'mounted', 'prolongs survival', 'other sites', 'Unless', 'Age≥18 years', 'can', 'amendable to', 'pneumonitis.|Evidence', 'not older', 'except female', 'using these', 'N0;||', 'irradiation.|Patients', 'Ability', 'compromises the', 'uncontrollable', 'cannot quit', 'irradiation)|Unable to', 'except if', 'can not swallow', 'not including', 'no urgent', 'near', 'completely', 'with the exception reported', 'no visible', 'no more', 'Not available', 'precludes', 'no relevant', 'NOT', 'neostigmine)|Patients', 'pump', 'radiotherapy;|Unsuitable evaluation', 'intention of', 'not opposing', 'higher than', 'need', 'except for', 'Apart from', 'no witnessed', 'except from', 'usually three', 'immediately', 'other relevant', 'elderly', 'could not', 'with the exception of:||Cytotoxic agents when administered as a', 'other form', 'unless they', 'withdrawal', 'no use', 'not excluded.||OR||Untreated', 'not', 'can cause', 'Not', 'diabetes.|Patients', 'plan|Active', 'From the', 'measured from the interproximal CEJ to the depth of the interproximal pocket', 'Withdrawal', 'with the potential for relapse (', 'Age|Type 2', 'with the exception of the occasional use', 'patients|patient', 'absence', 'naive', 'in addition to', 'no malignant', 'post term', 'with the exception of the use of', 'interfering', 'experience', 'children|Child', 'allowed per institutional guidelines)||Patients must', 'needs', 'no clear', 'exception', 'although', 'unresponsive', 'exhibiting', 'epithelial', 'compromises the benefit', 'in addition to oral anticoagulation for 6 months,', 'except patient', 'Except for', 'except 2', 'with the exception of:', 'not eligible', 'not the', 'lack the', 'no apparent', 'no marketing', 'with the normal outcome;|Positive', 'except those', 'nment-', 'identify', 'discontinued', 'poorly', 'post', 'pathologically', 'cysts|Negative', 'Tool|Not have', 'prevents', 'outpatient', 'unwilling to', 'permitted', 'NICU,|Active', 'unless otherwise', 'apart from', 'Narcan training:||not', 'with the exception of the psilocybin used within this study)', 'high', 'by', 'cannot control', 'excluding', 'must measure ≤24 mm', 'precluding', 'except minor', '3', 'can affect', 'procedures|Patient', 'with the exception stated in the inclusion criteria', 'never received acupuncture', 'absence of', 'neoplasmatic history in the anamnesis,|prevalent', 'except novel', 'allowed per institutional', 'includes', 'with the exception of hydroxyurea', 'between', 'patients|Patients', 'no intention', 'not exceeding', 'other than', 'with the exception of', 'unrelated', 'fibroma)|History', 'pterygium', 'are eligible', 'from January 1st', 'ages of', 'implants|Not', 'ability', 'acceptable', 'Not owning', 'Exception', 'requires ICU', 'not received', 'with the exception of alopecia|Prior palliative', 'not taking', 'breech position|Scheduled ECV||', 'Not giving', 'age-', 'Do', 'aside from', 'rather than', 'skin)|Abnormal', 'etc.).|Taking', 'cannot', 'no opposing', 'Assault-', 'excepting', 'preventing', 'unless', 'not emancipated', 'no', 'stroke|Greater than', 'able to understand and give his consent|Patient affiliated to the health insurance||', 'cannot communicate', 'naïve', 'do not', 'not to', 'greather than', 'Not A']","['computer users|The ability to continue working||', 'shoulder|Post-traumatic', 'Non-invasive ventilation', 'clinically significant GI', 'severity of DSPN.|Patients', 'bisphosphonate', 'tapering doses of', 'mild to moderate depressive episodes', 'anabolic treatment.|Participating', 'surgery|BMI', 'under effects', 'yoga', 'acute increase in blood pressure (BP)', 'clearly related to NSTEMI|ST-segment depression>1mm/6 leads', 'dry eye syndrome.|Clinically significant', 'Ophthalmologic', 'mild to moderate alcohol use disorders.|Has', 'non-prescription medications', 'single agent rituximab/obinutuzumab', '>100 g carbohydrates', 'near eyes', 'suitable for inclusion.|Subjects achieved', 'non-therapy-induced', 'observable', 'resectable;|Have not received', 'above grade 2', 'Serious', 'full-thickness rotator cuff tear', 'of:||Adequately treated', 'non-target', 'CRITERIA', 'excluded', 'ICD-10 F10.x)|A current', 'PAP) therapy', 'boundary value).|3', 'suitable for HSCT', 'suitable for participating in this trial in opinion of the investigator', 'oculoplastic', 'fellow eye|Determination by Investigator of macula-off status', 'suitable for radical surgery', 'singleton', 'lasting at least 10 minutes.|Ability to understand and willingness to sign a written informed consent document.||', 'getting', 'lack effective treatments;|Expected survival period', 'Once treated', 'intra-articular infiltration of the trapezio-metacarpal joint)', 'emergency department|Subjective', 'interventions;|Chronic kidney disease', 'strabismic amblyopia', 'low pressure≤90mmHg', 'grade 1', 'non-medically induced', 'proficient', 'diagnosed by emission computed tomography', 'before cataract', 'Prader-Willi Syndrome', 'older|discharged', 'incompatible smartphone', 'Early', 'suitable for local therapy', 'Non-segmental', 'ACR/EULAR 2016 criteria.|For SAPS', 'injuries|neurological', 'ABS', 'Self-Criticism', 'breastfeeding.|Prisoners|Adults', 'non-autoimmune allergic diseases', 'micropapillary', 'invading the GI-tract', 'primitive reflexes', 'might interfere with the study outcome.|An', 'reparable', 'salvage chemo-immunotherapies;|No measurable', 'amenable to catheter placement', 'below the functional occlusal plane|incisor', 'carbon dioxide', 'nephrotoxic', 'TMJ|systemic', 'stroke|Vascular', 'musculoskeletal limitations|Uncontrolled hypertension', 'anticoagulant therapy)：||Prothrombin time (PT)', 'some form of', 'Field', 'amenable to local therapies', 'gluten-containing products', 'low-density lipoprotein cholesterol', '12-lead electrocardiography', '30)|Pregnant', 'amenable to biopsy.|Radiologically measurable disease', 'non-revascularized', 'long diameter ≥10mm', 'shelter stays', 'strong', 'sudden', 'S768I', 'screening||Concerns', 'interferes with iron', 'third trimester of their pregnancy', 'mono-infection', 'under usual clinical practice conditions', 'adult', 'prophylactic doses', 'site investigator determines', 'CPAP)|Previous', 'Institute for maternal', 'suitable for mobilization sessions', 'worse than New York Heart Association Class (NYHA) IIB|Inability', 'grade 3B|Transformation', 'Mount Sinai Health System', 'at room air', 'expressed advanced', 'legs|Pathologies', 'Criteria:||age', 'non-myeloablative', 'perceive', 'scale|Decreased', 'schizo-affective disorder', 'aesthetic zone).||', 'parastomal', 'injection sites', 'Klebsiella spp.', 'wide-local excision', 'muscular dystrophies', 'FS', 'immune diseases.|Other persons', 'lactating|any', 'listed in inclusion criteria;|Any chemotherapy;|local treatment', 'severity grade 2 or 3', 'environmental exposure', 'core biopsy;|Tamoxifen', 'amenable* to biopsy', 'myeloproliferative neoplasms.|Abnormal resting hemodynamic function', 'Congenital', 'suitable related', 'daily headache', 'cytologically-confirmed', 'Young toddlers', 'under AME|Patients', 'predisposing to preterm', 'substances used in restoration.|Presence of general or', 'unexpected', 'grade 2 or less', 'SPAI-G', 'premalignant', 'fellow eye', 'severe degree', 'culprit coronary artery||CS', 'lasting between 21 and 35 days', 'immunosuppressants|Pregnant', 'neurotrophic', 'personal computer, laptop- this includes', 'pericardial effusion', 'attempts|A risk of regurgitation patients|History', 'medically-required', 'influence stomach', 'intra-uterine contraceptive device', 'PD group only)|native English', 'full dose of one of the regimens', 'artery target vessel', 'non-culprit vessel.|Ostial', 'screening.|Pregnant', 'cervical lymphatic rainage area', 'pharmacologically induced', 'stage 1-2-4-5||Being illiterate|Not', 'meeting minimum exercise guidelines', 'Grade III-IV from the New York Heart Association)|Chronic kidney disorders|Malignancy|Severe autoimmune disease', 'despite resolution', '3rd trimester', 'interferes with any study procedure|Current', ""Movement Disorder Society-Unified Parkinson's Disease Rating Scale"", 'volar aspects of the arm.|Participants', 'or|Relapsed', 'immunosuppressive use,|Periocular', 'varicella-zoster virus infection', 'acutely symptomatic', 'stressful organisational', 'mild to moderate renal impairment', 'operating room nurse||', 'NSCLC).||C. Prior', 'suffering', 'arrhythmia;|Serious', 'class III obesity - BMI', 'suitable for clinical trials', 'medically prescribed', 'mouth openings', 'peripatellar', 'Depo-Provera®', 'accurately measured.|Hearing impairment', 'drug-induced parkinsonism', 'mild to moderate speech troubles', 'hypopharynx', 'IDH-mutant', 'non-FMC63', 'Stage 2', 'inspiration O2', 'effects)||Current', 'diameter of the target arteries for conduits of the internal mammary arteries', 'suitable for participation in the', 'self-report)||', 'CTCL.|Have relapsed', 'severity of the disease', 'Accart-Ville', 'non-alcoholic liver disease', 'Primary Care PTSD Screen', 'IMWG criteria (Appendix C', 'tolerated.|Uncontrolled', 'post-procedural antiplatelet/anticoagulation regimen', 'allowed;|Serious', 'acute use', 'non-peritoneal metastasis', 'Refractory', 'non-injected measurable', 'reducing dose of', 'donating', 'upper limb practice', 'present:||Oligo-or anovulation', 'connective tissue- related', 'UNL|AST', 'controlled with supportive therapies', 'stage IV NSCLC;|Patients', 'MDS-EB', 'mellitus,|Cardiovascular diseases,|Pulmonary diseases,|ASA', 'Youth smokers', 'residual lesions', 'potentially unstable', 'sauerkraut', 'considered cured', 'ophthalmic', 'peri-implantitis (', 'injury|Vertigo', 'sample collected', 'Pre-existing', 'acute event', 'valvular', 'other class of analgesic', 'American Heart Association (AHA) definition', 'criteria-based', 'invading the gastrointestinal (GI) tract', 'pandemic', 'substantially', 'acuity|bilateral phacoemulsification cataract surgery', 'its outline.||7', 'side', 'suitable for treatment', 'site of surgery|periodontally healthy', 'jigsaw', 'cumulative exposure', 'could cause unacceptable safety risks or compromise compliance with the protocol.|Known', 'non-pacemaker', 'MDACC', 'Connective tissue', 'antilipidemic', 'emergent', 'independently.|Not regularly', 'Clinically obvious', '2019-related', 'new-onset', 'intra-ocular inflammation|retinal', 'sulfonamides|Documented', 'full understanding of the purpose', 'any of its', 'write in Catalan', 'Dutch MEDPED', 'first-line platinum-', 'C-PAP', 'peri-implantitis', 'non-weight-bearing CT)|Suspicion', 'adult growth', 'Brain', 'American Joint Committee on Cancer', 'Prader-Willi syndrome', 'clinically relevant medical', 'time|Self-reported', 'SARS-CoV-2 infection', 'genital regions', 'secondary', 'ureter)', 'test.|Pregnant', 'swab.|Be', 'non-healed', 'medium', 'acute event|Pregnancy', 'enrolled.|History of', 'basement', 'gravis;|Unable to communicate', 'nasotracheal intubation', 'place the patient at a higher risk of receiving investigational treatment.|History of clinically significant', 'non-pharmacological therapies', 'IHS4', 'ambulation|Acute', '3 months or longer', 'IDD|On maintenance treatment', 'NOS|High grade B-cell lymphoma', 'cured', 'high risk', 'since the pathology is linked to the X chromosome', 'NEI scale', 'positivity|Eastern Cooperative Oncology Group (', 'scars', '≤5x ULN|Total serum bilirubin', 'active', 'tumor tissue samples.||3', 'cruciate ligament rupture|a history', 'secondary to diabetes', 'under the care of an oncologist, or|Health professionals involved', 'medical institution.|Patients', 'mitomycin-C', '3.Active', 'development.|Signs', 'Sanofi', 'admit to intensive care unit in postoperative period|Patients with the end of operation', 'minimally invasive', 'partially controlled by medical treatment', 'prednisone', 'affects the methodology for conducting a hemoperfusion procedure', 'equal intervals between', 'refractory advanced', 'self-help', 'specifically', 'SpO2 sensor', 'gastroesophageal', 'unknown primary', 'maximum tolerated): Sulfonylureas', 'interfere with cooperation with the requirements of the trial.|Is pregnant', 'IRFARPC criteria', 'Italian population).||', 'subjects).||Stage 2 and 3||Inclusion', 'in vitro reactivity test', 'modify the wake-sleep rhythm', 'negative|Stage IV', 'primary endpoint(s)', 'Other than', 'squamous', 'liberal', 'on room air)', 'ipsilateral chronic', 'impacting nutrient absorption', 'stage IV-V.|known', 'primary mobility', 'ICD-10-GM U07.1 G', 'heavy', 'Anovaginal fistula Rectovaginal fistula Perianal', 'enteric pathogens', 'haplo donor must', 'flu-related', 'well-controlled', 'Type IV, V', 'Successfully completed', 'index patient.|Pregnant', 'upper extremity|Presence of', 'ipsilateral side.|Corticosteroid injection', 'radically cured', 'fever|Prior receipt of any VSV-vectored vaccine|Receipt of another IP within 3 months prior to enrollment', 'stable diet', 'orally absorbed', 'Esophageal', 'non-ischemic', 'full battery of psychometric assessments', 'low-stage cancers', 'local)|Acute urinary', 'near future;|Patients receive', 'transabdominal echo|absence of informed consent to participation in the study', 'fermented foods', 'necessitated', 'upper limb hemiplegic', 'after birth||For', 'extensive chronic graft', 'MRI.|Relevant', 'below:||absolute', 'leg varices.||', 'neoplasm;|Concurrent', 'non-ATN AKI', 'hospital-acquired', 'Mellitus,|Patients with', 'including:|Inability to', 'measurable on CT/MRI', 'lober', 'distal implants|Healed sites', 'genetically determined Marfan syndrome', 'liver enzyme CYP2D6', 'grade 2 or 3 unless', 'without remission', 'can cause', 'Substantial', 'MRD examination.||', 'smokers.|Positive', 'PEG-G-CSF', 'test diets.|Participants', 'reachable', 'Non-Caucasian subjects.|Subjects', 'Q1-2021', 'requiring treatment', 'buccal mucosa', 'partially thrombosed right portal vein|Hepatic vein thrombosis', 'gonadotropin-releasing', 'CNLC Ib', 'central nervous system toxicity', 'reducible', 'non-hormonal intrauterine device', 'index child whose behaviour', 'Post-traumatic', 'months;|Pathologically confirmed', 'aerosol', 'injection sites.|History', 'Taiwan', 'primary ovary insufficiency', '≥2|Uncontrolled', 'under stable control', 'Criteria 2', 'extremely', 'Non-sterilized', 'meeting measurable disease criteria', 'large cell lung', 'mild', 'clinically significant abnormal', 'under-table elliptical', 'adequately', 'faecal', 'CNS-directed local therapy', 'non-obstructive catheter', 'ICD-10 F32.0; F32.1', 'perineal', 'intestinal microbiota', 'Functional Class 3 III-IV', 'between 2006', 'Mid-urethral sling placement||', '3 minutes', 'peri-operative', 'could confound T and B cell subset results|Have a concurrent', '≥37.7ºC oral', 'catchment of selected rural health centers;|Provide informed', 'exhibiting threatening behaviors', 'clinical judgment|4', 'H&Y', 'hypoperfusion,|Hemodynamically unstable', 'explant', 'non-medical conditions', 'grade III/IV', 'to betablocker therapy|History of', 'low-risk drinking', 'non-child bearing potential', 'msec.|Serious', 'RA criteria', 'indications', 'exertion', 'another eye disease', 'malignancies;|At least 1', 'cytotoxic T lymphocyte-associated', '3 consecutive days', 'grade 2 toxicities', 'occlusal surface;|Good general health', 'adequately reversed', 'music', 'low-fodmap diet', 'unknown', 'non-smokers|Normal', 'influence the outcome of the study|History', 'Electronic Health Record documentation', 'ulcerated', 'site staff', 'preclude adequate absorption of DZD9008.||Prior/concomitant', 'excluded.|In-field progression', 'Induced', 'bpm||Significant', 'grade 4 immune related adverse event (irAE)', 'Non-metastatic', 'non-commercial RNA-', 'could significantly affect the pharmacokinetic', 'platinum-based therapy', 'High risk', 'Diagnostic and Statistical Manual-V (DSM-V) criteria', 'Atopic', 'intercurrent', 'grade 3 or above', 'been treated', 'prevents effective use of the audio-visual content', 'full active range of motion in the involved', 'Zoom-administered', 'hemolysis)|In', 'suitable for participation, whatever the reason', 'slow-release', 'QTc formula', 'injection', 'non-oxygenated', 'temperature thermal scan', 'maxillofacial', 'non-Latino', 'pathology', 'glutamic oxalacetic transaminase≤3 times the upper limit of normal,|Renal function', 'in each lung and more than 10 lung lesions', 'neutropenia.|Coagulopathy.|Severe', 'full haplotype', 'Non-GC immunosuppressive medications.|Allowable IS', 'clopidogrel use', 'predominantly', 'American College of', 'local', 'Gastroenterology Department', 'index hospitalization)|treatment', 'growth', 'pose excessive', 'Poorly differentiated', 'post-traumatic amnesia', 'M0.||', 'sodium thiosulfate', 'AT THE', '2020||', 'non-treponemal (T2) serology', 'non-sterile males', 'Prophylactic use', 'herbal', 'suitable for', 'PD)', 'nipple-areolar complex of the PND breast side', 'deemed necessary:||glomerular filtration rate (GFR)', 'SURVIVOR||Recurrent', 'topical eye drops', 'residual invasive disease', 'Hormone Replacement', 'fusion-positive', 'interferes with physical activity,|Pregnancy', 'hypoxemic respiratory failure.|Patients should', 'Culprit lesion', 'invading mesenteric vein', 'influence the Gastrointestinal Microbiome|Had', 'intercurrent illness.|Active', 'syndrome|Pregnant', 'suitable to participate in this clinical study', 'DSM-V|Diagnosed', 'Non-Acute', 'controlled by medication|Left ventricular ejection fraction', 'hypoglossal', 'Early-childhood', 'grade two or above', 'old|Historical', 'Primary Care Healthcare Centers', 'temperature|Poor healing', 'nicotinamide', '≥ grade 3 irAE or', 'clinically significantly less than lower limits of normal', 'highly effective method of contraceptive', 'peri-menopausal symptoms', 'salvage radiotherapy;|age', '3-Tesla MRI examination', 'Grade 2 or higher heart failure', 'poor tissue oxygenation', 'adequate tissue', 'Non-hysterectomized', 'secondary KMT2A', 'render', 'Grossly', 'remotely-supervised', 'requiring treatment;|Other interventional clinical studies have', 'shoulder', 'non-prescription/prescription', 'compensated', 'grade ≥3 GI', 'likely to disrupt the', 'highly effective form of', 'mild cognitive impairment"".|Patient', 'under lying disease e.g.||Diabetes,|Hypertension,|High risk pregnancy|Any wound', 'requiring the use of steroids', 'low Hb', 'could cause bladder dysfunction', 'months|Histologically confirmed', 'Diagnostic criteria for CNSV||The presence', 'systemically free', 'stable aided', 'unlabeled', 'primary indication', 'stable regimen deemed best', 'secondary to an accident of', 'American Heart Association guidelines', 'Fridericia-corrected QT interval', 'under stable dose', 'non-contrast CT-scan', 'abuse)|Coinfection with', 'suitable by the transplant selection committee', 'non-squamous cell carcinoma', 'balloon retrograde transvenous', 'large', 'schizoaffective', '≥Grade', 'American Academy of Dermatology criteria', 'site of needle punctures area', 'under age', 'suitable for enrollment;||Angiographic Exclusion Criteria:|Heavily calcified lesions;|Presence of aneurysm in the target vessel;|Acute', 'Non Hodgkin', 'ETDRS chart', 'trauma-related', 'great vessel stenosis', 'related term', 'any grade', 'non-hormonal contraceptive methods', 'single-gene mutation', 'A1/A2 segment of the anterior cerebral artery', 'intensive', 'index PCI).||', 'septal', 'Investigator.|History', 'moderately hypofractionated', 'inflow-outflow)|Live expectancy', 'metastasized', 'durable remission', 'requiring IV anti-microbial treatment|Patient', 'CMV immunoglobulin', 'Medical', 'clinically significant diseases', 'Non-English speaking|Unable to access the internet|Not practicing in the U.S.|Not', 'IAP in labour)', 'post-Covid syndrome', 'lowest - 33rd percentile', 'site of administration', 'reactive', 'curative-intent', 'microbiota composition).|Veganism|Lactose', 'bones', 'decisional capacities', 'Grade 3.|Schools', 'could significantly affect folate status', 'applied ICIs', 'interfering with', 'voluntarily.||', 'non-prescribed', 'procedure|Pre-existing', 'partial shoulder flexion or abduction', 'osseous', 'lines of standard therapy', 'nasotracheal', 'medically prescribed diet|Participants not willing to stop consumption of fermented products', 'protein S deficiency', 'COVID-19 related', 'PD-L1 IHC 22C3 assay', 'early follicular phase', 'signaled', 'drug-positive', 'ocular', 'peri-rectal', 'insulin resistance', 'hypocaloric diet', 'medical intervention;|The', 'HbSC', 'in room air|Patients', 'harmful', 'equally affects', 'Group B', 'surgical plan', 'non-opposition||Exclusion Criteria', 'medicated', 'largest diameter.||For', 'baseline|Adequate organ', 'Successful', 'Infected', 'interfere with cooperation with the requirements of the trial|Is', 'interfere with fine motor functions', 'PD-L1 antibody', 'Specifically excluded', 'appropriately', 'N2-3', 'corrected', '5-year Overall Survival (OS)', 'controlled by medications.|QTcF ≥ 470 msec', 'chemically related', 'investigative site;|have', 'benign', 'duodenotomy', 'M1 NED);|ECOG performance status', 'inserted their pessary', 'hormone replacement', 'AP-HP', 'PD-L1 agent', 'targeting', 'aprevious', 'ALK inhibitors', 'diabetes|Previous', 'epilepsy|any unstable', 'in MS are allowed as these medications', 'wild type FLT-ITD', 'invasive diagnostics', 'Maxilla', 'could interfere with chemotherapy', 'suitable to be enrolled', 'ankle-foot orthosis to minimze contributions', 'past-year', 'emergency room of the HPNCL', 'para', 'pleomorphic undifferentiated sarcoma', 'F50.1', 'non-surgical', 'neovascular', 'bicycle ergometer', 'American Joint Committee on Cancer AJCC Staging Manual', 'heavy-duty standards of the new', 'baseline|Contra-indications', 'tumor per local', 'ROME IV criteria (exclusion of constipation', 'SHCN||', 'Low auditory and/or visual acuity', 'life-threatening condition', 'freshly', '1 cycle', 'Type I diabetes mellitus', 'non-employees of', 'preclude compliance with the protocol', 'adequate understanding', 'ileal', 'Lesch-Nyhan syndrome', 'highest', 'cytologically confirmed', 'thoracic', 'influence hemodynamic changes', 'vaginal', 'passive mobility', 'low laying placenta', 'older.|Histological', 'non-lower GU tract', 'outpatient', 'Rome IV criteria|Non IBS-C|Moderate to severe', 'non malignant systemic', 'PD-L1 or CTLA4', 'ST-segment elevation', 'TAK-771-3005).|Participant who experiences', 'suitable to be included in the study', 'endocrine-related', 'stage III disease should', 'carbon monoxide (CO) level', 'patients;|Preoperative neoadjuvant', 'suitable for evaluations,|To undergo another surgery', 'Non ST-elevation myocardial infarction', 'study;|At least 10', 'transfusion', 'suitable for selection', 'hemothorax', 'only - currently', 'SARS-CoV-2 RT-PCR', 'suitable to participate in this clinical trial for', 'moderately ill', 'Neuro-muscular diseases', 'breastfeeding;|Absolute', 'adequate understanding or cooperation;|participation', 'nontraditional funding sources', 'Non-convulsive epilepsy|Suffered from status epilepticus', 'breastfeeding.|Serious', 'nurse in intensive care units|Nurses', 'deformity|additional amputation|neuromuscular disease', 'adverse vaccine', 'AIDS);|Active', 'greater than ten (10) days', 'non-malignant etiology', 'PD-L-1 expression', 'enamel abrasion', 'suitable for blood', 'ankle', 'suitable for participation in the study', 'write Turkish,|Hemodynamically stable,|No previous experience', 'apply:||Medical Conditions||Liver disease of other aetiologies', 'upper limb study|Wounds', 'hormone replacement|Note', 'third-year', 'non-surgically sterile', 'primary caretaker', 't(4;14', 'therapy-associated symptoms', 'upper limb resulting', 'fresh frozen', 'very deep', 'interferes with assessments', 'examined', 'non-hospitalised', 'non-small cell lung cancer);|A', 'renally impaired patients||Patients', 'under stable', 'at stable dose', 'Permanent', 'sino-nasal', 'severely affects lung', 'depo-medroxyprogesterone', 'lasting longer than 3', 'medical marijuana', 'proximal', 'etc.|Alcohol consumption', 'long-term treatment', 'between enrollment and 30 days prior, unless their dosage will', 'T0-2', 'lacunar infarct', 'highly effective birth control.|Participants', 'sinoatrial heart block|History', 'treated accordingly', 'peri-implant bone loss', 'non-contrast CT', '-related', 'Pustular', 'etc.|History of', 'Shigella spp.', 'Volunteer to take part', 'non-emergency dental procedures', 'stable refraction', 'esophageal catheter', 'anti-cancer therapy', 'blood', 'age|self-reported', 'first-line therapy', 'inspiratory flow limitation|Predominantly', 'non-penetrative stimulation', 'Anti-', 'excipients|Lympho-depleting', 'hereditary', 'AID group', 'non-hematologic', 'licensed', 'old|Chronic', 'largest diameter', 'DSM-V criteria.|No', 'LH-RH analogue', 'AMD-related', 'full cycle of', 'Shaffer', 'samples collected', 'Stage IIIC', 'regularly|could not follow the protocol of this study', 'Stage IB-IIIA', 'SH-Tripeptide-1', 'neonatal unit at Randers', 'disease).|Non-traumatic extensively carious hence restorable', 'ALK inhibitor should continuously', 'formulation.|History of severe', 'blinded phase', 'acquired', 'post-acute', 'abnormal transaminases', 'T790M mutation', 'voluntary', '1.5 SD below the education adjusted cutoff on the', 'grade III meningioma', 'cystectomy|Concomitant', 'Diagnostic and Statistical Manual of Mental Disorders (', 'preclude receipt of study injections', 'caries', '50×103.|Pregnant', 'psychological disorders|Parents', 'non-breast malignancy|Active', 'non-medical', 'amputation|Osso-integration|Metal implants|Diabetes|Vascular cause of amputation', 'musculoskeletal domain).||ii', 'interfere with assessment|History of', 'suitable for ablation therapy', 'secondary symptoms).||', 'low grade histology)|Surgical protocol', 'necrotic tissue with', 'economic constraints', 'deemed unsafe', 'confined space;|Allergy', 'above.|Self-reported', 'primary site|Patient', 'patient|Pregnant', 'mild to moderate clinical symptoms of', 'long-term corticosteroid therapy', 'plantar wart', 'IPSS-R / ELN classification', 'suitable to the experimentation', 'Full permanent dentition', 'secondary GBMs', 'infection.|Clinically significant', 'low level of literacy', 'muscle biopsies', 'pyelonephritis|Hospital-acquired pneumonia (HAP)', 'Pregnancy;|Prior', 'non-fertile', 'medically prescribed activity limitations', 'AFF', 'worsen', 'epithelial cells', 'vulvo-vaginal pain', 'vaccine;|There', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5): problem with falling asleep', 'full dose of ETI|Use', 'non-lactating.|Females of', 'active phase (dilatation 4', 'mellitus.|New-onset', 'focused', 'dependence|Clinically significant', 'nursing|Uncontrolled', 'gemcitabine-based', 'Non-aneurysm|Penetrating', 'immunoglobulin A nephropathy', 'ultraviolet A', 'inadequately controlled', 'hypercoagulation', 'CYP3A4', 'non-GVHD', 'occlusal contact.||', 'primary care', 'grade II to IV in Sinclair Scale;|Participants', 'non-pharmacological treatment', 'assent form (signed by legal representative if participants is', 'metabolic-associated', '≥90 minutes/week of physical activity|Self-reports', 'tumor-invasive', 'intra-aortic counterpulsation balloon.|Valvular stenosis', 'block1||Successful primary', 'localised', 'vit-C', 'intact', 'that affects fundus examination', 'study|Good general health', 'guideline-directed medical therapy', 'High grade', 'haemorrhagic', 'breastfeeding.|Synchronous', 'suitable to undergo', 'Empty Can (3 or more', 'Smokers||Previous', 'cytologically-confirmed resectable', 'nutrient', 'obstructed', 'adequate understanding of the study', 'Rome III constipation', 'migraine', 'implant site', 'following:||age>65|Diabetes mellitus|End Stage Renal Failure', 'marijuana)|Significant', 'very severe', 'injection substances', 'unsatisfactory', 'employees', 'prolonged', 'Granulocyte-monocyte colony', 'suitable for contrast-enhanced', 'locally progressive', 'Schuylkill)||', 'under guardianship|Non-cooperative', 'Screening.|Clinically significant', 'Trans-RosaLEE study', 'VZV', 'dual-tumour location.|known RAS mutation|Peritonitis', 'Third-line', 'T3~4N+M0', 'psychiatric medications.|Diagnosis', 'for DM', 'operating room', 'mental diseases;|No', 'largest residual nodal mass', 'over 30° when', 'preoperative', 'cleansing', 'Grade A', 'Salbutamol)|Inter-hospital', 'untenable', 'progressive-addition', 'platinum-containing therapy', 'screening', 'chronic severe', 'middle of the night to check', 'African', 'thoracic cage', 'increases in blood pressure', 'allele', 'stability|ongoing', 'moderate intensity activities', 'month.|Pregnant', 'glargine', 'Ability', 'Non skin related', 'upper right second', 'ICDAS II score', 'stenotic', 'corticosterone', 'negative', 'experimental arm unless the investigator agrees to treat only after discussion with the RTQA team.|Is currently participating in', 'complications|Other', 'measured anytime prior', 'surgeries.|Recent', 'full understanding of the study content, process', ""primary cause of participant's"", 'hypothalamic-pituitary-adrenal axis', 'moderate sedation', 'clinically significant', 'wheeze', 'urothelial', 'anterior', 'insulin dose', 'Wilkes', 'MRI|pregnancy|acute', 'non-carious cervical lesions|Patients', 'incompletely treated TB', 'Turesky', 'tibial nails', 'peri-anal abscess', 'second remission', 'selected districts|provide pregnancy care|chief doctor', 'stable doses', '4/10|No', 'gastrointestinal', 'suprapubic catheters', 'acute bereavement period', 'inconsistent with the Senza System guidelines', 'deemed contraindicated|Patients', 'Adjust-Unlikely', 'non-GI infections', 'NOACs;|Severe', 'esophagus||Locally advanced', 'concentrate radiofrequency fields', 'Clinically confirmed', '3 - History', 'inactive phase, should be', 'non-MRI-compatible', 'unknown origin>38.5 ° C occurred', 'tested on treatment naïve', 'recent', 'mild to moderate irritation', 'without a', 'in the brain', 'Clostridium difficile', 'histologically-', 'BSA).|Self-rated', 'non-autologous', 'ventilator-associated', 'dull', 'cholinergic enhancers', 'cytologically non-small cell lung cancer', 'inflammatory system', 'nasojejunal tube', 'shaft', 'fatal hemorrhage', 'subacute', 'non-traumatic amputation', 'ascites;|Paroxysmal', 'non-related', 'Norplant', 'B)|Acquired', 'manifest', 'secondary spontaneous', 'Non-inclusion criteria', 'suitable for local treatment', 'DNA detection', 'home-based', 'radiofrequency.|Pregnant', 'SH III-V|Ulnar physeal', 'non-transplant', 'Type I', 'deemed medically stable', 'in-utero', 'non-exercise group', 'last', 'grade II or III', 'OR|Two predicted pathogenic GALC', 'intra-ocular metallic fragment', 'numerical pain rating scale', 'CD1a+', 'hormone replacement therapy', 'IgG type', 'self-mutilation', 'new measurable disease', 'solitary', 'non-pharmacological pain', 'full length of canal.|Teeth', 'medial malleolus avulsion fractures', 'deemed related to the study treatment', 'surveillance|Adequately treated', 'ankle range of motion', 'injection into knees', 'urogenital', 'radiologically stable', 'gender-based', 'BCL6', 'LVAD|Pediatric patients|Patients', 'preclude study', 'castration resistant prostate cancer', 'place the patient at higher risk from his/her participation in the study', 'which may complicate the AtaCor EV-ICD Lead System', 'subclavian arteries', 'months,|Reported', 'suitable for evaluation as the target lesion', 'Group 4)||Each healthy', 'is unsafe', 'unable to undergo a', 'medically-acceptable', 'space-occupying lesion', 'non-decompensated', 'ALK negative', 'uncompleted', 'age;|Pathologically confirmed', '①', 'radicular LBP', 'culprit lesion,|The', 'immunoglobulin E (', 'high-throughput', 'poorly-controlled hypertension', '2015);|Nucleic acid test', 'influence insulin sensitivity', 'stimulation', 'Swan-Ganz catheter)|Metallic fragments', 'with curative intent', 'systemic steroids).||NOTE', 'TIMI)', 'platinum-containing regimens', 'ST wave', 'pelvis|Poorly controlled', 'related to CKD.|Dialysis dependent', 'single-barrier form of', 'first-cycle studies', 'interleukin 2 [IL-2]', 'Arm', 'lesion.|American Joint Commission', 'Down syndrome|Children', 'on dialysis|Organ transplant', 'distal end of the target lesion|The target lesion', 'sauna', 'remains stable', 'AGC diagnosis', 'glutamic aminotransferase (ALT)', 'protocol-specified inclusion criteria', 'insulin|Uncontrolled intercurrent illness', 'peri-articular', 'full Hamilton Depression Rating Scale', 'suitable for participation after comprehensive evaluation|5 Refuse the treatment', 'Epstein-Barr virus', '≥3 years before the first dose of study drug', 'effective form of', 'oral', 'from previous surgical', 'neuro-oncology', 'acute phase.||', 'mild to moderate stress', 'Paoli-Calmettes Institute|Signature of the informed consent specific to the PANDORE-PANC study|Patient affiliated to a social security system', 'ruled out of the study', 'neurological pathology|Current', 'non-compressible', 'study|Regular use', 'Pre-Admission Clinic', 'any other reason', 'reduction of the lateral joint space', 'ER -', 'study;|Acute', 'forces undercover units in the Israeli army.|Are fluent', 'Grade Ⅱ', 'central overread', 'non-commercial panels', 'VR headgear', 'a', 'Early Stanford', 'connective tissue disease;|uncontrolled diabetes;|uncontrolled', 'Mycobacterial', 'meeting this criterion', 'low level microsatellite instability', 'non-contrast cardiac CT', 'CMV end organ disease', 'index knee|Previous', 'hormone treatment;|pregnant', 'medically-accepted method of birth control', 'lasting for more than 6 months', 'exhaustion', 'central nervous system drugs', '1);||Stage Ib Group', 'dual', 'psychosomatic', 'discrimination contribute to your', 'inoculation site', 'implant related surgery|Surgery', 'increased', 'early-onset', 'upper limb arterial access.||Patients', 'Italy', 'increase risk', 'DORIS remission', 'Tetrahydrocannabinol', 'age', 'distal-pancreatectomy', 'plasma-derived FIX protein products', 'Cheyne-Stokes Respiration', 'newly diagnosed', 'Non-professional athletes', 'hemodynamically significant', 'diabetes):||Hemoglobin', 'low frequency', 'surgery.|Uncorrectable', 'unrelated to menses)|Have a', 'new diagnosis', 'assisted laparoscopic', 'bone-setting treatment', 'suitable for this study;|Previous major surgery', 'dampness syndrome.||', 'IV|acutely thrombosed haemorrhoids|patients', 'angina|Clinically significant', 'insulin type 1 diabetes', 'over', 'middle abdomen', 'EGFR', 'primary advanced', 'air.|marked dyspnoea', 'Insulin Infusion', 'under the curve reference values', 'Modic I', 'Opadry II Blue [hypromellose', 'hips', 'index knee|Radiologic', 'required hospital admission', 'Diagnostic and Statistical Manual for Mental Disorders-Fifth Edition (DSM-V', 'Mepolizumab|Allergen', 'alcohol intake', 'Stage IIIA', 'known to affect colonic motility', 'requiring medical treatment|Medical conditions', 'neuro-ophthalmology', 'first-ever ischemic stroke', 'toxic symptoms', 'upper gastrointestinal tract', 'life-saving', 'higher.|Clinical', 'Narrow iridocorneal', 'peri-implant marginal bone loss', 'hypothalamic-pituitary-adrenal axis.|Patients', 'lumbar region which could prevent the lumbar puncture', 'severity to polysorbate).|Has', 'mouth rinses', 'suitable for nasal administration', 'C-Mill harness contact', 'Primary Hyperparathyroidism Pregnancy', 'investigator.|Patient group', 'site of injection', 'lifestyle|Body-Mass-Index (BMI)', 'meaning curative treatment', 'wearing glasses', 'None - county-level vaccine', 'DSM IV TR®', 'interval', 'grade II or greater', 'HIV)||Clinically significant', 'mental health to fill', 'First-year', 'infected', 'relapsed', 'inadequately effective after the minimum treatment', 'rubella vaccine', 'non-benzodiazepines', 'TNF-α agents', 'primary treatment - A', 'non-hematopoietic organ function:||Renal function', 'sustain', 'successfully completed the DBP', 'implantation of a biventricular pacing system', 'device', 'stage 1-3.|No indication', 'ICD-10-CM', 'could justify the syndrome', 'reported', 'protocol-defined inclusion/exclusion criteria may apply', 'upper limb study', 'full six-month research period', 'diagnostically relevant', '2016)35|Acute', 'hearing aid', 'inherited', 'durable LVAD|History of chronic dialysis|Pre-existing', 'radically treated', 'months|Age 18+|Enrolled', 'toxicity related', 'Diagnostic and Statistical Manual of Mental Disorder (DSM V).|For the group without', 'hair', 'site of TSS attachment|Subject is pregnant', 'Prader-Willi)|Eating', 'emergency surgery|The bowel stricture', 'mono-infection|Parasitemia level', 'NYHA', 'use|Self-reported', 'curatively treated', 'suitable for definitive therapy', 'Wood units|Red blood cell alloimmunization', 'Oxford University student', 'moderate stress', 'iRECIST version (v)1.1 assessment', 'femoral neck', 'high rate', 'stage IV features', '-0.50 to -8.00 D in each eye', 'self-identified Hispanic/Latinx', 'infection;|Uncontrolled', 'Müllerian', 'reoccurring', 'hormone receptor- negative', 'Non-cirrhotic', 'intra-orbital debris', 'unknown risk to a developing fetus', 'interferes with the capacity to understand', 'primary cause of SE', 'complicating', 'enteric bacterial overgrowth syndrome', 'thinnest point.|Known sensitivity', 'infantile onset disease', 'At term', 'worse than usual', 'site PIs.|Unresectable', 'Excessive', 'Stevens-Johnson Syndrome', 'Stage ⅠB', 'history)|current', 'stroke unit of', 'deemed to require', 'patients;|Received', 'minimally invasive gynecologists', 'NGS)|Age', '≥CTCAE Grade 2|Major surgery', 'NRS pain score', 'plausible', 'IFNγ pathway (', 'kosher', 'non elective', 'compound,|Who', 'moderate to high', 'irradiated', 'surgery|Able to play games', 'myelodysplastic disorder.|Positive test', 'Full term', 'XELOX|Severe', 'hormone receptor', 'ove 40 severe', 'early stage of chemotherapy', 'Enterobacter spp.', 'office BP', 'non-small cell lung cancer.||B.', 'subsegmental PE', 'site of cannulation', 'sacroiliac joint surgery;|Found', 'non cardiac', 'could interfere with absorption of study treatment.|Concurrent hematologic', 'radiologically stable.|History of', 'systemic therapy.|8', 'tyrosine', 'PD-L1 and', 'ascending myelopathy phenotype', 'Central nervous system', 'index level shows stenosis', '≤Grade 1', ""non-Hodgkin's lymphoma(NHL"", 'LI-RADSv2018 criteria', 'American Joint Committee on Cancer Classification', 'study.|Chronic uncontrolled', 'muscle degeneration', 'interferes with walking|Pregnant', 'augment', 'speaks English', 'highly reliable', 'exception of:||Palliative', 'awakening', 'intrauterine device.|Diabetes', 'unregistered', 'absent', 'daily', 'manager', 'researcher considers unsuitable to participate in this study', 'clinically-significant', 'grade 8 literacy level', 'stable', 'mimic PMR', 'offices', 'designee', 'documented', 'Non-Squamous', 'non-squamous NSCLC.||Patients', 'non-dependent', 'midline|Physical findings', 'posterior', 'IWG 2006', 'large-area', 'wild-type tumors', 'Clostridium difficile infection|Known pregnancy', 'amenable to radiation therapy', 'platinum-therapy', 'suitable for participation in the study to receive ICP-332', 'assess', 'face-down) position', 'mustard greens', 'communication|myocardial infarction', 'grade III or IV thrombosed external', 'full time-employment.||', 'Diagnostic Interview-Revised.|Participants', 'implantation of the device', '1st degree relative', 'region|another aetiology of neuropathy|previous allergic reactions', 'PD-L1 immunohistochemical test', 'intervention;|Presence of tendon', 'discharge through', 'minimally invasive technique', 'contagious', 'some degree', 'ORA-BLEND', 'MPH formulation', 'high resolution computed tomography (HRCT) scan', 'thoracic spinal cord Emergency operations', 'attenuated', 'hypotension|high grade', 'could jeopardize compliance with the protocol.|Major trauma', 'pulp', 'Transfusion', 'local treatment;|4', 'supra-esophageal manifestations', 'steps|Self-reported', 'maintain recommended blood Phe levels', 'Serratia spp.', 'unclear origin', 'first time;|aged ≥60 years;|been able to communicate simply in writing', 'locally advanced/inoperable', 'dive', 'unprotected', 'under general anesthesia.||', 'Included journals', 'index date|2. Enrollment in Medicare Part A, B', 'G6PD deficiency)|Having', 'non-keratinizing carcinoma', 'per the 2016', 'non-smoking|BMI', 'diagnostic criteria', 'surgical treatment.||', 'impacting the objectives of the study.|Positive', 'full understanding in participation of the study', 'amenable to locoregional therapy', 'could impair participation in this study|History', 'far-infrared radiation', 'relationships with any member of the research team.|People with known', 'ipsilateral pleural space.|Ipsilateral thoracic', 'NMDA receptor.|Cohort', 'infants|Receiving', 'protocol-required', 'clinically relevant electrocardiogram (', 'insulin x glycaemia/22.5', 'severity of the heart disease|Admitted', 'meningeal', 'uric acid', 'intra-uterine devices', 'metabolism-related', 'metastasis|Endoscopically non-accessible mass|Pregnant', 'inhaled albuterol|The parent', 'between menarche', 'age;|Body mass index', 'Relapse occurs', 'false-positive rate', 'could influence the study outcome', 'highly effective contraceptive method', 'mastectomies ff', 'C)|Severe', 'PD-L2).|Radiation therapy', 'non-brain sites', 'outside', 'utilized', 'elevated', 'breastfeeding.|Active', 'radically resected', 'staged).||', 'self-report).|Currently', '3rd edition).|Experienced long lasting and frequent', 'femur fractures|Open', 'genital area (', 'eligible.||Severe', 'visits.|Adequate', 'Non-clinical faculty members', 'IDH2', 'extra-CNS disease', '3,|Morning', 'uteri', 'full scale intelligence quotient', 'non-magnetic resonance', 'between donor', 'substantially affects ability to safely complete rehabilitation', 'photo-sensitive epilepsy|Visual', 'extending beyond the rectum', 'self-reported sensory motor disorders', 'Non-IRA stenosis not', 'locally-advanced', 'influence pupillary reflexes', 'CSF-1', 'Heart Age estimation', 'injury|Post-operated', 'index date.|Participants', '≤2mg daily of', 'maxilla', 'potentially nephrotoxic drugs', 'right sided', ""mild Alzheimer's diagnosis"", 'inter-current illness', 'chemo-radiotherapy.|Prior', 'post-traumatic', 'Lung Bulla', 'coordinated', 'hip joints', 'back|Possible raised intracranial pressure', 'PD-L1 inhibitors', 'suitable for the period after end of trial', 'Calgary depression Scale item', 'alcohol', 'non-biologic investigational drugs', 'ocular rosacea', 'Systemic anti-cancer therapy', 'femoral bone', 'secondary - Disease status', 'effective methods of birth control beginning', 'mucopurulent', '3-10|Age', 'wide-field radiotherapy', 'lateral', 'porto-systemic shunt surgery', 'non-pregnancy', 'without lipiodol', 'non-surgically resectable', 'below the ULN', 'Stage 2-', 'with the Chronic Kidney Disease Epidemiology Collaboration formula', 'stage 3a)|Hemoglobin', 'bacterial', 'component', 'met|Uncontrolled', 'on room air', 'HPV', 'constraints of follow-up defined', 'radiologically grade 2 or higher', 'humeral greater tubercle or glenoid cavity|Obtaining informed written consent||', 'shock|coma|severe', 'self-identified', 'Stage I', 'suitable for treatment|Have been treated with antitumor agents', 'minimum 2', 'any related', 'secondary to medical cause o', 'siblings', 'index lesion', 'suitable for the treatment of this study', 'mismatched unrelated', 'replicating', 'central retina', 'first-born child', 'punctual', 'less|H&Y', 'age;|clinical diagnosis', 'mg/24', 'interventional requirements.|Be pregnant', 'grade II or higher', 'unknown onset stroke', 'African American""|Uncontrolled', 'primary health care', 'non-prescription medicines', 'clinical', 'complete remission', 'Tears', 'on room air if there is any clinical indication for determination.||Exclusion Criteria||Non-elective', 'cardiac rehabilitation', 'flu-like symptoms', 'allowed.|Active', 'clinically unstable condition', 'high-resolution', 'TB).|Serious', 'glutamic oxaloacetic transaminase', 'physical', 'drug-related', 'Stage 1.5-', 'secondary to breast cancer treatment|The participant', 'prophylactic use):||Blood routine', 'suitable for participating in this trial.||Subjects with', 'Type II Diabetes|Unstable', 'narrow angles', 'H. pylori when', 'Cytomegalovirus', 'amenable for PCI treatment', 'PD group only)|diagnosis', 'de-immunization', 'Class IV', 'long-term use', 'Ш', 'post-traumatic OA', 'alter the absorption, distribution', 'non-heling wounds|Wagner', 'low dose prophylaxis|known immune disorders', 'site investigator.|Assessed', 'although', 'suitable for starting standard of care combination immunotherapy', 'Nutrition Risk Screening 2002', '4|Secondary', 'bradycardia|Patients', 'few than 5 studies', 'origin', 'high-dose corticosteroid', '≥CTCAE grade 3', 'mild to no symptoms', 'NON-CNS', 'PD for more than 3', 'periapical radiolucency|Furcation', 'follicular-stimulating hormone (FSH) levels', 'deemed more', 'in the head and neck region', 'TIMI grade 0 and inferred occlusion time', 'ulnar', 'insufficient data.|Victims of assault', 'castration level, PSA increases', 'non-compliant', 'Vumerity', '3-gene', 'under general anesthesia|Disease', 'tumor-associated edema', 'fibromyalgia criteria', 'secondary headache disorder(s) apart from', 'mild to moderate acute COVID-19 cases', 'adequately completed', 'interventional', 'under surveillance.||Patients', 'under provocation', '1)≥18;|2', 'non-medical students', 'extraction socket to the crest of the alveolar ridge', 'April 2020: For the second half of the study', 'ventricular outflow tract gradient', 'could not collect feces|the quantity of fecal samples', 'extraction-required', 'Diagnostic and Statistical Manual of Mental Disorders-fifth edition)', 'non-GCB', 'could cause the participant', 'respiratory', 'between sorafenib', 'traffic vehicle', 'permanent guardianship', 'TAU', 'ACR-EULAR classification', 'adequately treated', 'non-invasive testing', 'refractory to', 'severity', 'platinum-', 'QTc>470 ms', 'admitted', 'diagnosed by the respective specialist.|That the subject agrees to participate in the project by signing the informed', 'Moderately Ill', 'cerebellar', 'non-culprit lesions', 'intestinal', 'between -0.75', 'GM-CSF', 'successfully completed the operation', 'surgery)|Therapeutic', 'forced', 'M2 morphology', 'Rome III criteria|Patients with any condition', 'clinically stable', 'admitted to', 'auditory', 'folic acid', 'etc;|Inadequately controlled', 'Minimally invasive procedures', 'woman|ASAII-III|Patients', 'any grade. Non clinically significant', 'subjective', 'narrow anterior chamber angles', 'venipuncture;|Confirmation', 'higher.|Severe', 'ankle-brachial index (ABI)', 'severity of', 'enrollment.|Liver', 'sarcopenia', 'Rome IV', 'interfere with cooperation with the requirements of the trial.|Patient', 'highly effective contraceptive', 'injury.|Single-level injury|Minimal surgical incision.||', 'subunit 10A', 'MDRD calculation.|Individual', 'antihypertensive medication.|Significant', 'lasting 28 days ±4 days', 'histotype', 'non-CNS', 'beverage', 'tuberculosis|Contagious', 'interpreter services', 'Fibromyalgia Symptom Scale', 'non-contributory', 'Post COVID-19 Functional Status Scale', 'non-infectious', 'preclude adequate absorption of', 'present)|Seborrheic', 'secondary tricuspid regurgitation', 'contraindications|Structural heart disease|Corrected QT', 'pegvaliase-pqpz', 'ATXN1', 'between 2019-2022||', 'therapeutic', 'requirement for hearing aid on', 'Non-melanoma skin', 'great arteries', 'moderately differentiated;|The', 'generally refers', 'regional', 'surgery targeting bone metastases', 'related to previous', 'insulin-', 'aving completed the', 'researcher thinks it', 'stage 1 palliation', 'may significantly affect drug absorption, distribution, metabolism and excretion.|Have', 'PD patients:||45 years', 'allowed.|Uncontrolled', 'TENS application site|cancer|cardiac pacemaker|allergy', 'digestive', 'lymphopenia', 'specifically defined', 'non-adherence to the study protocol|active knee inflammation|range', 'melanoma|Locally advanced', 'amenable to treatment', 'Relevant', 'pregnancy|Self-reported', 'anatomical anomalies', 'low risk', 'Imvamune', 'may significantly affect vision', 'myopic', 'prescription', 'psychiatric disorders.|Prisoners.|Minor', 'patient|Patient', 'cross-matched', 'moderate-severe', 'Lung for Carbon Monoxide (DLCO)', 'can benefit', 'instead', 'intra-articular steroids', 'influence the investigation|Systemic therapy', 'ECOG-PS', 'lack effective treatment methods.|(6', 'requiring HLA', 'connective tissue disease (CTD)', 'stably controlled', 'meets 1 of the following', 'non-nicotine-based', 'Profound', 'IHC(2+', 'lactating|Leukopenia', 'Uncomplicated', 'complement', 'initially', 'hematopoietic system', 'Philadelphia', 'highly effective birth control measures', 'Stage IV pressure ulcer', 'speak', 'any systematic disease', 'Burnout syndrome criteria', 'islet/pancreas', 'very low', 'older|History', 'high', 'living donors.||', 'American College of Sports Medicine', 'single-food', 'suitable to use the test product for', 'stage 3', 'SYSTEMIC', 'CMAM guidelines', 'potential', 'highly-effective method of contraception.|Signed written informed consent', 'organ transplantation);|No', 'DW-MRI', 'non-FMT care.||', 'Type II', 'LV-free wall', 'radiological manifestation', 'intra-cerebral pressure', 'site of measured disease by', 'Anti-tumor treatment', 'major', 'suitable for clinical research', 'stage IV', 'untreated', 'pretreatment timepoints', 'non-lactating.||', 'postoperative intraocular hypertension', 'C-SSRS', 'HMA monotherapy', 'index date', 'schedule.|Able to swallow medication.|Subjects', 'unknown cause', 'MRI|Severe', 'intracerebral clip', 'definite Hp infection', 'anomalie del tratto respiratorio', 'non-healing wounds', 'stage 4+ chronic kidney disease', 'suitable for topical treatment', 'insulin preparations', 'sympathetic nervous system', 'mild to severe', 'still', 'upper-limb disorder|Major hearing/visual', 'therapeutic devices', 'drug induced', 'SMA III', 'vegetables high', 'Amenorrhoeic', 'primary prevention.||', 'conjunctival', 'spastic phase.|The degree', 'autoantibody-associated', 'dbGaP-based', 'long diameter > 15 mm', 'PaCO2≥50mmHg;|Similar', 'emergency room alive||', 'secondary to schizoaffective disorder', 'thiazide-like diuretics)|Mineralocorticoid receptor', 'IgE.|Uncontrolled', 'achieved|surgery scheduled', 'grossly', 'months,|severe', 'successful', 'At Risk Mental State (CAARMS)', 'considered only if there is definite progression [see Appendix 3 for the definition of measurable lesions', 'other stones.||', 'ALK fusion oncogene|Symptomatic', 'TAVI||Concomitant', 'anastomotic sites', 'UV-rays', 'months;|Unilateral', 'non-interventional) study', 'Sepivac', 'satralizumab|Active', 'sex.||', 'DoD-VA criteria', 'tendinopathy|At', ""American Diabetes Association's definitions"", 'grade 1-2', 'stable weight', 'In terms of population||Pregnant', 'use||Regularly', 'ISTH BAT>3', 'preclude treatment', 'ureter', 'resisted', 'under 50 minutes', 'early 2nd trimester', 'non-subfoveal', 'radius', 'dramatically', 'low-risk pregnancy|Lives', 'ROME IV criteria for IBS', 'upper airway tumor', 'Hepatic', 'sleeplessness', 'MRI|Localized', 'catchment area of the clinical study facility', 'old;|Active', 'controlled by alternative therapy alone', 'in 2020-21|Age', 'CMV-seronegative', 'study;|Allergy', 'pain', '3 criteria', 'non-advanced', 'Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (', 'robot', 'current', 'visualized', 'genomic risk of', 'Glutamic Oxaloacetic Transaminase (', 'FR', 'suitable for direct vision internal urethrotomy;||14', 'Diagnostic Criteria', 'excepted', 'functioning', 'non-cooperation|severe', 'II.|scheduled for elective', 'injection site', 'MDRD method', 'histologically-confirmed', 'baseline.|Co-existent ocular disease', 'topical', 'D cardiac disease', 'locoregionally advanced', 'in-person||', 'non-inclusion criteria.|NI-7', 'ocular surface staining||Schirmer', 'one level disc prolapse.|≥', 'pre-diabetes)|Inability to comprehend', '68Ga]Ga-PSMA PET/CT', 'neoadjuvant', 'recurrence', 'Black', 'American Diabetes', 'Developmental', 'large vessel stroke|Functional score (mRS)', 'protocol-related procedures', 'events.|Important', 'version 2.2020', 'PAP-causing disease', 'precluding', 'immunosuppressed', 'culprit lesion', 'extrinsic causes', 'Neuro-oncology biorepository for archiving of', 'Grade 2 sensory neuropathy', 'leiomyosarcoma.|Previous', 'non-compressible vessels|Diagnosis of CLI', 'dependence', 'nomads', 'uni', 'prescribed', 'ocular surface|Any structural change', 'SINGLE-ROOTED MAXILLARY', 'first dose of study drugs.|Known hypersensitivity', 'non-colon', 'C13', 'IGG4-related disease.||', 'ALK-negative', 'Burkitt', 'buccal CEJ to the depth of the buccal', 'trastuzumab', 'successfully performed', 'lower blood glucose', 'as:||Pre-menopausal', 'COX- 2', 'lowered', 'in stomach', 'screening|Isolated', 'highly communicable diseases.|Those', 'FDG-PET avid disease', 'C1-C5|Demonstrate', 'Clinically unstable', 'sitting', 'dependence.|Co-morbid', 'selected age range|children', 'Primary Care Health Centre', ""could jeopardize the subject's safety"", 'upper gastrointestinal tract surgery;|Presence', 'subcortical', 'study|Received', 'year', 'peri-procedural period|Edema', 'suitable for elective', 'imaging TCD', 'sharp', 'medical unstable conditions', 'moderate to severe intellectual disability', 'insulin daily|Uncontrolled hypertension', 'history;|increased blood', 'Clinical', 'prostate.|High', 'IDH-wildtype', 'uncorrected', 'primary result was', 'peri-apical', '1;|Prohibited', 'Grade 2 or 3', 'non-HBV', 'few minutes', 'Non-vasectomized', 'disease', 'jugular', 'besides', 'castration-sensitive prostate cancer', 'upper jaw] only', 'suitable for the study drug|3', 'Stable', 'Salmonella spp.', 'site of needle punctures', 'osseointegrated', 'transsubclavian', 'on room air||', 'subsequent anti-dsDNA', 'sitting position|Full comprehension', 'IRS', 'primary level and above C.', 'objective fever', 'suitable for recruitment after investigator evaluation', 'prognosis', 'live-virus vaccination', 'Metabolic', 'differentiated', 'high-dose methotrexate-based', 'large vessel', 'between March 2022 and March 2023.||', 'in uncontrolled', 'advance', 'genitofemoral area', 'Definitive', 'other individual', 'quantitative assay;|Patients', 'following:||Serum M-protein', 'refractory to standard over-the-counter medications', 'worsens', 'test treatments|Pregnancy', 'DNA-based', 'adeno-associated viruses', 'screen', 'low dose spinal anaesthesia', 'Porto criteria [6]|Aged', 'Forty -Two patients', 'intracerebral clip|Pregnant', 'Non-surgical sterilization', 'simultaneous', 'non-culprit vessel', 'Kenny-Caffey syndrome', 'IBS-C', 'prescriptions', 'secondary headache', 'community-acquired pneumonia', 'chemoradiotherapy.||Specific exclusion criteria', 'seriously abnormal laboratory examination', 'booster dose of the Pfizer', 'index', 'new york health association (NYHA) class II or higher', 'gun).|History', 'chemoradiation', 'glutamic oxalacetic transaminase(AST)', 'under SO|Recurrent', 'prostatic urethra', 'IgG) replacement', 'tested by MinerVa MRD assay)|Pregnancy test done', 'severity of the response', 'could', 'suitable for the study;|Any active infection', 'organ function.||', 'contraceptives', 'permitted', 'implantation of a', 'GCH1', 'Hg)|Current severe', 'second-line|Presence', 'mild to moderate systemic', 'AWGS 2019 consensus update', 'days);|insulin-dependent', 'clinically abnormal', 'Tako-tsubo syndrome', 'skin testing|Renal', 'low-quality OCT', 'histological findings.|Male', 'grade 2 or higher', 'registration|Acute', 'lower limb functions', 'life-threatening pathology', 'non-anti-tumor', 'youth assent||', 'self-report)|age', 'single-strap', 'excised', 'cranial', 'Non-physicians', 'ankle level|If', 'peripheral nervous system disorder', 'index catheter ablation', 'under bronchoscope|Non-visible lesions', 'Tested', 'suitable for the patients participating in this trial', 'papain', 'American Joint Committee on Cancer (AJCC) eighth Edition', 'non-cancer-related', 'site reaction', 'non-target vessel', 'treatment|complex', 'primary tumor.|The patient is', 'significant', 'very uneven', 'clinically-indicated', 'Ankle', 'positive;|Other', 'nucleic', 'KRASG12C mutation', 'could interfere with cognition;|Any major', 'upper urinary tract', 'under stable glycemic control', 'volunteer services)||For ROADmAP RCT', 'Type II diabetic', 'dyspnea|current', 'primary systemic therapy', 'PD-L1-positive', 'ACR criteria)|Grade 1 to 3 Kellgren-Lawrence femorotibial', 'non-prescription supplements', '≥5|Intra-articular injection', 'low preference', 'EGFR-cMET double antibodies', '3 fish oils', 'Non observance', 'Low-risk pregnant', 'CMV DNAemia - peripheral CMV DNAemia', 'HEP B', 'low doses of', 'successfully eliminated', 'extremely high', 'Nissen', 'worse than leg pain.||', 'diarrhea;|Clinically significant', 'healed.|Obvious', 'randomization||Asthma-related', 'unhealed toxicity', 'under 18|Patients', 'poorly controlled headaches', 'any other stimulation device', 'sedentary', 'neurological disease,|A recent surgery,|A difference', 'mental health conditions', 'computed tomography;|Have been', 'self-report)|Adequate vision', 'speak English||Fully vaccinated', 'non-cleft craniofacial surgery', 'primary tumour)||', 'Fredericia criteria (QTcF)', 'Non-Ryan White Clinics|Clinics', 'general anesthesia', 'Articles 1121-6 to 1121-8 of the Public Health Code.|Subject', 'dietary regimen', 'insulin secretagogues', 'intra-abdominal abscesses', 'auriculoventricular block.|Pregnant', 'Grade 2 or lower', 'infarction;|②', 'implement', 'multiple gated acquisition (MUGA) scan', 'increasing dose', 'accessible', 'subjective symptoms:||Visible', 'primary health care center)||Inclusion', 'stage 3B', 'mental health services', 'first-generation', 'sustained', 'Equal numbers', 'medication)|Articular cartilage lesion', ""lasting longer than 3 months' [16]"", 'substance use', 'other products', 'reduced crown length', 'likely to be exacerbated', 'Surgery,|obesity', 'test|Current', 'implant-based reconstruction', 'neck judged unsuitable for the procedure', 'injection site.|Known allergy to any of the', 'correct', 'middle cerebral artery supply area', 'low-moderate level', 'between 05:00 and 10:00, based on', 'Institut Pasteur of Lille|Available to follow', 'grade 1-3A)|Marginal zone lymphoma', 'months.|Refractory severe', 'Community-based organization sites', 'specifically targets T cell co-stimulation', 'emotional trigger', 'total hip replacement|informed', 'undetected', 'preclude apheresis procedures', 'pericardial disease.|Acute coronary syndrome', 'CRITERIA:|Histologically-', 'histologically free', 'clinically significant abnormal safety', 'data.|Patient', 'ACS)||High fistula', 'PD-L2 agent', 'ureteral', 'in-office procedure', 'perioperative', 'exfoliated', 'full-mouth bleeding score', 'below zero station||', 'CVD risk calculator', 'etc.|Pre-existing', 'FIM);|EDSS score', 'Vascular', 'nonsyndromic TAA;|Signed informed consent;|Patients', 'light-based', 'conjunctiva', 'ustekinumab)||Exclusion criteria', 'heart-failure|Secondary causes', 'Rome IV Criteria|Additional criterion', 'non-specific neck', 'pneumonia|Malignant', 'continuous', 'medically significant', 'index shoulder.|Enrolled', 'low energy|Active smokers', 'National DPP;|Not comfortable', 'progressive', 'systemic treatment|Known', 'proximal surface', 'perpendicular', 'may receive red blood cell transfusions)||Adequate Liver Function Defined As:||Total', 'South Kingston', 'or||failed use', 'mild COVID-19 upper respiratory tract infection', 'no measurable lesion', 'displaced', 'indwelling', 'Lublin criteria', 'knees;|Clinical manifestations', 'stage IV cancer', 'Evolut', 'non-permitted', 'upper arm circumference', 'spondylolisthesis|Spinal', 'female|Consultant', 'glutamic-oxaloacetic transaminase', 'initially treated', 'III|undergoing', 'anti-synthetase syndrome', 'upper extremity|Injured unaffected', 'ipsilateral pleural space.|History', '3rd day, 10th day,', 'ST segment', 'maxillary', 'month.|Clinically significant', 'EOLC|Previous', 'under spinal', 'lack of detection', 'full dose', 'behavioural difficulties', 'extended endopelvic resection', 'Untreated', 'cardiac-related', 'neck', '3.Type 1', 'only|Clinical mobility', 'been', 'non-fulminant', 'mouth facial', 'cardiologic', 'Acute respiratory distress syndrome,|any ventilated', 'low birthweight', 'non-rheumatological inflammatory diseases', 'in hip', 'C-SSRS)|Motor condition', 'between the ages of 18- 45|Having', 'American Joint Committee on Cancer [AJCC] staging manual version 8.0)', 'NCCN 2020 classification)|No', 'Cruciate Ligament Reconstruction', 'study.|Self-reported', 'neurosurgery unit', 'incompletely healed', 'related to sexual intercourse/contact', 'clinical judgement.||o', '≥4 cycles', 'expectant', 'blast crisis|Intermediate', 'interfere with cooperation with the requirements of the trial.|History of bleeding diathesis', 'vital sites', 'may not offer additional supportive', 'non-investigational', 'failed', 'PD-L1 status|Participants', 'non-operatively|patients', 'pathologies|Pregnant', 'communicable', 'Intellia-sponsored', 'injectable', 'genes most strongly', 'mellitus|Started SGLT2 inhibitors', 'lower limb motor sequelae|Patient', 'suitable for the VDyne System', 'Diagnostic and statistical manual of mental disorders -V);|Motor difficulties', 'arrival time', 'non-specific binge', 'staff|Self-reported', 'Midface area', 'surgeon|Previous', 'atopic', 'interferes with their normal activities', 'imaging-confirmed', 'metabolized through CYP3A4/5|Is currently', 'immunosuppressive therapy.|Mental illness', 'could cause knee pain|Evidence of', 'insulin delivery', 'stenotic degree', 'Probable', 'Thero2-01S22', 'sulfonamides', 'insulin pump therapy', 'suitable for cementless acetabular', 'full understanding of the content, process', 'related to', 'between January 2016', 'esophageal gastric junction.|Necessary clinical information cannot be provided during the research process', 'long-term hormonal therapy', 'primary care)|Received', 'rare driver alteration', 'old', 'meeting these inclusion criteria forms the exclusion criteria', 'Madison', 'systems;|11', 'Service users||have co-morbidity', 'stable-dose', 'unmanaged', 'longest diameter', 'performed', 'prophase', 'study.||Dose', 'non-target lesion', 'ICF.|BCG', 'full-term neonates:||Neonate', 'full age', 'existential', 'Stage 2).|AKI', ""Diagnostic and Statistical Manual of Mental Disorders [DSM-5] Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult)|Participants who's 1st degree (blood) relatives"", 'weeks.||Admitted to the', 'equivalent);|Immunosuppressive doses', '20 minutes', 'low-back-pain', 'under observation', 'High grade follicular cell lymphoma Grade 3b (3bFL)', 'related to underlying', 'exception', 'worse than 1.0', 'electronic tablets', 'block;|previous', 'm-2|Scheduled for elective day-case lower abdominal', 'percutaneous', 'coagulopathy.|Pregnant', 'classes III', 'knee', 'Eligibility:||Unrelated donor', 'alter the absorption of study drug|Patients', 'lutetium Lu 177 dotatate', 'mid-sleep on free days later than 5:00 AM on the Munich Chronotype Questionnaire (MCTQ', 'biochemically', 'nutrient drink', 'which affects balance', 'pregnancy.|Parity', 'injuries|Concomitant', 'mild to moderate motor impairment', 'American|Unable to read', 'in general legally non-competent.|Prisoner', 'selected', 'weeks.|Elective', 'reproduction.|possible', 'pocket', 'proportion of sclerosis', 'maintenance-dose of ATD', 'esophagogastric', 'fixed', 'central nervous system infection', 'regurgitant', 'under forced', 'distal metaphyseal radius', 'suitable for participation in this trial for', 'clinically serious', 'exogenous', 'lymphoplasmacytic', 'non-consenting', 'cytologically.|Failed', 'musculo-skeletal', 'non-protected exposed vessels', 'ongoing', 'mid-portion Achilles', 'injection into', 'rocket', 'preclude contact lens wear', 'preclude the conduct of the investigation procedures|Allergy', 'mild to moderate', 'left main coronary artery|Severe', 'NSCLC:||Stage IV', 'insulin pump system|Subject', 'culprit lesion|Baseline STEMI', 'Possible for positive', 'urinary bladder', 'clinically significance.|Screening positive', 'age|Scheduled', 'moderate to severe dysmotility', 'could cause constipation', 'stated).|Alanine', 'old|After', 'post high', 'gluten|Smoking|Alcohol', 'low-risk prostate cancer', 'chronically damaged skin', 'dexamethasone metabolism', 'emergency', 'Stage 3', 'young girls', 'curative systemic', 'non-surgical weight loss', 'consensus of helicobacter pylori in 2017', 'American Diabetes Association guidelines', 'preparing for pregnancy', 'neural', 'stannous fluoride', 'list ovarian', 'adequate organ function.|Have recovered to ≤ grade 1', 'diagnostic criteria of nOH', 'mild-moderate levels', 'intra-aortic balloon pump - IABP', 'pulse floating', 'nurse practitioners', 'immediate', 'Canadian Armed Forces', 'non-inclusive', 'Epstein Barr virus infections', 'old|Non-elite athletes', 'adequate dose of SSRI', 'full-term)|Completion of', 'transfemoral', 'pericardial friction', 'indicates twin', 'plantar heel', 'insulin pump|On', 'primary driver|Teen', 'non-vasectomized', 'above the upper reference', 'pure variant sarcomatoid', 'defect|Life expectancy<2 years|Inflammatory bowel disease|emergency', 'Metabolism-Related Fatty Liver', 'CHEK2', 'non-reactive', 'insulin-treated', 'fluid，Intrathecal', 'unaccepted', 'EAC)|Clinically staged - cT1-4', 'Doppler ultrasound.|Thyroid gland function', 'laptop', '3rd level', 'hypokalemia|Maternal', 'low-risk', 'JAK-STAT signaling', 'distant metastasis|Planned surgical treatment|Fluency', 'relapse|Symptomatic', 'Stage IIIB', 'nasojejunal', 'hilar', 'first-line targeted therapies', 'latest recorded', 'supplies', 'stage T1N0M0).|Preoperative ultrasonography', 'Memory', 'smear).|Eclampsia|Uncontrollable blood pressures', 'estrogen-containing', 'minimally invasive supracervical hysterectomy procedure', 'wrist', 'critical upper', 'secondary to the formation of new blood', 'only)|Clinically', 'muscle invasive', 'recovery room', 'pins', 'midfoot|Intraarticular fracture', 'metabolic', 'neglected', 'poor spontaneous activity', 'large infarction', 'pregnancy.|Neuro-muscular', 'erupted', 'cortex|mid-cingulate|subcallosal', 'will cause limited cooperation', 'long-QT syndrome.||QTc', 'isolated Class V', 'ACR criteria for the classification of RA||18 years|Both', 'FL3B)|Relapsed', 'm)RNA', 'insulin-like', 'maxilla/mandible', 'surgically', 'highly effective contraceptive measure [defined', 'systemic treatment.||11', 'CSS', 'plasma-derived FVIII concentrates', 'subsequent', 'SYNB1934 formulation', 'slow', 'between 2˚of inversion', 'connective tissue diseases', 'relugolix-containing therapy', 'mild to intermittent claudication', 'age|Histologically confirmed', 'patients|elective', 'stage Ib ⅱA', 'long-term', 'robot-assisted surgery|Patients', 'without curative', 'post-traumatic stress disorder', 'M2 MCA segment', 'mycobacterial', 'calorie', 'full night C-PAP titration study', 'under judicial', 'pain relief', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (PCL-5) score', 'suitable for four separate venipunctures', 'older|Good general health', 'interfere with cooperation with the requirements of the trial.||Is', 'Grade I', 'highly effective (', 'suitable for interview', 'no relief after treatment', 'autistic', 'site investigator||Cohort 2', 'unusual', 'Type A dissection', 'hemodialysis.|Patients', 'ER-positive', 'preclude MRI scanning', 'irregular income|Households', 'low dose metformin', 'stovetop', 'Tanner', 'left main coronary', 'selinexor.|Serious', 'immune related reactions', 'cooling devices', 'femoral artery', 'focal neurologic symptoms.|Have', 'acute toxicity of previous treatment', 'TransCon', 'protocol section', 'articular', 'T3', 'DS|Age', 'preparations', 'Diagnostic and Statistical Manual of Mental Disorders V (DSM-V', 'hysterectomy.|Intracavitary', 'evaluable', 'years|Pregnant', 'upper rectum', 'calculated', 'adeno-squamous cell carcinoma', 'ALK', 'diabetes|English-speaking|baseline', 'edoxaban|Moderate', 'SMI-DOAC combination', 'peri-implant', 'grade 1,2|normal cardiac', 'tingle', 'often-severe', 'low compliance or willingness to take the drugs', 'urinary stones', 'EMTs than paramedics', 'study.|Pregnancy', 'rest', 'non pCR', 'protocol-specified laboratory tests', 'Acinetobacter spp infection.|Incomplete medical records for the following essential', 'intra-cardiac defibrillators', 'radiation-induced', 'standardized', 'meeting the clinical diagnostic criteria of', 'formulation.|Active gastrointestinal bleeding', 'SIRPα fusion protein', 'pure clear cell carcinomas', 'initially gathered', 'archival tissue result||Progression of disease manifest', 'typical symptom', 'cumulative dose', 'H3K27M mutation', 'ACR/EULAR 2010 classification criteria.|For SS', 'diagnostic criteria from the ""Diagnosis', 'non-English speakers', 'between the', 'pericardial effusion|Myocarditis|Participant', 'Swiss norm (', 'tickle', 'disclosed on Health Assessment Form which mean that participant is not healthy|Allergy to lidocaine|Allergy', 'foveal center', 'low flow oxygen', 'asymptomatic', 'infection;|Other', 'PD-L1；|Known', 'non dilated LV', 'having unsafe', 'age||Acute', 'second', 'antihypertensive', 'T790M', '≥12 months.|Is', 'influence gastrointestinal motility', 'post-treatment', 'immunoglobulin G', 'high glucose', 'non-Hispanic Black', 'extremely severe', 'C-reactive protein', 'pneumonia.|Preoperative', 'agitation|Hemodynamic', 'phase II part only) following', 'estrogen-containing contraceptives', 'non-specific conditions', 'Canada.|Current smoker', 'that affects digestion', 'C3-7 multilevel cervical spondylitis myelopathy', 'invading adjacent organs', 'received||', 'large incisional hernias', 'cease', 'highly sensitive', 'could interfere with magnetic stimulation safety (epilepsy', 'malignant', 'precentral', 'meeting one', 'successfully resected', 'after successful', 'anesthetic plan', 'ILAE 2017 criteria|Children', 'BRAFV600E', 'upper limbs.|Congenital', 'Idiopathic', 'venous thrombosis:|Presence', 'ilio-femoral vessel disease', 'absolute increase', 'suitable for surgical treatment|Patients', 'Stage 4', 'full thickness rectal', 'Acutely', 'connective tissue disease', 'could lead to the development of tissue hypoxia', 'preventive methods 2)normal', 'non-inclusion criteria;|refusal of the patient to further examination', 'hemorrhage|Patients', 'histopathology showed', 'mild persistent', 'first-line (1L)', 'Stage 2.5-', 'central nervous system', 'parenteral nutrition|Patients receiving', 'non-ovarian clear cell', 'skincare products (per investigator discretion', 'Duchenne Muscular Dystrophy (DMD)', 'PD-associated', 'angle glaucoma', 'diabetes.|Type II', 'suitable for participating in this trial in opinion of the investigator.|Subjects', 'venous circulation', 'non-culprit lesion', 'cytologically-confirmed head and neck', 'comfort', 'esophageal lumen circumference.|History of', 'unknown risk of adverse events', '5-Fluorouracil', 'Depo-Medrol', 'non-live COVID-19 vaccination', 'non-hepatic origin)|Subject', 'under WHO', 'non-acute', 'medically controlled', 'etc.)|A current episode', 'Ohio Appalachian county', 'invading pulmonary blood vessels', 'intent', 'site of block|allergy to the', 'lumbar-sacral radiculopathy', 'mild genitourinary system infection', 'adjuvant).||', 'dementia-', 'diseases.|Is mentally', 'Sliding', 'supracostal approach|under general', 'any type|Children', 'suitable for the selection', 'cytologically proven', 'moderate to severe erosion', 'fresh samples.|Eastern', 'non-injured upper extremity.|Patients', 'short', 'choledocho-duodenal', 'First Degree', 'first -', 'exhaled', 'student', 'non-symptomatic', 'extrahepatic deposition', 'group -', 'abuse.|Active smoker', 'CB-011', 'institutional guidelines before the performance of any protocol-related procedures.||', 'Pre-eclampsia', 'small-vessel disease', ""3 month|The patient's"", 'proximal tibia', 'institutional guidelines.||Severe', 'pain|Having temporomandibular joint pain', 'implantable progestogen-only hormonal contraception', 'predominant', 'GDM', 'endanger the patient', 'catheter;|Prior', 'presumable', 'influence the drug metabolism from 72 hours before administration to discharge', 'multiple doses', 'treatment area', 'non-resident', 'antidepressant treatment,|Not', 'non-GCB DLBCL', 'low light', 'medication|Symptomatic', 'non-pulsatile tinnitus', 'enrolled|Clinically unstable', 'above second degree', 'CTNNB1', 'first-generation antiandrogens', 'moderate-vigorous physical activity per week|have diabetes', 'tricuspid valve mechanical valves;|cannot understand or are unwilling to give informed consent', 'gadolinium', 'suitable for BOTH determination', 'Socioeconomically disadvantaged', 'nestling fruit', 'spine;|concomitant', 'sacroiliac joints', 'visceral disease|De novo', 'exertional', 'Man - 21', 'interfere with therapy|pregnancy', 'membrane-associated', 'site outside of the urinary bladder', 'stage IV)', 'γ-hydroxybutyrate|Other', 'unmanageable', 'non-culprit', 'located in supplementary motor area', 'site of the block.|History', 'depression.||Main', 'mild systemic disease', 'upper limb level', 'DSM-5', 'second generation', 'phlebotomist|Diagnosed active', 'right-handed;||Inclusion criteria for', 'Non-essential', 'preclude cardiac', 'Depo-Provera', 'non-malignant', 'non-hyperkeratotic', 'endocrinopathies', 'lower limbs', 'visits.|Full-term', 'consumption of illicit psychoactive substances', 'controlled with standard medical therapy', 'intra-cardiac mass', 'Relapsing-remitting', 'NYHA).|Severe myocardial injury：TNT、TNI、CK-MB > 3 ULN.|Accumulated dose of doxorubicin', 'extend length of treatment', 'elective phacoemulsification', 'early gastric cancer', 'non-melanomatous skin cancers', 'identify dominant', 'deemed unresectable', 'IDH1', 'managed per local guidelines', 'mild-to-moderate plaque psoriasis of the scalp', 'GMC component.|Measurable disease', 'site investigator.|Known medical', 'High degree of', 'Intravenous', 'Augmented', 'tuberculosis', 'grade 2 and above determined', 'non-Prentiss)|Concurrent', 'clinically cured', 'self-reported activity levels', 'quantitative detection', 'ocular surface', 'highly effective starting', 'full Achilles tendon rupture', 'intubated', 'unknown origin|Ulcerations/erosions', 'subcostal', 'feels better', 'microsatellite stable', 'unstable', 'non-dominant', 'pregnancy 2', 'limbs', 'large B-cell lymphoma|HHV8-positive DLBCL', 'self-prescribed diet', 'low grade histology).||', 'Dr. Driesen', 'distal interphalangeal joints (CMC', 'moderate to severe', 'central nervous system disease', '|Known', 'well', 'without liver', 'hours;|Diagnosed', 'central canal', 'old|Normal', 'longest diameter of target lesion', 'full-diastolic blood', 'Ehlers Danlos Syndrome', 'Pre-diabetes', 'deceased donors', 'Siblings)||Genetic', 'self-criticism|Meet', 'anti-anxiety', 'contralateral', 'age|Acute', 'non-target lesions', 'regular gynaecologic', 'discharge to hospice', 'successfully received;|2', 'unrelated to the malignancy', 'ISS≥16,|severe', 'NKG2D ligand expression', 'Conjunctival', 'central nervous system disorder', 'meeting 2016', 'vitreous', 'low mood', 'etc.).|Active cancer|Cardiovascular', 'molecular targeted therapy', 'full escalation', ""interferes with the subject's level of consciousness"", 'medically confirmed', 'mild to moderate stages', 'non-enhancing respectable', 'stage III(AJCC', 'stage of decompensation', 'old|Singleton pregnancy|Give informed consent and able to participated||', 'moxibustion 2 weeks before enrolment', 'pacemaker use|Patients', 'incompletely treated', 'non-covalent BTK inhibitor', 'moderate to severe PH', 'e', 'suitable for postoperative radiotherapy', 'Non-small cell lung cancer', 'fresh frozen plasma (FFP)', 'site healed', 'Twins Pregnancies.||Breech', 'site (center heart team).|Femoral', 'months|High grade AV block', 'after remission', 'inhaled glucocorticoid|Vaccination', 'hormone replacement|ELIGIBILITY CRITERIA', 'seizures.|Multiple factors', '160 smokers', 'KMT2A-R status', 'Group 4)||Significant illness', 'derived', 'parent||', 'under 65|Severe cognitive impairment', 'long-acting β2 agonist', 'RX', 'suitable for endovascular treatment', 'ambiguous', 'diagnostic criteria of sarcopenic obesity', 'ankle pain.||', 'ipsilateral', 'spastic', 'demonstration of causality),|Patient', 'cannabis|Self-reported', 'polymorphic', 'etc.|Reported diagnosis', 'lasting for > 48 hours.|Infection', 'non-hepatic disease|History', 'study|Excessive pain', 'hepatorenal', 'non-improving', 'near-infrared', 'peri-implant site', 'restrict the active exercise ability of participants or involve skeletal', 'their general condition', 'Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition)', 'middle cerebral artery M1 segment/distal', 'Non-surgical cervical cancer', 'Non union Bone defect', 'non-live vaccines', 'EF≥50% (', 'legally authorised representatives', 'hyper-functioning', 'CABG|Isolated', 'low dose cytarabine-based', 'non-inclusion:||Chronic allergies|Neurological disorders|cardiovascular', 'between tTG', 'clinically important', 'suitable to join the study;|10、HIV infection;|11、Any situation that the researchers', 'higher than grade', 'MRI|non-visualized nodule', 'on room', 'uncooperative', 'any of its excipients', 'Dutch language|Diagnosed with PCOS', 'surgery|Prominent', 'mellitus|Confirmed ischaemic heart', 'irregular heartbeat', 'intermittent', 'researchers', '=< 21 days prior to registration.||OR', 'low back', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.|Participants', 'mid-gut axis', 'systemic immuno-modulatory therapy', 'B7-8', 'ankle level', 'Histologically confirmed', 'medically effective means of birth control until they have completed their assigned therapy', ""could impair the subject's ability to complete the study.|7"", 'below the malleolus|Target ulcer', 'Type IV renal tubular acidosis|Diabetes mellitus', 'drug addiction', 'mucinous', 'glinides', 'Investigator.|Prior solid organ', 'ICSI|Major', 'suitable for examination', 'non-English speakers.||UGA', 'peri-wound', 'months；|Stable daily dose(s', 'End-Stage Renal Disease (ESRD)', 'vasectomized', 'Axis I affective', 'grade 1to3 b).|Post mastectomy state', 'B7-H3 antigen expression', 'full process of basic immunization', 'iliac arteries', 'investigator.|Pregnant', 'parent(s)/legal', 'proprioceptive', 'oligo', 'non-small cell lung cancer|Age', 'between the carious lesion', 'stomach.|Advanced', 'CD20', 'infrequently', 'suitable for participating in this clinical trial', 'severity to ERT.|Busulfan', 'candidate', 'self-reported daily habit', 'High-dose glucocorticoids', 'stage 4', 'post-thrombotic', 'non-squamous', 'ankle sprain history', 'on room air||Renal function', 'Shwachman-Diamond Syndrome', 'ascertained on', 'issues||Acute respiratory tract infection', 'criteria:||Locally advanced', 'ankle of', 'could significantly affect skin', 'metal fragments', 'interventional Cholangiocarcinoma clinical trial|Patient', 'Sidekick Health app and capable', 'any origin', 'sequential organ failure assessment score', 'primary tumour;|presence of suspicious', 'ethnicity||', 'severity assessment of pneumonia', 'emotionally unstable', '2', 'age|Prisoners|Children|Pregnant', 'retro', 'CYP2C9', 'autoimmune', 'Histopathologically confirmed', 'ICD-10 F19.x)|Presence of medical reasons', 'H2-receptor antagonists/H2 blockers', 'environmentally related', 'ipsilateral ureteral', 'requiring only a steady dose', 'unresolved', 'antigen-based', 'might cause fragile skin', 'Systemic signs of inflammation|B1: Fever|B2:', 'age|Pregnant women|Prisoners|Vulnerable populations', 'colorectal unit', 'participation unsafe', 'interfere with cooperation with the requirements of the study.|Currently participating', 'Diagnostic Arm', 'Grade ≥3', 'non-autoimmune disorders', 'outcomes.10|Non-traumatic cause of pain', 'amenable to surgical', 'under local anesthesia.|Loss of buccal bone', 'Left distal radial artery can', 'age,|Full-time', 'recommended)||Active', 'platelet transfusion', 'could interfere with ERG execution;|For', 'unrelated to gastroschisis|Evidence of bowel perforation', 'disorder|respiratory disorder|metabolic disorder|sepsis|rare disorder', 'intra-epithelial carcinoma', 'low ovarian function', 'Non-endometrioid endometrial cancer', 'greater', 'pure-tone average', 'hospitalised', 'trial.|Cardiac', 'Egyptian ministry of health (MOH) protocol', 'class 4', 'German language', 'interferes with the ability of the patient to participate in the trial', 'non-gonococcal urethritis', 'requiring advanced intervention|Currently participating in another investigational study', 'full dose chemotherapy', 'steno-occlusive abdominal aortic', 'biventricular', 'Continuous IV infusion', 'under AME scheme;|Patients living', 'more||', 'prompted the intubation', 'Non-English speaking|Significant range of motion limitations', 'self-proclaimed', 'distraction', 'American College of Sports Medicine pre-exercise screening tool', 'removed|Vital', 'tanning booths', '2 or greater', 'site investigator.|Blood products', 'Previous', 'irregular astigmatism', 'implement recommended data collection tools.|English speaking', 'reproductive organ|antibiotic', 'can be accurately and serially measured in', 'non-central nervous system (CNS) disease.|If participant', 'suitable to participate', 'thyroidism|confirmed', 'genital bleeding.|Undiagnosed vaginal discharge', 'non-nasal ENKTL', 'immunoassay', 'months|Patient', 'lactated', 'musculoskeletal disorders|cognitive impairment', 'between domiciled periods', 'tested before treatment started Using more than two kinds of', 'gaze-evoked nystagmus', 'lower extremities.|thromboembolic diseases', 'ASAS modification of the Berlin algorithm for', 'trimalleolar', 'irregular menstrual cycle|Pregnant', 'ICD-10 codes', 'suitable for correction with the', 'permit', 'supraventricular', 'adequately treated;|Gastrointestinal stromal', 'non-radicular', 'grade III or IV', 'low ovarian reserve', 'maceration', 'stroke（（In', 'Non-cardiac causes', 'Histologically confirmed initial diagnosis', 'stress', 'Platinum resistant', 'Rome IV criteria for constipation', 'periodontal tissue support.|Occlusion showing sufficient inter-arch', 'microneedling', 'pure tone average (PTA; average', 'clinically severe', 'Somatic Symptom Scale-8', 'mild to moderate COVID-19', 'orthotopic', 'successfully crossed', 'older|Being', '2 degree heart blocking', 'femoral approach impossible|Known severe', 'non-opposition', 'stabilized', 'chemistry.||', 'ankle foot orthosis (', 'age|Patient', 'image-guided', 'Media', 'festival', 'Theo-Dur®', 'on room air by', 'focal', 'lumber', 'Transderm-Nitro', 'caused', 'chronically', 'CP,|who start', 'above.|Clinical diagnosis', 'disease-specific therapies', 'malformed', 'using these topical agents', 'alive', 'locally known standard therapies', 'Receive', 'SCD)|Advanced', 'bi-polar', 'stable MS', 'local use of', 'education|Known', 'stable situation', 'low-potency topical corticosteroids.|No occurrence', 'full therapeutic doses of', 'handicap', 'non-healing wound', 'Screening.||Contraceptive use should be', 'bariatric', 'lethargic', 'ostial', 'any malignant tumor', 'Somatic Psychoeducational Intervention.|Researchers', 'intra-mural', 'sacroiliac joint fixation;|Requires', 'issue|Current use', 'non-Hispanic White', 'Android)|Access to mobile', 'intent|Significant', 'hard drinking|smoking|class', 'non-traumatic hand pain', 'institutional guidelines', 'involve- ment', 'E. coli', 'mid-range ejection fraction', 'serious abnormal', 'HIV-associated', 'other immune-modifying drugs.|Use of', 'may jeopardize the implant', 'requiring the initiation of an anti HER2 containing regimen|First line treatment', 'Traumatic', 'very high', 'muscle relaxant', 'large vessels', 'metabolic altering', 'pregnancy)|Common', 'congenital abnormalities.|Stillbirth', 'isotope scan', 'CT/', 'imaging)|Active', 'complete required forms and willing and able to adhere to the scheduled follow-up visits', 'large screen', 'C3-C6', 'OPG-induced', 'Moderate', 'Gravidas', 'irregular thickening', 'secondary)|History of deep vein thrombosis|Pacemaker|Artificial joints', 'membrane peel).|IOP', 'Swan', 'full-thickness rotator cuff tears', 'Living donor', 'intra-thoracic', 'infection|ED induced', 'unsupervised', 'Index-SC', 'severity than the above will also be grounds for exclusion', 'under treatment', 'esophageal abnormalities|History', 'amenable to surgical treatment|Physical examination', 'suitable for participating in this trial.||Adult healthy', 'basal', 'Non-ambulant people and people with a', 'lasting at least 3 months,|Individuals willing to participate in the study||', 'catheter related', 'central nervous system involvement', 'following:||1st relapse', 'NCI.|Have measurable disease', 'brain', 'rouxii|Patient', 'symptoms', 'F20.x)|Receive', 'depression.|Non-fluent/limited English proficiency|Self-reported', 'Non-pediatric inpatients', 'old|Newly diagnosed', 'suitable for analysis', 'index date|Participants must voluntarily give written informed consent form (ICF)', 'interscapular', 'B7-H3 expression', 'achieved', 'failure', 'musculoskeletal', 'non-resectable', 'African-American', 'mimic IBS symptoms', 'following:||Pain', 'acute effects of', 'cardiopulmonarybypass', 'mild to moderate dry eye', 'CMV', 'Other', 'influence of drugs', 'full age of consent', 'neuroendocrine', 'Significant', 'meniscus tears', 'exercise.|Major concurrent', 'distal intracranial large vessels', 'alter sensor readings versus', 'medium term', 'chronic analgesics', 'inconsistent with', 'upper extremity vasculature', 'unrelated', 'obstructive', 'presumed', 'third molars)|have', 'interferes with skin', 'PHQ-9M', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition', 'osteoarthrosis|cardiac', 'peri-ocular infection', 'COVID19', ""culprit's vessel"", 'AST(SGOT)/ALT(SGPT', 'Non-emergent', 'low grade non-invasive', 'Primiparous', 'core study.|Willingness and ability to comply', 'extend into/involve the small bowel (e.g. those at the ileocecal valve)', 'resolved', 'first-ever', 'Cohort B', 'meeting diagnostic criteria', 'interferes with treatment', 'T3-T4', 'vulvo-vaginal atrophy)|Post-menopausal', 'Unstable', 'tumors|poorly differentiated tumors|poor soft-tissue conditions|neurovascular invasion around', 'related artery (reference vessel diameter', 'etc.;|MRI', 'Turkey', 'relapsing', 'obvious', 'site of sensor implantation.|Plan to undergo', 'grade salivary gland carcinoma Adenoid', 'Refusal|Hemodynamically unstable', 'booster dose).|Participants', '60 minutes of', 'suitable for TEE examination', 'Monochorionic twins', 'stable sexual partner', 'confirmatory', 'and||Good general health', 'low user dependency', 'Gynecologic Oncology at Carilion Clinic', 'provocable', 'lasting ≥30 min；B', 'other sites;|No', 'adequate', 'malformative syndrome|History of', 'age|Intermittent', 'high-quality CBCT', 'TGFBR2', 'Necker Enfants Malades Hospital|Information and consent of holders of parental authority', 'liver-related', 'freshly obtained', 'ADA criteria;|Use of illicit drugs', 'site investigator feels could have an immune modulatory effect.|Use of', 'non-lactating;||', '4.Expected survival time', 'secondary to conditions', 'non-cannabis', 'varicella-zoster', 'SARS-CoV-Ⅱ', 'azole fungicides', 'K3-4||', 'Diagnostic and Statistical Manual of Mental Disorders (DSM) -5 Checklist', 'drug', 'IgG4-positive', 'immunoassay drugs;|2', 'Non-Hodgkin', 'specifically excluded from eligibility.||History of any of the following medical conditions', 'amenable to curative therapy', 'Tilburg Frailty Indicator', 'Medically', 'engaging', 'ME-CCT intervention|Independently living|English-speaking', 'non-', 'molecular typing', 'mmHg).|Uncontrolled', 'unexplained by pressure', 'low attenuation area', 'chromosome', 'hormonal', 'suitable for radical resection', 'teeth', 'POCBP', 'handled', 'unprovoked or|1 episode', 'self-identified LGBTQ+|Any alcohol', 'slides', 'Sleep Laboratory', 'substance', 'abdominal', 'refractory to second-line', 'surgery.|Tumor', 'Esbjerg municipality|Able to write', 'extracranial', 'Type 1', 'High Joint Demand', 'Botulinum toxin', 'ocular/vision diseases', 'Non-squamous', 'PD-L1.|Active autoimmune disease', 'reticular', 'interfering with gingival inflammation', 'menstrual cycle.||hormonal variations related to the menstrual cycle', 'living donor', 'excessive intake of alcohol|Presence', 'chest wall', 'Central Nervous System (CNS) depressants', 'calipers', 'radical', 'near term', 'resective', 'Timed Up&Go (TUG)', 'non-prescription', 'non-elective', 'suitable for the test;|Patients', 'secondary schools.||', 'systemic anti-infective', 'acceptable annual limit established by the US Federal Guidelines (effective dose', 'under oral metformin', 'B7-H3 expression;|(5', 'cytologically-documented', 'vomiting.|Previous', 'unclear etiology', 'infection|Active systemic', 'Rome IV Criteria of functional constipation*', 'highly effective contraceptive measures', 'considered unsafe', 'PD-L1 status|Confirmed availability of representative tumor specimens|Measurable', 'large refractive errors', 'GP Tokyo 2018 criteria.|Surgical decision of inoperable patient (if one or more of the following criteria is met', 'tricuspid valve repair', 'corneal graft|Anticipated', 'trigeminal', 'suitable for participation in the study|healthy volunteers in a similar age group', 'stage IV heart', 'habits,|Patients smoking', 'Table 1', 'ULN);|C-reactive protein', 'RA|Pregnancy', 'rent)|Significant', 'influence their testosterone level.|Anyone taking any kind', 'cancer|Locally advanced', 'toxic effects', 'compatible', 'without curative intent|Patient', 'GI symptom-causing foods', 'notable impairments', 'Beighton score|High intensity resistance training (', 'completed', 'behavioral', 'since 2010|Undergoing ovarian function suppression', 'narrow angle glaucoma|chronic hypotension', 'CMIA).|Negative', 'immune related', 'middle of the night/early', 'clinically significant forms', 'individualized care', 'non-English speaking', 'peri-implantitis|>12 months of follow-up after therapy|Patients managed in our center||', 'stable dose', 'between', 'PP', 'upper extremity|Entrapment neuropathy', 'Related', 'amenable to PCI||', 'asthma,|7-12 years', 'M1 segment of', 'male sex', 'organ transplants', 'non-colorectal', 'specifically targeting T-cell co-stimulation', 'between cycloplegic', 'Sarna', 'site laboratory).|Liver failure', 'non-oncological', 'old|Locally advanced', 'interferes with the study aims', 'American Diabetes Association (ADA) criteria', '||Inclusion', 'any grade alopecia', 'T3-T4aN1/N1cM0', 'American Joint Commission on Cancer [', 'Morton s neuroma', 'in the breast with a', 'life expectancy≥3', 'non-carious', 'vitamin E', 'culprit vessels', 'intra/extra-hepatic).|Measurable common', 'stimulateur', 'postmenopause', 'stroke|Fugl-Meyer Upper Extremity score: minimum 10/66', 'Li-Fraumeni', 'primary Axis I', 'narrow irido-corneal angles', 'ethnic minority', 'suitable for repeated', 'enough tissue', 'IGH-CRLF2', 'tested by Signatera MRD assay', 'neurodevelopmental disorder|Be over 18 years old and literate|Having a child(s)', 'Gastrointestinal Symptom Rating Scale', 'intra-articular glucocorticoid injections)|Insulin use|Hospitalization', 'ST segment elevation);|Acute coronary syndrome', 'large restorations', 'dissection.|Bacterial endocarditis', 'Covid-19 group must', 'coiling', 'mild-to-moderate levels', 'hypertrophy.|Clinically significant', 'Good Start Matters study.|Aged', 'epilepsy;|Uncontrolled', 'can tolerate', 'rays', 'Diagnostic and Statistical Manual of Mental Disorders (5th edition DSM-5', 'screening):||Uncontrolled', 'histological specimens', 'preclude adequate absorption of osimertinib.|Active second malignancy', 'essential oils', 'hormone receptors', 'different', 'stage 1', 'months|Significant', 'tested for gonorrhea', 'American Diabetes Association (ADA)|Hemoglobin A1c (HbA1c)', 'grade 2, 3, and 4', 'before performing radical surgery', 'Additional', 'site of the block.|Coagulopathies', 'AMI', 'masticatory muscles),|full dental arches', 'consent|Large', 'injection site.|Chronic opioids dependence', 'applied into a', 'SGLT2-i', 'upper extremity|In the', 'Davis Comprehensive Cancer Center', 'secondary to medical cause).||A female participant is eligible to participate if she is not pregnant', 'concurrent', 'suitable for participation in the trial。', 'adapt', 'organ transplant', 'antibody titer', 'single-gene', 'antidepressant therapy', 'inducing Torsade de Points', 'influence the study results', 'intellectually disabled', 'influence the endpoints of the study', 'rate-controlled', 'pump surgery|Postoperative exploration for', 'non-pregnant', 'non-eligible', 'primary series of', 'Follicular', 'Viral', 'hindering', 'false-positive', 'cardiomyopathy|Acute', 'perinatal women|Heavy smoker.||', 'PD-L1 expression detection', 'inter-current', 'Stage 3A', 'gynecologic', 'Love Attitudes Scale-Short Form (LAS-SF', 'first to', 'insulin regimen', 'index procedure|Bystander disease', 'irregular intervals of time', 'β0', 'use|Current', 'vascular disease.||', 'connective tissue', 'constraints', 'single', 'less.|Reactive', 'lower ureteric stone', 'ICD-10 diagnosis', 'included.||Age group', 'supplemental oxygen.||ii', 'non-enhancing', 'ST segment elevation myocardial', 'under safeguard justice, guardianship', 'Erasmus MC', 'patellofemoral', 'might interfere with ability to', 'first-time pregnancy', 'at term', 'may interfere with the fNIRS assessment', 'invasive TNBC', 'major abdominal', 'Grade 1', 'Axillary', 'non-exposed group', 'prompted', 'suitable for participation in the study;|Pregnant', 'or>75', 'between 20 and 90', 'moderate risk of IMN', 'implant', 'non-drug therapy', 'gastric arteries', 'swallowing', 'radiologically confirmed HC', 'duodenal', 'profound', 'EBV-positive', 'Non-invasive', 'significantly contribute to lung disease', 'Henoch-Schonlein purpura', 'parent-reported)||Parent', 'omega-3', 'sacroiliac joint, which may in the opinion of the Primary Investigator confound measurement of outcome variables;|Has', 'Primary Sclerosing Cholangitis)|Active malignancy', 'CLIA-certified', 'suitable for standard treatment;|PD-1', 'ICG injection beyond the submucosa|Visual inability to identify the', 'refractory to standard therapy', 'interfere with cooperation with the requirements of the trial|Receipt of any live vaccine', 'non-irradiated disease', 'cancer|Adequately', 'site of injection.|Cranial bone', 'Impella 5.5', 'interventional randomized trials', 'secondary to immune-mediated', 'professional', 'fellow level volunteers', 'therapy-related', 'probiotic', 'ACR criteria', 'tumor tissue sample', 'right', 'admitted to Assiut University Hospitals', 'relevant', 'Non-ophthalmic surgery|Mallampati', 'Swiss Academy of Medical Sciences https://www.samw.ch/en/Publications/Medical-ethical-Guidelines.html)|No informed', 'platinum-based drugs', 'cooling mattresses', 'evidence-', 'evaluable tumor focus', 'insulin glargine.|Alcohol', 'ancillary', 'intensively', 'preclude compliance with the protocol,|Is under guardianship, curatorship', 'low glean score|Previous treatment', 'second-year', 'adequate to hear information presented in age-appropriate videos of social', 'statins;|Pregnant', 'above|Individuals', 'non-anchored VAS', 'non-squamous NSCLC.|Have', '≥92%.|Left', 'low back pain|Cases', 'survivor', 'non-heavy', 'formula', 'could favor intestinal perforations', '≥ grade 1', 'Supportive', 'valvular|Atrial', 'line', 'ALK-positive', 'extensively restored', 'first-degree relatives.||Exclusion criteria', 'pharmacologic', 'stage III or above', 'Cervical', 'deemed significant', 'Diagnostic and Statistical Manual of Mental Disorders-V', 'unknown Her-2 expression', 'Extracranial', 'indication|Pre-operative', 'CDK4/6|inability to swallow', 'Extrahepatic', 'study|Concomitant', '≤6-year-old|2', 'Cingal', 'highly effective non-hormonal', 'influence flow', 'could result in immunosuppression', 'Specifically', 'insulin pump)|Hypersensitivity to loud noises|Incapable of lying still', 'dilatative', 'IV|Failed', 'Winston-Salem', 'low grade dysplasia (LGD)', 'non-biological agents', 'fetal tachycardia;|pre-labor', 'androgen-producing tumors', 'therapeutic vaccines', 'upper extremities', 'self-report|Individuals', 'strabismus surgery;|History of cervical', 'Diagnostic and Statistical Manual of Mental Disorders V criteria', 'clinically significant red', 'injection treatment', 'Persistent', 'Drug Abuse Screening Test (DAST)', 'semaglutide', 'frequent', 'local internal organs', 'above recommended', 'absolute positive).|children', 'Transfusion-dependent', 'multifocal', 'Severity Scale', 'distal limb', 'ICD-10 coding.|15 years of age or older', 'study;|Structural damage', 'mechanical liw back pain', 'medication||No taking', 'Institute-Common Terminology Criteria', 'refusing antibioprophylaxis', 'stye).|Active', 'T10', 'primary series', 'enrolled.)|Clinically significant', 'myopathy;|Clinically significant', 'oncolytic', 'DZ twin pair', 'ultraviolet A radiation', 'menopause|Completed', 'Annex 4);|Severe infections', 'neck area', 'high dose oral', 'peptic ulcer|Severe associated disease|History of', 'study|Clinically significant infection', 'saccular', '5-Syndromic', 'non-inclusion:||history', 'ALK positive', 'hard palate, the case', 'mono-species', 'mimic MS', 'Type II diabetes', 'Gallium-68 or Copper-64 DOTATATE scan', 'scheduled', 'Dominant', 'medical records', 'anti-internal factor antibodies', 'high grade MDS', 'that may lead', 'implantation of a pacemaker|Pregnancy', 'abnormalities)|Hydrosalpinx untreated.|Recurrent', 'dysfunction.|clinically significant', 'Child', 'First Affiliated Hospital of Xi', 'suitable for rubber dam isolation', 'T3-4N2-3M0).|Eastern Cooperative Oncology Group performance status', 'mumps', 'peripheral manifestation of axSpA', 'NIA-AA', 'chronic use', 'investigative site', 'Saudi', 'non-radiographic Axial Spondyloarthritis', 'open', 'low to moderate physical activity', 'rather than arm pain', 'IMWG 2016 criteria', 'Altered', 'interferes with cognitive testing|Vision impairment', 'esophagus;|Tumors of the esophagus', 'cytomegalovirus(CMV', 'non-English speaking|other medical conditions', 'primary tumour)||Exclusion', 'inhibitors - SSRI', 'eye ointments', 'withhold', 'OR|Two predicted pathogenic GALC mutations', 'between 1 to10 ULN', 'FOX', 'Type 3', 'periprosthetic', 'monosaccharides', 'index hospitalization|Neurological condition', 'bone-modifying agents|Smokers', 'wild-type', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis', 'mandibular jaw that permits the placement', 'immunosuppressive doses', 'Stage III', 'lymphocyte percentage', 'ipsilateral pleural space', 'hyper-fluorescent puncta', 'Axis I', 'required elective', 'stage of', 'extubated', 'condition|≥', 'upper urinary tract being', 'pathological', 'operating room with anaesthesia', 'alopecia);|Previous', 'above daily recommended alcohol intake for men', 'dysregulated', 'epidural).|Intracranial', 'self-report)|Black race', '3rd degree', 'environment', 'Advanced', 'non-traumatic cause treated', 'post-transplant', 'responding to the conventional treatment', 'unanimous', 'secondary to other conditions (neoplasm', 'Temporomandibular Joint and/or masticatory muscles', 'not receive', 'peri-implant mucositis', 'some', 'regular consumption', 'nodal masses', 'epilepsy|Intracranial', 'second-generation EGFR TKI', 'heterotopic ossification|Cognitive', 'ischaemic', 'Lancaster General Health', 'index knee', 'saw', 'myotic', 'non-muscle', 'potentially damaged nerves', 'natural menses', 'SpO2-target of 95%)||', 'FDG-PET scan.|Left', 'and/or devices', 'FT538 - inhaled', 'tumoral', 'severe than step 2 other', 'Inadequate', 'inflammatory process & decrease oxygenation', 'cancer|Clinically significant', 'Escherichia coli', 'grade 3B', 'normal', 'personality change', 'screening|Active', 'moderate to', 'sibling donor', 'site of injection|Any contraindication for ESP|Known', 'stomach', 'Non-asthmatic', 'intra-oral metal body piercings', 'ankle-foot orthosis', 'organ-donor)|Follow-up procedure', 'time|active uncontrolled', 'meta-PM classification', 'metropolitan area', 'low-dose', 'modification of diet in renal disease (MDRD) formula', 'concerning', 'numeric pain scale', 'could cause neuropathy', 'Present', 'medically supervised pregnancy test', 'tumor tissue must be', 'femoral BMD T-score', 'non-inclusion criteria||Patients', 'HSCT).|Advanced', 'COVID-19.|Tobacco', 'low-density lipoprotein cholesterol LDL-C', 'worse than grade 1|Anterior uveitis', 'individual.|Clinically significant', 'widespread', 'over 1,200 folds.|Contraindication', 'HF；C. Severe', 'rituximab treatment', 'female|Advanced', 'AHT medication|History of hypertension', '5-HIAA', 'ASAS criteria|Patient', 'NTRK1', 'non-progressive', 'wrist area', 'Major', 'place the subject at risk', 'Chronically', 'pelvis', 'interferes with the aim of the study', 'non-migraine', 'forearm', 'PD for 5 years', 'cigar equivalents', 'very severe intensity', 'Mild', 'febrile neutropenic episode.|Septic shock', 'should take', 'Natural', 'substantially reduce seizure threshold', 'childhood', 'highly effective birth control methods', 'full', 'blast crisis', '12-month pre-index period|Evidence of', 'non-resorbable', 'NEI scale|Have been', 'full-thickness', 'breastfeeding|acute', 'single-cycle degree', 'study|Person under guardianship or curatorship', 'mycobacterium tuberculosis', 'N-terminal pro-BNP', 'low education', 'antegrade flow', 'therapy|Sexually active', 'interferes with successful administration of', 'access site', 'resistant', 'considered stable', 'Grade IV operation qualification', 'Non-arteritic anterior ischemic optic neuropathy', 'proteinuria.|Pre-eclampsia', 'inclusive).|Self reported sleep problems', 'ischemic stroke,|time', 'lasting a minimum of 24 hours', 'mRECIST v1.1)|Received', 'Ortho Evra', 'idursulfase-IT', 'TAK-771-3005', 'primary location', 'shoulder surgery.|Patients', 'high-energy trauma', 'navicular bone', 'unaccustomed', 'convalescent', 'metastasized to the brain', ""diagnostic criteria of Berlin's definition for ARDS;|invasive ventilation time < 48h;|PaO2/FiO2"", 'HIV-positive', 'osteomalacia|Active', 'high degree', 'non-nodal lesions', 'stoke)|Chronic', 'Non-gestational diabetes', '3).|Uncontrolled concurrent', 'intra-cardiac thrombus', '3 through', 'malnourishment', 'urinary retention', 'safely accessible to tumor biopsy', 'impairing judgement, making adequate', 'NADH-cytochrome b5 reductase deficiency', 'non-breastfeeding', 'PD-L1 + CPS', 'self-', 'arterial', 'type 2.||', 'chemotherapy|Disease-free interval', 'Article L. 1121-8', 'suitable for neoadjuvant', 'concern related to the change in cognitive performance', 'disorder|Post-traumatic stress', 'life expectancy;|HIV', '3mm away from the optic nerve and brainstem', 'mellitus|Pregnant|Insulin treatment|Severe', 'confirmatory)|Not taking', 'HbA1C≧6.5%', 'ventricular trigeminy', 'low grade PrCa', 'locally accredited laboratory', 'stabilized|Uncontrolled', 'subject|Current', 'non-parental', 'oncologic', 'higher', 'Gd positive', 'study drug);||Absolute count', 'PCOD||Endometriosis|Uncontrolled', 'spontaneous menses prior to enrollment.||7', 'parenteral nutrition|insulin-dependent', 'ATXN7', 'lower extremity impairment.||', 'any form', 'non-hormonal contraceptive', 'Dutch language||', 'mute', 'systemic therapy.|Had major surgical procedure', 'clinically symptomatic', 'non-valvular atrial', 'intra-abdominal abscess', 'low literacy levels', 'proteasome inhibitors|Known', 'deemed stable', 'non-standard formula', 'emergency purposes', 'non-related.|Stage', 'non-food allergies', 'fellow eye.|Posterior staphyloma|Anisometropia', 'drug-induced', 'de-novo', 'grade I-III', 'separated into loose exclusion criteria', 'IV.|Sever osteoporosis', 'surgery|Previous', 'Non-pregnant adult', 'mental health', 'Cedars Sinai hand clinic', 'proven by', 'suitable for BCS|the tumor', 'severity index PASI', 'stigma', 'can alter visual function', 'sport', 'weaned for more than 2 years', 'primary source', 'repair|Concomitant', 'moderately dependent', 'JIA|Polyarticular onset of JIA', 'low dose systemic', 'soya', 'EBV-DNA', 'amenable for further curative treatment|metastatic disease|other co-morbidities', 'ACC-ASCVD risk estimator+)|Untreated HTN', 'Mount Sinai Health System.|Attending', 'critical by the doctor.|Person', 'list|Recurrent unstable angina', 'Non-inflammatory', 'insulin replacement therapy', 'upper-extremity support', 'non-addictive', 'highly effective contraceptive methods.|Endocrinopathies', 'intra-articular injections', 'aortic', 'Meniscal', 'Insulin meal dosing', 'organ-related disorder', 'condoms', 'absolute decrease of', 'other BTK inhibitors.|History of', 'moderately severe', 'unrelated donor available for stem cell donation', 'COPD)|In-patient', 'refractory to conservative', 'Diagnostic and Statistical Manual of Mental Disorders 5th edition', 'full course of treatments', 'Non-steroidal anti-inflammatory drugs (NSAID)', 'ICU,|Mechanical circulatory support', 'Contrast media', 'expressive', 'interventional eye', 'non-antibody therapy', 'hamstring', 'LVEF<50%)', 'umbilical', 'muscle growth/hypertrophy', 'low-grade glioma', 'end-of-life care', 'post-second trimester abortion', 'cerebral', 'Gn-RH analogues', 'connective tissue diseases etc;|Secondary arterial hypertension;|Alcohol', 'coronal', 'restrict ability to perform study-related', 'highly effective methods', 'full ﬂexion', 'investigational', 'exists|Other', 'healed', 'suitable for intervention procedure;|Known hypersensitivity', 'congenital airway', 'unknown laterality;|Patients', 'the trial;|Subjects', 'Rome IV;|Complete spontaneous bowel movements', 'Texas class', 'Pre-op', 'non-prescribed barbiturates', 'ultrasound|HIV-uninfected|Willing', 'ambulatory', 'age|Advanced', 'articles L. 3212-1 and L. 3213-1', 'non-small cell lung cancer)|All patients', 'acute phase treatment', 'idiopathic', 'hernia|Previous', 'under general', 'rather than', 'epilepsy;|Prior', 'suitable for MRI scans.|Patients', 'PD-L1 immune checkpoint inhibitors|Patients', 'successfully completed', 'threatening', 'severity to prevent', 'screening|Retinal', 'non-dysplastic', 'months.|patients examined', 'aneurism', 'constraints related', 'systemic therapies', 'saddle anesthesia', 'upper limb', 'long diameter > 10 mm', 'successfully cured', 'skilled', 'between the tip and the plafond', 'drive', 'staples', 'Glycerol|Clinically significant', 'systemic antibiotics', 'TIMI flow', 'high-flow', 'smear', 'cachexia-related', 'non-infectious pneumonia', 'various', 'plasma-derived FVIII', 'etc.||', 'scleral', 'grade 2 or above', 'investigator.|Abnormal skin', 'non-head and neck', 'intracranial arteries', 'above|Stable', 'labelled', 'uncomplicated', 'self reported fear of childbirth|is a multipara|under 32 weeks', 'American Joint Committee on Cancer (AJCC) Cancer', 'requiring IV anti-infective', 'requiring treatment|Patients', 'inducible', 'peri-bronchovascular', 'chest-xray', 'Athens-Clarke County', 'Bipolar I', '140 millimeters', 'Obstetrician', 'Non-daily', '>30° to <90°', 'non-active', 'Non-Syndromic', 'chronic urticarias', 'studies.|Abnormal', 'radicular', 'consecutively', 'hallux', 'N.B. uncomplicated', 'Legally Acceptable Representative(s) [LAR(s', 'non-squamous cell', 'non-consecutive', 'simple urinary tract infection', 'once daily|Read', 'closed', 'middle cerebral artery (', 'resection|Pre-existent', 'its', 'non-restorable.|Teeth closed', 'Rotterdam criteria by the presence', 'lower limb', 'BL-B01D1;|Previous organ transplantation', 'induced', 'block;|Serious', 'preclude intake of the investigational products.|Participants may not be receiving treatment', 'site plaque psoriasis', 'GnRH-', 'pancreatic', 'axillary', 'lasting for more than 12 weeks).|Able to perform physical therapy', 'specifically a pre-disposition', 'first-generation anti-androgen therapy', 'intra-vaginal contraceptives|Norplant System®|Depo-Provera®|Intrauterine device', 'mellitus|Self-reported', 'hepatocellular', 'allowed.)|Pre-hospital naloxone administration', 'Adjustment', 'related to dry eye syndrome|Those', 'cumulative total', 'Saxenda', 'post-apheresis', 'withdrawn', 'worse than back', 'unusual frequent', 'severity of surgery classification;|Scheduled', 'non-hospitalized depression', 'urine human chorionic gonadotropin', 'irrespective of treatment duration', 'old|Singleton gestation|Nulliparous|Vertex presentation|Gestational', 'injection area', 'alternative medicine', 'surgical team||', 'South Africa|Not mentally', 'non-convulsive electroshock treatment', 'suitable for participation in this trial', 'IHC 1+ or above', 'suitable for inclusion by their General Practitioner', 'requirements;|Blood', 'injection site,|Infections', 'Primary Immune Deficiency Treatment Consortium', 'Sport-subscales ≥95%).||Healthy', 'under judicial protection|Patient under guardianship', 'esophageal perforation.||Patients', 'angina|Coronary', 'suitable for endocrine', 'refractory to intrathecal chemotherapy', 'cytologically-proven', 'influence metabolism', 'Diagnostic and Statistical Manual of Mental Disorders, 5th Edition', 'operative', 'excluding', 'two', 'preclude obtaining the informed consent', 'under 1 year old', 'self-injury|Parent', ""American Diabetes Association's (ADA) definitions"", 'Limoges epilepsy screening', 'located in the implant region.|Patient', 'Uncontrolled', 'Beijing', 'Liver disease;|Active', 'site for injection', 'reactivated', 'index level', 'eligibility criteria delineated below', 'any underlying', 'lesion|4', 'IMWG consensus', 'index ankle|Has', 'suitable for existing', 'psoriasis);|Controlled', 'clinical manifestation', 'cm|Local', 'De Maria', 'PD activity', 'Early recanalization', 'adequately-treated', 'multiple unsuccessful', 'between hip fracture', 'distal radius fracture.|Patients with function deficits', 'in the neck area|sensory disorders|dislocation of the jaw in the past|taking', 'atient group):||left ventricle ejection fraction', 'RR', 'Decompensated', 'ART).||', 'stage III tumors', 'influence the cutaneous state.|Subjects participating', 'mild to moderate crowding', 'alter the impact of exercise on tumor outcomes', 'lamina propria', 'hands', 'non-oncological reasons)|Concurrent', 'Basal', 'resident-handling', 'stable antiretrovirals', 'post-operatively||American Society of Anesthesiologists (ASA) risk score', 'intra-bony', 'Topical use of drugs', 'optic', 'menstrual', 'exceeding the 99th percentile', 'other', 'primary reason', 'non-injured', 'Wild-type unresectable RAS', 'Non-Hodgkin Lymphoma', 'Systemic', 'higher|Eligible', 'ocular surface (auto-immune disease', 'Portico valve);|The', 'dMMR)disease.||Known acute', 'Confirmed', 'Non-melanotic skin cancer', 'harassment,|long-term', 'lips', 'salmon-colored mucosa', 'sclerotherapy', 'DIED:|Enrolled in MC1137', 'affects drug absorption|those who cannot tolerate venipuncture', '1 differentiated', 'anabolic steroids', 'full-dose', 'hyper', 'macromolecular protein', 'non-objection to participation', 'C3-C7 intervertebral discs', 'intolerant;|Self-reported', 'site of block.|Coagulopathy', 'positive', 'OC||Ovarian', 'alkylating agent', 'ERT dose', 'non-compliance', 'EBV', 'eyes', 'irregular user', 'injection sites|Diagnosis', 'imperfecta);|Has a condition that', 'Axis I condition', 'destructive', 'Chromosome', 'deemed incompatible', 'ICD-10 codes I50', 'computer skills.||', 'Individual', 'non-operative', 'micro-vascular', 'middle of the night, unable to fall asleep after waking', 'standard', 'AIH)|Clinical diagnosis', 'etc;|Part C and D:', 'referred otalgia.||', 'term', 'moderate-to-severe', 'under 8 weeks', 'Although', 'Fudan University Affiliated Cancer Hospital', 'non smokers|smokers||', 'monovision', 'site of therapy', 'and related', 'Le-Fort', 'Neuro-Oncology biorepository for archiving of microdialysate', 'symptomatic', 'Bruton tyrosine kinase inhibitor', 'disease|regular use', 'moderate', 'locally recurrent(unresectable', 'urological', 'grade II or above heart function', 'injection regimen|If', 'Neuro-Oncology(RANO)', 'applied restorative', 'probable', 'acutely unstable', 'amenable to surgical therapy.|A', 'suitable to aortocoronary anastomosis', 'grade 2 and above continues to occur;|Other conditions determined by the researcher that may cause', 'mild-severe', 'ASAS 2009 criteria,|Hospitalized', 'irregular heartbeat.|The Daily Activity Scale', 'labral', 'Clarity App|Regularly eats', 'locally cured', 'protocol systemic chemotherapy', 'Gynecologist', 'Strong', 'NSLBP', 'requiring treatment|History of', 'confirmation by', 'interferes with absorption', 'ankle foot orthosis', 'periampullary', 'Gastrointestinal', 'genetically-modified T- cells', 'old|Bridging', 'mutation;|Locally advanced', 'Grade glioblastoma', 'ankle-brachial index assessment', 'patients;|English', 'index date.|Patients', 'Bronchiolitis|A', 'infusion pump', 'DCIS|Severe', 'medications|High risk', 'intermittent IV infusion therapy', 'ST-segment elevation myocardial infarction', 'eria:||Aged', 'amenable to local therapy', 'including||Measles outbreak|Planned', 'site of maximal knee', 'Non-English-speaking', 'face transplantation.|Aged', 'suitable for radical radiotherapy', 'Diagnostic and Statistical Manual of Mental Disorders version V (DSMV criteria', 'etc.;|Pregnant', 'indwelled', 'hours|Stable', 'GT1 through', 'insulin therapy,|PEDIS Classification stage 1 and 2|Does not have', 'despite treatment|Class II or greater', 'secondary to age-related', 'Diffuse', 'immunosuppressive therapy;|5', 'FT538 product', 'extending to the', 'SDHB)|BRCA 1 associated protein -1', '15 fractions)|Patients who have', 'mid-sagittal view of the fetal head', 'rent', 'metachronous', 'outside the central nervous system', 'Newly histologic diagnosis', 'suspected|Active', 'interstitial', 'Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) criteria', 'signature|One', 'non-invasive', 'Dining Services', 'index diabetic', 'amenable to SBRT', 'normal|Expected survival', 'tongue', 'with related', 'adequate organ function.||', 'non-cancer-related conditions', 'cervicogenic', 'years|Significant', 'Wide-necked', 'cancer|Tumor tissue (archival', 'Clinician-Administered', 'non-invasive ventilation', 'definitive', 'QI|Current unstable diagnosis', 'intercurrent illness|Uncontrolled', 'primary diagnosis', 'lower extremity.|Arthritis|Sprain', 'class V', 'Oligo-ovulation', 'site of surgery|Body weight', 'suitable for participants.||Exclusion Criteria', 'DSM5 classification|Benefit from social security or benefit', 'non valvular atrial fibrillation', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)', 'Relationships Sabotage Scale', 'pure organic', 'central nerve system', 'diameter of 5mm or more', 'Resisted', 'corneal disease;||2', 'auxiliary', 'toxic reactions', 'molar germs|Patients', 'pedal arteries', 'unsuitable for tDCS', 'non-degenerative neurological conditions', 'shoulder area', 'upper extremity musculature', 'immunosuppressive therapy|they', '12-14 of gestation).|Verbal', 'alter tear film physiology;|Having', 'Inpatient', 'PTSD|bipolar disorder|MDD|schizophrenia|at risk of suicide(Columbia', '""', 'medications.||Hepatic', 'peroperative', 'poorly-controlled', 'discharge from hospital|no brace after surgery|sufficient verbal', 'drug product formulation|Active infection', 'salivary PCR||', 'suitable for autologous hair transplantation', 'Singleton term', 'positive HBsAg|or', 'periodic', 'new-generation drug-eluting stents;|Length', 'plyometric training;||', 'overwhelming', 'femoral head|acute hip fracture|sequelae', 'optimally tolerated', 'MPS III disease', 'Neuro-cognitive impairment', 'show', 'peroneal arteries', 'visble', 'non-clinically significant', 'in the neck (cN0),who underwent', 'both selective lens', 'Ukrainian Medical Information System', 'non-prescription drugs', 'synchronous', 'suitable for procedure;|Known allergy', 'upper limb functions.|Participants', 'intra-aortic balloon pump', 'relapsing remitting', 'systemic therapy.||Active', 'consentement', 'site conducting the study', 'Diagnostic and Statistical Manual of Mental Disorder - Fifth Edition (DSM-5);|Abstinence from cocaine for at least 48 hrs.||Exclusion Criteria', 'difficult|Acute', 'best-corrected visual acuity', 'non-gastrointestinal surgery', 'intra-articular derangement;|Radiological findings', 'recently.||', 'could complicate the surgical phase', 'Fridericia formula', 'thrombus', 'decompensated', 'adequate understanding or cooperation;|Participation', 'upper limbs', 'high-grade serous', 'non-dilated examination', 'Rome III criteria.|Previous', 'triangular area', 'nearby', 'diameter of extrinsic lesions should', 'PD-L2 drugs', 'study|Person under legal', 'unrelated to prematurity', 'allogeneic', 'age-related disorder', 'MVA-based', 'mushrooms', 'face-to-face sessions.|Additionally', 'IgG', 'intervertebral', 'mental health care (GGZ in Dutch)|For GP', 'Psoriatic', 'acute stage;|Allergic reactions to medications', 'High grade B Cell Lymphoma', 'Invasive', 'Declaration of Helsinki', 'AIDS|Neurologic', 'PD-L1', 'between 01/03/2030', 'rectum|Patients judged unfit to participate in the study by medical staff', 'muscle biopsy', 'preclude self-administration', 'non-intensive regimen', 'non-ambulatory', 'ST-segment', 'amenable to resection', 'non-opioid pain medication', 'environmental factors', 'spermicide|cap', 'Diagnostic Interview for Anxiety', 'sacral', 'IBS-D.|Participants', 'active phase of the first stage of labor||', 'emergency setting.|Liver', 'study.|Previous', 'drug-related pneumonia', 'medication regimen|Male', 'audiometric', 'aligners|General joint', 'hard palate', 'personal care', 'suitable for the time being (surgery', 'American College of Rheumatology criteria,|Western', 'vomiting,|Symptomatic', 'non-Gore device', 'suitable for repeated assessment in accordance with RECIST v1.1.||Subject', 'E. AFP & GT', 'medically-accepted contraceptive', 'unrelated to their weight', 'After COVID-19 nucleic acid detection', 'DJ insertion.||', 'anchorage area of the implant|Person on legal protection|Pregnant', 'chronic HD program.||Exclusion', 'platinum-refractory', 'Pittsburgh scale', 'preclude administration of', 'mild to moderate smokers', 'lower extremity', 'to the anterior cruciate', 'AFC<5', 'emergency dispatch center', 'SmPC)||', 'third dose', 'Atrioventricular reentrant tachycardia (AVRT)', 'acute phase of the illness', 'second molars', 'lack effective treatment', 'tattoos', 'hormonally-impregnated intrauterine device', 'extending to more than three surfaces', 'Regional Severe', 'Early SB2.||An individual', 'baseline|Active', 'Stage Ib3', 'largest diameter ≤5', 'severity per Clinical', 'at AS', 'random text', 'selected diabetes clinic', 'low-calorie', 'Movement Disorder Society (MDS) criteria', 'primary infertility|Having', 'in form of', 'low expression', 'Grade 2 or greater', 'postrenal', 'potentially sensitive', 'metabolic disorders.|Pregnant', 'lesion(s)selected', 'steroids into the knee osteoarthritis', 'lower back', 'VF testing|History', 'Temporomandibular', '3D ultrasound||', 'permanently', 'incessant', 'infectious', 'native coronary artery|Severe', 'total dose', 'extract', 'hernia', 'hormone-receptor positive tumors', 'low doses radio-', 'non-IPF chronic fibrosis Interstitial Lung Disease', 'signature||', 'recurrence|Enrolled', 'negligence - physical', 'Mount Sinai West.||', 'confirmed', 'reduced', 'official endurance', '3-recent', 'non contrast', 'Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI', 'patients|End-of-life|Patients', 'systemic therapy|Known', 'without effective contraception', 'unresectable advanced', 'PANSS-EC', 'traveling', 'prosthetic treatment.|Having', 'clinical grounds', '≤Grade 2', 'GLP-1 class', 'cytology.|Locally advanced', 'grade 2 (Ulcer of the skin', 'systemic absorption.||6', 'stable dose of', 'C|Pre-existing', 'centrally', 'thoraco-lumbar curvature', 'Echo-Duplex study', 'neurological flushing', 'prepubertal', 'IBS-SSS score', 'gastric', 'diaphragm', 'PMR', 'non-psychotropic medications', 'mild cognitive impairment;|Those', 'Third-year', 'clinically significant condition', 'HAMD scale|Be conscious', 'non-MR', 'treated', 'cruciate ligament repair surgery', '5-blood disorders', 'us|Highly motivated patients.||', 'before cardiac intervention', 'Nurse-Family Partnership program', 'recovered childhood asthma/allergies', 'highly effective contraception', 'grade II', 'general practitioner.||', 'implants', 'ureteric stones|single kidney', 'non-sustained', 'unable to play', 'could interfere with their participation in the study.|The subject has', 'originally took', 'ligament Alignment of lower extremity', 'metabolism-related fatty liver', 'latest PMR relapse', 'recovery', 'cerebrum area', 'gastroesophageal junction', 'preclude protocol therapy|Subjects deemed unable to comply with study', 'antidepressant-induced', 'grade 3B|high-grade B-cell lymphoma', 'graft', 'degeneration', 'non-clinically', 'under glasses', 'Diagnostic and Statistical Manual of Mental Disorders (DSM-5)', 'age;|Sufficient', 'personality disorders;|History', 'silicone.|Confirmed', 'pregnancy|Age', 'yellow fever', 'low-carb diet', 'lumbar puncture.||The', 'index knee graded', 'sponsor.||Adequate organ function:||RENAL', 'Medacta Mpact 3D Metal MonoCer', 'anogenital', 'metabolic diseases|previous brain', 'consumed', '3 months|Can', 'invading', 'ipsilateral ankle', 'under general anesthesia|Patients', 'since admission|Active infection', 'ascending aorta|Residual aortic dissection following', 'investigators.|Stable dose', 'Cohort I', 'central', '||Hospitalized', 'exercise|Significant', 'Membranes|High', 'Grade 1 peripheral', 'any form of', 'Spontaneous', 'ambulatory liver', 'neovascular age-related', 'upper extremity', 'large vessel disease.||', 'worse than 20/40', 'stable form', 'radionuclides', 'severe than Class I|ongoing', 'aorto-iliac lesion', 'immune related adverse events', 'Insulin-treated', 'non-melanoma skin', 'period;|Uncontrolled', 'mental retardation|predictability of long periods of stay abroad|anticipation', 'topical use permitted)|Pregnancy', 'vulva', 'unsuitable to take', 'tripterygium', 'Non-emergency', 'American|Able to read', 'mid-stage.|Subjects must provide', 'Factor B', 'amenable to curative surgery', 'intra operative', 'requiring IV treatment|Human immunodeficiency virus', 'results.|Intensive exposure', 'monogenic cause', 'compared to experimental product', 'index-procedure||', 'nursing|Active renal', 'stable maintenance therapies', 'from tissue or plasma(ctDNA)', 'parotid', 'C5-C8', 'clinically evident disease', 'High-resolution CT scan', 'pathogenic', 'blindness)|Age', 'elective', 'fentanyl patches', 'low dose Ara-C', ""mid-stage Alzheimer's"", 'cerebrospinal', 'Haplo-SCT candidate', 'non-atherosclerotic lesions', 'cervical spine.|Tumor', 'dysmorphic markers', 'IBS-SSS≥175|Able to safely undergo', '>1 severe', 'honey', 'femoral head|Surgeon considers the patient appropriate for the core decompression procedure', 'conditions;|Sufficient', 'suitable for SBRT', '1st degree of relative from each patient participant', 'amenable to standard-of-care', 'ICD|previous', 'non-hormonal vaginal preparations', 'undifferentiated', 'Atrioventricular', 'interferes with study procedures|Social', 'JAK2', 'supervisory', 'Clostridium difficile toxin', 'post organ', 'urgent', 'medium-taster individuals', 'ankle-brachial pressure index', 'tobacco smoker', 'suitable for enrollment in this study', 'suitable for treatment with anterior discectomy', 'fractures|acute inflammatory diseases', 'agents.|Concomitant use of', 'horizontal', 'multiparametric flow cytometry', 'gradually diminish', 'unprovoked', 'influence lipid', 'febrile 24 hours prior to or', 'incapacity to read the information and not object to the research.|Patients', 'amino acid', 'CES-D', 'unsuitable for proper', 'MUSC OB clinic||Exclusion:||a', 'extensive metastasis.|Patients', 'criteria:||Peripheral neuropathy|Patients', 'central nervous system metastases', 'opiates)|Significant unstable', 'BNCT||Pregnant', 'ICD-10 code', 'irregular menses', 'Recurrent', 'stage 2', 'femur hip|Deemed', 'site-reported):||High', 'non-endocrine therapy', 'narrowangle', 'STT interval', 'preclude adequate absorption distribution', 'Cerebrovascular diseases|Diabetes|Severe hypertension|Chronic obstructive pulmonary disease', 'human papillomavirus', 'above the clinically significant range', 'mild to moderate PD', 'devices sensitive', 'might interfere with contact lens', 'plantar orthoses', 'lower urinary tract symptoms|Need a', 'without the ability to return for visits', 'related to lipid metabolism||i', 'age related', '3rd trimester|pregnant', 'first remission<12 months', 'suprapubic', 'implant-supported', 'Grade II-IV aGVHD per MAGIC', 'AD meds', 'breastfeeding|acute respiratory', 'status||Dose', 'intestinal transit time 6 weeks', 'penetrative', 'miglustat', 'Grade ≤1', 'clinically significant angina', 'ACR 1990 fibromyalgia diagnostic criteria|fulfilling the ACR 2016 fibromyalgia', 'musculoskeletal injury;|who have apraxia', 'freshly cut', 'without evident instability can be added.||', 'marcoumar', 'Erasmus MC|Provision of written informed consent|Only', 'any other organs', 'ADRD', 'Non-English speaking and reading parent/guardian', 'grade 1 of 4', 'non-abrasive', 'largest wheal diameter of ≥6 millimeter (mm)', 'ankle-brachial index', 'primary mediastinal', 'ICD-10 made', 'host', 'inducer of cytochrome P450 (CYP) 3A4', 'ALK fusion genes', '≥6 sites', 'sibling).|Pregnant', 'intra-parenchymal', 'A1-1 group', 'grade ≥3 tonsillar hypertrophy.|Current clinically significant', 'baseline', 'PD-L1 IHC 22C3 pharmDx test', 'salicylic acid', 'cold', 'DNA VHB+', 'MRI;|Chronic phase of', 'adolescents', 'Confidential Page 32 of 105||-', 'affects drug absorption', 'non-inclusion', 'inhaled reliever', 'mild to moderate uncontrolled', 'atrial', 'Grade 2 toxicities', 'Abbot corp', 'persistent', 'influence on eye health', 'ipsilateral invasive tumors', 'requiring IV antibiotics', 'syndrome|Post-thoracotomy', 'narrow therapeutic range', 'muscle-skeletal', 'surrounding supporting tissue', 'microsatellite instability-high', 'Ilioinguinal', 'medical history.|If', 'radiologically isolated syndrome|Individuals', 'surgery,|Known', 'lasting longer than 7 days within 30 days of randomization|Be up to date on recommended immunizations', 'distal femur around', 'inhalants', 'overactive', 'UHMWPE allergy;|Is mentally incompetent (if questionable, obtain psychiatric consult);|Is a prisoner;|Is pregnant', 'non-affected ear||', 'at screening|Known', 'investigator.|Active bacterial', 'surrounding', 'prophylactic treatment).|Subjects with AEs from previous treatment', 'mediastinal', 'Rome criteria', 'potentially curative', 'dexmedotimidine|preoperative QTc prolongation|preoperative', 'showed', 'sebaceous', 'MAD study.|Availability', 'users|Previous', 'biopsy.||For dose escalation', 'requiring IV antimicrobials', 'permitted.|Any investigational', 'criteria||Previous', 'income-related', 'stage IV (AJCC version 8) lung cancer', 'highly effective birth control upon enrollment', 'ensure effective contraception', 'Poorly controlled', 'Under general anesthesia||', 'ICD-10 G93.3', 'hypomanic episode', 'Diagnostic and Statistical Manual of Mental Disorders (DSM)', 'M0):||No prior therapy', 'Clinically relevant', 'suitable for related tests.|2', '150 minutes', 'second degree', 'intra-articular', 'SPORT S-ICD Study', 'Clostridium difficile 16S rDNA', 'requiring the use of medication|Fasting blood glucose', 'insulin reactions', 'undetectable', 'non-alcoholic fatty liver disease;|Age', 'irritation', '≥6 joints', 'preclude safe exercise participation', 'Type A aortic dissection', 'PD-L1) analysis', 'diameter of 1:1 to the', 'emergency departments', 'years|Elective', 'Rome IV symptoms criteria', 'intra-operative', 'C1-C5', 'under pelvic ultrasound|Women', 'apheresis||Haploidentical Related Donor:||Haploidentical parent', 'study|Receive investigational treatment', 'highly effective contraceptive methods', 'Expanded Disability Status Scale', 'ACR-TI RADS category', 'progressions', '10-year', 'single-canal', 'parent artery', 'self-declaration).|Participant', 'HIT).|Medically confirmed', 'L1-inhibitor', 'TNF-α] antagonists', 'potentially malignant lesion', 'disease,|Adequately treated', 'pericardial fluid', 'total', 'Egg donor cycle|Chromosome abnormality;|Adenomyosis', 'maximum tolerated', 'BCOR-altered', 'nasotracheal route', 'gender reassignment', 'others)|Symptomatic', 'relieved', 'uni-dimensional measurable', 'mentally.|Do', 'phototype III', '3-months following course.||', 'early', 'insulin pump', 'no myocarditis', 'Stage IV renal insufficiency', 'insulin like growth factor-I', 'after organ transplantation.|T lymphocyte abnormality', 'OA grade', 'without awakening|Moribund state', 'primary investigator', 'Extracorporeal membrane oxygenation', 'vertebral arteries', 'diagnostic', 'mild to moderate menstrual cramp', 'Quantitative study:||All nurses working on the premises', 'Prevention Services Task Force)', 'under temporary', 'primary hypothyroidism|On', 'lacked effective treatment;|ROR1+', 'anti-CTLA-4)|age', 'altered', 'primary systemic vasculitis', 'riteria:||Self-identified', 'intravenous drop infusion', 'listed risk conditions', 'hour)|Receipt', 'Rectal', 'platinum refractory ovarian cancer|Participants', 'instrumental', 'platinum-sensitive', 'non-child bearing', 'hormone-releasing', 'non-cancer', 'suitable for the study', 'Respiratory System||Asthma|Cystic fibroses|Chronic bronchitis|Emphysema|Airway obstruction|Interstitial lung diseases|Pulmonary hypertension|Lung neoplasms|ARDS||Disorders', 'Grade III or IV osteoarthritis', 'without menses', 'non-toxic marker used', 'American Diabetes Association', 'primary lipid disorder|Unable to maintain diet intervention', 'Endometrial', 'de-addiction treatment', 'non-autoimmune diseases', 'CMV seropositive recipients.||', 'years;|Uncontrolled', 'physically', 'valve)|Moderate', 'primary source of', 'no new', 'ipsilateral neck levels', 'following:||Serum M-protein ≥0.5 g/dL', 'positive-airway pressure', 'surgical specimen', 'febrile event has', 'contrast', 'irinotecan-based regimens', 'alternative', 'grade 3 or above occurred', 'could cause significant agitation|Ongoing use of any cannabinoid-related products', '≥12 months.|Eosinophil count', 'notable', 'corticosteroids;|cytokines;|large doses of commercial probiotic', '1:1 through Propensity Score', 'ciliary', 'ipsilateral upper urinary tract reconstructive procedures', 'inadequate', 'subcostal retraction', 'ATM', 'Non-Specific', 'suitable for patients', 'sensitive', 'non-lactation period;|Fertile', 'surgery|Oral antibiotics', 'suitable for the patients', 'balneotherapy', 'acute phase of illness', 'primary radiographs|With fracture reduction', 'site-reported)|Uncontrolled', 'in remission', 'Botulinum Toxin', 'intercurrent severe', 'considered eligible.||', 'unbalanced', 'harmful use or', 'stage I', 'haplo-identical related donor', 'cerebrovascular', 'adequately resected', 'additional', 'non-progressing', 'pure tone audiometry results', 'cognitively', 'Intermittent', 'middle third of dentine confirmed', 'Non-pregnant', 'American Spinal Injury Association Impairment Scale', 'tablets', 'collected', 'ulcerative', 'visually significant', 'blast percentage', 'adequate baseline tumor sample', 'unsuitable for entry', 'massive', 'high grade', 'site of cannulation.|Patients', 'Assiut University heart hospital||', 'intestinal wall', 'PD-L1 inhibitors.|Patients', '3-month', 'sequential organ failure assessment (SOFA)', 'AML-M3', 'Varicella zoster', 'life-threatening consequences', 'Non-naive patients', 'salivary', 'Very High', 'low-level', 'non-specific antibody test', 'life threatening', 'Axis I psychiatric illness', 'Alternative', 'under dietary treatment', 'kinetic indicators', 'scoliosis)|Clinical', 'first-degree relative of the Investigator.|The', 'immunodeficient', 'lesions(s).|Radiographic evidence', '1[PD-L1]', 'adequate organ', '2)|Previous', 'between completion of CNS directed therapy', 'Grenoble', 'hypotension', 'biphosphonates|Local', 'expected to prolong', 'non-reproductive potential', 'screening;|Clinically significant illness', 'hearing aid device,|Amaurosis|Accommodation', 'ET-based therapy', 'influence refractive development.|Keratoconus', 'under radiation', 'non-physician healthcare', 'specifically co-stimulates T cells', 'ROME IV', 'rather than neck', 'myeloid', 'insulin-dependent', 'screening|New York Heart Association Class 3 or 4', 'suitable for radical treatment', 'PVB)||', 'T3.|Patients', 'Grade II or above by the New York Heart Association', 'a:||Normal', 'preclude conduct of the study procedures', 'surgeon|Pain radiating', 'peri-implantitis lesions', 'non-threatening', 'uncontrolled', 'BM|Sensation of incomplete evacuation', 'Malignant', 'PD-L1 inhibitor.|Has any history', 'cyclosporin A', 'CNS-active', 'non-dominant hand||Enrolled', 'neck region.|Patients', 'under the care of the Active Surveillance clinic', 'related anemias', 'suitable for participating in the clinical trial.|Subjects who have received', 'older|Advanced', 'adequately controlled', 'Permanent molars', 'Non-Alcoholic Steatohepatitis', 'which may mitigate chemotherapy-induced', 'non-combustible', 'intracranial ICA', 'influence the study result|The subject with', 'GFD|Unwillingness', 'ischaemia|Pregnant', 'membranes),|Acute', 'tested for pregnancy (see Section', 'suitable for ET installation', 'full-term', 'peak-dose dyskinesia', 'Prior', 'under calm breathing||', 'graduated', 'Counselors:||Inclusion criteria', 'follicular phase', 'old|Bilateral', 'non-athletic healthy', 'scapular region', '≤5', 'undewent', 'surgery|Recent', 'may significantly alter drug absorption of oral drugs', 'successfully treated.||13', 'Stage 1', 'skill-based groups).|Young people will be excluded if they have', 'sero-positive donor', 'Inguinal', 'lumbar spine (lombosciatalgia)|Use', 'Cardinal Symptom Index (GCSI)', 'strangulated', 'CT).|Systemic', 'non-covalent BTK', 'non-contrast computer tomography (', 'barium meal', 'third degree superficial', 'African-American|Age', '2-dimensional', 'medically effective contraception', 'System.|The', 'Activation|ST-Segment Depression', 'cancer', 'STOP-Bang questionnaire', 'MCDI-WG|use', 'occlusion|Existed', 'radiological', 'lips relaxed).||', 'musculoskeletal system|Have diseases', 'suitable for participation as judged by the Investigator', 'premolar', 'metastatic|is', 'middle trapezius', 'hip joint.|Patients that are', 'M2 segment', 'suitable for inclusion evaluated', 'lymphoma)|adult', 'requiring urgent', '≤2 prior induction regimens', 'suitable for interventional embolization', 'transplantable', 'Pathologically confirmed', 'Type 1-2)|Fracture', 'pathologically confirmed', 'irreversible', 'index procedure.||', 'high school equivalent)|Right-handed||', 'eligible.||Relapsed', 'refractory to locoregional therapy', 'hematologic malignancy|Neutropenia', 'could interfere with absorption of study treatment.|Prior exposure', 'N1-N2；T2-4', 'lumbar region with DEXA evaluation||', 'non-clear renal cell carcinoma', 'moderate smoker', 'mental health provider.|Reports', 'Ascitic', 'intrinsic red blood cell defect', 'pregnancy|Pre-existing', 'inflammatory', 'Permanent-salary staff working', 'clinical diagnosis', 'urethra', 'primary arthritis|secondary arthritis|aseptic necrosis of the', 'Type 2).|May', 'Overt', 'DMDs|Confirmed diagnosis', 'underlying', 'self-manage', 'site tongue', 'rectus fascia', 'prior', 'Post-traumatic neuropathy', 'wolff-parkinson-', 'radicular symptoms.|Previous cervical discectomy', 'osteochondral lesion|BMI', 'HIV)-positive', 'ipsilateral thigh', 'wounds', 'large area', 'corneal ectasia', 'non-squamous histology.||Note', 'under study', 'intolerance；|Peripheral neuropathy', 'years|Refractory', 'High Risk of', 'infection|active dermatosis|unrealistic expectations', 'kg)|Foscarnet|Ganciclovir|Valganciclovir|CMV-directed cytotoxic T lymphocytes||Planned receipt of the following', 'incisional biopsies', 'instability|Non-sinus rhythm', 'neurological disorders,|Having a', 'proximal radioulnar joint and is otherwise|Patients willing', 'requiring treatment;|Any organ metastasis', 'apparently been', 'refractory to first-line therapy', 'considered acute', 'Full-term', 'prevent', 'anorexia', 'active phase of', 'study.|Non-healing wound, ulcer', 'antihypertensive medication;|age 40', 'humerus', 'second trimester of pregnancy', 'specifically target T cell co-stimulatory', 'EBV-related', '≤-0.75 D|Anisometropia', 'mellitus|Clinically significant', 'study|Adequately', 'maximum diameter ≤ 3cm|ECOG-PS score', 'in-house clinician', 'ILD)/non-infectious', 'per-trochanteric', 'questionnaires|Attendance', 'uncompensated', 'full hospitalization|Participant co-morbid', 'adequate dose of the manufactured product', 'laser', 'stable CLL.|History', 'non-dilated', 'ONLY||Active', 'SARS-CoV-2 genome', 'Symptomatic', 'limit understanding of instructions;|Cultural limitations reducing abstraction', 'anteromedial cheek regions', 'severity of pulmonary hypertension', 'immune system', 'BHFS', 'Pathologic', 'under fluoroscopy', 'genitourinary', 'Female', 'criteria:||DSM-5 Attention-deficit hyperactivity', 'months|Abdominal', 'proximal interphalangeal', 'blast phase', 'consent.|Type 2', 'move|Life threatening', 'local treatment.|At least one measurable lesion', 'moment of randomisation', 'osteoporosis|A', 'regional anesthesia', 'suitable to enter this study', 'rotavirus vaccine', 'fibrosis|Active tuberculosis|Postobstructive pneumonia|Suspected bronchial', 'PD-L1 testing', 'specifically targeting T-cell costimulation', 'under poorly controlled.|Child', '3|Full term', 'non-third', 'intra-abdominal infection', 'SAME TIME', 'inotropes.|Presence of a', 'acceptable effective contraceptive measure', 'lumbar dermatome.|Red', 'Chinese', 'IHC 1+', 'susceptible in', 'botulinum toxin (Botox)', 'Non-English Speaking|Under 18 years old', 'Numerical Scale', 'Stage 5', 'drug use', 'arteriolar', 'through', 'visit)|Significant', 'auxiliary stage', 'not take', 'full-length spike protein', 'Grades 2', 'central nerve system metastasis;|HIV positive', 'reticulated', 'diseased tissue (sterile sampling', 'African American;|have been assigned the', 'Mount Sinai Hospital', 'self-report <6 hours/day of', '≤2 IU/dL', 'non-local pain', 'lactation;|Diagnosed', 'neuro-', 'CSF evaluation and contrast-enhanced', 'American College of Rheumatology/European Alliance of', 'non-chronic condition', 'prolapse|Grade III', 'Minimally Conscious State plus|Feeding through', 'Cognitive Reappraisal', 'centile', 'meniscal tears', 'index-procedure.||', 'secondary to trauma', 'self-compassion', 'alteration)||CD22-positive', 'essential', 'between the pathological', 'ROP', 'MRI.||', 'L.1121-7', 'ureteric', 'post-traumatic stress disorder|Neurological disorder', 'numerical scale', 'first-line', 'prohibited ≤14 days before the start of treatment', 'replacement', 'in room air', 'acute stage;|diseases of the thyroid gland;|therapy with any', 'peri-implant site) OR|Signs', 'low-potency topical corticosteroids|No', 'Central Nervous System (CNS) metastases', 'tumor tissue must still', 'signs', 'PD-L1 immunocheckpoint inhibitors', '(room air PaO2', 'scalp', 'Dutch language;|2', 'adrenal', 'CF', 'mild to moderate facial lipoatrophy', 'operation room', 'interest;|Severe general medical conditions;|Uncorrected', 'consumption', 'implantation site 12', 'hormone replacement|Any chronic skin condition', 'blast crisis now in second chronic', 'unsuitability for cancer drug treatment|Poor co-operation', 'unknown origin', 'actively', 'MRD-positive', 'mild punctate keratopathy', 'serious unstable', 'index-procedure', 'medically-prescribed', 'high dose', 'core antibody', 'first-line chemotherapy', 'positive|acute lymphoblastic', 'User', 'Laparoscopic', 'suitable for implantation of', 'under section', 'post-traumatic injury', 'ST segment elevation', 'infrared exposure|Inability to fit into the sauna device|Breast implants|Pregnancy', 'meeting these criteria', 'wear', 'very advanced', '-treated', 'psychiatric disease|High-blood pressure', 'coronavirus', 'peri-implant mucosa;|pain', 'effort-related', 'Angio-CT study performed', 'mPAP', 'low-dose radiation therapy;|They voluntarily participate', 'AIDS)- related illness', 'full understanding', 'diseases.|Concomitant', 'peroneal', 'mania;|life threatening', 'medication|pregnant', 'long COVID-19 3 months from the onset of COVID-19', 'non-invasive tumors', 'planned same day', 'diameter of 1 cm to 5 cm', 'suitable for treatment with TEAS.|Opioid hypersensitivity.|Psychiatric disorders', 'stage I uterine cancer.|Treatment', 'greater than NCI CTCAE grade', 'deceased donor kidney recipients.|Patient', 'third dose of', 'First Affiliated Hospital of Guangzhou Medical University were collected', 'injury|self-reported', 'sperm', 'afferent', 'CSF||Exclusion Criteria', 'unsuspected', 'Silent', 'obstruction)|Locally advanced', 'intra-cerebral hematoma', 'locally treated', 'place the subject at increased risk following exposure', 'Stage IV (T any', 'could cause unacceptable safety risks or compromise compliance', 'sore throat', 'requiring intervention.|Have', 'Non-Hispanic', 'suitable for PVI', 'Stage IIB', 'Drinks more than nationally recommended units per week', 'avian', '16-23 months of age|Step 2A', 'worse than or equal to logarithm of the minimum angle of resolution', 'Fractures', 'suitable for EaveTube(ET)', 'medically stable', 'invasive opportunistic', 'clinically stable state', 'hard tissue tumor of the oral cavity.|Supra-', 'Article L. 1121-16 of the French Public Health Code', 'twins', 'Calcium,|Pregnant', 'first degree relatives.||For', 'Nancy University Hospital.|Patients', 'lactating', 'accurately assessed at baseline', 'intra-ocular opacities|Macular changes', 'site of disease', 'humanized', 'Gingival recession', 'exploitable', 'grade 2', 'biopsied in situ carcinoma of the cervix uteri', 'non-involved', 'Diagnostic and Statistical Manual of Mental Disorder 5th edition(DSM-5', 'influence the vital prognosis', 'impacting facial volume augmentation', 'increasing stage)', 'primary sites', 'clinically evident causal lesions', 'Stage II NK||Clinical findings', 'clinically relevant abnormalities', '65||', 'upper limb or|Pulmonary embolism', 'CI500 series (CI512, CI522, CI532) cochlear implant.|Fluent speaker', 'sport activities', 'intervertebral disc', 'suitable for enrollment judged by the investigator;|13)Patients', 'high-purpose bone radiation therapy', 'preoperatively', 'Large', 'German Medicines Act', 'diagnostic criteria outlined', 'Ocular Surface Disease Index (', 'Non-Malaysian', 'Human Immunodeficiency Virus (', 'clinical stages', 'without claustrophobia.|Can understand the research process', 'ECOG 2', 'highly permeable', 'Section 6.5.|Pregnant', 'tetrahydrocannabinol', 'intra-abdominal', 'Stage Ib', 'Grade 2 or greater toxicity from previous anticancer therapy', 'admitted to ICU.|Those', 'despite its', 'IMP', 'Rome IV criteria|Ruled', 'IV.||Without mutation of', 'G8 geriatric screening test', 'modulatory effect.|Does', 'urinary', 'symptomology of infection may obscure the outcomes of this study|Other medical', 'high dose TBI (≥10Gy)', 'non-registered', 'unknown etiology viii', 'preclude comprehension of', 'refractory', 'mild to moderate corticosteroids', 'unstable dose', 'VAS)|Both', 'in room air|Karnofsky', 'primary cancer|Inflammatory breast cancer|History of', 'medically unstable', 'rehabilitation', 'identify the target volume and may determine uncertainties in CIRT dose distribution', 'creatinine|Negative Infectious tests (', 'primary HR+/HER2-', 'behavioural', 'could contribute weekly mood', 'IBS questionnaire', 'surgery|final', '5:2 programme', 'occlusal contact', 'Care|Stable dose', 'AI', 'adequate treatment;|26', 'tumour tissue sample (if available)', 'non-BRCA1/2m cancer', 'Alli)|prescribed', 'lumbar region and lower extremity', 'adjuvant', 'Grade 2 alopecia', 'emergency medicine nurses', 'contraceptive foams', 'Rome IV criteria|Have', 'potentially malignant adrenocortical carcinoma', 'low', 'acceptable form of birth control', 'Danish.|Referred to MRI', 'large specimens/case', 'self-reported disability', 'MA)|South', 'pericardial effusion|Baseline oxygen saturation', 'AMI||', 'Yersinia spp (', 'muscular strength', 'highly effective forms of', 'endometrial', 'age)|Diagnosis of ALS', 'stage', 'fibroid', 'preclude lumbar puncture.|History of known', 'MSI-high', 'female;|Regular', 'clinical I-III TNM stage', 'could alter the locomotion;|pregnancy', 'screening|Previous', 'thoracolumbar spine', 'ankle sprain history|""feeling of instability""', 'temporary', 'characterized', 'End-Stage Renal Disease', 'Secondary', 'influence the condition of the hand', 'medically not justifiable|Current', 'Rome IV diagnostic criteria|Patients', 'OR|Two bone lesions', 'non-hormonal contraceptives', 'ALK inhibitor', 'influence the flash glucose monitoring (FGM) sensor', 'inclusion|In remission', 'half-pint', 'white dot syndromes', 'platinum-containing', 'may significantly impair renal function', 'Italian version of the MMSE', 'low user-dependency', 'adequate organ function|Have a performance status', 'Contralateral', 'contrast allergy)|Pregnancy', 'accredited', 'diaphragmatic', 'elbow area', 'consume excessive amounts', 'mean PV', 'lymphoblastic', 'implant site.|Inadequate arterial flow', 'France)||Non-inclusion', 'non-small cell lung cancer|Patient', 'IgG4-related', 'eyes|Shrapnel', '12-ECG recordings', 'juxtafoveal', 'g', '≥1 prescription', 'carbon monoxide', 'N. meningitides', 'Internet-enabled', '3 months from the onset of symptoms', 'pathology;|received', 'generalized', 'A1 segment|Receive arterial thrombectomy', 'neuro-muscular', 'Weekly', 'full-thickness lesion', 'complement-dependent cytotoxicity crossmatch (CDCXM)', 'near the test sites', 'stable doses of', ""modify the patient's inflammatory pattern"", 'full remission', 'large cerebellar infarction', 'stable dose(s', 'intracardiac', 'self-reported change in body weight', 'clinically judged to be', 'PD-L1 etc', 'non-convulsive status', 'EBV-IgG', 'IgG4-RD Responder Index', '3 months or more.||', 'thalamic', 'stable on these medications', 'aortic sinusoid junction to the proximal cardiac margin of the innominate', 'non-irradiated', 'sepsis|Pulmonary', 'non-radical resections', 'exclusion.|Clinically significant', 'histology|non-visualized', 'researchers judged that the tumor is very', 'IM vaccination', 'bed-bound|Dementia|Residing', 'bi-malleolar', 'Danish University', 'eight-week long research study|Have a', '-1.00 to -3.50 D in each eye', 'secondary to the treatment', 'post-traumatic stress', 'prenatal depression', 'Institut Jérôme Lejeune|Patient whose parents or legal', 'influence the absorption of vitamin B12', 'AE', 'setting', 'less', 'large B cell lymphoma', 'mild-moderate-severe', 'guideline-recommended therapy.|Have', 'irregular', 'non-measurable lesion', 'polyneuropathy|Another', 'Class II division', 'acute stage of chemical and corrosive injury', 'index procedure|Thrombophlebitis', 'low stable doses', 'M1', 'non-tunneled', 'chemically related to study treatment', 'researcher judged', 'medications|≥18 years|Full', 'older|Consanguineous', 'statins|Engage', 'full-time student', 'rehabilitation programme', 'goldenseal', 'Pre-admission Clinic visit date', 'non-cooperative', 'months)|Contraindication', 'white spots', 'Viable', 'Bazett formula', 'medically significant condition', 'III', 'age|Mechanically', 'study.|Co-infection', 'influence gastrointestinal permeability', 'meeting DSM-5', 'researchers;|Clinically uncontrollable', 'PD medication', '/diastolic resting blood pressure', 'IBS-D (', 'brady-arrhythmias', 'obesity-related', 'Severe', 'high-dose oral', 'others:|Peripheral arterial', 'reflexes|Symptomatic', 'metabolic kitchen', 'surgery;|minimally invasive', 'NAFLD-fibrosis.||', 'pericardial effusion.|Major surgery', 'II|elective', 'non-hormonal IUD', 'TP53WT|Locally advanced', 'remains unstable', '17|Able to read', 'inhaled -ie', 'supportive', 'low SEP', 'PET.|Multiorgan transplantation.|Life expectancy', 'potentially alter absorption or excretion', 'any variety to the submental region for the duration of the study.|Has medication', 'naso-gastric tube', 'CNS treated', 'Non-ongoing', 'acute event|Diagnosis of', 'primary immune deficiencies', 'Diagnostic and Statistical Manual of Mental Disorders (DSM-V', 'Criteria||Unable to understand what the study involves|Unwilling', 'above|Genetically confirmed', 'morphologically with malignancy', 'simplified', 'face-down position', 'minimally invasive robotic', 'third edition of', 'Schulich School', 'ischemia', 'non-pathological', 'non-breast feeding', 'preclude stepping exercise', 'could jeopardize compliance with study requirements.||MAIN STUDY:||Inclusion', 'RA-associated', 'hard palate and floor of mouth;|No history of', 'stage IIIB', 'humeral', 'egg donation', 'bilateral', 'Specifically excluded from this study', 'surgically cured', 'teratogenic effects||* Therefore', 'articles L. 1121-5, L. 1121-7 and', 'American college of rheumatology - 2016 criteria|Between', 'important', 'controlled with alternative therapy/non-immunosuppression', 'EDA|Not receiving EDA', 'walk', 'amenable to curative therapy.|WHO performance status', 'CMV end-organ disease', 'interventional study.|Receipt of the last dose of anticancer therapy', 'zygomaticomalar', 'Hep C', 'suitable for Azacitidine(AZA) treatment', 'Grade III or IV', 'CNS', 'MRI||', 'Active Component Air Force personnel assigned or', 'except', 'non-mechanical methods|Patient', 'centimeters|overt', 'first-degree', 'Toddler', ""temporomandibular joint's anatomy"", 'Non-plaque forms of', '||Hepatitis', 'mild medical conditions', 'high dose vitamin B3 supplementation', 'vestibular therapy|uncorrected vision problems', 'under judicial supervision', 'PD-L1 assessment', 'mild to moderate anxiety', 'non-stable', 'in-hospital);|Prior', 'requiring therapy', 'Liver Clinics of', 'interfere with cooperation with the requirements of the trial|Has not recovered from adverse events', 'mild to major dementia', 'SIRPα targeting anticancer', 'arteriovenous', 'inducers - barbiturates', 'non-hospitalized', 'suitable for enrollment.|Patients', 'non-melanomatous carcinoma of the skin', 'below-knee bracing', 'mono-therapy medicament', 'influence the iron status.|Vegetarian athletes.|Having', 'lactic acid', 'listed for heart transplant;|Patients', ""occlusal relationships|Patient's consent to participate||Exclusion"", 'bone tissue', 'tablet', 'routine', 'site of occlusion', 'are judged by the investigators', 'WayToServe responsible beverage', 'Vegan', 'sexually-transmitted infection', 'relocate', 'SARS-CoV-2 N-protein', 'borderline', 'buccal mucosa|T1', '3 years prior to enrollment', 'over time.||', 'masses', 'non-lactation period.|Fertile', 'systemic treatment|Interstitial lung disease/pulmonary fibrosis|History', 'stroke|History', 'medically prescribed cannabis', 'pericardial tamponade', 'hemostasis|Acute', 'controlled with diet', 'full code', 'stable MG', 'related form of Vitamin B6', 'systemic antineoplastic therapy', 'low-stage skin', 'immunosuppressant IV-Ig', 'Multiple', 'study)|Blood', 'well-defined', 'clinically uncontrollable', 'metal joints', 'primary problem|≥', 'preclude adequate absorption of DAY101.|Patient', 'spirometry|No', 'listed in Exclusion Criteria (', 'suitable for contact lens', 'patch-type electrocardiograph|A', 'thoraco-abdominal aortic dissecting aneurysm', 'non-pharmacological', 'Taiwan regulations', 'undiagnosed', 'Sport S-ICD Study', 'GI tract;|Cardiovascular diseases', 'PMS2', 'new episode of fever', 'bulbar', 'subjects)|Clinically relevant', 'calcium channel blocker', 'codes', 'molecular differences', 'ectopic', 'existing', 'adequate organ function', 'mid-thigh', ""hypovolaemia|Adam's-Stokes"", 'upper segment', 'partial-or', 'diagnostic criteria of the newly released', 'prism', 'Rome IV questionnaire', 'female.|Contraceptive use', 'under medical conditions', 'ICD-10 Z86.010)|History', 'that affects ability', 'IDSA guidelines', 'Chronic rhino-sinusitis', 'primary diagnosis|Patients', 'II,|required', 'refrain', 'Stage II', 'upper torso.|History of', 'Faladje', 'sixty-five years|Biopsy-proven', 'non-pregnancy period', 'enrollment|Peripheral', 'radiation-induced sarcomas.|Known', 'CKD]-EPI formula', 'primary IgA', 'CSF))|Persistent', 'Healthy|Non-smoking|Non-diabetic', 'EtOH for 24h prior to test', 'jin bu huan', 'insulin doses', 'segmental', 'reliable', 'protocol-defined inclusion criteria', 'C)|Uncontrolled', 'index shoulder surgery', 'diffused', 'Piece record', 'swollen joints', ""unrelated to the patient's chronic constipation|Use"", 'stumble', 'PSI guides was abandoned.|Patients that', 'aura', 'sequelae|Revisions', 'rectal', 'primary source of their knee pain', 'non-oncology vaccines containing', 'parent-rated', 'immunosuppression|Perioperative desensitization|Pregnant', 'non-pharmacological interventions', 'lower respiratory tract - allergic asthma', 'municipal health', 'intramuscular', 'affecting the anterior iliac crest.|Infected', 'fovea|Fellow eye', 'non-auditory', 'fish products|Positive serology', 'excipients|Severe', 'molecular features.|Age', 'non-HA', 'steroid-dependent', 'mild-to-moderate', 'PD-L1 therapy', 'lower respiratory tract infection', 'hypomanic episodes.|Regularly', 'immune-mediated', '2 minutes', 'methacholine|Child', 'PD-L1)', '12-16 months of age|Step 2B:', 'C2-T1).|Surgery', 'medicinal consumption of psychoactive drugs.|3 consecutive VRISE', 'left open)|Children who should not move before dressing', 'unrelated to the target shoulder', 'positive for ctDNA', 'L1-L4', 'worse than -12 dB', 'electric', 'Asthmatic', 'specialized', 'mild to moderate acute pancreatitis', 'intra-abdominal surgery', 'grade III-IV|existing', 'lumbar MRI|Those', 'ascending aorta', '|Significant', 'months.|Active', 'Co-incidental shunt', 'IMD||', 'symptoms|Significant', 'Full time healthcare professionals', 'years|A', 'low failure rate', 'Investigator.|Known', 'Blood system:|6.1.1', 'upper extremity not', 'Suitable for PVI||', 'between first trimester', 'high-sensitivity urine pregnancy', 'neonatal unit', 'FND symptoms.||', 'primary neoplasm.|REGISTRATION', 'intra-uterine device', 'abundant', 'history.|Regular oral', 'extremely dense breasts', 'diet.|Pharmacological induced', 'grade ≥3 tonsillar', 'ACR 1991 classification.|Known allergy', 'large-area irradiation', 'related to AD|Previous', 'mid-QRS plateau', 'rectal area', 'ACR Criteria or 1987', 'made more than one year ago|Age of 18 years or older', 'requiring detoxification', 'multiple territories.|Known history', 'femoral', 'in room', 'Formalin-fixed', 'II|scheduled', 'ipsilateral upper extremity|History of', 'in males|Platelets < 125,000 cells/mm3|ALT', 'limitations)|Documented room air oxygen saturation reading', 'Nicotine)|Acute suicidality', 'secondary to tumor|Non-ambulatory', 'non traumatic rotator cuff tears', 'Rome IV criteria for the diagnosis', 'post-ovulation methods', 'articles L. 3212-1 and L. 3213-1 of the Public Health Code', 'ipsilateral shoulder', 'mediastinitis|Medical', 'old.|Able', 'second-line standard regimens.|At least one', 'clinically significant.|Acute infection', 'lower permanent premolars.|Intact buccal enamel surface with n erosion', 'emergency services', 'infection|Pregnancy|Heparin-induced', 'live-attenuated', 'upper extremity of the dominant', 'intermediate risk of recurrence', 'high grade serous ovarian cancer', 'renal', 'illegal use', 'refractory to medical treatment', 'early fullness, postprandial discomfort', 'could alter or limit final postoperative visual prognosis|Patients', 'rRT-PCR', 'non-cooperation of the family', 'PE)|PE symptom duration', 'only manifestation of', 'suitable for participating in this study', 'stool pathogens', 'lower extremity.|Prior history of surgery in the lower extremity.|Neurologic or', 'neonatal', 'operation|Hemodynamically unstable', 'adequate form of', 'large chain retail pharmacy chain', 'new episode', 'adjuvants', 'men,|Control record', '3+', 'non-completion of the questionnaire', 'stage IV);|Patients', 'any other diseases', 'podocyte genes', 'aging', 'in appendix', '0.014 ""guidewire can cross.||', 'Mild AD', 'OP) tumors|Primary cancer', 'unlikely to survive', 'under 3000 g', '65||*', 'influence brain development', 's', 'primary tumor', 'under general anaesthesia.|Subject', 'screening.|No', 'C.|Fatal', 'critically', 'non-pharmacological agent', 'insulin dependent', 'radiographically', '≥6 months;|Patients', 'etc.|History of severe', 'transient', 'tumor|Clinically significant', 'in the area of the tumor lesion;|Presence', 'site of the oral cavity or oropharynx.|Must', 'patella', 'other causes', 'under judicial protection|Patient not', 'interfere with calcium metabolism', 'Tay-Sachs', 'low-carb', 'age.||Morphologically confirmed', 'study|Uncontrolled', 'T3-4/N+M0', 'impairment of the verbal production', 'Epstein Barr virus', 'Epirubicin-cyclophosphamide', 'medically', 'acceptable method(s', 'structural', 'mechanistically related', 'NSCLC).|ALK-positive', 'highly effective contraception methods', 'unavailable', 'indolent', 'Second trimester', 'inflammatory response', 'irinotecan-based', 'listed above status', 'mood', 'stage IIIb', 'PD-CRS', 'margin-free', 'Squamous', 'treatment|Pre-existing', 'peer-facilitated', 'PTLD|Uncontrolled', 'accurately be measured in', 'Immunosuppressed', 'psychiatric diagnosis|Open to communication', 'therapy;|self-reported', 'expanded bleeding index', 'First-line', 'medically uncontrollable', 'Diagnostic and Statistical Manual of Mental Disorders) MDD', 'refractory hypertension|History of', 'lower-extremity amputation', 'suitable for this clinical study', 'poorly healed', 'preclude testing|Pulmonary rehabilitation program', '≤6 cm in', 'low dose prednisone', 'low levels of parental acceptance', 'non-MR-compatible', 'PD-L1 immunohistochemical results', 'drug-related toxicity on monotherapy', 'non-valvular', 'non-menopaused', 'affects drug', 'males)|Severe renal disease', 'ChT', 'Insulin deficiency.|HbA1c', 'SpO2≥92%.||', 'unduly increase the risk of toxicity or limit compliance with study requirements', 'suitable for study participation', 'Primary brain', 'Sequential', 'months)|Acute', 'high-functioning', 'mental disorders;|Patients', 'diameter of < 10 mm seen on', 'large B Cell lymphoma(DLBCL)|Prior', 'pelvic', 'chapparal', 'molecular features', 'protein-based', 'poorly-compensated', 'Axis Group I', 'splenomegaly', 'condition;|Current', 'days|Central', ""stable to receive the product per the investigator's evaluation|Repeat leukapheresis"", 'IMWG criteria', 'invading the liver);5', 'extensive shoulder', 'menthol', 'chest', 'neoplasms);|Uncontrolled', 'hospitalization;|Previous', 'hepatobiliary', 'post-infarct', 'digestive system', 'M1-scheme', 'Primary Osteoarthrosis|BMI', 'low complement', 'HRS guidelines', 'full criteria for BN according', 'Fc-bearing proteins', 'LVAD', 'non-oncological origin.||', 'cardiological', 'liver metastatic', 'sepsis type', 'months);|Mild ankle instability (score within 24.5-27', 'non-invasive conditions', 'perennial', 'adequate OCT||Key Exclusion Criteria||Macular edema', 'unresectable MCRC.|Patients', 'non-adenomatous polyps', '\\f', 'under this protocol.|Prior', 'primary care|not currently', 'Adolescent', 'surgery|Severe', 'admitted to Duke University Hospital.||Infant inclusion criteria', 'high-dose', 'moderate level of depression', 'influence gastrointestinal', 'requiring in depth medical treatment|Active', 'grade 2-3', 'Indeterminate', 'oriented', ""St. Mary's Health Clinic|hypertension diagnosis|obese"", 'suitable for such patients.|The', 'riociguat', 'residual stomach after previous', 'injection-related', 'unmedicated', 'under guardianship|Adults', 'cardiac', 'lower limb beyond', 'histopathologically confirmed', 'emergency setting', 'could jeopardize the safety of the subject or compliance', 'non-cooperation', 'between 3 and 17 years|difficulty in', 'under study.|Stable medical', 'emergency department||', 'self-reported)|Drug test', 'age;|Scheduled', 'clinical trials.|Age', 'occlusal', 'specially designed', 'bulky', 'a:||Severe', 'high grade)', 'both laparoscopic', 'bi-allelic disease-causing variants in any one of the T1HLP genes (LPL', 'Previously treated', 'medical adhesives', 'locally required authorization', 'panel-reactive HLA', 'very-high-risk', 'etc.)||•• Note', 'U.S.', 'internet||', 'concomitant', 'dissected', 'Non-small-cell Lung Carcinoma', 'deep sites', 'place the donor at increased risk for complications from leukapheresis', 'non-payied bases.||', 'gynecological laparoscopic surgery.||', 'suitable for practice by the service midwives', 'intra-articular bleeding of the study', 'non-stimulant ADHD', 'meeting the indication', 'any organ system', 'clinical judgement of the investigator to be in stable state', 'any other', 'other related', 'other investigational', 'protection measure|Other research with exclusion period time ongoing|All the inclusion criteria not met', 'recurrent severe', 'power seating.|New chairs', 'antihypertensive drugs;|Genetic', 'American College of Rheumatology', 'measurements|Self-reported', 'Little Rock|COVID-19', 'non-live', 'Non-neoadjuvant', 'lasting 24 hours', 'breastfeeding|Current', 'myocardium in regions remote from area of intended scar exclusion', 'PD-L1 immuno-histochemistry (IHC)', 'exceeding the level of the gastroduodenal artery as measured by', 'dyslipidaemia|Taking', 'platinum resistant', 'ARC clinic.|Under', 'astigmatism|strabismus|acute', 'Non-aneurysms|Penetrating', 'nasolabial fold area.|Those', 'upper limb circumference', 'severe other condition', 'suitable for skin biopsy|Body mass index', 'Clinically significant', 'Lower limb', 'unit|Non-acute', 'high grade non-muscle', 'IMP.||Highly effective contraception', 'non invasive', 'Discrimination', 'non-compressible vessels', 'site of injection.|History of allergy to the study drugs', 'taking IV Bis-phosphonates', 'advanced', 'contrast.|Pathologically', 'coagulation', 'some other', 'prenatal substance', 'partial dose of NTLA-2001 was received.|A', 'non-neurogenic', 'measures described', 'secondary to prior therapy', 'wounds|unhealed', 'booster doses', 'carcinomatous meningitis|Uncontrolled intercurrent illness', 'American College of Rheumatology of', 'low-active', 'only - females', 'stage III B/III C', 'suitable for intensive chemotherapy:||75 years', 'High', 'pharmacogenetic', 'primary school level|Individuals not being able to read', 'Risk Pregnancy|Gestational', 'American Academy of Dermatology Consensus Criteria', 'injection site|have pain', 'suitable for accurate repeated', 'NET|Documented', 'overt', 'internet', 'insulin pump|Lives', 'Google Play|Reading proficiency', 'pregnancy|previous', 'related significant', 'tumour tissue is available for storage', 'neurological disorder|Any recent', 'primary LHON associated mutations', 'retroperitoneal', 'genital lesions)|either not', 'methylated', 'radiation.||Documented', 'Stage 2 T1D', 'screening;|Known', 'malaria|Known', 'researchers|Primary', 'epilepsy;|Previous', 'CA199', 'non-smokers|Subjects', 'criteria', 'on room air ≥92%', 'ceased', 'salvage chemo-immunotherapies', 'non-obese', 'Cheek', 'adequate dose/duration', 'Teeth', 'suitable to use AAF', 'Unilateral', 'suitable for participating in the study', 'radiation-related toxicity requiring', 'study', 'Autosomal', 'clinically relevant condition', 'widely', 'biopsy)|short-term', 'newly transferred nurses', 'lower extremities', 'age.||', 'intra articular', 'suitable for accurate repeated measurements.||Adequate haematological function', 'partner|Partner', 'large B-cell lymphoma', 'L3-L4', 'Young infants,12-14 weeks', 'non-CNS disease.|Is', 'radiographically unstable', 'interfere with participation|Prominent initial non-speech-language impairments', 'diabetes.|Pre-existing', 'ALL)|No', 'non-race-based', 'endorsed the attention check questions correctly.||', 'infection;|Human papillomavirus', 'between two posturography', 'self-report.||Exclusion:||Patients', 'L2-L3', 'suitable participants', 'tumor tissue Biopsy samples', 'hearing|Current', 'VHL related', 'antegrade', 'BCL6 rearrangements', 'influence the result of the study', 'surgery;|Symptomatic', 'before COVID-19 vaccination', 'interfering with steroidogenesis', 'NART).|current', '≥7 glasses of alcoholic', 'non-nicotine', 'marijuana', 'conditional', 'mandibular', 'approximately 1 pint', 'malignancy- Uncontrolled', 'highly effective contraception.|Have', 'uninterruptible', 'core-needle biopsy', 'lateral neck position', 'interfering with cognitive performance', 'Danish University||', 'standard-of-care', 'might interfere with study conduct', 'listed for heart', 'translational study.|Measurable disease', 'dietary intake of', 'below T10.|More than one site of spinal cord', 'lower limb spasticity', 'same-sex behavior', 'clinically involved nodes', 'clinically significant abnormalities', 'post-bronchodilator', 'suitable for participation in this study by investigators', 'site-reported', 'Richard-Campbell', 'intracardiac electrograms||', 'ACR 1987 criteria', 'anaesthesia', 'suitable for wearing glasses);|Participation of the drug clinical trial within three month and the device clinical trial within', 'infections,|neuromuscular', 'Eaton', 'long-covid', 'interfere with cooperation with the requirements of the trial', 'Non-ambulatory|Moderate', 'multicentric', 'Diagnostic', 'Le Mans', 'related to the selected tooth||Exclusion criteria for teeth||Cavity', 'Failed', 'HIV.|History', 'dysfunction;|Uncontrolled', 'low vision', 'DOAC-SMI combination', 'might interfere with the study drugs kinetics', 'T3-T6|Potential acuity', 'NMOSD International Consensus Diagnostic', 'active phase', 'immunologically', 'DX lead', 'might interfere with, the conduct of the study', 'active phase of the illness|Able to comply with the interviews|The total score of the Hamilton Depression Rating Scale', 'within the visual axis|Neovascularization', 'amenable to surgical resection', 'clinically significant hemorrhage', 'highly expressed;|Male', 'space-occupying lesions', 'post-tuberculosis sequelae', 'concentric', 'American College Rheumatology (', 'Central Retinal Arterial Occlusion', 'non-pharmacological agents', 'non-reactive HIV', 'could cause urinary symptoms', 'influence the condition.|Allergies', 'Non-Chinese|Mentally incompetent to give informed consent', 'suitable for implantation surgery.|Systemic active', 'published guidelines', 'suitable for participating in this', 'Eating Disorder Unit from June 1, 2013, through', 'distal vessel diameter >1.5mm;|Only one', 'TGFB2', 'hot', 'IPA-', 'immunosuppressive therapy.|Acute', 'tumors.|Painful', 'listed in section 5.5.|History', 'suitable for participating in the clinical study', 'contrast media', 'toxic manifestation', 'sciatic', 'pathologic', 'limit maximal effort contractions|Brain', 'highly', 'Multiple organ', 'points.|Active', 'infection controlled', 'malabsorption', 'high-dose methotrexate', 'month;|Only one eye', 'PD with RKF', 'under guardianship|Conscious patient, able', 'infection|Active hepatitis C|Refusal', 'adequate understanding or cooperation', 'influence ability to complete assessments', 'SSc', 'platinum-etoposide chemotherapy', 'inhalation', 'patient|selecting', 'temporomandibular joint, orthopedic treatment', 'cervical level|Abnormalities', 'life-threatening CDI defined', 'Furthermore', 'AIDS;|Active', 'unstimulated', 'Stage IV).|Patients', 'angle-closure glaucoma', 'suffered', 'clinical-related', 'biodegradable', 'site of the procedure|Coagulopathy,|Use of anticoagulants|Hypersensitivity to medications|Pregnant|Use of', 'acute phase of the disease', 'preclude reliable assessment', 'enrolment into', 'influence the safety of the subject or the compliance of the test', 'Bilateral symptomatic', 'Thrombotic', 'related to their infection-associated', 'high-frequency resection', 'researcher thinks can harm the safety of the subjects and expose the research results to unnecessary risks', 'Non-Hispanic|Race', 'site of disease amenable to biopsy', 'related to stroke).|Implanted electronic device.|Epilepsy.|Metal', 'influence tissue inflammation', 'post-COVID condition', 'substantial', 'urogenital area', 'anxiety related to surgery', 'allogenic organ transplantation.|Active', 'lumbar region|Cases in which communication and cooperation are provided Exclusion criteria;|Not', 'MoCA))|allergy to capsaicin', 'reporting intake of', 'testicular', 'tumour intended', 'may cause non-compliance', 'medically unstable condition', 'scheduled to undergo cleft', 'sexes|A', 'Marsh 3a or greater', 'cutaneous', 'Mutua Terrassa', 'grade 2 prior', 'submesenteric artery root region (area 253);|Patients', 'PD-MCI', 'cracked', 'muscle strength', 'large moles.|Pregnant', 'between 2015 and 2021||', 'ICD-10-GM', 'age.|Locally advanced', 'interferes with the ability to understand study participation requirements', 'low dose cytarabine', 'palbociclib monotherapy', 'eligibility assessment.||Participants', 'Coincident', 'comorbid', 'Newly-onset', 'Non-smoking', 'quantitative PET data analysis', 'alternative resources as necessary', 'etc.|History of receiving', 'general understanding of study procedures', 'large arteries', 'non-ST-segment', 'with measurable disease', 'epigastric', 'Condoms', 'higher||Arm', 'medically reliable', 'PNH-mediated', '3-d total score of', 'grades K', 'intervention|Dementia that would prevent participation in the intervention', 'HIV;|4.Active', 'for MMA.|Participated in a clinical trial of another', 'first-degree relatives', 'requiring IV diuretics', 'primary home;|Have any health conditions', 'epithelial defect).|If', 'non-COPD', 'other etiologies', 'unilateral location', 'muscle-skeletal disorders', 'topical doses', 'PD-L1/PD-1|Age', 'with curative intent|Able', 'anticonvulsants|Clinically significant', 'Marsh 3a', 'vascular', 'days|preoperative', 'screening.|Previous', 'non-ablative laser', 'angina|acutely', 'eating', 'preclude self-administration of ambroxol up to 6 tablets daily', 'parenteral', 'ALK fusion oncogene', 'oesophageal', 'intra-cranial clips', 'mindfulness-base', 'NON-CNS lesions', 'non-steroidal anti- inflammatory drugs', 'in either eye', 'near the resection margin when opening the surgical piece', 'serious Covid-19|Pregnancy.|Bedridden|Insufficient', 'insulin.|History of', 'index date)|Age', 'vegan', 'PHQ-9 questionnaire', '01/12/2021', 'Rome IV diagnostic criteria', 'for which 1st-line', 'mild to moderate carpal tunnel syndrome.||', 'non-concomitant', 'TIMI score', 'might jeopardize safety or scientific integrity of either trial|unable to communicate sufficiently with study personnel', 'long-term antiplatelet therapy', 'Prolonged', 'virtual reality headset', 'non-binding', 'immersion', 'low-grade prostate cancer', 'Associated', 'completely', 'low-profile balloon-expandable device', 'de novo', 'non-surgical cervical cancer', 'real', 'enrollment;|Symptomatic', 'non-dihydropyridine', 'epilepsy|Clinically significant', 'low grade dysplasia', 'radiographically evident', 'foveal', 'moderately', 'study;|Self-reported', 'genetically confirmed', 'surgical site.|Parasternal sternotomy.|When the STERN FIX Sternal Stabilization System', '≥14 days', 'greater than 10 mg/day', 'enamel', 'full-mouth plaque', 'unresectable malignancies.|Patients', 'injection site|Renal failure', 'Primary Care Service Line (PCSL)', 'intra-articular injection', 'non-ocular conditions', 'i3', 'multidisciplinary approach|High NRS detection', 'hypercortisolism;|already', 'locoregional therapies.||', 'interferes with the completion of the initial', 'FSHD2', 'multiple', 'large cell lung cancer', 'Rome III constipation diagnostic criteria|Constipation Severity Scale score', 'newly-acquired', 'LM-PCI|Three-vessel', 'muscle quality', 'PD-L1 CPS', 'Inquired', 'Preeclampsia|Gestational', 'NICU.|Singleton gestation.|Gestational age 28w0d to 36w6d at birth.|Postmenstrual', 'other parts', 'SpO2 signal', 'self-reported ancestry', 'AT determination', 'IBS Quality of Life (', 'poorly responsive', 'visits;||', 'lumbar region and lower extremity region', 'related syndromes.|Ages', 'mildly abnormal', 'chronic pancreatitis|History', 'infusion;|Severe liver dysfunction', 'life-threatening', 'Metastatic', 'could not reach', 'intra-pleural injection', 'non-invasive methods', 'discharged,|Glomerular', 'other than', 'stable use of', 'moderate to vigorous physical activity per day.|If participant does not pass Physical Activity', 'Non-implant related surgery|No Swedish citizen', 'high-risk surgery', 'non-prescription medication', 'lasting for at least 2 months', 'AI-based Lunit INSIGHT for Mammography (version 1.1.4.3,', 'American College of Rheumatology criteria', 'moderate to severe gingival', 'high protein diet|Use of', 'Adjustable', 'short remission', 'American College of Obstetricians', 'areas.|Active electronic implants', 'intra-articular pathology', 'antepartum period of', 'genomic testing.||Table', 'DSM-V criteria', 'large-scale', 'some other experimental treatment', 'could impair absorption', 'meeting the International Headache Society diagnostic criteria', 'USPSTF guidelines', 'implanted defibrillators', 'uterine malformation;|Presence of', 'criteria for target lesions', 'moderate to high disease activity', 'Gault formula', 'financial', 'late', 'grade atrioventricular block', 'SCLC Exception', 'upper gastrointestinal endoscopy', 'ankle jerks', 'influence the performance of the motor program', 'parenteral nutrition', 'Clostridioides difficile', 'form.|Able to read', 'radiographically normal periapical region', 'unmedicated depression;|24 item Hamilton Depression Scale', 'interfering topical', 'second-degree', 'prenatal ultrasound|Syndrome associated anomalies', 'intended curative resection', 'breastfeeding|Previous', 'clinically significant lung', 'suitable for the trial', 'volar forearm', 'Diagnostic and Statistical Manual for Mental Disorder 5th Edition', 'Codes', 'non-fluctuating', 'connective tissue disorders.|Women', 'non-traumatic knee pain|Age', 'procedures|Pregnant', 'lower limb joints|Pathologies', 'occlusal surface already sealed', 'indolent B-NHL', 'non-Hispanic Black childhood', 'balloons', 'foster', 'fistula||Known', 'grade macrophage activation syndrome/hemophagocytic lymphohistiocytosis', 'low-grade serous', 'European Parliament', 'injury|Self-identify', 'between 01/03', 'Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision', 'age.|Verified COVID-19', 'grade 2 toxicity may be excluded);|Inadequately treated central nervous system (CNS) metastases', 'non-medicinal studies', 'under tutelage', '30%≤FEV1<80%)||uncontrolled', 'under general anesthesia||', 'Blis Q24 application sites', 'Non-business', 'long-term drug intervention', 'high-performing elderly (', 'primary hip', 'injection site.|Coagulation', 'could justify the syndrome||', 'hypersensitive', 'site of the electrodes', 'ocular surface|Lens', 'ICCMSTM scoring', 'interfere with cooperation with the requirements of the trial.|Is', 'non-responsive', 'test.|Able to take oral medication.|Has ability to understand and the willingness to provide', 'stomach|Large', 'self-management', 'self-application of vaginal products', 'neglect syndrome|Right', 'affects drug absorption;||Participants', 'Non-Small Cell Lung Cancer', 'cruciate ligament reconstruction', 'endoscopically visualized lesion', 'sibling', 'metastatic melanoma.|Willing', 'effective methods of contraception', 'Hep B', 'non-constipated IBS', 'second generation androgen signaling inhibitor', 'loading dose', 'long-term benzodiazepines.|Starch', 'high - very', 'non-restorable teeth', 'distal upper limb pain', 'Haplo-HSCT', 'African American|Unable', 'nitrile|Pregnant', 'primary vaccination', 'individual', 'specimens', 'non-small cell lung cancer);|Patients', 'under elective', 'premolars', 'grade III-IV;|The subject', 'Overall Health', 'known', 'emergency from Monday 6am to Thursday 12pm.|Patients able to understand the protocol', 'early stage', 'second-generation', 'mild to moderate dementia', 'standard-of-care medications', 'non-compliant)|Patient', 'grade III', 'Mantle-Cell Lymphomais eligible after initial therapy', 'MINI|Clinically significant', 'ESAT6', 'requiring treatment.|Participants', 'cytology.|Radiographically measurable disease', 'EGFR-TKI.|patients', 'primary diagnosis,|If taking', 'myeloproliferative neoplasms', 'full crown', 'septicemia.|Foot', 'brain.|Previous', 'core-needle biopsies', 'corneal radius', 'self-reporting', 'non-obstetric surgery', 'computer/tablet', 'articles L 1121-5 to L 1121-8', 'doi:10.15829/1560-4071-2020-4083||', 'T4b', 'collateral ligament', 'Love Attitudes Scale-Short Form (LAS-SF)||', 'monthly income', 'LASIK(Laser-assistant in situ keratomileusis', 'azasugars', '-mass index', 'consent|active suicidal', 'C2-3|Subjects', '15 minutes apart', 'considered node-negative|Estrogen', 'ureters', 'unfractionated', 'mid-face region', 'ankle movement can be included in the scope of the case.||', 'non-melanomatous skin cancers)|Concurrent illness', '4-1BB agonist', 'proven effective contraception|Person', 'locally advanced', 'suitable for intensive chemotherapy:||≥75 years', 'HCV-associated', 'American College of Rheumatology / European League', 'study|Medicated high', 'study.||Prior organ transplantation', 'poorly visualized', 'without systematic absorption', 'medical intensive', 'tanning', 'acceptable form of', 'Graft', 'retropharyngeal lymphatic drainage area (VII)', 'patients|Disturbed', 'Chronic', 'low-income neighborhood', 'largest myoma', 'curative intent)||Uncontrolled pleural effusion', 'substance induced', 'Non elective', 'calyceal', 'unrelated donor', 'intratracheal', 'Non-specific', 'Upper extremity', 'CTCAE toxicity grade is', 'lobe thyroidectomy;|The', 'influence inclusion.|history of', 'nasolabial fold area', '3-9 months of age||', 'surgical criteria:||a', 'suitable for receiving tRNS', 'Oxford Scale', 'some other lower extremity muscle', 'could jeopardize the safety of the patient and his or her compliance in the study.|Pregnant', 'primary lesion.|Stenosis', 'requiring IV injection', 'negative).|Active', 'non-biodegradable', 'near-infrared fluorescent', 'fractures', 'hard stools', 'suction', 'without evident', 'mid-face', 'mRECIST criteria', 'pleural', 'mesh-like', 'between consecutive lines of therapy', 'cool extremities', 'surgical gloves|Patients', 'insulin-like drugs', 'preclude PET/CT', 'disseminated', 'TNF-α', 'prophylactic factor concentrate.|Previous deep vein thrombosis', 'TAK-771-', 'low-invasive cases', 'preclude satisfactory completion of the study protocol', 'sagittal plane', 'non-chronic indications', 'Instent', 'teratogenic effects', 'suitable for ET installation.|<70% of HHs', 'permanent', 'second-line standard therapy', 'neck-related', 'lactation|Not', 'Emergent', 'clinical judgement|Any disease or condition', 'esophageal-gastric ulcer', 'Middle-aged', 'uveitis|epiretinal glioses', 'C]/100.4 degree Fahrenheit [°F', 'pathologically confirmed resectable', 'Wright-Patterson Air Force Base', 'short-gut syndrome', 'Non-English speaking|History', 'acrylic related jobs||', 'mid-face|History', 'sex.|Self-reported', 'ankle joint.|Clinical signs of myopathy', 'exposure.|Autoimmune', 'SARS-CoV-2', 'suitable for the patient to participate in this study', 'connective tissue disease|PAH associated', 'interfering with main outcomes|Drinking', 'non-melanomatous skin cancer', 'severity criteria', 'shock|Non-ischemic causes', 'clinically significant illness', 'frontotemporal', 'suitable for ablation treatment|Those', 'grade III and above of NYHA classification', 'diabetes|Uncontrolled infection|Exacerbation in autoimmune', 'investigator;|Manifest refraction cylinder', 'insulin to control diabetes', 'R3918-PNH-2022 [NCT05131204]', 'sterilisation).||', 'horizontally', 'self-declared', 'ALK translocations.|History of', '35.|Self-reported', 'rectal channel', 'Autoimmune-mediated', 'suitable for intensive chemotherapy', 'Primary', 'Omicron variant', 'non-controlled/severe', 'commencement', 'post-bilateral oophorectomy', 'influence the cutaneous state.|Subjects participating in other similar nutraceuticals', 'ST-elevation', 'LRRC', 'interfere with VR engagement', 'natural', 'medial branch', 'negative|Malignancy|Current concomitant', 'blood-brain barrier compromise|Previous', 'Genetically confirmed', 'intestinal absorption of nutrient and experimental product|Serious traumatism', 'applied O2 supplement', 'mgdl-1;|C-reactive protein', 'same', 'metabolic disorders|major', 'nicotine use', 'Low amniotic fluid volume that responds to maternal hydration', 'inflow artery free from the significant', 'PD-L1 expression', 'deficit-blood', 'controlled by medication', 'Cancer', 'extraction site', 'need periodic', 'temporomandibular', 'influence pain sensation|Current', 'pterygium', 'Zeiss', 'Citrobacter spp.', 'illicit', 'primary root canal treatment', 'high-risk', 'unscheduled', 'multiple-gated', 'MSA-C', 'Heavy', ""APACHI II score|Development of the patient's need"", 'periodontal furcation involvement', 'Highly effective contraception', 'index foot', 'atheromatous', 'diffuse', 'Exacerbated chronic obstructive pulmonary disease', 'lower limbs;|Pregnancy', 'possible', 'greenstick', 'mentioned above.|Major surgical procedure', 'treat', 'end of induction immuno-chemotherapy.|The longitudinal length of the PTV-esophagus overlap', 'preclude HS facilitation|Known', 'sulphonamides', 'skinfold', 'weight|began', 'Physically', 'Class IV heart function', 'grade 2||-', 'suitable for inclusion in this study', 'women)|Self-reported', 'Ultimaster Nagomi stent||Complex Procedure Inclusion Criteria||Subject', 'greater than or equal to 50%', 'could induce uterine contractions', 'more;|High', 'stroke;|Complete', 'associated', 'index date||', 'specifically targeting checkpoint pathway inhibition', 'ulceration|Esophageal', 'heel', 'supplemental oxygen.|Previous treatment', 'unplanned', 'worse than 8.0 diopters of myopia', 'Summary', 'non-alcoholic fatty liver disease', 'Modic type-1 changes', 'Neonatal Pediatrics', 'left sided', 'other immune checkpoint', 'Needing invasive mechanical', 'inpatient', 'lower limb ischemic necrosis;|Paraplegic patients;|Patients', 'months.||6', 'suspicion thereof', 'accessory', 'in a country where there is a risk of yellow fever virus (YFV)', 'grade movement', 'preclude adequate absorption of oral', 'spent', 'primary TAR in 2022.|There are', 'Carbon monoxide dispersion (DLco)', 'electromagnetic', 'intravenous nutrition;|Previous', 'vessels|metallic cardiac valve(s)|a', 'non-STEMI', 'suitable to join the study;|10.HIV infection;|11.Any situation that the researchers', 'only salpinx torsion', 'POEM', 'glutamic-pyruvic transaminase', 'unknown etiology', 'C difficile', 'FFPE tissue samples', 'hyperlipidemia)|previous', 'secondary to stricture).|Inability to provide', 'single,|Not', 'intra-abdominal tumor', 'anterolateral location ROM', 'high grade atrio-ventricular block', 'invading important', 'breastfeeding||Concerns related to glucose metabolism', 'micro-bleeds', 'emotional', 'mild stage', 'infection.|Severe', 'Castration Sensitive Prostate Cancer', 'esophageal varices;||B.', '.|Upper', 'ankle stretching', 'Primary diagnosis', 'primary treating physician', 'C4-C7||', 'Calgary Syncope Symptom Score', 'stage IV breast cancer', 'Bayley III.||', 'pituitary', 'half-lives', 'moderate to vigorous physical activity', 'angiographically significant', 'exercise-', 'worse epithelial disease', 'supraphysiological doses of', 'superior', 'worse than Eastern Cooperative Group (', 'fungal', 'glabellar', 'Diagnostic and Statistical Manual of Mental Disorders (DSM-5', 'suitable for participating in the clinical trial', 'Transient', '3-4', 'ICD-10 G93.3)|No informed consent for study participation', 'could lead to difficulty complying with the protocol|Any disability', 'non-isolated IUGR', 'retrograde transaortic approach', 'extrahepatic', 'intratumoral', 'stent delivery.|Subject', 'Grade Ta', 'grade 2 or above A.N.', 'visitor', 'injection grid.|Has', 'cross-section', 'diameter of 12~36 mm', 'high-sensitivity', 'not limited.||', 'unknown edema', 'may encourage problems', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition);|BMI', 'immunosuppressive drug|In standard practice', 'non-hepatic origin', 'atezolizumab-specific criteria', 'self report:(7', 'related to pulmonary', 'colorectal cancer|Part', 'heart', 'senior registrar', 'Investigator.|Vital signs', 'lasting between 14 and 30 days|Parents of the pediatric patient agree to participate in the study', 'requiring treatment|Accompanying', 'African descent|female|≥', 'largest lesion', 'connective tissue disease|Reoperative coronary artery bypass', 'light smoker', 'II.|Age', 'researchers judged that there was a risk of hemorrhage;|Within the first 5 years of administration', 'lower jaw]', 'subacute-chronic ischemic stroke', 'influence on pupil reaction', 'grade two or more', 'specimen)|Capability to give written informed', 'mild hyper-', 'highly selective inhibitors targeting CSF-1/CSF-1R. Previous', 'located', 'alter the absorption, distribution, metabolism', 'diseases|Devitalized', 'exceeding 5 mSv in the last 12 months or 10 mSv', 'poorly filled', 'non-neuroendocrine tumors', 'grade III and IV according to NYHA)', 'exercise induced', 'absolute', 'hemodynamically unstable', 'midface area', 'first-trimester', 'AlloDerm', 'Duo-Stim IVF', 'central-line', 'second-line', 'primary diagnosis of BN', 'abrupt closure', 'raise blood glucose', 'Li-Fraumini syndrome', 'Diagnostic and Statistical Manual of Mental Disorders (DSM-5).|Participants will be included if they have had at least one', '≥1.5 times the upper limit of reference range).|History', 'IEC).||In the escalation stage', 'subcutaneous', 'tricuspid', 'pseudoexfoliative', 'deemed related', 'related co-morbidity|Reasonable', 'could take pseudo ephedrine.||', 'Central Nervous System (CNS) tumor involvement', 'non-autoimmune conditions', 'preclude adequate absorption, distribution, metabolism', 'etc|Ongoing use of', 'suspicious', 'controlling', 'stopping', 'non-binaries', 'absorption', 'development|Partial', 'allowed.|Available tissue from the primary tumor', 'indeterminate', ""could jeopardize the participant's safety"", 'microbiome related outcome assessment|Participants', 'at recruitment|Severe chronic obstructive airway disease|Severe', 'flexible', 'non-metastatic', 'Mulligan', 'mesial-distal', 'third molars', 'suitable', 'Diagnostic and Statistical Manual of Mental Disorders,', 'pediatric B-Cell ALL', 'highly effective birth control', 'not find new lesions', 'bronchoscopy|Untreated', 'criteria:||include known pregestational diabetes,|known', 'severity of hemophilia', 'old|Undergoing', 'study|Systemic anti-cancer therapy', 'infraclavicular fossa', '12-lead ECG|Indication', 'large vessel occlusion', 'mild to moderate crowding malocclusion with', 'outside the CNS.|The', 'GAD-7 questionnaire|In screener', 'outdated', 'large amount', 'American Joint Committee on Cancer (AJCC)', 'Blast cells', 'male|healthy|non-smoking|normal', 'stroke||', 'Full term production', 'THC/cannabinoids', 'injection interval.|Treatment', 'official/local immunization', 'large-diameter stools|Presence', 'TUG Test||', 'adoptive', 'primary metastatic', 'ACR-EULAR', 'absorbable', 'RECIST v1.1)||Participant', 'inhaled hormones);|Suffers', 'ROME IV criteria for children||', 'ineligible;|ECOG score', 'could interfere with treatment or understanding of the nature', 'low malignant potential ovarian', 'suitable to participate in this study', 'pancreatic mass', 'non-alcoholic steatohepatitis', 'syndrome|Major', 'old.|Age', 'single-episode', 'microsatellite instability test', 'fulminant', 'coronary arteries', 'laboratory):White', 'proportion', 'conditions.|For', 'individually', 'neuroleptic', 'medications|Self-report', 'hydrochloride|Significant history', 'non-urothelial tumors', 'insulin for', 'related to PMDD.|Follow any exercise programs', 'long-acting nitrates', 'biopsy - persistent', 'PD symptomatic', 'Thulium', 'post', 'Long Term Health Condition', 'after fascia iliaca block + sedation', 'endocrine', 'spinal', 'mechanical ventilator support', 'clinically evident', 'low-risk indeterminate', 'prominent', 'emergency room', 'stable on medical management', 'ankle joints', 'non syndromic;|Signed', 'personal computer', 'Relapsed', 'Ib zone', 'severely', 'known to affect appetite', 'foveola;|Subretinal haemorrhage involves', 'acute period', 'Obvious', 'select', 'incurable', 'hormonal injectable', 'non-hormonal', 'stage IV renal', 'intravenous', 'suicidality', 'genetically modified cell product', 'appropriately treated', 'American Eye Association [9];|(2', 'Unversity of Virginia||', 'study)||', 'proximal humerus', 'DSM IV (e.g. psychosis', 'booster sessions', 'Australian Diabetes (', 'DSM IV', 'nuchal translucency scan Family history', 'weeks|Pre-existing', 'SH-Polypeptide-29', 'EBV-compatible', 'MIUC|Participants treated', 'reproductive tissue', 'low rate of contraceptive failure', 'under sedation', 'intracorporeal presence', 'Non-Steroidal Anti-Inflammatory Drugs (NSAID)', 'In terms of population:||Pregnant', 'II|no', 'tested before vaccination；|People who received', 'high fever|Pregnancy|Insufficient', 'primary', 'influence ocular health', 'carbohydrate intake', 'stage liver', 'SA2', 'suitable for plasma exchange', 'preclude delivery', 'self-report)|Severe', 'AV', 'grade II-IV', 'highly-effective contraceptive method(s)', 'insulin sensitivity)|Gastrointestinal tract surgery|Pregnancy', 'infusion-related reactions', 'donate', 'out', 'Device-related inclusion', 'white matter degenerative changes', 'CMV immunoglobulin G [IgG] seropositive', 'secondary to PTS', 'recruitment', 'full-mouth bleeding score (', 'suppress the immune system', 'ICS doses', 'below the transfusion threshold', 'could be related to a', 'low back pain', 'Diagnostic and Statistical Manual of Mental Disorders, DSM-5.|Patients who are unable to express consent', 'mid-face volume deficit', 'ankle-brachial index (ABI) assessment', 'difficile', 'mild to moderate gingivitis.|Male', 'Critical', 'Aortic', 'long-term oral', 'successfully completed||Major surgery', 'Quinze-Vingt ophthalmological examination', 'highly effective forms', 'to', 'unexplained', 'clinical manifestation warrants', 'medical disorder|Current severe', 'PD of', 'below the laboratory lower limit of normal on most', 'insulin deficiency', 'mineral', 'low immune function', 'tested genes', 'clenching.|Immunosuppressed', 'retinal', 'non-visceral', 'smoked', 'laparoscopic abdominal', 'suitable for long-term oral', 'self-help programme', '6', 'machine', 'sacroiliac joint', 'could prevent neuropsychological assessment|Language disorders that', 'In-Tube) test', 'high grade dysplasia', 'Medtronic', 'influence glucose', 'preferred.||Tumour tissue sample', 'Greater Victoria', 'listed in section 7.5.3', 'PET', 'grade IV|Participation', 'Radicular signs', 'IVT', 'pack-year smoking', 'fracture', 'distal anchoring area', 'cytologically documented', 'non-CNS disease.|Major surgical procedures', 'considered measurable if progression has been demonstrated', '≤33mm;|Stenosis degree', 'inhaling bronchodilator', 'regionally advanced', 'toxic reaction', 'Minimally invasive', 'nicotine use disorder', 'occupational', 'Coexisting', 'live', 'Stage 1 cancer', 'patients|medically unstable', 'Rehabilitation', 'pharmacological effects', 'hypocaloric', 'considered smokers', 'Progressive', 'Long-term', 'grade 4', 'frank', 'Stage IVB endoemtrial cancer|consent', 'uncontrolled increase of aortic diameter', 'Adequately treated', 'MAPS-D', 'preclude full participation in the study.||-', 'CP', 'ALK positive NSCLC', 'maintained', 'Diagnostic and Statistical Manual of Mental Disorders.|Have a past history', '≥12 seconds', 'primary caretaker for their infant.|Having a', 'NCIR)|Plan to stay in North Carolina', 'low-potency topical corticosteroids.||iii', 'non-emergent', 'Class III or IV', 'ILAE guideline|Patients', 'enrollment|Requirement', 'Fuchs spot', 'somatic', 'patch-type electrocardiograph', 'PD-L1 mAb', 'ankle/foot', 'intraoperatively', 'unplanned);|Covid19', 'routine test', 'may affect absorption of oral medications', 'non-obstructive epicardial coronary arteries', 'life-threatening situation', 'meeting the 2012 Berlin diagnostic criteria', 'clinical departments|voluntary participation||', 'available.||Inclusion Criteria specific to each Arm||Inclusion Criteria', 'PI.||••Formalin-fixed', 'non-sanitized surgical infection,|Use', 'upper thigh', 'risankizumab-rzaa', 'IMP|Concurrent', 'structurally related compounds', 'depositary gestagen', 'study entry.||', 'carcinoma;|No', 'naïve', 'non-traumatic|Available', 'full upper permanent dentition|Well-aligned teeth', 'suitable for participation in the clinical trial', 'papulopustular rosacea)|Age spots/Telangiectasia||Telangiectasia', 'peri-implant sites with PPD ≥6 mm', 'physician|Current', 'connective tissue disease;|Other malignancies', 'neuromuscular blocker', 'cardiac-related causes', 'old|Resectable', 'potentially cause drug-induced hair loss', 'hysterectomy).||', 'mandibulary anterior region|non consent', 'without effective control', 'transvenous', 'secondary to', 'intolerance|Clinically significant', 'Temporary', 'low level laser therapy', 'Mallya cap', 'primary DSM-5', 'ipsilateral pleural', 'non-functional', 'non-routine', 'Proximal ureteral stones', 'discharge diagnosis', 'inflammation;|recent', 'resected', 'encephalopathy.|Known', 'flow cytometry-confirmed', 'head;|Psychiatric comorbidities', 'suitable for MR', 'Walkasins|Self-reported', 'suitable for lumbar puncture', 'could significantly affect their balance and gait|All subjects will be capable of following directions for the protocols', 'recurrent', 'cataract|Compromised', 'seizure.|Participant', 'irregular day', 'synthesis|Current', 'Newly-occurring pneumonia', 'central nervous system diseases;|(12', 'high-sensitivity troponin algorithms|Multivessel', 'primary diagnosis|Chinese traditional medicine', 'breastfeeding|unstable', 'housing arrangements', 'acute stage', 'ST-elevation myocardial infarction [STEMI', 'urine protein positive;|3', 'Seronegative for', '4.||Have', 'inclusive).||Contraceptive use', 'age|Self-reported', 'sports', 'serious', 'full diagnosis', 'agent|Confirmed', 'grade A', 'under', 'leukocytes', 'non-oxygen inhalation', 'DSM-V', 'Minimally Invasive', 'None||-', 'castration resistant (CRPC)', 'Age<18', 'neoplasia).|Chronic', 'complicated', 'controlled by medication).|The', 'could modify immunity', ""suitable for enrollment in the Investigator's opinions"", 'nonspecific', 'largest residual mass must represent', 'mild senile groin eczema', 'recreational', '≥450mL of', 'not', 'Grade ≥3 immune-related', 'influence immune response', 'malignancy.|Tumor diameter', 'present', 'lower back muscles', 'reflex', 'old.|Histologically confirmed', 'R-CHOP|Prior', 'chest abdomen', 'HLH.|High dose', 'latest VF tests', 'Berlin definition;|Endotracheal mechanical ventilation', ""Diagnostic and Statistical Manual of Mental Disorders (5th Edition)'s criteria (DSM, American Psychiatric Association, 2013).||"", 'medically uncontrolled', 'upper extremity finger for a period of one-hour', 'non-irradiated lesion', 'primary immunodeficiency;|Patients', 'amplitude-modulated', 'PSP)|Histologically confirmed', 'visible', 'condition.|Previous', 'diameter of the periapical radiolucency ranged', '.|From the same geographical area', 'physician.|Bilateral', 'good', 'MSI high CRC', 'authorized', 'waist hip ratio', 'grade I', 'medications.|Tobacco smoking', 'airway obstructions.|Inability to perform the required exercises.|Inability to attend the', 'that affects clotting', 'topical eye/nasal drops', 'could lead', 'low dose aldosterone antagonist', 'full-thickness DFU', 'very poor risk cytogenetics', 'severity of this disease', 'Diagnostic Arm of the study', 'under general anesthesia.|Lung nodules should be up to 3 cm in diameter and located in right', 'unfinished', 'suitable for SOC therapy', 'Operational Unit of', 'suitable for participation in this study', 'intra-ventricular mass', 'pregnancy|receive', 'preclude PrEP initiation', 'Spine Clinic of', 'primary neoplasm|REGISTRATION', 'primary lead', 'excluded.|Self-reported', 'transdermal|Progestogen-only hormonal contraception', 'Danish general practice|GPs', 'peptic', 'IGF-1', 'functional', 'Mitomycin-C', 'assessable', 'older|Active', 'months|Histological', 'Newly treated', 'medication use in which alcohol consumption', 'central nervous system；|Patients', 'Systemic disorders;|Individuals', 'sulfonylurea|Acute symptomatic', "">160'|Advanced liver"", 'pregnancy', 'DSM 5', 'natural resolution', 'NSAID arm', 'female|good', 'Self-administered', 'large-volume paracentesis|the use', 'Extramedullary', 'Tumor tissue', 'without microbiologic evidence of', '18F-fluorodeoxyglucose', 'only for patients);||', 'hypogonadal', 'inked margins).||', 'Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision', 'under guardianship', 'suitable for curative multimodality treatment', 'unidentified', 'Syncope Unit of Auxologico with a diagnosis of possible or certain reflex syncope', 'virus vaccine', 'low habitual consumption of fatty fish', 'primary infertility|Having regular menstrual', 'preclude delivery of stimulation', 'participation|Current', 'Non-Western', 'Centre for Disease Control', 'primary small cell histology||Localized', 'are unknown. For this reason', 'PD-L1 status.||', 'L.1121-8 of the Public Health Code:||Pregnant', 'site investigator feels could have an immune modulatory effect Note: Topical', 'medically treated', 'mosaicplasty', 'diabetes.|People use insulin', 'Great Britain)', 'adequate dosage', 'C5) antibodies', 'SmPC.|Body mass index (', 'for current infection)|Uncontrolled anxiety disorder', 'suitable for ATG treatment.|A', 'index child', 'heterogenous', 'upon excavation of caries.|Rapid exposure', 'ALK-targeted TKIs.|Previously received more than 1 regimen', 'measurable', 'stage III-V', 'primary degenerative', 'non-invasive support|Suspected', 'O2 sat <90%)|Statin Intolerance|High-sensitivity Troponin I', 'lasting more than two weeks', 'corrected-to-normal', 'mucous', 'break-up time', 'locally recurrent', 'Stage 2+ AKI', 'municipal drinking', 'between 21:00', 'chemically induced', 'craniocerebral', 'evolution', 'alternative cause', 'poorly differentiated', 'seasonal influenza', 'PDx', 'Low-dose', 'cytologically-', 'FV Leiden', 'need', 'semi intensive.||', 'under general anesthesia', 'mild to moderate facial acne vulgaris', 'suitable for pulmonary function test', 'malignancies|surgically unmanageable', 'full spine X-ray', 'external', 'American Diabetes Association (ADA)', 'Oral', 'Ocular Surface Disease Index questionnaire', 'acute exacerbation phase', 'unclassified', 'self reported skin condition', 'MDRD formula', 'corporis', 'residual invasive cancer', 'non-correctable', 'AD involvement.|Worst pruritus', 'total number of metastatic sites', 'preclude receipt of the study drug.|Unwilling', 'mild-to-moderate crowding', 'without cohabitation', 'SP', 'bone marrow).||Active', 'Stage III or IV', 'primary cemented', 'panoramic', 'CKD stages', 'durable', 'insulin dosing regimen', 'IBS', 'diseases treated', 'internal jugular vein||', 'on room air obtained', 'PD', 'Actively', 'de-epithelialized gingival graft (DGG) from the palate|Willingness to provide', 'lasting for several days;|In the opinion of the Investigator', 'live-attenuated vaccines', 'PCR-', '3 or more', 'self-consent|Understand', 'H. Prior', 'upper respiratory tract infection);|Pregnant', 'transdermal|progestogen-only hormonal contraception', 'Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation', 'non-orthopedic injuries', 'meets the Lugano2014 criteria: lymph node lesions', 'psychiatric disorder.|No', 'excessive intake of alcohol.|Positive screen for drugs of abuse', 'lactulose', 'lutetium-177-PSMA', 'prognosis;|Cannot tolerate', '5-MeO-DMT', 'TAA', 'suitable for TAVI.|Patients', 'influence the outcome of the study', 'atrioventricular', '12-20', 'NGS analysis has been', 'primary uveal', 'endocarditis|Acute myocarditis', 'similar', 'non-light-based', 'could change the mesiodistal diameters of the teeth.|Teeth', 'retrospectively collected andv available data.||', 'bleeding tendencies', 'Rome III', 'ICD-10 code E28.2', 'controlled by medication;||(vi', 'definitively treated', 'preschool stage||', 'highly effective starting at time of informed consent', ""C|auto-immune hepatitis|Wilson's"", 'non-specific', 'NAFLD advanced fibrosis', 'hard of hearing', '110 lb).||', 'Investigator.|Active', 'insidious', 'ICD|ophthalmological', 'greater than CTCAE Grade', 'seasonal', '±15kg', 'meeting our criteria', 'no menstruation', 'on room air.|Patients with prior', 'lower extremity venous ulcers', 'influence the dissolution', 'hearing aids', 'HCV.|Lab', 'conscious', 'African-American|Parents', 'emergency situations|Pregnant', ""interferes with the educational process,|Transferring to another school,|The participant's right to withdraw"", 'ALK fusion', 'Non-squamous cells', 'reproductive organs.||(2', 'Vision Analogue Scale', 'suitable for participating in this clinical study', 'women|Left', 'another PD-1', 'EXTEND trial must', 'non-traumatic)|Patients classified 3A 3B', 'ever', 'American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual', 'scores of', 'bone', 'study.|Rampant', '/products', 'persisted', 'tumor tissue block', 'SGLT2i|Pre-existing', 'muscle-invasive', 'non-valvular atrial fibrillation', 'Group B (', 'skeletal', 'IBS-D', 'clinically documented||Exclusion criteria for', 'tumor-related', 'may start after study', 'mild to moderate symptoms|Female', 'central nervous system tumors', 'sling|Participant', 'mandibular molars', 'inclusive.|Good general health', 'smoking-related products', 'anticipated', 'electronically implanted', 'supracollicular', 'without stopping', 'avium-intracellulare infection (MAI)', 'gout.|Malignant', 'hemorrhagic', 'consent).|Have relapsed', 'Central Nervous System (CNS) involvement', 'immunoglobulin M', 'refugees', 'NOS|ALK-positive', 'PR positive', 'low-dose aspirin;|age', 'highly effective contraceptive methods.|Capable of', 'may contribute to different chronic', 'effective dose', 'implant -retained overdenture.|The', 'statin related', 'ST segment elevation of', 'extensive stage', 'on steroids|Patients', 'linear immunoglobulin', 'Diagnostic criteria', 'systemic AE therapy;|Patient', 'related to TBI|Active substance abuse', 'preclude the application of fNIRS device', 'epithelial', '3-', 'Non-English speaking', 'site of block', 'Upper trapezius, SCM', 'Trifocal TFLIO130C', 'receive', 'radiological symptoms', 'reflux-related conditions', 'severe pelvic inflammatory disease.|Active lower genital tract infection.|Pregnancy.|Women who do not', 'RA-related', 'epidemic', 'sensitive teeth|restorations', 'grade 2-4', 'primary etiology', 'minimally symptomatic', 'ACR/EULAR', 'grade III-IV', 'post- menopausal range', 'index date.|T2D diagnosis', 'high fever', 'sever', 'stage IVc)|Previous treatment', 'monotherapy', 'transitory', 'narrow therapeutic window', 'coenzyme Q-10', 'non-live vaccine', 'Ghent criteria', 'shoulder dystocia', 'Bilateral Sagittal Split Osteotomy', 'tele-rehabilitation|Persons', 'Swan-Ganz catheter', '≤80% corneal diameter.||Study Procedures:||Only', 'Full', 'mild traumatic brain', 'accepts text messages', 'age-related', 'without measurable disease', 'anomaly|Uncontrolled', 'time intervals between CT', 'culprit-lesion', 'hormone blockers', 'non-malignant medical illnesses', 'non-inferiority', 'reflux-related', 'preclude successful', 'media', 'older|Patients', 'reversed', 'morphologically confirmed', 'surgery;|Pulmonary', 'amenable to a curative treatment', 'shock;|Severe', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5', 'Prader-Willi', 'SARS-COV-2 infections', 'stated in section 3.3.1.|For healthy', 'freshly cut, serial sections', 'stroke|no', 'post-herpetic neuralgia', 'bloating|Significant', 'unsuppressed', 'ankle sprain', 'Grade 3B', 'other immune', 'full term', 'PD-MCI Level', 'below the level of the horizontal line from subnasale.|Any previous', 'Non-CTIMP study participation is allowed.|Sibling of a BLIPA participant', 'nurse prescriber', 'minimum stable', 'site of needle entry||-', 'image-supported', 'requires', 'index procedure|Symptomatic', 'user', 'Carcinoma.|Uncontrolled', 'Antigen-Based Rapid Test', 'lower extremities|Unable', 'first remission', 'Debio 0123', 'cleft palate', 'carbazepine', 'needed further operative', 'Acute', 'Active', 'periocular', 'IPSS-R', 'High Grade', 'connective tissue disorders', 'clinically indicated.|Single rooted', 'nucleic acid test (NAT)', 'moderate-vigorous', 'considered unsuitable.||2', 'ethanol', 'problems,|Able to read', 'stereotaxic', 'Dutch hospital||', 'self-composed', 'interventional research.|Minor patient|Protected adult patient|Vulnerable', 'primary strategy', 'site of needle insertion', 'congenital', 'considered measurable disease', 'non-reassuring', 'amiodarone:||Failed', 'third-degree', 'absolute value', 'write Turkish language,|having', 'unable to receive', 'American College of Rheumatology-', 'ventricular', 'non-systemic', 'long-term inotrope therapy', 'Insulin Free', 'Upper ureteric stone', 'coronavirus vaccine', 'lower limb mechanical axis', 'largest dimension as measured in the diagnostic CT', 'study|Chronic concomitant treatment', 'uncontrollable', 'meeting past-month diagnostic criteria', 'metastatic', 'urine|Relapsed', 'interferes with cognitive testing||Exclusion criteria', 'little', 'supine', 'non-palliative', 'portal vein.|Prior treatment', '6.5%|secondary', 'trophic', 'intra-articular injections);||Physiological doses', 'nadir', 'site of stimulation', 'intra-articular corticosteroid injections', 'middle third of the root|clinical attachment loss of five mm', 'intermediate stenosis', 'Phologically confirmed', 'low dose aspirin', 'scoring', 'glenohumeral', 'Type A dissection|Requires', 'American College of Obstetrics & Gynecology', 'enteric-coated', 'spontaneous"").||Exclusion', 'p16-positive', 'American College of Cardiology', 'primary supratentorial', 'non-compatible', 'General', 'attenuation', 'freshly collected tumor tissue before study enrollment', 'not yet authorized', 'Nail Psoriasis||', 'secondary form of', 'inclusion|Uncontrolled', 'lymphatic disease|Peripheral', 'protocol.|Myocardial infarction', 'curative', 'xanthine).|Non-membership', 'pharmacological', 'ocular antihistamines', 'finger muscles', 'unresponsive', 'bronchially', 'Immunoglobulin A', 'd-dimer', 'prenatal care|Abnormal anatomical fetal findings', 'tumor tissue', 'inter-ridge space', 'required;|Two', 'stable sobriety', 'unresectable', 'invasive', 'site of application of the therapy*.|Severe', 'stable dosage', 'Ehlers-Danlos syndrome);|Previous', 'hormone sensitive prostate cancer.|Receipt', 'Cockroft-Gault formula', 'Rome IV criteria|Not following', 'index event) neurological', 'unhealed wounds', 'lines of therapy', 'non-contrast', 'cm.|Stable', 'activity', 'post-traumatic rhinoplasty', 'Rome IV criteria', 'serostatus', 'diabetes.|Implanted', 'late stage of liver failure', 'post-surgical', 'positively-charged glass slides', 'syndrome.||Rheumatoid', 'protein powder', 'insulin resistance.|absence of signs/symptoms', 'index PCI)|Pregnancy|Unable to provide consent', 'high dose busulfan', 'Presumed', 'low dose opiates', 'post-contrast', 'meeting', 'transperitoneal', 'high-quality 3D voltage mapping cannot', 'severity of OA 2 to 4', 'gluteal fold', 'high level', 'nail', 'wide-necked', 'ACS)|Pulmonary embolism|Myocarditis|Valvular heart disease|Hypertrophic', 'hypothalamic-pituitary level', 'exacerbated', 'emergency department', 'neurological', 'pack-year', 'suitable operative', 'unable to understand the consent form, and determined by investigator with', 'alternative medicines', 'non-structural', 'diabetes|Uncontrolled thyroid', 'insulin pump|Patients', 'TMZ-related', 'radiologically-normal pancreas|VAPOR Bioresource', 'enteric infections|Pancreatitis|Indication', 'slow-flow', 'suitable for or denied', 'complement-dependent', 'antibiotics|Other', 'African ethnic backgrounds', 'Needing', 'Google', 'radiologically resolved', 'supraglottic', ""place patient's safety"", 'occasional', 'disorders|Grade IV Hill´s flap valve|Pregnancy', 'accurately record', 'pain|Able to communicate verbally|Pregnant', 'full-time', 'inhaled allergens', 'local site', 'first degree', 'stage D', 'prohibited', 'full doses', 'ALK-AlCl', 'could cause nasal obstruction', 'Normally resident', 'unaltered dosage)|Left handedness', 'bronchiectasis|Patients', 'microbiota related conditions', 'Clostridium difficile infection', 'implanted', 'protocol-defined', 'study|Chronic Obstructive Pulmonary Disease exacerbation', 'high grade glioma', 'stage endometrial', 'upper ureteric stone|size', 'monoamniotic twin', 'depression', 'successfully treated', 'first-line formula', 'non-surgical procedures', 'End-stage Liver Disease (MELD)', 'factor II', 'abnormal electrocardiograms', 'DSM-V alcohol', 'heterogeneous', '5-time chair stand', 'suitable for enrollment.||9', 'insulin use|Current', 'other investigational drugs', 'mitomycin C', 'pembrolizumab product components;|Pregnancy', 'T3-4', 'distorted', 'ankle of affected leg||', 'expected live', 'Impella placement||Meets criteria for MAC sedation:||Able', 'Non-restorable teeth', '≥50%.|12-lead ECG', 'unconjugated', 'self-directed', 'OTOF gene.||Patient', 'PerceptTM PC||', 'unrelated donors', 'botulinum toxin|Patients', 'seated', 'etc.)|Intra-abdominal infection|Urinary tract infection||Bacterial meningitis||Estimated', 'PD-L1 monoclonal antibody', 'Oxford University', 'disorder,|Cervical dysplasia,|Endometrial cancer', 'inhaled', 'suitable for repeat measurement', 'androgens', 'excessive', 'mandible', 'year|Contraindication related', 'FOLFIRI.|Uncontrolled', 'CMV reactivation', 'cross time zone pilots', 'endovascular embolization.||', 'pacemakers', 'intra-cranial neurosurgery', 'cycled', 'formaldehyde', 'could interfere with daily activities', 'Sidekick Health app', 'mid-face volume|Participant', 'study.|In-stent', 'extensive subependymal disease', 'FiO2', 'severity of AD', 'ULN|Severe', 'Low-HER2 expression', 'DNR order|Non-ambulatory', 'non-registered product', 'applied investigational', 'macrosomic baby', 'inducer|Major', 'with topiramate', 'non-severe', 'block.||Clinically important', 'multidisciplinary', 'manage lochia', 'C5,', 'ICD-10 F2x.x', 'highly effective double', 'echocardiography|Chronic severe', 'non-smoker', 'low-dose chemotherapy', 'Exception', 'impairs business', 'corneal transplant', 'site of epidural puncture', 'AML--', 'visually induced', 'requires treatment', 'grade II or III Degree', 'implant-', 'compared', 'initially lethal injury|age <18 y', 'Sore throat', 'unless', 'clinical stage', 'hypochromic', 'Myelofibrosis Secondary to PV', 'membrane dystrophy||Inclusion Criteria', 'medically treatable', 'dysplasia|Severe', 'CNS-specific treatment', 'poloxamer 407', 'older|primary', 'deemed cured', 'albumin-bound', 'Cerebral', 'technique', 'hemodynamic', 'surgical revascularization|nontraumatic amputation|peripheral vascular procedure|cerebrovascular accident|or hospitalization', 'related to CF', 'electromagnetic fields', 'major cause of dementia.|5', 'influence the result of the trial', 'vitamin C', 'clinical phase II and III)||HR+/HER2-', 'pure alcohol per day', 'not used', 'Rome IV criteria.||', 'multidisciplinary expert group review should be conducted to confirm IPF', 'genetically proven', 'clinically unstable', 'assent||', 'Non-penetrating', 'classic', 'suitable for thoracotomy', 'highly effective contraception.||', 'site level.', 'Low fertilization rate', 'non-MRI safe metal', 'persisted for more than 2 months|At least 8 points', 'upper arm deltoid area', ""reflected by the patients' choice|Are"", 'following:||Idiopathic pulmonary fibrosis|Idiopathic nonspecific', 'first-time', 'ICD-10 codes F70-F79', 'glutamic oxalacetic aminotransferase', 'thickeners', 'full understanding of the study', 'primary sclerosing cholangitis|Have immune deficiency syndrome|Previous', 'non-IMDC causes|CTCAE v 5', 'naps|any', 'Type I diabetes', 'non-metastatic)|received chemotherapy', 'highly-effective contraceptive method', 'from the peripheral serosa', 'ALT≤2.5×ULN（Normal upper limit', 'IgG) therapy Note: Individuals', 'dosing', 'other manifestation', 'large spleen diameter of more than 10cm', 'epilepsy|Uncontrollable', 'central nervous system surgery', 'SARS-CoV-2.|Body mass', 'surgical cavity||', 'non-topical hormonal therapy', 'monoallelic dominant mutation', 'PD prescription', 'primary unknown])|A', 'MM', 'primary modality.||', 'mobile tongue', 'tested for PSCA expression', 'approximately 2000 kcal/day', 'GM-CSF|Any', 'Mount Sinai Hospital,|Undergoing', 'nipple-sparing mastectomy', 'central nervous', 'plantar-flexor', 'colleagues 2016.|Neurological Control', 'non-syncopal causes', 'grade level', 'Estradiol 2 mg+ Dydrogesterone10', 'mild anterior crowding lower', 'general', 'injection site.|Significant cardiac dysfunction', 'tyrosine-based inhibition motif domains', 'considered intolerable', 'affiliated', 'Stool for H. pylori antigen +', 'Neuro-Oncology biorepository for archiving of', 'mmHg|Cheyne-Stokes', 'strictures', 'supratentorial', 'gangrenous', '2D', 'suitable for other', 'largest diameter of 3 cm|Child-Pugh liver function class', 'Interdisciplinary Simulation', 'first-episode', 'related', 'grade IV', 'adjustable', 'clinically significant.|Uncontrolled', 'suitable for pre-medication.|Pre-existing', 'self-reported function', 'COPD)|asthma exacerbation.||', 'HER2- unresectable', 'non-drug-related', 'insulin treatment', 'shaved', 'influence the outcomes|Smoking', 'preclude restricted', 'regular-strength', 'latent', 'in therapy', 'related to their diagnosis of', 'below the renal artery level|Expected survival time', 'interfere with cooperation with the requirements of the trial.||19', 'ears', 'weekly', 'ASD', 'comparable', 'lasting ≥30min', 'irinotecan injection', 'SARS-CoV-2 vaccination', 'Pre-operative', 'irresectable', 'spinach', 'invasion into', '3rd trimester of pregnancy', 'sino-nasal disease', 'IL-12.|Previous', 'in either', 'under physiotherapy treatment||', 'unilateral', 'subtotal', 'cooling sprays', 'non-reactive pupil', 'breastfeeding||Concerns related to glucose metabolism||i', 'Carbon Monoxide', 'self-reported', 'eligible|Able to read', 'non-emergency cesarean', 'AFE', 'acceptable', 'central nervous system disorders', 'months|HIV', 'patellar realignment)|important', 'surgery|Ocular malignancy|Proliferative diabetic retinopathy', 'Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition', 'sequentially', 'confined to the ipsilateral cervical lymph exclusion criteria node', 'influence balance|sedating medication', 'non-high', 'unknown location', 'stimuli|Significant', 'cytologically confirmed.|', 'head', 'Castration Resistant Prostate Cancer (CRPC)', 'senile', 'upper anterior teeth', 'gender reassignment treatment.|Blood PSA levels', 'sedation', 'interferes with oral feeding', 'adequate cough.||', 'Non-GC immunosuppressive medication', 'grade immune related adverse events (irAEs)', 'non-medical reason', 'IMDC classification', 'hyperglycemia.|Inborn', 'non-diabetic renal disease', 'non-surgical conservative', 'Ehler-Danlos Syndrome', 'partially', 'below 17.54|having', 'lasting for the duration of CT-STAR', 'AND|No', 'C3G', 'nonprescription', 'Hypercoagulability|Acute', 'reward functioning|Pregnancy', 'expanded standard kidney donor', 'may receive FT538', 'requiring the constant use of', 'unsuitable for inclusion', 'needed to receive', 'highly effective birth control method', 'Syndromic', 'Cardiac decompensation|No', 'immunosuppressive washout impossible', 'incisional', 'lower limb fracture', 'ST-Elevation Myocardial Infarction (STEMI)', 'enrolled.|History of non-infectious', 'addressed', 'total hip', 'place the infants', 'amenable for surgery', 'axillary level', 'post-COVID syndrome recommended', 'suitable for use', 'sexes;|Patients', 'LIAISON XL', 'NF1 mutation identified', 'suitable for tumor enucleation.|4', 'non-arthroscopic surgery', 'AKT3', 'menstrual cycle', 'myasthenia);|Clinical diagnosis', 'kills sperm)|Intrauterine device', 'function.|Third year of', 'Prolific', 'IV).|Recent', 'been ruled', 'non-essential hypertension', 'second-line chemotherapy', 'Third Level intensive care', 'joints', 'inoperable', 'needing high flow oxygen therapy', 'paranoia', 'twin', 'factor IX', 'locally advanced/metastatic', 'circumferential', 'DAS<1.6', 'dominant', 'MenB vaccines|Able', 'nalmefene elaidate', 'requiring administration', 'non-alcoholic fatty', 'muscular', 'secondary orifices', 'transfers', 'meeting the', 'tumor tissue samples can be', 'under the care of a cardiologist', 'Dutch perioperative guideline:|Doubt by the surgeon', 'preclude study participation.|Contraindications', 'detectable', 'ACR 2010 criteria', 'narrow therapeutic index', 'positive).||', 'varicella-zoster virus', 'Non elective operation', 'elbow', 'hormone receptor positive', 'High grade gliomas', ""non-Hodgkin's lymphoma"", 'Diagnose', 'in a context of ischemic', 'Screening|Fertile male', 'unbearable', 'Emergency', 'Axis I mental disorders', 'ultrasonography|Uncontrolled', 'invading the GI tract', 'diagnostic criteria of autism spectrum disorder', 'investigator.|History of', 'Non-cardiac co-morbid conditions', 'non-endometrioid adenocarcinoma', 'ineffective', 'older.|Pregnant', 'infertility clinic|BMI<25 kg/m2|AMH>1 ng/mL||', 'Non-female', 'tumor manifestation', 'requirement.|Active', 'on room air <85%)', 'cytologically b', 'suitable consultee', 'full active care', 'group)|major GI tract surgery', 'CR1.5 upper limit of normal', 'Upper limb', 'site of irritation；|refused to sign the informed consent form', 'etc.)|not', 'general containing calcium', 'systemic', 'investigator.|In acute attack.|Abnormal', 'long-term toxicity', 'surrounding area', 'discrete', 'excessively drowsy', 'toxic megacolon', 'marked', 'Non-English speaking|Significant cognitive impairment|Major cardiovascular conditions', 'directly', 'platinum-based', 'etc.)|A positive', 'preclude blood draws|recent hospital admissions', 'implantable', 'locally advanced/recurrent', 'TIMI grade', 'ST-elevation myocardial infarction', 'ADA criteria', 'esthetic zone', 'CXL.||', 'general safety|Pregnancy|Alcohol', 'intra-auricular', 'non-drug', 'Passive Smoker', 'class', 'N3 rank.|Full-time', 'tested', 'welding-related', 'height|Surgically sterile', 'interfere with cooperation with the requirements of the trial.|Has', 'ipsilateral leg|Second-look knee arthroplasty|Inability to communicate', 'non-urothelial bladder cancer', 'non-Hodgkin lymphoma', 'female;|Diagnosed', 'insulin replacement', 'full four-month course training', 'congenital diseases|Absence', '5-year', 'Uncorrected', 'stage on', 'pupillary', 'low dose', 'anesthesia', '2nd degree', 'reversible', 'systemically administered corticosteroids.|aGVHD induced', 'non-restorative', 'teratogenic effects of FDG in addition to the radiation exposure', 'usually live attenuated vaccines', 'preformed donor specific antibodies', 'hours|Regular', 'grade 2 or 3', 'excluded by the protocol', 'extremely late', 'CMV) DNA', 'Dandy modified criteria|For healthy', 'stage IV diseases', 'clinicallly significant', 'self-injurious behaviour', 'influence the immune system', 'cytomegalovirus', 'non-autonomous', 'used to enhance', 'deemed reliable by the investigator.|Is', 'surgery)|Diagnosed', 'Extra-hepatic metastases', 'screening.|Fever', 'irinotecan after progression from', 'ultra-rapid', '≤6 months', 'CGM|Language difficulties', 'long-term oral hormone therapy;|Are in the period of', 'subretinal hyperreflective', 'suitable for resistance training sessions', 'hyper-fluorescent signal', 'non-gastrointestinal indication', 'Unambiguous', 'bias the pain assessment),|Patient included in an interventional research protocol,|Patient under guardianship', 'treatment|Insulin-dependent', 'size.||Significant', 'non-small cell lung cancer', 'listed under the ""', 'non-Finninsh-speaking', 'low-perfusion area', 'Administration;|Uncontrolled', 'self-diagnosed', 'primary series and', 'Stage V', 'G8 screening tool|Severe physical', 'orally', 'child', 'mild upper extremity motor impairment55;|age between', 'expansion', 'lasting for > 6 months', 'Grade ≥2', 'None||', 'Locally recurrent', 'baseline|Uncontrolled', 'cataract|Severe optic', 'suitable for long-term', 'Grade I - II', 'mild to moderate COVID-19 infection', 'mild to moderate IDD|exercised', 'non', 'Anti-tumor vaccine', 'Severity Index (PASI)', 'ST elevation', 'related to the trial.|Sex: female|Age', 'secondary to medical cause', 'Hamburg-Eppendorf|Main', 'molecular diagnosis', 'non-enteric', 'PD-L1) immune checkpoint', 'wide-field radiation', 'lower extremity and spine.|Subjects who have discontinuity', 'nervous', 'non-intensive targeted therapy', 'PD-L1 treatment', 'UMSARS II item 2 ≤ 2||Controls', 'Stage IB', 'low FT4', 'intrabronchial tumor|Prior', 'fusion proteins|Known prior', 'soju', 'high grade B cell lymphoma', 'catheter', 'central nervous system metastases (CNS)', 'injection site|Coagulopathy Allergy', 'blast chronic myelomonocytic leukemia|Known', 'hypoplasia||', 'catheter placement', 'ischemia|significant', 'low grade STS', 'tears', 'forceps', 'suitable for the clinical trial', 'evaluated', 'clinical MDT;|The physical state score', 'molecular-genetic tests', 'listed in section 7.5.3 of the protocol', 'glyceroltrinitrate', 'Ehlers-Danlos', 'non-steroidal anti-inflammatory drugs', 'liver', 'clinically apparent', 'non-malignant tumors', 'ridge', 'stage IV of the', 'alveolar ridge.|Minimum bone width 5.5 mm', 'medical conditions||Serious', 'full injection of the drug', 'upper respiratory infection).||Positive for any of the following', 'grade Ⅱ', 'influence refractive development|Any condition', 'surgical specimens', '3-9 months of age', 'cardiac scan', 'low-calorie diet', 'Diagnostic examinations related', 'non-uniform pigmentation', 'copper-containing', 'Large B-cell lymphoma', 'containment', 'non-ocular', 'masticatory muscles', 'full age subject to a measure of legal protection', '≥ grade 3', 'msec|Uncontrolled concurrent', 'lasting for at least 3 months', 'decreased', 'long-term radiation exposure', 'stable regimen', 'IV)|terminal', '%', 'viral etiology', 'could determine artifacts', 'Urogenital Distress Inventory item ""Do you experience', 'Diagnosed', 'highly effective contraceptives', 'developmental age', 'limb-girdle pattern', 'efficient', 'prefrontal', 'upper arm of the study extremity|Scheduled kidney transplant', 'IIC', 'middle schools.|Grade', 'systemic inflammation|Use', 'castration-resistant prostate cancer;|Participants', 'NM-ASSIST)|Cognitive impairment', 'third', 'multistation N2 disease', 'low cardiac output', 'accelerated phase', 'grade I cardiac', 'human influenza challenge', ""near-fall occur with participant's falling"", 'central nervous system (CNS', 'lumbar spine', 'traumatic', 'T0 scan', 'geriatric rehabilitation', 'electrophysiological', 'higher than 20mm|Inability', 'intra-pancreatic', '3rd degree AVB', 'carbon monoxide [DLCO]', 'clinically significantly abnormal', 'non-traumatic', 'imminent', 'high school;|competence in spoken', 'glaucomatous', 'meeting the inclusion', 'post-nasal drip', 'pseudo-seizures', 'cerclage', 'without', 'American Diabetes Association criteria,|HTN per 2017', '500 IU/ml', ""Ehler's-Danlos Syndrome"", 'influence the ability of the research participant to respond to the procedures of the study', 'Arm B', 'worse seeing eye', 'white-white', 'study||GAP Vanderbilt||Known diagnosis of appendix', 'multi-organ', 'mild-moderate', 'score high', 'subtest', 'pancreatic malignant tumor', 'topical form on the face', 'first-line immune checkpoint inhibitor-containing therapy', 'prolonged use of', 'ocular causes of', 'Cardiac Magnet||Resonance Imaging:||For patients', 'deceased donor', 'lower limb bone surgery|Patient', 'excipients.|Contra-indicated', 'EEG', 'High dose', 'Marburg', 'adolescent', 'disorders|Self-reported', 'applicable', 'non-ST-elevation', 'rocuronium induced', 'another', 'stent', 'intra-medullary nails.||', 'passive', 'LVAD).|Scheduled for', 'prediction|non-elective', 'preclude administration of digoxin', 'Meige', 'STOP-Bang', 'years|Uncontrolled', 'suitable to participate in this clinical trial', 'diameter of the base of the atrial septal tumor', 'non-hormonal birth control', 'HPA', 'left main stem', 'mildly effected', 'left heart sections.|Patients', 'first-diagnosis', 'enrollment;|Active', 'granulocyte-colony-stimulating factor', 'BW/4 weeks', 'or|Significant', 'specific', 'ROME IV criteria||Participant or their legally authorized representative has the ability to provide informed consent', 'extensive systemic disease', 'fluzoparib', 'IMP).|Not yet recovered from surgery', 'De novo small cell neuroendocrine prostate cancer', 'PSMA PET', 'near-daily basis|Allergic', 'intra-muscular', 'primary or metastatic|Admission to surgical intensive care unit', 'C;|Uncontrolled', 'NIV', 'pure growth', 'PR-positive', 'and|Clinical Frailty Scale score', 'non-radiotherapy target areas', 'near the stimulated area,|pacemaker,|vestibular disorders', 'Non-primary', 'Axis 2', 'transgender', 'hours|Acute severe', 'period.||Teeth related criteria:||Intact thick biotype gingival tissue', 'analgesia)|application of', '12-lead ECGs', 'skin related surgery', 'site-reported)|Significant', 'neurotypical sibling', 'age|Patients', 'Uncooperative', 'GvHD)|Suffering from any other', 'Acute-on-chronic liver failure', 'planned', 'intra vaginal discomfort', 'C-reactive protein threshold level.|Diagnosis', 'study.|Intra-articular cortisone injections', 'appointment', 'Measurable', 'conservative', 'Hu5F9-G4', 'electric devices', 'uterine', '1.|Documented diagnosis', 'varus', 'fermented milk', 'Grade 2 prior', 'non-melanotic skin cancer', 'instability;|After extubation', 'low BP', 'specifically those with', 'meeting discontinuation criteria', 'Isolated ulna fracture', 'fractionated', 'CR1 without CBL mutation|JMML', 'erythrocyte growth factors', 'diagnostic criteria of', 'expanded CAG repeat', 'incarcerated Those', 'Locally advanced', 'site since radiation', 'labor;|Unable to understand English', 'non-simple IgA', 'low appendicular skeletal', 'unclear consciousness', 'meeting criteria', 'remission', 'years|critical', 'high titer inhibitor defined', 'resident-handling device||Inclusion criteria for care staff:||• Responsible', 'severity assessed', 'Alternatively', 'Sport S-ICD Study investigator neither encourage nor discourage performance of any given sport.|Patient understands that The', 'Unresolved', 'grade III-IV of NYHA criteria', 'I|Primary', 'primary caregivers', 'multidisciplinary cardiac team consisting of cardiovascular physicians', 'MRI-identified', ""suitable for the study per investigator's discretion"", 'Glaucomatous optic nerve head', 'consecutively treated', 'months|Previous', 'Hemodynamically unstable', 'clavicle', 'TIMI 0 flow', 'primary oral pathology|Bad oral hygiene|High', 'suitable for surgery', 'margins of the resected specimen', 'left hand|Comfortable', 'corneal erosion', 'interfere with cooperation with the requirements of the trial.|Has significant', 'older|Revised', 'isolated', 'self-injury', 'under investigation', 'unknown origin.|Patients receiving', 'CT', 'clinically significant disorders', 'adequately treated.|Requires', 'full term of', 'standard-of-care treatment', 'low dose (<=0.1', 'mol-MRD remains positive after the morphologic remission of AML.|No', 'OSCC)|group II', 'stage IV disease', 'relapsing MS', 'extranodal sites', 'EAC)|Able to swallow a Tylenol sized', 'Singapore||Non-Smoker:||Participant', 'Heller', 'acute phase|noun naming below cut-off|verbs naming below cut- off||', 'Pre-hospital stroke', 'clear', 'primary running related injury outside', 'lungs|Concurrent', 'apparent', 'high-density lipoprotein cholesterol HDL-C', 'unstoppable', 'full extension', 'under the standard sections for protocols among protocol reference materials', 'index event', 'place the subject', 'low level of physical activity', 'Diabetic Foot -IWGDF.|Patient with control analysis', 'index date:||A diagnosis', 'mid-face|Received', 'mid-peripheral visual field dysfunction', 'abnormal history', 'grade 2 or more', 'state||Inclusion Criteria', 'transfer;|Pregnant', 'suitable to have blood', 'considered unsafe to undergo sedation', 'ST-elevation myocardial infarction (STEMI)', 'above-listed inclusion criteria|Current', 'moderate / severe', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth', 'site of surgery 5', 'place the patient at undue risk to undergo the agents included in the conditioning regimen', 'Objective 1', 'extranodal', ""FPIES criteria after ingestion of cow's milk|patient uses beta blockers"", 'tibial', '= 10)||Exclusion criteria:||•', 'lasting 30 minutes', 'low galactose diet.|Hypersensitivity', 'alter the absorption, distribution, metabolism or excretion', 'diagnostic criteria for dementia', 'fever).|Self-reported', 'between 1 and 2 cm', 'IO+TKI', 'castration-resistant prostate cancer', 'Non-communicable', '|Maternal', 'moderate persistent', 'increasing risk of', 'v.5.|Grade 2', 'low grade lymphoma', 'HBsAg-', 'suitable for enrollment judged by investigators', 'in-stent', 'Non-arteritic CRAO', 'could interfere with judgment of the efficacy of the investigational product', 'PD-L1 test|Subjects voluntarily joined the study', 'Axis I,||', 'fibromyalgia.|Elevated', 'Class III-IV', 'unrelated to', 'H3K27M', 'proven by cytology|Clinical', 'post-operative', 'suitable organ', 'coagulopathy;|Poorly', ""very often')|Functional impairment reported"", 'RAT-confirmed', 'equation;|is judged to be', 'soft tissue coverage.|Surgical incision for whole tendon exposure', 'induction phase', 'Non-responder', 'thigh thrust', 'ST-segment elevation myocardial infarction|Myocardial infarction', 'South', 'hormone use', 'non-corrected', 'genetically modified T cell', 'Densiron-68 tamponade.|Age=', 'right anterior occipito-iliac', 'effective methods together', 'cirrhosis.|Active', 'SARS|Nosocomially-acquired', 'Botulinium toxin', 'hematological', 'extra corporeal', 'drugs', 'discharge to the community||', 'non-prescription drug', 'adequate organ functions', 'full ophthalmic examination', 'sedating', 'Inhaled', 'treatment|Dissected', 'non-smokers|Being first degree relatives', 'severe', 'basilar artery', 'suitable for ACH', 'Primary Progressive', 'peri-implantitis|Implants', 'skin', 'worse).||', 'likely to respond to', 'dizziness|clinically significant', 'Grade II or higher', 'visceral neuropathies)|Neuropathic conditions', 'membrane oxygenation (ECMO', 'granulocyte-colony', 'previously failed surgical attempts', 'acute phase of their ischemic stroke (', 'could jeopardize the safety of patients and their compliance in the study.||Multiple primary malignancies', 'regulatory', 'microsatellite instability', 'abnormal', 'Non-opposition', 'metal devices', 'refractory to standard medications', 'organ-related', '3-or 4-part proximal', 'proven', 'neurosurgery department', 'Non controlled', 'at initial diagnosis', 'second-line therapy', 'Non-molar maxillary teeth', 'Non-university students.|Non-university students from', 'systemic immune suppressive therapy', 'predominantly high frequency hearing involvement', 'nonimmunosuppressive therapies', 'critical', 'Normal', 'experimental vaccine.|asplenia', 'Non-low-grade EEC', 'infection.|Significant', 'suitable for genetic analysis', 'designed', 'CR);|Relapse after', 'use|Known', 'one unit', 'bronchopleural', 'use|Active mood', 'Reliable', 'lesions located', 'drinking habits.|No psychological problems', 'index knee|An', 'in response', 'grade I/ II.|Non-alcoholics', 'undergo', 'Non-melanoma', 'could indicate meniscal displacement', 'questionnaires|Patient', 'requiring', 'influence the absorption of drugs', 'Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for methamphetamine dependence.||', 'study;|Previous', 'without assistive device||', '≥37 weeks', 'Grade 2', 'suitable for or are not willing to accept standard treatment;|ECOG physical condition', 'intra-uterine device (IUD)', 'corticosteroid replacement', '≥210 g alcohol/week', 'sleep related', 'TIPS;|Pregnant', 'mild-to-moderate self-perceived hearing difficulties|Possession of a', 'heart|Heart contusion|Cardioversion', 'Symptoms', 'self-harming behavior;|5', 'non-malignant hematologic diseases).|Patients able to travel to', 'very high-risk', 'criteria:||IgE-mediated', 'Tako-Tsubo', 'stage III-IV', 'online EMDR).|Patients', 'enlarged', 'wide-awake', 'upper chest', 'might interfere with endpoints or compromise participant safety', 'under restraint|Patient', 'apical periodontitis|Radiographically', 'Internet-enabled mobile device', 'first-line treatment', 'pathologically-confirmed', 'constitute the DEC103 treatment;|Actual abuse of alcohol', 'Type 4', 'meningococcal infection', 'castration sensitive', 'non-treated dyslipidemia),|General anesthesia', 'diagnosed', 'Hormone receptor positivity', 'systemic AV valve|Documented', 'coffee-flavored milk', 'otorhinolaryngology', 'MR|Previous', 'non-STEMI|Concomitant', 'suitable for the group', 'stressor related disorders', 'radical doses', 'amenable to curative', 'manage', 'TIMI 2-3', 'at rest', 'stage II', 'papillary', 'low-grade cervical intraepithelial neoplasia.|Prolonged QTcF', 'Muscle-invasive', '≥1 uninvolved', 'healing process)||', 'non-cariogenic', 'old;|Requiring', 'dose', 'diarrhea.|Significant', 'insufficient Norwegian language skills', 'spherical', 'non titanium', 'neonatal jaundice|Not currently', 'clinically significant infection', 'de novo MBC', 'Severity Index', 'kindergarten level', 'insulin injection', 'salt-restricted diet', 'low or high', 'register code J44.9', 'suitable for joining the group', 'H. pylori related', 'non-objection', 'injury|Having systemic', 'illness|Clinically relevant', 'breathing room air', 'Age', 'site-specific criteria', 'medical', 'PD-L2', 'central nervous system stimulants', 'apparatus disposable', 'PBH||', 'hypodensity', 'healthy', 'cytological', 'Non-syncopal causes', 'Pre-Diabetes.|Current severe', 'vertebral', 'insulin-sensitizing', 'chronic', 'positive screen', 'between 2 and 3 cm).|Clinical AJCC stage IB', 'lactide polymers', 'Ehlers-Danlos Syndrome', 'Index young man.||', 'endometriosis-related condition', 'weeks|Fetal', 'adequate dose', 'ALK/ROS1 fusion', 'aorto-iliac occlusive lesion', 'non-sanitized', 'Third-year student', 'from initial diagnosis biopsy', 'malalignment', 'lived', 'American|Ability to read in English and provide informed consent||', 'PD-L1 status', 'suitable for prior surgical treatment.||6.The main organ function', 'University', 'non-Parkinsonian)', 'mild forms).|Diseases of the kidneys and urinary tract', 'Diagnostic and Statistical Manual of Mental Disorders, 5th edition [', 'non-objection to participate', 'medicinally induced', 'non-cholera', 'new or', 'non-cooperative|patients', 'primary form of', 'Adults;|Skeletal', 'Diagnostic and Treatment Standards for', 'with spermicide', 'Moderately severe', 'flow cytometry', 'inducers of CYP1A2', 'stimulating growth factors', 'INR followed closely.||Concomitant', 'malabsorption|Hypersensitivity to theophylline|Current treatment', 'insulin pumps', 'AKs', 'central nervous system diseases', 'lowest amount of', 'Impella', 'Screening.|Oral', 'esophageal', 'Latent', 'ICF.|Unilateral', 'pain|Self-reported', 'suitable for inclusion for other reasons', 'version 2022)|No history', 'Catecholaminergic', 'may alter or reduce visual acuity', 'lissencephaly', 'full-time|Not', 'PDL1', 'reened', 'low risk of recurrence', 'disease.|Adequately treated', 'maximum tolerated dose', 'insulin resistance|presence of signs/symptoms', 'subclavian', 'Type II).|History of cancer', 'hard tissue lesions|Heavy', 'tolerate', 'soap', 'non-French speaking', '⑨ History', 'catchment area', 'not foreseen by the study protocol', 'plasma FVIII', 'C1-INH', 'Uncontrollable', 'American College of Sports Medicine (ACSM)', 'culture-positive', 'mounted', 'requiring new', 'Axis 1', 'ocular/vision examination manual', 'LES-related', 'Moderate-severe', 'Primary DSM-5', 'insulin blood levels', 'Screening', 'researchers take it', 'non-melanomatous skin', 'non-insulin hypoglycemic drugs', 'connective tissue disorder', 'clinically significant deviation', 'non-hematological', 'unrelated to the pain', 'muscle group', 'Non-Chronic', 'ALS|Does not', 'Central Nervous System (CNS) tumours', 'atezolizumab.||P. Uncontrolled', 'sterilised', 'peritoneal', 'non-opposition|Person affiliated', 'non compatible', 'cyto-/histologically confirmed', 'amenable to anatomical surgical resection', 'non-IgE-mediated', 'non-measurable', 'spontaneous', 'Isolated', 'Sevilla oranges', 'exposed bones', 'Primary symptomatic', 'meets the criteria for being measurable', 'old|Underwent', 'non-squamous advanced', 'fractured neck of femurs', 'hard tissues of the oral cavity.|Cavitated carious', 'non-shoulder', 'heart|Lack of properly acquired EP', 'relapsing-remitting', 'skin area', 'neonatal jaundice|Currently being seen', 'occular', '3rd cycle', 'old|Primary', '10 to 15 days after transplantation', 'Criteria Phase I:||Diagnosis different from the elegible histological subtypes.|Previous treatment', 'post-traumatic arthrosis', 'PEM)/post-exertional', 'non-small cell lung cancer;|Initial', 'MDT)|Radically treated', 'over 40 °', 'flow cytometry-confirmed diseases', 'intracranial', 'corneal dystrophies', 'Down syndrome.||Patients', 'malignancy;|Clinically significant', 'non-keratinizing', 'insulin administration', 'weeks|Single-level herniation', 'CSF neurotransmitter profile', 'heterosexually abstinent', 'large B-cell', 'booster dose', 'proband|FIRST-DEGREE RELATIVES', 'PI3K', 'CMV sero-positive', 'other immune suppressive medication', 'muscle length.|History of any surgery to hip', 'folate|Recent', 'DOACs).|Prior treatment', 'Colonoscopies', 'suspected', 'poorly controlled', 'silver', 'ventral plaque|Severe', 'Second', 'injection of facial muscles', 'grade ≥3 breathlessness on', 'site of block.|patients', 'clinically significant abnormality', 'post-radiotherapy pneumonitis.|Medical Records of patients', 'decreasing dose', 'low-potency topical', 'tolerated', 'ALK-fusion', 'prenatal care', 'preparation', 'suitable for participation of the clinical trial.|Subject', 'motivation.|Pregnant', 'rather than bilateral', 'suitable for surgical intervention.|With Herscovici type D fractures', 'MCI||Current smoker|Current', '1:||Previous receipt', 'best-corrected visual acuity (', 'DSM IV criteria).|Suspected', 'greater than', 'asynchronous', 'apex.|Short root length.||', 'non-interventional trial.||', 'HAV', 'successfully performing a test after trying', 'acute phase', 'between sitting', 'shall take effective contraception', 'excessive intake of alcohol', 'suitable for standard treatment', 'shown', ""Aide Médicale d'Etat)|Active"", 'mild to moderate disease', 'of:||Symptomatic', 'maxillomandibular', 'Elective', 'severity of liver disease', 'blackouts Further exclusion criteria apply', 'investigator.|Clinically significant', 'Dutch language', 'abemaciclib on the developing human fetus', 'halal', 'first relapse|High-sensitivity', 'large doses', '3+ by ICH', 'acute', 'secondary causes', 'Gilbert', 'non-restorable tooth located in anterior maxillary arch', 'previous', 'non-Hodgkin', 'packed', 'preclude needle biopsy', '3rd year', 'toxic polyneuropathies', 'legs', 'NATA-accredited pathology', 'Large B-cell Lymphoma', 'Finnish language|a deep primary', 'screening.|Uncontrolled', 'may jeopardize the ability of the patient to undergo the procedures outlined', 'malignancy|Recent', 'smoke?|Do', 'facilitative technology', 'stage III', 'index date (date of aflibercept injection', 'non-recurrent', 'ocular manifestations|Rash', 'molecular subtype', 'upper respiratory tract', 'with curative', 'aucun autre traitement que la chirurgie', 'low grade gliomas causing visual impairment', 'aggressive', 'vertebral arteries or|Body mass index', 'eligibility determination|Eligible', 'articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the public health code', 'middle-aged', 'surgery.|Uncontrolled', 'more|diffuse', 'screening|Serious', 'non-targeted advanced', 'non-insulin-dependent', 'secondary objectives', '1)Urinary', 'low-grade histology', 'Investigator.|Patients treated', 'Chest HRCT|Evidence', 'amenable to biopsy', 'internal tissue', 'same kitchen', 'tibial tuberosity||', 'pacemaker', 'Non-keratinizing', 'upper extremity neurological abnormality', 'peribulbar', 'corneal thinning of', 'IgG4-RD;|Status classified', 'urticaria.|Significant', 'Subacute', 'apixaban|Clinically significant', 'Acceptable', 'reduced PK', 'neurological joints', 'site of venipuncture', 'unrelated to lung cancer.|Received local radiation therapy', 'listed in Section', ""unrelated to HD|Intercurrent disease that may impact participant's performance|Chronic"", 'AGH', 'non-small cell lung', 'stroke)|co-existing', 'female|Stable', 'poor', 'non-standard local ablative therapy', 'ostium of the right coronary artery,|Patient', 'contrast-enhanced', 'could interfere with the study', 'arrhythmias|Active', 'long-term drug treatment||', '12-lead ECG', '3 months', 'effectively', 'under planned', 'DIAMOND,|Active risk to self', 'coils', 'ECMO|secondary transferred from another ICU|readmission in the ICU|initial limitation of care', 'non-interventional study,|Patient', 'narrow therapeutic index of CYP2C8', 'spray', 'Grade 2 immune-related', 'CMV)', 'could jeopardize their safety in a weight control program', 'self-reported visual', 'Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis', 'investigator|Myocardial infarction', 'primary systemic malignancy', 'erosion', 'subretinal', 'below the cut-off levels', 'IHC', 'interferes with sleep', 'installed', 'peri-surgical period;|Planned use of additional', 'cervical', 'injection sites with the potential to interfere with the study results', 'preclude stationary', 'early awakening', 'Spastic', 'consumption of citrus fruits', 'granted', 'spectral-domain optical coherence tomography', 'primary debulking surgery', 'human fetus', 'opioid exposure', 'etc.).|Taking', 'secondary spontaneous pneumothorax|Lung bullae', 'Residual invasive disease', 'BCL2', 'classification|Unstable', 'circulation', '3 months|Physical status', 'K3 level', 'grade III or IV as classified by the New York Heart Association (see appendix E', 'Rancho level of', 'self-report|able', 'femoro-distal vessels|Possible post-dilatation', 'AB0 incompatibility|Newborns', 'non-controlled hypertension', 'type I', 'inclusive)|Do not', 'interfere with assessment of safety or reactogenicity', 'MTB', 'grade IV hemorrhoidal disease|Rectal prolapse|History of proctological surgery', 'multigated', 'end', 'distal lesion', 'of the oral cavity, oropharynx', 'Ethiopia.||', 'low grade glioma', 'can alter the ANS', 'worse than the radicular pain', 'erupted canines', 'carbo-platinum', 'done', 'any etiology', 'disease-related', 'ral', 'under general anaesthesia', 'index laparoscopic', 'months.|Able', 'M2 branch', 'requiring IV', 'complete', 'highly effective method of', 'suitable for participation in the clinical trials.|Subject who is pregnant', 'clinical unit||Depression', 'low handgrip strength', 'glaucoma|Clinically significant', 'iliac arteries disease', 'full year of life', 'remains uncontrolled', 'regular consumption of', 'forehead area', 'Unexplained', 'bronchodilator', 'PMD ranging from - 2dB and below', 'non-sanitized surgical', 'abuse.|Self-reported', 'favorable', 'univentricular', 'radiologically confirmed', 'hydrochloric acid).|Any prior', 'hypoand', 'actively treated', 'Severely', 'Non-applicable', 'islet-cell tumors', 'technical default', 'amenable to biopsy|Expected life expectancy', 'systemic treatment|Pregnancy', 'non-endometrioid', 'Depo Provera', 'screening.||Vital', 'red', 'non-melanomatous', 'Gentofte', 'hepatic', 'patients|Ipsilateral upper extremity fractures', 'DSM-V substance', 'moderate intensity exercise per week.|Serious illness', 'surgical site|Untreated malignancies', 'problems,|Missed anterior teeth,|Carious anterior teeth,|Intrinsic', 'Non-responder to the treatment of any other', 'full TOFHLA instrument', 'Grade A-D', 'MTX-HD', 'clinical manifestation|Had', 'stage Ib;|Stage', 'preclude adequate absorption of capivasertib.|History of another', 'material', 'unvaccinated', 'mild to moderate plaque accumulation', 'locally recurring cancer', 'Ellman grade 2', 'unhealed', 'chlamydia-positive', 'sacroiliac joint,|acute', 'PD-L1 TPS', 'controlled by diet alone', 'inclusive|Physically active', 'primary diagnosis,|A diagnosis', 'ovarian', 'suitable to receive', 'online', 'catheter-related', 'emergency room visit', 'Grade II', 'Adolescent Brain', 'central nervous system effects', 'older|Self-reported', 'epithelial ovarian-', 'Skilled', 'first-line||', 'low grade dysplasia,|Confirmation of', 'listed in https://www.malattierare.gov.it|Patient', 'optimized', 'autologous', 'locally use', 'refractory to standard of care', 'gingivitis group', 'Prohibited Concomitant', 'women|Other', 'Bilateral', 'primary team||', 'severity to limit full adherence to the study', '.|Bone secondaries not', 'unknown cause occurred', 'interferes with functional activities', 'serotonin-', 'impedes daily activities.||3', 'lactulose to control their encephalopathy are not allowed.|Had a', 'LI-RADS v2018', 'amblyopic eye', 'flow-cytometry', 'Awake', 'under ICPI treatment', 'crowded room', 'grade II lymphedema', 'molecular diagnostics required', 'non-pregnancy related', 'cimetidine|Current', 'grade II/III|History', 'coccygeal area consistent with', 'Stage IV', 'grade 3b', 'Vanderbilt', 'single-payer', '-2 to', 'non-central nervous system (CNS)', 'long-acting insulin', 'with occasional rescue inhaler', 'low flow oxygen needing neonatal unit admission||', 'Top 10 personalized', 'controlled', 'venous', 'calls', 'OCD|on', 'inevitable', 'Pregnancy|Neuromuscular', 'behavior|Current', 'suitable for inclusion', 'migraine group', 'L1-S1', 'suitable for this study', 'primary sclerosing cholangitis|Patients', 'implanting physician.|Be capable', 'metabolic diseases.||8', 'TNBC', 'laparoscopic', 'Under the care of a', 'full stomach', 'upper middle thoracic', 'Primary mediastinal', 'kinesio tape', 'contracture|Fracture', 'Expanded Disability Status', 'suitable for pelvic exenteration', 'gastric restrictions', 'muscle pain)|Gastrointestinal', 'requiring IV analgesia', 'study.||Exclusion Criteria||Glaucoma', 'pupils', 'influence dependent variables|Recent surgery', 'antiandrogen-refractory', 'ipsilateral extremity|Additional procedures', 'potentially explosive', 'hip', 'surgical area', 'Helicobacter pylori infection.|Antidepressant', 'distal', 'unaffected', 'unequivocal', 'beta-human chorionic gonadotropin', 'anogenital area', 'scapular dyskinesis', 'seizures|Expected relocation', '2019-ncov', 'evaluation|Clinically significant', 'sport related', 'aorta', 'noninfectious', 'months;|Hematological indexes', 'could exacerbate', 'lasting less than one hour.|Undergoing surgical procedures', 'periventricular', 'suitable for dienogest treatment', 'Diagnostic and Statistical Manual of Mental Disorder - Fifth Edition (DSM-5);|Subjects without', 'preclude answering the survey questions', 'raw material', 'midline', 'de-identified', '3rd edition).|Response', 'requiring insulin', 'orthostatic', 'suitable for enrollment', 'spinal cord', 'PD-L2.|Have', 'primary molars', 'malformative', 'interferes with their ability to hear music', 'Stage III/IV', 'non-insulin dependent', 'low albumin', 'medullary', 'syndromic', 'hemorrhage|epi-retinal', 'related to defecation', 'general medicine', 'perforated', 'humoral', 'highly effective', 'carbon monoxide (CO)', 'formalin-fixed', 'place the patient at higher risk of potential treatment complications', 'site-reported):||Unicuspid', 'under tutelle', 'highly malignant B-cell lymphoma[HGBCL', 'HER2', 'could cause the angiographic', 'secondary to the involvement of the spleen by DLBCL per the investigator', 'celiac', 'smoking|Unable to read', 'clinically relevant', 'NRS>3 scores in the PACU||', 'left main coronary artery', 'clinically confirmed', 'related to trauma|Hypersensitivity to the study products', 'non-iatrogenic peripheral neuropathy|Patients', 'rotationally unstable pelvic ring', 'hydrocortisone replacement', 'implanted into the skin||Combination method', 'Continuous', 'non-motor status.||Inclusion', 'anatomical sites', 'synthetic', 'smoking|Pre-existing', 'cervix.|Clinically significant', 'drainage', 'site of the lesion.||', 'primary sclerosing cholangitis)||In symptomatic', 'kidney', 'peroneal neuropathies', 'uninterrupted', 'diagnosis;|Previous', 'despite initial', 'high-resolution manometry', 'proportion of crescents confirmed', 'Grade II and III Study Grades', 'institution guidelines', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) diagnosis', 'active B', 'splenius', 'former', 'inclusive;|Trans-epidermal', 'grade III or IV) glioma', 'ABA', 'DAPT)is maintained', 'clinically relevant illness', '1.Patient', 'mellitus.|HBeAg-positive', 'above-listed inclusion criteria|Do', 'contraceptive films', 'non-erosive reflux disease||', 'narrower sense', 'L1-2', 'neurovascular bundle', 'middle', 'any complementary alternative medicine methods', 'upper trapezius', ""neurosurgical team's recommendations"", 'psychiatric disability|No', 'seropositivity for HIV', 'resident-handling device||Inclusion criteria', 'TIMI grade 3, there is no dissection that affects the flow', 'in the spine', 'other curative hormones', 'install the free FreeStyle link application', 'grade Ⅲ to Ⅳ cardiac insufficiency', ""Fredericia's QT"", 'allow remote interviewing|Medical', 'primary headache', 'Timed Up and Go test||', 'jaw or to improve speech|Can', 'TAO optic neuropathy', 'tibial surfaces|Neuropathic arthropathy|Osteoporosis', 'filtrate', 'Group 2', 'below knee', 'endanger the safety of patients', 'materially', 'distal radius (AO 23-B', 'mg);|Acute', 'deceased donor)|BMI', 'Generations 2', 'stable ones', 'Post-traumatic Stress disorder', 'Vitamin E', 'suitable for central determination', 'GI malignant', 'expressed', 'index date||Kidney failure', 'related donor', 'low back or neck', 'multidisciplinary team', 'site investigator feels could have an', 'anatomical area', '≥60 years;|active cancer|chronic kidney disease;|chronic lung disease', 'moderate/severe', 'reproductive system|with reproductive system infection', 'DSM-V (', 'age|Identify', 'tested for HIV', 'elicited']","['within the previous 12 months|Contraindications', '6 months prior', 'within the past 3 months to their', 'within 14 days prior to initial use of the study drug', 'within 5 years before enrollment;|Breastfeeding patients；|Patients', 'within 7 days before the first medication', 'in the previous two weeks.|Consumption of probiotics', 'while taking', 'during the 12-month period before study treatment|Any investigational treatment', 'within 14 days or five half-lives', 'for the first phase of the study;|Those who do not volunteer', 'in the past 60 days or test positive', 'in the 3 months prior to enrollment;|A history', 'within 3 months of enrollment', 'at least one of the following criteria:||Relapsed', 'prior to apheresis|Prior CAR-T therapy', 'within next 12 months|Do not reside', 'within 12 hours prior to surgery', 'within 24 hr. D', 'in the past 3 months|Subjects treated', 'prior to the study enrollment', 'in the last month', '≥12 months prior to enrolment', 'in the next 6 months;|Subjects', 'at least 6 months prior to Randomization|Serum cortisol (morning measurement', 'in next 12 months', 'within one month of the surgery date', 'prior to Week 0 Visit', 'within the last 18 months|they', 'after knee / hip', 'within the last 3 months;|Previous', 'within 28 days of TG6050 administration|COVID-19 vaccination', 'during the last month;|patients with', 'within 14 days prior to the first dose of study treatment.||8', 'in the last 4 weeks.|Individuals who did not complete', 'within 6 months of the first dose.|Has the', 'within 4 half-lives', '28 days ± 7 days)', 'in the last 3 months.|Catabolic diseases', 'during the screening period and before the first administration>38.0℃', 'more than 1 year ago', 'for 4 weeks', 'in the last 6 months;|presence', 'prior to study day', 'for at least 5 days prior to', 'besides TACE', 'after 1 cycle of the standard regimen', 'within 180 days before screening|Myocardial infarction', 'in the first week of the study', 'within 6 months after the end of the study.|Willing and able to follow trial', 'within 2 months of Baseline', 'in the last one month|Orthopedic', 'up to 8 kilohertz', 'within at least 3 months after the last dose of FS-1502', 'within 12 weeks prior to apheresis|Suspected', 'within 48 hours prior to enrollment', 'between the research team', 'since at least 12 weeks before screening visit', 'within the past 3 months.|For', 'Currently', 'within the past 6 months|Significant', 'consent to participate', 'during the duration of the study.|Subject', 'within the previous 2 months', 'within 1 month prior to the first dose administration.|Subject/Patient', 'in the previous 3-months', 'management platform for the upload', 'at least 30 days from most', 'last year prior to enrollment', 'within 1 month of screening).|Acute', 'within the last 6 weeks before study', 'during the study period|Hypersensitivity', 'within 2 weeks before the start of study treatment', 'more than five cups', 'at least 4 weeks prior to initiation of study drug dosing', 'during the 3 months before the intervention start date|major dietary changes', 'within 14 days prior to screening:||Serum', 'for the past 6 months.|Have', 'at a time during the first 6 months of the study', 'at the Screening visit (V1)', 'at the time of Visit 1', 'prior to participation in this trial', 'within the indicated period before the baseline visit', 'within 12 months prior to the first dose in this current', 'within 3 years after first DMT', 'within the prior 15 years.||', 'within the study', 'within 24-48 hours.||Critical', 'in the 14 days before first IMP administration', 'within 28 days prior to day 1 of protocol therapy|People of childbearing potential', 'within the last 6 months of study entry', 'beginning at least 4 weeks before study initiation', 'for the past 4 weeks', 'during the study period.|Neurologic', 'pregnant|Previous', 'within the past 12 months prior', 'within the last two years', 'within the ensuing 1 month', 'for at least 180 days after the last dose of study treatment:||Refrain', 'within 4 weeks of start of study drug', 'within 28 days prior to the first dose of IMP', 'within 7 days prior to check-in.||Other exclusions||Receipt of blood products', 'within 28 days prior to administration of this trial', 'within 6 months of Visit 1.|Has corrected VA', '4 weeks prior to the screening', 'routine bedtime later than 1:00 AM', 'within 4 weeks of baseline visit|Prescription topical medications', 'for at least 4 months after the last dose of study drug.|Subjects', 'within 3 months)|Pregnant', 'within the past 2 years', 'within six months prior to screening.|History of positive', 'during the one month prior to screening', 'before first-line induction chemotherapy', 'within 1 year before screening', 'within 14 and 28 days', 'pelvic disease.|Individuals', 'investigator.|Medical history of', 'after all relevant standard of care cancer therapies', 'during the course of disease|Slow cytologic response', 'during the study.|History of current', 'within the last year', 'within 3 months of screening scan', 'in the 12 months before', 'at the end of acute treatment', 'in the last 6 months prior to', 'before administering the study drug).||Radiotherapy', 'within 1 month before enrollment.|Patients', 'during run-in phase', 'after allogeneic hematopoietic stem cell', 'in the past 6 months|Current consumption', 'within 6 months prior to signing the informed consent form', 'for more than 3', 'within one month before the test', 'during the research protocol|to will to participate in this study||', 'between themselves and partners', 'within the prior 3 months.|Active duty military.|History of', 'at the time of recruitment|No', 'within 4 weeks prior to screening;|Treatment', 'within 72 hours before dosing|Intake', 'during screening but before the first dose', 'over the last three months', 'Medical history of', 'within 14 days prior to trial entry', 'within the last 4 weeks prior to screening', 'during the study period|Lung cancers', 'within one hour after the first suctioning procedure', 'within 6 months from screening', 'within the previous 2 years', 'for at least 1 year|At least primary school', 'during a', 'within 12 weeks prior to enrollment.|Patients', 'at the time of enrollment.|Chronic', 'within 8 weeks prior to initial dosing.|Any surgical', 'at the time of onabotulinumtoxinA', 'at time of staff', 'at the time of signing the ICF.|Provision of a signed', 'within 3 weeks prior to check-', 'at least 30 days before study entry', 'in the last 30 days,|Patients', 'within 6 months)|Use', 'within 4 weeks prior to first dosing.|A positive', 'within the last 2 weeks|Individuals', 'within 14 days before the first dose of study intervention|Participant', 'at dose of =< 10mg of prednisone', 'during the period of use of the ingestible thermosensor', 'within 30 days of the first dose of study treatment|A', 'less than 30 minutes', 'within 30 days prior to study drug administration|Class', 'over previous 4 weeks at screening', 'prior to entering study', 'during the active procedure period', 'within 2 weeks of', 'at lower pole of size 10mm -20mm||', 'up until 6 months', 'within 12 months before the onset of the training.|Subjects', 'within 4 weeks prior to the first dose of study treatment;|19', 'at least 1 days per week|BMI index', 'in the last 30 days before enrollment;|Acute inflammatory status', 'within 3 months of screening.|Participant', 'within the 4 weeks prior to the planned date of viral challenge.|Intends to receive', 'within 4 weeks prior to administration of the investigational product', 'in the past 7 days|COVID-19 positive', 'within 2 weeks prior to Cycle 1', 'within the past year|Current', 'before the first administration of study drug.|Received', 'within 4 weeks before the first dose of the investigational drug;|2', 'within the previous 28 days', 'at time of screening|Systolic blood pressure', 'in the past 2 years|Spinal surgery', 'in the last month in the vein', 'at the time of Day 1|Active', ""at least 4 weeks' duration prior to the start of Cycle 1"", 'within 28 days prior to enrolment.|Receipt', 'during the preceding 3 weeks|Myocardial infarction', 'at least 3 days interval', 'for at least 1 month following their last study treatment requirement', 'prior to Cycle 1 Day 1.|Patients', 'within 4 weeks of screening|Use', 'in the last three months.|Use', 'for > 1 year|on using closed-loop hybrid insulin', 'within 1 week prior to screening', 'within 1 year of the last menses', 'throughout the day on weekdays', 'in the last six months|If', 'prior ICI therapy||Failure to recover', 'within 5 years before screening', 'prior to study', 'within 3 months prior to the IMP administration', 'during this 90-day period', 'at least 3 years beyond completion of cancer therapy', 'one month after administration of study medication.|No', 'within 7 days before starting study treatment).|Total serum bilirubin', 'after previously receiving selective FGFR inhibitors', 'within 4 weeks of screening visit.|Participation in another clinical study', ""during the subject's time enrolled"", 'within seven days prior to investigational agent injection||Laboratory abnormalities', 'for at least 6 months|Ability', 'after the last therapy;|In relapsed', 'at least 6 months before enrolment', 'at least 1 visit', 'within the 6 month period prior to baseline;|History', 'within 3 months after the last dose of SAIL66', 'at the time of diagnosis of the', 'throughout the whole duration of this', 'at time of the (first) administration', 'within 30 days of the first prescription of palbociclib|Having', 'for at least one month and do not', 'in the last six months|Able to understand', 'within 4 weeks of study agent', 'at the time of an inclusion to the study|the impossibility of obtaining clinical', 'at time of coronary angiography|Patients', 'within 14 days prior to the first dose of investigational', 'after taking ≥4 kinds of', 'within 28 days before to the first dose of study treatment', 'within 14 days', 'in the last 30 days', 'within study districts|Are not willing', 'in the last 14 days prior to randomization.||Exclusion criteria||Life-threatening', 'for at least 12 consecutive months prior to screening', 'within the last 5 years|For caregivers', 'for at least 180 days after the last dose of study treatment.|Ability to understand', 'in the last year|vestibular', 'within 3 mm', 'within 30 days prior to enrollment into the', 'the past 8 years.||', 'within 7 days prior to the first study drug administration', 'within 2 weeks before screening;|Frequent smokers', 'at the anticipated needle entry site.||9', 'for the next 6 months;|smoke', 'within 4 weeks or', 'within the last 2 years from Screening|Any lifetime history of a suicide attempt|Known medical history', 'within 80 to 140 days prior to C1D1 for MM.|Patient', 'preceding year|Willingness to comply with follow-up requirements', 'within three years prior', 'within 8 weeks prior to baseline|Use', 'within the past 6 months|A', 'for at least 4', 'within 4 weeks before treatment', 'after standard therapy|At least one measurable', 'more than 1 year', 'within 10 days prior to enrollment', 'within 2 weeks before', 'pre', 'the previous 2 weeks and minimum life expectancy', 'after treatment, provided that no', 'for at least 3 months after the last dose of study-drug.|For', 'during the previous month', 'within 4 weeks before screening', 'for 4 months following the last dose of study', 'within 30 days prior to screening.|Intake of an investigational drug in another trial within 30 days prior to screening.|Patient not able to understand', 'in the last 2 weeks|SDH', 'within 3 months of enrollment|Any prior', 'at least 3 months prior to screening.|Currently', 'within 36 hours before randomization;|Symptomatic at screening', 'within 2 months prior to study entry', 'throughout the study period AND follows all oral hygiene', 'in the past they must', 'before first administration of investigational product.|Body weight', 'last 30 days', 'performed greater than 24 months before', 'at least 12 weeks of gap prior to first homologous booster vaccination', 'within 12 weeks before initiation of the treatment', 'after 2 courses of treatment with the standard regimen', 'for at least 6 months after the last use of', 'within 28 days prior to the first dose', 'until 3 months after the study', 'at the time of the study completion visit in their primary treatment study', 'within 7 days prior to initiation of the first Treatment Cycle.|Male', 'starting the night before each scheduled study visit.|Agree', 'at the time of inclusion:||use adequate', 'at least 4 weeks prior to enrollment.||Participants', 'in the past 6 months.|People', 'within prior two weeks of first dose of study drug.|History', 'within the target knee >', 'within 3 months before enrollment;|Secondary', 'during the trial.|Have', 'for 3 months after the final dose||', 'at the time of enrolment|Known HIV sero-positivity', 'previous history|Claustrophobic|Blindness|History of mental illness|Patients in strict isolation', '3 months prior the beginning of the trial).||', 'for at least 3 years prior to the signing of the informed', 'at the block site)|need for', 'Newly obtained', 'in the past 30 days|planning to move from the Kansas City area', 'in past 12 months.|Any factor', 'within 4 weeks of baseline visit|Phototherapy', 'within 28 days (90 days', 'after tolerance test', 'within 3 months prior', 'within 6 months before signing the informed consent form', 'at least 2 weeks of the nightshift', 'more than 5 cigarettes per day within 3 months before administration of investigational product', 'up to 2 weeks before surgery', 'within first 24h Neuromuscular disease Diaphragmatic', 'at least 1 cm below the patent renal', 'at time of screening.||', '3 months before surgical periodontal treatment', 'within six months of the first administration date|A person', 'within 6 months prior to initiation of therapy', 'within 30 days prior to first dose (Cycle 1/Day 1', 'during the screening period;|HbA1c>8% (', '6 months after the final dose of', 'last dose intake', 'during the previous year', 'Newly pathologically', 'at the time of progression||Participants can have received up to 3 months of', 'within 30 days prior to IMP treatment start', 'after the last treatment.||Patients who', 'after corticosteroid therapy', 'in the 7 days or', 'at the time of enrollment.|Chronic lung disease', 'at least 4 of 8 questions', 'for at least 8 weeks after the last dose', 'any time prior to enrollment', 'for at least 4 weeks apart from', 'within 5 years prior to study treatment.||Note: The 5-year', 'within 3 months after study completion', 'more than 500 mL', 'throughout the study.||Negative', 'within 6 weeks prior to baseline', 'within 6 months before screening:||congestive', 'within the 12 weeks prior to enrolment|Donation', 'within 8 weeks|Severe active', 'at the time of randomization;|Concomitant treatment', 'after 1/1/2020||', 'within the past 2 years|Current', 'before the first administration of investigational', 'older than 6', 'within the next 12 months;|able to access the internet', 'within 30 days of screening.|History of organ transplant', 'prior to initial administration.|XZB-0004', 'at the time of signing the informed consent|Are', 'at the time of informed consent.|Recurrent/metastatic', 'before donation was greater than 133umol/L.||', 'before the screening period are', 'within past 7 days)', 'in the last year', 'at least 2 weeks before', 'within the last 1 year|The patient must', 'at least 6 months prior to treatment', 'at the time of recruitment 9', 'continue to not consume these agents', 'after 8 weeks', 'within 42 days prior to registration.|Symptomatic congestive heart failure', 'within 3 months prior to the Baseline Visit.|History of', 'during the last six months prior to enrollment', 'in the breast', 'in the past 2 months.|Any associated', 'within 2 months prior to the first study drug dose.|Allogeneic HSCT', 'before midday|Access to internet', 'at least 6 months post-injury|Spinal', 'for the duration of the study and 180 days after the final dose of study treatment.||', 'after induction therapy', 'at time of enrollment|a cell phone able to send/receive text messages|Self-reported', 'during the study.||Have', 'within the last 30 days|Part', 'since the diagnosis of breast cancer|or', 'at least 1 week prior to study drug administration', ""don't think clinical trials are appropriate"", 'their first or second kidney transplant;|Patients', 'between January 1, 2016', 'prior to screening Visit 1a.|Subject', 'last 12 months', 'during the study treatment.|The need', 'within 24 hours before surgery;|(4', 'within 28 days)|Indwelling', 'within 14 days before the initiation of study treatment', 'at the time of screening.|In good general health', 'at the involved', 'at any time or other anticancer therapy', 'while using the exoskeleton', 'at least 12 months prior to the development', 'within 1 month of the experiment day|Participation', 'within 6-months', 'within 6 months prior to the start of study intervention', 'within 16 weeks prior to Step 2 registration.|Receipt', 'within 3 months prior to the first dosing;|live attenuated vaccines', 'within the last three months prior', 'more than 3 doses', 'at least 3 nights per week and', 'within 28 days of enrollment|CRC participants', 'during the 7 days prior to treatment;||', 'during the 6 weeks immediately prior to Visit 0', 'longer than 2 weeks.|Participant', 'within the last 24 months|English', 'at least 6 months after ACS.|Group', 'within 30 days of Screening|Subjects', 'within 1 year of screening', 'within 28 days before randomization|Patients', 'within 5 years prior to the first dose of the study drug', 'admission to orthopaedics|complete data||', ""in the next 3 months' specific diet"", 'in the 30 days prior to the first infusion;|History of', 'within 3 months after the end of the study;|Female', 'within 3 months prior to study treatment administration', 'in the last 12 months|history of brain', 'At the time of provisional registration||Patients', 'within 14 days prior to the first dose.|Has received', 'in the 3 months before the V0 visit', 'over the past year presented', 'past two weeks prior to baseline examinations.|History of', 'within prior 4 weeks.|Non-hepatic', 'before the 3 months preceding the study.|Participants', 'within 5 years before screening.|Suspected', 'at least weekly', 'more than 2 months before the start of the Ramadan fast|percentage', 'at any time prior to admission.|Severe burns', 'prior to nivolumab treatment||Other protocol-specific inclusion/exclusion criteria apply', 'at least 1 grandparents', 'within 60 days of first dose of IP.|Current clinical radiographic', 'within the previous 12 weeks.|Patients received', 'at least 6 weeks prior to randomization);|Active metastases', 'at least 4 months of treatment', 'in prior 4 weeks|Have', 'in the 6 months before the study.|Patients', 'at the time of obtaining consent|Current participation in a MIBC clinical trial', 'at least 3 months after initial IST', 'within last 3years|Online access|English literate||', 'before Screening or', 'for 3 years', 'within six months before the first dose of', 'within 30 days of baseline', 'throughout their participation and for 90 days following the last dose of PRTH-101.|Subject', 'between September 2020 and November', 'within 3 months prior to the first dose', 'during the 3 days prior to study start|Immunosuppressors', 'during the study period and within 6 months after the last administration of the study drug', 'for at least 1 year.|Age', 'within past year', 'during the study period|Subjects', 'at the time of cardioversion;|Cardiac glycosides administration', 'during or within 6 months of completion', 'within 60 days of consent to enroll', 'within 5 years prior to study enrollment', 'within the previous 2 months.|Simultaneous participation', 'within one month prior to participating in this study', 'after remission.|Signed written informed consent', 'at Screening / before vaccination.||Diseases', 'at the beginning of each treatment session', 'lifetime history of other', '≥90 days prior to or planned', 'within the past year unless', 'during the last three months before entering the study.||absence of coagulation', 'within three months of the study enrollment', 'Last-week average back pain', 'extended to the cornea.||Exclusion Criteria', 'within 4 weeks before entering the study.|Allergic to bortezomib', 'within 6 months prior to first study medication', 'at least four times a month but less than 15 times a month', 'at any time in the absence', 'after January 2022', 'at least 30 days before the first administration of trial medication until 30 days after trial completion:||Use', 'after initial therapy', '6 months 0 days - 35 months 30 days);|The availability of written', '4 weeks prior to the study;|Glucocorticosteroids', 'at least 8 days prior to and during study treatment', 'within six months of infusion', 'at the time of a visit', 'at the Screening Visit.|Medicated IOP => 20 mm Hg and <= 44 mm Hg for the study eye', 'planning vaginal', 'for more than 48 hours', 'over last 30 days of consuming alcohol', 'at least 12 months before pregnancy', 'active', 'at baseline and post-NAST.||', 'within 48 hours prior to application of treatment.|Subject is pregnant', 'during the time of participation in the study', 'within 30 days prior to the start', 'within a specified time frame.|The', 'in the previous 30 days|Subjects', 'during preoperative', 'in past 6 months', 'for ≥5 years', 'at the next visit.|Any acute cardiopulmonary condition', 'during the study|Patient', 'in the screening period after completion of neoadjuvant', 'at least 3 months after burn injuries', 'within the past six months.|Those', 'during the course of the trial', 'in the past 3 months;|Patients', 'in the last 3 months|BMI', 'at least 1 day', 'in the week before the', 'Prior to this study:||Severe', 'in the 3 months preceding inclusion (declarative)', 'more than', 'during the 12-week treatment period|Active', 'within 2 weeks prior to of study drug.|Any unresolved', 'at least occasionally', 'in the last 6 months|Liver', 'difficult.||History of', 'past two months||Neurological disorder', 'within 3 months before biopsy', 'at the time of cancer', '6 months after the occurrence of thrombosis', 'in the month before the start of the study', 'within the last 14 days of screening)||Note', 'within the past 2 months', 'at the time of study registration||Past', 'in formal employment', 'within 1-2 months after surgery.|Patients', 'at least 1 contrast enhancing', 'for at least 8 weeks prior to Visit 1.|ACQ-7 total score', 'in the last three months;|History', 'onset < 24 hours before admission;|Successful percutaneous coronary', 'since initiation of cefepime', 'at least two prior therapies', 'within the last year|Pulmonary exacerbation', 'within 30 days prior to receiving the investigational vaccine;|Receipt of attenuated live vaccines', 'during dental examinations|The dentist', 'for at least 120 days plus 30 days', 'for at least 6 months after the last study treatment', 'at least 6 months after receiving', 'within 14 days prior to the first dose.|Presence of', 'throughout cycle 1 until cycle 2 day', 'within 72 hours of Cycle 1 Day 1', 'at least one measurable', 'within 5 years before enrollment;|Allogeneic organ transplant', 'for at least 7 days prior to enrollment)|Hemoglobin', 'at least six weeks ago', 'within 7 days before administration of investigational product', 'within 24 hours of symptoms', 'in the past 24 months', 'during the last 5 days before screening.|Any type', 'in the past 24 months|Any prior exposure to,', 'for more than 3 years', 'within the last month|Participation', 'at screening.|Current', 'within 1 week prior to the first investigational product administration', 'within 28 days prior the start of Cycle 1|Corticosteroid use > 30 mg/day', 'in the previous 6 months.||(7', 'responses||', 'last 5 years prior to inclusion|History of', 'within 14 days prior to study entry', 'last year in lower limb', 'within 24 hours prior to randomization;|Presence', 'patients.|First time affected.|No visual', 'infection,|more than 2 mm', 'at Screening visit.|Written', 'for at least 3 months prior to study entry', 'within 6 months of enrollment', 'within past 6 months|Self-reported', 'within 3 months post-discharge', 'throughout the duration of the study.||', 'before transplantation', 'within 2 weeks prior to study enrollment).||Organ Function Requirements||Adequate', 'at least 7 days prior to treatment with daratumumab', 'within 7 days before screening):', 'more than 12 weeks', 'medical history shows', 'within previous 2 years', 'before enrollment', 'admission initial CAM-ICU', 'within 4 weeks prior to Week 0 Visit|Unwillingness', 'within 12 months prior to screening.|Positive test for', 'within 30 days prior to Screening|Donation of blood', 'for 2 weeks after surgery', 'within the past 5 years.|Acute', 'at least 3 months before screening||Key', 'within the last 6 months.|Known', 'at least 6 months prior to enrolment in this study.|For', 'within 4 weeks of first dose of study drug.|Malabsorption syndrome', 'within the next 2', 'within 47 hours of the', 'within 1 year after study treatment.||10', 'during the last 12 months prior to randomization.|≥1 clinical relapse', 'during conditioning (Campath®', 'within 6 months of screening.|Participation in another study with any investigational product', 'within 500μm', 'at the time of pre examination', 'within one year||', 'throughout the study.|Subject', 'before the first dose of IMP|Previously participated in a clinical study', 'prior to Day 11 post-dose of the study.|Has', 'at the time of written informed consent', 'within 24 weeks of', 'less than 14 days old', 'during and for 3 months after the treatment period', 'at the time of Screening;|Body weight', 'within the 5 days prior to', 'at the time of initial evaluation', 'for at least 8 weeks after the last dose of study drug to minimize the risk', 'within the last 12 months|Patient', 'in the past 6 months|Individuals', 'in the last 1 year|Severe visual', 'within 4 weeks before the screening visit.|6', 'within 28 days before the study drug administration', 'within 30 days or receipt of', 'in past month of', 'prior medication', 'within the 2 weeks prior to Screening', 'within 7 days prior to the start of the', 'previous 12 months from the beginning of experimental therapy;|congestive heart failure', 'prior to initiating', 'within the past 2 weeks;|The pain', 'at the time of study|Medroxyprogesterone acetate', 'more than three suicide attempts', 'within the previous 3 years except', 'within 4 weeks of Visit 1/', 'within 10 days of enrolment', 'within 14 days prior to first dose of study therapy).||Total bilirubin', 'at least 3 months prior to first dose.|With history of', 'Within at least the past 3 months must', 'more than 3 kg', 'at time of recruitment', 'more than 6 months;|Between', 'within 3 months prior to prior to Day 1', 'in a 6 week period within 3 months of enrollment.|Capable of giving', 'for 24 weeks after the administration of the last dose of the investigational therapy.||', 'within previous 90 d)||Non-sinus rhythm|Significant', 'within 30 days of enrollment', 'for 30 days after the last visit', 'after previous use of', 'more than 500 milliliters', 'in the previous 14 days.|Unexplained', 'for at least 3 months after the last', 'at least 1 month', 'for at least 180 days after the last dose of study treatment', 'within 52 weeks after', 'in the past 6 months;|Those', 'within 28 days prior to first dose of study treatment.|Participants', 'in the 24 hour period prior to testing', 'for 12 months following', 'at the time of enrollment/consent.|Subject', 'after at least one cycle', 'within 180 days before randomization|New York Heart Association (', 'for less than 5 years prior to Screening', 'for 4 days after the last dose of', 'for at least 3', 'within 3 weeks before first dose of study drug', 'within 30 days|Hepatitis C virus (HCV): subjects known', 'prior to Screening', 'at the time of hospital admission]).|Contraindication to rivaroxaban use', 'in the comprehensive', '48 hours after percutaneous coronary', 'within the prior 3 years|Estimated glomerular filtration rate', 'last 5 months prior to Screening Visit 1', 'within 30 days prior to treatment|Open chest surgical repair', 'within last 3', 'within 4 weeks of study', 'more than 30', 'during the screening period and baseline period', 'within 30 days prior to the planned treatment', 'before start of the study treatment.||Has recovered from any toxic effects', 'within the last year|Participation in another clinical trial', 'within 24 hours before surgery (radiocontrast agents', 'within 2 years of screening', 'in the month preceding inclusion', 'for at least 3 days||', 'for 24 hours and must', 'within 4 weeks of treatment', 'in the past 3 months|Unable to understand the questionnaire', 'within 5 years before the first administration', 'within 28 days prior to treatment;||Adequate major organ function', 'within 45 days of hospital discharge', 'before the first dose of SerpinPC|For Part', 'for > 6 months|Use', 'at the tooth extraction site', 'at least 2x weekly', 'for the length of the intervention)|Have not previously enrolled in the study', 'within 6 months before treatment|History of', 'greater than 3 months post-surgery', 'within 2 weeks(Or five half-lives', 'at least 1 month prior to enrollment', 'prior to the SCI', 'at the time of signing informed consent', 'in the last 3 months|Participation', 'in preceding 3 months', 'over the past 12 months.||BMI', 'within 5 years prior to initial administration', 'within 30 days).|Exclusion criteria', 'before admission|History of', 'within last 3 years|Online access|English literate||', 'for the past three months', 'in the knee', 'during this hospitalization|Acute respiratory failure', 'at any time during the study.|Other clinically active', 'in the next 12 months.|Subject', 'within 1 month before screening.|Use of', 'calcifications|More than 1 previous episode of', 'at least 6 months before trial|Tumor stage pT2a-3b', 'within one month prior to surgery|Severe anaemia', 'for up to 12 weeks after the last dose;|Subjects who thoroughly learn', 'within three months after enrollment', 'within 4 weeks prior to randomization.|Subjects', 'within 4 months).|Involvement', 'at the time of enrollment.|For Step 1B', 'within 14 days)', 'at the time of Screening|Prior complete', 'within the last 2 years prior to the start of the study|Epilepsy|Obesity', 'in the screening of anxiety symptoms', 'during the duration of the study.|Major surgery procedure', 'at least 2 measurements', 'at screening/baseline measurement;|A history', 'for at least 6 months,|Applying to the', 'within 10 days|daily opioid use', 'in the last 3 months|Previously', 'within 28 days before the screening visit.|An acute illness', 'within 2 weeks of a vaccination', 'at least 12 weeks;|Willing', 'prior to initial dosing.|The participant', 'in the past 12 months|Has below 6th grade', 'throughout the duration of the study.|Current swab-positive', 'during the whole study', 'in the last 3 years', 'within 8 weeks of the date of first administration', 'during the time the participant', 'for at least 6 months after the final dose of study treatment||Negative hepatitis C virus (HCV)', 'within last six months;|Pancreatic injury', 'for more than 96 hours', 'before transplant', 'within the last 3 months|Any medications', 'every three months', 'within the previous 24 months except', 'at least 15 days of pain', 'emergency ≤ 6h', 'during therapy', 'within 72h)|Evidence of', '> 72 hours', 'within 3 months prior to the screening visit', 'within 2 weeks before the first study drug', 'within 4 weeks of initiation of study treatment.|Known dihydropyrimidine dehydrogenase (DPD)', 'within 48 hours|Prescribed cefepime', 'administered', 'at Week 52 visit', 'within the last 2', 'in next 14 months|Positive urine', 'within last 90 days|Pregnant', 'within the last 3 months|Prior', 'for at least 7 days prior to enrollment', 'for 48 hours after receiving', 'on the Montreal Cognitive Assessment [', 'in the 3 months before inclusion', 'within 2 cm of the treatment area', 'within the past 3 months||', 'whose dressing had to', 'more than 30 days', 'within 30 days before study enrollment;|The investigator judged', 'within 4 weeks prior to study drug', 'within 4 weeks prior to IMP treatment start', 'at the time of admission.|Severe head trauma', 'before the surgery|Urine leakage', 'during the study participation period|Performing', 'prior to signed informed consent', 'in the last 6 months.|Use', 'within 3 months before screening;|Use', 'within the previous 30', 'within the 6 months before enrollment', 'within 30 days prior to baseline', 'within 7 days of initiation', 'last 5 years|Infectious disease', 'prior to their baseline visit', 'at baseline visit/assessment||Experiencing homelessness', 'within last 12 months|Documented', 'throughout the study.|Willingness', 'for less than 6 consecutive months', 'within 3 months before vaccination.|Have', 'early starting work…).|Separation of the baby', 'within 12 mo of screening', 'for at least 4 hours.||', 'within 30 days after;|have body weight', 'after exposure to ibrutinib', 'within 4 weeks before the first administration of the study drug', 'at the time of enrollment.|At the time of enrollment family must live', 'within the past 2 years.|Have', 'at least 6 months after end of last', 'During the screening period of ≤1 week', 'at least 1 protocol-defined measurable', 'prior to the decision to start', 'within 30 days|prisoners|FDA-', 'within 4 weeks prior to study', 'within the next 6 months|corticosteroids', 'during the 3 months prior to screening', 'within the last 3 years.|Under', 'within 3 three weeks of the experiment|Have', 'within 1 week prior to C1D1)|Haemoglobin', 'in history', 'within 1 week of baseline|Use', 'at the time of screening).|Chronic alcoholism', 'etc.)|Significant history', 'in the past 3 months', 'for 30 days after the last dose of IMP', 'at the time of admission.|Admitted', 'following definitions:||Blood routine', 'prior to any screening procedures', 'within 12 weeks of screening', 'at baseline of ≤7 mg/dL', 'within 3 months after first study drug', 'during the study|Willing to maintain current eating patterns', 'at least one of the criteria:||Transform program participant', 'at baseline screening.||Subject', 'preceding 6 months', 'during childhood', 'within 30 days before screening', 'within 1 year prior to start of', 'in the past 3 years prior to consent', 'within 2 weeks prior to signing informed consent', 'within 1 year after receiving the last dose of study drug.|Pregnant', 'with the exception of those', 'within 28 days prior to the first dose of study medication', 'at least 1+', 'at least two years', 'within 2 weeks before the first administration', 'at the time of randomization|subject', 'within 5 years before the first dose', 'during the study.|Documented history of', 'at Screening or within 6 months prior to enrollment', 'within 4 weeks prior to baseline;||16', 'within 14 days before the first administration.||Except:', 'within 14 days before the treatment of the study drug),or Hemoglobin≥80g/L(No red', 'for at least 3 months duration', 'within 4 weeks prior to signing informed consent', 'within 28 days prior to starting study treatment.|Exposure to high levels of ultraviolet', 'within 180 days prior to surgery||', 'at time of the (first) administration of IMP.|Severe ischaemia', 'after 6 weeks', 'approximately 4 cups', 'for at least the last one year', 'in the 4 weeks before or after each study vaccination.|Received', 'within 14 days prior to apheresis', 'after surgery.|In patients assigned to', 'at the time of informed', 'following completion of routine care first-line therapy', 'within 2 weeks of receiving the first dose of study', 'continue the current', 'in the 8 weeks prior to Visit 1', 'within three months prior to', 'before apheresis', 'polyps;|Previous history of', 'within 12 weeks of initiation of the study.|Subject not eligible for syringe-based liposuction', 'within 3 months prior to use of the study drug', 'at least 8 weeks prior to', 'after the first cycle', 'in the last 5 years', 'in the 7-12 age', 'Lifetime history of any of the following', 'in the past 10 days,|able to provide', 'for 3 years prior to the first dose of study treatment', 'more than 4 weeks', 'during the past 24 months.|Positive ELISA', 'in the month before the study initiation.|Having', 'current time zone for the duration of the study||Subjects ready to give voluntary', 'within 2 weeks of the first dose', 'within 30 days prior to Baseline', 'at the time of study entry.|Failure by the participant to attend three consecutive Step 1 study visits.|Intercurrent illness', 'within the past 24 months|Currently', 'through 120 days after the last dose of study therapy.||', 'within 28 days prior to the Screening Visit or plans', 'within 2 mo of starting the study', 'at least one year', 'within 6 months prior to entry.|Active infection', 'within the 72-hour timeframe|Patients', 'within 30 days of enrollment.|Known history', 'within 2 weeks prior to cycle 1 day 1|Clinical significant', 'within 28 days before viral treatment', 'at least one of the following hypotensive symptoms:||Baseline', '6 months to < 1 year', 'within the last two years|Pregnancy', 'for at least 14 days prior to the first dose of trial treatment', 'within 6 months after the last dose of study drug.|Participant', 'over the 3 months post-study', 'pre-presbyopic age range', 'at least 3 months after the last dose of study drug.|Subject', 'prior 18 months', 'within 2 weeks prior to first dose', 'within 2 years of', 'within past 180-days', 'more than 28', 'within one month of the Screening Visit', 'within 2 weeks before signing the informed consent form', 'for at least 6 months after the last trial;|Those who have no', 'continue their normal exercise routines', 'within following 1 year of the DBT exam.||[For', 'during the intervention period|the ability to read Chinese', 'within the past 2', 'within the past 90 days to the day', 'within the last 12 months|a', 'at the time of Screening.|Participant', 'mg/ day equivalent to prednisone', 'in the last 6 months|Diagnosis', 'within the previous fourteen', 'after surgery', 'at least 3 mm', 'within 6 months prior to initial administration.|Active autoimmune diseases', 'within 7 days of enrollment)|Platelets', 'during the screening period;|Patients', 'within the last 12 months.||Untreated hypo-', 'in the last 48-72', 'during the study.|Occurrence of arterial/', 'within 14 days before enrollment', 'prior to developing COVID-19|Severe asthma', 'for 2 months after receipt of the vaccine.|Investigator belief', 'within 6 weeks prior to enrollment|Patient', 'within 3 months before entering the study', 'after optimal medical treatment', 'within the 3 months before the first dose of tracer', 'at least 6 months after the functional prosthetic loading of the dental implant||', 'less than 24 consecutive months', 'at diagnosis|Contraindications', 'completed 24 months of follow-up after surgery initial surgery.||', 'within 28 days before the start of study treatment', 'previous 5 years|Previous medical assisted reproduction technique|Lynch syndrome', 'within 2 weeks of first receipt of study drug', 'prior year|Diagnosed with some form of', 'in the pre-menopausal', 'for at least 3 months|The', 'within 2 weeks of CT simulation', '48 hours prior to', 'at admission to the intensive care unit,|Patients', 'prior to each Experimental Session', 'for < 8', 'during the study period||Inclusion Criteria', 'within 6 months prior to randomization|Significant', 'within 30 days before the screening visit', 'within 6 months of the study,|History', 'at least 6 months after drug product infusion.|Live vaccines', 'over the last twelve months before the study.||', '≤72 hours before Meta10-19', 'within last 90 days|Febrile condition', 'at time of screening.|Moderately to', 'at the time of signing the informed consent|Part B', 'within 8 weeks of Screening.|Known', 'within 1 month;|Severe liver', 'within the last 5 years|clinically meaningful laboratory abnormalities|moderate to severe', 'during the study period;|Average', 'at the time of signing the informed consent|A negative', 'within 30 days of Baseline.|Treatment', 'prior to signing the informed consent', 'within 1 weeks|Live attenuated vaccines', 'within 8 weeks before signing the ICF.||Patients', 'at least 8 weeks prior to initiating participation', 'hazardous', 'during the study.|Any other', 'at least 20°', 'prior to the diagnosis of COVID-19.|The investigator judges', 'past year)||limited emotion awareness', 'in the first 6 months of randomization|According to the investigator', 'during previous elective procedures', 'time within 12 months before signing', 'within the next 14 months|Currently', 'with the last', 'history on pre-enrollment questionnaire of cluster headache symptoms', 'in the last 3 months|Corticosteroid injection application', 'one month after the end of the study.||', 'within 4 weeks prior to baseline study procedures|gastrointestinal(GI', 'one month prior to surgery', 'at the time of informed consent.|A body mass index', 'at the time of screening|Acute gout', 'at least 3 months|After 2-week run-in', 'at the time of initiation of 1L treatment Exclusion', 'more than 16 weeks', 'within 4 weeks of beginning study treatment.|Uncontrolled', 'at the time consent', 'more than 14 days before registration', 'within the previous 4 weeks;|Use of topical steroids', 'within 6 months prior to vaccination', 'during the 3 days prior to injection visit (V1)', 'at the time of most recent labs taken before starting Ketogenic diet.|AST', 'within 3 months before the first dose.|QTc prolongation', 'during the term of the study||', 'within 4 weeks before enrollment', 'within 15% of normal range', 'in the 3 months before conception||Exclusion', 'within 1 week before screening;|Have', 'Medical history', 'Ongoing', 'within 30 days prior to surgery', 'within 4 weeks of the first dose of study treatment', 'for 6 months prior to listing', 'in the last 3 months,|Those', 'at least 1 month after TCG/PSG cessation.||IRCCS', 'within one month of study treatment|Life expectancy', 'in the last 30 days|Fecal', 'during the study treatment period', 'at the time of signing the informed consent|Cisgender', 'during the 30 days before Screening|Use of', 'within the next 48 hours', 'in the last 3 months;|Metabolic', 'within 30 days prior to the first dose', 'history of cardiovascular', 'in the last 24 hours', 'for at least 3 months|Subject able to understand and provide informed', 'prior to catheter', 'during the study|Previous illness', 'at least 6 months apart)|At screening', 'within the framework of an organizational protocol established', 'within the last two years|People who', 'in the last 6 months prior', 'for at least 1 month', 'within 2 years after cell infusion.|Patients', 'after CR obtained from initial chemotherapy', 'for six months afterwards', 'prior to Screening Visit 1', 'for at least 6 months after the last administration of study treatment|Men', 'for at least 2 weeks before starting to use the test drug;|There', 'for at least 30 days', 'in 5 years', 'at least 6 weeks before taking study treatment', 'within past 12 months)|Requires', 'in the 6 months prior to baseline visit', 'within the past six months.|Subject', 'within 5 years prior to surgery|Systemic', 'in the past 3 years.|History', 'pre-emptive|For', 'within the first 14 days of their ICU admission||Exclusion criteria:||Contra indication', 'within 6 months prior to the dose of study drug', 'in the past 2 years or|At least one', 'within 6 months of conception', 'immediately after admission', 'within the last 3 months|Sensory impairment', 'problems.|History', 'in the next 12 months|Cognitive impairment', 'for at least one year following transplantation.|Patient agrees to comply with the protocol', 'within the next 5 hours|Patients deemed at', 'within the last 3 years||Significant', 'throughout the study period|Individuals taking', 'within 30 days of initiation of investigational product.|Subjects', 'since the initiation of last systemic therapy', 'during the supplementation', 'at the following time points:||IVIG-', 'at least 10 cigarette/day', 'rather than EC.|Specimens with prior', 'more than 5-fold ULN|Use', 'need to confirm', 'within 4 weeks prior to the first dose of the study drug', 'within the last 28 days prior to randomization.|Any prior investigational agent for nmCSPC/mCSPC.|Known', 'within 5 years prior to initial administration of XZB-0004', 'up to 20 mg or dose', 'within the first 6 months after the start of RT', 'prior to initiation of study treatment', 'within 3 months|Diagnosed', 'for at least 3 days after the last dose of study intervention||Male', 'within the past 72 hours|Moderate-to-severe', 'for at least one month', 'personal history/diagnosis', 'in CT/MRI', 'at their back and/or lower limbs', 'within the last 5 years.|Voluntarily decided to participate in the study', '3 months before the start of the study', 'for at least 14 days prior to this study', 'on the currently targeted malignancy', 'continuous > 12 months', 'within the previous 6 months prior to signing the ICF', 'during the course of the study|Live', 'within 72 hours prior to the first dose of study drug.|Unresolved', 'medical history of', 'within 4 weeks prior to study entry.|Following', 'within last 12 months from date of export||Exclusion Criteria', 'within 1 month prior to initiation of investigational procedure', 'postbiotic||', '22],|History of endocrine', 'at the time of the collection of the phenotypic data.|Patient', 'at least > 28 days prior to date', 'within 28 days prior to study vaccination;|Enrolled', 'within 30 days prior to Step 1 registration and while participating in the study', 'within 1 year prior to Screening|Current', 'at the time of signing the ICF.|Participants who', 'within 3 months before signing informed consent', 'within 4 weeks prior to enrollment|Has multiple', 'in the last 6 months|For', 'prior to spirometry:||SABA for equal to or greater than 6', 'within a period of 5 half-lives', 'within 2 weeks before the first dose of investigational drug', 'while on study.||Note', 'prior to completing', 'in the', 'before and during study participation', 'for at least 1 month prior to Screening.|Subjects', 'within 6 months after the last administration of platinum-', 'within the last 6 weeks', 'ended (', 'for at least 6-months', 'within 24 hours after surgery', 'pregnant|Currently', 'within 3 months|Received', 'within 1 month before cell reinfusion;|3.5', 'at least one biomarker supporting intestinal inflammation|Planned', 'Concomitant', 'within 28 days prior to start of treatment', 'within the last 2 weeks.|Individuals', 'Within 28 days before enrollment', 'between the 2 Week Historical Period', '4 weeks or before|Patients', 'over 15 years old.|Contraindication', 'within one month of enrollment|Currently', 'lasted more than three months', 'in the past 6 months|currently', 'at the time of screening|Enrolment to another interventional study', 'previous history of', 'before 1 year', 'at least 12 months after discontinuation of all study treatments', 'in the past 12 months.|Treatment', 'more than 14 consecutive days', 'within normal range.||', 'within 4 weeks before initiation of study treatment.|Patients', 'within 24 hours|Immunosuppression state|Severe organ dysfunction|Complicated', 'within 2 weeks prior to enrolment|Mental incapacity', 'in the past month', 'within 6 months prior to registration.|Severe pulmonary dysfunction', 'during the study.|History of', 'in the past 6 months prior to registration|No', 'at least 6 months.|Patients', 'for at least 3 last months|Albuminuria >35 mg/day', 'for at least 6 months|Stable doses', 'within 2 months before screening.|History of organ transplantation', 'within the 12 months prior to consent', 'for at least 90 days prior to the first dose of the study', 'up to 6 months from', 'within 3 days prior to taking study treatment', 'preceding 12 consecutive months)||Ability to complete questionnaires by themselves', 'within one year 4', 'at onset of index-procedure.|Patient', 'within 12 months of', 'after treatment evaluated by the evaluation of the investigators).|Those', 'for at least 3 weeks|Oral consent from the child', '48 hours before chemotherapy;|Patients', 'during the study period.|Administration', 'within 2 hours prior to randomization.|Fertile participants', 'in the past 36 hours|Upper or', 'for 12 months after cell infusion', 'within 3 weeks before enrollment|chemotherapy', 'for at least 16 weeks after the last dose of experimental treatment.||', 'through 120 days after the last dose of the study', '48 hours after admission', '35 days prior to starting|investigational product', 'for 5 months after the last dose of study treatment.|Female', 'within 30 days before Visit 1', 'during the 6 months preceding the study.|absence of pathologies', 'in the past 3 months.|Factors influencing light', 'within the past month|Having', 'for at least 1 year after study treatment', 'within 4 weeks prior to the start of LB101', 'within 45 days prior to enrollment', 'at Screening or Baseline', 'within 9 months prior to screening.|Positive test result', 'during the study timeframe;||Has undergone more than one inpatient', 'at the time of screening|Person', 'at least the epidermis', 'within the target knee >90 days prior to randomization', 'within 4 weeks before the first dose of study treatment', 'in the last two years|Is', 'within 8 weeks before first dose of study treatment', 'at least 14 days before the first administration of the investigational treatment', 'within 4 to 6', 'for at least 3 months prior to screening', 'past month;|between 18 - 75 years old.||Exclusion Criteria', 'prior to the study.|Students', 'lasted beyond 20 weeks', 'for the last two years', 'within 4 months before randomization|Positive result', 'within six months of the diagnosis.|Receiving', 'during the six months', 'within 90 days prior to entry.||Any', 'at Screening or Day -1', 'before screening;|apheresis', 'within 6 months prior to screening.||Prior treatment', 'within 4 months prior to Day 1.|Subjects', 'during the index procedure;|Pregnant,', 'concurrently', 'maximum lenticule thickness', 'in the past.|History of', 'at least 6 months before Screening', 'greater than 0.2mm', 'at the time the patient receives the lymphodepletion regimen', 'within 30 days prior to screening|Female', 'at VGHTC|Eligible', 'within 1 year of screening|For', 'for at least 6 months after the end of study treatment.|Patients who understand the contents of the clinical trial', 'within 30 days prior to the first dose of trial treatment', 'for less than 6', 'past 24 hours', 'within 14 days prior to administration;|Subjects', 'in the past 60', 'administered 14 days prior to initiation', 'during the fasting window|Pregnancy|Diabetes mellitus|BMI drop to < 18.5kg/m2', 'during activities of daily', 'in the past 6 months;||13', 'prior to enrollment.||', 'affecting the', 'more than 3 times|Unstable', 'at least 1 prior trial of standard first-line', 'within 5 weeks before enrolment.|Ability to', 'within 8 weeks prior to the Screening', 'in the diagnosis', 'within previous 2 years of the first dose of the study treatment', 'within the United States|PATIENTS', 'during cell transfusion;|Negligent', 'within 6 months before enrollment', 'for at least 3 months.|All participants must', 'within 5 days of original Run-', 'during treatment determined by the investigator', 'within 14 days prior to the first dose.|Have', 'clinical history or', 'up to 32 weeks before screening', 'at the time of inclusion', 'within 5 years before prescreening', 'at least 3 months before Screening', 'within the reference range', 'requiring at least a 2-day admission|Ambulatory|≥ 6 month life expectancy', 'within 4 days prior to the first dose (≤4 days from the first dose);|First presence', 'within three months before the trial', 'while receiving study drug', 'within 30 days of study enrollment.||Uncontrolled', 'in two different times, should only', 'within 4 weeks before the start of the study dose', 'after receiving conventional treatment', 'throughout the study.|low self-reported', 'at time of diagnosis', 'during the last 12 months prior to screening', 'at least 2 confirmatory tests', 'following foods/supplements', 'for ≤48h before trial entry|3', 'within 4 weeks before the first dose of the new crown vaccine', 'within 7 days of onset of index event', 'during a period of depression', 'within 6 months prior to randomization.|Diagnosed', 'prior to Screening visit', 'for at least 3 month before screening visit.||', 'in 7 days preceding', 'over at least the last 3 months.||The', 'within 3 years prior to entering the study', 'in the previous month.|Pregnancy', 'at least 20%|Being', 'during the 5 years prior to Baseline Visit.|History of', 'within 24 hours before any study related procedures', 'within 2 weeks before screening.|Patients', 'within the past 14 days prior to study registration|International Normalized Ratio (', 'within 7 days prior to enrollment:||Steroids', 'before the first dose of study drug;|≥ 2 weeks after', 'their year 1 rotations', 'in the past 1 month', 'during the study.|Presence of', 'study|More than 2 weeks absence', 'within 24 hours on the day of vaccination', 'within less than 3 months', '1 year', 'prior to treatment.|Participants', 'within 28 days before or after inflammation', 'during the implementation period', 'after definitive therapy', 'within 5 years prior to Screening 1', 'within 48 hours of study enrollment|Fever', 'for at least 8', 'for at least 6 months after the last dose of study drug', 'in the last 6 months|Has', 'within 7 days prior to the first dose of study drug.||Known', 'at least 2 weeks prior to the screening', 'in the past;|Those', 'within 3 months before dosing', 'within 2 months prior to check', 'at Screening.|Ability to communicate well', 'within two weeks;|signed written', 'within 3 months ahead.||After V1', 'medication prior to randomization', 'for at least 30 minutes|A requirement', 'for 3 months after treatment', 'at first diagnosis|Post-treatment', 'for at least 15 years', 'throughout the study.|occasional use of', 'past 12 months prior to Screening Visit 1', 'following IV immunoglobulin', 'within the last 6 months|Any', 'within three months prior to the start of the current study', 'within 2 months prior to randomization', 'within 2 weeks before the first study drug administration.||History of other', 'within 2 weeks prior to the day of study vaccination.|Planning', 'within 1 month prior to the expected date of the first dose', 'for at least two', 'within 1', 'during the 4 weeks prior to the start', 'at least 3 months prior to screening', 'within last 30 days', 'during the screening period for participants', 'within 6 months prior to enrollment；||Patients', 'within 30 days after receiving the study', 'for at least 1 week', 'during the study period|Participated', '4 months after the operation||', 'personal history of no', 'in the past 12 months before baseline assessment|Previous lobectomy', 'within 8 years|5.Informed consent', 'within the last 24 months', 'at the time of cardioversion;|Administration of QT-prolonging drugs', 'within 7 days before enrollment Negative;|Substance abuse', 'at time of participation|Currently following a diet|On medication', 'within 3 months prior to inclusion|Diabetes|Severe chronic disease', 'in the past 12 months|symptomatic patient', 'over 18,|informed consent', 'within the next 12 months|Recent serious injury', 'in the past and no evidence', 'prior to the first dose of the study drug', 'within 7 days prior to screening;|Chronic', 'at least 1 year post', 'more than 3 units', 'within the 4 weeks prior to signing the informed consent form.|Subject', 'at least five', 'at least one of the ADA definitions', 'within 2 weeks before the first visit;|Subject not presenting', 'at least 2 weeks prior to randomization;|Patients', 'since ≥3 months|Confirmed flare', 'during or after operation;|Previous (< 2 weeks', 'during the 3 months before enrollment.||', 'toes|Open fibula fractures|Open', 'for the next 30 days', 'within the first two hours after the massage application', 'within 180 days prior to Screening', 'within the last 2 weeks', 'prior to enrollment||Significant trauma', 'within 6 months prior to randomization.|Modified Rankin score', 'at the time of dosing).||Any condition', 'in the 12 weeks after enrollment|cognitive', 'prior to first dose of study treatment.|Patients', 'At least 14 days must', 'in the last 24 hours|Microscopy confirmed', 'at the time of enrollment||Patients', 'medication.|Approximately 12 months after the first study vaccination.|The', 'last 5 years iv', '< 3 kg', 'within 28 days before enrollment.|Females', 'during their stay in the pediatric intensive care unit', 'in the 3 weeks prior to signing ICF|Immunocompromised', 'for at least 4 weeks prior to taking the cocktail', 'between 30 and 80 years;|ongoing therapy with levodopa;|fulfillment of requirements', 'with the last dose administered', 'in the last 6 months|Using', 'within 6 months.|Contraindications', 'between completion of CNS-directed therapy', 'within 28 days before study enrollment through study completion.|Investigator site staff', 'within 3 months after the last study administration.|8', 'in the previous 4 weeks,|Supplementation with pro-', ""within 4 weeks of last dose of study vaccine|As per Investigator's medical judgement"", 'within the past 2 weeks prior to study agent administration.|Receipt', 'within 14 days before screening):||Absolute neutrophil count (', 'within the last 12 months.|Patients willing', 'within 30 days prior to Screening|Exposure', 'within the preceding 90 days.||12', 'at least 7 days apart', 'during the past 6 months|diagnosis', 'appropriate dose of (SSRI)', 'within 6 months before screening;|Able to communicate', '14 days prior to enrollment', 'within six months prior to entering the study', 'at least 2-weeks', 'in next 6 months except for', 'within less than 4 weeks prior to randomization', 'during the study|History of', 'at the completion of the 4', '<6 months', 'within 14 days (3 months', 'longer than 3 months', 'at least 12 months of screening', 'for the duration of the study|Participants', 'within 30 days of screening;|Subjects who participated in any other', 'in the last 1 year|Patients', 'prior to BSL', 'within 3 months prior to initial dosing', 'within the previous 6 months prior to screening|Extreme fatigue', 'at least 2 days per month over the last 12 months.||', 'at the time of index date||Exclusion criteria||1', 'within the past 18 months (B) For', 'in the last 3 weeks|Taking', 'within 6 months before initiation of study treatment|Clinical signs', '7 days prior to Cycle 1', 'within 48 hours prior to the first dose of study drug', 'within 2 weeks prior to start of any of the study interventions|Participants', 'within 30 days of last dose of SerpinPC|Any other significant', 'within 2 years prior', 'after last treatment dose on this study|Provide written informed consent|Willingness to provide', 'at the time of signing informed consent.|Body weight', 'within 60 days prior to randomization.|Subjects', 'less than 6 months before enrolment', 'during two weeks of therapy||', 'within 1 month before informed consent.|Subjects', 'within 4 hours before randomization.|Treatment', 'within 14 days before the first administration of the drug', 'within a few months', 'within 12 months of screening.||Severe Cardiovascular disease', 'less than 20 degrees', 'in the 12 months prior to the study visit', 'within 3 months prior to hematopoietic stem cell collection', 'at least 6 months after the last use of chemotherapy;|11', 'nutrient', 'at time of eligibility assessment', 'within 2 weeks before baseline|Pregnant', 'within 10 days of first dose of study treatment', 'within 4 months prior to screening.|Subject did', 'within the last 2 years from screening.|Known medical history', 'during the study period;|Asplenia', 'recent intake of', 'at least one year prior to enrollment|Having no to low substance', 'within the past 90 days prior to screening', 'at least 28 days apart from the previous cytotoxic chemotherapy', 'suspicious malignance', 'within 30 days prior to the first trial administration;|Hypertension', 'in the last 6 months|Having', 'within the last 5 years with the exception of', 'within 30 days prior to study vaccination', 'within 6 months of Screening|Any malignancy', 'up to 100mg per day)|Patients', 'within the previous 6 months', 'prior to infection', 'within one month of the Screening visit.|Patient', 'through 12 months after the last dose of rituximab|Subjects', 'within the last 12 months;|Unstable dose of diuretic', 'prolonged', 'during study treatment.|Patient', 'employees', 'within 30 days after the last dose of durvalumab.|Patient', 'three times within the past year', 'for at least 6 months after the last administration of study treatment|Presence', 'prior to entering this study||Prior therapy', 'during the study period.|If', 'for at least 24 hours on a study unit', 'for at least 30 days after study termination|Subject is capable to', 'within 4 weeks prior to and', 'throughout treatment with apalutamide will be', 'within 6 weeks prior to Day 1', 'in the last 3 months|daily', 'during trial participation and until 6 months after end', 'within the previous 2 weeks.|Subject', 'within 7 years prior', 'prior to the first dose', 'prior to initial administration of the study drug', 'within 28 days prior', 'during the trial|positive', 'within 4 weeks prior to the start of study', 'at night shifts.||Individuals', 'within 3 months after the last dose of study drug.|Life expectancy', 'within 6 months prior to enrollment;|A history', 'preoperative', 'at the time of screening)|Participants and caregivers', 'while taking study treatment||Other protocol-defined inclusion/exclusion criteria', 'at time of consent', 'within 1 week before the trial', 'during the 3 months prior', 'between 3 and 14 migraine days per month;|Have completed', 'throughout the duration of the study|Must live', 'at least 6 months after the last dose (to avoid', 'in the month prior to the start of the study', '3 months prior to screening', 'in the last six months||', 'in the month preceding inclusion|Patient in exclusion period', 'within 14 days prior to the treatment.|Medical history (', 'within 12 months of completion of 1st line', 'at maximal dose', 'within 2 weeks after the last dose of study treatment', 'while taking the medication.|Women', 'at least for four weeks', 'within 3 months of screening.|Is', 'within the three months preceding the planned', 'within 1 month before screening', 'in the last six months;|Engaged', 'within the prostatic urethra|Subjects', 'within 5 times the half-life of the investigational product', 'within 6 months before treatment;|Suffer from serious', 'within 3 years prior to initiation of study treatment', 'prior to the index procedure|Anatomy', 'within the past 12 months.|Any', 'for higher rates', 'during the last 3 months;|Uncontrolled T2D', 'in the last 12 months.|Presence', 'in the last 3 months|Not', '< 28 days prior to the start of study treatment.||Previous', 'within 7 days of C1D-7)|International Normalized Ratio (', 'within 7 days before infusion', 'higher|At least 3 months post-amputation', 'within 6 months of baseline', 'transplantation.|In past 6 months', 'prior to biopsy', 'within 28 days after previous', 'within 6 months prior to start of study treatment', 'during the study.|Current use of', '7 days prior', 'longer than 7', 'athletes|Younger than 12 years', 'else than due', 'newly-', 'over 1g', 'within 3 months of any planned study procedures', 'within 3 months prior to and up to two days following index date|Atrial', 'at the time of the second injection Taking any analgesic medication before the application', 'at least 6 weeks post', 'for at least 3 months before inclusion', 'index admission treated', 'in history;|a history of', 'within their social network', 'within 4 weeks prior to first cevostamab infusion||a', 'within 4 weeks prior to enrollment.|Other', 'after they have resumed their pre-exacerbation maintenance asthma therapy', 'before randomization', 'for at least 14 days for', 'within 6 months prior to the expected initial application date', 'in the last 7 days before the study.|History of ventricular', 'prior and after)', 'within the previous 3 months prior to Baseline', 'within 5 times the elimination half-life', 'during the last month|Treatment with antibiotics|Respiratory', 'previous 8 weeks', 'for six months prior to enrollment', 'at least 1 line of endocrine therapy', 'within 24 hours of the time of surgery|Cardiogenic shock', 'at time of study entry|Eastern', 'in the previous 6 months.|History', 'prior two months', 'during the study period;||5.4', 'period prior to start of study treatment', 'within 23 hours of study', '6 weeks prior to (to obtain', 'within 2 weeks of the start of study treatment', 'during treatment||History of prior', 'in the last year.|Objective', 'performed three months', 'within 60 days of the screening visit', 'past two years', 'within the 4 weeks preceding', 'during the duration of this', 'after 3 months post-eradication', 'within 7 days before the first dose', 'prior to admission', 'recent', 'within 1 month before the first administration', 'at Screening for', 'within 2weeks prior to investigational', 'pre-existing stent(s', 'within 6 months.|Pregnant', 'within 2 years except', 'within the last 24 hours.|Participant already admitted', 'within 12 months after BCG', 'in the humerus.||', 'within 60 days prior to Visit 1', 'at least 3 months after the last dose of protocol therapy||Childbearing potential defined', 'within 24 hours prior to inclusion', 'in past 2 years', 'more than 3 months;|Patients', 'within 30 days before operation|Use special balloons', 'during the 30 days prior to study entry.||Tumors of the central nervous system', 'in the past 6 months|Known', 'in the 4 weeks before the study|Patients', 'at term submitted', 'during at least one of three repetitions', 'for 7 months after study treatment discontinuation', 'separated by more than 3 months.||', 'within the first week of life', 'within 4 weeks of completion of first platinum-based', 'for 12 months after SPVN06 SRI.|Subjects who are', 'throughout the class', 'within two weeks prior to start of the study.|Participation', 'at the time of the traumatic event to ensure', 'within 28 days prior to the first dose;|Severe infection', 'recent 3 months', 'within 72 hours prior to', 'since 2017-2021', 'after the last attacked', 'within 2 years prior to initiation', 'within the range', '≥ 3 months before screening.|≥ 6', 'prior to date of randomization', 'after six months of structured training||', 'at the time of signing the informed consent.|Participants must', 'within 4 weeks prior to the first dose of study intervention.||Note', '7 months after the last dose of study treatment|Males', 'at least 4 weeks prior to study drug administration', 'within 1 week prior to the Screening visit', 'within 12 weeks prior to the booster vaccination.|Chronic use', 'within last year.|History of', 'within three months before', 'within 4 weeks prior to initial administration|During the screening period/before the first administration', 'for at least 7 months after the last dose of study treatment', 'after the optimal medical treatment', 'within 3 months prior to informed consent', 'at least 3 prior MM treatment lines of therapy', 'management within 90 days before screening|Previous', 'at the Screening EGD|Avoiding solid foods', 'before 37 weeks', 'while on treatment.|Eastern', 'within the last 6 months prior to study', 'for at least 5 years prior to trial entry', 'within 30 days before the first dosing date|Those', 'at least two years from their last delivery.||', 'at least 12 months prior to study start|Weight', 'within 28 days of dosing', 'during the study drug use period', 'within 28 days of dosing|Other', 'at the screening is over 85 kg', 'within the AVB mechanism', 'within the month preceding infection treatment', 'during the study therapy', 'during the period of study participation.|Absence', 'throughout the study.|Use of any prescribed', 'within one month before the start of this study.|18-60', 'within 14 days prior to first dose of study drug.|Major surgery', 'within 2 weeks of screening.|Participant', 'last', 'within 12 hours before cesarean delivery|multiple pregnancies|Participated in other clinical studies', 'formula);|After 3 months of treatment', 'for the first 24 hours|initiation of continuous electroencephalographic', 'at the time of Dose1 Day 1.||Systemic infection', 'treatments;|History', 'up to 8 hours before the physical therapy', 'within 4 weeks before signing the ICF;|vaccination with live', 'during screening shows clonal cytogenetic abnormalities|Meet the severe', 'within 7 days before the first administration.|Expected survival time', 'in the previous year|Hospitalisation', 'in the last 2 months|Patients', 'within 12 months.|Unstable angina pectoris', 'throughout the duration of study participation', 'within six months;|Have', 'for 3 weeks', 'within the central 9 mm', 'before the first HIV-related', '6 months', 'within 30 days after study participation.|Participation', 'for 3 months prior to screening', 'within 2 weeks before the first dose of investigational medicinal product', 'between the screening period', '6 months of age', 'within 8 weeks or 5 half- lives', 'within 5 or 4', 'at time of recruitment into the study', 'in the past 2 weeks|Willing to comply with all study assessments and procedures|Must not be', 'throughout study participation outside of LIBR.|Stated willingness to comply with all study procedures', 'prior to each study.|are sexually active', 'within 60 days of screening|Severe renal dysfunction', 'within 28 days before randomization', '2 weeks prior to the blood', 'during the trial.|People are currently', 'at least two days after enrolment|If subject', 'within 4 weeks before the first dose;|Received', 'at least 2 weeks prior', 'within the last 3 months|History of', 'at least one vessel', 'at the time of transplant.|Must need', 'at the time of written informed consent||Patients', 'within 6 months before signing the informed consent form);|14.5', 'within 14 days or 5 half lives', 'after 5 minutes', 'during cystoscopy', 'preceding 3 months for 3-serial days|Use', 'during the diagnostic proces||', 'within the last year|reports experiencing', 'within the past 6 months of screening.|Receiving', 'within 30 days of the planned start of study therapy', 'for at least 1 month prior to CD19', 'for at least 28 days post the last dose of study treatment.|Moderate', 'within 30 days prior to enrollment;|History of', 'at the time of consent.|Recent diagnosis', 'throughout Step 3.|Ability and willingness', 'prior to initiation of study screening.|Male', 'within 14 days of starting study drug', 'post-gastric bypass on upper', 'at the time of severe', 'for at least two months to screening', 'within the last 2 weeks|Patients', 'prior to surgery)|Expected to receive', 'within 42 days prior to enrollment)||Corrected QT interval', 'at initial screening', 'within 4 weeks prior to randomisation).|Body weight', 'during the study;|Use of', 'for at least 12 weeks before', 'longer than 2 consecutive weeks', 'during the study period;|Malignancies', 'within 48 h prior to the first dose of investigational', 'at least 3 days after SBRT', 'during the protocol,|botulinum toxin injection', 'within ≤ 14 days prior to treatment.||Note:', '5 half-lives', 'within 6 months of the baseline', 'before the first dose of study drug；||Patients', 'within 2 weeks prior to the enrollment', 'within any 12-month', 'within 56 days before enrollment|Patients', 'within the previous 6 months||iii', 'within 3 weeks|Radiation therapy', 'within 7 days|good coagulation', 'in the past 1 year should', 'at study enrollment||Histologically', 'before enrollment;|Plan to', 'within 10 days before the surgery', 'within 14 days of Day 1.||The', 'within 1 week from time of injury)|Patient', 'within the past month before screening|Planned blood donation for other purpose than this study', 'in the last three months.|Uncooperative patients', 'during admission to the emergency department|COPD exacerbation rejected', 'within 4 weeks before the screening visit|Acute decompensated', 'within 24 weeks prior Screening Visit 1', 'in the past 12 months without fixation', 'least three months', 'within 72 hours prior to receipt of study', 'during the study period|Participants', 'within last 2 months prior', 'within 12 weeks of screening|Any history of vitrectomy', 'between screening assessment', 'longer than 45 minutes.|The', 'within 18 months from the', 'Before the first dose', 'within three months before the planned date of the first study vaccination', 'at the initiation of treatment.|Patients', 'within the past month with', 'within 1 year before the study', 'within 30 days before the first dose Administration of study.|Any', 'within 14 days before enrollment.||Subject', 'for at least 2 months', 'within the first 5 years of the', 'more than 3 times higher than the upper limit of normal', 'for at least 4 months after the last dose of study drug to minimize the risk of pregnancy.|Subjects', 'within 4 hours after', 'within 24 hours prior to enrollment.|Diaminodiphenyl sulfone', 'likely to affect participation or outcomes', '< 12 months before first dose of study drug', 'for > 6 weeks before enrolment;|Administration', 'in the last 10 days|Absence', 'within three months before the procedure|Unstable angina', 'within 4 weeks before Cycle 1, Day 1 or anticipation', 'at the time of screening||Absolute Neutrophil Count (ANC', 'past 48 hours', 'in the past 3 months|Continuous', 'within 28 days prior to treatment|No prior radiation therapy to the tumor', 'within 7 days prior to randomization;|Known', 'Within the last 30 days', 'in the past week|Diagnosis', 'within the 3-month study period', 'within the next 18 months|Another household member', 'up to 24 months prior', 'within 30%;||Healthy', 'during the study;|Current', 'within 48 hours before the first administration of the study drug.|Those', 'within 3 months prior to study entry.|Use', 'within 8 weeks or 2 weeks respectfully', 'within 14 days prior to inclusion;|Woman of childbearing potential', 'within 3 weeks before the first dose', 'in preceding 4 weeks prior to visit', 'within 6 weeks before the first use of the study drug|Oral fluorouracil', 'prior to participation|No', 'for 7 months after the last dosing;|Volunteer to participate', 'within the period of 30 days prior to 30 days following the', 'within indicated therapeutic range', 'after treatment, free of disease progression', 'within 2 months', 'past 3 month prior to the Screening visit.|Use of any of the following', 'within 3 months prior to study drug infusion', 'after surgery;|ASA grade', 'for at least 1 year prior to screening', 'within 6 years prior to the day of', 'in the last 3 months|Currently participating', 'within 30 days prior to administration', 'within the 6 months prior to initiation of', '5 elimination half-lives', 'in the next 4 years||', 'previous 12 months', 'within 4 weeks before screening.|With six months before screening', 'before the diagnosis', 'at the time of protocol enrollment|Autologous', 'at time of inclusion|Well defined', 'within the 12 months preceding study visit 1.|Currently participating in another study', ""within 6 months after treatment.||The major organs' function"", 'during the 4-week', 'within the past 6 months.|Person', 'for at least 30 days after the last dose of TU2218', 'within 3 half-lives', 'within 28 days before administration of investigational product', 'after previous vaccination.||Participants', 'within 15 minutes before', 'within the past 5 years;|Known', 'prior to study start', 'within 30 days prior to study drug dosing', 'within the last 3 months|Lactose intolerance|Celiac diseas|Food allergies|Specific dietary regiments', 'for 12 months prior to the planned date of study intervention', 'in that time to the number', 'within 14 days prior to initiation of study treatment', 'newly diagnosed', 'within 28 days.|Known', 'during the trial period;|Used live', '5 weeks prior to starting IMP', 'continue for the duration of the study.|Patient available to attend', 'after the last dose of study intervention', 'within 7 days prior to the first dose of the study drug.||14', 'within 14 days prior to day -6 of protocol therapy|The patient is unwilling to stop', 'within the six weeks prior to enrolment|Emergency surgery', 'within two weeks before treatment;|Severe infection;|Drug abuse', 'at least 1 standard treatment regimen', 'within 24 hours prior to study drug', '5 half lives prior to the first dose of study', 'at the time of inclusion|Unstabilized', 'at the time of cardioversion;|Uncontrolled', 'within 2 days prior to initiation of treatment', 'within 28 days prior to day 1 of protocol therapy|Cardiac function', 'occurring < 6 weeks from enrollment Group', 'within 6 months before enrolling to the study', 'within 2 weeks before first dose of the research drug;|Have participated in any clinical trial within 3 months before screening;|Refuse to stop', 'before enrollment are allowed into the study provided that they', 'within the last 6 months.|Pregnant', 'within 42 days prior to Cycle 1, Day 1', 'within the previous 6 months.|Potentially unstable', 'within 12 weeks before screening.|Intravenous iron', 'within 24 weeks prior to', 'at time of consent|Weight', 'in the last 12 months|Acute infections', 'during the 3 months prior to the screening', 'within one week (Day -7 to Day -1) before the patient receives their first infusion of CA9hi-1.|Calculated', 'more than 4 weeks prior to the first dose', 'at screening.|Patients with active', 'within 28 days prior to first dose of study treatment', 'at the time of screening;|Hypersensitivity', 'during the intervention period', 'within the past two years|Any circumstances', 'within 30 days prior to enrollment', 'for 4 or more', 'within 2 weeks before randomization.|Received major organ surgery', 'at the time of signing the informed consent|Are able', 'within 12 months before enrollment;|History', 'more than 6 contractions per hour', 'while indoors||Serum', 'at the time of screening.|History of suicide attempt.|Syndrome of', 'within the previous 30 days.|Requiring', 'pre-syncope|Blood pressure values', 'during the last 30 days', 'at the time of recruitment', 'up to one month before blood sampling|Puberty', 'at baseline <100/60 mmHg|Contraindications to', 'ended from any', 'within the last 2 weeks before randomization', 'within 14 days preceding the first dose of study drug.|Prior', 'within 30 days prior to this research;|Having', 'in the next 2 years', 'at least 5 days a week for at least 3 consecutive', 'within 28 days prior to first study treatment|Prior treatment', 'within 4 weeks before the initial treatment', 'for at least 12 weeks prior to Screening Visit 1', 'within 1 year before the first dose of study', '5 half lives of the investigational drug', '28 days after the last tumor treatment', 'within 1 year on and after index date', 'prior to procedure', 'during the study period.|History', 'old.|More than 6 years', 'within 14 days before administration of the first dose of IMP.|The', 'within 12 weeks prior to enrollment.|Tocilizumab', 'during the time of menstruation.|Abnormal laboratory test results of clinical significance', 'within last 12 months', 'up to 2 years old|ASA Status', 'for 4 weeks before the baseline study visit.||', 'within 14 days prior to screening.|Any H2 antihistamine', 'at the same time detected HCV RNA copies of positive;|Patients', 'within 2 weeks of the first dose of ADI-PEG', 'lasted for 3 months', 'at least 4 weeks prior to enrollment.||', 'four months of first-line induction treatment', 'for 6 months before screening;|History', 'at least one oral medication per day', 'prior to protocol treatment start', 'in the period less than 2 months before the start of the study;|Patients', 'within 6 months prior to Visit 2.|Have', 'within 28 days prior to registration;|Steroid therapy', 'within 24 hours of first consultation to the Gynecological Oncology team|Are undergoing', 'for 4 months after stopping study treatment', 'more than 6 months prior to starting study|Self-reported', 'during the study.|Subject is able to forgo changes in baseline medications', '≥14 days before receipt of study vaccine', 'within 24 hours prior to the research scan', 'history within 3 months before randomization', 'within the last 2 months|History of', 'at the time the subject', 'at least 8 days/month migraine days', 'in last six months', 'within the next 6 months|Subjects', 'within 6 mounths|Maxillary', 'for the duration of study participation.|Not breast feeding.||', 'in aim 1a', 'for two or more times after CR', 'within 3 months;|Patients', 'pain,|Being addicted to alcohol', 'after 2 or more', 'prior therapies||Cohort 4', 'within less than 4 weeks prior to screening.|Use', 'after the last dose of study', 'history', 'within 1 week before randomization;|25', 'at the time of enrollment.|Patient', 'during the study|Cancer diagnosis', 'prior to study treatment', 'within the past 48 months.|Documentation', 'within ≤ 2 years before study enrollment', 'in the past 30 days|meet', 'at flatland', 'at the time of study enrollment.|Smoked cigarettes', 'within 24 weeks prior to randomization', 'for 30 days after the last dose of the study', 'during the last 6 months.|Subjects', 'after the initial tumor reduction surgery', 'within previous 6 months|Severe heart failure', 'within the preceding 6 months|Coronary artery bypass surgery|Current stable angina pectoris', 'within 4 weeks prior to obtaining', 'before start of the study treatment:||Hemoglobin', 'at the knee', 'at the time of recruiting', 'disorder.|Intent', 'within 28 days prior to Cycle 1, Day 1 or', 'at time of consent.|Patients', 'at or after the diagnosis', 'within 30 days of hospitalization', 'at least 1 year prior to Visit 0.|Participants', 'at birth', 'within 6 months prior to inclusion|Recent food allergy < 3 months prior', 'IDD|between 6 and 17 years', 'during the first 3 years of', 'within 3 days prior to first study drug administration', 'within 1 month prior to the first dose administration', 'within 14 days of day -5', 'within six months before the first administration of the study', 'within 4 weeks prior to initiation of study treatment.|Known', 'before surgery', 'at the time of signing the consent form|HIV-1 infection', 'at the Screening visit', 'during the study period||', 'within the range 18 to 35 kg/m2', 'within one year of enrollment', 'at the time of screening stage', 'within 1 month before enrollment;|Suffering', 'within 1 year prior to screening.|Has', 'throughout the treatment', '24 hours per day).|Premorbid', 'more than 5 cigarettes', 'in the opinion of the Investigator will interfere with the trial.|Has', 'less than 6', 'for 1 month after.||', 'while on this study', 'Emergency Department', 'at any time from HSCT procedure until the time of randomization.|Has severe', 'in the last 3 years|Have', 'within 2 cm of the selected treatment area|Topical salves', 'within 30 days before starting SNDX-5613|Participant', 'within six months prior to first dose of the IMP', 'at least 1 year after menopause', 'currently receiving daily montelukast', 'within 1-2 months after surgery.|Died', 'after surgery;|Patient who signed an informed consent form to participate', 'within the last 4 weeks prior to the study examination date|Severe polyneuropathy', 'during the study.|The patient', 'within the projected duration of the study|Any mental or medical condition', 'within 24 hours before the surgery|Patients', 'within 14 days prior to signing the informed consent form:||Vaso-occlusive crisis', ""throughout the study;|The patient's"", 'within 60 days of study', 'in the past 6 months|Treatment', 'in the next year|Overweight ot', 'within the last 6 months|Body Mass Index (BMI', 'within 3 months before screening;|Subjects', 'within 72 h prior to initiation of study treatment', 'within 28 days of A2B530 infusion|Unstable angina', 'in the past six months|the unwillingness to stick to the training schedule', 'in the zone', 'during the last 2 years before baseline||', 'for at least 4 weeks||', 'within 4 weeks of administration of the first dose of treatment.|History of', 'within 3 months before screening;|Any condition that', 'three months after screening', 'within at least 2 weeks prior to administration of Investigational Product(IP', 'within the observation period', 'at the time of screening.||Acute conditions', 'within the study treatments|Current competitive NCAA', 'within 5 years prior to Screening.|Evidence', 'in the past month that', 'within the 6 months prior to screening', 'within 48 hr prior to dosing', 'at least 6', 'within 6 months prior to the first dose|Severe infection', 'more than 20', 'at least 4 weeks before', 'within 28 days prior to implantation surgery', 'for the duration of the study period|Allows the investigators', 'last 2 years|Neurological diseases|Cardiovascular diseases', 'during the study period;|Concurrent', 'except time to therapy)|Use', 'within 4 weeks prior to enrollment|Previously', 'for 180 days', 'at routine screening ultrasound|Suspicion of CNS', 'at time of the (first) administration of IMP.|Use', 'for at least 4 months', 'prior to the first administration of investigational product', 'within the last 12 months.||5', 'within 60 days prior to Visit 0|Major', 'within 28 days prior to the first dose of AMG', 'at Screening and not planning to start', 'at least 4 weeks.|Allergy to fluorescein', 'during the 3 months before surgery|Patient refusal', 'within 6 months prior to', 'in the 24 weeks before Baseline (Day 0)|Prior', 'at the time of signing the informed consent.||Have SCA1', 'at enrollment 10', 'for at least 1 year.||13', 'within 24 hours after burn', 'for the cohort)|Dwelling not found', 'within 14 days of study vaccination.|Agree', 'for one month after.||', 'in the past 3 months|major psychiatric illness', 'within the last 3 months|Mandatory treatment', 'over last 6 months|major hearing/visual', 'within 6 months prior to the first dose of study drug.|Other severe', 'at the time of informed consent', 'one month before enrollment.|Those', 'within one year before', 'in last 7 days|Variceal bleed in', 'throughout the study period.|The subjects can communicate', 'within 18 months of screening|Seizure', 'for at least 72 hours and off antifungals', 'in the past 12 months', 'at the time of screening.|Woman of childbearing potential not protected', 'within six months before enrolment|Breastfeeding', 'within the past 90 days.|Have', 'within 30 days before the first dose of the study intervention', 'at the involved levels;||Has documented', 'within the range 18 to 32 kg/m^2 (inclusive)', 'within 24 weeks', 'before screening', 'at the time of the Screening Visit.|Post-acute COVID-19 syndrome (', 'within 7 days before the first dose of study treatment.|Life expectancy', 'more than 3 months|NRS scale', 'during which they', 'within the past 6 months)|History', 'in the next month', 'after 5 years of the end of treatment|living', 'pre-test survey|Employee Inclusion Criteria:|Employed', 'within 6 months prior to day 1 of treatment', 'throughout the study.|Willing to follow the protocol', 'within 6 months from study', 'breast.|History', 'at the time of the procedure;|Suspected advanced', 'during the study treatment period;|Patients', 'more than once per week', 'within one moth of study entry.|History of', '12 months', 'within 3 months before administration;|Imaging shows tumor', 'within 48 hours prior to randomisation;|Severe', 'within 6 months before the start of study treatment', 'within 6 weeks of current', 'within 28 days prior to initiation of study treatment', 'over 1 year should', 'at the time of consent', 'up to 3 OAM', 'in the next 5-12 weeks|Score', '1 week after the end of the study;|or who donated 400 mL', 'during the observation period,|pregnancy', 'within the last 5 years|Planning to start another treatment for their knee OA', 'for 30 days after the last dose of study drug', 'absent', 'within 4 months before inclusion.|Current enrollment', 'for 180 days after the last', 'for 14 days before first treatment|ANC ≥ 1,000/μL|Platelet count', 'before TIL collection.|Uncontrolled', 'at least 1 line', 'within 4 wks prior to study', 'in the last 8 weeks|Children admitted to any', 'last 1 year prior to screening', 'during the examination.||', 'within the first 3 months before screening', 'for at least 1 month prior to Screening', 'at the time of CKRT initiation.|Non-ATN AKI', 'the ability to give informed consent', 'at the time of signing the ICF.|Healthy', 'within 28 days before study intervention administration.|Participation', 'within 28 days prior to administration;|Did not receive endocrine therapy', 'during the course of the study.|Inability to understand the local language', 'within 30 days before the first IMP dose.|Pregnant or', 'within 7 days prior to receiving the experimental drug treatment;All', 'within this time period', 'within 12 hours after the occurrence of myocardial infarction', 'in the past week|Any potential', 'more than 6 months)|At least', 'within 30 days prior to screening|Known hypersensitivity', 'in the past month [> 4', 'within 6 weeks prior to treatment|Presence of protruding', 'within 5 years prior to randomization', 'in the last 90 days', 'lasted for more than 4', 'the time of signing the ICF', 'within 4 weeks before the first dose of study medication.|Pregnancy', 'within 4 weeks prior to initial administration of the investigational drug;|ILD', 'for six months before the trial;|Treatment with glucocorticosteroids', 'over the 3 months prior to date of first dose of study drug.||Chemotherapy', 'after enrollment through 28 days after trial vaccination', 'at least 3', 'within the next 3 months|Contraindication', 'within the 3 month period prior to baseline;|Any cataract surgery', 'within 3 months of the screening', 'in the past 30 days|Lip', 'within 3 months before randomization', 'for the duration of the study effective contraceptive measures include', 'within 1 year prior to enrollment;|Patients', 'within 14 days):', 'within 90 days prior to study entry.||iii', 'at time of first assessment', 'during the entire intervention', 'within 1 week prior to C1D1 are acceptable.|Participation in other clinical trials', '6 months after the end of treatment.||', 'in the past 3 months.|Enrollment', 'admission time for inpatients', 'during the last three months|Patient', 'within 7 days of initiating study', 'within 180 days before screening.|History', 'during the study period.||Within 3 months before screening', 'within 30 days prior to insertion of the Flume catheter', 'in the range of 25-40 kg/m2', 'at Department of', 'within 6 months prior to C1D1', 'within one hour if lens is worn', 'in the baseline', 'during the conduct of the entire study', 'within 1 month after finishing the', 'during the preceding 2 months', 'within 3 days before the first dose', 'prior to ICU admission;|Pregnancy', 'within 2 weeks prior to screening', 'within 28 days prior to study', 'at the time of screening.|Use of a', 'at any time in the course of their disease', 'within 1 year prior to screening;|Site staff', 'separated by ≥ 6 hours', ""in the past two weeks|Obtain the consent of the child's family||"", 'during the active', '< 6 months prior to the first dose of study', 'during the study.||Note', 'at least 4 weeks after all previous chemotherapy', 'within 3 months prior to screening|Any medical condition', 'prior to injury|BMI <40', 'within 12 weeks prior', 'at least 4h per week training|Biceps/triceps function|healthy(study', 'within four weeks of screening', 'within 3 months after the end of the trial', 'within the past thirty (30) days of the study', '< 4 weeks', 'more than 6 months.|Patients', 'within the 12 months prior to registration', 'in the last 1 year', 'preceding 5 years|Severe psychiatric disease||Patients referred', 'within 12 months prior to check-in', 'prior to dental', 'within 6 months prior to Screening Period', 'during the period indicated prior', 'within 24 hours prior to the start of IP administration', 'for at least 90 days after the last dose of BMT', 'at the time of enrollment.|Have', 'up to three months prior to trial entry', 'at least 3 months of combination therapy', 'within 10 days prior to the start of study', 'within 4 weeks before dosing|Any lifetime history', 'within 12 weeks before screening', 'within 1 week prior to registration', 'for least 4 months after the last dose of study intervention:||I.', 'cancer.|Medical history of abdominal surgery', 'within 3 months of Visit 1', 'for at least 3 months;|FIQ-Total score', 'in the last 3', 'for greater than 1 year|On', 'at least 6 months before the participation', 'within 4 weeks prior to leukapheresis', 'any time prior to study', 'rather than Covid-19|Patients', 'within 1 month prior to Screening', 'within the last 2 months.|More than three surgical treatments', 'through 6 months after bevacizumab treatment discontinuation.|All participants', 'in the previous 3 months|Patients treated', 'within the past year prior to screening', 'during their participation in parent study KGBI', 'within 3 months prior to screening;|Subjects', 'in the oral cavity|secondary obesity|type 1 diabetes|type 2', 'within 2 weeks prior to the initial', 'within 14 days|Biologics', 'less than 3 years before inclusion', 'within 4 weeks before the first administration of ETH-155008', 'within 4 days prior to the first dose of TY-2136b', 'prior to starting therapy.||Subjects', 'stroke)|3 months or greater', 'during the study period.||Female', 'within 2 weeks before the first administration;|Within 2 weeks before the first administration', 'at 14 weeks', 'hypersecretory conditions|History of medical', 'after 42', 'continued to control symptoms', 'within 8 weeks prior to study entry,|Systemic', 'within one month after last trial treatment application.|Isotretinoin', 'within 30 days prior to screening.|Use of', 'during the current hospital stay|Patients', 'within 12 months of screening|Use', 'protection Legally protected', 'within last 4 months', 'at the time of signing the ICF.|Patients', 'within 7 days before study treatment initiation', 'within 4 weeks of the the first planned dose of brigatinib.||Minor surgical procedures', 'at screening time', 'within the range +4.00 to -9.00 DS', 'for at least 1 week.|Subject able to give', 'within 4 weeks prior to first dose of investigational medicinal product (IMP', 'three times per week', 'within 6 hours of time of', '30 days prior to the study.|Presence', 'rTMS||', 'at onset of back pain', 'at any time of the study.|Exposure', 'more than 1 year prior to the screening', 'within the past 6 months|Additional medical conditions', 'during the last 21 days before screening.|Known treatment', '<12 month prior to recurrence|Non-resectable', '< 6 months prior to screening.|Acute', 'within the last 6 hours,|No', 'in the last 6 months.|Will', 'at time of screening.|Currently resides', 'prior to screening).|Patients', 'less than 3 months before start of the study|Pregnant', 'by 14 days before the first dose of study drug.|Any condition', 'within 6 months before first dose of study treatment', 'at least 6 months of experience', 'before onset', 'within 4 weeks.|Chemotherapy', 'at night, travel for long periods of time', 'within 21 days prior to study entry', 'in the past 6 months|Meet one of the following criteria', 'within 3 months prior to enrolment|Subject', 'during the first 2 cycles of study treatment', 'within two weeks before enrollment;|Patients', 'for 1 week after stopping of investigational drug.||Other protocol-defined inclusion/exclusion criteria may apply', 'within 6 months before the first administration of clinical trial drugs.|Those', 'within four weeks of the first dose of study treatment.|At high medical risk', 'while taking study treatment', 'planning within 3 months of Screening', 'within 12 months prior to baseline|A history of', 'in the 3 months prior to signing ICF.|Those', 'before the 3 months', 'in the next 12 months;|not previously', 'within 4 weeks before study initiation.|Diarrhea', 'within 4 weeks (28 days', 'within the last 30 days with any investigational drug.|Concurrent administration of any other', 'within 24 hours of the planned dose of study vaccine', 'III within 3 months prior to informed consent', 'within 28 days prior to initial dosing', 'prior to induction of hypertrophy|able', 'within 6 months of treatment', 'within 3 months prior baseline', 'within the last 12 months prior', 'at the first administration of CA9hu-1', 'within 28 days before the start of the study treatment;|Long-term', 'for at least 90 days after the last dose of galunisertib', 'in the 6 months prior to signing ICF', '3-6 months', 'prior to initial treatment.|A', 'within 4 weeks before the first dose of study treatment.|Presence', 'between January 2008', 'within two hours', 'within 28 days before the first dose of study drug', 'at the screening visit.|Hospitalization', 'at least 2 weeks after completion of therapy', 'in past 3 months|current smokers', 'within 14 days before leukapheresis', 'within three months before the first dose of', 'within 3 months prior to inclusion', 'after prior hypomethylating agents.|Relapsed', 'within five months after the final dose of atezolizumab.||M.', 'for at least 7 days', 'within 1.5 ULN.|Informed consent obtained.||', 'in the last two months|Parent previously accessed a mindful parenting', 'within 6 months before the start of treatment', 'within following 1 year of the DBT', 'past six months prior to screening', 'occurring less than 30 days before signing the informed consent form', 'in the time of diagnosed|primary cancer', 'before the randomization;|Patient', 'throughout the study treatment', 'within 24 hours after LAAC;|5', 'at the location', 'within 3 years prior to treatment start', 'within 1 year after infusion', 'at screening.|Other inclusion criteria', 'at least 90 days after the last study treatment administration|Male patients', 'during trial treatment', 'within 72 hours prior to the first dose of study drug|Patients', 'for their first lumbar spine surgery|Radiographic evidence', 'within the last 4 weeks.|History of', 'at A', 'for at least 4 weeks after completion of the definitive therapy', 'within the past 15 years', 'in the 2nd', 'prior to specimen collection', 'medical diagnosis', 'within 30 days prior to Ad-TD-nsIL12 administration.|Blood transfusions', 'within 28 days prior to the first dose of the interventions', 'for the duration of the study', 'at the time of viral therapy.|Other investigational medications', 'within 3 months before Visit 1', 'during the study,|Willingness to follow all study procedures', 'personal history of', 'at least six months after their Covid-19 infection', 'in sexual intercourse', 'within the prior 5 years', 'until 1 year after the last cell transfusion', 'within 2 months before inclusion.|Positive result', 'within 7 days prior to the hospitalization', 'in the next 3 months|History of', 'at least 1 spots per subject)|Agreeing not to be exposed to the sun', 'for less than 12 months', 'within 3 months of procedure.|Previous', 'while on study drug', 'within the past 6 months.|Craniectomy', 'within 6 months of registration', 'throughout the study|absence of unstable', 'prior to study medication.|People', 'at the time of enrollment.||', 'within 28 days before enrollment.||11', 'within 12 months after consolidation', 'prior to any study specific', 'within the normal', 'last year before enrolment', 'within 4 weeks before the medication', 'for at least 72 hours (complete) with cefiderocol', '7 days prior to initial dosing;|Cardiovascular diseases', 'less than 6 weeks after completion of breastfeeding|Exposure to the sun', 'within RDA', 'within 14 days.|Those', 'after all standard therapies', 'at 72 hours post-surgery increased', 'within 30 days before surgery|women', 'during at least the last 12 months', 'within 1 month or received', 'within 3 months before enrollment;|He had received', 'within the prior 3 months.|Any target vessel', 'within the past 5 years from screening', 'within 5 years prior to baseline', 'within 1 month prior', 'at least 2 times the slice thickness', 'within previous year|Persons currently involved', 'prior to PET/CT imaging', 'at the Screening Visit', 'in last 3 years|Known', 'for three months after completion of treatment.|Patients are fully informed', 'within 72 hours of symptom onset', 'within 4 weeks before the first administration;|Accept solid organ', 'at least 3 cm', 'within 6 months prior to screening|Cell therapies', 'within 180 days|Known history of cytotherapy', 'within the 6 months prior to the study vaccine', '5 days prior to admission', 'within 7 days post-delivery', 'within 28 days post-HSCT', 'at the time of consideration for study enrolment.|Symptomatic brain metastasis', 'for at least six months before enrolment', 'for ≥ 12 weeks prior to Randomization', 'during and', 'within 14 days before administration;|Did not receive', 'within 12 months after consolidation intensification after CR', 'during the study intervention period', 'over 18 years', 'in the past week or', 'in the last 5 years.|History of any significant', 'within 9 months', 'after first-line treatment', 'metastases.|Dominant', 'within 2weeks prior to investigational drug administration;|Patients', 'at the Screening', 'over 2 weeks of run-', 'within the 30 days before the screening', 'within 3 months prior to randomization|History of', 'pre-operatively', 'for at least 3 months before first scheduled study drug administration', 'within the previous 7-days', 'within 30 days before screening except', 'for the duration of study participation.|If the potential participant', 'recent French recommendations', 'prior to surgery.|Stages 2-3', 'medical history unsuitable for participation', 'at time of first assessment||', 'at least one of the cardiac risk factors', 'clinical', 'prior sexual activity', 'within the 8 weeks prior to the first dosing', 'in the last 2 months before the study||', 'for at least 12 months after', 'in the next 4', 'within the last 2 years|Subjects', '< 1 week prior to screening', 'within 14 days before receipt of study vaccine', 'TNT|Performing ≤90 minutes', 'at the start of treatment.|Simultaneously treated', 'within 3 months before enrollment;|18', 'more than once a week', 'in the 3 weeks prior to run-in', 'After comprehensive examination', 'during the study period.|Taking', 'within the last 2 years|One of the following illnesses', 'within 30 days prior to the informed consent', 'in two dedicated days (', 'within the last 6 months.|decreased function', 'preceding 4 weeks|No contraindications to the application of C.alata extract in solution including|No', 'preventing implantation.|Previous implantation', 'within the last 14 days;|Prior treatment', 'within 4 weeks prior to the start of this study.|Prior treatment', 'within the week prior to the Ketamine', 'within 180 days prior to the day of screening', '5 through 6 years', 'in first line after 21/Jan./2021', 'at the time of first dose of study treatment.|Participants', 'within 6 months of baseline;|Chronic use of', 'within 28 days before the administration', 'past 12 months any injections', 'within 6 months of the anticipated', 'prior to the initiation of the study medications.|History', 'within 14 days prior to planned', 'within 1 year before receiving the experimental drug treatment;|Those who have previously received', 'within one week of study entry.|Participants', 'within 4 weeks before medication;|A', 'at least 3 months after date of concussion)', 'for at least 180 days prior to the day of screening|Haemoglobin A1C (HbA1c)', 'within 14 days prior to the first administration of the study', 'for equal to or less than 3 weeks', 'Hospital admission within 2 hours after birth;|The diagnosis', 'for at least 6 months|able to read', 'for less than for less than 18 months.|Patients lost to follow-up for more than 3 years', 'within 2 weeks prior to the first dose of study drug', 'during for 90 days after the study.|Cognitive ability for possible to make self-decision', 'within 7 days before treatment meets', 'at least 6 months prior to screening.|For radical', 'within the three months preceding the planned administration of the vaccine candidate.|Receipt of any vaccine', 'during the examination,|Children had enamel hypoplasia', 'during the during the inpatient days of the study', 'at the time of delivery)|Active', 'within 4 weeks prior to the first administration of this study', 'within 28 days prior the first dose of study drug', 'for at least 3 months following', 'within 2 months of study', 'within 6 months of study', 'during the trial;|Has any current', 'within the past eight weeks', 'within 4 weeks prior to screening||Exclusion Criteria', 'within 30 days prior to enrolment.|Subjects', 'more.|Adequate', 'at the start if each patient requires', 'for at least 4 weeks before enrollment;|Participants', 'within three months before study Visit 1(day 0)|Ocular surgery', 'for 30 days after stopping study treatment||', 'post-IO standard of care therapy).|Patient must be', 'during the past 3 months', 'post-exertional', 'within 14 days|Active central nervous system', 'within 4 weeks prior to sample being taken', 'within 30 days prior to admission', 'in prior 2 weeks||', 'last offered|Commit to continue annual reviews', 'within 8 weeks before first dose', 'in the last 12 months|Latest', 'during an incremental exercise test to volitional fatigue', 'within the month prior to randomization|History', 'during 12 months period', 'within the past two years.|They', 'within 72 hours prior to dosing.||Participants', 'within 5 years before randomization', 'previous two years;|Anticipates being able to wear the study lenses', 'greater.||Medical history', 'within the past 12 months.|Participants', 'within 6 months before the first dose.|Subjects', 'at the puncture site.|Coagulopathy.|Cognitive disorders.|Unstable cardiovascular disease.|History of psychiatric disorders.|History of drug', 'Undergoing', 'perforation.|Prior', 'within 6 months prior to Day 1 for individuals', 'at any time prior to or', 'during study period|No', 'within four weeks of presentation|Inability', 'within 6 months prior to Day 1|History of', 'prior the first dose of study drug', 'prior to start of study treatment.|Patients', 'at least 6 months before entering the study', '72 hours prior', 'for 6 months after the last dose;||', 'within 2 weeks of their Baseline visit', 'prior to selection,||Additional inclusion criteria', 'past one (1) year|History', 'last 3 months', 'at the Department of Cardiology of AHEPA University General Hospital', 'in the past 3 months before T1|Allergy to test product/control', 'within the last three months before enrolment|No previous surgical treatment', 'within the last 12 months|Positive drugs', 'at least 3 to 5 per irritation):', 'at least 2 times a week)||', 'one month prior to enrollment', 'within 4 weeks before the first dose of study drug', 'within the last 45 days', 'at least 1 of the screening visit days (Day -14', 'at time of dosing', 'after previous surgery', 'after week 20, 24', 'for at least 30 days before starting therapy.||', 'at the time of the first HIV-related code|At least six months', 'within 6 months before enrollment showed', 'in the next 6 months.|Currently', 'within 7 days prior to the study;|Underarm body temperature before vaccination>37.0°C;|The subjects participated', 'within 3 months before the first dose', 'for at least 6 months prior to Screening|Receipt of a live vaccine', 'within 6 months prior to IP administration|Intra-articular', 'within the last six months|Are', 'respiratory', 'at least 1 extracranial', 'within 8 weeks before randomization', 'past 2 years||Provider participants:||Inclusion Criteria:||Provider', 'within 6 months before the screening period', 'within 6 months prior to randomization.|Has evidence', 'at the time of screening||Those with', 'following preoperative therapy', 'during the time period between CAR T cell infusion and first cevostamab infusion', 'within 4 hours of ROSC||', 'during the treatment phase', 'at least 8 weeks prior to cycle 1 day 1', 'at the time of signing the Informed Consent Form (', 'at the time of signing the informed consent.|Body weight', 'within 6 months of Visit 1', 'more than 8 weeks', 'within 90 days before screening', 'prior to the entrance to the study', 'within 6 months of treatment procedure|Severe lung disease', 'in the last 3 months|Those', 'auditory', 'prior to participation in the study', 'at the time of signing the informed consent.|Participants who', '1 month prior to enrollment', 'throughout study intervention', 'within 7 days prior to the first dose of the investigational product', 'within 3 months before the first administration;|Those', 'at time of screening|PROSTATE', 'at least 6 months prior to drug administration', 'continue to maintain treatment', '≥4 weeks prior to the first dose of investigational drug', 'within 30 days preceding the index procedure', 'any time prior to study entry.|RADIOTHERAPY', 'last 5 years|Struggling', 'at Duke University Hospital.||Exclusion Criteria', 'within 12 weeks prior to Screening.|Receipt', 'in the 3 months after enrolment|Significant', 'for at least 3 months prior to the screening.|History of', 'before starting all subsequent cycles', 'in previous 3 months|History of', 'within 4 weeks of the first dose of treatment', 'during study recruitment', 'after 24 hours from its diagnosis|MAP<65 mmHg', 'at least 15 ASCVD', 'at the screening visit after 5 min', 'at least 30 days|At least 18 years', 'within 6 months|Prior treatment', 'photosensitivity|positive history', 'last treatment.||EXCEPTION', 'within 8 weeks prior to screening.|Participated', 'in the two weeks between the initial screening', 'within 30 days preceding the first dose of study vaccine', 'within 14 days of Day 1', 'within 3 months.|Clinically significant', 'in the upper and lower extremities (below the elbow / knee joint', 'at least 1 month prior to screening', 'within 6 months prior to screening.|Subject', 'while on the unit', 'throughout the Double-Blind Dosing Phase', 'at least 8 consecutive weeks', 'during the index procedure)|A', 'for at least 12 weeks||', 'within 7 days prior to drug', 'during the screening assessment for', 'prior to screening|You may not be able to participate in this study', 'within 1 months prior to the start of the trial', 'within last 2 years|Diagnosis of severe', 'during pregnancy|< 6 months', 'in 6 months', 'within 12 months of screening.|Participant', 'during the first 12 hours after nerve block application|positive patient history', 'in last 6 months.|Subjects', 'within 4 weeks before radioembolization|More than 2 previous TACE', 'in the last 60 days;|Chemical dependency/alcoholism;|Chronic use', 'within 6. 3 years||7', 'within 5 years prior to consent', 'throughout its course', 'within 48 hours before', 'during this period', 'between 12-32 weeks', 'within 3 months before randomization||Systemic', 'within the normal range', 'prior to screen visit', 'within 72 hours after surgery', 'at the time of baseline', 'at the time of enrolling in the study|iii', 'within 10 days before first dose of YK-029A.|Concurrent EGFR', 'within 30 days before signing the informed consent form', 'within the past 4 weeks.|History', 'within 6 months prior to the first scheduled dose of the IP|Subjects who donated whole blood', 'within 4 weeks prior to registration', 'up to 30 days after each vaccination.||NOTE', 'in 6 months before screening', 'for at least 30 days after the last dose of study agent.|History', 'last until 12 months after last dose of study drug', 'within the past six', 'within the stent|Pre-dilation', 'within 1 year|Having mental', 'within 9 months before entry', 'within the next year|Concomitant use of or unwillingness to avoid', 'at least 3 months prior', 'prior to chest CT|Lack of social security affiliation', 'at the time of signing informed consent|World Health Organization (WHO)', 'in last 3 months|illicit drug', 'within the last week', '7 days before intervention:||Blood routine should meet', 'within 4 weeks of the first dose of treatment.|Patients', 'for 180 days following the last dose for females', 'within 6 months after the end of the study treatment period', 'for at least 6 months after the last dose of study treatment', 'within the past year|History', '5 half-life periods before screening', 'within the last 4 weeks)|ANC ≥ 2.0 × 109/L', 'since at least 12 weeks before the beginning of the study', 'prior to the start of concurrent', 'within 2 weeks of the first dose of study drug.|Major surgery 4 weeks prior to starting study drug', 'within the', 'within the previous 6 months.|History', 'within 28 days prior to the first MBS303;|Active', 'within 30 days prior of the study screening', 'within 18 months', 'within 14 days prior to screening;|Subjects', 'within 3 days prior to the study', 'over the past 24 hours.|Ability', 'within last', 'within the previous 3 months;|Patients', 'in the last 2 years prior to the first dose of study treatment', 'within 3 months before administration,|Major surgery', 'within 30 days prior to screening/admission', '> 1 week prior to Cycle 1', 'less than 2 cm;||3', 'within 4 weeks prior to initial administration;|History of inherited', 'within 1 week prior to enrollment.|Any unresolved toxicity', 'within 1 weeks before the start', 'before enrollment to rule out MI.|Corrected QT interval', '> 3 months before the date', 'within less than 2 weeks before first study intervention administration', 'during the introduction period;|The', 'within 24 hours;|The', 'within 30 days prior to the first dose of study intervention|Major surgical procedure', 'for 12 hours prior to each visit', 'greater than 6 Woods Units|Emergency cardiac procedure', 'three months prior to and', 'during the 12-month period before the study treatment|Recent use of topical tretinoin', 'within the last 30 days)|Recent', 'in the past 6-months|Are', 'through to study end.||Has any medical disease', 'prior to receiving the study treatment.|Male subjects', 'within 3 months postpartum', 'within 30 days of inhaled', 'less than 3 years', 'within 3 weeks prior to the first dose of study interventions', 'at least 20 hot flushes per week).||Patients', 'for at least 12 months after their last study treatment.|Negative HIV test', 'in the past 14 days;|Hemoglobin', 'within 7 days before starting the study drug', 'between 3 months and 24 months old|Have loose', 'prior to starting therapy', 'at the time of the cross-sectional evaluation|For the ECMO group', 'in the last 3 months|Patients', 'within 12 months of screening.||For', 'prior to treatment.|Individual', 'recently than 8 weeks', 'at least 3 months prior to enrollment', 'for 6 months before the screening|History of', 'within the past 6 months;|Have', 'at least 6 months before study entry)|All', 'within 4 weeks prior to the first dose of study', 'prior to entry into', 'within three days of surgery', 'for greater than 3', 'within 3 months of consent', 'within 3 months of Screening', 'undergoing treatment|No PSMA-targeted therapy ongoing|Inability or unwillingness to undergo', 'during the screening', 'within 4 weeks prior to screening.|History of', 'at least 12 weeks.|Patients must meet the following requirements for laboratory tests', 'before the blood draw|Wearing glasses', 'for at least 2 weeks prior to the start of the experiment.|Subjects', 'within 2 weeks prior to first dosing of study treatment.|Liver disease', 'prior to entrance to the', 'breastfeeding -hormone replacement therapy-|tobacco use|musculoskeletal injury/disorder', 'within 48 hours prior to taking the study drug|Female', 'for at least 6 months after the last dose of study', 'for at least 4 weeks prior to the first dose of investigational therapy', 'at least 6 months after administration.|Subjects', 'within 4 weeks prior to enrollment.|Patient', 'for at least 14 days prior to screening.|Parent(s', 'within 6 months before study entry.|Clinically significant', 'bile duct caused', 'at least 3 months|Presence', '6 months of screening', 'within the 2 weeks prior to the D2C7-IT', 'within past 2 years', 'in the screening period', 'during the previous 6 months；|Potentially unstable', 'for up to 22 hours iii', 'for at least 3 months after the last dose', 'within 4 weeks of Visit 2|History of', 'for at least 4 weeks|The', 'at the time of SARS hospitalisation', 'before the baseline visit||Participation', 'within 7 days prior to check', 'within 12 months prior to the first dosing day.|Current enrolment', 'within 28 days of registration;|Major surgery', 'at least 1 year prior to enrollment', 'at the time of enrollment|Patient', 'at least 1 day apart)|ALT', 'during surgery or study therapy;|Known', 'prior to the stroke|Patients', 'within the last 6 months.|Congestive heart failure', 'more than 6 times;|Patients', 'natural history', 'at the time of treatment', 'at least 4 weeks prior to randomization|Sufficient', 'in the past 12 months.||Exclusion criteria:||• Patient visits', 'within 2 weeks from Screening/Baseline', 'at the time of enrollment to meet the', 'within the framework of an interdisciplinary', 'within 2 weeks before study', 'within 14 days before the first dosing date|OTC', 'in the last 12 months.|Acute suicidality.|Acute', 'at time of inclusion.|Subject', 'within eight weeks before screening|history of alcohol', 'at time of screening.|Using', 'within one month before enrollment;|Other circumstances', 'in the next six months.|Other conditions', 'before admission to the neonatal/newborn', 'at least 20% growth', '≥12 months after therapy should have progressed after', 'within 1 week of first receipt of study drug', 'during the study.|Positive', 'at least 4 weeks prior to start of study drug', 'within 60 days of Baseline', 'any time prior to enrollment|Previous treatment', 'at time of registration|WHO performance status', 'within 5 months after the final dose of atezolizumab.||Treatment', 'before surgery .|ECOG performance status', 'throughout the testing period;|Facial manifestations of atopic dermatitis.||', 'for at least 3 months prior to Baseline).|Parent(s)/legal guardian(s', 'at least once every 3 weeks.|Primary', 'throughout this study', 'within the last 12 months|Current', 'within the last 6 months;|Patients', 'during the past six months.|Multiple', 'in the previous 5 years),|hypersensitivity to any investigational food', 'for at least one of the following autoantibodies at screening', 'in the month prior to Day 0;|Subject', 'within 1 year or willingness to get a vision test.||', 'within 4 weeks prior to first dose of the study drug', 'within 7 days prior to the first dose of study drug.|Have', 'in the range of 41 to 80 points.|Patients', 'at the time of Screening.|Has significant', 'more than 2 years ago', 'within 12 months of receipt of the most', 'within the past 3 months|using transdermal hormones', 'within 72 days before first dose', 'within 30 days of any planned study', 'criteria:|at least two', 'for 30 days after completion of the study.|Negative', 'within the last 3 months);|Documented', 'within 2 weeks before randomization', 'during the last 12 months.|Patients', 'for 7 consecutive days', 'within 14 days of first dose of the IMP|A history of any ongoing', 'previously', 'past 30 days', 'more than 4 hours', 'during the 6 months before inclusion.|If the patient need Doppler ultrasound examination', 'at the time of Screening visit', 'in the past 3 months|Chronic use', 'within the 18 months prior to the start of treatment', 'within last 12-months|Active', 'at least ten hours', 'within 24h prior to randomization.|Has received', 'within 5 years.|Clinically significant', 'for at least 12 months.||History', 'within 3 months before booster immunization;|The', 'for at least 6 months of a category 1 multiple sclerosis DMT', 'regimen.|Plans to father a child while enrolled in this study', 'within 3 months before the screening date|Patient or guardian', 'for six months', 'within 30 days prior to the first dose of', 'within 72 hours of the first dose of study intervention', 'over the next 6 months.|Able to provide', 'within 6 months after the end of the medication；|Other conditions', 'prior to', 'in the past two years from date of diagnosis of', 'during the selected study period', 'within 3 years prior to the screening visit', 'at least during 24 hours before each session|Drug therapy', 'calculator)|Within 12 months prior to study entry', 'within 24 weeks prior to the date informed consent', 'within 4 weeks prior to the Screening', 'within the past 6 months prior to screening', 'on the cold test for the target tooth.||', 'at least 3 months after their hospitalization in intensive care medicine', 'at the time of enrollment.|Persistent severe', 'within the 30 days prior to inclusion', 'within 52 weeks prior to randomization.|HIV-infected', 'at time of consent|Ability to speak', 'within 2 weeks before the first dose;Systolic blood pressure', 'at least half of the days of 6 months', 'during the trial period；|Participants', 'within 3 months after the last dose of study drug||Concurrent participation', 'at Screening or Day -1.|Current', 'at time of consent||Inclusion', 'for the next 3 months|unable', 'within 3 months prior to the baseline visit', 'after their curative intent therapy', 'during the study.|Toxicities of prior therapies', 'for their chief complaint|Signed informed consent', 'within 14 days and', 'within the last four weeks|Myocardial infarction', 'during the study period and within 6 months after the end of the study period', 'within 14 days of Day 1|Participants', 'within the previous three months;|Hematological abnormality', 'between the patient and the investigator', 'within the 2 months preceding enrollment.|Current participation in study therapy', 'after neoadjuvant chemotherapy.|Medical oncologist', 'in the 3 months prior to screening.|Patients', 'prior to Screening.|Patients', 'within 30 days to the screening date|Stroke confirmed', 'prior to the first dose of study drug', 'within the three months before study enrollment', 'at least six weeks of', 'within 3 months before the screening', 'within 72 hours|Have a clear contraindication', 'within 6 months before cell transfusion;|3.4', 'within 90 d of screening are excluded||ii', 'longer than 6', 'within 12 weeks before randomization.|He received allergen-specific immunotherapy', 'at least 15 days before inclusion|Patients', 'in the last 6 months|patients', 'during study participation.|Subjects', 'at least 14 days prior to the start of alectinib administration.||D. Prior', 'following criteria:||ANC≥1.5×10^9/L', 'while enrolled in the study', 'at inclusion', 'within 4 weeks prior to assignment/randomization|Known', 'within 48 hours before randomization;|Within three days before randomization', 'immediately prior to randomization|Are', 'within 6 months prior to entering the study.|Has received prior therapy', 'past 12 months prior to inclusion.|Subject', 'in the 3 months prior to the screening period', 'at 2 hours', 'current', 'within the 3 month period prior to baseline;|Previous penetrating keratoplasty', 'within the 12 weeks prior to the Screening', 'within the last 90 days prior to inclusion|Karnofsky index', 'within 10 to 14 days prior to screening.|Patients', 'continue', 'within 4 weeks prior to the initial administration of the study', 'in the past 6 months;|Systemic', 'at the time of Screening.||Have VWM disease', 'at Screening or Day -1.|Donation', 'within 14 days prior to the study drug', ""during the 'no-cream' familiarization session"", 'in the past 5 years except for', 'within 24 hours of starting treatment).|Allergy to any of the components of the study', 'within 4 weeks|History of', 'at least 7 days before the first dose of study treatment', 'prostate;|Previous history of', 'during 6 months before the trial;|Vaccination of the pregnant', 'within 3 months|Recurrent urinary tract infections', 'within 6 months prior to visit 1.|Comorbidities', 'within 4 weeks prior', 'during the 12-months pre-index/baseline period|Any claims', 'within 7 days (+ 3 day window', 'last year|Native Arabic patients||', 'the 12 months prior to EHR screening', 'in the past six months|Willing', 'breastfeeding;|Receiving', 'at time of registration.|Pre-', 'during the last three months.|Written informed consent for study participation.||', 'at the time of inclusion.|The immediate', 'for the prior three months|Are not willing/interested', 'for 1 month after the end of treatment,|Negative serum pregnancy test', 'within 24 hours of last', 'at least 6 months after drug product infusion', 'within the range of 19~26.0 kg/m2', 'during feeding', 'within some of the genital vitiligo areas.|At least 1', 'prior to dosing.|Participation in more than 3', 'at the time of the assessment of its eligibility for', 'for at least six weeks duration', 'within last 3 months', 'prior to initiation of the JAK inhibitor', '2 months prior to the start of study participation;|Pregnant', 'at time of stroke', 'at least 6 months before', 'during the trial period;Patients', 'within 2 weeks of screening|Participation', 'during the 6 months before Screening||', 'at the time of the fat harvest procedure', 'during screening.|Current or past', 'within the previous 5 years|enrolled in clinical trials in which investigators', 'in the last 6 months', 'before week', 'within six months of the first date of treatment', 'for the first time|at least 18 years', 'after one or several interventions', 'in the last 3 months|Use', 'within 10 kg', 'for at least 12 weeks after', 'within 14 days prior to screening', 'throughout the study participation.||For', '1 year before randomization', 'within 14 days prior to treatment study', '30 days prior to index procedure', 'within one year prior to screening|Rituximab', 'within 12 weeks of', 'previous three months', 'in the previous 4 weeks before', 'in the 48 hours prior to hospitalization;|Having done some intense', 'more than 8 hours per week', 'during the Screening period', 'appropriate|Major', ""at least '"", 'within 1 year prior', 'before the first dose of study intervention', 'at the time of registration;|Chronic Obstructive Pulmonary Disease exacerbation', 'within 6 months after the standard therapy of locoregional advanced', 'within 6 months of first administration of DZD9008', 'within 2 years before enrollment.|Botulinum toxin', 'during or after most recent', 'between the completion of CNS-directed therapy', 'in the past 2 weeks.|Have', 'during the study.|Known', 'at the time of testing at ≥37SA, non-invasive', 'at the time of application,|Stable health status', 'throughout youth study participation).||', 'during registration|request to be dismissed from study|failure to give informed consent|emergency', 'within 2 years prior to the first dose (the alternative therapy', 'within 3 months prior to leukapheresis||The following', 'within the past month.|Patients', 'in the past 12 months.||History', 'for the last 3 months|Body mass index of 25kg/m2', 'during screening prior to study', 'within the last three months|Individuals', 'during the last 3 months', 'their close relatives.|Participants', 'within 14 days before first trial product administration', '30 days before', 'within 1 year before the first administration;|There', 'during or after their most recent therapy|PART 3', 'within 14 days or 5-half-lives', 'within the past 6', 'within 2 weeks of study start', 'at the time of signing informed consent||', 'at the time of enrollment', 'within 6 months)|History', 'within 30 days of study Day', 'in the past three', 'within 30 days prior to screening.|In the opinion of the Investigator', 'at Screening and within 24 hours of initial treatment', 'in prior 30 days', 'within the previous 12 months||History of', 'within 28 days prior to registration.||Note', '30 days after EOS', 'within 14 days or live', 'before operation.|There was no serious', 'prior to initial γ9δ2', 'at exam 3 and one', 'throughout the study', 'within 3 months of signing the informed consent', 'in night shifts', 'within three months prior to time of', 'within 30 days prior to screening.|Patient', 'prior to the start of study treatment', 'at least 4 weeks prior to the first dose', 'within 12 weeks before', 'in the first week after birth,|Having a congenital', 'in the past 4', 'within 3 months prior to randomization.|Subjects who regularly consumed alcohol', 'previous two months', 'within 14 days before treatment): international normalized ratio', 'more than three months', 'for the last 4 weeks,|who will be able to walk independently', 'within 3 days prior to randomization', 'at time of procedure|Active', 'within the last 1 year.|Those', 'after at least 2', 'within 4 weeks prior to the first dose of study treatment.||11', 'within 30 days of the end of study|Participation', 'within six weeks', 'at the time of the study|Being', 'at study enrollment.|Participants', 'more than 4500 euros', 'at the time of the assay', 'within 3 months of last cisplatin administration.|Stratum', 'within 6 months prior to the first dose', 'during the screening period', 'in the last 8 weeks prior to Screening.|Patients', 'at least 1 cigarette per day', 'in the last 3 months.|Have', 'within the last 2 weeks|Current', 'during the course of the study', 'last 12 months)', 'longer than 2 months before entry', 'within 90 days after dosing of study drug.|Use', 'in the past 6 months;|History', 'lactation.|Medical history of chronic disease (CLD', 'prior to visit 1|eGFR≥30 ml/min/1.73m2', 'at the time of', 'medical history', 'within 1 month from', 'during the two weeks prior to the first administration of IMP', 'within 12 months prior to study entry.c', 'within the eligibility range', 'at the time of signing the informed consent form', '<6 hours', 'during the lactation', 'for two weeks via self-report', 'within six months prior to participation in this project;|Paresis', 'at least one month of post treatment follow', 'at the time of the parent/legal guardian signing the informed consent form||Audiological', 'within 30 days before intervention', 'for at least 3 months after the last use of the study', 'throughout study intervention.|Patients', 'within 7 days prior to the initiation of study treatment.|Patient', 'at least 5 km', 'during the study.|The', 'for ≥3 months|No treatment', 'insufficiency;|Long-term', 'in the past 2 weeks|Participants', 'within 3 months prior to enrollment|Known active', 'within Canada|Aged', 'before induction of general anesthesia.|Patients', 'within one week after admission', 'between completion of local therapy', 'History', 'at the time of study enrollment|Adolescent', 'last two months,|any', 'prior to (first) study drug administration', 'within 1 month prior to screening.||13.Therapy', 'through at least 90 days', 'within 3 months prior to the study;|Subjects', 'within 72 hours of head injury|Meet criteria', 'within the past sixty', 'for at least 6 weeks duration.|Foot posture', 'within 24 hours prior to each', 'within 6 months prior to the dosing of the study drug', 'within 28 days before enrollment|Patients', 'surgical history deemed by the coordinating investigator', 'at least 1-year after starting the GFD|Assessment of the intraepithelial lymphogram', 'last six months they should', 'in the next 3 months|Lost 10 or more pounds', 'within 3 months of the enrollment|Patients unable to cooperate with stereotactic body radiotherapy|Patients', 'in the past 2', 'within the last 10 days prior to Day -1.|History', 'within 6 months before first administration', 'within past 3 months', 'longer than 45 consecutive', 'within 60 months of symptom onset', 'during the last 48 hours prior to the initial assessment of the', 'within 1 week before the inclusion', 'within 90 days prior to the Screening Visit or', 'in the last 3 months|Active', 'within 12 months from first dose of study intervention', 'during the past 1 month||History of', 'for at least 6 months after the last dose of study drug(s).||', 'within previous 30 days|Currently participating', '14 days prior to baseline', 'at any time prior to enrollment', 'within the past 2 months|Willing', '15 days prior start', 'within the last 12 weeks prior to', 'within the previous 48 h|preexisting cardiac', 'in the 30 days prior to enrollment', 'from 4 weeks before enrollment to the time of randomization.|Previous history', 'during the three months prior to enrollment)|Regular use of', 'During ICU treatment', 'within 28 days prior to enrollment|Other cancer', 'within three months;|Infectious aortic disease、Takayasu arteritis，Marfan syndrome', 'after the block|Patients', 'at the time of enrollment|Active', 'drug 30 days before the study procedure.||A confirmable diagnosis', 'within the three months prior to screening date', 'for at least six months before enrolment;|Caring', 'within 6 months of the onset of steroid-', 'at least 4 months before enrollment|hemiparesis', 'within the past three years- -', 'within 60 days before initiation of study', 'before the onset of the disease', 'more than 12 hours from the onset of', 'in the past six months|Previous spine', 'within one month of screening', 'in the past 2 years;||9', 'at time of enrolment||', 'before experimental treatment initiation.|Serious infections', '30 days prior to enrollment', 'for 3 months after the last dose of study drug.||Exclusion', 'within 4 weeks of randomization|Treatment with', 'at the time of the study|Etonogestrel implants', 'before the identification', 'during the study period||*Is eligible for', 'at least 4 weeks prior to infusion;||Presence of', 'within 1 month prior to study', 'at least 12 weeks|Adequate hematologic', '6 months after the last dose of liposomal doxorubicin', 'during the screening period recognized', 'at least 18 years.||Availability', '3 months prior to and', 'at the time of signing informed consent.|Potential candidate', 'within 2 weeks prior to the start of study dosing.|Having', 'lasted for more than 1 month to 3 months.||', 'during the past 2 months', 'At the time of screening', 'within 72 hours before the first dose of dostarlimab', 'in the past three months.|The study eye', 'in the last 6 months|Time between the first YOMEPOP session and the date of the operation less than 28 days|Refusal', 'within the last 4 weeks must demonstrate', 'within the past 8 weeks before screening;|take weak/moderate', 'at any time between presentation', 'in last 2 weeks', 'in the next 52 weeks;|Absolute', 'within 42 days prior to enrollment)||Seronegative', 'in the past 3 months;|Able to tolerate', 'for at least 6 months|The', 'within the 12 months prior to Visit 1', 'within 14 days prior to Day 1', 'within 14 days prior to randomization|Mixed', 'before initiation of screening', 'before cesarean delivery by ultrasound（Placenta previa', 'prior to initiation of any study treatment.|Patient', 'at time of study entry.|Participants', 'within 5 years of Screening.||8', 'within 3 months before receiving the experimental drug treatment;|Those who', 'at least one week prior to first study drug administration until donating the last sample of the study.|Subjects', 'at time of consent.|Subject', 'in the next 24 hours', '6 months after myocardial infarction', 'at the time of Screening.|Subjects', 'prior to randomization.|Ongoing', 'within 8 weeks preceding the first dose administration.|History of', 'for ≥3 years before the first administration of IMP.|Adequately treated', 'exception of', 'at least 4 weeks', 'in the past 6 months|Anticipating major surgery', 'within the last 6 months;|Acute bacterial', 'within 7 days of surgery', 'more than 72 hours after infusion', 'within 2 weeks of screening', 'within 4 weeks following', 'at the time of assessment.||', 'within 1 month prior to Screening.|Subject', 'while on medical therapy', 'within the indication of the EAP', 'before administration.|The last dose of the previous investigational product', 'within 24 hours prior to treatment.|A child', 'within the last 4', 'within 12cm from the anus', ""within 4 weeks prior to the study's initial dosing;|Treatment"", 'within four weeks prior to baseline|Regular consumption of probiotic', 'within 7 days before the first dose of study', '< 24 hour before randomization;|Need of', 'within 90 days or', 'within 180 days of first HD', 'at time of enrollment|Subject', 'the two years', 'within 12 months prior to Visit 1;|(for selected healthy adult', 'within 1 year before', 'within 48 h before screening;|Those who participated', 'continue for the duration of the study.|Available to attend', 'within 42 days of Cycle 1 Day 1', 'within preceding', 'hand.|A history', 'within 3 months before Screening|Significant instability of the index knee|Malalignment', 'in the past while on linaclotide', 'within the next 30-days.|Cognitively', 'in the first year of function20', 'within 4 weeks prior to first dose of study drug|Presence', 'within 8 hours of onset/last', 'within 28 days prior to screening', 'up to 12 months before enrollment', 'within 6 months prior to signing ICF', 'within 14 days)||Hemoglobin(HB)≥90g/L;|Absolute', 'any time prior to the index date.|This will allow', 'throughout the study period; this procedure allows', 'within 5 years prior to the screening visit', '30 days before enrollment;|5', 'during the course of the study;||19', 'at the time of study entry.|Male', 'within the last 4 weeks before inclusion|Pre-COVID history', 'for 150 days following completion of trial therapy', 'inpatient admission more than 3 weeks', 'for the first time within 2 days before randomization;|At least one of targeted COVID-19 symptoms exists', 'at the time of screening|BMI', 'in the previous three months', 'pre-enrollment', 'within 28 days before administration', 'in the last 2 years prior to first dose of study treatment', 'in the past 30', 'after medical', 'within 6 months prior to initial medication', 'within 5 days prior to first dose of study treatment', 'at baseline of', 'within 3', 'during the last 2 months', 'in recent 14 days', 'in the next 12 months;|Left', 'up to 5 years old', 'during the last 6 months|Known', 'within last month.|Cognitive', 'in the 6 months prior to the study screening', 'in the past 30 days)|Willing', 'at an equivalent dose ≤ 10 mg of', 'within 28 days before screening||3', 'within the last 6 months.||5', 'within one week of day 1 cycle 1).|Individuals', 'in the last year.|Type 1 diabetes', 'within 7 days prior to the first dose of study drug.|Known', 'in the past year|Severe', 'during the study.|Be', 'over 3 attempts of airway establishment during airway management|change of anesthesia plan', 'at the time of consent|Confirmation', 'within five years prior to the first use of the study drug', 'for at least 3 months prior to Screening', 'within 8 weeks prior to first dosing.|Receipt of an investigational product', 'within the last year);|Experiences alarm features', 'in the past 1 year;|Serum', 'longer than 2', 'over the past 6 months.|History of diarrhea', 'within ≤ 72 hours before treatment', 'during pregnancy', 'in the past 2 months.|Suspected', 'within 3 months prior to initial use of the study drug.|Within 2 weeks prior to the initial use of the study drug', 'within 48hr prior to sample collection.|Patients', 'within 7 days prior to study treatment', 'within the next 3 days.|Hypersensitivity', 'following the last dose of study intervention.||Core', 'in the past 10 days|Emergency', 'prior to randomization);|Patients', 'in the past 3 months.||Known', 'more than 3 months.|Willingness', 'for 6 months or more', 'in the past 6 month prior to sample collection', 'in the past 60 days prior to the blood draw', 'throughout study', 'within 28 days prior to the start of therapy|No', 'at the time of registration|Chronic obstructive pulmonary disease exacerbation', 'within 12 months.||5.History of pneumonitis', 'for at least 3 months|Capable of attending physiotherapy', 'before the intervention .|Patients examined', 'within two years of consent.|No evidence of', 'within 6 months before inclusion', 'before surgery;|With contraindications', 'within the past year', 'for three months following their last dose of alectinib.||C. Patients with rapidly', 'within 28 days prior to study treatment', 'in the 3 months preceding enrolment', 'at the time of the OIT study', 'for at least 6 months prior to randomisation', 'within 12 months prior to enrollment', 'on night duty', 'within 3 months prior to the use of the study drug;|Smokers', 'within the next 18', 'Previous history', 'since they have different', 'within 14 days plus', 'within 6 months prior to signing ICF.||Presence of the following cardiac conditions:||New York Heart', 'at least 6 abnormal reactions', 'during study participation', 'within 28 days of starting study', 'more than 2 months.|No', 'within 4 weeks.|Patients', 'for at least 6 months|Is alert', 'more than 75 years old', 'within 6 months prior to inclusion', 'at the test area|Wounds', 'for previous 6 months', 'at the time of study|manic phase|florid', 'within the last two week|Sun exposure', 'over the 3 months before study participation', 'within 6 months prior to initiation of treatment|Any active', 'within one year of Screening.|Participants', 'throughout study participation until 90 days after the last IP dose', 'within the previous 6 weeks.||History of smoking||If <30 years', 'during periods of activity', '14 days before first study', 'at any time including of pN0(i+', 'within 1 year prior to the screening visit;||18', 'within the past 90 days|18 years', 'at least 6 month post-acute', 'within 6 months prior to Day 1 of Cycle 1|Tumors', 'during the test period', 'within 24 hours of cannulation', 'at least 1 year before the screening visit', 'at time of consent|Hemoglobin A1c', 'at least 1-year', 'within 1 week prior to screening;|Screening', 'before inclusion or going to start', 'within 24 hours of study sessions|For', 'within the last 3 months|Known', 'after pre-enrollment', 'after radiation therapy', 'within 14 days before baseline', 'within 28 days after the treatment starts', 'within the specified time frame.|The time from the last use of', 'at least 1 of the following criteria:||Oral cavity', 'within 4 weeks of Study Day 1|History', 'for at least two months,|Those', 'within 30 days prior to first dosing', 'within 1 month or 5 years half-life of the research agent', 'in the 6 months before screening', 'at the same time.||Malignant tumor', 'prior to the procedure', 'within 12 months prior to treatment allocation.|Previous treatment', 'during the study period.|Chronic stable', 'during the previous 6 months.(Rasquin', 'in CR/PR', 'for at least three months', 'for at least 30 days after the last dose of study drug:|Refrain', 'during the therapy|Severe visual', 'within the past 3 months before screening.|Prior', 'in the first 6 months of the', 'recent use', 'with the exception of alopecia', 'within 2 weeks of their Screening visit.|At Baseline', 'within 1 month of study', 'within 4 weeks prior to baseline.|Evidence', 'prior to the start of the study', 'for the duration of the study.|Able', 'within 7 days prior to the first dose of study treatment.|Use', 'at the time of radiotracer administration|Medical condition', 'therapy|The time from onset (finally normal', 'in the study eye.|Post-traumatic cataract', 'at prescreen;||D', 'surgery 28 days before the first dose could be enrolled', 'within 4 weeks after study treatment', 'for ≥ 12 months', 'in the past 5 years prior to enrolment;|Women', 'in first', 'in the last 6 months,|Individuals', 'previous three years.||Exclusion', '3 months prior to Screening', 'within 6 months prior to recruitment|pregnancy or breastfeeding|been treated', 'within 4 weeks before treatment;|Pregnant', 'at screening visit', 'within 7 days prior to study drug administration', 'at the time of the screening;|History of', 'continuous', 'within the last 30 days before the first-line', 'within 3 months prior to enrollment;|Acute myocardial infarction', 'within 14 days before the first dose of study', 'in the past 6 months prior to Screening Visit)|Acutely decompensated', 'bovine', 'last 5 years|Oncological genetic syndrome|End-stage renal disease', 'following criteria：||Blood biochemical tests', 'within 14 days before the treatment of the study drug)|Written informed consent in accordance', 'preceding 24 consecutive months)|Patients of', 'during sexual intercourse from the time of the first study drug administration', 'progressive', 'greater than 1 year prior to screening', 'in the past 9 months', 'in the prior 3 months', 'at the time of informed consent): 20 years', 'within 1 month before the first study drug administration;|The presence', 'last two years', 'past 2 years|Received', 'during the experiment.|Subjects had no exercise training program', 'Bispebjerg Hospital department M1.|Being able to participate in basic mobility activities', 'for the next 12 months|English-speaking|Willing', 'continue to do so for 100 days after the last dose of study drug|Male', 'after the surgery,|The patient is not discharged', 'at least 3 years', 'within AX-158.||Clinically significant abnormal test results', 'in next 24 hours|Patients who', 'in the past 12 months.|Subject', 'up to 6 months post-partum|Untreated', 'within 1 year prior to the trial', 'in the first screening of Emergency Intensive Care', 'for the duration of study treatment', 'during the test', 'within 42 days prior to enrollment', 'at the time of screening.|Active COVID-19 infection', 'within the last 6 months|History of', ""in the last 6 months|Parkinson's disease|History of"", 'within three months prior to the start of the current', 'at least two health assessment tests||', 'in the last 30 days;|Fulminant', 'more than +1', 'within 14 days before or after inflammation', 'within 6 months before randomization|Malignancy', 'at the time of research', 'in last 12 weeks before screening;|History of active', 'within 6 months before Screening', 'throughout the period of sample collection|Subjects', 'at the time of signing the ICF;|Histopathologically', 'within 7 days]', 'in the last month prior to study entry,|Shaving/depilation of the arms in the last 14 days before inclusion,|Mental incapacity', 'since the combination therapy', 'within 14 days prior to registration.|WOCBP', 'for three months after the last administration of alectinib:||Agree to take', 'within the same intervention.||', 'within 4 wk)|Use', 'within 4 weeks of first dose of study drug.|Previously', 'within the past 6 months;|active', 'for 1 month following the last dose of study', 'in previous 12 months|Ability to provide', 'within at least 14 days before chemotherapy);|6.1.3', 'within the last 6 months,|Severe', 'during a period of one year', '3 days prior to SBRT', 'within 4 weeks prior to initiation of study treatment.|With', 'during and within 3 months after the end of medication', 'for 7 days preceding the lab', 'for 6 months from study enrollment', 'during the screening process prior to the first dose of study', 'for 3 months duratoin.||', 'within 30 days prior to the AV fistula', 'for 5 months after the last study treatment.|Patients', 'after initial treatment', 'within 30 days before surgery of either:||≤30%', 'for at least 90 days after the final dose of study drug|Inability', 'before starting chemotherapy;|availability of informed consent of the patient to participate', 'within the last 4 years|Uncontrolled', 'more than 2 years', 'for at least two months before the screening.||Exclusion criteria||Insulin-dependent', 'within 2 weeks prior to treatment', 'at least 2 days per week|Patients', 'at least one prior line of therapy', '< 12 months', 'at any time|previous IDI|any condition', 'within the last 5 years;|Severe', 'within 4.5 to 24 hours of last known well', 'within 4 weeks prior to screening|Uncontrolled intercurrent illness', 'prior to completing a standard regimen', 'during the study outside the protocol.|Has', 'last 5 years Outside.|A history of', 'during screening prior to study entry', 'within 7 days of study onset - paracetamol', 'within 5 d', 'for at least 12 weeks after the last dose of the IMP.|Availability of', 'within 2 years prior to Randomization', 'within 4 weeks prior to the first dose of study treatment.||9', 'at least 12 weeks before screening;|Not', 'the past 6 months', 'within 56 days prior to Screening', 'within last three months.||Participants', 'in the 24 hours prior to the test', 'during the past year|Presence or', 'for at least 3 months after the last dose of study-drug', 'after allogeneic hematopoietic stem cell transplantation；||Basically normal', 'within 48 hours prior to screening.|Smoking', 'continue abstinence', 'during the screening phase;|Medical history', 'prior to initial administration of the study drug;|Other', 'in the past 3 months.)|- Past year', 'previous 2 months', 'for at least 4 weeks before dosing.|Reports regular bedtime', 'for the first vaccination', 'within 14 days prior to the screen phase', 'lasted for at least one week', 'within 2 months prior to the Baseline', 'at least 1 medically', 'at birth <35 weeks', 'more than 1 month', 'at time of informed', 'prior to screen work', '72 hours before enrollment confirmed', 'within 3 months of randomization', 'within 2 weeks prior to the first dose of epcoritamab.|Prior history of another', 'past two years|Active', 'within 4 weeks of study therapy.|Monoclonal antibody therapy', 'within 7 days)', 'at the time of screening|Peripheral white blood count', 'within 6 months prior to the first dose of study drug', 'within the previous 14 days|A history', 'within 4 weeks before the first drug use;|The', 'within 4 weeks prior to randomization;|Patients', 'within 3 months of Visit 3 (Baseline)', 'during study follow-up,|Treatment', 'prior to Day 1 of this study', 'within previous 6 months|Has experienced', 'within the 3 months prior to consent.|Treatment with another investigational agent', 'within 30 days prior to therapy|Uncontrolled', 'within 3 weeks before the first administration of the study drug', 'longer than two months', 'within 30 days after surgery;|Need', 'for 3 months after final study drug administration', 'within 1 month prior to inclusion', 'at the time of screening|Prior', 'within 6 months prior to the screening visit', 'in 3 months after receiving the investigational drug', 'within 12 weeks prior to screening', 'during the period covered', 'within 48 hours before start of study period', 'throughout the study.|Acetaminophen', 'at the time of prestudy visit', 'within the prior 3 months;|both partners endorse being', 'within 4 weeks before enrolment', 'within 3 weeks prior to enrollment.|Intraarticular', 'within 2 weeks prior to initial use of the study drug', 'within 2 months prior to dosing.|Current smokers of more than 3 cigarettes', 'in the last 24 hours.|Anti-sars-cov-2 IgM antibody', 'at the time of informed consent.||2', 'within 4 weeks of study therapy|Live', 'within the previous 12 months)|Experiencing', 'within 5 half-lives', 'at least 7 years', 'during the day', 'in the first hour of life', 'prior to this admission', 'for at least one', 'three times a week|18 years or older|Deaf', 'within past one month.|Those', 'within 6 months prior to signing', 'within 5 years of study enrollment', 'post abortion', 'in the month of their birthday and, thereby', 'within one week of the study|Evidence of', '6 months prior to the start of the treatment/study.|Currently using', '≤30 days after receipt of any study', 'for 23 weeks', 'during the trial period', 'within the last 2 weeks prior to randomization|On', 'within 14 days before screening):||Hemoglobin', 'preceding 5 years|Eastern', 'prior to admission|3', 'within previous 6 months.|Participants', 'within 1 month before screening.|Pregnant', 'during the current hospital', 'within 14 days prior to intervention.|Participation', 'within one year.|High myopia.|Use of any drugs', 'on the face or scalp', '3 months after the last dose of the study drug.||Darolutamide', 'within 7 days following each study vaccination.|History of vaccination', 'at least one previous', 'for at least 3 months', 'medical history clinical laboratory evaluations', '≤4 weeks prior to the first administration of Investigational Product', 'within the last 12 months|Regular consumption', 'within the last 28 days before randomization', 'throughout the study.|Has severe', 'at least 6 months after the last study drug administration', 'in the last 6 months|Patients', 'within the 2 weeks before the start of the study', 'within 3 months prior to the study.|those who smoked more than 10', 'at least 4 weeks from administration of a killed vaccine', 'within 6 months prior to screening;|Any unsuitable to participate in this trial judged by the investigator', 'at any time after the estimated date of conception', 'within this study|Life expectancy', 'within the past 3 months|infection', 'during the 3 month period prior to baseline', 'within 30 days before enrollment|ineligibility for participation', 'after the last dose of', 'between the previous anti-tumor therapy', 'within 1 week of starting treatment.|Allergies', 'within 7 days before start of study treatment.|Female', 'last month prior to inclusion,|Diagnosed', 'within 2 weeks prior to the start of administration of study treatment', 'within 5 years before study start|Participation', 'prior to resection', 'more than 3 years after the first dose of cladribine tablets||', 'within 6 months before the start of study', 'over six hours', 'at time of signing Informed Consent Form|Ability', 'during preparation', 'during the study period and within 180 days after the last administration of the study drug;|Obtain the informed consent signed', 'during the study period.|Donors', 'within 4 weeks prior to randomisation)|Platelet count', 'at least 7 days before study treatment', 'within 2 months prior to initial medication', 'stay|Able to give informed consent', 'for the test for', 'in the past 3 years|No', 'within the last 3 years.|Presence', 'at the time of diagnosis,|Person subject to legal protection scheme', 'previous six months', 'after first intravenous diuretic administration', 'during treatment;|Known history', 'within 28 days prior to the start of study', 'during the 6 months preceding of the first dose', 'at least 1 TACE treatment；||', 'within 12 hours before study visits', 'ongoing', 'disorder;|Less than 1 year', 'at the time of initial administration of clinical trial drugs e', 'at the time consent is obtained);|Histological or', 'within the 6 months before study treatment initiation', 'period starting 28 days (Day -28', 'at least 6 months before the study.|They should', 'in the past 30 days prior', 'one week prior to', 'in the last 90 days before the first dose of ranibizumab|History of', 'within 14 days prior to randomization:||Hemoglobin', 'at least 1 month prior to Baseline', 'within 3 months prior to the first dose;|Subjects', 'more than 3 times', 'for at least 8 hours prior to drawing blood', 'within the last 12 weeks before', 'prior to the start', 'at least 6 months clinical', 'during the last 4 weeks|Weight < 10 kg', 'at least 1 measurable', 'During the second-line', '2 hours', 'within 4 weeks before baseline or', 'within 5 years|serious medical illness', 'at least 1 prior', 'at the time of enrolment,|Subjects', 'in the past two weeks', 'at least 6 months prior to Visit 1', 'in the 3 months prior to study visit', 'during medical interview/anamnesis', 'in the recommendations released', 'within 7 days prior to registration.||Adequate Organ Function Laboratory Values||Absolute neutrophil count (', 'at least 48 hours before treatment', 'during the study.|Stroke', 'within the last 6', 'at the time of inclusion.|Patient affiliated', 'over 3 months.|Use of medication', 'over two years duration', 'within 4 weeks of initiation of preparative regimen', 'within 60 days following', 'within 14 days of the first dose of study drug', 'within 7 days prior to the first dose of study intervention', 'at three months after SARS-CoV-2 infection', 'at least 1 lymph node', 'after all curative measures', 'after at least 4 months', 'at any time', 'dose for 4 weeks before randomization', 'within 4 weeks (28 days) before enrollment.13', 'for > 3 months).|Subject', 'at the time of the study', 'in the last 3 months|currently', 'within 30 days after the final dose of trial therapy', 'for at least 1 month prior to commencing the study with no intention to change dose prior to completion of the study.||', 'for at least > 1 month|Patients', 'for at least the time needed', 'during the study participation', 'within the last 6 months|hemodynamically significant', 'within the past 12 months', 'while receiving treatment', 'within the last 24 hours|Pre-existing', 'at the time of signing the Informed Consent||•', 'within 12 weeks before apheresis', 'within a limited', 'within two months of visit', 'within 2 years prior to check in.|Use', 'within 200 µm of the fovea|If', 'less than 2 weeks ago', 'at least 12 months prior to the development of advanced/metastatic', 'within 1 year prior to', 'within 60 days prior to the start of the present', 'for the last 30 days.||', 'within 28 days prior to the first dose of the investigational product', 'more than 1 drink per day for', 'after prior standard of care therapy.|Cohort 4', 'during the study;|4', 'within 60 days before initiation of screening', 'throughout Step 2.|Ability', '<1 month', 'within 14 days prior to randomization.)|Use of any investigational product', 'in the past six months|no', 'within 8 weeks of baseline visit.||', 'at least 2 years.|Axillary vein of', 'within 1 month before baseline;|Aphakia', 'within 7 days prior to first dose of study treatment.|Symptoms', 'less than four weeks prior to enrollment', '< 28 days prior to receiving the first dose of study', 'within the current episode', 'in the prior 6 weeks', '≤20 mg/day', 'during hospitalization|The subjects', 'at the time of recurrence of disease.|Participants may have', 'within 24 hours from stroke onset', 'for at least 180 days after the last dose', 'between 6 and 20mm', 'since January 1, 2020', 'within the last five years', 'discontinued at least 30 days after enrolment|Patient able to cooperate with the', 'at the time of inclusion|Pregnancy', 'within 4 weeks prior to initiation of study treatment.|Patient', 'within 72 hours before administration of investigational product', 'during the 12 weeks prior to the ICF signing date.|Use of', 'more than 4000 kcal per day', 'during the surgery|Inability', 'within the last 3 years', 'during the study period.|Recent initiation', 'in the past 12 months||Father', '98 days after the pregnancy start date', 'within 30 days before enrolment.|Hypersensitivity to niraparib', 'within the last four weeks.|Any other', 'for ≥ 96 hours', 'within 28 days before receiving the study drug', 'for at least 3 months prior to the first dose.||9', 'at the first day phone call of the diagnosis', 'within 4 weeks prior to the first dose of study drug;|Patients', 'within 12 months prior to first dose of study treatment.|Exclusion of HIV', 'within 2 weeks prior to the start of study dosing|Toxicity', 'prior to baseline visit.|Willingness', 'within 6 weeks before the first use of the study drug', 'at or after enrolment.||Benralizumab Taiwan reimbursement criteria:||≥', 'within 3 days before starting the study medication', 'within the last 3 months|current drug abuse', 'within 3 months prior to Day 1|Aphakia', 'at any time during the study', 'within 90 days prior to the screening visit', 'within the next 24 hours;|Requires oxygen therapy', 'within 3 months before administration of investigational product', 'more than 3 standard cups', 'more than 1000ml|Patients', 'during the previous 3 months|no', 'in the last 1 month.|Have', 'at the screening', 'at the baseline visit||The investigators recruit', 'for the last 6 weeks', 'within ≤ 28 days prior to treatment', 'within 2 weeks prior to enrollment|Systemic cytotoxic chemotherapy', 'within 14 days of treatment initiation.|Patients', '4 hours before delivery|Patients', 'at least 3 years|MMSE', 'for at least 7 months after the last medication;Female', 'within 6 weeks prior to the first dose of study treatment.|Local radiotherapy', 'for at least 72 hours prior to all study visits', 'within 7 days before Check-in of Period', 'within 3 months prior to the prestudy', 'within the last 6 months|History', 'more than twice weekly|Consumption of', 'within the year prior to Screening', 'after the assessment of a multidisciplinary team because', 'within 42 days prior to enrollment)||NOTE', '6 months after the end of the study', 'at first time and 10ml', 'at least 90 days of', 'within 30 days prior to dosing.|Use', 'during the Treatment Period', 'within the past 6 months;|Receipt of blood', 'at any time excludes the', 'in the first line', 'in the next 12 months|Incarceration|Refusal to participate in study', 'on the patient would be acceptable', 'for ≥3 months', 'during the six months of the trial.||History fits the definition of migraine:||Have', 'over the next six months|Failure', 'within 2 weeks before the first use of the investigational drug', 'within 9 months before Screening.||Key Exclusion Criteria', 'within 1 week prior to surgery', 'in the previous 4 weeks|Not under the care of', 'after waking', 'at least 30 days prior to enrollment|Has traveled through 3 or more time zones', 'during the subsequent study', 'in the 7 days preceding enrolment', 'within 2 weeks||Clear indication', 'within 24 hours of admission is considered likely.|Severe chronic respiratory disease', 'for at least 1-year|Pain intensity level', 'within 4 weeks before the first use of the study drug', 'embedded tissue blocks', 'one month before treatment|Patients', 'for three months after completion of treatment;|The patient is fully informed and voluntarily', 'within last 2 weeks.|Creatinine clearance', 'at both baseline and follow-up|Presence', 'within one month of the first dose date', 'lactation;|History', 'at least 1 episode', 'for at least 4 weeks prior to sampling', 'within 1 week before the first intake of study intervention.|Participation', 'during the study.|History of drug', 'at the time of enrollment.||4', 'in the previous month to allow safe completion of the cardiopulmonary exercise test (CPET)', 'during first seizure', 'within 14 days prior to randomization.|pregnant', 'in last month', 'within the last 90 days prior to the screening', 'at least 3 months|No', 'for 2 weeks', 'for at least one year|Comfortable sending', 'more than 6 months.|KPS', 'during the study period;|Subjects', 'within 4h30 after onset of symptoms,|MRI performed 24h after IVT||For the DIS cohort', 'within 28 days prior to the first dose of study treatment', 'in the previous 30 days|Past', 'within 28 days of the last drug administration of the study.|Those who do not respond to surveys', 'at the time of signing', 'up to 8 weeks before the study|Having skin problems', 'within 30', 'within 12 months', 'who go directly to randomisation', 'during the study period and up to 90 days after the last study medication', 'at least 2 weeks', 'at time of blood collection|Intake', 'within 2 weeks of enrollment.|RECIPIENT', 'through 4 months after the last dose of protocol treatment|STEP 2 RANDOMIZATION:|Patient must', 'within 2 years requires', 'prior to enrollment|Fully understand the treatment protocol', 'within the past year|binge drinking', 'during hospitalization after deisolation.|Patients', 'within 6 weeks from the screening', 'within 28 days prior to study vaccine', 'up to 14 days prior to study visit||', 'at least 4 weeks later', '1 month history', 'at the time of the first vaccine', 'at least 4 weeks before Screening and willingness to use', 'within 4 weeks, donated blood', 'within 30 days prior to the first dose of Sipuleucel-T|Documented', 'within last 5 years', 'within 2 weeks prior to study', 'less than 100 days.|Systemic', 'in the last 3 months.|ability', 'menses at least one year prior to screening', 'up to 3 months prior to the study).|patients not capable', 'within last 7 days|Active', 'at the time of screening.|Serious eating disorders', 'after operation Vulnerable', 'within the past 2 weeks|Has', 'aaaa', 'for the past twelve months.|Pregnancy', 'for at least 90 days after the last dose of AU409||Should', 'within 6 months prior to enrolment|Subject', 'at the time of signing the informed consent form;||Ongoing', 'within the previous 3 years', 'within 4 weeks before Screening', 'during 4 weeks prior to screening', 'within three months before baseline', 'in the last 3 months prior to blood sampling|Use of', 'in the past 6 months||', 'within 5 days prior to randomization', 'within 18 months prior to screening.|For', 'during study phase.|Currently', '12months before screening', '< 4 weeks prior to first dose of lymphodepleting', 'preoperatively for', 'within 2 weeks or 3 half-lives', 'at least 3 months prior to receiving investigational product', 'within 30 days before the first administration', 'within 2 weeks before first administration', 'within one year before enrollment in the study.|The treatment area', 'at least 3 times/week', 'at least 3 days a week for the last 3 months|no', 'at the time of screening|Patients', 'in the past 3 months|Pregnant', 'at time of consent|Confirms conversational fluency', 'within 4 weeks before the screening visit.|The participant', 'prior to enrollment|Severe pulmonary hypertension', 'after ≥ 2', 'at admission < 24 hours||', 'at baseline.|Subjects taking', 'Cornell medical index', 'at the time of switching', 'within six months', 'during the last 18 months prior', 'more than 20o decrease in IR', 'within 4 wk', 'within 6 months before study enrollment', 'within 7 days of the index procedure|Able and', 'at the start of treatment in this trial', 'within 14 days prior to vaccination.|Positive', 'for 1 year or more', 'after first line', 'for at least 6 months after the last IMP administration|Ability', 'within 3 months prior to the Screening Visit', 'within 6 months prior to screening|A positive test', 'within the past 5 years of Screening', 'during the study duration', 'in the year prior|Dysuria on the IPSS', 'for at least 3 months prior to randomization;|HbA1c level', 'within the projected duration of the study', 'prior to randomization;||', 'prior to any trial-related', 'within two years post-transplantation||', 'for 3 months following last dose of study drug||', 'within 6 weeks prior to randomization.|Receiving', 'over the last 6 months|Patients', 'within 7 days prior to entry||The', 'within the past 3 years|Participants', 'within the past 3 months)||Healthy', 'within one moth of study entry.||Wash-out periods', 'within 6 months of randomization.|Uncontrolled infection.|History', 'within 7 days prior to enrollment.|Patients sign informed consent', 'during all the study.|Female', 'within 90 days after the last dose of any study treatment', 'within past 6 months)|Uncontrolled', 'Admission to hospital', 'for six months following duration of study participation', 'for 1 year after the last dose of study treatment.||Note', 'within 4 weeks prior to signing informed consent.|Patients', 'at the time of inclusion into the trial|further exclusion criteria apply', 'within 30 days of beginning investigational product', 'at least 3 items from the Rivermead Post-Concussion Symptom Questionnaire)|Glasgow Outcome Scale-Extended', 'in the past 12 weeks.|Not', 'in the last three years prior to screening', 'within half a year before operation.|Severe', 'at the time of inclusion|Language barrier', 'in the last 5 years;|(4) Those', 'within 4 weeks prior to the first dose of study treatment.||Note', 'more than five days', 'at the Department of Medical Oncology', 'at least 30 days in between the last dose on a prior study', 'after CT-scan assessment.||Remark', 'within 6 months prior to registration|Significant vascular disease', 'within 14 days of randomization.|Requiring hospitalization', 'within 28 days prior to registration)|Aspartate aminotransferase', 'ended at least 4 weeks prior to first dose|Adequate Hematology laboratory data', 'within 30 days prior to screening|Has', 'before MRI', 'within 3 months prior to Screening|History of', 'after 2 weeks of wash out', 'following criteria:||Hematology (need not', 'in the last 90 days|18', 'within the next six months||', '15 days or less', 'less than 1 year before inclusion', 'in the last 14 days', 'within 4 weeks prior to first dosing.|Administration of P-gp inhibitors', 'at least 15 years prior to study enrollment', 'within 12 months following the Screening Visit.|A participant', 'within the past 3 months|Any', 'within the last 12 months.|Lifetime history', 'within 14 days before screening;|Have used', ""past six months.||Children's medical records"", 'within 30 days before surgical treatment|There', 'within four weeks to the planned start of study treatment.|Other prior', 'for the last one month|Pregnancy', 'prior to the study|Use', 'within four weeks prior to the first dose of study treatment', 'during the past six months|Alcohol consumption of more than 2 drinks per day or the equivalent', 'in the past 3 months|Contraindications', 'within 2 weeks prior to Meta10-19 infusion', 'received at least 2 weeks prior to enrolment||', 'at time of surgery', 'within 30 days prior to treatment|Presence of', 'at time of enrollment.|No provision of written', 'pre-dispose', 'for at least 1 year', 'during the study.|Informed', 'less than five years before participation', 'up to 14 days before participating', 'within 180 days of previous platinum treatment.||Have measurable disease', 'at the time of enrolment for the training course.|Students', 'within 24 hours prior to Visit 2/', 'at least 1 month prior to the', 'within the last 7 days', 'at the time of letermovir', 'within 3 months of enrollment|Currently adhering', 'between each time interval);|14.6', 'within 4 weeks before the start of treatment', 'last 5 months', 'during active study phase.|Abnormal bowel patterns', 'over 500 mL', 'after previous treatment with', 'separated by at least 2 cm', 'within 6 months prior to initiation of investigational procedure', 'throughout study treatment.|Participants', 'at least six weeks before taking study treatment', 'within 5 years with the expection of', 'within 90 days of', 'at any time during the pregnancy participating in EPPICC', 'in the past 6 months|A', 'within 3 months from randomization', 'prior to initiation of radiation therapy (standard protocol for', 'in the whole body except', 'within 2 weeks before the first dose of study drug', 'quitting', 'at least 1 of the IV AEDs must have been', 'during the research|Active', 'within the last 6 months|Never smoker', 'within the previous three months', 'within 14 days or five', 'before the first study medication should', 'at the time of approach.||Clinicians:||Oncologists', 'at the time of the signature of the', 'in the past 2 weeks;|Subjects', 'within 12 months prior', 'within 1 month prior to treatment;|Patients', 'for at least one hour prior to the start of the intervention||', 'previous 5 years', 'within 6 hours or less', 'for at least 60 days prior and willing', 'up to 14 months prior to the first day of their LMP before conception', 'during 30 days period before informed consent', 'within 5 days prior to the first dose of study', 'more than 6 months before inclusion|Hospitalisation', 'more than the equivalent of 5', 'for at least 14 days prior to the first dose of the study intervention.;|Patients', 'at initial presentation|received', 'within 7 years before', 'before enrollment；||', 'within the past month|Able to run one-quarter', 'within 7 days prior to the first dose of study drug.|A', 'in the first 6 h after admission', 'at least 30 days before the administration of trial medication until 7 days after trial completion.||Of note', 'within the past 3 years|Individuals', 'after at least 7 days of stable supplementation regimen||Pregnancy', 'at the time of the first dose of study medication;|Weight', 'within the 12- months prior to procedure', 'within the 6 months', 'before hospitalization;|The patient', 'at the time of screening.||Have documented', 'for ≥7 consecutive days within 60 days prior to screening.|Need', 'while enrolled in this study', 'at the time of visit|Severe', 'injection site)|History of', 'within the last 2 years.|Major depressive disorder', 'within 28 days prior to registration;|Use', 'for at least one month prior and one month after study', 'post-operative length', 'for 12 weeks|Able to participate in a structured mindfulness-stress reduction', 'at time of randomization', 'in the last six months)|Uncontrolled thyrotoxicosis|Neuromuscular', 'prior to initiation of study drug.|Any surgical procedure', 'within 2 weeks.|History', 'at least 1 catecholamines', 'more than 1 pelvic organ resected||', 'within 8 weeks before the first dose of study', 'more than 12 months prior', 'within three years prior to the time of recruitment', 'after prior asparaginase-based', 'in the past 1 month.|History', 'within 14 days preceding', 'during the treatment.|Patients', 'within 1 year prior to Screening', 'within the last six months;|Major gastrointestinal tract surgery', 'history of immune deficiency disease', 'during the surgery', 'within the last two years|People with', 'pre-operative baseline information', 'within one year of screening', 'in the past month 4', 'within the previous five years|Previous', 'within the past 5 years before the screening', 'in the past 3 months|Nut', 'than 6 months before enrolment', 'past 12 months prior to study start.|Subjects', 'within 7 days prior', 'within preceding 6 months', 'at the time the samples', 'within 30 days prior to enrollment;|Patients', 'at least 4 months.|Participants', 'during the last 6 months|pregnancy|any systemic condition', 'within six (6) months of completion', 'within 14 days before the first dose of study agent', 'up to three days before any of the in-person study visits', 'the night before or after MDMA', 'during the trial|Anyone who is pregnant', 'within 30 days before administration.|Have a', 'within 48h before administration of investigational product', 'during the study period|Patients', 'chronically at least three (3) months prior to study entry', 'for at least 30 minutes/day to play', 'within 4 weeks before the first study drug administration', 'at the time of informed consent|Able and willing to give informed consent', 'in the 6 months prior to the index hospitalization|Procedure', 'within the past 2 years|significant sensory', 'within 2 years prior to screening|Current', 'in the last 5 years may be included', 'within 36 months prior to participating', '6 months after discontinuing study treatment.||', 'from the time of obtaining', 'at least 4 out', 'within 6 months before screening.|As judged by the investigator', 'in the last year.||', 'within the last 12 months|Any intraocular', 'within 24 hours prior to starting Isatuximab', 'post operative', 'in the first screening;|Pregnant', 'on day -1', 'within 1 month before enrollment', 'within 7 days before laboratory examination', '14 days before randomization', 'prior to QLF31907 administration|All subjects of', 'during last 36 months|Known central endobronchial lesion', 'for 7 days prior to the MRI scan', 'within 6 months prior to first study drug', 'at any time during the study|Received semipermanent soft-tissue filler treatment', '14 days before enrollment', 'within 3 months prior to study entry.|Patients', 'within the month leading up to departure', 'since day of screening', 'within 4 weeks before screening.|NSCLC', 'during the 3 days prior to vaccination', 'at the time of spinal', 'within one month of the study', 'within 6 months before randomization.|Hypertension', 'at least 35', 'after frontline systemic therapy', 'four weeks prior', 'within 4 weeks prior to enrollment.|Intravenous', 'during the test;|Within 2 weeks before screening', 'for at least 90 days prior to initiation of one of the available study treatments', 'at the time of consent.|Be able', 'within the prior 2 weeks', 'during the study period and within 6 months after the last study drug', 'within 1 days prior to IP administration|Subject', 'within 4 weeks of baseline visit|Receipt of live vaccine', 'in the 2 years prior', 'at least 6 months prior to enrollment)|Asymptomatic', 'within 24 months from', 'within 3 months before enrollment', 'during the preceding 24 hours)|History of', 'in the past 7 days', 'at the time of screening.||', 'within the prior 24 months', 'within 30 days prior to the patient enrolment visit', 'November 2021 to June 2023)|Sufficient', 'for at least 30 days after the intervention|Patients eligible for microanastomosis', 'within 28 days prior to the first study treatment.|Treatment', 'during study period.|Patients', 'within 4 weeks of screening', 'in the past year;|Pregnant', 'for 6 months prior to registration|For', 'during the observation period', 'in the previous six weeks,|with psychological severe', 'within 3 months.|Received', 'during 6 months', 'during the test period until the last follow-up;|9、Those who voluntarily participate', 'for 3 months after the last dose of', 'during study participation until the end of treatment administration', 'prior to dosing.|Known hypersensitivity', 'for more than 2 years', 'within one month of the doctor visit', 'within the last 12 months.|Subject', 'in the year', 'within 7 days prior to study drug', 'in the last 6 months|Known', 'before the 34th week of pregnancy|Birth weight', 'within the last 6 months|do', 'within 30 days prior to the first dose of trial drug', 'during the past 12 months.|History of a', 'prior to intervention|other', 'at the time of screening.|Acute on', 'at the time of enrollment.||In addition', 'through 11 weeks after', 'within 2 weeks prior to Visit 2/', 'for at least 3 months after the last dose of investigational product|Be currently participating in another T1D treatment study|Have hearing loss', 'within the last 12 months prior to study treatment|History of lower face surgery', 'within past 24 months', 'within 6 weeks prior to Step 2', 'in the past ≥2 years', 'within 3 weeks|Radical Surgery', 'within 3 years|Need combined treatment of hemodialysis|Be allergic', 'within 24 hours|Do-not-resuscitate', 'within the range of 19 to 40 kg/m2', 'prior to IVT|Currently', 'within 2 years prior to baseline|Treatment', '1 month following to the non-inclusion of the participant', 'at the end of consolidation||Acute lymphoblastic Leukemia', 'during or after treatment', 'within 6 months prior to randomization.|Received', 'before the operation|To have an oncological disease|To', 'while on this agent.||Symptomatic', 'at least 5 years before enrollment);|There are', 'after recovery', 'within the last 12 months|currently experiencing more than fleeting suicidal thoughts', 'within the last 6 hours,|No use of IV vasodilators', 'within 14 days prior to enrollment.a)|Other malignant', 'within 14 days prior to inclusion.||', 'preceding 3 months.|Study tooth', 'prior to and', 'before starting this pilot', 'within 14 months before the knowledge;|Thyroid Stimulating Hormone (TSH)', 'past 12 months', 'within 1 year after study treatment', 'for 6 weeks prior to enrollment', 'at least 6 months ago', 'more than 5 cigarettes per day', 'prior to apheresis.|Positive', 'within the past 5 years', 'within 5 ears before the first dose of study', 'during the study period.|At least 6 weeks', 'before 2 weeks of the first dose vaccination;|Subjects have', 'for at least 30 days prior to the first administration；|Able', 'less than 4 weeks prior', '14 days on and 7 days off)|Phase II', 'within three months before inclusion|Uncontrolled', 'at least 2 weeks before the first dose', 'in the 5 years prior to the Screening Visit.|Presence of fever', 'within 48 hours of study enrollment', 'after two 1-hour training instructions each time;|Patients', 'during active study phase.|History', 'within 7 days from enrollment', 'prior to performance of any study-specific procedure.||', 'within 4 weeks prior to start of treatment|Previous treatment with', 'within the last six months prior to study treatment|Active', 'within 30 days preceding Day 1.|History', 'for at least 5 months after the end of the treatment', 'within 2 months before enrollment.||(6', 'within 12 hours|Attending physician does not believe participation', 'mmHg|BMI>40 kg/m2|Diabetes|Familial hypercholesterolemia|Past', 'in the past 12 months|Known history of a', 'within 90 days after the final dose of tiragolumab', 'within 48 hours prior to initiation', 'during the study.|Use of another investigational product', 'within the ninety', 'in the past 1 month|Patients', 'within 24 hours before the first dose of study', 'within 6 months prior to screening.|Other', 'within 30 days prior to Baseline [Day 1]', 'any time prior to screening.|Subject', 'during laparoscopy||REGISTRATION: Any of the following', 'within the last 5 days of the day of randomization|A score', 'within the previous year;|a current', 'within 3 months|Inability', 'for at least 4 weeks before screening', 'surgical history: decline in ovarian reserve', 'in the last 6 months|GERD evolving', 'more than 30 years old', 'within the next year.|Patients', 'at least 6 months before screening', 'during screening prior to study entry|Obvious non-cardiac cause', 'within 7 days before study enrollment', 'for at least 12 weeks prior to Visit 0 with no changes', 'within 48hoursor 5half-lives', 'after discussing', 'within 1 month before vaccination;|Subject', 'at the specific study site.|Willing', 'within last 90 days|Elevated QTC', 'prior to starting study', 'within 2 weeks before the intervention|Foods for special medical purposes', 'in the past 1 month.|Continuously', 'for ≥ 6 weeks', 'at the time of examination|Persons', 'within 30 days prior to the dose of study drug|Any', 'enjoyment', 'in the past 12 months|HIV-negative|moderate', 'following previous/concomitant', 'at the time of signing the Informed Consent|Antiparkinsonian medications', 'within 4 weeks prior to the first QLS31903 administration', 'in the next 6 months|Deep vein thrombosis', 'in the last 6 months|Chemical peel', 'for at least 6 months before Study Entry|On', 'at least 3 months prior to first cevostamab', 'within 6 months prior to baseline visit.|4', 'within 3 years before first study vaccination', 'within 14 days of randomization', 'within previous 90 d)||Non-sinus rhythm|Significant QTc prolongation', 'within previous 8 weeks', 'over the next two months', 'within 1 week before Cycle 1 Day 1.||', 'discontinued', 'during the subsequent', 'within a month before screening|Symptoms', 'in the past 14 days', 'more than 6 weeks', 'within the last 18 months (duration of treatment', 'at time of injury', 'during the study', 'at the time of the index procedure|TIPS procedure', 'throughout the study|Negative pregnancy test', 'within a period corresponding to', 'within the past month before screening|Blood donation', 'within six months.|Active', 'within 6 months before screening.|Excessive', 'period until 120 days after the last study drug', 'within 6 months from the screening', 'within 6 months of signing ICF.|Non-hematological', 'for more than five years after diagnosis', 'within 30 days prior to initial dosing', 'during the study|For', 'during the study.|Any facial laser treatment', 'within 15 minutes', 'within 4 days', 'between 12 months to 6 years before', 'during the screening period before receiving the first administration of IMM2520', 'within the past five years;|Poor image quality', 'at the time of cardioversion;|Bradysystolic atrial fibrillation', 'for 5 years since initiation of that therapy.||', 'at least 2-4 weeks', 'within 24 hours since admission', 'in the last 3 weeks|Travelled across 1 or more time zones', 'within 1 month prior to registration.||Laboratory', 'for 6 month intervention period||', 'within the last 2 years.|2', 'at the time of initiation of study treatment', 'for 4 weeks after the administration of the last dose of the investigational product', 'in 3 months prior to randomization.|LDL ≥190 mg/dL.|Treatment', 'in the previous 30 days|Patients', 'within 12 months of screening.|Presence of any surgical', 'in the prior 3 months before the study begins', 'within one month after the initiation of adjuvant chemotherpay;|combined', 'in the last eight weeks.|HIV-negative', 'more than 3 days prior to study randomisation', 'sexual abstinence', 'prior standard first line chemotherapy', 'during the study treatment', 'within 2 weeks before randomization): i. The absolute value', 'within 6 months prior to study dosing.|Clinically significant', 'within 4 weeks prior to first dose (Cycle 1, Day 1', 'less than 4 weeks prior to study', 'within 42 days prior to enrollment)|Alanine aminotransferase', '> 6 months prior to enrollment|no evidence', 'within 2 weeks before the baseline assessment;|A PHQ-9 question 9 score higher than 2', 'prior to planned diagnostic', 'within 4 weeks prior to enrollment;|patients', 'within 4 weeks before screening.|Persons', 'after recurrence;|They received', 'at least one', 'within 30 days before the signing of the ICF.|Severe infections', 'within 30 days of Visit 1', 'prevent the practice of physical exercise', 'within 6 weeks.|Allogeneic stem cell transplantation', 'for at least 6 days', 'at the time of informed consent|Both partners to consent to participate', 'within the last three months;|Subjects', 'within 12 months prior to Screening.|UPCR ≥1.0 (Class III/IV +/-V', 'at least 1 week prior to first dose of cevostamab.||Received', 'during the study period.|An arterial/', 'within 4 weeks prior to randomization.|Active central nervous system', 'within the last six months|statin intolerance|withdrawal of consent|loss', 'at least 28 days prior to the start of lenalidomide', 'within 1 year|Known', 'within one week prior to the drug administration day.|those', 'during the last 30 days prior to informed', 'in the previous 3 months|Concurrent participation in another interventional research study|Receipt of', 'within the 5 years prior to screening|Positive', 'within 30 days post autologous stem cell transplant', 'since January 1', 'at least 2 meals into the smartphone app on ≥5 days||', 'before the first administration of the study treatment', 'within the past month of a prescription', 'within prior four weeks', 'Within 7 days of ischemic stroke', 'within 4 weeks before the start of study', 'within 4 weeks from the time of enrollment;|Researchers', 'at least 3 months prior to start of conditioning.|No previous', 'within 14 days prior to the first dose of the study products', 'within the 6 months prior to randomization.|Patients', 'during study|History of', 'at Dana-Farber Cancer Institute.|Medical clearance', 'before starting bevacizumab.|History of life-threatening', 'within 2 weeks prior to the first dose.|Subjects with active', 'within 7 days prior to sample being taken', 'during study screening', 'Recent', 'within 4 weeks before the first dose of study treatment|The tumor is HER-2', 'within 24 months', 'prior to the index TBI|Ability of participant', 'within the past year|Diabetes', 'within 72 hours of life', 'within 6 months after the end of the study.|Female', 'at the time of intervention;|Patients', '8 days after resumption of bowel activity', 'within 15 degrees', 'during the screening period after at least one week from SPS therapy', 'within 1 week before the Screening', 'within 3 months|are willing to receive', 'at least three WSLs', 'within 4 weeks before the first use of the study drug;|Serious', 'for 6 months after.|Patients', 'within 5 years of recruitment', 'at least 6 months after the last dose of study intervention', 'more than 3 months before the examination|previous intravitreal application', 'in the last 3 months|Other medical conditions', 'within one week prior to initiation of first dose of treatment', 'in the last 3 months|Conditions', 'within 12 months before Screening', 'within 24 hours prior to the first dose of IP will not enter baseline', 'within 6 months before signing the informed consent', 'within 14 days prior to the first dose of study drugs.|Have', 'less than 3 months before the start of the trial;|Long-term', 'within 30 days prior to study dosing.|Have', '6 months to 8 years', 'planning to change', 'last 3 months Tumor disease', 'in the past 6 months|Systemic corticosteroid treatment', 'for 1 month after (EOT', 'within =< 14 days prior to receiving the first study treatment|Presence', 'within the last 3-months', 'within 10 days prior to the expected initial application date', 'within the last 6 months|Active', 'in the last 3 months|Systemic arthritis', 'at the time of enrolment;|Surgical treatment', 'in 1 month', 'within 12 months prior to randomization.|Prior radiotherapy', 'between enrollment and 30 days prior to enrollment', 'prior to admission to the ICU|chronic kidney disease', 'within 10 years', 'within 3 months of screening visit', 'at least 30 days prior to the Kerecis® xenograft', 'in the past 3 years', 'within 24 hours before the study visits.|Inability to follow the procedures of the study', 'in past 6 months|Able to provide', 'at least 8 weeks prior to randomization', 'during the hospital stay|Patients', 'within 28 days prior to first dose of study', 'while not taking', 'for 90 days after the last dose.||', 'within 2 weeks before Study Day 1 or 5 half-lives', 'during the past one year', 'ULN|Creatinine ≤ 1.5 x ULN|Albumin', 'within the projected duration of the study.|Other conditions', 'prior to taking study medication|Those', 'during the duration of the study.|Non-anaemic', 'through 6 months after the last dose of study therapy', 'within 14 days prior to or after study vaccine.|Bleeding disorder', 'within the 12 months prior to Screening', 'within 3 days before vaccination', 'prior to study enrollment.|Patient', 'within 12 months of enrollment.|The', 'last 4 weeks prior to screening', 'during the trial period and 8 weeks after the last test drug administration', 'for the past 6 months|Able to participate in', 'within 30 days preceding the first dose administration', 'for 3 months prior to screening).|Severe', '1 month prior to the baseline clinical evaluation.|Subjects who participate in', 'within 1 year after the first transplantation;|Patients', 'after remission', 'more than 6 months before randomisation', 'at least 3 months for the subject;|Adequate organ function;|Subjects', 'for less than 5', 'in the last twelve months;|MSM', 'in the recent past 24 h', 'within the past month.|Prior invasive', 'within 1 year prior to screening.|HIV positive', 'within 4 weeks prior to the first dosing.|Pregnant', 'within 3 months of initial screening visit', 'within 2 weeks before the study drug administration', 'in the last month before inclusion|Subject unable to understand the purpose of the research', 'prior to treatment;|Any disease', 'post-completion', 'Congenital maxillofacial deformities mainly cleft', 'up to 2 years post', 'before inclusion/randomisation', 'within 3 months prior to enrollment', 'for the past 3 months minimum;||No more than 1/3 of participants', 'at least 7 days prior to treatment', 'at any time during the day|Diagnosis', 'after 2 or more prior', 'within three months of visiting|Immunosuppressants', 'within the last 5 years.||', 'within the 7 day period prior to baseline', 'during the study until seven days of the last oral medication|Willing to receive', 'within 2 weeks before enrollment;|Severe comorbidities', 'within 1 week)|Has received', 'in the previous six months', 'at least 3 months prior to Day 1', 'during RT', 'prior to Cycle 1, Day 1', 'in the last year|clinically leading asthma disease', 'for the past month||', 'recent 6 months', 'within 14 days of enrollment.|History of', 'more than three months after CT', 'during the study period and within 6 months after the end of the study period;|Understand', 'cancer|Patient', 'within 5 years before Screening', 'immediately prior to study drug', 'within 4 weeks prior to Visit', 'for the time being', 'for at least 12 weeks after the last dose of the IMP.|Male patients must', 'during the previous 4 weeks', 'within 1 month prior to receiving the experimental vaccine.|Received subunit', 'within the intervention framework.||Inclusion Criteria', 'more than 6 months|Pre-transplant', 'within two weeks of screening||Subjects with a', '3 times treatment per weeks|Kt/V≥1.2', 'before treatment.|Patients with successful', 'within 4 weeks of first TG6050 administration|Immunodeficiency', 'for at least 5 months', 'continue with the same treatment', 'at the time of consent.|Sex', 'within 1 month after the end of this study.|Smoking', 'within past 12 month|History of', 'before 24 hours of age||Infants', 'familiarisation / baseline screening', 'within the 6 weeks prior to baseline|Has', 'within the last 6 weeks before', 'within the past 2 weeks;|Subjects', 'within the past 6 months|digestive diseases|difficulty chewing', 'within 3 months before the study);|Allergy to the', 'within the last 3 years.|Previous', 'during the 90-day', 'for six months after the last administration of vemurafenib', 'likely to interfere with the study drugs', 'within 28 days of Day -1.|Received', 'within the 3 previous years', 'within 4 weeks of the first dose of study drug.|Known', 'during the study,|exercise tolerance limited', 'within 2 months after the first administration.|Patients who are', 'at least six months prior to enrolling', 'within 6 hours prior to index', 'within 3 months prior to study enrollment|patients', 'within 7 days prior to the start of treatment', 'past 30 days prior to Screening Visit 1.||Bronchial thermoplasty procedure', 'limping for more than 1 day,|Chronic weakness', 'within the past 1 year.|History of depression', 'at least five years||', 'within 14 days before randomisation.||', 'within 2 years prior to Day 1 of Cycle 1|Primary central nervous system', 'within 14 days before registration|No', 'at the time of assessment|Patients', 'within 4 weeks prior to first dose;|Within 2 weeks before the first dose', 'within 3 months prior to initial administration of ETH-155008.|Have', 'during the study period|Inability to provide informed consent|Planned major surgery', 'within the last 6 months|Known unstable', 'at least 3 months since original tumor treated', 'in the 3 months before enrollment.|Have', 'during the study period.|Concurrent', 'after prior radical radiotherapy', 'within 3 months prior to the study', 'within 2 weeks prior to the first administration date', 'within the preceding 3 months of', 'within 28 days prior to first dose', 'at least 12 weeks after completion of antiviral therapy', 'within 7 days of Cycle 1 Day 1 to meet', 'within 30 days prior to signing ICF', 'at least 7', 'within 2 years after menopause', 'while on', 'within 14 days before the first use of the drug;|With known', 'within 1 month prior to screening.||15', 'within 12 months of last treatment.|Relapse', 'within 14 days prior to the first dose of study treatment.||Presence', 'in the past 6 months;|Medical history', 'for at least four weeks before study initiation.|Be healthy', 'within 24 hours prior to the start of study treatment.|Females', 'for at least three months.||Exclusion', 'within 28 days of first dose of study drug', 'during exercise SpO2<85%|Cardiovascular contraindication', 'within two (2) weeks prior to operation|Pregnant', 'within 4 weeks before the first dose;|Presence', 'within 30 days prior to screening', 'within 2 months before the inclusion', '< 12 hours', 'during the study period.|Average', 'while on therapy', 'during the 6 months prior to study inclusion;|34', 'at least 1 course of treatment', 'within 14 days.|Systemic treatment', 'at least 3 months before the screening visit;|HbA1c 7.5-11.0%', 'within 4 weeks prior to initial administration.|Patients', 'within 14 days prior to IP administration.|Administered', 'within 30 days prior to enrolment.|Planning to receive', 'at the time of hysterectomy', 'their close social', 'in the 3 weeks prior to recruitment.|LVEF', 'within 48', 'within 2 weeks prior to the study drug', 'previously received the following therapies', 'within 3 days before receiving the first study drug administration', 'during the study period and within 6 months after receiving the test drug;|Patients', 'at the time of screening;|Willing, able', 'one month prior to investigation|Blood pressure', 'within the last 2 weeks,|Current emphysematous blebs,|Severe B-12 deficiency.|Bleomycin chemotherapy', 'completed > 6 months prior', 'during the same procedure', 'more than 6 months ago', 'in the 3 months before the test;|Test positive', 'within 6 months;|4', 'within the last week on the test site area', 'within 3 months prior to the first dose of the drug', 'within 12 months of their', 'within 6 months of randomization|Surface area', 'within 3 days of pressure equalization.|Failure', 'within 4 weeks prior to signing Informed Consent', 'within two weeks of screening|Subjects', 'last dose >30 days prior to screening', 'per month', 'within 2 weeks prior to the start of the study', 'after exam 3 through', 'greater than 2/3 of their length', 'in past 3', 'within 4 weeks before starting the study drug', 'in the three months prior to the study.|Use of', 'at least 4 weeks prior C1D1.|NI-8', 'within 48 weeks of screening', 'for the past 6 months', 'for six months after the test;|The patient agrees to participate', 'within the past 3 months)||Participant', 'within the last 6 months|Food allergies', 'within 28 days prior to vaccination', 'within 6 months prior to cycle 1 day 1', 'at the time of screening.|Use of immunostimulatory', 'at the time of recruitment|Participants', 'up to 4 doses', 'within 14 days before enrollment meet the following requirements:||Blood routine examination', 'more than 14 drinks per week', 'in the next 12 months;|Platelet count', 'at least 90 days prior', 'within 3 months prior to Day 1 vaccination.|History of alcohol', 'for at least 120 days after the last dose of study treatment.|The participant', 'over 12 to 72 hrs.|No', 'within 5 days prior to leukapheresis', 'within 90 days before enrollment', 'within 6 months before the first administration', 'within 30 days before study entry', 'at day +60 after transplant', 'within 3000 μm of the center of the macula.|Patient', 'within 30 days of last dose of SerpinPC.|Any other significant', '< 6 months after completed', 'within 30 days prior to enrolment', 'within 28 days before the first administration.|Special diets', 'within 14 days;|The body temperature', 'during screening period showed', 'within at least 4 weeks prior to baseline visit.|5', 'within 3 months prior to the first dose of study drug.||Systemic', 'within 4 hours from transplant', 'within 2 weeks before the first study day', 'within 3 months before enrolment', '6 months after the last dose of liposomal', 'within 24 weeks prior to the screening', 'within 48 hours of enrollment', 'within 3 months prior recruitment', 'within 3 years.|Subjects', 'at first trimester', 'within 2 years.|Expected lifespan', 'within 180 days of study enrollment', 'for at least 3 days to', 'at least for 6 months', 'within 3 months prior to Screening|Treatment', 'during the 14-weeks intervention|Not able to comply with study intervention', 'within 7days before enrollment.||Known acute', 'at least 1 of', 'emergency use authorization', 'within six months prior to enrolment|Recent unsuccessful PCI', 'in the past 3 months|any', 'within the past month|Body Mass Index (BMI', 'within 28 days prior to the first dose of IMP|Prior exposure to immune-mediated therapy', 'within 48 hours of any medical conditions', 'prior to first administration of investigational drug', 'after general anesthesia', 'for at least 24 hours|No pressure ulcers', 'within 1 week before the screening', 'within 12 weeks prior to randomization|Women', 'at the time of study enrollment', 'within 4 weeks before the first dose of the trial', 'during the clinical study.|Use of', 'at the following', '4-8', 'at least six months prior', 'within 30 days of IP administration.|Has', 'prior to randomisation|Pregnancy|Suspected', 'during the screening period despite medical management', 'within 30 days;|Pregnant', 'more than 37.4 degree|Emergent', 'during the last 4 weeks before signing the ICF', 'in last 3 years', 'during the year prior to screening|Chronic mechanical ventilation', 'pre-disposing', 'within 2 cm of the selected treatment area|Acid-containing', 'after the last IP administration.|Women', 'within 3 months after the trial', 'for at least 3 months after the final dose of study drug|Adequate', 'within six months prior to enrolment', 'within 4 weeks prior to the initial administration of XZB-0004.||There', 'of the oropharynx.|Asymmetry of the tonsils', 'during the duration of study drug use', 'within 180 days after the end of the study treatment', '5 year', 'within 4 weeks prior to enrollment.|an expected survival', 'within 3 weeks before', 'before starting any specific procedure', 'within 24 hours of onset of ACS', 'within the past 12 months.|Disease', 'at least 1 month prior to enrolment|experiencing CIPN', 'within the next 3 months', 'at least 4 weeks before the start of the study', 'within 28 days prior to the administration of this trial', 'within 3 months of [18F]FPIA injection', 'at time of conception|Diagnosis of a condition for', 'for the period from the 1st administration of', 'at the same time are not excluded；|Patients', 'within 3 years', 'within 7 days prior to screening;|(6', 'within the past 3 years.|Has', 'within 6 months before administration', 'four weeks before', 'in the last six months.|Having', 'at time of', 'in the past 3 years;|5', 'during the 3-month follow-up period', 'during the screening period;|There', 'within 3 months prior to screening', 'for at least 30 minutes|Inability', 'previous 24 hours', 'at least one minor', 'at least after 1 year of the DBT exam.|Benign Cases', 'within 1 year of signing the informed consent', 'past two weeks', 'after 15 min of', 'after exceeding the recommended therapy options for', 'at least 4 weeks prior to initial administration', 'during the participation of clinical trial.|Individuals', 'within 48 hours prior to ASP5354 administration', 'within 1 month before surgery', 'within the previous 30 days', 'within the period of their study participation period.|Current', 'before enrollment.||Laboratory inspections must', 'within two weeks prior to entry into', 'for 12 months or more', 'in the past 6-months.|History', 'before admission', 'at least 6 months prior|Self-reported', 'sexual partner)access to a portable technology device', 'during the intervention period.|Investigator believes', 'Previous', 'for >3', 'more than 4 weeks prior to the enrollment of this', 'for ≥ 3 years', 'within 24 hours prior to the procedure|Generalized skin', 'for > 2 years prior to enrollment', 'within 6 months from completion', 'within 6 months of screening', 'within 30 days prior to the index procedure|Blood dyscrasias', 'last year', 'within 2 weeks before enrollment;|Those who receive', 'within 30 days of screening.|Receipt of any HBV vaccine', 'within the previous 6 months|Corneal decompensation', 'for 180 days after the last study drug administration', 'within 56 days of Day 1', 'within 7 days prior to step 2 randomization', 'throughout study duration||To', 'at least 2 weeks prior to screening', 'in the 15 days before the procedure', 'within 2 weeks prior to treatment.|Prior organ transplantation', 'up to 4 g/day', 'within 4 weeks prior to the inclusion visit', 'within 1 month prior to study entry.|Use of', 'throughout the duration of the study.|History', 'within 72 hrs prior to the first dose of any study', 'within 90 days prior to enrollment||', 'pathways|History', 'within the past 5-years', 'before surgery|Appropriate for active surveillance', 'within six weeks prior to the screening', 'within the past three-years', 'within 7 days prior to first dose', 'previously been enrolled in this study.|Any participant who', 'within 3 months of study', 'in the past 8 weeks', 'on admission', 'in the last year|Sacral neuromodulator', 'through 180 days after the last study dose', 'within the last 12 months to the affected limb||Medical', 'within the last 6 months.|Have', 'during the period from 24 hours prior to administration of each period to the time of the last blood sampling|Subjects', 'after 26 weeks', 'within 10 days of the onset of insulin therapy', 'during baseline period', 'by 4 weeks prior to screening', 'in the first 24 h of life', 'within 3 months.|BMI', 'past three months before the beginning of the study|Females', 'within 6 months prior to Day 1|Major surgical procedure', 'within 5 months after the final dose of study treatment', 'past 1 month', 'prior to study enrolment.|Study participant', 'past medical history may affect drug metabolism', 'at time of enrollment;|Blood', 'at the time of intervention,|Parent/adult', 'within 1 months prior to joining the study.|Subjects', 'during the period of administration of study drug', 'in the first segment|Stenosis of the right coronary artery', 'while on the study', 'during the Screening', 'during the 3 months following inclusion', 'for 4 weeks after each dose escalation||', 'within the first three months of the study', 'after two or more weeks of standard non-surgical treatments', 'prior to Screening);|Patients', 'during the 8-week EMI study period', 'at least 10 days before first dose', 'in the past month.|History', 'more than 3 hours', 'within 6 weeks prior to Screening visit.|Participant', 'within 3 months prior to the day of vaccination', 'within 30 days prior to Day 1;|receipt of another investigational medication', 'registered the time-point', 'within the last 6 months|Having', 'at the time of signing the informed consent|Participants who can lie still for 1 minute|Capable of giving signed informed', 'after one year of enrollment', 'prior to injury', 'during the study period and within 3 months after the last study administration;||', 'since 2015', 'prior to study|Sign of', 'during the whole research.||', 'during menstruation,|Not having', 'at least 8 weeks);|Organic mental disorders', 'prior to starting study treatment.||Prior radiotherapy', 'within the previous 4 weeks|College', 'within the past 30 days.|Participant', 'at the time of qualification', 'at least 4 minor', '1 day 1', 'over a 30-minute period', 'at least 2 years prior to the start of the study.|Patients in', '4 weeks prior to the baseline evaluation|Subject', 'history|Currently experiencing/receiving', 'heart;|Treatment', 'in the last 3-6 months', 'within 4 weeks before the first use of the', 'within 4 weeks prior to enrollment', 'at the time of screening visit', 'Apparently', 'at the implantation segment|Pre-existing', 'at least 30 days after the last dose of study drug.|Agree to notify the investigator immediately', 'infants;||Between the 28th-36th weeks of gestation|Weighing', 'during the 4 weeks preceding the vaccination visit', 'their first term', 'prior to registration.||Note', 'administration|Any prior receipt of', 'within 1 year of the screening visit', 'in the last cervical smear', 'within 28 days', 'prior to planned', 'within 5 days', 'within the range of 18.0 to 35.0 kg/m2', '5 months to <8 months', 'for 4 months after the last dose of pembrolizumab', 'within the last 7 days prior to the start of the study|Medical treatment for wrinkle reduction', 'within 4 weeks;|The patients', 'personal history', 'at least 2 of these symptoms', 'for more than one month', 'last 2 months;|Current', 'in the next 3 hours', 'during the screening visit||', 'at the time of procedure.|The subject', 'within 28days before starting bevacizumab', 'at invasive', 'at the time of the signature of Informed consent form', 'within 3 months of starting', 'for 30 days after the final dose of study', 'within the last three (3)', 'within 90 days prior to or following SBRT', 'within 2 weeks prior to enrollment.||', 'within the last 12 months|known', 'in the last 6 month.|patient', 'within 10 weeks of', 'prior to starting the medication.|Patients', 'during study treatment.|Participants', 'at the time of screening.|Those', 'within 1 week prior to study enrollment.||', 'in the 3 months prior to signing ICF.||Has known', 'at 1', 'within the previous 3 months', 'within the past 30 days prior to screening;||Takes', 'prior 12 months', 'within 7 months after the last study drug use', 'throughout the study.|Subject must agree', 'during the screening period;|Severe', 'at the screening visit.||', 'in the past 3 months.)|- Current', 'at least 6 weeks', 'within five years|Pregnant', 'for the duration of pregnancy', 'within 3 months prior to first dose.|Known', 'within 14 days before administration;|Patients', 'prior to any examination', 'during the study period.||9', 'within 14 days prior to screening to allow for postoperative healing of the surgical wound', 'at the time of surgery was ≤18 years.|The included patients', 'in the first 3 months after confirmed', 'for 5 months after the final dose of atezolizumab', 'within 100 days of the first medication;|Received', 'within the past 3 months).||*Note', '<28 days prior to administration of PRTH-101.||a', 'for the 3 months prior to screening', 'within 2 weeks before the first dose of study drug;|Participated', 'within 6 months of study administration', 'after previous allogeneic', 'within 4 weeks prior to study enrollment infusion', 'within 28 days prior to the start of their initial systemic', 'within 30 days prior to surgery|ASA IV (', 'previous 30 days before study drug', 'prior to Visit 1', 'within 28 days of the start of study.|Chronic inflammatory disorders apart', 'for the duration of the study|Adult', 'before ultrasound examination', 'within 30 days before the first dose of trial drug', 'within 48 hours', 'during the 30 minutes immediately prior to IP initiation.||Participants', 'within 30 days|(Herbal', 'at the screening visit.|Individual', 'at the time of consent.||Histological confirmation', 'within 28 days prior to enrollment.|The patient must', 'more than 12 hours from the diagnosis', 'within 3 months after the last administration of the investigational product', 'at dosages equivalent to', 'within 14 days after treatment', 'within 1 month prior to the first dose of the investigational product|Those', 'at the time of inclusion without', 'in the Department of', 'at the baseline visit', 'longer half-life', 'prior to randomisation', 'within 28 days prior to Screening.|Any exposure', 'over the past year', 'up to 2 g daily', 'in the last three months', 'during the last 6', 'within 3 years before enrollment', 'ileostomy|More than three doses', 'during the trial,|Consuming', 'at the time of the screening visit', '6 months old or newer', 'ended more than 9 months ago', 'during the 28 days prior to vaccination', 'within the last 60 days prior to screening|Class IV', 'at time of data extraction|Age', 'at the time of the study intervention administration.|Healthy participants', 'within 3 months of diagnosis', 'than three months', 'in the 3 months prior to the study.|Patients treated', 'within 8 weeks of screening.|Current', 'within 60 days prior to Visit 1.|Have', 'within 7 days of study entry', 'last two months', 'within 6 months prior to administration', 'at the time of diagnosis.|Treatment', 'in the 12 months before Screening)|Known human immunodeficiency virus', 'at least 1 week before first dose of study drug', 'in the last 30 days|Systemic', 'within the past 3 months|Unstable residential arrangements', 'more than 9 standard cups', 'during the past year.|Pregnancy', 'within 2 weeks prior to first study treatment administration', 'prior to starting ladarixin', 'within 1 week of starting preparative therapy|Known seropositive for HIV', 'for at least 3 months prior to the first dosing', 'within one month;|not willing', 'within 14 days before.|The previous', 'prior 12 months.|Participant', 'in the last 48 hours before the evaluations;|Have respiratory', 'within 3 months before the first dose.|Received radiation therapy to the lung', 'within 6 months prior to the start of the study;|Any condition', 'within 30 days prior to study vaccination.||*High-dose', 'prior to initiation of study', 'before pregnancy', 'at least 1 hour', 'since last', 'within 14 days before the first dose of study interventions', 'within 1 month prior to study entry;|Having', 'within the last 6 months prior to surgical treatment', 'within 4 weeks prior to the start of HSCT conditioning regimen', 'During the first trimester of pregnancy|Singleton pregnancies||', 'within 4 weeks of the first administration of IMP.|Presence of any', 'within 30 days prior to Visit 2/Baseline', 'within 24 hours, the participant', 'within 6 months of study entry', 'within 6 weeks prior to first dose of study drug.|History of', 'within 3 months before the first dose of IMP', 'within 4 weeks before screening|Antihistamines intake for', 'within 2 months History', 'at the time of enrollment.|Patients', 'in the opinion of the PI', 'within the 6 months prior to Screening', 'within 4 weeks of', 'within 7 days of beginning investigational product', 'for at least seven days were enrolled in this study.||', 'within 2 weeks following discontinuation.|2 or more', '> 6 months prior to enrollment|Diagnosis', 'within the last three months.||E.', 'after taking written informed', 'program prior to their participation in the study', 'past', 'for at least six months prior to entering the study', 'within 2 weeks before the first study dose;|Patients', 'prior to TKI|Patients', 'within 4 weeks prior to the Screening visit', 'required|Less than 3 months', 'within 90 days prior to or', 'neuropathy);|regular intake of probiotics', 'within 24 hours of receiving the first dose of study medication|Female', 'at 4 hours in the peritoneal balance test);|Sign the informed consent form voluntarily.||Exclusion', 'at least once|does not', 'prevent sole contact|Pathological conditions', 'at least 7 days prior to Visit 2', 'during the past 6 months', 'more than 3 times the upper limit of normal', 'within the last 90 days.|Subjects', 'prior to starting therapy.|Untreated active', 'within 72 hours before', 'within 14 days prior to initiating study treatment)||Note', 'within the past 3 months.|Uncontrolled', 'with the exception of', 'within 1 year prior to the screening visit', 'within 3 months prior to the screening', 'within 3 years prior to the start of study', 'within 4 weeks of administration of a first dose of study treatment|Autoimmune disorders', 'in at least 4/7 days/week', 'within 1 week prior to study treatment.|Use of medications', 'in the preceding 12 weeks prior to screening;|Have', 'at least 2 weeks apart', 'history of surgery', 'within 12 weeks after radical prostatectomy;|PSA', 'at the time of consent.|Histological, cytological', 'in the past 3 years|Self-reported', 'within the past 5 years|Lesion in', 'after at least 8 hours fasting)|Diagnosis of any other', 'at Screening.|Admitted to the hospital for treatment', 'within the previous 6 weeks', 'can allow medical treatment', 'At least 1 measurable', 'for at least 12 weeks prior to', 'during the course of the study.|YAG laser capsulotomy', 'for at least 3 months since completion of prior treatment.||PRE-REGISTRATION', 'for 150 days after the last dose', 'prior to five years', ""at the screening visit.|In the Investigator's opinion"", 'previous two months||Subjects', 'within the last 2 months|Other', 'within the past two', 'within the 6 months prior to Baseline Visit', 'within 14 days of study administration', 'in the last 6 months.||', 'within ≤ 6 weeks', 'while using the study drug', 'prior 8 weeks|consumption', 'within 2 weeks', 'for at least 14 days after the last dose of the investigational medicinal drug', 'in the next 3-4 months', 'weekly intake of alcohol', 'within the last year.||', 'within 24 hours prior to administration of LR769|have a', 'at least 1 year following repair|PAH classified', 'for at least 5 days', 'at the time of the start of treatment.|Concomitant', 'for at least 2 hours|requires critical care', 'up to 2 grams [g', 'past history of', 'in the last year|Urogynecological conditions', 'Acute injuries|Non-athletes', 'within 30 days prior to baseline visit', 'during the survey', 'during the assessment', 'within 3 months prior to study screening.|Study', 'within 45 days prior to transplant', '30 days prior to baseline.|UV light therapy 30 days prior to baseline.|Clinically significant', '< 6 months prior to Visit 1', 'within 48 hours before administration;|Subjects', 'in the past 12 months|Self-reported', 'before study entry', 'within 4 weeks before administration', 'at the medical institution.|Histologically confirmed', '72 hours prior to or', 'at least 6 months before screening.||', 'on admission###', 'within 4 weeks before the first dose.|Participation', 'prior to the study less than 130 mmol/l.|Serum', 'within 14 days before screening', 'before signing informed consent);|Carcinoma in situ', 'at the Screening Visit (serum)', 'after antihypertensive drug|Myocardial infarction', 'at least 3 months prior to baseline', 'in the last 4', 'within 2 years prior to the first dose of the study treatment', 'prior to start of study enrollment', 'at the time of the enrollment in the study', 'within the past 12 months.|Cohort 3', 'before renal biopsy;|Complete clinical', 'within 14 days without', '3-months', 'in the last 5 years|patients incapacitated', 'at least 3 months previously', 'longer than one', 'in the past four', 'within 15 days prior to inclusion|Non-steroidal anti-inflammatory drugs (NSAIDs)', 'before the first dose of study drug', 'within 28 days of enrolling in the study', 'throughout the duration of their study participation.|Able to understand and sign the informed consent form (ICF)', 'within 4 weeks of protocol treatment|Checkpoint inhibitor refractory', 'prior to inclusion|Maternal pulmonary edema', 'within 7 days prior to the', 'in past 30 days|non-pregnant|willing', 'in the 4 weeks prior to screening.|Currently taking another investigational drug', 'for at least three months 2', 'at time of data extraction', 'within the past', 'within 7 days of study drug administration|Had dilatation', 'at least 1 TACE treatment；|Contrast-enhanced', 'during or within 12 months of completion of therapy', 'at least 3 months prior to enrollment.|Participants will be', 'for less than one year prior to screening;|Inadequate supervision', 'before enrollment or within 6 months', 'within 6 months prior to Day 1.||', 'within 5 years of treatment can participate in this trial;|Previously received', 'within the past month, the Participant', 'between 12 and 22 weeks gestation.|Participants', 'after one of the following regimens:', 'within 4 weeks from enrollment can be included', '7 days prior to first study drug administration until the end of the study.|Subject', 'on the day', 'within the past 12 months prior to screening', 'at least 4 months', 'within 12 months preceding the Screening Visit|Current participation', 'within next 12 months', 'within 4 weeks after being diagnosed;|Progressive aggravation of jaundice', 'at time of presentation|Medical contraindication', 'prior to the index TBI 4', 'within 14 days;|Patients', '72 hours prior to and', 'within 1 month after sending our e-mail', 'at Screening.|Subjects', 'within the scope', 'ovaries).|More than 4 weeks after the end of previous', 'last dose received', 'within 6 months prior to randomization.||Key', 'within five (5) years prior to screening', 'within the study duration.|Intraocular inflammation', 'within 14 days before the first day of the drug', 'within 1 week or five half-lives', 'within 3 months after the last administration of the test drug.||The', 'at least 2 weeks before the first administration of study intervention', 'possible.|Aged 3 years to 10 years old', 'during the period starting 3 months prior to the study intervention administration', 'Newly admitted', 'at the time of signing the informed consent form|Participant', 'in the past 6 months.|Is', 'within 4 weeks prior to study treatment', 'survived for more than 5 years', 'after standing up', 'within 12 months prior to treatment initiation in order to control laryngeal', 'for the effectiveness assessments', 'within 2 weeks before enrollment.|Once', 'three months before the study|Pumpkin seed', 'over 1.25 years', 'within 6 months from', 'at the time of signing informed consent.|Continuance of', 'within the 3 months prior to Day 1|History of dependence', 'within three months of the Screening Visit.|Patient', 'within 14 days before the first study drug administration.|Live vaccinations', 'at least five of the following symptoms currently:||i', 'after at least 2 prior', 'during the last month.|Participants', 'for at least 5 years', 'at the time of study participation.|Subjects', 'up to 1 cycle', 'within the previous year prior to Screening', 'within 3 days prior to the first dose', 'within 28 days of dosing.|Received investigational Ig', 'within 12 weeks.|Prior', ""within the last 8 weeks).|Jehovah's"", 'within 8 weeks or 4 weeks respectfully', 'pre-malignant', 'at the time of the informed consent', '7 days prior to and', 'within 4 weeks prior to the first use of the study drug', 'within 90 days prior to surgery.|History of', 'within last 7 days|Patients', 'within 14 days prior to taking the study drug|regular', 'one month after administration of study medication.|For', 'within 2 weeks of first dose of study treatment;|Participants', 'prior to catheter placement (Exception', 'up to 325 mg once daily', 'eyes|Eye', 'for at least 1 month prior to Screening||', 'within 4 weeks of visit 3', 'within 3 months prior to', 'at the time of SE occurrence.|Participants who pre-emptively opted out of the study.|A known', 'within past 6 months)|Patients', 'within 2 cm of the selected treatment area', 'more than 25||', 'during dilated slit-lamp biomicroscopy', 'within a week', 'in the past 15 months', 'within 7 days of study start|Any condition', 'within 4 weeks of baseline', 'after last dose of', 'at start of study.||Parents', 'before enrollment (', 'prior to starting treatment', 'at least three months ago,|Able to follow two-stage verbal commands', 'period starting 90 days before the study intervention administration', 'at the time of inclusion|Patients have used', 'confirmed|Positive', 'ALL|More than 4 weeks', 'prior to the first dose of study intervention.|Previous', 'prior to inclusion visit||For CHR-P:||Clinical', 'within 12 months.|Mentally competent', 'within 4 weeks preceding the start of study treatment.|Unwillingness', 'within 4 weeks prior to initiation of treatment', 'within 6 months prior to Visit 1', 'during enrollment of any chronic pain', 'over the past 2 years|Participants', 'at the time of study initiation', 'at least 4 times every month after the end of the treatment', 'within 6 months;|Left ventricular aneurysm formation', 'within 28 days before first dose of IP.|Subjects', 'within 3 weeks prior to first dose of study', 'during the 3 months preceding randomization', 'more than 8 hours/day|Not', 'within 28 days before starting the study drug', 'before the screening', 'in the last 6 months|Eso-gastro-duodenoscopy', 'within 4 weeks or five times the half-life of the investigational product', 'at least one oral', 'prior to the study', 'through the Geisinger Clinic', 'within 30 days after the study procedure.|Patient', 'in the previous 3 years prior to study', 'at least three hours before the scheduled exercise', 'during the period of participation', 'at the time of providing informed consent', 'within 3 months.|Enrolled', 'during the study period;|People', 'within 4 weeks prior to screening.|Patients', 'within the last 2 months|Recent', 'at least 6 months ago|HbA1C level', 'in the previous 28 days before Day 1 of this', 'within 4 weeks prior to initial use of the study drug;|10', 'more than 1.0 EDSS point', 'for at least 12 weeks after the last dose of study intervention|Female', 'after the last treatment on this study||Active central nervous system', '1 month prior to Visit 2', 'within 3 months prior to Screening.|Subject', 'at the time of enrollment except', 'within 30 days from the start of administration until the last administration||Exclusion Criteria of', 'before the first dose of VTD-101 ointment', 'before 24', 'within 28 days before the first administration of the study treatment', 'within the last 5 years|Severe', 'within 28 days of study entry.|Female', 'before participating in the study', 'within the last 3 months- requires documentation of ALC', 'at least two of the following criteria', 'for at least one month prior to screening visit||', 'within 4 weeks prior to the treatment day.|Unable to comply with study procedures', 'during operation', 'at the time of signing the informed consent.|Evidence of biomarker', 'within 12 months of Baseline', 'prior to study participation', '14 days after the second dose of Covid19', 'within the past one year.|Concomitant disease or condition', 'within the first 7 days of ECMO|Patient', 'at any time during pregnancy||', 'within 24 hours of injury', 'at Screening and Day -1', 'prior to the investigation', 'continue receiving these medications', 'within 3 months prior to Day 1|Intraocular surgery', 'within 8 weeks after the last administration of the trial drug|Sign', 'previous 30 days', 'within 6 months of screening date', 'during the pre-study screening phase', 'during the study period and within 6 months after the last dose of XZB-0004.||', 'last six months', 'larger than 1.5 cm||', 'at any time after screening through study completion||Reproductive', 'at least 3 symptom-free', 'in the last 12 months.|Subjects', 'in these restorative movement', 'in the past 6-months', 'in the last 3 years.|Any', 'within 2 weeks after administration of the last dose of study treatment.||Concurrent medical', 'tumor.|Pre-existing', 'within 1 month before randomization;|7', 'previous 12 months from the beginning of experimental maintenance', 'in the prior 3 months;|Have', 'after 12 months', 'at the time of registration|Uncontrolled', 'within the advanced', 'at the time of signature of the ICF.|Subject', 'within 28 days before first study drug', 'onset to randomization', 'for least 14 days before blood collection|Active cancer', 'within 4 days of the baseline visit|tobacco', '48 hours apart', 'within 2 years prior to the first dose', 'at the time of consent.|Generally', 'at the time of signing the ICF.|Patients must', 'within 2 weeks prior to the first dose of study treatment', 'within 28 days or 5 terminal half-lives', 'within 3 months before', 'at least 3 months before disease progression and must have a gap of at least 4 weeks from the', 'within 7-days prior to start', 'within 24 months prior to', 'in the last 10 days', 'for at least 5 days prior to the procedure', 'throughout the trial period;|Be able to communicate well', 'prior to the first dose of study therapy;|20', 'radiolucent', 'for the past 3 months minimum^;||Maximum of 7 participants per site', '6 months after final drug administration.||', 'within 4 wk)|Known gallbladder', 'after previous radical prostatectomy', 'within 14 days prior to the first dose of study drug', 'within the past 6 months|Practice', 'within the previous 2 years except', 'within 6', 'within 1 month prior to the first dosing;|any drug', 'within one week of stroke', 'within 4 weeks prior to the Baseline', 'within 4 weeks per standard of practice', 'maximum 1 month prior to inclusion', 'over the past 6', 'at least 4 years', 'more than 4 days', 'within 6 months after treatment', 'within 2 weeks of entry onto this study', 'during the study|Donated', '4 weeks prior to data', 'within 2 weeks prior to trial', 'in the last 6 months,|Presence of previous musculoskeletal surgery,|Pregnancy,|Having', 'at least 2 days per week.|Less than 2 bowel movements', 'following curative resection', 'within four weeks prior to dosing.|Clinically significant', 'for 3 months post study', 'within 3 months before screening.|Those', '6-month duration of the intervention', 'for at least 8 weeks', 'within 5 years or less before signing the informed consent', 'within 6 months before the start of the study|an expanded disability status scale', 'on the A-2 test of the Syntax Comprehension Battery', 'concurrent', 'during any of the 7 days prior to surgery', 'within 60 days prior', 'within 1 year of Screening/Baseline', 'more than 5 cigarettes per day on average', 'within 1 month before the study', 'past 30 days prior to the screening visit.|Use of any live vaccines', 'during the stay in the CRC.|Seville oranges', 'within 30 days of the last study visit|Participation', 'prior to transplantation', 'at least 12-month after the index procedure', 'within the last 12 weeks|Has experienced', 'after definitive therapy with', 'within the previous 6 months.|Received', 'in the last 30', 'at the time of injection.||Eastern Cooperative Oncology Group (', 'during this period.|Subjects', 'recent (', 'within 7 days of screening:||Temperature', 'during the study;|Those who cannot', 'at time of surgery;|Patient', 'on the brain scans.||', 'less than 8 weeks prior to enrollment', 'in the previous 1 month|Clinical signs', 'users|More than 3 levels', 'within 30 days prior to randomization.|Modified Rankin score of ≤ 3|TIA', 'at least 6 months follow-up||', 'at least three months', 'within 30 days prior to registration|History', 'within 12 months of treatment.||NOTE', 'prior to index surgery.||Prospective', 'within three months.|Patients', 'within the prior 12 months|History of', 'within 30 days prior to enrolment|The', 'for 5 years since treatment began', 'over the past 2 weeks.|Predicted life expectancy', 'for two weeks prior to the study', 'at the time of the procedure', 'at least 3 visits)|Willing', 'within the past 6 months|Current major depressive disorder', 'permitted until day 1 of study participation', 'at least one hand.||', 'within the timeframe of the study', 'within 5 years prior to enrollment|Positive', '3 months prior', 'during the study period and within 3 months after the last administration of the study medication', 'for at least 4 weeks prior to first dose of study treatment after radiotherapy', 'within 3 years before study registration', 'before first dose of study drug', 'at least 4 hours a day', 'during the study.|History of a surgical procedure', 'within 14 days before screening;|Consuming', 'in the month before the study begin.|Having', 'in the month prior to the study||(2', 'at the time of the Screening Visit.||WOCBP may', 'at least 1 month for fluoxetine', 'within 28 days before the first dose of study treatment.|Central nervous system', 'within the last 2 years|People with lung cancer', 'within the last 3 months before trial enrollment', 'more than 3 months before surgery', 'within 2', 'before enrolling at Baseline Day 1|Participant', 'within 30 days before enrollment;|Diagnosed', 'after enrollment', 'at the time of signing informed consent.|Body mass index', 'in the field', 'requirement to maintain a mean arterial pressure', 'within 14 days before trial product administration.|Clinical evidence', 'in the emergency department', 'for 1 month following IP administration|Use', 'in the past 1 months', 'outpatient basis for visits', 'before surgery.||', 'within 3 months prior to the', 'between 8 and 13;|Level of Cognitive Function (', 'at term', 'within 12 months of randomization', 'within the past 6 months||', 'within 2 weeks before screening|Systemic', 'at the Screening Visit|Evidence of', 'within the preceding 45 days|Cerebrovascular accident (', 'for more than 12', 'of at least 30 days', 'within 4 weeks before the first use of the drug;|Plan', 'within past 5 years;|Renal', 'at screening visit|Participants', 'within 1 week of roflumilast administration', 'during the pre-treatment period;|Participants', 'at Screening and', 'within 3 months.|Subject', 'at the time of screening;|Patients', 'within 12 hours.|Prisoner|Intubated|Unable to swallow oral medications', 'within the last 12 months;|Be', 'within 2 weeks before the first dose.|immunosuppressive drugs', 'at least one of the following compensatory behaviors:||Set an alarm', 'for at least the past 6 months.|Patients', 'within 6 months prior to signing informed consent', '14 days before dosing until after the Follow-up', 'within the past 4 weeks prior to the day of screening', 'at time of informed consent signature|Informed Consent Form (ICF', 'for at least 3 months before the study;|daily insulin dosage', 'for 30 days after last dose|Female', 'within the 12 month period prior to screening;|HBsAg(+', 'within 10 days prior to the first dose of study drugs.|Evidence', 'within 8 weeks prior to the Screening visit', 'within 2 weeks prior to initiation of study treatment|Patients', 'over 8 weeks', 'within 6 months prior to enrollment', 'at time of EEG placement|Inability to place four', 'at least 1 cytotoxic chemotherapy agent', 'at surgery|Need for crestal augmentation procedures', 'within the treatment area plus', 'within the last 24 hours|Allergy', 'in 14 days after symptom onset by clinicians|Sign the informed consent||', 'vulgaris||', 'within 1 month of participation.|Anytime in life', 'in the previous 6', 'at the time of admission and/or', 'at least one month before this', 'at the time of screening|High inotropic requirement', 'within the past 4', 'within 4 weeks prior to the study', 'within 72 hours of starting therapy', 'up to 6 months post full vaccination', 'at Screening Visit', 'in the past 7 days is more than 1.5 times of the basic value', 'within 1 month of', 'at time of consent|Clinically indicated', 'in last 3 years||', '6 months prior to start of the study treatment', 'within 30 days prior to viral treatment.|Participants', 'in the last 2 years;|Contradictions', 'within the last', '48 hours prior to the study administration of either study period until donating', 'within 5', '72 hours prior to the first dosing', 'at the time of catheter change', 'within the past three years', 'within 30 days or five half-lives', 'in the previous three (3)', 'for at least 6 months before study enrollment', 'prior to first dosing treatment', 'within 72 hours prior to the first blood', 'prior to PCI', 'within the next year', 'within 90 days prior to screening', 'during the study Worse than', 'during 24 hours prior NL examination', 'within 24 hours prior to index surgery)|Unresponsive state', 'within 6 months prior to signing informed consent.||31', 'on their target knee|Plan to have knee surgery', 'the past 6 months|reports', 'at Screening.|Known acute', 'during the conduct of the study;|history of', 'within 1 week prior to the first dose of study drug.|Known', 'after January 1, 2023|Member', 'at Cycle 2 Day 14 (+/- 4 days)', 'at the study center', 'recent three months', '3-months prior to baseline assessment|Does not', 'within the past 2 weeks', 'within 180 days of protocol enrollment', 'for 12 months post-dosing|Patients', 'within 30 days.|Patients', 'within the last year.|Bleeding', 'at least 1 year prior to the study.||Between 18', 'at the time of signing the informed consent.||Female participant', 'after the tMG study;|planned thymectomy', 'at baseline (implementation of', 'at the time of signing Informed Consent|Karnofsky performance status (KPS)', 'during the treatment period plus', 'within 7 days or', 'at the time of consent.|Subject who can consent in English.|Subjects', ""within 28 years prior to treatment|In the investigator's"", 'preceding 24 consecutive', 'within 6 months;|7', 'within 7days prior to study drug administration.|Drugs', 'within 3 months before treatment.|Pregnant or lactating', 'within 48 hours before administration).|Allergy to', 'in the last 2 months||', 'prior to screening visit', 'prior to initiation of zimberelimab', 'for SCCHN.||R/M', 'within the past 2 years prior to screening.|Positive results', 'at least 2 weeks prior to C1D1', 'during therapy||Creatinine clearance (mL/min', 'at two (2) adjacent', 'within 6 months of the first dose of study medication', 'within 12 months from the study enrollment.||Population', 'for at least 6 months.|Previously', 'in the month prior to pre-study screening', 'within 60 days prior to study entry', 'in the past year|Known', 'within 3 months of screening|Irradiation', 'within 14 days before drug administration', 'during Screening.|Known', 'within 4 weeks of randomization', 'for the duration of study participation.||', 'within the past 90 days prior to the day of screening;|Known', 'within 8 weeks of Screening', 'for at least the previous six months)|history', 'more than 150 km', 'within 1 month prior to Visit 1', 'at aforementioned dose and duration within 28 days following receipt of study vaccine', 'within the last six months|Any', 'within last month|Seriously ill', 'within 3 months prior to the experiment day|Recent hospital admission', 'within 5 years|Prior radical', 'services|Within 3 years of diagnosis|Able to demonstrate', 'within the last 3 months.|Exposure', 'within 1 month before surgery|Incomplete', 'in 4 weeks prior to inclusion', 'at the time of study screening.|Only', 'at the time of signing the informed consent.|Ability to undergo', 'in the 4 weeks prior to enrollment', 'within the range of', 'within the last 6 months|Are', 'within 4 weeks prior to the start of this study.|Received', 'at least 200mL post-bronchodilator', 'within 5 years;|The', 'up to 14 days', 'dose for 4 weeks', 'within 4 weeks prior to inclusion.|Any medication', 'at the time of the study visit', 'within 3 weeks prior to initiation of study treatment', 'lasted for 3 days', '3 half lives', 'for at least five days a week', 'within 1 year prior to Visit 1', 'within 24 hours from onset (', 'during the Screening/Run-in Period', 'for at least 2 weeks prior to enrollment', 'for the last 3 months|The', 'within 6 months from start treatment|On-line', 'at least 7 days prior to the start of study treatment', 'for at least 3 months|and', 'in two six-ounce', 'after evaluation by the UREC', 'within 3 years prior to the first dose;|History of serious', 'at the same time', 'within screening', 'less than 4 weeks before the IPN-21-SENSE injection', 'within 3 months of the start of the', 'in the 12 months', 'within 6 months of completion', 'within the last 12 months prior to screening|A confirmed', 'prior to start of study intervention', 'at the time of dosing).|Diagnosis of', 'throughout the trial period', 'within 30 days prior to the blood draw|Protected', 'at the time of recruitment;|There', 'within 7 days prior to Day 1 of Cycle 1.|Has', 'within the last 3 months prior to inclusion|Infection', '1 month before first dose', 'at any time during the study;|Any contraindication to MRI', 'last hospitalization', 'during exercise via self-report', 'within 12 months of Visit 2/', 'in the terminal stage', 'after one cycle of prior therapy', 'during the study period and within 6 months after the end of the study', 'in the last 6', 'Persistent', 'at the time of enrollment|Receiving another investigational agent', 'at the time of informed consent|Body weight', 'within 3 months of the anticipated first dose of study medication.|Subjects', 'for 3 months after stopping the treatment.|Use of oral', 'within 6 weeks of Visit 1', 'during the study period.|Inability to understand and follow study procedures', 'within 3 weeks prior to screening', 'more than 14 standard drinks per week', 'at the time of screening|Any condition', 'past 24 months prior to Screening Visit 1.|Peak flow variation', 'more than 12 hours.|Acute type A aortic dissection', 'prior to receiving the first dose of study treatment', 'within 1 year prior to study entry.|Patients', 'within 12 months;|Expected survival period', 'within one week before randomization.|Patients', 'prior to randomization;|Live vaccination', 'longer than 8 weeks', 'in the past 12-months', 'within 4 wks.)|Prior', 'within 4 weeks prior to Screening', 'within 4 weeks prior to admission', 'in the 3 months prior to the screening', 'at the baseline visit;|Uncontrolled/', 'during the study.|Enrollment in other research studies', 'within 3 months prior to joining the study.|Subjects', 'within 2 weeks prior to enrollment.||7', 'within 1 year after receiving study treatment.|Stroke', 'within the last four weeks.|Participant', 'between Visit 1 (day 1', 'at least 12 months before screening', 'at the time of Screening|History', 'in the first 3 days after the surgical intervention', 'at the time of surgery.|At the time of surgery', 'in childhood', 'prior year', 'at least 6 months', 'within 2 years after cell reinfusion', 'at least 8 weeks', 'minimally three months prior to screening seen prior to 76 weeks after randomization iii', 'within 6mo of screening', 'within 3 months prior to screening.|History of', 'at least one week before the start of the study', 'within health clinic', 'at least one of the following:||Obesity', '7 days prior to study drug administration', 'within the past 28 days', 'prior to data', 'lasted for at least 12 months', 'within 4 weeks of first dose of study drug.|Active', 'recent (6 months', 'for 2 months prior to enrollment', 'within 28 days prior to study entry', 'at the time of trail entry', 'within the last 28 days before inclusion', 'within five years', 'after resting for 5 minutes', 'after at least two', 'within 5 years prior to the first dose of investigational drug', 'in the last six months;|MSM', 'at least 6 months experience regardless of manufacturer.|The PI', 'preceding 4 weeks;|Malignancy', 'within 2 months prior to vaccine administration', 'in the month prior to enrollment|Use of', 'within the last 6 months|Known sensitivity', 'within the past 3 months,|4', 'for 6 months prior to inclusion|Evidence of', 'at least 2 hrs before administration of an', 'within 4 weeks of RT start', '> 1 year', 'within the last two week|Use of', 'within last 4 weeks prior to screening|Diagnosed', 'in the 3 months before the clinical trial.|Difficulty', 'preceding 1 month|Wedge pressure', 'within less than 4 weeks', 'within the 3 months prior', 'for at least 1 month)|Patient', 'within four weeks prior to inclusion', 'for at least six weeks', 'during the study|Contraindications for MRI', 'within 7 days before the first dose of the investigational product', 'within 5 years before the first administration;|Known endoscopic signs', 'at the time of his visit to the emergency room', 'within 4 weeks or five half-lives', 'within 2 weeks prior to the Screening Visit:||Cosmetic', 'during the study|Unable to tolerate', 'prior to 6 month follow-up', 'since enrolling in the double-blinded treatment period', 'prior standard therapy', 'before after surgery within 6 months post-surgery', 'at the time of enrollment.|They', 'during the Screening Phase', 'within prior 1 year', 'up to 14 mm', 'in the last 4 weeks.|Patient capable', 'for ≥3 months prior to screening|subjects', 'in the knee replacement system', 'within past two years', 'at least 3 months before enrollment.|Have', 'in past 6 months|History', 'previous 56 days.|Donation of plasma by plasmapheresis', 'at the time of dosing).|Other medical or', 'within 14 days before entering the study;|have', 'at least six weeks prior to enrolling', 'in the limb.|Conditions that', 'in < 6 months after curative intended locoregional irradiation of the head', 'within 6 months before enrollment.|Has', 'within 3 years before the first administration', 'within at least 7 months after the last dose of T-DM1', 'at least 6 months)|Subject', 'at time of signing ICF|ECOG Performance Status', 'in the last 1 year|Having a', 'before surgery||', 'in the past 3 days followed by 100 mg/die per os).||', 'at the time of cardioversion;|Identified contraindications to the sinus rhythm restoration', 'during the whole trial period;|According to the judgment of the investigator', 'more than 1 week before the first dose of study', 'within 14 days before the first dose of nivolumab', 'no', 'at least 10||', 'for at least 5 nights/week|Sleep patterns', 'within the last 6 months of the screening', 'prior to treatment initiation|Detection of circulating DNA', 'within 24 hours prior to the start of the study', 'after the last dose of study treatment||', 'more than 6 months after completion', 'within 4 weeks prior to screening.|Ongoing', 'within 30 days before baseline visit', 'at least 2 of the following 3 self-reported', 'after prior', 'in the past 3 months|difficulty participating for technical/logistical issues', 'at least 14 days before the first dose of study treatment.|Prior organ allograft.|Use', 'onset at least 1 of 11 COVID-19 symptoms', 'at the time of enrollment|Patients', 'within previous 3 months.|They', 'in the next 12 months|Eosinophilic', 'within the previous five years', 'within 3 months prior to hematopoietic stem cell collection.|Had diseases', 'within 3 months prior to randomization;|Arterial/venous thrombosis', 'in the last five days|Receiving chronic warfarin therapy', 'within 6 months prior to the procedure', 'at the time of signing the informed consent form;|Histologically confirmed', 'within 2 weeks.|Participant must not', 'within 4 weeks prior to the first dose of study treatment', 'last 24 months', 'within 72 hours prior to allocation', 'at the time of signing the informed consent form;|Histologically', 'within 2 weeks prior to enrollment;|Subjects', 'within 3 months prior to screening，or', 'within 1 month prior to the expected date of the first', 'during the period from 2012 to 2021,|Regular follow-up', 'at least 4 weeks prior to enrollment in study.||', 'at the time of screening.|Hepatitis B surface antigen (HBsAg)', 'at Screening and within 24 hours prior', 'history of prior', 'within 14 days prior to check', 'constitute seizures|History of seizures', 'in prior 24', 'in the past 12 weeks.|Intent', 'in the past 3 months.|Failure', 'within 3 months prior to the first administration of the study drug', 'at the time of signing the informed consent|Body weight', 'within 6 weeks before enrollment;|Patients', 'prior to the first dose|Patient', 'within past 6 months.|Distant', 'within 1 month before signing the informed consent form (', 'for more than 1 year|Patient unable', 'consistently', 'within 6 months prior to first dose.|History of infection', 'within 14 days before randomization', 'at least 20 hours per week of clinical', 'within the previous 2 years,|any', 'for at least 4 weeks after the last IP administration|Subjects', 'over the past 6 months.|Subject', 'prior to random', 'within past 5 years;|chronic steroid use', 'within a month prior to screening', 'post-transplant', 'within six months before the procedure|A contraindication', 'within 14 days prior to the first study treatment', 'within the previous 3 months|Surgery', 'within 4 weeks before screening.|Treponema pallidum antibody positive', '14 months or more', 'prior to their injury|Previous patellar', 'at least three times weekly for the past month|Stable residence', 'before treatment', 'within 7 days prior to administration of the first dose of study therapy.|Have', 'within 7 days of cycle 1 day 1', '6 months after the last dose of study drug.|Measurable disease by CT', 'during the 6 months prior to Screening.|Subject', 'within the last 5 years)|Enrolled', 'more than 10', 'in the next 3 months', 'within 3 months prior to signing ICF.|Those who smoked more than 5 cigarettes per day', 'during the dutasteride treatment period', 'within 1 year prior to screening', '14 days prior to', 'within 180 days of first therapy', 'at the time of enrollment|Uncontrolled', 'within the last two years.|Severe misuse', 'within 4 weeks unless', 'within 14 days of Cycle 1 Day 1', 'after hospital admission|History of', 'within 1 week prior to signing informed consent.|Pregnant', 'within the last 6 months', 'at the time of enrollment is more than 18 years old', 'up to 30 days after the third dose.|Suspected', '1 months before the study;|Taking', 'within 5 times the half-life of the investigational drug', 'in the next 2 years|Individuals', 'throughout the treatment period and for 6 months after the end of treatment.||', 'within 2 weeks prior to the first study treatment;|Clinically significant', 'within 2 months before taking study drug.|Taking', 'within 30 days before the screening', 'at the Online Therapy Unit between Nov 4 2013', 'at the start of the study', 'within 7 days prior to the period', 'within 2 cm of the selected treatment area|Artificial tanners', 'within 48 hours prior to randomization', 'within 60 days before Step 2 entry.|Receipt', 'at least one treatment', 'within 24 hours prior to enrollment|History of', 'within six months.|Patients', 'within 7 days before the first administration;|Known allogeneic organ transplantation', 'within 14 days prior of the index procedure|Acute MI', 'within 1 year of pregnancy', 'within the previous two', 'requirement prior to first dose of', 'for 3 months after the last administration of the study drug.|Patient', 'at either Screening or Day -1.|Has', 'within the last 6 months|History of known', 'within the networks', 'within one month of study entry', 'within 12 months prior to study entry|Received teriparatide', 'within 1 week before operation;|Subjects refused to accept radical resection', 'in screening', 'surgery to treat chronic pain', 'within 2 years before the first dose.|Receipt of major surgery', 'within 4 weeks before the first administration;|Have received the following therapies', 'within 7 days of the first trial drug administration', 'within the previous 2 weeks', 'at least 3 weeks', 'during the 3 months prior to inclusion', 'within 24 hours prior to first dose of lenvatinib', 'at 4cc/second not possible', 'in the past 5 years.|Patients', 'within 24 h before the test.|History of', 'within 6 months before randomization', 'within 14 days prior to the administration of the study drug|have', 'throughout the study.|Any participant', 'within 28 days,|Radioimmunoconjugates', 'during the time period for use of', 'within the past 5 years prior to Visit 1.||Exceptions:||non-metastatic', 'within 28 days prior to study initiation;|Factors', 'previously been treated', 'within three months prior to inclusion|Treatment with antidepressants|Treatment with', 'at any time during study|Anti-lymphoma therapy', 'recent 12 months indicating', '90 days prior to screening.|Obesity', 'During pregnancy;|Have participated', 'within 4 weeks of Day 1', 'within 24 hr|Presence of burr', 'within 3 months after the last cell transfusion;|Sign informed', 'at the time of operation|Unilateral', 'at the time of informed consent；|Patient', 'within 2 weeks before the study therapy begins;|Participated', 'during one month before saliva sampling.|Patients', 'in at least one', 'within the 7 days before inclusion', 'at least 4 weeks prior to the first treatment.||Male participants:||A', 'within target range of therapy', 'within the previous 1 month', 'after January 1', 'during the course of the study.|Participant', 'past 12 months prior to inclusion', 'after two lines of therapy', 'at least 14 days before the initial administration of the trial therapy', 'within 90 d prior to screening visit', 'Before Tax)|past history', 'within 1 month prior to screening.||14', 'at least two months after vaccination', 'in the past two months', 'in the two weeks prior to the screening|History', 'prior to admission eGFR', 'within 7 d prior to infusion of U16 infusion', 'at the time of informed consent.|PSG criteria', 'within 6 months before the cell reinfusion;|New York Heart Association (', 'within 3 months before Screening', 'within the previous 12 months demonstrating', 'at the time of CKRT', 'in the past 1 year;|Severe/unstable', 'within 3 weeks of the first course of trial treatment;|Pregnant', 'at least 30 patients/month', 'within the past year.|Has', 'at least 3 times per week', 'within the next 6 months|Planned', 'within 16 weeks prior to enrollment', 'within 6 months of pre-treatment', 'within 8 weeks of Visit 1.|Any use', 'before enrollment||Presence of significant', 'within the last 6 months.|Conditions', 'at the time of screening.|Pharmacological', 'within 48 h before and', 'at least 90 days after the last medication', 'within the preceding 14 days|Any condition', 'within 28 days before participating in this study|Long-term unhealing', 'at time points indicated', 'within the last 6 months.|Subject', 'at least 6 months after discontinuation', 'throughout the study period||', 'for at least 2', 'within 48 hours prior to Step 2 entry.|To avoid pregnancy', 'within 30 days prior to Visit 1/Baseline.|Subject', 'at the time of signing the informed', 'in the last 2 years|History', 'within the past 7 days|Signs', 'any time prior to Visit 1 or', 'during this period.|Subjects participating', 'within 3 months before the study', 'within 14 days prior to study intervention', 'before 60 years', 'is mandatory.|Sufficient restorative', 'within the past 3 months|Received', 'within 4 weeks prior to enrolment|Non-Decompensated', 'within two months prior to the study', 'at the day of signing the informed', 'within 14 days of study therapy|IMiD agent therapy', 'within 3 months before study drug', 'within 18 months prior to signing of the', 'at least 3 months before U16 infusion;|Life expectancy', 'during any sexual contact', 'at least 3 times a week.|Be willing to provide informed consent', 'previously received the following lines of systemic therapy', 'admission history', 'prior to study treatment administration', 'at least 4 weeks prior to screening||', 'until 3 months after the last dose of study vaccine;|Participant', 'within 28 days.|Any use', 'in the last 8 weeks|To', 'in the six months before screening', 'within the last five years|Participants', 'within the first week of life,|major congenital malformations,|chromosomal syndromes,|inherited', 'within 24 months prior to Screening', 'within 12 weeks from the last dose of', 'within 1 month;|Mean Gastroparesis', 'up to 4 cups per day)|Having', 'for at least 12 months before signing the informed consent', 'at least 1 prior wAIHA treatment regimen.|At least one sign', 'at least 7 days before the first dose of study treatment.|Spinal cord compression', 'less than 4 weeks from study entry', 'within the past 5 years.|Orthopedic', 'within the 3 mo prior to Visit 1', 'for the first time|ASA', 'during the clinical screening visit', 'for at least 14 days prior to first dose of study intervention', 'more than 12 months ago', 'within 48 hours of onset of event.|Current', 'within the last 3 months|Presence', 'during the last two weeks of the study run-in phase', 'at time of inclusion', 'during four of the past six', 'preceding 24 consecutive months)|Patient must', 'within the last 5 years.|Severe kidney impairment.|Aspartate aminotransferase', 'for 30 days after receiving the last dose of the study drug', 'within 14 days before the start of trial treatment.||Table', 'within 3 months before enrollment to exclude', 'after treatment|who were practicing yoga', 'in next 6 months.|-', 'within 7 days of leukapheresis', 'after at least 7 days without growth', 'longer than 4 consecutive weeks', 'during the month prior to the study;|Participating in a structured', 'within the past 30 days of screening', 'within 30 days prior to consent', 'throughout the Double-blind Treatment', 'in the past four weeks', 'more than one year', 'within 7 days prior to enrollment.||21', 'in the last 5 years|Back', 'more than 6.0 Diopters', 'for the duration of the study.||', 'within 28 days prior to the 1st dose of CHS-006', 'within the past 3 years.|Subject', 'within the last year|History of/', 'within the study period', 'in the last 5 years.|Pregnancy', 'previously treated with redifferentiation agents', 'within the past 3 months.|Pregnant', 'left half of the body.|Participants should be able to walk without support for 10 m.|MMSE score', 'within the previous month', 'at least 4 weeks on the same anti-HIV medications', 'within 24 hours treated', 'within 14 days before the first dose (Daily dose', 'within the past six months prior to Screening|Current enrolment', 'more than 5 times every two', '90 days prior to screening|Has', 'within 2 weeks before the first dose of study drug.||Active', 'for the last 15 years.|Report', 'throughout the study period.|Planned intervention similar to those abovementioned', 'within 4 weeks prior to', 'for at least 30 days prior to inclusion after medical advice;|Possibility', 'period of time after surgery|Patients', 'at least 3 months||', 'within 2 weeks of the first dose of study intervention', '14 days after they have completed their course of oral steroids', 'within 2 weeks before the first dose)|Serum creatinine ≤ 1.5 1.5 x upper limit of normal (ULN)', 'Rehabilitation Department of our university', 'within the last two months', 'before being treated', 'within 12 months.|Patients', '7 days prior to the start of the intervention.|Pregnant', 'within the past 12 months of study entry|History of', 'on 24 hours ambulatory', 'at room air||Present', 'during the 4 days prior to the start of the investigation', 'within 3 days prior to the first dose of study treatment.|Currently', 'within 2 weeks of C1D-7.|Patients', 'within 30 days prior to treatment.|Open chest surgical repair', 'within 30 days prior to enrolment.|Positive for', '15 weeks', 'at the time of screening.|Any CAR cell therapy', 'within one month prior to initial screening', 'more than 6-months', 'for 4 weeks prior to the day of screening of the metformin', 'within 4 weeks before the first administration;|Any type', 'in the past 3 months|exercising', 'for at least six months after the end of the FLA', 'in the last 5 years prior to IMP treatment start', 'at time of consent|Body mass index', 'during the taste test', 'within 12 weeks prior to screening.|Prior treatment', 'within 4 weeks prior to enrollment|Radiation therapy', 'within 3 years prior to study vaccination.||Have', 'within 6 months prior to treatment', 'within 3 weeks prior to start of study treatment|Clinically significant', 'at the involved levels', 'at the time of informed consent per Investigator assessment.||Adequate organ function', 'hospital Admission to hospital from emergency department||', 'within 28 days prior to first dose of study treatment.|Live', 'more than 4', 'within 30 days|Active', 'within 1 month prior to the', 'greater than 5%', 'within five years|Severe physical disability', 'within 4 weeks before first dosing.|Had', 'within the past 3 years.|Bleeding', 'within 28 days before the first dose of study treatment', 'following the', 'during the trial|There is central nervous system', 'less than 1 week before registration|Patients', 'for at least 30 days after the last dose of study treatment', 'during or within 24 hours of study days', 'prior to starting the diet.|On low carb', 'in the past 3 days', 'for at least four', 'within 30 days prior to the first dose of trial therapy', 'during the study(other than the study products).|Previous use of', 'last 3 months prior to study start (date of treatment', 'within 7 days.|History', 'at the time of E-CPR use|Patients', 'within the past 5 years.|Any other reasons', 'for:||Approximately six weeks', 'in the month prior to study screening.|Blood loss', 'during the next two years -|breastfeeding|consuming', 'within 24 months of the baseline visit', 'prior to the first treatment', 'within the 6 months|Diet free', 'within two weeks prior to the first dose of trial therapy.|Administration of a live', 'within 3 months before study', 'at time of consent.|Fit for endoscopic therapy', 'at the time of signing the ICF;|Able to understand the study procedures', 'at least 3 days prior to the first refraction used to establish stability.||Two consecutive manifest refractions', 'in the month preceding the study,|Taking', 'more than 30 days prior to the study', 'after the first cycle of', 'in the past three months)|Not participating', 'within one week prior to surgery', 'within 7 days prior to entry', 'Obstetric', 'during the test.|Known', 'Within 7 days prior to initial drug administration', 'for at least one month before study enrollment.|Active pregnancy', 'within 7 days of the first dose of', 'within 1 year after trial', 'within 4 weeks prior to screening;|Have', 'more than 12 months after the end of adjuvant endocrine therapy', 'within 48 hours of surgery|Subjects', 'in less than 3 months|Other', 'within 4 weeks from the screening visit', 'for the last week', 'within 2 weeks prior to the first dose of', 'at the time of screening;|Hyperthyroidism', 'at least 4 prior', 'within 2 years before the first dose of study', 'within 4 weeks prior to the first dose.|Subjects with active', 'within the duration of the trial', 'within 12 months prior to Day 1 of Cycle 1|History', 'at the time of prostate', 'within the past two months.|are taking', '48 hours prior to the expected initial application date to PSV', 'within ≤ 2 years before treatment', 'within one year prior to study entry', 'for at least 6 months after completion of adjuvant treatment', 'in the last 6 months|antiaggregant', 'within 180 days before randomization||Patients', 'in the last month|Women', 'at the time of investigation', 'within 3 weeks of study registration', 'at doses equivalent to > 10 mg', 'within 28 days before enrollment', 'within 2 weeks of the screening visit', 'post 8 rounds of intralesional steroids', 'within 6 months prior to screening visit', 'during 3-4 weeks prior to treatment', 'at the time of enrolment|Has', 'at time of screening.|Has', 'within 90 days prior to first study vaccination.|Participants', 'within 4 weeks before first dose of study drug', 'after phase 1 of', 'within the past month;|Those', '14 days prior to the start of baseline visits', 'within 14 days prior to the first dosing', 'within 14 days prior to initial administration;|A history', 'At least 6-months', 'at least 3 months from completion of blood or marrow transplant', 'in the 12 months prior to study treatment|Previous use of', 'in dose', 'At least 6 months of diagnosis', 'within the last 7 days prior to the start of the study', 'continually ongoing and retrospective studies', 'within 12 months prior to screening.|Have medical', 'during the past 6 months|Patients', 'during the six months period before the pre-study', 'within 30 days prior to enrollment.|Immunosuppressive medication', 'at least 3 nights per week and last for at least 3', 'within 5 days prior to dosing,|Evidence of', 'in the next 6 months|Planned travel across time zones', 'at the time of the index operation|no', 'during and within 1 year after trial completion', 'at least 3 months post HIV', 'least half of the time with the parent involved in intervention.||Exclusion criteria', 'in the last 3 months|The child', 'for at least 3 months|No glucocorticoid therapy', 'while on study medication', 'in the last two months||', 'during screening may participate in the study', 'during the study period and within 3 months after the end of the study period;|Patients', 'at time of enrollment|Normal OCT', 'in the past 3 months;|5', 'throughout the study.||', 'in the original surgical specimen|Presence', 'within 6 months prior to the study', 'before treatment|A history of', 'up to 18 years|patients', 'during the abdominal liposuction phase|Patients', 'within 3 years before screening', 'within 6 months prior to randomization|Serious', 'during the first dressing;|Affiliated to a social security scheme;|Having signed a free', 'during the current episode', 'at least two prior standard-of-care treatments', 'within 8 weeks prior to screening', 'in the past six months||', 'before the first administration:||Neutrophil count (', 'within 7 days of', 'within 3 months prior to treatment.|History of intravitreal', 'during the trial period and 120 days after the last dose of the test drug', 'at the time of signing the informed consent.||Have one of the following', 'before the first dose of study', 'within 3 months;|History', 'after hip fracture|can use standard implants||', 'within the last 2 years for their clinical care', 'within 3 months of inclusion|Risk of major amputation', 'previously received up to one line of', 'at the time of inclusion|Participants', 'during the 2 months prior to', 'prior to receiving the first study drug dose and continues to have', 'within 1 year after infusion should', 'within the treatment area', 'for three months thereafter', 'for at least 6 months duration', 'during the past four weeks;|Use of vaginal', 'at least 3 mo before entry', 'within 2 weeks before the first dose of study treatment.|Subjects', 'within the last 12 months||Confirmed positive', 'within 2 weeks before the baseline assessment.|Patient Health Questionnaire-9', 'in the last month before enrolment,|cognitive decline', 'more than 200%', 'with 28 days before the first medication', 'in the past 2 years', 'last time receiving the investigational drug did', 'over the previous 24 months', 'within 2 months of Randomization)|Subjects', 'at week 0', 'for at least 2 weeks after participating in the study', 'at screening measuring ≥320 µm', 'within past 12 months of screening', 'prior to first dose of study treatment.|Prior malignancy', 'prior to the first', 'within 28 days prior to the first dose of study drug', 'during the trail.|COVID-19 PCR test should', 'within 4 weeks week prior study|Periodontal treatment', 'within 12 months prior to screening', 'after 4 weeks', 'in the upper limb;|central neurological lesion;|diagnosed psychosis', 'after Step 1 entry', 'within 3 months of the study.|Subject', 'within 1 month prior to screening', 'throughout the period of taking study treatment', 'at time of enrollment|Pregnancy', 'at least 3 months.|Participant', 'more than 3 times per day', 'within 7 days prior to the first dose.||4', 'during the current depressive episode|Transcranial magnetic stimulation', 'since 6 months', 'for 3 months prior the', 'during the study;|Alcohol', 'in the past 30 days|A', 'at the time of screening).||Cardiovascular diseases', 'in the past 2 years|Regular alcohol consumption', 'within 14 days prior to study treatment administration', 'within 6 months before signing the ICF.|Use of', 'in the previous 12 months', 'for at least 1 week prior to screening', 'in the three months prior to screening', 'DORIS|Ophthalmologic evidence of', 'at the time of enrollment.|Subject or their Legal Authorized Representative (LAR)', 'medical history reported', 'for recurrence.|Must consent to allow', 'after initial treatment for', 'at Screening for HIV 1 or 2 antibody', 'prior to study enrollment|Hemodynamically unstable pre-enrollment|Severe', 'recent (6 mo', 'within one month after the initiation of first-line', 'within 28 days prior to initiation of study treatment|Clinically significant', 'before the first administration.|Those who need', 'within 24 hrs of check-in', 'within the past 2 months.|Individuals', 'during study treatment|History of severe', 'within the past 1 year.|Patients', 'within 30 minutes post-partum', 'for at least 12 consecutive months with follicle-stimulating hormone (FSH)', 'during the study period|Diagnosis', 'at screening or Day -1 for substances of abuse', 'within the preceding 6-months;|Have', 'prior to first study treatment|Contraindication', 'within 4 weeks prior to registration -||Exclusion Criteria', 'during the screening phase|Blood clotting disorder|Tendency', 'at least 3 days', 'at least twice a week', 'within 1 month prior to the first dose of study drug|Congestive', 'within 6 months before the first medication;|Those', 'before starting the program', 'after diagnosis', 'for 6 months after the last dose of ifosfamide', 'for at least six months after the end of the maintenance treatment.||', 'within 1 month before and after IP immunization.|Female', 'in the last 90 days|Positive', 'for 72 hours prior to', 'prior to standard-of-care surgery', 'within the last 2 months', 'within 12 months after treatment', 'over the past 3 months)||', 'within 4 weeks prior to signing the informed consent；||Any of the following', 'within 15 months prior to enrollment.|If < 16 years', 'within 3 months before administration', 'in the month leading', 'within two weeks of the scheduled date of administration of DWP16001', 'within 14 days prior to C1D1).|Haemoglobin', 'within 6 months before screening.|With other medical', 'during entire', 'within 6 months prior to screening.|History of', 'previous one year', 'within the last 12 weeks', 'for five years.||Exception', 'during the 3 months prior to randomization', 'within 30 days prior to randomization.|Individuals', 'after taking apixaban.|Patient satisfies two or more dose reduction criteria', 'for 5 years', 'within the 24 hours prior to V1;|damaged skin', 'prior to radical surgery;|Normal marrow function', 'surgical history for previous 6 months', 'in the last 12 months|Patients', 'within 28 days before first administration of study drug', 'within 6 months prior to randomization|Unwillingness', 'within the limits presented in', 'within the first year follow diagnosis|performance status', 'within 6 weeks', 'at least 2 weeks prior to the start of the study', 'at pre-balloon placement evaluation.|Acceptance of responsibility', 'induced', 'within 4 weeks of the first administration of the IP.|History of any', 'within 7 days prior to the first dose of study drugs', 'for at least 6 months after the administration of IMP.||Medical histories', 'at time of randomization|Patients', 'past 24 months prior to Screening Visit 1.|Airflow variability in clinic FEV₁', 'within 3 months prior to study vaccine', 'no more', 'within 72 hours of the intended', 'prior (', '3 months after treatment shows', 'more than 15', 'within 4 weeks prior to the start of PYX-201 treatment', 'at the time of pre-examination|Child', 'at study entry.|Imaging-documented measurable', 'within the last 7 days|Patients', 'during 2013/01/01 to 2020/12/31||', 'within 2 months prior to screening', 'after the last dose of study treatment.|The participant', 'within 30 days prior to Week 0 Visit', 'while receiving', '6 months after last dose of the investigational medical products', 'within 10 days prior to screening|Malignancy', 'at any time prior to inclusion', 'in the last year.|Living with a smoker', 'prior to starting study intervention|Has', 'within the past 3 months.|Have', 'in the last 6 months|History', 'within 48 hours of burn|more than 20%', 'during the screening period examination.|History of', 'prior to receiving the first dose of study drug', 'previous caesarean section|No', 'between screening', 'at least 6 months after the last trial treatment.|Those who', 'at time', 'for at least one month|Subjects', 'for the first time Patients', 'during the last six months|Pregnant/lactating', 'continuous 8-weeks', 'within 30 days prior to day 1 of protocol therapy).||If the urine test', 'at any time during the study.|WOCBP with a', 'within 5 months prior to', 'after at least 1 prior systemic therapy', 'within the last 90 days', 'within 2 weeks before randomisation|allergic to any of the medicines', 'after two attempts', 'within the following ranges', 'during study conduct', 'previous four 4', 'within the past 1 year;|Neurological', 'within 6 weeks prior to study', 'within 1 day prior to the date of conception', 'within the last one year.|Any other', 'within 3 months prior to randomization', 'for prior 1 month', 'in the last 6 weeks|Unstable COPD', 'before first study drug', 'during the 2020-2021 season', 'on the evaluation site', 'at the intervention site|Those who weigh', 'past one month.||', 'past year', 'while attempting', 'for 12 consecutive months', 'in the three months prior to receiving the study vaccine;|Patients', 'diagnosed within 3 months of enrollment', 'for 3 months after vaccine administration', 'diagnosis|Prior', 'at least 2 individuals', 'within the first 24 hours of randomization', 'within six months prior to administration', 'at screening.|Surgery', 'within 1 year|Acute liver disease', 'during the study period|Written informed consent', 'in the past 3 months|Other', 'within the last 3 months|eGFR<45ml/min|History of oral SGLT2i|Estimated survival period', 'within 3 months before enrollement', 'during the intervention period that prevents them', 'during the duration of this study|BMI', 'during the first six months after surgery', 'within 2 weeks prior to study Radiotherapy;|Participation', 'prior to the actual intervention.||B', 'within the previous month and foreseen', 'within 28 days prior to the dose of study drug.|Is', 'where the electrode dressing can be placed properly.|The wound', 'within 3 weeks prior to administration of the study drug', 'within the past year.|Participant', 'more than 14 days', 'at Screening and Day 1.|Participant', 'within 30 days prior to enrolment.|Seizure disorder', 'for at least 5 consecutive', 'in the 3 months before study', 'within 3 months prior to time of screening.|Plans to', 'within 4 weeks before first dose of study treatment', '7 days prior to first dose of study drug', 'within 2 weeks before enrollment', 'within 3 months prior to Screening|Participation', 'during the 90 days before screening regardless of medical records.|Treatment', 'for 4 months after the last dose of', 'within 12 weeks of Visit 2/', 'within 12 months before consent', 'at the time of informed consent;|In-patient', 'in the past 3 months|History', 'within 6 months of the screening visit.|The', 'during the study period|Mental incapacity', 'time history of', 'during Cycle 1.|Investigators should review the vaccination status of potential study', 'at the time of cycle 1 day 1', 'orally.|At least 1 measurable', 'at least 3 months before participation', 'in the last 12 months before screening.|Life expectancy', 'within 30 days prior to the first administration of the study drug', 'within the two last years before study inclusion)|Active autoimmune disease|Active chronic', 'within 24 months prior to screening', 'within 6 months prior to enrollment|Difficulty with', 'for 6 weeks prior to visit', 'within 3 months prior to the start of treatment', 'before enrolment and either:||•', 'within 180 days prior to the screening visit.|Personal', 'within the week prior to screening;|Patients', 'within the 30 days prior to treatment initiation;|Patients', 'within a specified time period prior to receiving the study drug:||Major surgery', 'at least 1 of the following conditions apply:||Not', 'during their participation in this clinical study.|Can communicate', 'prior to study vaccination', 'after receipt of CD19-directed therapy.|Measurable', 'in the previous 4 weeks', 'within 4 weeks prior to the start of study dosing', 'within the past week.|Subject', 'within 4 weeks prior to the first dosing', 'history group)|The participant', 'for 12 months after the final dose of', 'within 1 month prior to treatment initiation.|Evidence of', 'within 30 days before', 'prior to randomization.|', 'at one time, the subject can take dissolving tablets', 'within 7 days of onset', 'during the 3 months before inclusion', 'At least one', 'within the last 12 weeks|Physical health conditions', 'within 14 days)|No', 'in the last 30 days|Active', 'within 7 days of determining eligibility|Hemoglobin', 'in the 3 years before study entry', 'during stance', 'in the 3 weeks following last trial vaccination', 'within 6 months prior to the first dose.|Subjects with severe', 'during/after most', 'within 14 days prior to the start of PYX-106', 'within 6 months prior to the study enrollment|unstable angina', 'emergency surgery|Need', 'throughout the investigation,|Acute wound', 'for at least three months post-onset|Prescription', 'Medical University of', 'within 1 week of screening', 'within 4 weeks before randomization.|long-term', 'in the past 12 weeks|Poor understanding of the spoken', 'within the past 10', 'during the first 28 days after Day 1.|History of', 'at both Screening', 'within 3 mo|Current', 'during the screening period and before the first administration> 38.5℃', 'less than 6 months||', 'within 6 weeks prior to screening', 'planning to give birth outside', 'during the 6 months prior to screening', 'in the 6 months prior to screening;Heart disease', 'lifetime history of', 'during the conduct of this trial until the End of Treatment Visit|Participants', 'during the study.|Administration of', 'within 5 years prior to screening', 'clinical evaluation and imaging of the retina|History of', 'within 3 months prior to the initial dose of the investigational drug.||Myocardial', 'Glenrose Rehabilitation Hospital (Edmonton, AB', 'prior to lumbar puncture', 'in the last one week;|Have', 'in the past 3 months.|Subjects', 'at the time of screening.|Subject', 'preceding 3 months|Currently participating', 'at least 14 days.|Patients', 'within past six', 'within two weeks', 'within 10 days prior to testing):||Absolute neutrophil count (', 'within 14 days prior to the first administration of study medication', 'within the past 2 years|Ongoing', 'at the time of relapse', 'for 1 week following the study treatment.||Psychiatric illness/social', 'within 4 weeks before first dose;|Patients', 'in the past 3', 'in the last month.|Radiation therapy', 'within 7 days prior to initiation of study', 'within six months prior to screening', 'at the Screening visit.|Participants treated', 'within four years', 'within one month of study treatment|Hyperbaric chamber sessions scheduled', 'shorter than 7 days', 'other day', 'in the past four weeks to six months', 'within the last year prior baseline visit', 'medical history of:||Central nervous system', 'within 30 days prior to the day of enrollment', 'within 4 weeks prior to administration of pembrolizumab.||21', 'at least 6 months prior to signing informed consent.|Other than the medications explicitly stated', 'while receiving study treatment', 'past 12 months).|We will also exclude individuals', 'within 4 weeks prior to first dose of study treatment', 'prior to surgery|Previous surgery', 'within 60 days of Screening', 'at the time of testing|Participants', 'at the time of the collection of the phenotypic data.|There', 'in the month preceding the', 'within 4 weeks prior to the first dose.|Patients', 'during the last 30 days prior to and', 'at the time of the study|Not', 'within 4 weeks before the first dose', 'pre-term delivery', 'within the past 3 months.|Females', 'at the time of consent|Karnofsky scale', '≤2 weeks prior to initiating protocol therapy.|Previous', 'more than 7 days', 'within 2 weeks of study', 'during the trial period and 8 weeks after the last administration of the trial drug;|The subjects voluntarily joined the study', 'within the past 24 months.|Those', 'for three months after the last administration of alectinib.||C. Male', 'within approximately 12 months', 'within 7 days before the investigational product administration', 'within 24 weeks prior to registration', 'for at least 4 weeks prior to enrollment', 'within 12 weeks of cell therapy.|Presence of known', 'within 56 days prior to the initial dose of study medication|Non-steroidal anti-inflammatory (NSAID)', 'within the past two years|history', 'since less than 3 weeks', 'more than 14 standard units per week', 'within 30 days prior to the first IP administration.|Exposure to prescribed', 'in the last 3 months prior', 'within 4 weeks before administration of the study drug.|The participant', 'within three months of the', 'at least 30 days before Visit 1 through visit 26w (26 weeks', 'within 6 months before signing the informed consent form;|Participated in any other clinical trial within 30 days before signing the i informed consent', 'over 7 days', 'for 1 year following JWCAR029 infusion.||', 'at least 4 weeks prior to the start of the screening', 'for three consecutive days', 'past-month suicide attempt||', 'at time of enrollment|Able to feed orally|Family intends', '2 weeks prior to the screening', 'during the study.|Severe', 'in the lung parenchyma that the clinician feels cannot be accessed successfully using the', 'in the past four months||', 'in next 4 days.|Terminal', 'within 60 days of baseline', 'at the time of informed consent|Diagnosis', '1 month after the last visit', 'a:||Clinical history of T1D', 'within 1.5 times the upper limit of normal values', 'for any reason', 'within 28 days before the first dose of study', 'within 8 weeks from screening', 'during the 6 months following the end of treatment', 'in the past 12 months|Speak', 'at any time,', 'within one month prior to the start of the study', 'during the current', 'in the past 1 month.|Laboratory examination of coagulation function should show', 'within the our hospital system.||', 'within the range 18.0 and 29.9 kg/m^2', 'at least 6 months.|Shoulder pain', 'within 2 years prior to entry into the study', 'within 30 days after the last administration|Those who are infertile', 'within the 3 months prior to enrolment|Other intra-articular injections', 'within 2 weeks before the first dose', 'during the time it is worn', 'last 24 hours prior to randomization|Elevated', 'in the previous 6 months|Previous', 'last 48 hours prior to baseline study assessment;|Use', '1 at time of first dose', 'pre-dialysis BP', 'at the day of signing informed consent||Histologically', 'throughout study enrollment|Safe to exercise', 'within 4 weeks prior to initiation of study treatment', 'at least 6 weeks after the end of vitamin B12', 'within 30 days)|history', 'within 6 weeks prior to Screening', 'within the next hour', 'before inclusion', 'in past 12 months', 'at time of starting deucravacitinib.|Patients currently enrolled in another investigational study.|Patients', 'after the previous administration of any vaccine|History of', 'within 3 years before the first dose of study drug', 'in the prior 4 weeks', 'within the last 5 years except', 'before the first dose of study treatment.|Patients must not have', 'within 28 days before enrollment 12-lead electrocardiogram no', 'history (3)', 'Wine 30mL', 'at the time of screening;|pia meningeal metastasis', 'for at least 2 years', 'during the 6-month', 'within 6 months prior to enrollment|late first-line treatment', ""last two years.|Alive|Patient's preferred"", 'Within the', 'within two weeks prior to Cycle 1 Day 1.||Inadequate liver function', 'at time of surgical evaluation', 'after first-line', 'within the last 12 months;|Have', 'during study participation;|Willing to and', 'for >14 days', '3 months prior to screening - hormonal contraceptive', 'within 18 to 32 kg/m2', 'during the 6 month study period|Pregnant', 'prior to admission to the ICU|history', 'at time of admission|Current participation in another investigation drug', 'less than 1 pool', 'within previous 12 months of alcohol', 'within the past 1 month);|Night shift', 'at least 14 days prior to enrollment', 'over the past 3', 'in the past 1 year;|Consumption', 'more than 5 years ago', 'within the 3 months period prior to baseline;|Intraocular use', 'within 30 days prior to Screening', 'at the puncture site;|Subjects', 'within 14 days before testing.||White blood cells', 'within the 30 days prior to signing the ICF', 'previous 2 months.|No plan', 'within the previous 5 years|Autoimmune pancreatitis|Surgical removal of any portion of the pancreas||ii', 'for at least 2 weeks after completion of definitive therapy', 'within 5 years prior to screening.|Patients', 'at the time of the study vaccinations', 'during the follow-up study;|Currently participating', 'during the study period.|No', 'past six months', 'at thentime of cardioversion;|Acute myocardial infarction period', 'at least 28 days before the first dose of study treatment', 'at the time of SARS hospitalization', 'within the past 3 months|Patients', 'during the length of duration of the CT-scan.||', 'at least 1 year', 'within 2 weeks prior to initial dosing', 'in the year of recruitment|The subject', 'exceeding the unresolved', 'within 2 weeks prior to initial', 'during the screening period|Infection', 'for at least 2 weeks before the first dose)', 'prior to the', '3 days', 'at time of screening', 'within 12 months prior to Screening Visit 1', 'during active adjuvant treatment', 'within 3 months after the examination', 'in the 3 months prior to screening;|Those who are', 'in the past.|Febrile illness', 'within 28 days prior to trial', 'within 3 months prior to Visit 1|Diagnosed', 'within 6 months of study Day 1|Pericarditis/clinically', 'within six months.|presence of a history of', 'within 24 months before consent', 'for at least 6 months after tooth extraction', 'within 30 days or 5 half-lives', 'within 6 months prior to the screening.|LVEF < 50%|Blood oxygen saturation', 'within 28 days prior to registration.|Participants', 'during the year prior to the', 'within 1 month or', 'within the last year|Patient', 'within 4 weeks before dosing|Intake', 'during the initial Axi-cel treatment', 'for the correction', 'within 30 days of study start', 'at the time of surgery.|Prisoners', 'in the last six months|Having dental', 'within 14 days before inclusion', 'at the designated time points.|11', 'within 4 weeks prior to Screening|History', 'within 8 weeks after the last', 'in the last 3 months;|PHQ-9 score≥20', 'within 90 days|History of', 'screening|Personal history of pancreatitis|Current/planned', 'within six weeks|Women', 'at the time of screening.|Radiotherapy to multiple sites within 3 weeks before start of protocol treatment', 'at least 28 days from', 'within 3 months prior to Screening.|Contraindication to the use of the wrist-worn telemetry device', 'prior to entering the study', 'throughout the period of sample collection.|Heavy', 'within the last 3 months of study enrolment', 'within 8 weeks prior to the first dosing of the test drug;|Subjects', 'continue to follow REVLIMID', 'at the time of first administration of lymphodepleting chemotherapy', 'during the duration of the study', 'at least 1 year following shunt repair||WSPH Group 3 PH', 'within 60 days of study vaccination.|Have', 'at Day 1 visit|Successful completion of the Optimization period based', 'during the follow up were', 'after stable treatment).|Serious chronic', 'their first hormonal treatment', 'after the first line of therapy|Age', 'within 1 hour of birth', 'during the study duration|Treatment', 'for 4 weeks after initiation', 'past year.|Positive', 'within the past 12 months.|Uncontrolled', 'in the past 5 years|Uncontrolled', 'within 28 days.|Major surgery', 'prior to randomization.|Participant', 'at least 3 months after receiving the last dose of the vaccine', 'within 1 week prior to enrollment).||Bone marrow function', 'more than 4 weeks prior to the first dose.|Symptomatic congestive heart failure', 'within one month prior to administration of the study medication', 'at the time of screening;|Active', 'within the 6 months prior to the first dose of study drug', 'personal past', 'more than 15 g/L', 'within 5 years prior to the day of screening', 'at least 6 months after the last dose of study', 'within 5 months after the last', 'for 1 week prior to', 'within 7 days prior to the first treatment.||', 'within the 12 months prior', 'within 3 months after the last dose of study drug', 'within 3 days before the first study drug administration', 'at time of informed consent.|Patient', 'within 30 days of the study procedure.|Rutherford classification', 'past 3 months', 'while on trial', 'at least 2 months', 'in the last 3 months|Having', 'during the study period;|18', 'within 4 weeks prior to the prestudy', 'within the last 2 years|Insulin-dependent', 'prior to low intensity activities', '6 weeks prior to start', 'in the past 4 weeks|History', 'within 2 weeks before receiving IMP', 'within the past 3 months|History', 'at time of registration||Adequate excision', 'last onset time of TIA', 'more than 5 years', 'at the time of signing informed consent|Diagnosis', 'at least 2 weeks prior to randomization', 'for at least 5 years before signing the informed consent.|The presence', 'within the past 12 months|concurrent enrollment in another research study judged by the study investigators', 'within four weeks', 'during the participation of clinical trial.|Those who agrees to exclude the possibility of pregnancy', 'within 7 days without', 'throughout the study period.|Use of', 'descending colon).|Absence of', 'lasted for three months before first oral dose', 'within one year of treatment|Pregnant', 'in the 3 months prior.|A', 'for at least', 'within 4 weeks prior to initial administration of the test drug (note:', 'within 90 days prior to screening;|3', 'within the past 30 days', 'at baseline and', 'within 14 days.|Local glucocorticoids', 'within 30 days prior to the first', 'within 48 hr before dosing', 'within 4 weeks of investigational agent injection.|Active infection', 'include 9 months', 'within 2 weeks prior to screening until admission to the unit.|Performance of', 'at least 3 of the following five metabolic risk', 'within 3 years prior to first dose of study treatment', 'for less than 6 weeks', 'more than 3 times a week', 'for six months||Be', 'for at least 2 weeks', 'where the potential participant does not', 'within 2 years prior to the planned', 'at least 28 days after receipt of study', 'less than 4 months', 'within 2weeks before initiating study treatment.|Prior organ transplantation', 'within 6 months before enrollment.|Neck tattoos', 'within 30 days of assessment', 'during the past 12 months', 'for all screening/tests', 'out for external review', 'within 6 months prior to study.|Subject', 'within 14 days before the first dose of study drug.|Serious', 'within 2 months prior to dosing;|Has participated', 'at the time of the 12-month follow-up', 'within 10 days prior to the start of study intervention)|International normalized ratio', 'within last month', 'in the last 15 days|Poorly', 'transmission|History', 'in the past 12 months|For TGW', 'within 1 week from the screening visit||Individual', 'within three half-lives', 'within 3 months prior to study enrollment|Patient unable to walk|Patient who', 'within 28 days before the first study medication', 'in the last 12 months|Prospective study arm', 'within 72 hours before administration', 'for 28 days after the EOS visit.|Females of childbearing potential', 'within the 4 months prior to screening|Active', 'in the past 5 years|Regular use', 'within 2 weeks positive', 'before starting therapy.||Has a', 'more than 12 hours from the time of', 'during the study||', 'within the past 6 months.|Patients', 'during the study.|Have', 'for the past 6 months|Weight', 'within 7 days prior to first study intervention', 'within 28 days prior to screening visit', 'at least 4 months prior', 'separated by 2 to 6 months', 'at the time of informed consent.|Willingness to provide pre-and', 'before conditioning', 'in the last three months.|Having', 'within 28 days prior to enrollment|For', 'at the time of informed consent.|Capable of providing written informed consent', 'within 28 days prior to and including the screening visit.|No chronic use of oral', 'within the past 13 months', 'for at least 30 days after the last dose of blinded investigational product.||', 'prior to the first dose of 18F-FPIA', 'in the last 5 years before the screening', 'during Screening', '1 drink = 5 ounces', 'since radomization', 'in the past 3 months.|Persons', 'within 7 days before enrollment.|Those', 'in the month prior to or up to 9 days after the encounter at the participating practices||', 'for 12 months after last dose of epcoritamab', 'last for 24 consecutive months', 'previous history of any mental problems', 'over the last 4 weeks', 'for 1 month', 'at the baseline assessment|history of chronic GI problems', 'at home|Be able to read', '≥ 8 weeks', 'within 3 months before the first study drug administration', 'at a dose ≥ 10 mg per day of', 'within 28 days prior to Step 1 registration|For', '1.1)|No previous systematic treatment', 'throughout the extent of the study term|Female', 'at screening.|History of threatment', 'within 4 weeks prior to the dosing of the study drug', 'within 30 days of the first study intervention administration on Day 1', 'during the study period；|Alcoholics，or', 'prior to trial enrolment', '< 6 months before inclusion', 'within 7 days before blood routine test', 'in the 3 months before', 'during the sampling', 'at least 5 Years', 'within the last 12 weeks prior to randomization', 'at time of study entry.|Statement of ability to take oral medication', 'more than 3 months', 'prior to the date when they', 'during the 7 days prior to treatment;|For', 'within 1 year before the first dose', 'at the time of signing informed consent and assent|Diagnosis of T1D within 100 days of randomization.|Positive', 'for the effectiveness', 'at the time of signing the informed consent);|ECOG score', 'within 14 days prior to the first dose of trial', 'within last 2 years', 'at time of radiation', 'within three months;|Patients', 'within 3 months of Screening.||Participants', 'at screening;|with the classification of KDIGO', 'during the clinical screening', 'at time of the first study blood draw|Patients', 'on the gynecological examination', 'during the inclusion', 'within 30 days before the start of study', 'within 1 month|Non-English speaking', 'within 7 days prior to first dose of study treatment', 'during the 30 days before screening.|Prior', 'in the past 24 hours|Known', 'for 1 year', 'for at least 3 weeks prior to study treatment', 'within 4 weeks prior to study screening', 'in the last 1 month', 'for at least 4 weeks prior to the screening period and should', 'within 14 days before first dose of study treatment:||Absolute neutrophil count (', 'at the time of enrollment|Weight', 'within 3 months prior to screening.|Coagulation', 'less than two weeks', 'following prior systemic therapies', 'after the last platinum-based', 'in the last 4 weeks|intradialytic', 'less than 6 weeks', 'in the past 3 months.|History', 'history in the past 1 year', 'before first study treatment', 'in the past 60 days prior to CAR T-cell infusion.|Participants', 'within 1 year of Screening', 'within 30 days|Combined', '<3 days of exercise', 'for 4 weeks after the administration of the investigational product', 'in 7th grade', 'at time of screening|History of', 'for the past year', 'within 4 weeks|Stable', 'within 14 days before the first administration):||Absolute neutrophil count', 'at least 72 hours after validation of the', 'preceding 12 consecutive months).|Ability to understand and the willingness to sign a written informed consent', 'within 6 months of prior', 'within 14 days prior to the screening visit', 'at least 7 morning', 'within 28 days prior to first dose of study drug.|History', 'in the last three years||', 'at the time of Screening.|BMI', 'within 28 days prior to the start of immune checkpoint', 'within 48 hours of', 'during the whole treatment period until 120 days after the last study drug administration', 'while on treatment.|Patients who received', 'during the 90 days prior to enrolment|Life threatening', 'within 8 weeks of Visit 1.|Do not', 'in the 6 months following treatment.|Diagnosis', 'within 48 hours before administration.|Surgical procedures', 'prior to enrollment|Any previous', 'within 60 days prior to the study vaccination', 'prior to surgical management|No contraindication', 'at least 7 days', 'within 180 days of initial dose', 'at the time of the PET scan visits|Allergic response to study radiotracers', 'within 4 weeks before the first drug use;|As', 'at time of screening|Underlying', 'prior to surgery', 'prior to stem cell infusion.|Disease Status', 'within 2 weeks prior to the first dose of study treatment|Patient', 'within 30 days prior to study enrollment.|Participant', 'prior to the first dose;|Female', 'during the pre-study phase', 'within 14 days before screening;|Those who had donated blood', 'within 24 hours before surgery', 'during screening tests', 'within 3 months prior to treatment', 'within 2 weeks before the first intake of study intervention.|Known tendency', 'at the time of dosing', 'within the 4 weeks before study drug', 'prior to first dose.|Eastern', 'within 1 week of the baseline visit', 'within 10 days prior to start of study treatment', 'after treatment for the condition', 'at the time of cardioversion;|Degree II - III', 'within an exclusion period', 'problems||', 'last 8 weeks', 'at least 2 previous standard', 'within 30 days prior to screening.|As a result of screening', 'in the past 3 months;|Those', 'in the last 2 years unless', 'longer than three months||', 'more than 20 degrees of mobility', 'within 4 weeks before inclusion|Subject treated', 'occurring < 6 week from enrollment Group', 'at the time of informed consent.|Histologically', 'within 5 days of enrollment into the', 'at time of clinical referral', 'within the last 4 weeks', 'in the last 6 months;|Coagulation disorders', 'within 3 months before screening;|At screening', 'throughout the study;|Use of', 'during each study period', 'within the first year', 'outpatient procedures', 'within less than 28 days prior to randomization', 'within 6 months of screening.|Participant', 'within the past 12 months.|Has', 'within 5 years before entering the study', 'within 1 month of Visit 1', 'prior use', 'within 7 days before first study treatment dose):', 'within 6 months of signing ICF.|Seropositive for', 'since first symptoms|Calculated Glasgow-Blatchford score', 'more than 48 hours', 'within 28 days prior to initiation of study treatment.|Resolution of all acute toxic effects', 'for at least 5 months after last dose of Isatuximab', 'at the time of consent|Prisoners|Unable to provide informed consent|Unable to read', 'within 2 weeks after the last dose of study', 'within the previous three months;|allergic to Lidocaine', 'more than 3 months prior to study enrolment;|At least two', 'within the last 12 months associated', 'at the time of inclusion|Imaging done', 'at least 2 months prior to enrollment|Signed informed', 'before the first dose', 'within 4 weeks prior to the first dose of GEC255.|Has', 'within one-month preceding study visit', 'at the start of PYX-201 treatment.|Major surgery', 'lasted for 3 days or more;|Use probiotics', 'in the last 90 days of treatment', 'in the last 3 years;|Vaginal', 'for more than 3 months FEV1/FVC', 'during the last 4 weeks.|Claustrophobia not coping with MRE examination.|Metal objects and medical devices', 'before enrollment and in trials administration', 'pursue eventual 3-stage ileal', 'at the time of the study|Capable of', 'throughout the entire course of the study', 'more than 3 months|Not', 'at least two years prior to screening.||', 'in the past 24 hours', 'within 7 days of Screening Visit', 'in the past one month;|Use', 'for less than 12 months.|Neurological', 'at least 3 months|Stable dopaminergic treatment', 'at least 3 months before study entry', 'during their intensive care stay.||', 'within 4 weeks prior to Cycle 1 Day 1', 'within the last 6 months of Baseline Visit.||4', 'within the last 2 weeks)||We', 'in the next 12 months', 'within 4 weeks prior to study Day 1 or', 'within 2 weeks prior to initial first administration', 'at time of trial enrollment', 'at least one episode of', 'at least 3 minor', 'within 6 months before the inclusion', 'within the first 2 weeks;|Patients', 'within 30 days prior to the first dose of study treatment', 'longer than 2 weeks;|(4', 'within 6 months prior to screening.|Participation', 'at the time of admission to the intensive care unit', 'during history', 'prior to testing,|A history of any', 'eligible for first line systemic therapy', 'for at least 24 hours.|Aware of people, time', 'throughout their participation in the study|Values of the complete blood count', 'at the study site).|Suffers', 'within the 1 month prior to Day 1|Planned contact lens use', ""improvement after more than 3 days' regular clinical treatments.||"", '<6 months ago', 'for 30 days after the trial ends.||', 'within 60d prior to participation;|Hematocrit <35%;|Pregnancy', 'within 1 week prior to the first administration of the study drug.|Antitumor therapy', 'within 7 days prior to initial administration', 'within 3 days prior to first dose of venetoclax.|Received live attenuated vaccines prior to initiation of study treatment.|History of', 'for at least half the days of the last 6 months|Back pain', 'prior to the study.||', 'within 30 days of first IMP administration', 'within the previous week with no major', 'within 4 weeks prior to study drug administration', 'within 8 weeks prior to randomization', 'within the next 3 months|Self-reported', 'within 4 weeks prior to the first dose of the study drug.|Have', 'more than 1 year before', 'at the time of treatment|The caregiver', 'within 24 hours of childbirth between 1/2012', 'longer than 12 months prior to inclusion', 'at least 8 years', 'after the last dose of investigational drug|Men', 'iteria:||Age 65 years and older', 'at the beginning of the pregnancy', 'in the next three months', 'at least 3 months before the screening', 'within 3 months prior to first dose of study treatment', 'in the first 5 years', 'in his first month', 'within 14 days of the start of SBRT', 'within the last 12 months).|Diagnosed with', 'last for 1 year||', 'before blood testing.||', 'within 2 weeks before Helicobacter pylori infection testing', 'within 12 months of Visit 1.|Unresectable cancer', 'within 14 days prior to the screening', 'less than 1.0', 'at least 6 months after termination of study therapy.|Subjects', 'within 5 years except', '6 days prior to the study|Allergy', 'during the last 6 months||', 'past ten years', 'lifetime history', 'within 90 days before screening irrespective of medical records|Have', 'Recently', 'since at least 3 months||Patients', 'in the first 24hours|Need for', 'within 14 days prior to routine blood tests;||Kidney', 'within 30 days prior to the first dose of SUBLOCADE', 'at the Department of Cardiology', 'no history of', 'before the first dose of IMP|Previously participated', 'within 24 weeks prior to randomization;|Treatment', 'within the last 12 months confirming the diagnosis', 'during the imaging steps.|Patient', 'within 6 weeks prior to randomization)|Known', 'prior to the acute event', 'in past 3 months|Regular participation', 'before hospital admission.|Chemotherapy', 'within 12 months preceding', '48 h prior to blood sample collection', 'prior to the first dosing day', 'eight weeks prior to the start of the study,|Those who had', 'throughout the study period until 3 months after the last dose', 'within 14 days before the test', 'within 14 days of ANC assessment', 'within the last 365 days', 'prior to starting', 'at all and 10 cm indicates the', 'during the study;|Pregnancy', 'more than 6 months prior to the date of study', 'between the supranuchal line', 'within 6 months prior to baseline|Women', 'in the year prior to receiving the', 'during this entire', 'within 3 months before this HSCT|Patient', 'Exclusions:||A history', 'within 10 minutes', 'at least 6-months prior to study enrollment.|Lack of', 'within the past 12 months except', 'at least one day', 'within the past four weeks;|Use', 'within less than 30 days before signing the ICF.|The confirmed', 'for 7 months after the last administration of the study drug', 'in the 24 hours before surgery|Patients treated', 'prior to participation in any study-related', '<30 days', 'within 1 month of study entry|History', 'at the Screening Visit.|Females', 'during the past 12 months prior to screening visit', 'palsy.|Under 4 years and over 18 years.|Participants', 'within the last 12 months|Use of medical', 'until 28 days after the last dose of ropeg.||Women', 'performed 3 months prior to inclusion', 'within the last 6 months;|Persistent', 'in the past 9 to 24 months before screening', 'at screening.|Positive results for', 'at the time of screening|Two paired measurements', 'prior to the initiation of the', 'within 72 hours prior to ED/UCC presentation|Suspicion', ""after more than 3 days' regular clinical treatments.||OR"", 'within 4 weeks prior to screening;|Use of', 'during previous month', 'within 7 days before the first study drug', 'within 30 days before screening.|Female', 'for at least six months;|with cognitive frailty', 'at least 2 weeks prior to study intervention', 'at time of study entry.|Willingness', 'within 12 months of study recruitment)|Renal replacement therapy|Systemic treatment', 'within 90 days prior to enrollment;|Within the last six months', 'within 2 weeks prior to the expected date of the first dose', 'three months on the same dose)|weight stable', 'at least 4 weeks prior to enrollment||rosuvastatin < 10 mg', 'at time of signing the written informed consent.||Patient', 'at MRI visit', 'within 1 month before the first dosing date', 'within 12 months before', 'within 1 month before the screening.|Those who are addicted to smoking', 'within one year post treatment|Any aortic valve repair', 'within 28 days prior to enrollment', 'in the 3 weeks preceding inclusion', 'within last 90 days prior to the index date|Individuals', 'history of a', 'within 6 months prior to screening|History', 'within 10 days of screening|Confirmed', 'prior to the first administration of IP.|Excessive intake', 'within 3 months before baseline', 'within 7 days prior to receiving study drug', 'in the last 12 hours', 'within 14 days prior to the first dose', 'prior to baseline;||15', 'in the past 6 months;|A change', 'within 3 days before randomization|Mechanical heart valve', 'within 5 years from the end of treatment', 'within 3 months prior to screening.|Blood donation', 'within 2 weeks of pre-treatment', 'within 14 days prior to randomization;|History of (non-infectious', 'within 3 months before screening;|The', 'in the first 12 months', 'over past week of 3 or more', 'within the 30 days before signing informed consent', 'up to 14 days after the last administration date of the investigational product', 'past 5', 'since the onset of symptoms.|Poorly controlled', 'before jaundice onset,|AST>50 IU/L', 'within four weeks before enrollment', '8-25 mm', 'any time prior to administration of the study intervention', 'at time of informed consent.|No', 'more than 8 weeks before inclusion', 'in the two weeks leading', 'within 6 months prior to enrolment.|The patient is', 'for at least 12 weeks.|No clinical treatment for neck pain', '3 days before randomization', 'within the past 3 years|Prior', 'within the range of clinical acceptability in medical history', 'over the prior month', 'within 10 days of screening|Two or more', 'in the previous 2 weeks', 'within 2 weeks prior to the first drug administration', 'within the last 14 days to', 'within last six months|History of', 'within 2 months before the start of the trial;|A serious', 'during this', 'more than one time per year.|Reported', 'less than 30 days', 'within the previous two weeks of', 'within 3 weeks of signing', 'at least six weeks after the date of the amniotic membrane transplantation procedure', 'within 28 days of starting study treatment', 'in the past one month', 'within 14 days prior to enrollment.|Serious infection', 'during the study|Subject', 'recent history', 'within 4 weeks of the first dose of', 'for at least 3 months after last study treatment occurred in the maintenance phase', 'within the 4 months before Visit 1 and must', 'within 30 days before the visit', 'during the 24-hour monitoring period|Individuals', 'within 4 weeks before single collection', 'within the last 14 days of screening)||Creatinine =< 1.5 x ULN', 'more than 6 months;|At least', 'in the last 1 month.|Using hormonal contraception', 'within 6 months prior to Screening', 'for 2 weeks before testing days and for the duration of the study|Able', 'within 4 weeks prior to the first dose of treatment.|Allergy', 'for ≥3 months prior to randomization.||Any subject taking', 'in the past 3 months;|Subject', 'consistently for more than 4 weeks may participate provided their routine', 'throughout the study||BCVA worse than 20/400', 'after the last dose of study intervention|Willing', 'for at least 7 days prior to baseline', 'within 1,5 D range', 'during the duration of this study', 'within 3 months before informed', 'within 14days prior to the first dose of investigational product', 'within 14 days prior to first cevostamab infusion', 'within the last 5 years|7.Not appropriate to be', 'within 1 month.|Subjects', 'during study participation|For', 'within 9 months of screening', 'within 7 days prior to first dosing.|Participant', 'within 24 hours of the end of surgery', 'in the 3 months before the clinical trial.|People', 'during the study period and within 3 months after the end of the study', 'after the tumor', 'during study period|Children', 'within 7 days prior to stem cell mobilization|DONOR', 'within 6 weeks prior to first administration', 'in 24 hours before', 'before induction|Difficult airway|Severe hepatic', 'during or within 12 months of the most', 'within 3 mo', 'at the time of enrollment.||Exclusion Criteria', 'within 3 months prior T1|Use of probiotics', 'during surgery|patient', 'within 7 days before screening|Those', 'for at least 3 months after the last dose of the study intervention', '1 Day 1', 'within 4 weeks prior to dosing|Less than 14 days after last acute disease|Volunteers', 'before admission to the', 'within 30 days prior to enrollment|Body mass index', 'in the 12 months prior to Screening', 'within 30 days of randomization', 'at time of non-opposition to participate to the study|Patient', 'at Month 6|Having access to the', 'within the 4 weeks prior to study initiation.|Current', 'within 3 days of the first administration of study treatment', 'within 3 months prior to check', 'in the past 3 months)|people who', 'throughout study participation.||Age', 'within 4 weeks of dosing.|Positive test for', 'within ≤ 2 weeks of first dose of study', 'within 30 minutes', 'within one year prior to', 'infusion time of <15 min|Phlebitis', 'during the 14 days prior to enrollment', 'within 12 weeks before the first administration;|Poor control of diabetes', 'within two weeks after the end of the trial（In', 'prior history', 'Recurrent', 'for at least 2 weeks prior to Visit 2/Baseline', 'at the time of consent.|Healthy', 'since time of biopsy||Currently on renal dialysis', 'within two weeks of', 'during the period of trial', 'Before cell reinfusion', 'within 14 days prior to Check-in', 'within 2 weeks prior to randomization', 'within past 7 days Musculoskeletal', 'within 6 months|Life Functional Status (', 'within the past 3 months|Factors judged to limit adherence', 'within 7 days of receiving the first dose of study treatment.||', 'at least 2 consecutive standard of care CT scans', 'after treatment|Patients', 'undergoing (first or subsequent', 'at admission', 'within 3 months prior to screening.|13', 'in the last six months', 'within the last year.|Subject is', 'for 12 months after the end of treatment.|Voluntarily agrees to participate', 'within 28 days of the first study vaccination', 'within one year of study enrollment||Planned', 'within 3 months prior study|Removable major prosthesis', 'within the last 12 months.|Evidence of TB infection', 'over 18 years old|Volunteer to participate in the program||', 'within 1 year of screening;|Patients', 'during the duration of the duration of the protocol', 'within one year of the study treatment|Current', '1 month after discontinuing', 'within 6 months of Cycle 1 Day 1', 'during the 16 weeks of the trial|Use of refractive/therapeutic contact lenses', 'within the previous 30 days.|Subject', 'in the last 3 months|Positive flexion rotation test (Rotation restriction', 'while on 1-4', 'monoinfection|At least', 'within the past 12 months prior to randomization', 'during Screening may', 'drugs|≥1 year before prison release (release dates', 'during the 14 days prior to vaccination', 'within 1 month from the Index date in accordance with the indication', 'during the follow-up', 'within the preceding 2 weeks.|Is', 'within the last 6 months.|Those', 'within 5 years;|Patients judged by the researchers', 'within 28 days prior to the first administration;|Participated in other clinical trials within 28 days prior to the first administration;|Concomitant', 'before pregnancy.|Urogenital infections.|History of', 'through 3 months following vaccine administration', 'within 7 days prior to the hospitalization period', 'at the time of the study|Aged 18-30|GAD7 score of 10', 'during the study period|Use of anticoagulants|Use', 'within 2 years of baseline', 'during study participation.|Patients', 'during surgery|less than 1 months|cyanotic', 'during the study|History of psychiatric illness', 'within 14 days of study entry', 'at the same time,', 'after first- and second-line therapy', 'in the last 60 days', 'one month or more', 'within last 6 months prior to', 'at the time of consent signature.|Voluntarily signed written informed consent form (ICF) before performance of any study related screening procedures.|Phase', 'in the case of', 'within 6 months prior to the first dose|Major gastrointestinal surgery', 'within 4 months before inclusion.||Positive', 'for 12 months after the last dose of study medication.|Participants', 'during the whole', 'at least three electrocardiograms(ECGs', 'within 60 days prior to enrolment.|Receipt', 'during the 5 years prior to randomization.|History of human immunodeficiency virus', 'within the last 3 months|Patients', 'within the previous 3 years with the exception', 'within 48 hours before the first administration of the study drug.||Vaccines', 'within 24 weeks before screening', 'within six months prior to enrollment.|Participant', 'within 6 months prior to enrollment;|uncontrolled', 'within 2 weeks prior to study Day 1 or', 'within 24 hours before the first dose of study intervention', 'within 28 days prior to receiving first dose of protocol-indicated treatment', 'within the prior 2 months is more than 2', 'within 2 years after surgery', 'within 28 days prior to enrollment||Participants', 'prior to the one', 'within the last 5 years', 'in the past six months|Having', 'in the past 3 months.|Participant', 'within the last 6 months|No', 'within 5 minutes).|In the opinion of the investigator', 'before 6 months of treatment.|Subjects', 'within the first 6 hours of life, continued for 72 hours', 'within 6 months|History of', 'prior to starting any treatment', 'within 60 months of surgery|Corneal Disease', 'during prengnancy|No illicit drug', 'prior to dental treatment', 'within three months；|implantation of', 'within the previous 3 months;|revascularization of the lower limb', 'within the past 6 months;|Use', 'within 2 weeks prior to leukapheresis', 'baseline', '1 month prior to Screening', 'within 28 days prior to first study drug', 'within 2 years prior to study start', 'discontinued at least 2 weeks before first dose or five half-lives', 'in the last year);|Occlusal treatment', 'within 28 days / 5 half-lives', 'in the past 12 weeks;|Dietary supplements', 'at least two experienced', 'within four weeks of study', 'within 3 days before the first administration.|There is central nervous system', 'in the 6 months prior to screening resulting', 'prior to the dose of study drug', 'at time of randomization.|Treatment with IMP can', 'at least 4 weeks prior to randomization.||', '12 hours before starting the study|being', 'within 3 days prior to first administration', 'before onset;', 'persistent', 'more than 12 months prior to screening', 'within 5 years prior to study vaccination.|Have', 'within 8', 'their partner(s)', 'within the preceding 12 months|Coronary artery bypass surgery|Current stable', 'within the range 18 to 40 kg/m2', 'for 12 weeks|Able to participate in a structured walking program', 'within 10 days prior to study drug', '<2 weeks from baseline|Major medical illness', '< 1 week before 68Ga-NY104 PET/CT', 'prior to treatment', 'during previous 12 months).|Willing to travel', 'within the past 6 months.|Intolerance', 'within the reference range of the institution).|No', 'within the previous 4 weeks', 'in the past 2 years.|Abdominal fistula', 'within the last 6 hours', 'within the last 2 weeks|Initiated', 'in past 12-months', 'within 4 weeks prior to enrollment|Treatment', 'no higher than -0.75DC;|Is presbyopic', 'for 30 days after ending', 'within 30 days prior to treatment start', 'At least 8 years', 'within 60 days prior to study entry.|Thrombolytic therapy', 'within two weeks before randomization', 'for the last 4 weeks/1mo', 'in the last 24 hs', 'for at least 12 months.|Concurrent first-generation anti-androgens', 'within 3 months of', 'within 4 weeks prior to the first dose of study drug.||3', 'within 4 weeks prior to Day 1|Untreated', 'at least 3 months', 'within 3 months before signing the informed consent form', 'in the past 6 months|Severe lung disease', 'at the time of enrollment.|Neurologically healthy', 'for at least 1 year prior to screening||Or,||Individuals of', 'within the 6 months prior to the first dose of trial treatment', 'prior to any study procedures', 'within 2 weeks prior to initial administration of the experimental drug;|Pleural effusion', 'after HSCT', 'for at least 12 months', 'MRD;|Within 3 days prior to initial treatment', 'after pre-dilating', 'within 14 days prior to the first dose of study treatment|Patients', 'since 3 at least months', 'within the previous 1 month or 5 half-life period', 'within 2 months before', 'during the last six months', 'at least 4 weeks after initial trauma|If allocated to add-on exercise protocol participant must feel able to prioritize the intervention structure|Communication language', '≥3 months after the', 'within three months of trial entry.||J.', 'throughout the study nor they agree to a', 'within 1 week before enrollment;||Vital organ functions', 'within 7 days before starting treatment', 'prior to adequate treatment for bacteremia', 'before first line', 'in the month prior to enrollment', 'within the first 4 weeks of enrollment', 'within 6 months prior to the start of study treatment', 'within the framework of the competence network can take place upon request', 'within the last 10 days', 'within 3 months prior enrollment.|Intolerable serious cardiovascular', 'at the screening visit:||HR', 'within the past 3 months;|Drug', 'at least 1 SpA', 'for at least 3 months.|Willing and able to continue current diet', 'on or before day', 'at time of signing ICF.|Histological confirmed MpBC', 'for the control group|Individuals', 'in the last year prior to either Screening or Day -1.|Has', 'for at least 90 days after the last dose of study treatment.|Have', 'within 3 months prior to first dose of study intervention.|Hepatitis C antibody test result', 'within 90 days of the index procedure.|Chronic renal dysfunction', 'within 48 hours of the', 'at least 4 weeks must', 'within 30 days prior to Week 0 Visit|History', 'within one week prior to screening/baseline;|Self-reported', 'in the 4 weeks following each study vaccination', 'allograft history', 'within 4 weeks of the first dose of study therapy|History of prior', 'within the next 12 months', 'within last 3 years.|Any medical', 'during the last 30 days before inclusion', 'within 7 days prior to the first dose of study', 'within 6 months after the study drug infusion.|No history', 'within 28 days prior to baseline visit', 'for 2 weeks or more', 'within the 4 weeks before Screening Visit 1.||Prohibited medications/procedures||Treatment', 'within 6 months prior to study entry', 'throughout the study.|Receipt of any licensed', 'within 4 weeks prior to the 1st scheduled dose of study treatment', 'since the last injection.|Breastfeeding', 'subjects|Tobacco history of more than 5 packs/year', 'at the time of signing the informed consent.|A non-pregnant', 'within 60 days prior to registration.||Adequate bone marrow', 'within 14 days prior to the start of the clinical study|Positive rapid test result', 'during that period of time must', 'in the last 12 months.|Has', 'within 6 months before registration', 'in the next year|Have epilepsy|Have cardiovascular disease|Current pain', 'throughout their participation in the study considering their strict following', 'within 14 days prior to enrolment|Any medical', 'within 2 weeks before the RCT|Received acupuncture', 'during the study period', 'less than 3', 'within 28 days before enrollment.|Has', 'tumor|Within 5 years before enrollment', 'within 28 days prior to registration)|Platelets', 'after fracture;|Willingness to participate in this study', 'for at least 2 months before recruitment to the study|Daily free sugar intake ≥5% of the daily energy intake||', 'within 4 weeks before signing the informed consent.|Participants', 'within 3 months before informed consent signing', '7 days prior to the start of the study.|Participants do not', 'within 4 weeks before the first dose of the study drug', 'QTcF]);|Within 3 months before the first dose', 'in the last 3 months||', 'within 6 months following treatment withdrawal||OR', 'at least 2 weeks prior to study dry administration', 'past 12 weeks prior to BSL', 'prior to surgery||', 'at the time of screening).|Schizophrenia', 'at the time the parent/legal guardian signs the informed consent form||For US - Age', 'last for more than 3 months|Those', 'at the time of signing the informed consent;|Histologically', 'within the last six months|currently', 'within 30 days of the baseline visit|Presence of any condition', 'prior to dosing.|Have', 'history of pre-existing', 'in the past;||Iodine', 'at least 4 times in the past year|the last', 'ended less than six months ago|Research participant', '6 months after the last dose of IMP', 'at least 3 months;|IIEF-5 questionnaire scores below 20||', 'at the time of written', 'last six weeks before start of this trial treatment.|Known milk product allergy.|Not able to understand information.|Do not', 'for at least 6 months A score of', 'during the study|Underwent Filler injection (collagen,', 'at their initial screening visit 1a', 'at least 3 doses of N-803 and all doses of VRC07-', 'within 9 months of Screening.|Electroconvulsive therapy', 'in the past 6 months;|Patients', 'medication history of', 'during the treatment', 'within 1 year prior to the first administration of the study drug.|History of Participating in another investigational clinical trial within 90 days before the first administration of the study drug.|Poor', 'within the study;|History of oncological disease', 'prior to C1D1', 'within the past 28 days prior to start of study treatment', 'within the last 3 months|Severe infection', 'after the last treatment.|Life expectancy', 'within 7 days prior to the year', 'within 24 ~ 48 hours', 'in the last 30 days prior to participating', 'in the past 6 months prior to randomization.|Documented active', 'within the 12 months prior to the first dose of study drug', 'within 7 days prior to initiation', 'within 7 days prior to index procedure', 'throughout the duration of the study|Patients', 'within 30 days prior to C1D1', 'within the past 6 months|Evidence', 'within 7 days of an Experimental Session', '3 weeks prior to initiating dostarlimab', 'within the 90 days prior to study', 'at 2 h after ingestion of a', 'within the past 2 years|on', 'within the last 7 days prior to the start of the study|Systemic therapy', 'history at the site of', 'within 3 years before screening);|8', 'onset of two or more of the symptoms', 'for the last 3 months prior to screening', 'for at least 12 weeks|Signed', 'within 4 weeks before the research', 'at least 3 months prior to Baseline Visit', 'prior to concussion episodes|Diagnosis', 'within 30 days before the first dose of study treatment.|The', 'in the past 3 years|Known', 'in the last month for', 'within 2 years of first dose', 'within 2 weeks prior to initial administration', 'within the previous 7 days of W1D1).||Note: A', 'at least two years prior to screening', '≤120 days before study enrollment', 'after 3 months of physiotherapy|a tendon amenable', 'within 7 days prior to Screening through Day 60 of the', 'after receipt of', 'in the last 1 month.|Have history', 'at least two weeks', 'throughout the duration of the study||', '30 days prior to screening', 'in the last 3 days.|Signs of', 'at least five years', 'at least 12 weeks prior to screening', 'prior to the underlying', 'illness|Treatment', 'more than one child', 'within 1 year #', 'within 42 days', 'for more than 120 minutes/week', 'at the time of ovarian stimulation', 'within 4 weeks of Visit 2/', 'within 6 months prior to Meta10-19 infusion;|Patients', 'during thumb-index finger', 'during the last 12 months|Have access to Internet', 'within 2 months of screening', 'within the last 12 months|Person under legal', 'for at least 6 weeks.|For', 'within 30 days prior to the first dosing;|prescription medications', 'through the duration of the study.|Availability of a caregiver', 'past 5 years;|History', 'within 3 months prior to the screening visit|Presence of any inherited', 'within the past 12 months|Use of a hearing aid|Received a cochlear', 'in the first week after injury causing more than one day impairment', 'within 12 months of enrolment.||', 'throughout the study intervention', 'at the baseline in-office visit', 'prior one year.|Self-reported diseases', '1 after hormone replacement therapy', 'continue their antenatal follow-up,|No', 'within the past 7 days', 'in time off work', 'for at least 4 weeks prior to start of study treatment|Other malignancy', 'during dose escalation', '8 to 20 mm', 'for at least 3 months after the last dose of study drug', 'within 4 weeks before the first dose of study drug;|Serious infection', 'inadequate', 'within 2 weeks before apheresis', 'within 2 weeks before enrolment', 'within the past 6 months;|Field', 'at least 3 repair procedures/year||', 'for 3 months prior to or', 'for the next 4 months;||G', 'during past three months;|Neck surgery', 'on the targeted tumors', 'within 12 weeks of assessments', 'within 4 weeks prior to the first dose of the investigational product|Patients', 'within the screening period:||Absolute neutrophil', 'within 4 weeks of the first dose of nivolumab', 'within 7 days of first RP3', 'within 2 weeks prior to the first dose of study drugs.|Previous', 'over 1 year before inclusion;|Uncontrolled', 'within 3 days prior to study treatment', 'within the first 4 weeks', 'within the 3 months prior to baseline', 'for two months after vaccination;|The girls', 'during the interval', 'at pre-operative', 'within 6 months|Uncontrolled', 'within 5 years for', '8 weeks', 'within 60 days after the study', 'additional', 'within 4 weeks prior to the first dose of the study drug.|Patients', 'within the 30-day Screening period', 'within 28 days of Day -1.|Individuals', 'within a period of 6 months prior to injection of [68Ga]Ga-DPI-4452.|Any', 'in the last 3 months|long', 'within three months prior to the first IP administration', 'within 16 weeks of Study Day 1|Any', 'within 7 days prior to administration.|Any major surgery', 'within 28 days prior to day 1 of protocol therapy||Agreement', 'within the 3 months prior to study entry', 'greater than 480 milliseconds', 'for at least 4 weeks prior to taking the cocktail|further inclusion criteria apply||Healthy subjects and F4', 'at least 28', 'within 2 weeks prior to initial administration of the trial drug', 'throughout the study duration and', 'prior to 12 months of amenorrhea', 'within 3 weeks of the first dose of study drug', 'within half a year', 'before participating in the study,|Agreeing to participate', 'within 14 days before the first administration', 'period of time (more than 2 months', 'within the state in', 'at least 2-week', 'At the time of enrollment', 'within 28 days of the planned start of study drug', 'within 2 weeks of starting study', 'within 7 days before the laboratory examination', 'within 7 days prior to treatment.||Female', 'during Screening Visit', 'during the past month|Other associated', 'within 7 days prior to the first dose of trial treatment', 'at the time of CAG.|Among', 'during this study', 'within the previous 90 days', 'at least 3 points.||', 'more than 2 days per week', 'during the experiment,|Participants and their families', 'within 7 days of enrollment|Concurrent', 'during study treatment.|Active', 'within 7 days prior to apheresis', 'within the last 30 days', 'during the last six weeks prior to the', 'within 2 weeks of study enrollment|5', 'during the 6 month study period', 'for at least 3 weeks prior to baseline', '5 times a week for 12 weeks)||', 'within 1 week before enrollment', 'at any time prior to screening', 'within the head', 'for ≥5 years；|Women', 'for 1 month after the end of trial', 'within the past 12 months;|Women', 'within 3 hours prior to Visit', 'at least 2 months after the use of a', 'last 5 days', 'at both screening', 'hospital.|At least 20 years', 'within one month);|advanced chronic kidney disease', 'within 7 days before the first dose of HTMC0435', 'within 2 years', 'at least 4 weeks prior', 'within 3 months prior to initial administration', 'within 1 month prior to receiving the experimental vaccine.|are', '15 days prior to start', 'at Day 1', 'since at least 8 weeks prior', 'on the patient', 'during the course of the study.|Hypotensive individuals', 'at time of traumatic injury', 'in the past 3 months|People', 'within the appropriate screen time frame', '6 months before the first study vaccination.|History', 'within 2 years after cell infusion', 'within 30 days prior to the screening', 'for at least 90 days after the last dose of study treatment.||A female', 'within previous 2 days.|Patient ≥ 18 years', 'up to 7', 'within 3 months prior to randomization.|Regular consumption of probiotics', 'prior to blood collection', 'within 28 days of the study', 'between 4 and 5 cm.||Lesions must', 'within the past 90 days before screening', 'at the time of testing|Development and cognition', 'within 30 days prior to inclusion', 'within 6 months from the screening period to the administration of the study drug|Have', 'within 28 days before baseline to treat pancytopenia', 'for 28 days prior to study intervention administration', 'before first LU', 'within the past 6 months prior to enrollment.||10', 'within the previous 2 years.|Major surgery', 'during the study,|No additional sedation-analgesic medication', 'during the study period;|12', 'at least one week prior to planned start', 'within past 2 months', 'within 30 days before the screening;|History', 'for 4 months after the last dose of protocol treatment', 'within a week after fracture;|pregnant', 'at the time of recruitment|absence of exacerbations', 'for at least six months', 'in the past', 'at least 2 weeks prior to the first administration of study treatment', 'within six months|History of', 'within three months of the Screening visit.|Patients hospitalized', 'during the study.|Reported participation', 'last 7 days', 'at the time of consent.|GOG Performance Status', 'within 2 weeks prior to lymphodepletion', 'at least 6 months after The last dose of adjuvant', 'at the time of starting study treatment', 'for at least 2 months after the end of cetuximab treatment', 'during or after therapy with platinum-', 'within 2 weeks before the start of treatment;|Patients', 'within one month from the brain injury to continue clinical care', 'within 72 hours prior to study registration', 'for the previous 4 weeks', 'within the preceding 1 month of Screening.|Has', 'within 60 days', 'within 3 months prior to enrollment;|History', 'at the time of dosing|Recent donation', 'for at least 28 days before baseline|Able', 'past 2 months|reported use of opiates', 'within 30 minutes|IABP', 'within 180 days before enrollment', 'prior to enrollment.|Rituximab', 'within the last month.|History of known', 'at least 4 weeks prior to study entry', 'within 3 days of MB-102 dosing|The participant', 'within 5 days before the first dose of study drug|Any condition', 'approximately 7.5 months', 'before randomization.|Received', 'for the duration of the study|Use of any consumer-based', 'within 6 weeks before the first dose of the study drug', 'within 30 days prior to enrollment|Protected', 'within 24 hours is <', 'after the last dose of magrolimab', 'in the past 2 years|Pregnant', 'at time of evaluation|Use', 'within 30 days or', 'within 5 years|Hyperthyroidism', 'at least one of the following conditions exists:||Patent foramen ovale', 'at least 2.0 standard deviation', 'no less than 4 weeks prior to study entry.||', 'at least 8 weeks prior', 'in the previous 30 days).|Able', 'at the time of vaccination', 'onset prior to age', 'within 6 months prior to recruitment.|Active', 'during the last 6 months|Inability', 'Prior', 'within 4 months prior to Day 1 for individuals with', '1 week before the start of the treatment', 'during the past 3 months;|Other', 'before into undergoing surgery', 'within 3 months|Subjects voluntarily signed the informed consent', 'at any time during the 12 months prior to Screening', 'during or within six months of completion of the adjuvant chemotherapy', 'after prostatectomy: BCR', 'at least 30 days prior to Screening;||Must', 'within 4 weeks prior to enrolment', 'in the past 12 months|Physical limitation', 'prior to institutionalization', 'pre-dose days required', 'for at least 48 hours', 'at the time of cardioversion', 'within 2 years prior to the study treatment', 'at time of signing informed consent', 'at least one of the complaints', 'at least one network member to participate', 'within two months of the screening', 'likely to impair immune response', 'within the last 3 months|Participation', '48 hours prior to the expected initial application', ""during a fall)|Patient's physiotherapist"", 'within 2 weeks prior to inclusion', 'before Cycle 1 Day 1.|Current', 'in the 12 months prior', 'within past 4 weeks', 'within 28 days prior to the first dose of the investigational product|An interval', 'within the next 45 days', 'prior to radiotherapy|Patients', 'emergency surgery|If the subject includes those', 'within 3 months prior to C1D1.|Grade', 'within 8 weeks prior to beginning trial treatment', 'in the last four weeks|History of', 'for at least 5 years;|Person', 'at least 4 months after the final study drug', 'since treatment', 'within 4 weeks prior to screening', 'Tanning History', 'in the last 8 weeks.|Active', 'at least 3 months prior to Screening', 'within 3 months prior to the screening visit.|Significant', 'for at least 5 years prior to enrollment', 'within 4 weeks prior to the first dose of study treatment administration', 'within 28 days prior to the 1st dose of CHS-006;|NSCLC', 'at transplant.|Negative crossmatch with donor.|If female', 'within the past year.|Patients', 'within 6 months prior to Screening|Sublingual', 'planned to receive', 'at the time of enrollment||Willing to provide written informed', 'within 14 days from the commencement', 'within the 6 weeks prior to signing the IC or inclusion document.|Deep facial chemical peel', 'at time of inclusion)|Anatomic constraints making', 'in last 12 months', 'at least one of the following requirements during screening', 'in the past 12 months|History of other', 'within 7 days prior to enrolment', 'within 14 days before randomisation 8', 'within the year leading', 'within the past 12 months|Have', 'within the previous 5 years;|Documented', 'within 2 weeks from study', 'within 30 days of screening', 'within the past 6 months.|Screening 12-lead ECG', 'during their participation in the study.||', 'during the treatment period', 'within 12 months of baseline visit|Presence of pulmonary hypertension', 'before initiation', 'continue until 3 months following receipt of vaccine|As applicable undergo', 'within 6 months prior to the Screening visit.||Use of the following therapies', 'within 12 months|If', 'during the last month', 'within the 30 days prior to Screening.|History of', 'in previous 2 weeks;|Administered', 'prior to baseline.|Participants', 'within 7 months;||*Female', 'at a daily dose greater than 40mg', 'within 4 weeks prior to the first dose of study treatment.|Presence', 'at randomization make the individual unsuitable for the study', 'within 4 weeks', 'within 2 months prior to Screening|Heavy', 'during the study period and within 3 months after the end of the study treatment', 'within 1 week before the first', '<6 weeks prior to admission', 'within 6 months prior to the Screening visit.|The use', 'at two different stimulus', '3 months onset from', 'in the past 6-weeks.|Participants', 'within 7 days prior to IMP', 'continue to receive', 'at time of study enrollment|Comorbidities', 'last 8 weeks before first study drug administration.|Subject intends', 'at least 14 days prior to receiving a study product.||', 'within 3 weeks prior to the first dose of study', 'within the previous six months', 'at time of screening.|Participant', 'within 1 month prior to surgery|Provision of signed', 'by V/Q scan', 'in the last 6 months);|is pregnant', 'during the time of data collection.||', 'for at least 3 months.|TSH', 'in the past 12 months before the baseline assessment|Previous lobectomy', 'within the last three months', 'within 5 years prior to study', 'in the past and their condition', 'within the last 1 year.|Participants', 'within 4 weeks prior to screening.|Received red', 'within 6 months of their', 'for 12 hours', 'at least 28 days apart from the previous major surgery', 'within two weeks of entry into study.|Contraindications', 'prior to providing documented', 'within 30 days prior to treatment administration.|Non-tolerance', 'prior to randomization', 'at least 14 days prior to the start of treatment with resolution', 'prior to their antiviral treatment', 'within 6 weeks prior to start', 'prior', 'while receiving investigational product', 'within 14 days of start of protocol therapy', 'at the time of screening|Adequately recovered from any acute illness', 'within 4 weeks prior to treatment initiation.|Non-healing wound', 'for 5 years or more', 'within the first 6 hours of life,|-First dose of', 'within the last three months.|Those', 'within the last year.|Chronic immunosuppression.|Individuals', 'since at least 3', 'during two weeks before the enrollment in the study|A contradiction to any', 'at the distal end of the visceral branch vessel', 'prior to initiation of study treatment|Treatment', 'within the first 6 months of screening', 'within 3 months before screening.|History of', 'after failure', 'less than 48 hours before the start of the study', 'within 120 days prior to the first dose of study treatment', 'changed 3 weeks prior to the recruitment visit.||', '6 months after inclusion', 'at the initial examination', 'within 4 weeks of first dose.|History', 'within 1 year|Those who', 'within 6 months of initial response', 'within the past six months;|Patients', 'prior to Baseline Visit', 'past 8 hours).|Effective cough.|Negative leak test', 'At least', 'more than 14 units', 'prevent', 'in the study eye|Condition', 'in the past 3 months prior to the first dosing', 'likely to impede fetal growth|not smoking', 'less than 6 years', 'at the time of the study|Cervical fractures', 'for 30 days after completion of study', 'for 2 weeks after the last dose.|Stable diet', 'within 4 weeks before the random grouping;|Patients', 'in English|Patients', 'at least 12 weeks from radiation', 'within 2 weeks before enrollment;|Not recovered', 'during the 4 weeks prior to study', 'at least 14 days before', 'within 2 weeks prior to initiation of study treatment', 'at the time of signing the informed consent.|Weight', 'within the previous month|Functionally impairing radicular', 'at least 3 times a week|training', 'within the last 12 months;|Organ transplantation', 'within 14 days before the first administration);|6.1.2', 'within 3 months of the last dose of consolidation therapy', 'during the meetings||', 'within 12 weeks prior to', 'in three months prior to the study|Pregnant', 'within 24-36h.||', 'prior to day 1 of therapy.|Receiving', 'within 3 months prior to receiving the trial', 'during the study period|Willing', 'at the time of enrolment', 'at the time of screening.|Histologically', 'prior to birth', 'at least 3 months before screening', '48 hours before admission to the ICU', 'within 8 weeks prior to enrollment', 'within one month', 'within 8 weeks prior to dosing.|Any reason', 'in the first 4 weeks|Suffering from other endocrine system', 'within 24 h before the MRI and/or', 'within 12 weeks prior to the', 'for the first time||', 'within 1 week of the first dose of study', 'prior to his entrance to the study', 'in the 3 months prior to inclusion|Previous', 'at the screening visit', 'during the past four weeks prior to screening visit', 'after the last administration of the study drug;|A', 'At least 20 years old', 'within the 12 months prior to screening|Any planned', 'before initial unipolar ablation', 'in the past month.|Have used', 'at baseline <2;|Subjects', 'during the 6 month period prior to baseline', 'within 6 months of visit 1|Be using', 'during the last 3 months|Any', 'in < 3 months|Severe', 'prior to thrombectomy', 'prior to MDT)|Treatment plan', 'for 1 week or more', 'during pre-index period', 'at least 4 weeks prior to the baseline', 'in the last five years', 'within 6 months prior to treatment initiation', 'during the study period.|Receipt of any investigational product', '18 weeks prior to screening', 'in the past year).||', 'within 7 days prior to enrollment;|Receipt', 'within the ""weeks off"" time period will not', 'within 14 days before the first dose of HTMC0435|Active infectious', 'before enrollment/randomization', 'within the past year.|Bleeding', 'at the time of study enrollment|Patient', 'at time of consent)|Parent/guardian able to consent', 'more than 3 years prior to enrollment', 'at least 3 months prior to the first dose of investigational drug', 'specifically administered to treat LMD', 'greater than 30 days||Absolute neutrophil count (', 'within previous 90 d)|Non-sinus', 'within three months prior to investigation,|peripheral revascularization', 'patient,|at least 4 months post-diagnosis,|between', 'up to two months prior to inclusion', 'within 3 months of signing consent', 'within 28 days prior to imlifidase treatment|Desensitisation treatment(s)', 'more than 3 years prior to enrollment|Any participant', 'within 30 days of the index cardiac surgical', 'in the last year;|Pregnant', 'within the last 3 months|BMI', '14 days prior to first study drug administration until the end of the study.|Subject', 'in the past 90 days', 'within the previous thirty (30)', 'prior to 36 weeks)|Maternal HIV', 'within 1 month of the first visit', 'at least 1 of the following urinary symptoms over', 'within 28 days of the start of study treatment|Treatment', 'at least two weeks prior to first dose of study treatment', 'prior to futibatinib', 'during the study;|Received', 'at time of MRI scan', 'at the time of potential enrollment', 'during the last month.|Prescription of other malate-', 'at least 3 months prior to screening.|Pre-bronchodilator', 'neurological history', 'at least 3 months prior to inclusion', 'during the long TUG', 'their diet', 'in last 12 months|Children', 'in the 6 hours prior to the beginning of the study;|Participants', 'during the 12 months prior to screening', 'at the time of the first dose of INZ-701|In the opinion of the Investigator', 'at least 7 days prior to baseline.|Bronchodilator reversibility', 'at the time of signing the informed consent form.|Expected survival', 'within 2 weeks prior to apheresis', 'over the duration of the study|are currently', 'during the duration of the study.||', 'within 6 months before treatment initiation', 'within 6 weeks of enrollment|Treatment', 'more than 14 units of alcoholic beverages per week within 6 months before Screening', 'prior to screening.||Standard treatment regimen', 'within 3 days of screening', 'within 72 hours before surgery', 'within 60 days prior to Week 0 Visit|Received IV', 'at the time of interview', 'at Screening or Day 1', 'within 24 hours prior to the start of IP administration.|WOCBP', 'within 6 months before Cycle 1 Day 1|Clinically significant', '15 days prior to randomization;|Known', 'within 1 month after the end of this study;|Smoking more than 5 cigarettes per day within 3 months prior to screening，or', 'within 4 weeks before clearing the lymph cells', 'within a year', 'within 4 weeks of study enrolment.|Have', 'in the past 30 days|able', 'within 3 months of screening', 'within 14 days before treatment);Absolute count', 'within 2months of starting antibiotics.|If individual', 'at any 4 cm segment|Able to commit', 'within 2 months of the baseline', 'within past six month', 'for at least 2 months prior to screening.||*', 'within 60 days prior to initiation of study treatment', 'for at least 6 months|Moderate-severe', 'after last prior line', 'in the last 6 months|Chronic treatment', 'in the liver.||', 'at least 2 prior', 'for at least 3 months|Nightmare', 'at least 12 weeks prior to screening,|Concerning', 'after 5 half-lives', 'for 5 months after the last dose of IP', 'at time of screening.|Subject', 'prior to age 20|Healthy', 'at the time of screening:||Absolute neutrophil count (', 'within 5 years prior to first dose', 'post- transplantation', 'in last 12 months|Seasonal allergic rhinitis|Chronic rhinosinusitis', 'within 4 weeks|Other', 'after MRI', 'at the time of randomization', 'within the 3 months before screening', 'in the next 48 hours;|Other', 'at least 48 hours prior to enrollment.|Patients', 'within a clinical study', 'approximately October', 'within 2 years prior to first dose of the investigational drug', 'at study entry.|Women', 'at the time of the screening', 'within the past 3 years**.||*Exceptions', 'in the past 6 months|Botulinum toxin injection', 'within the past 3 months.||Intra-operative', 'in the last 12 mo', 'within 24 months prior to enrollment|Kidney transplant', 'for at least 3 months after the last treatment;|Patients who volunteered to participate in this study', 'within seven days prior to administration|History of', '7 days prior to venetoclax.|Concomitant', 'RA;|≥ 6', 'within 8 weeks prior to screening|Evidence of', 'injections 3 months before enrollment|have', 'prior vaccine', 'for 1 year following JWCAR029 infusion', 'at the time of signing the informed consent.|Females must', 'for at least 1 year.|Pre-bronchodilator', 'within 45 days prior to screening', 'at the next clinic visit', 'currently', 'surgical history', '3 months prior to screening;|Female', 'prior to study entry.|Judgment', 'at least 6 months prior', 'three months prior to enrolment', 'within 24 months before signing the informed consent form|A', 'within 14 days prior to the first dose of study drug.||For', '90 days prior to screening', 'within 1 year', 'for at least 2 weeks prior to Day 1|Participation', 'during the last 3 months|affiliated', 'within 6 weeks or less prior to intended study drug', 'within 30 days before vaccination / the first dose of the', 'within 7 days prior to C1D1.|Sexually active', 'at least 12 months after the last vaccine', 'for the first time with alternative sentences', 'over the 6 months post-study enrollment|Weight loss', 'prior to screening;|Prior treatment', 'at the time of enrollment|Recipients', 'in the last 2 years||Any disorder', 'within the last 8 weeks;|Medications to', 'in three months prior to screening', 'during the initial 6-month period after diagnosis', 'within 90 days prior to screening.|Those', 'at the time of signing informed consent|Body mass index (', 'at least six months', 'less than 8 g/dl.|Active', 'before receiving study treatment', 'during the 7 days after investigational medicinal product (IMP) administration', 'in the past 3 months;|History', 'after previous emergency department contact', 'within 10 days prior to screening', 'within the last 3 years.||Evidence', '48 hours before examinations|inability to communicate', 'within 3 days prior to screening', 'for two months', 'throughout 90 days after final study intervention administration.|Male participant', 'within the same influenza season', 'within 12 weeks of the start of study treatment|Prior treatment', 'within 7 days prior to through 28 days after trial vaccination', 'during the 24 hours before their scheduled surgery', 'more than 600 mg', 'within 1 year after enrollment;|Patients', 'within 3 months prior to receiving the first dose of the study drug', 'within the past three months', 'greater than 3 times', 'at least 3 months ago|Acute diarrhea', 'prior to first dose of study medication|Are taking', 'within 6 months of starting the intervention', 'within 24 hours before onset of MI|active', 'at least 4 or more', 'within 3 days before baseline|History', 'before the first administration of study drug', 'during the time of the study.|Sexually', 'within 3 months prior to administration', 'within the last 6 months.|Treatment', 'within 30 days prior to first dose of study drug', 'within 90 days prior to screening.|Regular', 'prior to administration', 'at least 15 minutes apart prior to randomization', 'up to 16 years old', 'within 12 months after enrollment.|Inability to comply with study', 'in the 4 weeks prior to initial dosing.|Patients', 'in the 4 weeks prior to signing ICF.||**Topical', 'in the last 4 weeks', 'one month before enrollment.|Body Mass Index (BMI)', 'after 2 times instructions;|Alcohol abuse', 'within the last 180days.|Participants with', 'for at least 120 days post', 'through 3 months after the last dose of study therapy', 'within 6 months before treatment', 'within 14 days of first dose of study drugs||Based', 'within 2 weeks|Have received', 'last six months||Exclusion criteria:||Children', 'within 2 weeks prior to Day 1|Major surgical procedure', 'within five days prior to screening|Use of GLP-1RA', 'within 90 days prior to Screening', 'during the whole study.|Female of childbearing potential should use', 'at the beginning of the study)|Patient without medical insurance coverage', 'within 5 half lives', 'after treatment.|History of psychiatric illness', 'for at least 1 year.|Participants who voluntarily agree', 'within 12 weeks prior to initial administration.|Autologous hematopoietic stem cell transplantation', 'within 2 weeks prior to dosing.|Has evidence', 'in the past three months.|Patients', 'within 14 days of 1st dose', 'in the 12 months before screening|Unexpected events', 'within 12 months of pre-screening).|Male', 'within the previous 28 days|Confirmed severe', 'prior to index bronchiolitis episode|Premature', 'at the time of signing the ICF.|Currently meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition', 'within two weeks or', 'for more than 3 days|Ages', 'in the past 3 months;|4', 'more than 38.5 degrees', 'within one month before screening', 'prior to first vaccination', 'at least 2 x ULN', 'within 14 days prior the first dose of study', 'within 24 hours of randomization', 'within 4 weeks prior to the first dose of the investigational drug.|Received', 'before 6 months', 'after 3 courses', 'within 90 days||Evidence', 'prior to surgery|Incurable', 'at least two years|Averaging', 'for at least 14 days prior to first dose of study intervention|Has severe', 'within 3 days prior to initiation', 'at the time of cardioversion;|Heart rate', 'within one months of the Screening Visit.|Patient', 'at least 7 months after the last IMP administration', 'within 3 months of Week 0 Visit|History', 'for the past 3 months', 'within 14 days prior to the start of study', 'during the previous 2 weeks', 'within 15 to 30 minutes after administration of 200-400', 'at least 2 weeks prior to start of study', 'within 2 hours', 'at the time of signing informed consent；|Body weight ≥50.0 kg for', 'in the last 4 weeks|Patients', 'within 14 days before Dose1 Day 1', 'within 2 weeks of Visit 2|Willing', 'in the past month preceding screening;|Be', 'within 6 months before screening', 'past 12 months;|History', 'within 90 days of enrollment to a substudy', 'within the last 1 year.|Systemic application', 'tumors;|Previous history', 'for ≥ 3 months', 'within 2 weeks before screening|6', 'during the study protocol', 'within 3 months prior to first dose of study intervention.|Positive pre-study drug/alcohol screen', 'after the pre-transplant', 'within 14 days of treatment.|History of', 'in past 2 years.|4', 'within the last 1 month or 5 half-lives', 'during this time', 'prior to either imaging', 'within 5 years.|History of pelvic radiotherapy', 'for greater than 1 year', 'available', 'for at least 3 consecutive days or 3 per day and /', 'within 2 months after the end of the study', 'in the last 2 months', 'within less than 6 months after the last treatment with', 'up to 2 months prior the', 'SE:||According to the judgment of the principal investigator', 'within the past year.|Participants', 'more than 12 weeks before', 'up to 6 months|Have internet', 'in the past are eligible', 'within 1 month before screening|Unable to perform', 'after 2 cycles', 'within 2 weeks prior to study baseline', 'within the preceding 3 months|Have', 'during the month before selection.|Patient', 'within 30 days before signing the ICF', 'within 12 months prior to study treatment|Any', 'during the course of the study.|Patients', 'while on study|Has', 'in the next 3 years', 'for less than 24 h', 'during the study period and within 6 months after the last administration of the study drug Measures: For male', 'for 180 days after the last dose of study treatment.||11', 'within 2 weeks prior to starting study treatment', 'within 6 weeks prior to Day 1|Participants', 'throughout the duration of the study|Use of', 'for 12 weeks', 'at least 1 day/ week', 'within 30 days of the initial', 'within one week (Day -7 to Day 1', 'within 24 weeks before Screening', 'in the past 6 months|Previous', 'within 90 days of enrollment);|A major', 'in the 4 weeks prior to the knowledge', 'within 3 months prior to IP administration|Administered NSAIDs', 'within 6 months|surgery of the involved joint with 6 months|received', 'more than 2', 'in last 3 months.|Presence', 'during pre-Maintenance upfront therapy', 'within 90 days prior to the screening', 'in the last 6 months|Immunosuppression', 'in the 4 weeks preceding', 'at least 4 weeks prior to', 'during the run-in period', 'in the 3 last months|Non-steroidal anti-inflammatory drugs therapy', 'within one month of enrollment into this study.||5', 'immediately next', 'during study treatment.|History', 'after the last dose of darigabat.||A male', 'at the time of screening|clinical evidence', 'at consent|Completing', 'planning to become pregnant', 'within 1 week before the first dose;|Has not fully recovered from any intervention-related toxicity', 'within the past three months Those', 'at the moment of patient enrollment', 'during the study period.|Patients who regularly use', 'within the Northwestern Medicine Chronic Opioid Use registry system', '48 hours', 'within 7 days prior to study enrollment', 'within 30 days prior to first anticipated dose of TIL.|History of allogeneic organ transplant|History of', 'within 12 hours before the procedure;|Patients', 'at time of consent|Able to adhere to the study visit schedule and other', 'for 2.5 months following', 'up to 3 months before recruitment|Organ transplant|Plan to move out of greater', 'for the past 4 months.|Participants', 'any time prior to randomization', 'within 30 days before the first dose of study', 'within 24 hours of admission)|patient', 'within 12 months prior to the first dose', 'management within 90 days before screening||Glycaemia-related', 'within 48 hours prior to the randomization', 'during the last 6 months.|Current', 'within the previous year of', 'during the study period||The third part', 'within 2 weeks before enrollment.|Severe liver', 'while the patient', 'within 14 days prior to initiation of treatment', 'for at least 3 months.|Participant', 'within last 3 months|Antibiotic therapy', 'throughout screening', 'prior to HY', 'within 6 months prior to initial administration', 'in the 6 months prior to screening.|Participants', 'throughout the study treatment period', 'at least 4 weeks before examination', 'within 3 months of screening|Have', 'maximum 8 weeks', 'previously received any', 'at least 6 months prior to study', 'for the first time.||', 'within 1 month of Screening', 'pre-molars', 'within 42 days prior to enrollment)||Patients', 'within 3 months prior to screening;Arrhythmias', 'within 14 days prior to administration of PRTH-101.||a', 'within 2 weeks and fully recovered', 'within 12 months to the last therapy', 'at least 12 months prior to study', 'within 1 week prior to randomization|Have', 'in the past ___ months|Muscle relaxants', 'within one week before the start of the enrolment|Participation in any other clinical studies', 'within 28 days prior to the first dose of study drug administration', 'at the time of neuroimaging;|The operator feels', 'in the last 6 hours', 'during the clinical screening visit.|Metal implants', 'last dose more than two months prior to enrolment.||Exclusion criteria:||Participants', 'within 100 days before first dosing.|Evidence', 'during treatment (separation of file', '≤60 days prior to the study injection', 'within 3 months before the start of treatment.||IV', 'within 6 months before randomization.|Clinically relevant electrocardiogram (ECG)', 'during the intervention unless participants reach out for triage', 'within 2 years of Screening', 'during the study.|Involvement in the', 'at the beginning of the treatment', 'within 4 months prior to vaccination', 'within 14 days prior to IMP treatment start', 'at least 6 months.|Participant', 'within 4 weeks before randomization per Summary of product characteristics', 'at the time of the first IP bolus', 'in the last 2 years|Any disorder', 'at the Screening and Baseline visits.|Average', 'within 4 weeks prior to enrollment.|Participation', 'within 30 days of the screening biopsy', 'at the time of screening||☞', 'in the past 12 months|Under 18|Unable to give informed consent for participation in the study', 'before performing any procedure', 'during the study.|If participant', 'after radiation|ELIGIBILITY CRITERIA', 'before embryo transfer.|Those with', 'for three days added to their standard post-operative', 'within 6 months prior to the enrollment', 'within 2 months of enrollment', 'at least 90 days', 'within 1 week before the first medication', 'healthy,|without regular systemic', 'within the first 2 weeks', 'within 4 weeks before the first use of the study drug.|Received', 'within the past 6 months.|Participants', 'during the last 12 months.|patients must carry', 'in the last 3 months|have', ""at the time of study subject's randomisation.|Subject's consent to use reliable"", 'within the prior 4 weeks.|Polymorphic VT', 'history of four or more lifetime sexual partners|Self-reported', 'within 28 days prior to first dose administration of the IP:||Leukopenia', 'in the last 2 years', 'within 7 days before the enrollment', 'after preceding induction', 'within the last 6 months under treatment', 'at least 3 out of 7 nights in the week prior to Baseline', 'prior to initiation of therapy', 'for at least one month prior to the screening visit', 'within 14 days prior to registration', 'within 30 days prior to treatment|Complex percutaneous coronary intervention', 'within 3 months of screening:||Ataxia', 'least.||History of', 'in the last 3 months|Confirmed', 'within 100 days prior to first epcoritamab administration|Primary central nervous system', 'within 3 months after the end of treatment', 'admission to hospital for any reason 5', 'within 14 days of Screening.|Unable', 'prior to the first HIV-related', 'within 72 hours', 'more than three', '72 hours', 'for at least 3 months before signing the informed consent', 'at the time of screening|Uncontrolled asthma', 'for at least 4 weeks prior to the screening visit', 'at least 2 years prior to screening|Participation in another interventional clinical trial', 'during the procedure present', 'within 12 weeks|History of', 'throughout the study period,|Patient accepting the', 'within 6 months after the first complete remission', 'within three months prior to receiving the first dose of the study drug.|Pregnant', 'for at least 8 doses', 'within 6 months of Visit 1/Screening', 'before the first dose of this study.|Exclusion periods from other studies', 'within the last 1 week.|People', 'at the time of initial diagnosis', 'within 6 months before the first use of the study drug', '≥ 3 months prior to study entry.|Signed', 'for at least 24 weeks following the last dose', 'prior to study entry;|Patients', 'within the next 180 days after operation.|Severe neurological deficit', 'in the last 3 months prior to the FMT', 'within 5 times the half-life', 'for at least 18 months', 'within 4 weeks prior to first dose of study', 'for at least 6 months of study participants', 'in the past 6 months.|Subject', 'in the next 6 months', 'in the last 6 months||', 'at time of consent|Patients', 'within 2 weeks before enrollment of this study.|Those who attending other', 'for at least 4 weeks prior to Screening', 'within 6 months before the day of vaccination', 'within 5 years prior to first administration', 'in the previous 6 weeks', 'within the last 3 months', 'prior to randomization).|Age', 'prior to baseline', 'within 72 hours prior to Day 1', 'within 30 days prior to baseline MRI', 'at least 5 days a week for at least 5 hours per day)|Those', 'in 30 days|Those', 'within 2 weeks prior to the first', 'within 2 weeks of initiation of TTF|Must', 'within 1 week prior to C1D1', 'within 3 weeks prior to receiving the first dose of trial treatment', '6 months prior to randomization|Pregnant', 'for diagnosis / care / referral to the', 'within 14 days of ANC', 'in the last 3 months,|It', 'within 3 months prior to Visit 1', 'within 1 month before enrollment;|Taking', 'within the previous 6 months|Pathologies', 'within therapeutic range', 'within 4 weeks prior to the Baseline Visit.||Exclusion Criteria', 'within 16 weeks prior to Step 2 registration.|Documented', 'within 30 days|Coagulopathy', 'within 2 weeks before the first use of the study drug', 'previous year*', 'at least one offspring after spontaneous pregnancy||', 'after CR', 'in the 3rd step intensive care unit|Being', 'within 6 months before treatment.|Having', 'within 24h|patients unable to consent', 'no history', 'within the past 6 months|additional medical conditions', 'during the past 2 years).|Pre-existing', 'between the time of any prior systemic treatment', 'at any time from 4 weeks prior to Screening Visit 1 up to and including the Baseline Visit.||Participants who experience', 'in the last 3 months,|Not', 'within 7 days before leukapheresis collection', 'the time of recruitment', 'within 7 days prior to screening;|Known', 'within 24 hours of', 'greater than 25 dB', 'for 8 weeks or longer', 'after surgery within 6 months post-surgery.||B. Exclusion Criteria||Patients', 'in the next 6 months|Breastfeeding|Myocardial infarction', 'within 3 months prior to screening;|Those', 'in the 2-Week', 'within the 2 weeks prior to Day 1|Active non-ocular infection', 'within 48 hours of the date', 'more than 3 cm.||5', 'within normal institutional limits||OR||Creatinine Clearance', 'in the previous 6 months|Use', 'within 3 months.|Is', 'while receiving study drug treatment', 'within the past 3 weeks.|History', 'within 6 months of randomization', 'within 56 days prior to dosing.|Receipt of blood products', 'within 5 years before signing informed consent.|The investigator considers', 'in the 12 weeks prior to Screening', 'within 1 year prior to screening;|Subjects', '6 weeks', 'for ≥ 6 months|Bell Score', 'within 4 weeks prior to initial administration of the test drug', 'within 12 months of screening.||Any of the following', 'r', 'immediately for', 'within the last 6 months,|lumbar spinal surgery', 'at the time of surgery||', 'during the entire study treatment period|For subjects', 'within the previous six (6) months', 'within 6 months before the first dose', 'within last 6 months),|clinically significant', 'at the time of screening.|The', 'within 4 weeks prior to the start of treatment', 'within duration of participation', 'within 14 days of study drug', 'clinical history of', 'before they reach 30+0 weeks', 'in the previous 5 years|No personal history of', 'prior to enrollment', 'pre-existing', 'within the next 6 months|Current participation', 'for at least 90 days after the last dose of study', 'at baseline shows', 'more than 4 months', 'within the past six months.|with', 'at the time of screening|Current', 'before enrollment into this study.|Allogeneic', 'longer than 24 months|Smoking|Previous surgery', 'prior to Day -1.|Family history', 'past year|Normal pap smear deemed to be negative', 'within 3 months|Any', 'within 7 days prior to laboratory examination', 'within the past 12 months.|Intra-articular', 'for less than 1 year', 'within 2 weeks or endocrine therapy', 'within the prior 12- months', 'within 1 year prior to the first dose.|Known to have', 'within the past 6 months.|Women', 'management of', 'within the past 3 months|Expected', 'in the last three months;|Severe hepatic impairment', 'for at least 3 months after the last study drug', 'since at least 3 months||PD', 'previously treated', 'during the first 24 hours of life||', 'within 6 months|Patients', 'within 4 weeks prior to start of study treatment|Thrombotic', 'more than 6 months after', 'within 5 years of screening', 'within 28 days before enrollment;|3', 'at study entry.||', 'at more than 2', 'while on-study', 'less than 2 months before the informed consent document', 'in last 12 weeks|Any degree', 'for 180 days after the last dose of treatment.||20', 'within 28 days of cycle 1 day 1)|Willingness to provide', 'before one week after ERCP', 'before the first study drug administration.||Other exclusion criteria||Prisoner', 'at the time of obtaining', 'more than 35|Patients', 'within the past 3 months|Pregnant', 'for at least 3 years prior to IMP treatment start', 'prior to the first dose of study intervention', 'within 4 weeks of the first administration of the IP.|Chest X-ray', 'for 1 year after the last dose of study drug', 'in last 2 months|Active', 'during the last 12 months', 'previously received more than 1 biologic agents', 'within 6 months before randomization.|Major surgery', 'within 1 month prior to the first dose of study drug.||Patients', 'during the first 4 weeks of pregnancy', 'within the last 6 months prior to start of study treatment', 'within 24 hours before the', 'within 2 weeks prior to the investigational product administration However', 'more than 24hr|Elective surgical admission', 'in the 30 days prior to dosing.|Use', 'during the trial;|Able and willing to provide', 'Within 30 days after clinical diagnosis', 'within 6 months prior to screening.|Severe', 'longer than 1 year.|Volunteer to participate in this clinical study', 'within the last four weeks or less than wash out period of the chemotherapy agents', 'in the past six months|Have', 'within the last 3 months prior to screening.|Unable', 'testing.|Between 7 months and 2 years', 'during the study.|Laboratory test results before randomization', 'after TURT||', 'for the first time (first time users', 'at time of pre-intervention', 'within 4 weeks before the administration of lymphocyte clearance', 'post-traumatic stress', 'within 1 month (28 days', 'within 45 days of randomization|Planned medical treatment of all qualifying non-culprit lesions', 'at time of consent.|The patient was confirmed', 'within the 3 months prior to prescreening;|HV', 'last six months before hospitalization', 'prior to Visit 2.|Have', 'within 7 days.||', 'within 14 days prior to scheduled', 'within 24 hours pre-dose', 'in the 2 years preceding the study screening', 'at least one week before the first administration of lazertinib Except', 'at the time of enrollment.|Is an appropriate candidate', 'at time of enrollment|Aged', 'for at least 48 hours after the first study procedure.||', 'within 14 days prior to the first treatment', 'at least 3 lines of', 'at any time;', 'during the identification period (0/01/2014 to 09/30/2021', 'within recent 3 years', 'prior to receiving the first dose of study drug;|or', 'at least 4 weeks prior to study enrollment.||B.', 'throughout study treatment', 'continue to use', 'in previous 12 months||', '1 month prior to screening', 'at the measuring site (the mouth)|They', 'in the last month,|use', 'exceeding the equivalent of', 'within 24-36 hours', 'within the prior 30 days of study onset - cyclobenzaprine', 'at any time from the first day of their LMP', 'within 6 months before randomization|Patients', 'within 4 weeks prior to administration of the investigational product.|Patients who,', 'on the last biopsy available.|Age', 'in the 4 weeks preceding the first test session|Diagnosed', 'within 31 days of diagnosis', 'at least 6 months from diagnosis', 'for at least 3 months|7-day average', 'within 4 weeks before the first dose;|Central squamous cell carcinoma', 'at night', 'for at least 3 consecutive days immediately prior to the Day -14 screening', 'at the line of resection', 'within the previous 2', 'for ≥ 3 years before Screening', 'within the previous 18 months', 'within 7 days of the Baseline assessments', 'within 14 days of study therapy|PI therapy', 'within one week preceding first study drug administration.|History of drug', 'in the 12 months preceding the inclusion|All protected', 'within the last 3 months|Systemic regular anti-inflammatory', 'in 4 weeks', 'after the first remission', 'at the time of study|Individuals with', 'within 10 days before receiving the first dose of the study drug', 'between 2014 and 2022.||', 'within 4 weeks of first infusion of study intervention', 'at time of signing Informed Consent Form|Eastern', 'within 24 hours prior to the first dose', 'while on the study|Willingness to comply with restrictions', 'at the time of inclusion|Received first-line treatment', 'in the past 3 years;|Have', 'within a previously irradiated field', 'at least 6 months prior to screening', 'during the whole trial period', 'recent exposure', 'during the study|History of COVID-19', 'within 14 days of informed', 'at least 1 documented', 'at least one of the following criteria', 'for at least 12 months prior to screening.|Documented treatment', 'at the time of the examination', 'less than 48 hours old', '1 month prior to study enrollment|Able to tolerate', 'within 8 weeks of screening', 'within 1 year after receiving the last dose of study drug.||Known seropositive', 'up to 3 prior', 'within 14 days prior to screening.|Any', 'during previous 4 weeks or', 'within 14 days prior to C1D1).|WBC', 'within three minutes of standing', 'within one week before screening;|Those with', 'within the past 3 months|diabetic', 'within 30 days of SSRS/FSRS', 'within the previous 5 years|Any active', 'at birth||For', 'in the past 12 weeks||', 'for 7 days following last radioligand administration', 'the previous 2 weeks prior to baseline', 'in the ear region|H/O', 'prior to enrollment does not exceed 300 mg/m^2|Age', 'within 14 days prior to randomization.|History', 'for at least 12-months prior to screening', 'within 5 years prior to the baseline', 'bilateral', 'at least 30%', 'at least one of the following three impingement tests', 'less than 6 months', 'within 5 months after the final dose of study treatment|Treatment', 'within 4 weeks prior to first dose;|Patients', 'during the trial period and', 'within 56 days before randomization|Patients', 'for at least 30 days prior to enrolment||Exclusion', 'at least 2 weeks before the start of study drug', 'within 3 months prior to the trial start', 'for at least 6 weeks prior to final screening', 'within 4 weeks prior to first administration of the study drug', 'within 3 days prior to initial administration.|Adverse reactions', 'within 6 months prior to initial medication|Subjects', 'within 7 days before or after each study intervention', 'within past 6 weeks.|Any abnormality', 'within the next 12 months|Hemodynamic instability|Refractory', 'at least 14 days prior to baseline.|Having', 'within 30 days before enrollment|Preexcitation in', 'during the 90 days prior to study drug dosing.||Estimated', 'during the trial 9', 'within 4 weeks or 5 times the elimination half-life prior to the first dose of the investigational drug.|Treatment', 'within 30 days from the initiation', 'within 8 weeks prior to informed consent', 'at least 50 percent', 'within 4 weeks before the first dose;|Previous therapeutic surgery', 'at the time of the study||ii', 'before surgery|Participating in conflicting clinical study', 'within the past 12-month', 'within 6 months before randomisation', 'within 5 years prior to signing the informed consent form.|Known', 'within 7 days before first priming vaccination', 'within 28 days of study treatment initiation', 'before enrollment;|Expected to', 'within 30 days prior to screening.|Subjects', 'during the 1 month period prior to', 'at the time of screening|Weekly average', 'within the past 1 year.|Have', 'at the time of admission', 'during the conduct of the study apart from the study', 'within 30 days prior to Visit 1|Employees of the study site or their immediate families|Pregnancy|Hypothyroidism', 'within 5 terminal elimination half-lives', 'six months after LEEP|No residual material available', 'more than 48 hours after surgery', 'at the time of randomization|Vaccination schedule in accordance with the current recommendations in France|Informed consent', 'continue the current regime of pharmacotherapy', 'during the study|Known', 'within 7 days prior to the first dose study treatment.|Evidence of', 'within 1 month;|Myocardial infarction', 'for 24 Weeks post', 'within 4 weeks before first cevostamab infusion', 'within 14 days before randomization|Patients', 'in the last 30 days.|The', 'within 14 days of the Screening Visit', 'within 6 months before the first dose of study treatment', 'within 14 days of study entry.|The', 'during the experiment.|Participation in other', 'within 2 years before study entryKnown|Central nervous system', 'more than 1 year before the screening', '5 half lives of study treatment', 'within 2 weeks of start of study treatment', 'time within 1 year prior to screening.|Use of injected', 'in the week before the cesarean', 'during the participant identification period;|Participants', 'at the time of enrollment);|Sustained clearance', 'within 2 weeks after the study treatment', 'since prior', 'within 2 years prior to the first study drug administration.||Abnormal heart function', 'after surgery after fracture etc.)|Those', 'within 3 months before the first administration;|Have a history of', 'within the past 6 months|Chronic oral steroid use', 'within the 3 month period prior to baseline', 'for the next three months', 'in the last 5 years (arm A)|patients', 'at the time of screening to undergo chemotherapy', 'within the three months before screening;|Specific restrictive', 'at time of screening|GYNECOLOGIC CANCER', 'at least one guardian consent', 'less than 1 year', 'for at least 6 months prior enrollment', 'within the past 4 weeks|A', 'in the four months preceding enrolment.|Patients on medications', 'at least 6 months||', 'for less than 3 months prior to screening.|Plan to change', 'within 28 days of start of study drug', 'within 12 months of DME diagnosis|No contraindication of', 'within the 5 years prior to the informed consent date|Bladder stones|Medical contraindication', 'within 6 months prior to registration', 'in stages', 'during study period|History of', 'leading ≥1 training session/week|Caregivers', 'within 24 months before informed consent', 'within 4 weeks before apheresis', 'within the last 28 days prior to withdrawal', 'in the previous 4 weeks of surgery|Patients', 'within the past 12-month period prior to Screening Visit 1.||General medical history||Negative', 'at the time of ICF signature', 'within 3 months', 'within 90 days prior to screening|Compromised', 'at the screening assessment', 'within 4 weeks of starting therapy', 'prior to surgery|Planned', 'in the last 2 years|2-year average', 'during the 2-week treatment period until after Visit 2|Has no other conditions that', 'within 14 days of study initiation', 'Index Men:||Identify', 'during the exam', 'more than 15 diopters of refractive error|The subject', 'for at least two weeks before treatment initiation.|Asymptomatic brain metastases', 'fatigue excluded', 'within 6 months prior to enrollment|History of', 'within 180 days before the day of screening', 'during study|Malignancy of', 'within the last 7 days prior to randomization', 'during the study|Received mesotherapy', '7 days prior to randomization', 'within 72 hours before receipt of any study', 'at the screening visit.|Participants', 'within the last 6 months)|Current use of', 'within 14 days of the first dose of study', 'within the 6 months preceding Screening.|Subject', 'applied 3 hours before the application.|Not taking', 'within 1 week prior to Day 1 of protocol therapy.|Patients', 'Within 6 months before cell reinfusion', '1 year before enrollment;|Subjects', 'within 3 years prior to randomization', 'within 1 week of dosing|Epileptiform discharges', 'within 14 days prior to the first dose of study drug.|Use', '5-time chair stand test|have', 'for at least 6 weeks||', 'for 3 months after the last administration of the study', 'at the Screening Visit.|History of any cancer', 'within 30 days of completing the survey.|Patient/ providers willing to complete the survey.||', 'at the time of inclusion|Having undergone surgery less than 1 year ago', 'at least 3 times per week|Able to complete two hours of moderate', 'prior to preoperative therapy', 'at the time of cardioversion;|Class III antiarrhythmic drugs administration', 'during the CPET;|Body weight', 'throughout the study||▶ Medically acceptable contraceptive', 'longer than 12 hours daily.|Participant', 'prior to enrollment||CD123 positivity', 'at the time of screening|Patient with', 'monitors;|Have high', 'during screening', 'within the next three years.|Only-eye', 'prior to randomization per country guidelines.||ii', 'within 2 weeks after study treatment administration', 'within five days prior to registration', 'during the preceding 3 months', 'at least one endocrine therapy', 'within 30 days prior to the first dose of the investigational product|History of smoked', 'at least 30 days prior to administration of IMP', 'within ninety (90) days prior to enrollment', 'more than 3', 'prior to participation', 'within 3 months of Study Visit 3|History', 'at least 1 unprotected', 'approximately 500 mL', 'at least 1 child', 'in the previous year.|Subject currently involved', 'in doses of >10 mg', 'during the study.|Patients who received cytotoxic chemotherapy', 'at the time of the experiment', 'at least 6 weeks prior to screening', 'at the time of signature of the informed consent form', 'after receipt of a vaccine', 'performing', 'treatment three times a week||', 'through 180 days after the last dose of study treatment.|Male', 'at least 12 months', 'within 7 days prior to', 'within 14 days prior to administration.|Have received', 'at least 28 days prior to study vaccine application', 'within 3 months of the baseline', 'within 2 weeks prior to apheresis;|Received', 'within 7 days prior to first dose of study treatment.||Must', 'within the last 3 months|Patient unable to comply', 'at least 12 consecutive months', 'Within 2 months of initial diagnosis', 'within four weeks before enrollment;|According to the judgment of the researchers', 'prior to cryoablation', 'at the time of recruitment|Pregnant', 'in the last 6 months before inclusion', 'in the active phase', 'during initial testing', 'in the previous 3 months before the qualifying stroke.|High-sensitivity', 'previous 24 consecutive months', 'within 30 days;|Echocardiography found', 'at day of enrollment|Neck pain patient', 'within 7 days before the study enrollment', 'at the time of the UT;|BMI ≤ 30 kg/m²;|With', 'within the 3 months prior to screening', 'throughout the study period', 'between 2 consecutive', 'within recent 72 hours before the vaccination.|Known history of', 'at time of screening;|Allergy', 'more than 1 standard unit of alcohol per day', 'unknown onset seizure.|Known', 'for the preceding ≥4 weeks', 'in the past six (6) months', 'at screening period and Day 0', 'within 1 month;|Urgent blood transfusion', 'for at least 1 month||', 'within 4 weeks of first TG6050 administration|Prior treatment', 'between two symmetrical points not exceeding 2 kg/cm2|Individuals', 'within three months prior to the trial;|Taking', 'within the last 1 month||', 'at least 2 B-lines by', 'within five half-lives', 'at least 3 calendar days||', 'within at least 3 years from the time of screening', 'within 4 weeks prior to baseline|BMI', 'prior to starting the protocol)|Recent', 'within 1 week of initial study drug dosing', '7 days prior to the first dose', 'within 3 months prior to screening.|Regular use', 'for at least 1 week prior to first dose of study therapy.|Platelets', 'within 48 hours);|SARS-CoV-2 etiology test', 'within the preceding 4 weeks', 'between 2 weeks before written informed consent', 'within 6 months of the screening visit', 'within the past 12 months prior to Screening|Use of electroconvulsive therapy', 'medical history and the presence of the', 'for at least 12 months).|Premenopausal', 'MRI)prior to', 'at the time of informed consent.|The', 'in the past two', 'more than 4 cm', 'in the past 6 months prior to study enrollment.|Patients unable to take enteral medications', 'within the previous 2 months.|Clinically relevant', 'for 4 months after the last dose of study treatment|Capable of understanding', 'within 6 months prior to randomization', 'within 2 weeks of day 1 of the protocol.|Total bilirubin', 'in the last 4 weeks (exception', 'for the first time by the study psychiatrist', 'within previous 30 days|Stroke', 'within the scope of web-based intervention', 'after the screening period suggest', 'within six months prior to the start of the study', 'within 28 days of study drug', 'patients|Pre-operative', 'prior to cycle 2|Life expectancy', 'in the next 24 months|Prisoner|Other contraindications', 'within the prior 4 weeks|Capable of', 'for at least 6 months after the last dose of study treatment|Have', 'after undergoing coronary angiography', 'within the past 12 months.|Attending the 2022', 'performed 28 days prior to study entry', 'within 7 days prior to screening.|Any LTRA', 'during the previous', 'during active study phase', 'in the 6 months prior to randomization.|Subject', 'at the time of randomization|Onset', 'for at least 8 weeks prior to screening', 'at 34 weeks 0 days to 36 weeks 5 days of gestation', 'after the last dose of study treatment', 'within the last 30 days before procedure.|Subject', 'within 2 weeks prior to study drug', 'within 30 days of screening|Participants', 'within 30 days prior to first exposure to study', 'within 2 weeks prior to first dose of study treatment', 'within 28 days prior to initiation of study treatment.|Resting', 'after deisolation.|Patient have the ability to ambulate', 'within 4 months of the date of that study completion visit.|Subjects', 'at least 90 days after the last dose of imatinib.||Patients', 'less than 2mm).||', 'within 2 years before the first dose', 'within 6 months of the first Experimental Session', 'within 6 months prior to first dose', 'less than 4 weeks prior to baseline', 'within 4 weeks before', 'during the last 5 years;|Patients', 'within the last 2 months;|Patients', 'at inclusion prior to administration of the Study Product', 'greater than 12-weeks', 'within 1 year before enrollment', 'during the previous 6 months；|Have', 'within past 12 months):|Suicidal Ideation Item 1', 'previous year.|A history', 'within 7 days before the first trial drug', 'within 2 weeks before the first dose.|History', 'within 3 weeks of Visit 1', 'last two weeks of the intervention', 'within 7 days prior to the first dose of study drug', 'within 28 days (Day 29', 'within the past 4 weeks', 'during the last 4 weeks', 'within 1 week of the first dose of study intervention.|Major surgery', 'in the past 12 months|inability', 'within 14 days prior to Day 1|Able to comply with treatment', 'within 5 years prior to initiation of study treatment', 'prior to study drug', '8 weeks before surgery', 'more than 3 times normal)|Presence', 'within the last 3 days prior to the start of the study', 'during at least 15 of the 30 days preceding enrollment|Is a patient', 'at least 24-months prior', 'within two weeks prior to screening|Treatment', 'during the study period and 120 days after the end of the study', 'while on study.|Patients must not', 'within 6 months (180 days) prior to enrollment||Note', 'within 56 days prior to baseline|Self-report', 'within 2 months of randomization', 'at the time of screening.|Impaired', 'last onset occurred within 2', 'within 28 days of the first dose of study drug', 'for at least 30 days prior to screening.||For definition of SOC', 'during the trial;|Has previously experienced', '15 days/month for more than six months', 'within 6 months|Receiving ART regimens', 'within 30 days of Screening.|Have difficulties', 'within 3 years prior to transplantation|ABO blood', 'within one month prior to investigation', 'at study start', 'within 10 days prior to first dose', 'within the last 6 weeks before inclusion|Use of hormonal therapy', 'within 52 weeks of', 'within 3 months prior to Day -1', 'within past 6 months of the screening', 'over 7 days ≥ 4', 'at least two of the following clinical criteria', 'within 24 hours prior to participation', 'at the time of enrollment.|Other protocol-defined exclusion criteria may apply', 'between 1 and 3;|being', 'within the past 2 years unless', 'prior to beginning therapy', 'since less than 5 years', 'at least one year prior to the index date for each of the specific diseases', 'for at least 4 weeks prior to screening)|Pregnancy', 'within 6 months following first remission||3 or more', 'within 12 weeks|Atraumatic amputation', 'for at least the past 3 months||', 'last 3 years|Chronic', 'in the three months prior to the', 'during the 3 months before the screening visit.|Use', 'in the 2 weeks prior to first trial vaccination', 'within the past 5 years;|current', 'within five years prior', 'within 14 days prior to the first dosing;|any', 'within the last year|American', 'after pre-hospital medical assessment|Patient objecting to participating in research', 'after the operation', 'within 4 weeks before the first administration α Antibodies or CD47/SIRP', 'menses for 12 months prior', 'after radical resection.|Patients', 'within 30 days of HCT day', 'within 3 months of signing', 'within 1 month of participating', 'within 2 weeks prior to the first dose of FT538|Live vaccine', 'within the past month of', 'within 4 weeks of registration', 'within the prior 1-8 months|HbA1c≥8%', 'during use', 'within the first 24 hours from presentation.||Exclusion', 'within the past 14 days', 'within 60 days of Visit 2', 'more than two years', 'within the past thirty (30) days with', '120 days prior to study', 'during the conduct of the study', 'in the 12 months prior to screening;|A history of mental', 'at least 3-4 times a week', 'pore size assessed', 'within 6 months prior to screening.|Proliferative retinopathy', 'within 8 weeks prior to the study blood draw|Participant', 'for at least 4 months after the last dose of study intervention:||Refrain', 'Newly diagnosed', 'at least 14 days prior to the start of IMP', 'during and within 1 year after trial completion;|Work', 'at the time of enrollment.|Total brain metastases', 'for at least 14 days after discontinuation of oral CAB', 'at the time of first SAR445419 administration corticosteroid', 'in last two months)|after', 'for at least 6 months before entering the study', 'within 12 hours of', 'within 180 days prior to Day 1.|Current', 'within the past 7 calendar days.||', 'continue to take them);|Clinical dermatologists', 'within 8 weeks prior to dosing;|Plan to', 'within 30 days of the study procedure.|Patient', 'within 1 month;|Without any', 'more than 72 hours', 'within 14 days):||Hemoglobin', 'in 3 months after using HCQ.||D. The initial date of taking', '30 days after last dose of venetoclax;|Previous participation', 'prior to screening', 'within 1 month prior to the expected initial application date.|Subjects', 'at the time of drug initiation.|Patients who receive', 'within 72 hours prior to registration', 'within 1 week', 'within 7 days prior to the first dosing', 'in the last 6 months.|Not', 'in the next 30 days', 'Medical history with more than two', 'within the previous 12 months,|antibiotic intake', 'for the time period outlined below and', 'within the past 6 months|Smoking', 'within 30 days of inclusion', 'within the last 3 days prior to the start of the study|Any topical medicinal products', '≥ 6 months', 'at least 30 days prior to Visit 2|Allergy', 'less than 2 months prior to study entry.|Premenopausal', 'since they participated in this clinical trial', 'within 56 days prior to the first administration of study treatment.|Unwilling to follow the lifestyle', 'at the inclusion visit||', 'within 6 months of prior to initiation of investigational procedure', 'within 1 week prior to enrolment;|Participated', 'past 24 months prior to Screening Visit 1.|Airway hyperresponsiveness', '3 months before', 'in the previous year before starting the treatment', 'before operation', 'within 6 months of the screening;|Any medical history', 'within 7 days prior to study enrolment', 'within the territory of the ACA segments', 'more than 8 cm', 'before the trial', 'at the time of cardioversion;|Uncorrectable', 'during the last 12 months|use of', 'within 2 weeks prior to the', 'within 24 hours; 16)', 'within one month before the first study day.|Subjects', 'within 4 weeks prior to the first study drug treatment', 'over the last six months|unable to communicate in English', 'within 30 days prior to study start', 'within 12 months of Screening', 'after HCT.(2', 'during the postpartum period||', 'within 12 months prior to the first dosing day.|Current enrollment', 'at least 3 months from the first administration of the study intervention to the last administration of the study intervention', 'within the 6 months prior to study enrollment.||20', 'within 5 years|Able to understand the protocol', 'within 30 days after the first administration', 'during the screening period.||Note', 'after initial treatment regimens', 'in the last 12 months prior to enrollment|previous pyloromyotomy', 'within the previous 2 years|Currently taking', 'at the time of signing the informed consent', 'within 3 months prior to Screening', 'antibody positive', 'at the time of consent|Cognitively able to provide consent', 'at least 2 months prior to study entry||', 'at the time of enrollment).|Tumors', 'within the previous 2 weeks|Severe cardiac', 'during last 3 months|Other', 'during the baseline 30-day diary assessment', 'within 30 days as part', 'within the last 4 hours', 'within the 24 months before screening with intravitreal (IVT) injections of an', 'within 4 weeks prior to baseline period;|Current smokers', 'at the time of menstruation', 'within the 28 days prior to screening.|Participant', '1 month before', 'in the hamstring muscles at least 1 month before the study', 'post-trial access program', 'within the last 72 hours', 'during the 6 month study period|Currently', 'within the 5 years prior to baseline|Prior LASIK or radial keratotomy surgery', 'more than 6 months.|Subjects', 'within 3 months prior to the first dose|Having', 'at the time of inclusion|Diagnosis', 'within 4 months before inclusion.||The above information', 'within 30 days of enrollment|Use an assistive device', 'following the last dose of study drug', 'within past 5 years.|Previous therapy', 'within 1 week prior to the first dose of study treatment.|Participation', 'within 3 months of EnteroTracker® procedure|Inability to provide', 'within 48 hours;|Stroke', '>6months prior to start of', 'within the last three months|Participation', 'within the previous 6 months before Screening', 'in the past two weeks|If the participant is', 'within three days of the chest trauma', 'for the last 3', 'within the last 14 days.|Platinum-based', ""at least 8 weeks' duration and should have"", 'within 6 months after end of former first', 'within 14 days.|Patients', 'at any time point', 'during the screening process', 'administered for more than 14 days before the study medication.|Human immunodeficiency virus', 'during the year.|Those who are', 'in the past 3 months|Body', 'within 8 weeks from time of screening visit', 'within 2 years prior to screening', 'throughout the trial', 'within 14 days prior to the first dose of KM602', 'administered in last 3 months', 'between 12 and 18 years|Stable conditions', 'within 28 days prior to the first MBS303 administration', 'during the study period.|Subjects who', 'for one week prior to PET scanning', 'within 30 days prior to Screening|Gastrointestinal disorders', 'within 6 months after signing the informed consent form to the last medication||', 'for at least three months|present', 'needing >6 months', 'before onset of jaundice,|Aspartate transaminase', 'throughout the study||', 'past medical history', 'within the last 5 years prior to screening', 'up to 20 mg daily', 'prior to enrollment.||(2', 'prior to the antiviral therapy', 'within two weeks of leukapheresis.|Subjects must', 'within 30 days before informed consent.|Subjects treated', 'in the last 1 week;|Oral', 'during study participant', 'following initiation of 1L metastatic melanoma (MM', 'for the affected patellar tendon', 'within 2 weeks before treatment.||Previous anti-tumor', 'within 4 weeks prior to the (first) study drug administration', 'within 30 days before this study|Pulmonary', 'within 3 months of participation|History of', 'within 28 days of cycle 1 day 1', '1 month prior to Screening.||Ambulatory', 'over the next 6 months', 'in the previous 30 days', 'within 4 weeks of the study|Active treatment', 'within normal ranges||', 'disease.|Medical history', 'within the past 12 months;|Uncontrolled hypertension', 'within 12 hours of study visit|Current', 'until 12 months after last dose of study treatment.|Patient', 'in the range of', 'no higher than -0.75DC', 'within 2 weeks before the surgery.|Lung ultrasound abnormalities including patches, pneumothorax', 'related:||Study history of live', 'pre-study baseline', 'within the last 2 weeks before study start.|Acute myocardial infarction', 'medical inquiry.;|History of', 'within 1 week of study participation.|History', 'within 3 months before vaccination', 'within 14 days or 4 half-lives', 'within 6 months after the final dose of study treatment', 'throughout the duration of the study|Participants', 'within 90 days of the Screening Visit.|Use of a', 'at the time of the assessment for admission to the protocol', 'less than 2 years|Blood', 'within 48 hours prior to C1D1', 'within 2 weeks after intervention', 'while on study treatment', 'at time of study entry.||ECOG performance status', 'for at least 5 years|Signature', 'within 4 weeks prior to start of treatment', 'at the time of signing the ICD', 'prior to documented', 'within 30 days prior to screening/enrollment|Any condition', 'for at least 72 hours AND|Is afebrile', 'within 7 days before treatment', 'within the 6-day period immediately following this date', 'within 2 weeks of injury.||', 'within the previous 7 days.||Acute illness', 'during a screening visit', 'within 18 months prior to the baseline study visit', 'in the last 6 months.|Diagnosed', 'within 24 months of Day 1 of this study', 'in the last 24', 'in the next year|other smoker', 'pelvic', 'in the previous 6 months.|Uses', 'within 5 years prior', 'within 28 days prior to the first dose of', 'in the last 6 months||-', 'in the last 8 hours.||', 'for at least 2 years|Throughout the study', 'in the last 3 weeks.|Known', '< 3 months old finding', 'within 8 weeks prior to the implantation|Suitable', 'within the past 12 months.|Those', 'at the time of consent|History of', 'at least 2.5 mm', 'during the mastectomy', 'within 7 days prior to IMP treatment start.|Bone marrow function', 'in the past 3 months;|Modification', 'within 5 years (', 'following the last dose of treatment.|Male', 'within 4 weeks prior to randomization.|History of immediate', 'at the puncture site.|Severe respiratory', 'in the last year.|Current', 'at the 60°/s', 'within 12 months prior to first cevostamab infusion', 'at 2 years', 'in 24 hours >1.0g;|Any', 'lasted > 6 months and < 10 years', 'for 24 hours after stopping study medication', 'within 2 weeks before the start of the study treatment(Including compound cantharidin capsules', 'within 14 days prior to the first dose of study drug.|Major surgeries', 'within 7 days before the first use of the study', 'pre-eclampsia,|Breech presentations|Antepartum hemorrhage|Cephalopelvic disproportion|Body mass', 'within 6 months;|Severe cardiopulmonary', 'during the last 28 days.|Prior treatment', 'within 90 days prior to screening|Previous', 'within 1 month prior to screening|Currently', 'in the past 12 months.|ACQ-6 ≥1.5', 'in previous 2 weeks', 'at least 1 highly effective method', 'less than 1 year prior to randomization.|Participants', 'at the beginning', 'during the 3 months before enrollment.||Female', 'within 2 months prior to the first dose of the investigational product', 'within 4 weeks of the first dose', 'and||8 for 16 or more years', 'within six months of the screening visit', 'within the past 6-months', 'for at least three months;|Scores 28 or more', 'for at least 2 weeks prior to start of study intervention', 'following initial curative treatment', 'at the time of signing the Informed Consent)|Person informed about study organization', 'within 4 weeks of the first dose of study', 'prior to surgery|Contraindication to Ferric Carboxymaltose', 'within 6 weeks of the 1st dose of FT538.|Presence', 'at least the past 12 months', 'at screening before randomization', 'within 6 months prior to enrolment.|Receipt', 'at least 1 week prior to Cycle 1, Day 1)||Known', '7 days prior to admission to the clinical trial unit until completion of the final onsite follow-up visit', 'at the time of screening|Subjects', 'within 3 months prior to Screening.|Clinically significant', 'within the next 3 months|Metal implants', 'within 12 months or less', 'within 6 months of study enrollment|Non-sterilized', 'within 4 weeks before screening;|Those', 'within 3 months thereafter).|Diagnosis', 'within 1 month after adequate', 'before start of intervention', 'within the 4 week period prior to screening', 'within 180 days prior to screening', 'within the planned area', 'within 28 days before enrollment|Patients judged to', 'within 2 years prior to start of study treatment', 'Comorbid', 'in the head or neck', 'after the initial Axi-cel infusion;|CD19 status', 'past 12 months or more', 'in the lower extremities|recent spinal', 'within 3 months prior to randomization.|Those', 'in the last 4 years|≥ 6 weeks', 'at baseline and 2, 5, 8, and 11 months postpartum', 'at least twice per year', 'at time of informed consent|Adenocarcinoma', 'for 15 weeks after the last IMP treatment.|Suspected hospital-acquired', 'within 4 weeks before dosing', 'within 1 week before study initiation.|Other vaccination', 'during the trial', 'during active participation in this study.|Willing', 'at the time of signing the', 'within 6 months before screening;|The level', 'in the past 1 year', 'after the first attack', 'within 1 month before onset|Not willing', 'within 1 year prior to Screening.|Had', 'at time of enrollment|Positive test', 'within 8 weeks before signing the ICF;|therapy', 'immediately prior to the first IP bolus initiation.|The participant', 'high-dose', 'at time of consent|Participant', 'less than 6 months prior to enrollment', 'within 3 months before signing the ICF', 'during the study.|Pregnant', 'within 5 years|Any other', '1 month after the study', 'at the time of initiation of stimulation', 'for up to 6 months of initial observation', 'within 14 days before the first dose of a trial drug.|Inability to swallow', 'within two years from screening', 'dialysis.|History', 'at the time of obtaining consent to participate', 'on the test site.|Skin type falling under the Fitzpatrick Scale skin types', 'at least 12 hours', 'in the normal function', 'prior to surgery.|Are', 'after admission', 'at the time of indications for surgery', 'at the time of signing the informed consent form: the age of the subjects', 'prior to leukapheresis', 'within 8 weeks prior to graft', 'within the previous six months;|have', 'Within two weeks of Visit 1', 'within 5 years prior to screening|Disease', 'within 6 months prior to study entry.|Symptomatic', 'for at least 30 days prior to enrollment', 'within 28 days of first dose of study drugs|Palliative', 'within 12 weeks of study intervention', 'at the time of surgery', 'concomitant', 'within 3 months|Refractory hypertension', 'within 4 weeks;|The patient', 'during the last three months|Vascular surgery of the arm|Peripheral vascular disease', 'within 4 weeks prior to lymphodepletion.|Hepatitis B infection.|Hepatitis C', 'within 7 days before the first cell transfusion', 'within 7 days|Albumin ≥3 g/dL|Lymphocyte', 'within 28 days prior to beginning study treatment.|No', 'during the inclusion period|parents', 'within 28 days prior to enrollment;|Has', 'within 3 years since starting the treatment；|Subjects', 'within 30 days prior to enrollment|Major', 'within the potential treatment area', 'prior 30 days|Active', 'within 6 months before randomization.|History of gastrointestinal perforation', 'at least 1', 'within 26 weeks prior to enrollment.|Live vaccines', 'for at least 3 months after the last use of', 'within the 3 weeks prior to enrolment|Subjects', 'at time of enrollment|Unable to feed orally|Family planning to move', 'at least 3 months prior to study entry.|WOCBP must return a', 'at least two recurrences for this study', 'before surgery|History', 'for at least 12 hours', 'for at least 5 months after the last dose of treatment with eculizumab|Subject affiliated to a social security regimen|Subject', 'within 7 days of patient inclusion', 'within 6 weeks prior to screening;|Pregnant', 'within 4 weeks (28 days)', 'at time of screening|Participants', 'within 6 months.|Subject', 'within the first month after diagnosis||', 'during the 3 months prior to screening.|Use of any prescribed or nonprescribed medication including antacids', 'before treatment;|Medical history of', 'during the study|Previous surgical treatment of the target knee using mosaicplasty', 'in the 4 weeks before screening||', 'in the knee at least 3 days per week', 'in the last 24 hours),|Severe granulocytopenia', 'at the time of the study)|Patient definition', 'within the last month', 'for at least 3 months|Ability', 'within 6 months', 'within the study period|Any', 'within three months before study registration', 'at the time of room', 'at the time of visit', 'at the time of randomization.|Female participant', 'within the last 2 weeks before inclusion', 'in previous 6 months', 'at the time of signing informed', 'within study districts|Are willing', 'within 2 weeks after the intervention).|Evidence of', 'in the last 6 months|Has a guardian', 'within 12weeks prior to screening', '3 times per week', 'at the time of the index procedure|Serious angiographic complication', 'within 14 days prior to randomization;|Has received', 'for at least 6 months', 'within 1 year before recruitment|Patients', 'within 48 hours before start as well', 'for at least 4 months after the last dose of study treatment', 'before cesarean', 'prior to cataract surgery', 'in at least 1 of the parent studies (R3918-PNH-2021[NCT05133531', 'within 6 months after CR', 'within 4 weeks prior to the first administration of the drug.|Live vaccine', 'within 72 hours before the study group', 'within 14 days prior to the first drug administration', 'within 28 days prior to IMP treatment', 'within the 5 years prior to screening', 'at any time in the past.|Patients complicated', 'within the previous 5 years', 'at the time of screening.|Habitually wear soft contact lenses', '8 weeks earlier before administration', 'within two years;|With', 'at the time of adjuvant treatment', 'during the trial|patients', 'screening|Expected survival', 'during the study.|Use of any', 'newly identified', 'last 5 years', 'within 3 months before registration.|Non-healing wound', 'prior to Week 0', 'at least 12 weeks after the last dose', 'within the 6 months prior to beginning the study.|Use of', 'within one year of the screening', 'within 7 days prior to inclusion', 'within 28 days of the 1st dose of FT538.|Completion of initial COVID-19 vaccination series', 'within 24 hours of surgery 2', 'within 6 weeks before Day 1', 'at the time of inclusion|Taking omega 3 supplements', 'within 14 days prior to registration on study', 'within the past 6 months prior to enrollment.||9', 'last few months|History of', 'prior to enrollment)|Explicit', 'at time of surgery.|Has life expectancy', 'more than three times normal', 'within 48 hours before admission.|Acute kidney injury.|Acute', 'before surgery|The patient had', 'during the projected study period', 'after ~4 weeks of therapy', 'in the past six months', 'within 28 days prior to start of study drug', 'for 6 months prior to registration.|For', 'more than 5cm;|Multilevel segments', 'within 8 weeks prior to study enrollment', 'within 14 days of study enrollment', 'within months of donation/consent', 'throughout the study period|capable to complete the forms for registration of signs', 'within the last two weeks.|Treatment', 'after myocardial infarction|prolonged', 'in the last five years|Parent', 'within 6 months before randomization|Significant', 'at least 1 of the following IV', 'within 6 months prior to study inclusion|Major surgery', 'throughout the treatment period and until 6 months after the treatment period.|Subjects must', 'in the last month|medical conditions', 'at least 4 weeks prior to C1D1', 'within 12 months from the first dose of study intervention', 'within the last 3 years possibly', 'within 1 week prior to the expected date of the first dose', 'within four weeks before enrollment;|Simultaneous treatment', 'within 6 months after signing the informed consent', 'in the last 12 months.|Abnormal', 'within 72 hours prior to study dosing', 'for at least 1 year.||In', 'in the past can be enrolled', 'within prior 48 hours;|Blood glucose', 'within 3 months before the first study', 'within 30 days before vaccination;|History of COVID-19', 'with incomplete blood count recovery (CRi)', 'within 2 months after the end of cetuximab treatment', 'within 4 weeks before enrolment and within 3 days before treatment start.||', 'at the time of signature of the main study ICF|Performance status', 'within 28 days before signing', 'within 2 weeks prior to starting treatment.|Patient', 'during the previous two months', 'before starting any screening procedure.||', 'while the mother', 'within the past 5 years;|documented myocardial infarction', 'during the course of the study.||Administration of a live', 'prior to Experimental Sessions', 'within 28 days Radiation therapy', 'within 60 days prior to screening', 'within the last 14 days|those', 'in the last 6 months,|The', 'within 3 months prior to randomization;|Patients', '48 hours prior to admission|Norepinephrine infusion', 'cardiorespiratory', 'within 30 days prior to receiving the first dose of investigational treatment.|Patients', 'in the last year|Congenital bleeding disorder|Pregnant', 'within two years', 'within 6 months prior to randomization.|Subjects', 'within 4 weeks prior to first dosing.|Administration of medications', 'one month prior to and/or', 'during the 10 days prior to surgery', 'within 1 week of initiating treatment', 'at least ≥1 filling pedal vessel', '3 months after last', 'during the month before selection|Patient', 'within 2 months after study completion;|Use', 'during the 3 months prior to', 'within 3 months prior to study vaccination;|Suspected', 'during the', 'within 7 days of first dose of the investigational product(s)|Disease progression', 'within 6 months||', 'during and after study intervention.|The investigator', 'at the Screening Visit.|History of', 'at the time of signing the Informed Consent Form (ICF', 'within 5 minutes of each other', 'in the past 12 months|willing to provide written informed consent||', 'in time', 'in the last two months prior to recruitment', 'within 30 days before signing the ICF.|Use of medicinal products', 'in aim 1b do not', 'throughout the duration of the study.|Use of 5-HT4 receptor agonists', 'at least 3 months prior to dosing.|Sexually active', 'for at least 8 consecutive weeks before', 'at 4 years) after the baseline CT', 'lifetime history of engaging', 'in past 3 months|neurogenic bladder|pelvic floor surgery', 'and|Less than 32nd', 'at the operative site.|Have', 'during the intervention period.|Have a high', 'During the study Treatment Phase', 'within 12 months on', '>=6 months prior to Day 1.|Active', 'at the time of registration', 'at least 60 percent', 'after more than six weeks', 'within the normal range.|Patients voluntarily joined this study', 'for at least three mounts||', 'within 2 weeks of first administration of study drug|Uncontrolled', 'during activities,|insidious onset of symptoms not', 'through 30 days after ASP5354 administration.|Participant', 'within 2 weeks before the procedure;|Tandem extracranial', 'in the past 12 months||Exclusion Criteria||Known', 'within established normal limits', '7 days after the isolation period', 'after liver-', 'for at least 2 weeks prior to the first administration of the study drug.|9', 'in past 3 month|Patient', 'during the physical and gynecological exams', 'within 7 days prior to the first dose', 'training time less than 3', 'within 14 days prior to registration.||Platelet count', 'within 8 weeks prior to graft implantation.|History of', 'Action Step 3 on the Participant Suicide Risk Screening form: found in protocol)|Need for detoxification|Active psychosis', 'in the past three months;|ALT', 'at least 1 prior anticancer regimen', 'more than 12 months prior to enrolment', 'within 2 weeks before screening.||● PartB:||All subjects||Breastfeeding', 'during maximal cardiopulmonary exercise test.|Comorbidity', 'in the 4 weeks preceding the first test session|Having', 'during the last 2 months|Having', 'for at least 4 weeks before the first dose of study treatment', 'within 30 days prior', 'at the time of random administration', 'within 5 years', 'within 3 days or', '6 months post-', 'within 30 days prior to the screening period', 'during the last 6 weeks|Previous spine surgery|Neurologic disease', 'within the recommendations of the Danish National Health Authority', 'within the 2 weeks prior to Day 1|Use', 'in the previous year|deep vein thrombosis|cardiovascular disorders', 'prior to performance of any study-specific', 'within 4 weeks of the first dose of the study drug|Participant', 'post-bronchodilator', 'Prednisone equivalent)|No prior', 'within 60 days prior to randomization|Patients', 'prior to the first refraction used to establish stability', 'within past 2', 'within 2 months prior to the expected initial application date', 'within 30 days of starting trial therapy.||Known', 'within 7 days prior to assessment|Hemoglobin', 'in the last echocardiography|Decompensated', 'in the time of the study||Exclusion criteria:||acute affliction', 'over eighteen years', 'during the observation period|Patients', 'at least 12 weeks prior', 'at the time of inclusion|Undergoing surgery', 'at time of inclusion.|Subject prone', 'for two hours following product application', 'prior to enrollment.|Cytotoxic chemotherapy', 'for at least 2 years||Inclusion Criteria for the', 'within 24 hours prior to the dose of study drug', 'after the first week of treatment on', '< 8 g/dL|Quantitative', 'within 7 days before C1D1.|Hemoglobin', 'during the study||Smoking||Current', 'during the study per investigator|Personal', 'for at least 4 weeks prior to beginning the study', 'within the 6 months prior to the screening', 'in the past 4 weeks', 'at least 6 weeks after bilateral oophorectomy', 'within the last 2 years.|For', 'for at least 6 months;||', 'at least 90 days following completion of radiation', 'after previous antineoplastic therapy', 'for dose escalation phase', 'anaphylaxis|Recent', 'at the time of inclusion|Performance status', 'within 28 days before inclusion', 'within 30 days prior to the first dose of IP', 'continue the original treatment.|Agree to provide archived tumor tissue samples', 'greater than 6 months', 'within 3 months of Day 1.|Is pregnant', 'within 5 years of treatment enrollment', 'prior to Cycle 1, Day 1.|Treatment', 'within the prior 6 months|use', 'at 12 weeks after starting chemotherapy', 'prior to admission|recent abdominal surgery resulting', 'before starting treatment', 'within 3 years prior', 'within 12 weeks prior to visit', 'before treatment.||', 'while receiving Venetoclax|Use effective contraception', 'within 28-days before Week -1', 'in 3 months prior to screening', 'DLBCL;|A history', 'in the past eight weeks.|Frequent', 'within 3 months after enrolment.|Not willing to give written informed consent for', 'within last 2 months', 'within 3 months prior to enrolment|a major chronic co-morbid medical condition', 'after PDx therapy);|4.Dose expansion', 'pathologic', 'for the last 6 months).|Metastatic disease to the brain', 'within 6 months prior to randomization;|Use', '6 months prior to screening|Known', 'within 48-hour of regular visit', 'in the past 2 months', 'within the electroporation', 'Nursing', 'over the past 3 months', 'prior to DC vaccine', 'at the time of inclusion.|No', 'after the radical prostatectomy', 'prior to dosing.|Prolonged QT interval', 'during the medical interview/physical examination', 'within 90 days prior to screening.|Not', 'at physiological doses', 'at time of operation|Presence of ileostomy/colostomy|J-pouch', 'within the past 6 months.|History', 'during 12 weeks prior to screening', 'over time during the', 'for the time between the treatment visit/s', 'past 5 years', 'for up to two weeks prior to enrollment.|Patients', 'within 60 days before study intervention administration', 'within a 4 weeks.|Those', 'within 3 months prior to the screening period', 'within 1 week before the study', 'at least 4 weeks between scans', 'past two months|Suicide attempt', 'during study treatment', 'within 14 days of study', 'within allowable criteria', 'within the last five years|pregnancy|illiterate|younger than 18', 'at the time of signing informed consent.|Diagnosis', 'prior to vaccination,|having a', 'at least 12 weeks before the date of implantation|At least 3 mm', 'block.|Successful PCI', 'at least 3months prior to enrollment', 'during the course of study', 'infection|more than three urinary', 'for at least 3 days after the last dose of study intervention||Capable', 'in the last 12 months|Have been', 'at least 6-months prior to enrolment|Non-obstructive spirometry', 'after initial training', 'for one month after receiving the last dose of therapy|Ability to understand', 'for ≥ 4 weeks', 'following features:||Increased expression of MYC', 'within 3 weeks of baseline assessments', 'for at least 2 weeks prior to randomization', 'within 9 months prior to enrollment|Patient capable of providing written informed consent|Patient willing', 'in 3 years before the first medication.|Has multiple factors', 'within 4 weeks of cycle 1 day 1', 'within 5 years of screening|History', 'at least 7 days prior to the start of any study', 'within 14 days prior to the initial administration of study', 'at the last 2 visits before the end of study', 'in the last 6 months,|Those taking', 'before starting bevacizumab', 'within 30 days of study entrance.|Patients', 'within 4 weeks before initiating study treatment.|HIV-positive', 'for at least 6 weeks prior to screening.||', 'in the 1 month prior to Day 1|Major surgery', 'during the Screening period.|IOP', 'within past 12 months', 'within 4 weeks prior to the first administration of study drug;|Radiation therapy', 'in the last 10 years', 'in the impacted or more impacted leg|Fracture', 'within 12 weeks of screening.|Subject', 'their prior consent', 'within 60 days prior to study initiation.|Personal', 'after ≥ 1 line', '14 days after the last dose of', 'during the pre-TAVI electrocardiogram', 'within 14 days prior to the first dosing of', 'within last 6 months,|uncontrolled', 'admission to ICU|Allergy to sugammadex', '< 1 year prior to screening|Glycated haemoglobin', 'Criteria||Present', 'within 3 years prior to the first dosing of study drug', 'within 7 days prior to the start of LB101', 'within a 3-month', 'within 5 years of entry|Use', 'at least 6 months after the last dose of study medication.|Patients', 'at least 12 months before study enrolment', 'at Visit 1/Screening', 'within the Screening period.|Has a', 'within 28 days prior to Cycle 1 Day 1', 'within 2 months before entering the trial', 'within 12 months prior to randomization|History', 'one month before inclusion', 'within 3 months prior to dosing;|Previous', 'within 14 days prior to the first dose of study treatment||', 'within the last 3 months|Use', 'within 3 months prior to signing the informed consent', 'for up to 3 months after last dose of study drug', 'within 30 days before enrollment；|Known coagulation dysfunction', 'during the last 3 months|not', 'within 28 days prior to the first dose of FT538', 'in the last five (05) years;|Participation', 'at least 2 weeks later', 'before the onset', 'within 3 months prior to study inclusion', 'prior to surgery|Contraindication', 'during the 7 days before the first dose of radioligand (PET subjects', 'within the past five years', 'within one month before enrollment;|For the benefit of the subject', 'within 4 weeks before the first medication;|Subjects', 'after hematopoietic stem cell transplantation', 'within the last 180 days.|Participants', 'during the course of the six-month study period', 'within the past three', 'up for 12 months', 'comorbid', 'in the last 90 days of laser treatment', '6 months after the last dose of 64Cu-anti-PD1 [', 'previously been treated with', 'within the next three months.||', 'within 6 weeks prior to the first dose of the study drug.|Have', 'at least 2 years', 'Coronavirus 2', 'previous 5 years.||Any chronic', 'before Screening', 'within 14 days of day', 'at the baseline', 'within 30 days after enrollment or receipt of study vaccine).|Receipt of any vaccines', 'within 2 weeks prior to screening.|Systematic treatment', 'at least 6 months prior to screening.|MRS score', 'for at least 14 days', 'more than twice', 'during the study period|Pregnant', 'for at least 90 days after last treatment administration', 'during the study period;|5.2', 'during the past 2 years;|Women', 'within 8 hours of treatment sessions', 'within 30 days of study enrollment', 'within 14 days prior to randomization|RBS', 'within one year prior to treatment initiation;|participated', 'in the 3 months prior to signing ICF', 'within 4 weeks prior to Step 2 entry.||No CDC', 'in the month following concussion||Exclusions:||- head laceration||Control', 'for at 6 months after the administration of IMP.||If', 'during or after standard therapy', 'for three consecutive days)|Medically cleared', 'within the normal limits for beginning enoxaparin sodium injections|not', 'in the IVC.|Patients', 'within 28 days prior to the beginning of the study', 'without prior', 'during the past 24 months.||Have at least two UP/Cr ratios', '30 days after full coronary revascularization)|Indication', 'preceding 3 weeks', 'throughout the study chemotherapy', 'within 7 days of the hematology laboratory sample obtained', 'within one week of continuous wear', 'at least two months after vaccination|For fertile', 'for at least 6 months post-treatment', 'at the time of first diagnosis', 'within the last 3 months|spa therapy', 'at least 3 days in the past year they', 'since injection.||Previously', 'less than 2 years', 'Hospital for 4 clinic visits||', 'within 4 weeks of IP', 'for at least 3 months)||Exclusion Criteria', 'within 30 days prior to entering the study.|The tumor', 'within past 3 months for Cambridge', 'within 30 days post', 'at the time of proposed surgical resection.||', 'within 1 year prior to index PCI|Active', 'at study entry', 'within 12 months was more than 50 %', 'within 30 days of randomization|Use of any', 'within 2 weeks prior to the investigational', 'pre-operative clinic', 'after one cycle neoadjuvant.|ECOG', 'after receiving at least first-line systematic treatment', 'within the first 10 days.|Patient', 'within the 8 weeks before the baseline visit|Patients', 'at any time during pregnancy||Cohort 2||Diagnosis', 'in the prior 6 months)|Reports', 'after prior anti-PD-1/', 'within the last 1 year', 'within 3 months prior to the screening visit.|Unable/unwillingness to complete study specific diaries', 'prior to treatment initiation', 'within the last 30 days prior to screening|Pregnant', 'at least 6 months.|Patient', 'within the past 180 days', 'within 30 days prior to administration;|Subjects', 'within 30 days prior to screening visit', 'within 2 weeks prior to screening visit', 'at time of treatment.|Known history', 'in the last 12 months.|Consuming metabolism-altering drugs', 'prior to enrollment|Patient', 'at least three days a week for the past three months)|Low', 'within the preceding eight', 'at the time of screening|Subjects taking', 'prior 3 months', 'within 3 months after administration of IP||A', '8 AM', 'doubling time over six months|PSA value', 'throughout the study.|Smoking,|Having a lifestyle deemed incompatible', 'for 6 months after the last dose', 'within 28 days prior to registration.||', 'within 6 months of Visit 2/', 'during screening/washout|Women', 'in the past 21', 'within 14 days prior to the first dose of the investigational drug', 'recent prior', 'within recent 3 month', 'at the time of admission,|Patients', 'within 1 year prior to screening.|History', 'in the last 6 months;|Diagnosis of myogenic Temporomandibular Disorder', 'within 4 weeks prior to entering the study', 'weeks after radical prostatectomy|Aged', 'in the 12 months prior to the first administration of the study drug', 'at signing of informed consent|Type 2 DM of minimum 5 years duration', 'in the past 1 year.||', 'within the past 6 months before first dose.|Major surgery', 'for ≥ 14 days', 'at least 2 weeks prior to randomization|If', 'in the last 12 months;|Acute', 'within 1 month prior to screening;|8', 'within 6 months prior to screening;|Is', 'within the three months preceding the first dose of study vaccine', '<8 hours', 'in last 3 months|presenting', 'at least 2.5ml or', 'during the previous three months|Refuse to sign informed consent', 'within 4 weeks before first administration of DZD9008.|Any cytotoxic chemotherapy', 'throughout the treatment period and for 6 months after the treatment period|Sign the written informed', 'at the time of enrollment.|Subject', 'during the participation of clinical trial.|Those who voluntarily decide to participate', 'within 3 months prior to enrollment|thrombosis', 'at least 6 months after the last dose of protocol therapy.||Childbearing potential defined', 'within 1 month;|Subjects', 'within 14 days prior to the required', 'past history', 'within 120 days of the date of the genetic sample collection', 'continue for 1 year after all treatment', '6 months prior to the start of the experimental trial|Use of PEA supplements', 'within 3 months prior to experiment', 'between 4 and 24 months prior to the start of the study||Health care', 'within 7 days prior to initiation of treatment', 'for 3 months after treatment.|Subjects/Surrogate decision maker', 'within six weeks prior to surgery.|Female', 'within 7 days prior to the first dose);|Be able to provide', 'within 6 months of the first study intervention administration', 'within the 2 weeks prior to surgery', 'interfering with normal', 'within 30 days prior to study', 'within 4 weeks prior to enrollment|Radioimmunotherapy', 'for three months after the last administration of entrectinib:||Agree to take', 'within past 30 days.|History of', 'within one month prior to screening visit', 'within 6 weeks of Screening', 'within the month prior to the initial visit.|Treatment', 'at time of initiating study treatment', 'within 30 days of Screening', 'within the last 60 days|Have', 'in the month prior to screening|Use of (foods with) pre-, pro-', 'during ATI.|Receipt of any', 'within 7 days prior to Study', 'within 3 months of inclusion|Iloprost expected', 'during the study.||*Methods of contraception', 'during the study period|Stable body weight', 'after allogeneic hematopoietic stem cell transplantation', 'no more than one lung lobe', 'within 12 months before the start of the study', 'at diagnosis.|The patient or family', 'within 7 days of the first dose administration', 'during the period covered by', 'in last 2 weeks|Initiation of allergen-specific immunotherapy', 'during their HF hospitalization', 'in the last month.|Probiotics used', 'in the past 6 months|Subjects', 'within the 6-hour STS', 'in the 3 months', 'during the study.|Use of known', 'within 4 weeks prior to the start of TY-2136b treatment', 'for at least 7 days after the last dose of lenvatinib:||Be abstinent', 'within 2 weeks before the RCT|Participants', 'within 3 months prior to enrollment;|Acute coronary syndrome;|Patients', 'within 3 weeks of start of study intervention.|Is', 'during time period 2015-2018||', 'at two or more', 'within 2 weeks prior to Cycle 1, Day 1||Patients', 'prior to introduction of HY', 'at least 1 of the following conditions apply:||a', 'at least 4 weeks prior to screening', 'within one year of baseline', 'pre-term', 'prior to first dose of study treatment', 'at least one additional', 'within 4.5-24 hours', 'within 3 months before first study vaccination', 'at least 6 months earlier)|to have already received', 'after trauma & lt', 'within the past 1 year.||-||', 'within four weeks of the first administration of a clinical trial drug', 'more than 4 cups', 'last two weeks prior to entering', 'at least 8 on the', 'within 1 year prior to signing informed consent', 'in the last 3 months.|High', 'preceding 24 consecutive months', 'during the pre-surgical anaesthesia consultation', 'in the previous month', 'in the 7 days before Baseline (the prospective observation period', '3 months before recruited', 'in the last 6 months|Medical revascularization', 'in the past 6 months', 'within 7 days prior to enrollment|Patient consent', 'within 12 months before the first administration of the drug', 'during the oral glucose tolerance test', 'within 14 days prior to receiving the trial drug', 'at the time of randomization) should', 'for 30 days prior to Screening/Baseline through the second in-person visit|Have a study partner available to help', 'within the last 8 weeks prior to enrollment', 'within at least 6 months after the last dose of investigational drug;|Voluntarily participated in this study', 'prior to study randomization|At least one', 'within 2 weeks prior to Cycle 1, Day 1|Received oral', 'within 3 months of screening:||Hepatomegaly|Splenomegaly|Participant', 'in the 2 years prior to randomization|Active', 'within the 4 months preceding study treatment', 'medical history|no history', 'within 7 days prior to the start of investigational product', 'within 2 weeks prior to the first dose', 'within 30 days after vaccination / the last dose of the studied vaccine.|Prior vaccination', 'after the surgery.||', 'within the previous 2 years|Receiving/prescribed', 'within the past 12 months|Able to communicate', 'within 14 days before registration.|Unable to adhere to the study procedures.|Evidence', 'at least 24 hours before experiment).|Menstruation', 'within 5 days prior to the day of screening', 'less than 1 year before', 'within 4 weeks of starting the study treatment', 'after at least 4', 'at least 24 months after nephroureterectomy.|Subjects who cannot', 'in the past 5 years;|Patient', 'within 3 months|Sinus infection', 'within 3 months from enrollment to the end of the trial', 'at the time of data collection|Autism spectrum disorder', 'for the duration of study participation', 'within three months|Patients', 'within 6 months prior to receipt of study vaccine', 'within the previous', 'within 28 days prior to registration)|Participant', 'at least 2 weeks prior to the first study treatment administration', 'within 2 weeks prior to first dose of Ensifentrine/ Placebo', 'prior to start of therapy', 'in the 3 months before screening', 'for at least 5 half-lives', 'within one week before operation|Severe cardiac dysfunction', 'at the time of recruitment.|Pregnant', 'within the range of 18 to 30 kg/m2', 'within 7 days prior registration', 'maximum 6 months old when they', 'for at least one year)|Have', 'within 4 weeks before the inclusion|Subject previously treated', 'within the past year).|The families', 'within 6 months prior to the start of any study treatment.|Congenital', 'post-delivery', '30 days after trial', '≥5 times per week', 'at pre-inclusion gastroscopy', 'prior to entering the study.|Subjects', 'within study period', 'within 12 months prior to screening.|Is unable to refrain', 'within 8 weeks,|ongoing consumption of ethanol', 'since at least one year', 'within the 3 months prior to screening.|A confirmed', 'within 6 months of the Screening Visit', 'medical history related to the digestive system', 'in the last 12 (twelve) months (CNS Resolution 251', 'within the last 5 years.|18 years old', 'within 30 days of Screening|A history', 'at the time of enrollment.|COVID-19 diagnosis', 'at Screening and Day 1|Women', 'after pancreatectomy|history of total parenteral nutrition', 'prior to any procedures', 'within 2 weeks of the first dose of study medication|Active', 'at first diagnosis', 'within 3 years prior registration', 'at the time of CAG', 'within 30 days before SBRT', 'since the first dose of ranibizumab', 'at least 1 of the following', 'at the first admission to NICU ≥12 hours||', 'within 1 week prior to Cycle 1/Day 1.||(11)Patients', 'within 12 months before informed consent', '1 month prior to screening.|Intake of probiotics', 'within 3 hours of bedtime', 'in the last 6 months|Being', 'within 60 days before enrollment', 'within 7 days before', 'within 3 months prior to the first administration', 'in last 6 months', 'within the unit.||', 'at the time of signing the ICF.|Patients in the screening period met the following criteria', '3 months prior to first study drug administration', 'within one year before receiving', 'within the general treatment cohort', 'within 6 months before.|Female', 'for 7 days following', 'within 3 months before screening.|Participant', 'within 28 days of the start', 'within 12 months.|Those', 'admission to intensive care unit', 'within the 12 months prior to the first dose of study', 'enrolment.|Having 12 months documented pre-study treatment', 'during their screening visit', 'before January 1st', 'within at least 6 months after the last administration of the investigational product.||', 'at the time of a', 'at least 7 months after the final administration of', 'prior to the first dose of study drug.||Solid Tumors', 'within 3 hours of trial enrollment|Answer ""yes"" to a', 'during a longer period of time', 'at the time of signing the ICF.|Body weight', 'weeks prior to screening', 'in the second test may be included in the study;|Need', 'within the 6 months Prior to the first dose of study drug', 'for less than 2 years.|Medical history', 'at least 3 months after the last dose of protocol therapy||A', 'prior to Day 1;|participation', 'index of', '6 months before the study.|Any subject complaining', 'in the lower limbs', 'within 6 months prior to screening.|Have', 'on the day of the investigation', 'within 14 days prior to the study agent administration', 'within 1 week.||', 'within the past 5 days|Insufficient mental', 'within 28', 'at least 20 minutes', 'on taking first step', '< 4 months before randomization.|Anticipated need', 'within the three months prior to screening', 'within the past 6 months|additional neurological conditions', 'within 14 days before study entry', 'after registration.|History/physical examination', 'at the time of diagnosis|Multiple pancreatic nodules|Diagnosis', 'before 40 years', '< 30 days', 'prior to the screening period should stabilize', 'within 3 years|Provided voluntary', ""prior to admission|Parkinson's disease"", 'within the last 6 months|Heart', 'in the wound.|Subject', 'in the last 24 hours|Taking 2 or more cups', 'within 60 days after end of anti-CD38', 'within 90 days prior to screen', 'camera|Current', 'within 4 weeks before the first dose of study drug.|Medical history of', 'during the training session', 'within 1 year before Screening', 'within 6 months prior to screening.|Those', 'within the 3 months prior to enrolling in the study|Be', 'within a six-month period', 'within 12 months before randomization.||main organ function', 'prior to study enrollment', 'over the last 3 months.|Stabilized', 'at least 2 weeks before the first administration', 'within 3 months|History of active', 'within 14 days prior to study drug', 'within 14 days after injury|18-75 years', 'within his/ her regular treatment', 'before the first dose of SerpinPC.|Historical', 'during the last 3 months|Be pregnant', 'within 7 days prior to IMP treatment start', 'after last dose of study drug', 'in the past 14 days.|Participation', 'within 60 days before the screening', 'prior to the diagnosis', 'within the past 5 years prior to screening', 'at the time of screening)||', 'before enrollment to rule out myocardial infarction.|Cardiac ejection fraction', 'prior to treatment|Expected survival', 'in the last 6 months|Medical conditions', 'within 14 days prior to randomization;|Active', 'within 6 months before first administration of DZD9008.|Any evidence', 'within the previous 12 months.|Patient', 'within 28 days for', 'for at least one month after the final dose of larotrectinib', 'during the taking of measurements', 'during the 7 days prior to study enrollment.||', 'within 4 weeks before screening;|Abnormal blood pressure response', 'within 10 days prior to week 0 visit', '1 year prior to this study.||', 'after their first ovarian stimulation cycle', 'within 1 weeks before the first dose of the investigational drug;|6', 'in prior 3 months', '> 48 hours', 'in the first 12 months|Previous history of', 'within 4 weeks before enrollment.|Poor control of hypertension', 'during the last 4 weeks.|Subjects', 'at start of', 'after at least 1 line', 'one month after SARS-CoV-2', 'less than 6 months ago', 'within 2 weeks of baseline', 'more than 6 weeks prior', 'within 28 days prior to the first dose of IP', 'during the past month.|Smoking', 'throughout the study.|Must have a minimum daily insulin requirement', 'within 8 weeks prior to the first dose or donated double red cell within 16 weeks prior to first dose.||14', 'at least 1 week', 'within 30 calendar days of Screening exam', 'within 60 days postpartum|having', 'within the next month;|Aggravated allergic history', 'during the 30 days following cataract surgery.|History', 'over 4 weeks', 'at least 4 weeks prior to first dose of study treatment', 'preceding 36 months', 'within 2 weeks prior to study start', 'more than six hours|patients', 'At least 1 year of working experience', 'within 3 months before the start of treatment', 'in the last 3 years.||Antibiotic intake 6 months before • the screening', 'within 3 months before screening.|Blood donation', 'after stable treatment', 'within 7 days prior to the first dose of trial', 'within 30 days prior to signing informed consent|Subject unwilling', 'for at least the past three', 'for five months after the last administration of atezolizumab:||Agree to take', 'at least 7 days apart.||', 'prior to initiation of any study-specific procedures', 'in the ICU for a diagnosis', 'for at least 6 weeks', 'within 6 months after the end of the study|Serious psychological', 'in the past 3 years;|Imaging (CT', 'within 16 weeks prior to screening|Active proliferative diabetic retinopathy (PDR)', 'within 30 days from the day of the inclusion', 'at time of transplant surgery)|Candidates', 'within 6 months before enrollment;|Patients', 'within the last 5 days prior to the start of the study|Any topical medication', 'for the first time;|No distant metastasis', 'less than 3 times per', 'less than 1 month.|Intra-articular knee pathologies', 'within 1 month before screening;|Patients', 'at least 6 months of one of the following', 'within 4 weeks prior to the enrollment', 'for at least 4 weeks prior to Screening Visit 1.|Pre-BD', 'before the beginning of the study', 'approximately 1 year of the screening visit', 'for at least 3 months after receiving the last dose of study drug', 'within 3 months of study intervention administration', 'within 4 weeks of last dose of study vaccine', 'within six months prior to screening visit', 'within 4-weeks', 'within 1 year after completion', 'within 90 days of study entry.|Serum', 'in the next 4 months|Out', 'in the four weeks', 'for at least 12 months prior to conducting the study||', 'wthin half-year', 'in the 3 months prior to the study', 'within one week of study entry', 'during the study.|Eating disorders', 'during their normal class period', 'training at least twice', 'within the last 3 months;|Oncology;|Previous lung transplantation', 'at least three episodes', 'during the study period;|Patients', 'in the pre-surgery status', 'during the vaccination phase of the study.|History of', 'least six months of healing after tooth extraction|Adequate dimension of the attached gingiva', 'within 3 days prior to registration', 'after 3 months of radiotherapy', 'during the study.|Evidence', 'within 6 hours prior to study drug', 'during screening.||', 'within 30 days prior to Visit 2/', 'within 30 days of inclusion.|Patient', 'within 6 months prior to signing ICF.|Surgery', 'in the past 3 months|Engaged', 'within 14 days prior to randomization.|Serum', 'within one year of the study treatment', 'within 6 months of the Screening Visit.|Prior XEN45', 'at time of Screening|No evidence', 'within 3 months of recruitment.|Subject', 'within 2 weeks after the last administration of the study drug.||13.12-lead ECG', 'at least 18 years', 'within 7 days prior to first dose of study', 'within 2 weeks prior to the first dose of study', '72 hours of symptoms,|American Society of Anesthesiologists (', 'during the study period|History of', 'more than 400 mL', 'during the past 6 months|Being', 'during a physician supervised', 'at least 2 months prior to enrollment||Exclusion criteria', 'recently than 3 months', 'within 14 days before the first dose of study treatment', 'within 7 days of enrollment', 'within 60 days prior to', 'prior to completion of any study-related', 'At least 12 years', 'until 6 months after the end of IP administration', 'within the past 6 months|Unable/unwilling', 'for at least six months prior to study drug', 'within the range of 1.8 mmol/L to 4.9 mmol/L', 'within 30 days prior to receiving the first dose of investigational treatment', 'within the range of 18.5 ≤ BWI', 'up to 4g/day to treat mild discomfort.|Use', 'within 30 days prior to registration.|Age', 'during the screening period and baseline period;|Subjects', 'in the last greater than >1 to less than <6 months', 'at the time of signing the consent form', '3 months.|At optimal volume status', 'prior to distal pancreatectomy', 'within 6 months of last dose of study', 'at least 6 months before.(20)|Females', '6 weeks before recruitment.|Specific dietary regimen', 'at screening.|Received any experimental therapy', 'during the study period;|Previous', 'for at least 12 weeks prior to screening', 'in the past 12 months.|Congestive heart failure', 'after the optimal medical treatment;|Urine protein', 'over the last month', 'for at least 1 months after the last dose,|Understand', 'in the last 36 months', 'during the trial;|Allergy to any drugs;|Participation', 'within 14 days prior to laboratory tests', 'prior to surgical repair of', 'Chronic', 'within 14 days)a', 'throughout study participation until 90 days after the last IP dose.||Note', 'prior to starting study therapy', 'during baseline', 'within 5 years prior to initial administration of the experimental drug', 'at least 3 months prior to Screening Visit 1.|Pre-BD', 'during the study period|Other pathologies', 'within the specified timeframe prior to dosing.|Has previously', 'in the last 1 year|Cognitive', 'within the past 3 months.|History', 'during daily time-restricted eating|RECTAL', 'within 6 months prior to randomization;|Subjects', 'period|At least 4 half-lives', 'within the screening phase.||Inability to consent to take', 'within past 30 days.|Confirmed', 'at least 30 days before the administration of trial medication until 30 days after trial completion.||The', 'during the past 5 years', 'in the affected upper extremity|Having scoliosis|Having', 'at the time of informed consent;||Meets the trial criteria for', 'more than 6 years', 'in the next 6-12', 'within 6 weeks before treatment', 'in the last two years', 'less than 3 months ago', 'within 7 days prior to first dose of study medication|Are', 'in at least 1 interrupted day of desired physical activity', 'within 6 months of signing informed consent form', 'within the Milan criteria', 'before time of injury|Patients', 'within the past 12 months.||For Cohort 1 and 2:||Suspected', 'during the clinical trial period', 'at 24 months (±60 days', 'within 4 weeks before the first dose of study medication.|Permanent discontinuation of prior sorafenib or lenvatinib therapy', 'within the past 3 years;|Women', 'within 7 days from the lab test||Absolute neutrophil count (', 'at time of blood collection to ensure steady-state|Patients', 'within 30 days after the date of enrollment', 'within 30 days of enrolment|Genetically', 'in the 48 hours prior to the period', 'within 1 year prior to Screening.|Clinically significant', 'during the trial period and 8 weeks after the last administration of the test drug;|Estimated survival≥ 12 weeks;|Sign a written informed consent form', 'within 1 month before the first TACE treatment;||', 'within the prior six months.|Known sensitivity', 'for at least 1 week prior to the first dose after drainage', 'for more than 6 weeks', 'before participation.|Age-', 'for the duration of the', 'at least 15 days of HA/month', 'within six months of study initiation|BMI', 'undergoing', 'placebo.|Discharged before day 7|Meeting the criteria for psychiatric disorders', 'within the past 3 months|Scores', 'five half-lives', 'within 6 hours of birth,|other known causes', 'at the time of starting DZD9008 with the exception of', '4 to 6 weeks interval)|Between 18-45 years', 'within four weeks prior to start', 'outpatient basis', 'within 4 weeks of the first administration of IP.|Has received', 'within the past 6 months|Prolonged', 'history before the first dysmenorrhea', 'during screening/initial', ""during surgery|Patient's refusal"", 'at least 20', 'within 8 weeks', 'within 6 weeks prior to screening;|Historical', 'within 28 days or 5 times the elimination half life (', 'surgical history that could result in any anatomical changes related to corrugator muscle', 'within 2 years of enrollment', 'at the time of positive', 'within 28 days prior to the start of study treatment.|Patient', 'since radiation.||8', 'for at least moderate', 'during 7 days prior to randomization.|Willing', 'at any time before screening', 'more than 25%', 'within 90 d of screening', 'at the time of screening|Cirrhosis', 'up to 6 months before randomisation', 'during the trial.|Willing to use', 'in the next 6 months,|pregnant', 'in the next 3', 'within the previous 12 months', 'at baseline and referred', 'more than 6 months).|Normal', 'Emergency Department||', 'prior to initial radiographic evaluation', 'within 6 months prior to study entry,|Galactose', 'for at least 3 months.||', 'at least 24 hours after cold somatostatin analogue injection', 'during hospitalization', 'medical history);||', 'for minimum 6 months|Functional hearing|Normal inner', 'during the study.|Subject', 'within 3 years.|Participant', 'after the last dose;||12', 'within eight weeks.|Current', 'during or after most', 'at the block side|coagulation disorder|BMI>35', 'at the time of index surgery|Any', 'after inhalation', 'during the past 1 month', 'within 30 days prior to the first dose of study intervention.|Is', 'in the past 3 years);|100-normalized score', 'prior to enrollment.|White blood cell', 'in the past 30 days|Pregnancy|Enrolled', 'before diagnosis', 'within 3 months prior to baseline.|Pregnant', 'within 3 months of the study enrollment', 'within 12 weeks before the first administration', 'at the time of inclusion|Person under guardianship', 'within a week of vaccination.|Have', 'at the time of screening.|Participant', 'at randomization', 'over 2 weeks', 'through 6 months after the last dose of study intervention.|Phase 1 only', 'within 28 days following receipt of study vaccine', 'for at least 6 months|Appropriate', 'for ≥3 months|Have confirmed', 'within 3 months before randomization.|Subjects', 'at at least 4 weeks post-injury', 'after taking the drug', 'within 28 days of screening.|Subject', 'at the time of the parent/legal guardian signing the informed consent form', 'within 7 days prior the first dose of study', 'within 1 month before enrollment;|13', 'within 30 days prior to Cycle 1 Day 1', 'during the 6 months before screening', 'during the week.|Positive COVID-19 test at prescreening', 'at the time of screening.||Diagnosis of', 'within 60 days prior to study screening|Patient', '14 days for seasonal influenza', 'at prior', 'more than 3 months.|Terminal', 'at the time of study initiation.||Individuals', 'during the phone', 'after the initial reduction surgery|Patients', 'between 8 and 12-years-old.|speak fluently', 'within 4 weeks before the first dose of the study Note: Physiological doses', 'less than half a year', 'within 1 mo of Visit 1', 'within the 6 months prior to screening.|Clinically significant', 'within 3 months prior to study entry', 'over the past two months;|Currently pregnant', '1 week before enrollment.||8', '3 months or more', 'within previous 7 days of screening', 'within 1 month prior to the dose of study intervention|Requires', 'after first or second line', 'within 90 days prior to enrollment.|Subject', 'during the period of the study|Signed', 'for 14 days after study medication', 'within 3 months of consenting into the study||', '> 12 months', 'in the month prior to the test;|Those', 'within 28 days before the study', 'for at least 90 days before screening', 'for at least five months after the last atezolizumab administration', 'in the previous 4 weeks,|Having', 'for 4 months after completion of ruxolitinib', 'within 30 days of Visit 1;|Have', 'within 6 months after exemption);|Previous history', 'in the past three months', 'before the first administration.|Inability to tolerate', 'least half of oral intake', 'within 2 weeks prior to randomization.|Use of B cell-depleting', 'during the 28 day Baseline', 'during the screening period.|Evidence of MM', 'within 2 years before screening', 'for at least the last 6 months|Diagnosis', 'within 2 years of study entry', 'in the past of three months before the beginning of the study', 'within 52 weeks prior to screening;|Drug', 'within 4 weeks of study enrollment.|Have any of the following conditions', 'within 4 weeks before inclusion|Subject presenting', 'within the year prior to the first dose of study drug.|History of', 'more than 2 hours communicate normally in Mandarin||', 'in the impacted or more impacted leg|Inadequate response to stimulation', 'prednisone daily dose > 20 mg or equivalent dose', 'at the time of consent.|Evidence', '8 weeks before baseline', 'within the past 5 days;|Women', 'within 4 weeks before administration of the study drug', 'prior to cycle 1 may be included', 'less than 4 weeks from the date of the first documented disease progression', 'prior to November 2020|AND able to understand and communicate in', 'Last measurement of TSH', 'within 14 days prior to neoadjuvant therapy.|Uncontrolled', 'at least more than 4 terms.|Course of', 'at the time of surgery|Diagnosed', 'at the week 50', 'within the past 3 months before study recruitment', 'prior to study treatment).||15', 'within 4 weeks prior to start of trial treatment phase', 'during the 4 previous weeks', 'during treatment', 'prior to standard of care treatment.|Patients', 'within 2 weeks prior to screening.|Had', 'within 14 days of enrollment)|Hemoglobin', 'for human chorionic gonadotropin (β-Human Chorionic Gonadotropin', 'within 3 months of study completion|Participation', 'within recommended doses are permitted', 'before the start of study treatment.|Being', 'within 90 days of the screening', 'within 14 days of the first dosing.|The consumption of grapefruit/grapefruits production', 'within 6 months prior to study', 'after the first PET-CT scan', 'within 4 weeks before the first dose of study', 'within the last 5 years|Patients', 'more than the equivalent of 10 cigarettes per day|Is', 'within 6 months prior to screening|Administration of a prescription', 'for at least 6 months prior to Baseline.||Participants', 'within the last 4 weeks before the screening date|Medical history of', 'within 1 week before laboratory examination', 'at least 2 years+2 months post vaccine/control', 'at the time of enrolment,|drug-resistant epilepsy', 'within 14 days prior to first dose of study drug', 'within 12 months before Baseline:||Systemic', 'at least 4 weeks prior to randomization', 'within 2 weeks prior to starting study treatment.|Radiotherapy', 'at least 6 hours before the procedure,|refusing to participate', ""for the first time;||The patient's laboratory tests"", 'past 30 days or less than 5 half lives of the investigational product', 'at least five days a week.|Written informed consent', 'prior to the index stroke event', 'within 4 weeks prior to randomization；|The presence', 'for at least one month.||', 'within 2 weeks prior to enrollment.|The', 'within 8 weeks of Screening.|Donation of whole blood', 'within 14 days prior to dosing;|Current', 'at the time of the first dose of KM602|Pregnancy', 'within 14 days before enrollment.|Participants', 'within 2 weeks of the time of protocol enrollment in CLL', 'over the past 2 years', 'in the emergency room', 'over 204 kilograms', 'within 12 weeks of last', 'at the time of informed consent||Part 1', 'within the past 2 years.|Diagnosis', 'during the previous 3 months', 'within the 3 month period prior to baseline;|Use', 'during the next 25 months.|Subjects', 'during the past 6 months|Estimated', 'within 12 months prior to screening.|Patients', 'within 3 days before receiving the first study drug', 'medical history of marked', 'after first line treatment', 'within 18 to 30 months of original diagnosis', 'in the exclusion criteria', 'within 6 months before the screening', 'within 28 days prior to the 1st planned dose of CHS-006;|Receipt of live', 'within 7 days prior to initiation of study treatment', 'during, and after treatment', 'within 28 days of cycle 1 day', 'during at least 6 consecutive months', 'in the last 7 days|Not', 'within 28 days after vaccination', 'in at least 3/7 days/week for the past', 'during study duration.|Subject', 'within 72 hours of', 'within 5 years before screening|Known', 'after provider recommendation)|At least 18 years', 'in less than 1 month ago.|Pregnant', 'within 6 months of surgery', 'before transplantation;|Central nervous system leukemia;|Arterial', 'prior to 2 years', 'within 24 hours prior to sending', 'within 30 days', 'at least 3 months after TG6050 administration', 'within 2 months of baseline', 'Injection of inactivated viral vaccines', 'inpatient', 'within 7 days prior to enrollment|Mother', 'for 6 months after completion of treatment.||', '90 days prior to registration||NOTE', 'at the time of signing the ICF.|Naïve patients', 'within 3 months of study enrollment.|Myocardial infarction', 'prior to enrollment:||Hematology', 'during the experiment.||-', 'within 8 weeks before enrollment|Oxygen (O2)', 'within the previous 30 days.|Stroke', 'within 30 days prior to entry', 'within the next 12 months,|history of', 'after radiotherapy', 'at either Screening', 'within 4 weeks of the first administration of IMP.|History of severe', 'within 6 months;||Clinically significant', 'before the first administration of the study drug', 'within 3 years before randomization', '≤ 28 days', 'at the time the ICF', 'at least 3 months prior to study start||', 'within 30 days prior to first dose', 'in the last 2', 'within the 4 weeks before Screening.||For', 'since birth', 'for at least the 3 months prior to study enrollment.|Able to read', 'at three time periods', 'during the clinical exam|Neck pain', 'within 56 days prior to administration of the study', 'in the past 6 months;|Subjects', 'prior to treatment|Portal hypertension', 'Williams classification);|absence of marked', 'within 28 days prior to inclusion', 'within 14 days prior to the first administration of any study', 'within 4 weeks prior to the first dose of study intervention.|Previously', '14 days prior to the first Investigational Medicinal Product (IMP) administration', 'at the start of the recruitment,|reside in a targeted county,|interested', 'within 30 days prior to Day', 'within 7 days of study therapy.|A', 'within 14 days before the first dose of study drug', 'in the past 2 weeks|Chronic', 'during the last 3 months|patients', 'during the last 12 hours', 'during the year following discharge|legal protection', 'last days of', 'prior to study participation after receiving detailed information on the purpose', 'more than 14 U per week', 'within 12 weeks prior to randomization', 'prior to Pemetrexed + Cisplatin Therapy:', 'in past 30 days', 'within 1 week before the start', 'prior to inclusion', 'within 30 days before the first dose of study drug', 'for the study duration', 'prior to the start of IMP administration', 'within 2 weeks prior to Meta10-19 infusion|Patients who participated in other clinical trials within 30 days prior to enrollment|Patients', 'during the study period.|Any confirmed', 'within 36 weeks', 'at time of screening;|Exclusionary laboratory results', 'During the dose expansion portion of the study', 'within 60 days prior to consent', 'in the early', 'within 28 days prior to the Screening Visit', 'for 6 months', 'within 30 days prior to study entry.||iv', 'within 1 month prior to the expected initial application date', 'at least <1500 g', 'at least one inclusion criteria', 'at the time of the study|Women', 'within 6 months prior to the screening', 'at the time of signing informed consent.|Must', 'within 4 weeks before first dose of study', 'within 5 minutes of ingestion of the first capsule.|Prior exposure to ARN-75039.|Positive serology for hepatitis B virus', 'within the previous three month|Have a work', 'surgical history (', 'within 24 hours after the onset of stroke', 'at the time of signing the informed consent/assent.|Participants', 'in next 6 months|Engaging', 'adjusted 28 days baseline diary.|Subjects', 'for 3 consecutive days', 'within 6 months of the first dose of study', 'within 6 months prior to enrollment|Interventional procedure', 'during the 6 months pre-index period.|Patients', 'at time of inclusion|Weight', 'in the last 3 months;|Planned to', 'within 2 weeks before the first dose of LP-168', '7 days before dosing', 'within three months before the procedure|A life expectancy', 'within the next 30-days.|Have access', 'in the last year.|Fixed deformities', 'in the last year|cognitive impairment limiting', 'during the screening period and the research process', 'for ≥3 years before', 'in the past 6 months;|Substances', 'half-lives', 'more than 2 weeks prior to the microwave', 'within 7 days before the first dose.||10.Spinal cord compression', 'for 3 months after the trial ends', 'prior to the start of IMP', 'within 2 years before the first administration|Synchronous', 'within 2 weeks of study entry', 'within 8 weeks after the last administration of the drug', 'at the time of visit 1.|Undergoing', 'within 1 month before the first administration;|Have suffered', 'in the past 6 months;|Despite', 'for at least 3 months prior to enrollment', 'for at least 4 weeks', 'within 3 years prior to inclusion', 'during inclusion visit', 'within the previous 12 months prior to the planned date of viral', 'within 24 weeks of initial invitation|Greater than 24 months lapse of survey completion after baseline surveys completed|Additionally', 'within 4 weeks (', 'past 14 days', 'within 8 weeks prior to the initiation', 'within one month prior to enrollment', 'after completing', 'at least 30 years', '3-4', 'within 8 weeks before screening', 'before preoperative therapy', 'within 2 weeks prior to Day', 'history at screening', 'during the study.|Participants are able to understand and voluntarily sign consent', 'within 6 months after screening', 'for at least 3 months after initiation of test drug to avoid pregnancy', 'at least 2 cm from any stented area.|Subject', 'usually done 8-12 weeks apart', 'within 30 days before screening;|Unable to complete the visit task', 'during the month prior to screening|Circumstances', 'during the evaluation process||Criteria for exclusion from the study:||Withdraw to any period', 'for at least 8 weeks prior to screening.||', 'prior to starting investigational medicinal product (IMP)', 'within 7 days prior to 124I-Evuzumitide', 'within 6 months;|History', 'within the last 12 months.|Those', 'up to 2nd degree', 'for the next three months||Exclusion criteria', 'within 7 days prior to receiving the first dose of study medication', 'within 3 months up to', 'within 3 weeks prior to the first dose of study drug.|Hypersensitivity', 'before administration', 'within 1 year prior to enrollment', 'over approximately 6 weeks duration', 'in the past 6', 'within 18.0 to 32.0 kg/m^2', 'at the time of the study|The subject', 'within 14 days of the study entry', 'within the next 30 days|Rural residence location', 'for 48 hours', 'after 1 cycle of standard regiments', 'during the first 28 days following the study vaccine', 'within 14 days (+3 working days', 'in 6 months preceding', 'within 14 days prior to the first dosing;|over-the-counter (OTC)', 'within 14 days.|Radiation therapy', 'at the Oregon Health & Science', 'in the 3 months prior', 'during the trial;|Donated blood', 'during the years 2018-2020', 'within 28 days prior to initial medication;|People', 'within 10 days of screening', 'throughout the duration of the study.|Received', 'within 4 weeks prior to randomization.|Concomitant', 'during screening.|Severe', 'within 12months prior to screening.|Participation in a clinical research study involving the administration of an investigational', 'within 1 month of the Screening Visit', 'during the study period|Recommended follow-up by means of either continued', 'at least 1 week apart', 'at the Screening Visit.|Extensive colonic resection', '<6 months since completion', 'within 4 weeks or 5 times the half-life time', 'within at least 12 weeks after the last dose', 'during the 6 previous months', 'within 1 month of screening', 'within the previous 12 months.||Active infection', 'prior to registration', 'during the flushing break', 'for at least 9', 'within preceding 3 months|Coronary revascularization', 'within the range of 19.0 to 26.0 kg/m2', 'within 3 months prior to screening|Prior exposure', 'within 30 days of screening|Ongoing toxicity', 'within 60 days of first dose', 'less than 1 month before the start of the', 'within previous 5 years|Ongoing', 'less than 3 months prior to screening.|The need', 'at the time of screening.|By self-report', 'in the previous 28 days.|Have received', 'outpatient or|≥ 3 weeks', 'within 60 days of starting the study', 'within 2 weeks prior to registration', 'within 1 year before first receiving the study drug', 'at least 4 weeks before the study);|Alcohol intake', 'during study', 'at the time of visit 1.|Clinical history of asthma', 'for five months after the last administration of', 'during the last one year', 'in the next year;|History of', 'preceding six months', 'within last 6 months)|Right', 'for at least 3 years since completion of last treatment with exception of', 'within 6 months prior to the study.|Acute', 'within 5 years prior to the start of study treatment.|Patients', 'During Activity||', 'during the study.|The subject', 'within 1 year before enrollment;|17) Those', 'within 72 hours prior to the start of study drug', 'within 24 hours before randomization', 'at any time in the', 'for less than 1', 'prior to initial administration:||Did not receive major surgery', 'in the last 3 months.||normal laboratory values', '≥ 3 months', 'throughout the study.|Receipt of blood/plasma products', 'for at least 8 weeks after the last dose of study drug.||F.', 'within 90 days of the initial signed informed consent', 'within the past month', 'During', 'prior to this trial.||3', 'before stroke.||', 'place at least 6 months prior to the start of the study.|Adequate', 'at least 4 weeks after the last dose of letermovir.||Note', 'within 7 days prior to study inclusion', 'within 3 months prior to drug infusion', 'for less than 2 weeks;|Patients', 'at the time of recruitment|>5 liters of oxygen', 'after curative therapy.|Uncontrolled intercurrent illness', ""within 30 days of the volunteer's expected enrollment"", 'within the past month, 3 or 12 months respectively prior to screening', 'within four months of', 'at least 7 months', 'prior to start of study treatment', 'within 2 weeks prior to Screening', 'at any time prior to screening.|Received', 'before starting therapy.|Patients', 'within previous 90 days', '7 days prior to or', 'during study participation.|Participant', 'prior to receiving study products', 'within 7 days before C1D1.|Total bilirubin', 'within 1 month before treatment', 'within 4 weeks prior to treatment;|Patients', 'within the last six months|Adolescents', 'within 28 days of cycle 1 day 1)|Serum creatinine', 'prior to enrolment', 'within four weeks or five half-lives', '90 days for biologics).|Clearly', 'more than 14 units alcohol', 'for 4 months', 'throughout the study participation', 'during which time', 'in 8 weeks prior to inclusion', 'within 24 hours prior to randomization|Progressive', 'within 28 days prior to Day 1', 'throughout the study period.||', 'within 14 days before the first study treatment', 'within 24 hours after enrollment;|Subjects', 'within the previous 6 months|Low-income', 'in the past 6 months.|people', 'within 24 hours after onset||The criteria of', 'within the following', 'at time of conception|Multi-fetal', ""prior to patients'"", 'at routine screening ultrasound Suspicion of', 'within 12 hours of hospital presentation.||Exclusion Registry', 'within a month after the second vaccination', 'throughout this period', 'at least 2 weeks before the first administration|Signed', 'in the last 15 days|Use of another', 'at time of planned pancreatoduodenectomy', 'at least 90 days before recruitment.||', 'at the time of enrolment;||Hospitalized patient', 'in the past 4 weeks|large doses of commercial probiotics', 'for at least 10 stanable', 'after the last IP administration', 'within 5 to 15cm from the anus', 'with the exception of alopecia.|Prior history of', 'in 24 hours of the mechanical ventilation', 'within the first 30 days of this study|Pulmonary', 'within five weeks following their last dose of', 'within the screening', 'preceding 4 weeks.|Malignancy/Avascular', 'within 30 days of index procedure.|Prior vascular surgery of the target lesion.|Lesion length', 'at enrollment.|Provision of signed', 'within the following 3 years|other', 'during the last 6 months;|body weight of volunteers should not go beyond 20% of the ideal body weight', '< 3 months before 68Ga-NY104 PET/CT', 'for ≥3 months prior to randomization.||Be on a', 'within 14 days prior to first dosing.|Administration of CYP3A4/5 inhibitors', 'Preoperative', 'within =< 1 year', 'within the last three months|delusional', 'within 5 minutes of assuming seated', 'within 28 days prior to the start of study treatment', 'at the measurement site', 'within 2 weeks of the first dose of study drug', '6 weeks prior to study', 'prior to invasive dental procedures|Use', 'at least 1 additional', 'within 30 days before enrollment', 'preceding 12 months', 'more than 1 SD below the mean score', 'within the 2 months before the beginning of the study', 'in the next 1 year|Ovarian', 'at least 3-months after this initial biopsy', 'during the study|Subject cannot', 'during the previous 10 years|signed consent to study participation||', 'for at least 4 weeks before study enrollment.|At least one measurable', 'after treatment, provided that no exogenous', 'during the study period.||Active tuberculosis', 'within 4 weeks prior to the first dose of study treatment|Current', 'for at least 7 months after the last dose of study', 'within 2 weeks prior to administration of study treatment|Participant', 'within in 28 days prior to registration|Participant', 'for the length of the intervention)|Previously enrolled in the study', 'prior 12 months|Meets diagnostic criteria', 'in the last 28 days', 'in year', 'since starting medication', 'within three months before the procedure|Sudden cardiac death event', 'within the first 3 months of the screening period of this trial.|Patients', 'prior to study.|Any medical condition', 'at time of registration)|AML in CR1 with poor', 'candidates.|Willing', 'at time of informed consent.|Is capable of understanding', 'within 14 days prior to the laboratory examination', 'within the 6 months prior', 'within the next 12 months on the', 'within 28 days prior to administration of study treatment.||A', 'at the time of signing the informed consent form;||Current', 'within 7 days before randomization.|Patients with central nervous system', 'within 4 weeks before the first dose of study intervention|Receipt of live', 'since at least six months before the beginning of the study', 'during the duration of the study.|History', 'for at least 6 months after the last IMP administration||Other study protocol-defined', 'at least 6 days per week', 'for at least 1 week prior to the examination.|Depressive', 'in the last three months;|Have donated', 'within 30 days before the first study', 'between July 1, 2021', 'during daily activities|Pain', 'within 4 weeks prior to Cycle 1, Day 1', 'all 5 inclusion criteria', ""at physicians'"", 'within 30 days of planned treatment start|Systemic cytotoxic chemotherapy', 'post', 'within 2 months before the first dose of study drug.|Received', 'last at least 2 months', 'during the study period not less than 120 days after chemotherapy', 'within the upper urinary tract.|Target stone', 'in the month prior to study allocation - Poor understanding of the inform consent language', 'after the previous systemic anti-tumor treatment', 'in the past year', 'within the last 12 months;|(6', 'additional 24 weeks following stereotactic radiosurgery administration', 'within 30 days prior to randomization', ""at least 3 years.||All participants'"", 'three month prior to screening|Drug washout period', 'within 6 months prior to Visit 1/Screening.|Subject', 'during the period of the trial|Must be willing to wear', 'within 1 month prior to Day 1|Evidence', 'throughout the operation', 'within 7 days before the first administration', 'within 60 days or', 'at least 2 weeks from last cytotoxic chemotherapy', 'in the next 2 months', 'within 2 weeks of starting study treatment', 'at 3 months before', 'during the study course.|Communication partners', 'within 72 hours before the first dose of study intervention', 'during the time of study', 'at least 14 days prior to Day +1||Contraindicated medications', 'prior to study entry', 'within the past 3 months.|Gastrointestinal', 'intravenous', 'within the last 3 months|Pregnant', 'within 48 hours.||', 'within 1 week prior to enrollment;|Patients', 'at least 2', 'in the last month and/or', 'within the last four weeks|In-house stroke|Myocardial infarction', 'At least 3 years', 'at least 1 patent outflow', 'at least 2 weeks before study drug', 'in the last month or 500 mL', 'during the study.|Patients', 'within 3 months of Baseline', 'at least 4 weeks before the first administration shows that the lesion', 'within 30 days prior to administration of the study', 'within 6 months before Day 1.|Has', 'within the study period|Planned MRI', 'except for the following vaccinations', 'prior to initiation of study treatment|History', 'in the last 90', '1 prior to start', 'in the past 3 months prior to Baseline', 'within the 12 weeks after', 'At the time of temporary registration', 'within 4 weeks of study entry.|History of or', 'at the time of enrollment.|6 months to 3 years after diagnosis', 'within 1.5 standard deviation', 'in the past 6 months|Any', 'during the operation', 'None', 'within 60 days before inclusion', 'at time = 0);|Have', 'for 60 days after the last dose of AU409', 'within 6 weeks of the first dose of study treatment.||6', 'at least 1 dual', 'before starting to use the trial drug;||The', 'within 6 months before the first medication', 'symptoms);|Has been', 'for at least 7 days prior to first dose of study treatment.|Participant', 'prior to the first injection', 'during the 12 weeks of the study.||', 'in the past week', 'at the time of surgery|Patients', 'within 28 days before the first does of investigational', 'from at least one', 'within the preceding three months', 'within 24 hours of symptom onset|Target vessel QFR-MR>250mm Hg*s/m||', 'at least 3 months before mobilization', 'within 14 days of first visit', 'within 4 weeks prior to the first dose of study treatment.|Known hypersensitivity to', 'at least 3 months|BMI', 'in the past 6 months|Current treatment', 'at least 4 weeks before the', 'at least 1 day after insertion of pleural drain', 'within 3 months of screening.|For', 'during their participation in the study', 'after the first 12 months of', 'at the time of informed consent|Body Mass Index (BMI', 'before admission was less than 6', 'within 1 month before the start of treatment', 'within 9 months prior to the first administration;|Subjects', 'during the previous 6 months', 'more than 1 year ago should also', 'for 12 months after the end of study', 'within 2 weeks prior to registration||a', 'within 5 years prior to the study', 'within the duration of the study.|Clinically relevant findings in laboratory parameters', 'within 8 weeks before Screening or incomplete recovery', 'at time of allo-SCT.|Written informed consent', 'within 60 days or received', 'during the study period|Ocular surgery', 'at the time of approach.||Clinicians:||Cancer risk physicians', 'within the past 1 year|Main', 'at the time of data', 'at doses', 'within 15 days||Exclusion criteria :||Non-lupus', 'at time of study entry|Indwelling', '30 days of age', 'within 2 weeks prior to the first dosing.|Known allergies', 'within 14 days prior to', 'within the past 18 months', 'within 2 weeks before the first administration of the investigational product.||2', 'within 2 months prior to study drug infusion', 'within 15 minutes of', 'within 2 years of entry', 'within 4 weeks prior to first dose.|Had a history of', 'during the last 4 weeks prior to study treatment initiation', 'within 12 weeks of Screening Visit|UC limited', 'at least 30 mins', 'throughout the trial and 3 months following discontinuation of study treatment', 'within the past 12 months|Parent', 'within the past 2 years except', 'at the previous', 'at the needle insertion site|Pregnant', 'within the last 30 days|Coronary artery bypass graft (CABG)', 'within 70 days prior to enrollment.|A', 'after surgical and /or', 'within 4 weeks prior to the first dose', 'within the last 12 months|scheduled', 'within 28 days before vaccination.|Received gamma immunoglobulin', 'within 28 days prior to enrollment;|Patients', 'at the time of signing the ICF', 'after subsequent re-challenge', 'within 28 days from study vaccination', 'within one week prior to injection visit (V1)', 'within 12 weeks after study treatment.||3', 'within last 30 days|Planned CABG', 'within 6 weeks of screening', 'in the last months.|Those who are', 'in the 12 months prior to screening', 'in the next year|advance kidney', 'within the past 2 months.|Use', 'within 4 weeks of administration of the study drug', 'within 2 weeks prior to Day 1|Severe', 'within 4 weeks prior to the first dose of', 'in the last 12 months before inclusion);|Age', 'more than 100 km from', 'within five months after the first consultation|orthopedic', 'within 28 days prior to randomization', 'in the previous radiotherapy area', 'within 28 days before the first dose of the investigational product', 'within three months prior to screening|Known', 'prior to catheter placement|Platelet count', 'after antihypertensive therapy', 'during the study.|Any positive', 'in the next 6 months;|Nervous', 'during a prior', ""after 24 hours after their admission|patients who couldn't finish all of the study steps.|patients"", 'within 4 weeks prior to the', 'at Month 6 and 12||', 'within 4 weeks prior to study drug administration.|the', 'in the last month|Blood potassium', 'after at least one treatment', 'during all testing procedures);|Heavy alcohol consumption', 'in the 5 years prior to enrolment|positive', 'during the intervention', 'during the trial;|Allergy', 'within 30 days prior to stem cell collection', 'after the initial standard of care', 'prevent physical exercise.|Contraindications to physical exercise detected', 'any time prior to screening|Currently', 'for less than 3 months', 'within 7 days prior to the first dose.||', 'within 3 months||', 'during the session.||', '30 days', 'within the last 3 months|Cohort 1', 'at their pre-exercise echocardiogram', '28 days prior to Vaccination', 'in the last 2 year|Last 2 A1cs', 'within 7 days prior to randomization', 'at least 8 teeth||', 'prior to COVID-19', 'during the last three months before the trial;|History of long-term use', 'within 6 weeks before enrollment', 'within next 7 days|Has decision making capacity', 'in the next 12 months;|Fibrinolytic therapy', 'within 24 hours of testing|no', 'within the last 6 months.|Evidence', 'within 3 months.|Patients', 'at the time of study registration', 'within the past 3 years|Subject', 'during the study period.|Any', 'within 4 months before', 'within 28 days prior to the first dose of FHND5071', 'within 7 days before the day', 'within the past 6 months of the (first) study drug', 'within 24 hours prior to presentation|Desire treatment', 'in the 7 days prior to randomization', 'less than 3 months', 'within the timeframes specified', 'during the clinical trial period.|23', 'at satellite location', 'throughout the treatment period and within 3 months after the end of treatment;Fertile', 'for the first time and', 'in the last five years|uncontrolled hypertension|difficulty complying', 'within 28 days before the first study administration', 'within 72 hours prior to randomization', 'during the 2 weeks prior to initiation of the baseline', 'prior to the start of treatment|Active', 'for at least 4 months after treatment', 'within 2 weeks before randomization;|Subjects discontinuing antipsychotics', 'within 28 days of cycle 1 day 1)|Aspartate aminotransferase', 'within 2 weeks prior to first dose of study drug', 'for at least 5 years leading up to the Screening Visit', 'within the previous 12 months of the current', 'within 60 days prior to study', 'during the 6 months preceding', 'at the time of signing the informed consent|Participants', 'within 12 months before informed', 'within 1 month of trial', 'imaging:||More than', 'within 7 days of study intervention administration', 'within 1 month before the screening.|With addicted to smoking', 'within the past 3 months.|Having', 'at the time of signing the written informed', 'within the 28 days prior to and including the screening', 'within the prior 6 months|History of external beam radiation therapy to the head and neck area|Diagnosis of HIV', 'within 2 weeks of start of study intervention', 'within 7 days of first day', 'within 14 days before the first administration of the study treatment|Fertility', 'within 6 months before recruitment', 'within 12 weeks before Day 1/baseline|Pregnant', 'within 90 days)|hypersensitive', 'in the last 6 months|He had neck surgery|Suspicion of malignant', 'while they or their partner', 'last > 6 months', 'within 30 days prior to entering the study.|History of other', 'in the past 12 months.|Be', 'for 8 weeks prior to enrollment.||Inclusion Criteria', 'in the 4 weeks prior to inclusion', 'for at least 7 months after the last dose of study drug', 'for at least the past 90 days||Non-inclusion', 'within the last 6 months:||RTX', ""at the investigator's discretion"", 'within 3 months before screening', 'at the time of screening|Males', 'in the 6 months prior to initiation of the study.|Abnormal liver function', 'within the past 7 days||', 'during the duration of the study;|Has', 'more than 24 months prior to randomization|Presence', 'within the past 5 years|Uncontrolled', 'at least 28 days', 'within 7 days before the study enrollment.||', 'within 3 months prior to vaccination;|Administration', 'in the last 5 years.|History of', 'after 1mg dexamethasone inhibition test (1mg-DST).||', 'within 6 months before signing the informed consent.|Prior autoimmune disease', 'within 4 weeks prior to baseline visit', 'prior to the first dose of study drugs', 'within the 6 months prior to start of the study treatment.|A history of chronic', 'within 2 weeks prior to initial drug administration).||9', 'for at least 1 week prior to C1D1.|Measured', 'prior to initial', 'within 8 weeks of surgery', 'within the past 3 months', 'at least 3 years||', 'within 5 days prior to study enrollment|Hemodynamically abnormal', 'at any time in his life and complaining', 'between 3 months', 'at the time of cardioversion;|Sick sinus syndrome', 'within 3 months|Fractures', 'up to 2.00D', '48 hours before the first dose of the research drug to the end of the study;|Have', 'during the follow-up period', 'prior to diagnostic', 'prior to starting study treatment', 'in the next 12 months.|History of', 'hospitalization time not exceeding 24 hours', 'throughout study participation|Fluent English Speaker|Capacity for', 'within 4 weeks before the inclusion|Subject treated', 'in the last 5 years for alcohol', 'within 4 weeks prior to initial medication;|The', 'in the current episode.|have', 'diabetes|History', 'during the first week (', 'Hospital since January 1999 to December 2015.||', 'within 30 days prior to informed consent', 'at least 4 weeks before the first administration', 'during 3 months prior to the study||Chronobiologic', 'after screening by pediatric orthopedic surgeon', 'before starting study intervention.|Have', 'at the time of consent.||Sex', 'in the last 30 days;|Pregnancy', 'prior to the screening magnetic resonance imaging (', 'within 30 days prior to the first administration of study medication', 'within 12 months of Day 1 of this study', 'in the past 12 months.||Exclusion', 'for at least 28 days prior to vaccination', ""within 2 years after their partners' cell"", 'for at least six months after the end of the maintenance treatment.||Female', 'Prior to surgery participated in', 'prior to starting study drug', 'within the anogenital tract', 'within the previous 3 months.|Systemic', 'in the past three years', 'for at least 14 days prior to first dose of study treatment|Active', 'newly detected', 'within 30 days prior to study enrollment|Written informed consent/assent|Karnofsky score', 'within 5 years prior to randomization.|Has', 'within 6 months prior to screening;|Patients', 'at the initial screening visit', 'at least 3 months before surgical periodontal treatment (baseline day', 'Years.|Patient undergoing', 'within the previous three years||Severe', 'within 6 months prior to initial', 'within 4 weeks of study treatment administration', 'prior to first dose of blinded IP.||Adequate bone marrow', 'at least 5 and lower than the norm-derived', 'in the last 6 months|Dementia|Institutional', 'in the previous 48 hours', 'within 1 month of scheduled surgery', 'within 90 days', 'in the last 8 weeks', 'during the open challenge.|Written informed consent', 'prior to the diagnosis|Being', 'within two weeks of the first dose of study treatment.|Concomitant', 'management program', 'within the past year|Persons undergoing', 'for 3 days before and for the duration of the study.|Willing to collect', 'within 14 days prior to the first dose of study drugs|Anticoagulant', 'prior to treatment start).|Intake', 'over 65 years', 'out of two weeks', 'within 4 weeks before the first study administration.|Patients', 'for three weeks', 'within 90 days prior to Week 0 Visit', 'within 5 years of treatment;||(17', 'within 4 weeks prior to the first dose of the investigational product', 'at least 1 year after anthracycline', 'after ≥ 8-h', 'in the previous 30 days|Participants', 'during the study of any of the non-inclusion criteria', 'within less than 28 days prior to randomization;|Active', 'throughout the study duration', 'previous 5 years)|Use', 'in the impacted or more impacted leg that', 'within 3 days before vaccination.|Allergic history to any', 'within 24 hours;|Abnormal liver', 'since at least 3 months||All', '1 month after delivery|Willing to deliver', 'within 3 months|Significant', 'within 2 weeks before study treatment', 'more than 5', 'prior to tissue sampling procedures.||', 'at the time of signing the informed consent form (ICF).|Participants who are', 'within the last 6 months|Planned', 'recurrent', 'within the 4 weeks prior to study enrollment', 'within the last 14 days of screening', 'at the time of the first dose <10 k/μL||Eastern', 'during sexual intercourse|Women', 'during the 18 months following the study treatment', 'within 28 days;|History of abdominal fistula', 'within previous 3 months', 'within 3 months prior to or after the research scan|Suspected breast lesion', 'past 5 years.|Negative for', 'maximum 30 days old.|Patient', 'prior to signing informed consent', 'at least 3 days a week,|Turkish native speakers,|For', 'within 3 months prior to Baseline Visit', 'within 30 days before Screening or within five times the', 'within the United States.||', 'at the time of data collection.|Hospitalization', 'for at least 3 days in the 6 weeks prior to Visit 1', 'within 3 months|Recent adding', 'during the procedure|Uncontrolled coagulopathy|Taking antiplatelet drug', 'within 7 days before the first use of the study drug', 'past year before screening', 'within 6 weeks prior to randomization|Active', 'within the past 24 months', 'within 2 years before first dose of study treatment', 'within two weeks before the first dose', 'during the 12-months pre-index period', 'within 30 days.|Mechanical', 'at least 2 members of the Medical Advisory Board (', 'at the time of the procedure||', 'in the last year;|Not receiving TMS therapy', 'longer than 6 months prior to this date)|Evidence', 'in the month preceding the inclusion', ""throughout the study|Deemed appropriate for pump therapy per investigator's assessment considering previous history of"", 'during the duration of the study except', 'in the last 30 days prior to the start of the screening phase', 'within 14 days prior to initiation of study treatment.|Ability to understand', 'at the time of evaluation|Eligible', 'During screening or before cell transfusion', 'within ten years', 'at admission of study|Primary', 'for up to 15 hours||ii', 'during the first prenatal care visit.|Participant', 'less than 4', 'for more than 1 week', 'for at least 1 month at prescreening', 'prior to start of conditioning', 'in the past 12 months|Severe vision', 'within 90 days of screening.|Moderate', 'dental fluorosis.|Presence of carious', 'for at least 6 months prior to inclusion|No history', 'within 3 months prior to treatment administration.|Donation of plasma', 'during or 3 months prior to index date|Surgery', 'within 7 days before screening', 'within 6 months prior to start IMP', 'at least 1 week prior to screening visit', 'at the time of signing the informed consent form|At Screening', 'within 1 month before enrollment;|4', 'within 3 months prior to the first dose of study treatment.||Uncontrolled', 'within 48 hours before administration of investigational product', 'during the study.|Treatment', 'during stay', 'Within 2 weeks before cell reinfusion', 'for six months following their last dose of vemurafenib', 'last 8 months', 'more than 12 months', 'prior to first dose of study drug', 'years;|Expected survival time ≥3 months;|Initial DLBCL', 'within 12 months prior to enrollment;|Patients', 'within 2 weeks before first scheduled study drug administration', 'in the past 4 weeks|MELD-Na', 'present', 'for at least 90 days after dosing', 'throughout the study|Subject consumes excessive alcohol', 'within the trial period of 24', 'for at least one year', 'within 4 weeks|Have', 'during the 3 months before surgery', 'within the past 5 years;|Pregnancy', 'in the past month.|Methods of physical destruction', 'within 6 months of screening.|Patients', 'within 7 days of first administration of IP.|History', 'before baseline', 'in the last month;|Women', 'within 30 days prior to the first dose of trastuzumab deruxtecan', ""at least 3 months' duration"", 'for six months after the last therapeutic dose', 'within the next 9 months of study period|Multiple sclerosis', 'performed at screening', 'throughout the study period.|Corticosteroids should be stopped', 'after first-line surgery/radiotherapy/chemotherapy', 'within 28 days before study', 'chemotherapy;|History', 'within two weeks before first dose of study drug', 'throughout Step 1 if participating', 'for at least five', 'within the past 2 weeks|Active', 'during the inclusion visit|Confirmed receipt', 'at the time of randomization.||Adults', 'in the last 3 months.|History of', 'during the conduct of the study|History of any illness that', '48 hours before the planned date of the first study vaccination.|Acute respiratory illness', 'within 15 days', 'within 3 months prior to the start of the experimental trial', 'at least 3 months before inclusion', 'at least 6 months apart - peak', 'within the last 3 months.|Current enrollment', 'for two years', 'up to 6 months after the last dose of study drug', 'in the prior 12 months|diagnosis unclear after history', 'within 14 days before screening）||Adequate Hematological function', 'in the 6 months prior to study entry.|Tumor load', 'within 28 days of randomization.|Known history of', 'within 2 weeks of the first dose of study treatment.|A', 'at the time of signing the informed consent.||Type of Participant', 'within the 12 months prior to signing consent', 'During the study treatment period and within 3 months after the end of the study treatment period', 'within the last 6 months prior to screening', 'within 2 weeks before dosing|Currently enrolled in another clinical study', 'before the procedure', 'authorized', 'during the prior 6 months prior to screening visit', 'within ≤ 6 months before treatment|Uncontrolled hypertension', 'at least 6 months prior to study treatment administration)|True abstinence', 'within 6 months before the selected treatment', 'within 4 weeks prior to initial administration', 'in the last 30 days;|Intestinal obstruction', '1-6 months prior to study entry||', 'treatment;|History of', 'more than 6 months after the last radiotherapy', 'in the treatment areas', 'within 4 weeks before administration of the first dose of DO-2||patients', 'within 4 weeks of the first dose of treatment for another health-related', 'within the normal range can also', 'within the past 7 days|History', 'likely to induce neutropenia', 'in the last 6 months.|Previous significant', 'within 30 days prior to signing the informed consent;|have', 'within 12 months prior to first dose of study', 'within 6 months after the initial remission', '>5 days per month.|Current', 'in the last study', 'prior to any study specific procedure,||', 'within the past 48 months)|Echocardiographic evidence', 'within 72 hours before the first dose', 'during the last month before enrolment|Impossibility to provide informed consent', 'within 3 weeks', 'during the last two months', 'over the last three months.|Previously', 'within the 90 days prior to Day 1', 'within 4 months before Day', 'within 4 weeks before randomization', 'within 7 days or less', 'before signing informed consent.|Subjects', 'one time time/week', 'within 1 year.|Combined', 'at the time of signing the ICF.|Having', 'for at least 3 years', 'at least three injections', 'at least 1 of the specified signs/symptoms attributable', 'at least 3 days per week.|The participant', 'prior to simulation', 'within 30 days prior to treatment administration.|Participation', 'within 1 week prior to randomization.|Have adequate organ function.||', 'within 30 days before signing the informed consent', 'aphakia|History', 'within 180 days prior to consent', 'within 48 hours.|Participants', 'prior to Screening.|Any other medical', 'in the past 3 years.|Drug', 'before the first dose (subjects with fever', 'within 4 weeks|Any non investigational anticancer therapy', 'within 28 days prior to the first dose of investigational drug', '1 week before', 'in the past month.||5', 'for at least 4 weeks prior to screening', 'within 180 days before enrollment|New York Heart Association (', 'within 24 months;|Inability to understand written', 'Age>40 years|Presence', 'within 4 weeks prior to screening.|History of allergy to', 'within 4 weeks before using the research drug', 'within 56 days (8 weeks', 'during the study period;|Pathological examination', 'lasting ≥3 months beyond chemotherapy completion', 'in the last 6 months|Use of more than two', 'for at least 12 weeks prior to screening.||c', 'at the time of screening.|CSU duration for ≥ 6 months prior to screening', 'at least 4 hours.||', 'within 7 days prior to start of trial.|Subject', 'after previous standard treatment.||Patients', 'within 28 days before the start of treatment', 'within 30 days of screening|Are currently', 'at the time of enrollment/randomization.|Subject', 'within =< 6 weeks prior to registration.|Patients', 'within 4 weeks before enrollment.|All toxicity', 'within 3 months prior to screening.|Subjects', 'within the first minutes', 'solely for the purpose', 'within 8 weeks of study enrollment', 'within the 5 half-life of the drug', 'within 3 months of the MRI', 'for 2 years or more', 'psychiatric history', 'within 6 days of symptom onset', 'prior to dosing;|Participation', 'in past 3 months', 'within 1 year prior to screening.|Subjects', 'within 4 months before inclusion|Current enrollment', 'within 7 days prior to the first dose of study drug.|Patients', 'before starting the treatment', 'within 30 days after surgery', 'more than 2 months', 'within 7 days prior to registration.|Men', 'within 2 months prior to Check-in.|Donation of blood', 'during the trial.|Pregnant', '3 months ago', 'for at least 30 days prior to the screening visit', 'while on study', 'within the preceding 3 months', 'within 4 weeks before first dose of study drug.|Received', 'within 2 months before initiating', 'at least once', 'during their current hospitalization|Able to consent|18 years old', 'within 2 weeks before the first dose of study treatment', 'within 2 weeks before screening):||Neutrophil (ANC', 'within 2 weeks prior to start of study drug', 'at the time of starting study', 'within 6 months prior to the first dose.|Subjects with', 'loaded at least one year', 'during the study;|Women', 'for at least 1', 'for 8 weeks prior to enrollment.||Exclusion Criteria||A lifetime history', 'at the time of intubation', 'at the time of screening.|Known intolerance', 'within the last 3 months prior to Day 1', 'three times a week', 'within three months before fecal sampling|Physically', 'lactation|Poor compliance during steps 1 and 2 of cause-related', 'before first-line chemotherapy', 'within 2 weeks prior to treatment.|Major surgery', 'at least 4 weeks after completion of the treatment', 'within 30 days of apheresis procedure:||The participant', 'at least 3 m', 'within 4 weeks before the first dose of the investigational', 'within 14 days before randomization.|Have received', 'at the time of Informed', 'During Study', 'during the study therapy;|Known', 'within 6 months prior to initial administration of the experimental drug', 'for 3 months', 'past 2 weeks||', 'within 180 days (6 months', 'at time of enrollment|Diagnosis', 'one-year follow-up', 'within the last 60 days', 'prior to starting therapy|FCBP', 'at least 3 weeks before baseline', 'prior to first administration of Investigational Product (', 'within 14 days): TBIL ≤ 1.5 times the upper limit of normal', 'within 5 mm', 'at study entry.|Patient and investigator signed', 'at either Screening or Day -1.|Estimated glomerular filtration rate (eGFR', 'at time of ostomy site takedown', 'during thrombectomy;|Moderate/severe', 'within the previous 6 months||ii', 'within 14 days prior to study', 'within the two weeks prior to registration', 'in the 2 weeks before enrollment, including:||Proton pump inhibitors', 'within the prior two years|Have unstable', 'within 4 weeks before the first dose of HTMC0435|Past surgical history', 'within 8 weeks of baseline', 'at least 1 year prior to D1', 'for 2 months after the trial', 'within six months prior to', 'within 3 months prior to enrollment;|allergy', 'prior to cycle 2', 'within 1 week to control symptoms of', 'prior pregnancy;|Objectively', 'for at least 90 days after the last application of the study drug', 'within 12 months before admission', 'for ≥4 weeks prior to screening', 'during the trial screening', 'at least one of the following criteria:||Have undergone', 'for at least 15 years|Family history', 'more than 3 minutes', 'within the past 2 weeks|Is able to electronically access informed consent', 'actual', 'within 28 days prior to study enrollment', 'at the two', 'up to 4', 'for at least five years', 'within 1 month before biopsy.||Patients', 'for ≤48h before trial entry|Symptoms', 'during the research process,|Serum', 'in the past 6 months;|age <18', 'over last 4', 'for 14 days after the final dose of sulfasalazine.||Subject', 'at least 4 weeks prior to study', 'pre-dose FEV1', 'within 3 months before the screening visit', 'in the facial', 'before administration of study intervention|Is', 'between the two measurements|Thyroid-stimulating hormone (TSH)', 'within 1 week prior to Screening', 'within a 12-month', 'in the past two years|had', 'within the previous two years.|Participants', 'for at least 14 days prior to first dose of study', 'within 4 weeks prior to first dose of CTX-712.|History of', 'within the specified time period prior to apheresis:||Administered any', 'within 14 days prior to registration:||Adequate hepatic', '12 to 24 weeks', 'in the protocol.|Treatment with biologic agents', '30 days before the procedure|Right ventricular failure', 'within the previous 48 hours', 'prior to Screening.|NOTE', 'in the 3 months prior to enrollment', 'for the duration of the trial', 'at least 3 months of follow-up', 'within 6 months prior to Screening|If', 'within 1 week prior to enrollment', 'within 3 months prior to the first study drug', 'on the first hospitalization||', 'prior to signature', 'within 6 months prior to study vaccine dose.|Study personnel', 'within the preceding 14 days', 'in the last month,', 'for three months after the last study treatment', 'during the first 24h|Need of more than 3 passes', 'up to date', 'during the first visit (W0)', 'at trunk and lower extremities', 'within past 3 months.|History', 'for three years or more', 'within 4 weeks prior to the first dose of study therapy;|16', 'within 1 year of baseline||', 'for the prevention of RSV', 'previously received', 'on the index knee', 'prior to consideration of participation in the study||Inclusion Criteria', 'less than 3 months|neurological disease|history of lumber spinal surgery|pregnancy|active skin', 'more than 4 days per week.|Positive', 'within four weeks prior to start of enrollment', 'at day of inclusion|Signed written informed consent', 'during the study.||Exclusion', '48 hours prior to scintigraphy|anti-cholinergic', 'within two months', 'at the time of screening;|Severe cardiovascular disease', 'for 5 years prior to the first administration of the study drug', 'for at least three months||', 'before operation.|Complete auxiliary examination', 'previous two months.|Isotretinoin use in the previous six months.|Light procedures', 'pre-bronchodilator/pre-dose FEV1', 'within the 6 months prior to study enrollment', 'for at least one year after enrollment in the study.||', 'prior to covid-19 infection', 'within 4 weeks prior to enrollment;|participation', 'during or after prior therapy', 'within 3 months prior to screening;|Previous lung resection', 'in the 1 months after enrollment|Subjects', 'during the last year|≥ 1 routine', 'at the time of enrollment|Current treatment', 'within 3 months prior to first dose of study intervention.|A', 'for 3 months after the last dose of peposertib', 'in the last 6 months,|No', 'during the three months prior to enrollment', '6 months to 14 years', 'within 100 days of the first dose', 'within the previous year', 'during the duration of the study|Inability to suspend oral medications', 'within 7 days prior to screening', 'during ordinary conversation', 'at least 7 days before the first dose', 'within 60 days prior to enrolment', 'within 3 minutes', 'in the previous 90 days.|End-stage', 'within 2 weeks of the first administration', 'within the next 6 months.|Other conditions', '3 month prior to randomization|use', 'within 6 weeks of', 'within the first 6 h after admission', 'period prior to their baseline visit', 'ending in ""ximab"" or ""zumab""', 'within 24 hours prior to and 70 days after the administration of the investigational product.||Inclusion Criteria', 'within 6 months before the first administration;|Active autoimmune disease', 'in the 6 weeks prior to Visit 1.|Any asthma exacerbation', 'in the last 30 days|Undergoing treatment', 'at the first clinic visit|Willing to', '< 2 weeks prior to screening', 'during or before the RT period;|Patients', 'during the 30 days prior to study entry.||5', 'within 15 years', 'at any time during participation in the study', 'within 10 days prior to study intervention administration', 'within 4 weeks of treatment.||9.The subjects volunteer to join the study', 'within 7 days after study start.|Any condition', 'within the past 5', 'within 6 months after the end of study', 'randomization|History', 'within 3 months from the onset of', 'past 12 months|Individuals', 'past 6 months day non-prescription injection drug', 'in the past 3 months|Physician', 'at the time of enrollment 10', 'during the Screening Phase.||Participants', 'within 7 days', 'within the last 12 months;|Subjects', 'within 14 days of enrollment|Platelet transfusions', 'within 48 hours of a suspected', 'within the last 6 months.|Having', 'prior to study entry|participants', 'at least 2 weeks prior to study enrollment', 'within 30 km away the riding center', 'within 14 days of the initiation of study drugs,|5c', 'at time of randomization;|Breastfeeding', 'within 4 weeks before the first dose of the investigational drug', 'within 4 weeks before initiation of the study|Pregnancy', 'within 14 days of study therapy|Radiotherapy', 'within 28 days prior to the first dose of SYNB1934 through final safety assessment in RWP', 'at the pre-study visit.|Has been committed', 'during the last 12 months|assumption', 'within 90 days prior to enrollment', 'within 14 days prior to initial administration of the trial drug', 'in the one week before or after each study vaccination.|Received', 'within the past 5 days.|Subject', 'within 2 years before Screening', 'during the study.||Replacement doses of', 'at the time of consent|Willing', 'for at least 4 weeks before the screening', 'within the past 1 month.|Currently', 'within the past 3 months||Blood', 'within the 90 days prior to screening.|Intracranial', 'within 28 days before grouping', 'within 5 years prior to initial administration;|A history', 'at least 3 years previously', 'within two weeks before first study drug administration', 'within 2 years prior to first dose of study intervention', 'in the past 30 days|Own a smartphone', 'at least 7 days before receipt of study vaccine', 'within 1 year previous to study', 'previous 48 hours prior to the surgery.|Patient', 'following the last dose of study intervention', 'within the last two years per protocol.||13', 'within 28 days of their first treatment', 'at the 2 hours of the Oral Glucose Tolerance Test (OGTT)', 'within 3 months.|Receipt of', 'prior to or', 'for at least 90 days prior to randomization|UPCR ≥ 1.0 g/g', 'within 4 weeks prior to the first dose.|Presence of toxicity', 'before the first dose of study drugs.|Symptomatic', 'within 12 weeks prior to study treatment', 'prior to randomisation to the group.|Patients', 'onset of two or more symptoms', 'more than 7 standard units per week', 'within the past 30 days.|Subject', 'within 24 hours prior to Day 1', 'at least 2 meals per', 'at least 4 weeks prior to the start of study', 'at least 6 weeks ago', 'during daily time-restricted eating|PROSTATE CANCER', 'at least 6 months prior to screening).|Barrier methods of contraception', 'in the 4 weeks prior to Visit 1.|Experienced', 'within the last three years', 'within 2 years prior to Screening', 'for at least 6 months after last drug administration of the investigational procedure', 'within 2 years prior to enrollment', 'for the duration of the study treatment', 'at 4 months and8 months after surgery respectively|Patients', 'within 3 months before screening;||Healthy', 'within 4 weeks of study enrollment.|Receipt', 'for at least 8 weeks prior to screening|Subjects', 'at time of knee injury', 'for 7 days following last radioligand administration.||Male', 'within the previous month|Have', 'within 48 hours prior', 'within 3 weeks or', 'at first or second site.|Typical indications', 'within 12 months after ASCT', 'for ≥3 months).|BMI', 'within 4 weeks prior to Screening.|Pregnant', 'during the screening period|Leptomeningeal disease.|Symptomatic brain metastasis.|Presence', 'within 6 months prior to the Screening visit|A history of', 'within 48 hours.|Women', 'C.|History', 'at least once a month', 'at least 3 months prior to the Baseline visit', 'within 2 weeks before the first use of the study drug|Patients', 'at least 45 kg', 'for at least 90 days after the last study drug administration if their', 'in the past 6 months|Use', 'within 1 year prior to initial medication', 'at any time after screening||Reproductive', 'during the study.|Use of beta-adrenergic blocking agents', 'within 24 hours prior to surgery|Unable to provide consent independently|Allergy', 'within 14 days prior to treatment.|Has', 'at time of enrollment.|Ability to understand and willingness to sign an IRB approved written informed consent document', 'during the study period|Seizure disorder|Photosensitivity|Hearing', 'in the baby', 'last for at least 2 months', 'within 6 months prior to study start.|Planned surgical intervention', 'at time of enrolment|Participation of the', 'during the study period.|AHF', 'in the next year', 'within last 2 weeks.||Serum', 'through their primary care provider|Medical complexity', 'within the first two weeks of randomization', 'at least once|have capacity', 'in the last 2 years|Last A1c', 'within 72 hours prior', 'less than one week ago', 'over the past 12-months|Neck diameter, length and angulation that meets labeling requirements', 'within 2 weeks prior to the start of study dosing', 'at least half of the grocery shopping for their', 'at the time the informed consent form (ICF)', 'for at least 14 days prior to screening', 'within 72 hours before enrollment for', 'within 6 months before the consent session', 'at least two', 'for >2 years', 'during the study period|Readiness to exercise', 'for the duration of the study.||Effective contraceptive measure include', 'within 6 months before the first administration;|QTcF ≥ 480 milliseconds', 'within 24 hours prior to Visit', 'accident)|Stroke onset', 'at screening and Day -1.|For participant', 'within 4 weeks prior to the start', 'within 1 week of the first dose of VS-6766||Exposure to', 'within 5 days before the 1st dose of FT538', 'following the last dose of study intervention.||(b', 'within one year prior to screening', 'during childbirth', 'at the time of randomization.|Use of any investigational drug', 'in the last 1 year|In those with', 'in three months prior to the study|Use of topical depigmenting agents', 'within the last six months', 'since last menses', 'for ≥3 days within 1 week prior to enrollment', 'past five years', 'within 3 months before enrollment;|Have', 'within the past fourteen', 'after treatment', 'before joining the group', 'within 7 days of first dose', 'within past 24 months||', 'within less than 72 hours before first study intervention', 'within 14 days prior to start of study', 'within 7 days prior to treatment administration.|Donation of whole blood', 'in the last 3 months.|Subjects', 'within the last 10 years.|Known', 'during the six months prior to the study;|Following', 'within 1 week prior to randomization', 'within 14 days prior to treatment', 'within 7 days prior to treatment', 'for at least 1 year before enrollment||', 'within 1 month prior to the first scheduled dose|Subjects', 'within 6 months prior to study inclusion|Serious', 'in the last 3 months|Immunosuppressive', 'at least one of the following two criteria', 'within 2 weeks prior to or 2 weeks after any of the study investigational product administrations.|Receipt of an investigational study agent', 'within the last 15 years.||Treated with lifestyle management', 'within 2 weeks of baseline.|Treatment', 'at least for the upcoming', 'within 8 weeks prior to enrollment.|Thalidomide', 'for 5 years since initiation of that therapy.||a', 'within 6 months prior to screening', 'for at least 90 days after the last dose of assigned treatment.|ECOG performance status', 'last month|Able to understand', 'within 1 week prior to C1D1)|Platelet count', 'within 30 days of screening|Any other', 'site|No history of', 'at least one of the following criteria:||Five or more years of professional experience', 'at 7th month or earlier', 'within 12 weeks before the administration of the first study drug', 'more than 6 months|At least two', 'within 72 hrs of study drug', 'after administration of the study drug', 'within 7 days prior to C1D1.|Has', 'within the previous 72 hours', 'within 12 months of screening', 'within 3 days prior to receiving the first fraction of SBRT', 'continue to increase for 2 weeks);|Steroid', 'within 42 days prior to enrollment)|Creatinine clearance', 'during the study period and within 3 months after the last study drug use.||', 'in the last three months prior to', 'within the 1-month period before the baseline examination', 'during three months prior to the study;|≥4 kg of body weight loss', 'in the 7 days preceding vaccination', 'within three weeks before the first study day', 'within 28 days prior to and including the screening', 'within 3 months before the first dose of study drug', 'last dose at least 6 months prior to study vaccine|Understands', 'at least 6 weeks prior to start of the study', 'for at least 3 months|have', 'within 4 weeks prior to the first dose of KM602|Prior treatment', 'during the study period.|Recipient', 'within 6 months prior to the first dose of the investigational product|History', 'within 60 days prior to enrollment', 'within 30 days prior to cycle 1 day 1', 'for 30 days prior to study entry.)|Previously', 'pre-operative', 'within 7 days prior to the first dose of', 'at the time of study enrolment', 'within 28 days prior to randomization.|Current', 'during the whole study period.|Any', 'at doses equivalent to or', 'within 8 weeks prior to screening.|Last injection', 'before the start of this trial', 'in the last 12 months|Episode', 'within the previous 12 months.|History', 'in the 3 months before inclusion|Either', 'within the past 4 months.|Participants', 'through 7 days after the last dose of lenvatinib', 'in the previous month prior', 'within 1 month before admission.|Pancreatic diseases.|contraindication', 'within the past two years', 'at the beginning of the study|attends the preschool 2 days or 3 days a week', 'within 30 days prior to enrolment of the current', 'at the French Paraneoplastic Neurological Syndrome Reference Center', 'within the previous four weeks', 'within 14 days or 5 drug elimination half-lives', 'at least 30 days before the administration of trial medication until 30 days after trial completion', 'prior to consent to prevent study procedures', 'injuries,|More than 12 months from the injury to surgery|More than 8 months', 'at the Cleveland Clinic would apply', 'during routine', 'at least 2 weeks prior to protocol treatment', 'within one week prior to initial administration', 'in the last 6 months|Those', 'at least one day/week', 'within 28 days prior to enrollment.|Prior minor surgery', 'within 4 weeks before the first administration of study drug|Participant', 'within 14 days of treatment day 1.|Positive results', 'performed 2 hours after the second intravenous', 'before treatment;|Prior patients', 'in the next 18', 'at least one evaluable', 'for at least 2 weeks after the last dose of study drug.)|Participated', 'within the last 1 month|cardiovascular events', 'before week 12 postpartum', 'within 60 days prior to enrollment.|Subject', 'within 4 weeks prior to baseline;|Uncontrolled', 'within 1-14 hospitalization', 'within 1 month prior to randomization', 'within 7 days of randomization.|Able to tolerate', 'during wakefulness at the time of cardioversion;|Hyperthyroidism', 'greater than 400 mL', 'throughout the study|Participant is compliant', 'in the 28 days prior to the first study drug administration|Use of', 'during the study|Women', 'within 48 hr prior to dosing;|Donated blood', 'during the first 5 days since hospital admission|Abscess', 'within 14 days or 5 elimination half-lives', 'within 6 months from the time of signing the consent form until the completion of the administration of this study.|Subjects', 'for at least 90 days after the last dose of TST003', '<4 weeks', 'throughout the entire duration of the trial from screening until last follow-up visit', 'within 4 weeks prior to screening;|Patients', 'at time of registration', 'during the 4 weeks prior to screening', 'within the past 180 days prior to the day of screening;|Subjects', 'within the 3 county area', 'preceding 12 consecutive months)|Patients must agree', 'over 300 pounds', 'through 180 days after the last dose of study therapy|Patients must be able to swallow oral medications.|Patient consent', 'during their first-line therapy|All', 'in the inclusion criteria.||Patients', 'within 3 months prior to signing the Informed Consent form', 'pre-medication', 'lasting 2 weeks or longer', 'within 14 days (+ 3 working days', 'within 28 days prior to the first dosing', 'within 7 days prior to enrollment.||18', 'before 30 days of screening', 'within 30 days prior to screening.||Exclusion criteria', 'prior to study drug administration', 'within 24h prior to the first dose of IMP', 'by the first degree relative.||', 'at time of enrollment|Use', 'at least 12 months prior to enrollment;|adult partecipants between', 'less than 3 months before the', 'Bynum Standard 1-year definition', 'within 3 hours distance from', 'last 3 months prior to inclusion||', 'in the 28 days prior to the first study drug administration', '5 months after the end of study treatment', 'at Screening Visit 1).|Participant', 'within the previous 6 months|link', 'in the past month;|severe visual impairment', 'within one year', 'within 30 days prior to Visit 1|All', 'during the last 4 weeks|probiotics', 'within the 90 days prior to screening', 'in the 6 months prior to the trial', 'within 14 days before treatment', 'more than 5 years prior to enrollment.|Any', 'within 4 weeks prior to baseline;||17', 'within 2 weeks of entry onto this study.|Radiation therapy', 'within last 12 months|Other medical conditions', 'within 4 hours prior to administration of ketorolac', 'within 60 days before randomization|Agree to use', 'prior to Screening Visit 2).||General medical history||Negative', 'at least for the upcoming 3 hours', 'for at least 24', 'At least 1', '5 days per week', 'up to 2 g/day', 'for at least one year|Individuals', 'during or after most recent line of therapy', 'within 3 days before the first dose of trial drugs', 'within 12 weeks prior to inclusion', 'during their hospitalization Arthritis', 'within 28 days prior to the first dose of the IMP', 'within the last 30 days prior to the research scan)', 'within 12 weeks prior to randomization|Confirmation of disease status', 'within 14 days before the first dose of durvalumab', 'within the last 3 months prior to', 'prior to enrollment.|Patients', 'less than 3 months before participating', 'prior to or up to 30 days after 1L therapy initiation|At least 18 years', 'within the head and neck', 'within 36 months before enrollment', 'for >12 months each', 'within 7 days prior to study', 'since the last antitumor therapy', 'during the screening visit', 'at doses greater than 10 mg/day of', 'currently taking daily', 'within 4 weeks of study entry', 'within 14 days prior to the examination：||Neutrophil absolute count', 'for the first time before enrollment', 'throughout Step 4.|Ability and willingness', 'Acute', 'last 5 years|Oncological', 'within 14 days prior to the start of study treatment.|If the participant', 'within the target knee joint', 'at the time of the first dose', 'in the 6 months prior to screening', 'in the past 3 months;|In addition to the tumors', 'within 14 days before the first dose of study treatment.||4', 'Active', 'within the previous 12 months|performs', 'during the procedure', 'at nuchal translucency scan|Family history', 'during the time of study participation||•', 'in the range', 'in last 30 months from date of export|Last A1C value', 'at least one ongoing research project', 'within 1 year.|Patients', 'within the past 12-48 months', 'within 30 days prior to the first dose of study interventions|Prior exposure', 'within the previous 3 months.|History', 'within the past 60 months', 'within the past 1 month|Pregnant', 'at least two of these three movements', 'at the study site)|Previous enrolment', 'during the current depressive episode', 'during the Screening Period', 'within a month will', 'in the 12 weeks before the first dose.|Cavity lung lesions', 'in the past 5 years', 'within 14 days after the conclusion of the study;|Failure to show', 'within 28 days prior to the first dose of the study;|Other', 'within 2 weeks prior to baseline', 'within prior 10 days:||Presume', 'for at least the minimum time required', 'preceding 4 weeks', 'in the past year|1+ social determinants', 'since enrolling in the study', 'prior to diagnosis', 'at least 2 of the following', 'within 30 miles of UVMMC', 'at least 2 of 3 levels', 'during the trial.|Patients', 'at time of first dose of study treatment', 'absolute value', 'at any time before screenings', '< 4 weeks prior to bronchoscopy.|Voluntary', 'medical plan', 'recently', 'greater than 5 years ago', 'within 2 weeks prior to screening.|Use', 'within 4 weeks prior to randomization.|Has', 'at least 3 years prior to study entry', 'within 12 months from registration||Patients', 'at any time following treatment', 'at the time of the surgery', 'for at least two months', 'within 30 days prior to the first QLS31903 administration|Prior treatment targeted', 'in the operative', 'at the start of treatment', 'within 2 weeks before first administration use of the study', 'at the time of consent|Karnofsky performance status', 'At least 1 superficial cutaneous', 'more than 3 years', 'up to 1 month prior to and', '7 days before starting treatment', 'within 30 days prior to the first drug administration', 'within 14 days)||Blood', 'in the next 4 months', 'within 3 months of screening|Use', 'within 30 days of the planned start of study treatment', 'within 4 weeks from the screening', 'in the year after enrollment.|Portal hypertension', 'at the time of pre-inclusion', 'within 5 years before screening;|Subjects with the following conditions:', 'in the previous 1 month;|Have received', 'for at least 6 weeks prior to treatment||Prior to start of treatment:||Magnesium level', 'within 4 weeks of first dose of SIM0237.|Any other', 'prior to screening.|Subjects', 'within 30 days prior to the first dose of study intervention', 'at screening or D-1.|Use of', 'within 14 days before randomisation;|Presence', 'within 4 weeks before screening.|Within six months before screening', 'ongoing sexual relationship', 'within 6 months prior to first dose.|Human immunodeficiency virus', 'at least 7 days prior to baseline.|ACQ-6', 'discretion;|Current', 'within 90 days of surgery', 'within the prior 4 weeks of informed consent;|History of', 'preceding 24 consecutive months).||Patient must', 'prior to injection of ICG', 'within 4 weeks before the first administration|An active', 'prior to first dose', 'Sever', '2 weeks prior', 'within 60 days prior to screening.|Previous', 'within 30 days prior to the 1st dose of CHS- 006;|History', 'within the previous 12 weeks of the', 'within the last four weeks', 'at least 6 months after the last use of the test drug;|Volunteer to join the study', 'within 3 months prior to the first dose of study drug.||8', 'at the time of to the inclusion', 'within 7 days prior to the T0 scan', 'within 60 days before Baseline: typical or', 'within 3 months prior to the first trial dose|Previously enrolled', 'through their 12-month follow-up', 'within 1 month prior to the Screening visit.|Current urinary tract infection', 'in the last 24 months', 'during run-in', 'within one month before the test)', 'during the study period|The', 'at least 10 days before the start of treatment', '1 month before the start of treatment', 'at least 1 of the following at least 30% of the', 'within three month', 'within 4 weeks prior to the first dose of study drug', 'Criteria:||Age 65 years', 'during vaginal intercourse through 90 days after investigational agent administration', 'mental history', 'within 3 months|Allergic to', 'prior to collection', 'within 6 months of screening.|Any', 'given more than a year before this experiment', 'within 3 months before receiving the experimental drug treatment', 'in the past four week|Insulin-dependent', 'within 3 months of the start of study|Currently breast feeding', 'within the month before starting the study.||', 'within 7 days before the laboratory test', 'at least 1 available standard therapy', 'within the last 6 weeks prior to randomization;|History of', 'within the times specified before surgery', 'within 30 days prior to treatment', 'for at least 3 months||', 'while taking the IP', 'At least 5 years', 'within ≤2 years before screening', 'during the last year of poor glycemic control (HbA1C', 'within 1 week before screening', 'within 4 weeks prior to Visit 1', 'between 4 weeks and 24 months prior to recruitment|If', 'at least 10%', '5 half lives', 'at the time of collection.||6', 'within 4 weeks before the first drug use', 'within 14 days prior to Visit 2', 'after they', 'over the last 6 months', 'at the time of surgery.||', 'within 6 weeks before the start of treatment', 'more than 6', 'during or after operation', 'within 6 months;|20)Patients', 'during the study period.|Use of the EcN probiotic strain', 'during the study period.|Must', 'during the study|Dilation of esophagus required|Insufficient Dutch', 'after evaluation by the trial host.|Those', 'past 12 months.|Airway hyperresponsiveness', 'within 28 days prior to the start of Cycle 1', ""within one year of the study's start date"", '> 6 months', 'in the past 2 months prior to the enrollment|Had history of probiotics', 'at the time of cardioversion;|Pregnancy', 'at any time during pregnancy||Cohort 2||No', 'within the last 7 days.|Reported use', 'within study period||', 'at the time of the first surgical dressing|Children', 'within 2 years of study enrollment', 'features.|Current', 'at least 3 months ago', 'for three months starting from the study drug', 'for at least 3 months prior to the screening visit', 'within 4 weeks prior to randomization', 'within 4 weeks prior to pretreatment|Those', 'within the past 12 months|Had', 'within 60 days of randomization||Chronic infection', 'within 2 weeks prior to treatment.|Participants', 'within the next 8 weeks', 'for at least 14 days after the last dose of the investigational medicinal', 'for 4 weeks prior to the first assessment||', '14 days before entry the study|Use of any', 'criteria prior to January 1, 2020.|Last valid', 'within 10 days prior to registration', 'within 6 months from the signing of the informed consent for screening', 'every 28 days', 'within the past year specifically for their cough', 'within one month of study day 1', 'within 2 weeks prior to signing informed', 'in a month', 'within 2 months after study completion;|had', 'more than 14 drinks/week', 'within the study period for any of the joints', 'within 12 months prior to study screening|Previous receipt', 'likely to limit survival', 'during the two year study period.||Cardiovascular surgery includes the', 'past 1 year', 'for 6 weeks', 'at time of screening||Any contraindication', '6 weeks prior the start of the study', 'at least 6 months prior to the first dose', 'within 2 weeks prior to enrollment.||13', 'within 6 months.||', 'anesthesia.|Any', 'at the time of AAVAnc80-hOTOF administration', 'at the time of first dose 14', 'within 7 days of study entrance', 'during Ramadan.||', 'within 30 days prior to surgery;|American Society of Anesthesiologists (', 'within 4 weeks prior to the [', 'within 1 month prior to this study;|The investigator considers', 'within 12 months from the end of last anti-HER2 therapy.|Measurable disease', 'within 24 weeks|History of', 'at the study site)|As judged by the investigator', 'within 1 month and those who take drug', 'at baseline < 6.2;|Pregnancy|Subjects', 'within 3 days prior to receiving the first study drug administration', 'at the time of consent.|Subject', 'in the last 4 weeks.|Surgical history of the upper quadrant.|Metabolic diseases.|Ingestion', 'after at least 6 h free of parkinsonian drugs', 'within 56 days prior to registration', 'within 6 months after', 'within the past 90', 'within 6 months before inclusion|For', 'at initial screen);||', 'grade>1 within 4 weeks prior to enrollment', 'within the last 6 months|Uncorrected sensory perception disorder|Patient', 'within 3 months prior to the planned', 'within 365 days) date of institutional review board approval for this study', 'one month prior to inclusion|Treatment', 'within 14 days)||Neutrophil', 'within 72 hours before study enrollment', 'at least 1 year prior to informed consent', 'at the anticipated surgical entry site', 'for <1 week or topical steroid treatment', 'Personal history', 'within 30 days of screening;|Have', 'in the week preceding the 24-hour urine collection.|Person protected', 'within 14 days of the onset of symptoms;|healthy', 'in the past 2 years prior', 'within 2 weeks prior to the investigational product administration Note', 'at the time of screening.|Chronic cardiac failure', 'within last 1 year|Pregnancy', 'in the previous 7 days|Quantitative', 'within 14 days prior to registration|Adequate', 'before surgery|5 Adequate fresh tumor tissue', 'at time of signing informed consent.|Must have', 'for at least 8 weeks prior to screening;|Take effective contraceptive measures;|Voluntarily sign informed consent to participate in this study;|Willing', 'within 56 days before the first dose of the investigational', 'in the last 5 years；|Note', 'for at least 4-weeks prior to screening', 'within 4 weeks prior to study;|History', 'during the year prior to screening|History', 'at the time of videoconference screening', 'during defecography.||Inclusion', 'after 6 months after the first complete remission', 'at the time of screening.|Any history data', 'throughout the Screening Period.|Hospitalization', 'within 1 month', 'previously reported diagnoses', 'within 3 months before the signing of informed consent', 'within the past 4 weeks prior to Baseline.|History', 'within 3 weeks prior to inclusion|Epilepsy', 'in the past 1 year;||(15', 'within 6 months before randomization;|Left', 'within 2 weeks before the first visit;|Subject', 'within 10 days before receiving the first dose of study drug', 'within 30 days before informed consent', 'for four months after receiving the protocol treatment.|A participant', 'during the 30 days preceding the inclusion;|Occurrence of', 'at the time of the baseline visit:||Corneal astigmatism', 'within 7 days prior to C1D-7', 'in the previous 6 months', 'review.|Mandatory pre-treatment formalin-fixed', 'within 2 months of surgery', 'at the time of consent;|Received', 'within 12 months after planned study drug', 'within 4 weeks prior to Day 1.|Use of', 'within 2 weeks prior to the Screening', 'within one week before enrollment.|The result of', 'during the study|Have', 'before starting a keto-', 'within 2 weeks before enrollment;|Have', 'during 3 months before enrollment.|Body mass index (', 'since these procedures', 'for 8 hours', 'within 180 days before enrollment||Patients', 'prior to initiation of study treatment.||Treatment', 'during the two months prior to the diagnosis of the', 'diseases|More than 3', 'within 2 years before the first administration', 'prior history of', 'in the last 3 months|Drug', 'within 12 weeks prior to the screening', 'prior to ED', 'at time of balloon placement between', 'throughout the study;|Blood donation', 'after birth', 'in the diseased', 'newly obtained', 'at the time of randomisation', 'at least 20 cigarettes per week', 'at the index site before fracture fixation|Patients', 'within 28 days prior to initial administration;||Sufficient elution of previous treatment', 'throughout the treatment period and for 6 months after the treatment', 'for at least 3 months prior to study enrollment', 'within 3 months prior to screening.|Patient', 'for at least 28 days prior to Day 1', 'during enrolment.|Clinically', 'in the visit);|known pregnancy;|documented treatment for schistosomiasis', 'at the time of registration;|Hepatic insufficiency resulting in clinical jaundice', 'for 1 month following the last dose of study intervention', 'within the last 30 days|Active', 'before hospitalization', 'within 14 days prior to initiating study treatment)||Cockcroft-Gault', 'within the last 6 months prior to the screening run-in', 'within 24 hours of hemorrhage onset.|Endoscopic evaluation done after hospital admission.||', 'prior to the first dose of the investigational', 'within the past 3 months.|Patients', 'for the past 1 month and while participating in the', 'within 5 months after the last dose of study treatment.||Other Exclusions:||Patient', 'last systemic therapy', 'for 2 months to prior', 'after January 1, 2017.|Availability', 'in the last 5 years|Patient', 'at the time of the study.|Patients under total', 'prior to the start of the study medication.|Patients', 'at any time from 4 weeks prior to the Screening Visit up to and including the Baseline Visit.||Participants who experience', 'within 24 months before randomization', 'within three months before the first dose of alectinib.||I.', 'within the last 12 months|Active substance', 'in the 5 years prior to screening', 'at least one of the following prior to initiation of', 'in the past 2 weeks;|Long-term', 'within the last 30 days|Unable to travel to The University of', 'in the previous 4-6', 'within 2 months before signing the ICF', 'within 6 months:||Myocardial infarction|Unstable angina|Cardiac angioplasty', 'in the 4 weeks prior to the', 'at least 12 months no menses', 'within 3 weeks of testing', 'during screening period', 'in the past 12 months.||If', 'during the study.|Antibiotic', 'at least 1 year old);|Optimal HF medical therapy.||Exclusion', 'in the previous month|primary hyperparathyroidism|revascularization of the lower limb', 'within 2 years of the diagnosis', 'at least following', 'for less than 48 hours', 'within 14 days before the visit;|The presence', 'in the past>6 months', 'at least 3 months|The', 'within 48 hours after vaccination', 'in the previous 1 months', 'during and after procedure', 'within 48 h', 'in the 3 months prior to the study|a history of anterior', 'prior to the first dose of study', 'in 2', 'Previously', 'throughout the trial.|Concomitant diseases', 'within 10 hours of', 'at the time of patient enrollment', 'prior to 3 months of age.|Has', 'within 10 days prior to study treatment initiation', 'within 3 months after SOR|One eyed|Vitrectomized fellow eye|Retinal detachment', 'within three months of screening', '> 3 months prior', 'during the study period and within 6 months of stopping treatment', 'within 4 weeks before the first dose;|Previous received experimental medication', 'during the last three months', 'within 14 days before the experimental maintenance treatment initiation.|Adrenal replacement steroid doses', 'within 6 h of DMT', 'within 6 months prior to treatment initiation.|Major surgery', 'for 1 week prior to and', 'at least 1 month prior to screening - a double', 'for at least 1 year||', 'at least 7 days prior', 'greater than 4 mm', 'within 1 week before the first dose', 'during the study period and within 6 months after the last administration of the study', 'within two months prior to treatment', 'involvement.|Prior history', 'during the past 2', 'at the end of treatment', 'managed with replacement therapy', 'within 28 days of', 'within 10 days before the first dosing day', 'within 3 months prior to initiation of study treatment|History of', 'within the last 15 years', 'within 4 weeks prior to study entry.|Known', 'at least 3 unformed', 'during the screening;|Willing', 'for six months after the last dose of study treatment to allow for clearance of', 'within 30 days prior to screening|Is currently enrolled in another investigational drug', 'during the conduct of the study.|Drink alcohol in excess', 'at the toe', 'prior to current hospitalization', 'within 2 weeks before first dose of study drug.|Previously', 'after conventional anticoagulant therapy', 'within the last 6 months prior to registration|History of', 'over past 30 days prior to Visit 1', 'in previous 4 weeks before first visit|History of current', 'within the 4-week', 'for at least 28 days', 'within 4 weeks prior to entering the study|Prior treatment', 'at least one month before the start of the study,|Children', 'within the past 72 hours|None-to-mild ARDS', 'during the 3 months prior to the Screening Visit.|Excessive intake of', 'within 3 months;|history', 'within the projected duration of the study through 12 weeks after the last dose of study treatment.|Use of ribose', 'within 30 days of receiving study drug therapy', 'at least 90 days prior to registration.|History of', 'in the week before delivery|Severe thrombin dysfunction', 'within 10 days prior to the start of study intervention)|Hemoglobin', 'between 3 and 28 days prior to radiotracer injection', '1 month after discontinuing investigational product', 'medication history of probiotics', 'at the time of signing the ICF|Has', 'during the 5 previous years.|4', 'history of', 'history of taking standard medication', 'within the 6 months period prior to Screening', 'within 1 month before signing informed consent', 'for the current episode', 'within 100 days of Visit 2|Presence', 'within 14 days prior', 'unless', 'within 2 years after their cell reinfusion;|(7', 'after at least two prior therapeutic regimens', 'during the screening visit.|Negative pregnancy test', 'prior to first study drug until End-of-Study', 'after previous treatment', 'during the next 6', 'last 12 months at pre-screening', 'in the next 1 months|Patients', 'within 28 days prior to the first dose (counted from the date of the last treatment', 'post- menarche', 'throughout the body', 'before the first dose of study drug;|≥ 2 weeks', 'within 1 week prior to randomization;|Current', 'within 3 months after the last study treatment.|As', 'within 14 days of platelet assessment||Total serum bilirubin', '≥6 months prior to enrollment.|Known', 'at least 45 years', 'likely greater than 3', 'within 30 days of screening.|History of', 'during the time the patient', 'for at least 48 hours prior to enrollment', 'in the 2 years prior to enrollment.|History of', 'prior to first cevostamab infusion.||Current', 'within 4 weeks of first study agent', 'for more than 120 min/week', 'within 6 months prior to randomisation.|Vaccination', ""before 6 months of age|The patient's legal"", 'during the previous three months', 'in the past 4 weeks;|Any', 'through 120 days after the last dose of pembrolizumab', 'in the 2 months before enrollment', 'for at least 6 weeks prior to baseline visit.|Lives', 'within 14 days or', 'at least 5 min below 88% saturation', 'during the last 21 days before screening.|Ongoing treatment', 'within 30 days prior to registration.||Appropriate', 'for the last 6 months|Receiving four-hour hemodialysis treatment', 'at least 4 weeks prior to Screening', 'for at least 30 days|Have', 'in the previous 30 days|Otitis', 'within 3 months before the first administration', 'within 2 months before entering the study', 'prior to crossing the lesion.|Thrombolysis of the target vessel', 'prior to index date', 'in the previous 12 months before Screening', 'within 7 days prior to the first dose of the investigational product(s)||Patients', 'at least 6 months after primary TKA|Being able to stand', 'in the past five years', 'within 12 calendar months of Day 1 of this study', 'within 7 days before the first dosing date|Depot injection', 'within the last 6 months|Regular consumption', 'within 2 weeks of the first day of study therapy', 'within 30 days from the stroke||', 'in the past 12 months|Known', 'within 12 months prior to first dose', 'after resting for 5 min prior to each reading', 'during the last 6 months', 'at the time of the polysomnography done within 3 months)||', 'for at least 28 days prior to the first injection', 'over 3 weeks duration', 'within 4 weeks of Screening', 'within the last 14 days of screening)|Hemoglobin', 'at the time of signing the informed consent form|Able to speak and', 'within 30 days of surgery.|Patient has no', 'in the 30 days prior to screening', 'within 1 week prior to tagraxofusp-erzs treatment', 'during the past 3 months.|Able', 'within 2 weeks before first dose of study treatment', 'during the course of this study||', 'in the next year due to participation in a research', 'conditions:||Less than 4 weeks', 'within 1- month of the baseline examination', 'within 28 days prior to the first dose of FHND5071;|Medical history of', 'before Screening/Baseline visit', 'within 28 days before randomization.|Have received', 'over the past 3-months.|Is', 'at least 4 weeks prior to initial administration of the trial drug', 'within 3 years prior to Day 1', 'within 3 months prior to initial medication|There', 'within 6 weeks prior to Step 2 registration.|For', 'at least 6 months prior to screening|Abstinence', 'during the duration of the intervention|Substance abuse', 'for the first time', 'within 2 min when', 'last year,|In the laboratory examinations', 'at time of screening|Cyclophosphamide', 'during the first 3 days of life', 'in the ICU', 'within 30 days prior to study entry.||ii', 'for 24 months', 'within last 3 years|Severe cognitive', 'for previous 2', 'more than 5 units', 'within the 8 weeks prior to the inclusion', 'within 28 days of Week 0', 'at any dose', 'at the time of screening.|Hospital-', 'within 3 months before apheresis', 'at baseline', 'within 14 days prior to ASP1002 administration', 'within 28 days;|Those', 'at any time during the study|Temporary soft tissue filler injections in the', 'within 3 months of using the experimental drug|The subjects', 'within 2 weeks prior to blood', 'within past 2 years requires review', 'during the last 3 months before inclusion', 'for 2 years.|Patients', 'within the last five years)|Primary', 'for 30 days after the last dose (please see Section 10.4.2 for', 'congenital abnormality|Only pairs', 'within the previous 90 days.|Subject', 'within 4 weeks prior to starting study treatment.||In any case', 'for 1 week after the last', ""prior to the subject's"", 'within 1 month prior to Screening 1|Personal', 'within 30 days of the first dose administration unless', 'prior to first contact', 'for at least 5', 'in the last 12 months|COPD-related', 'for at least 6 months after the last', 'within 4 weeks prior to the first dose of trial treatment.||Note:', 'at screening/baseline measurement', 'within 12 months prior to the first dose in this current trial', 'after at least 1 prior line of standard therapy', 'for at least 6 months prior to the Screening Visit.|Subject must be able', 'at Screening or Baseline|Liver function test values', 'at the time of diagnosis', 'at the study site', 'within 12 months prior to study', 'for at least 7 days prior to the first dose of study drug', 'in the past month|Will be residing', 'within 2 weeks prior to initiation of study treatment|Prior', 'for at least 6', 'within the projected duration of the trial', 'up to 6 target measurable nodes', 'during the current hospitalization', 'at time of informed consent', 'at Screening and Baseline.|Moderate-to-severe', 'at screening less than or equal to 6.5', 'at the trial', 'at least 3 months before the enrolment', 'except for myopia.|Provision of consent', 'within the last 2 years|Difficulty', 'within 6 months of the first dose of study drug|Concurrent', 'within the last 4 weeks prior to the first intake of study intervention.|Febrile illness', 'after 2 courses of induction chemotherapy;(2', 'at the time of the first injection with the 6-month triptorelin formulation', 'within 2 weeks prior to the expected initial application date', 'at the time of screening.|Is', 'within 6 months prior to treatment.|Patients', 'within one week|organ', 'within 24 of onset', 'within 7 days prior to enrollment.|Subjects voluntarily sign', 'during their participation in the study|A minimum of 20 natural teeth', 'during the last three days.|You', '4 weeks before enrollment|HIV positive', 'during the last 30 days.|Severe hypertension', 'within approximately 1 year', 'within 30 days of day 0.|Receipt of a live vaccine', 'within the past 6 months|known', 'for 3 months after the last dose of bendamustine', 'within the last four weeks.|Patients', 'within 6 months prior to screening|Any reason', 'within 7 weeks prior to surgery.||', 'within 4 weeks prior to study treatment initiation', 'within 30 days of registration', 'for 12 months', 'in the last three months.|Patients', 'within 4 weeks of screening.|Subjects', 'maximum 4 days', 'post biopsy', '36 months previously', 'during the study period.||', '5 times ULN', 'at the time of starting study treatment/randomization', 'before study inclusion.|Negative', 'more than 50%', 'within 5 years,|able to read', 'in the past 2 years prior to the surgery', 'at the onset of the episode', 'throughout the study.|No health conditions', 'in last 90 days|Presence', 'before allocation.||Applicable to children', 'at the same time (', 'within 14 days prior to initiation of study', 'for 4 weeks before the baseline study', 'within 6 months before', 'prior at least 4-weeks', 'within 28 days of the first dose of study', 'continue the current regime', 'greater than 20', 'within 14 days prior to initiating study treatment.|[Males', 'within the past 6 months;|Receipt', 'at least 2 hrs before administration of an H2 blocker.|Treatment', 'before inoculation;|Family history', 'for the last 60 days', 'while taking study', 'within the past 2 years|History of overt clinical stroke', 'within the 6 months prior to the recruitment period', 'within the last 6 months prior to', 'within one month of study day', 'within three days after CT scans|underwent qPCR', 'during the 6 months|No evidence', '7 months after the last dose of study drug', '<6 months prior to enrollment', 'either|HPV-negative status', '30 days prior to surgery|Emergency surgery|Other surgery 30 days prior to colorectal surgery|Neoadjuvant radio-', 'within 30 days of birth.||', 'in the past 6 months|Changes', 'within 2 weeks before the RCT|Received immunotherapy', 'for the next 3 months', 'within the normal reference range', 'within 5 years|Timed up', 'in either', 'for more than 5 years', 'at time of enrollment|Pre-pregnancy body-mass index', 'within 12 months prior to randomization.|Pregnant', 'between last dose', 'within 24h before the first dose of study', 'at the time of signing informed consent.||Patients', 'within 1 year prior to Screening|In', 'within 28 days prior to first study treatment|Last treatment', 'within 48 hours prior to ablation', 'within 6 months prior to randomisation;|Subject', 'within 1 week before treatment;|No birth plans', 'preceding 24 consecutive months).||A FCBP', 'prior to Screening Visit 2).||Treatment of asthma', 'causes|Being', 'within 1 week prior to enrollment;||Vital organ functions', 'at least 3 months prior to the', 'at the time of ICF', 'following requirements:||Prothrombin time/international standardized ratio', 'last two years|pregnant/lactating', 'at the time of enrolment.|Symptoms', 'through 120 days after the last dose of trial', 'history of DVT|Patient', 'at the time of the consent date.|Patients', 'within 6 months before screening.|The laboratory examination', 'for at least 3 days', 'at first surgery', 'within 4 weeks before the administration of lymphocyte', 'greater than 6 months.||If', '2 months after surgery', 'at starting dose', 'longer than 3 months|Hemodialysis treatment', 'within 28 days prior to treatment', 'at least 1cm', 'within 6 weeks before enrollment|Normal cerebrospinal fluid (CSF)', 'within 1 month before consent', 'within 3 weeks prior to the first dose.|Receiving radiotherapy', 'at the time of screening|Positive blood tests for HIV', 'less than 2 months before the start of the Ramadan fast|patient', 'after receiving prior chemoradiotherapy', 'during exercise', 'during the 3-month study period|Medical procedure scheduled', 'in the past 12 months)|ready to make lifestyle changes to', 'for at least 6 months after last study treatment', 'within 4 weeks before study entry', 'within 4 weeks prior to the screening visit', 'at least 30 ml/kg', 'at least one symptom', 'within the last 2 weeks|Platelets ≥ 100 × 109/L|Total bilirubin', 'within 3 months prior to screening.|Are', 'within the past 18 months||Symptoms', 'within one week', 'within the 3 months prior to', 'within 3 weeks before receiving the experimental drug;|participated', 'within 30 days prior to Visit 1 (Day 1', 'within the past three months.|History', 'within 4 weeks of baseline.||Safety', 'within 30 days prior to screening;|Had vaccine', '1 year before screening', 'following administration', 'within five years|Suffering from', 'within the Department of', 'during the study period;||Patients', 'within 2 weeks before randomization;|Patients', 'within 6 months before recruitment.||5', 'at the start of the study|Presenting', 'onset in the past 3 months', 'at least 36 calendar months prior to enrollment|Patients', 'within 24 hours before taking study medication.|hepatitis B surface antigen HBsAg positive.|hepatitis', 'for at least 12 weeks', 'within a period sufficient', 'at week 47 visit||a', 'for 3 months after the last dose.||Specific inclusion criteria||8', 'during the duration of the study.|Has a currently', 'within 28 days prior to the start of study intervention.||Absolute neutrophil count (', 'within 6 hours of symptom onset', 'within 1 month prior to the start of study|Known difficulties', 'at screening', 'in the exclusion criteria.||EXCLUSION CRITERIA:||For', 'at the time of the signature', 'at time of screening|If', 'at the time of study entry)|Written informed consent', 'after the ""Speckle Anthra"" study', 'within 30 days of screening.|Respiratory medication', 'within the last three months;|Vitamin', 'in the four weeks prior to inclusion|Vaccine refusal||Indication', 'within 24 months of the screening', 'more than 4 weeks prior to the first administration of this', 'within 3 months before enrollment;|Those who need', 'more than 24 hours', 'prior to study enrolment|Serum Na', 'outpatient visit', 'at least one cytotoxic agent', 'within 12 months prior to inclusion', 'for 8 weeks following the last dose of study', 'during the last 3 months prior to the start of the study', '72 hours before hospitalization', 'within the 3 months prior to enrollment', 'for at least 1 month,|AND', 'at least 6 months after the last dose.|Subjects voluntarily participate', 'during the index procedure.|Patients', 'past 2 weeks', 'last 4 months prior to study entry,|Non-invasive', 'during past month', 'within 30 days before registration.|Hepatic insufficiency resulting', 'within 2 months prior to admission', 'attributed to a', 'within 6 months prior to enrollment.|A', 'prior to the index date.|Age', 'within 5 years before screening.|Positive results', 'within 30 days before Study Day 1.|History', 'prior to injection', ""at the time of assessment)|As per the Investigator's judgment"", 'prior or adjacent to (', 'within the last 14 days', 'in the 6 months prior to Day 1 of Cycle 1 of', 'within 4 weeks|A person', 'at the time of entering the study', 'during or after previous', 'following initial systemic therapy|Bodyweight', 'for 180 days after the last dose of treatment.||', 'during the course of the study|History of currently', 'at the time of randomization|History', 'throughout the Double-blind Treatment Period;||7', 'last onset of ischemic stroke', 'past 30-day', 'before enrolment to rule out MI.|Corrected QT interval', 'at least 1 cigarette', 'during the study period.|Current', 'within 5 years prior to enrollment', 'in the past 12 weeks.|Initiation of', 'within 6 months before study initiation.|Participation', 'within 6 months of the screening', 'within last 30 days.|Patients', 'at time of screening|Self-identifying', 'between January 1, 2003', 'cycle|more than 6 hours', 'at the time of the study|Norelgestromin', 'after histological evidence,|Advanced', 'within 56 days prior to the first dosing.|Plasma donation', 'at the time the legally authorized representative', 'for ≥3 years before the administration of IMP', 'at the time of screening.|Benign prostatic hyperplasia', '2 weeks before treatment start', 'within 28 days before randomisation 6', 'within five months following their last dose of atezolizumab.||D. History', 'for ≥28 days after the last dose of study', 'within 60 days after enrolment in the study.|Positive testing for COVID-19 within 3 months of enrolment', 'at any time after achieving', 'after primary therapy', 'within 4 weeks prior to study inclusion', 'after trauma and|Presumptive duration of operation not exceeding', 'for at least 6 months from the screening date until after study dosing', 'within 2 weeks of the experiment day|Inability to personally provide written informed consent', 'in 24 hours.|Taking supplemental probiotics', 'within 14 days of study entry.|Patients', 'within 24 hours before Visit 2.|Have active', 'for at least 28 days prior to first dose of study drug.|Any of the following', 'within ≤ 28 days before treatment|Acute myocardial infarction occurred', ""in Epic's"", 'Past', 'during the 48 hours', 'prior to the first dose;|Subjects', 'within 3 months prior to signing ICF.|Those', 'within 7 days of study enrollment', 'Current', 'within 8 weeks prior to the time of screening.|Any', 'within one to six months of the clinician', 'in the past 12 months before first dose of treatment', 'within 3 days of study Day 1.|Participant', 'during the preceding 3 months;|End-stage', 'at the time of study|Recent COVID illness (must be symptom free for > 10 days', 'prior received', 'at least one dose of cladribine tablets', 'within the last 2-months||Non inclusion', 'during the 6 months preceding the study|presence', 'for prior 3 months', 'within 2 weeks of Screening', 'past 12 months.|Airflow variability in clinic FEV₁', 'prior to screening;||Patients', 'following criteria:||Blood routine examination standards', 'at the clinical staging', 'at least for 6 months|Children', 'before the 24th week of gestation', 'within the range of intended use', 'at least two weeks prior to first study drug administration until donating the last sample of the study.|Subjects', 'within 4 weeks after the end of study.|Donated', 'in 24', '72 hours prior to Visit 1|Have', 'within 5 months after the last dose of study', 'less than 2', 'in your past history|Accompanied by', 'within the past 5 calendar days', '< -5 dioptre||', 'within 3 days of intended study', 'over 3 consecutive days on bladder diary', 'in the next 12 months||', 'more than 12 months before inclusion.|Use of investigational drugs', 'for the duration of clinical follow-up).|Provision of written', 'within 16 weeks prior to randomisation', 'before first dose of study treatment', 'for at least 5 years.|Past medical history of any kinds', 'during the study until 180 days after the last dose of study drug.||Male', 'within 6 months prior to signing informed', 'more than 1 time zone', 'during or within 6 months of use of capecitabine.|Patients', 'prior to any review', 'within 14 days prior to enrollment', 'within 12 months before signing the informed consent form', 'prior to initial treatment.|Overactive CYP3A4', 'in the last 180 days prior to consent|Known history of', 'within 24 hours prior to study entry.|Persons', 'within 7 days preceding the lab assessment', 'within 14 days before screening|Presence of', 'during the neurophysiological evaluation|Sedated patients|Minor patients|brain death|Known deafness|Pregnant women|Prior inclusion', 'within 28 days or', 'within 90 days before the day of screening', 'at any time during the study.|Subject', 'in the last twelve months;|Self-reported', 'more than 8 on', 'within 1 week of dosing|Exposure to', 'within 28 days prior to study drug administration.|Positive test for alcohol', 'for the past 6 consecutive months', 'at least one line of platinum-', 'prior to enrollment.|Any', 'within 14 days prior to group', 'during the study period；|Anti-il-17 antibody active', 'within 24~48h have progressed significantly', 'in the first 5 years of', 'within 5 years prior to the first dose', 'for at least 8 weeks before screening', 'in past 2', 'within 15 days after surgery|After tumor reduction', 'directly', 'within 6 months prior to the screening period', 'during the trial|History of alcohol', 'scoliosis|Previous history', 'within the last six months;|Evidence', 'within 14 days prior to initiation of protocol therapy', 'in room prior to enrollment|Anticipated patient stay', 'following the completion of concurrent chemotherapy', 'in past month', 'scheduled to receive', 'within 30 days after end of trial;||Medical history', 'in the 2 weeks prior to screening', 'more than 8', 'medical history question and inspection of nasal passage.|Presence of', 'within the first 4 hours after CABG', 'within 4 weeks of dosing|Evidence of disease', 'within 2 weeks prior to IMP treatment', 'within 1 week before first study treatment', 'for the first time with a cortical or', 'continue for 1 month', 'within the past 5 years prior to Screening', 'at the start of the study|having no time for participation in program|receiving pharmacological psychiatric treatment', 'within two weeks prior to the screening', 'within 1 year of recruitment|Current treatment', 'for more than 6 months', 'in the past 2 years.|Diagnosis', 'within 14 days after the completion of screening||', 'through 180 days after the last dose of the study treatment.||', 'within the preceding 1 year', 'within the past 6 months.|Previous receipt of an investigational malaria vaccine', 'during this same period**.||* Acceptable', 'at least 12 months prior to screening', 'within 4 weeks;|had not received', 'during the 12 months period of enrollment of the study;|Diarrhea onset', 'within the range of 18~28kg/m2', 'within 6 months before lymphodepletion.|Known', 'within the past 3 months.|Underwent', 'within the preceding 30 days', '<1 year', 'in the last 24 mos.', 'pre-transplant', 'at the time of enrolment.|Previous vaccination', 'for at least 3 months before the start of treatment', 'within 3 months)|Patients', 'within the projected duration of the study;|Subjects', 'at the time of consent.|Histologically', 'within 14 days prior to the first dose|Can not follow approved birth control methods', 'in the last 3 weeks prior to baseline', 'within 6 months before the start of treatment.||II', '5-year', 'within 14 days (inclusive) before the screening;|Have undergone any', 'for the past 12 months;|Not systematically trained', 'after the end of treatment', 'in the 2 weeks prior to the beginning of the study;|Participants', 'in the week preceding study', 'within 30 days after the treatment of the target lesion.|Known allergies', 'within 7 days prior to the first study intervention', 'after these therapies.|ECOG performance status', 'at the time of the MII-pH', 'within normal institutional limits.|Clinically normal', 'within 14 days before the first intake of study', 'within 4 weeks of treatment start.|Participants must be able to understand', 'Prior to this study:||Type 1 diabetes mellitus(T1DM', 'within 14 days before randomization.|Allergic to and /', 'while taking Onlife', 'within 3 months|Participated', '8 to 12 years- old', 'more than 1 year before enrollment', 'within past six months', 'prescribe', 'at time of colonoscopy||For CD', 'during the previous weeks liable to interfere with the assessment of the cutaneous acceptability of the study product', 'within 30 days after the last', 'within 6 months|Recent', 'within 1 week prior to Day 0||Active acute', 'for less than 6 months;|Under treatment', 'at least one of the following', 'in the past 2 years|Patients', 'within 14 days prior to the first dose of study intervention', 'within 14 days of initiating study drug', 'within 2 weeks prior to the first dose of study treatment|Significant', 'within 12 months before screening.|Any', 'after declaration of', 'within 28 days of the start of study treatment|Any investigational', 'within 2 months prior to randomization).|≤ 5% weight change', 'within 3 months,|Excessive alcohol', 'within 14 days before enrollment|Patients', 'within 24-48 hours', 'within 1 month before enrollment;|Patients', 'within 90 days after the last dose of any component of the study treatment regimen.||Arm', 'within last 2 years.|CAP scores more than equal to 248 and less than or equal to 270 dB/m', 'examination|More than 2', 'in the previous year', 'within 4 weeks before the first administration;|Participated in clinical trials of', 'in the previous 4', 'at least 6 months prior to Screening', 'within 3 months of the first dose', 'within 4 weeks prior to enrollment.|Known', ""at least 6 months' duration|Age"", 'after initial curative therapy', 'within 12 weeks of each other', 'within the past 12 months|Prior anterior/apical suspension', 'in aim 2 must||be employed in CMHCs', 'within 12 months prior to Screening|Participants', 'within the last two weeks)|Recently experienced', 'at the time of the study|Medroxyprogesterone acetate', 'within 24 weeks prior to Randomization|Major surgery', 'for 4 months after the study drug infusion);|Sign the informed consent before the trial', 'for at least 1 month prior to starting the study', 'in the 3 months before the V1 visit', 'in past 2 years|Those', 'for at least 120 days after the last dose of study intervention||Female', 'from the time that the baseline tissue was obtained.|Prior locoregional', 'within 12 weeks prior to baseline', 'in the past year||', 'past year while being equipped', 'in past 1 year', 'at least 1 year prior to study entry.|They', 'within the past 6 months.||(If Participant began taking a supplement', 'within 24 hours', 'within 2 weeks prior to the first dose of study treatment.|Cytotoxic', 'immediately prior therapy', 'within the range of 18.0 to 30.0 kg/m2', 'within 3 months after treatment.||', 'for at least 3 seconds', 'within 2 weeks before treatment until EOT follow-up', 'before starting study treatment', 'at the time of implantation', 'prior to randomization;|JAK inhibitors', 'within 30 days prior to procedure;|History', 'in the past two months|Patients', '8 weeks before the start of the study', 'for six months after their last dose of medication.|Patients', 'at the time of testing of', 'within 4 weeks before the study', 'for 30 days after completion of the study.|Hormonal contraceptives', '7 days prior to randomization.|If', 'for > 6 months', 'within the last 5 years||', 'before the start of study treatment', 'in the previous 6 months;|Decay / abscess', 'prior to the start of treatment.|Resolution of any toxicity', 'within 1 week prior to Meta10-19', 'within 28 days before the first dose', 'during the study.|Enrollment in another study', 'within 12 months after procedure;|Patients', 'last 24 hours prior the procedure;|Any sign or symptom', 'for 6 months after study drug', 'within 3 months after the last dose of study drug||a', 'at least 3 months from any cell therapy', 'less than 1 month before start of the study', 'preceding 3 months', 'at time of screening.||b', 'at least', 'within 48 hours after randomization', 'during the past 14 days|Subject', '7 days before screening', 'within 30 days after vaccination with the trial vaccines;|A serious', 'longer than 12 months prior to inclusion.|Parent/legal guardian', 'rather than cholecystectomy.|history', 'within 28 days prior to the enrollment', 'at least 7 days after CABG', 'for at least 5 years prior to Visit 1', 'within one year prior to the screening', 'in the baseline period compared to the screening', 'in the last 3 months;|Subjects', 'within 6 weeks from randomization', 'managed with replacement therapy.||History', 'at least 14 days prior to study treatment', 'before 01/12/2022', 'for at least 3 months;|Estimated GFR', 'at least 3 months.|Planning to', 'within 4 weeks;|Any investigational', 'for at least 90 days', 'within 1 month of signing informed consent.|Considered', 'within 2 years of study', 'within 6 months of Visit', 'within the past 14 days prior to study registration c Hemoglobin (Hgb)', 'within 6 weeks before harvest;|Oral fluorouracil', 'at least 1 month after the end of the study.|Male subjects must agree to practice 2 highly effective methods', 'within 1 month prior to vaccination', 'outpatient IV', 'at the block site', 'in CT perfusion.|Baseline NIHSS obtained before procedure', 'in the next 2 years;|Participants', 'more than 3 and', 'within 2 months after radiotherapy', 'more than 30 days prior to registration', 'with the exception', 'at the time of signing the ICF.|Histologically', 'within 4 weeks prior to the first dose.||3', 'nervous', 'in prior 3 months.|Platelet count', 'at least twice a year', 'prior to randomization.|Participants', 'within 30 days prior to inclusion|History of food', 'within the past 6 months', 'at the time of enrollment.|History of autoimmune pneumonitis', 'after 4', 'within 1 week prior to the first dose of study', 'during the initial', 'within 6 months prior to screening.||5', 'within 2h after surgery|Unstable', 'within the previous 5 years,|dietary restrictions', 'for the first phase of the study;|A first-degree relative', 'at least 1 negative', 'within the last 14 days of screening)||eGFR', 'over last 3 months|History of at least one unsuccessful effort of', 'after 15 min', 'within 6 months prior to Day 1', 'pre-transplantation)|Recipients', 'during the study.|Has participated in an interventional clinical study', ""within 6 months of study participation.|As per the Investigator's discretion"", 'prior to enrollment.|Leptomeningeal carcinomatosis', 'in the past 5 years|current', 'after 01 January 2011|1L treatment', 'in the last 2 years.|Positive screen for', 'for at least 30 days after the last dose of assigned treatment', 'at time of in-formed consent.|No', 'within past year|Actively', 'in the last three months.||', 'at Screening and at Baseline', 'within the past 4 weeks prior to treatment start|Neutropenia', 'during the study;|Any other diseases', '>6 months', 'within the next 6 months', 'within 24 months Adult', 'within the last 6 months|Individuals', 'within less than 2 years||Cardiovascular disease', 'at the screening stage indicate', 'at least 7 days prior to enrollment', 'for at least one month after the final study visit;|Oral glucocorticoids', 'history to the investigational drug', 'within 4 weeks prior to the screening', 'in the last three months before treatment', 'while awaiting transplantation', 'at time of discharge||Previous', 'during the Screening Period prior to||Week 0 Visit:||Baseline', 'within two months of visiting', 'at time of screening/postoperative evaluation)|(Increased', 'for at least 90 days after the last dose of the study drug', 'within 4 weeks prior to the first administration of the study drug;|Major surgery', 'within 3 months prior to date', 'at the time of parental consent.|Overall good health of the child subject', 'within 3 months prior to Screening 1', 'within 7 days before surgery;|Patients', 'during the course of the study||Other protocol defined Inclusion/Exclusion criteria may apply', 'during the study.|Currently has a schedule that includes nighttime', 'in the past 90 days|Diabetes|Autoimmune diseases', 'between Screening Run-In Phase Visit I', 'for at least 60 days prior to registration.|Patients', 'on the labial surface of either maxillary', 'within 4 weeks prior to enrollment|Lesions', 'at screening.|Clinically significant', 'during the 6 months before enrollment', 'before oocyte retrieval|Recipient', 'within ≤ 6 months before treatment|Cerebrovascular accident occurred', 'within 30 days prior to Visual-ICE treatment;|XRT', 'within 1 week prior to C1D1).|Alanine aminotransferase (ALT)', 'with the reappearance', 'throughout the night', 'within the previous 5 seasons.||', 'in the last 12 months prior to enrollment|Previous pyloromyotomy', 'within 100 days prior to first cevostamab', 'prior to 16 weeks', 'in the last three months.|Exhibits another form of', 'in the past 24 months prior to Screening', 'unclear history', 'during the past 2 years', 'within 8 weeks prior to Week 0 Visit', 'at the time of signing informed consent.|Diagnosed', 'prior to first treatment after TCR|Started anti-MM treatment after TCR MM eligibility|Eastern', 'for next 1 year|Households not involved', 'for at least 30 days prior to Visit 1 and during the study|Neurostimulators: 30 days prior to Visit 1|Current use', 'for at least 3 months after the final dose of study drug|Voluntarily sign the informed consent form, understand the trial procedures', 'in the last 3 months|MoCA score of <26|Significant', 'within 4.5 hours after stroke onset.|The', 'after the last dose of investigational drug', 'after 8 subjects', 'within 6 months prior to initiation of treatment|Any bleeding', 'at Screening and Baseline', 'during study period|Any', 'within six months prior to study entry', 'the 2 weeks prior to enrolment.|Minimum life expectancy', 'within the 12-month period', 'within the last 6 months.|Any', 'within 7 days prior to initiation of the first Treatment Cycle|Platelet count', 'prior to informed consent.|Received immune globulin', 'during study protocol', 'before the last day of follow-up.|Has', 'while on trials', 'greater than 3cm', 'in the past 6 months|Clinical', 'within the last 28 days', 'within 10 days prior to the start of study intervention)|Creatinine', 'within the first 24 hours after the operation,||', 'more than 6 months', 'within 4 weeks before first dose of the research drug', 'more than 1.o diopters', 'within 6 months prior to the first dose of study treatment', 'Newly diagnosed participants', 'within 3 days prior to receiving the first dose of study drug', 'within 3 days before the first dose of brigatinib.|No', 'within next 3 months', 'within one month.|Combined', 'within 4 weeks [prior to allocation.||Note: Participants', 'in the previous 6 months|Those', 'within last six months', 'in the previous 3 months', 'for 3 months after completion of treatment.||', 'at the time of enrollment);|Have visible consolidations/ground', 'at onset undergoing', 'within 30 days before the first dose of study intervention', ""within the site's laboratory reference"", 'within the past 5 years|Active', 'within the last 3 months|Surgical menopause', 'potential.|Patients whose daily alcohol consumption', 'within the 6 months prior to recruitment.|Hepatitis B', 'during screening.|Treatment-naive', 'within 12 weeks of Visit 2/Baseline', 'for at least 6 months before enrollment', 'pre-trial treatment', 'within 14 days prior to use of the study drug;|Patients', 'during the study;|Patients', 'within 14 days before randomization.|Has received (', 'during the course of the study.|Has sickle cell disease', 'prior to athletic activity)', 'within 6 months;|The functional indicators', 'at Screening or Day 1|Has', 'At least one measurable lesion.||', 'in the prior 6 months', 'the past 6 months before signing the ICF.|Impossibility to insert', 'within the past 6 months|Are', 'prior to surgery|Prisoners', 'for the last 5 years;|History of the cardiac surgery', 'within one hour', 'at least 8 hours of assistance to the care recipient per week|Does not intend', 'for past 5 years|Patients', 'within 90 days of screening.|Prior treatment with BIIB131', 'at Visits 1 and', 'within 4 weeks before the first use of the drug', 'in the impacted or more impacted leg|Existing thrombosis', 'for the last 6 months', 'at the hospital.||', ""after ingestion of cow's milk|patient suffers from symptoms"", 'at least one 2-week rotation', 'within 28 days prior to IMP treatment start', 'lasting for 12 months', 'during three months before the start of the study;|Being', 'within the past 7', 'within 30 days prior to enrollment.|Active chemotherapy', 'for at least 14 days prior to the start of IMP administration', 'for 4 months thereafter;||14', 'chronically at least one', 'within 3 years before screening.|Evidence', 'within past 12 months|Chronic inflammatory diseases', 'for at least 1 month|Years of education', 'within the previous 3 months|Current active', 'within the past 30 days.|Participation', 'in the past 30 days prior to randomization', 'during the study.|Current', 'over past 6 months)|BMI', 'post-procedure', 'during medical history', 'within 3 weeks prior to the first dose of study intervention.||Recent', 'at time of enrollment', 'within the therapeutic range', 'at least 3 occasions', 'one month before or after submitting', 'within 3 months prior to enrollment.|Current', 'within 24 hours before study initiation|Diarrhea', 'in 2020', 'within the past 6 months|Clinically significant', 'during general anesthesia', 'within the previous 6', 'three times during the', 'within 60 days of screening', 'past 12 months|Have', 'within 1 month prior to Screening|ESRD confirmed', 'at least 3 months after delivery||', 'at least 4 weeks prior to start of study intervention', 'in 1 week', 'Concurrent', 'within 14 days prior to the dose of study drug', 'at the time of first dose of study intervention', 'within 6 months before randomization|Treatment in another interventional clinical study', 'at the time of Screening.|Has chronic constipation', 'within 2 calendar days of randomization.|Lymphopenia', 'within the last 4 weeks of', 'pre-bronchodilator', 'at least 4 weeks prior to the first dose of study drug', 'last month) psychiatric diagnosis', 'within the prior month to meet this requirement', 'in the last 3 months)|Documented allergy to', 'throughout the entire study period||', 'within 2 weeks of dosing|Known history of', 'during or after CDK4/6 inhibitors combined with endocrine adjuvant therapy', 'within 6 months prior to randomization.|Subject', 'within 3 days prior to study', 'at least one):', 'at the lower forearms', 'within 30 days as demonstrated', 'within 6 weeks prior to screening.|Known history', 'within the 30 days preceding', 'during the clinical investigation', 'planning to receive', 'at time of implantation.|Subjects must be', 'within 2 years prior to randomization', 'more than 30 days before screening', 'within last 12 months|Lumber', 'prior to initiation of', 'within 72 hours prior to the start of study treatment', 'during study period', 'at Screening defined', 'for 3 months after the last dose of study drug', 'within 6 months of', 'in past 6 month', 'within 6 months of enrollment.|Patients', 'within the last year;|Thyroid Stimulating Hormone (TSH)', 'last seen well to admission', 'within ≥ 5 half-lives', ""for at least 6 months|An unanesthetized Schirmer's test score ("", 'in last 6', 'Baseline', 'within the 28 days prior to screening.||Participant', 'last dose of vaccine', 'within 28 days following receipt of study', 'in the 3 months prior to vaccination', 'within 6 months of start of study', 'after 12 weeks', 'prior to the start of study treatment|The patient', 'within 28 days prior to receipt of study vaccine', 'at ≤90 days after diagnosis', 'within 14 days prior to the first dose of study drug.|Preexisting', 'for 180 days after the last dose', 'within 2 weeks prior to the first dose of study treatment;|Participants had been', 'within 2 weeks of enrollment -', 'within 2 weeks prior to administration', 'in the 6 months prior to enrolment|Any', 'within 12 weeks before the study drug', 'within 30 days prior to and after administration of study intervention', 'after 1996', 'up to 90 days after the procedure', 'within 8 weeks after radical prostatectomy (RP)', 'within 1 week after participation in this study', 'within 12 weeks prior to the booster study vaccination', 'within 15 months prior to inclusion|Participant able to understand the objectives', 'to four times per week', 'within 6 months prior to Screening.|Previously', 'for ≥5 years。|Women', 'within three months prior to screening', 'within 36 months prior to screening visit', 'at the time of screening|Diagnosis of', 'after taking lipid lowering drugs|Pregnant', 'for at least 4 weeks after medical imaging assessment|Other', 'in the 3 weeks before the first study day|Presence', 'within 7 days prior to the first dose of study treatment', 'within 30 days prior to registration.|FDG-PET/CT scan', 'within the previous 12 months|Pregnant', 'within the past year|Internet access', 'More than 3', 'within 2 months cannot', 'within 2 months);|The', 'at least one week prior to the first treatment', 'within 4 weeks before screening|patients', 'for at least 4 weeks prior to the first dose of study treatment', 'within 3 months before initiation of study treatment|Active', 'before starting study treatment.|Subjects', 'at least 3 months after pre-treatment', 'within the last four weeks|Chronic inflammatory bowel disease', 'before the five week follow up|Unsuitable for inclusion', 'within 6 months of IMP treatment start.|History', 'within 2 months before signing the ICF.|More than 4', 'planned by the physician|uterine contraction', 'previous year', 'throughout the 10-week study period and fill out the study questionnaires', 'any time prior to screening;|Take any', 'at the time of surgery|Subject', 'at the time of enrolment;|Has', 'at time of baseline despite ACEI', 'during the study that', 'within 28 days before first dose of IP', 'within 7 days before leukapheresis', 'in the past 12 months.|(Expected', 'at least 8 week prior (note that this includes persons', 'prior to screening|Any serious', 'in the past 15 days', 'more than 20 mg prednisolone per day', 'during the trial period and 120 days after the last test drug administration;|The subjects voluntarily joined the study', 'at the time of treatment that would impair the ability of the patient to receive', 'at the time of consent.|Participant', 'within the previous 6 months;|Presented', '14 days prior to the start of the Dose Optimization Phase', 'for at least approximately 1 without changing', 'for the duration of the prospective observational period|Participants', 'within 28 days before informed consent', 'for 12 months after receiving', 'within the past 10 years.|Have', 'in the last 6 months|Body Mass Index', 'before screening.|Except for atopic dermatitis', 'during the advanced', 'during the study period|Unable to ambulate', 'last 1 month', 'for more than 3 months', 'within 14 days of disease onset.||Previous participation in this study', 'at least 60 min per', 'within 12 weeks prior to admission visit', 'within 48 hours of first', 'for 3 months before Screening Visit 1.|Use of one of more additional daily', 'during the study.|Female', 'prior to starting therapy.)||Preexisting peripheral sensory neuropathy', 'within less than 3 weeks', 'within 6 months prior to the screening visit;||11', 'outpatient units participating', 'during pre-screening', 'at least 2-months prior.|Participants', 'within 6 months of Screening', 'within 3 months;|The', 'within the preceding 6 months', '1 month to 14 years,|No more than 12 hours from the moment', 'more than 4 doses', 'within 7 days prior to Cycle 1 Day 1.|Has', 'during the trial||Patients who have received', 'greater than 2cm', 'in the 30 days before inclusion;|Patients who had', 'within past 5 years', 'for 3 months before the start of the study', 'for 28 days after study drug discontinuation', '1 month before first treatment', 'within 10 days prior to the start of study intervention', 'at least some days', 'requirement prior to incident COVID-19 infection.|Alanine aminotransferase', 'before the age', 'within 12 months of Screening.|Use', 'up to and including the time that the symptoms leading', 'within 28 days prior to the first administration of study drug', 'at the time of enrollment|Participant', 'within 30 days prior to screening|Estimated glomerular filtration rate', 'within four months', '< 1 month', 'for at least two weeks prior to and until the completion of the study.|are', 'prior to index ACS event,', 'within 2 weeks before the first administration of the study', 'throughout the whole study period', 'before starting the study', 'within the previous 6 months.|Current', 'for at least 84 days following investigational product discontinuation even if', 'within 4 weeks prior to the first dose of investigational product', 'in the past 6 months.|Current participation', 'before starting', 'within 52 weeks prior to randomization;|Not suitable', 'within 3 months prior to starting study|Obesity induced', 'within one month.|Those', 'for >6 months', 'within 6 months prior to enrollment||Patients', 'prior to study registration', 'at least 1 month since ending other investigational', 'within 1 month prior to screening;|Subjects', 'within ≤ 4 weeks before treatment', 'within the past 3 months prior to dosing.|Persons', 'at the time of the first dose of study treatment.||Current evidence', 'within 2 weeks of the first dose of study treatment|Participants', 'at the time of signing informed consent；|Glycated haemoglobin (HbA1c)', 'within the past six mounts|Physically not able to perform', 'within the last 12 months|Treatment', 'at least one of the legal', 'at the time of their', 'for at least 2 years prior to screening of study intervention', 'through 60 days after the treatment administration.|Presence of', 'after receiving explanation', 'in the last 12 months within the year before the initiation of benralizumab.|Provision of signed written informed consent form (ICF', 'at least 12 weeks', 'in the last 12 months|RBC transfusion', 'within the last 3 months)|Systemic', 'within six months of enrollment.|Limited English proficiency.|History', 'prior to the hypothalamic injury.|If', 'before the first dose of LP-168', 'during the study period.|Persons', 'at least 4 weeks prior to start of AU409 administration', 'prior to vaccination', 'in 28 days before the start of treatment;|Regardless of the severity', 'at the time of screening tests|Men', 'prior to conduct', 'at the time of screening.|Joint', 'last 6 months', 'for ≥5 year;|Single', 'within the prior year|Has at least 5 close network affiliates', 'approximately 2 weeks prior to the planned date of viral challenge until the poststudy', 'within 2 days', 'through 5 weeks of the study.||Patients', 'within 1 months prior to the first IP administration|Subjects', 'within the past 6 months|HER2-positive', 'within 24 months pre-conception', 'at least 2 hours', 'during the study period.|Subjects', 'within 4 weeks before the first administration', 'during study period|Patients', 'for the next 6 months||', 'within 1 year of previous', 'within 90 days of the last study medication', 'lasting 6 months or longer', 'within 28 days of study treatment', 'at the study hospital', 'in the last 5 years.|Have any condition', 'within the past 48', 'within two weeks prior to surgery', 'within 1 year prior to baseline.|History of', 'within the past 12 months prior to inclusion.|Subject', 'previous history', 'at the time of randomization.||', 'during the 6 months preceding the study;|absence of', 'in the past 6 months|Uncontrolled', 'within 1 week prior to the second', 'within 10 days of being discharged', 'within 180 days after the last dose of oxaliplatin-containing', 'within 30 days|Females of', 'within 3 days prior to study inclusion|History of', 'in the past year|reside', 'within 12 months of study recruitment.||Inclusion', 'within the 2 weeks prior to treatment allocation.||Note:', 'during the screening period.|Patients', 'within 14 days of registration.|Participants', 'within the past 30 days prior to the screening visit', 'within 24 hours prior to the study vaccination.||Male', 'during the trial.|Any medical history', 'within last 6 months', 'within the last 6 months.|Alcohol consumption', 'more than 48', 'during the study period.|Fertile', 'within a month.|Those', 'at least one month ago,|Children', 'at least 6 months posttreatment completion|Patient', 'within 7 days prior to Visit 2', 'within 28 days prior to C1D1', 'at the time that the clinical team approaches the', 'within previous 30 days', 'Co-infected', 'past 6 months', 'at least 1 month before starting the study', 'within the 14 days prior to C1D-7.|Medications', 'in the last 3 months.|For', 'during the Run-In period', 'for 7 or more consecutive days', 'within the past month.|lacked a history of neck', 'at the time of study|Etonogestrel implants', 'medical history d', 'in the last 4 weeks prior to participation', '14 days before dosing until after the Follow-up visit', 'for up to 24 weeks.||Exclusion criteria', 'within 3 months before screening;|Those', 'in the next six months', 'throughout their participation during study treatment', 'more than twice the upper normal limit|Bilirubin', 'within the first 14 days after the laboratory test results', 'at the time of recruitment|no', 'within 12-months of consent to participate', 'within 2 months prior to Screening', 'in the last', '<1 month before/after PCI||', 'for the duration of protocol treatment', 'after first attempt', 'at least 3-months.|Pain intensity', 'within 24 hours and can', 'through IV 48 hours prior to first IP administration.|Those', '< 6 months prior to initial unipolar ablation|Absence', 'for 14 weeks', 'in the past 5 years except', 'during previous immunotherapy;||(16', 'within the 3 month period prior to', 'within 8 hours after', 'within 4 weeks of dosing|Females', 'at the time of enrolling in the study|Must be able to communicate with the investigator', 'within 4 weeks prior to the first dose.|Significant malnutrition', 'within 3 months.|Intracranial tumor', 'throughout the study.|Dosed in another clinical trial', 'within laboratory normal limits|25(OH', 'post-operative', 'at least 4 points', 'past 28 days thus no longer', '8-14 days old approximately 10 participants', 'in the 12 months prior to screening|Receipt', 'At least 12 months prior to enrolment on the same ET treatment', 'in the next 3-months', 'in the last six months.|People', 'for at least three weeks|The DOAC', 'at any time during participation in the study.|Has received or plans to receive', 'within 5 half-lives|Received', 'within 7', 'at least 6 months prior to participation;|Berg Balance Scale score', 'within the month prior to screening', 'at least 2 weeks prior to study drug', 'obstetric history', 'within 30 days from Screening Visit', 'within 2 weeks before the first use of the study drug;|Those', '> 6 months prior to signing consent.|Patients', 'in the last 6 months prior to screening.|Symptomatic heart failure', 'etc.)|More than', 'within the prior 2 years.||23', 'during study including', 'within two days', 'within 1 month prior to Day 0', 'more than once', '3-6 weeks later', 'within the screening phase.||ABI occurring', 'within 55 to 100 kg', 'within 3 months prior to enrolment|The patient', 'during the evaluation will be', 'within three weeks of the experiment|Be nonsmoking||Have no alcoholic intoxication||No alcoholic addiction|< 3-4', 'for 5 months after the last dose of study treatment result', 'within the past 6 months;|Other surgery may be allowed based upon judgment of the physician-clinical', 'prevent vaginal delivery;|not', 'within 30 days prior to randomisation.|History of', 'within the past 3 years.||Note', 'within 72 hours prior to receiving', 'within 28 days prior to administration of study intervention', 'for at least two weeks prior to study enrollment|sinonasal surgery', 'between 3 and 5 years previously.|Subject follow-up', 'since the beginning of his teeth whitening.|Subject', 'within 12 months prior to randomization', 'outpatient clinic|Volunteer||', 'before enrolment', 'prior to Day 42', 'within 7 days before enrollment', 'for 6 months prior to transplant', 'within the previous 30 days prior to their Baseline Visit', 'at Screening|Use of', 'within 1 year prior to Visit', 'at least 6 months for surgery', 'in the 2 days before study treatment start|Participant', 'within 7 days prior the first dose of study drug.|History of (', '3 months before screening Convulsive Therapy', 'at screening ≤ 25g/l.|Have', 'replacement;|More than 18 years', 'within 4 days of surgery.|Has been', 'within 12 weeks prior to randomization;|Hospitalization', 'within the respective reference', 'within 4 weeks before initiation of study treatment.|Treatment', 'in the next few months|If', 'for at least 14 days prior to first dose of study treatment', 'in the last 3 months.|If taking any dietary supplements', 'at 1 week and 3 months after randomization.||', 'within 3 months prior to enrollment);|M1a/b', 'disease|Medical history of', 'within 12 months prior to Screening|Current', 'at least 5 years||', 'during the study period.|Individuals', 'within 3 months before enrollment met', 'within four weeks prior to enrollment', 'prior to R/M', 'within the 1 month prior to Day 1|Corticosteroid use', 'within 3 months of initial therapy', 'within 1 month before screening;|(9', 'within 9 months;|diagnosis', 'during prior 6 months', 'during the 30 days prior to the eligibility', 'within 8 weeks prior to Screening', 'within the last 4 weeks|Live vaccines', 'for 4 months after the last dose of IMP', 'at least 4', 'within 6 months before first dose.||Inability to swallow tablets.|Use', 'within 28 days prior to registration|No', 'within past month', 'in the next 15 months', '14 weeks prior to screening;|Patients', 'after delivery', 'within 2 weeks before screening.|Presence of any abnormal', 'between -1 and +1.|Respiratory stability', 'within 30 days before procedure', 'more than 3 days', 'within 28 days prior to enrollment.|Past participation', 'within 3 days prior to the initiation of study treatment.|Patient', 'within 30 days of the study procedure', 'within the one month prior to entry into', 'within 30 days prior to the day', 'for the duration of the study period;|be willing and able to provide', 'within 7 days prior to the first administration of study', 'within 14 days prior to the first dose of study drug.||--Of note', 'within 4 weeks prior to baseline;||14', 'allowing for sharpening of imaging examinations|previous intraocular surgery', 'within the limit of normal.||9', 'within 2 months prior to the first administration;|Received live', 'within the last year.|Not attending the center regularly', 'in the past one week', 'for at least 6 months after completion of study therapy.|Patients', 'for at least 3 months after the last dose of study treatment', 'throughout the study period;|Difficult', 'for at least 3 months before screening', 'during daily time-restricted eating|GYNECOLOGIC CANCER', 'within the major', 'within 4 weeks or less before the first use of the study drug;|Subjects', 'within one', 'within 14 days before blood sample collection', 'prior to the start of treatment', 'within 30 days prior to study drug administration', 'in the past 2 years.|Currently exposed', 'in the last year of', 'in the 4-weeks', 'at least 48 weeks)|Signature', 'within 24 hours after ERCP|Age', 'scheduled to undergo', 'within the available range', 'at least 6 months after the treatment visit', 'during the study.|Sexually active', 'within the projected duration of the trial.|Positive serology test results', 'four weekly pre-surgical evaluations', 'for at least 60 seconds', '5-year survival', 'at least 2/3 consecutive electrocardiograms (ECGs)', 'within 1 month prior to receiving the experimental vaccine;|Participating', 'within 30 days before the first dose of the study medical device', 'before starting therapy.|Has previously', 'in the last 6 hours,|The', 'at the end of the procedure', '6 months after the end of the study period Effective contraceptive measures', 'during the Screening period.|Elevated Troponin I levels', 'within 30 days prior to the first administration.||Patients whose medical history', 'in the past six months|Ages 18 years', 'pre-operative baseline information available for retrospective', '1 week prior to enrollment', 'during at least the last two months before the screening visit;|Diagnosis', 'after Adjuvant Therapy', 'at least 5 years before', 'within 3 months after the last study administration;|Subjects voluntarily joined the study', 'for at least 14 days prior to the first dose of study intervention.||Has', 'prior to Baseline', 'after 1 kind of', 'within prior 4 months', 'at screening|If of reproductive potential', 'within 30 days prior to Day 1.||Part C', 'within 4h30 after onset of symptoms|Repeat MRI performed', 'in the screening', 'in the last year|could understand test', 'previous night)', 'last two weeks', 'within 30 days prior to registration.|History of Urolift.|Contraindications to', 'during the study;||12', 'at enrollment', 'less than 6 months prior to enrollment|Patient', 'within 24', 'at least three months before surgery.||', 'within 6 months prior to administration of study vaccine', 'within 12 months before enrollment', 'in past six months', 'within 6 weeks before the first administration of study drug', 'within 4 weeks of enrollment', 'at time of randomization.|Female subjects must', 'throughout the duration of the trial until the last dose of darigabat', 'within the four weeks prior to diagnostic assessment', 'within the last two years|People', 'at the time of device placement|Subject agrees to comply with all follow-up', 'up to 2.0 × ULN', 'within the last six months|History of', 'within the last year.|Severe infection', 'past 2 years', 'within past 6 months', 'within the last month.||Exclusion criteria:||Current thoughts of self-harm', 'within the 14 days prior to Day 1', 'at Screening and prior to dosing|BMI', 'within the 12 months following', 'during the investigation.|Use of', 'within the past 1 year', 'for 12 weeks after the last dose of treatment.||Key', 'within 12 weeks', 'at least 1 week apart.||Cardiac safety||History of', 'within 28 days prior to enrolment', '>= 12 months ago', 'during the period 273 days prior to the pregnancy start date', 'in the last 4 months prior to inclusion|Use of', 'more than once per week.||Individuals', 'less than 4 weeks prior to enrollment', 'at least 4 years old', 'in the last 6 months|Smokers', 'throughout the duration of the study', 'previous intake', 'within the previous two weeks', 'after preoperative therapy', 'throughout the duration of the study.|Received strong', 'At least 20 years', 'within 28 days prior to day 1 of protocol therapy||Meets', 'last at least 30 minutes', 'at least 4 weeks after central nervous system', 'anticancer treatment|At least 14 days from palliative radiotherapy', 'within the protocol mandated time period||Reminder', 'in the last 3 months|Voluntarily sign', 'Aphasia|Unable to give', 'less than 12 weeks before', '6 months to 2', 'in the last 5 years|expected non-compliance', 'at 2 timepoints', 'within 4 weeks after initiation of therapy', 'within 3 years prior to enrollment', 'in the past five years);|Primary', '12 months after last menses', 'between the signing of the informed consent form and within 6 months after the end of the study', 'throughout the duration of this trial', 'at baseline, reexamination may be performed', 'within the first 5 years of follow-up|Active', 'groups.|During one year from the start of the study(6 months', 'within 14 days of TG6050 administration|Breastfeeding', 'within 12 months|lack of', 'within 6 months prior to baseline.|Any previous treatment', 'within 28 days prior to administration', 'structurally related to amide-type', 'within the past five years.||12', 'within 1 year prior to screening|Administration', 'in the past month|history of', 'at least 6 months prior to screening|Individuals', 'within the last 3 months|Current', 'within 30 days prior to study treatment initiation', 'within the past 3 years', 'within 48 hours before the first administration of investigational product.|Those', 'at least 25% of face', 'within the previous 1 month|Any', 'at the time of signing informed consent|Histologically', 'within 6 months prior to screening.|Other active', 'within 100 days prior to first dose of epcoritamab.|Treatment', 'for at least one month after the final dose of larotrectinib.||Exclusion Criteria||No', 'during the experimental period|were requested to maintain their regular daily life style', 'within 12 months of enrollment', 'administered within 3 months prior to initiation of study.|History of', 'during surgery', 'at least 4 weeks before initiating study', 'in past 180 days|Structural abnormalities of the heart', '< 3 months', 'within 1 month prior to screening|Participant', 'within 28 days prior to vaccination;|Subjects', 'throughout the course of the study||Exclusion:||Any clinically relevant', 'within the last 12 hours|Use of', 'at the time of the study|Currently living', 'within 4 weeks preceding the start of treatment.|The toxicity of previous anti-tumor treatment', 'for at least 4 weeks before screening|Eastern Cooperative Oncology Group (', 'within 14 days);|Neutrophil count', 'within the last year|Has a', 'within 2 months prior to', 'within the past 3-months', 'within in the past 3 months;|Receipt', 'prior to the screening visit', 'at least 30 days from last benefit).||5', 'within 48 hours prior to the administration of PDNO.|Known active', 'prior to registration.||', 'within the first 3 months', 'in the past five years.|6）Pregnancy.|7）Not', 'within 2 months prior to dosing.|Current smoker of more than 5 cigarettes per day.|Any regular use of', 'within 28 days before randomization.|Toxic reaction', 'in the past 12 months.|having', 'less than 48 kilograms', '8 hours per day', 'within 7 days);|Liver', 'throughout the study.|History of stomach', 'chronic', 'partner)||', 'within 6 months prior to first dose.|Previous stem cell transplantation', 'in the past two years|Are', 'in the 12 months prior to screening.|Major surgery', '14 days prior to clear lymphatic chemotherapy', 'the past two hours just', 'within 7 days before the laboratory examination).||Hepatic functions', 'in the next 18 months', '72 hours after the patient received the high-dose', 'within 24 hours of onset|NIH Stroke Scale', 'within 7 days before study enrollment|Total', 'within 14 days or live vaccine', '30 days after the last dose (please see', 'at the time of the signature of the ICF;|Patients with dry eye symptoms', 'within 2 weeks of the first dose of study treatment', 'within 6 months prior to drug dosing.||8', 'within 5 years of', 'within 6 months prior to randomization|Evidence', 'during the screening period must', 'within 2 weeks of cycle 1 day 1.||Severe', 'within 1 month prior to study entry.|Patients', 'during the duration of the study.|Students', 'at least two mature', 'up to 2 g daily).|Participation', 'within 6 weeks before the start of study treatment.|Allogeneic', '3 months after surgery)|Normal mammogram', 'during the last 12 months prior to inclusion.|Willing to', 'within 12 months prior to enrollment.||12', 'for the past 3 months.||', 'during the previous four weeks', 'within the 14 days prior to the start of IMP administration', 'within six months prior to first dose of study drug', 'in the last year|The presence', 'within 5 year prior to screening', 'within 4 weeks before the start of study treatment', 'University', 'within the 6 months prior to beginning the study;|Use of', 'prior to administration of the study intervention.||Abnormal cardiac conditions', 'within 30 days|no', 'pre operative', 'up to 15 days of evolution).|Impaired safety', 'at least 8 hours a day', 'for at least 2 years.|Patients', 'within the last 10 years', 'less than 72 hours before surgery;|Presence of bulbo', 'during the therapy|Intensive therapy', 'within 2 years prior to the date of the start of treatment', 'within 90 days of the index procedure|Subject', 'within 1 month|Started', 'during the last 2 years).|Known positive', 'within 6 weeks prior to', 'in the next 1 year after', 'in the last 6 months|Have', 'at the time of signing the informed consent.|Participants who are', 'within 4 weeks before first dose of study drug.|Tertiary-interstitial effusion', 'past 2 years before Screening', 'at time of screening.||Has', 'within last 3 months.|Have received', 'more than 6 months before signing the informed consent', 'after randomization|History of focal/grid laser', 'at least 3 hours/week.||', 'within 28 days of the first dose of study therapy.|Prior', 'within age', 'throughout participation', 'within 6 months after signing the informed consent form', 'newly', 'in the past 6 months.|Participant', 'for the duration of study', 'within 72 hours prior to the', 'at least 2 months before enrollment|presence', 'in the last 4 weeks prior to first dosing of study treatment.||Malignancy', '7 days before each study visit', 'within 1 year;|Systemic hemodynamic', 'lasting until 1 week after the last fraction', 'within the past 24 months|Seen', 'in the last year.|Major mental disorders|Poor communication skills', 'for at least two weeks', 'within 5 days before Visit 1', 'no more than 4 weeks after starting initial therapy', 'in the previous three months prior to providing fecal specimens|use', 'within the 3 months|patients', 'at the time of inclusion.|Any circumstance that', 'prior to start', 'during the study period|Use of any investigational product', 'at first screening;|Pregnant', 'within 2 hours before the administration of test', 'within 4 weeks prior to enrollment.||Patients', 'within 14 days prior to registration||', 'within 30 days before randomization', 'within the last 2 weeks prior to receiving the first dose of investigational treatment', '15 days prior to Day 1', 'in the past 2 years.|Patients participating simultaneously', 'within 12 months|Decompensated chronic diseases', 'within the past 5 years|Tuberculosis|Health or psychological diagnoses', 'more than 12 months prior to EHR screening', 'within 4 weeks prior to enrollment;|Pregnancy', 'within 16 wk)|History', 'during study time frame.|Inability to understand', 'for 24 hours', 'within 2 weeks before the intervention|Nutritional supplements containing probiotics', 'before entering the group', 'within 1 year before study screening|Euthyroid', 'within 4 weeks prior to the first dose of study drug.||7', 'for at least 6 months prior to Visit 1;|Have', 'within 1 month before screening.||5', 'within 1 year prior to the screening', 'for at least 3 months prior to entry into the study', 'at least 20 years', 'in the 30 days prior to study enrollment|Acute', 'within 30 days prior to receiving the treatment administration', 'in the past 3 months|Participants', 'within 1 week before apheresis', '12 months after LEEP|A valid', 'within 28 days prior to initiation of study', 'before surgery: For this study', 'for >6 months|Severe arthritis', 'within 4 weeks prior to participation in this clinical trial||', 'at least one of the following criteria:||Ascites (present', 'within 24 hours prior to start of IMP', 'within 30 days of vaccination', 'within the previous 1 year', 'at least one of the following criteria： ANC<1.5×10^9/L', 'within 14 days prior to dosing.|With', 'between 3 months to 2 years', 'within 14 days prior to the study', 'within the past 3 months prior to enrollment', 'during study period|Participants', 'before trauma;|The investigator considers not appropriate for enrollment', 'during the three previous months|Patients', 'within 12 months|Documented', 'in past 3 months|unusual', 'unknown primary;|Eastern', 'within 7 days prior to the first dose of the investigational drug', 'at the operative', 'within the first week of transplantation.|Patients refusing participation in the study', 'within 6 months before baseline|Use of', 'within 3 years prior to Cycle 1 Day 1', 'within 4 weeks before the first medication', 'Within the defined washout periods for prior', 'for at least one of', 'within 3 mo prior to Visit 1', 'for 1 year after the last dose of the study', 'at least 30 days prior to the study until', 'more than five years', 'At the time of the baseline examination of the study the participants must be dental students', 'in 12 months', 'within 6 weeks from', 'hospital readmission),|Pregnancy', 'during the subsequent 1 year.|AIDS Related B Cell Lymphoma', 'within 90 days of Visit 1|Meet', 'within two weeks before or after the tongue', 'within the past 2 years||Instability', 'during the period of the study).|Seizure disorder/epilepsy', 'within 28 days before first dose||Have', 'within 90 days of ozanimod', 'within one year prior to screening|Current', 'medical illness.|Currently taking', 'in the past two years', 'within 2 months of the primary lesion；|Patients', 'within 3 months prior to initiation of study treatment', 'at the Cleveland Clinic o All altruistic living donors', 'in the target area.|Skin abnormalities', 'within one year prior to participation.|Glucose intolerance', 'within 24 months before enrollment|Received', 'affecting the brain.|History', 'within 4 weeks prior to the screening period', 'within 24 hours.|Using', 'within the first 6 months after the administration of NFS-02', 'within the past year before enrollment in this', 'after 24 hours of adept 38 blood', 'at the screening visit.|Persons of childbearing potential', 'within 2 weeks before screening):||Blood routine examination', 'at least 6 months prior to', 'during the 12 months preceding the', 'in the past 10', 'within the previous 2 weeks;||Type 2 diabetes', 'at the time of the moving-related', 'within 120 hours prior to randomization.||Initial onset of the COVID-19-related', 'cancer|Able', 'within 100 days', 'within 7 days before the first dose of study drug', 'RHNe|Patient', 'within the last 12 months);|History of', 'for greater than 3 months', 'during the 3 months prior to the Screening Visit.|Has received another new', 'at time of bronchoscopy.|Scheduled for navigational bronchoscopy', 'at the inclusion visit Specific criteria', '28 days prior to cycle1 day 1(C1D1', 'within the last 3 months.|History', 'within the last 6 months|have', 'preceding one year.|Uncontrolled intercurrent illness', 'believed to be able to benefit from this study', 'more than 1 Litre', 'for at least 3 days after surgery|Patients', 'in the past five years);|Had', 'for at least 2 years prior to enrollment', 'at time of SARS-CoV-2', 'at time of initial screening', 'in the last 3 months', 'during Session 1)|Active substance abuse disorders', 'following standards:||Bilirubin（BIL）<1.25 times the upper limit of normal (ULN);|Alaninetransaminase(ALT)', 'in the past year|HbA1c reading', '6 months after discontinuing the study medication', 'within the normal range.|Myocardial enzyme profiles', 'within 6 months prior to operation;|Has', 'within 14 days prior to the hospitalization', 'during the study.||', 'within 2 weeks before the baseline', 'within the previous 1 month;|cerebrovascular accidents occurred', 'within 2 months before signing', 'in the past 30 days|Score greater than or equal to 6 on the', 'during the study period and|Those who agreed to participate', 'for at least 12 months|Women', 'within 3 months before vaccination.|Serious', 'within 28 days prior to initiation of study treatment.|The', 'during this time period', 'prior to first dosing', 'for at least 90 days after the last dose', 'during the 6 months immediately', 'at the screening visit.|Have reliable', 'at the time of study', 'within the last 12 months|High alcohol intake', 'before undergoing valve replacement', 'prior to dose 1 of the', 'while taking niraparib include', 'within three months', 'within 7 days prior to treatment initiation|Stable doses', 'at least 3 months prior to the study', 'within the study period|Subjects', 'within 6 months prior to the index hospitalization|Diagnosis', 'within 90 days prior to study entry', 'within 12 months prior to study entry.|Use', 'within the previous 3 months|pregnants|patients who disagree', 'within the last 12 months', 'within 24 hours of the end of', 'in the last 3 months|Signs', 'plans extended travel inconsistent with the recommended visit interval', '12 hours before any clinic visit', 'during dose interruptions', 'at the time of informed consent.|Patient', 'prior to Day 0||', 'within the lesion', 'at least 35 hours per week', 'within six months|History of oral steroid', 'within 7 days).||(2', 'at least 2 months after the last use of', 'within 12 weeks prior to screening.|Participant', 'within 15 days (washout period', 'within the past 4 weeks|Intake of LOLA', 'booster dose', 'during the first treatment', 'before, or the time interval', 'within the last 12 months.|Subjects', 'within the past 30 days of study enrollment', 'within 3 ft', 'at the time of a laparotomy', 'between 1 and 2 years prior to Day 1', 'within the 4 weeks before Screening.||Prohibited', 'within 1 month before screening;|During screening', 'for greater than 6 months prior to screening', 'during activities of daily living', 'at least 7 days prior to starting protocol therapy', 'prior to stroke would fulfil for this inclusion criteria', 'throughout the entire program', '6 weeks before recruitment.|Specific nutritional therapy', 'for at least six months;|Positive', 'in the past 6 months|Had', 'for at least 30 days prior to starting investigational product', 'within the last 12 months.|DSM-5', 'within 8 weeks prior to signing of the ICF.|Any prior malignancy', 'for at least 3 months prior to Visit 1', 'within the last 6 years', 'within 3 months before the index', 'the past 12 months', 'at least 1 month before dosing).||Males', 'at the time of signing the informed consent.|At', 'past at least 3 months before the study will not be included in the study', 'pregnant.|Prior', 'at Screening', 'prior to the first dose of study treatment', 'within 60 days after the last dose;|Patients', 'within 4 weeks prior to the first dose of study therapy', 'in the 7 days preceding the inclusion visit Person subject to a measure of legal protection (safeguard of justice, curatorship, guardianship)', 'for less than 10 years.|Non-insulin dependent Type 1 diabetic.|Less than 50 years', 'within the laboratory reference range', 'within 24 hours prior to the start of treatment', 'during the 6 month study period|Planning to move from the Houston', 'within 14 days of the first study drug administration', '2 weeks prior to randomization;|Sphingosine 1-phosphate receptor', 'during the last 6 months of antiviral therapy', 'within the past 5 years|Individuals', 'within 72 hours prior to CNA3103', 'within last six months|History of new', 'during the first two days of menses', 'for at least one month before study enrollment.|Baseline plasma glucose concentration', 'within the past 6 months;|history of', 'within 4 weeks prior to the first dose of this study;|17)Patients', 'prior to screening||Must', 'within the last month.|Subjects with any', 'within the 2 weeks', 'before onset.||', 'previous two months.|Other dermatological pathologies', 'within 30 days of enrolment.|Presence', 'within the previous 2 days', 'within 2 months prior to signing the ICF.|Participation in clinical trials of medicinal products', 'throughout the study.|Participation in other studies involving', 'prior to study enrollment.||Reproductive potential', 'within 6 weeks before the first dose of study treatment', 'within the previous 2 years.|Treatment', 'within 14 days prior to administration of the first dose of IP', 'more than 5 cigarettes per day;|For', 'at time of study entry|ECOG performance status', 'within 4 months of study', 'within the last 3', 'less than 48 hours', 'within the past 6 months.||10', 'within 3 months of study participation', 'at the indicated starting dose 22', 'throughout study participation.|Must be able to attend all visits', 'within 28 days prior to Screening', 'within the 4 weeks before inclusion;|Patient', 'in the 6 months prior to Screening.|Additional exclusion criteria apply', 'at intake', 'at least 4 months prior to study entry).||In', 'within one weeks before the first dose of study drug.|History', '90 days prior to the first dose of trial treatment', 'within the six months prior to screening', 'within 6 weeks before', 'before study at least 6 month not on medication', 'at the time of screening||', 'for at least 8 weeks||', 'for at least one week prior to first dose of study drug', 'within 28 days after vaccination with IP.|Receipt of blood transfusion', 'within 3 months prior to the expected initial application date', 'at the time of signing the informed consent.|Histologically', 'up to 4 different methods', 'within 2 weeks before screening', 'within one week preceding first study drug', 'for at least 6 months||', 'during the 7 days prior to baseline', 'prior to the bronchoscopy||', 'at least 3 months following study treatment discontinuation', 'acute', '6 months before admission', 'previous', 'at time of surgery.|Patients', 'at least one of the following four tests', 'within 4 weeks before screening|7', 'in the past month for the purpose of treatment of the disease', 'during pre-anesthesia', 'prior to inclusion|Fetal growth restriction', 'at screening.|Known to have', 'within 6 months of screening.|Malignancy', 'within the last six months;|participants', 'in the last 2 weeks', 'in the 30 days before IMP', 'within 2 weeks of the baseline visit', 'at time of injury|Body Mass Index', 'within 2 days prior to the first dose of TY-2136b', 'greater than 500 mL', 'during this study|Has', 'at time of referral', '2 weeks prior to Meta10-19 infusion|Treatment', 'prior to being enrolled in the study', 'within two weeks before randomization|Patients', 'during the three months prior to admission to the study.|Pain must', 'within the last 6 months prior before registration.|Transmural myocardial infarction', 'in last 3 months|Need', 'prior to attempted IOL implantation.|Any', 'prior to surgery 14', 'within 8 days prior to start', 'within 3 months before admission.|Hospital-acquired', 'prior to participation in the', 'within the period of 1 August 2017 to 31 October 2019', 'before chemotherapy', 'time within 8 weeks before signing the ICF;|the use of', 'at the time of screening.|At screening', 'for the 8 weeks prior to Screening.||17', 'D||No history', 'within the 2 years before Screening', 'within 48 hours prior to procedure;|History', 'within 14 days of baseline treatment.|Subjects', 'during the study period and within 6 months after the end of the study period;Male subjects should agree', 'within 4 weeks before the first use of the drug;|There', 'at the time of eligibility', 'in the past year.|Pregnancy', 'during sexual intercourse for the duration of the study', 'within 30 days prior to the first dose of study drug', 'within 14 days before the first use of the study drug', 'during the physical examination', 'previous two years', 'at Screening and predose on Day 1', 'during and for 3 months after the study;|Agree with research procedures', 'within 14 days of the first dose of the study', 'before study intervention intake.|Lipase', 'in the last 3 months|Contraindication for ovulation stimulation|BMI>25 kg/m2|AMH<1 ng/mL', 'for more than 7 days may be considered if the trauma occurred more than 1 year ago', 'within 60 days before the first date of administration', 'within the 52 weeks prior to Screening|Positive test', 'within 4 weeks prior to initial medication;|Have', 'for at least 3 months after their final study treatment||', 'at baseline must', 'at the time of informed consent.|Voluntary agreement to provide written informed consent', 'within 30 days prior to Visit 1', 'within 6 months prior to first study treatment', 'within 1 month before administration', 'within 1 month prior to enrollment', 'within 30 days or 5.5 half-lives', 'in the past three years.|A scheduled surgery', 'previously completed', 'prior to randomization|Absence of', 'before the first dose of study treatment.|Adequate', 'within the last three months|The patient does not', 'within 2 years before enrollment', 'within the last 4 weeks.|Use of', 'at least 14 days apart from the traditional Chinese medicine', 'within 2 weeks of Day 1 of study treatment.|Known', 'in the 4 weeks preceding the first study vaccination', 'within 12 months of screening visit', 'within the normal range of laboratory values', 'within the prior 5 years|Pregnant', 'in stages II or III', 'within < 4 intervals', 'at the time of the phone screen may be referred for treatment', 'within six months prior to the first administration of clinical trial drugs', 'during the last treatment period', 'within the past 3 years prior to first dose of study treatment||* Note: Participants with usual basal cell carcinoma of the skin', 'prior to each treatment.||', 'within 7 days of starting of treatment', 'preceding 24 hours|Order', 'within 7 days of day 1', 'four weeks prior to trial start', 'at least 1 year.|Participants', 'algorithm|D-dimer level', 'at least 1 year after allo-SCT.|Enrollment', 'within the first 2 years after the operation', 'for at least 3 months prior to screening).|Subclinical', 'during the whole trials period', 'at DFCI.|Not undergoing', 'between 2 to 4 weeks', 'within the past three months|Have another', 'up to 28 days after the last vaccination.|Individuals', 'at least 3 months before LYN-005', 'at least one month before the study.||', 'within 30 days or 5 x T1/2 whichever', 'within 3 days|any', 'within the normal value range can participate in this study', 'at least 28 days prior to study treatment', '3 months', 'during the study|Per the discretion of the investigator', 'within 2 months before administration,|Subject/Patient', 'in the past 3 years.|Having', 'within the past 3 months.|Primary', 'in the past 3 months.|Receipt', 'management of neck pain', 'during their participation in the study KGBI', 'in the past 5 years;|For subjects', 'at any time in the past', 'over 6 months since these 2', 'during the first three months of the study', 'during previous studies|Unable to give informed consent', 'within 3 months prior to the first', 'within 1 months prior to informed consent|Stroke', 'within 28 days prior to', 'within 3 months before admission;|Cumulative oral', 'in the first 2 years after menopause|Experiencing vasomotor symptoms||', 'in the past 4 weeks|The use', 'prior to starting study intervention.||Has', 'immediately prior to index event', '3 days prior to initial treatment', 'within 30 days prior to the first dose of T-DXd.|Prior treatment', 'after TKA,|do not complete the study,|developing', 'within 24 hours before sampling;|Any medical', 'past 3', 'within 4 weeks before screening.|Patients', 'hospitalization-based', 'within 14 days prior to Day -1', 'for 7 months after the last dose of protocol treatment', 'during the past month.|De Quervain tenosynovitis', 'within the past 28 days preceding informed', 'within 30 days prior to randomization/first day of treatment.|any physical aggression toward', 'more than 15g', 'in the last 12 months|dysphagia', 'at least 12 months|Live', 'onset within 24 hours, and|Patient', 'during the study.|Vaccinated', 'within 6 weeks prior to treatment', 'pre-mix', 'within 4 weeks|Known', 'during Study SEP361-308.|Female', 'between 4 and 24 months prior to the start of the study||Parents:||- parent', 'within 3 weeks before the start of the study', 'within 3 years.|Pleural effusion', 'within 3 months prior to Screening.|Hypersensitivity', 'within 2 days prior to surgery', 'at least 4 hours', 'in 4 months (initial intensive treatment', 'in the last 5 years.|Known', 'while receiving immunostimulants.|Known history', 'before 26 weeks', 'within the last 2 weeks prior to starting study drug', 'at least for the next 48 hours|≥ 18 years', 'at the time of the first Screening Visit.||Physical Status Classification', 'during the previous anti-PD-1', 'within 28 days prior to enrollment.|Measurable disease', 'within 3 months before screening.|Within 12 weeks before administration', 'within three months of enrollment.||', 'at Weeks 0, 8', 'within 1 day prior to initiation of study drug.|Hypersensitivity', 'within 4 weeks of the first dose of study drug', 'at the time of the signature of ICF;|3 to 10 rating', 'within 30 days prior to study entry', 'in the last 3 months|Have', '7 days prior to the first dose of study drug', 'within the last 2 years', 'within 3 months before screening.|Willing', 'within 5 years from Screening', 'for 2 years', 'during the entire study', 'within 6 months before enrollment.|Currently receives treatment with', 'after initiation', 'within 30 days of first treatment', 'in the last two weeks)|Currently taking', 'in the past year|Subject', 'prior to study participation.|History', 'within 60 days before the screening date|Adult', 'whose length and width can be', 'at Screening or site check-in.|Patient', 'within 24 months prior to study treatment|Previous use of any', 'at least 3 days a week', 'at the time of entry into', 'up to 3 months before the examination|pregnancy|lactating mothers', 'within 100 days prior to the first dose;|3)Patients', 'within 4', 'agents);|Recent', 'within random 14 days meet', 'within 28 days or five half-lives', 'within the last 180 days', 'within the 14 days prior to the start of alectinib administration', '> 6 months prior to inclusion', 'within the past 60 days received', 'throughout the duration of the study.|Received strong breast cancer', 'within 3 months prior to the day of study vaccination', 'for at least 2 weeks prior to study treatment', 'within 7 days before the diagnosis', 'prior to first AF', 'for at least 6 months after completion', 'within the last three months before enrolment|No diagnosis', 'within 5 months after the final dose of atezolizumab.|Current treatment', 'for >72', 'within 28 days prior to registration', 'following two categories are included:||(1', 'within 4 weeks prior to study entry', 'within 7 days before the first dose of study treatment', 'before randomization to confirm eligibility.|History', 'at least 12 months prior to the', 'within 14 days or Campath', 'within 6 months before randomization.|History of', 'within the past 4 weeks|Have taken dietary supplements', 'after explaining by the researchers', 'at least two weeks before the first injection date', 'within 7 days prior to Screening', 'period prior to Day 1 of Cycle 1.|Is willing to provide pre-existing', 'at the time of starting study treatment|Active infection', 'within 30 days prior to study procedure', 'after initial PRRT|No', 'for at least 12 months prior to Screening Visit 1.|Documented treatment', 'within the first 14 days of', 'within 12 months before screening', 'at least 14 days prior to the first dose of study medication', 'within 14 days prior to the first dose;|Subjects', 'within less than 2 weeks before signing the ICF.|Use of medicinal products', 'during the examination', 'within 4 weeks prior to treatment start', 'during the study;|In the opinion of the investigator', 'within 14 days prior to day -6 of protocol therapy|Clinically significant', 'in the past three years.||History of any of the following:||Seizure', 'clinical history', 'preceding 1 year', 'after 3 months,|any terminal disease', 'within 30 days prior to the first dose of study', 'during treatment|pregnancy or', 'within 14 days)||', 'within 4 weeks of enrolment into the study', 'during the study period；|Other', 'consent|Normal', '8-week staff mindfulness course', 'at least 7 days prior due to', 'less than 90 days prior to', 'at diagnosis', 'within the previous 30 days|Subjects', 'up to 4 weeks prior to starting study treatment.|Endocrine therapy', 'within 14days before initiating study', 'at the current time or one month in advance|Taking', 'for the next 16 months;|willing to complete the activities', '7 days prior to inclusion', 'during previous chemotherapy', 'within 7 days prior to study entry', 'during the screening period to rule', 'within 56 days prior to the dose of study drug|Plasma donation', 'within 14 days prior to randomization;||Hematologic abnormalities', 'within 10 min', 'throughout the entire course of the study|Documented', 'within 5 days prior to the day of randomization', 'in the past 30 days', '14 days prior to screening', 'at least 4 weeks to ensure symptoms', 'within the last 5', 'within 1 month before vaccination;|Subjects', 'within the past 2 years prior', 'within 4 weeks prior to the first dose of study drug.||Patients', 'within 30 days prior to the first dose of study drug.|Conditions', 'for the duration of the study.|Satisfactory dental care performed', 'during the study period.|Willing to maintain habitual dietary', 'within 6 months before the first dose of study medication', 'within 3 months before screening|New York Heart Association', 'prior to Day 1.|Participants', 'for at least hundred days after the last study treatment', 'throughout their participation in the trial', 'throughout the study period|Subjects able to comply with the protocol requirements|Informed consent', 'during the past 3', 'in the 3 months prior to screening', 'for at least 4 weeks prior to baseline.|Neuroimaging', 'in the last 4 weeks,|Not using curcumin', 'within 8 weeks of Visit 1.|Historical', 'within the past 60 days of assessment', 'within 1 year|Inborn errors', 'at the time of Screening', 'prior to randomization;||Alkaline phosphatase', 'at the time of the surgery.|Patients', 'before the first injection', 'within the last 3 months prior to the Screening Visit (month is defined', 'prior to or immediately following delivery', 'prior to first day of study treatment.|Patients', 'within past 3 months|History of any', 'at the beginning of the stimulation process.|Ability to participate', 'over the last 6 months|Followed', 'in the past month.|Unable to stop', 'within the 72 hours prior to the screening visit', '14 days prior', 'within normal institutional limits||Adequate renal function', 'minimum 8 months prior to the Screening/Initiation visit', 'outpatient services.||', 'within 2 cm of the inguinal ligament.|Patient', 'for at least three years', 'more than 6 mL).||', 'within the previous year requires', 'establish prior to transplantation', 'within 7 days before the laboratory test)', 'within 72 hours prior to the start of TY-2136b treatment', 'prior to Visit 0 (Day 1).|Known RB1 mutations', 'within 3 months prior to screening.|Any clinically Laboratory tests', 'at the time of screening', 'in the 4 weeks prior to receipt of the first study vaccination.||Note', 'within 6 months prior to screening；|Alcohol', 'in the last 12 months', '5 days before surgery', 'within 90 days before the first dose of study', 'during the study period.|Initiation of desensitization therapy', 'within 12 weeks of screening|Any change', 'during the study;|Consumed soft drugs', 'within 5 years except for those', 'in the next year|Willing and able to follow study procedures||', 'at the time of registration|Patients', 'within 4 weeks prior to the first dose of trial treatment.||Has', 'within 6 weeks of entry into the trial||Exclusion Criteria||Patients with exclusive', '6 months to less', 'at time of enrollment.|RECIPIENT', 'within 12 months before randomization', 'in the last 3 months.|Present food intolerances', 'in the two weeks prior to leukapheresis.|Has', 'prior to the first treatment.|Concurrent participation', 'within 14 days prior to starting dosing', 'during the study.|History of more than', 'less than 7 days documented', 'while receiving trial therapy', 'in 24 hours refractory to the standard medical treatment.||', 'within the range of 25 - 45 kg/m2', 'at time of randomization|Gait speed', 'at least 1 month prior to starting study intervention', 'at the time of signing the ICF.|ECOG（Eastern Cooperative Oncology Group） performance status', 'within 30 days prior to Visit 0 (Day 1', 'within the last 12 months|A', 'within 2 weeks prior to Cycle 1, Day 1.|Patients', 'in the last 8 weeks|Previous history of', 'within 24 hours after birth.|Length of hospital stay', 'in the last 6 weeks', 'less than 14 days from the end of the previous clinical study.|Uncontrolled', '7 days prior to the first study drug', 'less than 4 weeks before the end of treatment', 'during the 4 weeks prior to the ICF signing date', 'during the last 5 years', 'in the 4 weeks prior to screening|Listed for lung', 'at the time of the first dose of study treatment.|Radiographic', 'at Screening or Day -1.|Use', 'within 3 months before the stroke|Concurrent', '1 week before screening', '<15 days before evaluation;|Ability to undergo study procedures', 'in the 3 months before the screening visit.|Signed written informed consent', 'surgery 28 days before the first dose', 'During the first 4 weeks of treatment', 'at the time of enrollment;|Known', 'recent enough to support the technology', 'within the past 1 year);|Participants enrolled', 'within 14 days prior to the start of study treatment.|Inactive vaccines', 'within 30 days prior to registration|ECOG Performance Status', 'within 1 month after visit 1', 'at least 1 previous line of', 'during intake', 'before enrollment.|The measurable', 'within the last 2 weeks||No', 'for at least 4 weeks prior to randomization', 'within 7 days before starting therapy', 'during hospitalization.|Any major', 'within 6 months prior to screening;|Received', 'at least 6 doses of vaccines have been', 'in the 2 months prior to beginning', 'within the 4 weeks prior to signing ICF', 'following standards:||Blood routine examination', 'within the past two months before anticipated enrollment', 'at the time of enrollment.|One additional', 'at the time of the first dose of IP.||SE warranting', 'for at least 1 year|Those', 'prior to any screening', 'within the previous 3 months.|Surgery within 3 months before the stroke.|Concurrent inflammatory conditions', 'within 30 days before screening.|Use of', 'inferior to 24||All', 'in the last 24 weeks while on angiotensin converting enzyme inhibitor', 'at time of informed consent and', 'after the last dose of the previous investigational', '≥2 weeks prior to Screening', 'prior to starting their next cycle of treatment', 'since presenting to medical attention', 'at least one sexual partner', 'at least one month before this study|Subject', 'within 2 weeks prior to enrollment', 'within 3 months prior to randomization|Major surgical procedure', '6 months prior to baseline.|Use topical medications', 'in this study', 'during pregnancy|smoking history|presence', 'at the time of consent.|Has', 'within the past six months', 'during the research', 'previously treated for curative', 'within 3 months prior to screening|Known', 'at the time of signing informed consent|a', 'At least 6 months', 'more than 5 times per week.||4', 'up to 12 M prior inclusion', 'prior to cancer treatment.|Patients', 'three times, for two weeks each', 'within 3 months,|emergency operation', 'within the past 3', 'within 5 years before screening;|(2) Those who test positive', 'after two or more', 'at week 47 visit||CD4', 'inhibitors||', 'within 7 days of the randomisation', 'within the past 8 weeks.|History', 'at least 2 weeks before the first dose of medication', 'before the first administration', 'within the next 3', 'within 2 calendar days of randomization.|Known', 'in the previous 6 months)|Any cardiovascular event', 'within 14 days prior to randomization.|Platelets count', 'in the last 12 months.|Active diagnosis', 'at the time of informed consent signature|Male', 'before the coronary artery fractional blood flow reserve test|Prior coronary artery bypass', 'during the whole study|Willingness in participating to the intervention', 'during the last 3 months before inclusion|Receiving optimal symptomatic', 'at the time of intake|Previous intravitreal treatments.|Refusal to sign informed consent', 'at the time of diagnosis|In morphological first complete remission regardless of', 'for 30 days after their final study', 'within 3 months after surgery.|Nutrition risk score', 'within 3 months prior to screening.|Have any other conditions', 'within 6 months after receiving', 'within 28 days prior to start of protocol', 'within 6 months before the study;|Corrected QT interval', 'at least 6 months after the last dose of protocol therapy||Childbearing potential defined', 'within 12 weeks of enrollment', 'within 1 day of enrollment', 'at the time of enrolment.|Known', 'for at least 1 year|Free living to the extent that participant', 'within 30 days prior to randomization;|Severe dental', 'past month) psychopharmacotherapy', 'prior to ACLR|Post-surgical complication', 'within the last year|Presence of a caregiver', 'in the two previous years.||', 'within the past 3 months.|Patient', 'at time of index stroke', 'within the last 12 months|Female', 'within 60 days after screening Visit 0', 'within 14 days prior to the first dose of investigational product;|Presence', 'within 30 days prior to Day 0', 'within the past 1 year|History of', 'within 2 weeks before the first dose;|Patients', 'within half a year of the study|Not', 'post-screening', 'after treatment are eligible (note', 'within the last 12 months|Live', 'within 28 days prior to the first dose of study', 'within 30 days prior to the day of enrollment|Any condition', '3 months to', 'within 6 months prior', 'at the time of screening.||History of', 'for at least 42 days after the one-time use of the Gleolan study', 'for 1 year or longer', 'male|Aged between 12 months to 11 years|phototype', 'at the dose of 12 mg daily', 'up to 3', 'at least for 6 months before screening', 'within 5 years of screening|Live', 'within 28 days of Week 0 Visit', 'within 2 weeks of Visit 1', 'during or before pregnancy|History', 'within the specified time window', 'within the past 6 months.|Be', '12 hours prior to treatment|Patients', 'over 4', 'for the last 2 years||', 'within 6 months prior to study vaccination', 'after surgical and /or locoregional therapies|No', 'at the time of obtaining informed consent for trial participation|Patients', 'within 1 month prior to the screening', 'within 1 year prior to screening|Participants', 'within 24 hours prior to vaccination;|Participating', 'in the first 3 months.|The researchers', 'within 2 weeks prior to the first use of the study drug', 'at least 30 minutes', 'within 6 months of last dose of platinum therapy', 'within the past year.|Class III or higher heart failure.|Undergoing novel therapy', 'for 4 weeks following final dosing', 'at the index date|Have', 'prior to last prestudy IgG infusion', 'within 14 days)|Parenteral nutrition|Current', 'at the time of consent.|No indication', 'within 12 months of the start of induction therapy', 'within three weeks', 'within the past five years|Gastrointestinal surgery', 'within 1 year of study entry.|10', 'since the last dose of prior standard platinum-', 'at time of enrollment||Exclusion Criteria||None', 'during the trial until at least 4 months after the last dose of protocol treatment', 'within 1 month before screening;|Active cancer', 'within 30 days of enrolment', 'during the specified period of the study||-||', 'within 28 days of enrollment.|Patients', 'within 7 days prior to the first dose of trial treatment.|Diagnosis', 'at least 1 year after menopause.|Subjects should understand the nature', 'within 1 month prior to the start of the study intervention|Had', 'at the time of enrollment|A diagnosis', 'after clinical intervention.||3)', 'history taking', 'within the last 12 months|Significant', 'within the past one year', 'during Visit 1|cannot weigh', 'within 14 days before the first dose of trial therapies', 'at screening).|Vaping less than 3 months', 'within 72 hours prior to receiving the first dose of study medication', 'in past 3 years;|Participant', 'at the time of enrollment.|Known', 'within one month of enrollment', 'within 5 years before enrollment', 'within 2 weeks prior to Meta10-19 infusion；|Treatment', 'within 6 months before first dose of study medication', 'prior to initiation', 'within 1 month after the end of the trial;|Be able to read', 'at least 2 minutes|Able', 'Continuous', 'within 2 weeks|Patients', 'previous CV-event', 'preceding 12 consecutive months', 'in the 2 years before screening;|EDSS <=6.0;|Able and willing to give written informed consent', 'at greater than prednisone 5 mg daily', 'more than 20% change', 'within 4 weeks prior to initiation of study treatment|Treatment', 'medical history medical records', 'within 30 days prior to study entry.|Known', 'within 6 months before enrollment|Serious', 'within the last 4 weeks prior to surgery', 'in the last 6 months before the first assessment', 'more than 1 time/week', 'within 28 days prior to start of protocol therapy||Oxygen (O2)', 'etc.);|Within 2 weeks before the first administration', 'within 7 days prior to consent.|Participants', 'in the dose', 'within two weeks prior to the planned date of', 'younger than 1 year', 'during the course of the intervention.|Participants must', 'during the trial participation', 'within 72 hours of the validation of the', 'within the next 28 days', 'within three months of the Screening visit', 'within 4 weeks before starting treatment', 'within 6 weeks of last dose of', 'within 4 weeks before the first use of the drug;|Received', 'at the incision site.|a history', 'within 6 months before enrolment', 'within 14 days prior to C1D1.|Uncontrolled', 'before 4 weeks before enrollment', 'in the past 1 year|Clinically confirmed', 'within 6 months prior study start.||-', 'personal history of any of the following conditions', 'over 8 weeks|No', 'for six months after the discontinuation of study medication.|Has', 'during the 6 months prior to study', 'at least 6 (six)', 'for at least 6 months after the last dose of study drugs', '14 days prior to enrollment):||Absolute neutrophil count (', 'at least after 1 year of the', 'in 14 days before intervention', 'within the past 15 years||', 'within 1 year prior to Study Visit 3', 'for ≥ 30 days prior to the first dose of study treatment', 'previously treated|No ongoing requirement', 'during the whole trial period||', 'within the last 30 days.|History', 'within the lower limit of normal', 'within the past 1 month|recreational drug use', 'within 4 weeks prior to Screening|Anticipated initiation', 'within 4 weeks of baseline.|Anakinra', 'over the past 6 months|Serum potassium', 'within 2 months after the final dose of', 'in last 18 months of >140/90', 'throughout induction/labor course', 'at least 2months duration', 'within 2 days prior to any endoscopic', 'within 14 days prior to C1D1.|Women', 'within 4 weeks before the start of the study', 'within 60 days before the scheduled dose of study drug.|Had', 'throughout the study unless they are', 'within 4 weeks of study initiation|Current participation', 'within 1 year prior to signing Informed Consent form|Stable', 'within 60 days prior to entry.||The following treatment', 'while arm 2 subjects', 'last 2 hours', 'NICU for more than one month', 'within 30 days prior to first dose of study treatment||Examples', 'area.|More than half of the roots resorbed', 'in the last six months|Any change', 'within 7 days prior to enrollment', 'prior to proceeding', 'up to 4 weeks prior to study inclusion', 'within 3 months|Signed informed consent||Exclusion', 'within 14 days of study treatment administration', 'during the 28 days or', 'within the previous 30 days.|Be', 'within 24 hours with', '6 months after the end of capecitabine treatment', 'within 6 weeks of first administration of NUC-3373|Corticosteroid treatment', 'in the three months prior to the inclusion visit', 'during the first month after any intraocular surgery', 'for at least 1 year after the infusion.||', 'in the lung', 'at least one year before the start of the study.|Grade 7||', 'within 14 days of study entry.|Known', 'within 30 days prior to the initial dose of the study medication', 'within 4 weeks prior to Visit 2/', 'after completion of neoadjuvant therapy', 'within 3 months of enrollment|Lower extremity deep venous thrombosis', 'within 4 weeks prior to randomisation', 'prior systemic therapy', 'at the time of informed consent.|Subject', 'after enrollment is acceptable).||Inclusion Criteria - Retrospective', ""during the last 6 months after the participant's inclusion.||the participant"", 'prior to entry into the study.||Note', 'CR≤1.5 times the upper limit of normal range (ULN)', 'previous 12 ± 2', '28 days prior to start of study treatment', 'less than 3 months before the start of the protocol,|impaired alertness', 'within 2 weeks prior to Cycle 1, Day 1', 'for 30 days after the last dose of study', 'within 1 day of the fovea of the macula.|OCT examination', 'prior to undergoing any screening', 'for 6 months from randomization|Previously', 'within past 2 weeks|Obesity', 'during the investigational procedure.|Patients should', '3 prior to the use of the test device', 'prior to the start of', 'at least 4 weeks before screening.||Participants', 'last for at least two months', 'within 28 days before', 'in the last two years||Specific exclusion criteria', 'at the time of initiation of therapy', 'in the last six months.||', 'at time of enrollment|Subjects with', 'within 30 days before Screening.|Unwilling to consume', 'preceding 12 consecutive', 'within 3 months|Neck Disability Index (NDI)', 'at the first second is < 0.70', 'at least 6 months duration', 'during the clinician-administered interview', 'during the 4-week period before study', 'in the past 2 months;|NB-UVB', 'within 56 days prior to study drug', 'at the beginning of treatment', 'at the time of randomization;|Obvious', 'During the screening period', 'in the last four months|Periodontal treatment', 'at the time of study entry', 'within 4 weeks prior to the start of PYX-106 treatment', 'within 3 months prior to the administration of study vaccines', 'in the last 2 months|able to participate', 'within 6 months of Screening.|Consume', 'in the previous 3 years', 'within the past 8 months', 'during the last 4 weeks prior to screening', 'within 14 days.|Hypertrophic cardiomyopathy', 'at any previous time', 'within 72 hours of informed consent|Able']","['>12.5 mg/dL).|Are', '≥80×109/L|Hemoglobin', '+/- 10 days of enrolment)|Statin naivety|LDL-C', '≤ 60 days prior to the index', '≥ 40%)|Systolic blood pressure', '≤ 5 x ULN.||--Renal:||Estimated', '>0.1 mSv', 'more than 6 months;|Female', '> 40 m-2||', '≥10%', 'between 18.5-24.9', '1 month -10 years', '> 1000 mg/gm', 'score of 0 to 1.||', '18 - 75', '≥2000 IU/mL', 'between 13 and 17 years|Sufficient', '≥ 8g/', '0-1.|Gastroscopy', 'Over 18 years|Chronic', 'PI)|Able', '< 60 mL/min/1.73m2;|White', '>45 kg;|female', '+/- ADT)||Non-metastatic', '> 100/nL|Total bilirubin', '<20%', '≥ 20 and < 60 mL/min/1.73m2', 'less than 135kg', '≥ 60×10^9/L.|Liver', '> 18|resistance', 'Images', '≥18 and ≤40', '0 to 2|Patients', '≥30 mIU/mL', '< 2h.|≥18 years', '>140 mm Hg', '≥ 10 mIU/L', 'Infants 24- 34 weeks of gestation|On', '< 2.5 x upper limit of normal (ULN)', '< 1.5|PTT < 1.5 x control|Female', 'between ears <= 10 dB for 1kHz-6kHz', 'from 18 to 65 years;|Tested positive', '>16mm,|NYHA functional class', '> 6.5 %|Known', '> 2,0 mg/dl', '≥ 30 g/L 9', '4-10 years', '< 1.5x ULN', 'Grade 1 status', 'score ≥1.5.|Subjects must', '< 140 or > 500 x 10^9/L', '> 90 mL/min/1.73 m^2', '< 25 ml/min/1.73m2|Patients', '>25|infectious disease', 'III-IVb;|There', '7 points', '-18.5 - 24.9|Those providing', '4 kg/cm2', '< 40 y/o|Post-operative', 'greater than or equal to 24.|The', '>90% visual diameter stenosis|Presence', 'I-III,|Ability', '0-1;|Child-Pugh class', '20 - 30 years,|non-smoker,|systemically', '+pain', 'within therapeutic range of intended use of', '>6.5|Subjects', 'score equal to 0|IHE-induced %', '≥ 1x10^9/L', '≤ 250 mm', '65 to 75 years old', 'between 18.0 kg/m2', '>1,000 copies/mL sustained', 'older|Type II or III', '3-8', '< 12 g/dl', 'excluded', '≥9.0 g/dL.|Absolute neutrophil count (', '≥ 37.8°C', 'within normal range', '< 0.75 × 10^9/L', '>= 400 mL', '≥70 mg/dL', '> 140/90 mmHg', '25-45 years|BMI', '<7 mm', '≤ 4', '<40%|Severe aortic', '65 years old', 'transaminase does not', '4 to 17', 'findings', '< 1 year.|In the opinion', '≥ 6.5% and ≤ 11%.||', 'class IV heart failure', '14-19 y).|Fully', 'above 8%|Diabetes mellitus', '>= NYHA', '≥18 years.|INOCA', '< 3.0 g/dL.', '14-80 years', 'dose 2.5 mg/kg/day', '≥18 to ≤65 years', '± 2h', '18 -80 years|Severe', 'between 25 and 70 years', '≥ 60mL/min|Serum', 'score A', '≤2.5x ULN', '< 15 ml/minute', '12-65', '> 40 kg/m2.|Taking', '≥ 18 kg/m2', '6 to 17 years inclusive', 'age|greater than 5 years', '< 3.0 × 109/L;|the number', '<25%|The patient', 'between 20', '>24', '18 or over|Suffer from stress urinary incontinence', 'between 2015', 'equal to or more than 18 years', '≥ 3mm/5min', '≤ 60 mmHg||Before the first administration of investigational', 'greater than 7.0% to less than or less than or equal to 11.0%.||', '≥ 8.5 g/dL|Absolute', '100-109', '≤-1.1 to >-2.5', '>=1.5xULN', '>5 times ULN', 'scores ≥3).||', '≥ 35 g/L', '<= 2', '> 250 msec.|Any factors', '≤ 60 mg/dL', '≥ 100 ×109/L；||Blood', 'entrapment', '7.0-11.0%', '>= 1.5 X 109/L', '≥18 years.|Histologically', '> 20 mmHg', 'more than 70%|symptomatic stenosis|asymptomatic stenosis|elective surgery patients|signed', '18 to 70 years', '> 270', '> 325 mg/day', 'greater than 30,000/mcL', '18-70;||②', '≥1.5 ·', '> 100 10^9/l|Patient', 'from 18.5 to 30 kg/m2.||', 'more than 40%', '22-80 years', '≥ 18|Ability and willingness to give', '19-80|the patient', 'between 50-70 years.|Patients', '>3 times upper limit of normal', '<3.4 or >11.0 x 103/mm3', '36-42', 'at least minimum', '18.5-31.9|Willing', '≥1.5x10^9g/L', '≥48 hours|On contact precautions', 'less than $12,760', '≥ 25)||', '> 2 times', '25-55 years|Minimum 6 weeks chronicity of adhesive', '> 18 years|Performance index', '> 2.0 mg/dl||B.', 'between 18 and 44 years', 'between 34 and 78', 'from 80 - 92 %|O2 therapy', '< 70) sought specialist help', '≥120g/L', 'Younger than 18 years', '50 to 70 years inclusive', 'more than 18.||', '≥ 9 g/dL|Platelets', '> 365 pg/mL', '≤ 1.5 x institutional upper limit of normal', '> 18 years|patient presenting with:|ALF', '= 125 mL glass', '< 1.5 x ULN|AST/ALT', 'more than 15 months prior to inclusion', '0 or 1||Adequate', 'lower than 60 or over 90 mmHg', '> 7 days prior does not count', 'greater than or equal to 6 months', '< 35', '⑦ Refuse to sign', 'greater than 140/90', '18-85 year-old', 'greater than 35', '≥ 25 kg/m2)|Dyslipidemia', '> 18 age|asa 3-4|patients', '+/- 15 min', '>100 mg/dl', '45 and 65 years', '18 - 75|ECOG ≤ 1|Patient', 'above primary school', '≤ 2.||7', '>4', 'less than one year.|Contraindication to 18FDG-PETscan', '≤ 27.0 kg/m2', '> 70 years|Presence', '>1.0g/day;|Serum potassium', '≥100 mg/dL||Unstable', 'I/II/III;|Laparoscopic surgery;|Informed', 'between 50-65 years', '1 ounce', '< 16 years).|5/6', '>470ms', '<30 events per hour', 'above 250', '≥ 15 mL/min per Cockcroft', 'on day of surgery', '>= 1.5 cm', '> 5% CLL involvement', '≥0.2 ng/mL', '10 to 18|23', '>75 x 109/L', '< 90/40 mmHg', '3~8 years', '<90 mm', '> 130mg/dl', '1 or greater', 'less than 30 minutes', 'within normal limits', 'greater than 18.5 and less than 32 kg/m2', '> 90 beats per minute', '<45 years', 'between 18 and 60 years;|Presence of pain', '55 and older', 'less than 95 %', 'less than 60 mmHg).|Long-term', '≤6.5 g/dl', '>150 min/week', '≤ 1.2 x normal', '> 140 / 90 mmHg', '≥20 at Screening', '>0.35kU/L', '<= 275', '≥ 45', '≥ ± 3', 'less than or equal to 1.5 times ULN;For subjects who frequently take', 'less than 9 g/dL.||', '≥ 50 mL/', '5.0', 'long diameter≥10mm', '≥ 20 mg/100', '35 years old', '>450 millisecond', '< 25)|Pregnancy|Patients', 'greater than 18 years', '≥100 x103/μL|Hemoglobin', '90 to 150 mmHg', '0 to 10', '< 10 ms', '<1,500 kCal/day', '< 60 mL/min/1.73 m2', '≥ 30 kg/m2|Insulin', 'less than 1.0 mmol/l', '18 years or', '≥ 400 mg/dL|LDL', '> 18|Non anastomotic biliary strictures', '18-80 years|Admission', 'older than or equal to 65 years', 'less than 30 ml/min/1.73 m2;|Patients', '<88%', '≤1.5 times the upper limit of normal (ULN)', '18 -70 years', 'long diameter ≥ 10mm', '18-20', '1.5-1.9 times baseline', 'complete response after treatment', '18-60 years|body weight', '≥60g/L', '< 45 ml/(min×1.73m2)|Women', '18 - 39 years', 'greater than 0.2 ng/mL', '>2 years.|Any unresolved', '≥110 mmHg)|Spinal cord injury|Cancer diagnosis', 'equal or less than 80', 'fasting|1-18 years', '≥ 18.5|University student', '≥ 40%', '<5 mm', 'from 18-65 years', '≥65-74', '</= 100', 'greater than 2.5 times the upper limit of normal|Serum creatinine', '≥0.1 millivolt', '3-60|Intact proprioception', 'more than 10 mg', 'higher or equal to 65', 'between 9', 'less than 1 year|Known', '< 3 months from symptom onset', '>30 min/day exercise 3 or more times/week', '18 years or older|Up to 2 cm tear size', '<50 years old, should', '18 years old and older', '<17 Kg/m2|use', '- higher or equal to 30).||Exclusion criteria:||•', '≥18 years|Female||Diagnosed', 'between 0 and 10||', '> 6 months 4', 'greater than 2.5 mg/dL|Cancer', 'between 19 and 50 years', '> 50.0 x 109/L', 'more than 18 year.|CKD patient', '0-1|Pregnancy', '< 140|Diastolic pressure', 'score less than 18|Have', '65-75 years;|Complaint', '19.0 - 28.0 kg/m^2', '> 25g/L', '< 450 msec', 'criteria;|Nugent score ≥ 7;|lactobacillary grade', '>14.7', 'Class II-IV', '> 3 times ULN', '<1.5x control.|Participants', '50-54 mmHg', 'less than 450 mSec.|No', '>/= 30 mg', '> 6.5%|Significant debilitating chronic cardiac', '≥ 80 cm', '≥18 years old;|are', 'more than or equal to [', '> Class II|Left', 'less than or equal to the upper limit of the normal range', 'years to 60', '>18.|Subject', '< 5 x ULN', 'lower than 100 mmHg', 'LDH|age 19-69 years|presence', '1 - 4', '</= 4 weeks', '≥40 mL / min', '=< 15 days prior to registration)|Pulse oximetry', '18 through 45,', 'permitted.||9.Creatinine clearance < 30mL/min', '≤ 150 mg/day', 'older than 80', 'above 14 for IOS', '>10,000 copies/mL)|Kidney', '= 18 years', 'greater than upper limit of normal per institutional cut-off', '> 5 times of upper normal', '<20.||', '> 25%|Bilirubin ≤ 3.0 mg/dL', '20-50 years|gender', '≥ 45.0 kg', '≤ 1.5 times the upper limit of the normal value', '≥90mmHg);|A history', 'score of the Eastern Tumor', '> 42', '20-50', 'less than or equal to (<=) 90 days before informed consent', '> 105mmHg)|Recently', 'greater than the lower limits of detection of the assay.|HIV-infected', 'greater than 18 years.|Weight', '>1.2', '<= ULN|aspartate aminotransferase', '14-009873', '≥7,5%|More than 3 years', '≥ 60.||If patient does not', '> 0.1%', '>11mm', 'between 18 and 30 years|Able to understand', '= 200 mL', '> 150mmol/L', '≤ 29.9 Kg/m2', '>25 mmHg', 'II-III)|Patient', '15 kg or more|', '≥18 years;|Patients', '> 1.5 to 3 times the upper limit of', '3-12', '> 4', '18-40-years', ""0-3.||Exclusion Criteria||The participant's compliance"", 'outside the normal range', 'less than 30 ml/min/1.73 m2', 'less than 70 mm', '≤2', '=< 450 ms', 'I - III;|Operation time: 15min~1h;|BMI18.0-29.9；||', 'at least 25 years', '18 yrs|Elective', '≥ 500/ μ', '<24).|Subjects', '≥ 18|diagnosis', '19 years of age', 'less than 6\'2""', '0.2 ng/mL or higher', '> 95th percentile', '> 18 years old', '< 18 years.|Weight < 50 Kg.|Refusal', '0 → 3', '4+ or', 'less than 2.5 times ULN', ""+||E. Wilson's disease：ceruloplasmin < 20 mg/dl||Strict exclusion criteria：patients"", '≤ 2.5 × upper limit of normal value (ULN)', 'under five years', '≤ 5 X', 'class III and IIII', '≤ 3 times the upper limit of normal value', '≥18 years|Planned', '6-30||', '20 to 60||', '2 to 16 years Intraoperative diagnosis', '< 90 g/', 'rating I', '> 40|Legal', '18-85 years|Predominant axial', '1 to day 550/Month', '16-30years)|Male traceurs|Parkour', '> 4.8 to 5.0 mmol/L', '≥ 50%.||Sign the written informed', '< 8 ng/ml||', '18.5 to 42.0 kg/m2|Willing', 'letter score ≤ 75 and ≥ 24', '90 days.||Female', '= 0 directly', '18 to 30 kg/m2|Voluntarily given', '18 or older|Self-reported', '>= 3 weeks prior to study treatment|Strong inhibitors of CYP3A4/5 and CYP2C19:', '>7', '≤ 2.0 × upper limit of normal', 'under 10 years old', '≥100 ng/L|End-Stage Renal Disease (', '0 or 1.|At least one', '≥18 years.|Subject', '> 3 times upper limit of normal).|Unwillingness', '< 7', 'at least 20 mm Hg', '> 25 kg/m2)|Normal', '≥500/mm^3', '< 2.5 × ULN', '> 5 mL', '>3 months.|Histopathological', 'between 18 and 65 years.|Diagnosed', 'less than 25 Kg/m2.|History', '≥ 30 kg/m^2', 'greater than 3', '>18 and <65 years.|Signed', 'Stage 2', '>= 70 mL/min/1.73 m^2 OR|a glomerular filtration rate (GFR)', '0 - 2|Alanine transaminase (ALT)', '< 8 g/dL', 'less than 34cm', '> 100,000/uL|Complete', 'less than 8 cm', '>40 kg/m2).|Psychiatric disorder.|Opiod dependence', 'B-cell lymphoma', 'older than 6', '18 years to 40', '< 50%.|A history', '> 1.0', '≥450 pg/', 'more than 90/140|2nd', '0-2;|No', '>2 mm', 'than 50% reduction of proteinuria', 'under 6 and over 12 will', 'lactate dehydrogenase', '35 and older;|embryo transfer planned', 'Over 20 years', '> 3|patients', '+/- 10 degrees', '5 to 16 years', '≥ 1.5', '> 100mmHg）；|Pregnant and lactating', '< 6 months)||', '> 105', 'between 80 years old', '<3.0 x103/μL|Absolute', 'between 35 and 42', '18-35 years.||', '-65 years', '4-5', '≥ Grade', 'between 18-70 years|Scheduled', '> 6 months.|Participant', '3 times a week', '>2 times', 'greater than 3 months.||Have measurable', '<0.26 or >', 'below the lower limit quantification', '0 or 1.|Subject', '0-1|Have', '≥25% or the', '<18 years or >45', '< 50%|Recent thromboembolic events', '< 40ml per', '≤ 6).||Known', '> 2;|History', '>50|for age control group age', 'greater than 12,000 with investigation showing general good health', '14-17', '3 to 18 years|Have been lived', '≤ 39 kg/m2|If biologically', 'above 40 C', 'between 18 and28 kg/m2|Male', '12-15 years', '18 - 50 years', '> or = 0.5 kg/m2', '≥ 19 years|Male', '2C', '≤ 1.5 times upper limit of normal value (ULN)', '< 20|Age ≥18 years.|Written informed consent of the patient', 'between 18.0 and 26.0 kg/m2', '< 1.0 x lower limit of normal (LLN)', 'score of 0 or 1.|Expected survival period', 'before 32SA arriving at term', '18-80.|Having', '≤ 30.|No', '18-75 years;|BMI', '<10 pm/mL', '≥25 mm', 'subsequent CR', '< 22.85', 'below 0.8', '> 8.0mm', 'equal to or greater than 20%', '≥18 <65 years', '18 to 49 years', '≥ 38.3°C', '<40 ml/min/1.73m2', '16-40', '>=100,000/mcL|hemoglobin', '≥ 18 years.||Adequate', '50 or over|Glogau Wrinkle Severity Scale', 'class III or IV', '≥ 1 million', '>= 13);||', '>24;|Effective', '< 120×10^9/L.|A', '50 mL/min', '2.5 g/dL)|For', '> /= 4', 'Claudin 18.2 positive', '140 - 179 mg/dL', 'from 18 to 65 years.|Informed', 'equal and over 17', '> 40 mIU / mL.||Unsterilized', 'greater than 2.0', '= 8 g', '7 or more', '0-2.|Resolved', '18-75;|Subjects', '< 35 2', '6-12%||', 'less than 18 years.|Patients refuse', '>/= 20', '>5.5mmol/L', 'scores of < 30%', '≥ 18 to ≤ 80 years', '>= 25 kg/m^2|English', '19.0-30.0 kg/m2', '≤10.5% if background diabetes', '≤9.3 µmol/L)||', '> 5 × ULN||IL-8', '18 to 65 years inclusive', '>=2', '50-64|Postmenopausal women|Recent', '<100 IU/ml', '=< 1.5 times institutional ULN', '≥ 140 mmHg', '>= 70 mL/min/1.73 m^2', '< 40', 'stage 3/4.|evidence', '≥ 0.5 kg', 'below 90mmHg', '< 20 ng/mL|Able to provide informed', 'RV>175% pred|CAT≥18|>50%', '0-1;|Laboratory test results', '18 or older;|Diagnosed', 'not older than 12 weeks before enrolment.|All', 'greater than 3 months||Participants', '18 or above|Patients', '≤ 2.5 x ULN.|Adequate hematologic function', '> 2 × upper limit of normal (ULN)', '29-15 mL/min/1.73m^2', '≤ 12%).||Note', 'more than 1.5.|Hospitalized surgical treatment', '> 15|Patients have anxiety', '≥135 mmHg', '5 degrees', '>= 18 years|Histological', '< 3 × institutional ULN).||The participant', 'years|Minimum 2 cm diastasis', 'from 25-30||', 'do not', 'at least 10-years per the opinion of the treating', '≥3 months;|Adequate organ performance', '≤ 2.5 times the upper limit of normal.|Serum bilirubin ≤ 1.5 times the upper limit of normal', '<0.3 mcIU/mL', 'score ≤15', '<400 copies per mL', '> 160mmhg', '< 88%', '≥ 21', 'at least 50kg', '≥ 126 mg/dL', 'between 26 to 40|Able to provide written informed consent in English||', 'older than 1 month and younger than18 years', '18.5 to 27.0 kg/m2', '18 years or older', '≥ 40 years|Body', '>160/>110 sustained', '18 years or above', '> 18 years|Being', 'score is 0 or', '≥ 0.8 ≤1.0 g.kg-1', '≥ 100,000/µL|Total bilirubin', '≥ 35 kg/m2', 'greater than 30 days prior to enrollment', '45 kg or more', 'younger than 70 years', '> 45|Serum PSA levels', 'greater than upper limit of the scale', 'neonates.||', '≥30 ml/min/1.73m2||Elevated', '<1% expression of estrogen receptor', '≥ 50,000/mm3', '>17 and <30|Meets clinical', '^9/l', '18 or older)|Willing', 'more than or equal to >', '<60 minutes/day outdoors or <2.5 hrs per week', '>100mcg/dL||', '>18 years-old', '>4 ng/ml', '12 to 16', '> 45 kg', '12.1', '≥ 94 cm', '100-300×109/L', '> 3 times upper limit of', 'below 100 mmHg systolic', '≤ 1.|Adequate organ', '≥ 10 cm', '≥ 2.0*', 'less than 6 months|Children', '> 35|patients', '+/-25%', '< 18 years|Conditions', 'before enrolment and|Agree to the birth control methods', '< 90 on', '≥ 18 years|Proficient', '< 2.5', '≥ 40%,||The', 'HLA)-B 1502', '>1.1)||HELLP syndrome', '<100 ng/mL assessed', '> 150 µg/L|Acute', '< 3 times the upper limit of normal', 'I-II||', '20-45|Both', 'Complete response (CR)', '≥ 5 g / L', '≥1.5 × ULN', '> 6mm|Smoking', '> 12mEq/L|Ketones', '7-11.0%', '>18|Provide care', '3-9', '≥ 50,000/L Patient', '<= 4|PIGD phenotype|Stable', '< 1', '< 1,5 hours of structured physical activity pr', '<6', '90°', 'between 0.77 D and 4.53 D', 'between 18.5 - 30 kg/m2||', '<10 ng / ml|No', '≥55kg|90 mmHg', '≥30ml/min', 'over 180/100 mmHg', 'above 20mg/day', '≥50 ng/dL).|Patients', '<30mL/min/1.73m2', '> 139 mmHg', '≤ 2.5 times ULN;Stage', 'score of 0,1；|Life expectancy', 'at least 10 mm Hg', '<3 months.|Participant', 'greater than 12 months||Participants', '≥ 15;|Cognition', '> 47%', 'over 165mmHg', '≥ 100,000/mm³|Hg', 'week 20', '≤ 1.2 × ULN', '< 1.1 ng/ml.|Subjects', '≥10 mg/dL', '≥1%', 'lower than 30 ml/', '< 50 G/L);|Renal impairment', '≥30g/L.|Urine', '<200 cells/mcL', '≥ 13;||6', '> 37.5°C', 'more than 18 years||', '≥ 40kg/m2', 'less than 55% of the predicted value', '≥18 and ≤75 years;|ECOG score 0-1;||Breast cancer', 'stages II or III', 'less than 6 years or more than 16 years|Poor asthma control', 'between 20 and 50 years', 'score of 24 or less', '≥3 months;||Laboratory results', '>18.0 and <30.0 kg/', '<120μmol/L', '>= 8||Inadequate organ function', '< 2.5%|Patient', '>120 msec', 'less than normal', '6-18|Being', '18 years and older|willing to avoid foods', '≤1.5 x limit of normal', '> 2.5mg/dl', '45 dB hearing level (HL', '19.0-26.0 kg/m2', '41-49%', '< 18 and > 90 years', 'class A-B', '≥ 14', '>45%', '400 mL or more', 'more than or equal to 135kg|Subjects need', '02 to 12 years old', 'score of 10 to 15', 'score of < 9', '≥ 103 copies/mL', '> 50 RU/mL', '> 20 and < 50|Ability to understand the study', '≥ 7', '≥ 1,500 cells/mm3|Lymphocytes', 'time|free of visual impairment', '27.0-44.9 kg/m^2|Maternal', 'more than 12 weeks', '> 35 kg/m^2|Present values', '≥ 18;|Primary', 'before enrollment', '≥18 and ≤50 years', '1.3 mg/dl', '18+ years old', '<50 mmHg|Those', '4 to 12 years referred', '>12 and <18 years', '10 cmH2O or lower', '>8|Low suicide risk', 'above 18-years', '< 53|pain over', 'later than 3 years', '10-13,|scoliosis', '< 13 g/dl|thrombocytopenia', '≥ 6 months；|Age', '18-80.|A', '<45 kg', 'less than 6 times the drug', '23.5 hours/day', 'minimum 20 or greater', '>= 5.2 mmol/L', '= 0', '18.5 to 36.0 kg/m2', '≥ 30 mL/min/ 1.73m2', '<30 kg/m2', '≤ 2.5 times the upper limit of normal values', '≥130/85 mmHg', 'greater than 80%||', '≥ 1.5 cm', 'likelihood', '≥18 years|Patient', 'greater than 1,5 times the upper limit of normal (ULN)', '0-2|Stable androgen deprivation', '>15 on the Depression', '1.3 mls 0.5%', '> 3/10', '≤ 5 × ULN）', 'class 2B or better', '18-90|People', '≤ 30.0 kg/m2.|Medically healthy', 'B-cell-depleting therapies', 'limit of normal', '≤ 7.25', '6 to 10 years', '18.5 to 50 kg/m^2', 'rate,|greater than or equal to 50', '< 10% of body surface', 'from 50 to 99% amenable', '> 3', '≥ 470ms|Has', '5 to 9 years.|Presence', 'per 4 weeks', '< 12', '≥1.5 mm', '≥ 250 mg/dL', '>120 ms', 'functional class III or IV', '< 40%|Clinically', 'over 19 years or older', '= 2||Presence', 'below 6 months', '< 8.5%.||', '< 25 mL/min/1.73m', '< 1,500 cells/mm3|Serum', '≤ 2.5 ⋅ ULN|Serum', '>4.8 mmol/L', '>40 years', '>30 kg/m^2', '≥ 18 yrs|ECOG', '18-45|Male', '>1.5 times the upper limit of normal', 'under 65 years|participants who do not understand Danish|severe communicative', '0-1.|At least one', '≥18 years|Currently', '21-45 yrs|Employed', 'no more than 1.3-3.0||', '1 drink', 'less than 1 year|Dependence', '<3 months|Patients', '>= 24|No significant', '< 500 IU/mL', '≥ + +', '> twice the upper limit of the normal', '0-1.|Expected', '5 times per', '≥12 weeks,|low', '>200 cells/mm3', 'between 18-70', '≥ 50 mmHg', '> 40', 'below 200/mm3', 'between 18.5 and 29.9 kg/m2', '≥ 5 mg/day', 'above or equal to 3 months prior to screening', '<30%|White blood cell count', '>83%', '1.5 times ULN|If already', 'older than 65 years', 'between 21-35 days', '≤ 2.5 x ULN.||', '3 to 18 years', 'between 18.5 kg/m2', '≤ 2.5 times ULN', 'IV 2g/day', '70 mmHg', 'at least 3 months)|TThe guardian should understand and sign the informed consent form', '≤ 4 months', '18 years old or above', '18 to 85|With', '> 35', 'score of 3 or less', '> 2 weeks', '>6 mIU/L', '> 100 mmHg|Unstable angina', '16-30 years', '≥12 g/dL', '≥ 3|History', '2-negative', '≥ 470 ms.|Any', '1.1 following tumor resection.|Participants', '> 0.5 mm);|4', 'mAb', '≥ 500 μg Q3W', '<50% of the total lesion', 'at least 21 kg/m2', '≤ 1.5 × ULN.|Estimated', '≥ 30 to < 60 mL/min/1.73 m²,|severe', '≥1.5*', '0 ~', 'score of >= 21', '≥40', 'more than 10 mSv', '> 50 years old', '50 kg.|Fitzpatrick skin', 'score more than 4|Clinical presentation', 'service more than six months.||', '45 to 65 years', '≥35 and ≤75 years old', '≥ 2.8 g/dl.|(PT)/INR', 'therapy).|At least 18 years', '2-3', 'score 3 to 4', '> 2 norms', 'do not exceed twice the normal upper limit;|Patients', '≤0.80 ng/mL', '< 5 x ULN|Albumin', '<3 months;|Received', '< 400 copies/mL', '> 30 degrees extension deficit', 'from 35.5 to 36.9 °C', '>1.5 mm2', 'II', '<37 weeks|pregnancy', '≤2.5 times of institutional upper limit of normal', 'more than one hour', '>CTCAE v5', '≤3.0×ULN*', '< 25%;|Uremia dependent', 'between 30 and 80', '64 BioVentrix CIP-0067', '≤ 2.0 mg/dL|AST', '< 6-9 months', 'more than 30', '18 years old ≤ age', 'grade II to IV).|Patient', 'greater than or equal to 3×10^9/L', 'between 20-45 years|Pain', '≥ 104 copies/ml', 'upper normal', '18|Anyone unable to comply', '31 - 84 months', '> 5.5 mmol/L', '≥ 10 copies', 'greater than 2x normal.|Currently', '< 90 mL/min/1.73 m2|AST', '<35g/L', '>= 90 g/L', 'more than 20 teeth;|Absence', '> 3.02kPa', '<90 mL/min/1.73m2', '=< 1.5X ULN', '0 to 2|At least', '> 20 mg/day', '≥ 6 months;|At least', '≥75 x109/L', '12-18 weeks', '0-3.|Patient', 'more than 60', '>170', '0 or 1+', '≥ 40 kg/m2.|For', '>= 18 years|Able to provide', '18 and above|Diagnosed', '≥85 cm', 'on:||A. 18 years or more', '≥ 100,000/mcL Hemoglobin', 'between 16 to 36 injections distanced 1 centimeter (cm) from each other', 'I, II physical status.|Undergoing', '<0.8 g/kg/d', 'less than or equal to 63.||', '<13', '>2.0|Active phlebitis', '≤ 5 ULN', '≥ 40mmhg', 'less than 50 kg.|In', '≥ 2 to ≤ 30 years', '≤ 10×109/L', 'between 18-50 years|Body Mass Index (BMI)', '18-70 years;|Hunt-Hess grade IV-V', '≥ 70%', '≥ 39 letters)||', '>= 1', 'score <600 MET indicating physically', '≤ 10 ng/mL', '> 10 000 ng/mL', '≥ 18 to ≤80', 'class III of 4 by', '<18 years;|No', 'above the limit of', '15 mm or greater', '≥ 30%', '< 65 years', '</= 5 X institutional (Upper Limit of Normal', '18 - 75 years;|Fulfilling', '100,000/μL', '0-2))|Written', '<15 mL/ min/1.73 m2)|Pregnancy|Arrhythmia', '≤ -4 mEq/L', '≤ 10.0 mmol/L.|No', '≥12 weeks;|Participant must', '16 or 18', '<50% affection of the scalp surface.|Stable disease', 'total score of at least', '18 to 80 years inclusive,|Females participating', '> 3 times per week', '> 2.0 x the upper limit of', '0 or 1.|Willing', '≥18 years;|STEMI', '>18 years)|Clinical', 'less than 10% of body surface area (BSA)', '> II stage|Patients', 'score of ≤ 7|ECOG PS', '≥ 2 mm|the', 'above 140 mg/dl', '18 and 34', '25~50', '> 3+4', 'greater than 48 hours ago', 'less than 10 mm|The patient is', '0 - 1|Agreement', 'applied,|Over 70 years', '<18 years)|Participants', '<20 ng/ml)|Individuals', '<18 and >85|pregnancy|patients', 'maxillofacial', '<50x103/l', 'over 159 mmHg', '≥ 100,000', '=< 1.5 X upper limit of normal (ULN)', '> 18 years|unruptured and ruptured', 'between 2014 and 2021|Those', '≤ 2.||Adequate organ function', 'greater than 3000 IU/day;|Therapy', '60 years or above;|LTCF residents', 'less than 70 mL/minute', 'between 18 and 32 kg/m2|Medically', '6 to 11 years|read/speak', '< 80 years', '≥18 years old.||', '= 13|Motor', 'less than 1 month prior to baseline', '≥ 1.5 cm.|Age 18 years', '<=1.5 UNL', '≥2x ULN', '≥ 65 years|Patient', '1-5', 'less than 1 month.|Taking treatments', '< 10% body surface area 2', '≥ 100 × 10 ^ 9 / L；|Hemoglobin', 'between 18 -36 years.|Athletes score falling above 4', '1.5-3.0mM|High', '> 0.7', 'less than or equal to the', '>= 30%', '>190 mgdL-1', '2.5%', '0-2|Age', '<1.0', '> grade 1).||Note', '> 60 cm|Prior therapeutic cranial irradiation|Leptomeningeal dissemination', '< 7.5%|not', '≤ 90 days|Subject', '≤ 1.0 × ULN', '≥ 1.5 × 10 ^ 9 /L;|platelet count', 'between 18.5 and 35.0 kg/m2|Is free-living', '≥ 18;|Being', '< 25 mL/min/1.73 m^2', 'above institutional normal||The study', '%<40%', 'less than or equal to 5 times ULN', 'is>3 times the upper normal limit (ULN)', '≤ 5 X institutional upper limit of normal|creatinine <2 X', 'onset <50 years', 'greater than 140 mmHg systolic', '≥ 1.5 K/', '35.5 - 37.5 °C', 'between 6 and 12 years|ethnic Chinese|residing', 'from 4 to 6 mm|Patients', '>35 kg/m2]|Patients', '<50% must', '> 3500 mg/g', '≤ 1.5 × upper limit of normal ( ULN)', '5-13 years|Medically', '18.5 to 35 kilograms per meter squared (kg/m2', 'greater than 5 times the upper limit of laboratory normal value', 'greater than 45 Gy.||Note', '≥18 years;|Diagnosis of AMI', 'fewer than 25%', '≥ 18 years|Planned', 'qXR', '18-65;|Current/acute', ""evacuating operation|Patient's agents are informed and consent the"", '1.1 criteria', '< 1.5 times the upper limit of normal', 'less than one-third', '>3-fold upper limit of normality', '<150 minutes/week', '> 14 units/week|Vigorous', '<20 days', '=< 1.5 × ULN', '≥ 1.5;|Jaundice>171.1umol/L;||C.', 'above 3 mg/L;|Former', 'below the institutional ULN', '<= 2.5 upper limit of normal value', '>50 mL/min/1.73 m2', '≥ 470 ms', 'between 37-42', '> 5 × ULN||④ Understand and voluntarily sign the informed consent form', 'between 30-65 years', 'between 10% - 19%', 'equal to or higher than 3.0g/dl.|Qualified', '≥ 18 years|Both', 'cadaver donors', '>= 40 kg/m2;|Severe', '<8 or >65', '18-55|DEERS', '18-30 years|Healthy', '< 30ml/min', '18-90', '0, 1, 2', '<100g/L|Obvious', '<25 dB HL', '≥16.5 kg/m2', '>90 cm', 'levels II, III, IV and VI).||', 'less than 5 drug half-life from the date of first administration;|According', '0 or 1||Patients', '> 0.8', 'equal to lower than 5 times of ULN', 'B-positive', 'more than 5x ULN', 'between 18-35 years.|BMI', '≥1.0×10^9/L|Absolute lymphocyte count', 'menopause.|Under 35 years', '18-60|Diagnosed ""healthy""', '>4x upper limit of normal|eGFR < 25 ml/ min/ 1.73 m2|Hemoglobin <7 g/dL', '0, 1+ or 2+', '> 20 ng/mL', 'from 13 years', 'less than 22;|skin lesions', '≥ 2500/µL', '≥ 18 years.|Histological diagnosis', '≥ 1.5 × 109 / L|Platelet count', '> 5 x ULN|Patients', '> 160 mmHg', '<100X109/L|hemoglobin <8g/dL|patient', '28-day', 'lower to 40mg/dl', '> 35 kg|Life expectancy', 'between 0-5 years', '> 30 ml/min per', '≤ 25', '≥ 15 mL/min/1.73 m*2', 'maximum diameter of a', '18-years', 'greater than 20 points.||', '> 3x reference', '>1000 ng/mL|White', '≥18 years|Patients giving their consent for the', 'greater than 9%', '0-1;|At least one', '>II', '≥ 10 g/dL.|Hepatic function', '>35 kg/m2|Active', '>1.5 x 109/L|Platelets', 'between 4 mm or more', '19 to 45 years|Body weight 55 kg or more', '>4 years old', '18 to 55 years', '< 1.6 mg/dL', 'less than 40 mg/dl', '<200 cop/ml', '11 to less than 18 years', '≥ 1000/', 'treatment;||Adequate BM function', 'lower than 82||', 'more than 80 puffs/week', 'between 4 and 18 years||', '3 and above', '≥45 kg', '≥ 30 grams', '65 mmHg', '< 30 ml / min', '≥ 5.6 mmol/L).||Hepatic', 'least 18 years', 'deficiency|Hyperoxaluria|Hyperuricemia|Haemochromatosis|Sickle cell anemia|Serum Creatinine', '≥ 189 mg/dL', '<6 months).|History', '> 25°', 'between non-paretic', '0-1|Expected survival time', 'between 18-40 kg/m2.|If', '< 1.7 nmol/L', 'less than 2x upper limit of normal.|ALT', '7-11', '17~36 mm', '<18 years|Emergency', '≥ 10 g/L', 'B', '1 to < 2 years 0.6 0.6 2 to < 6 years', '≥4% from baseline value', '≥ 354µM)|Mechanical', 'depressed', '>2.5', '≥18 and ≤64 years.|Current', '10-25 years', '≥ 28 kg/m2', '3 criteria|Age', '≥60 years|Diagnosed', '>= 120 mmHg)|History', '≥400 pg/mL', '<45 mmHg', '>35 Kg/m2|Stroke', 'functional class III', '≥ 25 and ≤ 40 kg/m2|Planned resection', '> 9%);|Diseases of the blood', 'greater than or equals to 8 mm', '> 180/110', '> 9 g/dL|Bilirubin ≤ 1.5 mg/dL|PT', '≥ 14 mmHg', '< 12 g/dL,|incapable of surgery', 'greater than 140/90 mmHg', '>= 1,500/mcL|Platelets', '<1.5×109/L', '> 30 kg/m^2', 'above 18 years', '=< 1.5 institutional upper limit of normal', '12 Years to 18 Years|Patient', '≥18kg/m2', '>1.5ⅹ109/L', '≤ 8', '95 mmHg,|50 bpm ≤ HR ≤ 100 bpm,|Or value', '≤ 20 points|General condition', '>8', '≥ 2.5 mL.', '6 or older', 'positive);|33', '>10 µIU/ml', '≤ 16', '≥18 years.|Proven', '<1.5 g/L|Haemophagocytosis found', '50-89|Do', '>2', '≥ 18 years|Able and willing to voluntarily complete the informed consent process.|Diagnosis of phenylketonuria', '<5.7 kg/m2', 'scores ≥ 22', '> 40|central nervous', 'between 20.5 - 45 m/kg2|between', '≥18 years;|Established diagnosis', '≥2 of', '≥7.5% to <10%|Part B', 'at least 3 mm', 'greater than 30 breaths per minute', '≥500 parasites/uL|Diagnosis', '≥ 190 mg/dL||xii', '≤ 5 times the upper limit of normal', '≥ 100 × 10 9 /L；③', '10^4 copies/mL', '18 to 55|Willing and able to provide', 'between the first anti-VEGF injection', 'less than 12 months.|Contraindication', 'less than 18 years or more than 40', '>= 70,000|Calculated clearance', '> 7.5|have a', '18.5 to 31.0 kilogram per meter square (kg/m2', 'Index score of ≥ 1|Agree', 'below 2.5 times the upper limit of normal', '<15 ml/min per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI', '= (140 - age', '> 23|no', '≥ 24', '> 19 but less than 40||', '> 18-year', '>160 mmHg systolic', '140-age', '< 0,59||', 'between 18.5', '> 4 weeks before study enrollment', '1-3,|No', '> 50% of scalp surface', '18 to 65', 'II-III class', '18 years and', '≥ 50×109/L;|There', '≥ 40g|IPSS score', '0-1||Adequate hematologic', '> 400 mL', '≥350 cells/ µl', '< 110 μmol/L', '< 75 bpm', '≥ 1);|Confirmed', '> 75x10ˆ9 /L', '> 140', 'less than six months', '< 18 yrs|T3-T4 staging|Unable to understand the verbal', '5 - 40', '20 years or more', '6-17 years old', '< 450 ms.||', '0-1;|without', '> 95th', 'score II', 'I-III|Mini-mental State Examination (MMSE)', '≥5.0 times the upper limit of normal (ULN)', '12-18|Speak English|Permission from pediatrician', '> 50 mm Hg', 'Females|Stage I/II', '>110 mmHg', 'greater than 140 mmHg', '2-4 x/year)|minimum of 10%', 'does not', '< 50 OR|Radiographic', ""25-30 kg/m2.|Don't receive"", '≥ 100,000/mcL|Total', '18 to 69 years,|Diagnosis of axSpA', 'above 55 diopters', '>500 ng/ml', '≥35; 2', '=< 3 x ULN|Creatinine clearance of', 'Above 18 years', '>90 days', '<100/nL)|Concomitant', 'score > 16', '≥1 time or', '> 160mm Hg systolic', 'above 35|Patients', '< 5 times the upper limit of normal', '≥1/week', '≥ 100 000/mm3|Hemoglobin', '<1,000 cells/mm3|Serum', '<16 years', '≥ 27', '10.0 g/dL)|Potassium', 'older than 2', 'above 5 mg', 'greater than 40mg', '5 to < 6 years', '>= 2 first-degree relatives', '<HAMA<21', '>40 kg/m^2|Estimated', '> 18 kg/m2|Listed', '>= 5.6 mmol/L', 'between 30-70|More than 6 months after the stroke|Able to walk more than 10 meters independently|MMSE score of 24||', '50% of total body cavity', 'score <20', '<= 50%', 'older than 14', '≥10% BMPC', '> 5 years', '>6 years', 'AIDS.|Dry', 'between 18.5 and 24.9 kg/m2', '>15 year', 'considering 20%', '=1 spirits', '< 20mL/min/1.73 square meter', '>= 9.0 g/dl', 'greater than or equal to 750/uL|Platelet count', '18.0 to 40.0kg/m^2|The', '1%≤AF burden≤99%', '> 2mg/dL', '<80 mL/min', '≥ 22 mmHg.|Patients', '≥ 50×', '<2.5 x upper limit of normal (ULN)', 'Low back or leg pain', '> 3 g/day', '>140 kg;|Body height', 'between 20-40', 'more than 10 degrees', '18-80 years|Diagnosis of', '24.9-29.9 kg/m²|Maintaining', '>440msec in', '≥18 years|Term gestational', '>60).|Participant', '≤ 2.|Female', '> 1.5 x ULN', 'Score ≥27)||', '> 240', '> 450 ms|PR', 'Alkaline phosphates', '> 20 minutes', '≥ 40', '> 35 mIU/mL', '>0.70', '25 to 40 years', '>= II|High', 'greater than or equal to (>=) 30 days prior to the day of screening|Glycated', 'none', '> 1|Hypertonic', 'above grade 1 related', 'score of 24 and above', '3-36 months', '≤ 1.5 x upper limit of normal', '>28', '3-6)|Presence', 'at least 50% of time in direct patient care|availability', 'below 60 kg', 'total T lymphocytes;|Voluntarily', '-15 to 30 degrees', 'above 8|Combined surgeries', '>155', '≥1.5×10^9/L', '< 2.5 x upper limit of normal', '<100 µg/l', '≥ 2|Uncontrolled hypertension', 'score of ≥70 or performance status', '≤ 2.3', '50 to < 95 mmHg diastolic.|Negative', '≤140 and', '18 to 69 years,|Day', '≥36', 'greater than the lower limit of detection', '≥80% of the predicted normal value', 'score ≥3);|with diagnosis', 'between 15 to 29(include', '3.0 g/dL)|Serum', 'more than 2kg', '>= 50,000 / Ul|Serum', '> 3.0 x 109/L', '> 30 mg', '< 18 years old', 'L1 therapeutic antibodies', '> 48h,|Readiness-to-wean', '0-2|No', '>50 years|Suffering', '≥ 4||', '12-leads', '≥ 20 mmHg', 'score of 5 or higher', 'between 19 and 60 years', 'above upper limit of normal value', '18-65 years|Type', '>=20 milligrams', '< 75|Clinically able', 'between 40 kg and 90 kg', '> 130/80) concerning to the treating clinician for', '= aspartate aminotransferase', '<15 mL/min/1.73m2', 'follows:||At least', '≥18 years|Histologically', '> 25 kg', '<7.5 mmol/L', 'above 20 years', '<35 kg/m^2||', '< 3,000 cells/mm3;|Suspected', 'high/high', '<60 minutes/week', '>300 mg/g', '1-Less than 18 years', '≥6 months to ≤12 years', 'under 100 IU/mL', '18 and 84', '≥ 30mL/min', '≥42 kg.||', 'QTcF ≤450 ms', '> 1.5×ULN', '≥ 18 years;|Naïve', '>= 1500 milligrams', '0-2|Consent', 'higher than the patient', '> pain score', '<1.5×109/L;|platelets <100×109/L;|hemoglobin', 'above dose level 4', '≥42 days);|Did', '≥ 18 and ≤ 85', '45-80|Diagnosed', '< 50ml/min / 1,73m2|Hearing', 'only)||Under 18 years', 'only:||At least 21 years', '≥ 40 ml/min.|Coagulation function', '10 years or older', '≥ 3x10^9/L', '≥ 65', 'less than 10 functional', '≥ 2+', '≥ 150 mg/dl', '≥450 msec for', '< 60 dB HL', 'above 800mg/m2', 'I-III|Children', '< 50 copies/mL|Stable', '≥ 50 ml/min;|Good', '1/2, PALB2', '>= 18 years||Patients', '18-70 ASA grade I-II', '= 7.5-14%|English-', '≤8.0g/dl', '≥ 45 years', 'at least 19', 'at least 6 months.|Fluent', '> 90 mmHg);|Those', 'class II to IV).|Evidence', '≤ 2.5 times the upper limit of normal (ULN)', 'question 9 score higher than 2', 'score less than 3;|Liver function', 'I only)|Be proficient', '>= 6|Willing to be randomized|Care', '<2000 IU/mL', '≤5 × institutional ULN|Total', 'greater than 7 days', '< 50 ml/min|Anticoagulation|RNI', '4|Ineligible', 'longer than 450 millisecond', '2022-2023', '50 through 69 years', '≥ 10.0 mg/dL', ""Children's Hospital"", '≥ 18 years|Diagnosis of', '≥ 8.5', '≥ 1 gram per day', '≥125 pg/mL when', '≥9g/dL', '>180mmHg', '< 2+', 'between 16 to 20 years old.|', '≤ 3.0 × ULN', 'between 40-70 years', '1.1;|Normal function', 'more than 3 bowel movements per day', '18.5 to 35 kilogram per square metre', '≥ 305 IU/mL)|Patient', '150/100 mmHg', '>5/8', '> 24 hours|intracranial findings', '3+7', '≥ 40|CAP score ≥ 250|10 ≤ TFC ≤ 13|TMS >5', '<500 IU/ mL', '2.00 to 4.00 mm', '> 3x normal)|Presence', '≥ 18 years.|Patients', '<18 and ≥80 years.|Shock', '2, 3 or 4|Who', '2-3 years', '>400 pg/mL', '25-30 kg/', '>= 40 kg/m2|Clinically', '18 - 80', '< 2.5 mm|Diabetes mellitus type', 'greater than 10 pack-years', 'Siblings||at least 18 years', '18 years or over|diagnosis', '< 12 months prior', 'between 2 and 17 years', '<18 years|Pregnant', 'lower than 2,000/uL', '< 3000/mm³', 'between 13 and 18 years old', '≥51 and ≤80 mmHg', '18-65 Pain', '≥ 21 and ≤ 80', 'at least 3 months;|7)The', '>=', '> 170 beats per minute', 'more than one site|Redo/follow-up', '12)|Race: 50% African American', '≥38.0°Celsius', '18-75 years|Symptomatic', '3-14 months old|Mothers', 'Age≥18 years old', '18 years and over|Able to provide', 'below 18 or over', '> 85cm', '450 ml or more', 'between 40 and 75', '30 - <40 kg/m2|Within 5% of', '≥ 6.0|Individuals', '≥20-pack-year', '> 60 mL/min/1.73', '0-1;|Major organ functions', '≥ 90g/L;|Blood', '<1 year,|3', '≥ 1,5;|Concomitant', '> 1.0 g', 'service more than six months||', '> 11 years|JIA', '≥80% tumor body burden', 'between +5.0D y +34.0D|Transparent', '>3%|Indication of', 'between 12 and 17 years old', '≥ 20 mm；|Left', '18.5 to 33.0 kg/m2', 'score less than or equal to 10 or||Patients', 'at least 10 kg', '20-35|Term pregnancies', '≥18 years|Histological', 'at least 1 years', '>2 times the upper limits of normal', 'long-term treatment', '30 to 65 years inclusive', 'greater than 4.5;|Vaginal odor;|STI', '>= 8 g/dl', '19 years or older||Inclusion', '< 30%.|Age', 'equal to 1|Serum presepsin', '7.5%', '2-45', '> 18 years|ruptured', '≥ 22 and≤90 years', '<15)|Severe', '21-45 years', '10 cm scale|BILAG C', 'less than or equal to 1.5mg/dL|Alanine', '35 years or older.|For GWI cases', '>= 50ml/min', 'greater than 100,000/mcL', 'greater than 1.5cm', '0-1.|Adequate hematopoietic', 'high-impact', '18 years or older|The patient', '6MWT.|At least 18 years', '15kg', 'above 65 years old', '≥10 pack-years', '≥2.8g/dL', '28-6156', '>160/100).|History', '≥18|HCT-CI < 3', 'over 30 kg/m2||', '<2 times UNL).|Patients', '< 3.0', 'between 18-110 years', '>34 mL/m2', '0, 1 or 2.|Presence', '40-74|Recent', 'between 18.0 and 30.0 kg/m2', '≤2.5 cm', '>1.5X ULN', 'HbSS', 'less than 0.5/Mb', '< 90 minutes', '< 2.3', '> 3 mg/mL', 'I ≥5 mm', '0-4', '20 PIE', 'score of < 19', '≥20 years|operable', '> 1mcg/kg/min)|Gestation|Current', '6 to 12', '>6/12 or >', '> 1000 copies/ml', 'less than 6 months|Contraindication', '≥200 ng/mL.', 'licensed', '< 95 mm Hg', 'under 50 years', '>= 100,000/mm^3|Total bilirubin', 'less than 21|Age greater than 65|not', '50-68 years', 'no more than 15', '>2 times upper limit of normal)|Those', 'positive 4', '>37.5℃', 'greater than 0.65|Be able', ""<95%,|renal impairment,|allergy to any of study's drugs,|history"", '> normal', '>600ml', 'CRCL≥60mL/min', '8-13 years|Children whose parents/guardians', 'less than 35', '<100 g/L;etc.||3', 'C)|Other indications', '14-26', '> 45 mmHg', 'equal to 60 years', '≥ 8g/dl;|Renal function', '=<1.5 ×ULN', '> 30%);|history', '- 60 years', '> 10%.||', '> 35 kg/m2|Whole blood donation of 1 pint', '1 year', '<10 g/dL|Bone', '≥50 mmHg', '>140 mm Hg systolic', '> 5 minutes', '≥3 months;||7.Eastern', '<1.5 x 109/L.|Platelet count', '21 years, able to provide', '>100||Prior HBV vaccine', '< 15 mL/min/1.73 m2', '> 2 times the upper limit of normal|Platelet count', '< 85 g/L.|Post', '<90 mL/min/1.73 m2', '>3 mm', 'from 6 to 18 years.|The children', '> 55 mm', '< 10 %|Physically able', 'less than 18 years.|Immunosuppression', '> 12.5 g/dL', '3 ≤ WISCI', '≥ 350', '< 35 kg/m2|Elective surgery setting|Clean wound field', '1.5 to 3.5 mm', '<5.7', '≥ 9.0 g/dL.|Hepatic function', '≤ 2.5 times the upper limit of normal.|Kidney', '≤ 2.5 x ULN.|Calculated', '<1.5 X the upper limit of normal', 'status|Younger than 18 years', 'over 6 years old need oral consent', '≥ 1.0', '≥18 and ≤65 years.|BMI ≥18 and ≤35 kg/', 'turns 50 years', '> 50 mL/min|Serum', '>15 mm', '≥ to', '> 7% and ≤ 10%|eGFR ≥ 60 mL/min/1.73m²;|Able to provide', '45 to 74 kg|Elective upper limb surgery', 'not <1.5 cm', '≥ 135 g/l', 'nicotine patches', 'between 32 weeks of amenorrhea', '>18 years|Previous diagnosis of EoE', 'under 70 years', 'months;|Patients', '<95 millimeters', '<14|IPSS score', '<=2.5 X institutional upper limit', '< 8|Score', 'at least 7 days must', '18-75|Being exposed', '<80', '<1 years.|Pregnancy', 'higher than 160 mmHg', '>110mmHg)|Expected survival', '≤ 1.5 x IULN', 'between 30-80', 'more than or equals to 6.1%', '<150*109/ml', 'pregnancy|full-term', 'from 7 to 14 years old', 'between 18.5 to 34.9 kg/m2', '23 or higher', 'greater than or equal to 18,|Untreated ES-SCLC patients|Provided written informed consent||Histologically', 'more than 3 units', '≤', 'x 100 <90%]|Infant', '25.0-45.0|Not able', 'equal or more than the', '18-65|giving consent', '60 minutes.||Persistent', '< 90 g/L);|Patients', '≥3 times the upper limit of normal (ULN)', '≤ 90', '≤ 18', 'at least 10 pack×years or more.|Those', '1 day on the basis of the last application date.).|Subjects', 'over 35', '>50 x109/L|Estimated', '4-10×109/L', 'under current litigation.|Is', '<30 ml/min./1.73', 'below such thresholds', '>30 kg/m2;|Allergies', '<18).||Active liver disease defined', '65 years|Patients', '≥ 30 packs/year)|Absence', 'age|Older than 18years', '>= 0.2', '≥0.60', 'less than 2+', 'toxic potential', '≤ 8.0 mm', '> 30);|Patient', 'between 30 and 70 years.|Subject', '18-35|Able to understand written', 'less than 2 months;|Unstable', '60-90 beats/min', '< 60 ml/m2', '≤ 28 days before treatment.|Previously', '18-65 were included', 'between 14 to 28 weeks pregnancy.||', '≥ 2× the upper limit of normal [ULN', '<100 x 109/L Hemoglobin', '< 2.5 x ULN|Serum', '≤ 2.5x ULN|Adequate renal function', 'from 25-34.90 (Kg/m²', '≥ 65 years;|Body', '30% to 50%', '>/= 18|Physician-', 'above 1.2X upper limit of normal (ULN)', '=< 5 mg/day', '<40 kg.|Current', 'between 25- 45 kg/m²', '< 10s;|Fluorescein', 'II to IV|Has', '≥100 mm', '> 6);|diagnosis of Long Covid', '18 and over||', '≥ 0.75)|Normal', 'between 6-10,|To receive IV treatment upon the request of a', '<18 years|Acute myocardial infarction', 'less than 10 seconds.||', '> 8.0% and < 12.0%|Willing to use', '140 - age', '>1.25 x ULN|AST>1.25 x ULN|Creatinine', '< -2.0', '>= 100,000/mm^3|Serum', '< 1,3 mmol/l', '> 50mm|Moderate', 'between 26 and 75 years', '=< 2 weeks', 'less than 80% of predicted value||', '18-70 y|Ejection fraction', 'older than 55 years.|Volunteers', '< 45mL/min/1.73m2).|They', '≥18 years;|Evidence of', '> 175%', '> 10 mg/day', '< 15mm', '6 or higher', '<10 ng/ml).|Concurrent', '≥75 x103/L', '<6 months', '≥ 0.5 cm', 'Functional Class III or IV', '≥ 200/µL', '50.0 kg or more', '> 6.5 mmol/L|triacylglycerol', '2013-2020', '>=1D', 'between 18.5 and 30.0 kg/m2||', '25-30 kg/m2', '≤1.5 x ULN*|ALT', '≥ 160', 'interval ≤470 msec', '≥50% of the liver|Severe', '≤2.5 x ULN.||', '18 or older|Meeting', 'within 50.0 to 100.0 kg', '>=60', 'greater than 350', 'polyneuropathy|More than one lifetime event of', '≥ 120', '12-47 months', '≥ 10%', '> 45 years-of-age', 'at least 300 µm', '≥150 ms', 'older than 90 years', 'less than 18', '< the fifth percentile).|Previous', '50-90% diameter stenosis', '3-10', 'under 50', '≤ 5 × ULN.|Cannot', '>2.0-5.0×upper limit of normal range)|Participation', 'less than or equal to 40 ml/min/m2.|Contraindication', 'above 18 years old, regardless of gender;|2', '< 20 or >80 years', '00.|Able to give informed assent', '>160 mg/dL|Vaccination', 'less than one year|Inability', '≥6 months;|Organ function', '> 350 cell per μL', 'between 40-100Kg', '>60mL/min', 'or 3.0 mg/dl', '> 2 X upper limit of', 'scores', '<50 years||', '≥ 60%', '≥18 years|VAS pain level', '27 kg/m2', '≥21 years|Outpatient', '≥ 18 years', '19.0-26.0 kg/m 2 (inclusive)', '≥140 and <180 mmHg|At 4 weeks from', '<50mg/dL', '<=1', 'less than 120 mmHg', 'less than 0.70', '18 - 85|60', '≤ 1.5;||', '18-54|Female|Pre-menopausal|Can', '< 10mm/5 minutes', '<18 years|Inability to provide', '≥10 points.||Exclusion Criteria of the previous', 'between 6-12 years||', 'greater than normal', '≥ 25 kg / m2)|Willing', 'between 18 and 55 years', '>=60 mL/min/1.73 m^2', '< 90mmHg;|SBP drop ≥ 20 mmHg', 'equal to or greater than the standard dose', 'not more than 1 line', '>70 dB HL', 'less than 15', '≥ 6 months.|Agreement', 'more than 210 grams per week).|unable', '>= 60.|Willing and able to adhere', '< 480 ms||Is able to swallow oral medications', 'Diseased', 'from 18 to 60 years||Amsel criteria', 'score 0 or 1', 'less than the duration of the', 'need intrasinusal pyelolithotomy.|Patients', '20 minutes of the Lincoln/Omaha', '> 5 times the upper limit of reference range', 'over 75,|More than 3 days from the onset of an', 'greater than or equal to 70 g/L', '> 14 and ≤ 50 years old.|Rule', 'years and older on Day 1|Judged', '≥3 months.|Eastern', '≥ 50.|Patient', 'between 18-80 years|Time of onset: within 1 week|NIHSS score', 'older than 18 years|One', '> 21 units', '≥50 kg;|The volunteer', 'less than 2 mL', '> 5 norms', '+/- concurrent', '≥ 25 degrees', '20-30 minutes', '≤1.5-fold the ULN of the study site|Creatinine', '>= 22 years|Known diagnosis', '≥12 weeks.|5', '> upper normal limit (ULN)', '>10 %', '20 to 25 kg/m.|Being', 'measured 2mm', '<10 g/dL', 'BM relapse', 'greater than the laboratory upper limit of normal.|Other factors', 'polymer-free sirolimus-', 'younger than six years', '> 4|Presenting', 'more than three times per week', '>18""||', '>= 12 months prior to screening', '≥ 300 mg/day', '>=3 scores|lung', '≥ 18 years.|Patient', 'maximum exercises or', '> 125 pg/mL', 'twice the upper limit of normal', '> 3.4', '15 years old', '18 years and older;|Understand the content of the ICF', '18 to 65|Meeting', '<150 minutes', '18-45 years|pregnant|attended', '3 or greater', '= 0.85 x male', 'less than or equal to (≤) 750 micrograms(μg)/Liter(L', '>= 60%.||RECIPIENT', 'above 1.5 x ULN.|Active hepatitis B virus', '≥ 130 mEq/L|Age', '≥ 100 x109/L', '1 = thick/yellow', 'women|Aged 60 years or older', '0 to 2|Histologically', '1.1;|Female patients', '12-18', '0 or 1.||Histologically', 'above the detection limit', '3 times or more the upper limit of normal', '18-55 y|Individuals can give', '≤ 1.5 x ULN||Creatine phosphokinase (', '≤ 1.5 times ULN;|10)Female', '≥ 140', '≥ 80 × 109/L', '≥ 12%|History', '≥ 50% / Troponin I', '55-70 years|Formal diagnosis', '≥38.0 degree Celsius', '≤ 90 percent (%)', '> 2.5 × ULN', 'less than 15 years duration', 'less than 3 months;|Unable', '>52 ng/dl', 'between 120-169 mmHg|stable dose of medication', 'negative', '≥ 18|ECOG Performance Status', '0 or 1.|Measurable', '2 or more times from the upper limit of the norm;|Alcohol abuse', '> 18|Signature of the informed consent||', '˂50,000/μL', '≤35 kg/m2.||', '≤ 100 U', '> 150 kg', 'between 19 to 65 years|The', '110 lb)|Evidence', '19 to 55 years', '> 200 U/L', '>15)|Nocturnal Paroxysmal', '18-75;||Inclusion', '1 to < 2 years', 'greater than or equal to 95th percentile', '60-90 mm/Hg|not', '< 7.30', '≥30 mL/min/1.73 m^2|Unequivocally positive', '0 to 25 dbHL', '≥20|TRD - failure', '>/= 60 years', '< 3 times of the normal value', '>1.0 x 109/L', '≥18 year', '< 7.|History of', '> 50 %', '65 and older', '> ULN;|Alkaline phosphatase', '>20 ml/min/1,73m2||', '≥ 1.5×109/L;|Platelet count (PLT)', '50-93 kg', '≥ 38SA', '<= 2.5 x institutional upper limit of normal', 'between 18.5-24.9kg/m2.|All', '≥90 diastolic)|metabolic syndrome|renal disease|chronic respiratory', '>= 60%||', '1.7', '>5|experimental', '4-18 years', 'between -1.0 and -2.5', '18-70', '>sm1', '16 or 17 years', '18 years of age', 'greater than 30 mmHg', '10/01/2013 to 09/30/2022)|At least 18 years', '1.Histologically-', '40 kg/m2|diagnosis of', '18.5 to 45.0 kg/m2', '35 to 45 kg/m2||', '19-24', 'less than 30 cm', '> 2.5 x UNL', '> 450 mL', 'transfer|More than 2 doses', '≥15mm', '>7.0', '6 years old', '> 80', '>2mm', '< 5X ULN|Platelet count', '≤ 7.5 mm', '3-70|Diagnosis of r/r', 'long-term opioid', 'I-II:||Adult.||No', '= 6.5-11%', '11-17 years', 'between 18 and 65', '≥2 ULN|White blood cell count', 'between 50 and 60 years', '1 or less', '18 - 80 years', '≥ 1.5 × 109/L|Platelet', '≥ 50%.|Diffusing', '≥ 1.5 times the upper limit of normal (ULN)', 'between 40.0 and 90.0 kg, inclusive', 'over 45)|Able to understand information sheet', '> 1.5 to <= 3.0 × Upper Limit of Normal (ULN)', '0 to 1.|Female', '> 4mm', '≤ Grade 2', '> 10mg/day', '≥2,000/mm3', 'at least 37', '40 - 89', 'I-IIb', '> MoCA score', '0-1;|Adequate', '6 months to 25 years', '≥1,000/mcL|Platelets', '25 - <60 years|BMI', 'more than 24 weeks', 'from 15 to 65 years', 'between 18.0 and 32.0 kg/m^2', '2-4', '22-79|Diagnosis', 'score of 4+', '0 - 2', 'no more than 150 μmol/L', '>38°C', 'score of 0 to 2;|Confirmed', '>1.5 times the upper limit of normal (ULN)', '21 years or above', '< 35%', '≤ 2.5 mg/dL', '> Grade 2', '>1000/mL|PLT', '100,000 /L|Hemoglobin (', '5%, cream', 'between 25 - 29.9)|Agrees to be audio', '≥ 18 years||Ability to provide written informed consent', '>5 years|World Health Organization (WHO) performance status', 'no more than one', '0-1.|Participant', 'greater than 3 ng/ml.||', '>3 mmHg/L/min', '>130 g/l).||', '< 150mmHg.||', '>7.5%)|BMI ≥ 25 Kg/m2||', '>ULN;|HCV antibody(+', '≥40 ml/min/1.73m2', 'between 50 and 80', '= Per study staff discretion', '< 1,500 /μL|Lymphocytes < 800', '< 38 kg/m²', '≥ 2 mg/L', '> 3 times the upper limit of normal);|Patients', '≤ 12 months;|Participation', 'at least 1 parent/legal guardian to consent', '>5x109/L', 'between 50', ""under 18 years old, the patient's parents agreed"", 'greater than or equal to (>=) 18 years', '≥30·0 kg/m2', '>1×', 'at least 19 years', '< 45', '<10g/dL||functional', '> 24h|Patients', '>60%|Serum involved/uninvolved', '>=35 years', '≥18 years|6.5%≤HbA1c≤11%||Clinically', 'Older than 60 years;|Completed 6 or more', 'reproductive', '< 10x ULN||Adequate Renal Function', 'Under 18 years old|100 years', '<60 ml/min/1.72 m2', '<5', '100 U/mL||Study-specific inclusion', '18~80 years old', '≤ 1.5 upper limit of normal', 'B-C)|History', 'more than 20 mmHg|More than two', '<7.4mm', '<16mg/mL', 'upper limit of normal', '18.0 to 30.0 kilograms per meter square (kg/m^2', 'between 18 and 25 kg/m2|Masters', '280 dB/m', 'below 50% or below the lower limit of laboratory test', 'score of 17 and below', 'before 37 weeks', '1 or 2;|children', '≥18 and ≤ 65 years', 'mainly', '>15° varus/15°', 'more than one month', '18-30|Free', '<100x109/L)|Constitutional symptoms|Maximum', '> 21', '3 ng/mL', 'less than 80 g/l', 'functional class II, III', '≤ 1.5 times upper limit of normal', '≥ 90', 'worse than Snellen', 'between 28 and 35 kg/m2', 'Type I', 'at least 15 degrees', '>2.5 mL/day', '>60 up to 80 years', '> 9g/dL', '≥ 60 years;|diagnosis', '<4.00 ng/dL', '< 25,000/mm3', '< 20 ng/mL.', 'fewer than 12 months', '0-2||', '<23', 'greater than 18 years old and less than 80 years', '≥ 24weeks||', '≥100×10^9/L||Bilirubin', 'grade II or III', 'score of 4-8', '>=5)|those who', 'CD1a+', 'does not occur.|The', '0 or 1|Has measurable', '2 to 18 years', 'below 34 weeks', 'students|age 18 years', '|Severe', '≥61 repeats', '30 to 34', 'III-IV|Presence of peritonitis', 'equal to or less than 20mm).|2', '< 30 days;|Presence', '≤30 mL/min', 'above 30', '50 milliSieverts', 'greater than 6.0 mg/dL', '<100 g/L.||', 'not older than 2 weeks', 'patients|50 years', '< 40g|Existence', '≥1.5×109/L;|Platelet', 'less than (<) 90 mL/min/1.73m^2', '<3.0 x103/μL)|Persistent', '>=18 kilograms per meter square (kg/m^2', 'score < 1.9||', 'Participation', '> 40 mL/min', 'personal experience', '0 to 6 D Distance', '<60 ml/min/1.73m2', '≥90g/L', '≥ 80 × 109/L;|Biochemistry', 'more than 65 years', '< 12 months|On waiting list', '>18 years|Have', '≥350 pg/mL', '2 to 4', '</= 45', '>4.|Inability to undergo', 'less than 18|inability to understand English', 'less than 35 kg/m2|Subjects should be able to understand the', '≥ 100).|Any', '6 months to 9 years', 'functional class IV;|Severe', '≥110mmHg|Acute myocardial infarction', '≤ institutional ULN', '12 to 16|With', '>30 mg per day equivalent diazepam|Current daily', '> 6 months;||', 'assistance - with', 'between 18 and 65 years|Scoring', '25 - 29.9 kg/m^2);|Owns', '< 50 × 109/L', 'does not change', '≥2cm proximal', '≤30 kg/m²', '> 35)|unstable', 'between 19 and 64 years|American Society of Anesthesiologists physical status', '≥ 2.5 mm', '9-12|specialize', 'between 18 and 67 years', '<50%；|Atrial fibrillation', '7-30 days after injury|Injury level', 'oxygen', '5 to 77 IU/', 'greater than or equal to 5.7 percent', '≤ 1800 g).|Prenatal', '<6 months prior to first dose).|Have', '<18 or > 40)||Have received', '45-70 years|Body mass index', '> than 50 units', '> 18 years,|Patients', '>90×109/L', 'outside the reference ranges', '-mutated', '≥ 40 kg/m2', '≥ 2 g/dL|Female', '<45 mL/min/1.73 m2|Type', '≥ 9 points', '18-50 years.|Participants', 'greater than 75 years', '5 and 70 years', '>20ng/mL.', '≥30', 'between 18-70 years|APACHI II is', 'is:||Greater than Class I', 'equal to or greater than II', '< lower limit of normal', '≥18 years|Patients followed in medical oncology', 'parental/guardian consent', 'functional class', 'less than 4|Age 40-80 years', '18 - 60 years', '> 30 minutes', '>18 years|>1', '≥ 9 g/dL|Creatinine', '>= 70%||Documented', '≤6.5%', 'less than 18 years', '0-1.|Subject', '≥ 35 ≤ 85 years|body mass index', '≥ 2 years|Lansky', '> 30;|Comorbidities', 'Stage II to III', '17 years.||', '0-17 years|Access', '>1 that', 'at least 12 weeks.|World', 'less than 18 years old must provide written assent', '<21.|Participant', '≤ 18 years|Refuse to participate', 'above 60|Histologically', '1-2|Body mass index', '≤ 3.|Coincident', '0-2|Patients', '≤ 50 × 10^9/L', '<50%|Systolic blood pressure (BP)', 'longer than 3', '< 110 μmol/L|T3', '11 or higher', 'at least 5 weeks prior to first dose of study product.|Participant', '20-49 years', '9-12|had', '> 4|Beck Depression', 'between 18.0kg/m2', '18 to 40 years', '> 3 x upper limit of normal', '35', 'exceeding 150mnts / week.|Symptomatic', '<30 breaths/min', '<=5 × ULN', 'Stage 1,2 or 3', '18 years or older.|Presenting', 'equal to 17 years', '<18 years old', 'above 40°C', 'outside the reference range', '≥ 70 mg/dL|Patients', '+/-10 years', '>5.7||', 'I-III|Between 40-85', '≤ 2.0 mg/dL|Confirmed', 'between 30 and 60 years', 'Obesity class II', '2.5 - 7 years', 'less than 2 weeks before vaccination;|Participation', '40-100 mmHg', '> 1.5 x UNL associated', '> 2.5)|In', '18 to 90 years', '>21 kg/m2', '>1.2 ULN', '< 4x109/L)|Clinically', '>= 1 week prior to study treatment|Substrates of CYP3A4/5', 'between 18 and 27kg/m2', '75-175 nmol/L)|eGFR', '6 months and above', 'Infants:37-41 weeks', '≥ 17|Terminal phase', '< 4;|BMI ≤ 45;|Patient willing and able to provide written informed consent', '> 1.0cm;|ECOG score 0-2;|Bone marrow function', '1 to 3.|Body mass index', '≥ 20 kg.|Performance status', '< 50 beats per minute', '<8.5 hours', '< 37 weeks', '< 10 x ULN|Serum', '≥ 18 years;||Patients', 'more than 37°C', '30 to 55 years', '>2 grades;|10', '28 th- 30th', '35-', '18-75 years;|Primary breast cancer', 'equal to or over 35||Hospitalization', '>= 3,000/uL.', '> 1000 IU/mL', 'between 18 years to 60 years', '≤ 4.00 g/L|Subject able', '0-30 +/- 10 degrees ankle plantarflexion', '≤2.5 × institutional ULN|Serum creatinine', 'from 70 to 75', '≥6.2mmol/L', '≥ 18 years||Patients', '15 cm.|Uterine size', '>95 mmHg)|Morbid', 'between 18 and 40 years.|Maximal', '< 24 months|pregnancy', 'Over 45 years', '< 60 A.U', '> upper limit of normal (ULN)', '>150 μmol/l', 'Younger and Older Adults||Age', '>5 times the upper limit of normal', 'more than 7', '> 100 mm Hg diastolic', '≤ 3.0 x', '≥1.5×109/L|Platelet', 'longer than 3 years', '>60 mm', '≥60,', 'over 20 mg/l|patient', 'between 101 mL to 449 mL', 'less than five years', '≤ 30 mg/day', '27-30|Who', '20-60 years,|Agreement', '>18 years,|Those', 'between 19 and 70 Male', 'A class', '<3 seconds', '≥ CTCAE', '1.1', '6-17-years|Presence of overweight/obesity|Youth', '> 2 cm', '≥ 26.5)];|Ability', 'over 450 umol/l|signs', '> 1.0cm;|ECOG score 0~2;|Bone marrow function', '≥75 mg/day', '≤ 1.29 mmol/L', 'between 18-65 years.|Employed working within', '>100mmHg)|Hypotension', '<35%|Liver function tests', '≥ 45 mL/min', '> 10.0 mm|Proximal', '< 34 weeks', '5 -10 % predicted', 'are||≤ 50% of the normal predicted values.||Oxygen', 'score of 133 and above after being screened', '< 30|Concomitant antiviral therapy', '5% or more', 'between 32 weeks of amenorrhea and 36 weeks of amenorrhea + 6 days', '>1.0g.|Uncontrolled', '=< 2.5 x ULN|Left ventricular ejection fraction', '× 0.85/72 × serum creatinine', '40-70 years|Agreed', '28-', 'at least 1.0', 'ranges from 18-50 years', 'less than 88%', '19-35|Confirmed ovulation', '< 18 kg/m2|Extremely', '>=12 weeks after completion of HCV therapy', 'longer than 10 years', '>= 500/mcL||Platelets', '> 55 regardless.|History', 'between 20 and 65', 'score of 0 or 1||Adequate organ function', '≥1 month (30 days', 'over 18 years||', '≤ 2|Patients', '>= 1500/mm^3|Platelet count', 'between 10-36 months', 'II-V MTP bilaterally).|Patients', 'from 4,000 to 10,000 cells/mm³', '≥ 1.0 x 109/L', 'Stage I-B3', 'above age', '≥ 3 months.|No', 'negtive', '18-65 years', 'score of 4 or', 'less than 1 year|Patient', '140-160 mmHg', '2 cm between the tumor', '20-45', '38 - 42', '>100 or <40 bpm.||iii', '≥20 g/L', '≥18 years|An', '> 30 ml/min/1.73m2.||', '5% - 19%', '<50 kg.|Any significant', 'shorter than five years;||Abuse of products;||Alcohol', '34 - 36 weeks', '<8 g/dL|Absolute', '≤ 3', '≥18|Signature of Informed Consent|Advanced', '<40 beats per minute.|Positive', 'individuals|18-35 years', 'less than 1 month', '> 3x upper limit of normal (ULN)', 'exceed these ranges', '> 2 upper limits of normal', '<= 2.5 x institutional ULN', '0 or 1;|21', '<70 × 109/L|Pulmonary', '> 450', '>= 14 days after the last dose of a', '<chronic kidney disease', '47 to 100 beats per minute', '12-24 years', 'less than 23 days', 'between 18 and 35 kg/m2', '> 1.0 diopter|Uncontrolled diabetic retinopathy|Iris', '<1.7 mmol).|Parental refusal to participate', '>100,000/mm3', '>2;|Allergy', '>= 60%|Histologically', '≥ 350 mg/', 'less than 8 mm', 'between 0.7 and 1.3', '> Grade 3 dysphagia|Presence', 'greater than 4 square centimeters', '<2 x 30 min/week).|Age', 'between January 2017 and January 2023', '> 48 mmol/mol', 'above 150 systolic', '> 280 lbs', '18-65||', '21-32 years', '6-10|Received', '≤ 5.5||', '< 19 or > 40 years.|Height<150 cm', '>= 20|Histology proved', '18-39 years', '15% of body weight.||EXCLUSION', 'older than 24 hours from time of', '≥ 140mmHg', '> 190', '18 to 60 years|no', '0-18 years.|Pediatric', '≤ 90.0', '> two times upper reference', 'below 45mL/min/1.73 m²).|Patients', '> 160 mmHg|Resting', '≤ 3000 ng/mL', '≥ 23kg/m2', '≥ 1.5 × 109 / L', 'greater than or equal', '65 and older|Undergoing non-cardiac', '150 ml of wine)|Those who smoked more than 5', '50%', 'exceeding 2000 IU/ mL', '≤ 50%', 'greater than 45 kilogram (kg)', '< 7 days before the start of the study|Use', '> 5.18 mmol/L', '> 10|Patients', 'between 40-60 years.|All patients will suffer from post mastectomy lymphedema.|All', 'Grade II-IV', '1x10^4 copies /mL);|Human immunodeficiency virus', 'greater than or equal to 35)|High', '<100/min)|Patient', '≥ 18 years|BMI', 'higher than or equal to 85mmHg', 'at least three months.|Patients', 'between 24 and 28 weeks', 'greater than 32', '<92% in ambient', 'less than or equal to 2.0 mg/dl|Room', '80% predicted and above', '0-2||Exclusion', '>20%', 'between 6 and 12 years||', '≤ 30%', '>11.1 mmol/L', '25.0 to 45.0', '1-3)|Possible', '22 to 45 years', '>72h and less than 7 days of disease', '0-1|At least one', '>50 kg', '≥ 7.0 mmol/L)|Gastroenterological', '18 and above who can provide', '50-100 beats/minute', 'Younger and', '>4 x upper limit of normal', '105 or older', '<11.0 g/dL', '≤ 2.3 LogMAR', '16-34', 'marrow function:||Hemoglobin', '<10 g/dL|HbA1c', '≥ 4/10)|currently menopausal', '> 8.0 g/dl|Platelet', '> 10x', 'class III or greater', '≤ 2.5×upper limit of normal (ULN)', 'interval', 'between 25-45;|Overweight population', '≥ 12 years|AD', 'grade II or greater', '< 50', '< 75 years', '18-49|Not', '0-1.||Participants', 'z-score', 'partial remission (PR)', '> 34', '≤ Level 1', 'between 18 and 30 kilograms/meter', '<10 g/dl)|recent', '< 3', 'after 2 or more', 'between 32+0 to 36+6 weeks', '<18 and >55 years|Individuals', '≥5.3 mm', '>20 years old', '>7 days).|Patients', '<5 cig/day', '> 120bpm)|Atrial fibrillation', '< 100*10^9/L.|Hemoglobin < 90g/L.|Serum Creatinine', '+/- chemotherapy|18 years', '> 8%.|Patients', '≥ 5.64 mmol/L', 'pregnant', '30 to 40 years', 'score ≥ 11', '<38.5°C', '>= 19 years|Biopsy confirmed', '<30mL/min', '0 or 1;|Appropriate', '<10%.|Trial participants', 'at least 3 months||Women', '<0.05 Snellen|pregnancy|missing informed consent form', '≤ institutional upper limit of normal', '< 50 mL/min/1.73m2', '18+ years.|Understands Danish or English', '> 176μmol/L;|Any', 'above 37.5', '≤26 kg/m2|Three', '≥ 290 µm', '≤ 30 cc', '≥ 18 years.|Understand oral', 'greater or equal to 30 mmHg', '< 24)|Need', 'lower than 70 mm Hg', '< 20 °', '≥ 80x 10^9/L', '= 0mm/5min', '>18 and <75 years||', 'less than 30%', 'more than or equal to 18 years|American society of Anesthesiologist 2', '< 80 × 10', 'at least 2 months prior to the start of screening', '< 90/50 mm', '>3 months', 'between 25-55kg/m2|English', '≤1.5-fold the ULN of the study site Creatinine', '≤ 2.5 × upper limit of normal', 'between 6 and 36 months|Toddlers', '< 18 years.|Lack of cooperation.|No', '≥50%;||The level', '1.1/RECIL.||I-7', '0, 1 or 2', '≥ 90 × 109/L', '< 90ml/min/1.73 m^2)|daily use of', '> 40ml/min', '≥16 years', '>13', '≥ 70%.|Patients must', '>4|Patients', 'class II or', '< 30 mL/min/1.73 m2', '>60 mL/min', 'inherited', '≥ 100g/L;||White', '≥4 cm', '≥6', '2.87 mg/L', '18-65 years|Diagnosis', '≥ 75,000/mm3', '≥90 g / L Note', '≥1 day/month', '> 3 x the upper limit of normal range (ULN)', '3 times or higher than upper normal', '18-60 years.|Be willing and capable of giving informed', 'above 50.0 kg', '>80 years|known', '1:1 patient observation', 'B-cell', 'above 160/100', 'from 18 to 24.9 Kg/m2)||', 'higher than 100 BAU/ml|The ability', 'less than 6', '0.2-0.7 mg/dL|Creatinine', '90% of patients', 'under 160mmHg', 'greater than or equal to 2 weeks', 'of III or IV', '≥ 37.5°С', '2 - 18 years', '-24kg/m2', 'less than 6 months old', '20-80%)|Inclusion criteria', '≥ grade 4', '≥Grade 3).|Prior', 'upper limit of normal);|Aspartate aminotransferase', 'Under 18 years old or above 99 years', 'above 3|Agree to participation and fill', '> 3.0 mg/dL', '≥65 years old, regardless of gender.|The patient', '400 μm.||', '>11 units', '6%', 'at least ≥2 ng/mL above the nadir', '< 134 or > 148 mmolL-1||Women', '<=2', 'at least 60', 'More than 18 years', '> 2 mmol/L', 'between 4.5 and 24 hours|Informed consent from the patient', '≥3.|History of', '18 to 40:||absence', '>/= 15 mm per short axis', 'at least 10/10th in binocular.|Ability to give consent', '≥90cm', 'Stage II-IV)|underwent surgery', '570 mL of beer, 750 mL', '≥ 3.0 x 109/L', 'between 25 to 48 years', '< 48 h||', 'II-III||', '> 10 mmol/L);|Urine', '< 1000 copies/mL', '55 years or older', '> 5,6 mmol/L|Elevated', '<=40%', '18 to 90 years.|Patents', '>14 units/week', 'twice weekly', '≤ 7.|Sufficient organ', 'between 20 to 65 years', '≤ 10000/uL', '>1.5 × institutional ULN', 'complicating', '≥1,500/µL|Hemoglobin ≥8 g/dL|AST', '≥ M2', '20-30 kg/m2||', '40 and older', '250 mL) beer', '35 mcg/min', '>82.5%', '20-75', '18-75y', '= eGFR（CKD-EPI）×', '20 minutes|Able', '≥ 1 mm', 'more than 20', 'at least 6', '≤ 15 cm from the anal', ""5' < 7|Bayley Cognitive Score < 7|Presence of certified diagnosis"", '<140 k/mm3|Hemoglobin', 'less than one year|Solitary kidney', 'between 3.3 × 106 copies/mL to 6.6 × 106 copies/mL|Female', '<0.15x10⁹/L', '18 and above presenting', '≤ 2|Time', '2.5 and 0.5 month prior to hydroxychloroquine treatment', 'less than 2.5 times the upper limits of normal).|The patient must willingly provide written, informed consent after being informed of the procedure', '> 18 years.|Naïve', '≥ 2000/mL|Platelets', '> 180/110mmHg after treatment);|Patients with previous patent foramen', 'from 30 to 65 years||Completion', '< 11', '<27%', '18 years onwards|Signed written informed consent', '≥ 18 and ≤ 85 years old', 'more than 90%', '0 ~ 1 in the', '18-55 years||Parental Inclusion Criteria:||Couples', '≤ 2.5 ULN', '≥ 18 years;|Patients', '≥ 18 years|Non', '< 350 cells/ mm^3', '>30g/day)|Pregnancy', '>100 mmHg;|Stroke', '≥ 1.5 K/cumm|Platelets', '≥50mL/min', 'retching 24 hours before chemotherapy;|Use', '≤2 times the ULN if there', '5-17 months', '<12 months).|Patient', 'no more than 3', '<24h', '18+|Non-cancer', '≥ 40 ml/min/1.73m2.||Cardiac', '≥ 50%', '≤1.6 mg/dL|Total', '0 or 1.||Subjects', 'less than 13.8g/dL||Participants', 'over 2.0㎎/dl).|20', '>50 pg./ml', '0-2|Adequate organ function', '≥ 4 and ≤ 8', '0-3|Life expectancy', '≥140 g alcohol/week', '= 80', '>200/μL)|known', '≤2 mg/dL', 'complete remission (CR)', '> 470', '> 140 metres|Patient-specific', '>90 or <50 mmHg', 'mutation.|NSCLC', '>95 mmHg', '> 90 mL/min', '>200 mmol/', '< 18 years;|unconfirmed diagnosis', '8 to 10|IPSS Score', '≥ 2.8g / dL', '>3.14', '≥ 18 years.|Karnofsky Performance Status', '≥18 to ≤60 years||Additional inclusion criteria', '25 to 80 years', 'above lower limit of normal', '18 years - 60 years', '+ 0.92 (', '18 or above|Smoke', '>80 g/L', '>120 g/l', '> 40|Patients', '0-1.||Patient', '≤ 10mm/5min', '<2500 g', '18 to 70.|Subjects', '0-2|Patient', '7-17 years', '> 250 mL or', '≤ 1.5 × ULN.||', 'metastases.|7', '60 years', '=< 1.5 mg/dL', '≥27 kg/m2', '≥ 5 /', 'less than 3 months experience', '>1.5 mg/dL', 'score of ≥ 8;67|3', 'between (10-50)||', '= serum glutamic oxaloacetic transaminase', '<0.3', 'female|Over 18 years', 'hypertension≤ 160mmHg', '>= 5 mm', '>18 years', '0 to 3', 'less than 4 weeks prior to inclusion', 'Younger than 44 years', '>1.3', 'I-II', 'more than 12 weeks;|The', '≥120 g/L.|SF', '0-21', '50 ≤ WOMAC C ≤ 90)|Patient able to understand the requirements of the trial', '40 years or above', '>18.5 and <32.0 kg/m2', '≤ 5 X ULN.|Adequate renal function', '3/3', '≥ 18 years)|Ability to provide', '≥ 32', '< 1%', 'started ≤ 6 months', 'C)|Surgery', '>18 years|native', '6.1 of the SmPC', 'score 0 to 1|Adequate organ function|At least 1 lesion', '0 to 2.||Adequate hematologic function', '6.5% < HbA1c', '≥ 18.0 kg/m2', '>10 mIU/ml', 'less than 1 month;|Caregiver of patient already cared', 'stable', '18 - 65||', '18-25|Possession', 'no more than 12 weeks between the completion date of the final surgery', '18-70,|Disc herniation', 'documented', '20 g', '18 years or older.|Eastern', '< 90 g/L', '< 6)|High risk', 'between January 2011', '18 and above who', '< 10ml/min)|With', '<150 mL/h', '>17 years old', '> 21 mm Hg', '> 30 mm Hg', '18 to 65 years old|Chronic', '≥ 50*', 'QTcF≥ 450ms', '> 1.7 before', 'Over 18 years old', '> 8 g / dL', '≤650/mm3|Hemoglobin', '<40%.|Severe', '>= 1.2 ULN', 'above 6.0%|Random plasma glucose', '18 - 80|English', 'between 15 and 40 years', '> 2|Violation of standart protocol (anesthesia', '34 weeks', '18-35||', 'at least 3', '<50 ml/min)|Actual', '>18.5 kg/m2|Healthy', '≤ 8 cmH2O', 'under 35|Healthy', '≥80×109/L', '> 30 minutes/day of', 'less than 50.0 kg', '≥1.5x10^9/L', 'lower than the detection limit', '<6 months|limb amputation|dementia', 'between 8 weeks+0 days and 25 weeks+6 days||', 'greater than 30%', '< 30 Kg/m2|Age < 18', '≥45 mL/min/1.73 m2|No', 'conjugated', 'younger than 6 and over 10 years', 'II - IV||', 'more than 450ms', 'at least 24 weeks.||The patient', 'from 18 years|Signed', 'from 0', '=weight', 'SF®', '19 or older|Is to undergo elective', 'between schizophrenia', '˃100,000/mm3|Estimated', '0-1|Expected lifetime of not', '< 18 years-old.|Previous', '> Grade 1)|Patients', 'from 18 to 80 years', '>40kg/m^2;|Subjects', 'between the 16-18 years||', '> 40 years|Inactivity', '≥ 60m|Patient/authorized', '<=1 X institutional ULN||Urinalysis', '1-6 months)|Hemiparesis', '≥90 ml/min per 1.73 m2', '200-500mcg/24', 'score of more than five', 'between 18-65 ASA I-III BMI', '≥ 50ml/min，NYHA grading', '> 2 g/dL', 'score 0 ~ 2;|PTCL', '<11g/dl', '3 or more times a day and lasts', '>= 40%', '>3.0 g/dL|Subject', '≥160 mmHg systolic', ""above patient's dietary calcium intake"", '18-77 years|Ability to provide', 'at least 0.5 teaspoon', 'under 18 or over 80 years', 'between ≥ 18 and ≤ 65;|Absence', 'higher than the upper limit of normal', 'Stage I-III', '>1.0', '> 10mmol/L);|Urine', '> 115', '≤ 35.0 kg/m2', '≥ 1.5 x ULN，Creatinine', '>18 years|American Society of Anesthesiologists score', 'between day 0 and day +100 from transplant;|Signed informed', '≥ 12 years', '> 2|Contraindication of decannulation', '<50 ml/min|Dementia', '≤ 480 ms.||Patient able', 'stage III to IV', '> 1:1000 by', 'Male|165 cm < x < 180', '≥ 1.5×109/L；|Platelet count', 'to 150 ng/L', '< 4 weeks', '35 -41 weeks to complete the', '≥ 9 g/dL|Adequate', 'greater than 1000 mg/dL.|Age', 'older than 79 years', '>40 kg/m2|History', '<59 ml/minute/1.73m2', 'between 20-80 years', '≥ 14 mmol/L', '≤ 1.5 × ULN;|Doppler ultrasound evaluation', '=< 5 years', '≥ 6.0%', '> 93%', '>70% stenosis', 'under general anesthesia.||', '< 30|Heart failure|Peripheral arterial disease|Active malignancies beyond', 'Score of ≤ 40|Telephone Interview for Cognitive Status', '≤ age ≤ 65 years', '≥100 x 109/L|Hepatic function', 'over 60', '≥ 90g/L.', '3-4|Symptomatic', '>70;|Signed informed consent', 'above the detection limit of the', '≥ 25 km/kg²', '>60 years|Scheduled', '≥ 24.||', '> 75th percentile', '20% of their ideal body', '< 5 x upper limit of normal (ULN)', '>= 30 years old and =< 75 years', '≥ 3.0×109/L.|Platelet count', 'III-IV periodontitis|Compliantpatient', '0-2,|ASA≤3.|At least 18 years', 'between 500-2000 grams', '18-25.|Nulliparous', 'between 3 and 24 years|Multidrug dependent', 'less than 37+ 0/7 weeks or more than 42+0/7 weeks|neonatal', '≥ 1.5*', '90 adult', '>1 cm3', 'measured more than two times', '> 120 mmHg', '≥ 48 mmol/mol', '>= 18 years|Karnofsky', 'score of Edinburgh Handedness Inventory is above 60 to ensure', 'outside the range of 90 to 140 mmHg', '> 1.5 × ULN.||4', 'above 100', '> 11.5 g/dL', 'over 60 years', 'less than 5%', '>2500g', '1-4|Ileal conduit', '≥ 25kg/', 'between 01 Jan 2016 and 01 July 2021|Treatment', '≥ 30', '< 24%)|Illicit drug use (cocaine, marijuana', '>/= 3,000/microL', '3 years and older', '<30 ml/min./1.73 m2', '≥6 points', '<3 after dose titration', '≥40 kg/m2.|Uncontrolled', '<100×10e9/L', '20 to 600 times the recommended daily dose', '< 20%),|patients', 'greater than or equal to 48 hours||', '=< 2.5 X ULN|Alanine aminotransferase (ALT)', '≥ ≥90g/', '18 - 35,|At least', '>150', '> 29', '> 100 X 103/µL Hemoglobin', '5-12 years|Foreskin', '<2 months prior to screening|Dependent', '> 90 mL/min/1.73m2', 'equal to or greater than 120', '> 100 or < 40 beats per minute', '< 2.8 mg/dl|Haemoglobin level', '< 8.0 g/dL|pregnancy|any physical', '<3.0 × ULN)|Serum', '16 and over', '19kg/m2', '≥2,000/mcL|Platelets', '<120 mmHg', 'score of 0 to 1;|Expected survival', '6-12year|vertical', '> 70%|Hemoglobin', '18-65|DSM-5 Diagnosis', 'score of 0-2.|Patients', '18-45|Meeting', 'bigger than 4', '18-75 years.|Able', '< 72 h', '18- 50 years old', '≥10 mmHg', 'less than 20%', '20 - 65,|Volunteer.||', 'score of < 2|Child-pugh', '≥ 30/100', '≥90mmHg;|24-hour', '≥ 18 years.|Absence', '18.5 - 30.0 kg/m2', '>90 mmHg.|A', '> 90 or < 50 mmHg', '<20 ml/kg/day', '18-65 years|Speaks', 'heterosexual abstinence for the duration of the study', '4-weeks', 'less than 30%.|Use of cholesteryl ester transfer protein (CETP) inhibition treatment', '<126 mg/dL;|testosterone', '>1.5 times the upper limit of normal PTT', 'over 18 years.||', 'outside', '1, 3, 4 or 5', 'elevated', '>=100,000/microliters', '15-59 years', '>A', '15-70years', 'Long-term Residents', '≥37.3℃', 'count||100 x 109/L', 'below 18', '≤ 35.0 kg/m2.|Weight', '6 and over', 'less than 20 or greater than 90', '>500 IU/ml|History', '18 or older|Referral to the', '=< 1.5 x the upper limit of the normal range', '> 60 mmHg)|Stroke', 'between18-30 kg/m^2(inclusive', 'lower than 30%|Severe', 'over 18 years old;|2', '<0.7)|COPD', 'negative).|Solid organ', '2.2 ≤ pupil size', 'men|60-80 years', '5 or higher', 'less than 9 months', 'from 25 to 45 years', '>100 pg/mL', '+/- 10 lb', '0-1|Be willing to give', 'below 7 mg/dl', '>7.0%', '< 1.5 K/mm3', '< 10 g dL-1', '45 to 55', '≥ 0.5 x 10^9/L', '11.1 mmol/L)|Criteria', '> 20 breaths/min', 'more than 2.5mg/dL', '≥1 and <16 years', '≥ 12 to < 18 years', '<34', '< 45 ml', '1.60-1.90', '≥300 milligram per gram', '① no need', '< 30 ml/min/1,72', 'Females|18-45 years', '≥ CTCAE level', '>50 mL/min/1.73 m2||Before enrollment', 'greater than or equal to 15 mmHg', 'no greater than 4 mg per day', '>= 100,000/uL|Hemoglobin', '6 to 14 years;|Under the condition', '>150 mmol/L', 'eGFR≥30mL/min/1.73m2 and <50mL/min/1.73m2', '<50% of predicted', '>Grade 2', '< 2;|Adequate kidney', '>2.0 x upper limit of normal (ULN)', '< 220μmol/L;|Lung function', '> 50 weeks', '>= 60%).||Demonstrates', 'between 13 and 15 mm', '≤ 2.5 times UNL', 'equal to or greater than 12%', 'between 18 to 85 years', '+/- insufficiency', '≥ 2.0 g/dl||All', 'above 100 mmHg', '≥ 18 years|ECOG', '≤ 13 weeks + 6 days|20 years old ≤ Age', '>220 msec', '>1 cm', 'between 18-35', '≥ 18 years.||', 'BMI)of 28.0 to 45.0 kg/m2;||', 'more than 3 months.|Subjects', 'class 2', '0-2|Laboratory assessments', '?""', '<1000 grams birth weight', '≥IV;|Allergic to dexmedetomidine', 'than 150 minutes', '14 to 19 years 11 months 29', 'minimum of 18 years', '≥ 13 mmol/L.', 'less than 90 mins', '> 180 mmHg systolic', '>3', 'below 45', '<0.5', '>0.5 but <10', '>14 units/week|Smoking|On', '≥ 18 years|Willing to provide', 'at least 18 years or older', 'older than 16 years.||Pregnancy.|Sternotomy', '≥ 400 pg/mL;|For', '> 350 microns', '19-9|Peritoneal Carcinomatosis Index (PCI)', '<0.15 ng/mL', '≥ 60', 'less than 100×109/', '≥ 18 years.|Breast', 'greater than or equal to 2,500/µL|Absolute', 'over 250 pounds', 'incision|long-term', 'between 6 and 21 years', 'less than 35 kg|Are', '≤ 0.5', 'greater than 1000', '≥ 1.5 × 109/L|Platelet count', 'English||Intra-operative', 'from 7% to 11%;|Overweight', 'Fewer than 15% of the cases', '≥ 1%', '≤ 3 × upper limit of normal', '≥3.5 mmol/', '≤ 10 fractions', '< 2.5 X institutional upper limit of normal ALT', '>=G3', 'between 2 and 3', '>22.2mmol/L|Baseline', '>/=55%', '30-65 years', '<100 mmHg.|Patients', '≥ 20', '>C);|Patient', '>20mg/d', 'between 18 and 65,|Individuals without', '≥18 years old, <80 years old', 'between 18 years and 80 years', 'over 19 years', '≥45%', '≥ 100 × 109/', 'less than 3mm)|No', '≥ 1 year|Histologic diagnosis', '≥ 18 years|Available', '350 to 470 msec', '>4·78 mIU/L', '< 7 kgs', 'between 18 and 88', '18-75 years|Vaccination', 'between 25 - 30 kg/m2', '≥75 minutes/week', 'less than 500 IU/mL before the first dose of study drug', '> 2 times the normal', '≥ 9.|Patients', 'between 21-89 years', '≥60 mL/min per 1.73 m2;|patients', '+5 left bisegmentectomy|Patients', 'between 30 and 55 years', '≥ 140/90', 'between 30 - 90 minutes', '≥5 mm', 'I-IV|Approval', '= 1-3;||Signature', '>2 cm', '20 to 55 years.|Subject must', '>= 3.5)||Metastasis confined to the', '≥ 25', '<30 mL/min/1.73m^2', '18 to 60 years', '>37.2°C', '0-1.|Female', '≤40 kg/m2|Willing', '≥ 20/20', 'between Q and T waves', 'Stage I', '≥ 18 years|Biopsy', 'Kindergarten', '≥ NYHA Class 2,|QTc >480', '>= 18 years|American Society of Anesthesiologists (', 'minimum 2', '=< 15 days prior to registration)|Platelet count', '< 50%', '1-newly', '18.5 30.0 kg/m2;|The', 'I-IV:||Withdrawal', '2 - 14 hours', '=< 3 x institutional upper limit of normal (ULN)', '1-2.|Consent from', '≥ 75 years old|Consultation', 'less than 0.7 FEV1', '<18.5 kg/m2;|Bio-impedance phase', 'over 18 years', ""≥5% and <30%|Static Physician's"", '≤ 2.5 X institutional upper limit of normal (ULN)', '≥18 years and ≤75', '≥0.2 mIU/mL', '18.0 to 32.0 kilogram per meter square (kg/m^2)|A total body weight of more than (>)', '≥ 1000 cps/ml', '< 3 x institutional', '>= 100,000/mcL|Total', 'II and III', '<30 mL/min)|ESLD', '≥ 30 kg/m2', 'retrospectively enrolled)|Exposure', '> 8cm', 'Reproductive', '> 225 mL/kg/year', 'between 18 and 65 years|Subject', 'less than one year,|severe', '>18|sinus rhythm|informed', '≥ 20 ng/mL|World Health Organization (WHO)', '≥ 100.0 x109/L', '> 70% predicted', 'up to 1.5 times the upper normal limit of normal', '< 100 × 109/L', '<18 kg/m2', '>= 7.0 mmol/L', 'does not exceed 60 years', 'stage 5 CKD', '18-39 years.|Histologically', 'grade II or higher', '< 300 mmHg.||', '>=90 mmHg', '≤ 24 hours', '10-19 hyperpigmented', '> 150 IU/dL.||Additional', '>= 55 years|Age', '> 9mmol/L);|Coagulation', '28-day cycles', '0 to 1.|Primary lesions', 'above or they', '>75yo then PSA', '≤2.5 x institutional upper limit of normal.|Adequate renal function', '=< 3 x institutional ULN|Serum creatinine', 'mellitus,|Collagen disorders', '+ 0.74', '≥ 2000/μL|Neutrophils', '>2nmol/L', '> 30 mg/mmol|Current', '11.1 mmol/l', '≥ 95%', '2-3 mm', '< 18,5', '18 -35 kg/m2', 'I to IV', '>=18 years and <80 years', '< 3 months.|Participation', '≥18 and <28 kg/m2', '≥18 years and ≤ 75 years', '2x the upper limit of normal', '>18 years|Informed', '20 and 24', '> 15 cm from the anal', '>5.0 U/ml).|Participating', '≤ 2.0 x upper limit of normal (ULN)', '= 1)|Vaccination', '> 38', 'smokers', '> 1.26 g/l', '≥ 40 µmol/L', '18 or over|Informed', 'more than 16 years', '>125', '≤ 2 times ULN', 'matched', '18-38|Exercise', '> 18 years old.|≥', 'long-term use', 'over 18 years old.||Medical Records', '>= 9.0 g/dL|Absolute', '>18 years|Atherosclerosis', '<20%||', '1-3 days/week', '7-17', '> 42.5', 'at least 75% of the participants.|Children', 'class 2B', '>= 3 months', '=< 2.5 times the upper limit of normal', 'UA', '3 - Mild', 'Ⅰ-Ⅱ ,|18-80 years old', 'between 7 to 89 years', '< 3.0×109/L', 'above these cut-offs', 'levels ≤ 2.5 times the ULN for', '< -8 diopters.|Strabismus', '>18 years old', 'greater or equal to 19 years', '> = 50%||', '≤degree 1 and|no furcation involvement.||', '0-1|Age', '> 6 cm', '< 20/30|Other neurological or orthopedic', '≥ 21 years|Able to understand the informed consent form', 'less than 25 kg/m2|Are younger than 22 years', '≥ 50.0 kg', 'between 2.81 and 10', 'ranges from 18 to 85 (inclusive)', 'Grade 2 or higher', '< 6 seconds above control', 'between 55 and 80 years', '>129 mgdL-1.||', 'Stage 2]:||History', '~ 30 kg/m^2|Subjects', '18.5 to 25 kg/m2', '< 5|AMH : < 1.2|Planning', '> 150 mg/L|Pregnancy', '<45%', '<30 percent).|Bradycardia (HR<50 b/m).|Chronic kidney disease', '≥ 12 weeks.||11', 'between 20 and 40°.|Treated', '<19 years', '1 - 60 days old', 'more than 3 months|age 18', 'score of more than 3,|able', '≥ 80 g/L||Criteria', '<80 mg/L', 'more than 80 mmHg', '≥125 mmHg|had', 'at least 3 months;|Patients', '≤ 18years', '>1.5 × institutional', 'between 2002-', '<40 kg', '≤ 2 x ULN|total bilirubin', '>40||Some', '>1.5', '< 18 kg/m2|Contraindication', 'greater than or equal to 8', 'above 36 weeks|Scheduled', '>45 mL/min', '>10°', 'below 90/50 mmHG', '<1.5 ULN', '0-2|Able to read', 'requires intermittent', '< 18 years|Treatment', '≥ 100,000/', '≥ 35.|Has', 'greater than or equal to 30 mL/min', '>5.0 mmol/L.|Unable', '20-22', '≥ 1,500/mcL Platelets*', 'above 300 msec', 'at least 20 seconds', '>3.5 g/day', '> 93', '> 210g/week', '<12 months;|History', '18 years - 75 years;|(5', 'old.|More than 10', '≥ Grade 2);|Medical history', '< 40 kg', 'less than 24)|patients', 'at least 42 years', '≥ 28 g/L;||Renal function', '≥18 years;|④ Basic cognition', '≥18 years|Able to consent', '6 and 17 years', '4.3 or higher', '18 years or greater|Both', 'At least 33 weeks', 'from 6-11 years', 'wild type.|Cohort 5', '≤1.5 ULN', 'higher than 120 beats/minute.|Injuries', '≤ 2.||Adequate organ', '>= 18 years||PRE-REGISTRATION', '> 7.0%,|At least', '≥1', '≥12 to <18 years', '<1 cm between the tumor', 'between normal to overweight', '0-1;||⑨', '11mm', '= 5', 'A or', '≤ 1.5 × ULN', '> 8.5%);|Use', '<100 g/L)|Baseline', '>40 and <75 years|A', '18-75 years|Physical Condition Score', '>35 kg|Ability to understand the study instructions', 'males).|Immuno-compromised', '>75,000/ mm3', 'severity', '10 mg/day', '>1500 grams|Parents/legal', 'between January 2014', 'at least 200 mL', '≥450 ms', '< 6 mm', '148-221 pmol/L', '> 300ml', 'COPD|Aged 40 years', 'between 50 and 85 years', 'greater than 4 weeks', '> 1 cm and < 25 cm|Patient can understand', '= 400 mL', '> 90 mm Hg diastolic', '< 15mmHg;|Male', '> 45', 'between -0.75', 'score ≥1', '>18 yrs', '> 25 ng/mL', '≤ 2 ULN', 'exceeding 3x ULN', '50-85', '< 12 years;|History', '>100 bpm.||Pregnancy/Lactation||Pregnant', '+/- 5.0.)|Acute illnesses', '> 2.7 cm', '> 1,000 / mm3', '≥18 years).|Have', '>40 ml/min/1.73 m^2 calculated', '> 15|Participants also agree not to enroll', '>2.5 × ULN', 'At least 7 days must', '≤ 0.5mIU/L', 'between ≥ 18.0 and ≤ 32.0 kg/m2', '≥100 ×10^9/L', '≤ institutional upper limit of normal (ULN)', '< 14 years', 'from 18 to 45 years', '> 100', '<90%||', '0 to 1', '< x1.5 upper limit of normal range', '7 to 17 years old', 'at least 4 cm', '≥6 Units of transfusions of pRBCs for the prior 24 weeks', '=<59 ml/min/1.73m2', '0-10)|are', '< 3.0 × upper limit of normal', '< 24', '=< 5.0 times Upper Limit of Normal', '=< 3.0', '> upper limit of the normal', '5 to 15 years born', 'exceeded 20 % of the ideal weight', '4 cm', '>= 3.4 mmol/L', '18 to 80 years.||Patients', '> 5 mm', '≤ 30 mL/min)|Upper arm circumference', '< 50 pg/mL)||', '> 18 years', 'better than 35 letters;|Any degree', 'above ULN', '18 to 40 years||', '>3 times upper limit of normal (UNL)', 'over 18 years olds;|Who accept to participate', '≥ 2500/µL.|Lymphocyte count', '-12-year-old Myopia', '2022).|Age above 18 years.||', '18 and older|Fluent', '0-2.|Has', '≤ 2 × upper limit of normal (ULN)', 'distant metastases|MMRd', '<18 or >60 years', '≤ 5 × ULN', '≤ 25 mg', '≤1 x 10^9/', 'between19-26 kg/m^2(inclusive);|Normal', '>6)|Have', 'one month to up to 16 years', '≥ 3)|Able to give', '< 30 ml/min)|pregnancy|Benign', '18 to 60 years inclusive', '<30%|Cardiogenic shock|Patients', '》60 years|American Society of Anesthesiologists (', 'class II', '≤ 13 g/dL', 'between age of 25 and', '<94/80cm.||Psychiatric/psychological suitability||Each participant', '<= 1.5 mg / dL|Adequate', '< 15 mL/min/1.73m^2', '≤ 7 mm', '> 450 milliseconds', 'years;|Body', '2-5 years', '≥ 2.5 mg/dl', '≥ 80 years', '≥ 2.5 g/L', '≥ 18|Possess a sleeping partner', 'between 20 and 40 kg/m2|ASA I, II patients', 'stones,|smaller than 10 mm', '<1.5 Upper Limit Normal (ULN)', '<18 yo', '> 180mg/dl', '>24 hours|Patients', 'At day 90 after treatment||Exclusion Criteria', '>= 18 years old from January 1', '3-9 months|Participation', 'positive airway pressure therapy or home', '≥ 24kg/', '< 4mmol/L.|Patients', '≥70 years', 'dose equivalent', '≥3', '60- to 90-year', '30 U/L', 'QTcF>450 ms', '< 36°C', '≤ 100x10^9/L.|Hemoglobin < 9g/dl.|Patients', 'above 40mL/min/1.73m2;|Individuals', '≤7%,', 'Between 7-16 months', '< 3 weeks prior to', '≤75,000/uL|Hemoglobin', '8-17', '18-30 years', '< 1.5 × ULN)|INR', 'score of >30', '>159 mmHg', '<15 mmol/L|Elevated', '3-7):||Outpatients.|Able to provide developmentally appropriate informed assent', '1A and 1b:||Use', '≥ 3 months.|Persistent', '≥ 80 mL/min|Normal', '≥ 15 years;|ICD-10 codes', '≥3|At least 3 months', '≥1.5×109/L;|Platelet count', 'below 35%,|emergency surgery', 'less than 1%.|10', '≥ 18 years;|Able', '45 mL spirits', '> 1.5 mmol/L calcium', 'more than 2 lines;|The guardian of the subject can understand the purpose of the trial', '>= 14 days after local XRT', '≥ 40 mIU/mL', '45-90 years|uterine', '≥20 cm2|Present', 'less than 18 years|Inability to speak', '≥0.5×10 9 /L', 'than or equal to 6 weeks|English', 'equal to or higher than 50% of the lower limit of normal range;|Liver function', '≥100,000/mm3|White', '> 18 mmHg', '< 0.5×109/L', '> 25 degrees)|surgery of', 'guidelines|Able to provide', '>= 1.5 x 10^9/L (=', '> 1.5 times the premorbid level', 'Schwartz', '>= 2000/uL', '18-75|HbA1c', '≥18', 'ranges from 1.5 years to 5 years||', '4-9', '>100 mmHg', 'more than 70', 'under 18 years||-', 'greater than 5g/L.', '>30 kg/m2|Malnutrition', 'above 50 years', 'above definition', 'Above 18', '>11.5 g/dL|Platelet', 'less than 7 cm', '6-18 years|Proved', '> 5×ULN', '<152 and >213 cm|body mass index', 'score 1 ≥1)|Catchment area of Hospital Sønderjylland|Deferred informed consent obtained from patient or patient', '18-65|Pain level', ""under 18 years|can't be able to read"", 'MV shorter than 48', '≥6 and <18 years old', '40-65 years', '≥ 50×109/L', 'between 0.7 and 1.2 ortriphasic', '6 to 35 months', '18.5 to 25.0 kg/m2||', 'less than 5 mm', 'less than 3 years', '> III|Conversion', 'score of 20 to 28 (inclusive)', 'between 30 to 70 years', '< 8,5 g/dl|Granulocytes', '> 1 year.|Presence', 'at least 80%|Subsequent', '≥30 and <40 kg/m2|Provision of signed', '< 7 kg/m2', '18-45 years;|Single term', '≥ 20 ng/mL', 'no more than one drink daily', 'above NYHA II', 'above 105 mg/dL|Triglycerides', '>30 kg/m2will', '>100 U/L.', '< 24/min', '18 to 85||GERD patients with complaints of regurgitation', '4-7.|People', '>1.5 × upper limit of normal (ULN):', '18-70 years old', '> 270°', '15-20 year-old', '≥70%', '20 L/min', '≥ 50%.|Patients able to comply', '< 2,500/', 'formula ≥50 mL/min', 'between 18 and 75，male or female.|ECOG 0-1.|Expected', '< 3x normal', '18 - 75 years|Non-progressive', 'between 8 and 17 years', '<50 kg', '<100 µg/g', '≤ upper limit of normal (ULN)', 'functional classification.|History of a current diagnosis', '11.1 mmol/L', '≥ 50%.||Female', 'high', '> 1 ng/ml', '> 100×109/L;|Normal values', '12 weeks.|At least 1', 'Older than 7 years', '> 480 msec', 'I to II|Patients', '< 3 weeks prior to registration)|Platelets', '≤ 2.5 × ULN;|Albumin (ALB', '<80g/L', '< 0,27', '>38 kg/m2', 'Patients(above 18 years', '<10%)|STEC-HUS', 'male volunteers|19 kg/m^2 ≤ BMI', '> 8.0 g/', 'more than 1.5 times of the upper limit of normal', 'between 21-75 years.|Subjects must fulfill the criteria', 'Type II', '≤ 85|PVC burden', 'more than 22 / min|Oxygen', '> 470 ms regardless', '≥ 50%.|The subject and his/her', '15 to 40 (inclusive)', 'greater than class I', '>13.|Peak flow rate ≤ 12 ml/sec', '< 30%', 'above', '65 - 80)|ASA', 'stage IV', 'under 18 or over 64 years old|Pregnant women|Disease status', 'greater than or equal to', '6 months or more.||', 'greater than 3 months;|Adequate liver', 'measured ≤ 80% of the normal predicted value', 'are:||(Oligo)metastatic disease|Histologically', '>= 7.5 mg/week', '> 65 years', '90-day', '<8.0 g/dL', '<7.0% or >10.0%.|Patient not', '≤ 2×ULN', '=< 1.8 mg/dL|Ability', 'less than 1% per year.|Ability to understand', 'IIIC', '23-Dec-202210abnormalities', '1-3|Willing and able to consent in English or Spanish|No', '< 6.0', '≤ 5x ULN.|Aspartate transaminase (AST)', '1.It', '3-17 year', '≥ 90 g/L;|Platelet', '≥ 14)||', '<35 kg/m^2', '≥ 30 mL/min.|Activated', '≥50×10^9/L', 'between 18 to 60 years', '16 - 24 years', '<60%)|respiratory', '< 90 mmHg', '21 and above', 'less or equal to 3 times the upper limit of the institutional normal', '≥ 20 teeth.|Patients', '± WBRT|Age 18 - 80 years|ECOG', '>140/90mmHg after the use', '6-8 weeks', '< 150,000 / μL|Hemoglobin < 6.2 mmol/L', '< 100/min', 'more than 35 kg/㎡', '<1.5×ULN.||Exclusion Criteria', '≥ 4)|Self-reported', '< 8.0 g/dL|Serum Creatinine', 'no greater than 2', '> 70 years old * Patients', 'less than 30%|Most', '<0.20 x 10 3 /μL or <0.20 G/L', '< 95% saturation', '^9/L (=', '=< 135 U/L', '>86 mmol/mol', '10 weeks', '≥ 100 × 109/L|Serum', '> 13.0 years', '>220 mmHg', '≤ 5% of mean normal laboratory levels', '>= 100,000/mm^3|ELIGIBILITY CRITERIA', '2-10 years', '≤ 10 G/L', '18 years and above;|(C', '18-75||Having', '≥ 11.1 mmol/L', '30-60|Evidence', '0 days and up', 'lower than 85/55', '20 mg/kg IV', '> 10 mm;|30', '0-1.||10', '</= 2 cm', '≤ 3 X ULN', '>= 1000/mm^3|For', '1, 2, 3 cancer|Cancer types', '< 120 ms,|Fridericia corrected interval', '18-32 kg/m2(inclusive);|Male', '≥ 10 mmHg', 'outside the range of 90 to 140 millimetre of', 'from 18 to 75|Agree to participate', '≥35 kg/m2|scheduled', '<36 weeks', 'less than 40kg|subjects', '> 3 grams/d', 'score of 5 or greater', '≤ 5 × ULN|total bilirubin ≤ 1.5 × ULN', '≥ 100 × 10^9/L||Hemoglobin', '15 or more', '< 9 gm/dL', '≥12 weeks;|Histologically', '≥100 mmHg);|Abnormal', 'between 28-30 Criteria', '≥50% diameter', 'less than -950HU', 'II or more', ""?'"", '>1.5mg/dl.|Participant', '< 50 bpm', '>70mmHg;|Vasopressor', '35-60 years|3 or more', 'more than 4 hours', '≤ 2;|Baseline NIHSS', 'greater than the last 15 days|qSOFA score 0, 2', '0-1|Good organ function:||Blood', 'between 16 and 25 years', '<110 g/L', 'Grade 4', 'between 2013', '> 130mmHg', '> 470 msec.|Any', '≤ 60 or ≥ 100', '>55|Diabetes duration 10+ years.|Chronic kidney disease (CKD)', '≥100 × 109/L', '≥ 12', '<100 x 109/L.|Haemoglobin <90 g/L.|Alanine aminotransferase', '75-150 min', 'greater than 10 mm Hg', '0-1.|The patient', '20-80|Scheduled', '> 100 x 109/L iii', 'between 10 and 15.9 mmol/L', '≤ 2.5 x institutional ULN', '>450 ms.|Clinically significant', 'less than 40 mIU/mL.||Men of reproductive potential', 'between 2.5 to 8 years', '>200 copies/mL', '>2.75 mmol/L', 'III-IV)|Hypokalemia', '≥18 years and able to understand the purpose of the study', '< 2.2 L/min/m2', '<90 minutes/week of physical activity|Self-report', '<1 times the normal upper limit', '≥ 25 g/L|Creatinine clearance (CrCL)', '<2cm)|Known', '+-year diabetic', 'after january 1st 1968|Known infection', '<90/60 or >140/90 mmHg);|Low blood oxygen saturation', '21-64 years', '1）18-65 years', '>3|Neck Disability score of 20%', '> 2/10 cm', '≥32 kg/m^2 to ≤39.9 kg/m^2', 'between 18 and 75 years old', '10-21 years', '>8.0 mmol/mol', 'Older than 21', '2 cm from the natal cleft.|Distance', '24-2', '<18 years;|Diagnosis', 'inclusive)|Minimum 200 ml of fat', 'less than 0.5 cm', '≥ 20 years', '>2.6 mmol/L', '70-100 mg/dL|Alkaline phosphatase', '>40)|Patients', 'm2', '>= 1000 / mcL|Platelets', '≥15 ng / dl', '≤ 1.|Life expectancy', '> 1 month||', '≥ 18 years|One or more', '< 100,000 cells/mm3', '≤ 2 mg/dl', '≥ 18.6 mm', '4 or more', '19 U/L', '≥1×104/ml', '> 60|Gender', '≥ 75 × 109/L', '60-90 degrees', 'less than twelve months from', 'greater than 50% of the tumor and does not include', 'between 60% to 70% predicted', '40-60 years|Complaints', 'less than 10% of body surface area', '≥ 7.0 mmol/L', 'score less than or equal to (<=) 7', '18-70 years.|Clinical', '5ml/min·1.73m2|The 24-hour urine volume ≧', ""above 18 years' old|Elective"", '≥18 years;|Understand and voluntarily sign the written informed consent form;||Study', '30-70 years|Primary osteoarthritis', '> 1.5 the ULN', '≥140 and <180', 'at least 50%', '≤ 1.5 × ULN;|Doppler ultrasound assessment', '1%', 'score ≥ 10', '25 to 65 years', '< 20 points||III', '≤ 1.|Sexually', 'greater than 150 minutes per week', '>150 mg/dL.', '<80,000/μL', '1-2|Complete', '>= 30 mL/min|ELIGIBILITY CRITERIA', '25-40 years', '≥1 x 109/L|Hemoglobin', 'less than ≤ 90%', '≥ six months', '<50% visual', '= 1.65', '≤ 1.5;||Prothrombin time (PT) and', '≥18 years|ST-elevation myocardial infarction', '> 70 mmHg）;|Patients', 'equal or less than 3.0 mg/dL', '≥ 18 and ≤ 80 years|Body mass index', 'score of ≤ 3', '>= 18|Life expectancy', '≤ 1.5 mg/dL', '< 0.3 mL/min', '≤19 kg/m²', 'less than 500mg', '28-31 to separate individuals with', '>325mg', '>200 mL', 'being 18 years', '5-15 years', '>20 units/week', '< 20 or > 45', '>9.0 g/dL|Platelets', '≥100 × 10^9/L||Liver function', 'between 45 to 65|O degree to 20-degree', '10 cm', '< 7%', 'above the 99th percentile Upper Reference Limit', '≥1.5 × 109/L|Platelets ≥100 × 109/L|Hemoglobin', '≥500 msec', '≤2.5 ULN', '6 - 120 months|Weight', '18 years ≤ age ≤ 65 years.|Voluntarily sign', '≥ 18 years old|Employee', '≥ 12 weeks.||Subjects should', '> 2.0 mg/dL|Liver', '>15 eosinophilic granulocytes per high', '≥90 g/L|Total bilirubin level≤1.5×ULN|Alanine aminotransferase (ALT)', '> = 18 years.|Whether there is', '≥ 24;|Fluent', '< 48 hours after randomization.|New oxygen', 'before 32 weeks', '> 1cm response evaluation criteria', '>200/110', '≥50×109/L', '45-65|Sedentary', 'V1 and V2).|Subjects', '< 1mL/kg/hr', '+/- 10 dB across 500Hz-4kHz', '< 50 years', '<20 kg/', '>= 7.0 g/dL', '≥ 110g', '> 40-55', 'I to III||', 'between the 5th and the 85th percentiles interpreted relative sex', 'greater than 1 year|Patients', '<40 or >70 years|subjects', 'between 20-35 years', '≥50 mL/min/1.73 m2|Human immunodeficiency virus', '2-3 points', '≥ 2,400 U/mL.|Patient', '≤ 1:4', '150 mL wine', '≥12 weeks;|Women', '18 - 79 years', 'under 70 of age||', '≥18 to 95 years', '> 40 IU/l', '≤ grade 1;|Women', '≤ 1.5 mg/dL|In', '> 400mg', 'between 18 and 45', '≥18 years old;|Those who', '≥ III;|Patients', '7 - 80 years', '<25%.|History of', '≥ 18 years|Diagnosis of STEMI', '≥25 g/L', '≤ 7 days', '>30ml/min/1.73m2', 'between 20 - 70', '≥ grade', '≥ 10mg/dl', '> 2 times higher than upper normal', '≥ 40Kg；|Subjects of', '> 150 mEq/L)||Patients', '>10 mg daily', '≥6 months.|During the study', 'not less than 10', '>1.5 × institutional ULN,|Urine protein-to-creatinine ratio', '<10g/dl||Contraception', '=<1.5 x Institutional upper limit of normal (ULN)', '>40%', 'class III/IV', '1 month - 12 years', 'more than 6 months||', '≥ 116 mg/dl', 'less than 18 years old', '20 - 30,|Healthy', '3days/week', 'equal to or above 6 months prior to screening', 'over or equal to 19|ECOG', '=< 3.5 times upper limits of normal', 'less than 1 year.|All', 'equal or above 34', 'between 4 years and', 'elevations', '≥ 30 mL', '≥3 months.|For', '65 years or more', 'Multifetal', '<200', '18-65||Meet', 'not to exceed the upper limit of normal', '18 or older|Indicated', ""1.2.3 IOL;|Patient's willingness to participate"", '>98cm', '≤2.5 times the upper limit of normal value', '> 30 mg/gr', '≥ 3ULN', '≥25 kilograms per meter squared (kg/m²)|Presence of', '>35|Pregnancy', 'greater than or equals', '> 160 mg/dl', '15 to 49 years', '> 1,000/mcL|Platelet count', '> 1.5 mg/dl', '50-75 years old', '<0.8', '< 470', '≥300 mL;|unable to give informed consent|need of clean intermittent self-catheterization', 'age|Greater than', '≤ 36 months', '< 0.70', '> 80 ml/min/1.73 m2||No proteinuria', '< 1000/mm3)|Thrombocytopenia', 'less than 30 ml/min/1.73m2)|Patients', 'from 1 to 1+', '>2000 IU/mL', '18.5-30.0 kg/m2.|Women', '>2×ULN;|total bilirubin level', '19 or above to under 80', '≥100 or ≤60', '0-1;|The', '≥ 2.5 mmol/L.|4.Primary', '<60,000/mm3', '≤1.5 x 10^9/L', 'over 18 years old|agree to participate and sign the informed', '> 30 mL', '<50%', 'more than 16 rows.|slice thickness ≤ 0.625mm', '>4 kg', '≥1000 /µL|Hemoglobin', '< 30 kg/m2', '18-65|Body mass index', '< 40 mmHg)|Patients', 'AST≤ 2 times the upper limit of normal;|Serum creatinine', '>8% prior', ""1- Patient's inability to provide"", '<2.1', '< 60 kg', '≤ 3 x upper limit of normal (ULN)', '≥ 18 years|Intertrigo', '18 and 40 years', '0 - 1;|Have', 'greater than 240', 'less than 60mmHg', '>15 drinks/week', '< 60 mL/', 'between 40 and 90 years||', '>180 days', '≥ 2,500 g', '< 6 months prior to enrollment', '≥125 cm/sec', '≥ 150 × 109/L', '1-month', '< 20|No willingness', 'score higher than 5', '45 mL/kg/min', '0-1|Patient', 'greater than 4000 milliliters', 'less than the lower limit of normal', '≥2；|Clinical', '≥ 103', 'lower than 60 mmHg;|Diagnosis', '>9%|Uncontrolled', '>3 months;|all', '19 or older and 55 or less', '18-40 years', 'less than 50%.|Previous', '> 1.5 mg/dL|Hgb', '> 7.5%', 'upper extremity|MoCA score of', 'score of ≥ 16 and ≤ 30', 'from 18 to 70 years.||', '≥ 18 years.||Patients', '<60 days', '30 times/min', '< 35 kg/m2|All', '75 × 109/L)|Hemoglobin', '≤ 3x upper normal limit', '>= 90 days prior to the day of screening', 'more than or equal 18 years old', 'at least 70%', 'III-IV).|Anamnesis', '≥ 450 mL', '18-60|both sexes|BMI', '50 to 90 millimetre of mercury', '0 or 1|Negative', '>159umol/L);|Patients', 'at least 1.5', 'greater than 30 %|Pathologies', '< 65 mmHg)|Patient', 'and free triiodothyronine (FT3)', '22 years or older', '1)|Non-smoker|Willing', '≥ 18 years||', '<130/80 mmHg', '18-65,|To', '≤ 1.5 x IULN|AST(SGOT)/ALT(SGPT', 'between 37-40 weeks|Absence', '≥ 0.5.||', 'between 18 to 40 years inclusive', '< 15 mL/min)|NYHA IV', 'upper to 1', '8-item self-report', '≥ 9g/dL', '> 2cm', 'below normal', '90 degrees).|The', '18+)|COPD stage 1 or 2|Identified by their family doctor', '>Level 1', '≤ 15', '0-1.|8', '< grade 2', 'I - III', '<2.5ULN', '=< Grade 1', '≥ 18 years who agreed', '> grade 1).|Uncontrolled', '≥ 2 x upper limit of normal);|Serum', '≥40.|Not have', 'under 22 mmol/l', '> 5 × ULN - 10 × ULN', '> 9.0g/dL|Absolute neutrophil count (', 'disease', '50 kg.|Male', 'from 0.01 to 1.0|Control', 'between 13 and 17 years', '< 24 months post-transplant', '≥2units/day', 'less than 18-year-old;|Comorbidity', 'above 25 years', '> 75||III', 'greater than or equal to (>=)18 years.|Diagnosis of clinically typical AK', '< 50 bpm.|Patients', '35-80 years', '≥ 17.5', 'outside 20/400', '<18 years|Lack of consent to participate', 'less than 5', '18.0 to 35.0 kg/m2', '<10th percentile', '> 1 to 2 × ULN', '< 150 mm', '14 to 18 years;|have', '> 40 and <70.|Bilateral knee pain', '>= 30mL/min/1.73 m2|>=18 years', '=< 30 ml/min', '≥18 and ≤32 kg/m^2|Body', '≥ 4|Morbid', 'cover < 10% of body surface area', 'at least 30% of the daily', '>480 ms', '≥ 12 weeks from the time of', '>500mg/day', 'more than 10%', '100.4°F', '1-3|Traumatic', '<4 wk', '≥ 200 cm/sec', '> 18 years|ischemic stroke|stayed', '32 to 37 weeks', '<100 ng/ml', '≥ 18 years,|Intact appropriate tissue', '40-60%', '0 to 75 years', 'Score of more than or equal to 5', '8-positive', '> 18 years regardless', '≥110 mmHg);|Percutaneous coronary intervention', '>40% to <=90% of the predicted normal', '≤ 5.0 times the upper limit of normal', '>2mg/dL', '6-30 years', '≥ 3.0', '≥ 18.5', '≥ 60 mL/min|Blood glucose', '≥ 25 cm', 'under 18 years old|patient', '≥ Grade 3.||12', '≥35|Current or', '0-1.|No combination', '40mg + ezetimibe 10mg.||', '≥75 years old', 'between 88 and 100%', 'between 22 and 50', '> 40|Systemic therapy', '> 3 times upper limit of normal', '< 1 year|Unable', 'between 30 and 85 years old|Having', '≥30 to ≤700 IU/ml.|Moderate', '≥ 1.5 x 10⁹/L|Platelet count', '<10g/dL);|Bone', '≥200 copies/mL', '≤ normal upper limit 1.5 times,', '≥40 dB', '≥ 10 grams', '18-45 years,|having', 'less than 40 kg/m2||EXCLUSION', '80 mg/m²', '18-70 years|A', '>18 mg\\dL', '≥ 130 mg /dl', 'score of 17 or higher', '12 or above', '≥2|Docetaxel-rechallenge', 'equal to 2 or less than', '≥18 years.|Newly', '> 1 g.|Pregnancy', '>= 8.0 g/dL', '≤1.5-fold the ULN of the study site||Women', '≥18 years)|ICU survivors', '79-110', '18 or', '≤ 1.5 times the upper limit of normal value', '≥1.5×109/L;|Hemoglobin', '< 4 mg/ml)|Subjects', '≥ 305 µm', 'less than 1 cm.|Lung dose constraint', 'II ≤ 16', 'less than 3 weeks before the study', '≥ 40|CAP score ≥250|CFT = 13|TMS < 6|Patients physically able', '+ 1.41', '20-30 mg/day', 'score of 0', '> ULN;|Total bilirubin level ≥1.5 × ULN', '< 5x ULN', '0 ~ 1', '<100 x103/μL)|Persistent', '> 30kg||EXCLUSION', 'at least 12 weeks|Adequate hematologic', '1.5 109/L', '> 103', '8.0 - 8.1.0', '≥ 18 years|Clinical signs', '< 12 kg/m2|Subject', '20)|Postpartum females', '≥18 years|Patient has signed', '< 8 g/dL.|Presence', '1.1 standard;|The main organ function', 'between 24 to 120 hours prior to randomization|An absolute air conduction hearing threshold', 'Develop dose', '> 11 mmol/L', '≥150 ng/dL', '20 to 60 years|ASA physical status', '0-2)||Tumordisease', '60 or older;|2', 'from 100 to 125 mg/dL|Glycated', '> 2x ULN', '≥ 9.0 g/dl|INR/PT/aPTT', '6m- 18y .||', 'less than 90 years', '=< 1', '≤ 18 mmHg', '<2 years', 'more than 50 mL', 'more than twice;|Patient', 'greater than or equal to 10^3 CFU/field;|Hospitalized', '≥ 28 days prior to the', 'less than 20ml/', '= 0)|Normal', '≥45 years', '18 ≤ age < 65', 'age.|At least 30% of subjects', '1 group of 25 healthy', '≥ II.||', '>= 1,000/mm^3|Platelet Count', '18 or older;|meets', '>120', '< 90 mm Hg', '< 50 mg/dl', '<30 kg|Those', '≥55kg', 'age|Greater than or equal to 6 months post', '≥50 K/cumm', '20 to 30 years.|Their', '>85th', '≥1.0 g/dL', '18 or older.||EXCLUSION', '≤1.5xULN', 'older than 40', '≥ 85 mmHg', '>8.0 %', '0-1；||--Patients', 'Class II or III', ""between 6-12|The child's consent to voluntarily participate"", '> 1 month and ≤ 39 years', '18 years or older|have', '<13g/dL|Platelet <60,000/µL|Severe kidney disease patient', '≥38mmHg|Signed informed consent prior to the initiation of any study mandated procedures', '≥ 18 and < 30|Maintenance', 'no more than +2.50D;|Can', 'between 18 and 75 years|Patients', '<18 kg/m2|Currently', 'between 30-50;|Be', '20 mg/L', 'at least 4 weeks', 'maximum 1mg/kg/', 'PD years ± 15 years);|oral', '> 18 and < 90 years;|Organ-localized prostate cancer', '≥2.|Pregnant or', '<100×109/L|Known', 'over 18 years old|Written consent', '≤ 75 years', 'less than 8 days before or after', '≥ 19 years||', 'between 18 to 80 years|Tinnitus Handicap Inventory ≥ 48|Chronic', '18-70|Diagnosis of', '18 - 99 years|Diagnosis', '30 to 65|EDSS score', '< 40%', '≥ 3cm||', '^ 9 / L；|Absolute neutrophil count (', 'greater than 0.5 cm||Pain clinic', 'less than 50kg.|Before the test', '≤ 500 mg/dL', '> 85 years', '>0.8x 109/L', '> 2.0', '>5cm', '20years', '50% of patients', '= activated', '> 18 years|Post-stroke', '≥2 and ≤11', '≥ 18 years-old.|participants', '< 8)|age 18-65 years', '<=2.||Must', '0-2|Able to provide', '≤ 1.2', '≤ 30 kg/m2', '≥ 180', '2 times above normal', '> 480', '< 5 years', '<100 or >180', '2.5-4.0mm', '<105', '> 35|Body weight', '<1% of all breast malignancies.|Pregnancy', '< 1.5', '≥ 9.0 g/dl|calcium', '0-2;|The', '<3 stools per week', '<50mmHg', '≥ 18 years|Muscle cramp', '< 500 cells/µL', '>450 mL', '1 or 2-||', '≤ 2.5 times the upper limit of the normal value', 'at least 7 or more', '- 100', 'between C3 to C7|Is', '18-70 years;|Patients', '50 dB HL', 'no greater than 2 mg per day', '≥30mL/min|Sexually', '>,= 18 years', '>600 pg/mL', '>= 100000/μL', '<18 years).|People', '≤ 90g/L', '≤22.5mm', '<30 mL/min', '> 30°', 'over 40 years', 'over 18 years of age|Caucasian race|Living kidney donor', '<1000 copies /ml', '> 21 alcohol units per week', '0 to 4 scale', '< 2 x ULN|Total bilirubin < 1.5 x ULN|Serum', '≥18 to ≤ 65', '< 1 month or > 6', '< 90% predicted normal', '6-17 years', '>/= 10 mm', '> 130 mmHg', 'score ≤ 2;|Participants', '≥ 4 mm', '≥ 18-years', '≥50%', '≥30 kg/m2', '4-8 cm', 'higher than three times the upper limit of normality', '>9 %', '≥8 g/dL', 'score of < 12 months', '<60 milliliter per minute per 1.73 square meter (mL/', '<IV', '≥ 50 mL/min||', '> 100 mmHg', '> 90g/L', 'above 18|Access to a', 'less than two mature', 'less than 3 years|If', '≥ 18 years old;|In the first 2 days', '<0.4 mIU/L', 'Under 50', '< 25%', '> 7.0 mmol/L,|Body mass index', '<1.5 times the normal upper limit', 'between 30-64 years old', '> 5 mmol/l|Absolute neutrophil count', '15 years and under', 'less than two years', '65 and over|Patients', '<30 mL/min),|moderate-to-severe', '1 month postpartum', '>50,000', '≥ 9', '<18.|individuals who', '> 30.|Type 2 diabetes mellitus.||', 'longer than 2', 'between 18-30 years|Equal distribution', '< 1000 copies/ml', '</= 50', 'less than 12 months.|Pregnancy.|2nd', '≥ 100%', '= 7', '> 90 percentile', '> 100 mmHg)|Patients', '18.5-39.9|Able', '0 to 2.||', 'below 37.3℃', 'unfavorable', '> 2000 IU/mL', '=< 7.5 mg /day', '0 or 1|Capable of understanding', '20-55 years', '≤ 50 mL', '≤ 10 mg/L|BMI', '≥ 90 g/L；|Biochemical examination', 'score 50%', 'from 18 to 35 years', '≥2 months;|Stable dose', 'outside the range of 90 to 150 millimeter of mercury', '> 50 years|Willing', 'greater than or equal to 18 years||', '300 mg', '≥ 70', 'greater than 2 times the upper limit of normality;|Severe', '<2000g).|Use', 'below 80', '0-2|The', '18-24|Have', '>0.1 mEq/L below lower limit of normal', 'between 18-70 years', 'higher than the detection', '>=50 kilogram (kg', '>= 0.01%', '>80 years|Acute coronary', 'less than 3 years|Pregnancy.|Target lesion', 'less than 45 beats per minute', '≥ 6;|With', '<120 ms;|Reliable', '>140/90).|Patients', '18 to 75 years|Fitzpatrick skin types', '≤34 weeks', '18 to 70', '> 18 year-old|The surgeries', '< 19 kg/m2.|History of', '>= 75,000/uL', '> 1.68', '≤ 40 kg/m2|No', '≥50,000 /µL|Patients must', '≤ 10mm', '> 1.5 times higher than upper normal level|eGFR', 'above/equal 20', '≥18.0 to ≤35.0 kg/m2|Medically', '>450msec', '6-16 years;|Signature', 'between 30.0 and 39.9 kg/m2||Females', '> 1.5 × ULN.||Coagulation', '10^9/l', '>= 18 years|Patients must exhibit', '<= 1||', '≤ 0.80', '< 18 years old|Body mass index', 'global score of 0.5', 'Killip class II or more', '40-85 years|Diagnosis', '≥ 113 mg/mmol', 'Grade 2 or higher diarrhea).|The patient', '> 3 diopters', 'no more than 2', '20-65 years|Pain', '55 -75 years', '≥ 10 years', 'high intensity exercise', 'greater than 600 μm or less than 500 μm', '≥ 58', '≤ 1 ULN', '>95%', 'Pregnant,|Emergency', 'above 3 times the ULN', '≤ 2.5×ULN', 'Greater than 18 years old', '15 weeks.||Mentor inclusion', 'above 160 mmol/', 'controlled to less than 500 and', '>35 kg/', '< 150 minutes per week', '1.18-75 years', '=< 3 times the upper limit of normal', '> 200/', '≥ 3 months|At least one', '<20|Subjects who gained', '≤200 ms', '≤ 1.5 × ULN|Total', '≥100 x 10^9 / L iii', 'score <17|Bladder cancer', '18-65|Knowing', '≤ 1.5ULN', 'lower than 17.5', '0 - 1', '0-1.|Minimum', 'II-IV|NCCN-IPI risk score', '≥ 1.5X upper limits', '≥6.5%', '≥18 years.|Subject must provide written informed consent', 'above 40', 'more than 149 mm Hg', '≤ 30.0 kg/m2||', '> 146 mEq/L', '<=3*ULN', '>2.0×10^9 /L', '> 72 hours before inclusion|Readmission to the same ward after discharge|Hospitalization', 'greater than or equal to 50|Echocardiogram', '18-24', '≥ 1+', 'less than 34', '≥75 years', '<200 L/min IV', 'between 24-40', '40-75years', '≤ 10%|Patients', '3-20 kg', '≤ 100000;|Substantial', '>10).|For', '>15º', '< 60 milliliters', '≤ 242|Major', '>18 years and <80 years', '>= 1.5 ULN', 'greater than or equal to 75 or less than 18|Patients', 'levels ≤ 2.5 × ULN', '2+ requires', '>= 3 ULN', '75 years', '>6 hours', '≥100×109/L；|Biochemical tests', 'Less than 18 years-old', '3', 'ranges greater or equal to 140 mmHG', 'between 84 and 99|Beck', '> 144/94 mmHg;|Have', '≥ 5.6 mmol/L).|Hepatic', '>= 1000/mcL', '18 and 70 years);|CD19+ B-NH', 'scores > 22||', '>14 units per week', '≥18 years;|definite diagnosis', '5-7,|Not afraid', '> 22 kg/m2', '< 1 year', '≥ 1.5 ×103/L);|Platelets', '>38.5°C', 'more than 50 years', '19.00 to 26.00 kg/m2', '>30 years', 'less than 4 weeks from the end of the previous clinical study', '18-55 yrs', '≥ 1,500/mcl|Platelets', 'less than 18||Diagnosed chronic pulmonary disease.|Severe', '> 12|Inadequate response', '= 284 mL of beer', 'under 18|Inability to consent', 'older than 35 weeks', 'from 0 to 10', '150 mL or 5', '<35%).|Platelet count', 'remained stable', '1 year.||', '<50,000', 'between 140 and 199 mg/dL', '+/- 3%)|Non-smoker|Able', '≥ 25 kg', '> 20 pack-', '1-4)|Ability to provide', '< 5 mIU/mL)|Current smoking', '>1.5 ×ULN.||Adequate', '18-35 years|Sufficient', 'Individuals ≥18 years', '<30 mmHg', '90 to < 150 mmHg', '≤ 30 mL/min|Concomitant', '≤ 2||', 'equal', '12 to 20 years', '5.7-6.4%', '<2.0 mg/100 mL', '85-119 mmHg', '≤ 75 years old', '>3.0mg/', '> 14 units/week', '45 U/L||', '≥ 18 years|Performance Status', 'Urology||', '>= 30 mL/min/1.73 m^2', '>30 mL/min||Coagulation - prothrombin', 'between 25-45|able to travel regularly to the study location|interested', '>50 years', '<= 1.5 x ULT (upper limit of normal value', '20% or more', 'longer.||Hemoglobin:||≥ 11.0 g/dL', '> 60ml / min|LVEF', '< 18 years or', '18-75 years old', 'more than 30 g/ day', '2 to 17 years old', '≥ 65 mm', '4&5|Any patient unfit', '> 25 mmHg', 'ALT≤ 5 x ULN', '0 to 2;|Informed Consent Form is signed', '3 or', '>5%|people', '18]F-PSMA-1007 PET/CT', '≥ 75 x 10^9/L', '>9 HAD', '>26', '40-69', '≤ 1.5 × ULN。||', '≥ 16;|Time from', 'between 1/1/2010', 'between 18.5 kg/m^2', '> 200 mg/dL', '≥90 milliliters per minute', '18.5-24.9),|Not', '<6 months).|Using', '≥ 1.5 × 10 ^ 9 / L', 'class II-IV', 'from 18 to 90 years|amputation', '<40%.|Use', '≤ 35%', 'impaired', '0-2|Current', 'between 5.5 and 10.5 g/dl', '> 2 times the upper limit normal.|ECOG performance status', 'requires dilation', '>55 years', '18-50 years.|Willing', '≥ 120 ms', '≤ 5 times UNL.||No history', '1990 and 2010.|Minimum score of 4 on the', '< 12 months', 'between 4 and 18 years.|Informed consent signed by parents/guardians.||', '≤ 35 kg/m2|Between', '≥45 and ≤100 bpm|Temperature ≥35.5 °C', '90%', '= 10 g', 'Stage 2-4', '≥ 3 months.|Patients', 'a:||18-75 years;|At least one', 'score < 24/30;|alterations', '<48h', '100 g/L', '>=1.5 cm', 'less than 500 cells/', '3b - 5', '< 1 year|Any factor', 'III or IV category', 'I-III.||No', '0-28', '≥ 20 ng/mL.|Current', '> 91%.|Left', '>35 years|Type 1 diabetes', 'moldable', 'upper normal limit', 'between 18.5 to 40 kg/m2', '> 3 times the upper limit|Stubborn constipation', '> 30mm||', 'less than 50.0 kilograms (kg)', '≤ 2 weeks', 'between 30 and 75 years|Diagnosis', '>6 cm', '≥ 50', '≥ 9.5%', '130-139', 'more than 0.5 teaspoons', '≥ 5%|CD19 expression', 'younger than 3 years old', '> 12 Children', '≥ 1,500 cells/mcL', '<- 2', '≥ 18 years|Signed', 'equal to 0', '>14|Acute', '≥ 18.5 kg/m2', '< 470 ms', '>= 50 mL/min/1.73 m^2', '=< 3 x ULN|Alanine transaminase (ALT)', '50 or older', '18.5-30|Able', '18.5-24kg/m2', 'at least 4 weeks after the end of whole brain radiation', '> 3|Prenatal examination reveal', '1-Pt', '18 to 60 years old|Those', '≥3.0 x upper limit of normal [ULN', '≥ 20 kg', 'within normal institutional limits||', '≥ 15%', '40-', 'above criteria', '80-150x106 CAR-T', '>T', 'at least 1 mm', '3-7', '18 to 60 years)|Understands Danish||', '50.0 kg.|Female', 'less than the threshold value', '≥ 30 kg/meter squared', 'between 18 and 65 years|Free of pain', '18 years old or greater.|Eastern', '0-1.|Good organ function|The', 'from 17 to 22', '=< 3 x institutional ULN|Patients', '≤ 75 kg', '≥200/μL', '>= 40 ml/min', '≥ 2000 units/ml', 'above 100kg|Known', '> 2 ×', '< 4000/μL', 'greater than 75', '<30 mL/min/1.73m2', 'greater than or equal to 10.7', 'between 11-15|English speakers.|Migraine group', 'equal to or exceeding 500 ml', '<3 months).|Have', 'or free calcium ≥6.5mg/dL(≥1.6mmol/L', '>= 20 years', '<50kg;|Body Mass Index (BMI)', '<6 months old', '53-75 mmol/mol', '≥ 1 gram per gram', '≥ 18 years.|Performance status', 'vegetarian', 'between January 2016', '>30 kg/m2.|Failure', '=1.5 x ULN', 'between 3 defecations per day and 3 per week', '<7 mmol/L', '3-6 years', '< 100,000 µL-1|Exempt from', 'between 55 - 90 mmHg', '≥ 70 years', '<3 months)|Recent surgery', '> 460 ms', 'less than 90 mmHg', '≤ 39 year', '>=25)|Diabetes', '0 or 1.|Adequate renal', '60 or over||', '≥ 2000 IU /ml or 10000', 'less than 2 months prior to starting the study', '3x/week', 'lower than 3.9 mmol/L.|Patients', '>10 year;||Adequate', '>=1,500/mcL||platelets', '≥ 126 mg/dl|A', '>100.4 F', '2 or higher', 'between 18 years and 65 years', '≤ 17,5 kg/m2,|A willingness', '18-60|medical', '≤ 1||Adequate organ function', 'score standardization', '>0.8', 'Grade II or III', '<1 g/24', 'upper limit of 65 years', 'less than 7 mg/dl', 'equal or higher level than the', '≥ 60% of predicted', 'migraine|Taking more than 3 alcoholic units', '≤2.5 x ULN', 'greater than ULN|Participant must understand the investigational nature of this study', 'between 37-42 weeks of gestation|Not', '<18 months', '≥ II;|Cardiac ejection fraction', 'from 18 to 40 years old', '5-6/6', '>/= 6 months)|On', '18 - 60', '1-34', '>= 9.0 g/dL', 'less than 30 min', '0-1|Hemoglobin (HGB)', 'A/B/C', '<9 cm/s|NYHA class', '≥ 60 mL/min|Participants', '<50%)|Obstructive multivessel coronary atherosclerosis', '18 or above;|Caregivers', '≥ 15 mm);|ECOG score of', 'between 50-100 kg|Healthy', '>4kg', '>155/95]|Breathing', '≥40 kg/m^2||History', '<30 ml/min', '≥ 27.5', 'equal or more than 30 ml/min', 'below the lower reference limit).|Other condition', '18 or older|Within 12 weeks after starting ICI treatment for cancer|Cognitively oriented', 'at least 12 weeks|At least one', ""female's vagina"", '≥70|Females with a', '< 3.0X ULN|Bilirubin ≤1.5 x ULN', '≥ 10 ⁴ copies / ml', '< 50 or > 120', '≤1.5-fold the ULN of the study site', '> 500 ms', 'more than or equal to 1.7 mmol/l|High-density lipoprotein', '20% ≤ FEV1 ≤ 60% of predicted', '> 11.1mmol/L', '160 mg/dL', '≤ 180/104 mmHg,|Heart rate', '≥ 45 ml/min/1.73m2|Stable doses', '≥ 30||', 'CCr)≥60ml/min', 'between 10°', '15-49', '≥5.0 mEq/L|Serum bicarbonate', '<6|Recent', '≥ 18 years|Able to swallow water||', '> 48 hours|Obtained written informed consent', '>20 mm Hg decrease', '18 years||', '> 30 minutes;||Inclusion Criteria', '=< 2|Hemoglobin >= 80 g/L', '> 90 g/L', '>=65 years|Primary', '≥ 8.0%', '30-70 years', 'between 2 and 3 of the functional category of', 'class I or', 'greater than 25cm²', 'between 18 to 65 years|No', 'under 18 years old|Pregnant', '≥2.5 cm proximal', '≤ 5.0×ULN', 'between 3.0 and 10.0 mg/L||', '>=1 year and <18 years', '> 100 x 10^9/L|Patients', '0 or 1|Histological', '0-25 years', '<4 years', '18-50 yrs', '<15.|Patients', '<150,000/mm3|Absolute neutrophil count', '1, 2', '≥ 18|Report of snoring|Prior', '>4 mm', '≤ 10 mg daily', '≥18 and ≤60', 'topical treatments.|Patients above the', '50% White American', '> 102 cm|women', '≥18 years|Willing and able to comply with clinic visits', 'less than 60 degrees.||', '>=half of the maximum approved dose', '1-current', '<50 nmol/L.|The subject', 'score <13', '> 200 mg/dL|Cancer', '> 50 mmHg', '≥ 18 years to ≤ 75 years|Pathologic', '92% or greater|Participants', '>120 kg', 'no more than 1 days per week', 'less than 24 hours', '≥ 3mm).|Willing', 'less than 60 %', '< 12 months)|Patients', '> 120 days and < 18 years', '≥ 30 years', '< 40 mg/dL.|If', '1 to 15 year', '<=140', '3-18 years；|Proteinuria', '≤ 5 x ULN|Total bilirubin', '6 - 35 months', '≤ 30.0 kg/m2', '≥ 18 years and ≤ 80', 'C - D)|Barrett', 'at least 20kg', '>1.5 times ULN.||Any of the following cardiac criteria:||Mean', '< 7.4 mmol/L)||History', '≥ 15 times one hour', 'at least 5 medications.||Exclusion Criteria', '10 pack years.|Be aged', '≥3 months||Adequate organ function', '> 3 x normal', '18-70|Radicular', 'between 18 and 35', '>5||', '<5 g/dL|Blood', '>= 1.0', '++ but negative', '6.0', '>300 pg/mL', '< 150 days prior', 'nclusion', '51-75 years old', '>75%)|Those', '≥ 1.0 U/mL', 'between 40-70 years.|All the genders.|Participant', '1-3|Underwent', '18.5 or more', 'from 11-15 mm', '> 16cm', 'I - II', '≥ 3.|≥10% body surface area (', '20 cigarettes/day|Those', '< 3,000 cells/mm3|Absolute neutrophil count (', 'between 11 and 17 years', '18 and 40 years.|Current neck pain.|Presence', 'more than 3 times', '2-5', '> 50% HRmax', '≥ 10 days;|Participation', '< 16 years|Document', 'above 7 ng/mL', '1.5 times higher than normal).|Other', 'under 12 and over 8 years|Presence of obesity', '≥ 48 mmol/mol|History', 'less than 5 years.|Subject', '≥ 6 mm', '2/3 lung', 'greater than 50 kg.|Patient', '<3 × ULN', '> 2 times upper limit of normal (ULN)', '=< 14 days from', 'greater than 3 times the upper limit of normal|Serum', '65 and above|Currently', '1 and ≤ 3', '99 lbs;|(for', '< 150 mg/dL', '>= 2.9 m/s', '12-60 months years old|Healthy', 'III-IV;|unstable angina', 'stage II, III and IV of', 'equal to -2 mL/min/1.73 m2/year', '18-60 years.|Gingival', 'between 60-75 years|BMI', '≤ 1.5 × ULN；⑧', '>=10 grams/deciliter(g/dL', '≥ 18 years old;|IgA nephropathy', 'more than 350 µm', '>11', 'between 10', '- Urgent/emergent', '>30kg/m²)|Professional athletes|Pregnant', '≥2 years|Heterozygous', 'Stage II (Thase and', '0 to 2', 'draws.||Less than 2 acceptable', '≥150 min/wk', '18-45 years|Singleton', 'between 35 and 80 years|BCVA ≥ 75 letters', 'between 55 and 75 years and >1800 pg/mL', '>7 mg/dL.||Individual Level Exclusion', 'at least 2 weeks to judge', '≤ 1.5xULN', '> 60 days from', 'between 30 and 60 years||Evidence of prior', 'at least 1 cm2', '4 or', '≥ 4.0 mm', '> 18 years old,|Patient', '>15 mmHg.|Any', '90 to 140 mmHg', '< 5 x', 'from 18 to 65 years|Both genders', '1.5 mg/dL', '<35%)|(6', 'greater than or equal to (>=) 3.5 kilogram (kg)|Parent(s)', 'less than 12 months|The', '≥ 18 years|Colon cancer', '< 15', 'less than 2 weeks ago', '>= 1 and =< 24 obtained =< 30 days prior to registration|REGISTRATION', 'less than 6 months|Diagnosis', 'male|Aged 18 to 85 years|Scheduled', '≥100 mmHg);|Corrected QTcF interval', '>450 mL);|Have', '18 till 70 years.||', '≤ 2x upper limit of normal', '≥ 10mg/dL', '20 - 50', '≤ 10bpm.|Patients', '< 2 L/min', 'greater than 50 bpm.|Diabetic', '< 25 dB HL', 'less than six months)|Intra-', '+/- combination Abiraterone', 'less than 20% of the lungs', 'between 13 years and 17 years and 11 months|Good understanding of written', '< 50 kg|Age', '≥ 3 × 10^9 /L', 'individuals|Above 18 years', '< 1.5 × ULN', 'from 13 to 16 years', '< 30cc/kg', '60 or older', '<40 years|Patients', '< 1800/mm3)|Inability', 'equal or less than 60 bpm', '<1 month', '>150u mol/', 'score of 3 or', '≤ 22.|Iron deficiency.|Vitamin B12 deficiency', '> 10mm||Lesions', '>= 75,000/uL.', 'less than 10 years;|7', '≤ 1.5 × institutional ULN', '>-2 and <2 SD', '50 to 90 mmHg', 'less than 100 μm', 'from 40 to 55 years', '<90mmHg', 'Under age', '< 1 cm', '3.5 × 10^9/L', '0-28days);||Being', '>150mmHg', '> 0|Taking > 5 mg/day', 'ISI)|between 18 and 35 years', '>5,5 mmol/L)|Major adverse cardiovascular event', 'Stage 2||Men', '=< 65%', '≥65 years|Self-reporting', '1.1.|No more than one', 'higher than the lower limit', '≥200 mL)', '≤ 2.5 × ULN', '≥ 2.5 G/L|Patients', 'less than 65 mm Hg', '< 30 cm.|Infants', '≥1000 g|having', '-arrythmia -Linguistic', 'Older than 18', 'less than one year.|Subject', 'Stage IV/V', 'score of 10 or more', '3-6)|poor oral hygiene|periodontal', '<0.6 cm2/m2|Patient', '<110 pounds|Diabetes', '> 500 mg/', '0 or 1|Histologically', '65-80 years', '<60 minutes/day', '<170', 'greater than or equal to 3', '≤ 35 kg/m2', '> 37.5℃', 'between 18-35 years;|≥150 min', 'between greater than or equal to 25 and less than or equal to 35 kilogram per meter square (kg/m^2)', 'from 30 to 75 years old|Participants', '>30 g/day', '<2', 'above institutional normal', 'at least three months|No', '>= 1% blasts', '> 160 mgHg', '≥ 30g/L. 3', '> 40 kg/m2|Haemodinamic', 'between 18 and 60 years|complaining', '< 90 ml/min)|Interfering treatment', 'less than or equal to 60 minutes', 'grade 2 or better from', '> 12 mg/dL', '20 or over|Willing to participate in this study', '≤ 4 days prior to screening', 'more than 20.000/cmm|Patients', '60-89 mL/min/1.73 m2)|Chronic renal impairment', 'less than 12 years old', '≤ 1.5 × ULN;|Investigators evaluated', 'Individuals 18 years old or older', '<300', '18 to 40', 'Stage IIIB', 'I-III.||', 'over 35 kg/m2', '≤ 3.0 × ULN;|Serum', '25 - 29.9 kg/m2 s', 'more than 8 mm', '>= 6.206 millimoles per liter', '≤ 1.5 x ULN', '12-80 years old', '≥3 months|Prior to the enrollment', 'more than 470ms;|When screening', '≥ 480ms', '>185mmHg', '>14 ng/ml', '>3 and <12 in width or length', 'between 4 and 12 years,|no neurological', '≤ 3 mg/day', '>=2 cm', 'less than 3|Qualifying Stroke Event', '≥ 75 × 10 9 /L（75', '> 38.5°', '≤ 72h.|PCR positive', '> 5.7 %|Abnormal', 'maximum 6 years after the age', '18.5 to 31.9 kg/m2', 'requires referral', 'greater than 85 mmHg', 'greater than (>)', '≤ 2.0 times the upper limit of normal|Adequate social support', '>37.0℃', '< 60 mL min-1', 'I to II|Scheduled', '1 group of 25 Fibromyalgia', '≥ 500 IU/mL', '≤ 5 times ULN', '≥200 mg/ 24h', 'between 12-16 years.||Overbite', '=< 2.0 times Upper Limit of Normal', '≥15 × 106/ mL|PR <32%||For OA:||sperm concentration', 'from 20- 60 years', '< 5 mg/L', '≥2 patients.|Pain score', '19-24kg/m2', '≤ 1.5 x', '>460', '≥18mm', '1 or 2;||8', '≥18 and ≤49 years', '937-951 - Table', '18-30 kg/m2.|The', '≥ 90 mL/min', '< 18 years|Patient not eligible for', '<4mm', '<30ml/min', '>2 ULN.|Prior treatment', '≥ 50 mL/min', '20-70yrs', '18-65 years;|2', 'below 15 µg/L', 'between 18 and 90 years', 'B-C;||A.', '100U/mL', '<140/90 for ≥1 month prior to randomization).||Note', '< 100,000', '≤1.0 g.|Blood coagulation test standards', '18-50 years;|Diagnosis', '0 or 1|Hematological', '5 or more years prior', '>1mg/dL', '> 125 mg/dL|Fasting', '< 45 ml/', 'between 01/01/2010', '≥ 70% and <100%', 'between 60-80 years', '30-60|BMI', 'at least 3 months|No', '18-65 years seen', '18 years and above', '≤1.5x upper limit of normal', '≥25 kg/m²', 'I-III|elective spine surgery||', 'above T10.|Known', '>150/90 mmHg).|Orthostatic hypotension', '18-80|US resident|Individuals who endorse yes', 'greater than 140', 'greater than 3 times the upper limit of normal', '< 2.5×ULN；|serum creatinine', '≥ 90g/L', '<2g/ 100g', 'PLT)greater than or equal to 80 × 109', '≥ II', '= 360 mL', '>250 mcg/g', 'over 18 years old|Chronic shoulder pain', 'between 18 and 40 years', '> 35 kg/m2)||Inclusion criteria', '≥ 305', '0 to 1.|Has', '≤ 3 ×', 'greater than 18.5', '37-41 weeks', '<10g/dL', '> 90 x 10*9/L|BMI', '≥ 1.0 x 10^9/L|Platelets', 'less than or equal to 60 points', '1 oz 40%', '< 160 mmHg', '≤ 1.5 X institutional upper limit of normal', 'months])|International', 'between 45 - 84 mm.||', '≥ 80', '≥ 19 years.|Body weight', '≥ 70 points', 'slow', '> 18 years|General condition WHO', 'from 1.5 to 18', '>20 g/day', 'greater than 30;|Allergic', 'greater than or equal to [', '< 3)|absence', '> the normal control median', '≤60 or ≥100 bpm|Sinus tachycardia', 'older than 70 yr||ASA class IV', 'between 18-80', '18-50|applying', 'lower than 1,500/μL', 'less than 15 ml/min/1.73 m2);|Known', '>= 20', '≥ 18 years|Biopsy-proven', '1 and 2 of study:||Have', '≥500 copies/mL', 'grade 0-2', '≥80% predicted', 'greater than 40 ml/min||', '5-7', '≥ 50 years,|PSA', '≥1.5 ×', '>18 years|Greater than 3 months', '7-9', 'between 7 to 12 yeas|Children', 'III/IV)|Elevated', 'Age≥ 18 years old', '>93%', '≥18 y of age', '≥12mm', '= 75', '>32', 'less than 30 days before participating', '1 drink/day', 'long-term', '2018|23-80 years', '>25||Exclusion Criteria', 'between 19+6 and 36+6 weeks', 'less than 45mL/min', 'less than 30 minute', '> 1.5X the upper limit of normal', '15-21,|currently', '<70% predicted', '≥ 10 mmol/L', '>18 years.|Performance status', '8-11 months of age|Step', '18-40 years|Normal', '< 18 years|Pregnant', '18 to 65;|Pathological type', 'stage I to IV)|Patients', 'Class IV heart', 'CCTA|Uninterpretable', '<50% Diagnosis', '<3.0 mmol/L|Sodium', '≤ 3|Excessive airway mucus secretion', '< 32 weeks|birth', '≥ 450 ms', '≥ 1%|HER2', '> 50 Kg|Haemoglobin', 'more than 30 years', 'before January 1st 1968', '>=3).|Have evidence', '≥ 50% retention', '<120 ms|QRS duration', '< 0.01%', '>1500g.||', '≤ 2 years', 'between 18 and 30 kg/m2|Body weight', '≥30 kg/m2|regular', 'not older than 2', 'confirmation', 'scores of 17-23(>17', '=<12', 'above 180 mmHg', '< 30|No', '=< 4x upper limits of normal', 'Stage 2-4 ovarian', 'between 23.0 and 34.9 kilograms per meter square (kg/m^2)', 'scores of 18.5 to 34.9.||', '>1 use', '>T - (', 'Class II or above', '≥ 37.5 °C', '18-70 years|In', '= weight (kg) / height', '≤ 5 x ULN|FEV1', 'I-III.|Documentation', '0-1；|Expect', '55 to 80 years', '1 or more', '18-75 years.|Lung function capacity capable', '<2L', '≥80 years', 'higher than 5ULN', '≥ 3.0 cm', '< 68 cm', 'more than 140 grams per week', '4-40', '>2.0 times ULN.|Geriatric Depression Scale', '18-49 years', '>2.6.|Patients receive', '≤ 2.5 times the ULN|TSH range', '< 18ans|Clinical Stage T3', '190 mg/dL', 'above this threshold', '> 15 mL/min/1.73 m^2', 'above 160 mmHg).|Known', '≥ 500mg/dL;|Diagnosis', '≥ 12 weeks;|Normal function', 'equal or above 55 kg', '> 200 μg/dL', 'score greater than 12.|Subject', '< 10ng/mL', '>350 cells/mm3', '≥65 years', '1.5 X 109/L', '7 to ≤21', '>= 2 years before enrollment', 'at least 1 designated symptom ≥2', '≥ 100mg/L', 'above the', '< 1 year|Pacemaker', '+/>18 years|Recruited from Duke University|Local community members||', 'between 20 and 50.|Knee varus', '= 2,500-12,000/mm3', '= alanine aminotransferase AST', '> 3 times the upper limit of normal.|Neutrophils < 1x10^9/L.|Platelets', '<20%.||', '> 6/10.|Participants', '≥12%', '6 to <12 years', '0-1.|Both', '0-2;|Expected', '≥ 490µm', 'greater than or equal to 30 yrs|Established', '<148pmol/L),|Serum', '≥12 s.||', 'score < 21', '0-1.|4', 'I subjects||', '≥16 at screening|Currently participating', '< 2.0)|Females', '< 7.35 D', '≥1.5', '=< 1.5 x ULN|Albumin', '>100 mmHg diastolic)|Acute', 'Abemaciclib', '≥ 30g/L', '>= 50 mL/min per 24 hour urine test', '> 5);|Stabilized dose of mood', '>50% of wound', 'less than or equal to18 years', '=< 1.5 institutional upper limit of normal (ULN)', '18 to 65 years old', '≥S2);|ALT continues to be normal', '0-1|6', 'B or C) before study entry;|2', 'score of 5 is the cut-off', '18 to 45 years inclusive', '< 45% noted', 'between 175-216 days', 'above institutional', '95%', 'less than 6 months.|Radiation', '≥5x ULN', '<15% calories', '>4 units/day)|Allergy', '>G', '>60 years.|American Society of Anesthesiologists physical status', '0-1;|Sufficient', '≥ 55 %', '≥ 5%', 'above 4.9 mmol/L)|Anormal', 'under 40 years', 'greater than or equal to (>=) 18 years to less than or equal to (<=) 55 years', 'between 14 to 24|Meets diagnostic clinical criteria', 'between 1-2.5, inclusive', '<4', '≥18 years),|Affiliated to the', '6 to 24 months old|Caregiver', 'greater than (>) 1 year', '>550msec', '55 to 90 mmHg', '>= 1000/mm^3|ELIGIBILITY CRITERIA', 'between 65 & 80 ys|elective', '< 15 mL/min/1.73', '<45 kg/m2||', '<30 mL/min|Hemodynamic instability', 'between 25-40||Both', '< 4000 µl', '2 times of normal value upper limit;|The', '> 70 mmHg).|Have evidence', '21-99', '>35 s', '37', '18-65 years|Body mass index', '≥ 30kg', '≤ 2.|Patient', '≥ 500 IU/mL.', '10g/dL', '≤ 20ng/ml', 'more than 24', '22-28', 'between measurements.||If the subject meets', '0.06-1.3 mg/dL|Able to give', '28-85 years old', '60 kg to 100 kg.|Healthy volunteers should', '6MWT', '≥ 200,000 IU/ml', 'greater than 20%', 'under 65 years', '> 12,000 or < 4,000 cells/μL', '<70%', '≥ 3.0 × 109/L.|Platelet count', 'less than 90 days', '<12 months;|Intolerant', '> 2)|Ability to understand', '< 18 or > 35;|Asthma', '10 mm Hg', '≤ 30 mmHg', '20-80', '≥ 55kg', '<15%', 'C-reactive protein', '>2 min', 'More than 10 weeks', '7 to 17 years', '>140/90 mm', '18.5-24.9)||', '> 15 standard units per', '≥18.5 to ≤30 kg/m2.|Clinical diagnosis', '≥2+', '< 11.1mmol/l.|BMI', 'below 400um', '1,7 mmol/l|Reduced', 'letter score ≥ 79', '>29|Abdominal perimeter', 'over 110 points from the PMS', '≥ 1.0g;|Patients', '≤1.5x ULN|Baseline proteinuria', '>3x ULN|Signs', '≥ grade 3 irAE', ""1-3|Patient's ulcer"", 'greater than 15 years', '0 or 1;|informed consent signed', '≥ 40 kg/', '> 25 O-Log score', '60 to 80 years""|Patient', '>180 g/L;|WBC', '≤ 1.5 times the upper limit of normal [ULN', 'at least 3 months.|A', '≥ 0.2 ng/mL', '18 years or older.|Subject willing and able to comply with study procedures', '≥50 and ≤80|Both smoker', '< 4||non', '55-75 years', '0-1.|Estimated', 'less than 35 kg/m2', '18-75;|Colonoscopy biopsy', '18 - 65 years)|Overweight', '≥15/', '> 1.7', '> 18 years.||High-risk SMM', '≥ 2.8 g/dL', '< 34%', '≥ 50 ml/min', '≥ 5.2 mmol', 'between 200/7', '>200 mm Hg systolic', '≤ 90 mmHg.|Capacity to', '<3.0 mg/dl', '0-1;|6', '30-75', '≥1cm and <14cm)|The participant', '< 2', '>= 21 years,|Ability to provide informed consent,|HbA1c done within 6 months of recruitment', '>37 gestational', '> 1.50 D', '> 3.0 g/dL', '18 - 89', '< 36 kg.m-2,|Age', '≥ 5|Able to differentiate', '≥ 50 mL/min/1.73 m2', '>9', '≥ 80g/L', '24 to 32 days:||If', '<5% of', '≥50 ml/min', '> 9', 'ruptured', '> 500 pg/ml', '<3.5 g/dL|International', '0-2.|Patient', ""≥18 years.|A patient's"", '0-2|English proficient|If', '>= 1,000/mcL|Platelets', 'lasting < 30 minutes|articular crepitation', '>20% of the surfaces|Periodontal', '< 35%|moderate', 'between 35 and 45.|Had', '4-10 ng/mL|If prior', '5.6 - 6.9 mmol/L', '≤ 3 weeks prior to study', 'between ≥0.5 to 3.0 grams (g)/g/day', 'younger than 55 years', 'I-', '>2.5 × upper limit of normal|Lactating', 'score of ≥4 out', '>8%', '>300 households', 'between 20-50 years.||Chronicity of radicular', '29 kg/m2|Normal', '≥ 3.0 mg/dL', '<60 mL/min', 'greater than 1000 IU/mL', '6-23 months', '27 November 2017', 'between 3 to 6', '>= 100,000/mcL', '≥150 min per week', '<18.5 kg/', 'partial response (PR)', 'more than 300 pounds', 'grade 0-1', '≥2cm distal to the most distal coronary artery ostia|Proximal', '<346ng/dl', '≥ 30 years;||Because', '65 or older|Speak English', '4 - 18 years', '≤50ml/min', '> 2 hours', '>8).|Willing not', '30% or greater', '4-7 weeks', '> 20', '= 300 mmHg)|Presence', '=< 75 years', '≤ age ≤ 85 years;|Idiopathic', 'at least 18 year-old', '>= 1.5', '> 1000 U/mL.|Moderate', '1-2 and 3', '>1×104 copies /mL or >2000 IU/ml', 'employee', '< 6 months ago', 'to 18 years|pregnancy and lactation|patients', 'maximum score is 25', '29-550)).|Able', 'between 18-75 years||Exclusion', '> 4x upper limit of normal (ULN)', '≥ 1,000/mm3', 'earlier than 37 weeks', 'equal to 120 msec', '≥18 years|Patients must', '100,000/mm3', '< 26', 'long-term follow-up after administration Sex||Male', '> 16.0 g/dL', '> 40 =', '≤1.5 ×ULN', 'tests)|Testosterone free level greater than 10pg/mL|Hematocrit', 'short', 'above Class II|History of psychiatric', '≥265 mg/dL', '≥90 mL/min', 'reactionsCounter-indications', '>21 days', '40 to 68', '≥2 cm proximal to the', 'stage 2):||Signed', '≥140 systolic', '0-1 points;|(4', '> 2.5 mg/dL', '<2 ng/dl', '19 years of age or older', '>36 mmHg', '1 year or more', '50% or more', '<++', '12 to 17 years', '< LLN 13', '<0.5 x103/μL|Platelet count', 'at least 1 year||', '≤1.5 mg/dL', '18 - 65 years', '>3 mg/dl', '7% to < 8%', '<2 years|Pregnancy|Clinical history', '>= 3/10', '1.1 criteria;|estimated', 'between 8 years', '65 and older|Difficulty', 'between 18-40 years.|Normal husband', '10.0 g/dL', '<6).|For', 'between 1 to 40 years', '≤ 1.5× ULN', '> 35.|Previous hip /knee/', '> 80 cm', '>100x 109/L', 'Between 4-16 years', '=< 2', 'dose ≥ 0.4 μg/kg/min', '<100 × 109/L', '>= Grade 3).|HBV', 'exceeded the inclusion', 'greater than 3.0%', '≥ 50 x 109/L', '< 60 mL/min/1.73 m2||x', 'between 18.0 and 32.0 kg/m2 inclusive', 'exton 20ins.|Eastern', '4-12', '21-80', '50 to 95 mm Hg for diastolic.|Participants', 'measured greater than the 95th percent', 'score of 3 or 4', '90% of the items.||', '≥ 150mmHg', 'predominant', '> 1 cm', '≥9.0 g/dL;Platelet count', 'older than 60 years', '<277 pmol/L', '3-9 years', '≥4 and <16 points', 'above the upper limit of detection', 'above 18 years|patients', 'greater than or equal to 85th percentile', '30-64 years', 'better than distance', '<55 for', 'between 40-60 years.|Unilateral', 'ocular media', '18.5 to 35.0 kilograms per square meter (kg/m^2', ""20 weeks' gestation||Hypertension"", '≥ 18 y|Written informed consent', '≥240 mg/dL.|Fasting', '> 2/3', 'patients;|Patients underwent', '>=12 on the', '6-24h after onset', '18 and older|Patient able to understand requirements of the study', 'Being 65 years', '≤ 100 mg/day', '≥ 1.0 cm', '≥6g/', 'younger than 16', '≥ 100×109/L|The', '1 MSM||18 years', '18+ and', '0 or 1.|Phase', 'between 50-100 bpm', 'B class', '>18.0 kg/m2', '2 to 6 days||', 'profusely', '5 % or more|Patient', '1 - 18 years', '= 4 weeks', 'assessment.|Unwilling to sign', '≥ 1,500/mcL;|Platelet', 'equal or superior to 20 mmHg', 'II-IV|6 min walk distance', '0-2 points.|Normal results of laboratory tests', 'at least 2g per deciliter', '<4 mm or >8 mm', 'between 20- 30 years', '18-75|Not', '<18 years|Pregnancy or breast', '>140mmHg or <90 mmHg', 'more than half a', '≥ ++', 'under 18 years old|pregnant|no need for', 'ranges between 18.5:24.9 kg/m2.|Patients', '> 140 msec', '<50 ml/min', 'greater than or equal to 9%', '> 1.7|Platelets < 50,000|Renal Failure', '≥12 weeks;||9', '≤500 IU/L', '18 to 35 kg/m^2', '≥ 3 months;|Use', '<18.5 or >35 kg/m2|An ulcer', 'between 01 January 2000 and 31 December 2022', '<2.5', '> 70% stenosis', '>2.0 times ULN', 'acute drop of the GFR', 'between 4 years and 17 years;|difficulty in', 'twice a day', '≥8 points', '>12;|History', '15 minutes|Unable to operate', '<4.6', '12 to < 18 years', '18-50 years', '10 cm x 10 cm x 5 cm', '>75 years', '> 65 mmHg', '> 150/95 mmHg', '>7|In the opinion', 'smaller than 51 centimeters', 'between 0.15 and 0.4 ng/mL', '26-32', '> 3 months)|BMI', 'less than 55 mmHg', 'below the limit of quantification', '20 mm', '≥ 18 and ≤ 85 years;|Plan', '≤ 80% of predicted value', '>= 3 months prior', '< 80g/L', '100 109/L', '≥ 35 weeks', '<= 20|Reduced peak hip', '>50 ml', '<7.32;|', '>= 20,000/uL||Minimal', 'more or equal to 23 kg/m2.|In', 'equal to or higher than 75×10^9/L', '>50 mL', '=< 2.0 mg/dL|Participants', '<13 g/dl', '≤ 2 × Upper limit of normal value', '> 1.2).|Proteinuria / hematuria / glucosuria', '< 25 × 109', 'less than 60% of the patient', '≥ 18 years|Proximal', '>= 20 kg', 'higher than 1000 copies/mL', '> 1 -year||', '> Upper Limit of Normal', '<60', 'between 13-20 years|Available', '18 to 65 years old;|Able to provide informed consent and read', '0-1 myoma', '≤ the upper limit of the therapeutic range', '< 3000/', '≥ 45 mL/min/1.73m2|Stable doses', '18 years or older.|Patients', '> 0.20', '<18|Patients', '3IQ)|Able to', '0.6 mg/dL||Age', '18 to 35 kg/m2', '<LLN', '≥ 18 years|Current length of intensive care stay', 'S/β-thalassemia', 'between 28 and 35 days', '± 4 days maximum difference', '≥ 4|History', '45 mL/min', '≥ 4.0 × 10 9 / L', 'less than or equal to 3 years from original', '90-160 mmHg', '>= 20 mm', 'over 99 mm Hg', '> 8%)|Subject', '≥ 60 ml/min.|Prothrombin time (PT)', '< 60ml/g/m3', '>5.0 mg/L.|At least three', '< 110 μmol/L.||12', '>= 40 mL/min per the Cockcroft-Gault formula', '7-10', '≥ 92', 'less than 500 IU/mL', 'greater than ULN|Have measurable disease', '<50,000/mm3|Serum', '≥ 65 mmHg', 'less than 2 weeks', '>2.|Patients', '≤ 3 ⋅ ULN', '>11 mg/dL)|Renal insufficiency', 'follows:||At least 8', '400 meters|Can read', '3b/4', '< 50,000 per mL', '≥ 50%;||', '>6)|individuals', '≤ 30 mL/min/1.73 m2', '<70 mg/dL', 'greater than 24-hour stay', '< 500 IU/mL|The', '≥18 years when signing the informed consent form', '≤ 25% of the dressing area', '18-85 years;The diagnosis', '< 100,000).|Known peripheral neuropathy', '≤ 2.5 x ULN.||Cardiac function', '< 100 g/L;|Coagulation function', 'tuberculosis', '>= 60 ans|Poor', 'greater than 35 weeks', '> 2 and', '>90 beats per', '0-1;|Has', 'WBC)greater than or equal to 3.5 × 109', '≤ 75 years.|Hoehn', '15mm', 'less than one year|Known', 'lens removal', '≥12 and ≤65 years', 'drop', '+/- purine analog', '≤ 1.5 × ULN；||Subjects', '> 3 months', '>= 60%', 'I - III||', '> 1.5 x institutional upper limit of normal (ULN)', 'from 32 weeks', '50', '< 5 L/s|have', '> 5 points', '> 160', 'between 8- 18', '0 to 1.|Patients', '≥ 3×10^9/L', 'less than 2 months|Heart disease', 'between 18.5 and 29.9 kg/m^2|stable', '< 18 years:||1A', '≥470 ms', '≥ 19 ③', '0, 1 or 2.|Adequate seizure prophylaxis', '> 1.5 mg/dl)|Chronic', '>70)|Ability and willingness to provide', '? Must', '>/= 3,000/mm3|platelet count', 'between 5.7∼6.4%', '50 to 90 bpm|Any laboratory value', '≥ 19 years', '≥ 50 % pain relief', '≤ 15%.|Pregnant', '18-65|Overweight/obesity', 'less than 4 weeks prior to study', '>18 years and <80 years|ST-segment elevation myocardial infarction', '> 7.0%', '> 400 IU/day', 'less than upper limit of normal (ULN)', '5 to 15 years born before', 'at least one', '> 103 copies /ml', '100-125 mg/dL)||', '>= 2 cm', '≥ 75%).|Patients', '10^6 copies/ml', 'more than 90%(%', '≤ 5 UNL', '10-18|absence', '≤2.5 times ULN', 'subjects|between 18 and 35 years', '18-30 kg/m2', 'I-III.|LVEF', '=< 5.0 x ULN.|RECIPIENT', '10*9/L);|Subjects', '> 35 kg/m2|Patients', '19-30 kg/m2', '> 45%', '> 120 msec', '>30 ml/min/1.73 m2', '> 30% of marrow-bearing bones', '>45||', '0-1||Adequate organ', '≥150 mmHg', '>37.5C', 'older than 40 years', '< 1.5 x ULN||*', '2.6-2.9 m/s)|10', '> ULN;|Blood amylase', '< 90mmHg;|Dopamine dose', '18-25', '≤ 3 times institutional upper limit', 'upper limit 2.5 times;Serum', '> or = 1,500/mm3', '18 years old.||', '<90 g/L', '≥ 1800 g', '> 20 mg/L', '< 40kg / m2', '>60 ml/min.|Atrial', 'over 18 years|surgery', 'within 24 months', '18-65|having', '≥ 160 mmHg', '=285 ml beer or 25 ml spirits', '≥ 8 years duration', '18.5-44.9 kg/m^2|Paternal', 'not consenting', 'less than 20 functional', '35 years to 65 years.|BMI', 'between 18 and 25 points', '> 1.5', 'less than 60 ml/min/1.73 m2', 'more than 180 minutes of exercise per week', '≥ 300', '>90%', '> 1.5 x the Upper Limit of Normal (ULN)', '≥ 90g / L||B.', '≥ 10 g/dL', 'between 20-40 years', '20-65yrs', 'score 0 or 1|There', '< 2.0 g/day', 'score ≤ 19', 'Abnormal', '≥ 100,000/mcl|Absolute', '≥ 200', '≤ 1.0× upper limit of normal (UNL)', 'less than sixteen years', '>38.0°C', 'equal to or greater than 5/10|Patients', '<18 or >35 kg/m2|Active', 'January 1st, 2008', 'lower than 35%)|Presence', '>= 50% of cellularity', 'between 2009 and 2015', '≥60 mL/min;Serum', '>= 18 years||Because no', '>102cm', '≥ 1 and ≤ 26 years', '> 2|Patients', '> 2,000 mg/ g creatinine||Other laboratory', '> 450 msec|QRS', '1000-1200 g', 'more than or equal to 100 mg/ dl', '≥ 85 g/L', '>160', '≥9);|KPS score', '≥ 1500/uL', '<9 g/dL', '≥ 1.5ULN', 'higher than 38.3', '30 years', 'at least 12 weeks|World', 'above the lower limit of normal', '> 250 milliseconds', '18 - 65|First-time transplant|ABO', 'understand Chinese||', 'less than 3|Prior endotracheal intubation', 'below 9 while not', '≥ 9.0 g/dl', 'under 18|sinus pathology', '25 or higher', '≤ 20%|Presence', '26-32 cycle days.|Fully healthy', '<=5 x ULN g', '18 years or older.|Subject', 'Class II filling', '>20mmHg', '9 to 16 years,|are able to read', 'II-III', '> 90 beats/min|Respiratory rate', '<40%),|uncontrolled', '9-10 weeks|Weight', '0 or 1.|Participants', '≤ 200mg/L', '18 years to 75 years', '≥7.5%', '≤ 5%', '25.0 to <30 kg/m^2 plus', '≥1.0×109/L', 'equal or less than 102 cm', '> 18 years;|Person', 'III-IV', '0-1|Estimated life expectancy', '18 years;|The targeted wound', 'between 10 and 19 years||', '≥ 0.3×10^9/L', 'Being 60 years', 'exceed 3 times the upper limit of normal value)||9', '0-10 scale|Oswestry Disability Index', 'between 40 and 55 kg/m2', 'less than or equal to 3 kg', 'of 30kg/m2', '<2.5 x institutional upper limit of normal', '18-65 years.|The patients', '=< 2 mg/dL', '≥0.2 mg/mg', 'more than 2 times the layer thickness);|Clinical pathology', '< 2.5 X institutional upper limit of normal', '≤ 3.0 ULN', '3 months to 15 years||Presents for care', 'no more than 30 minutes of exercise', '≤ 2.|Patients', '0 to 1;|Life expectancy', '30-70 ng/mL', '<90 milliliter per minute per 1.73 meter square [mL/min/1.73m^2', '0 or 1|Expected', 'between 21 and 70 years old', '>30% of predicted normal', '< 100*109/L;|Renal insufficiency', 'greater than or equal to 30kg/m2', '18-25 kg/m2|Subjects should be able to give', '18-80 years|Not taking cardiovascular medications|No', '≥ 18|Able to read', '>2 times the ULN', '≤ 1.5 times upper limit of normal (ULN)', '≤ 0.50 D hyperopia|Cylinder', 'between subsequent steps', '18,5 - 30 kg/m2||Inclusion', '≤ 2.5 times the upper limit of normal|ALP ≤ 2.5 times the upper limit of normal|Serum creatinine', '≤ 30 kg/m2|Conform to the', '≥ 100 × 10^9 / L', '>=150 min/', '≥ 40% predicted', '<2|For the HTN', '<=13.9mmol/L;||', 'more than 3 times the normal upper limit', 'less than 1 mm|Hemodynamically significant', '≥ 18 years|Subject', '≤ 2cm|Informed consent', '0-1||Normal organ function', '<38℃', '> 140/90 mm Hg', '50 x 109/L)|Allergic', 'less than or equal to (<=) 35 kg/m^2.|Participants', '≥ 24;|fluent', 'less than 15 degree|functional range of', '≥ 15% after CRT-D implantation', 'above 18 y old undergo', 'below 45)|Known severe', 'At least 18 years', '<35%|Ability to understand and willingness to sign', '9-12|do', '≥27·0 kg/m2', 'at least 10 pack years', '≥90mmHg);|Abnormal', 'less than 100 IU/mL', '13-18 years', 'grade II-IV)|Stroke', '18-60;|Participates', '≥ 3,000/', 'between 2.3 LogMAR and 0.5 LogMAR', '<22 points)|Self-reporting', 'more than or equal to102 cm', '> 3.0 times upper limit of the normal', 'less than 30 mL/min.|Participants', '≥ 2 and < 6', 'equal to or greater than mild', 'over 65 years;|Body mass index', '<90', '≥ Grade II', '> 30|Severe', '≥1,500/mm3', '≤ 1.5×upper limit of normal', '≤ 24);|history', '< 7);|2', '=< 2.5 X institutional ULN|Creatinine < ULN', '> 65 years|who', '≤ 15ml/min);|Severe mental disorder;|Acute', '≥14)|Body', '>10 kg', '0 or 1.||Presence', 'score ≥ 3)||', '50 to 75 years', '<24 hours prior to day 1 of treatment.|Contraindication to MRI', '>C3', 'females|Pain more than 1 month.|Piriformis syndrome', '> 30 minutes|post-traumatic amnesia', 'greater than upper limit of normal', '≥ 1.5 × upper limit of normal', 'Neutrophils≥1.5*', 'minimum of 10 percent (%)', 'less than 24 months', '1-3 score', 'between 0 and 5', 'assesses the extent of disease', '≥ 5.5 cm', '18 and 70', 'less than 7%.|Able', '≥18 kg/m2|Be willing', '<3 mg/dL)|AST(SGOT)/ALT(SGPT', '<80,000/µl', '< 35 kg/m^2|Able', '<20 ml/min/1.73 m2', '30-45 years|Capable', '>= 100,000/mm^3|Absolute', '≤ 55 years', '3-5cm', '>1', '?', 'and weight|Able to provide informed consent', '≤ 1.5 ⋅ ULN', '<=1.5 × ULN', '≥25 and ≤60 years', 'less than 4 weeks before vaccination', '35 years old and 65 years', '≥100,000/μL', '>1cm', 'score of 16 or lower', '0-1 points', '>30 kg|The participant', 'equal to or greater than 18', 'less than 1 year.|Subject', '15-28 days old approximately 10', '50-75', 'between 19 to 35 kg/m2', '≤ 37.5', '< 4.0×109/L', '5-12 years', '> or equal to 18|History', '18-75|Suitable', '=< 6 months', 'greater than 160 mmHg', '11-17', 'people）.|Previous history', '≥4 mm', '>50 mm', '14 units', 'above 18 years;|Signature', 'scores 0-1', 'between 20 0/7 weeks and 25 6/7 weeks|Absence of chromosomal', '≥100 ng/mL', '≥ 3x ULN;|or', '> 25 years', '≥ 600 mg/', '>99th', 'at least 7', '< 35 kg/m2||Diagnosed', '< 45%', '>75% ROM loss', '< 10s|Able', '≤ 40 copies/mL', '80-proof alcohol', 'less than 70%.|COPD', '> 18 years;|right brain injury', '20 years old', '0 to 1.|aged 18-65 years', '<15', '18-80', '> 60', 'greater than or equal to 95% adherence', '>200 mg/dL', '> 250 mg/dL', 'over level 1 in CTC AE', 'between 45 years to 80 years old|Prostate enlargement', 'under 16|Unable to understand and communicate', 'weigh 50 kg', '45 mm Hg', '> 3|Positive screen', 'neutrophils ≤ 1,500/uL', '45 to 60 years old', 'more than 40 y/o.||', '1-18 years.|A negative pregnancy test in', 'score of 0 or 1.|Histologically confirmed', '<50%|HFpEF not', '0.8 mg/dL', 'G3 NET.||pancreas', '< 6 times upper limit of normal (ULN)', '> 50 mL/min/1.73 m2||eGFR', 'younger than 89 years', '≥19 years old', '< 6 g/L', '≥ 90 mmHg|Fraction', 'less than two', '> 18 years.|Subject has provided informed', 'between 18 to 65 years;|Meet the threshold', '>3mg/', 'between 45- 55 years.|Male', '0 or 1.|Adequate organ', '<7,500 steps', '14-30 years', 'I & II', '< 3.0 g/dL', 'between 13 and 26 gestational weeks', 'between 20-28 kg/m2|aptitude', '>110 ms', '1 units ≈ 360 mL beer', '≥1.5 cm', '20 IU/day', '≥ 90% from baseline)|The subject gives consent to the study', '< 6', 'Grade ≥1', '≤ 5.30 mmol/l|Triglycerides', '< 1.2 mmol/l', '> 24 hours', '< 9 g/dL', '> 40 inches', '<10%', '<100 109/L', '≥10 mg/ day', 'at least 1°C', ""less than 5 '"", '<30 ml/min/1.73 m2);|Infiltrative heart diseases', '<1.0×109/L', 'above recommendations', '> 24 hours||Abnormal transcranial Doppler', 'from 18 to 70|40-60%', 'score of 3 or more,|history of', '>101.0 degrees Fahrenheit', '≥ 3 × 109/L', 'score 24>|Not doing laughter yoga before|Being able', '>12 hours', '75 × 10^9/L', '≥ 12.5', 'between18-30 kg/m^2(inclusive);|Voluntarily sign', '12 ≤ age < 18', '^9/L.|Received', '<9%|Able to', 'greater than first-degree.|Patients', '65-85 years.|Non-smoking.|English', '≥ 30mmHg', '<100 m', '>250.|Signed', '>2.5mg/dL|Creatinine', '18-65,|Having', '2-18|having a', '0 or 1|Adequate organ function|Life expectancy', '>1g/24h', '>1.5 times ULN.|Severe hepatic impairment', '<16.5 inches', '18 and 70 years);|The patient', '< 100 x 10^9/L.|Presence', 'greater than 28 weeks', '≥ 70 years|OMS 0-3|Pathology', 'older than 8 years', '12 to 17 years inclusive', '>2x the laboratory upper limit of normal (ULN) range', '≥100 x 109/', '>8.0', 'score 1.0 or better', '1.0 cm^2', '>= 8 g/dL)|For', 'resectable', '≥100,000/microliters(μL', '> ULN|Aspartate aminotransferase', '≥8 g/dL|Platelet count', '< 25 kg/m2||', 'Score of', '<150μmol/L.', '6-10 years', '≥8 years', 'score of <9', 'between 2 and 3;|Latency', '≥ 50kg(man', '>18 and <65|Within 12 hours after brain injury|Control group', '11-25|Age', 'only]|Score of 3 or more', '=< 10%', '<3 cm;|technically', '11-18', 'lower than 18 years|absence', '>15)|Insomnia', '>2.5 mmol', '≤ 3 × ULN|Serum', '>=70%', 'less than 1 month before,', '> 180/100mmHg', '> 180 mm Hg', '≤2.5×upper limit of normal (ULN)', 'equal to or above 10.0 years', '22-34', '≥ 2000 IU/ml', 'less than 3cm', 'between 3 to 24 months.|Clinical diagnosis', 'less than 45 bpm', '< 60% predicted', '< 5', '<9)|The use', '0-1;|ASA score', '16-45 years|Sufficient', '41 years', '>18 years.|Eastern', 'younger than 18 years old', '< 89 mg/dL', '= 0).|Patient able', '≥ 20 mL/min/1.73m2', '40-60 repeats', '≥3 mg/dL', 'more than 40', '≥ 5.|Age > 18 years', '≥ 10mm|Resection', '45 mL', '3 or above', 'Score 0-1|Those who understand the research procedures', '≥2+ in intensity', 'above the J-point', 'between 0-3.||Healthy', 'I II-IVA stage', 'less than 50 Kg|Inability to provide', '> -2SD or >P10|Asymptomatic', '≥55%', '≤ 3.25 mm', 'at least 1 of', '>0,96mg/dL', '2', 'below 50,000.|Allergy to Fiasp insulin.|Current administration of oral', 'MRI.|The', 'Zikiale', 'more than 18 years|systolic blood pressure of more than 130 mmHg', 'long-term online', 'no least than 5', '<18 years|Symptomatic orthostatic hypotension (defined', '12-60', 'more than or in addition to Permobil', 'over 450 msec.|Clinically relevant', '=< 1.5 times the upper limit of normal', '> 1.5 × ULN|History', '≥ 5)|age 18-80 years|provides', 'between 18.5 - 25 kg/m2', '8-21 years', '2 to 70 years.|Performance status', '35 inches', '≤ 10 × ULN|platelets', '1.1 times above the upper limit of normal', 'less than 50 × 109/L', '> 2.07', '>/= 12 years;|Diagnosis ""definite""', 'higher than 18.0', '> 1 positive cell per 10^-5', '5 cm', '≥50%;||Women of', '> 4 weeks', '20-29|Regular menstrual cycle', '>=18 years old', '<80% of', '2.5 hours).||', 'less than 25,000/ul', '> stage 3).|Subjects not able to provide informed consent.|Enrolled', '≥50 kilograms (kg)', 'between 18-48 years|ASA class II', '28 days.|Age ≥18 years', 'equal to or shorter than 1.5 times of ULN', 'between 50 and 90 years|no negative', '≥ 18 and < 90 years.|Diagnosis', 'at least 3 months||Patients', '>18|Adequate visual', '<4|Major', '>18 year', '>= 9.0 g/dL.', '> 10 mg', '0-1|Child-Pugh score', '<6.|Baseline NIHSS obtained before procedure', '> 13 mm', '37-42', '18 - 55|primary diagnosis', '≥1,600 pg/mL', 'Inherited', 'less than 18|Unable to give', 'outside the normal', '> 150/100', 'class 4', 'between 60 and 80 years old', '≥ 80 g / L', 'more than 37.0 °', '>40 and <75 years|Patients', 'grade dysplasia|Currently', '> 210/110 mmHg', '1.5cm × 1.5cm', '≤ 45 kg/m^2.|Have', '130-149', '≥ 80% of the predicted value', '120 g/', '20 teeth', 'between 20- 50 years', '= 18-60|Diagnosed', 'greater than or equal to 6.5 percent', '= 355 mL', 'above 18 years,||Pathologically', 'greater than or equal to 30%', '>= 80 x 10^3/mm^3', '> 2 IU', '0-1;|Except', '≥ 6 months.|Those', 'consistent with normal', '+ physical barrier method', 'more than 10 times', 'missing more than 50% of their dentition or their dentition', '≥ 18 years|Able to comprehend', '=< 2.5 × ULN', 'Under 18 years', 'between 13 years and 17 years and 11 months', '≤ six months prior to screening visit', '18-69 years', '≥ 50 mL/min;|Liver function', '10.0 - 10.3', '≥ 18 years and ≤ 80 years.|Both', 'more than 50% from baseline.||', 'between 55-69 years', '≥ 18 years|Symptoms of', '= 37 weeks', '≤ 2.5 times ULN;|Pulmonary function', '≥ 38.5°C', '> 45|Inflammatory arthritis|Narcotic use', '>300 mg/g|Since', '< 6 months|Infection', '6-7', '> 2xULN', 'less than 10% of the lower limit of normal', '>2.5 mL', '≥3 mm', 'more than 1x10^3 copies /mL', 'at least 6 weeks prior to initiation of study treatment', 'requires more', '0-1', '≤ 1.5 mg/dL|AST', '< 6 months', 'score of 26-30;|Elderly', '49 years to 65 years)|The', '>13mm', '≥3)|over the', 'between 40-80 years', '≥ 30 ml/kg/min', '≥500 ms', 'less than 7 days between screening', '>6', '> 7 units/week', '<10 years', '≤ 1.5 ⋅ upper limit of normal (ULN)', '≤0.6 cm2/m2', '> ULN|Total bilirubin', '<1500 g', 'between 18 to 65', '<70 years', '≥ 175.|Participants', 'FC', '> 126 mg/dl|Individuals', '< 30|Preserved', '≥18 years;|Diagnosis', '<0.8 ng/ml.|Any of the following', '= 285mL of beer', '≤ 40 kg/m^2', '<50 beats per min', '≥ 6.0', '>=30 mL/min', '≥2 prior to the', '14 years', '> 0.25,|elevated', '1/3 and more', '>=200/cubic millimeter (mm^3) and their viral load', '> 10mmol/L)', '<100,000/µ L', '> 5 kPa', '= GER', '2018).|18 years or older', '25-40)||', '13-18', 'requires therapeutic immunosuppression', '> 470 ms', '< 45mL/min/1.73 m2', '> 2.5 mg/dL|Hematocrit < 0.34 or 0.50 L/L|A major', '16 or younger 2- Biopsy specimens', '≤ 20;|Unable', '≥ 90 mL/min/1.73m^2||', '≥18 kg/m^2', '<5 mmol/L;|Stable regime', '0-3|Adequate hematopoiesis', '>90 mmHg.||5', '> 3x upper limit', '3~6 years', 'Absolute', '>17 and ≤37', '1 unit=360 mL of beer', 'less than 72 hours before randomization|Written', '22-26mm|Refractive', '≤ 1.5 times the upper limit of normal;|Subjects voluntarily joined the study', '> 30 kg||Patient', '18 to 30 kg/m2|Woman', 'greater than 50% of the total liver volume', '95 years', '>1500/mm3', '≥90 mm Hg', '19.0-32.0', '>35|Multilevel severe', '< 10mm/5min;|Tear', 'at least 5', '1.|Participant', 'greater than 120% motor threshold', '≥ 90 mL/min/1.73m2)||', 'complete response to BCG', '≥ 70 years ≤ 85 years', 'below 30 ml/min/1,73', 'equal to or similar', '≤ 1.5 x upper limit normal (ULN)', '50 mg/dL', '>40 mIU/mL', '≥ 45kg/m2)|Height < 5\'0""|Patients', 'under 42 years', '35-85 years||Presence of the', 'higher than 220/110 mm', 'pets', '> 2 times per week|Medical conditions', '> 50%', '< 18 years|currently pregnant|neutropenic', '<30%)|Intolerance', '>20 units/week)|reported', '> 350 cc|Urinary retention', 'B-type', '≤ 2;|Life expectancy', '≥ 90,000', 'less than 6 cm', '> 52,5 kilograms', '> 800ml', '≥18 years when signing the informed', '< 2.5 times the ULN', 'equal to 150 mmHg)|Able to understand', '> 18 years)|Patients', 'not exceeding 10%', '≥6 months|The disease', 'between 18.5 - 40 kg/m2.|Live', '0-1+', 'colour modification', '>7)|Unable to take retention enema', '> 28 pmol / L', '1):||Age 18 or older|Written', 'equal or superior to 15 kg/m2|Mother', '<40%', '54 to 66 Gy/25 to 35 fractions', '55-74 years', '>100 mm Hg', '>7.5', '<3 cm|English', 'rating scale,|Diagnosed', '>7 years', '<100 IU/mL.', '1 only)|Be 18-34 years', 'between18-65 years|American Society of Anesthesiology score II-III|Body mass index', '>= 27%', 'requires sternotomy', '≥ 1.5× ULN', '≤ 1.5 × ULN；|Coagulation function', '> 23|No', '7-12;|Children whose score', 'older than 24 years old and above 50 years', '≤ 60 ml/(min * 1.73m2);|2', '< 21 or > 80 years old|BMI', '≥18 years;|Prenatal Edinburgh postnatal depression scale', 'less than 70.|Children', 'less than 40 out', '15 to 30 years,|From', '≥ 1.5/nL', '0 or 1;|The', '<50% VAS reduction', '≥ 180mmHg', 'at least 6 weeks', '50 - 65 years|Own', 'between 100 and 300 ng/ml.|25-OH-Vitamin D levels', 'Stage IVB', 'FAC)|More than 20 seconds', '≥ 18 years||Inclusion criteria - none-to-mild', 'Stage II/III', '>2kg', '< 35 ml/', 'score 0 to 2.|All', '30 and above', '18 - 55 years', '30-45 years|vegan', '< 30 mL/min/1.73m2', 'grade 0', 'score of 0 or 1.|Has', 'above 95', '≤ 60 mmHg', 'at least three weeks before the trial|Individuals on', 'at least 180 day shave', '≥ 37+0', '50-70,||', 'more than 30)|NMES contraindication', 'between age', 'between 30cc', 'long-term bedridden.|There', '< 280 dB/m', 'greater than Level 2', '18-75 years|Moderate-severe', '18-24|patients', '>15 eos/HPF', '>2 times the upper limit of institutional reference range)||Indication(s', '0-1 Detection of biomarkers', 'foster care', '≥ 40 years;|ASA', '≥ 4|Quick', '18 - 65 years|BMI', '< 5 times the half-life', '<1% positive', '=< the institutional upper limit of normal', 'Stage 1 or 2', '≥ 35kg', '=< 6 cm', '=< 1.5 x ULN|Activated', '< 90%', '≥ 60 years', '≥ 1000/μL', 'between 24 hours to 7 days after the planned randomization', '≥3 at Baseline.||', '≥ 50% stenosis', '18 and 65 years||', '18-65|Having', '≥40 years', '≥ 3.|Previous prostate surgery', '≥ 18 years.|Informed', '> 1.5x upper limit);|Major surgery', '> 3.0 mg/dL|History', '>=8|are willing', 'less than 40%|Pulmonary impairment', 'between 27 to 45kg/m2|Type', '<8mg/dl)|Pregnancy', 'grade I-III||6', 'less than 3 months;|Cachexia', '19 years', 'younger than 65 years', 'between 18 years and 80 years|Histologically', '≥ 100g/L', '≥ 8', 'between 18.5 and 35 kg/m2.|Physically able', '=18 years||Exclusion', '≥3 months.||Normal function', '≥ 80 g/L|Neutrophil', 'Class III', '≥20 mm Hg', '≥6mm', 'pain relief 50%', 'under 18|Hearing disability', '> ULN)|Signs', 'below the 5th percentile', '<=-0.50D;|Written Informed Consent;||', '15 mmHg).|Significant abnormalities', 'between -6D', 'basal', '1.5×109/L);|Platelet count', 'below 18 or older than 55|Refusal of inability to give', '2.0-6.5', '140-180 mmHg', '>1.3 mg/dL.|Participants', '≥ 70|Ability to read', '>=1 cm', '>18|By the surgeon´s evaluation fit', '20-50 years|Sub-acute', '≥ 3.0 × 10^', '> 20g/d', '<60ml/min', 'between 18 and 80 years', 'I-IV', '60-90 ml/min/1.73m2', '<=1.5*upper limit of normal (ULN)', '40.0 kg', '> 150 min', 'between 40 and 65 years', '>110 mmol/L', '40 to 80 years', '< 10);|Presence', '<55 years', '4 (CTLA-4)', '<= 0.2 mg/kg/day', '≥ 30 kg/m2.|Presence', '≥ 3 mm', 'above 35|Contraindication to receiving', '>III', '>30Kg||', '≥45.0 kg', '23-32 days', '<30 ml/min per 1.73m2)||Clinically-significant', '≥ 5 g/L', 'between 13-26 gestational weeks', '≥40 kg/m2', '18-65 years.|Acute', '18+,|diagnosed with Binge', '≤1,000/mm3|Absolute', '^9/L||-Absolute neutrophil count (', 'greater than 18', 'less than 90', '1 and 2):||HF', '≥ 20 and ≤ 70 years', '20 or over', '≤ 1.5 ULN', 'score between 35-45|They', '≥ 60%||Adequate organ', 'less than 35 kg/m2|symptomatic', '>35 kg/m²)|Insufficient', 'above 1.2', '>100 ng/L', 'between 100∼125 mg/dL', '≥ 20 grams', '≤ 2.5 x', 'greater than 10 pack years', '≥ 30 g/L;||Serum creatinine', 'less than 12 or', '80% or more', '>39).|Anxiety/depressive disorder', '≥500 μg/day', '>40 kg/m²),|Severe organ failure,|Previous', '< 9 g/dl', '>=75 min/wk', ""18 and above.|Obtain the subject's informed consent and sign the informed consent form.|The subject is able"", '>20x109/L;|Troponin I level', '10-day', 'between 3-6 years', 'Older than 18||', '</= 70 days', '0-1||', '18 - 45|Phototype I to IV', '>80 years', '≥60 mmHg;|Patients', 'more than 3 times the upper limit of normal', '2-18 years', '18-90 years', '>200 mmHg', '=< 50%', '15-25 mg per week', '± 12 months', '0 to 2|Life expectancy', 'less than or equal to 60 minutes of', 'between 18.5 to 29.9 kg/m^2 (inclusive)', '>18 years;|absence of structured physical activity', '=< 11.5 mg/dL', '≤ 1.5 times the upper limit of normal;|There', '0-1|Participants', '≤ 4,500 g|Postnatal age ≤ 11 days', 'younger than 18|Patients', '18 years or older).|Histologically', 'between 18 and 32 kg/m^2||', 'nurse', '≥1.5×10^9/L;|Platelet count', '<135 mmol/L', '≥55, gender unlimited;||(2', '1 to 4', '≥ 1 500 cells', '≥ 1.5 × 10 ^ 9 /', '4 and above', '≥18 years.|Patients must be able to write', '10% or more', '1;||Vital', '≥24 hours;|Sedation', '≥ 50 kg and < 100 kg.|Vital signs', '≥ 1.5 × 109/L;|Absolute', '≥ 7.|Willingness', '90-120 mmHg', '>=48 hours', '+/- 10 years', '<1.03 mmol/L', '60 to 86 years|Clinical dementia rating scale', '<70 mEq/L', '≥300 pg/mL', '<30 14 days after the symptom onset of COVID-19', '>480 ms.|Has', '< 5.0 × ULN', 'above 1.5 times the upper limit of normal;|Patients', 'scores 3+4, 4+3', '4-7)|No', 'above 30 kg/m2||', '> 1.8 mg/dL', 'less than 15 years', '50 to 80 years', '<75 mL/min/1.73m2', '<= 60 mL/min/1.73 m2', '<12 g%', 'I inhibitor', 'greater than or equal to 75,000/uL', 'over 350 cells/mm³', 'greater than 70% compliance', '≤ 3 x', 'less than 10 ml/min', '6.1-6.9 mmol/L', '>= 16 weeks', 'older than 45', '25 to 57 years.|Non-smoker', '<60 years old|Subjective METS <4|Inability to give', '<15 mL/min/1.73 m2|Known', 'over 18 years Chinese', '1,500/mm3', '<50 mmHg.|Those', 'thicker than 10 mm', '< 50% of the total CNV lesion', '≤ 1.5 mg/dL|Aspartate transaminase (AST)', '<60 mL / min / 1.73m^2]|Renal', 'above 20%', '=186×', '> 2.0.|Patient', '> 550ms|2nd', 'equal or greater than 35 m/kg2;|Previous', '36 to 71 months', '>= Grade 3', 'patients.|Over 18 years', '≥18 and ≤90 years.|History', '≥ 18 years|H', 'between 18 and 65 years|able', '≥ 85 mmHg)|Obesity', '>60 mg/dL|Serum', '≤ 35 kg/', 'less than 30 minutes|Having', '>110 mmHg|Those', '= 200', 'greater than III,|patients', 'adequate', '>18 years|Histological', 'times/min', '> 65 kg|c-peptide', 'greater than 3 months;||7', '<20 years', 'true', 'under 10 years', 'long-term opiates', '< 18 years|pregnant', '4-12 weeks).||', '18 years and older|The diagnosis', '>3|Patients', 'at least 10 alleles', '<=2.00D|BCVA >=0.8|Anisometropia <=1.50D|Confirmed to no use', '>= 60 mL/min.||Participants', '≥ 70 × 103/mL|Hemoglobin', '≥ 8 x 109/L||Hepatic:||Bilirubin ≤ 1.5 x upper limit of normal', '> 21)|Good sleepers', 'between 15 to 25 years|Have smoked', '>0.7', '> grade 1.|Poorly', '< 3 aspirations', '≤1.5 times the ULN', '-0.75 to -6 dioptres)|23', '> 2 units/day', '>1g/dl below normal', '≥ 18 years||Complete resection of the tumor', '<40%|Ability to perform', '>= 10 mm', '>20 x 109/L|Hemoglobin', 'older than 50 years', 'between 18 and 30 kg/m2 inclusive', 'below or equal to 20 degrees', 'enrollment.|Uncontrolled infection.||History of', '> 45 kg/m2', 'greater than 38°', '< 60 x 10^9/L', '< 2.0 mg/dL|Able to provide informed', '18.5 - 32.0 kg per meter square', 'score ≤3|The clinical', '18-85', 'between 18 and 35 kg/m² inclusive.||Additional inclusion criteria', '> 7.35)||', '> 2 times baseline', '10-45', '5 to 18 years', 'over 18|indications for', '19 test,|Presence of an obstacle', '=<', 'from 7 to 14 years', 'greater than 1.5-fold the ULN', '< 90 mL/min/1.73m^2', '≥75, prior stroke|One point', '<60 ml min-1 1.73 m-2', '<36 weeks|Griffiths', '1-3', '> 10 points.||', 'less than 21 years', 'Z-score (', '< 500/mm3', '18 years or older|Past follow-up', '≥ 18|MS', '> 20 ng/mL Significant', '18 to 99 years', '50 to 100|Visual potential', 'thinner than 490 microns', '≥15 mm', '≤ 8)|Suspected', '+ / HER2-', '≥100×10e9/L.|Alanine Aminotransferase', 'equal to or better than 1.0', 'AFP drop of 1 log', '<2.5 cm', '18-60years old|ASA class', '>500 IU/L', '>= 50 mL/min/1.73m^2', '< 55% predicted', '150 mL of wine);|Test', '>3 times the upper limit of normal 2.3 Characteristic findings', '6 months-14 years', 'long term support', 'less than or equal to 5 pmol/min/mL', 'greater than 140 mm Hg', '24 - 36 months', '<90 mmHg.||', 'less than or equal to 18 years old', 'greater than or equal to 30 Kg/m^2', 'below 11.0 g/dL', '1cm2 or more', 'score of 6).|Current', 'between 25-40 kg/m2.|Regular', '0-33);|Tear film', 'at least 5 years', '> 50 mL/min', '>38.5oC', 'between 21 and 38 years old', ""'s"", '<55%.||G. Prior', '1.5 ≤ institutional', 'less than 50 y.o', '< 60 mm Hg', 'Stage II-IIIA Squamous cell lung', '> 18.5 kg∙m-2||', '18 years old or older)|dental', '^9 / L', '>2 mg/dL|AST', '≤ 1.5 mg/dL|Hemoglobin', 'less than 40%;|Treatment', '18 years or older|Non-ICU professional staff', '< 28 weeks', 'at least 18.|In', '< 20µg/L', '0-1;|Expected survival time', 'between the 34th and 37th week of pregnancy|Birth weight ≤2500 g and ≥1500', '≥ 100,000/mcL', '=< 2.5 x ULN (=', '4-10', '1x10^3 copies /mL);|Human immunodeficiency virus', '≥ 18 ≤ 28kg/m2;|The', '18-80 years.|BMI', '≥100g/L;||INR≤1.5', 'therapy.|At least 18 years', '150 or less', '>25 kg/m2|17-item Hamilton Depression Rating Scale', '1 line of treatment', '60 mm', '>17 years', 'between 25 and 35 kg/m²|Subject', '18-65 years;|Diagnosis', '≥ 9.0', '>60 mL/min/1.73 m2', '>300 minutes', '24-26 weeks of pregnancy)|Must be able to swallow tablets|Agree to participate in', 'score ≤26.55|Couples', '< 1.5×upper limit of normal', '< 3.0 mg/dL)|Aspartate', '= 300', 'exceeded 1.5 times of the upper limit of normal', 'class A or B', '>= 10,000 copies HIV RNA/mL', '≤ 3||EXCLUSION', '≤1 % per year', '> 0%', '≥ 3mmHg', '≤ 88%.|Has', '6-15 months|Households', '65 or older old', '≥ 100.4 F/ 38 C', '5 mm or more', '≥40 kg/m2.|Smokes', '> 90 g/l|Planned', '< 10%', '40-65,|having entered the', '<1.0 x 109/L', '≤ 10 seconds', 'score of 7 to 9', '40-70', '≥18 years old.|Written informed', '0-2||Triple Negative', '>50% stenosis of the', 'Stage 3/4', '< 3.0 g/dl.|Patient', '> 18 years|Life expectancy', '>= 16 years', 'greater than 470 ms', '18 to 40 kg/m2', 'diagnosed at', '≤ 5 days per month.|Lack', '>= 18 years.|PRE-REGISTRATION', 'upper limit of', 'between 6 and 10', '40 mg/day', 'between 22 and 75 years', '14 to 35 years old', '>25 kg/ m^2 for overweight participants', '<4,000/mm3', '≥ 35 Kg m-2|Unstable', '0-10);|Admission time equal to or greater than 48', '> 40 IU/L', '28 0/7 - 37 6/7', 'lower than 18.5kg/m2', '>50mmHg).|Who', 'greater than or equal to (>=) 1.25 mm^2 (0.5 disc area)|GA can be photographed in its entirety by FAF', '6.5', '18-50|Address', '<3mm', 'larger than the bore of MRI machine', '≥18 years||Triple', '>3 times normal', 'I-III,|Radiograph evidence of OA', '≥ 18 years|Treatment', '≥200 ng/mL', '> 100 beats/min or < 50 beats/min', '<30 mls/min/1.73 m2,|history', '≥ 18 years|Patients', 'below the normal reference range', 'grade ≥II', '< 1 x UNL', '> 2h before the application of the technique.||', '>2 times the upper limit of normal', '≥1000 pg/mL', '≥ to 10% regardless', '< 27kg', '≤ 2.5 x IULN|Creatinine ≤ IULN', 'less than 30%;|acute', 'score ≥3;|Heart, lung', '≥ 100.5 degrees F).|Time', '≤2.5 × ULN|creatinine clearance ≥30 ml/min', '≥ 130 mmHg', 'present:||SARS-CoV-2 infection||A', '<200 cells/mm3', 'minimum 150 min', '< 2 weeks', '< 35|Willingness to avoid', '≥ 18 and ≤ 70', '1500/μL', '18 to 45 years|Patients', '>10% of their body weight', '25 IU/L', '> 88 cm', '>200 minutes/week', '1.1 with the', 'every 21', '<3×109/L', '18.|Low back pain', '<15 headache', '> 40||B. Personal', '>1/4 of defecations', 'without transfusion.|Hemoglobin ≥ 9 g/dL', '33-64 students', '6-12hours/', '≥ 2000 IU/mL', '<18 and >40|Study', 'vitamin E', '>7.5.|Immunocompromised', '=QT/(RR^1/3));||Woman', '< 3 weeks prior', 'equal to or greater 5th percentile|Mother', '>1000/mcL|Hemoglobin', '≥ 3 months;|There', '0 or 2', '0 to 2|Adequate', '≥ 18 y.o.|neurosurgical removal of peripheral nerve tumor', '0 to 2.||Adequate organ function', '≤ 1.0 D', '< 30%)|Any clinically significant', '≤ 2.5 ×ULN', '≥2200 pg/mL', '≦3 ULN', 'more than two years prior to study', 'score B (2~8)', '0-1.|Age', '<65', 'long-term to cold test', '-10 diopters or higher', '18-65 years||Exclusion', '> 4.0 m/s', '> 1/3MCA)|Patients', '> 500 msec', '125 mL', 'lower than 18', '/ 460 ms', 'greater than 115 kg', '<= 1.5 x institutional upper limit of normal OR|Creatinine clearance', '≤1.5 times ULN', '1):||Age greater than or equal to 30 yrs|Able to', '<6 weeks', '20-40°', '< 126', '≥ 400 mL', 'than 15 years', '18-45 years|Outside', '< 0.1 ng/ml', 'younger than 18', '>3x the upper limit of normal', 'above 2 mg/dL', '≥55 mm', 'class ≥B iii', '<60 mls/min/1.73 m2', '< 3 × upper limit of normal', '18-40 kg/m2.||All', '>29%', '< 1.5 × upper limit of normal (ULN)', '≤ 2.5 times high normal', '≤ 0.8', 'below 18 yrs|Use of', 'between 40-75|average daily consumption', 'higher than 60 kg', '>22|Use two questions to screen', '18-26', '45 U/L|Shortening fraction', '< 18 years|Ventricular septal defect|History of', 'less than 80;|at least one', '≥2 ng/mL above', '18+|presence', 'infarction;|Less than 1 year', 'above 100,000/µL', 'grade II-IV|Left', 'less than 60%||A history', '<12 g/dl', '<0.4', '18 years),|Experience with frequency lowering,|Hearing thresholds', 'older than 71 years', '<1 year.|5', '18 or older|Stated', '< 75×109/L|Hemoglobin <90 g/L|Aspartate', '>1.5 times ULN.||Adequate coagulation', '≥ 3.0 × 109/L;|Platelets', 'I-II|Patients', 'greater than or equal to 25|Able to participate', '15cm for IJ', 'above upper limit of normal (ULN)', '> 2;|History of spleen resection;|Loss', 'above these limits', '>1.5 dioptres', '10 years', 'more than 1200 g and less than 1000 g', 'between 18.0-26.0 kg/m2', '≤ 100.0 kg.|Able', '= 360 ml', '18 or older|Is', 'less than 65 years|non English-speaking|unable', 'male|report', 'exceeding 3 times the upper limit of normal', '0 to -15', '18-35 kg/m2.|Diagnosis', '> 100/uL', 'class III or', '>40 IUnits/L|Ability to understand and willingness to sign', '< 22', 'less than 100 x 10^9 /L|Hereditary', '≤ 80 mg/dL', '<= 10 g/dl', '≥ 4 days.||', '< 18', '= 12 g)|Administration of another investigational product', '16-25 years', '18-59 years|Shoulder width of', '< 30.|Current orthopedic limitations', '≥ 10 mm', '< 30 ml/min/m2|Active', '5~12 years', '> 35 kg/m2|Laparoscopic sleeve', '<16', '≥2 cm|the presence', '< 25 mL/min', '> 300 lbs', '>25', '<90 mmHg;|Severe', '> 200 µmol/L)|Diagnosis of psychiatric disorders', 'between 18 and 50 years', 'score 28', '0-2;|Child-Pugh score A period;|Have not', '18-75 years|BMI', '< 140 mm Hg', 'score 2 to 5.|Patient', '< 18.5 kg/m2|Pregnant|Allergy', '12-35 years', 'installation.|≥70% of HHs', 'score of 3', '≤2.5 x ULN|Total', '> 18)|Eligible for a', '> 18 years.||', 'under 30 ng/mL', '≥18 to ≤55 years.|Subject', '>10|severe', '≥ 100, 109/L)|INR', '<50% diameter', '<45 years)|Pregnancy', '>/= 12', 'between 18 and 70 years|Functional status', '7 and above', 'nationals,|Below 50 years', '> 150 mm Hg systolic', '>2 μg/kg/day.|Current levothyroxine', 'injection.|Unsatisfactory', '18.5-40 kg/m^2|Willing', 'between 18.5 and 24.9||', '≥ 30 min', '2-7', 'greater than or equal to (>=) 180 days prior to the day of screening|HbA1c from 7.5%-10.5%', '59.4-60 Gy', 'Elevated', '≥III', 'Class III/IV', 'score of 0 to 1|If', '>14g/day', '> 1*103', '18-years-old', '< 1.2*10^9/L', 'A minimum of 18 years old', '18-75;|Pathologically', '≥ 18 years|Admission to the', '>4mm', '<0,7 ng/dl', 'greater than or equal to 8 g/dL|Total', '=360 mL beer', 'greater than 450 ms.|People', '< 40%)|Patients', '≤8mg/ml', '6 consecutive', '+-20|Anisometropia ≤ 1.50 D|Myopia evolution', '> 0.45||NAFLD', '≥ 200 mg/j)||Patient', '18 or over|Patients', '<50%.|Have', '20-70 years|No', 'IB', '≥ 75', '≥1.5 × 10^9/L|Absolute lymphocyte count', 'at least 75% of the function', '< 2.0 mm', 'routine examination:||Hemoglobin', '>36 mg of nicotine', '> 40 g/d', 'at term', '>18 years||', '> 30 mL/ min / 1.73', '18 years or older;|Diagnosis', '> 18 years|Signed', '≥ 1.5 × 10 ^ 9 / L；|Platelet count', 'more than or equal 18', '>15 alcoholic units per week', '≤ 2|9f', '6 to 11 years', '> 2-fold the upper limit of normal (ULN)', 'more than 18 years old;|The informed consent', 'equal to or greater than 7', 'lesser than 30 milli liter per min/1.73 meter square (mL/min/1.73 m^2', '18 and over.||', '≥ 18 years|Planned appendectomy', 'between 20 and 40 years', '>75years or age<18years.|2', '24-27.9;|Blood', '≥18 and <75 years', 'less than 50% of the total score', 'no younger than 18 years', '< 2.5 times the upper limit of normal|and/', 'above 140/90 mmHg)|Donated blood 3 months prior to test', '≥75g/L', 'at least 12 weeks||', '<1 month post-surgery', '18', '0 to 1|Life expectancy', '0 - 2.|If', 'between 2 and 5', '>3.5', 'score 2-', '≥ 470 millisecond', '<25 years', 'longer than 3 months|Good cognitive function', '≥450ms, QRS≥120ms obtained', '≥ 35 kg/m2;|smokers;|individuals', '*|hsCRP < 2 mg/L *', '≥10 mIU L-1 or <', 'less than 3 months.|Subject', 'least 20 years', 'long term health', '1 to 3|Patient', 'less than one year.|Severe cognitive', '0-10cm', '<2|Within 14 days of study registration', '< 100 mmHg', 'less than 1 month|History', '60-100', 'than 150', '18-60|Lumbar radiculopathy|No', '> 2.0mg/dl;|9.Those', '<14 or >65', 'between 18 and 89 years old', '>35 hours/ week', 'under 18 or over 75 years', '> 8.0 g/dL', 'above, and their', 'ER', '>0.44 s', '≥ 10th percentile', '≤2.5 times the normal upper limit', '4-Symptom Questionnaire', 'equal or less', '>40 kg/m²|Participation', 'at least 12 weeks when signing the ICF.|Patients', '< 10g/dl', '< 32%', '≤ 29.9 kg/m2', 'class II and below.|Normal', 'equal to 8', '> 40% of predicted', 'outside the reference range for the population being studied may', 'less than 9%', '>18', '≥ 18|Men', '≥ 470', '1.5 × 109', '>20 weeks', 'less than 4 weeks before', '≥ 18 years old|Radiographically documented', '>4.2 mIU/', '<18.0 or >30.0 kg/m2.||Women', '17.5 to 30.4 (inclusive)', '30.0 kg/', '≤ 5 x upper normal limit (ULN)', '6-24 hours', '< 45%;|Left', '20 dB', '≥ 30 mL/min per 1.73 m^2', '≥ 2.5 times the upper normal limit', '≤ 100', '>500/mm3', 'childbearing', 'less than 12 months.|Subject', '>400 pg/ml', 'between 60 and 80 years', '≥180 mmHg|Hemoglobin < 7g/dl|Fetal', 'therapy.||At least 1 measurable', '> 50 years', 'than 50 percent', '≥ 90 g/L|Serum creatinine (Cr)', '< 16 h/day.|Being', '> 12%', '≥ grade 1', 'INDIVIDUALS:||Inclusion Criteria:||• 18-90 years||', '<3 times UNL', '<= 90 beats per', '3-17 years', '>2x ULN', '≥ 5 × 10^2 copies/L', 'distilled', '30-55', '2.5 mg/dl', '≥ 85umol/L', '0-90 +/- 10 degrees.|Individuals', '> 35 kg/m2|Bronchial', '≥ 18 years,|first', '>9).|They do', 'Class II facial deformity|absence', '>400IU/day', 'score of 24', 'less than or equal to 48 hrs after hospital admission;|presence', '≥ 1,000', '≤ 2.5× ULN;|Ability to provide', 'last intake <48 hours', '9-16 years', '< 200 copies/milliliter', '≤ 0.6', '<60 ml/min/1.73 m^2', '≥ G2', '<18|Refusal to sign informed consent', '18 and above 49|Unmarried women|Hope to become pregnant', '> 12 and < 35 years', '15 out', '55.0 kg or more', '<100,000 cells/mm3', '>6mm', '7 or higher', '< 30k', 'Stage III B/C/D cutaneous', '≥ 20≤ 30|history', '< 40 mL/min/1.73 m2', 'at least 18 years old|Having', '32-37 Gestational', '≥ 2000 g', '>40mg/day', 'less than 5 times per day|Report', '0 to 2||', '> 10%', '<12', '30-49 years', '>=140 mmHg', '18 to 30 kg/m2', '> 1cm|Able', '=< 1.5 mg/dL.|Ability', '≤ age', '> 1800 pg/ml older than 75 years', '18-60 years.|Male', '≥ 18 to ≤ 85 years', 'Unreachable', '≤ 3 x UNL', '14-27 years.|Unilateral impaction of the maxillary canines', '≥ 28 days', '≤ 94%.|Decreased level of consciousness', '> lower limit of detection).|Active', '<40%|presence', '>160 mmHg', '18 to 50|English speaking|Pre-eclampsia', 'week;|More than 30%', 'free-floating', '18 to 35||Male|Athletes', '< 30 mL/min', 'eligibility', '18-90|Have lifelong histories of', 'at least 2 years|Young', 'IV|Treatment with chemotherapy', '<30 kg/m2||', '≥500 copies /mL. Syphilis test positive.|Those', 'between 25+0 and 31+6 gestational weeks,|-RDS', '0-100 mm).||', '> 1.5 times the upper limit of normal Hemoglobin', '<9.5', '<1,500/mm^3', 'less than 18 or more than 40 years|chronic', '> 10h per waking day', '< 150 plt/microliter|Inability', 'A-B', '≥9 g/dL', '<100mmHg', '> C', 'Score 0 to 1.|Histologically', '25-80 years', '> 75 years|Excessive use', 'Grade 2 to 4', '>70years)|Ischemic stroke|Chronic Obstructive Pulmonary', '≤ 15 cm from the anal verge);|UC', '≤ 1.5 X ULN|Cholestrol', '< 3xULN', '≤2 years', 'greater than or equal to 35g/L.||7.Women', 'longer than 8 weeks', 'no less than 30ml · min', '≥1400 pg/mL', '>12|REN users across the United States', '>100 beats/minute', '18 years or older|Able to provide informed consent|Able to complete electronic entry of patient reported outcomes', '> 100 x 103/µl', '=< 3 x ULN|Calculated', '> 18 and < 70 years|Ready', '22-45 years', 'above or equal to 18 years assigned', '3.5 × 10 ^ 9 / L', '18 years.|patients older than 65', '0-III', '≤ 1.5 × ULN；||j', '≤ 30 mL/min|Hepatic', '<3 months.|Severe', '> 3 times the upper limit of normal value', '≥ 4', ""6).|If individual's assigned sex"", 'maximum disease activity)|Criterion', '52 years or older', '24- 38', '>15 µg/L', 'from 18 to 70 years|Patients', '>60.|Adequate', '≥0.420 mmol/L).||Women', '40-55 years.||', 'above 110', '0 or 1;|Patients', 'at least 6 months', '< 20%|Planning', '< 60 mEq/L|Able', '> 50000/mcL|PT/aPTT', 'between 18 to 70 years', 'between 18 and 85 years', '< 40 or >60 years', '≥3 normal upper limit (ULN)', 'deemed unfeasible/high-risk', '1.1 criteria)；|Advanced', '18-70 years|Preoperative Mini-Mental State Examination score', '≥ 18 years|Bicuspid', '< 92% for 5 min or longer', '2.5 x UNL', '≥200 mg/24', '>=100,000/mcL|Hemoglobin', '=< 7 days prior to randomization)||If disease', '>= 50 x 10^9/L', '18-49)||ii', '³ 26|In case', '≥ 27|Positive', 'between 0 and 16 years', '≥ 25 g/L', '<18 or >89', 'At least 21 days or 5 times the half-life', '≥ 60ml/min.|Expected survival', '0-1;|Postmenopausal', 'class III-IV)|Pericarditis', '18.5-32.0 kg/m2', '>30 mL/min/1.73 m^2 calculated', 'Z-score).||Population', '<500/ml3;|Food', '>140/90 mmHg', '>= 40 kilograms||For', '45 years-75', 'larger than 1.5 mm', '> 20 seconds', '<100mmHg.|Cardiorespiratory fitness <80%', 'greater than 135 kg', 'between 0 to 17 years|Residence in FVG region|Outpatient', 'outside the normal reference', 'between 20-60 years', 'greater than 50 mmHg', '≥ 100 × 10 ^ 9 /L|hemoglobin ≥ 90g', '=< 2.9 mmol/L', '≥65 years|having Hong Kong ID|Chinese', '18.5< [BMI]', '>=100 mg/dL', '≤ 140 beats/minute', '≥15 events/h', '> 90', '21 years or older', 'equal or greater score of 5 on the scale', 'between the ranges of 18.5 and 35.||', '> 1 year', 'greater than 30 kg/m2|Diabetes', '≥90g/L;|Serum', '≥ 28 mm/h', '> 450ms', '< 37.3℃', '16-60', 'scheduled', '10-11 years', '>300mg/g).|Regular loop', '0', 'more than half of the', 'more than 60 mmHg', '25-55 years', '> 2 ng/dL', '> 140mmol/L', '50-64 years', 'less than 60 mmHg', '>= 100 x 10^9 / L', '=< 2|Histologic', 'less than 3.5 mmol/L', 'lack of written consent iii', '>7 mmol/l;|LDL cholesterol', '≤ 1.5×ULN);|The', '≥ 55 kg', 'equal to or higher than 1.5×10^9/L', '>= New York Heart Association Classification Class II', 'Child', '>4.5 mmol/L|on antihypertensive', 'between initial breast conserving therapy (surgery', '40 - 60 years', 'between 18 to 40 years|Females', '>5.6 mmol/l', '=< 1.5 × upper limit of normal (ULN) per', '>= 1500/mm^3|REGISTRATION', '≥3.0 × upper limit of normal (ULN)', '=< 4', 'Klebsiella', '> 5|History', 'over 40', '18-75 years；|Histological', '? The', '> 20% clue cells', '>=18', '>30,000 cells/mL', '≤ 1.5 × upper limit of normal (UNL)', '5 - 18 years', 'ranging 17 cm to 40 cm);||Are willing and able', '17.5 mmol/L', '3 years or more', '16 years', 'between 18', '1 or higher', '< 150 X 10^9/L', 'Influenza A and B antigen', '= 2.5 upper limit of normal', '≥ 9.0 g/dL|Creatinine', '≥12 weeks.||Patients', '> 180°', '< 45 ml/min', '60 to 90 beats per minute', 'at least 3 months.||Hepatitis B Surface Antigen (HBsAg)', '≥350 within 6 months of the first dose of study treatment', 'younger of 18 years', '18-70 years|Candidate', '> 8.0%', '18 to 45 years', '>= 60 ml/min', 'score ≥ 10)|Patient', '≤1.5 x institutional upper normal limit', '≥ 75 × 109 / L', '<1.0 x 10 3 /μL or <1.0 G/L', '130-180', 'greater than 6 months||Adequate organ and marrow function', '>3/12)||Exclusion Criteria', '< 1 g.||4', '>5 g/L', 'less than 3m', '> 2.0 cm', '<1,500/microliter|Thrombocytopenia', '40-80', '≤ 3-fold ULN', '75-160 mg);|age', '≤ 1.5 × ULN；|Female', '≥1 g/dL', '≥ 1.5 × 109/L（1500/ μ L）', 'more than 90% reliability', '≥90 g/L.||The', 'less than 100 mmHg', '0-1;|Life expectancy', '40 to 70 with facial ptosis', 'wild-type', '<80 years', '≥ 18|Verified COPD', 'less than 100', 'over 20 years old', 'less than (<) 200|A', '12-13', 'above 18|Completed curative treatment for HNSCC of the oral cavity', 'greater than or equal to 1 gout flare', 'higher than 15%', '≥1,500/μL', '> 0.75 mm', '>=13,|Antidepressant', 'Stage III', '≤ 2.||Both', '< 12 months.|Current diagnosis', 'subsequent remission||B.', '>90 days|agree', '<50% predicted on most', '2 to 3', '6 to 18 years old', 'less than 60%', '<3hrs of life).|Major congenital malformations', '< 1.5 APTT', '≥ 3.5 mmol/L', '≥1,500/mcL|Platelets', '<3.5 x 109/L', '<60 mm Hg', '60 minutes', '> 3.5 points', '18-75 years,|Diagnosis', '> 10 mg daily', '≤ 60 years old', 'between 40.0 and 120.0 kg, inclusive', '> 3.5 cm', 'less than or equal to (<=) 40%', 'between 10 to 18 years', 'between 9-14 years', '1b and 2a', '< 3 x ULN|Bil(T', '0 to 1|Confirmed histologic', 'less than 60 percent of their time in direct patient care 9', '18 - 65|Both sex|HAMD-17 score', '16-35', 'greater than twice the ULN', '≥12 weeks', 'I/ II', '> 20 mm', '>5% steatosis or|CAP', '18-60|DSM-5 criteria', '> 35 mL/min)||', '≥30 kg/m2),|Type', '> 10 g/dL|Platelets', '<104 copies /ml', '> 38.5℃ fever', '>ULN|History', '3-10 ng/mL|If', '>7.25 and <7.35', '>48 mmol/mol', '>= 100,000/mm^3|Estimated', '=< 1.5 x ULN|Alanine aminotransferase (ALT)', '60 years old', 'at least 10 years', '18-45|pregnant', '≥ 1.5 x 10^9/L|Platelet count', '2.5 times higher than the baseline value before', '+/- 1 year)|French or reading', '≥30 mmHg', '>11 mM', 'less than 10°', 'CPET;|More than 18 years', 'less than 90 mL/min/1.73 m2', 'above 2x the upper limit of normal)|Signs of infection', '≥1.5ULN', 'endoscope', 'over 18years|Subjects willing to provide', 'imaging.|More than 5%', '≥80g/L', 'B-cell type', '20 - 29.9 kg/m2', 'visuospatial', '>100 U/L', 'more than 10', '28-34 weeks', 'greater than 18 years,|Periodontal status ranging', '> 18 years.|Individuals', '≤ 7weeks|Willing and able to give informed consent', '>= 50 mL/min/1.73 m^2|Human immunodeficiency virus', 'stage I-IV)|Age', '≤ 3.0 times the upper limit of normal', '=< 21 days (42 days', '>1/4 of', '≤ 150kg;|WHO', 'less than 139 units/day.|Current use', 'less than 5 times ULN', 'within therapeutic range of intended use of anticoagulants||9.1 Hepatitis B positive', '≤ 35 kg/cm2;|fracture', '≥ 4×109/L', 'between 18 and 65 years|Severe', 'score ≥70', '>6 months ago', '≥50 and ≤85 years;||Meet', '> 160 µmol/L', '> 250 pg/ml', 'less than 70%.|Children', 'score 0~1;|The organ function level', '3.9-10mmol/L <52%', '>21 seconds and <180 seconds.||', 'TBIL≤ 2×ULN', '96% or', '≥ Type 6 2', '<94%', '≤ ULN.|ECOG performance status', '>= 1.5 x 10^9/', 'normal', '<10 mm', 'advice|Aged 18 years or above|Within 7 days of onset of stroke', '≥ 3);|Patients', 'above 20 / 200', '1-', '≥18 or ≤80 years old', '18≤age≤80.||Histologically', '> 1.0x109/L', '60-80 kg', 'greater than 11 years', '>5%, <95%|Patient', '> 1.5 times the upper limit of normal Creatinine', 'between 18.5 and 25.||', 'and 70 years', 'at least 3 weeks', '< 18 years|impairment', '≥ 1.5×ULN.|Judged', '< 18 kg', 'greater than 2.5 times the upper normal', '≥1.5 × 10^9/L|Platelets ≥75 × 10^9/L||Patients', 'less than 18.5 and above 29.9 kg/', '< 130 g/L', 'Between 18-35 years', '100-125 mg/dl)|HBA1c', 'Score of 15 or higher', 'between 2004 and today.||', '≥18 years.||', '45-75 years', 'Between 5 and 70 years', 'less than 1 cm', '>=20 mm', '≤ 460 msec', '>2X the upper limit of normal (ULN)', '>15%|Patient', '> 30||Having', '1+ or greater', '18-40 years|Postpartum', '100 mmHg', '0-33 NEI scale)|TFBUT', '>21 units per week', '5-39 years', 'equal to or less than III/', '≤ 1.5 × upper limit of normal value (ULN)', '60-74 years', '10-20 mm.|BMI', '≥ level 2', '>2 times the upper limit of normal reference value', '≥ 90 mmHg).||Gastrointestinal', '≥30 mL/', '= 1 pack /day x 10', '<50%.Poor hypertension control', '≥ 50kg/m2', 'males|18 to 80 years', '18 - 45 years', '≥35 at the time of screening|Contraindication', '< 190 mg/dl', 'before first dosing >110 mmHg;|Diastolic blood pressure (', '≤ 6', '≤ 20 mm', 'above 40 years', 'equal to / more than 6 months', '16-29 years', 'Grade I to III', 'Score of ≥11 and ≤13', 'widespread', 'stiffness', 'between 2 year and <18 years', 'score of 0 or', '45-70 years', '>21 units', '< 5 cm', '≥3.5 mmol/L', '≥ 8.0', 'permissive', '<5 s', '30 minutes per', '> 10mm', '≥ II;|There', '<7h per 24-h period', '< 30g/L', '> 2x the', '15 units', '≥ 2 +', '< 18 kg/m2', 'below <20 IU/mL|Those', '18-80 years|Chronic', '> 180/100 mmHg);|Contraindication', '> 2 ng/ml.|Postoperative', 'minimum level of pulmonary reserve', '> 21cm', '≥ 135 mg/dL', '9-12|greater than or equal to 2', '< 2000 IU/ml', 'at least 90 days after the last medication', '> 90 mmHg)|Hypotension', 'requires urgent', 'less than 24h|Patients who signed informed consent|CTA', '42 kg/m2', '1.1.|Women of childbearing', '> 1.5 x UNL', '≥75,000/µL', '< 10g/dl)|thyroid disorder|neoplasm', '> 300 mg/dL', '≥ 10 mg/L', '≥ 80 × 109', '> 6|Positive screen', '≤ 40kg/m²', '>7.5%.||15', '> Grade 2).|Participants', '< 30 mL/minute', '≤ ULN', 'more than 500 milliliter (mL)', '> 2.5x', '≥ 18 and ≤ 80 years', '≤ 1.5 x ULN|Creatinine clearance', '≥ 90,000/mm3|Hepatic', '≤ 1.5*ULN;|Myocardial injury', '> 18 years|Diagnosis of chronic stroke', 'less than 180 beat/', '> 1.0 g.|Coagulation abnormalities', '≥ 1,500/mcl||Adequate', '18 to 80 years.||Adequate renal', '=< 1.5 x institutional upper limit of normal', '>35 inches', '5-26).|Wraparound', '< 12 months;|Patients', '12-15 years|CP', '≥ 18 years|Diagnosis', '<50 cps/mL', '18-85|Limited', '0-1|Adequate organ function|BMI', 'above 37.3℃', 'between 27mm - 48mm|Acceptable proximal', '30 to 70;|Type 2 diabetes', '≥ 2.5 times the upper limit of normal|Bilirubin', '< 30 ml/', 'less than 5 years|Age', '>5%', 'more than or equal to 25 kg/', 'II patients|Singleton pregnancies', '< 45 mL/min/1.73 meters squared', '≥ 5.7%)||Previous', '120-160 g/L', 'I to VI', 'equal to 70 points', 'greater than or equal to 20 years', '15-min', '>2 mmol/L)|Renal|Liver', '>64)|Progressive', '18-64|Sexually', '< 2.0 × 109/L', '> 3mg/l', '> or= 28 weeks|Low', '> 18 and < 90 years|Admitted', '≤ 2|Accepting', '2.5 to 4.5 points', '>150 mL', '19.0-40.0 kg/m2;|Diagnosis', '<18', '< 18|Body mass index', '˃150,000/mm3|Estimated', 'for this inclusion criteria', '<70 kg|Normal', '≥.5 × 10^9/L', 'male latex', 'more than 1mL/kg/hr if', 'level||5 ×upper limit of normal (ULN)', '18 or older|Oral cavity disease', 'less than 13 points', 'within 50 to 100 kg', '<60 mmHg', '> 70 years', 'between 25 to 50 years', 'AKP2.5 upper normal limit', '<50 mL/min', '≥ 5.7 mmol/L', '≥ 5.6 mmol/l)||For', 'above 2 years old', '> 180mmHg', 'below 60%', '50 and 90 years', '> 3 times the upper limit of normal|creatinine', '≥18 years.|HIV', '>1×10e3 copies/ml', 'above 55 years', '> 7%', '60-89 mmHg)|Volunteers', '< 90 mmHg)|Patient', '1-3|BMI<30kg/m2||', '>1.0 mg/dL);|Poor', '<16.5 mm', '20-28 weeks', '> 470 msec obtained', '>3cm', '40 kg/m2', 'from 5 kg', 'Ø 7 or 8 mm', 'more than18 years old||', '>130 or <100 millimeters', '<200 cells/μL', 'single tumor ≤ 10.0 cm', '≥ 50×10^9/ L', '≥30 ml/min', 'grade <= 2', '20.0 - 34.9 kg/m2.|COVID-19', '> 16.8mmol/L', '18 to 60 years.|Except', 'higher', '16-24', '>132 μg/L', 'from 30 to 80', '60 or higher.||', 'class A-B8|Adequate', '>10ⅹ109/L', 'above 40 units per liter', '=< 1.5 x ULN|Creatinine clearance of', '18 to 65 years old.|ALT < 5 ULN.|CHB', 'Score ≤ 2', '≥ 22 years', '≥ 7%', 'but < 500 ms', '3 or above irAE', '≤3.0-fold the upper limit of normal (ULN)', '3b/4 trial', 'between 30,0 - 39,9 kg/', '> 1.0mm', '20 - 40 mg + ezetimibe 10mg', '25-40 kg/m2;|patient', '≤ 3.0', 'score <13|Lower extremity trauma|A prior', '4 to 20 weeks after RP|Previous hematologic', '50-80 %', '1 or fewer', 'score of 2', '≥ 18 years,|Healthcareworkers working', '<50ml/min.||II', 'score of 4 or more', 'longer than 20 mm', '18-80 year', '>18 years old|Estimated', '≥ 4 points', 'activated', '18 and above|DSM-5 opioid use disorder', '=< 1.8 times upper limit of normal', '<18 years|Local', '<60 mL/min/1.73m2;|Age ≥70 years.|Written informed consent||', '>3.|The subject', '>= 75 x 10^9/L|Hemoglobin', '> 1500/mm3', 'more than 2 times the upper limits;|Not well', '<24', '18-75 years|Either gender|Patients with ACLF', 'hypovolemia;|Anemia;|BMI 30 kg/m2', 'CVC,|Over 18 years', '> 5.6)||', '≥9.0g/dL', 'greater than or equal to 80×10^9/L', 'higher than the upper limit of detection', 'B-cell lymphoblastic leukaemia', '≥ 60 to < 90 mL/min/1.73 m²,|moderate', '3 to <18 years', '>30 days post-surgery', 'birth|Aged 18 years', 'stage II-IV|Knowledge of', '< 3 months before', '< 34 weeks|Singleton pregnancy|Inborn birth', '< 30ml/min)|Active', '>1×103 copies /mL', '<10mg/dL', '2-3-4||Hoehn-Yahr Staging:||Stage', '18-65|requiring', '< 60 years', 'between 18 years to 35 years', '50-60', '≥ 40th percentile', '5% cream.|Subject', '< 65', '> 1.5.|Has', '18 to 40||Recreational athletes able', '< III|Age', 'Criteria:||18-35 years', 'higher than 5%', '18-75 years old.|Karnofsky (KPS) physical status', '25-hydroxyvitamin D levels', '≥12 and ≤75 years old', '>= 18 years old|Ability and willingness to provide written informed consent|Admitted', 'greater than 30', '≤ 1.|Patient', '>= 20 years|Ease', 'Severity', '≥80% adherence', '≥ 10 mm Hg', '≥ 150', '≥1.5 x ULN', 'new/', '+/- biliary sphincterotomy of', '18 years and above|Patients', '< 4mmol/L', '>30 kg/m2;|Enrolled', 'more than or equal to 130 mm Hg', '18 ≤ age ≤ 70 years', 'between the 10th-85th percentiles|Expert clinical diagnosis', '≤ 42', '140 mmHg', '50 years', '> 5h/wk)|Good health status', 'greater or equal to 1 day/week', '25-70 years|BMI', '=< 2.5 X ULN|Estimated creatinine clearance of', '>24 points;|Has signed an informed consent to the study.||', '≤30 mL/min/1.73m2)|NYHA', '<1 month before any possible study start date|Shift work', '<18 or >85||Active alcohol', 'measured', '> 55 years', 'between 40.0 and 100 kg, inclusive', 'higher than 30/min', 'reterms;||between 32-37', '≥38 weeks)||', 'greater than 30 cc.|Metastasis', '≥ 4 years and < 18 years', '≥ 4 mm.|Study tooth', '<5 mg/daily', 'first relapse', 'Younger than 65 years', 'above (16) years old 2.Complaint occur', 'within 18.0 kg/m2', 'partial response', '20-50,000/mm3||', '18-40|Body Mass Index', 'above 40 cm', 'I-III|General anesthesia', '≥3.0x10^9/L', '> 40 kg/m2.|Unable', '≥ 3 × ULN|Prior', 'outside institutional range of normal', '>450 pg/mL', '> 4cm', '<18.5 or >35kg/m^2|reduced', '>0||', '18-75|underwent coronary artery bypass surgery||', '> 10 ng/ml|Subject', '> 5%)|Any orthopedic limitation', '4 (CTLA-4) inhibitor therapy.|Is', '≥25.0 kg/m2', 'condoms', '30 or higher', '<1.5cm2;|29', '> 1500 cells/mm3|Creatinine ≤ 1.5 x ULN', '>0.30', 'class A', '<35 years', 'Stage 2||Hospitalization', '< 60 mL/min/1.73m2|previous', '13 - 18|As', '<10 g/dl||Sickle cell disease', '25-OH', '18 years or older.||', '< 19 years|known allergy', '>3.0 mg/dl', '> 9|Cholecystectomy', 'between 24 and 32 days', '≥ 1.5×109', '≥60 years|Diagnosis of COPD', '< 50 % Pain relief', 'greater than 3 months', '≤ 1.5 times ULN;||Serum creatinine (Cr)', 'II-IVA;|adequate', '<450ms', '≥ 15 kg.||Sex', 'score ≥70.|Those', 'multiple endocrine', '12 to 16 gm/', 'greater than 0.6', 'II-IV ovarian', 'unilateral than 2 cm', '2 or 3', 'cerebral', '<5 years 6 months|Resident', '≥ 2.0×109/l', '0-24 weeks', '18.5 to 32.0', 'breastfeeding).|At least 18', '18.5 - 24.9|Abdominal circumference', '>120 mm Hg', '> 18 years old|At least', 'greater or equal to 12', '>4 years', '≥ 0.5 mL/sec', '< 1.5 × institutional UNL.|albumin', '15 to 30 minutes', '≤ 60 min', 'above institutional ULN.|Serum', '<90bpm-||', '≥ grade 3 IrAE', '< 20 ml/min /1.73m2', '0.2 or more.||', 'I-III|BMI ≥35 kg/m2', 'less than or equal to 150 minutes', '≥ 18 years|Histologically', '≤ 45', '>= 1.2 ULN),|Gamma-glutamyl transferase (GGT)', 'ia||Adults 18 years', 'greater than 29.9 kg/m2', '≥ 1.5 × 109', '≥ 4,|Dementia|Peripheral polyneuropathy|Pregnancy|Chronic opioid', 'equal to or lower than 2 times of ULN;|Kidney function', '≤ 55%);|Acute coronary', 'Grade C or D', '<6.1U/gHb|Severe', '< 18 or > 89', 'more than 1.5 times the laboratory normal.|Known glucose level', '0-2.|no', '< 96%', '18 years and older and younger than 80 years.|Start of the treatment', '<20mm', 'AST≤5 × ULN', '10^12/L', '≥ 100 mmHg', 'more than ± 3-5 days', '> 12 months.|In addition', 'less than 31 kg/m^2|Speak', '18 and older;|Being', '<150 U/', 'score of 18-26|No', '≥30 to ≤150||History of one of these 2', '25-70 years', '>5', '2.0-7.0', '< 20 minutes 3 times/week|Able to understand', '<2 pack/year', '18-45 years|Primipara', 'grade 2 or higher cardiac insufficiency', 'equal to or greater than 11', '90-130/60-80 mmHg).||', '≥ NYHA Class', '>/=', '25 cm^2 on', '4-7', 'female', '≥40×10^9 /L', '>180 minutes', '4-7 days/week', '0 or 1|Abs neutrophil count', '≤ 24 points', '50 years or more', '<70 g/L).|Acute', '1 to 3)|Intermediate stage', '50+', '>4 weeks', '1 or 4.|Radiographs', '≥50 and ≤ 90 mmHg|Heart rate', '18 to 50 years', '≤ 1.5×ULN', 'older than 75 years', '45 U/L.|Serum albumin', 'between 18-80 years|Diagnosis of first-ever subcortical stroke', '≥ 12 weeks.|Cervical cancer', '19-65 age range|Female|BMI', '> 2.9)|Oligomenorrorrhea', 'more than or equal to 90 cm', '< 90 beats per minute', 'between 20 and 30 kg/m^2|No orthopedic issues', '> 7.0 mg/dL.||Measurable', '< 50% or below the lower limit for normal', '120 kg.||Healthy', 'less than 63 or more than 5 asymmetries', '18.5-24.9|Individuals', '1 TO ARM 2): Not', '≤ 2.5 x ULN.|Patients', '>4;|megaesophagus;|III type', '</= 10.0%|Body mass index', '< 120 mEq/L', '20-75 years|Patients', 'more than 0.4 mm', '1 = 30 January 2023', '>18 years)|basic knowledge', '≥ 18 years|patients', '> 6 mm', '> 5kg', '1.1 criteria.|Known', 'between 0.2 (inclusive) and 0.6', '45-75|Has', 'greater than 5', 'greater than 50 ug/L', '3-4 points', '3,4)|Untreated periodontitis.|Poor oral hygiene', 'skilled', 'mental disorders 5', '>6 mm', '> ULN.|Any', '< 90 mL/min/1.73m^2||For', '≥ 3 months.|Subjects', 'over 55 years', '< 90 mL/min', 'less than (the same age', '< 55 years|Previous', 'less than 40.0 kg|Known', '18 to 30 kg/m2||', '45-65 years||Both', 'greater than 160/100', '< 1.5 x ULN|BUN/Cr < 1.5 x ULN||Adequate immune system', '≥ 50%;|Informed Consent/Assent', '10 and 18 years||', '≥1 at screening/baseline', '< 3×10^9/L', 'type II', '≥ 18 year-old.|Diagnosis', '≤ 1.5 × ULN|Aspartate aminotransferase', '> 20°', '<0.6|Life expectancy', '< 130 mmol/l', '≥19 and <70 years', '>4mm).|Complication', 'lower than 30,000/microliter', '2 and 3', 'less than 80gm', '0-34+6 through', 'overall patient criteria', 'from 18 to 40 years', 'between 2 to 12 years', '≥3 months;|Measurable', '18 years and older;|SSc', 'less than 12.1g/dL', '≥ 36 weeks', '45 to 70 kg', 'from 60 to 70 years', '≥3 months;|Recurrent', '≥3.0 g/dL', '< 1 year.|Presence', '≥1.5 x', '> 50 mmHg;|Pulmonary nodule', 'more than 12', '<=1.5 mg/dL', '< 300 ng/ml', '140 millimeters', '>= 60%.|Leukocytes >= 3,000/microliter and < 12000/ microliter.|Absolute neutrophil count', '≤ 5 x ULN|Patients', '<5 red', '>32 weeks regardless of birth weight', '≥ 50×109/l', '≥130 mm Hg', 'between >18 years', '6.1 - 6.4%', '≥ 9.0g/dL', 'controls):||17-45 years', '>120 or <50', '≥0.5', '18 years or older.|You', '> 190 mmHg', '<60 minutes per week of moderate-', '=< 5 x ULN', 'between 15 D and 28 D power range||', '0-3', '18 years or older|Open', '< 75 x 10^9/L|Haemoglobin ≤ 8.0 g/dL', '25-35 kg/m2|Normal', 'outside normal', '>3×109/L', 'above 1L.||Female', '> 18 years.|Stable patients should have complaints of', '≥ 18.|Patient', '≥ 80 g/L', '<50%|Subject', '≥ 50 ng/L pg/mL', '< 30%;|Patients', '>0.8 x 10³/microliter', '< 1 month|Oral consent', '≥58 kg', '0 to 2.|aged', '0-2|ELIGIBILITY CRITERIA', '> 34 weeks', 'score less than 3 scores;|metal', '35-75|Any', 'between 01/06/2020', '0 - 10', '≥ 1.5 × 10^9/L|Platelets', '< 1.8', '37 %', 'equal to or greater than 1 mm,|class I', '>= 18 years|Score', 'between 16 years and 40 years', '7 to 12', 'monovalent', '≥ 5 times per day).|Participants', 'between 1 and 4', '≥ 40mL/min', '<220 cells/mm3', 'younger than 13 years', '>= 50%.||Patients', '≤1.5 x institutional upper limit of normal (ULN)', 'pass 25 dB HL', '<1.0 meter/sec)||', '<160 U/L', '≥100 mmHg diastolic', 'Asian origin|≥18 years', 'less than 2 years.|Patients', '>= 12 weeks|Participants', 'criteria:||Refusal to sign', 'Score A', '≥100x10^9g/L', 'score of ≥33,', 'between 18 and 35 years.||', '> 3 × upper limit of normal (ULN)', '≥ 100,000 / mcL||•', 'greater than 1.5 × ULN', 'Pre-', '<3 months to live)|A', '> 24 hours|Written informed consent', '< 80*10^9/L|placental', 'scores greater or equal to 20', '19 to 30 kg/m2', 'greater than or equal to 50 kg', '× Upper limit of normal (ULN)', '≤ 75 years.|Subject', '≥ 30 mL/min/1.73 m2|Patients', '> 5%', 'project.)|At least 18 years', '>= 15 years|Living', '< 2).|Parent vessel', 'more than 5mm', '37 to 42', '50 mg/dl', '≥ II.|13', '≤ 80', 'greater than 13.|The participant suffers', '<90 mmHg|Normal', '>1|Uncontrolled', '> 35 kg/m2|allergy', 'Over 18 years old|Those who agreed', '≥ 90 mm', '> 100 kg', '18 years and over.||', '5-6', 'II to III|Are', 'above or below this age', '10 to 17 years', '18-70)|presence', '<0.9', '≥ 7mmol/L);|Abnormal', '>= 2', '≤ 2 × ULN', 'less than 6.9 g/dL', '0-2||Participants', ': least 55 years', '1-30 day||', '≥ 1,500/mcL.|Platelets', '<200 c', '> 1.0cm', '>0.3nmol/l', '= 15-28', 'over 3', '≤ 3×ULN.|Renal function', '>IV Contraindications', 'from 18 to 85 years old', '< 1.5 × 10', '> or equal to 30 mL/kg min||', '1.1 criteria|Estimated life expectancy', '> 6%);|Disorders', 'under 18', 'above the lower limit of measurement.|Subjects', '>500 mg/', '>10%', '>40 g / day)|Disturbance of consciousness', '≥ 470 ms.|Hypertension', '<20%||Hemodynamic instability', '< 150/μl', 'between 2 to 12.5||', 'not more than 2 weeks', '5-19 points', '≥ 3)|Willing to make', '>25 kilopascals', '≤ 70%', '20.0 cm^2 measured', '> II|Inability to speak', '0-33).|Participating', '< 2.5 times the upper limit of normal', '> or = 18 years||At', 'score of 24 or more', '1-adult', 'within normal institutional limits|AST(SGOT)/ALT(SPGT', 'Impaired', 'basically normal', '18-45 years|regular menstruation||', '31-B1-B3', '< 18 years', '≤ 4 cm', 'excluding', '> 18 years|Invasive mechanical ventilation', '> 30 kg/m2)|pregnant', '≥ 30 mEq/L', '≥7.0% to ≤10.5%|Body mass index', '> 18|Metastatic setting', '> 1 mm', 'at least 18 years|The', '≤ 21', 'at least 18 years|diagnosis of T2DM', '41-60 points', 'I-II.|Hypospadias surgery.||', 'greater than or equal to 35.0 kg/m^2', 'between 55 and 75 years|Able to do', '>= 3 months|Adequate hematologic', '< 70 mL/min /1.73 m2', 'less than 6 months.|Patient', '≤ 5×ULN.||10', '20 to 40 years old', 'more than 14 days', 'between 18 and 65 years,|Ambulatory pwMS with definite diagnosis', 'less than 19 years', '<30 min duration', '< 15 IU/mL', 'four times a day', '160-179 mmHg', '< 45 min-1.|Electrolyte level outside normal range', '≥ 18 years old 2', '3-5 years', '<5 kg change', '> 120 milliseconds|Any', 'over 18-50 years.|During the study', 'between 18 to 50 years||Exclusion Criteria||Pregnant', '=< 3 x institutional ULN|Hemoglobin', 'over 18 years.|Patients', '< 6 months;|Episode', 'above 20 years|Singleton|Gestational', '10-18', 'under 18 years|severe cognitive', '≥ 18 years;|Written informed', '<50 beats per minute', '4-21 days after the', '16-45 years', '19 to 70 years old|Those', '-24', '≥ 18 and ≤ 64 years.|Type 2 diabetes mellitus', '20-40', 'below 90%', '2.5 times higher than the upper limit of normal).|Moderate', '≥ 90 diastolic mmHg', 'between 0-7', 'above 35|Research-related', '>/=18|Eastern Cooperative Oncology Group (', '≥ 18 years;|Aortic', '< 18 years|No', 'greater than or equal to 1000/mm^3', 'between the acupuncture treatment', '< 6 months|Pre-existing', '>1 h before delivery.|Surgery', '≥ 18 years|BRCAwt', '20 mu g/L', 'under or equal to 50.|ECOG 0-1|Patients', '19 or older||Patients who agreed to the research protocol', '≤ 3 × ULN.|Creatinine ≤ 1.5 × ULN', '>180/120 mmHg).|If', '> 18 years,|admission', '>3x ULN|History', '≤1.5×ULN;||Aagree to provide', '>1.5 × upper limit of normal (ULN)', 'less than 30 ng/mL', 'below 76 years old', '17-28 kg/m2||Male', '≥ 0.1%', '≥22 years old|Score ≥15 on the 7-item', 'below or equal to 20/40 and above 20/200', '> grade 2.|Hepatic insufficiency resulting', 'between 65-85 years', '> 12 years', '>12 weeks', '11 above;|A negative', '≥ grade 2', '> 1.5 x ULN|AST/ALT', '< 1.5×ULN；|total bilirubin level', '< 2.5 X ULN', '<10 µIU/ml', 'between 35 kg and 90 kg', '1 and 2,|willing to participate,|Pediatric', 'lasting more than 8 days', '18- 35 years old', 'above 60 years', '>1 units/day', '< -12 mmol/l', '18 years old ≤ age ≤ 80 years old', '18 years old or older.||', '7.5% to 10.5%', 'score of ""', '< 11 seconds|Unable', '=37 weeks).|Healthy birthweight', '≤ 4.0', 'than 50 ml /', '7 to 17 inclusive', 'between 350 to 450 msec', '> 30 Kg/', '<8 g/dL', '≥ 30 kg/m2.|-', '18 and 49 years', '> Upper Limit of Normal (ULN)', 'score of 5-14', '<1.0x109/L', '≤ 3 m)|Use', '< 30 points|Informed consent is signed', 'over 65 years old', '≥1500 pg/ml', 'equal to or lower than 1.5 times of ULN;|Coagulation function', 'nitrogen>17.9 mmol/L', 'ia:||Male/female', '≥ 10 g / dl', '≥800 ng/mL', '1-4', '< 35 kg/m2|Otherwise healthy', 'over 3%|Subjects', '>= 60 years.||', '19-85 years|Patients', '>4.2% in pH metry while off PPI|Exclusion', '0-1).|Slight', '>upper limit of normal (ULN)', 'patients||age < 55 years', '0 - 2.|Ability to understand and sign the informed', '≥18 at time of', 'between 7 and 12 years;|The child', '≥18 yeas', '>2cm into the IVC from the', '≥ 1500', '< 1.5 times the upper limit of normal value (ULN)', 'at least 5 minutes', '9-12', '12-17|Confirmed binge alcohol use event reported to the surveillance system', '50 years old|Provision of informed consent', '>= 60%)||Administration of a live', 'between 3 and 6 years|do', '>40 milli-International unit/ml', 'more than 40 mIU/mL', '20-25 years', 'Confirmed', '≥ 80 mL/min/1.73m2', '≥ 7.5%.|Serious', '>3 sec daytime', 'between 50 - 100 bpm', '> 7.5', 'between 18 and 40 years.|Clinically significant', 'below 30%', '≥ 50%)|More than 40 mg/ml', '>5kg', 'lower than 35;|With', '18-35-years-old', 'between 30 kg/m2 - 34.5 kg/m2||', '<55 bpm', '= (140-years-old', '≤ 1.5 times the upper limit of normal.|Alanine aminotransferase (ALT)', 'below or equal to 20/200 and above or equal to 20/400', 'under 16 or over 60 yrs|Degenerative', '≥50 kg.||', '50-90 years old|2', '> 35|Patients', '0 to <18 years', '>/= 18 years|Diagnosis of', '±10 years', '<100,000.||', '< 1.5 times the upper limit of', 'negligible', '<4 hours', 'between 30 and 70 years', '≥ 18 and < 80 years', '18-60 years.|ASA I-II.|Both sexes.|Shoulder surgery.||', '>4.0 mg/dL|WBC <2.0 x 109/L|Hemoglobin <8.0 g/dL|Absolute', '<45 ml/min/1,73m2|P-cortisol', '0-28d', 'over than 21mmHg', '<9|Last A1C date occurred', 'higher than the', 'greater than 2;|Language', '> 24 mmHg', 'positive', 'less than 50 mmHg', '<3x/week)|vegetarian', '>59 hours', '> 30mmHg', '≥ 35', 'fewer than 6', '≥35-40 kg/m2)|Type', '> 8.5', '<12.0 g/dL', '≥ 60 to ≤ 89 mL/min/1.73 m^2|Hemoglobin', '12 weeks', '≥3 months;|At least one', 'I to IV|Subject', 'over 120 ms', 'patient groups:||- 18 years or older', '≥ 90 g/L).|Alanine', 'greater than 30 kg/m2|Pregnant', '> 1.5 centimeter (cm)', '> 85 mm', '1a and 1b:||Body mass index (', 'between 25 and 30 mg/kg2', '18-60 years|Free', '> 25 kg / m2)|Abnormal', 'between 2 and 5;|Patients understand the purpose of the study', '=< 3.0 mg/dL', 'between 90 and 140 mmHg', 'at least 40 years|Ankle/Brachial Index (ABI) of', '< 50.000/mm3)|Contraindication', 'Less than 6 weeks', 'more than 10mg per day', 'global score of 0.5 or 1.0', '2-13 years', '>5 years', '18 or older.|Diagnosed', '≥ 1.5 × 10^9/L|platelets', '≥43 mmol/mol', '<11 g/dL', '>=9 g/dL', 'II patients', '± 20%', '≥ 60 years|Scheduled', '< 3.0 × upper limit of normal.|Total bilirubin ≤ 1.5 × the upper limit of normal', '>3|severe visual', '≥30 ml/min/1.73 m2', '50-74 years', '> 30|Presence', '>10-pack-year', '≥ 1.5 × 109/', '<21', '≤ 1.5 mg/dl', '≥2.0 mg/dL', '≤ 2 hours', 'poorly assessable', 'less than 30 mL/minute/1.73 m2', ""less than 1 year's duration"", 'Between 18 to 75 years', 'II-IV|Receiving', '≥ 35 Kg/m2.|Those', '25 - 40', '> 16 years;|2', '>450/470ms', '>= 40 mm', 'less than 2 years|CKD 4-5', 'dose ≤ 5 mg', '25.0 to 40 kg/m2|average self-reported', '=< 480 ms||Note', '≥18 to ≤35 years.|Weight', '> 2 × ULN', '≤ 35/min', 'over 6 cm', '> 60|Poly-metastatic', 'ranges from less than 40 years.|BMI < 35kg/m2.|Normal', 'higher than adjacent', '>=12 months', 'greater than 90 mm Hg', '> 75,000/mm^3|Total', '60 - 100 bpm)|had', '≥1 hour.|ANC ≤ 0.5x109/L.||Patient', 'equal to or higher than 21', '> 1.3 or PT prolongation', '≥ 60 years|Diagnosis', '< 20ng/ml|Gleason Score 6 or 7|Having', '>126 mg/d|Weight', '18 years old ≤ age ≤ 70 years', 'below 40%|Asthmatic', '≥9 gm/dL', '0.0 - 6.0.|At', '<75 μm', '< 18 or ≥ 85 years.|Cardiogenic shock', 'between 25%', '100-125 mg/', 'between the 10th minute', '+ - 3||', '0-1.|Capability to swallow intact tablet', '> 120 mg', '=< 15 days prior to', '≥ 2 weeks', '≤ 2|The', 'more than 0.5 mg/mg', 'minimum 4 years', '< 1 g.||5', '>100 mls', '>= 60 mL/min per 24 hour urine test', '110-125 mg/dL', '≥ 18 years;|Written', '</= 8 weeks', 'greater than or equal to 18', '<5.1', 'shorter than the following', 'than 50 kg', 'probable', '50-85 years', 'between 21 and 65 years old|Is voluntarily', '<40 years', '>1.0 cm', '90 years old.|Pain', '≤ 2.5 × ULN；⑦', '20 years old;|diagnosis of', '<TAB>within normal institutional limits||AST/ALT', '< 3.0 x the upper limit of normal (ULN)', 'between 18 and 65;|score', '>20 mm Hg systolic', 'seropositivity', 'at least 28 days prior to the first dose.|Subjects', 'occupying more than one-third', '> 65 y/o|bilateral', '< 8 cmH2O', '18 - 40', 'daily dose <10 mg', 'children parents/legal', 'less than 5 years ago', '0-1.|non-small cell lung cancer', '< 40 beats/min', 'more than 12 weeks.|Able to understand', '>= 18 years old|Cognitively capable of following direction', '<90%', '≥ 200 mg/', '> 4 mm', '> 1.5 x institutional ULN', '≥ 90 dB HL', '= 360 mL beer', 'between 18-60 years', '< 0,2 µUI/L|Chronic', 'grade III or above', 'greater than (>) 40%', '≥ 40 ng/mL', '> 200', 'qualify', '≥ 100,000/µL|Partial thromboplastin time (PTT)', '>75,000/mm3).|Serum', '≥18 years|Informed consent|Neutropenia', '= 2.||Male', '>10);139|Orthopedic problems prohibiting TC', 'less than 90 %', '<70 mmHg).|Hypo-', '18.5-29.9|No', '3 years and 16 years', '>30 days and <52', '< 10.65.||', 'lower than the standard cut-off value', '0.6-12,000 U', '18 years old', 'more than 140/90 mmHg', '1, 9', '<45 ml/min', '<1.5X normal|Creatinine clearance', '<37', '≤ 1.5 × ULN.|No', 'PTH(1-34', 'at least 1 year', '≤ 6.4%', '< 2500 grams|APGAR scores', 'greater than 2mm', 'preventing echocardiography|Absence of written', 'more than 50%.||', '< 30 ml/min/1.73 m2)|5.Serious', '20-35 kg/m2|Adequate', '18 to 80 years;||Signed informed consent form.||', '> 1500/mm3)|Platelet count', 'two consecutive rises', '< must', '≥60-year-old presenting', 'more than 1x10^4 copies /mL', '≥ 4.0*', '≤ 6.0 mg/dL', '1.5', '< 9 kPa', '> 70 x 109/L|AST/ALT', '≤ 10%', '< 200 mg/L-1|Triglycerides < 150 mg/L-1|Normoglycemia', '≥ 2 mm', 'less than 20,000 per microliter', '> 97 percentile|For individuals < 2 years', '50 to 95 mmHg', '>30 Gray', '≤ 5.0 × ULN', 'rising', 'less than two years after menopause);|Received', '99 mm Hg', '> 68Ga-PSMA activity', 'between 65 and 84 years', 'lower than 45 beats/minute', 'more than 5 kg', '>= 30 kg/m2|Rural resident|English speaking|Physician clearance to participate|Able to walk', 'less than 100 x 103 / L. 15', 'less than 38|Absence of', 'between 2-5 years', '≥ 70%|Having', '> 2.0cm', '<7 years', '18 to 40 kg/m^2', 'between 50.0 and 120.0 kg, inclusive', '> 0 AND/OR|GC dosage', '>100', '≥40 years referred', '> 91dB HL.|Excluding', '10-12,|Having', 'I/II),|More than 18 years', 'older than two years', '>25%', 'at least 11.5', '<1.5×ULN.|Eligible patients', 'over 40||', '≤ 210 pg/mL|Hematocrit', '≥90×10^9/L;|Hemoglobin', '>= 60%)|Life expectancy', 'less than 15 or more than 35 years', '≥ 3 ×', '>1000m', '90 g/L', '≥ 39||', '0-2 score;|9.Voluntarily participate', 'greater than or equal to 36', '>= 51 mL/min/1.73 m^2|Human immunodeficiency virus', 'between 64 and 83', '> 12', '0 or 1.|There', '> 194.5 mmol/L', 'less than 3 mm', '≥16 prior to the treatment|Signed', '≥', '≤21', 'less than 8 weeks or more than 26', '50-89 mmHg', 'equal to or greater than 8', '> 125 mg/dL|Unable', '20 mg/day', '> 47,5', 'shorter than 30 minutes', ""male's"", 'from over 18 to under 75 years', 'women)|18-40 years', '≥ 300/mm3', 'less than 1.5 times the normal value', '<90 or >140 mmHg', '>27', 'larger than 20 mm', '18-80 years|Participant', 'function#||International normalized ratio', '≤ 0.30', '25-60||', 'lower than', '>/= 18years', 'above two years.|Unilateral UPJO.||', 'pH 7.01 to 7.15', '≥ 1,500/mcL|Platelets', '2 times higher than the upper limit of laboratory normal value', '<75 years old', '>450 milliseconds|Any', '40-60 years', '> 7 days prior to enrollment', '1 TO ARM 2): In', '<45 mL/min', 'stage III - IV', '≤ 440 msec', 'between 14 -22 weeks', '> 5 times of the upper limit of normal value', '> +1.00 Diopters|CCTS', '> 10mmol/L);|Severe', '45-80 years', '> 90g/L|Platelets', 'at least 24', '>40%.|Patients', '18-30||', 'greater than 30 kg/m2', '18-65,|to', 'II-III|Elective off', '≥ 200 pg/mL|Able to provide', '18 - 70 years', '≤ 1.5 x upper limit of normal(ULN', '< 1.5 x ULN|Fasting glucose', '100 mL to 499 mL', 'less than the limit of detection', '<3 months)diagnosed on', '≤ 60', '≥ 100,000/ μ', '≥ 40 mm;|At', '≥ 176.8mmol/L', 'greater than 24 months prior', 'least 42 years', '> 90 days', '< 8 g/dL|Pregnant', '≥ 2', '≥102 cm.|Read', '<1.00 D||Exclusion criteria:||Participants', 'between 18-75 years', '>24 breaths/min||', '>138 nmol/L', '7 to 10', '>=6||', '≥300 pg/ml', '< 3.5 mEq/L', '16-18', '< 1.5 ULN', '< 4.5 mmol/L|Systolic blood pressure', 'less than 12 mm', '>2.0', '>64.||', '>18 years.|GFR <45 ml/min/1.73m2', '> 25%', '≥50× 109/L(without', '150 m', 'wider', 'less than 70', '>2×upper limit of normal (ULN)', '<32 weeks', 'poorly-controlled', '≥ 1.5 x 109/L.|Platelet count', '<50 ml per minute', 'between 12 and 60.|Subjects must complete all screening assessments', '<1.5 x upper limit of normal', 'greater than ULN', '=< 5 X ULN', '≥ 6.5%|Triaged out', 'less than 40 kg', '≥ 1.3 cm', '18 to 40 kg/m2.|If', 'Female|Age Range', '≥ 15 to ≤ 29 mL/min/1.73 m^2|Moderate', '<18 years|Initiation of ECMO', '< 3 × 109/L', 'from 50Gy to 66Gy;|ECOG', '0-1;|Estimated survival time', 'equal to 1.0 standard deviation below the test score normed for age', '<50% of predicted normal.||- Concurrent', '< 35%)|Atrial fibrillation', 'under 50 years-of-age', '< 80×109/L|eGFR <60 mL/min/1.73 m2', '>50 mg/day)].|Use', '≥ 3.0mg/dL', '1.5×109/L', '18 to 60 years|T2DM||', '≥12 weeks|Non-surgical sterilization', 'between 18-25 years|Permanent', '≤ 4 doses', '≥10 mm', '18-65 years|without', '18.5 to 40 kg/m^2', '> 1.5 x upper limit of normal', '<= 5 x ULN', '≥91%', '12-17', 'III to IV', '>= 45 mL/min', 'no younger than 18-year-old.|Ineffective', '1.5×10^9/L', '> 25 mm', '14.0 - 14.4', '90 or higher', '12 and above', '13-30 years|Symptomatic', '≥ 70.|Life expectancy', 'between 25 and 40 kg/m2||', '18-65 years|Both', '> 7% or >', '≤ 33 mmHg', '3-4 months', '< 0.1ng/ml', '> 25,000 / mm3', '- 105', '1 individual', '<11)|Opposition to data processing from the older adult', ""less than 7.5%;|The patient's"", '≥ 80 points', 'II-IV', 'greater than 95 mmHg', 'II ou', '>2.00 mm', '> 12 weeks.||Subjects', '>= 75,000 / mcL', 'less than 2.0/Mb', '<18 years;|Unable', '<3', '6-24 months', '≤ 1.50 D', '> 40%', '18 and older', 'greater than or equal to (>=) 19 years', '< 30 ml/min/1.73 m2|Severe', '65 years or older.|People', 'above 18 years old', 'higher than the lower limit of detection', '>= 30 mL/min', '6 km/h', '< 20', 'above the upper limit of normal);|Known', '18 years old|Patient', 'between 18 to 50 years', '> 65 years old', '>18 mmHg)|Subject', '≥ 1.5 x 109/L', '≥ 46', '>110 ms|Second-', '<3.5 meq/L', '≥ 100×109/L', '≥ 104 copies/mL', '18 and over,|Diagnosed', '≥1000 copies/mL', '65 years', 'below 20mm from internal cervical', 'between 18.0 and 30.0 kg/m2.||', '± SLND|Able to read', '50-75 yo', '< 30 years', 'between weeks 37-42)|Bishop score is less than 6', '>470 msec', '≤ 1.5 ⋅ ULN|For', '< 6 months before inclusion', '>/= 8 weeks before', '>200mg/dl', '12 to less than 18 years', '≥ 10 points.|No', 'requires use', '≥ 50.0kg', '1.1patients must have', '≤ 60 mL/min', '12% or more', 'more than 1.2 times of the upper limit of normal value', 'more than 3 months', '0-2;|9', '≥18 years;|diagnosis of INOCA;|availability', '>0.35 kU/L)|patient suffers', '18 years and over', '≥50% of the HRCT', '5-day', '>/= 18 years', 'lasting 4-72 hours', ""< 10|Sjogren's syndrome|ECOG status"", '>0.5', 'less than 150 minutes', 'PR level of positivity ≥34 %', '≥40 mmHg||Subject', '>100 beats per minute', '>14 units per', '0 to age', 'greater than 4', '≥ 5.0 cm', 'older than 18', '≥ 1.5 times ULN', '< 2h40min||', 'disease;|More than 3', 'grade II or above', '9-12|have', '>145 mEq/L)|Hyperkalemia', '>30 kg/m2|Coagulation dysfunction', '17.5 to 35.0 kg/m2', '1 week to meet', '≤ 2.5 × institutional upper limit of normal', '90-95%', '< 19', '27-30', '> 3000/mm^3|Platelet count', '≤ 2.||Exclusion', '< 60 ml/min/1.73 m^2', '<1×ULN.|Patients must sign informed consent', '< 15|PSA ≤ 30 ng/mL|Prostate volume ≤ 90', '20-45 years|Healthy', 'between 18-40 days', 'less than one year|Subjects', 'QTcF≥ 470 ms', 'LVEF≥45%|At least', 'less than 6 weeks', 'less than daily', '> 2-fold the ULN', '<50mL/min/1.73m2', '2-12 years', '> 200 mL', '19~45 years in', '≤ 1 week before start of the study treatment.|Known severe', 'between 25 and 65 years', '= 7-12)|Metabolic acidosis', 'equal to or shorter than1.5 times of', '≤1.5 x upper limit of normal', '<100,000/μL)|Significant', '≥18 years.|Unresectable', '<1 year|Enrolment', '^9/L|Absolute neutrophil count', '<80%|completing screening', 'between the anterior and posterior edges', '18-75||Indication', '>248 dB/m', 'less than 12 months||Minimum dosage', '>5 × ULN', '6 to 12 years|Patient', '140 mmHg.|Moderate', '2022-002616-24Study Code#', '≥ 0.2 ng/mL.|Age ≥ 18 years-old.|Willing to provide', '> 90mmHg),patients', 'at least >12 weeks.|Normal organ', '>30 genes analyzed', '≥ 130/85 mmHg', '≥ 150 mmHg', '>= 1,000/microliter.|Platelets', '<= 1.5 x ULN|Creatinine <1.5 x ULN', '1.1 criteria.|Documentation', '>= 8%', '< 4.5h', '180/110 mm Hg', '150 mL grape wine', '> 18||Exclusion criteria', 'more than 3 cm', '≥100,000/mm3).|Patients', '>7.5 mg/d', 'below the lower limit of normal', 'less than 12 m', '18-99', '=QT/RR1/3', 'score of Montreal Cognitive Assessment (', '146 mmol/L', '11.1 mmol/L)|Ability', '20-60 years)|Stable', '18-0010', '≥100,000/mm3', 'between 18 and 65 years.|Fulfilled the 2010', '< 18 years;|Nugent score < 7;|presence', '≤ 25 years', '> 18 years|New diagnosis', '30,000/μL', 'between 18 and 25 kg/m2||', '2-5)|Patient', '-23 mm', '18-45 years|Both', '> 20 relative units', '1-3|open nephrectomy', '≤ 3 Upper Limit of Normal (ULN)', 'score 0-1||', '264μmol/L', '> 4mmol/l)|Drug toxicity', 'Chronic phase', '≤ 1.5 x the upper limit of the normal range (ULN)', '> 2000 IU/ml', '<70', '3-6', '<2% loss', '< 22);|A', '≤3.0 x ULN', '≥1.1×109/L', '90-99 mmHg', '≥18 years|Established histologic diagnosis', '≤ 1.0 upper normal limitation', '<2)|Being able', '> 26 mEg/L', '> 18yrs|Informed Consent|Sterile Urine culture', '3.0-4.0 m/s)|10', '>= 4.0 x 10^9/L', '<120 ms', '> 5ml/kg', 'less than 17.5kg/m2', '≥18 years)|Planned', 'total of 70', 'male', '40-75 years', '= 2|>25-40', '> 30', '>2 x ULN', '<30 mL/min/1.73 m²', '< 30', 'over 250 pounds|pass', '≤ 2', '> 170 mmHg', '≥ 80×109/L', '18 to 30 years|Anterior Knee pain|An', '≥ 16 mmol/L.||OR||ABG', 'less than 2 months', '≥ 90g/L;||Coagulation', '6.5-10%|Age', 'over 75 years', '< 1.5×ULN；|No', '+/- surgery', 'between 60-75 years', 'Grade A or C periodontitis|Presence', 'between 40 and 80 years', '>= 3 mg/L', '19-35,|Literate|Effective communication.||', '< 3,000/ mm3', '≥90 and ≤140', '< 5%ile|A diagnosis', '15-year', '0-1 5', '≤ 50', '≥65 ,', '≥ 100mmHg', 'indicated|Age older than 21', '> 450 msec', '> 1mm', 'younger than 3 months', '≥ 17', 'above 15 cigarettes per day|Concurrently', '≥ 18 years old who:||are', '>3 X institutional upper limit of normal (ULN)', '≥ 55 years|Written', 'between 18.5 and 29.9 kg/m2.||', '21-35.|No contraindications', 'less than 30 ml', '>30 kg 13', '≤ 1.5 X ULN', '0-1;|Adequate organ function;|Life expectancy', 'more than the upper limit of normal', '≥0.2ng/mL', '> or = 35|Participation', '< 2000 IU/mL', '=< 15 days prior to registration)|Alanine aminotransferase (ALT)', '≥60 mL/min/1.73m^2||', '< 6 mm).|Missing', '>35 Kg/m2|CKD', '≥ 30 kg/m2)|Bleeding', '50% to 90%', 'Score of 10 or higher', '18 to 65 years;|Subjects must give informed consent to the study before the study entry', 'distant metastasis;||Patients', '≤ 40mm', '<70 years|Having', '≥30 at time of delivery)|Concern', 'criteria:||Unable to provide', '18.0 to 30.0 kg/m2', '≤9%', '≥1.5 × 109/L;||Platelet count', '≥19 years', '12 - 20', '>0.80.|Any', 'neutrophils≥ 1.5×109/L', '≥ 18 year||', '> 3mm|Ipsilateral arm', '6-12 weeks', '36 years', 'less than -3', '<25', 'permanently', '>65', '18 to 65 years|BMI', '≥ 1g', '≥1.75', 'over 159 mm Hg', '>600 pg/ml', '> 500 ms.|Known', 'greater than the upper limit of normal', 'at least 21 days', '<=140 mm Hg', 'between 2.5 to 6.5', '≥ 18|Adequate organ', 'total dose', 'male ≥450 ms', '≥0.5 × 109/L|Serum bilirubin', '> 10 g/dl|AST(SGOT)/ALT(SGPT', 'between ICF signature', '<10 seconds', '≥80 g/L', '< 18 or > 80 years|Urogenital', '<40 kilograms', '<40mg/dL', 'score is 0~1;|The', 'from 40 to 70 years inclusive.|Verified diagnosis', '>10 bilateral', 'between 18 and 30 years|Subjects able to give', '< 5cm', '<200/µl', '110 lbs', '≥1.5 ×10', '>20 errors|The', '>9%)|Patients', '^9/L. Note', '≥90 g/L', 'confirmed', 'reduced', '> 30 mg/L.', '>325mg/day', '18-70 years|Diagnostic', '90 g/', 'laboratory)|younger than 18', '>=1,500/mcL|Hemoglobin', '>= 1.2 ULN),|Bilirubin', '> / = 38.0 degrees Celsius /100.4 degrees Fahrenheit', '5 to 18 years old, including:||The parents', '18.5-30', 'less than 30 kg/m2.||', '≥ 60 ml/minute||', 'older than 18 years,|signed informed consent', '< 10 cm', '≥1.5 ×ULN', 'greater than or equal to 2°||', '18 to 48 months', '> 45 mm Hg) C', '>2mg/dl).|Thyrotoxicosis.|Pheochromocytoma.|Known', '≥40 kg/m2.|Inability', '20 - 35 kg / m2||Exclusion', '≥ 1000 IU/ml', '>92%', 'more than 35years', '<50m', '> 140 mmHg', '< 100,000/mm3|Hemoglobin < 9 g/dL|Creatinine', '20 to 50 years.||', '= 360 ml beer', '≥50% stenosis of the internal carotid', '<30 days prior to Screening', '≥ 30 times/minute', '18 or greater|No', '0-18 months|Resides', '0-2.||EXCLUSION', '18-70 years|Patients', '>20 years', 'between 5 - 10 mm', '≤1.5 × ULN.||Note', 'greater than 500 ms', '80-130 milligrams per deciliter', 'deemed not', '≥ 2.|Received', '< 80 mL/min/1.73 m^2.|Triplicate', 'at least 1 of the', '6-13', '>2xULN', '≤ 0.3%', '> III', 'at - Least 5 mm', '>the upper limit of reference', 'from 22 to 50 years', '≥18 years|Ability to sign', 'I-III,|Patients', 'between 17 -25 years', '> 40 or >', 'score from 0 to 1.|Must', '≥1+ considered', '24-59', '>18 years|stable clinical conditions|Diagnosis', '18-65 years.|Patients', '≥ 28 kg/m2|Infertility', '≥ 23', '≥ 18 years old|Anticipation', '> 320mOsms/L', '18 - 90', '≥ 1000/mm3', '30 years|Literate/English speaking||', 'between 50-65', '>88cm', 'between 18 and 30 kg/m^2', '^9 /L);|Adequate liver function', '>1.8mmol/l|Willing', '0-2|adult', 'between 18,5 kg/m2', '≥ 100,000/mm^3', '>= 5 years', 'below 50', '< 15 ml/sec||', 'between 18 and 49 years', '< 60', '> 500 mL', '≥ 18 yo|Sex=female|Patients', '> Normal range upper × 1.5|Blood CPK', '≤80 years', '> 32 kg/m2|Pulmonary hypertension|Peak', '> 30 ml', '50%;|Estimated', '18-64 years', '≥100×10^9/L', 'complete response has', '> 90mmHg).||Severe', '< 100', '<15 mL/min/)|Chronic', '<110 mmHg||Main', '> 18 years).|Participants willing and able to comply with the study procedures.||', '1 and 4.|A pre-bronchodilator/pre-dose FEV1', '18 mg/dL', 'equal to or greater than 18 years', '70 times/min', '>18 yrs|indication', '> 18 years|parent', 'at least 5 years;|Willingness', '19 and older|Able to complete activities', '≥ 60 mL/min/1.73 m2', 'Between 6 - 20 years', '≤2 x upper limit of normal ULN|Alanine aminotransferase (ALT)', '15-17 years', '< 30 minutes|Crepitus', '17-25', '18-64|Currently', 'B to E)|Need', '≥15% and ≤40%|Subject', '> 2 years', 'grade II', '< 14 cm', 'less than 10 mg/day', '>40 and <115', '≥10 cigarettes/day).|Energy', 'from the screening triplicate', '1000 cps / ml);|Patients', 'between 5,000 to 150,000 asexual parasite count/μl', '1 or 2.||', '≥ 17 mmHg', 'I-III|Ability', '5-9', '<60mmHg)||', '0-36 months|Agreement to take', 'more than 3 years before date of randomization', 'above 1000 m', '>0.5x109/L|Platelets', '+ parent questionnaire scores below the expected value', '>/= 3 years', '> 38 or', 'below 3.0×the upper limit of normal (ULN)', '≥50 ng/mL and <200 ng/mL', '≥1.5x10^9/L，Platelet count', ""titers higher than the upper limit of the study center's normal).|History"", '≤ 45)|Participant', '≥ 450ms', '10-15 freshly cut', 'score of 0 through', '=< 3.0 x ULN', '>300 mg/day', 'LVEF<50%', '± 5%', '> 2 times ULN', '≥50% QTc interval', '≤ 1.5 x upper normal limit (ULN)', 'between 1st January 2019 and 30th September 2022.||', '<6)||Patient', '> 35,|history', '8-14', '<1.3 mmol/L)|If', '< 490 and', '> 3x ULN', '>= 18.0 to <= 30.0 kg/m2', 'greater than 20 g/day', '≤ 9 mg/day', '>250', 'less than 2 times the normal value', '18-90 years|New', '≥ 50% predicted', 'older than 3-months.|Children', '≥18 years;|Subjects comply', 'increase 3 times the upper limit of normal', '30-60 minutes', '< P97|Any general', '> 1.5 x ULN.|Presence', '≥ 39),|Suffering', '<30 days', 'less than 33 weeks', '<25.0 kg/m2|Absolute', '< 1.5 institutional ULN', '≥ 5', '> 18|Elective', 'from 18 years old', '40-80 years', '50 mSv.|Liver function', '≥80%|Male', '1 to 4 Osteoarthritis||', 'within therapeutic range of intended use of anticoagulants||Abbreviations', '< 1g', '>130 bpm', '≥2.00 mm', 'between 18 to 50 years|American society of anesthesiology', '< 30ml/min/1.73', 'from time of original diagnosis', 'between 18 and 85 years old', '>60)||', '1) provide', 'canines|Above 11 years', '12-19 ng/ml).|Their', '≥ 250', '≤CTCAE grade 1', '30-59 mL/min/1.73 m2', '≥ 2.0x109/L', '20 to 69', 'less than 3.5|Previous pelvic surgery|Emergency surgery', 'under 7 years', '18 to 50 years old),|affiliation to a social security scheme', '6 to 16 years', 'greater than or equal to 3/10|affiliated', '≤ 4cm', 'greater than 20 mm Hg', '≥21|Subject must have', 'lower than 15%', 'less than or equal to 1.5 x upper limit of normal (ULN)', '≥35 kg/m2|Pregnant|Chronic fatigue', '<1%', '30-75 years|Transthoracic', 'from 30 to 80 years', 'scores ≥ 15;|Patients Health Questionnaire-9', '> 45;|Obstructive', '≥ 200 mg/dL', '>= 84 days after infusion|Donor leukocyte infusion', '>=1.0 cm in diameter', '<18 or > 35 kg/m2|systolic blood pressure', '<21)|Neuromusculoskeletal disorder', '>= 12 weeks', '90 days|Personal', '> 2.5 mm||', '≤ 4.00D', '>1.5x the ULN|Estimated creatinine clearance (eCrCl', '≥18 years,|Subject', 'greater than or equal to (≥) 30', '0 ,1', '>1.5 X ULN', '18-64', '< 85).|Presence', '≥ 3 months.|Fertile', '≥ 60ml/min.|For those', '37 weeks)|fetus', '> two times of normal levels', '>50', '18 years or older|BCVA', 'spontaneous pain|presence', '1 or 2', '> 20 μg/l.', 'more than 120 beats per minutes', '≥1,500/mm^3', 'between 18 and 65 years.|Diagnosis', '18-30years|Tennis', 'more than 2.5 cm', '≥ 40 years', '>35', '6.4% ≥ HbA1c', '≤ 100,000', '<85%', '≥ 3.0 × 109/L；||Platelet count', '> 2 times higher than upper normal level|eGFR', '≤ 1.5 x the upper limit of normal (ULN)', '>60 mL', '16-17 years', 'later than 4 times plasma half-life', '18.5 - 28 Kg/m2', '1 to 3 years', '18-21 years', '<45ml/min/1.73m²,|No', 'greater than or equal to3 months.|At least one', '4-18;|Being', '18.5 to 40.0 kg/m2', '≥ 18 and ≤ 60 years', '18-59 years', 'over 18|Endoscopically', '=< 1|Participants', 'Basal cell', 'higher than or equal to 130mmHg', '0-1.|Has', '6 weeks before', '≥ 7 mm', 'at least 24 hours after resolution of', '≥ 1.5×109/L', '7 to < 18 year', '6 years', '> 300 mL/min|RKF < 100 ml/day|Hemodynamically stable', '65 years or older.||', 'class III, IV or V', '30 mL/min||Ability to understand', '18 - 70 years,|MADRS score', 'chronic phase', 'less than 30 days', '1 symptom', 'needed.|Presence', '30 to 60 years|Insomnia disorders (ICSD-3', '> 100 x 109/L', '+/- 5', '> 50mL/min/1.73m^2.|RECIPIENT', '> 18y.o.|No contraindications', '7-30 years', 'between 5 and 9 mm', '≤ 110 ms', '≥ 1.5 × 10^9/L;|Absolute', '>1 year|Rutherford classification of 2, 3 or 4.||', '≥ 100*10^9/L', '≥ 8 g/dL', '≥ 5 points', '> 140 mm Hg systolic', '25-35 kg/', 'form.|8 to 13 years', '18 to 60 years||', '> 400 mg/dL', '≤ 5 times the upper limit of normal (ULN)', 'III-IV|History of', '18 years ≦ 75 of age.|Histological', '≥130 mg/dl|Android', '< 30ml/min/1,73m2)|Death', 'less than 12 months', 'requires treatment,|Not', 'resident', 'less than 24 hours.|Use', '> 1)|Contraindications to', '>1.0g;|Obvious', '=< 1.5 times institutional upper limit of normal (ULN)', 'Score ≤2|18-85 year', '18 to 67 years old', 'mental disability|Lack of compliance with the protocol', '≥60 kg', '≥ 0.5cm2', '>85% of predicted value', '<26|In case', '≥ 37', '20 mSv)|Completed more than 6', '≤ 200 mg/L', '<150 minutes per week of moderate-', 'greater than 90', '1-Age', '≤1.5 x upper limit of normal (ULN)', '≥3 at 2 or more', 'at least 3 points', 'criterion).|Long Coronavirus Disease', 'over 50 years', '20 years', '≥ 460', 'at least 50-80 years', '≥ 20 mm', '<150,000.|Medications', '> 280 dB/m', 'males|≥ 30 years', 'at least another', '≥ 3 mmol/l|Fibrinogen', '≥18 and ≤25Kg/m²,|For', 'between 18 and 35||', '18 - 35 mg/m2', '≤ 2.||11', '18 to 60', '0 to 10)|Be', '53.0-96.7', '1 to 3|scheduled', '> 2000 mg/g', '>1.5mg/dl', '75 years and older|PS score ≥1', '18 - 60 years|BMI', 'greater than or equal to 14 weeks', 'less than 1/3 of the gland volume by', '< 7 g/dL', '=< 1|Hemoglobin', '> 12 weeks;|Written informed consent obtained before', '>100 bpm', 'warranted', '18-45 years', '>100 mL or', '≥18 yrs old;|Pathologically', '<50 copies/mL.|A', '< 1% expression of', '< 5,5 kg/m2', 'less than one month|Contraindication', '≥40%', 'equal to or greater than 30 kg/m2).|HbA1C greater than 5.6%;|IGF-1 level', 'lower than 25', '≥ 20/20;|No', '≥140/90 mmHg', '< 30 ml/minute', 'outside normal range or < 1.5 x109/L|White Blood Count', '18 - 35', '≤ 3 ULN', 'below 1.5 times the upper limit of normal', 'between 18 - 60 years', '< 40 kg.|Participant', '< 0.8', 'between 4 and 18 years.|Motor disability.|Affectation', '18-40 years|in', 'I-III).|Female.|At least 18 years', '≥ 0.5 x 109', '< 20% before the', 'between 18 - 65 years', '18-65|Patients', '18 to 28 years.|Rugby', 'less than 15 ml/min/m2|Moderate', '>5% of body weight', 'less than 7 days', '≥ 2.5 pg/ml', '> twice the upper limit of normal', 'greater than 1.5 times the ULN.|Have clinical signs', 'between 16 and 24 years|Must', '≥6 mm per quadrant', '≥18 years;|Histologically', '0 to 17', 'above and below the', 'less than 0.2', '18-80||', 'not more than six weeks', '19-60 years old', '≥18 years)|Confirmed HIV', '> 16', '>6L NC|Known', '25.0 to 45.0 kg/m^2|smartphone ownership|willingness to install the Fitbit mobile', 'over 18|Patients with', '> 2|Positive screen', '8-10)|PSA', 'less than 35kg/m2|Be', 'between 100 to 3,000 μmol/L|A', 'between 20 to 65 years old|BMI', '>35|Subjects', '>100 IU/L', '=< 3.0 x ULN|Serum', '≤ 5 × upper limit of normal value (ULN)', '≤ 2 x ULN|Albumin', '≤ 2.|Have', '> 1500/mm3.|Platelet count', '≥ 100 × 109/L（100', 'Stage Ia', '≤1.73 nmol/L', '≥ 500 IU/ml', 'between October 1, 2015', '< 0.|Pregnancy|Known', 'less than 5 half-lives', 'greater than 72$|had fewer than 49', 'more 60', 'C class', '23-25 years|presenting', '<= 10 dB,|Written', '≤ 340 ms', '≥ 45.0', '> 360 mg/m2', '< 5.6 mmol/L', '>= 2400 mg/m^2', '53-86', '18 years to 80 years.||', '> 10mmol/L]|Urine', 'lasting more than six months', '≥ 75 years|≥ 2', 'greater than or equal to 65mmHg', '<3x normal', '< 22)|Moderate/severe', '> 3|contraindication', '<1.7', '≤ 45%', '≥ 32 weeks.|Birth', '≥ 60|Age', '5/10 pain level', '≤ 3mm', '>40 mL/min', '> 18 years|Acute ischemic stroke', '< 60mmHg', 'from 0 to 12 years old|Nusinersen treatment|Benefiting from a NIV|Current monitoring', '≥18 years||', '3-6 mm', '18,5-30 kg/m2', 'score 0 or 1).|Absence', 'below 18 years|Denial of written informed', 'between 20 and 80 years', 'upper 65 years', '≥ 1|ECOG performance status', '> 5||', '>2 mg/dL)|Those', '>= 18 years.|Radiographic evidence', '< 1.5 x ULN', 'later than 24:00|Gastroesophageal reflux disease', '≥20 mg/day', '1.5 × 109/L', 'more than 48 hours||', '35-75 years.|Type', '>8.0 g/dL|White cell count (WCC)', 'better than or equal to 0.10', 'less than or equal to (≤ ) 450 millisecond', '≥ 60 mL/min).|Paraffin', 'At least 24 weeks of prospective documentation', '≥ 8.5 g/dL', 'lower than 40%', '<50 or >100 beats per minute.|Subject', '<15 mL/min/1.73 m²', '<12.0%', '18 to 80', '14 - 45|History of', 'less than one year.|Already', '> 95 mmHg', '≥ 130 kg;|Vegetarian food;|Other associated neoplasia;|Patient', '≥ 2 × upper limit of normal (ULN)', '< 1% per year', 'below ≤18 years', '≥ 2 cm', '> 21 units/week', 'less than 2 hours per week.|Serious lower limb injury', '>80 IU/L)|Pre-', '4.0 to <5.0 years', '65-99 years|Able to travel to Brigham', '> 1.5 times upper limit of normal', '≤ 35 kg/m2.||Healthy', '<25ml per minute per 1.73m2 body surface area', 'between 18 and 74 years old', '>0)|California residents|Wifi', '<15 years', '18-49|have', '20 and 70 are eligible', '21 - 80 years', 'guidelines)|Non-smoker', '>18 years|Patients', '> 2.5 x upper limit of normal', '>6mm|Males and', 'requiring IV antibiotics', '> 10th percentile and < 90th percentile)||', '40-85 years', '≥40 cm/sec', 'less than 80', 'above 400mg/m2', 'below 1500 g', '18-65', '>18 years|-', '≥ 20 years|Measurable', '-90 years', '> 35 mm', 'II-II|elective', '< 30 mL/hour', 'age|>85 years', '22 to 65 years', '0-1;|Clinical', '> 50% stenosis', 'score for dry eye classification', '≥40mL/min', '>90umol/L)|Maternal', 'above sea level', '>15 years', '20-50|Being', '<50 × 109/l', '> 40);|Patient', '≤ 10 mm', '16 to 30', '>18 years)||', 'minimum of 10 meters', '< 110', 'at least 3 months', '≤ 2.5*ULN;|Serum creatinine (Cr)', '< laboratory standard),|VAS≤2/10||For A2 Group', '≥ 1.5 × 109/L', '>30%', 'less than or equal to 3x upper limit of normal', '>26 kg/m2|Diagnosis', '> 100 mg/dL)|Alcohol', 'more than twice the upper limit of the normal range|Changes', '4.5-9.0 hours', '>=0.6 Bethesda units', '> 25', ""≥ 50% of the manufacturer's"", '<99% and >85%', '≥0.5×10^9/L||Absolute neutrophil count (', 'at least three months;||Adequate', '> 3.2)|Indication to start', '≥10 mU/L', '400 ml|Patients', '> 6 and < 16', '≥ 30%.|Subject', 'at least 70 points', 'between 12 and 18 years)|Diagnosis of CHD', '≥0.3×10^9 /L', '< 18 years|Liver', 'from 1 to 2+', '0 to 1|Participants', '20 degrees or more.|Subject', 'nodes.|More than 10%', 'less than 50 mg/dL', 'between 2019', '≥65 years old;|The screening results', '> 18 years.|Native', '< 1,0 mmol/l', '< 30mL/min).|Presence', '4-point FWS', '>60 min', '18-89 years|diagnosis', '> 1.5x ULN.|Participant', '≥ 14 years|Probable', 'least 50 years', '≥100×109/L;|Hemoglobin', '≥ 60 x 109/L', '<350pounds)|Total cholesterol of 240-300 mg/dl', '>=21 years', '≥ 470ms', 'Between 18-45 years', '> 75 x109/L', '35 days', '0-3|Ability to understand and willingness to sign', 'between 0 to 2000 IU/mL', '20 to 39 years', '> 150', '≥40mm', 'Stage 1):||A history', '> 3-6 months)|Pain score', 'greater than 2 times the upper limit of normal);|18', '1 and 2', '≥ 6.5%|Fasting', '≥18 when signing the ICF;|Expected survival period', '>3)|Severely sarcopenic', '3 - 7 mmol/l', 'more than 2.5 upper limit.|LVEF', '>25|Individuals', '≥ 95%|Viral load', '14 units per week', '≥ 18 years;|Suspected', '150 minutes', '5-30%,|No', '<', '≥ 75 mg/day)|Long-term', 'second degree', 'over 5 cm', '≤ 15 mmol/L', '> 18|mothers must understand information given', '150 min', 'above 55%;|Women', 'undetectable', '< 5 times of the upper limit of normal value', '>30 x 109/L', 'White', 'short-term', 'I-IV,|Signs of', 'less than 1000/mm3', 'at least 60 for subjects greater than 16 years', 'less than - 4 points', '>35.0 kg/m2', 'between 3.0mm to 5.5', '<50×109/L', '≥30 mL/min', 'outside the local laboratory-defined limits of normal', '< 40 ml/min/', '12 to 17 years old', 'less than 35.||', 'preoperatively|Intra-operative', '< 140,000/mm3|Total', '<70% of predicted', 'at least 12 weeks|Subjects', 'Women|Over 60 years', 'less than 40%;|Treatments', '150 EDs.|Participant', '<3 × ULN).|AST', '< 1 years);|Women', 'less than 3', 'more than18 years', '≥ 153', '0-7 days', 'greater than 35.|Pregnant.|Cervical tumors', '<37.5°C', '2 to 80 years', '≥ 10 points', '×', '≥ 3cm', '=< 28 days prior to first dose of protocol-indicated', 'below 13 years and above 26', '> 1.4', '92% or higher', '0-1|Expected survival', '<2 ×106', '10-year', 'less than seven days|complex skin disorders', '<140/90mmHg', 'over 20 kg/m2', '8 to 13 years;|Under the condition', '≤ 1.0 UNL', '18-30', '= 3200 mg oral', '>3000 m', '>16.5 g/dL)|Subject', 'condom', '<20% of total bilirubin', '< 5X upper limit of normal', 'recruiting.|Patients younger than 16 years', '≥ 65 years|Undergoing', 'between 3 and 17 years', '>3X', '> 10|Positive screen psychosis', '> 140 cm', '≥450 cells/mm3', '≥2 points;|The subject', 'more than 30 weeks', '>2.5 mg/dL', '>18 years;||11', '>85 mmol/mol)|History', 'relieved', '18 to 75', 'less than 40%;|The score of the preoperative simple mental status examination (MMSE)', '≥ 1.10;|Attainment', '≥ 4.0×109/L', 'Early stages', '0 to 3 years old', 'less than 75 years', 'at least 300 pg/ml', '5-7 years|Children', 'early', '>12%', '18-45 years,|no', 'scores < 12', 'less than 12 weeks', 'examination;|Agree to maintain the same skin care regimen', '20 years or older', '4.|Patients taking bisphosphonates|Any sites', '0-1;|Dose escalation phase', 'years and older', '> 460 msec for', '>= 18 years||AML', '18 and above at time of informed consent.|Chronic', '< 8.0 g/dL', '≥50% to <70%', '18 or more|A', 'below 50%', '≥ 50mmHg', 'between 1/1/2007 - 12/31/2022|Resident', '≥ two weeks after the first test', '≥ 35g/L;|Coagulation function indicators', '25-30 kg/m2,|The number of normal deliveries ≤', 'below -2SD and above +2SD;|IGF BP3 level', 'under 5 years', '> 17', 'Stage 0-III', '≤2|Adequate', '>5.6 mmol/L||Renal:||d', '18-60 years old', 'months.|Cerebral', 'greater than 450 lbs (', '>30).||', '44-30 milliliters per minute', '<3xULN', '20 to 30 mg prednisolone', '≥ 8).||Exclusion Criteria', '≥ 100 GI/L).|Haemoglobin', '≤ 500 msec', 'refusing to participate|families', '<5 years|Platelet count', '>3|Emergency surgery', '>3 months after last', '6 to 35 months, inclusive', '≤ 60 bpm or ≥ 100 bpm', 'less than 180 mmHg', '<30 cc/min/1.73 m2', '< 18 years and >80 years|Reoperation|Emergent', '< 150 cm|Body weight', '10-14 years.|Children', 'over 18 and under 80', '<2× upper limit of normal (ULN)', '≤ 2.5 x ULN.|Renal function', 'less than 298 pounds', '≤ 3 x upper limit of institutional', '18 years or above|The patient', '> 50 mg/kg;|New', '> 35 kg/m2|Refusal', '2-8', 'between 18 to 65 years', '> 3000 mg/g)|Diabetes', '6-15 mm|stones history', '≤ 1.5x institutional upper limit of normal (ULN)', '≤ 7|Presence', '<93%', '> 30 kg/m2', 'at least 12 weeks prior to screening', 'older than 18 years old|and', '≥ 125 g/l', 'N0-2', '< 3 times the upper limit of normal (ULN)', '^9/L(No', '≤ 29', 'between 18 and 64 years old', 'between 25 and 45 kg/m2', '> 6 months;|No', '≥130mg/dL)|High', '≥9 g/dL||Adequate', '< 10:00pm', '18 or over|Must', 'greater than (>) 1.2 x upper limit of normal', 'from 18 to 60 years', 'from 140 to 199 mg/dL||', '0, 1 or 2.||', '>=100 g/L', '>= 7 days for short', '>= 1000/mm^3', '< 60 mL/min/m2', '≥12 weeks||Adequate', '>= 8 g/dL', 'between 3 and 18 years||Steroid dependant Nephrotic Syndrome', '>=18 years.||ECOG', '5-7 years old|Body temperature', '> 2.|Consent to the study possible', '2.5 to 5', '> 3 seconds', '15-24%', '15-19', 'I-II.||', '90-110 mmHg|At Randomization', '60-85 kg', '35-44', 'above-mentioned pathologies', 'normally.||⑩ Sign informed consent', '≥3 months', 'between 18.5 and 29.9 kilograms per square meter (kg/m^2)', 'under the age', 'than 75%', '> 7.5 g/dl', 'longer than 24h', 'between 18 and 32 kg/m2', 'At least 22 years', '≤96%', '6 to less than 12 years', 'less than 10% of body surface area (', '25 to 65', '≤ 2 ×ULN.|Be', '> 4×109/L', '≥ 4).||Intermediate-', '≥ 13', '> 5% of base weight', 'score of ≤ 90', '88-93%', 'less than 140 beats/min', '> 150%', '>1.5 times the upper limit of', 'between 1-2 years', '<19 mL∙kg-1∙min-1', 'greater than 50%', 'Positive', '61-80 points', '21 to ≤ 80', '45 and 100 kg', '25-35 kg/m2||+', '≥ 17 points)||Adult', '>60|Able to understand', '< 300 after', '≤ 5.5|Patients', '< 50 %', '= 3.||', '> 30.0 kg/m2|Waist circumference', 'over 21 years', 'R65.20 or R65.21', '>50 µmol/l|Ongoing', '≤ 10mg/day', '60-80 mmHg)|had', '>= 9.0 g/dL|REGISTRATION', '≤ 55mmol/mol', '< 30 ml per minute per 1.73 m2 of body surface', '50 to 65 years', 'I or II adult', 'above 90 bpm', 'stage I', 'greater than to or equal 18 years', '18-30years.|Participants', '< 150 min', '≥ 90g/L. 2', '> 2.5 x ULN', '≥18 years;|Have', '≥ 20 pack per year', 'more than 18', 'greater than or equal to 18 years', '<1.0 x 109/L|Platelet count', '≥ 18 years)|ASA score', '65 or older', '18 years and older inclusive|Body mass index', '≥ 90 x109/L;Hemoglobin', '+/- 2 weeks', '<190 mg/dL', '23-35 years.|BMI 18.5 to 29.9 kg/m2.|A', '≥ 25 g/L.||3', '6-9%', '50 to 90 beats per minute', '>= 1.5x10^9/L', 'greater than 75% of the circumference', '12-15|Volunteering to participate', '12-36', '50 kg to 110 kg, inclusive', '100 ng/dL||Patients', 'eligible', '>1.5× the upper limit of normal (ULN)', 'lower than 3.9 mmol/L;|Patients', '≥ 20/50.|Previously held a valid driving license', '≥18 years and ≤75 years.|A clinical diagnosis', '4-6mm', '0-2.|Estimated', '≤5 × ULN', '>0.50 D of', '≥50% and < 100%', 'less than 6 months before registration', 'distant metastatic disease|Uncontrolled', '18-65 who', '≥18 kg/m2', '≤ 3%', 'above 40 Units per Litre', '≥ 50,000/μL', '≥25mm', 'least 50 kg', '>25 kg/m2|We', '≥27 kg/m^2', '>30 kg.||Participants', 'greater than 440', 'greater than or equal to 26 kg/m2', '18 to 79 years', '≥18 years old', '< 21|agreed to participate|lived', '≥2.5×ULN (≥5×ULN in case of subjects', 'guidelines.|Phase II', '< 150 min/wk', 'surgery;||', '≥18.5 and ≤30 kg/m2', '<1.5 × upper limit of normal (ULN)', '19 to 27|Stable weight', '≤ 0.3', '≥ 150 mg/dL||Pre', 'greater than New York Heart Association (', '>30 kg.|The participant', 'class II div', '<15 mL/min|Requiring', 'at least 2 months post', 'under six years', '>3.0 mg/dL', '0-1|All', '>=1% detected', '>250 ml', '500 ms or higher', 'less than 6 months)|Patients', '≥ 28 g/L', '> 2.8 m/s', '> 15)|Moderate to high', 'between 16 and 80 years', 'between 4 and 11 cm', '1.1 times the upper limit of normal', '>= 5.6 mmol/L.', '≥ 5/10', '<500 IU/ml', 'score of > 3 %', 'between 6 and 16 years|FEV1 > 60%|Child referred', '= 27Kg/m2|AHI', 'less than 1 year & more than 3 years', '0 or 1.|Tissue', 'exercise;|Presence', 'agent ±', 'over 65 mmHg', '< 90%|Severe nervous system disease', 'II - question', 'lower than 50', '=360 mL', '<1500g|Parents agree', '0 - 4', 'less than 35 ng/ml', '≥9g/dL;|Lymphocyte count', '1-Day', '<100,000 per mm3|History', '< 18|Does not', '≥100×109/L', '< 3.0 mg/dL).|Calcium levels', '≤ 25%', '< 9', 'ml/min', '10-20 ng/mL', 'greater than 12 months', 'Score, Class', '13 to 18 years old|Attend', '≥150/95 mmHg', '≥ 60 kg', '0-1 7', 'upper limit of 150 mmHg,|45 mmHg', '< 90 days', '> 5 days preoperatively|Fistula', '12 to 18 years old', '≤1.5-fold', '15-30 years.|Participants', '>50|Taking oral treatment', 'class for 1 to 2', 'from 60 - 70', 'at least 12 weeks.||Is medically', '<200/mm3.||History', '18+ years old|Proficient', '≤ 1.5x the upper limit of normal', '≤ 1.5×ULN.|Adequate renal function', '70-79 years', '≥ 3.|Patients', '1 month to < 6 years', '≥ 21)|CDR', '18-75 years.|Duration of illness', '<2,5%|Treatment', 'at least 99% certainty', '>=4|Survival expectancy', '0-1|No', '≤1.5 × ULN', '40-years', '≥ 5 mm', 'at least 50.0 kg', '>= 18 years.|Participant or legally', 'cyclosporin A', '15-24,|Being', '> 60 years|primary', '>30 minutes|Auditory', '<20 ng/mL', '= 220-', 'equal or greater than 5', '18-35|History of', '0-1 score|Be able to understand', '0 or 1.|Histologically', 'III-IV.|cardiac', '< 10g %', 'less than 10s|Guardianship/trusteeship|Pregnant', 'between 30% and 70% of the predicted value|ability to walk', '< 100,000/mm3||White', '6-18 years', 'score ≤ 7;|Adequate organ function', 'Uncompleted', 'less than 30 days before inclusion;|Pregnancy', '≥18 years|ECOG performance status', 'Over 40 years', 'Female||˂ 21 years', '18-70 years|For preclinical cohort', '<7', 'Under 18 years old|Contraindication', '≥8 g/dl', 'younger than 20 or older than 70', '> 25,000 / microliter', '≥ 160 mg/dL||ix', '≤ 32.0 kg/m^2.|Non-diabetic', 'greater than or equal to 2 minutes', '<100 and >60', 'over 18 years old|Having', '< 350 cells/mcL', 'less than 60|prior myocardial', '>/= 2', '> 2.5mg/dL', 'between 1 and 3||', '≤ 5 times the ULN', '≤ 5x ULN.|Willingness', '≥10 mut/Mb', '< 36 weeks', '18.|Physically incapable of', 'below 160 µmol', '≥ 30 ml/min/1.73m2', '< 12 breaths per min;|History', '> x3 the upper limit', 'less than [<] 30 milliliters', '=< 3', '> 12 months duration', 'minimum 18 years|Positive', '≥ 3 months.||5', '< 2.5 mEq/L', '≥3 months.|Locally advanced', 'between 3 and 10 years', '>30 Gy', '> 30 ml/min/1.73m2', 'older than 20-year', '≥1 to ≤ 4', '≥100,000/mm^3)|Patients', '< the institutional lower limit of normal (LLN)', 'equal to or above 11.0 years', '-4a).；|ECOG', '≥90 g/L;|Liver function', '≤5', '<3 months|Technical failure of the CRT system|Intentional preference', '0 and 18|Patient', 'personal free consent', '≥ 175', '≤ 18 years old ≤75 years', '< 1.5 x 10^9/L).|Presence', '<1m/second', 'eligible to enroll.|Usual acceptable', 'score of ≤ 38 or|perceived', '≥ 11 seconds|Able', 'above 24 points', '≥ 45 kg', 'Stage 1', '≥17.5 kg/m2', '> 5 kg', 'between 18.5 and 35 kg/m2', 'below 18.5', '>400', 'greater than 200 mmHg', 'more than BDT 10000|Households involved', '≥ 10mmol/L', 'Older than', 'above or equal to 6.5%.|Current', '≤ 2 times the upper limit of normal values', '18 to 75 inclusive|Substance use disorder', '≤ 1.5 × Upper limit of normal value', '11-14', '18-75.|Understand', '≤ 5 x ULN|Estimated', '< 28ºC of temperature', '> 2 times of upper normal limit（ULN）', 'Between 19 aged', 'at least 45 kilograms (kg', 'over 18|Previous H&N', '15 or younger', '<1% per year include:||Tubal ligation', '18 and 65 years', 'score of ≥ 11 and < 26', '=< 7 days prior to randomization', '= weight', '> 1:1000', '>10.0)|Use', '≤ 1.5;|Prothrombin time (PT) and', 'between 18 - 55 years', '≥25 kg/m2', 'at least 6 months|CAPS-5 score', 'lower 2500gr', '=bA1C', '18-75 years||', 'greater than or equal to 12 weeks', '1-2 inclusive', 'between 6 and 35 months on the day of the first study vaccination.|Born', 'between 24 and 73 letters', '>105 mmHg', 'from 65 years', '<18 or >40kg/m2|Cholestasis', 'less than 45 ml/min', '<35', '<30.0 kg/m2', '> 35 kg/m2,|Being free', '7.0-10.0 percent', '50.0 - 90.0 kg', '< 40%|Be willing to provide informed consent', 'score of ≤2||', '≤ 2||Participants', '<10.0 g/dL', '> or = 50', '11-point scale', '≥ 18.5.|Sexually', 'between 25-35 kg/m2|Fasting', 'lower or equal to 50mls/min)|Contraindication', 'between 1:00 pm', '<100,000/microliter.|Clinically significant', '<18 years|Retransplantation', '> 92%', '7.0 mmol/l', '>2.5 times ULN', '<17.1μmol/L', '=< 12 months||', 'months.|No', '53', '6-8', '≥1.9 mg/dL', '>10 mm', '< 96', '± 2 kg)||', '5-25% blasts', '18 and above|Have registered at least one', 'less than 3 times upper limit of normal', '> 38|Active malignances', '≤2.5 x the upper limit of normal (ULN)', 'less than 30.0 kg/m2', '18.5 to 24.9 kg/m2).|Patients', '30-80ml', '>18 hospitalized', '<= 2 ULN', '<11 g/dl', '≥ 90×109/L|Liver', '≥40 kg.|The', '>23 mmHg', '< 30mL/min/1.73m2', 'less than 6 months.||The', '>5 mIU/L', 'I to III|Refractory', '> II', '> 1/3 of the volume of the lobe', '< 50/nl', '> 3-times ULN leads', '>1 mgL-1;|Total cholesterol', '= aspartate aminotransferase)|history', '> 18 years old, regardless of gender;|patients', 'more than 10 mL/kg', 'greater than three times the normal upper limit|Patients', 'less than 75 years old', 'lower than 45/min', '60-75 years', 'between 18.5 to 24.9 kg/m2.||', '18-65 years.|Spanish', '= 24 g/day', '≥ 2 times a week', 'under 18|Absence of written', '3-4 times a', 'between 2-17 years old|Hemoglobin <12g/dL|Solid tumors', '≤ 3.0 × upper limit of normal (ULN)', '> 38.5℃', '≥ 126 mg/dL||viii', '<25 ml/min/1.73m2', '49', '<1% failure rate per year', '>= 1.2 upper limit of normal [ULN', '=< 7 days prior to randomization)||Glomerular filtration rate (GFR)', '0-6 months', 'at least 22 years', 'lower than 75%', '=< 7 days prior to randomization)||Pediatric', '>9%', '=< 3 X ULN', '< 75 G/L|GFR < 80 ml/min/1.73m2|Weight <16kg|History', '18-25 kg/m2||', '>5.7 (PDM/DM', '>50mL/min', '< 25µg/L', '<= 1.5 x', '>6.1 mmol/l', '>10|Acutely suicidal|Previous', 'no more than 2 lines.||Note', '≤ 13|Participants must', '≥50 ×109/L', 'Stage C or D)||iv', 'more than 15 months|Households', 'between 23.0 and 29.9 kilogram per meter^2 (kg/m^2)', '18-75|Smoking', 'under 18 years old|Patient', '≥ 6 months to < 8 years', '37-40', '> 4.5 hours', '> upper limit of normal [ULN', '>/= 3 weeks of', '> 160 mm Hg', '≥18 years old and < 70 years old', 'from 0 to 4', '140-199 mg/dl', '>1000 mg/dl', 'between and inclusive of 18 and 65 years', 'drop <90 mmHg', 'I-II|18-65 age group|operated', 'partial response or better per IMWG response', '<1.5 x ULN|For', '≤ 14 points.|At least one family member', 'prolonged to >480 ms', '8 to 65 years;|Diseases', 'more than 14 units', 'ATTR||', '<50mL/min', '≥ 12 mmol/l', '< 50%|Unstable angina pectoris', '≥20 teeth)|Patients', 'item 9', 'from 350 to 450 ms', '< 50%)|abdominal', 'between 18 to 75 years||', 'between 18 and 60,|Participants who are', '1-2.|Able to adhere to the study visit schedule and complete all study', '>18-<65 years', '<100 x 109/L', '< 6.0%', '> 8 g/dL', '≤ 1.5 x ULN.|Willingness', '≥480 ms', 'between 18 and 80 years,|patients', '< 40 mg/dl', 'players 17 years', '≥ 95th', '>99', 'I-V)|Uninterrupted', '> 30|Recent cerebrovascular', '< 18 years-old|History', '≥ 80 X 109/L', '>=90 days before screening of any of the', '> 3 units', '700 g to less than or equal to 1,250 g|Appropriate birth weight', '≥18 and ≤ 28 kg/', '27 weeks', '< 30 ml / min / 1,73 m2', '< 35 kg/m2|GFR', '< 1.0×109/L', '< 300 mg/dl|Blood', '≥ 90%).|Severe infection', '≤ 2.5 xULN', '7.3.1)|Current use', '<8 mg/mL', '4 years to 10 years 11 months of age', '≥ 1 year', '= 0.|DH', 'B-cell lymphomas', '<3.||Key', 'Stage 1-3', '≥ 18 years|Willing and able', 'Vegetarian', 'less than 35 years', 'between 18 and 25 kg/m²|Non', '> 35 kg/m²', '14-75 years', '> 10.0 g/dL.)|International', '≥ 60 ml/beat', '>160 millimeter of mercury', '>1.7', 'less than 7 weeks', '≥ 35 kg/', 'Abnormalities', 'between 60 bpm and 100 bpm', '>40 m2/kg', 'More than 18', '≥ 0.5cm', '>24 hours.||', 'between 18 and 99 years|Comminuted', '3-4;|State', 'less than 12 months|Pregnant', '1.1 target lesion', 'less than 25', '>430 ms', '≥25 kilograms per meter squared', '≥10^4 cfu/ml.|Midstream', 'greater than 450 ms', '<30%|Patients', 'the 80%', '> 102 cm', '>10.5 mg/dL', 'outside normal range *', '> 1.5 times of the upper limit of normal', 'between 50.0 to 90.0 kg', '≥ 18;|Weigh', '≥4 mm).|Sufficient interarch space.|Sufficient vestibular', '4-39 weeks', '0-1;|Adequate organ function;|Baseline', '> 20 points.|Subject', '< 1.5 X normal|Creatinine clearance', '≥ 60 years.|ECOG Performance status', 'below 50 years', '5-C', '> 90 cm', '12 years or more', 'before enrolment and;|Agree to use', 'less than 3.0 g/dl.|Patient', '18-35', '18-39', '< 18 years|Pregnancy|Not appropriate', '> II|Age < 21 years', '>2 times upper limit', '>3x the upper limit of normal (ULN)', '18 to 80 years.|Patient', '> 2 times the upper limit of normal value', 'less than 8 years.||Note', '>25 U/L', 'lower than 4', 'letter score of', '>100,000/µL', '≥5.0 mEq/L', '>450 milliseconds', '≥ 100.000/µl', '> 85th percentile', 'score ≤1;|Life expectancy', '>= 1.0 x 10^9/L', '22-30', 'than 4', '≥ 3 cm', 'Grades I-III|There', '<60mL/min/1.73m2|Those', '<60 mL/min/1.73m²', '≥ 8g /dL;|Blood biochemical indicators', 'Stage 5', '18 and over.|Pregnant', '> 20|Other', '> 14 mg/dL', '18-65|BMI', '<18 and >40 years|Overweight', 'less than 15.|Cognitive impairment', '< 12 years', '< laboratory standard),|VAS>5/10||For A1-3', 'score 0-2', '> 2.5 8', 'patients||Age < 55 years', 'class I or II', '0-2|Adequate organ', '25 to 60', 'significant exclusionary abnormalities', 'longer than three months', '< 35|Written informed consent', '<500 ANC', '< 37.5℃/99.5℉', 'greater than 12.0mm.|If the', '18-70.|Patients', '>3.5 mg/dl.||', '≥60/mL', '≥ 4 weeks beyond treatment', 'Over 18 y.o.|Cronic pain', '> 2.0mg/dl;|9、Those', '≤ 1.5 × UNL.||Patients', '0-15', '≥ 9 g/dL', 'greater than or equal to 100 cells/mm3', '>3 cm', 'greater than or equal to 75 kg|Signed', 'Female||Right-handed|≥ 18', '> 10%|Hypercoagulable condition', '25 to 45 years old|Fluent spoken', '5 to 9', 'classroom|younger than 19 years', '>2 points', '> 2', '< 5 g/dL)|Barcelona Clinic Liver Cancer (BCLC)', '≥1 times/month)||Poorly', 'I-II-III-IV||', '<60 mL/min/1.73 m2)|Positive', 'between the two', '≥25 mL/min/1.73 m2|On', '40 mg', 'between 20-year-old and 85 years old|patients referred to the', '= 30', 'higher than 51 umol/L;|Patients', '<100,000/mm3', '6-15', '> 30 kg/m2|hepatic insufficiency', '>1.5×ULN.|Previous use', '≥140', 'I-II|FMPS < 10%|FMBS< 10%|<10', '4 to13 years||', 'more than 50ml / min / kg|more than 5h', '≤ 14 days before first dose|Patients', '18-99 years;|For', '≥21 years', '> 30.|Altered mental status.|Patient', '≥ 35 years', '18 years or older|Willing to provide informed', '< 30×109/L', '20-42', '≥ 18 years;|Brazilian resident;|Symptomatica COVID-19', '4', '7-14', '≥ 60 ml/min/1.73m2', '> 221 umol/L);|History', 'more than 3 sites', '=< 1.6', 'under 17 years||', '6 to 52 weeks', '> 0.80)|Angina', '> 65 inches the patient', '18 years or older admitted to the intensive care unit;|Anticipated', '≤5 × institutional ULN|CrCL', '18.0 to 35.0 kg/m2inclusive.|Have', '15-34 years', '> 45|Current use', '40 - 140', '< 6hrs prior to each recording session', '18 Years and Older|Written informed consent of the volunteer to participate', 'lower than 90%', '=< 1.5 x the upper limit of normal', '1.5 - 4.5|Fatigue', 'below the normal range', '≥ 25,000/mm^3|hemoglobin', '>=85% BMI', 'between 18.5 and 30.0 kilograms per meter squared (kg/m²', 'IB-IIIA', '≥ 18 and ≤ 75 years.|ECOG', '< 50 copies/ml', 'equal to or greater than two standard deviations', 'above baseline pre-PCI', 'between 2020 and 2022', '45-80kg', 'from 6 month to 16 years.|Generalized convulsive status', '≥75 x', 'less than 19 or more than 60 years old|ASA >III|Genito-urinary infection|Immunodeficiency|History', '2.5 x ULN', '65-90 years', '<3000/ µl)|Active peptic ulcer', '<7|Without bystander', '< 1.5 x upper limit of normal', '≥ 3;|4', 'equal to or', '≥18 years.|Clinically', '18.5 - 25kg/m2)|Regular', 'III-IV)|Inability to exercise', '≤ 2.5 x ULN', '>1.5mg/dL', 'signs', '≥10% body surface area (BSA)', '85th or greater', '< 1.3|Creatinine clearance ≥60 mL/min', '< 24 hours)|Asymptomatic up to the moment', 'maximum of 1 target occlusions', '> 25 cm).|History', '0 or 1.|Patients', 'neutrophils≥1.5×10^9/L', '≤ 3.0 × ULN).||Bone marrow function', '< 18 years|BMI < 35 kg/m2', '30 ml/min/1.73 m2);|Life expectancy', '<1800 g),|inability to start', '<30 ml/min./1.73m2', '>27 kg/m2|signed', '≤ 50||', '>10)|Maximum of 2', 'between 18.0 and 32.0 kg/m2', '< 30.|Subject', '< 3x upper limits of normal', '≥ 50%;|Signed informed consent', 'stage B', '50 x 109/L).|Alanine', 'between May 2017', '<100×10^9/L', '>1.5 times the upper limit of normal reference value', '>= 40 years', 'between 1-12|Obtaining an informed consent form from the child patient and', '> 28 days|Having had', 'least 10,|The patient', '≥ 18 years old', '≤ 92', 'above 100 mg/dl', '> 75,000/mcL|Total', '> 200 ng/mL', '= < 6', '≥ 320', '> 50', '≥100 000/µL|Hemoglobin ≥9.0 g/dL', '>= 1 day prior to study treatment|Strong inhibitors of CYP2C9', '≥ 1.5 × 10 ^ 9/L', '> 6.5%', '<20', 'between 0-18 years,|having', '> 150 ng/dL', '≥ 40 IU/ml', '≥ 3x10^9', '17-25 years', '> 10ng / ml|General condition', '≤ 2-month apalutamide', '40-60;|Female', '<80%|Use of', '18 or older.|Patients', 'less than 1.3 mmol/l', '19 to 55 years.||Those', '38.0-38.9°C', '0, 1, 5 or 6|Presence', '> 1.5 times the upper limit of normal', '60 - 80 years', 'less than 30.0 kg/m2|Scheduled', 'C-reactive', 'at least 90 days after the procedure).||**True', 'Upper Limit of Normal value, ULN', '> 5.2 mEq/L', '> 2.5 X', '≥ 60ml/min', 'under 50 years old', '<=0.05', 'greater than [>] 40 kilograms per meter square [kg/m²', '> 0.39 ng/mL|no', '8 to 33 IU/L|Total bilirubin', '> 50ml/m2).|Patients', 'less than 100 IU/mL before the first dose of the study drug', '≤ 1.5xULN|AST', '≥ 20% to <40%.||OR total score of 9', '40-65 years;|4', '0-2|At least', '≥ 18.0 to ≤ 33.0 kg/m^2.|New to treatment', '8-16 years', '<1 or > 2', '23-64)|Women', '< 30|Subject', 'below 65 mmHg', 'Level 2', '>7.5%)|Patients', 'over 18 years of age|Diagnosis of first episode', '< 30|Candidate', 'under 18 years old', '+ T cell count', 'worse than 20/25', '≥ 90 × 109/L；||Hemoglobin', '5 times', '≥ 200 mg/j', '125 mL)', 'less than limit of detection', 'older than 3 months', '< 25 kg', '18-89', 'meets', 'class 4 or 5', 'score ≥ 30', '≤ 75', '> 3.5 mmol/L)|Pregnancy', '> 16 years', '<27 mL∙kg-1∙min-1', '≥ 18 years)|A diagnosis', '= or > 16 years|Biological', '8-12 years', '6.5 and 10.0 %', 'greater than or equal to 3|MRI tumor volume', 'more than two times the laboratory', 'less than the upper limit of normal value', 'between 24', '> 5°', '18 years or older|Histologic diagnosis', 'score 8 or higher', '>= 3,000/mcL', 'less than 40%.|Severe', '<=90 mm', 'score of 17 or greater', 'above NYHA class II', '25-65|defining', '≥0.01%', '≥ 8|No need', '5 or greater', '>200 IU/mL', '≥ 18 Willing and able to provide', '≥ 30 mm', 'below the 95th percentile', '2,3,4', '< 220 μmol/L;|Lung function', '> 90 mmHg|Pulse rate < 40', '<30 ng/mL', '> 360', '3 to 17 years', '<200 per millimeter cube', '>180 mm Hg', '<18 years|Pregnancy', 'higher or equal to 30).||Exclusion criteria:||Concurrent', '3 to 24 month old', '<89%', 'above upper limit of normal', '>18 years old.|Twin pregnancy.||', '>480 ms;|Complete left bundle branch block', '<140/90 mmHg;|fasted blood glucose', 'below 30 kg/m2.|Patients', '3 or more nights per week', 'No older than 21', '1 or 2|The', '≥ 50 years', '3:||1', 'greater than or equal to the upper limit of normal', '20,000/mm3- 50,000/mm3', '≥12 weeks；|Eastern', '>= 7.5%', '2 times greater the the normal]|Active', '> 70% predicted|For', '>= 1 week prior to study treatment|Patients', '>2 ng/mL above', '≥350 cells/µL', '>250 nmol/L).|Pregnant', 'more than 35', '≥12 months;|Understand', '≥ 50 mL/min(Creatinine clearance', '< 35Kg/m2||', '> 40kg', '≥100×10^9/L，Hemoglobin >', 'from 0 to 5|Stable', 'at least 50 mL/kg/min', 'than or equal to 10 years', '> 5mol/L', '<11.1 g/dl', '70 % or more', '≥ 1.5 x 10^9/L', '≥ 10 mg/dL', '< 1% nuclear', 'between 18-65 years||Diagnosed', 'greater than 18 and equal or', '>1.3 mg/dL', '> 1.5 K/UL', '≥ 23|Reduced', '>= 50%', '60 years or older', '< 35%|Women', '≤ 18.5 kg/m2|medical', 'Class II, III', '≥20 and ≤50|Detection', '≥10 g/dL', '=< 2|Histologically', '≥20%', 'grade III above|Severe hypertension', 'more than three months.|Subject', 'younger than 18 years;|Secondary causes', '> 2 mg/Dl', '≥ 2 months post', 'over 10|Residing in the village over the last 3 months|Be', '< 30 ml/min|AMI', '≥18 years to ≤35 years', '≤ 34 weeks', '< 18 years|history', '0-1|Ability to', '<200/mm^3', 'I-II status|Patients', '≤ 24', '≥ 90g/L;|White', 'higher than 2000IU/ml', '0 or 1|Demonstrates', '30-45 years', 'less than or equal to (<=) 55 years', 'greater than 90%', '28-35-40% to reach', 'greater than their chronological age||', 'very poor;|(2', '≥ 38.0', '< 12 years.|Severe forms of alopecia', 'to 70 years', '> 3.5 mm', '≥16 weeks.|Presence of measurable', '≤ 2 x', 'from 0 to 3|Fluent', '>=12 weeks', 'minors older than age', '0 or 1;|7.Take the shorter', '< 3.||For fertile', '0-36 months', '<5hrs', 'greater than 60 min|American Society of Anesthesiology (', '< 1,000/uL', '< 30)|Body Mass Index (BMI)', '>100 mg/dL||Either', 'less than 80%', '≥ 2.5 ×', '≥ lower limit of normal', '18 or older|Able', 'lower than or equal to 25%|At least a', '18-55|Endorse', 'less than 1% per year', 'shorter than one', '< 50|All fertile participants must agree', '18.0 to 32.0 kilogram per meter square (Kg/m^2)|A total body weight', '<75 years|Low', '<3.0 x ULN', '<12 months.||Out-of-hospital cardiac arrest', '> 21 mmHg].|Neuromuscular disorders', 'criteria|FEV1 ≤ 45%', 'grade 2', '≥ 90 g/L;||Total bilirubin', '≥ 90%', 'more than 2', 'Under 18years|Over 74 years|Patient', '≥ 18 years|Patient', 'between 1 year', 'higher than 4|Decrease', '> 18 to ≤ 60', 'Stage B', '> 250 lbs (in order', '60 to 89 mmHg|Those', '1-3)|Age', '18-75 years;|Pathologically', '>30)|Varicose pathology of the lower limbs', '<14|Having', 'no more than once a week', '>3x the upper limit of normal.|Any', 'at least 1/3 of', '>3ⅹ109/L', '18-66', '4-6', '< grade 1', '<4,000/μL/', '<30 kg/m2|Willingness', '≥ 100 × 109/L.|Hemoglobin', '≥470 msec (', '≥ 1.0 g', 'score greater than 37.5.|Contraindication to the use of electrotherapy.|Use of', '≥ 1500/µL', '>= 5% blasts consistent', '60-69 years|GFR <75 ml/min/1.73 m2', '50-80|PD diagnosis', '10 mg/day);|Received', '< 65 years|Pregnancy|Previous', '0, 1', '0 or 1.|The', 'less than 28 days old newborns', 'equal to or greater than 35', '≥350 cells/uL', '<37 week', '<5.0 X ULN', '18-65|Getting', '≥ III|Cardiac ejection fraction', '≥ 1*104 copies/ml', '50% adults;|All', '<30 g/L;|estimated', '>2.5*upper limit of normal value', '≤ 1.5x upper limit of normal (ULN)', '<11.0 g/dL|Serum ferritin', 'greater than 3);|Patients', '18-60 years', 'equal to or below 0.3 logarithm of the minimal', '</=2|Patients admitted', '≥12 years', 'score of > 7', '≥ 40 ml/min|At least', 'greater than 12 points|subject received', '> 18 years|Forefoot pain', '0-1.|With', 'I,II and III', 'positive-expressing tumors', '135-145', '≥ 40 mL/min', '< 28 weeks|Singleton and multiple', '≥15 mm.||d）Normal anchoring', '≤ 75 years|TIA', '≤ 5 seconds', '>= 3.2 g/dL', 'nutrition|Less than 12-months', '≥ 60 mL/', '29.5 mL/1 ounce', '< 30ml/min|history', '<7h or >', '20-49 years;|Natural conception;|Single pregnancy;|Plan', '≥18 and under 75|Predicted survival', 'greater than 12 over the study', 'between 18 years old and 80 years', '≥95% of', '≤ 50 umol/L', '<30 mL∙kg-1∙min-1', 'older than 40 years.|BMI ≥30.0 kg/m^2', '18 or 19', 'less than 30mL/min', '> ULN', '≥ 2|4', '=) 150 milliliter (mL)', '<25.0 or >35.0 kg/m2|Regular use', 'guidelines for older', '< 32 mm', '≥180/110 mmHg', '> 90 mmHg', '0 or 1|At least 1 measurable', '< 18 yrs|hypertension', '25-65 years,|who', '≤ 470 ms', 'less than 80 years', '= or > 30 kg/m^2', '<TAB>>=60 mL/min/1.73 m^2', '<3 years', '< 40%;|Patient', '>= 28 days|Cellular Therapy', '≥ 3%', 'greater than or equal to 10 percent|Plans', 'less than 50 kg', '< 22.00 and', '≤ 5 x ULN', 'clinic|Less than 17 years old||Exclusion Criteria', '< 490 3', '≤ 2.5× ULN iii', '> 18 and < 30 kg/m2|Endometrial', 'volunteer adult patient', 'between 18-50 years', 'at least 6.0mm.|2.0 D or less', '< 4000g,0-3 years', '≥100 x 10/L', '<18 years|Patients', 'repair)|Age 18 years', 'below 75%', '≤ 5%).|It', 'less than 1 year|Participation', '18.5-28)|Understand', 'score of ≥3 and ≤18|HD', '4-12 years', '>30 and <60 ml/min/1.73 m2).|Written', '≥7.0 mg/dL|ACR/EULAR', '≥ 1.2 x 109/L|Platelets', 'I or more', '≥750/ uL the patient', '15 or greater', '18-25 years', '12 to 17|Adolescent(s', 'greater than 40 kg/', '>= 30mL/min||Contraception:||Woman', 'between 40-70 years|Well-oriented', '>70 ml/min/1.73m^2||International', '18 years and older|Willing and able to provide', '> 5.0 × ULN|TBL', '30.0 kg/m2', 'greater than 88 (>88', '5 - unassisted', '12-19 years-old|Own', '1 month', '>52', 'less than 80 %', '>= 18.5 to < 39 kg/m2|Have', '21-80 years', 'than 50 ml / h', '>300 pg/mL when', '≥ 12mm', 'equal or less than < 88 cm', '3-4.|Known', 'low', '>180/100 mmHg', '< 500 cells/', '≥18 years old|≥6 months', '>1.5cm', '≥ 18 years-old|Patient', '< 110 mmHg', 'from 2 years to less than 18 years|Xeljanz', '14-50 years;|Diagnosis', 'less than six weeks', '≤ 2 ×', '≥ 50.0 ×109/L', '± 10 years', '<2.8 mmol/L', '≥ 20 years|Chronic', '≥ 90 mmHg', '18-80|Myofascial', '≤3.0 times the upper limit of normal one week before enrollment.|Subjects', '>38.1 degree', 'less than -0.75D or more', '≥ 100 x 109/L', '≤ 1.5xULN;Hepatocellular carcinoma', '≥ 5.6 mmol/L', '<90 or >180 mmHg', '3-4.|Bone marrow transplant', '18.5 - 34.9 kg/m2', 'lower than 90 mmHg', 'greater than 3 months.|Eligible', 'energy intake', '> 30|Poor U/S', 'over 24 hours', '> 35|Pregnancy', '>=18 and less than (<) 30 kilogram per square meter (kg/m^2', '18-99 years|pre-planned', 'less than 17 Kg', 'between 0 and 25 years', '45 mL 40% spirits', '≤ 5 days).||iii', '> 9|Willing and able to provide', 'score ≤ 1.|Must', '≤ 135 U/L.', '<18 year', '> 10^3 copies/mL', '< 0.7)|Severe', 'three of more', '18 years and older|Use', 'at least 12months.|Willing and able to comply with the requirements', '1-2|Straining|Sense of incomplete evacuation|Sense', 'greater than the upper limit of normal (ULN)', 'Functional Classification of class 2B', 'greater than 100.5 degrees Fahrenheit (F)', '1 to 5 benefiting from a 3T MRI', '>=75 years old', '≤ 5.0 x ULN.|Patient', '> 80 g/L', '≥ 6 months|18-35 years', '0-3.||Participants', '4"" score', 'greater than 2 mmol\\L', '>5 mmol/l;|Age', '≥ 1.5 × upper limit of normal (ULN)', '>150 kilograms (kg', 'between 4 and 8 weeks prior to enrollment', 'cancer|Greater than or equal to 3 months post-', '>8)|The subjects can communicate', '<= 2 times the upper limit of normal (=< 3 weeks prior to registration)|Alanine transaminase (ALT)', '>10 packyears', 'class III-IV', '< 1 y)|Engagement', '< 100,000/mm3', 'less than one week prior to the start of the study', '<18|presence of autonomic nervous system diseases', '>= 12 months of amenorrhea', 'at least 30 days', 'greater than or equal to 50% radiation of pelvis|Patients', '≥ 40 kg', '≥ 80×109/L.|Biochemical examination', 'between 25 and 40 kg/', '≤ 4.00 D', '≤ 40', '1st episode', '>2000', '≥ 80,000 /μL', '< 80 mmHg', '< 10 microbleeds', 'more than 3 times a day', '> 130/80 mm Hg', 'between 18 and 80 years old.|2', '20-65 years||For the FM arm:||fulfilling the', '> 18 years|Must', '≥ 27.0 kg/m2|Living', 'score of 2 or greater.||', '≥ 18years', 'thiazides', '7-10 points.||For', 'score of more than 8', '0-1 points;||The function', 'between 7-10,|Skin-tissue integrity,|No communication problem,|The spoken language is Turkish,|Voluntary', '≥ 90 g / L.||Hepatic', '> 12 weeks|Histologically-', 'between 18.5 and 25 kg/m2|Clinical exam normal|Subject', '< 10 g/dL|Self-reported', 'I to', '>21 units/week', '>= 65 years', 'less than 45/min', '> 9.0 g/dL|Total', '7-12', '≥15 cm', '>120 days before study intervention', 'II to IV', '< 150,000/ml', '0 or 1.|For', '>3|brachytherapy', '12 to 17 years;|Under the condition', '≥1.5×109/L|Platelet ≥100×109', '5-50%', '55-85', '≥ 10.0 g/dL.|Absolute', '>120 mmHg', '> ULN|eGFR < 90 mL/minute/1.73 m2', '1, 18 ≤ age ≤ 75 years', 'January 2000 to 31st', '< 30%|Single kidney', 'at least 5% blasts', '14 - 25 years.|Participants', '< 17.0 kg/m2', '< 28 kg/m^2', '19 or older|Those who voluntarily', '≥18 years to ≤75', '<18 years|Those', '>= 15 mm', '≥18 years', '≥ 40 mL/min/1.73 m²', 'I-V.|Minimum score of 12', 'between 18 and 60,|Participants who are not addition to smoking', 'less than or equal to 1.5 × institutional upper limit of normal (ULN)', '> 7.0)|Individuals', '≥ 19 years|Weight', '> 4 weeks prior to screening', '≥ 1.5 times', '1.2-1.3', '10', '30-85 years', '18 Years to 75 Years;|ECOG physical score 0-2 points', 'illegal', 'will range', 'between 0 and 2|able to communicate', 'at least three months.||Participants', '<1,500 cells/mm3', '≥ 100x109', '≥ 7mm', '>2 months', '<35%', '≥18 years|American Society of Anesthesiologists physical status Ⅰ-Ⅱ|singleton', '0 or 1 measurable disease', 'greater than 420 pounds - scanner', 'functional class HF', '> 10%|Claustrophobia', '4.4-7.2 millimoles per liter', '>2 mg/dL)|Anemia', '≥2+ protein on dipstick urinalysis', '> grade 1)|Patients', 'between 3 and 10 years.|Belonging', '>=21 days after the completion', '>3mm', '> 9 g/dL;|Platelets', '<1hr drive', '< 1.2 4', '≥45kg', 'greater than 30 mm', '≥ IV', '≤ 1.5 × ULN.||Evidence of', '< 3 x', '15 to 44.9 mL/min/1.73m²', 'from 19 to 40 years', '<150,000/microL', '≥ 2 years', '>/=18 years', '≥ 2.5 kg.|Parents/legal guardians', 'less than 3.0 mg/dL|Aspartate aminotransferase', 'I-III|Patients', 'III or IV', '≥50% guideline directed doses', 'greater than or equal to 37 weeks|No prior', 'scores ≥3%', 'greater than 26', 'less than 8 years', '> / = 38.0 degrees Celsius/100.4 degrees Fahrenheit', 'Age≥ 18 years', '> 18 years||', 'four separate occasions.||', '<= 135 mmol/L', 'between 160 and 255 L/min', '≥ 18 years.|Chronic', 'greater than grade 2', '50-78', '>23/30||', '<1 g/24 hour', '≥ 2.|Unstable', '>540 min/day', 'I-III;|Scheduled', '18 years or older|Have', '0-1;|Recurrent', '≤ 3 s', '> 2 times upper limit of normal)|Alcohol abuse', '≥ 50 mL/min/1.73', '17.5 to 35 kg/m2', '≥ 100 G/L|Serum creatinine', '≥ 18 to 75 years', 'Functional Classification III or IV', '≥ 9||', 'I - III.||', 'between 19 and 75 years|Subjects', '1.5 times higher than normal values', '25+5 years', '≥ 45ml/min|Total bilirubin', '>= 18 years.|Eastern', 'more than 50% above the nadir', '> 2 months)|Lifetime', '< 40 mg/dL', '≤ 1.5 x ULN.|International normalized ratio', '≥ 7 g/dL', '75 X 109/L', '≤ 1.5 times the upper limit of', '> 1 × ULN', '18 years old - 75 years', '≥ 70;|Age', '>60 mmol/L', '> 1.4 mg/dl)|Psychiatric', 'more than 7 days.|Tumor tissue sections', '18 and 80', '< III.|Muscle relaxant', '34+0-36+5 weeks', '20 to 59 years', '40-90%', '4 weeks before the trial entry;|Pregnancy', '<15ml/min/1.73m2', 'more than 40 or|BMI', 'below 200%', 'above upper limit of normal)||Other', '>50%', 'years;|Ineligible', '<110 mm', '65-99.||', '> 3 sec', '≥25%', '15 to 50.||', '= 3.0 g/dL', '1-7years.|ASA physical status', '< 150 mg/dL|Left', 'younger than 60', '≥ 1 year.|Hemoglobin A1c (HbA1c)', '>7%', '> 4.5 kg', '<8.5', '> 20 points|PSA', '≥40 years|Signed informed', '200 g/L', 'more than 45kg|Patients', 'between 18-50|No', '≥1,500/mm3|Platelets', '≥ 18 years old|Patient should understand, sign', '1-2 upon testing performed', '<100 mmHg', '0-3 years', '1 to 12 months', '18.5 to 24 kg/m2', '<20|Current', 'setting', '<1 cm', '50- 60 years|Presence of OA of the knee', '≥3 months;|The physical status', '18 or greater|Abdominal', 'between 18 to 45 years old|Right-handed|No', ""greater than 6'"", '> 0.676)|Able', '20 to 65 who', 'less than 50% or greater than 90% of the internal diameter|Procedure', '≥12 mo', '> 90)|Heart', '≥ 10|age', '>2.5 times the upper limit of normal (ULN)', 'less than or equal to 60 mL/min/1.73m^2|History', 'greater than or equal to (>=) 12 and less than or equal to (<=) 65 years', '>480 ms;|complete', 'above 150/100 mmHg', 'Older than 18 years', '≥18 years;|Scheduled', 'older than 48 hours', '40-85 years|Documented diagnosis', '>35|Prior', '< 150 mmHg|Mechanical ventilation', '=< 1.5 x ULN||Corrected', '+/- axillary).|Estrogen-receptor', 'equal to or less than 40%|Have', 'greater than 50,000 cells/L', '≤ 3x the upper limit of normal (ULN)', '> 3 months|Non-pregnant', '>120 μmol/L)|Liver enzyme abnormalities', '≥ 18 years|Having', '10-20 ng/', '≥40|Contraindications to surgery', '≥12 years old', '>24 hours', 'between 22-32 weeks', '>or equal to 18', 'III', '3 class', 'between 18 - 25 kg/m2|had', 'above 160/100 mmHg', '>=18cmH2O before', '≥ 90 mL/min/1.73 m²,|No proteinuria', 'below 20% of predicted value,|PEP', 'at least 1 bowel motion per week', '60 and older', '≥ 3).|English-speaking', '≤ 5×ULN', 'at least 12 weeks||Sex', '>2 d);||Fulfilling ≥1 of the', '≤ 150 mm', '48 to 96 hours after sedation', '>2|Has', '> 1.5x10ˆ9 /L', '> 2.0 x the upper limit of normal', '> 100 mm', 'greater than 3 years', 'from 0 to 0.5', 'above or equal to 126 milligrams per deciliter', 'hildren', '11-18|Diagnosis of', '>7 units/week', '>= 1500/uL|Total bilirubin', 'scores >8', 'under 18 years.|If the available images did not', '18-30|Individuals', 'pH < 7.0', '≤ 90 mmHg|Diastolic blood pressure', '> 7500', '>22breaths/min', '18 or over', 'between age 25 and 64 years|Patients', '<50 copies / ml', '> 4 ULN|Estimated', 'at least 70% of the predicted value', '≥ 19 and ≤ 50 years', 'Score <24).|Having', '>= 65 years|Diagnosed', 'greater than 1 x 103 copies/', '>30kg/m2|Prediabetes|Type 2', '≥ 37.3℃', '≥ 5.7%', 'I-IV|be', '=< 15 days prior to registration)|Total', 'between 95 - 140 mmHg', '14 to 42 weeks', '≥30 g/L', 'more than 12|Q max', '<103 copies/mL', 'less than 60 years.|Patients', 'at least 18 years to 60 years|Written informed consent', '≥ 9g/', '> 50% above recommendations', '≥18 years.|Willing and able to consent to participate', 'between 21 to 60 years', '0-1|Child-Pugh', 'B or C', 'over 25 kg/', '> 150 μmol/L', '≥5.7%', '> 18||', '18 to 49 Kg/m2', '4-1BB recombinant fusion protein|Known', '≥ 85 cm', '18-24 yr|English-speaking|Current', '= 3', 'between 15-60 years', 'between 18 years and 75 years.|Histologically', 'score ≥ 26', '≤ 29.5|Anterior', '18 - 60 years|Vitamin D deficiency', '≥200c/mL', 'between 1 and 15 cigarettes', '10 and 18 years', '65 mm Hg', 'from 19 to 35 kg/m2', '≤ 1.5 g/L).|Infection of the proposed', '<1 year prior to signing informed consent', '200 mmHg', 'Less than 18 years', '> 2.75 mmol/l', '>16 years old', '68 DOTATATE', '> 18 years|Undergoing', 'more than 25 kg/m2', '>= 30,000/uL', '>50 x109/L|Creatinine clearance', 'between 20-45', 'stage IIIB', '>800ml', '<50 bpm', '≥ 27 kg/m2|Female', '0 or 1;|Estimated survival period', '≥ 37.5°C /', 'at least 3% to 12%', 'less than 6 months', '>12 on the', 'between 18 and 60 years', '<1.5x normal for age', '20 to 45;||Married', 'between 7.4mm', '>5/h', '≥ 100,000/mm3', 'score of 5 to 6', 'greater than 5 kg', '10-100 x109/L|Platelet', '≥ 18 years|Subject can', '≤ 1.5', '> 18 years|Metastatic', '12 to 17', 'least 50 % of all team members should accept', 'under 70years old,|Ability to give', '5 through 18 years', '≥ 25.||', '5 mm', 'male.|With normal', '0-2||Patients', 'greater than 2', 'at least 40kg', '≥ 3.0g/dL', 'grade 0 to 1', 'lesions stages of Phase Ia', '20 dB minimum air-bone', '≤2.5 × institutional ULN|Creatinine Clearance', '19 to 70 years', '≤ 5|Brain MRI', 'greater than 25,000/mm^3', 'above 1.5 x ULN', '≥90mmHg);|Patients with', '< 5 mmHg', '18 to 84 years|Patients', '≥ 5 days||', '≤ 70|life-threatening', '≥2.8 g/dL|Aspartate', '≥20 but <90 ml/min/1.73m^2', '<25 Kg/m2', '≥20 pack', '>1000 copies/mL', '≥ 100 × 109', '18.5 to 35 kg/m^2|Demonstrated', '< 60 mm', '≤ 2.5 × UNL', '≥25kg/m²', '> II|Coagulopathy', '≥ 110 mmHg', 'within normal institutional limits;|AST(SGOT', '> 56', 'above 34.5 kg/m2.|Patients', 'I-III', '> 100mmHg).|PRE-REGISTRATION', '> 10', 'Grade III or IV', '>10 mg', 'less than 12 months after initial sprain', 'between 36 and 37 weeks', 'exceeding 1.2 x upper limit of normal (ULN)', '2 ml/min/1.73m2', '18-65 years|Compos mentis|Diagnosed', '2-12 and 35-50 years', '< 10mm', '7-16 years-old', '18 and 65 years|Independent decision-making', '>18 yrs|Diagnosed', '> 10 mm diameter.|Imaging findings', '> 11 mg/dL', '> 45 IU/L)|Low', '< 80%', 'score of 25 points', 'less than 3 cm', '≥1.5 × 109', '≥140/90', 'Child-Pugh Class', 'under 18 years old.||-', 'greater than 40 cm/H2O', '≥50 mL/min', '≥ 18 years;|A confirmed', '≤ 300 mm Hg', '>12 weeks|Willing and able to comply with all study requirements', 'not more than 28 days after Kauleenamine treatment', '> 173', '>220 ms', '<130 pmol/L', '>6.4', 'after 37 weeks', '≥ 9 g/dL.|International', '≥30)|late trimester of pregnancy', 'between 18 and 30 kilograms per metered square', 'high-grade', '> 50% dose reduction of NHA', '1.5 times the upper limit of the normal range', '>480 um|myopia < -8 dioptre|hyperopia', 'meet', '< 25 kg/m2', '12-16 years', 'greater than 3 times the upper limit of', '60-70 Gy', '<140 mmHg', '>130/80 mmHg|fasting triglyceride (TG) level', '25 less than 6 years', '≥ 8.0 mmol/l', '>= 50 mL/min', 'II-IV)|KCCQ-OSS score', '≤1.5 × institutional ULN', 'between less than 25 and greater than 35 kg/m2.|Subjects', '18-80|Patients', '< 130 BPM', '< 8.0 mmol/L|Fasting', 'less than 1 year', '>= 100,000/mm^3|Hemoglobin', '1-18 years|fulfill the criteria', 'greater than or equal to 60', 'grade II or more', '2 or', '0 - 90 days', '<18 and >80 Patients who do not provide informed consent', '12 to 65 years', 'lower than 0.6 g/cm2', 'greater than the maximum for the scanner', '18-75||', '0-2|Participant', '≥ 31 g/dL', '≥ 4/10|AND', 'between 40 - 70 year|Body Mass Index (BMI)', '≥ 18', 'under 18|Presence of any severe', '> 9.0 g/dL', '=< 7 days prior to randomization)|Aspartate', '>40 millimeters', '<50.000|Pregnancy', '< 0,5 µg/kg/min,|Absence', '< 2 cm', '>16 years.||', 'greater than or equal to 5.|Total dT count', '25.8 - 134.8 IU/L', '≥3 episodes', 'above prior to trial entry', '>83', '≥12 weeks;||Blood test', 'score 0-1;||Adequate hematology', '<=12 weeks prior to Day 1', '< 22cm', 'greater than 4|Patient', 'from 4 months to 4', '< 80 bpm', '≥ 1000 prior to catheter', '> 1.5 x 10^9/L|Platelets ≥100 x 109/L|International normalized ratio', '1.2 mg)|current participation', '<40|Provides written informed consent', '20-50 years.|Both', '>2x ULN.|Patients', '≤18 or ≥80 years', '<= 1.5 x upper limit of normal (ULN)', 'less than 900 pg/ml 6', '18 - 35 kg/m2', '≥ 5 times the upper limit of normal', '> 60 mL/', '< 3*', '≥7.5 mg/dL', 'PBC.|Incomplete response', '> 2 kg', '>7.0mmol/L', '1-3a', 'less than 3 months|Pain cause', 'over 16 years', '≤ 2.5 × Upper limit of normal value (ULN)', '7-8 years', '≥18 and ≤65 years.|Diagnosed', '< 25 ml/min', '> 5 lesions.|Lesions', 'more than 35 Kg/m2.|Patients', 'Z-score', '≤ 5 x upper limit of normal', '≥70 years old|Attending', '= eGFR（CKD-EPI', ""spermicide.|Patient's"", '≤ 1 year;|Known', '≥ 50,000 cells/mm3|ANC', '<28 days', '≥ 450 milliseconds', 'very high-risk hypertension', '6.1 of the SmPC of the respective medicinal products', '17.5 to 32 kg/m2', '≥ 9 cm', '<155 cm|Alcohol', 'greater than 3ng/mL|No', '≤12,000 U/d', '< 120 g/L', '18-100|At risk', 'greater than 12 weeks.|Patient has given', '>185 mmHg', 'between 405 and 952 nmol/L),||', '> 18 years||Exclusion', 'I-II|Thai adult', 'Upper Limb 2.0', '≥ 25%|English speaking||', 'greater than or equal to 108 cfu or organisms', 'between 18 and 65 years', '< 110 mg/dL', 'Younger than 5years of', '94% or lower;|Be able to follow the', '≥ 4*109/L;|Blood', '8-18', 'at least 18 years;|ECOG/WHO performance status', '> 18 years;|Patients', '18-64|BMI', '18-70 Enrollment', 'less than 10 years', '≥ 50%);|evidence', 'less than 18 years.|patients', '≥ 11.1 mmol/L|An', '15 to 45 years', '< 9 g/dL|Thrombocytopenia', '≥ 200 mL', '>', '< 0.7', '2-17 years', '≥18 years|Subjects', '>= 3ng/mL.', '18-50 years|Body mass index', '>= 75,000/mcL', '> 50% predicted.|For patients', 'less than 12.0mm.|Participants', '< -7 diopters', '18-5-30 kg/', '1.1)|Be able to comply with outpatient', 'more than 3', '<70, >90 mmHg.|Clinically significant', '18 to 55|elevated overall score', 'ICD-10 C43', '≥ 3.5 mg/dL', '< 28 kg/m2', '<1,500/microliter.|Thrombocytopenia', '180 to 209 days of age', '≤ 140', '>210 msec', '<3 years before', '≥ 9.0 g/dL|Absolute', 'older than 12 years', '250 mL)', 'I patients|scheduled for liposuction for abdomen and flanks and body contouring', '≥9 g/dL|Platelet', 'greater than or equal to 6.5%', 'I, II and', '>1,5UNL', '18 and 60 years', '≤ 20 French (Fr)', '<15 mL/min/1.73 m2).|Females', 'above from -0.75 D', 'II-IIIA', '≥ 3 mg/L', '2a, 2b, 3, 4a, 4b', '=< 1.5 x upper limit of normal (ULN)', '> 60ml/mn|LVEF', 'more than 9.5 gm/dl.||', '12-19 years', '45%', '18 to 24 (inclusive) years', 'less than 1', '>5/10', '≤ 15%', '<95 mmHg', '>=18 years', 'less than 21at time of screening|RECTAL', 'greater than 3.0 × upper limit of normal (ULN)', '≥18 years|the', '0-2|FEV1 ≥1 litre', 'Grade III or above', '25 - 29.9 kg/m^2);|Agrees to be audio', 'Stage II', '>3D', '<5.65 mmol/L.|During', '≤1.5 mg/dL||Negative', ""≥20 and ≤ 60 years'"", 'less than 30 ml/min', '≥ 60 mL/minute', 'between 18 and 65 years;|Body weight lower than 113 Kg;|Level', '7 prior to enrollment', 'less than 5 clearance half-life', '≥160 mmHg SBP', '< 90 or > 140', '≤3,000 /mm3,|Platelets ≤100,000/mm3,||Biochemistry:||Estimated', '<90 days|Heart', 'stage A', '≥ 100 × 10 ^ 9 / L||D.', '< 2 × 109/L;|AST', 'Class II to IV', '> 18 years|', 'under 18 years)|Part of the first education year', '0 or 1.||Adequate organ', '18-29 kg/m2.|Willing', '<50% they', '< 12.0 g/dL', '< 190/110 mmHg', '≤ 1 day per week', '>= 18 years|Measurable disease', '1b Study||Inclusion Criteria:||Adult', '≤ 2cm', '<6 months|Use', 'less than 13 6/7 weeks', 'less than 1/2 vessel diameter；3 point', 'above 5 mmol/l|Ongoing', 'long-term participation', 'between 2014 and 2018|received', '40-70 years', '≥ 50% (<12 years', 'equal to or greater than 37', 'between 28-32 weeks', '≥ 16 years', '≥ 2.0|All', '>=1.45||', ""hallway'"", '≥ 155 mEq/L', '18-85 years old', '<460ms female)|Symptoms', '≥ 3+', '≥ 0.40|Atopic', 'between 8 and 14 years', '≥450ms for', '>= 0.2 ng/mL', '<45%.|Inability to comply', '≥50 but <200 copies/mL', '≤ 14 days', '≥ 18|Performance status', '> 100,000mm3', '>25% of bowel movements categorised', '100 and 2,000 mg/g', '18,5 - 24,9 kg/m2|metabolically', '≥60 mL/min|Total bilirubin', '>=1,500/microL|Hemoglobin', 'I-II|Children', 'required|18-65 years', '<1 month);|Current', '18-75 years|PS score', '8-65 years|Ability', '> 3 x ULN', '> or equal to mL/kg', '≥0.1×10^9/L|Platelet count', '>20 %|The subject', 'greater than 18 years|Medically able to participate', 'from 50 to 60 years.||2', '≥ 50ml /min', 'greater than or equal to 120 msec', '≥8 and ≤30 mm.||', '< 1000 cps/mL or 200 IU/mL', '> to +', '-75 years', '≥ 1×104 copies/mL', '> 5 mIU/L|Renal disease', '≤ 1.5 × ULN，ALT、AST ≤2.5 × ULN', '< 21)|Subthreshold', '≤ 100 k/uL|Hyperviscosity', 'more than 2 times the upper limit of', '≥ 65 mm Hg', '<18.5 or >30 kg/m2|Chronic', '=< 3 x institutional', '≤ UNL', '≥ 3.0 × 10^9/L', '18-25,|Bilateral', 'below upper limit of normal', 'greater than 75 minutes/week of vigorous physical activity)|SUPPORT TEAM', 'surgery.|At least ≥1 measurable', '< 140/90 mm Hg', '> 103 IU/ml', 'more than 60;|BMI 25-39.9 kg/m2;|aspartate', '≥3 months.||', 'greater than or equal to 18 years|Not receiving any', '18 to 70 years|Ability to read', '≤ 1.5 ULN;|Creatinine ≤ 1.5', '> 5', '> 30 kg/m²;|Subjects', '≥95 mmHg', '>30%.|Presence', 'score of 0.5', '=< 6 months prior to pre-registration|PRE-REGISTRATION', '<20.|English-speaking|Receive care', '> 2.8 g/dL|Alanine', 'at least 16 points', 'less than 125 kg|Age', 'more than 18 years', '≥30 mL/mi||F.', 'less than 10cm', '± 2', '≥25 on 17-item Hamilton Rating Scale for Depression', '< 1,5 hours', 'between 18 and 65 years old|Sign research', '≥ 5 mmHg', '≥18 and ≤55 years', 'three times the upper limit of the institutions normal', 'greater than or equal to 25 mmHg', '> 30 g/d', '<500mg.|Blood glucose', '< 5mm', '< 2 / Karnofsky Performance Status (KPS)', '≥10 pack-years|Chronic', '11.1 mmol/L)|Patients', '>80 mg/dL', 'between 3 years and', '>1.5x 109/L lymphocytes', 'greater than 7|patients', '35 to 55 years', 'after 33 weeks of gestationand', '<18 years|Cardiogenic', 'do not exceed twice the upper limit', '50 kg or more', '< 90 mmHg|Concurrent', '<59||', '≥18 years|Patient able to understand the purpose of the study', 'between 5.7-6.4%||', '≥ 18 years|Clinical', '25 - 45 years', '>6.4%', '14-18 years,|Good', '100×10^9/L', '> 19"" and < 32""|Back length', '55 and 75', '18-35 kg/m2|patients', '37-weeks', '28/*28', '18-45|Healthy', '≥10% BSA', '< 18;|severe cognitive', '18 years of age|Speak', '18 to 25 years', '> 1.5cm', '18 years or older|Scheduled', 'above 650mg/day', 'more than 10 minutes||', 'equal to or greater than 25 kg/m2.||And', ""between 28 till 37 weeks'"", 'less than one year|Cerebro-vascular event', '<50 copies/ml', '> 35 kg/m2|allergies', '> 35 IU/L', 'between 5 mm', 'younger than 19 years and older than 64 years', '≤ 100 g/L', ""<90 g / l);|The patient's"", '18 or older;||A', '18 years and older', '0-1.|Absolute neutrophil count', 'stage 0', 'score 0 or 1.|Histologically', 'above the nadir', '<20 mL/', '1-27 days old|Birthweight < 2500 g', '< 50×109/L', '34.5 kg/m2', '<15 × 106/ mL|PR <32%', '≥140 and/or', 'I patients|Age', 'A-B.|HBV DNA<2000 IU/ml.|Women', ""over 250 pounds|answer 'no' to all questions of the Physical Activity"", 'at least 65 years old|People must', '>12.5 kPa|A FibroSure', '1.5 to 2 units', '> 6.5|cancer', '≥ 3)|Severe', '< 1.5*10^9/L.|Platelet count', 'ethnic', '≤ 75%', '>= 65 mmHg', 'between 18 and 25||', '>ULN', '≥80 cm', 'less than 5 times response', '<1year', '0 or 1|Histologic', 'less than 1 year|Patients', 'I/', 'no more than 12 months prior to randomization.|Be between 18 and 75 years', 'greater than or equal to twice', 'above 18 years,|Lenght of ICU stay of', '≥ 40kg;|The', '> 11 / CHILD class', '≥6.1mmol/L', '18 years and older.|The patient', '1 and 2|Patient', '≥ 20 mm Hg', '≥30kg/m²|English', '< 105 cycles/min/L|Decision', 'between 25-50', '> 3×ULN.|If female', '≥ 60%||Normal', '≥ 30 mL / min/1.73 m2', '≥ 3x upper limit of normal (ULN)', '≥ 180mmHg;|Inability to attend', 'over 18|Ability to provide', '>15 g/dL;|Serum', '>40;|American Society of Anesthesiology (', 'less than 12cm|Having no', '> 500ms', 'less than 30 kg/m2.|Pain', '> = 6 mm', '> 97th percentile', '≥1500/mm3', '30-50 years', 'between 12 and 60 years|Patients', '≥15,000/mm^3|Participant', '>= 13.0 years', 'screening)|Age range', 'less than and equal to (<=) 500 per cubic millimeter', '50-70% HR max', '≥ 60||', '<12 months of presence', 'lower than 7.|Intoxication with', '≥ upper limit of normal', '> 130 mg/dL', '> 5 cm', '≤ 140/90mmHg', '> 2.5 ULN', '0-1.|Women', '≥30 (ng/dl)/(ng/ml', '≥ 40 mmHg', '18 and younger', 'greater than 12 months;||12', 'between 4 and 8 on the', 'score of 65 or greater', '<30)|hepatic failure', '18 years or older|Must', '>= 18 years and <=75 years', '13-25|Have', 'shorter than 12 months', '18-32 kg/m^2;|4', 'beer 3.5%', 'between 18,5 e 24,9|Hamstring', 'over 140 mmHg', 'distant metastasis;|No multiple', '0-2；|All', 'above the dentate line', '4 or 5', '18.0 to 27.0 kg/m2', 'between 18 and 69 (inclusive) years', '≥9 g/', '0-1|Patients', '> 35 Kg/m2|Pharmacological treatment', '< 200 cells/μL;|Receipt of', '> 9 g/dL', '<22 mEq/L|Consumption', '3 HS|Previous use of the experimental treatment|Unauthorized drugs', '≤ 1.2 x upper limit of normal', 'greater than or equal to 5.0 mm', 'female|18-65 years|residency', '>16 years', 'between 2 consecutive clinic visits', 'between 54-', '≤ 2.5 times ULN|Creatinine ≤ 1.5 mg/dL', '≥ 3 of', 'equal to or greater than 30mm', '≥60 ml/min|Male', '>2 times than upper normal', '5.7-6.4%||ii', '< 25 mm|Participants', '> = 60 years old', '0 to 2.|The', '< 13|Other', 'under 40 ml/kg/mint|participated', '18-65||Do not', 'below 3.5', '<11.5 cm', '>= 18 years|PATIENTS', '19.0 and 24.9 kg/m2.|Long-term residence', 'Class III to IV', 'long-term application', '≥2.0 × 109/L|Absolute neutrophil count (', '<50 copies/mL', '≤ 2,000/mm3', '≤ 5× ULN', '> 614 mg/dl|IgM', '≥91 and ≤140 mmHg', 'colonic adenocarcinoma|Patient 18 to 90 years', '≥30%', '> 70%||≥ 18', '≥1,500/mm³', '0 or 1|Patients able', '>= grade 3 reactions', '>= 100,000/mm^3|Creatinine =< 1.5 x upper limit of normal', '≥ 6 months', '1-3|Scheduled surgery', 'less than 900 pg/ml;|The results', '19 to 26', '< 5|Sedentary behaviour', '≤ 1 × ULN.|Aspartate aminotransferase', '> 4 ng/ml', '50 to 100 kg', 'less than 10 mm', '0-1|For intervention arm only', '≤ 5 × ULN；||Creatinine ≤ 1.5 × ULN', '3+', 'between 18 and 65;|Karnofsky score ≥ 60', 'between 6-18 years', '55 years and older and those', 'between 1500 and 2000 g', '109/L', '> 140 kg', 'less than 14 days.|Must sign', 'from 18-45 years', '50-64)|Women', '18-55 years.|Diagnosed', '>= 18 years|Diagnosis of', 'above 99%ile', '20-65|Have', '≤18;|Not', 'aging', '≥1500/µL|Platelets ≥100,000/µL|Hemoglobin ≥9.0 g/dL', '8 to 15', '≤ 40%', '>3L/min', 'above 750mg/m2、pirarubicin', '=', 'higher than the detection limit of the analytical method', '<3.0 X ULN', '> 4|major neurological', '8 or higher', '≥ 2 diarrhea', '= 80 ml/min', '<500m', '<150,000', '>= 75,000/mm^3', 'above the 5% limit', '> 100 bpm', '18 and older||Subjects', '>/=350 cells/μL', '≥ 10mm', '1 cm to 5 cm', 'score of 19 or more', 'present:||Hemoglobin ≥ 90g/L', 'greater than or equal to 18 years of age|Eligible', '18+ years of age|be able', '≤ 3||', 'FC II', '> 60 mL / min', '≥ 25 kg/', '≥2', '≤ 7', 'T< 35', '< 3.5 g/dL|Screening', '> 3 X ULN', '>12months；||ECOG PS', '≤10.0%||i', 'between 8 to 10 years|Children', '> 100%', '13-17 years', '< 40 mm', '< 90 mL/min/1.73 m2', 'eligible.|18 years', '>150 pg/ml', '≤ 8%', '≥ 4.5 cm', '34th - 66th percentile', 'at least 18 years|Ankle/Brachial Index (ABI) of', '> 1.5 × ULN；|Liver function', '≤ 2.|Total', 'equal or above 18 years|Eligible', '≥ 30 mL/min', '≥ 24 mm', '< 541|For UC', '< 3×upper limit of normal', '18 years old and above|Participants', '≤ 450 meters', '>2 years ago', '18-69;|Male', '75 × 109/L', '60 to 90 kg;|Histologically', '140 CLL trial', '> 50 kg', '18-70 year', '≥ 20/100', '18-85|Subjects', 'xerostomia;|Previous use', '< 1500 mm-2.|Corneal opacification', '>440 ms', '0 to 1.|Received', '≥ 25 IU/L', '3-5 days', '0-25', 'Functional Class II-IV|Forced Vital', '≥ 45%', 'greater than 1 month', 'I-II-III', '<2 year|Active', '<90 mmHg||', '≥ 40 mL/min.|Serum', 'between 25 and 35 years old', '≥100 μg/L', '<18 years|Twin', '>= 18 years|An', '< 24)|Comorbidities of the', '< 20 ng/', '<10.5 g/dL', '≥ 171 μ', 'less than 5% of whole', '7.5% or higher', '≥40% and ≤95% of predicted normal', '>150 mg/dL|fasting', 'suppressed', '=< 2|Patients', '>5 ml', 'under 6', '≥ 75,000/μL||Participants', '18-75 years old|The study population', 'from 18 to 70', '1.2 mg/dL', '>16 mg/dL|Patients', '≥ 150 mg/dL', 'outside the range of 90 to 140 millimetre(s', 'between 19 and 24|MoCA score', '< 60 mL/min', 'objective ≤ 140/90', 'greater than or equal to 65|Self reported difficulty', '<5mm', '=< 55 years', '<1,000/mm3|Hemoglobin levels', '< 4', '> 0.4 to maintain', 'more than 18 years old', '≤ 75ml/min/1.73m2', '≤ 1.5 x IULN|Total bilirubin', '<30 14 days after the symptom onset of COVID-19.|6', '≤ 2.5 UNL', '14 to 17 years', '> 18 years|Twin pregnancy', '>75 years||', 'long-term alcohol', 'between 7-12 years|Exposed', 'less than 5 times the half-life', 'above 4.0 mmol/L.|Archival', '>= 30 mL/minute/1.73 m^2', '≥ 0.3 μg/kg/min + vasopressin', '≤40%).||11', 'score of 10', 'above 37 weeks', '> 5 times the upper limit of normal', 'at least 12 weeks.|At least 1 measurable', '< 85 lbs.', 'less than 70 fL.|Blood glucose level measurement', '≥ 30 g / L.||Renal', '≤ 1.5 times the upper limit of normal value;||', '3-6 months prior', '≥100×109/L Hemoglobin', '35% or less', 'relative <55 years', '≤ 140/min', '18 years or older|internet', 'radiotherapy;|having 6 mm or more', '≤1.5 X ULN', 'better than 75', '≥92%', '≥ 12 weeks||Adequate hematologic', '< 140/min', '≥ 90 g/L.|AST、ALT ≤ 10 × ULN', '>9||', '<1.5×ULN', '<35 weeks', '>3 and <24 months', '≥27 kg/m²', 'between 13-18 years', '18 or older|Cocaine', '< 10 %', '< 1% per year|refrain', 'from baseline to week 4|Subject', '10 to 13 years', '<5.6 mmol/L', '> 1.5 uln', '> 30,000 or <', '0-2;|In', '> 2 tests', 'exclusionary|One individual per household may enroll', '16)/CBFβ-MYH11;|Accompanied', '=< 1.5 x ULN', '>20 beats/minute', 'between 18 and 30 kg/m2||', '≥3 X ULN', '>90 Decibels [dB]', '> 40mL/min', '14 to 65 years;|Diagnosis', 'more than 750 mL', '>= 1.5 x 10^9/L', '≥70% of the population median', '> 29)|Current', 'less than 4 mm', '≥ 18 years|Admission', '10 mm Hg diastolic', ""150 Bachelor's level counselors"", ""up to 26 weeks'"", '18 - 65|ASA', '≥ 90% product compliance', '18 years or older.|Students', '≥ 1,500/mm3', '≤ 1.5 times UNL', 'less than 30 ml/', 'younger than 18 or older than 35 years', '=< 5.0 x ULN.||RECIPIENT:||For', '≥200', '<= 5 x ULN||Coagulation:||h', '> 75 years.|Another type of urinary incontinence', 'less than 21', '> 9g/dL;|Patients', '<12.5 g/dl', '<72', '404 Oral Liquid treatment.|Judged to be not applicable to this study', 'does not exceed 30.0 kg/m2|Free-living/', '0-1.|Expected survival time', '≥ 60% and ≤100% of the predicted normal values', '≥5 years', '12 to 24 weeks after the first symptom of stroke', '≥1.5 × 109/L', '≥ 1.5 X 109/L', '≤ 3.0 mg/dL', '>2x in a week', 'between 18 and 70 years).|BMI ≥ 35 kg/m²;|Subjects', '>1|Subjects', '=4|Age of onset of disease', '≥19 kg/m2', '> 25 dB HL', 'score of 1.0+)|If on', '297.1, 298.8, 295.4', '> 18 years|Patients', '50 years.|Male', '≤ 3 × upper limit of normal (ULN)', '< than 1.4 meters/second|Ability', '25-35 Kg/m2|Ability', '<3 months)|Any', '≤ 12 months prior', 'less than 3 cm（*The', '>18 y.o.;|The patient', '>= 18 years|Histologically', 'ranges of motion', '<70%|Hypersensitivity pneumonitis|Scleroderma', 'II or III', 'more than 10 degrees varus', '> 1.5×109/L', 'score of ≤ 24;|Use', '> 50% predicted', '>1.5×109/L)|Serum bilirubin', '≤5cm', '>= 40 kg', '≥ 9.0 g/dL|INR', 'below or above the limits', '2a', '<15 mL/min/1.73 m2;|3', '<40 kg;|Enrolled', 'between 1 and 17 years', '> 1.5 x ULN|AST', '>50%|Diastolic dysfunction', 'score 0 - 2;|Life expectancy', '> 18 yo)|≥5', '≥ 45ml/min/m2', '>60 8', '>360 μmol/L', '> 180 mmHg', '< 60 mL/min/1.73m2', '1-84', '<1000 cells/μL', 'performed|At least 18 years', '≥ 0.05 µmol/L', '>2.|Has clear evidence of', '<12%|Adequate circulation', '+/- 15%', '2 to 10 years,|scheduled for elective day', 'from 18 to 65 years.||', '<60 ml/min);|drugs', '>1.5 x ULN', '≥ 1.5 × 10^9 /L', 'below 200)|History of', '≥ 12 weeks;|Adequate hematologic', 'score of 4', '4-25', '> 3|Singleton', '≥ 30 mg/g', '≤ 70 years', 'equal or greater than 10mm', '≥55-90 years', '< 3 weeks prior to registration)|International normalized ratio', '45.0 kg', '≥5mm', 'twice or more', 'between 0.5 - 25', '30-40 kg/', 'score 0-1.|Toxic reaction', '≥1.5 × 10^9/L', '>=10 mm', 'less than or equal to 2', '< 50%;|Previous', '< 40%.|Patients', '3.4 mm', '27.0-35.0 kg/m2|Able', 'higher than 1.5', '> 1.5)||10', 'Under age 18|Non-English speakers|Those', 'between 29 days and 18 years', '< 60 mL/min/1.73', '<110μmoI/L', '>300 μm', '≥ 34', '7-9 hours per night||', '≥ 27 kg/m2', '6m- 18years', 'score of 4 or greater', '< 50,000/µl', 'greater than (>) 5 years', ""male patient's sexual"", 'between 18 and 75 years.|Clinical diagnosis', 'between 30 and 75 years old', 'less than 18 years|Lower than 5th grade reading level', 'prior to 27 weeks', 'functional class II, III or IV', '> 200 ms|QRS duration', '60 or greater', 'I or II', '≤ 30 days of study enrollment', '19 years or older', '0 to 100 mm', 'hypertension;|Anemia;|Less than 1 year', '≥ 1.0 × 109/L', 'from 18 to 80.|ASA # or', '< 55%', 'less than eighteen years.|For sexually', '25-cm', 'two-times the upper limit', '≥18 years;|TNBC', '20-24 weeks', '>95 g/m2', '1-3|Stable dopaminergic therapy', '18-65 and', '<70|Schizophrenia', '>1.5 ULN', 'between 18.5-30 kg/m2|Weight', '≤110µmol/L，blood', 'Less than one year', '18-65 years|Patients', 'between 18 to 38|Subject willing and able to comply', 'score of 13 or greater', '> 0 and ≤ 10', '≥50×10^9/L;|Proper organ function', '≥ 60 mg/dL', '<35%|Non-ST elevation', 'ranges from 2 to 3cm;|cN0', 'meniscus tears|The patient', '> 600 mg/dL', '>2cm', '<1000 copies/mL prior to the start of study treatment', '≤ -1.5', '≤ 1.5 x UNL', 'B-cell hematologic malignancies', '1-3||', '≤ 28.0 kg/m2', '>=20', '< 50 beats/min);||(4', 'more than 18 years.||', '1.1;|Previously received at least two', '< 60ml/min', 'Functional Classification', 'at least 0.5 teaspoons', 'Stage I - IIIC2', 'under 7-years', 'less than 5 years', '≥ 18 years.|ECOG', 'greater than or equal to 27 kg/m^2|HgA1C', '<24 months postpartum|Nulliparous', '160-170', 'rating ≥ III;|Cardiac', '≥ 6 months;|8', '19.0 to 32.0 kg/m^2|Body', '0-3 antigen', 'above 5 times the ULN', '≥ 100 mm Hg', '≤ 450 ms', '3 to 9 years', 'between 45 and 70 years', '> 80 g/day', 'more than 25 breaths per minute', '≥ 3.0×109/', 'over 18 years old', 'over 24 years old||-', 'between 6-18', 'Grade II or higher heart failure', 'less than', '≥ 130 mg/dL|Waist circumference', '3 times normal value;|Serum creatinine', '> 30 kg/m2|absence', '<10 g/dl', '< 130 or > 150 mmol/L).|Pregnancy.|Unwilling', 'from 25 to 60', 'at least 1', '≥3 x', '>= 9 g/dL|Patients', 'over 18 years|history of laboratory-confirmed', 'less than 3 times ULN;4）Blood Clotting', '< 18 mmHg', '≥ 3)|Concurrent participation', 'greater than 60 mL/min', '≥ 3|Brain', '≥18 years.||Participant', 'between 19 to 55', 'greater than 24 hours', '< 28%|Platelets < 100,000/µL|Serum creatinine > 1.8 mg/dL|INR', '> 1.85', '18 to 55 years|Male', '4-7 years.|Apparent', '2.5 g/dL)||Alanine', '>= 50 mL/min per Cockcroft-Gault equation', '≥30mL/min', '4 years and over 18 years', '>140 mmHg', '≤ 400 lbs|Willing', '≥ 2.0mg/dl', '<= 400 mg/dL|10-year', '>50 hours/year', '> 1.0 ng/mL', '<20/200)|Satisfying', '1.2', '≥63,|BRS score <3,|fluent', 'less than 22 (<22)', '6-8.5', '>= 9 g/dL|ELIGIBILITY', '18-65 years.|CHB', 'greater than 7;|Lactobacillary grade', '<50 mmHg).||Matched Control Individuals:||Have', '>2%', '<5.0°;|Medium/high', '1 mmHg', '>10%||Group 4||1', '50 years old|LDL cholesterol levels', '≥ 60ml/min;|Coagulation function', 'less than 0º', '>5 kg', '<20 packs years', '>= 42 days', '> 18 kg/m2.||', '≥ 38 and ≤ 126 U/L||Having', 'above pain', 'less than one year|Patient refused', '35 and 43-47', 'Between 32 and 37 gestational weeks,|The first blood collection attempt', '< 65 mm Hg', 'between 30% and 70%, inclusive', '> 60 years old', '< 1.5 times of the normal value.|IL-13Rα2', '> 1.25 x the upper limit of normal||xi', '<90% of pills', 'US)|stage 4', 'criteria - 7 fields CFP)||', '18 to 40 years;|35 to 41 weeks of pregnancy;|Singleton pregnancy;|Plan', '≥ 14 and ≤ 17|Clinically', '0 - 5', 'Malaysia|aged 18-65 years', 'above 35 years', 'less than 50% or lower than the lower limit of the laboratory test range', '< 200 mL/', '≥1 to <18 years', '≥20/min)|Admission', '25 mmHg', '< 3.0 mg/dL', 'less than one year|Patients', '≥1% of tumor cell nuclei', 'shoulder surgery|Anticipated return home the same day', '18 to 75 years|BMI', '0-2;|Those', '≥ 1.5x', '>2|Missing consent from', 'Score of 33 or higher', 'Below 18 Yrs', 'below lower limit of institutional normal range).||g', 'movement disorders.|The', 'between 30-64 years', '2)||Approximately 60', 'greater than 10%', '≥ 15mm;);|Those', '> 2.0-fold above the ULN', '< 3.0 × ULN;|Serum', '< 23)|Any', '1.1|Overexpression of fibroblast activation protein of the target lesions', '>37/0 weeks||', '> 1 year|Willing', '18 to 40|Male|Players playing football for > 1 year||', 'between 4 years and 18 years', 'under 20 years', 'between 18~70 years.|Fulfilling the 2010', 'oxymetazoline.|Less than 18 years', '>0', '> 9g/dL;||Patients', '< 150RU/ml', '18-65 years|Willingness to join and complete the nutritional', '≥ 50 mg/j', 'between 2 and 8 years old||', '> 5 times the upper limit of normal (ULN)', '< 18 years|In-hospital', 'Stage 3,4),|Receiving', '<=1.5 X institutional upper limit of normal', '> two times upper reference levels', '18-60 years.||', '90-140 mmHg', '< 25 years', 'higher than 5.4', 'High', '>180 mmHg', '15 and higher', '≥18 years|Subjects must have the', '≤ 0.9.|Common', 'limit adherence to participation', '>= 1 cm', '13-16', '≥ 100,000/μL', '≥ Grade 3|Echocardiography', '0 to 1;|Normal', '≤ 65 years', 'between 18~70 ,both gender.|Initial diagnosis', '>450 ml', 'I - II|18≤BMI≤30 kg/m²|Outpatient', '< 50,000 per microliter', '≤ 2 points', '> 1.6kg/week', '=< 6 months prior to registration|REGISTRATION', '6 Abdominal cavity', '≤ 5.0x ULN', '<500 IU / mL', 'less than 7', '+ donor): pregnancy', '20 SAS)|40-70 years', '< 135 kg', '< 5% blasts', '<5 mmol/l/', '≥ 0.5 g/g', '18.0 to 40.0 kg/m^2|The subjects signed', '> 480 milliseconds', 'RA criteria|Being', '≥ 18;|Histologically', '<2.5 mIU/L', '-2N1', '< 142/150', '<90 ml/min/1.73 m2', 'greater than 120 mmHg', '>150 mmHg', 'more than 500 mL blood', '>45 mL/min|Women', 'more than 450 mL', '4-12 years|Child', '1 to 12 years|Residence', '≥ 1.5 × 10^9 / L', '22 and below', 'below 50 or above 90 mmHg', 'more than 2 times the upper limit of normal', '0-1|Life expectancy', '≥ 12 weeks from the start of study treatment||Key', 'old.|Males or females.|Healthy', '≥30% and ≤90% of predicted', '18 years and older|Histologically', 'less than 85 years old and more than 18 years old', '3-5.||', 'between 90 to 140 mmHg systolic', 'requires antibiotic', '<20 ng/mL).|Stroke', '18-40 kg', '> or = 100 000 mm3', '<1 L/min', '> 10|Behavioral Activation for Depression', 'Female|17-40 years', '18 to 45 years,|3 to 24 months postpartum|Criteria of', 'III-IV)|Patients', 'for more than 12 months until', '≥ the 95th percentile', '18 - 40 years', '>4x10^9 /L', 'greater than or equal to 100mg/dL', '<0.5 nmol/h/L', '36-60 months', '>3 times the upper limit of normal value', '<80 g/L||alanine', '<=35 mL/min/1.73 m2', '< 18)|Mental disorders', '≥ 10%);|Any', '≥ 90 mL/min/1.73 m2|Absence', '> 18 years old Patient able', '>5,6 mmol/L', '≥ 3 months;|Participants', '> 400 mg/dL).|Participants', '<2.0 mmol per litre', '50%;|Older than 18', '> 3);|Patients', '≥ 80×109/L;||Biochemical', 'between 65 and 85 years.|No previous', 'within normal limits.|Serum creatinine', 'at least 70|The number', '1 cm', '≤ 40,000/μL|Known', 'large B-cell lymphoma', '>= 60mL/min/1.73m^2||', '< 2.5 times the upper limit', '18 to 35', '≥ 18.0 to ≤ 32.0 kg/m2|All', '>10years does not', '< 60 ml/min/1.73 m2', '>38.5 degrees', '≤ 15 cmH2O.|Few', '> 30kg/m².|Any psychological', 'from 1 to 10 years', '≤ 2;|Tumor progression', 'between 20 years', '< 14 years and > 30 years;|presence of structured physical activity programs', 'less than or equal to 75 years', '≥ 27+0 and < 33+0 weeks|Spontaneously', '18-90 years|novel', '=< 1.3 mg/dL', '>45 ml/min', 'more than 10 units', '> 1.5-fold the ULN', '0 or 1.|Adequate', '2.0).|100-300 HHs', '<LNL', '< 1.5 times the upper limit of normal value.||', 'lses than 3 months prior to study', '>/= 18||', '< 5 x upper limit of normal', '< 18 ans|Pregnant', '≥ 160/100 mm Hg', '> 3.0 mg/dl', '≥34 µmol/L;|creatinine', 'greater than or equal to (>=) 50.0 kilograms (kg)', '18 and above, reside', 'less than 400', '≤ 30 weeks', '≤ 100x10^9/L.|Hemoglobin < 9 g/dl.|Patients', ""18-65 years old|Haven't"", '≤ grade 2 prior to leukapheresis|Patients', 'Grade I or IV', '<1 year|Any type of cognitive impairment', '18-75 years|Italian mother tongue|written and informed consent', '≥25 kg/m2|Able', '>ULN+4s', '>150 mg/dL', '< 0.2×109/L', '>6.5%', '>2 × ULN', 'January 2000', '18 years and over|Right-handed|Having signed', '≥1.0×10^9/L', 'greater than or equal to 4 times a day.|Must', '<27+6 weeks', '18-77 years', '≥ 9 g/', '> 100 BPM', 'greater than or equal to 50 kg.|In good health', '*does not', 'below 15', '≥IV;|Body weight', '<= 65%', '< 33%', 'less than 2 hours,|Afraid of goldfish', '≥ 18 years old,|Turkish', '≥ 70 mL/min/1.73 m2', '≥10 L', 'rating ≤50;|Able to comply', '>/= 4.|The patient', 'below the 75th percentile|Attained 19 years', 'more than 500', '<3.0 k/mm3|Serum', '< 18 and > 90 years;|Contraindication to radical prostatectomy procedure;|Non-organ confined', '18.5 to 30 kg/m2', '75 109/L', '>400 ng/mL;|TSAT', '≥90 mmHg)|Urine', '>400mg/dL', '≤ 5×ULN;|Serum creatinine (Cr)', '< 10 g/dL);|Thrombocytopenia', '18-42', 'more than 160 mmHg', '> 155 or <120 mmol/L|Contraindication to either study fluid', '<1 x 109/L)|Hypertriglyceridemia', '< 24 hours prior to the study start.|Currently', '6-24 headache days per 28 days', '>0.75×10^9/L', 'women|18-70 years', 'clinically significant abnormalities', 'over 18 years old||The exclusion criteria', '<150 min', '<10 g/dL|Platelet count', '> 90%||Any of the following laboratory findings', 'score of greater than 3', '18-32 kg/m2', '<400 IU/L,|Total', '< 18.5 kg/', 'score of 3 to 6', '>= 19', '1-2 points', '>6.4 (diabetes)|Last A1C value', '≦2 upper limit of normal (ULN)', '≥10 mm Hg', '≤ 59 years|GFR <85 ml/min/1.73 m2', 'above the ULN', 'transgender individual|Be 18 years', '15 and 45 years', '< 30 g/l|History', 'etc;|(7', 'over eighteen years', '6 to 16 years|Elevated', 'not more than 100 kg', '14-17 years old|BMI z score', 'less than or equal to 1', '>10 cigarettes per day', '30 - 45 years', 'at least 21', 'sex|Aged 18 years old', '< 80', '<2years of age)|Scald', '> 100mmHg)|PRE-REGISTRATION', '<50,000 platelets per µL)|Pregnancy', '> 8 WU', '>= 18', 'I to III||Patients', '18 years of age|Unwillingness', 'between 18 and 80 years|BpMRI', '1 to 15 years old|Whose 2 parents', '≥ 50 mL/min/1.73 m2).|Patient', '≥160 mL', '≥ 80ml/m2', '>18 to 45 years', 'between 18 and 90 years;|Glasgow', '< 18 years;|underwent surgery for', '<15,000/mm3.|Patient', '> 0.5 ng/mL|FIV/', 'Individuals older than 80 years', 'greater than 6.5%.|Subjects', 'complete response', '7, 1997', '≥ 26.5 μ', 'I-III|Undergoing elective pelvi-ureteric', 'greater than 4.5 cm', '≥1.5×109/L', 'Stage IIIB/IIIC', 'under 60 years', 'higher than 500 IU/ml', 'score of above 2', 'grades 4 and 5.|Presence of', '<3.0 x ULN)|aspartate aminotransferase (', 'higher than or equal to 25 kg / m 2', '110 lb', 'objective', '< 18 y.|Pregnant', '1.1.|ECOG 0-1.|Adequate organ function.|Life expectancy', '≥ 90 cm', '38-60 kg/m2,|age', 'greater than 6 months', '> 2.3', 'least 50% diameter stenosis', '≥36 months', '+/- 3 kg', 'class 2-3 COPD|Forced', '>90mmHg', '>100 mm Hg)|Weight', 'above 72%', '≥26 mm|Patients', '>10 pack per year', '≤ 78 and ≥ 24 letters', '≥ 1.5 x 109/L|Platelets', '18-24 years', '>50mmHg', '≥ 4|Shoulder', 'between II and III|Mini Mental State Examination', 'Less than 3', '≤ 12 weeks', '≥ 100 mg/dL', '<100×109/L', '> 45 ml/min/1.73m2', '> 35).|Chronic inflammatory orthopedic disorders', '<500 mg/day', '<=3|Patients', 'less than 1 year.|Known CYP2C19 status.|Known cardioembolism', '<65% predicted', 'score is 25 and', '18-60 years;|Be able to understand the purpose of the experiment', 'below 0.5 Snellen|In', 'last intake <48 hours before intervention', 'not 0-0.5', '≤ 2 mg/dL', '10 to 40 cigarettes per day|Woman', '≥ 100 K/cumm', '>750×109/L', '4 ng/mL', '≥100,000/μL|Hemoglobin ≥9.0 g/dL', '≥6 mm,|Bone levels', 'better than or equal to 20/40', '<=2.5 x ULN', '<4.9 mmol/L)|Subject', '> 3.3 μg/dL(=33.0', '< 0.9g/L', '<60 mg/day|Greater', 'score 0-1', '18-64 years|Receiving 3 x weekly', 'I-II-III||', 'scores of 9+', '> 3mmol/l|Severe', 'at least 16 weeks', '>50 breaths per minute', 'below 26;|Agree to receive', '> 30 ng/dl', '>3 x', '14-18', 'more than 360 mg/m2', '≥ 18 years old|Affiliation', '≥2.5×ULN;||Hepatic impairment', 'between 18 and 30|Reporting at least a', 'between 18 to 30 kg/m2|Healthy', '>11mg/dL);|Renal insufficiency', '18 years or older|Physically capable of engaging', '≥ Level 3).|The toxicity', '≥85 mm Hg', '< 16 years', '≤ 30mmol/L', '< 30,000 Plt/uL', '18 to 80 years old', 'between 60 and 100 kg', '≥28 g/L', '>= 36 weeks', '<180 mmHg.|3.Serum potassium', '≥ 20 ng/mL||Multiple lesions', 'less than 40 %', '≥20 mmHg', '≥50 kg.|Healthy', '0-2.|Patients', '>50 mL/min/1.73m^2|Persons', '<1 year|Female', '>= 100000/uL', '≤ -6.0 diopter', 'minimum 20%', '> 3 × upper limit of the normal range (ULN)', '≥ 3.5 L/min', 'between 18 and 80 years|both sexes|pre-', 'peak', '<1% per year', '≥90 cm', '<35%)|Patients', '≥14 years', 'at least three', '>2.3mmol/L|Have', '>1.5 × ULN|AST', 'scores <50%of', '1%,', '> 150 mmHg systolic', 'below 18 years old', '13-63 years|Bariatric surgery type (LSG or RYGB)||', '1 - 4cm', '< 30.0 kg/mˆ2||', 'between four (4)-16 years', '≤ 7 g/dL|Hepatosplenomegaly|Patient', 'between 18 to 40 years|unexplained', '> 2|Hepatic encephalopathy', 'score of 0 to 1.||3', '>70%', '>5%)|Allergy', '≥6 requires', '≤ 0.50 D myopia', '> 1', '> 0.3 µg/kg/min|Patients', '35 to 85;|no excessive', '≤ 3.0×ULN*', '≥ 0.44 m/sec to < 1.0 m/sec|IL-6', '≤ 75 years.|Evidence', '≥70 dB hearing loss', '> 35).|Patients', '≥45 kg|Calculated', 'less than 3 months old', '≥ 1.0 × 109/L|Platelet count', 'below 100 or above 140 mmHg', 'less than 12-week duration', '≥ 60 ml/', '< 45%|Presence', '> 120 beats/min', 'less than 25 ml/min per 1.73 m2.|Medical history', '≥ 12 months.||', '≥ 400)||', '5-18y|(Living', '0 to 2|Adequate renal', '≥20 millimeters', '18 and older|Currently', '>10% marrow blasts', '>1,500/', '> 18 years|No', '> 18.5', 'less than 20/25', '+/-20%).||', '≥ 90×109/L', '0-2.|With', '> 180/110|Known', '18 or older|Localized', '< 3|English-speaking|with', '≥ 3 ml/min/1.73m2', '≤ 2.0 mg/dL', '< 13,000 U/L)||According', '19-26 kilogram per meter square (kg/m^2', 'greater than 400 mL of', 'practical experience', 'less than or equal to 1.5 times ULN', 'more than 442μmol/L', '>= 40 years.|Have', '< 45 mL/min/1.72m^2', 'less than 12.5 g/dL', '<60 mL/min/1.73m2|Hematocrit', '≥ 100 × 109/L);|Hemoglobin', '>=55)|Diagnosed musculoskeletal chronic pain', '≥ 2 points', '< 20 x 10^9/L', '≥ 12 weeks.|Patient', '≤ 40.0 kg/m^2', 'Red Flag', '≤70);|Informed consent not signed', '<=10 mL/min', '18 to 32 kg/m2', '> 100 mm Hg', 'more than 30 kg/m2|informed', '≥ 60 ml / min', '1 to 3', 'over 450 ms', 'from 18 to 80 years old.||', '0 or 1|Adequate', '≤ 1.5x ULN', '≥ 2 times the upper limit of normal', 'lower than 90 ml/mn', 'between 28-36 weeks', 'less than the 5th percentile', '≥2.|The patient is', '>100 mL/hour', 'less than 3months ago|Lower extremity weakness', '20-25 kg/m2.||Exclusion', '>12 months old, <7 years', '<2 year', '< 1.5 times of the normal value', '≥18 years|Patient is willing and able to give', '≥ 3 points', '≤ 57', '< 18 years old|Pregnant', 'between 2 cm x 2 cm x 0.1 cm deep', '> 95th percentile).||', '<15 mL/min/1.73 m2', 'recipients,|participant', 'at least 2 years', 'from 18 to 65 years', 'm2 and < 35 kg/ m2.||', 'score of 3 or more', '≥ 92%', '>3 times the upper limit of normal', 'more than 1000 copies/ml', '< 1.5 G/L', '24-28 weeks', '>1|REM < 1 million', '>30kg/m²)|chronic fatigue', 'at least 01 sexual intercourse', 'Miletus|Hypertensive.|Abnormal Cholesterol', '12-17 years', '13 years old and up', '>400 mg/dl', 'sign separate consent', '18 or older|Second-degree burn wounds of', 'Stage C', '≥18,', 'below the minimum quantitative limit', '18 yrs or older|Spanish-speaking||Recent homelessness', '18 - 55 years.|Both', '> 10 millimetres of mercury', 'Age≥18 years；Meet', 'less than 5 hours per night on weeknights', '≥ 60 minutes/week', '18 and 80 years', '< 30 mL/min)|serious', 'under 4 years;|previous', '<3|Previous operation of the paretic limb', '>50 mmHg', 'score of 6 or above;|Voluntarily participate', '< 30mL/min)|Current', 'between 18-30', '<60 ml/min,|Aspartate', '≥ 25 kg/m2', '>30 days.|COPD', '30-40 kg/m2|Weight stable', 'above ULN.|Deviations from normal', 'less than 24 months).|More than 3 months', '> 3 × upper limit of normal [ULN', '≥ 18 and ≤ 75 years|Healthy', '>110 mm', '18 and older.|CMML diagnosis', '≥ 1.0 g/L', 'less than 80% of the predicted value', '6-7|Including', '<9 g/dl', '< 125 mEq/L)|Complete', 'between 18 and 75 years old.||', '≥ 500/dL|Platelet count', '7-10 days after initial treatment.|Patients', 'no more than three metastatic', '18-65 years,|ASA score', 'class III/', 'vaccines).|Long-term', '> 26', '<15 ml/min.|AMI', '≥ 40mmHg', '> 7 days,|Neonate', 'at least 50 kg', 'less than 2 years', '< 1 month from symptom onset', 'drinking 14 units', 'Class II or higher', '≤ 0.50 D', '≥ 65 years', '≤ 1.5 times the upper limit of normal', '18 through 55 years.|Fitzpatrick', '> 15 mm', '< 6 months prior', '< 92%(without oxygen', 'greater than 50', 'less than 14 days', '18-25 kg/m2', '>300mg/day', '18 to 65 years', '≥18 years|Native', '> 50cc', '> 2.|Any', '>2|Significant', '0 to 5 years||', '<90 days prior', '>=5.6 mmol/', '10 to 17 years:||Healthy children', '18-79 years', '> 24 in spite of treatment', 'from 2 to 5', '11-12 years', '< 45 mL/min', '≤ 2.5 times the upper limit of normal', '>= grade 3', '>= 100 x 109/L|Aspartate', '< 2L', '≥ 1,000 /mcL|Platelets ≥ 80,000', 'between 18 and 120 years', 'between 18.5 and 30 kg/m2|Health status', '=< 2x institutional upper limit of normal (ULN)', '≥3 episodes of', 'minimum 18', 'does not confound results', 'less than 20×109/L;|Patients did not respond to glucocorticoid therapy', '451 umole/L)|Creatine phosphokinase (CPK)', 'higher than the lower limit of detection);|Untreated', '> 3 months 6', '< 100 mg/L-1|IMC', '>2.0 cm', 'greater than (>) 7 days in duration]|Severe dilatation of the', '≥60 mL/min/1.73m2', '4-12 months', '≤ 2.5', '>= 50|Patient', '> 90%)|Administration', 'between 4 and 12 years old|ASA', '<35 kg/m2|Ability', '≥ 20 ml/min/1.73m2||', '<2;||13', '≤ 30 kg/m²;|Having', 'no more than 6 months);|There', 'less than 30 minutes to fall asleep on average|Severe Clinical', '18 - 30 years|Confirmed', '≥10 letters', 'less than 60 days prior to apheresis', '>= 24 months', 'between 18-65', 'SE:||At least 6 minutes', '≥ 35 mol/l|Transaminases', '≤ 5 × UNL', '≥ level', '≥ 160 mm Hg', '> 8|Be receiving', '18 years old or older', 'I-IV|Must', 'local regulations|The', '20-60 years', '>45', 'I, II and III', 'older than 36 months', '≥ 89%', '18 kg/m2', 'greater than 6', '<90×109/L.', '≥2 d);|History', '18 years old and 80 years', '>85 or <50 mmHg', '≤ 2.5||× ULN；⑥', '≥3|Target lesions', '< 3,000/µL', '≥10L or more', 'better than 20/25', 'above 32 kg/m2.|Inability', '>100 IU/ml', '19.0 to 26.0 kg/m2', '< 110mg%', 'between 24 and 30 kg/m^2', '≤2.5×above upper normal range', '>= 1500/uL', '<6th grade reading level', '>3s longer than the control', '≥4 (range 0-10', '≥60 mL/min/1.73 m2', '≥1.5 x upper limit of normal', '<1000/mm3', ""1-3,|Participant's"", '<30 g/L;|preoperative', '< 3.0 mg/dL)||Adequate', '20-54 years|24-hour', 'greater than 1.0', '18 - 75 years||', '>=18years|Informed Consent', '> 30 Gy)|Grade ≤ 1 toxicity', '≥18 and ≤75 years old', 'higher than the normal range', '<92%', 'Pregnancy|Adult patient subject', 'between 18 and 28 kg/m2', 'class II and above physical disability', '≥ 2000 copies/ml', '18-65 years||', 'more than or equals', '> 30 mL/min/1.73m^2', '=< 2.|Patients', '>500ms', 'between 21-50 years', '100-125 mg/dL', '≥ 37.3°C', '>= 3', 'above the second percentile|At least stage four', '≤ 13.3 mmol/l;|6', '21-60 years old|Those', '18-40', '> 11|Eligible to receive', '18-65|Agree to participate', '> 24/30|Age between', '≥1+ after IHC test', '19-25', '≥ 18 years|Healthy volunteers or volunteers', '>35|History', '40 or more', 'younger than 18 years', 'less than 30º of', 'greater than one year', '< 40|Patient', '30-120 minutes|the', '≤ 18.5 kg/m^2', 'from 5 to 8 years,|able to follow verbal commands', '120 ms', '18 years or older).|Identified', '>3 times ULN', 'more than 50.0 kg', '≥50 years', 'between 4 and 18 years old', 'between 18 and 85.|Subjects', '5 years or more', '> 1.5 cm', '>30 breaths/min.|Patients', 'between 1st January 2014 and 31st December', '≥45 years;|Undergoing elective', 'at least 30% racial/ethnic', 'from 22 to 65 years.||It', 'from 0 to 16 years', '< 18 years|Fibroids not accessible', '> 12 weeks.|Females should', 'less than 70|Previous', '> 2.5 x ULN,||Microbiology:||Positive', '18 to 85 years', '≤ 12 g/dL', '< 70 premorbid full scale Intelligence Quotient', '130-190 mg/dl', '>140/90mmHg).|Long', 'above 6', '≥40 mL/min per the Cockcroft', 'less than 5 years prior to enrollment', '<3 x ULN', '≤ 1.5×ULN；|Serum', '≥18 years|PCR-confirmed', '≥ 90mm', '≥ 40 mIU/mL).||A', '>= 3 g/m^2', '18 - 50', 'at least 24 teeth|the ability', 'not more than 5', 'less than 50%.||5', '≥ 18 years,|presence of arrhythmic storm', '18 years old or older on day of signing the informed consent.|Histological confirmation', 'greater than 11%', 'Level A or Level B evidence-', 'under 35.|Must', '<24 months|Infants', '> 250 msec', 'from 3 to 8 years|first', '>1 to 2 × ULN', '> 45 mL/min', '2, 3', '440 ms demonstrated', 'between 18 and 90 years|Level of', '< 1,25 UNL', 'between 18 and 35 kg/m2 inclusive', 'between 20% and < 45%', '1-3|Patients', '>90 mm Hg', '≥3 (24', '≥65 mm', '≤ 100 cc', '> 88', '13 to < 16 years', 'more than 19 years', '≤ 2.5 x upper limit of normal (ULN)', '≤ 2.5 x IULN|Creatinine clearance', '>1.4', '≤ 60 days prior to index procedure|≥ 18 years old', '12 weeks.|NSCLC', '< 300 mmHg', '30-55 year', 'grade 0 or 1', '<50 years old', '>90 years', '18-64|identify', 'more than 24 weeks prior to screening', '≥ 2.5 g/dL.|LDH ≤ 3 x ULN.|aPTT', '<25%', '>90 mmHg;|Triglycerides', '≥ 18 years-old.|Subjects', '≤ 55', '> 2mg/dL;|Blood', '≥50%.|The organ function level', '≥3mm', '≥ 100×109cells/L', 'equal to or greater than 1.5', 'between 60 and 85 completed', 'between 25-45 years', 'between taking the radiological records', '≤ 10 × upper limit of normal', '>= 70|Ability to read', '>3.38 mmol/L', 'Over 30 years', '> 3 times the upper limit of normal|History of', 'than 60 kilograms|Current smokers', 'less than 1 cm from the treatment area.|Urinary', '18.5 to 24.9 kg/m2|Considered', '< 2.8mmol/L', '6 - 12 months prior.|Computer experience', 'class III', '0-1|Histologically', 'between 18-65 years|All', 'greater than 40%', '1.1.|Estimated survival time', '< 7%.|Fully dependent', '18-65.||Exclusion', '≥ 2.0×109/L', '<-2SD', '18-75.||Adapted', '<6.5%|Poor blood supply to the wound', '< 1.5 cm midline shift', '6-11 years', '<1.0 g;|At least', '18-45 years||Exclusion', '18 to 40 kg/m2|Elective', '≥ 2.5 times the upper limit of normal', '0 or 1||', '≥35 years|Diagnosis of Type 2 diabetes|Absence', '>=70|Patients', '≤ 10×ULN', '19 - 45 years', '≥ 1500/mm3', '<5 ng/L', 'greater than 1.5 times the normal value', '≤ 5 times ULN|No ascites', 'less than 60 ml/min/1,72m2;|Participating', 'greater than or equal to 18 years|Undergoing', '> 160 mmHg|diastolic blood pressure', 'above 25 apm;|Use', '>2.0|Activated', '30 - 75 years;|Normal', '>= 90g / L', '0 or 1.||Have', '> 18 years|ECOG', '30-50 kg/m2', '>25.0 to < 32.0 kg/m2', '< 18 years;|NYHA Class I or IV', 'scores < 25', 'between 18-75 years old', 'less than or equal to (<=) 10%', 'less than 1 %):||combined', '≥18 years.|Eastern Cooperative Oncology Group (', '>22 alcoholic', 'between 10 and 25 degrees|They', 'from (25-30kg/m2)||', '450-500 meters', '18 and older.|In', '12 months)|Self-reported', '>=50 years', '>17 units', '≥2 pregnancies', '>18 years;|written informed', '> 20%.|WD G3', '≤ 35 kg/m2|Untreated', '>90% sites observed|Probing Depth', '>1:100|History of', 'Between 18 and 40 years', '>4.0mu/l', '< 18 years:||Lansky performance status', '18-35|Volunteering to participate', '1-7 years', '1.18 years or older', 'more than three months|Those', '>=25||', '35-42,|Vaginal delivery planned,|Do', 'above normal', 'less than or equal to 2.5 × ULN', 'no more than 12 hours after surgery),|If the patient', 'equal to 1', '18-32 kg/m2||Additional', '>250 to <=500 microgram', '> 130 mm Hg', '18 to <40 kilograms/meter', 'therapy.|At least', '≥ 6 months|Adequate hematologic', '6 to 10', '< 25 ng/mL||a', 'greater than 42 cm', '≤ 9%', '≥12% and ≥200 mL', 'equal to or greater than 60 % and < 90 %', '≥ 2|Any degree', '21-45', '>20 mg/L', '>=21 Years', 'greater than or equal to18 years.|Eastern Cooperative Oncology Group (', '> 28 g/L', '≥ 18 years old||For A1 Group', '<=2 weeks prior to Day 1.|Use of any of the', '≤ 2.5x ULN', '< 9.0g/dL)|ALT/AST', 'between 6 and 17 years', 'TMS)||More than 3 depressive episodes', '> 20%.|Neuropathic', 'above 95% before entering the group', '65-79 years;|have access to the internet', '≥450 msec', 'score ≤ 3;||Normal hemodynamic indices:||Blood cell count', 'less than 24 weeks', '< 70% of predicted', '≤ 35 bpm', '50% of participants should', '> 20-25 g/d', 'score of 11 or greater', 'Grade II or above', 'Over 49 years old,|The', '15 mmHg', '>5% within 3 months prior', '> 20 kg/', '470 ms', '≥ 15/50);|Has', '< 10 disc areas (25.4 mm2)|Absence', '≥ 11|White blood cell count', '≥ grade 2.|History', 'less than 100/60', '> 105 pg/mL', '40 to 80, inclusive', '12-21', 'Greater than 5 prior deliveries||Non-pregnant', '15 to 39', '> 1.2 mg/dl', '≤ 1.5 × ⑤ the upper limit of normal (ULN)', '>2,000/microL|Absolute', '18.5 kg/m2 or more', '<50mmHg)|Electrocardiogram', '0-1;|The patient', '≥ 60 kg and < 110 kg', '< 80 years old', 'score <26', '≤ 5 × upper limit of normal (ULN)', '18 years', '< 30 days', '> 200 ug/', '> 1.5 times the upper limit of normal range', 'Under 40 years', '9.0% or 24-hour urinary protein quantification', 'more than or in addition to power', 'between 1-3 daily oral medications', '≥1% tumor', '18.0 kg/m2 or more', '< 3 years', 'greater than 18 years.||', '> Grade 1.||*White', '≥45mL/min', 'plantar fasciitis', '≥18 and ≤ 30 kg/m2|Being', '>2.5 mL red', '< 30,000/µL at', 'February 17, 2014', '<1', 'four-week', '> 180', 'greater than 5×109/L', '60', 'between 18.5-30 Kg/m²|Subject', '> 3,|severe mental', '≥140 or ≤90', '>1.1 x ULN|Urine protein/creatinine ratio', '1, 2 or 3.||', '< 80% predicted and', 'at least 80% predicted|The participant', 'between midnight', '< 18 years and > 45 years.|≥13 weeks of gestational age|Multiple pregnancy|Smoking|Gastro-intestinal diseases', '18 kilograms/square meter (kg/m^2', '≤ 1.5× upper limit of normal (ULN)', 'Over 65 years', '<75 years', '> 500 IU/ml', '> 2.0 mg/dL', '18.0 - 23.9 months|without', 'less than 5 years duration|Recent HbA1c', '45 and older', 'above 24 kg/m2', '≥ 80%', '>= 12 months of age', 'less than 40 mg/dL', '≥100 ×109/L|Total bilirubin', 'sibling', '>=60 minutes', '>/= 1,500/microL', '20 /32)|Refraction', '12.5mg daily', '< 90 mL/min/1.732 m^2 calculated', 'class II or higher', '≤ 1.5 times the upper limit of normal|No', '> 100 bpm.|History', '< 500 cells/μL.||', '19 and older|is Parent or legal guardian of child enrolled', 'more than 450 lbs', '< 1.0 x 10^9/L', '2 to 16 years|Over', '≤ 1.5 × ULN.|Estimated survival', 'less than or equal to 45 milliliters/min/1.73 m2', '> 2500', '>1400 cm/s', '≥ 30 mm/hr', '0-2;|Adequate', '≥ 125 times/minute', '> 15 for males and >13', '18-65.||', '≥50 years;|Medical assistance provided by the psychiatry', 'score ≤ 2|International', '> 2 times per any week', '> 45 minutes', '1month to 6months', 'less than 1%', 'less than 18 years;|presence', '<19 on the', '3-6)|Measurable', 'lower than grade', '≥300/μL|Undetectable', 'grade III', '>25|Contraindication to IV', '>10 mg/day', 'greater than 30 cc', 'equal to 18 years', '18 to 30 kg/m2||Those', '≤ C.||', '18-30|Taking', '≤ 2.5 × upper limit of normal range (ULN)', '≥ 12 years and < 18 years', '≥ 25 mmHg', '60 years or over', '≥ 75,000 /mm3|CD4+', '20- 65 years', '≥ 50 copies/mL', '≥ Class', '18 years and above at time of enrollment|Subjects not', '<5 years', '61-80', '< 2 times upper limit of normal (ULN)', '25-35 day cycle length', '≥3 months.||Subject must', '21 to 75 years old|Able', '> grade 1;|Patients', '18.4-29.9 kg/m^2.||Exclusion', '19 ≤ BMI', '< 1.5|Activated', '≥90 g/L，total', '>22 years', '>3|Surgery', 'at least 1.5 cm', '≥30yrs|COPD diagnosis', '< 3 times ULN,|Creatinine clearance', '0 to 5', 'guideline.||-||', '16 to 19', '<0.6cm2/m2|Both', '40 - 70 years', '3 to 5 years', '=< 16 years', 'I-IIA', '12-18 years old,||- 2', '<6.5%|Satisfactory', '>110mmHg', '<60 days abstinence', '4-10 weeks', '18-100 years|Isolated proximal humerus', '1-patients', '>100 beats/min);|Low', '7.38-7.42', '18-30|Body mass index', '< 70|Presence', 'between recruitment-consent and start of the study|Physical or mental health limitations', '≥ 100,000 cells', 'classification II or III', 'stage C', '>= 18 years|Scheduled', '< 50 ng/dL', '≥100 × 109', 'more than 8%', '> 20%||', '50 puffs/day', '15 minutes apart', '> 99.5°F/37.5°', 'less than 70%', '< 1.5× upper limit of normal range (ULN)', 'at least 18 years', '<220 ms', '<6 months|Concomitance', 'score equal to 0', '>120 beats per minute', '> 9 g/dL|Platelets', '18.5 to 29.9 kg/m2|Willing', '≥ 18years||Hospitalization', '≥40 and ≤ 75 years;|Diagnosis', '≤ 2.5 × institutional ULN|Adequate renal function', '< 1.5 x 109/L.|Platelet count', '>4WU', 'more than 400 mL', 'below 30 nanograms per liter (ng/L', 'More than 29 days old', '>60 units/', '≥ 1.5 x G/L|Platelet count', '> 1.0 LogMAR', '80 years or older', '< 240/mm3).|History', '> 50,000', '< 10 g/dL', '18 to 99 years|Pre-menopausal', '<4 g/L', 'score of 8 or higher', 'grade 4 OA', '<=13.9mmol/L.||', '60 - 80 years||', '18-60 years.|Hip', '>35 kg/m 2 .|Patients', '<125 x 109/l.|Documented', '15-21', 'between 10 PM', '> 50%|pulmonary artery systolic pressure', '< 0.8 ng/mL +', 'greater than 30 IU/L).||Participant', 'between 15-32 kg/m2', 'less than 1 ng/mL.|Patients', '> 39 years', '20-38 years', 'within therapeutic range of intended use of anticoagulants.|Criteria', 'class II or above', '≥ 12 weeks|Phase I', 'greater than 8%).|Active infection.|Serum', 'between 65 and 74 years', 'greater than 10', 'grade 4|Individual', 'more than 2g/dl', '<30 mL/min|Bilirubin', 'greater than or equal to 0.8×10^9/L', '> 1.2', '< 35|Scheduled', '=< 40%|Receipt', '0 or 1||Pathologically', '<60%|BMI', '25-60 ml/min/1,73m2', '> 18 years.|Participant', '> 65mmHg', 'at least 12 weeks|Body weight', '≥ 40 mm),|Pain described', 'higher than 14', '2.5mm', '≥20 mm', '= 75 x 10^9 per liter', '≥4.0×10^9/L', '> 1.5 X institutional ULN', '< 2 × ULN', 'complete response [CR]', 'higher|At least 18 years', '< 1.5 ×ULN', '≤ AL ≤ 30mm', 'between 18 and 30', '< 14mmol/L', '≥60 years.|Age <60', '≥60 ml/min', '< 1 g.||Blood coagulation function', '> 185 cm/sec', '≥ 18 years;|Acute', 'less than 30', '17 years', '1 year - 3 years', '< 1 weekly stool)|Chronic diarrhea', '≤ 1.25 times UNL', '10-20;||', 'higher than 110 mmHg', '1 D to 8 D Astigmatism', '≥160 mmHg', '≥ 9 g/dl', '≤ 1||Normal', '≥3 months|Willing to', '1-10 visible', '> 30 g/day', '0-18 years', '<=2 weeks', '1 ≤ FAC ≤ 3);|Diagnosis', '<1.5 times the institutional ULN', '>115', '18+ years)|Patient', '>23)|Age', '< 12 months|Pregnant', '< 3 mmol/L', '≤ 1.5 times ULN;|Normal thyroid function', '≥90g/L;|liver', 'mm；|Suitable', '=< 60 days prior to pre-registration.||PRE-REGISTRATION', '≥18 years 3a', '18 or greater', '8-20 mm', '≥ ""11"" will also', '<=1750 mg/L', '>1 pack/day', 'above the upper limit of normal||xi', 'Menarchal', '> 2500 g|Weigh', '>1.5 x ULN per discussion', '100-299 µg/l', 'Under age 65|Individuals who do not', '6-month mortality', '≥ 100 x 109/L.|Renal function', '0 or 1|Participants', '≤ 35 kg/m2||', '≥ 3.0×10^9/L', '40.15 inches', '< 10^9/L', '<2.0 mg/100 mL.|Total bilirubin', '≥2.5 × ULN', '≥ 1),|4', '≤80 years old.||Fit to the definition of', '>1.5 x ULN|Serum', 'between 18.5 and 24.9 Kg/m2.|Patients', 'permanent', '<25%;|Diagnosis of', 'NIV+/-HFNC', '2-patients>18', '>160).|Pregnant', 'more than 400 ml', '65 or greater', 'at least 20', ""20 to 60's year old"", '≥45.0kg', '≥470 ms.||Current', '> 2 X ULN', '≤1.2 mg/dL', '+/- supercharged', 'deeper than to the outer third of dentine', '18.5 - 35 kg/m2||', 'A or B', '+6 weeks', '>5% change', '≤ 25 μmol/L', '48-60 years', 'score of 17 or more', '≥200 ng/mL).|Subject', '6-12 years||Confirm', '≥ 110)|History', '<50 D', '> 4 mm|Class I or II', '> 2.5 x ULN|Lactating', 'I & II)|knee', '>92%|No use of pressors', '< 30%|Severe respiratory', 'under 16 years old|Participants', 'American race|Age', '27 or greater', '≥ 50,000/', '> 3 cm', 'stage IV malignancy|Any', 'greater than or equal to 30).||', 'greater than or equal to the', ""> 3x's the upper limit of normal"", '≥ 21points', '>99.5 °F/ 37.5 °C', 'levels ≤ 3 times the institutional upper limit of normal (ULN)', '2.5 X ULN', '18 - 75 years', '18-75 years;|Prediabetes;|Body mass index', '< 0.7.|Subject', 'diet|Scheduled to receive', '> 2,000 IU/mL', 'infarction;|More than 18 years', '≥ 0.3', '40-65 years|Both', '≥ 40,000 IU/wk', '60-89 mL/min', '> 18 years|Not', '= serum glutamic pyruvic transaminase; ULN = upper limit of normal.||', '>30 g fibre/', '>= 0.2 ng/mL|Age', 'above 159/99 mmHg', 'less than 5 Diopters|NPDR levels', '<90/60 or > 140/90', '>= 2 years and < 18 years', '< 1.3 x the', '> 76', '<25%.|Subject', '≥ 75 × 10 ^ 9/L.||7', '> 2500/ μ', '≥ 1.5 x 109/l', '75,000 per mm3);|Serum', 'between 18 months', 'Score of class', '≥ 90 g/L;|Neutrophil', '45-80 years|Volunteer to participate', '≥ 28/30', '11 to 27 years|Included', '< 3months', '60 mL/min', '<200 copies/mL obtained', 'Long term medication', '≥ 60mL/min', 'level 1 and 2|Able to follow verbal direction for', '≤ 3 months before entry into the study|clinical suspicion / presence', 'less than 2||', '>44 years,|Three or more root', 'between 18 and 65 years old', '12-71 months', '> or = 18 years < 60', '≥2 x ULN|Stage 4', '=< 1.5 x upper limit of normal', '>=100,000/mcL c', 'elevation).|Hematologic disorder.|AIDS.|Advanced liver', '>50% stenosis', '35-65 years', '> 60 mL/min/m2||For', 'levels ≤ 1.5 × ULN', 'over 60 years old', 'for≥ 18% of', '>= 8 g/dL|Creatinine', '≥ 3 times upper limit of normal', '≤ 1.5 times the upper limit of normal.||', '50 years or older', '35 kg/m2;|Capable', '> 12 months', 'class I- III||', '≥ 5 (inclusive)', '≥100×10^9 /L', '> 3x/week', '< 18,5 and >24,9 Use of', '1-2|Being', '≥ 480 milliseconds', 'less than or equal', 'greater than 3 years ago', '>70 mL', '>24-30||', '<60 mL/min/1.73 m2', '>38.0 °C', '^9/L', '≤ 1.5 x institutional upper limit of normal (ULN)', 'under 18|Intolerance of the ultrasound contrast agent SonoVue|Refusal of participation', 'between P and R waves (PR)', 'over limit of normal (ULN) range', '18 years or more||Criteria', '> 5 x ULN', '> Grade 1', 'maximum 36 month before enrollment)|Active cancer treatment', '> 35|Able to understand the risks/benefits of the study|Able to give', '≤ 500 cells/mm3', 'less than 10', 'between 13', 'B-cell-like (GCB)', '> 21 mmHg', '≥ 2mm', '>30 ml', '3)Bilirubin ≤ 1.5 times the upper limit of normal', 'greater than 20 Fr|Development of obstructive biliary symptoms', 'twice the upper limit of', '>35 kg/m2', '+/-', '>1.1', 'between 18 and 26', '< 23', '>33|Self-report', '=< 3.0 x institutional ULN', '≤1.5 x ULN', '> 10 mm', '<30 ml/min/1.73 m2,|Hemoglobin <10 g/dL|Gastrointestinal', '< 5 times the upper limit of normal;||24h', 'score of 3 or higher', '18.5<BMI<21', '≤2.5 x ULN|AST', '>70%|>18 y.o.|Informed', '≥ 90mmHg', 'no more than 2 times of the upper limit of normal values (ULN)', '>12 weeks.||The function', '≥ 30 to ≤ 59 mL/min/1.73 m^2|Mild RI', '<10)|Acute', '≥10 pack years|Pregnancy|Absolute', '<30%;|According to Cockcroft-Gault', 'score of ≤0.27', '>160|Diastolic Blood Pressure', 'greater than 150 mmHg', '> 18 years old|Patient is able to give', 'more than score 2', '≥ 125,000/µl', '50 ≤ DM 90', '18 to 75 years.|HbA1c', '<= 1.||Have', '>= 1,500/mcL', '>10 times of upper limit of normal(ULN', '> 4,0 IU/L.|Combined', 'Spanish|At least 18 years', '1 to 3 fibroids|maximal', 'at least 30 kg|Suitability', '2.|Age', '18 to 85', '<2.5 X ULN', '< 2.5 mg/dl|Aspartate', '≤ 5 x upper limit of normal (ULN)', '<1month', 'above 18)|Undergoing elective', 'V1.1;|At least 4 weeks after the', 'less than or equal to 1.5 times ULN;Activated Partial Thromboplastin Time (APTT)', 'score of ≥ 50%.||The', 'more than 21 units/week', '<2.0 x103/μL|Absolute', 'higher than 500 copies/mL', '0-28days);||Unstable', '< 75 X103/mm3', '> 18 kg/m2|Patients', '> 1.67 x ULN|Taking', '2h-PG', 'greater than grade III or IV', '< 8.0 mmol/L', '≥12', '45 years', '≥3 months;|Fertile', '≤10.5% if background diabetes medication', '<76|Visit', 'English.|Older than 18 years', '< 3000/mm3', '≥50ml/min', 'within therapeutic limits', 'greater than or equal to 12 years;|One', 'Over 18 years old|Having the', '< 6 months)|Patients', '<30 ml/min/1.73m²|Subject', 'Early Learning Composite|severe', '<20 mL/min/1.73m2|Any', '>200', 'I-III|Between', 'between 2% to 20%|Females of', '≥ 16 kg body', 'greater than or equal to 50%', '≥18 and ≤30 kg/m2', 'more than 1.5 upper limit.|AST', '< 1000/mm3|Pancreatitis', '>2x/wk|premenopausal', '≤ 5 cm', '≥ 200 mg', 'long-term care facilities', '65-110 mmHg', '> 3).|Any medical conditions', '<50', 'older than 70 years', '≥ 100 × 109 / L|Serum bilirubin', 'greater than 35 kg/m2|Individuals', '18.5 to 30.||', '> 50 mL/min/1.73m2.|Absence', '18 - 40 years||', '≤5.0-fold the ULN of the study site', '1, and 2||', '≤ 0.1%)|Myelodysplasia|Acute lymphoblastic', '≤ 6cm', 'under 36 months|scheduled', 'between 18 and 32 Kg/m2.||', '2-4 mm', 'score of 16', 'at least 16 weeks ago|Only applicable', 'above population mean', 'A according to', '60kg or lower', '≥75×10^9/L|Creatinine clearance', '≥75 x 109/L', '< 3 x ULN.|Alanine aminotransferase (ALT)', '≥ 6.|A new', 'above these', 'inpatient', 'between 18-40 years', '>18 years|interested', '>= 60 mL/min', '20 to 45 years', '> 1.5 x 109/L|Hemoglobin', '≤ 3 * institutional ULN|Creatinine ≤ 1.5 * institutional ULN', '18-75 years;|ASubjects', 'more than 42 mmHg', '≤30 kg/', 'less than or equal to the upper limit of the normal', '2.18-60 years', 'gender|older than 18', '>3x normal', '≥ 17.1 μ', 'from three qualified ECG screenings', '>85', 'less than or equal to 49%||', '30 minutes', '> 10%|Evidence', '> 500 ms.|Patients', 'between 1-5.5,|To', '<30 ml/min/1.73 m2', '0 to 1|No', '≥2+ and 24h', '>130μmol/L', '≤ - 3', 'at least 110', 'at least 10', '≥90 mmHg)|8', '16~32 kg/m2', '≥130 mmHg', '18 - 41 years', '< 37.5°C', '≥95th percentile', '≥ 18.0', 'higher than 100 mmHg', '≥ 100 x 10^9/L', '≥10', '>4|Participation', '> 3 times the upper limit of normal);|the presence', '≥50% of tumor cells stained', '≤ 100 x 10⁹', '> 18 years old.||', '> 6 cm below the left costal margin', 'II or', '100×109/L', '18-40 kg/m2', 'between 10 and 16 years old', 'greater than 50% above the upper limit of normal|If sexually active', 'lower than 50%', '= 2.59 mmol/L - 4.89mmol/L|Body', 'I/II Ab', '>= 18 years < 65 years', '< 0.80', '> 10mmol/L', '1 - 2|Age', 'less than 60°', '<30.||', '<5%', '< 20 kg/m2|Body', 'greater or equal to18 years|Outpatients|Patients', '>5 cm', '18-40.|Nullipara', '> 450 ms', '≥ 38°C', '> upper limit of normal', '< 27|Inability to speak', '≤ 3.0 × upper limit of normal', '-C screen score|has', 'greater than 160 mmHg.|Patients', 'between 20yrs-40yrs|Tenderness', '10^4 copies/ml', '6-15 months|Voluntarily consented', 'score ≥5', '62-169cm)|Participants', 'partial removal dentures.|Tumour(s', '-4a', 'from 4yrs to 12yrs', '>17', '=< 15 days prior', '> 70%', '>50% all planes', 'Female|Over 18 years', '18-28 years', '≥115 g/m2', '6-10 weeks', '30-60mL/min', '>30)|severe arthritis', '=< institutional upper limit of normal (ULN)', 'greater than or equal to (>=) 6|Participants', '< 70,000/mm3', '>30 mg', 'pituitary', '>4.5h', '>= 50% of predicted', '≥ 2 × upper limit of normal [ULN', '4 - 21', '≥ 21 years.|Histological', 'between 19 to 50 years', '100-599 mg/dL', '≥12 weeks,|Immunocompetent,|Positive research', '≤1.5× upper limit of normal value (ULN)', '≤ 3.0 x upper limit of normal', '<2 doses of Hib', '< 50 mL/minute/1.73 m2', '< 100,000/uL)|Morphologic', '≥ 1.5 times the upper normal', 'greater than 70 U/day.|Patients', 'greater than 2 times the upper limit of normal|Abnormal TSH|History', '>= 50% =< 15 days prior to registration.|REGISTRATION', '0 to 2||Adequate', 'longer than 1 hour', '≥ 60 mL/min;|Total', '< 55 years|BMI', '18 or older.||', '<30ml/min/1.73m2', '≥13 to <18 years|If they', '3_18 years', '<65 years', 'up to -12 dioptres', '< 50 mmHg', 'lasting more than 5', '10 - 17', 'between 0.4 - 4.0 mIU / L|aPTT', '35-45', '0-2', '6 to 12 years|The', '>/=150,000/mm3|HgB', '3-4', 'outside the range', '2 or above', '55 - 65 years', '≥9 g/dL|Absolute', 'score of at least 4', '<1 year|Any factor', 'pH ≤ 7.0', '>= 84 days after TBI', '=< 2.0 mg/dL', ""between 18-65|presenting to the general practitioner's office|with depressive symtomatology||"", '> 60/min', 'older than 20 years.|Histologically', '≥45% predicted', 'between 73 and 34 letters', '≤ 5 × ULN）；|6.3', '> 5 mL/kg', 'greater than 4.5 inches in length|Able to follow directions', '6 mm', 'less than one year', '≥1×109/L', 'greater than 180 mm Hg systolic', '≤ 90 mmHg', 'normalized reference values).|Weight', 'equal to or higher than 90g/L', '1)Neutrophils≥1.5*109/L', '> 18 years;|recovery from', '≥ 30 breaths per minute', 'greater than 18|Upper extremity dialysis graft/fistula||', '<30 years', '≥ 100 000/µL', '≥7.0 g/dL', '0-2.|Life expectancy', '21～31 kg/m2', 'greater than 35 kg/m2', '≥ 0.25 D over', '> 10)|Use of', '< 4.9 mmol/L', '≥10^5 cfu/ml', 'II-III degrees', '<10 mmol/L', '<24 h', '18 years and older|Decompensated', '< 22 cm', '> 120', 'decrease to <90 mmHg', 'between 40-60 years', '22-01-T0037', '21-65 y/o|Receiving pap smear', 'Stage IV NSCLC|Eligible', '≥18 years.|Negative pregnancy test', '18.5-24.9 kg/m2', '< 6 abnormal', '≤ 60%', 'at least 10% of each other.|Evidence of abnormal bioimpedance ratio', '≥ 30 ml/min/1.73 m2|Age', '> 53mg/', 'more than or equal to 6.0 mmol/', '> 6 months.|The', '≥ 3 times the normal limits', '>= 5.|No prior', '≤1.5 times the institutional upper limits of normal (ULN)', '> 5.5 mmol/L).|New', '> 30)|Systemic disorders', '≥100 x 109/L', '18 to 65 years.|Participants', '≥18 and ≤65 years', '< 30 ml/min)|Known psychosis', 'between 18.5 to 27.5 kg/m².|Able to understand and provide signed informed consent prior to study enrolment.|Willing', 'levonorgestrel 52 mg', '>24.|Right-handed', '≥75 years|Benign gallbladder', '≥ 38.5℃', '18 - 85 years', 'above 18 years||', 'above the 90th percentile||', 'letter score', '≥ 50 mL/min.|Any', '0 - 14 days|Born', '30 to 220 mm|Reference vessel diameter of 4 - 6 mm|The', '> 60 ml/min|No', '3% or greater', 'I to III|Patients', 'long-term topical', '≥ 90 g/L;|Serum', 'above-the-knee', '55 to 75', '5-21 years', '< 2.5 x institutional upper limit of normal (ULN)', '<6).|IVT', '≥ 1.6', 'less than 4 weeks prior to study treatment start.|Major surgery', '< 1.5 times the upper limit', 'gender|08-14 Age|Visual acuity', 'I-II|posted', '> 120 μmol/L', '1/2 antibodies).||History', '16 ≤ EASI', '<2.0|Willing to participate', 'over 65|Proximal femur fracture', '3 to 12).|Willingness to give', '58-91 millimoles per mole', '3-4)|Patients with asthma', 'between 50 - 79 years', '2-6 years|Being', '>= II', '90 mmHg', '≥ 18 years.|Histologically verified non-metastatic', '> 18 years|type 1 diabetes', 'less than 1 % per year', '> 18 years;|Indeterminate', '10 to 30 years|diagnosis', '≤2.5 X upper limit of normal (ULN)', '+/- 1 year)|study level matched', '≥ 18.5 to < 30 kg/m2', '≥ 18 and ≤ 75', 'greater than the upper limit of the normal value of the laboratory department of the research center)|Contraindications to metformin', '> or = 18.5 kg/m2', '≤ 20 points', 'higher than the maximum FDG uptake', '≥1 year|Subject', 'greater than moderate)||c', 'older than 80 years', '< 2+ or 24-hour urine protein quantity < 1g', '<2 cm breast cancer;|clearly visible', '18 years to 64 years old', '200~1,000 mg/g Cr', 'less than or equal to11 g/dL', '<50.000 per μL;|Inability', '>5).|Participants', '0, 1 or 2|Able', '12-18/min|PO2', '12-24 months', '90g/L', '65-85', '>70 years', '>140mmHg', '≤ 42.3mg/FEV1 %f all', '≤ 1 x ULN;|The patient', 'score of ≥5', '≤ 250 mg/dl.|Female', '>= 9 g/dL', '+/- prosthetic rehabilitation,|children', '= 50', 'level II repair)|Genital hiatus', '0-1 point.|Histologically', '6mm or greater', 'energy meter', 'above the shoulder line', 'after age 40 (', '< 18.5 or ≥ 35;|Outpatient or day', '<18 years old|MI', '18-65 years;|Have', '0.7 109/L;|6.2', 'exceeds 1.5 times the upper limit of the normal range', 'eighteen', '<0.70', '>2.5×ULN', 'above normal reference', '< 1.5 x upper limit of normal (ULN)', '6 years;|Subjects older than 10', '≥21 years;|living together with the', '≥ 18 and ≤ 80 years.|One', '+ - 6', '4-6 weeks', '>1.5 × ULN|Aspartate aminotransferase', 'between 18- 50 years.|All patients', 'upper limb fractures;|Level', '≥41 contiguous', 'equal or less than 3 times the upper normal', '0-1.|Patients', 'between 8-17 years', '> 30 mIU/mL', 'greater than 8.0 g/dl|Serum ALT', 'at least 30% of subjects', 'score of ≤ 2', '>100mmHg', 'between 11-19|They', 'score ≤ 4;|Living', "">0.2 nmol/h/mg|Participant's parents or legal guardian consent to participate"", '≤ 93% OR|PaO2/FiO2', 'greater than or equal to 13% taken at or within 3 months of the initial screening', 'suitable', 'tracheostomy|Do-not-reintubate', '1 or more first degree relatives', '> 60 years|Patients', '75 x 109 / L;||ii', '< 1.5 x institutional upper limit of normal', 'over 12years', '>40°C', '>18|Stage I-IV', 'greater than 1.25-times the upper reference', 'First--degree relative', '> 1;|Clinically significant', 'from 18 to 35', 'Novice', '>2.8 m/sec', '>14 years|chronic', '< 100 beats/min', '≥150 minutes/week', '>0.2 ng/ml', '≤ 2|Patient', '2 to 11 years', '< 1500/mm3|Platelets', '<18 or >40 kg/m2.|Currently', '<8||Mild', '< 35 Kg/m2.||', '≥18 years|Diagnosis of head and neck cancer', '≤ 2.5 × institutional ULN', '≥50 to <85 years', '≥ 100 mg/dL||viii', '>500 pg/mL', '≤1.5 × upper limit of normal (ULN)', '≥ 100 × 109/L', '0 or 1|Women', 'II or above', '< 35%)|local infection', '< 70%', 'between 18 and 32 kg/m^2||CHB participants:||CHB infection', '< 30.0 pg/ml|Self-reported', 'less than 80% of the lesion', '> 5x ULN', '33 mmHg|Use', 'more than equal to 30', '> 5 x ULN|Total bilirubin', '0-2|Must', 'greater than 18 years old, inclusive.|Pathologically confirmed', 'from equal to or greater than 12 years old to less than 18 years', 'Functional Class', 'greater than or equal to 10', '> 1.5 × ULN', '7-8mm|Patients', 'greater than or equal to 8.0 g/dL', '18-70|At least 2 hours', 'III or more', 'between 18 and 42 years', 'equal to or more than 60 years', 'between 18 and 32 kg/m^2', '≥ 18 years|Signed written informed', 'less than 45ml/min', '18.5 to 29.9 kg/m2', 'less than 40 patients|Concurrent', '<9.5 g/dL', '>3ULN|Total bilirubin', '< 1.0g;|For', 'between 1st January 2002', '18-75', 'greater than 100 beats per minute', '>5 mEq/L)|Hypercalcemia', '15-month study', '1 or 2||', '>800 pg/ml', '≤ 3× times upper normal limit(ULN', '<30 milliliters', '500 µm|Residual stromal', '< 60 mmHg', '≥10 within 7 days prior to entry', '38°C', '> 6 months|critical illness', 'degree II or higher', 'greater than or equal to 25', 'greater than 110 mm Hg diastolic', '>64 years', 'less than or equal to 95 mm Hg', '90-100mmHg|Female', '> 22 mmol/L||Patients', '1.5 × institutional upper limit of normal', 'lower than 90', 'lower than the normal', '≤ 1.5 × ULN；||After the completion', 'between 18.5 and 25 kg.m2||', '> 130 beats per minute', '≥ Grade 2);||Medical', '≥ 50ml/min', '>= 20%', '≥ 15 per high', 'greater -1.00 D and', 'male).|BMI ≤ 30.0', '> 470 milliseconds', 'participants|Full term', '≥140 mg/dL', '>=15%', 'score of 0 to 2.|Subjects', '< 60g/L;|Patients', 'less than 3 mm.|Tumor', 'between 3 and 12 years', '< 30 km·m2||', 'FiO2)≤ 300 mmHg', '≥ 100 * 10^9/L', 'between 18-45 years|Any', '28)|≥18 years RVEF<50% (', '15-28 points', '>12 wk', '>0.30 mcg/kg/min', '>0.5 mg/kg/j before', '>21 mmHg', 'between 4 and 12 years,|spasticity level MAS≤2,|mental level sufficient to understand commands given,|and', 'for at least 12 weeks.|Willingness', '≥ 200mg/dL', 'from 18-65 years.|body mass index', 'between 18 and 75 yrs old||', 'greater than the extent of fibrosis', '15-24|sexually active|identifies', '> 5mm', 'antibody test.|Presence of Hepatitis B surface antigen (HbsAg)', '> 1.5 and ≤ 2 x ULN', '18 to 75 years|Histologically', '>2 times the upper limit of normal (ULN)', '≥18 to ≤80 years', 'tissue slides', '0-1;|(e', '> 2.0 times the upper limit of normal value', 'less than 6 months prior', '≥150 mg/dl', '> 400 mg/dl', 'between 1cm and 3 cm', '24-32 days)|Those', '≤60mm', '< 39.9 kg/m2.||', 'between 18 and 70 years old', '< 150 days prior to study vaccine', '> 2.50', '> 18 years|Clinical diagnosis', 'score ≤ 2', '> 70%.|Participant must demonstrate', '>90 to ≤120 mL/min/1.73 m2', '<18 years|Poor understanding of the Spanish', 'distant metastatic disease', '> 1.0g;|Patients', '>37.9oC', 'more than 70% stenosis', '<70 g/L', 'over 65,', '18-44 y|Are able to swallow the iron pills', '13-16).|Refractive error', 'between 8 and 18 years|Planned', '≥ Grade 3', '18-60 years.|ASA', '10.5-13.5 months', 'I to V of the neck', '< 92% in ambient air', '>= 1000/uL', '< IV', '≥2.5 × upper limit of normal [ULN', '19 or higher', 'below 50 mg/dL.|Those', '≤ 20 kPa;|Signed written informed consent form.||', '> 34 weeks|Infants', '<9.6 g/dL).|No', '> 2).||', '18-65|Have', '≤ 2.5xULN;Hepatocellular carcinoma', 'under 18 years', 'less than 150 kg|Patients', '>5 mm', '≥55 years', '6-17|Removing flexible', '>140 or <90 mmHg', 'before first dosing >70 mmHg;|Ability to provide', '< 1500', '≥100*109', '> or = 2.5 mL', 'longer than 2 hours|The patient', 'greater than 17', '≥ 15|Presence', '> 30kg', '≥ 90 g/L', 'between 1-3 days of the postpartum period|Women', '≥ 18 years|Plan to obtain the majority', 'grade ≥1 diarrhea)that', '≤ 5.0 times the upper limit of normal value', 'at least 2', 'older than 18 years old', '>60 mM.|Subject', 'smaller than 20 years', '>5 min', 'between 20 and 65 year.|Fasting', '> 24)||', '4 times daily|5', '19 and 69,|American Society of Anesthesiologists (', '18 to 45 years;|Conform to the', '< 60 ml/min', '< 100 x 10^9/L).|Presence', '<3,5 mmol/L', '>50|Morning stiffness', '≥30 kg/m2),|Hypersensitivity', '>=100', '>18|Patients', 'exceeding 480 milliseconds.|Current presentation', '<24.9|Are pregnant', 'more than 37.0', 'higher than the lower detection limit of the research center.|19', 'I', '< 60mL/min/1.73m²|History', '10-16 years|Cobb', '<30 min', '<24 cm', '≥10,|identify', 'from 25 to 75 ml/min/1.73m2', 'less than or equal to (=<', 'less than or equal to 10.5 g/dL', 'grade of', '>30 minutes', '30 to 55 years inclusive', '=< 7 days prior to registration', '≥ 18 years||diagnosis', '≥ 18 years who', '18 to 30 kilograms per meter squared (kg/m²', 'less than 18.5.|Relevant food', 'Functional Classification|Chronic obstructive pulmonary disease', '50-90.|Ability to understand', '35|Pregnancy|Severe obstructive', '≥ 75 ×109/L', '140 - Age', '≤ 20%', '<= 10 days from diagnosis', '≥ 1.5 times the upper limit of the normal value', '18-25 kg/m2|Understanding', 'More than or equal to 18 years old', 'greater than 90 days', '< -3.0).|Presence', '< 10c/day', '3-5，category 3', '≥ 15 mm', '> 30 ml/min', '8-18 years', '18 years or above|Participant is willing and able to give informed consent for participation', '≤ 1.5 × ULN；|3', '>95|Heart rate <92||', '<18 years|Pregnancy|Epilepsy|Medication that reduces the seizure threshold', '4 to <18 years|Bariatric surgery', 'between 50 and 60 years old', '<100', '> 0.4 ng/mL', '100-300 ng/mL', 'lasting > 24 hours', 'score of >2', 'APTT>1.5×ULN', '<1 year|Patient', '≥50% FiO2 need', 'above the detection limit of the analytical method', 'grade II-IV', '≤3.0 times the upper limit of normal', 'longer than 5 half-lives);|Those', '< 30 ml/min|Liver', '<4 kg', '≥1.5×109/L;||Platelet', '≥ 200/', 'critical drop', '>7/10)|severe', '2016);|Relapsed', 'from 5mm to 7mm', '≥400 cigarettes/year)|Known', 'above 40 unit per liter (U/L', '22C3 pharmDx)|Melanoma cohorts', '≥ 100 × 109/L；|HB', '18.5 to 32.0 kg/m2', 'residents.|Greater than 18 years', 'requires special precautions', 'at least 25 degrees', '< 18 and > 45 years', '18-35 years', '≥10kg.||Patients with', 'greater than 400 mL.|There', '≥ 4 points.||', 'newborn,|37-40 weeks', 'less than 1 month.|Patients', '3 to 18', '24 hours', '≥ 30 g/L', '<1.5x109/L', '≥ grade II', '>= 3 months|Evidence', '<6.5cm', '12 to <18 years', 'less than or equal to 8 weekly', '6.0-6.4%', 'from 8 to 17 years|Female and male', 'over eighteen years;|presence of', '<50%|QTc interval', 'form|18-70 years', '≥ 3.5×109/L', '> 18 years|Diagnosis of heart failure', '>100 pg/ml', '30-45|Have', 'score', '20 Caucasian', 'long-term oral', '≥ 4,9 ng/ml||', '<100,000 or >600,000|Urinary protein', 'HCV-RNA', '≥ 1.0 ×10^9/L', 'sarcoma.|(2)younger than 18 years', '≤ 50bpm', 'maximum three times per measurement)|Been informed of the nature', 'between 18 and 80', 'between 18 and 35 kg/m2|Willingness', '≥ 4 and ≤ 9', '<13 weeks', '13-25 years', 'fewer than 5 medications|Currently', '< 2.5 x ULN', 'less than 50 or more than 100 beats per minute', 'less than 30%|Known', '18+ years', '-7 to', 'score of 0.5 or higher', '5%', '1.1 criteria).|Have received', 'between 35 and 65 years', '<90% of birth weight', 'between 11+0 - 13+6 weeks', '< 18 years|surgery', 'between 40 and 65 years|Type 2 diabetes|naive', '> 180.|Heart rate', '> 2 ULN|For inclusion', 'facility;|LVEF ≤ 40%', '18.5 to 35.0 kg/m2', 'score of >3.5', '= 4 to 6 mm', '≥1-point', '≤ 3xULN||Individual who', '<45mL/min/1.73m2)|Complete', '≥ 4)||', 'long-term drinking', '< 500 cells/μL.|Haematological neoplasia', 'more than or equal to 85 mm Hg', '< 50 milligrams per deciliter', '0 or 1|Time', 'from 10 to 20.|FVC ≥ 40 %', '1 of the study', 'less than one', '≥3 year', '≥ 18 years and ≤ 75 years', 'exceeding 100 ng/mL', '< 30 ml/min/1.73m2', '> 50 IU/dL.|Any', '≤ 40%|Ferritin < 100 ng/mL', 'four or more', '6', 'score is', '≥18 years||Immunocompromised', '≤ 30.|Have', 'from 2 to 10 years.|Sex', '> 24', '> 18-year-old', '18 years or older.|Subjects', '>90cc|Comorbidities', '> 12.0 x10^3/mm3', 'less than 3 months', 'less than 40 mm', 'between 5-7|Ability', '>= 50/mm^3', '4-8 years', '50 kg', '≥ 60 ml/min', 'less than 1% per year.|Signed written', 'above the lower limit of detection of the assay);|Had', '≥2% 6', 'below 25 g/day)|Pregnant', '>12 months).||', '≥ 18 years|Need', '>=18 to less than (<) 30 kilogram per square meter (kg/m^2', '> 140/90', 'greater than the upper limit of normal value', '0-10', '≤ 1.|Intention to treat', '< 70|presence', 'between 18 and 43 years old|and', 'more than 499 mL', '< 60 ml/min/1,73 m2', 'greater than or equal to 50 years old', '11 g/dl', '6 to < 10 years', '≤ 1.5×ULN.|Renal function', 'I - III|Both genders.|Height', 'Long-term', 'ANC)≥1.5×10^9/L', '≥ 1:80', '≥30 and <50kg/m2-At least three', '< 50 ml/min/1.73 m2)|Body', '≤ 10 mg/day', '5 to 17)|Affiliated', 'more than18 years.|Healed edentulous area', '3-4.|Secondary Epilepsy', '> 55 mm|hypertrophic cardiomyopathy|valve disease', '<500mg', 'between 6-12 years.|Co-operative', '≥ 0.5 times the lower limit of normal', '> 50 kg/m2|Atrial', '≥100 x 109/L|haemoglobin', '>= 3 years', '= partial thromboplastin time', '>1.7.|Patients', '1: 18 to 32 kg/m2', '>51%', '15-29 millilitre', '≥10% extent', 'between 19.0~26.0kg/m2', '0 to 1;|Estimated', '> 38°C', '< 7.5 cm', '+ 5 mm.|Inability to treat', '18-65.|To', 'more than 3 months.|The', '≥100 mmHg);|Have', 'greater than 28 kg / m2', '41 - 150 µg/L', '≥ 50 mL/min;||Coagulation', 'between 18-65 yrs|IMC', '40-65 year.|Perform greater than 4 hours per week', 'Less than or equal to 160 mm Hg', 'Class III or IV', '6 to 24 headache', '< 13 years 1.2 1.2 13 to < 16 years 1.5 1.5||≥ 16 years 1.7', '15 ng/L', 'between 60 and 75 y inclusive|BMI', '≥ 185 mmHg', '≥ 1.0 U/mL]).||-||', '≥9.0 g/dL', '≥ 1.0 x G/L', '≥ 8.5 g/dL.||12', '> 10 mg / day', '>3 times the upper limit of normal [ULN', '>/=3 (female', 'frequently than 1x/month', '<3 yrs', '20 years to 80 years|Type II and III', 'greater than 1 mm', '> 700,000 cells/mm3;|Total', '< 50kg', '≥3).|The survival', '>10mg/day', 'changes≤5% in the 4 weeks prior to screening.||', '≥100/min', '1.5 x 109 / L', '> 3 hr/week', '45-65 years', 'Children displaying', '≥ 70 years|Symptomatic severe', '< 7.0mmol/l', '<150', '>160mmHg', '0-1|HCC', '30-59 mL/min', '<60 beats per minute|Arterial blood pressure', '<50 ml/min.||For', 'second dose', '18-70 years);|For the 100 chosen subjects identified for Phase 2', '≥18 and ≤75 years', 'older than 65-year-old', '>1,9 ng/dl', '< 1000 IU/mL', '23-C', '> 12 mg/dl.|Patients', '150 mL of', '10-18|Cobb', 'occlusion', '≤ 2.2 l/min/m²', '< 100 mmHg|eGFR < 30 ml/', 'between C3 and C7', 'under 270 Lpm', '>40 D and', '30 - 70 YO)|BMI', 'greater than 1 x 103 copies/mL', '> class II', '=< 2.5 mg/dL', 'under 40 ml/kg/min|participated', '18-30|Not', '65 or over', '2 years or older', 'II patients|18-45 years', '< 1.5 times of the upper limit of normal', '≥ 10%.|Serum M-protein', '0-30);|being', '<=2.5 X institutional upper limit of normal', 'Class II alterations', '< 30%|Chronic heart failure', '< 100 x 10^9/L|Adults legally protected', '> grade 1', '>= 50 copies HIV ribonucleic acid', '18-70 years;|Body condition score', '>20', '>2.2', '≥ 1.5×109/L.|absolute', '1-18 years', '> 15 ml/min/1.73 m2', '< 0.5.|Necrotic tissue in leg wound', '≥18 years|partnered', '>30 BMI <17', 'after 2 minutes of standing', 'more than 18.|Patients', '≥ 6.5 mmol/L', 'score of ≥ 28*||The ADHD-RS-5 score', 'Meets', '> 30 ng/ml', 'more than 120 IU/L', 'greater than 0', '≥75×109/L', '≥18 years|Patients', '0-100-mm', 'older than 1 year', '> 90 mmHg.||Clinical', '≥3 mmol/L', 'lower than 30%', 'above the ULN.|Positive test results', 'between 3-17 years', '≥ Grade 2', 'allowing exception to this criterion', '≤2.5 × ULN', '10 -25 degrees;|No', '<70%|Identification of', 'Sub-registry.||', '4 to 7)|Willing', '/ 50mg/dl', '> 1.5)|If the patient', '24 points', 'equal to or greater than 20/30', '≥ 100×10^9/L', '>2.5x the upper limit of', '<100 kg||', '0.1', '≤ 2.|Subjects', '1/2 mutated cancers', '<5.|Cooperation and understanding to strictly comply', 'over 65 years', '40 mmHg', 'between the time they are first contacted', 'greater than 2 mmol/L', 'from 18 to 70|American Society of Anesthesiologists (', '≥ 2).|Prior', '≥1.5 times ULN', '≥0.8× 10^9/L|Platelet count', 'between 12 weeks 0 days of pregnancy', '≥150,000/mm³', '> 4|Aged over 18 years', '< 7,0 kg/m2', '≥ Grade III;|Cardiac', '> 20 years', '≥ 4.0 × 109/L；||Absolute neutrophil count (', 'neutralizing', '≤ 2|3', 'score of ≥', '> 12x109/L', '< 1 year|Currently pregnant/breast feeding', '< 30%|Platelet count', '>12.5', '3 or higher', '< 30 ml/min', '> 190 mg/dL||ix', '> 3 units/day', '≤ 2 x ULN', '>/= 4 times the ULN', 'between 18-42 years', '> 60 mL/min', '30%', '>= 25 kg/m2', '=< ULN', 'E1-E3', '≤ 10.5 g/dl||', 'score of 14-26', '<50 years', 'less than 45 ml/min|Severe', '≥ 50%|Estimated lifetime', 'greater than or equal to 0.5 cm3||e', '6-15-month-', '< 50 ml/min.|Night-', '≥ 0.5 × 109/L', '< 50 copies/mL', 'more than 5', 'under 40 years|Insufficient', '<60 mL/min.|Patients', 'between 30 and 60', 'below hip height', 'less than 1 SD compared', '65', '≥ 1 cm', 'than or equal to the upper limit of the normal range', '100mgx2/day', '<26)|Actively', '0-1.|No', '18-75;|open', 'over 160 mmHg', 'less than 80% of curriculum', '≥2400 U/mL|Presence', '≤ 12 months before start of study treatment.||Patient', '≥ 30 mg/kg2', '<10% change)|Willing to maintain', '> 50 ml/min', '45-70 years|Signature', '≥35', '<30|Female patients', 'grade A', '≤6 years or', '<5 x ULN|Ability to understand', '18 years or older|With', 'score ≤ 24 points', 'between 25-65 years-old|single tooth loss', '< 60 cm H2O', 'Smoker|at least 18 years', '≤ 5ⅹULN', '>18 years|Paroxysmal', 'less than 2 years|Pain', 'less than 12 of', 'between 50 kg', '18 - 90 years', '>2|Diagnosis', '≥16 years,|A', '≥ 100 x 109/L|Haemoglobin', '≤ 7|Focal', '20 - 35 kg / m2||Inclusion', 'from 18-75 years', 'more than 10 mm', 'above 150', 'below 37.5℃', '> 4 ULN', 'less than 4', '> 18 years|Peripheral artery occlusive disease|Eligibility', '<3 x upper limit of normal (ULN)', '< 3 months prior to the', 'non pregnant', '0 or 1.||Laboratory values', '10^9/L', '<500/mm3', 'I - II|Body mass index', '<40 kg/m²);|Use', 'less than 6 months.|Decision', '16-53', '24-28 weeks of gestation,|OGTT', '35-55 years|Diagnosis', '<90 millimeters', '< 90 mmHg)|Refusal', '≥ 10^3 copies/ml', 'between 18 and 85 years;|Generally', '< 120°', '60 years and over|Binge', '= weight /height2).|Health status', '<-3', '=QT/(RR0.33).||Correction of', '>29.9', '≥ 3.0 × 109/L', '18-65|Radicular', 'at least 5 half-lives', '20 or greater', '1 Indications：Relapsed/refractory', '65 years and', '18.5-30 kg/m2', '<0.8×109/L', 'Adequate', '>50kg/m².|3', '≤ 15 ng/mL|diagnosis of', '≤ 2mm;|More than 12', '>= 50%.||', '> 350 pg/ml||', '24 weeks', '<= 1.5 ULN', '< 13;|(5', '18-45|irregular', '145 or less||', '>95 mmHg.||The patient must', '18 - 65|Having', '<<This will not apply to patients', '> 2.5 mg/dl', '1 or 0 to baseline', '< 25% from U/S', 'between 18 weeks 0 days to 23 weeks 6 days', 'epilepsy|Less than 4', '≥ 5 cm', '> 20|Gleason Score', 'IV', 'older than 18 years', '0-18', 'long-term survival', '40 to 70 years', 'less than or equal to 3 × ULN', '< 12 points,|Obesity 3 degrees and above', '> 100 degree F and/or|Nasal', '65 and over', '≤ 1 year', '< 35%|Pregnancy or', '4-5).|Patients', 'score of ≤ 1', '< 92%', '<60 ml/min/1.73m2)|Hereditary', 'from the normal range', '< 100 x 109/L.|Hemoglobin < 6.0 mmol/L', 'younger than 50', 'equal to 6', '> 25 mmHg|Right', '≥1.5ULN);|On dialysis', '>35kg/m2', '<20 score', 'grade I', '> upper limit of normal (ULN) + 4 seconds', '<= 4 x 10^9 per liter', '> 3.5', '=< 2|Considered transplant', '≥ 25 - ≤ 35 kg/m2||Normal', '1.5-fold', '>50% of their working day', 'equal to or greater', '4.5-5 mm diameter', '>20 mg', '18 years or older.|Patient', '<40 kg/m2', 'dose 50 mg', '18-65 years|both', '6.1%', 'between 18 and 55 years|EDSS', '18-24.9 kg/m2', '≥ 3 months)|Patients', '≥3 months;|The', '≤ 1.0g;|Coagulation function', '≤ 4 times the upper limit of normal', '≥6.5%)|Self-reported', 'less than 6 weeks|Evidence', '20-80 years', '< 30 g/L', '>60 ml/min', '1 and 2||', '> 35)|Active infection', '1 glass', '18-39 years|Participants', 'over 18 years|Proficiency', 'above the metatarsal', '13-18 years)|Overweight', '< 50 mm Hg|no more', '<70% of the population median', '0-2;|experience', 'I - III|BMI', '>30 o', 'score of 2 or above', '>85th percentile', '>= 60 mL/min per 24-hour urine test', '> 75 years', '< 18 y.o.|neurosurgical treatment', '> 18 years;|systemic health conditions', 'less than 45', '7-9 points', '≥ 1,500 /μL|Platelet ≥ 100,000 /μL|Hemoglobin', '=kg/cm2)<30%', 'Between 18 and 75 years', 'between 30 kg/m2', '≥60 years', '<4.91 mmol/L', '≤ 60 mmHg.|Sitting', 'scan.|Greater than or equal to 15%', '< 40 mL/min', 'under 18 years|Cannot complete and understand study materials', '≤ 6 months prior to start of the study', 'more than or equal to 88 cm', 'greater than 200', '> 30 - 100 mg/day', '≥ 9g/L', '≥ 75×109/L', 'less than or equal to 6 mm', '<47.00D|Axial eye length', '> 30 and ≤ 75 years;|Treatment', 'less than 80°', '50-80', '=< 11', '> 65', '≥ 40|Presence', '> 9%', 'at least 18', '180,000 to 320,000 per mm³.||', '18.5-35 kg/m2,|who', 'between 45-150 kg', 'INR≤1.5', '> o', 'pregnancy', '≥ 18 years.|Study participants', '>8 hours).|Smokers', '18-65y', '31-A1-A3', '≥ 100,000/mcL.|Total', '>90', '18 years and over|Adult', '=<1.5 x ULN', 'between 7-12 years', '>= 1.5 x 10^3/uL', '0-1|Neutrophils', '18 to 59 years', '> 120 mm', 'greater than or equal to 50,000/mm^3', '≤ 2|Signing informed consent', 'less than 12 months;|Abnormalities', '>Grade 1', '≥ 37 weeks', '≥1.5xULN', 'been prescribed regularly.|Bone protective agents', 'months；|Eastern', '19 to 24 years', '<1.0×ULN.|Renal function', '< 18.5 kg/m2', '> 2cm away from the site of a metastatic lesion', '>30 min/week', '<40 kg/m^2||', '< 460 ms', 'I and II and those', '<30 mL/min/1.73 m2|Currently enrolled', '≥ 5.|Inborn|Written parental', ""male's penis enters"", 'from 18 to 70 years|Discernment', 'was<100 * 10 ^ 9/L.||Exclusion', '18 years and older|Removal', 'grade of 0 or 1.|Adequate hematologic', '> 120 mmHg)|Tachycardia', '1-3 times /week', '≥ 28 g/L|coagulation', 'B or more', 'younger than 25', '<70)|Unwilling', 'portosystemic', '≥1.5×10^9/L.|Platelet count', 'Above 21 years', '> 38°C for more than two weeks', 'Q4-2019', 'under 19 or over 70 years', '> 1.25 x UNL|CPK', '≤ 480msec|Women', 'between 18 and 39 years old.|Predicted', '19 or older', '≥ 1 year|Afebrile', 'hospital|Less than 3', '18.5 - 29.9 kg/m2)|Able', '18 years|Caring', '18-75|undergoing', '10 g/dL|Absolute', '18-65 years old', '5-18 years', '10-30kg||', '> 40|Pregnancy', 'between 90 and 160 mmHg', 'between 35.5-37.5 ºC', '0-2.|At least 1 measurable', '25 - 49.9', '≥7', '≥ 1.5 × 10 9 /L；② Platelets', '<60mL/min/1.73m2', 'of 19.0 to 40.0 kilograms per meter squared (kg/m²)|Males', '≥ 45/mL/min', 'more than 90 days|Have signed written informed consent to participate', '> 2 ULN', '< 150 min/week', '≥9g/dl', '≤ upper limit of normal value', '< 50%|History', '=< 2.5 x ULN', '17-65 years', '<60 mL/min/1.73 m²', 'long-term COVID-19-related', 'B-type Natriuretic Peptide (BNP)', 'measurable', '≥ 60 years old', '> 15 points', '≥ 60 mL / min or more', 'I-II)||Overriding', 'greater than or equal to 30', '>91%', 'between 90 (inclusive)', '≥ 3).|Subjects', '65 or over|One or more', 'over 70 years', '≥ 6.5%', '<2.000x10⁹/L', '≥18 years|Participants must', '≥4×109 /L', 'between 1 and <18 years', '90 mL / min.|Vital', 'score ≤ 24/30).||Lateral', '≥ 5.6 mmol/L)|Arabic', '< 5.7 mmol/L', 'less than 6 months|Type 2', '44 to 147 IU/L|Alanine', '> 1.40),|asymptomatic PAD', 'lactation.||Patients < 12 years', 'below 18.5 or above 29.9 kg/m^2|irregular', '> 19', '3-5', '≤ 15 years', '=C scale)|Patients', '<60 ml/min.|Currently', 'Findings', 'less than 70.000;|Internationa Normalized Ratio', '≥ 100 x 109/', 'age|Over 42 years', '30 to 35 fractions', 'greater than 2.0mg/dl', '> ULN;|Subjects', 'higher than D8.|Peripheral neuromuscular pathology', '> 1 year|Ability to sign', '≥ 102 cm', 'less than 6 months|Evidence', 'less than 4mm', '19.0-30.0', '< 2.0 mm).|Participation', 'score of >= 5% for the 10 year', 'older than 38 years', '22 or older', '≥150/90', 'between 18-29 kg/m2.||', 'above 400um', 'lower than 85', '>50ml/day).|Other', 'not recovered more than 35 days', '>10mm2 and <100mm2||', '< 50 L/', '>= 7 years', 'I-II,|Scheduled', '15-Item Geriatric Depression Scale', '≤ 3 times the upper limit of normal', '>= 30kg|Planned allogeneic HCT', '>/= 65 years', '≥0.30x10⁹/L', 'less than (<) 14 years', '≤75,000 per μL', '≤ 30 mL/minute', '≥1.0 ng/dL.|Age', '> 450mL', '0-', '5 to 10', '> 1.5 cm difference', '12 years old or more.||', '> 5 mIU/mL', '> 103 copies/mL', '≤ 68 kg', '18--99', 'leakage', '> 92%.||Female', 'more than 165 kg', '<60 min/week', '≥ 30% and ≤ 90%;|Before the screening period,', '> 25 kg/m2', '>480', 'less than six feet tall', '≤ 3 × ULN', 'III-IV|Severe aortic', 'approximately 50% or more', '< 30||', '> 2.5x upper normal limit', '20', 'between January 2019', 'less than 30 or older than 75;|Diseases', '≤ Class 1', '1 positive', '≥ 25|Owns', '18 years to 99 years old', '18.0 to 28.0 kg/m2', '>40 Kilograms(kg)/meter square', '40-60 Years||', '< 1 year)|Pregnant', 'between -1.00 D and -10.00 D', '≤ 2|Life expectancy', '>135 mmHg', 'below 65 years', '< 3rd percentile|EFW < 10th percentile', '+ 0 Days|at the maternity ward of the Reims University Hospital|parents are older than 18', '> 2|Dysuria', '5 or more times per week|History', '155- 170 cm', '35 ml/kg/min', '< 1000 mm3', '<5;|Pregnant', '>140/90', '>500 pg/ml', '> 200 mmHg', '> 1000/mm3', '180 degrees', '≥ 30 packs/year)|Former', 'less than 18 years old or signed informed consent of the patient', 'at least 52 weeks', '1]:||Greater than or equal to 3', 'above 25 kg/m2,|Have', 'over 150 kg),|Blood triglyceride level', 'between 4 and 18 years', '32 -- 35 mmol/L.||', '=< 3|Ability', '≥2 X ULN', '12 months to 59 months|Family does not', '> 75 %', '6 months to 14 years', 'Euroscore II < 9%|The', 'larger than 10 x10', '15 to 25 mg/week', 'less than 2cm;|the condition', 'same score +/- 1).||', 'between 18 and 64 years', '0-2;|Patients', 'patients||Age 55+ years', '26.0 kg/m2', '< 21kg/m2', 'lower than 90 or', '>= 45%', 'score ≥ 12', '>5 points', '< 110 beat per minute)|Patient', '≤ 12 months.|Uncontrolled', '< 2000IU/mL', '18-month', '< 32 weeks', '45 mm or more', 'between 30 and 84 years.|Seeking', '140 - Age))/(72 x', '≥100 g/L', 'below:||Hemoglobin 9.0 g/dL;|Absolute', '>18 and <85 years|Signed informed consent||', '16 - 29|Engaged', '≥ 7.5%', '≤ level 1', 'greater than or equal to 20%', 'greater than 5 times the upper limit of normal', 'greater than or equal to 6 years old', '>65 years|Echocardiographic LV EF', '3 or more', '<30 mL/', '>7 and >14 drinks per week', '> 2)|Ophthalmological', 'between 18 and 65 years|Current', '<=2.0*ULN', '19 years to 75 years|eGFR < 90 mL/min/1.73m^2', '≥12 weeks;|At least 1 measurable', '<135 mEq/L|Serum potassium', '≤ 8 mg/dL', '<10mg/dl.|Recently', '<1.5x ULN', '≥ 1.4', '<18 years', 'UroTainer', '<= 1.5 x ULT', '5th - 85th', 'equal or greater than 0.7', 'between 3 and 6', '<2 months prior to administration of PRTH-101.||Subject', 'less than 4 weeks prior to SPVN06', '> 4 times the ULN', 'greater than 12 mmHg', 'better than or equal to Snellen', ""30-60years|Bell's palsy"", '<4 months', '<1cm', '1 month to < 6 months', '< 15 mmHg', '3.5 mmol/ L).|Ultrafiltration', 'At least 40 years', '45 mL of 40% spirits', 'Ocular Discomfort &', 'outside of the normal laboratory defined range', '>= 18|Prior tissue diagnosis of', 'between 8 points to 21', '>/= 12 weeks.|Participant', '≥3 g/dL.|For', '≤ 2|Subject', '> 85th', 'between 15 and 26 years', 'ANC)≥1.5×10 9 /L', '<300);|Informed consent', '> 40 mmHg', '0.90 or less', 'per-operative', '> 18 years old and > 85 years', 'below 50 years and above 80', '> 1.50D;|Using', '≤ 1.5 × ULN|Left ventricular ejection fraction', '<40 µg/L', '<18 years|Secondary causes', '≥45 kg||', '21 years old', '≥ 50%|A', 'between 20 and 28', '≥ 200 mmHg', 'trial|Aged over 16', 'Less than or equal to 140 mg/ dl.|Participants', '≥50 kg.|In', 'pH range', '>10', '>5 microbleeds', 'between 100-180', '18-75 years;|Be able', '=< 14 days prior to registration)|Aspartate aminotransferase', '6/96', '= blank', '11.0 or later', '≥ 65≤ 85', '<90 mmHg', '<3)|Patients', '> 30 kg/', 'below 90 mmHg', '<10 lesions.|1B', '<80 mL/minute|Supine', '>38.0oC', '33 %', '>or= 55%', '>75,000/mL|Total', '≥250 mmH₂O', '≥120/min', '18 years and over|BMI', 'from 18 to 75 years', '20.0 to 39.9 kg/m2|Diagnosed', '> 50 years|BMI', '< 21 days prior to the first dose of study treatment', '≥ 2.5 x upper limit normal', '20-50 years', 'at least 60 mL/min', '=< 3.0 x upper limit of normal (ULN)', '<23 points', 'between 18.5-39.9 kilogram per meter square (kg/m2', '< 8|There', 'greater than six', '≥ 18 years,|Hba1c 7-11%,|Renal function', '≥ 1.5 times upper limit of normal', '≥ 15mm', '18 Years', '< 80,000/mm3).|Disseminated', '18 to 85, inclusive', 'at least 45 kg', '=< 1.5 x institutional ULN', '≥ 45 mmHg', '>12 weeks|Body weight', '2 to 5', '< 30 mL/Kg.h', 'less than 25 and 34.5 kg m2|Breastfeeding', 'between 18 and 65 years,|patient residing', '=< institutional upper limit of normal', '<1.5 x ULN', '≤ 90 years', '>600 μM', '≤ 1.5 x ULN|Negative', 'between 18.5 to 26.0 kg/m2.|Normal', '18-29 kg/m 2', 'requires urgent intervention', '>= 60x10^9/L', '>1.90m)|Patient', '> 1.5x ULN', 'between 7am and 10', '2cm < lesion', '≥110 mmHg);|Patients', '≤ 1|Adequate organ', '>=3ULN|Platelet', '≥10^', '≤ 1;|Adequate organ function||', '≥5 cm below the left costal margin', '> 70 or <', 'none||-', '>2.0×109/L', '≤ 60 mg/dL.|Medical', '> 5 units/day', 'less than 50 beats/min or more than 100 beats/min', '< 6 months|multiple life-threatening', 'less than 50×109/L', '<140', '20 - 70 years', '≤ 93%', '> 10% of body weight', 'scores of', '>18 years|Confirmed diagnosis', '0 to 1.||', '≥ 12 g/dL|be capable of understanding', '<10', '18 to 60 years old.|Serum pregnancy test', 'at least 15 millimeter', 'younger than 20 years', '27-month study', 'N1-2', '<150,000)|Current use', '< 10 words', '≥ 50 mL/min|PT', 'more than 94 cm.||', 'over 18||', 'between 8-18 years', 'from 18 to 75 years old||', '> 18 years|Written Informed Consent|All', '> 150 mcg levothyroxine per day', '≥300 mg/day', 'equal or more than 0,', '11-18 mm|Target', '540µm ± 50||', '> 2 or <', '> 10 × ULN', 'older than 18 years||diagnosis', 'diagnosed;|The', '18-34 BMI', '0-1||One or more', '>1.2|Platelet count', '<25 g/L.|Uncontrolled', '90 to 150 mm Hg', '≤ 1.5×ULN.||', 'score of < 8 points', 'from 4 to 6', 'less than 100 mmHg.|Have', '≥1,000/mcL', '< 6 weeks)|Specific', '40 years to 80 years', '<2500g|No matching', '≥ 9.0 g/dL.||2', '4 - 12 years', '<18 kg/m2|Pregnancy|Inability', '>= 5 days prior to study treatment', '18-75|Patients', '4 through 7 years', 'precludes', '18-35,|Willingness', '10-14 years', 'over 440 ms', '≤ 1.5 × ULN;|Serum', '< 3|Refractory', 'greater than 5 mm', 'Spanish|≥18 years old.||', '>10xULN|Active drug', '≥ 35|unable', 'between 18.0 and 27.9 kilograms per meter^2 (kg/m2', '≥140/90 mm', '7-9 points)|Absence', 'withdrawal', 'PR positive', '100-150mmHg', 'score of 39', '<Age<60;|No', '>1.5x ULN', '2.5 D or less', '< 1 year|co-prescription of NSAIDs', 'over 20 years', 'below 60 ml/min/1.73 sqm body surface', '≥ 1,500/mcL|platelets', 'at least 20/30|History', '50 years to 90 years', '≥ 60 mL/min/1.73 m2.|Direct', 'from 18 to 75 years old', '<95th percentile|Specific obesity', 'under 18|Hospital admission', '> 4 ng/mL and < 20 ng/mL|Patients', '< 100×10^9 / L|Patients', '1 to 24 months (inclusive)', '< 2+ or 24-hour', '≥18 and ≤70 years.|Ability and willingness', '0 or 1||Haematological', '≥ grade B', 'between 100 and 125 mg/dL)|Stable', '>= 30kg/m2|Consistent', 'male patient', '< 6 mmHg', 'under or equal to 27|Right-handed||ii', '≥ 5% blasts', 'greater than 2 times the', '≥ 140mm', '>140 g/week', '≥ 100 × 10 ^ 9 / L', '<9 g/dL);|If', 'greater than 1.3 and less', '+ 0 weeks gestation|<10 kg', '≥45 mL/min', '0-1|Child-pugh A||The function', '60-90mL/min/1.73m2', '<10 x 109/L)|Known', 'score of <15.|Patients', '> 25kg/m2|Dyslipidemia|Altered', '≥18 years and ≤65 years', 'under 18|Person under guardianship', '> 1.8pg/ml', '>= 18.0 to <= 32.0 kg/m2', '> 6%);|Hemostasis disorders', 'over 60 mins.||', '109', '< 40x10∧9/L|Blood glucose', '>1.5xULN，hemoglobin <120 g/L', 'score ≥ 24|Physically able', '<=750 micrograms/Liter', '> 110', '>= 18 years|Clinical', 'less than 18 yrs or more than 80 yrs,|Women', '400 ml/day', '≤ 3.0 x ULN', '30-50 kg/m2|Individuals', 'must:||Practice true', '> 25.0', '≤ 4.|TIA', '≥ 60 mL/min', '38 years', '>150*10E9/L', '> 1000', '= QT/', 'FISH.||Phase I (dose escalation phase):||HER2 expression is', '>70 on the Lansky', '<1000/μl|Confirmed', 'later than two weeks before', 'between 18-45 years', '> 95%', '< 2,500/μL', '≥ 21mmHg', 'older than 5 years', 'grade 2-4', '>1.5 times the ULN', '<18|Planned combined cases', 'warfarin|pregnancy|mentally', '0 to 1.|Women', '> 5 points,|Critical hypoxemia', 'between 18 to 65 years;|Have a Patient Health Questionnaire-9', '> 2 x normal', 'less than 26)|Patient', ""> 13.|Barrett's"", '< 100,000/mm3|Hemoglobin < 9.0 g/dl|ALT', 'more than 16 year.|Willing to sign', '≥2 years', '5-9 years', '≥ 18 years or older', '≥ 75,000>µL|Hemoglobin', '≤ 3;|Patients understand the purpose', 'ISUP>2).|More than 50% of positive', '< 80|Percentage of fat [%', '≥ 350/mm3', '>38°', 'greater than 400 mL', '<0.5)|Obesity', '>0.5cm/year)|Saccular aneurysm', '>18 years|Diagnosed', 'Household member of person with laboratory', '≥ 1,500/µL|Platelet count', 'at least 90 mL/min/1.73 m^2', '0-2|Being able', '1-3A', '<20 or >35kg/m2|physical dependence', 'between 12 and 60 years', 'at least 1 cm', '=< 1.5x institutional upper limit of normal', '≥18.5 kg/m2', 'between 18.0 and 30.0 kg/m2|Free from', '> 1 year||Patient', '15 weeks),|good communication skills', '<35 kg/m2', 'between 19 and 75 years|American Society of Anesthesiologists physical status', 'between 18 and 75 years.||A minimum of 18 teeth, wisdom teeth', '≤ 1g;||Lung function', '≤ 1.5 × upper limit of normal', '> 18 years old|Patient', 'over 300 pounds', '1-2.|Sign', '> 10.0×109/L', '< 12 months||•', '>176.8µmol/L;|Persistent', '24-hour recall period', '≥ 100mg/dL', '≤1 × 109/l', '0-1.|Histologically', '> 2 mg/dL', 'support.|Refusal to participate|Persons', 'from 18 to 85', '≤ 75 years.|TIA', '≤ 5.5mm', '≤ 3 cm', '>470 ms', '18 and over,|Volunteering to participate', '≥ 1 % of the total lymphocyte count', 'shorter than the cycle duration', '≥18 years and ≤75 years', '>65 y.o', '18.0 to 38.0 kilogram per square meter (kg/m^2)|Stable renal function', '> 2x normal)|Uncontrolled', '≤ 5', '< 4.7)|meets criteria', '27.0 to 40.0 kg/m2', '≥800 pg/mL', '18 to 85|Single', '< 8) after', '≥5 times the upper limit of normal', 'value≥ 240db/m)|Age≥ 18', '≥ 5%|Subjects enrolled', 'minimum 50 puffs/day', '≥11 g/dL', '>18 mg/dL', '≥30 mL/minute', '> 90|Heart Rate', '≥6 years', '18 or older', 'pres-ence', '≤ 110 g/L', 'II-iva', 'provided.|3', '≥3 months.|Have', '<2+ or 24h', 'T0-4a N0/N2c M0', 'Operable', '18 to 89 years', '> 3.0mg/dl', '≥20 mg/dL;|Consumed more than 5', '> 2 × institutional ULN', '18 and 25 years', 'greater than 105 mmHg.||Change', 'between 5-17 years|Diagnosis of', 'less than 90 days.|Pregnancy.|Chronic obstructive pulmonary disease', '>= 60.|Histologically', '≥2cm distal to the most distal coronary artery', '<30|Non hostile', '<3 stools', 'between 0.250x10⁹/L to 0.299x10⁹/L', '18 or over|All', '< 12 g/dL', '<= 5mg', '13 and 24 weeks of gestation|Having', '>2|Neurological impairment', 'more than 50kg(45 kg or more', '≤ 3 months', '< 100 mmHg|Stable', '≥ 5]|Live', 'more than 20 years', '< 95%', '1 (PD-1)', '≥3 years old ≤ 11 years', '>3 X institutional upper limit of normal', '≤ 3 times the upper limit of normal value (ULN)', '≤ 35||', 'between 40 and 100 bpm (inclusive)', '10-15', '≥1×10^9 /L', '>6.5mm', '18 to 85 years old', '1-2', 'less than 1 year.|Systemic glucocorticoid', '>4)|Either', '≥ 3,500/μL|Platelets', '<20 mL/min/1.73m2', '<50 x109/L', '15 L/min', '<50%).|Current', 'no minimum daily dose', '< 30 mL/min/1.73 m²', 'at least 2-point', '> 80cm', '≥ 50kg', '16-19 years|Are English-language speakers|Are', 'less than 50%.|History of', 'between 0 (none) and 10 (extreme) in the ear', 'under 50 years;|Confirmed', 'between 18-40', '18.5-40 kg/m2|Able', '<90k)|Documented evidence', '18-30 kg/m2|singleton pregnancy|the first day of the', '≥ 3 months', '>= 1,500 / uL|Platelets', '≥ 50,000/mm', 'I-II,|uncomplicated', 'greater than or equal to 3|Patients', '<24).||Controls', '<1000 mg/day)|Current treatment', 'maximum 50% tendon thickness', '<15 ml/min/1.73m2', 'from 12- 18 years', '≤ 1.5-fold upper limit of normal (ULN)', 'older than 14 years|Inability to understand the study procedure', '>45 mL/min||Women', '> 5 years|Signed informed consent||', '≥ 0.15 ng/mL', '> 10cm', 'less than 1500 g', '≥18 and ≤ 34.0 kg/m2', '≥50% of predicted level', '> 3months)||', '0 or 1;|Patient able to understand the information related to the study', 'SpO2<93%', '< 36°', '>40 kg/', '>180', '>= 5mg', 'less than or equal to 3 x ULN', 'center|younger than 19 years', '25-45).|Good oral hygiene', '14-18 years', 'between 12-20 years', '50-70 years', '≥ 40 kg/m2|Eclampsia', 'between 50.0 and 100.0 kg, inclusive', '> 9.0 g/dL||Adequate', '≥ 8 mg/dL|Platelet', '≥ 1,500/µL|Platelets ≥ 100,000/µL|Hemoglobin', '≥18 kg/m^2|eGFR', 'more than 3 years', 'Class II or greater', 'greater than 100 mmHg', '18-80 years', 'grades III and IV', '0-1.||I-4', 'less than 50 or', '≥18 years|Ability and willingness to provide informed consent', 'from 50 to 65 years', '≤ 1.5 ×', '8 to 16 year.|Male', 'older than 16 years', '125-450 10 9/l.|comorbidities', '< 100 ng/ml', '≤3.0 times ULN', '≤ 1.02 mmol/L', '8 mm||Group 2:||with upper scleral', '< 30 levels', '> 18 years|Radiological findings', '>90 mmHg', '18 or over.|Non-small cell lung cancer', '≥ 15', '≥ 30 kg/m²|History', '>mild|Tricuspid Sub', 'between 40 to 80 years old', '> 10 times the upper normal', 'at least 2L', '18 to 75 years|Sufficient command of the French language to understand the instructions|No', '<3 months of', '< 2.5 × the upper limit of normal', '≤ 1.5 × ULN;|International normalized ratio', 'responses', 'C', '> 100mmhg', '≥ 20 years|Enrolled', '0 or 1;|Participants', 'platelets≥100*109/L', '> 35|Metabolic', '>= 90x10^9/L', '<80%', '≥ 4mm', '> 40.|Other', '> 15 mg weekly', '≤ 65%', 'requires at least the', '< 70', 'ALT≤1.25 x ULN', '90 days.|Patients', '> 300 mg/g', 'better than 20/30', 'less than 32 weeks', '> 3-times the upper limit of normal', 'less than 3 months prior to study', '<55 beats per minute (bpm)', '<15 mL/min/1.73m2|Previous', '≥ 18 years|Confirmed', '60g/L<Hb≤100g/L;|Willingness', '>40kg', 'more than 12 weeks|7、Transplant', '<100 000/µl *', '< 80 g/L;|the', '>2.5 × ULN|acute viral hepatitis', '> 50 ml/min.|Total', '> 0.2ng/ml', '≥ 1.5 × 10^9/L||-Platelet count (', '≥ 1.5 × ULN', 'scores ≥ 10', '>92%.|ECOG <2;||(11', '1.5 - 3.5', '18 and 55 years', '> 0.25 mmol/l', '< 22)|Asthma', 'between 18.5-28.0 kg/m2', '≥18 years|Written informed consent', '>20ml/kg', '< 30ml/min);|treatment', 'less than - 3.|Receipt', '<10 mg/dL|Serum BUN', '>0,64 ng/dl||Polycystic', 'over 30 ng/mL', '> 21g/day', '> 7', 'above 38.2 degrees Celsius', '0 Chronic Lymphocytic Leukemia', '60 mmHg diastolic|Allergy', 'under 80 years', '(PT)/International normal ratio', '≤ 145 mmHg', '>20 years|Patients', '> 85%', 'American|identify', '>= 30 mL/min/1.73 m^2 to < 45 mL/min/1.73 m^2', 'lower than 2 months.|Patients', '≥18 years-of-age', '>74.9 mmol/mol', 'under 55 must', '1 to 4+', '10-17 year', '>18 years.|Obesity hypoventilation syndrome', 'score of 10~20', '>= 30 days prior to screening', '≥600 pg/mL|Patients', 'more than 6', 'between 15 and 24 years', 'above 40%', 'between 19+6', '<7mm)|Man', '1 and 15 years', 'requires specific treatments|medication', '=<1.5 x upper limit of normal', 'from 18 to 25 kg/', '> 2.0 x 109/L', '≤ 3.0×ULN', '20 to 50 years', '> 6)|Minimal', 'I-IVa', '> 6 months', 'between 18-35years||First pregnancy', '< 30mm', 'between 25-30 kg/m^2)|Renal insufficiency', '≥ 25mmhg', '15-20 years', '≥III;|The presence', '≥6 months to <13 years|Planned', '> 65 kg||Patients', '≥18 years|Thin', '20-40 years', 'equal to or more than 130 mmHg', '< 4,000 /mm3', 'less than 11g/', '60 to 85 years|Persistent', '20 or more', '>20 mmHg elevation', '1L olaparib maintenance monotherapy following', 'Being 65 years old', '>8.5 % (69 mmol/mol', '≤40%)|18-70 years|Not', 'greater than the upper limit of the normal value', '> 6 ppm|Is', '≥ 1,500/mm3|Platelets', 'between 4 and 9 months', 'than 50', '≥ 2.5 times UNL', 'between 40 and 85 years', '< 18 years;|Pregnant', '≤ 24.9 g/m²/h;|Be', 'multiple myeloma;|3.According', '≤1.5 x ULN||* However', '19.0~28.0 kg/m', '12-30 years|Presenting to the', '< 65 years discharged home from ULHG', 'meeting', '>18 - Patients', '≥3cm', '>120 mg/dL', 'greater than 10 per high', '12 to 21 years', '≥20', '≤ 5 x UNL', '≥ 9.0 g/dL;|Adequate', '20-30 minutes each', '+/- reinduction therapy|Fully recovered from', '≤ 4.8 mmol/L', '< 75,000 cells', '>2.9g/dl;|AST', '34.6 inches (F)', 'greater than 60 degree', '≤ 35.0 kg/m2;|5', '≥ 30mm', '≥3%', '> 60|Life expectancy', 'below 100 x 109/L', 'over 120', 'at least 6/10th binocular,|Patient', '<60 minutes', '< 90|Alcohol', '<30 mL/min/1.73 m2', '< 16kg', 'at least 6 months|Optimum oral hygiene|Maximum', 'over 18 years|Clinical indication for', '≥30 and ≤ 85 years old|Pain', '≥ 18 year-old', '≤ 1.5 × ULN.||Cardiac', '≥ 21 years', '20% fall', '≤ 1.5 × ULN；|Normal', 'under 3 years old||', '32 and 35 weeks', '>= 70|Life expectancy', '≥ 100 × 10^9 /L', '< 5 ribs)|Signed', '> 30 years|BMI', 'at least PR', '≥60 mL/min.)|Fully informed', 'between right', '2000-200000/', '≥12 weeks;|Subjects', '≥ 30bpm', '+ coach', '>1.1 ULN|If', '> 18 years old|Presence of criteria', '45 - 75 years|Scheduled', 'better than logMAR 0.3', 'between 18.5 and 40 kg/m2', '> 10% tumor cell positive', '>2 mg/', 'scores ≥3)|arrhythmia|Renal dysfunction', '≥100x10^9/L.|Screening values', 'Disorder|Less than 30 minutes', '0-2.||', 'greater than 40.1 inches', '<50,000|diagnosis of coagulopathy|presence', '≥18 years|Body mass index', '< 2.0 × ULN)|Serum', '≥ 3,000/mcL|absolute', '>470 12', 'under 18 years old|Does not', '≤ 24.9 kg/m2|Able', 'between 18-40/ patients suffer from TMJ', '40%v/v', 'below 18 years old|Neck deformities,|Presence', 'greater than daily physical activity', '≥18 years|Elective', '<80 mmHg', '<50 x 109/L|HbA1C', '18.5 to 27.0kg/m2|If', '18 and 65', '7.8-10.2 mg/dL', '≥ 18 years;|Participant', '< 0.5 ml/kg/hr', '> 50% of', '> 18 and <', '<1 year,|History of', '< 5% change', 'score of 0 or 1', 'long-term chronic diarrhea', '>2)|History', '0 to 22 years||Patient', '>200 pg/mL', 'above 2', '0 or', 'above the criteria', 'at least 99%', '>5 years prior to signing informed consent', '< -2.5', 'less than 500g.|Known allergy', 'never', '> 90%', '>18 years old and < 90 years', '> 2,000 IU/ml', '≥75 years|Advanced CKD', 'XI score of >10', '< 2 years|medical conditions', '< 3 weeks prior to registration)|Prothrombin time =< 1.5 times upper limit of normal (=', '19-25 kg/m2)||', '< 4 months', '>0.6 x 103/mm3', '0 - 50 %', '>110 on the', '≥ 60 mL/min/1.73 m^2', '≥ 2mg/dL)|Pregnancy/', '< 60mL/min/1.73m2', '> 9 g/dL|Platelet count', '18 to 60 years old', '18 to 50 years old', 'below 300 µg/L', '≤ 2|Hepatic function', '18-75 years old;|(2', '> 3-times the upper limit of normal (ULN)', '> 3|Head', 'mode;|Greater than 18 years', '<40', '>= 55 years|Eastern', '≥18 years|COPD eligible for NIV treatment|Prescription', '≥ 1,000/uL|Platelet count', '110 lbs)', '18-70 years|ejection fraction', '> 5.5 milliequivalents per liter (mEq/L', '< 130mmol/L|AST', '≥130 mmHg and <170 mmHg', '≥3 within 30 days before the first dose of study medication.|Arterial', '≥41 years to ≤ 85 years.|Clinical diagnosis', 'II, III', 'T3-4', '4 mm', 'resection.||Greater than or equal to 50', '0 - 2|Willing to provide', 'less than 3 months old|having been', 'Score ≥60|Being able to communicate', '<2.78mmol/L', 'Between 55 - 90 years', '30-65 years.||', 'I, II risk groups', 'between 5 and 70 years', '</= 1.5 mg/dL|4', '> upper limit of quantification', '20 or above', 'at least 65 dB', '< 1 million sperm|Aspermia', 'A', '< 100 µg/dL', 'from 18-40 years', 'at least 90 minutes.|18 to 80 years||', 'greater than or equal to 10)|Have', '60 to 90 mmHg diastolic', '≥50%.|Objective evidence', 'greater than 50 mm', '≤ 125 umol/L', '< 24;|history', '<6 months.|Hospitalisation', '> 22.2 mmol/L.|Allergies', '≥ 30 g/L;||Serum', '≥ 12|Relapsed', '≥ 1.5 x 109', 'levels exceed twice the upper limit of the normal range;|Participation', '<2.5 times of the upper limit of normal', '≥ 20yrs', '≥ 1.7 × ULN', '≤ 2.0 × ULN', 'younger than 14 years old', '50 mL to 499 mL', 'less than -1.00 D or greater than-5.00 D', 'above 150 mg/dL|HDL', 'equal or less than 60 bpm|Patients', 'between 2010 and 2022|Patients', '= 3|>3 = 4||BMPC%||>15-20', '> 500 mdet', '65-85 years', '>=34 weeks)||Exclusion criteria:||Patients', '≥ 18 years|Stage I to III', '>99°centile)|fetal', '30% to 50%.|All', '>2.0 mg/dl', '>7 years ago', '13-18||', '<18 years|Open wounds', '< 220 ms,|Interval between Q and S waves', '> normal reference value', '6-8 years', '>= 30 mL/min to < 45 ml/min', '<50mmHg The', '<50,000/mm3', '>18 years old)|Pathologically documented', '≤ 12|Hour-glass', '> 1.2 mg/dL|A', '≥ 100 x 109/L.|Total bilirubin', '> age', '≥ 19 and ≤28 kg/m2;|Subjects', 'greater than 0.5 mm^3|Patients', '> 1.5 mg/dL', '>40mmHg||', '2 to 16 years|Are under the', '>=0.6 BU', '18.5-30.0 kg/m^2', '> 5.||', 'between 1 and 5.5;|Signed informed', '40 to 60 years', '1,500/μl)|platelets', '< 1 liter', 'require IV antimicrobial therapy', '> 2.5 mm', '6 to 35 months:||Healthy children', '9 - 18 years', '<20 ng/ml', '> 110 mmHg', '1|Body', '< 35/min', '≤ 1.5×ULN;|International Normalized ratio', 'older than 46 years', '<= 1.5 upper limit of normal value', '>18 years|access', '<40y or >50yrs||', 'between 18 and 75 years', 'greater than or equal to 1,000/µL|Platelets greater than or equal to 75,000/µL|Hemoglobin', '36-45', '<50 mmHg', 'between 18.5 and 35|Willing', '≤5 times the upper limit of normal', '>= II;|KPS >=30%|Having', '>50% luminal loss', '7-16', '<1.50 on', '<30 ml/', '3-5 μm', 'asymptomatic Hepatitis C virus', '<50×109/L|Hereditary', '>50mm', 'less than 30%|Unstable Heart', '≥-6.0D', '18-45|Diagnosis', '≥ 126 mg/dL||vi', '> 200 copies/mL)|Undetectable', '>2 nights per week', '130-179 mmHg', '> 470 repeat twice for', '<1 ng/mL', '≥37 weeks||', '0-1.|Life expectancy', '≥2 weeks;|At least', '≤ 1.5 ∙ ULN|For', '≥18 years|Written informed', '<50 b.p.m', '> 430 msec', '> 5 times the normal upper limit', 'greater than the upper limit of normal range', 'scores more than 24|patients', '2 to 3 OA', '≥ 2.5 kg.|Participant', '> 3.5 g/day', 'score of 3 to 5 points).|Written informed consent', '<125 x 103/mm3).|Positive', '> 60 mm g', '< 20%|Patients deemed', '≤ 40 years', '1, 1+&2', '2.5 ×UNL', '<2+', 'above 3 times the upper limit of normal', '>= 2 mg/dL', 'over 18 years.|Patient not objecting to the analysis of their data||', 'below 30|ASA I-III', 'equal and more than 22||', 'elevation', '< 20 years or older than 80', 'between 2500 - 4000', '≤ ULN|OR TBL >ULN to ≤1.5x ULN', 'nephrectomy||Exclusion criteria:||Patients under 30 years', 'stage II-III', 'below the Lower Limit of Normal', '>15º)|inability to sign informed consent', 'more than 26 weeks', '≥ 40 ml/min/', 'greater than or equal to 1.5×10^9/L', '18.5-40', '≤ 9.0 g/dL', '<1.04mmol/L', '65 years and older', 'requires treatment', '≤1.5-fold the ULN of the study site aPTT', '40-60', 'equal to (', '≥7.0 mg/dL', 'not exceeding 0.5 cm', '+/- 1 year', 'general problems|good oral health|age', '<1.5x Upper Level of Normal (ULN)', '> 30 ml/min|Known', '6-10', '≤ 1+', '170, 180, 10, 80, 90', '>=1500 mg', '<30)|Pregnant', 'below the limit of quantification).|Known', 'unless', 'between 18-65|Who volunteered to participate', '18-60 years||', '>= 100/min', '18 to 74 years', '18 to 75);|presence of T2D diagnosis', '<3,000 or >15,000|Platelet count', '> 50%.|Volunteered to enroll this study', '> 40 kg/m2', '30-', '> 7%);|ong-term', '100-125 mg/dl', 'greater than 24.9 kg/m2,|Having', '10 to less than (<) 18 years', '>2.5* the upper limit of normal (ULN)', '>18.5kg/m2', 'from January 1997 to December 2007.||', 'between 20 to 30 years', '18 years or older|Subject able to provide Informed Consent', '≥3g/dl;|Thyroid', '≥18 and ≤80 years;|Moderate-to-severe', '>= 2|Non-', '>2.0mg/dL', 'greater than 50cm', 'less than half a year.|Subjects', '6-10,|The', '≥50%.|Sign the informed consent form;|Good compliance', 'later than 49 days after surgery', '>94%', '≥96 mm Hg', 'at least 12', 'robust', '≥65 years|Bilateral dry-AMD|ETDRS-corrected visual acuity', '≥ 50.0', '18 or above', '21387374|Age <= 18 and => 65 years|EDSS score <= 7|Disease duration < 10 years|On', '≥ 9.0 g/dL', 'between between 36 and 59 months', '≥ 6；|The', 'years|Greater than 3 months', '> 24 consecutive months', '37 weeks to 42 weeks', '1.1 definitions', '<5 years old||②Clinical diagnosis', 'more than 12 weeks.|Ability', '≤ 35', '> 2x ULN|12-lead resting electrocardiogram (ECG)', 'between 18-65 to control', 'intolerated', '18 years and above|Fitzpatrick', '<3.0 mg/dL|AST(SGOT)/ALT(SGPT', '< 50,000/mm3', '>3,750 mg/day)|For', '≥ 1mm', '≥ 0.3 mg/dl', '0 or 1|Patient', '< 2,500', 'lower than 30%|Eighteen', '<20 ms', '≤ 35 kg/m2,|those who signed the', 'above stage Ⅲ', 'more than or equal to 6', '>300μm', '=< 2.0 x ULN', '≥12 weeks;|11.Capable', '<80°|Individuals', 'over 75 years old', '≥0.25|Patient provides', '≥ 100 × 10^9/L|hemoglobin', '> 3 times the upper limit of normal', '>450ms', 'at least 50.0 kilogram (kg)', 'between 18 and 65 years old|Class', '> 1.0 g|People', '≥100×10^9', 'at least 36 weeks gestation.||', 'more than 100 mmHg', ""≥ 25.|Subject's responses"", 'less than 50 bpm', 'score of 10 or greater', 'Irreversible', '≥18 and ≤65', 'more than 21', '≥9g/dL);|Liver function test', 'basal cell', '≥ 60 × 10 9 /L', 'greater than or equal to 6.5%.|People can understand the research process', '<15mmHg|PH', '25.0 - 35.0||', '> 12 weeks.|The', 'three or more months', 'respects normal tissue tolerances', 'Stage I only)|Clinical', '> 5cm H2O', 'form|Age', '50 kg;|Willingness', 'between 18 and 39 years', 'above 900 pg/ml', 'between 1,000 to 150,000 asexual parasite count/μl', '≥17, or|depersonalization score of ≥7', '0 or 1|For', '> 200/uL', 'under 16 years', '≥ 32.0 kg/m2.|Positive', 'exceeded 3 times of the upper limit of normal value', '150-499 mg/dL', '> 34),|Receiving therapeutic levels', '≥18 to ≤45 kg/m2', '> 1.5 mmol/L', 'above 7%)|Dysphagia', '≥ 50 kg|The', 'between 17 to 26||OR||Participant', 'I to III.|Open abdominal hysterectomy', ""less than 50% of theory)||NIV's start from"", '≤ 70)|co-morbid', '> 0.90', '0-2 points', 'born', '≥ 6 years and < 18 years', 'above the upper limit of the normal', '≤3.0 x ULN||Alanine aminotransferase (', '< 24 points;|Cognitive dysfunction', '≥ 8 weeks|Lansky', '> 70 mmHg|Inotrope', '50 units/', '18 - 40 kg/m2 inclusive|Full comprehension', '> 1000/uL', '19 and 50 years', '<1.5×109/L|Platelet count', '>40', 'at least 10 seconds', '≥120 or ≥80', '<95%', '≥ 18 years|Carrier', '> 3.0 pg/mL 2', '18-45 years;|Body', '≤ 50 mmHg', '> 115 mm Hg', '=<29 ml/min/1.73m2', 'been stable/improving', 'below 18.0 years', '≥140 mm Hg', '<3.2 mmol/L', '≥25 dB', '22-40|BMI', '≥18 years-old', '<90% room air', 'greater than or equal to 90g/L', '> 15', '>325 mg/day', '> 35 pg/mL', '=150 ml', 'higher than 95 mmHg', '< 1% marrow blasts', 'Objective', '≥40% and <80% of predicted', '> 8%', 'less than or equal to grade 1).|Absence of any local', '5-10', '<400 copies/mL', 'between 18.5 and 38|A negative', '> 24 months.|Other inclusion criteria', 'equal or better than 0.00', 'male|18-65 years|completion', '78-19 letters', '≥ 20%)||', '> three times the upper limit of normal', '13-month study', '≤ 80 % of predicted value', '30-59 ml/min per', '< 3 x ULN', 'under 18 or over', '<40%.|History of pericarditis.|Previous stroke.|Presence', '<90 mmHg.|Prior', '≥8', 'grade IV', '125,000-550,000/mm3|White', '≥37.3℃/ mouth temperature ≥37.5℃);|A', 'III - IV', '20 - 40 mg', 'less than 5 years.|Pregnant', '< 90 hypertension', '≥ > 15 mmHg)|One-lung', '≥ 0.5 LogMAR|The', '>= 180 mmHg', 'upper extremities.|Arthritis', '55 or over|Confirmed', '> 38.5 ℃', '>-2+', 'greater or equal to 18 years old', '=< 28 days prior', 'greater than 25 and', '50 years and older', '18 years or older|The patient is able', 'since resection|cT1a/cT1b', '≤ 1.5 times the upper limit of normal (ULN)', 'below 9.0 g/dL', '18 and over', 'maximum 18 years old|Anemia', 'less than or equal than 100', '20 on the 17-item Hamilton Depression Rating Scale|Average pre-operative', '≥50 mL/min/1.73 m2', 'A, B', '<45 mL/min/1.73 m2', '< 17 years', '0 to 1.|Participants', 'mouth opening <2.5cm', '4-related', 'I-IV)|Cancer', '0, 4, 5 and 6', 'Greater than 50% of the volume of the lesion', '18.5-35 kg/m2|Are', 'under 18 years|Lack of', 'greater than 40 years', 'more than 50%', '≤ 2.5 X institutional upper limit of normal', '> 1.6 mg/dL', 'below the maxillary sinus should', '> 8|18-70 years', '> 40kg/m2|Allergies', '12 or older', '<50% of the recommended number', '≤ 0.4 or ≥ 4.3 mIU/L.|Individuals state', '<2 years|Woman', '18 to 74', '>10 mmHg', '<70%;|Hemoglobin', '>90min', '< 10%|Willingness', 'greater than 20', '< 6 months old', 'less than 30 ml/min/1.73 m2)|Skin disease', '<12 months', 'score of 0 to 4', '≥ 3.0% of baseline', 'more than 70%||', '≥3 different time points)|Diagnosis', 'between the 15th and 80th percentile', '0-1;|Patients', 'transporter 2 (SGLT-2) inhibitors', 'score < 26.|English language proficiency insufficient to', '<1x/year', 'above 30% .||', 'minimum 2 cm margin', '> 35kg/m2', '≥ 65%', 'variability|≥ 20%', 'score between 13 and 18)|Resides', '=< 1.5 X ULN', '> 20-years', 'over 75 years old;|Admission to the', 'elder than 18', '= 100 x 10^9/L', '≥ 18 years.|Histologically', '60-80', 'above the upper limit of normal', '≥ 100 g/L', '<18.5 or >30 kg/m²|Are', '≥ 18|Karnofsky performance status', 'score of ≤ 4;||9', '>= 60 mL/min/1.73 m^2', 'upper limit of normal;|written informed', '≤ 80 years', '≤ 1.5 x normal range', 'between 36.4 °C and 38 °C', 'acceptable', '> 126 mg/', '< 80mL/min', '65 and over|followed', '>1 mg/dL', '40 to 55 years', '3- 6 weeks;|Voluntarily provide', '<40ml/minute', '14-20 G', '18|The patient', '≥2.5 × ULN|Abs neutrophil count', '>= 5', '6.5%', '≥ 18 years old;|At', 'O2 < 95%', '≥ 18 years|Participants', 'greater than or equal to 4', '>2 years', 'equal to or greater than 48 hours|SAMA', '177µmol/L', '≥3 months;|Histologically', '36 months or more', 'score of ≤ 10;||10', '<37 weeks|Birth weight', 'within 18.0 kg/m^2 to 32.0 kg/m^2', '< 18 years|absence of HE|LT', '18-64,|To', '> 400 pg/ml', 'between 65 and 90 years', 'within 18.0 kg/m^2 to 33.0 kg/m^2', '4-6 hours', 'Readiness', 'frequency minor of 2 days/week|BMI', '> 40 breaths per minute', '<25,000 / µL', '^9 /L', '35-74 years|High-risk', '>2.5 x ULN', '≥22 years', '>45 years', '17-item version', '< 0.5 x 10^9/L;|Platelets < 20 x 10^9/L;|Reticulocyte count', 'between 6 to 36 months of age,|Parental Education above', '≤ 1000IU/ml', 'more than 1000 copies /mL', '<10.0 g/dl,|Absolute', '≥ 1 litre.||13', 'between 0-14 years', '≤ 3×ULN', '20 vps', 'Score of more than 6', '>= 18 years|AML', '< 15.|All', '< 200 copy/ml', '≤ 2.5× ULN', '≤35 kg/m2', '≥ 140 mm Hg', '≤ 2.5 × institutional ULN.||Weight||The participant', '> 30kg/m2|Age', '>460 msec', '<30', '>60', 'requires treatment;|A GCSI total symptom score', 'between 18 and 40|Self-reported', '70 years', 'less than 90g/L', '>10% above upper limit of normal', 'requires mandatory continuation', 'therapeutic range of anticoagulant|Total bilirubin ≤1.5 × institutional upper limit of normal', 'from 19 to 65 years', '<1 year|Contraindications', '> 4.0mg/dl', '4 to 12 years', '≥ 2|All criteria', '<10g/dl', '18-3540|Female', '<20ml/min/1.73m2)|Liver', '≥18 years.||Adequate hematologic', '≥500 pg/mL', '5-26', 'long term care facility.|Subject', '>= 40 mL/min', '< 50 × 109/L);|Patients', '> 80 ml/kg/day', '23- 24.9 kg/m2', '≥18 years.|Minimum', '≤ 40 bpm', 'more than 23 kg/m2', '> 1.5×', '≥90mmHg|Patients who agreed to participate', '0-2|Able', '20-89', 'long-term medication', 'no more than 3 prior', '= 2', 'between 18 to 55 years', '< 5mm;|Inability to walk;|Allergy', '≥100 μg/day', '≥ 12 weeks', 'I - IV,|levels', '0 to 1+ by IHC', 'less than 30 ml/min per 1.73 m2 of', '18-70 years', '<6 months|Pregnancy||Vulnerable', '>= 18 years||Postmenopausal', '>= 4 ng/ml|REGISTRATION', '60 years or above.|Older', 'less than 50%', 'greater than three years', '<= 48 hours', '<5 years|absolute', 'Minimum 18 years', '18 years and over|Able to understand the risks/benefits of the study|Able to give written informed', 'less than one year|Presence', 'score of 25 or higher', '18 years or older.|Greater than 6 months', 'score ≤ 2;|Have', '18 years or older.|Clinical Screening Committee', '= 1)|Subject', 'from 6 to 12 years||', 'score of ≥ 5', 'women|21-45 years', 'between 45-65 years.(57)|Patient', 'III-IV level', '18 - 45 years|Scheduled', '=< 35 kg/m^2|Must', '≥18 years|Affiliation', '20% to 50%.|ALT', '>= 18 kg', '< 60 mL/min/1.73m2|""Positive""', '≥ 1×104/ml', '< 10 ng/mL', '≥ 30mL/min and < 60mL/min.|Hepatic', '4 (CTLA-4) inhibition therapy.||Participants', 'stage 5', 'greater than or equal to Grade 2 per the', '<50 copies/mL to', 'greater than 50% of the transurethral resection specimen (b)', 'following relief of', '19~55 years', 'less than 48', 'stage II to IV', '18-50|Males', '> 3x normal', '<25%).|In the case', 'scores >3', 'less than 30 times/minute', 'been completed', 'less than 70 years|The', '≥3 stools/day', '<5% blasts', '≤ 1.1 x ULN', '≥ 1,500/mcL|Platelets ≥ 75,000/mcL|PT', 'above 18', '>50 ml/min', '< 10 mg/dl|ALT', '= 25', '≥18 years|Participants', '+ 0/7 weeks|exclusive', '19 years or', 'greater than 1 cm', 'class 1,2, 3', '1 to <2 years', '≥60 mL / min.|Be', '=< 3.0|Aspartate aminotransferase', '6 months to less than 18', '≥400 ng/dL;|sedentary', '0-2;|Pathologically', '=<10 x upper limit of normal (ULN)', 'between levels I and II', '<0.5 ng/mL', 'Between 18-55 years', 'normative z-score', '≥ 100 x 109/L.|Hepatic function', '< 20|History of physical', 'at least 2/10 and less', '≥ 30 kg/m2|Patient', '40 to 70.|Primary diagnosis', '18-23,|Able', '≤ 1.5 x ULN|Coagulation', '25 between 6 and 25 years', '> 10 mg/L.|Participation', '34-44 weeks', '≥ 60.0mL/min', '≥2cm', '>=50%', '0 or 1', '<90 g/L;|Renal', 'period;|Estimated', 'less than 18 or more than 25', '< 18 years Skin condition', 'under 10', 'at least 50 years', '> 1.5 x 109/L', '1.1 via CT', '18 <= age <= 50', '> 130 msec', 'younger than 18 years and older than 65 years|Those', '< 60 mL/min/1.73 m2|Positive', '180 or less', 'greater than or equal to (>=) 180 days before screening|HbA1c from 7.0%-11.0%', '≥ grade III', '>55 dB', '>35s', '>40 or <18|Parturient refusal', '≥ 38 kg/m2.|Use', 'I - III|Patients', '<90 days)|Requires', '≥18 years|Diagnosis of', '≥18 years|diagnosis', 'naive', '≥ 20,000/L|Creatinine ≤ 1.5 X the ULN', '< 50,000 cells/mm3', '≥ 40%||', 'VHI-10)63 score < 10', '> 100 mmHg|any major', '≥18 to <80 years', '≤ 1 times the upper limit of normal', '> 1.5g', '> 100 × 109/L;|ANC > 1000 cells/mm3|Human Immunodeficiency Virus (', '18 years or more.||', 'less than 30 mL/min/1.73m2', 'greater than 60', '≥ 9 and ≤ 52 U/L', '6-11 age', '< 24 hours', '> 55 mmHg', '< 90', 'from 25-34.9 Kg/m2.|They', '< 50 beats/min', '>40 kg/m2', '100 cc normal saline', '> 3-fold ULN', '6 years old or older|They', 'less than 2', '< 2.5x upper limit of normal (ULN)', '> 30 minutes per day, ≥ twice per week', '≤ 2.0 cm', 'agent).|At least 18 years', 'RC tear', 'Upper or', '≥55mm', '≥ 3 times upper limit of normal.||19', '≥ 2.5 × ULN|Alanine aminotransferase (ALT)', 'between 18 and 35 years', '< 3000/mm3||-', '>30 kg/m2)||', '<1cm2', 'long-term care facility|Does', '< 7 days before the start of the study|Use of topical', '> 140mmHg', 'less than 2.5', 'People ≥18 years', '≥ 110', '< 3.5 mmol/l).|Hyponatremia', '>= 100mg/dL', '≥19.|Signed written informed consent', 'less than 30 right before', 'score 8 or more', 'scores <2;|Radiographic examination reveal focal pancreatic lesions;|No', '< 60%', '30 mL/min/1.73m2 ≤ eGFR', 'older than 89 years', '4-17 years', '≥30 ml/min/1.73 m2|Hepatic', '<8||Mild Dementia:||Participants living', '≤ 2 times the upper limit of normal', 'more than 1×10^6/mL);|Erectile dysfunction', '0-1.|Expected lifetime≥ 3', '18 years and over||', '< LLN', '>11 mg', 'score ≥15, and <25%', '<30%|Unable to understand the risks, benefits', '-70 years', 'ӀI-IӀӀ.|Singleton', '≥ 50 kg', 'V1-V6', '<24 months prior to Screening).||Prior/', '1-3b)|Marginal', '< 30 mL/min/1.73 m2)|ALT', '8-16', '25.1 - 44.9 kg/m2)|Elevated', '> 480 milliseconds.||Patient', '≤ 2.5 times the upper limit of normal value', '< 200', '≥ 450', '≥ 5)|Informed', '≥60 mL/min;|Serum', 'toxic megacolon', '0 year', '0 or 1.|Absence', '< 20%', '=< 3.0 x ULN|Corrected', 'above 400 mg/mL', 'Incarceration|Under 18 years', 'clearance||≥ 60 ml/min', 'at least 50 kilograms (kg)', '1-3|MOCA', 'between 60 and 100 Kg;|Agree', '> 30 minutes/day', 'over 18 year', '≤ 1', 'more than 8', '>= 24||', '> 150 umol/l', '>= 30%)|Patients', '50 to 90', 'score ≥4;|Have motivation to quit', '0-1.|Organ function', '> 20 mg/d', 'from 03 to 06 years', 'pregnant women;|Basic reading', '≥1,500/mcL|platelets', '≥5||For', 'more than 4 week.||', '< 0.90', 'between 0 to 2||', '>= 30 ml/min', 'more than 150 mmHg', '≥65 years.|More than 6-month', 'class', ""under 18 years old|The patient's refusal|Difficult airway story before|Congenital"", '-2', 'less than 100 cells/mm3', '>=90 mmHg||', 'score of < 6/60,|Severe hearing impairment', 'younger than 50 years', '18+ years.|Histologically', '18-85 years', '> 4/10,|AND', '18-25 yrs|able', '≥ 60 ml/min;|Patients', 'lower than 10%', '>15 cm', '≥ 18 years|Periodontally', '≥ 1.5 × 10 9 /L', '≥20 teeth', '>90 or <60 mmHg', 'from 18 to 24.9 kg/m2.|The study population', '<1 year', '150 cm', '≥ 38.0 C', '2.5 kg.||', '<97 mL/min', '≤1.5 upper limit of normal', 'females|Aged 18 years', '6.2 for details)||Cyclophosphamide within 3 months of baseline.|Rituximab', '4.2 ≤ 2;|absence', 'above 40 °C', '> 2 times UNL, TB', '<3 months prior to any possible study', '12 years', '≥ 8 year older and', '≥1.5×10^9', '5-year', '>= B7|Patients', '≥ 30 kg/m2|Willingness to participate', '<5 x ULN', 'between 50 and 70 years', '0 to 1|Demonstrates', 'more than 25% of the target variables', '= 12.5 mL', '≥ 8 g/dL|Coagulation', '> 3 times the upper limit of', '≥ 1.2L or > 40%', '≥40 mg', '<20 ng/ml.|Prostate', 'above 2.5 x ULN.|Epileptic seizures', '>14U/wk', '<120', '≤ 2|Ability to read Danish|No serious', '>= 100,000/microliter.|Creatinine =< 1.5 × institutional upper limit of normal.||Baseline respiratory requirement', '100-139 mmHg', '> 91%', '< 2.8 mmol/L', '18-70 years|a', '9-12|have standing orders', '0 to 1|Have', '≥ 18 years|At least one', '18.5 and 35 kg/m2', 'greater than or equal to 27.0 kilograms per square meter (kg/m^2', 'Activated', 'result.|Left', '<= 1', 'C grade', '≥45 and ≤100 bpm', '>30kg/ m^2 for obese participants||', 'C or D', '18 years or older|A', '>35|previous pelvic radiation therapy', 'between 18 and 35 kg/m2||', '≥18 years|First', '≤ 1 month (30 days)|Liver', '30-40', 'grade 2 or 3', '≥ 2.5 g/dL|International', 'less than 130,000/uL|Participation', '35 kg/m2', '16-30', '≥18 years|2', '<60/ min', 'score less than 18|Having orthopedic', '< 1.05)|CPET', '>30 kg/m2|active smoking', '> or = 150 mmHg', '≥18 years.|ECOG performance status', '> 24h', '≥18 years and ≤ 65 years', 'over 6-week', '< 2.0 mg/dL', 'between the 50th and 95th percentile', 'scores equal to or greater than the clinical population mean of the questionnaire manual)||', '<80 years|From', '< 5 years.||Secondary', 'from 2000 to 2019.||', 'between 18 to 80 years old;|ALT', '≥18 years|Women of childbearing potential', '18-75 (inclusive)', 'below 9.0 gm/dL', '≤ 1.5 times of upper limit of normal (ULN)', '50% or score', 'µmol/L);|The', '≥ 25.0 kg/m2;|sleep issues', '0-1|Lymph', 'basal cell/squamous', '> Grade 0', 'exposure;|Reporting', '≤ 30|Acute illness|Abnormal thyroid function|Admission', '< 6 years|Enrolled', '0 or 1.|Haematological', '18 and over||Exclusion Criteria', '≤ 13 weeks', 'nformed Consent Form (ICF)', '= 13.2 to 17 gm/dL', 'Prognosis', '1.5 mg/dl', '>65 years', '< 30mmHg', 'greater than 2 times the upper limit of normal', '>1 and <25cm²', 'at least 3 days.||', '3 to 18).|Diagnosed', '1.5D or greater', '18-60|able to understand spoken English sufficiently', 'lower than 1 year;|Any', '≥60 mL/min x', '4-week intervals', '=< 2.0 mg/dL.||Aspartate aminotransferase', '=< 2.5 x institutional ULN', 'from 18.5 to less than 25.0', '> 60 years', '> or = 18 years', 'within therapeutic range of intended use', 'A-band ultraviolet radiation', '≥ 65 mmHg.||Exclusion', 'between 18 and 80 years|MAFLD', '>= 26%', '>= 60|Negative pregnancy test done', 'been less than 4 weeks from the completion of treatment to the administration of this study', '≥20 using', 'between 30 and 65 years', '18-65 years|systemically', '> 1,5', '=< 10 mg', '=< 2|Male', '<2.5 x ULN', 'from 4 points', 'between 45-80', 'per day or', 'between 18 and 25 kg/m²||', 'more than 28 weeks', '≥ 5 years|Age', 'child', '50% children', '>35 kg/m2|coagulopathy', '50 L/min||', '6-12 years|Documented community diagnosis', 'more than 25 cm.|Ptosis', '> 70 mg/dl', 'at least', '>18 years|LVEF ≤40%|Extensive coronary artery disease', '>21 and <40', '=< 3.0 x ULN|ELIGIBILITY CRITERIA', '> 18 years;|absence of structured physical activity', '< 1000 cps/mL or 200 IU/mL per local testing', 'equal or more than 6', 'Lansky 70%|Each patient must', 'dose above 10 mg / day', 'greater than 30 kg/m2|History of diabetes|History of', '6-33 summing', 'from 6 to 12 years.|Children', '15.4 and 15.5 of this', 'below 0.9', 'between 4 years and 7 years.||Mandibular second', 'less than 30 weeks', 'less than 500 cells/mm3', '6 or below', '≥ 4 weeks prior to start of study treatment||Require', '10 or higher ⁴ / ml', '18 years to 45 years.|first trimester', '24-hr prior to study', 'A)|Greater than or equal to 18 years', '> 35kg/', '18 to 84', '<90 days).|those', 'non', '> 8|Aged > 18||', '50-100', '>18|patient presents', '< 1/10', 'greater than or equal to 26|Subjective', 'less than 50 grams', '≥ 60 mL/min|Serum ALT', '> 150 pg/mL', 'scores ≥ 20;|Current thoughts of suicide', '<50|Unable to do', '> 200/microliter', '30-50', '< 7 years', '<100,000/μL|have', '>1.5×ULN', '18-27 kg/m2.|Sufficient', '>40)|heart failure|uncontrolled', '<88 mL/min', 'between 5-10', '≤ 30 years', '≥ 30 kg/', '> 100g/L', '<=2.5 X institutional upper limit of normal (ULN)', 'greater than 2.33', '>100 mm Hg).|Weight', '1;|Adequate', '0-12 months|According to the', '> 1.25 x the upper limit of normal||viii', '4 class concerns', '60 and above', 'less than or equal to 12 years', '≤ 1.25 times the upper limit of normal', '18-65 years.|EDSS', 'less than 2 mm', '6 and 16 years', 'less than 10%', '≥ 3.5', '35-42||', 'between 6-24 months', '> ULN).|Patient', '< 80 dB HL', 'older than the age', '≥1.5×109 /L;|Platelets ≥100×109', '>27 units/week', '≥1×103/', '18 to 40||', '18-60', 'between 80 and 150 days prior to study|Have decision-making', '≥ 200 IU/mL', 'at least 1,500 pg/ml', '≥ 3||5', 'between 18 and 25 years.|Primary diagnosis', '<65mmHg.|Taking', '18 and 70 presenting', 'Latinx family of', '18-80 years|Not', '5-8)', '>150,000 x 10^9/L', '<2.5 g/dL', '< 18 years|Refusal', 'more than 3 months|7', '18 ~ 45', 'patients||age ≥ 55 years', '1)18-35 years', 'higher than 90 mm Hg', '<24 hours prior to the', '50% ≤ LVEF ≤ 55%', '≤ 3 × Institutional ULN', '< 3 months)|Severe cognitive', 'between 0 - <19 years|Radiological', '≥ 30ml/min', '> 15 x 10^9/L 7 days before', '≥ 1.20 D', 'less than 250 microns from the corneal endothelium;|abnormal', '>6 months', '> 1.25 x', '35-37˚C)||', 'younger than 18|nonpregnant', '=< 1.5 x ULN|No', 'above 35.|Acute', '>100 beats per minute|Male', '17 and 26kg/m2', '<= 0.90', '>18years.|Having one or more', '< 34 weeks|acute', 'larger than trace', '< 30 mL/min per 1.73m²;|Liver failure', '<30 ml/min/1,73', '5.0 or later', '12-18 years', '<20 min/day', '17 - 25 years|Mild-to-moderate crowding', '≥ 0.5 g/dl', '≤ 1.5 x institutional ULN', 'at least 3 months.|Have', '> 5 cups/day', '>3.0 ×109/L', '< 110 μmol/L 12', '≤ 200 mg/L.|Urine protein <+', 'older than 18 years|Sufficient command of the Dutch language|Being able to understand the', '≤ 1.5xULN or>50ml/min', '21 years', '>= 12', '1 - Patients', 'greater than 1.0g;|15', '≥2.5 X ULN|Total', '50 x 109/L)|Active', '41.4-60', 'above-mentioned inclusion criteria', 'between 18-35|pregnant', '>=100*10^9/L', '> 18 years|persistent/permanent', '> 5.0 mmol/L', '0 to 2;|6)Expected survival', '=< 15 days prior to registration)|REGISTRATION', '1-year', '<40%.|Uncontrolled', '<130 mmol/L)|Dyskalemia', 'score of 14 - 26', '≥ grade 3', 'between 2500 and 4200 g', 'score of 16-20|Insurance', '≥18 years|presenting to the', '≤ 130 mm Hg', '6 at least three times a week', '≥ 75,000/', '45 to 55 years', 'requires specific and', '≤ 4mg once a day', 'requires no intervention', '>= 18 years old|Within 4 weeks of study entry', '<1 at least', '5.2 mmol/L', '> 1.5 × ULN).|Malignancy', 'decreased', '> 18', '>= 50%||Note', '18 years and 55 years);|Localized', 'more than 3 months.|Patients fully understand the protocol', '> 6.5%|History of', '<100x109/L)|Constitutional symptoms', '18 years and above.|Subject', '15-48 months|Children', 'younger than 18 or older than 40', '45 to 90 beats per minute', 'higher than 145 mg/dL.|Previous', '110', 'between 60 and 90 mmHg', '20-30% of patients', '>1.5 before surgery|Pre-operative', 'greater than or equal to (>=) 25 millimeter of mercury', '0 to 2.|The effects', '>= 100,000/mm^3', '≤3× ULN', '<45 beats per minute', 'between 20-70', '21 to 65 years old', '<80,000/µL on Day 1 of', '≤ 2 cm', '> 18 years|full', '> 75 years.|An', '1.1 and', 'less than 60s', 'between 18.5 - 30 Kg/m2.|Participants', 'at least 3 days|More than or equal to 65 years', '≥ 35% predicted|CT mucus plug score', '> 48', '≥ 1.5 × 10^9/L', '20 mm Hg', '>=9.0 g/dL', '≤ 36˚C or ≥', 'more than 6 months', 'January 2020 to December', 'between 18.5-29.9 kg/m2|Understands the procedures', '< 30 kilogram', '>400 mL', '4-16', '> 400 mg/day', '< 25%|Mean pulmonary pressure', '21 to 90 years', '>NYHA I', 'between 80 and 35 letters', '≥ 75 × 10^9/L', '≥20 years', '> 3 × ULN；|Renal function', 'greater than -6', '<3 years|Currently receiving treatment', '≤ 2 tests', '<ULN', '>/= 2,000/mm3', '>30 kg/m2.||', 'Anesthesiology)III-IV|Patients', '2 to 3 points', '< 430 msec', '< 45 beats per minute', '≤ 3.0 mg/ml', '15m ≤ from the margin;|4', '>35|Known', 'degree II or above', '= 19 -37|Have daily access', '< 100%|≥50%, <70%', 'greater than or equal to 1.8.||', 'being 65 years', 'II - III', '=< grade 3', '≥2 days|Residing', 'more than 60%', '≥35-39 kg/m2', 'greater than 1|Body mass index (', '>= 1500/mm^3', '<95% predicted|Asthma Control Questionnaire (ACQ-7): Score ≥1.5|In', '30 times/minute', 'between 18 and 30 years', '>1.5 times ULN', '60 and over,|Experiencing two or more of the', 'without', '>140 mmHG', 'more than or equal to 130/85 mmHg', '2 points)|Absence of', 'less than 65 years', '≥ 10.0 g/dL|WBC', '>= 18 years', '<6 months 2', '> 30 ml/min.|Women', 'older than 60', '≤ age ≤ 42 years;|Number', '≤ 1.5 × ULN；|Color', '=< grade 2', '19-year-old', 'score is 0 or 1', 'less than 5 mmHg', 'between 20-60 years.|Patients', 'class IV symptoms|symptomatic severe', '≥ 90 g/L;||Serum', 'upper limb bone surgery carried', '3|>30-40', 'more than 70%', '≥ 18 years.|Eastern', '≥ 2|Measurable disease', '<1.5 x upper limit of normal (ULN)', '3-1)|cardiovascular stability||', '<1 year|Comorbidity', 'between 45 to 90(include', '> 2 x ULN', '>1.5× upper limit of normal', '≤400 mg/day', '≥75 × 10^9/L|Hemoglobin', '0-1.||', 'greater than 6 months|For', 'greater than 3 months from time of enrollment', '65-79 years', '2009 Equation for 18 years old patients.|Pregnancy|Neoplasm|Infections', '0-1.|Absence', '≥ 20%', '≥ 1.7 mmol/L', '≥ 7 mm|Tear', '<3 cm', 'above 2.|Untreated hypertension', '> 2 g/l', '1 and Phase 2a', 'less than or equal to 30 dB HL', 'from 0 to', '>97%|Patients', '≥ 10', '5-7|8', '> 12 weeks|Absence', '0-2;|Life expectancy', '> 30%', '0 to 1;||Sufficient', '<1.5 × ULN', '3-4 L', '≥19 years.|Patient', 'older than 50 years old', '18-35|Medically healthy', '> 11.1 mmol/l', 'than 4 cm', 'between 2 and 3.||', '< 1500 mm3', '<100 ng/ml.|Prior', '> 16 with pelvicfracture', '<6 inches', 'less than 18.5 kg/m2', '1.1 after prior', '≤ 6 mm', 'less than 12 mmol/L).|Severe', '15 to 19 years', '> grade 3', '>300 mg/dl', '< 80/ units per liter', '≥ 2);|History', 'greater than 12 weeks|Opioid', 'ON <6 months prior to the study', '≤ 18 years', '≥ 18 years old,|Patient', 'greater than 24 months', '≥ 2.5 mL', 'between 18 and 75.|Confirmed', '≥ 3.2 g/dL', '≤ 1.5xULN or < 3×ULN', 'greater than 3 times the upper limit of normal (ULN)', '≥ 18 years|Diagnosis of diarrhoea-predominant', '20-28|age', '< 16|Ability to complete all study procedures||', '<400 IU/L|liver biopsy', '< 30% normal level', '≥ 55 years', '>4 weeks before', '< 240)|active', '5 to 15 years old|Attend the asthma clinic', '< 500 IU/mL obtained', '≥ 38.0 degree Celsius', 'less than 200 mSec', 'class NYHA III', '1 to 3.|Participant', '≥ 6 points', '10x lower than what is found', 'at least 45%', '>= 1,000/mm^3', 'score of 18 to 26.|Participants', '≥18 years.||Histologically', '< 1.5 X ULN', '1 or 2),|For', '20 and above', 'between 18 and 32 kg/m2|Subject', '>4 points', '60 years and old', '>= 7 days after the last dose of agent.|Antibodies', '18 and 75', '>150 kg', '≥ III', '≥70×109/L', '> 2 days', '3 months and older', '≥ 100.4˙F|Unstable health conditions', '> 30 mL/min/1.73 m2||Baseline Audiology', '>2500g|Possible match', '≥18 years.|Diagnosis', '16 or greater.|Eastern', '>480 msec', '≥ 2 UNL', '>= 12 continuous months of amenorrhea', 'over 18 to 65 years', 'between 18 and 25kg/m2|Able', '18-55 years|Body Mass Index of 25-40 kg/m2|Not', '≥ or equal than 10mm', '>0.4', 'NIV', '18.0 to 32.0 kg/m2', '≤ 90 or ≥ 160', '< 50mmHg or', '< 35kg / m2', '0-28 days);||Gestational', '≥18 years.|Diagnosis of TTS.|Available', '≥3 cm', 'years|Pre-stroke', 'identify', 'time < 36 hours；|PaO2/FiO2', '18-65|To have', '1-5 metastases', '>= 50 mL/min/1.73m^2 73m^2', '≥20 years);|Definitive', '< 28 kg', '> 1.5 times the upper limit of normal.|Suffering', '> 6.1 mmol/L|Abnormal', '2 or more.||', '≥10mm', '≥ 38.0°C', '≥ 45 mL/min.|For', '<1 g/24 hours.|Prolongation of', '0-2.||5', '≥140 mmHg', 'M184V/I', '< 18 years|Known allergies', '>18 years old.|Both sexes.|Diagnosed', '≤ 30 kg/m2;|A willingness', 'Assigned', '> 2x normal', ""?' and completed"", '<15 million/ml', '18.5 - 29.9 kg/m²|have', '>7.5%', '≥90 mmHg);|History', '19 years to 75 years|eGFR ≥ 90 mL/min/1.73m^2|Body weight', '<45;|HgA1c.>8.0%|History', '< 1% failure', '50-unlimited|Found', '> 10mg', 'planned', '≥ 40%|Women', '≥ 5 kg', 'Functional Class (', 'at least 25 milliInternational Units per milliliter of urine (mIU/mL', '18-45|Overpronation foot', 'more than or equal to 4 uM', 'prolonged <= 6 seconds.||', '>3x upper limit of normal (ULN)', 'below two years.|Bilateral UPJO.|Recurrent UPJO.|Malrotated', '30 to 35kg/m2|Able', '> 12 IU/mL', '< 25 ng/mL', '>38 °C)|prostatectomy', '70% to 99% stenosis', '>=18|UTRD', '≥ 3 g/dL', 'Measurable', 'levels ≤ 2.5 x ULN.|International normalised ratio', '> upper limit of normal);|Patients', 'higher than the lower limit of the detection value', 'class 4= incapacitating disease', 'between 18 to 45 years', '1-2h after IVT', '11.1 mmol/L)|Random', 'below 18 years', 'over 18', 'score 0 or 1;|Adequate organ', '< 20 ng/mL||Note', '60-65%', '≥20 mg/L', 'score ≥2；|Patients', 'less than 12 lymph nodes examined', '>=40 milli international', '>450 msec', 'no more than 1 year|Ability', 'over 18 years old,|Having no barriers', '≥ 100 × 109/L；||The', '<50,000/µL.|Clinical history', '< 5th percentile|Bishop score < 7|Intact fetal', 'greater than 30|Eye', '> 900 pg/ml|have', '>= 1,000/uL', 'between 18.0 and 30.0 kg/m^2', 'less than 29 Kg/m2||', '>119 msec', 'greater than or equal to 4 mm', '18 to 75 years old', '-15 years', '<1.5 X ULN', '=< 2.5 x upper limit of normal', 'at least twice prior to 24weeks', 'below 100mmHg;|use of', '>3years)||', '= 0.133 kPa).|No', 'less than 19', 'more than 80%', '≤ 15.|ECOG performance status', '18-85|Within 8 hours of the onset of stroke symptoms|There', '>120 mL/min/1.73 m2', '≥15 mm|Subject', '> 14 points)||Evidence', '>18 years|cancer', '3.1-6.0', '6-month', 'between 55-75 years', '< 85% recorded', '< 3 cm', '< 6 months|Patient', '20-30 years', '>3 months)|Modified', '0 - 16 years', '<30 milliliters per minute', '< 13.0 years', 'protein C deficiency).|Participant', '>100 or <60', 'than at least', '>40 kg/m2.|preoperative', '≥18 years|Identified', '40% or above', 'over 18|Patient consulting a general practitioner', '50-90 bpm', 'minimum sensitivity 25 IU/L', '> 75 mg/day', '≤ 1.5*upper limit of normal', '<140/90 (NOTE', '> 13', '1 or 2|Patients', 'between 6', 'between 27mm - 48mm|For', '>= 1,000/mm^3|Platelets', '> 30 mL/min', 'from 30-60 years', '> 240 mg/dL', '20%', 'LumisTM 150', 'higher than 500 IU/mL', '>= 18 years|ELIGIBILITY CRITERIA', '> 150 cm.|Present diabetes.|Present dyslipidemia', '< 1 month', '≥ 90 g/L;|Absolute', 'more than 0.1', '< 24 h.|Pregnant', '> 5.5mmol/l', '1 child', 'above 3 x upper limit of normal (ULN)', '≤ 28 kg/m^2.|The', '≥ 90mmHg|Evidence', 'exceeding 30 g/day', 'between 25-40 years', '1.75-6.0 mm.|Those', 'above from baseline through the course of antibiotics', '20-29% marrow blasts|All', '6 mm or greater', '20 IU/mL', '≥ 75|Currently hospitalized', 'narrow', 'greater than or equal to 36 on the PCL-5', '>= 18 years||', 'than 2.0.|Patient should have', 'between 18 to 75 years', 'myalgic encephalomyelitis / chronic', '<20 or >85||History', '<30 ml/min/1.73m2||Pregnant', '5-6 points', '> 1 lymph nodes', '≥ 95g/L', '=< 7 days prior to re-registration', '< 80%)|Hypersomnia|Periodic Limb Movement', '18 - 80 years,|Visual acuity', '≥75 years of age||Diagnosis of clinical', '1+', '> 13;|Elevated', '≥50 mL/min/1.73', '2-2.5 mm|levator', '≤ 1.5 × the upper limit of normal (ULN)', 'Younger than 18', 'I,', '<15 mL/min/1.73m²', 'Low', '600 mg/4 ml intramuscularly', 'Stage I NK|Decreased nerve density', '<200 mm3', '>2 mg/dL.|ECG', '1 cm between the tumor', '≥37 weeks and <42', 'at least 12 weeks', '5-7 days before surgery', '<11', '> 5 kU/l', 'above or equal to 18 years', '>40 kg/meter square', '>7%;|Monoclonal gammopathy;|Pregnancy;|Body mass index', '≥ 1.5-fold from', '<1)|More', 'more than 2.5-fold the upper normal limit).|21', '2.5 × institutional ULN', 'long-term care', 'greater than three months', '>7gm%|Less than 24h away from emergency care||', '>= 1,000/mm^3|Platelet count', '> 30 mm|cervical dilatation', '> 2.5 times the upper limit of normal (ULN)', 'less than 12.0', '35 - 55', '>65 years|Malignancies|Liver', '18-65 years|Non-smokers||', '< 350 cells/uL', '19 to 80 years|FMA Upper scores more than 25 and less than 58|Patients whose lesions', 'between 18 and 50 years old;|Be able', 'less than 30 × 109/L', '<0,5 mIU/L', 'between 3 and 22 µg/dL', '18-40 years|Antibody + T1D <30 years', '< 190mg/', '||- not able to read', '≥ 40 years;|BMI', 'at least 10mm', 'score of ≥8|Has', '≥ 2 × ULN', '≥ 100,000/µL', '≥ 35%', '>230ms', 'from 0 to 8 months.|The course', '< 40%,|Use', 'diagnostic criteria|Agreed to be', '> 100x109/L', 'not less than 6 months.|Adequate function', '>55 ml', '> 1.5 x institutional', 'Grade II or greater);,|Documented', '0-1;|Predicted survival', '130-159 mmHg', '<50% of the liver|BCLC classification', '25-65 years.||', 'over 65 years|knee', '18-45|Being', '<30%', '>1%', '> 4.5)|Signed', 'greater than 15 mg/day.|Patients', '>35 kg/m2|contraindications', '≥40 mL/min/1.73 m^2|Patients', '≤ 5 times the normal value upper limit', '≥ 18 years||Screening', '> two', '1 MSM||Under 18 years', 'poloxamer 188', 'between 40 and 90', 'above a baseline', '< 45 ml/min/(1.73', '< 25 g/L||Others:||Patients', '≥60%', '18 to 74 years|localization of the primitive: breast, lung', '<20 and >12 /min.||', '≥++ or 24-hour urine protein quantity', '<100 IU/mL', '8-18 years|Signature', '< 50,000/uL', 'from 20- 35 years', '> 60ml/min.1.73m2||Aged', '4-10ng/ml', 'less than 60%;|History of', 'between 19.0 and 26.0 kg/m2', '≥ 4/10', '0.1 mg day given', '0-Is', '> 3 x', 'greater than 12 weeks|The', '90g/L).|Creatinine clearance', '≤1.5 times the upper limit of normal value', '≤ 1.|Known', '2 to 17 years', '>1 &', '+/- preventer', 'between 1952 and 1966|Living in', 'vaper.|Vegetarian', '≤ 3 months)；|Already', '≥110', '>50 units', '18 and 60 years old', '<=2.5 x Upper Limit Normal (ULN)', '≥ 8.0 g/dL|Creatinine', '> 65 years|low-dose', '≥ 1.2L', '> 1.3', '0-1；|Forced', '< 1.2 × 109/L', '>= 6 and < 40 years', '≥300 ng/L', '40.0-49.9||', 'from 18 years and over|Be', '1-week', '>21', 'stage II-IIIb resectable', 'between 16-35 kg/m2|Forced', '≥18 years;|Submitted to first allogeneic stem cell transplant', 'from 5.7 to 6.4%|2-hour OGTT levels', '>18yo', '<1 (Exception to this criterion', 'less than or equal to 10.0 percent', '65-99', '25-35 kg/m2|Stable', '25-45 years', '18-70;Female;|Pathologically', '>133 μmol/L', '>20 mmHg', 'between 19 and 45 years', 'greater than 30 g/day', 'less than 14', '≥ 1×103/ml).|Has', '<18 years.|Pulmonary infiltrates suggesting pulmonary edema', '≥ 60 mL/min;|Coagulation function', '25-30 weeks', 'Less than 8 years', '<9h SB/day,|experienced', '≤40ml/min', '<35 kg/m2|Male', '< 24 hours before randomization.|Suspected', '≥ 3,000/µL|Platelets ≥ 120,000/µL|Normal', '<= 90', '>= 100,000/mm^3|REGISTRATION', '<30%|Severe', '≥125 pg/ml)|eGFR', '>470', '≥ 30 mL/min.|Liver function', '20 and 60;|Score on the', '>= 45 ml/min', 'between 10-17', 'less than or equal to 3 times ULN', 'greater than or equal to -6.0 D', '≥ 90 g/L.||Kidneys', '<3000/mm3', '< 2.5×upper limit of normal', '≥100,000/µL', 'requires antibiotic therapy|Patients', '≥ 3.0 g/dL|International', '≥ 22 mmHg.||Exclusion', '≥ 2.0 × 109/L', 'between 5 and 17|Maximum', 'less than 80mL/min', '>140mmHg systolic', 'requires treatment|current abuse of alcohol', '≥ 10-≤18 years', '18-75 years.|Willing', 'less than 18 years|Patients', 'more than once', '≥50% of tumor cells|Local IHC results', '≥180/110 mmHg;|Previous', 'IIIB', '≥ 37,3°', '< 80 ml/min/1.73 m2|Proteinuria', '≥100 000/µL|Hemoglobin ≥9.0 g/dL|Creatinine', 'no better than logMAR 1.6 in better seeing eye', '38-42', 'less than 12 months|Severe dysfunction of the heart', 'greater than or equal to (>=) 200', '>18 years|be able to read', 'Score 0 or 1|Patients', '18-55', 'PR negative', '≤ 50 years', 'levels to ≥ 3X ULN', '67 per facility', '≤ 2|Able', '>= 28 days after the completion', '42 to 62 days of age', '> 16,|ongoing', '25-45 years|waist', '<15 ml/s', '10^9/L|Adequate renal function', '</= 5 mg', '≥3 months;|Patients', '>=100,000/microL|Total bilirubin', 'score of >15||History of surgery', '18 and 65, regardless', 'less than 72 hours', '4.5-7.5 months', '18 to 35 years old', '> 20 inches|Any other reason', '<60%', '< 2000 mg/g', '<1500/mm³', 'Grade 0-2', '18.5-29.9 kg/m2)||', '< 3:00 / MSFSC', '≥3 x ULN', '< 21', '> 0.7 kilounit per liter', 'at least 12 weeks.||Adequate', 'under 12 years', 'gt;40 mL/min', '25-60', '+ high dose cyclophosphamide)|Patients', 'above 18 years||for matched control', 'above 18 years|Diagnosis of', 'greater than 90 mmHg', '>0.35kU/L.|For', 'score of score of 18-23', '<6-month', 'greater than 3 mm.||', '<3 at time of discharge.||', '≤ 60 hours per week.||', '<1,000 neutrophils / mL', 'greater than or equal to 10^8 cfu per day', 'over 18 years,|linezolid', '< 30 mL/min/1.73 m^2).|Patients', '<90 mL/', '≥ 1.5x109', 'score of 36 or', '≥ 2.0', 'oximeter', '≤7 years', '18-65,|2nd', 'Grade II or higher', '>=2|Completion of ""IF', '0-1.|Availability of archival tumour biopsy tissue', 'less than 20 weeks', '≥ 0.9', 'January 2010', '<35%|Uncontrolled fungal', '≤ 40.0 kg/m2|Meet', '<40% measured <5 year', '> 150 mmHg', '4 or greater', '1-2||', '=< 480 msec|Creatinine = calculated', '>= 30/35 Kg/m2;|No', 'abnormal', 'at least 4', '6-14 years', 'more than 35|patients', 'less than the legal age of consent', 'greater than one week|written informed consent', 'from 4 to 10 points', '≥4', 'between 18 and 70 years', 'First-degree relative', '≥12 years to ≤65 years', 'Score-Based', 'distant metastatic disease on CT/MRI scans', 'proven', '> 5 x ULN|Aspartic acid', '18-89 years', '= estimated glomerular', 'greater than 550lbs', 'greater than 65 years', '>130 mmHg', 'less than or equal to five times normal', 'more than 1x103 copies/mL', '90-100 mmHg', 'less than 5 pack- years', '>/= 18 years|>/= 2', '≥ 50%;|Thyroid function', '4-6 years', '90-day follow-up', 'between 18 and 40 year-old||', '≥18 and ≤75 years|Sustained remission', 'less than 45 years', '18-75.|Patients voluntarily', 'at least 12 weeks|Female', 'between February 2008 and June 2012|Willing and able to provide informed written', '> 160/100', '50% of biofilm', 'score of', 'age<18 years;|presence', 'above grade II', '≥ 60 mm', 'Class II', 'Normal', 'two 2 mm', '<24 points', '≥ 1.0x109/L', '16 years or older', 'less than 1.5 x ULN|Serum', 'stages IV and V', 'at least 2 days per week', '5-12 years.|Parent-reported', '50-80 years', 'Short', '< 10 mIU L-1', '<12 months|Individuals', 'from18 to 65 years', '≥ 1500/μL.', '20-70 years', 'between 18 years and 75 years,|Eastern', '20-75 years', 'less than 40 kg;|Volunteer', '< 3 × ULN', '>100 or <40 beats per minute.|Positive', '≥90 mmHg', '≥ 5% after CR', 'dose ≤ 10 mg daily prednisone', '<25K', 'at least 50% or greater', 'Over 18 years old,|For patients', '18.5-30.0 kg/m2|Fasting', 'better than', '> 40 years', '> 50 mL/min/1.73m2', '<75 minutes/week', 'less than 30 minutes||', '> 24/30|Ability to walk', '30 to 60 years', '18.5 to 30 kg/m^2 inclusive', '1 to 17 years', '50 years and older|Lives', 'between 37-40', 'Over 80 years|Healthy', '>18y and <75y|morbid obesity', 'above ULN).|Estimated', 'below 32%', '<0.5 or >5.0 mU/L', '<18 years.|Not available', '150 mg dose strength).||H.', '≥ 20 pack', 'greater than or equal to 20', '14 to 40 years||', '1 TO ARM 2): Patients', 'at least 9.7 inches diagonally', 'from 25-40', 'greater than or equal to (>=)50 kg|At screening', 'equal or less than 2.0 mg/dL', '< 30ml / min / 1.73m2);|Significant', 'Greater than or equal to 18 years', '> 2 times the upper limit of', 'I-II-III|BMI', 'I & II|both genders,|≥', '< 13 years', 'inhibiting exercise', 'less than 4years and more than 18 years', '≤ 3 x ULN|Total Bilirubin', '< 1.3|for healthy', '≥ 15 times one hour).|Those', '>= 40 mL/min|Human immunodeficiency virus', '≥ 0.5 ∙', '> 35 kg/m2)|Hemoglobinopathies|Arteriopathies', '< 1.5 mg/dL', '>450 ms', '> IV|preoperative', '< 500/μL', '≥3 in combination', '≥ 60||Individual', '≥ 1,200/mm³|Platelet', '< 4;|stable medical', 'more than 30%', '18-50|Having', '> 40 mIU/mL', '18 - 48 years', 'less than 50% reduction in wound size', '< 60 mL/minute|History', 'between 18 and 55 years|available to attend', '≥37 weeks', '<27 weeks', '40 years', '< or =', 'Grade 2', '<20|Current dietary', '< 70 mmHg', '36.4 °C and above', 'greater than 10 mm', '>=1', 'younger than 19 years and older than 35', '<100 x 109/L)|Bleeding disorders', '<1 year|Lung disease', '≥ 100', 'greater than (>) 25 mmHg', 'between 16-60 years.||Flexor', '40 IU/L', '< 1 year|Uncontrolled Hyperthyroidism|Hypertrophic', '≥ 100 mg/dL|Triglycerides', '10 to 24 months|Given informed written consent', 'Stage II-IV.|Must', '≥18 years|Diagnosis of MM', '0-1;|At screening', '≥3 times per day', '≥ 25kg/m 2', 'between 5 and 16 points', '>130/90 mmHg)|Intolerance', '≤1.5× upper limit of normal (UNL)', 'between 2 and 12 years', 'grades 9-12|Male', 'between >22 kg/m2 and <40 kg/m2.|Has', 'greater than or equal to (>=) 18', '< LLN|Hemoglobin < LLN|Any', '18 years or over', '≥60 mL/min.||Heart', '1.5 x 109/L', '>80 g / day', '=< 3 years', '< 200 ng/ml', '>140', '> 1/3 of the', 'stage III-IV', '≥ 80 × 10^9/L', '>0|Woman', 'worse than 6/12|Diagnosis of clinically relevant eye disease', '>450 milliseconds).||b', 'Older than 5 years', '>75yo', '1.18 years old ≤ age', '20-24.9 kg/m².||', '≥18 years)|First dentofacial orthopedic consultation', '0-18 years|The', '18.5-29.9 kg/m2', '0-2|Controlled', '18-60|Premenopausal', '≥ 3.0 × 10^9/L;|Platelets', '0 to 1|Patients', 'at least ≥ 18.0 kg/m^2', '<20 ml/min/1.73m2|Use', 'between 20 - 75 years|Previously', '=< 2.5 times institutional ULN', '10-14 weeks', '≤ 5 times the upper limit of normal value', '18.5 - 24.9 kg/', '< 1.0', 'between 18 and 30 kg/m2', '>= 9gm/dL|White', 'more than 1/3 of participants', 'less than or equal to||10.0 cm', '<1.5 times the upper limit of normal.|Voluntarily participate', '≥1.7%', 'between 12 to 15 years.|Children with normal', '> 400 mg/dL|Dialysis treatment', 'postural drop', '>0.80', 'manage', '1.1 criteria);|The', '≥ 180 mmHg', '> 470 msec', 'stage II', '>500 mL blood', 'greater than 160 or less than 95 mmHg', '18-75;|ECOG score', '>=1,500/microliter', 'scale|Owns', '> 10 centimeter', '= 375 mL', '≥60 mL/minute', '>grade 1 despite standard medication，or hypoalbuminemia', '>30 but <60 mL/min', 'Resides', '≥ 3 years', '≤1.5 upper limit of normal||', '≥ 90,000/μL.|Have', '≥II', '+/- androgen deprivation therapy or|Locally advanced', '> 8;||Level of', '>24 months to <18 years', '> 35 kg/m2|hospitalization', '< 51 μmol/L', '≥1.5×10^9 /L', '< 1,000/µL|Hypertriglyceridemia', '> 65 mm|Refusing', '≥0.75×10^9/L', '>/= 3|Stage I-III', '18 years||4.Biological', '< 18 years|Patients', '>30 kg/m2|Patients', 'bigger than toes,|Individuals not able to stand still', 'between 20 and 60 years||', '> 18 years|Symptomatic COVID-19', '< 60);|Patients', '1.2 mg/dL|Indirect', '140 - Age)/72', '≤ 1.5 X institutional upper limit of normal Or CrCL > 50||-', '> 18|BMI > 30 kg/m2|Requires', '≥ 60 to 85 years|Ambulatory individuals|Written informed', '< 20ml/min', '95% for ≥F3', '=< 1.5 x ULN|Aspartate aminotransferase', '≥50 mL/m2;|Suffering', '18 to 75 years', 'I or', 'score of 5 or more.||', '<12 and >18 years', '≥ 88 cm', '≥70 years.|Be living', '> 1.5 ×109/L', '≥ 6', '≥18 years willing', 'between 18 and 75 years|Performance Status', '≤ 94%', '>=18 years;|Clinical presentation', '≥ 30 cycles.min-1', '25 - 60 years.|Fluent', '18 years to 80', 'three or more', '≥ 1', 'more than 20 times', 'and≤80 years old', 'greater than 400 copies/mL', '≥40 kg/m²', '< 3 months', '>= 18 years.||Patients must exhibit', '>= 1000/mm^3|Platelet count', '≥25', '< 1 year|Patient', '>302 mg/m^2 daunorubicin', '<= 1+(unless urine protein', 'requiring 20cc/kg', '>37.5°C', 'older than', 'between 18 and 85 years|Critically ill', '<8 g/L', '<18|Smoking|Diabetes Mellitus', '≥ 2|NT-proBNP level', '≥ 32 g/L', '< 60 year', 'less than 48 kilograms', '220-450', '18 years or older|Being', '<2 times UNL', '>2,5 for', '1-18 months|ALSFRS-R score', '140 mmHg.|Patients', '≥ 19 years to < 55 years', '<7.2', '37 weeks', 'below 5 kg|Current participation', 'Negative', '≥ 10.|Subject', '≤ 10 g/dL|Platelet count', '18-45 inclusive', '≥ 30 mL/min|Female', '>50 g/d', 'III to IV|Unable to provide', '20 ~ 30 kg/m2', '≤ 10.0%', '< 16 kg/m2.|Known', '- 18 years', 'over 45.0 kg', '<500 ng/mL', '18 years or older|Ability to speak', 'above 21 years old', '90 - 140 mmHg', 'below 89%', '18 to 65 years|are', '>1.5x the upper limit of normal', '≥ 1500/mm3|Creatinine ≤ 1.5 × upper limit of normal (ULN)', '≥30 mL/Min per 1.73m²;|Systolic blood pressure', '>= 10 mg/week', 'less than 1% failure rate', '>900 pg/mL', '0-2|Adequate', 'below 50 %', '< 0.1 decimals', '>=100,000/mcL||total bilirubin', '>= grade 2', '≥30)|Heavy smoker', '<30 mL/min/1.73 m2|Liver', '≥ 9 g/dL||Adequate', '<30ml/min);|Patients', '18.5-30.0', '14 to 18 years', '≥160 µmol/L;|hemoglobin <80 g/L', 'less than or equal to 75 years|Willingness', '+ 1 confirmatory test', '>6months', '3G', '≥90 or ≤60 mmHg', '≤ 59 U/L', 'Latino|identify', '<7.0 g/dl|Platelet count', '< 18 years old|not agreed to provide', '≥20,', '45', '18 to 55 years inclusive', 'less than 70)|Substance dependence', 'equal or over 18 years', 'between 27 weeks 1 completed day', 'greater than 1.5mg/dL)|Left', '>= 75 years|Eastern', '≥ 2 to < 18 years', '140 µmol/L', '≤ 3.0 x IULN|Creatinine clearance', '> 1000ng/ml', '75-year-old', '>= 50K', '> 37+0', '> ULN x 1.5', '> 200 mg/d', 'outside normal range or < 125 x109/L|Hemoglobin', '4-item', '14-19', 'younger than 60 years', 'class -≥3', ""<12 4.2-4 weeks of DOC||5.informed consent obtained from the patient's legal representative.||"", 'midazolam.|Pregnant', 'quantitative', '> 48ml/m2', 'IIB', '≥ 75 x 10⁹/L|Serum bilirubin', '5.5 - 9.0', '18 to 80 years', '70 to 95 years old|Having signed', '7.0% to 10.0%', '1-3.||', 'score of 24 or', 'older than 50', 'equal to or above 18 years|Male', '≥ 8 years', '>480 msec.|Ongoing', '100 × 109/L', '0-1.|Available tissue of', 'between March 01, 2014', 'between 45', '≤ 1.5 times of normal upper', 'greater than 130 millimeter of mercury', 'maximum 60 mg/day', 'less than 50% stenosis', 'I or II)|Patients', '/T2', '19-35,|Fasting regularly', 'above is usually', '24-h', 'Score ≥ 60%', 'score of < 20', '≥ 35 kg/m2|Chronic use', '< 35 %', 'between 12 and 17 years|Atraumatic lower extremity pain', 'less than 5 cm', '< 1 year|Uncontrolled hypertension', '18 years old or older.|Diagnosis', 'greater than or equal to 5', '≥ 1.5 *', 'between 10 and 15 years', '≥50% stenosis', 'PD ≥5mm', '>3|Cardiac', 'less than 80 lbs|Use', '19 years and', '≥6 points.||', '> 6.5%|Age 14-17', 'between 40 and 90 kg', 'Visit II', '>15 dB HL', '<1 g/ L)|Presence', '18.5 to 24.9 kg/m2).||', '> 89 mmHg', '≥12 weeks|Measurable', '>= 6', '>160/100 mmHg', '>1 year', '22-55 years', 'at least 20 years', '< 1cm2 or/', '> 1% blasts', '<3.0 kg', 'high-dose per reference chart', '< 18.5 kg/m2|Calorie-reduced diet', 'equal to 16 years of age|Tolerating levels of pressure support', '=< 2.5 X ULN', '>35 weeks of gestational', '≥3 months.|Ann', 'below 18 years or above 80 years.|Patients', 'between 18.5-30 kg/m^2||', '≥ 18 years.|Be', 'above the ULN|Estimated glomerular filtration rate < 60mL/min/1.73 m2 body surface', '>150 mm Hg', '≥ 30 ml/min', '< 10', '18-49 years|Decide', '≤ 5 x', '37th to 41+6 weeks', 'greater than (>)1.5 × upper limit of normal', '10*9/L', 'less than 2500 copies/mL', '>7cm', '20 mg', 'younger than 18 years-old|Patient', '< 2.0 x ULN.|Bilirubin', '≤ 1.5 times the upper limit of the normal range', 'I and II scheduled', '>1.5 × ULN', '>= 15 mL/min/1.73m^2||Total Bilirubin', '> 1.5 times of the upper limit of normal value', 'not more than 1', '13-25', '1,000/μL', 'stage II or III', '60 to 70 years', '18 years to 75 years|Confirmed diagnosis', '≥ 100 G/L|Serum', '-2.5 months.||negative', '> 12 months;|Patients sign', '> 221', '18 - 85|ECOG performance status', '<90×109/L;|Those', '>70% diameter stenosis', '> 1 million per microliter', '< 13|Patients', '8-11 years', '< 10|Able to speak', 'over 6 years', '18 to 70.|Pathological type', 'negative)|Stage II to III|With', '> 60ml/min|Adequate hepatic function', 'score of 7', '> 7mm', 'between 30 to 44(include', '≤ 3 x ULN', 'from racism', '>15|Able to understand the commands|Had a function', '=< 2.5 X institutional ULN|Creatinine clearance', '6000-12000U', '18 years and older|At least one symptom', '<50 kg;|Haemoglobin', '3|Anaplastic Oligoastrocytoma', 'less than 150', '18 and 70 years', '> 90 days|age', 'outside of 18.5-34.9.|History', '40-79', '<5 years ago', '30-75 years', '≤ 350 mg/dL', '≥3×ULN', '0 to 1.|Histopathologically', 'T3-4a or N+', 'between 16-42', '<18 years;|Pregnancy;|Chronic', '<24 months|Have a presence', '= weight divided', 'less than (<)1 percent', 'less than 1.5 times the upper limits of normal', '0-2|Adequate organ function||', '≤ 2.5 × institutional', '≥ 50 kg ≤ 90 kg', '18 or older|Have documented', '≥ 18 years.|At least one measurable', '≤ 3 times the upper limit of normal (ULN)', 'more than or equal to 50%.|More than four weeks', '<60 mL/min/1.73m2', 'class IV angina', 'between or equal to 25 to 35 kg/m2', '> 0.5 G/L|Patients', '≤1.5×ULN or ≤3.0×ULN', 'score of 4 ≥ on item', 'below 5 kg', 'from 40 to 50years', '23-64)||', '>12 months prior to screening', '4|Psychosocial', 'At least 42 days must', '> 41 U/L||C.', '≥ 50%||Normal Organ', 'Score 2 or more', '18+)', '≤ II|Age', '>3 x upper limit of normal', '=< 1|Platelets', '>30%.||Unresponsive', '<5% within 3 months of treatment).|Patient consent to change', '18 and above', 'thromboembolic event', '15-45|To', '≥2.5 g/dL|International', '18-45', '60 to 75', '≥18 years or >2% reduction in BMI', '18-65|having alarm symptoms', '<1500/mm3', '≥200 ml', '≥25 mL/min/1.73 m2.||', '18-65 years|Have', '>10% of body weight', '≥48 mmol/mol', '≤ 5.0 x ULN', '>58.3%', 'score ≤ 25', '≤ 1.5 × ULN.||10', '≤ 1.5x Institutional Upper Limit of Normal (ULN)', '≥80% of patient', 'greater than 115', '0-1|Receipt', '≥1.5×109/L;Hemoglobin', '0 ~ 1;|7', '≤ 1.5 upper limit of normal (ULN)', '>5mL', '> 1.5 mg/dL).|Alcohol', '< 50 mg/dL.||', '<40 ml/min/1.73 m2', '≥ 18 years)|meeting the clinical', '> 6 months||', '≥ 55%', '≥100 x 10⁹/L', '≥18 to ≤64 years', '18-80 years|Diagnosis', 'better than +0.25', 'over 30', 'between 58%-82%', 'between 4', '≤ 3.0 times ULN', '18-', '0 -1.||Locally Advanced', 'grades 1 or 2.|Receive general anesthesia', '<12 weeks', 'I, II or III|Free', '≤ -2.5', '> 12 weeks', '0 or 1|Absence', '≤ 1.5 x upper limit of normal (ULN)', '≥30)|serious', '18-80 years|diagnosis of stroke', '>2|Prior', '4-5-6|Laparoscopic nephrectomy|infection', '40 - 90 mmHg', '>30 days prior to diagnosis', 'booster dose', '18-60,|Have', '< 60 mL min-1 1.73 m-2||xiii', '>= 500/uL', '<1500 gm', 'neutrophils(ANC)greater than or equal to 1.5 × 109', '40 inches', 'I, II, III', '≥90%', '≤ the upper limit of normal.|Vital signs', '≥24 hours', 'Below 18', '>2.0 mmol per litre.||', 'poorly controlled', '18 to 35 years||', '≥100 mmHg', '<3 7', '>30', '4-8 for', '>450', 'above 90%', '18 and over,|Patients', 'class I', 'over 18 of years|Understand danish and understand the', '18-31 years;|have', '≥50 mL/min/1.73m2', '18-30 Singleton pregnancy Gestational age', '≥185mmHg,', 'Ocular melanoma;|Mucosal melanoma;|Distant metastases;|Impossibility of radical resection of the tumor', '50 and 70 years', '3-5|50 CD ileo-colonic', '>1.5 cm', '=< criteria x ULN||Creatinine clearance', '<65 years|Unable to consent|Chronic pain medication usage', '≥ 100 × 10^9/L|Hemoglobin', '>= 34', '<90 mm Hg', '18 and 75 years', '>35%', '3 months||Liver', '<37 weeks', 'between 18 and 80 years|Unilateral ISSNHL|Onset', '18-65 years|American Society of Anesthesiology score', '>430 milliseconds', '>=3,000/', 'up to 19', '> 110 mmHg.|Renal failure', '<60 years', '≥3×upper normal limit', 'Eligible', '> 30 mmHg', '<40 or >', 'between 50 and 80 years', '<30 mL/min]).|Participant', 'greater than', 'above institutional normal.||Participants', 'more than or equal to 1 per month)|Have oral', '18 to 30 kg/m2|Those', 'greater than or equal to 7 mm', '> 3.0', '> 60 mm Hg', 'Score ≤7', '25-32 kg/m2;|Habitual diet', 'between 24.0 to 28.0 kg/m2', 'between 6 - 10', 'between 25-40|not', 'less than 4 weeks', '< 18 years|Pregnancy|Coagulations disorders|Anticoagulant therapy', 'score is 3 or more', 'greater than 98.6o F', '≤ 51.3 µmol/L).|Serum', '5-15', '8-70 years|Effective contraception', '≥ 16', 'more than 5 cm|use', 'above 60 degrees of flexion', '18-64 years)||', '18-35|Removing flexible', '<15 IU/ml', 'less than 48 hours', '1-2|Undergoing', '150-189cm)|Participants', 'III-VI|Presence of', '≤ 1.5 X ULN|ALT', '≤ 80 mm Hg', '< 8G/L', 'over III', '> grade 2', '1 day post', '=< 7 and surgeon', 'above 37', '< 18 years.|ECOG performance status', '> 35,|glomerular filtration rate (GFR)', '>150,000/mm^3|Hemoglobin', 'between 1 Jan 2010 and 31 Dec 2020|Patients', 'less than 50 kg or more than 120', '≥18.5 and <30.0 kg/m2.|Healthy', 'between 90-170 mmHg', '<45', '= between 16-26', '< 75,000 cells/mm3|Current', '> 150/95)|current illness', 'at least 25 mIU/mL', '<1.5 mg/dL', '≤ 300 mmHg', 'IIIB-C', '0-1|≥6 months of follow-up', '18-50', '>25 kg/m2', 'MS|25-60 years', '<30ml/min|Prior coronary artery bypass', '≥ 100 °', '< 16 mmol/L', '60 - 89|Moderate', '≤ 2.5 x upper limit of normal', 'to sunlight', '4-12 years old.|For the foveation therapy group', '>2.5× ULN', '≥100g/L', '≥ 60 mL/min.||The', '< 33Systolic pressure', '90 to 139', '<30 mL/min/1.73m2.|Women', '>90 mmHG', '<6 points', '≤ 50% stenosis', '> 60%', 'greater than 90%||', 'below the 10th percentile', 'I and II', '< 35 kg/m2||', '≥90g/L||Liver', '18-70|To receive', 'abnormalities', '≥18 years;|diagnosis', '0-1.|Within 7 days before treatment', '<3 years old and >10 years', '350 mcg/min.|Severe', 'longer than 450', 'below or above 18 years|Comorbidities like', '<135 or', '10-13 years', '>8%||The presence', '< x3 upper limit of normal', '< 20,000/uL', 'stage III', '≥2.8 g/dL.||Prothrombin time (PT) ≤1.5 × ULN', 'greater than 20 years duration', '≤ 7 days.|Temperature', '>160/90 mm', 'less than 12 months;|Patients', 'more than 3 consecutive months', '18 years or older;||Gestation beyond the first trimester', '70', '≥ eight weeks to nine months before assessment|(B', '≤ 1cm lower calyceal', '18 years old or above|Participants must sign', '> 2xULN|Has', '≥ 12 weeks from the time of enrollment|All patients', '<1 percent', '18.5-29.9', '> 2.|Patient', 'partial remission', '> 1100 mg/dL).|Urine M-protein', '>250)|Having', '<400 ml||', 'S-ICD', '>18 and <80 years Patients capable of providing informed consent Patients', '≤ 7 centimeters', '4-7 years', '≥ IIIB', 'no more than 12 hours.||In', '<= 1|Participants', '≥ 30 IU/L', '18-65,|Being', '> 60 pre-operatively', 'disease conform', '≥ 40 IU/mL', '25 years or younger', '5 units', '≥18 to ≤60', 'over 1000', '<1 year)|Pregnancy', '60-80 y', '< 30 ml/min|History', '≥1 of the', '= erythropoietin', 'less than or equal to 5 times the upper limit of normal.|Serum creatinine less than or equal to 1.5 mg/dl|Total', '0-42', '< 18 or > 60 years', '19 or over 30,|alcohol', '< 13.0 g/dL|Serum Creatinine', '>= 5.2 mmol/L.|Understand the test procedure', '> 2 times ULN|Pregnancy', 'partial response to', '63.9 mmol/mol)|Any', '> 14mmol/L|pH < 7.25|Serum bicarbonate', '≥ 3000/µL|Neutrophils ≥ 1500/µL|Platelets', 'more than 75 years', '7-18 years', 'equal or more than 7%', '0-59 months', '≥ 3.0×109/L', '>18 years old|arterial hypertension', 'maximum 6 weeks before registration', '≥ 9g / dL', 'onset < 75 years', '0 to < 8 years', '18 or older female|Patient must', '=< 3 x ULN (=', '≥470 msec', '≥ 24 kg/m2|No', '< 0.5 or', 'equal to or lower than ≤ 1+', '18-45,|Having', '>=3 mg/dL|Systolic blood pressure', 'greater than 6 months.|At least', '20 to 26', '>2+)|Subject experienced', '>100/min', 'between 18 years and 70 years of age(inclusive', 'between 01 August 2021 and 31 December 2022', '>70 g/week', 'between 0-2 years', 'between 50 and 75 years', '≥ 3', '18-21.|Patient', 'score of > 2 standard deviations below the mean', '≥ 60;|Written informed', 'less than 80|at least one', '18-85 years|Fitzpatrick', '30 mL/min/1.73m2', 'above the upper three limits of normal', '>18 to 60 years,|Diagnosed with lower ureteric stone', '18.0-26.9 kg/m2|Healthy', '≥4 criteria', 'less than or equal to (<=) 40.0 kilograms per meter square (kg/m^2)||', '>= 1.0 x 10^9/L|Platelet count', '≥50 but <1000 copies/mL', '≥ 8|Serious', '> 9 g/dL|ANC', '>18 years.|Total knee arthroplasty', '>=0.2 mg/kg/day', '=< 6x upper limits of normal', '≥90 mmHg,|Diastolic blood pressure ≤90 and', '> 2.5X', 'four-phase', '<2cm.||', 'between 4 and 8 kilograms', '5 years or above', '< 6 ng/mL)|Use', 'below 65 mmol/L.|Patients', '12 years 0 months 0', 'at least 50 words', '<30 mL/min).|Patients', '>45mmHg', 'between 3-6 months prior to enrollment.|Subject', '140-159 mmHg', '18 years and over,|Having', '≤ 2.5 × ULN|Creatinine clearance', '< 2.5 years', 'therapeutic response', '< 50%,or have|pacemaker', '< 19 kg/m2.|Unintentional', '>10%);|Uncontrolled hypertension', '<9.0 g/dL|Platelet count', 'greater than 37 weeks', 'III or above', 'adult|50.0kg≤Body weight≤90.0kg and 18.0kg/', '<500/mm3 9', 'above the lower limit of measurement;|14)Evidence', '≤ 65', '18-55 years', 'between 18-25,|who', 'between 14 0/7 and 34 6/7 weeks', '> 3.5 D', '<183x10^9/L', 'over 40 ml/kg/min|did', '>60 days or >2', '>=18 years.|Eastern', '>18 yr|Clinical diagnosis', '< 12 months|Complex', '20-35 years', '<30ml/', 'at least 1x/week', '≥ 18 years|Informed', '≥ 1,500/mcL', '5.7-6.4%).||', '<2.5×103 copies/ml', '10-1', '< 13 g/dL', '45 to 75 years;|Screening', '< 100,000/µL)|INR', 'between 18 and 45 years;|Presence', 'for ≥5 years|Presence', 'more than 3.|Patient', '<300/mm3|Patients', '>= 18 years old', '18-90 years||', '≤ 90mmHg', '=< 20 mg /day', 'outside these limits', 'greater than 35 kg/m2|Presence', '<20×109/L);|HIV', 'younger than 65 years|Cohort 1', '≥ 100 × 109/L;||Hemoglobin', '< 1000/mm³', '15-40', 'disorganization|distrust|hallucinatory', '> 35|Taking', '> 40 kg);|Patients', 'Stage II NK|Decreased', '> 2.5 times of the upper limit of normal value', '≥ 1.5 mg/dL|Severe', 'between 160 and 195', '18 to 85|Having no', 'least 50.0 kg', '≥60 mL/min', '45-48 kg', '< 20 ng/mL|Active', 'above 18 years|Signed consent', '=< 500 IU/mL', '< 1500g||', '> 7.5|Having', '≥18 and older|Confirmed', '20% background muscle', '>20,000 per microliter', '1, 2, 3 or 4', 'between 18 to 80 years|Signed written informed', '> 40 kg/', '≥ 18 years|Acceptable', '< 30,000 µl', 'between 01 January 2022 and 31 December 2022 (Population A', '18 to 29 years', '>9%||', '≥ 12%', 'equal or superior to 10 mmHg', '< 7.0 mmol/L|Fasting', 'greater than 35 kg/m2)|Patients', '18~75 years old', '<30 ml/min per 1.73 m2.|Current', '0-1 +', '> 440 msec.|Received', '18-30|Speak and understand', 'greater than 470 milliseconds', '1-3|surgical', '<70%;|Hemoglobin abnormality;|hypertension treated with more than 2', '<2.5 X institutional upper limit', '≥1.5 ×109/L', '>1,21mg/dL', '<120 msec', 'UCVA).|Less than or equal', 'greater than the potential benefit of treatment.|Use of effective contraception', '≤ 1.5 * institutional ULN|AST', '<29.9kg/', 'between ten to nineteen years old.||', '>190', '18 and 65 years inclusive', '>5mm to < 20', 'less than or equal to (≤) 9.0 gram per deciliter', '≥ 500 cells/μ L', '< 40%|Subjects', '18 years or older;|Have', '≥ 75 years old', '< 30 ml/min/1.73 m2', '≤ 24.9 kg/m2', '15-25|At least one year', '± demethylated drugs.||(2', '>= 21 days must', '>100 mm', '<2000 IU/ml', '15 - 29', '>1,500/µL Platelets', '> 2 times the upper limit of normal value);|Uncontrolled hypertension', '≥1 dependent', '≤1.5 times the upper limit of', '18 to 80 inclusive (subjects', '>30mL', '> .65 when', '<26', 'less than 10% of the body surface area', 'between 20-30|Positive reaction', '≥ 40 kg/m²', '1', '125', '≥19 years|Patients', 'between 20-40 years.|Body', '< 0.1 ng/mL.|malignancy', '≥45 mL/min|Serum', '90-minute', '≥ of six months.||', 'Over 18 years', 'from 18 to 99|Able to consent', '0-2;|Survival', 'class IV', 'from January 2012 to', '0 to 18', 'more than twice the upper normal', '>=5 vertebrae', '20 cigarettes/day||Patients', '≥ 18|Patients', '≥5.6mmol/L', '> 105 mmHg', '18 to 90years|AF', '< 50,000/μL|Infection', '> 1.5 x', '≥ 0.5', '1-2-3,|who', '≥12 weeks.|ECOG Performance status', '> 2)|age range', 'requiring IV', '≥ 2.5', 'lower than 40 mg/dL', 'than (<) 50 copies/milliliter [mL]', '≥ 100 x 10^9/L|Haemoglobin', 'less than 15 on', 'upper limit of normal value', 'greater than 1.5 cm', '20 ng/mL', '200 IU/ml', 'under age 18', '≥90 g/L；|Neutrophil', '> 35 Kg/m2|Pregnancy', '≥ 12%within previous', '>= 1500/mm^3|Total bilirubin', '18-80 years;|Signature', 'stage II or', '≥7.0%', '>38℃', '>2,5%', 'over 18 years old|At least', '18-65|Being able', 'score of <24', '≥ 60 ml/m2', 'between june 2018', '≥12 years|Documentation', '0-1;|HER2 positive', 'above or equal between 18 to 65 years', 'greater than 135 mg/dl', '> 450 ms|Uncontrolled', 'greater than or equal to 18 years|Current or past', 'less than grade 3', '= 12.5 days', '<60 days of abstinence', '3 times the upper limit of normal', '>480 ms.|Complete', 'Grade NYHA);3', '≤ 30%|History', '< 60 mL / min / 1.73 m2', 'between 18 and 45 years', '< 110 or >150 g/L', '> 50 copies/mL', '<100,000/mm^3', 'higher than 210 g / week', '≥180 mmHg', '< 90|less than 5th grade reading level|Left handed|Non-native', '≥25 kilogram per square meter (kg/m²', '>1 10^9/l|Platelet count', 'more than 2.5 mg /dl', '> 3 g/L', '≥ 55 and ≤ 75 years', '0-2|Absolute neutrophil count (', 'younger than 16 years', '≤ 1.0 ULN;|Inactive infection', '0 or 1|Male/', '<28', 'between symptom onset and first visit', '≥ 35|Immune suppression', '4-5μm thickness', '>=4', '>38.0°C||', '<30 X 109/L', 'Functional Class III', '35.0-39.9', '≤ 1.5 × ULN.||Coagulation', 'less than 40% of predicted', '≤5×ULN. 3', '<470 msec.|Are able', 'from 6 to 18 years||', 'pregnant|Does not', 'long-term hormonal', '> 35.|Women', '≤ 2.5 × ULN;|Alanine aminotransferase (', '<3rd percentile', '≥ 37 wks', '≥ 1.0×109/l', 'I, II', 'between 18-50 years|BMI', '<180 mmHg', '50% or greater', 'above 5 kg', 'greater than or equal to18 years.||', '≥110 mmHg', 'less than 28 kg', '≥ 2,000', 'from 18 to 80', 'between 18-65|having TMJ pain', 'less than 6 months.|Any', 'class II to III', 'I-III||', '< 29 ml/min/1.73m2|Mean blood pressure', '≥9.0 g/dL.|Liver', 'less than 85 points.||', '18~28 kg/m2', 'scores of 0-3', 'less than 50', '<= 5 x ULT', '≥ 550 mdet', '< 55%.|Uncontrolled hypertension', '< 2 years', 'Stage 3b', '18 years old or above|A clinical diagnosis', 'between 50.0 and 115.0 kg', '≥ 70 years,|Patient', 'Above age 80', '0-2|Serum', '≤ 1.5 times the upper limit of normal value (ULN)', '>800 μg/day', 'Grade II', '≥ 18 years;|Chest', '>90 mm Hg diastolic', '≥ 27%', '< 20 cc/min.|GI', '18 to 70 years old', '< 25 kg/', '18 years|above 65 years|individuals taking', '<18 years old or >64 years', '> 2000IU/mL', '≥10 grams(g)/deciliter(dL', 'less than 60 years', '2000-2011.||Exclusion Criteria', 'less than or equal to 5 x ULN', '> 65 years|Informed', '≤ 40 kg/m2', '>37.9°C', '52 inches or', '≥18 and ≤34 lbs/in2', '≥ 18 years|Ability to provide', '≥ 1×109/L', '< A2)|physical', '≤ three', '≥18 to ≤35 kg/m2', '≥ 100×109/L.|Hemoglobin', '18 years or older||Patients', '≥10 hours per week', '≤ 12 months', '>= 50,000/uL', '> 10.0 × 109/L.|Patients', '2.5 mg/m2/day', 'IC1]:||Contraindication', '≥ 41', '> 160/100 mmHg', '>60mmHg', '≤ 1.5 × upper limit of normal (ULN)', '1.5 mg/dL|A', '6.0 to 11.0|report food', '≥1.0 g/dL.', '> 8.6mmol/L', '>18 years|Ability to provide', 'over 18 years|ASA', '>35 years', '> Normal range upper × 1.5|eGFR', 'between 25 and 35 kg/m^2|Little to no recent exercise training experience', '≥ 25%', '<35%).|The participant', 'greater than C2N2)|Patients', '≥ 240 mg/dL).|Diabetes', '< 25 (normal weight', '≥ 600 pg/mL.4', '= (140 - age[years', '< 50 beats per minute [BPM', '≥75×10^9/L', '6 months or more', 'scores ≤ 30%', '≥50 kg', '< 5%', '>40%;|Has', '≥ 18y', '< 26|major', '0 to 2.|Life expectancy', 'above 18 years.|Currently not', '≥ 18 years and ≤ 65 years', '>= 1,500/uL.', '2.5 - 5 mmol/l', 'I or II disorder;|Presence', 'higher than or equal to150mg/dl', '>24 weeks', '>8)|<3mm', '19', '≥ 0.2 mV', '≥ 75 years', '>7.5% after the use', 'two-lumen temporary CVC', '≥ 4 years and < 8 years||', '≥ 1,500/µL', 'younger than 5 years', '≥65 years|Lymphoma', '18-75 years', '< 117 g/L)|Any', 'between 4 to 10.|Children with', '≥37.5°C', 'above minimum criteria for', 'Stage IV', '<300 mg/g', '>20 mm', '<3×10^9/L', 'greater than 15° will be included in the study.||', 'IV-VI', '65+ years).|Participant', 'II-', 'between 18.0 and 30 kg/m2', '≤ 3x ULN', '≥ 12 weeks.|Recurrent breast cancer', '≥100*109/L', 'controlled', '≤ 5.0 times ULN', '≥ 15 events/h|stable', '≤ 1500 g', 'noninvasive', '45 min', '>160/100 mmHg.||Uncontrollable hypokalemia', 'scores I - III,|Aged', 'higher than 30kg/m²', '18 to 75 Having given their informed', '≤ 0.50 mm', '< 25 participant', 'between 18 and 60 years|Patients', '≤ 18 years old ≤ 75 years old', '≥60 ml/min.|Patients', '18 to 30 years', '≥550 pg/mL', '=< 1.5 times upper reference', '≤ 5×ULN||Patients', '>50% of the', '≥ 2.5 g/dL|Fertile', '> 1X upper limit of normal (ULN)', '> 8x/week', '≤ 75 years.||', '> 900 pg/l', 'greater than 40 kg/m².|Patient', '=< 28 days prior to first dose of protocol-', '>250U/L', '1 line', '≥ 7 mmol/L', '75.0 × 109/L', 'under 18|Not fluent in English|Blind', 'between 18 and 30 years.|BMI ≥ 30-39.9 kg/m2|How', '40+ years.|Adult', '< 1 year||No', '>= 7.5 mg/dL', '> 18 years||controls Inclusion criteria:||The controls', '18-75 and can stand|No', '>3 months ago', '≥2.0×10^9/L', '< 100,000/μL', '> 50 kg|', '<30% of percent predicted', 'between 18 and 75 years|Diagnosis', '>18 and <65|Within 12 hours after brain injury|GCS', 'between 65 and 85 at entry', '≥30 kilogram per square meter (kg/m²', '> 30 kg / m2', 'at least 60 for subjects 16 years', '>2.0 times ULN|GDS score of ≥5', '< 3.5 mg/dL|Albumin', 'between 20 and 35 kg/m2|Currently', '>= 18 years old|Participant', '<1.5', '30-800ng/mL', '≥ 20|BMI', '>55 centimeters', '≥93%', '≥ 103 copies/ml', '> 65mm', '>18 years.|Diagnosis', '>95', 'navicular drop test over 10 mm', 'more than 12%', '≥70 dB HL', '4-12 weeks', '1/1/2010|At least 18 years', '18 years or above|planned', '≥ 16 mmHg', '10 pack/year|Treatment', '10 degrees valgus', 'for three years).||Any of the following abnormal', '< 60,000 /mm3)|Active cancer', 'score of 4 and above from the', '≤ 1.5 × ULN.|Have', 'Women;|18-50 years', '> 1×10E3 copies/ml', '< 7 hours).|treated', '> 1.5|Platelets < 50,000/mm3||Confounding', '45 mL of', '≤ 14 days|Filling defect', '> 6.|Informed consent', '< 40 weeks', 'less than 24', '< 12 months|contraindication', 'less than 1.0 standard deviation below the test score normed for age', '≥ 10|Age', '≥18 years|The presence', '≥ 3 unformed', '40 - 100 bpm', '≥18 years|Referral for US assisted placement||', '≥ 1,500/L', '<180 cm', '>0.5 g/g', '< 50% normal', '≤ 1.5 times ULN', 'Younger than 7 years', 'greater than 24;|Absence', '> 18 years old|Ability to understand and willingness to sign', '≥145 mm Hg', '>= 70%)|Metastatic disease', 'below 6 years or above 18 years', '18 to 65 years.|In', '0-2|Ability of the participant understand and the willingness to sign', '>470 milliseconds|History', 'up to 3', '</=', '≥0.5×109/L.||Kidney', '> 38.5°C', 'score <24)|Active cancer', '<10 ng/dL||', 'younger than 12 years', 'Identify', 'III and IV', '<80% predicted', '≥ 37.5°', 'class II or greater', '2.8 mmol/L', '<14 weeks', '<60 bpm', '10-75% of Stenosis', '>90% of predicted normal', '>300 mg/dL', '≥2 to ≤ 25 years', '135-180 mmHg', '60+ years|Both', '>25|GMFCS', 'equal or less than 40%|age between 18-80 years||Inclusion criteria', '20-75 years.|Patients', 'greater than three months.|Patients', 'no older than 2 weeks', '30-89||', '> 50 mL/min;|Liver function', '≥ 100 IU/mL', 'between 18-80 years', '≤ 5×ULN.||(3', '>2.0 times the upper limit of normal (ULN)', '< 80000/mm3;|Unwillingness', '<30 × 10^9/L||Warm', '12 to 60 years', 'between 18 and 30|Have no known', 'between parents or', '> 120 mL/min/1.73m^2', 'deeper than 4 mm.||', '≥1.5×109/L|Platelet count≥75×109/L|Hemoglobin', 'class II heart failure', '≥ 100×109/L.||The', '>85 g/L);||', '<2.5mm|Coronary spasm', 'score 4+3', '= II-III.|Able', '> 1.5 × institutional ULN.|Total bilirubin', '20-50 years|chronic', '1.1 criteria;|An Eastern Cooperative Oncology Group (', '18 to 70 years.|Patients', '>12 months.|At least 1 month after a', '> 40 mmHg;|Patient', '≥18 years < 75 years.|Right-handed', 'less than 150,000 and more than 450,000', '18-80|To participate', '0-3|Meets screening', '± 5 years).|MMSE', '≥ 60 mL/min.||Cardiac', 'more than 30s', '<=5 percent', 'between 37+ 0/7 and', 'between 18 and 100 years', 'between 8-28)||', '60 minutes prior to specimen', '< 11.0 g/dL', 'between March 15, 2020', '8 to 10', 'significant abnormal', '≥ 50,000/mm3|International', '>=20kg/', 'between 2500-4500 g|1.-5', 'no more than', '3 times the upper limit of normal|No', '≥ 1.5x109/L', '<60%|Ascites', '> 450 millisecond', 'less than 100×109/L', 'between 18.0 to 32.0 kg/m2', '19-4035 kg/m2|Female', 'fixed dose combination', '≥ 2,000/mm3', '18-65|A', '>10mg PO', '≥5%;|Patients', '> 50nmol/L', '< 2.0', '<30 ml/min per 1.73 m2.|Who', 'between 7-18 years', 'at least 18-85 years', '11236', '> 110 msec|PR', '> 30 kg/m2.|Contraindication', '> 1000 copies/mL', '< 2.5 mg/dL', '≤ 60 years', '< 5 3', '≥ 100 mg/dl', '≤ 1.5 times the upper limit of normal values', 'younger than 1 year', 'equal numbers', '≥ 7|Absence', '10 mm', '1 doctors|Above 21 years', '>7 cm', '< 60 mL/min/1.73 m^2|Aspartate aminotransferase', '> 30 kg/m2).|Cases', '≤ 55%', '<72h', '<60 kg days', 'less than 30 kg/m².||3', '≥ 1.5 UNL', '>115 kg.|Use', '≥ 3+;|Patients', '≥ 5 × ULN', '<=100', '> lower limit of detection', '<40 kilograms|ASA score', '< 200 mmol/day|UACR < 30 mg/mmol|All', 'iOS 8.0 or higher', '3 to 9 years:||Healthy', '≥ 18 yo,|Signed informed consent', '>460 ms', '≥ 30 mL/min;|Total', '> 6', 'II to III', '≤ 60 bpm', 'upper trapezius', 'between 24 and 32 weeks', 'score of 2 points', '< 0.5 x lower limit of normal);|Liver function test', '< 3.0 x ULN', 'more than 25%|Patients', 'less than 28', '5% variation of the', 'between 18.5 and 30 kg/m2||', '≥ 15 µIU/mL', '< 100 IU/mL', '≥ 18 years.|Metastatic', 'at least 12 weeks.|Women', 'between 18 and 40', '>300 ng/dl', '≥ 70 years;|Life expectancy', '>30 mL/min', 'less than 9 g/dl.|You', '>NYHA 2', '18 - 55 years|body mass index', '< 470 ms.|Known', '< 50mL/min', '>= 100,000/mcL||International', 'greater than 26.0mm;|Trauma', 'less than 180mmHg', '50-65', '1-7', '<40%:||A', '>4.0 m/s)|25', '> 9|Those', '19-29 kg/m2|AMH', 'between 18-65 years', '18-4 0 years', '> 90 beats/min', '24 weeks 0 days', '>10 min loss of consciousness', '≤ 4 years', '< 150,000/μL|Have', 'more than 100 copies / L;hepatitis C virus (HCV) antibody', '614x10^9/L;|Class IV patient', '>150 mg/day|eGFR', '> 450 pg/ml', '> 40 kg/m2.|History', 'between 1.3 logMAR and 0.4 LogMAR', '>2.0 mg/dL', '<50 mg/dl', '≥ 1.50 g/L|0.9 g/L', '<10 x 104/μL|Aspartate', '≤ 30 days prior to the patient enrolment visit', '<3 or >12 cm|Abdominal aortic aneurysm disorders|Pregnancy', '> 1.5 ULN', '> ULN|Female participant', '>/= 100,000/Ul', 'between 25 and 40 kg/m2)|Diagnosed', '≥ SUVmean', '< 20 μM).|Positive test', '<15 mL/min/1.73 m2|Administration', '65 years or older', '≥ class II', 'more than 40 kg/m²|The', '18 years or older)|Able', '≤ 80%', '≥18 years||Diagnosed', 'more than 300 mL', 'III and above patients|Patients', 'likely to impact', '≤ 2.0 x ULN', 'at least 12 weeks.||6', 'greater than 480ms', '1000 - 2500 grams|Admitted', '18-28 kg/m2;|For', 'times (< 6:00am, > 10:00am', '≥ 2||', '≥18 years.|Patients', '≥ 5 million sperm/mL', '≥18 years|Year', '<100,000', '≥ 9 g/dL|Individuals', '13-19||Exclusion', '≤ the upper limit of normal', '≥ 1.5 GI/L)|Platelets', '<45 with|New', '< 40 kg/m2|American Society of Anesthesiologists', '≥ 1000/mm3|Platelet count', '≤ 24 mm', 'stage 3b', '65-74', '< 500 IU/mL|Variceal status', '> 120 beast/minute', '≤ 2.5× upper limit of normal (ULN)', '6 months prior to the', '>35 U/L', '≥ 0.3 mg/dL']","['more than 8 cups', 'None', '≥2 episodes', 'at least 1 measurable', '>30 minutes', '2 hours', 'less than 5 half-lives', '130 ml wine', 'at least 1 prior', '= 12 g/day', 'outside of the US', 'greater than 90 days', '1 mg/kg/day', '≥ 15 mm', 'primary', '>2 times/week', '<3 months', 'daily treatment the', 'females', 'more than 8 years', '≥ 2-year', 'January 2011 to January 2022.||', '100 mg/die per os', 'three or more times weekly', 'long-TUG).||', '≥20 mg/day', '≥ 50-year-old', '1 to 3 lung metastases', 'cytology;|At least one', '≥2 in the last year', 'single at Screening', 'outside the scalp.|Patients', 'outside of routine', 'more than 2 hours per day', 'hysterectomy|NSAID use', 'more than 6 hours', 'Outside these periods', '2 or more years of experience providing', 'less than 12 months postpartum,|test positive', 'once 25 (', 'persistent', 'to', '≥ 300 µm', 'dose >10 mg/day', '>14 units', '6 mg/kg', '10 mg', '≥ 500 cells', '2-5 mismatches', 'greater than or equal to 0.5 mg', 'same drug(s', 'less than 1 training session/week', '2-day', 'greater than or equal to 3', '<28 days prior to first dose', 'less than 12', 'more than 2 cups/day)|Patients', 'greater than 4 mg per day', '≥2 on the first item', 'scooter|Currently', '< 12 months|Diabetic patients|Familial hypercholesterolemia|Abuse', '≥2.75mm|Target', 'more than 1/3 of the', '> 24', 'lesser than or equal to (≤) 12 years from diagnosis', 'more than 10 mg/kg', 'more than two', 'greater than 5 days per week||F.', '> 2 of the 9', 'maximum 2mg/daily', 'first or second line', '≥3 over', 'greater than (>)', 'exceed 50 μmol/L);|ALP', 'more than 1 month after treatment.|Chest', '<', '≥1 subsequent dose of lutetium-177', '>4', 'at least 1 dose of PBCAR product', 'minimum dose', '≥ 6 months.||Only', 'maintained', 'Ketamine|Previous trial', '≥ 100 and ≤ 550 meters', 'Physiologic doses', 'C|At least one', '30 or more', '≥ 75 x 109/L;|Hemoglobin ≥ 90 g/L;|Serum', '≥ 1/3', 'maximum of 4', '2 weeks prior to the study start date', 'more than one symptom', '≥2 x 10^9/L', 'stem cell/bone marrow transplant|Continued', 'insulin pump)|Contraindication to', '2 months', 'subsequent', 'none', '>20 g/day', 'maximum tolerated', 'at least one eye', '> 8mm.|Keratinized mucosa', 'fewer than 4', 'maximum one prior', 'maximum dose', '3 mg bid', '1 year.|History of', 'two separate tests.|Glucose tolerance test', '>20', '1 drink/day', 'long-term', 'less than 4 months ago.|SARS-CoV-2', 'more than 1 month，Conduct catheter', '> 1.5 x ULN|Total', 'more than 30% of the', '≥ Grade 2', 'more than 24h apart', '≥1 dose', 'more than 1 year', '≤25 mg/week', 'lower than -6.00D|Coexisting', '500 mg/dl)||Participants', 'once a month', 'pneumothorax', '1 dose', 'maximum relevant', 'at least two weeks', '≥ 2 doses', 'at least twice per day).|Use of', '≥ 20 mL/min/1.73 m^2', 'daily basis', 'hormone?|Chronic use', 'dose escalation', '1 or more', '2 times or more', 'high dose methotrexate', '> 4', 'maxillofacial surgery', 'long term safety', 'single dose', 'once daily|Use', '25% of bowel', '10 mg/d', '≥ 20 mg', 'treatment|Current use', '≥ 10 mg', 'more than rash', 'maximum frown', 'more than 5', 'recurrent', '≥1000 mg/day', '≥2 in one system', 'disease.||At least 1', '<3 months prior to study', '≥ 0.2µg/kg/h', 'More than 10', 'GIST)|At least one', 'more than 3 allergens', 'more than 2 units', '>40 grams/day),|Subject/Patient', '2 years', 'greater than six months)|ability', 'more than 15 cigarettes', 'over 2 or more', 'dose greater than 10 mg/day', 'greater than 10 mg', 'one prior endocrine therapy', '≥ 1.5 x 103/l|platelets', 'maximum of 14 consecutive days before screening', 'maximum of 7cm', '>1 prior', '> 15 minutes', 'distant', 'less than 7 mm', 'more than 12 months', '≥ 75 years;|Infarction', 'rather than HF', 'more than 24', 'greater than 1', 'at least two weeks prior to enrolment in this study.|Active', '2-week period', 'different than the', '3-month', 'daily intake of', '> 1 day', 'melphalan 200 mg/m2.|Known', 'for at least five', 'more than 5 years before the diagnosis', '≥ 52', 'follows:||Single', 'more than 26', 'minimum use duration 1 year)|Adult (minimum age', 'greater than or equal to 2 months prior to baseline', 'more than 5 days after the occurrence of the first symptom', '>21/', '≥ 2 classes', 'less than five times of upper limits of serum metanephrine||', '≥ 3WU', 'more than two weeks', 'greater than 12 months', 'dose equivalent to > 10 mg/day', 'more than 4 hours per', 'greater than 1 year', 'more than 30 days|18 years', 'daily dose of more than 10 mg', 'At least 12 weeks of prospective documentation', 'one of the following:||CD19+', 'more than 1 cm', 'pathogenic/', ""more than 12 months.||'consider' implies"", '500 ml', 'therapeutic anticoagulation|Pantoprazole', 'voriconazole)|Current', 'At least primary', '2 times per week', 'dose of Johnson & Johnson vaccine', '50mm~70mm of 100mm', '> 2 hours', 'total dose 3 g over 3 months', '≥ 10|Prior therapy', 'greater than 150 minutes/week', '8 mg/dl', 'single electrocardiogram (', 'more than the standard postop treatment', 'more than 2 months', '≥ 5 μ', '≥ 100 x 103/l|hemoglobin', 'once for confirmation.|Subject has', 'more than 12 weeks|whose pain', 'for at least 48 hours', '≥ 500 mg/dL.|Have', 'swallowing,|Able', '≥ 7Gy x', 'Newly hired', 'VAS).|At least one', '1000mg', '≥ 28 g/L|Serum', 'more than', 'hypoglycemia.|Two or more', 'maximum 15 days before and 5 days after admission to ICU)|Maximum administration', '2-dimensional', '200 mg/m^2 melphalan', '≥ 300 mg/j', '≥ 7 days', '>30 days', '>1010 cfu/dose', 'completed 2 weeks prior to study drug administration', '2 weeks prior to screening', 'more than 2 weeks', 'Two methods', '600 mg twice daily', 'one or both legs)|Dependent', '1) those', 'greater than one', 'long term illnesses', '≥ 5 on', '>14 drinks/', '>14 alcoholic drinks', '≥ 0.3mg/', '≥2 new', '2-3 weeks for completion of', '> 30 days', 'more than 10 years.||', 'More than 3 times per week', 'maximum frown when assessed', '≥ 12 months,|unilateral', '≥ 14', 'more than 10 mcg/min', 'more than 12 weeks', '≥64 at 4°C (v)', 'tablets|At least one', '>=approximately 3 months).||Bone', '2 mo before the study till', '> 20 if', '186 x', 'lacunar', 'at least 8', '> 20 g/week|Evidence of', 'regular intake', '20', '4-variable Modification of Diet in Renal Disease equation', 'pelvic radiotherapy|History of major co-morbidity', 'more than 12 months,|Current medication', '2-month', 'daily for at least 1', 'disease.|At least one', '10mg or 15mg', '1 drink', 'maximum of 1 month||Inclusion Criteria:||Healthy singleton', '<1600 kcal/day', '> 4 months', '12', '10 days|The need', 'more than 14 units', 'greater than 2 months prior to enrolment', '≥ 5 mg/day', 'minimum 12 weeks', '≥1 prior', '≥2 h', 'more than 30 g', '> 2 weeks', 'pelvic radiotherapy.|Patients', 'once weekly', '≥1 year', 'at least 1 year of amenorrhea', '3 or more', '>100 km from', 'daily treatment|Use', 'online pre-screening', 'at least 1 month', 'one or more daytime drops <100 mmHg', 'small doses', '1 months prior', '8 mg QD', '≥ 1 year', '≥40', 'higher than medicated', 'more than 10 mSv', 'initial dose', '2-3', 'Two or more', 'fluxio hemorrhoidalis', '≥ 2 days per week', 'more than 30', 'at least one', '5 x 5 cm', '5% within', 'dose of oral levothyroxine', 'first episode of', 'greater than 30 days.|Patients', '≥2 contiguous leads', '2 months after the', '≥ 1 of the following', '> 20 mg/day', '<2 defecations/week for >3 months', 'once a month or more', '< 1.5 ULN|blood', 'frequent replacement lenses||Maximum of 1 habitual wearer per', '≥6 months|Stage 2', 'over 25 years', '> 1mg/kg/j', 'more than mildly reduced kidney', '10mg IV bumetanide challenge', 'higher than the lower detection limit', '≥5 half-lives', '> 2', 'more than 250mL', 'more than or equal to 3 months', '> 10 mg/d', '≥500 μg/L|Soluble', 'at least 1 measurable lesion|At least 42', 'medications|Concomitant', '≥20 grams/ day', 'total daily dose either <50 μg or >375 μg.|Current', 'at least two', 'at least 12 continuous months', '5 or more', 'higher than the initial value', '4', 'more than 10 cigarettes/day', 'once every 3 months', '≥1 of the', 'higher than the lower detection limit or', 'regular practice of breath awareness', '20 minutes.||Refusal to sign', '≥75 prior exposure days', 'replacement', '2-3 blocks', 'infection:||Consecutive', 'less than or equal to 2.||', '2 weeks prior to enrolment', 'prenatal ultrasound|Absence', 'routine care.|Enrolled', '<1 month prior to test day', 'less than 1 hour', 'more than two liter-per-minute', '≥ 50.|Lesion', 'less than one-third', '≥2 asystolic pauses', 'greater than 1cm', 'older,|Rectal', 'once-daily Itch NRS', 'Therapeutic doses', 'more than 1 prior', 'power', '≤35/65%)|RV/LV pressure ratio', '<14 days prior to Day 1', 'high dose', 'more than 180', 'changed the dose', 'maximum of 70 years', 'ComB', 'scores ≥ 3', '≥ 6 weeks', 'at least 4 weeks prior to first dose', '≥1000 mg per day over', '> 1000 IU/ day', '>20 hours per week', 'more than 1 line', 'Regular', 'at least two years', '>1', '75 g of glucose);|presence', 'first and', 'fermented food', 'minimum of 3', 'Implanon).|Complete sexual abstinence', 'more than 5 kg of body weight', '<14 days post injury', '>2 CT', '≥2 years', 'once at the discretion of the Investigator', 'more than 6 cups', 'episodes', 'prophylactic', 'at least 7', 'more than 4 weeks', 'greater than 350 mg/m^2', 'at least 1 cm', 'more than 2 years.|Readiness', 'more than 3mm；|Hemoglobin >90g/L', 'more than 35', '<3 months before', 'more than 10 days', 'at least three of the six clinical criteria', 'fewer than 6 months', '≥2 weeks of each NSAID', '1 year of first dose of study', '<5 days', '≥2 from previous', '>2', 'greater than 20 miles from the study site', 'regular cycle', 'two separate procedures', '4g/L)|Positive', '20 min', 'after surgery', '> 24 hours', '>500 ml', '80 mg/m^2|No', 'for at least 24', 'daily to control autoimmune phenomena', 'higher than 140/90', '>1 day per week', 'more than 4 new', 'HSCT):||Autologous HSCT', 'greater than seven', '20 mg/l', 'more than 2', '≥ 75 x 10^9/L;|Hemoglobin', 'daily/every', 'referred', '7-8/8', 'long-term restricted', 'routine hematological', 'more than 2 points', '1-2', 'more than 2);|History', '≥ 50kg', 'greater than 250 mcg', '< 7 days', '≥ 3 months', 'trauma|More than one', 'at least 2 weeks duration', '≥ 1 to < 10.|Participant', 'at least two hours per week', '> 40 g', 'greater than 2 weeks from start of study treatment', '≥ 12 consecutive months', 'greater than 12 hours.||', 'toxic aggression.||', 'more than 6 months;|Patients', '1-week intervals', '≥95 g/m2', 'high dose thiotepa', 'emergency use authorization', '2', 'single episode', '≥10 mg/d', 'at least 1 month before check-in (Day -1', '> 1 mg/h|Low', '≥300 mg/m2.|Already', 'at least on', 'for Switzerland).||', 'chemotherapy|More than one', 'higher than 100/min', 'more than 10 degrees', 'routine treatment', '2 forms of effective methods', '> 20 minutes', '10 or more', '15 mg daily).|Females', 'less than 6 months)|Pregnancy', 'drugs|More than 3', 'exceeding 300 mg/day|Participants', 'greater than 1 year from the date of consent', 'for 2 minutes', '> 4 weeks', '≥ 15', '<3 months of', 'greater than or equal to 3 months duration', '2 weeks prior', '≥ 6 months prior', 'more than 80% of the', 'recurrent history', '≥ 3 months after transplant', '> 10 mg', '2 points|Emergency of surgery:', 'more than 2 prior', 'two or more', '≥6 months|Knee', 'dual energy x-ray', 'twice consecutive blood pressure measurements', 'at least 90 days', 'curative', '250 mg with low', 'more than 30 min/week|Have', '> 40 g/day', 'grapefruit', '≥ 4||', '2-12 hours after the first intravenous', '>5 mg daily', '≥ 18 years|If', 'more than one week continuously;|sign informed', '2-dose', 'partial', 'more than 10 times', '> 7', '2-2.5 UBEs/day', 'more than 1 months after the healing of the', 'more than three', '≥3 mm', '≥ 7.5%|Blood creatinine', 'more than 6', '3 x ULN', '2 of 3 measurements', '≤1.5 g/L)|Hemophagocytosis', 'once', 'two times the upper limit of normal', '>30Gy', 'outside the window', '≥ 5 mg', 'more than three investigational', '≥ 24 weeks before randomization', '≥1 month', '> 50%);|Large', '= 75 hours', '≥20', '>500 mg/day', 'higher than the daily', '5 years)|Rheumatologic disease|Avascular', 'at least 5', '≥ 480 ms)|New', 'long half-lives', 'Fixed CT', 'more than a', 'more than 30 kg/m|Waist circumference', 'once a week for 45 min to 1.5 hours', '>18yr', '≥2.|People', '5 cups or more', 'injection;|Pregnant', 'less than normal range of motion', '≤1 mg/d', '≥ New York Heart Association', 'first episode', 'more than 12 weeks prior to screening', 'daily dose equal to or greater than 0.4 mg/kg', 'First', '= 2 mg daunorubicin', '≥ 2 years', 'training program 6 months prior to the start of the experimental trial|Any kind of injury/incapability', '≤ 12 weeks prior to study', 'fewer than 3', '1 year prior to screening', 'less than or equal to 0.5mg/kg', 'Requires', '≥ 1 month', 'only 1 out of 6', '2 h after admission', '≥ 27|fluent in', '= 2 mg epirubicin', 'daily dosage ≤ 100mg', '≥2 and <18 years', 'once-daily', 'more than 2 times', 'One', 'multiple consecutive doses', 'long time;|Arterial/', 'TS by 30-cell', '≥2 measurements);|Abnormal coagulation function', '≥ 1 prior', 'newly obtained', 'spontaneous abortions|history of embryo transfer failure', 'more than 2 months before the visit', '100 mg/0.75 mg)', 'Single', 'at least 4-fold increase', '10 mg daily prednisone', 'once or not', '>1cm);|Subjects who', '1 mg doxorubicin', 'dose> 10 mg/day', 'more than ""', '2 doses', 'greater than 10mg daily of', 'more than 10 cig/die', '≥ -2 points|Positive', '≥ 2 weeks prior to the first administration of study treatment.|Previous', '12 consecutive months', '1 year', '≥ 240 mg / m2', '>1 new symptom on the', '<1 month)|severe chronic', '≥ 8', '10 min ≤5', '>35 days', 'long term of', 'more than 16mg', '≥2 outpatient', 'more than 45 minutes|The', 'at least two cell lineages)|Haemoglobin < 9 g/dl', 'same regimen after', '12 months|No prior', 'more than 14 units per week', '25% of', '|a history', '30 mg, methylprednisolone 6 mg', '≥ 28 days;|HER2', 'changed deliberately.||', 'therapeutic doses', '250 Hz to 8000', 'at least 1 dose', 'January 2020)||', 'once the', 'at least five', 'patient.|Failed', 'more than once prior', 'maximum use of 6', '30 minutes per day', '1.5 mg of bumetanide', 'once a week', 'more than 21 units', 'Doxorubicin/Cyclophosphamide', 'greater than 10 pack years', '2-year-followup visit|Willing', '100 x 109/L|AST', '≥1.2 g/kg/d', 'more than needing more', '≥ 4 daily', '≥ 2+proteinuria on', '≥8|Patients', 'CLL).|At least one', 'at least posterior-anterior view', 'daily diary|Completes', '≥2 mm greater than the', '>72 hours', 'more than 2 standard alcoholic drinks per day or more than 10 drinks per week', '> 10 mg/day', '1 mg of doxorubicin', 'higher than the Upper Limit of Normal', 'more than 5 years.|Diabetic polyneuropathy', 'maximum tolerated dose documented', '500 mg/dL', 'bilateral', 'less than 6 months', 'greater than or equal to 1500 mg to less than or equal to 2000 mg', 'R responses.|History', '1, 2c, 4c', 'daily dose', 'once per week for', '5 mm', 'at least 12 weeks.|Patient', 'greater than 2', '≥ 1 g of', 'greater than two months prior to screening', '≥3 times per week', 'regular use', '≥ 4 prior', 'scores', 'less than 1 month postpartum,|test positive', '≥ 2 different body areas', '30-75 minutes', '≥ 18 years', 'distant history', '>10 mg', 'MRI||', '≥10ppm', '7-day', 'high dose vitamin B3 supplementation', 'for more than 24', 'once paired with mentee', '≥6 months', '≤100mg/d);|Have', 'higher than 45 ml/mn', 'more than 1 month after receiving', '≥ 9g/dL|Creatinine clearance', 'prolonged', '20-30 minutes', 'MRI||At least two', 'one pre-treatment', '≥ 18 years;|Affiliated', 'more than two doses', 'less than 1 year', '300 mg oral daily', '≥ 2 x SUVmax normal', 'greater than 4 weeks after surgery', 'piRADS scores 3-5|Prostate', 'greater than 3+', '2 of 3', '20 mcg/kg/min', '2-3 months', 'for ≥48 hours', '≥ 18', '>14 drinks per week);|History', '>20 mg a day', 'exceed 1,5 x ULN', '1-3', 'routine', '220 -', 'more than 90', '> 25 mg/week', '325 mg', '≥ 6 at', 'changed dosage of', 'origin|an index knee arthroplasty', 'more than 1 year|Willing', '1 January 2022 to 31 December', '≥ 20 mg/day', 'general', '≥ CTC AE', 'less than 12 hours', 'at least six months duration.||5', '≥2 times per', 'at least 5 years', 'less than 48 hours before the study|Have', '2 or less IOP lowering medications||', 'Multiple', 'more than 3 days a week', '1 week)|In medical treatment', '= 0.45 mg mitoxantrone).|Pregnant', '≥8', '>12 months;|Requirement', '≥ 200 mL', 'once per month', '≥ Type C)|(3', '≥ 1 month to <1 year', 'more than 3', '≥ 8 and ≤ 18 years', 'approximately 500 mL', 'greater than 14 consecutive days', '125 mL wine', '≤ 28 days prior to', 'existing', 'daily use', '≥ 4 weeks', '<2 weeks', 'greater than the lower limit of measurability', 'weekly', 'trial', '<12 months', '2-4', 'long term medications', '40 mg/day', 'two consecutive examination dates', '≥ 28 days prior to screening', 'between', 'outside the target range.|Neck pain associated', '≥2 grades', '20 mg or less per day', 'acceptable', 'reliable', 'gestation|single pregnancy|18 to 45 years old||', 'stages 1-3', 'more than 20 teeth.||', 'one year duration will be included in the study.||', 'more than 10 years', 'at least six', 'one social', '10 mg/day).|NI-13', '>2 years', '< 2 weeks', '≥ 12 months', 'once at the discretion', '≥ 470 msec', '>1 week', '2 - 3 weeks', '>3 glasses per day or', 'less than 10 days', 'more than five years before the start of experiment', '≥6 consecutive months', 'scores greater than 21', 'at least 1cm', 'maximum tolerated dose of ACEI', 'more than one month', 'dose higher than 10 mg / day', 'fewer than 12 months', '≥80', '> 20 mg daily', 'more than 6 months duration', '≥1.25 x the upper limit of normal (ULN)', '> 5', 'two-year', 'daily cannabis', 'more than 2 pre-study', '≥ 2 months prior to Screening', 'dose > 10 mg', 'for 2 year after administration of ZVS101e;|The study eye', '≥ 400 mL', 'on 2 consecutive', '2 times the upper limit of normal;|Patients', 'more than 24 hours', 'more than 1000 ml.|Patient refusal', '2 to 4', '≥ 12 weeks', '100 mg/day);|Platelet count', '≥ 15 days', '> 0.01%)||', 'more than 20 g', 'one, two or three', '|Concomitant', 'approved or investigational', 'retropharyngeal', 'exceed 50 μmol/L),|AP', '>2 hours/day', 'More than two lung nodules need', '2 x ULN,≤ 3 x ULN', '2 months prior to consent', '≥ 14 days', '= 28 February 2023)||', 'more than 12/24h|Affiliated', 'permitted.|1 cycle', '>15 cigarettes per day', '> 1 mg/h|Not', 'maximum 1 prior', 'approved dose', 'exceed 30 kg/m2.|All', '≥ 4 months prior to study entry.|Prior', 'researcher prior to attendance', '5 half-lives', 'One or more', '>2 time', '≥2 mg/kg/day', 'More than 1 cigarette per week', '≥ 99th percentile', '2 weeks prior to randomization', '1 year after enrollment', '≥2 times the upper limit of normal', 'ethnic', 'higher than 30 mL/min/1.73m2', 'maximum 2', 'Two years or more', '>25', 'High Dose or', '≥ 18 ≤35|HgA1C', 'bilateral oophorectomy.|Voluntary written consent', '≥10 g', 'chronic disease,|Having multiple', '1 January 2019', 'more than two years', '≥ 20 to 65 years', 'single', 'daily functioning||Exclusion Criteria', '≥1500 mg daily', '≥21 alcoholic drinks', '>0.1mg/kg/day', 'daily treatment', 'women)|At least one', 'more than II degree', '>800μg/day', '≥100 within 8 weeks prior to screening mg/d', 'more than 72 hours', 'physiologic doses', 'immunosuppressant)|Concomitant therapy', '2-6 degree', '≥ 100 000', 'at least two weeks between feeding periods', 'more than 7', 'one arm more than the', 'greater than minimum doses', 'greater than 35w6d|Body Mass Index (BMI)', 'one or more', '30-day', '≥1 time/month', 'dual', '≥500mg/day', '4.25% dextrose solution', '≥ 6 months', 'increased', 'more than the average', '>= 1 week prior', 'long term health', 'more than 2 times per week of regular physical activity', 'for at least 60 minutes)|Any patient who is', '>14 days apart', '2 prior', '≥ 1.5 x ULN', '3 mg BID 6 days before surgery', 'more than 8', '≥ 2 of the following', 'more than six months', 'Regular use', 'more than 1 year of follow', 'greater than [', '≥2', 'more than 2 times the vessel diameter；5 points', '10 mg/mL', 'oral daily dose ≤ 3000 mg', 'increased dose of ICS', '≥20mg)', '≥2 for participants on', '<1 year', 'greater than 100 mg/day', '5% of', '≥6 consecutive', '2|≥ 2 prior', 'maximum tolerated dose/maximum allowable dose', '>10mg', '≥ 5 years', 'less than 2).|Knee', 'Continuous use of', '5 menses prior to enrollment.||If', '≥ 1,000', 'ULN)|Pregnant', 'more than one vessel', 'greater than six months ago may', '≥ 3 months after targeted', '≥ 2.Endoscopy', 'more than 5 years.|Current', '>2 inches', 'greater than or equal to 1', 'greater than or equal to 180 days before screening|HbA1c', '≥ 30 days', '2 mg/kg', '≥ 100 meters', '3||One or more', 'scores between 20 and 24 +', 'greater than or equal to 6 hours to maintain a mean arterial pressure', 'routinely', 'Daily,', '5 mg/day', '≥ 8 hours', '≥ 28 days', '<1yr', '≥ 75 minutes', 'Repeat', '≥ than 1 standard deviation', '>100mg QD', '45º)|Time', '≥2 weeks', 'frequent', 'stable dose 6 weeks before starting treatment|Have access to the internet', 'older.|One', '>3 months', 'at least', 'daily ICS', '>7 days consecutive treatment', 'outside the range of the available', '2 mm).|Patients of', '5mg twice daily', '>14 drinks/week).|Unique', 'two separate', 'One repeat of laboratory assessments', '≥6', '≤300 mg/g via', '≥ 4', '10 mg or less', '≥ 2mm;|intake', '15-centimeter', 'greater than 24 hours|and/', '1 mg, 3 mg,', '≥2 weeks.|Ability to swallow', 'dual antiplatelet therapy', '≥2 times/week', '30 mg', '> 500 ml coffee daily', '≥ 25 g/L', '≥ 99.5 F/ 37.5 C', '≥2 on', 'maximum of 2', 'less than 10%', 'dose greater than the equivalent 10 mg of', 'long term tracheostomy', '>14 days', '>1 cm);|Patients', '>14 units/week', '< 140/90mmHg by 24', 'for more than 14 consecutive days', '> 1 year', '≥ 500 ml prior to administration of the study medication', 'higher than 1.5', 'more than 20', 'at least 6', 'greater than 7 of 30 past days', '≥ 1 line of therapy regardless of the timing', '2 to < 6 years', 'calorie intake', 'high-dose', 'one-week', '=1 wine', '≥1 dose of IMP|Known hypersensitivity', 'more than six weeks duration', 'mcg/min', '2 accessible non-adjacent teeth', '≥ 50%', '≥ 1 unplanned', '≥ 2 years from completion of radiation therapy', '2-4 days', 'chronic use', 'half or less', 'once the repeat', '<3 months)|Recent trauma', '1-year', '12 or more', 'daily for greater than 2 years', '≥ 28 days before the first dose', '≥2 on item 9', '60 mg of', '> 80 g/d|BMI', '50 mg dexketoprofen', 'toxic effect(s', '≥ .5|Demonstration', 'more than one week before the start of the study', '≥ 8 g/dl|Able to', '>500 mg per day', '2-D', '≥ 1.5 × 10^9/L', '1 but no more', 'canine relationship malocclusion|maxillary anterior crowding', '2 to 3', 'at least 1', 'at least 1 prior cytotoxic chemotherapy-', 'one prior', 'greater than 450 milliseconds', 'one ore more', 'daily dosage', '≥20 mg', 'more than 9 pre-operative', 'daily', 'at least 1 line', '> 10 mg daily', 'more than 3 times/week', '2 years to 4 years', 'at least 14 of the 17 segments of the LV myocardium.|Sinus rhythm', 'more than the equivalent dose to tablet prednisolone', 'analyses|At least 18 years', '2 weeks before surgery.;|Patients', 'at least one-line', '>5 mg daily|Daily use', 'more than 15 mcg/min', '12-week observational period', '≥ 100,000/mm3|Hb', '84 g per week', 'at least 3', 'one sided', 'more than 10', 'more than 6 months before inclusion', '> 2 time', '1 REGISTRATION:|Patient must', 'more than 5 kg variation in body weight', 'more than 70%', 'more than 6 months of', '≥ 1.5x', 'more than 30ml per month)||', 'greater than 6 months prior', '≥ 1.7 mmol/L', '10 mg daily', 'first', '2 weeks', 'higher than the upper limit of normal', '≥ 8 consecutive', '≥ 12 years', 'more than one week continuously#|sign informed', 'pneumothorax for example)|Insufficient level', 'Rotterdam', 'daily consumption', '≥ 24.||', 'higher than', 'dose-escalation', '>20 consumptions', '≥1 mcg per day', '≥ 2 months', '>=30 days prior to the day', '80 mg QD', 'more than 500 mL blood', 'more than 3 mg twice daily', '20mg twice daily', 'First episode of pericarditis', 'greater than equivalent of 10 mg daily of', '≥ 30', '≤100 mg/d)|Those', '2-year-followup visit||Exclusion Criteria', 'one-time', '≥140 mg of', 'New onset of septic shock', '>2 mg/kg/day or', 'fasted for at least 8 hours', '≥ 7 years||', '≥ 1.0×109/L', 'less than 14 days before enrollment', 'once a day', '≥ 9 nmol/L', 'more than 1', 'Two', 'at least 14||', 'frequency of exercise activities', '> 10,|clinical cut-off on Depression subscale', 'outside', '≥ 20/25', '> 10mg', '2-year', 'More than 1 prior', 'half-life', 'daily for 5 days', 'more than 2 consecutive weeks', 'outside the range +2.5 Diopters', 'requires therapy for cancer', '>=1 psychotherapy', '≥ approximately 3', '≥1 acute', 'capsule', 'at least 12 weeks duration', 'two separate tests|Fasting', 'greater than 2,500 meters for', '≥ 7 days continuously||Patient exclusion', 'at least of', '12 and 32 weeks of the', 'routinely than the', '≥10 mg/day', 'prednisone equivalent', '≥ 60%|Hemoglobin ≥ 10g/dL|Patients', '≥10mg', 'for at least 7 days', 'Twice a day', 'more than one year', 'at least two months of lead', '≥ 10 mg/day', '2 hours after a 75 g glucose load', 'baseline|Emergency procedure|Poor CT', 'outside a 30-mile radius', 'one of the', 'long term', 'subsequent 12 months - minor', '1 month|CABG within 3 months|PCI within 1', '≥6 months;|At baseline', 'high doses', 'at least 6.4%;|fatty liver index (FLI)', 'more than 3 months;|AST', 'more than 60 min/month', 'more than 1 dose', 'more than 7 consecutive days', '≥ 20', '<1 year prior', 'at least one dose', 'participation.|Major', 'small amounts', 'Romantic/Sexual', 'more than 90 days', 'more than 1 allo-HSCT.|Presence', 'greater than three months', 'daily for >3 months)|Weight', '>10mg daily', 'treatment.|Pregnant', '≥5 mm', '>30 days post-surgery', 'more than twice the respective reference', '12.8 mg/kg', '≥ 19 years.|Clinically', '50mg, three times a day', 'more than 10 mg/day', '<3 months before inclusion', 'more than 4', '25 ≤ GFR', '≥ 25', 'twice daily medication', 'dosing.|Concomitant use', 'minimum 2', '≥ 5 prior', 'more than 440 ms', '2 weeks before surgery', 'more than three months.|At enrollment', 'mitotane|Previous unsuccessful surgery', 'more than 48', 'for more than 15 days', 'more than 10 mg/day;|the', '2 or more recurrences', 'at least two years duration', '1 cytotoxic chemotherapy regimen', 'cN1', '≥2 well-conducted', '2-hr PG', 'at least 12 months.|Patients', '≥ 10 mg per day', '2 methods', '> 25 percent', '1 cases.|Normal shape', '≥ 12 weeks.|function', '20mg of', '25 mg/week', 'dose > 10 mg/day', 'at least three', 'Daily Diary (UPDD', '≥9 at Baseline.|Must', 'long-term assignment', '12 consecutive months of', 'changed their medication for', '2 or 3', '≥12 months.||Treatment', '> 1', 'more than 1 week', 'infection)|history of blood clots', 'less than 3 months old', '>2 mg/kg/day', '>5 hours', 'more than 0.4 L per', 'more than 400mL', 'higher dose', '81mg of', 'daily low-dose', '14-day', 'twice per month', '> 5mg/day', 'dose >10mg/ day', 'less than 12 days after onset.||', 'rather than', '1 to 3', '≥ 2 times the upper limit of normal', 'greater than 30mm', 'at least 2 years', 'minimum 2 weeks prior to the first day of study therapy|Exposure to', '≥1', '>14 consecutive days', '≥2,', 'bilateral orchiectomy.|Metastases', '≥4', '1)', 'more than twice', 'more than eight 80 g portions', 'more than 3 days', '10 mg/day', '1 of 6 different WHO EUA', 'at least 12 months of amenorrhea', 'at least PASI', '45 ml', 'at least 2 weeks of', '≥3 years', '2-weeks', 'Short', '≥ 8 mmHg|Patients', 'various', 'for at least 6 months.|Patient', '2 and 3', '2-6.5 cm', 'less than 2 years', '> 10 mg daily equivalent', '≥ 100 K/', 'at least 1 designated symptom', 'less than 14 days', '≥ T1b)|Obtained signed', '≥1000mg daily', 'first onset <3 months ago', 'more than 20 mg/day', '>1/40', 'more than the', 'frequency unchanged for at least 4 weeks prior to Visit 2/Baseline.|Subject', 'greater than or equal to 20% expression', 'more than 30%', '2 consecutive follow-up visits', '≥ 1 in each component', 'greater than 12 months duration', '≥ 1.0 optical', 'therapeutic', '≥ 100', '≥3', '≥ 12 weeks.|Normal', 'Frequent', 'once to determine', '>45', '>500 mL', 'greater than 6', 'exceed 2 times the upper limit of the normal value', 'greater than or equal to 12 months of amenorrhea', 'for more than 48 hours|patients', 'more than 15', 'more than three doses', 'dose > 10mg/ day', 'high-dose chemotherapy', '≥ 30 days prior', 'above the ULN)|Active', '≥ 750 cells', '≥ 2|Having', '≥1 g/g', 'more than 8 hours', '8 years)||', 'changed', '≥ 12 continuous months of', 'greater than 360 mg/m2.|Positive', '> 1 year.|Presence', 'stroke|Less than 1 month passed after onset of stroke|Upper', 'daily to weekly', 'at least 20 out of the last 28 days.|Participants', '≥ 10%.|Uses', 'once monthly or more', 'daily reusable', '≥ 6 months prior to transplantation||Donor Inclusion Criteria:||Age 18', 'multiple', '2-week', '<3 x ULN', '14-day cycle length', '≥2 years before the first dose', '≥ 5 years before the first dose of study', 'once daily', 'repeat', 'daily intake', '≥ 6', 'more than 1 cycle', 'high', '2 or less', 'three or more', 'more than 3 months prior to End of Run-In visit', 'during surgery', '≥1 g/day', 'twice daily basal', 'two', '≥ 1', '>10,000,000 copies/mL', 'more than 20 times', 'more than 360 mg/m2;|Hypersensitivity', 'more than 14 days', 'Fixed deformities|History', 'once daily oral', '≥12 months of', 'major', 'chronic', 'for ≥ 7days', '30', '≥3mm', 'greater than or equal to', 'One month before the first administration', '>2 standard alcoholic drinks per day', '① use of', 'one of the following conditions', 'maximum of 3 isocenters', 'less than 1% failure rate', '≥25 weeks gestation,|At least one', 'maximum of 7 days before the start of treatment', '>5 BU', 'after surgery / re-intubation.|Patients', '14 or more', '1.5 mg/dL);|history', '10 mg prednisolone', '10 mg may', 'long term follow', 'At least one', '2-6 mL', 'over than score 2', 'one-time peripheral venipuncture;|Infection', 'more frequent than once per month)|Insulin dependent', 'emergency use', 'higher than 100/min.|Any', '25 Gy', 'therapeutic trial', 'more than 14 days|Pre-existing', '15 or more', '1 year prior', 'once baseline', 'greater than 50%||', 'more than 5% of basal', 'greater than 5 mg/day', 'more than 4 hours', 'Year 1-5|Current enrollment in anesthesiology', '>15 days per month', '≥ 50%|Target vessel', 'SSW)|Six or more', '≥ 12', '≥10 mg per day', 'osseous metastatic disease', 'greater than 5 days per week|Walking aid', 'only 1 infusion of', 'chronic use of', '≤80 years;|scheduled for elective', 'half-maximal inhibitory concentration (IC50)', '≥ 1.5 x', '2 consecutive', 'maximum tolerated dose', 'endocrine therapy.|Participants', '>1 year', 'more than 24 hours.||', '≥ 2 mg/kg/day', '20 hours', 'greater than 60 milligrams', 'maximum of 3', '24-2', '35 g', 'two or more clinic visits', '≥7 ppm|Able to read', 'maximum of one month prior to inclusion.||', '≥ 20 years', 'higher than 6.|A', '2 mg/kg/day to', 'more than 1 month after treatment;|Symptomatic', '20 mg', '30mg oxycodone per day', '4 or more', '72 x serum creatinine', '12 weeks', 'more than 8mg', '≥ 1.5 SD', 'more than 7 days', 'minimum 2-3', '2 to 7', '≥ 28 g/L;|Total', 'steroid use', 'Chronic decongestant', '≥10 mg oral', 'stem cell', 'Chronic Respiratory Disease', '≥ 10mg', 'one or more times per week||', '≥6 months).|Normal', 'greater than 5 years', 'regular', 'melphalan', '≥70', 'greater than 12 consecutive months', 'once-monthly', '>20 units/week', 'new', 'one year follow up||', '≥ 5 cigarettes per day', 'daily doses', 'more than 10 units per week', 'greater than or equal to 90 days', '> 48 hours', '≥ 1.5 nmol/L', '>14 alcoholic drinks per week', '17.5 mm^2 (1 and 7', 'more than 3/year', '>2 units', '≥ 2 weeks', '50 miles of the Cal Poly campus|Owns', '>10 mg/day', '≤ 28 days prior', '5 x 5.2Gy', 'daily questionnaire||Key Exclusion', 'more than -6', '≥ 100 000/uL', '≥6 at time of', '≥ 1 of', '≥9 g/dl', '<2 hours', 'less than 8 mg/dl', '≥60 years|at least 2', '≥ 50%;|Myocardial enzyme profile', 'more than 4 weeks prior to the first dose of study therapy', '400 mg QD', '2-6', '≥12 hours', 'one year', '≥2 chest/abdominal CT', 'visit)|Concomitant', 'greater than 6 months.|Subjects', 'at least 2 weeks before the start of study', '≥ 1 per week', '>10 mg daily', '60 or more', '5mm to 10mm', '168 g per week', '14 or more days per month)|Abnormal', 'more than one episode of', '1 to 2', 'changed her topical cleansing / care products', '≥ 16 h/day', '1 mg orally', 'lt;1.0 x 10 9', 'more than 15 g', '≥ R1)|Patient', '≥ 4.||', '1) Multiple lung lesions', 'more than 2 months before inclusion', 'outside of TriNav device', 'more than 5 half-lives).||Subjects', '>1 year ago', 'more than five', 'more than one donor', 'more than 400 mL', '>28 days', '1 to 4 hours.||', 'more than 25% of the', '10-25 mg/week', 'more than 1500 mL', '> 12 months amenorrhoea', 'greater than 25%', 'higher than 5 mg/day', 'higher than lower detection limit or', 'two menses', 'daily ≥20 g', '20mg per day', 'greater than 10', '5-minute', 'greater than 14 drinks per week', 'tanning', '≥ 150 mg/dL|LDL', 'more', 'Chronic', 'more than ten', '20mg daily', 'changed medical conditions.||', 'greater than', 'more than two times a week|Control', 'less than 4 weeks', 'more than one-third', '≥2)', 'greater than equivalent of 5 oz of liquor', '≥', '1-month', '≥ 6 months from completion', 'greater than or equal to 2', 'more than 3 months prior to enrollment', '20 mg/day', 'more than 3 months||', 'more than three months', 'greater than prednisone', '≥ 1 LA segment', 'maximum allowed dose of 6 g per day.|Participants', 'maximum of 10', '≥80mg Lasix', '> 12 months)|Radiation therapy', '30 mg of torsemide', 'more than 2 weeks one month before vaccination', 'More than 18);|Having', '100mg twice daily', 'changed no more', 'older.|At least one', 'higher than upper limit of normal', '≥20 mg daily', 'more than 4 months before Visit 2/Baseline.|Subject', '>10 mg QD', 'daily for more than 2 hours', 'three consecutive times', 'more than 25%', 'more than 10 consecutive days', 'toxic reactions', 'more than 5 years', 'more than 1 cigarette per day', '20 mg/d', '25-35 days length)|In', '≥ 2', 'etc.);|At least one', 'more than 15 minutes', '30-day screening', 'Iopromide 370', '1500 per mm3);|Platelet count', '≥ 2+ regurgitation', 'more than 10%', '≥ 480 ms)||New', 'more than 30 days prior to screening.|Presence of known', 'greater than or equal to 6 months|Injury level', 'more than 10 weeks before entering the', 'lamotrigine 200mg/d', '>170/110mmHg)|Uncontrolled', 'greater than 1 day per week', 'one year of CrossFit experience', 'Two consecutive', 'exceed 5 times the upper limit of normal values', '1 mg/kg/day or', '≥ 3', '2 or more', 'SNRIs));|Previous history', 'changed their IFN-β', 'once daily|Expected to receive', 'for at least 5 minutes', 'at least 1 year.|Participants', '> 12 months', '≥ 6.5%|History of', '≥ 1 month after surgery', 'one of the following', 'first 24 hours postpartum,|Primiparous,|Episiotomy', 'higher than 3 ml/mn/year|a', 'daily access to', '10 days|Subjects taking', 'outlet;|Previous rectal', 'more than one cycle', 'one', 'more than 2000ml', '≥ 4 weeks prior to the experimental maintenance treatment', 'at least 18.||', '<2 years', '≥2 years.|Outpatient', '=28 days', '≥ 3 times in 24', '12 to less than 18 years', '20 mg daily', 'semen', 'more than 3 months', '≥ 1 year.|HBsAg positive', 'twice daily', 'more than 14 days after onset', 'maximum of 30%', '≥ 1 mm||Inclusion', 'toxic megacolon|History', 'more than 3 months);|The', '80 g/L);|Serum creatinine', 'at least 1 year of treatment', '25 mg/day', 'greater than one year.||', 'ICC)|At least 1 measurable', 'more than 3 months prior to study entry|Eastern', 'greater than 12 months post-menopausal)|Participation', 'greater than 22 mmHg', '>5 episodes', '≥ 8.5 g/dL|Creatinine', '>30 days post-surgery)||Anatomic', 'more than 270', 'at least two or more encounters', '>150/90mmHg', 'more than 1.5 mL/kg/h', '≥ 8.0 g/dL|International', 'for at least 48 hours and satisfied the weaning criteria', 'greater than two', '60 mg/m2/day', '1', '≥ 2 months prior to study enrollment)||', '<12 weeks)|Recent', '2-month period', 'once per week', '>100 mg daily)|Fish oils', '≥ 25mmHg', '≥2 times weekly', 'recurrent UTI per patient report', 'greater than 1.5 cm', '2 methods of birth control', '≥ 1 h.||', '>2 weeks', '>= 14 days prior to registration|ELIGIBILITY CRITERIA', 'less than 100mg/day', '≥6-month', '≥10', 'upper primary first or second molars bilaterally.||', '≥7 mean monthly headache', 'maximum tolerated doses', '8 diopters or more', '>1 to <7 days|and/', '45 min delay', 'higher than the detection', 'high stress screening result', 'above 14 weeks', 'more than 48 hours', 'more than 1/3', 'once in an adhoc', 'total daily dose equivalent of', '≥0.05', 'permanently', 'one jaw,||', '45 ml of spirits', 'at least 21 days', 'at least two consecutive evaluations', '100 mg/L', '>1.5 mg%)|Grade', '>5 minutes', 'half-lives', 'online', 'once,', 'New', 'more than 30 minutes', '> 10mg/ day', 'greater than 20 cigarettes', '200IU/ml', 'At least two', 'more than 100mL per session', 'SCS),|Cesarean delivery by', 'greater than or equal to 1000', 'at least 1 value', 'generalised', 'more than 3 weeks', 'outside of', 'greater than 5 days per week;|Current smokers', '≥ 25%', 'one year|On multiple daily injections (', '1 or higher adverse reactions', 'resection;|Metastatic disease;|Previous', '≥2 non-adjacent teeth', 'maximum of 6 months', '2 IV attempts should', '≥ 2.8 g/dL|CLCR', '>20 mg/day', '12 months||No prior', '> 1 month', 'One-time', '10-14 days prior to', '≥ 1500 cells/', 'only applicable', 'outside of study', '≥ 12-month', 'conjunctiva', 'maximum of 24 months', 'maximum 2 biopsy-', 'more than 1 episode', 'first cycle of', 'more than 1L', '> 18|Willing and able to understand and', 'one form must', '≥ consecutive', '12 mg/dL', 'pathology;|At least 1', 'long term before the procedure', '≥2 self-reported', 'more than 14 alcohol units per week', '≥ 60 days', '100mg or less', 'once at', 'dose greater than 400 micrograms per day', '<2g of protein', 'long term supplements', '≥ 12 months of', '1 of cycle 1', '12 or more months', 'more than 14', 'starting within 3 months after chemotherapy', '>10mg/d', '≥ 20mg/day', 'more than 200mg', 'maximum dose ≤20 mg/day', '≥ 105 bacteria per', '≥ 19 to ≤ 55 years', 'Younger than 19 years', '> 14 for men', 'more than 2 years', '< 12 months', '≥ 50%||History', 'more than 2 years.||Exclusion Criteria', 'times a week', '1 year after enrollment.|Dementia', '≥ 5', 'physiologic doses ≤ 0.2 mg/kg/day', '≥2 kg', 'more than 3.0.|Known', 'upper and lower clavicular lymph', '≥ 75 g/L', '≤ 2 weeks', 'daily symptom diary', 'dose equivalent to >10 mg', '≥126 mg/dL)|Chronic', '<14 weeks', '<4000 times/24h', 'dose equivalent to > 10 mg', 'more than 1 month', 'more than 60 minutes', '1 year prior to the', '≥16.0 kg/m2', '1 or 2', '12 weeks|Cryotherapy', '1-6 months', '20 g of alcohol', 'more than 2 months|Lumbar puncture', '>100 mg/day', 'two or three', 'higher than lower detection limit or >0.05 IU/ml', 'at least first-line', 'only 2 episodes of', '≤100 mg/d', 'more than 4 cups of Caffeinated beverages per day|Any', '2 weeks|splenectomy', 'eligible|At least one', '≥ 2 years|participation', 'Mandible|At least four', '12 months.|Expected to', 'single-agent', 'more than one', '>10 mg per day', 'changed dose', '≥3 months|ability', '30-day safety', 'once at the discretion of the Investigator.|Subjects', '1 or 3 minutes', 'for at least 3 months', '≥ 500 µg/l|Presence', 'regular use of', '1 mg doxorubicin equivalent to 2 mg epirubicin', '≥2 degrees', 'greater than 20 pack year', '≥ 10 minutes', 'single dose of', '≥ 0.8 g/g', '≥100 mg/L', '≥ Grade 3', '100 mg/0.75 mg', '1, 2', '< 1 year|Pregnant', '>4 months', 'long half-life', 'January 2006-', 'Recurrent', '>= 90 days', 'protein|Lower than 0.5 of', '≥ 2 per', 'scores at least 1.5 standard deviations below healthy', 'at least 2', '>20mg/day', 'less than 7 days', 'one cycle', '>1 mg/kg', '≥2 at screening', 'higher doses', '>14', '> 20 mg', 'at least two hours before NST|having', '2-']",[],"['anticipated to require', 'planning to undergo', 'Intending to become pregnant', 'inappropriate sexual', 'will exit the study', 'Rescreening', 'repeated', 'Requirement for', 'unwillingness to cooperate with the requirements of the protocol|Any condition that,', 'never initiated', 'unable to consent|Pregnant', 'anticipated to become', 'requires', 'Unlikely to adhere to the study protocol', 'planned to undergo', 'preventing the reading of', 'candidates', 'referred', 'able to read', 'eligible for inclusion in this retrospective', 'immunomodulators.|Treatment for', 'remain', 'interfering with', 'excessively', 'planned receipt', 'Hypersensitive to any', 'likely to be needed', 'screening.|Participants', 'preventing use of', 'need to use immunosuppressants;|(11)', 'unable to adequately', 'kosher diet', 'interfering with treatment', 'planning to become pregnant', 'evident', 'likely', 'can be measured with', 'interfering in', 'expected', 'plan', 'need of replacement', 'potential risk of', 'Employee', 'planning to use', 'potential risk of bleeding was', 'interfering with participation such', 'inappropriate for', 'eligibility', 'mellitus|History of', 'hypertension|Presence', 'interfering with the', 'retro', 'bleed', 'clinical examination||', 'eligible to participate', 'likely to impact participant safety', 'planning to participate', 'likely to be pregnant', 'Clinical suspicion', 'plans', 'AST);|History of', 'hypersensitive to any', 'cyanoacrylate', 'shortness', 'clinical suspicion', 'clinical signs of', 'expected to require', 'eligible for', 'indication', 'planning on becoming pregnant', 'prepared', 'never completed a', 'Experienced', 'splenectomy', 'centres for', 'sunbathing', 'able to', 'planning to become', 'managed for', 'potentially interfering', 'Resistance to or', 'unwillingness of', 'symptoms endorsed', 'planning to be pregnant', '14c|Known', 'elected', 'Willing to', 'is indicated for', 'unwillingness to take oral drugs|Hypersensitivity', 'never previously', 'Symptoms of', 'conditions;|pregnant', 'biochemical evidence', 'negative).||', 'planned administration', 'Anatomy', 'preventing them from attending the research clinic and receiving the interventions|Pregnant or', 'agreed to', 'known', 'unwillingness to complete study procedures', 'pericarditis.|Planned for', 'need an', 'submitted', 'disease.|Planning to', 'low risk in', 'low risk for', 'prevention', 'Continuing to', 'undetectable', 'interested to', 'probable', 'practiced true abstinence', 'anticipated to not', 'symptoms of', 'Changes in', 'expect to', 'evaluated', 'will refuse', 'preventing ability', 'scheduled', 'handwritten diet', 'angina|Uncontrolled', 'unable to complete', 'candidates for', 'applied into', 'requirement for', 'at risk of becoming pregnant', 'precluding', 'unwillingness to undergo', 'qualify', 'integrated into a', 'Scheduled', 'unwillingness to give informed consent for participation', 'likely to take', 'likely to influence', 'evidence for', 'potentially causing', 'Low risk pregnancy', 'suspected', 'slow', 'likely to confound interpretation of the study results|Evidence of', 'immunotherapy for', 'abstinence through', 'likely to be', 'open', 'Documented', 'planning to see a medical provider', 'clinical suspicion of', 'anticipated to need', 'scheduled to start', 'Planning to', 'unwillingness', 'stool|Agree to receive', 'likely to undertake this diet', 'pill', 'Willing to consider', 'interested in attending occupational therapy interventions', 'Eligible', 'specific plan', 'signed', 'Diagnosed', 'scheduled for a', 'referred to', 'enamel flaws', 'unwillingness to use reliable contraception', 'dementia;|Unsuitable for participation in this study assessed by investigators;|Patients who', 'chronically', 'Plans', 'can to', 'inhibiting activity', 'abstinence for', 'ADD)|Absence', 'Evidence', 'documented', 'electrocardiogram', 'Admitted to', 'never received', 'preventing the patient from entering the study', 'Referred for', 'planning for', 'need treatment;||Tumor related', 'likely to have', 'Planning', 'will', 'signs of progression', 'planned intervention.||', 'imminent', 'preventing the achievement of the task.|Drug', 'scheduled to', 'unwillingness to', 'at risk of developing serious', 'lack of', 'higher|Pregnant', 'anticipated difficult', 'no other', 'inconcluyent', 'agrees to return for the prospective portion', 'eligible for this trial.|Participants', 'able to tolerate', 'clinical symptoms suggestive', 'Appearance of a', 'need immunosuppressants;|People', 'activities', 'unable to comply', 'clinical evidence', 'intention of becoming', 'indicated to', 'Appearance', 'low risk for suicide.|Participants who', 'symptoms related', 'active risk of', 'weeks,|Willing to discontinue', 'status.|Eligible for', 'swelling.|Presence', 'able to feed orally', 'preventing them from', 'suspected auto', 'indicated', 'likely to be pregnant.|6', 'plan to', 'Enjoyment', 'eligible for this study.||③Patients', 'expected to receive', 'clinical risk factors;|Cryptogenic stroke complicated with patent foramen ovale', 'unwillingness to swallow', 'eligible for inclusion', 'cycles|Scheduled to', 'etc.|In the', 'biochemical signs of', 'seated', 'women|Actively', 'setting', 'suspicion of the presence', 'operated', 'compliance.|Surgery for', 'eligible', 'diseases|Documented', 'produced', 'expected to undergo', 'calls of', 'criteria:||Involvement in', 'likely to prevent', 'planning to receive', 'pericardial effusion|Unstable', 'Intent to delivery', 'cytology;|Estimated survival', 'unable to take', 'preventing the', 'converted to', 'wheelchair|Fall risk', 'symptoms', 'chemoradiation', 'Need for', 'interested in', 'suspicion', 'visible', 'II|admitted for', 'planning to travel', 'low risk prostate cancer', 'planning to discontinue', 'physiologically incapable', 'anticipated the need for', 'fertility', 'Hospital worker', 'Leukemias in', 'failure', 'expected to suffer', 'permitted', 'admitted for', 'anticipated to receive', 'Concern', 'subjected', 'despite', 'available for', 'Technical University', 'planned to start', 'expecting to', 'syndrome.||Abnormalities', 'English|Able', 'anticipated to', 'old.|Expected to receive', 'interfering with participation', 'subtypes.|Measurable', 'Significant', 'incapable of', 'pulpal', 'planned', 'planning to become pregnant while enrolled', 'compliance with intervention', 'eligible for the study', 'Black|Assigned', 'likely to interfere with participation in', 'disorders|Currently', 'cannot receive', 'low risk cancer', 'unable to', 'referred to the thigh', 'comorbidity|Known', 'likely to impact the advisability of radiotherapy|Any other', 'continuing', 'lying', 'eligible for entry in', 'clinical signs of pneumonia', 'Stated', 'treatment plan', 'feeding jejunostomy|Plan of', 'unwillingness to consume, study foods in Module 2 (e.g.,', 'stricture', 'changes that impair assessment of', 'likely to increase the risk of complications from', 'stable|willing to participate', 'unwillingness to comply with trial requirements|Use', 'condition(s)', 'able to take oral medications.||', 'unable to comply fully with study procedures', 'applied to', 'permitted to', 'need to receive further treatment.|Patients', 'intent', 'can interfere', 'high risk', 'significant', 'planned administration of', 'Equioxe Proximal', 'likely to interfere', 'low risk of transmission of', 'active', 'parenchymal', 'substantial risk of', 'use|Interest', 'commitment', 'expected to need', 'anticipation that', 'likely to become pregnant', 'willing to', 'able to communicate', 'painless', 'seeking', 'need of', 'Sponsor|Able to', 'impairing the', 'Candidates to', 'attributed', 'suspicion of', 'can be', 'need to replace', 'neurosurgeon|Contraindications for', 'unwillingness to comply with the study requirements', 'signed the', 'anticipated to undergo', 'likely to alter absorption of study treatment.||Any of the following', 'interest for', 'able to use', 'limit for', 'suspicion for', 'referred for', 'require', 'Interested in', 'eligible for inclusion need', 'expected use', 'unwillingness to participate in', 'likely to receive', 'planned to receive', 'likely to need', 'disease||Personal requirements:||Inability', 'symptoms arising', 'women|Unable to', 'eligible to', 'images to confirm diagnosis.||', 'Able to ambulate', 'clinical manifestation of', 'covered for head', 'intention to become', 'linguistic ability in order to participate', 'requirement in', 'clear', 'permitted to receive', 'auditory impairment||Mild', 'planning for pregnancy', 'clinical risk assessment', 'potential risk of reactivation evaluated', 'Intent', 'anticipation of', 'refusing', 'Suspicion', 'uncrowned', 'intention to become pregnant', 'Plan', 'Expected to', 'planning to live', 'will receive', 'clinical signs of hypoperfusion', 'hypoglycemia.|Previous or current', 'likely to undergo', 'clinical symptoms of', 'need', 'permitted to enroll.|History', 'willing to use', 'likely life', 'agrees to receive', 'attempting', 'unwillingness to give informed consent to participate in the study', 'can cause', 'pericardial effusions', 'testing for', 'limiting', 'changes expected', 'expectation', 'clinical signs of infection', 'superior', 'interfering with study procedures||Inclusion criteria controls||Signed', 'likely to require', 'calipers.||（3', 'interfering with respirometry', 'NIV other', 'Requiring', 'planning to start', 'at risk of', 'exhibiting', 'planned use', 'consulted for', 'imminent risk to self', 'at risk of self-harm', 'attributed to the', 'declares', 'evidence', 'replacement)|Planned to receive', 'progressed on', 'practiced sexual', 'planning to enroll', 'OCT|The', 'planned surgery).|Subject', 'Admitted for', 'prevent', 'at risk of infection', 'managed per local guidelines', 'likely pathogenic', 'imminent risk of', 'eating behaviour', 'expected to', 'Willing', 'substantial', 'planned to', 'indicated to receive', 'inadequately', 'at risk', 'English|Permanent', 'unreasonable', '3', 'unwillingness to give informed consent', 'paying', 'potentially active', 'need for', 'eligible for inclusion into the study', 'interfering with exercise performance;|concomitant', 'concern for', 'ulceration.|Known', 'planning to initiate', 'able to understand', 'treated', 'unwillingness to consume a', 'intention to perform', 'symptoms for', 'cannot', 'attributed to', 'pheochromocytoma;|Taking', 'preventing', 'Excluding', 'consent to receive', 'willing to undergo BCS', 'clinical evidence of', 'investigator.|Unable to', 'planned administration of trial medication', 'epilepsy|taking', 'anticipated use of', 'planning to get', 'Candidates', 'resistance', 'Indication for', 'lack access', 'eligible to start', 'pancreas to', 'mucosa.|Presence of a urinary artificial sphincter', 'Cohort A', 'is prescribed', 'likely to recur', 'preparing to receive', 'planned to get', 'initiation', 'intention of becoming pregnant', 'Cohort 2:||Cohort 1:||Patients', 'unable for', 'admitted', 'planning to be', 'caregiver', 'planned for', 'at risk for', 'reduced risk', 'can receive', 'screening;|History', 'home|Ability', 'admitted to', 'excluded.|Known', 'plans for', 'planning to', 'Planned', 'Able to tolerate', 'Eligibility', 'Existing', 'low risk for progression', 'at risk of having', 'compliance with', 'interfering with electrocardiogram (', 'Absolute indications for', 'scheduled to undergo', 'Refusing', 'converted', 'scheduled for', 'clinical signs', 'pressure>110mmHg)|Expected', 'unwillingness to comply with the protocol requirements', 'eating', 'indication for', 'unable to discontinue', 'bear weight|Assessed', 'surrogate||', 'sarcopenia', 'suspicious', 'precluded esophagectomy', 'clinical signs of the infection', 'unwillingness to receive', 'maxillofacial', 'plans to', 'interfering with the study', '①', 'attributed to a', 'interfering with study procedures', 'requiring', 'sleep aid', 'planning on', 'consecutively', 'intention to', 'needed|Estimated', 'symptoms that', 'samples', 'applied in', 'permission to', 'biochemical indexes', 'placement.||Exclusion', 'ending own', 'immersion', 'diagnosis', 'willing', 'signs', 'Suspected', 'plans to start', 'planned for resection', 'anticipated', 'preventing participation', 'scheduled to have', 'agrees to discontinue', 'meeting the', 'concern of', 'can be measured Long diameter', 'permitted to enroll.|Oral', 'preventing the participant from', 'diagnosed', 'low risk', 'expected to benefit', 'need decompression', 'planning to give birth', 'Referred to the EP', 'willing to conduct clinical follow-up', 'investigated', 'clinical judgement suggest', 'hypertension|Patients with', 'performed', 'Withdrawal', 'old|Sexually active', 'permitted for', 'active cavity', 'suspicion that', 'actively', 'anticipated life', 'electively', 'planning a', 'antivirals for', 'acceptance to', 'unable to have', 'lactation|Patient', 'changes in', 'need investigator', 'evidence of', 'moderately for', 'schizophrenia,|No access', 'anticipation of the need', 'low risk of relapse', 'hypertension|Presence of', 'indicated for', 'Candidates for', 'interfering with the ability', 'candidates to', 'likely to lead', 'unable to consent|Confusion', 'initiate', 'receive', 'Refusal', 'wAIHA for', 'cardiac]|Known', 'varicocelectomies', 'complying with the study procedures', 'modify their treatment regimen', 'planning to become|Have', 'potential', 'interested in becoming pregnant', 'hypersensitive to radio-opaque contrast', 'injuries||', 'able to receive', 'Need of', 'IM injections', 'requirement to', 'able to have', 'anticipated to take', 'need to', 'Able to', 'interfering with their', 'anticipated use', 'scheduled to receive', 'supported);|Current', 'planning on starting weight loss', 'exogenous', 'concern', 'planning to take', 'resulting in', 'clinical manifestation', 'sleep onset', 'planning', 'moderately to', 'Known', 'planning on becoming', 'able to follow study protocol', 'hospitalization.|High-risk population.|Bronchitis', 'inhibitor)|history of']","[""Informed consent must be obtained prior to start of the screening process. Procedures conducted as part of the patient's routine clinical management (e.g."", 'inability or unwillingness to understand the essence of the study', 'Informed consent by the supervision of the children|6~13 years old (including both the 6 and 13)|SE range:', 'Written informed consent to store samples and perform', 'intellectual disability/cognitive impairment', 'inability to provide informed consent', 'a:||Ability to understand the subject information and to personally name, sign and date the informed consent to participate in the clinical trial.|Provided written informed consent.|Healthy', 'Inability to provide informed consent.|For participants', 'The exclusion criteria for Veteran participants will be assessed via self-report and verified by VA', 'Able and willing to provide a written informed consent|Subjects requiring', 'Is enrolled in the American Lung Association Lung Health Cohort', 'Informed Consent and Compliance||Must provide written informed consent||Must be willing and able to communicate and participate in the whole study||Demographics and', 'etc.),|Inability to consent and follow the procedures of the study', 'Capable of understanding the written informed consent document', 'Written informed consent before trial treatment and prior to any trial specific procedures.|Male', 'inability to give informed consent|denial', 'screening|Any other reason that, in the study PI opinion', 'stay|able to understand the study consent form (with interpretation services if needed)||', 'Written informed consent obtained from the patient|Severe emphysema with indication for BTVA:|bilateral', 'Ability to understand and willingness to sign a written informed consent in accordance with ICH/GCP regulations before registration and prior to any trial-specific procedures.|Confirmed diagnosis', 'Patient unable to understand study information and attend study visits.|Patient did not give consent to participate.|Patients who have had a', 'Able and willing to provide informed consent and adhere to study protocol;|Women', 'Not able to speak/write/read norwegian language', 'Inability of the patient to follow the sessions', 'Inability to comply with study and follow-up procedures|Prior IL-15, IL-2, synthetic IL-2, or IL-2v based therapy|History of severe allergic or', 'r Patients:||English speaking adult', 'Able and willing to provide a written informed consent；|Eastern Cooperative Oncology Group (ECOG) performance status', 'understand or read Danish incl. instructions and questionnaires|Any other condition', 'Informed Consent signed before starting any procedure foreseen by the study;|Liver', 'The exclusion criteria for parents are||a reported', 'genetic or chromosomal anomaly|Probable rapid extubation', 'Inability to perform physical activity', 'Unwillingness to fast', 'Patient capable of understanding, signing and dating the written informed consent at baseline visit prior to randomization.|Patient', '6、Women who can accept biopsy', 'Able to understand and provide informed consent.|Natural born', 'able to understand and speak Turkish,|ECOG performance scale score of 0, 1 and 2|Being literate|Owning a', 'above|Ability to provide informed consent|42 normal controls: No', 'Inability to provide informed consent', 'Informed consent signed by the patient prior to any study related procedure indicating', 'Unable to follow commands or provide consent. 5. Are not medically/psychologically stable 6', 'Inability to travel to participate in the workshop.|Patients with a diet excluding animal proteins (vegetarians', 'Willingness to cooperate with intervention measures and inspection time 4', 'Inability of self or caregiver', ""Any other condition that limits the eligibility of obtaining informed consent or may affect the volunteer's ability to participate in the study;|Pregnancy or breast-feeding;||Severe and"", 'Unwillingness or inability to participate in the study|Currently own an Apollo device', 'Ability to understand and the willingness to sign a written informed consent document；|Aged ≥18 years old;|Histologically or cytologically confirmed', 'agrees to complete all aspects of the study.||', ""understands and signs the pregnant partner's ICF.||"", 'Not willing to participate in the study|Forms with missing answers were not included in the evaluation', 'Inability to follow study procedures|Institutionalized persons|Asylum seekers', 'Not able to eat ad libitum meal|Not able to perform the exercise bout|Daily smoking|For', 'Patient stay', 'Ability to provide informed consent|Diagnosis of', 'Informed consent signed and dated by the patient and the investigator|Age ≥18 years and ≤ 75 years', 'Written informed consent obtained from subject|Diagnosis of CF|Aged', 'period|Able to understand written/spoken English - all study participants will be provided with an overview of the study goals, research activities and tasks', 'inability to understand the information given|person deprived of', 'Written informed consent to study procedures', 'Subjects whose parent(s) or guardian(s)', 'Inability to comprehend written consent form or provide informed consent|BMI', 'Written informed consent must be obtained before any assessment is performed.|Participant', 'Able to provide written informed consent voluntarily;|Age', 'Written informed consent.|Male', 'Able to provide informed consent|Age', 'inability to consent|chronic renal replacement therapy', 'parents/caregivers of', 'Written informed consent to participate in this study is obtained|The subject is an out-patient', 'able to understand the content of this experiment', 'Patient has given', 'Completed consent form, baseline survey', 'Written informed consent must be obtained prior to any screening', 'Inability to comply with protocol-mandated hospitalization', 'Able to sign informed consent|Biopsy-confirmed intermediate/high', 'Able to understand and give informed', 'Written informed consent to participate in the study|Willingness to actively participate in the study and to come to the scheduled visits|Female', 'Inability to sign the informed consent form;|Current use of', 'weeks|Ability and willingness to provide written informed consent||', 'Patient admitted to the Grau-du-Roi Follow-up', 'capacity to consent to the project;|With', 'Patient refusal||Dementia patients|Poor ventricular function', 'Written informed consent is signed by adult participants themselves，and the minor participants is signed by a', 'Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.||Inclusion Criteria for', 'The Informed Consent form signed by patients and/or legal representatives must have been approved by the IRB for the current study.|Patients must have the ability and willingness to comply with study procedures.||', 'Written informed consent must be obtained.|Healthy Chinese', 'Capable of understanding and complying with the protocol.|18 years of age or older but less than 60 years', 'Patient refusal|Spine deformities|Coagulopathies|Infection', ""screening|Any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol"", 'Written informed consent|Patient', 'Written informed consent to participate|At least 18 years', 'Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments|Positive skin prick', 'Written informed consent for participation in the study|In the period between April 1, 2021, and September 31, 2022, all COVID-19 positive frail patients identified by', 'no exclusion criteria', 'Able to provide informed consent after reading', 'Inability or unwillingness to follow directions for study procedures', 'Inability to comprehend written and/or spoken English|Inability to provide', 'Ability to provide', 'Inability to elicit', 'Ability to understand the nature and objectives of the study and to appreciate the risks involved|Ability to stand in an MRI machine', 'Informed Consent as documented', 'Not able or unwilling to sign consent.|Currently pregnant', 'inability to provide', 'Inability to speak or understand English|Previous diagnosis of', 'Written informed consent prior to any study-related procedures.|At time of study are a young adult', 'Able to sign Informed Consent|Scheduled', 'Inability to provide informed consent due to cognitive', 'Patient under guardianship, curatorship,', 'Lack of parental consent|ASA status', 'Inability of unwillingness to consent|Steroid therapy', 'Informed written consent from the volunteers.|Healthy volunteers between', 'Inability to follow the procedures of the study', 'Inability to comply with study and follow-up procedures.|Women', 'Written informed consent for participating in the study and written standard version of informed consent for cardioversion accepted at the Department of', 'Subject should understand, sign, and date the written ICF prior to screening.|Male', 'Inability to understand the aims of the study and/or protocol procedures|Hypersensitivity towards', 'Not willing to abstain from vaginal intercourse for 1 week following laser therapy|Use of', 'Informed Consent Form (ICF);|Adults with diagnosed', 'Able and willing to provide a written informed consent;|Age', 'See inclusion criteria', 'Able to understand and willing to sign the informed consent;|Aged', 'Written informed consent to participate in the study', 'Understands and provides written informed consent and willing to follow the requirements specified in protocol.||2', 'Informed Consent Form (ICF) was obtained from the patients.||Diagnosed relapsed', 'Not willing and signing an informed consent, and not willing to consume fungtional bread', 'Inability to understand and/or respond to the study questionnaires that are in Swedish.|Inability to provide an informed consent for participation in the study,', ""Informed consent form for participation in the study signed by the subject's legal representative;|Subjects of either sex under the age"", 'capable to understand and comply with the protocol', 'Ability to understand the protocol and to agree to and sign a written informed consent', 'Able to sign the ICF and agree to comply with the requirements of the study;|Subjects with pathologically confirmed', 'Written informed consent must be signed before implementing any trial-related', 'Is capable of understanding informed consent and is willing and able to provide written informed consent.|Is willing to comply with all protocol procedures.|Healthy', 'inability to sign an informed consent|inability to comply with follow-up|associated', 'Willing to sign the ICF and follow the requirements specified in the protocol.||2', 'University of Michigan students', 'Inability to complete 3 research MRI scans', ""The patient's refusal to continue participate in the investigation"", 'Informed consent signed and dated|Healthy participants who are determined by medical history', 'Informed consent of the parents or patient.|Patient must be, in the investigator opinion, able to comply with all the protocol procedures.|Age', 'Ability to understand and the willingness to provide verbal informed consent, if 18 years or older', 'Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study', 'Written informed consent according to ICH/GCP regulations before registration.|Age', 'Untrained|Any response of ""yes"" on the PAR-Q+|Physical limitations', 'patient guardian refusal||_ Children', 'Not giving Informed, Written Consent|Diagnosis of', 'inability to lie supine', 'not being fluent in Italian language;|refusal to sign informed consent;|lack of an electronic device with internet access (i.e. computer, mobile phone)', 'Written informed consent.|Healthy', 'Written informed consent to participate in the study|Age', 'Not able to comply with the study procedures based on the judgment of the assessor', 'Able and willing to give written consent|Male;|≥ 18 years', 'Able to provide informed consent to participate in the study.|Subject is older than 18 years.|Subjects should be', 'liver|Able to understand and adhere to study requirements, and voluntarily give informed consent||', 'Written informed consent of the subject to participate in the study', ""Written informed consent form must be signed by the patient or the patient's immediate family members before enrollment.||"", 'The exclusion criteria include', 'Able and willing to provide written informed consent and to comply with the study protocol.|Adult patients,', 'Willingness to participate in the trial|Being older than 18|Have not been fully vaccinated against COVID-19 (those who did not get any vaccine', 'Inability or unwilling to give informed consent|Women who are pregnant, breastfeeding or', 'Written Informed consent|Patients', 'Inability to comply with the instructions defined and exposed during inclusion|Refusal of participation by the patient or one of the legal guardians', ""She's newly married.|Women"", 'able to understand written and spoken Urdu.|A score of 1', 'Inability to complete follow up or comply with study procedures|Previous corneal graft', 'Not willing to', 'Inability to comprehend or participate in', 'Informed consent of patients or their legal representatives to participate in this study|consecutive adult', 'University students', 'Able to provide informed consent for', 'Informed Consent signed by the subject|≥ 18 years of age|Recurrent,', 'Able and willing to provide a written informed', 'Willing and capable of complying with follow-up examinations for the duration of the study.||15. Signed informed consent or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment.||', 'Informed consent obtained before any trial-related', 'understands the purpose and procedure of the study and is willing to participate in the study', ""The patient's peripheral shallow venous blood flow is smooth"", 'Is fluent in English and have a', 'Unwillingness to comply with masking requirements per hospital policy||ii', 'Written informed consent obtained from the subject|Male or female', 'Inability to provide informed consent (e.g. presence of a legal guardian, prisoners)|Active psychosis', 'Inability or unwillingness of research participant and/or legal guardian/ representative to give written informed consent.', 'Patient refuse to participate.|The anatomy is altered due to severe', 'Inability to read English will cause a staff member to be excluded from the study', 'Inability or unwillingness to provide informed consent|Three-month nutritional supplement|Age', 'Inability to comprehend and follow instructions as in dementia', ""Instability of patient's medical condition.|Presence of any diseases that could affect the study results.|Participants"", ""psoriasis.|Baseline Investigator's"", 'Inability to provide', 'inability to root', 'Inability or unwillingness to give informed consent;|Blood pressure', 'inability to provide informed consent|acute pulmonary edema', 'willingness to try to obtain that', 'states willingness to comply with all study procedures and is anticipated to be available for all study visits.|', 'Written informed consent according to ICH/GCP (', 'Able to provide', ""Subject's age"", 'Willingness to participate in the research Being in the 14-18 age group Being a female student High', 'Not willing to participate in the study|Pregnant', 'Written Informed Consent of the subject to participate in the study', 'Inability to enroll in the study and initiate the first dose of RLS-0071 within 9 hours of life.|Known major congenital and/or', 'Cardiovascular disease|Respiratory disease|Recent (', 'inability to provide informed consent or participate in the study procedures as proposed', 'Patients or families', 'Written Informed Consent and willingness to comply with the study restrictions.|Sex', 'Able to understand a written informed consent|Willing and able to comply with all study requirements including potential CYP 2C19 genotyping', 'capability to understand the objectives of the research and to fulfill the Term of Consent||', 'Willingness to sign a written informed consent document.|Male or female', 'nformed consent form dated and signed|Woman undergoing COS for', 'Informed consent form|Willing and ability to undergone a navigational bronchoscopy||', 'Not willing to participate in the study', 'Written Informed Consent to participate in this study||', ""patient's refusal"", 'Written informed consent|Male', 'Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information|Age', 'Able to comprehend and follow the requirements and restrictions of the study', 'Written Informed Consent obtained.|≥12 years old', 'Informed consent of the parents or patient.|After surgical resection', 'Not willing to report their symptoms using the', 'The exclusion criteria', 'genetic risk of allopurinol hypersensitivity syndrome', ""Inability of the trial subject's custody holder to read"", 'inability to lie still,', 'Agreement to participate in the study', 'Not able to sign the informed consent|diagnosticated with cachexia', 'Unwillingness to either complete the study requirements or to be randomized into control', 'females)|Written informed consent to the participation in the study||', 'Consent to participate not given', 'Willing to accept blood draws', 'patient less than 18 years old,|redo surgery,|urgent', 'Patient sign Do not resuscitation', 'Able to provide voluntary written informed consent of the participant prior to any screening procedures|Male', 'Written informed consent must be obtained', 'parents/guardians', 'capacity to consent', 'Not able to read in Spanish|Not able to give their consent', 'months;|Availability of parents or legal guardians to provide free and informed consent to participate in the study||', 'Informed consent / assent obtained|Must have completed Week 52 on', 'Written informed consent obtained before any trial-related procedures are performed|Male', 'Inability to consent to the study, severe mental illness', 'Able to give informed Consent|Above 18 years old||', 'Inability to cooperate with the oral examination|Severe neuromuscular incoordination|Reluctant', 'The physical condition does not', ""Patient's"", 'Written informed consent obtained prior to study enrollment.|Male', 'provided informed consent or assent', 'Inability to accept the privacy policy and terms of use of', 'Able to understand the study and voluntarily sign informed consent.|Male', 'Inability to communicate in either Dutch or English|Weight', 'Lack of social security affiliation|Patient under guardianship', 'Not being between the ages', 'Not being willing to participate in the research,|The presence of any facial anomalies', 'Literate or able to communicate in Chinese and Taiwanese', ""Not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation.|Unlikely to be able to comply with clinical investigation procedures according to the Principle Investigator's/Co-investigator's judgement.|Unable or unwilling to return for recall appointments for a period of 5 years.|Severe non-compliance to Clinical Investigation Protocol as judged by the PI"", 'Written informed consent and any locally-required authorization (e.g., HIPAA in the USA) obtained from the subject prior to performing any protocol-related procedures', ""The patient's main tissues"", 'Adult caregivers (mothers,', 'Inability to comprehend and to follow all required study procedures.|Have a recent history', 'years|Written informed consent (', 'Patient informed of the implementation of the study, its objectives', 'Patient less than or equal to 21 years', 'Able to understand study requirements', 'Inability to cooperate by providing a complete medical history.|Ineligible tumor tissue samples for next-generation sequencing of genetic testing.|Undesirable compliance.|Having a known additional malignancy', 'Patient Informed consent form (ICF)', 'Patient-related', 'Able to sign the informed consent|Age', 'Completed Informed', 'Inability to give informed consent (', 'The exclusion criteria will', 'Informed consent provided by the subject or legally authorized representative.|Diagnosed', 'inability to consent and to follow the procedures of the study|emergency surgery', 'Unwillingness to be part of the study|Primary tricuspid valve disease|Patient already scheduled for tricuspid valve repair/replacement|Cardiac', 'Patient should be', 'inability to give informed consent to participate in the registry', 'able to learn to use Cup B', 'Availability of signed and dated informed consent of the patient to participate in the study;|Patients with moderate combined hyperlipidemia, defined as:||Total cholesterol level', 'points;|Estimated survival time', 'Patient Informed consent form (ICF) signed;|M &', 'Able to understand and speak Turkish,|Who agreed to participate in the research||', 'Patient capable of giving consent', 'understand and follow verbal orders (', 'Agree to follow the experimental treatment plan', 'Written informed consent obtained.|Age', 'Ability to understand and willing to sign an informed consent form (ICF)|Male and female patients, age', 'Inability to perform the neuro-cognitive or functional tests', 'Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;|Male', 'Incapable of participating in the study based on the assessment of the nursing staff|Toothless or', 'Unable to provide own informed consent', 'Written informed', 'Patient unable to feed orally,|Patient under legal protection, guardianship or curatorship,|Patient with an', 'Able and willing to comply with the treatment/follow-up schedule and requirements.||7', 'profile;|Written consent from the legal guardian or the patient himself||', 'Written informed consent provided;|Male or', 'Inability to consent for services due to', 'Provided written informed consent before performing any trial-related procedures;||2', 'Patient enrolled in the FIL_FOLL12 trial (documented by the signature of the study informed consent);|Availability of biological samples:', 'Informed consent as documented by', 'Patients or', 'patient admitted to the room|Patient spent ≥1 night', 'Ability to comprehend and provide a signed and dated informed consent form|Stated willingness to comply with all study procedures and attend all scheduled clinic visits', 'inability to sign informed voluntary consent', 'Willingness to provide', 'Signed Patient informed consent and Privacy consent documents||', 'Informed consent of parent(s) or legally acceptable representative (LAR) of participant and child assent', 'Lack of demographic information, clinical history', 'Inability to understand and follow instructions|Severe lower extremity stiffness with a score of 3 or more', 'Patient whose', 'Not being able to communicate in Swedish', 'Patient admitted to the hospital with a', 'no consent is given by the patient and/or caregiver for participation', 'Able to consent and agree to participate in the study.|3', 'The exclusion criteria were', 'Inability to speak, read or understand English|Having a medical or physical condition', 'Inability to provide informed consent;|Patient who, judging by the study team, does not have a condition for decentralized follow-up', 'Inability to provide informed consent|Lack of internet connection', 'Able and willing to provide a written informed consent|Scheduled to undergo', 'Inability to give informed consent e.g., due to significant', 'Not willing to become research subjects|Allergy to tranexamic', 'Lack of sufficient viable retinal cell', 'Informed consent by the patient and/or his/her', 'Able to understand and willing to provide informed consent and able to comply with the study procedures', 'Availability of gBRCA1/2 test results||Transvaginal pelvic US', 'Inability to communicate', 'Not able to consent for participation|Includable participants not longer living in Norway', 'Ability to comprehend and willingness to provide a written ICF before enter the study;|Male or non-pregnant', 'Lack of consent of patient or legal guardian', 'Patient unable or unwilling to consent|Patient not having', 'Written informed consent is signed by adult participants themselves，and the minor participants is signed by a guardian;|Participants should be', 'willingness to continue treatment for intervention (>80% adherence),|not achieving glycemic targets', 'Availability of the Informed Consent Form of the Patient Information Leaflet (PIL) signed and dated by patient.|Men and', 'Written informed consent|Histologically confirmed endometrila', 'Able and willing to complete the informed consent process', 'Inability to provide informed consent (', 'Willingness to provide a written ICF before entering the study;|2.', 'Inability to speak/understand the Dutch language|Severe psychiatric problems (history)|Neurodegenerative disorders|Substance abuse|Severe cognitive comorbidity', 'Unwillingness to comply with masking requirements per hospital policy||iii', 'Written informed consent obtained to participate in the study and HIPAA authorization for the release of personal health', 'Neurodiverse development', ""Written informed consent is obtained by both patient's parents or legal guardians"", 'Able & willing to participate in the study', 'Able to speak and understand Turkish,|Conceiving naturally,|At the end of the gestational week', 'Inability to give consent|Acute coronary syndrome', 'Capable of understanding and complying with protocol requirements.|Male', 'Refuse to sign informed consent', 'Inability to provide informed consent in English or Spanish||Concerns arising', ""Patient can understand the study's meaning and"", 'Inability to give informed consent|Previous ovarian cancer diagnosis', ""Patient's status"", 'genetic equivalent ≤ 3.0 x ULN and primarily unconjugated)', 'Informed consent: signed written informed consent before inclusion in the investigation|Sex, age:', 'Inability or unwilling to give informed consent.|History of', 'inability to consent to participation in research.', 'Informed Consent as documented by', 'Informed consent obtained prior to any trial-related activities；|Male', 'Patients can consent and screen with a', 'Availability of written informed consent of the patient to participate in the study;|Patients', 'Patient unable to give consent|Patient on', 'Written informed consent to study procedures;|Male', 'Inability to provide informed consent|history of', 'Inability to provide informed consent|Inoperable due to', 'inability to cook in their homes|cognitive deficits impeding the ability to participate or provide informed consent|current treatment for cancer|liver', 'Not fluent in conversational English;|Any health condition', 'Written informed consent', 'Ability to provide informed written consent|Willing to comply with all study procedures and be available for the duration of the study.|Ability to take oral medication.|Willing to provide blood', 'Informed consent obtained before any study-related activities (study-related activities are any', 'Written informed consent;|≥18 years of', 'Willingness to stop their participation in the trial|Being younger than 18|Have been fully vaccinated against COVID-19', 'Unwillingness to be part of the study,|Patients with poor 2-dimensional imaging quality', 'Patient inclusion criteria:||Patients must', 'Inability to properly follow protocol as determined by the Principal Investigator', 'Unwillingness to give consent for participation', 'Written informed consent obtained from subject|', 'Able and willing to complete and provide written informed consent prior to any study procedure', 'Patient enrolled in other clinical trial during the EAP.|Patient aged', 'capable of understanding and complying with the protocol and willing to sign a written informed consent', 'Inability to complete the entire study programme|Previous participation in an MBSR', 'Inability to comply with the instructions defined and exposed during inclusion', 'Inability to lie still for the entire', 'Written informed consent to participate in the study;|Age 18 and over;|Clinical diagnosis of one of chronic respiratory diseases (COPD,', 'Not giving consent', 'Inability to sign consent form|Inability to speak English|Emergent surgery|Current smoker|Smoking', 'Availability of signed informed consent|Adult men', 'Patient admitted at AUCH', 'Written informed consent|Adults', 'Able to provide written informed consent prior to any study mandated procedures.||Able to lie comfortably on back for up to 90 minutes']","['Females with childbearing potential must comply with using highly effective methods', 'chemotherapy.|Recent surgery.|Uncontrolled', 'If the patient is not able', 'Additionally, the', 'True abstinence', 'Participants that sleep with pets will additionally be excluded, as this interferes with the device', 'Not caring for a family caregiver to a person with dementia', 'months|Household does', 'If a subject reports', 'pregnant women|postpartum', 'Is a US Veteran|Meets', 'Additionally, patients of childbearing potential must continue', 'pregnant and breast feeding', 'For women', 'ULN.|Child patient', 'Is under', 'Participants unable to tolerate', 'Pregnant and', 'Female subjects should', 'Being a', 'Is clinically', 'Being a nursing home resident', 'Pregnant patients,|Those', 'TIA.|Pregnant or breastfeeding.|Recent MI', 'The patients should comply with all the following inclusion criteria.||Adult subjects', 'Being a family caregiver', 'The patients who are included in the', 'Chinese males', 'Is pregnant/breastfeeding|Is', 'Pregnant participants|Presence of', 'A pregnant/non-pregnant', 'Additionally, patients must have fully recovered from all acute toxic effects of prior therapy.||NOTE: Cytoreduction with hydroxyurea', 'The persons selected', 'The persons selected for the study', 'Is unable or unwilling to provide informed consent', 'participant.|Female participants must be', 'The male', 'The pregnant', 'female volunteers cannot be', 'gadolinium.|Male and', 'The diagnosis', 'The presence of the following diseases', 'Additionally, you cannot be involved in another investigational drug study during your participation in this study', 'Female of', 'Female subjects must not donate', 'female of childbearing potential', 'Additionally, it is not known', 'The presence', 'Being a nursing', 'pregnant and', 'If they have', 'If the tumor had invaded', 'Females of', 'A male participant must agree to use highly effective contraception', 'Inability to obtain informed consent from the patient, family member or legal representative,|The presence of a focus of non-sanitized surgical', 'If a subject meets', 'pregnant woman|Age', 'If an', 'The patients', 'true abstinence', 'Is at least the local legal age', 'The first-episode', 'pregnant women:||Chinese', 'If child', 'If the habitual residence', 'The use of', 'pregnant patients.|Patients', 'Female subjects', 'Females of childbearing potential should have a', 'age of', 'old.|Ability to provide', 'Is at least the legal age', 'A child with', 'Females of childbearing potential', 'suicidal|Currently pregnant', 'Being willing to participate in this study.||', 'Women of childbearing age', 'Is female', 'Women who incomplete in the data collection forms', 'A female', 'pregnant participants will be', 'The subjects are', 'AML)|Women who are', 'The child', 'pregnant or', 'Unwilling to follow the study protocol|Self-reporting usual engagement in activities that have a', 'Females of childbearing potential.|Males', 'not pregnant', 'A male participant of', 'A child', 'Females of childbearing potential (', 'Unwilling to consent||Children with asthma||Inclusion Criteria:||Asthma diagnosis|Currently enrolled in Baltimore City K-8 Public School participating in', 'Is not able to commit to the 6 weeks of intervention and the one-', 'Unwilling to sign informed consent', 'Young adults', 'A current', 'Unwilling patients', 'Women of', 'Participants who cannot take orally', 'have an', 'Is between 18 and 35 years', 'The radial puncture fail the first time', 'pregnant patients;|patients', 'Is pregnant', 'Is a', 'yo|Pregnant women.|Breastfeeding women.|Consent not given|Claustrophobia|Incapacited subject or', 'anemia|Pregnant or lactating women|In addition to the above, those who', 'Participants who do not consent|Have a', 'Participants provision of a signed and dated informed consent and/or assent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.|Participants who is willing and able to comply with scheduled visits', 'Is HIV-1', 'Participants who do not consider themselves healthy|have', 'Inability, for whatever reason, to provide informed consent.|Language barrier|Mother is from a refugee camp|Mother has no access to phone', 'not proficient Norwegian language skills', 'Not pregnant', 'pregnant and lactating', 'If the parent', 'The children', 'The patient', 'Children who', 'Additionally, it should be noted that periodic abstinence (e.g., calendar, ovulation, symptothermal,', 'Additionally,', 'Adults have', 'children otherwise', 'Additionally, the effects of niraparib on the developing fetus are unknown.', 'The parent', 'methods.|Male participants agree to practice true abstinence', 'Female of childbearing potential', 'FTX-6058,', 'being pregnant', 'The participants must', 'Women of childbearing potential not', 'Participants who do not', 'The participants', 'If they had', ""If the patient's signature"", 'Being a COPD patient', 'Impossibility to perform the neuropsychological evaluation (communication problems such as hearing loss or aphasia', 'Impossibility or', 'Additionally, the presence of any of the following conditions will exclude a participant from study enrollment:||Children']","['Signed written Informed Consent Form,|Patients aged', 'capacity to provide informed consent or refusal', 'volunteering to participate in study|not have any musculoskeletal disease||', 'Patient refusal to participate|Age <65 years.|Emergency surgery|Pre-existing', 'Patient under guardianship', ""Patient's refusal|Allergies to any study medication|Local skin infection on the site of QLB injection||3"", ""Patient's refusal|Poor compliance"", 'Understand the specific process of the test, voluntarily participate in the test, and sign the informed consent form in writing（In healthy people and', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Male or female', 'The patient understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and treatment of the study procedure.|Age', 'Provision of the Free and Informed Consent Form by', 'The patient or his/her guardian voluntarily signed the informed consent；||Adult Patients with', 'The subject must be a', 'r parents and their children', 'Patient does not want a surgical treatment|Patient does not want to participate|Positive history for surgery due to injury of the hurt wrist beforehand|Positive history for surgery due to injury of the opposite wrist beforehand|Additional injuries to the hand and forearm', 'The subjects voluntarily participate in this study who are able to read, understand, and sign the ICF before participation;', 'patients who do not meet the inclusion criteria|patients currently receiving 15 or more hours per week of treatment for their destructive behavior|Diagnostic and Statistical Manual-5 diagnosis of', 'refusal to consent|lost to follow-up', 'Subject capable of giving informed consent and participating in the process of consent.||', 'The patient has any active autoimmune disease', 'Refusal to sign consent|Any pathology or condition (active tumor, pregnancy, breastfeeding) that the investigators believe may compromise the safety of the subject or the objectives of the study|Persons who have had a', ""Patient's age ≤ 18 years;|Acute myocardial infarction with ST segment elevation;|Treatment"", 'able to understand written or spoken commands|Having grade 3-4', 'The subject himself/herself or one legal guardian/agent of the subject is required to fully understand the study and voluntarily sign a written informed consent.|Ages 5 to 35', 'Refusal to give informed consent|Contraindication to venepuncture', 'signing the informed consent', 'The subject must have a known', 'The subject underwent a nasal wash/aspirate as part of standard of care testing during this study visit.|The subject is currently receiving or has received', 'The affected tooth is in the acute inflammatory stage;|Those who have bad habits', ""Parent's consent to participate in the study|Stable clinical status|The child's motor skills should be at a level to be able to play with play dough and should be developed according to his age,|The child's ability to speak and understand Turkish.||"", 'Provision to sign and date the consent form.|Stated willingness to comply with all study procedures and be available for the duration of the study.|Be a male', ""The subject's previous history of antitumor therapy meets one of the following conditions:||Previous recipients of"", 'The child is 5.00 to 7.99 years of age|The child participant and their parent are both non-Hispanic White||Exclusion criteria are:||Non-proficiency in English on the part of the parent or the child|The parent is <18 years old|The child or parent identifies with another racial/ethnic identity in addition to White', 'To agree to participate in the study|To be the age is', 'Signed written informed consent|Patients who have received', 'The subject was fully informed of the trial purpose, nature, methods, and possible adverse effects, voluntarily acted as the subject, and signed the informed consent form prior to the start of any study procedures.|Healthy subjects', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Women of child-bearing potential', 'The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study|The subject refuses to sign the consent|It is impossible to give the subject informed information|The patient is under safeguard of justice or state guardianship|Contraindication to Acetazolamide Diamox® injection.|Absence of temporal acoustic window (non visualization of the cerebral parenchyma, no recordable intracranial vessel).|Insufficient temporal window (visualizable brain parenchyma, no recordable MCA)|Internal or', ""parents' refusal for participation in the study|ASA III and VI patients with history of"", 'The patient has any history of active autoimmune disease', 'able to provide informed consent|able to communicate in the local language|no', 'Patient willing and able to give consent|Participation in BIO|STREAM.HF|HeartInsight-capable CRT-D device implanted', 'The subject selection will be according to the following criteria:|Age range between 20-45 years.|Male', 'Willing and capable to give informed consent for the participation in the study after it has been thoroughly explained|Not more than little experience with psychedelic substances|Experience in Buddhist meditation: participants have a minimum of 1000 hours of lifetime formal meditation practice, e.g. Mahayana (Zen) Theravada (Vipassana) Buddhism or Mahamudra/Dzogchen as primary meditation background, familiarity with longer periods of meditation in a retreat setting.|Body mass index (BMI)', 'Provision of informed consent prior to any study-specific procedures.|Male', 'refusal of follow-up during the study F. Patients are considered by the investigator to be unsuitable for participation in this study', 'Refusal of consent|Pregnancy|Conditions making the patient unable to fill out questionnaire online, through email or over the phone including with cognitive dysfunction,', 'Signed written informed consent;|Male or female', 'The subject who has', 'The patient shall sign the Informed Consent Form.|Aged 18 ≥ years.|Histological or cytological diagnosis', ""Patient's unwillingness to continue participating in the study|Absence of a temporal window for transcranial dopplerography"", 'The parents will be excluded if they cannot understand and sign a consent form and are not willing to follow the the clinical trial procedures', ""The patient's compliance is affected or the subject is at high risk of treatment complications.|COVID-19 infected persons"", 'Signed written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up assessments.|Age', 'Lack of written informed consent|Allergy to antazoline or propafenone|Intolerance of anatzoline or propafenone|AF related to significant', 'must agree to learn about the procedures for preservation of sperm before starting treatment.||', 'Refusal to participate in the study|Not affiliated to the social security system|Minor or under legal protection|Patient with a history of breast cancer|Patient previously treated for breast cancer|Patient', 'agreed to participate in the study program', 'The subject who has clinically significant disease with liver, endocrine system, immune system', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Radiologic and other clinical evidence leading to a diagnosis of NCFBE|1 CF-causing mutation', 'Willing to sign written informed consent, able to communicate well with researchers', 'Provision of written informed consent|Male and female patients|Weight', 'Refusal of staff member to participate|RSI performed in patients < 18 years old.', 'The diagnosis was biliary atresia|Living donors were either the father or the mother|3months ≤age ≤ 36 months||', 'refusal to accept relevant', 'parental consent to participate in the study will be included in the study.||', ""nipple)|Parents' consent to research participation||"", 'Participants capable of giving signed informed consent signed before any study-specific procedure', 'The diagnosis and classification of patients with FGIDs were in accordance with the', 'Willingness to adhere to protocol as evidenced by written informed consent;|Patients with clinical diagnosis of', 'capable of giving informed consent and complying with study procedures.|Between the ages of 18 and 55 years (inclusive)', ""Patient's refusal of pupilometry measurement.|Pre-existing pupil abnormalities.|history of pathologies with dysautonomic impairment (advanced"", 'The subject must give written informed consent prior to any procedure related to the clinical investigation.|Adult person 18 years of age or older.|The subject has an external skin lesion', ""Patient's age will range from 40- 55 years.|Their"", 'Patient refusal,', 'patient does not comply with study procedures such that safety of the trial is affected then they will be withdrawn from the study.|Female patients with reproductive potential must have a negative urine or', 'not willing to participate in research|have any disease|those who are not with the baby', 'capable of becoming pregnant must agree to take precautions', 'Patient 65 years', 'Refusal of the patient to participate in the study.|Minors under 18 years of age and over 79 years of age.', 'provided written informed consent;|Age', 'Not accept the informed consent form|Age', 'Unwilling to consent to microvessel ultrasound imaging|Younger than 21 years of age', 'Signed written informed consent.|≥ 18 years of age and < 75 years old.|BMI ≥ 18 kg/m2.|Histologically confirmed NASH (defined as the presence of steatosis,', 'written informed consent (according to the guidelines of the Declaration of Helsinki) of parent(s)', 'Provision of informed consent prior to any study specific procedures.|Patients (', 'The patient has received other therapy including radical radiotherapy', 'Patient does not understand, sign, and return consent form|Patient is pregnant|Inability to perform regular electronic reporting', 'Patient does not have ABC/MBC|Patient', ""Subject's age is ≥35 years and ≤80 years;|Subject has"", 'The patient did not agree to participate in the study.|There are not enough medical records or medical examination books.|The patient moves out of the treatment unit (not for professional reasons).|The', 'The inclusion criteria will include:||Informed consent of the participant|All women who are 18 years old', 'Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures|Use of highly effective methods of birth control', 'The parents will be excluded if:||There is report of ongoing physical or sexual abuse|They have plans to terminate the pregnancy|The woman', ""Patient's age under 7.|Presence of"", 'The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;|The subject is', ""patient's refusal|lack of communication in French|inability to give free and informed consent|surgery under anesthesia"", 'Signed Written Informed Consent;|Willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study|Males and Females, 18 years of age;|Histologically confirmed', 'The subject must be 18 years of age or older|The subject must be a patient with massive', 'r patient participants:||Individuals of all genders', 'Willing and able to provide informed consent.|Established diagnosis of OA of', 'The patient is 65 years', 'The patient was pathologically diagnosed as', ""Be willing and able to provide written informed consent for the trial. (Participants with cognitive impairment will be enrolled. Cognitive function will be assessed by the treating physician or designee through a neurological examination. The formal consent for such participants will be obtained from their legally authorized representative. For cognitively impaired adults who are enrolling in the study by consent of a legally authorized representative, assent of the subject is required for the subjects with the ability to communicate assent. This assent will be documented in subject's consent note.)|Be 18 years of age or older on day of signing informed consent.||Have the following combined histological and molecular criteria:||Cohort 1:"", 'The trial exclusion criteria included any of the following:||infertility', 'provision of informed consent prior to any study specific procedures|diagnosis of non-ST-segment elevation acute coronary syndrome', 'Tobacco smokers|Under the age of 18 years old|Potential subjects unable to accurately estimate the number of average betel nut chews per day (will be able to re-present for enrollment if they are able to make an accurate estimate of chews per day after keeping a personal record chew', 'Have provided informed consent to be included in the study|Geriatrics', 'Provision of signed and dated informed consent form.|Stated willingness to comply with all study procedures and availability for the duration of the study', 'Refusal to sign the Free and Informed Consent Form and/or Term of assent|Estimated survival less than 12 weeks|Previous adverse reactions associated with EPO|Estar em uso de EPO e inibidores do fator de indução de hipóxia', 'The subject has received any', 'willing to commit to entire 2 years of follow up visits.|(Controls) Matched to each case on age (+/-1 month', ""patient's refusal to participate|any"", 'The patient had received', 'Willing and able to give informed consent, can communicate in English|Age between 18 and 65 years inclusive|Live in England|BMI ≥27 kg/m2 or higher', 'Refusal of the patient or his/her legal representative|Life expectancy', 'willingness to wear the 24-h automated blood pressure monitoring (ABPM) device.||Exclusion Criteria||Children will be ineligible to participate in the study if they meet any of the following:||Other cardiometabolic', 'Willing and able to give written informed consent for participation in the study.|Healthy', 'Refusal / inability to participate or provide consent|Contraindications to injection', 'The patient has or will get a', 'Refusal to start PPI medication', 'The inclusion criteria', 'Refusal of the patient from surgical treatment;|Presence of contraindications to surgical treatment;|Severe forms of diabetes mellitus (', 'Willing and able to give informed consent for participation in the study|Male or female patients,', 'The patient must sign an informed consent form;|Age 18-75 years old', 'Participants capable of giving informed consent|Sex', 'The subjects voluntarily joined the study and signed the informed consent', 'Signed written informed consent.|Age', 'The patient is diagnosed with central nervous system', 'Refusal to participate.|Cervical radiculopathy pain recurrence after surgery.|Previous attempt of', 'The patient is allergic to lidocaine and midazolam|The site to be biopsied has a high risk of bleeding such as', 'capable of reading, understanding, and following instructions of the procedure to be applied.|Subject is able and willing to comply with the treatment.', 'Signed written Informed Consent.|Male and female', 'refusal of the patient, previous head and neck surgery or', ""The Investigator's decision that a healthy volunteer is to be excluded in the interests of the volunteer.|Any serious adverse event occurring to a healthy volunteer and associated with intake of alcohol and/or the study product.|A healthy"", 'Provision of signed and dated informed consent form|Stated willingness to comply with all procedures in the VNS-Enhanced Stroke Recovery Program|Aged', 'refusal to participate|enrolment in other intervantional study', 'a:||Able to understand and sign an consent form (ICF)', 'Patient older than 18 years|Surgery criteria', 'Willing and able to provide written informed consent approved by institutional review board (IRB)', 'The eligible criteria for parents are:||parent of a child with medical complexity', 'signing of informed consent at Screening) through the Week 52 study visit.|Participant', 'Provision of signed and dated, written informed consent prior to any study specific procedures.|Must be willing and able to communicate and participate in the whole study.|Healthy male', 'proficient written and spoken English.|Parent/ primary must have capacity to provide informed consent to participate.||', 'The subject is currently participating in another clinical investigation.|Pregnant or breastfeeding', 'patient of childbearing potential: Must agree to use', 'Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific', ""The subject consisted of the physician's confirmation of chronic hemiplegia|onset"", 'The patient has a known hypersensitivity', ""Patient's refusal|Known allergies to study medication|Inability to comprehend or participate In pain scoring"", 'The subject selection will be according to the following criteria:|Age', 'Provision of informed consent prior to any study specific procedures|Male and female 18 through 65 years of', 'acceptance for participation in the study|Healthy', 'refusal to provide informed consent|Subject is pregnant and/or breastfeeding or intends to become pregnant during the study', 'Willing to sign the informed consent, and willing to attend follow-up visits.|Male individual at least 6 years of age with a diagnosis of XLRS and documented', 'Patient 18 years', 'written informed consent signed prior to enrolment.|age 18-75 years', 'Provision of informed consent prior to any study-specific procedures.|Age', 'Understand spoken and written English||', 'capable of becoming pregnant.|Penicillin allergy (Penicillin is used in the manufacturing of the cellular therapy product and therefore patients with a documented', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Age ≥ 60 years', 'complying with the study protocol；|No medical comorbidities', 'signing of informed consent at Screening) through study completion.|Participant', 'refusal of participation,', 'The patient must have given their free and informed consent and signed the consent form|The patient must be a member or beneficiary of a health insurance plan|Patient with CRPS of the upper limb according to the Budapest criteria.|Patient newly treated', 'The subjects voluntarily joined the study, signed the informed consent form, and had', 'The inclusion criteria for the CMHC local trainers are:||Employed in participating CMHCs|Completed a Generation 1 TranS-C training (', 'Has given written consent to participate by signing the Informed Consent Signature Form|Is', 'agreed to participate in this clinical study, receive corresponding treatment, and signed the informed consent.||', 'Refusal of participation', 'Subjects does not meet the Inclusion Criteria', 'The subject has tumor,', 'not willing to participate', 'The subjects must voluntarily sign the informed consent, and the subjects are willing and able to comply with the visits, treatment plans, laboratory assessments, and other requirements of the study.|Age', 'unwillingness to provide the samples or clinical information needed for the study;|History of', ""||Participants' medical records are eligible for abstraction only if all of the following criteria apply:||Availability"", 'Unwilling to participating current clinical trial|Cannot tolerate SGLT2-i therapy|Not willing to join the study|History of', 'refusal of informed consent', 'Refusal to participate,|Has a pacemaker or a neurostimulator,|Has an insulin pump,|Coagulation disorders,|Current thrombophlebitis,|Current pregnancy,|Burning sensation at the treatment area,|Current cancer,|Insensitivity to warm or to pain,|Current infection (tuberculosis, etc.), especially of the surgical site,|Current fever,|Bladder wound during cesarean,|Under guardianship or conservatorship, deprived freedom, or in the custody of correctional authorities,|Keloid scar from previous cesarean,|Previous tecar therapy,|Strong hypertension (systolic > 150 or diastolic > 100)', 'Capable of giving informed consent|Stated willingness to comply with all study procedures and availability for the duration of the study|Male', 'provided written informed consent|Age', 'Refusal to sign an informed written consent, Cases with Chronic leukemias,', 'The patient must be a member or beneficiary of a health insurance plan|Patient admitted to the ICU with at least one positive', 'Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)|The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study|Male', 'intellectual retardation)|Addictive behaviors|Current major depressive disorder', ""Patient's refusal to participate|Multifetal pregnancies|Gestational age"", 'The diagnosis can be clarified by 18F-FDG PET/CT examination|The presence', ""patients who didn't consent"", 'The patient will be excluded from the study in the event of the presence of at least one of the following criteria:||Having undergone ankle, knee', 'The patient cannot be younger than 18 years of age or older than 85.|The patient cannot have sleep apnea', 'All patient presented to ED', 'Parental refusal of participation.|Chest infection', ""The individual's desire to leave the study,|Inability to perform the ball squeezing motion,|Feeling unwell during IV catheter placement (such as"", 'Provision of signed and dated informed consent form|A resting SpO2 of >93% on room air.|Stated willingness to comply with all study procedures and availability for the duration of the study|Male or female', 'Capable of giving signed informed consent as described which includes compliance with the requirements', 'Unwillingness to provide informed consent.|Enrollment into a treatment protocol prescribing antibiotic prophylaxis.|A diagnosis', 'Refusal to take part in the study|History of', 'The informed consent was signed before the study, fully understood the content and process of the study and the potential adverse reactions.|Ability to complete the study in accordance with the protocol requirements.|Chinese healthy', 'Refusal of participation by the patient or one of the legal guardians', 'agreed to participate in the study and have signed the free and informed consent|Patients affiliated to a social security system (including', 'Written consent to participate in the study|For women', 'The patient has an', 'The patient had any systemic illness', 'Patient must not have any prior treatment for the current breast cancer', 'Provision of signed and dated informed consent form|Male or female', 'The following criteria exclude a subject from participating in this trial:||Preterm birth infants with <37 weeks', 'willingness to sign of informed consent in writing.||', 'volunteering to participate in the study||', 'Patient refusal', 'Provision of signed and dated, written informed consent prior to any study specific procedures.|Healthy', ""patient's work-related stress"", ""The participants' age range from 35 to 45 years|their body mass index is"", 'volunteering to participate in study|not have any systemic,', 'Understand and voluntarily sign the informed consent form for this study;|18-75 years old', ""willingness to provide informed consent (parent/guardian), parental consent (parent/guardian) and assent (minor participants) and the ability for participants to comply with study requirements|They are the child's primary caregiver, i.e., they are the adult who spends the largest proportion of time caring for the child (e.g., cleaning, feeding, etc.) or they spent an exactly equal proportion to another caregiver (e.g., parents each with 50% of childcare responsibilities).|They reside"", 'The child patient has to be ≥2 years old and < 8 years old', ""The participants'"", 'Provision of signed and dated informed consent form (ICF)|Healthy adult', 'Refusal of the patient|Recent myocardial infarction|Anti-coagulated patients', 'Adult patient or representative of the adult patient who has read and understood the information letter and signed the consent form. 7.', 'Parents or caregivers not understanding the Italian language|Patients affected by', 'Willing and able to read, understand, and sign the IRB-approved ICF.|Between the', 'written informed consent for participation to the study.||Exclusion criteria||To be enrolled in the study patients must not:||Have not enough pathological material removed at surgery available both for mandatory routine histopathological diagnosis', 'Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.||All patients of childbearing potential must have a', 'refusal to sign consent form.', 'The patient is taking', 'Refusal to participate in the study|Body Mass Index < 18.5 kg/m2 or > 35 kg/m2|History of neuromuscular disease.|History of allergy to neuromuscular blockade|Scheduled to transfer to the intensive care unit', 'The subject must fulfil all of the following inclusion criteria to be eligible for participation in the study unless otherwise', 'Patient opposed to the use of their data', 'signing the informed consent document.||', 'agreed to provide two cerebrospinal fluid samples (before treatment and within one week after disease progression) for genetic testing;||Women of childbearing age need to take appropriate contraceptive measures and should not breastfeed three months after screening and discontinuing study treatment. ""Before starting administration, the pregnancy test was negative, or one of the following criteria was met to demonstrate that there was no risk of pregnancy:||Postmenopause is defined as amenorrhea at least 12 months after age greater than 50 years', 'Provision of signed and dated informed consent form|Stated willingness to comply with study procedures and availability for the duration of the study|Have a documented history of', 'The subject voluntarily joins this study and is able to sign the informed consent form with good', 'whose parents refused participation', 'Refusal to consent|Alcohol use > 14/21 gm/week cutoff|Other causes of chronic liver disease|MELD > 12|Hepatic and', 'provision of consent from heads of', 'Patients who sign the informed consent form and are willing to complete the study according to the plan;|Aged from 18 to 80 years old;|ECOG equals 0 or 1;|Not receiving lung cancer surgery before;|Confirmed to be invasive', 'Signed Written Informed Consent. Before any study procedures are performed,subjects will have the details of the study described to them, and they will be given a written informed consent document to read', 'The subject is above 50 years old or', 'The patient or his/her guardian understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and treatment of the study procedure;|Age 18-75 years old, gender unlimited;|Patients', 'The patient is eligible for participation in cardiac rehabilitation|The patient has signed the standard rehabilitation agreement provided by the rehabilitation centre', 'The following criteria must be met for subjects to be eligible for inclusion into the study||Subjects indicated for the treatment of paroxysmal AF', 'provided written consent to have their clinical data added to the registry||', 'Withdrawal of written informed consent', 'Refusal to give informed consent|A previous thromboembolic event of the brachial artery|Acute infection of the upper extremity', 'appropriate written informed consent is required.||In addition, patients need to meet the criteria of one of the following study groups:||Group 1', ""Patient's opposition to the study|Notion of an abnormal"", 'Be willing and able to comply with study procedures and give written informed consent|Self-reported to be healthy|Within healthy BMI weight range (18.5-23kg/m2)||', 'Willing and able to follow all study requirements|Eighteen (18) years of age or older|Subject is willing and able to follow all study requirements|Subject will undergo a colectomy||', 'refused to sign informed consent|pregnant and breastfeeding|has severe chronic comorbid diseases (cancer,', 'Patient refusal to epidural analgesia,|Contraindications of epidural analgesia', 'The subject is a Veteran.|The subject is', 'The patient with missing', 'laboratory||Refusal to provide written informed consent', 'a:||Able to provide voluntary written informed consent on the approved ICF, understand the study requirements, and are willing to follow and complete all the study required procedures.|Male or female', 'patient or guardian', 'not willing to participate|history of', 'Signed written informed consent|Diagnosis of symptomatic osteochondral or chondral lesion of the talus, deemed by surgeon amenable to arthroscopic treatment with debridement and microfracture|Age of 18-65 years|Subject is willing and able to comply with all study procedures, including visits', 'Willing and able to give informed consent for participation in the study|Sufficiently fluent English to understand and complete the tasks|Registered with a GP and consents to GP being informed of participation in the study||Participants need to meet a number of concurrent clinical criteria:||Current criteria', 'The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (', ""patient's death"", 'Signed Written Informed Consent|Male or female', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study and availability for the duration of the study|Males and females', 'patients unable to sign informed consent', 'The following criteria will exclude a participant from the study:|Anyone that has a tree nut allergy.|Women', 'parental refusal|minor parents or under judicial protection|newborn who already have been discharded home before inclusion|hospitalisation after the first 48 hours of life|only palliative care', 'The patient is between 18 and 85 years old|Providing CRPS diagnostic criteria by using the Budapest Clinical Diagnostic Criteria.|The patient has had', 'Patient who does not speak French|Patient unable to read', 'Refusal to give informed consent|Any condition that would limit the ability of the patient to give consent|Psychiatric cares|To be deprived of liberty|To be under administrative supervision', 'Lack of written informed consent after a time of reflection|Patients participating in other therapeutic research or having participated in research for which the exclusion period has not ended|Patient under court protection, guardianship or curatorship.|Patient unable to give consent.|Pregnant or breastfeeding woman|Patients with digestive disorders for which a chronic inflammatory bowel disease has not been excluded|Patients with fructose intolerance or glucose or galactose malabsorption|Patients with known', 'The subject has a history of', 'The subject has given written consent to participate in the study.|≥18 years of age', 'Unwilling to participate in Zoom sessions and have their voice and face recorded for research purposes.|Currently tends a vegetable garden (as measured by if they have tended a garden in the past year or are planning to tend a garden (outside of this study) in the coming season)|Moving out of the area in the next 5 months|Non-English speaking', 'The subject is participating in this study, or is in a period of exclusion determined by a previous study|Consent refusal|Patient with a polymicrobial blood culture|Patient with a second episode of bacteremia|Moribund patient', ""Parents' refusal to study participation.|Patients with poor coronary vessels targets.|Patients with poor cardiac systolic function"", 'intellectual retardation)|Addictive behaviors|Current major depressive episode', 'Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.|Aged at least 18 years', 'ia:||Provide written informed consent (signed and dated)', 'The patient will not be included in the study in the following cases:||Inability to read Russian', ""Parents' refusal to study participation.|Patients with dyskinetic or ataxic cerebral palsy|Patients need surgery for hip contracture/deformity|Severe mental dysfunction|Poor controlled epilepsy|Advanced respiratory,renal or hepatic impairment|Allergy to study medications|Block contraindication as skin infection"", 'provided written informed consent', 'The inclusion criteria of the study were determined as being an', 'Refusal to participate;|Hypersensitivity', 'Signed written informed consent in accordance with International Conference on Harmonization-Good Clinical Practice and national/local regulations|Male', 'Refusal to participate|Previous enrolment in the study|Outside of hospital catchment|Language barrier|Direct admission following birth without having been discharged', 'signing the informed consent form.||', 'patient does not have', 'neoplasm;|Refusal to sign written informed consent', 'Patient older than 18 years.|Definitive diagnosis', 'The patient must be 18 years of age or older.|Patients', 'Having provided written informed consent|Women', 'The following inclusion criteria must be met for each subject:||Paediatric subjects (<6 years', 'volunteers|Signing of informed consent by participants and head of the study|Understanding of German language in order to be able to follow a lecture', 'Refusal to participate in the research,|Diagnosing metastatic breast cancer (', ""The subjects who don't meet the inclusion criteria, being old age geriatrics (more than 50 years old"", 'The patient must be willing to sign the informed consent form.|Age ≥18 years and ≤70 years.|Histologically-confirmed', 'Willing and able to provide written informed consent.|Age', 'complying with all study procedures.|Willing to provide blood samples for genetic analyses of APOE and GBA.|Willing and able to self-administer or administer by a caregiver oral ambroxol medication, from day 1 to study end', 'The patient could not tolerate further examination aimed at clarifying the cause of the disease or refused to accept further examination aimed at clarifying the cause of the disease due to poor general condition', 'The subject is an adult, man or woman (', 'The patient was examined and delivered at the First Affiliated Hospital of Shandong First Medical University (Qianfo Mountain Hospital of Shandong Province)|Clinical diagnosis of', 'Signed written informed consent from any patient capable of giving consent.|Male or female patients, 40 to 80 years of age.|Documented clinical diagnosis of', 'Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).|The decision to initiate treatment with commercially available Sogroya (somapacitan) has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.|Male', 'The subject is participating in a therapeutic study', 'Provision of Free and Informed Consent in writing, signed and dated;|Age according to the indicated population;|Patients diagnosed with', 'Any patient whose physical condition will preclude them from', 'Willing and able to sign informed consent|Subject is able and willing to complete all procedure and follow-up visits indicated in the protocol|Absence of urinary retention|Prostate volume:', 'Capable of giving written informed consent prior to any study related procedure', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Male, 18 years old or older|Histologically or pathologically confirmed', 'Patient who did not complete treatment or all measurements obtained', 'Willing to sign informed consent form;|Chinese healthy', 'compliance with the protocol.', ""Patient's refusal"", 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Men', 'Refusal to sign informed consent|Paediatric population|ASA physical status IV|Emergency tracheal intubation|Independent Predictors of difficult Videolaryngoscopy (Neck extension < 80°, macroglossia, interincisor distance < 3 cm, anatomical alterations of the neck, cardiac surgery, ear-nose-throat surgery)', 'Refusal to participate in the register or inability to understand the informed consent.|Age under 18.|Patients who have already undergone previous flutter ablation procedures.', 'refusal to sign the informed consent form', 'Understand the research procedures and methods, volunteer to participate in the study, and sign the informed consent|Scheduled to undergo', 'Willingness to provide written informed consent. For decisional impairment', 'Refusal of procedure or participation in the study.|American Society of Anesthesiologists classification (ASA) class III or IV.|Coagulation disorders (', 'Willingness to provide', 'Patient willing to provide signed informed consent and willing to comply with all required study schedule events, where safe and feasible.|Patient is', 'PD|Current patient at', 'Subject does not understand or is not able and willing to sign the study informed consent or be verbally assented.|Subject has had the seasonal influenza and/or the SARS-CoV-2 vaccine', 'capable of childbearing and contributing viable sperm must be willing to comply with contraception requirements and not donate ova or sperm while on the study and for 1 month after that|A negative pregnancy test at baseline must be obtained for individuals capable of', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study||Participants must have histologically', 'The patients included in this study should have received', 'The patient is willing and able to comply with the protocol and has provided written informed consent;|Male or female', 'The subject is scheduled for elective', 'Refusal to give consent or', 'Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.|Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses.|Female', 'Patient refusal to epidural analgesia.|History of cardiac', 'capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).||', 'is willing to withhold desensitizing treatment', 'Willingness to provide informed consent to participate in the Target-CR Study|Must be able to read and speak English well enough to provide informed consent and understand instructions|Age', 'Refusal to participate|Contraindication to the use of Dexamethasone|Patient with corticoids intake for various reasons|Contraindication to regular use of postoperative analgesics like', ""Patient's refusal.|Altered mental status"", 'Willing and able to provide informed consent|Male', 'The subject is a non-pregnant', 'Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures|Patients fulfilling the', 'months：During the periods from four months to one month prior to the date of initial use of', 'Refusal of patients.||Patients with renal or liver dysfunction.|Patients', 'approval to sign an informed written consent, patient with', 'The patient or his/her guardian voluntarily signed the informed consent;||Adult Patients with', 'The patient must have given their free and informed consent and signed the consent form|The patient must be a member or beneficiary of a health insurance plan|Stenosis', 'The patient has a previous history of', 'The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S.', 'Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)|The decision to switch from DPP4i treatment to commercially available oral semaglutide has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study|Participant with last measurement of HbA1c', 'willing to provide informed consent prior to any study related assessments and/or procedures.|Able', 'Patient opposing to participate in the study.|Patient subject to legal protection measures (guardianship, curatorship or safeguard of justice)', 'The patient must be between 4 and 12 years old at the time of informed consent.|Patients diagnosed with food allergy to eggs and/or milk (clinical history compatible with', 'Parental refusal for participation.|Children under antibiotics treatment', 'Written consent;||A patient who voluntarily provided a written consent form before participating in a clinical trial;|A patient who voluntarily provided written consent for genetic research for genetics and/or', 'Willing and able to provide written informed consent for the trial.|Male', 'consent of parents/guardians', 'patient or guardian agrees to the study protocol and the schedule of clinical follow-up', 'complying with the specified study requirements, provided written Informed Consent can complete the electronic diaries', 'Patient does not object to the processing of his or her data||Only for', 'The patients signed the informed consent and participated in the study voluntarily;|Age', 'appearance of', 'Withdrawal of Informed consent by a volunteer and/or a parent of a volunteer;||The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;|Availability of inclusion/non-inclusion criteria before vaccination;|Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;|The established', 'complying with research procedures and cooperate in the implementation of the entire process of research', 'Willing to provide written informed consent.|Signs and symptoms of suspected', 'Refusal to consent|Inability to access internet', ""patient to understand the character and individual consequences of the clinical trial|In the investigator's judgement"", 'The subjects voluntarily participated in the study with full informed consent and signed written informed consent form;|Recurrent/metastatic', 'The subject must provide written informed consent prior to any study related', 'Capable of providing written informed consent', 'The patient or his/her family refused to participate in the clinical trial;|Severe heart, lung', 'Refusal to participate in the study|History of neurologic deficits or neuropathy affecting the brachial plexus|Infection at the site of the block application|Coagulopathy|Pre-existing respiratory dysfunction|Allergy to local anesthetics|Uncooperated patients who cannot reliably answer verbal pain evaluation', 'patient refusal', 'Refusal to sign the informed consent form.', 'hours|Provided written and informed consent (patient or carer)||Australia only||•', 'Patient of legal age (', 'refusal to participate|contraindication to the use of local anesthetics|contraindication to the use of general anesthesia|contraindication to regular use of postoperative analgesics like', 'Have provided written informed consent prior to being entered into the study.|Be between 18 and 75 years of age', 'Patient presented with common warts in dermatology opd||', 'Patients who sign the informed consent form and are willing to complete the study according to the study protocol;|No previous history of', 'Subject must provide written informed consent.|Age', 'The patient has been diagnosed with', 'signing the informed consent, the age is 18-75 years old', 'Refusal to participate in research protocol.|Patient under administrative supervision|Pregnant', 'whose written consent cannot be obtained|who undergo surgical tracheostomy', 'Patient unwillingness or incapability to provide informed consent|Need for subcontinuous', 'Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.|patients must have confirmation', 'Patient refusal to participate in the study.|Patients with a previous history of', 'Patient does not understand, sign, and return consent form|Inability to perform regular electronic reporting|Patient', 'refusal to participate|allergy to the study drugs|chronic kidney disease (creatinine>150 μmol/L)|mental illness|liver', 'lifestyle.|Voluntary acceptance of participation in the study||', 'Patients willing and have signed consent.|Nonpregnant', 'Willing and able to provide written informed consent.|Male', 'patients who do not want to participate', 'Refusal to be included|Allergy or unsuitability to any composition of study drugs', 'The subjects voluntarily participated in the study with full informed consent and signed written informed consent form;|Aged ≥18 years and ≤75 years when the subject signed the informed consent;|Histologically confirmed', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Aged ≥ 18 years|Documented history of dry eyes', 'Refusal to participate|Younger than 18 years|Incapacitated', 'Have provided consent for research by signing the Information and Consent for research form;|Have given appropriate operative consent for a sacroiliac joint fixation procedure as standard of care using the SiJoin® Transfixing Sacroiliac Fusion Device;|Are skeletally mature', 'patient refusal to participate|known', 'able to provide written informed consent|Within 6 weeks of discharge from hospital following admission for bronchiolitis|Child aged', ""The students' age will range from 9 to 11 years.|Normal weight, Overweight"", 'Patients than or equal to 75 years old|Clear', 'Provision of signed and dated informed consent form|Stated willingness to comply with all study procedures and availability for the duration of the study|Diagnosed with cutaneous angiosarcoma of the breast or scalp', 'The subject is willing to provide written informed consent for the trial.|Be ≥ 18 years', 'Be willing to voluntarily participate in the study after reading the informed consent form.|Adult patient over 18 years of age who has completed growth', 'capable of becoming pregnant: use of highly effective contraception', 'The patient was over 18 years old.|The Eastern Cooperative Oncology Group Performance Status score ranged from 0 to 1.|Patients', 'Willing and able to give consent/assent;|If under the age of 18, guardian(s) is/are willing and able to give consent;|Prior study treatment with EB-101.||']"
